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CONCURRENT ORAL SESSION 1: PAIRED RENAL EXCHANGE
1
A NATIONAL LIVING DONOR KIDNEY EXCHANGE
PROGRAM AS THE LOGISTIC SOLUTION FOR
INCOMPATIBLE COUPLES

2
REPORT FROM A 60 TRANSPLANT CENTER
MULTIREGIONAL KIDNEY PAIRED DONATION PROGRAM
M. Rees1, R. Pelletier2, S. Mulgaonkar3, D. Laskow4, B. Nibhanupudy5,
J. Kopke6, A. Roth7, U. Unver8, T. Sandholm9, J. Rogers10
1
University of Toledo Medical Center, 2Ohio State University, 3St Barnabas
Health Care, 4Robert Wood Johnson Univ Hosp, 5Florida Hospital Transplant
Center, 6University of Cincinnati, 7Harvard University, 8University of
Pittsburgh, 9Carnegie Mellon University, 10Wake Forrest University
Introduction: Sixty US transplant programs in 21 states have partnered to
increase the access of their patients to a large pool of incompatible pairs for
kidney paired donation.
Methods: Donor/recipient characteristics were entered into a web-based
matching program; characteristics include ABO, gender, ethnicity, HLA
specificities, unacceptable antigens, height, weight, PRA, reason for ESRD, and
relationship of the donor (if any). Since February 2007, computer match runs
have been performed every 4-6 weeks generating a solution that simultaneously

3
THE DEVELOPMENT OF A SUCCESSFUL MULITREGIONAL KIDNEY PAIRED DONATION PROGRAM
R. Hanto1, W. Reitsma2, F. Delmonico1
New England Organ Bank, 2New Jersey Sharing Network
Using an optimization matching algorithm the New England Program for
Kidney Exchange (NEPKE) efficiently matches incompatible donor/recipient
pairs. In 2006, the Mid-Atlantic Paired Exchange Program (MAPEP) and other
individual transplant programs began sharing data with NEPKE. This is a
report of the success of two regional programs working together to increase the
probability of participants in both programs finding a compatible match.
Methods: Incompatible pairs and non-directed donors (NDD) are referred to
NEPKE through transplant centers. Donor and recipient ABO, HLA and recipient
HLA antibody screening are entered into the computer database. Utilizing the
optimization program, searches for compatible matches are conducted every
30 to 45 days. The program identifies potential 2 and 3-way matches, NDD
chains, and list exchange chains. Following the determination of compatibility
NEPKE notifies transplant centers involved of the potential match and centers
accept or decline the offer. Transplant centers notify their pairs and preliminary
crossmatches are performed. A conference call is scheduled to coordinate
simultaneous donor nephrectomies and recipient transplants. Surgeons speak
prior to incision to ensure simultaneous donation.
Results: From July 2005 to January 2008, 193 pairs and 11 NDDs have
entered NEPKE. During this time frame over one thousand possible matches
were identified, with the majority of these matches involving the same pairs
in multiple matches. After “optimizing” and eliminating multiple matches
13 two-way exchanges; 15 three-way exchanges; 8 three-way list chain
exchanges; and 26 NDD chain matches were offered to transplant centers as
possible matches. Most common reason offers were declined include: positive
crossmatch (16%); donor factors (16%). and recipient inactive or transplanted
(24%). Four potential offers occurred in MAPEP alone pairs, 31 in NEPKE
alone, and 27 offers were cross-regional. Of the 8 matches that moved forward
to donation and transplantation, seven involved NDD chains and one involved
a 2-way exchange. Of the 19 transplants resulting from these matches, 17
involved NDD chains.
Conclusion: Using a computerized optimization algorithm to match 2 and 3
way exchanges, NDD and list exchange chains has lead to a substantial increase
in the number of KPD matches and transplants performed. Cross-regional
coordination is feasible and expands the number of transplants performed
beyond the ability of individual exchange programs.
1
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M. Klerk De1,2, M. Witvliet3, B. Haase2, F. Claas3, W. Weimar1,2
1
Erasmus Mc University Medical Center Rotterdam, Dept. of Internal
Medicine, 2Dutch Transplant Foundation, Leiden, The Netherlands,
3
National Reference Laboratory for Histocompatibility, Department of
Immunohematology and Blood Transfusion, Leiden University Medical
Center, Leiden, The Netherlands
Background: Over the last decade, strategies to expand the living donor pool
have increased. In the Netherlands we embarked on a national living donor
kidney exchange program in 2004. We here report the results achieved with
242 incompatible couples enrolled over four years.
Methods: In the Netherlands, with a population of 16 million, all seven kidney
transplant centers agreed on a joint protocol, in which donor/acceptor criteria
and the logistics of the donation/transplantation procedures are described.
Donor kidney exchange takes place on an anonymous basis, while the allocation
is the responsibility of an independent organization, the Dutch Transplantation
Foundation. Allocation criteria include bloodtype (first identical, then
compatible), HLA match probability within each actual kidney exchange donor
pool and the wait time on dialysis. All the cross matches between the recipients
and their newly matched donors are centrally performed in the National
Reference Laboratory for histocompatibility in Leiden. A computerized match
procedure runs every three months. Donors travel to the recipient centers to
ensure short ischemia times.
Results: From January 2004 until December 2007 we registered 125 pairs with
blood type incompatibility and 117 pairs with a positive cross match. Median
PRA in the ABO blood type incompatible group was 2% (0-100) and 46%
(2-100) in the positive cross match group. Sixteen match procedures were
performed. The median input of new donor-recipient pairs was 14 (range 7 –
22 pairs) and the median number of couples participating in a match procedure
was 47 (range 16 -66 pairs). On the basis of allocation criteria the computer
constructed 132 ABO compatible cross match negative new donor-recipient
pairs. These 132 pairs were derived from 82 positive cross match pairs and 50
ABO blood type incompatible pairs. The median PRA of the matched recipients
in the positive cross match group was 42% (2-100) and in the ABO blood type
incompatible group 0% (0-38). There was no statistically significant difference
in success rate between the positive cross match group (70%) and the couples
with non-O recipients in the ABO blood type incompatible group (76%). We
were least successful for ABO blood type incompatible pairs with blood type O
recipients, but for 21/87, 24% there were possibilities.
Conclusion: The Dutch living donor kidney exchange program resulted in a
55% (132/242) successful match rate. The success of a living donor kidney
exchange program depends on collaboration between the transplant centers,
supervision by an independent allocation organization and centrally performed
cross matches.

optimizes for quality and quantity of transplants in 2-, 3- and 4-way matches as
well as altruistic donor initiated chains.
Results: The number of unique recipients included in each match run ranged
from 56-101 while the total number of pairs in the pool ranged from 74-121.
In the February 2008 match run there were 4 altruistic donors available. In the
first year of operation, six match runs completed the entire process of match run
to transplant resulting in 17 transplants (4 additional transplants are scheduled
and 17 possible transplants are undergoing further evaluation). The number of
crossmatches required per match run has varied from 7-48. Of the 21 transplants
performed or scheduled, 4 have resulted from simple 2-way paired donations
and the remaining 17 transplants were made possible through altruistic donor
initiated chains. Of the 60 participating transplant programs 18 have entered
pairs. Seven centers have enrolled more than 10 pairs and two centers have
enrolled more than 50 pairs each.
Conclusion: Large pools of incompatible pairs from a multiregional alliance
of transplant programs has increased the likelihood of identifying matches for
these difficult to match patients.
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EXCHANGE LIVING-DONOR KIDNEY
TRANSPLANTATION; ITS MERIT AND LIMITATION
K.H. Huh1,2, M.S. Kim1,2, M.K. Ju1,2, H.J. Ahn3, D.J. Joo1, S.J. Kim1,
S.I. Kim1,2, Y.S. Kim1,2, K. Park3
1
Yonsei University College of Medicine Department of Surgery, 2Yonsei
University College of Medicine The Research Institute for Transplantation,
3
Department of Surgery, Kwandong University College of Medicine
The shortage of donor organs is one of the major barriers to transplantation
worldwide, and especially in countries where cadaveric organ donations
are limited. An exchange donor (swap) program between two families was
launched in Korea in 1991. After the success of direct donor exchanges, we
have developed the swap-around program by enrolling many kinds of unrelated
donors. We report here on our results of exchange living-donor kidney
transplants.
From September 1995 to September 2006, we performed 1,163 kidney
transplants. The living-unrelated donors (LURDs) were composed of 129
exchange donors and 269 non-exchange donors. We compared the results of
exchange donor transplants with non-exchange donor kidney transplants.
Compared with the non-exchange group, exchange group spent a lot of time on
pretransplant dialysis until transplantation. And the proportion of preemptive
kidney transplant was extremely lower in the exchange group (3.9%) than
in the non-exchange group (14.1%) (p=0.005). In exchange group, blood O
type kidneys were restrictively allocated to blood O type recipients (78.9%)
compared to non-exchange donor group (54.4%) (p=0.007). Therefore the
proportion of ABO identical matching transplantation of the exchange donor
group was significantly higher than that of the non-exchange donor group
(87.6% versus 75.1%) (p=0.004). The overall 10-year graft survival rate
(86.3%) for exchange donor kidney transplants was comparable to that for
non-exchange donor (82.3%) and one-haplomatch (81.2%) kidney transplants
(p=0.2994) (Fig.). The incidence of acute rejection was similar between the
exchange (32.0%) and non-exchange (29.3%) donor groups. In multivariate
survival analysis, the donor type (exchange versus non-exchange) did not
impact on the graft survival rate. We can expect excellent clinical results by the
exchange living-donor kidney transplant program as an option to reduce the
donor organ shortage. But the exchange program has a considerable limitation
in blood O type recipients.

5
OUTCOME OF LIVING DONOR KIDNEY EXCHANGE
POOL MATCHING CAN BE MAXIMIZED BY NOT LIMITING
CHAIN LENGTH
E. de Buijzer1, B. Haase1, W. van der Deijl2, A. Bomans2,
M. de Klerk1, W. Weimar3
1
Dutch Transplant Foundation, 2Eurotransplant International Foundation,
3
Dept. of Nephrology, Erasmus Medical Center
Introduction: Since January 2004 the Netherlands has a successful Living
Donor Kidney Exchange (LDKE) program. Over these 4 years, the matching
algorithm was adapted to match a pool of donor-recipient pairs for doublets in
2004, for triplets in 2005 and for maximum possible chain length in 2007.
Methods: In the Dutch national LDKE program, donor and recipients pairs
can be included if they are unable to donate directly to each other, either due

2

to blood type incompatibility or due to immunological reasons. The pool of
donor-recipient pairs is matched 4 times a year. The LDKE algorithms used
donor HLA and recipient unacceptable HLA antigens to determine all possible
combinations in a pool. We compared the three algorithms to study whether the
chain length would affect the number of recipients that could be helped.
Results: Until 2007 the maximum number of pairs in a chain was limited to
3. As of 2007 there is no limit anymore on the donors and recipients in a chain
of pairs that can donate to each other. This resulted in an exponential growth
of possible combinations. Based on theoretical grounds, using this algorithm
would result in helping more recipients with a living donor kidney transplant.
In the pool of January 2007 57 pairs were included. Matching for doublets
resulted in helping 8 pairs. Matching for triplets resulted in helping 12 pairs.
However, using the new algorithm without the limitation of the chain length
resulted in successful matching of 17 pairs. In order to help these 17 pairs the
maximum chain length required was 6 pairs.
Conclusion: The results of LDKE matching can be increased substantially by
matching a pool of donors without limiting the chain length.

6
IMPACT OF ALTRUISTIC UNBALANCED PAIRED
KIDNEY EXCHANGE & DONOR/RECIPIENT ATTITUDES
TOWARDS PARTICIPATION
L.E. Ratner, A. Rana, E.R. Ratner, J. Kelly, D.J. Cohen, V. Ernst, D. Kornfeld,
I. Wiener
Columbia University
Background: Altruistic Unbalanced Paired Kidney Exchange (AUPKE) utilizes
compatible live donor/recipient pairs (D/R) to exchange with incompatible live
D/R pairs to allow all recipients to receive a compatible donor kidney.
Purpose: 1) To determine the impact of AUPKE if practiced in its simplest
form using ABO compatible, but non-identical donors (ABONI) at individual
centers. 2) To determine patient s attitudes towards AUPKE to be able to
effectively encourage participation.
Methods: At initial evaluation, potential donors recipients were administered a
survey regarding attitudes toward AUPKE. A 5-point Likert Scale was utilized.
Results: 1396 (22.8%) ABONI live donor txs were performed in the US in 2005
of which 91% of the donors were blood group O. Recipient survey respondants
were more likely than donors (p=0.002) to favor participation in AUPKE in the
absence of any advantage to themselves. However, a number of circumstances
increased the propensity to view AUPKE favorably for both recipients donors
(p<0.05) (see figures 1 2 respectively).
Conclusions: 1) AUPKE can have a profound impact on the number of live
donor renal txs. 2) In its simplest form, utilizing ABONI donors AUPKE can
be performed at individual centers without requiring large sharing networks or
complex computer algorithms. 3) Blood group O recipients with incompatible
donors are likely to be the primary beneficiary of AUPKE. 4) D/R attitudes
are not static, and can be influenced in favor of participating in AUPKE,
particularly if there is a perceived benefit to the recipient. 5) Both donors
recipients are more willing to participate in AUPKE if their intended recipient
or donor (respectively) are enthusiatic about participating. 6) Finally, AUPKE
reflects a major paradigm shift for live donation, converting a private resource
(the donor) to a shared or public one.

7
SELECTING THE BEST COMBINATIONS IN AFTER
MATCHING A POOL OF LIVING DONOR KIDNEY EXCHANGE
PAIRS
E. De Buijzer1, B. Haase-Kromwijk1, W. van der Deijl2, A. Bomans2,
M. de Klerk1, W. Weimar3
1
Dutch Transplant Foundation, 2Eurotransplant International Foundation,
3
Dept. of Nephrology, Erasmus Medical Center
Introduction: Computerized matching of a pool donor-recipient pairs in the
Dutch Living Donor Kidney Exchange (LDKE) program resulted in a huge
number of possible combinations of donor-recipient pairs that could donate to
each other.
Matching a pool of donor-recipient pairs implies that some pairs can be
matched with many others, whereas for other pairs only one or no combination
can be found. For allocation a computerized selection was required according
to preset conditions.
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EXPERIENCE WITH 100 GOOD SAMARITAN KIDNEY
DONOR CANDIDATES
W. Zuidema1, L. Kranenburg2, R. Erdman2, M. Hilhorst3, M. de Klerk1,
J. IJzermans4, W. Weimar1
1
Internal Medicine, Erasmus MC, 2Medical Psychology and Psychotherapy,
Erasmus MC, 3Medical Ethics, Erasmus MC, 4General Surgery, Erasmus MC
Background: Living donation provides for an increasing proportion of
kidney transplants. However, not all patients have a suitable living donor.
For patients without willing donors the only option is to wait for a deceased
donor kidney. Patients with willing but incompatible donors have the choice to
participate in a living donor kidney exchange program. Unfortunately, in case
of ABO incompatibility the success rate for O recipients in these programs is
disappointingly low (24%). Good Samaritan kidney donation may be a solution
for patients without willing donors, for recipients of ABO incompatible
couples or for both categories at the same time in domino-paired procedures.
We describe the results of such a program in which one Good Samaritan can
make 2 transplants possible.
Methods: We prospectively collected data from all individuals that made
inquiries about altruistic kidney donation to non-genetically and nonemotionally related patients.
Results: 100 donor candidates approached us since the year 2000. All were
sent written information on living kidney donation in general and on our Good
Samaritan protocol, which includes a psychological evaluation procedure.
(SCL-90 and an in-depth interview). On the basis of written information 28
persons decided not to donate, 5 have not decided yet and 5 were referred to
another center. We enrolled 62 potential donors in our screening procedures,
and found medical and/or psychological contra-indication in 14 instances,
while 11 procedures are still pending. We accepted 37 individuals for donor
nephrectomy. One person withdrew consent. The remaining 36 Good Samaritans
made a total of 55 kidney transplants possible: directed donation in 6 cases, and
11 undirected anonymous donations to patients on the wait list. In 19 cases we
arranged domino-paired procedures in which Good Samaritans were coupled
to recipients of unsuccessful ABO incompatible crossover couples. The donors
of these couples agreed to donate to wait list patients according to routine
allocation criteria.
Conclusion: Integration of programs for Good Samaritan donation and living
donor kidney exchange results in true synergy.

9
NEW YORK STATE GUIDELINES FOR LIVE-KIDNEY
DONATION
M. Gallichio1, J. Bromberg2, D. Distant3, T. Powell4, D.Cohen5, D. Conti1
Albany Medical College, 2Mt. Sinai Medical Center, 3SUNY Downstate, New
York, 4New York State Department of Health, 5Presbyterian Hospital, New York
The kidney transplant wait list continues to rapidly increase. In response, living
kidney donation rates have tripled in the past decade. This area continues to
evolve: individuals with higher medical risk and non-traditional relationships
with recipients are now frequently considered for live donation. To address
concerns about these practices and to protect potential live kidney donors (and
recipients). New York State Department of Health (NYS-DOH) convened
a committee (COMM) to develop guidelines for centers performing livedonor kidney transplants. The COMM. consisted of representatives of all
NYS Transplant Programs, expert outside consultants, transplant physicians,
surgeons, mental health professionals, live- kidney donors, coordinators,
and DOH staff. The COMM. addressed 3 areas: 1) Medical Evaluation; 2)
Non-Medical Evaluation (donor advocacy, informed consent, psychosocial
evaluation, long-term follow-up); and 3) Unrelated Donors (“Solicited” donors,
paired donation, non-directed donation). The Medical Evaluation Sub-COMM.
emphasized minimizing the risk to the donor and adopted the recommended
minimal screening guidelines as articulated by the Amsterdam Forum, and
addressed areas of particular concern in expanding the range of acceptable
medical criteria for donation: renal function, hypertension, obesity, glycemia,
malignancy, cardiovascular risk. The Non-Medical Evaluation Sub-COMM
focused on the importance of the psychosocial assessment of the potential
donor, who must understand the risks and benefits, not be subject to coercion,
and maintain autonomy in deciding whether to proceed with donation. The
Unrelated Donor Sub-COMM emphasized the specific elements needed in the
evaluation process for this “new” type of donors who have neither a biologic nor
a long-standing emotional relationship with the potential recipients. This group
stressed the importance of understanding donor motivation in each type of nontraditional donation, additional elements in the informed consent process, and
protection of donor and recipient privacy. These guidelines have been approved
by the NYS Transplant Council and are intended to be consistent with and
complementary to the UNOS Living Kidney Donor Evaluation Guidelines
1
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PATIENT OUTCOMES IN TWO STEROID-FREE
REGIMENS USING TACROLIMUS MONOTHERAPY AFTER
DACLIZUMAB INDUCTION AND TACROLIMUS AND MMF IN
LIVER TRANSPLANTATION
T. Becker1, G. Otto2, I. Bilbao3, D. D’Amico4, M. Colledan5, A. Bernardos6,
C. Broelsch7, H. Isoniemi8, J. Pirenne9, J. Jaray10
1
Medizinische Hochschule Hannover, Germany, 2Universitätsklinikum Mainz,
Germany, 3Hospital Vall d’Hebron, Barcelona, Spain, 4Azienda Ospedaliera
di Padova, Italy, 5Azienda Ospedaliera Spedali Riuniti, Bergamo, Italy,
6
Hospital Virgen del Rocio, Sevilla, Spain, 7Universitätsklinikum Essen,
Germany, 8Helsinki University Central Hospital, Finland, 9UZ Gasthuisberg,
Leuven, Belgium, 10Semmelweis University of Medicine, Budapest, Hungary
Introduction: Evidence has shown that long-term steroid administration
after liver transplantation is a predisposing factor to infectious and metabolic
complications. Similar complications are associated with multi-agent
immunosuppressant use. Providing optimal immunoprophylaxis while using
a minimum of immunosuppressant agents could be key to improving clinical
outcome in liver transplantation.
Methods: 627 patients were randomised. Patients in the full analysis set (TAC/
DAC, N=305; TAC/MMF, N=297) received an initial daily TAC dose of 0.15
mg/kg. DAC induction was administered twice: 2.0mg/kg intraoperatively
and 1.0mg/kg given once during Week 1. MMF was administered at 2 g/day
to Day 14 and thereafter at 1 g/day. Both groups received a single steroid
bolus (≤ 500mg) on Day 0. Target TAC trough levels were 10-15 ng/ml up
to Day 42 and then <10 ng/ml. The primary endpoint was incidence and time
of first biopsy proven acute rejection (BPAR) requiring treatment. Secondary
endpoints included patient/graft survival, creatinine clearance (Cockcroft and
Gault) and adverse events.
Results: Patient study completion rates were similar (TAC/DAC, 72% and
TAC/MMF, 68.7%); study discontinuation due to any adverse event was 15%
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Methods: In order to select the best possible combination in a match, sorting is
performed based on preset conditions. These conditions are:
1. Helping as many as possible recipients
2. Blood type identical matches before blood type compatible to avoid
accumulation of blood type 0 recipients in the pool while draining the blood
type 0 donors
3. Most difficult to match patients first based on a match probability
4. Short chains preferred
5. Patients preferably dispersed over multiple centers
6. Longest number of days on dialysis
7. Number of negative X-matches
By changing the sort order, the outcome of best possible combination can be
influenced.
Results: In the LDKE pool of January 2007 57 donor-recipient pairs
participated. Depending on donor and recipient factors, like blood group, HLA
and PRA, some pairs can be matched with multiple other pairs. Matching this
pool without limiting the chain length of pairs that can donate to each other
resulted in 3.427.603 possible combinations. Using this sort order resulted
in the selection of a single combination that was considered to be the best
according to the pre-defined conditions.
Conclusions: By sorting according to preset conditions, a single combination
of matched pairs can be selected from a huge set of results after LDKE matching
of a pool of recipients.
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in both groups. TAC trough levels were comparable and reflected protocol
guidelines. Of completers, 6% in the TAC/DAC group and 4% in the TAC/
MMF group took steroids and 66% of TAC/MMF patients took MMF at Month
3. The incidence of treated BPAR was 18.5% (TAC/DAC) and 17.8% (TAC/
MMF) (ns). Three-month patient survival (Kaplan-Meier method) was 91.8%
(TAC/DAC) and 91.6% (TAC/MMF); graft survival was 88.2% and 87.8%,
respectively.
Generally, adverse events were reported less frequently in the TAC/DAC group
(Table 1).
Table 1: Most Frequently Reported* Adverse Events –% of Patients

Infection
Renal & Urinary
Metabolism Disorder
Gastrointestinal Tract
Hepatobiliary
Blood & Lymphatic System
Respiratory
Vascular
Nervous System
Immune System
General
Musculoskeletal

TAC/DAC
N=305

TAC/MMF
N=297

52.1
43.6
36.4
32.8
31.8
25.2
25.9
23.6
19.3
20.3
13.8
6.9

55.9
39.4
42.4
39.1
34.7
37.0
27.3
20.2
23.2
20.2
17.8
8.4

FAS; *>5% in either treatment group
Rates of bacterial infection were 18.4% with TAC/DAC and 23.2% with
TAC/MMF, hepatobiliary infection was 8.2% and 8.1%, CMV was 6.2% and
8.8%, HCV was 7.2% and 5.1%, respectively. Indicies for renal function were
similar between the two treatment groups. Calculated creatinine clearance
for completers at Month 3 was 69.7 mL/min (TAC/DAC) and 66.6 mL/min
(TAC/MMF) and mean serum creatinine was 104.3μmol/L and 98.1μmol/L,
respectively. Low incidences of de novo diabetes mellitus (>30 days antidiabetic
treatment) were reported during Months 2-3 in both groups: 5.4%/221 patients
in the TAC/DAC group and 6.2%/227 patients in the TAC/MMF group.
Conclusion: The two tacrolimus-based regimens optimised immunoprophylaxis
while eliminating risks associated with steroids. Although efficacy outcomes
were comparable between TAC/DAC and TAC/MMF, safety outcomes,
especially blood and lymphatic disorders, metabolism disorders, gastrointestinal
disorders, and infection tended to be less frequently reported with maintenance
therapy consisting of tacrolimus monotherapy than with tacrolimus/MMF dual
maintenance therapy.

11
RENAL FUNCTION IN LIVER TRANSPLANT
RECIPIENTS ACCORDING TO THE IMMUNOSUPPRESSIVE
PROTOCOL: THE TRY STUDY
F. Saliba3, N. Janus1, S. Karie2, J. Dumortier3, N. Launay-Vacher1,
Y. Calmus4, C. Duvoux5, R Lorho6, G. Deray1, G.P Pageaux7.
1
Pitie-Salpetriere, Paris; 2Edouard Herriot, Lyon; 3Paul Brousse, Villejuif;
4
Cochin, Paris; 5Henri Mondor, Créteil; 6Pontchaillou, Rennes; 7Saint-Eloi,
Montpellier, France.
The TRY study was designed to evaluate 1) the prevalence of kidney disease
after liver transplantation (LTx). and 2) the potential differences in the clinical
course of patients’ renal function (RF) depending on the immunosuppressive
drugs they receive. We describe here the RF of liver transplant recipients
according to the immunosuppressive protocol, before transplantation (BT). at 1
month (1M). 1 year (1Y) and 5 years (5Y) after LTx.
Methods: TRY (liver Transplantation and Renal insufficiencY) is a French
retrospective, multicenter observational study. The data collection was
performed at 4 time points: BT, at 1M, 1Y, and 5Y after LTx. RF was assessed
with the aMDRD formula.
Results: 1508 patients were included from 15 centers. Changes in GFR were
compared according to the immunosuppressive protocol:
-group “CNI+MMF” where patients received a CNI associated with
mycophenolate mofetil (MMF) at 1M, at 1Y, at 5Y.
-group “CNI” where patients received a CNI without MMF at 1M, at 1Y, at 5Y.
In this group, most patients received only CNI and some CNI + Azathioprine.
There was no difference between those 2 sub-groups on RF. All those patients
were thus pooled in the same group and compared to “CNI+MMF”.

4

In both groups, the GFR decreased as compared to BT: -18.9% in CNI+MMF”
vs -26.5% in “CNI” at 1M (NS). -18.1% vs -30.6% at 1Y (p=0.035). and
-14.6% vs -33.3% at 5Y (p=0.013). The decrease in GFR was significantly
lower in group “CNI+MMF” as compared to “CNI” although mean GFR BT
was significantly lower in the group “CNI+MMF” (88 vs 96 mL/min/1.73m2,
p=0.0009).
In addition, comparing the 117 patients who were on CNI+MMF at 1M and at
1Y, and at 5Y with the 677 patients who were on CNI alone at each time, the
decrease in GFR was also significantly lower in the “CNI + MMF” group at
1Y and 5Y (cf. Table 1).
Conclusion: The reduction in GFR was less pronounced in the group
“CNI+MMF” even if these patients were significantly more at a renal risk since
their GFR BT was significantly lower. At 1Y and at 5Y, there was no difference
in CNI blood levels between the 2 groups, suggesting that the sustained lower
decrease in GFR observed in group “CNI+MMF may not be only explained by
a reduction in CNI exposition.
Table 1: Relative decrease in GFR in patients with or without MMF and
comparison
of
CNI
blood
levels.
GFR,%

Blood levels, ng/ml

1M

FK

1Y
CsA

FK

5Y
CsA

FK

1Y

5Y

1M
CsA

CNI+MMF,
-16.62
n=117

-15.50

-14.61

274.55

9.53

154.47

8.43

158.77

5.92

CNI, n=677

-26.09

-29.38

-32.85

342.66

11.83

199.98

8.51

135.17

6.31

p

NS

0.05

0.02

NS

<0.0001 NS

NS

NS

NS

12
SINGLE-CENTER EXPERIENCE OF FIRST 1000
CASES OF ADULT-TO-ADULT LIVING DONOR LIVER
TRANSPLANTATION
D.H. Jung, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B Moon, T.Y. Ha,
J.H. Ryu, E.J. Lee, E.S. Yang
Department of Surgery, Division of Hepatobiliary Surgery And Liver
Transplantati
The outcomes of first 1000 adult recipients undergoing living donor liver
transplantation (LDLT) in a single center from February 1997 to January 2006
were retrospectively analyzed. Recipient mean age was 47.9+/-8.6 years. Major
primary diagnoses included hepatitis B virus-associated cirrhosis (n=845).
acute liver failure (n=56). hepatitis C virus-associated cirrhosis (n=33) and
alcoholic liver disease (n=30). Primary liver malignancy was detected in 300
patients. Graft types were right liver grafts (n=651). left liver grafts (n=176)
and dual liver grafts (n=173). Most right lobe grafts had middle hepatic vein
outflow pathway through reconstructed or native vessel trunk. Median graft-torecipient weight ratio was 0.97. Retransplantation was performed in 9. Overall
1-year, 3-year and 5-year patient survival rates were 89.3%, 84.7% and 82.9%,
respectively. Five-year patient survival rate was 73.8% and 87.1% in patients
with and without hepatocellular carcinoma, respectively. The most common
causes of patient mortality and morbidity were hepatocellular carcinoma
recurrence and biliary complication, respectively. Five-year hepatitis B
virus reinfection rate was 7.3% after high-dose hepatitis B immunoglobulin
monotherapy combined with rescue antiviral therapy. Overall perioperative
recipient mortality rate within first 3 months was 5.8%, whereas perioperative
mortality rates in the 1st, 2nd, 3rd, 4th and 5th 200 cases were 12%, 6%, 5.5%,
3% and 2.5%, respectively. A total number of 1175 living donors recovered
without sequelae except 1 case of renal failure requiring kidney transplantation.
The most important point of donor selection criteria for right liver harvest was
preservation of at least 30% of the whole liver mass with full preservation
of hepatic venous drainage. In conclusion, the perioperative mortality rate
decreased much according to the accumulation of surgical experience. Prudent
selection of patients with hepatocellular carcinoma appears to be critical to
achieve favorable long-term survival. Biliary complication was not overcome
by technical refinement and remains as the most serious drawback of adult
LDLT leading to deterioration of quality of life.
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DOES LIVING DONATION OFFER AN ADVANTAGE IN
SURVIVAL AFTER PEDIATRIC LIVER TRANSPLANTATION IN
THE MELD/PELD ERA?: ANALYSIS OF OPTN/UNOS DATA

14
THE DOMINO LIVER WORLD TRANSPLANT
REGISTER (DLTR) PERSPECTIVE ON DOMINO LIVER
TRANSPLANTATION.
H. Wilczek, M. Larsson, B-G. Ericzon
Department of Transplantation Surgery, Karolinska University Hospital
Huddinge, Karolinska Institute
Background: The DLTR was founded in 1999. It registers data on liver
transplant recipients who received explanted livers from other patients who
themselves underwent liver transplantation. As of Dec 2007, 48 hospitals in
17 countries have been reporting domino liver transplantations (DLT) to the
register. Currently 60–65 DLT: s are done annually worldwide.
Results: By December 31, 2007 a total of 625 DLT: s in 615 patients were
recorded. The male/female ratio is 75% and 25%, respectively, with a mean
recipient age at the time of transplantation of 54.4±9.6 years (range 17.0 – 73.9
years, median 55.6 years). Overall, the frequency of retransplantations amounted

15
THE POSITIVE EFFECT OF PROSTAGLANDIN E1 ON
HEPATIC MICROCIRCULATION FOLLOWING CLINICAL
LIVER TRANSPLANTATION IS ENHANCED IN STRONG
ISCHEMIA/REPERFUSION INJURY
M. Angelescu1, E. Klar1, T. Kraus2
Dept. of Surgery, Rostock University, Germany, 2Dept. of Surgery,
Krankenhaus Nordwest, Frankfurt, Germany
Background: Literature data suggest that Prostaglandins have a beneficial
impact on graft quality following liver transplantation by their vasodilating
and cytoprotective effect. However, prophylactic as well as therapeutical
administration in graft non-function is still a controversial issue. The aim
of this study was to analyze the dose-dependent effect of Prostaglandin E1
(PGE1) on hepatic microcirculation in clinical transplantation by continuous
thermodiffusion monitoring, and to define which patients will benefit most
from PGE1-therapy.
Methods: In 30 liver transplant recipients a thermodiffusion probe was inserted
into liver segment IVb for intra- and postoperative quantification of hepatic
microcirculation. On the second postoperative day PGE1 (Alprostadil) was
intravenously administered at a gradually increasing dose (0.1–0.6 μg/kg/h).
Dosage was titrated by 0.1 μg/kg/h in one-hour intervals. Microcirculation was
quantified prior to PGE1-administration, at the end of each dosage interval, as
well as 3 and 12 hours after therapy was completed. Perfusion increment during
PGE1-application was correlated to intraoperative microperfusion (PERFop).
postoperative peak transaminases (ASTmax, ALTmax) and cold ischemia time
as parameters reflecting graft quality.
Results: Hepatic microperfusion significantly increased from 69+2ml/100g/
min to 80+3ml/100g/min at a dosage of 0.2μg/kg/h (p<0.005). Maximum
perfusion (89+5ml/100g/min) was achieved at a dose of 0.4μg/kg/h (p<0.001).
High perfusion increment during PGE1-administration correlated with
low intraoperative microperfusion (PERFop<60ml/100g/min – perfusion
increment 55% vs PERFop>80ml/100g/min – perfusion increment 29%). high
postoperative peak transaminases (ASTmax>1500U/l – perfusion increment
76% vs ASTmax<500U/l – perfusion increment 30%). and a cold ischemia time
greater than 9 hours (CIT>9h perfusion increment 47% vs CIT<9h perfusion
increment 29%).
Conclusion: Low-dose Prostaglandin E1 significantly improves hepatic
microcirculation following liver transplantation with no further beneficial effect
above 0.4μg/kg/h. The highest perfusion increment is seen in patients with
compromised microperfusion at the end of transplantation, high postoperative
1
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Y. Cho1,2, T. Steljes1, J. Cicciarelli1,2, I. Hutchinson1,2, M. Stapfer2, R. Mateo2,
L. Sher2, R. Selby2, Y. Genyk2
1
National Institute of Transplantation, 2USC School of Medicine
Background: Recent studies demonstrated better outcomes of graft and patient
survival in living donor liver transplantation (LDLT) compared with those of
whole liver (WLT) and split liver transplantation (SLT). However their results
often utilize recipients from both pre and post model-for-end-stage- liverdisease (MELD/PELD) implementation.
Aims: This study retrospectively compares LDLT, SLT, and WLT in pediatrics
in the MELD/PELD era by examining the OPTN/UNOS database with the
intent to identify recipient factors that may impact outcomes.
Materials and Methods: From January 1, 2002 to December 31, 2006, 1,976
liver transplant (LT) in recipients age<12 years old were reported to the OPTN/
UNOS. Of these, 298 LDLTs, 384 SLTs, and 1,294 WLTs were identified.
Multiple organ transplants were excluded from the study. The log-rank test was
used for comparison of the two survival curves.
Results: Unadjusted graft survival rates of LDLT (85% at 1-yr and 82% 3-yr)
were not significantly different to those of SLT (81% at 1-yr and 75% 3-yr,
P=0.11) and WLT (81% at 1-yr and 75% 3-yr, P=0.08) (Figure). Patient survival
rates of LDLT (91% at 1-yr and 90% 3-yr) were also not significantly different
to those of SLT (90% at 1-yr and 86% 3-yr, P=0.54) and WLT (88% at 1-yr
and 84% 3-yr, P=0.12) (figure). Incidence of primary graft failure was 3.4%
for LDLT compared with 3.9% for SLT (P=0.70) and 3.5% WLT (P=0.91).
Incidence of graft loss due to vascular thrombosis in LDLT group (6.0%) also
was not significantly different than those of SLT (6.0%, P=0.98) and WLT group
(5.1%, P=0.91). Incidence of biliary tract complications was the highest in SLT
(2.1%) among 3 group, but the differences were not statististically significant
(0.7% in LDLT, P=0.13 and 0.7% WLT, P=0.96). In multivariate analyses, both
adjusted graft and patient survival rates of LDLT were not significantly different
than those of SLT (Relative Risk (RR) =0.79 (95% CI: 0.59-1.07). P=0.13 for
graft and RR=0.77 (0.52-1.14). P=0.19 patient) and WLT group (RR=0.92
(0.71-1.18). P=0.50 for graft and RR=0.75 (0.53-1.06). P=0.10 patient) after
adjusting for confounding factors such as PELD and regraft.
Conclusion: In the MELD era, both SLT and WLT in pediatrics yielded
comparable graft and patient survival to LDLT.

to approximately 5%. The vast majority of the livers used for DLT came from
FAP/amyloidotically afflicted donors (99%). but DLT using livers from donors
with metabolic diseases other than amyloidosis have also been reported to the
Registry. In 8 cases the DLT liver was used as a split and transplanted into 16
recipients. The survival in FAP patients who became liver donors themselves
did not differ from those FAP patients who did not donate a liver. The overall
1-year, 5-year and 8-year graft survival in DLT recipients was 80%, 66% and
63%, respectively. The most common domino liver donor mutation was the
Val30Met. Overall, patients with malignancy diagnoses amounted to 43% in
the Val30Met group and to 53% in the non-Val30Met group. Domino recipients
transplanted because of malignancy had significantly inferior survival rates
compared to non-malignant recipients. In total, 185 out of 615 DLT recipients
have died. Tumour recurrence and septicaemia accounted for the majority the
deaths (40%). A significantly better graft survival was observed in recipients
of non-Val30Met mutated livers compared to Val30Met mutated livers (5-year
survival 85% and 74%, respectively p<0.05).
Discussion: Patients accepted for Ltx can themselves, in carefully selected cases
serve as hepatic organ donors. In experienced hands the procedure is safe both
for the domino donor and the recipient. The immediate and short-term outcome
in the domino recipients is excellent. The more long-term survival must also be
deemed good, in view of the poor pretransplant condition and dismal prognosis
domino recipients have without transplantation. As expected, the survival
among domino recipients transplanted because of malignancy is inferior to that
in recipients without malignancy Recipients of Val30met mutated livers show
inferior survival rates to recipients of other TTR mutated livers. The reason for
this difference is not clear. Domino livers make a valuable resource, but there
is a need for caution and vigilant long-term monitoring because of the hitherto
relatively unknown TTR kinetics following DLT and a risk of transferring the
donor disease to the domino recipient.
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serum transaminases as indicator of hepatocellular injury, and cold ischemia
time above 9hours. We conclude that particularly patients with strong ischemia
– reperfusion injury will benefit most from PGE1-therapy.
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DONOR TREATMENT WITH STEROIDS REDUCES
INFLAMMATION AND IMPROVES GRAFT FUNCTION
AND OUTCOME FOLLOWING DECEASED LIVER
TRANSPLANTATION
A. Pascher1, F. Ulrich1, K. Kotsch2, A. Reutzel-Selke1, O. Kuecuek3, A. Lun4,
S. Tullius5, P. Neuhaus1, J. Pratschke1
1
Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow, Berlin,
Germany, 2Inst. of Medical Immunology, Charité, Campus Mitte, Berlin,
Germany, 3Deutsche Stiftung Organtransplantation, Berlin, Germany, 4Inst.
of Lab. Medicine, Charite, Campus Virchow, Berlin, Germany, 5Division
of Transplant Surgery, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA, United States.
Body: In brain death (BD). induction of inflammatory cytokines leads to an
intensified YR injury and an increased rate of primary non-function or acute
rejection after liver transplantation (LT).
Methods: In a prospective randomized treatment-versus-control study in 100
BD donors we investigated whether corticosteroid treatment of the deceased
donor is able to attenuate BD-associated damage in clinical LT. Donor treatment
(n=50) consisted of 250 mg methylprednisolone at time of BD diagnosis and a
subsequent infusion of 100 mg/h until recovery of organs. A liver biopsy was
taken immediately after laparotomy and blood samples were obtained after BD
diagnosis and before organ recovery.
Results: Following steroid treatment, cortisol plasma levels were significantly
higher (pcO.O5) and a significant decrease of soluble interleukins, MCP-1
and IP-10 was observed. Corticosteroid treatment resulted in a significant
downregulation of ICAM-1, TNFa, MHC class II, FasL, IP-10 and CD68
intragraft mRNA expression. Significantly lower AST and bilirubin levels in
the posttransplant course were accompanied by a decreased incidence of acute
rejection and ischemic type biliary lesion.
Conclusions: Our present study verifies the protective effect of steroid
treatment in deceased donor LT, suggesting it as a potential therapeutical
approach especially for marginal donor livers.

17
DONOR MANNOSE-BINDING LECTIN DEFICIENCY
TRIPLES THE RISK OF POST-LIVER TRANSPLANTATION
INFECTION.
D. Worthley1, D. Johnson2, D. Eisen3, S. Heatley4, M. Dean5,J-P. Tung5,
H. Harley6, R. Padbury7, J. Scott8, C. Mullighan9, P. Angus10, P. Bardy11,12
1
Royal Brisbane And Women’s Hospital And Queensland Institute of Medical
Research, 2Department of Infectious Disease, Austin Health, 3Department
of Infectious Disease, Royal Melbourne Hospital, 4Australian Red Cross
Blood Service, 5Australian Red Cross Blood Service, 6Department of
Gastroenterology and Hepatology, The Royal Adelaide Hospital, 7South
Australian Liver Transplant Unit, Flinders Medical Centre, 8Statistics Unit,
Royal Brisbane and Women’s Hospital and Queensland Institute of Medical
Research, 9Pathology, St. Jude Children’s Research Hospital, 10Victorian Liver
Transplant Unit, Austin Health 11Division of Haematology, Royal Adelaide
Hospital and Institute of Medical and Veterinary Science, SA, Australia
12
Department of Haematology, The Queen Elizabeth Hospital, SA, Australia.
Background: Mannose-binding lectin (MBL) is an important mediator of
innate immunity, primarily synthesized by the liver. MBL deficiency occurs
in approximately 40% of the population, is primarily due to polymorphisms
in the gene encoding MBL (MBL2), and is associated with an increased risk
of infection. Clinically significant infection (CSI) is the chief complication
following liver transplantation (OLT). We have examined associations between
donor and recipient MBL status and transplant outcome in a large retrospective
study of OLT.
Methods: One hundred and two consecutive adult donor-recipient liver
transplant pairs were identified through the Victorian Liver Transplant Unit,
Australia. Donors and recipients were genotyped for promoter (-550H/L,
-221X/Y) and coding (codon 52Cys, 54Asp, and 57Glu) MBL2 polymorphisms
by PCR-SSP. MBL deficiency was defined as any deficient MBL2 coding allele.
Pre-OLT and post-OLT sera was analysed for functional MBL activity using
the ELISA-based mannan-binding and C4-deposition assays. The primary
clinical endpoint was CSI, defined as symptomatic, invasive, microbiologically
confirmed infection. Episodes of pneumonia where confirmatory testing failed
or was impossible, but with typical clinical and radiologic features were also
considered CSIs. Secondary endpoints were graft rejection, hospital stay and
transplant failure. Multivariate analysis of the factors associated with CSI was
performed using logistic regression.
Results: The median duration of post-OLT follow up was 4.5 years (range
2.1-8.1). Thirty-eight percent of patients developed post-OLT CSI. Thirty-nine
percent of donors and 35% of recipients had MBL2 coding mutations. Twentyseven percent of patients receiving an MBL sufficient liver compared to 55%
of patients receiving a liver with an MBL2 coding mutation developed CSI
(p=0.005). In multivariate analysis CSI was significantly associated with donor
derived MBL deficiency (OR 3.34, 95% CI 1.35-8.3, p=0.009), increasing
recipient age (OR=1.001, 95% CI 1.00-1.001, p=0.044) and CMV prophylaxis
was protective (OR 0.22, 95% CI 0.078-0.616, p=0.004). Recipient MBL status
did not influence OLT outcomes.
Conclusions: Transplant recipients of MBL deficient livers have a significantly
increased risk of developing post-OLT CSI. Post transplant immunoprophylaxis
with recombinant MBL is likely to be beneficial in this setting.

18
TERLIPRESSIN AS THERAPY FOR RENAL FAILURE
AND HYPONATRAEMIA IN PATIENTS WITH LIVER FAILURE
AWAITING TRANSPLANTATION
E. Prakoso, D. Koorey, S. Strasser, G. McCaughan, N. Shackel
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred
Hospital, Sydney
Background: Renal failure and hyponatraemia are associated with increased
morbidity and mortality in patients with liver failure. We performed an analysis
of terlipressin therapy for renal failure and isolated hyponatraemia (hypoNa)
in patients with liver failure at the Australian National Liver Transplantation
Unit (ANLTU).
Methods: A retrospective analysis was performed on patients at the ANLTU, who
received terlipressin for a minimum of 24 hours for the indications of renal failure,
either hepatorenal syndrome (HRS) or nonHRS, and isolated hyponatraemia
(serum Na <130 mmol/L without renal failure). Response was defined as: (a) the
return of serum creatinine to ≤133 μmol/L in HRS, (b) normalisation of serum
creatinine (≤110 μmol/L) in nonHRS renal failure, and (c) an increase in serum
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DOMINANT T CELL REGULATION ACHIEVED EX-VIVO
VIA IFN-GAMMA/STAT-1 SIGNALING AND NITRIC OXIDE
INDUCTION
G. Feng1, R. Francis1, W. Gao2, T. Strom2, M.Oukka3, K. Wood1, A. Bushell1
Transplantation Research Immunology Group, Nuffield Department of
Surgery, University of Oxford, 2Transplant Research Centre, Beth Israel
Deaconess Medical Centre, Harvard Medical School, 3Center for Neurologic
Diseases, Brigham and Women’s Hospital, Harvard Medical School
Background and Aims: IFN-gamma is usually considered to be a proinflammatory effector cytokine, but increasing evidence indicates that it also
plays an important role in regulating the development of T cell responses in
vivo. We have exploited this potential and have previously shown that naïve
CD4+ T cells stimulated with allogeneic bone-marrow derived DC ex-vivo in
the presence of IFN-gamma results in a population of regulatory T cells with
the capacity to prevent skin graft allograft rejection. The aim of this study was
to identify the origin and key mechanistic steps involved in development of this
population with a view to possible translation to the human setting.
Methods and Results: Stimulation of CBA (H2k) CD4+ T cells with B10
(H2b) GMCSF/TGF-beta conditioned bone marrow derived DC (BM-DC) in
the presence of 5ng/ml IFN-gamma results in (i) preferential apoptosis within
responding Foxp3-ve cells (49.0±3% apoptosis versus 9.5±7.0% in Foxp3-ve
and Foxp3+ve cells respectively, P<0.05); (ii) STAT-1 dependent inhibition
of Th17 responses; (iii) direct conversion of Foxp3-ve into Foxp3+ve cells
(input population <0.5% Foxp3+ve; resultant population 17% Foxp3+ve
demonstrated using Foxp3-GFP-reporter mice). Furthermore, using a system
in which naturally occurring Treg and non-Treg can be distinguished on the
basis of stable cell surface markers, we demonstrate that IFN-gamma driven
conversion of Foxp3-ve precursors is partially dependent on the presence of
pre-existing regulatory cells.
To explore in more detail the mechanisms responsible, inhibition of NOS using
L-NMMA resulted in a striking dose-dependent decrease in Foxp3+ve cells
from 40.0±6.3% without inhibitor to 33.4±15.4% with 0.1mM, 18.2±14.4%
with 0.5mM and 4.5±2.6% with 1.0 mM inhibitor (P<0.05). In addition,
provision of a NO donor (SNAP) in the absence of IFN-gamma replicates the
IFN-gamma effect in that the proportion of Foxp3+ve cells increased from a
baseline of <10% to 22.1±16.9%, 33.0±24%, 49.5±14.9% and 67.9±15.4% at
1

0.1, 0.2, 0.3 and 0.4 mM SNAP respectively. These data indicate an important
role for NO in the emergence of allo-reactive, Foxp3+ve adaptive regulatory
T cells.
Conclusion and Significance: When total CD4+ cells are driven by allogeneic
APC in the presence of IFN-gamma, a combination of apoptosis of non-Treg,
expansion of existing Treg and conversion of non-Treg precursors results in
a 5-8 fold increase in the proportion of Foxp3+ve regulatory cells and the
emergence of a dominant regulatory T cell population that can control allograft
rejection. The data presented in this study provide mechanistic insights into this
process and indicate adjunctive and alternative strategies which may enable
translation to the human setting to provide robust populations of regulatory T
cells for use in both transplantation and autoimmune disease.

20
ADOPTIVE TRANSFER OF CD4+CD25+ REGULATORY
CELLS COMBINED WITH LOW-DOSE SIROLIMUS
PRESERVES SUPPRESSIVE FUNCTION OF REGULATORY
T CELLS AND DELAYED ACUTE REJECTION OF RENAL
ALLOGRAFTS IN CYNOMOLGUS MONKEYS
H. Chen, A. Ma, S. Qi, L. Song, G. Yu, Y. Hu, H. Dun, Z. Xiong,
D. Xu, P. Daloze
Research Center, CHUM, Notre-Dame Hospital, University of Montreal.
Exploring new immunosuppressive strategies to induce donor-alloantigenspecific hyporesponsiveness is an important challenge in transplantation.
CD4+CD25+ regulatory T cells have been known to play an important role in
transplantation and autoimmune diseases. However, therapeutic applications
are limited by poor capacity of CD4+CD25+ regulatory T cells. In this study,
isolated CD4+CD25+ regulatory T cells from cynomolgus monkeys were
expanded efficiently in vitro by a co-culture system. These cells expanded
50-60-fold in 4 weeks, and expressed high levels of CD25+ and FoxP3+
regulatory molecules. Expanded cynomolgus CD4+CD25+ regulatory T cells
were anergic and suppressed the proliferation of autologous PBMC in donor
alloantigen-dependent and cell dose-dependent fashion, and the suppression
was partially reversed by anti-TGF-?1 and anti-IL-10 neutralizing antibodies.
Adoptive transfer of expanded CD4+CD25+ regulatory T cells without any
immunosuppressant could prolong survival time of totally MHC-mismatched
renal allografts in cynomolgus monkeys compared to naive control group
(MST, 38.0 ± 19.7 vs. 6.7 ± 2.5 days, p = 0.0261).
Our previous study proved that sirolimus is a potent immunosuppressant with
10- to 100-fold greater potency than cyclosporine in prevention of allograft
rejection (H. Chen, et al, J Immunol. 1994; 15: 3107?18). To reach feasibility to
clinical transplantation, our study addressed the hypothesis of whether a shortterm sirolimus therapy will profit the generation of the CD4+CD25+ regulatory
T cells in vitro, and whether exposure of CD4+CD25+ T cells to sirolimus
can preserve suppressive function of regulatory T cells and can prolong the
allograft survival.
Our results showed that low-dose sirolimus (< 50 nM) could permit the
expansion of cynomolgus CD4+CD25+FoxP3+ regulartory T cells in vitro.
Our preclinical study is the first report a tolerance-inducing strategy, adoptive
transfer of CD4+CD25+ regulatory T cells combined with sirolimus of 14-day
short-term and low-dose (0.5 mg/kg/day) therapy preserved suppressive
function of regulatory T cells and delayed the onset of renal allograft rejection
in cynomolgus monkeys, compared to the group of sirolimus treatment
alone and controls (MST, 39.3 ± 19.6 vs. 29.0 ± 4.0 days and 6.7 ± 2.5 days,
respectively, p = 0.2602, 0.0229). Even though the cell numbers of CD4+ T
cell subsets were found to decrease in peripheral blood, sirolimus selectively
enhanced the ratios of CD4+CD25+ regulatory T cells to CD4+ T cells. In
addition, the frequency of CD4+CD25+IL-10+ (type 1 regulatory cells) cells
was elevated in combined treated monkeys. This study provides a platform for
forthcoming preclinical study of regulatory T cells in nonhuman primates as
cellular immunomodulators.
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Na level by ≥5 mmol/L from baseline in isolated hypoNa.
Results: Between August 2003 – February 2007, 85 patients (61M, 24F) with
median age of 52 years (range 27-78) were treated with terlipressin. Seventysix patients received 1 course of terlipressin, 6 received 2 courses, and another
3 received 3 courses (total courses = 97). Indications for terlipressin were type
1 HRS (13). type 2 HRS (41). nonHRS renal failue (18). and isolated hypoNa
(25). Median duration of treatment was 6 days (range 1-60). Baseline MELD
score was >25 in 79%. Aetiology of liver failure was mostly viral hepatitis
(42%) and alcohol (41%). For all indications, terlipressin resulted in an
overall improvement in serum creatinine from a median of 164 to 116 μmol/L
(p=0.001) and an increase in serum Na from a median of 128 to 134 mmol/L
(p<0.001). Response rates for type 1 HRS, type 2 HRS, nonHRS renal failure
and isolated hypoNa were 15%, 51%, 39% and 76% respectively. There were
26 (27%) adverse events (19 pulmonary oedema, 2 cyanosis, 3 chest pain, 1
livedo reticularis and 1 bleeding ischaemic gastric ulcers). After the initial
terlipressin therapy, the follow-up duration was 27 days (range 1-1248). The
overall mortality was 66%. In the survival analysis, those who responded to
their initial terlipressin therapy had a significantly better survival (p=0.004).
The median survival of patients who responded was 65 days compared to 16
days in those who did not respond. Thirteen (15%) patients underwent liver
transplant after terlipressin therapy and these individuals had a significantly
greater survival (p<0.001). The 30-day survival rate was 85% in patients who
were transplanted and only 31% for those who did not have a liver transplant.
Conclusions: Terlipressin therapy resulted in improved renal function and
increased serum Na in patients with advanced liver failure. However, overall
prognosis is poor without liver transplant. Those who responded to terlipressin
survived longer, allowing these patients to be listed for liver transplant.
Therefore, terlipressin may be used as a bridging therapy in patients with renal
failure and isolated hypoNa who are awaiting liver transplant.
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DIRECT FUNCTIONAL ACTIVATION OF
CD4+CD25+FOXP3+ T CELLS BY INTRAVENOUS
IMMUNOGLOBULINS PROMOTES SKIN ALLOGRAFT
ACCEPTANCE
A.R. Bushell2, T. Tha-In1,2, J. Kwekkeboom1, H.J. Metselaar1, K.J. Wood2
Erasmus Medical Center, Rotterdam, The Netherlands, 2Nuffield Department
of Surgery, Oxford, United Kingdom
Intravenous Immunoglobulins (IVIg) is an effective treatment for T cell mediated
graft rejection and autoimmune diseases. IVIg treatment is associated with rapid
clinical improvements without the side effects of global immunosuppression.
This prompted us to ask whether IVIg might enhance directly the suppressive
function CD4+CD25+Foxp3+ regulatory T cells in vitro and in vivo.
In vitro, mouse CBA/Ca (H2k) total CD4+ or CD4+CD25- responder cells
were stimulated with C57BL/10 (H2b) splenocytes, and human CD4+ or
CD4+CD25- cells were stimulated with allogeneic antigen presenting cells.
In vivo, 1*105 total CD4+ or CD4+CD25- T cells of CBA/Ca mice were
adoptively transferred into CBA/RAG1-/- mice, and one day later transplanted
with a tail skin graft of C57BL/10 mice. IVIg was administered i.v. on day
1,3,7,10 and 14. Human Serum Albumin (HSA) was used as a control. Binding
of IVIg and activation status of Foxp3+ CD4+ T cells were determined.
In vivo, only when total CD4+ T cells, but not CD25- T cells, were adoptively
transferred, IVIg protected against T-cell mediated rejection of the fully
mismatched skingraft (MST: IVIg >100 vs HSA 16 days, p<0.01). IVIg binds
to 16±2% of Foxp3+ T cells, while binding to Foxp3- T cells was minimal.
Furthermore, IVIg treatment resulted in activation of CD25+ T cells as
detected by increased expression of phosphorylated ZAP70/Syk, which could
be abrogated by specific tyrosine kinase inhibition. In vitro, IVIg inhibited
the alloproliferative response of murine CD4+ T cells by 75±25%, but after
depletion of CD25+ T cells, this inhibition decreased to 17±12% (N=6, p<0.01).
Similar results were found in human MLR, where depletion of CD25+ T cells
resulted in twofold reduction in IVIg mediated suppression. Significantly,
incubation of human CD4+CD25+ with IVIg enhanced their ability to suppress
allogeneic T-cell proliferation (IVIg 63±8% vs HSA 37±10% of inhibition,
N=5, p<0.05) .
Our results identify a novel pathway through which IVIg treatment induces
direct functional activation of both mouse and human regulatory T cells.
Immediate binding and activation of regulatory T cells is one of the mechanisms
in the immunomodulatory repertoire of IVIg, which allows rapid inhibition
of allogeneic responses, and therefore can be a valuable tool after organ
transplantation.
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MAINTENANCE OF TREG POPULATION AND
PROLONGATION OF ALLOGRAFT SURVIVAL BY
HEPATOCYTE GROWTH FACTOR IN MHC-INBRED CLAWN
MINIATURE SWINE
M. Oku1, M. Okumi1, H. Sahara1, H. Tsubouchi2, A. Shimizu1, M. Sada1,
K. Yamada1
1
Frontier Science Research Center, Kagoshima University, 2Department of
Digestive and Life-style Related Disease, Kagoshima University
Aims: We have previously reported that 12 days of FK506 facilitates the
induction of tolerance to fully allogeneic kidneys in MGH miniature swine.
The aims of this study are (1) to determine whether the same regimen facilitates
the induction of tolerance to fully allogeneic kidneys in DNA-typed MHCinbred CLAWN miniature swine; and, if not, (2) whether hepatocyte growth
factor (HGF) has beneficial effects on graft functions.
Methods: 7 CLAWN miniature swine recipients received fully MHC
mismatched kidneys with 12 days (days 0-11) of FK506 in an identical manner
to that used for MGH miniature swine. Average blood levels were maintained
between 35 and 45ng/ml, which uniformly facilitates the induction of tolerance
to renal allografts across fully MHC mismatched barriers in MGH miniature
swine. Four recipients received FK506 alone (Group 1) and three received 12
days of FK506 with either 7 days (0.03mg/kg/day) or 14 days (0.015mg/kg/
day) of HGF starting at day 11 (Group 2) infused through a catheter placed in
the renal artery. Statistics were calculated using Students t-test.
Results: In contrast to our previous report in MGH miniature swine, no animal
treated with FK506 alone (Group 1) became tolerant despite using an identical
protocol. These recipients developed either a severe acute rejection crisis (Cre
>9mg/dl) or complete rejection within 3 weeks post KTx. In contrast, all three
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recipients that received HGF (Group 2) maintained stable renal function in
the first 2 months, although grafts were eventually rejected beyond day 80.
Although creatinine levels were similar between the groups immediately after
discontinuing FK506 (1.9 mg/dl Group 1 vs. 1.9 mg/dl Group 2 at day 13).
there was a significant difference in the creatinine levels 7 days after cessation
of FK506 (9.5 mg/dl Group 1 vs. 1.9 Group 2 at day 18, p=0.002). Notably,
a marked decrease in the percentage of CD4+CD25+Foxp3+ cells in the
peripheral blood during the induction period was seen in Group 1, while HGF
treated recipients maintained this population (p<0.02).
Conclusions: This study demonstrates: (1) a 12 day course of FK506 failed to
induce tolerance across full MHC mismatched barriers in CLAWN miniature
swine; (2) a short course of HGF inhibited acute rejection and was associated
with higher levels of CD4+CD25+Foxp3+ Tregs. These data suggest that
CLAWN miniature swine may be a more stringent large animal model to
test pre-clinical tolerance protocols and that a short course of HGF prolongs
renal allograft function and may either augment or maintain Treg cells. To
our knowledge, this is the first demonstration of the immunoprotective effect
of HGF in a large animal model and suggests that HGF may be useful as an
adjunct to induce tolerance by regulatory mechanisms.

23
ALLOGRAFT TOLERANCE AFTER IN VIVO EXPANSION
OF TREGS WITH IL-2/IL-2 MAB COMPLEXES
K. Webster1, S. Walters1, T. Mrkvan1, O. Boyman2, S. Grey1, J. Sprent1
Garvan Institute of Medical Research, 2Ludwig Institute for Cancer Research
Regulatory T cells (Tregs) are a small subset of lymphocytes crucial to tolerance;
they actively mediate unresponsiveness to self-antigens and negatively regulate
responses to foreign antigens. This capacity for such comprehensive regulation
holds therapeutic promise for many fields of medical biology, including that
of transplantation. Indeed the ability of these cells to diminish the allogeneic
response to a graft has been well documented in animal models. However, graft
acceptance can only be achieved when large numbers of Tregs are present, as
at 5-10% of CD4+ T cells they are too few to elicit this outcome. While in vitro
methods for the expansion of Tregs are the subject of much research, the in
vivo expansion of these cells is also desirable.
In vivo, interleukin 2 (IL-2) is required for maintenance of peripheral Tregs, and
stimulates these cells by binding to a trimeric high-affinity receptor, composed
of an α; chain (CD25). β; chain (CD122) and γ;c chain. By contrast, a dimeric
intermediate-affinity β;γ; receptor is expressed by “resting” T cells, such as
memory CD8+ T cells, and NK cells. Hence, depending on the cell stimulated,
IL-2 can effectively suppress or boost the immune response. Recently, a novel
approach to enhancing IL-2 mediated T cell proliferation was observed in our
laboratory (Boyman et al. 2006). The combination of IL-2 and an IL-2 antibody
(clone S4B6). was found to stimulate the proliferation of T cells bearing the
β;γ; receptor, to a far greater extent than cytokine alone. In contrast, the
combination of IL-2 with IL-2 antibody clone JES6-1, selectively enhanced the
Treg (α;β;γ; receptor) population. Thus the potential exists to utilise IL-2/IL-2
mAb complexes to stimulate different subsets of IL-2 responsive cells, and thus
direct the immune response towards immunity or tolerance.
We found that administration of IL-2 and IL-2 mAb clone JES6-1 to mice,
rapidly and selectively boosts the Treg population to 50-60% of CD4+ T cells.
Intriguingly, these Tregs upregulated cell surface molecules important for
activation, adhesion, migration and suppression, showed enhanced function in
in vitro suppression assays, and demonstrated significant proliferation to IL-2
in the absence of TCR stimulus. To test the efficacy of these expanded Tregs in
restraining an allogeneic immune response, we utilised an islet allograft model.
C57BL/6 mice were treated with IL-2/IL-2 mAb (JES6-1) complexes prior to
transplantation to achieve optimal Treg expansion and function. As expected,
control C57BL/6 H-2b mice rejected their H-2d islet allografts with a MST of
~19 days (n=10). In marked contrast, 80% of IL-2/IL-2 mAb treated C57BL/6
mice did not reject their H-2d islet allografts (MST >100 days, n=22). We are
currently examining the response to secondary BALB/c allografts to determine
the nature of tolerance. The survival of grafts long term after only a short
treatment protocol, and in the absence of constitutively high numbers of Tregs
or immunosuppressive drugs, holds potential for therapeutic application.
1
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IMMUNOMODULATION INDUCED BY A CD28
ANTAGONIST IN KIDNEY ALLOGRAFT BABOON RECIPIENT.

25
INFUSION OF ALLOGENEIC MESENCHYMAL
STROMAL CELLS CAN DELAY BUT NOT PREVENT GVHD
AFTER MURINE TRANSPLANTATION
M. Kambouris, B. Turner, L. Sinfield, H. Cullup, D. Hart, K. Atkinson,
A. Rice
Mater Medical Research Institute
Multipotent, mesenchymal stromal cells (MSC) are emerging as means
of immunosuppression for patients with steroid refractory graft-versushost disease (GVHD). Despite clinical use, pre-clinical data is lacking. We
established an in vivo model using MSC to control GVHD and determine
their mode of immunosuppression. In vitro our MSC highly suppress T cell
proliferation, even at low ratios of 1 MSC per 100 T cells. We then examined
the effects of donor-derived intraperitoneally (IP) or intravenously (IV) injected
MSC on GVHD in a myeloablative conditioned, full mismatched model of
haematopoietic stem cell transplantation (HSCT) [UBI-GFP/Bl6 (H-2b) to
BALB/c (H-2d) ]. 4x10*5 donor-derived MSC/mouse were injected 4hrs pre or
24hrs post HSCT then mice were monitored daily for GVHD. Only mice given
MSC IP 24hrs post HSCT showed a signficant delay in death from GVHD,
where median survival was increased by 10 days (d) (d7 vs d17, p<0.001.
We then investigated if MSC delivered IP pre or post HSCT altered cytokinedriven trafficking of cellular effectors known to play a role in GVHD via timed
sacrifice. Control mice (HSCT and no MSC or MSC and no HSCT) were also
sacrificed daily for 6 days following HSCT. We found that MSC given postHSCT enter an environment of significantly increased activated dendritic cells
(DC) in the spleen and at d3 and d6 post HSCT, mice given MSC pre HSCT had
increased levels of activated splenic DC compared to mice treated with MSC
24hrs later. At d3, we also saw more IFN-gamma in spleen washings in mice
treated pre HSCT compared to controls. We then determined the role of MSC in
GVHD control in a minor mismatch model [UBI-GFP/Bl6 (H-2b) to BALB.B
(H-2b) ]. MSC were given various MSC infusions, either: d1, 7, or 14; d1 and

26
MECHANISMS OF ANTIGEN-SPECIFIC SUPPRESSION
MEDIATED BY DOUBLE NEGATIVE REGULATORY T CELLS
Z. Li1, M. Ford1, K. Young1, J. Gao1, B. Joe1
1
University Health Network, 2University of Toronto, 3Toronto General
Research Institute
Regulatory T (Treg) cells, found in both mice and humans, have been
demonstrated to play an important role in controlling the development of
various immune pathologies including transplant rejection and autoimmune
disease development. Recent data have demonstrated that treatment with
ƒÑƒÒ-TCR+CD3+CD4-CD8-NK1.1- (double negative, DN) Treg cells
can inhibit autoimmune diabetes development and enhance allo- and xenotransplant survival in an antigen-specific fashion. However, the mechanisms
of DN Treg cell-mediated antigen-specific suppression of immune responses
remain largely unknown. Here, we demonstrate that DN Treg cells can acquire
donor alloantigens and present these antigens on their cell surface following
alloantigen exposure in vivo. Furthermore, only DN Treg cells that had
acquired high levels of alloantigen in vivo were able to induce cytotoxicity of
primary activated syngeneic CD8+ T cells. DN Treg cell acquisition requires
specific interaction between the high affinity peptide/MHC and the specific
T cell receptor. Interestingly, activated B cells are more efficient than mature
dendritic cells at donating alloantigens to DN Treg cells. Furthermore, DN Treg
cells are able to kill dendritic cells but not B cells. These data provide new
insights into how Treg cells can mediate antigen-specific T cell suppression and
may enhance our ability to use DN Treg cells as a therapy to prevent transplant
rejection and autoimmune diseases.

27
PRO-TOLEROGENIC PROPERTIES OF RAPAMYCIN
THAT FAVOR INDEFINITE HEART ALLOGRAFT SURVIVAL
MEDIATED BY REGULATORY T CELLS.
G. Raimondi1, B. Matta1, P. Santos1, Z. Wang1, A. Thomson1,2
1
TE Starzl Transplantation Institute – Dep of Surgery, University of
Pittsburgh, 2Dep of Immunology, Univrsity of Pittsburgh
A short course of Rapamycin (Rapa; 1mg/Kg/day i.p. d0-9) combined with
post-transplant infusion of allo-Ag specific Treg (AAsTreg; d7) promotes
tolerance induction in a mouse vascularized heart transplant model (BALB/c
to C57BL/10 [B10]; unmanipulated). We investigated the cellular effects
associated with Rapa administration that permit (and are probably necessary
for) the success of the protocol.
Method: B10 naïve animals and B10 recipients of BALB/c hearts received
Rapa (1mg/Kg/day i.p.; 7 days) or were untreated. The T cell profile in
different lymphoid compartments was evaluated. Additionally, ex vivo T cell
reactivity against donor-derived DC and susceptibility to Treg suppression
were investigated.
Results: Administration of Rapa to naïve animals significantly reduced lymph
node T cell absolute numbers (abs#) (approx 2-fold). but the incidence of CD4+,
CD8+, and Foxp3+ cells was preserved. Splenic T cell abs# were not altered,
but the incidence of CD4+ and CD8+ cells was increased. Strikingly, the abs#
and incidence of splenic Foxp3+ cells was markedly reduced. Rapa exerted a
striking effect on the thymus: total cellularity was reduced 8-fold. The frequency
of double-negative (DN) cells was markedly increased, while that of doublepositive (DP) cells was reduced. The proportion of single-positive (SP) cells rose
significantly and, strikingly, among the CD4+ SP cells, the frequency of Foxp3+
cells increased 3-fold. Administration of Rapa to heart allograft recipients
exerted distinct effects. Splenic and lymph node T cell abs# dropped (greater
effect on CD4+ than CD8+ cells). but the proportion of Foxp3+ T cells increased
significantly. CD4 T cells purified from spleens of transplant recipients treated
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N. Poirier1, C. Mary1, E. Allain-Launay1, T. Haudebourg1, K. Renaudin2,
X. Tillou1, S. Le Bas-Bernardet1, K. Georges1, B. Vanhove1, G. Blancho1
1
INSERM Unit 643, 2Anapathology unit, CHU Hotel Dieu
Aims: Blocking selectively the CD28/B7 activation pathway and not the
CTLA-4/B7 inhibitory pathway during initial antigen exposure, is one
promising candidate strategy to promote tolerance. Here, we studied such a
blockade in a baboon kidney allograft model using sc28AT, a non activating
monovalent CD28 antagonist, alone and in combination with Tacrolimus.
Methods: Papio anubis received life-supporting kidney allografts (full MHC
class II mismatch, stimulation index >10). The animals were divided into four
groups: A) control group (untreated, n=3); B) sc28AT induction monotherapy
(daily i.v. 4mg/kg during the first 25 days, n=4); C) Tacrolimus monotherapy
(through level: 10-20 ng/ml upon 90 days, n=4) and D) combination of group
B and C (n=4).
Results: Although sc28AT monotherapy modestly prolonged graft survivals
at this dosage (mean survival 10,5±1.8 d. vs 6.6±0.3 d. for control group) it
induced a down-modulation of CD28 expression in circulating T cells without
modification of T cell counts and no cytokine storm. At rejection, we observed
an inhibition of B cell infiltration, an increase of CTLA4-positive T cells in the
cellular infiltrates and an enhancement of IDO and HO-1 expression within
the graft. Tacrolimus monotherapy was suboptimal in prolonging graft survival
(50% of acute rejection at one week and 50% at the treatment discontinuation).
whereas selective blockade of CD28 potentiated Tacrolimus in preventing
acute graft rejection (no early rejection episode in the first month). Moreover,
circulating CD4 CD25+ Foxp3+ CD127low regulatory T cells were quickly
increased in bitherapy recipient (from day 1 or 2). These recipients exhibited
at one month a nearly 4-fold increase in Tregs as compared with Tacrolimus
monotherapy recipients (4,7±0,8% of CD4 T cells vs 1,2±0,3% respectively).
Finally, CD25+ T cells extracted from these bitherapy recipients were found to
be suppressive even in a ratio of 1 CD25+ to 128 CD25- cells.
Conclusion: Blocking CD28/B7 and not CTLA4/B7 interactions in baboon
with an antagonist monovalent Ab against CD28 revealed no immunological
toxicity, synergized with Tacrolimus in preventing acute rejection, promoted
upregulation of immunomodulatory mechanisms and enhanced the proportion
of circulating Tregs.

d7; or to mice with established GVHD (>25% weight loss with other surrogate
GVHD markers more than 14d post HSCT). Mice given MSC therapy after
GVHD onset showed no increase in survival compared to controls. However,
MSC administered prophylactically at d1 (4x10*5/mouse) or d7 (1x10*6/
mouse) showed significantly increased survival compared to controls but not
in the multiple injection (d1 and d7) or the d14 alone cohorts, suggesting that
the timing of MSC administration is important for their impact on GVHD. In
summary, IP injection of MSC influences GVHD and survival and may have
in vivo influence on activated DC. Elucidation of the mechanism by which
MSC control GVHD may ultimately lead to wider application of their use to
assist HSCT.
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with Rapa showed stronger ex-vivo reactivity to donor DC than cells from naïve
animals, confirming that Rapa permits T cell priming but promotes anergy
induction and/or conversion to Foxp3 expression. Additionally, CD4 T cells
isolated from untreated recipients showed a significant degree of “resistance”
to in vitro suppression of proliferation by titrated numbers of Treg. Such
“resistance” was not evident in T cells from Rapa-treated recipients. Moreover,
Rapa treatment prevented allograft T cell infiltration, and elevation of serum IL-6
(responsible for the observed T cell “resistance” to Treg suppression). Finally,
preliminary results indicate the capacity of Rapa to significantly reduce the
proliferative capacity of in vitro-generated memory T cells, whose contribution
to transplant rejection has been well demonstrated.
Conclusion: Rapa contributes to tolerance induction at multiple levels. It
lowers circulating T cells by reducing thymocyte development and favors Treg
ontogeny. In transplant recipients, Rapa causes additional T cell decreases that
correlate with its ability to favor activation-induced cell death (AICD). The
increased proportion of splenic Foxp3+ cells correlates with both the Tregsparing properties of Rapa and its reported induction of Foxp3 in T cells.
Finally, Rapa exerts significant anti-inflammatory activity that favors Treg
suppressive function, even at the level of memory T cell regulation.

CONCURRENT ORAL SESSION 4:
CORNEA AND BIOARTIFICIAL ORGANS
28
PROLONGATION OF CORNEAL GRAFT
SURVIVAL FOLLOWING ADMINISTRATION OF
3-HYDROXYKYNURENINE.
A. Khan, A. George1, S. Zaher1, C. Germain1, H. Fu1, and F. Larkin2
Department of Immunology, Division of Medicine, Imperial College London,
Hammersmith campus, London, UK and 2Moorfield’s Eye Hospital, London. UK.
Indoleamine 2,3-dioxygenase (IDO) has been shown to prolong corneal graft
survival. IDO modulates the immune response by depletion of the essential amino
acid tryptophan and by the production of kynurenines which act directly on T cells.
We have therefore investigated the role of the kynurenines in corneal graft rejection.
In order to assess the effect of kynurenines on T cell responses, the molecules
were added into both mixed lymphocyte reactions and anti-CD3/CD28 bead
stimulation of T cells. In both human and mouse 3-Hydroxykynurenine (3-HK)
and 3-Hydroxyanthranilic acid (3-HAA). but not L-Kynurenine or Quinolinic
acid, inhibited T cell proliferation. This was accompanied by significant cell T
cell death. There is no evidence of induction of regulatory T cells as shown in
the mouse by failure to induce FoxP3 expression. Neither 3-HK nor 3-HAA
has a major effect on dendritic cell function, nor do they affect apoptosis or the
activation status of corneal endothelial cells.
In order to determine if these agents can prolong graft survival we carried
out corneal allografts in a murine model. Administration of 3-HK on a daily
basis to BALB/c mice receiving a C3H corneal graft resulted in considerable
prolongation of graft survival (MST of controls = 12 days, of treated = 19
days). This was seen when the 3-HK was given between day 1-7, 7-14 or 1-14.
Chronic administration of 3-HK resulted in no significant alteration in CD4,
CD8 or FoxP3 positive splenic T cells.
These data therefore indicate that one mechanism by which IDO prolongs
corneal graft survival is by the production of kynurenines, in particular 3-HK
and 3-HAA. In addition it highlights the potential of these molecules as agents
for preventing allograft rejection.
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29
EFFICACY OF A STEROID-INDUCIBLE PROMOTER FOR
LENTIVIRUS-MEDIATED TRANSDUCTION OF THE CORNEA
S. Klebe, D. Parker, A. Clarke, H.M. Brereton, D.J. Coster, K.A. Williams
Flinders University
Corneal transplantation can restore vision to patients with corneal opacities.
The evidence for efficacy of systemic immunosuppression in such patients is
extremely limited. Topical corticosteroids are currently prescribed long-term
in all patients for prophylaxis and treatment of graft rejection, but are tapered
in eyes with stable grafts. Kaplan-Meier corneal graft survival within Australia
is 51% at 15 years, and the most common cause of failure is immunological
rejection. Ex vivo gene therapy directed at the donor cornea shows promise
for modulating corneal transplant rejection in animal models and may
eventually provide adjunctive treatment for humans. Use of an appropriate
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viral vector coupled with a glucocorticoid-sensitive promoter might permit
inducible expression of a therapeutic transgene after administration of a
topical ophthalmic steroid. Ophthalmic steroids penetrate the eye effectively,
and topical administration would provide a convenient method for controlling
transgene expression.
Aim: Our aim was to investigate a steroid-inducible promoter for use in gene
therapy of the cornea.
Methods: A 320 base pair sequence encoding five glucocorticoid response
elements (GRE) from the rat tyrosine aminotransferase gene, upstream of the
adenovirus 2 major late promoter TATA box/initiation site was cloned into a
non-replicative, self-inactivating, VSVG-pseudotyped lentiviral vector (LV)
carrying the ovine interleukin 10 (IL10) gene. A similar vector carrying the
simian virus 40 (SV40) promoter was used for comparative purposes. A549
cells and ovine and human corneas were cultured in vitro in the presence or
absence of dexamethasone. Transgene expression was assessed by an ovine
IL10-specific ELISA.
Results: A549 cells were transduced with LV-GRE-IL10 and cultured for 48
hours in medium containing 0, 2.5 nM, 50 nM or 1000 nM dexamethasone.
Expression of secreted IL10 was 45-fold higher in samples from cells cultured
in the presence of 50 nM and 1000 nM dexamethasone than in the absence of
dexamethasone. Dexamethasone withdrawal resulted in the return of secreted
IL10 to control levels. Ovine corneas were transduced with LV-GRE-IL10
and organ-cultured in the presence or absence of 50 nm dexamethasone.
Basal expression of IL10 was low in the absence of dexamethasone. After 9
days of organ culture, supernatants from corneas transduced with LV-GREIL10 and cultured with glucocorticoid contained 9 times the concentration
of IL10 detected in supernatants from control corneas, and 3 times more
than supernatants from corneas transduced with LV-SV40-IL10 at the same
multiplicity of infection. Human corneas were then transduced with LVGRE-IL10 or LV-SV40-IL10 and organ-cultured for 9 days in the presence or
absence of 50 nM dexamethasone. Levels of IL10 in supernatants from corneas
transduced with LV-GRE-IL10 or LV-SV40-IL10 were approximately 14 times
and 12 times higher, respectively, than in supernatants from transduced corneas
cultured without dexamethasone.
Conclusions: Transduction with a lentiviral vector containing a steroidinducible promoter resulted in a 35-fold upregulation of IL10 expression in
A549 cells and a 9-fold upregulation in transduced ovine and human corneas.
The expression levels were equivalent to (human). or superior to (ovine) levels
achieved by a vector containing the SV40 promoter. The promoter showed low
leakiness in the absence of dexamethasone.

30
LENTIVIRUS-MEDIATED GENE TRANSFER TO THE
OVINE AND HUMAN CORNEA
D. Parker, S. Klebe, H.M. Brereton, D.J. Coster, D.S. Anson, K.A. Williams
Flinders University
Patients disabled by blinding corneal disease can be treated surgically by
corneal transplantation, but many grafts fail from allograft rejection. Gene
therapy of the donor cornea can modulate corneal transplant rejection in
experimental animals but the most appropriate vector for gene transfer has yet
to be determined.
Aims: Our aims were to explore the use of a recombinant, non-replicative, selfinactivating, VSVG-pseudotyped lentivirus in the ovine and human cornea.
Methods: Lentivectors (LV) that carried the enhanced yellow fluorescent
protein (eYFP) gene under the control of the simian virus 40 early (SV40)
promoter, the phosphoglycerate kinase (PGK) promoter, and the elongation
factor-1α; (EF) promoter, or that carried the ovine interleukin 10 (IL10) gene
under the control of the SV40 or the cytomegalovirus (CMV) promoter, were
constructed. Ovine and human corneas were transduced in vitro and organcultured for up to 15 days. LV-mediated expression in transduced ovine and
human corneal endothelium was assessed by fluorescence microscopy, realtime quantitative RT-PCR or ELISA. Gene expression was compared with
expression driven by analogous adenoviral vectors following alterations of
transduction period duration and vector dose, as well as in the presence or
absence of polybrene. The stability of eYFP expression in ovine corneas and the
influence of IL10 expression on graft survival following ex vivo transduction
of the donor cornea was assessed following orthotopic corneal transplantation
in outbred sheep.
Results: LV-SV40-eYFP transduced 80-90% of ovine corneal endothelial cells
after in vitro organ-culture, and eYFP expression was maintained for at least
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RISK FACTORS FOR FULL-THICKNESS HUMAN
CORNEAL GRAFT FAILURE WITHIN THE AUSTRALIAN
CORNEAL GRAFT REGISTRY
K. Williams, T-L. Kelly, M. Lowe, C. Bartlett, D. Coster
Flinders University
Aims: Our aims were to examine graft survival and visual outcome after
corneal transplantation and to identify risk factors for graft failure within a
large, prospective national register.
Methods: Records of 17,090 full-thickness (penetrating) corneal grafts were
examined within a prospectively-maintained, national database, with annual
archival follow-up extending from one to 22 years. Information was available
on the recipient, donor, eye bank practice, surgical procedure, and on postoperative outcomes. Kaplan-Meier survival analysis was used to indicate
variables of interest for Cox proportional hazards regression analysis. A model
clustered by individual patient to control for inter-eye or inter-graft dependence
was constructed to identify variables best predicting penetrating corneal graft
failure. Visual acuity in the grafted eye was measured by best-corrected Snellen
acuity (without pinhole).
Results: The major indications for corneal transplantation were keratoconus
(32%). bullous keratopathy (26%). failed previous graft (19%). corneal
dystrophy (7%). and herpetic eye disease (4%). Probability of corneal graft
survival was 0.87 at one year, 0.73 at 5 years, 0.62 at 10 years and 0.51 at
15 years. Variables predicting graft failure in multivariate analysis included
transplant centre, location and volume of surgeon’s case-load, graft era,
indication for graft, number of previous ipsilateral grafts, lens status, corneal
neovascularisation at the time of graft, history of ocular inflammation or
raised intraocular pressure in the eye to be grafted, graft diameter, early suture
removal, and post-operative events including graft neovascularisation, rejection
episodes, need for refractive surgery to the grafted eye, and arrangements
for recipient follow-up. No factors relating to the donor (including donor
age) or to eye bank practices (including corneal preservation time) could be
demonstrated to influence graft survival in multivariate analysis. The major
reasons for corneal graft failure were irreversible rejection (31%). corneal
endothelial cell failure (21%). infection including recurrent herpetic keratitis
(13%) and glaucoma (8%). The desired outcome of corneal transplantation was
improvement in vision (70%). pain relief (4%). structural repair of a damaged
globe (6%). improved cosmesis (<1%) or a mixture of two or more of these
reasons (19%). A best-corrected Snellen acuity of 6/12 or better was achieved
by 45%, and of less than 6/60 by 26%, of grafted eyes at last follow-up.
Conclusions: The short-term survival of penetrating corneal transplants is
excellent, but long-term outcomes are no better than for vascularized organ
transplantation. The attrition rate of corneal grafts is slow but inexorable.

32
COMPARISON OF IMMUNOSUPPRESSION RELATED
TOXICITIES AND COMPLICATIONS IN OCULAR
SURFACE TRANSPLANT AND RENAL TRANSPLANT
RECIPIENTS: IMPLICATIONS FOR COMPOSITE TISSUE
TRANSPLANTATION
G. Mogilishetty1, D. Hair2, R.R. Alloway1, M.J. Everly2, L. Cole1, M. Meyer1,
A. Govil1, P. Roy-Chaudhury1, E.J. Holland2 and E.S. Woodle1.
1
Transplantation and 2Cincinnati Eye Institute, University of Cincinnati,
Cincinnati, OH.
Body: Ocular surface transplant (OST) differs from routine cornea transplant
by exposure to surrounding vascularized recipient tissue, enhancing rejection
risk. Improved OST results are achieved with systemic immunosuppression
(IS). We evaluated OST and renal transplant (RT) patients (pts) managed at the
same center to determine differences.
Methods: Pts receiving OST or RT were retrospectively analyzed at
0,3,6,12,24mos post transplant for demographics, IS exposure, efficacy and
toxicity variables. The RT matched control was based upon IS regimen and
followup. Anemia defined as Hct<35%. Leukopenia defined as WBC<4000.
Results: 66pts received 74 OST and were compared to 32 RT. Demographic
characteristics of gender, age, and primary transplant were similar between
the groups. IS maintenance of tacrolimus, Cellcept (MMF). and steroids was
similar between groups, with RT receiving Simulect induction. IS exposure is
summarized
below.
Immunosuppression Exposure
IS Agent @ 0, 3, 6, 12, 24, 36mo
Prednisone mean dose (mg/d)
MMF mean dose (G/d)
Mean tacrolimus level (ng/mL)

OST (n=66)
-, 11, 9, 10, 5, 1.5, 1.5, 1.3, 1.1, 1.2
7.2, 7.9, 7.8, 6.7, 6.8, -

RT (n=32)
164, 9, 6, 5, 4, 5
2.1, 2.1, 2.1, 1.9, 1.6, 1.5
1.6, 9.0, 8.6, 8.2, 7.6, 6.7

Outcome and toxicity variables are summarized below. 95% of OST pts visual
acuity scores improved, with 53% >20/200. No reports of PTLD.
Outcome and IS Toxicity Variables
Variable
Mean Followup (yrs)
Rejection (%)
Graft Survival (%)
Patient Survival (%)
SrCr (mg/dL) at 0, 3, 6, 12,
24mo
New onset HPT@1yr (%pts)
New Onset DM (%pts)
Cardiovascular Event (%pts)
Anemia@1yr (%pts)
Leukopenia@1yr (%pts)
Infection (%pts)

OST (n=66)
2.0 + 1.6
19%
77%
100%
0.9, 1.0, 1.0, 1.0,
0.9, 1.1
5%
2%
2%
13%
0%
5%

RT (n=32)
2.8 + 0.8
25%
97%
94%
7.2, 1.3, 1.3, 1.4,
2.2, 1.5
9%
9%
13%
9%
13%
16%

p-value
NS
NS
0.006
0.02

<0.0001
NS
NS
0.05
NS
0.001
0.03

Conclusion: OST pts demonstrated remarkably reduced IS related toxicity.
These observations indicate underlying systemic disease significantly
influences IS related toxicity profiles. This experience suggests composite
tissue transplant recipients experience substantially fewer adverse effects with
systemic IS.

33
PERMANENT REVERSAL OF AUTOIMMUNE DIABETES
IN NON OBESE DIABETIC MICE AFTER LENTIVIRAL
HEPATIC INSULIN GENE THERAPY
B. Ren1, B. O’Brien1, M. Byrne1, E. Ch’ng1, M. Swan2, R. Gijsbers3,
Z. Debyser3, A. Simpson1
1
University of Technology Sydney, 2University of Sydney, 3IRC KULAK and
KU Leuven
Type I diabetes (TID) mellitus results from the T-cell mediated autoimmune
destruction of the insulin-producing pancreatic beta cells. Exogenous insulin
therapy cannot mimic the precise physiologic control of blood glucose
concentrations achieved by beta cells and debilitating complications develop
due to fluctuations in blood glucose levels. Gene therapy is one strategy being
actively explored to cure TID by affording non-beta cells the ability to secrete
insulin in response to physiological stimuli. In a recent study, we used a novel
surgical technique to express furin-cleavable human insulin (INS-FUR) in the
livers of streptozotocin diabetic-Wistar rats using the HMD lentiviral vector
(1). Normoglycaemia was observed for 500 days (experimental endpoint). a
significantly longer period than previously reported and this was the first to
report, permanent reversal of diabetes using a lentiviral vector. The aim of the
present study was to determine if our methodology could reverse diabetes in
the most widely used autoimmune model of diabetes, the non obese diabetic
(NOD) mouse. Lentiviral vectors were produced using 293T cells and then
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28 days in vivo in recipient sheep after orthotopic corneal allotransplantation
of a transduced donor cornea. However, the kinetics of LV-mediated gene
expression were slower than those achieved by comparable adenoviral vectors.
Further, 24 hour transduction of ovine corneal endothelium with LV-IL10
resulted in mRNA levels that were logarithmically lower than those achieved
by an adenoviral vector. Shortening the transduction period to 2 hours led to a
further reduction in gene expression. The addition of 40 μ;g/ml polybrene to the
transduction mixture restored expression to levels comparable to those attained
after a 24 hour transduction period, but at the cost of associated toxicity for
corneal epithelium. Allografts transduced for 2–3 hours with LV-SV40-IL10 in
the absence of polybrene were rejected at a median of 25 days (n=7) compared
with 18 days in the combined sham-treated and LV-SV40-eYFP control group
(n=14) (p=0.026). Vectors containing the PGK or EF promoter were not more
effective than LV-SV40-eYFP in driving transgene expression in ovine corneas,
but LV-CMV-eYFP generated significantly better, faster expression at low
multiplicity of infection. Interestingly, LV-mediated eYFP and IL10 expression
was significantly higher and more rapid in organ-cultured human corneas (the
eventual target species of interest) than in ovine corneas.
Conclusions: Ovine and human corneal endothelial cells were efficiently
transduced by the lentiviral vector. LV-SV40-IL10 prolonged ovine corneal
allograft survival to a modest, albeit significant extent. Species differences
were apparent in LV-mediated transduction efficiency, but promoter exchange
significantly improved transgene expression levels.
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purified and concentrated by tangential flow filtration and ultracentrifugation
(40,000g/4h). Following delivery of INS-FUR or empty vector (3.5 x 108
transduction units) to spontaneously diabetic NOD mice (blood glucose
>14mM). mice were monitored for body weight and blood glucose levels.
An intravenous glucose tolerance test (IVGTT) was performed after a 14
h fast in untreated (n=6). empty vector-transduced (n=10) and INS-FURtransduced NOD mice (n=10). together with non-obese resistant (NOR)
mice (n=10) as an additional control. At various times after the infusion of
glucose (1 g/kg body weight). blood samples were collected and assayed for
glucose, c-peptide and insulin. Liver, pancreas, kidney, spleen and lung were
harvested at the experimental endpoint (5 months). Expression of insulin was
determined by RT-PCR, immunohistochemistry, and transmission electron
microscopy. Triple immunofluorescent staining for the pancreatic hormones,
insulin, glucagon and somatostatin was performed on pancreas and liver tissue
sections. Immunofluorescent staining was used to identify CD4+/CD25+ T cell
populations within the spleen.
We have achieved 37„b1.9% (n=5) transduction efficiency of hepatocytes in
vivo. Mice treated with INS-FUR, exhibited reversal of hyperglycaemia within
48h and normoglycaemia was maintained for 5 months, without the induction
of hypoglycemia. IVGTTs revealed that insulin-transduced mice showed
similar responses to elevated blood glucose concentrations as nondiabetic NOR
mice. The transduction procedure resulted in expression of several beta cell
transcription factors (PDX-1, Ngn3, Nkx2.2, Pax4, Pax6). pancreatic hormones
glucagon and somatostatin and significant hepatic insulin storage in granules
characteristic of beta cells. No beta cell transcription factors or pancreatic
hormones were expressed in the livers of animals treated with the empty
vector alone. Liver function tests remained normal and there was no evidence
of lymphocytic infiltration in the livers of HMD/INS-FUR-treated animals.
Numbers of CD4+/CD25+ T cells by immunoflurescent staining, significantly
increased (P<0.01) in HMD/INS-FUR treated NOD diabetic mice. Importantly,
pancreatic exocrine transdifferentiation did not occur. Our data suggest that this
regimen may ultimately be employed clinically to cure TID.

34
IMPROVED OUTCOME OF PORCINE HEPATOCYTE
TRANSPLANTS IN ACUTE LIVER FAILURE RATS BY
CULTURE WITH NANOPARTICLES AND COLLAGEN
Z. Chen1, W. Zhu1, W. Guan1, H. Cai1, F.Tang1, L. Lu2, S. Qian2
1
Hepatobiliary Surgery, Nantong University Affiliated Hospital, 2Department
of Immunology and General Surgery, Cleveland Clinic
Acute liver failure (ALF) is a life-threatening condition with high mortality.
Due to the potent regeneration capacity of the liver, temporary liver function
support, by hepatocyte transplantation may provide critical time for ALF
patients to recover through liver regeneration. Use of xenogeneic hepatocytes is
considered an approach to relief of limited hepatocyte sources, but the outcome
has been poor due to profound immune responses including both cellular and
humoral. In this study, we used a novel approach; porcine hepatocytes were
cultured with polylactic acid-O-carboxymethylated chitosan (PLA-O-CMC)
nanoparticles, embedded in rat collagen gel. The gel blocks were transplanted
into the peritoneal cavity of SD rats whose ALF was induced by i.p. injection
with D-galactosamine (gal). 48 hr after D-gal injection, 5 x l07 porcine
hepatocytes alone (Group A). porcine hepatocytes embedded in collagen gel
(Group B). and porcine hepatocytes cultured with PLA-O-CMC nanoparticles
plus embedded in collagen gel (Group C) were transplanted (n=55 in each
group). Without hepatocyte transplant, only 18.5% animals survived by POD
14. Porcine hepatocyte transplant significantly improved animal survival (Group
A, 56.3%, Group B, 62.5%, Group C, 75%, all p<0.05 compared to controls).
Plasma levels ofHGF and VEGF, which have been widely used for indication
of liver regeneration in ALF, were monitored following transplantation. Plasma
HGF was elevated posttransplantation with a peak at 12 hr, and declined
thereafter. Plasma VEGF levels were peak at 72 hr post-transplant. Group C
showed significantly higher plasma HGF and VEGF levels, compared with
other groups. Liver pathologic examination showed more hepatocytes with
double nuclei, richer mitochondria and rough endoplasmic reticulum in Group
C rats, suggesting active regeneration. In conclusion, transplant of porcine
hepatocytes provides a critical time window for hepatocyte regeneration in
this animal model. Nanoparticle plus collagen gel may function as temporary
barriers to attenuate immunological attacks.
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35
TISSUE ENGINEERING USING PARTIAL INTESTINAL
GRAFT AS A POSSIBLE SCAFFOLD FOR LIVER
REGENERATION IN PIGS
T. Hata1,2, S.Uemoto1, E. Kobayashi2
1
Department of Surgery, Kyoto University, 2Division of Organ Replacement
Research, Jichi Medical University
Portal hypertension is serious condition with multiple symptoms such as
ascites, variceal bleeding, encephalopathy and eventually liver failure.
Various therapies including radio-interventional and surgical portosystemic
shunt have been applied, in order to improve it, with the increasing risk of
encephalopathy and possible reduction of effective hepatic blood flow. Once
liver failure occurred, cadaveric and living donor liver transplantation is only
option, whereas limited number of donor results in serious shortness of graft
and causes ethical and social problems all over the world.
To make a breakthrough in this situation, we have developed a new method of
partial intestinal graft as a portocaval shunt, with the strategy to innovate the
effective shunt system with hepatic function, and demonstrated the possibility
for the scaffold of liver regeneration.
First, we established rodent model using luciferase transgenic Lewis (Luc-LEW)
rat as a donor of partial intestine and syngenic Lewis (LEW) rat as a recipient
with anastomosing the host portal vein (PV) trunk with graft artery and host
inferior vena cava (IVC) with graft PV. In vivo bioluminescent imaging showed
graft survival by portal blood flow for 1 month and histologically the graft wall
structures were preserved except mucosa. In another model, we evaluated the
intensity of luminescence from hepatocyts of Luc-LEW rat transplanted into
intestinal lumen of syngenic LEW rat. We confirmed the increase of intensity
by the host hepatectomy, suggesting the possibility of scaffold.
Then, to apply this system to preclinical porcine model, we measured the shunt
volume through porcine partial intestinal graft ex vivo and the satisfactory
results were obtained. According to all results, we established an autotransplantation model in pigs. In this model, we donated terminal ileum, and
engrafted it to the same pig with anastomosis similar to rodent model: the host
PV trunk with graft artery and host IVC with graft PV in side-to-end fashion.
We performed 4 operations using miniature pigs without portal hypertension
and confirmed that sufficient blood supply to the grafts was well observed and
the graft walls were preserved histologically.
We showed that partial intestinal graft can be applied to portocaval shunt in
pig. This new technique might lead to the new concept of intestinal scaffold
with the possible application for various kinds of tissue regeneration from stem
cells.

CONCURRENT ORAL SESSION 5:
GENOMIC AND MOLECULAR DIAGNOSTICS
36
A FOXP3 POLYMORPHISM THAT INFLUENCES GRAFT
SURVIVAL AFTER KIDNEY TRANSPLANTATION
C. Baan1, A. Peeters1, J. van de Wetering1, J. IJzermans2, W. Weimar1
Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The
Netherlands, 2Surgery, Erasmus MC, University Medical Center Rotterdam
CD4+CD25+FOXP3+ regulatory T-cells are crucial for the balance of
immunological reactivity to self and non-self. A short (GT) n allele has been
associated with increased FOXP3 promoter activity. We studied the influence
of recipient FOXP3 genotype on clinical outcome of kidney transplantation.
DNA from 684 recipients who survived at least 1 year and with a follow up of
6 y (median; range 1-12 y) was genotyped. Maintenance immunosuppressive
therapy consisted of calcineurin inhibitors in combination with MMF or AZA.
Acute rejection occurred in 23% of the patients.
For (GT) n genotype, recipients were divided into two classes: short alleles (£
15 repeats; class S) and long alleles (>;16 repeats; class L). As a result of its
location on the X-chromosome and allele location, 78% the female patients
and 50% male patients are carriers of the FOXP3 S-allele. Graft survival
was associated with the studied gene polymorphism (log rank p=0.02). This
beneficial effect of the FOXP3 polymorphism was observed in grafts exposed
to prolonged cold ischemia time and acute rejection. Graft survival of deceased
donor kidneys (exposed to >14 h cold ischemia) transplanted in carriers of
the S-allele (N=205) was significantly better than those of L-homozygotes
(N=142). 89% vs 82%, respectively, p=0.02. These graft survival rates were
comparable to grafts from living donors with short ischemia times. Also in
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37
INTEGRATIVE GENOMICS TO IDENTIFY NON-HLA
ALLOGENIC KIDNEY-SPECIFIC TARGETS AFTER KIDNEY
TRANSPLANTATION
M. Sarwal, L. Li, P. Wadia, R. Chen, M. Naesens, D. Miklos, A. Butte
Stanford University
Aims: To identify if serological responses to allogenic non-HLA renal
compartment-specific antigens can be detected after renal transplantation (txp).
Methods: 36 paired pre- and post-transplant (mean time 25 months) serum
samples from 18 pediatric kidney allograft recipients were used for identification
of de novo non-HLA antibody formation assessed using Invitrogen ProtoArray
(v3). measuring signal post-pre. Probes from the Protoarray and cDNA
microarray platforms were re-annotated to current NCBI Entrez gene identifiers
using AILUN. 34 cDNA arrays (GSE: 3931) from 7 normal kidney regions
(inner and outer cortex, inner and outer medulla, papillary tips, renal pelvis and
glomeruli; see Table) were analyzed for compartment-specific genes by SAM,
and the highest-ranked genes in each compartment (KS two-sample test p <
0.001) and were ranked against each individual patients numerical antibody
response across the 5057 proteins on the Protoarray.
Results: In 83% of patients (15/18). kidney-specific serological responses
against the renal pelvis were the first to be detected, followed by responses
against renal cortex. Control gene expression data sets from other solid organs
(GSE: 1133; lung, heart, pancreas) did not demonstrate immune-response
enrichment. The presence of these antibodies was not associated with donor
specific HLA class I or II antibody levels.
Conclusion: We demonstrated de novo formation of circulating non-HLA nonABO antibodies after txp, irrespective of HLA antibodies, are detected against
kidney-specific protein targets. As these antibodies are not seen against other
solid organs, the response is likely allogeneic. The renal pelvis and renal cortex
have the highest immunogenic potential. Two selected pelvis and cortex targets
and localizations were confirmed by IHC. This study provides a roadmap of
renal compartment-specific non-HLA antigens generating post-transplant
alloimmune responses, opening the door for clinical correlations with posttransplant dysfunction.
Table A: Allo-antigenic targets by anatomic regions mapped between cDNA
microarray and ProtoArray Human Protein Microarrays
Anatomic
region of
kidney

# of genes up in
region

Measured on
ProtoArray

Overlapped
Percentage
(cDNA and
ProtoArray)

Glomeruli

842

161

19%

Inner Cortex

900

201

22%

Outer Cortex

1405

336

24%

Inner Medulla

37

9

24%

Outer Medulla 150

29

19%

Pelvis

2299

466

20%

Papillary Tip

675

167

25%

38
PROBABILISTIC (BAYESIAN) MODELING OF GENE
EXPRESSION IN TRANSPLANT GLOMERULOPATHY
T. Brown1, J. Hawksworth1,2, O. Cheng3, D. Leeser2, A. Stojadinovic2,
D. Tadaki1, E. Elster1,4, R. Mannon3
1
Regenerative Medicine, Naval Medical Research Center, Silver Spring, MD,
2
Surgery, Walter Reed Army Medical Center, Silver Spring, MD, 3National
Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Bethesda, MD, 4Surgery, National Naval Medical Center, Bethesda, MD
Introduction: Transplant glomerulopathy (TG) is a distinctive lesion identified
on allograft biopsy associated with rapid decline in glomerular filtration rate
and poor outcome. Recent evidence increasingly supports an immunologic
pathogenesis of TG, however the molecular pathways involved have not been
elucidated. Furthermore, use of gene expression data to reliably predict TG has
not been previously published.
Methods: Retrospective review of 963 renal transplant core biopsies from 166
patients identified TG in 20 biopsies from 18 (10.8%) patients. A cohort of
patients (n=32) with stable function (SF) allografts were studied for comparison.
TG was graded by the current Banff classification and 43/52 samples were
stained for C4d. The biopsies were analyzed for transcript expression of 87
genes with quantitative real-time PCR. Data was analyzed using Bayesian
modeling software, and dependence relationships between transcript expression
and TG were established. A probabilistic Bayesian model was generated and
validated to predict histopathology based on gene expression signatures.
Results: The mean grade (±SD) of TG was 2.65 ±0.49. Of the stained biopsies,
peritubular capillary C4d deposition was identified in 15/18 (83.3%) with TG and
8/25 (32.0%) with SF (p<0.001). Interestingly, the resulting probabilistic model
illustrated a critical relationship between CD86 and TG. TG was also predicted
by upregulation of CCL2, CCL3, CCL5, CXCL9, IL-8, IL-10, and ICAM gene
expression. Ten percent of the samples were excluded randomly from the initial
model, and subsequently used for validation. In the validation analysis, the model
effectively predicted TG (area under the curve (AUC) of 0.92; 90% positive
predictive value (PPV) ) and SF (AUC of 0.866; 83% PPV).
Conclusions: This study provides a compelling and clinically relevant example
of the combination of quantitative gene expression with probabilistic Bayesian
modeling to predict renal allograft pathology. Potentially important molecular
pathways associated with transplant glomerulopathy were also identified. The
application of this integrated approach has broad implications in the field of
transplant diagnostics and interpretation of large data sets.

39
URINARY CELL mRNA PROFILES ACCURATELY
PREDICT RENAL ALLOGRAFT INTERSTITIAL FIBROSIS AND
TUBULAR ATROPHY
T. Muthukumar, R. Wanchoo, D. Dadhania, R. Ding, C. Snopkowski,
C. Chang, B. Li, V. Sharma, S. Seshan, M. Suthanthiran.
Nephrology and Transplantation Medicine, Cornell University Medical
College, New York, NY, USA
Renal allograft interstitial fibrosis (IF) and tubular atrophy (TA) are predictive
of graft outcome and their presence can only be ascertained by allograft biopsy.
Renal tubular epithelial cell-mesenchymal transition (EMT) is a critical event
in the development of IF. We reasoned that mRNA phenotyping of urinary cells
that includes measurement of mRNA for tubule specific proteins, and mRNA
encoding proteins implicated in EMT would be informative of renal allograft
status with respect to presence or absence of interstitial fibrosis and tubular
atrophy.
We tested our hypothesis by urinary cell mRNA profiling of 75 renal allograft
recipients. We obtained urine samples at the time of diagnostic or protocol
allograft biopsies; 25 urine specimens from 25 renal allograft recipients
with biopsy confirmed episode of chronic allograft nephropathy (CAN) and
50 samples from 50 recipients with normal graft biopsy and stable graft
function (Normal Biopsy). We isolated total RNA from urine cell pellets and
reverse transcribed to cDNA. We developed a pre-amplification assisted real
time quantitative PCR assay in our laboratory and ascertained EMT/IF by
measurement of mRNA levels of TGFβ1, α-smooth muscle actin (αSMA) and
E-cadherin (ECad) and TA by measurement of mRNA of Uterine Sensitization
Associated Gene-1 (USAG-1) & NaK2Cl transporter (NKCC2) both expressed
in tubular cells. mRNA copies were normalized to 18S rRNA copies and
correlated with the allograft status.
Urine specimens from the CAN group expressed higher transcript levels of
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patients (N=160) who experienced a graft rejection episode an effect of the
FOXP3 polymorphism was found. The 5-year graft survival of rejectors who
were carriers of the S-allele was 14% higher than that of non-carriers of the
S-allele, 91% vs 77%, p=0.0003. In the multivariate analysis the FOXP3
S-allele proved to be an independent variable associated with reduced risk for
graft failure (odds ratio 0.59, 95%CI 0.39-0.91, p=0.015).
These data show that the recipient FOXP3 genotype is associated with
outcome after kidney transplantation. Carriers of the FOXP3 S-allele and thus
with increased regulatory T-cell capacities showed superior control of tissues
damage due to non-immunological and immunological events leading to in
better graft survival.
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EMT/IF genes compared to Normal Biopsy group. Tubular atrophy in CAN
was evident by the reduced levels of expression of USAG-1 and NKCC2
compared to Normal Biopsy group (table).

MONDAY

mRNA*

Chronic Allograft
Nephropathy (N=25)

Normal
Biopsy (N=50)

P (Mann-Whitney
test)

USAG-1
NKCC2

Tubular
Atrophy

median copies (normalized to 18s rRNA)
2.7
127.5
40.9
278.5

<0.0001
<0.0001

TGFβ1/ECad
αSMA/ECad

Interstitial
Fibrosis

16.8
0.43

0.01
0.01

5.99
0.12

• mRNA copies were measured by pre-amplification assisted real time quantitative
PCR assay and expressed as copy numbers per one microgram of total RNA
By the use of receiver operating characteristic curve analysis, USAG mRNA
predicted CAN with specificity of 88% and sensitivity of 80%. The calculated
area under the curve was 0.85 for USAG-1, 0.80 for NKCC2 (both P<0.0001).
0.67 for TGFβ1/E Cad and 0.67 for αSMA/E Cad (both P=0.01).
We conclude that urinary cell mRNA profiles that include levels of mRNA
encoding tubular proteins and mRNA encoding proteins implicated in EMT
offers a noninvasive means of ascertaining renal allograft status with respect
to presence or absence of interstitial fibrosis and tubular atrophy. These
biomarkers besides obviating the need for allograft biopsies may help improve
the outcome of renal transplantation.

40
WHOLE BLOOD GENOMIC BIOMARKERS OF ACUTE
ALLOGRAFT REJECTION
P. Keown, Z. Hollander, G. Cohen Freue, D. Lin, R. Balshaw, R. Ng, A. Mui,
R. McMaster, B. McManus,
University of British Columbia
Transplant patients are currently monitored regularly by blood tests, organ
function tests, and the tissue biopsy, an expensive and invasive procedure. The
Biomarkers in Transplantation (BiT) team is seeking effective and minimally
invasive biomarkers of heart, kidney and liver acute and chronic allograft
rejection.
The BiT team has enrolled more than 500 heart, kidney and liver transplant
patients and collected more than 20,000 blood, urine, and tissue samples over 3
years. Genomic, proteomic and metabolomic approaches are used. The current
analysis focuses on microarray analysis of PAXgene whole blood samples
from heart, liver and kidney transplant patients. Samples were collected before
transplant and at weeks 1, 2, 3, 4, and 12 and analyzed with Affymetrix HG
U133 plus 2.0 microarrays. Samples were defined as acute rejection (AR) or no
rejection (NR) based on organ-specific biopsy criteria. Single time point analysis
was performed for each organ separately using the robust version of eBayes
available in the Linear Models for Microarray Data (limma) BioConductor
package. A false discovery rate (FDR) cut off of 1% was used. Classifier genes
were identified for each organ by applying Stepwise Discriminant Analysis
(SDA) with forward selection on the statistically significant probe sets. Leave
one out cross-validation was done using Linear Discriminant Analysis (LDA).
Nine probe sets were identified that best differentiated AR from NR heart
samples. Seven differentially expressed genes made up the classifier set that
differentiated liver AR and NR. Nine genes were essential in the kidney
classifier. Thus, BiT identified an initial set of genes from each heart, liver and
kidney transplant samples that can differentiate rejection from non-rejection.

41
INDOLEAMIN 2,3 DIOXYGENASE (IDO) AS
DISCRIMINATION FACTOR FOR LONG-TERM FUNCTION
AFTER RENAL TRANSPLANTATION
D. Abendroth1, M. Marzinzig1, J. Kaden2
1
Center of Surgery, University of Ulm, 2Vivantes Hospital Friedrichshain,
Berlin
IDO suppresses T-cell reactivity via degradation of tryptophane and is
upregulated by the proinflammatory cytokines IFN-γ; and TNF-α;. There
is evidence, that IDO is promoting tolerance. We investigated the impact
as a decrimination factor concerning the long-term function after kidney
transplantation.
Patients and Methods: In a consecutive group of patients transplanted between
10/1989 and 10/1991 (n=168) treated either with quadruple drug induction
(QDT, n= 136; ATG-F, CsA, AZA, MP) or triple drug (TDT, n=32; CsA, AZA,
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MP) as immunosuppressive therapy, we investigated the role of IDO as a marker
for rejection as well as a predictive tool for long-term function. Concentration
of l-kynurenine was analyzed by the method published by Fuchs et al. 2002
(using only uv-detection). L-kynurenine (IDO-activity) was detectable at very
low levels (n=150; 2,51 + 0,66 μmol/L) in serum of healthy volunteers and
were significant increased (p<.001) in non-rejecting renal allograft recipients
(n=150; 5,4 + 2,5 μmol/L). We differentiated two groups of patients, all with
no surgical failures, no delayed graft function, no rejection episode and no
infections including CMV-reactivation within the first 2 months: Gr.I (n=28)
involved patients showing IDO levels < 4,0 μmol/L, Gr.II (n=25) > 5,5 μmol/L
at day 21 and thereafter at least for 3 times. There was no statistic difference in
demographic data between both groups.
Results: Gr. I showed 1/5/10 year graft survival of 100/89/71% vs. Gr.II with
87/54/29% (p<0,001 at year 5 and 10, all data death censored). The median
survival in Gr.I was 120 months vs. 63 months in II. Gr.I included 25% patients
with TDT vs. 14% in II. Patients with 120 and more months of survival (n=25,
47%) showed in 80% QDT, given as “bolus”- therapy in 85%.
Conclusion: Monitoring of IDO is a novel non-invasive tool of immune
monitoring. Acute rejection is associated with an early simultaneously
increased serum concentration prior creatinine. There was a clear significant
differentiation between both groups showing IDO as a discriminating marker
concerning long-term renal function. The role of induction therapy might be
kind of a ”silencing” factor representing the balance between inflammation and
immunosuppressive therapy.

42
DEVELOPMENT OF A NONINVASIVE MOLECULAR
DIAGNOSTIC ASSAY FOR ALLOGRAFT MONITORING:
AUTHENTICATION WITH AN EXPERIMENTAL MODEL OF
CARDIAC TRANSPLANTATION
M. Mehra, A. Khanna, J. Xu, C. Baquet
University of Maryland, Baltimore
Background: More recently, analysis of a peripheral blood transcriptomic
signature to identify acute cellular rejection has been proposed using Allomap
test. This test is based on microarray analysis of gene expression using RNA
isolated from blood and the biopsies of cardiac transplant recipients. This
score dependent test is based on the analysis of expression of number of genes
that results in a complicated score system that may reflect the post-transplant
ischemic injury therefore, a number of times a high score may be recorded in
the absence of rejection. Therefore, analysis of expression of a small number
of genes in blood from cardiac transplant recipients using a efficient test that is
easy to perform and analyze, could provide a practicality and clinical utility for
cardiac transplant recipients. Using splenocytes and cardiac allograft tissues
from histocompatibility mismatched rat cardiac transplant recipients, we
analyzed the transcriptomic patterns expression of IL1R2, PDCD-1, which are
part of Allomap scoring system and stromal cell-derived factor-1 (SDF-1). the
only known biological natural ligand for chemokine CXC receptor-4 (CXCR4).
whose expression increases in rejecting allografts and during cardiac damage.
Methods: Heterotopic heart transplantations were performed (n= 12
immunosuppresed allografts; n=9, untreated rejecting n=3) and isografts
n=3) using histocompatibility mismatched rat strains, Wistar Furth (WF) and
Lewis (LEW). as donors and recipients. Immunosuppression regimens used in
3 recipients each was CsA (2.5 mg/kg/day). TAC (0.25 mg/kg/day) and SRL
(0.25 mg/kg/day) for 30 days. Recipients were monitored for rejection using a
validated heart palpation scale. Samples for mRNA analysis were isolated from
spleen, native and allogeneic cardiac tissues. Using Real Time PCR, the results
are expressed as relative fold expression with respect to ƒÒ-actin.
Results: Intragraft mRNA expression of IL1-R2 (p<0.01). PDCD-1 (p<0.05)
and SDF-1 (p<0.01) was significantly increased in rejecting allografts
compared to the isografts. In the periphery, similar findings were observed in
cells derived from splenocytes of allogeneic animals compared with isografts
for IL1R2 (p<0.001). PDCD-1 (p<0.01) and SDF-1 (p<0.01). A comparison
of mRNA expression of these biomarkers demonstrated similar expression in
splenocytes and allograft tissues for IL-1R2 (59.15 ¡Ó 2.96 vs 54.36 ¡Ó 5.1).
PDCD-1 (42.44 ¡Ó 3.68 vs 45.47 vs 3.58); SDF-1 (40.67 ¡Ó 6.5 vs 37.82 ¡Ó
5.78). Immunosuppressed animals were noted to exhibit marked suppression of
IL1-R2, PDCD-1 and SDF-1 mRNA and no differences in expression of these
genes as a function of type of immunosuppressant used.
Discussion: These in-vivo findings provide direct evidence for the validity of
the peripheral circulating transcriptomic markers IL1-R2, PDCD-1 and SDF-1
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for the determination of quiescence or rejection in cardiac transplantation. Thus,
peripheral transcriptomic signals in the domains of IL1R2, PDCD1 and SDF-1
are reflective of ongoing intragraft events, thereby providing support for their
diagnostic utility in cardiac transplantation. The validation of these markers
in clinical samples will have potential of a noninvasive multiplex molecular
diagnostic assay for monitoring of rejection in cardiac transplant recipients

M. Naesens1, L. Li1, L.H Ying1, P. Sansanwal1, T. Sigdel1, N. Kambham1,
E. Lerut2, O. Salvatierra1, A. Butte1, M. Sarwal1
1
Stanford University, CA, USA, 2University Hospitals Leuven, Belgium
Introduction: A better knowledge of the molecular mechanisms associated
with the use of deceased donor (DD) kidneys for renal transplantation could
pave the way for targeted therapy to bridge the survival gap between DD and
living donor (LD) kidneys.
Methods: A total of 53 human renal allograft protocol biopsies were included
in this study, 18 training set (9 DD, 9 LD) and 10 test set biopsies (5 DD, 5
LD) obtained at implantation prior to revascularization, 18 post-transplantation
protocol biopsies (9 DD, 9 LD) and 7 additional paired post-transplantation
samples. No graft had delayed graft function. Whole genome expression
profiles were assessed using Affymetrix HG U133 Plus 2.0 microarrays and
validated using qRT-PCR.
Results: The biopsy samples obtained at implantation segregated in 2 distinct
groups according to donor origin, with a cluster of 319 unique identified
genes higher expressed in DD compared to LD kidneys, and 329 genes lower
expressed. PAM perfectly classified the blinded test set samples. Using pathway
analysis software we identified a significant local renal overrepresentation of
complement genes of both the classical (C1Q, C1R, C1S, C2, C3, C4). the
alternative pathway (C3, CFB) and the common pathway (C6, C7 in DD
implantation biopsies. Complement gene expression in deceased donor kidneys
related to donor death, but also correlated with the length of cold ischemia time.
The gene expression differences between living and deceased donor kidneys
in implantation biopsies were no longer present in the biopsies obtained after
transplantation. However, there was a significant overexpression of C1Q, C1R,
C1S, C3 and CFB genes in biopsies obtained after transplantation, regardless
of donor source.
Conclusion: Our study provides an in-depth analysis of the gene expression
differences between pristine kidneys from living and deceased donors, with
a major overexpression of complement genes in deceased donor kidneys and
continuous upregulation of complement genes after transplantation. Targeted
therapy interfering with complement activation, prior to organ recovery, during
organ storage or in the post-transplant period, is an attractive therapeutic target
that deserves further investigation.

44
ISCHEMIC REPERFUSION INJURY AND ITS
INFLUENCE ON THE EPIGENETIC MODIFICATION OF THE
DONOR KIDNEY GENOME.
M.D. Parker1, P. Chambers2, J.P.A. Lodge3 and J.R. Pratt1
1
Leeds Institute of Molecular Medicine, Leeds, United Kingdom, 2CR-UK
Mutation Detection Facility, Leeds, United Kingdom and 3Department for
Organ Transplantation, Leeds, United Kingdom

In clinical transplantation, there is a link between organ ischemia and damage
that occurs upon reperfusion. This is caused by O2 and OH free radicals that
are formed by the degradation of ATP to Hypoxanthine during ischaemia,
and by the further conversion to Xanthine upon organ reperfusion. Oxidative
damage of 5-methyl-Cytosines (5mC) in genomic DNA is known to be capable
of converting such 5mC to unmethylated Cytosines for which no known DNA
repair mechanism exists. We hypothesise that such oxidative damage leads to
aberrant demethylation of CpG sites in regulatory sites within gene promoters
of donor tissue. Normally, such methylated CpG sites control the accessibility of
DNA binding proteins to regulate transcription factor binding, and therefore gene
expression. Conversion of methylated cytosines to non-methylated cytosines by
oxidative damage in post-ischaemic organs may modulate gene expression in
donor organs and affect transplant outcomes in the short and long term.
Kidneys were exposed to 4 hours cold ischaemia and 2 hours of reperfusion.
Ischemia/reperfusion injury (I/RI) was assessed by histopathology and DNA
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TLR4-MYD88 SIGNALING IS REQUIRED FOR
THE DEVELOPMENT OF MOUSE CHRONIC CARDIAC
ALLOGRAFT DAMAGE IN A MODEL OF CHRONIC CARDIAC
ALLOGRAFT REJECTION
G. Chen, H. Wu, K. Wyburn, J. Yin, J. Eris, S. Chadban
Collaborative Transplantation Research Group, University of Sydney/Royal
Prince Alfred Hospital
Toll like receptors (TLRs) play an important role in innate immunity but
also provide a link between innate and adaptive immunity. MyD88 is a key
TLR signal adaptor. A recent clinical study reported that activation of innate
immunity in heart-transplantation recipients through TLR4 contributes to the
development of chronic rejection after cardiac transplantation. In this study,
we aimed to determine whether TLR4-MyD88 signaling is required for the
development of chronic allograft damage using TLR4-/- and MyD88-/- mice in
a model of chronic cardiac allograft rejection.
Methods: Cardiac transplants were performed: B6.C-H-2bm12 (B6.H-2bm12)
hearts to WT, MyD88-/- and TLR4-/- mice (all C57BL/6-H-2b – single MHC
class II mismatch) as allografts (n = 6-8/group) and C57BL/6 to C57BL/6
isografts (n = 5). Blood and tissue were harvested at day 49 after transplantation.
Cell infiltration, fibrosis and vasculopathy were assessed histologically (grade
0 – 5). CD4+ cells were extracted from spleen and examined by FACS to
determine subpopulations including CD4+Foxp3+ cells.
Results: All hearts remained pulsatile until sacrifice. Histology of TLR4-/and MyD88-/- recipients showed protection from leukocyte infiltration
(1.2±1.1&1.0±1.1vs 3.2±1.4, p < 0.01). fibrosis (0.75±1.0& 0.6±1.2 vs 2.6±2.0,
p < 0.05) and vasculopathy (0.28±0.6 & 0.04±0.1 vs 1.9±2.2) compared to
WT recipients. By FACS, the ratio of CD4+FoxP3+ regulatory T (Treg) cells
to total CD4+ cells at day 49 post transplantation in spleen was significantly
increased in TLR4-/- and MyD88-/- recipients versus WT allograft and isograft
mice (18.1±0.2 & 19±0.9% vs 12.9 ±1.1 & 11.8±0.2%, P <0.01).
Conclusion: Absence of TLR4 and MyD88 signaling reduces chronic allograft
damage in a murine model of chronic cardiac rejection. One mechanism of
protection may be enhancement of regulatory T cell function. Regulation
of Treg generation via the TLR4/MyD88 pathway may be one important
consequence of cross-talk between innate and adaptive immunity.
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EXPRESSION PROFILING OF HUMAN KIDNEY
BIOPSIES FROM LIVING AND DECEASED DONORS REVEALS
CANDIDATE SIGNALING PATHWAYS

methylation by bisulphite modified PCR. Primers were designed to assess
methylation in the promoter of the Complement C3 gene – known to be
important in the donor inflammatory response to I/RI. Our data produced an
epigenetic map of the rat renal C3 promoter and identified methylated CpG sites
coincident to cytokine response elements and NF-kB binding sites. A similar
map has been produced for the rat renal TGFβ promoter. Analysis of the samples
showed a significant (p<0.05) decrease in methylation in the C3 promoter in
response to ischemia, and a further decrease in response to reperfusion. In
order to assess site specific demethylation at the IL-1/IL-6 response element
(RE). and the NF-κB binding site, we have undertaken pyrosequencing of
the genomic DNA taken from our tissue samples. Preliminary results from
pyrosequencing show that compared to normal rat kidney the CpG sites within
the IL-2/IL-6 RE and the NF-κB binding site are less methylated following I/
RI. Since such epigenetic modification is believed to be stable and heritable to
daughter cells upon mitosis, we speculate that aberrant demethylation in genes
linked to chronic allograft nephropathy (CAN) such as TGFβ may play a role
in chronic fibrotic changes after transplantation. To assess this we are repeating
this study in a model of CAN.
In conclusion, the findings of aberrant demethylation of DNA resulting from
ischemia and reperfusion injury describe an unrecognised phenomenon in
transplantation. Aberrant demethylation has been linked to the development of
tumours and our data suggest a similar mechanism of gene dysregulation may
be initiated by the ischaemic insult inherent in organ transplantation. These
data may contribute to a further understanding of the how the short lived and
transient ischemic insult influences chronic pathological changes that occur
even in syngeneic models of transplantation in the long term.
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HSP-27 INHIBITS HUMAN CARDIAC ENDOTHELIAL
CELL AND SMOOTH MUSCLE CELL PROLIFERATION
AFFORDING PROTECTION AGAINST GRAFT
VASCULOPATHY.
M. Rose1, D. Trott1, C. McManus2, A. Robinson2, M. Dunn2
Imperial College, 2Conway Institute, University College, Dublin
Recent evidence suggest that maintenance of high levels of hsp27 in the
vessel wall protects against transplant and non-transplant atherosclerosis. Thus
proteomic studies have demonstrated that cardiac biopsies from long term
cardiac transplant recipients, without cardiac graft vasculopathy, demonstrated
significantly more hsp27, phosphorylated at ser82 and 78, than patients who
developed graft vasculopathy. In order to understand the mechanisms, we have
investigated the effect of over expression of wild type and mutant hsp27 on
vascular endothelial and smooth muscle cells proliferation. Primary and immortal
human cardiac endothelial (HMEC-1) and smooth muscle cells (hTERTSMC)
were infected with adenoviruse 5 carrying wild type and mutant hsp27 cDNA.
Numbers of cells were counted over a 7 day period. Proliferation of both types
of primary and immortal cells was inhibited by over-expression of wild type
hsp27 and mutant versions of hsp27 that mimic the phosphorylated protein. In
contrast, the hypophopsphorylated mutant promoted cell division compared to
the empty vector control. In HMEC-1 cells proliferation was 41.4 +/- 9.3% (wild
type hsp27). 115.8 +/- 6.4% (hypo-phosphorylated hsp27). 34.0 +/- 5.8% (hyperphosphorylated hsp27) and 24.6 +/- 5.9% (anti-sense hsp27) relative to the empty
vector control (mean +/- SD, n= 5 experiments). Taken together these results
suggest that a critical level of endogenous hsp27 is required for normal cell cycle
control and that it is the phosphorylated form of the protein that functions to inhibit
cell division. Proteomics was used to identify the proteins and pathways involved.
Infected cells were lysed and proteins were separated by 2-D gel electrophoresis,
detected by silver staining and analyzed using Progenesis software.
Four proteins associated with the actin cytoskeleton were found to be
significantly upregulated in cells over-expressing wild type hsp27 compared to
the mutant hyper- and hypo-phosphorylated forms. They were human moesin
(involved in connecting cytoskeletal structures to the plasma membrane) and
the actin/tubulin-binding proteins stathmin, tubulin-specific chaperone A (a
tubulin- folding protein) and coactosin-like protein (binds to F-actin). Actin
filaments are a major component of the contractile ring and essential for
cytokinesis and hsp27 is known to be a modulator of F-actin polymerization.
Thus we hypothesize that over-expression of hsp27 inhibits the growth of cardiac
endothelial and smooth muscle cells through control of actin polymerization
and this function is modulated by phosphorylation of hsp27 protein. These
results suggest that hsp27 is a natural regulator of endothelial and smooth
muscle proliferation; future studies will investigate endogenous inducers of
hsp27 and gene therapy as methods of inhibiting graft vasculopathy.
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TGFE946; AND LONG TERM ACCEPTANCE OF
INTESTINAL ALLOGRAFTS BY ALY/ALY MICE
J. Wang, Y. Dong, J. Sun, I. Williams, K. Newell
Emory University
Long term treatment-free survival of intestinal allografts has proven elusive.
Intestinal allografts survive indefinitely in aly/aly mice with defective NFκ;B
signaling. Our data suggest that this may be due to effects of TGFβ;.
Methods: C3H intestines transplanted into C57BL/6 wild type (WT) or aly/
aly mice were assessed for rejection by histology. T cell migration to graft
lymph nodes (LN) and the intraepithelial compartment (IEL) was examined
by flow cytometry. T cells (107) from aly/aly mice with long term surviving
intestinal allografts were transferred into WT mice undergoing intestinal
transplantation to assess transferable tolerance. Some aly/aly recipients also
received unmanipulated T cells (107) from WT or TGF receptor II dominant
negative (TGFRII DN) mice or magnetic bead purified (>90%) naive (CD44lo)
T cells.
Results: Non-splenectomized aly/aly mice reject heart allografts with normal
kinetics indicating that they are not globally immunosuppressed. Transfer of
aly/aly T cells into skin-grafted RAG-/- mice resulted in rejection suggesting
that T cell function is not directly impaired. Consistent with this, reconstitution
of aly/aly mice with WT T or B cells failed to promote rejection. There were
no differences between WT and aly/aly recipients in the tempo of T cell
migration to the allograft LN or IEL compartments. Another possibility is that
regulatory mechanisms contribute to prolonged allograft survival. However,
CD4+CD25hi and FoxP3+ cells were reduced 2-3 fold in aly/aly vs. WT
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recipients and transfer of cells from aly/aly long term allograft acceptors
into WT recipients of intestinal allografts failed to transfer tolerance. This
suggested that an alternative regulatory mechanism may contribute to allograft
acceptance. To examine the role of the regulatory cytokine TGFβ;, T cells
from TGFRII DN mice were transferred into aly/aly recipients at the time of
intestinal transplantation. In contrast to WT T cells transfer of bulk, or purified
naïve, T cells from TGFRII DN mice caused prompt rejection.
Conclusions: Indefinite survival of intestinal allografts in aly/aly mice appears
not to be due to intrinsic defects in T or B cells, impaired migration of T cells to
allografts, or regulation mediated by FoxP3+ cells. Rather, rejection mediated
by TGFRII DN T cells that can not be regulated via TGFβ; suggests that TGFβ;
contributes to long term intestinal allograft survival. Ongoing experiments to
quantify TGFβ; production and determine the responsiveness of aly/aly T cells to
TGFβ; may help to confirm this hypothesis.

48
JAK/STAT SIGNALING PATHWAYS IN THE
INFLAMMATION RESPONSE DURING LIVER ISCHEMIA/
REPERFUSION INJURY
J. Kupiec-Weglinski, C. Freitas, Y. Zhai, R. Busuttil
Dumont-UCLA Transplant Ctr
The JAK/STAT signaling is one of the major pathways for cytokine signal
transduction. The signal transducer and activator of transcription 1 (STAT1)
is mainly activated by IFN-gamma. The activation of STAT1 by IFN-gamma
has been implicated in hepatic inflammation. We have shown that activation
of Toll-like receptor (TLR) 4 complex initiates pro-inflammatory response
leading to liver ischemia/reperfusion injury (IRI). Indeed, TLR4 signaling
in vitro activates STAT1, which in turn triggers production of type-1 IFNdependent CXCL10 (IP-10). This study was designed to analyze the crosstalk between STAT1 and the MAP kinase (ERK) downstream of JAK/STAT
signaling pathways.
We used a mouse liver model of partial warm ischemia (90 min). followed by
reperfusion (6 h). First, we employed STAT1 KO (n=17) and control WT (n=16)
mice. The hepatocellular damage, as measured by sALT levels (IU/L). was
significantly decreased in 10/17 STAT1 KO mice (p<0.005); the remaining 7/17
of STAT1 KO showed sALT levels comparable with WT. Hence, we distinguished
two groups of STAT1 “protected” vs. “nonprotected” STAT1-deficient recipients.
Histology revealed minimal sinusoidal congestion without edema/vacuolization
or necrosis in STAT1 KO protected group. The induction of mRNA coding for
TNF-alpha/IL-6 was higher in STAT1 KO nonprotected livers. The expression
of CXCL10, the product of STAT1 activation downstream of TLR4 in Type I
IFN pathway, was profoundly and selectively depressed in livers from STAT1
KO protected mice, as compared to IRI susceptible livers. Similarly, Western
blot-assisted phospho-ERK expression was up regulated selectively in the
STAT1 KO protected group. In the second series, C57BL/6 mice were treated
1 h prior to liver ischemic insult with JAK-2 inhibitor (Tyrphostin AG490; 40
mg/kg, i.p.; n=5). or vehicle (n=5). The hepatocellular damage, as measured by
sALT levels (IU/L). and histology was significantly decreased in AG490 group,
as compared with controls (mean = 12770 vs. 28770; p<0.05).
In conclusion, the disruption of JAK/STAT signaling by inhibiting JAK2
uniformly ameliorates the inflammatory immune response in liver IRI. However,
the blockage of STAT1 alone is insufficient to reproducibly exert cytoprotection.
As JAK2 is upstream of STAT1 as well as upstream of MAP kinase (ERK). this
study highlights the role of both signaling pathways in hepatic IRI.

49
DAMAGE TO ETHANOL-INDUCED MURINE FATTY
LIVER GRAFTS MEDIATED BY LPS RECEPTOR CD14
T. Theruvath1, Z. Zhong1, J. Lemasters1,2
Medical Univesity of South Carolina, Center for Cell Death, Injury and
Regeneration, Department of Pharmaceutical and Biomedical Sciences,
2
Department of Biochemistry and Molecular Biology
Background: Ethanol causes hepatic steatosis. Transplantation of ethanolinduced fatty livers from otherwise healthy donors results in higher rates of
graft dysfunction and failure. The LPS receptor CD14 has been implicated to
play a detrimental role after lean liver transplantation, but its impact after fatty
liver transplantation remains unclear.
Aim: Accordingly, our aim was to compare ethanol-induced fatty liver grafts
from wildtype and CD14 deficient mice to test the hypothesis that CD14
increases TNFα; release and reactive oxygen species (ROS) formation in fatty
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INHIBITION OF NF-KAPPA B AND/OR NFAT
ACTIVATION AUGMENTS OR ABROGATES
IMMUNOMODULATORY EFFECTS OF DONOR SPECIFIC
TRANSFUSION.
R. Goto1, K. Yamashita1, S. Ueki1, M. Taniguchi1, T. Suzuki1, T. Shimamura1,
H. Furukawa1, K. Umezawa2, M. Ozaki1, S. Todo1
1
1st Dept of Surgery, Hokkaido University, 2Dept of Applied Chemistry, Keio
University
Background: Both NF-κB and NFAT signaling pathways play crucial roles
upon activation of T cells and subsequent alloimmune responses. Inhibition
of these transcription factors suppresses T cell activation and proliferation;
however, it has been shown that use of carcineurin inhibitors block AICD
and abrogate tolerance induction in certain protocols. Also, recent works have
shown that NFAT activation is involved in functions of regulatory T cells.
Tolerance can be successfully achieved by costimulation blockades together
with donor-specific transfusion (DST). while the effects of NF-κB and/or
NFAT blockade in combination with DST are unknown.
Aim: To clarify the role of transcription factors, NF-κB and NFAT, on DST
mediated immunomodulation, the effects of a novel NF-κB inhibitor, DHMEQ
and tacrolimus (TAC) together with DST were examined in mouse heart
transplantation.
Methods: A fully MHC incompatible C57BL/6J (H-2b) cardiac graft was
transplanted into BALB/c (H-2d) mouse. DST (20x106 donor splenocytes) was
given at 7 days before grafting. DHMEQ (30 mg/kg/day) was administered
i.p. for 14 days following DST. Tacrolimus (1.5 mg/kg/day) was given i.p.
for 14 days starting from either day -7 (D-7) or day 0 (D0). IFN-γ (ELISpot).
apoptosis (annexin V). intracellular CD154 and Foxp3 expressions in CD4+ T
cells were assessed. CFSE-labeling technique was applied to track alloreactive
cells in vivo.
Results: Control mice rejected allografts within 8 days (n=7). In a sharp
contrast, DHMEQ plus DST allowed long-term graft acceptance for over 100
days in 5 (62.5%) of 8 animals (Figure). whereas DHMEQ monotherapy and
DST alone modestly prolonged graft median survival time (GMST) to 16 (n=7)
and 34 days (n=12). respectively. DHMEQ significantly induced apoptosis
upon activated CD4+ T cells (n=3, p<0.01 vs. control). Furthermore, frequency

of IFN-γ producing cells and donor-specific alloreactive CD154+CD4+ T
cells were significantly reduced (n=3, p<0.05 vs. DST alone) in the spleen
of DST+DHMEQ treated cardiac recipients. Conversely, CD4+CD25+Foxp3+
T cells were increased in these animals when examined on days 0 and 7.
Interestingly, the beneficial immunomodulatory effect of DHMEQ plus DST
was abrogated (n=7, GMST: 50 days, Figure). when NFAT was inhibited
together with NF-κB (DST+DHMEQ+TAC (D-7) ). This phenomenon was
associated with significantly lower in vivo development of CD4+CD25+Foxp3+
T cells (n=4, p<0.05) and inhibition of pro-apoptotic effect of DHMEQ on
allo-reactive CD4+ T cells (n=3, p<0.05). In contrast, 8 (88.9%) of 9 animals
accepted heart allografts for over 100 days when tacrolimus was administered
starting from day 0 under the DHMEQ plus DST protocol.

Conclusion: Inhibition of NF-κB activation enhances the immunomodulatory
effect of DST by promoting deletion of alloreactive but generation of regulatory
T cells in vivo. Such immunosuppressive effect can be either augmented or
abrogated by NFAT blockade, depending on the timing of inhibition.

51
KIDNEY ISCHEMIA REPERFUSION INJURY
UPREGULATES EXPRESSION OF NKG2D LIGANDS (RAE-1
AND MULT-1) BY INTRINSIC KIDNEY CELLS THROUGH
TLR4-MYD88 SIGNALING
G. Chen1, S. Chadban1, K. Wyburn1, S. Alexander2, A. Sharland1, H. Wu1
Collaborative Transplantation Research Group, University of Sydney/Royal
Prince Alfred Hospital, 2Central for Kidney Research, The Children Hospital
at Westmead
NKG2D is an activating receptor expressed on NK cells and CD8+ T cells.
Ligands for NKG2D including RAE-1, MULT-1 and H60 in mouse, may be
upregulated by tissues in response to stress. A study in mouse macrophages
described upregulation of RAE-1 in response to stimulation through TLR4
by LPS. We have shown that TLR4 mediates kidney ischemia reperfusion
injury (IRI) and also observed RAE-1 upregulation in IRI kidneys. We now
determined whether: 1) kidney IRI could induce the expression of NKG2D
ligands: 2) expression of NKG2D ligands is TLR4 dependent; 3). bone marrow
(BM) derived cells or parenchymal kidney cells express NKG2D ligands.
Methods: Kidney-ischemia was induced for 22 min in WT (C57BL/6).TLR4-/-,
& MyD88-/- and Balb/c mice for 45 min. Blood and tissue were harvested at
days 1, 3 & 5 for C57BL/6 TLR4-/- & MyD88-/-and days 1, 3, 5, 7, 14 a &
28 for BALB/c mice. Primary cultures of mouse tubular cells (TECs) were
also subjected to ischaemia (mineral oil overlay for 1 hr) or TLR4 activation
(LPS stimulation). BM chimeric mice were generated by transplanting BM into
irradiated recipient mice before IRI was induced.
Results: In C57BL/6 mice, RAE-1 mRNA level in IRI kidney was increased
from day 1 to day 5, peaking at day 3 compared to sham operated kidney
(14-48 fold increase, P < 0.001) measured by real time PCR. RAE-1 protein
was detected in renal tubular cells from ischemic kidney but not from shamoperated control by flow cytometry. MULT-1 mRNA expression was also
increased from day 1 to day 5 (15- 51 fold increase, P <0.005). H60 mRNA
expression was not detected in IR kidney from C57BL/6 WT mice however
was increased in IRI kidney of BALB/c mice from day 1 to day 28, peaking
at day 7 and 14 (9 – 64 fold increases, p< 0.01 to 0.001) compared to sham
operated kidney. Both RAE-1 and MULT-1 mRNA levels were reduced in
TLR4-/- and MyD88-/- IRI kidneys (2-8 fold reduction) versus WT controls
(P < 0.01). TLR4-/- and MyD88-/- primary cultured TECs submitted to IRI in
vitro also showed less RAE1 and MULT-1 mRNA expression than WT controls
(p < 0.01). LPS stimulated RAE-1 and MULT-1 expression in WT but not in
TLR4-/- TECs. TLR4-/- mice bearing WT hemopoietic cells had significantly
lower kidney RAE-1 and MULT-1 mRNA expression after IRI versus WT mice
with TLR4-/- BM (p < 0.05).
Conclusions: Kidney IRI causes expression of NKG2D ligands including RAE-1
MULT-1 and H60 and kidney parenchymal cells are the dominant source. TECs
1
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liver graft injury.
Methods: C57BL6/J wildtype (WT) and CD14 knockout (B6.129SCd14tm1Frm/J) mice on a BL6 background (KO) were used in all experiments.
Mice were gavaged with ethanol (6 g/kg) or water. Serum ALT, hepatic
triglycerides, and serum TNFα; were assessed 12 h later. In other experiments
livers were explanted and transplanted into WT mouse recipients after 18 h
of cold storage in UW solution. Serum ALT and TNFα;, graft necrosis by
histology, and apoptosis and lipid peroxidation in non-necrotic areas by
TUNEL and 4-hydroxynonenal (4-HNE) immunostaining, respectively, were
measured 8 h postoperatively.
Results: After ethanol treatment, histology showed comparable lipid
accumulation in parenchymal cells of WT and KO livers, corresponding to a
measured 10-fold increase of triglycerides. ALT and TNFα;, however, did not
increase after ethanol treatment of WT and KO mice. After sham operation,
ethanol-treated WT and KO mice did not differ in ALT, necrosis and apoptosis.
After transplantation ALT increased from 150 ± 42 U/L after sham operation to
29,833 ± 2,276 U/L in WT liver grafts compared to 11,259 ± 1,685 U/L in KO
grafts (p<0.01). Similarly, necrosis increased from 0% after sham operation
to 35% in WT grafts vs. 11% in KO grafts (p<0.05). Apoptosis assessed by
TUNEL also increased from 2 ± 0.2 cells per high power field (HPF) after
sham operation to 24.9 ± 4.9 cells/HPF after transplantation of WT livers. By
contrast, TUNEL was 11.3 ± 3.2 cells/HPF after transplantation of KO livers
(p<0.05). After sham operation, serum TNFα; serum was 4 ± 2 and 6 ± 2 pg/ml
in ethanol-treated WT and KO mice, respectively (n.s.). After transplantation,
TNFα; increased to 80 ± 33 pg/ml in WT graft recipients but only to 26 ± 7 pg/
ml in KO graft recipients (p<0.05). Furthermore, lipid peroxidation assessed
by 4-HNE staining also increased in WT grafts, which was markedly less in
KO grafts.
Conclusions: The LPS receptor CD14 enhances storage/reperfusion injury
to ethanol-induced fatty mouse livers grafts and leads to increased TNFα;
and ROS generation. Targeting the LPS receptor CD14 in fatty liver grafts
might therefore decrease graft injury after clinical transplantation and permit
increased use of marginal fatty livers to increase the donor pool.
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can be stimulated to express RAE-1 and MULT-1 by ischemia or LPS via the
TLR4 pathway in vitro and deficiencies in this pathway provide protection against
IRI and RAE-1 and MULT-1 expression in vitro and in vivo. Thus, kidney IRI
causes upregulation of NKG2D ligands by parenchymal kidney cells via TLR4.

MONDAY

52
GENERATING ISLET ALLOGRAFT TOLERANCE
BY BLOCKING NF-KB ACTIVATION AND PREVENTING
APOPTOSIS.
D. Liuwantara1, J. Gunton1, A. Yam1, S. Walters1, E. Marino1,
A. McShea2, S. Grey1
1
Garvan Institute of Medical Research, 2Combimatrix Corp.
Transplantation of islets of Langerhans is a potential therapy for the treatment
of type I diabetes (T1D). However, the clinical applicability and widespread
use of this therapy is severely hampered by the requirement for a large number
of islets per subject, and by the need for heavy immunosuppression to ensure
successful islet graft survival. The reasons underlying the requirement for
large numbers of islets and heavy immunosuppression are multifactorial, but
in general relate to massive loss of beta-cell mass and function after grafting
mediated by both immune and non-immune factors. Activation of NF-kB and
beta-cell death by apoptosis are major factors in mediating islet graft failure.
Previously we have reported that A20 was the highest expressed anti-apoptotic
gene up-regulated in beta-cells. A20 has a dual function in beta cells; A20
inhibits NF-kB activation and prevents cytokine-induced apoptosis. These data
support the concept that A20 is a major islet protective gene.
We examined whether genetic engineering of islet graft with A20 could delay
or prevent islet allograft rejection. To do this we utilised an islet allograft
transplantation model, i.e. islets were isolated from BALB/c (H2d) mice and
transplanted into streptozotocin (STZ) -induced diabetic C57BL/6 (H2b)
recipients. A20-gene transduction was achieved using recombinant-adenovirus
mediated gene transfer, and A20 expression was confirmed by western blot and
immuno-histochemistry. We found that control allografts were rejected by ~20
days (MST ~14.3 ± 3.4 days, n = 25). In marked contrast, we found that A20expressing islets exhibited prolonged allograft survival. Indeed in the absence
of additional immunosuppression, ~21% (5/23) of A20-expressing islet grafts
survived long term (i.e. >100 days).
A20 has both anti-apoptotic and an anti-inflammatory function. We questioned,
which of these two functions was involved in the mechanism of prolonged
allograft survival. To test whether A20-mediated protection was due to NFkB-inhibitory function, we transplanted adenovirus-induced Iκ;Bα;-expressing
islet grafts from BALB/c mice, into STZ-induced C57BL/6 diabetic recipients.
Blockade of NF-kB activity was confirmed by inhibition of NF-κ;B dependent
genes Cxl2, Ccl2, Cxcl1, Cxcl10, TNF, IL-6 and A20, in vitro after IL-1β;
treatment. As expected, C57BL/6 mice vigorously rejected BALB/c grafts with
a MST of ~15 days (n = 12). NF-kB-blocked islet-grafts were also rejected with
a similar tempo (MST ~15 days, n = 26). Similar results were achieved when
islets were pre-treated with the NF-kB-inhibitor “pyrrolidine dithiocarbamate”,
(n = 12). Therefore, we found that blockade of NF-kB alone did not replicate
the protective effect of A20-over-expression.
Our findings demonstrate that genetic engineering of islets to express A20 resulted
in prolonged allograft survival, consistent with the induction of a state of allograft
tolerance. In future we will investigate whether A20 could further improve
allograft survival if used as an adjunct with sub-optimal immunosuppression.

53
SIGNALING THROUGH MUCOSAL MYD88 DEPENDENT
TLRS INFLUENCES SMALL BOWEL ALLOGRAFT
REJECTION
Z. Zhang, Y. Lu, K. Chen and J. Fryer
Northwestern University Feinberg School of Medicine, Chicago, Illinois,
United States.
We have previously shown that TNFR independent activation of graft-derived
NFκB increases gut permeability and augments small bowel (SB) allograft
rejection in mice. We hypothesized that interactions between Toll-like
receptors (TLR) with products from the luminal flora as well as endogenous
ligands released due to ischemia/reperfusion injury are required in mediating
mucosal NFκB activation and accelerating small bowel allograft rejection.
To identify the involvement of determine whether TLRs are involved in
SB allograft rejection, epithelial cells were isolated from SB (B6) isografts,
allografts (B6→BALB/c). and non-transplanted B6 SB controls and subjected
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to western blot analysis. We found that in normal SBs, TLR5 and TLR9
were strongly expressed, while there was minimal expression of TLR2 and
TLR4. The expression patterns of TLRs in SB isografts were similar to those
of normal SBs. In SB allografts TLR5 and TLR9 expression was unchanged
compared to controls on POD3 and POD5, while TLR2 and TLR4 expressions
were remarkably upregulated by POD5. These findings suggest that epithelial
TLR2 and TLR4, but not TLR5 and TLR9, signaling pathways are involved in
SB allograft rejection. To determine the role of MyD88, a downstream adaptor
protein that mediates intracellular signaling for most TLRs, in SB allograft
rejection, SBs from MyD88-/- and MyD88+/+ (wt) mice were transplanted into
BALB/c recipients and were evaluated for epithelial NFkB (p65) activation
and gut permeability to Alexa Fluor labeled-Dextran probes on POD5. Our
results revealed that NFkB activation in the epithelium of MyD88-/- allograft
was markedly reduced compared to the wt allografts. Furthermore, we showed
that while gut permeability was increased significantly in wt SB allografts
compared to isografts, this was significantly reduced with the MyD88-/- SB
allografts. Accordingly, mucosal inflammation including villus sloughing and
lymphocyte infiltration were noticeably minimized in MyD88-/- SB allografts.
These data indicate that TLR2 and TLR4 interactions, via MyD88 signaling,
may contribute to escalating mucosal inflammation during SB allograft
rejection and may possibly contribute to the unique volatility associated with
SB allograft rejection episodes.

CONCURRENT ORAL SESSION 7: RENAL PATHOLOGY
54
A PROTOCOL BIOPSY ANALYSIS FROM AN NIH
MULTICENTER PEDIATRIC RENAL TRANSPLANT TRIAL
REVEALS NO ADVERSE EFFECT OF STEROID AVOIDANCE
ON THE HISTOLOGICAL EVOLUTION OF CHRONIC GRAFT
INJURY
M. Naesens, N. Kambham, T. Sigdel, J. Waskerwitz, O. Salvatierra,
M. Sarwal
Department of Pediatrics, Pathology and Surgery
Aim: To assess the subclinical histological evolution in the first year of an
open-label NIH-CCTPT multicenter trial of 130 pediatric renal transplant
recipients, randomized to steroid-free (SF; n=60) or steroid-based (SB; n=70)
immunosuppression.
Methods: 268 protocol biopsies performed at 0, 6 and 12 mo, were blindly
analyzed by a single pathologist using the Banff, CADI and CNIT classifications.
All indication biopsies with clinical acute rejection (AR; 23.3% for SF and
21.4% for SB) were excluded from this analysis. The histological and clinical
parameters were assessed using multivariate generalized-estimating-equations
statistical analysis.
Results: Subclinical AR was present in 12.2% SF vs. 8.5% SB bx at 6 mo and
0% SF vs 5% SB bx at 12 mo (p=NS); borderline AR was seen in 2.4% SF vs.
8.5% SB bx at 6 mo and 10% SF vs. 5% SB bx at 12 mo (p=NS). Despite the
pristine condition of the kidneys at implantation, regardless of steroid exposure,
there was a significant trend increase (p<0.0001) in chronic tubulo-interstitial
damage; 35% of 6 mo bx and 53% of 12 mo bx demonstrated IFTA; with
moderate/severe changes (IFTA grade 2-3) in 6.8% and 10% of 6 and 12 mo
bx respectively. The prevalence of biopsies with ischemic glomerular changes
(p<0.0001). tubular microcalcifications (p=0.009). vascular intimal thickening
(p=0.0008) and the number of sclerosed glomeruli (p<0.0001) increased over
the first year after transplantation, without any difference between the SB
and SF group. A critical risk factor for IFTA injury by multivariate analysis,
independent of time after transplantation, was smaller recipient size.
Conclusion: In this first ever serial histological analysis, embedded in a
randomized multicenter pediatric study of steroid avoidance, we found significant
progression of chronic graft injury in the first year post-transplantation in both
study arms. Small recipient size is the primary risk factor for tubulo-interstitial
damage, likely related to vascular size discrepancies between recipient and the
graft, resulting in chronic graft ischemia.
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55
ARE PROTOCOL BIOPSIES INDICATED IN A LIVE
RELATED RENAL TRANSPLANT PROGRAM?

56
PATTERNS OF ACUTE REJECTION IN KIDNEY
TRANSPLANT RECIPIENTS TREATED WITH ALEMTUZUMAB
INDUCTION AND STEROID-FREE MAINTAINANCE THERAPY
F. Wright, A. Bingaman, J. Palma-Vargas, P. Foster
Texas Transplant Institute
Background: Alemtuzumab (Campath 1H) has been used as induction therapy
for kidney transplant recipients with acute rejection rates reported by us and
others of 7 to 20% at one year. The histologic type of rejection and the time
frame for occurrance after treatment with alemtuzumab have not been well
established. This study is a retrospective single center review of acute rejection
episodes of kidney transplant recipients treated with alemtuzumab induction
with respect to the kinetics and histologic patterns of acute allograft rejection.
Methods: From 11/01/03 to 10/31/06, 416 kidney transplants were done.
All patients had negative T and B cell flow cytometric crossmatchs and
received induction therapy with alemtuzumab 30mg IV intra-operatively,
methylprednisolone 500-750 mg during the first 24 hours, and were then
maintained on tacrolimus (target level 5-7) and mycophenolate mofetil
(MMF) without steroids. All episodes of biopsy-proven acute rejection
(AR) were reviewed. Patients in pre-transplant desensitization protocols or
with documented non-adherence with medications were excluded from the
analysis.
Results: A total of 44 of 416 patients (10.6%) experienced AR during the study
period, with a mean follow up of 28 months (range 14- 48 months). Of the AR
episodes, 19 (43%) occurred within the first 3 months post-transplant, 13 (30%)
occurred between 3-6 months, 5 (11%) occurred between 6-9 months, 1 (2%)
occurred between 9-12 months, and 6 (14%) occurred more than one year post

57
HISTOPATHOLOGIC PARAMETERS ASSOCIATED WITH
ACUTE ANTIBODY MEDIATED REJECTION CORRELATE
BETTER WITH THE DEVELOPMENT OF CHRONIC
ALLOGRAFT INJURY COMPARED TO PARAMETERS
ASSOCIATED TO ACUTE CELLULAR REJECTION
J. Pisrch1, J. Torrealba1, J. Pascual2, F. Lopez3, A. Djamali1, S. Knechtle1, H.
Sollinger1, M. Samaniego1
1
University of Wisconsin, Madison, Wisconsin, 2Hospital Ramon y Cajal,
Madrid, Spain, 3San Rafael Hospital, New Haven, Connecticut
Chronic allograft injury/rejection (CAI) is a major cause of allograft failure
in clinical transplantation; however its precise pathogenesis/etiology is poorly
understood. In order to investigate histopathologic parameters of acute rejection
associated to the progression to CAI we evaluated 167 kidney transplant patients
from 2002 to 2005 that had undergone at least 3 consecutive kidney biopsies
during that period (632 biopsies). We analyzed biopsies for acute cellular
(ACR) and antibody-mediated rejection (AMR) and subsequent development
of severe CAI, including severe chronic transplant glomerulopathy (TG).
interstitial fibrosis, tubular atrophy and/or chronic allograft vasculopathy.
30 patients (18%) developed severe CAI. The development of CAI was strongly
associated with a biopsy diffusely positive (>50% peritubular capillaries, PTC)
for C4d (p<0.014, RR 4.41). capillary leukocyte margination (p<0.008, RR
3.57). intimal fibrinoid necrotic arteritis (p<0.02, RR 7.8). severe interstitial
mononuclear inflammation (p<0.018, RR 9.3). Parameters not associated with
the development of severe CAI were focally positive C4d (<50% positive PTC).
acute tubular necrosis, interstitial hemorrhages, any degree of tubulitis, acute
glomerulitis, intimal cellular arteritis, recurrence of primary glomerulopathy
and arteriolar hyalinosis.
62 patients (37.12%) developed mild to severe TG. Only the diffuse pattern of
C4d staining and not the focal pattern was associated with the development of
TG (p<0.0006, RR 10.2).
In conclusion, the majority of histologic parameters associated with the
development of severe CAI were related to findings traditionally related to
acute AMR more than ACR. In addition, persistent severe chronic mononuclear
interstitial inflammatory infiltrate of the allograft, regardless of any degree of
tubulitis seemed to also correlate with ulterior development of CAI.

58
RENAL BIOPSY APPEARANCES AFTER ANTIBODY
INCOMPATIBLE TRANSPLANTATION: EARLY GLOMERULAR
MARGINATION AND SUBSEQUENT CAPILLARITIS IN
RELATION TO CLINICAL STATUS AND DONOR SPECIFIC
ANTIBBDY LEVELS
R. Higgins1, K. Chen1, R. Hamer1, N. Krishnan1, S. Fletcher1, D. Briggs2,
J. McKinnell1, D. Zehnder3
1
University Hospital, 2Histocompatiblity Laboratory, UK Blood and
Transplant, 3Warwick Medical School
Background: The current understanding of the histological appearances of
antibody-mediated rejection is described in the Banff 07 classification of renal
allograft pathology. The aim of this study was to compare the classification
with the findings in our programme of antibody incompatible transplantation.
Methods: Renal biopsies from patients with donor specific antibodies (DSA)
to HLA were scored by Banff 07, and were stained for CD45, and a subset also
for CD20, CD68 and CD3. Numbers of positively stained glomerular cells, and
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S. Guleria1, S. Jain1, A. Dinda1, S. Mahajan1, S. Gupta1, D.Bhowmik1,
S. Aggarwall1, S. Tiwari1, A. Panigrahi1, N. Mehra1
1
All India Institute of Medical Sciences, 2All India Institute of Medical
Sciences, 3All India Institute of Medical Sciences, 4All India Institute of
Medical Sciences, 5All India Institute of Medical Sciences, 6All India Institute
of Medical Sciences, 7All India Institute of Medical Sciences, 8All India
Institute of Medical Sciences, 9All India Institute of Medical Sciences, 10All
India Institute of Medical Sciences
Aim: The aim of the present study was to assess the impact of protocol
biopsies in tacrolimus based immunosuppression era in a live related renal
transplant program.
Material and Methods: Sixty six live related renal transplant recipients were
randomly allotted to a protocol biopsy group (Group I) or a non protocol biopsy
group (Group II) Both groups were put on immunosuppression which consisted
of tacrolimus, Mycophenolate Mofetil/Azathioprine or steroids. Protocol
biopsies were carried out in Group I on day thirty, Ninety and one year post
transplant with an intention to treat.
Both groups were analyzed at the end of one year with regard to graft survival,
patient survival and the serum creatinine.
Results: Group I consisted of 30 males and four females with a mean age
of 36.55 years. Group II consisted of 30 males and two females with a mean
age of 31.58. The number of HLA mismatches in Group I was 2.7 and in
Group II was 2.4.Group I had 29 patients on Mycophenolate Mofetil and 5 on
Azathioprine while Group II had 24 patients on Mycophenolate Mofetil and
8 on Azathioprine. Tacrolimus was given at a dose of 0.15 mg/kg adjusted to
blood levels of 8-12 ng/ml during the first three months and 6-8 during the
next three months and 4-6 ng/ml thereafter. There was no difference in both
the groups with regards to the warm ischemia time or the cold ischemia time.
There was no significant difference between the mean tacrolimus level between
the two groups at one month, six month and one year. Group I had 18.75% of
sub-clinical rejection at one month, 9.09% at six months and none at twelve
months. However the incidence of CNI toxicity was 12% at one month, 36%
at six months and none at one year. Group II had 5.88% acute rejection in the
first month, 2.9% by the end of six months and none at the end of one year.
There was no difference in graft survival, patient survival or the mean serum
creatinine between the two groups.
Conclusion: Protocol biopsies have a limited role in a live well-matched renal
transplant program with tacrolimus based immunosuppression in the short
term. However the long term impact needs further evaluation

transplant. Of the rejection episodes within the first 3 months post-transplant,
9/19 occurred within the first 30. Histologic analysis showed that 9/19 (47%)
of rejection episodes within the first 3 months included an antibody mediated
component (6/9 within the first 30 days.) In contrast, 3/25 rejection episodes
(12%) which occurred greater than 3 months post-transplant were antibody
mediated. Of the 12 patients with antibody mediated rejection, 3 patients had
panel reactive antibody (PRA) levels > 30% at the time of transplant.
Conclusion: This large experience with alemtuzumab induction therapy
with a steroid-free maintainance protocol, demonstrates that the majority of
rejection episodes occur within the first 6 months post-transplant, with the
largest fraction in the first 3 months. A significant number of early rejection
episodes are antibody mediated and occur in unsensitized recipients. Allograft
dysfunction early after transplantation with alemtuzumab induction warrants
aggressive investigation, including biopsy with appropriate studies to identify
antibody mediated rejection.
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total cortical cells per high power field (hpf) were counted.
Results: 36 patients had 72 renal biopsies; 29 patients had pre-transplant
plasmapheresis to remove DSA. 29 biopsies were performed 30 minutes after
graft reperfusion. The mean number of CD45+ cells per glomerulus was higher
than in control antibody compatible grafts (p<0.04). The number of glomerular
cells was associated with the DSA level (p<0.01). and 8/8 patients with
greater than 5 CD45+ cells per glomerulus had rejection or oliguria, compared
to 11/21 with up to 5. In the first 10 days post-transplant, 25 biopsies were
performed in 20 patients, 13 of whom proceeded to ATG or OKT3. Although
PTC 3 margination and C4d deposition were specific for rejection, their
sensitivities were low. PTC3 leucocyte margination developed by day 2 after
transplantation, but the extent of cellular infiltration rose to peak levels by day
6. PTC C4d staining was not seen in the first 5 days after transplant, even in
the presence of rejection, but was present in the majority of later biopsies with
rejection. In biopsies with leucocyte subset staining, the glomerular cells were
1% CD20+, 66.6% CD68+, and 32.4% CD3+; the interstitial cells were 1.8%
CD20+, 50.2% CD68+, and 48% CD3+.
Conclusions: Glomerular margination of lympho-histiocytic (CD45 +) cells
occurred early after transplantation and was associated with DSA level and
early graft dysfunction. The Banff 07 PTC margination scoring system was
easy to apply, PTC3 was always associated with rejection, but PTC1-2 were
not specific for serious rejection. A significant proportion of the leucocytes in
glomeruli and renal interstitium were CD3+. C4d was not seen in PTC for the
first few days after transplantation, even in the presence of cellular margination,
and this requires further investigation.

59
DECREASED INTERSTITIAL FIBROSIS AFTER RENAL
TRANSPLANTATION OBSERVED WITH INHIBITION OF
THE RENIN-ANGIOTENSIN SYSTEM (RAS): RESULTS OF A
MULTICENTRE PROTOCOL BIOPSY (PBX) STUDY. D. RUSH
FOR THE CANADIAN FKC008 STUDY GROUP.
P. Nickerson, D. Rush1, A. Boucher2, S. Cockfield3, C. Girardin4, G. Knoll5,
J-G. Lachance6, D. Landsberg7, J. Shapiro8, A. Shoker9, S. Yilmaz10
1
Health Sciences Centre, 2Hopital Maisonneuve-Rosemont, 3University of
Alberta, 4CHUM Hopital Notre Dame, 5The Ottawa Hospital, 6Hotel-Dieu
de Quebec, 7St. Paul’s Hospital, 8Diamond Health Care Centre, 9St. Paul’s
Hospital, 10Foothills Medical Centre
We reported a multicentre randomized study in which patients were randomized
to PBx at 1, 2, 3, 6 and 24 months (PBx arm; n=121) or to biopsies at 6 and
24 months only (Control arm; n=119). Patients in both arms were biopsied at
implantation and treated with TAC/MMF/prednisone. The aim of the study was
to determine the effect of detection and treatment of early subclinical rejection
on chronic histology (ci+ct ≥2) at 6 months. We found no benefit of early PBx,
possibly because the prevalence of subclinical rejection was <10% between
months 1-3. In the ITT biopsied population (n=192). the prevalence of ci+ct ≥2
was 2 vs. 3%, 20.5 vs. 35%, and 39 vs. 48% in the Control and PBx arms, at
implantation, 6 months and 24 months, respectively. The preliminary logistic
regression analysis, adjusted for 14 baseline prognostic variables, showed that
the only independent correlate of ci+ct ≥2 at 24 months was having received a
kidney from a deceased donor (ATC 2007).
In this post-hoc analysis, we determined the effect of RAS inhibition with ACE
inhibitors (ACEi) ± AII receptor blockers (ARB) on interstitial fibrosis. Of the
192 biopsied patients, 100 (52.1%) never received ACEi/ARB and 92 (47.9%)
received ACEi/ARB at some point during the study. By logistic regression, use
of ACEi/ARB was associated with a decrease in ∆ fibrosis ≥0.5 between 6-24
months (p=0.0072).
We next evaluated a cohort of 101 patients that had both a 6 and a 24 month
biopsy. Of these, 70 were designated the No ACEi/ARB group, of which 12
(17.1%). had a mean ACEi/ARB exposure of only 109 ± 64 days (range 3-198
days). The 31 remaining patients, the ACEi/ARB group, had a mean exposure
of 479 ± 96 days (range 314-840 days). The number of patients that had ci+ct
≤ 2 at 6 months and ci+ct ≥2 at 24 months was 22/70 (31.4%) in the No ACEi/
ARB group; and 5/31 (16.1%) in the ACEi/ARB group (p=0.001). The final
logistic regression analysis showed that neither the original randomization
variables (treatment arm, donor age->50 vs. ≤ 50- and donor status –living vs.
deceased). nor any other variables except for ACEi/ARB use had a significant
effect on the progression of ci+ct ≤ 2 at 6 months to ci+ct ≥2 at 24 months (χ2
4.277; odds ratio 0.234; CI of odds ratio 0.059-0.927; p=0.0386). There was
no effect of ACEi/ARB use vs. no use in terms of the ClCr (77.62 ± 21.52 vs.
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76.20 ± 22.32 ml/min) or Hgb (139.6 ± 14.6 vs. 138.6 ± 13.5 g/L) respectively,
at 24 months.
These findings suggest that progression of interstitial fibrosis in renal transplant
patients under TAC/MMF/prednisone and ACEi/ARB may be decreased in
comparison to those under TAC/MMF/prednisone and no ACEi/ARB, and call
for randomized trials that include both clinical and histological endpoints in
such patients.

60
DONOR AGE AND THE SUSCEPTIBILITY TO CHRONIC
CALCINEURIN INHIBITOR NEPHROTOXICITY LESIONS IN
PROTOCOL BIOPSIES AFTER RENAL TRANSPLANTATION
M. Naesens, E. Lerut, H. De Jonge, Y. Vanrenterghem, B. Van Damme,
D. Kuypers
Departments of Nephrology and Pathology, University Hospitals Leuven,
Belgium
Background: Although histological lesions typically attributed to chronic
calcineurin inhibitor nephrotoxicity (interstitial fibrosis/tubular atrophy
[IFTA], arteriolar hyalinosis [ah], glomerular capsular fibrosis [gcf] and
glomerulosclerosis [gs]) are major determinants of long-term graft outcome,
little is know about the risk factors for development of these lesions.
Methods: 252 adult renal allograft recipients, all treated with the combination
of tacrolimus, mycophenolate mofetil and corticosteroids, underwent protocol
biopsies at implantation and at 3, 12, and 24 months after transplantation.
In total, 722 good-quality renal allograft biopsies (179 for indication and
543 per protocol) were reviewed and scored according to the updated Banff
classification. Risk factors for the histological evolution were assessed using
uni- and multivariate ordered logistic regression and generalized estimating
equation statistics.
Results: Already in the first 2 years after transplantation, and mainly in the first
months after transplantation, there was a progressive and significant increase
in IFTA, gcf and gs scores (all p<0.0001). These chronic lesions were closely
interrelated. Higher donor age (> 50 years compared to < 30 years and 30-50
years) was associated with higher IFTA scores at implantation (respectively
p=0.0002 and p<0.0001). with higher IFTA at all time points after transplantation
(p<0.0001). with a significantly and gradually higher increase in IFTA by time
after transplantation (p=0.009) and with earlier onset of IFTA progression
(p<0.05). Kidney allografts from older donors also had significantly more
arteriolar hyalinosis lesions at all time points after transplantation (p=0.007).
Other risk factors for higher IFTA included prior biopsy-proven acute rejection,
which in itself was associated with higher donor age (p=0.04) and the number
of HLA-DR mismatches (p<0.0001). Exposure to tacrolimus, as measured
using all tacrolimus pre-dose trough levels performed in the first 2 years
after transplantation (N=13,667). was neither associated with the histological
appearance of the renal grafts, nor with progression of histological damage.
At all protocol biopsy time points, there was a highly significant correlation
between donor age, chronic tubulo-interstitial damage and MDRD creatinine
clearance (p<0.0001).
Conclusion: High donor age impacts on renal allograft histological evolution
beyond the immediate peritransplant period. Donor age forms a major
determinant of the histological appearance of the graft and, more importantly,
of the increase in chronic histological lesions typically attributed to calcineurin
inhibitor nephrotoxicity. Progression of histological damage suggestive of
calcineurin inhibitor nephrotoxicity is not directly related to tacrolimus blood
levels, and should be interpreted carefully.

61
PREDICTING GRAFT OUTCOME WITH EVALUATION
OF PRE-TRANSPLANT KIDNEY BIOPSY USING A
CUMULATIVE PATHOLOGY SCORE
R.B. Munivenkatappa1, J.C. Papadimitriou2, C.B. Drachenberg2, A. Haririan3,
F. Rasetto4, M.M. Cooper1, E. Schweitzer1, L. Campos1, R. Barth1,
S.T. Bartlett1, B. Philosophe*1
1
Department of Surgery, Division of Transplantation, 2Pathology, 3Division
of Nephrology. 4School of Pharmacy, University of Maryland School of
Medicine, Baltimore, MD 21201
Predicting graft outcome after renal transplantation using marginal donors based
on donor histological features has remained elusive and is subject to institutional
variability. We propose a pre-transplant donor pathology scoring system that
reliably predicts graft outcome regardless of recipient characteristics.
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Recipient’s characteristics

0.8 (0.6-1.1)

0.12

Recipient BMI

1 (0.9-1)

0.12

Recipient history of DM

1.6 (0.8-3.3)

0.16

Recipient history of HTN

0.5 (0.2-1.4)

0.20

Induction

0.5 (0.2-1.4)

0.20

Delayed Graft function (DGF)

0.7 (0.3-1.3)

0.21

Recipient sex (Female)

0.8 (0.3-1.6)

0.47

Steroid Withdrawal

1.6 (0.5-5.3)

0.48

Recipient Age (Years)

1 (0.9-1)

0.67

Table 3: Multivariate analysis with donor characteristics, cold ischemia >36 hrs and recipient
characteristics, induction agent, steroid withdrawal and DGF

Donor’s characteristics

AGE

58 ± 13

Age

MALE

64%

Gender (Male)

61.50%

AFRICAN AMERICAN

53.8%

Race (AA)

18.90%

DM

44%

Terminal Creatinine

1.23 ± 0.5mg

HTN

86%

HTN

40.20%

HLA MISMATCHES

99.70%

DM

7%

PEAK PRA

11.4 ± 25.2%

CVA’s

59.10%

DGF

52.10%

ANTI-CD25

84.30%

CNI’s

92%

STEROID WITHDRAWAL

11%

MMF

91%

Cold ischemia (Hrs)

33±10

49±15

Figure 1: Graft survival Kaplan Meier curves of the Low risk (CP <7).
Intermediate risk (CP 7-11) and High risk (CP >11) groups and six year graft
survival were 84%, 67% and 41%, p =0.002.

62
A SYSTEMATIC STUDY OF LINEAR C4D DEPOSITION IN
GLOMERULAR CAPILLARY LOOPS IN RENAL TRANSPLANT
BIOPSIES

Table: 1 Demographics of recipient’s and donors.
Maryland Aggregate Pathology Index (MAPI)
Index Score
Absent

Pathology Variable’s

Univariate (RR) (95% CI)

P

Present

Arteriolar Hyalinosis

2.8 (1.3 – 6)

0.007

3

0

Glomerulosclerosis >15%

2.3 (1.3 – 4.3)

0.007

2

0

Interlobular artery wall to lumen ratio >0.5

2 (1.1 – 3.6)

0.03

2

0

Periglomerular fibrosis

3.7 (1.2 – 12)

0.03

4

0

Scar

2.2 (1 – 5.3)

0.06

2

0

Table: 2; Univariate analysis for histopathological variables in pre-implantation wedge biopsies; Based
on the hazard ratio an index score value was attributed to each parameter and were added resulting in
the Maryland Aggregate pathology Index (MAPI). Score ranges from 0-13
Prognostic Indicators

Multivariate (RR) (95% CI)

P

MAPI

1.15 (1-1.3)

0.01

Donor Age >60 years

0.5 (0.2-0.9)

0.02

Donor cause of death (CVA)

1.4 (0.6-2.6)

0.49

Donor history of HTN

0.9 (0.4-1.9)

0.81

Donor Terminal SCr > 1.5

1 (0.4-2.3)

0.98

Cold ischemia >36 hrs

0.8 (0.4-1.7)

0.57

0.4 (0.2-0.9)

0.02

Donor Characteristics

Recipient Characteristics
PRA >40%

Recipient HLA Mismatch

MONDAY

We retrospective analyzed 286 imported deceased donors which were initially
rejected by other centers due to donor parameters between 1/00-6/05. All
kidneys were re-biopsied at our center prior to implantation. Morphometric
analysis performed consisted of measuring and calculating wall to lumen ratio
(WLR) of glomerular-size arterioles, interlobular, and arcuate/interlobar arteries;
calculating% glomerulosclerosis (GS); depicting the presence of arteriolar
hyalinosis (AH). scar (SCAR). and periglomerular fibrosis (PGF). The patients
were followed for a mean of 33±25 months. Multivariate Cox analysis was done
to evaluate the predictive value of these variables to graft outcome.
Recipient demographics are summarized in table 1. AH, GS>15%, WLR>0.5
of interlobular arteries, PGF, and SCAR were found to independently predict
graft outcome; The relative risk for each variable was rounded to an index score
and the sum created the Maryland Aggregate Pathology Index (MAPI) which
ranged from 0 to 13 (table2). MAPI reliably predicted outcome, independent of
donor and recipient parameters (table3). Kaplan Meier curves for transplants
with low (0-<7). intermediate (7-11). and high (>11) MAPI scores were
significantly different; six year graft survival was 84%, 67% and 41% for low,
intermediate and high MAPI, p =0.002 (figure1). The relative risk of graft loss
increased 15% for every MAPI point increase. Patients with PRA <40% had a
six year graft survival of 87%, 71% and 57% (p=0.035) for low, intermediate
and high groups in comparison to patient’s with PRA >40% who had 60%, 27%
and 0% (p=0.15 not significant). respectively.
MAPI is a reliable predictor of graft outcome after renal transplantation in marginal
donors, independent of other donor and recipient parameters. The relative risk of
graft loss increased by 15% for every point increase in MAPI score. Previously
sensitized patients with PRA >40% have a very poor outcome when transplanted
with higher MAPI kidneys and this combination should be avoided.

E. Vilayur, P. Trevillian, R. Nanra, A. Gillies, B. Jones, S. Carney, M. Heer
John Hunter Hospital
Background: Circumferential C4d staining of peri-tubular capillaries is one of
the major criteria for diagnosis of antibody mediated rejection under the Banff
schema. However, C4d staining by immunoperoxidase using a polyclonal
antibody allows interpretation of glomerular staining patterns. We present the
first systematic analysis of the histological and clinical significance of linear
C4d deposits in glomerular capillary loops.
Methods: Since 2002 we have performed routine C4d staining of all transplant
biopsies using both immunoperoxidase and immunofluorescent techniques.
These include implantation biopsies, 3 month protocol biopsies and service
biopsies done for clinical reasons. Linear diffuse or linear focal C4d staining
was readily differentiated from focal granular mesangial deposits. Biopsies
were scored using light, I.F. +/- E.M. and graded using Banff criteria. Clinical
data (e.g. serum anti-HLA antibodies, proteinuria, GFR) were used to support
the histological diagnosis where appropriate.
Results: 536 biopsies from 181 patients were examined. Linear diffuse (LD)
or linear focal (LF) C4d staining was observed in at least one biopsy from
55 patients (LD=27, LF = 28). The following diagnoses were made in these
patients:
1. Transplant glomerulopathy (TG): 15 patients (LD=14, LF=1)
2. Delayed acute antibody mediated rejection (DAAbMR): 6 patients (LD=3,
LF=3)
3. DAAbMR and TG: 4 patients (LD=4)
4. Recurrent glomerulonephritis (GN): 4 patients (LD=3, LF=1)
5. Acute tubular necrosis: 2 patients (LD=1, LF=1)
5. Acute antibody mediated rejection: 3 patients (LD=2, LF=1)
6. Chronic allograft nephropathy: 1 patient (LF=1)
7. Normal/minor transplant changes: 20 patients (LF=20)
14 of 55 patients (26%) with glomerular capillary C4d have lost their grafts.
11 of these patients had TG (LD=10, LF=1). 2 had TG + DAAMR (DF=2)
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and one had recurrent GN (LF=1) Overall 19 of 181 (11%) patients had TG
(LD=18,LF=1). The 5 TG patients with surviving grafts had TG diagnosed
on protocol biopsies and 4 were known to be highly sensitised with donor
specific antibodies. In these patients the LD glomerular C4d has persisted in all
subsequent biopsies even though 4 grafts still function well.
Only 2 of 98 implantation biopsies showed LF C4d. Of these, 13 patients had
LF C4d in their 3 month protocol biopsies with normal histology. In 11 the
C4d was transient, not appearing in subsequent biopsies. In 2 the LF C4d has
persisted (both highly sensitised recipients)
Conclusions: Linear diffuse C4d staining in glomeruli is invariably a marker of
significant disease in kidney transplant biopsies. It is always found in patients
with TG with or without DAAbMR. It is found in 3 month protocol biopsies
in highly sensitised individuals with donor specific antibodies, the majority of
whom have already developed early TG. Linear diffuse staining in glomeruli
also predicts graft loss. It is likely that LD C4d staining in glomeruli is an early
marker of chronic or subacute antibody mediated rejection and therefore may
be used to direct us toward treatment strategies.
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THE INFLUENCE OF DONOR AND RECIPIENT
ETHNICITY ON OUTCOMES FOLLOWING DONATION AFTER
CARDIAC DEATH KIDNEY TRANSPLANTATION
J. Locke, D. Warren, F. Dominici, A. Cameron, M. Leffell, A. Zachary,
J. Melancon, D. Segev, A. Singer, R. Montgomery
Johns Hopkins University
Background: Although the majority of deceased donor kidneys are donated
after brain death (DBD). increased recovery of kidneys donated after cardiac
death (DCD) could reduce the organ shortage and is now a national priority.
Racial outcome disparities in DBD renal transplantation have been well
described and we sought to determine if such outcomes also occur with DCD
kidneys.
Methods: Adult recipients of deceased donor kidney transplants between 1993
and 2006 were evaluated based on UNOS data. Black and white recipients
of deceased donor kidneys were stratified by donor ethnicity (white or black)
and type (DCD, standard criteria DBD, and expanded criteria DBD). Deathcensored graft survival was analyzed by Kaplan-Meier (unadjusted) and
Cox proportional hazards analyses (adjusted multivariate clinical judgment
model). Multiple sensitivity analyses were performed, including multivariate
models based on forward and backward selection as well as stratification by
transplant year to account for changes in immunosuppression and matched
control analyses. Results were robust to all sensitivity analyses and model
diagnostics.
Results: We found strong evidence that DCD kidneys from black donors
perform best in black recipients. In fact, for black recipients, DCD kidneys
from black donors confer a 57% reduction in the risk of graft loss compared
to standard criteria DBD kidneys from white donors [AHR 0.43, 95% CI 0.23
to 0.84, p=0.002]. Further, black recipients of DCD kidneys from black donors
have a 5-year death censored graft survival that is not statistically different from
white recipients of standard criteria DBD kidneys from white donors [83.8%
vs. 83.5%, p=0.5], the best deceased donor option for white recipients.
Conclusion: Our findings indicate that DCD kidney transplantation is
not associated with the same racial outcome disparities as DBD kidney
transplantation, and further, that DCD kidneys from black donors provide black
recipients with the best long-term graft survival.
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64
ORGAN PROCUREMENT AND TRANSPLANT IN
“CALCULATED RISK” DONORS IN ITALY. GRAFT AND
RECIPIENT SURVIVAL
C. De Cillia1, S. Venettoni1, L. Rizzato1, A. Ricci1, D.A. Mattucci1,
P. Grossi2, A. Nanni Costa1
1
Italian National Transplant Centre, Istituto Superiore di Sanità, Roma, Italy
2
University of Insubria, Varese, Italy
Introduction: The imbalance between organ donation and demand continues
to represent one of the main issues in transplant activity, thus “non standard”
organ transplantations have been performed over the years. The “calculated
risk” protocol has been in use nationwide.
Aim of the study: Aim of this study is to review organ procurement in Italy
and related transplantations from 2003 to 2007, then to assess graft outcome
and recipients survival among transplants carried out from 2003 to 2005.
Material and Methods: “Calculated risk” donors have been divided in
7 categories: 1) HBsAg+ 2) HCV+ 3) HBsAg+ and HCV+ 4) HCV+ and
HBcAb+ 5) HBcAb+ 6) Meningitis 7) Bacteremia
All “calculated risk” effective donors and all organs with related transplants
from the 1st of January 2003 to the 31st of December 2007 have been reviewed.
Afterwards organ and recipient survival data concerning transplantations
which were carried out from the 1st of January 2003 to the 31st of December
2005 have been analyzed and compared with those concerning the sample of
all transplanted in the same period of time.
Results: 980 “calculated risk” effective organ donors with 2571 donated organs
in all (240 hearts, 818 livers, 1432 kidneys, 20 pancreas and 61 lungs) were
reported between the 1st of January 2003 and the 31st of December 2007. In this
period 2458 patients were transplanted with the 2571 organs (57 double kidney,
15 liver/kidney, 16 kidney/pancreas, 2 heart/liver, 2 heart/lung, 42 double
lung). Table 1 shows heart, liver and kidney transplants divided according to
the risk category.
Heart
HBsAg+
HCV+
HBsAg+HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
Total
Liver
HBsAg+
HCV+
HBsAg+HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
Total
Kidney
HBsAg+
HCV+
HBsAg+HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
Total

2003
1
3
0
0
40
0
2
46
2003
1
6
0
2
113
0
8
130
2003
2
14
0
2
207
0
9
234

2004
6
1
0
3
47
0
3
60
2004
10
12
0
3
149
4
11
189
2004
24
28
0
10
259
5
15
239

2005
2
1
0
1
38
4
1
47
2005
7
11
1
5
139
9
3
176
2005
6
16
0
6
251
12
5
296

2006
1
2
0
0
22
4
5
34
2006
7
10
1
6
80
10
19
133
2006
9
10
0
4
132
15
33
203

2007
3
4
0
0
36
4
6
53
2007
9
11
0
3
126
9
33
191
2007
8
16
0
6
205
18
50
303

Total
13
11
0
4
183
12
17
240
Total
34
50
2
19
607
32
74
818
Total
49
84
0
28
1052
50
112
1375

Table 1.
Graft and recipient survival appears to be comparable to that concerning the
sample of all transplanted in the same period of time, except for hearts provided
by HBsAg+ organ donors and livers provided by meningitis and bacteremia
organ donors categories. Table 2 shows recipient survival in heart, liver and
kidney transplants.
Recipient survival
Heart
All transplanted sample
HBsAg+
HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
Liver
All transplanted sample
HBsAg+

1 year
%
84,7
60
90
100
88,7
100
87,5
%
86,5
84,2

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

2 years
%
82,1
60
90
100
85,2
100
87,5
%
82,5
84,2

3 years
%
81
60
78,7
100
83,8
100
87,5
%
79,4
84,2

4 years
%
78,9
60
78,7
100
82,2
100
87,5
%
77,9
84,2
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91,9
100
100
87,8
84,6
88,8
%
96,9
100
98,5
100
96,7
100
94,5

89,6
100
100
82,6
76,2
76,6
%
96,1
100
98,5
100
95,8
100
94,5

86,5
100
100
77,1
66,6
72,1
%
95
96,2
98,5
100
95,6
100
94,5

86,5
100
100
76,5
66,6
72,1
%
93,7
96,2
98,5
100
94,8
100
94,5

Table 2.
Conclusion: Graft and recipient survival appears to be satisfying in every risk
category; whilst data regarding HBcAb+ category are several, those regarding
the other categories are quite few. The positive issues of this study, along with
the improvements in trating these infections, should encourage to enlarge the
range of organ choice in order to increase organ procurement.

65
IDENTIFICATION OF ORGAN CHARACTERISTICS
UNSUITABLE FOR IMPLANTATION IN THE UNITED STATES
T. Mone1, M. Nowicki2, M. Stadtler1, V. Simmons1, C. Chinchilla2,
R. Mendez2, R. Mendez2, T. Shah2, Y. Cho2, S. Takemoto2
1
OneLegacy, 2National Institute of Transplantation
As a possible consequence of public disclosure of center survival rates in the
United States, organs from consenting donors may not be utilized because of
a low expected benefit to the recipient. This study examines the reasons for
non-utilization with the aim of identifying characteristics of organs not suitable
for transplantation in the United States, which could possibly be implanted
elsewhere.
Reasons for non-procurement and discard were examined in a retrospective
record review of 2,136 potential deceased donors for whom consent was
obtained from 2001-2006. Cases with consent for organ donation but blood
tests indicating positive serology may not be procured or reported to the national
registry so we augmented data from the local organ procurement agency with
results from the serologic laboratory. Statistical significance was tested using
two-tailed chi-square.
During the period of study, procurement records indicate consent was obtained
for 4,223 kidneys, 76% (n=3,231) were transplanted, 6% were not recovered
(n=237) and 18% (n=751) were discarded after procurement. The most common
reason given for non-transplantation was histological findings in the biopsy
accounting for 475 (51%) of the non-transplanted kidneys. Organ quality (n=96,
10%). virology (n=111, 12%). donor history (n=48, 5%). ischemia (n=32, 4%).
anatomic (n=25, 3%). no recipient available (n=4, 0.5%) were other reasons
given for non-transplantation.
CMV virology results were reported for 1,514 of the 2,136 donors in the
procurement database. Results were positive for 69% (n=1,046). The discard
rate was 26% when positive compared to 23% for CMV negative donors
(P=0.11). Hepatitis serology (HCV and/or HBV) was positive in 10% (n=145)
of reports with a 37% discard rate when positive versus to 24% (P=0.001)
when negative. There were no reported positive HIV results and 4 positive for
HTLV-I/II with organs from 2 of these donors discarded.
Review of serology data obtained testing donors (‘shut down cases’) identified
372 additional donors with positive serology for hepatitis viruses (HCV and/
or HBV). 7 for HIV and 32 for HTLV-I/II. These results indicate an additional
393 donors have not been procured because of positive serology indicating
infection with one or more viruses.
Retrospective examination of records in a single procurement region in the
United States suggests that over 6 years, as many as 1,732 additional kidneys
were not transplanted (54%). The majority of kidneys were discarded because
of biopsy or, to lesser degree, virology serology findings. Other studies have
indicated histologic evaluation may not accurately distinguish poor and good
kidney function after transplantation. Furthermore, certain viruses, HTLV-II in
particular, may not have an immediate impact on the recipient health. Some of
the donors maybe considered even if some serologies are positive (i.e. HTLVII) or a compatible recipient (HBV+ or HBV vaccinated) is available. These
results indicate dramatic increases in deceased donor organ transplantation
may be achieved by utilizing kidneys that are currently discarded.

66
FACTORS PREDICTIVE OF THE DISCARD OF ECD
KIDNEYS DO NOT PREDICT OUTCOME
F.L. Delmonico1, K. O’Connor1, R. Pietroski2, K. Meyer4, G. Lipkowitz3,
J. Stoff1, D. Schaubel4, R. Merion4, F. Port4, A.B. Leichtman4
1
New England Organ Bank, 2Gift of Life Michigan, 3LifeChoice Donor
Services, 4Arbor Research Collaborative for Health
Extending the opportunity of transplantation of kidneys from expanded criteria
donors (ECD) has been limited by the high rate of ECD discard. We investigated
the relationship between donor characteristics that are highly predictive of
kidney discard and post-transplant outcomes.
Methods: As part of a U.S. Health and Human Services sponsored research
grant (1 H39 OT 00123-01). factors predictive of ECD discard were determined
using Logistic Regression models adjusted for multiple donor and recipient
factors. The predictive value of those factors were then tested against several
post-transplant outcomes, including delayed graft function (DGF). graft loss,
length-of-stay (LOS). and a combined outcome (of delayed graft function, graft
loss or death during the first post-operative year).
Results: Five factors were statistically predictive of discard: percent
glomerulosclerosis (GS) 10-19% compared to GS equal to 0% (OR=2.07,
p=0.013); GS > 20% compared to GS equal to 0% (OR=4.61, p<0.0001); a final
pulsatile perfusion pump resistance > 0.4 compared 0-0.2 (OR=2.95, p=0.005);
age > 70 years compared to 50-59 (OR=3.27, p=0.0020); and the presence
of kidney cysts (OR=1.89, p=0.005). Of these factors, none was predictive of
DGF, LOS, or the combined outcome. Only age > 70 was predictive of graft
failure counting death as an event (HR=1.91, p=0.034, and only age > 70 (HR
= 2.38, p=0.025) and GS > 20% (HR=3.22, p=0.022) were predictive of death
censored graft failure. However, 55 of 256 (22%) kidneys recovered from ECD
under the age of 70 years, and with a resistance less than 0.4 and GS less than
20% were discarded.
Conclusions: Reflecting widely held beliefs within the kidney transplant
professional community, GS, resistance and age are highly predictive of
ECD kidney discard. However, this study disputes the misperception of a
relationship between those factors predictive of discard and several posttransplant outcomes. Transplant centers should reexamine the criteria by which
decisions to discard ECD kidneys are being made.

67
EARLY RESULTS OF A CONTROLLED NONHEARTBEATING PROGRAMME
J.A. Akoh, S.B. Bradshaw, M.B. Walker, J.B. Barwell, M.D. Denton, T. Rana
Plymouth Hospitals NHS Trust
Introduction: The continued mismatch between supply and demand for organs
has led to the development of controlled non-heart beating donation (CNHBD)
programmes. Between April 2006 and March 2007, 159 CNHBD yielded 307
kidneys in the UK. Key considerations in establishing a CNHBD programme
include the difficulty in prediction of asystole, logistical issues relating to
the process and outcomes of CNHBD organs. We present our experience of
CNHBD in a University Hospital with a mixed critical care unit a transplant
centre serving a population of 2.2 million.
Methods: Prior to implementation of CNHBD, a steering group determined
that the programme was feasible and an implementation committee produced
protocols covering all aspects of the programme. All referrals for CNHBD
between January 2005 and January 2008 are included in this analysis. The
cause of death, withdrawal-to-asystole, machine perfusion, organ usage, warm
and cold ischaemia times, delayed graft function, early and late graft function
were analysed.
Results: During the period, 79 patients were referred resulting in 35 proceeding
to retrieval and 61 kidneys being successfully transplanted. Forty-four patients
did not proceed because of delayed asystole (15). declined/no assent (10).
medical unsuitability (14). early asystole (4) with one becoming brain stem
dead prior to withdrawal of treatment. Of the 35 donors, 18 had intracranial
haemorrhage, 10 hypoxic brain damage and 7 traumatic brain injury. The
median time from withdrawal of futile life-sustaining therapy to asystole was
15 min (IQR 10.0-23.0). The median primary warm ischaemic time (systolic
blood pressure <50 mmHg to perfusion) was 20 min (IQR 16.0-27.0) and the
median cold ischaemic time was 18 hours (IQR 11.7-20.00). Forty one percent
(16/39) kidneys preserved by machine perfusion showed delayed graft function
compared to forty-five percent (10/22) of kidneys preserved in cold storage.
The median time to halving of serum creatinine was 7 days.
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HCV+
HBsAg+HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
Kidney
All transplanted sample
HBsAg+
HCV+
HCV+HBcAb+
HBcAb+
Meningitis
Bacteremia
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Conclusion: Structured implementation resulted in a successful CNHBD
programme providing 61 successful renal transplants from 35 CNHBDs’ in 3
years – contributing about 35% to the total number of transplants during the
period .We consider early involvement of all stakeholders contributed to the
success of the programme. Donors generally reached asystole quickly despite
low levels of ventilatory support and relatively little circulatory support.

68
DECEASED DONOR KIDNEY TRANSPLANTATION
USING EXTENDED CRITERIA DONOR KIDNEYS
FOLLOWING PULSATILE MACHINE PERFUSION--SHORT
TERM OUTCOMES
A. Basu1, I. Dvorchik1, C. Morgan1, H. Tan1, J. Donaldson1, B. Yelochan1,
S. Stuart2, P. Randhawa1, A. Marcos1, R. Shapiro1
1
Thomas E Starzl Transplantation Institute, 2Center for Organ Recovery and
Education
Aim: We studied early outcomes of deceased donor kidney transplantation using
machine perfused (MP) extended criteria donor (ECD) kidneys and compared
these to results of transplantation using ECD kidneys that were cold-stored.
Methods: Forty-four sequential kidney transplants were done after MP using
ECD [per United Network of Organ Sharing (UNOS) criteria] between May
2006 and December 2007. MP was done using the Waters RM3 (Waters
Instruments, Rochester, MN) or the Lifeport Kidney Transporter (Organ
Recovery Systems, Des Plaines, IL) machines. MP was continued until pump
parameters were optimal for transplantation, which was then performed. The
control group consisted of 88 transplants that were done using cold-stored
ECD kidneys that were transplanted into age-matched recipients between
October 2002 and November 2007.All patients received pre-conditioning
with Alemtuzumab (Campath 1H) followed by Tacrolimus monotherapy, with
spaced weaning where applicable. Statistical analysis was done using SPSS
15.0 (Chicago, IL, USA). Incidence of delayed graft function (DGF). donor
hypertension and donor cause of death were compared using the likelihood
ratio Chi-square test. Donor and recipient age, donor terminal creatinine, length
of hospital stay (LOS) after transplantation, readmissions within 3 months,
number of dialysis within 30 days post transplant, number of rejection episodes
and cold ischemia times (CIT) were compared using t-test with Levene’s test
for verification of equality of variances assumption.
Results: The CIT was significantly longer in the MP group (32.1+/-9.6 vs
24.4+/-7.6 hours, p<0.0001).In spite of the longer CIT, no difference was
noted in the incidence of DGF between the MP and control groups (p>0.38).
No difference was noted in the incidence of hypertension in the donor (p>0.7)
or, in the causes of donor death (p=0.32). No significant difference was noted
in the donor age (61+/-7.7 vs 61+/-6 yrs, p=0.85). donor creatinine (1.6+/-0.9
vs 1.5+/-3 mg/dl, p=0.84). recipient age (61+/-9.7 vs 61.5+/-9.1 yrs, p=0.68).
LOS (9+/-14 vs 6.4+/-3.8 days, p=0.22). readmissions within 3 months
(0.9+/-1.4 vs 1+/-1.3, p=0.68). number of dialysis treatments 30 days posttransplant (0.45+/-1.3 vs 0.82+/-1.8, p=0.23). or rejection episodes (0.61+/-1.1
vs 0.7+/-1, p=0.7). The LOS tended to be longer, and the number of dialyses
tended to be fewer in the MP group.
Conclusions: Early outcomes are similar using MP ECD kidneys with longer
CIT compared with non-MP ECD kidney transplants. This finding may have
important implications for the transportation and sharing of kidneys across the
various UNOS regions.

69
KIDNEY TRANSPLANTATION FROM EXPANDED
CRITERIA DONORS: EXPERIENCE IN A SERIES OF 197 CASES
T. Karatzas1, A. Gompou2, G. Zavos3, J. Bokos3, B. Papanikolaou4,
G. Miserlis4, S. Drakopoulos5, M. Koukoulaki5, K. Xiromeritis6, A.
Papachristodoulou1
1
Second Propaedeutic Department of Surgery, University of Athens, 2Hellenic
National Organization of Transplantation, 3Transplantation Unit, Laiko
General Hospital, Athens, Greece, 4Transplantation Unit, Laiko General
Hospital, Athens, Greece, 5Surgical Department of Transplantation,
University of Thessaloniki, Medical School, Thessaloniki, Greece, 6Surgical
Department of Transplantation, University of Thessaloniki, Medical School,
Thessaloniki, Greece, 7Transplantation Unit, Evangelismos General Hospital,
Athens, Greece, 8Transplantation Unit, Evangelismos General Hospital,
Athens, Greece, 9First Department of Surgery, University of Athens, Medical
School, Athens, Greece, 10Second Propaedeutic Department of Surgery,
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University of Athens
The persistent shortage of organs for transplantation universally has resulted
in the implementation of strategies for utilizing organs from extended criteria
donors (ECDs). Most transplant centers encourage the use of kidneys from
ECDs, having one or two risk variables.
Objective: We retrospectively reviewed our cadaveric kidney transplantations
(KTx) from ECDs and examined their impact on patient outcome and graft
function, rejection episodes and survival.
Patients and Methods: ECDs data reported from Registry of the National
Organization of Transplantation of Greece and KTx medical files, were
reviewed. Totally 742 cadaveric KTxs were performed during a 5-year period
(2001-2006). of which 197 (26.6%) kidneys were provided from ECDs and the
rest 545 (73.4%) from conventional donors. ECDs in our series included:
- Expanded age limits (≥ 65 yrs, ≤ 5 yrs)
- Age > 55 yrs with 1 or 2 of the following criteria: donors with history of
diabetes (DM). hypertension (HT) > 10 yrs, cause of death a cerebrovascular
accident (CVA) and serum creatinine (Cr) > 1.5 mg/dl.
Kidneys were not accepted for transplantation if a donor met three or more
criteria. No specific donor upper age limit was excluded from consideration.
The patient parameters examined included: age, sex, length of hospitalization,
patient and graft survival, rejection episodes, graft function (urea, Cr, GFR).
DGF and cause of graft loss.
Results: Kidneys provided from ECDs were: 71 from donors ≥ 65 years or
older, 11 from pediatric donors (≤ 5 years). 51 from HT, 7 from DM and 57
from CVA and Cr > 1.5 mg/dl. Several donors had two risk factors. Of the 161
KTxs eligible for inclusion analysis, 131 (81.87%) had functioning graft at
5-year follow-up, with Cr ranging from 1.5 mg/dl (Pediatric donors) to 2.66
mg/dl (DM donors). Actuarial graft survival of KTxs at 1 through 5 years was
85.3%, 77.8%, 68.2%, 60.0% and 65.0% respectively, mean urea was 76.4,
89.2, 95.2, 94.4 and 94.4 mg/dl and mean Cr was 1.95, 2.30, 2.40, 2.60 and
2.60 mg/dl respectively. Among the 161 KTxs, 73 (45.3%) presented EGF,
as post-transplant dialysis was not required. Of these 63 (86.3%) remain with
functioning graft 5 years post-transplant. The rest 88 (54.7%) KTxs developed
DGF and required one or more dialysis sessions post-transplant. Sixty-eight
(77.3%) of these had functioning graft 5 years post-transplant and 20 were lost,
with rejection being the most common cause of graft loss. KTxs from older
donors presented moderately increased rejection rate, urea (74 mg/dl) and Cr
(2.15 mg/dl). compared to pediatric donors. KTxs from HT, DM, CVA and Cr
>1.5 mg/dl donors presented increased rejection rate, urea (range: 78-98 mg/dl)
and Cr (range: 2.25-2.66 mg/dl). 5 years post-transplant.
Conclusions: The utilization of ECDs significantly increased our donor pool
of KTx in the last 5 years. Extreme donor age alone is not a prohibiting factor
in KTx. Donor HT, DM, CVA, or Cr 1.5 mg/dl and DGF, all had an adverse
effect on renal function and survival at 1 to 5 years, but none reached statistical
significance.

70
CORRELATIONS BETWEEN RESPONSES TO CDC
GUIDED SCREENING QUESTIONS FOR HIGH RISK
BEHAVIOR AND RESULTS OF EIA ANTIBODY SCREENING
ASSAYS IN POTENTIAL DECEASED ORGAN DONORS
M. Mozes, M. Harmon, A. Jaramillo, B. Labuda
Gift of Hope Organ and Tissue Donor Network, Elmhurst, Il, USA
Introduction: In 1994 the CDC published guidelines for classifying donors
of organs, tissues and cellular products as “High Risk” based on responses
to questions designed to identify behaviors which increase risk of HIV
transmission. Laboratory screening tests for transmissible viral diseases
including HIV, HCV and HBV are routinely performed on potential deceased
organ donors.
We examined whether there is correlation between affirmative responses to
screening questions and the incidence of positive antibody screening results
for HIV. Additionally, we examined the correlation with HCV and HBV EIA
testing.
Methods: Retrospective analysis of records from 4877 consented deceased
donor cases age >10 from 1995 to 2007 was performed. Donors were divided
into two groups: “CDC High Risk” (CDC-HR) where an affirmative answer (s)
to at least one CDC recommended screening questions was given (N=561) and
“Non-CDC High Risk” where no affirmative answers were given (N=4316).
Serological screening results for HIV-1/2, HCV, HBcAb and HBsAg were
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available in all cases.
Results:
Group
CDC High Risk*

N (%)
HIV
HCV **
HBsAg
HBcAb**
561 (11.5%) 5 (0.9%)
77 (13.7%) 5 (0.9%)
66 (12%)
4316
Non-CDC High Risk
16 (0.3%)
171 (3.5%) 17 (0.4%)
243 (5.6%)
(88.5%)
TOTAL
4877
21 (0.4%)
248 (5.0%) 22 (0.5%)
309 (6.3%)
*CDC High Risk was determined by screening questions only, other CDC recommended screening
including physical assessment findings, hemodilution etc. were not included in this analysis.
** p< .0001

Results: All patients had elevated IL-6 at baseline. (Mean ± SD shown in
the table, only means are graphed for clarity). Despite the small sample
size, reduction in IL-6 in the Solumedrol infusion group at explantation was
significant (p=.02). Though IL-6 level at other time-points was statistically
similar, the SD stabilized in SoluDRIP subjects but not controls. OTPD trend
appeared favorable, although unconfirmed in this sample.

71
METHYLPREDNISOLONE INFUSION EFFECTIVELY
DECREASES PLASMA INTERLEUKIN-6 (IL-6) AT
EXPLANTATION IN ORGAN DONORS AFTER BRAIN DEATH
M. Mathur1, M. Stadtler3, S. Collazo3, T. Mone3, R. Hawthorne3,
C. Chinchilla4, V. Pravica4,5, F. Petersen2, K. Bahjri2 and I. Hutchinson4,5.
Loma Linda University Children’s Hospital1and Health Research
Consulting Group2, Loma Linda, CA; OneLegacy3, National Institute of
Transplantation4and University of Southern California5, Los Angeles, CA,
USA.
Background: IL-6 is a key pro-inflammatory cytokine upregulated after
Brain Death (BD) in humans. It leads to adhesion molecule activation and
leukocyte invasion in all organs. Pre-explantation organ dysfunction is a
direct consequence of inflammation, and renders many organs unsuitable for
transplantation. Functionally, IL-6 elevation correlates with deteriorating donor
cardiac function in humans and its upregulation in kidney and liver donors
worsens ischemia-reperfusion injury in recipients. Corticosteroids modulate
gene expression of pro-inflammatory cytokines (including IL-6) thereby
ameliorating the inflammatory cascade after BD. Reduced inflammation may
help to improve the number of transplantable organs procured from each donor.
(The current average is 3.6 organs out of a possible 8 in the United States).
Though a bolus dose of Methylprednisolone (Solumedrol) is a component of
hormonal resuscitation in hemodynamically unstable BD donors, its plasma
half-life is <3 hours and independent of the dose given.
Aim: To determine whether Solumedrol given as a continuous infusion
suppresses inflammation after BD better than usual care, using IL-6 level as a
marker for the degree of inflammation.
Methods: Clinical data and serial blood samples were prospectively collected
from 11 BD subjects (ages 15-65 years) after obtaining research consent. All
patients received a 30mg/kg Solumedrol bolus as a part of usual hormonal
resuscitation. Five randomly selected patients also received Solumedrol infusion
(100mg/hr) until explantation (experimental SoluDRIP group). while the other
6 served as controls. APACHE II scores (range 12-26) were similar between
groups. Plasma IL-6 at baseline; 8, 16 and 24 hours after the Solumedrol bolus
and at explantation was quantified using IL-6 ELISA (Biogen®) with a lower
limit of detection at 4 pg/ml. IL-6 levels were compared between groups at
each time point using student t-test with alpha at .05.
Plasma IL-6 (pg/ml) and OTPD
Time-points
Baseline
8 Hours
24 Hours
Explantation* (p=.02)
Actual OTPD

SoluDRIP
Mean
709
444
232
129
4.0

SD
755
697
378
120
2.1

Control
Mean
849
607
510
668
3.00

SD
587
672
709
422
2.1

MONDAY

21/4877 (0.4%) potential donors tested HIV-1/2 antibody positive. The
incidence in the CDC-HR group was 5/561 (0.9%) vs.16/4316 (0.3%) in the
Non-CDC HR group (p= 0.15).
The incidence of HCV+ tests in the CDC-HR group was 77/561 (13.7%) as
compared to 171/4316 (3.5%) in the Non-CDC-HR group (p<.0001). The
incidence of HBsAg + tests in the CDC-HR was 0.9% vs. 0.4% in the NonCDC HR group (p=.18). The incidence of HBѕAb+ tests in the CDC HR group
was 66/561 (12%) vs. 243/4316 (5.6%) in the Non-CDC HR group (P<.0001).
Summary and Conclusions: There was a trend for higher incidence of positive
serology for all tests in the CDC HR group but this was significant only for
HCV and HBcAb. The majority of positive cases for each of the tests were in
the non High Risk group. These data need further confirmation and should be
considered when contemplating routine prospective NAT testing for potential
organ donors. Considerations of logistics, cost and potential inadvertent loss of
donors and organs associated with prospective NAT testing need to be weighed
against the current low incidence of disease transmission.
Conclusions: Continuous Methylprednisolone infusion reduces plasma IL-6 at
explantation significantly compared to current donor management. Suppression
of inflammation by Methylprednisolone infusion should be further investigated
to determine whether clinical outcomes such as organs transplanted per donor
and recipient graft survival can also be favorably impacted.

CONCURRENT ORAL SESSION 9:
XENOTRANSPLANTATION – COAGULATION/ISLETS
72
THE INNATE IMMUNE RESPONSE AND ACTIVATION OF
COAGULATION IN α1,3-GALACTOSYLTRANSFERASE GENEKNOCKOUT XENOGRAFT RECIPIENTS
M. Ezzelarab1, C.C. Lin1,2,3, H. Hara1, D. Ayares4, A. Dorling2, D.K.C. Cooper1
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, PA
2
Department of Immunology, Imperial College London, Hammersmith
Hospital, London, UK 3Department of Surgery, Chang Gung Memorial
Hospital, Kaoksiung, Taiwan 4Revivicor Inc., Blackburg, VA
Background: Acute humoral xenograft rejection (AHXR). frequently
associated with disseminated intravascular coagulation (DIC). remains a major
challenge in pig-to-primate xenotransplantation (Tx). The precise factors
initiating graft intravascular thrombosis, particularly when the predominant
pathology is thrombotic microangiopathy (TM). remain to be elucidated.
Upregulation of donor tissue factor (TF) in the xenograft has been implicated
in these processes but the importance of recipient TF has not been addressed.
Methods: Organs and aortic patches from α1,3-galactosyltransferase geneknockout (GTKO) pigs were transplanted into baboons (n=18). with or without
immunosuppression. Immunohistochemistry was used to identify IgM, IgG,
complement deposition, cellular infiltration, and primate TF expression in
the graft. Baboon TF mRNA in the graft was measured by qPCR. Baboon
monocytes and platelets were isolated from peripheral blood before and after
Tx, and analyzed for TF activity and by flow cytometry. Functional TF activity
was determined by clotting assays after mixing monocytes and platelets with
recalcified Factor VII (FVII) -deficient plasma with or without FVII.
Results: In all grafts (with or without immunosuppression). IgM, IgG, and
complement deposition was present, with neutrophil and macrophage infiltrates
(some cells expressed TF). and intravascular fibrin deposition and platelet
aggregation characteristic of TM. Clinical and/or laboratory features of DIC
occurred in >50% of organ xenograft recipients. Before Tx, monocytes and
platelets did not express TF or display TF-dependent procoagulant activity.
After pig aortic patch Tx, circulating recipient platelets (but not monocytes)
expressed TF and promoted TF-dependent clotting in recalcified plasma.
After pig organ Tx, recipient platelets expressed TF as early as day 3, while
monocytes began to express TF later. Furthermore, the organs expressed high
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levels of baboon TF mRNA.
Conclusions: Irrespective of the presence or absence of the adaptive immune
response, the development of AHXR is associated with the expression of TF
on recipient monocytes and platelets. TF expression by innate immune cells
of the recipient may be a major procoagulant factor that contributes to the
development of TM. Pigs transgenic for tissue factor pathway inhibitor (TFPI)
should have advantages in preventing AHXR.

73
HUMAN COMPLEMENT REGULATORY PROTEIN
EXPRESSION ATTENUATES THROMBIN GENERATION BY
GALTKO LUNGS
R.N. Pierson1, T. Stoddard1, S. Kelishadi1, T. Zhang1, C. Avon1, E. Welty1,
A. Laaris1, X-F. Cheng1, D. Ayares2, A.M. Azimzadeh1
1
University of Maryland Medical Center, 2Revivicor, Blacksburg, VA
Purpose: Hyperacute lung rejection (HALR, defined as significant graft
injury within 4 hours) is usually observed when GalTKO lungs are perfused
with human blood. We evaluated whether the additional expression of human
complement regulatory protein protects GalTKO lungs from injury.
Methods: Heparinized fresh human blood expanded with fresh frozen plasma
was used to perfuse GalTKO lungs expressing CD46 (hMCP) (n=4) or
CD55 (hDAF) (n=1). Pulmonary function was assessed by measuring flow,
pulmonary vascular resistance (PVR). airway pressure, and gas exchange.
The results obtained from these studies were compared with the findings from
previous perfusions of GalTKO lungs (n=14). Surviving lungs were censored
at four hours.
Results: Median survival for the GalTKO (114 min, range 15-360) and
GalTKO/hMCP (135 min, range 90-240) groups were not significantly
different. The average PVR at 10 minutes was 88±68 mm-Hg/L and
215±236 mm-Hg/L for GalTKO and GalTKO/hMCP, respectively (p=
0.46). Preliminary data suggest that, as expected, complement activation
is well controlled in GalTKO lungs expressing complement regulators.
Surprisingly, addition of hCD46 or hDAF attenuated thrombin generation
at 15’ (mean Δ; F1+2 = 0 nM) versus the GalTKO group (mean Δ; F1+2 =
4.6±8 nM) (p=0.0028). Platelet activation as measured by BTG levels did not
significantly differ between GalTKO (mean Δ;BTG = 251±134 IU/ml) and
GalTKO/MCP (mean Δ;BTG = 300±68 IU/ml). and neutrophil and platelet
sequestration were not prevented.
Conclusion: Though GalTKO lungs are not fully protected against HALR
by expression of human complement regulatory proteins, our observations
demonstrate that coagulation cascade activation is partially attenuated.
Additional strategies to better control platelet activation and prevent neutrophil
sequestration may prove pivotal to protect GalTKO lungs from injury by
human blood.

74
COAGULATION CONTROL USING GENE TRANSFER OF
HUMAN DAF AND THROMBOMODULIN IN PIG TO PRIMATE
XENOTRANSPLANTATION
Y. Miwa1,6, K. Yamamoto2, A. Katayama1,7, T. Nagasaka3, A. Onishi4,
M. Iwamoto5,4, K. Kadomatsu6, K. Uchida3, A. Nakao7, T. Kobayashi1,7
1
Department of Applied Immunology, Nagoya University School of
Medicine, Nagoya JAPAN, 2Department of Transfusion Medicine,
Nagoya University School of Medicine, Nagoya, JAPAN, 3Department of
Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, JAPAN,
4
Department of Development Biology, National Institute of Agrobiological
Sciences, Tsukuba, JAPAN, 5Prime Tech LTD, Tsuchiura, JAPAN,
6
Department of Biochemistry, Nagoya University School of Medicine,
Nagoya, JAPAN, 7Department of Surgery II, Nagoya University School of
Medicine, Nagoya, JAPAN
Introduction: Coagulation disorder such as thrombotic microangiopathy is
one of the remaining problems after hyperacute rejection was successfully
suppressed in xenotransplantation from GT-KO cloned pigs (lacking Gal
expression) or human (h) DAF transgenic pigs (expressing complement
regulatory proteins). One possible cause is assumed to be the molecular
incompatibility in coagulation system between pigs and primates, which
suggests that porcine thrombomodulin (TM) in endothelial cells binds human
thrombin, but cannot effectively convert human protein C into activated protein
C (APC). We previously reported that complement activation certainly causes
endothelial activation, resulting in subsequent procoagulation. The purpose of
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this study was to clarify the protective effect of hDAF and hTM expression in
pig endothelial cells on coagulation disorder.
Methods: hDAF-expressed porcine aortic endothelial cells (hDAF-PAEC)
were collected from hDAF cloned pig. hTM-expressed PAEC (hTMPAEC) were obtained from hTM gene transfection by electroporation. After
incubation with human sera, endothelial cell activation was evaluated by semiquantification of porcine inflammatory gene expression. TM co-factor activity,
namely APC production capacity in human aortic endothelial cells (HAEC).
PAEC and hTM-PAEC was determined using APC specific chromogenic
substrate S-2366. Clotting assay was performed by mixing the cells (1_105)
with human plasma including clotting buffer. Inhibition assay was conducted
by anti hTM (EGF 5 epitope) monoclonal antibody which specifically blocks
the binding site.
Results: hDAF-PAEC almost completely suppressed the upregulation of
pig tissue factor and plasminogen activator inhibitor-1 mRNA induced by
preincubation with human sera, and consequently improved the shortened
clotting time. Although APC production capacity in PAEC showed as low
as one-tenth of that in HAEC, some clones of hTM-PAEC expressing the
same level of TM as HAEC exhibited compatible level of APC production
capacity. Inhibition assay demonstrated that anticoagulant effect of hTM
expression was observed not in stable condition, but in activated condition
of PAEC.
Conclusions: hDAF expression in PAEC alleviated the inflammatory response
such as upregulation of TF and PAI-1 mRNA, resulting in prevention of
the subsequent procoagulation. hTM expression in PAEC regulated the
procoagulant state particularly in activated condition (e.g., induced by antibody
binding, complement activation or infection). The production of cloned pigs
expressing both hDAF and hTM genes which are useful for coagulation control
is in progress.

75
DELETION OF GAL INHIBITS THE INSTANT BLOODMEDIATED INFLAMMATORY REACTION (IBMIR)
FOLLOWING EXPOSURE OF PORCINE NEONATAL ISLETCELL CLUSTERS (NICC) TO HUMAN BLOOD.
W.J. Hawthorne1, D.M. Simond1, A.T. Patel1, J. OHara1, K. Waite1, K. Moyle1,
E. Salvaris2, N. Fisicaro2, S.L. Londrigan3, A. Lew3, E. Favaloro1, S.C.
Robson4, M. Nottle5, A. d’Apice2, P.J. Cowan2, P.J. O’Connell1.
1
The Centre for Transplant & Renal Research, Westmead Millennium
Institute, Westmead, 2St Vincent’s Health, Melbourne. 3The Walter and Eliza
Hall Institute of Medical Research, Melbourne, 4Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, 5University of Adelaide,
Adelaide.
Aims: To determine the effect of deletion of the Gal antigen, with or without
expression of CD39 and treatment with activated protein C (APC). on IBMIR.
Methods: Purpose bred piglets lacking α1,3-galactosyltransferase (Gal-/-) or
wild type (WT) controls were used as NICC donors. Select Gal-/- and WT
NICC were also transduced using an adenoviral vector expressing human
CD39 (CD39) & treated with 1.25 or 2.5ug APC. 5,000 NICC were exposed
to 7ml of human blood in a heparin bound loop system on a rocking incubator
for 60 mins.
Results: Gal-/- NICC showed less clotting & reduced platelet (Plt) & neutrophil
consumption compared to WT control NICC. Gal-/- NICC expressing human
CD39 and treated with 2.5ug APC demonstrated the greatest reduction in clot
size, reduced Plt, neutrophil, fibrinogen & D-Dimers consumption compared
to all other NICC. Histology also demonstrated that Gal-/- NICC transduced
CD39 treated with 2.5ug APC were the most intact having less infiltration of
neutrophils than the WT clots.
Conclusions: These studies clearly demonstrate that more than one strategy
or agent will be required to prevent the full extent of IBMIR. Removal of
αGal must be part of the strategy to prevent the early innate response to NICC
xenografts.
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TRANSGENIC OVEREXPRESSION OF HUMAN EPCR
CONFERS PROTECTION AGAINST INFLAMMATION AND
COAGULATION

77
OVER-EXPRESSION OF CD39 IN TRANSGENIC MICE
AFFECTS NKT CELL DEVELOPMENT AND FUNCTION –
IMPLICATIONS FOR LIVER XENOTRANSPLANTATION
S. Pommey1, S. Robson2, A. d’Apice1, P. Cowan1, K. Dwyer1
Immunology Research Centre, St Vincent’s Hospital, 2Beth Israel Deaconess
Medical Center, Harvard Medical School
Introduction and Aim: The critical shortfall in human donor organs has led
to renewed interest in xenotransplantation. Genetic modification of the donor
animal by deletion of Gal or expression of complement regulatory proteins
has overcome hyperacute rejection. In an attempt to overcome acute vascular
rejection, the next immunological hurdle, we have generated transgenic mice
and pigs that express human CD39 (hCD39). CD39 is a major vascular and
immune ectonucleotidase that, in concert with CD73, hydrolyses extracellular
ATP (a ¡¥danger¡¦ signal) and ADP (a platelet agonist) to the anti-inflammatory
molecule adenosine. In mouse models, we have shown that the expression

1

78
INHIBITION OF THE INSTANT BLOOD-MEDIATED
INFLAMMATORY RESPONSE (IBMIR) BY EXPRESSION
OF HUMAN CD39 ON PORCINE NEONATAL ISLET-CELL
CLUSTERS (NICC).
D.M. Simond1, A.T. Patel1, S.L. Londrigan2, J. O’Hara1, K. Waite1, K. Moyle1,
S. Ginn3, E. Favaloro1, M. Nottle4, A. Lew2, E. Salvaris5, N. Fisicaro5,
S.C. Robson6, A. d’Apice5, P.J. Cowan5, P.J. O’Connell1 and W.J. Hawthorne1
1
The Centre for Transplant & Renal Research, Westmead Millennium
Institute, Westmead, 2The Walter and Eliza Hall Institute of Medical Research,
Melbourne, 3Gene Therapy Research Unit, The Children’s Hospital,
Westmead, 4University of Adelaide, Adelaide. 5St Vincent’s Health, Melbourne.
6
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.
Aims: IBMIR is elicited upon exposure of porcine neonatal islet-cell clusters
(NICC) to human blood. The aim of this study was to investigate whether over
expression of the anti-thrombotic ecto-nucleotidase CD39 can inhibit IBMIR.
Methods: NICC were transduced using an adenoviral vector expressing
human CD39. Transduced or wild type NICC were placed in 7ml human
blood in a heparinised loop system for 60 min. 1.25 or 2.5μg activated
protein C (APC) was added to select loops to down-regulate coagulation and
inflammation. Clot weight, haematological parameters, coagulation factors &
immunohistochemistry were assessed.
Results: Clot formation, platelet sequestration into clots and neutrophil
consumption were significantly reduced with the combination of CD39
expression & 2.5μg APC when compared with CD39 or APC alone. Reduction
in consumption of monocytes and eosinophils and an increase in basophils
were seen in those loops containing CD39 NICCs with 2.5μg APC. CD39expressing cells were mainly localised around the periphery of the NICC.
There was less neutrophil adhesion and infiltration in NICC with CD39 plus
APC when compared with wild type NICC with CD39 or APC alone.
Conclusions: Transduction of NICC with CD39 inhibited the thrombotic
effects of xenogenic IBMIR and worked synergistically with a clinically
relevant dose of APC.
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E. Lee, J.C. Roussel, B. Lu, L. Murray-Segal, O. Ischenko, A. d’Apice,
P. Cowan, H. Gock
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Australia.
Background: Despite success in overcoming hyperacute rejection in pig-toprimate xenotransplantation, organ xenografts are still susceptible to a number
of insults leading to graft failure, including ischaemia-reperfusion injury
(IRI) and acute vascular rejection (AVR). The contribution of IRI is currently
unknown but both conditions involve inflammation and coagulation. The latter
is a particular problem in AVR, one feature of which is widespread thrombosis
within small blood vessels. Our strategy to counter these effects is to overexpress
and increase the distribution of human coagulation and inflammation regulators
in donor tissue. The endothelial protein C receptor (EPCR) not only enhances
protein C activation to regulate coagulation, but generates anti-inflammatory
and cytoprotective signals to endothelial cells via the PAR-1 receptor. However,
expression of EPCR is limited to large blood vessels. We recently generated
C57BL/6 transgenic mice expressing human EPCR (hEPCR) from the H-2Kb
promoter, which we have previously demonstrated drives transgene expression
in both large and small blood vessels.
Aims: To examine the phenotype of the hEPCR transgenic mice with regard to
coagulation and inflammation.
Methods: (1) Tissue expression and distribution of hEPCR were determined
by immunohistochemistry. (2) Anti-coagulant phenotype was assessed in two
ways. (i) Tail bleeding time: the tails of anaesthetised hEPCR (n=4) and wildtype (WT) (n=4) mice were transacted near the tip and immersed in warm
saline, and time to cessation of bleeding was recorded. (ii) Resistance to
intravascular thrombosis: anaesthetised hEPCR (n=8) and WT (n=9) mice were
injected with 0.6μ;g collagen/g body weight via the jugular vein. Survival and
lung histology for thromboembolism were assessed. (3) Anti-inflammatory and
cytoprotective phenotype was examined using an in vivo kidney IRI model.
After removal of the right kidney, the left renal pedicle of hEPCR (n=9) and
WT (n=20) mice was clamped for 18 minutes followed by 24 hrs of reperfusion.
Body temperature was maintained at 37ºC during surgery. Renal function
was determined by serum creatinine and urea levels, and tissue damage was
assessed by histopathology.
Results: (1) hEPCR was widely expressed in small and large vessels in all solid
organs in the transgenic mice. (2) (i) hEPCR mice had a prolonged bleeding
time compared to WT mice (mean = 2.6 ± 1.1 min versus 10.8 ± 1.9 min,
p<0.02). (ii) hEPCR mice were more resistant to collagen-induced intravascular
thrombosis than WT mice (survival rate 75% versus 22%, p<0.05). and showed
fewer pulmonary thromboemboli. (3) hEPCR mice were more resistant to
renal IRI than WT mice, with superior renal function at 24 hrs (mean serum
creatinine 39 ± 2.3 μmol/L versus 82.6 ± 10.0 μmol/L, p<0.01; mean urea 16
± 1.1 mmol/L versus 31.5 ± 2.8 mmol/L, p<0.01). Histopathological analysis
confirmed less renal injury in the hEPCR mice compared to WT mice.
Conclusion: Overexpression and wide distribution of hEPCR protects against
IRI and collagen-induced thrombosis, consistent with increased regulation of
coagulation and inflammation, and results in only a mild bleeding phenotype.
Transgenic expression of hEPCR may therefore be a useful donor genetic
modification in xenotransplantation.

of hCD39 protects against renal ischaemia-reperfusion injury and affords
a survival advantage in a cardiac transplant model. However, enhanced
adenosine generation in the hCD39 transgenic (hCD39tg) animals may have a
wider impact because of adenosine¡¦s well documented influence on thymocyte
development and T cell proliferation. Transgene expression is under the
control of the murine H-2Kb (MHC class I) promoter and TCR£\ enhancer,
which together would be expected to drive high expression in the thymus and
therefore potentially accentuate any effects on thymic maturation. We therefore
investigated the effect of hCD39 over-expression on the development and
function of leukocytes in hCD39tg mice. We paid particular attention to NKT
cells, which (at least in rodents) form a large resident population within the liver
and may be responsible for the spontaneous acceptance of liver allografts.
Methods: The development and maturation stages of thymocytes and
peripheral lymphocytes in hCD39tg and wild type (WT) mice were analysed
by flow cytometry. Lymphocyte function was assessed in vitro and in vivo
using anti-CD3/anti-CD28 antibody stimulation and intra-peritoneal injection
of £\-galactosylceramide respectively.
Results: Flow cytometric analysis revealed two-fold higher expression of
hCD39 in the thymus of hCD39tg mice compared to the spleen and liver,
and this was associated with a marked reduction in total thymocyte number
compared to WT mice. Thymic maturation was arrested at the CD4+CD8+
double-positive stage resulting in a deficiency of both CD4+ and CD8+ singlepositive thymocytes, and hCD39tg mice exhibited a peripheral CD4+ T cell
lymphopenia. Residual lymphocytes displayed decreased proliferation in
response to anti-CD3/anti-CD28 stimulation evident at day 4 of activation.
Notably, hCD39 transgenic mice had a profound deficiency in NKT cells,
which was particularly marked in the liver (more than 30% reduction versus
WT). Surviving NKT cells displayed impaired IFN-ƒ× and IL-4 production
following in vivo injection of £\-galactosylceramide as demonstrated by
intracellular cytokine staining and ELISA, respectively.
Conclusion: Our data strongly suggest that over-expression of hCD39
affects T lymphocyte and, in particular, NKT cell development and function.
Given the importance of resident NKT cells in rodent models of hepatic
transplantation, we will explore the relevance of this deficiency using a murine
liver transplant model. This may have significant implications for the future of
liver xenotransplantation.
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79
CYTOKINE-MEDIATED UPREGULATION OF
TRANSGENE EXPRESSION IN TRANSGENIC PIG
ENDOTHELIAL CELLS
E. Salvaris1, M. Nottle2, A. d’Apice1, P. Cowan1
1
Immunology Research Centre, 2University of Adelaide
Background: We have previously generated transgenic (Tg) pigs expressing
human CD55 and CD59 from the murine H-2Kb (MHC Class I) promoter and
demonstrated significant expression on solid organs and islets. This expression
is sufficient to prevent hyperacute rejection (HAR) of pig-to-baboon renal
xenografts. Because MHC class I expression is upregulated by proinflammatory
cytokines, we investigated here whether transgene expression in porcine aortic
endothelial cells (PAEC) isolated from the Tg pigs could be upregulated by
treatment with various human and pig cytokines.
Aim: To determine the effect of treatment of CD55-CD59 Tg PAEC with
different cytokines (human TNFalpha, IFNgamma and IL-1beta; porcine
IFNgamma) on transgene expression.
Methods: PAEC were isolated from CD55-CD59 Tg and wild type (WT) pigs
and purified to >95% purity using MACS beads and an anti-CD31 monoclonal
antibody. Low passage primary cultures were treated separately with human
TNFalpha (10ng/ml). human IFNgamma (5ng/ml). human IL-1 beta (5ng/
ml) or porcine IFNgamma (5n/ml) for 24 or 48 hours. Cells were analysed for
CD55 expression by FACS.
Results: Untreated Tg and WT PAEC stained for human CD55 had a mean
channel fluorescence (MCF) of 120 ± 10 and 21 ± 2, respectively. Treatment
of Tg cells with human TNFalpha or pig IFNgamma for 24 hrs increased
CD55 expression 3.4-fold and 4.1-fold, respectively, with no further increase
observed between 24 and 48 hrs. In contrast, treatment with human IFNgamma
or IL-1 beta had minimal effect (<0.3-fold increase). Cytokine treatment of WT
PAEC had no effect on MCF.
Conclusions: Our results suggest that the use of the cytokine-inducible H-2Kb
promoter to express protective transgenes may offer considerable advantages in
the inflammatory environment of the xenograft. Indeed, effective suppression
of HAR using our CD55-CD59 pigs as donors may be due in part to transgene
upregulation by primate TNFalpha. Furthermore, it opens the possibility for
cytokine treatment of cultured Tg pig islets to boost transgene expression prior
to transplantation, although counterbalancing of these positive effects with
induction of potentially detrimental molecules such as SLA must be taken into
consideration. The lack of effect of human IFNgamma is intriguing, but not
unexpected in the light of earlier reports of species-specificity in the efficacy
of this cytokine.

80
REDUCED INSULIN REQUIREMENTS IN TRANSIENTLY
IMMUNOSUPPRESSED NON-HUMAN PRIMATES
TRANSPLANTED WITH MICROISLET P™ (ALGINATE
ENCAPSULATED PORCINE ISLETS): A NON CLINICAL
SAFETY STUDY
I. Stuiver, L. Ricks, W. Soo Hoo, M. Patel, N. LaFontaine, A. Basu,
MicroIslet, Inc.
Due to our consistent success in rodents, a non-clinical/non GLP study in nonhuman primates was initiated. Initial studies indicated that a transient course of
immunosuppression was necessary to promote an increased duration of graft
survival. Juvenile pig islets were encapsulated in a biodegradable alginate
microcapsule and transplanted (Tx) at a dose of 30,000 ± 3000 IEQ/kg into 19
transiently immunosuppressed Rhesus Macaques. The safety study consistst of
4 arms: Two animals with a single Tx for 6 months; Six animals with two Tx
for 6 months; Five animals with a single Tx for 12 months; Six animals with 3
transplants for 12 months. Body weight, blood glucose, fasting blood glucose,
glycosuria, insulin, porcine c-peptide, HbA1C, fructosamine and duration of
graft function were monitored. IVGTTs monitoring the diabetic state were also
performed.
Diabetes was induced with a single dose of streptozotocin into heathly Rhesus
Macaques and confirmed by a significant rise in daily blood glucose levels,
diabetogenic fructosamine and IVGTT glucose levels. The diabetic animals
were maintained on 2-3 daily doses of insulin (Humulin® and/or Lantus®)
for at least 1 month prior to transplantation, to confirm stable diabetes. Three
days prior to Tx, the animals were administered therapeutic levels of two
immunosuppressive agents, Tacrolimus (FK506) and Sirolimus (rapamycin).
The trough levels were monitored throughout the course of administration, for
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a duration of 6 weeks, after which each agent was gradually tapered off starting
with Tacrolimus. Encapsulated islets were transplanted at a dose of 30,000 ±
3000 IEQ/kg 2 days after initiation of immunosuppression and blood glucose
and animal health monitored closely. No product related adverse reactions
were observed throughout the study. Normoglycemia (80-150 mg/dl) was
achieved for several days after Tx, after which 0.5-1.5 units of insulin was
necessary to maintain blood glucose levels below 250 mg/dl for a duration of
2-4 weeks. Though there was a progressive increase in insulin requirements,
several animals maintained reduced insulin requirements for up to 6 months.
In two arms of the study, the effect of retransplantation on acute rejection
was monitored. The majority of animals responded similarly to the second
and third Tx as to the first Tx. At necrospy, gross pathological examination
revealed no peritonitis and the peritoneal membrane was clear and glistening.
No organs were affected by the transplants. However in some animals, small
pin-point adhesions were observed on or near the bladder. Minimal evidence
of residual beads remained in singly or multiply Tx’d primates at the time of
their termination, which illustrates the biodegradable nature of the product.
The dissolution of the encapsulated islet reduced the duration of efficacy but
did not effect the safety of the animal. The data derived from this study will
be submitted to the FDA as part of an IND package for the initiated of Phase I
safety studies in man.

CONCURRENT ORAL SESSION 10:
PANCREAS TRANSPLANTATION
81
ABSENCE OF THROMBOSIS FOLLOWING PANCREAS
TRANSPLANTATION: IT CAN BE POSSIBLE.
F. Vistoli1,2, G. Karam1, U. Boggi2, M. Giral1, C. Croce2, M. Del Chiaro2,
C. Moretto2, F. Mosca2, J-P. Soulillou1 and D. Cantarovich1
1
Institut de Transplantation et de Recherche en Transplantation – Centre
Hospitalier Universitaire de Nantes, Nantes, France 2Regional Referral
Center for Treatment of Pancreatic Diseases, Tuscany Region and University
of Pisa, Pisa, Italy
Background: Although significant improvements in surgical and medical
procedures, vascular thrombosis (T) accounts for more than 70% of all technical
failures after pancreas transplantation (PTx).
Methods: Between May 1996 and November 2007, 472 PTx (94.5% primary)
were performed in 2 European Institutions, including 320 simultaneous
pancreas-kidney transplants (SPK). 27 simultaneous cadaver pancreas living
kidney transplants (SPLK). 88 PTx alone (PTA) and 36 pancreas after kidney
transplants (PAK). Recipient’s age ranged from 20 to 61 yr (mean, 40).
The majority of grafts (n= 453) were enteric diverted and more than half
(n= 259) with portal insulin drainage. Prophylaxis with heparine, low-dose
aspirin and/or sodium warfarin was systematically given. Graft function and
vascular monitoring (daily plasma C peptide and color echo-doppler) were
routinely performed. Multivariate Cox proportional hazard model was used
to investigate the impact of 56 different variables related to donor, recipient,
transplantation and immediate postoperative period as putative risk factors
of thrombosis.
Results: One and 5-year overall pancreas survival was 85.5% and 75%,
respectively. Patient survival was 95% at 1 year and 91% at 5 years.
Graft failure due to complete thrombosis occurred in 5.7% of recipients
(SPK+SPLK= 5.8%; PTA= 4.5%; PAK= 11%) after a mean of 5.8 days
following PTx (SPK+SPLK= 6 d; PTA= 5.3 d; PAK= 5.5 d). According to
univariate analysis [pValue (Hazard ratio) ], cold ischemia time (irrespective
to perfusion solution used) was the major factor influencing pancreas
thrombosis (0.0001 [2.6]). followed by steroid avoidance (0.02 [HR 2.5])
and more recent transplant period activity (0.04 [HR 2.4]). Donor body mass
index (0.09). thymoglobulin induction (0.09). non-local harvesting (0.12)
and waiting time (0.16) failed to reach a statistically significance but were
included in the multivariate analysis. No pancreas thrombosis occurred in the
95 recipients (20.1%) with cold ischemia <10 hours. Cox regression analysis
[pValue (Hazard ratio) ] confirmed cold ischemia time as the powerfull
variable risk factor for thrombosis [0.0001 (2.7) ], as well as steroid
avoidance [0.02 (2.6) ] and the more recent period of centre activity [0.008
(3.2) ]. Cox analysis also demonstrated that pancreas cold ischemia time
reached statistical significance after 11 hr, with a consistent and progressive
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PANCREAS TRANSPLANT ALONE (PTA) AS AN
INDEPENDENT RISK FACTOR FOR THE DEVELOPMENT OF
RENAL FAILURE
J. Scalea 1, J. Nogueira2, L. Campos1, A. Haririan2, R. Barth1, B. Philosophe1,
S. Bartlett1 and M. Cooper1
1
Dept of Surgery and 2Medicine, University of Maryland, Baltimore, MD,
United States.
Background: Pancreas transplant alone (PTA) is a controversial procedure.
Without clearly demonstrating improved patient survival, many recipients
report improved quality of life. Nephrotoxic side-effects of maintenance
immunosuppression may significantly exacerbate diabetic renal injury posttransplantation.
Methods: A retrospective review of patients receiving PTA over a 14 year
period (1993-2007) at a single institution was completed. Patient demographics,
surgical outcomes including infections and episodes of rejection, and patient/
graft survival were analyzed. Patients were classified according to stage of
chronic kidney disease (CKD) based upon calculated CrCl. A subset of patients
in this cohort developed ESRD requiring kidney transplantation (KT). Student’s
T-test was used to determine significance.
Results: 132 patients with an average age of 40.1 were identified. 7 patients
were retransplated, 1 received a third pancreas. Mean graft survival was 3.26
yrs (0-11.3y) with 23 pts (17%) lost to follow-up. One and five year patient
survival was 96.6% and 91.5% (mean – 7.15y). 9 patients presented with a
CrCl < 60mL/min preoperatively; whereas 57 patients did so post-PTA. Mean
pre-txp CrCl was 110.4 mL/min vs 72.3 post-txp (p<0.0001) with average
follow-up of 3.68yrs. All but 13 (9.5%) patients showed a decrease in CrCl.
Mean decrement was 33 mL/min. 13 patients developed ESRD and required
KT. Average time following PTA for KT was 4.36 yrs. 21/53 patients early in
this series received ATGAM or OKT3 induction and developed post-txp CKD.
All 13 patients requiring KT were among this group (p<0.0001). 28/70 patients
receiving Thymoglobulin as induction had post-txp CKD. All patients received
a calcineurin inhibitor (CNI) for maintenance immunosuppression (IS). 83
total pts had an episode of rejection (10 developed ESRD/KT). In pts with
post-txp CKD (CrCl<60). graft survival was 3.2 yrs v. 2.4 yrs for those without
(p=0.13). Patients requiring KT, however, pancreatic graft survival was 7.9
yrs vs 2.9 yrs (p<0.0001). Mean CrCl was 96 mL/min for patients with early
pancreatic graft loss at an average follow-up of 6.29yr. CIT for those with and
without RF requiring KT were 20hrs and 19hrs respectively (p=NS). Deceased
donor ages for those requiring KT was 19.4 vs. 24.3 yrs old (p=0.02). Pre-txp
CrCl for those requiring KT was 88 mL/min compared with 112 (p=0.05).
Conclusions: Pancreas transplant confers an increased quality of life not
easily quantifiable. Patients that undergo PTA are at increased risk for CKD/
KT. Comparing age, gender, race, donor age, and IS, PTA is an independent
risk factor for the development of kidney disease. Recipients of pancreatic
allografts with increased survival demonstrated lower CrCl. Patients developing
renal failure occurred early in this series reflecting improved patient and organ
selection. Preoperative CrCl should best guide appropriate intervention for
those with Type I DM.
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PREDICTORS OF NEW ONSET DIABETES AFTER
PANCREAS TRANSPLANT
N. Neidlinger, N. Singh, J. Odorico, H. Sollinger and J. Pirsch
University of Wisconsin Department of Surgery, Division of Transplantation
Introduction: The incidence, cause, and risk factors for new onset diabetes
(NODM) after successful pancreas transplant (PTX) are undefined. Small
series and case reports have suggested that immunosuppression and donor
factors may play a role, and that serum markers and glucose tolerance assays
may predict NODM. We sought to analyze risk factors for NODM after PTX.
Methods: We retrospectively reviewed 686 consecutive pancreas transplants
performed over a 12 year period at our institution. We analyzed patients
with combined kidney-pancreas and solitary pancreas transplants that had at
least 6 months of pancreas graft function. All patients underwent systemic
venous drainage and were maintained on steroid-based immunosuppression.
We reviewed the association of early potential risk factors with the onset of
NODM after PTX including donor weight, race, body mass index (BMI).
and cytomegalovirus (CMV) status as well as recipient age, weight, sex,
race, CMV status and BMI at time of PTX. Furthermore, we evaluated postoperative weight gain, median fasting glucose levels at 1week and 1 month
post-transplant, presence of rejection, primary vs. non-primary transplant,
immunosuppressive agent, graft leak and need for re-operation as potential
risk factors. We defined NODM as two consecutive hemoglobinA1C (HbA1C)
values greater than 6.5 mg/dl.
Results: Of the 686 transplants, 58 (8.4%) developed NODM. For short
term analysis, patients were stratified by their HbA1C level at 6 months after
transplant. The only risk factors that were associated with the risk of NODM
at 6 months after PTX were high pre-PTX weight, hyperglycemia within 1
week and 1 month after PTX, and donor CMV status (see table). With regard
to CMV, donor +/recipient – patients were at highest risk among all groups.
At long term follow up (8-12 years). significant risk factors for NODM using
Kaplan-Meier analysis were hyperglycemia at 1 week (p=0.007) and 1 month
(p=0.003) after PTX, recipient CMV negative status (p=0.04). non-Caucasian
recipient race (p=0.03) and rejection episode within the first 6 months (p=
0.00006). Induction immunosuppression and choice of calcineurin inhibitor
did not affect NODM, nor did weight gain of more than 5 kilograms or 10% of
total body weight within in the first 6 months after PTX.
HgBA1C at
6m post TX.

RISK FACTORS
Mean Wt. at
TX (kg)

< 6.0
6.0-6.5
> 6.5
P-VALUE

72.0± 14.2 (n=
474 )
74.2± 9.2 (n=
41)
81.3± 19.9
(n= 13)
0.02

Median Fasting
Glucose 1 week
(mg/dl)
104.5 (n=285)

Median Fasting Donor CMV
Glucose 1month positive
(mg/dl)
98.5 (n=365)
87% (n= 240)

Donor CMV
negative

118.2 (n=22)

107.0 (n =27)

4% (n= 25)

5% (n= 13)

144.2 (n=2)

131.0 (n=5)

9% (n= 11)

1% (n= 2)

0.003

0.0002

0.01

94% (n= 231)

Conclusion: Obesity, early hyperglycemia, donor positive and recipient
negative CMV status and non- Caucasian race are important risk factors for
the NODM after PTX.
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NEGATIVE IMPACT OF DE NOVO ANTI-HLA
ANTIBODIES AFTER SIMULTANEOUS PANCREAS-KIDNEY
TRANSPLANTATION
D. Cantarovich1, F. Vistoli1, G. Karam1, M. Giral1, J. Dantal1, G. Blancho1,
J.P. Soulillou1 and J.D. Bignon2
1
Institut de Transplantation et de Recherche en Transplantation (ITERT).
2
Laboratoire d’Histocompatibilité, Etablissement Français de Sang (EFS).
Centre Hospitalier et Universitaire de Nantes, France.
Background: A pancreatic graft, which includes exocrine and endocrine
tissues, a large segment of duodenum and multiple lymphe nodes, is highly
antigenic and immunogenic. In fact, the incidence of rejection is higher and
graft survival is lower when compared to a kidney transplantation. Whether
de novo post-transplant anti-HLA sensitization could be in part responsible of
these observations is not known.
Aim: To prospectively test the development of de novo anti-HLA antibodies in
recipients of SPK according to different immunosuppressive regimens and to
evaluate the impact on rejection and graft survival.
Patients and Methods: From december 1999 to december 2007, 106 non-
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augmentation in the hazard ratio (from 2.5 to 6.2) following every single hr
up to 19 hr.
Conclusion: Pancreas allograft thrombosis could be avoided if transplantation
is performed below 10 hr of cold ischemia. After this time-point, the risk
of thrombosis and graft failure increases progressively within time. In
addition, the non use of steroids significantly favour the risk of thrombosis.
These 2 variables suggest that inflammatory processes related to brain
death and ischemia reperfusion syndrome can be main reasons of graft
thrombosis. Logistic strategies to reduce cold ischemia and systematic use
of antiinflammatory drugs in the donor and during the postoperative period
could improve the outcome of pancreas transplantation.
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anti-HLA-immunized (i.e. PRA <5%) recipients (60% men; mean age 40±7
yrs; range, 23-61) of primary SPK were evaluated. All patients received
Thymoglobulin induction, calcineurin inhibitor or sirolimus and MMF. AntiHLA antibodies were routinely tested by Elisa and/or Luminex screening tests
and confirmed for class I and class II by Luminex.
Results: 39 (37%) patients were screened positive and 22 of them (21%) were
confirmed having de novo anti-HLA antibodies (64% donor specific). 40 (38%)
patients were included in a CNI-based/steroid-free regimen, 56 (53%) received
the same regimen plus steroids for 3 months and 10 (9.4%) received sirolimus,
MMF and steroids without CNI. The incidence of de novo anti-HLA antibodies
was, 17.5%, 15.4% and 60%, respectively (CNI vs sirolimus, p=0.001). The
rejection rate in patients with anti-HLA antibodies was significantly higher than
in those without anti-HLA antibodies: 45% vs 8% (p<0.0001). Graft survival
(censored for death and technical failures) was also negatively and significantly
impact by anti-HLA sensitization: for the pancreas 96% vs 68% (p=0.0003)
and for the kidney 99% vs 80% (p=0.05) at 5 years.
Conclusion: de novo anti-HLA antibodies (mostly against the donor) were
found in a relatively high proportion of patients (21%) following SPK. These
patients experienced significantly more rejections and had significantly lower
grafts survivals than non-sensitized patients. Recipients under sirolimus seem
to develop more sensitization than recipients under calcineurin inhibitors and
the absence of steroids did not influence sensitization.
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PANCREAS ALLOGRAFT REJECTION BANFF
WORKING GRADING SCHEMA
C, Drachenberg1
1Department of Pathology, University of Maryland, 2Banff Pancreas
Consensus discussion Group
The schema consists of 6 main diagnostic categories, some of which may
occur concurrently. The severity of the pathological process is graded based
on the global assessment of the biopsy. In addition, the extent of fibrosis
and parenchymal atrophy are also assessed to determine the “stage” of graft
sclerosis.
1. NORMAL
2. INDETERMINATE Septal inflammation that appears active but the overall features do not fulfill
the criteria for mild cell mediated acute rejection.
3. CELL-MEDIATED REJECTION
Acute cell mediated rejection
– Grade I/Mild acute cell mediated rejection
Active septal inflammation (activated, blastic lymphocytes, ± eosinophils) involving septal structures:
venulitis (subendothelial accumulation of inflammatory cells and endothelial damage in septal veins,
ductitis (epithelial inflammation and damage of ducts). Neural/perineural inflammation.
and/or
Focal acinar inflammation. No more than 2 inflammatory foci^ per lobule with absent or minimal
acinar cell injury.
– Grade II/Moderate acute cell mediated rejection
Multifocal (but not confluent or diffuse) acinar inflammation (≥ 3 foci^ per lobule) with spotty
(individual) acinar cell injury and drop–out.
and/or
Minimal intimal arteritis
– Grade III/Severe acute cell mediated rejection
Diffuse, (widespread, extensive) acinar inflammation with focal or diffuse multicellular/confluent
acinar cell necrosis.
and/or
Moderate or severe intimal arteritis
and/or
Transmural inflammation – Necrotizing arteritis
Chronic active cell–mediated rejection. Chronic allograft arteriopathy (arterial intimal fibrosis with
mononuclear cell infiltration in fibrosis, formation of neo-intima)
4. ANTIBODY MEDIATED REJECTION =C4d positivity** + confirmed donor specific antibodies
+ graft dysfunction
Hyperacute rejection Inmediate graft necrosis (≤ 1 hour) due to preformed anibodies in recipient’s
blood
Accelerated antibody mediated rejection Severe, fulminant form of antibody mediated rejection
with morphological similarities to hyperacute rejection but occurring later (within hours or days of
transplantation).
Acute antibody mediated rejection Specify percentage of biopsy surface (focal or diffuse).
Associated histological findings: ranging from none to neutrophilic or mononuclear cell margination
(capillaritis). thrombosis, vasculitis, parenchymal necrosis.
Chronic active antibody–mediated rejection. Features of categories 4 and 5.
5. CHRONIC ALLOGRAFT REJECTION/GRAFT SCLEROSIS
– Stage I (mild graft sclerosis) <30% of the core surface
– Stage II (moderate graft sclerosis) 30–60% of the core surface.
– Stage III (severe graft sclerosis) >60% of the core surface

30

6. OTHER HISTOLOGICAL DIAGNOSIS. Pathological changes not considered to be due acute
and/or chronic rejection. e.g. CMV pancreatitis, PTLD, etc.
Footnotes: # Categories 2 to 6 may be diagnosed concurrently and should be listed in the diagnosis in
the order of their clinicopathological significance.
* See table 2 for morphological definition of lesions.
**If there are no donor specific antibodies or this data is unknown, identification of histological features
of antibody mediated rejection may be diagnosed as “suspicious for acute antibody mediated rejection”,
particularly if there is graft dysfunction.
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C4D POSITIVE INTERACINAR CAPILLARIES
CORRELATES WITH DONOR-SEPCIFIC ANTIBODY
MEDIATED REJECTION IN PANCREAS ALLOGRAFTS CORRE
J. Odorico1, J. Torrealba1, M. Samaniego1, J. Pascual2, Y. Becker1, J. Pirsch1,
H. Sollinger1,
1
University of Wisconsin, Madison, Wisconsin, 2Hospital Ramon y Cajal,
Madrid, Spain
The deposition of the complement split fragment C4d in peritubular capillaries
of renal allografts is considered a reliable histologic marker of antibodymediated rejection. Its role, however, in pancreas transplant (PTx) is less
characterized, with only rare case reports published in the literature. To further
characterized the value of C4d in PTx we included in the present study 27 PTx
biopsies from 18 patients (Pts) transplanted between 2004 and 2007.
Biopsies were immunolabeled with anti-C4d Abs and scored for allograft
rejection according to the Maryland criteria. The presence of C4d was graded
in interacinar capillaries (IAC). islets, interstitium and small and medium-size
vessels. Sera obtained at the time or within 5 days of the biopsy were analyzed
for the presence of anti-donor specific antibodies (DSA) by the flow-based
fluorescent-conjugated beads technique (LuminexR). 14 biopsies (51.8%)
showed at least 5% C4d+ IAC (range 5-90%). Of those, 5 biopsies (18.5%)
revealed diffuse labeling (>50% C4d+ IAC) and 9 (33.3%) showed focal
staining (5-50% C4d+ IAC). C4d+ IAC (>5%) was significantly associated
with the presence of strong DSA (>500 MFI) for either Class I or Class II
(p<0.004). Considered separately, both the diffuse and focal patterns of C4d
staining of IAC were also significantly associated with Class I and Class II DSA
(p< 0.04 and 0.046, respectively). C4d staining of the media or endothelium of
small and medium-size vessels was a common finding in all biopsies without
any association with DSA. Similarly, staining of islets and parenchymal
interstitium was not statistically associated with DSA. 9 Pts with C4d+ biopsies
and clinical rejection were treated. Of those, 7 Pts received corticosteroids,
with the addition of IVIg (3 Pts). Thymoglubulin (3 Pts). plasmapheresis and
rituximab (1 Pt) and increased maintenance immunosuppression (4 Pts). By the
time of this report, 3 Pts had failed allografts (back on insulin therapy and no
detectable C-peptide). 1 Pt had marginal function (on insulin therapy but with
detectable C-peptide) and 5 Pts had excellent allograft function and glucose
control.
Our findings support the role of C4d labeling of PTx biopsies in the diagnosis
of antibody-mediated rejection and emphasize the staining of IAC as the most
valuable histologic parameter for the diagnosis.

87
C4D+ ANTIBODY MEDIATED REJECTION AND
CAMPATH INDUCTION ARE RISK FACTORS FOR GRAFT
LOSS FOLLOWING PANCREAS TRANSPLANTATION
R. Munivenkatappa1, E. Schweitzer1, C. Drachenberg2, E. Mccann3, A. Dock4,
D. Kukuruga2, L. Campos1, J. Papadimitriou2, S. Bartlett1, B. Philosophe1
1Surgery, Division of Transplantation, University of MD School of Medicine,
2Pathology, University of MD School of Medicine, 3Pharmacy, University of
MD School of Medicine, 4The Living Legacy Foundation of Maryland
C4d + antibody mediated rejection (AMR) has been demonstrated in kidney,
cardiac and lung transplantation even in the presence of significant T cell
depletion. C4d + AMR following pancreatic transplantation has not been well
characterized and is therefore analyzed
We retrospectively analyzed 257 recipients from Jan 2000 to the present with at
least 3 months of follow up. The mean follow up was 34±29 months. We excluded
grafts with early thrombosis due to technical failure. The impact of demographic
variables, HLA, PRA, re-transplantation, and induction, immunosuppresion,
was analyzed using a multivariate Cox proportional hazard test.
The mean age of the recipients was 47±9 yrs with 44% female and 91%
Caucasian. The cohort was divided into three groups based on the induction
agent received. There was no significant difference between the groups for
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Recipient Characteristics Anti Lymphocyte

Anti CD25

Anti CD52

N

192

27

20

Age (mean yrs)

47±8

49±10

39±8

0.6

Male/Female (%)

106 (55%) /86 (45%) 18 (67%) /9 (33%)

10 (50%) /10 (50%)

0.5

p

Caucasian/AA (%)

179 (93%) /13 (7%)

24 (89%) /3 (11%)

14 (70%) /6 (30%)

0.003

% PRA (mean)

16±29

22±34

5.4±10

0.8

HLA mismatch

4±1

4±1

4±0.9

0.7

Re-Txp/denovo (%)

19 (10%) /164 (90%) 5 (18)%/22 (82%)

1 (5%) /19 (95%)

0.3

Biopsy C4d+/C4d-

3 (13%) /20 (87%)

1 (14%) /6 (86%)

3 (43%) /4 (57%)

0.2

Steroids @ DC/No
steroids

174 (97%) /6 (3%)

25 (100%) /0 (0%)

18 (95%) / (1 (5%)

0.6

Table 1. Recipient Variables and Induction Immunosuppression
Multivariate COX ANALYSIS
RR (95% CI) p
C4d+ Antibody Mediated Rejection (AMR)

5.9 (1.6-21.6) 0.008

Acute Cellular Rejection (ACR)

2.1 (1.1-4)

0.02

5 or 6 HLA Mismatches

2.2 (1.1-4.4)

0.03

PRA >40%

2.1 (1-4.4)

0.04

Campath Induction

3.8 (1-14)

0.05

Table 2: Recipient variables and their risks of graft loss.

Figure 1: Pancreas graft survival as a function of induction.

MONDAY

the recipient parameters except for recipient race (table 1). By multivariate
analysis, the relative risk (RR) for graft loss in patients who were induced
with anti CD52 was 3.8 compared to those who received anti lymphocyte
induction or anti CD25 (p=0.05). Patients with C4D+ AMR and acute cellular
rejection (ACR) had a RR for graft loss of 5.9 and 2.2 respectively, (p=0.008
and 0.02 respectively). The RR for graft loss in patients with 5 or more HLA
antigen mismatches was 2.2 (p=0.03) and 2.1 for patients with a peak PRA
>40% (p=0.04, table 2). There was no difference in 8 year graft survival
between patients induced with Simulect or Anti-lymphocytes (65% and 58%
respectively). Patients induced with Campath had a significantly lower 1
year graft survival compared to the others (62%, p=0.05, figure 1). Patients
with ACR had a similar 8 year graft survival compared to patients without
any biopsy proven rejection (52% and 62% respectively). Patients with C4D+
AMR had a significantly lower 1 year graft survival compared to the others
(27%, p=0.004; figure 2).
Recipients of pancreas transplants who experience no rejection have an
excellent long-term graft survival. C4D+ AMR was present in nearly half the
patients induced with Campath and both of these factors were associated with
the highest risk of graft loss.

Figure 2: Pancreas graft survival as a function of rejection.
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ANTIBODY-MEDIATED REJECTION OF THE
KIDNEY AFTER SIMULTANEOUS PANCREAS-KIDNEY
TRANSPLANTATION (SPKT): ALEMTUZUMAB IS NOT
SUPERIOR TO BASILIXIMAB AS INDUCTION TREATMENT
J. Pascual1, J.D. Pirsch1, J.R. Torrealba2, J.S. Odorico1, A. Djamali3,
Y.T. Becker1, G. Leverson1, S.J. Knechtle1, H.W. Sollinger1, M.D. Samaniego3
1
Department of Surgery, Division of Transplantation, 2Department of
Pathology and Laboratory Medicine, 3Department of Medicine, University of
Wisconsin School of Medicine and Public Health, Madison, WI, USA
The information on the best regimen to prevent antibody-mediated rejection
(AMR) after simultaneous pancreas-kidney transplantation (SPKT) is
particularly limited. A retrospective comparative cohort study was performed
including 136 SPKT patients transplanted in 2002-2005 receiving maintenance
immunosuppression with tacrolimus, MMF and prednisone. Two groups were
compared: those who received induction with alemtuzumab (n=97) and those
who were induced with basiliximab (n=39).
Donor and recipient characteristics were similar. Biopsy-proven kidney acute
cellular rejection (ACR) was more frequent with basiliximab (2-yr 12.8%
vs 3.1%, p=0.04). but the incidence of biopsy-proven kidney AMR was
similar (2-yr 18% with basiliximab vs 13.8% with alemtuzumab, p=NS). No
differences in prevalence were detected considering early AMR (<91st day) or
late AMR (>90th day) separately. Multivariate analyses showed that the only
detected significant risk factor for AMR was female gender (adjusted Hazard
Ratio [HR] 2.97, p=0.016). The biopsy-proven kidney rejection was associated
with clinical pancreas rejection in 13 out of the 21 AMR cases (62%). without
differences between both groups. Post-rejection kidney graft survival was
similar in both groups (2-year basiliximab/alemtuzumab 94.7/91.2%). but
death-censored kidney survival was lower with alemtuzumab (100/91.2%,
p=0.05). The predominant cause of kidney loss was death-with-function with
basiliximab (n=3) and acute or chronic active AMR with alemtuzumab (n=5).
Pancreas survival was similar between both groups. More pancreas losses due
to acute rejection occurred in alemtuzumab treated group than in basiliximab
treated group (4 vs 1). Nearly all early episodes resolved with treatment and
were not associated with worse graft survival. Conversely, late AMR episodes
carried a worse prognosis, with decreased two-year kidney (61.5% vs 96.2%,
p<0.0001) and pancreas graft survival (47.7 vs 92.3%, p<0.0001). Late AMR
was associated with graft loss in multivariate Cox models (kidney loss HR
3.34, p=0.05 and pancreas HR=3.22, p=0.049).
AMR was common in SPKT recipients. ACR is better prevented with
alemtuzumab than with basiliximab, but no relevant difference is found
between alemtuzumab and basiliximab in AMR. Late (as opposed to early)
AMR episodes were associated with significantly decreased kidney and
pancreas survival rates despite treatment. Preventive and/or different treatment
strategies are required to address late AMR in SPKT.
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IMPROVEMENT IN DIABETIC NEUROPATHY AFTER
SUCCESSFUL PANCREAS TRANSPLANTATION DETECTED
BY CORNEAL CONFOCAL MICROSCOPY- TWO YEAR DATA
S. Mehra1, M. Tavakoli2, A. Tavakoli1, N. Parrott1, R. Malik2, T. Augustine1
1
Manchester Royal Infirmary, 2Division of Cardiovascular and Endocrine
Sciences, University of Manchester
Introduction: Successful pancreas transplantation (PTx) in Type 1 diabetes
has been shown to prevent progression of retinopathy and nephropathy but to a
lesser extent neuropathy. Data suggests that small nerve fibres are the earliest to
repair, however, their assessment has been limited due to the invasive nature of
skin/nerve biopsy. Corneal confocal microscopy (CCM) is a rapid, non invasive
in vivo clinical examination technique which quantifies corneal small nerve
fibre damage and repair and which acts as surrogate marker for peripheral and
autonomic neuropathy.
Method: 42 Type 1 diabetic patients undergoing combined pancreas and
renal transplantation (PTx). 7 non diabetic patients with end stage renal
failure (ESRF) (eGFR<10) undergoing renal transplantation (KTx) and 14
non diabetic control subjects (C) underwent corneal confocal microscopy to
quantify corneal nerve fibre density (NFD). nerve fibre length (NFL) and nerve
branch density (NBD) within 1 month of transplantation and at 6 month and
yearly interval over 2 years.
Results: Corneal NFD (no.mm2) (11.8 1.9 v 42.7, P =0.0001). NBD (no.mm2)
(4.3 1.3 v 29.0 2.9, P=0.0001) and NFL (ìm) (2.2 0.8 v 8.8 0.6, P=0.001) were
significantly reduced in diabetic patients at transplantation compared to control
subjects, respectively. 25 patients underwent repeat assessment 6 months after
successful PTx. HbA1c (5.6±0.1 v 8.3±0.3, P<0.0001). NFD (18.2 1.3 v 10.8
1.9, P= 0.001) and NFL (3.50 0.3 v 1.9 0.4, P=0.002) improved significantly.
In patients with ESRF NFD (27.5±4.6, P=0.05). NBD (19.8±2.8, P=0.05) and
NFL (5.2±0.9, P=0.003) were also significantly reduced but to a lesser extent
than patients with diabetes. However, whilst KTx resulted in an improvement
in eGFR (48.8 ±4.7, P<0.0001) there was no improvement in NFD (30.7±5.4,
P=0.66). NBD (20.8±3.1, P=0.62) or NFL (5.2±0.9, P=0.97).
Conclusion: Despite severe neuropathy in Type 1 diabetic patients undergoing
PTx, small fibre repair can be detected within 6 months of PTx using CCM.
ESRF alone can result in nerve damage but successful renal transplantation
has no benefit. Corneal confocal microscopy is a novel, non-invasive, in vivo
clinical examination technique which may be used to diagnose neuropathy
secondary to diabetes and chronic kidney disease and may also be employed to
assess the benefits of therapeutic intervention.
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NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN
(NGAL) AS A BIOMARKER TO PREDICT ACUTE TUBULAR
NECROSIS (ATN) IN RENAL TRANSPLANT ALLOGRAFTS.
A. Panigrahi , J. Shidhiki , A. Margoob , D. Bhowmik , S. Tiwari ,
S. Guleria3, N. Mehra1
1Dept of Transplant Immunology,All India Instutute of Medical Sciences,
2Dept of Nephrology, ,All India Instutute of Medical Sciences, 3Dept of
Surgery, ,All India Instutute of Medical Sciences
Neutrophil gelatinase-associated lipocalin (NGAL) is being reported one of
the most dramatically up-regulated genes in the kidney after ischemia, and was
found to be a highly predictive biomarker of acute kidney injury in patients
undergoing cardiac surgery. We therefore tested the hypothesis that serum
NGAL represents a novel early biomarker to distinguish between rejections or
acute tubular necrosis in patients undergone life related renal transplantation.
Post transplant serum samples collected from 175 recipients of living donor
kidneys with in the 1st week of renal transplantation and 30 health controls
were tested retrospectively for the detection of NGAL. The detection of
NGAL has been done by ELSA Kit using manufactures instruction.12% of
patients who had experienced with acute tubular necrosis in the first week of
post transplant showed a significant rise in NGAL (501.25±192) as compared
to the health controls (88.75±53) and also patients having well functioning
grafts (190±91.65 ).However we did not find any significant change in the
1
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2

2

level of NGAL among those patients having early acute (90±8.6) or chronic
rejections (154.5±46.6). when compared to the well functioning grafts. Other
way patients at their pre transplant levels showed a remarkable change in
their NGAL levels (1180±503.6). when it was been compared to their post
transplant serums (195±85.9). Additionally we also found a significant
positive correlation of serum creatinine with the rise of NGAL among the post
transplant patients. Therefore measurement of NGAL in post transplant period
could be a predictive biomarker for the assessment of graft function, especially
to distinguish between rejection and ATN.

POSTER BOARD NUMBER P1 – 288
91
ASSOCIATION OF PRETRANSPLANT SOLUBLE
GLYCOPROTEIN 130 (SGP130) PLASMA LEVELS WITH EARLY
POSTTRANSPLANT ACUTE TUBULAR NECROSIS (ATN) IN
RENAL TRANSPLANT RECIPIENTS.
M. Sadeghi1, D. Volker1, I. Lahou1, C. Naujokat1, R. Weimer2, R. Fabrice2,
J. Schmidt3, A. Mehrabi3, M. Zeier4, G. Opelz1
1Institute of Immunology, Department of Transplantation Immunology,
University of Heidelberg, Germany, 2Department of Internal Medicine,
University of Giessen, Germany, 3Department of Visceral Surgery, University
of Heidelberg, Germany, 4Department of Nephrology, University of
Heidelberg, Germany
Objective: Kidney biopsy is the gold standard for diagnosing acute rejection
(AR) and acute tubular necrosis (ATN) in the kidney transplant recipients.
It is of great interest to find non-invasive diagnostic tools for identification
of patients at risk of ATN or rejection. Previously, we reported that high
pretransplant sIL-6R plasma levels are associated with posttransplant ATN. In
this study we examined associations of pretransplant plasma levels of another
member of the IL-6 subfamily with posttransplant renal outcome.
Patients and Methods: Between March 2000 and November 2007, pretransplant
sIL-1RA, IL-2, sIL-2R, IL-4, IL-6, sIL-6R, sgp130, IL-10, TNF-α, and IFN-γ
plasma levels were studied in 138 renal transplant recipients. Seventy-five
patients had immediate graft function (IGF) posttransplant. Biopsy-proven
AR occurred in 24 patients during 12.9±9.7 posttransplant days. ATN was
diagnosed in 39 patients within 13.1±10.6 posttransplant days by biopsy.
Results: Pretransplant, serum Cr. (p=0.009) and proinflammtory sIL-6R
plasma levels were higher (p=0.006) in patients with posttransplant ATN
than in patients with AR. Conversely, pretransplant anti-inflammatory sgp130
plasma levels were lower in patients with ATN than in patients with AR and/or
IGF (p=0.003 and 0.002 respectively).
Conclusion: Patients at risk of ATN showed a preactivated immune system
immediately pretransplant, with high proinflammtory sIL-6R and low antiinflammatory sgp130, suggesting a strong contribution of the IL-6 cytokine
family to the development of ATN. It might be useful to measure sIL-6R and
sgp130 plasma levels pretransplant to identify patients that have an increased
risk of developing ATN posttransplant.
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THE INVOLVEMENT OF ACTIVATED T CELLS AND
CYTOKINES PRODUCTIONS CORRELATES WITH CLINICAL
OUTCOMES IN CHRONIC RENAL ALLOGRAFT REJECTION
I. Humar1, Z. Puretic1, N. Goreta1, Z. Mihaljevic2, M. Puc1, J. Sertic1
1
University Hospital Zagreb, Croatia, 2Vet Inst Zagreb, Croatia
The induction and maintenance of immune tolerance to transplanted tissues
constitute an active process involving multiple mechanisms that work
cooperatively to prevent graft rejection. We hypothesize that vascularized
transplants have the potential to activate naive T cells in the absence of
secondary lymphoid organs, when no other alloactivation pathways are present.
The priming and effector pathway could be operative for the lifetime of the
allograft and thus contribute to the development of chronic rejection (CR).
Antibodies are produced by cells, and in this sense all rejections are cellular.
The difference is: (a) are grafts destroyed by the action of antibodies or (b) by
direct cellular cytotoxicity, as occurs with cytotoxic T cells (CT).
Aim: In order to provide further insight into the immunologic basis of CR,
a cross-sectional analysis of cellular and humoral immunity in human renal
allograft recipients with or without deteriorating renal function was performed.
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ACUTE ANTIBODY-MEDIATED REJECTION (AMR) OF
THE KIDNEY ALLOGRAFT: IS THERE ANY DIFFERENCE IN
OUTCOMES IN FOCAL VS DIFFUSE C4D STAINING CASES?
J. Pascual1, J.R. Torrealba2, A. Djamali3, G. Leverson1, Y.T. Becker1,
S.J. Knechtle1, H.W. Sollinger1, J.D. Pirsch1, M.D. Samaniego3
1
Department of Surgery, Division of Transplantation, 2Department of
Pathology and Laboratory Medicine, 3Department of Medicine, University of
Wisconsin School of Medicine and Public Health, Madison, WI, USA
The significance of focal deposition of C4d in peritubular capillaries (PTC) is
not well known. Given that some reports have suggested absence of impact
on survival, the usual approach to these cases is not aggressive treatment,
as it is when the staining is diffuse. From 2002 to 2005, 829 isolated kidney
transplantations in adults were performed at our institution. Alemtuzumab
induction was used in 613 of them, 602 without primary non-function. In
addition to MMF and steroids, immunosuppression was based on CsA (n=294).
tacrolimus (n=187) or CNI-free (n=121). Our main interest was to analyze
the significance of mildly stained C4d positive forms of AMR, so we defined
“Focal” staining as less than 25% of PTC stained, and diffuse more than
25%. During 2.5 years of mean follow-up, biopsy proven C4d-positive AMR
was diagnosed in 128 patients (21.2%). 58 early (before day 90th, E-AMR)
and 70 late (after day 90th, L-AMR) cases. Among the 58 E-AMR cases, 49
were diffuse and 9 were focal, whereas among the 70 L-AMR cases, 54 were
diffuse and 16 were focal. C4d diffusely positive E-AMR cases were treated
with plasmapheresis, IVIg and rituximab, and C4d diffusely positive L-AMR
cases with IVIg and rituximab. Usually, focal (<25% PTCs) cases remained
untreated.
Two-year post-AMR graft survival was: E-AMR Focal 33% vs E-AMR
Diffuse 50%; L-AMR Focal 55% vs L-AMR Diffuse 60%; the number of focal
cases was low, and the numerically evident differences were not statistically
significant (log-rank p=NS).
However, post-AMR graft survival censored for death with function was

significantly lower in E-AMR Focal vs Diffuse (41% vs 67%, p=0.04).
Focally positive C4d AMR if remain untreated carry a worse prognosis than
previously thought, and graft survival is significantly affected. Probably, any
C4d deposition in the allograft, in the context of graft function deterioration,
should be aggressively treated as a conventional AMR episode.
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EFFECTIVE REDUCTION OF IMMUNODOMINANT DE
NOVO DONOR SPECIFIC ANTI-HLA ANTIBODY LEVELS
DECREASES RENAL ALLOGRAFT LOSS.
M. Everly1, J. Everly1, P. Brailey1, B. Susskind1, L. Arend1, A. Govil1,
S. Young1, R.R. Alloway1, A. Tevar1, E.S. Woodle1
1
University of Cincinnati, Cincinnati, Ohio, USA
Background: Traditionally, acute rejection (AR) reversal has been defined
by histology and function (serum creatinine). Despite successful AR reversal
(by serum creatinine and histology). many patients have sustained unaffected
humoral alloresponses due to persistently elevated DSA levels. The purpose
of this study was to determine whether reduction in DSA levels during AR
treatment influences graft survival.
Methods: Renal allograft pts with AR between 1/1/2003 and 10/1/2007 and
DSA measurements [Luminex platform with Labscreen single antigen beads] at
AR and 14 days post were analyzed. DSA levels were quantified by converting
fluorescence intensity to molecules of equivalent soluble fluorescence (MESF).
In all pts, DSA were absent pre-transplant. Immunodominant DSA (iDSA) was
defined as DSA with highest MESF. AR was defined by biopsy (bx) /Banff
criteria. Rejection reversal was defined as histologic resolution or a serum
creatinine (SCr) decrease to within 115% of baseline. Survival analysis was
performed using STATA/SE v9.2.
Results: Of 90 pt with AR, 16 had serial DSA evaluations and were analyzed
(Table1). Ten patients had a <50% reduction and 6 patients had a >50%
reduction in de novo iDSA titer at 14 days post-AR diagnosis. Median followup was 21.417.1 mos. Pts with <50% reduction in iDSA had reduced graft
survival by Kaplan Meier (p=0.039, Log-rank) (Figure 1).
Table 1: Patient Demographics Stratified by iDSA Reduction
AMR, pts (%)
Peritubular capillary C4d, pts (%)
Class I DSA, pts (%)
Class II DSA, pts (%)
Mean iDSA level at biopsy
Rejection Reversal, pts (%)
Recurrent Rejection, pts (%)
2 year Graft Survival (Kaplan-Meier)

iDSA
Reduction>50%
2 (33)
4 (67)
4 (67)
2 (33)
620,195 437,472
5 (83)
1 (17)
100%

iDSA
Reduction<50%
7 (70)
9 (90)
3 (30)
7 (70)
324, 857 232,990
9 (90)
1 (10)
63%

p-value
NS
NS
NS
NS
NS
NS
NS
0.039

Figure 1. Death Censored Allograft Survival Stratified by iDSA Reduction at 14 Days After Biopsy

Conclusions: This data indicates effective treatment to an iDSA reduction of
greater than 50% within 14 days of initial biopsy has a positive impact on long
term renal allograft survival.
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The prospective study of possible risk factors for CR is based on 6,7+- 3,7
years (form 1-19 years).
Method: To assess whether peripheral T cells control immune responses in
immunosuppressed renal transplant patients, we analyzed the suppressive
capacities of these cells using limited dilution and serum level of cytokines
(sCD30,TNF-á, IL-2 and IL-2R). pre and post- transplant in 116 renal
transplant recipients. MHC-reactive alloantibodies were detected by standard
CDC. Cox regression model was used to assess the significance of PRA, Thp,
cytotoxic T lymphocytes, serum concentration of sCD30, IL-2, IL-2R, TNF-á
and glomerular filtration rate, (GFR) on graft survival. All P values are twosided and considered statistically significant if less than 0.05. All calculations
were performed by STATA 7.0
Results: Allogeneic stimulation of patient’s peripheral blood mononuclear cells
was associated with T-cell proliferation. CTL frequencies of donor-reactive
lymphocytes and the number of individuals who responded to donor antigens
per group were statistically higher in CR patients versus non CR control (P<
0.032). In CR group significant difference is present between measurements
r=1.163.66; P< 0.05, opposite to non CR recipients. Serum level of sCD30,
IL-2, sIL-2R have no difference while mean level of TNF-á is significantly
correlated with chronic rejection (P=0,025) and GFR. Development of de novo
antibodies in patients with functioning grafts presage subsequent failure with
OR=3.92. Thus, there were significantly more failures in those who developed
antibodies (P=0,01).
Conclusions: T cells with alloreactivity against anti-donor-responsive T cells
are readily detectable in renal allograft recipients during treatment with full
dosage immunosuppression and long term function. Significant difference
of TNF-á and renal function are interrelated. Both immune reactivity and
tolerance are the net result of immune responses with opposing, i.e. enhancing
or suppressing properties. Immunological quiescence, like immune reactivity
is thus not per se an inert situation, but an active state, in which checks and
balances have resulted in responsiveness in recipients with chronic rejection.
Patients with persistently detectable anti-donor immune reactivity, with
deteriorating kidney function, may benefit from alterations in therapy directed
at controlling activated T cells or B cells, depending on the type of alloreactivity
detected.
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INTRARENAL CD20+ CELLS DO NOT PREDICT
CLINICAL OUTCOME IN ACUTE RENAL ALLOGRAFT
REJECTION.

96
SIX YEARS POSTTRANSPALNT FOLLOW UP OF RENAL
RECIPIENTS WITH RESPECT TO HLA ANTOBODIES AS
PREDICTING FACTOR OF CHRONIC REJECTION

I. ten Berge1, C.G. Scheepstra2, F.J. Bemelman1, A.T. Rowshani1, K. Van
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt
Pathology, Academic Medical Centre, Amsterdam
Introduction and Aim: The role of intrarenal CD20+ B cell infiltrates in
renal allograft rejection has yet to be elucidated. Recent reports suggest a
correlation between CD20+ B cell aggregates and poorer clinical outcome.
This finding would enable the identification of a group of patients that
would benefit from the administration of anti-CD20 antibodies (rituximab).
However, these studies did not differentiate between scattered infiltrates of
B cells and clusters of B cells. Therefore, we retrospectively differentiated
between CD20+ cells in aggregates and CD20+ cells distributed throughout
the interstitium. The same was done for CD3+ cells. We related CD20
counts, CD3 counts, Banff classification parameters and positive staining
of peritubular capillaries for C4d, a marker of humoral rejection, to clinical
outcome.
Materials and Methods: From 50 patients with clinically suspect and
histologically proven first acute renal allograft rejection 54 biopsies were
taken and immunostained (CD20, CD3, C4d). Immunosuppressive drug
treatment consisted of cyclosporin or tacrolimus, mycophenolate mofetil
and low dose prednisone. Rejection treatment consisted of pulse doses
methylprednisolone. In each biopsy the total scores for CD20+ cells, CD3+
cells and the aggregates of CD20+ cells and CD3+ cells were expressed
per High Power Field of vision (1 HPF = 0.024 mmƒU). The interstitial
immunopositive cells were scored according to a system shown in table 1.
Immunostaining for C4d in the peritubular capillaries was scored as follows:
No positive staining = 0; 0-25% positivity = 1; 25-75% positivity = 2; >75%
positivity = 3.
Response to therapy was defined as decrease in serum creatinine level to
maximally 125% of the lowest value prior to the clinically diagnosed episode
of allograft rejection. Statistical analysis was performed with SPSS-software,
using the Mann-Whitney rank-sum test for differences between unpaired
groups of variables and Spearman rank correlation test for correlations.
Results: A significant correlation was observed between interstitial
infiltrates of CD20+ cells and CD3+ cells (Spearman¡¦s correlation
coefficient r = 0.720, p < 0.001). suggesting that B- and T cell infiltrates
occur in a concurrent fashion in rejection. Surprisingly, no correlation was
found between intrarenal B cell infiltrates and C4d-positivity, a hallmark
of humoral rejection. In contrast to previous reports, no correlation was
found between the number of CD20+ cells, either in aggregates or in the
interstitium, and response to conventional therapy. Of the Banff parameters
only the presence of endothelialitis was an indicator of poor response to
therapy (Mann-Whitney rank-sum test, p-value 0.043). C4d-positivity in
peritubular capillaries was an indicator of poor clinical outcome as well
(Mann-Whitney test, p-value 0.010)
Conclusion: In contrast to other studies, we did not find a relationship between
a high number of CD20+ cells in renal allografts upon rejection, either in
aggregates or in the interstium, and poorer clinical outcome. Therefore, our
results do not warrant anti-CD20-antibody therapy for allograft rejection in
patients with high CD20+ cell counts in the biopsy.

I. Humar, Z. Puretic, L. Bubic, V. Kerhin-Brkljacic
University Hospital Zagreb
Aims: Chronic graft rejection that remains the main cause of graft loss after
renal transplantation in subset is associated with anti-HLA antibodies. Evidence
has accumulated in recent years that HLA antibodies may be responsible for the
chronic failure of transplants. With the recent availability of improved antibody
detection methods, we wish to demonstrate conclusively, in a larger series of
patients, that the presence of HLA antibodies does indeed predict chronic
graft failure. Since only about 5% of functioning patients can be expected to
fail in one year, it is difficult in short time to obtain a clear answer to this
question. If it is shown that patients with HLA antibodies fail at a higher rate,
clinicians will be convinced to monitor their patients and to intervene with
other immunosuppression to eliminate the antibodies. Also, among those who
have no antibodies, immunosuppression might be reduced.
Methods: Prettransplant sera of 273 recipients were obtained and between
1-37.2 years posttransplant. The presences of anti-HLA antibodies were
determined with standard complement dependent cytotoxicity and ELISA.
Statistical analysis Survival curves were estimated using the Kaplan-Meier
method. Cox regression model was used to assess the significance of PRA,
serum concentration of creatinine and graft survival. All P values are two-sided
and considered statistically significant if less than 0.05. All calculations were
performed by STATA 7.0 (Stata Statistical Software: Release 7.0. College
Station, TX: StataCorp LP.)
Results: 33.3.7% of recipients had HLA reactive alloantibodies after
transplantation. The incidence of antibodies post transplantation was 17%
among those who had antibodies prior to transplantation, and 73% among those
who did not have pre-transplant antibodies. In subset of 180 renal patients,
who did not have pre-transplant antibodies, 1.5% of patients had lost graft in
this study period. In 93 recipients with incidence of anti–MHC alloantibodies
17.5% failed, compared to 2.2% failure among 180 patients who did not develop
antibodies statistically significant. PRA, had statistically significant effect after
transplantation for graft lost due to alloantibodies (P =0, 01) and 3.92 relative
risk higher in this selected group. With respect to type of immunosuppression
used in our transplant center, we found a wide range of percentage antibodies
formed. Four combination of immunosuppressive therapy (1.CsA+S+I;
2.CsA+S+CC; 3.CsA+S; 4. S+I) had statistically significant effect after
adjustment. First and third combination of drugs, as compared with second,
did increase the risk of graft failure (relative risk with first and third is, 1.79;
P<0.0158).
Conclusion: These results suggest that eliminating some combination as
a priority would have a less negative effect on graft survival and risk for
chronic rejection. Post transplant detectable alloantibodies are risk factor for
chronic allograft rejection, suggesting that humoral mechanisms are rather the
cause than consequences of chronic rejection. On average, kidneys that have
experienced an anti-MHC alloantibodies production manifest loss of function
and reduced probability of long-term survival. Although this current data is
based on single center study, those patients who developed de novo antibodies
have a significantly greater chance of failure.

Table 1. Histological scoring of interstitial CD20+ cells and CD3+ cells
score

nr. cells

0

0-2

1

3-10

2

11-20

3

21-40

4

41-80

5

> 80

34
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FUNCTIONAL GRAFT AND PATIENT SURVIVAL
OF RENAL TRANSPLANT RECIPIENTS WITH BIOPSY
CONFIRMED ACUTE REJECTION (BCAR) AND USE OF ATG
OR OKT3
A. Kainz1,2, R. Kramar3, B. Mayer4, R. Oberbauer1,2
1
KH Elisabethinen, Linz, Austria, 2Medical University of Vienna, Austria, 3KH
Wels, Austria, 4emergentec biodevelopment, Vienna, Austria
OKT3 and ATG are frequently used in renal transplant recipients for the
treatment of BCAR. It has never been elucidated however whether the use of
these agents is associated with graft and patient survival.
Therefore we studied the association of the drug use and transplant failure or
death in patients with BCAR. We made use of 2310 transplants from 1990 to
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PROLONGED COLD PRESERVATION AND INTERTITIAL
FIBROSIS/TUBULAR ATROPHY IN NON HUMAN PRIMATE
KIDNEY GRAFTS
E. Preussing1, M. Bigaud1, A. Maxime2, N. Volker3, W. Grazyna1
Novartis Institute for Biomedical Research – Basel, 2Hopital de Hautepierre
– Chirurgie Générale & Transplantation, 3University of North Carolina,
Laboratory of Nephrology
Prolonged cold preservation prior to transplantation (Tx) is recognized as a
major risk factor for the development of interstitial fibrosis/tubular atrophy
(IF/TA). the main causes of late kidney allograft dysfunction and loss. Hence,
prolonged cold ischemia is included in the protocol of most of “chronic
rejection” (CR) models described, without clearly understanding the impact
of cold ischemia on IF/TA in the absence of allostimulus. In the context of
our attempts to study CR in NHP kidney allografts (Wieczorek et al., 2006).
we attempted to clarify this point by monitoring the appearance of IF/TA in
kidney autologous grafts submitted to prolonged cold preservation prior to reimplantation.
Methods: Five cynomolgus monkeys underwent autologous kidney Tx. The
grafts were preserved in cold University of Wisconsin solution for 24 (n=3)
or 40 hrs (n=2) prior to implantation back into the donors. Contralateral
nephrectomies were performed, so the autologous grafts were life supporting.
Post-Tx care lasted six months and included monitoring of kidney function
using urine production and serum creatinine (Screa). Histological changes in
the kidneys were also evaluated using protocol biopsies (at week 1, 2, 4, 8, 12,
16, 20 and 24) as well as at necropsy (week 26).
Results: Prior to surgery, all animals had normal renal function, with mean
urine production of 100-300 ml/day and Screa levels of 80-110 μmol/l.
Upon re-implantation, the kidneys subjected to 24 hrs cold ischemia had a fast
functional recovery as shown by urine outputs that, after an initial reduction of
25-50%, went back to normal within 2 days. Meanwhile, Screa levels increased
by 2-5 folds and returned gradually to normal within 2-4 weeks. Signs of focal
or diffuse acute tubular necrosis (ATN) associated with minimal interstitial
edema and mixed inflammatory infiltrates were observed in kidney biopsies
up to week 4 and disappeared thereafter. Overall, normal kidney function and
normal kidney histology were observed from week 8 until termination.
More severe tissue injury and delayed graft function were observed for the
kidneys subjected to 40 hrs cold ischemia. Urine output dropped by 90-95%
during the first 2 days and returned to normal within a week post-Tx. Screa
increased constantly from day 1 to 5 post-Tx (up to ~1500 μmol/l) before
starting to slowly decline. About 2 months were required for Screa to lessen
to ≤200 μmol/l and 6 months to return to 100-150 μmol/l. Mild diffuse ATN
with interstitial edema, focal inflammatory infiltrates and IF were observed in
biopsies during the first 4 weeks. Signs of minimal IF persisted up to week 12.
At necropsy, minimal to mild IF/TA was observed and scored as ci1 and ct1
according to the Banff classification.
Conclusions: In the absence of allostimulus, cold preservation limited to 24 hrs
has only minimal impact on the functional recovery of NHP kidney grafts and
does not trigger the development of IF/TA for up to 6 months. Nevertheless,
1

delayed graft function and IF/TA development become significant with cold
preservation prolonged beyond 24 hrs. This should be taken into consideration
when studying CR in kidney allografts.
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IS DE NOVO MEMBRANOUS GLOMERULONEPHRITIS
(MGN) A FORM OF CHRONIC HUMORAL REJECTION (CHR)
? CORRELATION WITH C4D DEPOSITION AND DONOR
SPECIFIC ANTIBODIES (DSA)
A.B. Collins1,2, W. Wong1,2, S. Saidman1,2, N. Tolkoff-Rubin1,2, N. Goes1,2,
D. Ko1,2, A.B.Cosimi1,2, R. Colvin1,2
1
Massachuetts General Hospital, 2Harvard Medical School
De novo MGN is one of the more common de novo glomerular diseases arising
in renal allografts, yet its pathogenesis is unknown. Studies in rats argue that
non-MHC antigens in the glomerulus can serve as a target of alloantibodies
that induce de novo MGN (Thoenes, Lab Invest 41: 321, 1979) and a recent
publication associates the onset and loss of HLA-DSA with proteinuria due
to de novo MGN (El Kossi, Clin Transpl 22: 124, 2008). We therefore sought
evidence of features of CHR in the form of C4d in peritubular capillaries
(PTC) in grafts with de novo and recurrent MGN and other types of de novo
glomerular disease among cases over the last 10 years with sufficient tissue
in the MGH renal tissue bank and database. During this time CHR was
diagnosed on 8.4% of 738 transplant biopsies. C4d was detected by triple layer
immunofluorescence in frozen tissue; HLA-DSA was detected by cellular and
solid phase techniques.
The results show a strong association of PTC C4d in recipients with de novo
MGN among 17 patients (20 biopsies).
De novo MGN

N pts
17

N C4d+ PTC
7

De novo FSGS

14

0

De novo IgA
De novo HCV
De novo misc GN
Recurrent MGN

3

0
4
3
1

5

%C4d+
41% (p=0.017 vs
all de
0% novo
combined)
0%
2
50%
0
0%
20%

Only de novo hepatitis C virus (HCV) GN had a similar level of association
with C4d, an association previously noted. Recurrent MGN and HCV were not
statistically different from de novo. Three de novo MGN patients were tested
for HLA-DSA and were positive (3 class I, 1 also class II). One patient had
three biopsies over 4 years all with de novo MGN, but C4d was present only in
the last biopsy. CHR was diagnosed in 71% of those with C4d+. We conclude
that C4d+ in PTC, the hallmark of CHR, is strongly associated with de novo
MGN, but not other de novo GN except for that of HCV. The lack of a tight
association argues that different antigens are the target of de novo MGN and
CHR. The association may be due to a propensity to form alloantibodies of any
type or promotion of an immune response to glomerular antigens secondary
to injury mediated by HLA antibodies. In any case, this study supports a
previously unrecognized relationship between chronic antibody mediated
rejection and de novo MGN.
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100 EARLY MARKERS OF CHRONIC ALLOGRAFT
NEPHROPATHY: POTENTIAL ROLE FOR ALPHA-SMA
STAINING ?
F. Kleemann1, B.W. Beaumont2, M.J. Merrilees2, H.L. Pilmore1
1
Department of Nephrology, Auckland City Hospital and 2Department of
Anatomy with Radiology, University of Auckland, New Zealand
Aim:
Chronic Allograft Nephropathy (CAN) is the commonest cause of kidney graft
failure.
Biomarkers to detect early changes of tubulointerstitial fibrosis are urgently
needed. This study examined the potential role of the most commonly used
epithelial mesenchymal transition (EMT) and fibroblast activation markers.
Methods:
A total of 81 serial renal transplant biopsies from 25 patients, including time
0 (implantation biopsy). 3 months and 12 months post transplantation as well
as diagnostic biopsies, were stained with monoclonal antibody to α-smooth
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2005 entered in the Austrian Dialysis and Transplant Registry. Of these subjects
724 experienced a BCAR. Multivariable time to event analysis was used to
identify the effect of polyclonal antibody use on graft and patient survival in
this population.
OKT3 use was associated with a numerical higher hazard ratio (HR) for
functional graft loss compared to ATG use when adjusted for PRA, HLA
mismatch sum, number and year of transplantation (HR = 1.73, 95% CI 0.91 –
3.30). Twenty five percent of OKT3 users exhibited graft loss after 0.72 years
whereas only 7.5% of ATG treated subjects experienced functional graft loss
(Log rank p = 0.059, Wilcoxon p = 0.015).
The use of OKT3 was not associated with reduced patient survival when
compared to ATG users adjusted for similar covariables as functional survival
(HR = 1.29; 95% CI 0.657 – 2.545). The median patients survival was 9.07
years in the OKT3 group and 10.38 years in the ATG group (Log rank p =
0.306).
These data suggest that ATG use in renal transplant recipients with BCAR
is associated with prolonged functional graft survival. Causal inference can
however not be drawn from this associational study.
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muscle actin (α-SMA). A subgroup of 10 patients (30 biopsies) was also stained
for E-cadherin, β-catenin and vimentin.
Cortical tubulointerstitial staining was quantified by point counting of 10 high
power fields per biopsy. Data were analyzed using the two-sided t-test with
significance level p<0.05.
Results: All biopsies had been assessed by a histopathologist. 13 patients had a
histological diagnosis of CAN at an average of 105.8 +/-42.1 days and 12 were
classed as normal at an average of 230.5 +/-143.2 days post transplantation.
The CAN and non-CAN groups did not differ with respect to mean age
(48.1+/-17.4 years vs 44.7+/-11.9 years, p=0.6). gender distribution,
immunosuppressants used (cyclosporine or tacrolimus + mycophenolate or
azathioprine + prednisone). and percentage of deceased donors (77% vs 50%,
p=0.17). The 10 patient subgroup profile was similar to the whole group.
Interstitial fibroblasts stained for α-SMA; tubular epithelial cells (TEC) did not
stain. α-SMA staining was significantly higher in the CAN group at 3 months
and revealed peak levels significantly earlier than in the non-CAN group.
Table 1: Allograft pathology and function and α-SMA staining results
Banff ci score at implantation
α-SMA staining at implantation
α-SMA staining peak time
α-SMA staining at peak time
α-SMA staining doubling time
α-SMA staining at 3 months
Creatinine at 3 months
Length of follow up
Creatinine at end of follow up

CAN
0.1 +/-0.3
6.8 +/-3.0%
98.4 +/-66.7 days
26.6 +/-9.5%
40.0 +/-48.4 days
21.2 +/-5.7%
180.5 +/-37.8 mcmol/L
846.2 +/-647.6 days
212.2 +/-140.5 mcmol/L

non-CAN
0.0 +/-0.0
2.8 +/-2.8%
199.1 +/-144.0 days
8.1 +/-5.8%
136.1 +/-101.5 days
5.4 +/-2.2%
129.3 +/-36.2 mcmol/L
747.3 +/-623.6 days
128.2 +/-31.2 mcmol/L

t-test
p=0.35
p=0.004
p=0.041
p<0.001
p=0.009
p<0.001
p=0.003
p=0.7
p=0.06

TEC of both groups stained for E-cadherin (30-40% of tubules) and vimentin
(0-35%). but with no change in staining over time in either group. β-catenin staining
at time 0 was variable and there were no differences at the other time points.
Conclusion: α-SMA staining increased significantly earlier than the
histopathological diagnosis of CAN (40.0 +/-48.4 days vs 105.8 +/-42.1 days,
p=0.001). Interestingly, despite no difference in the chronic Banff score at
implantation, expression of α-SMA was significantly greater at time 0. There
may be a role for routine α-SMA staining in the early prediction of interstitial
fibrosis, despite the unclear role of EMT in the development of CAN.

MINI-ORAL SESSION 2: IMMUNOSUPPRESSION 1:
MYCOPHENOLATES AND NOVEL AGENTS
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101 DOES MYCOPHENOLATE MOFETIL CONFER
CLINICAL BENEFIT OVER AZATHIOPRINE IN RENAL
TRANSPLANTATION? A SYSTEMATIC REVIEW AND METAANALYSIS.
S. Knight1,2, N. Russell1.3, L. Barcena1, P. Morris1
1Centre For Evidence In Transplantation, Royal College of Surgeons of
England, 2Oxford Transplant Unit, Oxford, UK, 3Cambridge University
Department of Surgery, Cambridge, UK.
Introduction: Mycophenolate Mofetil (MMF) has increasingly become the
anti-metabolite of choice in immunosuppressive protocols since its introduction
in the early 90’s, replacing azathioprine (AZA). Initial large multi-centre
RCTs showed a clinical benefit in reducing the incidence of acute rejections,
but without significantly improving graft survival at 1 year. More recently
it has been questioned whether this benefit is significant when using newer
formulations of Cyclosporine (Neoral) and Tacrolimus.
Methods: A detailed literature search was performed using the Transplant
Library from 1995- June 2007. The library, produced by the Centre for
Evidence in Transplantation, included all randomised controlled trials (RCTs)
in organ transplantation from 1995 to the present day at the time the search
was conducted (it now goes back to 1970). For trials before 1995 we searched
Medline and Embase combining all search terms for MMF and AZA. All
RCTs which directly compared the use of MMF to AZA from time of renal
transplantation were included. All trials were assessed for quality using the
Jadad scoring system. Outcome data were extracted independently by 2
reviewers, and the results were analysed using the meta-analysis software
Review Manager. All groups were analysed with a fixed effects model and
confidence intervals (CI) were set at 95%.
Results: 20 studies were identified which met the inclusion criteria; these
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included a total of 3218 transplant recipients. Study quality is poor, with
a mean Jadad score of 1.4 and only 2 studies scoring ≥; 3. MMF is found
to significantly reduce the risk of acute rejection and importantly its action
is independent of type or formula of Calcineurin Inhibitor (CNI) used (18
studies, 3043 patients, RR 0.63, 0.56-0.71, p<0.00001). The risk of graft loss
is also significantly reduced in patients treated with MMF (14 studies, 2800
patients, RR 0.76, 0.60-0.97, p< 0.03). There is no significant difference in
patient survival between the two groups, nor in renal transplant function as
determined by serum creatinine. There is no significant difference in rate of
CMV infection, anaemia, leukopenia or rates of malignancy. There is however
a significant increase in GI side effects with MMF. Use of MMF results in a
greater risk of vomiting (4 studies, 1487 patients, RR 1.27, 1.01-1.61, p<0.04)
and a greater risk of diarrhoea (6 studies, 1903 patients, RR 1.56, 1.32-1.84,
p<0.00001).
Conclusion: We have shown that MMF used with a CNI does indeed confer
a clinical benefit over AZA by reducing the risk of acute rejection and also
in reducing graft loss. We have also shown that this beneficial effect is
independent of whether MMF is used in combination with Sandimmune,
Neoral or Tacrolimus.
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102 A 12-MONTH, PROSPECTIVE, RANDOMIZED, SINGLE
CENTER, OPEN LABEL PILOT STUDY TO EVALUATE THE
SAFETY AND EFFICACY OF MYFORTIC® IN COMBINATION
WITH TACROLIMUS AND THYMOGLOBULIN® IN EARLY
CORTICOSTEROID WITHDRAWAL
N. Weimert1, R. Alloway1, A. Vinks1, A. Rike1, S. Young1, M. Cardi2,
G. Mogilishetty1, E.S. Woodle1
1University of Cincinnati, 2The Christ Hospital
Background: Mycophenolic acid has been proven effective in the prevention
of acute rejection in kidney transplant patients however, its narrow therapeutic
window has limited the utility of universal dosing. The safety and effectiveness
of enteric coated mycophenolic acid (EC-MPS, Myfortic®) has not been
evaluated in kidney transplant recipients undergoing early corticosteroid
withdrawal. The aim of this study was to evaluate the safety and efficacy of
Myfortic® in combination with tacrolimus and anti-thymocyte globulin in an
early corticosteroid withdrawal (ECSWD) protocol. Secondary objective is to
determine the pharmacokinetic-pharmacodynamic and genetic variables that
would impact exposure to EC-MPS in a corticosteroid withdrawal protocol.
Methods: This prospective, randomized, single center open label pilot study
was designed to investigate the safety and efficacy of mycophenolic acid
sodium given as a loading or standard dose in combination with tacrolimus
under ESWD in patients undergoing kidney transplantation. In addition, a
subset of patients was also enrolled in a concurrent pharmacokinetic study
to evaluate the pharmacokinetic (MPA and MPAG trough and 12 hour
AUC) and pharmacodynamic (IMPDH activity baseline and AUC) profile of
mycophenolic acid sodium.
Results: 45 patients were enrolled. Baseline patient and transplant
demographics were comparable between patients with load or standard ECMPS dose. Patient and allograft outcomes were similar between groups
as illustrated in table below. More patients in the no load group had acute
rejection, however multivariate analyses revealed no risk factor associated with
an increased of acute rejection. UGT enzyme profiles designed to determine
the presence of differences in EC-MPS metabolism also revealed that in
patients where data was available most were negative for UGT1A9-275/2152
polymorphisms, with 90% (33/37) of patients possessing the wild-type SNP.
Indicating no alteration in metabolism would be present. However, 20%
(7/35) of patients did possess UGT2B7 variant which may change the amount
of the acyl-glucoronide metabolite increasing their risk for gastrointestinal
and bone marrow toxicity. The average MPA AUC at 40 days post-transplant
was 46±12 mg*hr/dL in the no load group (n=11) and 54±15 mg*hr/dL in the
load group (n=12). which was not significant (p=0.18). One patient in each
group had an MPA AUC < 30, the threshold value associated with efficacy in
the first month post-transplant. At 3 months, 40% (4/10) patients had an MPA
AUC < 30 mg*hr/dL versus 8% (1/12) in the load group, however this was
not statistically significant, p=0.14. No pharmacokinetic or pharmacodynamic
marker was able to predict acute rejection or toxicity which maybe the result
of inadequate power.
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Conclusion: Based on the overall rate of acute rejection and 12 month
allograft function, EC-MPS appears to be effective in a tacrolimus based early
corticosteroid withdrawal protocol. Genetic and pharmacodynamic markers
associated with MPA exposure and clinical outcomes may need further analysis
with a larger sample size to validate results found in this study.
Load (n=22)

P-value

Graft Survival

100% (0)

91% (1)

0.46

Patient Survival

100% (0)

100% (0)

0.13

Acute Rejection ≥1A

17% (4)

5% (1)

0.35

BKN (viremia & viuria)

17% (4)

9% (2)

0.665

CMV

13% (3)

5% (1)

0.608

GI SAE

17% (4)

9% (2)

0.665

PTLD

4% (1)

0% (0)

1.000

Average Scr (mg/dL) 6 mo

1.4±0.4

1.3±0.2

0.32

Average Scr (mg/dL) 12 mo

1.4±0.3

1.3±0.3

0.27

**included BKN, viremia and viuria
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103 ACUTE REJECTION EARLY AFTER RENAL
TRANSPLANTATION IS ASSOCIATED WITH ELEVATED PRETRANSPLANT IMPDH2 EXPRESSION IN CD4+ CELLS
S. Bremer1,2, R. Mandla1,2, N.T. Vethe1,2, I. Rasmussen1,2, H. Rootwelt1,
P-D. Line3, K. Midtvedt4, S. Bergan1,5
1
Department of Medical Biochemistry, Rikshospitalet University Hospital,
Oslo, 2Institute of Clinical Biochemistry, University of Oslo, 3Surgical
Department, Section of Transplant Surgery, Rikshospitalet University
Hospital, Oslo, 4Medical Department, Section of Nephrology, Rikshospitalet
University Hospital, Oslo, 5School of Pharmacy, University of Oslo
Background and Objectives: Mycophenolic acid (MPA) mediates
immunosuppressive effects by inhibiting inosine monophosphate
dehydrogenase (IMPDH). Measurement of IMPDH activity has been suggested
as a pharmacodynamic approach for individualization and improvement of
MPA treatment. However, IMPDH enzyme activity, as well as gene expression,
is influenced by factors like the current immune status and immunosuppressive
therapy, displaying wide inter- and intra-individual variability.
The objective of this study was to examine the expressions of the two
IMPDH isoforms, type 1 and 2, in blood cells from renal allograft recipients
pre- and post-transplantation and following initiation of immunosuppressive
therapy, including MPA. Possible associations between the IMPDH 1 and 2
expression, acute rejection episodes, dialysis pre-transplant and the current
immunosuppressive treatment were investigated.
Materials and Methods: Whole blood, CD4+ cell and reticulocyte samples
were collected from 30 renal transplant patients pre- and post-transplantation.
The expressions of IMPDH 1 and 2 were analyzed by real time RT-PCR and
quantified using a housekeeping gene index.
Results: During the follow-up (12–19 days post-transplant). 11 patients (37%)
experienced acute rejection (median day 12, range 3–19 days). The patients
with rejection demonstrated higher IMPDH2 expression in CD4+ cells pretransplant than non-rejecting patients (median expression 1.26 vs. 0.87
respectively, P=0.017). There was a trend towards higher rejection rates in the
population receiving dialysis pre-transplant (n=16) having 8 (50%) rejection
episodes, while 3 (21%) of the patients without dialysis (n=14) experienced
rejection.
Conclusions: Elevated IMPDH2 expression in CD4+ cells pre-transplant
may be an indicator of increased immune activation, caused by e.g. presensitized lymphocytes, and thus explain the association to higher risk of
acute rejection. Exposure to dialysis is associated with non-specific cellular
activation, alloreactivity and increased risk of rejection early post-transplant.
This supports the observed trend towards more frequent rejections among the
patients receiving dialysis pre-transplant compared to non-dialysis patients.
Characterization of IMPDH 1 and 2 expression in transplant patients is
important considering the action of MPA on IMPDH and the potential for
pharmacodynamic monitoring of MPA by measuring IMPDH activity. Further
studies are, however, needed to evaluate the clinical implications of different
IMPDH expression levels.

104 IMPDH ACTIVITY IS CORRELATED WITH THE 3757T>C
POLYMORPHISM IN THE IMPDH TYPE 2 GENE IN MMF
TREATED KIDNEY TRANSPLANT PATIENTS
T. van Gelder1, F. Sombogaard1, R. van Schaik1, R. Mathot1, K. Budde2,
W. Weimar1, P. Glander2
1
Erasmus Medical Center, 2Charité University, Berlin, Germany
Introduction: Mycophenolic acid (MPA). the active metabolite of MMF,
reversibly inhibits inosine monophosphate dehydrogenase (IMPDH) to
prevent graft rejection. It is thought that pre-transplantation, total IMPDH
activity mostly consists of constitutively expressed IMPDH type 1, whereas
post-transplantation IMPDH type 2 from activated lymphocytes has the major
contribution. The considerable post-transplantation inter-individual variability
in IMPDH activity may be caused by functional polymorphisms in the IMPDH2
gene. The aim of this paper is to compare IMPDH activity with functional
polymorphisms in the IMPDH2 gene.
Methods: A cohort of 100 patients was prospectively monitored for
pharmacokinetics (MPA plasma levels) and pharmacodynamics (IMPDH
activity) of MMF treatment. Patients received MMF, tacrolimus and steroids
for immunosuppressive therapy. Blood samples were taken pre- and posttransplantation (pre-morning dose, 0.5, 1, 2, 6 and 12h after MMF intake). The
enzyme activity of IMPDH in PBMCs was measured using a validated HPLC
method. IMPDH activity and MPA exposure was calculated as the area under
the activity or concentration–time curve (AUECact and AUCMPA) using a
linear trapezoidal rule. Genomic DNA from all patients was analysed for the
IMPDH2 3757T>C polymorphism by a newly developed TaqMan 5’-nuclease
assay.
Results: From 80 patients (age 19-76 years). a full AUCMPA and AUECact
could be calculated on day 6 (range 3-11) post transplantation. In 12 patients
the IMPDH2 3757C allele was found (10 heterozygous and 2 homozygous
individuals). giving an allele frequency of 6.9%.
The presence of an IMPDH2 3757C allele correlated with a significantly higher
total IMPDH activity in post transplantation patients under MMF exposure
(AUECact 420±320 vs. 265±160 h*ìmol/s/mol AMP; p=0.035). whereas
the polymorphism was not correlated with pre-transplant IMPDH activity
(54.4±44.2 vs. 53.3±37.2 h*ìmol/s/mol AMP; p=0.82). AUCMPA was not
significantly different between the two IMPDH genotype groups (42.0±18.0
and 35.5±19.1 h*mg/L; p=0.18).
Conclusion: The 3757T>C polymorphism in the IMPDH2 gene is
significantly correlated with IMPDH activity, measured as AUECact after renal
transplantation. Whether this genotype is also associated with increased risk of
acute rejection will be subject of future studies.
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105 POPULATION PHARMACOKINETICS OF
MYCOPHENOLIC ACID IN COMBINATION WITH FREE OR
REDUCED DOSES OF CALCINEURIN INHIBITORS DURING
THE FIRST WEEK IN RENAL TRANSPLANT: THE SYMPHONY
STUDY
H. Colom1, I. Fernández De Trocóniz2, A. Caldés3, F. Oppenheimer4,
J. Sánchez Plumed5, M.A. Gentil6, D. Kuypers7, M. Brunet8, H. Ekberg9,
J.M. Grinyó3
1Pharmacokinetics And Biopharmacy Dept. Pharmacy Faculty. Universidad
De Barcelona., 2Pharmacy And Pharmaceutical Technology Dept. School of
Pharmacy, University of Navarra., 3Nephrolgy Dept. Hospital of Bellvitge.,
4Nephrology Dept. Hospital Clinic Barcelona, 5Nephrology Dept. Hospital
Universitario La Fe., 6Nephrology Dept. Virgen Del Rocío University
Hospital, 7Nephrology And Renal Transplantation Dept. University Hospitals
Leuven, University of Leuven, 8Pharmacology Department (Cdb). Hospital
Clinic Barcelona., 9Nephrology And Transplantation Dept. Lund University,
University Hospital.
Background: The objective of Symphony clinical trial was to test the safety
and efficacy of immunosuppressive regimens based on low doses of xenobiotic
drugs in combination with Daclizumab, mycophenolate mofetil (MMF) and
corticosteroids. A pharmacokinetic substudy was carried out to investigate
the effect of those immunosuppressive regimens on the pharmacokinetics of
mycophenolate acid (MPA).
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Objective: To develop a population pharmacokinetic (PK) model for MPA
that accurately describes the time profile of plasma MPA concentrations after
daily oral administration of mycophenolate mofetil (MMF) on day seven after
kidney transplantation in the studied population.
Patients and Methods: 58 patients from 9 sites in Spain and Belgium received
either standard-dose of Cyclosporine (CsA). MMF and corticosteroids (n=13).
or daclizumab induction, MMF and corticosteroids plus low-dose CsA (n=14).
low-dose Tacrolimus (Tac) (n=12) or low-dose Sirolimus (SRL) (n=19).
Sampling was performed on day seven after transplantation, before and
at 20, 40, 75 min, 2, 3, 6, 8,10 and 12 hours post-dose. Population analysis
was performed using NONMEM VI. Covariates screened were gender, age,
body weight, renal function (serum creatinin, creatinin clearance, BUN)
and hepatic enzimes and bilirrubin, haemoglobin, haematocrit, albumin and
inmunosupressive co-therapy (CsA, Trl or Srl).
Results: The PK of MPA was best described by a two compartment open
model with first order absorption and lag time. Although some of the individual
concentration-time profiles showed the evidence of enterohepatic recirculation
(given by a secondary peak between 6 and 12 hours) it could not be succesfully
modeled in the present study. It suggested that this phenomenon did not
influence the PK of MPA to a large extent in the studied population on day
seven after renal transplantation. Inter-individual variability (IIV) was included
in total plasma clearance [CL, (41%) ], and central distribution volume [VC,
(161% ) ]. The inclusion of the exposure to CsA (C0hCsA,μg/ml) as a covariate
in the model for the total plasma clearance, reduced the IIV of this parameter
from 47% to 41%: CLMPA=20.5 x (1+2.17 x C0hCsA) L/h. According to
this relationship, CLMPA would be smaller in patients receiving Tac or Srl
than in those receiving CsA. CLMPA would increase with increasing CsA
exposure (2.17 L/h increase in CLMPA with each 1 &#61549;g/mL increase
in C0hCsA). The final population estimates for the other PK parameters were:
VC=23.3 L;VP, volume of distribution of peripheral compartment=684 L;
CLD, intercompartmental clearance =33.8 L/h; KA, 1st order rate constant of
absorption =0.80 h-1and Lag time=0.28 h.
Conclusion: The developed population PK model adequately describes
the time profiles of MPA on day seven after kidney transplantation in the
studied population. It incorporates the exposure to CsA to predict the total
drug clearance. CLMPA increases with increasing CsA exposure, that may
be explained by the inhibition of multidrug resistance-associated protein 2
(MRP-2) by CsA. The CLMPA prediction by the model developed could help
to optimize the MMF dosing in the de novo renal transplant patients to achieve
the required exposure to avoid acute rejection episodes.
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106 FIXED AND WEIGHT BASED MYCOPHENOLATE
DOSING IS NOT IDEAL FOR INDIAN TRANSPLANT
RECIPIENTS
G.T. John1, V.M. Annapandian1, S.B. Mathew2, G. Basu1, G.H. Fleming2,
S. Varughese1,
1
Dept. of Nephrology, Christian Medical College, Vellore, 2Dept. of Clinical
Pharmacology, Christian Medical College, Vellore
Background: Weight based dose of mycophenolate has been recommended for
renal transplantation.
Aim: To determine the relationship between the weight adjusted mycophenolate
(MPA) dose and drug exposure (AUC) among Indian renal transplant recipients
at Christian Medical College, Vellore, India.
Patients and Methods: We studied steady state pharmacokinetics of MPA
in 120 consecutive renal allograft recipients who underwent transplantation
at our centre between Jan 2004 and Nov 2007, receiving MPA (mofetilMMF/sodium-MNa) along with cyclosporine/tacrolimus and corticosteroids
as primary immunosuppression. After renal transplantation, the total drug
exposure (MPA-AUC 0-12). was quantified using HPLC, within one month, at
3 months, 6 months and thereafter as required. Equivalent dose of MPA was
calculated considering 22 mg of MNa ≡ 30 mg of MMF.
Results: Among recipients, 76.8% were males. Average recipient age was
34.9±12.0 years. Deceased donors accounted for 6.7% of the allografts.
Among live related donors 81.4% had ≥2 HLA class1 antigen matches with
their recipients. 50% of patients received basiliximab and 3 (2.5%) received
ATG as induction. Along with mycophenolate (MMF-46.7%, MNa-53.3%).
70% of patients received Tacrolimus and the rest, Cyclosporine. Average MPA-
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AUC’s of 45.4±17.7mg.h/L and 55.5±19.2mg.h/L were achieved with average
doses of 35.6±9.1mg/kg/day and 29.0±8.6mg/kg/day of MPA within and after
3 months respectively. Only 65% and 56% of patients achieved the target AUC
of 30-60mg.h/L within and after 3 months respectively. The average doses
of MPA among patients who had AUC <30, 30-60 and >60mg.h/L were not
significantly different (31.4±8.3, 32.3±8.7 and 32.9±6.3mg/kg/day respectively,
p=0.921). The median (min-max) dose in above groups were also similar [1750
(1500-2250). 1750 (1000-3500) and 2000 (1250-2500) mg/day respectively].
Among those who achieved the target AUC of 30-60mg.h/L, 20% required
<25mg/kg/day, 43% required 25-35mg/kg/day, 26% required 35-45mg/kg/day
and the rest 11% required >45mg/kg/day of MPA. If a fixed dose of 2grams/
day were to be used, 16% of patients would achieve an AUC of <30mg.h/L,
and 23% would overshoot to >60mg.h/L within 3 months of transplantation.
With the same dose, after 3 months, 53% of patients would cross the upper
limit AUC of >60mg.h/L. With a weight based dose of 30mg/kg/day, only 55%
and 42.5% of patients would achieve the target AUC of 30-60mg.h/L, within
and after 3 months respectively (10.8%, 39.2% would cross the therapeutic
limit of 60mg.h/L).
With level (AUC) controlled mycophenolate dosing we observed biopsy
proven acute rejection rate of 15.8% (10.8% early rejection within 1 month).
graft loss-2.5%, and CAN at 1 year-1.7%, patient loss-1.7%, UTI-24.2%, CMV
disease-9.2%, TB-1.7%, leucopenia-12.5% and diarrhea-4.2%. The average
eGFR (abb. MDRD) was 72±22.5, 72.5±18.3 and 63.8±20.1ml/min/1.73sq.m.
at 1,6 and 12 months respectively.
Conclusion: A fixed or weight based dosing of mycophenolate is not ideal and
fails to achieve target AUC in a significant percentage of Indian renal allograft
recipients. Level controlled mycophenolate dosing is recommended for renal
transplantation in India.

POSTER BOARD NUMBER P1 – 304
107 COST-EFFECTIVENESS ANALYSIS OF ADVERSE
EVENTS IN LOW TOXICITY IMMUNOSUPPRESSIVE
REGIMENS. PRELIMINARY RESULTS OF THE QUALITY OF
LIFE SUBSTUDY WITHIN THE SYMPHONY STUDY.
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Introduction: The Symphony study compares 4 immunosuppressant regimens
in renal transplant patients in terms of clinical outcomes, resource consumption
and gained health related quality of life (HRQoL). Here we focus on highlighting
the importance of avoiding adverse events (AE) in order to gain quality of life
and to minimize the treatment costs in kidney transplant patients during the
first year of follow up.
Objective: To compare the cost and the HRQoL of patients with mild or severe
AE during the first year after kidney transplantation.
Subjects and Methods: In total, 156 renal transplant recipients at 14 Spanish
centres were included in the Symphony study. Patients were randomized to 4
immunosuppressive regimens, all in addition to MMF and steroids. Only six
patients had not suffered an AE during the follow up. Cost per patient & year
(CP) in patients with mild or sever AE was obtained by adding up the average
costs of its most consumed resources (biochemical test –BT, hemogram -HM,
nephrologist’s consultation -NpC, nurse´s consultation -NsC and hospital
admittances to transplant unit -HATU). Health related quality of life was
measured by the SF-36 Health Survey and translated into standardized utilities
by the SF-6D. Independent samples test was used to evaluate the differences
between groups in HRQoL during the first year after transplantation.
Furthermore, mean cost-effectiveness scores were calculated in both groups by
dividing the respective total costs and gained utilities.
Results: an analysis was performed with 148 patients. No statistical significant
differences between the 4 immunosuppressant regimens in age, gender,
opportunistic infections or AR were found. Mean utility score in patients with
mild AE was higher than in patients with severe AE (0.812 & 0.763 respectively;
p= 0.060). 1st year mean cost in patients with mild AE was 20,082 € instead of
34,738.29 € (in patients with severe AE).
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1st YEAR COSTS/patient
BT
HM
NpC
NsC
HATU
TOTAL COST/patient

MILD AE
Mean (SD) - €
173.15 (49.91)
161.13 (43.19)
3,107.76 (1183.65)
219.67 (22.08)
16,572.51 (12976.93)
20,082. 51 (13,586.43)

SEVERE AE
Mean (SD) - €
216.90 (91.99)
185.50 (78.45)
4,401.11 (3383.12)
324.28 (457.95)
29,281.48 (19637.18)
34,738.29 (21,251.43)
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108 RANDOMIZED TRIAL OF SODIUM MYCOPHENOLATE
AND BASILIXIMAB IN COMBINATION WITH REDUCED
OR STANDARD CYCLOSPORINE EXPOSURE IN OLD
RECIPIENTS OF KIDNEY TRANSPLANTS FROM DECEASED
DONORS
M. Salvadori, M.P Scolari, S. Stefoni, E. Bertoni, S. Sandrini, P. Rigotti,
V. Cambi, G. Civati, L. Boschiero, G. Piredda
Renal Unit Careggi University Hospital
Introduction: Old recipients of kidney transplants (KTx) are at increased risk
of cardiovascular diseases, infections and cancer. The current strategy of organ
allocation favors the use of aged donor organs in old recipients (old for old). but
this increases the risk of delayed graft function. In addition, old donor kidneys
are highly immunogenic, increasing the risk of acute rejection (AR). Attempts
to overcome these hurdles combining anti-CD25 antibodies, MMF and steroids
in a calcineurin inhibitor (CNI) free regimen, failed because of high AR rate
(>50%). with about 60% of patients reintroducing CNI.
Patients and Methods: In this controlled, randomized, multicenter, parallel
group, open-label trial we investigated whether cyclosporin for microemulsion
(CsA) at reduced initial exposure plus enteric-coated mycophenolate sodium
(EC-MPS) (Group 1) might improve the 12-month renal function in old KTx
recipients, in comparison with standard-CsA exposure plus EC-MPS (Group
2). CsA exposure was measured according to CsA whole blood levels 2 hours
after the morning dose (C2).
Transplant recipients aged >55 years were randomized to Group 1 (Month 1-2:
900 ng/mL, then 800 ng/mL) or Group 2 (Month 1: 1500 ng/mL, tapered to
1000 ng/mL by Month 6 and 800 ng/mL thereafter). Both groups received ECMPS (2160 mg/day for 5 days, then 1440 mg/day). basiliximab (20 mg on Day
0 and 4) and short-term steroids (stopped by Day 8). After the enrolment of
about 50 patients, an increased incidence of early biopsy proven AR (BPAR)
was evident. Therefore the protocol was amended allowing for continued lowdose steroids up to M12. To avoid overimmunosuppression, starting EC-MPS
dose was reduced to 1440 mg/day.
Results: Overall, 117 patients (Group 1: N=49, Group 2: N=68). mean age
59.2±5.2 and 60.4±5.1 years respectively, were enrolled. Mean donor ages
were 62.0±6.8 and 63.6±7.4 years. The 12-month probability of BPAR was
10.8% in Group 1 and 18.1% in Group 2 (p=NS). Mean creatinine clearance
(Cockcroft and Gault). was better in Group 1 (50.6±13.7 Vs. 47.4±16.8 mL/
min). but not significantly. The 12-month graft survival (uncensored for death)
was 91.7% in Group 1 and 95.5% in Group 2 (p=NS). In Group 1, there were 4
failures: 2 patients died (cardiac arrest; pulmonary embolia) and two others lost
the graft (primary non function; renal infarction). In Group 2, 3 patients died
(sepsis; myocardial infarction; stroke). Within the 53 patients in both groups
who underwent early steroid withdrawal, 12 (22.6%) had a BPAR within 3
months, all of them of grade I and easily reversible with steroid boluses. Only
4 out of the 64 patients on low dose continuous steroids had a BPAR (6.2%).
Anemia, hypertension, leucopenia, urinary tract infections and cytomegalovirus
infections were the most frequent adverse events, with no significant differences
between the two groups.
Conclusions: The combination of EC-MPS, basiliximab and low dose steroids,
either with low or standard dose CsA, is highly effective in preventing BPAR
and well tolerated in old recipients of kidney grafts from old deceased donors.
Early steroid withdrawal might increase the risk of mild, reversible BPAR.

109 MYCOPHENOLIC ACID PLASMA CONCENTRATIONS
AND ACUTE REJECTION RATE IN HIGH RISK VERSUS
LOW RISK RENAL TRANSPLANT PATIENTS RECEIVING
MYCOPHENOLATE MOFETIL.
T. Van Gelder1, N. Gafner2, On behalf of all FDCC investigators
1
Erasmus Medical Center, 2Roche Basel
Introduction: Mycophenolic acid (MPA) plasma concentrations have been
found to be predictive of the risk of developing acute rejection after renal
and cardiac transplantation. Guidelines for the implementation of therapeutic
drug monitoring (TDM) for mycophenolate mofetil (MMF) have been
published. In these guidelines it is recommended to perform TDM in selected
patient populations. In order to better define such subpopulations, a posthoc, exploratory analysis on the FDCC database was performed to study the
relationship between MPA plasma concentrations and the incidence of acute
rejection in high risk versus low risk renal transplant (rtx) patients.
Methods: In a randomized controlled trial (FDCC-study) rtx patients were
treated with MMF, corticosteroids and either cyclosporine (CsA -n = 488) or
tacrolimus (TRL -n = 413). Abbreviated MPA-AUCs (3 samples within the
first 2 hours after administration) were measured on day 3, day 10, week 4 and
months 3, 6 and 12, to calculate MPA-AUC0-12h. Patients were followed for
12 months. Patients were defined post hoc as “high risk” if they had one or
more of the following characteristics: delayed graft function, second or third
transplantation, panel reactive antibodies > 15%, 4 or more HLA-mismatches.
All other patients were considered “low risk”.
Results: In the full study population of 901 patients, a MPA-AUC0-12
below 30 mg*h/L on day 3 after transplantation was associated with a risk
of developing acute rejection in the first month of 35/308 (11.4%). compared
to 33/517 (6.4%) in patients with MPA-AUC0-12 above 30 mg*h/L (p =
0.018). A total of 491 patients (54%) were classified as high risk, of whom 254
were on CsA treatment and 237 on TRL. In high risk patients the difference
in rejection incidence (14.6% vs 7.9%) was comparable to the whole study
population, while in low risk patients there were similar rejection rates above
and below30 mg*h/L (5.5% vs 4.4%). In the subgroup of high risk tacrolimus
treated patients the difference in the incidence of acute rejection in the first
month between patients with MPA-AUC0-12 below or above 30 mg*h/L was
most pronounced: 16/66 (24.2%) vs 18/171 (10.5%); p = 0.012.
Conclusion: In an analysis of all patients there was a significant relationship
between MPA AUC and the risk of developing acute rejection after renal
transplantation. In a post hoc subset analysis of high risk and low risk, the risk
of acute rejection is higherhigh risk patients had a higher risk of rejection and
there was a significant difference in the incidence of acute rejection between
high risk patients with MPA-AUC0-12 above or below 30 mg*h/L. In contrast,
a difference in risk of acute rejection in low risk patients with MPA-AUC0-12
below or above 30 mg*h/L was not observed. This supports the recommendation
to perform TDM for MMF in selected patient populations.

POSTER BOARD NUMBER P1 – 307
110 THE EFFECT OF A NOVEL NUCLEAR FACTOR K
(KAPPA) B ACTIVATION INHIBITOR ON THE RENAL
INFLAMMATORY RESPONSES IN RENAL ISCHEMIA
REPERFUSION IN RAT
H. Kono1, K. Nakagawa1, S. Morita1, T. Koshida1, K. Shinoda1, T. Shinojima1,
A. Miyajima1, K. Umezawa2, M. Oya1
1
Keio university, the department of urology, 2Keio university, the department
of applied chemistry
Purpose: The purpose of the study was to investigate the effect of a novel nuclear
factor ƒÈB (NFƒÈB) activation inhibitor dehydroxymethylepoxyquinomicin
(DHMEQ). which is derived from epoxyquinomicin C, on the renal
inflammatory responses in renal ischemia reperfusion.
Materials and Methods: DHMEQ was intraperitoneally administered at
8mg/kg to Lewis rats on a daily basis after the onset of ischemia reperfusion
(DHMEQ post-treatment group). The second group of rats was injected once
intraperitoneally with DHMEQ just before renal artery clamping (DHMEQ
pre-treatment group). The third group of rats was not administered DHMEQ
(control group). For the DHMEQ pre-treatment group and the control group,
only saline was administered daily. Urine samples were collected daily from rats

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

39

MONDAY

In addition, the respective mean cost-effectiveness ratios were 24,739.61 €
(mild AE) and 45,526.51 € (severe AE).
Conclusions: cost effectiveness analysis highlighted the economic and
HRQoL impact of severe AE during the first year after kidney transplantation.
This burden should be considered when comparing the efficiency of different
immunosuppressive regimens. Finally, sensibility analyses should be applied to
resource consumption and costs to manage the uncertainty of these outcomes.
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placed in metabolic cages for 24 hours. The kidneys were harvested on either
day 1 or 7 after renal artery clamping from each group of rats. Thereafter, renal
sections were made and stained with either hematoxylin and eosin, Masson
trichrome, PAS stain, or some immunohistochemichal agents. Then they were
examined using light microscopy. The clamping time was thirty minutes.
Results: In the DHMEQ pre-treatment group, the urine volume for 24 hours
from days 1 to 3 after ischemia reperfusion was significantly larger than in
the control group (p<0.05). In comparison with the control group, the serum
creatinine level of the DHMEQ pre-treatment group decreased by 60% and
BUN level decreased by 50% at day1. The kidneys of the DHMEQ pre-treatment
group at day1 demonstrated less severe lesions in the tubulointerstitium, with
a loss of the brush border, the detachment of epithelial cells from the basement
membrane, and interstitial edema. P65 which is a subunit of NFƒÈB was
mostly detected in renal tubular cytoplasm of the kidneys of the DHMEQ pretreatment group at day1. And significantly higher levels of granulocytes were
present in the kidneys of the control group at day1. TUNEL stain revealed
higher levels of tubular cell apoptosis were detected in the kidneys of the
control group at day 1.
The kidneys from the DHMEQ pre-treatment group and post-treatment
group at day 7 demonstrated less interstitial fibrosis in comparison with the
control group.
Conclusion: Treatment with DHMEQ before renal artery clamping may
therefore be useful for ischemia reperfusion injury in the kidneys.
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111 MONITORING CELLULAR IMMUNITY AFTER KIDNEY
TRANSPLANTATION: THE IMMUKNOW® ASSAY DOES NOT
PROPERLY REFLECT CHANGES IN T CELL REACTIVITY
R. Olsson1, A.K. Lidehäll2, M. Engstrand1,2, J. Henriksson1, G. Tydén1,
O. Korsgren2 and L. Wennberg1
Departments of 1Transplantation Surgery, Karolinska University Hospital,
Huddinge, Stockholm and 2Clinical Immunology, Uppsala University,
Uppsala, both in Sweden.
Background: To optimize kidney graft survival, and to minimize the risk
for complications (such as acute rejection, infection and malignancy).
there is an obvious need for methods to properly monitor the degree of
immunosuppression. Recently, the ImmuKnow¦ assay was marketed as such
a method. The ImmuKnow® assay measures PHA-induced ATP production
of the recipient’s CD4+ T cells, and correlations between the ATP production
and the relative risk of both acute rejection (high ATP production, ≥525 ng/
ml) and infections (low ATP production, ≤225 ng/ml) have been reported.
Presently, we are including patients in a study comparing the results of the
Immuknow¦ assay with changes in cellular immunity against cytomegalovirus
(CMV). Approximately 80% of all adults are seropositive to CMV and it causes
significant morbidity in immunosuppressed organ transplant recipients.
Materials and Methods: Nine CMV seropositive kidney transplant recipients
(4 deceased and 5 living donors) have so far been evaluated in this study. All
patients received 500 mg of methylprednislone immediately prior to surgery and
maintenance immunosuppression was composed of tacrolimus in combination
with prednisolone and mycophenolate mofetil (n=4) or azathioprin (n=5).
Recipient T cell reactivity was analyzed immediately before transplantation and
at 1 week, 2 weeks and 1 month postoperatively using both the ImmuKnow®
assay (Cylex Inc., Columbia, MD, USA) and a novel method developed at the
Department of Clinical Immunology, Uppsala University Hospital, Sweden.
In brief, recipient blood was stimulated with CMV-specific proteins (a lysate
produced from CMV-infected fibroblasts and overlapping peptides spanning
the entire pp65 and IE1 proteins, respectively) in vitro and the number of CD4+
or CD8+ T cells producing IFN γ was separately determined by fluorescenceactivated cell sorting (FACS). For statistical analysis, paired comparisons were
made using the Wilcoxon Matched-Pairs Signed-Ranks test.
Results: During the first month after kidney transplantation, there were no
significant changes of the ImmuKnow® results. Moreover, both total peripheral
CD4+ and CD8+ lymphocyte numbers were unchanged. However, one week
post-transplantation the CMV-reactive CD4+ lymphocytes were significantly
reduced compared to pre-transplantation data [median 700 CD4+ cells/
ml (range 0-41 600 CD4+ cells/ml) vs. median 6 950 CD4+ cells/ml (range
250-92 250 CD4+ cells/ml) ], whereas the number of CMV-reactive CD8+
cells remained unchanged.
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Conclusions: During the first month after kidney transplantation the
ImmuKnow® results did not change. Considering the heavy immunosuppression
given during this postoperative time period, the ImmuKnow® assay does not
seem to properly reflect early changes in immunosuppression. In contrast,
T cell reactivity against CMV is markedly decreased suggesting that this
analysis may be a better alternative for immunological monitoring after organ
transplantation. In addition, assays for T cell reactivity against other dormant
viruses (BK, Epstein-Barr) may further improve the sensitivity and specificity
of this method.
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112 DIFFERENT IMPACT OF MAINTENANCE
IMMUNOSUPPRESSIVE REGIMENS ON THE IMMUNE
RESPONSE OF RENAL TRANSPLANT RECIPIENTS
R. Weimer1, S. Deisz1, F. Renner1, H. Dietrich1, V. Daniel2, S. Kamali-Ernst3,
W. Ernst4,
W. Padberg5, G. Opelz2,
1
Department of Internal Medicine, University of Giessen, 2Institute of
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar,
4
Dialysis Center, Langenselbold, 5Department of Surgery, University of
Giessen
The Symphony study showed superior 1-year kidney graft outcome on a Tacr/
MMF maintenance regimen. To analyze effects of different maintenance
regimens on clinically relevant immune parameters of Th1/Th2, B cell and
monocyte responses, we assessed CD4 helper activity, immunoglobulinsecreting cell (ISC) formation, neopterin and intracellular cytokine production
in a prospective randomized study of 84 renal transplant recipients (CsA/Aza,
CsA/MMF, Tacr/Aza) at 2 years posttransplant.
Two-year patient and graft survival were 100% and 93%, respectively.
Tacr-based immunosuppression was associated with lower neopterin
levels (corrected for graft function; p=0.01). increased IL-2 (p<0.0001,
CD4 cells; p=0.007, CD8 cells) and CD4 cell IL-4 responses (p=0.008)
compared to CsA. The impact on cytokine responses was confirmed by
multivariate logistic regression (p<0.0001, CD4 cell IL-2; p=0.01, CD8
cell IL-2; p=0.046, CD4 cell IL-4). Patients on MMF versus Aza therapy
showed suppressed CD4 helper activity (p=0.009). CD4 cell IL-4 (p=0.01)
and IL-10 responses (p=0.001) together with lower ISC responses (p=0.04,
SAC I; p=0.006, PWM) and a profound decline in IL-6R expression on B
cells (p<0.0001). Logistic regression confirmed suppressed CD4 cell IL-10
responses (p=0.008) and B cell responses on MMF treatment (p=0.02, ISC
formation; p<0.0001, B cell IL-6R). The highest T-cell responses of the
B-cell factor IL-10 were observed on Tacr/Aza therapy (p=0.005, CD4 cells;
p=0.02, CD8 cells) which coincided with early graft loss due to acute vascular
rejection in this treatment group only (n=3). Potent immunosuppressive
effects were found on Tacr/MMF, the only regimen being associated with
downregulation of CD4 cell CD28 and CD8 cell IL-2R (CD25) expression
(p=0.03 and p=0.02, respectively). Tacr treatment provided an independent
factor predicting better 2-year graft function (creatinine clearance; p=0.01,
logistic regression).
Our data suggest that a Tacr/MMF regimen was most effective in its impact
on immunological parameters being associated with better graft outcome.
Previously shown graft protective effects of Th2 responses (enhanced CD4
cell IL-4, decreased CD4 helper activity and IL-10 responses) may be
achieved by Tacr (IL-4) and MMF therapy (CD4 help and IL-10). Monocyte
and B cell functions playing a role in chronic allograft nephropathy were
suppressed by Tacrolimus (neopterin) and MMF (B cell IL-6R expression;
ISC responses).
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113 NGAL (NEUTROPHIL GELATINASE-ASSOCIATED
LIPOCALIN) IS A NEW AND SENSITIVE MARKER OF KIDNEY
FUNCTION IN CHRONIC KIDNEY DISEASE PATIENTS AND
RENAL ALLOGRAFT RECIPIENTS
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114 DIALYSIS TIME IS A RISK FACTOR FOR LONG-TERM
DECEASED-DONOR TRANSPLANT SURVIVAL
M. Gallichio, S. Yarlagadda, A. Rainow, O. Elbahoul, D. Conti
Albany Medical College
The duration of dialysis prior to transplantation has been shown to be a risk
factor for renal transplant survival. However, these analyses, in deceased-donor
renal transplantation, failed to control adequately for donor and procurement
risk factors which may have a significant impact on allograft function and
survival. For example, three-year survival of expanded criteria donor kidneys
is significantly less than standard criteria donor kidneys. To adequately
control for these donor-related variables, we analyzed long-term graft survival
rates in deceased-donor recipients of paired kidneys derived from the same
procurement procedure, preserved in the same manner, implanted by the same
surgical team, subjected to similar cold ischemia times (CIT) and treated with
the same immunosuppressive protocol. Recipient pairs consisted of 1 recipient
whose dialysis duration was less than 1-year (mean 6 months, Group A) and 1
recipient who was treated with dialysis for more than 1-year (mean 31 months,
Group B).
Between 11/1990 and 11/2002, 71 deceased-donor procurement procedures
provided kidneys for 1 Group A and 1 Group B recipient at our center. In
all cases paired kidneys derived from the same procurement procedure were
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115 POST-TRANSPLANTATION ANEMIA AND THE IMPACT
OF IMMUNOSUPPRESSIVE THERAPY: DATA FROM THE
TRANCEPT OBSERVATIONAL STUDY
H.T. Da Silva1, U. Heemann2, P. Merville3, C. Bernasconi4,
H-U. Meier-Kriesche5
1
University of Sao Paulo, Sao Paulo, Brazil, 2Technical University, Munich,
Germany, 3Hopital Pellegrin, Bordeaux, France, 4F. Hoffmann-La Roche,
Basel, Switzerland, 5University of Florida, Gainsville, USA
Renal transplantation is often the treatment of choice for patients with chronic
kidney disease (CKD). many of whom have renal anemia. Immunosuppression
is one of several factors known to influence Hb levels following transplantation.
One commonly used immunosuppressant drug following transplantation
is mycophenolate mofetil (MMF). which can be introduced in the late posttransplant phase to allow reduced dosage of the more nephrotoxic CNIs
(cyclosporine A [CsA], tacrolimus [Tac]) or steroids.
Using data from the TranCept study, we report an exploratory analysis on
the relationship between Hb levels at enrollment and factors that may impact
upon anemia, looking in particular at immunosuppressants. TranCept is a
multicenter, observational, global study in 4399 patients of all ages who were
introduced to MMF due to declining renal function or intolerance of previous
immunosuppressive drugs, or who were receiving MMF since transplantation.
Patients were transplanted 6 months to 20 yrs before enrollment in the study.
Our exploratory analysis has evaluated data from 3692 adult patients (>18 yrs)
using descriptive statistics, non-parametric univariate tests and multivariate
linear models, with a significance level of 5%. Anemia was defined as <12 g/
dL for females, and <13 g/dL for males.
Mean Hb (SD) at enrollment was 12.7 (+/-2.2) g/dL and 713 (19%) had Hb <11
g/dL. As previously reported, post-transplantation Hb values fell with declining
renal function. Hb levels were not dependent upon time after transplantation.
There was a negative dose-effect relationship for Tac (p=0.04) and particularly
for CsA (p<0.0001); multivariate models including age, gender, GFR and
duration of MMF treatment confirmed this result. Patients who had a CNI
reduction up to months 6 (n=608; CsA dosage decrease >40 mg/day or Tac
> 1 mg/day) had improved Hb levels after 1 yr compared with patients with
no CNI reduction (n=3084; p=0.0014). Hb improvement was independent of
GFR at 1 yr and of the change in GFR from enrollment. Lower Hb levels were
observed in patients receiving sirolimus vs CsA and Tac (12.0, 12.7 and 12.7 g/
dL, respectively; p=0.0008). Hb levels were almost identical in patients treated
with MMF and azathioprine, with no dependence of Hb levels on MMF dose
or time from MMF introduction, indicating that MMF does not increase the
prevalence of post-transplantation anemia. Those patients with anemia had a
higher incidence of a composite endpoint of graft loss, acute heart failure, MI,
coronary artery disease or stroke vs patients without anemia (13.4% vs 9%
respectively, p<0.001); anemia (but not Hb) was an independent risk factor in
models including also GFR and age (p=0.03).
We conclude that patients with reduced graft function should be evaluated for
anemia. Patients who are at risk of anemia complications may require a reevaluation of their immunosuppressive treatment.
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J. Malyszko1, J. Malyszko1, H. Bachorzewska-Gajewska2, S. Dobrzycki2,
E. Koc-Zorawska1, M. Mysliwiec1
1
Medical University, Department of Nephrology and Transplantation,
2
Medical University, Department of Invasive Cardiology
Background/Aims: Very few biomarkers exist for monitoring chronic kidney
disease. NGAL (neutrophil gelatinase-associated lipocalin). a member of
lipocalin family, has been recently prove useful in the quantitation of CKD.
Because of its small molecular size (25kDa) and resistance to degradation,
NGAL is readily excreted and detected in urine The aim of the study was to
assess whether NGAL could represent a novel, sensitive marker of kidney
function in adult patients with CKD and kidney transplant recipients. We also
studied possible relations between serum NGAL, creatinine and estimated
GFR in 92 non-diabetic patients with CKD stages 2-4, 80 non-diabetic
kidney transplant recipients on triple therapy: calcineurin inhibitor/MMF or
azathioprine, prednisone) and healthy volunteers (n=30, mean age 50 years).
Methods: NGAL was evaluated using commercially available ELISA from
ANTIBODYSHOP (Gentofte, Denmark). We assessed kidney function
according to the simplified MDRD formula.
Results: Serum NGAL, creatinine was significantly higher and eGFR was
significantly lower in kidney allograft recipients and patients with CKD over
controls. NGAL were similar in the same stages of CKD in patients with CKD
and kidney allograft recipients. NGAL rose gradually reaching the higher value
in the stage 4 CKD. Serum NGAL was related, in univariate analysis, to serum
creatinine, hemoglobin, hematocrit, leukocyte count, eGFR. Predictors of
serum NGAL were creatinine, and eGFR in patients with CKD. In the healthy
volunteers, serum NGAL correlated with age, serum creatinine, eGFR, and
leukocyte count. Serum NGAL was related, in univariate analysis, to serum
creatinine, urea, hemoglobin, hematocrit, white blood cell count, duration of
hypertension, age, eGFR albumin. In multiple regression analysis, predictors
of NGAL were eGFR, white blood cell count and albumin explaining 85% of
NGAL concentration. When eGFR was substituted by creatinine the results
were the same.
Conclusion: NGAL should be investigated as a potential early and sensitive
marker of kidney impairment/injury, which might provide an additional
accurate measure of kidney impairment in CKD and kidney transplant
recipients, particularly at advanced stages.

preserved in the same manner and recipients of paired kidneys were treated
with the same immunosuppressive protocol. Demographics between the
groups were similar with respect to age, gender, ethnicity, CIT, diabetes, and
retransplant status.
Actual 1-year graft survival was 96% in Group A and 92% in Group B (p=NS).
Actual 5-year patient and graft survival (n=71 in both groups) was 97% and
82% in Group A and 89% and 66% in Group B (P<0.05 for graft survival).
This analysis of paired deceased-donor kidneys corroborates earlier analyses
and demonstrates that a one-year duration of dialysis pre-transplant is a
significant risk factor for long-term renal transplant outcome.
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116 KIDNEY TRANSPLANTATION ONLY PARTIALLY
RESTORES ESRD PATIENT SURVIVAL
A. Leichtman1, K. McCullough2, R. Wolfe2
1Dept of Medicine, Div. of Nephrology, U. of Michigan, 2Arbor Research
Collaborative for Health
Introduction: Kidney transplantation is now accepted as providing a
survival advantage compared to remaining on dialysis. The extent to which
deceased donor kidney transplantation restores normal longevity has not been
quantified.
Methods: We compared median lifetimes for the general US population,
wait listed patients (WL). most of whom were on dialysis, and deceased
donor kidney-alone or kidney-pancreas transplant recipients (KT). Estimated
lifetimes were based on the 1996 Interpolated Abridged Life Table from the
US Public Health Service for the US Pop; prevalent samples of active WL
patients taken on Jan. 1 of 1988, 1990, 1994, 1998, and 2002; and 1987–2004
transplant recipients. Both WL and PT data were from the Scientific Registry of
Transplant Recipients with extra death ascertainment from the Social Security
Death Master File. WL and PT lifespan medians were based on the average
estimated median lifespan for candidates who were active on the waitlist on
January 1, 2004.
Results: At each age, the median lifetime was shorter for dialysis patients than
for KT, and KT lifetimes were less than half that of the comparable age group
of the general US population.

POSTER BOARD NUMBER P1 – 314
117 THE RELATION BETWEEN TRANSPLANT
CENTER VOLUME AND THE OUTCOMES OF KIDNEY
TRANSPLANTATION: A SYSTEMATIC REVIEW
J. Kim1,2,3, T. Louis2, B. Astor2,3, E. Boulware2,3, D. Al-Riyami1, N. Powe2,3
1Toronto General Hospital, University Health Network, University of
Toronto, 2Johns Hopkins Bloomberg School of Public Health, Johns Hopkins
University, 3Welch Center for Prevention, Epidemiology and Clinical
Research, Johns Hopkins University
Background: Hospitals performing a higher volume of procedures have been
associated with more favorable patient outcomes across numerous surgical and
medical disciplines. The relation between transplant center volume and kidney
transplant outcomes remains uncertain.
Objective: To systematically review studies relating kidney transplant
procedural volume in U.S. and non-U.S. kidney transplant centers to the
survival of patients and their allografts.
Data Sources: English-language articles in MEDLINE (1 Jan 1965 to 1 Oct
2007). EMBASE (1 Jan 1980 to 1 Oct 2007). the Cochrane database, and
reference searches from retrieved articles.
Study Selection: All studies examining transplant center volume (i.e., the
number or rate of kidney transplant surgeries performed over a specified period
of time) as a predictor of kidney transplant outcomes (i.e., patient and/or
allograft survival) in adult recipients.
Data Extraction: One investigator used a standardized form to collect key
study characteristics and results while another independently reviewed the data
for accuracy and completeness.
Data Synthesis: Eight of 18 studies (44%) showed a positive and statistically
significant relation between center volume and graft survival (i.e., higher center
volume is associated with higher graft survival). Center volume in 2 of 6 studies
showed a positive relation with patient survival. The methodologic rigor of
the studies varied widely and was generally suboptimal. When the studies
were grouped into those from the U.S. (10 studies). those including patients
transplanted since 1985 (11 studies). and those of the highest methodologic
quality (6 studies). a total of 4, 6, and 3 reports, respectively, continued to
display a volume-outcome relationship.
Conclusions: A center volume effect may exist in kidney transplantation
but firm conclusions cannot be drawn due to methodologic shortcomings of
existing studies. Volume-based policies in kidney transplantation can neither
be endorsed nor rejected at this time.
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Conclusion: Compared to the general age-matched population, dialysis and
transplantation incompletely restore lifespan. Some of the differences in
survival might reflect differences in patient selection with the least healthy
patients excluded from certain therapies, but these adjusted analyses account
for many patient variables. Thus, differences between WL and KT survival
probably reflect true differences in the efficacy of therapeutic modalities.
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118 GERIATRIC RECIPIENTS OF DECEASED DONOR
RENAL TRANSPLANTS DEMONSTRATE EQUAL GRAFT
SURVIVAL TO NON-GERIATRIC POPULATIONS
A. Sener, E. Schweitzer, M. Cooper, L. Campos, S. Bartlett, B. Philosophe,
R. Barth
University of Maryland School of Medicine
Renal transplantation has become increasingly prevalent in the geriatric
population accounting for 13.2% renal transplants performed nationally. We
reviewed 3297 renal transplant recipients from our transplant database over the
last 15 years to evaluate outcomes in the geriatric population. We used KaplanMeier survival estimates and logrank estimates of statistical significance. Our
center has performed 468 living (LDRTx) and deceased donor renal transplants
(DDRTx) in patients over the age of 65 years old since 1991. We have
performed 14.2% of all renal transplants in patients over the age of 65 years
old, 5.7% of transplants in patients over 70 years old, and 1.8% (60 transplants)
in patients over 75 years old. Geriatric recipients (over 65 years old) of DDRTx
demonstrated 83.0%, 74.1%, and 64.1% graft survivals at 1, 3, and 5 years.
Geriatric DDRTx recipients had overall equal graft survivals to adult DDRTx
(p=0.49). Geriatric recipients of LDRTx demonstrated 1 year graft survival of
94.3%, 3 year graft survival of 88.8%, and 5 year graft survival of 72.3%. These
results were better than geriatric DDRTx recipients (p=0.04). but not as good as
graft survival in adult (18-64 years old) LDRTx recipients (p=0.006). This was
predominantly driven by poorer graft survival in LDRTx recipients older than
75 years (p=0.004). Graft survival in geriatric LDRTx recipients 65-69 years
old (p=0.04) and 70-74 years old (p=0.4) had more equivalent outcomes to
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adult LDRTx recipients. These data support the good outcomes of both LDRTx
and DDRTx in the geriatric population. DDRTx geriatric recipients had similar
graft survivals to adult DDRTx recipients. LDRTx geriatric recipients had
better outcomes than geriatric DDRTx recipients; although, not equal to the
excellent results of younger LDRTx recipients.
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I. Soveri1, H. Holdaas2, A. Jardine3, N. Eriksson4, B. Fellström1
1Department of Medical Sciences, 2Rikshospitalet, 3University of Glasgow,
4Uppsala Clinical Research Center
Background: Metabolic Syndrome (MS) is a risk factor for cardiovascular
disease (CVD) and diabetes mellitus in the general population. Renal transplant
recipients (RTR) have unfavorable metabolic conditions, partly due to
immunosuppression. Some, but not all studies in RTR have shown that MS has
adverse effect on graft survival.
Aim: To study MS as risk factor for renal end points in RTR. To investigate the
effect of fluvastatin treatment on renal risk in RTR with MS.
Methods: In total, 1708 stable RTR without diabetes mellitus in the ALERT
trial were randomized to treatment with fluvastatin or placebo. Follow-up was
7-8 years (ALERT-extension trial). MS was defined at baseline using ATPIII
definition. The registered renal endpoints included graft loss and graft loss or
doubling of serum creatinine.
Results: In the ALERT study, 29% of the non-diabetic RTR had MS. Graft loss
risk was increased in RTR with MS [RR (95% CI) ] 1.40 (1.10-1.78). RTR with
MS also had increased RR for losing renal graft or doubling in serum creatinine
1.27 (1.02-1.59). No favorable effects of statin treatment were observed.
Conclusion: RTR with MS are at higher risk for losing renal graft. Treatment
with fluvastatin does not reduce the risk.
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120 NEGATIVE IMPACT OF PRETRANSPLANT
COMORBIDITY IN GRAFT AND PATIENT SURVIVAL IN
KIDNEY TRANSPLANTATION.
A. Sanchez-Fructuoso2, I. Perez-Flores1, N. Calvo3, N. Ridao4, M. Giorgi5,
M. Marques6, A. Rodriguez7, A. Barrientos8
1
Hospital Clinico San Carlos, 2Hospital Clinico San Carlos, 3Hospital Clinico
San Carlos, 4Hospital Clinico San Carlos, 5Hospital Clinico San Carlos,
6
Hospital Clinico San Carlos, 7Hospital Clinico San Carlos, 8Hospital Clinico
San Carlos
Aims: To report pre- and peritransplant comorbidity. To study whether it could
predict patient and graft outcome after kidney transplantation. To validate and
compare several comorbidity indices in this population.
Methods: We retrospectively collected the next comorbid condition: heart failure,
left ventricular hypertrophy (LVH). myocardial infarction, cerebrovascular
disease, peripheral vascular disease, chronic pulmonary disease, peptic ulcer,
mild liver disease, vascular calcification, urinary tract pathology, diabetes pre
and postransplantation, acute tubular necrosis postransplantation, renal function
at discharge and at one year postransplantation. We analyzed the impact of
each one of them in the survival of 500 kidney transplantation performed in
our unit between 1999 and 2004. We studied the ability of two comorbidity
indices to predict patient and graft outcome by using a Cox regression model.
The Charlson Comorbidity Index (CCI) and a novel prognostic index proposed
to Hernandez were the indices used. Based on the ROC curve for CCI, the
patients were divided into different groups: low and high comorbidity (≤2 and
>2, respectively).
Results: There were a high number of patients with some comorbidity at
baseline (67%). The most common comorbid factors in our patients were: LVH
(55%). diabetes pre- and postransplantation (23% and 10.3%) and liver disease
(8.5%). The overall 5-years-patient and graft survival were 92% and 83.5%,
respectively. Of comorbidity indices examinated, the model containing the CCI
showed the best profile and the urinary tract pathology did not improve this
model. After adjustment for covariates, patients with high comorbidity had an
increased mortality after kidney transplantation (HR 7.74, 95% CI 1.49-40.01,
p = 0.015). The main causes of death depending on score of comorbidity were:
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121 GLOMERULONEPHRITIS FOLLOWING RENAL
TRANSPLANTATION
P. Keown, W. Chailimpamontree, S. Dmitrienko, G. Li, R. Balshaw, A. Magil,
D. Landsberg, R.J. Shapiro, J. Gill, and the Genome Canada Biomarkers in
Transplantation Group.
University of British Columbia, Vancouver, Canada.
Introduction: The study correlated patient risk factors and treatment with
the case incidence, cumulative probability, kinetics, and consequences of
glomerulonephritis (GN) following renal transplantation in 2026 patients
received a primary renal transplant in a single Canadian centre.
Results: The frequency of PTGN varied according to the category of original
disease. Post-transplant GN was most common (94/734; 12.8%) in subjects who
had biopsy-proven GN in their native kidney, was intermediate (9/159; 5.8%)
in those with presumed GN not confirmed by biopsy, and was least frequent
(4/1133; 3.6%) among those who had chronic kidney disease due to other
causes. Independent predictors of PTGN were male gender, non-Caucasian,
younger age, presence of prior GN (p<0.05 in Cox regression model). The most
common histological forms of PTGN were IgA nephropathy which occurred in
61 subjects (3.0%) and FSGS which developed in 53 subjects (2.6%). while all
other forms occurred in < 1% of subjects The cumulative probability of PTGN
increased over time reaching 15.7% (Kaplan-Meier Estimate) by 15 years
post-transplant, and was almost three-fold higher in patients with prior GN
than in patients whose original disease was due to other causes (KM estimates:
24.3% vs 10.5%, p=0.001). The incidence of PTGN was significantly greater
in patients transplanted during the period1996-2005 compared with those
transplanted prior to this date (p=0.02). The probability of graft survival at
15 years was significantly reduced in patients with PTGN (10.2% vs. 69.7%;
0.00001).
Conclusion: The cumulative frequency of PTGH has not declined with new
immunosuppressive agents. PTGN occurs in 15.7% of patients by 15 years
post-transplant and IgA and FSGS are the most frequent forms. PTGN is most
common in patients with GN in their native kidney, and is an important cause
of accelerated graft failure.

POSTER BOARD NUMBER P1 – 319
122 SERUEM FROM RENAL TRANSPLANT RECIPIENTS
IMPROVES MARKERS OF IN VITRO ENDOTHELIAL CELL
ACTIVATION COMPARED TO DIALYSIS RECIPIENTS, BUT
NOT TO BASELINE LEVELS.
S. Sen1,2, W.Y. Sun3, T. Coates1,2, S. McDonald1,2, C. Bonder3
1Transplant Immunology Laboratory, Department of Nephrology And
Transplantation Services, The Queen Elizabeth Hospital (TQEH). Woodville
South, Australia, 2Department of Medicine, University of Adelaide, Adelaide,
Australia, 3Institute for Medical and Veterinary Science (IMVS). Adelaide,
Australia
Introduction: Cardiovascular disease (CVD) is over-represented as a cause
of death in patients on renal replacement therapy (RRT). with transplantation
reducing but not reversing this risk. The endothelium plays a crucial role in CVD
in chronic kidney disease (CKD). with both atherosclerosis and arteriosclerosis
occurring at increased rates. Risk factors, including tumour necrosis factor
(TNF) alpha, CRP, and uraemic agents such as p-cresol are predictive of CVD
risk in CKD patients. Other markers of endothelial activation and inflammation
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119 METABOLIC SYNDROME AND RISK OF RENAL GRAFT
LOSS IN THE ALERT TRIAL.

cardiovascular disease and malignancies in patients with high comorbidity, and
infection in low score group (p = 0.031). Comorbidity also was related to graft
outcome in the adjusted model. Rejection and high comorbidity score were the
main risk factors for graft failure during the first month postransplantation (HR
2.17, 95% CI 1.07-4.40, p = 0.031; HR 2.29, 95% CI 1.04-5.06, p = 0.039,
respectively). However, the CCI is the strongest predictor of graft survival after
first month, even when we censored for death with functioning graft (HR 2.24,
95% CI 1.12-4.48, p = 0.02).
Conclusions: Our results suggest that: 1) High pre-transplant comorbidity is
one of the main risk factor for renal graft failure and patients mortality. 2) The
CCI is a great tool for the prediction of outcome in kidney transplantation. 3) A
best control of comorbid condition might be one of the most important aims to
improve the results in kidney transplantation.
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have also been found to be increased in dialysis patients, including ICAM-1,
VCAM-1 and MCP-1. VCAM-1 expression can also be increased on cultured
human umbilical vein endothelial cells (HUVECs) after exposure to serum
from haemodialysis patients, but increased apoptosis has not been described.
We hypothesised that renal transplantation reverses the effect of uremic toxins
on vascular endothelium, and investigated this potential effect using an in vitro
culture system.
Methods: Cultured HUVECs were exposed to serum from stable transplant
patients on calcineurin inhibitor treatment (n=10). haemodialysis recipients
(n=10) and healthy control subjects (n=9). Patient demographics were collected,
as well as baseline biochemistry and haematology. A cytokine immunoflow bead
kit (Bender MedSystems) was used to measure circulating levels of TNF alpha,
V-CAM, I-CAM and other markers of endothelial activation and inflammation
in serum samples. Serum from subjects was added to normal HUVEC culture
conditions at 20% concentration for a minimum of 4 and a half hours, with
0.5ng/ml TNF alpha added after 30 minutes to maximise stimulation. Cells
were then prepared for either flow cytometry for VCAM-1 expression, or lysate
preparation for Western Blotting. The latter were later analysed for markers of
cellular senescence, including Akt phosphorylation and ERK.
Results: Renal transplant recipients’ serum induced significantly lower
V-CAM-1 expression on HUVECs compared to haemodialysis patients’
serum (MFI 77.6 versus MFI 88.8, p<0.05). Western blot analysis for Akt
phosphorylation and ERK showed reduced intracellular protein in HUVECS
exposed to renal transplant patient serum compared to haemodialysis patient
serum. These differences could not be explained by baseline serum levels of
circulating inflammatory mediators including TNF between renal transplant
serum and haemodialysis patients serum, and importantly did not return to
levels achieved by normal control serum.
Conclusions: Renal transplantation partially reverses the effect of uraemic
serum on endothelial markers of vascular damage. The causal factors remain
to be elucidated. This in vitro assay may be used as a tool to investigate the
nature of proinflammatory markers of endothelial damage as well as evaluate
the effect of alternative treatment regimes/interventions on markers of vascular
damage.

POSTER BOARD NUMBER P1 – 320
123 DOES CHANGE IN URINARY NEUTROPHIL
GELATINASE-ASSOCIATED LIPOCALIN (NGAL) PREDICT
ALLOGRAFT FUNCTION?
P. Roy-Chaudhury, I.A. Meyer, R.R. Alloway, M. Meyer, E.S. Woodle, A.
Jane, M. Bennett,
P. Devarajan, C.V. Thakar,
University of Cincinnati.
Introduction: Ischemia reperfusion injury (IRI) influences short-term and
long-term allograft function; creatinine is not tissue specific and does not
represent the magnitude of cellular injury. Parikh et al reported that absolute
levels of urinary NGAL at 24 hours were predictive of delayed graft function
(DGF). We examined whether NGAL, followed over time during the first seven
days post-transplant can predict on-going ischemic injury.
Methods: Prospective collection of serum and urine specimens was performed
post-transplant at 4hrs, 6hrs, 24hrs and daily from day 2 to day 7. Patients
were divided into 2 groups based on renal function, delayed graft function
(DGF) or immediate graft function (IGF). DGF was defined as the need for
dialysis at 7 days. All other patients were considered to have IGF. Urinary
NGAL levels were analyzed by ELISA, standardized for urine creatinine
levels, and expressed as ng/mg of creatinine. NGAL levels at POD1 and POD2
minus POD1 were expressed as mean and median, and compared by t-tests for
univariate comparison.
Results: Twenty consecutive kidney transplant recipients (85% male, 70%
Caucasian, 35% deceased donors) were evaluated. ESRD origin included
hypertension (n=8). diabetes mellitus (n=3). PCKD (n=3). IgA Nephropathy
(n=3). FSGS (n=1). and glomerulonephritis (n=1). with 1 unknown. Three
(15%) experienced DFG. All patients with IGF had NGAL values of < 1,000
ng/mg at POD1. The mean value of urine NGAL measured on POD1 in the
DGF group was 64,224ng/mg as compared to 668.3 ng/mg in the IGF group.
(median IGF =343ng/mg versus 13,059ng/mg for median DGF). The mean
difference between POD2 and POD1 NGAL levels for IGF patients was –
366ng/mg versus 319,744ng/mg in DGF patients. Log NGAL levels at POD1
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and POD2 minus POD1 were significantly different between the two groups
(P <0.05). All patients in DGF group had an increase in NGAL between POD1
and POD2; 14/17 (82%) IGF patients showed a decline in NGAL levels at
POD2.
Conclusions: This study confirms that patients without DGF usually have urine
NGAL levels of ≤1000ng/mg. Additionally, an increase in NGAL, an indicator
of ongoing IRI, is observed in all patients with DGF. In contrast, the majority
of patients who show a decline in NGAL go on to improve their renal function
over time. Temporal changes in NGAL (a tissue specific marker of IRI) may
be a useful addition to the predictive accuracy of a panel of biomarkers for the
early diagnosis of delayed graft function.

MINI-ORAL SESSION 4:
IMMUNOBIOLOGY 1: COMPATIBILITY
POSTER BOARD NUMBER P1 – 321
124 ADMINISTRATION OF DONOR ALLOANTIGEN VIA THE
RESPIRATORY TRACT GENERATES CD11C+ REGULATORY
CELLS AND INDUCES HYPORESPONSIVENESS TO FULLY
ALLOGENEIC CARDIAC GRAFTS
N. Shirasugi1, Q. Zhang1, D. Iwami1, O. Aramaki2 and M. Niimi1
Surgery, 1Teikyo University and 2Nihon University, Tokyo, Japan.
Backgrounds: Soluble proteins delivered through mucosal surfaces
(the respiratory tract and the gastrointestinal tract) can induce peripheral
unresponsiveness, which has been termed mucosal tolerance. We have
previously reported that administration of donor alloantigen via the recipients’
respiratory tract induced hyporesponsiveness to fully mismatched cardiac
allografts in mice and generated regulatory cells. Here we show in this model
that the regulatory cells, which were induced by administration of donor
alloantigen via the recipients’ respiratory tract, contain CD11c+ population
secreting higher amount of IL-10.
Methods: CBA mice (H-2k) were given 1x107 C57BL/10 (B10, H-2b)
splenocytes via the trachea (pretreatment). Seven days later, the CBA mice
underwent transplantation of B10 hearts. In adoptive transfer studies, CBA
mice (primary mice) received the pretreatment and 7 days later, CD4+ cells or
CD11c+ cells were purified from the spleen of the primary mice and the CD4+
cells (2x107) or the CD11c+ cells (1x106) were adoptively transferred into the
naive CBA mice (secondary recipients). which were given transplantation of
B10 hearts immediately afterwards. Cytokine profile of the CD11c+ cells was
also examined.
Results: Untreated CBA recipients rejected B10 allografts acutely (median
survival time (MST). 8 days). The pretreatment induced prolongation of B10
allograft survival in CBA recipients (MST, 85 days). Secondary CBA recipients
given not only whole but also CD4+ splenocytes from the primary mice had
significantly prolonged survival of B10 allografts (MST, 89 and 68 days,
respectively, compared to those in control recipients with adoptive transfer
of naive whole or CD4+ splenocytes, MST, 9.5 and 12 days, respectively).
Surprisingly, adoptive transfer of CD11c+ cells, which were purified from the
pretreated primary CBA mice, also induced prolonged B10 allograft survival
in naive secondary recipients, (MST, 75 days, compared to those in control
recipients with adoptive transfer of naive CD11c+ cells, MST, 9 days). When
restimulated in vitro with LPS, the CD11c+ cells purified from the pretreated
primary CBA mice demonstrated up-regulation of interleukin (IL) -10 and
down-regulation of IL-12, whereas naïve CD11c+ cells produced higher
amount of IL-12 and only small amount of IL-10. Fourteen days after the
adoptive transfer of the CD11c+ cells purified from the pretreated primary
CBA mice into naïve secondary recipients with B10 cardiac allografting, CD4+
splenocytes were purified from the secondary recipients and were adoptively
transferred into naive CBA recipients (third recipients). The third recipients
underwent B10 cardiac grafting immediately afterwards. The third CBA
recipients enjoyed remarkable prolongation of cardiac allografts (MST, >90
days, compared to that in CBA recipients with adoptive transfer of naive CD4+
cells, 12 days).
Conclusion: These data suggest that; 1) administration of donor alloantigen via
the recipients’ respiratory tract induced CD11c+ regulatory cells (presumably
regulatory dendritic cells (DC) ). as well as CD4+ regulatory cells, 2) regulatory
DC produced higher amount of IL-10, and 3) regulatory DC induced CD4+
regulatory cells in vivo.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Monday 11 August 2008

Oral Abstracts
POSTER BOARD NUMBER P1 – 322
125 EFFECT OF B-CELL DEPLETIONAL THERAPIES ON
ALLOIMMUNE HUMORAL RESPONSES IN A MURINE MODEL

MONDAY

B. Book Indiana University
There is growing interest in B-cell-directed therapy in transplantation, yet
there are limited data on its immunologic impact. We report the effect of two
distinct B-cell depletion regimens on allo-antibody (Ab) responses using
a murine model. B-cell depletion was accomplished with a BR3-Fc fusion
protein (soluble BAFF antagonist), and anti-BR3 (dual function BAFF agonist
and cell depleter). C57BL/6 mice received BR3-Fc or anti-BR3. Initial flow
cytometric (FCM) analysis documented B-cell depletion and recovery. Cohorts
received one dose intraperitoneal (IP) anti-BR3 (200?g/mouse). BR3-Fc (200
?g) was given IP twice weekly for 6 weeks (wk). To examine the impact of
B-cell depletion, immunization was performed at 7 days (D) after the dose
of anti-BR3 and 14 D after the first dose of BR3-Fc. Cohorts of mice (n=3)
were immunized IP with BALB/c splenocytes (2x107 cells) and boosted 1
month later. Controls included no anti-B-cell therapy (positive control, PC) and
autologous sera for negative control. Serum samples were obtained weekly for
6 weeks. Two-fold dilutions of sera were incubated with cells and secondary
anti-IgG- or –IgM-FITC. Binding was detected by FCM. The sum of the
mean fluorescence channel was calculated after subtracting autologous serum
control. Statistical analyses used Kruskal-Wallis one-way analysis of variance
and Dunn’s Method of pairwise comparison. B220 expression in peripheral B
cells was determined at baseline, 1,2,4,6,8,10 and 12 wks post therapy by FCM.
Statistical analyses utilized Student s t-test (p<0.05 was significant). Anti-BR3
led to rapid B-cell depletion from 42% to 6% at one week with recovery to
35% at 12 weeks(wks). BR3-Fc required 4 wks for B-cell depletion from 43%
to 8% and continued to be low at wk 12 (7%). Both agents suppressed the allo
Ab response. IgG, but not IgM Allo-Ab was suppressed significantly with antiBR3 and despite recovery of peripheral B cells a booster response was delayed
and the level reduced. There was a slight effect on antibody with BR3-Fc. This
difference could be due to small sample size, the level of B-cell depletion at
time of immunization, or a qualitative difference in residual B cells. From a
clinical perspective, the more rapid and complete inhibition with anti-BR3
makes it a more favorable agent to move into clinical trials.

Conclusions: This assay may be used together with clinical isoagglutinins and
a functional assay currently under development in our laboratory to detect B
cell specificity as well as B cell activation in response to A and B antigens.
Together, these tools will help to identify candidates for ABO incompatible
transplantation by providing information for a more complete and accurate risk
assessment.

Figure: Percent of CD19+ B cells specific for blood group A and B antigens,
as detected by flow cytometry using PBMCs and A/B antigen-coated
fluorescent beads

POSTER BOARD NUMBER P1 – 323
126 IDENTIFYING CANDIDATES FOR ABO-INCOMPATIBLE
TRANSPLANTATION: A NOVEL METHOD TO DETECT B
CELLS SPECIFIC FOR ABO BLOOD GROUP ANTIGENS
L. West3, S. Gelowitz1, L. Guembes Hidalgo2,
1
University of Alberta – Medical Microbiology and Immunology, 2University
of Alberta – Department of Medicine, Alberta Transplant Applied Genomics
Centre, 3University of Alberta – Departments of Pediatrics, Surgery, and
Immunology
Intro: Infant candidates for ABO-incompatible transplants are currently
identified by the absence of circulating anti-A and anti-B antibodies. While
antibody titre is generally a good predictor of whether a patient can safely
receive an ABO incompatible transplant, it cannot distinguish between
endogenous anti-A/-B antibodies and those passively acquired through
administration of blood products. Recipients of ABO-incompatible grafts
during infancy maintain a persistent donor-specific deficiency in anti-A and/
or anti-B-antibodies. However, it is unclear whether these children may be
retransplanted with additional ABO-incompatible grafts since donor A/Bspecific B cells, if present, may lead to hyperacute rejection if another ABOincompatible graft is given during immune maturity.
Methods: A flow cytometry-based conjugate assay was designed to detect and
quantify A/B antigen-specific B cells in human splenocyte/PBMC populations.
BSA conjugated to A or B antigen was immobilized onto fluorescent beads to
screen the blood group-specificity of CD19+ B cells. B cell enrichment and
panning onto BSA-coated plates was used to decrease Background:
Results: Initial results show that cognate interaction between B cells and A/B
antigen-coated beads resulted in antigen-specific labeling of CD19+ cells using
PBMCs from A, B, or O donors (Figure). Although only a small percent of
peripheral B cells recognize A/B antigen-coated beads, this is consistently much
higher than background levels and is expected due to a diverse B cell repertoire.

POSTER BOARD NUMBER P1 – 324
127 SINGLE-TUBE CROSSMATCH ASSAY FOR
SIMULTANEOUS DETECTION OF ANTIBODIES REACTIVE
WITH DONOR ENDOTHELIAL CELLS AND LYMPHOCYTES.
J. Holgersson1, S.M. Johansson2, D. Hauzenberger2, P. Grufman3,
M. Alheim2
1
Karolinska Institutet, 2Karolinska University Hospital, Huddinge, 3AbSorber AB
Conventional flow cytometric crossmatch testing using donor T and/or B
lymphocytes, is adequate to detect HLA class I- and II-specific antibodies.
Despite negative lymphocyte crossmatches (LXM). approximately 15%
of kidney transplants undergo early rejections some of which are due to the
presence of non-HLA specific antibodies reactive against donor endothelial
cells (EC). A flow cytometric endothelial cell crossmatch (ECXM) test (XMONE®; AbSorber AB, Stockholm) for detection of antibodies reactive against
donor EC was recently developed. This assay is based on the isolation of
EC from donor peripheral blood using magnetic beads carrying antibodies
specific for the angiopoietin receptor, Tie-2. Apart from EC, a large number
of lymphocytes are also present within the isolated Tie-2+ fraction. This latter
finding encouraged us to evaluate whether XM-ONE® could be used as a
single-tube crossmatch assay for simultaneous detection of antibodies reactive
with donor endothelial cells and lymphocytes. Comparison of the T-/B-ECXM
and the conventional T/B-LXM were performed using sera from hitherto 28
patients undergoing evaluation for living-donor kidney transplantation. We
demonstrate a highly significant correlation between the two assays with regard
to the T-cells, which was lower with regard to the B-cells. Importantly, a second
follow-up study using sera from patients with known levels of panel reactive
antibodies (PRA) and donor cells confirmed the initial results. In conclusion,
both donor lymphocyte- and EC-reactive antibodies can be detected using this
novel single-tube crossmatch assay.
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128 CHANGES IN DONOR SPECIFIC AND THIRD PARTY
HLA ANTIBODY LEVELS AFTER ANTIBODY INCOMPATIBLE
TRANSPLANTATION; PRODUCTION, ABSORPTION AND
DONOR-SPECIFIC MODULATION.
R. Higgins1, D. Briggs2, D. Lowe2, M. Hathaway2, R. Hamer1, N. Krishnan1,
D. Zehnder3
1
University Hospital, 2Histocompatibility Laboratory, UK Blood and
Transplant, 3Warwick Medical School
Background: After HLA antibody incompatible transplantation, it is recognised
that donor specific and third party HLA antibodies may be found in the blood,
and that there is a donor-specific fall in these levels during the first 40 days.
However, the changes in antibody levels have not previously been described
in detail.
Methods: HLA antibody level, both donor-specific (DSA) and third party,
were measured using the microbead method in 44 presensitised patients who
had renal transplantation.
Results: Compared to 3rd party HLA antibodies, DSA fell in the first 4
days after transplantation, in a pattern compatible with absorption of
antibody onto the graft. Falls in DSA were detectable for Class I and DR
during the operation (p<0.01). and over days 2-4, Class 1 had 57.8% fall
compared with 20.2% for 3rd party (p<0.001); HLA DR fell 63.0% vs
24.3% (p<0.001) and DP/DQ/DRB fell 34% vs 17.5% (p=0.014). Peak
DSA levels occurred at a mean of 13 days post-transplant, and this peak
was higher than pre-treatment levels in 25 (57%) patients, and lower in
19 (43%). in some patients with sustained and profound falls developing
soon after the transplant. The incidence of rejection was higher in those
who had the greatest change in DSA posttransplant, both rises and falls
(p<0.01). DSA levels subsequently fell in all patients in a donor specific
manner (p<0.0001). and the magnitude of the fall was greater in those who
had an early rejection episode (67.1% fall in DSA after rejection vs 33.5%
fall after no rejection, p<0.03).
Conclusion: These data show the patterns of rise and fall of DSA posttransplant in antibody incompatible transplantation and provide a framework
for rational investigation of the pathogenicity of DSA, and also the production
and elimination of DSA.

POSTER BOARD NUMBER P1 – 326
129 DONOR SPECIFIC LYSATE LUMINEX®
CROSSMATCHING: COMPARISON WITH LUMINEX®
CHARACTERISED HLA ANTIBODIES.
E. Tsiopelas1, S. Deayton1, A. Fleet1, G. Bennett1, P. Bardy1, P. Coughlan1,
G. Russ1,2,3, P. Coates1,2,3
1
National Transplantation Services, Australian Red Cross Blood Service,
2
Department of Nephrology and Transplantation Services, The Queen
Elizabeth Hospital, 3Department of Medicine, University of Adelaide
Introduction: The optimal means of detection of Donor Specific Antibodies
(DSA) for renal transplant has not been determined. Lysate crossmatching is a
novel technique wherein donor Class I and Class II glycoproteins are captured
on fluorescent microspheres. We compared this new method with standard
Complement Dependent Cytotoxicity (CDC) and Luminex® HLA antibody
(Ab) identification.
Methods: Donor lymphocytes isolated from peripheral blood or spleen are
used as the source material for HLA glycoproteins. The kit used will not
identify incompatibilities due to anti DQ or DP allo antibodies. Whole blood or
spleen cell suspensions are layered on a lymphocyte density separation media
washed and counted. The packed cells are completely lysed using kit lysis
buffer. After centrifugation to sediment the cell membranes, the supernatant
(lymphocyte lysate) is transferred into a clean tube. Lysates were tested using
Tepnel LifeCodes DSA kit to detect IgG antibodies to donor–specific Class I
and Class II HLA. The DSA Luminex® Beads ($1950 AUD/96 test) are mixed
with the donor lysate and capture the solubilised HLA, making a donor-specific
HLA target for Ab’s in the serum sample. After capture of donor HLA, coated
beads are incubated with patient serum and subsequently anti-human IgG
phycoerythrin (PE) is added to the beads and analysed on Luminex machine.
Selected patient sera were also tested for the presence of HLA antibodies by
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Tepnel Lifecodes Class I and Class II Identification (ID) kits. These kits are
composed of different Luminex® Beads to which affinity purified Class I and
Class II glycoproteins are conjugated. Where DSA could not be determined
by Id kits, due to high Panel Reactive Antibodies (PRA%). Tepnel LifeCodes
Single Antigen Bead (SAB) assay ($2500AUD/24 Tests) was used to determine
the presence of DSA.
Results: Four patient groups were studied comprising patients 1) undergoing
desensitisation protocol (n=8). 2) with grafts from live donors (n=18). 3)
with grafts from deceased organ donors and early rejection episodes (n=8)
and 4) with grafts from deceased organ donors and no rejection episodes
(n=13). Sera of all groups were tested by Luminex®bead assay for the
detection of HLA antibodies. There was complete concordance between
antibodies detected with Luminex® SAB and with Donor Lysate cross
match in all groups studied. Both Luminex®SAB and Donor Lysate assay
consistently detected DSA in CDC crossmatch negative patients. Sample
lysate preparation time was comparable to CDC preparation time. Frozen
donor lysates were stable and allowed crossmatching to be performed
retrospectively in living donors without the inconvenience of requiring
fresh samples.
Conclusion: Tepnel LifeCodes DSA assay: i) is more sensitive than the
current CDC crossmatch ii) is a cost effective method in detecting DSA
compared to performing Single Antigen bead. iii) has a strong correlation
between positive DSA crossmatch and the presence of low titre DSA. iv)
is useful in monitoring patients undergoing desensitisation protocols by
evaluating decreases in DSA crossmatch values over time v) allows the
crossmatch to be performed at any time since multiple vials of donor lysate
can be stored frozen for up to two years.

POSTER BOARD NUMBER P1 – 327
130 SUCCESSFUL INDUCTION OF MIXED CHIMERISM AND
TOLERANCE WITH NON-MYELOABLATIVE CONDITIONING
IN MICE PRE-SENSITIZED WITH FULLY MHC MISMATCHED
SKIN GRAFTS
V. Levesque, P. Bardwell, F. Haspot, M. Sykes
Transplantation Biology Research Center
A growing number of patients do not qualify for organ transplantation
because they have been pre-sensitized to donor MHC via previous transplants,
pregnancy, and blood transfusions. These patients have extended wait list times
and inferior graft outcomes. The ability to induce donor-specific tolerance in
pre-sensitized recipients would represent a major clinical advance, broadening
the pool of eligible transplant recipients. While lethal irradiation has been
shown to allow engraftment of high doses of allogeneic bone marrow in presensitized mice, such regimens would be neither appropriate nor effective
in the clinical setting. We used pre-sensitized B-cell deficient μMT B6 mice
lacking antibody to assess the ability of non-myeloablative bone marrow
transplantation (BMT) regimens to tolerize pre-sensitized T cells. 12 weeks
after skin grafting μMT B6 (H-2b) mice with fully MHC-disparate B10.A
(H-2a) tail skin, we administered anti OX40L, anti-CD40L, anti-CD4, antiCD8, and anti-NK1.1 monoclonal antibodies along with sublethal 3Gy total
body irradiation (TBI) and high dose BMT. Mixed chimerism and donorspecific skin graft tolerance were achieved in these mice. Pre-sensitized WT
B6 mice receiving the same regimen 40wks after skin grafting also achieved
mixed chimerism and accepted donor skin grafts. We further refined this
regimen to include only Day -5 CD4 and CD8 T-cell depleting monoclonal
antibodies and Day 0 anti-CD40L along with 3Gy TBI and high dose BMT.
Using this non-myeloablative “minimal regimen” we were able to establish
multilineage mixed chimerism in 8 of 8 pre-sensitized μMT B6 mice, and
donor-specific skin graft tolerance in 5 of 7 chimeras, while third party skin
grafts were rejected at a median of 12 days. Our results indicate that T-cell
tolerance can be established in pre-sensitized hosts without the use of lethal
irradiation. In future experiments we will use the minimal regimen to establish
mixed chimerism and tolerance in pre-sensitized WT B6 mice after allowing
alloantibody to clear.
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131 HEPATIC ARTERY THROMBOSIS AFTER ADULT LIVING
DONOR LIVER TRANSPLANTATION: RISK FACTORS AND
MANAGEMENT FOR SUCCESSFUL OUTCOMES

POSTER BOARD NUMBER P1 – 329
132 GRAFT LOSS AFTER ORTHOTOPIC LIVER
TRANSPLANTATION DUE TO THROMBOSIS AFTER
EMERGENCY USE OF RECOMBINANT FACTOR VIIA
F.A. Helfritz1, S. Ciesek2, M. Neipp1, C.P. Strassburg2, R. Lueck1,
J. Klempnauer1, T. Becker1
1
General-, Visceral- and Transplantation Surgery, Hannover Medical School,
2
Gastroenterology, Hepatology and Endocrinology, Hannover Medical School
Background: The genetically engineered recombinant activated factor
VII (FVIIa) was primarily developed for treatment of bleeding episodes in
hemophilia patients with inhibitors. Several studies have shown efficacy and
safety. Furthermore the use in patients with liver disease and consequently
with complex coagulopathies was examined in different studies for both
prophylaxis and therapy of bleeding complications as well as in orthotopic
liver transplantation (OLT).
Case reports: Between 2002 and 2004 amongst others 5 patients with bleeding
complications after OLT were treated with FVIIa as a rescue therapy. All of
them suffered from graft loss due to thrombotic complications and needed
mandatory retransplantation (Re-OLT).
Pat. I was treated with 240 kIU on the first postop. day. Just some hours later a
thrombosis of the arteria hepatica was diagnosed through ultrasound.
Pat. II was treated several times with a total of 3360 kIU between the 2. and the 5.
postop. day due to persistent diffuse bleeding. Multiple thromboses in the inferior
cava vein as well as in several intrahepatic vessels were diagnosed afterwards.
The patient died due to multi organ failure a few days after Re-OLT.
Pat. III was treated with 480 kIU on postop. day 1. On day 3 thrombosis of the
portal vein as well as hepatic artery was diagnosed leading to mandatory Re-OLT.
Pat. IV was treated with a total of 720 kIU on the first postop. day. Due to a
thrombosis of the hepatic artery also this patient needed Re-OLT.
Pat. V was treated with a total of 1440 kIU on the day of transplantation.
Bleeding was stopped, but due to a thrombosis of the hepatic artery a Re-OLT
was necessary. The patient died after Re-OLT with multi organ failure.
Discussion: Treatment with FVIIa is established in patients with hemophilia
and inhibitors. The action of FVIIa, in contrast to other procoagulatory agents,
limited to the site of vessel-lesions due to its dependency to initial existence

POSTER BOARD NUMBER P1 – 330
133 ANATOMICAL VARIATIONS OF THE ORIGIN OF
SEGMENT 4 HEPATIC ARTERY AND THEIR CLINICAL
IMPLICATIONS
B.H. Cho, H.C. Yu, G.Y. Jin, J.H Lee
Chonbuk National University Medical School
Ischemic complications in remaining part of left liver following massive
resection such as living donor right hepatectomy or right hepatectomy with
caudate lobectomy for the type 3a hilar cholangiocarcinoma has been haunting
surgeons for many years. Postmortem dissection of 62 livers was performed
to investigate anatomical variation of the principal artery for segment 4 (A4).
The origin of A4 was examined separately in the liver with (n=46) or without
(n=16) aberrant left hepatic artery (abLHA). In the liver, A4 was found to be
extra- or intra- hepatic branches of the right, left or proper hepatic arteries,
categorized into four different types according to their origin. The right hepatic
artery (RHA) type, originated from the right or right anterior hepatic artery
(RAHA). was the most common pattern in our series. The A4 roots still had
a strong tendency of stemming from the RHA (n=12) even in the livers with
abLHA (n=16). Among the RHA type, the A4 arising from RAHA (n=2) is
supposed to be the most dangerous form of a variant, which can possibly cause
ischemic change in the remaining part of the liver. In the era of living donor liver
transplantation (LDLT) using right lobe of the liver, paying particular attention
to the point of origin of A4 is prerequisite especially when the lateral section
is relatively small. Arterial injuries to A4 during split liver transplantation
may also cause an increased risk of hepatic artery thrombosis and ischemic
cholangiopathy.
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134 AN ARTIFICIAL BILE DUCT MADE OF
BIOABSORBABLE POLYMER CAN SERVE AS A SUBSTITUTE
FOR NARROWED PORTIONS OF THE EXTRAHEPATIC BILE
DUCT
M. Miyazawa, M. Aikawa, Y. Toshimitsu, K. Okada, K. Okamoto, I. Koyama
Saitama Medical University International Medical Center
Extrahepatic bile duct stenosis due to inflammation or cancer is now treated
by removal of the affected area. As of this writing, however, no grafts for
replacement of the excised tissue are available. Our group investigated whether
an artificial bile duct made of bioabsorbable polymer could serve as a substitute
for narrowed portions of the bile duct.
Materials and Methods): The experiments were performed using hybrid
pigs (n=11). After laparotomy under general anesthesia, the extrahepatic bile
duct was identified and ligated around the confluence with the cystic duct. A
week later, the animals were re-laparotomized by the same method and the
bile duct on the hepatic side of the ligature was resected. The cut end was
connected to the duodenum using a bioabsorbable artificial bile duct fabricated
from a copolymer of polycaprolactone and polylactic acid reinforced with
polyglycolic acid fibers. The materials selected for the graft normally degrade
inside the body within 6 to 8 weeks of implantation. There was no prior cell
seeding on the artificial duct. The grafts were recovered for gross, histological,
and blood chemical studies at 4 months after the surgery.
Results: All recipient pigs survived until sacrifice for collection of the implants.
A week of ligation of the extrahepatic bile duct dilated the duct to about 1 cm
in diameter and increased T-bil to 1.9 }0.7 mg/dL. T-bil had returned to the
pre-implantation level in all but 4 animals at post-implantation. Examinations
of the grafts revealed complete freedom of stricture and the regeneration of a
neo-bile duct of about 1 cm in diameter from the graft site in 10 of 11 animals.
Gross observation of the graft from the 1 remaining animal revealed stricture at
the anastomosis site and poor bile duct epithelization.
Conclusion: We have concluded that this bioabsorbable polymer bile can serve
as a replacement for narrowed portions of the bile duct.
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D. Mulligan, A. Moss, S. Reddy, K. Mekeel, T. Byrne, E. Carey, M.E.
Harrison, H. Vargas, D. Douglas, J. Rakela
Mayo Clinic Arizona
The risk of hepatic artery thrombosis (HAT) in adult live donor liver transplants
(LDLT) is estimated between 3.8 and 5.6% in most series, but as high as 30.8%
in others, and remains a major source of graft loss after LDLT. This is a single
center analysis of the risk factors that contribute to the development of HAT,
as well as the management that may contribute to graft salvage. Since 2001,
78 LDLTs have been completed at our institution. 14 patients (19%) developed
HAT after transplant, however only 6 patients (8%) had eventual graft loss
and the remaining grafts were successfully salvaged. In 13 patients the HAT
developed between 0 and 6 days after transplant (mean 4.5) and in one patient
it developed late on POD#41. A logistic regression of risk factors found that
cold ischemic time and graft to recipient body weight ratio were significant
risk factors contributing to the development of HAT (Table 1). Aggressive
intervention in 7 of the 14 patients (50%) resulted in graft salvage, which
included thrombectomy, revision and systemic anti-coagulation, including
intra-arterial TPA in three patients. The single patient with late thrombosis has
good graft function and is being treated with coumadin. 6 patients (8%) had graft
failure, and 5 were re-transplanted. One patient died prior to retransplantation,
and one patient died after retransplantation. In summary, a low GBWR appears
to be a risk factor for the development of HAT, but if it does occur aggressive
post operative management with thromectomy and thrombolytic therapy when
indicated can decrease the risk of graft loss and need for retransplantation.

of tissue factor (TF). As an adverse side effect a strong exprimation of TF
can lead to thrombembolic incidents. So far only rare cases of thrombembolic
related diseases are described. But above mentioned cases implicate a potential
increase of the risk of thromboses after OLT through application of FVIIa. Thus
the treatment with FVIIa in this collective of patients – in our opinion – should
be critically discussed and only conducted as an ultima ratio.
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135 INTRAOPERATIVE PORTAL VEIN STENTING FOR
PORTAL VEIN STENOSIS IN LIVING DONOR LIVER
TRANSPLANATION
C-S. Ahn, S-G. Lee, S. Hwang, K. Kim, D-B. Moon, H-Y. Ha, G-W. Song,
D-H. Jung, J-H. Ryu
Asan Medical Center
In cirrhotic liver, portal thrombosis or stricture, which preclude portal flow
and make collateral veins, are not uncommon due to the portal hypertension.
But maintaining the adequate portal flow is essential for initial graft function
and its regeneration after living donor liver transplantation (LDLT). Usually
thrombectomy or venoplasty is applied to improve portal flow and easy
anastomosis, but it may be insufficient if the luminal narrowing is located at
more proximal portion. In that case, we placed portal vein stents intraoperatively
to keep the portal vein wide.
After the explantation of diseased liver, we examined the portal stump, if the
lumen was narrowed we have performed thrombectomy or venoplasty. Direct
portogram was taken through inferior mesenteric vein just after the anstomosis
and reperfusion of the graft and intraportal stents was inserted. We applied
balloon dilatation when the lumen was not fully expanded after stenting. Some
of collaterals of portal vein were also embolized during portogram, to prevent
portal flow steal.
From Jan.2004 to Nov.2006, 615 adult to adult living donor liver
transplantations were performed in Asan Medical Center. In 114 cases
(18.5%). portal vein thrombosis or stricture were detected. We did direct
portograms in 20 cases (3.2%). The patients were 14 men and 6 women.
The underlined disease were hepatitis B associated cirrhosis in 14, alcoholic
cirrhosis in 3, others in 3, and 8 of them had hepatomas. In three cases, we
did only portogram without stenting, and we inserted 20 stents (metallic
stent diameter 1cm, length 4-8cm) in 17 cases. Balloon venoplasty was
applied in 6 cases, which showed severe narrowing after stent insertion. Coil
embolization of coronary vein was performed in one case. The median follow
up period was 20 months (1-34 months). and all patients has good portal flow
until now except one case who expired at postoperative10 month due to the
intracranial hemorrhage.
In conclusion, in the case of severe portal vein stenosis, intraoperative stent
insertion can be a simple but good solution to get sufficient portal flow to the
transplanted graft and long term good results.

POSTER BOARD NUMBER P1 – 333
136 THE CLINICAL OUTCOME OF THE CORONARY
ARTERY BYPASS GRAFT SURGERY INTERVENED BY
ISCHEMIC PRECONDITIONING: A SYSTEMATIC REVIEW
Y.P. Li, Z.P. Zhen, Y.C. Huang, N. Zhao, L. Feng, Y.S. Li, L.L. Pang, L.L. Li,
C.T. Zhang, S.F. Li,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
Coronary artery disease (CAD) is the major cardiovascular disease and
predominant cause of death for the middle-older aged. WHO forecast ischemic
heart diseases will become the first cause of death in 2030 according to the
current trend in 2007. The coronary artery bypass graft (CABG) surgery is
an effective treatment for CAD, but with adverse effects of ischemia and
reperfusion injury (I/RI) on myocardium. Both clinical trials and animal
experiments have confirmed that ischemic preconditioning (IP) can reduce I/
RI to myocardium and increase myocardial tolerance to subsequent long-term
ischemic insult. However, so far, the IP is still not be popularized into clinical
practice. The present systematic review first summarized the effects of IP
intervention protocols on clinical outcome of CABG surgery.
Materials and Methods: An electronic search of Medline, Embase and
Cochrane Library from 1966 to 2007 was performed. Two reviewers excluded,
included and assessed RCTs independently. The evaluation criteria for
methodology were followed the cochrane systematic review handbook (version
4.2.5). We used the postoperation mortality as the primary outcome and serous
indicators as well as postoperative care parameters as the secondary outcomes
to assess clinical outcomes of IP intervention.
Results: Fourteen RCTs including 14 comparisons (501 patients aged
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from 40 to 70) with 6 B and 8 C quality met inclusion criteria, which had
3 double-blind studies and five sorts of IP protocols. No death happened
during the follow-up period of those trials. The ATP intervened groups by 2*
(3minI+2minR) protocol in the end of 10 minutes cross-clamping (p=0.005).
the mechanical ventilation (p=0.002). free of inotropic agents (p=0.0007)
and duration of using inotropic agents (p=0.04) were statistically significant
different from control group. No marked difference of ICU time (p=0.88).
using another 2* (2minI+3minR) protocol (275 patients) was confirmed.
Serous CTnT/I and CKMB only show descending trends, and cannot be
quantified by meta-analysis.
Conclusion: The systematic review confirmed IP could protect myocardium,
restore ATP in myocardium, reduce mechanical ventilation, and administrate
no or less inotropic agents for CABG patients, but not decrease the time
in ICU.
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137 PRESERVATION OF RECIPIENT’S MIDDLE HEPATIC
VEIN (MHV) IS USEFUL FOR RECONSTRUCTING
MHV TRIBUTARIES IN LIVING DONOR RIGHT LIVER
TRANSPLANTATION
H. Tashiro, H. Ohdan, T. Itamoto, H. Amano, A. Oshita, K. Ide, T. Asahara
Department of Surgery
Background: A right liver graft lacking the middle hepatic vein can cause
congestion of the anterior segment in living donor liver transplantation. Various
solutions designed to overcome this problem have been reported, including a
right liver graft with the reconstruction of the middle hepatic vein tributaries
using various interposition vein grafts. We did not use the extended right hemiliver graft including the MHV trunk because of the negative impact on donor
safety.
Method: Since Jan 2005, we have usually performed the reconstruction of
MHV tributaries of the liver grafts using the recipient’s own MHV trunks
when there are significant MHV tributaries (> 5mm in diameter) during
the donor hepatectomy The recipient hepatectomy was completed with
preservation of middle hepatic vein tributaries. In the right-liver living
donor transplantation, the middle hepatic vein tributaries draining segments
V (V5) and VIII (V8) of a right lobe graft were reconstructed with the
recipient’s own middle hepatic vein. When the recipient’s middle hepatic
vein is too short for reconstruction of the V5, the recipient’s right or left
hepatic vein which was harvested ex vivo from recipient liver was used as
an interposition graft between the V5 of the liver graft and the recipient’s
middle hepatic vein. The preservation of the MHV trunk was excluded
when hepatocellur carcinomas (HCC) was located on the ventral side of
the MHV or was not at least 1 cm away from the MHV trunk in patients
with HCC.
Results: These techniques were used in 16 branches of V8 and 15 branches
of V5 among 21 patients. The 3-month patency rate of the V8 and V5
reconstructed were 92% and 76%, respectively. All liver transplant patients
that underwent these operations are alive. On the other hand, in 15 patients
that did not undergo preservation of MHV trunk because of HCC, the 1- and
3- year survival rates were 75% and 75%, respectively. The patients without
reconstructed MHV tributaries had a significant increase in ALT on day 14
(344 } 243 versus 152 } 114 IU/L, p=0.029). The patients in whom the MHV
tributaries in the right liver graft were reconstructed using the recipient fs
native MHV trunk showed excellent results of low portal vein pressure (PVP)
(13 }4 mmHg) after reperfusion, compared with the PVP (18 }6 mmHg) of
those without reconstructing the MHV tributaries in right liver grafts. Except
the ruptured HCC case, there was no recurrence of HCC among 14 patients
with HCC that was reconstructed MHV tributaries, with mean follow-up of
17 } 7 months.
Conclusions: The use of the recipient fs own middle hepatic vein is a suitable
option for reconstructing middle hepatic vein tributaries (V8 and V5) in rightliver living donor transplantation.
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140 GLYCINE PROTECTS LIVERS FROM REPERFUSION
INJURY DUE TO PNEUMOPERITONEUM FOR
LAPAROSCOPIC LIVING DONOR HEPATECTOMY: AN IN
VIVO MICROSCOPY STUDY

D. Ysebaert, G. Roeyen, P. Abrams, K. De Greef, S. Francque, P. Michielsen,
P. Jorens, T. Chapelle
Antwerp University Hospital
Patients with neuroendocrine tumors (NET) of the pancreas often present with
liver metastases, so diffuse that they are no longer suitable for hepatic resection,
even not in a staged way. Extensive liver/pancreatic resection combined with
simultaneous liver transplantation has been considered a treatment option, however
results are very poor (5-year patient survival = 47%, 5-year disease free survival =
24%). due to incomplete tumor resection (Lehnert, Transplantation 1998).
Therefore, we adopted a two-stage treatment modality for NET’s with diffuse
unresectable liver metastases, consisting of 1) aggressive radical resection
of primary tumor site (outside liver). 2) a waiting period of > 6 months for
ruling out extrahepatic disease and observation of natural behaviour of the
tumour, 3) thereafter orthotopic liver- (pancreas) -transplantation to resect all
liver metastases, and to treat pancreatic insufficiencies. Risks of surgery and
immunosuppressive therapy after transplantation must of course be balanced
against natural course of the disease.
Since 2002 n=7 patients were enrolled in this protocol, meanwhile we hade to
exclude n=3 patients with evidence of tumor recurrence during waiting time,
n=1 is in his waiting time. Three patients (mean age 41,3 y) were transplanted:
2 MEN-1 patients after 95% pancreatectomy for malignant insulinoma
and glucagonoma and cluster liver-pancreastransplantation, 1 patient with
malignant somatostatinoma after extensive distal splenopancreatectomy and
solitary liver transplantation.
Although long-term follow-up is necessary for definite conclusions, mid-term
follow-up (mean: 55,3 (36-70) months) is excellent: no recurrence so far in
those patients with survival > 5 years.
Although excellent but only mid-term results are achieved, these promising
approach should be reserved for young patients (< 50y) who have a chance to
be cured by this agressive approach and who can endure extensive surgery.

A. Nickkholgh1, M. Al-Saeedi1, C. Flechtenmacher2, H. Bruns1, M. Zorn3,
R. Liang1, M.W. Büchler1, C.N. Gutt1, P. Schemmer1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Dept. of
Pathology, Ruprecht-Karls University of Heidelberg, 3Central Laboratory,
Ruprecht-Karls University of Heidelberg
Background: Laparoscopic organ retrieval has been successfully performed
for human living donor liver transplantation (LDLT). Experimental
pneumoperitoneum induces ischemia/reperfusion injury (IRI) in liver most
likely via activation of Kupffer cells. Glycine has been shown to ameliorate
reperfusion injury in various animal models. Thus, this study was performed to
assess its effects on liver after pneumoperitoneum.
Materials and Methods: Sprague-Dawley rats (200-230 g) underwent CO2
pneumoperitoneum (12 mmHg) for 90 minutes. Some rats received i.v. glycine
(1.5 ml, 300 mM) 10 min before pneumoperitoneum. Controls were given
the same volume of Ringer’s solution. Subsequently, transaminases, hepatic
microcirculation, and latex beads phagocytosis to index both liver injury and
Kupffer cell activation were investigated. Analysis of variance (ANOVA)
followed by t test or ÷2 (or Fisher’s exact) test were performed as appropriate.
Results are presented as mean ± SEM.
Results: Glycine significantly decreased AST, ALT, and LDH after
pneumoperitoneum from 145 ± 19 U/L, 53 ± 5 U/L, and 500 ± 58 U/L in
controls to 94 ± 4 U/L, 40 ± 2 U/L, and 334 ± 27 U/L, respectively (p<0.05). In
parallel, glycine significantly blunted the permanent adherence of leukocytes
to the endothelium by up to 35% of controls (p<0.05) while the rate of
phagocytosis decreased by more than 50% (p<0.05).
Conclusion: Glycine decreased IRI after CO2 pneumoperitoneum most likely
via inactivation of Kupffer cells and an improved hepatic microperfusion.
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139 LIVER TRANSPLANTATION FOR ACUTE LIVER
FAILURE
S. Sevmis1, H. Karakayali1, F. Ozcay2, A. Torgay2, U. Yilmaz3, N. Savas3,
B. Demirhan4, B. Bilezikci4, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery,
2Baskent University Faculty of Medicine, Department of Anesthesiology,
3Baskent University Faculty of Medicine, Department of Gastroenterology,
4Baskent University Faculty of Medicine, Department of Pathology
The only proven therapy for patients who are unlikely to recover from
acute liver failure (ALF) is liver transplantation. Therefore, recognition and
urgent referral to a transplant center is extremely important. In this study, we
evaluated 23 ALF patients who had undergone liver transplantation (LT) at a
single center during a 5-year period. The reasons for transplantation for the
23 ALF patients were 5 hepatitis A; 6 non-A, non-E hepatitis; 2 autoimmune
hepatitis; 6 fulminant Wilson’s disease; and 1 Amanita phalloides (mushrooms)
poisoning, 1 cytomegalovirus virus infection, 1 hepatitis B, and 1 due to both
hepatitis B and toxic hepatitis (with leflunomide). Ten were female and 13 male
and the mean age was 12 &#61617; 8 years (range, 16 months to 30 years). Six
received right liver lobe grafts, 2 received whole liver grafts, and the remainder
left or left lateral lobe grafts. All of the patients recovered from hepatic coma
the day after transplantation except five. Overall 5 patients died at the 2nd,
8th, 12th, 45th, and 81st postoperative days due to three brain death, adult
respiratory distress syndrome, and sepsis with multiorgan failure, respectively.
Eighteen patients (78.3%) are healthy at a range of 2 to 69months’ follow-up.
Worldwide experience with living-donor LT for ALF is limited but when it is
required, living-donor LT is the only option for ALF in the countries with low
organ donation rates. In such conditions, preparation of the donor in a limited
time is a major problem. At our center, we have been able to decrease this time
interval to approximately 3 hours including the liver biopsy of the donor.
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141 MYOCARDIAL PERFUSION SCINTIGRAPHY-A
SENSITIVE TOOL FOR CARDIAC EVALUATION
IN ASYMPTOMATIC DIABETICS FOR PANCREAS
TRANSPLANTATION
S. Mehra1, A. Tavakoli1, N. Parrott1, P. Arumugam2, T. Augustine1
1
Department of Pancreas and Renal Transplantation, Manchester Royal
Infirmary, 2Department of Nuclear medicine, Manchester Royal Infirmary
Aim: The aim of this study is to evaluate our method of evaluation for
significant silent coronary disease prior to listing for pancreas transplantation,
its sensitivity and implications.
Methods: All patients referred for pancreas transplantation to our institution
undergo a stress myocardial perfusion (myoview) scan, which if positive,
triggers referral to cardiology for further evaluation, prior to transplant listing.
Patients are counselled that coronary evaluation could uncover significant silent
disease requiring invasive coronary management before transplant listing.
Summary: Between January 2001 and October 2007, 238 patients were
referred for pancreas transplantation. Complete evaluation data were available
in 201 asymptomatic patients who underwent detailed coronary evaluation .9
patients underwent pre-referral coronary angiography (normal). 15 patients
didn’t undergo myoview scan (2 adolescents, 3 short onset of diabetes, 4
dobutamine stress echo,6 others). 177 patients underwent myoview scans of
which 116 (65.5%) were normal and were activated. 61 (31.4%) patients had
positive myoview scans which were graded as mild to moderate reversible
ischemia (31) or significant reversible ischemia 30 (17%) and referred to
cardiology for further evaluation. 12 of the mild to moderate group were
considered insignificant and activated without angiograms. 16 of this group
underwent angiogrm and 4 required intervention for significant lesions upon
full cardiology evaluation, awaited (3). In the significant group 30 patients
have undergone angiography with PTCA/Stent (8). CABG (3). Normal (6).
Moderate not requiring intervention (6). Diffuse cardiac disease with no
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138 TWO-STAGE TREATMENT OF LIVER
METASTASIZED NEUROENDOCRINE TUMORS OF THE
PANCREAS, INCLUDING CLUSTER LIVER-PANCREAS
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possible intervention (2) Awaited (5). 108 transplants have been done in this
period with 2 perioperative coronary deaths with a normal angiogram.
Conclusions: Significant silent coronary disease is present in about 20% of
pancreas transplant referrals. Stress myocardial perfusion scanning is a sensitive
non-invasive method of identifying patients requiring intervention without the
need for coronary angiography in all patients. The mild to moderate positive
group requires a more critical cardiology evaluation prior to listing. With this
approach there is very low incidence of perioprtative coronary events.
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142 SUCCESSFUL SIMULTANEOUS PANCREAS AND KIDNEY
TRANSPLANTATION FROM ABO-INCOMPATIBLE LIVING
DONORS.
T. Kenmochi1, T. Asano2, K. Saigo1, M. Maruyama1, N. Akutsu1, C. Iwashita1,
K. Otsuki1, T. Ito1
1Department of Surgery, Chiba-East National Hospital, 2Department of
Surgery, Teikyo University Hospital
Objectives: As an option for the treatment of type 1 diabetic patients with endstage renal disease (ESRD) because of a limited use of brain dead donors in our
country, we have introduced simultaneous pancreas and kidney transplantation
from ABO-incompatible living donors.
Patients and Methods: Recipients were 31-year-old female (Case 1). 30-yearold female (Case 2). and 30-year-old male (Case 3). All patients were type 1
diabetes with ESRD. Their serum C-peptide levels (CPR) were ƒ0.03ng/ml
and hypoglycemic shocks were frequently occurred. Serum creatinine level
was 7.55 mg/dl in Case 1 and Cases 2 and 3 had 2 year and 3 year history
of hemodialysis. Donors were mothers (58,55,60-year-old). Although ABO
blood types were incompatible (A ¨O in Cases 1 and 3, AB ¨B in Case 2).
they fulfilled our donor criteria for living pancreas and kidney transplantation.
Pretransplant treatment for the recipients to decrease an anti-A antibody
titer was achieved by splenectomy, double filtrated plasmapheresis, and
plasma exchange according to our protocol for ABO-incompatible kidney
transplantation. Segmental pancreatic graft was transplanted into the right iliac
fossa using bladder drainage technique and the kidney graft into the left iliac
fossa. Quadruple therapy by tacrolimus, MMF, predonisone, and basiliximab
was used for immunosuppression.
Results: All donors showed no complication including pancreatic fistula,
diabetes, and renal dysfunction. In all recipients, the pancreas and kidney
grafts functioned immediately after transplantation, resulting in a rapid
decrease of serum creatinine levels and insulin independency. All recipients
showed positive serum CPR (2-5ng/ml). and decreased HbA1C (8.5 to 4.5%
in Case 1, 7.5 to 5.5% in Case 2, and 9.0 to 5.9% in Case 3 at two months).
No hypoglycemic episode was experienced after transplantation. IgM and IgG
titers of anti-A antibody did not elevate more than 8 folds during two months.
An antibody-mediated humoral rejection as well as an acute cellular rejection
was not observed in both cases. Normal blood glucose curve as well as normal
insulin secretion was obtained from 75g-oral glucose tolerance test performed
at 4 months in all cases. Although surgical complications were not observed,
cytomegalovirus antigenemia was positive in case 2 and 3.
Conclusions: Our clinical data clearly demonstrated that ABO-incompatible
pancreatic transplantation is possible using the protocol for ABO-incompatible
kidney transplantation. Simultaneous pancreas and kidney transplantation
from ABO-incompatible living donor may become an effective tool for type 1
diabetic patients with ESRD especially in our country.

50

POSTER BOARD NUMBER P1 – 340
143 40 CASES OF DUODENO- DUODENOSTOMY IN
PANCREAS- TRANSPLANTATION: SINGLE CENTER PROOF
OF A SAFE AND SIMPLE TECHNIQUE
R. Viebahn1, P. Schenker1, P. Petersen2, N. Ertas1, A. Wunsch1, M. Schaeffer1,
H. Klein3
1
Knappschaftskrankenhaus/Ruhr- University, 2University of Tuebingen,
3
Klinikum Bergmannsheil/Ruhr University
Kombined pancreas- kidney transplantation (NPTX) is a life- saving procedure
in patients with type I diabetes who suffer from end stage kidney disease and
improves quality of life significantly in a small subgroup of diabetics who require
pancreas transplantation alone (PTA). Different technical procedures have been
develloped successfully to perform pancreas transplantation with special respect
to exocrine drainage: Bladder drainage by duodenocystostomy (DC). enteral
drainage by side- to side duodenojejunostomy (DJ) or duodenojejunostomy
via Roux en Y technique (DJR). Recently first experiences were reported about
direct anastomosis between the duodenal segment of the pancreas transplant
and the duodenum of the recipient (DD).
Since all enteral drainage procedures are associated with the so called „tail
down“ position of the pancreas transplant the donor duodenum frequently
touches the recipients duodenum so that a DD seems to be a promising
technique.
Material and Methods: Between 4/1998 and 3/2008 145 NPTX were performed
under the responsibility of the presenting author in two different institutions. Due
to the fact that no standards were given for the mode of exocrine drainage, DD was
performed eventually between 1998 and 2005 when topography of the transplant
allowed it. After 10/2005 all NPTX were performed in the Boggi- technique
were the transplant portal vein is anastomosed to the mesenteric vein so that both
duodena touch each other. In all these cases DD was performed so that a total
of 40 cases was operated using DD. In the other cases 103 DJ and 2 DC were
performed. From the DJ cases a control group was generated wich mathed by age,
CIT, donor age, duration of diabetes and the prevalence of coagulation disorders.
Results: Patient survival was 100% in the DD group and 97% in the DJ
group, pancreas graft survival was 95% (DD) vs 90% (DJ) after 1 year. No
DD insufficiency was reported in the DD group, 2 patients in the DJ group had
to be switched to DJR due to insufficiency. Both recipients were the pancreas
had to be removed after early graft thrombosis in the DD group experienced
uncomplicated closure of the duodenal opening wereas one of 4 patients in the DJ
group required relaparotomy due to insufficiency of the jejunal closure. The need
of oral sodiumbicarbonate substitution was slightly lower in the DJ group.
Conclusion: Duodenoduodenostomy is a safe an easy form of exocrine drainage
in pancreas transplantation. It is equivalent to other well established techniques
and extends the possibility of anastomotic sites especially in recipients who
have a second transplant or had prior surgery wich does not allow other enteral
anastomoses.
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144 SIMULTANEOUS KIDNEY PANCREAS
TRANSPLANTATION USING RAPID STEROID TAPER WITH
PROTOCOL BIOPSIES: COMPARISON OF R-ATG VERSUS
ALEMTUZUMAB
R. Heilman, K.S. Reddy, A. Moss, M. Mazur, K. Mekeel, H. Chakkera,
D. Post, D. Mulligan
Mayo Clinic Arizona
Body: In Jan 2005, we expanded the use of rapid steroid taper protocol with
rabbit antithymocyte globulin (r-ATG) induction to patients (pts) receiving
simultaneous kidney pancreas transplantation (SKPT). In Jan 2007, we started
using induction with Alemtuzumab (Alem) and report our experience in this
group of pts compared to a retrospective cohort of pts receiving r-ATG.
Of the 64 SKPTs performed at our center between Jan 2005 to Nov 2007,
53 pts received immunosuppression with rapid steroid taper (11 pts received
positive crossmatch Txs with long-term steroid use). 33 pts received induction
with r-ATG (1.5 mg/kg x 4 for a total dose of 6mg/kg) while 20 pts received
induction with Alem (30 mg single dose). Maintainance immunosuppression
consisted Tacrolimus and MMF. Steroids were discontinued after post op day
4. Protocol biopsies were performed at 1 month, 4 months 12 months and every
year thereafter.
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The mean age of the pts is similar between the groups (r-ATG 45 13 yrs, Alem
44 16 yrs). All were primary Txs except one pt in the Alem group who received
a previous kidney Tx. Four pts became insulin dependent (r-ATG group: 2
vascular thrombosis, 1 noncompliance; Alem group: 1 glucose intolerance) and
2 pts lost the kidney graft (both in the r-ATG group: 1 CAN 1 noncompliance).
Other Tx characteristics, acute rejection, CMV infection, BK nephropathy,
graft and patient survival in the 2 groups are shown in the
r-ATG (n=33)
97%
36%
12%
6%
21%
6%
100%
94%
91%
22

p value
NS
NS
NS
NS
NS (0.23)
NS
NS
NS
NS
0.0001

Conclusion: In non sensitized pts, SKPT using rapid steroid taper and
induction with either r-ATG or Alem is safe and effective. Both induction
agents are associated with excellent short term outcomes and the incidence of
acute rejection, CMV and BK nephropathy are similar between the two groups.
Alem is easier to administer and is less expensive. Further long-term follow-up
is needed to confirm these excellent results.
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145 COMBINED PANCREAS AND EN-BLOC KIDNEY
TRANSPLANTATION FROM VERY SMALL PEDIATRIC
DONORS
J. Sageshima, G. Ciancio, L. Chen, H. Illanes, R. Garcia, G.W. Burke
University of Miami, Surgery, Kidney/Pancreas Transplant
Objective: Very small pediatric donors are underutilized in pancreas
transplantation (Tx) for fear of inadequate islet cell mass and increased risk of
technical complications. The aim of this study is to determine the lower age and
size limit for pancreas donors.
Methods: We retrospectively reviewed 11 type 1 diabetic uremic patients who
received a pediatric pancreas and en-bloc kidney Tx with Thymoglobulin plus
daclizumab induction and triple maintenance immunosuppression (tacrolimus,
steroids, and mycophenolate or sirolimus).
Results: All donors were 7 years old or younger and weighed 30 kg or less; of
those, 8 donors were 4 years or younger and weighed 16 kg or less. The youngest
donor was 17 months and the smallest donor weighed 11 kg. All recipients were
adults weighing more than 60 kg (Table). Postoperative anticoagulation was
used to prevent thrombotic complications. No patient required either dialysis or
long-term insulin therapy after Tx. With median follow-up of 27 months (range:
8 mo – 7 years). patient, pancreas and kidney graft survival were 100%. Current
mean serum creatinine is 1.3 mg/dL and HbA1c is 5.4%. No acute rejection
episode was observed; polyoma virus-associated nephropathy was seen in one
patient 32 months after Tx (current creatinine: 3.6 mg/dL). One patient who
received organs from a 13 kg donor lost the left kidney 10 days after Tx due to
renal artery thrombosis while retaining the function of the right kidney (current
creatinine: 1.6 mg/dL). Another patient ruptured the right kidney due to renal
vein stenosis, which required mesh repair. Four recipients developed splenic
vein thrombosis, which was successfully treated with intravenous heparin
infusion. Mixed-meal challenge tests performed > 12 months after Tx (n=2)
demonstrated normal glucose tolerance and C-peptide response.
Table
Donor Age: 3.0 (1.4 – 7) years
Donor Body Weight: 15 (11 – 30) kg
Kidney Weight (Lt + Rt): 90 (47 – 157) g
Recipient Age 45: (39 – 56) years
Recipient Body Weight: 70 (60 – 85) kg
Donor/Recipient Weight Ratio: 0.22 (0.15 – 0.40)
Cold Ischemia Time (Pancreas/Kidney): 23 (16 – 28) /24 (14 – 30) hours
Warm Ischemia Time (Pancreas/Kidney): 50 (37 – 69) /66 (50 – 106) minutes

Conclusion: Our observation suggests that combined pancreas and en-bloc
kidney Tx from very small pediatric donors demonstrates excellent outcome.
Although technical complication rates might be slightly higher than with adult
donor pancreas Tx, organs from very small donors seem to have the capacity
to meet the metabolic demand of adult recipients. Donors aged as young as 2
years and weighing as little as 15 kg should be considered for pancreas Tx.

146 EFFICACY AND SAFETY OF OCTREOTIDE
PROPHYLAXIS FOR PREVENTING TECHNICAL
COMPLICATIONS AFTER PANCREAS TRANSPLANTATION£ºA
META-ANALYSIS OF RCTS
Y.P. Li, L.L. Li, Y.S. Li, D. Long, L.L. Pang, N. Zhao, L. Feng, S.F. Li,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
Technical complications related to the exocrine are major causes leading
to graft loss after pancreas transplantation. Octreotide has been widely
used in the management of minimizing these complications. However,
the role of prophylactic octreotide remains controversial. The objective of
this review was to determine evidence for the effectiveness and security of
prophylactic octreotide for preventing technical complications after pancreas
transplantation.
Methods: We searched the Cochrane library (2008, Issue 1). PUBMED
(1970 to Feb 2008) and EMBASE (1974 to Feb 2008) and selected six studies
concerning prophylactic octreotide for preventing technical complications after
pancreas transplantation. Of these, three RCTs (enrolling a total of 82 patients)
were identified. Meta-analysis analyzed the data. Types of outcome measures
included pancreatitis, fistula, thrombosis, rejection, hemorrhage, infection,
pancreas and pancreas survival.
Results: Octreotide group had lower levels of serum amylase and amylase in
the applied period, though the difference reached statistical significance only
for serum amylase in the first postoperative day. The incidences of technical
complications had no significant difference between octreotide group and
control group. The value of OR for pancreatitis was 0.41 (95% CI 0.06 to 2.94).
1.13 (95% CI 0.06 to22.10) for fistula, (OR 2.06, 95% CI 0.32 to 13.13 ) for
thrombosis, 0.96 (95% CI 0.35 to 2.61) for rejection, 0.67 (95% CI 0.12 to
3.67) for hemorrhage, 0.71 (95% CI 0.06 to 8.19) for infection and 0.65 (95%
CI 0.15 to2.86) for pancreas survival. The differences between the two groups
in patient survival at 6 and 12 months were not statistically significant.And
there was not any significant effect of octreotide on CsA or FK506 absorption.
Conclusions: Currently available evidences from RCTs do not support
prophylactic octreotide for preventing pancreatitis, fistula, thrombosis,
rejection after pancreas transplantation. And there is unavailability on pancreas
and pancreas survival. Until more research is completed, the effectiveness
of prophylactic octreotide following pancreas transplantation cannot be
determined because studies published to date are flawed by biases. Large,
appropriately designed RCTs are needed.
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147 OUTCOMES OF SOLITARY PANCREAS TRANSPLANTS
RELATED TO INDUCTION THERAPY AND TRANSPLANT
TYPE
J. Odorico, S. Hanish, Y. Becker, H. Sollinger
University of Wisconsin Hospital And Clinic
We sought to review our experience of solitary pancreas transplants over the
last decade and evaluate outcomes with different induction strategies.
A single institution, retrospective review of 133 consecutive solitary pancreas
transplants from 1997 to December, 2006, was performed. The analysis
included 48 pancreas after kidneys (PAK). 24 pancreas after simultaneous
kidney pancreas transplant (PASPK). and 61 pancreas transplants alone (PTA).
Patients received either daclizumab or basiliximab (anti-Il2R) or alemtuzumab
(ALEM). End points evaluated were time to initial biopsy proven rejection,
patient and graft survival, death censored graft survival, and opportunistic
infections. Outcomes were compared among different induction groups for the
entire cohort and then for each transplant type. Analysis was performed using a
Kaplan-Meier Cox proportional hazards model.
For the entire cohort, patient survival was significantly worse at two years
in the ALEM group vs. anti-IL2R (88% vs. 100%, p=0.02). The Alem group
also trended toward more opportunistic infections whereas the anti-IL2R
group trended toward less graft loss. Time to initial rejection rates were not
significantly different among the groups. ALEM trended toward less rejection
at 2 years. Death censored graft loss was significantly better in anti-IL2R
vs. ALEM (18% vs. 33% at 2 years, p=0.01). Subgroup analysis revealed
that in PAK, ALEM had a 100% incidence of opportunistic infections within
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the first year whereas the incidence in anti-il2R was only 15%, (p<0.02).
Further, PAKs in the ALEM group experienced significantly higher two year
recipient mortality vs. anti-IL2R (20% vs. 4%, p=0.006). whereas there was
no advantage to ALEM with regard to rejection rates in PAK patients. In
contrast, there was a trend toward improved rejection rates in ALEM treated
PTA patients compared to other induction agents, whereas patient mortality
and graft survival rates were similar between the induction groups. In general,
lower opportunistic infection rates were seen in PTA patients compared to
PAK patients.
Analysis of solitary pancreas transplants treated with different induction
strategies reveal that anti-IL2R monoclonal antibodies or alemtuzumab
are associated with acceptable graft and patient survival. The higher risk of
opportunistic infections and poor patient outcomes in PAK recipients receiving
alemtuzumab calls into question its use in this setting.
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148 FORTY SEVEN CONSECUTIVE PANCREAS
TRANSPLANTS WITHOUT STEROIDS; A SUCCESSFUL
ALTERNATIVE
A. Asderakis, A. Ilham, C. Puliati, R. Chavez
Transplant Unit, University Hospital of Wales, UK
Background: The widely known adverse effects of long-term therapy with
steroids have motivated interest in steroid-free immunosuppression. It is
especially attractive in pancreas recipients because it avoids the increased
insulin resistance, lipid problems, and eye complications caused by steroids.
This should be counterbalanced with the increased risk and detrimental effect
of a rejection occuring in Pancreas Transplantation.
Methods: We evaluated the outcome of a steroid-free immunosuppressive
protocol in pancreas transplant recipients. Between December 2004 and
March 2008, a total of 47 pancreas transplant recipients received steroid-free
immunosuppression, consisting of induction with thymoglobulin (1.25 mg/kg
for five days). and maintenance on tacrolimus adjusted to a target trough level
between 5-10 ng/l for the first month (and 4-8 subsequently) and Mycophenolate
Mofetil up to 2g daily (median dose 1g).
Results: 32 patients received simultaneous pancreas and kidney transplant
(SPK) and 15 pancreas after kidney transplant (PAK). Median recipient age
was 38 years, median donor age was 40 and mean HLA mismatch was 4.2.
Patient and pancreas survival rates were 95.7% and 84%, respectively. Pancreas
censored for death survival was 87%.
Among the SPK there were 3 grade IA and IB biopsy proven rejections as
well as 2 biopsy proven borderline rejections, which were treated giving an
overall rejection rate of 15.6% (including borderline). Two of those patients
presented with severe rejection 3 months post-transplant. The first one due to
severe gastroparesis and malabsorption lost both the kidney and the pancreas
despite aggressive treatment. The second one had steroid resistant rejection and
was successfully rescued with ATG, repeated steroid pulses and Rituximab.
Only this patient requires long term maintenance steroids following her
treatment. There were also two presumed pancreas only rejection in the PAK
group, diagnosed on the basis of elevated amylase, CRP and absence of clinical
symptoms of pancreatitis, that were treated successfully. None of them required
long-term steroids.
Reasons for patient loss included one death from aspiration pneumonia, and
one early cardiovascular death.
All other patients who have been treated for rejection have been off steroids
for the duration of follow-up. Patients with functioning pancreata have a mean
HB1Ac of 5% and normal insulin and peptide C levels.
Conclusion: Excellent graft survival with a low incidence of acute rejection
can be achieved using a fully steroid-free immunosuppressive regimen using
appropriate induction treatment.
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149 ASYMMETRIC DIMETHYLARGININE (ADMA)
CONCENTRATIONS ARE ELEVATED IN RENAL TRANSPLANT
RECIPIENTS
M. Klinger, R. Krawczyk, W. Weyde, M. Krajewska, K. Madziarska
Department of Nephrology And Transplantation Medicine, Medical University
Cardiovascular morbidity and mortality remain high after renal transplantation.
ADMA is a strong endogenous inhibitor of nitric oxide synthase, and by
reducing nitric oxide availability it may trigger pro-atherogenic effects. The
aim of the study was to evaluate ADMA levels in two groups of renal transplant
recipients (RT pts): 1) 18 RT pts between 6 and 24 months post-transplantation
(median GFR, aMDRD formula: 66.4 ml/min) and 2) 24 RT pts over 60
months post-transplantation (median GFR: 68.6 ml/min). All RT pts received
an immunosuppressive regimen with calcineurin inhibitors. The control group
encompassed 37 healthy volunteers. The tested groups were matched with
respect to age and gender. ADMA concentrations were measured by the HPLC
method. The plasma ADMA levels (mean ± SD in μmol/l) in the study groups
were 0.84 ± 0.36 in the healthy controls, 1.09 ± 0.52 in the RT pts 6-24 months
post-transplantation (p=0.06 versus controls). and 1.23 ± 0.71 in RT pts >60
months post-transplantation (p<0.05 versus controls).
Conclusions: Plasma ADMA concentrations rise during the post-transplantation
period, reaching significantly higher values than in healthy controls five years
after transplantation.
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150 LONG TERM RESULTS AFTER SIMULTANEOUS
PANCREAS-KIDNEY TRANSPLANTATION USING DONORS
AGED 45 YEARS OR OLDER
P. Schenker, O. Vonend, A. Wunsch, M. Schaeffer, R. Viebahn
Ruhr-University-Bochum
Background: With the shortage of organ donors there is a critical need to use
all available pancreas grafts for transplantation.
Methods: From 06/1994 – 12/2006 we performed 340 pancreas transplantations
(317 SPK, 5 PTA, 18 PAK) including 69 (20%) transplantations from donors
aged 45 years (y) or older. Pancreas grafts from older donors (OD) > 45y
were analyzed for graft and patient survival as well as surgical complications,
compared to results from younger donors (YD) < 45y.
Results: Overall patient, kidney- and pancreas graft survival were 89%, 78%
and 70%, with a mean follow up of 79 month. Recipient characteristics were
comparable in both groups. In the OD group mean donor age was 47.8y (±2,1)
vs. 27.9 y (±10.3) in YD group. Cumulative patient survival was (OD vs. YD)
96% vs. 98% after 1y, 82% vs. 91% after 5y and 82% vs. 88% after 10y. 1-,5and 10-year kidney survival were 82%, 72%, 57% in OD and 93%, 83%, 73%
in YD. Pancreas transplant survival were after 1-,5- and 10-y 69%, 60%, 45%
in OD and 88%, 76% and 72% in YD. There were 14 (20%) cases of venous
thrombosis in the OD group and 25 (9%) in the YD group (p= 0.012).
Conclusions: The results demonstrate that utilization of pancreas grafts from
donors > 45 years results in acceptable outcomes after SPKT and could expand
the organ donor pool. In the OD group patient survival is slightly lower than
in the YD group, whereas pancreas graft function is significantly inferior
(p<0,01). Since venous thrombosis is the main reason for pancreas graft loss in
OD group, anticoagulation is essential.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Monday 11 August 2008

Oral Abstracts
MINI-ORAL SESSION 7:
ORGAN PROCUREMENT AND PRESERVATION
POSTER BOARD NUMBER P1 – 348
151 HTK: WHY DOES IT APPEAR TO CAUSE DELAYED
GRAFT FUNCTION FOLLOWING PROLONGED COLD
ISCHAEMIA?

Results: Fig.1: Change in Energy Charge
24 hours.

Fig.2: Change in Uridine Levels over
24 hours.

Energy Charge is reflective of what is happening in ATP, ADP and AMP levels
and is calculated from the equation:
Energy Charge = (ATP + 0.5*ADP) / (ATP + ADP + AMP)
The high energy charge seen with HTK plateau after 5 minutes, by 60 minutes
it begins to drop, following the same trend as other samples. The plateau is due
to the excess glucose being available, but after 1 hour this is beginning to be
used up.
The low level of Uridine, needed for glycogen production, found in HTK,
means that at reperfusion there will be none available for glycogen synthesis;
whilst the higher concentrations found in LS and UW may be advantageous to
these livers following reperfusion.
Glycogen is found to have disappeared from hepatocytes which were preserved
in HTK after only 5 minutes, whilst it was still visible in hepatocytes perfused
in UW after 2 hours and in those perfused in LS glycogen was still present
after 24 hours.
Conclusion: HTK contains α – Ketaglutarate, which allows the TCA cycle
to continue, even in anaerobic conditions, so using up the lactate produced
by glycolysis. This means that more glucose is required for glycolysis to
occur; therefore glycogen is broken down in the liver into glucose. This can
be seen by the initial high energy charge, due to glycolysis occurring and
the rapid breakdown and depletion of glycogen from hepatocytes. Once the
glycogen has been broken down and all the glucose used up, glycolysis can
no longer occur, so the TCA cycle also has to halt and hence the decline in
energy charges.
Overall HTK does well for the first 2 hours but then any advantage seen
initially starts to disappear. A liver perfused in HTK and transplanted after 120
minutes would react like one from a person starved for a period, as it has no
energy charge, glycogen store or ability to synthesis glycogen due to lack of
Uracil. Whereas LS and UW show higher levels of uracil and do not lose their
glycogen content to the same extent.
These results go someway towards answering the question of why HTK causes
delayed graft function after longer periods of cold ischaemia.

152 N-ACETYLCYSTEINE BEFORE CEREBRAL
ANGIOGRAPHY INLUENCES GRAFT FUNCTION AFTER
KIDNEY TRANSPLANTATION FROM DECEASED DONORS
B. Grandtnerova1, J. Miklusica2, L. Laca2, M. Fani2, M. Adamik2, E. Kurca3,
K. Machalekova4, H. Polacek5
1
Transplant Centre, Faculty Hospital Martin, 2Clinic of Vascular and
Transplant Surgery, Faculty Hospital Martin, 3Clinic of Neurology, Faculty
Hospital Martin, 4Institut of Pathological Anatomy, Faculty Hospital Martin,
5
Clinic of Radiodiagnostics, Faculty Hospital Martin
N-acetylcysteine (NAC) is a potent antioxidant that scavenges a wide variety
of oxygen-derived free radicals. It may prevent contrast agent-induced
nephrotoxicity as well as decrease reperfusion damage in experimental
transplantation.
Objective: to evaluate influence of NAC administration before cerebral
angiography (AG) in brain death donors on subsequent kidney graft function.
Patients and Methods: Organ donors were sorted into 3 groups: group A (n=19)
– cerebral AG without NAC, group B (n=37) – 600 mg of NAC administrated
IV immediately before AG, group C (n=24) – clinical determination of brain
death only. Mean age was 44 ± 2.9 vs 40.7 ± 2.5 vs 41.8 ± 3 years (p = ns).
best GFR (Cocroft – Gault formula) 2.0 ± 0.18 vs 2.27 ± 0.11 vs 1.67 ± 0.11
ml/s (B vs C p < 0,01). S-Na before harvesting 147 ± 3 vs 143 ± 1 vs 144 ±
2 mmol/l (p = ns). Kidney recipients were sorted into 3 groups corresponding
with their donors. Mean age was 44.5 ± 2.8 vs 49 ± 1.6 vs 47.8 ± 2.3 years (p=
ns). cold ischemia time 883 ± 56 vs 768 ± 63 vs 703 ± 69 min (p = ns). median
compatibility index 9.5 vs 13 vs 12 (p = ns). In zero biopsies, the extent of
glomerular sclerosis, tubular atrophy and interstitial fibrosis was comparable
between all groups; the extent of mild arteriolar hyalinosis was slightly higher
in group B. Neither the numbers of delayed graft function nor rejection episodes
were significantly different.
Results: After transplantation, we found significant differences in 24-hour
creatinine clearance corrected for body surface area between 3 groups of
recipients. At day 7: CrCl was 0.49 ± 0.08 vs 0.87 ± 0.08 vs 0.94 ± 0.1 ml/s
(p < 0,01); at the 1st month: 0.72 ± 0.05 vs 0.93 ± 0.07 vs 1.14 ± 0.1 ml/s (p
< 0,01); at the 3rd month: 0.75 ± 0.07 vs 0.97 ± 0.05 vs 1.19 ± 0.07 ml/s (p <
0,001) and at one year (group A and B available only): 0.84 ± 0.09 vs 1.26 ±
0.13 (p < 0.05).
Conclusions: Our results suggest that kidney graft function up to one year
after Tx was significantly better if brain death donors were pre-treated with
NAC before cerebral angiography. However, kidney graft function from donors
pre-treated with NAC was still slightly worse that from donors with clinical
determination of brain death only.
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153 RECOVERY OF WARM ISCHEMICALLY DAMAGED
KIDNEYS USING THE AIRDRIVE PERFUSION SYSTEM
M.C. Schreinemachers1, B.M. Doorschodt1, M.M. Idu1, R.H. Tolba2,
T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands,
2University Clinic of Aachen, Aachen, Germany
Introduction: The gold standard for preservation of warm ischemically damaged
kidneys is cold storage (CS) using HTK solution. However, hypothermic
machine perfusion (MP) has proven to be beneficial in the preservation of warm
ischemically damaged kidney grafts. Recently, a disposable perfusion system
for oxygenated hypothermic preservation of kidney and liver grafts has been
developed, the Airdrive (AD). For use with the AD, also a new low-viscosity
perfusion solution was developed, named Polysol (PS).
The aim of the study was to assess the efficacy of the AD MP system in
combination with PS, for the preservation of warm ischemically damaged
kidney grafts in a porcine autotransplantation model in comparison to CS using
HTK or PS and uninephrectomy controls.
Methods: Pigs (25-36 kg) underwent left nephrectomy after clamping the
renal vessels for 30 minutes. Kidney grafts were flushed with PS (n=6) or HTK
(n=6) and stored for 20 hr at 4 C (CS) or flushed with PS and perfused in the
AD (n=6) for 20 hr using PS. Pulsatile perfusion was performed with a mean
arterial pressure of 20 mmHg at a temperature of 2-6 C. After the preservation
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C. Corps1, M. Shires2, D. Crellin2, D. Potts3, J. Pratt2, R. Smolenski4,
J.P.A. Lodge1
1
St. James’s University Teaching Hospital, 2LIMM, Leeds University,
3
Department of Biological Science, Leeds, University, 4Harefield Hospital,
Imperial College London,
Introduction: Several papers recently comparing HTK to other preservation
solutions in both liver and kidney transplants, suggest that HTK is as good, as
or better than UW for short cold ischaemic times, such as in live donation, but
not as efficient for longer periods of cold ischaemia, causing a higher number
of cases of delayed graft function. Work carried out in our institute looking at
energy levels, metabolites and histology show some reasons why this occurs.
Methods: Livers were perfused with HTK, UW or a LS (a new phosphate based
preservation solution, under development at our institution) and at various time
points, tissue samples were taken to be analysed for ATP and metabolites by
HPLC, or for histological analysis.
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period, the preserved kidney was heterotopically implanted and the contralateral
kidney removed. As controls, pigs underwent uninephrectomy (Uni, n=4).
Renal function was assessed daily for seven days. Seven days posttransplant,
animals were sacrificed and the kidney grafts removed.
Results: All animals survived for 7 days. All PS-AD and PS-CS preserved
grafts showed immediate function, as demonstrated by urine production within
the first 24 hr after reperfusion as compared to 3 out of 6 in the HTK CS group.
Renal function of warm ischemically damaged grafts preserved using PS-AD
did not differ from renal function of non-transplanted, non-ischemic kidneys in
the uninephrectomy control group. Peak serum creatinine and peak blood urea
values did not differ between both groups (PS-AD 286.7 ± 37.0, Uni 170.8 ±
27.1 umol/l, p=0.053 and PS-AD 10.0 ± 1.4, Uni 6.5 ± 1.0 umol/l, p=0.105,
resp.). Both the Airdrive MP and Polysol CS groups showed improved renal
function compared to HTK stored grafts (creatinine area under the curve (AUC)
p<0.0001 and p<0.001, resp.) with more favourable results for PS-AD when
compared to PS-CS (creatinine AUC, p<0.001). PS-AD creatinine clearance
rates did not differ from the Uni group and were higher than the HTK and PSCS groups (creatinine clearance rate AUC, PS AD vs HTK CS p<0.0001, PS
AD vs PS CS p<0.01).
Conclusion: Perfusion preservation of warm ischemically damaged porcine
kidney grafts using the novel Airdrive MP system in combination with the new
Polysol solution results in improved preservation quality compared to CS using
HTK or Polysol. A complete functional recovery was seen in the Airdrive MP
group, comparable to non-transplanted controls. This study demonstrates for
the first time that full functional recovery of pre-damaged kidney grafts can
be achieved with oxygenated pulsatile perfusion using the Airdrive MP system
with Polysol.
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154 UTILIZATION OF PULSATILE PERFUSION WITH
TISSUE PLASMINOGEN ACTIVATOR CONTAINING
PERFUSATE IN DECEASED DONOR KIDNEYS WITH
EXTENSIVE INTRAGLOMERULAR THROMBOSIS
D. Nghiem, K. Sureshkumar
Allegheny General Hospital
Introduction: Pulsatile perfusion (PP) is known to improve delayed graft
function and tissue plasminogen activator (tPA) can lyse thrombi. We studied
the role of PP with tPA containing pefusate in deceased donor kidneys (DDK)
with 50% thrombosed glomeruli and hence rejected by other transplant
centers.
Material and Methods: Fourteen DDK with extensive intra-glomerular
thrombi on primary biopsies were preserved on a RM3 apparatus using HTK
solution containing 200 mg of tpA. Wedge biopsies were performed prior to
and after PP with tpA containing perfusate.
Results: Causes of donor death were: closed head trauma for 8 kidneys, anoxia
for 2 kidneys and stroke for 4 kidneys. Average donor age was 33.3 years (range
17-55) who had final 24 hour urine volume of 1933 ml (1300-2500). terminal
serum creatinine of 1.8 mg/dl (0.3-3.3) and BUN of 20 mg/dl (11-29).Donor
had an average WBC count of 10,000/μL (4,000-20,300) and a platelet count
of 128,000/μL (53,000-474,000). The kidneys were preserved by PP with tpA
containing perfusate and had initial flow of 47 ml (19-105) which improved to
111 ml/min (55-196) after 16.17 hours (7-24). Resistive Indices (RI) decreased
from 0.69 (0.4-1.57) to 0.26 (0.12-0.45) at 4.2 degrees C (3.2-5.1).Biopsies after
PP showed a reduction in the extend of microvascular and glomerular thrombi
from 50% to 23%. Recipients averaged 54.9 years of age (range 37-67). received
antibody induction,4 days of steroids and maintenance immunosuppression
with calcineurin inhibitor and MMF. Average cold ischemia time was 35.5 hours
(22.4-51.1). One patient had primary allograft non-function, 3 required transient
hemodialysis and 10 had prompt allograft function. Average recipient follow-up
was 10 months (1-18).with serum creatinine of 4.3 mg/dl (1.9-9.7) at 1 week,
2.0 mg/dl (1.4-3.2) at 1 month and 1.8 mg/dl (1.2-2.9) at last follow-up.
Conclusion: 1) Reanl allografts with extensive microvascular thrombosis
showed improve biopsy appearance following PP with tpA containing perfusate.
2) Improvements in PP parameters such as decrease in RI and increase in flows
permitted successful transplantion of such kidneys which otherwise would have
been discarded. 3) PP with tpA containing perfusate appears to be beneficial for
kidneys with extensive microvascular thrombosis.
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155 GENES ASSOCIATED WITH HEART FAILURE DETECT
KINDEYS AT RISK FOR DELAYED GRAFT FUNCTION
T. Mueller, L. Cairo, P. Halloran
University of Alberta
A recent review described biological processes associated with heart failure
[N Engl J Med 2007; 356: 1140-1151]. In particular, alterations in myocardial
energy metabolism seem to reflect chronic heart failure. Our hypothesis was
that transcript changes of genes associated with heart failure can also score
kidney injury at time of transplantation.
Based on the described biological processes, the corresponding metabolic
pathways were identified (KEGG library) and one representative gene chosen
arbitrarily: ACAT1 – fatty acid utilization; G6PC glucose utilization; PPARA
– fatty acid metabolism; SDHC respiratory chain; ATP6V1A ATP synthase;
NDUFS1 oxygen consumption; PPARGC1A – oxidative phosphorylation;
SLC6A8 creatine transporter; CKMT1 mitochondrial energy homeostasis;
ABCA1 ATP transfer. The expression of these heart failure genes were measured
in post-reperfusion implant biopsies of a total of 117 kidneys (53 DD, 64 LD
kidneys) using Affymetrix microarrays. The transcriptome was analyzed by
unsupervised hierarchical clustering and principal component analysis (PCA)
methods and related to clinical phenotypes.
The transcript levels of the heart failure genes differentiated the kidneys into
two major groups, group A comprising 51 (47 LD and 4 DD) and group B 66
samples, resp (17 LD and 49 DD). These groups were significantly different for
the occurrence of DGF (group A 2%, group B 15%, p < 0.05). The heart failure
transcriptome further revealed two subclusters within the group B kdineys that
differed in regard to long-term transplant function (s-crea month 1 to 12, p <
0.05).
The PCA analysis shows the continuity in the distribution of the kidney
samples, from LD kidneys on the right to the DD kidneys on the left. The
kidneys that developed delayed graft function (DGF) are scattered to the far
left. DGF cases due to post-transplant factors (i.e. hypotension n=2 and sepsis
n=1) are indicated by circles, they distribute randomly.
Thus the heart failure transcriptome scores the quality of donor kidneys at
time of transplantation. This indicates stereotyped injury and repair responses
among different organs, and demonstrates that altered metabolism is a common
theme in organ injury
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156 ORGAN DONATION PROCESS IN THE NETHERLANDS
BETWEEN 2005 AND 2007 QUANTIFIED; MAJORITY OF
DONOR POTENTIAL LOSS EXPLAINED BY RELATIVES’
REFUSAL
H. van Leiden, N. Jansen, A. Hoitsma, B. Haase-Kromwijk
Dutch Transplant Foundation
Purpose: The Netherlands are still confronted with an absolute shortage of
organ donors just like many other countries. The last 10 years the number of
deceased heart beating (HB) and non-heart beating (mainly NHB category 3)
donors fluctuated around 200 donors, except for the year 2007 (257 donors).
With the Dutch Medical Record Review, implemented in two thirds of all
hospitals in the Netherlands from the years 2005 to 2007, we had insight in the
number of potential organ donors. We quantified the major issues in the process
of organ donation and could explain changes in the number of donors yearly
referred for organ donation, that paralleled changes in donors referred for organ
donation in the whole country in the years 2005, 2006 and 2007.
Material and Methods: Medical records of patients died in intensive care
units (ICU) from 64 hospitals during the years 2005 to 2007 were reviewed by
transplant coordinators and donation officers. Data regarding organ donation
were collected in a centrally registered database.
Results: The medical potential of ventilated HB donors, and NHB donors
aged 65 years or younger fluctuated around 480 donors. Doctors detected these
donors in 96% (2005) to 99% (2007) and consulted the national Donor Register
(DR) more often as well (from 87% to 92% in 2007). In the DR Dutch citizens
can record their will on donation. The registered consent rate for donation in
the DR, when consulted, increased from 17% in 2005 to 21% in 2007, while the
registered refusal rate remained stable (17-18%).
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157 KIDNEY TRANSPLANTATION FROM UNCONTROLLED
CARDIAC DEATH AND BRAIN-DEATH DONORS.
COMPARISON OF EARLY RESULTS.
O. Reznik1, S. Bagnenko1, I. Loginov1, A. Ananyev1, A. Skvorzov1,
I. Ulyankina1, Y. Moysyuk2
1Transplantology Department of Saint-Petersburg’s State Research Institute
For Ememrgency, 2National Research Institute of Transplantology and
Artificial Organs
Introduction: Due to the lack of donor’s organs the interest to such resource of
organs as uncontrolled donors after cardiac death (uDCD) is appeared. The number
of brain dead donors is unsatisfactory in Russia, and only uncontrolled NHBD
(Maastricht category II and IV) can use as a recourse for kidney transplantation
according to legislation. The use of kidneys from uDCD remains disputable. The
main problem is ischemically-reperfusion injuries which caused by significant
warm ischemic time (WIT). This problem leads to the need to have the reliable
tool for estimating quality of kidneys before transplantation, and good instrument
for preventing inevitable ischemic-reperfusion injury after this one.
Materials and Methods: From December 2005 till July 20 were studied 3 groups
of recipients. The results of transplantation of 21 pump perfused kidneys (study
group, PP DCD) were compared with 17 cold stored kidneys (control group, CS
DCD) from the same 22 uDCDs. All DCDs were II category (Maastricht class.,
1995). The WIT was defined as the time between cardiac arrest and the start of
initial perfusion of kidneys “in situ”. In this definition didn’t include the agonal
period with unstable hemodynamic. The 30-minute advanced cardiopulmonary
resuscitation was obligatory in each case. Average WIT was 42.7±1.6 min (min
34.0; 65.0 max). The recipients of kidneys from brain-death donors compounded
the comparison group (n-31). The kidneys from BDDs underwent cold storage
method of preservation. The characteristics of uDCDs and BDD are shown in Table
1. The comparison of early postoperative results is presented in Table 2 and Fig.1.
Table 1. Characteristics of donors groups.
Parameters

BDDs, n-28

Age
Dopamine, mkg/kg/min
Serum creatinine, mmol/l
Diuresis/last hour

40,0±2,0
4,7±0,5
89,3±5,4
0,8±0,1

uDCDs,
n-22
49,3±1,5
10,0±0,8
125,9±17,3
0,3±0,1

p
<0,001
<0,001
<0, 05
<0,001

Table 2. Comparison of early postoperative parameters
Parameters
Immediately function
Delayed function
Heamodialysis/30
Creatinine D21
Creatinine D 90
Discarded kidneys
Rejection episodes/30
PNFT
Surg.complications
CCcocomplications
*p >0,05; **p<0,05.

Control DCD group
(cold-stored). n-17
3 (18%) **
14 (82%) **
4.9±0.9**
376.9±27.4**
177.0±7.4**
5
4
3

Study DCD (pump
perfused) group, n-21
10 (48%) *
11 (52%) *
2.3±0.6*
213.0±30.0*
139.7±7.0*
1
1
0

Comparison BDD
group, n-31
23 (47%) *
14 (53%) *
2.7±0.3*
206.7±23.5*
124.0±4.8*
0
2
0

3

1

1
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When the DR was not decisive or not consulted, relatives had to decide for
donation. Relatives were not requested in 10% of these cases. Most reported
reasons for not requesting were absence of the relatives or strong emotions
among relatives. The relatives’ refusal rate was 66% in 2005 and increased
to 71% in 2006, but decreased significantly to 59% in 2007. Of the medical
potential 68-69% was finally not referred for organ donation in the years 2005
and 2006, but in 2007 this total loss was 59%. Thereby, refusal by relatives
accounted for about 60% of this lost group of potential donors during these
years.
Conclusion: The potential of organ donors is 2-3 times higher than the number
of donors reported for donation. Most issues in the donation process from
donor identification till donor referral, including consent in the DR improved in
recent years. The increase in donation in 2007 can be explained by a decrease in
refusal by relatives. Thus far relatives still turned out to be the most restrictive
factor in the organ donation process. Therefore the request process among
relatives still need special attention to increase the number of organ donors in
the Netherlands.
Fig.1 Serum creatinine in different groups of recipients (DCD PP – recipients
pump perfused kidneys from DCD, DCD CS – recipients of the cold stored
kidneys from the same DCDs, and BDD – recipients of the cold stored kidneys
from BDD)
Results: The use of the recovering effects of pulsatile perfusion has allowed
the use for transplantation the kidneys from uDCD with good clinical results.
At the same time, 5 pair kidneys from control group were discarded and results
were worse: the rate of immediate function in study group was 30% higher than
in the control group. The creatinine level in control group was two times as high
on day 21 and in 3 months after transplantation, compared to the study group.
The results of transplantation pump perfused kidneys from uDCDs don’t differ
from results of transplantations of the cold stored kidneys from BDDs on 21st
and 90th day after operation.
Conclusion: The use of machine perfusion is the effective instrument for
improving uDCD kidneys function as well as for enlarging kidney’s donor’s
pool.

POSTER BOARD NUMBER P1 – 355
158 IMPROVED PRESERVATION OF THE RAT HEART
USING CELSIOR SOLUTION SUPPLEMENTED WITH A
RECOMBINANT HUMAN NEUREGULIN-1 PEPTIDE
A. Jabbour1,2, L. Gao1, J. Kwan1, A. Watson1,2, X. Liu3, M. Zhou3,
R.M. Graham1,2, M. Hicks1,2, P.S. Macdonald1,2
1
Victor Chang Cardiac Research Institute, 2St Vincent’s Hospital, Sydney,
Australia, 3Zensun (Shanghai) Sci & Tech Co., Ltd., Shanghai, China
Background: The neuregulin-1/ErbB receptor complex plays a critical role
in normal heart function and in the adaptation of the heart to injury. In adult
cardiomyocytes NRG-1 protects against myofibrillar disarray and promotes
cell survival, via pro-survival pathways involving ERK1/2 and PI3-K/Akt via
activation of ErbB2/4 receptors. We have shown previously that rhNRG-1,
a 61-amino acid receptor-active recombinant human neuregulin-1 (beta2a
isoform) peptide improves cardiac function and survival in various animal
models of ischaemic, dilated and viral cardiomyopathy.
Hypothesis: That the addition of rhNRG-1 to a commercial preservation
solution (Celsior; C) improves cardiac preservation after prolonged hypothermic
storage.
Methods: Pre-arrest indices of cardiac function were measured in 46 isolated
working rat hearts. Hearts were arrested and stored for 6 hours at 2-3°C in C
± rhNRG-1 (14nM). A second group of hearts were pre-treated with rhNRG-1
(14nM) for 15 minutes prior to arresting the heart, a third group at the time of
reperfusion, and a fourth group at both time points in addition to storage in C
+ rhNRG-1. A final group of isolated hearts were pre-treated with the PI3K
inhibitor, Wortmannin, before storage in C plus rhNRG-1. After storage, hearts
were remounted and functional measurements repeated. Total and phosho-Akt
were assessed by Western Blotting.
Results: Recovery of cardiac function was significantly better in hearts stored
in C plus rhNRG-1 vs. C alone. Post-storage recovery of each parameter is
expressed as a percentage of its pre-storage baseline (mean ± SEM). Cardiac
output recovery increased from 1.4±0.62 to 21.2±7.9 (p=0.03). Coronary flow
recovery increased from1.7±1.1 to 39±11.5 (p<0.01). Heart rate recovery
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increased from 32.2±8.6 to 75.7±11.7 (p=0.01). Treatment with rhNRG-1 prior
to cardiac arrest and at the time of reperfusion, in conjunction with storage
in C plus rhNRG-1 did not provide any incremental benefit over storage in C
plus rhNRG-1 alone. Pre-treatment with rhNRG-1 prior to cardiac arrest alone,
resulted in improved preservation of the stored rat heart compared with control.
Western blotting revealed increased expression of phospho-Akt in rhNRG-1
stored hearts (p<0.05). confirming up-regulation of the PI3K/Akt pathway; an
effect abrogated by Wortmannin (p<0.05).
Conclusions: rhNRG-1 improves transplanted heart function after hypothermic
storage by activation of the pro-survival Akt pathway. rhNRG-1 shows promise
for enhancing donor heart preservation.

POSTER BOARD NUMBER P1 – 356
159 THE CLINICAL SIGNIFICANCE OF THE HYPOXIA
INDUCIBLE FACTOR-1Α AND C4D IN IMPLANTATION RENAL
BIOPSIES AND POST-TRANSPLANT BIOPSIES.
S. Lee1, S.J. Kim1, D.J. Kim1, S.G. Park1, S.J. Hyun1, J.E. Oh2, E.S. Nam3
Department of 1Surgery, 2Internal Medicine and 3Pathology Hallym
University College of Medicine, Seoul, Korea
Purpose: Hypoxia inducible factor-1α (HIF-1α) is induced in response to
ischemic states and in turn activates transcription of several growth factors
implicated in cell survival. These growth factors have been recognized as
role players in the development of chronic allograft nephropathy (CAN). C4d
depositions in the peritubular capillaries of renal allografts have been reported
to be sensitive markers of acute humoral rejection. The purpose of this study
was to determine the effects of HIF-1α expression and C4d deposition in
implantation biopsies of renal allografts.
Materials and Methods: Implantation biopsies and 22 rejection proven
biopsies of 54 renal transplantation recipients (Male: Female=31: 23) in
Kangdong Sacred Heart Hospital from December 1996 to July 1999 were
done. Immunohistochemical studies were performed using mouse monoclonal
antibody (1: 1000, Novus Biological Inc., Littleton, CO, USA) as the primary
antibody and CSA (Catalyzed Signal Amplification System, Dako, Denmark)
as the secondary antibody for HIF-1α. Rabbit polyclonal antibody (1: 200
Biogenesis, UK) and DAB kit (Dako) were used for C4d detection. Expression
of HIF-1α was defined as positive nuclei staining under 10 HPF (high power
field) and C4d deposition was defined as 1+ when the pericapillary deposition
was under 50% and 2+ when over 50% and 0 when there were no traces of
deposition.
Results: HIF-1α was demonstrated in 19 cases (35%) of the 54 implantation
biopsy cases. The expression of HIF-1α was statistically higher in the deceased
donor group compared to the living donor group. The HIF-1α positive group had
a longer mean cold ischemic time than the HIF-1α negative group but was not
statistically significant. The age of the donor and HIF-1α expression showed no
correlation. Expression of HIF-1α of the implantation biopsies also showed no
difference in the rejection group (n=22) compared to the non-rejection group
(n=32). There was no significant difference of HIF-1α expression in the graft
loss group (n=7) and the graft functioning group (n=47). C4d deposition was
detected in one implantation allograft biopsy (1.9%). The C4d positive patient
developed acute accelerated rejection on the fourth postoperative day. HIF-1α
and C4d were demonstrated in 22 (100%) and 11 (50%) of the 22 rejection
biopsies, respectively. In patients who showed rejection, HIF-1α expression
was significantly higher in the rejection biopsies compared to the implantation
biopsy group. HIF-1α expression of the patients who showed rejection within
one month and those with rejection later than three months after engraftment
showed no significant difference.
Conclusion: Expression of HIF-1α in implantation biopsies showed significant
correlation with deceased kidney donors. The relation with cold ischemic time
was not statistically proven but the HIF-1α positive group showed a tendency
of longer cold ischemic time. Biopsies from the renal allografts with rejection
showed significantly higher expression of HIF-1α compared to the implantation
biopsies. The deposition rate of C4d was extremely low in implantation biopsies
that we could not prove any relevance with acute rejection.
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160 A NEW CLASS OF OXYGEN CARRIERS IMPROVES
LONG-TERM STORAGE OF PORCINE AND HUMAN
PANCREATA FOR SUBSEQUENT ISLET ISOLATION
H. Brandhorst,1 B. Theisinger,2 M. Iken,3 M. Ott,3 O. Korsgren,1
D. Brandhorst,1
1
Department of Clinical Immunology, University Hospital, Uppsala, Sweden;
2
Novaliq GmbH, Heidelberg, Germany; 3Department of Gastroenterology,
Hepatology and Endocrinology, Hanover Medical School, Hanover, Germany
Objective: Shipment of explanted organs is frequently associated with
prolonged ischemia deteriorating viability of transplanted tissue. Previous
studies in human islet transplantation demonstrated that storage on oxygencharged perfluorodecalin (PFD) does not prevent ischemically induced
pancreas damage compared to storage in UW-solution. In contrast, experiments
in rats indicated that perfluorohexyloctan (F6H8). a semifluorinated alkane
characterized by lipophilic qualities and a relatively low density (1.33 g/cm3).
improves yield, viability and posttransplant function of islets isolated from
long-term stored pancreata compared to PFD (1.93 g/cm3). The present study
investigated therefore the efficiency of this potential oxygen carrier to facilitate
islet isolation from long-term stored porcine and human pancreata.
Materials and Methods: Freshly resected and UW-perfused pig pancreata
(n=6) were dissected into the splenic or connective lobe and stored for 12 ±
2 hours in oxygen-charged F6H8 or PFD. Human research grade pancreata
were subjected to oxygenation in F6H8 (n=5) or PFD (n=5) for additional 24
hours subsequent to UW-storage of 11 ± 1 hours (F6H8) or 10 ± 2 hours (PFD).
Subsequently, the intrapancreatic partial oxygen pressure (pO2) was measured
utilizing a fiber optic technique. Human and porcine islets were isolated and
purified as previously described. Islet quality control assessed yield, glucosestimulated insulin release determined as stimulation index, viability and
recovery after 3 days of culture.
Results: Compared to F6H8 the pO2 measured in the core of pig pancreata
was decreased utilizing PFD (10.1 ± 5.2 vs 3.5 ± 3.0 mm Hg, NS). Although
yield of islet equivalents (IE) did not differ between pig pancreata stored in
F6H8 or PFD (2600 ± 340 vs 3640 ± 1050 IE/g, NS) recovery after culture
was significantly improved after storage in F6H8 (51 ± 7 vs 29 ± 3%, p<0.05).
Moreover, glucose stimulation index was enhanced in islets isolated after F6H8
storage (1.9 ± 0.2 vs 1.3 ± 0.3, p<0.05).
The intrapancreatic pO2 in human pancreata was significantly higher after
storage in preoxygenated F6H8 (8.9 ± 4.6 vs 1.2 ± 0.5 mm Hg, p<0.05). This
correlated with significantly increased yield (4220 ± 430 vs 2680 ± 360 IE/g,
p<0.05) and viability (80 ± 3 vs 51 ± 6%, p<0.05) of islets isolated from F6H8stored pancreata. In addition, recovery after culture was enhanced after F6H8
storage compared to PFD (84 ± 5 vs 49 ± 5%, p<0.01). No significant difference
was found regarding human islet in vitro function.
Conclusions: The dense and firm structure of the human pancreas seems to
require the utilization of lipohilic oxygen carriers that can penetrate into deeper
tissue layers of cold-stored pancreata. In contrast, the specific histomorphological
structure of the pig pancreas seems to facilitate the release of oxygen into the
pancreatic core. The present data suggest that F6H8 is superior to PFD in terms
of supplying oxygen to large mammalian pancreata if successful islet isolation
is intended. The posttransplant function of islets isolated after pancreas storage
in different oxygen carriers is under current investigation.
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161 ISOLATION, CHARACTERISATION AND
DIFFERENTIATION OF A NOVEL BIPOTENTIAL
PROGENITOR CELL FROM THE ADULT PANCREAS
P. Shiels, K. Stevenson, A. Mac Intyre
University of Glasgow
We have isolated a novel progenitor cell population from adult rat pancreatic
ducts, termed pancreas derived progenitor cells (PDPCs). Here, we report
the in vitro culture, selection and characterisation of Thy1.1 positive and
Thy1.1 negative PDPC sub-poplualtions. These cells exhibit bipotentiality for
differentiation into both pancreatic/hepatic cell types.
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162 HEPATOCYTE TRANSPLANTATION: A POTENTIAL
NEW THERAPY FOR HEMOPHILIA B
K. Ohashi1, K. Tatsumi2, M. Shima2, Y. Nakajima3, A. Yoshioka2, T. Okano1
Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s
Medical University, 2Department of Pediatrics, Nara Medical University,
3
Department of Surgery, Nara Medical University
Background: Hemophilia B is a recessive X-chromosome linked congenital
bleeding disorder, and the bleeding diathesis in these individuals is due to a
failure in the production of biologically active coagulation factor IX (FIX).
Achieving >1% coagulation activity results in significant improvement in the
quality of life of the hemophilia B patients. Since hepatocytes are the primary
and sole responsible cell type for the production of FIX, establishment of cellbased therapy using hepatocytes should be highlighted. Extensive experimental
and clinical studies suggest that hepatocyte transplantation offers an promising
therapeutic option for acute and metabolic liver diseases. The present study
was designed to establish cell transplantation therapies using mouse model of
hemophilia B.
Method: Donor hepatocytes were isolated from C57Bl/6 using two-step
collagenase perfusion method. Hepatocytes were separated from nonparenchymal cells using low-speed centrifugation (hepatocyte purity >99%).
Isolated hepatocytes (1.5 x 106 cells/recipient) were transplanted into the liver
of factor IX-knockout mice (FIX-KO) mice (C57Bl/6 genetic background). In
some of the recipient mice, additional hepatocyte transplantation procedure
was performed 15 days after the initial transplantation. Engraftments of the
transplanted hepatocytes were determined by fluorescence in situ hybridization
(FISH) and quantitative real-time PCR for FIX expressions. Therapeutic
efficacy of hepatocyte transplantation was determined by measuring plasma
FIX activity of the recipient mice using 1-stage clotting assay based on the
activated partial thromboplastin time.
Results: In the FIX-KO mice that received hepatocyte transplantation, the
plasma FIX activities increased at 1-2%. An additional increase was achieved
by repeated procedure of hepatocyte transplantation. Close correlation between
FIX mRNA expression levels of the liver and plasma FIX activity levels was
observed. FISH analyses demonstrated that transplanted hepatocytes had been
engrafted within the liver parenchyma. We have confirmed the persistency of
the therapeutic effects up to 12 weeks (the length of the experiment). None
of the recipient mice developed a humoral response against the de novo
synthesized FIX protein.
Conclusions: The present study confirmed that engrafted hepatocytes within the
liver of hemophilia B possess full functionality for clotting FIX productions. In
all, these data provide the proof-concept feasibility of hepatocyte transplantation
as a new mode to provide therapeutic benefits in the treatment of hemophilia B.
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163 INHIBITORY EFFECT OF RAT MESENCHYMAL STEM
CELLS ON LYMPHOCYTE PROLIFERATION
Y. Lu, K. Gao, C. Cong, Y. Yuan, L. Wei, S. Li, Y. Chen, C. Qiao, Y. Li,
J. Cheng,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
The objective of the research is to investigate the mechanism of inhibitory
effects induced by rat MSCs on nonspecific mitogen stimulated lymphocytes
(LCs) and lymphoblasts (LBs). In this study, 2nd to 8th passage MSCs
prepared from Sprague-Dawley (SD) rat were used. LCs were separated from
spleens of SD rats. Mixed lymphocyte reactions of mitomycin C treated MSCs
with ConA-stimulate LCs or LBs were performed, and the growth inhibition
effect was tested through MTS assay. Cytotoxicity of MSCs against naive and
ConA-stimulated LBs were detected after coculturing for 24 hours by lactate
dehydrogenase release assay. Apoptotic rate of ConA-stimulated LBs was
measured on flow cytometry after incubating with MSCs for 9 hour in ratio
of 10: 1. After treatment with blocking antibodies of FasL, TGF-¦Â and IL-10
respectively, MSCs were cocultured with ConA-stimulated LBs to observe
apoptosis and growth inhibitory effects. The main outcome measures included
adhesive bone marrow derived CD29+, CD44+, CD45-, CD54+, CD95+ and
SH-2+ MSCs. FasL, TGF-¦Â and IL-10 production of MSCs were visualized
by immunocytochemistry. MSCs exhibited a dose-dependent growth inhibitory
effect on ConA-stimulated LCs and LBs. When treated with anti-FasL and
IL-10 blocking antibodies, inhibitory effects of MSCs on LB (MSCs: LBs=1:
10) proliferation decreased from 100% to 54.2 ¡À 7.4% and 68.7 ¡À 8.8%
respectively, and apoptosis induction effect on LBs decreased by 27.0 ¡À
4.3% and 73.3 ¡À 10.2% respectively. Treatment with anti-TGF-¦Â blocking
antibody had no significant influence on those effects of MSCs. These in vitro
phenomena demonstrate that MSCs could suppress lymphocyte proliferation
induced by ConA, and the inhibitory effects of MSCs against activated LBs
were significantly stronger than naive LCs. FasL and IL-10, rather than
TGF-¦Â play an important role in MSC-mediated suppression of lymphocyte
proliferation.
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164 MECHANISM OF ANTIGEN SPECIFIC MESENCHYMAL
STEM CELLS-MEDIATED IMMUNOREGULATION: NEW
INSIGHTS FROM AN IN VIVO STUDY
E. Morelon7, H. Perrin1, A. Hennino3, M. Vocanson2, J-F. Nicolas5,
J-L. Tourraine4, O. Thaunat6
1
INSERM U851; Edouard Herriot Hospital, Lyon, France, 2INSERM U851,
IFR128, Lyon, France, 3INSERM U851, IFR128, Lyon, France, 4INSERM
U851, IFR128, Lyon, France, 5INSERM U851, IFR128, Lyon, France,
6
Edouard Herriot Hospital, Lyon, France, 7INSERM U851; IFR128; Edouard
Herriot Hospital, Lyon, France
Background: Mesenchymal stem cells (MSCs) are nonhematopoietic bone
marrow stromal cells that support haematopoiesis. MSCs immunoregulatory
properties suggest that these cells might be potent candidates for the treatment
of allograft rejection. However, the immunoregulatory features of MSCs have
been mostly demonstrated in vitro, and little is known so far regarding the in
vivo mechanisms supporting MSCs-mediated immunoregulation.
The aim of the study was to analyze the effects of MSCs in vivo, on an antigenspecific immune response.
Methods and Results: We have established and characterized by flow
cytometry murine primary MSCs. C3H10T1/2 and S17 murine MSC cells lines
were also used. All these cells were able to inhibit lymphocyte proliferation in
vitro, in a dose dependant and CMH independent fashion.
The allergic contact dermatitis (ACD) is a well defined mouse model in which
the intensity of the CD8 T cell-mediated antigen-specific immune response is
reliably quantified by the measure of oedema 5 days after DFNB rechallenge
on the ear.
The subcutaneous injection of 1.106 primary MSCs or S17 cells at the time
of sensitization resulted in a 50% reduction of ear oedema, demonstrating the
inhibition of ACD in vivo. This inhibitory effect was not observed when MSCs
were injected during the rechallenge (secondary contact with DNFB) or after
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We have observed a time course of both morphologic and gene expression
changes indicative of hepatic lineage differentiation by use of a serum free
FGF-4 containing differentiation protocol. These cells express albumin,
CYP2B1 and store glycogen, typical features of mature hepatocytes. Previous
studies have demonstrated hepatic differentiation of a number of different
cell types, including bone marrow derived MSCs, MAPCs, endometrial and
pancreatic derived MSCs. The Thy1.1 positive subpopulation of PDPCs share
the morphological phenotype and express a number of cell surface markers
with these populations, including CD44 +, CD24-, CD45-, CD31- and CD34.
In contrast to this, however, Thy1.1 positive PDPCs appear to be a distinct cell
type, expressing GATA4, HNF3beta and alpha feto protein, which have not
been described as expressed for any of these other cell types.
The Thy1.1 sub-population also displays the capacity to form islets in vitro,
when cultured with nicatinomide. No morphological evidence of islet like
clusters was observed using the Thy1.1 negative population. Neither insulin
nor glucagon was expressed within this population. In contrast, Thy1.1 positive
PDPCs could readily be induced to a pancreatic lineage with characteristic
morphological changes resulting in three dimensional islet like structures and
the transcriptional expression of PDX-1, insulin and glucagon.

MONDAY

Monday 11 August 2008

Oral Abstracts

non specific irritation. This suggests that the beneficial effect of MSCs is rather
the consequence of a MSCs-mediated inhibition of the DNFB-specific immune
response than a non-specific anti-inflammatory effect.
To further challenge this hypothesis, we have analysed the events taking place
in the draining lymph nodes at the time of the initiation of the DNFB¡Vspecific
response. We found that lymphocyte proliferation and IFNƒ× secretion were
not altered in treated animals, suggesting that MSCs do not modify the antigen
presentation and the priming of CD8+ T cells. In contrast, we demonstrated
that effector cell infiltration at the inflammatory site (measured by CD4,
CD8, IFNƒ× mRNA expression in mouse ear) was significantly blunted by
the presence of MSCs. Experiments are currently performed to determine the
mechanisms of by which MSCs are able to modify the homing of effector cells
(chemokines secretion, skin homing receptor expression).
Conclusion: We demonstrated for the first time that MSCs have the
immunoregulatory properties in vivo in the ACD model. Our data suggest
that MSCs-mediated immunoregulation is antigen-specific and relies on their
ability to reprogram the homing of effector cells.
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165 DONOR-DERIVED MESENCHYMAL STEM CELLS
SUPPRESS ALLOREACTIVITY OF KIDNEY TRANSPLANT
RECIPIENTS
C. Baan1, M. Crop1, J. IJzermans2, I. Alwayn2, W. Weimar1, M. Hoogduijn1
Department of Internal Medicine, 2Department of Surgery Erasmus Medical
Center
Introduction: Human mesenchymal stem cells (MSC) have immunomodulatory
capacities. They have shown to be effective in the treatment of graft-versushost-disease. However, their effect on alloreactivity in human solid organ
transplantation is still unknown. In this study, we isolated MSC from donor
tissue and examined their immunosuppressive effect on recipient anti-donor
reactivity, before and after kidney transplantation.
Methods: Anti-donor reactivity was established in mixed lymphocyte reactions
(MLR) of 14 living kidney donor-recipient pairs. Recipient PBMC were
isolated before and 1 month after transplantation, and stimulated by g-irradiated
donor PBMC and fully-mismatched third-party PBMC. Perirenal fat derived
MSC from donors and third-party controls were added to the various MLR in
a 1: 5 ratio and proliferation measured by 3H-thymidine incorporation. The
proliferation of lymphocyte subsets was analyzed by flowcytometry after PKH
labelling of responder PBMC.
Results: Donor MSC significantly inhibited the recipient anti-donor
reactivity pre- and post-transplant MLR with comparable efficacy. The
immunosuppressive effect of MSC appeared to be independent of the donor
source (autologous or allogeneic). Flowcytometric analysis showed that MSC
inhibited the proliferation of CD4+ and CD8+ T lymphocyte subsets in pre- and
post-transplant MLR. MSC not only reduced the percentage of proliferating
responder cells, but also their number of cell divisions. MSC had no effect on
B or NK cell proliferation.
Conclusion: Donor MSC significantly inhibited the proliferation of alloactivated T cells before and after transplantation. This capacity of MSC may be
useful to control graft rejection in solid organ transplantation medicine.
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166 MESENCHYMAL STEM CELLS PREVENT ACUTE
REJECTION IN EXPERIMENTAL RENAL TRANSPLANTATION
M. Alessiani1, S. Zonta1, T. Rampino2, M. Gregorini2, F. Frassoni3, M. De
Martino1, A. Ibatici3, G. Piotti2, G. Bedino2, C. Piacenza2,
1
University Of Pavia Department of Surgery, IRCCS policlinico San Matteo,
Pavia, 2Neprology and dialisis Unit, 3Oncoemathology Unit and cell
transplant centre San Martino Hospital, Genova
Mesenchymal stem cells (MSC) are multipotent cells that can differentiate into
various mature cell types. MSC prefentially home to damaged tissues, where
they may contribute to cell regeneration and repair. In addition, MSC have
immunomodulatory effects. In vitro, MSC inhibit T cell proliferation induced
by alloantigens and mitogens and prevent the development of cytotoxic T cells;
in vivo, they prolong the survival of experimental skin and cardiac allografts.
As yet, the effects of MSC in renal allograft have not been explored. We
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investigated whether infusion of MSC modifies the course of renal allograft
in the rat model.
Transgenic Sprague–Dawley (SD) rats expressing enhanced green
fluorescence protein (EGFP) were used as MSC donors. Syngraft (Lewis
RT1 to Lewis RT1, Fisher F344 to Fisher F344) and allograft (Fisher F344
to Lewis RT1) orthotopic kidney transplantations were performed following
bilateral nephrectomy. Group A: rats were infused with saline solution in
renal artery soon after grafting. Group B: rats were infused with intraarterial
3X106 MSC. No immunosuppressive therapy was administrated. Animals
were sacrificed on day 7 and kidney was removed for morphological
study. Creatinine clearance was measured on days 0, 3 and 7. Tubulitis
and vasculitis were scored according to Banff classification on Movat
pentachromic stained renal sections, analysing respectively 150 consecutive
tubuli and 10 arteries/section. ED1 and CD8 positive cells were evaluated by
immunohistochemistry.
The transplant procedure was comparable in both groups in terms of total
ischemia time, timing of surgical procedure and post-reperfusion graft diuresis.
MSC improved renal function in group B vs group A. Tubulitis resulted less
heavy in MSC treated (B) than in not treated (A) rats (score% tubuli, T0:
B=64.5%, A=36%, p<0.005; T3: B=2.6%, A=12.8%, p<0.0001). Vasculitis
was significantly less severe in group B than in group A (V0: B=50%, A=16%,
p<0.0001; V3: B=33%, A=70% p<0.0001). MSC reduced inflammatory
infiltrate; in group B ED1 positive cells number was lower in comparison with
A (number of cells per microscopic field B=42.8±8.6, A=78.1±2.1, p<0.005)
and CD8 positive cells were significantly reduced in group B than in A (B=
14.8±8.4, A=29.4±0.5, p<0.05).
Our study demonstrates that MSC infusion significantly attenuates acute
cellular rejection in the absence of immunosuppresive therapy.

POSTER BOARD NUMBER P1 – 364
167 INTERLEUKIN-10 ENGINEERED MESENCHYMAL STEM
CELL THERAPY TO PREVENT ISCHEMIA-REPERFUSION
INJURY IN LUNG TRANSPLANTS
S. Salgar, E. Manning, S. Pham, S. Li, J. Mathew, P. Ruiz,
Department of Surgery, University of Miami
Aim: Following lung transplantation, early graft dysfunction due to ischemiareperfusion (IR) injury is a serious problem occurring in about 30% of the
patients. Viral interleukin-10 (vIL-10) is a potent anti-inflammatory cytokine.
Mesenchymal Stem Cells (MSC) have immunosuppressive properties and can
serve as a vehicle to deliver vIL-10. In this study, autologous MSC and vIL-10
engineered MSC were tested for their ability to prevent lung IR injury.
Methods: Bone marrow derived MSC from Lewis rat were transduced with
rvIL-10-retrovirus & selected on neomycin (1mg/ml for 7 days). Left lung
ischemia was induced by clamping left pulmonary artery/vein/bronchus at
end inspiration. Following 120 min of left lung ischemia, Group A, rats
received vIL-10 transduced MSC (~15 x 106; i.v.); Group B, received empty
vector engineered MSC; Group C, received MSC; and Group D, received
saline. Group E received no ischemia or MSC. At 4h, 24h, 72h, & 7 days
following ischemia, blood was collected from left and right pulmonary
veins, separately.
Results: Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was reduced
(P<0.05) at 24h post-IR injury in Group B (138+ 86; n=9) and Group D
(87+39; n=10). compared to MSC-vIL10 (353+105; Group A; n=10) treated
animals. By days 3 & 7 following IR injury with MSC-vIL10 therapy
oxygenation levels approached normal (475+55 & 435+33; n>9) but empty
vector control was low (238+164 & 217+158; n>9). As early as 4h following
IR injury lung function was improved significantly (P<0.05) in MSC-vIL-10
group (319+94 mmHg; n=7) compared to untreated controls (63+19 mm
Hg; n=6). Long-term cultured MSC (passage >25) therapy increased PaO2/
FiO2 slightly (152+51 Vs 87+39 in controls, 24h post-IR; n > 8). However,
earlier passage MSC (p1 to p6) therapy increased PaO2/FiO2 significantly
(454 + 59) at 24h post-IR. Extravasation of Evans blue dye (as a measure
of capillary permeability/damage) was lower (P<0.5) in MSC-vIL10 treated
animals. Bronchoalveolar lavage from IR injured lung at 24h post-MSCvIL10 therapy demonstrated reduced (P<0.05) inflammatory cells (x106)
compared to untreated controls (Granulocytes, 2.8 Vs 5.4; Macrophages, 3.3
Vs 2.9; CD4 T cells, 0.6 Vs 2.2; CD8 T cells, 1.1 Vs 3.1). IR injured lungs
(4h reperfusion) with no treatment had a higher (P<0.05) injury score (3.5 +
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168 SURVIVAL AND PROLIFERATION OF MESENCHYMAL
STEM CELL TREATED BY BMP-2 AND TRANSDUCED WITH
PFUG-TF LENTIVIRAL VECTOR AFTER CARDIAC DELIVERY
IN VIVO VISUALIZATION
Z. Shen, S. Xue
The First Affiniatied Hospital of Soochow University
Objectives: To provide theoretical support at the cellular level for future
clinical application in the treatment of myocardial diseases with MSCs.
Methods: Marrow mesenchymal stem cells (MSCs) were selected from the
marrow of SD rats and were induced with BMP-2. MSCs stably transduced
with a lentiviral vector carrying pFUG-TF reporter gene that consists of firefly
luciferase, monomeric red fluorescence protein, and truncated thymidine
kinase (fluc-mrfp-ttk).The acute myocardial infarction model of nude rat was
established and the bone marrow MSCs were implanted into the acute infarct
site via topical injection. The survival and proliferation of implanted cells were
studied by the bioluminescence and positron emission tomography (PET)
signals.
Results: The primary cells grew well and displayed a fibroblast -like
morphology£®Fo11owing the time of passage increases£¬the positive
rate of CD29 increased£»CD90 decreased£¬the negative rates of CD34
and CD45 increased. Shape and arrangement of the cells changed after
induction with BMP-2. In RT-PCR analysis, The expressions of BMPRIA and
BMPRII£¬Nkx2.5 and GATA-4 were increased one week after induction. cTnT
mRNA expressed one week after induction while it was not observed before
induction. In immunocytochemical staining, cTnT and Cx-43 was expressed
two week after induction£®Expression of cTnT was strong three to four weeks
after induction£®The structure was dense and striation-like£®Cx-43 was
located beneath the membrane two weeks after induction£®In three weeks after
induction, the protein was observed at cell conjunctions£®It was granular and
dense, and located at conjunctions between cells of myotube- like structure four
weeks after induction. There is no difference between mesenchymal stem cells
transduced with pFUG-TF lentiviral vector and cells non-transduced in Trypan
blue cell viability. Cells transduced with pFUG-TF lentiviral vector express
cardiac transcription factors (Nkx2.5) and myosin heavy chain (¦Â-MHC).
Cells transduced with pFUG-TF lentiviral vector also express reporter genes
(fluc). The bioluminescence and positron emission tomography signals in study
animals increased progressively from week 1 to week 4.
Conclusion: (1) The surface antigen markers of MSC will change during the
process of culture, and the changes of these markers may reflect the changement
of cell purity or other unknown mechanism. (2) BMP-2 induces diferentiation
of MCSCs into cardiomyocytes via mediation of BMPRIA and BMPRII. (3)
Transducing mesenchymal stem cells treated by BMP-2 with a lentiviral vector
carrying pFUG-TF reporter gene has no adverse on cell viability, proliferation,
and differentiation ability. (4) Mesenchymal Stem Cell Treated by BMP-2
could survive and propagation in the acute myocardial infarction model
Keywords: Mesenchymal stem cells, Bone morpho-genetic protein-2, lentiviral
vector, bioluminescence, PET
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169 THE ROLE OF TOLL-LIKE RECEPTOR SIGNALING
IN ATTENUATING NEUROGENESIS OF NEURAL STEM/
PROGENITOR CELLS ALLOGRAFTS IN THE ADULT
HIPPOCAMPUS.
L. Phillips1, Z. Chen2, P. Carpentier2, T. Palmer2, S. Krams1, O. Martinez1
1
Surgery/Division of Transplantation, Stanford University, Stanford,
CA, United States, 2Neurosurgery, Stanford University, Stanford, CA,
United States.
Neural Stem/Progenitor Cells (NPCs) are self-renewing multipotent
progenitors that can differentiate into neurons, oligodendrocytes, and
astrocytes. Endogenous NPCs reside in the hippocampal dentate gyrus, a
region of the brain where the process of homeostatic neurogenesis continues
throughout adult life. However, the regenerative capacity of this endogenous
pool appears inadequate in a variety of central nervous system (CNS)
diseases and is severely impacted following cranial irradiation treatment for
CNS malignancies. Transplantation of NPC has the potential to repopulate,
or repair, damaged areas of the CNS. Whereas BrdU-labeled syngeneic NPC
grafts placed in the dentate gyrus differentiate and contribute to neurogenesis
within 28 days post-transplant, BrdU-labeled NPC allografts are not rejected
but instead, fail to differentiate. Interestingly, intraperitoneal injection of LPS
significantly reduces ongoing neurogenesis in the brain of normal adult mice.
These results suggest that inflammation may impair neurogenesis. Moreover,
because LPS is a potent ligand for toll like receptor (TLR) 4, these findings
suggest that TLR may play an important role in regulating differentiation
of NPC allografts. Thus, we investigated TLR2 and TLR4 expression in the
hippocampus of normal mice and mice that received a single intraperitoneal
injection of LPS (60 μ;g/kg). Using quantitative real time PCR we found that
TLR4 mRNA is constitutively expressed in normal hippocampus of Balb/C
(mean=0.026 relative units (RU) compared to GAPDH) and C57Bl/6 mice
(mean=0.028 RU). TLR4 mRNA expression is increased in the hippocampus
of C57Bl/6 mice by 4.7 fold (mean=0.13 RU) 72 hours after LPS injection.
TLR4 protein is expressed at highest levels on glial cells in the dentate gyrus as
determined by immunohistochemical staining. TLR2 mRNA was also detected
in the hippocampus of normal Balb/C (mean=1.48 RU) and C57Bl/6 mice
(mean=1.77 RU) but unlike TLR4, LPS injection did not affect TLR2 levels
in C57Bl/6 mice (mean=2.75 RU). However, the levels of TLR2 and TLR4 in
the normal mouse hippocampus are significantly lower than the corresponding
TLR levels in normal spleen (31.5 RU and 6.39 RU, respectively). These results
indicate that inflammation augments TLR4 expression in the brain and suggest
that TLR and the innate immune response may participate in attenuating
neurogenesis following transplantation of NPC allografts.
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170 3-D CULTURING OF HUMAN MESCHYMAL STEM
CELLS IN ROATING WALL VESSEL AS A FASTER METHOD
FOR IN VIVO REPAIR
S. Sharp1, W. Cerwinka2,3, C. Yates1, H.E. Zung1, L. Chung1
Department of Biology and Center for Cancer Research, Tuskegee
University, Tuskegee, Alabama, USA, 2Georgia Pediatric Urology, Emory
University School of Medicine, Atlanta, Geordia, USA, 3Department of
Urology, Emory University School of Medicine, Atlanta, Geordia, USA
The transplant community has been forced to consider other therapeutic
options for dealing with end-stage organ failure. Current challenges include
insufficient number of donor organs, negative side affects from continuous
immunosuppression, and immunological incompatibility dictate the need for
additional solutions. Human mesenchymal stem cells (hMSC) offer a new
therapeutic approach to circumvent these challenges. Within this study we
cultured commercially available hMSC harvested from human bone marrow,
onto a surgifoam a porous and absorbable gelatin, in microgravity conditions
utilizing the NASA designed Rotating Wall Vessel (RWV). To determine the
number of hMSCs attached to the surgifoam we quantified the DNA content per
spheroid. Surgifoam loading of 2, 3, and 4 million cells were evaluated in 10
ml medium with 3 million cells yielding optimal surgifoam cell loading. Time
to maximum spheroid size was also evaluated by harvesting spheroids at day 1,
2, 3, 4, and 8. Spheroid DNA was quantified and cell number extrapolated by
establishing a standard curve. Maximum carrier loading was seen at day 3 with
1
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1.3; n=5) compared to MSC-vIL10 (1.21+ 0.6; n=7) & MSC (1.6+0.9; n=6)
treated groups. Neutrophil infiltration, microvascular permeability and wet:
dry ratio of the lung were lower in MSC-vIL10 treated animals. Inflammatory
mediators IL-1á, MCP-1á, MIP-1á, & IL1-â protein levels were markedly
increased in the injured lung compared to sham operated controls; their
analysis in MSC, MSC-vIL10 treated & untreated groups are underway. MSC
were highly positive for stem cell markers CD29, CD90, and CD44 (70-95%)
and weakly positive for CD31, CD34, CD45, CD80, CD86, CD11b, MHC
Class II (0-24%).
Conclusion: MSC and IL-10 delivery via MSC to prevent IR injury in lung
transplants seems promising.
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a mean of 367,000 cells per spheroid. This is in direct contrast to other systems
that use longer time windows to allow for cell adherence to the scaffolding.
Upon, histological examination of the spheroids cultured in the RWV, we found
in the H&E and TEM that these spheroids exhibited multicelluar structures,
and close cell-cell contact. Upon further characterization of these spheroids we
were able to observe that 3 day spheroids retain their undifferentiated stem cell
characteristics (ability to differentiate into multiple lineages and expression of
stem cell markers). This was evidenced by these spheroids being induced to
chondrogenic (collagen II). osteogenic (von Kossa). and adipogenic (oil red
staining) differentiation by day 7 after induction, in the presence of lineage
specific differentiation media respectively. Although preliminary, these results
describe a novel model for the utilization of patient derived hMSC as cellular
therapy for organ repair. Mesenchymal stem cells are found in abundance in
bone marrow and may be easily harvested from bone marrow thereby avoid
rejection episodes and the waiting time for a cadaveric donor. These results
offer a strong case for exploring the possibilities that hMSCs when harvested
from the patients own bone marrow, introduced to the RWV system, and
transplanted in to a differentiation inducing media could be a link for in vivo
and or in vitro regeneration of organs for transplantation
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CONCURRENT ORAL SESSION 11: CAN AND FIBROSIS
171 THE ROLE OF EPITHELIAL-TO-MESENCHYMAL
TRANSITION IN TRANSPLANT TUBULOINTERSTITIAL
DAMAGE, THE FIRST 12 MONTHS
M. Vitalone1, P. O’Connell2, E. Jimenez-Vera1, A. Yuksel4, M. Wavamunno1,
C. Fung3, J. Chapman2, B. Nankivell2
1
Westmead Millennium Institute, 2Department of Renal Medicine, Wesmead
Hospital, 3Departrment of Tissue Pathology, Westmead Hospital, 4Histology,
Westmead Millennium Institute
Background: Tubular epithelial cell transition into myofibroblasts (EMT)
following injury has been postulated to cause the tubulointerstitial fibrosis seen
in renal transplants. The study aim was to prospectively assess EMT prevalence
by histochemistry and transcriptome profiling early after kidney transplantation;
in order to evaluate its contribution to later fibrosis. Methods: Protocol kidney
transplant biopsies at implantation, 1, 3 and 12months (n=85 biopsies, 24
patients). were dual-stained for E-cadherin and α;SMA (immunoperoxidase)
or S100A4 (immunofluorescence) to identify EMT. Interstitial fibrosis was
measured by image analysis using Gomori trichrome stains, and blinded
slides were scored by the Banff criteria. From snap-frozen samples, RNA
was extracted, processed into cDNA and hybridized onto 8K human cDNA
microarrays. Analysis for differential expression of EMT-associated genes was
validated by QRT-PCR of 12 EMT/MET markers.
Results: Transplant tubulointerstitial damage (TID) on protocol biopsy
increased from 34% at 1month, to 54% at 3months. EMT via α;SMA was found
in 61% of biopsies located in tubules, tubular lumen and interstitial space, but
was present at low levels across all times points and did not increase over
time. Using the less specific but a more sensitive marker, S100A4 showed a
much higher incidence of EMT, which also did not increase over time. Dual
staining with either marker of EMT (aSMA or S100A4) did not correlate with
TID (ci, ct, measured fibrosis) or serum creatinine on contemporaneous or
sequential histology at any time point, instead being correlated with subclinical
immune activity (r=0.6, P<0.05). In TID samples, microarrays showed
differential expression of 127 genes at 1month (B value>1, P<0.01) and 67
genes by 3months (B>1, P<0.015). predominantly associated with fibrosis,
tissue remodelling and immune response. Of the 173 EMT-associated genes
interrogated, 8.1% (COL1A2, MMP2, FAP, TWIST, etc) showed significant
differential expression at 1 or 3 months; however the remainder 91.9% were
not differentially altered or discordant to an EMT pattern (CTGF, TGFBR3
and TIMP2 all showing anti-EMT expression). QRT-PCR of 12 key EMT
markers showed appropriate up-regulation of 2 genes (S100A4 and BCAT) in
association with TID.
Conclusion: EMT was observed in protocol histology soon after transplantation,
but occurred in isolated tubular cells at varying levels on biopsy. It was
unaccompanied by evidence of intracellular EMT gene activation or subsequent
tubulointerstitial damage, suggesting a minor role in early transplant fibrosis.
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172 PROGRESSION OF INTERSTITIAL FIBROSIS AND
TUBULAR ATROPHY IN THE FIRST YEAR AFTER RENAL
TRANSPLANTATION: EARLY PROGRESSION ESPECIALLY IN
NON-HEART BEATING KIDNEYS
M.H.L. Christiaans1, M.A.C.J. Gelens1, F.M.E.G. Steegh2, J.P. van Hooff1,
R.J. van Suylen2, E.L.W. van Heurn3, C.J. Peutz-Kootstra2,
1
University Hospital Maastricht,department of internal medicine, 2University
Hospital Maastricht, department of pathology, 3University Hospital
Maastricht, department of surgery
Introduction: Chronic allograft damage is a major cause of graft loss. This is
already seen early after renal transplantation and is characterized by interstitial
fibrosis and tubular atrophy (IF/TA).
In this study we investigated which clinical factors are associated with the
increase in IF/TA from implantation to 12 months after transplantation in
patients receiving a tacrolimus (TAC) -based immunosuppressive regimen in
combination with mycophenolate mofetil (MMF) or sirolimus (SRL) and =<
10 days steroids.
Methods: From April 2003 until January 2006, two TAC-based
immunosuppressive regimens were in use: one with low dose (1 mg) SRL and
the other with MMF 500 mg bid. Steroids (10 mg/d) were stopped within 10
days. In patients who experienced biopsy proven acute rejection, steroids were
maintained or reintroduced, and tapered to 5 mg daily maintenance in the next
2 months.
Protocol biopsies were taken after revascularization (zero hour). at 3 and 12
months. All contained at least 5 glomeruli and 1 artery. From 59 recipients
both a zero and 3-month biopsy were collected. A 12-month biopsy was also
available from 56 of these recipients. A blinded pathologist scored the biopsies
according to the Banff 2005 criteria: IF/TA score 0: no interstitial fibrosis (ci)
and tubular atrophy (ct). 1: mild ci and ct (<25% of cortical area). 2: moderate
ci and ct (26-50% of cortical area). 3: severe ci and ct (>50% of cortical area).
Statistics: Data are given as median or percentage. SPSS was used for nonparametric testing (Wilcoxon). and multiple linear regression (independent
parameters: donor age, donor type, occurrence of acute rejection < month 3
(yes vs. no). type of additional immunosuppression (SRL vs. MMF). use of
steroids at month 3 (yes vs. no). anastomosis time, Cold Ischemia Time (CIT).
Results: Nineteen patients received a living kidney-donor (LK, 34%). 18
patients a post-mortal heart-beating kidney (HB, 32%). and 19 patients received
a post-mortal non-heart-beating kidney (NHB, 34%).
Recipient age at transplantation was 51 years, donor age was 48.5 years,
recipient male gender 62.5%, steroids-use at three months 18%, anastomosis
time 30 minutes, and CIT of the post-mortal donors was 18 hours.
In the zero hour biopsy, the IF/TA score was only significantly correlated
towards donor age (more in older donors). but not to the other parameters,
including donor type.
IF/TA score rose significantly both between month 0 and month 3 (from 0.64
to 1.27; p<0.001 Wilcoxon). and between month 3 to month 12 (from 1.27 to
1.50, p=0.04, Wilcoxon).
In a multiple linear regression analysis using progression of IF/TA score in
the first three months as the dependant factor and using the recipient, donor
and transplant parameters as independent factors, only donor source was
a significant predictor of the increase in IF/TA (p=0.004). The increase was
significantly higher in biopsies of NHB donors.
In multiple regression analysis of progression of IF/TA scores between 3 and
12 months none of these parameters were statistically significant.
Conclusions: In the first year after renal transplantation there is a significant
increase in interstitial fibrosis and tubular atrophy (IF/TA).
This increase is not related towards the use of SRL 1 mg vs. MMF 500mg bid,
the occurrence of acute rejection or the use of corticosteroids.
A major increase occurs especially in NHB donors during the first three months
after transplantation.
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173 RAPAMYCIN REDUCES VASCULAR INJURY BUT
EXACERBATES PROTEINURIA IN ASSOCIATION WITH
INHIBITION OF VEGF AND VEGF-R IN CHRONIC KIDNEY
ALLOGRAFT DYSFUNCTION

174 HOST ENDOTHELIAL AND MESENCHYMAL
CHIMERISM IN EXPERIMENTAL CHRONIC ALLOGRAFT
NEPHROPATHY
J.L. Hillebrands1, H. Rienstra1, M. Boersema2, A. Zandvoort1,5, A. Smit-van
Oosten5,
H. van Goor3, J. Rozing1, G.J. Navis4,
1
University Medical Center Groningen, Dept. Cell Biology – Immunology,
2
University Medical Center Groningen, Dept. Pathology and Laboratory
Medicine, Div. Medical Biology, 3University Medical Center Groningen, Dept.
Pathology and Laboratory Medicine, Div. Pathology, 4University Medical
Center Groningen, Dept. Internal Medicine, Div. Nephrology, 5University
Medical Center Groningen, Central Animal Facility
Background: Vascular and interstitial remodeling are hallmarks of chronic
allograft nephropathy (CAN). Vascular remodeling (transplant arteriopathy)
is characterized by occlusive neointima formation resulting from uncontrolled
smooth muscle cell (SMC) proliferation. Interstitial remodeling is characterized
by myofibroblast recruitment and proliferation culminating in interstitial

175 CTGF SIRNA CAN PREVENT RATS RENAL ALLOGRAFT
FIBROSIS
Y.P. Lu, G.H. Luo, J. Song, L. Yang, L. Luo, X. Ma, L.Y. Zhang, Y.P. Li
Transplantation Institute of west china hospital
Aim: CTGF is a highly profibrogenic molecule implicated in renal fibrogenesis.
Small interfering RNA (siRNA) is an effective tool to silence gene expression.
This study is to determine if siRNA targeting CTGF can inhibit CTGF
expression of rat kidneys in vitro and vivo and whether it can protect the kidney
from renal fibrosis in rats undergoing chronic allograft nephropathy (CAN).
Methods: Rat TEC-line (NRK-52E) anoxia model was built; siRNA-targeting
CTGF was transfected into cells by liposome package. The rat renal CAN
model, which was reinforced by cold ischemic injury, was built by using
Fisher344 rat and Lewis rat as donor and recipient, respectively. At 6w after
transplant, the recipients were divided into three groups: (1) Vehicle: vehicle
orally; (2) Control siRNA; (3) siRNA. The group 2 and 3 were given Control
siRNA and siRNA-targeting CTGF (0.1mg/kg). respectively Qd×14d by caudal
vein injection. The morphological changes and cytoskeleton remodeling in
NRK-52E cells were detected. SCr and the pathologic changes were measured
and observed; the expression of CTGF, E-cadherin, collagen I, IV and α-SMA
were assessed.
Results: After stimulated with anoxia, NRK-52E cells became round, enlarged
and cytoskeleton remodeled. The expression of CTGF were up regulated since
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H-T. Ko1,2, J.L. Yin1, V. Levidiotis1, K.R. Wybunn1, J.M Eris1, A/Prof Steve J
Chadban1
1
Renal Medicine, Royal Prince Alfred Hospital, 2University of Sydney
Background: Recent immunosuppressive therapy outcomes suggest
Rapamycin (Rapa) can halt chronic kidney allograft dysfunction (CAD). but
treatment with Rapa is often associated with new onset proteinuria. Vascular
endothelial growth factor (VEGF) has a significant role in atherosclerosis,
fibrosis and glomerulosclerosis. VEGF can induce migration and proliferation
of endothelial cells and regulate vascular and glomerular permeability through
VEGF receptor 1/2 (VEGR1) and (VEGFR2). The mammalian target of
rapamycin (mTOR) is known to regulate VEGF production, but the role of
the mTOR inhibitor, Rapa, in the VEGF/VEGFR meditated pathway, during
the development of CAD is unknown. In this study, we investigate the roles of
VEGF and VEGFR1/2 in a rat model of CAD,
Methods: F344 to Lewis rat kidney allografts were performed. Animals were
either treated with Rapa (N=6) or CsA (N=6) for 180 days. Alongside this
model, a model of CAD was developed. Animals were either treated with CsA
or Rapa for 10 days post transplantation, thereafter no immunnosuppresion was
used, until animals were sacrificed at 180 days. Glomeruli and arteries were
separated by laser capture microdissection. Results of the treatment with CsA or
Rapa were determined by renal function and histopathology. VEGF, VEGFR1
and VEGFR2 expressions were determined by immunohistochemistry and realtime PCR. In vitro the effects of Rapa or CsA on VEGF production was also
determined on endothelial cell tubular cells, mesangial cells and podocytes.
Results: The CAD model was confirmed at 180 days by the detection
of proteinuria and histopathological findings of intimal-arteritis and
glomerulosclerosis. These CAD changes were ameliorated in the 180 day
treated CsA (1.5 mg/kg) and Rapa (1.0 mg/kg). recipients, as demonstrated
by improved proteinuria, macrophage infiltration and glomerulosclerosis (all
p<0.01). In the 180 day CsA-treated and Rapa-treated groups the expression of
CXCR3, IL-10, IL-12, IL-18 and IFN-γ were reduced (all p<0.05). no change
was noted for TGF-β. Uniquely in the 180 day CsA-treated recipients, intimalarteritis was significantly increased compared to the Rapa-treated recipients
(p<0.05). Proteinuria was greater in the 180 day Rapa-treated recipients
compared with 180 day CsA-treated recipients (p<0.05). Moreover, the levels
of VEGF, VEGFR1 and VEGFR2 in glomeruli were significantly lower in 180
day Rapa-treated recipients (all p<0.05). Arterial levels of VEGF and VEGFR1
were reduced, in the 180 day Rapa-treated recipients however there were no
tubular expression differences. In vitro, Rapa and CsA did not inhibit VEGF
production in stimulated tubular and mesangial cells, Rapa however reduced
VEGF podocyte and endothelial cell production (p<0.05).
Conclusion: These results support the hypothesis that long-term Rapa but
not CsA treatment can reduce intimal-arteritis. Moreover Rapa can induce
significant proteinuria and one possible mechanism maybe by way of reduced
podocyte-VEGF and VEGFR1/2 production. These findings significantly
contribute to our understanding of the possible mechanisms and mediators of
CAD

fibrosis. Both transplant arteriopathy and interstitial fibrosis supposedly lead to
deterioration of graft function. The origin (graft vs. host) of neointimal ECs and
SMCs as well as interstitial myofibroblasts in CAN still is a matter of debate.
We therefore determined the origin of ECs, SMCs and myofibroblasts in an
experimental model of CAN in rats.
Methods: Dark Agouti (DA) allografts were transplanted to human
Placental Alkaline Phosphatase (hPAP) transgenic F344 rats. hPAP F344
rats constitutively express hPAP in nucleated cells which can be detected by
hPAP-specific immunostaining. DA isografts served as controls. Recipient
rats received ciclosporin (5 mg/kg) on the first 10 days after transplantation.
Contralateral nephrectomy was performed 10 days after transplantation. Renal
function was determined before transplantation and 4, 8 and 12 weeks after
transplantation. Recipients were sacrificed 12 weeks after transplantation or
earlier in case of poor condition. Grafts were processed for histological analysis
and severity of transplant arteriopathy, glomerulosclerosis and interstitial
fibrosis was determined. Furthermore, host EC, SMC and myofibroblast
chimerism was determined by specific immunofluorescent staining using the
following antibodies: RECA-1 (ECs). 1A4 (á-smooth muscle actin [SMCs/
myofibroblasts]). MN4-91-6 (DA MHC class I) and anti-hPAP (transgene).
Results: Compared with isografts, allografts presented with severe CAN
characterized by glomerulosclerosis, tubular atrophy, transplant arteriopathy
and interstitial fibrosis. These histological changes were associated with
reduced renal function as indicated by proteinuria and reduced creatinine
clearance. Graft survival was inversely correlated with the severity of
transplant arteriopathy. Immunolabeling for hPAP, DA MHC class I and
smooth muscle actin revealed graft origin (co-expression DA MHC class I and
smooth muscle actin) of virtually all neointimal SMCs in allografts. Similar
results were obtained for neointimal ECs. However, host EC-chimerism
was detected in peritubular and glomerular capillaries; 62% of glomeruli in
allografts contained host-derived ECs (RECA-1+hPAP+; ~2 host ECs/chimeric
glomerulus/cross-section). Staining for smooth muscle actin revealed increased
numbers of cortical interstitial myofibroblasts in allografts (vs. isografts).
indicative of interstitial fibrosis. Immunolabeling for hPAP, DA MHC class I
and smooth muscle actin revealed presence of both graft- and recipient-derived
interstitial myofibroblasts. Quantitative analysis revealed 53% of interstitial
myofibroblasts to be of host-origin.
Conclusions: Neointimal SMCs and ECs in CAN are graft-derived indicating
that endothelial repair as well as neointima formation in graft arteries are
mediated by cells residing within the graft. In contrast to vascular remodeling
in the larger arteries, the development of interstitial fibrosis involves both
graft- and host-derived myofibroblasts. These results suggest that interstitial
myofibroblasts are derived from distinct cell lineages, which may separately
or in concert contribute to interstitial fibrosis in CAN. We propose that hostderived mesenchymal progenitor cells are a putative target for therapeutic
intervention. Reduced mesenchymal progenitor cell recruitment is expected to
attenuate interstitial fibrosis resulting in prolonged graft function.
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6h, and reached its peak at 48h. The transfection efficiency of siRNA was found
over 85%. The silencing effect on CTGF mRNA/protein in siRNA group was
found since 6h/12h, and reached its peak at 12h/24h in the TEC cells. After
exposed with siRNA-targeting CTGF, the morphology and cytoskeleton of TEC
cells tended into normal range in the cell anoxia model, and fibrosis-associated
genes also down regulated. In rat renal CAN model, SCr (μmol/L) increased
gradually at 4w (110±55.84) and 6w (228± 43.27). At 8w, SCr in Vehicle,
control siRNA and siRNA group was 285±15.51, 278±10.21 and 190±24.02,
respectively. At 8w, the Banff score in siRNA group was 2.330.58, which was
significantly lower than that in Vehicle (5.001.00) and in control siRNA group
(5.671.52). p<0.05. At 8w, the expression of mRNA/protein (DQ ratio) of CTGF
were significantly down regulated in siRNA group (22.66±0.76/0.74±0.02) than
those in Vehicle (25.00±0.50/1.04±0.11) and in control siRNA group (25.00±0.86/1.00±
0.02). p<0.01. The expression of type I, IV collagen and a-SMA were also
significantly down regulated and E-cadherin lose was abated in siRNA group
than those in Vehicle and control siRNA group at 8w.
Conclusions: This study at first time shows that CTGF siRNA can significantly
inhibit the expression of CTGF and EMT-associated genes in rat kidneys
and can effectively prevent the fibrosis in cell anoxia model and in rat renal
allografts undergoing CAN. The results suggest that siRNA-targeting CTGF
has the potential to be a novel therapeutical strategy for anti-CAN.

176 ADENOVIRUS-MEDIATED ANTISENSE ERK2 GENE
THERAPY INHIBITS THE PROCESS OF EPITHELIALMESENCHYMAL TRANSITION AND AMELIORATES
CHRONIC ALLOGRAFT NEPHROPATHY IN A RAT MODEL
Z. Ding, X. Chen, Z. Chen, X. Chen, N. Gong
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College
Objective: To investigate the effect of Adenovirus-mediated antisense ERK2
(Adanti-ERK2) gene therapy upon the process of epithelial-mesenchymal
transition and the protection of graft against chronic allograft nephropathy in
vivo.
Methods: Male Lewis (LEW, RT11) rat received male Fisher (F344, RT11v1)
renal allograft. The recipients were divided into three groups: (1) control group
(no gene transfected); (2) vector control group (allograft transfected with AdLacZ, 5x109); (3) gene therapy group (allograft transfected with Adanti-ERK2,
5x109). All recipients were sacrificed for grafts and serum at 24 weeks after
transplantation. Morphometric analysis was used to determine the fibrosis of
grafts. Immunohistochemistry was used to detect the expression of E-Cadherin,
Vimentin, ¦Á-SMA and the infiltration of CD4+ T lymphocyte, CD8 + T
lymphocyte and ED-1 + monocytes. ELISA was used to detect the change of
TGF-¦Â1 in serum.
Results: The grafts in control group and vector control group showed with
graft interstitial fibrosis and infiltration of CD4+ T lymphocyte, CD8 + T
lymphocyte and ED-1 + monocytes in renal interstitium. In the control groups,
the renal tubular epithelial cells expressed less E-Cadherin but the interstitium
expressed more Vimentin and ¦Á-SMA in comparison with the gene therapy
group, indicating the Adanti-ERK2 inhibited the process of EMT in the
allografts. Meanwhile, the moderate fibrosis and less T lymphocytes and ED-1
+ monocytes infiltrating in the interstitium was observed in gene therapy group,
showing chronic allograft nephropathy was ameliorated. Compared with the
control groups, the serum expression of TGF-¦Â1 in gene therapy group was
down-regulated.
Conclusion: Adanti-ERK2 gene therapy inhibits epithelial-mesenchymal
transition of the renal tubular. This effect would be close relatively with graft
protection by attenuating graft fibrosis, decreasing infiltration of CD4+ T
lymphocyte, CD8 + T lymphocyte and ED-1 + monocytes in interstitium, and
down-regulating TGF-¦Â1 level of serum. .
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177 BIOLOGICAL AGEING IN PRE-TRANSPLANT RENAL
ALLOGRAFT BIOPSIES PREDICTS ORGAN FUNCTION AT 6
MONTHSPOST TRANSPLANT
L. McGLynn, K. Stevenson, K. LAmb, S. Zino, M. Brown, P. Shiels
University of Glasgow
As the number of available organs for transplantation is limiting the use of
organs from older, or marginal donors increases, though this may result in
poorer transplant outcome. Even though such organs may function adequately
initially, the presence of substantial physiological senescence will make them
more susceptible to the effects of transplant-related stress.
As a consequence, the biological age of the organ, rather than just its
chronological age, may have substantive impact on post transplant organ
function. This implies that the expression of genes involved in biological
ageing, should provide suitable reporters for investigating such a hypothesis.
We have undertaken an investigation using a range of markers corresponding
to a variety of biological ageing components, linking telomere biology, DNA
damage and cell cycle regulation.
We have analysed the expression of these markers in pre transplant renal
biopsies, taken immediately prior to organ engraftment, to determine how donor
age and the biological age of the organ at the time of transplantation impact
upon post transplant renal function, as determined by creatinine clearance (CC)
six months after transplantation.
Methods: Cortical biopsies of renal transplants were obtained using an 18
gauge needle from transplants of varying donor ages (9 years to 78 years old).
These were derived from cadaveric or living donor organs prior to engraftment.
Quantitative real time PCR (qRT-PCR) was used to estimate mRNA levels
corresponding to the reporter genes p16ink4a, XRCC5, POT1 and SIRT2. Data
analyses were performed using an SPSS statistical package. Power calculations
for biopsies were undertaken using the Minitab Statistical package where
?=0.52,?=0.05 and 1-? = 1.000.
Spearmans rank correlations were used to evaluate inter gene expression
comparisons.
Results and Discussion: Creatinine clearance at six months post transplant
showed significant negative correlations with donor age (p<0.000 n=59 ). DNA
damage (XRCC5 expression: p=0.043, n=43) and cell cycle (Sirt 2 expression:
p=0.048,n=41). in keeping with the previous observations describing poorer
post transplant function from older donor organs. No significant correlations
were observed with any of the other markers tested.
Older organs did display a significant positive correlation with p16 ink4a
expression (p=0.042, n=40). indicating elevated levels of biological age.
The level of p16 ink4a displayed significant positive correlations with Sirt 2
(p=0.001, n=51) and the telomere associated marker POT 1 (p=0.012, n=42).
The expression of POT 1 also showed a strong positive correlation with XRCC5
(<0.000, n=49) and SIRT 2 (<0.000). SIRT 2 correlated positively with XRCC5
expression (<0.000 n=53).
These data suggest that biological age strongly influences graft function post
transplant. The association between p16 and chronological age indicates that
the poorer outcome observed with older allografts is due to elevated cellular
senescence in such organs. Our data also indicate that DNA damage (XRCC5).
cell cycle destabilisation (SIRT 2) and telomere destabilisation (POT1)
contribute to post transplant graft function at 6 months.
These should provide useful prognostic markers for pre-transplant evaluation
of subsequent graft function.

178 INFLUENCE OF NICOTINE ON CIGARETTE SMOKE
INDUCED RENAL DAMAGE IN ORGAN TRANSPLANTATION:
AN IN VITRO STUDY WITH RENAL CELLS
M. Mehra, A. Khanna, J. Xu, P. Uber, C. Baquet,
University of Maryland, Baltimore
Background: Cigarette smoking accelerates and promotes the progression of
chronic kidney diseases and is also responsible for decreased quality of life
of organ transplant recipients. Since nicotine is the main pharmacologically
active constituent of cigarette smoke, we performed studies to understand the
complex relationship between Nicotine and immunosuppressive drugs with
respect to tissue repair molecules and oxidative stress the major players in the
development of transplant nephrotoxicity.
Methods: We studied HK-2: an immortalized proximal tubule epithelial (PTE)
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179 ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) AND
PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) DONOR
GENETIC POLYMORPHISMS ARE OF SIGNIFICANCE IN ONEYEAR KIDNEY ALLOGRAFT FUNCTION
M. Klinger, M. Krajewska, K. Koscielska-Kasprzak, D. Drulis-Fajdasz W.
Weyde, K. Madziarska, O. Mazanowska
Department of Nephrology And Transplantation Medicine, Wroc³aw Medical
University
The quality of the transplanted organ is a decisive factor for short- and longterm allograft survival. The genetic characteristics of the donor are significant
for ischemic reperfusion injury and repair. Therefore the aim of this study
was to evaluate the impact of functional polymorphisms of selected donor
factors involved in vascular wall damage. The genetic polymorphisms tested
were: fetuin A, homocysteine, plasminogen activator inhibitor-1 (PAI-1).
metalloproteinase 9 (MMP-9). myeloperoxidase (MPO). endothelial nitric
oxide synthase (eNOS). interleukin 1â (IL-1â). interleukin 6 (IL-6). and
C-reactive protein (CRP). and their effects on kidney allograft function one
year after transplantation were analyzed.
Material and Methods: The study group encompassed 89 donors (55 males,
34 females, mean age: 46.8±11.6 years) from whom 125 kidney allografts
were obtained. The source of donor DNA was cryopreserved lymphocytes
or splenocytes remaining after histocompatiblity typing. AHSG 1/2, MMP9
-1562 C/T, IL6 -174G/C, IL1â 3954C/T, MTHFR 677C/T, MTHFR 1298A/C,
NOS3 -786C/T, and PAI1 4G/5G single-nucleotide polymorphisms (SNPs)
were determined with the use of sequence-specific probe PCR (SSP-PCR) with
allele-specific primers and an HGH or DRB1 internal control. Genotyping of
MPO -463G/A and allele A of CRP -390C/T/A was performed as Acil or Spel
restriction fragment length analysis. NOS3 IV a/b polymorphism, which is
a VNTR (variable number of tandem repeat) polymorphism, was genotyped
by gel electrophoresis of the respective PCR-generated DNA fragment. All
genotyping procedures were verified by DNA sequencing of the selected
samples. The function of the transplanted kidney was evaluated on the basis
of eGFR using the Cockcroft-Gault or Modification of Diet in Renal Disease
(MDRD) equation. Statistical analysis was conducted using the Statistica 7.1

computer program.
Results: The presence of donor genotype aa of the eNOS gene polymorphism
was connected with worse kidney allograft function after twelve months
(p=0.003). Occurrence of the aa genotype was also linked with acute rejection.
Affirmation of the significance of the connection by multivariable analysis
proved the independence of this factor’s impact. Allograft function was also
significantly affected by donor PAI1 gene polymorphism. The lowest values
of glomerular filtration rate after twelve months were achieved by recipients
who received a graft with the homozygotic 5G polymorphism (p<0.004).
The remaining tested polymorphisms did not significantly influence one-year
allograft function.
Conclusion: It is shown for the first time that endothelial nitric oxide
synthase (eNOS) and plasminogen activator inhibitor-1 (PAI-1) donor genetic
polymorphisms are significant independent factors in long-term kidney
allograft function.

CONCURRENT ORAL SESSION 12: LIVER: VIRAL HEPATITIS
180 IN VIVO PROTECTION AGAINST HCV BY BROADLY
NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
N. Kneteman, M. Law, T. Maruyama, J. Lewis, E. Giang, D. Burton
Dept of Surgery, University of Alberta, Edmonton; Depts of Immunology and
Molecular Biology, Scripps Research Institute, La Jolla, Ca
Introduction: The extreme variability due to quasispecies evolution of HCV
has challenged efforts at both vaccine design and passive immunotherapy.
Two previous clinical trials attempting to prevent HCV re-infection after liver
transplant with human anti-HCV immunoglobulin preparations failed, as did a
recent trial with anti-HCV monoclonal antibodies (mAbs).
Methods and Results: Utilizing an Fab phage-display library, 115 clones with
specific binding to HCV E2 were isolated and 3 groups recognizing specific
antigenic regions were generated. After conversion to full length IgG1s,
binding affinities ranged from 0.4-6 nM, but only mAbs specific for antigenic
region 3 (AR3) reacted with both genotype 1a and 2a E1-E2 complex and cross
–neutralized JFH-1 virus and many HCV pseudotypes. To test the ability of
these broadly neutralizing AR-3 specific mAbs to protect against heterologous
HCV quasispecies as are encountered in clinical infection, 3 groups of 6 SCID/
uPA human liver chimeric mice with high level human hepatocyte repopulation
received 200mg/kg of 2 AR3 mAbs (AR3A, AR3B) or isotype control Ab IP
24 hours prior to IV inoculation with genotype 1a infected human serum (2 X
105 copies).
All 4 surviving control mice demonstrated high titre HCV. HCV was detected
in 5 of 9 mice in the treatment groups on day 1, but was cleared in all on day
6 after virus challenge. 3 of 5 AR3A treated mice demonstrated breakthrough
infection on days 14, 21, and 28 with 2 protected through 6 weeks. While 1
AR3B treated mouse demonstrated breakthrough at week 3, 3 of 4 AR3B
treated mice remained HCV negative through 6 weeks at which time Ab level
would be predicted to have declined to <10% initial neutralizing serum level.
Conclusions: These results demonstrate the ability to protect against a
heterologous HCV quasispecies swarm with mAbs against AR3 of HCV E2 and
raise the potential for such mAbs to achieve protection from HCV reinfection
after liver transplant.

181 DOES INTERFERON USE PRIOR TO LIVER
TRANSPLANT INFLUENCE HEPATITIS C OUTCOMES
FOLLOWING TRANSPLANTATION?
G. Smallwood, C. Fasola, A. Stieber, T. Heffron
Emory University School of Medicine
The most frequent reason for liver transplantation in this country is due to
complications of hepatitis C (HCV) with recurrence of HCV being universal.
Recent reports have shown that both patient and graft survival for the HCV
patient following transplant have decreased over time. Whereas use of
interferon products has become wide spread with the majority of HCV patients
are currently being treated prior to transplant.
Aim: To review the outcomes of HCV patients that have received interferon
products prior to liver transplant compared to HCV patients that never received
interferon prior to transplant.
Method: Single-center, retrospective review of patients transplanted for HCV
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cell line from normal adult human kidney obtained from ATCC by growing them
in OPTI-MEM (5% FBS). Using a 96 well plate, we cultured 10-5 cells in each
well overnight. The cells were replaced with serum free medium and treated
with SRL (100 nM). Nicotine (10-7 M, a concentration found in the plasma
of active smokers) and MMF (10 microM) either alone or in combinations.
After 24 h of treatment cells were treated with tetrazolium salt WST-1. Using
Real time PCR mRNA for TGF-ƒÒ, CTGF, NADPH oxidase components and
western blot for p22phox and NOX-1 protein expression was studied. The
results are presented as Normalized fold expression (Mean ¡Ó SEM, n=3) using
ƒÒ-actin as a reference gene and untreated PTE cells as a control.
Results: The results were calculated as the difference in percent inhibition with
respect to the OD of treated and untreated cells (all in triplicate). SRL (-52.7
¡Ó2.85%). Nicotine (-47.3 ¡Ó3.84%) and MMF (-53.3¡Ó2.4%) in isolation
resulted in significantly decreased viability of PTE cells. Combination of SRL
with either Nicotine (-63 ¡Ó2.3%, p<0.04) or MMF (-64.3¡Ó1.45%, p<0.02)
further worsens cell viability. More importantly, the combination of SRL and
MMF in the presence of nicotine has the worst effect on cell viability (-78 2%,
p<0.007) compared to SRL alone. Nicotine treatment of PTE cells resulted in
increased mRNA expression of TGF-ƒÒ (13.7 ¡Ó 1.3- folds). CTGF (14.45
¡Ó 2.2) OPN (10.3 ¡Ó 0.74). Renin (3.89 ¡Ó 0.52). p22phox (17.9 ¡Ó 1.06).
NOX-1 (16.45 ¡Ó 1.35) and Rac-1 (12.42 ¡Ó 0.87). and decreased mRNA
expression of antioxidants [Superoxide dismutase (SOD) 0.685 ¡Ó 0.15) and
thioredoxin (TXN) 0.472 ¡Ó 0.098]. The pretreatment of cells with inhibitor of
superoxide generator DPI reversed the effects of nicotine and Nicotine, SRL
and MMF treatment increased protein expression in PTE cells. Nicotine treated
also resulted in a significant increase in the secretion of TGF-ƒÒ protein in the
conditioned medium (p<0.01). The effects of SRL alone or in combination with
MMF on these markers were amplified in the presence of nicotine.
Discussion: The findings suggest that Nicotine amplifies the effects of SRL and
MMF on the viability of PTE and subsequent modulation of tissue repair and
oxidative stress markers. These results suggest that conventional renal sparing
regimens (SRL and MMF) possess an inherent potential for renal tubular
toxicity in transplant recipients with history of smoking. Ongoing studies in
animal and human conditions will further validate these sentinel observations.
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since December 1998 (n = 131). Patients must have received a primary graft for
a diagnosis of HCV and demonstrate survival greater than 3 months. Primary
endpoint is the effect of IFN exposure prior to transplant on post transplant
outcomes.
Results: Patients receiving interferon tx prior to transplant (preIFN group; n
= 45) had a more aggressive recurrence of HCV when compared to patients
not receiving interferon prior to liver transplant (noIFN group; n= 86). This
aggressive HCV recurrence was demonstrated by the preIFN group’s early
recurrence (181.1 ± 236 days vs. 303.4 ± 327 days; p = 0.031). frequency of
HCV recurrence [41/45 (91.1%) vs. 62/86 (72.1%); p = 0.013], and 1 year
HCV recurrence free survival [48.2% (± 0.05) vs. 20.0% (± 0.06); p = 0.005].
Most disturbing was the decreased patient survival in the preIFN group at
1yr. and 3 yr. [79.7% (± 0.06) vs. 90.5% (± 0.03); 65.7 (±0.08) vs. 75.9% (±
0.05); p = 0.05] when compared to the patients not receiving interferon prior
to transplant.
Conclusions: Based on this study, interferon use prior to transplant for the
HCV patient indicates poor outcomes following liver transplantation. Due to
the increasing numbers of HCV patients coming to transplant, validation of
these results should be of utmost importance.

182 EFFICACY OF INTERFERON Β; COMBINED
CYCLOSPORINE A TREATMENT IN THE RETREATMENT OF
CHRONIC HEPATITIS C -PROMISING ASPECT OF CONQUEST
OF POSTTANSPLANTATION HEPATITIS C
K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Background/Aim: A significant proportion of chronic hepatitis C patients
fails to achieve sustained virological response (SVR) even after the treatment
with pegylated interferon (IFN) combined ribavirin. The effective treatment
for patients who previously failed combination standard IFN plus ribavirin
or pegylated IFN plus ribavirin has not been established. Management of
these patients is the most challenging task. We have originally developed IFN
combined cyclosporine A (CsA) treatment and also reported its favorable antiHCV effect. CsA is an oral cyclophilin Inhibitor with anti-HCV activity
Methods: We included 59 patients (median age, 63) with 1) histologically
proven chronic hepatitis C, 2) genotype 1b and 3) non-responders and relapsers
to combination IFN plus ribavirin or combination pegylated IFN plus ribavirin.
We conducted the present study to confirm the efficacy, safety and tolerability
of our protocol. Serum HCV RNA level was 3900 KIU/ml. The treatments
consisted of an induction therapy, an intensified therapy and a maintenance
therapy. The induction therapy comprised intravenous 1 MU IFNβ; every 4
hours for the first 3 days, 1.5 MU IFNβ; every 6 hours for the next 4 days
and 2 MU IFNβ; every 8 hours for the following 3 weeks, totaling 168 MU
of IFNβ;. The intensified therapy was induction therapy shortened to 2weeks.
The maintenance therapy comprised of pegylated IFNα;2b and ribavirin. CsA
was given 4 times daily for a total dose of 200 mg during the induction and the
intensified therapies. Ribavirin was given twice daily for a total dose of 800 mg
or 600 mg during the maintenance therapy.
Results: The ETR and SVR rate of the present study were 73% (43/59)
and 59% (35/59). respectively. The relapse rate was 19% (8/43). SVR in
previous combination therapy relapsers was 80% (32/40) and that in previous
combination therapy non-responders was 16% (3/19).
Conclusion: We concluded that our protocol should be effective in relapsers
to the previous combination therapies. Host factor targeting treatment will
become a promising treatment option for posttransplantation HCV.

183 INTRA PORTAL DONOR SPECIFIC ANTIGEN
TRANSFUSION MIGHT PREVENT RE-INFECTION OF
HEPATITIS C VIRUS AFTER LIVING RELATED LIVER
TRANSPLANTATION IN HEPATITIS C HEPATIC CIRRHOSIS
Y. Sato1, S. Yamagiwa2, S. Yamamoto1, H. Oya1, T. Kobayashi1, H. Hokai1, K.
Hatakeyama1
1First Dept. of Surg., School of Medicine, Niigata University, 2Dept. of
Hepatology., School of Medicine, Niigata University
Re-infection of hepatitis C virus (HCV) is very important for prognosis after
liver transplantation of HCV cirrhosis. It has been reported that the 30 to 40%
of patients, who got IFN-ribavirine therapy became sustained virological
response (SVR) after liver transplantation. In the mechanism of re-infection
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of HCV, the peri-transplant immunity included the immunosuppression must
be very important for getting the solution of prevention of its infection. We
already reported that the intra-portal donor specific antigen transfusion (DST)
induced macrochimerism of donor-type NKT cells and obtained rapid reduction
of immunosuppression and steroid withdrawal. In this study, we investigated
about the influences of intraportal DST for HCV-reinfection after living related
liver transplantation (LRLT). (Patients and method) The 12 patients, who
underwent LRLT for the endo-stage of HCV liver cirrhosis from 1999 to 2007
in our hospital, were estimated about the influence of intraportal DST for reinfection of HCV. Immunological analysis by flowcytometry was performed
for the patient who got a spontaneous disappearance of HCV and 11 patients of
chronic hepatitis C who got SVR by IFN-ribavirine therapy.
Results: The 9 patients had gotten perioperative IFN therapy and intraportal
DST after LRLT. All patients could be steroid withdrawal within 2 months. The
HCV disappeared in the 6 patients of all (66.7%) after LRLT. The four of six
patients were SVR. Two patients, who could not be virological response, were
performed the IFN-ribavirine therapy after a progression to chronic hepatitis C
and the last patient did not get IFN-ribavirin therapy.
The patient who got preoperative IFN-ƒÀ revealed the macrochimerism of donor
type CD56+T cell in the graft liver one month after LRLT. The immunological
analysis about the patient, who got spontaneous disappearance of HCV two
months after LRLT, demonstrated that CD56+T cells strongly developed the
both FasL and TRAIL expressions and the suppressive receptor of NK2GA
expression. The ratio of NK cell and NKT cells among the leukocytes in the
peripheral blood was similar to the SVR patients of CHC.
Conclusion: The 66.7% of all patients, who got intraportal DST, disappeared
HCV after LRLT. In this study, the clinical and immunological findings
suggested that intraportal DST might affect for the clearance of HCV by the
both host immunity and IFN-ribavirin therapy.

184 INSULIN RESISTANCE, SERUM ADIPOKINES AND
THE RISK OF FIBROSIS PROGRESSION IN PATIENTS
TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE
COHORT STUDY
M. Charlton1, B. Veldt1,3, K. Watt1, J. Poterucha1, R. Wiesner1, J. Hay1,
C. Rosen2, J. Heimbach2, H. Janssen3
1
Mayo Clinic Division of Gastroenterology and Hepatology, Rochester,
Minnesota, USA, 2Mayo Clinic Division of Transplantation Surgery,
Rochester, Minnesota, USA, 3Erasmus MC University Medical Center,
Department of Gastroenterology and Hepatology, Rotterdam, the Netherlands
Diabetes mellitus is a risk factor for disease progression in patients with chronic
hepatitis C virus (HCV) infection. However, patients transplanted for HCV
might already be at risk of fibrosis progression even before diabetes mellitus
is manifest, if decreased insulin sensitivity occurs during immunosuppressive
treatment.
Aim: To investigate the whether the Homeostasis Model Assessment of Insulin
Resistance (HOMA-IR) can be used as a more sensitive tool to identify insulin
resistant patients at risk for rapid fibrosis progression.
Methods: Single center prospective cohort study. Serum insulin, glucose and
adipokines were measured at 4 months after liver transplantation in patients
transplanted for chronic hepatitis C between 1-1-1995 and 1-1-2005. Liver
biopsies were routinely performed at 1, 3 and 5 years after transplantation. All
patients gave informed consent.
Results: One hundred eighty-one patients were included; 27 patients (21%)
were treated for diabetes mellitus, all except 1 received insulin. Another 38
patients (15%) were pre-diabetic, defined as HOMA-IR >2.5.
During a median follow-up of 4.9 years, 51 patients developed advanced
fibrosis or cirrhosis. The 5-year occurrence of advanced fibrosis was increased
in patients treated for diabetes mellitus and in pre-diabetic patients (49.4%;
confidence interval (CI) 23.0-75.8 and 49.3%; CI 17.9-80.7, respectively)
compared to patients with normal insulin sensitivity (20.5%; CI 0.9-31.7)
(p=0.069 normal versus pre-diabetic and p=0.010 normal versus diabetes
mellitus). Neither leptin, adiponectin, insulin-like growth factor-1, tumor
necrosis factor-alpha or interleukin-6 were associated with development of
advanced fibrosis in univariate Cox regression analysis.
Time-dependent multivariate Cox regression analysis showed that insulin
resistance (Hazard Ratio (HR) 1.89; CI 1.05-3.41, p=0.033). donor age
(HR 1.43; CI 1.17-1.75, p<0.001). aspartate aminotransferase (HR 1.03; CI
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1.01-1.05, p=0.001) and bilirubin levels (HR 2.97; CI 1.14-7.72, p=0.026) were
statistically significantly associated with development of advanced fibrosis,
whereas steatosis, interferon treatment and body mass index were not.
In conclusion, HOMA-IR is an important tool to identify insulin resistant
patients at risk for rapid fibrosis progression after liver transplantation for
hepatitis C. Treatment with insulin alone had no significant beneficial effect
on the fibrosis progression rates, suggesting there might be a potential role for
treatment with insulin sensitizing agents.

U.P. Neumann, M. Bahra, J. Pratschke, P. Neuhaus
Charité, Virchow Clinic
The impact of donor age on outcome in hepatitis C positive liver transplant
recipients has been shown in a number of studies. However, analyzing large
liver transplant databases this effect has been proven for all other indications as
well. Despite this fact donor shortage is responsible for the increased acceptance
of marginal grafts in all patients. Aim of our study was to analyze donor age
related increase of fibrosis progression and mortality after liver transplantation
(OLT) in hepatitis C virus (HCV) -infected patients based on protocol liver
biopsies.
Overall 283 hepatitis C positive liver transplants in 259 recipients were
analyzed. Protocol liver biopsies were performed after 1-, 3-, 5-, 7-, and 10
years and staged according to the Scheuer score.
Overall post transplant patient survival figures were 86% at one year, 78%
at 3 years, and 72% at 5 years. Hepatitis C related patient death occurred in
41/259 (16%) of the patients. Donor age was significantly associated to overall
survival, hepatitis C related graft loss, and fibrosis progression.
The risk of hepatitis C related graft loss increased from 4.9% in patients
receiving a graft from a donor below 30 years to 14.2% in transplants with a
donor age between 30-50 years, to 27.1% in transplants with donor age between
50-65 years and 30% in older donors.
Donor age was significantly associated to all relevant outcome parameters in
hepatitis positive patients after liver transplantation. The strongest increase in
the frequency of hepatitis C related death was detected in transplants utilizing
donors > 50 years.

186 USE OF LIVER GRAFTS FROM DONORS OLDER THAN
70 YEARS IN RECIPIENTS WITH CHRONIC HCV
R. Charco1, A. Escartin1, J.L. Lazaro1, I. Bilbao1, H. Allende3, C. Dopazo1, M.
Caralt1, L. Castells2
1
Department of HBP Surgery and Trasnsplants, 2Department of Hepatology,
3
Department of Histology nt of Hepatology No
Abstract Document: The aim of the present study was to evaluate the outcome
of HCV infected patients underwent liver trasplantation (LT) with liver grafts
from donors older than 70 years.
Patients And Methods: Between 1998 and 2006, 438 underwent LT in our
Hospital, 230 of them due to chronic HCV infection. 127 of 230 HCV patients
received grafts from donors over 50 years. After exclusion for co-infection
HBV or HIV and split livers, 97 patients entered in the study.
The study group were patients underwent LT with donors aged more than 70
years (Group A, n=26). Control group was composed by patients underwent
LT with donors between 50 and 70 years (Group B, n=71). Data have been
prospectively recorded.
All patients survived for at least 1 year, with exception of patients who died due
to HCV recurrence. Median follow-up was 28.5 months (1.6-102) in Group A
and 37.7 months (3.5-112) in Group B.
Protocol liver biopsies were performed at 1, 3 and 5 years after LT or when
liver dysfunction occurred during follow-up.
Biopsies showing evidence of chronic hepatitis were scored for
necroinflammation and fibrosis according to Ishak index. Hepatitis without
fibrosis (F0). fibrosis without bridges (F1-F2). fibrosis with bridges (F3-F4)
and established cirrhosis (F5-F6).
Results: There were no differences in donor and recipient characteristics or
surgical aspects, except in UCI stay. Donors form group A has a shorter stay
in comparison with group B (1 day, r=1 to 8, vs 3 day, r=1 to 36, respectively).
During the follow-up no differences were found regarding the one-year acute

187 PRELIMINARY TRIAL OF ENTECARVIR
MONOTHERAPY AFTER CONVERSION FROM HEPATITIS
B IMMUNOGLOBULIN AND LAMIVUDINE THERAPY IN
LIVING DONOR LIVER TRANSPLANTATION FOR CHRONIC
HEPATITIS B INFECTION
H. Furukawa1, T. Shimamura2, T. Suzuki1, M. Taniguchi3, K. Yamashita3,
T. Kamiyama3, M. Matsushita3, S. Todo3
1Departmet of Organ Transplantation and Regenerative Medicine, Hokkaido
University School of Medicine, 2Division of Organ Transplantation,
Hokkaido University Hospital, 3Department of General Surgery, Hokkaido
University School of Medicine
Objectives: This prospective study to determine the safety and efficacy of
entecavir monotherapy after converted from HB immunoglobulin (HBIg)
and lamivudine (LAM) therapy for the patients with living donor liver
transplantation (LDLT) for chronic hepatitis B (HBV) infection.
Materials and Methods: From Sep. 1997 to Dec. 2006 LDLT was performed
in 118 adults in our center. Twenty four cases of patients with chronic HBV
infection who survived until the end of 2006 were involved in the study. All
patients had positive HBsAg before liver transplantation, of which 7 patients
had positive HBV-DNA. All patients received HBIg and LAM therapy after
liver transplantation. The patients had 5,000 IU of HBIG at anhepatic phase
during transplantation and daily for 7 days. HBIg was administered to maintain
HBsAb more than 500 mIU/ml first 3 months after transplantation and more
than 300 mIU/ml thereafter. The patients had 100 mg of LAM daily from the
day of transplantation. Entecavir was given in a dose of 0.5 mg daily. Of twenty
four patients in the study, 13 patients (group A) were converted to entecavir
monotherapy. Those were compared with the other 11 patients (group B)
with the continuous HBIg and LAM regimen. @Primary end point was the
recurrence of hepatitis B infection with positive HBsAg and HBV DNA. At
the entry of the study patients demographics were not significantly different
between two groups.
Results: No patients in both groups had HBV recurrence during the followup of 47 weeks. No difference was found in liver function tests between two
groups (group A vs B); total bilirubin (1.1 0.6 vs 1.1 0.5). AST (29 15 vs 25
8). ALT (27 16 vs 30 24). GGTP (58 65 vs 126 185). All patients in group
A continue on entecarvir without adverse effect. The patients in group B
received 7-11 times of 3,000 IU of HBIg to maintain HBsAb to 296.0 149.2
mIU/ml.
Conclusion: Entecavir monotherapy seems to be a promising agent to prevent
HBV infection after converted from HBIG and LAM therapy without significant
adverse effect. Further follow-up is necessary to confirm its efficacy.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

65

MONDAY

185 DONOR AGE PREDICTS RECURRENT DISEASE IN
LIVER TRANSPLANTATION RECIPIENTS WITH HEPATITIS C

rejection rate, incidence of CMV infection or incidence of vascular or biliary
complications.
A total of 189 liver biopsies were reviewed for the study. 19 patients developed
cirrhosis or died due to an aggressive recurrence, 3 (12%) in group A and 16
(22.5%) in group B (p=ns). Moreover, until 29 patients had developed at least
F3 degree fibrosis, 6 (24%) in group A and 23 (32,5%) in group B (p=ns)
Although there was a lower incidence of fibrosing cholestatic hepatitis in patients
of group A, differences were not statistical significant (11% vs 17%, p=ns).
Regarding HCV histological progression, the cumulative actuarial fibrosis
grade was similar between groups. Cumulative probability of developing graft
fibrosis ≥; F3 (fibrosis with bridges) at 1, 3 and 5 years was 23%, 64%, 64%
in group A vs 32%, 66%, 72% in group B, p=0.3. Cumulative probability of
developing graft cirrhosis at 1,3 and 5 years was 12%, 30%, 44% in group A vs
23%, 38%, 47% in group B, p=0.4.
There were no differences in the actuarial patient survival at 1, 3 and 5 years.
(Group A: 96%-77%-77% and Group B: 89%-70%-59% ).
Conclusion: Despite the small number of patients, liver grafts from donors
older than 70 years can be used in HCV recipients with similar results obtained
with the utilization of donors between 50 and 70 years old.
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188 ANTI-DONOR SPECIFIC HYPORESPONSIVENESS
INDUCED BY MINIMIZING IMMUNOSUPPRESSION CAN
LEAD TO SUCCESSFUL HEPATITIS B VACCINATION IN
LIVER TRANSPLANT RECIPIENTS
H. Tahara1,3, H. Ohdan1,3, Y. Tanaka1,3, H. Tashiro1,3, T. Itamoto1,3, T. Asahara1,3,
M. Imamura2,3, S. Takahashi2,3, K. Chayama2,3
1
Department of Surgery, Division of Frontier Medical Science, Programs for
Biomedical Research, Graduate School of Biomedical Science, Hiroshima
University, 2Department of Medicine and Molecular Science, Division of
Frontier Medical Science, Programs for Biomedical Research, Graduate
School of Biomedical Science, Hiroshima University, 3Liver Research Project
Center, Hiroshima University
Combined treatment with either a nucleoside or nucleotide analog and
hepatitis B immunoglobulins (HBIg) has been the gold standard for
prophylaxis of hepatitis B virus (HBV) reinfection after liver transplantation
(LT) due to HBV-related disease. However, indefinite prophylaxis with HBIg
has substantial drawbacks, such as escalating costs and the risk of emergence
of HBV envelope protein mutations. Therefore, active immunization with
an HBV vaccine would be a preferable alternative. Several groups have
attempted HBV vaccination of LT recipients against HBV; however, the
response rates of vaccination in all of these studies except for one trial using an
unconventional adjuvant in the vaccine have been very disappointing, ranging
from 1.9 to 40%. The immunosuppressive environment in LT recipients is
believed to elicit a poor response to vaccination. Minimizing the exposure of
the HBV-infected LT recipients to immunosuppressants would be beneficial
in inducing adaptive immunity against HBV by vaccination. In the present
study, in addition to efforts to minimize immunosuppression, prophylaxis
with HBV vaccination combined with continuous HBIg administration was
performed in 11 LT recipients who had undergone transplantation due to
HBV-related diseases. All participants received a recombinant HBV vaccine
subcutaneously every 4 weeks at a dose of 10ƒÊg in combination with HBIg
and lamivudine with/without adefovir. The response to vaccination was
defined as (1) a reconfirmed increase in the anti-HBs titer to >100 IU/l that
could not be explained by HBIg administration and (2) no decrease in the
anti-HBs titer to <100 IU/l after discontinuation of combined administration
of the vaccine and HBIg. If anti-HBs titers exceeded above-mentioned
responsive increasing level, HBIg substitution and the vaccine were
discontinued. The vaccine was continuously administered till given response.
The overall response rate to HBV vaccination was 72.7%. In order to evaluate
the immune status of the LT recipient vaccinees, we employed a mixed
lymphocyte reaction assay using an intracellular carboxyfluorescein diacetate
succinimidyl ester (CFSE) -labeling technique in response to allostimulation.
Irradiated stimulator peripheral blood mononuclear cells (PBMCs) were
cultured with CFSE-labeled responder PBMCs. By FCM analysis, the
number of division precursors was extrapolated from the number of daughter
cells of each division and from the mitotic events, and precursor frequencies
in CD4+ and CD8+ T cell subsets. This, then, allows to separately quantify
the number of viable CD4+ and CD8+ responder T cells that proliferate in
response to allostimulation. Patients showing a donor-specific hyporesponse
with a well-maintained response to the third-party stimulus always achieved
a sustained immune response to the vaccine. In contract, patients showing
a hyporesponse to both the donor and the third-party stimulus were unable
to do so, suggesting an excessively immunosuppressive state. On the
other hand, the following factors did not exhibit statistically significant
differences between the good and poor responders: age, sex, indication for
LT, HBV viremia, immunosuppressive regimen at the time of vaccination,
duration between vaccination and transplantation, duration between steroid
withdrawal and transplantation, and even tacrolimus trough levels. Thus,
inducing an antidonor-specific immunosuppressive status by minimizing
immunosuppression should enable posttransplant HBV vaccination to be a
promising prophylactic strategy.
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CONCURRENT ORAL SESSION 13:
NEW IMMUNOSUPPRESSIVE AGENTS
189 QUALITY OF REPORTING OF RANDOMIZED
CONTROLLED TRIALS IN SOLID ORGAN
TRANSPLANTATION.
P.J. Morris, L.H.M. Pengel, L. Barcena
Centre For Evidence In Transplantation, Royal College of Surgeons of
England And The London School of Hygiene And Tropical Medicine,
University of London, London, United Kingdom
We examined all reports in English of randomized controlled trials (RCTs) in solid
organ transplantation that were published between 2004 and 2006. Trials were
rated for methodological quality using the 0-5 Jadad scale with trials scoring 3 or
greater being considered as good quality trials. Two other quality features were
also examined, namely allocation concealment and whether analysis was based on
intention to treat. In addition, we examined the author instructions of the ten most
cited specialty journals for mention of the CONSORT statement. The CONSORT
statement was introduced in 1996 to improve the quality of reporting of RCTs.
For each report we recorded if a flow diagram or a satisfactory description of
participant flow at each stage of the study was included as is required by the
CONSORT statement. Funding sources (commercial, nonprofit or mixed) and
whether a trial was a single centre or multicentre trial were also recorded.
There were 334 RCTs over this 3 year period. Approximately a third of trials
(37%) was considered to be of good methodological quality, 34% used allocation
concealment and 45% of trials analysed data according to intention to treat. The
CONSORT statement was mentioned in the author instructions in 3 out of the
10 most cited specialty journals. Only a small number of studies included a flow
diagram (14%) but 65% of papers that did not include a flow diagram provided
an adequate description of withdrawals and dropouts. Funding sources were
declared in 63% of the reports. About a third of all trials (37%) was sponsored by
commercial companies, 18% of all trials was sponsored by nonprofit institutions
and 8% of all trials received mixed funding. Trials funded by commercial
companies or trials that received mixed funding were of better quality than trials
funded by nonprofit institutions. For example, 52% of trials funded by commercial
companies and 59% of trials that received mixed funding were considered to be
of good quality versus only 30% of nonprofit sponsored trials.
Sponsorship

number of studies Jadad >=3

ITT

64 (52%)
18 (30%)
16 (59%)
1

Allocation
concealment
51 (41%)
20 (33%)
12 (44%)
1

Commercial
nonprofit
Mixed
No funding
received
Funding not listed

123
61
27
1
122

25 (20%)

30 (25%)

36 (30%)

83 (67%)
16 (26%)
15 (56%)
1

There were 217 single centre trials conducted in 31 different countries and 117
multicentre trials most of which were conducted internationally, in the USA
or across Europe. A higher percentage of the multicentre trials was of good
quality compared to the single centre trials (53% versus 28%). used allocation
concealment (50% versus 27%) or intention to treat analysis (71% versus 31%).
Even though guidelines have been published to improve the quality of
reporting of RCTs, most journals and authors show insufficient compliance.
Trials that were funded by commercial companies appear to be of better quality
than nonprofit sponsored trials. As RCTs represent level 1 evidence in medical
practice these findings are disappointing.

190 IMMUNOSUPPRESSION BY A HUMAN ANTI-CD40
MAB, 4D11, IS NOT ABROGATED WHEN COMBINED WITH
TACROLIMUS ON CYNOMORGUS MONKEY RENAL
TRANSPLANTATION.
M. Uno1, K. Yamashita1, T. Suzuki1, T. Miura2, T. Itoh3, T. Aoyagi1,
M. Taniguchi1, T. Shimamura1, H. Furukawa1, S. Todo1
11st Dept. of Surgery, Hokkaido Univ. School of Medicine, 2Kirin Pharma
Company, Ltd, 3Dept. of Surgical Pathology, Hokkaido Univ. School of
Medicine
Background: The blockade of CD40-CD154 costimulation pathway
by anti-CD154 antibodies induces a potent immunosuppressive effect.
Addition of calcineurin inhibitors, however, has been shown to abrogate the
immunosuppressive effect of CD154 signal blockade in rodents and nonhuman
primates. Previously, we have shown that blockade of CD40-CD154 signal
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In the scheduled graft biopsies, a moderate-to-severe infiltration was noted
among the 4D11 administered animals at the early post-Tx period. These
infiltrating cells were mainly CD4+ and CD8+ cells and to a lesser extent
CD20+ cells. In contrast, such graft infiltrates, including all phenotypes,
were suppressed by 4D11 and tacrolimus combination. During the treatment
course of 4D11, all animals developed anti-donor antibodies and one of them
had also anti-4D11 antibody in sera. However, neither antibody was detected
in the 4D11 plus tacrolimus group unless the treatment was discontinued.
Furthermore, graft C4d was negative in the combined 4D11 plus tacrolimus
group. Peripheral CD20+ cells were transiently declined in the 4D11 treated
animals regardless of tacrolimus combinaion at the early post-operation
period, although the numbers recovered thereafter. MLRs against donor and
3rd party antigens were suppressed in both 4D11 and 4D11 plus tacrolimus
given groups. Drug interaction was not seen based on the concentrations of
4D11 and tacrolimus blood trough levels. No apparent side-effect including
thrombosis or thrombocytopenia was noted in the 4D11 administered animals
with or without tacrolimus.
Conclusion: The 4D11 inhibits both cellular and humoral responses against
donor antigens. Addition of tacrolimus strengthens these immunosuppressive
effects of 4D11. The effects of CD40 blockade by 4D11 are not abrogated but
enhanced when combined with tacrolimus in a non-human primate renal Tx.

191 A NOVEL HUMAN ANTI-CD40 MONOCLONAL
ANTIBODY, 4D11, FOR LIVER TRANSPLANTATION IN NONHUMAN PRIMATE.
T. Oura1, K. Yamashita1, T. Suzuki1, D. Fukumori1, T. Miura2, K. Kubota3, M.
Taniguchi1, T. Shimamura1, H. Furukawa1, S. Todo1
11st Department of Surgery, Hokkaido University School of Medicine, 2Kirin
Pharma Company, Ltd, 3Department of Surgical Pathology, Hokkaido
University School of Medicine
Background: We have previously shown that a novel human anti-CD40
monoclonal antibody, 4D11 significantly prolongs renal allograft survival in
cynomolgus monkeys.
Aim: In this study, we evaluated the immunosuppressive effect of 4D11 in a
non-human primate liver transplantation (LTx) model.
Methods: Orthotopic LTx was performed among cynomolgus monkey pair
(blood type identical, MLR stimulation index >5 and MHC class II DR β
mismatched). Liver grafting was carried out with or without clamping superior
mesenteric artery (SMA) during anhepatic phase. Venous-venous bypass was
not placed. In the control group, the SMA clamping technique was adopted,
and received no treatment. In the treatment group, 4D11 was administered
intravenously at a dose of 10 mg/kg on days 0, 4, 7, 11 and 14; 5 mg/kg
was given weekly thereafter. Graft survival, serum liver function tests, graft
histology (sequential biopsies) and MLRs were assessed.
Results: Graft survival and early serum ALT levels are show below.

Control animal died on P.O.D. 4 by fulminant graft rejection. Without SMA
occlusion during an anhepatic phase, post-Tx serum ALT levels were markedly
elevated, and 4 out of 5 animals were lost due to immediate or delayed hepatic
dysfunction. Histopathologic examination revealed severe ischemia reperfusion
injury in these liver grafts. In contrast, 4 of 5 recipients, underwent the SMA
clamping, are surviving by 4D11 treatment. Biopsies taken on P.O.D. 60 had
no acute cellular or humoral rejection. MLRs against donor antigens were
suppressed in long-surviving animals.
Conclusion: 4D11 treatment prolonged liver allograft survival in non-human
primate. Clamping the SMA during an anhepatic phase facilitated successful
LTx.

192 A NEW PROTOCOL OF CLONAL DELETION AND
ALLOGENEIC STEM CELL TRANSPLANTATION WITH NO
POSTTRANSPLANT IMMUNOSUPPRESSION IN LIVING
RELATED DONOR RENAL TRANSPLANTATION
H.L. Trivedi1, P.I. Terasaki, A. Firoz, A.V. Vanikar, V. Shankar,
V.B. Trivedi, H. Kaneku, A. Idica, P.R. Modi, S.I. Khemchandani
1Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS) - Gulabben
Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of Kidney Diseases &
Research Centre (IKDRC). 2Paul Terasaki Foundation, L.A., U.S.A, 3Dr. H.L.
Trivedi Institute of Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi
And Kamlaben Mafatlal Mehta Institute of Kidney Diseases & Research
Centre (IKDRC). 4Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS)
- Gulabben Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of Kidney
Diseases & Research Centre (IKDRC). 5Shri Krishna Hospital and Medical
Research Centre, Karamsad, Anand, India, 6Dr. H.L. Trivedi Institute of
Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi And Kamlaben
Mafatlal Mehta Institute of Kidney Diseases & Research Centre (IKDRC).
7Paul Terasaki Foundation, L.A., U.S.A., 8Paul Terasaki Foundation,
L.A., U.S.A., 9Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS)
- Gulabben Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of
Kidney Diseases & Research Centre (IKDRC). 10Dr. H.L. Trivedi Institute
of Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi And Kamlaben
Mafatlal Mehta Institute of Kidney Diseases & Research Centre (IKDRC)
Introduction and Methods: New modification of tolerance induction
protocol using clonal deletion, donor leucocyte, peripheral blood stem cell
infusion followed by total lymphoid irradiation, anti-T-cell antibody and
cyclophosphamide was introduced. Clonal deletion was monitored for
completeness by luminex single antigen bead testing and followed by intraportal donor adipose tissue derived mesenchymal stem cell + cultured bone
marrow infusion, and challenging with second donor leucocyte infusion. Remeasurement was done by single antigen tests. Absence of antibody response at
the end of challenge indicated complete clonal deletion. Twenty three patients
have been enrolled into this protocol, 3 have thus far been transplanted.
Patients 1 and 2 were transplanted with immunosuppression of Cyclosporin, 2
mg/kg BW/day and Prednisolone, 0.2 mg/Kg BW/day for 2-3 weeks followed
by gradual complete withdrawal. Patient 3 was transplanted without any
immunosuppression.
Results: Serum creatinine of first patient is 1.1 mg% at 36 days post-transplant
(10 days of complete drug withdrawal (CDW) ). of 2nd patient, 1.2 mg% at 35
days post-transplant (2 days post-CDW). third patient has 0.7mg% at 3 weeks
post-transplant. He is believed to be the first patient in history, transplanted
with no postoperative immunosuppressives. By the time of the Congress, he
will be 6 months post-transplant; 20 others are anticipated to be transplanted
without any immunosuppression in next 1-2 months. Antibody response at 1
month post-transplant in all 3 patients was absent.
Conclusions: Tolerance induction has been achieved using new clonal deletion
protocol with allogeneic stem cell transplantation in living-related renal
transplantation.
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by anti-CD40 mAb, 4D11, markedly prolongs renal allograft survival in
cynomolgus monkeys.
Aim: In this study, we examined the immunosuppressive effects of 4D11 when
combined with tacrolimus.
Method: Kidney Txs was performed between MHC incompatible (stimulation
index: >3 in MLRs) and blood-type identical cynomolgus monkey pairs.
Transplant recipient was given either no-treatment, 4D11, tacrolimus or 4D11
plus tacrolimus. The 4D11 was administered intravenously on days 0, 4, 7,
11 and 14 at a dose of 5 mg/kg, and once weekly at 2.5 mg/kg thereafter.
Tacrolimus (1 mg/kg/day) was given orally starting from day 0. Both agents
were discontinued at 6 month post-Tx, and no further immunosuppression
was given. Graft survival, serum anti-donor and anti-4D11 antibody levels,
peripheral lymphocyte population, MLR and graft histopathology were
assessed.
Results: Graft survivals, serum anti-donor antibodies under treatment, C4d on
graftectomy were summarized below.
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193 THE PERSISTENT ELIMINATION OF B CELLS
RESPONDING TO BLOOD GROUP CARBOHYDRATES
BY TEMPORAL DEPLETION OF B CELLS AND B-1 CELL
DIFFERENTIATION BLOCKADE: NOVEL CONCEPT IN ABOINCOMPATIBLE TRANSPLANTATION
H. Ohdan, T. Irei, T. Asahara
Department of Surgery, Division of Frontier Medical Science, Programs For
Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima
University
The use of ABO-incompatible liver grafts is a possible solution for the shortage
of donor organs for liver transplantation. Specific and persistent inhibition of
anti-A/B antibody (Ab) production might be necessary for successful ABOincompatible transplantation. We recently demonstrated that B cells with
receptors for A-carbohydrates belonging to the CD5+CD11b+ B-1 subset mainly
exist in the peritoneal cavity. We also demonstrated that calcineurin inhibitors
(CNIs) block T cell-independent B-1 cell differentiation but have no effect on T
cell-dependent Ab production in a mouse model. Similar to human blood group
O or B individuals, mice have naturally occurring Abs against human blood
group A-carbohydrates in their sera. B cells with receptors for A-carbohydrates
in mice belonging to the CD5+CD11b+B-1a subset, have phenotypic properties
similar to those of human B cells. These cells could be temporarily eliminated by
injecting synthetic A-carbohydrates (GalNAcƒ¿1-3,Fucƒ¿1-2Gal) conjugated to
bovin serum albumin (BSA) (A-BSA) and anti-BSA Abs. In mice that received
the injection of A-BSA/anti-BSA Abs, the serum levels of anti-A IgM were
reduced, but immunization with human A erythrocytes resulted in increased
serum levels of anti-A Abs. When combined with calcineurin inhibitor (CNI)
treatment, which blocks B-1a cell differentiation, and treatment with A-BSA/
anti-BSA Abs, the serum levels of anti-A Abs were persistently undetectable in
the mice even after the immunization. B cells with receptors for A carbohydrates
were markedly reduced in these mice. These results are consistent with the
hypotheses that CNI treatment prevents the replenishment of B cells responding
to A-determinants after temporary depletion of B cells. Based on these findings,
in order to permanently eliminate B cells responding to A/B carbohydrates,
we established a novel immunosuppressive regimen. In this regimen,
instead of treatment with A-BSA/anti-BSA Abs, anti-CD20 monoclonal Abs
(Rituximab) are administered 2 weeks before transplantation for temporarily
eliminating differentiated B-1 cells. Further, CNI and mycophenolate mofetil
are simultaneously administered for blocking B-1 cell differentiation and
inhibiting pre-existing plasma cells, respectively. We performed 5 cases of
ABO-incompatible living donor-related adult liver transplantation using this
regimen. In all cases, CD5+ B-1 cells disappeared at the time of the operation.
Both anti-donor blood group IgM and IgG titers were remained less than 8 after
plasma exchange. Intraoperative analysis revealed that CD5+ B-1 cells and IgMCD38+CD19+ plasma cells had also disappeared from their spleens. Therefore,
we did not perform splenectomy, except in 2 cases. In 1 case, splenectomy for
conducting subsequent interferon-therapy were required due to hepatitis C. In the
other case, splenectomy had previously been performed for esophageal varices.
Anti-donor blood group IgM and IgG titers remained at undetectable levels in
all cases. Further, an uneventful course without antibody-mediated rejection and
severe postoperative infections was seen in all patients, except in the previously
splenectomized patient with local bacterial peritonitis. Notably, all patients
showed rapid recovery of total IgM and IgG levels, probably because CNI per
se has no effects on T cell-dependent Ab production. This successful experience
indicates that this novel immunosuppressive regimen is suitable for safely
regulating B cells that respond to blood group carbohydrate determinants.

194 INDUCTION OF PROLONGED SURVIVAL
OF FULLY ALLOGENEIC CARDIAC GRAFTS AND
GENERATION OF REGULATORY CELLS BY PURIFIED
EICOSAPENTAENOIC ACID
D. Iwami1,2, Q. Zhang1, O. Aramaki3, K. Nonomura2, N. Shirasugi1,
and M. Niimi1.
1
Surgery, Teikyo University, Tokyo, Japan, 2Renal and Genitourinary Surgery,
Hokkaido University, Sapporo, Japan and Surgery, 3Nihon University, Tokyo, Japan
Backgrounds: Many studies have shown immunosuppressive effects of dietary
intake of fish oil rich in eicosapentaenoic acid (EPA) in various models such as
autoimmune diseases and transplantation, as well as its anti-atherosclerotic and
anti-hyperlipidaemic effects. However, its mechanisms remain uncertain. Here
we tested the ability of purified EPA to inhibit alloimmune response in mouse
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fully allogeneic cardiac transplantation model.
Methods: CBA recipients (H-2k) were given single injection of purified EPA
intraperitoneally on the same day as transplantation of a heart from C57BL/10
(B10) donors (H-2b). In the recipients with functioning B10 cardiac grafts
unrejected over 100 days, skin grafts from B10 or third party, BALB/c (H-2d)
donors were performed to determine whether the hyporesponsiveness was
donor-specific or not. Mixed leukocyte reaction (MLR) assay and enzyme
linked immunosorbent assay (ELISA) were also performed to evaluate the
effect of purified EPA on cellular alloproliferation and cytokine production.
To determine the presence of regulatory cells, adoptive transfer study was
conducted.
Results: Untreated CBA recipients rejected B10 cardiac allografts with median
survival time (MST). 8 days. In contrast, CBA recipients treated with purified
EPA (1.0g/kg) had significant prolongation of allograft survival (MST, >100
days, p<0.01). CBA recipients treated with 0.1g/kg purified EPA eventually
rejected allografts (MST, 13 days). In the recipients with functioning B10
cardiac allografts 100 days after grafting, skin allografts from donor-specific
B10 mice had significantly prolonged survival (MST, 15 days, p<0.01).
compared to that of third-party BALB/c skin grafts (MST, 7 days). In MLR
assay, treatment with 1.0 g/kg purified EPA suppressed alloproliferation of
splenocytes in the recipients. The treatment also inhibited production of IL-2,
IL-12 and IFNg by the splenocytes in the recipients. In contrast, production
of IL-10 by the splenocytes in the recipients treated with 1.0 g/kg purified
EPA was significantly increased (p<0.01). When splenocytes were harvested
from the recipients treated with 1.0g/kg purified EPA 30 days after cardiac
allografting and were adoptively transferred into naive secondary recipients,
the adoptive transfer induced significant prolongation of cardiac allograft in
naive secondary recipients (MST >30 days, compared to that in the recipients
with adoptive transfer of nave splenocytes, MST, 10 days).
Conclusions: Purified EPA induced significantly prolonged survival of fully
mismatched cardiac allografts, and generated regulatory cells.

195 PROTEASOME INHIBITION EFFECTIVELY TREATS
ACUTE CELLULAR REJECTION, ANTIBODY MEDIATED
REJECTION, AND PROVIDES LONG-TERM REDUCTION OF
DONOR SPECIFIC ANTIBODIES
M. Everly, J. Everly, P. Brailey, B. Susskind, L. Arend, R.R Alloway, A.
Govil, P. Roy-Chaudhury, G. Mogilishetty, E.S. Woodle
University of Cincinnati
Background: Current antibody mediated rejection (AMR) therapies (IVIg,
apheresis, rituximab, polyclonal antibodies) provide inconsistent and suboptimal
results and do not target the major antibody producing B-lymphocyte (plasma
cell). We report the first clinical experience of a novel agent (bortezomib) that
targets plasma cells. Bortezomib is FDA approved for treatment of plasma cell
tumors (multiple myeloma).
Methods: Acute cellular rejection (ACR) and AMR episodes were diagnosed
by Banff ‘97 criteria
(update 2005) and treated with bortezomib (1.3 mg/m2/dose x 4). Patients
(pts) were monitored by serial donor specific anti-HLA antibody (DSA)
determinations [Luminex/Labscreen beads] and quantified by converting
fluorescence intensity to Molecules of Equivalent Soluble Fluorescence
(MESF). Immunodominant DSA (iDSA) was defined as DSA with highest
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agent will allow us to better understand the benefit of inhibiting TNF-mediated
apoptotic effects in both cellular alloimmune response and allograft injury in
solid organ transplantation.
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MESF value at the time of rejection diagnosis. Non-iDSA was defined as the
DSA specificities with levels lower than the iDSA. In figures below, day 1 is
the first day of bortezomib treatment.
Results: Five patients (2 kidney/pancreas and 3 kidney transplant recipients)
with renal allograft biopsies consistent with AMR were treated with bortezomib
(median follow-up 6.9 months). Each patient also had coexisting ACR. In each
case, bortezomib treatment led to prompt ACR and AMR rejection reversal.
iDSA levels decreased significantly in all patients (except one patient who
has short follow-up). Most patients had several other non-iDSA specificities.
Bortezomib treatment also resulted in marked reduction of the non-iDSA
levels. For most DSA specificities, bortezomib therapy also provided long
term suppression for up to 6 months post therapy. Toxicity from bortezomib
included a transient grade III thrombocytopenia (1 patient) and mild-tomoderate nausea, vomiting, and/or diarrhea (3/5 patients). No opportunistic
infections were observed.

197 DEVELOPMENT OF CYCLIN KINASE INHIBITOR AS A
POTENT IMMUNOSUPPRESSIVE DRUG

Conclusions: Bortezomib therapy provides: 1) effective treatment for AMR
and ACR with minimal toxicity, 2) effective reduction in iDSA and non-iDSA
levels, and 3) long term suppression of DSA levels. These results indicate that
proteasome inhibition provides an effective means for treating both humoral
and cellular rejection. Thus, bortezomib offers a novel and promising approach
for treating humorally mediated rejection by targeting the antibody-producing
plasma cell.

196 PRE-CLINICAL ASSESSMENT OF GENZ-29155, A NOVEL
SMALL MOLECULE INHIBITOR OF APOPTOSIS WITH ANTIREJECTION EFFECTS IN NON-HUMAN PRIMATES.
A. Kirk1, T. Weaver1, A. Charafeddine1, F. Leopardi1, A. Agarwal1,
D.S. Batty2, J. Williams2, S. Nahill2
1
Emory Transplant Center, Atlanta, GA, United States and 2Genzyme
Corporation, Framingham, MA, United States.
Genz-29155 is a novel, oral immune-modulatory agent identified in a highthroughput screen designed to find inhibitors of TNF-induced apoptosis. The
molecular target of the compound remains under investigation but is likely
downstream of the TNF cell surface receptor. In vitro studies have shown
Genz-29155 to be an effective inhibitor of the TNF-triggered caspase cascade
but not anti-CD3 or Fas-mediated apoptosis, and thus may act by inducing
allograft resistance to immune attack rather than suppressing the alloimmune
response per se. It has been shown to synergize with sirolimus in murine
heterotopic cardiac allotransplant models. In order to test this promising new
agent in a more clinically relevant model of solid organ transplantation, we
studied Genz-29155 in a mismatched NHP (rhesus macaque) renal transplant
model. Genz-29155 (n=3) was administered (3mg/kg, IV, Days 0-14) with
sirolimus (1mg/kg, PO, Days 0-30). Five control animals received only
sirolimus and vehicle (1mg/kg, PO, Days 0-30). All animals were followed
serially by polychromatic flow cytometry to determine the relative and
absolute numbers of CD4+ and CD8+ T cell subsets in peripheral blood. Time
to allograft rejection, the primary end point, was determined by a significant
rise in serum creatinine and BUN, as identified with biweekly monitoring.
After diagnosis of rejection, allografts were removed for histological and
transcriptional studies, along with splenocytes for immune function assays.
In this pilot study, prolongation of rejection-free survival was significantly
improved with Genz-29155 and sirolimus combined vs. sirolimus alone (42.67
days vs. 17.20 days, respectively, p = 0.05). No significant depletional or
enhancing changes were observed in peripheral blood CD4+ or CD8+ T cell
subset populations; T (naïve). T (central memory). or T (effector memory).
Given these initial results, we have initiated a larger study (n=12) to optimize
the dose and duration of Genz-29155. Five animals, transplanted within the
past month remain alive and well in this study. Further investigation of this

M. Mehra, A. Khanna
University of Maryland,, Baltimore
Background: Currently clinically used immunosuppressive agents
cyclosporine (CsA), Tacrolimus (TAC) and Sirolimus (SRL) have though
improved rejection rates but have failed to promote long-term graft survival.
This is mainly because of side-effects associated with immunosuppressive
agents such as nephrotoxicity, malignancy and viral infections. Our studies
have shown that these drugs induce expression of cyclin kinase inhibitor p21,
overexpression of p21 in vitro and in vivo render lymphocytes less responsive
to allo-and mitogen-induced proliferation and prolong allograft survival in rat
heart transplant recipients.
Methods: We prepared recombinant p21 protein to explore its
immunosuppressive properties using in vitro and in vivo models. The purity of
p21 was confirmed by western blot and specific ELISA. The proliferation was
quantified by [3H] thymidine uptake assay. We also performed experiments to
study the effect of p21 protein on the levels of TNF-ƒÑ, IL-2, and IFN-ƒ× in the
conditioned medium of lymphocytes activated with and without either a p21
protein (20 U/ml) or the control protein for 24 h. Cytokines were quantified by
specific ELISA kits
Results: Recombinant p21 protein but not the control p21 protein significantly
(p < 0.01) inhibited proliferation of lymphocytes, which was similar to the
inhibition observed with CsA (p < 0.01), TAC (p < 0.01), and SRL (p < 0.01).
The treatment with p21 protein also resulted in the inhibition of IL-2 mRNA
in activated lymphocytes. The results demonstrate that the inhibition of
lymphocyte proliferation by p21 also results in significantly decreased protein
levels of IL-2 (p<0.02), IFN-ƒ×ƒnƒvƒàƒ¬ƒ~ƒ|ƒ~ƒ¤ƒw, and TNF-ƒÑ (p<0.03).
We also performed studies to understand the mechanism of these effects of
p21 on T lymphocytes, the findings suggest that using an intrinsically present
protein transduction domain p21 protein enters the nucleus of lymphocytes
and modulate the activity of transcription factors NFkB, NFATc and NFATp
resulting in the inhibition of lymphocyte proliferation. In vivo treatment of mice
with p21 protein rendered spleen cells less responsive to the anti-CD3-induced
proliferation, whereas no differences were observed between the effects of the
control protein and untreated animals. Recombinant p21 protein increased graft
survival in rats compared to control protein and untreated recipients, which
was similar to CsA. Intragraft expression of pro-inflammatory cytokines and
cytolytic markers was significantly decreased in p21 protein treated recipients.
These results demonstrate that recombinant p21 protein can be administered in
vivo to suppress lymphocyte function. Parenthetically, there were no apparent
differences in the health of mice after a week of treatment with p21 relative to
control mice. A renal histological analysis was performed on all of the animals
that received the p21 protein and did not demonstrate any of the abnormalities
observed with long-term CsA treatment.
Discussion: These results demonstrate that recombinant p21 protein inhibits
lymphocyte proliferation, expression of pro-inflammatory cytokines, and
promotes cardiac graft survival. Based on the known effects of p21 as one
of the potent inhibitors of the viral replication and tumor cell proliferation,
it is likely that its long-term use will not result in either malignancy or viral
infections in organ transplant recipients
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198 PEDIATRIC INTESTINAL TRANSPLANTATION AT THE
UNIVERSITY OF MIAMI: 13 YEAR EXPERIENCE
G. Selvaggi, T. Kato, P. Ruiz, J. Moon, S. Nishida, D. Levi, E. Island,
L. Smith, A. Tzakis
University of Miami
We here present the results in pediatric intestinal transplantation at our
institution from June 1994 through December 2007. We performed 180
intestinal transplants in 157 recipients. Primary grafts were 157 cases; retransplantation was performed in 23 cases and 21 recipients (two patients
received three grafts). The youngest recipient was 96 days old, the smallest
weighed 4.4 kg. Most common original diagnoses were gastroschisis,
necrotizing enterocolitis and intestinal atresia. Type of graft in primary
transplants was isolated intestine (I) n=29, liver-intestine (LI) n=27,
multivisceral (MV) n=92, modified multivisceral (MMV) n=9. In retransplant cases, grafts were I n=6; LI n=2; MV n=12; MMV n=3. Spleen
was included in MV or MMV grafts in 53 primary cases and 2 re-transplants;
large intestine was part of the graft in 65 primary cases and 6 re-transplants.
Patient survival for primary grafts was 62.6% at one year, 51% at 3 years;
graft survival was 59.4% and 47.5% at one and three years, respectively.
Infection was leading cause of death (n=34). followed by rejection (n=23)
and other causes (n=30). Rejection of any grade in primary grafts was
experienced in 65.6% of patients, severe rejection occurred in 19.7% of
cases. Only 8/31 patients who had severe rejection are still alive (25.8%);
additionally, 10/31 patients with severe rejection required a second intestinal
graft. GVHD was diagnosed in 18 patients (11.5%). PTLD in 18 patients as
well. The presence of spleen in the graft did not significantly increase the risk
of developing GVHD, but a trend towards less development of rejection and
PTLD was seen. Our experience in pediatric intestinal transplantation shows
improved patient and graft survival over the years. Rejection and infectious
complications still are the most difficult problems in the post-operative
management of such patients.

199 PEDIATRIC INTESTINAL RETRANSPLANTATION:
TECHNIQUE, MANAGEMENT AND OUTCOMES
G. Mazariegos1, Z. Machaidze1, K. Soltys1, G. Bond1, R. Jaffe1, D. Martin2, R.
Squires1, K.A. Elmagd2, R. Sindhi1
1Hillman Center For Pediatric Transplantation. Children’s Hospital
of Pittsburgh. Pittsburgh, PA. USA, 2Thomas E. Starzl Institute of
Transplantation. Pittsburgh, PA. USA
Background: Intestinal retransplantation (Re-ITx) has historically been
associated with high morbidity and mortality.
Methods/Aim: The records of all children receiving Re-ITx between
1990-09/2007 at our center were reviewed for incidence, indications, techniques
and outcomes of Re-ITx.
Results: 172 children received primary intestinal grafts. Fourteen children
(8.1%) were retransplanted with 15 grafts. Causes of graft failure were: acute
rejection (ACR, n=4). liver failure (n=2). chronic rejection (n=4). PTLD (n=1).
graft dysmotility (n=2). ACR with severe infection (n=1). and arterial graft
aneurysm (n=1). Initial transplants were: isolated bowel (IB) in 9, liver-bowel
(LB) in 5, and 1 multivisceral (MV). The mean time of initial graft survival
was 34.8 m (range 1-134). Re-ITx was with IB in 2, LB in 4 and MV in 9.
Cross match at initial ITx was positive in 2 patients. At Re-ITx, 4 patients
had positive cross match (1 B-cell+, 2 T-cell+, and 1 B and T cell+). Initial
immunosuppression (IS) was with Tac-Pred in 9 and rATG-Tac in 6 cases. ReITx was carried out under Tac-Pred in 7 and rATG-Tac in 7 and Campath in
1 case.
10 (71.4%) patients are alive with functioning grafts at a median current followup time of 44.1m (range 6-123.9). 4 patients died from PTLD, severe ACR and
fungal sepsis, bleeding from pseudoaneurysm respectively, at a mean time of
5.6 m post Re-ITx. After Re-ITx, 11 patients experienced rejection (5 mild,
3 moderate and 3 severe) but only one treated under rATG-Tac experienced
severe ACR. Current IS is with Tac monotherapy in 6, Tac/Pred in 3 patients
and Sirolimus/Pred in 1. All surviving patients weaned off TPN at a median
time of 23 days and are off of IV fluids.
Summary: Long term survival and outcome have improved in pediatric
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Re-Itx. This success rate may be attributed to improvements in IS protocols,
technical modifications, proper timing of Re-ITx and improved infectious
disease monitoring. Re-ITx frequently required LB or MV transplant after
initial isolated intestinal Tx. Careful patient selection and post transplant
management are essential to successful long term outcome.

200 A SEVEN-YEAR ITALIAN EXPERIENCE IN CLINICAL
INTESTINAL AND MULTIVISCERAL TRANSPLANTATION
C. Zanfi1, L. Ansaloni1, M. Cescon1, A. Lauro1, A. Dazzi1, G. Ercolani1,
A. Cucchetti1, M. Zanello1, L. Pironi2, A. Pinna1
1
U.O Chirurgia Dei Trapianti Di Fegato E Muliorgano-Sant’Orsola
-Malpighi-Università Di Bologna-Bologna-Italy, 2Chronic Intestinal Failure
Center (Head: Prof. L. Pironi) -University of Bologna – S.Orsola-Malpighi
Hospital, 3Chronic Intestinal Failure Center (Head: Prof. L. Pironi)
-University of Bologna – S.Orsola-Malpighi Hospital
Introduction: Adult isolated intestinal transplant is by now accepted
worldwide as the standard treatment for patients with intestinal failure and lifethreatening parenteral nutrition (TPN) -related complications. Here we report
the experience in intestinal transplantation in an single European Center.
Patients and Methods: Between December 2000 and March 2008,
we performed 39 intestinal transplants in 38 adult patients: 30 isolated
intestinal and 9 multivisceral (5 with liver). In 3 cases abdominal wall
transplant was added. All patients were adult, with a male: female ratio of
22: 17, a median age of 34 years (17-55) and median weight at transplant
of 57 kg (40-97). All these recipients were on TPN for a median time of
12 months (0-264). Underliyng diseases were mainly represented by short
bowel sindrome (16 patients). chronic intestinal pseudo-obstruction (9
patients) and Gardner Syndrome (9 cases). Indications for transplantation
were: loss of venous access (16 patients). recurrent sepsis (12 cases).
electrolyte-fluid imbalance (8 patients); reversible liver dysfunction
was present in 19 cases. Organ procurement was performed using an in
vivo tecnique. Immunosuppressive regimens were based on Daclizumab,
Tacrolimus and steroids (12 cases) up to 2002, and Alemtuzumab (25
cases) or Thymoglobuline (2 cases) combined with Tacrolimus thereafter.
Abdominal wall closure represented a serious problem in 12 patients
due to previous laparotomies and consequent reduction of the abdominal
cavity. We tried graft reduction, only skin closure, mesh closure, twostep abdominal wall closure and adbominal wall transplant. Rejection
monitoring was accomplished by performing graft ileoendoscopies and
intestinal biopsies through the temporary ileostomy 2 times/week in the
first month, 1 time every 15 days in the first 3 months and every month in
the first 6 months and then 1 biopsy every 3 months.
Results: After a median follow-up of 937 days (1-2603). actuarial 5-year
patient survival is 67% for isolated intestinal transplant and 33% for
multivisceral transplant (p= 0.03). while 5-year graft survival is 64% for
isolated intestinal graft and 33% for multivisceral (p=0.06). The main cause
of death was sepsis (68.7%). the main cause of graftectomy was untractable
rejection (50%). Among the 22 recipients alive, 77% has a normal bowel
function with a regular diet without parenteral support, 2 patients are on
parenteral nutrition (1 patient is waiting for retransplantation due to graft
trombosis) and 1 patient needs enteral support. We experienced 2 death
related to abdominal wall closure. No abdominal wall graft experienced
istological proved rejection. Graft versus host disease was not seen in our
series. Five patients experienced PTLDs.
Discussion and Conclusion: In our series, isolated intestinal transplant has
acceptable results in terms of patient and graft survival. In cases of pre-transplant
liver dysfunction associated to parenteral nutrition, timely isolated intestinal
transplant can prevent the progression to liver failure. A careful evaluation of
the remnant abdominal cavity is necessary in candidates to intesinal transplant.
When difficult abdominal wall closure is expected, abdominal wall transplant
seems to represent a reasonable strategy, especially if co-operation with plastic
surgeons is possible.
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201 PATHOLOGICAL FEATURES AND REGULATORY
CELL SUBPOPULATIONS ASSOCIATED WITH
SUBCLINICAL ACUTE REJECTION IN SMALL INTESTINAL
TRANSPLANTATION

202 FECAL CALPROTECTIN LEVEL IS A SENSITIVE
MARKER DETECTING SMALL BOWEL ALLOGRAFT
PATHOLOGIES
E. Akpinar1, J. Vargas1, T. Kato1, L. Smith2, E. Hernandez2, G. Selvaggi1, E.
Island1, J. Moon1, P. Ruiz3, A. Tzakis1
1
Miami Transplant Institute, Liver GI Transplantation, Miami-FL, USA, 2Dept
of Pediatric Gastroenterology, Univ of Miami, Miami-FL, USA, 3Dept of
Pathology, Univ of Miami, Miami-FL, USA
Introduction: Protocol endoscopy with biopsy is currently the gold standard of
small bowel transplant (SBTx) monitoring, however it is invasive, costly, needs
skilled operator, may require anesthesia and may cause complications. Fecal
calprotectin level (FCL) is a candidate noninvasive marker for posttransplant
monitoring in SBTx patients.
Material and Methods: A pilot study was performed to test the utility of FCL
measurements in follow up of SBTx patients. Ileostomy effluents were collected
at various postoperative days during endoscopy/biopsy procedures. FCLs were
measured by an ELISA based commercial kit using rabbit polyclonal antibody.
The results were retrospectively evaluated in combination with clinical,
endoscopic and histopathological findings. FCL values are presented as median
(min-max) ng/mg.
Results: FCLs were measured in 122 samples that were obtained from 29 pts at

Conclusion: FCL is a very sensitive test detecting ongoing organic intestinal
allograft pathologies. It is not useful differentiating rejection from other
causes of inflammation. It might be useful as prescreening marker to avoid
unnecessary endoscopies.

203 EFFECT OF BLOCKING CHEMOKINE RECEPTORS BY A
NOVEL COMPOUND, TAK-779, IN A RAT SMALL INTESTINAL
TRANSPLANTATION MODEL
H. Xu, Y. Ihara, S. Firdawes, S. Uehara, M. Fukuzawa, S. Miyagawa
Osaka University Graduate School of Medicine
Background: Small intestinal transplantation is one of the most important
treatments for patients with irreversible intestinal failure. Recently, the graft
survival rate has improved significantly due to the development of surgical
techniques and new drugs. However, the immune response of intestinal
transplantation is still difficult to control, compared to that of other organs,
because of the gut-associated lymphoid tissue. In this study, we investigated
the effect of blocking lymphocyte chemokine receptors, CCR5 and CXCR3,
with a novel small molecule compound, TAK-779. Immunological changes in
peripheral and graft-infiltrating lymphocytes were monitored using a rat small
intestinal transplantation model.
Methods: Dark Agouti (DA) rat (RT-1a) small intestines were heterotopically
transplanted into Lewis (LEW) rats (RT-1l). The recipients were treated either
with or without TAK-779 (10mg/kg/day, SC). for 10 days (day 0 to day 10)
after the operation. [Group S: LEW to LEW, Group A: DA to LEW, and Group
T: DA to LEW with TAK-779] Graft survival and histological changes, such
as lymphocyte infiltration, destruction of intestinal architecture, and villus
height (VH) and submucosal thickness (ST) of the graft, were examined. Graftinfiltrating lymphocytes were studied using immunostaining, and followed by
the fluoro-luminance Analyser. Furthermore, expression of the chemokine
receptors, CCR5, CXCR3 and CXCR1, on the graft-infiltrating lymphocytes
in the mesenteric lymph node (MLN) and Peyer fs patches (PP) were measured
by FACS analysis.
Results: Average duration of survival was greater for Group T than Group A.
[Group S: >50 days, Group A: 7.0 }0.3, Group T: 9.8 }0.5 days, p<0.05, Group
T vs. Group A]. Histological findings and graft scores were consistent with
the prolonged survival in TAK-779-treated animals. [VH & ST (mm); Group
S: 752 }35 & 45.1 }2.2, Group A: 467 }29 & 27.6 }1.8, Group T: 722 }40 &
38.4 }2.4, respectively. p<0.05, Group T vs. Group A] Immunohistochemistry
of the graft showed that the numbers of infiltrating CD4+ and CD8+ T cells
were significantly lower in Group T compared with Group A. In the FACS
analysis, while the percentage of each CD4+ and CD8+ cells was unchanged,
the numbers of both CD4+ and CD8+ cells were significantly suppressed in the
blood, spleen, and MLN of the recipient, and in the PP of the graft. In addition,
double-staining of graft-infiltrating lymphocytes in MLN and PP showed a
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H. Takahashi, T. Kato, G. Selvaggi, V. Delacruz, J. Gaynor, J. Moon,
S. Nishida, D. Levi, A. Tzakis, P. Ruiz
University of Miami
Introduction: Subclinical acute rejection (SCR) is a recognized notion in
various organ transplants and is defined as histopathologically proven acute
cellular rejection (ACR) without concurrent clinical indications of ACR. We
recently characterized SCR in small intestinal transplantation (Itx) and found
it has a negative impact on graft survival. The purpose of this study was to
investigate the histomorphological characteristics of SCR in Itx in comparison
with clinically significant acute cellular rejection (CSR).
Methods: SCR in Itx was defined as a biopsy showing histopathological ACR
without any clinical signs of ACR, including endoscopical findings, and not
treated with adjuvant immunosuppression. Histopathologically proven ACR
with clinical signs for ACR were defined as clinically significant ACR (CSR).
A total of 100 cases (50 cases for SCR and CSR) from 32 patients, which
showed histopathologically grade 1 ACR, were blindly reviewed without
information of rejection status and compared for the following histopathological
factors: number of apoptotic bodies in 10 representative crypts, “macroscopic
apoptosis”, inflammatory infiltrate in lamina propria, mucosal edema, blunting
of villi, vascular congestion and red blood cell extravasation. We used a semiquantitative scoring system which assigned a numerical score of 0-3 for each
histopathological factor. Using a 3-color immunofluorescence technique, we
also evaluated the population of CD4 (+) Foxp3 (+) regulatory T cells in the
inflammatory infiltrate.
Results: Among a total of 32 patients, 12 were male and 20 were female.
Median age was 1.3 year old, ranging from 0.26 to 52.5. The types of grafts
used in Itx were as follows: isolated intestine (n=6). liver-intestine (n=1).
multivisceral transplant (n=22) and multivisceral transplant without liver
(modified multivisceral transplant, n=3). The median number of biopsies from
each patient was 3, ranging from 1 to 14. SCR cases showed “big apoptosis”
more frequently than CSR cases (42% vs. 14%; p=0.004). CSR cases showed
severe blunting of villi (p<0.001). There were not significant differences
between SCR and CSR in the number of apoptotic bodies in 10 representative
crypts, inflammatory infiltrate in lamina propria, mucosal edema, vascular
congestion and red blood cell extravasation in lamina propria and submucosa.
Immunohistochemical staining for CD4 and Foxp3 revealed CD4 (+) Foxp3
(+) regulatory T cell populations in both SCR and CSR cases.
Conclusion: There were only minor differences in morphology between SCR
and CSR in Itx and regulatory cell subpopulations were seen in both situations.
Therefore, histopathological evaluation of biopsies by routine methodology
shows SCR cases having features compatible with a vigorous alloimmune
response and without other novel changes.

various periods after SBTx. Retrospective evaluation showed that 11 samples
from 6 pts with a level of 217 (116-499) coincided with rejection episodes, 6
samples from 3 pts with a level of 125 (105-509) coincided with viral enteritis,
51 samples from 21 pts with a level of 207 (101-507) coincided with nonspecific
inflammation, 11 samples from 2 pts with a level of 998 (146-1062) coincided
with chronic intestinal ulceration, and finally 50 samples from 19 pts with a
level of 43 (5-475) coincided with normal histopathological findings (Fig 1).
FCLs in patients with normal intestinal morphology were significantly lower
compared to all other categories. No significant FCL difference was found
between rejection and inflammation. FCL evolution in rejecting individuals
showed that FCL can predict rejection days before histopathological diagnosis
(Fig 2).
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significant reduction in the numbers of CD4+/- T cells expressing CCR5 and
CXCR3.
Conclusion: These results demonstrate that chemokines play an important role
in small intestinal graft rejection. TAK779 diminished not only the number of
the graft-infiltrating cells, and their expression of CCR5 and CXCR3, but also
the total number of recipient T cells that play a role in graft rejection.

204 HYDROGEN, A NOVEL MEDICAL GAS, PREVENTS
INTESTINAL DYSFUNCTION AND COLD ISCHEMIA/
REPERFUSION INJURY FOLLOWING INTESTINAL
TRANSPLANTATION IN RATS
B. Buchholz1, D. Kaczorowski2, R. Sugimoto2, R. Yang3, Y. Wang2, J.H.
Zhan2, K. McCurry2, A. Bauer1, A. Nakao4
1Department of Medicine, DIvision of Gastroenterology, University of
Pittsburgh, 2Department of Surgery, University of Pittsburgh, 3Department
of Critical Care Medicine, University of Pittsburgh, 4Department of Surgery,
Thomas E Starzl Transplantation Institute, University of Pittsburgh
Background: Cold ischemia/reperfusion (I/R) injury following small intestinal
transplantation (SITx) may cause several potential complications including
bowel dysmotility, inflammation and multiple organ failure. Hydroxyl radicals,
the most reactive products of ROS generated during IRI, play a critical role
in lipid peroxidation and graft injury. Recent evidence has demonstrated
that exogenously provided hydrogen (H2) eliminates toxic hydroxyl radicals
and thereby prevents I/R injury. In this study, we tested the hypothesis
that perioperative H2 inhalation can ameliorate cold I/R injury and bowel
dysfunction following SITx.
Methods: Syngeneic, orthotopic SITx (LEW rats) was performed with 3 hrs
of cold ischemia time in Lactate Ringer solution. In the hydrogen treated
group, both donor and recipients were treated with 2% hydrogen inhalation
1 hr before and 1 hr after reperfusion. Gastrointestinal transit was determined
by measuring the intestinal distribution of orally fed fluorescein-labeled
dextran and calculation of geometric center. Bethanechol-stimulated jejunal
circular muscle contractility was also investigated. Graft oxidative injury was
determined by measuring the tissue malondialdehyde (MDA) concentration, a
marker of lipid peroxidation, and reductive capacity.
Results: Inhalation of 2% hydrogen for 1 hr resulted in elevation of arterial
dissolved hydrogen levels to 578 ± 63 ng/mL compared to 158.5 ng/mL in
sham animals exposed to air. SITx with prolonged cold storage caused a
delayed intestinal in-vivo transit and decreased in-vitro jejunal circular muscle
contractile activity 24 hours after SITx. Hydrogen treatment attenuated graft
injury and resulted in significantly improved intestinal transit as well as
smooth muscle contractility in response to bethanechol. In air-treated SITx, I/R
injury initiated mRNA upregulation of inflammatory mediators such as IL-6
and MCP-1. Hydrogen inhalation treatment resulted in significantly reduced
upregulation of these inflammatory mediators 3 hrs after reperfusion revealed
by qPCR. Demonstrating an antioxidant effect, hydrogen inhalation resulted
in significant reduction of lipid peroxidation 3 hrs after transplant compared
to elevated tissue MDA levels in air-treated control grafts. Similarly, intestinal
reductive capacity revealed less oxidative injury in hydrogen treated grafts.
Histopathlogical analysis of intestinal grafts 3 hrs after reperfusion showed
pronounced mucosal erosion and massive epithelial lifting in air-control
grafts, causing increased intestinal permeability resulting in mucosal barrier
breakdown. These mucosal damages were significantly attenuated by hydrogen
treatment. Furthermore, intestinal I/R injury has deleterious effects on remote,
nonischemic organs including the lung. Preventing systemic effects of SITx,
hydrogen treatment significantly reduced neutrophil recruitment as well as
induction of mRNA levels for TNFα and IL-6 in lungs.
Conclusion: Hydrogen inhalation therapy significantly ameliorates cold
I/R injury and prevents remote organ inflammation following SITx via its
antioxidant effects. Administration of perioperative hydrogen gas may be a
potent and clinically applicable therapeutic strategy for intestinal I/R injury.
Table. Effects of Hydrogen for intestinal cold I/R injury (*p<0.05 vs SITx/air)
Geometric Contractility IL-6
mRNA
Center
(24h,
(24h)
100μM, gr/ (3h)
mm2/s)
Sham (air) 9.6
2.63
1.0
Sham (H2) 9.6
2.66
1.5
SITx (air) 5.8
1.23
3286.3
SITx (H2) 8.2*
2.56*
1484.4*
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reductive
capacity
(3h)

MDA
(3h, μM/
protein)

permeability PMN in
(3h, pL/min/ lung (3h,/
cm)
x400HPF)

1.65
1.58
0.84
1.20*

0.039
0.027
0.15
0.086*

0.36
0.30
0.88
0.50*

7.2
12.0
98.6
64.6*
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205 ANTI-THYMOCYTE GLOBULIN INDUCTION FAVORS
THE GENERATION OF FUNCTIONAL CD4+FOXP3+CD127-/
LOW REGULATORY T CELLS IN PATIENTS AFTER KIDNEY
TRANSPLANTATION
V. Sewgobind1,2, M. Kho1, L. van der Laan2, T. van Dam1, H. Tilanus2,
J. IJzermans2, W. Weimar1, C. Baan1
1
Department of Internal Medicine, Erasmus Medical Center, 2Department of
Surgery, Erasmus Medical Center
Background: It has been hypothesized that the clinical benefits of AntiThymocyte Globulin (ATG) induction therapy do not completely result from
immunodepletion, but may also result from induction of immunoregulatory
T-cells (Treg). In this prospective, controlled study, we investigated the
effect of ATG-induction therapy on the frequency and function of peripheral
CD4+FoxP3+ CD127-/low T-cells in kidney transplant patients.
Methods: After transplantation, 16 patients received ATG-induction therapy
(Thymoglobulin®) and triple therapy consisting of tacrolimus, MMF and
steroids. The control group (n=18) received triple therapy only. In the peripheral
blood of pre-transplant, 4 wks and 26 wks after transplantation T-cells markers
associated with immune regulation: CD25, FoxP3 and CD127 were analyzed
by flow cytometry. Within the FoxP3+ T-cell population, the CD45RO
(memory) and CCR7 (homing receptor) markers were characterized. To study
their suppressive capacities, pre- and post-transplant Treg were isolated and
cocultured with CD25neg T cells (Teff) in mixed lymphocyte reactions at a 1: 10
ratio, stimulated with donor- and third party antigens.
Results: Pre-transplant levels of CD4+FoxP3+CD127-/low T-cells were 6%
(median, ranging from 3-17%) of CD4+ T-cells. One wk post ATG induction
therapy, no measurable numbers of Treg were present. At 12 wks post ATGinduction therapy a higher proportion of first detectable T-cells expressed FoxP3
compared to the control-group (ATG vs. control-group; 8% vs. 6%, median,
respectively, p=0.02) and then returned to pre-transplant levels at 26 wks. This
increased proportion of CD4+FoxP3+CD127-/low T-cells resulted in a significantly
higher FoxP3+/FoxP3neg ratio than the control-group at 12 wks; (ATG vs.
control-group; 0.074 vs. 0.047, median, p=0.02). At 26 wks, the proportion
of memory T-cells exceeded that in the control-group (ATG vs. control-group;
75% vs. 67%, median, p=0.0053). which was mainly due to an increase in the
proportion of effector memory FoxP3+ Treg (CD45RO+CCR7neg). Although the
cell numbers of both Teff and Treg decreased after ATG immunodepletion, the
regulatory capacity of the Treg remained unaltered after transplantation, while
the proliferative response of the Teff diminished (p=0.0039 and p=0.0078;
donor and third party respectively). Depletion of CD25bright T cells resulted in
an increased proliferation against donor (p=0.0098) and third party antigens
(p=0.0020) at 26 wks post-transplant. Moreover, the isolated CD25bright T cells
were able to inhibit the anti-donor (65%) and third party response (77%) at a
ratio of 1: 10.
Conclusion: After ATG-induced immune cell depletion, a shift towards
CD4+FoxP3+CD127-/low peripheral regulatory T-cells with the memory
phenotype was measured in kidney transplant patients. Although the cell
number and the proliferative capacity of the Teff dramatically decreased, Treg
remained able to suppress the Teff against donor and third party antigens after
transplantation. These findings suggest that ATG treatment mainly affects the
function of the Teff and triggers the generation of de novo functional peripheral
regulatory T-cells by homeostatic proliferation.

206 INDUCTION OF CD8+ EFFECT T CELL APOPTOSIS
BY CO-TRANSPLANT WITH HEPATIC STELLATE CELLS, A
NOVEL APPROACH TO PROTECT ISLET ALLOGRAFTS
H-R. Yang1, G. Jiang2, J. Fung1, S. Qian1,2, L. Lu1,2
Department of General Surgery, Cleveland Clinic, 2Department of
Immunology, Lerner Research Institute, Cleveland Clinic
Spontaneous acceptance of liver allograft in many species indicates that
transplant tolerance is achievable, although the underlying mechanisms
remain to be elucidated. Interestingly, albeit liver allografts are accepted,
hepatocyte transplants in the same combination are promptly rejected,
indicating a pivotal role of liver tissue cells in immune suppression. We
have demonstrated a profound T cell inhibitory activity of hepatic stellate
cells (HpSC). which are known to participating in repairing and fibrosis
1
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207 A UNIQUE B CELL SIGNATURE ASSOCIATED WITH
OPERATIONAL TOLERANCE
K. Newell1, A. Asare2, A. Kirk1, T. Gisler2, M. Suthanthiran3, W. Burlingham4,
W. Marks5, L. Turka6, V. Seyfert-Margolis2
1
Emory University, 2University of California, San Francisco, 3Cornell
University Medical Center, 4University of Wisconsin, 5Swedish Medical
Center, 6University of Pennsylvania School of Medicine
Introduction: Decisions about the minimization and ultimate withdrawal of
immunosuppression (IS) would be facilitated by the identification of biomarkers
associated with operational tolerance (OT).
Methods: As part of an ITN/NIH supported study tolerant kidney transplant
recipients (off all IS for > 1yr with stable function, N=22) were compared
to recipients with stable function on IS (SIS, N=34). recipients with chronic
allograft nephropathy (CAN, N=20). and healthy volunteers (HV, N=18).
PBMC, whole blood total RNA, and urine samples from each group were
examined using flow cytometry, microarrays, and RT-PCR respectively.
Results: Analysis of microarrays revealed significantly higher expression of
B cell differentiation genes in tolerant recipients compared to the SIS and
CAN groups. Consistent with this finding, tolerant recipients also displayed
higher numbers of naïve B cells in peripheral blood and increased expression
of CD20 in urine relative to the SIS and CAN groups. No differences in Treg
or genes associated with regulatory cells were observed in tolerant recipients
relative to other groups. These analyses failed to demonstrate significant
differences between tolerant recipients and HVs although support vector
machine learning methods suggested potential differences in a number
of genes including NFAT and calcineurin. Finally, relative to tolerant
patients, those with CAN showed decreased numbers of T and NK cells and
expressed lower levels of genes associated with immune cell activation in
peripheral blood.
Conclusions: Differences in B cell numbers may be useful in identifying
tolerant renal transplant recipients or those predisposed to developing tolerance
and could potentially provide insights into the mechanisms of tolerance.

208 DONOR MARROW INFUSION IN KIDNEY
TRANSPLANTATION: RESULTS OF PRELIMINARY STUDY
M. Marvin, K. Ravindra1, R. Herzig2, K. Paris3, J. Buell4, S. Ildstad5
1Department of Surgery, University of Louisville, 2Blood & Marrow
Transplant Program, University of Louisville, 3Radiation Oncology
Department, University of Louisville, 4Department of Surgery, University of
Louisville, 5Institute for Cellular Therapeutics, University of Louisville
Introduction: Long-term function of renal allografts is compromised by
chronic rejection and adverse effects of immunosuppression. Achieving donor
specific tolerance has been the goal of the transplant community. Success has
been reported with donor stem cell transfusion in animal studies and prevention
of chronic rejection in cardiac allograft recipients in the clinic. This report
details the results of the initial phase of a study in humans.
Methods: A prospective phase I/II FDA approved pilot protocol was initiated
to evaluate the effects of donor graft facilitating cell (FC) /stem cell infusion in
kidney transplant recipients. Conditioning was performed with 200 cGy of total
body irradiation. Bone marrow processed to remove GVHD-producing cells
but retain CD8+/TCR- FC and stem cells was infused 24 hours post-operatively.
The dosage of stem cells was limited by the T cell dosage. The starting dose
was 1 x 105 T cells. This was increased in steps of 2 x 105 per patient. As
the study spans a 7-year period, the immunosuppression changed: 3 patients
received cyclosporine (CyA). MMF and Prednisone; 3 were induced with
Basiliximab and maintained on CyA (2) /FK (1). Cellcept and Prednisone; and
3 received Alemtuzumab induction and maintenance with FK and MMF. All
patients underwent tolerance testing and immunoprofiling studies.
Results: Of the 9 patients, 6 received live donor kidney transplants. One graft
was lost from arterial thrombosis on day 2. Delayed graft function was seen
in 3 patients. Good long-term graft function was seen in the other 8 patients.
Acute rejection was noted only in 1 and infectious complications (CMV-1,
Histoplasma-1) in 2 patients. Two patients died with functioning grafts – one
at 4 years from lung cancer and another from complications from diabetes
at 6 years. Six patients are alive with functioning grafts at mean follow-up
of 4.3 years with a mean creatinine at 1.3 mg/dl. No GVHD was detected in
any of the patients. Leucopenia and thrombocytopenia (nadir phase) was seen
in all patients at the end of 3 weeks and lasted 10-14 days. Macrochimerism
was not detected in any of the patients at any point. Notably, in spite of the
fact that durable engraftment was not yet achieved, none of the patients was
sensitized as a result nor did they experience immunologic sequelae. MLR
testing revealed delayed recovery of response to Candida and donor antigen in
patients induced with Alemtuzumab.
Conclusions: In our patients there were no untoward sequelae related to either
the conditioning regimen or marrow infusion. The incidence of acute rejection
even on long-term follow up has been low. We currently propose to reduce the
immunosuppression further in these patients.

209 THE ROLE OF B-CELL DEPLETION THERAPY FOR
DONOR-SPECIFIC B-CELL TOLERANCE AFTER ABOINCOMPATIBLE ADULT LIVER TRANSPLANTATION
Purpose: ABO-incompatible liver transplantation is often performed because
of organ shortage. Production of anti-donor blood type antibodies (Abs) is
suppressed following ABO-incompatible liver transplantation in most cases,
while non anti-donor blood type Abs still persist. This phenomenon suggests
the development of donor blood type antigen-specific B-cell tolerance. Previous
reports of B-cell tolerance following ABO-incompatible transplantation were
limited to infants. We investigated the mechanism of development of such
B-cell tolerance after ABO-incompatible liver transplantation using in-vivo
humanized mouse models, including of adult recipients.
Method: We studied 14 patients who received ABO-incompatible liver grafts
between 1996 and 2006. These patients were classified into three groups.
Group ‡T: 4 recipients (A to O in 2, B to O in 2 cases) aged around 1 year old
when they received the grafts; Group ‡U: 8 recipients (A to O in 3, B to O in
3, A to B in 2 cases) treated with rituximab as B-cell depletion therapy, ranging
in age from 6 to 50 years old at the time of transplantation; Group ‡V: 2 adult
recipients (one each of A to O and AB to A) who did not receive rituximab,
aged 42 and 44 years old at the time of transplantation. In order to investigate
the immune responses to the donor blood type antigens, we inoculated the
peripheral blood mononuclear cells (PBMCs) of the recipients into NODSCIDƒÁ-null mice (human PBMC-NOG mice) and immunized the mice with
the donor blood type antigens. Flow cytometry was performed for phenotyping
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during liver injury. Addition of activated (a) HpSC, but not quiescent HpSC,
significantly inhibited allo-DC induced-T cell proliferative responses
(MLR) in a dose dependent manner, which was associated with enhanced
T cell apoptosis (TUNEL). Neutralization of B7-H1 by anti-B7-H1 mAb
significantly reduced the HpSC-induced T cell apoptosis and reversed
the inhibition of T cell proliferation, suggesting a key role of B7-H1. To
evaluate this in vivo, BALB/c islets (300) were co-transplanted with 3 x 105
activated HpSC (B6) into STZ-induced diabetic B6 recipients. Co-transplant
with HpSC effectively protects islet allografts from rejection. This was
associated with reduction of graft infiltrating T cells and enhancement of
apoptotic activity. Co-transplant with HpSC from B7-H1-/- livers markedly
lost their islet graft protective capacity, associated with less apoptosis of
infiltrating cells. To determine the subsets of apoptotic T cells, T cells were
isolated from spleen, draining lymph nodes, and grafts for phenotype and
function analyses. On POD 8, a marked reduction of graft infiltrating CD4+
(30.7%) and CD8+ T cells (31.3%) was seen in HpSC co-transplant group,
as compared to islets alone, which was further progressed thereafter. CD8 T
cells dropped ~7 folds on POD 140. CD4+/CD8+ ratio was increased from
0.5 at the early POD to 2.0 in the long-term survival grafts. Adoptive transfer
of CFSE-labeled DES transgenic T cells was used to track the response and
fate of antigen-specific CD8+ T cells. The results showed active division
of DES+ cells within the allograft in both the islet only and HpSC cotransplantation groups. However, accumulation of these DES+ cells was
significantly lesser in the HpSC co-transplantation group as compared to
that in the islet only group (1.9¡Á103 vs. 10¡Á103 cells per graft). These
findings suggest that HpSC may not inhibit activation of antigen-specific
CD8+ T cells, but induce their robust apoptotic death, which is partially
mediated by inducibly expressed B7-H1 on HpSC. This could be one of
the important mechanisms by which tolerance in the peripheral organs is
maintained.
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to confirm the human cell engraftment and ELISA for detection of the human
anti-A Abs, anti-B Abs and total immunoglobulin produced in the mice.
Result: All mice were successfully engrafted with the human PBMCs as
determined by FACS and ELISA. In the mice inoculated with the PBMCs from
the Group‡T/‡Urecipients and immunized with the donor blood type antigens,
no anti-donor blood type human Abs were detected despite the production
of human immunoglobulins against other antigens. Strikingly, however,
significant production of anti-donor blood type human Abs was observed in the
mice engrafted with the PBMCs of the group‡V recipients.
Conclusion: In this study, we provide evidence of B-cell tolerance to blood
group antigens. Deletion is the primary mechanism of suppression of antibody
production in not only infantile, but also adult recipients of transplants
treated with rituximab, while anergy plays the key role in adult recipients not
receiving rituximab. This is the first report of adult B-cell tolerance after ABOincompatible transplantation.

210 PERIPHERAL CD4+CD25HIGHFOXP3+ T CELLS OF
HEART TRANSPLANT PATIENTS WHO EXPERIENCE ACUTE
REJECTION HAVE AN INADEQUATE IMMUNE REGULATORY
FUNCTION
C. Baan1, E. Dijke1, S. Korevaar1, A. Balk2, K. Caliskan2, L. Maat3,
W. Weimar1.
1
Internal Medicine, Erasmus MC, Rotterdam; 2Cardiology, Erasmus MC,
Rotterdam; 3Thoracic Surgery, Erasmus MC, Rotterdam, the Netherlands.
Introduction: This study explores the immune regulatory function of
peripheral CD4+CD25highFoxP3+ regulatory T cells during acute allogeneic
immune reactivity after clinical heart transplantation.
Methods: Peripheral blood mononuclear cells (PBMC) of 12 rejectors collected
before and during an acute cellular rejection (n=22) and PBMC (n=25) of
patients who remained free from acute rejections (nonrejectors; n=9) were
studied (time after transplantation: 7–138 days). The regulatory function of
CD4+CD25high T cells was examined by measuring the anti-donor proliferative
response before and after depletion, and their subsequent reconstitution
(CD25high: CD25neg/dim=1: 10). Additionally, flow cytometry was used to analyze
the expression of CD4, CD25, FoxP3 and CD127 (IL-7Rα chain).
Results: Between nonrejectors and rejectors, the% of CD25highFoxP3+ T
cells within the CD4+ T cells was comparable (median: 3.0% vs. 2.6%). Yet,
differences were found in the CD127 expression: CD4+CD25highFoxP3+ T
cells of nonrejectors had a significantly lower expression of CD127 compared
with those of rejectors (median fluorescence value: 18.0 vs. 26.8; p<0.0001).
Functional analysis revealed that depletion of CD4+CD25high T cells increased
the anti-donor proliferative response of both nonrejectors and rejectors
(p<0.001 and p=0.03). The suppressive potency of the CD4+CD25high T
cells, however, was significantly different: in rejectors only a 2-fold increase
(median) in response was measured, while the response in nonrejectors became
14 times (median) higher (p=0.001). suggesting lower regulatory function of
CD4+CD25high T cells of rejectors. Reconstitution of these cells confirmed
this observation: the response of CD25neg/dim effector cells of nonrejectors
was abundantly suppressed (p<0.0001). while the response of the rejectors
was scarcely inhibited (p=0.14). Within rejectors, the inhibitory effect of
CD4+CD25high T cells was comparable between samples taken before and those
sampled during rejection.
Conclusion: Peripheral CD4+CD25highFoxP3+ T cells of heart transplant
patients who experience acute rejection, on which an upregulated expression
of CD127 was found, showed inferior immune regulatory function in vitro
compared with those of nonrejecting patients. These findings suggest that
CD4+CD25highFoxP3+ T cells may be involved in preventing acute cellular
rejection after clinical heart transplantation.
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211 RECRUITMENT OF FOXP3 EXPRESSING T CELLS INTO
THE GRAFTS OF TOLERANT HUMAN LIVER TRANSPLANT
RECIPIENTS
Y. Li1, X. Zhao1, D. Cheng2, H. Haga3, T. Tsuruyama4, K. Wood5,
S. Sakaguchi6, K. Tanaka7, S. Uemoto2, T. Koshiba1
1
Innovation Center For Immunoregulation Technologies And Drugs,Graduate
School of Medicine, Kyoto University, 2Department of Surgery, Graduate
School of Medicine, Kyoto University, 3Department of Diagnostic Pathology,
Kyoto University Hospital, 4Department of Pathology and Biology of
disease, Graduate School of Medicine, Kyoto University, 5Transplantation
Research Immunology Group, 4Nuffield Department of Surgery, University of
Oxford, John Radcliffe Hospital, Headington, 6Department of Experimental
Pathology, Institute for Frontier Medical Science, Kyoto University,
7
Foundation for Biomedical Research and Innovation
Background: The recruitment of regulatory T cells (Tregs) into grafts has
been shown to be important for the development of operational tolerance (Tol)
in experimental models of transplantation. To determine if the recruitment of
Tregs correlates with continued graft survival in operationally tolerant living
donor liver transplant (LDLT) recipients, the expression of FOXP3 mRNA and
the presence of FOXP3+ cells were quantified in biopsies from tolerant, i.e.
immunosuppression free, liver transplant recipients.
Method: Liver tissue was obtained from 13 tolerant recipients using an
automated biopsy gun under guidance of ultrasonography (Gr-Tol). Total
RNA was extracted for cDNA synthesis. The expression level of the FOXP3
mRNA was quantified by real-time PCR. Immunohistochemistry and double
immunofluorescent stainings for CD4,CD8, and FOXP3 were performed
using paraffin embedded sections. The results were compared with
biopsy samples from the liver allografts of (i) recipients on maintenance
immunosuppression (Gr-IS) in whom biopsy samples were obtained in the
same manner as Gr-Tol before starting weaning IS, (ii) grafts removed as a
result of chronic rejection (Gr-CR) or (iii) from normal liver i.e. donor zero
biopsy (Gr-NL).
Results: The expression of FOXP3 mRNA in Gr-Tol was higher than that in GrIS and Gr-NL, but equivalent to that in Gr-CR (log FOXP3/HPRT ~106 Gr-Tol,
Gr-IS, Gr-CR and Gr-NL: 4.1 } 0.5, 3.6 } 0.7, 4.4 } 0.4 and 3.0 } 0.7; Gr-Tol vs.
Gr-IS p=0.06, Gr-CR vs. Gr-IS p<0.05, Gr-Tol, Gr-CR vs. Gr-NL p <0.0005,
Gr-Tol vs. Gr-CR NS). Immunohistochemistry and double immunofluorescent
stainings demonstrated that in Gr-Tol, FOXP3+ cells were readily detectable in
the portal area, accumulated within clusters of CD4+ and CD8+ cells and were
CD4+. Both the number of FOXP3+ cells and their frequency amongst CD4+
cells were significantly increased in Gr-Tol, compared to that in Gr-IS, Gr-CR,
and Gr-NL (The number of FOXP3+ cells; Gr-Tol, Gr-IS, Gr-CR and Gr-NL:
10.8 }10.8, 3.4 }6.7, 0 }0 and 2 }1.9 cells/10 portal areas, Gr-Tol vs. Gr-IS p
< 0.05, Gr-Tol vs. Gr-CR p<0.05, Gr-Tol vs. Gr-NL p < 0.05, Gr-CR vs. GrNL NS) (FOXP3+/CD4+; Gr-Tol, Gr-IS, Gr-CR and Gr-NL: 0.34 }0.21, 0.097
}0.12, 0 }0, and 0,14 }0.2, Gr-Tol vs. Gr-IS,-CR,-NL p<0.05).
Conclusions: This is the first report showing that CD4+FOXP3+ cells
accumulate in tolerant grafts after human liver transplantation. Our findings
suggest that the analysis of intra-graft expression of FOXP3 protein detectable
by immunohistochemistry, but not FOXP3mRNA, may aid the identification of
LDLT recipients who can successfully stop IS.

212 STUDY OF COMPLETE IMMUNOSUPPRESSIVE DRUG
WITHDRAWAL FROM LIVER TRANSPLANT PATIENTS
CONDITIONED WITH POSTTRANSPLANT TOTAL LYMPHOID
IRRADIATION (TLI) AND ANTI-THYMOCYTE GLOBULIN
(ATG)
A. Bonham, C. Esquivel, W. Concepcion, S. Strober
Stanford University Medical School
Previous studies in rodents have shown that immune tolerance to MHCmismatched heart transplants in recipients conditioned with posttransplant TLI
and ATG requires an infusion of donor bone marrow cells and development of
chimerism. In contrast, almost all Lewis rat recipients of ACI liver trasnplants
develop tolerance after TLI and ATG without a donor cell infusion (Millan, M.
et al, 2007, Transplantation, ). Based on these results, we developed a clinical
protocol in which liver transplant patients were conditioned with posttransplant
TLI (10 doses of 80cGy each) starting on posttransplant days 3-5, and 5 doses
of ATG starting on day 0. After conditioning, patients were maintained on
daily conventional doses of tacrolimus for 3 months, and then tapered to
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213 DEVELOPMENT OF OPERATIONAL TOLERANCE
AFTER PEDIATRIC LIVER TRANSPLANTATION IS
ASSOCIATED WITH THE ABSENCE OF EARLY REJECTION
AND THE PRESENCE OF HLA-B MISMATCH BETWEEN
DONORS AND RECIPIENTS
H. Ohe1, M. Yoshitomi1, T. Koshiba2, S. Uemoto1
1Department of Surgery, Graduate School of Medicine,Kyoto University,
2Innovation Center for Immunoregulation Technologies and Drugs, Graduate
School of Medicine, Kyoto University
Background: In the setting of our pediatric living-donor liver transplantation
(Ltx). 15% of all the patients (significantly higher proportion, compared
with those of other transplant centers) achieved complete withdrawal of
immunosuppression (IS). which is reffered to as operational tolerance
(Transplant Immunol,2007,17: 94). Nonetheless, some patients encountered
rejection while they were undergoing weaning from IS. It is,therefore,essential
to identify and characterize the differences that will enable patients in these two
distinct populations to be distinguished reliably.
Methods: The study groups consisted of group tolerance (Gr-Tol) in
which 88 patients are successfully weaned off from IS, and group rejection
(Gr-Rej) in which 22 patients experienced clinically evident rejection
during or after weaning process. The correlation between the clinical
outcome (success or failure of weaning IS) and following parameters was
assessed; donor/recipient age, donor/recipient gender, ABO compatibility,
HLA mismatch, graft size, early (<1month) rejection episode and initial
immunosuppression.
Results: There was no difference between Gr-Tol and Gr-Rej with respect to
donor/recipient age (Gr-Tol and Gr-Rej; 32y and 32y NS/35m and 26m NS).
or donor/recipient gender (Gr-Tol and Gr-Rej (female); 60% and 50% NS/60%
and 73% NS). ABO compatibility did not differ between the two groups (GrTol and Gr-Rej; identical: compatible: incompatible ;63%: 27%: 10% and 55%:
27%: 18% NS).The presence of HLA-B mismatch was more frequent in GrTol than that in Gr-Rej (Gr-Tol and Gr-Rej; 95% and 76% p<0.05 ). while
the presence of HLA-A or DR mismatch did not affect success or failure of
weaning IS (HLA-A Gr-Tol and Gr-Rej;73% and 76% NS, HLA-DR ;83% and
82% NS). Graft size did not differ between the two groups (GBWR Gr-Tol and
Gr-Rej; 2.9% and 3.2% NS). The patients in Gr-Rej experienced early rejection
(< 1 month) more frequently than those in Gr-Tol (Gr-Tol and Gr-Rej; 17%
and 50% p<0.05). Mean trough level of tacrolimus within 7 days after Ltx was
comparable between the two groups (Gr-Tol and Gr-Rej ;11ng/ml and 11ng/
ml NS).
Conclusions: Development of operational tolerance after pediatric Ltx was
associated with the absence of early rejection and the presence of HLA-B
mismatch between donors and recipients. Thus, those parameters may be
promising candidate for identifying recipients who can stop IS successfully
amongst the recipients who start weaning IS.

CONCURRENT ORAL SESSION 16: INFLAMMATION
214 GENE EXPRESSION PATTERNS OF MAJOR
PROINFLAMMATORY MEDIATORS DIFFER BETWEEN
ACUTE CELLULAR AND HUMORAL REJECTIONS AND
ALLOW TO DISCRIMINATE RENAL ALLOGRAFTS AT RISK
FOR FAILURE
O. Viklicky1,2, J. Slatinska1, I. Brabcova1, K. Bartosova1, P. Hribova2
Dept. of Nephrology, Transplant Center, Institute For Clinical And
Experimental Medicine, 2Transplant Laboratory, Institute For Clinical And
Experimental Medicine
Background: Early acute humoral rejection (AHR) is a rare complication after
kidney transplantation with poor prognosis and ill-defined pathogenesis.
Methods: Out of 730 patients who had undergone kidney transplantation in
2002-2005 and had received CNI+MMF+steroid based immunosuppression,
21 patients (2.9%) with early (POD 9) AHR were identified. As a control group,
a matched group of 43 patients with early acute cellular rejection (ACR) was
used. Using real-time quantitative PCR, the intragraft expression profiles of
proinflammatory and tissue injury markers (TGF-â1, FoxP3, TNF-á, MCP-1,
RANTES, HMOX1, CD3, CD20, and IgJ mRNA) during AHR and ACR were
analyzed.
Results: There was a higher intrarenal mRNA expression of RANTES (p<0.05)
while lower of HOX1 (p<0.05) during AHR as compared to ACR. Grafts that
failed as a consequence of AHR had revealed lower intrarenal TGF-â1 (p<0.05).
RANTES (p<0.05). CD20 (p<0.01). IgJ (p<0.05) and FoxP3 (p<0.05) mRNA
expression, while lower expression of CD3, CD20 and IgJ was found in grafts
failed as a consequence of ACR. The enhanced intrarenal expressions of
TGF-â1, CD20 and RANTES mRNA during early AHR were associated with
longer graft survival (Kaplan-Meier). Using Cox regression, the both lower
TGF-â1 and CD20 mRNA expressions during AHR were associated with the
risk of graft failure in the first year (OR 24.0; p<0.01 and OR 14.0; p<0.05
respectively).
Conclusion: A lower mRNA expression levels of proinflammatory and
tissue injury markers during early acute cellular and humoral rejections may
identify grafts with poor prognosis and thus requiring additional therapeutical
intervention.
1

215 SOLUTION TO A LONG-STANDING PARADOX?
DISPROPORTIONATE PROLIFERATION OF THE INDIRECT
PATHWAY DURING ACUTE REJECTION
H. Zaid, T. Brennan, T. Hayden, F. Liu, Q. Tang, S-M. Kang
UCSF Division of Transplantation
Although the existence of indirect alloreactive T lymphocytes is now firmly
established, the relative contributions of the direct and indirect pathways in
alloimmune responses have not been fully elucidated. The precursor frequency
of alloreactive T cells responding via the indirect pathway is thought to be at
least several orders of magnitude lower than for the direct pathway, which has
been estimated to be 5-10% of the T cell pool. Thus, the direct pathway has
been assumed to be the dominant mediator of acute rejection while the indirect
pathway has been implicated in chronic rejection. This paradigm, however, has
failed to explain the finding that the pace of acute rejection is largely unaltered
by elimination of the direct pathway.
To explore the relative contributions of the direct and indirect pathways to
the alloimmune response, we have developed a novel T cell receptor (TCR)
transgenic system that can simultaneously track the CD4-direct (CD4-d).
CD4-indirect (CD4-i). and CD8-direct (CD8-d) pathways after transplantation.
Using this system, we have observed a profoundly greater proliferation
of CD4-i T cells relative to CD4-d and CD8-d T cells after allogeneic skin,
heart, or islet transplantation. Furthermore, the robust priming of the indirect
pathway is associated with a much larger proportion of CD4-i T cells attaining
an effector phenotype, as defined by the production of IFN-gamma. To rule
out an artifact of our TCR transgenic system, we analyzed endogenous, wildtype T cells from the spleen and lymph nodes using ELISPOT analysis. In
naïve animals, T cells with indirect reactivity were undetectable by ELISPOT
analysis, while T cells with direct reactivity were abundant. However, 10 days
after skin or heterotopic heart transplantation in the BALB/c to C57BL/6
strain combination, CD4-i T cells comprised approximately 10% of the CD4+
response. Strikingly, by 60 days post-transplant, CD4-i T cells comprised 20%
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discontinuation at 6 months. Tapering was performed by gradual reduction of
the number of days per week of tacrolimus therapy.The protocol considered
patients with rejection episodes any time as experimental therapy failures to
be returned to standard anti-rejection and maintenance immunosuppressive
drug therapy. At present, 6 patients have been enrolled in the protocol,
and none have had rejection episodes. Patient 1 is off immunosuppressive
drugs at 7 months posttranplant, and patients 2 through 6 are receiving
tacrolimus 2,3,4, 5, and 7 days per week respectively. No severe infections
have been observed other than recurrence of hepatitis C in 1 patient that is
under treatment with interferon alpha and ribovirin with a good response. In
conclusion, we have applied the tolerance induction protocol of posttransplant
TLI and ATG that was successful in preclinical studies to patients undergoing
liver transplantation. The protocol has been well tolerated, and tapering of
immunosuppressive drugs has not been associated with rejection episodes in
the first 6 patients studied.
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of the IFN-gamma producing alloreactive CD4+ T cells, suggesting that CD4-i
T cells persist and are further enriched over time. Thus, the indirect T cells
appears to preferentially expand and accumulate relative to the direct pathway,
allowing comparatively rare CD4-i T cells to comprise a significant proportion
of alloreactive CD4+ T cells after transplantation.
Based on the increased relative priming of the indirect pathway, we hypothesized
that the CD4-i T cells would be further enriched in the effector cells migrating
to the allograft. Indeed, ELISPOT analysis of graft-infiltrating CD4+ T cells
7 days after heterotopic heart transplantation showed that CD4-i T cells
accounted for approximately 33% of IFN-gamma producing cells among graftinfiltrating lymphocytes.
Our results demonstrate that priming of the CD4-i pathway is favored after
transplantation and allows a rare population to rapidly become a major
component of the CD4+ T cell response in acute allograft rejection. These
findings on the fundamental differences in the dynamics of the CD4-i and
CD4-d pathways may have significant implications for rational design of
immunosuppressive and tolerance-induction regimens.

216 A NEW MECHANISM OF GRAFT REJECTION IN THE
COMPLETE ABSENCE OF ADAPTIVE IMMUNE CELLS
A. Kroemer, X. Xiao, K. Edtinger, N. Degauque, G. Demirci, X.C. Li
Transplant Research Center, Departments of Medicine And Surgery, Beth
Israel Deaconess Medical Center, Harvard Medical School
Background: While transplant rejection is primarily mediated by adaptive
immune cells such as T and B cells, which are also responsible for the specificity
and memory of rejection response, dismantling allografts involves many other
cell types including cells in the innate immune system. Because innate immune
cells do not express germ-line encoded cell surface receptors that recognize
foreign antigens, the assumption has been that these only participate in the
destruction of allografts when recruited by T cells. The ongoing difficulty in
creating transplant tolerance under stringent conditions has stimulated renewed
interests in the role of innate immune cells, especially NK cells, in the induction
of transplant rejection.
Methods: We used Rag-/- and Rag-/-IL-2Rγ;-/- double knockout mice as
transplant recipients to critically examine the alloreactivity of NK cells in a
stringent skin transplant model. Both Rag-/- and Rag-/-IL-2Rγ;-/- mice are
deficient for T and B cells. In addition, the Rag-/-IL-2Rγ;-/- mice are deficient
for NK cells, while the Rag-/- mice possess a large population of functional NK
cells. This allowed us to precisely study the role of NK cells in mediating skin
allograft rejection in the absence of adaptive immune cells.
Results: To ascertain the cytolytic activity of NK cells in Rag-/- mice, we
adoptively transferred CFSE labelled syngeneic B6 and allogeneic DBA/2
spleen cells into Rag-/- and Rag-/-IL-2Rγ;-/- recipients. Both syngeneic B6
and allogeneic DBA/2 spleen cells survived in the Rag-/-IL-2Rγ;-/- mice.
However, the DBA/2 cells, but not the B6 cells, were readily killed in the
Rag-/- mice, demonstrating that NK cells are potent effectors in allogeneic cell
rejection. Nevertheless, DBA/2 skin allografts were accepted by both Rag-/and Rag-/-IL-2Rγ;-/- mice without any sign of rejection (>100 days). Thus, NK
cells by themselves, though cytolytic to DBA/2 cells, fail to reject the DBA/2
skin allografts. To test the hypothesis that the activation status of NK cells
dictates their alloreactive potential, we treated the Rag-/- mice with IL-15/IL15Rα; complex to maximally stimulate the NK cells. As suspected, the IL-15
treated Rag-/-, but not the Rag-/-IL-2Rγ;-/- mice, readily rejected the DBA/2
skin allografts (MST=18 days). IL-15, when complexed to its private IL-15Rα;
chain, proved to be highly potent in stimulating NK cells in vivo, which in
turn expressed an activated phenotype that rendered them surprisingly potent in
mediating acute skin allograft rejection in the absence of any adaptive immune
cells. Furthermore, NK cell-mediated graft rejection did not show features of
memory responses.
Conclusions: Our data demonstrate that when fully activated and differentiated,
NK cells are potent alloreactive cells in allograft rejection. We further found
that IL-15 is critically important in this regard. Thus the fate of allografts
may depend on the activation status of NK cells and the availability of NK
stimulating cytokines. These findings may have important clinical implications
in models of transplantation tolerance and autoimmunity.
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217 SUSCEPTIBILITY OF ISLETS TO INFLAMMATION IN
A MOUSE MODEL OF DIABETES IS INFLUENCED BY THE
LEVEL OF EXPRESSION OF CD39
J. Chia1, T. Craig1, S. Robson2, A. d’Apice1, P. Cowan1, K. Dwyer1
1
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Victoria,
Australia, 2Beth Israel Deaconess Medical Centre, Harvard Medical School,
Boston, MA, USA
Background: Type 1 diabetes mellitus results from the autoimmune destruction
of pancreatic islets. Islet transplantation is a potential cure for this devastating
illness, but initial enthusiasm has been tempered by loss of graft function
such that only 15% of recipients are insulin-free at 5 years. This decline in
insulin independence is complex and not fully understood. Detrimental factors
include a destructive inflammatory response to islets transplanted into the liver,
metabolic exhaustion and recurrent β cell autoimmunity. We are investigating
protection of islet grafts by overexpressing various proteins including CD39,
which works in concert with CD73 to hydrolyse pro-inflammatory extracellular
nucleotides (ATP, ADP) to the anti-inflammatory molecule adenosine. We have
shown that expression of human CD39 (hCD39) on murine islets prevents
thrombosis when they are mixed with human blood. Others have shown that
inosine, a metabolite of adenosine, protects against development of diabetes
and rejection of transplanted islets.
Aim: To examine whether the level of expression of CD39 influences the
development of diabetes in the multiple low dose streptozotocin (MLDS)
mouse model.
Methods: 8-week old male CD39 null, hCD39 transgenic (hCD39TG) and
wild-type (WT) mice on a C57BL/6 background were treated with MLDS for
5 days. Fasting blood glucose levels (BGL) were recorded on day 0. Thereafter
non-fasting BGL were measured three times weekly. Mice with BGL of 15-20
and >20mmol/L for at least 2 consecutive readings were deemed hyperglycemic
and overtly diabetic, respectively. Histological analyses were performed to
assess the integrity of islets after challenge with MLDS.
Results: WT mice were hyperglycemic (mean BGL 19.4±1.5mmol/L) by day
30. In contrast, CD39 null mice were overtly diabetic (BGL 24.5±1.6 mmol/L,
P<0.05 versus WT) by this time, whereas hCD39TG mice were normoglycemic
(mean BGL 13.3±0.8 mmol/L, P<0.05 versus WT). Histologically, islets from
CD39 null mice were hypercellular and showed a higher level of apoptosis
than WT islets, and insulin production was severely hampered. Islets from
hCD39TG mice were normocellular and exhibited less apoptosis, and insulin
production was not affected by MLDS treatment.
Conclusion: The level of CD39 expression correlated with the severity of
diabetes in this model, suggesting that elevated CD39 expression may prolong
islet graft survival by preventing the recurrence of autoimmunity. Further
transplantation studies will address this question and determine the impact of
CD39 overexpression on the kinetics of mouse islet allograft rejection. Isolating
hCD39 expression to either bone marrow-derived circulating cells or the islets
via adoptive transfer experiments will be used to further define the mechanism
of protection in vivo. If expression on islets alone is found to be sufficient to
protect against immune-mediated injury, this may have clinical implications in
islet transplantation as islets may be supplemented with CD39 by gene therapy
prior to transplantation.

218 EFFECT OF ACUTE AND CHRONIC LITHIUM
ADMINISTRATION ON RENAL ISCHEMIA/REPERFUSION
INJURY IN RAT: THE ROLE OF NITRIC OXIDE
H. Emami1, S.S. Talab1, B.G. Nezami1, A. Elmi1, S. Assa1, S.M. Tavangar2,
A.R. Dehpour1
1
Department of Pharmacology, School of Medicine, Medical Sciences/
University of Tehran, Tehran, Iran, 2Department of Pathology, Shariati
Hospital, Medical Sciences/University of Tehran, Tehran, Iran
Introduction: Renal ischemia/reperfusion injury (IRI) is a major problem
in renal transplantation which occurs during the process of organ retrieval
and storage; and is closely associated with acute rejection episodes and late
allograft failure. However, recent studies have revealed a new phenomenon
called “chemical preconditioning” which can induce tolerance against the
ischemic stress via a variety of proposed pathways especially nitric oxide
(NO) system. Lithium is suggested to modulate the intracellular NO signaling,
although the exact mechanism underlying the drug’s therapeutic action is not
yet understood. In this study we investigated the preconditioning properties
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219 CYCLOXYGENASE-2 SELECTIVE INHIBITION
DOWNREGULATES METALLOPROTEINASE-9 ACTIVATION
AND IMPAIRS NEUTROPHIL MIGRATION IN HEPATIC
ISCHEMIA/REPERFUSION INJURY
A.J Coito1, T. Hamada1, S. Tsuchihashi1, S. Duarte1, R.W Busuttil1
1
The Dumont UCLA Transplant Center, Los Angeles, CA, United States.
Neutrophils are critical mediators in inflammatory liver injury. This study tests
the hypothesis that cyclooxygenase-2 (COX-2). a potent inflammatory mediator
regulates neutrophil recruitment in liver ischemia/reperfusion (I/R) injury.
Methods and Results: COX-2 -/- mice (COX-2 KO) and matched COX-2
+/+ controls (WT) were submitted to 90 minutes warm ischemia followed by
6h and 24h of reperfusion. The synthesis of PGE2 (pg/20mg protein: 636±192
vs. 1,167±157; p<0.008, n=4/gr). and TXB2 (pg/20mg protein: 169±117 vs.
652±291; p<0.04, n=4/gr) was significantly reduced in COX-2 deficient livers
at 6h of I/R injury, as compared to WT controls. Liver function, as evidenced
by the sGOT (IU/L) (6h: 1,505±1,125 vs. 15,502±11,344; p<0.03; 24h:
3483 vs. 974±193; p<0.01, n=5-6/gr). and sGPT (U/L) (6h: 2,639±1,930 vs.
15,466±7,552; p<0.003; 24h: 206±45 vs. 1,244±600; p<0.01, n=4-5/gr) levels
was significantly improved in COX-2 KO mice as compared to WT controls
after I/R. COX-2 KO livers showed overall improved histological preservation
after the I/R insult, contrasting with extensive sinusoidal congestion and
necrosis observed in controls. Moreover, the levels of anti-apoptotic BcL-2
(0.83±0.14 vs. 0.08±0.09, p<0.01; n=4/gr) and Bcl-XL (1.38±0.11 vs. 0.58±0.19,
p<0.01; n=4/gr) were significantly higher in COX-2 KO livers after 6h of I/R
injury. One of the most striking effects observed in COX-2 KO mice was the
markedly reduced neutrophil recruitment in livers after I/R as indicated by the
decreased levels of MPO activity (U/g) (6h: 2.0±1.0 vs. 13.7±4.3; p<0.01; 24h:
1.2±0.4 vs. 3.4±1.5; p<0.01; n=5-6/gr). and by the reduced Ly-6G neutrophil
infiltration at both 6h (35%, p<0.01) and 24h (50%, p<0.01). CXCL-2 mRNA
expression, a major neutrophil chemoattractant (6h: 9.1±0.7 vs. 11.1±0.7;
p<0.05; 24h: 3.1±3.0 vs. 10.0±3.5; p<0.05) was decreased in COX-2 KO
livers after I/R. Overall, leukocyte transmigration is dependent upon cell
activating chemokines, adhesive interactions, as well as matrix degradation
mechanisms. MMP-9 activity, which is induced and mediates liver I/R injury,

was significantly reduced in COX-2 KO livers at both 6h (2-fold) and 24h
(4-fold) of reperfusion. Indeed, Ly-6G neutrophils co-expressing MMP-9 were
highly detected in damaged WT livers and profoundly depressed in COX-2
KO livers after I/R insult. Interestingly, the addition of NS-398, a selective
COX-2 inhibitor, to fMLP-stimulated neutrophils, markedly depressed MMP-9
activation (5 to10 fold) by these cells in a dose-dependent manner. Furthermore,
the treatment of isolated neutrophils with MMP-9 inhibitor-I, a specific MMP-9
inhibitor, significantly disrupted their migration across fibronectin in transwell
filters (35% vs. 63%, p<0.004).
Conclusion: Our novel findings support the view of an important function for
COX-2 in the pathogenesis of hepatic I/R injury. Moreover, they evidence a
regulatory role for COX-2 on MMP-9 activation by neutrophils, which is likely
a key factor in the recruitment of these cells in liver I/R injury.

220 ROLES OF ISLET-ASSOCIATED HEPARAN SULFATE
(HS) AND HEPARANASE IN ISLET BETA CELL SURVIVAL AND
ISLET ALLOGRAFT REJECTION
C. Simeonovic1, F.J. Choong2, S. Popp3, A. Ziolkowski4, C. Freeman5,
C. Parish6
1The John Curtin School of Medical Research, The Australian National
University, 2The John Curtin School of Medical Research, The Australian
National University, 3The John Curtin School of Medical Research, The
Australian National University, 4The John Curtin School of Medical
Research, The Australian National University, 5The John Curtin School of
Medical Research, The Australian National University, 6The John Curtin
School of Medical Research, The Australian National University
Autoimmune destruction of pancreatic islets and the development of Type
1 diabetes in NOD/Lt mice correlates with increased expression of the HS
degradative enzyme heparanase, which targets HS proteoglycans in islet
basement membranes (BM) and the intra-islet extracellular matrix (ECM). Our
study investigated the role of HS in islet beta cell viability and the contribution of
heparanase to the rejection of islet allografts. Islet-associated HS was identified
by histological staining with alcian blue and by immunohistochemistry using
10E4 anti-HS mAb (Seikagaku) and the M.O.M immunodetection kit (Vector
Labs). BALB/c islets were dissociated into single cells using Dispase (1mg/
ml) and beta cells were identified by immunofluorescence microscopy using
guinea-pig anti-swine insulin serum and FITC-donkey anti-guinea pig IgG.
Beta cell-associated HS was removed by in vitro treatment with bacterial
heparitinase I, II and III (Sigma; 0.25U/ml) and cell viability was assessed after
2 days of culture by fluorescence microscopy using Sytox Green (Invitrogen)
to distinguish dead cells. Heparanase and ubiquitin-conjugating enzyme (UBC;
house-keeping gene) transcripts were analysed quantitatively in cDNA from
BALB/c (H-2d) islet allografts and CBA/H (H-2k) islet isografts at 3 – 8 days
post-transplant to CBA/H mice, using Taqman real-time PCR. Heparanase
protein was identified by immunohistochemistry in mouse pancreas and islet
transplants using polyclonal rabbit anti-heparanase antibodies. Islets in situ
were shown to be enriched in HS. Beta cells constituted 92.3 ± 3.2% (n=3)
of dissociated BALB/c islet cells. Heparitinase treatment of isolated islet
cells significantly increased beta cell death from 21.1 ± 6.8% (in controls) to
78.8 ± 7.3% (n=12; P<0.0001). Treated beta cells were rescued from dying
by culturing them on an exogenous ECM (prepared from PK-15 cells (a pig
kidney epithelial cell line); P<0.0001) or with 5-50 micrograms/ml heparin
(a highly sulfated analogue of HS; P<0.0001). Intragraft heparanase mRNA
increased 4-fold during rejection, compared to isografts and peaked at day 7. In
situ and post-transplant, islets showed intense staining of inactive heparanase
(proheparanase) protein. Alloimmune islet damage correlated with localisation
of active heparanase in the host cellular infiltrate and in the periphery of
transplanted islets, adjacent to infiltrating leukocytes. Active heparanase was
not detected in engrafted isogeneic islets. Our findings demonstrate that islet
beta cells require HS for survival and are exquisitely sensitive to loss of cellassociated HS. Since heparanase is the only mammalian endoglycosidase that
can degrade HS, our findings suggest that during rejection, host leukocytederived heparanase functions in disrupting the BM of engrafted islets and this
process represents an initial alloimmune assault. Thereafter, leukocyte-derived
heparanase and possibly donor islet-derived heparanase activated via cytokines
produced by infiltrating host leukocytes, degrade the intra-islet HS necessary
for beta cell survival. This mechanism of rejection could therefore potentially
involve a novel process of islet cell-mediated “self-destruction”. Our findings
suggest that inhibitors of heparanase may represent a novel anti-graft rejection
strategy for islet allografts.
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of acute and chronic lithium pretreatment in preventing renal IRI and the
involvement of NO pathway.
Materials & Method: Forty-eight adult male Sprague-dawley rats were
divided into six groups. All groups underwent right nephrectomy 14 days before
intervention. Groups 1 and 2 received acute intraperitoneal (IP) LiCl (40 mg/
kg) and 30 minutes later IRI was induced by clamping the left renal pedicle for
60 minutes. Group 1 (Acute Li+ L-NAME) received the nitric oxide synthase
inhibitor, L-NAME (10 mg/kg) 15 minutes before LiCl administration and
group 2 (Acute Li) received its vehicle. In groups 3 (Chronic Li+ L-NAME)
and 4 (Chronic Li). oral Li (600 mg/lit in water) treatment was started 7 days
before right nephrectomy to achieve the therapeutic plasma level of lithium.
Fourteen days after nephrectomy, animals received either L-NAME (10 mg/
kg) or its vehicle and renal IRI was induced 45 minutes later. Groups 5 and
6 (Control) received either L-NAME (10 mg/kg) or its vehicle 45 minutes
before IRI. Rats were killed 24 h after IRI, the blood samples were collected
and assessed for serum BUN and Cr level, and tissue samples were fixed in
formalin for histopathologic tubular damage scoring (H-score).
Results: The mean BUN, Cr and H-score were 154.6±29.46, 4.3±0.77 and
82±5%, respectively in control group. Acute Li significantly improved BUN
(116±20.1). Cr (3.35±0.95) and H-score (32±28%) in IRI animals compared
to those not treated with acute lithium (P<0.05); and L-NAME pretreatment
significantly reversed the protective effect of acute lithium (BUN= 175.5±8.37,
Cr= 4.93±0.173 ,H-score= 66±13%). Similarly, Chronic Li significantly (but
more potently) improved BUN (59±17.1). Cr (1.08±0.1) and H-score (7.5±5%)
in IRI animals compared to those not treated with chronic lithium (p<0.05)
and L-NAME significantly reversed the chronic lithium induced protection
(BUN= 15.3±19.2, Cr= 3.8±0.4, H-score= 26.3±3%). There was no significant
difference between rats treated with L-name alone (group 5) and the control
group.
Conclusion: Our study demonstrates that preconditioning of kidney with either
acute or chronic lithium protects renal tissue against ischemia/reperfusion
injury; and this phenomenon is mediated with Nitric oxide system. The results
suggest a potential application for lithium in terms of protecting the kidney
before transplantations and also reducing the risk of tissue rejection afterwards.
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221 HUMAN CYTOMEGALOVIRUS INFECTION HAS A
CRITICAL IMPACT ON LEUKOCYTE TELOMERE LENGTH
P.J.E.J. van de Berg1,2, S.L. Yong2, F. J. Bemelman1, I.J.M. ten Berge1 and
R.A.W. van Lier2.
1
Renal Transplant Unit, Dept. of Internal Medicine and 2Dept. of
Experimental Immunology, AMC, Amsterdam.
Introduction: Reduction of mean leukocyte telomere length is associated
with a high risk of cardiovascular disease but the basis for this association is
unknown. Cytomegalovirus (CMV) infection causes an expansion of highly
differentiated effector CD8+ T lymphocytes. Given the many cell divisions
during development to effector cells, we studied telomere length in relation to
CMV serostatus in healthy people.
Methods: Peripheral blood was obtained from 10 CMV seronegative and 10
CMV seropositive age- and sex matched healthy volunteers, as well as from
20 renal transplant recipients. The composition of the peripheral CD8+ T cell
compartment was studied by FACS analysis using the subset markers CD45RA,
CD27 and CD28. In addition, telomere length was measured by flow-fish, a
FACS based assay using telomere specific FITC-labelled probe.
Results: We found that the inter-individual variation in the mean telomere
length of blood cells is almost exclusively determined by the composition of
the lymphocyte pool and not by granulocytes or monocytes. Renal transplant
patients show a sudden and sustained drop in telomere length in the course of
primary infection, also the lymphocyte pool changed permanently to a more
differentiated state. CMV seropositive healthy individuals showed a strong
increase in numbers of highly differentiated effector CD8+ T lymphocytes and
the mean telomere length in CMV seropositive individuals was significantly
shorter than in CMV seronegative individuals (p<0,008). Importantly, the
mean telomere length appeared to be directly dependent on the size of the
CD45RA+CD27-CD8+ effector T cell pool (r=-0,74).
Conclusion: We show that the mean telomere length of full blood is
directly related to the differentiation status of the lymphocyte pool. Given
the established association of mean telomere length with cardiovascular
disease our data suggest that the quantity and quality of the cellular immune
response to CMV might be an etiological factor in the development of
atherosclerosis.

222 BI-DIRECTIONAL TRANSFER OF MAJOR
HISTOCOMPATIBILITY COMPLEX CLASS II MOLECULES
BETWEEN DONOR AND RECIPIENT CELLS IN VIVO
FOLLOWING SOLID ORGAN TRANSPLANTATION
W. Wong, K. Brown, S. Sacks,
King’s College London
Cells have the ability to exchange surface molecules with their neighbours,
including intact MHC molecules. The functional significance is unknown,
but it may be an important element of the immune response in areas such as
autoimmunity and infection. Transplantation is the only example in which
foreign MHC molecules are deliberately transferred between individuals. If
donor MHC molecules are transferred whole to the surface of recipient antigen
present cells (APC) such as dendritic cells, they will be recognised by recipient
T cells that would normally recognise them via the direct antigen presentation
pathway, despite being presented by recipient APC. These recipient APC will
also express self MHC molecules that can present donor derived peptides,
which are recognised by recipient T cells via the indirect pathway. Thus,
transfer of MHC class II complexes can potentially link allospecific T cells of
the direct and indirect pathways to enable bystander activation or regulation
(linked suppression). However, the extent of this phenomenon in vivo after a
solid organ graft is unknown.
Vascularised BALB/c or DBA/2 (both H-2d) mouse kidney or heart
allografts were transplanted into BL/6 (H-2b) recipients. Recipient spleens
were harvested at various time points post transplantation. Following
transplantation of BALB/c, DBA/2 kidneys or DBA/2 hearts, the number
of donor I-Ad positive cells within recipient spleen rose to a maximum of
28.4+4.8 cells per high power field (hpf). After co-staining for recipient
I-Ab, followed by digital overlay, cells positive for both donor and recipient
class II MHC molecules could be clearly seen, and were shown by confocal
microscopy to be co-localised on the cell surface. These double positive cells
rose to a peak of 32.92+13.95% and 26+1.8% of all donor I-Ad positive cells
for BALB/c and DBA/2 kidney graft recipients respectively. The majority
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of double positive cells were CD11c+ dendritic cells (62.5+7.3% following
BALB/c transplantation). however macrophages and B cells could also
acquire MHC class II molecules. The majority of cells positive for both donor
and recipient MHC class II molecules also expressed the co-stimulatory
molecules CD40 and CD86, suggesting a capacity to elicit a T cell response.
FISH analysis showed that donor cells were capable of acquiring recipient
MHC class II molecules and vice versa, demonstrating that MHC transfer is
bi-directional.
MHC transfer between donor and recipient cells is a common occurrence
following transplantation with up to 30% of cells expressing both donor and
recipient MHC molecules. This process represents a potentially novel and
major route of T cell activation which may link allospecific T cells of the direct
and indirect pathways, and the extent of the transfer suggests a significant role
for this antigen presentation pathway.

CONCURRENT ORAL SESSION 17: BK VIRUS NEPHROPATHY
223 INTENSIVE SCREENING FOR POLYOMAVIRUS
REACTIVATION AND A PRE-DETERMINED STEPWISE
MODIFICATION IN MAINTENANCE IMMUNOSUPPRESSION
THERAPY: A ROAD MAP TO IMPROVE THE OUTCOME.
R. Wali1, C. Drachenberg1, H. Hirsch2, E. Ramos1
1University of Maryland School of Medicine, 2University of Basel,
Switzerland
Intensive screening for the detection of polyoma viral reactivation can result
in early detection of this disease and will allow to change or modify the
maintenance immunosuppression therapy to prevent the development of graft
disease; polyoma virus nephritis (PVN).
We performed a prospective single center study. We randomly assigned de
novo kidney transplant (cluster randomization) to Intensive Screening (IS:
n=648) and Routine Care (RC: n=260) for the detection of decoy cells in
random sample of urine. This was complemented with urine and blood nucleic
acid testing for different types of polyomaviruses. All patients had biopsies
performed for detection of polomya nephritis (PVN). Both groups were treated
with pre-determined stepwise modification of maintenance immunosuppression
based on cell cytology and viremia (Step 1: decrease dose of cellcept by 50%,
Step 2: decrease dose of tacrolimus by 50%, or switch to sirolimus therapy,
Step 3: discontinue cellcept). Primary outcome included persistence of decoy
cells/viremia following each step in modification of immunosuppression every
three months and secondary outcomes included acute rejection, graft function
and graft loss.
Results: Polyomaviral reactivation developed in 11.7% in IS group and 40%
had PVN without changes in serum creatinine. The estimated cumulative
rate of primary outcome in the IS versus RC groups, 3-months (51% vs.
79%) relative risk (RR). 0.47; 95%CI,0.20-1.08;p=0.051); 6-months (20%
vs. 52%) (RR=0.67; 95% CI,0.38-1.20; p=0.009); and 12-months (2%
vs. 33%) (RR=0.88; 95% CI, 0.41-1.43; p=0.003). Secondary outcomes:
despite similar degrees of modification in maintenance therapy, rate of
acute rejection was non-significant (p=0.25). but 25% of patients in RC
group lost the graft compared to no graft loss in IS group. Patients who
continue to remain on tacrolimus vs. those who were switched to sirolimus
therapy demonstrated persistent viremia (OR=10.25; 95%CI, 1.2-92.0;
p=0.003).
Conclusion: IS for poloymaviral reactivation allows early detection of PVN
in the presence of stable graft function. Stepwise modification in maintenance
immunosuppression therapy resulted in early resolution of decoy cells as well
as viremia in both groups, albeit slowly in RC group. This intervention did not
prevent the graft loss in RC group. Thus we demonstrate that active surveillance
for polyomaviral activation after solid organ transplant allows an opportunity
to prevent the disease progression and prevented graft loss in the recipients of
kidney transplant population. The results of this study will allow to develop
a uniform protocol for immunosuppression therapy following reactivation of
polyoma virus.
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224 BK VIRUS (BKV) LARGE T-ANTIGEN (LTA) ATPASE
DOMAIN IS A PROMISING TARGET FOR DRUG DISCOVERY

225 CLINICAL CORRELATES OF BK VIRUS CAPSID
ANTIBODY SUBCLASS MEASUREMENTS IN KIDNEY
TRANSPLANT RECIPIENTS
P. Randhawa1, D. Bohl2, D. Brennan2, K. Ruppert1, G. Storch2,
B. Ramaswami1, R. Shapiro1, J. March1, S. Muner1, R. Viscidi3
1
University of Pittsburgh, 2Washington University at St. Louis, 3Johns Hopkins
Hospital
Background: The humoral immune response to BK virus (BKV) infection
is incompletely characterized. This study sought the clinical correlates of the
circulating IgG, IgM, and IgA antibodies to BKV VP-1 virus like particles
(VLP).
Methods: BKV-specific antibodies were measured in serum from 107 kidney
transplant recipients with evidence of active BK infection 1, 4, 12 wk, 6m, and
1 yr post-transplant using VLP-based ELISA assay. Viral DNA was quantitated
in urine and plasma using real time PCR.
Results: IgG titer at week 1, as measured by optical density, showed a
negative correlation with peak viral load in patients who went on to develop
viruria (r=-0.25, p=0.05). IgA titer at week 1 was lower in patients who went
on to develop viremia (0.15+/-0.19). compared to those developed viruria
(0.22+/-0.21). persistent viruria (0.23+/-0.31) or no viruria (0.25+/-0.21). On
analyzing immunoglobulin subclass distribution in individual patients, the
prevalence of IgG+IgA+ phenotype at week 1 was also lower in patients who

226 PROGNOSTICATION OF BKV NEPHRITIS USING
GENE EXPRESSION PATTERNS AND DEVELOPMENT OF A
COMBINATION REGIMEN OF IVIG, LEFLUNOMIDE AND
REDUCED TACROLIMUS (ILRT) TO OPTIMIZE OUTCOME
D. Dadhania1,2, C. Snopkowski1, R. Ding1, M. Aull1, J. Lee1,2, V. Sharma1,2, S.
Kapur1, S. Seshan1, M. Suthanthiran1
1
Weill Cornell Medical Center, 2Rogosin Institute
BKV nephritis is associated with >50% risk of renal allograft loss, and its
outcome is difficult to predict using viral load or renal histopathology. In the
current investigation, we tested the hypothesis that (1) heightened expression
of urinary cell granzyme B and CD103 mRNA levels predicts renal allograft
loss in patients with BKV nephritis, and
(2) renal allograft outcome following a diagnosis of BKV nephritis can be
optimized with a combination regimen of IVIG, leflunomide and Reduced
Tacrolimus (ILRT).
We collected urine specimens from 13 patients with biopsy confirmed BKV
nephritis and measured urinary cell levels of mRNA for granzyme B, a
cytotoxic attack molecule and CD103, a cell surface protein for intraepithelial
localization of CD8+ CTLs. Our data demonstrating that histological changes
at the time of BKV nephritis diagnosis were not informative whereas urinary
cell levels of mRNA for granzyme B and CD103 are predictive of allograft
outcome are shown in Table 1.
Table 1. Predictors of Renal Allograft Loss in Subjects with BKV Nephritis
Parameter
Biopsy Tubulitis
Score
Biopsy Cytopathic
Score
Granzyme B mRNA
(median copy number )
CD103
(median copy number)

Graft Loss (n=3)
0,1,2

No Graft Loss (n=10)
0,0,0,1,1,1,1,2,2,3

P value
n/a

1,1,3

1,1,1,1,1,1,1,1,2,3

n/a

113,000

2,265

0.01

10,900

470

0.02

Our treatment regimen for BKV nephritis consisted of a reduction in tacrolimus
dosage and removal of MMF therapy (N=14, historical control). and the
regimen was changed to the combination regimen of IVIG (2g/kg single dose).
leflunomide (20mg bid) in place of MMF, and reduced tacrolimus dosage
(trough of 3-5ng/ml) since January 2005 (N=13, ILRT regimen).
The overall graft loss rate in the historical control group was 50% whereas it
was 7.7% in the ILRT group (Table 2). Logistic regression analysis revealed
that ILRT therapy was associated with OR = 0.83 (0.008, 0.83; P=0.01).
Table2. Graf Loss Rate in Patients with BKV Nephritis
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P. Randhawa, G. Zheng, N. Farasati, C.J. Camacho and M.Bueno.
Departments of Pathology and Computational Biology, University of
Pittsburgh, Pittsburgh, PA, USA.
Background: Polyomavirus LTA is a hexameric protein with a helicase activity
that is powered by ATP binding and hydrolysis. The helicase function is critical
for viral replication. This prompted an evaluation of the suitability of BKV
ATPase domain as a target for drug discovery.
Methods: Protein modeling techniques were applied to BKV LTA using the
known crystal structure of SV40 LTA. The QuikChange multi site-directed
mutagenesis kit (Stratagene) was used to generate ATPase mutations in the
BKV-pBR322 plasmid. Viral replication in culture was measured using real
time PCR. Inhibition of LTA ATPase was measured by a colorimetric assay in
which the dye malachite green binds inorganic phosphate released following
LTA mediated hydrolysis of ATP.
Results: Alignment of 30 BK and 13 SV40 amino acid sequences in the
Swiss-Prot database showed 70% identity and 90% similarity. On homology
modeling, all ATP binding residues identified as being critical for SV40 LTA
ATPase activity were also present in BKV LTA. Transfection of viral DNA with
Lys420Ala, Arg421Ala, Asp504Ala, and Arg542Ala mutations showed only
2.46 fold increase in DNA copy number over 6 weeks, compared to a 2090
fold increase for wild type BKV DNA. This established that BKV LTA ATPase
activity facilitates viral replication.
CASTp method calculation of the LTA ATP binding pocket volume (338 Å3)
indicated that it was suitable for discovery of small molecule inhibitors. Sixty
two (62) kinase inhibitors obtained from the TimTek ActiTarg library were then
screened in a real time PCR based BKV replication system, and 3 were found to
show anti-BKV activity, as judged by a CC50/EC50 ration (selective index) >10.
To accelerate our drug discovery effort we initiated in-silico high throughput
screening for small molecules that bind the LTA ATPase domain. Virtual
docking of 24 compounds, calculations of energy binding, and correlation with
biochemical ATPase inhibition activity indicated that the docking and scoring
method developed will be useful for large scale screening of additional antiBKV compounds. Following up on this prediction, we used known chemical
structures of published Hsp90 and Rho-kinase inhibitors to search compound
databases and obtain a subset of 8294 small molecules capable of docking LTA.
Cross-referencing the top solutions obtained by energy ranking, we were able
to identify 50 compounds that bind LTA in all 6 conformational states. A subset
of 5 compounds simultaneously binds three different LTA domains, namely, the
ATP binding site, hexamerization surface, and hinge region.
Conclusions: Large T-antigen ATP binding site is a promising target for
discovery of anti-polyomavirus drugs. The lead compounds identified so far are
will need to be optimized for their anti-viral and pharmacokinetic parameters,
prior to experimental and clinical testing.

went on to develop viremia (viremia=14.3% versus viruria=42.2%, persistent
viruria=40.8% and no viruria=44.2%).On evaluation of serial samples, patients
who never developed BK viruria or viremia had IgA and IgM antibodies
detectable in respectively 26/43 (60.5%) and 7/43 (16.3%) of baseline
samples. Conversely, at the time of active viruria, ELISA assays performed on
serum detected IgA and IgM antibodies in only 78.0% and 52.0% of samples
respectively. Transient reversion to a seronegative state, defined as inability to
detect IgG, IgA, or IgM antibodies at one or more time points was observed in
18.4% of all patients This transient loss of antibody production to BKV capsids
was (a) independent of the relative prevalence of immunoglobulin isotypes at
week 1, and (b) not consistently related to the onset of viruria or viremia and (c)
occurred without augmentation of maintenance immunosuppression.
Optical density (OD) cut off values of 1.8, 0.84, and 0.24 for IgG, IgA, and
IgM, respectively, could distinguish PCR positive and PCR negative samples
with 91.2-95.1% specificity but only 28.6-41.7% sensitivity. A rise in OD
(delta OD) above the baseline for IgA, IgM or IgG had a sensitivity of 70.378.1% and a specificity of 67.2-72.0% for BKV viruria/viremia. Peak viremia
correlated with delta OD for IgA and IgM (r=0.37, p=0.003, and r=0.52,
p=0.001 respectively, while peak viruria correlated with delta OD for all three
immunoglobulin isotypes (IgG r=0.36, IgA r=0.36, IgM r= 0.43, p<0.004).
Conclusions: BKV activation as assessed by viruria or viremia correlates
imperfectly with detection of IgA and IgM antibodies to viral capsid proteins.
However, baseline immunoglobulin isotype measurement provides prognostic
information: low IgG and IgA titers are associated with a higher peak urinary
viral load and greater risk of viremia.
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Historical Ctrl (n=14)

ILRT Rx (n=13)

P value

Serum Creatinine
at time of diagnosis
(mean ± SE)

2.5 ± 0.23

2.3 ± 0.22

0.6

Graft Loss at 6 months
post diagnosis (%)

29%

7.7%

0.32

Graft Loss at last
follow-up (%)

50%

7.7%

0.03

BKV viremia clearance
(%)

n/a

82%

Our gene expression profiles suggest that renal allografts with enhanced
inflammation at the time of diagnosis of BKV nephritis diagnosis are at
increased risk for renal allograft loss. Our data also suggest that management
of BKV nephritis using a combination approach of IVIG, leflunomide and
reduced tacrolimus is associated with improved outcomes.

227 IMPACT OF RABBIT ANTI-THYMOCYTE GLOBULIN
INDUCTION THERAPY ON REACTIVATION OF BK VIRUS IN
RENAL TRANSPLANT RECIPIENTS
A. Agarwal, A. Metha, A. Turner, K. Kokko, N. Turgeon, P. Tso, K. Newell,
C. Larsen, A. Kirk
Emory University
Reactivation of Polyoma BK virus has been recognized as an important
cause of kidney allograft nephropathy and loss. BK nephropathy (BKN)
has been associated with potent immunosuppression regimens. The impact
of rabbit anti-thymocyte globulin (RATG) induction on BK viremia (BKV)
and BK nephropathy has not been well defined. RATG has been associated
with increased viral activation such as EBV. At our institution, all kidney
recipients are maintained on triple immunosuppression including tacrolimus,
mycophenolate and prednisone unless contraindicating complications require
a change. Prior to January 2007, no induction therapy was used and thereafter
RATG was used. Trough tacrolimus targets were not changed. Throughout
our experience, we have prospectively monitored for BKV. We now report
the results of a retrospective analysis of the impact of RATG on BKN and
BKV (primary end-points). BKV was monitored via serum BKV PCR at post
transplant months 1, 2, 3, 4, 5, 6, 9, and 12. In addition, CMV and EBV PCR
were performed based on clinical indications. Those with positive viremia
had reductions in immunosuppression. Evidence of renal dysfunction with
positive BK viremia led to renal biopsy. BKN was diagnosed by histological
and immunohistochemical changes. Univariate analysis included Student¡¦s
t-test, Mann Whitney test, Fisher¡¦s exact test, and log-rank test (p value
<0.05 was significant). Stepwise (forward step likelihood ratio method)
Cox regression model was performed to assess predictive factors for BK
viremia. Between January 2006 and December 2007, 275 isolated kidney
transplantations were analyzed (40 were excluded for clinical indications
that warranted changes). In total, 110 kidney recipients received no induction
(Group I) while 135 pts had RATG (Group II). There were no differences
between donor and patient demographics except for follow-up (I: 571„b148
days vs. II: 246„b102; p<0.01). Data was censored at one year follow up.
Patient (I: 97% vs. II: 99%; p=0.78) and graft survival (I: 95% vs. II: 99%;
p=0.63) were similar. Though one year actuarial incidence of BKV was
similar (I: 19% vs. II: 29%; p=0.11). BKV developed earlier in RATG cohort
(I: 163¡Ó22 vs. II: 108¡Ó 74 days; p=0.03). There was no difference in the
BK log viral copies/mL (I: 3.8¡Ó0.8 vs. II: 4.0¡Ó0.8; p=0.11). Although BK
nephropathy was more prevalent in Group I (I: 7.2% vs. II: 0.7%; p=0.01).
no grafts were lost to BKN. There was no difference in CMV (I: 23% vs. II:
12%; p=0.08) nor EBV infection (I: 3.6% vs. II: 6.2%; p=0.24). Multivariate
analysis revealed that only age (HR: 1.05 95%CI: 1.02-1.07; p=0.001)
and induction therapy (HR: 2.2; 95%CI: 1.2-4.1; p=0.01) were predictors
of BKV. The preliminary data suggest RATG leads to increased BK virus
reactivation; despite no evidence of changes in CMV or EBV infection.
However aggressive BK PCR monitoring could curtail the progression of
earlier BKV to BK nephropathy. Long-term follow-up is on going in order to
determine aggregate BK viremia and nephropathy.
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228 THE IMPACT OF CLINICAL POLYOMAVIRUS DISEASE
ON GRAFT SRUVIVAL OF PEDIATRIC KIDNEY TRANSPLANT
RECIPIENTS – AN ANALYSIS OF OPTN/UNOS DATABASE
Y. Cho2,3, B. Hardy1, K. Lemley1, J. Cicciarelli2,3, R. Mendez2,3,
I. Hutchinson2,3, T. Shah2
1
Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC
School of Medicine
Background: Polyomavirus-associated nephropathy often precedes renal
allograft dysfunction in adult renal transplant recipients. The OPTN/UNOS
began collecting information regarding polyomavirus test results using followup forms since June 30, 2004. The aim of this study is to evaluate the impact
of clinical polyomavirus disease (PVD) on graft survival after pediatric kidney
transplantation.
Methods: From Jan 2004 to Dec 2006, a total of 2,065 pediatric kidney alone
transplants (age 2-20 yrs) with functioning graft at 6 months were identified
the OPTN/UNOS data as of Aug 20, 2007. Graft survival rates were compared
for the following 3 groups: PVD group – Patients who had developed PVD
(n=57); no PVD group – Patients who had PV test and hadn’t developed PVD
(nPVD) (n=272); and Control group – Patients who had not performed PV
test on followup record (nPVT) (n=1,736). Univariate and multivariate Cox
regression analyses were performed to identify risk factors of graft loss.
Results: Overall graft survival rates of PVD group were not significantly
different from those of control group (nPVT group, log-rank P=0.25) and
nPVD group (log-rank P=0.97). In multivariate analysis, both nPVD (RR=1.55
vs nPVT, P=0.31) and PVD (RR=1.00 vs nPVT, P=0.99) were not significant
risk factors of graft loss after adjusting for age, race, and rejection treatment
within 6 months (Table). Pediatric patients may have a lower rate of graft loss
because they are able to mount a more vigorous immune defense against BK
virus than adult kidney transplant recipients.
Conclusions: Clinical polyomavirus (BK virus) disease may not be as
significant a risk for pediatric kidney survival as it is for adult recipients. Larger
prospective studies are needed to understand the impact of BK virus infection,
replication, and disease on pediatric kidney transplant outcome.
Table. Results of univariate and multivariate Cox regression analyses
Recip Age 15-20
vs 2-14
Recip Black vs
others
Rejection in 6 mon
vs none
CPVD nPVT
(control)
nPVD
PVD

Unadjusted
RR (95%CI)
1.47 (1.00-2.16)

P value
0.050

Adjusted
RR (95% CI)
1.48 (1.01-2.19)

P value
0.046

2.15 (1.43-3.22)

<0.001

2.10 (1.40-3.15)

<0.001

3.28 (2.11-5.01)

<0.001

3.17 (2.04-4.94)

<0.001

1.0
1.89 (0.82-4.32)
0.99 (0.54-1.82)

1.0
0.13
0.98

1.55 (0.67-3.56)
1.00 (0.54-1.83)

0.31
0.99

229 MYCOPHENOLATE HAS ANTIVIRAL PROPERTIES IN
BK VIRUS INFECTED VERO CELLS
P. Acott, P. O’Regan, P. Wornell, J. Crocker
IWK Health Centre
We previously reported mycophenolic acid (MPA) reliably reduces BK virus
(BKV) copy count in Vero cells (Green monkey kidney cell origin) with
infection from various BKV strains. Subsequently we explored potential
mechanisms including anti-metabolite effects and molecular markers of mRNA
production.
Vero cells were infected with BKV (NCCR rearranged VJ strain) by a 2 hr
incubation with 6.5 X 105 BKV copies, washed, then cultured for 1, 7, 14, 21,
28, and 35 days. Culture media with MPA (0, 2 and 8 mg/l) was exchanged
weekly. We quantified cellular protein and determined BK viral copy numbers
in both cell fractions and SN at all time points. RNA was extracted and reverse
transcribed for subsequent quantititative mRNA analysis for Transforming
Growth Factor Beta (TGFß). Collagen 1A1, Alpha Smooth Muscle actin
(α;SMA). and Heat Shock Protein 47 (HSP) relative to Ribosomal Polymerase
II (RPII) which we have shown remains stable in its expression in chronic Vero
cell culture ± BKV infection. Quantification of BKV replication and mRNA
was by quantitative real time PCR using the Roche Lightcycler 2.0.
MPA (2 and 8 mg/l) reduced BKV copy count greater than 1 log fold in both
SN and cells after day 14. There was reduction of protein amount by 50 – 75%
in chronic MPA exposed Vero cells consistent with an anti-metabolite effect
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without an increase in cytopathic effect. There was no difference at any time
point of HSP, TGFß or α;SMA mRNA levels. MPA reduced Collagen 1A1 in
chronic culture.
MPA appears to exert an anti-metabolite effect on viral replication and reduce
production of Collagen 1A1 in chronically infected cells exposed to MPA. Our
in vitro data suggests that Mycophenolate might have a protective effect in
BKV infected renal tubular cells with both antiviral and anti-fibrotic response.

N. Babel1, J. Fendt1, S. Karaivanov1, L. Stele1, H-D. Volk2, P. Reinke1
1
Department of Nephrology, 2Institute of Medical Immunology
Background: BKV reactivation plays the causative role in the development of
BKV associated nephropathy. The quantitative analysis of BKV load in serum
and urine for monitoring of BKV infection is well established. However, the
data on relation between BKV load in serum and urine is contradictory. Here
we performed a large cross-sectional and prospective epidemiologic study on
BKV load in urine and serum of renal transplant patients and analyzed the
correlation between both tests and clinical course of infection.
Methods: Total of 4,128 urine and serum samples obtained from 433 renal
transplant patients (female/male 175/258, mean age 50.5 years) were analyzed
for BKV positivity by real-time PCR. The prospective analysis included 7
measurements during the first posttransplant year.
Results: total of 23 (5.3%) and 63 (14.5%) patients were positive for BKV
in serum and urine, respectively. There was a good correlation between the
level of viremia and viruria (p<0.01). Interestingly, the BKV load rise in serum
was preceded by the elevation of BKV load in urine. The prospective analysis
demonstrated that the peak of viral load and number of positive patients appeared
during the 3rd and 5th posttransplant month for urine and serum, respectively.
While 100% of patients with BK viremia were BKV positive in urine, only
36.5% of patients with BK viruria showed simultaneous BKV positivity in
serum. However, gradual comparison between viremia and viruria revealed an
association between the level of BK viruria and percentage of BKV positivity
in serum: 91% of patients with high level viruria (more than 107copies/ml)
were BKV positive in serum. 22.2% of patient with persistent BK viremia and
high level BK viruria developed histologically proven BKVAN within 5 and 11
weeks after BKV reactivation in urine and serum, respectively. 60% of patients
with elevated viral load value in serum showed resolution of BK viremia within
a mean of 33 weeks.
The data obtained from this large prospective study demonstrate a good
correlation between BKV load in urine and serum. Since the peak of viral load
in urine appears 8 weeks earlier than the reactivation in serum and shows a
clear correlation with viremia, the analysis of BKV load in urine will allow
identifying patients with a high risk for BKVAN development at a very early
stage.

231 LOW PREVALENCE AND INCIDENCE OF BK VIREMIA
AND VIRURIA IN A SIMULTANEOUS PANCREAS/KIDNEY
TRANSPLANT (SPK) RECIPIENT POPULATION FROM A
SINGLE CENTRE
P. Boucek1, M. Mindlova1, T. Jedinakova1, F. Saudek1, K. Lipar1,
M. Adamec1, H. Hirsch2
1
Institute for Clinical and Experimental Medicine, Prague, 2Institute for
Medical Microbiology, Basel
BK-virus nephropathy (BKVN) has become a major cause of renal graft loss
following SPK in some transplant centers. The reported rate of BKVN of
5-7% may support the systematic screening of BK virus replication in SPK
recipients. We performed an analysis of the prevalence and incidence of BK
viral loads in plasma and urine as adjunctive screening tests for BKVN in a
single-centre SPK population.
Methods: Type 1 diabetic patients on immunosuppressive treatment (IS) with
at least one functioning graft following SPK in the Institute for Clinical and
Experimental Medicine in Prague in the period 9/1987-12/2006 were examined
for the prevalence study (point prevalence at 2/2007). Incidence was assessed
by another cross-sectional examination performed after one year. Viral
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232 MACHINE PRESERVATION OF KIDNEYS DONATED
AFTER CARDIAC DEATH DOES NOT REDUCE DELAYED
GRAFT FUNCTION: THE PPART STUDY
C. Watson1, A. Wells1, R. Roberts1, J. Akoh2, P. Friend3, M. Akyol4,
F. Calder5, J. Allen6, D. Collett6
1
University Department of Surgery, Addenbrookes Hospital, 2Renal
Transplant Unit, Derriford Hospital, 3Oxford Transplant Centre, Churchill
Hospital, 4The Transplant Unit, The Royal Infirmary of Edinburgh, 5The Renal
and Transplant Unit, Guys and St Thomas’s Hospital, 6Statistics & Audit
Directorate, United Kingdom Transplant
Background: Cold machine preservation has been shown to improve outcome
following transplantation of deceased heart-beating donor kidneys. To determine
whether cold machine preservation also improves outcome of kidneys donated
after cardiac death (DCD) we undertook a multicentre randomized controlled
trial in the UK comparing machine perfusion with simple cold storage.
Methods: One kidney from each DCD donor was randomized to machine
perfusion (Organ Recovery Systems LifePort device with KPS-1 solution).
the other to perfusion with UW (ViaSpan) solution followed by simple cold
storage. The primary outcome measure was the need for dialysis in the first
7 days (delayed graft function, DGF); secondary outcome measures included
total duration of dialysis; GFR at 1 week & 3 months (MDRD technique); and
3 month graft and patient survival.
A sequential design was used with the data inspected after 60 transplants and
then every 20. All recipients received basiliximab, mycophenolate sodium,
tacrolimus and prednisolone. The significance of the initial results has been
tested using paired T tests and McNemar’s exact tests.
Results: Recruitment was stopped after 46 donors when the unadjusted
sequential analysis concluded that there was no difference in the incidence of
DGF. 91 of the 92 kidneys were transplanted; one was not used for anatomical
reasons. One kidney suffered primary non function; it had been machine
preserved.
The results shown below represent intention to treat, but are not significantly
different when analysed according to actual treatment.
Machine perfusion
(n=45)

Simple cold storage Significance
(n = 45)
(p-value)

Recipient Age: Mean (StDev)

50 (14)

49 (14)

0.55

Total ischaemic time: Mean (StDev)

14h 55m
(4h27m)

15h 12m
(4h45m)

0.83

DGF incidence

26 (58%)

25 (56%)

0.99

Days to last dialysis: Mean (StDev)

6.5 (17.1)

4.7 (7.7)

0.53
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230 MONITORING OF BKV LOAD IN URINE ALLOWS
IDENTIFICATION OF PATIENTS WITH THE HIGH RISK FOR
BKV-ASSOCIATED NEPHROPATHY SEVERAL WEEKS PRIOR
TO DEVELOPMENT OF VIREMIA: ANALYSIS OF 4128 URINE
AND SERUM SAMPLES

DNA loads in plasma and urine were quantified by real-time PCR. Samples
containing >104 and >107 copies/ml were considered as high-level BKV DNA
positive for plasma and urine, respectively; samples with plasma levels 103-104
as low-level positive.
Results: Prevalence was assessed in 187 SPK patients (M/F ratio 102/85, mean
age±SD 44±9 years, diabetes (DM) duration 27±8 years, insulin-independence
in 156 (83%) ) at 1683 (median; range 42-6661) days from SPK or most recent
kidney retransplant. High-level replication in plasma and urine was identified
in 2 (1.1%) and 5 (2.7%) patients, respectively, with 1 additional recipient
having a low-level plasma replication. IS based on tacrolimus (Tac) was more
frequent in the positive high-level + low-level replication group (Tac/CyA 7/0
vs. 99/84; p=0.016). At 2/2008, one-year incidence data were available from
192 SPK recipients who were initially BK negative (n=167) or underwent
their first SPK in the preceding one-year period (n=25). High-level plasma and
urine replication was seen in 2 (1.0%, one recipient with new first SPK in
the preceding year; BKVN biopsy confirmed as stage B in both cases) and
3 (1.6%) patients, respectively, with low-level plasma replication occurring
in 1 additional SPK recipient. In all BK positive cases IS consisted of the
combination of Tac/MMF.
Conclusions: A rather low prevalence and incidence of BK viremia and
viruria were demonstrated in SPK transplant recipients in our centre. While
possibly influenced by its cross-sectional design, the study results may suggest
that additional factors such as more intensive immunosuppression could be
responsible for the increased occurrence of BKVN reported in other centers.
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GFR on day 7: Mean (StDev)

17.0 (14.6)

14.9 (13.2)

0.24

GFR at 3 months: Mean (StDev)

46.0 (18.1)

48.9 (21.3)

0.42

3 month graft survival % (95%CI)

96 (90-100)

100

0.16

3 month patient survival % (95%CI)

98 (93-100)

100

0.32

MONDAY

Conclusion: Cold machine perfusion of kidneys from DCD donors does
not reduce the incidence of delayed graft function in the context of the short
ischaemic times seen in the study.

233 MACHINE PERFUSION VERSUS COLD STORAGE IN
RENAL PRESERVATION: A COMPARATIVE IN VIVO STUDY
OF KIDNEY TRANSPLANTATION
G. La Manna1, A. Faenza2, D. Conte1, M. Cappuccilli1, B. Nardo2, R. Bertelli2,
L. Puviani2, N. Lanci1, M.P Scolari1, S. Stefoni1
1
Nephrology, Dialysis and Renal Transplant Unit, University of Bologna, St.
Orsola Hospital, 2Renal Transplant Surgery Section, University of Bologna,
St. Orsola Hospital
Introduction: The development of effective methods of organ preservation
represents a crucial achievement in reducing the magnitude of ischemia/
reperfusion (IR) injury. The two available modalities currently used for renal
preservation are cold storage (CS) and machine perfusion (MP). Although the
superior costs of personnel and technology of MP have limited its application,
there is increasing proof that MP is an effective strategy to lessen IR injury,
because it allows for the monitoring of flow rate, renal arterial pressure
and internal vascular resistance and, if necessary, allows for the addition of
electrolytes, nutrients and oxygen during storage.
Aims: This study was designed to compare the degree of tissue damage
after hypothermic preservation by MP or CS in an animal model of kidney
autotransplantation.
Methods: Twelve pigs underwent left nephrectomy after warm ischemic time;
the organs were preserved in MP (n=6) or CS (n=6) and then autotransplanted
with immediate contralateral nephrectomy. The animals were monitored for a
4-day period before sacrifice.
At each experimental step, haematological (creatinine, urea, sodium, potassium)
and urine (specific gravity, pH, proteinuria) parameters of renal function and
blood/gas analysis values were measured. Histological features, ATP content
from renal biopsy, perforin gene expression and organ weight changes were
compared before and after preservation with both techniques.
Results: No significant differences between CS and MP groups were observed in
terms of renal functional indicators and arterial gas/electrolyte analysis values.
However, during the 4-day follow-up period, the worsening of kidney function
in the CS group showed a rapidly progressive course, while serum creatinine
and urea tended to stabilize around the 3rd day post-transplant in the animals
who received machine-perfused organs. Histology revealed a comparable
extent of injury in both groups, even if one single animal transplanted with
a cold-stored kidney displayed extensively more damaged cells in the biopsy
taken before sacrifice.
The cellular ATP (μg per milligram of tissue from renal biopsy) was not
significantly decreased in machine-perfused kidneys (from 172.6±157.6 to
146.4±41.8, p=n.s.). while a considerable drop was found in cold-preserved
ones (216.6±151.6 to 58.2 ± 28.5, p=0.015).
The average fold increase of perforin mRNA expression above the level
measured before storage was 1.48±1.23 in the MP group (p<0.05) and
2.15±1.77 in the CS group (p<0.01). Thus, the study of apoptosis induction
revealed enhanced perforin expression after storage in both groups, but to a
significantly higher extent in the kidneys which underwent CS (p<0.001).
Organ weight was significantly reduced after CS (116.2±17.7 g vs 93.0±14.4 g;
p=0.032). but it remained quite stable for machine-perfused kidneys (111.5±4.4
g vs 111.2±5.6 g; p=n.s.).
Conclusion: The present model seems to suggest that machine-perfused
kidneys display a more limited cellular impairment in comparison with coldstored ones. According to our data, MP may help to prevent IR injury and limit
microstructural damage in organs for transplantation. Although the superior
costs in terms of personnel and technology of MP might limit its routine
application, this preservation technique possibly will be considered more
appropriate for grafts from marginal donors or for preservation times longer
than 24 hours.
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234 MACHINE PERFUSION VERSUS COLD STORAGE
PRESERVATION IN NON-HEART-BEATING KIDNEY
DONATION AND TRANSPLANTATION: FIRST RESULTS OF A
MULTICENTRE TRIAL IN EUROTRANSPLANT.
F. Van Gelder1, C. Moers², J.M. Smits², M.H.J. Maathuis², J. Treckmann², B.P.
Napieralski², M. van Kasterop-Kutz², J.J. Homan van der Heide²,
E. van Heurn², G.R. Kirste², A. Rahmel², H.G.D. Leuvenink², A. Paul², J.
Malaise², C. Randon², D. Ysebaert², J.P. Squifflet², R.J. Ploeg², J. Pirenne²
1
University Hospitals Leuven, Leuven, Belgium ² Eurotransplant MP Trial,
Leiden, The Netherlands
Rationale; Delayed Graft Function (DGF) after Kidney Transplantation causes
additional morbidity and cost, and may negatively affect graft function and
survival. Kidney grafts procured in Non-Heart-Beating Donors (NHBD) are
exposed to both warm and cold ischemia and thus particularly vulnerable
to DGF. Compared to standard Cold Storage (CS). hypothermic Machine
Perfusion (MP) has been reported to provide superior preservation. This fact
could be of great importance particularly for NHBD kidneys, but evidence to
support this view is limited in quality and numbers.
Aim: To compare the efficacy of MP vs CS for the preservation of NHBD
kidneys.
Methods: In an international prospectively randomized controlled trial we
enrolled kidney pairs of 82 consecutive NHBD. All NHBDs were Maastricht
category 3 (awaiting cardiac arrest/planned therapy withdrawal). One kidney
was randomly assigned to MP and the contralateral kidney to conventional
CS. Kidneys were allocated using the standard allocation algorithm. At time
of offer, the type of preservation (MP vs CS) and perfusion parameters were
not revealed. All 164 recipients were followed-up and 3 month data were
analyzed.
Results: Donor age (y) was 43 (17-67). Baseline demographics were comparable
between MP vs CS arms: recipient age (y) 49 (24-73) vs 52 (24-77). p=0.81;
preTx dialysis duration (days) 1542 (366-6402) vs 1448 (132-3904). p=0.48;
first/reTx 34/48 vs 34/48, p=0.56;% current PRA (0-5/6-84/85+) 71/11/0 vs
71/10/1, p=0.73;% of 0 HLA A,B and DR mismatches was 2.4 vs 3.7, p=0.5.
Cold Ischemia Time (CIT) (h) was 15 (4.3-28.9) for MP vs 15.9 (8.6-46.6) for
CS (p=0.7). Incidence of DGF was 53.7% in MP vs 69.5% in CS recipients,
p=0.027. Duration of DGF (days) was 9 (1-48) in MP vs 13 (2-43) in CS
kidneys, p=0.04. DGF < 7days occurred in 12/32 (27%) in the MP vs 6/51
(10.5%) in the CS arm, p= 0.028. Creatinine clearance (ml/min) at d7, d14,
1mth, and 3mth in MP vs CS was 13 vs 9, p=0.009; 23 vs 13, p=0.001; 46 vs 38,
p=0.078; and 57 vs 49, p=0.19, resp. PNF rate was identical after MP and CS
(2.4%). Acute rejection rate was 7.3% in MP vs 12.2% in CS kidneys; p=0.22.
Graft loss (<3mth) was identical after MP and CS (3.6%). Patient survival was
98.7% in MP vs 100% in CS recipients. Logistic regression analysis showed
that MP (p=0.035; Odds ratio 0.476) and CIT (p=0.009; Odds ratio 1.118)
independently had an impact on DGF.
Conclusion; This study demonstrates for the first time in a large controlled trial
that MP of NHBD kidneys reduces the incidence, the duration and the severity
of DGF and ameliorates graft function after kidney transplantation.

235 PRESERVATION OF KIDNEYS IN MACHINE PERFUSION
(MP) LIMITS ISCHEMIA/REPERFUSION INJURY.
M. Wszola1, M. Kosieradzki1, A. Kwiatkowski1, M. Bieniasz1, K. Ostrowski1,
P. Domagala1, A. Kaminska2, M. Durlik2, W. Rowinski1, A. Chmura1
1Department of General And Transplantation Surgery, Warsaw Medical
University, 2Transplantation Institute, Warsaw Medical University
Recent prospective and retrospective studies have shown beneficial effects of
Machine Perfusion (MP) on early and long-term graft survival. Histopathological
analysis undertaken in our center revealed significantly lower incidence of
chronic rejection, interstitial fibrosis/tubular atrophy in kidneys preserved by
MP. Ischemia/reperfusion injury (I/R-I) is thought to play a role in explaining
these findings.The aim of the present study was to assess activation of genes
associated with I/R-I depending on the method of preservation of grafts prior
to transplantation.
Patients and method: Between 2005 and 2006, sixty-nine kidney biopsies from
69 allografts were obtained. Kidneys prior to transplantation were preserved
by MP (n=26) or cold storage (CS; n=36). 7 kidneys were donated by living
related donors (LRD group).Deceased donors in the MP and CS groups didnot
differ regarding age, gender, hemodynamic status. Cold ischemia time (CIT)
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236 MACHINE PERFUSION VERSUS COLD STORAGE IN
TRANSPLANTATION OF KIDNEYS FROM OLDER DECEASED
DONORS: RESULTS OF A PROSPECTIVE RANDOMIZED
MULTICENTER TRIAL
A. Paul , C. Moers , J. Smits , H. Maathuis , J. Homan van der Heide , E. van
Heurn4, J.P. Squifflet5, J. Pirenne6, R. Ploeg2, J. Treckmann1
1
University Hospital Essen, Germany, Clinic For General, Visceral And
Transplantation Surg, 2University Hospital Groningen, Netherlands,
3
Eurotransplant Foundation, 4University Hopsital Maastricht, Netherlands,
5
University Hospital Brussels, Belgium, 6University Hospital Leuven, Belgium
Rationale; Delayed graft function after renal transplantation especially from
older donors negatively correlates with long and short term graft function and
graft survival. Retrospective studies suggest a beneficial effect of hypothermic
machine perfusion (MP) on post- transplant outcome when compared to
standard cold storage (CS) preservation.
Aim: Comparison of post- transplant outcome after machine perfusion vs cold
storage in recipients of kidneys derived from deceased donors ¡Ý 55 years
Methods: As part of an international prospective randomized controlled
trial n= 118 consecutive donation after brain death donors aged 55 years and
older were included between Novermber 2005 and November 2006. In each
donor one kidney was randomly assigned to MP and the contralateral kidney
to conventional CS. Eurotransplant standard allocation algorithms were not
affected by the trial. The accepting recipient center was blinded regarding
preservation mode and perfusion parameters. Primary endpoint of the study
was delayed graft function defined as necessity of dialysis in the first seven
days after transplantation. Furthermore standard donor and recipient data were
collected, as well as graft and patient survival, primary non function (PNF) and
acute rejection episodes. All 236 recipients were prospectively followed up
until six months after transplantation.
Results: Donor age was 63 yr (55-81). Baseline demographics were comparable
between the MP vs the CS arm: recipient age (year) 63 (11-79) vs 61 (7-79).
p=0.8; preTx dialysis duration (days) 1728 (417-5154) vs 1773 (149-3866).
p=0.5;% current PRA (0-5/6-84/85+) 105/12/1 vs 109/8/1, p=0.3;% of 0 HLA
A,B and DR mismatches was 8.5 vs 11, p=0.3. Cold ischemia time (CIT) (hr)
was 14 (3.5-53.75) in MP vs 13 (2.5-25) in CS (p=0.6). Incidence of DGF was
22.0% in MP vs 31.4% in CS recipients, p=0.07. DGF < 7days occurred in 10/26
in the MP vs 5/37 in the CS arm, p= 0.02. PNF rate was 2.5% in MP vs 10.2%
in CS kidney recipients (p=0.015) Creatinine clearance showed no differences
at day 7 and 14. The rate of acute rejections was not different between the
groups. When DGF occurred six month graft survival was significantly better
in kidneys preserved with MP than by CS: 84% vs. 60%, p=0.026. Logistic
regression analysis showed that MP (p=0.015; Odds ratio 0.432 vs CS) and CIT
(p< 0.0001; Odds ratio 1.145) independently impacted on DGF.
Conclusion: Hypothermic machine perfusion of kidney grafts from older
deceased donors lowers the incidence and duration of delayed graft function,
strongly reduces primary non- function and improves graft survival at six
months post- transplant.
1

2

3

2
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237 MACHINE PULSATILE PERFUSION AND ITS
PREDICTIVE VALUE FOR DELAYED GRAFT FUNCTION IN
CADAVERIC RENAL TRANSPLANTS (CRT)
G. Roelant1, J. Miller2, A. Haririan3, J. Nogueira3, B. Philosophe1, S. Bartlett1,
and M. Cooper1
1
Dept of Surgery and 3Medicine, University of Maryland, Baltimore, MD,
USA.2Living Legacy Foundation of Maryland, Baltimore, MD USA.
Background: As the number of patients seeking kidney transplantation
continues to rise, greater use of marginal and expanded donors has followed.
Increased volumes cannot supplant desirable outcomes. Clinicians have
developed an increased interest in machine pulsatile perfusion to guide
decision-making in organ utilization. We sought to determine variables
potentially predictive of delayed graft function (DGF) and develop a model to
assist in decision-making of utilization of CRTs.
Methods: A retrospective analysis of pulsatile parameters and the first 90 days
following transplant for all machine perfused renal allografts performed at a
single institution over a 4 year period was performed. Demographics, perfusion
parameters, organ criteria- standard (SCD). expanded (ECD). or donation after
cardiac death (DCD). biopsy results, DGF, and lowest Cr achieved in the 90
day study period was analyzed. Pump pressures were maintained constant,
flows measured, and resistance calculated.
Results: 187 CRTs (46 SCD, 113 ECD, 28 DCD) comprised the cohort. DGF
was recognized in 55% (21 SCD, 64 ECD, 17 DCD). Donor and recipient
demographics were similar in both groups (DGF v. No DGF).
Pump Parameter

DGF (n =102)
Mean + SD

No DGF (n =85)

Kidney Size

210.6 + 87.0

206.2 + 109.2

0.764

Pre-pump CIT (hr)

18.3 + 8.5

17.9 + 8.4

0.783

Total Pump Time

18.3 + 6.9

18.8 + 7.8

0.651

Initial Flow (ml/min)

103.9 + 28.8

103.2 + 35.2

0.881

8-hr Flow

147.8 + 35.4

153.8 + 37.1

0.284

p value

Initial Resistance

0.33 + 0.1

0.36 + 0.2

0.116

8-hr Resistance

0.20 + 0.05

0.20 + 0.06

0.607

Change Resistance 0-8hr

0.13 + 0.10

0.17 + 0.14

0.031

Init Res./Kidnney Size

23.0 + 19.3

18.6 + 10.2

0.048

Neither sclerosis, interstitial fibrosis, nor vascular changes on biopsy had a
statistically significant impact on DGF. For transplants without DGF, linear
regression demonstrates correlation in lowest achieved Cr with pumping
resistances at zero, four and eight hrs, and kidney size (p<0.05 for all).
Transplants that experienced DGF had one linear regression correlating with
final Cr -pumping resistance at eight hours (p=0.022). Linear and nonlinear
multivariate and neural network models were developed to attempt to predict
DGF by pre-transplant data.
Conclusion: The prediction of DGF based upon demographics and pretransplant data for pulsatile perfused renal allografts remains a difficult task
and the complexity and number of variables makes a simple model unlikely.
Numerous biases are inherent as only organs thought suitable for transplant
based on history and biopsy were initiated on pump. Pumping parameters
demonstrated the mean difference in starting to eight hour pumping resistance
was lower in those experiencing DGF as was initial resistance/kidney size
perhaps reflecting degree of pre-pump injury. Further subanalysis is ongoing
including duration of DGF.

238 ASSESSMENT OF AUTO-REGULATION AND
ENDOTHELIAL FUNCTION IN KIDNEYS UNDERGOING
HYPOTHERMIC PULSATILE PERFUSION.
I. Winburn2,1, Y. Yao1, J. Hill2, Z. Endre2, R. Walker2, I. Sammut1
1Department of Pharmacology and Toxicology,University of Otago, NZ,
2Department of Medicine, University of Otago, NZ
Introduction: Donor kidneys that have undergone hypothermic pulsatile
perfusion (HPP) have been reported to demonstrate improved outcomes
following transplantation. The underlying mechanism by which protection
is offered remains unclear. The preservation of endothelial function may be
responsible for the improved outcomes observed following HPP, however
this has not previously been studied. Endothelial function is a prerequisite of
renal auto-regulation; namely the ability of the kidney to maintain a constant
glomerular filtration rate in response to variations in perfusion pressure. This
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was similar: 23 6h in CS vs 28 7h in MP (p=NS). in both groups. There were
no significant differences between the recipients as to age, gender, duration
of ESRD treatment, PRA titres, HLA incompatibility and immunosuppressive
treatment. Biopsies were obtained 30 min after reperfusion and snap frozen
at 750C. Expression of genes for IL-1b, VEGF, hemoxygenase 1 (HO-1)
and hypoxia inducible factor 1 (HIF-1) was analyzed by real-time PCR.
Results: Mean Ct for m-RNA expression for HIF-1 in kidney biopsies 30 min
after reperfusion were: 0,63 1,54; 1,70 1,08 and 2,11 1,84 for CS, MP and LRD
group respectively (p=0.001 for CS vs MP; p=0.001 for CS vs LRD; p=NS for
MP vs LRD). Mean m-RNA expression for IL-1b, VEGF and HO-1 did not
differ significantly between the groups.
Conclusions: Mean m-RNA expression for hypoxia inducible factor 1 is
significantly higher in group of kidneys preserved by cold storage in comparison
to machine perfusion and living related donors. There is no difference between
MP and LRD group regarding expression of HIF-1. Ischemia/reperfusion
injury, which can affect early and long-term graft survival is reduced by
machine perfusion preservation of cadaveric kidneys. Ischemia/reperfusion
injury of kidneys stored by MP is similar to those observed in LRD.
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study details for the first time both vascular smooth muscle and endothelial
function during HPP. In addition we detail whether donor kidneys undergoing
HPP are capable of auto-regulation.
Methods: Kidneys were retrieved from Sprague-Dawley rats following renal
artery cannulation and perfused ex vivo with a modified Krebs Henseleit
solution (or Belzer machine perfusion solution for auto-regulation experiments)
under either normothermic (37ºC) or hypothermic (8ºC) conditions. Following
equilibration, perfusion parameters were recorded in response to angiotensin II
(AngII; 1x10-11-1x10-7 M) or methacholine (MCh; 1x10-9-1x10-4 M). Cumulative
pressure, flow and vascular resistance dose response curves were generated. The
vasodilatory effects of another endothelial dependent vasodilator, adenosine
diphosphate (ADP) were assessed in the presence or absence of an intact renal
vascular endothelium (denuded with 0.1% CHAPS). Auto-regulation during
HPP was investigated ex-vivo by pressure ramping experiments using AngII
(10nM). phenylepherine (5nM). ADP (1uM) and papaverine (100mM).
Results: Kidneys perfused at both 37ºC and 8ºC demonstrated dose-dependent
vasoconstriction in response to AngII (EC50 37ºC= 0.32±0.028nM vs. EC50 8ºC
= 9.0±1.39 nM; p<0.001). Only kidneys subjected to 37ºC perfusion vasodilated
(EC50= 187±35nM) in response to MCh. ADP did however induce vasodilation
(EC50=1330±295nM) in kidneys perfused at 8ºC. These vasodilatory effects
were significantly (p<0.001) reduced following endothelial disruption with
CHAPS. Auto-regulation was only induced in HPP kidneys following infusion
of AngII (10nM) as compared to controls (auto-regulatory index 0.78±0.10 vs.
1.129±0.04 respectively; p=0.037). Interestingly phenylepherine, administered
at an equivalent vasoconstrictor concentration, failed to induce auto-regulation
in HPP kidneys.
Discussion: This is the first time that auto-regulation and specifically
endothelial function have been described during HPP and our data indicates
that the endothelium remains active under these conditions. Although MCh
responses were not observed at 8ºC, the presence of endothelial dependent
vasodilation induced by ADP does imply altered MCh pharmacodynamics
during hypothermia. The underlying mechanism of AngII induced autoregulation is unlikely to be a product of AngII’s pressor properties given the
absence of auto-regulation with phenylepherine. The findings of this study
provide evidence to support the notion that pharmaco-modulation of HPP
kidneys is an exciting therapeutic strategy that can improve post transplant
function.

Fig 1

Fig2

CONCURRENT ORAL SESSION 19:
CLINICAL ISLET TRANSPLANTATION
239 EX-VIVO REPAIR OF DAMAGED HUMAN DONOR
LUNGS FOR TRANSPLANTATION
M. Cypel, M. Rubacha, S. Hirayama, J. Yeung, M. Anraku, M.Sato, M. Liu,
T.K. Waddell, M. de Perrot, and S. Keshavjee.
Thoracic Surgery, Toronto Lung Transplant Program, Latner Thoracic
Surgery Laboratory, University of Toronto, Toronto, Ontario, Canada, M5G
1L7.
Purpose: Lung inflammation and blood-alveolar barrier disruption are common
findings in injured human donor lungs. We aimed to evaluate the potential for
ex-vivo attenuation of lung inflammation, recovery of epithelial tight junctions
and improvement in lung function.
Methods and Materials: Human lungs from 10 different donors determined to
be unsuitable for transplantation were subjected to 12h of normothermic ex-vivo
lung perfusion (EVLP) with Steen solution. The perfused lungs were allocated
into 2 groups: EVLP (control) or EVLP with 4x1010pfu of trans-bronchial
AdhIL-10 (IL-10 group).Lung functional parameters were evaluated during
the perfusion period. Inflammatory cytokines and the tight junction integrity
protein ZO-1 were assessed in the lung tissue before and after treatment.
Results: Baseline donor lung characteristics were similar between the 2 groups.
Improvement from baseline in delta PO2/FiO2 was 129.838.7mmHg in IL-10
group vs 29.3 17.9mmHg in control group (p<0.05).ZO-1 protein stain showed
recovery of tight junction integrity (Fig.1) in 4/5 in the IL-10 group and 1/5 in
the control group. Donor lung inflammation was significantly decreased after
12h of perfusion in lungs treated with IL-10 gene therapy (Fig.2).
Conclusions: Repair of injured human donor lungs is achievable during
prolonged EVLP. Improvements in lung oxygenation capacity, restoration of
alveolar barrier integrity and attenuation of lung inflammation are enhanced by
ex-vivo IL-10 gene therapy.
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240 2007 UPDATE ON ALLOGENEIC ISLET
TRANSPLANTATION FROM THE COLLABORATIVE ISLET
TRANSPLANT REGISTRY (CITR)
R. Alejandro1, B. Hering2, F. Barton3, M. Appel4, F. Kandeel5, M. Garfinkel6,
S. Wease3
1University of Miami, 2University of Minnesota, 3The EMMES Corporation,
4The National Institute of Diabetes, Digestive and KidneyDiseases, 5City of
Hope Medical Center, 6University of Chicago
Primary aim: To summarize the findings from the Collaborative Islet
Transplant Registry (CITR) on human-to-human islet transplantation in North
America and one European center from 1999 to 2007.
Methods: With local IRB approval, participating centers reported pre-transplant,
six-month and annual follow-up information on islet infusions including islet
and donor characteristics, induction and maintenance immunosuppression,
insulin use, markers of diabetes control, hypoglycemia, metabolic measures,
laboratory findings and adverse events. Islet recipients give informed consent
for reporting their data to the Registry.
Results: As of September 30, 2007, CITR comprised 315 allograft recipients
(285 islet-alone and 30 islet-after-kidney) in sufficient detail for analysis.
They received 617 infusion procedures derived from a total of 672 donors.
Non-steroidal immunosuppression was used in the vast majority of the cases.
Ninety of the recipients (29%) received a single islet infusion, 153 (49%)
received two, 67 (21%) received three infusions, generally within one year
of the initial infusion, and five received four infusions. Insulin independence
(II) was achieved by 70% of the recipients, and was maintained for a median
of 24 months (11-48 IQR). Of those who achieved II, 82%, 72%, 48% and
37% were still II at 6, 12, 24 and 36 months later; 75-90% had islet function
three years later. Overall, about 10% lost their graft function by one year after
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241 RESULTS OF A MULTI-YEAR COMPARISON OF
ISLET TRANSPLANTATION WITH INTENSIVE MEDICAL
THERAPY ON THE PROGRESSION OF MICROVASCULAR
COMPLICATIONS IN TYPE 1 DIABETES
G.L. Warnock1, M. Meloche1, J. Shapiro1, Z. Ao1, P. Keown1, J.D. Johnson1,
B. Verchere1, N. Partovi2, D. Thompson1
1The University of British Columbia, 2Vancouver General Hospital
The British Columbia Islet Transplant Program is conducting a prospective,
crossover, cohort study comparing intensive medical therapy and islet cell
transplantation (ICT) on the progression of diabetic retinopathy, nephropathy
and neuropathy. A cohort of 44 patients was enrolled between January 2002 –
January 2005. All patients began intensive medical therapy upon enrollment
and then crossed-over to transplantation when an appropriate donor became
available. Patients received immunosuppression with ATG induction, followed
by tacrolimus and mycophenylate together with > 12,000 islet equivalents
(IE) /kg from 1 – 4 donors. 31 patients received 64 islet infusions. They were
followed for an average duration of 39 months post-ICT and 37 months for
medical treatment. Analysis was by intention to treat and endpoints were prespecified before the study began. We present an interim analysis of outcomes.
Comparison of median HbA1c (%) for all subjects showed 7.5±1.2 for medical
versus 6.7±0.9 for ICT (p<0.01).
Retinopathy was assessed using 7-field stereo fundus photography and graded
using the international scale. Progression was defined as nonproliferative
retinopathy advancing by 1 or more levels or proliferative retinopathy
reaching a severity that qualified for laser treatment. Progression occurred
significantly more often in subjects on medical therapy (10/82 eyes) than
after ICT (0/51 eyes) (p < .01). Considering only ICT subjects, progression
occurred in 6/51 eyes while on medical treatment than post ICT (0/51) (p
< .02).
The primary endpoint for nephropathy was rate of change in GFR measured by
blood clearance of 99mTc-DPTA measured every 6 months. GFR values were
analysed by linear regression to calculate the rate of change for each subject.
Individual patient results were combined to determine the mean intrapatient
rate of change in GFR. Change in GFR did not differ for ICT (-3.8 ± 12.7 ml/
min/yr) compared with medical (-5.1 ± 8.4). Both values are greater than the
general population (-1 ml/min/yr). Change in urinary albumin excretion also
did not differ between the groups.
Neuropathy was measured by nerve conduction studies of 7 peripheral
nerves performed annually. Values for each nerve were combined to produce
a composite value for each study and then the rate of change over time was
calculated. Baseline nerve conduction velocity (NCV) was 47.8 ± 6.2 m/sec for
medical and 47 ± 4.8 for ICT patients (P = NS). below the normal value of 53.9
± 5.4. Rate of decline was similar: – 1 m/sec/yr for medical and – 1.2 post-ICT.
Subgroup analysis of individual nerves or stratified by baseline NCV showed
no differences between the groups. We conclude that over 3 years, ICT results
in improved HbA1c and less progression of diabetic retinopathy compared
with intensive medical therapy.

242 METABOLIC OUTCOMES AFTER ISLET
TRANSPLANTATION
G.L. Warnock1, M. Meloche1, J. Shapiro1, Z. Ao1, P. Keown1, J.D. Johnson1,
B. Verchere1, N. Partovi2, D. Thompson1
1The University of British Columbia, 2Vancouver General Hospital
The British Columbia Islet Transplant Program has been active since March
2003 and is studying the effect of islet transplantation on the microvascular
complications of diabetes. As of March 2008, we have performed 64 islet
infusions in 31 recipients. All recipients had some degree of retinopathy and
nephropathy to be eligible for the study. 67% also had a history of severe
hypoglycemia. Patients entered intensive medical therapy until a suitable
donor became available. At the time of initial islet infusion, the average age
of recipients was 45.9 ± 8.5 yrs, diabetes duration 33.5 ± 8.7 years, weight
70.3 ± 11.1 kg, daily insulin dose 42.7 ± 14.6 units and HbA1c 7.1±0.7%.
The initial goal was to transplant > 12,000 islet equivalents/kg in 1 – 3
infusions. Some patients were given supplemental infusions to improve graft
function. Six subjects have stopped immunosuppression (skin cancer, CMV
infection, primary graft failure (2). immunosuppression side effects (2) ) and
four have not yet received > 12,000 IE/kg; the remaining 21 are the subject
of this report. Islets suitable for transplantation were isolated from > 75% of
donated pancreases and the mean IE per infusion was 494,000 ± 204,000.
One islet infusion has been given to 3 patients, 2 infusions to 7, 3 infusions
to 8 and 4 infusions to 3. The mean duration of follow-up from initial islet
infusion is 39 months.Twelve of the 21 patients (57%) are not taking insulin at
present. The average dose of the patients still taking insulin is 26% of their pretransplant dose. The median HbA1c post-transplant is 6.5% with no increase
over time. HbA1c compared favourably with intensive medical therapy which
was 7.5±1.2 (p<0.01). Severe hypoglycemia has been largely eliminated. The
mean fasting C peptide level in patients off insulin is higher than those still
taking some insulin (448 ± 184 pmol vs 241 ± 140 pmol, p< .01). All but 1
patient has remained C peptide positive since their last islet infusion. There
is no apparent decline in C peptide levels over time in patients remaining off
insulin. There is no correlation between C peptide levels or need for insulin
and number of IE/kg infused. We conclude that islet transplantation yields long
term function in patients with microvascular complications of diabetes, with
insulin independence at 3 years of 57%.

243 ISLET AUTO-TRANSPLANTATION AFTER TOTAL
PANCREATECTOMY: A CONTRAST TO ISLET ALLOGRAFT
OUTCOMES
D.E.R. Sutherland, A.M. Carlson, J. Blondet, G. Beilman, B.J. Hering,
A.C. Gruessner
University of Minnesota Department of Surgery
Introduction: Islet allografts with a large beta cell mass (>10,000 islet
equivalents (IE) /kg) are currently associated with a high rate of function
(C-peptide positive) and early insulin-independence (II). but after one
year II rates rapidly decline for reasons not clear (immunological or nonimmunological?). We have a large islet autotransplant (IAT) experience which
shows not only durable function but extended II rates even though the beta
cell mass, as estimated by #IE transplanted, is less than for islet allografts. IAT
outcomes give a minimum theoretical standard for islet allograft outcomes.
Methods: From Feb, 1977 to Nov, 2007, 152 adult patients underwent total
pancreatectomy (TP) and intraportal IAT to treat chronic pancreatitis. Islet
function was considered full in patients while II, partial if euglycemic on oncedaily long acting insulin, and failed if on a standard insulin regimen. Full/
partial graft function rates, as well as II rates, were calculated actuarially (death
censored) overall and by IE/kg. Comparison was made to published data from
the Collaborative Islet Transplant Registry (CITR).
Results: IAT patient survival rates at 1, 2, 5 and 10 yrs were 95, 92, 85 and
74%. IAT function rates (full/partial-combined) were 57, 54, 47 and 43% at
1, 2, 5 and 10 yrs; corresponding II rates were 30%, 26%, 15% and 10% (7
patients II>10 yrs). Of IATs that functioned at all, 95% still were 2 yrs later,
slightly higher than the 86% for allografts reported by CITR; however, 87%
of IAT recipients who achieved II were still II 2 years later, vs. only 30% for
allografts. IAT function correlated (p<0.05) with yield and was present at 1 yr
in 26, 79 and 82% of recipients of<2,500 (n=58). 2501-5000 (n=52) and>5000
(n=42) IE/kg; the corresponding II rates were 5, 41 and 65% (p<0.05). [In
contrast to CITR where II was virtually never reported with<5000 allogenic
IE/kg]. IAT function rates significantly (p<0.03) improved by era, at 1 yr 42%
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their last infusion. Key changes from baseline to one year after last infusion
were: HbA1c declined from 7.7+1.3% (mean+SD) to 6.2+0.9; C-peptide
increased from 0.1+0.2 ng/mL to 1.3+1.1; and the proportion experiencing
severe hypoglycemia events (80% pre-transplant) declined to 10%. About
one-third of the recipients experienced one or more serious adverse events
that were deemed related to either procedural or immunosuppression factors.
In all but 14 patients, these events resolved without complications. One of
the five reported deaths was due to viral meningitis. Ten cases of neoplasm
were reported.
Conclusions: Islet transplantation in 1999-2007 represents a promising
procedure for vastly improving glycemic control and nearly eliminating severe
hypoglycemia. Procedural complications have been virtually eliminated.
Undesirable effects of immunosuppression need to be balanced against the
benefits of the procedure. The registry is growing large enough to begin
identifying factors that affect success and identify the patients best suited for
islet transplantation.
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(1977-95). 48% (1996-2001) and 69% (2001-07).
Conclusion: Islet autografts that function (>half, correlated with yield) are
durable with three-fourths still functioning at 10 years, but the main contrast to
allografts is the durability of II; of the IAT recipients that achieve II, half are
still II at 5 and a third at 10 yrs, in contrast to the islet allograft recipients where
less than a fifth are still II at 5 yrs. Since islet allograft recipients maintain
C-peptide in the face of insulin-dependence, rejection seems an unlikely
explanation and most likely the viable islet mass engrafted in allograft recipients
is less than in IAT recipients (allogenic islets usually not fresh; procured and
preserved from brain-dead stressed donors; etc). The absence of diabetogenic
immunosuppression in IAT recipients also allows a smaller beta cell mass to be
adequate. The IAT results also belie the hypothesis that the portal vein/hepatic
environment is inherently hostile to islets, given the many IAT recipients who
have been II for more than a decade. Islet allograft protocols should try to
incorporate as many of the IAT favorable circumstances as possible for clinical
application.

244 USE OF ALEMTUZUMAB INDUCTION AND
CALCINEURIN-FREE LONG TERM IMMUNOSUPPRESSION
TO IMPROVE SHORT AND LONG TERM OUTCOMES IN
ISLET TRANSPLANTATION.
T. Froud1,2,3, D.A Baidal1, P. Cure1, A. Curry1, G. Selvaggi1,2, N.S. Kenyon1,
C. Ricordi1,2, R. Alejandro1,4.
University of Miami Miller School of Medicine, Miami, USA 1Diabetes
Research Institute, 2Department of Surgery, 3Department of Radiology,
4
Department of Medicine,
An important limitation of islet transplantation is the loss of functional islet
mass over time. To attempt to prevent these losses, a protocol was begun using
alemtuzumab (Campath 1H®) for induction, a relatively new agent that causes
profound, long lasting T-lymphocyte depletion, and reducing long term exposure
to calcineurin inhibitors, which are toxic to ß-cells. Two doses of alemtuzumab
were administered with the first islet infusion, a single dose with the second if
lymphocyte count was >5% and maintenance immunosuppression consisted
sirolimus indefinitely with tacrolimus for three months and mycophenolate
mofetil thereafter.
To date, three subjects have been transplanted using this regimen (group
A). All have been followed for more than 2 years after completion infusion.
Comparison, at 3,6,12,18 and 24 months post transplant, is with sixteen islet
recipients (group B) transplanted using daclizumab induction and sirolimus/
tacrolimus maintenance (Edmonton protocol).
Parameters examined include peak C-peptide during mixed meal tolerance test
(MMTT). mixed meal stimulation index (MMSI). acute C-peptide release to
glucose (ACPRg) and insulin requirements (ins/kg/day). Results are expressed
as intent to treat using mean±SE and unpaired t-test to compare each parameter
in both groups.
There were no significant differences in demographics between groups A&B
(mean age 41.3±1.76 vs 41.1±2.49 years; duration of diabetes 29.7±7.22
vs 27.0±3.10 years; insulin requirements 0.51±0.08 vs 0.48±0.02 insulin/
kg/day; islet equivalents (IEQ) transplanted 817,786.7±262,996.3 vs
917,708.2±65,778.5 IEQ/kg).
In group A, 2/3 subjects and in group B 14/16 subjects achieved insulin
independence; in those that did not, a second islet infusion was contraindicated
or declined. In group A, insulin independence and insulin requirements were
unchanged over the 24 months of follow-up, while in group B only 6/14 (43%)
remained insulin independent at 24 months. 8/14 (57%) had reintroduced
exogenous insulin for graft dysfunction (insulin/kg/day at 3 and 24 months:
group A 0.06±0.06 and 0.05±0.05; group B 0.02±0.02 and 0.15±0.06).
Comparing groups A&B, measures of graft function were better in group
A at three months (peak C-peptide 4.7±0.88 vs 3.5±0.18; MMSI 1.1±0.19
vs 0.7±0.06; ACPRg 1.34±0.42 vs 0.81±0.09) despite higher mean insulin
requirements (insulin/kg/day 0.06±0.06 vs 0.02±0.02). By 24 months the
discrepancy was greater, with group A remaining stable or improving slightly
compared to overall deterioration in group B (peak C-peptide 5.0±0.50 vs
3.1±0.29 p<0.05; MMSI 1.0±0.08 vs 0.57±0.1 p<0.01; ACPRg 1.31±0.61 vs
0.60±0.20) [see figure below].
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245 LONG TERM INSULIN INDEPENDENCE AND
RESTORATION OF FIRST PHASE INSULIN RELEASE
AFTER SUPPLEMENTAL ISLET INFUSION UNDER
EXENATIDE TREATMENT IN SUBJECTS WITH ISLET GRAFT
DYSFUNCTION
T. Froud, R.N. Faradji, T. Tharavanij, S. Messinger, A. Pileggi, D.A. Baidal,
L. Dinkins, G. Selvaggi, C. Ricordi, R. Alejandro
Diabetes Research Institute, University of Miami, Miami, FL
Objective: To assess the effects of exenatide on supplemental islet infusions
(SI).
Methods: Five subjects with islet graft dysfunction underwent SI under
Edmonton-like protocol in 2003 without exenatide (SI-C group) and 4 with
exenatide in 2006 (SI-EXN group). Clinical and metabolic profiles were
assessed every 3 months for18 months.
Results: SI-EXN group was on this drug for median time of 171 days preSI. Both groups were similar except for duration from post-completion to
graft dysfunction (648±34 vs 221±58 in SI-EXN and SI-C group respectively,
p<0.05) and duration of graft dysfunction before SI (664±83 vs 326±93,
p=0.03). SI-C and SI-EXN groups received mean of 8713±2123 and 5613±485
IEQ/kg, respectively (NS). Only 3/5 of SI-C patients achieved insulin
independence for 303, 403 and >1670 days after SI. All subjects in SI-EXN
group achieved insulin independence for more than 443, 621, 641, 654 days. At
18 months insulin independence was 20% in SI-C and 100% in SI-EXN group.
Comparing pre and post-SI, SI-EXN group had significantly lower A1C at 3-18
months and lower AUC glucagon at 6 and 15 months (p<0.05). AUC C-peptide
in SI-EXN group was significantly higher than SI-C at 3, 9 and 15 months.
Acute exenatide administration during intravenous glucose tolerance test at
15 month in SI-EXN revealed significantly increased acute insulin response
to glucose (difference 11±4.6 μIU/ml, p=0.02) which indicates improved first
phase insulin release [figure1].
Conclusion: Supplemental islet infusions under exenatide lead to insulin
independence, restore first phase insulin secretion and result in long term
insulin independence.
Figure 1: Insulin levels in SI-EXN group after intravenous glucose tolerance
test with (Exn+) and without exenatide (Exn-) administration before the test at
15th month post-SI.
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246 ISLET TRANSPLANTATION IN TYPE 1 DIABETICS
USING A CALCINEURIN INHIBITOR-FREE PROTOCOL
BASED ON EFALIZUMAB AND SIROLIMUS.

Patient
# of Islet Infusions
IEQ Infused
IEQ/kg
C Peptide at 4 mo
Insulin Independence
>30d
Duration of insulin
independence
Currently on
Insulin
HbA1c
decrease >2.5%

1
1
574,950
8,711
Yes

2
1
482,500
8,041
Yes

3
1
630,165
11,458
Yes

4
1
459,290
7,408
Yes

5
1 (2donors)
846,502
12,826
Yes

Yes

Yes

Yes

Yes

No

1.5 months

>8 months

>8 months

>5 months

3
weeks

Yes (3-5U/d)

No

No

No

Yes (4U/d)

No

Yes

Yes

Yes

Yes

Conclusions: Thymoglobulin induction followed by sirolimus and efalizumab
maintenance immunosuppression
is well tolerated and allows prolonged islet
*
allograft survival. This novel immunosuppressive regimen is the first CI/
steroid free islet regimen resulting in insulin independence with a single donor
islet infusion. By eliminating CI, this protocol minimizes nephro- and islet
toxicity and may thus improve long-term islet allograft survival and function.
Preliminary in vitro studies indicate that the mechanism (s) responsible for
graft survival in this setting may involve induction of T reg subsets.

247 HYPOGLYCEMIA AWARENESS AFTER ISLET
TRANSPLANTATION
C.B. Leitao, P. Cure, A. Pileggi, .D.A. Baidal, T. Tharavanij, D. Mineo,
K. Bernetti, T. Froud, C. Ricordi, R. Alejandro
Diabetes Researsh Institute, University of Miami
The aim of this study was to determine if optimal metabolic control achieved by
islet transplantation (IT) has sustained effects on hypoglycemia unawareness.
A retrospective cohort study was conducted in 29 IT recipients followed before
and after the procedure as treatment for unstable type 1 diabetes mellitus.
Hypoglycemia unawareness was accessed through a validated questionnaire
(Clarke score; score = 0 if no reported hypoglycemia; score >4 = hypoglycemia
unawareness) before and at end of follow-up. Subjects were grouped based on
graft function: off-insulin (n = 8). graft dysfunction (on insulin and stimulated
C-peptide >0.3 ng/ml, n = 13) and graft failure (stimulated C-peptide <0.3 ng/
ml, n = 8). The mean hypoglycemic score pre-transplant was 5.28 +/-1.56 and

248 RECURRENCE OF AUTOIMMUNITY IN ISLET
ALLOTRANSPLANT RECIPIENTS EVALUATED BY GAD65
AND IA2 AUTOANTIBODIES
D. Mineo1, K. Monroy2, P. Cure3, G. Allende4, C. Leitao5, T. Froud6,
G.W. Burke7, C. Ricordi8, A. Pugliese9, R. Alejandro10
1
University of Miami, 2University of Miami, 3University of Miami, 4University
of Miami, 5University of Miami, 6University of Miami, 7University of Miami,
8
University of Miami, 9University of Miami, 10University of Miami
Islet allotransplantation can restore insulin secretion and glucose control in
patients with brittle type 1 Diabetes (T1D). Allorejection, drug toxicity, hostile
hepatic environment and recurrence of autoimmunity may account for the
limited longevity of the islet graft.
In the present study, we aimed to determine in islet allotransplant recipients the
possible influence of recurrent autoimmunity on graft function and survival by
evaluating GAD65 and IA2 autoantibodies (AAbs) during the follow-up.
Forty-three patients with long-term T1D, who received an islet allotransplant
at our institution within different protocols from 2000 to 2006, were classified
as negative, converter or persistent according to their AAbs levels during
follow-up (positivity was defined by 2 or more values above the normal levels
for either or both type of AAbs). Kaplan-Meier (K-M) curves for islet graft
dysfunction and failure were analyzed.
Prior to transplant, 20 patients were AAbs positive (11 for GAD65, 4 for IA2 and
5 for both AAbs) whereas 23 were AAbs negative. After islet transplantation, 17
recipients persisted positive, 14 remained negative while 8 converted to positive
(2 to GAD65, 2 to IA2 and 4 to both); no data was available for 4 recipients.
K-M curves for graft dysfunction (36 recipients with islet dysfunction, 3 insulinfree) were not different among groups, while K-M curves for graft failure (23
recipients with islet function, 16 C-peptide negative) showed longer estimated
time to failure (mean±SE) in the AAbs negative (49±7months) and persistent
(47±7months) groups in respect to the converter one (44±8months).
Comparison among K-M curves became significant only after 3 years from the
first islet transplant, the AAbs converter group showing an earlier graft failure
compared to the persistent and the negative ones (p=0.039).
In conclusion, AAbs can persist after islet allotransplantation or even recur,
despite immunosuppressive therapy. While influence on graft dysfunction
seemed not relevant, recurrence of autoimmunity may contribute to reduce the
overall graft survival in the long-term.
Figure
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A. Posselt1, G. Szot1, L. Fong1, L. Frasetto1, U. Masharani1, J. McElroy1,
D. Ramos1, T. Rojas1, B. Hering2, P. Stock1
1University of California, San Francisco, 2University of Minnesota
Background: Although islet transplantation has become an option for treatment
of type 1 diabetes mellitus, the immunosuppressive protocols currently used
to promote graft survival rely on drugs with significant nephro- and beta
cell toxicities. Here we describe a novel immunosuppressive protocol using
sirolimus and the anti-LFA 1 antibody efalizumab that permits prolonged islet
allograft survival without the need for corticosteroids or calcineurin inhibitors
(CI).
Materials and Methods: Between February and December 2007, 5 consecutive
type 1 diabetic patients with hypoglycemic unawareness and normal renal
function received allogeneic pancreatic islet transplants. Islets were infused
intraportally after 48h in culture. Induction immunosuppression consisted of
2 doses of thymoglobulin given on pre-transplant days -2 and -1, sirolimus
(starting on d -1) and efalizumab (5mg/kg subcutaneously/week starting on d
-1 ). Maintenance immunosuppression consisted of sirolimus and efalizumab.
Results: All patients achieved insulin independence after single islet infusions
(mean IEQ=598,681; mean IEQ/kg=9,689). Four of 5 had appropriate
reductions in HbA1c and 3/5 remain insulin independent 5 or more months
after transplant. The other 2 patients resumed low dose insulin (approximately
10% of their original doses) 3-6 weeks after transplant and are awaiting a
second islet infusion. Blood glucose control is markedly improved in all
patients and none have experienced any hypoglycemic episodes. All patients
show persistent c-peptide secretion and have stable renal function. Side effects
associated with efalizumab were limited to transient irritation at the injection
site. Immunologic monitoring of these patients indicates that these clinical
effects are associated with an increase in the percentage of circulating FoxP3+
CD4+ regulatory T cells (T reg) and reduced allospecific T cell proliferative
responses.

an inverse and statistically significant correlation between it and pre-transplant
glycemic control, measured by A1c, was found (r = -0.37, P = 0.049). As
expected, a decline in the score was demonstrated posttransplantation (1.14
+/- 1.66, P <0.001) as was the proportion of patients with hypoglycemia
unawareness (10 vs. 86%, P <0.001). In addition, an increment in the threshold
for hypoglycemic symptoms was observed (59.7 +/- 9.5 vs. 41.7 +/- 18.5 mg/dl,
P = 0.001). These results were sustained even after patient’s stratification based
on islet function (off-insulin-pre: 5.63 +/- 2.00 vs. post: 0.00 +/- 0.00, P <0.001;
graft dysfunction-pre: 5.31 +/- 1.49 vs. post: 1.15 +/- 1.63, P <0.001 and graft
failure-pre: 4.88 +/- 1.25 vs. post: 2.25 +/- 1.91, P = 0.009). However, posttransplant scores were higher in graft failure group when comparing with offinsulin subjects (P = 0.016). Additionally, lower hypoglycemic score values were
correlated with better beta cell function (r = -0.396, P = 0.033 and r = -0.450, P
= 0.016 for fasting and stimulated C-peptide, respectively). In conclusion, stable
metabolic control achieved with clinical IT restores hypoglycemia awareness
and these effects have persisted even after islet graft failure.
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249 A DECADE OF MINIMALLY INVASIVE DONATION:
EXPERIENCE WITH 1175 LAPAROSCOPIC DONOR
NEPHRECTOMIES AT A SINGLE INSTITUTION
J. Leventhal, J.C. Caciedo, A. Skaro, A. Koffron, T. Baker
Northwestern University
The past decade has seen laparoscopic donor nephrectomy (LDN) transform
into a standard of care procedure for kidney transplantation. Furthermore, LDN
has evolved with the introduction of new technologies aimed at increasing
the efficiency and safety of the procedure. There are few large, single center
experiences detailing the results of LDN, its associated complications, and their
management. We performed a retrospective review of 1175 LDN performed at
our center for both pediatric and adult recipients from 10/97 thru 3/08. We
evaluated preoperative donor characteristics, intraoperative parameters and
complications, postoperative recovery and complications. A modification of
the Clavien classification (Leventhal et al Surgery, Oct. 2004; 881-90) was
used to grade complication severity.
Results: Mean BMI of donors was 26.9 (range 17-48) with 24.7% having
a BMI > 30 and 5.9% with a BMI > 35. 26% of kidneys had multiple renal
arteries. >99% were left LDN. The mean length of stay was 1.37 +/- 0.6
days, which decreased to 1.1 +/- 0.5 days for the last 450 cases. The overall
complication rate for our series was 4.2%. 19/1175 (1.6%) of pts experienced
an intraoperative complication, including 8 renovascular injuries; 7/8
renovascular injuries led to open conversion. 4 open conversions were elective;
our overall conversion rate is 0.9%. 31/1175 (2.6%) had a postoperative
complication. 15/1175 (1.2%) required readmission for complication
mgmt. 3/1175 patients have been lap. Reoperated for prolonged ileus and
internal hernia (2). respectively. When graded by severity, 19/50 (38%) of
complications were Grade 1 (Non-Life Threatening). 29/50 (58%) Grade 2
(No Residual Disability). and 2/50 (4%) were Grade 3 (Residual Disability).
There have been no cases of donor renal failure or death. Since 2003 we have
routinely used hand-assisted LDN (HALDN). 482 LDN were compared to
693 HALDN. Donor demographics were comparable between both groups.
Graft function was similar in LDN and HALDN kidneys. Intraoperative
and postoperative complication rates were also similar. Conversion rates
were 1.9% for LDN and 0.4% for HALDN. HALDN was associated with a
reduction in the number of operating ports and in operating room time. There
have been no cases of primary non-function. Urologic complications have
occurred in 3/1175 LDN renal transplants. Conclusions: Our series supports
the safety and efficacy of LDN/HALDN.

250 NOVEL SOURCES OF RENAL ALLOGRAFTS: KINDEYS
WITH INTRINSIC DISEASES, WORLD WIDE EXPERIENCE.
S. Fujita1, K. Nannba2, M. Nishi3, N. Mitsuhata4, Y. Tsutsumi5, R. Mannami6,
M. Mannami6, D. Nicol7
1University of Florida, 2Rokumeisou Pathology Center, 3Kagawa Rosai
Hospital, 4Kure Kyosai Hospital, 5Fujita Health University, 6Uwajima
Tokushukai Hospital, 7University of Queensland
Introduction: We embarked on a novel procedure gRestored kidney
transplantation (RKT) h in which 42 renal allografts were obtained from
patients with intrinsic disease including small renal cell carcinoma, ureteral
stenosis and renal artery aneurysm (Am J Transplant. 2008 Apr;8 (4): 811-8.).
In this report, we review the world-wide experience of this novel approach to
increase transplant numbers.
Materials and Methods: Cases of RKT were identified from MEDLINE and
through personal communication. Donor and recipient information including
long term follow-up was obtained by direct contact with transplant units
performing RKT as much as possible. Accumulated cases are summarized and
reviewed. As Australian cases will be presented elsewhere in this symposium
in more detail, they were exempted.
Results: A total of 210 cases of RKT were identified, including 78 small
renal cell carcinomas, 8 ureteral carcinomas, 21 benign neoplasm (including
15 angiomyolipomas). 8 nephrotic syndromes, and 95 various non-neoplastic
lesions. There was one local recurrence of ureteral carcinoma (15 months after
transplantation) and one remote recurrence of small renal cell carcinoma (9
years after transplantation).

88

Discussion: RKT is now being considered in a number of transplant centers
in North America, Europe and Asia-Pacific. The reported experience shows
comparable outcomes to conventional renal transplants. Transmission of the
donor disease appears extremely rare. This novel approach has a great potential
as an alternative source of renal allografts for patients who would otherwise not
be able to receive a transplant.

251 OUTCOMES OF TRANSPLANTS FROM KIDNEYS
REMOVED WITH SMALL RENAL TUMOURS COMPARED TO
CONVENTIONAL LIVE UNRELATED AND DECEASEDDONOR
TRANSPLANTS.
D. Nicol, N. Gibbons, A. Griffin, D. Wall, S. Wood, N. Isbel, C. Hawley,
S. Campbell, J. Preston, D. Johnson
Princess Alexandra Hospital
We have recently reported the successful utilization of kidneys from patients
with incidentally detected small renal tumours (< 3cm) for transplantation
(Nicol et al BJU Int 2008). Following ex-vivo excision of the lesion and repair
of the parenchymal defect the kidney is transplanted into selected recipients.
These restored kidney transplants (RKT) appear a novel means of increasing
the possibility of transplantation for selected patients who may otherwise not
receive a transplant. In this study we compare outcomes of RKT to other modes
of renal replacement therapy. During the period May 1996 to December 2007
49 RKT were performed at our centre. Recipients were considered suitable
for transplantation but marginal based on age and co-morbidities. Graft and
patient outcomes in this group were compared to conventional live unrelated
transplant recipients (n=120). deceased donor transplants (n=768) and to
survival of patientsl on the active transplant waiting list who did not receive a
kidney during this period (n=153).
Patients receiving RKT were significantly more likely to be older, have
diabetes mellitus and coronary artery disease compared to the other groups
(p<0.01). Kaplan-Meier survival analysis demonstrated that the recipients
of RKT kidneys experienced an early increase in mortality compared with
the other 2 transplant groups. By approximately 4 years post-transplant,
survival of the RKT kidney recipients was significantly superior to that of
dialysis patients who were accepted onto the renal transplant list but inferior
to that of deceased donor and live unrelated kidney transplant recipients
(who were both significantly younger and had fewer comorbidities).
Respective 1-, 3- and 5-year survival rates were 92%, 88% and 88% for
RKT recipients compared to 99%, 997% and 97% for live unrelated kidney
transplant recipients, 96%, 92% and 90% and 98%, 92% and 74% for
dialysis patients accepted onto the deceased donor kidney transplant list
(log rank score 10.4, p=0.005). In a subsequent matched cohort analysis of
the transplanted patients RKT, live unrelated and deceased donor recipients
were matched for age (within 2 years). gender and HLA mismatch. With
this there was no difference in overall survival between the 3 groups (log
rank score 0.09, p=0.77). No differences in graft survival were noted at
any time point in the 3 transplant groups. In the 49 RKT recipients graft
loss occurred due to recurrent FSGS in one case and death due to unrelated
causes in 4 cases. Only one recipient experienced tumour recurrence 9 years
post transplantation. This patient declined intervention and is currently
under active surveillance.
Conclusions: RKT using kidneys removed with small, localized renal tumours
following ex-vivo resection results in similar outcomes to conventional
deceased and live unrelated living donor transplants. It also appears to confer
a significant survival advantage for patients who would otherwise be unable
to receive a transplant. Despite the apparent contradiction of an intuitive
principal of transplantation and immunosuppression, these kidneys should be
considered for transplantation into carefully selected patients who may not
otherwise have access to renal transplantation increasing quality and length
of life
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252 THERE ARE NO ANATOMICAL BARRIERS TO
LAPAROSCOPIC DONOR NEPHRECTOMY

253 COMPARISON OF RECIPIENT OUTCOMES
FOLLOWING OPEN AND LAPAROSCOPIC DONOR
NEPHRECTOMY: AN ANALYSIS FROM THE AUSTRALIAN
AND NEW ZEALAND DIALYSIS AND TRANSPLANT
REGISTRY (ANZDATA).
D. Nicol1,3, N. Gibbons1, S. McDonald2, J. Preston1,
Renal Transplant Unit, Princess Alexandra Hospital, 2ANZDATA Registry,
Adelaide, Australia, 3University of Queensland
Introduction: Laparoscopic donor nephrectomy has been widely adopted
despite no randomized controlled trials having been performed comparing
recipient outcomes with open donor nephrectomy. Review of registry data now
appears the most feasible mechanism to compare outcomes. The ANZDATA
registry prospectively captures data on all renal transplants performed in
Australia and New Zealand including long term follow-up of recipients.
Aim; To compare graft outcomes among recipient of kidneys from donors
undergoing nephrectomy using open vs laparoscopic techniques, through
analysis of the ANZDATA registry following the introduction of laparoscopic
donor surgery in Australia and New Zealand in 1997.
Methods: Operative technique data for live donor transplants were collected
from May 1997 to December 2003; outcomes of all live donor transplants were
examined with follow up to December 2006. Donor and recipient demographic
variables and graft outcomes were compared between the laparoscopic and open
donor groups. Standard techniques for continuous and categorical variables
were used; Cox analyses used Kaplan-Meier and Cox regression analyses.
Results: A total of 1,474 live donor transplants were performed in 27
transplant centres in Australia and NZ. Of these 296 (20.08%) were performed
laparoscopically in 10 centres and 1,159 (78.63%) open in these centres and
the remaining 16 transplant units. Of the laparoscopic cases 237 (80%) were
performed in 3 centres whilst open nephrectomy was performed exclusively
1

254 PREDICTORS OF POOR EARLY GRAFT FUNCTION
FOLLOWING LAPAROSCOPIC DONOR NEPHRECTOMY
(LDN)
M. Cooper1, A. Haririan2, S. Jacobs3, M. Phelan3, B. Philosophe1,
S. Bartlett1 and J. Nogueira2.
1
Dept of Surgery, 2Medicine and 3Urology, University of Maryland, Baltimore,
MD, USA.
Body: LDN has become the standard of care in many transplant centers. Poor
early graft function remains an important complication. Medium and long-term
recipient outcomes are directly correlated with early allograft function. We
conducted a retrospective study to evaluate the risk factors for slow or delayed
graft function following LDN
Methods: Donor and recipient records from the first 1000 LDN were reviewed
(1996-2005).
Results: Slow graft function (SGF) was defined as Cr>3.0mg/dl at POD5 and
DGF as the need for dialysis within the first week following transplantation.
Donor variables examined included age, sex, race, BMI, eGFR, and number of
renal arteries. Recipient variables included age, sex, race, BMI, prior tx, pre-tx
DM, history of smoking and drug usage. Additional variables evaluated included
degree of relationship (LURT). HLA mismatch, antilymphocyte induction, de
novo CNI usage, R v. L nephrectomy, WIT, total OR time, and performance
of simultaneous deceased donor pancreas tx (SPLK). Univariate analysis was
performed with significance defined as p<0.05. Significant variables were then
included in the multivariate analysis.
Parameter

Univariate (OR,
95%CI)

p-value

Multivariate (OR,
95%CI)

Male Recip

1.48 (0.92-1.18)

0.04

1.49 (0.95-2.32)

0.08

AA Recip

1.68 (1.17-2.42)

0.005

1.34 (0.49-3.62)

0.57

p-value

Donor Age/decade

1.19 (1.02-1.39)

0.02

1.32 (1.08-1.60)

0.005

AA Donor

1.63 (1.12-2.37)

0.01

1.18 (0.43-3.23)

0.75

Prior Tx

0.36 (0.13-1.00

0.05

0.74 (0.24-2.22)

0.59

LURT

1.47 (1.02-2.11)

0.04

0.97 (0.58-1.65)

0.92

SPLK

0.33 (0.13-0.83)

0.02

0.41 (0.14-1.19)

0.10

Recip BMI/5kg/m2

1.49 (1.30-1.72)

0.000

1.49 (1.26-1.78)

0.000

HLA MM

1.18 (1.05-1.32)

0.003

1.14 (0.97-1.34)

0.10

R Kidney

2.52 (1.12-5.69)

0.03

2.87 (1.17-7.06)

0.02

WIT

1.00 (1.02-1.28)

0.02

1.16 (1.02-1.33)

0.03

Recip Smoke

1.48 (1.04-2.12)

0.03

1.40 (0.92-2.15)

0.12

Conclusion: Both donor and recipient variables may account for early allograft
function. Our results suggest that donor age, recipient BMI, male recipient,
WIT and right lap nephrectomies are independent risk factors for SGF/DGF
following LDN. Many are modifiable variables and worthy of intervention and
further study in an effort to improve outcomes.
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C. Crane1, V.W.T. Lam1,2, A. Alsakran3, L. Dealtry2, D.J. Verran3, A. Vasilaras3,
B. Ryan2, H. Lau2, H.C.C. Pleass2, R.D.M. Allen1,2,3
1
Department of Surgery, University of Sydney, Sydney, Australia; 2Department
of Surgery, Westmead Hospital, Sydney, Australia; 3Department of
Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia
Aims: To investigate the effect of living donor right kidney and multiple
donor renal arteries on donor and recipient outcomes after laparoscopic donor
nephrectomy.
Methods: Between September 1998 and December 2006, 200 laparoscopic
living donor nephrectomies were performed. The impact of donor right kidney
and multiple donor renal arteries on operative time, hospital stay, graft function
and donor and recipient complications were analysed.
Results: No donors were refused the option of laparoscopic donor surgery on the
basis of perceived anatomical difficulties. 200 donors underwent laparoscopic
surgery, 29 for donation of right sided kidneys. 34 donors had multiple renal
arteries found at the time of the donor procedure. The open conversion rate
was 7% with no significant difference between laparoscopic donor right and
left nephrectomy groups (2/28 vs. 12/172; p=0.975) and kidneys with multiple
renal arteries and single renal artery (5/39 vs. 9/161; p=0.112).
Right kidneys had a similar first warm ischaemic time (4 mins vs. 4 mins;
p=1.0) and second warm ischaemic time (31 mins vs. 30 mins; p= 0.804)
compared to those of left kidneys. Right kidneys had no significant effect on
complication rate while providing similar recipient graft function compared to
left kidneys.
Thirty-one of the 34 kidneys with multiple renal arteries required vascular
reconstruction of these vessels while 3 had small polar vessels and ligated.
Kidneys with multiple renal arteries had a longer second warm ischaemic time
(38 mins vs. 32 mins, p=0.002) but similar first warm ischaemic time (4 mins
vs. 4 mins, p=0.234) when compared to that of kidneys with single renal artery.
Kidneys with multiple renal arteries had no significant effect on complication
rate while providing similar recipient graft function compared to kidneys with
single artery.
Conclusion: With careful technique, both with the laparoscopic donor
nephrectomy and the recipient procedure, right kidneys and kidneys with
multiple renal arteries can be procured safely with no demonstrated adverse
impact on graft function and complication rates in the donor or recipient.

in 16 centres (n=390, 33.6%). Nineteen laparoscopic cases (1.28%) were
converted to open. There was no significant difference in donor characteristics
with respect to age, gender as well as relationship and matching with recipients.
Recipient groups were also identical with respect to age, weight, gender, preemptive transplantation and cause of renal failure.
The laparoscopic donor nephrectomy group had a significantly longer total
ischaemia time (3.16 hours) compared to the open donor group (1.61 hrs,
p<0.0001). The laparoscopic recipient group experienced a lower incidence
of rejection episodes 29.2% versus 38.6% (p = 0.002). In terms of technical
and other post operative complications and delayed graft function, there was
no significant difference between donor groups, including those in whom the
donor operation was converted from laparoscopic to open. There were a total
of 242 graft failures, 175 graft losses and 67 deaths with a functioning graft.
Among surviving grafts there was no difference in creatinine at any time point.
At 1 year and 5 years, the mean creatinine for the laparoscopic group was 138
umol/l and 138 umol/l and for the open group was 136 umol/l and 145 umol/l
respectively. Graft and patient survivals were similar in both groups (at 1 and 5
years – laparoscopic 95.6%, 87.5% and 99%, 95% versus open 95.5%, 85.7%
and 98.5%, 94.5%).
Conclusions: Based on analysis of all live live donor transplants performed
in Australia and New Zealand, there appears to be no difference in short or
long term recipient outcomes between open and laparoscopic live donor
nephrectomy.
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255 200 CONSECUTIVE HAND ASSISTED LAPAROSCOPIC
DONOR NEPHRECTOMIES – THE AMSTERDAM
EXPERIENCE.
I.JM ten Berge1, R.C. Minnee2, W.A. Bemelman2, K.AMI van Donselaar1, J.
Booij3, B.L.F. van Eck-Smit3, S. ter Meulen1, F.J. Bemelman1, M.M. Idu2
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of
Surgery, Academic Medical Centre, Amsterdam, 3Dpt of Nuclear Medicine,
Academic Medical Centre, Amsterdam
Introduction: The hand assisted laparoscopic donor nephrectomy was
introduced as a modality to facilitate the laparoscopic donor nephrectomy. The
advantages include: the ability to use tactile feedback, less kidney traction,
rapid kidney removal and shorter warm ischemic periods. There is an ongoing
discussion whether a laparoscopic donor nephrectomy should be performed by
a total laparoscopic procedure or by a hand assisted laparoscopic method. The
purpose of this study is to evaluate our results and investigate the frequency
and occurrence of delayed graft function.
Patients and Methods: All 200 consecutive living donors who underwent a
laparoscopic donor nephrectomy between January 2002 and July 2007 were
prospectively included in the study. Delayed graft function was defined as the
need for dialysis within the first postoperative week.
Results: The mean donor operative time was 177 minutes and the hospital
stay and a mean hospital stay for donors was 4.8 days. No conversions were
necessary, intraoperative complications and postoperative complications
occurred in ten donors (5%) and twenty-four donors (13.5%). In fourteen
recipients (7.0%) there were ureteric complications, including obstruction
in nine and leakage in four. Our one-year graft survival was 95%. Delayed
graft function was diagnosed is 12 patients (6%). Two risk factors for delayed
graft function were identified: counts per second on Tmax during renal donor
scintigraphy (odds ratio 15.33, 95% confidence interval (CI): 2.96-79.02) and
multiple renal veins (odds ratio 6.04, 95% CI: 1.24-29.45).
Conclusion: HALDN is a safe procedure regarding donor morbidity rates and
graft survival. The correlation between counts per second on Tmax during
renography and delayed graft function may represent hyperfiltration injury
of a relatively small donor kidney. When renal donor scintigraphy shows
asymmetric function between both kidneys, the question arises if we should
hesitate to transplant this functional inferior kidney or exclude the donor from
donation.

256 150 CONSECUTIVE HAND-ASSISTED LAPAROSCOPIC
DONOR NEPHRECTOMY: A SUCCESSFUL SINGLE CENTER
EXPERIENCE
P.W. Baron1, R. Ben-Youssef1, E. Franco1, A. Elihu1, A. Kore1,
D.D. Baldwin2, O. Ojogho1
1
Loma Linda University Medical Center, Transplantation Institute, 2Loma
Linda University Medical Center, Urology
Background: Hand-assisted laparoscopic donor nephrectomy (HALDN)
is a well-established technique for living kidney donation. We describe our
continuous success with HALDN.
Method: We reviewed the data of 150 consecutive HALDN performed from
Jan 2003 to Aug 2007. The initial 41 cases (G1) were compared to the next
59 cases (G2) and to the last 50 cases (G3). We analyzed the donor operative
time, estimated blood loss (EBL), serum creatinine at discharge (D/C), length
of hospital stay (LOS), recipient serum creatinine at D/C and delayed graft
function rate (DGF).
Results: All cases were completed laparoscopically. Operative time was
293 57, 278 44, and 290 53 min in group G1, G2 and G3. EBL was lowest
in G3 (p=0.001). Minor peri-operative complications occurred in donors
and recipients: minor bleeding controlled laparoscopically without blood
transfusion in 2 G1, 1 G2, and 1 G3 donors; mild rhabdomyolisis in 1 G1, 1 G2,
and 3 G3 donors; abdominal ileus in 4 G3 donors; epididimytis in 1 G2 donor,
and persistent left testicular pain in 1 G1, and 1 G2 donors. A recipient of a G3
kidney underwent exploration for kinked vascular anastomosis. A recipient of
a G1 kidney developed DGF due to hypotension after endomyocardial biopsy.
A recipient of a G1 kidney developed moderate hydronephrosis one week
posttransplant and underwent successful ureteral reimplantation. One recipient
of a G2 kidney and 2 recipients of G3 kidneys developed acute rejections 4,
2 and 8 days posttransplant, respectively. They were treated successfully. The
recipient mean serum creatinine at discharge was 1.3 0.8 mg/dL in G1, 1.2 0.4
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mg/dL in G2, and 1.6 1.4 mg/dL in G3 (p< 0.0001).
Table 1. Donor characteristics
Age (y)
BMI (kg/m2)
Renal arteries, n (%)
1
2
3
MeanSD=

G1 (n=41)
36.7 ±10.7
25.2 ±5.2

G2 (n=59)
34.2±10.4
25.8±2.8

G3 (n=50)
35.9±10.1
25.6±3.5

P-value
NS
NS

34 (82.9)
6 (14.6)
1 (2.4)

48 (81.4)
11 (18.6)
0

44 (88.0)
5 (10.0)
1 (2.0)

NS
NS
NS

G1 (n=41)
110.4±76.8
3.1±0.4
1.2±0.2

G2 (n=59)
80.7±49.5
3±0.2
1.2±0.2

G3 (n=50)
43.0±19.9
3.1±0.4
1.2±0.3

P-value
0.001
NS
NS

Table 2. Donor outcome (mean SD)
EBL (mL)
LOS (d)
Ser Creatinine @ D/C (mg/dL)

Conclusion: These data showed persistently excellent outcome with HALDN.
The procedure has minimal donor morbidity and supplies excellent quality
kidney allografts.

257 RENAL VEIN EXTENSION USING GONADAL VEIN. A
USEFUL STRATEGY FOR RIGHT KIDNEY LIVING DONOR
HARVESTED BY LAPAROSCOPY
P. Troncoso, J. Domínguez, S. Guzman
P Universidad Católica De Chile
Introduction: Vascular management of right renal vein during laparoscopic
living donor nephrectomy is still an unsolved problem. The shortness of this
vessel has limited the use of right kidneys in opposition to left kidneys. However,
in some instances the right kidney should be harvested, particularly when the
left kidney presents complex vascular anatomy. Based on the experience in
open donor nephrectomy, our unit has used donor gonadal vein to obtain longer
right renal veins in this setting.
Methods: Four consecutive living related donors with multiple left renal
arteries and indication of laparoscopic right nephrectomy were submitted to
this procedure. Three donors were female and the average age was 48,5 years
with a range of 30 to 61 years. The renal vein was controlled with a 30 mm
universal stapler and during the harvesting 5 to 6 centimeters of the ipsilateral
gonadal vein was included. The donor kidney was perfused and renal vessels
were prepared in cold conditions in the usual fashion. The gonadal vein was then
opened longitudinally and sutured to the donor right renal vein as a wide tube in
3 cases and as a spiral tube in one with 6-0 monofilament suture material.
Results: This procedure extended the bench work between 25 to 40 minutes and
permitted an extension of 2,5 to 3,5 centimeters of the donor vein. Transplants
were done in the usual mode and the vein enlargement facilitated enormously
the implant surgery. All receptors presented immediate graft function and no
complications were observed with this strategy.
Conclusions: Vein extension with gonadal vein is a simple and safe way to
enlarge the renal vein of right living donor kidneys procured by laparoscopy.
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258 TRANSFECTION OF NFƒÛB DECOY
OLIGODEOXYNUCLEOTIDES USING "EFFICIENT
ULTRASOUND – GENE TRANSFER" INTO DONOR KIDNEYS
PROLONGED SURVIVAL OF RAT RENAL ALLOGRAFTS
H. Azuma 1, H. Nomi 1, N. Ibuki 1, N. Tomita 2, R. Morishita 2, S. Horie 3,
S. Takahara 4, Y. Katsuoka 1
1 Department of Urology Osaka Medical College, 2 Division of Gene
Therapy Science, Osaka University Graduate School of Medicine, 3
Department of Urology, Teikyo University Medical School, 4 Department of
Advanced Technology for Transplantation, Osaka University Graduate School
of Medicine
Objectives: Nuclear factor κB (NFκB) plays a pivotal role in the coordinated
transactivation of a series of genes of cytokines and adhesion molecules that
are highly involved in the onset of acute rejection in organ transplantation.
We previously developed decoy cis-elements oligo deoxyribonucleic acid
against NFκB (NFκB-decoy) that effectively inhibited the activation of major
inflammatory mediators in vitro and in vivo. Accordingly, we hypothesized
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that transfection of NFκB-decoy into the donor kidney would prevent acute
rejection and prolong graft survival, and thus provide effective therapy for
renal acute rejection.
Methods: To transfect NFκB-decoy, we employed a novel approach using
ultrasound exposure with an echocardiographic contrast agent, Optison, and
clearly demonstrated successful transfection of NFκB-decoy into renal tissue.
The therapeutic effect of NFκB-decoy on renal allografts was then evaluated in
a rat renal allograft model (Wistar-Lewis).

Figure 2. Graft function and histology

Figure 3. Expression of cytokines and adhesion molecules in allografts

Figure 1. FITC-labeled NFkB-decoy transfer

Figure 4. Animal survival
Conclusions:ڤwe established a novel ultrasound-Optison-mediated gene
transfection approach and demonstrated the significant prolongation of graft
survival by the successful transfection of NFκB-decoy into the donor kidney in
a rat renal allograft model.
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Results: Ultrasound-Optison-mediated gene transfection procedure successfully
transfected the FITC-labeled NFkB-decoy transfer into renal allografts (Figure
1). In the control group, graft function significantly deteriorated with marked
destruction of renal tissue (Figure 2), accompanied by increased production of
major inflammatory mediators (Figure 3), and all animals died of renal failure by
9 days (Figure 4). In contrast, graft function (serum creatinine on day 2, NFκBtreated: 0.97 ± 0.16 vs. control: 1.84 ± 0.23 mg/dL, p<0.01) and histological
structure was well preserved (Figure 2) with significantly decreased expression
of NFκB-regulated cytokines and adhesion molecules, including IL-1, iNOS,
MCP-1, TNF-α, and ICAM-1 (Figure 3), in allografts transfected with NFκBdecoy. As a result, animal survival was significantly prolonged in this group as
compared to controls (Figure 4; 14.2 ± 5.2 vs. 7.1 ± 1.2 days, p<0.01).

259 LONG TERM SURVIVAL AND FUNCTION OF
ADULT PORCINE ISLETS CO-TRANSPLANTED WITH
ADULT PORCINE SERTOLI CELLS INTO RATS WITHOUT
IMMUNOSUPPRESSION.
D.J.G. White 1,2, C. Hasilo 2, G. Vilk 2, D.M. Mazzuca 2, A. Pepper 1, C. Gall 2,
A. MacGillivary 2, J. Melling 2
1 Schulich School of Medicine University of Western Ontario London Ontario
Canada, 2 London Health Sciences Centre University Hospital London
Ontario Canada
In our abstract (#485) titled "Adult Porcine Sertoli Cells Suppress The Xenograft
Responses to Porcine Islets In Rats More Effectively than Neonatal Sertoli
Cells” to be presented at this conference we report that adult porcine Sertoli
cells elicit no immune response as assessed by anti pig IgG when transplanted
into non-diabetic Lewis rats. Further, the IgG response to porcine islets when
co-transplanted with adult porcine Sertoli cells is also inhibited. Porcine islets
alone or porcine islets co-transplanted with neonatal porcine Sertoli cells induce
substantial anti-pig IgG responses when transplanted into Lewis rats.
We have now exploited this observation by co-transplanting adult porcine
islets and adult Sertoli cells under the kidney capsule of streptozotocin induced
diabetic Lewis rats. Recipients were transplanted at a ratio of 2000 adult
porcine Sertoli cells per islets and received either 1000, 4000 or 8000 adult
porcine islets mixed with the appropriate number of Sertoli cells to maintain
the 2000:1 ratio. Transplants of islets alone (1000, 4000 or 8000) acted as a
control. Recipients were tested for the presence of porcine insulin and porcine
C-peptide and were sacrificed for histological examination at days 74 and 186
(approximately six months). There were 8 animals per group.
All animals receiving the co-transplants gained weight and remained healthy
in contrast to controls. All animals sacrificed at day 74 showed the presence
of porcine insulin positive cells by immunohistochemistry and all produced
a porcine insulin response following intravenous glucose challenge. Basal
(unstimulated) levels of urinary C-peptide were 0.35ng/ml. Porcine insulin levels
ranged from 0.15ng/ml to 0.28ng/ml, islets alone were negative for porcine
insulin <0.02ng/ml). At six months post transplant immunohistochemistry
showed 3 of 5 grafts studied staining positive for insulin producing cells with
porcine insulin production varying from 0.12 ng/ml (1000 islets) to 0.82ng/
ml (8000 islets). C-peptide levels are currently being determined. None of the
recipients became normoglycemic. This is to be expected since porcine insulin
is highly inefficient in rats.
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Co-transplantation of porcine islets with adult porcine Sertoli cells may be a
solution to both the problem of supply and systemic immunosuppression in
islet transplantation for type 1 diabetes.
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260 VIRUS-SPECIFIC CD8+ T-CELL FUNCTION AND
PROTECTION FROM HCMV REACTIVATION/DISEASE IN
SOLID ORGAN TRANSPLANT PATIENTS
T. Crough1, C. Fazou1, J. Weiss1, S. Walker1, S. Bell2, K. McNeil2, A.
Galbraith2, S. Jones3, R. Khanna1.
1
Australian Centre for Vaccine Development, Queensland Institute of Medical
Research, Brisbane, Queensland, Australia. 2The Prince Charles Hospital,
Brisbane, Queensland, Australia. 3Cellestis Ltd, Melbourne, Australia.
We have longitudinally analysed human cytomegalovirus (HCMV)-specific
CD8+ T-cell responses in a cohort of solid organ (heart, lung, renal) transplant
patients. The detection of active virus replication correlated with reduced IFN-γ
expression by HCMV-specific CD8+ T-cells and an up-regulation of CD38
expression on the surface of virus-specific CD8+ T-cells, although there was
no significant change in the number of virus-specific cells. Most importantly,
analysis of IFN-γ production by virus-specific CD8+ T-cells in patients with
HCMV disease suggested that disease was associated with a reduction in CD8+
T-cell responsiveness to both structural and immediate-early antigens. Based
on these results, we have developed a novel diagnostic technology to monitor
the HCMV-specific CD8+ T-cell responses referred to as QuantiFERON®CMV. Evaluation of QuantiFERON®-CMV in healthy individuals and
solid organ transplant patients revealed that this technology was at least as
sensitive and with some HCMV epitopes more sensitive than the ELISPOT
for detecting ex vivo IFN-γ. Results from QuantiFERON®-CMV assays
showed 97% (36/37 individuals) agreement with the anti-HCMV serology test
in healthy individuals. Taken together, this study indicates a pivotal role for
IFN-γ producing virus-specific CD8+ T-cells in protecting transplant patients
from HCMV disease, and this protection is dependent on a broadly focused T
cell responses rather than a response directed towards any one single antigen.
Furthermore, QuantiFERON®-CMV is a simple, reproducible and reliable test
for the detection of IFN-γ in response to HCMV CD8+ T-cell epitopes, and
may be a valuable diagnostic test for the detection of HCMV infection and a
useful clinical tool for monitoring the immune response in immunosuppressed
patients during therapy.

261 AN ANALYSIS OF THE LIST AND DEATHS AMONG
CANDIDATES WAITING FOR A KIDNEY TRANSPLANT
F. Delmonico 1, M.A McBride 2
Transplantation Center, Massachusetts General Hospital, Boston, MA,
2
United Network for Organ Sharing, Richmond, VA
Background: The status (active versus inactive), demographic characteristics
and deaths of patients waiting for a kidney transplant were analyzed to make a
current assessment of the kidney waitlist. This report focuses upon the kidney
waitlist versus all other organ lists because most of the patients dying on
the list are in need of a kidney transplant. The "inactive" Status 7 within the
UNetSM system is a designation that transplant centers can define for wait list
candidates not currently suitable for kidney transplantation but theoretically
still an appropriate patient for transplantation. During the period of kidney
wait list inactivity the candidate accrues wait time but does not receive offers
for a deceased donor kidney. Finally, kidney listing practices may have been
influenced by a 2003 OPTN/UNOS rule change regarding the wait time
afforded to patients who are inactive on the list.
Methods: A snapshot of the waiting list on February 29, 2008 was reviewed
by organ type, age at listing and by the active versus inactive status of the
candidate on the list to determine total length of time in inactive status, time
of inactive status during the most recent inactive period, and total time on the
list. The pattern of inactivity among candidates waiting for kidneys was also
examined for those waiting between 2003 (after the rule change) and 2007.
Results: Since 2003, the kidney wait list has not increased in the total number
of active candidates, but only by the number and percentage of inactive.
Currently 33% of the list is inactive (>24,000 patients). Of the 24,226 patients
inactive on Feb. 29, 2008, 6333 (25%) have been inactive > 2 years. Of 20,234
patients inactive on Dec. 31, 2006, 9797 (48%) are currently inactive. Of the
27,289 patients added to the list in 2004, 6,275 (23%) are still waiting, and
2,430 of these are waiting in inactive status.
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Among the 2,431 candidates that died with inactive status while waiting for a
kidney during 2007, 53% were inactive for > one year over the entire course of
their time on the list, and 47% were listed as inactive status consecutively for
more than one year prior to their death.
Among the 4,642 candidates that died while waiting for a kidney in 2007, 73%
of the deaths were among candidates over the age of 50, and 26% were age ?
65. Nearly half of the candidates who died (47%) were White, 31% were Black,
and 15% were Hispanic, similar to the distribution of ethnicity among all the
candidates waiting during 2007
Conclusion: These data are indicative of a wait list that could conceivably be
managed more transparently by alerting transplant centers of those patients
remaining on the list inactive for more than one year, more efficiently by
transplant centers notifying HLA laboratories if patients are not going to be
activated for at least one year, and with a patient advocacy by posting an inactive
alert for patients inactive for more than 2 years. The causes of death on the list
should be examined to determine if those patients dying on the list (inactive)
within 2 years of listing were suitable candidates for transplantation.

262

PREGNANCY AFTER KIDNEY DONATION

H. Ibrahim, S. Akkina, E. leister, H. Guo, T. Rogers, A. Matas
University of Minnesota
The outcome of pregnancy in living kidney donors has generally been viewed
to be favorable, but previous studies have been small. Therefore, we assessed
fetal and maternal outcomes in a large cohort of female kidney donors at the
University of Minnesota.
We sent female kidney donors self-administered questionnaires that addressed
fetal (e.g., full-term deliveries, prematurity, fetal loss) and maternal (e.g.,
preeclampsia, gestational hypertension, gestational diabetes) outcomes.
Results Since June 1963, a total of 2,025 women have donated kidneys at
our institution. Of these, 965 reported ever becoming pregnant (822 donors
reported 2,416 pregnancies before donation and 223 reported 459 pregnancies
after donation). Pre-donation (vs. post-donation) pregnancies were associated
with a higher likelihood of full-term deliveries (83.7% vs. 72.3%, p<0.0001)
and a lower likelihood of fetal loss (11% vs. 19.8%, p=0.006). Pre-donation
(vs. post-donation) pregnancies were also associated with a lower risk of
gestational diabetes (0.7% vs. 2.4%, p=0.0004), gestational hypertension (0.4%
vs. 4.4%, p<0.0001), and preeclampsia (0.7% vs. 5.2%, p<0.0001). Logistic
regression analysis identified post-donation pregnancies as risk factors for both
adverse fetal (prematurity: odds ratio [OR], 2.3; 95% confidence intervals [CI],
1.27 to 4.17; fetal loss: OR, 2.2; 95% CI, 1.5 to 3.2) and maternal (combined
gestational diabetes, hypertension, or preeclampsia: OR, 5.81; 95% CI, 3.5 to
9.6) outcomes.
Conclusion: The risk of prematurity, fetal loss, gestational hypertension,
gestational diabetes, and preeclampsia in female kidney donors is comparable
to that seen in the general population, but higher than the risk in pre-donation
pregnancies.

263 USING VOCLOSPORIN PHARMACOKINETICS
(CONCENTRATION) AND PHARMACODYNAMICS
(CALCINEURIN ACTIVITY) TO PREDICT OPTIMUM
IMMUNOSUPPRESSION IN A PHASE 2B RENAL
TRANSPLANTATION TRIAL
H-U. Meier-Kriesche 1, A. Jevnikar 2, R. Alloway 3, T. Batiuk 4, I. Bajjoka 5,
P.R. Mayo 6, S. Ling 6, S. Mulgaonkar 7
1
University of Florida, Gainesville, FL, 2London Health Sciences Center,
London, ON, 3University of Cincinnati Medical Center, Cincinnati, OH,
4
Legacy Transplant Services, Portland, OR, 5Henry Ford Transplant Institute,
Detroit, MI, 6Isotechnika Inc., Edmonton, AB, 7St. Barnabas Medical Center,
Livingston, NJ.
Background: Voclosporin (VCS), a next generation calcineurin inhibitor,
developed for solid organ transplantation. Traditionally, calcineurin inhibitorbased immunosuppression is titrated to trough concentration ranges (C0).
VCS has been developed using calcineurin activity (CNA) as a biomarker
of immunosuppressant activity. Data just became available from a Phase 2b
renal transplant trial to explore the PK and PD of VCS as a means of dose
optimization.
Methods: A subset of de novo renal allograft recipients (n = 99) divided
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into three dose groups participated in a sparse sampling PK-PD protocol
which measured VCS concentrations and CNA at time 0, 1, 2, and 4 hours.
Drug concentrations were determined using LC/MS. CNA was determined
with a P32-based assay. Both PK and PD were analyzed using standard noncompartmental analysis, t-test, and receiver-operator characteristic analysis.
Data up to and including 180 days were stratified by clinical outcomes defined
as optimum and as rejection.
Results:
Variable
C0
AUC(0-4)
CNA0
CNAmin

Outcome
Optimum
Rejection
Optimum
Rejection
Optimum
Rejection
Optimum
Rejection

Mean ± sd
43.3 ± 26.7
33.4 ± 16.8
638.4 ± 398.4
564.2 ± 364.6
1.03 ± 0.44
1.33 ± 0.56
0.40 ± 0.30
0.59 ± 0.51

p

ROC

P

0.013

0.617

0.040

0.356

0.584

0.146

0.002

0.671

0.003

0.007

0.601

0.08

C0 = Concentration at Time 0, AUC(0-4) = Area-Under-the-Curve from 0 to 4 hours
CNA0 = Calcineurin Activity at Time 0. CNAmin = Minimum Measured Calcineurin Activity

264 RENAL FUNCTION, EFFICACY AND SAFETY OF
EVEROLIMUS (RAD) / ENTERIC-COATED MYCOPHENOLATE
SODIUM (EC-MPS) THERAPY AFTER CALCINEURIN
INHIBITOR (CNI) WITHDRAWAL IN DE NOVO RENAL
TRANSPLANT PATIENTS: FINAL OUTCOMES OF THE ZEUS
STUDY
K. Budde1, J. Klempnauer2, W. Arns3, C. Sommerer4, P. Reinke5, U.
Eisenberger6, W. Fischer7, S. Kramer7, F. Pietruck8
1
Nephrology, Charité, Berlin, Germany; 2Department of Visceral and
Transplantation Surgery, Hannover Medical School, Hannover, Germany;
3
Cologne General Hospital, Merheim Medical Centre, Cologne, Germany;
4
Department of Nephrology, University Hospital, Heidelberg, Germany;
5
Department of Nephrology and Internal Intensive Care, Campus Virchow
Clinic, Charité University Medicine, Berlin, Germany; 6Department of
Nephrology and Hypertension, University Hospital of Bern, Switzerland;
7
Novartis, Nuernberg, Germany; 8Department of Nephrology, University
Hospital, School of Medicine, Essen, Germany
Background: The ultimate aim of immunosuppressive therapy in
transplantation is to provide an efficacious regimen while minimizing nonimmune toxicities. By combining synergistic drugs, it may be possible to
reduce the exposure to individual agents and therefore avoid adverse effects
whilst maintaining favorable clinical outcomes. Until now, no therapy has been
recognized as being efficient in the prevention of long-term allograft loss due
to chronic allograft dysfunction (CAD) reflecting an unmet medical need in
transplantation. Therefore, the use of antiproliferative drugs like Everolimus in
combination with the withdrawal of CNI has become an interesting concept in
treating calcineurin inhibitor toxicity leading to chronic slow deterioration of
renal allograft function.
Purpose: The purpose of the here presented ZEUS study was to assess whether
an Everolimus /EC-MPS regimen after Calcineurin inhibitor (CNI) withdrawal
is as safe and well-tolerated in de novo renal transplant patients as the CNI-

265 COST-EFFECTIVENESS OF HYPOTHERMIC MACHINE
PERFUSION VERSUS STATIC COLD STORAGE IN KIDNEY
TRANSPLANTATION: FIRST RESULTS OF THE PROSPECTIVE
EUROPEAN RCT
H. Groen1, C. Moers2, J.M. Smits3, J. Treckmann4, F. van Gelder5, A. Rahmel3,
A. Paul4, J. Pirenne5, R.J. Ploeg2, E. Buskens1.
1
Epidemiology, University Medical Center Groningen, Netherlands; 2Surgery,
University Medical Center Groningen, Netherlands; 3Eurotransplant
International Foundation, Leiden, Netherlands; 4Abdominal and Transplant
Surgery, University Hospital Essen, Germany; 5Abdominal Transplant
Surgery, University Hospital Leuven, Belgium.
Introduction: Static cold storage (CS) is the most widely used organ
preservation method for deceased donor kidney grafts. Retrospective analyses
have indicated that preservation by hypothermic machine perfusion (MP)
may lead to improved outcome after renal transplantation. We performed an
economic evaluation of the use of MP versus CS with data from the recently
conducted European multicenter prospective RCT. This analysis concerns the
short term cost-effectiveness of MP versus CS, balancing cost of preservation
versus cost of renal dysfunction and related complications after transplantation.
This is the first MP related cost-effectiveness study to be based on prospectively
randomized clinical data.
Methods: The clinical study involved inclusion of 336 consecutive kidney
pairs from the same donor, one being randomized to MP and the contralateral
organ to CS. This short-term analysis’ scope comprised the clinical outcome
and costs up to one year after transplantation. The primary clinical endpoint
was delayed graft function (DGF). An economic evaluation was performed as
a cost-effectiveness analysis with the percentage of patients with a functioning
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CNA at time 0 was found to be superior to trough and AUC(0-4) as a predictor
of clinical outcome. In addition, ROC analysis suggests that trough was also
a useful predictor of clinical outcome. Maximum calcineurin inhibition in the
optimum group compared to the rejection group was 61% and 55%, respectively
when using time zero as baseline.
A discriminant analysis correctly identified 83.2% of patients as optimum
without rejection based on a combination of trough concentration and CNA.
Interestingly, the use of post-dose time points for concentration did not improve
predictive performance. PK-PD correlation between drug concentration and
CNA revealed a good relationship with an Emax of 1.5 ± 0.03 pmol/min/mg
and an EC50 of 97.5 ± 5.4 ng/mL.
Conclusions: PD based dose optimization using the direct measurement of
CNA may provide a more accurate means of dose titration than traditional
PK methods. PK factors with known variability in de novo transplant
patients such as polymorphisms in drug metabolism (CYP450) and transport
(p-glycoprotein) are summarized by direct measurement of the drugs molecular
target. This novel PD dosing paradigm for VCS will be explored more in detail
in upcoming Phase 3 studies.

based standard regimen but results in a better renal function.
Methods: This 1-year, prospective, open-label, randomized, controlled,
multicenter study compared the efficacy, safety and tolerability of an
immunosuppressive regimen with Everolimus and EC-MPS to that of
Cyclosporine (CsA) and EC-MPS in 300 renal allograft recipients. After
induction therapy with Basiliximab all patients were treated with CsA,
EC-MPS and corticosteroids for the first 4.5 months post transplantation.
Subsequently patients were randomized 1:1 to either a) (n=150) continue the
current regimen of CsA and EC-MPS (720mg BID) or b) (n=150) to convert
from CsA to Everolimus over a 4 week period and continue with Everolimus
(adjusted according to trough levels of 6-10 ng/ml) and EC-MPS (720mg BID).
Corticosteroids were prescribed according to center practice with a minimum
dose of 5 mg/day. Renal function of the two treatment arms was assessed by
the determination of Glomerular Filtration Rate (GFR), calculated according
to Nankivell-method as the primary endpoint. Additional renal endpoints
included GFR calculated according to Cockcroft-Gault and MDRD method,
Serum creatinine and slope of creatinine. Efficacy and safety endpoints implied
rejection episodes (treated and biopsy proven), graft loss, death, lost to follow
up, as well as treatment failure as a composite endpoint.
Results: Renal function outcomes of the first 147 subjects receiving
Everolimus/EC-MPS and 140 receiving CsA/EC-MPS completing 12 months
will be reported here. Final outcomes of all 300 subjects will be presented
at the congress. Groups were similar at baseline (timepoint of randomization
4.5 month post-transplant) for all reported renal function endpoints. Calculated
GFRs (Nankivell formula) were 64.4 ± 17.7 and 64.2 ± 15.5 at baseline,
respectively 72.3 ± 19.1 and 63.2 ± 17.5 mL/min/1.73m² at month 12 for the
Everolimus/EC-MPS and CsA/EC-MPS treatment group. Regarding efficay
and safety outcomes: For the 12-month study period BPAR was reported in
24/147 (16.3%) Everolimus/EC-MPS-treated patients and 18/140 (12.9%)
receiving CsA/EC-MPS. No patients in both treatment groups died. Graft loss
occurred neither in the Everolimus/EC-MPS nor in the CsA/EC-MPS group.
The number and proportion of patients withdrawn for adverse events at 12
months were 18/147 (12.2%) in the Everolimus/EC-MPS group and 8/140
(5.7%) in CsA/EC-MPS group.
Conclusions: In summary, the ZEUS study results confirm the expected
improvement of renal function after CNI withdrawal and the introduction of the
Everolimus/EC-MPS treatment in de novo renal transplant patients. Switching
the immunosuppressive regimen early after transplantation to an Everolimus/
EC-MPS therapy results in a safe and well-tolerated regimen. Definitive
conclusions about the effects of the ZEUS regimen will be provided at the
congress.
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graft after one year as the clinical outcome. Costs were calculated from a
hospital perspective: direct medical costs associated with hospital stay, dialysis
treatment and function related complications were included, and compared per
preservation modality. Missing data regarding dialysis treatment following graft
failure were imputed conservatively based on established clinical practice.
Results: MP significantly reduced the risk of DGF (OR 0.62; p=0.02) and also
reduced the risk of graft failure (HR 0.39; p=0.03). Costs of dialysis (€760 vs.
€940), graft failure or DGF (€136 vs. €193) and hospital readmission (€2,157
vs. €2,399) tended to be lower per patient with MP than with CS, but this
finding was not statistically significant. Costs of preservation with MP were
higher than with CS for each case (€842 vs. €167). Imputation of dialysis
costs contributed considerably to average dialysis expenses, which rose to
€4,354 for CS and to €2,564 for MP. Average total costs per patient after
imputation were €4,896 for MP and €5,309 for CS. Bootstrap analysis (5,000
iterations) showed that the baseline probability of cost-effectiveness for MP
was 71%. Further analyses including sensitivity analysis on the impact of
variation of the major cost components are currently performed and prepared
for presentation.
Conclusion: The clinical data show that MP has beneficial effects on renal
grafts compared to CS. The first results from this cost-effectiveness analysis
suggest that the additional costs of MP are more than compensated by savings
due to reduced costs of graft function related complications, especially of
reduced need for continued or renewed dialysis in case of DGF, primary nonfunction, or graft failure.

266 COMPARISON OF AN INITIALLY INTENSIFIED DOSING
REGIMEN VERSUS A STANDARD DOSING REGIMEN OF
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS)
IN RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY
ANALYSIS OF 75 PATIENTS.
W. Arns 1, P. Glander 2, C. Sommerer 3, T. Ariatabar 1, K. Eichele 4, W. Fischer
4
, M. Zeier 3
1
Nephrology, Köln-Merheim, 2 Nephrology, Charité, Berlin, 3 Nephrology,
Univ. Heidelberg, 4 Novartis, Nuremberg, Germany
Objective: The aim of this prospective randomized study was to investigate
whether an intensified dosing regimen of EC-MPS in comparison to a
standard dosing regimen will lead to higher MPA exposure early after
transplantation. Furthermore, we examined whether an initially intensified
dosing regimen will lead to better efficacy without compromising safety.
Methods: A total of 75 de-novo kidney transplant recipients were treated
with basiliximab induction and cyclosporine (CsA) and randomized to a
standard (SD) EC-MPS dose (1440mg/d; n=36) or to an intensified (ID)
EC-MPS dosing (day 0-14: 2880 mg/d; day 15-42: 2160 mg/d; followed
by 1440 mg/d; n=39). Safety and tolerability as well as the incidence of
biopsy-proven acute rejection (BPAR) and graft loss was assessed after 180
days of treatment.
Results: Incidence of BPAR was low throughout the study with a trend to
a lower rate in the ID group (1(2.6%) vs. 5 (13.5%). During the period of
intensified treatment, no rejections occurred (0 vs. 5 within 84 days, p=0.025).
No graft loss was observed, but 1 death recorded in the ID group after 3
months. Overall incidence of adverse events was comparable between both
treatment regimens. An ID regimen was not associated with a higher rate
of hematological disorders except a slight increase in thrombocytopenia
(anaemia: 8 vs. 10; leucopenia: 8 vs. 8, thrombocytopenia: 3 vs. 0). With
respect to gastrointestinal symptoms, more events were reported in the ID
group (76 vs. 58). The difference can mainly be ascribed to a higher incidence
of abdominal pain (8 vs. 4), diarrhea (16 vs. 13) and flatulence (8 vs. 2).
Infections were similar (62 vs. 65) with CMV in 1 vs.5 patients and rate of
malignancies was low (0 vs. 2) (ID vs. SD).
Conclusion: Based on these data, an intensified dosing regimen of EC-MPS
in combination with CsA can safely be administered and leads to a lower
risk of BPAR. This supports previous data showing that early adequate MPA
exposure is crucial for the clinical outcome. Larger studies are ongoing to
confirm the safety and efficacy of an initially intensified MPA regimen.
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LIVING DONOR LIVER TRANSPLANTS
267 COMBINED USE OF RITUXIMAB AND INTRA PORTAL
INFUSION THERAPY FOR ADULT ABO-INCOMPATIBLE
LIVING-DONOR LIVER TRANSPLANTATION
M. Tanabe1, S. Kawachi1, H. Obara1, M. Shinoda1, T. Hibi1, Y. Fuchimoto1,
K. Hoshino1, M. Sakamoto2, Y. Morikawa1, Y. Kitagawa1
1
Department of Surgery, School of Medicine, Keio University, 2Department of
Pathology, School of Medicine, Keio University
Background and aims: ABO-incompatible living donor liver transplantation
(ABO-I LDLT) in adult patients has been controversial due to the high risk of
liver necrosis and intrahepatic bile duct injury mediated by preformed antiABO antibodies. Since we first introduced intra-portal infusion therapy (IP)
into adult ABO-I LDLT in 1998, the concept of elocal immunomodulation f
in the graft liver has become the most critical breakthrough to overcome the
ABO-blood group barrier in Japan. In 2005, rituximab (anti-CD20 monoclonal
antibody) prophylaxis and rescue was applied in combination with IP to
selectively eliminate B cells thus permitting effective reduction of anti-ABO
antibody titer. The aim of this study was to analyze short- and long-term
outcomes to evaluate our current treatment strategy for adult ABO-I LDLT.
Methods: From 2005 to 2008, 12 consecutive adult patients underwent
ABO-I LDLT by the new protocol in our institution. As a routine approach
to incompatible cases, we performed preoperative plasma exchange and
splenectomy during transplant to reduce recipient fs antibody level against the
donor fs blood type. Baseline immunosuppressive therapy included tacrolimus/
cyclosporine, systemic steroid, and antimetabolites. IP regimen was composed
of methylprednisolone, prostaglandin E1, and gabexate mesilate. Rituximab
was used perioperatively with reference to the lymphocyte subset profile of the
peripheral blood.
Results: Anti-donor blood type antibody titers on admission ranged from x16
to x4096, which was effectively reduced to ≤; x128 on the day of transplant
by rituximab and plasma exchange. In 6 cases, the maximum anti-donor
blood type antibody titers reached to x128 to x512 within two weeks after
transplant, and persistently positive thereafter. Immunohistochemical study
revealed that the donor blood type antigen remained positive in the graft liver
at least for a year; however, none of them suffered from antibody-mediated
rejection, liver necrosis, or intrahepatic bile duct injury. These findings suggest
that eaccommodation f may have occurred. It took 6-12 months for the
peripheral CD20+ B lymphocytes to recover preoperative condition, although
hypogammaglobulinemia or retractable infection did not occur during this
interval. Subclinical cytomegalovirus infection did develop sporadically and
antiviral therapy was performed on such occasions. Two of 12 patients died of
sepsis and refractory cholangitis at 117 POD and 533 POD, respectively. The
other 10 recipients are currently alive with a cumulative 3-year survival of 78%
[range, 101 to 1102 days].
Conclusions: Intra-portal infusion therapy combined with rituximab for
adult ABO-I LDLT can be safely performed and provides excellent control of
antibody-mediated rejection with no major morbidities. Long-term prognosis
has now become comparable with ABO-identical/compatible cases.

268 COMPLETE HILAR PLATE LOOPING IN THE
LIVING LIVER DONOR PREVENTS RECIPIENT BILIARY
COMPLICATIONS
A. Soin, V. Kumaran, R. Kakodkar, N. Mohan, S. Saigal, N. Saraf, S. Nundy
Sir Ganga Ram Hospital
Background: Biliary complications remain a major cause of morbidity after
living donor liver transplantation (LDLT). The effect of graft hepatic duct(HD)
isolation by the complete hilar plate looping method on biliary complications
was assessed in 60 consecutive LDLT recipients.
Methods: The 216 LDLTs performed at our centre until January 2008 were
divided into 3 groups (A-C) of the first 75, next 81 and the last 60 cases
according to donor bile duct anatomic exclusion criteria and techniques
of donor dissection and biliary reconstruction. Donors with >3 ducts were
excluded in groups A and B but accepted in group C as long as >2 ducts were
close together. In groups B and C, meticulous attention was paid to inclusion
of all periductal tissue with the HD in the donor and recipient, avoiding close
dissection of the ductal confluence in the donor in pursuit of a single graft HD,
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and reconstructing segment 5 venous outflow in the recipient to prevent periHD venous congestion. In group C, additionally, the complete hilar plate and
Glissonian sheath around the HD was looped after full parenchymal transection
and inferior retraction of the portal vein. This thick cover of hilar plate around
the graft HD(s) kept any multiple ducts together, preserved the peri-HD arterial
plexus, and prevented their retraction. Single or multiple graft HD to recipient
HD or jejunal Roux loop anastomoses with fine PDS were standard in all
recipients. All roux anastomoses were stented, and duct-duct were not.
Results: The incidence of bile leak and stricture in groups A to C was 12%
and 6%; 6% and 3%; and 3% and 2% respectively. None of the patients had
associated arterial complications. The operative mortality in the three groups
was 13%, 11% and 5%; while the proportion of biliary complications needing
surgical correction were 35%, 40% and 0%. The rest were managed by
endoscopic intervention and/or percutaneous drainage. One patient in group
A died from biliary sepsis. In the donors, there were no biliary strictures while
the incidence of bile leak in the 3 groups was 4%, 4% and 3% respectively. Of
these, 2 patients – 1 each in groups A and B required temporary endobiliary
stenting and recovered. The rest had cut surface leaks which settled with simple
drainage.
Conclusion: This new technique of complete hilar plate looping during donor
surgery significantly reduces recipient biliary complications in LDLT. Most
complications that do occur are minor, do not result in mortality and can be
managed by non-surgical methods.

269 INHIBITION OF MITOCHONDRIAL BIOGENESIS
IN SMALL-FOR-SIZE LIVER GRAFTS

G-W. Song, S-G. Lee, S. Hwang, C-S. Ahn, K-H. Kim, D-B. Moon, T-Y. Ha,
D-H. Jung
Asan Medical Center
Background: Dual living donor liver transplantation (DLDLT) makes up a
unique situation which cannot be found in other types of LDLT. The atrophy
of one graft among trnasplanted two grafts without the derangement of liver
function is one of the unique phenomena which can occur only in DLDLT.
We called this phenomenon the vanishing graft syndrome (VGS) which was
defined that the graft volume decreased more than the half of original graft
volume measured at CT volumetry of donor. In this study, we tried to explain
this pecuilar phenomenon and elucidate the risk factors for graft atrophy.
Patients and methods: All clinicopathological data were collected
retrospectively. We compared all clinicopathological factors for the analysis of
host-related and graft-related risk factor for unilateral graft atrophy.
Results: From March 2002 to June 2007, 207 LDLT were performed by dual
donors. The VGS were observed in 19 cases. The median interval from operation
to occurrence of VGS was 7.85 months. For the analysis of host-related risk
factor, we compared MELD, UNOS status, original disease, GRWR, GV/
SLV, intraoperative transfusion requirement, type of graft combination. But we
could not find out statistically significant relating factor for graft atrophy. In
7 cases of VGS, antecedent causes for graft atrophy were evident (secondary
vanishing graft syndrome). Two episodes of biliary stricture, 2 hepatic vein
outflow obstruction (HVOO), 2 portal vein stenosis (PVS), 1 case of unilateral
acute cellular rejection (ACR) were observed. In 12 cases, there was no definite
antecedent cause for atrophy (primary vanishing graft syndrome). The primary
VGS was occurred more frequently in left-sided graft (p=0.034) but secondary
VGS did not show site preference. The portal vein flow and regenerative rate
during 1st postoperative month were significantly low in vanishing graft in
primary VGS. Graft steatosis, ABO, donor age, graft size or type did not
influence the development of graft atrophy.
Conclusion: In DLDLT, biliary stricture, HVOO, PVS or unilateral ACR can
cause secondary VGS. And the left-sided graft in DLDLT was more vulnerable
to primary VGS. In primary VGS, portal vein flow to vanishing graft and
regeneration rate were significantly low.

271 RIGHT HEPATIC LOBE AND KIDNEY
TRANSPLANTATION FROM THE SAME LIVING DONOR: 5
CASES INCLUDING 1 ABO-INCOMPATIBLE
S. Gautier, M. Kaabak, O. Tsiroulnikova, E. Kim, A. Semenkov, A. Filin,
H. Hizroev, A. Ammosov, E. Chekletsova
National Research Center of Surgery
Simultaneous liver/kidney transplantation (SLKT) is rather common procedure
in cadaveric organ transplantation. In practice of living donor transplantation
a few cases of left lateral sector and kidney harvesting from one donor were
described. Since 1997 to 2007 in our center totally 151 living donor right
hepatic lobe transplantations were performed. In 5 patients (4 male and 1
female 6 - 18 years old) right hepatic lobe and kidney from the same donor were
transplanted simultaneously. The indications for SLKT were Caroli disease
associated with polycystic kidney disease in 3 cases and biliary hypoplasia
associated with kidney dysplasia in 2 cases. All patients had advanced liver
cirrhosis and terminal renal failure (hemodialysis in 2 patients and peritoneal
dialysis in 3 patients). Donors were parents of patients (3 mothers and
2 fathers 31 - 44 years old). Two donors were ABO-identical to recipients,
other 2 donors were ABO-compatible and 1 donor was ABO-incompatible.
The donor’s procedure included right hepatectomy without middle hepatic
vein and nephrectomy (right in 4 cases and left in 1 case). The procedure in
recipient included hepatectomy, bilateral nephrectomy, orthotopic implantation
of right hepatic lobe and heterotopic implantation of kidney into right (3) or
left (2) fossa iliaca. In all cases after liver graft revascularization the kidney
graft was implanted and native ureter was used for urinary reconstruction.
The last step was biliary reconstruction. In 1 case of ABO-incompatibility the
recipient (6-years old boy with blood group O) received liver and kidney from
his 34-years old mother with blood group A. During preoperative management
the initial anti-A antibody level 1/16 was reduced to 1/4 by plasmapheresis.
All recipients received 3-drug immunosuppressive protocol including antiCD25 monoclonal induction, tacrolimus and mycophenolates. All recipients
are alive with good function of their first grafts. The follow-up is 8 - 54 mo. No
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Z. Zhong, H. Rehman, T. Theruvath, J. Lemasters
Medical University of South Carolina, Charleston, SC, USA
Background and aim. Mitochondrial biogenesis is required after partial
liver transplantation to compensate for increased metabolic burden, replace
damaged mitochondria, and support liver regeneration. Our previous study
showed that ATP production decreased markedly in small-for-size liver grafts.
Poor energetic production caused by failure of mitochondrial biogenesis could
inhibit recovery of graft function, suppresses liver regeneration, and eventually
lead to graft failure. This study investigated if mitochondrial biogenesis is
suppressed in small-for-size grafts, leading to compromised energy supply.
Methods: After harvest, Lewis rat liver grafts were reduced in size to ~50% ex
vivo, stored in UW solution at 0-1oC for 6 h and then implanted into recipients
of similar or greater body weight, resulting in a relative graft weight of 50%
(half-size) or 25% (quarter-size).
Results: Total bilirubin increased slightly after transplantation of full-size
and half-size grafts but increased ~100-fold in quarter-size (small-for-size)
grafts. Cell proliferation detected by 5-bromo-2’-deoxyuridine incorporation
increased from <1% in full-size to 17% in half-size grafts but did not increase
in quarter-size grafts, indicating poorer function and slower regeneration of
small-for-size liver grafts. ATP synthase-β (AS-β), a nuclear DNA (nDNA)encoded oxidative phosphorylation (OXPHOS) enzyme, protein expression
decreased after 18 h but recovered to the control levels after 38 h, suggesting
mitochondrial biogenesis. By contrast, AS-β in quarter-size grafts decreased
by 65% at 18 h but did not recover after 38 h. Cytochrome c oxidase (COX)
IV, another nDNA-encoded OXPHOS enzyme, also decreased substantially
in quarter-size liver grafts at 38 h. Mitochondrial DNA (mtDNA)-encoded
OXPHOS proteins NADH dehydrogenase-3 and COX II also decreased by
30% in quarter-size liver grafts (p<0.05). Furthermore, expression of PGC1α, a transcriptional coactivator that controls transcription of nDNA-encoded
OXPHOS proteins, and mtTFA, a nDNA-encoded transcription factor
that controls mtDNA replication and transcription, decreased markedly in
small-for-size liver grafts. mtDNA that encodes mitochondrial OXPHOS
proteins decreased by 30% in quarter-size grafts, indicating compromised
mitochondrial biogenesis. Alkaline gel Southern blotting also showed
that mitochondrial DNA underwent single-strand damage in quarter-size
liver grafts.
In conclusion, mitochondrial biogenesis is inhibited in small-for-size liver
grafts, most likely due to decreases of signaling molecules PGC-1α and mtTFA
and damage to mtDNA. Inhibition of mitochondrial biogenesis may contribute,
at least in part, to compromised energetic status and poorer regeneration and
graft function after small-for-size liver transplantation (NIDDK).

270 VANISHING GRAFT SYNDROME IN DUAL LIVING
DONOR LIVER TRANSPLANTATION
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signs of rejection were observed including ABO-incompatible case. Neither
intraoperative complications nor postoperative morbidity were observed in
donors. All donors returned to their former way of life including engagement in
sports. Living related SLKT is safe and lifesaving procedure in selected cases.

TUESDAY

272 OLDER AGE AND RIGHT HEPATECTOMY ARE
ASSOCIATED WITH INCREASED RISK OF INTRAOPERATIVE
COMPLICATIONS DURING DONOR HEPATECTOMY IN
LIVING-DONOR LIVER TRANSPLANTATION
A. Pirat1, A. Torgay1, S. Balci1, P. Zeyneloglu1, H. Karakayali2, G. Arslan1,
M. Haberal2
1
Baskent University Faculty of Medicine, Department of Anesthesiology,
2
Baskent University Faculty of Medicine, Department of General Surgery
The shortage of available brain-dead organ donors continues to limit deceaseddonor liver transplants. For this reason, living-donor liver transplant (LDLT) is
now accepted as an established treatment modality in patients with end-stage
liver disease. However, the major ethical and medical concern during LDLT
is safety of the healthy donor. Every effort should be made to optimize the
safety of donor during this procedure. Although several studies have focused
on the surgical complications in donors of LDLT, there are scant data regarding
the intraoperative complications that may occur in these patients. The aim of
this study was to evaluate the predictors of intraoperative complications during
donor hepatectomy for LDLT.
We reviewed the data of 114 consecutive LDLT patients who underwent
a lobectomy between May 2002 and February 2007. The data included
demographic features, intraoperative and postoperative transfusions, amount
of administered intraoperative crystalloid and colloids, intraoperative
hemodynamics, preoperative and postoperative laboratory values (renal and
liver functions), intraoperative and postoperative urine output, and length of
hospital stay. Intraoperative complications such as hypotension, hypertension,
arrhythmia, hypoxemia, hypothermia, and need for transfusions were collected
using anesthesia and patient charts.
Eighty-five (74.6%) of 114 donor lobectomies had at least 1 intraoperative
complication. The most commonly noted intraoperative complication was
hypothermia (n=70, 61.4%), followed by hypotension (n=38, 33.3%), need for
transfusions (n=16, 14%), hypertension (n=4, 4.6%), extravasation of IV fluids
into the arm (n=1, 1.1%), and brachial plexus injury (n=1, 1.1%). Patients who
had an intraoperative complication(s) were older (37.2 &#61617; 9.5 years vs
30.3 &#61617; 6.6 years P < .001) and had a larger graft volume (679 &#61617;
255 mL vs 482 &#61617; 203 mL, P < .001) than those who did not have these
complications. The frequencies of intraoperative complications for right and
left hepatectomies were 91% and 60% (P < .001). Multivariate logistic analyses
revealed that only age (OR: 1.1, P = .004) and type of hepatectomy (OR: 5.8,
P = .002) were independent risk factors for intraoperative complications. All
patients recovered fully, and the occurrence of intraoperative complications
had no impact on postoperative recovery and length of hospital stay.
In conclusion, older age and right hepatectomy were associated with an
increased risk of intraoperative complications during donor hepatectomy in
our LDLT series. Although these complications were mostly mild and did not
have a negative impact on the outcomes in these patients, it is imperative to
undertake all preventive measures to avoid physiological derangements in
otherwise healthy donors.

273 LAPAROSCOPIC HEPATECTOMY FOR A MODIFIED
RIGHT GRAFT IN ADULT-TO-ADULT LIVING DONOR LIVER
TRANSPLANTATION
K-S. Suh, N-J. Yi, J. Kim, W.Y. Shin, H.W. Lee, E-M. Kim, K.U. Lee
Departement of Surgery, Seoul National University College of Medicinen
To our knowledge, this is the first report of a modified right hepatectomy
preserving the middle hepatic vein (MHV) branches done completely by
hand-assisted laparoscopic surgery (HALS) under pneumoperitoneum in
adult-to-adult live donor liver transplantation (LDLT). Two young women
(24- and 25-year-old) volunteered to be a live donor for their parents who had
hepatocellular carcinoma. The donors expressed concern about a scar and a HALS
was performed. Mobilization of the right liver and the hepatic parenchymal
transection was performed under pneumoperitoneum. Parenchymal transection
was performed using a laparoscopic ultrasonic aspirator without the Pringle
maneuver. During parenchymal transection, 3 MHV branches were preserved
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using hem-o-lock clips. The graft was extracted through the site of the hand
port device. On the back table, the 3 MHV branches were reconstructed using
an artificial vascular graft. The graft was transplanted without any problem.
The operation time for the donors was 765 and 898 minutes including more
than 2 hours for wound closure. The donors did not require a transfusion or
reopertaion; they were discharged on postoperative day (POD) 10 and 14
with normal liver function. In conclusion, a HALS under pneumoperitoneum
for a modified right graft was technically feasible. This laparoscopic right
hepatectomy may be a new therapeutic option and may improve the quality of
life of donors participating in LDLT.

274 ADULT-TO-ADULT LIVING DONOR LIVER
TRANSPLANTATION USING EXTENDED RIGHT LOBE LIVER
GRAFTS
K.H. Kim, S.G. Lee, J.H. Ryu, C.S. Ahn, D.B. Moon, T.Y. Ha, D.H. Jung,
K.W. Kim, N.K. Choi
Asan Medical Center
Background: Adult-to-adult living donor liver transplantation(AALDLT)
using extended right lobe grafts has become as an treatment method to solve
the problem of graft insufficiency since Hong Kong group first successfully
performed for a 90-kg man with fulminant Wilson’s disease in May 1996.
The authors report their experience with adult-to-adult living donor liver
transplantation using extended right lobe graft in a single center.
Methods: From March 1998 to December 2007, 1576 AALDLTs were
performed at the Asan Medical Center. Among them, 23 AALDLTs using
extended right lobe graft were included in this retrospective study. 3 types
of techniques for hepatic vein reconstruction have been used to enable the
sufficient venous outflow drainage of extended right lobe grafts.
Results: There were 18 male and 5 female. The median age of recipients was
47 years (range, 19-62 years) and median MELD score was 20(range, 9-36).
Of 21 patients, 13 had HBV related LC, 7 had HBV related LC with HCC, and
3 had acute liver failure. The median percentage of steatosis was 5%(range,
0-15%), the median graft weight was 605 gm(range, 400-800 gm) and the
median GRWR was 0.86%(range, 0.69-1.16%). There were 2 in-hospital
mortalities caused by sepsis. The median age of donors was 28 yers(range,
16-39 years). Over the entire hospitalization period of donors, the mean level
of AST was 171.6¡¾84.8 IU/L, the mean level of ALT was 151.2¡¾61.3
IU/L, the mean level of PT(INR) was 1.56¡¾0.28, and the mean level of TB
was 2.85¡¾2.2 mg/dL. There was no donor mortality. As for hepatic vein
reconstruction in this study, there were 3 types of techniques in the following
order: 16 quilt venoplasties make ¡°common-large opening¡± using GSV and
PV of recipient, 4 direct RHV anastomoses and separate reconstructions of
MHV with interposition vein graft, and 3 separate RHV and MHV anastomoses
without interposition vein graft. Modification of graft procurement technique
by preserving S4b hepatic vein was performed in 3 cases.
Conclusions: The extended right lobe graft may provide an alternative option
to overcome the small-for-size graft in AALDLT if the meticulous donor
hepatectomy and complete donor selection can be performed for donor safety.

CONCURRENT ORAL SESSION 23:
LIVER IMMUNOSUPPRESSION
275 THE INFLUENCE OF INDUCTION THERAPY ON GRAFT
AND PATIENT SURVIVAL IN LIVER TRANSPLANT PATIENTS
WITH AND WITHOUT HEPATITIS C USING THE UNOS/SRTR
DATABASE
D. Moonka, D. Kim, A. Kapke, A. Yoshida
Henry Ford Health Systems
Studies to date have reported conflicting results on the effect of induction
therapy on recurrent hepatitis C (HCV) after orthotopic liver transplantation
(OLT). We used the United Network for Organ Sharing (UNOS) Scientific
Registry of Transplant Recipients (SRTR) to determine graft and patient
survival in OLT recipients with HCV who received induction therapy and to
compare them to HCV patients who did not receive induction and to HCV
negative patients.
Methods: We identified all patients who received an initial OLT in the SRTR/
UNOS database who had defined HCV antibody status. We excluded patients
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with live donors, multi-organ transplants, HIV, alemtuzumab induction or
incomplete follow-up. 40,796 patients were divided into 4 groups: HCV
negative without induction (18.904), HCV negative with induction (3,563), HCV
positive without induction (15,438) and HCV positive with induction (2,891).
Induction therapy was defined as “induction” dosing with thymoglobulin,
anti-lymphocyte globulin, OKT3, daclizumab or basiliximab. Groups were
compared for patient and graft survival using Kaplan-Meier analysis with log
rank tests. A Cox regression model was used to control for additional variables
including MELD scores.
Results: Overall, patients who received induction did better than those who
did not with 5 year survival of 76% vs 73% (p=0.001). HCV pos patients who
received induction did better than those who did not (71% vs 69%: p=0.008).
HCV neg patients who received induction also did better than those who did
not with five year survival of 79% vs 76% (p=0.001). Five year graft survival
was better in all patients who received induction than those who did not (70%
vs 67%: p<0.0001) and 5 year graft survival was better in HCV pos patients
who received induction vs those who did not (65% vs 62%: p<0.0001). On
multivariable Cox regression analysis, the following factors influenced patient
survival in HCV pos patients: African-American race (Hazard Ratio (HR) =1.38:
P<0.0001), recipient age by 10 year increments (HR=1.23: P<0.0001), donor
age by 10 year increment (HR=1.15: P<0.0001), MELD score at transplant
(HR=1.02: P<0.0001) and induction (HR=0.88: P=0.038). On multivariate
analysis, induction was also associated with favorable graft survival in HCV
pos patients (HR=0.86: p=0.004).
Patient Survival by HCV/Induction Status
1 year estimates

3 year estimates

5 year estimates

95% CI

Survival
Probability

95% CI

Survival
Probability

95% CI

HCV neg, No Ind

0.875

0.870, 0.879

0.816

0.809, 0.821

0.765

0.758, 0.772

HCV neg, Ind

0.896

0.885, 0.906

0.841

0.822, 0.851

0.787

0.769, 0.803

HCV pos, No Ind

0.868

0.862, 0.874

0.765

0.758, 0.773

0.690

0.681, 0.699

HCV pos, Ind

0.879

0.866, 0.891

0.790

0.768, 0.804

0.712

0.690, 0.734

*Log-rank test: p<.0001

Conclusion: Using the SRTR/UNOS database, induction dosing was associated
with at least equivalent patient and graft survival in all patients and in those who
were HCV positive. On multivariate analysis, induction dosing was associated
with improved patient and graft outcomes in all liver transplant recipients and
in HCV positive patients.

276 SPARE-THE-NEPHRON (STN) TRIAL IN LIVER
TRANSPLANT RECIPIENTS: INTERIM EFFICACY AND
SAFETY OF MYCOPHENOLATE MOFETIL (MMF)/SIROLIMUS
(SRL) MAINTENANCE THERAPY AFTER CNI WITHDRAWAL
D. Moonka1, L. Teperman2, L. Sher3, P. Marotta4, A. Sebastian5, B. Koneru6,
D. Patel7, G. Klintmalm8
1
Henry Ford Transplant Institute, 2New York University, 3University of
Southern California, 4London Health Sciences Hospital, 5Integris Baptist
Medical Center, 6Univ. of Medicine and Denistry, NJ, 7Roche, 8Baylor Medical
Center
Purpose: To compare the efficacy and safety of maintenance immunosuppression
with MMF and SRL to that of MMF and a CNI in liver allograft recipients.
Methods: Prospective, randomized open-label, controlled multicenter study,
294 patients who were maintained on MMF and a CNI were randomized
30-90 days after transplantation to receive MMF (1-1.5 g BID) plus SRL (2-4
mg/day; trough 5-10 ng/mL) and discontinue the CNI (MMF/SRL group) or
continue their current regimen (MMF/CNI group). Antibody induction and/
or corticosteroids were administered according to individual center practice.
Primary efficacy variables included the percent of patients with biopsy-proven
acute rejection (BPAR), graft loss, and death, and mean percent change in
calculated glomerular filtration rate (GFR; MDRD-6 equation) at month 12.
BPAR was assessed by Banff grade and Rejection Activity Index (RAI). Safety
outcomes included incidence of adverse events, malignancies, and opportunistic
infections at months 12 and 24.
Results: Interim 12-month data from 276 patients (MMF/SRL, n=139; MMF/
CNI, n=137) were analyzed; baseline characteristics were similar between
groups. Mean time from transplant to randomization was 54 days in the MMF/
SRL and 52 days in the MMF/CNI groups.

MMF/SRL

Mean GFR increase, baseline to month 12,%(n)

22.1% (52)

MMF/CNI
5.2% (59)

Patient survival to date

137 (99%)

132 (96%)

Graft survival to date

137 (99%)

132 (96%)

Withdrew from study

51 (35%)

27 (18%)

BPAR GradeII and RAI4

15 (11%)*

4 (3%)

BPAR Grade=I or RAI<4

13 (9%)

11 (8%)

* Includes 1 severe BPAR

Withdrawals in the MMF/SRL group vs the MMF/CNI group were primarily
due to skin connective tissue disorders (rash, ulcers, etc) 19 (14%) vs 0%,
leucopenia 7 (5%) vs 5 (3%), GI disorders 7 (5%) vs 5 (3%), and infections
5(3%) vs 4 (3%).
Conclusions: MMF/SRL appears to improve renal function at 1 year compared
to MMF/CNI-containing regimens but with more frequent rejections and more
patient withdrawals. Final results will identify the target patients in whom
stopping the CNI regimen may be feasible for improvement of renal function.

277 HEPATITIS C (HCV)- 3 STUDY: DOES
IMMUNOSUPPRESSION (IS) AFFECT HCV RECURRENCE
(HCVR) PROGRESSION AFTER LIVER TRANSPLANTATION
(OLT)?
G. Klintmalm1, C. Fasola2, L. Jennings1, Hepatitis C Study Group3
Baylor University Medical Center, 2Emory University, 3Multicenter (n = 18)
Aims: To assess the efficacy and safety of a steroid (Pred)-free IS regimen of
daclizumab (DAC), tacrolimus (TAC) and mycophenolate mofetil (MMF) to
minimize acute rejection (ACR), HCVR and adverse events post OLT.
Methods: Open-label, prospective, multicenter study (n=18) on 312 adult HCV
(+) recipients randomized (1:1:2) to 3 IS arms. Liver tests and histology were
done on clinical or protocol (days 90, 365, 730) basis. ACR graded according
to Banff schema and HCVR staged according to Batts-Ludwig classifications.
Main endpoints: ACR (Grade ≥2 + RAI ≥4) and/or HCVR (Stage ≥2 or Grade
≥3). Significant statistics: p ≤0.05.
Results: Arm 1 (n=80): TAC + Pred; Arm 2 (n=79): TAC + Pred + MMF; Arm
3 (n=153): DAC (days 1, 3 and 8) + TAC + MMF. All data (intention to treat
[ITT]; central pathologist) reported at 2 years in Arm 1, 2 and 3 respectively.
Graft and patient survivals were: 79%, 78%, 84% (NS)- 83%, 81% and 87%
(NS). ACR-free rates: 86%, 87% and 86% (NS). HCVR-free rates: 33%, 27%
and 34% (NS). Arm analysis showed severe HCVR (stage ≥3) in 33%, 28%
and 19% (p=0.08). Severe accelerated HCVR noted between years 1-2 in Arms
1 and 2. On patients with no HCVR in year 1, freedom of stage ≥3 at year 2
was: 75%, 85% and 93% (graph, p<0.01). Differences persist for Arms 1 + 2
(steroids) vs. 3 (no-steroids): 75% vs. 93% (p<0.01) and for Arms 1 (no-MMF)
vs. 2 + 3 (MMF): 80% vs. 93% (p<0.01). Although not significant (p ≤ 0.2),
similar results noted in other analyses (ITT/local path; per protocol/central or
local path). Similar HCV-RNA levels in all arms.
Conclusions: During this 2-year follow up period, this report suggests no
differences across arms in the incidence of HCVR. However once HCVR has
occurred, the rate of fibrosis progression is significantly lesser for recipients on
MMF or on the steroid-free regimens. Longer-term follow-up is indispensable
to confirm these initial findings.
Year 2 Freedom from Severe HCV Recurrence (Stage≥3) ITT/Central *
1
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278 A RANDOMIZED, OPEN-LABEL, COMPARATIVE
EVALUATION OF CONVERSION FROM CALCINEURIN
INHIBITORS TO SIROLIMUS VERSUS CONTINUED USE
OF CALCINEURIN INHIBITORS IN LIVER ALLOGRAFT
RECIPIENTS
M.F. Abdelmalek1, A. Humar2, F. Stickel3, C-M. Lo4, P. Andreone5,
R. Firpi-Morell1, E.S. Maller6, for the Sirolimus Liver Conversion Trial Study
Group
1
University of Florida, Gainesville, FL, 2University of Minnesota,
Minneapolis, MN, 3Hospital of the University of Bern, Bern, Switzerland,
4
Queen Mary Hospital, Hong Kong, 5University of Bologna, Bologna, Italy,
6
Wyeth Research, Collegeville, PA
Sirolimus (SRL) is a potent inhibitor of cell-cycle progression that represents
a potential alternative to long-term calcineurin inhibitor (CNI)-based
immunosuppression in liver allograft recipients. A prospective, open-label,
comparative clinical trial was conducted to evaluate the safety and efficacy
of conversion of maintenance liver transplant patients from CNI- to SRLbased immunosuppression. Patients were randomly assigned (2:1) to undergo
abrupt conversion (<24 hours) from cyclosporine (CsA) or tacrolimus (TAC)
to SRL, or to continue CNI for up to 6 years. The co-primary endpoints, both
assessed at 52 weeks after randomization, are baseline-adjusted, calculated
GFR (Cockcroft-Gault formula), and the cumulative rate of graft loss or
death. Eligible patients had received living or deceased donor liver allografts 6
to 144 months previously and had been treated with CsA or TAC since the early
posttransplant period. Randomization was stratified based on hepatitis C (HCV)
infection status and use of antimetabolite (either azathioprine or mycophenolate
mofetil) within 30 days before randomization. Baseline biopsies were required
for eligibility within 6 months of randomization for all HCV-positive subjects,
to rule out ongoing rejection, and for HCV-negative or HCV-positive subjects
with any lab abnormality in liver function >2X upper limit of normal within
3 months of randomization. A total of 607 patients were randomly assigned
over 4 years: 393 to SRL conversion (SRLC) and 214 to CNI continuation
(CNIC). Demographic characteristics are presented in the table; no significant
differences were observed between cohorts.
Demographic Characteristics of Patient Population
HCV positive by PCR, n (%)
Antimetabolite therapy, n (%)
Mean time from transplant to randomization, years
*Mean age, years
*Sex, male, n (%)
*Ethnicity,% Black
White
Other

SRLC (n=393)
46 (12)
151 (38)
4.0
55.4
269 (69)
5
80
15

CNIC (n=214)
27 (13)
88 (41)
4.0
54.7
146 (70)
3
80
17

*Calculations based on safety population: SRLC, n=389; CNIC, n=210.

This is the largest prospective, randomized clinical trial of conversion from
CNI- to SRL-based immunosuppression yet conducted in liver allograft
recipients. The last randomized patient reached the week 52 primary endpoint
visit in November 2007. Aggregate safety and efficacy data will be available in
time for presentation in May 2008.

279 STEROID-FREE IMMUNOSUPPRESSION IN LIVER
RECIPIENTS COMPARING TACROLIMUS MONOTHERAPY
AFTER DACLIZUMAB INDUCTION VERSUS TACROLIMUS
AND MMF – THE MARSILEA STUDY
G. Otto1, T. Becker2, I. Bilbao3, D. D’Amico4, M. Colledan5, A. Bernardos6,
C.E. Broelsch7, H. Isoniemi8, J. Pirenne9, J. Jaray10
1
Universitätsklinikum Mainz, 2Medizinische Hochschule, 3Hospital Vall
d’Hebron, 4Azienda Ospedaliera di Padova, 5Azienda Ospedaliera Spedali
Riuniti, 6Hospital Virgen del Rocio, 7Universitätsklinikum Essen, 8Helsinki
University Central Hospital, 9UZ Gasthuisberg, 10Semmelweis University of
Medicine
Introduction: Liver recipients treated with tacrolimus monotherapy after
daclizumab induction (TAC+DAC) experience less diabetes and fewer steroidresistant acute rejections compared with standard TAC + steroid dual therapy
(MASTER study; Liver Transpl 2005;11:61). The objectives of the present
3-month study were to evaluate the safety and efficacy of a novel TAC+MMF
steroid-free dual therapy compared with TAC+DAC.
Methods: A total of 602 patients received TAC+DAC (N=305) or TAC+MMF
(N=297) at an initial daily TAC dose of 0.15 mg/kg. Both groups received
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a single peri-operative 500 mg steroid dose. DAC was administered in two
doses at 2 mg/kg IV on Day 0 and at 1 mg/kg IV Days 7-10 to TAC+DAC
patients. MMF was given at 2 g/day to Day 14 and thereafter at 1 g/day in
TAC+MMF patients. Target TAC trough levels were 10-15 ng/ml up to Day
42 and then <10 ng/ml. The primary endpoint at 3 months was incidence
and time of first biopsy proven acute rejection (BPAR) requiring treatment
(superiority shown if treatment difference p<0.05). Secondary endpoints
included: patient/graft survival, creatinine clearance (Cockcroft and Gault)
and adverse events.
Results: Demographics were similar with 220/305 (72.1%) TAC+DAC
and 204/297 (68.7%) TAC+MMF patients completing the 3-month study.
Withdrawals were mostly for adverse events (14.8% vs. 15.5% patients). TAC
dosing and exposure were comparable across the groups and within the targeted
window. For patients completing the study, <6% patients required steroids
in each arm. The overall estimated rate of patients free from biopsy proven
acute rejection was not significantly different: 77.9% TAC+DAC vs. 81.3%
TAC+MMF. The incidence of BPAR requiring treatment (primary endpoint)
was 16.4% vs. 15.5% (ns), steroid-resistant BPAR was 3.9% vs. 2.0% (ns)
and patient/graft Kaplan-Meier survival estimates were 91.8%/88.2% vs.
91.6%/87.8%. Mean calculated creatinine clearance for study completers
at Month 3 was 66.6 mL/min TAC+DAC vs. 69.7 mL/min TAC+MMF.
In patients not diabetic prior to transplant, 18/221 (8.1%) TAC+DAC vs.
21/227 (9.3%) TAC+MMF patients required antidiabetic medication for >30
consecutive days.
Conclusions: Tacrolimus and MMF dual therapy allows for avoidance of
concomitant steroids. The regimen was as efficacious as tacrolimus following
daclizumab induction. Both steroid-free regimens resulted in low rates of acute
rejection and were well tolerated.

280 BENEFIT OF MYCOPHENOLATE MOFETIL, DELAYED
AND REDUCED TACROLIMUS AND DACLIZUMAB IN DE
NOVO LIVER TRANSPLANTATION – RESULTS FROM THE
PER PROTOCOL POPULATION AT 12 MONTHS
A.D. Mayer, J. Neuberger
Queen Elizabeth Hospital
Introduction: In the prospective ReSpECT study, primary liver transplant
patients were randomised to: A) standard-dose tacrolimus (target trough level
>10 ng/ml) for the 1st month; B) 2 g mycophenolate mofetil (MMF) + reduceddose tacrolimus (target trough level ¡Ü8 ng/ml); or C) 2 g MMF + reduceddose tacrolimus introduced on day 5 + daclizumab on days 1 and 7. Steroids
were given in all groups according to local protocol. Results from the intent-totreat (ITT) population at 1 year showed that 2 g MMF + delayed and reduced
tacrolimus + daclizumab was associated with significantly less impairment of
renal function compared with standard-dose tacrolimus. Here we present the
results of the per protocol (PP) population.
Methods: The PP population was defined prior to the sub-group analysis. It
consisted of patients from the full analysis set (FAS) who had no inclusion/
exclusion criteria violation, had at least one calculated creatinine clearance
(CrCl) value beyond 6 months, were treated according to the protocol, and did
not receive any prohibited medication during the first 14 days or for more than
1 week at any time during the study. A composite endpoint comprising freedom
from renal dysfunction (¡Ý20% decrease from baseline in calculated CrCl),
acute rejection, graft loss or death was also investigated.
Results: The PP population included 69, 67 and 67 patients in Groups A, B
and C, respectively, compared with 181, 168 and 168 patients in the FAS. The
mean difference in calculated CrCl from baseline to 1 year was significantly
smaller in Group C compared with Group A (-10.7 ml/min vs -22.0 ml/min,
p = 0.038), but was not significantly different between Groups A and B
(-20.50 ml/min). The number of patients receiving dialysis during the study
was similar in the three groups (8.7, 6.0 and 7.5% in groups A, B and C,
respectively). The incidence of biopsy-proven or presumed acute rejection at
1 year was significantly lower in Group C compared with Group A (9.0% vs
36.2%, p <0.001), but was not significantly different between Groups A and B
(25.4%). Death (n = 2, 0, 1) and graft loss (n = 1, 0, 0) occurred infrequently
in all three groups. The incidence of the composite endpoint at 1 year was
also significantly lower in Group C compared with Group A (70% vs 93%, p
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< 0.0001) or group B (85%, p = 0.001).
Conclusions: The results from the PP population confirm those from the ITT
population that 2 g MMF + delayed and reduced tacrolimus + daclizumab is
associated with less impairment of renal function compared with standard
tacrolimus treatment. Graft and patient survival at 1 year were not affected.
Furthermore, in the PP population, a significant reduction in the rate of acute
rejection was observed, further demonstrating the benefits of a 2 g MMF +
delayed, low-dose tacrolimus regimen.

281 EVEROLIMUS IS EFFECTIVE AND SAFE IN A SIXMONTH, RANDOMIZED, MULTICENTER CONVERSION
TRIAL IN MAINTENANCE LIVER TRANSPLANT RECIPIENTS

Y. Tanaka, H. Tashiro, K. Ishiyama, T. Asahara, H. Ohdan
Hiroshima University
Background: Although liver allografts are considered immunologically
privileged, no reliable immunological parameters exist for identifying patients in
whom immunosuppressants can be safely withdrawn. For minimizing/weaning
maintenance immunosuppressants, we established an algorithm determining
anti-donor alloreactivity based on multiparameter mixed lymphocyte reaction
(MLR) assay, wherein the number and phenotype of alloreactive precursors can
be quantified by combining CFSE-labeling and FCM analyses.
Methods: We enrolled 68 adults undergoing living donor liver transplantation
(LT). The initial immunosuppressive regimen comprised tacrolimus/
cyclosporine and methylprednisolone, which were gradually tapered off by
6 months after LT. Thereafter, therapeutic adjustments were determined by a
policy of slow tapering off in the case of completely normal liver function.
MLR assay was performed at 3–6 month intervals to monitor immune status.
In this assay, CFSE-labeled PBMCs from recipients were used as responders.
Irradiated autologous, donor, and third-party PBMCs were used as stimulators.
After coculture, the responder cells were stained with CD4 or CD8 mAbs along
with CD25 mAb, followed by FCM analyses. Divisions of reactive cells, which
were identified and determined by their CFSE intensities, were labeled from
0 to n as dividing time. The number of division precursors was extrapolated
from the number of daughter cells of each division and from proliferation
events and precursor frequency in CD4+ and CD8+ T-cell subsets. With use
of these values, proliferation events and proliferation index were calculated.
Stimulation index was calculated by dividing proliferation index of allogeneic
combinations by those of self-control.
Results: The simulation indexes in each CD4+ and CD8+ T-cell subsets and
CD25 expression on proliferating CD8+ T cells in response to anti-donor
and anti-third-party stimuli were analyzed using MLR; the immune status
of LT patients was categorized as hypo-response, norm-response, or hyperresponse for CD4+ T cells and as hyper-response for CD8+ T cells. Of the 68
patients, 33 had normal liver function at >6 months after LT. We examined the
fluctuation of immunosuppressants at 6 months after MLR in these patients. In
patients whose immune status was categorized as hyper-response for CD4+ or
CD8+ T cells (n = 4), immunosuppressants could not be reduced and instead
had to be increased. In patients with norm-response immune status (n = 7),
immunosuppressant tapering was abandoned. Immunosuppressant therapy was
successfully tapered off in patients with hypo-response immune status (n =
22). Of 10 patients with hypo-response immune status at >3 years after LT,
immunosuppressants were completely discontinued in 3. Despite anti-donor
hypo-response in CD4+ T cells in these “operational tolerance” patients, the
precursor frequency of anti-donor CD4+ T cells (mean = 5.2 ± 1.9%) was not
reduced compared to that in non-tolerance patients, suggesting that donorspecific immune tolerance is maintained via inhibitory/suppressive mechanisms
rather than via clonal deletion.
Conclusion: Algorithm based on multiparameter MLR assay can provide
a clinically validated rule predicting the success of tailoring/weaning
immunosuppression.

283 TACROLIMUS MONOTHERAPY IN LIVER
TRANSPLANTATION: ONE-YEAR RESULTS OF
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND PLACEBOCONTROLLED STUDY
J. Lerut
St-Luc University Hospital
Background: Minimal immunosuppression (IS) is desirable in organ
transplantation in order to reduce side effects and to promote the process of
tolerance induction.
Material and methods: Between February 2000 and September 2004,
156 adults (> 15 yrs old) receiving a primary liver graft were enrolled in a
prospective, randomized, double-blind, placebo-controlled, investigator-driven
single-centre study comparing tacrolimus (TAC)-placebo(PL) and TAC – lowdose, short-term (64 days) steroid(ST) IS. All patients had a 12 month follow-
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H.J. Metselaar1, F. Nevens2, M. Sterneck3, J. Dumortier4, L. Rostaing5,
E. Giostra6, E. Varo7, P. De Simone8
1
Erasmus Medical Center, Rotterdam, Netherlands, 2University Ziekenhuis
Gasthuisberg, Leuven, Belgium, 3Uniklinikum Hamburg-Eppendorf,
Hamburg, Germany, 4Hôpital Edouard Herriot, Lyon, France, 5CHU
Rangueil, Toulouse, France, 6Hôpital Cantonal, Geneva, Switzerland,
7
Hospital Clinico Universitario Santiago de Compostela, Santiago de
Compostela, Spain, 8Liver Transplant Unit, Pisa, Italy
Renal dysfunction is the most common complication in liver transplant
recipients. Almost one in five recipients develops chronic renal failure or endstage renal disease in the first five years post-transplant. Long-term treatment
with calcineurin inhibitors (CNIs) can lead to nephrotoxicity and declining renal
function in maintenance liver transplant patients. Everolimus, a proliferation
signal inhibitor, facilitates CNI elimination or CNI reduction that may lead to
improved renal function.
Methods: A multicenter, open-label, randomized, two-arm study was carried
out in maintenance liver transplant patients. The trial was of 6 months’
duration, with a 6-month extension period. Patients were included if they had
CNI-related renal impairment defined as creatinine clearance (CrCl) ≥20mL/
min and ≤60mL/min. Patients randomized to the control arm continued to
receive standard-dose CNI (cyclosporine or tacrolimus) ± mycophenolic acid
± corticosteroids. Patients randomized to everolimus either discontinued
CNI therapy or switched to reduced-dose CNI + everolimus (target C0 range
3-8ng/mL) ± corticosteroids. The primary endpoint was a between-group
difference of 8mL/min in the change in CrCl (Cockcroft-Gault) from baseline
to month 6.
Results: In total, 145 patients (72 everolimus, 73 controls) were randomized.
At month 6, 80% of patients receiving everolimus had discontinued CNI
entirely. The mean change in CrCl from baseline to month 6 did not differ
significantly between groups (everolimus 1.0±10.2mL/min, controls
2.3±7.8mL/min; p=0.463 [last observation carried forward method]). Among
the 111 patients who remained on-treatment, the median change in CrCl
from baseline to month 6 was numerically greater with everolimus (3.9mL/
min) compared to control patients (2.8mL/min). The small difference in
CrCl at month 6 was influenced by (a) a higher-than-anticipated rate of
CNI dose reductions in the control group (77% of patients received a dose
reduction and 26% had a dose reduction of >25%, against protocol) and (b)
the relatively long time post-transplant (mean >3 years). The rate of biopsyproven acute rejection was identical in both groups (1.4%) and there were
no graft losses. The safety profile of everolimus was consistent with that
reported in previous studies.
Conclusion. In the majority of maintenance liver transplant patients included in
this study, CNI discontinuation could be achieved after conversion to everolimus
without compromising efficacy. In patients who were treated with study drug for
6 months (on-treatment patients), the improvement in renal function (CrCl) was
greater with everolimus than in controls. CNI reductions were more frequent and
larger than anticipated in control patients, and the mean time post-transplant was
>3 years, factors that may have contributed to not meeting the primary endpoint.
Earlier intervention with everolimus to avoid CNI-related deterioration of renal
function is being investigated in follow-up studies.

282 STRATEGY FOR TAILORING MINIMAL
IMMUNOSURPPRESSION AFTER LIVING DONOR LIVER
TRANSPLANTATION: PREDICTIVE ALGORITHM BASED
ON MULTIPARAMETER MIXED LYMPHOCYTE REACTION
ASSAY USING CFSE-LABELING TECHNIQUE
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up (range 12–84).
Results: By day 7, 3 and 12 months, rejection treatment had been given in
3.8%, 17.9% and 21.8% (16 patients) of TAC-PL patients, respectively, and
1%, 10.5% and 17.9% (14 patients) of TAC-ST patients (ns). The total number
of patients treated at 3 .(16pts-20.5% vs 10pts -12.5%)and 12 (18 pts-23%
vs 15pts-19.2%) months was not significantly different between the TAC-PL
and TAC-ST groups. Corticosteroid-resistant rejection at 3 and 12 months was
recorded in 12.8% (10pts) of TAC-PL patients and 3.8% (3pts) of TAC-ST
patients (p 0.04). Vanishing bile duct syndrome was diagnosed in one (1.2%)
TAC-PL patient and four (5.1%) of the TAC-ST patients (ns).
Three- and 12-month patient survival rates were 93.6% and 85.9%, respectively,
in the TAC-PL group and 98.7% and 93.6% in TAC-ST group. Three and twelve
month graft survival rates were 92.3% and 83.3% vs. 97.4% and 92.3% (ns).
By one year, 78.2% of TAC-PL patients and 82% of TAC-ST patients were
on TAC monotherapy. When considering the 67 TAC-PL and 74 TAC-ST
survivors, these rates of monotherapy were 91% (61 pts) and 86.5% (64pts),
respectively (ns). At one year, 53.7% (36/67 pts) of TAC-PL survivors and
56.8% (42/74 pts) of TAC-ST survivors were on low-dosage (< 6ng/ml) TAC
monotherapy (ns).
Conclusion: Although more corticosteroid-resistant rejections were noted in
the Tacrolimus-Placebo group, these events did not influence graft nor patient
survival. Tacrolimus monotherapy can be achieved safely in primary adult
liver transplantation. Such strategy should lay the basis for further large scale
minimization studies in liver transplantation.
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284 IMMUNOSUPPRESSION FOR PRIMARY RENAL
DISEASE AND THE RISK OF CANCER IN SUBSEQUENT
RENAL TRANSPLANTATION
A.D. Hibberd1, P.R. Trevillian1, J.H. Wlodarczyk2, A.M. Stein1,
A.H.B. Gillies3, M.K. Heer1, A.G.R. Sheil4
1
Newcastle Transplant Unit, John Hunter Hospital and Faculty of Medicine,
University of Newcastle, Newcastle, Australia, 2Biostatistics Consulting
Service, New Lambton, Newcastle, Australia, 3Department of Nephrology,
John Hunter Hospital and Faculty of Medicine, University of Newcastle
Newcastle, Australia, 4National Liver Transplantation Unit, Royal Prince
Alfred Hospital, Sydney, Australia
Background: The aim of this study was to determine whether immunosuppressive
agents used to treat primary renal disease contributed to the risk of de novo
cancer after renal transplantation. The use of immunosuppressive agents after
transplantation and some viral infections are the two major risk factors for
cancer after transplantation.
Methods: This population based study consisted of 7953 renal transplant
recipients who received 9460 transplants between 1965 and 1990. The follow
up was 40 years. All data were derived from the Australian and New Zealand
Dialysis and Transplant Registry. The effects of these factors upon the risks
of developing either non-Hodgkin’s lymphoma (NHL) or carcinoma of the
cervix, vagina and vulva (CCVV)in subsequent renal transplantation were
determined by multivariate analyses: immunosuppression for primary renal
disease; primary glomerular disease; the use of anti-thymocyte globulin (ATG)
or anti-T cell monoclonal antibodies (OKT3); year of transplant; recipient age
at transplant; the use of cyclosporin A (CsA), azathioprine or prednisolone;
dialysis and sex. Proportional hazards regression models including the family
of study factors were used to estimate hazard ratios (95% CI’s) for each factor.
A stepwise backwards elimination method was used to choose study factors
to be included in the multivariate analyses. All analyses were done using
Statistical Analysis Software.
Results: The incidence of NHL was 165/7953 (2.07%) and the incidence
of CCVV was 94/3374 (2.79%). For immunosuppression for primary renal
disease the risk of NHL was 1.88([95% CI 1.23 to 2.88]; p=0.003) and the risk
of CCVV was 2.26([95% CI 1.30 to 3.92]; p=0.003). For primary glomerular
disease the risk of NHL was 1.45([95% CI 1.06 to 1.96]; p=0.01) and the risk
of CCVV was 1.725([95% CI 1.15 to 2.59]; p=0.009). With respect to recipient
age at transplant the risk of NHL was reduced to 0.49([95% CI 0.23 to 1.06];
p=0.07) for recipient age between 30 and 40 years but the risk of CCVV was
increased to 5.1 ([95% CI 2.17 to 11.97]; p=0.0002) for recipients aged up to
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30 years. In the presence of other immunosuppression after transplantation the
use of azathioprine or prednisolone reduced the risks of either cancer (p<0.001
for all four comparisons) and CsA reduced the risk of CCVV to 0.93([95% CI
0.89 to 0.96]; p<0.0001) but not NHL which was 0.98([95% CI 0.96 to 1.00];
p=0.13). Neither dialysis nor ATG had a significant effect on the risk of either
cancer. Transplantation before 1984 reduced the risk of NHL to 0.49 ([95% CI
0.35 to 0.68]; p<0.0001) but had no significant effect upon the risk of CCVV
which was 0.82 ([95% CI 0.54 to 1.26]; p=0.36).
Conclusions: The study provides evidence that the use of immunosuppressive
agents to treat primary renal disease before renal transplantation
independently increased the risks of NHL and CCVV during subsequent renal
transplantation:this is the first population based study to report this association.
The presence of primary glomerular disease causing renal failure also seemed
to increase the risks of both cancers. The risk of CCVV is also strongly related
to the recipient age at transplant.

285 IMMUNOSUPPRESSION IS A RISK FACTOR FOR
URINARY TRACT CANCERS IN RENAL TRANSPLANT
RECIPIENTS
A.T.H. Goh, Y.M. Lu, A. Vathsala
Department of Renal Medicine, Singapore General Hospital
Urinary tract carcinoma (UTC) occurs at a higher incidence in renal transplant
recipients (RTX). Increasing use of abdominal ultrasonography (US) permits
early diagnosis and intervention for UTC. Although postulated risk factors
for UTC include acquired cystic kidney disease and duration of dialysis, the
role of immunosuppression on UTC development post-transplant has not been
examined. This study examined duration of dialysis, development of native
renal cysts (NRC), duration of follow-up and immunosuppression used posttransplant, and correlated these to the occurrence of UTC. Type and amount of
immunosuppression administered was quantified using an Immunosuppression
Scale (IS), which accorded points for each immunosuppressant per year of
use: (Azathioprine-1, Cyclosporine-2, Tacrolimus-2.5, Mycophenolate-2,
mTOR inhibitors-2), or per treatment course: (IL2 receptor antagonists-5,
Antilymphocyte preparations-10).
1,118 RTX (55.3% Male, 83.7% Chinese, 69.4% deceased donor), on followup at our centre for at least 6 months between January 1995 and July 2007,
were reviewed. RTX underwent US of native and transplant kidneys within
1-month, then 5 yearly post-transplant (2-yearly for those with renal cysts).
26 (2.3%) with underlying polycystic kidney disease and 63 RTX (5.6%) who
did not undergo US or had undergone native nephrectomy, were excluded from
subsequent analysis. Suspicious lesions were further investigated, and treated
appropriately. With screening, 14 UTC (13 asymptomatic, 10 native renal cell
carcinoma (RCC), 4 transitional cell carcinoma (TCC)), were diagnosed at a
median interval of 5.8 years post-transplant, representing a 144-fold incidence
of UTC above the general population. 5-year patient survivals for RCC in RTX
vs. the general population were comparable (100% vs. 94%).
RTX were stratified into 3 groups: those with no cysts (No-NRC), pre-existing
cysts (Pre-NRC) and new native renal cysts (New-NRC). In comparison to NoNRC, RTX with Pre-NRC had a significantly longer duration of dialysis and shorter
duration of follow-up post-transplant, but nonetheless a 6.7-fold higher risk of
RCC. Furthermore, exposure to more potent immunosuppression was significantly
higher for Pre-NRC. Of note was the significantly higher duration of follow-up
post-transplant and the higher incidence of RCC in New-NRC vs. No-NRC.
Incidence and Risk Factors for RCC in Study Population
No-NRC
New-NRC
Pre-NRC
Number of RTX
388 (34.7%)
184 (16.5%)
457 (40.9%)
Number with RCC
1 (0.26%)
1 (0.54%)d
8 (1.75%)a
Dialysis Duration, yearse
2.5+2.7
3.0+2.6
5.0+3.9b, a, c
Follow up post-transplant, yearse
10.1+5.6
12.1+5.2d
7.7+5.6b, a, c, d
IS per yeare
3.5+2.2
3.3+2.8c
3.9+2.3b, a, c
a
Pre-NRC vs. No-NRC, p<0.05, b p<0.05 (ANOVA), c Pre-NRC vs. New-NRC, p<0.05,
d
New-NRC vs. No-NRC, p=0.000, e Mean+standard deviation.

These results demonstrate a strong association between duration of dialysis
with occurrence of renal cysts and the subsequent development of RCC upon
exposure to more potent immunosuppression following renal transplantation.
NRC development appears not to be arrested despite transplantation, as new
cysts continue to appear post-transplant and may predispose to the later
development of UTC. These results advocate for early and regular screening
for NRC in RTX so as to allow early detection and treatment of UTC in this
high-risk population.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Oral Abstracts

287 CURRENCY OF RECEIPT OF IMMUNOSUPPRESSIVE
AGENTS AND OTHER RISK FACTORS FOR LIP CANCER
FOLLOWING RENAL TRANSPLANTATION

Y. Miao, J.J. Everly, R.R. Alloway, T.G. Gross, M.R. First, A. Tevar,
C. Muthiah, M.J Everly, A. Webster, E.S. Woodle
Department of Transplantation, University of Cincinnati, OH
Background: Epidemiologic studies have established that transplant (TX)
recipients are at increased risk of malignancy. However, the influence
of immunosuppression (IS) on the biologic behavior of post transplant
malignancies has not been rigorously defined by substantive epidemiologic
data. The purpose of this study was to examine the influence of IS on the
biologic behavior of specific cancers by comparing stage-stratified diseasespecific survival (DSS) for specific cancers in transplant recipients and the
general population.
Methods: Data for de novo Renal Cell Cancer (RCC), Malignant Melanoma
(MM), Non-Small Cell Lung Cancer (NSCLC), and Colon Cancer (CC) in
transplant recipients [from the Israel Penn International Transplant Tumor
Registry (IPITTR)] were compared to data from the general population
[Surveillance, Epidemiology, and End Results (SEER) database from the
National Cancer Institute]. All cancers were staged by AJCC criteria. Fisher
exact, Chi-Square, Kaplan-Meier were performed using SPSS 15.0.
Results: Number of patients, age at cancer diagnosis, and stage-stratified DSS
are presented in the table below. Transplant recipients were diagnosed at an
earlier age compared to SEER patients for each cancer (all p values <0.001).
The proportion of patients with early stage (AJCC Stage I/II) RCC was greater
in transplant recipients; proportion of patients with early stage (AJCC Stage I/
II) MM and CC was greater in the SEER population.

M. van Leeuwen1, A. Grulich1, A. Webster2,3, S. McDonald2,4, M. McCredie5,
J. Stewart5, J. Amin1, J. Kaldor1, J. Chapman2,6, C. Vajdic1
1National Centre in HIV Epidemiology and Clinical Research, University
of New South Wales, 2Australia and New Zealand Dialysis and Transplant
Registry, Queen Elizabeth Hospital, 3School of Public Health, University of
Sydney, 4Disciplines of Medicine and Public Health, University of Adelaide,
5Department of Preventive and Social Medicine, University of Otago,
6Center for Transplant and Renal Research, Millennium Institute, Westmead
Hospital, University of Sydney
Purpose: Lip cancer occurs at greatly increased rates following organ
transplantation and in other immunodeficient states. However, understanding
of lip cancer aetiology, either in the context of immunodeficiency or in the
general population, remains incomplete. This study aimed to examine the
role of immunosuppression and other risk factors for lip cancer in a large,
population-based, Australian cohort of renal transplant recipients.
Methods: Diagnoses of lip cancer in a cohort of 8,162 renal transplant recipients
during 1982 – 2002 were ascertained through probabilistic data linkage
between the Australia and New Zealand Dialysis and Transplant (ANZDATA)
Registry and the National Cancer Statistics Clearing House (NCSCH). All
cancers within the lip rubric (ICD10 C00) were included; cancers of the skin
adjacent to the mucosa of the lip (ICD10 C43, C44) were excluded. Personyears of follow-up were accrued from the date of transplantation until the first
diagnosis of lip cancer, death, or last contact. Multivariate Poisson regression
was used to compute incidence rate ratios (IRR) for lip cancer during periods
of transplantation and dialysis, as well as risk factors for squamous cell
carcinoma (SCC) of the lower vermillion (‘lip-stick zone’) of the lip during
the period following first transplantation only. To account for changes in
immunosuppressive regimen over time, the regression models included timedependent covariates for exposure to the major immunosuppressive agents.
Results: 203 diagnoses of lip cancer were recorded after transplantation
(335 cases per 100,000 person-years), most commonly in the vermillion of
the lip. Incidence was significantly reduced (IRR 0.04, 95% CI 0.01 – 0.32,
p=0.002) after transplant failure and resumption of dialysis, returning to
near pre-transplantation level. During the first transplantation, SCC of the
lower vermillion (n=122) was independently associated with increasing age
(p<0.001), greater time since transplantation (p=0.001), increasing years of
prior dialysis (p=0.024), current use of azathioprine (IRR 2.60, 95%CI 1.35 –
5.01, p<0.001), and current use of cyclosporine (IRR 1.70, 95%CI 1.05 – 2.77,
p=0.032). Risk was significantly lower among females (IRR 0.29, 95%CI 0.18
– 0.46, p<0.001), and those born outside of Australia/New Zealand (p=0.008),
both surrogates for lower sun exposure. A non-linear association with latitude
was observed (p=0.015).
Conclusion: Lip cancer risk following renal transplantation appears largely
driven by the interaction between sun exposure and current receipt of
immunosuppressive agents. Current receipt of azathioprine, thought to
increase UVA photosensitivity, and cyclosporine, which inhibits DNA repair
mechanisms, may potentiate UV-related cellular damage and malignancy. The
fact that lip cancer risk was confined almost entirely to periods of transplantation
demonstrates that it is currency of receipt of immunosuppressive agents
that determines risk, and that the heightened risk is reversible on cessation
of immunosuppression. As lip cancer shares certain risk factors with nonmelanoma skin cancer (NMSC), these findings may inform the high risk for
NMSC widely documented in this group.

Renal Cell Cancer
IPITTR

SEER

84

57,029

Mean Age at Diagnosis

50+/-11

63+/-13

% of pts with early stage
(StageI/II)

73%

Stage I
Stage II
Stage III
Stage IV
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Malignant Melanoma
p
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57%
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32,13,8

0.012
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37,18,14

DSS at 1,3,5 Y

Non-Small
Cell Lung
Cancer

Colon Cancer

IPITTR

SEER

179

200,556

Mean Age at Diagnosis

57+/-9

67+/-11

% of pts with early stage
(StageI/II)

24%

27%

# Pts

p

IPITTR

SEER

72

137,466

p

<0.001

59+/-10

70+/-13

<0.001

NS

40%

54%

0.013

0.021

DSS at 1,3,5 Y
Stage I

84,60,18

86,65,54

NS

87,69,69

97,95,92

Stage II

60,--,--

70,34,21

0.014

88,30,30

93,86,81

0.001

Stage III

22,7,--

39,13,8

NS

67,35,26

86,68,60

<0.001

Stage IV

23,9,5

17,3,1

<0.001

9,--,--

43,14,8

0.003

DSS was greater for the SEER population for each stage of CC. DSS was
similar between populations for each stage of MM, for stage I, II and III for
RCC, and for stage I and III for NSCLC. DSS was greater for RCC in the SEER
population for Stage IV only. DSS was greater in the IPITTR population only
in Stage IV NSCLC.
Conclusions: 1) De novo RCC, MM, NSCLC, and CC are diagnosed at an
earlier age (by average of 10 years) in Transplant recipients; 2) Transplant
recipients with de novo cancers post transplant do not have a universally
lower DSS compared with the SEER population; 3) Rather, DSS varies
significantly by AJCC Stage and tumor type. In summary, these epidemiologic
analyses indicate that systemic IS does not universally enhance the biologic
aggressiveness of malignancies that arise following transplantation.
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288 TWENTY YEAR CANCER OUTCOMES OF A
RANDOMISED TRIAL OF IMMUNOSUPPRESSION
IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS
OF THE AUSTRALIAN MULTICENTRE TRIAL OF
CYCLOSPORINE WITHDRAWAL
M.P Gallagher1, A.C. Webster2, M.J. Jardine1, V. Perkovic1, A. Cass1,
J.M. Eris3
1
The George Institute For International Health, 2School of Public Health,
University of Sydney, 3Royal Prince Alfred Hospital, Sydney, Australia
Background: Malignancy is a well recognised complication of renal
transplantation, and cumulative incidence increases with time since
transplantation. Potential differences in carcinogenicity among components
of immune suppressive regimens are the subject of much interest and
debate. Until now, analyses have largely relied on observational data.
Randomised data is scarce due to the relatively long latency of most cancer
events and the paucity of trials with correspondingly sufficient follow
up periods. We present 20 year cancer outcomes from a large Australian
randomised trial.
Methods: This randomised, open-label, multicentre study allocated first
cadaveric renal transplant recipients into one of three different immune
suppression regimens: azathioprine and prednisolone (AP), long term
cyclosporine alone (Cy) or 3 months of cyclosporine followed by a switch to
azathioprine and prednisolone (CyAP). Following consent from the participating
Units, data from the study database was matched with the Australian and New
Zaland Dialysis and Transplantation Registry (ANZDATA) to provide 20 year
outcomes and malignancy rates. All records of incident non-melanocytic skin
(NMSC) and non-skin cancers were analysed, regardless of graft failure. The
Kaplan Meier method was used to compare malignancy-free survival among
the groups, using the log rank test.
Results: A total of 489 patients were randomised (AP = 158, Cy = 166,
CyAP = 165) in 7 Australian centres, with 20 year follow up data available
for 482 (99%) recipients with 7 (1%) lost to follow up. At a mean of 20 years
post transplant 295 patients had died (respectively 104, 97, 94) and 395
patients had died or lost their grafts (132,140,123). A total of 229 patients
were diagnosed with cancer at any time post transplant (174 with NMSC
and 95 with non-skin cancers). Overall median patient survival was similar
across the three groups (14.3, 16.9, 15.1yrs, p = 0.13) and the median time
to first malignancy or death was similar (6.6, 8.8, 8.9 yrs, p = 0.18). The
median time to death or first NMSC was not different among the three
groups (7.6, 8.6, 9.8 yrs, p = 0.23). Similarly, the median time to death or
first non-skin malignancy was not different among the groups (12.6, 14.8,
12.8 yrs, p =0.18).
Conclusions: Overall rates of all malignancy, taking in both skin and non-skin
cancers, is similar in these three different renal allograft immune suppression
regimens out to 20 years post transplant.

289 THE EFFECT OF CONVERSION TO SIROLIMUS ON
IMMUNE PHENOTYPE IN TRANSPLANT RECIPIENTS WITH
CUTANEOUS SQUAMOUS CELL CARCINOMA
R. Carroll1,2, P.N. Harden2, K. Wood1
Transplantation Research Immunology Group, Nuffield Department of
Surgery, John Radcliffe Hospital, Oxford, UK, 2Oxford Kidney Unit, Churchill
Hospital, Oxford, UK
Background: Renal transplant recipients (RTR) have a 3 fold increase risk of
cancer and substantially worse prognosis for late stage disease compared to age
matched controls. The risk of cutaneous squamous cell carcinoma (cSCC) is
×200 greater than the general population in the UK, with substantial morbidity
and mortality.
Conventional immunosuppressants are linked to this increased risk of cancer in
RTR. A new immunosuppressant, Sirolimus, has anti cancer effects. RESCUE
is an international randomized control trial investigating the efficacy of
Sirolimus in reducing in the rate of new cSCC in renal transplant patients with
a previous history of cSCC
In the non RTR population high numbers of FOXP3+CD25highCD4+ T cells are
associated with malignancy and predict poor prognosis and recurrent cancer.
There are no data on whether FOXP3+CD25highCD4+ T associate with cancer in
transplant recipients. This cell population could define RTR at increased risk of
cancer or cancer recurrence.
Patients and methods: 24 patients from RESCUE were enrolled in a sub
study. These RTR have prolonged graft survival (20.4 ± SD 7.5 years) and
advanced age (61.8 ± SD 9.9 years).
The immune phenotype of these patients was assessed by multi parameter flow
cytometry. The laboratory investigators were blinded to the immunosuppressive
regimens of the patients.
Flow cytometry was performed before study entry, to determine the baseline
immune phenotype. Assessment, 3 and 6 months after randomisation, has
been used determine the effects of conversion from conventional immune
suppression to a Sirolimus based regimen. The study will be un-blinded in June
2008.
In a concurrent study the immune phenotypes of RESCUE patients were
compared with age, sex and duration of immunosuppression matched
controls.
Results: Before entry into the RESCUE study the median (range) number
of FOXP3+CD25highCD4+ was 21 (6-96) cell/μl blood in RTR with cSCC. In
controls the median (range) was lower 16 (1-29) cell/μl blood (Mann Whitney
test p=0.013).
High numbers of FOXP3+CD25highCD4+ were associated with a history multiple
cSCC, recent tumour resection or occurrence of new cSCC during the study
period.
Patients in RESCUE had lower number of NK cells compared to matched
controls (Mann Whitney p=0.047). Over the study period the median (range)
number of NK cells increased from 63 (3-221) cell/μl blood to 138 (19-518)
cell/μl blood (Mann Whitney p=0.021).
Conclusions: In this population high numbers of FOXP3+CD25highCD4+ cells
and low NK cell numbers correlates with recurrent or multiple cSCC. This
immune phenotype may define RTR at risk of recurrent cSCC.
1

290 IMPACT OF KIDNEY TRANSPLANTATION AND CANCER
CO-MORBIDITY COMPARED WITH CANCER ALONE ON
EXPECTED SURVIVAL: A REGISTRY ANALYSIS FROM
AUSTRALIA AND NEW ZEALAND
A. Webster1,2, A. Hayen1, P.J. Kelly1, J.R. Chapman3, J.C. Craig1,2
1School of Public Health, University of Sydney,, 2Centre For Kidney
Research, Children’s, 3Centre For Renal And Transplant Research, Westmead
Hospital,
Background: Increased risk of cancer in transplant recipients has been
comprehensively investigated, but data describing the impact of the comorbidity of transplantation on cancer survival has never been examined with
respect to the broader cancer or general populations.
Aims: To examine the relative survival of cancer patients and transplant
patients with cancer, compared to the general population.
Methods: Using inception cohort data from the Australia and New Zealand
Dialysis and Transplant Registry, the New Zealand Health Information Service,
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Statistics New Zealand and the Australian Bureau of Statistics, we compared
5-year relative survival of transplant recipients with cancer and the general
population with cancer. Non-melanocytic skin cancers were excluded as data
are not available for the general population. Relative survival was calculated
as the ratio of observed survival of cancer patients and transplant recipients
with cancer, compared to the expected survival in the general population
of Australia and NZ, with the same age and sex distribution, over the same
time period. A relative survival ratio of 1 indicates that the survival rate is
equivalent to the general population, and ratios <1 indicate the survival rate is
lower (mortality rate is higher) compared to the general population (with 95%
confidence intervals)
Results: Data were available from all sources for the period 1988-2004.
There were 9,556 kidney transplant recipients of whom 1309 (13.7%) were
diagnosed with at least 1 cancer. There were 255,600 people with cancer
diagnosed in NZ. Overall, 5-year relative survival was 0.43 (0.40-0.46)
for transplant recipients with cancer, and 0.51(0.50-0.51) for the overall
cancer population, compared to the general population. Relative survival
of transplant recipients with cancer was lower for all age groups compared
to the overall cancer population (see graph). Five-year relative survival for
female transplant recipients with cancer was 0.45 (0.40-0.49) compared
with 0.54 (0.53-0.54) in the overall cancer population; for male recipients
with cancer the relative survival was 0.41 (0.37-0.45) compared with 0.47
(0.47-0.48) for males with cancer. The difference in relative survival for
males and females recipients with cancer was not constant and altered with
age (see table).
5 year relative survival by age and sex
Age
< 35 years
35-44
45-54
>=55
Sex
m
f
m
f
m
f
M
f
0.69
0.64
0.59
0.48
0.51
0.27
0.33
0.71
Tx +
cancer (0.57-0.81) (0.55-0.80) (0.53-0.73) (0.46-0.70) (0.39-0.55) (0.41-0.60) (0.22-0.33) (0.28-0.39)
0.74
0.77
0.66
0.74
0.54
0.67
0.45
0.46
cancer
(0.74-0.76 (0.76-0.78) (0.64-0.67) (0.73-0.75) (0.53-0.55) (0.66-0.68) (0.44-0.45) (0.46-0.47)

292 SEQUENTIAL TREATMENT WITH RITUXIMAB AND
CHOP CHEMOTHERAPY IN B-CELL PTLD – WILL RISK
STRATIFIED SEQUENTIAL TREATMENT BECOME THE NEW
STANDARD IN THERAPY?

291 IMPACT OF CANCER ON SURVIVAL AFTER KIDNEY
TRANSPLANTATION
A.C. Webster12, A. Hayen1, P.J. Kelly1, J.R. Chapman3, J.C. Craig12
1
School of Public Health, University of Sydney, 2Centre for Kidney Research,
Children’s Hospital at Westmead, 3Centre for Renal and Transplant research,
Westmead Hospital, Australia.
Background: Recently, the increased risk of cancer in transplant recipients
has been quantified comprehensively, but data describing the impact of cancer
on survival after kidney transplantation are sparse.
Aims: To evaluate the relative and absolute survival of transplant recipients
with and without cancer, compared with the general population with and
without cancer.
Methods: Using inception cohort data from the Australia and New Zealand
Dialysis and Transplant Registry (1963-2004), rates of death and standardised
mortality ratios (SMR) were calculated by age, sex and year compared to
the general population of Australia and New Zealand. Within the transplant

R. Trappe1, S. Choquet2, S. Oertel1, V. Leblond2, T. Ekman3, M. Sender3,
P. Mollee4, P. Reinke1, H. Lehmkuhl5, M. Hummel5, S. Jonas1, R. Neuhaus1,
G. Salles6, F. Morschhauser7, A. Jaccard8, D. Dierickx9, T. Lamy10,
B. Dörken1, I. Anagnostopoulos1, M. Raphael11, H. Riess1 for the German,
French, Swedish, Australian and Belgian Study Group on PTLD
1
Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Hôpital PitiéSalpétrière, Paris, France, 3Sahlgrens Hospital, Gothenburg, Sweden
4
Princess Alexandra Hospital, Brisbane, Australia, 5Deutsches Herzzentrum
Berlin, Berlin, Germany, 6Hopital Lyon Sud, Lyon, France
7
Hopital Claude Huriez, Lille, France, 8Hopital Dupuytren, Limoges, France
9
University Hospital Gasthuisberg,Leuven, Belgium, 10Hopital Ponchaillou,
Rennes, France, 11Hoptital du Kremlin Bicetre, Le Kremlin Bicetre, France
Purpose: This trial aimed to investigate the efficacy and safety of sequential
treatment with rituximab and CHOP-21 in patients with PTLD unresponsive to
reduction of immunosuppression.
Methods: An ongoing prospective multicenter phase II trial was initiated in
January 2003. Patients were treated sequentially with rituximab at days 1, 8,
15 and 22 (4xR) followed by four cycles of CHOP-21 combined with G-CSF
support starting 4 weeks after the last dose of rituximab (sequential treatment,
ST). To further improve the very promising results with ST reported at the
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Conclusions: Transplant recipients not only have increased cancer incidence,
but also increased mortality when diagnosed with cancer compared to the
cancer and general populations. It is not clear whether cancer treatment is
less effective in transplant recipients, or whether underlying morbidity from
ESKD contributes. A fuller analysis of the pattern of relative survival for
specific cancer sites will increase understanding, and inform surveillance and
treatment programs.

population, risk factors for early death were identified using Cox regression
(hazard ratios: HR; 95%CI), and absolute risk of death with and without cancer
(excluding non-melanocytic skin cancer) was estimated for different recipient
groups.
Results: Of 15,183 recipients (mean follow-up 9.0 years, total 135,968 years
of risk), 1642 (10.8%) developed cancer and 6,479 (42.7%) died. Overall, for
female transplant recipients SMR was 10.0(9.5-10.4), rising to 26.6 (24.2-29.2)
for those who also had cancer. For male recipients SMR was 6.5 (6.3-6.8),
but 22.8 (20.9-24.7) with cancer. Relative mortality rates varied by age and
sex (see graph), but for all age groups was greatly increased by cancer comorbidity. Female recipients aged 35-45 had SMR 23.6 (20.8-26.7) rising to
SMR 81.5 (59.0-112.5) after cancer diagnosis, for males of the same age SMR
were 12.4 (11.20-13.75) and 59.40 (45.2-78.2) respectively. For recipients over
55 yrs sex differences were less pronounced: for females SMR 6.9 (6.4-7.3)
and 20.6 (18.4-23.1) with concurrent cancer, for males SMR 4.6 (4.4-4.9) and
17.9 (16.1-19.8) respectively. Within the transplant population, older age and
male sex increased risk of death (transplanted >55yrs versus <35yrs HR 4.47:
4.15-4.83, male versus female HR 1.09: 1.04-1.15), as did diabetic ESKD
(versus glomerulonephritis, HR 1.78: 1.61-1.96) and graft failure (HR 3.81:
3.62-4.01), but white racial background was protective (HR 0.79: 0.73-0.85).
After allowing for these effects, cancer diagnosis increased risk of early
death more than four fold (HR 4.12: 3.84-4.43). Absolute risk of death at 1
year varies: for a young (<35yrs) white woman with glomerulonephritis and
no cancer, risk is 1:42, but rises to 1:10 with cancer. A non-white man aged
45-55yrs with diabetic ESKD and a functioning transplant, can expect a 1:17
risk of death at 1 year, rising to 1:4 with cancer.
Conclusions: Transplant recipients have death rates similar to people 30
years older in the general population, but cancer co-morbidity has devastating
consequences. It is unclear whether cancer is not treated, treated differently,
or if treatment is ineffective in this population. Further work on behaviour of
specific cancers may inform understanding of treatment, screening strategies,
and service provision.
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ITC meeting in 2007 a protocol amendment was introduced in October 2006.
As treatment response to 4xR was shown to predict overall survival, risk
stratification according to response to rituximab was introduced. In the amended
protocol patients with a CR after 4xR will go on with 4 additional applications
of rituximab while all others will go on with four cycles of R-CHOP-21 instead
of CHOP-21 (risk stratified sequential treatment, RSST).
Results: In this analysis from March 2008 a total of 86 patients are reported.
The median follow up are 24.6 months for ST (69 pts. included) and 6.4 months
for RSST (17 pts. included). 64 ST and 17 RSST patients were diagnosed with
monomorphic PTLD, 5/0 with polymorphic PTLD. 22/9 patients were kidney,
16/4 liver, 14/4 heart, 4/0 lung, 2/0 heart+lung, 3/0 kidney+pancreas transplant
recipients (8/0 others). Median age was 54/60 years. 59%/65% had advanced
stage of disease. 51%/67% of tumors were EBV positive. 78%/82% of patients
had late PTLD (i.e. later than 1 year after transplantation). LDH was elevated
in 69%/56% of patients. The overall response rate of ST was 88% (CR 65%, PR
23%). 73.7% and 62.0% of patients included were without disease progression
at one and two years, respectively, and 79.1% and 74.9% of patients responding
remained in disease remission at 1 and 2 years (Fig 1). Following ST, 33%
of patients suffered from WHO °3/4 infections. There were ten early therapyassociated deaths (17%), 6 due to infections, 2 due to haemorrhage, 2 due to
primary refractory disease. With RSST the overall response rate was 92% and
85% achieved a complete remission. 92.9% of patients included were without
disease progression at one year and with a median follow up of 6.4 months not
a single patient responding to treatment had disease progression so far (Fig
1). 5/15 patients (33%) suffered from WHO °3/4 infections. With RSST there
were two early therapy-associated deaths (16%), one due to infection, one due
to primary refractory disease.
Conclusions: This is the largest prospective study in PTLD. Sequential
treatment with rituximab and CHOP-21 + G-CSF is well tolerated and highly
effective. As compared to rituximab monotherapy more patients achieve a
CR with sequential treatment and time to progression (TTP) is very much
prolonged. Our first prospective data evaluating risk stratified sequential
treatment suggest even superior CR rates and further increased TTP with a
similar toxicity level.
Figure 1

CONCURRENT ORAL SESSION 25:
TOLERANCE INDUCTION MECHANISMS
293 MACROPHAGES DRIVEN TO A NOVEL STATE OF
ACTIVATION PROMOTE T CELL REGULATION AND ORGAN
TRANSPLANT TOLERANCE
E. Geissler1, H. Schlitt1, S. Inoue1, J. Hutchingson2, B. Brem-Exner1,
G. Koehl1, F. Faendrich2, K. Kronenberg1
1University of Regensburg, Department of Surgery, 2University Hospital
Schleswig Holstein, Kiel, Department of Surgery
Background: The use of immunomodulatory cells in organ transplantation
is a promising approach for tolerance induction. Here we describe a novel
tolerogenic macrophage population capable of enriching T regulatory (Treg)
cells and promoting tolerance.
Methods: Balb/c bone marrow, spleen and blood cells were cultured with
M-CSF for 5 days, and on the last day IFN-gamma (IFN-g) was pulsed into
the cultures to produce what we refer to as IFN-g-induced monocyte derived
cells (IFNg-MdCs). IFNg-MdCs were phenotypically characterized by FACS
and immunomodulation was determined by cell counting assays and FACS
analysis for Tregs. Mouse heterotopic heart transplantation was used to test
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in vivo effects.
Results: IFNg-MdCs express high levels of CD11c/b, MHCII, F4/80 and PD-L1.
They are positive for CD40 and CD86, but negative for CD80. Compared to
classically activated (M1) macrophages IFNg-MdCs express less CD40/
CD86, but higher levels of CD11c. IFNg-MdCs profoundly delete activated,
but not resting, lymphocytes (>60%), and cell contact (transwell system) and
caspases (caspase inhibitors) were found to be essential. Interestingly, IFNgMdC cultures are highly enriched for CD4+CD25highFoxp3+ Treg cells (41
+/-2%; n=27); direct comparison to classically activated macrophages and
dendritic cells showed only Treg enrichment with IFNg-MdCs. The same, or
even higher, proportions of Tregs could be detected when IFNg-MdCs were
generated from MACS-purified CD11b+ and CD4+ cell populations (1:1)
versus a standard mixed starting cell population. ELISA analysis of IFNg-MdC
cultures revealed high levels of IL-10 in comparison to standard monocyte
cultures (183 +/-42 ng/ml vs. <30 pg/ml, respectively), suggesting IL-10 as
one potential mediator. IFNg receptor signaling and CD40 interactions are
required for Treg enrichment, as shown using IFNg receptor and CD40 knockout mouse strains (C57BL6 mice). IFNg-MdCs derived from CD11b+ cells
and CD4+ lymphocytes of OVA-transgenic OTII mice showed enrichment of
Treg by 10-fold with high-affinity OVA peptide (323-339) versus Treg levels
using a low-affinity OVA peptide (OVA 323-334), suggesting antigen-specific
Treg cells could be enriched with IFNg-MdCs. Finally, a single post-heart Tx
(d+1) i.v. injection of 5 million donor (C3H)-derived IFNg-MdCs prolonged
allograft survival in Balb/c recipients from 8.5 +/-0.8d (n=5) to 21.4 +/-8.3d
(n=11; P=0.001).
Conclusions: IFNg-MdCs are a novel macrophage population capable of
deleting activated T cells and highly enriching remaining lymphocytes for
Tregs. These properties make this cell an attractive new cell therapy option for
promoting tolerance near the time of organ transplantation.

294 LIVER SINUSOIDAL ENDOTHELIAL CELLS
SUPPRESS ALLOIMMUNE RESPONSES VIA MHC CLASS II
RECOGNITION IN LIVER TRANSPLANTATION
M. Banshodani, M. Shishida, Y. Igarashi, Y. Tanaka, H. Tashiro, T. Asahara,
H. Ohdan
Department of Surgery, Hiroshima University
The liver is widely regarded as a tolerogenic organ. Although livers transplanted
across MHC barriers in mice are normally accepted without recipient immune
suppression, the underlying mechanisms remain unclear. To identify the cell
type contributing to the induction of such a tolerant state, we established a
mixed hepatic constituent cell-lymphocyte reaction (MHLR) assay. Irradiated
C57BL/6 (B6) or Balb/c mouse hepatic constituent cells (HCs) and CFSElabeled B6 splenocytes were cocultured. During the allogeneic MHLR
assay, whole HCs did not promote T cell proliferation. When liver sinusoidal
endothelial cells (LSECs) were depleted from among the HC stimulators by
magnetic cell sorting using anti-CD105 mAbs (an LSEC marker), allogeneic
MHLR induced marked proliferation of reactive CD4+ and CD8+ T cells,
suggesting possible tolerogenicity in CD105+ LSECs. Physical separation of
LSECs from responder-stimulator cells with a dual-chamber transwell culture
system in the allogeneic MHLR assay significantly reduced the suppressive
effects of LSEC on alloreactive CD4+ and CD8+ cell proliferation, indicating
that cell-cell contact was required for immunosuppression. Phenotypic analysis
by flow cytometry (FCM) confirmed that LSECs constitutively expressed all
molecules for antigen presentation (MHC class I, class II, CD40, CD80, and
CD86). To test the tolerance capacity of LSECs toward alloreactive T cells,
B6 splenocytes that had transmigrated in vitro through a monolayer of B6,
Balb/c, or SJL/j LSECs were restimulated with irradiated Balb/c splenocytes.
Nonresponsiveness and marked proliferation of T cells that had transmigrated
through allogeneic Balb/c LSECs and syngeneic B6 or third-party SJL/j
LSECs, respectively, were observed after the restimulation. Transmigration
across the FasL-deficient Balb/c LSECs failed to render the CD4+ T cells
tolerant. Thus, we demonstrated that FasL expressed on naive LSECs can
impart tolerogenic potential upon alloantigen recognition via the direct
pathway. The cells harvested after the allogeneic MHLR culture, using whole
HC stimulators including LSECs, were stained with annexin V along with
7-AAD. FCM revealed that the proliferation of 7-AAD-negative alloreactive
CD4+ and CD8+ T cells were detectable. These proliferating T cells during
the early stage of cell division were bound to annexin V. These findings are
consistent with a model wherein the FasL-induced apoptosis of alloreactive
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T cells activated in responses to LSECs is a critical event in induction of liver
allograft tolerance. We next established an in vivo model for evaluating the
immunomodulatory effects of LSECs on alloreactive T cells. LSECs isolated
from BALB/c mice were injected into recombinase-activating gene-2 (RAG-2)/
gamma-chain double knockout (WKO) B6 mice, lacking T, B, and NK cells,
via the portal vein (4 ~ 106/mouse). When orthotopic LSEC implantation into
the liver sinusoids was observed 7 d after the adoptive transfer, splenocytes
from wild-type B6 mice were intravenously injected into WKO B6 mice
via the tail vein (20 ~ 106/mouse). Seven days after splenocyte inoculation,
the mixed lymphocyte reaction (MLR) assay with splenocytes from these
recipients revealed specific inhibition of CD4+ T cell proliferation in response
to stimulation with irradiated Balb/c mouse splenocytes (n = 5). Thus, we
conclude that LSECs suppress alloimmune responses via MHC recognition
during allogeneic liver transplantation.

295 LIVER DENDRITIC CELLS ARE POTENT INDUCERS
OF REGULATORY T CELLS AND LIVER TRANSPLANT
TOLERANCE

296 CD25+GITR+ REGULATORY T CELLS PLAY AN
ESSENTIAL ROLE IN ALLOGRAFT PROTECTION
IN NON-LYMPHOPENIC TOLERISED PRIMARY TRANSPLANT
RECIPIENTS
A. Bushell, K. Wood
Nuffield Department of Surgery
Background and aims: Transient immunotherapy can lead to long-term
operational tolerance in rodent transplant models and in many cases, graft
survival correlates with the presence of induced CD25+CD4+ regulatory T
cells (Treg). However, unequivocal demonstration of function usually requires
adoptive transfer into lymphopenic hosts where homeostatic proliferation can
confound a clear interpretation of the ability of these cells to provide active
regulation of effector mechanisms. The aim of this study was to determine the
role of regulation in tolerised primary transplant recipients by specific targeting
of induced regulatory T cells.
Methods: CBA mice (H2k) mice were pre-treated with 200μg of the IgG2a antiCD4 antibody YTS 177.9 on days -28 and -27 plus a donor-specific transfusion
(DST) of C57BL/10 (B.10, H2b) blood on day -27. This induction protocol
leads to the indefinite survival of B.10 hearts transplanted on day 0 but more

Conclusion and significance: These data show that irrespective of the limitations
of adoptive transfer models for assessing Treg function, CD4+CD25+GITR+
T-regs play an essential role in early graft protection in primary transplant
recipients following tolerance induction. The data provide further support
for attempts to identify protocols that generate similar populations in clinical
transplantation.

297 THE POWERFUL T-CELL TOLERIZING
CONSEQUENCES OF BLOCKING EXPRESSION OF PRO-, NOT
ANTI-INFLAMMATORY MECHANISM
M. Koulmanda, L. Hoffman, A. Qipo, D. Hanidziar, H. Shi, Z. Fan, J.F. Flier,
T.B. Strom
Departments of Surgery and Medicine, Harvard Medical School, Transplant
Research Center, Beth Israel Deaconess Medical Center, Boston, MA
In hosts with diabetogenic auto-immunity, the onset of overt disease,
hyperglycemia, is known to coincide with loss of a critical portion of the islet
cell mass. Thus, restoration of a portion of the lost islet cell mass should be
sufficient to create euglycemia if a deficit in insulin producing tissue is the
sole cause of disease. It is notable that many potent T-cell tolerizing therapies
have failed to enable restoration of euglycemia in new onset T1D NOD mice
with or without transplantation of islets. Hence, we have searched for other
potentially complicating features, e.g. insulin resistance, that may serve as an
additional barrier to restoration of euglycemia. We now report that new onset
T1D is associated with inflammation induced insulin resistance created by
faulty phosphorylation of crucial elements of the insulin signaling pathway
(insulin receptor and IRS-1). To test the hypotheses that inflammation, insulin
resistance and T1DM disease expression are linked we have tested the effects
of select anti-inflammatory agents in T1DM NOD mice. We now report that
treatment for 15 days with alpha-1-antitrypsin (AAT) or 20 days with antiTNF-α (i) restores a euglycemic state in 14 of 16 or 22 of 24 treated new onset
diabetic NOD mice (ii) ablated insulin resistance and (iii) produces specific
tolerance to syngeneic, not acceptance of allogeneic, islets that is manifest
long after cessation of treatment of new onset diabetic NODs while preserving
other immune responses. In this experiment spontaneously diabetic (NOD-sp),
or formerly diabetic euglycemic AAT or anti TNF-α treated NOD rendered
diabetic with STZ (NOD-sp/stz) were transplanted with allogeneic or syngeneic
islets (see Table).
Recipients

Treatment

Normoglycemic/
Total # of mice used

None

NOD-sp

NONE

0/150

<60

None

NOD-sp

AAT

14/16

>300

None

NOD-sp

Anti-TNF-α

22/26

>300

NOD-scid

NOD-sp

NONE

5/5

14 –21 (n=5)

Donor (Islets)
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W. Li, R. Bakthavatsalam, K. Carper, J. Perkins, J. Reyes
University of Washington, Dept of Surgery, Div of Transplantation
Liver transplantation in mice results in spontaneous liver allograft acceptance and
subsequent systemic tolerance to other transplanted organs from the same liver
donor without requirement for immunosuppressive therapy. The mechanisms
underlying this phenomenon remain largely undefined. Our previous studies
have demonstrated that liver dendritic cells (DCs) and Foxp3+CD25+CD4+
regulatory T (Treg) cells contribute significantly to tolerance induction. Treg
appear to underpin the liver tolerance process. How Treg are induced and their
functional mechanisms in the regulation of liver transplant tolerance remain
undefined. In this study, we manipulated Treg induction in vitro by coculture of
CD4+ T cells and allogeneic liver DCs in the presence of TGF-beta and IL-2,
and examined the function of those Treg on inhibition of allogeneic immune
responses in vivo by adoptive transfer to the heart allograft recipients. We
further adopted Fms-like tyrosine kinase 3 ligand (Flt3L) mutation mice, which
have severe reduction in all types of DCs, to critically examine the role of liver
DCs in liver transplant tolerance in vivo by liver transplantation from Flt3L-/donors to allogeneic C3H recipients. Our results showed that liver DCs were a
more potent generator of Foxp3+CD25+CD4+ Treg. After 5-7 days culture at
1:4 ratio of DC:CD4 T cells, around 50% of CD4 T cells become CD25+ and
Foxp3+ compared to 25% in the spleen DC generated group. Adoptive transfer
of those CD4+ Treg generated from liver DC significantly prolonged heart
allograft survival compared to the CD4 treated controls. Moreover, the liver
grafts from Flt3L-/- mice were rejected acutely in the C3H recipients. MST was
6.3+/-2.3 days, P<0.001 vs 55+/-33 in WT controls. Immunohistochemistry
staining revealed that Foxp3+ cells were reduced, but IL-2, IL-10, and IFNgamma producing cells were increased significantly in the liver grafts and
recipient spleens from Flt3L-/- donors. Thus, liver DCs appear to have a critical
role in the induction of Treg, which underpin spontaneous acceptance of MHCmismatched liver allografts in mice.

importantly, generates CD4+ CD25+ Treg prior to transplant that prevent skin
graft rejection in a sensitive adoptive transfer model. To test for a link between
adaptive Treg and graft outcome in primary graft recipients, Treg were targeted
using either anti-CD25 antibody (PC61) or anti-GITR antibody (DTA-1). AntiCD25 antibody was delivered after tolerance induction but before transplant
(day -14), to manipulate induced regulatory cells in isolation from effector T
cells and anti-GITR antibody given peri-transplant (day -1 to +9.).
Results: Tolerised mice given a single dose of anti-CD25 antibody at a time
when adoptive transfer experiments had confirmed induced Treg to be present,
rejected their primary cardiac allografts acutely (a). A similar result was
obtained using the anti-GITR antibody DTA-1 (b). Importantly, acute rejection
in anti-GITR treated mice was not due to co-stimulation of effector cells since
rejection mediated by CD4+CD25- or CD8+CD25- T cells was not enhanced by
anti-GITR antibody and GITR cross-linking did not augment CD4+CD25- or
CD8+CD25- T cell proliferation in vitro in response donor APC as judged by
CFSE division history analysis (c).
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NOD-scid

NOD-sp/stz

C57BL/6

NOD-sp/stz

C57BL/6

NOD-sp/ stz
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250-300 days after
ATT or anti-TNF-α
treatment
NONE
250-300 days after
ATT or anti-TNF-α
treatment

11/11
20/20
7/7

>70 (n=11)
5 – 8 (n=20)
3 - 11 (n=7)

Despite cessation of therapy, remission of the diabetic state is durable
throughout long follow periods. Remarkably, treatments with agents that
primarily alter the fine texture of inflammation (as proven in our genome wide
DNA array studies), and may not directly target T cells restore self-tolerance
to beta cells in NOD-sp mice. In short, the restoration of euglycemia, selftolerance, and of and the faulty insulin receptor and IRS-1 phosphorylation
patterns can be corrected by treatment with alpha1 anti-trypsin (AAT), an
acute phase reactant with potent anti-inflammatory activity, and/or antiTNF-α.
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298 CASPASE INHIBITOR THERAPY SYNERGIZES WITH
COSTIMULATION BLOCKADE TO PROMOTE TOLERANCE
INDUCTION AND PREVENT ALLOSENSITIZATION IN ISLET
TRANSPLANTATION
J. Emamaullee1, J. Davis1, C. Toso1, S. Merani1, B. Tseng2, J. Shapiro1
1University of Alberta, 2Epicept Corporation
Background: Recent work has demonstrated that caspase inhibitor therapy
using EP1013 prevents early engraftment islet loss and thus markedly reduces
the human islet mass required to reverse diabetes in mice (Diabetes 2008). Data
investigating the ‘danger’ hypothesis suggests that reduction in graft apoptosis
should reduce the threshold for immunosuppression and potentially increase
the possibility for tolerance induction. Thus, the impact of combination of
EP1013 treatment with costimulation blockade therapies was investigated in
the present study.
Results: Islet allografts were completed in fully MHC-mismatched mice
(Balb to B6). Transplanted mice received either EP1013, anti-ICOS, CTLA4Ig, or combinations of these agents. When animals received vehicle, EP1013,
anti-ICOS, or EP1013+anti-ICOS, there was no difference in graft survival
(MST 16.8-27.5 days). CTLA4-Ig resulted in prolonged graft survival in
50% of the animals (MST 123.0 days), while EP1013+CLTA4-Ig resulted
in a significant increase in graft survival (91% >180 days; P=0.04). The
combination of CTLA4-Ig+anti-ICOS+EP1013 resulted in 100% graft
survival >180 days (N=8). Recovery nephrectomies were performed and
either same donor (Balb) or third party (C3H) islets were implanted to
test for tolerance. Retransplantation with Balb islets led to prolonged graft
survival in N=6/7 recipients, while use of C3H islets resulted in 100%
rejection, confirming donor-specific tolerance. Histological analysis of islet
grafts harvested from tolerant animals revealed low numbers of CD8+ and
CD4/Foxp3+ regulatory cells around the graft. Splenocytes harvested at
day 10 post-transplant revealed that animals receiving EP1013+CTLA4-Ig
have a reduced frequency of alloreactive IFNg-secreting T-cells (P<0.001
vs untreated controls; ELISPOT). Interestingly, animals receiving caspase
inhibitor alone had a significantly reduced frequency of alloreactive IFNgsecreting T-cells at day 10 post-transplant as well, even though this treatment
protocol results in no prolongation of graft survival. Alloantibody assays have
shown that our EP1013+CTLA4-Ig tolerizing protocol prevents both IgM and
IgG allosensitization (p<0.001 for IgM and p<0.05 for IgG vs. vehicle treated
animals). Further studies using in vivo tracking/proliferation assays and flow
cytometry are underway and should reveal the mechanism of caspase inhibitor
mediated tolerance induction in this model.
Conclusion: This study suggests that addition of caspase inhibitor therapy to
known immunomodulatory agents will improve clinical islet transplantation
by minimizing immune stimulation and thus reduce or negate the requirement
for long term immunosuppressive therapy. The approach also prevents
allosensitization, which may be an important component of chronic graft loss
in clinical islet transplantation.
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299 COMBINATION OF ANTI-LFA-1 AND ANTI-CD154
MONOCLONAL ANTIBODIES INDUCES TISSUESPECIFIC TOLERANCE TO NEONATAL PORCINE
ISLET XENOGRAFTS
H. Arefanian1, E.B. Tredget1, R.V. Rajotte1, R.G. Gill2, G.S. Korbutt1,
G.R. Rayat1
1Alberta Diabetes Institute, Department of Surgery, University of Alberta,
2Alberta Diabetes Institute, Department of Medical Microbiology and
Immunology, University of Alberta
Background: A variety of transient therapies directed against T lymphocyte
activation and function result in long-term islet allograft survival. However,
there are relatively few examples of durable islet xenograft survival using
similar short-term approaches, especially regarding highly phylogeneticallydisparate xenograft donors. Our previous study demonstrate that combined
anti-LFA-1 and anti-CD154 monoclonal antibody (mAb) therapy results in a
robust form of islet xenograft protection not observed with either individual
monotherapy. The aim therefore of this study was to determine whether
tolerance to islet xenografts could be achieved by transient blockade of
adhesion and co-stimulatory pathways using monoclonal antibodies.
Methods: Streptozotocin-induced diabetic B6 mice were transplanted with
2000 neonatal porcine islets (NPI) under the left kidney capsule and were
treated with short-term intraperitoneal injections of a combination of antiLFA-1 and anti-CD154 mAbs. Blood glucose levels (BGLs) were monitored
for 100 days post-transplantation at which time, all of the mice achieved
normoglycemia. The mice were randomly divided in two separate groups:
Group 1- mice were re-transplanted with a second party NPI. BGLs were
monitored for another 100 days and a survival nephrectomy of the first graftbearing kidney was performed. BGLs were measured for an additional 100
days to monitor the function of the second party NPI graft and a nephrectomy
of the second graft-bearing kidney was performed to determine that euglycemia
was graft-dependent. Group 2-mice were transplanted with full-thickness skin
from allogeneic BALB/c mouse or xenogeneic neonatal pig donors. Skin grafts
were inspected daily until the time of graft rejection, defined as necrosis of
the graft. In a parallel experiment, skin transplantation was also performed on
naïve immune-competent B6 mice and immune-deficient B6 rag-/- mice as
control groups. NPI xenografts and spleen cells from tolerant B6 mice were
harvested for further characterization using immunohistochemistry, RT-PCR
and flow cytometric analyses.
Results: Short-term administration of a combination of anti-LFA-1 and
anti-CD154 mAbs resulted in prolonged (>100 days) NPI xenogaft survival
in 40/40 B6 mouse recipients. The NPI xenografts contained well-preserved
islets with few mononuclear cells surrounding the NPI. Flow cytometric
analysis of spleen cells from tolerant mice demonstrated that CD4+ T cells
have higher expression of CD25, foxp3, PD-1, and CTLA-4 compared to that
found on naïve B6 mouse spleen cells. In addition, the expression of GITR on
CD4+CD25+ T cells was higher compared to the expression found on naïve B6
mouse spleen cells. RT-PCR and immunohistochemistry analyses of the grafts
from tolerant B6 mice showed high expression of IL-10 and TGFβ; cytokines
as well as foxp3, respectively. All of the mice (n=5) transplanted with a second
party NPI xenograft maintained normoglycemia for over 100 days post-harvest
of the first graft-bearing kidney. In contrast, all of the mice transplanted with
allogeneic BALB/c (n=5) or xenogeneic second party pig skin (n=5) rejected
their grafts (10.8 ± 0.66 and 15.8 ± 1.65, respectively).
Conclusion: These results show that a short-term administration of a
combination of anti-LFA-1 and anit-CD154 mAbs induces tissue-specific
tolerance to NPI xenografts and strongly suggest that this strategy may be
useful in clinical islet xenotransplantation.
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300 TARGETING OF COSTIMULATION BLOCKADE
RESISTANT T - EFFECTOR MEMORY (TEM) CELLS IN NONHUMAN PRIMATE RENAL TRANSPLANTATION WITH LFA-3IG (ALEFACEPT) PROLONGS ALLOGRAFT SURVIVAL
1

1

1

1

p-value
compared to
Group 7

Treatment Group

Rejection Free Survival

1. No Treatment

5, 6, 7, 7, 8

2. Sirolimus Alone

8, 10, 21, 23, 28

0.021

3. Sirolimus, DST

10, 6, 5

0.016

0.015

4. CTLA4-lg, Sirolimus, DST

13, 33, 44

0.028

5. LFA3-lg, Sirolimus, DST

18, 41, 49

0.033

6. CTLA4-lg, LFA3-lg, Sirolimus

80, 83, 131

0.336

7. CTLA4-lg, LFA3-lg, Sirolimus, DST

56, 105, 108,>168,>243

–

301 EMBRYONIC STEM CELL-DERIVED CXCR4+
DEFINITIVE ENDODERMAL PROGENITOR CELLS CORRECT
FACTOR VIII DEFICIENCY IN MICE
N. Zavazava2,4, K-M. Chan1,2, L. Xie3, M.E. Sarvida3, P.B. McCray Jr3,
W-C. Lee1,
1
Department of General Surgery, Linkou Chang Gung Memorial Hospital,
Chang Gung University College of Medicine, Taoyuan, Taiwan, 2Department
of Internal Medicine, University of Iowa and Veteran Affair Medical Center,
Iowa City, Iowa, USA, 3Department of Pediatrics, University of Iowa, Iowa
City, Iowa, USA, 4Division of Allergy/Immunology, University of Iowa, Iowa
City, Iowa, USA
Hemophilia A is a widespread common disorder caused by the abnormality of
plasma coagulation factor VIII (FVIII). Protein and serum product replacement
treatments as well as gene therapy for this condition unfortunately remain
unsatisfactory. Here, we exploited the pluripotent properties of embryonic stem
(ES) cells, to determine whether newly differentiated definitive endodermal
(DE) cells cure FVIII deficiency in a mouse model. Initially, enhanced Green
Fluorescence Protein (eGFP) transduced ES cells were cultured in a serum-free
medium containing Activin A and bFGF for 6- 8 days, then the differentiated
cells developed into an epithelial monolayer yielding more than 70% of CXCR4
expressing cells. The CXCR4+ cells were purified using immunomagnetic
bead separation to more than 99% purity. Molecularly, the CXCR4+ cells
express typical definitive endodermal genes in particular, FoxA2, Sox-17,
GSC, and HNF4£\. The CXCR4+ DE cells were then transplanted into carbon
tetrachloride (CCL4)-treated FVIIInull mice. The recipient mice were bled
and sacrificed at determined time point to determine the FVIII activity and
engraftment of DE cells, respectively. We found that DE cells not only readily
engrafted in the liver of recipient mice but also corrected FVIII activity of
FVIIInull mice. Genetic analysis and immune-fluorescence staining confirmed
that DE-derived cells were responsible for the production of FVIII. These results
demonstrate that ES cell-derived DE cells could further differentiate into liver
parenchymal cells as well as correct FVIII deficiency in a Hemophilia A mouse
model, suggesting an approach that could find application in the treatment of
hemophilias and possibly acute liver failure in humans.

302 HOXB4 REGULATES DIFFERENTIATION OF
HEMATOPOIETIC PROGENITOR CELLS FROM EMBRYONIC
STEM CELLS
N. Zavazava1, S. Bonde1, K.N. Chan2, W. Tabayoyong1
1University of Iowa and VAMC Iowa City, USA, 2Chang Gung University
College of Medicine, Taiwan
Embryonic stem cells are pluripotent, providing a great opportunity for
their manipulation into cells that could be used for the treatment of disease.
In transplantation, generating hematopoietic cells is of interest as these cells
may potentially be less immunogenic than bone marrow cells currently used to
induce mixed chimerism. More importantly, the newly developed cells lack selfrenewal properties, dying due to apoptosis after a few weeks in culture or in vivo.
Thus, a number of approaches have been pursued to improve on the generation
of hematopoietic cells. Incubation of ES cells with BMP4, a TGF-â homologue,
results in the upregulation of a number of genes including that of HOXB4, a
hematopoietic transcription factor that has been shown to promote proliferation
of hematopoietic stem cells. Transduction of ES cells with the HOXB4 gene
resulted in 100-1000fold growth advantage of CD45+ hematopoietic progenitor
cells. These cells hardly express MHC antigens. Transplanted in Rag2-/-ãc-/mice, they fully reconstituted bone marrow. To determine the efficacy of these
newly derived cells to engraft across MHC barriers, we transplanted them in
allogenic MRL or Balb/c mice. The cells engrafted long-term after sublethal
irradiation of the recipient mice, without the use of immunosuppression. These
chimeric mice were tolerant to donor-derived allografts, suggesting that the low
immunogenicity of these cells gave them an advantage over bone marrow cells
that are acutely rejected. Grafts were free of infiltrating cells and any signs of
chronic rejection. Studies on the T cell repertoire of these mice showed that
tolerance was not due to clonal deletion but rather due to T cell anergy. Thus, our
data show that high numbers of CD45+ hematopoietic progenitor cells can be
derived from embryonic stem cells and that these cells are poorly immunogenic
engrafting across MHC barriers. More importantly, they induce graft tolerance
without severe pre-conditioning.
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A. Kirk , T. Weaver , A. Charafeddine , A. Agarwal , F. Leopardi , R.
Kampen1, M. Starost2
1
Emory Transplant Center, Atlanta, GA, 2Veterinary Pathology, NIH,
Bethesda, MD
Costimulation blockade (CoB) of the CD28/B7 pathway has long been
suggested as a means of attaining indefinite, well-tolerated, antigen-specific
prophylaxis from allograft rejection. Although effective in rodent models,
CD28/B7 blockade is not alone sufficient to prevent rejection in more robust
primate models, including humans. The relative presence of allo-crossreactive
T effector memory (TEM) cells, is one mechanism of CoB resistant rejection.
Leukocyte functioning antigens (LFAs) found on the extracellular surface
of antigen presenting cells (APCs) and some activated parenchymal cells
contribute to the development of an immune response, however their potential
as therapeutic targets in transplantation remains to be elucidated. LFA3-Ig is an
approved agent for the treatment of psoriasis, shown clinically to specifically
deplete TEM cells in psoriatic lesions and peripheral blood. We hypothesize
that LFA3-Ig specifically targets CoB resistance cells, including heterologous
alloreactive T cell memory, while avoiding interference with peripheral
mechanisms that foster CoB-mediated allograft acceptance. To study this,
rhesus monkeys underwent MHC mismatched renal allotransplantation,
following confirmation of donor-recipient alloreactivity by MLR. CTLA4-Ig,
abatacept, CD28/B7 costimulation blocker was given 20 mg/kg IV on days -1,
0, 3, 7, 14, 21, 28 and 10 mg/kg IV on days 35, 42, 49, 56. LFA3-Ig, (0.3 mg/
kg IV) was given on day -1, 0, 3, 7 then weekly for a total of 8 wks. Sirolimus
was given orally (1mg/kg) on days 0 - 90 and donor specific transfusion (7 ml/
kg IV) on day -1. Animals were followed by polychromatic flow-cytometry to
quantify T cell subsets. Primary end point, allograft rejection, was determined
by a significant rise in serum creatinine and BUN. Renal allografts were
removed for histological and transcriptional studies, along with splenocytes
for immune function assays. LFA3-Ig synergized with CTLA4-Ig successfully
preventing renal allograft rejection in this model and leading to indefinite
survival in 2/5 animals (Table). This enhanced survival was associated with a
significant reduction in TEM cells in animals treated with LFA3-Ig compared
to animals without LFA3-Ig treatment (Figure). LFA3-Ig withdrawal led to
TEM re-population and rejection. This regimen, consisting of all clinically
available agents, promotes CoB-mediated graft acceptance without the use of
calcineurin inhibitors, steroids, or gross T cell depletion.
1
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303 USE OF MURINE MESENCHYMAL STEM CELLS TO
EXPRESS DONOR-DERIVED MHC CLASS I MOLECULES FOR
DONOR-SPECIFIC IMMUNOSUPPRESSION
C. Graeb1, K-W. Jauch1, C. Zuelke2, E. K. Geissler2, P. Camaj1
Dept. of Surgery, 2Dept. of Surgery
Aims: Graft rejection and multiple side effects of current immunosuppressants
are still of major concern in organ transplantation. Therefore, the introduction of
a donor-specific immunosuppression without conventional immunosuppressive
drugs is one of the main goals for the future. In previous experiments we
were able to show that donor-derived soluble MHC class I molecules have
the potential to downregulate in a donor specific manner the immune system
of organ recipients. In the past, viral vectors, among others, have failed to
express sufficient amounts of these molecules to induce a tolerogeneic state.
In our current experiments we describe the use of immortalized mesenchymal
stem cells (MSC), which by themselves have immunoregulatory capacities to
express donor derived soluble MHC molecules.
Methods: Gene construct: PCR cloning of the mouse MHC class I gene H2Dd
specific for the strain DBA2 was applied. RNA from mouse spleen was isolated
and amplified by RT-PCR using the Superscript III one step RT-PCR system
and cloned using Platinum High Fidelity Taq and TOPO into the pcDNA3.2
GW/V5 vector.
Soluble H2Dd gene construct: fusion of the gene fragments H2Dd with
the region of the soluble rat MHC molecule Q10a was performed by PCR
(H2DdQ10a) after identification by protein sequencing analysis. According to
cloning of the soluble form, the membrane bound form of H2Dd was cloned,
followed by transfection of mMSC with linear DNA.
Western blotting: membrane-bound MHC molecules were prepared from cell
lysates in Complete M EDTA-free lysis buffer, the soluble form was isolated
from culture supernatants by ultra-centrifugation through Vivaspin 500
columns. Proteins were separated using 12% SDS-PAGE, transferred to PVDF
membranes and detected by HRP anti-H2Dd antibodies (Ab).
FACS: FACS analysis of transfected cells was performed using anti-H2Dd-Ab,
FITC-anti-mouse-Ab, and anti-idiotypic-Ab as negative controls.
ELISA: in order to quantitatively evaluate expression of soluble or membranebound MHC molecules a H2Dd specific ELISA was developed using a
biotinylated-anti-H2Dd-Ab.
Results: By using the described PCR cloning technique, soluble (H2DdQ10a)
as well as the membrane-bound H2Dd were generated as confirmed by
sequencing analysis. Subsequent stable transfection of immortalized recipient
derived MSC (C57 BL/6) was confirmed by Western blotting and FACS
analysis. Quantitative expression of both forms of MHC molecules by antigenspecific ELISA revealed amounts (1000-1600ng/ml/1x106 cells) comparable
to those detected in our previously used hepatocyte cultures. After i.v. cell
injection of GFP transfected mMSC, cells were detectable in liver, lung, spleen,
and peripheral lymph nodes.
Conclusion: Our results show that mMSC can be used to efficiently express
adequate amounts of donor-derived MHC molecules in both, soluble and
membrane-bound forms. The use of immortalized MSC in general may
potentially add to a immunosuppressive effect induced by the soluble form of
donor MHC molecules.
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304 REGENERATIVE CELLULAR THERAPY: POSITIVE
REMODELING AFTER MYOCARDIAL INFARCTION USING IV
INJECTED MESENCHYMAL STEM CELLS AND CYTOKINE
ENHANCEMENT
S. Schrepfer, T. Deuse, W. Stein IV, R.C. Robbins, M.P. Pelletier
Department of Cardiothoracic Surgery, Stanford University School of
Medicine, USA
Purpose: The injured myocardium is thought to release signals via the blood
stream to mobilize stem cells from their major reservoir, the bone marrow, into
the circulation. However, additional local cytokine enhancement (CE) might be
necessary to attract stem cells to the site of myocardial injury and to stimulate
the immigrated stem cells to support tissue remodeling.
Methods:
MSCs were stably transfected with firefly luciferase for bioluminescence
imaging (BI), and labeled with CSFE for histology (H). High-throughput
proteomics and a battery of in vitro assays were used to profile 20 key cardiacspecific cytokines upregulated following MI for their effects on the biologic
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performance of MSCs. The next steps were to enrich the infarcted areas with
those cytokines that were found to be effective to fortify the injury signals and
to increase the number of IV injected MSCs migrated to the heart to strengthen
the stem cell-based repair potential. After LAD ligation, mice received IV MSC
injections and were closely monitored by in vivo BI and H. To investigate a
possible improvement of the contractile heart function by migrated MSCs, the
ejection fraction (EF), LVEDV, and LVESV were measured by a specifically
designed small animal micro-CT. Therefore, animals were scanned before, 24
hours, two weeks and six months after LAD ligation/MSC injection.
Results: Due to their large size (19um), huge amounts of IV-injected MSCs
were trapped within the pulmonary capillaries. Homing of IV-injected MSCs
into ischemic myocardium after LAD ligation was very inefficient and only
1±0.5 fluorescent positive MSCs per HPF were detected. Additional CE with
HGF 40ng/ml or VEGF 8ng/ml, however, significantly increased the MSC
homing to 11±4 cells/HPF and 7±4 cells/HPF, respectively (p=0.001 each). The
figure shows CT images of longitudinal and transversal axis of left ventricles,
captured in the systole. The CE-treated hearts showed no significant short term
benefit (14d measurements) in ventricle geometry (LVEDV, LVEDV) and EF.
However, after 6 months, a positive remodeling could be demonstrated for the
CE-treated hearts (see figure).
Conclusions: Positive remodeling after myocardial infarction can be achieved
by MSC injection combined with CE enhancement in the border zone to attract
IV delivered MSCs and to create a beneficial microenviroment.

305 PREVENT REMODELING AND REPAIR INFARCTED
MYOCARDIUM BY AUTOLOGOUS INTRACORONARY
MESENCHYMAL STEM CELLS MODIFIED WITH AKT IN
SWINES
Z. Shen1, Y. Yu2, W. Ye3, P. Jiao4, H. huang5, M. He6
1The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University, 4The First Affiniatied Hospital of Soochow University, 5The First
Affiniatied Hospital of Soochow University, 6The First Affiniatied Hospital of
Soochow university
Objective: This study aimed to engineer swine bone marrow-derived MSCs
to overexpress AKT1 and test the hypothesis that AKT1-engineered MSCs
were more resistant to apoptosis and could enhance cardiac repair after
transplantation into the ischemia swine heart.
Methods: MSCs were isolated from bone marrow and purified by centrifuge.
The proliferation and growth characteristics were observed in primary and
passage culture. Cell cycle was analyzed by measuring DNA content with
flowcytometer. The CDS (regulation domin of AKT1)AKT1-cDNA fragment
was amplified, then pPACKH1- Lentivector Packaging Kit was used to
transfect Mesenchymal stem cells. MI models were created by occluding
the distal LAD in 24 MEISHAN pigs£¨21-25 ©K£© with gelatin sponge.
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306 MESENCHYMAL STROMAL CELLS IN
RENAL TRANSPLANTATION: MIGRATION AND
IMMUNOMODULATION
S. McTaggart1,2, B. Jones1, G. Brooke1, C. Tracey1, L. Francis3,
K. Atkinson1,2
1
Mater Medical Research Institute, 2University of Queensland, 3Pathology
Queensland
Introduction: Mesenchymal stromal cells (MSC) migrate to sites of ischemic
damage and are immunosuppressive in vitro, making them attractive potential
candidates for immunotherapy in renal transplantation. In this study, we
assessed the migratory and immunomodulatory potential of MSC in a rat renal
transplant model.
Methods: MSC were isolated from rat bone marrow and characterised by both
surface marker expression and differentiation into osteogenic, chondrogenic
and adipogenic lineages. Orthotopic transplantation of the right kidney
was performed using fully mismatched rats (DA to Lewis) with syngeneic
transplants (Lewis to Lewis) as controls. PVG strain MSC (10-15x106)
were injected into the femoral vein of recipient rats at the time of transplant.
Immunohistochemistry was used to localise injected MSC and clinical course
was assessed by measurement of serum creatinine and histology of transplanted
kidneys. Rejection was assessed by a pathologist blinded to treatment group
and graded according to Banff criteria.
Results: MSC had typical cell surface phenotype, differentiation capacity
and were immunosuppressive in vitro. Third-party MSC injected into rats at
the time of allogeneic renal transplant were shown to preferentially migrate
to transplanted kidneys. However, MSC infusion failed to attenuate transplant
rejection with no significant difference in histology and serum creatinine
between allogeneic transplants and syngeneic control animals. Additionally,
the immune phenotype of splenocytes, as assayed by flow cytometry using a
panel of antibodies, was not modified by MSC treatment. In addition, in these
experiments there was no significant effect of MSC administration on serum
IDO activity.
Conclusion: Although in vitro studies have suggested a potential role for
MSC as a cellular immunosuppressive therapy, this data suggests this may not
translate directly into the in vivo setting of renal transplantation.

307 HEPATIC STELLATE CELLS MORE EFFECTIVELY
PROTECT ISLET ALLOGRAFTS THAN BONE MARROWDERIVED MESENCHYMAL STEM CELLS
H-R. Yang1, Z. Yin2, J. Fung1, L. Lu1,2, S. Qian1,2
1
Department of General Surgery, Cleveland Clinic, 2Department of
Immunology, Lerner Research Institute, Cleveland Clinic
The tolerogenic property of the liver has been demonstrated by spontaneous
acceptance of liver allografts, as well as tolerance to antigens that are delivered
through portal vein in many species. The involved mechanisms are not
completely understood. Although liver allografts are accepted in mice, but
hepatocytes transplants in same combination are acutely rejection, suggesting
a crucial role of liver non-parenchymal components (NPC) in protecting
parenchymal cells from immune attacks. We have demonstrated that hepatic
stellate cells (HpSC), well known to participate in liver fibrogenesis, markedly
inhibit T cell responses in vitro and protect co-transplanted islets allografts from
rejection in a mouse islet transplant model. Mesenchymal stem cells (MSC) have
also shown immune inhibitory activity. The aim of this study was to compare
the immunosuppressive effect of HpSC and MSC. To test the inhibition of T
lymphocyte proliferation in vitro, irradiated B6 (H-2b) HpSC or bone marrowderived MSC were added to a mixed leukocyte reaction where irradiated
BALB/C (H-2d) dendritic cells and B6 spleen T cells were used as stimulators
and responders respectively. To determine the immunosuppressive activity in
vivo, B6 HpSC or MSC were mixed with islets isolated from BALB/C pancreata
and transplanted under the capsule of the left kidney of Streptozocin-induced
diabetic B6 mice. Transplant of islets alone was used as control.B7-H1 knockout
mice were used to examine the role of B7-H1 in the immunomodulatory effect.
Both HpSC and MSC markedly inhibited T cell proliferative responses in MLR
in a dose dependent manner. At a T:DC:HpSC (or MSC) ratio of 10:1:1, T cell
thymidine uptake was almost completed inhibited by HpSC or MSC. None of
mice in the control group remained euglycemic by 15 days after transplant.
Co-transplant with MSC prolonged islet graft survival [medium survival time
(MST) 28days, compared to11days in islet grafts alone group]. Co-transplant
with HpSC markedly prolonged islet graft survival (MST>60days). 55% of
recipients that received islets plus HpSC remained euglycemic for more than
60 days. Expression of B7-H1 was up-regulated both in activated HpSC and
MSC, and was crucial in their immune regulatory activity. Cotransplantataion of
HpSC or MSC from B7-H1 knockout mice largely lost their capacity to protect
islet allografts from rejection (HSC, MST=26 vs >60, p<0.05; MSC, MST=14
vs 28, p<0.05). Immunohistochemical studies demonstrated a multiple-layered
capsule surrounding the islets formed by co-transplanted HpSC. However, this
multiple-layered capsule was not observed in co-transplantation with MSC. In
conclusion, both HpSC and MSC have strong capacity to inhibit an ongoing
allogeneic response in vitro. Co-transplantation with HpSC or MSC can protect
islet allografts from rejection. However, MSC are far less effective than HpSC
in this protective activity.
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HEPATOCYTE BASED INSULIN GENE THERAPY

H. Sollinger, T. Alam, D. Held, E. Forsberg
Surgery Department, University of Wisconsin, Madison, WI, U.S.A.
Gene-therapy based glucose-regulated hepatic insulin production is a promising
strategy to treat Type I diabetes. We have previously shown that hepatocytes
engineered with the insulin gene construct 3SAM2 (which has a liver-specific
albumin promoter coupled with 3 glucose inducible regulatory elements
(GIRE)s from the S-14 gene and a proinsulin gene modified for furin cleavage)
corrected fasting hyperglycemia, improved glucose tolerance, and stabilized
body weights in streptozotocin (STZ)-induced diabetic rats. However, due to
insulin insufficiency, postprandial hyperglycemia was not fully corrected and
weight loss in experimental animals was not reversed.
To increase the insulin output we generated a new insulin gene construct
(TA1). The new construct contains an additional translational enhancer
derived from vascular endothelial growth factor and the 3’-UTR from
albumin. TA1 retained glucose responsiveness and caused 20-30 fold higher
insulin production in isolated hepatocytes when compared to the old 3SAM2
construct. In this study, STZ-diabetic rats were treated with the TA1 insulin
gene construct. Our construct corrected fasting hyperglycemia during the first
4 weeks (treated diabetic rats (n=4): 117±31 mg/dl; STZ-diabetic rats (n=7):
457±83 mg/dl; normal rats (n=4): 94±15 mg/dl) and significantly (P<0.0001)
reduced postprandial hyperglycemia (treated diabetic rats (n=4): 374±51 mg/
dl; STZ-diabetic rats (n=7): 619±118 mg/dl; normal rats (n=4): 130±11 mg/
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The cardiac function was evaluated by magnetic resonance image(MRI)
measurements and echocardiography 4 weeks later. All the pigs were divided
into four groups: the control group(Group A, n=6), the DMEM group(Group B,
n=6), the MSCs group(Group C, n=6), and the AKT-transfected group(Group
D, n=6). The MSCs were transfected with the AKT1 gene (Group D).Then
autologous BrdU labeled stem cells(1¡Á107/5 mL) was injected into LAD of
the infarct heart by transcatheter in the group C and D. In the group B, 5 mL
DMEM was injected in the same distraction by same approach. In group A,
without injecting anything after occluding the LAD. Then after 4 weeks later,
the cardiac function and regional perfusion measurements were repeated by
MRI and Echocardiography, and the histological characteristics of the hearts
were also studied to assess MSCs engraftment. CX-43, BrdU and VWF were
tested with ELISA. VEGF, TGF-¦Â1were analysised in the same time.
Results: Before the cells implantation, the LV end-diastolic dimension(EDLVd)
increased and the stroke volume(SV) decreased in the MI hearts. After the cells
implantation, the MRI scans showed that the cardiac function was significantly
improved(compared with pre-implantation, P<0.05), and the implanted MSCs
prevented the infarct region from thinning and expanding, improved contraction
and increased perfusion in all groups relative to the control hearts(P<0.05).
The left ventricular chamber size were smaller (P<0.05) in the hearts with
being transplanted cells than that in the control hearts (P<0.05). Also, the
improvement was even markedly greater in Group D (compared with Group C
and B). The level of VEGF reached a¡¡high level 1 week after implanting the
MSCs£¬ but the level of TGF-¦Â1 decreased gradually.
Conclusion: MSCs could improve the cardiac function by attenuating
contractile dysfunction and pathologic thinning in this model of left ventricular
wall infarction. This improvement might result from myocardial regeneration
and angiogenesis in injured hearts by engrafted cells. Some cytokines played an
important role in repairing the ischemic myocardium. The overexpression AKT
of MSCs could resist apoptosis that caused by the ischemia microenvironment,
which was devoid of nutrients and oxygen, and the therapeutic benefit was more
powerful than that of MSCs. Combined gene transfer and cell transplantation
strategies will be an effective approach for the treatment of MI.
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dl). Although the blood glucose levels gradually increased over the 6 months
of study, the reduction in blood glucose levels of TA1 treated animals remained
significant (d73-103 measurements, mean±SDev: 248±140 vs 439±162 mg/
dl; P<0.0001).
For the first time we have observed significant weight gain in diabetic rats.
As shown in the figure, during the first four weeks, the rate of weight gain in
insulin gene treated rats was statistically indistinguishable from that of normal
rats. Beyond the initial one month period, treated rats continued to gain weight
but at a reduced rate. The overall benefit of a single insulin gene treatment on
body weight can last up to 6 months.
Our data demonstrates that the new and enhanced insulin gene construct was
able to greatly improve glucose-dependent hepatic insulin secretion in vivo. Our
construct established fasting euglycemia without any signs of hypoglycemia
and restored lasting weight gain. This study supports the feasibility of a gene
therapy-based future treatment for type I diabetes.

TUESDAY

309 COMPLETE REVERSAL OF STZ INDUCED DIABETES
USING ADULT PDPC CELLS
P. Shiels1, L. McGlynn1, D. Chen2, K. Stevenson1, A. Dorling2, A. MacIntyre1,
R.W. Davies1
1University of Glasgow, 2Imperial College London
Introduction: Cellular therapies hold potential for the treatment of diabetes.
Evidence that candidate cells which might fulfill this role, reside in the pancreatic
ducts, has been provided by rodent models of pancreatic regeneration. We have
sought to isolate such cells and demonstrate that they can mitigate the effects
of diabetes in vivo.
Methods: Novel candidate cells were isolated from adult rat and human
pancreatic ducts and characterized by ICC, FACs and RT-PCR. The ability
of these cells to mitigate the effects of diabetes was assessed in a doubleblinded trials in a xenogeneic mouse model of streptozotocin-induced diabetes
mellitus. Female C57Bl/6 mice (n=4 per treatment group) were made diabetic
by injection of streptotozocin (STZ) at a dose of 250 mg/kg on day 0 of the
experiment. PDPCs were injected into the tail vein on day 3 after STZ injection.
Control animals were given no cells. Blood glucose was monitored every 3
days. All procedures were conducted under authority of the UK Home Office.
Results: Direct intravenous injection of either rat, or human, PDPCs into STZ
diabetic mice, completely normalizes blood glucose levels for over 100 days
(Figure 1). Body weight and pancreatic histology in treated animals also appears
normal. Crucially, the insulin produced in these treated animals is principally
mouse in origin and is of both type I (embryonic) and II (adult). Human and
rat PDPCs do not appear to integrate into reconstituted islets in the respective
treatment groups. Detection of human or rat chromosomes in these groups
is at a frequency of less than 0.007% in These data indicate that the primary
mechanism of PDPC action is by stimulation of host tissue to regenerate.
Discussion: These results described for the first time the use of an adult human
cell type to achieve complete correction of diabetes in a rodent model for an
extended period of time. The results reproducibly demonstrate the feasibility of
using adult cells to regenerate damaged tissue and enhance our understanding
of the mechanisms relating to such repair. Furthermore, they suggest a means
for novel therapeutic intervention in diabetes.
Figure 1
Time course of blood glucose levels in STZ diabetic mice (n=4) treated with
PDPC cells. Group A: Control. Group B: Rat PDPC. Group C: Rat PDPC sub
population A. Group D: Rat PDPC sub population B. Group E: Human PDPC.

110

CONCURRENT ORAL SESSION 27:
ANITBODY AND COMPLEMENT
310 SPECIFIC INHIBITOR OF PLASMINOGEN ACTIVATOR
INHIBITOR-1 ATTENUATES MYOCARDIAL CELL
INFILTRATION AND GRAFT ARTERIAL DISEASES IN
MURINE CARDIAC ALLOGRAFTS
J-I. Suzuki1, M. Ogawa1, S. Muto2, Y. Yamaguchi2, A. Itai2, M. Isobe1
1
Tokyo Medical and Dental University, 2Institute of Medicinal Molecular
Design
Background: Acute rejection and graft arterial disease (GAD) in cardiac
transplantation limits the long-term survival of recipients; these processes are
enhanced by inflammation and thrombus formation. Plasminogen activator
inhibitor-1 (PAI-1) is critical in inflammation and thrombus formation.
Methods: To test the hypothesis that inhibition of PAI-1 can attenuate acute
rejection and GAD, we performed administration of the specific PAI-1 inhibitor
(IMD-1622) into murine recipients of cardiac allografts. Murine hearts were
heterotopically transplanted using major mismatch combinations for evaluation
of acute rejection and class II allomismatch combinations for GAD.
Results: Nontreated allografts of the major mismatch group were acutely
rejected (7.3 +/- 0.2 days), while the PAI-1 inhibitor prolonged their survival
(13. 7 +/- 2.4 days, p< 0.05). While severe cell infiltration and intimal thickening
with enhancement of inflammatory factors were observed in untreated allografts
(cell infiltration; 40.77 +/- 3.32%, intimal thickening; 28.60 +/- 6.35%) in the
class II mismatch group on day 60, the PAI-1 inhibitor attenuated these changes
(cell infiltration; 25.80 +/- 1.88%, intimal thickening; 8.07 +/- 3.46%, p< 0.05
respectively). RPA revealed that the PAI-1 inhibition markedly increased the
IL-10 (a Th2 cytokine)/ IFN-gamma (a Th1 cytokine) ratio compared with
that of the non-treated group. In vitro study showed that the PAI-1 inhibitor
suppressed antigen-induced T cell proliferation. ELISA analysis using
supernatants of the cell proliferation assay revealed that production of IFNgamma by the PAI-1 inhibitor treatment was suppressed (125.84 +/- 5.26 ƒÊg/
ml) in comparison to the control group (228.47 +/- 12.66 ƒÊg/ml, p< 0.05).
Conclusion: The PAI-1 inhibitor is potent for the suppression of both allograft
rejection and GAD because they are critically involved in the development of
rejection through the suppression of inflammation and thrombus formation.

311 PLASMA LIPIDS INFILTRATE ARTERIAL ALLOGRAFTS
AND ACCELERATE THE DEVELOPMENT OF TRANSPLANT
ARTERIOSCLEROSIS
A. Schiopu, S. Nadig, K.J. Wood
Transplantation Research Immunology Group, Nuffield Department of
Surgery, John Radcliffe Hospital, Oxford University, United Kingdom
Introduction: Transplant arteriosclerosis (TA), defined as diffuse intimal
hyperplasia in arteries of the transplanted organs, is the main pathological
process leading to chronic allograft rejection. Although this process is
mainly immune mediated, there are other important non-immune factors
that contribute to the pathogenesis of transplant arteriosclerosis. Lipid levels
are generally increased in transplant patients and lipids are known to be
heavily involved in the pathogenesis of native atherosclerosis in the general
population. Nevertheless, the relative importance of lipids for chronic
rejection is still unknown.
Material and methods: We have studied the influence of the lipid environment
on the development of transplant arteriosclerosis in a fully mismatched arterial
interposition graft model. CBA (H2k) arterial grafts were transplanted into
the abdominal aorta of C57Bl/6 (H2b) ApoE-/- mice kept on normal diet or
on a high-fat diet. Normolipidaemic wild-type C57Bl/6 recipients served as
controls. Due to impaired cholesterol transport and clearance, the ApoE-/- mice
have very high cholesterol and triglyceride plasma levels which are further
exacerbated when the mice are kept on a high-fat diet. The arterial grafts were
harvested 7 or 21 days after transplantation and we assessed the extent of
transplant arteriosclerosis, cellular and lipid infiltration into the neointima and
the expression of VCAM-1 on the endothelium, as well as plasma cholesterol
levels. The extent of transplant arteriosclerosis was expressed as percentage
of the area inside the internal elastic lamina which is occupied by the newly
formed neointima.
Results: Twenty-one days after transplantation CBA vessels transplanted into
the hyperlipidaemic ApoE-/- mice presented a 100% increase in transplant

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Oral Abstracts
arteriosclerosis compared to the wild-type C57Bl/6 recipients (34.4±13.4%
versus 16.6±10.5%, P<0.05). In the ApoE-/- mouse group kept on a high fat
diet plasma cholesterol levels were markedly increased compared to the
normal diet group and this resulted in further exacerbation of the pathogenic
process (40.2±19.6% intimal expansion). The Oil Red O lipid staining revealed
an intense diffuse lipid infiltration throughout the neointima in the ApoE-/recipients, whereas the lesions developed in wild type C57Bl/6 mice presented
only minimal lipid infiltration. We recorded a marginal increase in neointimal
macrophage content at 21 days in the ApoE-/- group compared to the control
(8.6±4% vs 7.1±3.7%), but this difference did not reach statistical significance.
Interestingly, no differences were recorded between the groups in terms of
CD4+ and CD8+ T cell infiltration or endothelial VCAM-1 expression, either
at 7 or 21 days after transplantation.
Conclusion: Our study further highlights the importance of post-transplant
lipid management in all solid organ recipients. We show that lipids exacerbate
the development of transplant arteriosclerosis in a dose-dependent manner
and heavily infiltrate the newly formed neointimal layer. The lack of
quantitative differences between the cellular infiltrate in vessels transplanted
into a hyperlipidaemic versus a normolipidaemic environment indicate that
lipids influence neointima formation by mechanisms other than increased
recruitment of inflammatory cells, possibly by alternative activation of
macrophages present at the inflammatory site. Future dissection of these
mechanisms might offer additional therapeutic targets for improvement of
long-term allograft survival.

J. Laurence1, B. Wu2, Y. Wang2, V. Lam1, C. Wang1, R. Allen1, A. Sharland1,
R. Stocker2, A.G Bishop1
1
Collaborative Transplantation Research Group, University of Sydney, NSW,
Australia, 2Centre for Vascular Research, Bosch Institute, University of
Sydney, NSW, Australia
Background: Endothelial dysfunction may contribute to graft failure and
systemic vascular complications in allograft recipients. We examined the
effects of the anti-atherosclerotic drug probucol on cardiac graft rejection and
recipient vessel function.
Methods: Rat allograft survival was assessed in the LEW>F344 and
PVG>DA heterotopic rat heart transplant models. In the LEW>F344 model,
recipient endothelial function was examined by relaxation of pre-constricted
thoracic and abdominal aortic rings in response to acetylcholine; intragraft
gene expression by qRT-PCR; and inflammation, rejection and fibrosis by
histology and immunostaining at six hours, three and twenty days after
transplantation. Sera of recipients were analyzed for interferon-γ (IFNγ) by
ELISA.
Results: Probucol 1% (wt/wt), given two weeks prior to, and throughout the
time following, transplantation prolonged allograft survival in the PVG>DA
(MST 8 versus 11 days, p=0.04) and LEW>F344 models (MST 31 versus >100
days, p=0.0002). No differences were observed between treatment and control
groups in graft infiltration by T- or B-lymphocytes or macrophages, or in the
expression of interleukin-2, IFNγ, inducible nitric oxide synthase, indoleamine
2,3-dioxygenase or heme oxygenase-1. No differences were detected in
serum IFNγ. Endothelium-dependent relaxation in response to acetylcholine
became increasingly impaired in both aortic segments adjacent to and distant
from the cardiac allograft. The extent of endothelial dysfunction increased
with increasing duration post-transplantation (p<0.05); probucol significantly
inhibited endothelial dysfunction (p<0.05). Endothelium-dependent relaxation
was also impaired in recipients of isografts, but this was similar to the
impairment associated with laparotomy and aortic cross-clamping without
transplantation.
Conclusion: These studies demonstrate for the first time that heterotopic
cardiac allograft is associated with systemic endothelial dysfunction, and that
probucol inhibits this process as well as rejection.

A. Dorling, S. Shrivastava, J. Abrahams, D. Chen
Imperial College London
Background: Transplant arteriosclerosis (TA), characterised by intimal
hyperplasia (IH) and vascular remodelling, is a manifestation of chronic
rejection (CR) which results in progressive ischaemia, fibrosis and organ
dysfunction. Many of the ‘synthetic’ vascular smooth muscle cells (VSMC)
that proliferate to form the expanding neointima are known to derive from
recipient vascular progenitor cells (VP). As such, they are not the targets of
ongoing alloimmune responses. Many pro-inflammatory factors, including
coagulation proteases such as tissue factor (TF) and thrombin, have been
shown to promote the development of IH. This study examined the impact of
expressing anticoagulant fusion proteins specifically on new VP infiltrating the
neointima during TA.
Methods: BALB/c aortae were transplanted orthotopically into C57BL/6
(WT) or α;-TFPI-Tg mice (backcrossed onto BL/6 for >12 generations). These
mice express membrane-bound human tissue factor pathway inhibitor (TFPI)
anticoagulant fusion proteins on α;-smooth muscle actin (SMA)-expressing
cells (VSMC and some VP). Aortae were harvested 6 weeks later and examined
for IH and by immunohistology. Dendritic cells (DC), CD4+ and CD8+ T cells
were purified using conventional protocols from recipient and donor mice,
phenotyped by flow cytometry and used to examine primary and secondary
allogeneic proliferative and cytokine responses. CD34+ VP were purified from
the peripheral blood of Tg or control mice following mobilisation into the
circulation by carotid artery injury.
Results: T cells and DC from α;-TFPI-Tg mice did not express the human TFPI
fusion protein by flow cytometry (compared to high expression on purified
control VSMC and a subset of α;-SMA-expressing VP). CD4+ and CD8+ T
cells mounted primary proliferative and cytokine responses to mature BALB/c
DC that were indistinguishable from those of WT mice. DC from the Tg
mice stimulated primary allogeneic responses from BALB/c T cells that were
similar to those initiated by WT DC. Secondary responses from transplanted
animals will be reported. Whereas aortae transplanted into WT mice showed
significant IH at 6 weeks, those transplanted into α;-TFPI-Tg mice showed
no IH. Immunohistology of aortae in WT mice revealed that IH consisted of
large numbers of cells expressing α;-SMA and E-selectin, in the absence of
a distinct endothelium. In contrast, aortae from the Tg animals maintained a
quiescent endothelium, beneath which were found α;-SMA+ cells expressing
human TFPI. CD34+ VP isolated from Tg mice were recruited into areas of IH
when injected into WT mice 1 week post-transplantation. These cells switched
on expression of TFPI and inhibited the progressive IH seen in controls.
Conclusions: The biology of VP is known to be crucially influenced by TF
and FIIa. In this study, we have shown that inhibiting the function of TF
on the surface of circulating recipient VP is sufficient to completely inhibit
the progressive TA that develops in aortae transplanted across a full MHC
mismatch (in the absence of immunosuppression). Despite mounting a normal
allogeneic immune response against the transplanted aortae, manipulation of
the VP in this way promoted regeneration of normal vascular architecture.
These results suggest a novel therapeutic strategy to inhibit the progressive
organ dysfunction of chronic rejection.

314 MODULATION OF ISCHEMIA REPERFUSION INJURY
BY THE NANOPARTICLE DELIVERY OF C3 SPECIFIC SMALL
INTERFERING RNA (SIRNA)
M.D. Parker1, P. Lu2, M. Woodle3, F. Xie3, P.A. Lodge4, J.R. Pratt1
Leeds Institute of Molecular Medicine, Leeds, United Kingdom, 2Sirnaomics
Inc, Gaithersburg, United States, Department for Organ Transplantation,
Leeds, United Kingdom, 3Intradigm Corporation, Palo Alto, United States,
4
Department for Organ Transplantation, Leeds, United Kingdom
RNA interference blocks gene expression using small unique segments of
gene sequence. This natural process can be exploited to reduce transcription
of specific genes and offers a new strategy to block gene expression. In
transplantation, it has been established that donor derived Complement C3 is
rapidly upregulated at the time of transplantation, and that such C3 contributes
to ischemia/reperfusion injury and inflammation during immune rejection of the
organ. This study sought to exploit a novel nanoparticle strategy to treat donor
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312 EFFECT OF PROBUCOL ON REJECTION OF
HEART ALLOGRAFTS AND TRANSPLANT RECIPIENT
ENDOTHELIAL FUNCTION

313 COMPLETE INHIBITION OF AORTIC TRANSPLANT
ARTERIOSCLEROSIS WITHOUT IMMUNOSUPPRESSION BY
MANIPULATING CD34+ VASCULAR PROGENITOR CELLS TO
PROMOTE REGENERATIVE REPAIR
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organs with siRNA to knockdown C3 gene expression in the donor kidney.
10μg of siRNA was packaged into synthetic polycationic histidine:lysine
nanoparticles to facilitate in vivo siRNA transfection. The nanoparticles were
added to Hyper Osmolar Citrate perfusion fluid and administered to donor rat
kidneys at the time of organ harvest. After 4hours of cold ischemia, the kidneys
were transplanted into syngeneic hosts, and 2 days later were harvested. C3, IFN
gamma, IFN alpha and IL-1 beta gene expression were then determined by RealTime PCR to assess the degree of gene knockdown and the effect of C3 gene
knockdown on other pro-inflammatory genes that could be influence by ‘off-target’
effects of siRNA. Histopathology of the tissues was performed to assess the effect
of C3 gene knockdown on post-ischaemic tissues, and immunohistochemistry for
C3 assessed the affect of C3 siRNA on local C3 deposition.
Delivery of naked C3 siRNA did not produce significant C3 gene knockdown,
however, using the siRNA packaged in the nanoparticle co-polypeptide at
ratios of 4.5:1, 3:1 and 1.5:1 w/w with C3 siRNA produced significant C3 gene
knockdown (50% / 61% / 46% respectively, compared to untreated control
transplanted kidneys: P<0.05, n=3/group). The use of a scrambled control
sequence of siRNA did not reduce C3 expression, suggesting the effect was target
specific. Assessment of off-target effects so far indicates the siRNA sequence
used did not itself induce an inflammatory response and analysis to date does
not indicate any toxicity associated with the in vivo use of the co-polypeptide
packaged siRNA. By histology, the reduced local expression of C3 in the donor
organ was associated with diminished acute tubular necrosis characteristic of
severe ischemia / reperfusion injury, and immunohistochemistry revealed a
marked reduction in the deposition of C3 in the transplanted tissues.
In conclusion, packaging siRNAs into the nanoparticles provides a novel strategy
to effectively reduce pro-inflammatory gene expression in the transplanted
kidney. The strategy offers clear clinical potential to reduce the local expression
of genes contributing to post-transplant inflammation and in the future we will
develop arrays of specific siRNA to diminish pro-inflammatory gene expression
in donor organs as adjunct therapies to conventional immunosupression or
tolerance induction.

315 ELICITED ANTIBODY RESPONSES TO IGB3
GLYCOLIPID IS DEPENDENT ON A NOVEL PATHWAY
H. Vaughan, N. Dodge, E. Mouhtouris, Y. Qin Li, J. Milland, D. Christiansen,
M. Sandrin
University of Melbourne
Background: Naturally occurring anti-carbohydrate antibodies, such as
those to the ABO blood group antigens, are mainly T cell independent and
IgM’s. Mice and pigs with a disruption in the α;1,3galactosyltransferase gene
GGTA1, which generates Galα;(1,3)Gal (α;Gal), have been produced in an
effort to combat the hyperacute rejection (HAR) of xenografts, caused by
naturally occurring antibodies to the major pig xenoepitope α;Gal. However
we, and others have shown that α;1,3galactosyltransferase knock out mice
and pigs (α;GT-/-) express residual α;Gal, which is synthesised exclusively on
glycolipids by another glycosyltransferase, iGb3 synthase (iGb3S). Therefore
the production of elicited anti-α;Gal antibodies to lipid α;Gal will be of
relevance in the rejection of α;GT-/- pigs in xenotransplantation. It has been
previously reported that anti-α;Gal antibodies elicited in α;GT-/- mice, after
immunisation with pig tissues, are T cell dependent.
Methods: Mice were immunized with glycolipids prepared from transfected
cell lines. ELISAs were used to measure anti-carbohydrate antibody titres. Mice
were treated with Mabs to CD3, CD4, CD40L and NK1.1 blocking antibodies
to examine if antibody production could be prevented in vivo.
Results: Our studies show that anti-α;Gal IgM and IgG3 antibodies produced
in α;GT-/- mice after immunisation with α;Gal glycolipids are CD4 and CD40
dependent but CD1 independent, suggesting other non-CD1 mechanism(s) are
involved in providing B cell help for the anti-iGb3 responses. Furthermore there
was no requirement for either Vα;14+NKT or NK cells for these responses.
Preliminary data suggest this novel presentation method is also observed with
the α;Gal related B blood group glycolipid.
Conclusions: These observations suggest an alternative pathway for lipid
antigen presentation, independent of CD1d, and raise the question of which T
cells are involved in the immune effector functions, which elicit strong specific
anti-glycolipid antibody responses in α;GT-/- animals.
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316 INDUCTION OF RENAL ALLOGRAFT
ACCOMMODATION IN DONOR SKIN-PRESENSITIZED
NONHUMAN PRIMATES BY SHORT-TERM INHIBITION OF
CIRCULATING COMPLEMENT
G. Chen1, S. Chen1, J. Li1, Y. Xiang1, S. Zhong1, H. Guo1, W. Wang2,
Y. Xiong2, S. Chen1
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College,
Huazhong University of Science And Technology, Wuhan, China, 2Kunming
Institute of Zoology, Chinese Academy of Sciences, Kunming, China
Background: The immunologically sensitized recipients with donor-specific
antibody (DSA) are considered to be at greater risk for the development of
acute humoral rejection following transplantation. Induction of self-protection
against DSA-mediated humoral injury known as accommodation may allow an
allograft survives continuously in presensitizated recipient. The present study
was undertaken to determine whether renal allograft accommodation could
be induced in donor skin-presensitized monkeys by short-term inhibition of
circulating complement, and to investigate its possible mechanisms via analysis
of intragraft protective gene expression.
Methods: ABO-compatible and MHC-mismatched rhesus monkeys were paired
as donor and recipient. Donor skin allografts were transplanted to presensitize
recipients 14 days prior to renal transplantation. The presensitized recipients
were allocated into the following groups: (1)no treatment; (2)CsA+MMF+Pred;
(3)CsA+MMF+Pred+Cobra venom factor (CVF, 0.05 mg/kg iv. on day -2 and
-1, then 0.02 mg/kg iv. every other day from POD 0-13). Renal allografts
transplanted into non-presensitized recipients served as controls. Serum DSA
and its mediated CDC were detected by FACS using donor lymphocytes as
targets. Intragraft Heme oxygenase-1(HO-1), Bcl-2 and Bcl-xl gene expression
at different time-point were determined by Immunohistochemical stainning.
Results: Donor skin-presensitization induced the production of DSA (mainly
IgG), which mediated elevated CDC against donor lymphocytes in different
degree. Without any treatment, renal allografts only survived for 3-4 days
(3,3,4 days) in presensitized recipients (P<0.05 vs. 10.7¡À2.5 days in nonpresensitized controls), which developed sereve actue humoral rejection
with massive IgG, C3, C4d and C5b-9 deposition. Triple therapy with
CsA+MMF+Pred did not prolonged graft survival (2,3,4 days), while adding
a short-term CVF therapy in the early period significantly prolonged graft
survival to a median survival of 145 days (41,140,>250,>435 days; P<0.01 vs.
other groups). Repetitive low doses of CVF treatment led to very dramatic fall
in serum C3 level and CH50 for at least 2 weeks, and 50% of monkeys received
this therapy survived continuously with normal renal function even after the
serum C3 levels returned to normal. Bcl-2, Bcl-xl and HO-1 were significantly
increased in long-term survival grafts via analysis of immunohistochemistry at
different time-points (especially on POD 50 and 100).
Conclusions: Donor skin-presensitization significantly accelerated renal
allograft rejection with predominantly humoral injury in monkeys, which
could not be prevented by regular CsA triple therapy. Additionally using CVF
in the early critical period allowed long-term renal allograft survival in most
presensitized recipients and most likely induced successful accommodation.
The establishment of accommodation in this model may be associated with
up-regulation of certain protective genes in grafts. These encouraging results
indicate that the complement inhibition-based strategy may be valuable in
future clinical cross-match positive or ABO-incompatible transplantation.

317 ONE POSSIBLE MECHANISM OF ANTIBODY
MEDIATED, COMPLEMENT INDEPENDENT TRANSPLANT
ARTERIOPATHY IN MICE
T. Hirohashi1, S. Uehara3, C. Chase1, P. DellaPelle2, P.J. Madesn1, P. Russell1,
R. Colvin2
1
Department of Surgery, Massachusetts General Hospital, Boston, MA,
2
Department of Pathology, Massachusetts General Hospital, Boston, MA,
3
Department of Pediatric Surgery, Osaka University Graduate School of
Medicine, Osaka, Japan
Purpose: Based on experimental and clinical studies, alloantibodies are
believed to be one of the pathogenic mechanisms responsible for chronic
transplant arteriopathy, a major cause of late graft loss. We previously
reported one pathway without the participation of complement that led to
the development of CAV in transplanted mouse hearts. We also found that
even non-complement fixing antibodies can cause late graft injury. There are
several possible mechanisms by which chronic vasculopathy can develop in
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the absence of complement. These include but are not limited to: direct effects
of NK cells, activation of NK cells or macrophages through Fc receptors, and
the effects of interferon-gamma on the proliferation of smooth muscle cells. In
this study we have focused upon the possible direct effect of NK cells in the
development of CAV using a monoclonal antibody treatment protocol.
Methods: This murine heart transplant system focuses on the use of double
knockout recipients. Hearts from B10.BR (H-2k) donors were transplanted
heterotopically to C57BL6 recipients (H-2b) contrived to lack both T and B
cell activity (RAG1-/-) as well as the gene for C3, a double KO B6.RAG/-C3-/-. Recipients received mouse monoclonal anti-H-2Kk(IgG2a), or both
the monoclonal anti-H-2Kk(IgG2a) and a monoclonal antibody directed
against NK1.1 cells (PK136). These treatments consisted of the following:
30μg of purified anti H-2Kk(IgG2a) antibody given i.p. on day +1 and 2x/
week thereafter, and in a second set of experiments, the previous treatment was
supplemented with 100ìg of anti NK1.1 antibody given i.p. on day-6, +1 and
1x/week thereafter. A control group receiving neither antibody treatment was
also included. On day 28, the transplanted hearts were removed and evaluated
histologically for coronary allograft vasculopathy (CAV) using the elastic
tissue stain (ETS), for C4d deposition by immunohistochemistry and for the
severity of CAV by morphometric analysis (neointimal index).
Results: In the anti-H-2Kk(IgG2a) antibody treated group, 9 of 10 transplanted
hearts developed coronary lesions. However, in sharp contrast only 2 of 7
transplants in the group receiving both the anti-H-2Kk(IgG2a) and anti NK1.1
antibodies developed vascular lesions (p<0.05). When the neointimal index
for lesion severity was employed, the index of severity of the former group
was 68.5±32.0% and of the latter group 12.8±25.4% (p<0.01). In the untreated
control group, 1 of 4 of the transplanted hearts developed CAV.
Conclusions: These data demonstrate that anti NK1.1 antibody treatment
strongly inhibits the development of complement independent CAV,
suggesting that the development of complement independent CAV involves the
participation of NK cells.

N. Satoda1, T. Shoji1, Y. Wu2, T. Fujinaga3, F. Chen3, T. Bando3, H. Date1,
E. Kobayashi4, S. Uemoto5, T. Koshiba2
1Department of Thoracic Surgery, Graduate School of Medicine, Kyoto
University, 2Department of Innovation Center for Immunoregulation
Technologies and Drugs, Graduate School of Medicine, Kyoto University,
3Department of Organ Preservation Technology, Graduate School
of Medicine, Kyoto University, 4Department of Organ Replacement,
Jichi Medical College, 5Department of Surgery, Graduate School of
Medicine,Kyoto University
Background: The outcome of lung-transplantation (Tx) remains inferior
to those of other solid organ Txs, despite the development of potent
immunosuppressants. This may result from the lack of non-or minimal-invasive
method to detect early rejection, in addition to its profound immunogenecity.
Recently, there is emerging evidence that the expression of FOXP3 mRNA (a
specific marker for regulatory T cells (Tregs)) is paradoxically up-regulated
within rejecting graft in clinics.
Methods: Orthotopic left lung-Tx was performed, using high-responder
combinations of outbred miniature swines (MLR >5000cpm) without
immunosuppression (IS) (Group-acute rejection: Gr-AR n=10). Ischemia/
reperfusion injury model was used as a control (i.e. solely by clamping the
vessels of the lung without Tx) (Gr-IRI n=4). Chest radiography and open
lung biopsies were performed to monitor rejection. The expressions of
FOXP3, perforin, Fas-L ,and IP-10 in the peripheral blood lymphocytes
(PBL) or the lung biopsy specimens were quantified at transcriptional
level by real-time PCR. Additionally, steroid pulse + 6 day-FK506
were administered to Tx recipients from post-operative day (POD) 4
or POD 6 as a rescue therapy (Gr-day 4 RT n= 6) (Gr-day 6 RT n=4).
Results: In Gr-AR, rejection was suspected with chest radiography after
POD6 (vs. Gr-IRI), but not before POD5. The specimens of biopsy in Gr-AR
displayed moderate AR on POD4 and end-stage AR on POD 7 or POD10 (graft
survival; 9.1 days). The expression of FOXP3 in the PBL reached its highest
value as early as POD 4, while FOXP3 in Gr-IRI remained low at the same
time point (p<0.0001). The FOXP3 level in PBL correlated with the intragraft
FOXP3 level during rejection (p<0.0001 R2=0.925). Unlike FOXP3, neither
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319 IMPACT OF DONOR AGE, DONATION AFTER CARDIAC
DEATH, AND RISK OF DISEASE TRANSMISSION ON RATE OF
ORGANS TRANSPLANTED PER DECEASED DONOR
K.J. O’Connor, J.W. Bradley, L. Sussman, R. Luskin, F.L. Delmonico
New England Organ Bank, Newton, MA, United States
Purpose: In an effort to increase the rate of organs transplanted per deceased
donor (OTPD), careful evaluation of the impact of donor age, donation after
cardiac death, and risk of disease transmission on OTPD is warranted. In this
review, the impact of these factors on a single OPO’s OTPD rate is examined.
Methods: All deceased organ donors from one OPO from 1/1/2004 to
11/28/2007 (n=841) were classified as DCD (donation after cardiac death) or
DBD (donation after brain death) donors and grouped by age < 50 years or age
> 50 years. Records were reviewed to determine the presence of any of the
following: anti-HCV+, HBCoreAb (IGM)+, history of cancer, CNS tumor as
cause of death, social/behavioral risk factors for HIV infection (e.g. IV drug
abuse). Donors with one or more of these findings were classified as risk factor
donors (RFD); all others were classified as no risk factor donors (NRFD).
Results: RFDs were encountered in 11.7% of all donors in this DSA. Among
the 4 subgroups the frequencies of RFDs were similar (range 8.9% to 11.8%,
table 1). Overall, RFDs yielded 0.72 less OTPD than NRFDs (2.42 vs. 3.14
OTPD; P<.001). OTPD rates differed significantly in both DCD age groups and
the younger DBD group; reduced OTPD differences in RFD were evident in
older DBD’s, but did not reach statistical significance (Table 2).
Table 1.
Age

Donor Type

RFD

NRFD

% RFD

0-49

DCD

10

102

8.93%

50-85

DCD

7

72

8.86%

0-49

DBD

52

354

12.81%

50-85

DBD

29

215

11.89%

Table 2.
Age

Risk

DCD-HBD

OTPD

Significance

Organs_Tx

Donors

0-49

NRFD

DCD

2.39

P<.001

244

102

0-49

RFD

DCD

1.60

50-85

NRFD

DCD

1.53

50-85

RFD

DCD

0.71

0-49

NRFD

DBD

4.12

0-49

RFD

DBD

3.06

50-85

NRFD

DBD

2.43

50-85

RFD

DBD

1.97

16

10

P<.05

110

72

5

7

P<.02

1459

354

159

52

P<.1

522

215

57

29

P values determined by t-test for Equality of Means

Discussion: Risk factors are associated with decreased rates of OTPD in
all cases. Since donor acceptance practices vary among DSAs, developing
standardized methods that incorporate risk factors for evaluating OTPD rates
will allow more accurate comparative analyses and targeted identification of
opportunities for improvement.
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318 VALUE OF FOXP3 MRNA IN PERIPHERAL BLOOD AS
REJECTION MARKER AFTER MINIATURE SWINE LUNG
TRANSPLANTATION

perforin, Fas-L nor IP-10 exhibited significant increase at any time point in GrAR. In Gr-day 4 RT, a rescue therapy from POD4, when the peak of FOXP3
was seen, significantly prolonged graft survival to 23.5 27.2days (p<0.001 vs.
Gr-AR). However, in Gr-day 6 RT, a rescue therapy from POD6, when rejection
was suspected by chest radiography, did not prolong graft survival (11.0 days
NS vs. Gr-AR). Similar to Gr-AR, in Gr-day 4 RT, the FOXP3 level in the
PBL increased at POD4 and thereafter, declined during IS administration, but
subsequently increased before chest radiography suspected late rejection.
Conclusions: Clinically relevant miniature swine lung-Tx model demonstrated
that FOXP3 mRNA in the peripheral blood lymphocytes may be more
promising candidate for a minimal invasive method to detect rejection at an
early stage, rather than chest radiography and conventional rejection markers.
Since the FOXP3 level in the peripheral blood lymphocytes would be likely
to be a useful indicator for rejection, regardless of whether IS is used or not,
the combination of FOXP3 level and current IS may contribute to improved
outcome of clinical lung-Tx.
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320 TEN YEARS OF NON-HEART BEATING DONATION IN
THE NETHERLANDS REVIEWED; ARE WE BETTER OFF?
H. van Leiden1, B. Haase-Kromwijk1, E. de Buijzer1, W. Weimar2
1
Dutch Transplant Foundation, 2Erasmus Medical Center Rotterdam
Purpose: The Netherlands stimulated non-heart beating category 3 (NHB3)
donation (donors awaiting cardiac arrest) at a national level to create an extra
pool of organs of deceased donors. Experience in the Dutch approach to fight
organ shortage illustrates the impact of introducing NHB3 donation on the
donor program.
Methods: Data on deceased donors in the Netherlands over the period
1998-2007 were analyzed.
Results: Although the number of NHB3 donors significantly increased, the
number of HB donors decreased at the same time. Therefore the total number
of deceased donors stabilized around 200 (+30), while only a shift towards
NHB3 donation was observed to 43% of all deceased donors until 2005.
NHB category 2 donation is performed only in some regions and contributed
for less than 6% of the deceased donors these years. Due to the increasing
number of predominantly NHB kidney-only donors the proportion of multi
organ donors among deceased donors decreased from 62% to 52%, affecting
the number of heart donors. Furthermore the discard rate of kidneys reported
for transplantation increased from 8% to 22%.
After focussing on this problem and stimulating HB donation again, the
percentage of HB among deceased donors increased to 66% in 2007, leading
to a stop in the decrease of MOD’s. Even more, the total number of deceased
donors, increased to 257 in 2007. This increase in HB donors resulted in a
considerable increase in the number of transplantations in the Netherlands
compared to the year 2006 (kidney 21%, liver 55%, heart 37%, lung 22% and
pancreas 30%).
Conclusion: The original aim of stimulating NHB3 donation to solve the
organ shortage by creating a new pool of donors has not been accomplished
and might even have harmed the heart transplant program. Results in recent
years did not decrease our suspicion of a competition between HB and NHB3
donation and stresses the importance of stimulating HB donation instead of
NHB3 donation.

321 IMPACT OF LEGAL REGULATIONS IN ORGAN
TRANSPLANTATION
D. Norba, G. Kirste
Deutsche Stiftung Organtransplantation
In the light of the upcoming European Directive based on Art. 152 of the Treaty
establishing the European community (TEC) the European Commission is
funding various projects related to organ donation and transplantation. In the
Alliance-O project (European Group for Coordination of National Research
Programmes on Organ Donation and Transplantation) DSO (Deutsche
Stiftung Organtransplantation) was in charge of investigating the legal and
ethical aspects of organ donation and transplantation across the participating
countries Germany, France, Hungary, Italy, Spain, UK, Portugal. Furthermore
a more general overview about the legal framework of organ donation and
transplantation was elaborated in the general report of the DOPKI project
(Improving the Knowledge and Practices in Organ Donation) in which 15 OPO’s
participated. Based on the investigations of these projects an overview about
the relevance and impact of regulations in organ donation and transplantation
shall be given.
It is important to distinguish legal regulations related to post mortem organ
donation that can be based either on Heart-Beating-Donation or Non-HeartBeating-Donation on the one hand and legal restrictions to living donation.
First of all it has to be stressed that in all the participating countries the main
cornerstones of organ donation and transplantation are regulated through
parliamentary act which has not been the case some 15 years ago.
The two major prerequisites for post mortem heart beating organ donation are
the brain death of the patient and the consent of the patient respectively his/her
relatives. This is true for all the participating countries. However the criteria
for brain death and in particular the regulations for the obtaining of consent
differ immensely. One of the aims of the Alliance-O project was to investigate
in detail the concepts of presumed consent and informed consent. The most
interesting finding of this examination was to find out that in the end in day
to day practice those two concepts do not differ significantly since the wishes
of the relatives of a deceased person are always respected no matter what the
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legal regulation says.
Differences can be found in particular regarding the acceptance of Non-HeartBeating Donation. Only in 4 out of the 16 countries that were examined only
in Croatia, German, Hungary and Poland NHBD is legally not permitted.
However only in UK the law allows Non-heart-beating Donation in all four
Maastricht Categories.
In terms of living donation existing regulations always imply a restriction in
order to protect the potential living donor or to prevent organ trafficking. Hence
it is only consequent that those restrictions are regulated by law since they effect
the right of the living donor do decide himself about his physical integrity and
it also deprives the living donor recipient from a possibly lifesaving treatment.
In all participating countries organ trafficking is penalized and living donation
has to be altruistic. The majority of the participating countries however require
a specially defined relationship between donor and recipient and 10 out of
sixteen countries have installed ethical committees that need to approve of the
planned donation or require an approval by court.

322 PRELIMINARY RESULTS OF A PROSPECTIVE
ALLOCATION POLICY OF EXPANDED CRITERIA DONORS
(ECD) KIDNEYS: COMPARISON OF CORRELATIONS
BETWEEN A CLINICAL AND HISTOPATHOLOGICAL
SCORING SYSTEMS WITH OUTCOMES
L. Santiago Re, D. Curcio, J. Goldberg, M. Rial, D. Casadei
Instituto De Nefrología De Buenos Aires
The best way to allocate ECD kidneys has not been fully elucidated yet.
Some transplant programs base their decision on whether to accept or not an
organ on the clinical characteristics of the donor (e.g. deceased donor score,
DDS) while others give more importance to the biopsy results (e.g. Double
Kidney Transplant Group, DKTG). In a previous retrospective study we
reported that donors clinical characteristics as measured by the DDS are more
relevant than the biopsy findings in terms of graft outcomes. Thus, we decided
to prospectively allocate ECD kidneys based on the clinical score. A kidney
biopsy was performed on all of them at the time of procurement but these
results were not considered for decision-making. A single kidney transplant was
performed in every case. The patients were divided into two groups according
to the DKTG score of the kidney they received in order to assess if there were
any differences in terms of 2-year graft function and survival in such cases that,
according to DKTG, should have received a single (3) or double (>3) transplant.
48 kidney transplant recipients of ECD donors performed between October
2003 and October 2005 were analysed. Donor age, HLA mismatch, CIT,
immunosuppressive regimen, induction use and 1-year acute rejection rate
were not different between both groups. No differences were found in the mean
values of creatinine clearance (p= 0.65) nor in the curves of mean values of
creatinine clearance over time (p=0.55) (MANOVA test, Figure 1).There were
no significant differences in 2-year graft survival either (table 1). ECD kidney
donors as defined by DDS can be safely used as single transplants in a cohort of
low immunological risk de novo kidney transplant recipients, and 2-year graft
outcomes are similar between kidneys that, according to the histological score,
should be used for single or double transplantation.
Figure 1

Group 0= DKTG 0-3. Group 1= DKTG 4-8
Table 1
2-yr graft survival
Cr Cl 12 (ml/min)
Cr Cl 24 m (ml/min)

DKTG 0-3
83%
56.2 29.2
43.4 19.5
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DKTG 4-8
92%
56.2 22.8
48.8 17.9

P value
0.281
NS
NS
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323 CONSEQUENCES OF ALLOCATING DECEASED
DONOR ORGANS BASED ON RECIPIENT ANTIBODY
SPCIFICITIES (CPRA)

324 INFORMING ORGAN ALLOCATION POLICY: DEFINING
EQUITABLE AND UTILITY-BASED AGE CUT-OFFS FOR
DONOR AND RECIPIENT AGE MATCHING
J.S. Gill1, P.W. Nickerson2, G.A. Knoll3, E.H. Cole4
Division of Nephrology, Universities of 1British Columbia, 2Manitoba,
3
Ottawa and 4Toronto, Canada.
In Canada between 1995- 2005, 28% kidney transplant recipients (KTRs) under
the age of forty received kidneys from deceased donors (DD) > 50 years, while
30% of KTRs older than 55 years received kidneys from DD < 30 years. In a
recent national forum on organ allocation, the Canadian transplant community
agreed that it was desirable to avoid allocation of “Old Donor kidneys” to
“Young Recipients” but no age cut-offs were specified.
Using data from n = 6,191 first, kidney only, transplant recipients between
1995-2005 provided by the Canadian Organ Replacement Register, we
performed a variety of multivariate regression analyses to quantify the potential
benefit of age matching. The benefit of age matching was calculated as the
difference between expected patient survival after transplantation, and death
censored graft survival. This benefit was determined at a variety of donor and
recipient age cut-offs. Pediatric recipients, recipients of pediatric DD kidneys,
and expanded criteria donor kidneys (donors ≥ 60 years) were excluded from
the analyses.
The life expectancy of recipients < 55 years was greater than their anticipated
graft survival at all donor age cut-offs explored (i.e. donor age 30, 35, 40,
45 and 50 years). Thus patients < 55 years would be expected to spend less
time on dialysis after transplant failure if prioritized to receive DD kidneys
from below each of donor age cut-offs we explored. Among recipients <
55 years, relatively small incremental benefits in patient and graft survival

325 THE IMPACT OF A NEW KIDNEY ALLOCATION
SCHEME IN THE UK
C. Rudge1, S. Fuggle1, L. Mumford1, R. Johnson1, J. Forsythe2
UK Transplant, Bristol, UK, 2Royal Infirmary of Edinburgh, Edinburgh, UK
In April 2006 a new UK national kidney allocation scheme was introduced in
response to concerns about equity of access to transplant for patients throughout
the UK.
The previous scheme, in place since 1998, was only partly national.
Approximately 50% of kidneys from donors after brain death (DBD) were
allocated nationally to well matched patients, while the remaining kidneys
were allocated according to local transplant centre policy. These allocation
arrangements contributed to inequity in access to transplant in terms of blood
group, ethnicity, HLA phenotype frequency and geography. Average waiting
times between centres ranged from one to over four years.
The principal aim of the 2006 scheme was to address the inequities by (a)
allocating all kidneys from DBD on a national, patient-specific basis, (b)
relaxing the priority afforded to HLA matching beyond 000 HLA-A, B, DR
mismatches and (c) prioritising other factors such as waiting time.
While all 000 mismatched patients and well-matched paediatric patients
continue to receive priority, 75% of kidneys are allocated to other patients on
the basis of a new points scoring system. This is based primarily on points for
waiting time and for HLA match linked to patient age, although points are
also allocated for other factors including donor-recipient age match and HLA
homozygosity.
The results of the first 18 months of the scheme show that 30% of transplants
have been in patients waiting at least 5 years for transplant, compared with 11%
of transplants in 2005 (the last year of the previous scheme), p<0.0001. The
effect on the UK waiting list is already apparent: by September 2007 only 10%
of patients on the active list had been waiting over 5 years, compared with 17%
of patients on the list at the end of 2005, p<0.0001.
Linking points for HLA match and age has resulted in young patients receiving
well-matched grafts, while older patients, who are less likely to be suitable for
retransplantation in the event of graft failure and thus have less need to avoid
sensitisation, do not wait for well-matched grafts which confer only marginal
benefit in terms of transplant outcome.
There have also been more transplants for difficult to match patients (24%
of transplants compared with 17% previously, p=0.0002) and HLA-DR
homozygous patients (20% of transplants compared with 11% previously,
p<0.0001).
Despite national allocation of all kidneys there has been no increase in average
cold ischaemia time (median 17 hours) and one-year graft and patient survival
have remained unchanged (93 and 97%, respectively).
The 2006 UK National Kidney Allocation Scheme demonstrates clear benefits
over the previous scheme, although geographical inequities will take time to
resolve.
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R. Kerman1, C. Van Buren1, S. Katz1, B. Kahan1, J. Lappin1, C. Olivarez2,
T. Shafer2
1The University of Texas Medical School-Houston, 2LifeGift OPO
The UNOS Board of Directors has approved the change from using Panel
Reactive Antibodies (PRA) to calculated PRA (CPRA). The CPRA is a
formulated PRA based upon the frequency of the specificities of HLA antigens
found in the donor pool and is expected to standardize the degree of patient
sensitization. Donor organs expressing unacceptable antigens will not be
offered to a recipient with donor (HLA) antigen specific antibodies (DSA).
Highly sensitive, single antigen bead and solid phase assays (Flow PRA and
Luminex) are used to identify these HLA antibodies (Abs). Each transplant
center can determine the criteria used for identifying an unacceptable antigen,
for example, based upon DSA titer or the fluorescence intensity (FI) coming
from the donor-specific single antigen bead. It is unclear whether Abs identified
by these techniques are clinically relevant for organ allocation.
We retrospectively evaluated Flow-PRA, flow cytometry crossmatching
(FCXM), HLA Ab specificities and titers of 300 pre-transplant (Tx) sera from
transplant recipients of deceased renal allograft donors transplanted following
a negative cytotoxic-anti-human globulin crossmatch.
The two year graft survival of 91% for the recipients (44/54, 81%) with
low-titer (1:16) donor specific HLA Ab and a negative (-) FCXM was
significantly better when compared to the 60% two year graft survival of
the 19% (10/54) of recipients presenting with (+) DSA but a (+) FCXM
(p< 0.001). Recipients (55/110, 50%) with non-donor specific HLA Abs
(high or low titer) and a (-) FCXM also experienced a better two year graft
survival of 89% compared to the 74% for the other 50% of recipients with
(+) FCXMs (p < 0.001).
These data suggest that in the presence of donor-specific or non-donorspecific HLA Abs you can not predict the crossmatch outcome without
actually performing the crossmatch which will then influence donor organ
allocation and graft survival outcome. In the face of low-titer DSA and a
(-) FCXM recipients experienced excellent graft outcome when compared
to recipients with (+) FCXMs. Therefore, donor organ allocation based
on CPRA (Ab specificity and unacceptable Ags) utilizing highly sensitive
single antigen bead and solid phase Luminex assays may disadvantage
recipients (no donor crossmatch) who could otherwise be successfully
transplanted.

were achieved as we explored progressively younger DD age cut-offs (i.e.
45, 40, 35 and 30 years). Thus our primary consideration in deciding on a
DD age cut-off was the anticipated number of DD kidneys above and below
a given donor age cut-off: The DD age cut-off < 35 years provided the best
balance of utility in younger recipients (52% of recipients 19-54 years would
be anticipated to receive kidneys from DD < 35 years), while maintaining
equity in access to kidney transplantation among older recipients (waiting
time for transplantation projected to increase by 16% among recipients ≥
55 years).
In summary, we recommend that DD donor kidneys under 35 years be prioritized
to wait-listed Canadian patients < 55 years. This recommendation was accepted
for implementation in our deceased donor kidney allocation algorithms at a
recent consensus meeting of Canadian transplant programs.
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326 EFFECT OF DONOR ETHNICITY ON KIDNEY SURVIVAL
IN DIFFERENT RECIPIENT ETHNICITY - AN ANALYSIS OF
OPTN/UNOS DATABASE
C. Callender1, W. Cherikh2
Howard University, 2United Network for Organ Sharing
Background: Previous multivariate analysis using kidney transplants during
4/1/94-12/31/00 from the Organ Procurement Transplant Network/United
Network for Organ Sharing (OPTN/UNOS) database has shown that Black
kidney donors were associated with poorer graft survival, especially when they
were transplanted into Black recipients. The present study was conducted to
see if this result still holds on a more recent cohort of US kidney transplants. In
this study, we have compared graft and patient survival of different donor-torecipient ethnic combinations.
Methods: 72,495 recipients of deceased and living donor kidney alone
transplants during 2001-2005 from the OPTN/UNOS database were included
in the analysis. To analyze the effect of donor-recipient ethnicity on graft and
patient survival within 5 years of transplant, and to adjust for the effects of other
donor, recipient and transplant characteristics, a multivariate Cox regression
method was used. Results are presented as hazard ratio (HR) with the 95%
confidence limit (CL) and p-value.
Results: Table below shows adjusted HR of graft loss and death within 5 years
of transplant for selected donor to recipient ethnicity combinations. HR>1
indicates worse survival, and HR<1 indicates better survival as compared to
the reference group (White to White).

1

Graft Loss
Donor to Recipient Ethnicity

P-value

HR [95% CL]

1.00

-

1.00

-

1.35 (1.22, 1.50]

<0.001

1.22 [1.06, 1.40]

0.005

Black to Black (N=6,550)

1.49 [1.32, 1.49]

<0.001

0.97 [0.88, 1.06]

0.47

Black to Hispanic (N=466)

0.87 [0.71, 1.07]

0.18

0.69 [0.51, 0.93]

0.01

Black to Asian (N=217)

0.69 [0.48, 0.99]

0.05

0.59 [0.35, 0.98]

0.04

Black to Other (N=106)

1.38 [0.93, 2.04]

0.11

0.90 [0.47, 1.74]

0.77

White to Black (N=8,555)

1.15 [1.08, 1.21]

<0.001

0.86 [0.79, 0.93]

<0.001

Hispanic to Black (N=1,311)

1.20 [1.07, 1.34]

0.002

0.92 [0.77, 1.09

0.32

Asian to Black (N=202)

1.26 [0.97, 1.64]

0.08

1.01 [0.69, 1.48]

0.97

Other to Black (N=178)

1.17 [0.85, 1.61]

0.34

1.15 [0.76, 1.75]

0.52

White to White (N=37,241)
Black to White (N=1,637)

TUESDAY

Death

HR [95% CL]

P-value

Summary: Results of this study show that kidneys from Black donors are
associated with significantly worse graft survival when transplanted to White
and Black recipients. Black donors are also associated with worse patient
survival when transplanted to White recipients. As a group, Black recipients
exhibited poorer graft survival regardless of the donor ethnic group. The
graft and patient survival rates for Asian, Hispanic and Other recipients were
not significantly affected by Black donor ethnicity. While transplantation
is beneficial for all ethnic groups, these results confirm the need to further
review and examine underlying causes of the reduced survival with Black
donors or for Black recipients. The medical literature has for some time noted
a higher prevalence of Blacks with underlying disease factors that lead to
End Stage Renal Disease and dialysis dependency. This analysis underscores
the need for increased diligence in identifying and treating these diseases in
minority populations and the need to identify ways to improve their posttransplant survival.

327 INFLUENCE OF DONOR TYPE ON ELDERLY KIDNEY
TRANSPLANT SURVIVAL AND ALLOGRAFT FUNCTION
L. Shen, S. Kuppachi, A. Agarwal, N. Turgeon, P. Tso, K. Newell, T. Pearson,
C.Larsen, A. Kirk
Emory University
Background: Patients aged 60 years and older account for more than 50% of
the people with end stage renal disease in the US. Use of living donor (LD) and
expanded criteria donor (ECD) kidneys has progressively increased to assist
with the growing demand for kidney transplants. Value of transplanting ECD
kidneys continues to be questioned due to concerns regarding decreased patient
survival and outcomes.
Methods: We performed a retrospective review to evaluate and compare the
patient and graft outcomes of kidney transplant recipients aged 60 years and
older stratified by donor type (LD, standard criteria donor (SCD) and ECD).
Results: Between January 2002 and November 2007, 195 living and deceased
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donor elderly kidney transplants were performed. Median follow-up was 2.0
years. Most (89%) were on renal replacement therapy (RRT) at the time of
transplant. Length of RRT prior to transplant was significantly shorter (p<0.01)
in the LD (1.5 years) when compared to SCD (3.6) and ECD (3.0). Length of
hospital stay was shortest in the LD (6.3 ± 5.0 days), followed by SCD (7.1 ±
4.0) and ECD (9.2 ± 8.5, p=0.001).
Donor type is a significant factor in patient survival. The survival rate at 1
month, 1 year, and 3 years for SCD was 98.4%, 90.5%, and 76.7%, for ECD
85.2%, 64.0%, and 44.8%, and for LD 100%, 94.3%, and 80.0% respectively.
Compared to the ECD, both SCD (p=0.012) and LD (p=0.05) recipients had
significantly higher survival rates. Delayed graft function was highest in the
ECD group (20.7%) followed by the SCD (16.8%) and LD (7.3%, p=0.15).
Acute rejection occurred in 6 (20.7%) ECD, 5 (12.2%) LD, and 9 (7.2%) SCD
(p=0.15).
Mortality rate of ECD was 34.5%, SCD 20.8%, and LD 14.6%. The mortality
of ECD was 1.7x rate of SCD as projected by UNOS. The mortality of LD was
0.7x rate of SCD. Two-thirds expired with a functioning renal allograft.
Pre-operative creatinine (p=0.055) was not different between groups. But,
pre-operative creatinine clearance (p=0.0013) was different (LD: 13.0 ml/min,
SCD: 10.7, and ECD: 9.5). Post-transplant creatinine was higher (p=0.007) and
creatinine clearance was lower (p=0.0002) in the ECD (1.7 ± 0.5 mg/dl, 44 ± 12
ml/min) than in the SCD (1.4 ± 0.5, 58 ± 17) and LD (1.4 ± 0.4, 61 ± 15).
Conclusion: ECD kidneys are an effective means of RRT but are associated
with significantly lower survival and reduced graft function in elderly patients.
Use of these grafts should be weighed against the risk of prolonged dialysis and
the availabilty of LD kidneys.
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328 THE RELATIONSHIP OF DONOR SOURCE AND AGE
ON SHORT- AND LONG-TERM ALLOGRAFT SURVIVAL IN
PEDIATRIC RENAL TRANSPLANTATION
A. Dale-Shall2, J. Smith1, M. McBride3, S. Hingorani1, W. Harmon4,
R. McDonald1
1
Seattle Children’s Hospital, 2Levine Children’s Hospital at Carolinas Medical
Center, Charlotte, 3United Network for Organ Sharing, 4Boston Children’s
Hospital
Limited pediatric data on allograft survival from advanced aged kidney
donors exists. To determine the influence of donor source and age on
allograft survival in pediatric renal transplant recipients, we analyzed
the Organ Procurement and Transplantation Network database. Allograft
survival for 7,291 pediatric renal transplants was evaluated. Up to 5 years
post-transplantation, graft survival was higher for living donor (LD) versus
deceased donor (DD) recipients. At 7 years, allograft survival was 71% in
18-54 year-old LD recipients, 59.1% in ≥ 55 year-old LD, and 45.1% in ≥
50 year-old DD recipients. An approximate 35% improvement in allograft
survival in 18-54 year-old LD recipients was observed. Multivariate results
showed that recipients of LD 35-49 (aRR 0.66, 95% CI 0.55-0.80) and LD
50-54 (aRR 0.65, 95% CI 0.45-0.94) have a graft survival advantage over the
ideal DD. In LD ≥ 55 years, no improvement in graft survival was observed
when compared to the 18-34 year-old DD. In summary, we observed in a
pediatric population, < 55 year-old LD kidneys afford improved long-term
allograft survival when compared to DD kidney recipients. Increasing
awareness of the long-term graft survival advantage for children receiving a
LD kidney, even from older donors, should be a priority.
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329 A MINIMAL, HIGHLY SPECIFIC AND SENSITIVE
GENE-SET FOR PERIPHERAL BLOOD-BASED
DIAGNOSIS AND PREDICTION OF ACUTE RENAL
TRANSPLANT REJECTION

330 CALCINEURIN INHIBITORS ARE A FACTOR IN
THE UNCHANGED RATE OF RENAL GRAFT LOSS
SURVIVING MORE THAN 5 YEARS: EVIDENCE FROM THE
ANZDATA REGISTRY
J. Fletcher1,2, S. Chang4, F. Mackie3, S. McDonald4, S. Alexander2
1Department of Paediatrics, Nepean Hospital, Penrith, Sydney., 2Centre for
Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney,
Australia, 3Department of Nephrology Sydney Children’s Hospital, 4Australia
and New Zealand Dialysis and Transplant Registry (ANZDATA)
We reviewed the rate of graft loss and effect of Calcineurin inhibitors (CNI) on
graft survival in children who received a renal transplant in Australia or New
Zealand over the last 30 years.
Methods: Data was obtained on all ESRD patients less than 20 years of age
and those with a functioning graft at five years via the ANZDATA registry. Age
at transplantation and immunosuppression at time of transplant and at 5 years
was analysed. Cohorts were divided into 5-year intervals from 1963 for graft
survival analysis and divided into 5- year cohorts from 1975 to 1995 for CNI
analysis. Impact of CNI use at induction out to 5 years on graft survival was
compared for 0-5 years and > 5 years using a multivariate logistic regression
model adjusted for year of transplant, age, sex, race, donor age, primary
disease, duration of RRT pre transplant, graft number, HLA mismatch, peak
PRA, donor source and initial CNI usage.
Results: There are 1763 children (<20 years of age) with ESRD and 1312
transplant recipients in the ANZDATA registry. 68% of children had received
CNI as maintenance immunosuppression. There were 657 functioning renal
grafts at 5 years. 68% of patients received CNI at time of transplant and 64%
at 5 years. We assessed the rate of graft loss after censoring for death. Graft
loss rate has remained relatively constant over the 30 years. In 1968-72 (4.56
grafts per 100 patient years) compared with 1993-97 (4.92 grafts per 100

331 PEDIATRIC LIVING DONOR KIDNEY
TRANSPLANTATION USING ALEMTUZUMAB PRECONDITIONING AND TACROLIMUS MONOTHERAPY
H. Tan, D. Ellis, M. Moritz, A. Basu, A. Vats, E. Erkan, J. Donaldson,
D. Connors, C. McFeaters, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Introduction: We have previously reported that Alemtuzumab (Campath1H) pre-conditioning with tacrolimus monotherapy provides effective
immunosuppression for solid organ transplantation. We extend our study to a
4-year experience of recipient pre-transplant lymphoid depletion and minimal
post-transplant steroid-free immunosuppression in pediatric living donor renal
transplantation.
Methods: Alemtuzumab pre-conditioning was used in 35 consecutive
unselected living donor renal transplant recipients between January 14th
2004 and November 7th 2007. Donor kidneys were removed laparoscopically
(LLDN). Post-operatively, patients were treated with steroid-free tacrolimus
monotherapy, and immunosuppression was weaned when possible. The mean
follow up was 21.5+14.5 mos.
Results: The mean donor and recipient ages were 34.5 + 7.7 and 8.3 + 6.0
years, respectively. The mean HLA mismatch was 2.6 + 1.1. LLDN was
associated with 0% delayed graft function (DGF). The mean creatinine (mg/
dL) at 1, 2, 3-yr was 0.89 + 0.44 (n=24), 0.87+0.37 (n=15), and 0.86+0.48
(n=7), respectively. The mean GFR (mL/min/1.73m2) at 1, 2, 3-yr was
69.2+38.1, 76.1+36.1, and 85.4+64.5, respectively. Patient survival at 1, 2,
and 3-yrs was 100%, 95%, and 95%, respectively. Graft survival at 1, 2, and
3-yrs was 100%, 89.7%, and 89.7%, respectively. The loss of 2 renal allografts
was related to vascular torsion of an intraperitoneal allograft 645 days after
transplantation and a patient death unrelated to the transplant. The cumulative
incidence of acute cellular rejection (ACR) at 1, 2, and 3 yrs was 2.9% (day 22,
preweaning), 2.9%, and 5.7% (day 834, postweaning), respectively. Weaning
was attempted in 46% of recipients. At follow-up, 12 (35%) of children were
tapered to spaced tacrolimus monotherapy, and 88.2% (n=30) were steroid free
and on tacrolimus monotherapy. There was no tissue invasive cytomegalovirus
(CMV) infection, no post-transplant lymphoproliferative disease, and no BK
viral nephropathy. There was no donor mortality or morbidity.
Conclusion: This study represents the largest series to date of unselected
live donor pediatric kidney transplant recipients receiving alemtuzumab
preconditioning, and confirms the mid-term safety and efficacy of this
approach. LLDN is not a risk factor for DGF or ACR in pediatric kidney
transplant recipients.

332 KIDNEY TRANSPLANTATION IN CHILDREN AND
ADOLESENTS - ANALYSIS OF OPTN/UNOS DATA
Y. Cho2,3, B. Hardy1, T. Shah2, J. Cicciarelli2,3, K. Lemley1, I. Hutchinson2,3
Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC
School of Medicine
Background: It is very important to investigate whether specific pediatric
allocation schemes can not only lead to minimization of waiting time, but also
to better clinical outcomes for children with end-stage renal disease (ESRD).
Materials and methods: We analyzed the OPTN/UNOS data for all patients
aged 2-20 years who received kidney transplants from living or deceased
donors aged 5-35 years between January 1, 1994 and December 31, 2006.
Multiple organ transplants were excluded from this study. The outcome of 4,125
deceased donor kidney transplants (DDKT) was compared with those of 6,456
living donor kidney transplants (LDKT) using univariate and multivariate Cox
regression analyses.
Results: Unadjusted graft survival rates of DDKT were significantly lower
than those of LDKT (HR=1.53, P<0.001). Chronic rejection was reported
in 416 (10.1%) of 4,125 DDKT group compared with 537 (8.3%) of 6,456
1
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L. Ying, L. Li, J. Martin, S. Hsieh, M. Sarwal
Stanford University
Background: A critical 11 gene-set for acute renal rejection (AR) diagnosis
in peripheral blood has been previously identified in our group using crossplatform hybridization of 71 unique peripheral blood samples with matched
biopsy diagnosis, with AR (n=44) and without AR (STA; n=27), with crosshybridization across 3 human microarray platforms: 30k cDNA Lymphochip,
44k Agilent and 54k Affymetrix HU133plus. In this study we proposed to
verify and validate this gene-set for AR diagnosis and prediction by peripheral
blood PCR-based analysis.
Method: Total of 147 peripheral blood samples were selected for 384-well
format multiplex ABI-TaqMan qPCR validation of AR diagnosis across 11 geneset. 50/147 (33 AR, 17 STA) samples had already been tested on microarray,
whereas the other 97 samples were new, time and immunosuppression matched,
peripheral blood samples (57AR, 40STA) and used as a test-set for blinded
prediction of AR diagnosis using qPCR across the most informative 11 genes.
57 sequential samples from 19 AR patients (at AR, 1-6 months prior to, and
after AR) were also examined by qPCR for these 11 genes for blinded AR
prediction, prior to biopsy proven AR. Prediction models were generated using
logistic regression analysis and p<0.05 considered significant.
Result: In the validation set of 50 samples, 9/11 genes were highly significant
for confirming peripheral blood-AR diagnosis (p<0.05). In the test group of 97
samples, AR was predicted with a very high level of sensitivity and specificity
(PPV and NPV> 90%). In the group of 19 AR patients with sequential samples
pre- and post-AR, expression for 3 of 11 genes were significantly elevated in
the pre-AR samples (vs. STA, p<0.03) but were not different between pre-AR
and AR values.
Conclusion: A highly specific and sensitive biomarker panel of 11 genes has
been derived and tested by cross-platform microarray analysis. this gene-set has
now been validated and further verified by multiplex PCR, for AR diagnosis
and prediction, even 3 months prior to the rejection event. Utility of this geneset should be further validated in real-time by serial longitudinal peripheral
blood testing, for more sensitive and specific minimally invasive monitoring
for graft rejection.

patient years). CNI use was protective for graft survival in the first 5 years post
transplant (Hazard ratio 0.65 [95% CI 0.44-0.96]) with loss of protection and a
trend to worse outcomes in those whose graft survived > 5years (Hazard ratio
1.41 [95% CI 0.77-2.59]) after adjustment.
Conclusion: The initial protective benefit of CNI use in the first 5 years
post transplant is lost after 5 years graft survival. CNI toxicity may explain
unchanged rate of graft loss in kidneys surviving beyond 5 years.
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LDKT group (P<0.001). Among black recipients, 65 (3.3%) grafts were lost
due to non-compliance as a contributory cause of failure compared with 126
(1.5%) among other races (P<0.001). A significantly lower incidence of noncompliance was observed in children (0.9%) compared with adolescent (2.2%
in age 10-14, P<0.001) and high teens (2.0% age 15-20, P<0.001). Multivariate
analysis showed that adjusted graft survival rates of LDKT were superior to
DDKT (HR=1.22, P<0.001) after adjusting for recipient race, recipient age,
regraft status, and HLA mismatch.
Conclusion: It is recommended that LDKT be offered first to children instead
of DDKT.
Table. Results of univariate and multivariate analyses.
Unadjusted
HR (95% CI)

P value

Adjusted
HR (95% CI)

P value

DDKT vs LDKT

1.53 (1.42-1.65)

<0.001

1.22 (1.12-1.34)

<0.001

Recip race Black vs others

2.01 (1.85-2.20)

<0.001

1.81 (1.66-1.98)

<0.001

Recip Age 10-14 vs 2-9

1.47 (1.30-1.66)

<0.001

1.43 (1.27-1.62)

<0.001

15-20 vs 2-9

1.91 (1.72-2.12)

<0.001

1.87 (1.68-2.08)

<0.001

1.51 91.35-1.68)

<0.001

1.39 (1.24-1.56)

<0.001

HLA mismatch (0-6)

1.14 (1.11-1.16)

<0.001

1.07 (1.04-1.10)

<0.001
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333 OUTCOMES OF PAEDIATRIC KIDNEY TRANSPLANTS
AFTER SWITCH TO SIROLIMUS
S.E. Kennedy1, F.E. Mackie1,2, G. Kainer1, E. Craig1, A.R. Rosenberg1,2
1
Sydney Children’s Hospital, Randwick and 2University of N.S.W, Sydney.
Australia
We report results of paediatric kidney transplant recipients converted from
calcineurin inhibitors (CNI) to sirolimus (SRL).
Since 2003, 15 child/adolescent recipients have received SRL at our centre. All
had initially received basiliximab induction with maintenance CNI, prednisone,
and either azathioprine or mycophenolate. The median age at time of transplant
was 11 years (range 23m-16y). SRL was introduced at a median time of 16
months posttransplant (range 2–90 months). CNIs were discontinued in 14
and reduced in 1. All were biopsied prior to conversion. Complete follow up
was available for 353 patient-months of SRL treatment (mean 23±13 months/
recipient). SRL was discontinued in one because of upper limb oedema and
one graft failed due to non-adherence. SRL was otherwise well tolerated. Mean
cholesterol levels 12 months after SRL were similar to baseline (4.78 ± 1.25 vs
4.86 ± 0.77 mmol/L, baseline vs 12 months post conversion respectively) but
there was an increase in the use of statin therapy (mean atorvastatin dose 1.7 vs
11.3 mg/day; baseline vs 12 months. P<0.01). No adverse effects of statin therapy
occurred. The mean triglyceride level increased with SRL use (2.0 ± 1.7 vs 2.7
± 1.4 mmol/L; baseline vs 12 months. p<0.05). Haemoglobin levels were stable
over 12 months (115 ± 12 vs 117 ± 19; baseline vs 12 months). Four recipients
have received darbepoetin therapy. The most recent ten recipients started SRL
within 20 months of transplant; all had histological evidence suggestive of either
acute or chronic CNI nephrotoxicity. Eight of this group have been followed for
at least 12 months. The mean GFR was unchanged during the first 12 months
after conversion (64 ± 12 vs 62 ± 12 ml/min/1.73m2; baseline vs 12 months after
conversion) but had fallen in those seven patients followed for 24 months (55 ±
15 ml/min/1.73m2. p<0.05 vs baseline). Four recipients had episodes of steroid
reversible acute rejection (AR) while taking SRL. We compared the number of
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AR episodes in the 9 recipients treated by SRL within 20 months post-transplant
to an age-matched historical cohort who had been treated with a CNI based
regimen (n=9). All in the control group had been treated for suspected AR
between 2 and 5 years after transplant. Rates of rejection after SRL conversion
were less than in controls during years 2 to 5 after transplant (0.01 vs 0.1
rejection episodes per month in SRL vs control; p<0.01).
We conclude that SRL conversion is well tolerated by paediatric kidney
transplant recipients and offers at least as good a degree of protection from
acute rejection as CNI based regimens.

334 EXTENDED ENROLLMENT AND ANALYSIS OF A
PROSPECTIVE STEROID-FREE IMMUNOSUPPRESSION
TRIAL SUPPORTS STUDY SAFETY AND EFFICACY
M. Sarwal, L. Li, O. Salvatierra, W. Concepcion, C. Wong, S. Alexander,
P. Grimm, J. Martin
Stanford University
Aim: To evaluate the long-term safety and efficacy of a prospective, singlecenter, pilot, steroid-free (SF) pediatric renal transplantation.
Methods: 112 consecutive pediatric renal transplant recipients of living
(n=88) and deceased donors were enrolled since 1999 in a steroid avoidance
protocol with extended Daclizumab induction (6mo), TAC and MMF. 105
matched recipients on a steroid-based (SB) protocol of induction (Daclizumab/
Thymoglobulin) +steroids+TAC+MMF were controls (33% propsective). All
SF and prospective SB patients had protocol biopsies at 3, 6, 12, and 24 mo
and for graft dysfunction. Statistical analysis including T, survival analysis,
chi-square, repeated measures were done by SAS.
Results: Mean follow-up for SF patients was 53.6 mo. SF patient survival
and death-censored graft survival at 1 yr was 99% and 100% and at 4 yrs
was 92% and 100%. SF patients had a low incidence of acute rejection (AR)
(7% vs. 28%, p=0.0001), with mean time to 1st AR at 21 mo. Significant
benefits in SF were seen for linear growth with maximal benefit in the <6 yr
old and excellent graft function (see figure). SF patients had significantly less
hypertension and hyperlipidemia (p<0.01) upto 4 yrs by mixed model. At 1
yr SF required more erythropoetin (25% vs 10%, p=0.004) and GCSF (18%
vs 0%, p<0.0001) skewed towards early study enrollment, but there were no
differences in hematocrit, EPO use, leucopenia or GCSF usage at 4 yrs. In
the SF group, there was 1 nodal PTLD, 2 CMV disease and 2 BK nephritis.
14% (n=16) broke SF protocol at mean 10 mo post-txp, with reccurrence of
primary disease in 6 patients. 3% SF vs 13% SB patients had PTDM at 4 yrs
(p=0.0035).
Conclusions: SF immunosuppression protocol offers excellent continued graft
and patient outcomes for pediatric renal txp recipients with significant benefits
for growth, rejection, graft function, hypertension, hyperlipidemia, PTDM, and
graft survival.

335 TWENTY YEAR OUTCOMES AFTER HEART
TRANSPLANTATION DURING INFANCY
R.E. Chinnock, T. Shankel, D. Cutler, R. Larsen, M. Kuhn, A. Razzouk,
J. Fitts, J. Johnston, L. Bailey
Loma Linda University Children’s Hospital, Loma Linda, CA USA
Purpose: The first successful heart transplant procedure in an infant was
performed in 1985. That patient is now 22 y/o, still with his first allograft. Since
then, much has been learned. Now we are better prepared to describe the longterm outcome of infant heart transplantation. We will describe the single center
clinical outcomes of a 22 year experience with infant heart transplantation.
Methods: The clinical data repository was retrospectively reviewed to
gather information on our patient survival, rejection history, cardiac allograft
vasculopathy (CAV), post-transplant lymphoproliferative disease (PTLD),
renal function, and developmental outcome.
Results: 102 newborns (0-30d) and 199 infants (1-12 mo) have undergone
heart transplantation. Actuarial survival at 20 years for newborns is 63%,
for infants it is 50%. There are now 7 infants who have survived beyond
20 years. The patient half-life for infant recipients is 17 years. The patient
half-life for newborn recipients is still undefined. Actuarial risk for rejection
beyond 10 years is 19%. Fifty patients have been diagnosed with CAV –
an actuarial risk at 20 years of 31%. Thirty-six pts have experienced late
(beyond 1 yr) rejection with hemodynamic compromise. This group had a
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57% risk for developing CAV within 2 years of this event. There were 25
re-transplants, and 3 have had a 3rd transplant. There have been 27 cases of
PTLD, with a 20 year actuarial risk of 18%, and a 48% mortality. Isotopic
glomerular filtration rates (obtained within the past 3 years) were available
for 74 pts with a mean +/- SD = 76+/-29 mL/min/1.73m2 (normal 80-120).
Six pts have undergone and 2 are awaiting renal transplantation. Fractional
shortening data (within the prior 3 yrs) was available for 125 patients with
mean±SD of 37±6 (normal 28-44%). Information for current educational
status (assessed by parental questionnaire) is available for 170 survivors. Of
these, 98 (57%) are normal, 68 (40%) require education assistance, and 4
(3%) are severely impaired.
Conclusion: Twenty year survival after heart transplantation in the first year
of life has now been demonstrated. Re-transplantation in 25 pts has been
required to achieve this result, and more could have benefited. Rejection
is still a concern, even in these presumed immunologically privileged
patients. Compliance during adolescence may contribute to late rejection
and graft loss, and is a significant concern. Rejection and CAV are the
largest contributors to late graft loss. PTLD is also a significant concern.
Renal function is acceptable for most, but strategies to minimize calcineurin
inhibitor use are needed. Educational performance is acceptable for most,
and consistent with results from other patients who underwent cardiac
surgery during infancy.

H. Lehmkuhl, S. Schubert, N. Hiemann, M. Dandel, C. Knosalla, M. Hübler,
O. Grauhan, R. Hetzer
Deutsches Herzzentrum Berlin
Purpose: Everolimus is used in combination with cyclosporine A (CsA) in
adult heart transplantation for prevention of acute rejection. There exists
experience in 19 pediatric renal TX with everolimus in children aged above 1
year. To date no experience exists in infant heart transplantation.
Methods/materials: To date, we performed 151 pediatric heart transplantations
(HTx). Since 12/2004 twenty six children received everolimus in combination
with CSA and steroids. We report on 5 HTx infants below the age of 1 year
exposed to everolimus. Graft rejection was assessed non-invasively by tissue
Doppler echocardiography (TDI) and intramyocardial electrocardiography
(IMEG). Dose of everolimus was initiated at 0.8 mg / sqm BSA and guided by
target trough levels of 3 to 8 ng/ml with concomitant CsA with C0 target levels
of 200–300ng/mL (1 month), 175–250ng/mL (2–3 months) and 150–200ng/
mL (4–6 months).
Results: The infants were 8, 6, 5, 4 and 3 months of age. 3 infants were
awaiting HTx on LVAD. Mean CsA levels were 214ng/mL and 296 ng/ml at 2
respectively 4 weeks after HTX and reduced at 3 and 6 months to a mean level
of 203 ng/ml respectively 188 ng/ml. Post-transplant everolimus trough levels
were 3.9 ng/mL at 2 weeks, 8.8ng/mL at 4 weeks, 6ng/mL at 3 month and
5.6ng/ml at 6 months. There were 2 rejection episodes in 2 infants which were
treated with steroids. Everolimus was interrupted in 2 infants at week 3 (wound
healing problem and renal dysfunction) and week 2 (poor enteral resorption).
Creatinine levels were normal in 4/5 children. 1 child´s kidney function with
crea max of 1.46 mg/dl at 2 weeks post HTx returned to normal by month 2
following discontinuation of everolimus. All but 1 of the infants had normal
serum lipids (max. Cholesterol 320 mg/dl at week 4 post HTx). There was no
significant thrombocytopenia. 1 Child experienced CMV infection. No severe
infection occurred.
Conclusion: In a routine clinical setting, everolimus in infants shows similar
efficacy and safety demonstrated elsewhere in adult HTX. Further controlled
studies in larger cohorts are warranted to define the role of everolimus in
pediatric heart transplantation.

337 THE BENEFIT OF SINGLE AND DOUBLE KIDNEY
TRANSPLANTATION FROM EXPANDED CRITERIA DONORS
AND DONATION AFTER CARDIAC DEATH
J. Sageshima1, G. Ciancio1, L. Chen1, T. Cordovilla1, D. Roth2, W. Kupin2, G.
Guerra2, L. Hanson1, G. Burke1
1
University of Miami, Surgery, Kidney and Pancreas Transplant, 2Medicine,
Nephrology and Hypertension
Purpose: The recent expansion of donor criteria to increase the number of
patients transplanted may be associated with worse outcome. The aim of this
study is to evaluate patient and graft survival, and renal allograft function
of expanded criteria donors (ECD) and donation after cardiac death (DCD)
recipients.
Methods: We retrospectively analyzed 411 consecutive adult patients
(November 2004 - October 2007, median follow-up 16 mo) who received
deceased donor kidney-alone transplantation (Tx) at a single center. The
pediatric en-bloc kidney Tx (n = 17) were excluded from the study. To decrease
discard and improve transplant rate, all kidneys were evaluated histologically
and via flow/resistance parameters while preserved on pulsatile perfusion.
The kidneys from ECD/DCD were Tx’d as single (n = 46) or double (n =
46) grafts based on donor age, renal function, medical history, histological
findings and flow/resistance. All recipients were induced with antilymphocyte
antibodies (Thymoglobulin, daclizumab and/or alemtuzumab) and maintained
with mycophenolate and tacrolimus. To reduce nephrotoxicity, tacrolimus was
withheld until serum creatinine levels fell down to 4.0 mg/dl and trough levels
were targeted to 5 - 8 ng/ml thereafter; corticosteroids were withdrawn from
majority of the recipients.
Results: The ECD/DCD kidneys were Tx fd into older patients than the standard
criteria donor (SCD) kidneys (SCD: 50.3 } 13.7, single ECD/DCD: 55.6 } 14.5,
double ECD/DCD: 59.7 } 8.6 year old, p < 0.001). This was associated with
lower 1-year patient survival (SCD: 98.3%, single ECD/DCD: 94.6%, double
ECD/DCD: 91.1%, p = 0.016). The ECD/DCD kidneys were associated with
significantly higher delayed graft function (DGF requiring dialysis within 1
week posttransplant) rate than SCD kidneys (SCD: 3.6%, single ECD/DCD:
13.0%, double ECD/DCD: 8.7%, p = 0.007), however only slightly lower
1-year death censored graft survival (SCD: 95.1%, single ECD/DCD: 93.5%,
double ECD/DCD: 90.2%, p = 0.044). The single ECD/DCD recipients had
significantly lower calculated GFR at 1 year than the SCD recipients (SCD:
63.8 } 16.7, single ECD/DCD: 49.3 } 17.1, double ECD/DCD: 61.5 } 20.6 ml/
min/1.73m2, p < 0.001) although the double ECD/DCD were recovered from
donors with lower GFR (SCD: 78.1 } 25.4, single ECD/DCD: 70.6 } 26.2,
double ECD/DCD: 56.6 } 24.1 ml/min/1.73m2, p < 0.001).
Conclusion: Although the SCD Tx has better patient and graft survival
than the ECD/DCD Tx, the utilization of ECD/DCD increases the number
of Tx, particularly into older recipients, without compromising the outcome
exceedingly. The double kidney grafting is an effective option to optimize renal
graft function of Tx from donors with less than optimal renal function.

338 PREEMPTIVE REPEAT KIDNEY TRANSPLANTATION
IS ASSOCIATED WITH AN INCREASED RISK OF SECOND
GRAFT LOSS IN PATIENTS WITH A SHORT DURATION
OF FIRST GRAFT SURVIVAL
O. Johnston, C.L. Rose, J.S. Gill
Division of Nephrology, St. Paul’s Hospital, University of British Columbia,
Vancouver, British Columbia, Canada.
Among first kidney transplant recipients, preemptive transplantation is
associated with a decreased risk of graft loss. Previous studies have shown
that second graft survival is lower in patients who had early first graft failure.
We performed this analysis to determine whether preemptive transplantation in
second transplant recipients (rPTX) is also beneficial, and whether the benefit
of rPTX is affected by the duration of first graft survival.
We determined in the risk of graft loss in preemptive and non-preemptive adult
(>18 years) kidney-only repeat transplant recipients (n = 6,140), captured in the
United States Renal Data system between 1995-2003, using a Cox multivariate
regression analysis, which included adjustment for multiple confounders.
Surprisingly rPTX was not uniformly beneficial (figure): Among patients with
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first graft survival ≤ 3 years, rPTX was associated with an increased risk of all
cause and death censored second graft failure. The risk of death censored graft
loss was also higher among preemptive transplant recipients with first graft
survival of 3.1-5.0 years. rPTX was only associated with a decreased risk of
graft loss in patients with first graft survival > 10 years.
We conclude that rPTX is associated with an increased risk of second graft loss
in patients with first graft survival ≤ 3 years and that there is no survival benefit
to rPTX in patients with first survival ≤ 10 years. The mechanisms underlying
the increased risk of graft failure in rPTX patients with short first transplant
survival should be further studied.

bleeding complication, either need for transfusion or reoperation while 4%
of patients who did not have a thrombophilia had a bleeding complication
(p<0.001).
Summary: No patients with a thrombophilia treated with anticoagulation
had graft thrombosis. Four patients with previous graft thrombosis and
thrombophilia were successfully retransplanted using anticoagulation. Onethird of patients on anticoagulation developed a bleeding complication. Our
study did not support more rejection in patients with thrombophilia reported
by others.
Conclusion: Thrombophilia is an underreported cause of graft thrombosis in
ESRD.
Anticoagulation prevents graft thrombosis in patients with thrombophilia.
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340 A SYSTEMATIC APPROACH TO MINIMIZING WOUND
PROBLEMS FOR DE NOVO SIROLIMUS TREATED KIDNEY
RECIPIENTS

* P<0.01
All Cause Graft Loss Death-Censored Graft Loss
Reference=1.00 (non pre-emptive repeat transplant)
Figure: Risk of pre-emptive repeat transplant graft loss by duration of primary
graft survival

339 ANTICOAGULATION AFTER RENAL
TRANSPLANTATION PREVENTS GRAFT THROMBOSIS IN
PATIENTS WITH THROMBOPHILIA
C. Hwang1, C. Pagano2, E. Alfrey1
1Department of Surgery, Southern Illinois University, 2Department of
Emergency Medicine, The University of California, San Diego
Introduction: Patients with thrombophilia and end-stage renal disease
(ESRD) are at increased risk for kidney graft thrombosis. We examined
if postoperative anticoagulation in renal transplant patients with known
thrombophilia prevents thrombosis.
Methods: Due to retrospective discovery of patients with thrombophilia after
catastrophic adverse events, we began studying patients at risk prospectively.
We considered risk factors to include previous graft thrombosis, frequent
fistula thrombosis, history of deep venous thrombosis, peritoneal dialysis,
or predialysis patients. Patients with thrombophilia pretransplant were
anticoagulated posttransplant. Patients’ charts were reviewed in a retrospective
manner. The data was entered into a relational database. Recipients received
calcineurin based triple therapy. The recipient age in years, type of transplant
(living donor vs. cadaveric), presence of thrombophilia, use of anticoagulation,
postoperative bleeding complications, and graft loss secondary to thrombosis
were examined. Categorical variables were compared using the unpaired
Students T-test. Nominal variables were compared using Chi-square.
Differences were significant at P < 0.05.
Results: Of 197 patients studied, 97 had thrombophilia including Protein C
deficiency (n=7), Protein S deficiency (n=4), Factor V Leiden mutation (n=4),
anticardiolipin antibody (n=6), lupus anticoagulant (n=8), prothrombin gene
mutation (n=1), antithrombin III deficiency (n=3), elevated homocysteine
(n=16), antinuclear antibody (n=1), mixed (any combination of the preceding,
n=27), or unknown (n=7). There were 24 patients that were HIPA positive.
There were no statistically significant differences between the two groups in
terms of age, HLA match, BMI, or incidence of acute rejection. Eight patients
with graft thorombosis were subsequently diagnosed with thrombophilia.
Four of these patients were successfully retransplanted using anticoagulation
with either heparin or argatroban and then coumadin for one year. None
of the patients who had a known thrombophilia and were anticoagulated
had graft thrombosis. Of the patients who were anticoagulated, 32% had a
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S.M. Flechner, H.Y. Tiong, A. Wee, L. Zhou, B. Lane, B. Mastroianni,
K. Savas, D. Goldfarb, C. Modlin
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation,
Cleveland, OH, USA
Purpose: Posttransplant lymphoceles and wound healing problems are
reported with greater frequency in kidney recipients given de novo sirolimus.
We report a program to reduce these problems based on the use of patient
selection; closed suction drains, and altered wound closure techniques.
Methods: Consecutive series of adult kidney-only recipients given antibody
induction followed by de novo sirolimus, mycophenolate mofetil, and steroids
were compared. Group 1- 103 patients transplanted with a weight restriction
<32 kg/m2; retroperitoneal closed suction drains placed at surgery (JacksonPratt or Blake); multilayer non-absorbable sutures, and no loading dose of
sirolimus. Sirolimus was introduced day 0-5 at 5mg. Group 2- A control group
of 204 patients were transplanted, many with BMI >30 kg/m2, with no drains,
and various suture techniques. All records and imaging studies were reviewed
for delayed wound healing and fluid collections greater than 3.0 cm after drain
removal.
Results: There was no significant difference in recipient demographics
between Group 1 and 2 groups, including mean age (47.8 vs. 48.4), BMI
(25.7 vs. 26.6), males (63.1% vs. 68.1%), whites (69.9% vs. 78.9%),
deceased donors (50.5% vs. 50%), Retransplants (8.7% vs. 7.3%), and
diabetics (27.9% vs. 28.4%). Median day drain removal was 18. There
was a significant (P <0.0001) reduction in lymphoceles identified, treated,
and treated by surgery in patients with closed suction drains (Table 1). In
addition there was a significant reduction in total (P=0.0054) and nonoperative (P=0.0095) wound healing problems. Multivariate analysis
demonstrated a dramatic reduction in lymphoceles in drained patients (OR
0.33; 95%CI .181-.596; p<.0001); while acute rejections (OR 3.14), DGF
(OR 1.54), and age (OR 1.16) increased the risk. Similarly, there was a
significant reduction in all wound healing problems in drained patients (OR
0.48; 95%CI .236-.997; p<.005).
Conclusions: A program of patient restriction by BMI, closed suction drains,
altered surgical technique, and no loading dose of sirolimus dramatically reduces
the incidence of lymphoceles and wound problems for patients starting de novo
on sirolimus based immunosuppression. Using this program wound healing
problems are similar or less than that reported with other immunosuppressive
combinations.
Number (%)
Lymphocele identified
Total treated

Group 1 Drained
N=103 (%)

Group 2
Undrained
N=204 (%)

Totals
N=307

23 (22.30)

95 (46.7)

118 (39.3)

0.0002

5 (4.8)

50 (24.5)

55 (18.3)

<0.0001
<0.0001

P Value

Operative drainage

2 (1.9)

29 (14.2)

31 (10.3)

Wound Problems Total

8 (7.8)

40 (19.6)

48 (15.6)

0.0054

Non Operative

3 (2.9)

29 (14.2)

32 (10.4)

0.0095

Operative repair

5 (4.8)

11 (5.4)

16 (5.2)

0.76
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341 AN OBSERVATIONAL MULTICENTER SPANISH
STUDY OF SURGICAL COMPLICATIONS AFTER
KIDNEY TRANSPLANTATION IN THE NEW ERA OF
IMMUNOSUPPRESSION

342 DIAGNOSIS AND SIGNIFICANCE OF TRANSPLANT
RENAL ARTERY STENOSIS
M. Allen1, F. Meybodi1, K. Busch2, L. Garry1, J. Raleigh3, J. Harris2,
K. Wyburn1, D.J. Verran1, J. Eris1, S. Chadban1
1
Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia,
2
Camperdown Vascular Laboratory, Sydney Australia, 3Dept of Radiology,
Royal Prince Alfred Hospital, Sydney, Australia
Transplant renal artery stenosis (TRAS) is a poorly understood entity with
incidence dependent on definition and imaging modality. Its clinical relevance
is complicated by the high frequency and multiple causes of hypertension
after kidney transplantation (KT). Doppler ultrasound is a frequently utilised
investigation modality after KT and should provide simple surveillance for
TRAS. However, diagnostic parameters specific to KT have not been elaborated
and the appropriate response to findings remains unclear.
Aim: To evaluate the value of TRAS surveillance using two ultrasound techniques
in the first 3 months after KT and to correlate findings with clinical management.
Methods: Consecutive KT patients underwent ultrasound assessment in a
hospital-based general ultrasound service on a routine basis and to investigate
transplant dysfunction. A diagnosis of TRAS was made after intrarenal
ultrasound (IUS) assessment using downstream waveform findings of ‘parvus
tardus’ and of resistive index (RI) <0.5. Findings were compared with a routine
outpatient assessment at 6-8 weeks after KT by a vascular surgery ultrasound
service assessing extrarenal (EUS) artery. The EUS diagnosis used well
established native renal artery criteria for a stenosis of >60% with maximum
peak systolic velocity (PSV) (>260cm/sec), demonstration of turbulence and
iliac to renal artery ratio (>3.0) as diagnostic parameters of a TRAS >60%.
Results were retrospectively compared with clinical data and outcomes.

343

RENAL TRANSPLANTATION IN THE MORBIDLY OBESE

W.M. Bennett, K.R. Henell, K.M. McEvoy, T. Batiuk, S. Pidikiti,
V. Douzdjian
Renal Transplant Program, Legacy Good Samaritan Hospital, Portland, OR,
United States
Renal transplantation is offered to many patients with severe co-morbidities
such as diabetes mellitus and atherosclerotic vascular disease but is often
denied to the morbidly obese, BMI > 35 kg/m2.(1) Since transplantation has a
survival advantage compared to dialysis despite morbid obesity, there is no a
priori ethical basis for denying transplantation in this population. We report a
large experience with high-BMI renal transplant recipients compared to nonobese controls. Of 626 consecutive kidney-only transplants performed between
1999 and the end of 2007, 94 were in morbidly obese recipients, 39 of whom
had BMI > 40. Demographics and outcomes are summarized in the table.
Graft Survival at 1 year (%)
Graft Survival at 3 years (%)
Deep Surgical Wound Infection (%)
Median Anastomosis Time (min)
Median Cold Ischemia (hours)
Median Length of Stay (days)
% Diabetic Cause of ESRD
% Living Donors
% Male
Median Age (years)
% Expanded Criteria DD Kidneys
% DCD DD Kidneys
Median BMI

BMI<30
n=439
92
84
1.7
31
9
6
28.6
39.5
57
49
20.3
3.9
24.7

BMI 30-35
n=109
92
86
2.8
33
12
6
40.4
32.5
58
53
28.4
6.8
32.2

BMI>35.1-40
n=55
88
70
7.3
34
13
6
47.3
34.5
40
51
19.4
5.6
36.9

BMI>40
n=39
84
74
10.3
34
13
6
41
28.2
51
51
21.4
3.6
43.1

There were no significant differences between groups in patient survival, while
the survival advantage of transplant over dialysis is clear. (Figure 1) Graft
survival in the BMI > 40 group was slightly but significantly worse than the
BMI 35-40 group, leading us to change our protocol to require a BMI < 40
prior to acceptance. As expected, wound infections were more common in the
most obese.
Conclusion: Renal transplantation can be offered to the morbidly obese since
transplantation carries a survival over dialysis and can be done relatively
safely.
Figure 1. Actuarial Patient Survivals, Transplant vs. Dialysis
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J. Pascual, F.J. Burgos, J. Zamora, A. Muriel, N. Plana on behalf of the
Spanish Surgical Complications after Kidney Transplantation Study Group.
Servicios de Nefrología, Urología and Bioestadística. Hospital Ramón y
Cajal, Madrid, Spain.
Surgical complications after kidney transplantation constitute an old problem
that requires revisiting in view of the increasing donor and recipient age and comorbidity, and the use of anti-proliferative immunosuppressive drugs that alter
tissue healing. We have assessed the prevalence of such complications and their
impact on survival rates in an observational study performed in 26 adult KT Spanish
units, including patients who received a KT during 2004 and were followed-up for
1 year (n=1434). Multiple organ transplants (n=41) and patients with insufficient
data (n=52) were excluded, so the final studied population comprised 1341 KTs,
including 16 double KTs. Mean donor age was 48.4±17.3 years, 97.2% were
deceased donors and 2.8% living related donors, mean recipient age was 51.1±13.5
years, 59% were males and 13.4% retransplantations. Initial immunosuppression
included steroids (99%), MMF (92%), tacrolimus (66%), CsA (18%), or sirolimus
(9%). Delayed graft function was observed in 37% and treated acute rejection
in 20.5%. During the first year of evolution, 8.6% of the grafts were lost and
3% of the recipients died. Cumulative incidences of the complications were:
wound (non-infectious) 6%, wound infection 4.8%, lymphocele 5.7%, perigraft
hematoma 4.8%, perigraft abscess 1.3%, vascular thrombosis 2.9%, vascular
hemorrhage 1.2%, urinary tract leaks 5.7% (ureteral 4.3%, bladder 1.3%), urinary
tract stenoses 5.5% (ureteral 3.8%, pyeloureteral 1.7%). In the univariate analysis,
the development of at least one complication was associated with 4-fold graft loss
risk (17.1% vs 4.9%, OR 4.04, p=0.0001). In the multivariate logistic regression
analysis, detected risk factors for graft loss were stroke as the cause of donor death
(OR 2.75, p=0.001), more than 3 HLA mismatches (OR 2.38, p=0.008), a low
serum albumin (OR 0.52, p=0.001), delayed graft function (OR 2.41, p=0.003),
treated acute rejection (OR 3.56, p<0.0001), ureteral or ureterovesical leak (OR
3.57, p=0.007), perigraft abscess (OR 26.8, p<0.0001) or vascular graft thrombosis
(OR 95.9, p<0.0001). Patient mortality was only associated with recipient age
(OR 1.09, p<0.0001) and graft loss (OR 3.92, p=0.001).
In addition to classical complications associated with graft loss such as DGF
or acute rejection, and surgical complications obviously determining lower
graft survival (vascular thrombosis and perigraft abscesses), ureteral leaks are
associated with 3.5-fold risk of graft loss despite surgical intervention, and
indirectly impair patient survival.

Results: From Jan 2004 to September 2007, 249 patients underwent KT with
minimum follow up of 3 months. They had 1077 hospital-based IUS in first 3
months (4.3 +/- 2.3 per patient) reporting 7 TRAS (including one occlusion)
(2.8%). Two of these IUS diagnoses were demonstrated subsequently to be
false positives.
In comparison, 191 patients additionally underwent routine EUS at 52+/-22
days after KT with 44 patients meeting criteria for TRAS >60% (23%)
(P<0.0001). For clinical indications or degree of stenosis, 19 of these patients
underwent CT angiography with one false positive finding.
Using the combination of imaging techniques for 48 TRAS, the site and cause
of stenosis was the result a kink adjacent to the anastomosis in 48%, mid artery
kink 25%, anastomotic 14% and donor atheroma 13%. Kinks tended to have
a more benign clinical course with only 2 of 31 patients requiring intervention
(7%) compared 6 of 17 patients with donor atheroma or anastomotic issues
(35%)(P<0.05). Donor origin and configuration of anastomoses were not
significant risk factors.
Conclusions: The incidence of TRAS is definition dependant. In the first 3
months after transplantation, it is 23% if based on extrarenal US assessment.
If based on need for intervention, it is 3%. The long term downstream effect
of clinically insignificant stenoses of >60% on kidney transplant function is
unknown but may be determined by longitudinal study provided that it is not
based on intrarenal US assessment.
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344 WEIGHT GAIN IN THE FIRST YEAR AFTER KIDNEY
TRANSPLANTATION IN THE U.S.
D. Steffick1, F. Luan2, S. Norman2, A. Ojo2
Arbor Research, 2University of Michigan
Background: Obesity is associated with inferior outcomes after kidney
transplantation, though much of the research on posttransplant weight gain
comes from small studies. We evaluated the descriptive features and risk
factors for weight gain during the first year after kidney transplantation in the
U.S. Weight gain following transplant appears to be common and multifactorial
in origin.
Methods: 61,365 recipients of solitary kidney transplants in the United States,
engrafted between 1/1/2000 and 12/31/2006, were studied. Multivariate
logistic regression analysis was used to evaluate the relationship between
weight gain and characteristics of the recipient, donor, transplant, and discharge
immunosuppression regimen.
Results: Most recipients gained weight in the first year following transplant
(68.6%), although some lost weight (29.6%), and very few stayed the same
(1.8%). Among those discharged with steroids as part of their maintenance
immunosuppression, 70% gained weight compared to 63.5% for those
without steroids (p<0.001). The median weight gain was 2.5kg (interquartile
range=9.9kg) for those without steroids and 4.1kg (interquartile range=10.9kg)
for those with steroids (Figure 1).

in addition to the known risk factor of corticosteroids. However, several less
easily modifiable factors, such as age, race, gender and cause of kidney failure
are also associated with gaining weight in the first year posttransplant.

TUESDAY
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Figure 1: Percentage of Kidney Transplant Recipients by Change in Weight and
Steroids at Discharge
The results from models of the odds of gaining 10kg+, 15kg+, or 20kg+ were
similar to each other. Factors significantly, positively associated with weight
gain were: younger age, African American, Hispanic, BMI at transplant of
25 or higher, primary diagnosis of diabetes, hypertension, or congenital/rare/
familial/metabolic disorders and zero HLA mismatch.
Factors significantly associated with lower odds of gaining 10kg+, 15kg+, or
20kg+ were: no steroids as maintenance immunosuppression, older age, male
sex, BMI less than 20 or missing at transplant, diagnosis of polycystic kidney
or tubular/interstitial disease, transplanted within 1 year starting ESRD or 6+
years after starting ESRD, and having a donor who was older, female, Asian,
died from stroke, or weighed more than the recipient.
Aside from corticosteroids, other maintenance immunosuppression regimens
had significant effects on the likelihood of gaining 10kg or more. With the
combination of tacrolimus and mycophenolate mofetil as the reference group
(the regimen for 51% of the sample), tacrolimus alone (HR=1.26, p=0.006) and
cyclosporine and mycophenolate mofetil (HR=1.36, p<0.001) were associated
with greater odds of 10kg weight gain. Conversely, tacrolimus and sirolimus/
everolimus (HR=0.81, p<0.001), mycophenolate mofetil and sirolimus/
everolimus (HR=0.73, p<0.001), and tacrolimus, mycophenolate mofetil, and
sirolimus/everolimus (HR=0.69, p<0.001) were associated with lower odds of
a 10kg weight gain.
Conclusion: Weight gain is common after kidney transplantation in the U.S.
Immunosuppressant drug regimen is significantly associated with weight gain,
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345 MORTALITY-PREDICTABILITY OF BODY MASS INDEX
(BMI) IN TRANSPLANT-WAIT-LISTED MAINTENANCE
HEMODIALYSIS PATIENTS: A 5-YEAR NATIONAL COHORT
STUDY
K. Kalantar-Zadeh1, E. Streja1, J. Jing1, C.J. McAllister3, G.M. Danovitch2, S.
Bunnapradist2
1
Harold Simmons Center for Kidney Disease Research and Epidemiology at
Harbor-UCLA, 2UCLA Kidney Transplant Program; and (3) DaVita, Inc; Los
Angeles and Torrance, CA
Background: Even though obesity appears associated with greater survival in
maintenance hemodialysis (MHD) patients, a phenomenon known as “obesity
paradox” or “reverse epidemiology”, obese MHD patients who are in the
waiting list for a deceased renal transplant are usually asked to lose weight.
We hypothesized that higher BMI in transplant-waitlisted MHD patients is
incrementally associated with greater survival during the waiting period.
Methods: By linking the 5-year (7/2001-6/2006) national database of a large
dialysis organization (DaVita Inc) to the Scientific Registry of Transplant
Recipients (SRTR), we identified 10,830 DaVita MHD patients, who were
transplant-waitlisted but did not receive any kidney transplantation over the
5-year period. Time-dependent survival model examined the assocaition of the
calendar-quarterly BMI (using 13-week averaged post-HD dry weight) with
survival adjusted for case-mix and time-varying surrogates of malnutritioninflammation complex syndrome (MICS).
Results: The 10,830 MHD patients were 59.1±15.4 years old and included
48% women and 37% diabetics. The 13-week averaged BMI was 27.4±7.1 kg/
m2. Unadjusted and adjusted survival analyses showed incrementally greater
survival with higher BMI>23 kg/m2 (see Figure):

Conclusions: Obese transplant-waitlisted MHD patients appear to have
greater survival that is incrementally associated with higher height-adjustedweight, i.e., a reverse epidemiology with dose-response phenomenon. These
findings question the benefit of recommending weight reduction during the pretransplant wait-listing in obese MHD patients.
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Number per year

Tx (% of centers)

LKD Evaluations (% of LKD Tx (% of centers)
centers)

MINI-ORAL SESSION 9: RENAL 3: LIVING DONORS

≤ 50
51-100
101-200
200+

21. 9
37. 5
23. 4
17. 7

43. 9
22. 8
19. 3
14

POSTER BOARD NUMBER P2 – 375
346 METABOLIC SYNDROME COMPONENTS BEFORE
LIVING KIDNEY DONATION AND LONG-TERM RENAL
FUNCTION OUTCOME FOR THE DONORS

BEFORE NEPHRECTOMY LAST FOLLOW-UP
GROUP 1
GROUP 2
GROUP 1
GROUP 2
Gender F/M

12/15

50/18

Age (yr)

45. 4 ± 12. 4

34. 2 ± 10. 5

Time after donation (yr)
BMI kg/m2
Triglycerides mg/dl
HDL-C mg/dl
SBP mmHg
DBP mmHg
Fasting glucose mg/dl
Microalb mg/24h
eGFR ml/min/1. 73 m2

27. 2 ± 2. 1
207. 5 ± 84. 9
35. 8 ± 6. 9
119 ± 11
77. 8 ± 7
94. 8 ± 9. 7
2. 6 ± 6. 2
94. 6 ± 23. 2

24. 9 ± 3. 1
105. 9 ± 45. 5
47. 1 ± 11. 3
112 ± 9. 5
71. 7 ± 7. 8
89. 1 ± 8. 7
5. 7 ± 11. 9
90. 9 ± 20. 7

eGFR
*P value corresponds to last follow-up comparisons
NS = no significant

12/15

*P

50/18

49. 6 ± 11. 8

42. 4 ± 11. 2

0. 004

4. 8 ± 3. 6

7. 8 ± 5. 5

0. 009

27. 2 ± 2. 9
219. 7 ± 92. 5
39. 7 ± 23. 3
119. 2 ± 10. 3
78. 3 ± 8. 8
93. 2 ± 11. 1
30. 3 ± 82. 3
65. 1 ± 15. 1

25. 9 ± 3. 6
139. 2 ± 94. 3
44. 9 ± 13. 5
112. 5 ± 13. 4
74. 7 ± 9. 4
98. 4 ± 10. 4
12. 2 ± 13. 6
72. 5 ± 15. 2

NS
0. 000
NS
0. 02
NS
NS
NS
0. 04

-34. 3 ± 31. 6 -19. 4 ± 19. 4 0. 006

17% of centers proceed with medical testing despite concerns with mental
health, cognitive functioning or substance abuse.
Follow-Up Practices: Only 38. 3% actively follow donors regarding
psychosocial health after donation. The professionals most often involved are
social workers (72%) and nurse coordinators (69%). The majority of followup is conducted via phone (83. 3%); though appointments (69. 4%) and
questionnaires (11. 1%) are also utilized. 65% initiate follow-up with donors
1-4 weeks post-operatively, whereas only 27% of programs maintain contact
at both 3-6 months and 12 months. 83. 3% offer post-operative psychosocial
support; 62% only under certain circumstances. This support is provided
by social workers (90%), psychologists (30%), and/or psychiatrists (28%).
Support is available indefinitely in 68% of programs.
Conclusion: The results of this survey clearly demonstrate that practices
utilized for the psychosocial evaluation and follow-up of LKDs at US Tx centers
are widely variable. Without routine follow-up of donors, Tx centers are less
likely to capture post-operative psychosocial issues that may result from organ
donation. Standardized psychosocial evaluations and post-operative follow-up
of LKDs should become a mandatory part of their care, which will require
increased support from health care policy makers.

POSTER BOARD NUMBER P2 – 377
348 CORRELATION OF RENAL FUNCTIONAL
MEASUREMENTS AND IMPLANTATION BIOPSY WITH
OUTCOMES IN LIVING DONOR RENAL TRANSPLANTATION
T.S.M. Tan1, A.S.T. Liew1, M. Teh2, M. Kaur1, C-L. Goh1, A. Vathsala1
Division of Nephrology, Department of Medicine, National University
Hospital 2Department of Pathology, National University Hospital
Background: Defining the level of renal function for suitability for renal donation
in living donor renal transplant (LDRT) is crucial to ensuring donor safety and
optimizing recipient outcomes. Creatinine clearances (CCT) as calculated by
24-hour urine collections, while commonly used, may under- or over-estimate
glomerular filtration rate (GFR) in patients with normal renal function as in
renal donors. Creatinine-based formulae have been likewise suggested to be
insufficient to determine suitability in renal donors; thus guidelines recommend
the need for supplementation or replacement of creatinine-based estimations of
GFR with radio-isotopic measurements. The aim of this study was to determine
the correlation of creatinine-based renal functional measurements in an Asian
population with implantation biopsies (IB), performed as part of a routine
protocol biopsy program, as well as recipient outcomes post LDRT.
Methods: 22 live renal donors and their recipients undergoing LDRT with an
IB between June 2004 and August 2006 were included in the study. All live
renal donors met standard criteria for suitability for renal donation with normal
renal function and no proteinuria. IB were scored semi-quantitatively based
on glomerular sclerosis, tubular atrophy, interstitial fibrosis, and arteriolar
narrowing, using a novel scoring system with a minimum score of 0, and a
maximum score of 12. Donor CCT was correlated with GFR calculated with
the abbreviated Modification of Diet in Renal Disease (MDRD) equation
(eGFR) and the modified MDRD equation for Chinese population (c-aGFR)
and IB scores. IB scores were likewise correlated with the incidence of delayed
1
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347 PSYCHOSOCIAL SCREENING AND FOLLOW UP
PRACTICES FOR LIVING KIDNEY DONORS (LKD) IN THE US
N. Schroder1, A. Haririan2, C. Welsh3 and M. Cooper4.
1
Department of Social Work; 2Medicine; 3Psychiatry and 4Surgery, University
of Maryland Medical Center, Baltimore, MD, United States.
Body: Psychosocial health of LKDs before and after donation is of great
importance. Unfortunately, this issue has been neglected to a large extent.
Although a psychosocial evaluation is considered a mandatory component
of all LKD evaluations in the United States, a standardized protocol does not
exist. Similarly, follow-up of donors after surgery appears to be an infrequent
practice, given the limited data available about post-operative outcomes.
Methods: We examined the variability in psychosocial screening and followup practices across transplant (Tx) centers by conducting a 68-question
online survey regarding practices and related donor issues. Several questions
allowed for more than one response. The survey was mailed via listservs of 2
professional Tx societies.
Results: Characteristics of the 69 participating Tx centers are summarized in Table 1.
Tx Center Characteristics

Psychosocial Screening Practices: 88. 3% of centers require donors to
complete a psychosocial evaluation, conducted by social workers (92. 5%),
psychologists (16. 6%) and/or psychiatrists (12. 9%). Psychosocial evaluations
are most often completed concurrently with the medical evaluation (84. 9%).
30. 1% may initiate it prior to medical evaluation and 9. 4% wait until after
their medical evaluation is complete. 87% inquire about mental health in the
evaluation, though only 30. 6% of centers use a standardized questionnaire. 98.
6% assess alcohol use and 95. 7% assess drug use. Utilization of standardized
questionnaires for alcohol and drug use is uncommon (24. 5%, 17. 4%).
Interestingly, 18% permit donation with alcohol abuse and 36. 7% with drug
abuse. 58. 3% allow donors with a recent history of substance abuse (current
abstinence of less than one year) to proceed with the evaluation process. More
than 95% exclude cocaine or heroine users, while 95. 1% allow marijuana users
to donate. Only 21. 7% require donors to stop smoking prior to surgery.
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J. Alberu1, M. Arvizu-Hernandez1, R. Bermudez2, L.M. Miranda2, A. Arvizu1,
M. Vilatoba1, L.E. Morales3, B. Gabilondo1, R. Correa-Rotter3, and F.J.
Gomez-Perez2.
1
Transplantation, 2Endocrinology and 3Nephrology, Inst. Nal. Ciencias
Medicas y Nutricion SZ, Mexico.
Background: Metabolic syndrome (MS) may represent an additional burden
for the remaining kidney of donors.
Aim: To evaluate the impact of 3 criteria for MS on long-term renal function of
individuals who donated a kidney.
Methods: Data regarding MS criteria and renal function were gathered for 95
kidney donors before nephrectomy (BN) and at last follow-up. For the analysis,
donors were divided into 2 groups: those with ≥3 criteria for MS BN (group 1),
and those with < 3 criteria for MS (group 2).
Results: The Table summarizes demography of the study population, metabolic
parameters and renal function obtained BN as well as at last visit.
Conclusions: A significantly greater decline in eGFR was observed for group
1 despite of a shorter time elapsed since nephrectomy. This finding suggests
that MS risk factors (RF) detected before donation can impact donor renal
function outcome. Whether strict supervision and specific intervention for the
correction of MS RF after nephrectomy could modify these results is a matter
that deserves further evaluation. These interventions ought to be included in
prospective studies.

63. 4
22. 2
11
3. 2
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graft function (DGF), acute rejection (AREJ) and eGFR, in LDRT recipients at
1 year post-transplantation.
Results: 22 living donors (45. 5% male, 45. 5% Chinese, mean age 41. 4 years,
mean baseline serum creatinine level 82. 5 (±23. 59) μmol/L) had a mean CCT
of 90. 57 (± 27. 09) mL/min, a mean eGFR of 84. 95 (± 16. 55) mL/min and a
mean c-aGFR of 69. 15 (± 44. 81) mL/min. There was no correlation between
CCT and eGFR, or c-aGFR in the overall study population and in the Chinese
subgroup. The majority of donors had an IB score of 0 (59. 1%, compared with
22. 7% with score 1, 9. 1% with score 2, and 9. 1% with score 3), and there
was no correlation between any of the renal functional measurements with IB
scores. Furthermore, there was no correlation of IB scores with outcomes post
LDRT in recipients (4. 6% had DGF, 22. 7% had AREJ at 1 year) nor with
1-year eGFR (52 ± 17. 31 mL/min).
Conclusion: As few LDRT donors had evidence of any significant histological
damage on IB, our study demonstrates that CCT remains a reliable and useful
screening tool for renal functional measurement in live renal donors. Moreover,
both abbreviated MDRD and c-aMDRD formulae have poor correlation to
CCT and should not be used as a substitute in live renal donors. Excellent
graft outcomes can thus be achieved in LDRT using standard measures of renal
function alone.
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349 LONG-TERM RISK OF HYPERTENSION AND RENAL
DYSFUNCITON IN LIVING KIDNEY DONORS
S.H. Kim 1, 3, H.E. Yoon 1, S.C. Park 2, B.S. Choi 1, Y.S. Kim 1, I.S. Moon 2,
B.K. Bang 1, S.Y. Kim 1, Y.B. Koh 2, C.W. Yang 1
1
Department of Internal Medicine, The Catholic University Of Korea, 2
Department of Surgery, The Catholic University of Korea, 3 Department of
Internal Medicine, Chung-Ang University
Background: Donor nephrectomy may result in remnant single nephron
hyperfiltration with associated hypertension and progressive renal dysfunction.
Our aim was to assess the long-term risks for kidney donors of developing
hypertension, proteinuria and renal dysfunction.
Methods: From 1969 to 2005, 1356 live kidney nephrectomies were performed
at Kangnam St. Mary’s hospital in Korea. We retrospectively reviewed patient’s
chart, blood pressure, serum creatinine, glomerular filtration rate and urine
protein. MDRD formula was used to estimate glomerular filtration rate.
Result: There were 152 (11%) donors who were followed 1 or more years
after nephrectomy. The donors were 44 ± 14 (range 21-87) years old, 73 (48%)
were males and median time since donation was 2. 5 (1-21) years. Mean serum
creatinine was 1. 17±0. 75 (0. 57-10) mg/dL, creatinine clearance 69±13 ml/
min. Blood pressure had increased from 113 ± 10/75 ± 8 to 116 ± 12/77 ±
8 (p < 0. 01), and 9 (6%) of the donors are taking antihypertensive drugs.
Urinary protein excretion after donation was not increased. Three (2%) donors
developed proteinuria (>300mg/day). Overall renal function is well preserved
after donor nephrectomy, but 3/1356 (0. 019%) of the donors developed end
stage renal disease requiring renal replacement therapy and 6 showed elevated
serum creatinine more than 1. 5 mg/dL.
Conclusion: Follow-up rate of living donor after donation is still low, but there
is an increasing tendency of chronic kidney disease after donation. Follow
up of all living kidney donors with blood pressure, creatinine clearance and
proteinuria was strongly recommended.

POSTER BOARD NUMBER P2 – 379
350 ARE WE TAKING A PROPER CARE OF THE LIVING
DONORS? A FOLLOW – UP STUDY OF LIVING KIDNEY
DONORS IN POLAND AND FURTHER MANAGEMENT
PROPOSAL
W. Rowinski 1, A. Chmura 2, M. Ostrowski 3, Z. Wlodarczyk 4, B. Rutkowski 5,
M. Bieniasz 2, M. Durlik 2, K. Dziewanowski 6, J. Matych 7, R. Grenda 8
1
Polish Union Transplantation Medicine, 2 Medical University Warsaw, 3
Pomeranian Medical School, 4 Collegium Medicum Bydgosiensis, 5 Medical
School Gdansk, 6 Regional Hospital Szczecin, 7 Medical University £odŸ, 8
Institute Child Health Center
The first kidney transplantation was done in Poland in 1966. Since that time
approximately 11 000 patients have undergone this procedure, but most of them
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received the kidney from deceased donors. Although the first living donor kidney
transplantation was done as early as in 1967 only 342 such procedures were
done (2. 7%), most transplants were performed (197) between 1997 – 2007.
Legal regulations in Poland require careful long-term follow-up of the donors.
The aim of this study was to review the results of the living donors follow
– up study in Poland. The questionnaire was send to eleven centers who
performed during last 10 years 197 LD kidney transplantations. The answers
came back only from 6 centers reporting data on 118 donors. In two centers
no follow-up of the donors was available. Donors (nearly all genetically or
emotionally related) were 23 to 61 years old (males, females). In no donor
any abnormality was found regarding cardiovascular function or metabolic
abnormalities. Eleven (out of 118 donors) has not reported to the control
visit. The follow-up of remaining donors ranged from 2 to 8 years. 4 donors
died (4-5 years after nephrectomy (due to cerebral hemorrhage, brain tumor,
stomach cancer and car accident respectively). The mean serum creatinine
rose from 0. 8 mg/dL to 1. 25 mg/dL, (but in two pts was over 2 mg/dL)
Calculated creatinine clearance (aMDRD) decreased from 95ml/min to 65
ml/min (p<0. 05). In 3 donors proteinuria (>0. 6g/24h) was observed 3-5
years after donation. Three patients experienced mild hypertension (two
requiring treatment), in the remaining donors the blood pressure remained
normal.
Conclusions: Since 2008 several changes have been introduced. Transplant
centers are obliged to report all data on each LD procedure with the followup data. The Living Donor Register is obligatory (no reporting, no financial
reimbursement from the Insurance). All donors are insured (by Alianz SA)
for 3 months from transplantation. Stem-wise interventional reno- and
cardioprotection program has been prepared to be used after nephrectomy for
life donors.

POSTER BOARD NUMBER P2 – 380
351 LONGITUDINAL STUDY ON RENAL EFFECTS OF
CHANGES IN BODY WEIGHT AFTER LIVING KIDNEY
DONATION: WEIGHT GAIN BURDENS THE REMNANT
KIDNEY
M. Rook1, H. Tent1, S. Hofker2, R. Ploeg2, J. Homan van de Heide1,
W. van Son1 and G. Navis1.
Departments of 1Nephrology and 2Surgery, University Medical Center
Groningen, the Netherlands
Whereas presence of overweight is associated with hyperfiltration and in
particular with renal function loss after (donor) nephrectomy, renal effects
of weight gain are currently unknown. Therefore, we analysed longitudinally
whether a post-donation increase in body weight had impact on long-term renal
filtration and renal adaptation.
We invited 55 consecutive donors (mean age at donation 47±12 years;
27% male) who completed the screening protocol with subsequent donor
nephrectomy in our centre in 2000-2002 for follow-up of renal hemodynamic
measurements. 37 donors consented (67%) and GFR (iothalamate), ERPF
(hippuran) and filtration fraction (FF, GFR/ERPF*100) were measured six
years after donation. Mean body weight increased from 77±12 kg to 81±13 kg
(range -9 to +20; p≤0. 01). BMI hereby increased from 25. 9±4. 4 to 27±4. 7
kg/m2 (p≤0. 01). After six years, single kidney GFR and ERPF had increased
by 25±8 and 99±33, respectively (both p≤0. 001). The amount of weight gain
correlated with the increase in GFR (R=0. 33, p≤0. 05), but not ERPF. Whereas
mean FF was stable, FF significantly increased in donors with weight gain and
decreased in donors with weight loss (R=0. 57, p≤0. 001).
In conclusion, post-donation changes in body weight or BMI affected renal
adaptation after nephrectomy. Weight gain induced higher filtration fraction,
indicating hyperfiltration, which potentially threatens renal function. Postdonation weight gain thus poses an extra burden on the remaining kidney which
can and should be prevented. This must be emphasized in donor screening,
evaluation and follow-up.
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352 EVALUATING POTENTIAL LIVING KIDNEY
DONORS BY RENAL FUNCTION EQUATIONS LEADS TO
UNNECESSARY REDUCTION OF THE DONOR POOL
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353 COMPENSATORY INCREASE IN GFR UP TO 10 YEARS
AFTER RENAL DONATION
U. Berg
Division Of Pediatrics, Dept. Of Clinical Science, Intervention And
Technology
124 (70 males) living kidney donors, 40±9 years of age with a BMI of 24.
9±3. 2 kg/m2 at donation, were repeatedly investigated with renal function,
blood pressure and urine albumin excretion rate 3 months after and then every
other year up to 16 years after donation. 69 donors were also investigated
before donation. Glomerular filtration rate (GFR) and effective renal plasma
flow (ERPF) were determined by renal clearances of inulin and PAH during
water diuresis and continuous infusion. Before donation absolute GFR and
ERPF (ml/min) was significantly higher in male donors compared with female
donors but when calculated in relative values (ml/min per 1. 73m2) there was
no difference between males and females. In those 69 donors investigated both
before and 3 months after donation GFR decreased from 104±13 to 69±10 ml/
min per 1. 73m2, i. e. 66% of predonation value and ERPF from 536±97 to
349±68 ml/min per 1. 73m2, i. e. 65% of predonation value.
123 donors were studied 3 months after donation and GFR was 69±10 and
ERPF 344±65 ml/min per 1. 73m2. GFR increased successively up to 10 years
after donation (77±11 ml/min per 1. 73m2) whereafter GFR remained stable.
ERPF, however, did not change during the follow-up. There was no difference
in relative GFR or ERPF between sexes during follow-up.

POSTER BOARD NUMBER P2 – 383
354 EFFECT OF PRE-DONATION BLOOD PRESSURE, GFR
AND PROTEINURIA ON THEIR POST-DONATION LEVELS
A. Rizvi, F. Jawad, E. Ahmed, M.N. Zafar, A. Naqvi
Sindh Institute of Urology And Transplantation
Objective: To study the impact of pre-donation blood pressure, 24 hours urinary
protein and GFR on the development of Hypertension (BP>140/90 mmHg)
(HTN), persistent protein excretion (>150mg in 24 hours) and declining renal
function GFR (¡Ü 60 ml/min) after live related donor nephrectomy. The role of
duration of nephrectomy was also analysed.
Methods: The records of 993 kidney donors were analysed. Pre and post
donation blood pressure figures were noted along with 24 hours urine proteins
and GFR results. The data was statistically analysed by using the t-test, chi
square test and logistic regression and p-values were obtained for significance.
Results: A total of 993 donors were studied. The mean age was 36. 6¡À10. 8
years, with the majority being < 30 years. The male to female ratio was 1. 1: 1.
Hypertension was found in 159 (16%) donors, proteinuria (>300 mg/24 hours)
in 42 (5%) and GFR ¡Ü 60 ml/min in 67 (7%) donors.
The multivariate analysis showed that age>40 years (OR=1. 6), pre-donation
systolic BP>130mm Hg (OR=1. 6), pre-donation GFR (¡Ü100 ml/min) (OR=1.
7) and pre-donation protein excretion >150mg/24hours (OR=1. 8) were
significant for development of post-donation HTN.
Post-donation low GFR (< 60 ml/min) was associated with age> 40 years
(OR=2. 6) and pre-donation systolic blood pressure >130 mm Hg (OR=1. 9).
Persistent proteinuria >150 mg/24 hours was related to high pre-donation
protein excretion >150mg/24 hours (OR=2. 6) and smoking (OR=1. 9).
Duration of nephrectomy was significantly associated with the development of the
studied factors. A period of ¡Ý10 years showed 27% donors to have hypertension,
8. 2% had GFR ¡Ü 60 ml/min and 14% had proteinuria >300 mg/24 hours.
Conclusion: Pre-donation factors play an important role in the evolution of
hypertension, proteinuria and declining GFR.
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355 IS LAPAROSCOPIC DONOR NEPHRECTOMY REALLY
THE WAY AHEAD?
S. Guleria1, R. Kumar1, S. Reddy1, S. Jain1, S. Aggarwall1, S. Mahajan1,
S. Gupta1, D. Bhowmik1, S. Aggarwall1, S. Tiwari1
1All India Institute of Medical Sciences, 2All India Institute of Medical
Sciences, 3All India Institute of Medical Sciences, 4All India Institute of
Medical Sciences, 5All India Institute of Medical Sciences, 6All India Institute
of Medical Sciences, 7All India Institute of Medical Sciences, 8All India
Institute of Medical Sciences, 9All India Institute of Medical Sciences, 10All
India Institute of Medical Sciences
Aim: The present study was carried out to assess the impact of the laparoscopic
donor nephrectomy on donor morbidity.
Material and Methods: Sixty consecutive live related donors were randomized
in to two groups. Group I underwent a laparoscopic donor nephrectomy
through a trans-peritoneal approach while Group II underwent an open mini
donor nephrectomy through a retroperitoneal approach. The laparoscopic
donor nephrectomy was carried out through a standard four-port technique
by a trans-peritoneal approach. The mini donor nephrectomy was carried out
through a six cm flank retro- peritoneal incision. Both Groups were evaluate
with regard to operative time, post –operative stay and the visual analogue pain
score at the time of discharge
Results: The mean age of the group that underwent open donor nephrectomy
was 47. 3 with a mean of BMI 19. 9 while that of the laparoscopic donor
nephrectomy group was 40. 6 with a mean BMI of 21. 9. There were 6 males
and 24 females in the open group and 26 females and 4 males in the laparoscopic
group. The mean operating time was 55. 23 minutes in the open group and 132.
34 minutes in the laparoscopic group.
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Renal function equations are advocated for cheap and simple estimation of
renal function. Many centres estimate glomerular filtration rate (GFR) by
these equations to evaluate potential living kidney donors. However, these
renal function equations were developed in populations with renal disease and
generally perform poorly in subjects without renal function impairment. We
therefore analysed MDRD and Cockcroft-Gault (CG) in comparison to true
GFR, before as well as after donor nephrectomy in 250 consecutive donors
who donated between 1996 and 2007.
GFR was measured as the clearance of 125I-iothalamate 4 months before and
2 months after kidney donation; MDRD and CG were calculated from data
obtained on these same days. GFR and CG were normalized for body surface
area to allow comparison with MDRD. Based on clinical practise, we applied
a hypothetical lower limit of 80 ml/min/1. 73 m2 by either MDRD or CG and
analyzed true GFR as well as post-donation outcome in donors considered noteligible to donate by renal function equations.
Mean donor age was 50±11 years, 56% female. For the entire population, predonation GFR was 103±15, CG 79±14 and MDRD 70±10 ml/min/1. 73 m2.
After donation, mean GFR was 65±11, CG 61±11 and MDRD 52±7 ml/min/1.
73 m2. When the limit of eGFR<80 was applied, 210 donors would have been
declined for donation by MDRD and 141 donors by CG. Donors with eGFR
below the threshold were significantly older and more often female.
Donors with MDRD<80 were 51±10 years old and had a GFR of 102±15 ml/
min/1. 73 m2. After donation, GFR was 65±10 ml/min/1. 73 m2 in this subgroup.
Donors with CG<80 were 55±8 years old and had a GFR of 99±13 ml/min/1.
73 m2. Post-donation GFR was 62±10 ml/min/1. 73 m2 in this subgroup. For
comparison: donors with either MDRD≥80 or CG≥80 had a post-donation
GFR of 70±10 ml/min/1. 73 m2 (both p<0. 05).
Thus, renal function equations considerably underestimated true GFR. Donors
who would not have been eligible to donate based on MDRD or CG below 80
ml/min/1. 73 m2, displayed adequate and acceptable remnant renal function
after donation. In conclusion, use of renal function equations for selection of
kidney donors lead to an unnecessary reduction of the donor pool. MDRD in
particular is not suitable for the use in donor screening.

Four years after donation 33% of the males and 25% of the females showed
hypertension (>140/90) but none had developed albuminuria not even
microalbuminuria.
In conclusion GFR increases up to 10 years after donation irrespective of donor
age at donation.
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The post –operative stay was three days in the open group and four days in the
laparoscopic group. There was no wound infection or chest infection in either
group. However the laparoscopic group had a significantly higher incidence of
ileus as compared to the open group. The visual pain score was 4 in the open
group and 6 in the laparoscopic group. At one-month post operatively there
was no difference between the two groups with regards to pain score. The graft
function was also similar in the two groups.
Conclusion: The mini open donor nephrectomy is time tested and has lesser
post operaqtive stay and pain than the laparoscopic donor nephrectomy group
especially in our settings where most of our donors have a low BMI. It may be
the procedure of choice in patients with a low BMI

MINI-ORAL SESSION 10:
IMMUNOSUPPRESSION 2 – LIVER AND LUNG
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356 CAMPATH-1H (C1H) INDUCTION IN ADULT LIVER
TRANSPLANTATION: SIX YEARS EXPERIENCE OF A SINGLE
CENTER.
P. Tryphonopoulos, D. Weppler, S. Nishida, D. Levi, J. Moon, A. Sornaraj, A.
Berlanga, G. Selvaggi, T. Kato, E. Island, P. Ruiz, A. Tzakis
University of Miami
Introduction: We report our 6 years experience with the use of Campath-1H
(C1H) induction in adult liver transplantation.
Materials and methods: Since December 2001, C1H induction with low dose
maintenance tacrolimus immunosuppression was administered to 166 adult
recipients of a liver allograft. Most common primary diseases were Laennec (n=60),
cryptogenic cirrhosis (n=31) and autoimmune: PSC (n=17), PBC (n=16) and AIH
(n=14). The first dose of C1H was administered immediately before (n=74) or after
(n=92) the transplant procedure. Follow up was until December, 2007.
Results: Five year patient and graft survival was 90% and 85% respectively.
There were 14 deaths due to stroke (n=2), chronic rejection (n=2), failure to
thrive/pneumonia (n=3), sepsis (n=2), hepatic artery thrombosis, HCC, prostate
cancer, graft lymphoma and non-compliance (one each). Seven patients were
retransplanted, for primary non function (n=2), portal vein thrombosis (n=1),
hepatic artery thrombosis (n=1), hepatitis B (n=1) and chronic rejection (n=2).
Thirty six patients had biopsy proven rejection episodes: mild (n=28),
moderate (n=9) or severe (n=3). The average tacrolimus 12 hour trough
levels were 6. 6, 5. 2 ng/ml and 2. 78 ng/ml for the 1rst, 3nd and 5th year
post-transplantation, respectively. There was no significant difference in the
outcome of the transplant so far, between patients that received C1H before or
after the transplant procedure.
Immunosuppression-related complications included A). Opportunistic infections:
most common were Herpes Zoster (n=19), CMV (n=3), and Herpes Simplex (n=3),
B). Neoplasms: skin cancer (n=3), Kaposi sarcoma (n=1), lymphoma (n=2) and
C). Nephrotoxicity: Five patients received a kidney graft for diabetic nephropathy
(n=2), nephrotic syndrome (n=1) and calcineurin nephrotoxicity (n=2).
Conclusion: The use of C1H induction with half the usual dose of tacrolimus
is an effective regimen in adult liver transplantation. The timing of C1H
administration does not seem to affect the clinical outcome so far.
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357 CONVERSION TO ENTERIC-COATED MYCOPHENLATE
SODIUM (EC-MPS) FROM MYCOPHENOLATE MOFETIL
(MMF) IN STABLE LIVER TRANSPLANT RECIPIENTS
– COMPARISON OF PHRAMACOKINETICS (PK) AND
GASTROINTESTINAL DISTURBANCES
T. Kato1, T. Panagiotis1, W. Wolowich2, K. Hamamura1, M. Torres1,
D. Weppler1, A. Tzakis1
1University of Miami, 2Nova Southeastern University
Purpose: To compare mycophenolate mofetil (MMF) and enteric-coated
mycophenoate sodium (EC-MPS) in terms of the phramacokinetics (PK)
profile and GI disturbances in liver recipients.
Patients and Methods: Twenty stable adult liver transplant recipients who
were taking MMF as part of their maintenance immunosuppression for more
than 1 month were enrolled. A 12 hour PK study was done before to convert
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to EC-MPS. Conversion to EC-MPS was done according to the standard
conversion rate. Another PK study was obtained at 28 days from the conversion.
GI disturbance were monitored using gastrointestinal symptom rating scale
(GSRS) prior to conversion, 1, 2 and 3 months from the conversion. Follow up
was until November 30, 2007.
Results: All 20 patients completed the study. At conversion, patients were
taking MMF 250-1000 mg twice daily. Average dose-adjusted (adjusted to
MMF 1000mg and EC-MPS 720mg) peak mycophenolic acid (MPA) level
(Cmax) and area under the curve (AUC) were 23. 1 mg/L and 24. 8 mg/L
(Cmax), and 36. 2 mg/L*h and 35. 4 mg/L*h (AUC), respectively before and
after the conversion. As expected, average Tmax was significantly delayed
after conversion (2. 88h vs 1. 06h, p=. 00001). Mean relative bioavailability
(F relative) was 1. 02 (EC-MPS vs MMF). GSRS revealed that diarrhea and
loose stools were significantly reduced at 3 month visit after the conversion
(p=. 0019 and. 0068, respectively). No other GI disturbance profiles including
abdominal pain, nausea, rumbling and stool urgency showed statistical changes
after conversion. No acute rejection was seen during the follow up period.
Four patients switched back to MMF due to complaints of constipation (n=1),
weight gain (n=1) and insurance coverage issues (n=2). All other patients opted
to continue using EC-MPS over MMF at the end of the trial.
Conclusions: Conversion to enteric coated mycophenolate sodium is safe
in stable liver recipients. EC-MPS provided the same drug exposure to the
patients in the standard conversion rate. Diarrhea was significantly reduced
after the conversion.
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358 EARLY IMMUNOSUPPRESSION WEANING AFTER
CADAVER LIVER TRANSPLANTATION USING ATG
INDUCTION AND RAPAMYCIN
V. Donckier1, A. Buggenhout1, R. Troisi2, V. Lucidi2, X. Rogiers1,
N. Nagy1, L. Craciun1, N. Bourgeois1, B. de Hemptinne2, M. Goldman1
1
Abdominal Transplantation and Immunology, Hôpital Erasme, Université
Libre De Bruxelles, Brussels, Belgium, 2Surgery and Hepatogastroenterology,
Universitair Ziekenhuis Gent, Ghent, Belgium
Background: Immunosuppression (IS) minimisation or withdrawal
(operational tolerance) is a major objective in clinical organ transplantation.
In liver transplantation (LT), several observations suggest that T cell depletion
in the peri-transplant period and avoidance of calcineurin inhibitors (CNI) may
favour tolerance induction.
Aim of the study: To allow early IS minimisation and possibly withdrawal
after cadaver LT, using high doses anti-thymocyte globulin (ATG) followed by
rapamycin-based IS.
Patients and Methods: Hepatitis C, autoimmune diseases and retransplantations were excluded. Recipients of LT received 3. 75 mg/kg ATG
from day 1 to 5, followed by rapamycin (started on day 7, target through level:
8-12 ng/ml). Steroids were given for the 1st month. Weaning was started after
month 3, according to clinical and biological data. Several immunomonitoring
tests were performed at various time points pre- and post-transplantation,
including mRNA microarray analyses on peripheral blood leucocytes (PBL)
and liver biopsies (LB).
Results: In 11 evaluable patients, IS has been withdrawn in 3, respectively
at days 140, 206 and 124 after LT. At days 286, 280 and 165 post-LT,
these 3 patients developed Grade 2 acute rejection (AR) which respond to
steroids and reintroduction of IS. AR post IS withdrawal was remarkable
for the predominance of polymorphonuclear cells and macrophages in LB.
Furthermore, interleukin-17 (IL-17) mRNA accumulated at the graft level and
IL-17 was synthesized by recipients’ PBL exposed in vitro to donor cells at the
time of AR. Among the 8 remaining patients, 2 developed AR under rapamycin
monotherapy, successfully treated with steroids. Of note, none of the 11 patients
maintained in the protocol developed post-transplant renal insufficiency or de
novo diabetes.
Conclusions: Rapamycin monotherapy is feasible after LT and ATG induction.
In contrast with CNI-based IS, this regimen is protective for renal function and
does not induce de novo diabetes. However, such regimen does not allow early
IS withdrawal. Preliminary results suggest that failure of operational tolerance
induction in these conditions could be related to activation of a Th17-mediated
pathway of transplant rejection.
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359 PHARMACOKINETICS (PK) OF TACROLIMUS FOR
A ONCE DAILY PROLONGED RELEASE FORMULATION
(ADVAGRAF®) VERSUS TWICE-DAILY (PROGRAF®) IN DE
NOVO LIVER TRANSPLANT RECIPIENTS IN A PHASE III
MULTICENTRE STUDY
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360 CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN
ADULT LIVER TRANSPLANT RECIPIENTS: AN ANALYSIS OF
LONG TERM EFFICACY
J. Thompson, D. Radosevich, A. Humar, J. Lake
University of Minnesota
Background: Several small studies have demonstrated that mycophenolate
mofetil (MMF) or sirolimus (SRL) may substitute for CNIs and lead to
improved renal function, but some have raised concern for rejection risk. We
report the largest series of adult LT patients in whom CNIs were withdrawn.
Methods: Patients transplanted 1995-2007, started on CNIs and taken off
for any reason (renal=85, neurologic=7, other=8) were studied. Tacrolimus
(TAC) was originally given to 71 patients and cyclosporine to 29. After CNI
discontinuation, 58 patients received MMF and prednisone, 42 received SRL.
Deaths, graft failures and biopsy proven acute rejections (BPAR) were extracted
from the LT database. Creatinine at time of CNI discontinuation, yearly and
at last follow up were recorded from medical records. Glomerular filtration
rate (GFR) was calculated using the re-expressed modification of diet in renal
disease (MDRD) equation.
Patients: Mean age was 54 years. Reason for transplantation: alcoholic
cirrhosis, 20; HCV, 31; cholestatic disease, 17; cryptogenic cirrhosis, 13; HCC,
4; other, 15.
Results: Mean follow up time was 28. 4 mo after CNI discontinuation
(MMF=30 mo, SRL=27 mo). Mean time to CNI discontinuation after LT was
47. 8 mo (MMF=67 mo, SRL=20 mo). Patient survival (%) at 1, 3 and 5 years
was 100, 96. 4 and 89. 9 in the MMF group and 95. 1, 78. 9 and 73. 3 in the SRL
group. Graft survival (%) at 1, 3, and 5 years was 100, 96. 4, 94 in the MMF

TABLE 1

Creatinine
Improved
(≥20%
decrease)
46%
32%
40%

Taken off for
Renal Insuff
Creat ≥ 2 at
CNI d/c

MMF
SRL
ALL

Creatinine
Stable
41%
47%
44%

Creatinine
Worsened
(≥20%
increase)
13%
21%
16%

Creatinine at
time of CNI
d/c, most recent
f/u (mean)
2. 2, 1. 8
2. 0, 1. 9
2. 0, 1. 8

55%

29%

16%

2. 3, 1. 9

62%

20%

18%

2. 6, 2. 2

GFR at time
of CNI d/c,
most recent f/u
(mean)
33. 3, 42. 1
40. 3, 45. 8
37. 6, 44. 3

Creatinine in mg/dL, GFR in ml/min. D/C=disciontinuation. F/U=follow-up
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361 MONITORING VIRUS SPECIFIC T CELLS MAY
IMPROVE THE MANAGEMENT OF IMMUNOSUPPRESSION
AFTER LIVER TRANSPLANTATION
R. Olsson1, A-K. Lidehäll2, M. Engstrand1,2, J. Henriksson1, H. Gjersen1,
O. Korsgren2, L. Wennberg1
1
Department of Transplantation Surgery, Karolinska University Hospital,
2
Department of Clinical Immunology, Uppsala University
Background: To improve the clinical outcome of liver transplantation, and
to minimize the risk for complications such as acute rejection and recurrence
of hepatitis C, methods to properly monitor the degree of immunosuppression
are needed. For this purpose, the ImmuKnow® assay was recently marketed
to monitor PHA-induced ATP production of recipient CD4+ T cells
(overimmunosuppression, ≤225 ng/ml and underimmunosuppression,
≥525 ng/ml). In the present study, we are including liver recipients pretransplantation to compare the ImmuKnow® results with changes in T cell
reactivity against cytomegalovirus (CMV). Moreover, we monitor the degree
of immunosuppression in liver recipients treated for recurrence of hepatitis
C (HCV) using ImmuKnow® as well as T cell reactivity to HCV specific
proteins.
Materials and Methods: We report data from seven CMV seropositive
liver recipients followed during the first month post-transplantation and
one patient treated for HCV recurrence. All recipients received 1000 mg of
methylprednislone at transplantation and the maintenance immunosuppressive
drugs were tacrolimus and prednisolone. T cell reactivity was measured pretransplantation, and at 1 week, 2 weeks and 1 month postoperatively or before
and 3 months after starting treatment of HCV recurrence (interferon α and
ribavirin) using both ImmuKnow® (Cylex Inc. , Columbia, MD, USA) and a
novel method developed at the Department of Clinical Immunology, Uppsala
University Hospital, Sweden. Briefly, after in vitro stimulation with CMV
or HCV specific proteins, the CD4+ or CD8+ T cells producing IFN γ were
separately determined by FACS, and expressed per ml blood. For statistical
analysis, paired comparisons were made using the Wilcoxon Matched-Pairs
Signed-Ranks test.
Results: During the first month post-transplantation, the ImmuKnow® results
remained unchanged. In contrast, one week post-transplantation both the CD4+
and CD8+ T cell numbers were decreased to 30-35% of pre-transplantation
values (31±8% and 34±10%, n=7, p<0, 05), and the CMV specific CD4+ T cells
were markedly decreased in all recipients [median 250 cells/ml (range 0-13 600
cells/ml) vs. median 3 350 cells/ml (range 350-45 150 cells/ml); n=7, p<0. 05].
Furthermore, after three months of treatment for HCV recurrence one patient
had unchanged ImmuKnow® result (75 ng/ml vs. 45 ng/ml ATP), suggesting
a continued overimmunosuppression. However, the patient developed HCV
reactive CD8+ cells (590 cells/ml) and the viral load decreased from >69x106
IU/ml to 8x106 IU/ml, indicating that the cellular anti-HCV immune response
was improved.
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M. Colledan5, B. Gridelli6, J.O. De Urbina7, J. O’Grady8, J. Dickinson9
1
Karolinska University Hospital Huddinge, 2Hospital Clinico Universitario
de Santiago, 3IKEM, 4Universitaets-Krankenhaus Eppendorf, 5Azienda
Ospedaliera Spedali Riuniti, 6Ospedale Civico, 7Hospital de Cruces, 8Kings
College Hospital, 9Astellas Pharma Europe
Introduction: Advagraf® (ADV) is a prolonged release formulation of
tacrolimus to enable once daily administration. A previous Phase II study in
liver transplant recipients has shown that the mean AUC of tacrolimus on Day
1 following administration of ADV was approximately 50% lower than that
for Prograf (PRG); however, the exposure was comparable by Day 14. The
objective of this study was to further describe the PK of tacrolimus for ADV
versus PRG during the first 2 weeks post-transplant.
Methods: Twenty five patients (ADV n=13, PRG n=12), participating in a
Phase III study, provided four evaluable PK profiles. The first dose of PRG was
0. 10 mg/kg/day and that of ADV 0. 2 mg/kg/day, with target whole blood trough
levels of 10 to 20 ng/mL. PK profiles (17 samples over 24 hours) were obtained
following the first administration of tacrolimus (Day 1), Day 3, Day 7 and Day
14. All samples were analysed using HPLC with tandem mass spectrometric
detection. Laboratory and safety parameters were also evaluated.
Results: The AUC0 24 mean values for ADV were 320 (Day 1), 452 (Day
3), 359 (Day 7) and 353 (Day 14) ng•h/mL. Corresponding values for PRG
were 217 (Day 1), 318 (Day 3), 249 (Day 7) and 283 (Day 14) ng•h/mL.
Dose normalised systemic exposure to tacrolimus for ADV on Day 1 was
approximately 77% compared to PRG. On Days 3, 7 and 14 AUC0-24 of
tacrolimus for ADV compared to PRG was approximately 88%, 117% and
84% respectively.
There was good correlation between AUC0-24 and C24 for ADV and PRG
(r=0. 96 and r=0. 86, respectively) with similar slopes.
Conclusion: This study has confirmed that systemic exposure to tacrolimus for
ADV normalises to that of PRG within 3 to 7 days post-transplant and that the
same trough level monitoring concept can be used for both formulations.

group and 97. 6, 85. 9 and 85. 9 in the SRL group. After CNI discontinuation,
there was 1 episode of BPAR in the MMF group and 6 in the SRL group (4
mild, 2 moderate). The MMF patient had severe irreversible acute rejection
and died during retransplantation. Two patients were restarted on TAC due to
MMF intolerance (weight loss), and SRL intolerance (mouth ulcers). Table 1
shows renal function results.
Conclusions: Based on our series, which is the largest and with the longest
reported follow-up, we conclude CNI withdrawal is safe in LT recipients
and provides for stable or improved renal function in greater than 80% of LT
recipients.

Tuesday 12 August 2008

Oral Abstracts

Conclusions: The ImmuKnow® assay was insensitive to the heavy
immunosuppressive treatment given during the first month after liver
transplantation. This suggests that ImmuKnow® may not properly reflect early
changes in immunosuppression. Interestingly, our finding that CMV specific
CD4+ T cells were markedly decreased one week post-transplantation supports
this hypothesis. Furthermore, in the recipient treated for HCV recurrence,
interferon α and ribavirin did not affect the ImmuKnow® assay, although the
recipient developed HCV specific CD8+ T cells and reduced the viral load.
In conclusion, these preliminary data suggest that monitoring T cell reactivity
against viruses (CMV, HCV) may be a sensitive clinical tool to monitor
immunosuppression in the future.

Results: The results of the PK portion of the study indicated that mg: mg
conversion from Prograf BID to Advagraf QD a. m. dosing resulted in equivalent
tacrolimus exposure in stable liver transplant recipients. 69 patients agreed to
the extension portion of the study, and 54 patients completed the third year
of the study. Attrition was due to lower extremity pain, headache, worsening
gastrointestinal acidity, increase bilirubin, chronic cholestasis secondary to
6MP, fatigue, elevated blood pressure, increased thirst, increased urine output,
granulomas on biopsy, granulomatous hepatitis, elevated liver function tests,
diarrhea, rejection, withdrawal of consent, patient’s discretion (year 1), lung
squamous cell carcinoma (resulting in death, year 2), renal impairment, noncompliance with protocol procedures, (year 3). Through the third year, renal
function remained stable.
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362 LONG TERM CALCINEURIN SPARING WITH
DACLIZUMAB USED IN AN OUTPATIENT LIVER
TRANSPLANT CLINIC
G. Smallwood, C. Fasola, A. Stieber, T. Heffron
Emory University School of Medicine
Background: The monoclonal antibodies to the CD-25 (daclizumab and
basiliximab) cell are currently used for induction therapy following solid organ
transplant. These agents have been used for short term use to spare the use of
calcineurin inhibitors during initial hospitalization.
Aim: The aim of this study was to evaluate stable liver transplant patients
receiving daclizumab on an outpatient basis while sparing the use of tacrolimus
for greater than two weeks.
Methods: Patients unable to tolerate tacrolimus due to adverse events (renal
or other reasons) were begun on daclizumab 1mg/kg given intravenously
weekly in an outpatient liver transplant clinic. This is an IRB approved study
with inclusion criteria requiring that the patients had to be off of tacrolimus
for at least two weeks. Patients were evaluated for both renal and transplant
outcomes.
Results: 51 patients received daclizumab while sparing the use of tacrolimus.
Patients receiving daclizumab was 50. 7 ± 12. 9 years of age, 331 ± 432 days
from transplant at time of tacrolimus sparing, 37. 3% (19/51) female, and 19.
6% (10/51) were African-American. Patients’ mean calcineurin free time was
39. 8 ± 17. 8 days. The renal group (n = 34) had improved GFR [28. 3 ± 9. 7
ml/min/1. 73m2 vs. 44. 4 ± 14. 4 ml/min/1. 73m2, p < 0. 0001], improved sr. cr.
[2. 07 ± 0. 7 mg/dl vs. 1. 37 ± 0. 36 mg/dl; p <0. 0001], while maintaining liver
function as described by ALT (p = 0. 326), AST (p= 0. 375), and T. bili (p = 0.
781). Patients sparing tacrolimus for other reasons (n = 17), maintained GFR
[51. 8 ± 28. 1 ml/min/1. 73m2 vs. 45. 5 ± 29. 8 ml/min/1. 73m2, p = 0. 260],
while maintaining liver function test. Only one patient (1. 9%) had histological
proven rejection while on daclizumab. Patients having rejection episodes prior
to daclizumab use (n = 4) did not experience rejection when off of tacrolimus.
Overall patient survival was 88. 3% and graft survival was 86. 3%.
Conclusions: Liver transplant patients can safely be immunosuppressed with
weekly daclizumab dosing on an outpatient basis while holding tacrolimus for
up to 40 days. With the use of daclizumab, adverse events from calcineurin
inhibitors have the opportunity to resolve.
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363 A THREE YEAR FOLLOW-UP STUDY OF STABLE LIVER
TRANSPLANT RECIPIENTS CONVERTED FROM TWICE
DAILY PROGRAF® TO ONCE DAILY ADVAGRAF (EXTENDED
RELEASE TACROLIMUS)
S. Florman
for The Tacrolimus Extended Release Liver Transplant Conversion Study
Group, Tulane University School of Medicine, New Orleans, LA
Purpose: To assess safety and efficacy three years following conversion from
tacrolimus twice daily (Prograf BID) to extended release tacrolimus (Advagraf,
previously Modified Release tacrolimus or MR) once daily (QD a. m. ) in stable
liver transplant recipients.
Methods: Seventy patients were enrolled in the pharmacokinetic (PK) portion
of the study (days 0-56). Sixty-nine patients were subsequently maintained on
Advagraf QD a. m. Patients were evaluated for Advagraf dosing and trough levels,
laboratory values, concomitant medications, graft survival, and adverse events.

128

Pre-Advagraf
Baseline
N=70

1 Year PostConversion
N=57†

2 Year PostConversion
N=56†

3 Year PostConversion
N=54†

Mean Dose (mg/
day)
Range (mg/day)

5. 3
(1-18)

5. 6
(2-16)

5. 5
(2-14)

5. 0
(1-12)

Mean Trough
Conc. (ng/mL)
Range (ng/mL)

7. 2
(2. 9-14. 7)

6. 4
(2-11. 7)

6. 2
(1. 5-12. 7)

5. 8
(1. 5-13. 6)

1. 3
(0. 5-2. 0)

1. 3
(0. 6-2. 3)

1. 5
(0. 5-3. 3)

Mean Serum
1. 3
Creatinine (mg/dL) (0. 6-2. 2)
Range (mg/dL)
† N = completers at each year

Patient and graft survival were 99% at three years post conversion. Through
three years, four biopsy confirmed acute rejections occurred in four patients;
two Grade I (days 153 & 233), one Grade II (day 400) and one Grade III (day
53). Through three years, multiple rejection episodes were not reported in any
patients. All episodes resolved with steroid treatment.
Medication use for diabetes and hypertension remains similar to usage at
conversion and at three years. There have been ten occurrences of glucose
intolerance (based on fasting plasma glucose of ≥ 126 mg/dL); two of these
required insulin therapy and three required oral hypoglycemic agents. There
were no patients with hemoglobinA1c ≥ 6%.
Conclusions: The three year data continues to support the safety and efficacy
of conversion from Prograf BID to Advagraf QD a. m. in liver transplant
patients.
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364 MTOR INHIBITORS (MTOR-I) AND LUNG
TRANSPLANTATION: CAN ITS USE BE JUSTIFIED?
P. Ussetti, M. Carreño, R. Laporta, C. Garcia-Gallo, T. Lazaro, A. de Pablo,
J. Ferreiro
Clínica Puerta De Hierro
Aim: To analyze the efficacy and adverse effects of mTOR-I in lung transplant
recipients.
Patients: Lung transplant recipients treated with mTOR-I for progressive BOS
or toxicity from other immunossupressive drugs (AZA or MMF).
Methods: mTOR-I were always administered in combination with calcineurin
inhibitors (CyA or TAC). The choice of sirolimus or everolimus depended on
their availability and/or the physician attending the patient. mTOR-I levels
were maintained between 5-10 ng/ml, CsA between 100-200 ng/ml and TAC
between 5-10 ng/ml.
We analyzed demographic data, mTOR-I type, evolution of FEV1 from 3
months prior to initiating administration of the drug until its withdrawal for
adverse events, or for a 12 month follow-up. The development of adverse
clinical or analytical effects were closely monitored during treatment.
Clinical response to mTOR-I in patients with BOS was considered favourable
when during the 12 month follow-up FEV1 levels were maintained, with no
more than 10% drop from their initial value.
Statistical analyses were performed using Chi-square, t-test and ANOVA.
Results: 36 patients received treatment with mTOR-I (16 sirolimus and 16
everolimus). mTOR-I was introduced for BOS in 28 cases, and for toxicity
associated to AZA or MMF in the other 8 cases.
In 17 of the 28 patients treated for BOS (60%), pulmonary function became
stabilized during the 12 month follow-up period (Table 1).
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FEV1 (ml)
-3 month

FEV1 (ml)
-1 month

FEV1 (ml)
baseline

FEV1 (ml)
+3 month

FEV1 (ml)
+6 month

FEV1 (ml)
+12 month

responders
(n=17)

18919 ±
738

1676±
643

1600±
574

1680±
590

1657±
590

1647±
548

Nonresponders
(n=11)

2622±
666

2214±
547

2001±
539

1704±
664

1499±
732

1474±
779

Analytical anormalities during the follow-up period included a significant
deterioration in renal function, increased lipids and decreased VCM (Table 2).
Creatinin

Creat.
Clearance

Cholesterol

HDL

LDL

VCM

Pre-mTOR-I 1. 5 ±. 48

60 ±29

192 ±39

66 ±20

97 ±33

89 ±9

Post-mTOR-I 1. 7 ±1 *
(*p<. 005)

52 ±30*

239 ±45*

77 ±23*

120 ±37*

86 ±7*

Treatment was discontinued in 14 of the 36 recipients (39%) due to the
development of adverse effects. The most noteworthy for their severity were 4
patients with nephrotic syndrome, with permanent hemodialysis being required
in 2 cases, and 4 episodes of diverticulitis which required laparotomy with a
temporary colostomy.
Conclusions: mTOR-I can stabilize pulmonary function in more than 50%
of patients with BOS. However, a considerable percentage of patients have
treatment withdrawn due to adverse effects which can be severe.
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365 PRONOSTIC FACTOR FOR MTOR INHIBITORS
(MTOR-I) PROTEINURIA AFTER LUNG TRANSPLANTATION

366 OUTCOME OF PATIENTS RECEIVING TACROLIMUS
AFTER LUNG LUNG/HEART TRANSPLANTATION – ONE
CENTER EXPERIENCE.
C. Chaparro, C. Gutierrez, S. Keshavjee
Toronto Lung Transplant Program
Background: Our institution standard immunosuppressive protocol includes
cyclosporine (CSA), azathioprine, and glucocorticoids. Since the introduction of
tacrolimus we have used it for different indications that include bronchiolitis obliterans
(BO), acute rejection, renal dysfunction, neuro- and gastrointestinal toxicity.
Objective: We reviewed the efficacy and tolerance among patients converted
to tacrolimus from CSA for different indications.
Methods: Retrospective review of those patients switched to tacrolimus from
CSA between Aug 1983 and January 2006. We recorded indication for the
switch, effectiveness of the switch and time to improvement.
Results: We identified 238 patients that were switched to tacrolimus from
CSA. Twenty-three patients were excluded for different reasons. Indications for
conversion among the remaining patients were: Bronchiolitis Obliterans (BO)
104 (48%), Acute Rejection 31(14%), neurotoxicity 25 (12%), renal dysfunction
24(11%), gastrointestinal intolerance to CSA 23 (10.5%), hirsutism 4 (2%),
difficulty to get therapeutic levels 3 (2%) and gingival hypertrophy 1 (0.5%).
Among the 104 patients switched due to BO, 45 showed stability in their lung
function, 6 improved, no major changes were seen in 25, and in 28 more there
was evidence of slow progression of functional decline. All patients switched
due to neurotoxicity, gastrointestinal intolerance and/or renal dysfunction
showed improvement over time (2 weeks to 6 months).
Conclusions: Tacrolimus is a good alternative for patients who present acute
rejection, chronic rejection, toxicity and/or intolerance to CSA. Despite being
a calcineurin inhibitor too, tacrolimus is well tolerated and appears a safe
alternative for those indications.
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367 DESCRIPTIVE ANALYSIS OF PULMONARY
TRANSPLANT PATIENTS, AFTER MYCOPHENOLATE
MOFETIL TO ENTERIC-COATED MYCOPHENOLATE
SODIUM CONVERSION TREATMENT.
A. Solé1, A. Pastor1, A. Saura1, E. Ansotegui1, R. Vicente1, J. Padilla1
Hospital Universitario La Fe, 2Hospital Universitario La Fe, 3Hospital
Universitario La Fe, 4Hospital Universitario La Fe, 5Hospital Universitario
La Fe, 6Hospital Universitario La Fe
Purpose: Descriptive analysis of pulmonary transplant patients, following
conversion treatment.
Methods: Clinical data compilation of pulmonary transplant recipients
following a conversion treatment from mycophenolate mofetil (MMF) to
enteric-coated mycophenolate sodium (EC-MPS) with a 12 month follow-up
period (visits at 5, and 12 days, 1, 3, 6, and 12 months).
Results: A total of 8 pulmonary transplant recipients were evaluated (5
women and mean age±SD 31. 3±13. 2 years). Seven patients had bilateral lung
transplant, and one patient a cardiopulmonar transplant. The main transplant
etiology was cystic fibrosis (50%). Following transplant, and previously to
conversion treatment, all patients were treated with anticalcineurinic agents
(100% tacrolimus), 37. 5% azathioprine, 62. 5% mycophenolate mofetil, and
steroids (100%). Seven patients had a rejection previous to conversion. Mean
time from transplant to conversion was 28. 6±38. 5 months. The main reasons
for conversion were: gastrointestinal intolerance to MMF (50%), previous
rejection (50%), post-transplant diabetes (37. 5%), and nephrotoxicity (25%).
During the follow-up period, the EC-MPS doses decreased from 855. 0±343.
6 mg/day at conversion visit (median 810. 0, range: 360. 0-1440. 0) to 642.
9±309. 3 mg/day (median 720. 0, range: 180. 0-1080. 0) at 6 months (7
patients), and 360±0. 0 mg/day at 12 months (2 patients). Anticalcineurinic
agents (100% tacrolimus), and steroids (100%) treatments were maintained
during the 12 month follow-up, except for one patient that changed tacrolimus
to cyclosporine after 1 month. Only one patient had a post-conversion rejection
(at one month). At conversion visit, the glucose, triglycerides, and creatinine
levels were 159. 1±142. 7 mg/dl, 321. 1±295. 2 mg/dl, and 1. 6±1. 1 mg/dl,
respectively, and after 6 months were 92. 0±46. 1 mg/dl, 155. 0±39. 6 mg/dl,
1
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P. Ussetti1, J. Rovira2, M. Carreño1, R. Laporta1, B. Sanchez1, J. Ferreiro1,
J. Campistol2
1
Clínica Puerta De Hierro. Madrid. Spain, 2Hospital Clinic. Barcelona. Spain
Objective: To study the frequency and prognostic factors of proteinuria in lung
transplant recipients treated with mTOR-I.
Patients: Lung transplant recipients treated with mTOR-I for progressive BOS
(n= 28) or adverse reactions due to others drugs (n= 8).
Methods: mTOR-I were administered in combination with a calcineurin
inhibitor (CNI) (CsA n= 5 or TAC n = 31). The choice of sirolimus or
everolimus depended on their availability and/or the physician attending the
patient. mTOR-I levels were maintained between 5-10 ng/ml, CsA between
100-200 ng/ml and TAC between 5-10 ng/ml (MEIA, IFPA).
We analyzed demographic data, diabetes, HTA and its treatment (diltiazem vs.
ACE-inhibitors), and duration of previous CNI treatments. Proteinuria was
evaluated before and during mTOR-I treatment.
Statistical analyses were performed using Chi-square, t-test and multivariate
logistic regression.
Results: 36 patients were treated with mTOR-I (18 sirolimus, 18 everolimus).
Five patients presented moderate proteinuria (0. 3 to 0. 5 g/L) before mTOR-I.
13 patients (36%) developed persistent proteinuria >0. 3 g/L during mTOR-I
treatment, and proteinuria was higher than 1 g/L in 8 cases. Mean time from
commencing mTOR-I to the onset of proteinuria was 15„b9 months (range
1-55). 4 of the 5 patients with moderate proteinuria prior to mTOR-I developed
nephrotic syndrome (p<0. 01), with renal failure, which required permanent
hemodialysis in two.
Patients who developed proteinuria had longer previous exposure to CNI (82„b42
vs 59„b35 months; p<0. 05). Other variables associated with proteinuria were
diabetes (RR 2. 9; p<0. 16), and HTA treated with diltiazen (RR 10. 6; p<0.
001). None of the patients treated with ACE-inhibitors presented proteinuria.
In the multivariate analysis only previous CNI treatments exceeding 60
months, and HTA treatment with diltiazen, maintained statistical signification.
Creatinine clearance tended to be lower (48„b19 vs. 60„b22; p=0. 09), and
mTOR-I treatment time tended to be longer (63„b56 vs36„b31; p=0. 09), in
patients with proteinuria >1 g/L with respect to those who did not develop the
same.
Conclusions: Proteinuria due to mTOR-I is not uncommon in lung transplant
patients treated for BOS, especially in recipients with diabetes and HTA treated
with diltiazen. Moderate proteinuria before mTOR should be considered a risk
factor for nephrotic syndrome.
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and 2. 7±2. 5 mg/dl, respectively (n. s). The pulmonary function parameters at
conversion visit: forced vital capacity (FVC), forced expiratory volume in one
second (FEV1), and FEV 25%-75% were 3300. 0±1162. 7 ml, 2994. 0±1103.
5 ml, and 3768. 0±1904. 2 ml/s, respectively, and after 6 months were 3547.
1±1020. 8 ml (p=0. 0224), 2894. 3±999. 8 ml (n. s), and 2797. 1±1574. 6 ml/s
(n. s), respectively. At 12 months (2 patients), the levels of glucose were 74.
0±4. 2 mg/dl, triglycerides 79. 5±3. 5 mg/dl, creatinine 5. 4±4. 7 mg/dl, FVC
3340. 0±70. 7 ml, FEV1 2370. 0±254. 6 ml, and FEV 25%-75% 1575. 0±714.
2 ml/s.
Conclusions: The conversion to EC-MPS treatment in lung transplant patients
was mainly due to gastrointestinal intolerance to MMF, and previous rejection.
A decrease in rejection rate was observed after conversion to EC-MPS. The
FVC improved during the follow-up conversion period.
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368 IMPACT OF EXTENDED-SPECTRUM BETALACTAMASE-PRODUCING ENTEROBACTERIACEAE
URINARY TRACT INFECTION IN KIDNEY TRANSPLANT
PATIENTS
M-F. Lam, K-C. Tse, T. Yip, T-M. Chan, K-N. Lai
University Department of Medicine, Queen Mary Hospital
Introduction: Urinary tract infection (UTI) is commonly seen in kidney
transplanted patients. Because of increased prevalence of Extended-spectrum
beta-lactamase (ESBL)-producing Enterobacteriaceae in the community,
transplant recipients with UTI caused by the ESBL strain are not uncommonly
seen. Whether UTI affects the allograft function is still controversial, the delayed
in using appropriate antibiotic, mainly carbapenems, treating UTI caused
by ESBL producing strain, may result in allograft damage or bacteraemia.
We studied the prevalence of UTI caused by ESBL strains and its impact on
allograft function.
Method: Kidney transplant recipients developed UTI from year 2003
to 2008 were retrieved for analysis. Asymptomatic bacteruria were
excluded. Patients received standard immunosuppressive regimes such as
prednisolone, calcineurin inhibitors, mycopheolate mofetil or azathioprine.
Patients infected with ESBL strains were treated with carbapenems while
other organisms were treated with either quinolone or cephalosporins. The
serum creatinine before the onset of UTI and 1 month after were used to be
compared. Hospital acquired defined as UTI developed after 48 hours of
hospitalization.
Result: Over the five year study period, there were total 87 episodes of UTI
detected in 36 transplant patients (female: 32) with age 44. 4±11. 7 yrs. The
average onset of UTI was 8. 8 ± 6. 6yrs after transplant. 24 patients had
recurrent UTI and 12 (33. 3%) of them received prophylactic antibiotics.
Patients with diabetic mellitus and vesicoureteric reflux (VUR) were 12
(33. 3%) and 15 (41. 7%), respectively. 30 episodes of UTI were caused
by ESBL producing bacteria which responded to carbapenems. However,
24 (80%) out of 30 ESBL producing UTI were community acquired. The
serum creatinine did not statistically significantly impaired after an episode
of UTI caused by usual stain bacteria (before: 170±90 vs 1 month after:
183±108 umol/L, p=0. 18) or ESBL stain bacteria (before: 160±107 vs 1
month after: 176±152umol/L, p=0. 13). Though patients with VUR, recurrent
UTI associated with frequency episode of ESBL-UTI, it was statistical not
significant (p>0. 3)
Conclusion: UTI seems have some adverse effect on the allograft function.
The high incident rate of community acquired ESBL-UTI suggests the usual
empirical antibiotics may not teat the infection at the earlier stage, which may
predispose the patients to have bacteraemia and allograft damage. Whether
patients with VUR, recurrent UTI and on prophylactic antibiotics predispose at
risk to ESBL UTI need further study.
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369 PNEUMONIA IN SOLID ORGAN RECIPIENTS: REVIEW
OF 217 EPISODES
H. Bonatti, R. Sawyer, T. Pruett, T. Schmitt, K. Brayman
University of Virginia
Background: Lower respiratory tract infection (LRTI) remains a leading cause
of morbidity and mortality after solid organ transplantation (SOT).
Patients and methods: A retrospective analysis of 217 episodes of LRTI in 143
SOT recipients from a single centre was performed.
Results: There were 94 men and 49 women (85% Caucasian) with a median
age of 51 (range 17-79) years including 50 renal, 86 liver, 6 pancreas and
one lung recipient. Forty patients had multiple episodes of LRTI. Median
APACHE 2 score was 17 (range 5-40), median temperature was 38 (range
35. 3-40. 2) centigrade, and median WBC was 12000 (range 100-106000).
Pneumonia developed at a median of 11 (range 2-191) days after the last
surgical intervention. 163 of the 217 LRTIs were nosocomial infections (60
ventilator associated). Overall crude mortality was 21% and was increased in
patients with multiple episodes of LRTI (25%) and after liver transplantation
(33%). In 40 cases no causative organism could be identified. Overall, 202
microorganisms were found (41 mixed infections): Staphylococcus aureus
(n=32) of which 81% were MRSA; E. coli (n=9), Klebsiella spp. (n=7),
Enterobacter spp. (n=11), Serratia spp. (n=12), Pseudomonas aeruginosa
(n=15), Stenotrophomonas maltophila (n=15), Acinetobacter spp. (n=9), fungi
(n=18) and viruses (n=17).
Conclusion: LRTI remains one of the most common and dangerous infections
in transplant recipients with higher mortality than in other populations. MRSA
is a particular problem. As a significant number of SOT recipients develop
multiple episodes of LRTI, a thorough reevaluation of the current guidelines
for the treatment of pneumonia is urgently needed.
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370 RELATIONSHIP BETWEEN INFECTION-RELATED
RENAL ALLOGRAFT FAILURE AND REJECTION RATE: UNOS
DATA ANALYSIS FROM 1990-2006
R. Parasuraman1, A. Patel1 , D. Kim2, M. Abouljoud2, G. Jacobsen3, and
K.K. Venkat1.
1
Division of Nephrology and Hypertension; 2Transplant Institute and
3
Department of Research and Bioststistics, Henry Ford Hospital, Detroit, MI,
United States.
Body: Long-term renal allograft survival has not improved despite significant
decline in acute rejection rate. Infections such as BK virus as the primary cause
and/or systemic infections requiring reduction or withdrawal of immunosuppression contributing to graft failure is observed clinically but not well
documented.
Aim: To study the role of infections as a primary cause or contributing factor
(death censored) for renal allograft failure and its relation to rejection rate.
Method and Results: The UNOS data from 1990-2006 was analyzed and 38,
286 first and only renal transplants that resulted in graft failure were identified
with 31, 420 having known contributory infection status. Results compared
between two periods (period I [1990-1996] and period II [1997-2006])
showed a significant increase in infection contributed graft loss from 6. 3%
(1037/16419) to 9. 1% (1360/14907) p < 0. 001 and a significant decrease in
treated for rejection rate from 20. 3% (3316/16302) to 12. 2% (1635/13350) p
< 0. 001 respectively. Other significant findings are shown in table1.
First renal transplants that resulted in graft failure (1990-2006)
Infection
Number of
Recipient death
Transplant year
contributing to
grafts failed
(%)
graft failure (%)
1990
1735
6. 4
20
1992
2176
5. 7
21. 1
1994
2847
6. 1
19. 1
1996
2542
7. 5
20. 4
1998
2215
8. 1
23. 5
2000
1871
9. 0
22. 3
2002
1509
9. 6
22. 2
2004
949
9. 6
20. 3
2006
407
10. 1
17

Any induction
medication
use (%)
27. 4
25. 7
83. 1
87. 9
84. 1
83. 8
86. 3
87. 2
89. 3

Treated for
rejection (%)
27. 7
23. 5
18. 5
14. 2
11. 3
9. 8
10. 4
10. 4
7. 1

The relationship between rejection rate and Infection Related Graft loss is
shown in fiqure 1
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Conclusion: Infections contributing to renal allograft loss has increased
significantly with corresponding significant decrease in rejection rate from
1990 to 2006. Increase use of potent induction and maintenance IS may explain
this additional important cause for poor long-term graft outcome.
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371 CHANGING PATTERNS OF CANDIDAEMIA
FOLLOWING SOLID ORGAN TRANSPLANTATION IN THE
ERA OF ANTIFUNGAL PROPHYLAXIS: THE AUSTRALIAN
EXPERIENCE.
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372 PULMONARY ASPERGILLOSIS AFTER SOLID ORGAN
TRANSPLANTATION: DIAGNOSIS AND TREATMENT BASED
ON SINGLE CENTER EXPERIENCES FOR 28 YEARS
K.H. Huh, M.K. Ju1,3, D.J. Joo1, S.J. Kim1, W.I. Yang2, M.S. Kim1,3, S.I.
Kim1,3, Y.S. Kim1,3
1
Department of Surgery, 2Pathology and 3Transplantation institutes Yonsei
University College of Medicine, Seoul, Korea
Pulmonary aspergillosis is a serious and lethal complication among organ
transplant recipients. This research wishes to review clinical manifestations

Sex (M:F)
Age (years)
Transplant organ
(Kidney:Liver)
No of transplantation
(1st:2nd)
Induction
Steroid only
ATG/ALG
IL-2 receptor
antibody
Time of infection
< 1year
1~2 years
2~5 years
5~10 years
>10 years

Invasive (n=9)
7:2 (77.8%:22.2%)
50.3 ± 8.4

Localized (n=13)
7:6 (53.8%:46.2%)
52.6 ± 8.1

Total (n=22)
14:8 (63.6%:36.4%)
51.5 ± 8.1

p-value
0.201
0.510

7:2 (77.8%::22.2%)

11:2 (84.6%:15.4%)

18:4 (81.8%:18.2%)

0.003
0.291
0.483

8:1* (88.9%:11.1%)

10:3 (76.9%:23.1%)

18:4 (81.8%:18.2%)

4 (44.4%)
4 (44.4%)

6 (46.2%)
2 (15.4%)

10 (45.4%)
6 (27.3%)

1 (11.2%)

5(38.5%)

6 (27.3%)

6 (66.7%)
0 (0.0%)
1 (11.1%)
2 (22.2%)
0 (0.0%)

1 (7.7%)
2 (15.4%)
5 (38.5%)
1 (7.7%)
4 (30.8%)

7 (31.8%)
2 (9,1%)
6 (26.2%)
3 (13.6%)
4 (18.2%)

0.272

* Previous underwent kidney transplantation
** M; male, F; female, YUHS; Yonsei University Health System, ATG; antithymocyte globulin, ALG; anti-lymphocyte globulin, IL-2; interleukin-2
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373 PREEMPTIVE VALGANCICLOVIR THERAPY IS NOT
ASSOCIATED WITH INCREASE IN CYTOMEGALOVIRUS
(CMV) DNA IN RENAL ALLOGRAFT BIOPSY SPECIMENS
COMPARED WITH VALACYCLOVIR PROPHYLAXIS
T. Reischig1, J. Nemcova2, T. Vanecek2, P. Jindra3, O. Hes2, M. Bouda1,
V. Treska4
1Department of Internal Medicine I, Charles University Medical School And
Teaching Hospital, 2Department of Pathology, Charles University Medical
School And Teaching Hospital, 3Department of Hemato-oncology, Charles
University Medical School And Teaching Hospital, 4Department of Surgery,
Charles University Medical School And Teaching Hospital
Aim: In our recently published randomized study (Am J Transplant 2008; 8: 69)
we observed similar incidence of CMV disease with preemptive valganciclovir
therapy as compared with valacyclovir prophylaxis. However, the 12-month
incidence of CMV DNAemia and biopsy-proven acute rejection during 12
months were both significantly higher in the preemptive group. The aim of the
study was to evaluate the presence of CMV DNA in renal biopsy specimens.
Methods: Renal transplant (RTx) recipients at risk for CMV (D+/R-, D+/
R+, D-/R+) were randomized to 3-month prophylaxis with valacyclovir (2g
q. i. d. , n=34) or preemptive therapy with valganciclovir (900mg b. i. d. for a
minimum of 14 days, n=36) for significant CMV DNAemia (≥2000 copies/mL
by quantitative PCR in whole blood). All renal biopsies (including 3-month
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S.V. Hal1, D. Marriott1, Q. Nguyen2, S. Chen2, T. Sorrell2, D. Ellis4,
M. Slavin3, and the Australian Candidaemia Study group
1
. Department of Microbiology and Infectious Diseases, St Vincent’s Hospital,
Sydney Australia, 2Centre for Infectious Diseases and Microbiology and
the University of Sydney, Westmead Hospital, Sydney Australia, 3Victorian
Infectious Diseases Service, Royal Melbourne Hospital, Melbourne Australia,
4
Mycology Unit, Women’s and Children’s Hospital, North Adelaide, Australia
Solid organ transplant (SOT) recipients have documented high rates of invasive
fungal infections (IFI). Candida species are the most commonly isolated fungi
accounting for 35% to 90% of all IFIs. These infections are associated with
significant morbidity and mortality rates between 5% and 77%. The aim of this
study was to determine the difference between incidence rates, risk factors,
clinical presentation and outcome between SOT and non-SOT patients, using
national transplant registries and data from the Australian Candidaemia Study
(ACS).
Between 2001 and 2004, the ACS collected clinical, epidemiological and
organism data on patients with one or more blood cultures growing Candida
spp. Information collected included the transplant status of patient and the
period between transplant and infection. SOT data was retrieved from the
respective transplant registries.
In the study period, 24 (2. 3%) of the 1068 patients with candidaemia had a SOT.
Transplanted organs during the study period included: liver (n=455), kidney
(n=1605), single lung, (n=57), bilateral lung (n=183), heart and lung (n=18),
heart (n=157) and pancreas (n=62). The overall incidence of candidaemia in
SOT patients was 9. 9 per 1000 transplant admissions compared to 0. 21 per
1000 admissions for non-SOT patients (p<0. 01).
In 54% of SOT patients, the development of candidaemia occurred 6 months or
greater post transplantation. Renal transplant recipients were significantly more
likely than other SOT recipients to develop candidaemia, 6 months or greater
post transplantation (OR 16. 5, p<0. 01).
SOT recipients with candidaemia were more likely to receive corticosteroid
therapy (OR 5. 9; p<0. 01) and antifungal prophylaxis (OR 3. 4; p< 0. 01) than
non-SOT patients. The 30 day mortality rate was not significantly different
between these two groups but SOT patients were significantly more likely to
die within the first 5 days of diagnosis compared with non-SOT patients (p<0.
01). Non-albicans candidemia was significantly more likely to occur in patients
(SOT and non-SOT patients) on antifungal prophylaxis (OR 2. 22, 95% CI:
1. 47 to 3. 35; p <0. 01). However, antifungal prophylaxis did not select for
fluconazole resistant Candida species (C. glabrata and C krusei).
In conclusion, SOT patients continue to have a high incidence of candidaemia,
the incidence and timing of which is influenced by the type of solid organ
transplanted. Apart from corticosteroid therapy, risk factors are identical to nonSOT patients with candidaemia. Antifungal prophylaxis did not select for more
resistant Candida species and did not alter mortality in SOT patients. All-cause
mortality was no different to non-SOT patients but remains high at 21%.

of pulmonary aspergillosis. Method) From January 1979 to December 2007,
3,215 patients underwent organ transplantation (2,954 kidney and 261 liver
transplants) were enrolled in this study. Results) Nine cases of invasive
pulmonary aspergillosis and 13 cases of localized pulmonary aspergillus were
occurred. Overall incidence of pulmonary aspergillosis was 0.684% (invasive
0.280% and localized 0.404%). Incidence of pulmonary aspergillosis after liver
transplantation (1.533%) was more common than after kidney transplantation
(0.609%). In clinical comparison between invasive and localized infection
recipients, there was no statistical difference in demographics, the number of
transplantations, immunosuppressive induction agents, and onset timing of
infection between the invasive and localized infection groups (p=0.201, 0.51,
0.291, 0.483, and 0.272, respectively). However, recipients with use history
of anti-thymocyte globulin/anti-lymphocyte globulin and liver transplant were
liable to invasive infection. And majority (6 among 9) of invasive infection was
occurred within 1 year after transplantation. Five invasive infection recipients
(55.6%) were diagnosed by pathologic study through transbronchial lung biopsy
and 4 (44.4%) recipients were revealed by sputum culture study or clinical/
radiologic study. Except two recipients with invasive infection, all infected
recipients were primarily treated by either amphotericine B or voriconazole.
The invasive infection recipients showed high mortality rate (55.6%, 5/9), but
localized infection recipients didn’t show mortality by aspergillus infection.
Conclusion) Clinical prognosis of invasive aspergillosis infection recipients is
fetal. Early diagnosis and application of an anti-fungal agent is sole strategies
for invasive pulmonary aspergillosis. Therefore, when an invasive fungal
infection is suspected, we should not delay in the use of an anti-fungal agent or
surgical intervention, if required.
Table. Clinical manifestations of pulmonary aspergillus recipients
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protocol biopsy) performed during 12 months post-RTx were assessed.
Results: A total of 59 biopsies in 35 patients in preemptive group and 57
biopsies in 32 patients with valacyclovir prophylaxis were available for tissue
CMV DNA analysis. CMV DNA was detected in 4 (11%) and 2 (6%; P=0.
467) patients in preemptive and prophylaxis groups, respectively. Overall, 4/59
(7%) and 2/57 (3%; P=0. 675) biopsies were positive for tissue CMV DNA in
preemptive and prophylaxis groups, respectively.
Conclusion: Preemptive valganciclovir therapy is not associated with
increase in tissue CMV DNA in renal allograft compared with valacyclovir
prophylaxis.
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374 PTLD DERIVED TUMOR VARIANTS OF EBV LATENT
MEMBRANE PROTEIN 1 INDUCE SUSTAINED ERK
ACTIVATION AND CFOS INDUCTION
O. Martinez1,2, M. Vaysberg1,2, B. Wong1, S. Lambert1,2, S. Krams1,2,
C. Esquivel1,
1Stanford University School of Medicine, Dept of Surgery, 2Program in
Immunology
Background: Post-transplant lymphoproliferative disorder (PTLD) is a serious
complication of organ transplantation and is associated with Epstein Barr Virus
(EBV) infection. EBV+ PTLD lymphomas express several latent cycle viral
genes including latent membrane protein 1 (LMP1), an oncogene required for
human B cell transformation. LMP1 is expressed in the membrane of EBVinfected cells and activates multiple signaling pathways including Erk, JNK,
p38, NF-κ;B and PI3K. Variant forms of LMP1 have been characterized on the
basis of sequence differences. The aim of this study is to determine whether
LMP1 isolated from PTLD tumors differs in sequence and signaling ability
from LMP1 derived from the B. 95 strain of EBV, originally isolated from a
patient with infectious mononucleosis.
Methods: LMP1 variants isolated from a panel of five EBV+ PTLD-associated
B cell lines were cloned, sequenced and classified according to previously
defined LMP1 groups. Inducible chimeric constructs containing the LMP1
C-terminus and nerve growth factor receptor (NGFR) transmembrane
domain were created for each tumor variant and expressed in the Burkitts B
lymphoma cell line BL41. LMP1 signaling in BL41 clones was induced by
crosslinking of NGFR. Activation of p38, Erk, Akt and JNK was assayed by
Western Blotting (WB) with phospho-specific antibodies. NF-κ;B activation
was assayed by WB for Iκ;B while cFos induction was analyzed by WB and
c-Fos activity was determined in DNA binding assays.
Results: Sequencing of LMP1 from PTLD-derived EBV+ B cell lines
revealed that all of the tumors could be assigned to LMP1 group A, B, or C
and were distinct from B95. 8 LMP1. All tumor variants of LMP1, as well
as the B95. 8 LMP1 isoform, could induce p38 phosphorylation within 30
minutes of NGFR crosslinking while Akt and JNK were activated within 10
minutes. All variants showed similar ability to activate NF-κ;B, as assayed by
Iκ;B degradation. However, Erk activation differed between tumor variants of
LMP1 and B95. 8 derived LMP1. All tumor-derived LMP1 variants induced
prolonged Erk activation (up to 3 hours) while the B95. 8 LMP1 variant
induced transient Erk activation. cFos is induced by the Erk pathway but
only during the sustained phase of Erk activation. Indeed, the tumor variants
of LMP1, but not B. 95 LMP1, were able to induce cFos protein. Similarly,
cFos binding to the AP1 consensus DNA binding site was only observed
in nuclear lysates induced by tumor-derived LMP1. Two mutations in the
C-terminus- aa212 (Ser vs Gly) and aa366 (Thr vs Ser) -are conserved in the
tumor variants of LMP1 compared to B. 95 LMP1. Point mutation of either
of these amino acids from the B95. 8 variant to the tumor variant version, in
the context of LMP1 activation via NGFR-LMP1 crosslinking, allowed for
sustained activation of Erk and subsequent cFos induction and binding to
the AP1 site. Thus, tumor-derived LMP1 has enhanced ability to induce the
cFos oncogene and this property can be localized to two amino acids in the
C terminus. These findings suggest that these specific amino acid residues
of LMP1 are important in determining whether EBV infection is benign or
results in PTLD.
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375 WU AND KI POLYOMAVIRUSES – NEW RESPIRATORY
VIRUSES IN ADULT HSCT RECIPIENTS
P. Ferguson1,2, N. Gilroy1,2, K. Bradstock2,3, T. Sloots4, M. Nissen4,
T. Sorrell1,2
1
Centre for Infectious Diseases and Microbiology, Westmead Hospital,
Sydney, Australia, 2Centre of Clinical Research Excellence, Infection and
Bioethics in Haematological Malignancies, 3Bone Marrow Transplant Unit,
Westmead Hospital, Sydney, Australia, 4Queensland Paediatric Infectious
Diseases Laboratory
Two novel respiratory polyomaviruses, WU and KI, were described in 2007.
Several prevalence studies have shown predominance of these viruses in
children. Three cases have been reported in immunosuppressed adults.
Aim: To describe the prevalence of WU and KI polyomaviruses in episodes of
respiratory tract infection in adult haematopoietic stem cell transplant (HSCT)
recipients.
Methods: A prospective cohort study of all adult HSCT recipients at Westmead
Hospital, Sydney, Australia was undertaken over 27 months. Symptomatic
patients had nose/throat swabs (NTS) and/or bronchoalveolar lavage (BAL)
specimens collected. Polymerase chain reaction testing of batched respiratory
samples for WU and KI polyomaviruses and 13 other respiratory viruses was
performed. Clinical data were collected prospectively following approval by
the Western Sydney Area Health Service Human Ethics Committee.
Results: Of 646 samples tested, 20/595 NTS and 0/49 BALs were positive for
KI or WU (3. 1%), with an annual prevalence of 1. 6% and 1. 3% respectively.
KI was detected in 10 episodes of respiratory tract infection involving 9
patients and WU in 7 episodes involving 6 patients. One patient had separate
episodes with each virus. Either virus was the sole potential pathogen in 10
of the 17 episodes of infection. Respiratory virus co-infections were present
in 6/10 KI infections, including three with rhinovirus, and 1/7 WU infections.
Pneumonia was present in 3/10 episodes of KI associated respiratory infection
and 4/7 episodes of WU; upper respiratory infection alone was present in seven
and three episodes respectively. One case of KI and rhinovirus co-infection 48
months post-HSCT was fatal. Two KI and three WU infections were managed
as outpatients. Sixteen of the 17 episodes of KI and WU- associated respiratory
tract infections occurred in allogeneic HSCT recipients: 4 were sibling donor
transplant recipients and 9 unrelated donor transplant recipients, including
three cord HSCT recipients. One autologous HSCT recipient had WU detected
with upper respiratory symptoms pre-HSCT (Day -9) and with pneumonia
before neutrophil engraftment occurred (Day +15). Graft versus host disease
was present in 7/10 KI and 4/6 WU infections involving allogeneic HSCT
recipients. Cases with KI and WU occurred a median duration post-HSCT of 9.
5 months (range 0-48 months) and 7. 5 months (0-157 months) respectively. All
patients were receiving immunosuppression. Lymphopenia (<0. 5x109/L) was
present in 7/10 KI infections (median 0. 2x109/L, range 0. 0-2. 4 x109/L) and
7/8 WU infections (median 0. 3 x109/L, range 0. 0-4. 6 x109/L).
Conclusions: WU and KI polyomaviruses have been detected in adult HSCT
recipients with respiratory tract infection. It remains to be determined whether
these viruses cause acute primary respiratory infection, or reactivation of virus
in tissue reservoirs following primary infection in childhood, in the setting of
immunosuppression and other viral infections.
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TUBERCULOSIS AND TRANSPLANTATION

M. Lindemann1, Y. Dioury1, S. Beckebaum2,3, V.R. Cicinnati2, G. Gerken2,
C.E. Broelsch3, P. Wrighton-Smith4, H. Grosse-Wilde1
1
Institut für Immunologie, 2Klinik für Gastroenterologie und Hepatologie,
3
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie,
Universitätsklinikum, 4Oxford Immunotec
Background: Despite the availability of anti-tuberculosis drugs, tuberculosis
(TB) remains a life-threatening condition in immunocompromized individuals
such as patients awaiting liver transplantation. Here, the major problem arises
from reactivation of latent TB. As immune responses to pathogens are commonly
reduced in this patient cohort, a sensitive method for the detection of latent TB
is necessary. Some years ago, an enzyme-linked immunospot (ELISpot) assay
for its detection became available (T-SPOT. TB, Oxford Immunotec).
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377 PIVOTAL ROLE OF THE NATURAL KILLER T CELL FOR
THE INDUCTION OF MIXED CHIMERISM IN THE THYMUS
T. Onzuka, Y. Tomita, I. Shimizu, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu
University
Purpose: Cyclophosphamide (CP)-induced tolerance is a mixed chimerism
based tolerance conditioning, which donor skin allograft tolerance is achieved
in recipients with MHC-matched minor antigen-mismatched donors. Invariant
Natural Killer T (iNKT) cell recognize galactosphingolipid on CD1d,
and produce several cytokines, such as IFN-γ, IL-4, and present several
immunoresponses. The aim of this study is to investigate the function of NKT
cells for the induction of mixed chiemrism in CP-induced tolerance.
Methods: DBA/2 (DBA; H-2d, Ly1. 1) mice and BALB/c (BALB; H-2d, Ly1.
2) wild type (WT), or iNKT knockout (KO) (Jα18-/-, BALB background)
mice were used as donors and recipients. In the first experiment, iNKT
KO recipients were reconstituted with iNKT cells from WT or cytokine
(IFN-γ, IL-4 or IL-10) KO mice with 3Gy whole body irradiation on day
-28. In the second experiment, WT recipients were pretreated with 2 μg of
α-galactcylceramide (GC) on day -7, -4 and -1 (group A), single doses of
α-GC on day -1 (group B), or on day 0 (group C). All recipient mice were
treated with tolerance conditioning, which consisted with 1x108 DBA/2
splenocyte (SC) on day 0 and 200 mg/kg CP on day 2. Donor skin grafting
was performed on day 28. The level of mixed chimerism (Ly1. 1+ cells
in Ly1+ cells) and the kinetics of donor-reactive T cells (Mls-1a-reactive
CD4+Vβ6+ T cells) were assessed by flow cytometry. The serum cytokine
was examined by ELISA assay.
Results: Donor skin graft was accepted in WT recipients treated with DBA
SC and CP. However, donor skin grafts were chronically rejected in iNKT
KO recipients treated with DBA SC and CP. Donor mixed chimerism was
diminished in the iNKT KO recipients at 8 weeks. Flow cytometric analysis

revealed the failure of donor mixed chimerism induction in the thymus,
suggestive of inadequate maintenance of central tolerance in iNKT KO
mice. Donor skin grafts were accepted in iNKT KO recipients, which were
reconstituted with iNKT cells from either IFN-γ, IL-4, or IL-10 KO mice and
treated with DBA SC and CP.
The immediate and the abundant production of IL-2, IL-4, and IFN-γ was
observed after the treatment with a single dose of GC. On the contrary, the
production of IL-2, IL-4, and IFN-γ disappeared in the sera of mice treated
with multiple doses of GC. All donor skin grafts were accepted in group B and
C, which received single dose of GC (group B, C), and iNKT cells showed
enhanced cytokine production. Whereas, chronic rejection of donor skin grafts
were observed in group A, which received multiple dose of GC, and iNKT cells
were failed to produce cytokines.
Conclusions: These results indicated that iNKT cells were essential for the
skin allograft tolerance. However, the major cytokines (such as IFN-γ, IL-4)
produced by iNKT cells were dispensable in the NKT cell function for the
induction of mixed chimerism.
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378 REQUIREMENT OF THE THYMUS FOR BREAKING
TOLERANCE TO RENAL ALLOGRAFTS VIA THE INDIRECT
PATHWAY
K. Yamada, A. Griesemer, Y. Ishikawa, A. Hirakata, M. Okumi, J. Etter, P.
Martins,
A. Shimizu, D. Sachs
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: We have shown previously that long-term tolerance to class I
disparate renal allografts in miniature swine can be induced by a short course
of Cyclosporine A (CyA). This tolerance persists when the graft is removed
and replaced immediately with a new, donor-matched kidney without
immunosuppression. After transplant nephrectomy, tolerance is lost over
approximately 3 months, but this loss can be hastened by injection of donor
class I peptide during the absence of donor kidneys. In this study, we examined
the role of thymus and the indirect pathway in the loss of tolerance. &#12288;
Methods: Four MGH miniature swine (SLAdd) received class I MHC
mismatched renal transplants (SLAgg) with a 12-day course of CyA to
induce tolerance. The primary donor kidneys were removed on POD 100 and
recipient-matched SLAdd kidneys were transplanted to keep the recipient
alive during the absence of the donor kidneys. Class I-donor type peptide
was injected subcutaneously 6 weeks after donor graftectomy. Second donormatched kidneys (SLAgg) were transplanted 12 weeks after the primary donor
graftectomy without immunosuppression. In 2 of 4 recipients, the thymus
was removed 80 days following primary kidney transplant in so no naïve T
cells would be generated during the absence of the donor antigen. MLR with
depletion of antigen presenting cells in the stimulators was performed to assess
sensitization of the indirect pathway.
Results: Both non-thymectomized recipients developed anti-donor class-I
IgG as well as anti-donor peptide antibodies (Ab) following class-I peptide
injection. The second donor-matched kidneys were rejected in an accelerated
acute fashion (< 5 days). In contrast, thymectomized recipients did not develop
anti-donor class-I Ab despite developing anti-peptide Ab. These animals did not
reject their second donor-matched kidneys in an accelerated manner. Indirect
MLR responses, assessing CD4 T cell activation via the indirect pathway,
increased after removal of the primary donor kidneys in non-thymectomized
recipients. &#12288;
Conclusions: The persistence of the donor organ is required for the indefinite
maintenance of tolerance. During the 3-month period of the absence of donor
antigen, the thymus appears to play an essential role in generating the CD4
T cell-help responsible for the breaking of tolerance. That these CD4 T cells
could be activated via the indirect pathway by donor peptide immunization
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Aim: To examine the performance of this ELISpot assay in the liver
transplant setting.
Methods: We analyzed 48 consecutive patients from our liver transplant waiting
list. They were tested with T-SPOT. TB, Mendel-Mantoux tuberculin skin test
(TST), and lymphocyte transformation test (LTT) using tuberculin as stimulus.
A patient questionnaire was used to gain information on TB exposure.
Results: Overall, four patients (8%) were defined as positive by ELISpot,
six (13%) by TST, and 28 (58%) by LTT. Interestingly, the patients
displaying positive results to T-SPOT. TB were positive also in the TST and
the LTT. The two patients who tested negative by T-SPOT. TB but positive
by TST were both born in Turkey; neither reported contact to an infectious
TB case and one had received the BCG vaccine. In addition, both patients
were positive to the tuberculin LTT. Thus, an in vitro lymphocyte response
was detectable to tuberculin, but not to TB-specific peptides; supporting the
assumption that these T-SPOT. TB negative patients were truly negative.
We considered the four patients with positive reaction to the T. SPOT. TB
to have latent TB infection as they reported exposure to TB patients or were
born in countries with a higher TB incidence relative to Germany. Active
TB was excluded on the basis of negative multislice computed tomography,
negative culture and absence of symptoms. These four patients were
repeatedly positive to the T-SPOT. TB test. The follow-up of one patient
with positive T-SPOT. TB reactions twice prior to transplantation indicated
that 1 and 2 months post transplantation reactions disappeared, showing
the effect of post-transplant immunosuppression. In another patient weakly
positive reactions prior to and at month 8 post transplantation significantly
increased at month 12, indicating that responses to T. SPOT. TB increase
with improved immune function. Furthermore, in two patients tested
two times pre transplantation the strength of reactions remained in the
same range.
Conclusion: Our data are the first evidence that T-SPOT. TB may be a valuable
tool for the diagnosis of latent TB in patients awaiting liver transplantation. It
could be necessary to test patients prior to transplantation as positive reactions
may disappear initially post transplantation.
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demonstrates the critical role of the indirect pathway in the loss of tolerance.

POSTER BOARD NUMBER P2 – 408
379 INCREASED PRODUCTION OF THE REGULATORY
T-CELL TRANSCRIPTION FACTOR FOX P-3 M-RNA IN
CAMPATH-1H AND DONOR HEMATOPOETIC STEM CELL
TREATED KIDNEY TRANSPLANT RECIPIENTS
R. Cirocco, J. Mathews, T. Valone, G. Burke, V. Esquinazi, J. Miller,
P. Ruiz, A. Tzakis
University of Miami School of Medicine
Donor Hematopoetic Stem Cells (DHSC) introduced after C1H treatment may
increase the number of regulatory T-cells (FOX-P3 levels) and facilitate long
term engraftment. FOX P-3 mRNA copy numbers in CD3+ cells of five different
groups were measured: 1. Normal laboratory volunteers and dialysis patient
(found to be equivalent-‘Normals’) (N=21); 2. C1H and DHSC treated kidney
recipients (N=2); 3. C1H treated kidney recipients (n=13); 4. Thymoglobulin
treated kidney recipients (Thy) (n=10) Zenopax treated kidney recipients
(Ze) (n=9); 5. Immunosuppressive regimens in groups 2 and 3 (tacrolimus or
sirolimus and mycophenolate) contained half the dose levels of groups 4 and
5. Lymphocytes were isolated from whole and the the RNA was extracted,
C-DNA was produced, and analyzed for levels of m-RNA transcripts for FOX
P-3 by real time PCR. These levels were standardized to the housekeeping
gene GAPDH.
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FOX P-3 COPIES/5000 CD3+ CELLS
Groups
Mean copy # ±SE
1 ‘Normals’
44. 9 ±5. 0
2 C1H + DHSC*
248. 8 ±39. 3
3 C1H
112. 7 ±16. 5
4 Thy
50. 2 ±12. 5
5 Ze
78. 7 ±14. 7

Days post Tx (range)
225-335
180-482
213-463
110-418

P Value between
2 vs 1 p=. 002
2 vs 3 p=. 025
2 vs 3 p=. 025
3 vs 4 p=. 038

* n=11, number of samples serially tested in the two patients.

There was a statistically significant difference in the FOX P-3 copies between
CD3+ cells from the C1H + DHSC patients vs the C1H patients (p=. 025).
There was also a difference when the CD3+ cells of the C1H + DHSC patients
or C1H patients were compared to those from ‘Normals’ (p=. 009 and p=. 002
respectively). CD3+ cells of the C1H patients had significantly higher FOX P-3
levels when compared to those of the Thy patients (p=. 038). All other statistical
comparisons were not significant. In conclusion the use of C1H and (more so)
of C1H + DHSC significantly increases the levels of Fox P-3 transcripts in
kidney transplant recipients, indicating a unique effect in inducing FOX P-3 in
T regulatory cells. This supports the rationale of using of C1H and DHSC as a
tolerogenic regimen in kidney transplant recipients.

POSTER BOARD NUMBER P2 – 409
380 COMPARISON OF LUNG AND KIDNEY ALLOGRAFTS
IN INDUCTION OF TOLERANCE BY A MIXED-CHIMERISM
APPROACH IN CYNOMOLGUS MONKEYS
A. Aoyama, C. Ng, T. Millington, S. Boskovic, T. Murakami, S. Houser,
J. Wain, J. Madsen, T. Kawai, J. Allan
Massachusetts General Hospital Transplant Center, Massachusetts General
Hospital
Background: We have previously reported successful induction of renal
allograft tolerance in nonhuman primates using a nonmyeloablative
conditioning regimen to produce a mixed-chimeric state in the recipient. In
this current study, we applied this same technique to lung allotransplantation
in cynomolgus monkeys.
Methods: Nine pairs of cynomolgus monkeys were used for left single-lung
transplantation. Donors and recipients were selected for compatible ABO
blood types and were mismatched at the MHC class I and class II loci. The
pre-transplant conditioning regimen consisted of total body irradiation (1. 5
Gy×2), thymic irradiation (7Gy), and anti-thymocyte globulin. The recipients
underwent combined lung and bone marrow transplantation on day 0, followed
by anti-CD154 mAb (6 doses over 12 days) and a one-month course of
cyclosporine to maintain therapeutic serum levels. Because moderate or severe
acute cellular rejection was found in three of the initial four lung recipients, the
regimen was modified by adding anti-CD8 mAb (days 0 and 2) in the subsequent
two recipients. Post-transplant administration of α1-antitripsin was also added
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in the last 3 recipients (reported to limit neutrophil infiltration and ischemia/
reperfusion injury in small animal models). The results were compared with 8
recipients that received kidney allografts using the same conditioning regimen.
Chimerism in peripheral blood was determined with flow cytometry.
Results: Two lung recipients were excluded from analysis because of graft loss
not related to rejection. Multilineage granulocyte chimerism developed in 87.
5 ± 7. 3% (max) in the lung recipients and 69. 8 ± 23. 5% (max) in the kidney
recipients (p= 0. 1036; data not available in one lung recipient). Slightly higher
levels of lymphocyte chimerism were found in lung recipients than in kidney
recipients (8. 4 ± 4. 9% [max] vs. 4. 1 ± 2. 2% [max], p= 0. 499). Nonetheless,
all seven lung recipients rejected their allografts by day 85 (85, 68, 55, 35, 26,
22, and 21 days), while the same regimen induced long-term allograft survival
without the need for maintenance immunosuppression in the kidney recipients
(>2500, >2000, 837, 755, 401, 373, 206, and 58 days) (p<0. 01).
Conclusions: Despite the successful induction of mixed chimerism in
recipients of fully mismatched lung allografts, we have not observed long-term
graft survival, as has been seen in an analogous kidney model. We suspect that
this organ-specific difference in the ability to induce graft tolerance relates to
the fact that the lung, being a barrier organ, exists in a more inflamed state,
which exerts a deleterious influence on the antigenicity, inmmunogenicity,
and tolerogenicity of this organ. Strategies to overcome this problem include
organ-specific modifications of the preparative regimen and the induction of
chimerism/tolerance in a delayed fashion, after the graft has been sustained for
several months with conventional immunosuppression.

POSTER BOARD NUMBER P2 – 410
381 DIFFERENT FOXP3 EXPRESSING REGULATORY
T CELLS IN THE LIVER CONTRIBUTE TO PORTAL
TOLERANCE
K. Carper1, W. Wang2, J. Perkins1, J. Reyes1, W. Li1
University of Washington, Seattle, Washington, USA, 2JiLin University,
Changchun, China
The liver has long been considered a tolerogenic organ that favors the induction
of peripheral tolerance. Portal venous injection (p. v. ) of allogeneic donor cells
has been shown to prolong the survival of subsequently transplanted allografts
(portal tolerance). However, the underlying mechanisms still remain undefined.
Accumulating data indicate that liver-residing leukocytes play an important
role in regulating self- and transplantation tolerance. In this study, we adopted
a mouse model of portal tolerance to characterize the liver leukocytes and their
contributions.
Methods: Gamma-irradiated C3H (H2k) spleen cells (SCs) were injected into
the B6 (H2b) recipients through i. v. or p. v. , and the liver nonparenchymal
cells (NPCs) and SCs were characterized phenotypically by flow cytometry
and functionally by MLR, ELISPOT, and immunohistochemistry assays.
Heterotopic heart transplantation was performed from C3H donors to B6
recipients at day 7 post-treatment.
Results: Heart allograft survival was significantly prolonged in the donor
antigen p. v. treated recipients. Mean graft survival time was 50. 2+/-30. 5
days (p<0. 01) vs 16. 5+/-3. 4 days in the i. v. treated recipients. The tolerance
induced by donor SC p. v. treatment was antigen-specific, demonstrated by
rejection of a skin graft from third party, but not donor mice in long-term
surviving heart allograft recipients. The TCR-alpha-beta+NK1. 1+ cells (NKT)
were significantly increased in the livers, and CD4+Foxp3+ regulatory T cells
(Treg) were markedly increased in both livers and spleens after p. v. but not i.
v. injection of C3H SCs. The CD4+Foxp3+ Treg expressed higher intracellular
CTLA4 and PD-1 and PD-L1 molecules on the surface. Interestingly, liver
NKT cells showed similar phenotypes as Treg, which were also Foxp3+, and
expressed high PD-L1 and moderate CTLA4 and PD-1. The T cells from
the p. v. treated mice demonstrated significantly suppressed antigen-specific
proliferative responses. Moreover, ELISPOT assay revealed that the T cells
from p. v. treated mice produced decreased IL-2, increased IL-4 and IL-10
in the livers and spleens, but decreased IFN-gamma in the spleens under
allostimulation in vitro, suggesting that the role of the Treg may contribute to
these responses. Further, significantly increased IL-4, IL-10, and IFN-gamma
production were detected from liver NPC under alphaGalCer stimulation,
suggesting the role of liver NKT cells.
Conclusions: Both NKT cells and CD4+ Treg appear to constitute Foxp3
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expressing-Treg, and underpin portal tolerance in this model. The two types of
Treg may function differently, demonstrated by their varied cytokine profiles.

POSTER BOARD NUMBER P2 – 411
382 MESENCHYMAL STEM CELLS ATTENUATE ACUTE
REJECTION AND SYNERGIZE WITH RAPAMYCIN LEADING
TO CARDIAC ALLOGRAFT TOLERANCE

POSTER BOARD NUMBER P2 – 412
383 CD4+CD25+ REGULATORY T CELLS COMBINED
WITH LOW-DOSE SIROLIMUS, BUT NOT CALCINEURIN
INHIBITORS, PRESERVES SUPPRESSIVE FUNCTION
OF REGULATORY T CELLS AND PROLONGS HEART
ALLOGRAFT SURVIVAL IN MICE
A. Ma1, S. Qi1, Z. Wang1, L. Liu1, D. Xu1, E. Massicotte2, M. Dupuis2,
D. Zhang3, P. Daloze4, H. Chen1
1
Laboratory of Experimental Surgery, Research Centre, Center hospitalier de
l’Université de Montréal (CHUM)&#61485;Hôpital Notre-Dame, Montréal,
Québec, Canada. , 2Institut de recherches cliniques de Montréal, Montréal,
Québec, Canada. , 3WHO Collaboration Centre of Immunogenetics and
Immunopathology, School of Medicine, Shanghai Jiaotong University, China,
4
Department of Surgery, Hôpital Notre-Dame, Université de Montréal,
Montreal, Canada
CD4+CD25+ regulatory T (Treg) cells, like immunosuppressant, are potent
suppressors, play an important role in organ transplantation and autoimmune
diseases. Our previous study demonstrated that CD4+CD25+ regulatory
T cells induced donor-alloantigen-specific transplantation tolerance, and
maintained both anergic and suppressive function on cell proliferation in cell
dose-dependent and donor-alloantigen-specific manner in vitro. In this study,
our objective focused on whether a combination therapy of CD4+CD25+
regulatory T cells with different immunosuppressant, sirolimus, tacrolimus, or

POSTER BOARD NUMBER P2 – 413
384 INVOLVEMENT OF PDCS IN THE TOLEROGENIC
FUNCTION OF CD8+CD45RCLOW TREG AFTER CD40-CD40L
BLOCKADE IN A RAT HEART ALLOTRANSPLANTATION
MODEL
X.L. LI, S. Ménoret, D. Chabannes, M. Hill, M. Heslan, C. Usal, M. Angin,
R. Josien, B. Le Mauff, I. Anegon
INSERM U643, CHU de Nantes, Institut de Transplantation et de Recherche
en Transplantation (ITERT) et Université de Nantes, Faculté de Médecine,
Nantes, France. ianegon@nantes. inserm. fr
Introduction: We have shown that CD8+CD45RClow T regulatory cells
(CD8+ Tregs) mediate tolerance to allografts after blockade of CD40CD40L interactions by CD40Ig. Tolerance was dependant on IFNγ;-induced
indoleamine 2, 3-dioxygenase (IDO) expression but the exact mechanism of
action of CD40Ig CD8+ Tregs remains unknown. The aim of this work was to
analyze the regulatory mechanisms and migratory profile of tolerogenic CD8+
Tregs, and the role of plasmacytoid dendritic cells (pDCs) in this process.
Results: By adoptive transfer and FACS analysis, we confirmed that tolerogenic
CD8+ Tregs were present in the spleen as early as 1 week after initiation of
CD40Ig treatment, and subsequently accumulated in spleen and graft but not
in lymph nodes (LN). The spleen was not necessary for generating tolerogenic
CD8+ Tregs since splenectomy on D0 or 3 months after transplantation did not
abrogate tolerance. In splenectomized recipients, accumulation of tolerogenic
CD8+ Tregs was found in grafts and bone marrow but not in lymph nodes,
and adoptive transfer of bone marrow cells but not those from lymph nodes
significantly prolonged graft survival. Nevertheless, the spleen was the main
storage organ of tolerogenic CD8+ Tregs since splenectomy after 6 months of
treatment triggered rejection. Thymus was also not necessary for the generation
of tolerogenic CD8+ Tregs since allografts were accepted long-term after
thymectomy on D0.
By using PKH-labeled CD8+ Tregs, we observed that tolerogenic CD8+ Tregs
homed to the graft and spleen whereas naïve CD8+ Tregs homed to spleen to a
lesser degree and not to the graft. There was less migration and no differences
between tolerogenic CD8+ Tregs and naïve CD8+ Tregs cells in the thymus,
LN, or bone marrow.
Tolerogenic CD8+CD45RClowTregs were FoxP3+ (10%), CD62L+ (60%),
and MHCII+ (40%). Contrary to mouse CD8+ Tregs, CD122 was weakly
expressed in CD8+CD45RClow T cells.
Inhibition of MLRs using CFSE-labeled CD4+CD25- T cells by tolerogenic
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W. Ge1, J. Jiang2, M.L. Baroja1, J. Arp1, R. Zassoko1, W. Liu3,
A.M. Jevnikar2, B. Garcia3, H. Wang1,2
1
Department of Surgery, University of Western Ontario, 2Multi-Organ
Transplant Program, London Health Sciences Centre, 3Department of
Pathology, University of Western Ontario
Mesenchymal stem cells (MSCs) exhibit many unique immunoregulatory
properties in vitro, however their immunosuppressive potential in preventing
allograft rejection is poorly defined. The present study was undertaken to
determine whether treatment with MSCs can prevent allograft rejection and
in combination with Rapamycin (Rapa) can induce graft tolerance in a mouse
cardiac transplant model. MSCs (1 million, i. v. ) from C57BL/6 donor mice
were injected into BALB/c recipients 24 hours after receiving a heterotopic
C57BL/6 heart graft. Heart grafts in untreated recipients were rejected by
severe acute humoral and cellular rejection within 7. 8±0. 5 days. Notably,
MSC treatment significantly attenuated graft rejection, doubling graft survival
to 15±0. 8 days which was comparable to the prolonged survival of 16. 5±0.
9 days achieved with Rapa (2mg/kg, orally, POD0-13). In marked contrast,
the combination therapy of MSCs and Rapa achieved indefinite heart graft
survival (>100 days) with normal histology and undetectable levels of
anti-donor antibodies. Splenocytes from long-term surviving recipients
demonstrated allo-specific hyporesponsiveness, indicating donor-specific
graft tolerance had been achieved. Compared with rejecting mice, splenic
dendritic cells isolated from tolerant recipients exhibited significantly
decreased expression of MHC II, CD40, CD80 and intracellular IL-12, as well
as a reduced ability to stimulate donor T cell proliferation as measured by
MLR that was accompanied by an increased Th2, but decreased Th1 cytokine
profile. In addition, tolerant recipients demonstrated significantly higher levels
of CD4+CD25+Foxp3+ regulatory T cells. Furthermore, MSCs from GFP
transgenic C57BL/6 mice appeared to home and persist within the recipient,
gradually increasing their presence in the bone marrow, lymphoid organs
and heart grafts of long-term surviving recipients when monitored on POD7,
30 and 100. We conclude that donor MSCs maintained within the recipient
long after infusion, attenuate acute graft rejection and synergize with Rapa
leading to heart allograft tolerance. This study suggests that MSCs may offer
various attractive therapeutic applications to the field of clinical solid organ
transplantation.

cyclosporine A, could prolong survival time of totally MHC-mismatched heart
allografts in mice.
The study showed that sirolimus could permit the expansion of CD4+CD25+
regulatory T cells in vitro. The suppressive function was neutralized when
CD4+CD25+ T cells co-cultured with tacrolimus (1. 0 nM) or cyclosporine A
(1. 0 nM), but not with sirolimus in vitro. When the concentration of sirolimus
was increased more than 100 nM, inhibitive efficiency was fallen. Based on the
ability of sirolimus to target effective T and B cells, but permit the suppressive
function of regulatory T cells in vitro and in vivo, an adoptive infusion of
donor-alloantigen-specific CD4+CD25+ regulatory T cells combined with a
14-day short postoperative course of low-dose sirolimus (1. 0 mg/kg) was
found to prolong heart allograft survival time (>60 days) in Balb/c to C57
mice. Even though the cell numbers of CD4+ T cell subsets were found to
decrease in sirolimus treated mice, sirolimus selectively enhanced the ratios
of CD4+CD25+ T cells to CD4+ T cells in spleens and peripheral blood,
respectively. However, combined therapy of CD4+CD25+ T cells with
low-dose cyclosporine A (5. 0 mg/kg) or tacrolimus (1. 0 mg/kg) reduced
significantly the population of CD4+CD25+ regulatory T cells and failed to
prolong the survival of heart allograft survival, compared to treatment with
immunosuppressant alone.
This study indicates that CD4+CD25+ T cells are more resistant to sirolimus
than other T cells. Sirolimus, but not tacrolimus or cyclosporine A, does not
block the proliferation of CD4+CD25+ regulatory T cells in vitro. Sirolimus
rather than calcineurin inhibitors, cyclosporine A and tacrolimus, preserves
suppressive function of regulatory T cells in pathologic immune responses to
alloantigens in transplantation, and calcineurin-dependent signals are required
for induction of CD4+CD25+ regulatory T cells.
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and naïve CD8+ Tregs was observed when using immature allogeneic pDCs
and myeloid CD4-OX62+ DCs, but less when using immature myeloid
CD4+OX62+ DCs and mature pDCs. Suppression of MLRs by tolerogenic
CD8+ Tregs was stronger vs. naïve CD8+ Tregs when using pDCs. Suppression
of MLRs by tolerogenic CD8+ Tregs was donor alloantigen-specific when
alloantigen was presented by both immature donor pDCs or recipient pDCs
loaded with donor antigens.
Suppression of CD4+CD25- T cells in MLRs by tolerogenic CD8+ Tregs was
cell contact independent. Contact between tolerogenic CD8+ Tregs and pDCs
was critical for their suppressive function. IDO and iNOS were involved since
the use of specific inhibitors abrogated MLR inhibition in vitro and triggered
rejection of tolerated grafts in vivo.
Conclusion: Tolerogenic CD8+ Tregs are generated as early as in 1 week after
CD40Ig treatment in the spleen, which is the main storage organ, and from
where they migrate into the graft. Bone marrow is an alternative generation
site for tolerogenic CD8+ Tregs. In vitro, the alloantigen-specific suppression
by tolerogenic CD8+ Tregs is preferentially mediated by immature pDCs.
Cell contact between pDCs and CD8+ Tregs is necessary for the tolerogenic
function through the induction of IDO and iNOS.
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385 ALLOGRAFT TOLERANCE MEDIATING CD4+T CELLS
DEPEND UPON INTERLEUKIN-5 (IL-5), NOT IL-4.
B. Hall, K. Plain, M. Nomura, N. Verma, G. Tran, R. Boyd, C. Robinson,
S. Hodgkinson
Faculty of Medicine, University of NSW, Sydney, Australia
CD4+CD25+T cells in CD4+T cells are required to mediate antigen specific
allograft tolerance and can transfer tolerance. We found tolerance transferring
CD4+T cells lose their capacity to transfer tolerance when cultured in MLC
unless supplemented with T cell derived cytokines. Which cytokines are required
to support these cells is unknown. We examined if the Th2 cytokines IL-5 and
IL-4 could promote survival of CD4+T cells from DA rats that tolerated a fully
allogeneic PVG heart graft over 100 days after a short course of non-specific
immunosuppression, usually anti-CD3 mAb. These cells were cultured with
PVG alloantigen in media supplemented with either IL-5 or IL-4 for 3 days
before transfer to irradiated DA hosts grafted with either specific donor PVG
or third party Lewis grafts. These hosts do not reject their grafts unless restored
with naïve CD4+T cells, which reject in 11-20 days (n=11). 2x106 fresh tolerant
CD4+T cells transferred tolerance to PVG grafts (7 of 9 survived >150 days)
but not to Lewis, all 5 rejected. Culture of tolerant CD4+T cells in MLC with
donor antigen leads to loss of tolerance transferring capacity in that all 7 PVG
grafts were rejected. Culture with ConA supernatant promotes the survival of
antigen specific tolerance transferring cells with 8 of 10 PVG grafts accepted
long term (>150 days) but only 1 of 10 Lewis grafts accepted with rejection in
10-20 days. Culture with IL-5 also produced cells that transferred tolerance to
PVG grafts (7 of 9 accepted) but not to Lewis grafts (2 of 7 accepted). Cells
cultured with IL-4 rapidly rejected all PVG in days 7-9 days (n=10) and also
rapidly rejected Lewis grafts in 7-10 days (n=10). Rejection times with IL-4
cultured cells were faster that restoration with fresh naïve CD4+T cells where
rejection occurred in 10-20 days. Culture of tolerant CD4+T cells with IL-5
partially retained the capacity to suppress rejection mediated by naïve cells
(n=10) with many grafts having only a transient rejection from day 12-20.
We found that naïve CD4+CD25+T cells cultured with alloantigen and IL-4
develop into alloantigen specific regulatory cells that express IL-5Rα, the
cytokine specific receptor subunit for IL-5. Also, that tolerant CD4+CD25+T
cells proliferate to donor antigen in the presence of IL-5 and express IL-5Rα.
These findings suggest that IL-5 acts directly on alloantigen specific
CD4+CD25+T cells and may be a key cytokine required to promote induction
and maintenance of allograft tolerance. Further, IL-5 appears to act on antigen
specific CD4+CD25+T regulatory cells, that have been originally activated by
IL-4 during a Th2 response. We have found human CD4+CD25+T cells when
activated by alloantigen and IL-4 also express IL-5Rα suggesting IL-5 may
also promote tolerance induction in man.
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386 INFILTRATION OF REGULATORY T CELLS IN THE
TOLERANT SKIN OF ALLOGRAFT IN A RAT HIND-LIMB
TRANSPLANTATION MODEL
M.J. Elliott, S. Wu1, L. Adamson1, D. Rahhal1, W-C. Huang1, Y. Wen1, W.
Breidenbach2, S. Ildstad1
1
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
2
Division of Hand and Microsurgery, Christine M. Kleinert Institute, Jewish
Hospital, Louisville, KY
Background: Over 30 hand transplants have been performed worldwide.
Contrary to prior predictions, control of acute rejection has been readily
achieved. Foxp3+ regulatory T cells (Tregs) has been shown to act as an
immunomodulator in peripheral transplant tolerance induction. The expression
of the transcriptional regulator Foxp3 is specific to Tregs. We examined
whether Tregs infiltrated the transplanted skin in a rat model of composite
tissue allotransplantation.
Methods: WF rats (RT1Au) were conditioned with 600 cGy total body
irradiation (day -1) and transplanted with 100×106 T cell-depleted bone marrow
cells from MHC-mismatched ACI donors (RT1Aabl) on day 0. Tacrolimus
was administered (days 0-10), as well as one dose of anti-lymphocyte serum
(day 10). Mixed chimerism in peripheral blood was confirmed by flow
cytometry on day 28 and then monthly. On day 29 the chimeras received
an ACI osteomyocutaneous hind-limb transplant (n=10). Six months posttransplantation, specimens of tolerant, rejected, and naïve skin were snap
frozen and immunostained with fluorochrome conjugated anti-Foxp3 and antiCD4 monoclonal antibodies. Stained slides were visualized under Leica TCS
SP5 confocal microscopy, and the number of Foxp3+ cells per high-power
field (HPF) was calculated. Twenty HPFs were randomly selected from each
skin specimen and counted by a blinded observer. Results were expressed as
average number of Foxp3+ cells/HPF.
Results: Six of ten animals exhibited long-term acceptance of the hind-limb
flap allotransplant. There is no difference in the chimerism kinetics between
the rats with tolerant graft and the rats with rejected graft. The overall average
chimerism level in these rats is 41.62% one month after transplantation and
decreased with time. Six months post-transplantation, all of them lost donor
chimerism in peripheral blood. At this time, Foxp3-CD4+ cells could be found
in tolerant skin, rejected skin and naïve skin, while Foxp3+CD4+ were only
detected in tolerant skin [figure1]. The number of Foxp3+ cells/HPF in three
tolerant skin samples examined to date is 14.8/HPF, 11/HPF and 7.6/HPF.
Conclusion: Although donor chimerism in peripheral blood was lost in all
rats with the present tolerance induction protocol by six months, 60% of them
exhibited long-term acceptance of the hind-limb allotransplants, which may
be associated with the infiltration of Foxp3+ Tregs into transplanted donor
skin. Numerous CD4+ T cells that infiltrated tolerant skin expressed Foxp3,
indicating predominance of Tregs over T effector cell function. Studies are
underway to deplete Tregs in vivo to confirm Tregs action as a mechanism of
promoting graft acceptance. These studies suggest that infiltration of T cells
in the skin of the composite tissue allografts may be beneficial and may not
always herald rejection.
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387 MINIMALLY INVASIVE VIDEO-ASSISTED KIDNEY
TRANSPLANTATION (MIVAKT)
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388 ADDITIONAL VASCULAR RECONSTRUCTION AND
SPECIAL VASCULAR ANASTOMOTIC TECHNIQUES – AN
IMPACT FACTOR IN EARLY GRAFT DYSFUNCTION?
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, D. Tacu,
E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni
Clinical Institute
Purpose: The aim of this study was to investigate the one week graft function
consecutive to additional arterial and venous reconstruction combining with
special anastomotic techniques during renal transplantation.
Material and Methods: 11 years renal transplant experience (1997 – 2008)
was assessed considering 855 renal transplantations (710 living and 145
cadaver, 807 adults and 48 pediatric) with an average of 81/year (116 in 2007).
In all cases, general preoperative evaluation, immunological and vascular
anatomy study was performed. 266 cases (31%) had vascular graft anomalies,
165 abnormal arteries and 101 abnormal veins.
Results: Special anastomotic and reconstruction techniques were used as
followed: double T-T anastomosis – 96 cases, T-L anastomosis – 9 cases
(cadaver donors), combined anastomosis – 3 cases; single trunk made by two
branches – 27 cases and we used the epigastric artery for small branches in
4 cases. 26 minor aberrant vessels were excluded, feeding a minor area of
parenchyma. Cava patch and venous reconstruction were used in 32 cases (11
from cadaver donors). Abnormal venous drainage was managed by classical
T-L anastomosis to the external iliac vein. One week graft failure (vascular
reason) occurred in one arterial reconstructed graft (0. 6%) and one venous
reconstructed pedicle (0. 6%) proving a reasonable result. Graft function was
96% – one year, 84% – 5 years and 80% – 10 years.

POSTER BOARD NUMBER P2 – 418
389 EVALUATION OF INFLUENCE OF NEPHRECTOMY
BEFORE AND AFTER KIDNEY TRANSPLANTATION ON
COMPLICATION INCIDENCE IN PATIENTS WITH ESRF IN
THE COURSE OF ADPKD
T. Sulikowski1, K. Tejchman1, Z. Zietek1, J. Rozanski2, L. Domanski2,
M. Kaminski1, M. Romanowski1, K. Ciechanowski1, A. Ciechanowicz3,
M. Ostrowski1
1Department of General Surgery And Transplantation, Pomeranian
Medical University, 2Depratment of Nephrology, Transplantology And
Internal Diseases, Pomeranian Medical University, 3Department of Clinical
Biochemistry and Laboratory Diagnostics, Pomeranian Medical University
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is
the entity characterized by the presence of multiple cysts in the both kidneys.
Symptoms of the disease may arise either from the presence of cysts or increasing
loss of kidney function. First symptoms appear usually in the third decade of
life: lumbar pain, urinary tract infections, arterial hypertension or renal colic
due to rupture of a cyst or coexisting nephrolithiasis. An early diagnosis, male
sex, large kidneys in sonography, arterial hypertension, hematuria and urinary
tract infections are predicting factors of the faster progress of the disease.
Aims: The aim of the study was to establish the indications for nephrectomy in patients
with symptomatic ADPKD bfefore kidney transplantation, and the assessment of
possible risk after renal transplantation without ADPKD nephrectomy.
Material and methods: The observed group consisted of 183 patients with
ADPKD from among 50 (27, 3%) underwent kidney transplantation during
7-years observation (2000-2007). Among those we observed 3 groups:
I –; patients with nephrectomy preceding transplantation; II –; patients
with nephrectomy during kidney transplantation; III –; patients without
nephrectomy.
Results: In the group I before Tx we observed: arterial hemorrhages, cases of
wound infections, splenectomy performed 4 weeks after ADPKD nephrectomy;
after Tx we observed: urinary tract infections, cysts infection on the other
side. In the group II we observed only 1 case of wound infection. In the group
III we observed: ascending urinary tract infections, infections of cysts, cyst
hemorrhage. Cysts hemorrhages and cysts infections lead mainly to ADPKD
kidney nephrectomy. 80, 95% of grafts were functioning correctly during
observation time.
Conclusions: 1. Unilateral nephrectomy seems to be well-founded preliminary
surgical treatment preparing the patients for kidney transplantation.
2. Bilateral nephretomy before or during transplantation eliminates ADPKD
complications and non significantly increase general complications.
3. The highest numer of complications was observed in group without
pretransplant nephrectomy, including graft loss.

POSTER BOARD NUMBER P2 – 419
390 PERIOPERATIVE ANTICOAGULATION AND
ANTIPLATELET THERAPY IN RENAL TRANSPLANT: IS
THERE AN INCREASE IN BLEEDING COMPLICATION?
M. Marvin, M. Eng, R. Kadiyala, R. Ouseph, R. Nagubandi, J. Gleason,
J. Buell
Transplant Center, Jewish Hospital, Louisville, Kentucky, United States.
Renal transplant recipients often have comorbidities requiring anticoagulation
or antiplatelet therapy. The effects of Warfarin may be reversed with plasma,
but those of Aspirin (ASA) and Clopidogrel are not easily reversed. We
evaluated the risk of bleeding complications of patients taking perioperative
ASA, Clopidogrel, Enoxaparin, Heparin or Warfarin.
Methods: Charts of renal transplant between July 2005 to June 2007 were
reviewed. Patients receiving perioperative anticoagulation and antiplatelet
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S.P. Mun1, S.H. Kim2
1Department of Surgery, Chosun University, School of Medicine, Gwangju,
Korea, 2Department of Surgery, Chosun University, School of Medicine,
Gwangju, Korea
Background: Minimally invasive surgery has been applied to nearly all fields of
surgery due to its advantages such as reduced morbidity, a better cosmetic outcome, and
early recovery. The recent advances in its technique have allowed us to use modified
minimally invasive surgical technique in the field of kidney transplantation.
Materials and methods: From January 2004 to March 2006, minimally
invasive video-assisted kidney transplantation (MIVAKT) was carried out in
20 patients. Many clinical variables were compared with the conventional
method. The length of skin incision was equal to the diameter of grafted
kidney, usually 7-8 cm. The incision was made between external iliac vessel
and bladder marked pre-operatively with ultrasound. Laparoscopic balloon
dissector was used to create the retroperitoneal space for the placement of the
grafted kidney. The external iliac vessels were lifted as much as possible and
surgical retractor was used. Sometimes intraluminal vascular anastomosis was
needed and the kidney was suspended to both neighboring sites of the vascular
anastomosis. Vascular anastomosis was performed under direct vision and with
video-assisted TV monitoring for the assistant surgeon. Ureteroneocystostomy
was carried out under direct vision. The grafted kidney was inserted into the
previously made retroperitoneal space.
Results: The total length of the MIVAKT incision was shorter than that for the
CKT (7. 8 cm versus 21. 2 cm, P < 0. 001). The degree of pain was also lower
in MIVAKT (5. 8 versus 7. 9, P < 0. 05). The operation time was 178 min, and
this was longer than coventional technique by 18 min, but the difference was
not statistically significant (P=0. 78). There was no difference between the two
methods as to the complications, graft function and episode of rejection. All
patients were discharged at 2 weeks postoperatively.
Conclusions: MIVKT is technically feasible and may offer benefits in terms of
better cosmetic outcomes, less pain, and quicker recuperation than conventional
kidney transplantation.

Conclusions: Vascular anomalies of renal pedicle were founded in 31% but
transplantation was performed due to special reconstruction and anastomotic
techniques which did not significantly increase the ischemia time and vascular
complications. Arterial and venous reconstruction combined with special
anastomotic procedures did not increase the risk of early graft failure. One
week graft function remained in very good condition. Accepting the borderline
vascular donor the number of transplantation could increase with 30%.
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therapy were identified. The need for blood transfusion, reoperation for bleed
and decrease in serum hemoglobin (Hgb) were compared to those on no
anticoagulation or antiplatelet therapy.
Results: 179 patients were identified. Pre-operatively, 37 were on ASA, 15
on Warfarin, 4 on Clopidogrel, 2 on ASA and Warfarin and 1 patient was on
Enoxaparin. Indication for therapy include prior deep venous thrombosis,
coronary artery disease, peripheral vascular disease, prior cerebral vascular
accident, valve replacement, prior endocarditis, hypercoagulable state and atrial
fibrillation. Indication of Warfarin use in 2 patients could not be identified.
Post-operatively, 19 were on ASA, 4 on Heparin drip, 2 on Heparin drip and
Warfarin, 1 on Enoxaparin, 5 on Enoxaparin and Warfarin, 3 on Warfarin, 2 on
ASA and Warfarin, 1 on Clopidogrel and 1 was on ASA and Clopidogrel.
Pre-operative anticoagulation and antiplatelet therapy did not increase
the incidence of reoperation for bleed. Pre-operative ASA, Clopidogrel or
Enoxaparin did not increase the need for transfusion. Despite correction with
plasma, Warfarin resulted in a greater Hgb (p=0. 02) although the number of
transfusion was not increased.
Post-operative Heparin drip was associated with an increased incidence of
bleeding complications. There was an increased number of transfusion (p=0.
001), an increased incidence of return to the operating suite for bleeding (p=0.
001) and a greater Hgb (p=0. 01) and%Hgb (p=0. 04). This occurred in all
patients with an elevated prothrombin time (PTT) >80 seconds. Although there
was a trend towards increased Hgb of patients on ASA and Warfarin postoperatively, the number of transfusion was not increased.
Conclusion: No significant risk of bleeding with pre-operative anticoagulation
was noted, although significant risk was present with post-operative Heparin
drip, especially with a supratherapeutic PTT.

POSTER BOARD NUMBER P2 – 420
391 COAGULOPATHY ASSOCIATED WITH
THYMOGLOBULIN INDUCTION THERAPY FOLLOWING
RENAL TRANSPLANTATION
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
Subsequent to the development of two postoperative hemorrhagic complications
on day 5 after renal transplantation associated with unexplained coagulopathy
(INR > 2. 5 ), we began to check the INR on postoperative day 2 in all renal
transplant recipients, beginning January 2005. Between Jan. 1st, 2005 and
Nov. 30th, 2007, 167 renal transplants were performed at our institution. All
patients received induction therapy with either Thymoglobulin (deceaseddonor and live-unrelated donor recipients) initiated within 24-hours of renal
revascularization at a mean daily dose of 1mg/kg continued through day 6
(Group A, n=154) or simulect (live-related donor recipients) 20 mg initiated
prior to revascularization and repeated on postoperative day 4 (group B, n=13).
All patients with an INR of > 1. 5 on postoperative day 2 were treated with
fresh frozen plasma (FFP) and/or vitamin K 1 mg intravenously to reverse the
coagulopathic parameters. Demographics between the two recipient groups
were noted to be similar for age, gender, ethnicity, diabetes and postoperative
serum albumin level.
The mean immediate preoperative INR was 1. 0 in both group A and B patients.
On postoperative day 2 the mean INR was 1. 2 in group A (range 0. 9-4. 8)
and 1. 0 (range 0. 9-1. 2) in group B recipients (P=NS). However, twenty-two
group A patients (14%) were noted to have an INR of > 1. 5 on postoperative
day 2 and were treated with FFP and/or vitamin K compared to no group B
patient (p=0. 01) No patient in either group sufferred a clinically significant
hemorrhagic complication.
Induction therapy with Thymoglobulin, compared to simulect, after renal
transplantation was noted to be associated with an increased rate of an elevated
INR on day 2. This trend towards a potentially dangerous coagulopathic state
did not reach statistical significance likely due to our small patient numbers
in group B and early treatment of the elevated INR. Nevertheless, these data
indicate that renal transplant recipients treated with Thymoglobulin induction
therapy should undergo careful monitoring of coagulation factor function
postoperatively.
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392 THE INFLUENCE OF KIDNEY VESSEL RESISTANCE
FOR FUNCTIONING GRAFT IN THE FIRST THREE MONTHS
AFTER TRANSPLANTATION.
M. Nowacki1, M. Kaminski1, K. Safranow1, T. Sulikowski1,
M. Romanowski1, J. Sieñko1, E. Ignaczak3, Z. Ziêtek1, M. Drozdzik2,
M. Ostrowski1
1Department of Surgery And Transplantation Pomeranian University of
Medicine, Poland, 2Department of Pharmacology Pomeranian University of
Medicine Szczecin, Poland, 3Szczecin University of Technology, Poland
Materials and methods: The aim of this study was to evaluate influence
of vessel resistance for kidney function three months after transplantation
and influence of changing vessel resistance for the functioning
transplanted kidney.
We analyzed 96 kidneys received from cadaver donors. The Kidneys were
harvested by classical aortical cooling method with 4 liters Eurocollins solution.
One of the kidney’s arteries was isolated by carefully dissection and prepared
for adding calcium channel blocker (C. C. B. ). The dose of Verapamil was 0, 1
mg in 10 ml 0, 9%NaCl solution. Two minutes before starting gravity perfusion
we injected (by syringe) Verapamil solution directly to the one of renal artery
(left or right) over one minute.
On the back table just after the harvesting procedure we connected a catheter
to each of the kidney’s artery and we measured renal flow of perfusion solution
during one minute. For examination kidneys with single artery were chosen.
Kidney function tests: levels of serum creatinine, urea and diuresis were
measured in the first and third day, after two weeks and then one and three
months after transplantation.
Results: 96 kidney transplants received from 48 cadaver donors had been
performed. There were two groups of recipients. First group of 48 recipients
that received kidneys without adding verapamil during harvesting and second
group of 48 recipients that received kidneys with injected verapamil 2 minutes
before starting gravity perfusion.
The level of perfusion kidneys after adding Verapamil was significantly higher
comparing to perfusion of kidneys without adding Verapamil (SD 161 ml/min
vs 111 ml/min). We observed negative correlation between the level of urea
on the third day after transplantation, level of potassium on 30th day after
transpalntation and difference of perfusion comparing both kidneys from each
group. We also noticed positive correlation between level of perfusion kidney
without adding Verapamil and diuresis on 90th day after transplantation [Rang
Spearman test].
Summary we observed that kidneys without adding Verapamil and with lower
level of vessel resistance functioned better during first three months after
transplantation. We also analyzed second group of recipients that received
kidneys with adding Verapamil just before starting gravity perfusion. We
noticed that improvement of perfusion by Calcium Channel Blocker Verapamil
does not influence the functioning graft after transplantation (p<0, 05), RR = 2,
[multivariable Cox analysis].
Conclusions: 1. Kidneys with lower level of vessel resistance function better
in the first period after transplantation.
2. Reducing level of vessel resistance by Calcium Channel Blocker does
not influence significantly for functioning kidneys in early period after
transplantation.
3. We observed significant decreasing kidney’s vessel resistance after
administering calcium channel blocker directly to the kidney artery before
starting gravity perfusion.
4. Kidneys received from donors with better biochemistry parameters of
functioning kidneys have better reactivity of vessel for Verapamil.
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393 SINGLE OR DOUBLE ARTERIES IN KIDNEY DONORS:
INFLUENCE ON THE DONOR LONG-TERM OUTCOME
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394 COMPLICATIONS OF OVERSEAS KIDNEY
TRANSPLANTATION : KANGNAM ST. MARY’S HOSPITAL
EXPERIENCE
B.J. Hyoung1, H.S. Hwang1, Y.J. Jeon1, S.Y. Lee1, H.E. Yoon1, B.S. Choi1, Y.S.
Kim1, B.K. Bang1, C.W. Yang1
1
Kangnam St. Mary’s Hospital, 2Kangnam St. Mary’s Hospital, 3Kangnam
St. Mary’s Hospital, 4Kangnam St. Mary’s Hospital, 5Kangnam St. Mary’s
Hospital, 6Kangnam St. Mary’s Hospital, 7Kangnam St. Mary’s Hospital,
8
Kangnam St. Mary’s Hospital, 9Kangnam St. Mary’s Hospital, 10Kangnam St.
Mary’s Hospital
Purpose: Recipients who undergo overseas kidney transplantation lack
medical insight regarding their perioperative and donor status. Therefore they
need careful medical attention during their posttransplant follow-up care. We
reviewed the surgical and medical complications of patients who went overseas
for kidney transplantation and returned to our constitution for continued care.
Methods: We identified 66 patients who underwent kidney transplantation
outside Korea between 2002 and 2007. The patients were transplanted in
China (n=63) and The Philippines (n=3). The mean age was 51±10 years with
a median follow-up of 15 months (range 9-31). We retrospectively reviewed
surgical and medical complications in these patients.
Results: Surgical complications were noted in fifteen (22. 7%) patients. These
included wound infection (n=1), wound dehiscence (n=4), lymphocele (n=4),
hydrocele (n=1), hematoma (n=1), renal artery stenosis (n=2), ureteral stricture

POSTER BOARD NUMBER P2 – 424
395 RISK FACTORS FOR TRANSPLANT RENAL ARTERY
STENOSIS
M.K. Heer1, P.R. Trevillian1, D. Hardy1, J. Attia2, P. Mcelduff3, D. Gillies4, S.
Ainsworth1, A.D. Hibberd1
1
Newcastle Transplant Unit, John Hunter Hospital, 2Division of Medicine,
John Hunter Hospital, 3Hunter Medical Research Institute, University of
Newcastle, 4Division of Surgery, John Hunter Hospital
Background Transplant Renal Artery Stenosis (TRAS) is a potentially serious
complication after transplantation. Prevention and early management of
TRAS may improve transplant and patient survival. The risk factors, natural
history and indications for intervention for TRAS are poorly understood.
Hence in this study we aimed to define the risk factors and natural history
of TRAS.
Methods: The study population consisted of 149 consecutive renal transplant
recipients who had 1042 duplex vascular scans at a single centre between
1999 and 2006. Routine assessment for TRAS on all recipients was done by
duplex vascular scanning (GE VIVID 307, multiphase transducer) at 1, 3 and
12 months and annually thereafter. Scanning was also done when clinically
indicated. All scans were done by one specialist. No morbidity resulted from
the scanning. The criteria used for the diagnosis of TRAS were: absolute
(transplant renal artery velocity to aortic velocity ratio and peak systolic
velocity); and, relative (hilar acceleration time, parenchymal perfusion, size
of the kidney, resistive index, presence of other vascular conditions and age
of transplant). Recipients were divided in two groups according to the time
at which the presence of TRAS was first discovered: early stenosis occurred
within 3 months or late stenosis occurred after 3 months from transplant. The
risk factors studied were, for the donor: age, presence of co morbidity, live
donor versus deceased donor, arterial injury at retrieval, CMV status and for
the recipient: age, sex, type of anastomosis, presence of DGF, HLA mismatch,
presence of vascular disease, vascular rejection and CMV status. Multivariate
logistic regression analysis was done on retrospective data using the SAS
programme.
Results: The recipient mean age was 46. 5 ± 12. 9 years and the M: F was
84: 65. The mean follow up period was 2. 45 yrs. The number of patients with
TRAS was 50 with a mean age of 48. 36 ± 11. 9 years and M: F was 29: 21. The
average time to diagnosis was 193 days. The site of stenosis was ostial (20), mid
segment (23), hilum (1), branch (2) and entire artery (4). There were 36 (78%)
recipients with early stenosis and 14 (28%) with late stenosis. None of the risk
factors for TRAS in the early stenosis group reached statistical significance.
But in the late stenosis group the presence of vascular rejection [hazard ratio:
4. 10 (95% CI 1. 12 to 15. 0)] was significant risk factors for development of
TRAS. More recipients in the early group [21/36 (58. 3%)] had resolution of
stenosis than in the late group [3/14 (21. 4%). (p=0. 019)].
Conclusions: Routine duplex vascular scanning of renal transplant recipients
detects significant numbers of TRAS without causing any morbidity. Early
stenosis usually resolved but late ones persisted implying different etiologies
for the two groups. Presence of vascular rejection is significant risk factors for
development of late stenosis. No risk factor was found to be significant for
early stenosis. Further prospective studies are needed to define the risk factors
for TRAS.
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M. Nilsson, I. Fehrman-Ekholm1, J. Steinwall2, S. Möller2, J. Holmdahl1,
M. Olausson1
1
Transplantation Institute, 2Sahlgrenska Academy
Introduction: Today kidney with the single artery is preferred for kidney
donation especially if laparoscopic surgery is planned. How often is the donor
left with double or triple arteries and has this any implication on long-term
kidney function, risk of thrombosis or hypertension?
Material and methods: All consecutive donors from 1983- 1989, who
underwent surgery at Sahlgrenska University Hospital, was reevaluated to find
out kidney function, presence of hypertension and outcome. The project was
approved of Ethic committee.
Results: Total 154 donor nephrectomy was performed during these years with
open, anterior technique. In 117 cases right kidney was removed and in 37
cases left kidney. The medical reports showed that 98 persons were left with
one single artery to the remnant kidney and 56 with more than one artery that is
36%. In fact six persons were left with 3 arteries. The meanage of the donor at
donation was 48 (SD12), range 19-73 years and present age was on the average
68 (SD 12), range 39-92 years
In the group with single artery the preoperative p-creatinine was 86 (SD 12), at
6 months 127 (SD 20) micromol/L and today on the average 20 years later (in
2007) the p-creatinine was 89 (SD 22) micromol/L. The highest p-creatinine
at six months was 176 and today 173 micromol/l. Of the total 98 from start, 96
were available at six months and 55 were analysed in 2007. 22/55 (40%) had
developed hypertension. Total 10 donors had died, 8 donors were living abroad,
and 4 donors did not want to join the study.
In the group of donors left with more than one artery the mean preoperative
p-creatinine was 87 (SD 11) and at six months 131 (SD 20) micromol/l. Today
in 2007 the mean p-creatinine was 100 (SD 45) micromol/l. The highest
p-creatinine at six months was 176 and today 330 micromol/l. Of the total 56
from start, 54 were available at six months and 35 were analysed in 2007. 10/35
(29%) had developed hypertension. Total 11 had died, one with ESRD. Two
were living abroad, one denied to participate and one donor had undergone
kidney transplantation due to renal carcinoma.
Conclusions: One third if the kidney donors are left with more than artery to
the remnant kidney. The 20-year follow-up shows no significant difference in
renal function or hypertension between those with one artery or more than one.
Although a small material there were two donors with ESRD in the double
artery group.

(n=2), bleeding at ureteral anastomosis site (n=1), and vesicoureteral reflux
(n=1). Seventeen (25. 8%) patients had medical complications, most of which
were opportunistic infections. Six patients (9%) had cytomegalovirus (CMV)
viremia, one of which had CMV pneumonia. Pneumocystis pneumonia was
diagnosed in three (4. 5%) patients. Two (3%) patients experienced a significant
fungal infection including invasive pulmonary aspergillosis and aspergillus
sinusitis. Five (7. 6%) patients had BKV infection, one of which was diagnosed
with BKV nephropathy. In addition to infectious complication, we experienced
thrombotic microangiopathy (TMA, n=1), and tertiary hyperparathyroidism
(n=1).
Conclusion: We recommend routine renal Doppler sonography and the
monitoring of CMV and BKV viremia. To prevent fatal infection, nystatin,
trimethoprim-sulfamethoxazole and oral gancyclovir prophylaxis are strongly
recommended.
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396 OCCLUSION OF POLAR/SMALL RENAL TRANSPLANT
ARTERIES SHOULD NOT BE MISDIAGNOSED AS ACUTE
REJECTION

397 PERSISTENT URETERAL STENOSIS AFTER KIDNEY
TRANSPLANTATION: INCIDENCE AND EFFICACY OF THE
TREATMENT WITH SELF EXPANDING METALLIC STENT.

A.O. Mahendran, P. Veitch, J. Webster, J. Buscombe, A. Hilson, B. Fernando,
P. Sweny
Royal Free & University College London Medical School
Aim: The investigation and management of graft dysfunction in multiple renal
artery (MRA) allografts is not well defined. The use of these grafts is increasing
with back bench arterial reconstruction being used to rescue marginal cadaveric
kidneys and demanding implantation techniques for live donor grafts with
multiple vessels. We have investigated the hypothesis that the late occlusion
of small arteries should be considered in the differential diagnoses of graft
dysfunction mainly to avoid a misdiagnosis of acute rejection in these grafts.
Methods: Following two index cases in our unit where a decrement in graft
function was consequent upon polar artery occlusion we designed and instituted
a screening programme for our MRA graft recipients.
We studied all MRA graft recipients (cadaveric and live donor) transplanted
between January 2006 and 2008 in our unit. Operative records yielded data
on multiple arteries, damaged vessels and the use of vascular reconstruction
on the backbench. Data was recorded on log plots of creatinine over time,
previous history of procoagulant state and thrombotic events, peri-operative or
post-operative hypotension, number of antihypertensive drugs, use of aspirin/
clopidogrel and urine protein/creatinine ratio.
Recipients were scanned using DMSA (Dimercaptosuccinic acid) imaging
to delineate perfusion defects. Positive scans were further imaged with
angiography.
Patients were stratified according to risk using; creeping creatinine, highest
number of arteries and smallest caliber arteries. The high risk recipients were
screened first.
Results: Our analysis identified a total of 92 recipients with MRA grafts, of
which 10 grafts had 3 or more discrete renal arteries and 16 had polar arteries.
25% of the grafts had vessel damage at the time of harvesting. The complex
vascular reconstructive techniques used included; side-to-side anastomosis of
similar sized arteries (“trouser technique”), end-to-side anastomosis of smaller
to larger arteries, anastomosis of polar arteries to epigastric vessels.
To date, 16 recipients have undergone DMSA scans, with 8 grafts demonstrating
hypoperfusion or discrete cortical defects that have been correlated to the
entry of a smaller artery in that area. Four of these patients were noted to have
“creeping creatinines” with inflection points on their creatinine slopes that we
have identified as the time of occlusion of vessel.
Conclusion: The data from our initial survey has led us to hypothesize that
MRA grafts are at an increased risk of graft dysfunction secondary to an
undiagnosed thrombosis or stenosis of a smaller renal artery. A creeping
creatinine in this cohort of patients should carry a high index of suspicion
initially for an arterial event rather than an acute graft rejection. The screening
programme we established is unique and hitherto unreported in the literature.
We propose a surveillance programme for MRA graft recipients; a baseline
DMSA scan within one month of transplantation followed by repeat scans
when clinically indicated and incorporated into the follow-up protocol for these
patients.
We have since expanded our study in two directions; extending the retrospective
analysis of MRA grafts to January 2003 (five years) and a prospective followup of newly transplanted recipients.

G. Pérez Suárez1, F.D. Romero2, D. Marrero3, J.M. Gonzalez-Posada4,
P. Gutierrez5, H. Vallés6, T. Pérez7, A. Rodriguez8, D. Hernández9
1
Department of Nephrology. Hospital Universitario De Canarias,
2
Department of Vascular Radiology. Hospital Universitario De Canarias,
3
Department of Nephrology. Hospital Universitario De Canarias,
4
Department of Nephrology. Hospital Universitario De Canarias,
5
Department of Urology. Hospital Universitario De Canarias, 6Department
of Vascular Radiology. Hospital Universitario De Canarias, 7Department of
Vascular Radiology. Hospital Universitario De Canarias, 8Department of
Nephrology. Hospital Universitario De Canarias, 9Department of Nephrology.
Hospital Universitario De Canarias
Background: Persistent Ureteral Stenosis (PUSt) is a cause of graft dysfunction
followed kidney transplantation (KT) and the surgical treatment has been
classically the election therapeutic approach. However the treatment by Self
Expanding Metallic Ureteral Stent (SEMUS) can be a therapeutic alternative
option. The aim of this study was to know the incidence of PUSt in our centre
and described the efficacy and safety of initial treatment with SEMUS.
Methods: We retrospectively analysed 999 consecutive recipients of cadaver
kidney transplantation. A double-J stent was systematically inserted at the
time of graft implantation and removed 2 weeks later. The definitive diagnosis
of PUSt was made by antegrade pyelography. Demographic and clinical
parameters of the donor and recipient were evaluated and follow-up after
SEMUS implantation was performed.
Results: Twenty seven patients (2. 7%) presented a PUSt at a median of 4
months after transplantation and in twenty two cases a SEMUS was placed as
the first therapeutic option. The remaining five patients (19%) needed surgical
treatment. Adjusted risk factors for PUSe were: donor age higher than 55 years
(OR=4, 2; p=0. 02) and obesity of the recipient (OR=5, 3; p=0. 01). Another’s
risk factors, such as acute rejection or cold ischemia time were not associated
in our study. During a median time of follow-up of 41 months (range 1-52
month), SEMUS restenosis was observed in 6 patient, two of then were treated
by a new SEMUS and the remainder four patient needed surgical treatment.
After SEMUS implantation, plasma creatinine levels decrease significantly (4,
5±2, 3 vs. 1, 8±0, 6 mg/dl; p<0. 0001). No severe complications in the graft or
the recipient were observed during the follow-up.
Conclusion: although large prospective studies are needed, the SEMUS
implantation may be considerer the first therapeutical approach for PUSt after
kidney transplantation because it is a minimally invasive procedure, safe,
effective and associated a low morbidity.
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398 UROLOGICAL COMPLICATIONS: ANALYSIS
AND MANAGEMENT OF 1525 CONSECUTIVE RENAL
TRANSPLANTATIONS
N.P. Karidis3, G. Zavos1, P. Pappas2, T. Karatzas3, J. Bokos1, K. Stravodimos4,
E. Theodoropoulou5, K. Diles1, G. Sotirchos1, A. Gompou6
1
Transplantation Unit, Laiko General Hospital, Athens, Greece, 2Department
of Radiology, Laiko General Hospital, Athens, Greece, 3Second Propaedeutic
Department of Surgery, University of Athens, Medical School, Athens, Greece,
4
Department of Urology, University of Athens, Medical School, Athens,
Greece, 5Department of Nephrology, Laiko General Hospital, Athens, Greece,
6
Hellenic National Organization of Transplantation
Urological complications after renal transplantation cause increased morbidity,
delayed graft function and occasionally lead to graft and/or patient loss.
Objective: The aim of this study was to analyze the causes and therapeutic
approaches of urological complications in renal transplantation and to relate
to patients outcome.
Patients and Methods: A consecutive series of 1525 renal transplants were
performed during a 24-year period. Renal grafts were provided in 814 cases from
living-related and in 711 from cadaveric donors. A Lich-Gregoire ureterovesical
reimplantation technique with minimal bladder wall dissection was employed
in all cases. Ureteral stents were routinely used in cadaveric transplants and
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exceptionally in the living-related. Urological complications were classified
according to mechanism and urinary tract site, involving: graft ureteropelvic
junction obstruction/stenosis (A), ureteral obstruction/stenosis (B), ureterovesical
anastomosis obstruction/stenosis (C), urinary leakage (D) and other (E).
Results: Overall, 96 urological complications (6. 3%) were encountered.
The rate of urological complications was expressed as the percentage of the
overall amount of urological complications (n=96) and the total number of
transplantations (n=1525) performed during this period.
Urological complications after renal transplantation

n

%

% total

Α

Graft ureteropelvic junction obstruction/stenosis

12

12, 5

0. 8

Β

Ureteral obstruction/stenosis

27

28, 1

1. 8

C

Ureterovesical anastomosis obstruction/stenosis

29

30, 2

1. 9

D

Urinary leakage

25

26, 0

1. 6

E

Other

3

3, 1

0. 2

Group C complications occurred in 29 cases (30. 2%), followed by 27 cases
(28. 1%) for group B, 25 cases (26. 0%) for group D, 12 cases (12. 5%) for
group A and 3 cases (3. 1%) for group E. Surgical intervention was required in
49 (51. 0%) of all urological complications and the rest (n=47, 49. 0%) were
treated either conservatively or by minimally invasive procedures.
Conclusions: Rapid diagnosis of urological complications in our series, assisted by
early post-transplant DTPA scan, routine ultrasonography and especially prompt
treatment, resulted in compensation of renal graft dysfunction in the vast majority
(n=90, 93. 8%) of cases. Surgical technique of graft retrieval and reimplantation is
of utmost importance in minimizing the incidence of urological complications.

MINI-ORAL SESSION 14: ISLETS

399 COMBINED ISLET AND HEMATOPOIETIC STEM CELL
ALLOTRANSPLANTATION: A CLINICAL PILOT TRIAL TO
INDUCE CHIMERISM AND GRAFT TOLERANCE
D. Mineo , C. Ricordi , X. Xu , A. Pileggi , R. Garcia-Morales ,
D.A. Baidal , T. Froud , L. Inverardi , N.S. Kenyon , R. Alejandro
University of Miami,
To prevent graft rejection and avoid immunosuppression-related side-effects, we
attempted to induce recipient chimerism and graft tolerance in islet transplantation
by donor CD34+hematopoietic stem cell (HSC) infusion. Six patients with brittle
Type 1 Diabetes Mellitus received a single-donor allogeneic islet transplant (8,
611±2, 113IEQ/kg) followed by high doses of donor HSC (4. 3±1. 9x106HSC/kg),
at days 5 and 11 post-transplant, without ablative conditioning. An ‘Edmontonlike’ immunosuppression was administered, with a single-dose of anti-TNFα
antibody (Infliximab) added to induction. Immunosuppression was weaned per
protocol starting 12 months post-transplant. After transplantation, glucose control
significantly improved, with 3 recipients achieving insulin-independence for a short
time (24±23days). No severe hypoglycemia or protocol-related adverse events
occurred. Graft function was maximal at 3 months then declined. Two recipients
rejected within 6 months due to low immunosuppressive trough levels, whereas 4
completed 1-year follow-up with functioning grafts. Graft failure occurred within
4 months from weaning (478±25days post-transplant). Peripheral chimerism, as
donor leukocytes, was maximal at 1 month (5. 92±0. 48%), highly reduced at 1
year (0. 20±0. 08%), and was undetectable at graft failure. CD25+T-lymphocytes
significantly decreased at 3 months, but partially recovered thereafter. Combined
islet and HSC allotransplantation, using an ‘Edmonton-like’ immunosuppression,
without ablative conditioning, did not lead to stable chimerism and graft tolerance.
Figure: Islet graft function with metabolic control (A) and peripheral chimerism
levels (B).

400 KIDNEY FUNCTION AFTER CLINICAL ISLET
TRANSPLANTATION
C.B Leitao1, P. Cure1, S. Messinger1, A. Pileggi1, O. Lenz2, T. Froud1,
R.N Faradji1, G. Selvaggi3, C. Ricordi1, R. Alejandro1
1
Diabetes Researsh Institute, University of Miami, 2Nephrology Division,
University of Miami, 3Surgery Division, University of Miami
The aim of this study was to determine the clinical course of kidney
function (KF) after islet transplantation (IT), identify clinical, laboratory and
immunosuppressive factors associated and the effect of non-albumin predominant
proteinuria in renal outcomes. A retrospective cohort study was conducted
in 35 type 1 diabetes mellitus (T1DM) transplant subjects. Demographic,
anthropometrical and laboratory data were recorded. KF was assessed by serum
creatinine, albuminuria and proteinuria and estimated glomerular filtration rate
(eGFR) was calculated by MDRD formula. Albuminuria/proteinuria ratio
was calculated in those with at least one proteinuria value >300 mg/24 h (n
= 19) and a stratified analysis was performed (ratio >0. 2: glomerular pattern,
n = 8; <0. 2: tubular pattern, n = 11). Overall eGFR remained stable during
follow-up. Even subjects with low eGFR and/or microalbuminuria (n = 10)
at baseline maintained stable values post-transplantation (61. 13 +/- 3. 25 vs.
63. 32 +/- 4. 36 ml/min/1. 73 m2, P = 0. 50). Six (20%) subjects progressed to
microalbuminuria, but sustained macroalbuminuria was not detected. A1c was
normal after transplant (6. 09 +/- 0. 09 vs. 7. 45 +/- 0. 11%, P <0. 001), but a
mild increment in LDL-cholesterol levels was found (101. 6 +/- 2. 3 vs. 93. 3
+/- 3. 3 mg/dl, P = 0. 01). Blood pressure remained stable during the follow-up
(119. 3 +/- 1. 6/71. 5 +/- 1. 0 vs. 121. 7 +/- 2. 3/71. 9 +/- 1. 6 mm Hg, P >0.
05). After multivariate adjustments, age was the only risk factor for low eGFR
(OR = 1. 78, 1. 22-2. 61) and LDL-cholesterol (OR = 2. 90, 1. 37-6. 12) and
previous microalbuminuria (OR = 6. 42, 1. 42-29. 11) for macroalbuminuria.
Tacrolimus was a protective factor against macroalbuminuria (OR = 0. 12, 0.
06-0. 26). A higher incidence of clinical significant proteinuria (>500 mg/24
h – 100 vs. 18. 2%, P = 0. 01) and a decrease in eGFR (<60 ml/min/1. 73 m2
-100 vs. 27%, P = 0. 01) at any time during the follow-up was found in patients
with glomerular pattern. In conclusion, KF remained stable after IT. A high
proportion of patients had proteinuria >300 mg/24 h, however, it seems to be
milder and with less impact on eGFR when albumin is not the major source
of proteinuria. Clinical IT continues to be a safe procedure for treatment of
unstable T1DM as long as aggressive treatment of conventional risk factors for
diabetic nephropathy is provided.

POSTER BOARD NUMBER P2 – 430
401 HYPOXIA INDUCIBLE FACTOR 1ALPHA (HIF-1ALPHA)
IS REQUIRED FOR SUCCESSFUL ISLET TRANSPLANTATION
AND INCREASING HIF-1ALPHA WITH DESFERRIOXAMINE
MARKEDLY IMPROVES OUTCOMES
R. Stokes1, K. Cheng1, C. Scott1, S. Yim2, S. Grey1, F. Gonzalez2,
W. Hawthorne3, P. O’Connell3, J. Gunton1
1Garvan Institute of Medical Research, Darlinghurst NSW Australia, 2NIH,
Bethesda, Maryland USA, 3NPTU, Westmead, NSW Australia
HIF-1alpha is a transcription factor which co-ordinates a program of cellular
response to stressors including hypoxia. In other cell types, HIF-1alpha
increases cell survival following hypoxic challenge. HIF-1alpha functions as a
heterodimer with ARNT, which we have previously shown to be important for
normal beta-cell function.
Hypothesis: HIF-1alpha is required for successful islet transplantation and
increasing HIF-1alpha will improve transplant outcomes.
Aim: 1. To investigate the effect of beta-cell specific deletion of HIF-1alpha
upon islet transplant outcomes in mice
2. To investigate the effects of increasing HIF-1alpha protein in human islets or
mouse islets upon islet-transplant outcomes.
Methods: 1. Islets were isolated from male mice with beta-cell-specific
knockout of HIF-1alpha (Beta-HIF-1alpha) or floxed-littermate controls. These
mice are inbred C57Bl/6. Beta-HIF1alpha mice have normal fasting glucoses.
Islets were transplanted into STZ diabetic C57Bl/6 recipients at 1 donor to
1 recipient (minimal mass islet transplant model). Nephrectomy on day 28
caused recurrence of diabetes.
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2. Mouse islets from floxed-control or beta-HIF-1alpha mice were treated with
DFO prior to transplantation.
3. Isolated human pancreatic islets from 9 separate donors were cultured
overnight in control-media, or media supplemented with desferrioxamine
(DFO), a small molecular stimulator of HIF-1alpha protein. Islets were
transplanted into diabetic SCID mice. There were 3 transplant groups, with
mice receiving:
A) Supra-physiological-mass transplant of 2000 control cultured IEQ (islet
equivalents)
B) Minimal mass transplant of 600 control cultured IEQ, or
C) Minimal mass transplant of 600 IEQ cultured with DFO.
For each human donor, at least one of each of the 3 transplant groups was
performed to avoid the confounder of inter-donor variability.
Results: 1. Recipients of beta-HIF-1alpha islets had markedly worse glucose
tolerance with average random glucose 21. 2±3. 2 versus 10. 8±1. 6 mmol/L in
control recipients (p<0. 001).
2. Control islets treated with DFO had significantly improved islet transplant
outcomes. DFO had no effect in transplants of beta-HIF-1alpha islets,
demonstrating that beta-cell HIF-1alpha is required for the beneficial effect
of DFO.
3. Recipients of 2000 control IEQ were cured in 42% of cases. Minimal mass
transplantation was ineffective: 600 IEQ cured 0% mice at 28 days. In
contrast, minimal mass transplant of DFO treated islets had a 53% success
rate (p<0. 001 versus group 600 IEQ control and p=ns versus 2000 IEQ).
Blood glucose levels were markedly improved in the 600 DFO treated
group compared to 600 IEQ control group (p<0. 0001) and did not differ
significantly from the 2000 IEQ recipients. This data demonstrates that
increasing HIF-1alpha in human islets prior to transplantation markedly
improves islet transplant outcomes. HIF-1alpha and DFO may have a
therapeutic role in human islet transplantation.
Conclusions: HIF-1alpha is a protective factor for islets after transplantation
and is required for successful transplant outcomes. Increasing HIF-1alpha
in islets pre-transplantation markedly improves glucose control. HIF-1alpha
protein may have a therapeutic role in human islet transplantation.

POSTER BOARD NUMBER P2 – 431
402 NEW PANCREAS PRESERVATION STRATEGY FOR
SUCCESSFUL CLINICAL ISLET TRANSPLANTATION
M. Shimoda1, H. Noguchi2, B. Naziruddin1, T. Ikemoto2, A. Jackson1,
N. Onaca1, M. Levy1,3, P.A. Grayburn1, S. Matsumoto2,3
1
Baylor University Medical Center, 2Baylor Research Institute, 3Baylor All
Saints Islet Laboratory
Background: Islet transplantation is a promising treatment for type 1 diabetes;
however still facing several challenges. Low success rate of clinical islet
isolation is one such issue. Previously we have shown that improving pancreas
preservation strategy substantially improved islet yields and success rate of islet
isolation with non-heart-beating donors (1). We hypothesized that improving
quality of pancreas at the time of procurement with new pancreas preservation
strategy will improve the success rate of islet isolation using brain dead donor
organs.
Method: From August 2006 to January 2008, 10 clinical grade human
pancreata were used for this study. Six pancreata were procured by transplant
surgeons based on whole pancreas transplantation procedure and all pancreata
were preserved by the two-layer method (standard group). Four pancreata
were procured by islet specialist surgeons with the new pancreas preservation
strategy (new strategy group). The new pancreas preservation strategy includes
pancreatic ductal preservation, complete trimming of pancreas before storage,
and oxygenated perfluorocarbon for pancreas storage. Islets were isolated
at our GMP facility. Isolated islets qualified for transplantation based on the
Edmonton protocol is considered as successful.
Results: All pancreata were preserved for less than 5 hours and there were no
significant difference between the standard group and the new strategy group.
There were no significant differences in donor age, body mass index and
pancreas weight between the standard and the new strategy groups. Average
islet yields in the standard group were 202, 452 ± 67, 427 islet equivalents (IE)
and in the new strategy group were 592, 023 ± 95, 586 IE. Hence islet yields
were significantly higher in new strategy group (P=0. 01). Purity was 63. 5±11.
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9 in the standard group and 58. 2±9. 3 in the new strategy. Average viability
of isolated islets were 92. 5 ± 1. 5% in the standard group and 96. 6±2. 1% in
the new strategy group. 2 out of 6 isolations were successfully qualified all
transplantation criteria (33%) in the standard group, while 4 out of 4 isolations
were qualified the transplantation criteria (100%) in the new strategy group.
All transplanted islets functioned well based on serum C-peptide levels and
improved glycemic control. Islets from the standard group transplanted into
two type 1 diabetic patients (each patient received one preparations) and
islets from the new pancreas preservation strategy group were transplanted
into two type 1 diabetic patients (each patient received 2 preparations from
the new strategy group). Both patients received islets from the new pancreas
preservation strategy became insulin independent.
Conclusion: New pancreas preservation strategy significantly increased islet
yields and resulted in high success of clinical islet transplantation. With the
new pancreas preservation strategy, the issue such as low success rate of islet
isolation might be solved.

POSTER BOARD NUMBER P2 – 432
403 ISLET TRANSPLANTATION FOR BRITTLE TYPE 1
DIABETES: THE UIC PROTOCOL
A. Gangemi1, P. Salehi1, B. Hatipoglu2, J. Martellotto1, B. Barbaro1,
J. Kuechle1, M. Qi1, Y. Wang1, E. Benedetti1, J. Oberholzer1
1Division of Transplantation/Department of Surgery/University of Illinois At
Chicago/, 2Section of Endocrinology/Department of Medicine/University of
Illinois at Chicago
This prospective phase 1/2 trial investigated the safety and reproducibility of
allogeneic islet transplantation (Tx) in type 1 diabetic (T1DM) patients and
tested a strategy to achieve insulin-independence with lower islet mass. Ten
C-peptide negative T1DM subjects with hypoglycemic unawareness received
1-3 intraportal allogeneic islet Tx and were followed for 15 months. Four subjects
(Group 1) received the Edmonton immunosuppression regimen (daclizumab,
sirolimus, tacrolimus). Six subjects (Group 2) received the University of
Illinois protocol (etanercept, exenatide and the Edmonton regimen). All
subjects became insulin independent. Group 1 received a mean total number of
islets (EIN) of 1, 460, 080±418, 330 in 2 (n=2) or 3 (n=2) Tx, whereas Group
2 became insulin independent after 1 Tx (537, 495±190, 968 EIN, p=0. 028).
All Group 1 subjects remained insulin free through the follow-up. Two Group
2 subjects resumed insulin: one after immunosuppression reduction during an
infectious complication, the other with exenatide intolerance. HbA1c reached
normal range in both groups (6. 5±0. 6 at baseline to 5. 6±0. 5 after 2-3 Tx
in Group 1 vs. 7. 8±1. 1 to 5. 8±0. 3 after 1 Tx in Group 2). HYPO scores
markedly decreased in both groups. Combined treatment of etanercept and
exenatide improves islet graft function and facilitates achievement of insulinindependence with less islets.

POSTER BOARD NUMBER P2 – 433
404 COMPOSITE ISLET-KIDNEYS REVERSE DIABETES AND
RENAL FAILURE ACROSS A FULLY ALLOGENEIC BARRIER
IN NONHUMAN PRIMATES
Y. Ishikawa1, A. Griesemer1, A. Hirakata1, H. Iwaki1, V. Tchipashvili2,
S. Moran1, A. Shimizu1, D. Sachs1, K. Yamada1
1
Transplantation Biology Reserach Center, MGH, Harvard Medical School,
2
Joslin Diabetes Center, Harvard Medical School
Background: We have previously reported studies in miniature swine showing
that transplantation (Tx) of prevascularized donor islets as part of composite
Islet-Kidney (I-K) reversed diabetic hyperglycemia across fully allogeneic
barriers, while the same islet-equivalents of free islets did not. In order to test
the potential clinical applicability of this strategy, we have extended it to a fully
allogeneic nonhuman primate model.
Methods: I-Ks were prepared in donor baboons by isolating islets from 60%
partial pancreatectomies and injecting them under the autologous renal capsule,
allowing for vascularization before allogeneic transplantation. These I-Ks
were removed at days 203 and 102 for allogeneic I-K Tx. To induce insulindependent diabetes (IDDM), all recipients received streptozotocin at 2000 mg/
m2 x (Body Surface Area). One animal required total pancreatectomy to induce
IDDM. After confirming IDDM by fasting blood sugar (FBS) >300mg/dl for 3
consecutive days, either I-Ks or free islets were transplanted (single donor to
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each recipient) with ATG (day -3) followed by MMF and low-dose tacrolimus.
Free islets were injected into the liver through the ileocolic vein. Islet function
was assessed by FBS and renal function was assessed by serum creatinine.
Standard CML/MLR assays were performed to determine allogeneic donorrecipient disparities.
Results: Two diabetic baboons received composite I-Ks and one diabetic
baboon received free islets across fully allogeneic barriers. All three recipients
had strong CML/MLR responses to donors pre-transplant, indicative of a fully
allogeneic combination. In the two I-K recipients, FBS decreased immediately
after I-K Tx and no insulin therapy was required throughout the experimental
period (days 225 and 279). BS levels averaged 82. 2+/-15. 6 mg/dl in the first
baboon and 125. 4+/-42. 7 mg/dl in the second. Normal creatinine levels (<1.
0mg/dl) were maintained by these life-supporting I-K grafts. In contrast, the
recipient of allogeneic free islets had unstable BS levels and required insulin
from day 60 (BS 400 mg/dl at day 60).
Conclusions: Life-supporting I-Ks from single donors achieved glucose
regulation without insulin therapy and maintained normal renal function. These
results demonstrate the feasibility of composite I-K Tx in a non-human primate
allogeneic model, and suggest possible clinical applicability for the cure of
diabetic nephropathy.

POSTER BOARD NUMBER P2 – 434
405 B LYMPHOCYTE DEPENDENT REJECTION OF
ISLET ALLOGRAFTS VIA INDIRECT RECOGNITION IN
AUTOIMMUNE-PRONE NOD MICE

POSTER BOARD NUMBER P2 – 435
406 QUANTIFYING PANCREATIC BETA-CELL
REGENERATION
E. Grossman1, J. Tao1, D. Lee2, A. Chong1
1University of Chicago, 2Rush University
Introduction: We have recently described functional beta-cell regeneration
in a mouse model of streptozotocin (STZ)-induced diabetes. We have
extended those studies to quantify the temporal relationship between betacell mass regeneration and eugylcemia. In addition, we report the use of a
novel bio-luminescence mouse model for the real-time in vivo quantification
of beta-cell regeneration.
Methods: C57BL/6 mice made diabetic with STZ (blood glucose >400 mg/
dl) received 200 syngenic islets under the left kidney capsule. Random blood
glucose levels were recorded weekly for 60 or 120 days (N=10/group), after
which the transplanted islets were removed via a left nephrectomy. Removal
of the kidney bearing the transplanted islets allowed for assessment of
endogenous beta-cell restoration and function. The mice were then sacrificed
30 days after the removal of the transplanted islets. Non-diabetic C57BL/6
mice and STZ-induced diabetic mice that did not receive islet transplantation
were used as controls.
In our bio-luminescence model, transgenic C57BL/6 mice expressing betacell specific firefly luciferase (luc) under the control of the insulin promoter
(MIP-luc) were similarly treated with STZ, islet transplantation, and
weekly glucose level recording for 120 days. Only the recipient’s native
pancreatic tissue express MIP-luc; the transplanted islets do not. Thus,
photons emitted correlate to insulin production from the native pancreas.
MIP-luc mice underwent in vivo imaging at 10-14 day intervals with the
IVIS® 200-Series imaging system, which is capable of quantifying emitted
bio-luminescence.
Beta-cell mass was quantified by microscopic examination of sectioned
pancreata stained with anti-insulin polyclonal antibody.
Results: Islet transplantation restored euglycemia (143-150 mg/dl), the
subsequent removal of the transplanted islets at 60 days and 120 days posttransplant resulted in a slight elevation of blood glucose levels to 230 ± 60 mg/
dl and 189 ± 31 mg/dl, respectively. The average beta-cell mass in the nondiabetic controls and STZ-treated diabetic mice were 1. 54 ± 0. 34 mg and 0.
094 ±0. 049 mg, respectively. There was an appreciable increase in beta cell
mass in all STZ-induced diabetic mice receiving islet cell transplantation: 0.
133 mg at 60 days (p = 0. 11) and 0. 914 mg (p = 0. 002) at 120 days posttransplantation.
In the MIP-luc mice, bio-luminescence was successfully used to quantify
baseline beta-cell function, destruction, and regeneration. (Figure 1) After
induction with STZ, bio-luminescence decreased to negligible levels, correlating
with severe hyperglycemia (>500 mg/dl). After 120 days, the MIP-luc mice
experienced an average 200% increase in photon emission compared to their
nadir; however, this represented an achievement of only 1-10% of baseline
intensity. Improved glycemic control correlated with an overall increase in bioluminescence consistent with beta-cell regeneration.
Figure 1.
A. Baseline.

B. STZ-treated.

C. After islet transplantation

Conclusion: This study confirms that restoration of beta-cell function is timedependent and correlates with increased beta-cell mass. It also suggests that
bio-luminescence imaging of beta-cells expressing luciferase may provide
real-time quantification of beta-cell regeneration.
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R.G. Gill3, T. Kupfer1, J. Beilke2, K. Pham1, J. Buhrman1
1University of Colorado Health Sciences Center, 2University of California,
San Francisco, 3University of Alberta/Alberta Diabetes Institute
Background: Islet allografts are destroyed rapidly in spontaneously diabetic
NOD mice. However, whether this process is more similar to conventional
allograft immunity, islet-specific autoimmune pathogenesis, or both remains
unclear. Islet allograft immunity is thought to require ‘direct’ antigen
recognition, involving donor expression of MHC class I and/or class II
molecules. In the present study we determined whether donor MHC expression
and/or host B cells were required for islet allograft destruction in autoimmuneprone NOD mice.
Methods: Islet allograft donors were either wild-type C57Bl/6 (B6; H-2b), B6
MHC class I deficient (β2m-/-), B6 MHC class II-deficient (I-Aβ-/-), or MHC
I/II double deficient (β2m-/- I-Aβ-/-). 450 islets from such donors then were
grafted beneath the kidney capsule of the following recipient strains: (a) nonautoimmune prone, streptozotocin (STZ)-induced diabetic BALB/c (H-2d),
(b) SZT-treated, pre-diabetic NOD mice (H-2g7), (c) SZT-treated NOD B cell
deficient (μMT), or (d) spontaneously diabetic NOD mice.
Results: In non-autoimmune BALB/c mice, islet allografts from wild-type B6,
B6 β2m-/-, or B6 I-Aβ-/- rejected in < 20 days (n=5-7/group). However, B6 class
I/II double deficient islets were accepted long-term (>100 days) in 7/7 BALB/c
recipients (p <. 01). However, in pre-diabetic NOD mice, B6 MHC class I/
II double-deficient islets underwent delayed rejection in 14-90 days in 5/5
animals. Interestingly, B lymphocytes played a significant role in islet allograft
rejection in NOD mice. B cell deficient (μMT) mice demonstrated delayed
rejection of wild-type B6 islet allografts relative to wild-type NOD mice (p <.
05). Importantly, the rejection of B6 MHC class I/II double deficient allografts
was entirely B cell dependent in that 5/5 MHC-deficient islet allografts survived
>100 days in STZ-induced diabetic NOD μMT recipients.
Spontaneously diabetic NOD mice demonstrated accelerated destruction of B6
islet allografts regardless of donor MHC expression. That is, islets from all B6
donor groups above were destroyed in spontaneously diabetic NOD mice in
<20 days (n ≥ 5 in all groups). Also, anti-CD4 treatment (but not anti-CD8)
significantly delayed the rejection of MHC I/II-deficient islets in 5/5 NOD
mice for >50 days (p <. 02).
Conclusion: In contrast to results using non-autoimmune mice, islet allograft
destruction in NOD mice can be independent of donor MHC expression. The
finding that rejection of such MHC-deficient islet allografts can be CD4 T cell
dependent and CD8 T cell independent further supports an ‘indirect’ mode of
allograft injury. Furthermore, while B cells are known to be necessary for the
development of autoimmune diabetes in NOD mice, they are also required
for acute islet allograft rejection in this stain. Importantly, in the case where
rejection is presumably dependent entirely on host indirect antigen (the

rejection of MHC class I/II double deficient islets), rejection appears to be
entirely B cell dependent. We hypothesize that NOD B cells are a major APC
for the exuberant indirect T cell reactivity demonstrated in this autoimmuneprone strain.
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407 LOCAL EXPRESSION OF B7-H4 BY TRANSDUCING
RECOMBINANT ADENOVIRUS IN ISLET GRAFTS INHIBITS
ALLOTRANSPLANT REJECTION
X. Wang1, J. Hao1, D. Merzger1, A. Mui1, Z. Ao1, B. Verchere1, L. Chen2,
D. Ou1, G. Warnock1
1University of British Columbia, 2Johns Hopkins University School of
Medicine
Allogeneic pancreatic islet transplantation has potential as a treatment option
for type I diabetes. One of the barriers to clinical islet transplantation is the
alloreactive T-cell response between the donors and recipients. Co-stimulatory
molecules, which play a major role in both initiation and termination of the
immune response to antigens during graft rejection, may be used to inhibit
allograft destruction. B7-H4 is one such member in the B7-CD28 family of
co-stimulatory molecules which has established negative regulation of T-cell
responses. To determine whether local expression of B7-H4 protein can protect
islet beta cells from damage mediated by immune rejection responses in islet
transplantation, we have developed a recombinant adenovirus expressing
a mouse B7-H4 cDNA (AdB7-H4). Mouse primary islet cells are mRNApositive by RT-PCR, but B7-H4 protein is negative in flow-cytometric analysis.
Primary islet cells were infected with AdB7-H4 to express B7-H4 protein in
a dose-dependent fashion. Treatment of fresh isolated islets by AdB7-H4
infection at an optimized condition of 5 pfu for 24 h did not show inhibition
of glucose-stimulated insulin secretion. To study the in vivo effects of B7-H4
over-expression on islet graft survival, 400 adenovirus-transduced islets
from donor BALB/C mice were transplanted under the left renal capsule of
streptozotocin-diabetic C57BL/6 (B6) recipient mice. The B6 recipient group
(N=12) that received AdB7-H4-transduced islet grafts established euglycemia
for 56. 5 days, compared with the recipient group (N=12) transplanted with
islets infected by control adenovirus (AdLacZ) for 14 days (P<0. 0001 by logrank test). When transplanted islets with left kidneys were removed from the
nomoglycemic AdB7-H4-treated B6 recipients after 60 days, their glucose rose
again, however, euglycemia restored after new islets from BALB/c donors were
transplanted into the right kidneys of these mice, confirming the capacity of the
initially and secondarily transplanted islets to function. Intraperitoneal glucose
tolerance testing confirmed that the insulin secretion and glucose levels in the
B6 recipients of AdB7-H4-transduced islets at 30 days post transplantation
are similar to those of normal controls. Splenocytes and renal lymph-node
cells isolated from the B6 recipients of AdB7H4-transduced islets showed
clear hyporesponsiveness to alloantigenic stimulation in mixed lymphocyte
reaction assay, compared with the control recipients of untreated islets from
BALB/c (P<0. 00003) or from third-party CBA mice (P<0. 002), indicating
that the inhibition of alloreactive responses is not donor tissue–specific. CD45+
leukocyte infiltration was less in the grafts transduced with AdB7-H4 at day 60
post-transplant, compared to that of day 10. Insulin expression remained strong
in the islet grafts treated with AdB7-H4 at day 60 post-transplant. We conclude
that local over-expression of B7-H4 by AdB7-H4 inhibits transplant rejection
to allogeneic islet grafts in vivo, suggesting translational potential for beta-cell
substitution with reduced immune injury.

POSTER BOARD NUMBER P2 – 437
408 INHIBITING DIPEPTIDYL PEPTIDASE IV ACTIVITY
IMPROVES HUMAN ISLET GRAFT FUNCTION IN
IMMUNODEFICIENT MICE WITH DIABETES
H. Yi, L. Tian, J. Hao, Y. Zhang, D. Sutherland, B. Hering, Z. Guo
Department of Surgery, University of Minnesota
Insulin secretion and beta cell differentiation, proliferation and survival are
regulated by both glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). However, they have extremely short halflives after secretion because of rapid degradation by dipeptidyl peptidase IV
(DPP-IV). Inhibition of DPP-IV could potentially improve the therapeutic
efficacy of GLP-1 and GIP. In this study, we investigated whether inhibition of
DPP-IV activity by NVP-DPP728 and by sitagliptin, the first DPP-IV inhibitor
to be approved by the FDA for treating type 2 diabetes, improves human islet
graft function in immunodeficient mice with diabetes. Human islets with
purity >80% and viability >90% from different donors were used. Diabetes
in immunodeficient nude mice was induced by injection of STZ. Diabetic
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mice with blood glucose level >400 mg/kg for at least 2 weeks were used as
recipients. Total 2000 IE human islets were transplanted into each diabetic
recipient. NVP-DPP728 at 30 mg/kg was given by gavage b. i. d. for 5 days
starting at the day of transplantation. Sitagliptin at 50 mg/kg was given by
gavage daily for 14 days. Normglycemia was defined as the blood glucose level
<200 mg/dl on 2 consecutive days. OGTT was performed in islet transplanted
mice that had been normglycemic for at least 1 week. Mice were fastened for 4
hours before OGTT. NVP-DPP728 at 20 mg/kg was given orally 1 hour before
challenging orally with glucose. Blood samples were taken at 0, 15, 30, 60
and 120 minutes after oral glucose challenge. The percentage of diabetic nude
mice achieving normglycemia after NVP-DPP728 treatment was significantly
higher than the control mice. At 3 weeks posttransplant, the percentage of
diabetic nude mice achieving normglycemia was 47% (N=19) without NVPDPP728 treatment, and 84% (N=19) with NVP-DPP728 treatment. NVPDPP728 treatment also significantly lower blood glucose in nude mice with
human islet grafts compared with control group after oral glucose challenge.
Blood glucose levels in nude mice with human islet grafts after oral glucose
challenge at 15, 30, and 60 minutes were 334±132, 305±137, 142±101 mg/
dl without NVP-DPP728 treatment; and 288±62, 215±71, and 77±36 mg/dl
with NVP-DPP728 treatment. In sitagliptin treatment’s experiment, without
treatment, the percentage of diabetic nude mice achieving normglycemia
was 7% at 1 week; 31% at 2 weeks; 46% at 3 weeks; and 53% at 4 weeks
posttransplantation (N=13). The average nonfasting blood glucose level was
352±108 mg/dl at 1 week; 241±118 mg/dl at 2 weeks, 233±98 mg/dl at 3
weeks; and 234±145 mg/dl at 4 weeks posttransplantation. With sitagliptin
treatment, the percentage of diabetic nude mice achieving normglycemia was
33% at 1 week; 58% at 2 weeks posttransplantation; 67% at 3 weeks; and 75%
at 4 weeks posttransplantation (N=12). The average nonfasting blood glucose
level was 283±135 mg/dl at 1 week; 225±140 mg/dl at 2 weeks, 181±142 mg/
dl at 3 weeks; and 180±131 mg/dl at 4 weeks posttransplantation. Our data
indicate that inhibition of DPP-IV can improve human islet graft function in
immunodeficient mice with diabetes.

POSTER BOARD NUMBER P2 – 438
409 INCREASED TOTAL INSULIN CONTENT AND
RESTORATION OF FIRST-PHASE INSULIN SECRETION IN
STANDARDIZED SMALL HUMAN PSEUDOISLETS
A. Faenza3,, G. Cavallari1,3, R. Zuellig2, R. Lehmann2, M. Weber1,
W. Moritz1
1
Clinic for Visceral and Transplant Surgery, University Hospital Zurich,
2
Division of Endocrinology and Diabetes, University Hospital Zurich,
3
Department of General Surgery and Transplantation, S. Orsola-Malpighi
University Hospital, Bologna
Background: Pancreatic islets can be dissociated into single cells and
reaggregated into so called “pseudoislets”, which are morphologically
equivalent to intact islets. Small islets are potentially less susceptible to
ischemic injury after intrahepatic islet transplantation and therefore a preferred
subset of an islet isolate. Here we describe a method to generate standardized
pseudosislets of small dimensions. The cytoarchitecture and in vitro function
of rat and human pseudoislets are compared.
Methods: Human islets were dissociated into single cells by trypsin treatment.
Fractions with defined cell numbers were seeded into single drops onto cell
culture dishes which were inverted and incubated for 6-14 days under regular
cell culture conditions. Newly formed pseudo-islets were analyzed for
dimensions, morphology, cellular composition and glucose stimulated insulin
secretion (GSIS).
Results: The volume of reaggregated pseudoislets strongly correlated with cell
number. Morphology, cellular composition and cytoarchitecture of reaggregated
human islets were comparable to intact islets. The insulin secretory capacity of
small pseudoislets (250 cells/islet) reached 160% after 6 days and 246% (p<0.
001) after 14 days of reaggregation culture compared to mixed populations
of intact fresh islets. Compared to intact fresh islets, the stimulation index of
small pseudoislets was improved by >2-fold (p=0. 007), partially also due to
a reduced baseline secretion. While first phase insulin secretion was nearly
absent in freshly isolated and cultivated intact islets, it was restored in small
pseudoislets. Total insulin content in intact and reaggregated pseudoislets was
inversely correlated to the islet size, with small islets storing up to 4-fold more
insulin than large islets.
Conclusions/Interpretation: The superior biological function with respect to
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the total insulin content, first phase insulin secretion, and stimulation index
validates small human pseudoislets as an ideal source for the improvement of
graft function in islet transplantation.

MINI-ORAL SESSION 15: ORGAN DONATION AND ETHICS
POSTER BOARD NUMBER P2 – 439
410 CONVERTING THE POTENTIAL FOR DONATION
AFTER CARDIAC DEATH INTO ACTUAL DONORS: A
COMPARISON BETWEEN BELGIUM AND THE U. K.

POSTER BOARD NUMBER P2 – 440
411 EVALUATING THE NON-HEART-BEATING DONOR
(NHBDS) POTENTIAL IN A LARGE LEVEL-THREE
UNIVERSITY HOSPITAL IN CHINA AND DONATION-RELATED
ISSUE
B. Zhu, P. Yun, Z. Liu, H. Xu
Jinan City Central Hospital
The termination of current organ source and to utilize organ donors according
to international principles is vital for the healthy development of transplantation
in China.
This study was designed to identify the NHBDs potential in a large levelthree hospital and donation-related issues. The charts of 502 patients who died
during 2007 in the Emergency Department including 48 deaths in its ICU were
reviewed. A randomized survey was conducted regarding donation. The mean
age of death in emergency room (ER) was 61. 75¡À18. 09, and 70. 04¡À13.
65 years in its ICU. 206 patients died in ER and 13 patients died in ICU were
under age of 60 years. The major causes of death in patients under the age
of 60 were sudden death (61. 64%), trauma (10. 04%), stroke (8. 68%), lung
disease (7. 76%), and heart disease (3. 65%). 23. 08% patients in ICU showed
abnormal liver function. The serum creatinine levels were 0. 92¡À0. 49mg/
dl when admitted into ER, and increased to 2. 04¡À0. 87 mg/dl before death.
Life-support were terminated in 7. 57% of patients in ER and 7. 76% patients
in its ICU under the age of 60 after receiving requests from family members.
The mean age of patients in ICU with decision of termination of life-support
was 41. 67¡À13. 35 years, and the duration from withdrawal of life-support to
declaration of death was16. 17¡À21. 34 minutes. 265 patients were dead on
the arrival at hospital, and 109 patients were documented with known duration
between death and arrival in ER (34. 05¡À20. 84 minutes). The mean age of
these patients was 53. 35¡À18. 78 years, and 15 patients were under the age
of 60 years. The presumed potential availability of NHBDs in this group was
ranged from 2. 99% (controlled) to 11. 94% (both controlled and uncontrolled).

POSTER BOARD NUMBER P2 – 441
412 RESCUE ALLOCATION FOR LIVER TRANSPLANTATION
WITHIN EUROTRANSPLANT: RESULTS OF A SINGLE
CENTER EXPERIENCE
A. Nickkholgh1, P. Schemmer1, T. Gerling2, J. Weitz1, M.W. Büchler1,
J. Schmidt1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Eurotransplant,
Leiden, the Netherlands
Background: Organ shortage has driven many transplant centers to extend
their criteria for organ acceptance. Graft allocation policies have been modified
accordingly. This report focuses on the impact of applying the so-called rescue
allocation (RA) strategy for liver transplantation (LT) in a single center within
the Eurotransplant (ET) area.
Methods: Liver grafts are considered for RA when the regular organ allocation
is declined by at least three centers or is averted due to donor instability/
unfavorable logistical reasons, thus entering a competitive or a single recipient
rescue organ offer procedure, respectively. The accepting center has the
advantage to select a recipient from its own waiting list for these RA grafts.
Results: Among 253 livers accepted at the University of Heidelberg between
January 2004 and December 2006, we transplanted 85 (34%) rescue allocated
livers. The indications for LT were: hepatocellular carcinoma (HCC, 43%),
chronic liver disease (55%), and acute liver failure (2%). Median cold ischemia
time for RA grafts was 10 hr (range: 4-17). The MELD score (mean±SD) was
13±7 (range: 6-40), and was 12±7 for recipients with HCC. Three (3. 5%) primary
nonfunctions (PNF) occurred after transplantation of RA livers. One-year patient
and graft survival were 84% and 75%, respectively. A comparison between the
recipients of RA livers and regularly allocated livers revealed no significant
difference regarding initial poor function (IPF), PNF, and surgical complications.
Furthermore, a median follow-up of 16 months revealed no significant difference
regarding patient and graft survival between the two groups.
Conclusion: The use of RA organs has increased the donor pool and
transplantation dynamics with satisfying results. The unique possibility to match
livers with recipients, which is left to the discretion of accepting center, should
be judged according to the center’s experience to decrease the waiting times for
a timely rescue of organs/recipients while avoiding futile transplantations.

POSTER BOARD NUMBER P2 – 442
413 UTILITY OF POLYCYSTIC KIDNEYS FROM DECEASED
DONORS FOR RENAL TRANSPLANTATION
N. Gibbons, H. Rhee, V. Kanagarajah, D. Nicol
Transplant Unit
Increasing incidence of end stage renal failure (ESRF) is compounded by
the limited number of available organs for transplantation. We report our
experience with transplantation of cadaveric kidneys from patients with
autosomal dominant polycystic kidney disease (ADPKD), as an option for
selected patients with end stage renal failure.
All files from deceased donors in Queensland, Australia, in the period of
1994-2007 were reviewed to identify 5 donors with ADPKD. Data on recipients
of polycystic kidneys was retrieved from the Australia and New Zealand
Dialysis and Transplant (ANZDATA) registry.
Nine patients were transplanted with follow up ranging from 6 months to
11. 5 years. Two grafts failed due to vein thrombosis and chronic allograft
nephropathy, both of which were unrelated to natural progression of ADPKD.
The remaining 7 grafts all continue to function. Follow up scans of two patients
demonstrated progressing cystic disease, whilst another showed regression.
Kidneys from deceased donors with adult polycystic kidney disease and
acceptable renal function can be considered for transplantation. Uncertainty
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L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
Donor Action Foundation, 2Eurotransplant International Foundation
Study aims: To compare conversion rates of potential donation after cardiac
death (DCD) in Belgium (opting-out system) and the U. K. (opting-in system)
and identify areas for improvement.
Materials: Data retrieved from a nationwide medical audit by UKT (NHS)
between April 2005 and March 2007 in the U. K. * (24 months, 31, 077 records,
259 records PMP/y. ) and a Donor Action Diagnostic Review in 26 Belgian
hospitals between Nov. 2006 and Oct. 2007 (12 months, 4, 821 records, 464
records PMP/y. , upper age limit for medical suitability: 70 yrs. )
Results: Of all patients ventilated at some point during their stay in ICU, 10.
8% (UK) and 8. 3% (Belgium) were reported to be medically suitable for DCD
organ donation. Significantly more suitable cases (21. 3%) were identified
in the UK than in Belgium (8. 4%, P<. 0001). Whereas the approach to the
next-of-kin was higher in the UK (88. 1% of identified cases vs. 78. 1%, NS),
consent rates were significantly higher in Belgium (88. 0% of all approaches)
compared to the UK (60. 3%, P=. 005). As a result, procurement rates were
significantly higher in Belgium (50% of all identified cases) than in the UK
(31. 2%, P=. 025).
Conclusion: Whereas both audits demonstrate an obvious room for
improvement within certain steps of the donation pathway (identification,
family approach, consent to donation), lower identification rates in Belgium
were compensated with higher consent rates and subsequent higher retrieval
rates thanks to a beneficial ‘opting-out’ legal environment.

1

The randomized survey found that over 15. 7% participants have discussed
interests in organ donation with their family members. The major issue related
to donation was that can family members consent to organ donation following
the death without a will from the donor. We therefore hypothesize that more
organs would be available for transplantation after initiation of NHBDs, and
believe that the use of NHBDs has potential in China. We are hopeful, that it
will become a major organ source that is developed in such a way so as to be
accepted in China and internationally.
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regarding the longevity of these kidneys and long term risks mean that they
should be offered to carefully selected patients who would not otherwise be
able to receive a transplant.

POSTER BOARD NUMBER P2 – 443
414 DUAL VS. SINGLE KIDNEY TRANSPLANTS IN THE
EUROTRANSPLANT SENIOR PROGRAM

TUESDAY

A. Rahmel1, J. Smits1, E. de Vries1, M. Slot1, J. de Boer1, I. Tieken1,
U. Frei2, H. de Fijter3
1
Eurotransplant, 2Charite, Berlin, 3LUMC, Leiden
Background and Aim: The Eurotransplant Senior Program (ESP) is a renal
allocation scheme based on age-matching, where organs from 65+years (yrs)
donors are assigned with priority to 65+yrs recipients, regardless of HLA.
The initial ESP protocol included an advice to transplant both kidneys when
the donor creatinine clearance rate (CrCl) was below 70ml/min. The aim of this
study is to investigate whether dual ESP kidneys have a similar graft outcome
compared to single ESP kidney transplants.
Patients and methods: All consecutive renal transplants performed between
Jan 4, 1999- Dec 31, 2005 and allocated via ESP were studied [N=2261].
Primary end-point was graft function at 1-year. Dual kidney transplants [N=27]
were compared to single kidney transplants (single RTX) where the donor had
a CrCl below 70 ml/min [N=951] and single RTX with a donor CrCl ≥ 70ml/
min [N=1283]. A multivariate model was build in order to identify additional
risk factors.
Results: 1-Year graft survival rates for dual RTX, single RTX with a CrCl
< 70ml/min and single RTX with a CrCL ≥ 70ml/min were 81%, 81% and
84% respectively (p<0. 0001). The multivariate model yielded the following
significant factors.
Variable

CIT (per hour, > 11
hours)
Cr Cl (≥ 70ml/min
vs. < 70ml/min)
Donor age (per yr,
>70 yr)

Relative
risk
(95%CI)
1. 015 (1. 001-1.
030)
1. 260 (1. 088-1.
459)
1. 030 (1. 013-1.
046)

p-value

0. 04
0. 002
<0. 0001

Factors not significantly associated with 1-y graft outcome were recipient age
(p=0. 2), retransplantation (p=0. 2), HLA mismatches (p=0. 8),%PRA (p=0.
9), dual vs. single kidney tx (p=0. 6), donor hypertension (p=0. 9) and donor
diabetes (p=0. 4).
Conclusion: In this 7-year cohort of old-for-old renal transplants there is no
evidence to advocate a dual kidney transplant in case of a donor creatinine
clearance below 70 ml/min. Factors detrimental for 1-y graft function are
duration of cold ischemic time (CIT) (>11 hours), creatinine clearance (< 70ml/
min) and donor age (>70 y). It still holds that the success of the ESP scheme
relies on the reduction of cold ischemic time.
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POSTER BOARD NUMBER P2 – 444
415 ORGAN PROCUREMENT AFTER EUTHANASIA
PROCEDURE
D. Ysebaert, G. Van Beumen, W. Van Donink, K. De Greef, G. Roeyen,
T. Chapelle, J-L. Bosmans, P. Cras
Antwerp University Hospital
Although euthanasia is banned in almost all countries of the world, it was
legalized in Belgium in 2002 for adults under strict conditions. Euthanasia
is defined as intentionally terminating life by a physician, on the request of
a legally competent adult, conscious at the moment making the request. The
request must be voluntary, well-considered, repeated and not the result of
any external pressure. The patient must be in a medically futile condition,
of constant and unbearable physical or mental suffering that cannot be
alleviated, resulting from a serious and incurable disorder caused by illness
or accident. If the person is not in the terminal phase of his illness, the 2
doctors performing the act of euthanasia must consult with a third doctor,
either a psychiatrist or a specialist in the disease concerned.
Between 2005-2007, 3 patients expressed their will for organ donation after
their request for euthanasia was granted. Patients were between 43-50 y old,
all suffering from a debilitating neurological disease, either after severe CVA
or primary progressive multiple sclerosis. They were totally dependent on
third parties for personal care and without quality of life. Written informed
consent about the procedure, after extensive explanation, was given by the
patient and their relatives. The Institutional Ethics Committee requested
this full written scenario with informed consent, and that the organ retrieval
should be performed as a non-heart beating donor procedure. There had
to be clear separation between the euthanasia request, the euthanasia
procedure and the organ procurement procedure. The procedures had to be
performed by senior staff members and nursing staff on a voluntary basis.
No media contact was requested by everyone involved for at least 3 months
to maintain anonymity between donor and recipients.
The euthanasia procedure was carried out on the requested date by the
patient, by three physicians, in the operating room. After clinical diagnosis
of cardiac death, the procurement team came in and performed the organ
procurement by femoral vessel cannulation (DBTL catheter) and quick
laparotomy for topical cooling. In 1 patients the liver, two kidneys and
pancreatic islets were procured and transplanted, in 2 other patients there was
additional lung procurement and transplantation. For this lung procurement
the body was intubated after death and ventilated. Organ allocation was
done by Eurotransplant, only in Belgium and the Netherlands, the only two
countries with euthanasia legislation. Transplant centers were informed about
the nature of the case and the elements of organ procurement. There was
primary function of all organs.
The potential in Belgium (and the Netherlands) could be substantial.
According to the Federal Control and Evaluation Committee Euthanasia (Year
Rapport 2006) the number patients with debilitating neurological disease that
had their request for euthanasia granted was 22/235 (2003), 27/349 (2004)
and 16/393 (2005).
The involved physicians, Transplant Team and Institutional Ethics
Committee, had the well-discussed opinion that this strong request for organ
donation after euthanasia could not be waived. A clear separation between
the euthanasia request, the euthanasia procedure and the organ procurement
procedure is necessary.
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POSTER BOARD NUMBER P2 – 445
416 KIDNEY TRANSPLANT LISTING FOLLOWING, LIVER,
HEART AND LUNG TRANSPLANTATION

POSTER BOARD NUMBER P2 – 446
417 APPROACH TO SOLVE ORGAN SHORTAGE IN JAPAN;
FROM PERSPECTIVE OF COORDINATORS OF INTRINSIC
MOTIVATION
Y. Uryuhara, N. Kambayashi
Graduate School of Business Administration, Kobe University
Japan has much lower level of deceased organ donation than the Western
countries. Since this is a serious social problem in Japan, various factors have
been considered to solve the problem of organ shortage. Although it was believed
that the most critical factor for the organ shortage is lack of a well-established
in-hospital system to convert potential donors into actual donors, no prior
studies attempted to analyze the problem from the perspective of in-hospital
coordinators f intrinsic motivation. Thus, we conducted a questionnaire survey
in Europe and Japan to identify the characteristics of in-hospital coordinators
who play crucial roles in organ donation. We compared their job satisfaction,
their pride in their work, their professionalism, their job core dimensions based
on Hackman and Oldham fs Job Characteristics Model, and job responsibilities
between 43 European and 73 Japanese in-hospital coordinators. Our results
demonstrated that the European coordinators have higher levels of skill
variety, task identity, task significance, autonomy, and feedback in their job
characteristics, take more pride in their work, and do their jobs with more
professionalism than the Japanese coordinators. These three factors also lead to
their job satisfaction and high performance of their jobs. These findings imply
that the Japanese coordinators need to be motivated to improve the arranging
process for potential donors to become actual donors. We suggest that redesign
of job responsibilities of the Japanese coordinators, systematic education and
training to foster their professionalism, recognition by healthcare professionals
and society to boost their pride should increase organ donation in Japan.

POSTER BOARD NUMBER P2 – 447
418 DONOR HIGH RISK SOCIAL BEHAVIOR AND
OUTCOMES IN CARDIAC TRANSPLANTATION
D. Xu1, D. Hartman2, K. Ludrosky2, J. Campbell2, R. Starling3, D. Taylor3, N.
Smedira2, G. Gonzalez-Stawinski2
1Northwestern University Feinberg School of Medicine, Chicago, IL, United
States, 2Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Cleveland, OH, United States, 3Department of Cardiovascular
Medicine, Cleveland Clinic, Cleveland, OH, United States
Objective: To investigate the impact of using donors with a history of high risk
social behaviors on recipient post-transplant outcomes.
Methods: Retrospective chart review queried cardiac transplants performed
at a single institution from August 1994 to November 2007 involving donors
known to have engaged in high risk social behaviors (HRSBs). Heart transplant
recipients were stratified according to the HRSB their donors had participated
in. Kaplan-Meier methodology was used to analyze overall survival rates, and
Cox proportional hazards regression was performed to determine the impact of
donor HSRBs on survival.
Results: Between August 1994 and November 2007, 143 donors were
identified with social histories containing the following HRSBs: IV drug use
(n=21), prescription narcotic drug use (n=20), marijuana use (n=79), cocaine
use (n=60), crack cocaine use (n=7), incarceration (n=69), multiple tattoos and/
or piercings (n=44), and alternative lifestyle participation (n=11). Viral screens
detected 11 donors who were hepatitis B virus positive (HBV), and 10 donors
who were hepatitis C virus positive (HCV) at the time of donation. Human
immunodeficiency virus (HIV) screens were negative for all patients at time of
donation. One-year and 5 year survival were 96. 1% and 84. 2% respectively
by Kaplan-Meier analysis. After adjusting for confounding influences, Cox
proportional hazards regression model found none of the donor HRSBs to be
significant determinants of the Kaplan-Meier survival rates (p = 0. 55). At last
follow-up, 8 patients (80%) that received a HCV positive donor converted
positive for the virus, while 5 patients (45%) that received a HBV positive
donor converted positive for the virus. However, no patient was detected to be
HIV positive at their last follow-up.
Conclusion: Using hearts for transplantation from high risk social behavior
donors does not seem to impact long term survival. There is a considerable risk
for viral transmission of hepatitis B and hepatitis C when these are detected by
pre-transplant screens. However, if pre-transplant screens fail to detect HIV,
then heart transplantation may be safely performed.

POSTER BOARD NUMBER P2 – 448
419 THE EFFECT OF RECIPIENT HEPATITIS C VIRUS
INFECTION ON OUTCOMES FOLLOWING HEART
TRANSPLANTATION.
A. Shafii, G. Gonzalez-Stawinski
Department of Cardiothoracic Surgery, Cleveland Clinic Foundation
Background: Insufficient data exists on the clinical course of hepatitis C virus
(HCV) infection in heart transplant recipients. Our study reports the outcomes
of heart transplantation (HT) in the pre-transplant HCV-positive recipient.
Methods: A retrospective analysis of the heart transplant database at our
institution was conducted to identify heart transplant recipients who were
HCV- positive prior to transplant. Demographics, serum transaminases, serum
bilirubin, serum albumin, graft function, incidence of post-transplant acute
hepatitis, and patient survival data were obtained by chart review.
Results: Between 1995 and 2006 ten patients underwent HT at our center who
at the time of transplantation were HCV seropositive. Mean age of recipients
was 47 years-old (range 23-69). Seven recipients were male and 3 were female.
At listing 9 patients had no cirrhosis. One patient had Childs B cirrhosis and
was listed for combined heart-liver transplantation. Two of 10 donors were
known to be HCV carriers. Post-transplant in-hospital survival was 100%. At
mean follow-up of 58 months (range1. 6 -145 months) 3 deaths occurred for
an overall survival of 70%. Only one death was linked to accelerated acute
hepatitis, the donor in this case was HCV negative. Transplant coronary
artery disease was detected in 2 patients at follow-up. Echocardiograms in all
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J. Schold2, T. Srinivas1, B. Stephany1, E. Poggio1, C. Miller1, M. Budev1, R.
Fatica1,
1
Cleveland Clinic, 2University of Florida
End-stage renal disease (ESRD) frequently complicates the course of patients
with prior non-renal solid organ transplants (liver, heart, lung;NRT) and
adversely impacts mortality and morbidity. NRT patients who develop ESRD
may often be referred for a kidney transplant (KT) evaluation. The principal
study aims were 1) To assess the incidence of KT candidate listing following
NRT and 2) To evaluate the rate of preemptive listing and donor quality among
these candidates and recipients and 3) To evaluate the efficacy of KT for each
type of NRT candidate that were dialysis dependent.
Methods: We examined data from the national SRTR transplant registry
for all KT candidates with a prior solid organ transplant from 1988 to 2006.
Demographic information and incidence rates of NRT candidate listing were
calculated and compared to trends in KT patients without NRT. The efficacy
of kidney transplantation relative to dialysis was assessed based on timedependent Cox models using the population of candidates with the applicable
prior organ transplant as a reference group.
Results: Overall 4, 699 candidates were listed over the study period; the
number of listings based on prior organ transplant is displayed in Figure 1.
The proportion of all kidney transplant listings that previously had a prior NRT
grew from <1% of candidates prior to 1990 to 3. 3% in 2006. 36% of NRT
candidates were listed prior to dialysis initiation as opposed to 22% of other
candidates (p<0. 001). 2, 480 patients received a kidney transplant within the
period, 24% received a transplant from a living donor which was similar to
non-NRTs (23%). Among deceased donor transplant recipients, NRTs and nonNRTs received 14% and 13% ECDs respectively. KT demonstrated a survival
advantage for each type of NRT candidate relative to maintenance dialysis.
Conclusions: Kidney transplantation candidates listed after a non-renal
transplant comprise a significantly growing population. NRT candidates are
listed prior to dialysis initiation more frequently than non-NRTs and receive
similar quality organs. The more frequent pre-dialysis listing of NRTs for KT,
likely reflects greater access to medical management by transplant physicians
and has implications for renal transplantation at large. Figure 1.
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survivors at last follow-up revealed a normal ejection fraction. In addition,
there were no cases of hepatocellular carcinoma and all survivors were without
evidence of hepatic dysfunction.
Conclusions: Overall 5-year survival of this patient group was comparable to
ISHLT survival data of HT recipients. Transplanting recipients known to have
HCV does not seem to increase the risk of developing hepatocellular carcinoma
or liver dysfunction.

POSTER BOARD NUMBER P2 – 449

less often be ascribed to rejection (7, 5% vs. 10, 7%), malignancy (7, 5% vs.
8%) and graft failure (26, 9% vs. 31, 4%). 10-year survival for women was
significantly better compared to men (55% vs. 44%); also, 10-year survival
was significantly better for women compared to men who had received a
female heart (60% vs. 42%).
Conclusions: Women who received female hearts performed best. In women
who received male hearts, clinical outcome was better compared with that of
men who received male hearts. A partial explanation may be that lower comorbidity in female recipients may play an essential role since a possible
advantage of receiving a female heart is lost in men.

TUESDAY

420 INFLUENCE OF ABO-COMPATIBLE
TRANSPLANTATION ON LONG-TERM OUTCOME IN
CARDIAC TRANSPLANT RECIPIENTS
A. Aliabadi, D. Dunkler, S. Mahr, M. Grömmer, M. Grimm, E. Wolner,
A. Zuckermann
Medical University of Vienna
Background: Cardiac transplantation is best therapeutical option for endstage heart disease. Previous reports on the influence of the AB0 system on
cardiac transplant outcome indicate that blood group identical transplants have
a better outcome than blood group compatible transplants. As the demand for
donor organs largely exceeds the supply, it is our policy to use blood group
compatible local donors for transplantation if no suitable AB0 identical
recipient is available. The aim of this study was to determine outcome after
blood group compatible transplants.
Patients & Methods: Between 1984-2003 a total of 915 cardiac transplants
have been performed at our center. Median follow-up was 127 months. Patients
were analyzed according blood group matching (AB0 identical (I) vs. AB0
compatible (C)). Moreover subgroup analyses within the different groups were
made to identify potential differences. Groups were analyzed for survival, graft
rejection and graftvasculopathy (CAD). Kaplan-Meier analysis was used and
log-rank test was performed to detect differences.
Results: A total of 81 transplants (8. 9%) were blood group compatible. The
majority (n=32) were 0A transplants (40%) followed by 0B (n=19; 23%), AAB
(n=17; 21%), BAB (n=7; 9%) and 0AB (n=6; 7%). Overall survival comparison
showed no significant difference in long-term survival (10-year) between the
two groups (I: 52. 2% vs. C: 42. 1%; p: n. s. ). Yet there was a clear trend
towards lower survival within the C group. (10a survival: 0B: 73. 3%, AAB:
58. 8%, BAB: 32. 1%, 0A: 27. 6%; p = 0. 0568). In contrast, Freedom from
acute rejection was significantly different between I and C groups (71. 4% vs.
49. 9%; p<0. 0001). There was no difference in incidence of CAD (62. 5% vs.
60. 3%) as well as severe CAD (76. 8% vs. 77. 9%).
Conclusion: The results of our analysis show that AB0 blood group
compatible transplants have similar outcomes in behalf of survival and CAD
as AB0 identical transplant. Yet rejection rates are significantly higher in AB0
compatible transplants. This finding needs further investigation.

POSTER BOARD NUMBER P2 – 450
421 EFFECT OF DONOR GENDER ON GRAFT SURVIVAL
FOLLOWING ORTHOTOPIC HEART TRANSPLANTATION
E. Lehmkuhl, H. Lehmkuhl, N. Hiemann, M. Dandel, C. Knosalla,
V. Regitz-Zagrosek, R. Hetzer
Deutsches Herzzentrum Berlin
Objectives: Clinical outcome for women compared with men following HTX
is assumed to be worse but is controversial.
Methods: Based on the general observation that men who receive a female
heart show a worse clinical outcome (48„b0, 6% vs. 46, 2„b1% for 10-year
survival), we studied the impact of donor gender on graft survival in 1263
patients with HTX for whom 32, 6% of donors were female.
Results: Of 229 (18, 1%) women transplanted, 146 (63, 7%) received a female
heart. Women suffered more often from dilated cardiomyopathy (70, 1% vs.
62, 7%), NYHA Class IV (37, 2% vs. 31, 2%) but less often from diabetes
(8, 7% vs. 16, 2%). Women showed a better 10-year survival rate (58% vs.
46%). Clinical outcome in women was better when HTX was performed
for dilated cardiomyopathy compared with ischemic heart disease and when
women were not bridged to HTX by an assist device. Gender specific aspects
of mortality showed that women died more often due to infection (30, 1% vs.
25, 8%) and hemorrhage (4, 3% vs. 2, 9%). However, cause of death could
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422 STANDARD IN SURVEILLANCE ENDOMYOCARDIAL
BIOSPY (EMB) PROTOCOL IN THE FIRST MONTH AFTER
HEART TRANSPLANTATION: TIME FOR A REAPPRAISAL?
C. d’Agostino1, A. Gambino1, G. Torregrossa1, G. Toscano1, G. Feltrin1,
F. Tona2, A. Andreotti3, A. Angelini4, G. Thiene4, G. Gerosa1
1
Cardiac Surgery Unit, 2Cardiology Unit, 3CNR, Neuroscience Institute,
4
Cardiovascular Pathology
Objective: EMB is currently the gold standard for acute rejection diagnosis in
Htx, especially within the first three monthes. We reviewed the rusults of weekly
EMB’s performed within the first month after HTx to validate their effectivness
in directing immunosoppressor therapy procedure related complications and
costs per patients (pts).
Methods: We reviewed a retrospectivly 500 consecutive adult pts who
underwent HTx from 1991 to 2007. There were 87 female and 413 male, 14 pts
were bridged to HTx while on VAD’s. Mean ischemic time was 160 ± 50 min,
104 pts recieved the heart from a marginal donors. Induction therapy consisted
of: steroid bolus alone in 38 pts (7, 6%) or associated with: thymoglobuline
(RATG) in 231 pts (46, 2%) lymphoglobulines (ALG) in 208 pts (41, 6%),
OKT3 in 23 (4, 6%).
Manteinance immunosuppresion therapy included: Cyclosporine (CSA) +
Azathioprine (AZA) ± Steroids (STER) in 377 pts (83%); other associations
of CSA or Tacrolimus and Everolimus or Mycophenolate mofetil ± STER in
all the other pts.
We plotted results of the first four EMB’s according to ISHLT grading.
Following our policy, all EMB’s greater than 3A were considered positive
for acute rejection and thus treated with 3-day steroids bolus. Our data were
analyzed with SAS statistical software. In order to evaluate if there was an
association between the observed variables, we have performed a Chi-squared
(÷2) test.
Results: None of the positive presented hemodynamic failure.
EMB 1st week: 30 positive (6%) and 6 inadequate (1, 2%);
EMB 2nd week: 113 positive (24, 5%) and 19 inadequate (3, 8%);
EMB 3rd week: 103 positive (20, 6%) and 32 inadequate (6, 4%);
EMB 4th week: 101 positive (20, 2%) and 34 inadequate (6, 8%).
EMB1 was negative in all RATG pts. Results of EMB1 are related to
induction therapy (p=0. 0043; á=0, 05) independently from manteinance
immunosoppression therapy. There was a highly significant relation between
usage of RATG and results of EMB1 (p<0. 0001, á=0, 05).
Conclusion: In our experience, EMB1 is strongly dependent on the type of
induction therapy. EMB1 was negative in all pts treated with RATG. EMBs
2, 3, 4 are indeed influenced by maintenaince immunosuppression. We
suggest that in all RATG pts EMB1 can be safely avoided. Accordingly, our
strategy has turned into a reduced surveillance protocol with EMBs performed
weekly starting from the second week, thus implementing early post operative
managment of HTx pts.
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423 ANEMIA IS A RISK FACTOR FOR SURVIVAL AFTER
CARDIAC TRANSPLANTATION

POSTER BOARD NUMBER P2 – 453
424 REGULATORS OF COMPLEMENT ACTIVATION IN
MULTIPAROUS VS. NULLIPAROUS HEART TRANSPLANT
RECIPIENTS.
E.R. Rodriguez1, W.M. Baldwin2, C.D. Tan1
1
Cleveland Clinic, 2Johns Hopkins University
Multiparity is thought to be an important factor that increases sensitization of
heart transplant recipients and as a corollary one may expect a higher incidence
of Antibody mediated rejection (AMR). AMR is a type of rejection with low
incidence but high morbidity and if unrecognized high mortality. Activation of
the complement cascade with deposition of complement in capillaries occurs in
AMR and is noxious to the allograft. In some patients activation and deposition
of complement occurs but it is not associated with clinical dysfunction of the
allograft. A protective mechanism may be the local activation of regulators of
complement activation (RCA’s).
Methods: Endomyocardial biopsies from 40 multiparous and 8 nulliparous heart
transplant recipients were evaluated at 1, 6 and 12 months after transplant. The
mean follow up was 4 years. Immunofluorescence for complement fragments
C4d and C3d and for 4 regulators of complement activation was performed. The
regulators of complement tested for included: complement receptor 1 (CD35),
membrane cofactor protein (MCP or CD46), decay accelerating factor (CD55)
and protectin (CD59). The presence of these regulators in capillary endothelial
cells was scored semiquantitatively from 0 to 4+. The data were correlated to
parity, age and clinical evidence of allograft dysfunction.
Results: Expression of CD35 and CD46 in capillary endothelial cells was
absent or weak in most patients. Expression of CD55 and CD59 in granular
pattern in capillaries was commonly found. Twenty seven of 40 patients (67.
5%) had expression of CD55 in capillaries and 15 of 40 (37. 5%) showed
expression of CD59. Only 18 of 40 patients (45%) expressed CD55 and CD59
concomitantly. The expression of regulators of complement activation was
variable over time. One of 5 patients with concomitant deposits of C4d and
C3d had severe dysfunction of the allograft. Two of these 5 patients showed
minimal expression of the regulators of complement CD55 and CD59 in

POSTER BOARD NUMBER P2 – 454
425 MICROVASCULOPATHY DOES NOT AFFECT THE
FAVORABLE OUTCOME IN FEMALE HEART TRANSPLANT
RECIPIENTS
N. Hiemann1, C. Knosalla1, E. Wellnhofer2, H. Lehmkuhl1, R. Hetzer1,
R. Meyer1
1
Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular
Surgery, 2Deutsches Herzzentrum Berlin, Department of Cardiology
Background: Women show a more favorable long-term outcome after
heart transplantation (HTx) than men, and we tested whether stenotic
microvasculopathy affects the more beneficial course in female recipients.
Patients and Methods: We studied 873 consecutive patients (35/151 premenopausal women [aged <40years]; median follow-up 12. 4 (95% CI 11. 4–13.
5) years) who received a primary heart transplant between 1986 and 2002. In 7,
750 biopsies harvested within the first post-transplant year endothelial disease
and stenotic microvasculopathy were evaluated by light microscopy (H&E).
Kaplan-Meier and Cox regression analyses were performed for major cardiac
events (lethal myocardial infarction, sudden cardiac death, graft failure, cardiac
re-transplantation).
Results: Endothelial disease was more frequent in pre-menopausal women
(72% vs. men 56%; p=0. 025), while stenotic microvasculopathy was found
equally in men (38%) and women (pre-menopausal 41%, post-menopausal
32%). Allografts from pre-menopausal female-to-male transplants more
frequently developed endothelial disease (78% vs. 65%; p=0. 021) and stenotic
microvasculopathy (46% vs. 28%, p=0. 024). Beyond the first 5 post-transplant
years women presented less often major cardiac events as compared to men,
independently of donor gender and stenotic microvasculopathy (p=0. 0001).
Multivariate regression analysis found women at lower risk for major cardiac
events (RR 0. 38; 95%CI 0. 17–0. 81), while stenotic microvasculopathy (RR
2. 15; 95%CI 1. 42–3. 26) and treated diabetes (RR 1. 65; 95%CI 1. 08–2. 52)
represented a higher risk for major cardiac events.
Conclusions: Stenotic microvasculopathy has prognostic impact on the
survival of male and female cardiac recipients; however, it does not affect the
more beneficial course of women in the long-term follow-up.

POSTER BOARD NUMBER P2 – 455
426 THE EXPRESSION OF CHROMOGRANIN A IN DILATED
CARDIOMYOPATHY AND ITS RELATIONSHIP WITH
MYOCARDIAL FIBROSIS
R. Chen1, Y. Xie2, Y. Yu3, Y. Zou4, C. Wang5, J. Ge6, Y. Yang7
1Shanghai Institute of Cardiovascular Diseases, Fudan University, 2Shanghai
Institute of Cardiovascular Diseases, Fudan University, 3Shanghai Institute
of Cardiovascular Diseases, Fudan University, 4Shanghai Institute of
Cardiovascular Diseases, Fudan University, 5Shanghai Institute of
Cardiovascular Diseases, Fudan University, 6Shanghai Institute of
Cardiovascular Diseases, Fudan University, 7Shanghai Institute of
Cardiovascular Diseases, Fudan University
Purpose: Chromogranin A (CgA) is widely distributed in the neuroendocine
system and considered as a diagnostic marker of the whole activity of
neuroendocrine system. A neuroendocrine activation has been described in
the process of dilated cardiomyopathy, which promotes the myocardial cell
apoptosis, the stimulation of myocardial interstitial collagen hyperplasia and
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A. Aliabadi, D. Dunkler, M. Grimm, E. Wolner, A. Zuckermann
Medical University of Vienna
Introduction: Reduced hemoglobin (Hb) levels are common after cardiac
transplantation. The aim of this analysis is to investigate the effect of low Hb
levels on long-term outcome in heart transplantation.
Patients and Methods: 797 one-month survivors after cardiac transplant
were evaluated. Average age was 51. 5±12. 7 and 82% were male. Median
survival was 153. 44 months. Average Hb levels for different time periods
were calculated for each patient. Patients were grouped according their gender
specific Hb levels (no anemia (A): male/female >13/12mg/dl; mild (B): m/f
12-13/11-12mg/dl; moderate (C): m/f 11-12/10-11mg/dl; severe (D): m/f
<11/10mg/dl). Prevalence, survival, causes of death and potential risk factors
of anemia were examined in the different groups.
Results: Prevalence of anemia slowly decreased during long-term followup after cardiac transplantation. (year 1 vs. year 5-10: A: 58% vs. 76%, B:
22% vs. 13%, C: 13% vs. 7%; D: 7% vs. 4%). Logistic stepwise multivariate
regression analysis revealed lower creatinine clearance, higher BUN and lower
body mass index as independent risk factors for chronic anemia. Severe anemia
was associated with significant lower short- and long-term survival (A: B: C:
D; 12 month survival: 98%, 96%, 90%, 67%; 120 month survival: 68%, 61%,
58%, 42%; p<0. 0001). In a sub analysis of three-year survivors, severe anemia
again was associated with worse long-term outcome (A vs. B vs. C vs. D: 120
month survival: 71%, 65%, 65%, 52%; p=0. 0268). There was a significant
higher rate of death from infection in the severe anemic group (A vs. B vs. C
vs. D: 9%, 22%, 23%, 41%; p<0. 01).
Conclusion: Prevalence of anemia slowly decreases during follow-up after
cardiac transplantation. Chronic anemia is associated with chronic renal
dysfunction and low body mass index. Chronic anemia significantly worsens
long-term survival, mainly due to infections.

subsequent biopsies.
Conclusions: The presence of regulators of complement in the endothelial
cells correlates with:
1. Absent or low amounts of complement C4d or C3d deposition
2. Dysfunction of the allograft was not seen in patients with expression of
CD55 or CD59.
3. Either CD55 or CD59 seem to be sufficient for protection against the
deleterious effects of complement activation in cardiac allografts.
4. The absence or low local expression of regulators of complement activation
was associated with deposition of C4d and C3d in capillaries and concomitant
allograft dysfunction (AMR).
5. The overall incidence of AMR in this cohort of multiparous heart transplant
recipients was 5%
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remodeling, and the imbalance of collagenI (COLI) and collagen III (COL
III). Losing the support of collagen, the function of left ventricular coverts
from pressure pump to capacity, and eventually lead to heart failure. The
CgA are released by sympathetic nerve terminals and counteract the actions
of β-adrenergic drugs. It is also showed that CgA can modulate fibroblast
cell adhesion and spreading in a differential manner. So it is speculated that
CgA could also contribute to regulate heart remodeling in patients with DCM.
However, the correlation between CgA and myocardial fibrosis remained
uncertain. In the present study, the expression and location of CgA and
myocardial fibrosis in DCM were observed, so as to give rise to the further
study in the role of the neuroendocrine of DCM and clinical evaluation of
myocardial fibrosis.
Methods; Surgical myocardial specimen from DCM patients, who were
underwent successful orthotopic cardiac transplantation, and the normal
myocardium were used for study objects. CgA, COLI and COL III expression
were analyzed by RT-PCR. Location and expression of CgA were assessed
by immunohistochemistry with anti-CgA antibody. The collagen specific
picrosirus red staining was applied on slides of heart samples from controls
and patients, and then the collagen volume fraction (CVF) was calculated.
Results COLI-mRNA and COL III-mRNA were generated in all DCM patients,
but not in the normal. CgA-mRNA was detected by RT-PCR in both normal
and pathologic myocardium, while its expression was significantly increased
in DCM (P<0. 01). It is performed by immunohistochemistry that cytoplasic
expression of CgA was showed in both normal and DCM paraffin sections of
myocardial samples. But a strong positive was produced in DCM slides (P<0.
01), densely arranged in the epicardial and endocardial myocardiocytes; while
only few sparse granules were found in the normal. Increase of CVF and COLI
deposition were obviously observed in DCM (P<0. 001). The deposition of
COLI was surprisingly identical with the strong positive arrangement of CgA.
Conclusions: It is demonstrated for the first time that the deposition of CgA
is related with the myocardial fibrosis of DCM, that is, CgA may influence the
process of myocardial remodeling and fibrosis. CgA may represent a key player
in nenuroendocrine regulation of DCM and it may be a potential diagnostic and
prognostic indicators of DCM patients.

POSTER BOARD NUMBER P2 – 456
427 THE RELATIONSHIP BETWEEN ENTEROVIRUS
INFECTION AND EXPRESSION OF CHEMOKINES IN
MYOCARDIUM OF DILATED CARDIOMYOPATHY WITH
ORTHOTOPIC CARDIAC TRANSPLANTATION
R. Chen, Y. Yang, Q. Guo, J. Ge, C. Wang, H. Chen
1Shanghai Institute of Cardiovascular Diseases,
Purpose: Dilated cardiomyopathy (DCM), a leading cause of heart failure
and heart transplantation in younger adults, is characterized by dilatation
and impaired contraction of the left or both ventricles; it may be idiopathic,
familial/genetic (20-48%), viral, and/or immune. On endomyocardial
biopsy there is chronic inflammation in 30-40% of cases. Myocarditis may
be idiopathic, infectious or autoimmune and may heal or lead to DCM.
Chemokines are the principle mediators of leukocyte infiltration and
inflammation. However, the expression of chemokine in the myocardium
has infected with viruses and its destruction function for myocardium has
not been studied yet. To study the prevalence of viral infection and effect
of chemokines in patients with dilated cardiomyopathy (DCM) by detecting
Enterovirus (Evs) RNA and the expression of chemokines in myocardium
and to evaluate the relationship among viral infection, myocardial damage
and cardiac function in DCM patients.
Methods: Myocardial specimens from 33 patients with DCM underwent
orthotopic cardiac transplantation were studied and normal specimens from
12 persons died of accident at autopsy were examined as controls. EvsRNA and expression of chemokines include monocyte chemoattractant
protein-1 (MCP-1), regulated on activation normal T cell expressed and
secreted (RANTES), γ-interferon-inducible protein 10 (IP-10), MCP-5,
macrophage inflammatory protein-1β (MIP-1β) in these myocardial
tissues were detected by RT-PCR. The cardiac function was studied by
echocardiography and the level of serum cTnI of these patients was
monitored quantitatively by using chemiluminescence method in all the
DCM patients.
Results: All the 33 clinically diagnosed DCM patients were proved by
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pathologic examination. Evs-RNA was found in 14 specimens and MCP-1
mRNA expression was found markedly increased in 7 of them. Meanwhile,
other chemokines were detected negative. Neither viral gene nor the
expression of MCP-1 was found in myocardium of control group. The
serum level of cTnI was found high (>0. 1ng/ml) in 2 patients with DCM
before heart transplantation and the Evs-RNA was detected in their donee
myocardium. The left ventricular systolic function of the DCM patients
were found poor as their average value of EF was 29. 4±11. 3. Compared
the virus gene postive and negative group, it was showed no significant
difference (P>0. 05). However, the left ventricular diastolic function (E/A)
was demonstrated significant statistic higher in virus gene postive group
than that in virus gene negative group (2. 22± 0. 44 vs 1. 78± 0. 34), P <
0. 05.
Conclusion: Nearly half of the DCM patients with orthotopic cardiac
transplantation were found to be infected by Enterovirus. In these patients viral
infection may alter the expression level of MCP-1, which provide migrating
signal, activate the cells and initiate the aggregating of the inflammatory cells
and then injury myocardial cells.
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428 ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION
|JAPANESE EXPERIENCE OF MORE THAN 1, 000 CASES
SINCE 1989
K. Takahashi, K. Saito, K. Tanabe, S. Takahara, K. Uchida, A. Aikawa, T.
Kinukawa, T. Kobayashi, N. Yoshimura, Y. Kamiryo
Japanese ABO Incompatible Kidney Transplantation Committee
We heve been making continuing efforts in ABO-incompatible kidney
transplantation since 1989 to expand the opportunities for kidney transplantation
from living donors.
From the Japanese registry, we have reviewed the long term patient and graft
survival of ABO-incompatible kidney transplantation.
This survey focused on 1, 012 patients who received ABO-incompatible kidney
grafts from January 1989 to December 2006 in whom monitoring follow-up
could be achieved in 92 institutions all over Japan.
The mean age of patients at surgery was 38 years (4 to 71) comprised 638
(63%) males and 374 (37%) females.
The overall patient survival rate at 1, 3, 5 and 10 years after transplantation
were 95, 93, 91 and 87%, with overall graft survival rate of 90, 86, 80 and
63%, respectively.
The graft survival rate has been significantly improved especially after 2001,
at 1, 3 and 5 years with 96, 94 and 90% (n=567), compared with those in the
period of 1995-2000 at 84, 79 and 76% (n=277) and in the period of 1989-1994
at 81, 78 and 68% (n=168), respectively.
The graft survival rate was significantly higher in patients aged 29 and
younger compared with those aged 30 and older (p<0. 01). There were no
significant differences between A-and B-incompatible recipients, number of
HLA mismatches, induction and maintenance calcinurine inhibitors and donor/
recipient relationships with respect to clinical outcomes.
Recent trend in Japan is the rituximab desensitization and avoidance of
splenectomy. Among 168 cases in 2006, rituximab was used in 69 cases and
splenectomy was avoided in 63 cases. Overall avoidance of splenectomy have
already reached up to 148 (15%) among 1, 012 cases.
This study confirms that the short-term and long-term outcome of ABOincompatible living kidney transplantation is excellent, and are similar to that
in ABO- compatible cases.
ABO incompatible kidney transplantation has become one of a standard, safety
and effective treatment choice for end-stage renal disease.
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429 COMPARATIVE STUDY OF LONG-TERM OUTCOMES
BETWEEN ABO INCOMPATIBLE AND COMPATIBLE LIVING
DONOR KIDNEY TRANSPLANTATION.

430 ELIMINATION OF SPLENECTOMY AND ANTICD20 THERAPY DOES NOT RESULT IN INCREASED
CHRONIC ALLOGRAFT NEPHROPATHY: A SINGLE
CENTER EXPERIENCE IN ABO-INCOMPATIBLE RENAL
TRANSPLANTATION
A. Singer, J. Locke, M. Haas, Z. Stewart, K. King, J.K. Melancon, D. Segev,
D. Warren, R. Montgomery
Johns Hopkin University
Background: ABO incompatibility (ABOi) remains a significant barrier to the
expansion of live donor renal transplantation. With the advent of plasmapheresis
(PP) and IVIg based desensitization protocols, it is now possible to perform
successful renal transplantation in the presence of ABOi. Our experience with
56 ABOi renal transplants suggests that elimination of splenectomy and/or antiCD20 therapy does not increase the extent of chronic allograft nephropathy or
the incidence of graft loss.
Methods: Patients were treated with a standard protocol consisting of pre- and
post-transplant PP/CMVIg, daclizumab induction, steroids, tacrolimus, and
MMF. Some patients also underwent splenectomy and/or anti-CD20 treatment
prior to transplant.

Results: Death-censored graft survival for the entire cohort at 1- and 3- years
was 100% and 93. 4% respectively. 3 patients died with a functioning graft.

431 RITUXIMAB THERAPY DECREASES ACUTE
REJECTION RATES AMONG SENSITIZED RENAL
ALLOGRAFT RECIPIENTS
D. Dadhania1,2, V. Sharma1,2, K. Wang2, R. Friedlander2, A. Menon2,
D. Serur1,2, M. Aull1, S. Kapur1, M. Fotino2, M. Suthanthiran1
1
Weill Cornell Medical Center, 2Rogosin Institute
Sensitized renal allograft recipients are disadvantaged for multiple reasons –
longer wait times, increased risk of acute rejection and compromised long-term
kidney survival. B cell targeted therapy may not only decrease acute rejection
rates but also improve allograft survival rates.
Herein, we report on the impact of Rituximab therapy (one dose of 1g (n=39)
or two 1g doses given two weeks apart (n=10)) on : (1) the depletion of
peripheral blood B cell subsets; (2) the percentage of lymph node B cell
subsets (the lymph nodes were retrieved from Rituximab treated patients
at the time of transplant surgery); and (3) acute rejection rates and graft
survival in 49 recipients with evidence donor specific sensitization: donor
flow cytometry cross- match positive and donor specific anti – HLA antibody
positive by the Luminex platform. All recipients received Thymoglobulin
induction at the time of transplantation, and 33 received Rituximab and 16
did not.
Rituximab therapy effectively depleted peripheral blood naïve B cell subset.
Data from flow cytometry analysis of peripheral blood cells obtained from 4
patients and analyzed for CD19+ CD27- (naïve subset) and CD19+CD27+
(memory subset) are shown in Table 1.
Table 1. In-vivo effect Rituximab on Naïve and Memory B-cell Subsets
B cell subsets

Pre Rituximab (n=4)

Post Rituximab (n=4)

P value

CD19+CD27-

4. 8 ± 0. 54

0. 28± 0. 06

0. 005

CD19+CD27+

0. 45 ± 0. 25

0. 17± 0. 05

0. 32

Interestingly, both B cell subsets were identified in the lymph nodes retrieved at
the time of transplantation from Rituximab treated recipients: CD19+CD27- :
16. 5 ± 5. 0% and CD19+CD27+: 9. 9 ± 4. 1% (mean±SE, N=6 patients)
Prophylactic Rituximab therapy was associated with a significantly decreased
risk of acute rejection at 6-months and one year post-transplantation, and a
trend towards improved allograft survival (Table 2).
Table 2. A significant reduction in AR Rates with Rituximab Treatment of
Patients with Donor Specific Antibodies
Rituximab
(n=33)

No Rituximab
(n=16)

Odds Ratio

95% CI

P-Value

6-montth AR

12%

33%

0. 23

0. 06, 0. 93

0. 039

1-year AR

16%

45%

0. 23

0. 06, 0. 87

0. 029

Graft
Survival

95%

75%

0. 26

In a multivariable regression model, Rituximab therapy was associated with
an OR of 0. 18 (0. 04, 0. 83; P=0. 02) for acute rejection episodes whereas
prophylactic IVIG therapy was associated with an OR of 1. 61 (0. 35, 7. 51;
P=0. 5).
Our data suggest that our Rituximab treatment protocol is associated with an
effective depletion of peripheral blood B cells but not the B cell subsets in the
lymphoid compartment. Importantly, prophylactic Rituximab therapy reduces
acute rejection rates in subjects with donor specific anti-HLA antibodies.
Lymph node profiling for B cell subsets may help optimize B cell targeted
therapy for the sensitized recipient.
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A. Aikawa, T. Kawamura, Y. Mori, M. Saneshige, J. Takasu
Department of Nephrology, Toho University
Aim: The aim of this study is to evaluate long-term outcomes of living donor
ABO incompatible kidney transplantation (ABOINCKTx) compared with
ABO compatible kidney transplantation (ABOCKTx).
Methods: Fifty ABOINCKTx and 119 ABOCKTx recipients were enrolled in
this study. All Tx underwent from1997 to 2004 (Mean follow-up ABOINCKTx
vs. ABOCKTx; 81 vs. 82 months). Immunosuppression was similar in both
groups except splenectomy and pre-conditioning (plasmapheresis and/or
plasma exchange) in ABOINCKTx. Blood group matching (donor to recipient)
in ABOINCKTx are as follows. A1 to O (n=13), B to O (n=12), A1B to A1
(n=6), B to A1 (n=5), A1B to B (n=8), A1 to B (n=6).
Results: Age and gender of recipients and donors, the relation of donor to
recipient, and HLA mismatch were not different between two groups. However
the rate of second Tx was significantly higher in ABOINCKTx than ABOCKTx
(7/50 vs. 3/119; p<0. 01). Incidence of biopsy proven acute rejection was
significantly higher in ABOINCKTx than ABOCKTx (22/50. vs. 20/119; p<0.
001). However serum creatinine levels were not different in any post-Tx years
between ABOINCKTx and ABOCKTx (ABOINCKTx vs. ABOCKTx; 1-yr 1.
18 }0. 39 vs. 1. 15 }0. 56; NS, 3-yr 1. 33 }0. 66 vs. 1. 23 }0. 93; NS, 5-yr
1. 44 }0. 84 vs. 1. 24 }0. 52; NS, 7-yr 1. 41 }0. 36 vs. 1. 51 }0. 79; NS. ) In
ABOINCKTx, all 50 recipients have so far survived, however only one patient
lost graft function due to chronic allograft nephropathy (CAN) 64 months postTx. In ABOCKTx, 3 recipients died of cancer and infection with good renal
function. One and 2 recipients lost graft due to antibody mediated rejection and
CAN, respectively. Graft survival rates in ABOINCKTx and ABOCKTx were
100% and 98. 3% at 1-yr, 100% and 97. 5% at 3-yr, 100% and 96. 6% at 5-yr,
and 97. 4% and 91. 8% at 7-yr, respectively.
Conclusion: Long-term outcomes including renal function in ABOINCKTx
were excellent and seemed to be equivalent to ABOCKTx despite of higher
rate of acute rejection.

3 graft losses have occurred secondary to recurrent disease (2) and patient
noncompliance (1). There were no significant differences in the number of
post-operative PP treatments or the incidence of acute rejection between the
treatment regimens.
Conclusions: In our experience, excellent short- and long-term function of
ABOi renal allografts can be achieved with PP/IVIg based desensitization
without the need for long-lasting B-cell depletion. Further, this reduction in
immune modulation has not resulted in an increase in rejection or chronicity
scores on 1-year protocol biopsies.
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432 CLINICAL SIGNIFICANCE OF B-CELL POSITIVE
CROSSMATCHES AND LUMINEX® DEFINED DONORSPECIFIC ANTIBODIES IN WELL-MATCHED HIGHLY
SENSITIZED PATIENTS FROM THE AUSTRALIAN
INTERSTATE EXCHANGE
H.S. Eng , S. Campbell , G. Russ
, P. Toby, H. Coates ,
P. Bardy1,5,6, G. Bennett5, S. Chang4, B. Tait7
1
Medicine, University of Adelaide, SA, Australia, 2Nephrology and
Transplantation Services, Queen Elizabeth Hospital, SA, Australia, 3Renal
Transplant Unit, Princess Alexandra Hospital, Brisbane, Australia,
4
ANZDATA Registry, Queen Elizabeth Hospital, SA, Austrralia, 5National
Transplant Services, Australian Red Cross Blood Service, SA, Australia,
6
Haematology-Oncology, Queen Elizabeth Hospital, SA, Austrralia, 7Victorian
Transplantation and Immunogenetics Service, Australian Red Cross Blood
Service, c/o Royal Melbourne Hospital, Victoria, Australia
A positive B-cell crossmatch (BXM) is controversial in kidney transplantation.
The Australian National Interstate Exchange (ANIE) prioritises sensitized
patients, aiming for greater HLA-matching. We retrospectively studied the
clinical predictive value of complement-dependent cytotoxicity (CDC) BXM
in patients with Luminex® defined class I (CI) and class II (CII) donor-specific
antibodies (DSA).
Ninety-one deceased donor renal transplant recipients matched at levels 1
(zero HLA mismatch and PRA>50%), 2 (1 mismatch, PRA>80%) and 3 (2
mismatches, PRA>80%) under the ANIE between October 2004 and December
2006 were studied and followed to July 2007. All patients had a negative CDC
T-cell crossmatch (TXM). Antibody specificity was defined using Luminex®
PRA and Single Antigen Bead assays.
There were thirteen (14%) graft losses between 0-31 months. Total rejection
rate was 40%, 92% biopsy-proven. Eighteen of 91 (20%) had humoral rejection,
13 with C4d staining. Thirty-one patients had negative peak and current BXM
and 29 had positive BXM with any serum. A positive BXM was not associated
with a higher risk of total rejection (p=0. 07), cellular (p=0. 46) or glomerular
rejection (p=0. 08) but was for vascular (p=0. 039) and humoral rejection (p=0.
02). A trend of poorer graft function was observed in BXM positive group at
1 year (MDRD, mean eGFR 42 vs. 53mL/min/1. 73mm2, p=0. 14). Seven of
31 (23%, 2 surgical, 2 rejection, 2 BK, 1 unknown) graft losses occurred in the
BXM negative group compared to 3 of 29 (10%, 1 rejection, 2 deceased) in
BXM positive group (p=0. 3).
Sera from 82 of 91 were analysed using Luminex®. Anti-HLA antibodies were
absent in 11 (13%) patients. Anti-HLA DSA were found in 33 (40%) and nonDSA in 38 patients (46%). DSA was a significant predictor for overall rejection
(p=0. 002), glomerular (p=0. 024), vascular (p<0. 001) and humoral (p<0. 001),
but not cellular rejection (p=0. 11). The eGFR of DSA group at 3 (p=0. 36), 6
(p=0. 5) and 12 months (p=0. 34) were not significantly different from patients
without DSA. Humoral rejection was more common in DSA-CI alone (n=14,
5/14, 36%, p=0. 005) or DSA-CI& CII (n=10, 6/10, 60%, p<0. 001) groups,
compared to patients without DSA (2/49, 4%). DSA-CI&CII was associated
with higher risk of total rejection (p<0. 001), cellular (p=0. 018) and vascular
(p<0. 001) rejection but DSA-CII alone (n=9) was not.
DSA was found in 18 of 29 (62%) BXM positive patients and 8 of 31 (26%)
BXM negative patients. BXM positive with DSA was associated with humoral
rejection (p=0. 001) but positive BXM without DSA was not (p=0. 1). Two of 8
BXM negative patients with DSA had humoral rejection (25% vs. 0%, p=0. 06).
Positive and negative predictive values of BXM and DSA for humoral rejection
were 31%, 93% and 41%, 96%. After adjustment for BXM, DSA remained a
significant risk factor for total (p=0. 028), vascular (p=0. 023) and humoral
rejection (p=0. 043). After adjustment for DSA, BXM was not a significant
risk factor for rejection.
A positive BXM in the presence of anti-HLA DSA is a predictor for vascular and
humoral rejection in sensitized patients. Compared to BXM, Luminex antibody
analysis allows greater predictive value for vascular and humoral rejection.
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433 SIMULTANEOUS KIDNEY PANCREAS
TRANSPLANTATION IN PATIENTS WITH POSITIVE CDC
B-CELL AND/OR FLOW CYTOMETRY CROSSMATCH
R. Heilman, A. Moss, M. Mazur, H. Chakkera, K. Mekeel, D. Mulligan,
K. Reddy
Mayo Clinic Arizona
We reviewed our experience with simultaneous kidney pancreas transplantation
(SKPT) in patients with positive CDC B-cell and/or flow cytometry crossmatch
and compared to SKPT recipients with negative crossmatch performed during
a concurrent period.
We performed 64 SKPTs from Jan 2005 to Nov 2007, 12 in patients with
positive CDC B-cell and/or flow cytometry crossmatch and 52 in patients with
negative crossmatch. Patients with positive crossmatch received induction
with low dose IVIG (100 mg/kg x 3 doses), r-ATG (1. 5 mg/kg x 4 doses) or
Alemtuzumab (30 mg single dose) and maintenance with tacrolimus, MMF and
steroids while negative crossmatch recipients received r-ATG or Alemtuzumab
and maintenance with tacrolimus, MMF and rapid steroid taper (discontinued
on day 4). One patient in the positive crossmatch group also received high dose
IVIG as part of desensitization protocol. Protocol biopsies were performed
at 1, 4 and 12 months and every year thereafter. Acute cellular rejection was
treated with solumedrol or r-ATG depending upon the severity of rejection and
antibody mediated rejection (AMR) episodes were treated with solumedrol,
plasmapharesis, IVIG and rituximab.
Transplant characteristics, incidence of acute rejection, infection rates, graft
and patient survival rates are shown in the table.
positive
crossmatch
SKPT (n=12)

Negative
crossmatch
SKPT (n=52)

p value

Previous transplant

42%

2%

0. 0006

PRA 0%

8%

94%

0. 0001

PRA >80%

42%

0%

0. 0001

Biopsy confirmed clinical acute rejection

42%

10%

0. 015

Subclinical rejection (protocol biopsy)

8%

6%

NS

Antibody mediated rejection

42%

0%

0. 0001

CMV infection

8%

17%

NS

BK nephropathy

0%

4%

NS

Kidney graft survival

83%

96%

NS

Pancreas graft survival

67%

92%

0. 03

Patient survival

92%

100%

NS

Mean followup in months (median)

20 11 (18)

17 10 (16)

NS

SKPT in patients with positive CDC B-cell and/or flow cytometry crossmatch
is associated with high AMR rate despite low dose IVIG and r-ATG/
Alemtuzumab induction. Pancreas graft survival is inferior in patients with
positive crossmatch while kidney graft and patient survival are similar to that
of negative crossmatch recipients. Majority of AMR can be reversed with
treatment but further long-term follow-up is needed to determine the impact
on graft survival.

434 HIGHLY SENSITIZED RENAL TRANSPLANT PATIENTS:
>10 YEARS SINGLE CENTRE EXPERIENCE WITHOUT
INDUCTION THERAPY.
M. Christiaans1, J. van Hooff1, M. Gelens1, E. van Duijnhoven1,
E. van Heurn2, E. van den Berg-Loonen3
1
Dept. Internal Medicine, University Hospital Maastricht, 2Dept. Surgery,
University Hospital Maastricht, 3Tissue-typing laboratory, University
Hospital Maastricht
Introduction: In Eurotransplant, highly sensitized recipients (PRA>85% in 2
sera, excluding autoantibodies) are transplanted with XM-negative donor via
the waiting list or via the AM (acceptable mismatch)-program. In most centres,
these patients receive induction therapy as additional immunosuppression.
However, in our centre we at most use triple therapy without induction therapy.
The purpose of this single-centre study is to provide the data about rejections
and long term graft survival.
Methodology: Retrospectively, all hyperimmunized patients transplanted in
our centre were studied.
Actuarial death-censored GS (Kaplan Meier) was calculated and compared to
the overall GS of cadaveric renal transplant recipients in our centre.
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Results: Between March 1989 and May 2006 873 renal transplants were
performed in our centre. Of these 47 were highly sensitized, 35 were performed
under the auspices of the AM program and 12 via the normal waiting list (male
21, female 26); 43% were 1st graft. Immunosuppression was CNI-based in all
(CsA 21, Tac 26). Additional IS: low-dose (<10 mg) steroids in all + AZA (18)
or MMF (19); no induction-therapy was given.
HLA-mismatch

0

1

2

A

46. 8

46. 8

6. 4

B

36. 2

57. 4

6. 4

DR

46. 8

46. 8

6. 4

1st biopsy-proven rejection < 3 months occurred in 24% and was lower in Tactreated patients (p=0. 04). Actuarial GS (censored for death) was as follows:
1yr 78%, 5yr 76%, and 10 yr 55%. Results were comparable to the overall
cadaveric renal transplant recipients (GS1 yr 83%, 5yr 72%, 10yr 56%).
Conclusion: On a single-centre level, cadaveric kidney grafts transplanted in
highly sensitized recipients without using induction therapy have an acceptable
rejection rate, especially in Tac treated patients, and excellent long-term graft
survival. These results are comparable to the results of the overall transplant
population in our centre.

435 RACIAL DIFFERENCES IN THE FREQUENCIES OF HLASPECIFIC B CELLS

Tetramer:
Group Race
nonsensitized

A2
Freq

black
white

No.

Freq

No.

1. 99

25

1. 73

26

P
sensitized

Freq

A24

B7

No.
2. 69
2. 14

0. 01

25

2. 86

26

2. 61

4x10-6

25
26
0. 13

black

3. 17

12

3. 53

11

5. 29

11

white

3. 10

31

3. 89

16

4. 33

28

mismatched black
for tet
antigen

4. 24

5

4. 28

6

white

3. 64

11

3. 39

5

P. Trevillian1, A. Hibberd1, M. Heer1, A. Gillies2, R. Nanra2, S. Carney2,
B. Jones2, A. Stein1
1
Newcastle Transplant Unit, John Hunter Hospital, 2Department of
Nephrology, John hunter Hospital
Background: In Australia, DD kidneys are allocated according to an algorithm
based on shared HLA, dialysis waiting time and a Tneg CDC XM. More
sensitive assays for detecting anti-HLA antibodies are not routinely used pretransplant. In our unit 42% of our wait-listed patients are sensitised to foreign
HLA (PRA of >20%). In only a minority of these patients is the specificity of
the antibodies known pre-transplant.
Methods: We report the outcomes in 5 recipients (age 21-65, 2M: 3F) of DD
kidneys who were transplanted across a Tneg CDC XM. Four were known to be
broadly sensitised (PRA’s = 40, 83, 85, 88%) and one had waited 13 years for
his first kidney offer (PRA = 11%). Two had lost previous grafts from chronic
rejection. Single antigen luminex profiles were available in 2 patients and in
each case donor specific antibody (DSAb), anti-MHC class I, was known to be
present pre-transplant. Three patients were given a single pre-transplant plasma
exchange and high dose IVIG (500-1000mg/kg) in the hours before surgery.
One of these was also given pre-emptive Rituximab.
Results: All 5 grafts suffered severe, accelerated rejection within 72 hours.
In 2 cases, hyperacute rejection was observed on the operating table (grafts
turned pink then mottled blue). One of these was removed 24 hours later
after the recipient developed a life threatening disseminated coagulopathy.
Histology showed glomerular thrombosis and multiple infarcts but patent large
vessels. The second patient had classical acute AMR on sequential biopsies and
remained dialysis dependent until a dramatic response to Campath “rescue” on
day 22. His function remains stably impaired after 2 years (eGFR=28ml/min).
Three grafts suffered C4d positive, chronic active AMR and 2 were lost at 3
and 9 months. The remaining graft continues to function poorly after 2 years
and appears about to be lost from refractory BK nephropathy.
All patients received a single dose of Rituximab and one patient received a
second dose. One patient received a course of OKT3 therapy. The five patients
received a total of 166 (1- 76) plasma exchange treatments, most with low
dose IVIG.
Retrospective testing showed all recipients had a B+ CDC XM and DSAb
(class I = 2, class I and II = 3) pre-transplant. All had Tpos and Bpos CDC XM
against donor cells a week post-transplant.
Conclusions: Organs should no longer be allocated to SR’s on the basis of
a Tneg CDC XM alone. We call for the introduction of mandatory luminex
screening of all potential DD transplant recipients in Australia and the
establishment of an “acceptable mismatch” program of organ allocation.

CONCURRENT ORAL SESSION 32:
LIVER DONOR ALLOCATION
437 DONATION AFTER CARDIAC DEATH LIVER
TRANSPLANTATION DOES NOT INFLUENCE EARLY
HEPATITIS C RECURRENCE OR OUTCOMES
J. Scalea, L. Campos, B. Philosophe, R. Barth
University of Maryland School of Medicine
Donation after cardiac death liver transplantation expands the available organ
pool but may be associated with specific complications. Little data exists on the
effect of DCD LTx on recurrence and outcomes with hepatitis C virus (HCV).
We analyzed results from 22 DCD LTx performed at our center over the last
5 years. Eleven DCD LTx were performed for HCV cirrhosis, 2 of these were
performed as combined liver-kidney transplants. Overall, DCD LTx median
donor age was 24 yrs old (range 16-53), median warm ischemic time (WIT) was
22 min, and median cold ischemic time was 6. 3 hrs. Median recipient age was
54 yrs old and MELD score was 26. WIT was shorter for HCV recipients (26
min vs. 20 min, p=0. 02). HCV patient and graft survival was 91% with a mean
follow-up of 22 months. Recurrent HCV has been histologically demonstrated
in 60% patients. Transaminases were not elevated in HCV recipients compared
to non-HCV recipients at 1 and 6 months; however, by 12 months HCV
recipients had significant elevation of transaminases (AST 192 vs. 30 U/L, p=0.
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A.A. Zachary, D. Kopchaliiska, M.S. Leffell, J.K. Melancon
Johns Hopkins University School of Medicine
HLA tetramers are comprised of 4 identical HLA molecules bound to
streptavidin and have been used, traditionally, to identify T cells specific
for the peptide bound to the HLA molecule. However, we have previously
shown that HLA tetramers can be used to quantify HLA-specific B cells
and that patients sensitized to the tetramer HLA antigen have significantly
higher frequencies of B cells specific for that antigen. We hypothesized
that there may be racially determined differences in either the baseline or
sensitization-provoked increases in frequencies of HLA-specific B cells that
may account for differences in rates of humoral sensitization. We determined
the frequencies of B cells specific for HLA-A2, -A24, and -B7 among two
groups of blacks and whites: healthy, non-transfused males and sensitized,
male renal transplant patients. The table shows the frequencies of tet+ cells
among CD19+ cells and number of subjects in each group. We found higher
frequencies of HLA-positive B cells among healthy black males which
reached statistical significance for cells specific for A2 and A24. The same
pattern did not occur among sensitized patients, however, when we examined
patients who had received a transplant mismatched for the tetramer antigen,
the HLA-specific B cells were appreciably higher among blacks vs. whites for
A2 and A24 (the antigens for which there were sufficient patients to make a
meaningful comparison) with the same percentage (210% for A2 and 158%
for A24) increase occurring in both racial groups.
Conclusion: Non-sensitized blacks have higher frequencies of HLA-specific
B cells than do whites. This may account, in part, for a higher incidence
of sensitization among blacks vs whites. However, once sensitized, the
proportional increase in B cells appears comparable in the two groups.

436 IT IS NO LONGER ACCEPTABLE TO ALLOCATE
DECEASED DONOR (DD) KIDNEYS TO SENSITISED
RECIPIENTS (SRS) ON THE BASIS OF A NEGATIVE T CELL
CROSSMATCH (TNEG CDC XM).
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06; ALT 142 vs. 26 U/L, p=0. 03). No HCV patients have developed cirrhosis
or experienced graft loss related to recurrent HCV, and only one patient has
required HCV therapy. Of all 22 DCD LTx, five patients were retransplanted;
three patients for hepatic artery thrombosis, one for bile duct necrosis, and one
for hepatic necrosis. The average donor age in retransplanted patients was 40
yrs old as compared to average donor age of 28 yrs old in other patients (p=0.
17). Only one of five liver grafts survived when donor age was above 49 yrs
old. No HCV recipient required retransplantation (p=0. 01). Median time to
failure in those patients requiring retransplant was 1. 2 months. Our results
support that DCD LTx can be successfully utilized for HCV patients without
additional risks of HCV recurrence, early cirrhosis, or graft loss. While HCV
may be associated with more indolent forms of graft failure, this has not been
observed with early follow-up.
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438 EXPANDING DONOR POOL USING STEATOTIC LIVER
GRAFTS
H. Noujaim1, E. Montero2, C. Ribeiro1, R. Gomes1, L. Curvello1,
F. Crescentini1, M. Casagrande1, J. Rodrigues1, M. de Miranda1, T. Genzini1
1
HEPATO – Hospital Beneficencia Portuguesa De São Paulo, 2UNIFESP
Introduction: The necessity of liver transplant (LTx) has increased each year
while the number of organs available has not. Options have been developed to
expand the donors’ liver pool, such as the use of steatotic grafts.
Purpose: To analyse the outcome of LTx when using grafts with different
degrees of steatosis.
Patients and methods: Between May/02 and Feb/08, 115 LTx performed
in 112 patients were analyzed. In all cases a liver biopsy was performed 2
hours after graft reperfusion. The 115 LTx were divided according to their
steatosis degrees in 4 groups: absent –ASG (n=36), mild –MSG (<30%)
(n=36), moderate- MoSG (30-59%) (n=26), severe – SSG (≥60%) (n=17).
The following donors´ and recipients´ data were analyzed: demographics data,
donor body mass index (BMI), MELD score, LTx indications, cold ischemia
time (CIT) and surgery time, hospital stay. The early (<30days LTx) causes
of regraft and death were assessed. Patients and grafts survival rates were
compared among 4 groups using Kaplan-Meier curves. Results significant
when p<0. 05.
Results: There was significant difference on patient survival between SSG
vs ASG (p-0. 005) and graft survival between SSG vs ASG (p-0. 001) and
SSG vs MSG (p-0. 01). Most of patients had MELD score between 10 and 20:
60%-MSG, 68%-MoSG, 47%-SSG, 56%- ASG (p-0. 6).
n- LTx/Pts

MSG
(36/35)

MoSG
(26/24)

SSG
(17/17)

ASG
(36/36)

p

Donors
Age (yrs)
BMI
AST (Ui/ml)
ALT (Ui/ml)
ITU stay (days)
Recipients
Age (yrs)
Weigh (kg)
Waiting time on list
(days)
CIT (minutes)
Hospital stay (days)
LTx indications
End stage liver disease
Cirrhosis + Tumor
Fulminante hepatic failure
Re transplant
Patient Survival (%)
(3, 6, 12m)
Graft Survival
(3, 6, 12m)

42, 8±15
25, 6±2. 9
115±159
80±104
5, 6±5

42, 7± 12, 3
25, 9±3, 7
98. 5±86. 7
66±47
4±3

40, 5± 14
24. 3±3. 7
105±105
77. 5±56. 7
5±3, 5

45, 5±13. 4
24, 7±2, 5
179±615
116, 10±182
7±5

0. 6
0. 2
0. 8
0. 4
0. 05

51, 6± 10, 4
73± 15

48±12
78± 17

54± 7, 4
71± 8

51± 10, 5
74. 5± 14. 5

0. 3
0. 4

522± 435

513±528

682±484

519±411

0. 6

633± 192
20± 15
20 (55. 6%)
14 (38. 9%)
1 (2. 8%)
1 (2. 8%)

602±159
17± 12, 3
18 (69. 2%)
4 (15. 4%)
2 (7. 7%)
2 (7. 7%)

600±135
32, 7± 34
14 (82. 4%)
3 (17. 6%)
0
0

596± 169
29± 22
25 (69. 4%)
9 (25%)
2 (5. 6%)
0

0. 8
0. 04
0. 3

95, 85, 80

78, 75, 75

65, 60, 60

100, 100, 90

0. 05

95, 85, 80

78, 75, 75

60, 50, 40

100, 100, 90

0. 01

Conclusion: In this study around 69% of liver grafts presented some degree of
steatosis. Nevertheless, only severe steatosis had negative impact on patients
and grafts survival rates when compared with other groups´ (mild, moderate
and absent steatosis). Future research must be carried out to further study and
therefore improve the results of LTx when using steatotic grafts, since it would
mean a significant increase in the donors pool.
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439 LIVER TRANSPLANTATION FROM CONTROLLED NONHEART BEATING DONORS: A SINGLE CENTER EXPERIENCE
OF 20 YEARS FOLLOW-UP
S. Yamamoto, H.E. Wilczek, C-G. Groth, B-G. Ericzon
Dept of Transplantation Surgery, Karolinska University Hospital Huddinge
Background: The use of liver graft from non-heart beating donor (NHBD) has
recently gained renewed interest because of the existing severe organ shortage.
The greatest hazard with NHBD grafts relates to a prolonged warm ischemia
in the donor which may cause primary graft dysfunction followed by ischemic
cholangiopathy. The first liver transplantation in Sweden was done in 1984,
but brain death criteria were not accepted until 1988. In this study, we have
retrospectively analysed the long-term outcome in recipients of NHBD livers and
in recipients of heart-beating donor (HBD) livers done during the same period.
Methods: During Nov 1984 – May 1988, we performed 40 consecutive liver
transplantations (LTx) in 32 patients. Twenty-four grafts were from NHBD
and 16 grafts came from HBD. Eight HBD grafts were imported from other
European countries and 8 HBD grafts were procured in Sweden. All grafts
were preserved in Euro-Collins solution. All NHBD met the criteria of brain
death and were in Maastricht class Category III (controlled NHBD). Donor
and recipient parameters (gender, age, blood type, diagnosis and preoperative
hospitalization), operative parameters (operation time, anhepatic time, cold
ischemia time and blood transfusions), postoperative peak laboratory liver
values, follow-up liver biopsies and supervening postoperative complications
were analyzed.
Results: More females and more preoperative hospitalizations were seen
in recipients of HBD grafts. No difference regarding donor and operative
parameters was found between the groups. The two groups had similar
postoperative peak ASAT, ALAT and total bilirubin. However, significantly
more hepatic artery thrombosis and biliary complications occurred in the
NHBD group (p=0. 0033 and p=0. 0345, respectively, log-rank test). Graft and
patient survival did not differ at any time point between the groups. The one, 5,
10 and 20 year patient survival after transplantation in non-malignant patients
was 61. 9%, 42. 9%, 42. 9% and 38. 1% in NHBD, and 63. 6%, 54. 5%, 54.
5% and 36. 4% in HBD, respectively. (p=N. S. ) Multivariate analysis revealed
cold ischemia time and peak ALAT to be independent predictive factors for
poor graft survival in the NHBD group. In 10 cases follow-up liver biopsy was
done 18-20 years post-LTx and in one case after 6 years. Only in 3 of the 11
cases signs of chronic rejection were seen and there was no difference of the
occurrence between NHBD and HBD.
Conclusion: NHBD grafts had a higher incidence of early occurring hepatic
artery thrombosis and biliary complications. However, there was no difference
in the long-term patient and graft survival between the groups. This analysis of
NHBD graft recipients, with more than 20 year follow-up, makes us believe that
controlled NHBD grafts can be a feasible option to increase the donor pool.

440 OUTCOMES OF LIVER ALLOGRAFTS FROM
DECEASED DONORS WITH A HISTORY OF MAJOR
ABDOMINAL TRAUMA
D. Verran1, I. Geenen1, M. Crawford1, J. Gallagher1, A. Shun2, M. Stormon2,
S. Strasser1, G. McCaughan1
1
Australian National Liver Transplantation Unit, 2The Childrens Hospital,
Westmead
Introduction: Major abdominal trauma in a potential organ donor may prevent
organ donation proceeding or rule out the procurement and usage of intraabdominal organs for transplantation.
Methods: Retrospective review from 1/1986-9/2007 of records of all deceased
donors with a history of trauma where the liver was procured and transplanted.
Also a review was performed of all declined deceased donor offers where
trauma contributed to the donor’s death. During this time period 42/1405
(2. 9%) of deceased donor offers were declined on the basis of either known
extensive liver trauma and/or ongoing major intra-abdominal haemorrhage.
Results: – in 15/312 (4. 8%) of accepted liver allografts there was evidence
of trauma to the allograft. The recorded injuries were predominantly liver
lacerations and were graded as Grade 1 (n=7), Grade 2 (n=1), Grade 3 (n=1),
Grade 4 (n=2) and Grade 5 (n=2). Liver lacerations were predominantly
managed by conservative measures at the time of allograft implantation
including argon bean coagulation, usage of fibrin glue (n=2), and suturing
(n=1). In 3/15 (20%) of the allografts procured major trauma to the right
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lobe precluded usage of the liver as a whole allograft. Hence 2 left lobes
[from back table cut down] and one left lateral segment [from in-situ split]
were procured for transplantation. In 3/15 (20%) of the liver allografts
intimal trauma of donor vessels required management on the back table
(suturing of hepatic veins in 2, discarding coeliac axis proximal to the hepatic
artery in one). The median recipient age was 43[3-69] years (2 paediatric
recipients). The median cold ischaemic time was 9. 58 (4. 59-15. 5) hours.
There were no cases of primary non function or initial poor graft function.
No relaparotomies were required for haemorrhage. The median peak ALT
and AST post transplantation were 812 (93-2170) IU/ml and 926 (161-1820)
IU/ml. Patient and allograft survival at 1 year were 9/13 (69%) for primary
grafts and 10/15 (66%) overall. There were 3 early deaths post transplantation
[<3 months] from hepatopulmonary syndrome, acute rejection and cerebral
haemorrhage. The 2 other recipient deaths were due to a cerebrovascular
accident and renal failure.
Conclusions: Acceptable results can be achieved using allografts from
deceased donors with a history of abdominal trauma. Management of the liver
trauma is dictated by the severity of the trauma. Consideration should be given
to discarding the right lobe and using the left lobe in cases of severe trauma to
the right lobe of the liver.

441 DOMINO LIVER TRANSPLANTATION (LT) IN
CHILDREN AND ADULTS WITH MAPLE SYRUP URINE
DISEASE (MSUD)

MSUD Pt Age (yr)/WT (kg)
25/69

51/61

Domino
Recipient
Age/WT

Domino
Recipient
Diagnosis

Current
Follow-Up
(mo)

HCC/HCV 42. 3

31/67. 8

65/83. 8

PSC

18. 2

9/38. 5

22/45. 6

PFIC

5. 5

16/83. 4

18/59

CF

1. 7

21/52. 5

20/90

Congenital Hepatic
Fibrosis

0. 5

Patient and graft survival is 100% at a mean of 13. 6 months and liver
function is normal in all. 4/5 MSUD donors received veno-venous bypass
and hepatic vein back table reconstruction with donor iliac vein. Implantation
was by piggyback technique in all non-MSUD patients and 2/5 MSUD
patients. Mean leucine, isoleucine, and valine levels (M/L +/- SD) in
MSUD patients were 333 +/-159. 9, 125+/-64, 290 +/-119 (Pre) and 205.
3+/-49. 3, 130. 5 +/-46. 5, and 310 +/-98. 1 (Post) respectively. Non-MSUD
domino recipient values were normal (138. 3 +/-36. 8, 60+/-28. 1 and 247.
2+/-58. 1) post LT and BC homeostasis has been maintained on unrestricted
diet in all pts. One domino recipient underwent successful angioplasty
of the hepatic venous anastamosis; there were no other complications
noted related to the domino procedure in either donor or recipient.
Conclusion: The selected use of explanted livers from MSUD patients
undergoing LT results in excellent outcomes and additional utility of a scarce
resource. Technical considerations include the consideration of veno-venous
bypass and/or reconstruction of the cava to facilitate anastamosis.

A.W. Avolio1, R. Barbarino1, M. Siciliano1, R. Gaspari2, V. Perilli2,
S. Agnes1
1
Dpt of Surgery – Transplantation Service, Catholic University of Rome,
Rome, Italy, 2Dpt of Anaesthesiology and Intensive Care Unit, Catholic
University of Rome, Rome, Italy
Body: Donor Risk Index (DRI) has been introduced to predict and quantify
post-transplant graft survival on the basis of donor data. However, also
recipient conditions strongly influence graft survival. Since the MELD has
been recognized as the best method to score liver disease in liver transplant
candidates, its prognostic significance has been taken in consideration also for
the evaluation of the post-transplant graft survival.
Patients Methods: In order investigate the role of both DRI and MELD in
predicting 4 year graft survival (4yGS), we retrospectively analyzed the Organ
Procurement Transplantation Network (OPTN) database relative to 16. 877
cases in the MELD era. Patients with hepatocarcinoma and re-transplants were
not included.
Results: Our results confirm those reported in the literature on 3yGS (DRI >
2: 4yGS=61%; DRI 1. 8-2. 0: 4yGS=64%; DRI 1. 6-1. 8: 4yGS=69%; DRI
1. 4-1. 6: 4yGS=73%; DRI 1. 2-1. 4: 4yGS=78%; DRI <1. 2: 4yGS=84%)
demonstrating a significant difference between classes (Log-rank, p<0. 01).
All cases were also stratified in 5 MELD classes: MELD 7-12 (N=2087);
MELD 13-15 (N=2388); MELD 16-25 (N=8443); MELD 26-39 (N=3695);
MELD > 39 (N=1264); Log-rank between classes: p<0. 01. For cases with
MELD < 16 the discrimination power of DRI was week, while for cases with
MELD 16, DRI put in evidence significant differences in graft survival. In
other words, patients in the MELD class 16-25 receiving organs with DRI > 2
achieved 66% 4yGS, while patients in the MELD class > 39 receiving organs
with the same DRI (> 2) achieved a 4yGS lower than 50%.
Discussion: Our analysis of 16. 877 OPTN cases demonstrates that to improve
overall graft survival we should take in consideration the combination of DRI
and MELD. In particular, high DRI organs should not be transplanted in high
MELD score patients.

443 THE APPLICATION OF MELD SCORE IN PATIENTS
SUBMITTED TO LIVER TRANSPLANTATION – A
RETROSPECTIVE ANALYSIS OF SURVIVAL AND THE
PREDICTIVE FACTORS IN THE SHORT AND LONG TERM.
I. Boin, R. Stucchi, M. Leonardi, J. Almeida, T. Seva-Pereira, E. Udo,
I. Pereira, C. Portugal, A. Cardoso, C. Caruy
Unit of Liver Transplantation – Unicamp
Introduction: – The model for end-stage liver disease (MELD) was developed
to predict short-term mortality in patients with cirrhosis. There are few reports
studying the correlation between meld and long-term posttransplantation survival.
Aim: The aim was to assess the value of pretransplant MELD in the prediction
of posttransplant survival.
Methods: -The adult patients (age > 18 years) who underwent liver
transplantation were examined in a retrospective longitudinal cohort of
patients, through the prospective data base. We excluded acute liver failure,
retransplantation and reduced or split-livers. The liver donors were evaluated
according to: age, sex, weight, orotracheal intubation time (tracheal-i),
creatinine, bilirubin, sodium, aspartate aminotransferase, personal antecedents,
brain death cause, steatosis, expanded criteria donor number and index donor
risk (IDR – Feng et al. , 2006). The recipients’ data were: sex, age, weight,
chronic hepatic disease, Child-Turcotte-Pugh (CTP) points, pretransplant
and initial MELD score, pre and posttransplant creatinine clearance, sodium,
cold and warm ischemia times, hospital length of stay, surgical time, blood
requirements, and alanine aminotransferase (ALT > 1, 000UI/l = liver
dysfunction). The Kaplan-Meier method with the log-rank test was used for the
univariable analyses of posttransplant patient survival. For the multivariable
analyses the Cox proportional hazard regression method with the stepwise
procedure was used with stratifying sodium and MELD as variables. ROC
curve was used to define AUC for MELD and CTP.
Results: A total of 232 patients with ten years follow up were analised. Overall
survival rate was 62. 3%, 47. 7% and 40% respectively for one, five and 10
years. The MELD cutoff was 20 and CTP cutoff was 11. 5. For MELD score
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G. Mazariegos1, A. Khanna2, H. Morton3, K. Strauss3, L. Cropcho4,
K. Gibson5, Z. Machaidze1, K. Soltys1, G. Bond1, R. Sindhi1
1
Hillman Center for Pediatric Transplantation, Children’s Hospital of
Pittsburgh of UPMC, Pittsburgh, PA, United States, 2University of California
San Diego, San Diego, CA, United States, 3The Clinic for Special Children,
Strasburg, PA, United States, 4Clinical Chemistry, University of Pittsburgh,
Pittsburgh, PA, United States, 5Medical Genetics, University of Pittsburgh,
Pittsburgh, PA, United States
Background: Classic MSUD has been treated successfully by LT. Extrahepatic expression of branched-chain (BC) keto acid dehydrogenase complex
in non-MSUD patients allows for the consideration of domino LT of MSUD
livers into these recipients.
Aim: Data from MSUD patients whose livers were domino transplanted were
analyzed to develop guidelines for consideration of MSUD livers for domino LT.
Results: 5 patients underwent LT for MSUD and had their livers transplanted into
5 non-MSUD patients. Demographic and outcome data are presented in Table 1.
Table 1.

442 OPTN DATABASE ANALYSIS SUGGESTS THAT THE USE
OF DRI AND MELD AS INSTRUMENTS TO OPTIMIZE THE
DONOR-RECIPIENT MATCH IN LIVER TRANSPLANTATION
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> 20, the risk factors for death were: red cell requirements, liver dysfunction
and donor’s sodium. For the patients with hyponatremia the risk factors
were: negative delta-MELD score, red cell requirements, liver dysfunction,
tracheal-i, and donor’s sodium. The regression univariated analyses came up
with the following risk factors for death: female sex, warm ischemia time, ICU
time, score MELD >25, glycemia, blood requirements, tracheal-i, recipient
creatinine clearance pre and posttransplant and age donor >50. After stepwise
analyses, only red cell requirement was predictive. Patients with MELD
score < 25 had a 68. 86%, 50, 44% and 41, 50% chance for one, five and
ten-year survival and > 25 were 39. 13%, 29. 81% and 22. 36% respectively.
Patients without hyponatremia were 65. 16%, 50. 28% and 41, 98% and with
hyponatremia 44. 44%, 34. 28% and 28. 57% respectively. Patients with IDR
> 1. 7 showed 53. 7%, 27. 71% and 13. 85% and IDR < 1. 7 was 63. 62%, 51.
4% and 44. 08% respectively. Age donor > 50 years showed 38. 4%, 26. 21%
and 13. 1% and age donor < 50 years showed 65. 58%, 26. 21% and 13. 1%.
Association with delta-MELD score did not show any significant difference.
Expanded criteria donors were associated with primary non-function and
severe liver dysfunction. Predictive factors for death were blood requirements,
hyponatremia, liver dysfunction and donor’s sodium.
Conclusion: MELD over 25, recipient’s hyponatremia, massive blood
requirements and high donor’s sodium were associated with poor survival.
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CONCURRENT ORAL SESSION 33: EVEROLIMUS AND
SIROLIMUS IN RENAL TRANSPLANTATION
444 A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE
THE SAFETY AND EFFICACY OF TWO DIFFERENT
SIROLIMUS (SRL) REGIMENS WITH TACROLIMUS (TAC) +
MYCOPHENOLATE MOFETIL (MMF) IN DE NOVO RENAL
ALLOGRAFT RECIPIENTS: PRELIMINARY 2-YEAR SAFETY
RESULTS FROM THE ORION TRIAL
S. Flechner1, S. Cockfield2, J. Grinyo3, G. Russ4, K.M. Wissing5,
C. Legendre6, J.B. Copley, for the ORION Trial Investigators7
1
Cleveland Clinic Foundation, Cleveland, OH, 2University of Alberta,
Edmonton, Alberta, 3Hospital Bellvitge, Barcelona, Spain, 4Queen Elizabeth
Hospital, Woodville South, Australia, 5Hôpital Erasme, Brussels, Belgium,
6
Hôpital Necker, Paris, France, 7Wyeth Pharmaceuticals, Collegeville, PA
Purpose: Compare the safety of 2 SRL regimens with TAC + MMF in renal
transplant recipients.
Methods: This open-label, randomized, multinational study enrolled 451
renal transplant recipients. Group 1: SRL (8-15 ng/mL, 12-20 ng/mL after
week 13) + TAC (6-15 ng/mL) with elimination at week 13 (n=155); Group
2: SRL (10-15 ng/mL through week 26, 8-15 ng/mL thereafter) + MMF (up
to 2 gm/day) (n=155); or Group 3: TAC (8-15 ng/mL through week 26, 5-15
ng/mL thereafter) + MMF (up to 2 gm/day) (n=141). All patients received
corticosteroids and daclizumab. Because of increased acute rejection rates,
Group 2 was terminated in June 2006 (after all patients were accrued). Offtherapy adverse events were collected for 1 month in all subjects after offtherapy date and after group 2 termination.
Results: At 2 years, investigator-reported AEs that were more frequent in
Group 1 included abnormal liver function tests, acne, generalized edema,
hyperkalemia, and proteinuria. In Group 2, these AEs were delayed wound
healing, hyperlipidemia, and thrombocytopenia. In Group 3, dysuria,
nervousness, sweating, and tremor were reported more frequently. Serum
potassium levels were significantly higher in Group 3 through most of the
study. Incidence of malignancies and anemia were similar among groups.
Group 11
Group 21
Group 31
Overall
(SRL+TAC- (SRL+MMF) (TAC+MMF) p-Value
Elim)
Anemia, 63/155
(%)
(40. 6)

73/155
(47. 1)

50/141
(35. 5)

0. 126

Erythropoietin use, 55/155 (35. 5)
2 (%)

64/155 (41. 3)

36/141 (25. 5)

0. 015

Delayed wound
healing, (%)

26/155 (16. 8)

39/155 (25. 2)

8/141 (5. 7)

<0. 001

Hyperkalemia, (%) 37/155 (23. 9)

18/155 (11. 6)

24/141 (17. 0)

0. 017

Hyperlipidemia,
(%)

64/155 (41. 3)

30/141 (21. 3)

<0. 001

156

55/155 (35. 5)

Lipid lowering
medication use,
2 (%)

94/155 (60. 6)

90/155 (58. 1)

69/141 (48. 9)

0. 106

Lymphoceles, (%)

23/155 (14. 8)

22/155 (14. 2)

11/141 (7. 8)

0. 121

All malignancies,
3 (%)

7/155 (4. 5)

3/155 (1. 9)

4/141 (2. 8)

0. 435

Median UPr/Cr
(range), n4

0. 21
0. 14
(0. 04-1. 78), (44) (0. 02-2. 10), (4)

0. 13
0. 037
(0. 00-1. 33), (59)

Tremor, (%)
34/155 (21. 9)
12/155 (7. 7)
34/141 (24. 1)
<0. 001
Collected for 2 years in groups 1 and 3; to time of study termination in group 2.
Concomitant, not prior to study enrollment; cumulative to completion or subject discontinuation
3
Collected for 2 years in all groups. 42-year data
1
2

Conclusion: Overall, SRL immunotherapy appears safe and well tolerated,
with a safety profile similar to TAC+MMF. In patients receiving SRL+MMF,
delayed wound healing and hyperlipidemia were more frequent. Tremor was
more frequent in the TAC-MMF group, which also had higher levels of serum
potassium. While proteinuria was significantly greater in Group 1, it was
minimal in all groups.

445 CARDIOVASCULAR RISK PROFILE OF RENAL
TRANSPLANT RECIPIENTS ENROLLED IN AN OPENLABEL, RANDOMIZED STUDY COMPARING 2 SIROLIMUS
(SRL) REGIMENS WITH A TACROLIMUS (TAC) +
MYCOPHENOLATE REGIMEN (MMF): PRELIMINARY
RESULTS FROM THE ORION TRIAL
G. Russ1, S.M. Flechner2, S. Cockfield3, J. Grinyo4, K.M. Wissing5,
C. Legendre6, J.B. Copley, for the ORION Trial Investigators7
1
Queen Elizabeth Hospital, Woodville South, Australia, 2Cleveland Clinic
Foundation, Cleveland, OH, 3University of Alberta, Edmonton, Alberta,
4
Hospital Bellvitge, Barcelona, Spain, 5Hopital Erasme, Brussels, Belgium,
6
Hôpital Necker, Paris, France, 7Wyeth Research, Collegeville, PA
Purpose: We analyzed cardiovascular (CV) risk factors in renal transplant
patients receiving 2 SRL regimens versus TAC+MMF.
Methods: 451 patients were randomly assigned to receive SRL (8-15 ng/mL,
then 12-20 ng/mL after week 13) + TAC (6-15 ng/mL) with elimination at
week 13 (n=155); SRL (10-15 ng/mL, 8-15 ng/mL after week 26) + MMF
(up to 2 gm/day) (n=155); or TAC (8-15 ng/mL, 5-15 ng/mL after week 26)
+ MMF (up to 2 gm/day) (n=141). All patients received corticosteroids and
daclizumab. SRL+MMF group was terminated in June 2006 (after all patients
were accrued) due to higher rates of acute rejection.
Results: The table shows 18-month on-therapy blood pressure, laboratory, and
ESA data. Blood pressure and use of antihypertensive medications were similar
among groups. Total cholesterol and triglycerides were significantly higher in
both SRL groups; LDL cholesterol was significantly higher in SRL+TAC-Elim
group; HDL cholesterol and use of lipid-lowering medications were similar
among groups. Hemoglobin differences were not clinically significant between
groups. New-onset diabetes mellitus was significantly higher in SRL+TACElim group (p<0. 001 vs SRL+MMF; p<0. 05 vs TAC+MMF). Of note, 21/120
patients in SRL+TAC-Elim group were receiving TAC at time of onset of
diabetes. Proteinuria, although significantly higher in SRL+TAC-Elim group,
was minimal in all groups.
SRL+TAC-Elim

SRL+MMF

TAC+MMF

Mean systolic BP,
mmHg (n)

134. 5 (64)

132. 9 (52)

134. 2 (94)

Mean diastolic BP,
mmHg (n)

78. 4 (64)

75. 7 (52)

79. 0 (94)

Antihypertensive agents, 136 (87. 7)
1 n (%)

133 (85. 8)

126 (89. 4)

Mean total cholesterol,
mg/dL (n)

213. 1 (52)**

188. 0 (86)

Mean HDL cholesterol, 57. 9 (62)
mg/dL (n)

59. 1 (52)

54. 4 (80)

Mean LDL cholesterol,
mg/dL (n)

115. 1 (51)

101. 9 (80)

Mean triglycerides, mg/ 228. 3 (64)***
dL (n)

221. 2 (52)**

153. 1 (85)

Lipid-lowering agents,
1 n (%)

90 (58. 1)

69 (48. 9)

222. 0 (65)***

120. 5 (56)**

94 (60. 6)
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Mean hemoglobin, g/
dL (n)

13. 5 (65)

13. 0 (52)*

13. 7 (93)

ESA, n

6

7

3

New-onset diabetes
mellitus, 2

27/120*†

7/117

12/110

Median UPr/Cr (range) 0. 28 (0. 06-2. 60),
0. 20 (0. 04-1. 15), (47) 0. 15 (0. 00-1. 21), (58)
(n)
(44)**
1
Concomitant, not prior to study enrollment; cumulative to completion or subject discontinuation
2
Defined: >30 days on oral hypoglycemic agents, insulin, or their combination and no pre-existing
diabetes; data cutoff in June 2006.
*p<0. 05, **p<0. 01, ***p<0. 001 vs TAC+MMF; †p<0. 001 vs SRL+MMF.

Conclusion: CV risk profile at 18 months varies among groups. Lipids were
adversely affected by SRL use. New-onset diabetes mellitus was more common
when SRL was combined with TAC; and numerically lowest with SRL+MMF.
Whether anti-atherogenic properties of SRL offset adverse effects on lipid
panels remains to be studied.

446 A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE
THE SAFETY AND EFFICACY OF CYCLOSPORINE (CSA)
DOSE REDUCTION WITH CSA ELIMINATION IN DE NOVO
RENAL ALLOGRAFT PATIENTS RECEIVING SIROLIMUS

Group I (SRL+CsA
minimization)

Group II (SRL+CsA
elimination)

p-Value

Nankivell GFR, on
therapy, mL/min (n)

61. 1 (71)

65. 2 (65)

0. 132

Nankivell GFR, ITT, *
mL/min (n)

49. 5 (105)

51. 6 (102)

0. 603

Serum creatinine, ITT,
μmol/L (n)

146. 2 (87)

148. 3 (86)

0. 831

BCAR, ITT, n (%)

15/105 (14. 3)

23/102 (22. 5)

0. 152

Graft survival, including 92/105 (87. 6)
death, n (%)

90/102 (88. 2)

1. 000

Patient survival, n (%)

94/102 (92. 2)

0. 632

17/102 (16. 7)

0. 562

94/105 (89. 5)

Delayed graft function, 14/105 (13. 3)
n (%)
*GFR=0 for graft loss, death, or missing values

447 EXPOSURE TO EVEROLIMUS, AND NOT TO
CYCLOSPORINE, IS ASSOCIATED WITH FREEDOM FROM
ACUTE REJECTION IN DE NOVO RENAL RECIPIENTS
G. Corbetta1, M. Salvadori2, M.P. Scolari3, F. Citterio4, P. Rigotti5, M. Cossu6,
A. Dal Canton7, G. Tisone8, D. Bonucchi9, F. Pisani10, G. Gubbiotti11,
G. Piredda12, E. Minetti13, V. Sparacino14, V. Goepel15, P. Messa16,
P.B. Berloco17, D. Montanaro18, P. Veroux19, S. Federico20 and M. Bartezaghi1.
1
Novartis Farma SpA, Origgio (Va); 2Careggi Policlinico Hospital, Florence;
3
S. Orsola-Malpighi University Hospital, Bologna; 4A. Gemelli University
Hospital, Rome; 5Policlinico University Hospital, Padua; 6SS Annunziata
Civile Hospital, Sassari; 7IRCCS Policlinico S. Matteo University Hospital,
Pavia; 8Tor Vergata University, Rome; 9Policlinico University Hospital,
Modena; 10S. Salvatore Civile Hospital, Coppito (Aq); 11S. Maria della
Misericordia Hospital, Perugia; 12S. Michele Hospital, Cagliari; 13Niguarda
Cà Granda Hospital, Milano; 14Civico Hospital, Palermo; 15S. Bortolo
Hospital, Vicenza; 16IRCCS Fondazione Policlinico Hospital, Milano;
17
Policlinico Umberto I University Hospital, Rome; 18S. Maria della
Misericordia Hospital, Udine; 19Policlinico University Hospital, Catania;
20
Federico II University Hospital, Naples.
Background: Concentration-controlled everolimus (EVRL) is highly effective
in preventing acute rejection (AR) after renal transplantation (Rtx) when
used in combination with reduced-exposure cyclosporine (CsA). Previous
analyses showed that low EVRL trough blood levels (BL) correlate with
the risk of AR, and a C0 of 3ng/mL (HPLC) was identified as the lower
therapeutic limit for EVRL when used with conventionally dosed CsA. Since
reduced calcineurin inhibitor (CNI) exposure may provide long-term clinical
benefits, the EVEREST (the upper target EVErolimus RandomizEd STudy)
trial investigated whether concentration-controlled EVRL targeting ‘upper’
BL (8–12ng/mL) allows a further reduction in CsA exposure without loss of
efficacy. The present analysis examined how EVRL and CsA BL affect the risk
of biopsy-proven AR (BPAR).
Methods: A 6-month, multicenter, randomized, parallel-group study in Rtx
patients (n=285) compared two immunosuppressive regimens: A) upper EVRL
(C0 8–12ng/mL) with very low-dose CsA (C2 600ng/mL, tapered to 300ng/mL
at M3); B) standard EVRL (C0 3–8ng/mL) with low-dose CsA (C2 600ng/mL,
tapered to 500ng/mL at M3). All centers determined EVRL C0 locally with the
FPIA immunoassay (Seradyn). A hazard model with time-dependent covariates
was used to conduct a survival analysis examining the influence of EVRL and
CsA BL on the risk of BPAR. Hazard rates (HR) for BPAR were determined
for several combinations of EVRL C0 and CsA C2 at four time points (D8,
D14, M1 and M3).
Results: Actual mean drug BL changed with time (EVRL from 6. 1 to 8. 2ng/
mL; CsA from 734 to 511ng/mL; see Table 1). The overall proportion of BPAR
(Kaplan-Meier) increased from 0. 03 at D8 to 0. 11 at M3. At M1 and M3 there
was a statistically significant correlation between a low EVRL C0 and increased
risk of BPAR (p<0. 05). On the other hand, there was no significant correlation
between CsA C2 levels and BPAR (p=NS). At M1, the simulation showed that
the risk of BPAR would significantly decrease if EVRL C0 was increased by
50% (HR 0. 31, p<0. 05) and increase if it were reduced by 25% (HR 1. 79,
p<0. 05). However, decreasing the CsA exposure by 25% would not change the
risk of BPAR (HR 1. 07, p=NS). A similar pattern was evident at M3.
Conclusions: Targeting an EVRL C0 between 8 and 12 ng/mL (FPIA) would
allow CsA C2 levels to be reduced even further, without compromising efficacy
and safety in de novo renal transplant recipients. Further studies are needed
to investigate if this approach of early and marked CsA minimization may
translate into improved long-term renal function.
Table 1. Hazard rates (HR) for BPAR in relation to EVRL (C0) and CsA (C2)
exposure.
Mean BL (ng/mL)

D8

Calculated HR for
BPAR

EVRL
C0

CsA C2

Overall
BPAR
rate

Increase Increase Decrease Decrease
EVRL
CsA by EVRL
CsA by
by 50% 50%
by 25% 25%

6. 1

734

0. 03

0. 71
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H. Tedesco-Silva1, J.M. Pestana1, F. Alfieri2, S. See-Tai3, for the Brazilian
Rapamune Study Group
1
Hospital do Rim e Hipertensão, São Paulo, Brazil, 2Wyeth Brazil, São Paulo,
Brazil, 3Wyeth Research, Collegeville, PA, USA
Purpose: The safety and efficacy of concentration-controlled sirolimus (SRL)
combined with reduced cyclosporine (CsA) exposure or CsA elimination at 3
months was compared.
Methods: This phase 4, open-label trial enrolled 207 patients at 9 centers in
Brazil between March 2004 and November 2005. Renal transplant recipients
were randomly assigned (1: 1) after transplantation to Group I: SRL (8-12 ng/
mL) + CsA minimization (125-250 ng/mL weeks 1-12, 50-100 ng/mL weeks
13-21, then 50-75 ng/mL thereafter); or Group II: SRL (8-12 ng/mL weeks 1-12,
12-20 ng/mL weeks 13-21, then 10-20 ng/mL thereafter) + CsA elimination
(125-250 ng/mL weeks 1-12, then 25% taper/week beginning at week 13).
All patients received corticosteroids. Antibody induction was permitted. The
primary endpoint was renal function at 12 months.
Results: Demographic characteristics were similar between groups. A similar
percentage of patients received living donor kidneys (70% Group I, 69% Group
II) and antibody induction (9. 5% Group I, 12. 7% Group II). The incidence of
delayed graft function was not significantly different between groups. At 12
months, renal function was similar between groups. Slope analysis of Nankivell
GFR (day 5 to month 12) showed improvement in both groups, with a higher
mean annual GFR change in Group II (12. 96 mL/min/yr) versus Group I (6.
74 mL/min/yr); the difference between groups was not statistically significant
(p=0. 06). Rates of biopsy-confirmed acute rejection (BCAR) at 3 months were
12. 4% in Group I versus 16. 7% in Group II (p=0. 43), and 14. 3% versus 22.
5% at 12 months (p=0. 152). Patient and graft survival were not significantly
different (ITT) between groups at 12 months. Patient discontinuation was
similar between Groups I and II (32. 4% and 36. 3%, respectively), although
more Group II patients discontinued because of lack of efficacy/graft loss (4.
8% vs 14. 7%, p=0. 018). Polycythemia and pneumonia were reported more
frequently in Group I, whereas abdominal pain and acne were more frequent
in Group II.

Conclusion: The comparative safety and efficacy of SRL immunotherapy
combined with low-dose CsA or CsA elimination was similar regarding renal
function, patient and graft survival, BCAR, and patient discontinuations from
treatment.
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D14

7. 0

679

0. 05

0. 55

0. 83

1. 35

1. 10

1-month GFR (mL/min) 58. 9±22. 2

56. 7±23. 2

NS

M1

8. 1

631

0. 07

0. 31*

0. 9

1. 79*

1. 07

6-month GFR (mL/min) 60. 0±16. 4

62. 3±15. 6

NS

M3

8. 2

511

0. 11

0. 44*

0. 74

1. 51*

1. 16
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448 TARGETING UPPER EVEROLIMUS BLOOD LEVELS
WITH VERY LOW-DOSE CYCLOSPORINE IS EFFECTIVE AND
SAFE IN DE NOVO RENAL TRANSPLANTATION
M. Salvadori1, M. Scolari2, E. Bertoni1, F. Citterio3, P. Rigotti4, M. Cossu5, A.
Dal Canton6, G. Tisone7, G. Cappelli8, F. Pisani9
1
Renal Unit Careggi University Hospital, 2S. Orsola-Malpighi University
Hospital, Bologna, 3A. Gemelli University Hospital, Rome, 4Policlinico
University Hospital, Padua, 5SS Annunziata Civile Hospital, Sassari, 6IRCCS
Policlinico S. Matteo University Hospital, Pavia, 7Tor Vergata University,
Rome, 8Policlinico University Hospital, Modena, 9S. Salvatore Civile
Hospital, Coppito (Aq)
Background: Everolimus (EVRL), a proliferation signal inhibitor, is highly
effective in preventing acute rejection (AR) after renal transplantation (Rtx)
and allows calcineurin inhibitor (CNI) reduction without loss of efficacy. In
patients treated with standard EVRL and low-dose cyclosporine (CsA), higher
trough EVRL blood levels (C0) were associated with a reduced risk of AR.
The lower therapeutic concentration limit for EVRL was set at 3ng/mL. No
dose-limiting toxicities were observed up to the highest C0 of 15ng/mL. The
EVEREST (the upper target EVErolimus RandomizEd STudy) trial investigated
whether increased EVRL exposure targeting upper EVRL C0 (8–12ng/mL), in
combination with a further reduction in CsA exposure, would maintain efficacy
for prevention of AR whilst improving renal function.
Methods: In a 6-month, prospective, randomized, multicentre, open-label trial,
de novo Rtx patients (Table 1) received either (1) upper EVRL blood levels
(8–12ng/mL) plus very low-dose CsA (C2 600ng/mL, tapered to 250ng/mL
by M6) or (2) standard EVRL (C0 3–8ng/mL) with low-dose CsA (C2 600ng/
mL, tapered to 400ng/mL by M6). All patients received basiliximab (20mg i.
v. D0, D4) and low-dose steroids. Primary endpoints were biopsy-proven acute
rejection (BPAR) and 6-month renal function (GFR, Nankivell). EVRL blood
levels were measured locally with Seradyn® immunoassay (FPIA).
Results: In the upper EVRL group there was a significantly reduced rate of
graft loss compared to standard EVRL, with both regimens having a low
rate of BPAR and excellent renal function (p=NS) as early as 1 month after
transplantation (Table 2). There were no significant differences between
groups regarding main adverse events (including hyperlipidemia, leucopenia
or infections), biochemical parameters or vital signs.
Table 1: Patient characteristics
No. of patients

Upper EVRL

Standard EVRL

142

143

Recipient age (years)

45. 4±12

45. 8±11

Deceased donor (%)

97. 2

97. 9

Donor age (years)

43. 8±14

44. 6±13

Mean PRA (%)

1. 6±6. 5

2. 1±7. 2

Mean no. of HLA mismatches

3. 4±1. 2

3. 5±1. 2

Cold ischemia time

13. 8±4. 9

14. 5±4. 7

Table 2: 6-month results

Conclusions: In de novo Rtx patients, increased EVRL C0 (8–12ng/mL)
combined with early reduction to very low-dose CsA was associated with a
reduced risk of graft loss in comparison with the control group. Both groups
had a low rate of BPAR and excellent renal function. Concentration-controlled
EVRL targeting a higher trough level (8–12ng/mL by FPIA) allows a marked
early reduction in CNI exposure without loss of efficacy, which may provide
long-term clinical benefits through further minimization of CNI side effects.

449 A PHASE II RANDOMIZED PHARMACOKINETIC
(PK) STUDY OF TACROLIMUS (TAC)-EVEROLIMUS (EVL)
COMBINATION FOR KIDNEY TRANSPLANTATION (KT)
D. Del Castillo1, J. Pascual2, M. Cabello3, L. Pallardó4, J.M. Grinyó5,
A.M. Fernández2, M. Brunet6
1
Servicio de Nefrología, Hospital Reina Sofía, 2Hospital Ramón y Cajal, 3Hospital
Carlos Haya, 4Hospital Dr Peset, 5Hospital de Bellvitge, 6Hospital Clínic
Tac-sirolimus combination in KT yields worse results than Tac-MMF.
However, the antiproliferative and antifibrotic effects of mTOR inhibitors
are promising in prevention of chronic allograft damage, and new strategies
for early use are justified. The combination Tac-EVL is attractive but
scarcely developed to date. An investigator driven phase II PK study was
done in 5 Spanish centers randomly comparing two fixed EVL dosages (0.
75 vs 1. 5 mg bid) in combination with Tac (0. 075 mg/kg bid for trough
levels 10-15 two weeks and then 5-10 ng/ml). No antibody induction was
allowed and all patients received steroid therapy. Complete 12-h PK curves
of both drugs (HPLC) were performed at days 4, 14 and 42 post-KT. After
day 42, EVL trough levels were adjusted at 3-8 and Tac at 5-8 ng/ml.
Thirty-five patients were randomized; in 34 (17 vs 17) full PK curve was
performed at day 4, in 27 (13 vs 14) at day 14 and in 26 (15 vs 11) at day
42. Doses, trough and maximal levels (Cmin, Cmax) and area under the
curve (AUC) are summarized [*significantly higher 1. 5 vs 3 EVL dose
groups, p<0. 01]
DAY 4
EVL
Daily
Dose
(mg)

1. 5

3

1. 5

3

1. 5

DAY 14 DAY 42

3

Tac Daily
Dose (mg)

12

12

10

12. 5

6

9

EVL Cmin
(ng/ml)

1. 1

1. 7*

1. 9

2. 6*

2. 4

3. 2

EVL Cmax
(ng/ml)

4. 1

10. 1*

6

13. 4*

5. 9

12. 4*

EVL AUC
(ng x h/ml)

26. 5

40. 9*

30. 3

49. 9*

36. 3

57. 2*

Tac Cmin
(ng/ml)

10. 6

8. 1

11. 4

10. 1

11. 4

10. 1

Tac Cmax
(ng/ml)

32. 9

36. 6

27. 4

36

26. 4

25. 9

Upper EVRL

Standard EVRL

P

Tac AUC (ng 192. 2
x h/ml)

154. 2

159. 4

214. 3

159. 6

177. 6

Delayed graft function
requiring dialysis (%)

23. 2

30. 8

NS

Tac AUC/
dose

12. 8

15. 9

17. 1

26. 6

19. 7

Probability of patient
survival (%)

98. 6

98. 6

NS

Probability of graft
survival (death
censored) (%)

97. 9

90. 2

<0. 05

Probability of graft
survival (not censored
for death) (%)

96. 5

88. 8

<0. 01

Probability of BPAR
(%)

11. 9

14. 7

NS

Steroid-resistant AR (%) 2. 1

6. 3

NS

BPAR ≥Grade II (%)

7. 7

0. 07

21. 0

NS

2. 8

Probability of treatment
failure (death, graft loss, 14. 8
BPAR, LFUP)

158

16. 0

Treated acute rejection rate was 17% (3 cases with each dosage), wound
healing was uneventful in 100% and linfocele was diagnosed in 2 cases (6%).
Including all PK points, a higher Tac Cmin was observed with the low EVL
dose of 1. 5 mg/d (Tac 11. 16. 4 with EVL 1. 5 vs 9. 45. 0 ng/ml with EVL 3,
p=0. 03), with equivalent Tac AUCs (16261 vs 17175, p=0. 70). EVL Cmin,
Cmax and AUC were very low with the initial dose of 0. 75 mg bid when
combined with Tac. The EVL 1. 5 mg bid seems to be the minimal initial
advisable dose for phase III trials. This dose is low to achieve >3 ng/ml during
the first 2 weeks, thus therapeutic drug monitoring is necessary to adjust it
after day 4th, especially in Tac-minimization regimens. This low exposure
EVL plus normal exposure Tac allowed 0% wound healing problems with
good efficacy. For Tac-minimization strategies, everolimus dosages above 3
mg/day are needed.
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450 COMPARISON AT ONE YEAR OF INTERSTITIAL
FIBROSIS (IF) BY AUTOMATIC QUANTIFICATION IN RENAL
TRANSPLANT RECIPIENTS (RTR) WITH CYCLOSPORINE
(CSA) DISCONTINUATION AND SIROLIMUS (SRL)
INTRODUCTION

Intent to treatment
Sirolimus (n=58)
Cyclosporine (n = 59)
On treatment
Sirolimus (52)
Cyclosporine (n=56)

Mean IF (%)

Grade I (%)

Grade II (%)

Grade III (%)

27±15
27±15

47. 5%
44. 8%

45. 8%
48. 3%

6. 8%
6. 9%

26±15
27±15

50%
46%

44%
46%

6%
8%

451 THE INCIDENCE OF DELAYED GRAFT FUNCTION
(DGF) FOLLOWING KIDNEY TRANSPLANTATION IS NOT
AFFECTED BY DE NOVO EVEROLIMUS THERAPY
C. Legendre5, E. Cassuto1, L. Rostaing2, F. Berthoux3, M.C. Moal4,
F. di Giambatttista6, J. Dantal7
1
Hôpital Pasteur, 2Hôpital de Rangueil, 3Hôpital Nord – CHU, 4Hôpital La
Cavale Blanche, 5Hôpital Necker, 6Novartis Pharma SAS, 7Hôpital Hôtel Dieu
Introduction: The proliferation signal inhibitor (PSI) everolimus combines
effective immunosuppressive and anti-proliferative modes of action. The
early post-operative course of kidney transplant patients at risk of delayed
graft function (DGF) was evaluated with de novo everolimus versus delayed
everolimus after one month of mycophenolic acid (MPA).
Methods: We report a planned primary 3-month analysis from a multicenter,
open-label, 12-month study. Patients were de novo deceased-donor kidney
transplant recipients at protocol-specified risk of DGF, with one or more
of the following characteristics: donor age >55 years, cold ischemia time
≥24 hours and <40 hours, or second/subsequent transplant. Patients were
randomized to receive de novo (E) or delayed everolimus (DE) after 1 month
of MPA treatment. The target trough range for everolimus was 3-8ng/mL.
For E patients, everolimus was initiated ≤48 hours post-transplant, with lowexposure cyclosporine (CsA, C2 target: weeks 0-8, 500-700ng/mL; thereafter
350-450ng/mL). The DE group received de novo MPA with standard CsA (C2
target 1100-1500ng/mL); after 4 weeks, MPA was replaced by everolimus
and CsA target C2 range was reduced. All patients received anti-IL-2 receptor
induction and steroids.
Results: In total, 139 patients were enrolled (65 E, 74 DE). In the E and DE
groups, respectively, donor age was >55 years in 80. 0% and 90. 5%, cold

452 POST-TRANSPLANT PROTEINURIA INDUCED BY
EVEROLIMUS (E). DEFINITION OF MAIN FEATURES BASED
ON COMBINED PATHOLOGY AND PROTEOMICS APPROACH.
E. Bertoni1, A. Larti1, L. Musante2, G.M. Ghiggeri2, R. Gusmano2,
M. Salvadori1
1
Renal Unit Careggi University Hospital, 2Laboratory on Pthophysiology of
Uremia Gaslini Hospital
Little is known on the mechanism (s) of proteinuria linked to everolimus
(E) and reports on the clinical outcome are limited. Aim of this study was to
characterize the E induced proteinuria and to verify whether proteinuria was
linked to apoptosis of renal cells.
We report clinical, pathology and laboratory features of 24 recipients of renal
Tx who were treated with E as first line drug and were followed for at least 6
months without changes of the therapy (median follow-up 8 months). Urinary
proteins were characterized by an integrated proteomics approach (quantitative
assays, two-dimensional electrophoresis, MALDI-TOFF, western blot).
Detection of renal cells apoptosis was performed by analysis of renal biopsies
with caspase 3 antibodies.
All but 3 recipients presented rapid normalization of renal function; 2 patients
were treated with steroid boluses because of acute rejection. After 6 months
renal function was normal in all. Proteinuria developed in all but 2 patients,
in concomitance with the recovery of renal function and persisted over
time. After 6 months, 4 patients still presented massive proteinuria (>3 g/24
hours), while the remaining 18 patients had intermediate levels (0. 5-2 g/24
hours). Composition of proteinuria was characterized by 2D-electrophoresis
and MALDI-TOFF spectrometry. A mixed tubular-glomerular pattern of
proteinuria was found in both high and low proteinuric patients with presence
of albumin, IgG, beta1 macroglobulin, alfa1 macroglobulin and free lambda
chains. All urines were also characterized by the presence of anti protease
inhibitors such as alfa 1 antitrypsin and alfa1 chimotripsin and by products of
tubular degradation never identified in other tubular diseases. Finally nephrotic
urines didn’t contain fragments of albumin and alfa 1 antitrypsin that are
normal urinary components in other nephrotic states. Analysis of renal biopsies
showed variable degrees of tubular apoptosis. Glomerular staining was limited
to cases with highest proteinuria.
E induces sudden increase of proteinuria of mixed glomerular and tubular
origin that reaches in some cases a nephrotic range and persists over time.
Composition of urinary proteins reflects structural changes characterized by
diffuse apoptosis of tubular epithelia and, more limited, of podocytes.
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E. Thervet1, A. Servais1, V. Meas-Yedid2, Y. Lebranchu3, I. Etienne4,
G. Touchard5, C. Legendre1, P.F. Westeel6, C. Olivo-Marin2
1
Department of Transplantation, Hopital Necker, 2Laboratoire analyse image
quantitative, Institut Pasteur, 3Service de Nephrologie, Hopital Bretonneau,
Tours, 4Service de Nephrologie, Hopital Bois Guillaume, Rouen, 5Service
de Nephrologie, Hopital Jean Bernard, Poitiers, 6Service de Nephrologie,
Hopital Sud, Amiens
Introduction: CsA conversion to SRL at week (W) 12 is associated with a
significant improvement in renal function. The aim of this study was to investigate
the effect of this conversion on interstitial fibrosis (IF), landmark of chronic
allograft nephropathy (CAN), in patients included in this prospective study.
Methods: The multicenter, prospective, randomized trial included 235 renal
recipients randomized at W12 to be switched from CsA to SRL (group A) or
to continue CsA (group B), in association with MMF. Routine allograft biopsy
(RB) was performed at W52 and a section imaged using a colour video camera
was analyzed by a program of colour segmentation image analysis which
automatically extract green colour areas characteristic of IF. Results were
expressed of% of IF and using Banff classification (grade I : <25%, grade II :
25-50% and grade III, > 50%).
Results: Despite significant improvement of renal function at W52, we
observed no difference on RB. On the other hand, there was a positive
correlation between renal function and the%IF on RB. HIgher than grade I IF
was diagnosed in more than 50% of patients.
Conclusion: Despite significant improvement in renal function after CsA
to SRL conversion at 3 months, we found no improvement of IF on RB at
W52. This may be due to a longer delay to observe histological improvement.
Improved renal function may be due to a hemodynamic effect. Finally, the
higher IF score than the one previously reported by others may be explained by
the use of expanded criteria donors. This urges the need for a better description
of the chronic lesion on RB.

ischemia time was ≥24 hours in 30. 8% and 33. 8%, and 10. 8% and 2. 7%
of patients had undergone one previous transplant. The primary endpoint (a
composite of biopsy-proven acute rejection [BPAR], graft loss, death, DGF
defined as 1 dialysis session during days 2-7 post-transplant, wound healing
events or lost to follow-up at month 3) occurred in 36 E patients (55. 4%) and
42 DE patients (56. 8%). There were 8 graft losses (5 E, 3 DE) and 6 deaths (4
E, 2 DE) by month 3. There was a similar rate of BPAR with E (10. 8%) or DE
(9. 5%). The incidence of DGF was also similar in the E and DE groups (24.
6% and 24. 3%, respectively). At month 3, creatinine clearance (CockcroftGault) was 43. 117. 6mL/min in the E group versus 41. 817. 0mL/min in the
DE group (n. s. ). Wound healing events occurred in 38. 5% E patients and 35.
1% DE patients, most of which were fluid collections (25/25 and 24/26 events
in E and DE patients, respectively). Prior to MPA discontinuation at week 4,
no significant differences in fluid collections were detected on ultrasound:
18/49 (36. 7%) E patients and 19/55 (34. 5%) DE patients. The incidence of
adverse events and infections was similar between groups at month 3. Study
drug was discontinued due to adverse events in 18. 5% E patients and 20. 3%
DE patients.
Conclusions: In kidney recipients at risk of DGF, the rate of DGF, and efficacy
and safety profiles at month 3, were similar between de novo versus delayed
initiation of everolimus after 1 month of MPA.
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453 SOLUBLE LYMPHOTOXIN PLAYS A CRITICAL ROLE IN
GRAFT-VERSUS-HOST DISEASE.

the CD154:CD40 pathway in B-cell activation. These sensitization-preventive
strategies also enhanced alloengraftment from same donor in sequential bone
marrow transplantation. Our findings may have important implications in the
design of immune-based therapies in management of immune memory induced
by alloantigen exposure or lymphopenia.

K. Markey1,2, A. Burman1, R. Kuns1, N. Raffelt1, E. Morris1, T. Banovic1,
H. Korner3, K. MacDonald1,2, G. Hill1,2
1Queensland Institute of Medical Research, 2The University of Queensland,
3Comparative Genomics Centre, James Cook University
TNF is a key cytokine in the effector phase of both graft-versus-host disease
(GVHD) and the graft-versus leukaemia (GVL) effect after bone marrow
transplantation (BMT). TNF neutralising antibodies are now established as
effective therapeutic adjuncts for the treatment of severe acute GVHD but are
not utilised for GVHD prophylaxis because of concern regarding leukaemic
relapse. TNF signals through the p55 and p75 TNF cell surface receptors
(TNFR), which also act as receptors for the soluble lymphotoxin homotrimer
(LTα3). The membrane-bound lymphotoxin heterotrimeric molecule (LTα1β2)
signals through the LTβ receptor. The function of these molecules in GVHD
remains unknown. Pharmacological agents are available which block either
TNF alone, or both TNF and LT and elucidating the roles of these molecules in
GVHD is essential for the design of rational therapeutic strategies.
We have employed well established preclinical models of GVHD to investigate
the roles of these molecules. We first utilised TNF-/- mice as donors and treated
recipients with a TNFR: Fc construct to neutralise both soluble TNF and LTα3
molecules post-transplant. The TNFR: Fc provided significant protection from
GVHD mortality in the absence of donor derived TNF (P<0. 0002). To examine
this further, we performed experiments using wild-type (WT), LTα-/- or LTβ
-/donor grafts. Recipients of LTα-/- grafts were protected from GVHD (P<0.
009) while LTβ-/- grafts induced GVHD equivalent to WT grafts. LTα was
generated primarily by donor CD4+ T cells after BMT as determined by realtime PCR. This data confirms soluble LTα3 but not membrane bound LTα1β
2
as a key pathogenic molecule in GVHD. Using this transplantation system
in the presence of luciferase-expressing, host-type leukaemia, we confirm that
GVL is maintained in the absence of soluble LTα3. Thus the neutralisation of
LTα3, in addition to TNF may represent an important therapeutic intervention
in transplant medicine.

454 CD154 BLOCKADE IMPAIRS GENERATION OF
CD8+ CD44HIGH/CD62LLOW/- EFFECTOR/MEMORY
T-CELLS INDUCED BY BOTH ALLOANTIGEN EXPOSURE
AND LYMPHOPENIA AND RESULTS IN PREVENTION OF
SENSITIZATION
M.J. Elliott, H. Xu, Y. Huang, L-R. Hussain, S. Ildstad,
Institute for Cellular Therapeutics, University of Louisville
Recipient sensitization to MHC alloantigens is among the most critical
challenges facing clinical transplantation. Effector/memory T cells (TEM)
are generated after exposure to alloantigens and identified as CD44high/
CD62Llow/−. T-cell depletion leads to lymphopenia-induced homeostatic
proliferation, driving naive T-cells to differentiate directly into memory T-cells.
These cells share not only the TEM phenotype but also function in allograft
rejection. We found that CD8+ TEM were detected in B6 mice (H2b) at 11
to 13 days after exposure to alloantigens by BALB/c (H2d) bone marrow cell
(BMC) infusion (Fig. A). The percentage of CD8+ TEM in the CD8+ cell gate
was significantly higher than in naïve mice (11.0 ± 1.6% vs. 2.7± 1.5%; P <
0.0001). Blockade of CD154 completely inhibited the generation of CD8+
TEM (3.1± 2.2%) and the level of CD8+ TEM was similar to naïve controls (P
= 0.59). When αβ-TCR+ T cells in B6 mice were depleted with anti-αβ-TCR
(day -3) and BMCs were infused (day 0), more CD8+ TEM (22.7 ± 10.8%,
P = 0.02) were detected at day +11 to +13 (Fig. B) compared with mice that
received BMC only (Fig. A). The level of CD8+ TEM in mice treated with
anti-αβ-TCR remained higher even 30 days after BMT (7.2 ± 1.0%). The levels
of CD8+ TEM were significantly lower in the mice treated with anti-αβ-TCR
plus anti-CD154 at day +11 to +13 (11.9 ± 8.1%, p = 0.04) or day +30 (2.6 ±
1.0%, p = 0.005; Fig. B) compared with CD8+ TEM in mice treated with antiαβ-TCR alone. These results suggest that the generation of CD8+ TEM T-cells
in the context of homeostatic proliferation and alloreactivity was decreased by
CD154 blockade. Moreover, the production of anti-donor-MHC antibody was
prevented in mice treated with anti-CD154 mAb, suggesting a specific role for
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455 SEGREGATION OF A GRAFT-VERSSUS-LEUKEMIA
EFFECT FROM GRAFT-VERSUS-HOST DISEASE BY THE
MODULATION OF DONOR CD8+ T CELL ACTIVITY
H.R. Cho1,2, B. Kwon2,3, J.S. Lee2,4, J. Kim2
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea,
3Deapartment of Biological Science, University of Ulsan, Ulsan, Ulsan,
Korea, 4Internal Medicine, Ulsan University Hospital, Ulsan, Ulsan, Korea
In the DBA/2unirradiated (C57BL/6 x DBA/2)F1 model of systemic lupus
erythematosus-like chronic graft-vs-host disease (cGVHD), donor CD4+ T
cells play a critical role in breaking host B cell tolerance, while donor CD8+
T cells are removed after transfer into the host and the remaining cells fall
into anergy. Previously we have demonstrated that in vivo ligation of GITR, a
costimulatory receptor, can activate donor CD8+ T cells, which subsequently
result in converting the disease pattern from cGVHD to an acute form (aGVHD).
In this study, we investigated the effect of an agonistic mAb against CD40
on cGVHD. Treatment of anti-CD40 mAb inhibited the production of antiDNA IgG1 autoantibody and the development of glomerulonephritis, typical
symptoms of cGVHD. The inhibition of cGVHD occurred because anti-CD40
mAb prevented donor CD8+ T cell anergy such that subsequently activated
donor CD8+ T cells deleted host cells including host CD4+ T cells and host B
cells involved in autoantibody production. In addition, functionally activated
donor CD8+ T cells induced full engraftment of donor hematopoietic cells and
exhibited an increased graft-vs-leukemia (GVL) effect. However, induction of
aGVHD by donor CD8+ T cells seemed to be not so apparent. Further CTL
analysis indicated that there were lower levels of donor CTL activity against
host cells in mice that received anti-CD40 mAb, compared with mice that
received anti-GITR mAb. Taken together, our results suggest that a different
intensity of donor CTL activity is required for removal of host hematopoietic
cells including leukemia vs induction of aGVHD. Therefore, it is possible to
segregate a GVL effect from GVHD by modulating the cytotoxic activity of
donor CD8+ T cells.
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ASSOCIATED TO A HIGH LEVEL OF CD45RC EXPRESSION:
THERAPEUTIC PROSPECTS FOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION

457 MECHANISM OF FC ACTION: FACILITATING
CELLS ENHANCE THE CLONOGENICITY OF HUMAN
HEMATOPOIETIC STEM CELLS IN VITRO
M.J. Elliott, T. Miller, F. Rezzoug, I. Fugier-Vivier, S. Ildstad
University of Louisville
CD8+/TCR- graft facilitating cells (FC) enhance engraftment of purified
hematopoietic stem cells (HSC) in allogeneic and syngeneic mouse recipients.
FC also enhance the clonogenicity of HSC in an in vitro assay for FC. The
majority of cells in the FC are tolerogenic precursor plasmacytoid dendritic
cells. In the present studies, we evaluated whether a similar FC exists in human
marrow. We recently developed a novel in vitro assay for FC function and found
that FC significantly enhance the clonogenicity and promote the generation of
more primitive multipotent HSC progenitors in vitro using a mouse model. The
CFC assay is used as an in vitro surrogate to enumerate primitive multipotent
HSC progenitors. In the present studies, we evaluated whether a similar FC
population exists in human bone marrow. CD34+ HSC were sorted from human
mobilized or vertebral bone marrow samples and placed in colony-forming cell
(CFC) assays in methylcellulose with or without FC immediately or after 18
hours of pre-incubation. Sorted CD8+ T cells were also incubated with HSC as
a control. Colonies were counted at day 14. Without preincubation, there was
no significant difference in the number of colonies generated by HSC alone
vs. HSC plus FC. Strikingly, when HSC were co-incubated with HSC for 18
hours prior to placement in the CFC assay, FC significantly enhanced colony
formation compared to HSC alone and HSC co-incubated with CD8+ T cells
(*P < 0. 005; Figure). These results suggest that FC exert a protective effect
on HSC and promote the generation of more primitive multipotent progenitors
from HSC. FC may therefore have a significant impact on initiatives to expand
and culture human HSC while maintaining their ability to retain their totipotent
“stem” properties.

458 REDUCED INTENSITY CONDITIONING FOR
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
DETERMINES THE KINETICS OF ACUTE GVHD
M. Kambouris1, B. Turner1, L. Sinfield1, J. Lange1, A-M. Burns1, R. Lourie2,
K. Atkinson1, D. Hart1, D. Munster1, A. Rice1
1
Mater Medical Research Institute, 2Mater Adult Hospital
Allogeneic haematopoietic stem cell transplant (HSCT) can be curative for
haematological and non-haematological malignancies but complications such
as graft versus host disease (GVHD) and transplant related mortality (TRM)
limit its widespread application. Preparative myeloablative conditioning
(MAC) controls malignancy and facilitates donor engraftment but contributes
to TRM by initiating cytokine release which drives acute GVHD. Reduced
intensity conditioning (RIC) regimens are replacing MAC. They attenuate
TRM and whilst GVHD onset is delayed, it is as severe and as frequent as
seen after MAC HSCT. There are currently no allogeneic murine models of
RIC HSCT limiting mechanistic studies. We developed murine models of
RIC-associated delayed-onset GVHD. In contrast to GVHD observed in
MAC HSCT recipients, we found that delayed-onset GVHD in RIC recipients
is characterised by low TNF-alpha production, “phenotypic activation” of
dendritic cells (DC), maintenance of functional host DC, increased regulatory
T cells (T-reg), functionally attenuated donor DC early post HSCT, rising TNFalpha and delayed emergence of activated donor DC which heralded GVHD
onset. The excess “activated” host DC that we observed after RIC might be
expected to drive earlier GVHD if they were found in a MAC HSCT setting, but
this was not the case. These findings underscore the fact that knowledge about
GVHD mechanisms gained in a MAC environment may not be applicable to the
RIC HSCT setting. Delineating the mechanism of delayed onset GVHD in RIC
HSCT recipients should generate opportunities to monitor and predict GVHD
in these transplant recipients, providing a window for early intervention.

459 PROPHYLACTIC INFUSION OF CMV SPECIFIC
CYTOTOXIC T-LYMPHOCYTES FOLLOWING ALLOGENEIC
HAEMOPOIETIC STEM CELL TRANSPLANTATION
E. Blyth1, K. Micklethwaite1, L. Clancy2, U. Sandher2, D. Gottlieb1,2,3
Westmead Millennium Institute, Westmead, Sydney, Australia, 2Sydney
Cellular Therapies Laboratory, Westmead Hospital, Sydney, Australia, 3Blood
and Marrow Transplant Service, Westmead Hospital, Westmead, Sydney,
Australia
Introduction: Cytomegalovirus (CMV) remains an important cause of nonrelapse morbidity and mortality in the setting of allogeneic haemopoietic stem
cell transplantation. Pharmacological treatments are associated with various
complications and treatment failure with CMV reactivation only adequately
controlled when immune reconstitution occurs. We report the results of a phase
I clinical trial of prophylactic infusion of CMV specific CD4+ and CD8+
T-lymphocytes generated by stimulation with adenovirus vector Ad5f35pp65
gene modified dendritic cells.
Methods: Cytotoxic CD4+ and CD8+ T-lymphocytes specific for the
immunodominant CMV pp65 antigen were generated by stimulation of donor
peripheral blood mononuclear cells with adenoviral vector AD5f35pp65 gene
modified dendritic cells. A cell dose of 2x107m2 was infused into 12 patients
on or after day 28 post allogeneic stem cell transplantation. The patients were
monitored for infusion safety and CMV reactivation, antiviral treatment,
graft versus host disease (GVHD), infection and disease relapse. They were
1
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L. Ordonez1, M. Chabod1, I. Bernard1, J. Damoiseau2, A. Saoudi1
1
INSERM U563, 2University Hospital of Maastricht
CD45 is a transmembrane phosphatase, which regulates the signaling in
immune cells. On T lymphocytes, it is expressed as different isoforms (such
as CD45RC, CD45RB, CD45RA, CD45RO) which result from alternative
splicing. In the rat, the level of expression of the CD45RC isoform divides
both CD4 and CD8 T lymphocytes into two subsets with different alloreactive
properties. The CD4 and CD8 CD45RChigh subsets contain alloreactive
effector lymphocytes, responsible for graft-versus-host disease (GvHD)
while the CD45RClow subsets regulate this disease. Studies in the rat have
established that the CD45RChigh/CD45RClow ratio among CD4 and CD8 T
cells varies according to the rat strain and is genetically controlled. A major
locus of control of CD45RC expression on CD4 and CD8 T cells has been
localized on rat chromosome 9, in a ~1 centiMorgan region which also controls
the susceptibility to various immune diseases.
The present study aims to investigate CD45RC T cell populations in humans
and to determine their alloreactive properties. We have shown that the level of
CD45RC expression on human peripheral blood T cells defines, as in the rat,
subsets of CD4 and CD8 T cells, which exhibit different cytokine profiles after
allogeneic stimulation. Particularly, we showed that under allogeneic stimulation
the majority of inflammatory cytokines are produced by CD45RChigh T cells.
In agreement with this result, SCID/beige mice humanized by human peripheral
blood leucocytes (PBL) enriched in CD45RChigh T cells succumbed to a
GvHD. By contrast mice injected with PBL enriched in CD45RClow T cells
remained healthy.
As the analysis of CD45RC expression on T cells subsets of 150 healthy donors
revealed a large heterogeneity between individuals, we hypothesize that the
CD45RChigh/CD45RClow ratio among T cells of donors could predict the
risk to develop a GvHD for the recipient. If so, further studies will look for
association between GvHD and polymorphisms of genes located within the
human syntenic region of the rat locus.
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compared with 54 historical controls who did not receive any form of adoptive
immunotherapy. Pre- and post-infusion CMV specific immune reconstitution
directed against pp65 CMV epitope was assessed by immunophenotype and
tetramer binding. Immune reconstitution to whole pp65, IE-1 and adenoviral
proteins was assessed with interferon ELISPOT analysis. CMV reactivation
was monitored with whole blood quantitative CMV PCR.
Results: Rapid reconstitution to pp65 with minimal or no increase in IE-1
immunity occurred in 5/12 participants. In 3/12 participants the IE-1 immune
response either matched pp65 or dominated the immune response. In the
remaining 4 participants, CMV immunity either remained unchanged or
decreased after T-cell infusion.
After a median follow-up of 218 days post T-cell infusion 6 episodes of CMV
reactivation in 4 participants occurred. All of these were associated with low
level viraemia and only 2 patients required pharmacological therapy in the
form of oral valaiclovir. None of these episodes were associated with evidence
of end-organ damage by CMV and none required treatment with intravenous
antiviral medications.
When compared with the historical controls the trial participants had less CMV
reactivation (33% vs 52%), markedly lower peak CMV viral load (mean of
669 copies/ml in trial participants vs 4394 copies/ml) and reduced need for
pharmacological therapy (50% of control group with CMV reactivation
required ganciclovir or foscarnet vs none of the study participants). Rates of
GVHD were similar (58% for trial participants vs 52% for controls).
There were no infusion related safety issues identified. 4/12 patients developed
graft versus host disease post T-cell infusion. These cases were all associated
with sub-therapeutic doses of Cyclosporine A or deliberate weaning of
immunosuppression. One participant developed secondary graft failure related
to sulphamethoxazole/trimethoprim therapy.
Discussion: This study confirms the safety of infusion of CMV specific
T-lymphocytes and the ability to detect T-cells with CMV specific immunity
in the early period post-infusion where the risk of CMV reactivation is highest.
The reduction of peak CMV viral load and the success of low intensity
pharmacotherapy is encouraging and suggests the efficacy of prophylactic viral
specific T-cell infusion.

460 BONE MARROW TRANSPLANTATION TEMPORARILY
IMPROVES THE FUNCTION OF PANCREAS IN
STREPTOZOTOCIN-INDUCED DIABETES
M.J. Elliott1, Y. Huang1, M. Kucia2, L-R. Hussain1, H. Xu1, M. Ratajczak2,
S. Ildstad1,
1
Institute For Cellular Therapeutics, 2James Graham Brown Cancer Center
The role of bone marrow-derived cells in pancreatic β-cell regeneration remains
unresolved. Under certain circumstances regeneration of insulin-producing
tissue has been detected. In the present studies we examined whether bone
marrow-derived cells are recruited to the site of moderate pancreatic injury
and contribute to β-cell regeneration. In mouse bone marrow, the majority of
cells which express the mRNA for pancreatic developmental markers (NKx6.1,
Pdx1, and Ptfl) are detected in the CD45-Sca-1+Lin- stem cell (SC) population.
In response to pancreatic damage, we have found that these cells are mobilized
from bone marrow to peripheral blood (PB), with peak in PB at day 5. These
cells are highly enriched in the pancreas on day 10 and 15 after streptozotocin
(STZ)-treatment. To test the hypothesis that pancreatic tissue injury induces an
SDF-1 gradient to chemo attract the SC, which express its receptor, CXCR4,
we evaluated the expression of mRNA for SDF-1 in the damaged pancreatic
tissue. SDF-1 was significantly increased in the pancreas after damage, with a
peak on day 10. These data suggest that damaged pancreatic tissue produces the
chemokine SDF-1 and that pancreatic damage is associated with mobilization
of bone marrow-derived cells containing mRNA for pancreas developmental
markers. To confirm a role for bone marrow-derived stem cells, we prepared
EGFP+ B6 → B6 bone marrow chimerism. In the EGFP+ chimeras, EGFP+
cells were detected around duct and islets and were positive for insulin after
STZ-treatment. However, STZ-induced hyperglycemia was reduced only shortterm for 49 to 77 days after pancreatic injury (Figure 1). These data suggested
that bone marrow-derived cells are mobilized into injured pancreatic tissue
and contribute to β-cell regeneration. Transplantation of bone marrow-derived
cells improves the function of injured pancreas, although the response is not
sufficient to restore normoglycemia.
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461 SUSTAINED EFFECT OF AUTOLOGOUS BONE
MARROW MONONUCLEAR CELL TRANSPLANTATION IN
PATIENTS WITH DIABETES 12 MONTH FOLLOW-UP
L. Chen, J. Dong, W. Hou, X. Hou, L. Sun, M. Dong, X. Zhang, K. Tang,
Y. Sun, Y. Fu
Endocrinology Department of Qilu Hospital
Diabetes is modern epidemics and a cure will have a global health impact.
Bone marrow stem cells (BMSCs) can transdifferentiate into insulin-producing
cells or induce endogenous ¦Â-cell expansion under certain conditions hence
offers a major therapeutic potential. We developed a prospective study to assess
therapeutic efficacy of autologous BMSC transplantation with one-year followup in patients with type 1 (T1DM) or 2 (T2DM) diabetes receiving autologous
BMSC transplantation or standard medical therapy. We treated 53 diabetic
patients (T1DM:
n=22, T2DM: n=31) with autologous BMSC transplantation, and 52 agematched diabetic patients (T1DM: n=27, T2DM: n=25) with regular oral
hypoglycemia agents (OHA) and/or insulin; these patients were followed up
for 12 months. Bone marrow mononuclear cells (BMMCs) from the bone
marrow aspirates of each patient were directly delivered to pancreas via
splenic artery with the distal luminal occlusion through an arterial catheter.
At 1 year, we observed improved glycaemic control in both transplantation
(T) and medical treatment (C) groups. The fasting blood glucose, 2-h
postprandial glucose, the area under the curve (AUC) during standard mixed
meal tolerance
test and HbA1c were reduced comparing with the baseline levels (P<0. 05).
However, patients received BMMC transplantation sustained better glycemic
control accompanied by the reduction in the exogenous insulin requirement
(P<0. 05). In contrast, the control group showed an increased daily insulin
requirement for the same follow-up period. Fifteen of the fifty-three
transplantation patients (28. 3%) established complete insulin independence.
This was accompanied by increased levels in C-peptide and its AUC in the
T group (P<0. 05). None of these parameters were changed in the C group
(P>0. 05). Comparing to conventional medical treatment, our study shows that
autologous BMMC transplantation has a sustained effect on glycaemic control
accompanied
by improved ¦Â-cell function with nearly 1/3 patients established complete
insulin independence. By overcoming the transplant rejection and donor
shortage, our protocol of autologous transplantation is safe and readily
applicable other clinical settings.
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CONCURRENT ORAL SESSION 35:
EXPERIMENTAL IMMUNOSUPPRESSION
462 CARDIAC ALLOGRAFT VASCULOPATHY IN
CYCLOSPORINE-TREATED MONKEYS DEPLETED OF CD20
B-CELLS

463 INHIBITORY EFFECTS OF ATACICEPT (TACI-IG) ON
CIRCULATING ANTIBODIES, B CELLS AND PLASMA CELLS
IN ALLOSENSITIZED CYNOMOLGUS MONKEYS
S. Boskovic, R-N. Smith, T. Kawai, O. Nadazdin, D. Sachs, A.B. Cosimi,
R. Colvin
Massachusetts General Hospital
Purpose: To evaluate the effects of atacicept (TACI-Ig; Transmembrane
Activator and Calcium-modulator and cyclophilin ligand Interactor
-immunoglobulin) treatment on B cell/plasma cell function in sensitized
cynomolgus monkeys.
Background: Organ transplantation for sensitized patients has been limited
by the lack of specific therapy to control alloantibody production and plasma
cell function. Atacicept (ZymoGenetics/Merck-Serono) is a recombinant
human soluble receptor that acts as an antagonist to BAFF (B cell Activation
Factor of the TNF Family) and APRIL (A Proliferation-Inducing Ligand), two
stimulatory ligands responsible for B cell maturation and survival. In mice,
TACI-Ig inhibits antibody response, survival of plasma cells and development
of autoimmune disease.
Methods: Cynomolgus monkeys that developed donor specific alloantibody
(DSA) after rejecting heterotopic heart allograft received 8 doses of atacicept
at 10 mg/kg S. C. , twice a week. Recipients were monitored over 3 months for
levels of DSA, antibodies to ABO blood group and gal[ƒÑ1, 3 gal] antibodies,
and peripheral B cells. Spleen biopsy was performed at one month to evaluate
splenic plasma cells by staining for immunoglobulin light chains via in situ
hybridization.
Results: After a one-month course of atacicept, all three recipients
demonstrated a reduction in DSA levels by 36. 3„b11% in anti-T and 24.
3„b11% in anti-B cell DSA, compared to pre-treatment levels. Similarly,
gal[ƒÑ1, 3 gal] xenogeneic antibody levels decreased by 55„b4. 4% in IgG
and by 60. 7„b27. 5% in the IgM fraction. Antibody levels to ABO blood
group antigens tested on two subjects with blood group A also showed

464 IMPACT OF IMMUNOSUPPRESSION ON UV-INDUCED
SKIN-TUMORS IN MICE: RAPAMYCIN IMPAIRS TUMOR
OUTGROWTH AND SHIFTS THE MUTATION TYPES IN THE
P53 GENE
G. Koehl1, P. Voskamp2, H. Rebel2, A. Gaumann3, J.B. Bavinck2,
H.J. Schlitt2, F. de Gruijl2, E. Geissler1
1
Department of Surgery, University of Regensburg, , 2Dermatology, Leiden
University Medical Center, Leiden, NL, 3Institute of Pathology, University of
Regensburg
Background: A significant complication in transplant patients is skin
tumors development under the necessary immunosuppression. It has been
shown that cyclosporine can inhibit DNA repair, may promote UV-induced
DNA mutations and thus enhance formation of skin carcinomas. Since some
immunosuppressants have recently shown antitumor-activities and affect
pathways involved in cell cycle progression and expression of DNA repair
genes (e. g. BRC1), we have tested if long-term treatment with the DNAsynthesis inhibitor mycophenolate mofetil (MMF) and in particular the mTOR
inhibitor rapamycin inhibits the development UV-induced tumors and affects
p53 mutations within the tumors.
Methods: We exposed hairless SKH1 mice to longterm UV-irradiation (250
J/m2/day from TL12 lamps). Typical immunosuppressive doses of Rapa or
MMF were fed to these mice during the whole experiment, while control mice
received no drug. Blood levels of these drugs were verified in sentinel mice.
Tumor occurrence and tumor load over time were monitored.
Sequence analysis was performed to assess DNA mutations in the p53 gene of
skin tumors.
Results: As expected in this model almost all tumors were classified
histologically as squamous cell carcinomas (or precursor lesions). Although
none of the groups showed a significant difference in the development of
tumors <2 mm in diameter, larger tumors took significantly longer to develop
in the Rapa group (n=10; median latency time of 190 days for tumors >4
mm) than in the MMF (n=10), or control (n=10) groups (140 days, and 125
days, respectively). Moreover, the average multiplicity of tumors >4 mm was
significantly lower in Rapa-treated mice (1. 5 vs. 4. 0 in controls at 200 days).
Mutational analysis of the p53 gene revealed that 100% of tumors from control
mice had mutations, while mutations were only detected in 67% and 70% of
tumors from Rapa and MMF-treated mice, respectively. Most interestingly,
however, while 88% and 90% of the mutations found in tumors of the control
and MMF mice, respectively, were classic C>T UV-signature mutations, these
mutations were less frequently detected (39%) in tumors from Rapa-treated
mice (p=0. 01; Fisher exact test; n=10-16 tumors/group).
Conclusions: While Rapa does inhibit tumor outgrowth, it does not appear
to affect the early onset of tumors (initiation). MMF does not affect tumor
development in this UV-skin cancer model significantly. Interestingly tumors
in Rapa-treated mice clearly show a reduced frequency of UV-signature
mutations in the p53 gene, which could be indicative of a selective mechanism
on the outgrowth of skin tumors.
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S. Kelishadi, T. Zhang, T. Stoddard, E. Welty, C. Avon, A. Laaris, X-F. Cheng,
A. Azimzadeh, R. Pierson
University of Maryland Baltimore School of Medicine
Rationale: Over 50% of clinical cardiac allograft recipients develop cardiac
allograft vasculopathy (CAV). Peri-transplant depletion of B-cells might inhibit
chronic rejection by reducing the precursor pool for anti-donor antibodyproducing plasma cells or by blunting antigen presentation to donor-specific
T-helper cells.
Methods: Thirteen cynomologus monkeys received MLR-mismatched
heterotopic cardiac allografts and “therapeutic” cyclosporine (CsA: target
trough >500ng/ml); five also received anti-CD20 therapy (á-CD20: 20mg/kg
IV on days 0, 7, 14, and 21). Anti-donor alloantibody was quantified by flow
cytometry. Surviving grafts were censored at 90 days.
Results: Three animals (2 with CsA alone and one with CsA+áCD20) were
excluded from analysis with beating grafts due to non-immune related
complications. Primary graft survival with CsA+áCD20 (median >90d) and
proportion of grafts surviving to 90 days (4/4) was increased relative to CsA
alone (median 71d, 3/6 >90d; p=0. 035). CsA+áCD20 inhibited CAV (median
CAV score 0. 2; range 0. 1-0. 34) relative to CsA alone (median 2. 1; range
1. 5-2. 4; p=0. 0013). Anti-donor alloantibody was detected in a minority of
animals in either treatment group.
Conclusions: When used with a dose of conventional CsA immunosuppression
that is “therapeutic” in this species, depletion of CD20+ B cells at the time of
engraftment attenuates chronic rejection (as CAV) and significantly decreases
the incidence of graft loss. Interestingly, attenuation of CAV occurred
independent of a measurable effect on anti-donor antibody incidence or titer.
This approach to attenuate CAV could be readily evaluated in the clinic.
Whether synergy exists (efficacy with reduced CsA exposure/toxicity) and
durability of the effect as B-cells recover over longer follow-up remain to be
determined.

marked reduction in IgM (from 1: 32 to 1: 4 and from 1: 64 to 1: 16) and in
IgG antibodies (1: 16 to 1: 8, 1: 64 to 1: 32). Two of three subjects showed
significant reduction of CD20+CD3- B cells transiently, with nadir one
month after last dose (83% and 73%). Splenic plasma cells were decreased in
all three subjects by 75% (mean of 103„b45 cells/mm2) when compared to
controls (mean of 293„b21).
Conclusions: Atacicept decreased B cell and plasma cell numbers and
reduced alloantibody levels, as well as gal[ƒÑ1, 3 gal] xenogeneic
antibodies and anti-ABO blood group antibodies, in sensitized cynomolgus
monkeys. Further testing of the efficacy of atacicept to lower pathogenetic
antibodies in transplantation is warranted by the encouraging results of this
pilot trial.
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465 GENERATING EFFECTIVE LOCAL
IMMUNOSUPPRESSION : PROTECTION OF ISLET
ALLOGRAFTS WITHOUT COMPROMISING SYSTEMIC
IMMUNITY

TUESDAY

S. Londrigan, R. Sutherland, J. Brady, Y. Zhan, E. Carrington, A. Lew
The Walter And Eliza Hall Institute
Local immunosuppression during islet transplantation is clinically desirable,
as it would reduce the requirement for systemic immunosuppression
to prevent graft rejection. We tested the efficacy of locally produced
immunomodulatory molecules to prevent islet allograft rejection by
transducing islets with Adv secreting molecules to deplete T cells or
block T cell activation. Transduced islets were transplanted under the
kidney capsule of diabetic mice, and graft survival was assessed by
normalisation of blood glucose levels. Adenoviruses delivering a CD4 T
cell depleting antibody (Adv-anti-CD4) or CTLA4Ig to block CD28/B7
T cell co-stimulation (Adv-CTLA4Ig), enhanced islet allograft survival
(up to 40% and 80% respectively). Importantly, we established that the
allograft protection afforded by both of these molecules occurred as a
result of immunosuppression that is locally restricted. Mice transplanted
with Adv-anti-CD4 treated islets or Adv-CTLA4Ig treated islets on one
kidney, were able to reject control islets grafted on the contralateral kidney.
This indicates that the systemic immunity in these mice remained intact.
Immunosuppressive effects can be restricted locally by our strategy.
In a mouse model, prolonged local blockade of T cell co-stimulation by
CTLA4Ig appears to be an effective way to educe significant protection
of islet allografts without compromising systemic immunity. The efficacy
afforded by local depletion of CD4 T cells may be improved using a
combination of antibodies to deplete other T lymphocyte subsets.

466 COMBINING SOCS1 OVEREXPRESSION WITH
DEFICIENCY IN IL-1 SIGNALLING PROTECTS ISLETS FROM
IMMUNE-MEDIATED DESTRUCTION.
K.L. Graham, C-Y. Lee, H.E. Thomas and T.W.H. Kay
St Vincent’s Institute of Medical Research, Fitzroy, Victoria, Australia, 3065.
A combination of inventions against allo- and auto-reactive CD4+ and CD8+
T cells is likely to be required to protect islets from immune mediated attack
following transplantation. Suppressor of cytokine signalling 1 (SOCS1)
blocks signalling by several cytokines that use the Jak/STAT pathway
including IFNgamma. Overexpression of SOCS1 in beta cells of diabetesprone NOD mice (RIP-SOCS1) decreases spontaneous diabetes by half.
Previous work suggests that SOCS1 overexpression controls the CD8+ T cell
response by reducing beta cell antigen presentation. IL-1R deficiency has
been shown to increase the ability of regulatory CD4+ T cells to suppress
expansion of CD4+ T effector cells. In this study we have used a combination
of SOCS1 overexpression with IL-1R deficiency (RIP-SOCS1/IL-1R mice)
in an attempt to control both CD8+ and CD4+ T cell-mediated destruction of
islets. RIP-SOCS1/IL-1R mice were completely protected from spontaneous
diabetes development and have significantly reduced insulitis compared
to control mice or either parental strain. Reduction in insulitis was due to
an overall decrease in all cell types invading the islets. Transfer of CFSElabelled autoreactive CD8+ T cells demonstrated that T cell priming and
activation in the pancreatic lymph node of RIP-SOCS1/IL-1R mice was
comparable to control mice however progression of these cells to the islet
and subsequent proliferation was reduced. This suggests migration and/or
function of effector cells could be impaired resulting in decreased beta cell
killing and protection from diabetes development. Because of the increased
protection with SOCS1 overexpression and IL-1R deficiency than with either
intervention alone, we are investigating the use of RIP-SOCS1/IL-1R and
RIP-SOCS1 islets in combination with soluble IL-1Ra in transplantation
studies to overcome allograft rejection.
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467 PREVENTION OF CHRONIC ALLOGRAFT REJECTION
BY BLOCKING OX40 COSTIMULATORY PATHWAY IN
CARDIAC TRANSPLANT RECIPIENTS
W. Ge1, J. Jiang2, J. Arp1, M.L. Baroja1, W. Liu3, Z. Lan1, D. Lian2,
B. Garcia3, X.C. Li4, H. Wang1,2
1
Department of Surgery, University of Western Ontario, 2Multi-Organ
Transplant Program, London Health Sciences Centre, 3Department of
Pathology, University of Western Ontario, 4Department of Medicine, Harvard
Medical School
Memory T cells (Tmem) endanger allograft survival by causing not only acute
rejection, but also chronic rejection (CR), which is the major cause of late allograft
loss. However, the precise role of Tmem in CR is poorly defined, and therefore,
effective treatments for preventing CR are still lacking. The present study was
undertaken to determine whether functionally blocking the OX40 pathway would
prevent Tmem-mediated CR in a mouse cardiac transplant model. Tmem were generated
using a homeostatic proliferation (HP) model. Lymph node T cells (2x106) from
CD40LKO mice adoptively transferred into congenic immunodeficient Rag-1KO
mice were allowed to undergo HP for 6 weeks. Upon undergoing HP, CD40LKO
T cells (i. e. CD44lo) acquired a memory-like CD44hi phenotype with high level
of OX40 expression measured by flow cytometry, suggesting that this novel
costimulatory molecule may support the effector function of Tmem. To determine
the role of Tmem in mediating CR, RAG-1KO mice harboring post-HP generated
Tmem were transplanted with fully MHC-mismatched BALB/c heart allografts.
Heart grafts in untreated recipients developed typical pathological features of
CR, characterized by interstitial fibrosis, arteriosclerosis, cellular infiltrates and
IgG deposition on POD100, indicating the establishment of a transplant model
with Tmem-mediated CR. In contrast, blocking OX40 signal by anti-OX40L mAb
(0. 25mg/mouse/day, days 0, 1, 3, 5, 10) completely prevented CR in this model
and heart grafts showed normal histology. Compared with untreated recipients
with graft CR, anti-OX40L mAb treated recipients demonstrated significant
downregulation of the Tmem population with lower OX40 expression and decreased
anti-donor cytotoxic T-lymphocyte activity, as well as reduced IgG deposition and
decreased IFN-γ, TNF-α and TGF-β expression in heart grafts. We conclude that
functionally blocking the OX40 pathway inhibits Tmem-mediated CR in a mouse
heart transplant model. This study identifies a key molecular pathway in targeting
Tmem in prevention of CR and may of value in clinical transplantation.

468 TARGETING ACTIVATED HUMAN LYMPHOCYTES AND
MONOCYTES WITH A NEW GENERATION OF POLYCLONAL
RABBIT ANTI-HUMAN LEUKOCYTE ANTIBODY (NEWRALG)
H. Xu1, Z. Liu1, A. Kirk2
1
Jinan City Central Hospital, 2Department of Transplantation, Emory
University Hospital, Emory University, Atlanta, USA
Thymoglobulin® was made by inoculating rabbits with human thymocytes,
and therefore, its effects in targeting activated lymphocytes and monocytes
may be limited. In light of this we have developed a new polyclonal rabbit
anti-human leukocyte antibody (newRALG) that specifically targets activated
T-cells and monocytes. newRALG was generated by inoculation of rabbits
with activated human lymphocytes and monocytes expressing high levels of
adhesion and costimulatory molecules followed by antibody purification and in
vitro evaluation. FACS found that newRALG blocked monocyte-derived CD40,
CD80, and CD86 and T cell-derived CD28 and CD154 with greater specificity
than thymoglobulin®. HLA class I and II-DR, cytokine receptors and adhesion
molecules were blocked as well as endothelial cell (EC)-derived CD54.
newRALG blocked all known major molecules expressed on both resting T-cell
and monocyte surface. newRALG depleted human and rhesus lymphocytes
and monocytes in a dose dependent manner after incubation with blood for 60
minutes. newRALG effectively inhibited mixed lymphocyte-endothelial cell
reactions (MLER). Additionally, newRALG-treated T cells upregulated multiple
molecules suggestive of a T-regulatory phenotype including CD25, CTLA-4,
GITR, OX40, CD25, Foxp3, and IL-10 as determined by RT-PCR and FACS.
In summary, newRALG blocks adhesion molecules, co-stimulatory molecules,
cytokine receptor molecules and other major molecules involved in allo-immune
responses in vitro more effectively than thymoglobulin®. newRALG inhibits
human lymphocyte proliferation and depletes human and rhesus lymphocytes
and monocytes ex vivo. This preparation results in a distinct residual T-cell
phenotype skewed toward a regulatory population. These results suggest that
this new polyclonal antibody will exhibit higher specificity for the relevant cell
populations mediating allograft rejection then currently available reagents.
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469 ACTIVATION OF TIM-3-GALECTIN-9 PATHWAY
IMPROVES SURVIVAL OF FULLY ALLOGENEIC SKIN
GRAFTS

470 A NOVEL NF-KAPPA B INHIBITOR, DHMEQ,
ATTENUATES ARTERIAL VASCULOPATHY.
M. Uno1, K. Yamashita1, T. Shibata1, R. Goto1, T. Oura1, M. Watanabe1,
S. Haga1, K. Umezawa2, M. Ozaki1, S. Todo1
1Department of General Surgery, 2Department of Applied Chemistry, Keio
University
Background: Previously, we have shown that a novel NF-kappa B inhibitor,
DHMEQ significantly attenuated cardiac allograft vasculopathy on chronic
rejection model in the murine heterotopic heart allo-transplantaion.
Aim: In this study, we further evaluated the effect of DHMEQ in vitro using
rat vascular smooth muscle cells (VSMCs) and in vivo using murine vascular
injury models.
Methods: In vitro: Primary LEW rat VSMCs from the thoracic aorta were isolated
and cultured by the explant method. We examined proliferation (3H-thymidine
incorporation), NF-kB nuclear translocation (immunofluorescence), apoptosis,
cell cycle progression (Flow cytometry), and their regulators (Oligo array and
Western blotting method) with or without DHMEQ treatment.
In vivo: Balloon injured vasculopathy model: The common carotid artery was
injured by balloon inflation in Sprague-Dawley rats. Pluronic F127 gel (20%)
containing with or without DHMEQ (100 μg) was administered to perivascular
lesion of the injured vessel. Cuff injured vasculopathy model: A polyethylene
cuff with LPS (1 μg/ml) was placed around the femoral artery in C57BL/6
mice. DHMEQ (20 mg/kg/day) was given i. p. daily until the time of sacrifice.
The injured vessels of rats and mice were assessed histopathologically on days
14 and 28, respectively.
Results: DHMEQ significantly suppressed proliferation of VSMCs after
10% FBS stimulation in a dose-dependent manner as compared to the control
(Fig. 1A). In VSMCs, p50 and p65 translocated into the nucleas at 8 hrs after
FBS activation, while that was inhibited by DHMEQ (15 μg/ml). Apoptosis
was not induced, however, cell cycle progression was arrested at G0/1 phase

Conclusion: Inhibition of NF-kappa B activation by DHMEQ suppresses
VSMC proliferation and ameliorates arterial vasculopathy. DHMEQ would
be a useful agent to prevent development of transplant arteriosclerosis during
chronic graft rejection.
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W. Feng, H. Wentao, Y. Jin, W. Ke, Z. Hongmin, Z. Weina
K.C. Zhonghua7
Institute of Organ Transplantation
Background: T cell immunoglobulin and mucin domain (Tim)-3 is a molecule
expressed on terminally differentiated murine Th1 cells but not on Th2 cells.
Identification of galectin-9 as a ligand for Tim-3 has now firmly established
the Tim-3- Galectin-9 pathway as an important regulator of Th1 immunity,
which results in apoptosis of Th1 cells. Thus, we want to test the hypothesis
whether activation of Tim-3-Galectin-9 pathway can improve survival of fully
allogeneic skin grafts.
Methods: The skin transplantation recipients (BALB/c to C57BL/6) were
treated with 100 μg of Galectin-9 or PBS from day 0 to day 7 consecutively
post-transplant. The mean survival time (in days) was indicated. Furthermore,
the recipients treated with Galectin-9 were sacrificed at days 7. The draining
Lymph nodes were harvested and Tim-3 and Tim-1 positive cells were
analyzed by FACScan flow cytometer. The recipient blood was collected and
the production of cytokine was detected by Enzyme-linked immunosorbent
assay (ELISA). In vitro experiment, responder spleen cells were labeled with
CFSE. T cell proliferation induced by anti-CD3 and anti-CD28 was analyzed
for CFSE intensities.
Results: We conclude that (1) binding of Tim-3 to its ligand Galectin-9
significantly inhibits rejection and prolongs the survival of fully allogeneic
skin graft in vivo. (2) Galectin-9 dose-dependently inhibits TCR crossing link
induced T cells proliferation in vitro. (3) interaction Tim-3 with galectin-9
selectively deletes Tim-3+ Th1 cells to dampen Th1 immunity and result in
prolongation of skin graft survival. (4) Galectin-9 significantly decreases
production of IFN-γ both in vivo and vitro. (5) CD8+ T cells subset was down
regulated by using Galectin-9 in vivo after skin transplantation.
Conclusions: Our results demonstrated that activation of Tim-3-galectin-9
pathway can remarkably suppress allograft rejection and increase survival of
major histocompatibility antigen mismatching skin grafts. These observations
suggest that Tim3 -Galectin-9 pathway plays an important role in the
termination of productive Th1-immune response and could lead to developing
novel therapies in transplant medicine.

by DHMEQ supplementation. This cell cycle inhibition by DHMEQ was
associated with suppression of genes such as Itgb1, Cdkn1a (p21) and PCNA.
Further, DHMEQ inhibited CDK1, Cyclin A, Cyclin B, Cyclin D3, p21, and
p36 protein expressions. In vivo, treatment with DHMEQ significantly inhibited
development of arteriosclerosis as assessed by intima to media ratio in both rat
balloon arterial injury (0. 51±0. 06 vs 0. 13±0. 02, p<0. 0001: Fig. 1B) and cuff
arterial injury models (0. 62±0. 14 vs 0. 27±0. 06 p<0. 01: Fig. 1C). In the cuff
injured artery, DHMEQ reduced the number of F4/80 positive macrophags in
the adventitia as compared to that of the control groups.

CONCURRENT ORAL SESSION 36:
CLINICAL AND EXPERIMENTAL LUNG TRANSPLANTATION
471 LIVING-DONOR LOBAR LUNG TRANSPLANTATION
FOR PULMONARY COMPLICATIONS AFTER BONE MARROW
TRANSPLANTATION
M. Yamane1, Y. Sano1, S. Toyooka1, M. Okazaki1, T. Oto1, H. Date2
1Department of Cancer And Thoracic Surgery, Okayama University, School
of Medicine, 2Department of Thoracic Surgery, Kyoto University
Objective: We report on our experiences in living-donor lobar lung
transplantation for patients with bronchiolitis obliterans as a complication after
bone marrow transplantation (BMT).
Methods: Between October 1998 and February 2008, living-donor lobar lung
transplantation (LDLLT) was performed in 49 patients with various end-stage
lung diseases at Okayama University Hospital. Among these, 6 patients with
pulmonary complications following BMT, aged 6 to 45 years (mean 23. 3
years), including 2 children were assessed. Diagnoses for BMT included acute
lymphocyte leukemia (n=3), aplastic anemia (n=1), myelodysplastic syndrome
(n=1) and acute promyelocystic leukemia (n=1). Bilateral living-donor
lobar lung transplantation was performed in 4 patients and right single lobar
transplantation was performed for a 13-year-old boy and a 6-year-old girl.
Results: Of 49 patients with LDLLT, 45 are currently alive (overall survival
of 91. 7%). On the contrary, in this cohort of 6 patients with LDLLT for
bronchiolitis obliterans after BMT, there were 1 early and 1 late death, and 4 of
6 patients are currently alive without recurrence of hematological diseases with
a follow-up period of 14 to 94. 3 months (mean, 48. 0 months). All donors have
returned to their previous lifestyles.
Conclusions: Living-donor lobar lung transplantation can be applied to severe
pulmonary complications including bronchiolitis obliterans and pulmonary
fibrosis after BMT. This type of procedure can be an effective approach and
alternative to conventional cadaveric lung transplantation for both pediatric
and adult patients who suffers from pulmonary complication following BMT
and would die soon otherwise.
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472 ASSOCIATION BETWEEN DONOR MBL PROMOTER
HAPLOTYPE AND GRAFT SURVIVAL AND THE
DEVELOPMENT OF BOS AFTER LUNG TRANSPLANTATION

473 SHOULD LUNG TRANSPLANT RECIPIENTS
ROUTINELY PERFORM AIRWAY CLEARANCE TECHNIQUES?
A RANDOMIZED CONTROLLED TRIAL

J.M. Munster1, W. van der Bij1, M.B. Breukink1, G. van der Steege2,
M.W. Zuurman1, B.G. Hepkema3, E.A.M. Verschuuren1, W.J. van Son1,
M.A.J. Seelen1
1
UMC Groningen, The Netherlands, department of Internal Medicine,
2
UMC Groningen, The Netherlands, department of Medical Genetics, 3UMC
Groningen, The Netherlands, department of Transplantation Immunology
Background: Lung transplantation is a well accepted therapy for end-stage
lung disease, despite relatively high mortality rates in the first years after
transplantation. Mannose binding lectin (MBL) is one of the recognition
molecules of innate immunity. In many populations, polymorphisms in the
gene encoding the MBL protein are common. Seven different haplotypes have
been described (HYPA, LYQA, LYPA, LXPA, HYPD, LYPB and LYQC),
in which those with exon polymorphisms or an LX promoter variant are
associated with absent or low levels of the protein, whereas the HY promoter
haplotype has been related to high MBL serum levels. In other solid organ
transplantation, genotype or serum levels of MBL, has been associated with
transplant outcome. Since there is some evidence that the MBL protein is,
besides largely produced in the liver, partly produced in the lung alveolar cells,
we were interested in both recipient and donor MBL genotype and their effect
on lung transplant outcome.
Material and Methods: All lung transplantations performed in our center, except
from retransplantations and combined lung-liver or heart-lung transplantations,
were included. Genotyping of the six known MBL2 variants (promoter: L/H,
Y/X and P/Q allele and exon: A/D, A/B and A/C allele) was performed in
both recipient and donor DNA. Univariate and multivariate analyses on graft
survival and the development of bronchiolitis obliterans syndrome (BOS) was
performed with Kaplan Meier (log rank) and Cox regression analysis.
Results: Of the 277 included cases, DNA was available from 200 recipients and
189 donors and genotyping of all three promoter SNPs was successful in 187
recipients and 184 donors and of the three exon SNPs in 191 recipients and 181
donors. Patients who received a graft from a donor with an X-allele (heteroor homozygote Y/X promoter polymorphism) had a statistically significant
better graft survival (N=184, p=0. 007, figure 1) and BOS-free survival (N=60,
p=0. 007). This association was still present after adjustment for recipient and
donor sex and age, time on the waiting list, immunosuppressive protocol, HLA
mismatches and the recipient X-allele (p=0. 034 and p=0. 008 for graft survival
and BOS, respectively). Recipient MBL genotype was not associated with
transplant outcome.
Conclusion: The donor X-allele, which corresponds to the LXPA haplotype
and is related to low serum MBL levels, was associated with superior lung
transplant outcome. Our findings might prove to be important in finding ways
to optimize outcome after lung transplantation.

P.E. Munro1, M. Bailey 2, H. Whitford 1, S.J. Ellis 1, B.M. Button 1, G.I. Snell 1
1
The Alfred Hospital, 2Monash University.
Background: Interventions such as thoracic expansion exercises, postural
drainage, forced expiration technique (huffing) and positive expiratory pressure
(PEP) have been used to assist airway clearance and improve lung function in
a variety of patient populations. These techniques are also widely used in the
management of lung transplant recipients both in the immediate post-operative
phase and in the presence of acute or chronic chest infection, however very little
is known about their efficacy. Clinical practice varies considerably, with some
clinicians recommending the routine use of airway clearance as a “proactive”
strategy, while others recommend a “reactive” approach with treatment only
when patients have a chest infection.
Objective: The aim of this study was to compare the effects of two commonly
used airway clearance strategies (proactive vs reactive) on a range of clinical
outcomes following lung transplant.
Methods: A prospective randomized trial design was used. Consecutive
patients at one month post lung transplant at The Alfred Hospital, Melbourne
were eligible for inclusion. Subjects were excluded if they were medically
unstable, ventilator dependent or had a contraindication to performing positive
expiratory pressure (PEP) therapy. Patients performed airway clearance using
PEP therapy either twice daily (proactive strategy) or only in the presence chest
infection (reactive strategy). Lung function (FEV1 and FVC), chest radiography
(Brasfield score), bronchoscopic airway characteristics (anastomotic healing,
patency and secretions) were assessed at one, two and three months post lung
transplant. Adherence was also measured.
Results: Of 60 consecutive patients, 36 (18 proactive, 18 reactive) were
recruited and completed the study. Both groups improved lung function (FEV1
72 ± 4% to 81 ± 4% p<0. 0001; FVC 69 ± 3% to 81± 3% p<0. 0001) and
Brasfield scores (17. 8 ± 0. 5 to 19. 8 ± 0. 5 p<0. 002) over the study period. No
significant differences between groups for any outcome were found. The vast
majority had fully healed, 100% patent anastomoses without secretions at three
months. There were no significant differences between airway characteristics
and incidence of chest infection. Adherence to both strategies was high (84%
proactive, 100% reactive).
Conclusions: Proactive airway clearance following lung transplantation was not
associated with a reduced incidence of respiratory infection, alteration of chest
radiographic findings, or improvement in airway characteristics and cannot be
recommended as part of routine clinical practice at this time. A further study
using these baseline measures would be appropriate to evaluate the efficacy
of regular airway clearance in the subgroup of lung transplant recipients who
have recurrent chest infections. The inclusion of a no treatment control group in
future airway clearance studies in the lung transplant population is warranted.
Supported by an Alfred Trusts Grant

474 LUNG TRANSPLANTATION IN RECIPIENTS 70 YEARS
OF AGE AND OLDER

Figure 1. Kaplan Meier survival curves including censored cases.
Y/Y = homozygote Y-allele, Y/X = heterozygote Y- and X-allele, X/X =
homozygote X-allele.
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Y. Toyoda, C. Bermudez, M. Zenati, B. Hattler, M. Crespo, J. Pilewski,
K. McCurry
University of Pittsburgh Medical Center
Objective: Controversy exists regarding the appropriate age limit for lung
transplantation. We present our data of lung transplantation for patients 70
years and older.
Methods: Retrospective analysis was performed for 257 consecutive lung
transplant recipients from 3/05 to 9/07. There were 17 patients aged 70 and
older at the time of transplant (Group A), 72 patients aged 61 to 69, and 168
patients aged 60 and younger (Group B). Peri-transplant factors and outcomes
were compared between Group A and B.
Results: The mean age of Group A was 73±1 years (range 70 – 81, 15 male
and 2 female) whereas Group B 48±1 (17-60, 85 male and 83 female) (p<0.01).
All patients in Group A had idiopathic pulmonary fibrosis (p<0.01) whereas
diagnoses in Group B included emphysema in 31%, pulmonary fibrosis
in 21%, cystic fibrosis in 15%, scleroderma in 10%, re-transplant in 7%,
primary pulmonary hypertension in 6%, sarcoidosis in 5% and others in 5%.
Lung allocation score was higher (p<0.01) in Group A (51±3) vs. B (41±1).
Preoperative mean pulmonary artery pressure was lower (p=0.02) in Group
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A vs. B (23±2 vs. 31±1 mmHg). All patients in Group A received single lung
transplant whereas 76% of Group B double lung transplant (p<0.01). There
were no significant differences between Group A vs. B in donor age (41±1 vs.
39±1) and gender (65% male vs. 47%). Cardiopulmonary bypass was used in
6% of Group A vs. 35% of Group B (p=0.01). Graft ischemic time was shorter
(p<0.01) in Group A vs. B (269±12 vs. 345±6 min). Duration of postoperative
mechanical ventilatory support was within 48 hours and within 5 days in
53% and 76% in Group A vs. 55% and 71% in Group B (p=NS). Significant
rejection was less common (p<0.01) in Group A vs. B. There was no significant
difference in over-all survival between groups (p=0.137, Log Rank).
Conclusion: Lung transplantation can be performed for carefully selected
patients 70 years of age and older with acceptable morbidity and mortality.
These patients have less rejection compared to younger patients, suggesting
that they may benefit with less immunosuppression.
Grade 2 and greater Grade 3 and 4
30-day survival
rejection (per biopsy) rejection (per biopsy)

1-year survival

Group A 2/53 (4%)

0/53 (0%)

93%

80%

Group B 134/1097 (12%)

55/1097 (5%)

97%

86%

p-value

<0. 01

NS

NS

<0. 01

475 THE IMPORTANCE OF DEFINING WARM ISCHAEMIC
TIME (WIT) WHEN UTILISING CONTROLLED DONATION
AFTER CARDIAC DEATH (DCD)LUNG DONORS

T. Oto1, L. Excell2, A. Griffiths3, B. Levvey3, S. Marasco3, P. Macdonald4, G.
Snell3
1
Okayama University Hospital, Thoracic surgery, Japan, 2Australia & New
Zealand Dialysis and Transplant Registry (ANZDATA), Adelaide, Australia,
3
Lung Transplant Service, The Alfred Hospital and Monash University,
Melbourne, Australia, 4Cardiopulmonary Transplant Unit, St. Vincent’s
Hospital, Sydney, Australia
Background: Even organs from an ideal donor will occasionally develop posttransplant Primary Graft Dysfunction (PGD) causing a significant morbidity and
mortality after solid organ transplantation. It is likely this situation represents
subtle undetectable levels of ongoing donor organ dysfunction. The aim of this
study is to investigate the association of PGD between lung and kidney and/or
heart recipients from the one donor.
Methods: From 202 multi-organ donors, contributed 231 consecutive lung
transplants at the Alfred Hospital, 378 kidney and 114 heart transplants
were subsequently performed at multiple centers across Australia and New
Zealand.
Results: From 202 multi-organ donors, 875 organs were used for 723
transplants. The incidence of PGD after lung, kidney and heart transplants
was 20% (47/231), 24% (92/378) and 20% (23/114), respectively. In paired
single organ recipients, PGD in one of the pair was a significant risk factor for
development of PGD in the other [lung: odds ratio=5. 63 (1. 72-18. 43), p=0.
004], [kidney: 3. 19 (1. 90-5. 35), p<0. 0001]. In multivariate analysis, same
donor heart PGD [3. 37 (1. 19-9. 50), p=0. 02] was an independent risk factor
for lung PGD, and same donor lung PGD was significant risk factor for kidney
PGD [1. 94 (1. 01-3. 73), p=0. 04], if the PGD status of the paired kidney was
not known.
Conclusion: There was an association for the development of PGD across
different organs transplanted from the same donor. Sharing the early allograft
outcome between the different transplant teams might create a window of
opportunity to intervene with therapeutic strategies to protect against the
subsequent development of PGD in other organ recipients.

477 STEPPING UP TO TAKE CONTROL: EARLY POSTTRANSPLANT REGULATORY T CELL DYNAMICS IN LUNG
ALLOGRAFT RECIPIENTS
N. Mifsud1, T. Higuchi2, D. Abud3, R. Meani2, M. Bailey1, G. Westall1,2,
G. Snell2, C. McLean2, T. Kotsimbos1,2
1
Monash University, 2The Alfred Hospital, 3Victorian Transplantation and
Immunogenetics Service, ARCBS
Experimental transplantation models have elucidated the importance of
tolerance in maintaining allograft function. Phenotypic advances for detection
of immunoregulatory T cells (Treg) enable characterization of Treg dynamics
in lung transplant recipients (LTR) and relate this to clinical outcomes.
All LTR, recruited from Jan 2006 to July 2007 (n=63), underwent standard
calcineurin-based immunosuppression. During routine post-transplant (PTx)
bronchoscopic evaluation (1 and 3 months PTx) both peripheral blood (PB) and
bronchoalveolar lavage (BAL) samples were collected for Treg enumeration.
The%Treg were measured by flow cytometry following staining with cell
surface expression biomarkers CD4, CD25, CD127 and intracellular FOXP3
expression. Histopathological acute rejection (AR) episodes were identified
in 29 LTR. Early PTx Treg dynamics in PB and BAL varied substantially in
individual LTR. Multivariate analysis revealed that%Treg in PB at both 1 and
3 months PTx [r =-0. 26, p=0. 04; r =-0. 34, p=0. 009 respectively] inversely
correlated with AR episodes but not in BAL. To date, CD4, CD8 and FOXP3
immunostaining has been performed on 28 transbronchial biopsies from 20
LTR with AR. CD4 T cells dominated the lymphocytic infiltrate in all but one
of the early AR episodes but CD4+FOXP3+ Treg (less than 5%) were detected
in only 17/28 AR episodes from 14 LTR (59% vs 63% at 1 and 3 months,
respectively). This study suggests that histopathological AR in LTR is not
necessarily all the same early PTx and that its diagnosis is inversely related to
the%Treg in PB. The mechanisms driving this relationship are highly clinically
relevant but as yet remain to be fully elucidated.
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B. Levvey1, T. Oto2, A. Griffiths1, K. Jones1, G. Westall1, H. Whitford1,
T. Kotsimbos1, T. Williams1, G. Snell1
1
Lung Transplant Service, The Alfred & Monash University, 2Okayama
University Hospital, Okayama, Japan
Donation after Cardiac Death (DCD) donor organs have potential to alleviate
the shortage of transplantable lungs. Our institution commenced using
controlled (Maastricht Category 3& 4) DCD lung donors in 2006, following 4
years of clinical research and protocol development. Currently there remains
a lack of detailed information regarding the clinical limits of Warm Ischaemic
Time (WIT) as a reflection of graft ischaemia and allograft damage. Similarly
the relevance of WIT to early and late outcomes for DCD lung transplantation
(LTx) is unknown. Published data refers to uncontrolled (Sweden, Spain) and
controlled (USA, UK & Europe) DCD lung donation experience, but rarely
reports WIT or defines how WIT is calculated.
Methods: Between May 2006 & December 2007, 22 referred DCD donors led
to 11 attempted retrievals resulting in 8 bilateral LTx (2 donors did not arrest
within prescribed time and 1 donor had unacceptable lungs). We documented
BP, HR, O2 sat at specific intervals from time of treatment withdrawal until
Pulmonary Artery (PA) flush preservation of lungs, then defined WIT in 3 ways:
A= extubation to PA flush, B=systolic BP<50 to PA flush, C=arrest to PA flush.
Early recipient outcomes (PF ratios, PGD grade, ICU & hospital stay) and long
term outcomes (rejection, readmission rates) have been closely monitored.
Results: DCD lungs from 3 lung-only donors and 5 multi-organ donors were
transplanted; mean donor age 26yrs (16-36), 5 were males. LTx recipients
consisted of 2 PPH bridged on IV prostacycline, 3 COPD, 1 LAM & 2 CF (1
re-LTx), with mean recipient age 42yrs (19-60). 1 PPH recipient required 24hrs
ECMO for PGD 3, otherwise mean PGD grade at 24rs =2, and mean PGD
grade at 72hrs =1.
Mean group PF ratio at 24hr was 307 (240-507); mean ICU stay was 9days
(2-21) & hospital stay was 22days (11-76). Mean WIT’s for all DCD donors are
listed in table below. All 8 recipients survive at a mean 251days (10-573) with
good performance status and lung function.
WIT A
WIT B WIT C
3 lung-only donors 60 mins
54 mins 48 mins
5 multiorgan donors 38 mins
27 mins 23 mins
Conclusions: WIT probably impacts on both early and long term LTx outcomes
thus accurate definitions are required to determine the true association of WIT
and these outcome measures, plus enable comparisons with other centres.
Considering all of these issues, we believe a WIT definition utilising only the
time of treatment withdrawal (eg. WIT A) is unlikely to accurately reflect the
true onset of DCD lung allograft ischaemia.
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478 DONOR BRAIN DEATH INHIBITS TOLERANCE
INDUCTION IN MINIATURE SWINE LUNG
TRANSPLANTATION
G. Veillette, A. Meltzer, A. Aoyama, M. Cochrane, S. Houser, J. Wain,
J. Madsen, D. Sachs, J. Allan, B. Rosengard
Transplantation Biology Research Center, Massachusetts General Hospital
Introduction: A short course of high-dose tacrolimus induces tolerance to
fully-MHC mismatched lung allografts in miniature swine. Prior research on
the induction of transplantation tolerance has utilized this model in which the
donor is a healthy animal. We now present results suggesting that donor brain
death inhibits tolerance induction.
Methods: All transplants were performed across a fully disparate MHC barrier
with 12 days of high-dose tacrolimus (target level 35-55 ng/ml). Donor brain
death was induced by intracranial inflation of a 30cc Foley catheter. Five hours
later, orthotopic left lung transplants were performed. Recipients received 12
days of high-dose tacrolimus. Animals were followed with daily routine labs,
weekly chest X-rays, and scheduled biopsies. In vitro studies (CML, MLR,
ELISA, and QPCR) were performed.
Results: We have previously reported a series of orthotopic lung transplants
in miniature swine performed across a full MHC-mismatch with a 12-day
course of tacrolimus (n=6). Five animals (83%) accepted their grafts and were
sacrificed with viable grafts after one year. One animal acutely rejected its graft
by POD 103. We performed a series (n=4) of transplants after inducing brain
death in the donor. None of these animals survived more than 45 days and all
had evidence of ISHLT 4/4 acute cellular rejection at necropsy. In vitro studies
(CML, MLR) indicated persistent response to donor (by MLR) despite the
immunosuppressive regimen. ELISA and QPCR were performed to evaluate
cytokine changes in donor sera and lung tissue after brain death induction.
Serum ELISA demonstrated statistically significant increases in concentrations
of IL-1 (p=0. 041), TNF-a (p=0. 0005), and IL-10 (p=0. 0132) following 5
hours of brain death. IL-4, TGF-B, and IFN-g concentrations were unchanged.
Quantitative PCR was performed on lung biopsy specimens before brain death
induction and at the time of implantation. There was a consistent two-fold
upregulation of IFN-g expression after brain death. IL-1 expression in lung
tissue also increased significantly (6 to 20 fold). There was no change in IL-4,
TNF-a, or MHC Class I expression following brain death induction.
Conclusion: Donor brain death appears to abrogate tolerance induction in a
swine model of orthotopic lung transplantation, along with significant changes
in donor cytokine levels and gene expression. Further studies are planned to
better characterize the mechanism of this induced rejection and to attempt to
find ways of avoiding it.

479 CHRONIC GASTRIC ASPIRATION LEADS TO
AUTOIMMUNITY AND AN AUGMENTED INDIRECT
ALLOIMMUNE RESPONSE FOLLOWING LUNG
TRANSPLANTATION IN MINIATURE SWINE
G. Veillette, A. Meltzer, M. Weiss, M. Cochrane, S. Houser, J. Madsen,
D. Sachs, B. Rosengard, J. Wain, J. Allan
Transplantation Biology Research Center, Massachusetts General Hospital
Introduction: Clinical evidence suggests that lung transplant recipients with
documented gastroesophageal reflux disease (GERD) are at increased risk for
graft dysfunction. Here, we present a large-animal model of gastric aspiration
following allogeneic lung transplantation, and test whether chronic aspiration
can lead to the development of autoimmunity (type V collagen) and/or the
augmentation of indirect alloimmunity (class I allopeptides).
Methods: Orthotopic lung transplants (n=3) were performed in miniature swine
across an MHC class I mismatch, followed by 12 days of high-dose CyA. We
have previously reported that this regimen induces long-term allograft survival
in 67% (n=6) of similarly treated animals. At the time of transplantation, transtracheal bronchial catheters were placed distal to the bronchial anastomosis. A
gastric tube was placed for daily gastric aspiration. Graft lungs were instilled
with gastric aspirate daily (3cc/hr x 8hr/day) for 50 days. Animals were
followed with daily CBC, and scheduled chest radiographs and biopsies. In
vitro studies, including CML, MLR, and peptide proliferation assays (PPA),
were performed.
Results: Two animals were sacrificed with non-viable lungs by POD 50. In
both cases the native lung was normal. The third animal survived 180 days
without evidence of chronic rejection. After immunosuppressive treatment, all
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animals demonstrated donor-specific hyporesponsiveness by CML and MLR.
Response to collagen V developed in both animals that rejected their allografts.
The surviving animal, apparently tolerant, had no response to collagen V by
in vitro assay. In all animals, a significant response to synthetic donor-derived
class I peptides developed. The most marked response was seen in the animals
rejecting their grafts.
Conclusion: A large-animal model of GERD following lung transplantation
resulted in a spectrum of clinical outcomes. The in vitro data suggest that acid
reflux promotes the exposure of antigenic type V collagen epitopes and also
enhances the indirect alloresponse to processed donor class I antigen, giving
mechanistic insight into the manner in which GERD may be deleterious to the
transplanted lung.

CONCURRENT ORAL SESSION 37:
LONG-TERM OUTCOMES IN RENAL TRANSPLANTATION
480 FORTY YEARS EXPERIENCE OF PREGNANCIES
AMONG KIDNEY TRANSPLANT WOMEN; PREGNANCY,
MATERNAL AND GRAFT OUTCOMES FROM THE
AUSTRALIAN AND NEW ZEALAND DIALYSIS AND
TRANSPLANT REGISTRY
V. Levidiotis1, S. Chang2, A. McDonald2
Royal Prince Alfred Hospital, Sydney, NSW, 2ANZDATA Registry, Adelaide,
SA, Australia
Fertility rates, pregnancy and maternal outcomes over 40 years in women aged
15 to 49, were investigated in 28329 patient-years of follow-up, in kidney
transplant women using data from the Australian and New Zealand Dialysis and
Transplant (ANZDATA) Registry. Fertility rates were 16 per 1000 patient-years
in women with a functioning transplant and 1 per 1000 person-years among
women receiving dialysis; relative rates to the Australian population were 0. 19
for transplant and 0. 01 for dialysed women. Absolute but not relative fertility
rates have fallen over time. Among women with transplant function, 577
pregnancies and 444 LB were reported. Of women becoming pregnant beyond
their first transplant year, 73% achieved a LB. Among transplant recipients, the
proportion of live births (LB) doubled. In a further analysis, matching parous
with nulliparous women, a first LB event was not associated with poorer 20
year graft (adjusted HR 1. 04 [0. 63-1. 70], P=0. 89) or patient survival. Twenty
years after a LB, 75% of transplant women remained alive; among the 69
who died, median duration to death was 12. 2 years. Maternal complications
included superimposed pre-eclampsia [27% (N=22 of 71) and graft loss (N=5,
1. 3%). After adjusting for age and decade, pregnancies in transplant women
were 7. 1 [3. 6-13. 7] times more likely to result in a LB compared to dialyzed
women (P<0. 001). Temporally, LB consistently increased in transplant
women, whereas surgical termination (SxT) declined. These data confirm a LB
event longitudinally, in transplant women, does not adversely impact graft and
patient survival. Nonetheless transplant women have very low pregnancy rates
and the absolute rate has declined over the last 40 years.
1

481 NEW HORIZON FOR OLDER PATIENTS WITH ESRD.
ECD PREEMPTIVE RENAL TRANSPLANTATION OFFERS THE
SAME LIVE EXPECTANCY AS THE STANDARD CRITERIA
DONOR (SCD) KIDNEY TRANSPLANTATION ON DIALYSIS.
P. Witkowski, A. Rana, M. Goldstein, K. Halazun, M. Hardy, L. Ratner
Department of Surgery, Columbia University
Background: Preemptive renal transplantation has a positive impact on both
patient and graft survival. Although studies have demonstrated the benefit of
preemptive renal transplantation, such analyses included mostly high quality
organs from living donors. There has been no research, however, examining
the role of preemptive ECD transplantation on patient and graft outcome. This
study aims to investigate whether preemptive ECD renal transplantation offers
an advantage over SCD kidney transplant in patients on dialysis.
Methods: 93, 806 adult UNOS de-identified patients who underwent renal
transplantation between 1995 and 2005 were analyzed. Living donor and
multiorgan transplants were excluded. 86, 176 patients which received deceased
organs were divided into two groups according to age.
Results: Among 66, 085 (79%) recipients younger then 60yo, 48, 474 (77%)
were on dialysis and received SCD kidneys, while preemptive transplants with
ECD kidneys were performed in 1, 204 (2%) patients. There were 20, 082
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(23%) recipients ≥60yo included. 12, 156 (60%) of these patients received
SCD kidneys on dialysis, other 850 (4%) recipients received ECD kidneys
preemptively. Survival of the patients ≥60yo after ECD preemptive renal
transplantation did not differ statistically from survival after SCD kidney
transplantation on dialysis (p<0. 05) (Fig. 1), whereas in younger recipients,
their survival after preemptive ECD transplantation was significantly worse
than with SCD transplants (p <0. 05) (Fig. 2). Graft survival was found to
be significantly shorter in preemptive ECD recipients when compared to SDC
organ transplantation, in both young and old patients (p<0. 05).
Figure 1. Figure 2.
Conclusions: ECD preemptive renal transplantation offers the same life
expectancy as SDC transplantation in patients ≥60yo on dialysis but not in
younger ones. Such preemptive procedures allow patients to avoid the morbidity
and additional mortality associated with waiting on dialysis for a suitable graft.
ECD kidneys should be used preemptively in older donors therefore extending
the repertoire of renal replacement therapies as well as organ pool in those
patients without compromising their survival.

482 ESTIMATED GFR AFTER TREATMENT OF ACUTE
REJECTION: A SURROGATE MARKER FOR LONG-TERM
GRAFT SURVIVAL AFTER KIDNEY TRANSPLANTATION

Patient Survival
HR [95%CI]

Graft Failure

P-value

HR [95%CI]

P-value

Rejectors vs. Non- 1. 74 [0. 84-3. 61]
rejectors

0. 14

4. 33 [2. 64-7. 10]

<0. 001

Rejectors Gr. 1 vs. 1. 99 [0. 78-5. 10]
Non- rejectors

0. 15

2. 11 [0. 90-4. 97]

0. 09

Rejectors Gr. 1 vs. 0. 77 [0. 20-3. 02]
Gr. 2

0. 77

0. 42 [0. 18-0. 96]

0. 04

Rejectors CsA
vs. Tac

N/A

1. 57 [0. 63-3. 89]

0. 33

N/A

R.M. Merion1,2, J. Moore2,3, R.J. Johnson4, C.J. Rudge4, S. MacDonald5,
G. Russ5, G. Fant6, D. Collett4.
1
University of Michigan, Ann Arbor, USA; 2Scientific Registry of Transplant
Recipients, Ann Arbor, USA; 3Arbor Research Collaborative for Health,
Ann Arbor, USA; 4UK Transplant/NHS Blood and Transplant, Bristol, UK;
5
Australia and New Zealand Dialysis and Transplant Registry, Adelaide,
Australia; 6US Health Resources and Services Administration, Rockville, USA.
Introduction: Standardized comparisons of kidney transplant outcomes
in different parts of the world have been challenging to undertake and very
infrequently performed. In this collaborative study, three large registries
undertook separate identical unadjusted analyses of short and long term kidney
transplant outcomes as a first step toward harmonization of analytic methods
across registries and to determine whether differences in major outcomes after
kidney transplantation were observed.
Methods: Separate cohort analyses of the outcomes of all first single organ
kidney transplants performed from 1988-2005 in the United States (US),
United Kingdom (UK) and Australia/New Zealand (ANZ) were performed
by the US Scientific Registry of Transplant Recipients, UK Transplant, and
the Australia and New Zealand Dialysis and Transplant Registry, respectively.
Unadjusted (Kaplan-Meier) patient and graft survival rates were calculated.
Patient survival analyses included all deaths (including those after loss of graft
function). Comparisons of unadjusted Kaplan-Meier point estimates from
the three separate models were made using normal approximation methods
to compare group survival proportions at one, five, 10, and 15 years posttransplant.
Results: There were 184553, 25095, and 9231 kidney transplants performed in
the US, UK, and ANZ, respectively, from 1988-2005. The proportions of living
donor transplants were 36%, 14%, and 30%, respectively. Male recipients
predominated (60-62%) in all three registries. Recipient age distribution was
comparable (6-7% pediatric and 5-8% >65 years). A much higher proportion
of recipients received transplants for diabetic nephropathy in the US cohort
(22%) compared to the UK (5%; 10% among cases where primary diagnosis
was reported) and ANZ (10%). There was a higher proportion of 0 HLA
mismatched transplants in the US (12%) vs. the UK (9%) and ANZ (6%), but
also a higher proportion of 4-6 HLA mismatched transplants (45% vs. 18% and
29%, respectively). Unadjusted deceased donor (DD) and living donor (LD)
graft and patient survival rates were significantly lower in the US compared
to the UK and to ANZ at five, 10, and 15 years post-transplant (all P<0. 0001)
(Figure). Deceased donor graft survival rates in ANZ were significantly higher
than in the UK at five, 10, and 15 years (P<0. 0005). Deceased donor patient
survival rates in ANZ were modestly but significantly higher than in the UK at
10 and 15 years (P<0. 05). Patient survival rates after living donor transplants
in ANZ were also modestly but significantly higher than in the UK at five and
10 years (P<0. 05) but not at 15 years. Within the more recent 10-year cohorts
(1996-2005), deceased donor graft survival rates at five years among recipients
with diabetic nephropathy were significantly lower in the US compared to the
UK and ANZ (61. 5 vs. 67. 8 and 70. 1; P<0. 0003 for both comparisons), and
not significantly different in the UK vs. ANZ (P=0. 42).
Conclusions: Preliminary analyses of data from three national transplant
registries have highlighted important differences in kidney transplant graft and
patient outcomes between the US, UK, and Australia/New Zealand. The next
step in this important collaboration is to undertake risk-adjusted analyses in
order to explore the role of case mix differences.

Conclusion: Pt survival was not influenced by AR status. An episode of AR
portends a poor prognosis for long-term kidney graft survival. There was no
significant difference in graft survival after AR in pts on Tac vs. CsA. In pts
whose eGFR post-treatment of AR returned to within 10% of baseline, there
was no significant difference in graft survival compared to pts that did not
experience AR. The eGFR post-treatment of AR may be a useful surrogate
marker of long-term kidney graft survival.
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M. Cantarovich, S. Paraskevas, P. Chaudhury, D. Baran, D. Keith, M.
Hassanian, D. Vrochides, M. Lipman, R. Mangel, P. Metrakos,
J. Tchervenkov, M. Ladouceur.
Departments of Medicine and Surgery, Multi-Organ Transplant Program,
and Department of Epidemiology and Biostatistics, McGill University Health
Center, Montréal, Quebec, Canada.
Purpose: To determine the usefulness of the estimated GFR (eGFR) after
treatment of acute rejection (AR) as a surrogate of long-term graft survival
after kidney transplantation (KTx).
Methods: We analyzed 603 pts (49±13 yrs-old), recipients of KTx between
05/1997 and 03/2007. Eighty pts with a first biopsy-proven AR were divided
into 2 groups (Gr. ), based on the post-AR eGFR (MDRD equation). Gr. 1
included pts whose eGFR returned to within 10% of pre-AR values within 3
months post-AR treatment. Gr. 2 included pts whose eGFR did not improve to
within 10% of pre-AR values. In a separate analysis, pts were divided according
to the baseline CNI.
Results: Pt survival at 1, 5 and 10 yrs was 96%, 90% and 82% in non-rejectors,
and 98%, 91% and 76% in rejectors. Pt survival at 1, 5 and 10 yrs was 100%,
90% and 80% in rejectors Gr. 1 and 97%, 93%, 65% in rejectors Gr. 2. Graft
survival at 1, 5 and 10 yrs was 92%, 85%, 73% in non-rejectors and 91%, 73%
and 51% in rejectors (P<0. 001). Graft survival at 1, 5 and 10 yrs was 94%,
81% and 66% in rejectors Gr. 1 and 84%, 58% and 19% in rejectors Gr. 2
(P=0. 04). A multivariate time-dependent graft survival analysis showed that
AR status (HR 4. 00, 95% CI [2. 23-7. 2], P<0. 001), age at treatment of AR
(HR 1. 03, 95% CI [1. 01-1. 05], P=0. 001), and Tac vs. CsA (HR 2. 54, 95% CI
[0. 92-2. 85], P=0. 094) had an important effect on graft survival.
Table 1. Age-adjusted hazard ratio (HR) for patient and graft survival
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484 THE IMPACT OF PROCEDURAL VOLUME AND
OTHER TRANSPLANT HOSPITAL CHARACTERISTICS ON
THE OUTCOMES OF KIDNEY TRANSPLANTATION IN THE
UNITED STATES
J. Kim1, T. Louis2, B. Astor2,3, E. Boulware2,3, N. Powe2,3
1Toronto General Hospital, University Health Network, University of
Toronto, 2Johns Hopkins Bloomberg School of Public Health, Johns Hopkins
University, 3Welch Center for Prevention, Epidemiology and Clinical
Research, Johns Hopkins University
Background: A larger volume of surgical procedures performed by a hospital
has been linked to improved patient outcomes. The relation between transplant
center/hospital characteristics (including volume) and allograft/patient survival
has received limited attention in the current era of kidney transplantation.
Objective: To determine the impact of transplant center volume and other
hospital characteristics (including profit status, total number of beds, and
academic status) on the survival of kidney transplant recipients (KTR) and
their allografts.
Design and Setting: A retrospective cohort study of incident KTR in the
United States Renal Data System from 1 Jan 1994 to 31 Dec 2003 with followup to 31 Dec 2004. Characteristics of transplant hospitals were retrieved from
the 1994, 1997, and 2000 Provider of Services files of the Center for Medicare
and Medicaid Services.
Main Outcomes: Graft failure (including death), death-censored graft failure,
and patient mortality at 1-year, 3-years, 5-years, and total study follow-up.
Results: Transplant center volume was defined as the average number of kidney
transplants performed by a hospital over the study period. The relative hazard
of graft failure for the fourth vs. the first volume quartile was 0. 87 (95% CI
0. 80-0. 96), after covariate and cluster adjustment (see Table). Similar results
were observed for all other outcomes and at 1-, 3-, and 5-years post-transplant.
Higher-order center volume quantiles revealed a consistent reduction in graft
failure and patient mortality at approximately 100 transplants per year. After
adjustment for center characteristics, the volume-outcome relation persisted.
Hospitals affiliated with medical schools and offering residency programs
showed a trend toward lower rates of graft failure but no associations were
observed for other center-level covariates. The findings were robust to various
subgroup and sensitivity analyses.
Conclusions: The highest quartile of transplant center volume was associated
with a consistent reduction in the risk of graft failure and patient mortality among
KTR. This finding persisted after adjustment for other center characteristics.
Future research to better understand the patient and provider factors underlying
this phenomenon should be made a priority in order to improve outcomes for
all KTR.
Table: Results of Cox Proportional Hazards Models for Transplant Center
Volume Quartiles
Study Outcomes

Follow-Up Times for
Cox Models

Graft Total
1. 00
0. 99
Failure follow- (Referent) (0.
up
93-1.
06)

0. 95
(0.
88-1.
03)

Volume
Quartile
1
(0-51.
1 per
yr)
N = 27,
126
121
centers

Volume
Quartile
2
(51.
2-82. 8
per yr)
N = 27,
107
50
centers

Volume
Quartile
3
(82.
9-140
per yr)
N = 27,
080
30
centers

Volume P Value
Quartile (Trend)
4
(140.
1-280
per yr)
N = 26,
303
16
centers

0. 87 0. 010
(0.
80-0.
96)

1-year

1. 00
(Referent)

1. 00 (0.
90-1. 10)

0. 94 (0.
85-1. 05)

0. 85 (0.
74-0. 97)

0. 011

3-years

1. 00
(Referent)

1. 01 (0.
93-1. 09)

0. 95 (0.
87-1. 03)

0. 88 (0.
78-0. 99)

0. 015

5-years

1. 00
(Referent)

1. 00 (0.
93-1. 08)

0. 94 (0.
87-1. 02)

0. 89 (0.
80-0. 99)

0. 012

DeathTotal follow- 1. 00
Censored
up
(Referent)
Graft Failure

1. 00 (0.
93-1. 08)

0. 97 (0.
89-1. 06)

0. 88 (0.
80-0. 96)

0. 038
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1-year

1. 00
(Referent)

1. 02 (0.
91-1. 14)

1. 01 (0.
89-1. 14)

0. 86 (0.
75-0. 99)

0. 047

3-years

1. 00
(Referent)

1. 03 (0.
94-1. 11)

1. 02 (0.
92-1. 12)

0. 89 (0.
78-1. 00)

0. 060

5-years
Patient
Mortality

1. 00
(Referent)

1. 02 (0.
94-1. 10)

0. 99 (0.
91-1. 09)

0. 90 (0.
81-1. 00)

0. 054

Total follow- 1. 00
up
(Referent)

0. 98 (0.
91-1. 07)

0. 94 (0.
86-1. 02)

0. 89 (0.
80-0. 99)

0. 027

1-year

1. 00
(Referent)

0. 97 (0.
85-1. 11)

0. 88 (0.
78-0. 99)

0. 86 (0.
72-1. 01)

0. 034

3-years

1. 00
(Referent)

1. 02 (0.
92-1. 12)

0. 91 (0.
83-0. 99)

0. 90 (0.
78-1. 03)

0. 045

5-years

1. 00
(Referent)

1. 00 (0.
91-1. 09)

0. 91 (0.
83-0. 99)

0. 89 (0.
78-1. 01)

0. 029

485 GENETIC TESTING IN FOCAL SEGMENTAL
GLOMERULOSCLEROSIS (FSGS) IS MANDATORY BEFORE
RENAL TRANSPLANTATION: RESULTS FROM THE ECOFTS
(EUROPEAN COLLABORATIVE FSGS TRANSPLANTATION
STUDY)
T. Jungraithmayr1, P. Cochat2, P. Pagel3, T. Knueppel4, G. Cortina1,
T. Neuhaus5, T. Seeman6, B. Toenshoff4, M. Winn7, B. Zimmerhackl1
1
Pediatrics, Medical University, Innsbruck, Austria, 2Pediatrie, Hopital
Herriot, Lyon, France, 3Genome Oriented Bioinformatics, TU, Munich,
Germany, 4Pediatrics, University, Heidelberg, Germany, 5Pediatrics,
University, Zuerich, Switzerland, 6Pediatrics, University, Prague, Czech
Republic, 77Medical Center, Duke University, Durham, North Carolina,
United States
Renal transplantation (RTx) in steroid resistant FSGS is complicated by high risk
of disease recurrence (DR). DR seems to be influenced by genetic background.
In this international survey a genotype-phenotype correlation is studied.
83 patients (P) with childhood onset of biopsy proven FSGS who had been
transplanted at least once were evaluated by standardized questionnaire. 75 P
were Caucasians, 6 Arabs and 2 Asians. Genetic analysis was performed in 53 P
for NPHS2 (mechanoreceptor) and in 7 P for TRPC6 (Ca++-channel).
Mean age at diagnosis was 6. 8 + 0. 7 years (y). The first RTx was performed
at age 12. 8 + 0. 8 y. 30 P (36%) recurred after a mean time of 152 + 55 days.
29P lost their graft, 41% of those due to DR. A second RTx was performed in
22 P with LRD in 5 P. 50% recurred after a mean time of 96 + 53 days. 11/22
lost their graft, in 72% due to DR. Screening for NPHS2 reveiled 11 P with
mutation, 7 P who were tested for TRPC6 mutations were all negative. P with
a homozygous or compound heterozygous NPHS2 mutation showed no DR
after RTx compared to 43% without mutation (p<0. 05, no results of 30 P, see
figure 1).
Mathematical modelling of the interaction between NPHS2 and TRPC6
indicates strong interaction between these two proteins. Mutations of NPHS2
seem to change the predicted configuration of Podocin with potential interaction
sites to TRPC6.
In conclusion, patients with NPHS2 mutations had a lower risk of DR.
Modelling indicates an influence of NPHS2 on TRPC6 with the potential to
change Ca-channel function. Thus, genetic testing for underlying mutations
is mandatory to improve long term outcome in FSGS. A prospective study for
optimization of treatment in recurring disease is urgently needed.
Supported by ESPN, APN, Universities Innsbruck and Heidelberg. http://
ecofts. uki. at

486 LONG-TERM FOLLOW-UP OF SOLITARY RENAL
ALLOGRAFTS FROM PEDIATRIC DECEASED DONORS 2
YEARS OF AGE OR LESS TRANSPLANTED INTO ADULT
RECIPIENTS
F. Wright, P. Foster, J. Palma-Vargas, A. Bingamam
Texas Transplant Institute
Background: Since 1986 our center has performed over 250 transplants in
adult recipients using single kidneys from donors less than 5 years of age. Our
previous reports (Ref 1) have shown that results of these transplants can equal
those of ideal adult donors. We also identified that kidneys from donors less than
24 months of age were more subject to technical failures and more vunerable
to acute rejection episodes. Here we report updated results on this higher-risk
group of adult recipients of kidneys from donors aged less than 24 months.
Methods: From May 1996 to May 2006, 50 solitary renal allografts from
donors < 24 months of age (median 14. 5 months, range 8-24 months) were
transplanted into adult recipients. Mean donor weight was 11 kg (range
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8-15kg). Technical details were previously reported (Ref 1). Induction
immunosuppression with tacrolimus, mycophenolate and steroid maintainance
was used. Steroid-free immunosuppression has been used since Nov. 2003.
OPTN/SRTR renal transplant data from deceased donors 18-34 years of age
nationally was used for comparison.
Results: One year graft survival for recipients of a solitary pediatric kidney
was 80%, compared with 92% for recipients of adult kidneys from “ideal”
donors aged 18-34 (p=0. 005). Of the allografts from pediatric donors which
failed within the first year, 8/10 failures resulted from vascular thrombosis, with
5/8 (62. 5%) thrombosis episodes from donors 8-10 months of age, compared
with 3/42 (7%) from donors 11-24 months of age (p=0. 001). However, longterm follow up demonstrates overall allograft survival of 72% for recipients of
single kidneys from pediatric donors less than 24 months of age (mean follow
up time 6. 4 years) compared with 73% 5 year survival for recipients of kidneys
from donors aged 18 – 34 years nationally (p value not significant).
Conclusions: Single kidneys from pediatric donors less than 24 months of
age transplanted into adult recipients result in excellent long term outcomes,
comparable to outcomes from “ideal” deceased donors aged 18-34 reported in
SRTR data. Solitary kidneys from donors less than 10 months of age have an
increased risk of early graft failure due to vascular thrombosis. Pediatric donor
kidneys from even the youngest donors should be transplanted as single units to
increase organ availability and optimally utilize donor resources.
Ref. 1: Transplantation Reviews, 13: 148-156, July 1999

487 PRETRANSPLANT MONOCLONAL GAMMOPATHY OF
UNDETERMINED SIGNIFICANCE (MGUS) AS A HIGH RISK
FACTOR FOR KIDNEY TRANSPLANTATION

A. Amato, V. Sparacino, S. Calabrese, F. Caputo, R. Mongiovi, B. Oliva,
R. Turdo, V. Vinti
UO Nefrologia E Trapianto Renale Ospedale CIVICO Palermo
Background: Renal transplantation from HCV-infected donors into
HCV-infected recipients represents one among the potential strategies
to overcome organ shortage and to further the number of patients having
timely access to renal transplantation. Its rationale lies in the idea that
the risk of transmission of HCV is less relevant and clinically harmful
in a subject who has already a chronic infection by the same virus. Some
criticism has been opposed to this viewpoint, because different genotypes
of HCV exist and it is not possible to rule out that infection with a different
genotype could behave as a new or different one and eventually worsen
hepatic prognosis.
Methods: 42 HCV-infected patients with end-stage-renal-disease have been
transplanted between 2000 to 2007 at our institution. 21 of them received a
kidney from an HCV-positive donor and the remaining 21 received a kidney
from an HCV-negative donor. They have been regularly followed-up for an
average time of 2, 3 and 3, 3 years respectively.
Group D+ (recipients of HCVpositive donors)

Group D- (recipients of HCVnegative donors)

Number of patients

21

21

Male/Female

13/8

10/11

Dialysis duration (yrs)

9, 0

8, 0

Dialysis duration (axcluding
those > 15 yrs) (yrs)

5, 26

5, 50

Age at transplantation (yrs)

48, 9

52, 8

HLA Mismatch

3, 7

3, 5

Follow-up (yrs)

2, 3

3, 3

Living donor

0

1

Second transplantation

2

3

Anti-HBc positive donors

2

3

HBV coinfection

1

2
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H. Adrogue2, H. Carbajal1, L. Solter1, O. Gaber1
1The Methodist Hospital, Weill Medical College of Cornell, 2Baylor College
of Medicine, 3The Kidney Institute
Introduction: Monoclonal gammopathy of undetermined significance
(MGUS) has an estimated prevalence of 3% in the general population, and
a 1% annual risk of transformation to myeloma or other lymphoproliferative
malignancy. Serum electrophoresis is part of the standard workup of kidney
transplant (KT) candidates in our center. Currently, guidelines do not exist for
transplant patients with MGUS. The incidence of MGUS and its impact on
patient and graft survival is unknown.
Methods: Retrospective, matched pair case-control study. Starting in the year
2000, all patients undergoing evaluation for a KT found to have MGUS were
included. Clinical and hematological data were collected, as well as current status
of the grafts and patients. MGUS patients who received a KT were matched with
controls at a 1: 2 ratio by age, gender, race, diabetes, type of donor, and date of
transplant. Kaplan Meier survival analysis was done using Wilcoxon testing.
Hazard rate plots were used to analyze the force of death for MGUS patients that
received a KT and for MGUS patients that remained waiting for a KT.
Results: Of the 501 kidney transplant candidates evaluated since 2000, 34
patients were found to have MGUS (6. 8%). Patients were 58% male, age 63.
2 SD10. 3; 52. 8% Caucasian, 38. 9% African-American, 8. 4% other. The
type of paraproteinemia was IgG in 83% of the patients. All the patients that
received a KT had a pretransplant Hematology evaluation, which was negative
for malignant disease. The presence of MGUS was not considered in itself a
contraindication for KT. Nine patients were transplanted. 8 patients received a
deceased donor kidney and 1 patient had a living non-related donor. Median
patient follow-up time after transplant was 18. 7 SD 15. 4 Seven patients (78%)
died in the MGUS group. The median time to patient death was 12. 8 SD 5. 8
months. Causes of death were cerebral abscess, lung cancer, sepsis, melanoma,
bacterial meningitis, myocardial infarction, and one unknown. There were 18
patients in the control group with a median follow-up 33. 4 months, and one
patient (5. 5%) died due to post-transplant lymphproliferative disease. Three
year survival was markedly decreased in the MGUS group: 22% vs. 94% in the
Matched control group (p = 0. 0013).
Conclusion: In our center, MGUS was a common finding in patients
undergoing evaluation for a kidney transplant. There were no cases of myeloma
or other lymphroliferative disease in the MGUS group. However, the early
post-transplant mortality compared to matched control patients was unsettling.
The causes of early death after transplant in the MGUS group are suggestive
of an important immune system dysfunction that may be exacerbated by
transplantation. These findings obviate the need for further accrual of data. A
survey is underway querying other kidney transplant centers about MGUS.

488 RENAL TRANSPLANTATION FROM HCV-INFECTED
DONORS INTO HCV-INFECTED RECIPIENTS: SINGLE
CENTER EXPERIENCE.

Results: One-year patient and organ survival proved to be identical for both
patients who had been grafted with HCV kidneys and those who had been grafted
with negative ones. Subsequent follow-up did not reveal significant differences.

One-year Organ Survival (death
censored)

Group D+ (recipients of HCVpositive donors)

Group D- (recipients of HCVnegative donors)

85, 7%

85, 7%

One-year Patient Survival

95, 2%

95, 2%

Organ Survival so far (Death
censored)

76, 2% *

76, 2% **

Patient Survival so far

90, 5% *

95, 2% **

* Mean follow-up 2, 3 years
** Mean follow-up 3, 3 years

The majority of patients in both groups developed HCV-RNA positivity after
transplantation, though only few have shown signs of active hepatic disease,
generally with mild elevation of liver enzymes. Interestingly, one patient in
the HCV-positive donor group died as a consequence of a HCV-related severe
acute hepatitits whose onset occurred early after transplantation.
In conclusion the consequences of renal transplantation from HCV-infected
donors into HCV-infected recipients remain only scarcely known, especially
in the long-term.
The major, yet uncommon, short-term adverse event reported is acute hepatitis,
which might be probably due to re-infection with a different HCV genotype
(thus specific for patients receiving from HCV donors) or reactivation of the
pre-existing infection.
However, as shown in this study, the short-term results are encouraging showing
a closely similar organ and patient survival of HCV-patients transplanted both
with kidneys from HCV-donors and with HCV-negative ones, suggesting
that, in this era of organ shortage, HCV-matching strategy should deserve
consideration as an alternative feasible source of kidneys for transplantation.
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489 DONOR DOPAMINE FOR THE PREVENTION
OF DELAYED GRAFT FUNCTION AFTER RENAL
TRANSPLANTATION: A RANDOMIZED CONTROLLED TRIAL
P. Schnuelle1, U. Goettmann1, S. Hoeger1, P. Brinkkoetter1, D. Boesebeck2, W.
Lauchart3, M. Smith4, A. Rahmel4, F. van der Woude1, B. Yard1
1
University Hospital Mannheim, 2German Organ Procurement Organisation
(DSO), Region of Bavaria, 3Organ Procurement Organisation (DSO), Region
of Baden-Wuerttemberg, 4Eurotransplant International Foundation
Background: Retrospective clinical data indicate that donor dopamine (DA)
may ameliorate cold preservation injury and improve initial graft function after
kidney transplantation. This RCT investigates a standardized regimen of donor
preconditioning with dopamine in human renal transplant recipients from a
brain dead donor.
Methods: Heart beating donors were randomized to receive or not to receive DA
(4μg/kg*min) after confirmation of brain death and given consent for donation.
Eligibilty criteria included hemodynamic stability with low dose noradrenaline
(<0. 4μg/kg*min), a serum-creatinine <1. 3mg/dl on admission and an increase
<2. 0 mg during intensive care. Allocation of organs was centrally directed
according to current Eurotransplant standards. DGF defined by the requirement
of >1 dialysis session post-transplant was the primary endpoint. Study analysis
was done on intent-to-treat.
Results: Donor DA infusion was given with an average duration of 368±268
min before harvesting of the kidneys (range 0-1929 min). Treated and untreated
donors were very similar in demographics, s-creatinine, and 24hr urine
production. 505 subsequent kidney transplants from 61 collaborating centers
were available for study analysis (DA treated n=234, Ctrls n=271). Baseline
characteristics of the recipients were well balanced. There were no significant
group differences in antigen mismatches, panel reactive antibodies, cold
ischemia time, and immunosuppressive therapies, which were administered
according to the local center’s practice. DA resulted in less DGF after
transplantation (25. 2% vs. 35. 1%, p=0. 02). Donor age (OR 1. 03; 95%CI 1.
01-1. 04), cold-ischemia time (OR 1. 07, 95%CI 1. 03-1. 11), and recipient’s
body weight (OR 1. 02; 95%CI 1. 003-1. 03) were significant determinants
of an increased risk in the multivariate analysis, but the beneficial effect of
DA was remained (OR 0. 58; 95%CI 0. 39-0. 87). DA mediated effects on
hemodynamics and urine production had no measurable effect on the primary
endpoint despite a marginal increase in systolic blood pressure (132 vs. 128
mmHg, p=0. 02) and last hour urine production (207 vs. 176ml, P=0. 005) in
treated donors.
Conclusion: Donor DA ameliorates DGF after kidney transplantation. It
remains to be seen if the beneficial effect translates in improved long-term
graft survival.

490 THE IMPACT OF PURINERGIC SIGNALLING IN RENAL
ISCHAEMIA-REPERFUSION INJURY
B. Lu, E. Lee, S. Robson1, S. Crikis, S. Rajakumar, A. d’Apice, P. Cowan,
K. Dwyer
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Australia
1
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
MA, USA
Background: Adenosine (ADO) signalling via the adenosine 2A receptor
(A2AR) imparts protection in mouse models of renal ischaemia-reperfusion
injury (IRI). ADO is generated by the sequential hydrolysis of extracellular
nucleotides by CD39 and CD73. CD39 and CD73 are recognised as integral
immune and vascular nucleotidases and essential components of regulatory T
cells (Treg). We have previously shown that mice transgenic for human CD39
(hCD39tg) are protected from renal IRI and that this protection is abrogated by
A2AR antagonists. The aim of the present study was to further delineate the
role of ADO in mediating this protective effect using mice deficient in CD39,
CD73 or A2AR, thereby disrupting each tier of the protective adenosinergic
axis. We anticipated that mice deficient in CD39, CD73 or A2AR would exhibit
more severe renal injury than WT mice in this model.
Methods: CD39 null, CD73 null, A2AR null, hCD39tg and wild type (WT)
controls (all on a C57BL/6 background) underwent right nephrectomy
followed by left renal ischemia for 18 min and reperfusion for 24 hrs. Mouse
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core body temperature was maintained at 37ºC for the duration of ischaemia. At
the conclusion of the experiment kidney function was assessed by measuring
serum creatinine (SeCr) and urea (SeU) and the kidney was removed for
histological analysis.
Results: In this model of IRI, WT mice exhibited marked renal injury with a
significant increase in SeCr and SeU. Histologically, the WT kidneys showed
extensive cortical injury characterised by tubular cell oedema and necrosis.
In keeping with the protective role of ADO, mice deficient in A2AR had
an elevated SeCr (82. 5 μmol/L) and SeU (32. 9 mmol/L) following IRI.
In contrast, hCD39tg mice displayed only minor injury, with a SeCr (45. 7
μmol/L) and SeU (17. 6 mmol/L) comparable to sham animals with minimal
histological changes (n=9). Administration of apyrase (a soluble form of CD39)
to WT mice resulted in a similar phenotype to that of the hCD39tg mice (Se Cr
49. 3 μmol/L, Se U 18. 4 mmol/L, n=3). Despite a lower SeCr in CD39 null
mice (51. 2μmol/L, n=9, P=0. 450) compared to WT mice (77. 8μmol/L, n=25)
the histological changes were similar. Interestingly, there was a trend towards
improved outcome in the CD73 null mice following renal IRI with lower SeCr
(53. 4μmol/L, n=9, P=0. 099) and injury score of kidneys from CD73 null mice
were less than that observed in WT mice.
Conclusion: We have established a valid model of renal IRI and can demonstrate
protection by the administration of apyrase or the expression of hCD39 both
biochemically and histologically, which was abrogated with deletion of the
A2AR. Unexpectedly, renal injury was not exacerbated in mice deficient in
CD39 or CD73, suggesting a complex interaction between infiltrating immune
cells, the vasculature and parenchymal expression of these receptors. Adoptive
transfer experiments will be performed to further investigate this interaction.

491 EPO AND ASIALOEPO PROTECT INTESTINAL
ISCHEMIA REPERFUSION INJURY IN RAT
T. Sawada, S. Mori, K. Kubota
Dokkyo University School of Medicine
Objective: Ischemia/reperfusion injury (I/R) in the small intestine is a serious
obstacle in intestinal transplantation. The protective effect of erythropoietin
(EPO) and its non-hematopoietic derivative, asialoEPO (aEPO), against (I/RI)
was investigated in a rat model.
Methods: The superior mesenteric artery of Wistar rats was clamped for 60 min,
and then released. The rats were divided into four groups (n=15 in each group):
sham operation (Sham), vehicle treatment (Vehicle), EPO treatment (EPO),
and asialoEPO treatment (AsialoEPO). EPO and asialoEPO were administered
subcutaneously at a dose of 1000 units/kg 10 min before clamping, 30 min after
the start of clamping, and just before declamping, followed by determination of
72-h survival rates, serum TNF-α and IL-6 levels.
Results: The survival rates at 72 h after I/R injury in the Sham, Vehicle, EPO,
and AsialoEPO groups were 100%, 33. 3%, 75. 0%, and 83. 3%, respectively
(P<0. 05). Blood TNF-α concentrations in the Vehicle, EPO, and AsialoEPO
groups at 6 h after I/RI were 4. 8 ± 1. 4 pg/mL, 1. 2 ± 0. 5 pg/mL, and 1. 0 ±
0. 5 pg/mL, respectively (P<0. 019). The concentrations of IL-6 in the Vehicle,
EPO, and AsialoEPO groups at 6 h after I/RI injury were 3867 ± 1103 pg/mL,
880 ± 253 pg/mL, and 937 ± 283 pg/mL, respectively (P<0. 034)
Conclusions: EPO and asialoEPO exert a strong protective effect against
intestinal I/R injury by inhibiting TNF-α and IL-6.

492 DONOR PRE-TREATMENT WITH AN HIFPPROLYLHYDROXYLASE-INHIBITOR IMPROVES FUNCTION
AND INCREASES LONG-TERM GRAFT SURVIVAL IN AN
ALLOGENIC RAT TRANSPLANT MODEL
M. Wiesener1,2, W. Bernhardt1, U. Gottmann4, F. Doyon4, B. Bucholz1, V.
Campean3,
S. Klaus5, B. Yard4, K-U. Eckardt1
1
Dept. Nephrology & Hypertension, Univ. Erlangen, 2Interdisciplinary Centre
of Clinical Research, Univ. Erlangen, 3Dept. Pathology, Univ. Erlangen, 4Dept.
Nephrology, Univ. Mannheim, 5FibroGen Inc. , South San Francisco
Besides immunological aspects, the long-term survival of a renal allograft
depends on the initial injury caused by the sequence of cold ischemia, warm
ischemia and reperfusion and is thus already determined at the time of
transplantation. Hypoxia-inducible transcription factors (HIF) are essential
for adaptation to low oxygen. Normoxic inactivation of HIF is regulated by
oxygen-dependent hydroxylation of HIF by prolyl-hydroxylases (PHD).
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Pharmacological inhibition of the PHD results in HIF accumulation with
subsequent activation of nephroprotective genes. We examined the effect
of donor treatment with a specific inhibitor of the PHD (FG-4497) on graftfunction in a rat model of allogenic kidney transplantation (KTx).
The Fisher-Lewis rat model of KTx was used. Isogenic transplantations served
as controls. Orthotopic transplantation of the left donor-kidney was performed
after 24h of cold storage. The right kidney was removed at the time of KTx
(acute) or at day 10 (chronic). 6h prior to kidney explantation, donor animals
were treated with a single dose of FG 4497 (40mg/kg i. v. ) or vehicle (Veh)
Recipients were followed up for 10 days (acute, n=6-8) or 24 weeks (chronic,
n=13-14).
Donor-preconditioning with FG 4497 resulted in HIF accumulation and induction
of HIF target genes, which persisted beyond cold storage. It reduced acute renal
injury (Serum creatinine FG-4497: 0. 66±0. 20 vs Veh 1. 49±1. 36; p<0. 05) and
improved histomorphology at 10 days. Donor-preconditioning improved long
term survival of recipient animals (mortality after 24 wks: 7/13 Veh vs. 3/14
FG-4497; 0/13 of the isogenic controls; p<0. 05 FG-4497 vs. Veh).
Pretreatment of organ donors with FG-4497 improves short- and long-term
outcome after prolonged cold storage and subsequent allogenic KTx. These
findings may have significant clinical implications.

493 PREVENTING KIDNEY INJURY BY PERFUSING DONOR
ORGAN WITH SIRNA-SOLUTION

494 PROTECTION OF RENAL ISCHEMIA INJURY BY RENAL
ARTERY INFUSION OF ICAM-1SIRNA
Y.P. lu, G.H. Luo, J. song, L. yang, L. luo, X. Ma, Y.P. li
Transplantation Institute
Aim: Studies have proven that ICAM-1 plays an important role in Ischemia/
reperfusion injury (IRI) of renal transplant. RNA interference (RNAi) with
Chemical modification has shown a strong silencing effect. This study is to
investigate the potential preventing role of infusion small interfering RNA
(siRNA) targeting ICAM-1 through renal artery in rat cold ischemia injury
(IRI) renal transplant model.
Methods: F344 rats underwent renal isografting. The recipients were divided

495 NEW TRENDS IN CLINICAL CARDIAC PRESERVATION
– COLD ISCHEMIA VS. WARM PERFUSION - BENEFICIAL
EFFECTS FOR THE ENDOTHELIUM G. Tenderich, A. El Banaousy, S. Schulte-Eistrup, U. Schulz, M. Tenderich,
M. Morshuis, L. Arusoglu, T. Kahayal, S. Stille, R. Koerfer
Dpt. Thoracic- And Cardiovascularsurgery
Background: Coronary transplant vasculopathy (TVP) is known to be
associated with an impairment of endothelium-dependent vasoreactivity after
heart tranplantation (HTx). Regarding the etiology of TVP, antigendependant
and independant factors (AIF) are responsible for injury of the endothelium.
Ischemic- and the resulting reperfusion injury are thought to play a major role
regarding AIF, with the initial leason to the endothelium. Warm donorblood
perfusion in a beating state of the heart using the organ care system (OCS)
leads to a dramatic decrease of ischemic time and is supposed to minimize the
resulting injury.
Methods and Results: Evaluation of the overall coronary vasodilator capacity
– coronary flow reserve (CFR) assessed by positron emission tomography
(PET) at rest andunder dipyeidamole stress was performed for noninvasively
investigation of 4 different groups of patient (pts):
A: 28 HTx-ed patients (24 men/4 women aged between 19 and 67 years (mean:
52. 5 + 12. 8) follow-up 365 – 483 days post HTx (median: 387d)
Recipient diagnosis: 18 CAD, 8 DCM, 2 VD
13 men and 15 women, aged 11 to 58 years (mean 33. 8 + 11. 1)
Diagnosis: 9 SHT, 8 SAB, 6 ICB, 4 Hypox. , 1 brain neoplasm
Ischemic time:
142 –285 min. (mean: 200 + 35)
B: 7 patients (2 men, 5 women, aged 59 + 8 years with atypical angina pectoris)
with normal CFR and without angiographic coronary artery disease
C: 23 patients (10 men, 13 women aged 58. 7 + 10. 3 years, regulary coronary
angiogram n = 9, minor angiographic coronary artery disease; stenosis <
25% n = 14; hypertension n = 15) with angina pectoris without/with minor
angiographic coronary disease
D: Group D:
10 HTx-ed pts. 375+/-56 days post HTx
Recipient age: 47+/-14y.
Donor age: 33+/-9y. Ischemic time:
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X. Zheng1, J. Jiang, X. Zhang, M. Beduhn, H. Sun, M. Suzuki, N. Kubo,
B. Garcia, A.M.J. Jevnikar, W-P. Min
1University of Western Ontario, 2University of Western Ontario, 3University
of Western Ontario, 4University of Western Ontario, 5University of Western
Ontario, 6University of Western Ontario, 7University of Western Ontario,
8University of Western Ontario, 9University of Western Ontario, 10University
of Western Ontario
Background: Renal ischemia-reperfusion (I/R) injury occurs in kidney
transplantation, and has no current clinical cure. Gene silencing using siRNA
to specifically knock down I/R-associated genes, such as inflammatory,
complement and apoptosis genes, may effectively prevent I/R injury. This
study was designed to prevent renal I/R injury by perfusing donor kidney
organs using siRNA solution.
Methods: C57/BL6 kidneys were excised and perfused with 200 μl of HTK
that contains 100 μg/ml siRNAs targeting Fas, TNFα, and complement 3
(C3) genes. siRNA-solution-perfused kidneys were implanted into syngenic
recipients. Forty-eight hours after transplantation, the grafted kidneys were
harvested. The I/R injury was assessed by renal function, histopathology and
immunohistochemistry.
Results: Perfusion procedure resulted in effective incorporation of siRNA
into kidney tissues, demonstrated by fluorescence-labelled siRNA that was
observed 30 min after perfusion. Gene expression of Fas, TNF-α, and C3 was
significantly knocked down 24 hours after perfusion with siRNA solution.
Perfusion with siRNA prior to transplantation remarkably reduced BUN and
serum creatinine levels. Furthermore, protection of I/R injury by perfusion with
siRNA was demonstrated by improved histopathology, attenuated apoptosis,
and decreased inflammatory cytokine secretion
Conclusion: This is the first demonstration that perfusing donor organs with
siRNA solution effectively delivers siRNA and induces gene silencing in
kidney. Silencing Fas, ΤΝF-α, and C3 using siRNA solution prevented renal
I/R injury, highlighting the promise of clinical application using siRNAbased therapy.

into three groups (each group n=9): (1)Normal saline (NS); (2)control siRNA;
(3)siRNA. Before transplant, the kidneys in three groups were infused either
with Ns or Control siRNA or ICAM-1siRNA (0. 1mg/kg) through the renal
artery with the renal vein clamped ex vivo. siRNA delivering was observed
through Light tools and fluorescence microscope in vivo. SCr was measured
and the expressions of ICAM-1 mRNA and Protein were accessed by realtime RT PCR and Western blot at 6h, 12, 24h, 48h and 72h post-transplant.
The severity of tubular necrosis and inflamed cells infiltration was assessed by
histologic evaluation.
Results: siRNA successfully reached rat graft through renal artery. The
immunohistochemistry (IHC) stain of ICAM-1 was observed in renal
tubular and blood vessel. Comparing with the NS and control siRNA group,
the histologic changes of IRI and IHC positive stain were less severe in
siRNA group. The expression of ICAM-1 mRNA/protein and SCr levels in
the isografts increased in a time dependent manner. However, Comparing
with the NS and control siRNA group, the expressions of ICAM-1 mRNA
and protein in siRNA group were significantly down-regulated from 12 to
48h post-transplant (p< 0. 01), especially at 24h (p< 0. 001). The values of
ICAM-1 mRNA/protein (DQ ratio) in NS, control siRNA and siRNA group
were 22. 83±0. 21/1. 37±0. 02, 23. 17±0. 21/1. 48±0. 07 and 21. 31±0. 21/0. 86±0. 04,
respectively. The values of SCr in siRNA group were lower than those in
other two groups in all time points, the differences from 12h to 48h were
statistically significant (p<0. 01), and the peak effect also appeared at 24h (p<
0. 001). At 24h, SCr (umol/L) in NS, control siRNA and siRNA group was
203. 54±39. 47, 216. 9±61. 65 and 100. 0±25. 80, respectively. The survival
rates in the flethal I/R injury rats after treatment with ICAM-1 siRNA
increased from 50% to 80%.
Conclusions: ICAM-1siRNA can significantly prevent and attenuate the renal
damage secondary to ischemia. It is the first demonstration that the siRNA can
be applied through renal artery infusion.
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42+/-12min.
OCS warm perfusion time:
250+/- 76 min.
Results: Coronary flow reserve was different in all 4 groups with different
levels of significance :
A: 1. 5+/-0. 4
B: 2. 5+/-0. 7
C: 4. 7+/-0. 8
D: 3. 7+/-0. 9
Conclusion: Warm perfusion of the heart using oxigenated nutrientenriched
donorblood may have a positive impact on the functional status of coronary
arteries regarding CFR.

496 POLYPHARMACEUTICAL SURVIVAL KINASE
ACTIVATION PROVIDES SIGNIFICANT CARDIAC
PROTECTION AFTER PROLONGED HYPOTHERMIC
STORAGE.
L. Gao2, J. Kwan2, A. Jabbour2, P. Macdonald1, M. Hicks1
St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: Three processes important to the preservation of donor heart
function after storage and reperfusion are maintenance of nitric oxide flux,
minimisation of intracellular calcium levels and minimisation of energy
depletion. We showed pharmacological modulation of these processes by
supplementing cardioplegic and storage solutions with either the nitric
oxide donor glyceryl trinitrate (GTN), sodium-hydrogen exchange inhibitor
cariporide and the poly (ADP-ribose) polymerase inhibitor INO1153 improved
post storage cardiac function1, 2 and was associated with activation of prosurvival kinases at reperfusion (ERK 1/2 by cariporide or GTN and Akt by
INO1153). The aim of this study was to examine the cardio-protective effect of
a protocol incorporating combination these approaches on the preservation of
haemodynamic function in the isolated rat heart after prolonged hypothermic
storage.
Methods: Pre-arrest indices of cardiac function were measured in isolated
working rat hearts after 25 minutes. Hearts were arrested and stored for 10
hours at 2-3°C in Celsior supplemented with either: 1) GTN (0. 1mg/ml); 2)
cariporide (10μM); 3) INO 1153 (1μM) alone or in combination (see Table
below). Hearts were remounted on the perfusion apparatus after storage and
indices of cardiac function were remeasured, then hearts were frozen in liquid
nitrogen for Western blot analysis.
Results: The values in the following table are post-storage recovery as
percentage of pre-arrest values (mean ± SEM):

TUESDAY

1

Supplement; n

Heart
Rate
(beats/
min)

GTN# 9. 9 ± 9 8. 0 ±
alone; 5
1. 7

0. 8 ±
0. 5

Coronary Aortic
Cardiac
Flow
Flow
Output
(ml/min) (ml/min) (ml/min)

3. 0 ±
0. 7

Car# alone; 6

17. 4 ± 10. 2

21. 0 ± 4. 3

1. 4 ± 0. 8

5. 8 ± 1. 2

INO# alone; 4

21. 5 ± 12. 5

7. 0 ± 2. 9

1. 1 ± 0. 6

1. 7 ± 0. 7

GTN + INO; 6

40. 2 ± 18. 7

15. 3 ± 10. 5

12. 1 ± 9. 5

15. 3 ± 10. 5

Car + INO; 7

28. 2 ± 12. 2

18. 8 ± 8. 7

3. 0 ± 1. 5

7. 3 ± 3. 4

GTN+ Car; 6

54. 5 ± 14. 7

48. 6 ± 12

17. 8 ± 10. 3

25. 7 ± 10. 6

GTN+Car+INO; 6 86. 4± 4. 4§
66. 9 ± 4. 5†
42. 2±10. 7*
49. 2 ± 8. 8¶
#GTN: Glyceryl trinitrate, Car: Cariporide, INO: INO1153; * P < 0. 02, † P < 0. 006,
¶ P < 0. 04 vs all doubly supplemented groups; § P < 0. 02 vs GTN+INO & Car+INO

The functional improvement in the triple supplementation was accompanied
by significant activation of Akt and ERK 1/2 as well as phosphorylation and
activation of their downstream target, GSK-3beta.
Conclusion: These data show supplementing a commercial storage solution
with multiple pharmacological agents targeted to activate different pro-survival
signalling pathways may be a useful approach to increasing the cold ischemic “shelf
life” of the donor heart and maximising function of “marginal” donor hearts.
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497 SERUM ANGIOPOIETIN 1 AND 2 ARE ELEVATED IN
DECEASED BRAIN DEAD DONORS AND PREDICT RENAL
FUNCTION AFTER TRANSPLANTATION.
H. Leuvenink, L. Koudstaal, M. Nijboer, H. Burgerhof, V. Nieuwenhuijs, J.
Homan van der Heide, H. van Goor, R. Ploeg
University Medical Center Groningen
Organs retrieved from deceased brain dead (DBD) donors show worse organ
function and more acute rejection episodes post-transplant than those derived
from living donors. To date, no relevant serum markers are available to predict
kidney function after transplantation. Angiopoietin 1 (Ang-1) and Angiopoietin
2 (Ang-2) are regulatory proteins that play an important role in vascular
inflammation. Ang-1 dampens the inflammatory response while Ang-2 boosts
it. In this respect, Angiopoietins could reflect the immunogenic state of the
organ and could be used as predictors of donor organ quality. Therefore, we
measured Ang-1 and Ang-2 levels in serum from 21 human multi-organ brain
dead donors and compared them to 20 living kidney donors. Serum samples
were obtained from DBD organ donors immediately after diagnosis of brain
death (T0) and just prior to actual organ retrieval (T1). Serum from living
kidney donors was used as a control. Serum Ang-1 and Ang-2 were measured
by ELISA.
In the serum of DBD donors, a profound rise in both Ang-1 and Ang-2 levels
were seen compared to living donors. Serum Ang-1 was significantly elevated
at T0 (T0: 360 ± 57 pg/mL vs. T1 158 ± 18 pg/mL) compared to living donors
(T0: 197 ± 32 pg/mL vs. T1: 156 ± 45 pg/mL. Serum Ang-2 levels in DBD
donors were higher at both time points (T0: 978 ± 159 ng/mL vs. T1: 873 ± 177
ng/mL) compared to living donors (T0: 295 ± 30ng/mL T1: 340±175ng/mL).
Ang-1 levels decreased significantly during the brain dead period comparable
to levels in living donors, suggesting a shift of the inflammatory balance
towards the direction of activation.
Interestingly, higher Ang-2 levels in the donor were associated with an
increased risk of rejection (T0 vs. T1 odds ratio (OR) 1. 003/1. 002 p=0. 03/
p=0. 049). Rejection was defined as biopsy proven rejection in the first year
post-transplant including all grades of interstitial and vascular rejection. Most
strikingly, the shift of Ang-1/Ang-2 ratio towards Ang-2 increased the risk of
delayed graft function (DGF) (T0 vs. T1 OR 0. 003/0. 003 p=0. 036/0. 051).
DGF was defined as the need for dialysis in the first week.
This study shows for the first time that both Ang-1 and Ang-2 are indicators in
the DBD donor of kidney (dys)function after transplantation. The Ang-1/Ang-2
ratio expresses immune activation of the renal graft-to-be and angiopoietins
appear to predict delayed graft function and rejection after transplantation. To
restore the Ang-1/Ang-2 balance may therefore be of great therapeutical value
to improve transplantation outcome of DBD donors. In this respect, Ang-2
neutralizing agents, which have recently been developed as anti-angiogenic
tumor drugs, could be of great value for that purpose.

CONCURRENT ORAL SESSION 39:
PAEDIATRIC LIVER TRANSPLANTATION
498 OUTCOMES OF LIVER TRANSPLANTATION FOR
UNRESECTABLE MALIGNANT LIVER TUMORS IN
CHILDREN: A MULTICENTER REVIEW
M. Nadler1, R. Shepherd2, J. Lowell3, G. Tiao4, L. Smith5, R. Anand6,
C. Song6, Split Group6
1
St. Louis Children’s Hospital, 2Department of Pediatrics, Washington
University School of Medicine, 3Department of Surgery, Washington
University School of Medicine, 4Pediatric Surgery, Cincinnati Children’s
Hospital, 5Department of Pediatrics, New York Presbyterian Hospital,
6
EMMES Corporation, Rockville, MD
Background: Treatment of hepatic malignancies in children is complex and
challenging. Because of their rarity, treatment is not standardized and outcomes
from large cohorts are not well documented. Complete surgical resection appears
essential for cure and with adjunctive chemotherapy, is the mainstay of therapy,
although many tumors are unresectable. In recent years, liver transplantation
has been performed successfully in children with unresectable tumors.
Purpose: To help focus on areas where treatment might be improved,
outcomes and risk factors for poor outcome were studied in a large, multicenter
cohort of children with primary hepatic malignancies who underwent liver
transplantation.
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499 DOES LIVING DONATION OFFER AN ADVANTAGE IN
SURVIVAL AFTER PEDIATRIC LIVER TRANSPLANTATION IN
THE MELD ERA? – ANALYSIS OF OPTN/UNOS DATA
Y. Cho1,2, T. Steljes2, J. Cicciarelli1,2, I. Hutchinson1,2, M. Stapfer2,
R. Mateo2, L. Sher2, R. Selby2, Y. Genyk2
1National Institute of Transplantation, 2USC School of Medicine
Background: Recent studies demonstrated better outcomes of graft and patient
survival in living donor liver transplantation (LDLT) compared with those of
whole liver (WLT) and split liver transplantation (SLT). However their results
often utilize recipients from both pre and post model-for-end-stage- liverdisease (MELD/PELD) implementation.
Aims: This study retrospectively compares LDLT, SLT, and WLT in pediatrics
in the MELD/PELD era by examining the OPTN/UNOS database with the
intent to identify recipient factors that may impact outcomes.
Materials and Methods: From January 1, 2002 to December 31, 2006, 1, 976
liver transplant (LT) in recipients age<12 years old were reported to the OPTN/
UNOS. Of these, 298 LDLTs, 384 SLTs, and 1, 294 WLTs were identified.
Multiple organ transplants were excluded from the study. The log-rank test was
used for comparison of the two survival curves.
Results: Unadjusted graft survival rates of LDLT (85% at 1-yr and 82% 3-yr)
were not significantly different to those of SLT (81% at 1-yr and 75% 3-yr,
P=0. 11) and WLT (81% at 1-yr and 75% 3-yr, P=0. 08) (Figure). Patient
survival rates of LDLT (91% at 1-yr and 90% 3-yr) were also not significantly
different to those of SLT (90% at 1-yr and 86% 3-yr, P=0. 54) and WLT (88%
at 1-yr and 84% 3-yr, P=0. 12) (figure). Incidence of primary graft failure was
3. 4% for LDLT compared with 3. 9% for SLT (P=0. 70) and 3. 5% WLT
(P=0. 91). Incidence of graft loss due to vascular thrombosis in LDLT group
(6. 0%) also was not significantly different than those of SLT (6. 0%, P=0.
98) and WLT group (5. 1%, P=0. 91). Incidence of biliary tract complications
was the highest in SLT (2. 1%) among 3 group, but the differences were not
statististically significant (0. 7% in LDLT, P=0. 13 and 0. 7% WLT, P=0. 96).
In multivariate analyses, both adjusted graft and patient survival rates of LDLT
were not significantly different than those of SLT (Relative Risk (RR)=0. 79

(95% CI: 0. 59-1. 07), P=0. 13 for graft and RR=0. 77 (0. 52-1. 14), P=0. 19
patient) and WLT group (RR=0. 92 (0. 71-1. 18), P=0. 50 for graft and RR=0.
75 (0. 53-1. 06), P=0. 10 patient) after adjusting for confounding factors such
as PELD and regraft.
Conclusion: In the MELD era, both SLT and WLT in pediatrics yielded
comparable graft and patient survival to LDLT.

500 OUTCOME OF NON-HEART BEATING DONOR (NHBD)
LIVERS IN PAEDIATRIC RECIPIENTS.
A. Bartlett, R. Vara, A. Dhawan, G. Mieli-Vergani, M. Rela, N. Heaton,
P. Muiesan
Kings College Hospital
Adult liver transplantation using grafts from non-heart beating donors (NHBD)
is associated with acceptable short and long-term graft survival. Little is known
about the outcome of paediatric recipients transplanted with livers from NHBD.
From April 2001, 158 livers were retrieved from NHBD using our previously
described rapid retrieval technique. Eighty-four were transplanted, of which
11 were paediatric recipients. Donor characteristics of the organs transplanted
into the paediatric recipients included a mean age 25. 5 years (10-64), intensive
care stay of 10. 2 days (1-14) serum bilirubin level of 25 (7-86) and inotropic
support in 4 of 11. The mean warm and cold ischaemic time was 17 (11-29)
minutes and 7. 6 (6. 2-12) hours, respectively. Indications for transplantation
included: various chronic liver diseases in 9, acute liver failure (ALF) in one
and re-transplantation for hepatic artery thrombosis in one. The mean recipient
age was 6. 4 years (8-156 months) with a median Child-Pugh score of 9 (7-13).
Liver grafts were transplanted as whole organs (n=3), reduced grafts (n=6),
formal split (n=1) or an auxiliary (n=1). When a NHBD graft was reduced
the remaining liver was used for isolation and transplantation of hepatocytes
for children with metabolic diseases. Six of the 11 grafts were reperfused
with arterial blood and all had biliary reconstruction by Roux-en-Y hepaticojejunostomy. The mean post-operative follow-up was 32. 3 months (7-67. 4)
months. Five of 11 developed biopsy proven acute rejection of which 2 had two
episodes. The mean AST (mmol/L) at day 1, 3 months and 12 months was 2820
(8471-489), 58. 5 (20-174) and 50. 6 (27-119). Two patients developed cut
surface collections that required percutaneous drainage. One patient developed
ductopenic rejection 18 months post-transplant and is being considered
for retransplantation. To date there have been no biliary complications and
the mean bilirubin (mmol/L) at day 7, 6 months and 12 months was 63. 2
(12-226), 9. 9 (4-31) and 10. 7 (6-20). In summary, LT with NHBD grafts in
paediatric recipients can be performed with low morbidity and excellent patient
outcome.

501 EFFICACY AND SAFETY OF CYTOMEGALOVIRUS
PP65 ANTIGENEMIA-GUIDED PREEMPTIVE THERAPY IN
PEDIATRIC LIVER TRANSPLANT RECIPIENTS
A. De Icaza-González, A. Hernández-Plata, J. Nieto-Zermeño,
L. González-Jorge, C. Zalles-Vidal, G. Varela-Fascinetto
Hospital Infantil De México Federico Gómez, Transplantation Dept
Background: Cytomegalovirus (CMV) infection is a significant cause of
morbidity and mortality in liver trasplantation. Ganciclovir is considered the
mainstay treatment for CMV infection; however, there is still controversy
on the optimal prophylactic strategy for CMV disease after transplantation
(universal prophylaxis vs preemptive therapy). In preemptive therapy
ganciclovir is started and given for a limited time, based on evidence of viral
replication using CMV-pp65 antigenemia or CMV-PCR. Preemptive approach
limits the cost of therapy and reduces the adverse effects related to ganciclovir
and drug resistance. The aim of this study was to analyze our experience on
CMV disease in pediatric liver transplantation and to assess the efficacy and
safety of CMV antigenemia-guided preemptive therapy. Incidence of disease
among different risk groups, survival, adherence to treatment and drug therapy
costs were also analyzed.
Methods: Single center, retrospective review of pediatric liver transplant
recipients during a 9-year period. Only patients that survived a minimum of
3 months after transplant and had an adequate CMV-antigenemia follow-up
were included. Patients receiving antiviral therapy for reasons other than CMV
infection were excluded. Demographics, risk for CMV disease, antigenemia
results, and relevant clinical data were analyzed. Descriptive statistical analysis
included Student’s t test and Pearson correlation test for continuous variables,
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Methods: Data from 2605 children listed for liver transplant in the Studies in
Pediatric Liver Transplantation (SPLIT) Registry between 1996 and 2006 was
studied. Patient and graft survival were compared amongst the types of hepatic
malignancies, and with non-tumor outcomes, and risk factors for poor outcome
for each tumor type such as timing of transplant from listing, donor type, age,
gender, and era of transplant were evaluated.
Results: A total of 176 children had hepatic malignancies, including
hepatoblastoma (HB, n=124), hepatocellular carcinoma (HCC, n=21),
hemangioendothelioma (HE, n=18), and ‘other’ tumor (n=13; undifferentiated
embryonal sarcoma (UES, n=5/13). Recipient age and gender were not
statistically significant in terms of outcomes. All deaths on the waiting list
(HB, n=3, HCC, n=2, HE, n=3) occurred prior to 2002. Five year patient and
graft survival rates from transplant were lower compared to non-tumor patients
(71% patient, 66% graft vs. 87% and 79%, p<0. 01), mainly related to tumor
metastases/recurrence: of 34 reported patient deaths in all hepatic malignancies,
24 were tumor related (HB, n=20, HCC, n=4). Two of five reported deaths in
patients with HE were related to severe cardiomyopathy. Five year survival
rates were improved in patients who received live donor transplants when
compared to deceased donor transplants (84% patient, 76% graft vs. 68% and
64%, p<0. 001). Five year patient and graft survival in the ‘other’ tumor type
category were better (100%, 92%, respectively) when compared to HB (69%,
64%), HCC (63%, 63%), and HE (65%, 65%) tumor types.
Discussion: Long term survival after liver transplantation for unresectable
hepatic malignancies in children compares favorably with reported survival
after primary resection. Timing of transplant may play a role in outcome: all
waiting list deaths occurred prior to use of the current UNOS PELD scoring
system; the improved outcomes in those receiving living donor transplants may
also reflect on the ability to time transplantation more effectively. However, the
majority of patient deaths after transplant were due to recurrence, particularly in
HB, where close attention to resectability vs. transplantation at diagnosis, and
effects of adjunctive chemotherapy, while beyond the scope of this analysis,
deserves detailed further study. In HE, the focus should be on preventing cardiac
mortality. Outcomes for ‘other’ rare tumors such as UES were uniformly good,
suggesting that primary liver transplant may be the preferred modality for
surgery for these multicentric hepatic malignancies.
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and Chi-square and Fisher’s exact test to compare nominal data. Overall
actuarial survival was calculated using Kaplan-Meier analysis.
Results: Forty patients were included for analysis. Twenty four had a history
of positive antigenemia (Ag+) and 16 had negative antigenemia (Ag-) during
their follow up. There were no demographic differences between groups. The
incidence of a Ag+ according to risk group was 77% for D+/R-, 63% D+/R+,
50% D-/R+ and 25% D-/R-. None of the 16 Ag- patients received ganciclovir
after transplantation. Among the 24 Ag+ patients, only 14 received preemptive
treatment based on clinical suspicion of CMV disease, more than 10 positive
cells in the antigenemia and high-risk status for CMV disease. Only one patient
with intermediate risk and 53 positive cells developed invasive CMV disease
that ultimately responded to treatment. The 10 Ag+ patients that did not received
treatment were asymptomatic, 5 presented one positive cell antigenemia, 3
patients had 2 positive cells, and 2 patients had 4 and 9 positive cells, respectively,
that reversed to Ag- under close clinical and laboratory monitoring. Actuarial
survival at 1800-days post-transplantation was similar between groups: 95%
for Ag+ and 100% for Ag- patients. There were no CMV-related deaths. In this
study, preemptive treatment saved more than 150, 000 USD.
Conclusion: CMV pp65 antigenemia-guided preemptive treatment is
affordable, safe, and effective. This study also confirms that positive CMV
pp65 antigenemia in liver transplant recipients with low and intermediate risk
for CMV disease does not mandate preemptive ganciclovir treatment, and
some of these patients might be closely observed with repeated determination
of antigenemia until its negativization.

502 LESSONS LEARNED FROM 120 CONSECUTIVE LIVING
DONOR LIVER TRANSPLANTATIONS FOR BILIARY ATRESIA
IN A SINGLE CENTER
A.D. Concejero, C.L. Chen, C.C. Wang, S.H. Wang, C.C. Lin, Y.W. Liu,
C.H. Yang, C.C. Yong, T.S. Lin
Liver Transplant Program, Department of Surgery, Chang Gung Memorial
Hospital-Kaohsiung Medical Center
Background and objective: Biliary atresia (BA) is the most common
indication for liver transplant in children. The aim of this study is to present
our experience in living donor liver transplantation (LDLT) as a treatment for
end-stage liver disease in children with BA.
Patients and methods: A review of transplant records from June1994November 2007 was performed. One hundred-twenty (120) BA patients
underwent primary LDLT. The mean follow-up period was 48 months.
Results: There were 62 males and 58 females. The mean age was 3. 6 years
(range: 6 months-19 years). The mean preoperative weight, height and computed
GFR were 13. 9 kg, 80. 3 cm, and 117. 5 ml/min/1. 73 m2, respectively. 32
patients were below 1 year of age, and 59 patients were below 10 kg at time of
transplantation. 115 had had previous Kasai operation prior to transplant. The
most common co-existing medical condition was congenital heart disease. The
mother was the most common donor. The mean donor intraoperative blood loss
was 70 ml. There were 4 donor complications with 2 donor reoperations. The
mean recipient operative time was 607 min. The mean recipient intraoperative
blood loss was 297 ml. 39 did not require blood or blood component transfusion.
The left lateral segment (77) was the most common graft used. 22 grafts
underwent venoplasty prior to implantation. Innovative techniques like use of
Foley catheter to reposition the graft in outflow problems and use of Gore-Tex
to approximate the abdominal fascia were employed. There were 33 operative
complications which included 4 reoperations for postoperative bleeding,
10 portal vein, 5 hepatic vein, 7 hepatic artery, and 7 biliary complications.
There were 4 in-hospital mortalities and 2 retransplantations. Most major
late complications occurred in recipients who received blood transfusion.
The posttransplant renal function was adequate in a majority; and metabolic
disturbances were not documented. The overall rejection rate was 20%. The
overall graft failure rate was 4% and the overall mortality rate was 5%. The
6-month, 1-year, and 5-year actual recipient survival rates were all 97%.
Conclusion: LDLT is a treatment for end-stage liver disease secondary to BA
that has yielded excellent recipient outcome and low donor morbidity.
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503 LIVER TRANSPLANTATION FOR SMALL CHILDREN IN
CHILE: EXPERIENCE AND LONG-TERM OUTCOME
R. Busuttil
David Geffen School of Medicine At UCLA
Introduction: The outcome of orthotopic liver transplantation (OLT) in
pediatric patients has improved in last decades, but the subgroup of small
children, weighting 10 kilograms or less, still presents several clinical problems.
Despite optimal results reported elsewhere, complications are more frequent
than in older patients, specially from vascular anastomoses. The aim of this
study is to present the experience of liver transplantation in patients weighing
10 kilograms or less, in a multicenter liver transplantation program in Chile.
Patients and Methods: From November 1993 to February 2008, we performed
348 OLT, 188 of them in pediatric patients younger than 15 years. 37 patients,
weighing 10 kilograms or less were transplanted. The data of these cases was
reviewed. Kaplan Meier test was used for actuarial survival.
Results: 37 children received 45 grafts. 6 patients required retransplant, 2 of
them received a third graft. Twenty patients were males (54%). Median age and
weight were 1. 1 years (range 8 months-6 years) and 8. 1 kg. (range 4. 8-10)
respectively. Primary liver disease was biliary atresia in 25 patients (68%),
Alagille syndrome in 4 (11%), fulminant hepatitis in 2 (5%), Byler disease in
2 (5%), neonatal hepatitis in 2 (5%), hepatoblastoma in 1 (3%) and metabolic
disease in 1 (3%). Grafts from living donor (segments II-III) were used in
23 cases (51%); deceased donor grafts in 22 patients (49%) (11 complete
liver, 10 reduced grafts, and 1 split-liver). Graft-to-recipient weight ratio was
greater than 1% in all the cases. Two patients underwent delayed abdominal
wall closure. Immunossupresion was based on cyclosporin or tacrolimus plus
steroids. Daily hepatic ultrasound with doppler was performed in the first 10
days after OLT.
Regarding vascular complications, 8 cases of portal vein thrombosis (PVT)
were seen, 5 hepatic arthery thrombosis (HAT), and one patient with both
(PVT-HAT). Of them, 10 required reoperation (7 PVT, 2 HAT and 1 PVTHAT). Five patients had biliary leaks, requiring surgical repair. There were 3
biliary stenosis managed percutaneously.
Patient survival at 1 and 5 years is 75% and 64%. Main cause of death within
this group was infection (7 patients, 19%).
Only 2 patients have died due to vascular complications. Of the 8 retransplants,
1 was due to HAT and 3 to PVT. There have been no deaths due to vascular
complications in the last 11 years, and no graft lost for this cause in the last 4
years.
Comments: Liver transplantation in small children is a major medical and
surgical challenge. Our results are comparable to countries with similar
conditions of pediatric liver transplantation, although still below large series
published. The improvement in the surgical technique in the last years has lead
to fewer vascular complications and trends to better outcome. This is the largest
series in our country.

504 ISOLATED LIVER TRANSPLANTATION IN CHILDREN
WITH CYSTIC FIBROSIS – THE ANLTU EXPERIENCE
S. Nightingale1,2, E. O’Loughlin1, S. Dorney1, A. Shun1,4, S. Strasser3,
G. McCaughan3,4, K. Gaskin1,2, V. Jermyn1, P. Van Asperen1,2,
M. Stormon1,4
1
Childrens Hospital At Westmead, 2Discipline of Paediatrics and Child
Health, University of Sydney, 3Royal Prince Alfred Hospital, 4Australian
National Liver Transplantation Unit, Sydney
Objectives: To review the experience of the Australian National Liver
Transplant Unit (ANLTU) with isolated liver transplantation (LT) in children
with cystic fibrosis (CF).
Methods: Retrospective record review of all children with CF with who
underwent LT since ANLTU began in 1986. Baseline and post-LT clinical and
laboratory data, as well as survival and outcomes were analysed.
Results: Eight children (6 male) were transplanted (median age 12yrs, range
11-16) between 1993 and 2005. Complications of portal hypertension were the
main indication for LT in four patients, with synthetic dysfunction a significant
factor in the remaining three. All patients were pancreatic insufficient. One
had diabetes at the time of LT, and two developed it soon afterwards. Three
patients had common bile duct strictures identified previously (two had
cholecystojejunostomies performed). Two patients were severely malnourished,
with BMI <1st percentile. Seven patients had pulmonary colonisation with

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Oral Abstracts
Pseudomonas aeruginosa prior to LT. One had previous colonisation with
Burkholderia cepacia which was eradicated before LT. Six patients had fungal
organisms cultured from sputum or bronchoalveolar lavage pre-transplant:
three with Aspergillus fumigatus, two with Candida albicans, and one with
Scedosporium species. All of these patients received antifungal therapy in
the peri-transplant period. FEV1 (% predicted) ranged from 59-116% preLT, and did not deteriorate significantly post-LT; indeed it improved in three
patients. Four patients required mechanical ventilation for less than 48 hours
post-transplant. All grafts were cadaveric: six whole livers, two split grafts.
One required delayed abdominal closure. A jejunal roux loop was used in all
cases for biliary-enteric anastomosis (existing loop used in the two patients
with previous cholecystojejunostomy). Four patients received cyclosporin,
and four tacrolimus. Six of our patients are alive, four now followed in adult
services. None of these have any known biliary complications. Of the two
patients who died, one succumbed to fungal sepsis on day 45 following
severe acute rejection requiring treatment with corticosteroids followed by
OKT3. The other died with respiratory failure on day 31, and was found to
have A. fumigatus and multiple strains of P. aeruginosa in respiratory cultures.
Surviving patients all have good graft function, except one patient who has
developed portal hypertension in association with macrovesicular steatosis
and minimal fibrosis on biopsy.
Conclusions: Isolated LT for CF is successful. The ANLTU survival
rate compares favourably with other published series. Roux loop biliaryenteric anastomosis in CF patients provides good long term biliary
drainage post-LT. Organisms colonising the lung should be determined
pre-transplant and antibacterial/antifungal prophylaxis instituted during
the peri-transplant period. Overall lung function does not deteriorate,
with improvement in some after LT. CF patients may be at increased risk
of septic complications following potent immunosuppression, as required
for acute rejection.

G. Yanni1, D. Shores1, P. Yorgin1, S. Sahney1, D. Cutler1, M. Shah1, C. Ejike1,
S. Abd Allah1, M. Mathur1, P. Baron2
1
Loma Linda University Children’s Hospital, 2Loma Linda University
Transplantation Institute
Aim: To assess the efficacy of Plasmapheresis (Therapeutic Plasma Exchange,
TPE) combined with Continuous Renal Replacement Therapy (CRRT) in
treating children with AHF and ACHF.
Background: Pediatric AHF is a rare and potentially fatal condition,
characterized by the development of hepatic encephalopathy (HE) with or
without cerebral edema, severe coagulopathy and multi-organ system failure.
Without liver transplantation (LT), there is a great risk for morbidity and
mortality. Hepatocyte regeneration and recovery has been demonstrated,
especially in young children but many patients may still require LT. Medical
therapy that can decrease the risk of neurological complications and improve
the coagulopathy may allow time for the hepatocyte regeneration and
also help to stabilize those patients waiting for transplantation. We report
our experience using TPE combined with CRRT in patients with AHF and
ACHF.
Methods: IRB approved retrospective chart review of all children with AHF and
ACHF who were admitted between January 1st 2004 to February 29th 2008.
Results: Eight patients were admitted, ages ranged from 22 months to 18
years. M: F ratio is 3: 5 Clinical presentations include acute abdominal pain,
fever, altered mental status (HE) and jaundice. Seven patients had AHF and
one had ACHF. Etiologies and pathology of the AHF include Acetaminophen
Toxicity (3) with 75-80% massive hepatic necrosis, Budd-Chiari Syndrome
(2) with central necrosis and thrombosis on the explanted liver, Idiopathic
AHF (1), Enterovirus AHF (1) with complete hepatic collapse (explanted
liver) and deteriorated Langerhan’s Cell Histiocytosis CHF (1) with 90%
cirrhotic explanted liver. Seven patients had HE (1 with grade II, 3 with
grade III and 3 with grade IV). Initial INR ranged from 2. 1 to 12. All patients
received combination of TPE and or CRRT. Duration of treatment ranged
from 1 to 7 days. Four patients (50%) had full spontaneous recovery with
intact neurological function, recovered hepatic synthetic function. Four

506 TEN YEAR EXPIERENCE WITH PREEMPTIVE
APPROACH TO CMV INFECTION IN PEDIATRIC LIVER
TRANSPLANTATION
T. Pillen1, G. Smallwood2, R. Romero2, T. Heffron2
1
Children’s Healthcare of Atlanta, 2Emory University School of Medicine
Background: Cytomegalovirus (CMV) infections in solid organ transplant
continue to be associated with increased morbidity and mortality. Currently
there are two approaches to CMV in solid organ transplant. One approach,
prophylaxis, consists of using ganciclovir type products (ganciclovir or
valganciclovir) for 3 to 6 months to prevent the development of CMV. We
know from several multicenter studies, especially liver transplant, which
indicate that CMV is only delayed with prophylaxis and not prevented. The
other approach is a preemptive approach which follows patients by polymerase
chain reaction (PCR) and treats CMV infection when CMV DNA is isolated.
Pediatric patients are considered to be at the highest risk of developing CMV
since most pediatric patients are CMV antibody negative recipient of a CMV
antibody positive organ.
Purpose: To evaluate our ten year experience with preemptive PCR monitoring
and treating CMV in pediatric liver transplantation.
Methods: Patients were routinely followed by weekly, serial blood draws
for CMV by PCR and did not receive prophylactic antivirals. At time of
seroconversion, patients were started on ganciclovir IV 5mg/Kg Q12H and
continued to be followed by PCR to monitor treatment. All patients received
the same immunosuppressive protocol of daclizumab 1mg/kg induction,
tacrolimus started 3-7 days following liver transplantation, mycophenolate
and steroids. Presence of CMV was confirmed by quantitative PCR (COBAS
AMPLICOR CMV assay, Roche). Patients slow to respond to treatment were
evaluated for resistance as determined by mutations of the UL54 (polymerase)
and UL97 (phosphotransferase) genes.
Results: From February 1997 till present, 187 pediatric patients received 210
liver grafts. A total of 66 (35. 2%) patients seroconvert with 72. 7% (48/66)
of patients seroconverting once, 22. 7% (15/66) seroconverting twice, and
3 (4. 5%) patients had 3 episodes of seroconversion. Mean time to initial
seroconversion was 51. 6 ± 62. 6 days with secondary re-conversion occurring
177. 2 ± 206 days following transplant. Tissue invasive disease occurred
in 22. 7% (15/66) of patients which included CMV hepatitis in 8 patients,
6 patients with CMV gastroenteritis and one pneumonitis. Based on CMV
seroconversion, patients were similar in respect to age at transplant (6. 9 ±
6. 4 yr. vs 6. 7 ± 6. 6; p = 0. 876), patients with CMV seroconversion had
longer hospitalization (36. 6 ± 30. 8 days vs. 26. 1 ± 24. 1 days; p = 0. 02),
with similar 1 year survival (90. 8% vs, 93. 1%; p = 0. 306). A mutation in the
UL54 gene at codon A692S was identified in one patient which appeared to
convey ganciclovir resistance.
Conclusion: Patients can be preemptively followed by PCR for CMV
without the use of antiviral CMV prophylaxis without increased incidence
of mortality in our series. By utilizing a preemptive approach, all patients
are not exposed to ganciclovir and hopefully will avoid the development of
resistant CMV.
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505 SUCCESSFUL USE OF PLASMAPHERESIS COMBINED
WITH CONTINUOUS RENAL REPLACEMENT THERAPY
(CRRT) IN TREATING CHILDREN WITH ACUTE HEPATIC
FAILURE (AHF) AND ACUTE-ON CHRONIC HEPATIC
FAILURE (ACHF)

patients (50%) were bridged successfully to liver transplantation and three
patients had subsequent full recovery (one had small water-shed infarct and
had partial neurological recovery). All patients with acetaminophen toxicity
had full recovery.
Conclusion: 1-TPE combined with CRRT appears to be an effective modality
for supporting children with AHF or ACHF awaiting liver transplantation.
2-Support with this therapeutic modality allowed time for spontaneous
recovery avoiding LT altogether in half of our patients, and in the other four
who eventually needed LT, improved their pre-transplant clinical condition.
3-A randomized Multi-Center trial should be considered in order to validate the
efficacy of this treatment modality.
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507 B7H1-OVEREXPRESSED SWINE ACCESSORY CELLS
INDUCE HUMAN REGULATORY TR1 SUBSET IN MHC
INCOMPATIBLE CONDITIONS FOR SUPPRESSION OF
XENOGENEIC REACTIONS
G-Y. Zhou, Q. Ding, X. Zhou, J. Tao, L. Lu, Y. Zhou, Z. Jiao, N. Yang, L. Xin
Shanghai Institute of Immunology, Shanghai Jiaotong University School of
Medicine
Type 1 regulatory T cells (Tr1) are active in induction of transplantation
tolerance. Our previous work demonstrated that Tr1 cells can be generated
from purified mouse CD4 T cells after treated with anti-CD3 mAb plus soluble
B7H1-Ig fusion protein. B7H1 is a member of the cosignaling molecule B7
family. In this study, Tr1 cells were also activated from human CD4 T cells
(hCD4 T) by B7H1-overexpressed accessory A431 cells in a way that at least
one DR-DQ haplotype is shared between the hCD4 T and the B7H1-positive
A431. When A431 were substituted with B7H1-transfected porcine iliac
artery endothelial cells (PIECs), hCD4 T cells were still able to differentiate
into human Tr1 cells if the expression of swine SLA-DR, instead of SLA-DQ,
on the PIECs was blocked with mAb. The activated Tr1 cells were potent
for inducing suppression of xenogeneic mixed lymphocyte-endothelial cell
response (xeno-MLER) by secreting cytokines IL-10 and TGF-beta. This
implicates that the MHC class II restriction might not really involved in the
generation of regulatory Tr1 cells. Accordingly, the PIECs were cotransfected
with genes coding for B7H1 and a class II transactivator mutant (mCIITA).
The mCIITA is a depressor for transcription of class II genes. Again, the
resultant B7H1-positive, SLA-DR-negative PIECs functioned well for
human Tr1 generation. Repeat stimulating hCD4 T cells with the mCIITA/
B7H1-cotransfected PIECs left a CD4-positive, CD25-negative, FoxP3negative, IFN-gammaR-positive, IL-10R-positive Tr1 population at purity
of 93. 6% (3. 8% in control), which down-regulated the xeno-MLER in a
dose-dependent manner. This suggests that the B7H1-positive, SLA-DRnegative PIECs might be utilized as a universal cellular reagent for inducing
transplantation tolerance via activating the regulatory Tr1 subset even in
histoincompatible conditions.

508 THE ROLE OF THE PD-L1 SIGNAL IN THE
REGULATION OF ALLOGENEIC IMMUNE RESPONSE
W. Li2, W. Wang1, K. Carper2, F. Malone3, Y. Latchman2, J. Perkins2,
J. Reyes2
1
JiLin University, Changchun, China, 2University of Washington, Seattle, WA,
USA, 3Children’s Hospital & Regional Medical Center, Seattle, WA, USA
Background: PD-L1, a homolog to B7, has recently been identified as a
ligand for PD-1, and is expressed on a variety of tissues and cells including T
cells (CD4, CD8, natural killer [NK] T cells, B cells, and antigen presenting
cells (APCs). PD-L1 negatively regulates T cell function, inhibits T cell
positive selection and development in the thymus, and plays a critical role
in the regulation of peripheral tolerance. The exact role of the regulation of
alloimmune responses by PD-L1 on each cell type remains unclear. In this
study we employed PD-L1-/- mice to evaluate the role of the PD-L1: PD-1
interaction in alloimmune responses in vivo and in vitro, and to further explore
the underlying mechanisms.
Methods: Heart transplantation was performed from PD-L1-/- donors or
recipients in MHC fully mismatched mouse combinations of B6/PD-L1-/- and
C3H strains. The immunologic function of allograft recipients was evaluated
ex vivo by ELISPOT, MLR, CTL, and flow cytometry.
Results: PD-L1 deficiency decreased Foxp3+CD4+ T regulatory cells
(Treg) and increased CD11b+ and CD11c+ cells in the spleens. Both T cell
proliferative activity and allostimulatory activity of APCs from PD-L1-/mice were enhanced. Heart allografts were rejected at an accelerated rate
in both PD-L1-/- donors and recipients. The mean survival time (MST) of
PD-L1-/- allografts in C3H recipients was 9. 3 ± 1. 1 days compared to
36 ± 37 days in WT controls (p < 0. 05); the MST of C3H allografts in
PD-L1-/- recipients was 8. 5 ± 0. 6 days compared to 13. 3 ± 1. 3 days in WT
B6 recipients (p < 0. 01). This was associated with significantly augmented
donor specific T cell proliferation and anti-donor CTL activities, and
enhanced Th1 or Th2 type immune responses of heart allograft recipients.
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Both Th1 (IL-2, p < 0. 05 and IFN-gamma, p < 0. 05) and Th2 (IL-4, p
< 0. 05) cytokine production were increased significantly in the T cells of
PD-L1-/- recipients. However, the T cells from the recipients of PD-L1-/donors revealed a significant increase in only Th1 cytokine IFN-gamma (p
< 0. 05).
Conclusions: Deficiency in the PD-L1 signal altered the balance of peripheral
lymphocytes, augmented the allogeneic immune responses of effector T cells
and allostimulatory activity of APCs, and accelerated heart allograft rejection
through the enhancement of anti-donor immune responses. Engagement of the
PD-L1 signal on either T cells or APCs may be necessary to induce transplant
tolerance.

509 COSTIMULATORY BLOCKADE-MEDIATED LUNG
ALLOGRAFT ACCEPTANCE IS ASSOCIATED WITH INTRAGRAFT ACCUMULATION OF CD4+FOXP3+ REGULATORY T
CELLS AND IS ABROGATED BY OVEREXPRESSION OF BCL-2
IN THE RECIPIENT
M. Okazaki, J. Lai, S. Sugimoto, C. Kornfeld, S. Richardson, F. Kreisel,
A. Patterson, A. Krupnick, A. Gelman, D. Kreisel
Washington University In St. Louis
Background: Lung allografts are more immunogenic than other solid organ
grafts. This results in higher rates of graft rejection and comparatively worse
survival rates after lung transplantation. The efficacy of tolerogenic strategies
after lung transplantation remains largely unexplored. We used a novel model
of vascularized orthotopic lung transplantation in the mouse to study the effects
of costimulatory blockade on lung allograft rejection.
Materials and Methods: Orthotopic vascularized mouse lung transplants
were performed in the Balb/c --> B6 strain combination. Recipients were
either not immunosuppressed or received costimulatory blockade with
MR1 (250 mcg, day 0) and CTLA4Ig (200 mcg, day 2). Balb/c lung
allografts were also transplanted into vav-Bcl-2 transgenic B6 recipients.
Lung grafts were analyzed histologically and by flow cytometry 7 days
after transplantation. In addition, intragraft CD4+ T cells were isolated by
flow cytometric sorting from Balb/c --> B6 transplants (day 7) that had
received MR1 and CTLA4Ig and their regulatory potential was tested in
mixed lymphocyte reactions in vitro.
Results: Nonimmunosuppressed Balb/c --> B6 lung transplants had severe
acute rejection 7 days after transplantation. The ratio of intra-graft CD8 : CD4
T cells was 2. 82 ± 0. 3 (S. E. M. ). B6 recipients of Balb/c lungs that had
received perioperative costimulatory blockade with MR1 and CTLA4Ig had
only minimal inflammation and the ratio of intra-graft CD8 : CD4 was 0. 98
± 0. 11. 39. 75% ± 4. 89 of graft-infiltrating CD8+ T cells expressed IFNgamma. 34. 25% ± 4. 41 of intragraft CD4+ T cells expressed Foxp3 indicating
a regulatory phenotype. CD4+ T cells isolated from these grafts induced
apoptosis of B6 CD8+ T cells that were stimulated with Balb/c splenocytes
in vitro and suppressed their proliferation. Unlike the case for wildtype B6
mice, by day 7 we observed severe acute rejection of Balb/c lung allografts
after transplantation into Bcl-2 transgenic B6 recipients despite administration
of perioperative costimulatory blockade. In these Bcl-2 transgenic recipients
the ratio of intragraft CD8 : CD4 T cells was 3. 52 ± 0. 11, comparable to that
observed in nonimmunosuppressed Balb/c --> B6 lung transplants. Moreover,
only 13. 3% ± 0. 22 of intra-graft CD4+ T cells expressed Foxp3. The
percentage of graft-infiltrating CD8+ T cells expressing IFN-gamma was 57.
3% ± 9. 68, which was higher than that observed in costimulation blockadetreated wildtype B6 recipients.
Conclusions: This study shows that acceptance of lung allografts after
administration of perioperative costimulatory blockade is associated with a
decreased ratio of CD8 : CD4 T cells within the grafts and with an accumulation
of regulatory CD4+Foxp3+ T cells within the allograft. Our in vitro studies
suggest that the regulatory function of these CD4+Foxp3+ T cells is at least in
part due to induction of apoptosis of alloreactive CD8+ T cells. This is further
supported by the increased ratio of intra-graft CD8 : CD4 T cells, the increased
expression of IFN-gamma in CD8+ T cells and allograft rejection observed in
Bcl-2 transgenic recipients.
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510 DENDRITIC CELLS PLUS TGF-BETA1
DIFFERENTIATED NAÏVE CD4+ T CELLS BUT NOT NATURAL
REGULATORY T CELLS PROTECT ALLOGRAFTS

511 ANTIGEN PRESENTATION BY EPIDERMAL
LANGERHANS CELLS INDUCES CD4 T CELL TOLERANCE IN
VIVO
E. Shklovskaya1, D. Gracey2, B. Fazekas de St. Groth2
1Centenary Institute of Cancer Medicine And Cell Biology, Newtown,
Australia, 2Department of Nephrology, Prince of Wales Hospital, Randwick,
Australia
The role of dendritic cells (DC) in the initiation of graft rejection is well
recognised. However, the function of different skin DC subsets in skin graft
rejection remains elusive. We have developed a novel mouse model to study
CD4 T cell responses to individual DC subsets in vivo. In this model, 5C. C7
T cell receptor-transgenic CD4 T cells cross-react with MHC class II IAs, in
addition to their specificity for moth cytochrome c peptide (pMCC) in the
context of MHC class II-IEk or IEb.
To test the function of epidermal Langerhans cells (LC) in CD4 T cell priming,
we constructed radiation chimeras in which IE-positive hosts were reconstituted
with IE-negative bone marrow (termed IE-®IE+). In these chimeras 97% of
skin LC and approximately 15% of migratory DC in cutaneous lymph nodes
expressed IE. As a control, we replaced 25% bone marrow in IE-negative

512 EXOSOMES CAPTURED, PROCCESED AND
EXCHANGED BY SPLENIC DENDRITIC CELLS SPREAD ALLO
– PEPTIDE BETWEEN DCS AND AMPLIFY ANTI DONOR T
CELL RESPONSE IN VIVO.
A. Montecalvo1, W.J. Shufesky1, S.J. Di Vito1, A.T. Larregina2, D. Beer Stolz3,
A.E. Morelli1
1
Department of Surgery, T. E. Starlz, 2Department of Dermatology and
Immunology, 3Department of Cell Biology, University of Pittsburgh
Exosomes are nanovesicles (60-100 nm) secreted by antigen-presenting cells
(APC) such as dendritic cells (DCs) and B cells, as well as other cell types
including T cells, mast cells, tumor cells, and intestinal epithelial cells. APC
derived exosomes accumulate MHC II-Ag, costimulatory (CD80, CD86), and
adhesion molecules (ICAM-1). Therefore, although the function of exosomes
has been not yet well understood, the evidence that those molecules are
topologically oriented facing outwards the plasma membrane, suggests the
possible role of exosomes as a ”vehicle” to spread allo-Ags between DCs to
prime directly anti-donor T cells response. Aims: We investigated, in vivo,
the ability of exosomes to transport allopeptides to recipient DC in secondary
lymphoid organs and their possible role to stimulate T cells anti-donor
response. Moreover we investigated whether graft-infiltrating DCs (GIDCs)
release exosomes ex vivo and the processing of exosomes captured by different
lineage of DC in the secondary lymphoid organs evaluating their impact on the
anti-donor T cell response following transplantation.
Methods: Exosomes from [C57BL/10 (B10), IAb] DC are pre-pulsed with the
BALB/c peptide IEα;52-68, and stained with PKH67 and H2DCF. 1H3. 1 TCR
transgenic cells were labeled with CFSE. DCs were infected with Ad/FasL/
eGFP.
Results: We confirmed by ultrastructural analysis that GIDCs from mouse
cardiac allografts release exosomes ex vivo. Moreover, immunoistochemistry
shows that exosomes are processed “in vitro and in vivo” by different DCs
subsets: myloid CD8-, lymphoid-related CD8α;+, and plasmacytoid CD45RA+
DCs, as well as the presence of eGFP in the multivescicular body of CD11c/
CD45. 1 splenocytes isolated from B10 mice i. v. injected with Ad/FasL/
eGFP infected FAS-/-/CD45. 2 splenocytes. IAb-IEα;52-68 exosomes bearing
CD80/86 elicited proliferation/activation of allospecific CD4+ 1H3. 1 T cells.
Conclusions: In the context of allograft rejection exosomes in the secondary
lymphoid organs are processed/exchanged by different DCs lineages as an
efficient acellular mechanism to spread allo-Ag, amplifying the anti-donor T
cell response via indirect pathway.
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M. Suthanthiran1, H. Yang1, V.K. Sharma1, P. Song1, M. Lagman1, C. Chang1,
R. Weir1, E. Chang1, G. Luo1, R.M. Steinman2
1
Weill Cornell Medical College, New York, NY, USA, 2Rockefeller University,
New York, NY USA
Naturally occurring Foxp3+CD25+CD4+ regulatory T cells (nTregs) play a
critical role in maintaining self-tolerance but their ability to prevent allograft
rejection remains unresolved. TGF-beta 1 can convert FoxP3 negative CD4+
T cells to FoxP3 positive CD4+ T cells, and dendritic cells (DCs) are potent
in generating alloreactive cells. We therefore hypothesized that a synergistic
combination of DCs plus TGF-Beta1 would differentiate naïve CD4+ T cells
in to alloantigen specific allograft protective cells. We tested our hypothesis
by establishing mixed lymphocyte cultures (MLCs) using H-2b C57BL/6
(B6) splenic CD11C+ DCs as stimulators and H-2d BALB/c CD4+ T cells
as responders, and we isolated CD4+CD25+ T cells after 5-6 days of culture
and tested their efficacy. Our studies showed: (1) the mean ± (SE) percentage
of CD4+Foxp3+ cells, at the time of initiation of MLCs, was 12±1% (by flow
cytometry), and increased to 87±2% (N=4) following stimulation of BALB/c
CD4+ T cells with B6 DCs plus 2ng/ml TGF-beta1. The percentage of Foxp3+
cells among the nTregs was 81±3% (N=4) (ex-vivo Tregs vs. nTregs, P>0. 05);
(2) the mean level of mRNA in ex-vivo Tregs for Foxp3 mRNA was 1. 10E+07
copies/ug RNA (N=11), and 5. 57+E06 (N=14) with nTregs (P>0. 05). In-vitro
regulatory experiments using BALB/c CD4+ CD25- cells as responders and
graded quantities of Tregs, proliferation was suppressed at 2 responder to 1
by nTregs (P=0. 01), but not at 4: 1 ratio (P=0. 20); ex-vivo Tregs were more
suppressive and suppressed up to 8: 1 ratio (P=0. 001 for 2: 1; P=0. 006 for
4: 1; P=0. 03 for 8: 1). In a full H-2 mismatched islet allograft transplantation
model, the mean ± (SE) survival of 500 B6 islets transplanted under the renal
capsule of diabetic BALB/c recipient was 7±1 day (N=18 control recipients).
Co-transplantation of 500 B6 islets with 500, 000 BALB/c nTregs did not
significantly prolong graft survival and was10 ±1 day (N=8 recipients) (P>0.
05, nTregs vs. control). In contrast, co-transplantation of 500 B6 islets with 500,
000 BALB/c ex-vivo generated Tregs prolonged graft survival significantly and
was 22±5 days (N=9 recipients) (P=0. 0003, ex-vivo Tregs vs. control; P=0.
009, ex-vivo Tregs vs. nTregs). The ex-vivo generated BALB/c Tregs were
alloantigen specific, and did not prolong the survival of H-2k CBA islet grafts
in BALB/c recipients; the survival time of CBA islets in the control BALB/c
recipients was 11 ±1 day (N=7 recipients) and 7±1 day (N=5 recipients)
following co-transplantation of B6 DC differentiated Tregs with CBA islets
(P>0. 05). Our data demonstrate that although the Foxp3 expression profile is
similar between natural Tregs and the DC plus TGF beta1 differentiated Tregs,
ex-vivo generated Tregs but not natural Tregs protect H-2 mismatched islet
allografts. Our study also shows that ex-vivo generated Tregs are alloantigen
specific. Finally, our strategy of using easily available CD4+ T cells rather than
the low abundant CD25+CD4+ as the cell subset to be differentiated with DCs
plus TGF-beta1 overcomes the significant challenge of generating adequate
numbers of alloantigen specific Tregs for clinical trials.

hosts with bone marrow from IE-positive RAG-knockout donors, to give
approximately 20% IE+ lymph node-DC but no IE+ B cells (termed IE+®IE-).
FACS analysis of cutaneous lymph nodes confirmed the expected pattern of IE
expression and indicated equivalent total numbers of IE+ DC in the two groups
of chimeras.
We measured the response of IE-restricted 5C. C7 CD4 T cells to subcutaneous
administration of pMCC emulsified in complete Freund’s adjuvant. Initial T
cell proliferation was similar between the IE-®IE+ and IE+®IE- groups, as was
the frequency of IL2-producing cells on day 6 (mean T cell recruitment into
division, 22. 4% and 24. 9%, respectively; mean frequency of IL2-producing
cells, 6. 7% and 5. 5%, respectively). Dramatic differences were observed after
day 6: at the peak of the proliferative response (day 10), the absolute number
of 5C. C7 T cells was 8. 6-fold higher and the absolute number of IFNγ+ Th1
effector cells was 650-fold higher in IE+®IE- mice as compared to IE-®IE+
mice (87. 8x103 and 0. 14x103 IFNγ-producing 5C. C7 cells, respectively).
Most importantly, by day 90, CD44high memory 5C. C7 T cells were found only
in IE+®IE- mice.
These studies indicate that LC do not support differentiation of Th1 effector
cells and fail to sustain CD4 memory. We are now testing these findings in
a skin graft model in which 5C. C7 T cells in B10. BR (H-2k) hosts respond
to IAs-bearing skin from either unmanipulated B10. S (H-2s) mice, B10.
BR®B10. S (H-2k®H-2s) chimeras in which LC express IAs, and B10. S®B10.
BR (H-2s®H-2k) chimeras in which dermal DC but not LC express IAs.
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513 POOR ALLOSTIMULATORY FUNCTION OF LIVER
PLASMACYTOID DC IS ASSOCIATED WITH PRO-APOPTOTIC
ACTIVITY AND DEPENDENT ON REGULATORY T CELLS
D. Tokita, T. Sumpter, G. Raimondi, A. Zahorchak, Z. Wang, A. Nakao,
M. Abe, G. Mazariegos, A. Thomson
T. E. Starzl Transplantation Institute, University of Pittsburgh
Background: Plasmacytoid (p) DC, that are comparatively abundant in
the liver are inherently tolerogenic. Recently, pDC have been implicated in
tolerance induction. Since the liver is located downstream of the gut, interstitial
hepatic DC are constantly exposed to bacterial LPS (endotoxin) resulting in
refractory ex vivo responses to this TLR4 ligand (gendotoxin tolerance h).
Not only are liver DC exposed continually to TLR ligands from the gut, but
levels of LPS may be elevated following liver transplantation. In this study,
we examined the function of liver pDC from control and LPS-stimulated mice.
We also investigated how exposure of mouse liver pDC to LPS in vivo affected
the outcome of their interactions with allogeneic T cells, including naturallyoccurring T reg.
Methods: Liver and spleen pDC (mPDCA-1+) were isolated from normal
C57BL/10 (B10) mice or animals injected (i. v. ) 2 hr previously with LPS
(100ƒÊg). The stimulatory capacity of pDC was evaluated by quantitation of
BALB/c CD4+ T cell proliferation and cytokine production in MLR. Cytokine
production was assessed by intracellular staining and ELISA. NF-ƒÈB
activation was determined by Western blot analysis. Notch ligand expression
by pDC was measured by quantitative, real-time PCR.
Results: Liver pDC expressed similar levels of surface TLR4 to spleen pDC,
but unlike spleen pDC, did not undergo NF-ƒÈB activation or maturation after
in vivo LPS stimulation. IL-10 production was greater for liver compared with
splenic pDC, whereas the former produced less IL-12p70. Compared with
splenic pDC, freshly-isolated liver pDC from LPS-treated mice were inferior
stimulators of allogeneic CD4+ T cell proliferation. Addition of neutralizing
anti-IL-10 mAb at the start of LPS-stimulated liver pDC: allogeneic T cell
initiation, significantly enhanced the proliferative response to a level similar to
that achieved with splenic pDC. LPS-stimulated liver pDC induce allogeneic
CD4+ T cells to produce more IFNƒÁ compared with splenic pDC. Moreover,
liver pDC from LPS-treated mice expressed a low Delta4/Jagged1 Notch ligand
ratio and skewed towards Th2 differentiation. Interestingly, in the absence of
naturally-occurring CD4+CD25+ Treg, similar levels of CFSE-labeled T cell
proliferation were induced by liver and spleen pDC. In addition, liver pDC
from LPS-treated mice promoted allogeneic CD4+ T cell apoptosis. However,
when naturally-occurring CD4+CD25+ Treg were removed from the responder
T cell population, immediately before the start of MLR, the pro-apoptotic effect
of liver pDC was reversed. These data suggest that Treg are rendered more
effective at inhibiting effector T cell proliferation in the presence of liver than
spleen pDC, and that naturally-occurring Treg may suppress the differentiation/
function of liver pDC.
Conclusion: Liver pDC are resistant to LPS stimulation in vivo, and are
inferior allogeneic T cell stimulators compared with spleen pDC. Their
depressed function is dependent on the presence of naturally-occurring Treg.
This property of hepatic pDC may contribute to inherent liver tolerogenicity
and the comparative ease of liver allograft acceptance.

514 GENERATION OF TOLEROGENIC DENDRITIC CELLS
FOR INHIBITION OF ALLOGRAFT REJECTION: MEDIATION
OF SUPPRESSION BY ILT3, ADRENOMEDULLIN, AND
APOPTOSIS?
P. Terness, S. Ehser, J-J. Chuang, F. Sandra, C. Kleist, L. Jiga, G. Opelz
University of Heidelberg, Institute of Immunology, Dept. of Transplantation
Immunology
Dendritic cells (=DCs) are strongly immunostimulatory cells. However, some
DCs can suppress the immune response and play an important role in induction
of tolerance to autoantigens. Studies showed that “Glucocorticoid Induced
Leucine Zipper” (=GILZ) – a molecule upregulated by glucorticoids, IL-10,
or TGF-beta – decides whether a DC stimulates or suppresses the immune
response. GILZ induces the expression ILT3, a membrane protein with a
long cytoplasmatic tail encompassing several inhibitory ITIM motifs. ILT3expressing DCs were shown by others to anergize CD4 T-cells or to convert
them into Tregs. Most intriguing, previous studies revealed that human heart
transplant recipients with stable grafts have circulating T suppressor cells which
upregulate ILT3 in donor antigen-presenting cells. In comprehensive gene
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scans (> 47, 000 gene transcripts) we observed that Mitomycin C (=MMC)
– an alkylating agent used in cancer therapy – upregulates GILZ and ILT-3
in human DCs. Increase of ILT3 expression was confirmed by quantitative
RT-PCR and FACS analysis. In cell culture studies the functional behaviour
of MMC-treated DCs was analyzed. DCs were briefly treated with MMC
(=MMC-DCs), washed and coincubated with T-cells. MMC-DCs arrested
proliferating T-cells in the G0/G1 cell cycle phase and the suppressed cells
could not be restimulated. T-cell suppression was antigen-specific. In the next
step, we verified the suppressive effect of MMC-treated DCs in a rat heart
transplant model. Recipients were treated before transplantation with naïve
donor DCs or donor DCs preincubated with MMC. We noted graft survival
rates of 9+0. 2 days (untreated controls), 5+0. 2 days (naïve DCs), and 30+0.
4 days (MMC-DCs). The induced suppression was donor-specific because
no prolongation of third-party graft survival was obtained after MMC-DC
treatment. The results clearly indicate that in contrast to untreated donor
DCs, which induce accelerated rejection, MMC-treated DCs injected into the
recipient inhibit acute rejection and significantly prolong allograft survival. In
addition to ILT3, MMC treatment of DCs upregulated adrenomedullin, another
potentially suppressive molecules, and induced apoptosis. Adrenomedullin is a
peptide which effectively controls arthritis in animal models by decreasing the
presence of autoreactive Th1 cells, inducing regulatory T cells and inhibiting
autoimmune and inflammatory responses. Based on experimental data, it was
held that apoptotic cells induce tolerance, whereas necrotic cells trigger the
immune response. Therefore, induction of apoptosis in DCs treated with MMC
might be another process rendering DCs suppressive. Our “in vitro” studies
showed that blocking ILT3 and adrenomedullin with specific antibodies,
and preventing induction of apoptosis in MMC-treated DCs abrogate their
suppressive effect. In conclusion, treatment of DCs with MMC renders the
cells immunosuppressive. MMC-treated donor DCs, injected into the recipient
before transplantation, suppress heart allograft rejection in rats. Our findings
suggest that the suppressive effect of MMC-DCs is mediated by overexpression
of ILT3, adrenomedullin and induction of apoptosis.

515 KIDNEY SPHERE DERIVED CELLS INDUCE THE
GENERATION OF IMMATURE DENDRITIC CELLS WITH A
REGULATORY PHENOTYPE AND CAPACITY TO INHIBIT THE
ALLORESPONSE
K. Womer, Y. Huang, P. Johnston, P. Agreda, R. Smith, E. Marban, H. Rabb,
Department of Medicine, Johns Hopkins University School of Medicine
Stem cells have great potential to regenerate damaged tissue after injury during
organ procurement. Despite accumulating evidence supporting the potential
of embryonic derived stem cells, substantial ethical and practical limitations
have increased interest in adult organ stem cell research. Thus, isolation and
characterization of adult organ stem cell function represents an important step
in applying stem cell based therapy to organ transplantation. Bone marrow
mesenchymal stem cells (MSC) have profound immunoregulatory effects
on dendritic cells (DC) and T cells, two cell populations important to the
alloresponse during kidney transplantation. As MSC have been identified in
virtually all post-natal organs, the aim of the current study was to determine
whether stem/progenitor cells with immunoregulatory function exist
within the adult kidney. Using a clinically applicable technique originally
reported for isolation and expansion of cardiac progenitor cells from human
endomyocardial biopsy specimens, we have identified a population of kidney
sphere-derived cells (KSC) from adult mouse with growth properties and
immunophenotype consistent with MSC. KSC were CD29+, CD44+, and stem
cell antigen-1+, while negative for hematopoietic progenitor markers (c-Kit,
CD34, CD31, CD133, CD45). When added to incipient bone marrow-derived
DC culture, KSC increased the generation of DC with dramatically reduced
MHC II expression (MFI: 113±6. 5 vs 679±125; p<0. 01), increased CD80
expression (MFI: 195±18 vs 85±4. 7; p<0. 01), and after LPS stimulation,
increased IL-10 production (135. 7+12. 4 pg/ml vs 46. 1+6. 9 pg/ml; p<0. 01),
and inability to stimulate CD4+ T cell proliferation in allogeneic (2. 1±0. 1% vs
53±1. 3%; p<0. 01) and nominal antigen-specific cultures (16±0. 8% vs 71±4.
4%; p<0. 01) as determined by CFSE staining. Effects on DC differentiation
and maturation were demonstrated in mixed and transwell cultures and after
addition of KSC conditioned medium, indicating soluble factors were active.
Mechanistic studies using neutralizing antibodies showed that KSC production
of IL-6 was partially responsible, although other soluble factors appear
contributory. Finally, direct addition of KSC but not KSC conditioned medium
to T cell culture inhibited mitogen-stimulated T cell proliferation (32±2. 1%
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vs 59±3%; p<0. 01), indicating contact-dependent mechanisms were active.
Thus, immunomodulatory effects of KSC on DC differentiation appear
predominately due to soluble factors, yielding an IL-10 producing DC with
very low expression of MHC class II, a phenotype consistent with a steady state
DC important for maintenance of peripheral tolerance, while direct effects of
KSC on T cell proliferation appear to require cell contact. These novel in vitro
findings provide a potential mechanism by which resident progenitor cells in
the kidney could alter the local alloresponse in vivo after transplantation. Our
findings also raise the possibility of KSC expansion ex vivo for use as cellular
therapy in kidney transplantation.
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516 THE USE OF FLOW CYTOMETRY TO MONITOR
ANTIBODY LEVELS IN ABO INCOMPATIBLE KIDNEY
TRANSPLANTATION
N. Krishnan1,2, R. Higgins1, P. Fleetwood2, D. Zehnder1,3, D. Mitchell3,
R. Hamer1,3, D. Briggs2
1
University Hospitals Coventry & Warwickshire NHS Trust, Coventry,
2
National Blood Service, Birmingham, 3Clinical Sciences Research Institute,
Coventry
Introduction: Current methods of measuring ABO antibody levels based on
the haemagglutination (HA) titres has the disadvantage of being both nonreproducible and having inter-observer variability.
Methods: We have therefore developed and validated flow cytometry (FC)
as a semi quantitative method to monitor the amount of IgG and IgM ABO
antibodies in individuals undergoing ABOi transplantation.
Results: To validate our method, we analysed plasma samples from 79 healthy
donors using the FC method. We have shown that in healthy donors, the
relative levels of IgG and IgM antibodies against A and B in subjects of blood
groups O, A and B were same as previously reported using the HA technique.
We also analysed 40 consecutive samples over 32 days from group O patient
who received group A2 kidney. On comparison, there is a significant positive
relationship between FC RMF (relative median fluorescence) and HA for both
IgM (p<,0.01) and IgG (p<0.01). We are currently analysing the blood group
IgA antibodies and its significance in ABOi transplantation.
Discussion: Our data demonstrates that FC monitoring of ABO-specific
antibodies in incompatible transplants is effective in terms of detecting
quantitative changes and reproducibility. We have simplified the FC method,
by overcoming the tendency of sensitised RBCs to agglutinate by using dilute
cells rather than use fixation buffers. Thus, FC may be a practical method of
measuring antibodies and monitoring changes in ABO antibody level.

POSTER BOARD NUMBER P3 – 378

D. Toki1, H. Ishida1, H. Shirakawa1, T. Shimiza1, K. Setoguchi1, S. Iida1,
S. Horita1, Y. Yamaguchi2, K. Tanabe1
1
Department of Urology, Tokyo Women’s Medical University, 2Division of
Pathology, Jikei University School of Medicine, Kashiwa Hospital
Background: Acute Antibody-mediated rejection (AAMR) has been recognized
as a major problem in ABO-incompatible (ABO-I) renal transplantation (RTX).
Anti-ABO blood-type antibodies had been thought to be the main cause of
AAMR. However, under the current potent immunosuppressive regimen, the
role of anti-ABO blood-type antibodies for AAMR is not clearly understood.
The aim of this study was to assess the impact of anti-ABO blood-type
antibodies on AAMR.
Methods: Fifty-eight patients who underwent ABO-I RTX at our
institution between March 1999 and December 2004 under an FK-based
immunosuppressive regimen were enrolled in this study. AAMR was diagnosed
by biopsies within one month after transplantation in conjunction with allograft

Anti-ABO blood-type antibodies

AMR (-)
N=39

AMR (+)
N=19

P

IgM titer ≥64 before plasmapheresis

21 (55%)

12 (63%)

0.5693

IgM titer ≥128 before plasmapheresis

10 (26%)

5 (26%)

0.9561

IgG titer ≥64 before plasmapheresis

26 (67%)

14 (74%)

0.5877

IgG titer ≥128 before plasmapheresis

19 (47%)

10 (53%)

0.7797

IgM titer ≥32 at biopsy

3 (8%)

2 (11%)

0.7182

IgG titer ≥32 at biopsy

5 (13%)

9 (47%)

0.0039
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518 BLOOD GROUP B PRIMARY AND REGRAFT
CANDIDATES ARE TRANSPLANTED WITH A2/A2B KIDNEYS
AT THE SAME RATE SINCE A ISOAGGLUTININS REMAIN
LOW
J.L. Smith1, C.F. Bryan2, M.R. Wakefield3, B.A. Warady4, C. Wang5,
D. Murillo6, P.W. Nelson7
1
Via Christi Regional Medical Center--Wichita, Ks, 2Midwest Transplant
Network--Kansas City, Ks, 3University of Missouri--Columbis Mo, 4Childrens
Mercy Hospital--Kansas City, Mo, 5University of Kansas Medical Center-Kansas City, Ks, 6Research Medical Center--Kansas City, Mo, 7St Lukes
Hospital--Kansas City, Mo
Introduction: It is important to know if the retransplantation rate of blood
group B candidates with A2/A2B kidneys in the A2/A2B to B allocation
system is equivalent to that of primary candidates. Eligibility to receive an A2/
A2B kidney is a low level of A isoagglutinins (<8). If graft loss increases A
titers, retransplantation of B candidates would be largely restricted to non-A2/
A2B donors.
Methods: We evaluated the incidence of A2/A2B kidney transplants in 274
consecutive blood group B candidates transplanted (225 primary, 48 second
and 1 third) from 1994-2007 using a donor service area-wide A2/A2B to B
deceased donor renal allocation system.
Results: The incidence of A2/A2B kidneys transplanted into blood group B
candidates for their first transplant was 27% (62/225) and was 24% (12/49)
for retransplant patients (p=0.6). A consistently low anti-A titer history was
exhibited before transplantation by 87% (184/212) of primary and 88% (43/49)
of regraft B recipients (p=0.3).
Conclusion: The A2/A2B to B kidney allocation system improves access
of primary and regraft B candidates to the same degree because anti-A IgG
titers usually remain low after graft loss. This system could provide wait list B
candidates in the United States with up to one-fourth more kidney transplants.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

181

WEDNESDAY

517 IMPACT OF ANTI-ABO BLOOD-TYPE ANTIBODIES
ON ACUTE ANTIBODY-MEDIATED REJECTION IN ABOINCOMPATIBLE KIDNEY TRANSPLANTATION

dysfunction. Morphological features of AAMR based on the Banff ’05 update
and other characteristic findings for AAMR previously reported, such as
mesangiolysis, interstitial hemorrhage, and cortical infarction. C4d deposition
for peribubular capillaries was not employed for the diagnosis of AAMR
because C4d deposition is commonly observed in ABO-I renal allografts.
Anti-ABO blood-type IgM titers were determined using saline agglutination
technique, and indirect Coomb’s test was used to measure IgG titers. To remove
anti-ABO blood-type antibodies, three or four sessions of plasmapheresis
before transplantation were performed, until anti-ABO blood-type IgM/IgG
titers decreased to a level of 1:32 or below. Splenectomy was performed at the
time of transplantation. We evaluated the association between anti-ABO bloodtype antibodies and the incidence of AAMR.
Results: The association between anti-ABO blood-type antibodies and the
incidence of AAMR is shown in Table 1. The incidence of AMR within one
month after transplantation was 33% (19/58). There is no significant difference
between anti-ABO blood type IgM /IgG titers ≥64 before plasmapheresis and
the incidence of AAMR. Even in the anti-ABO blood-type IgM/IgG titers ≥128
before plasmapheresis, no significant difference was seen between anti-ABO
blood-type IgM/IgG titers and the incidence of AAMR. Moreover, anti-ABO
blood-type IgM titers ≥32 at biopsy were not associated with the incident of
AAMR. Meanwhile, the anti-ABO blood-type IgG titers ≥32 at biopsy were
significantly associated with the incident of AAMR.
Conclusion: In this study, we revealed that only anti-ABO blood-type IgG titers
at biopsy were significantly associated with the incidence of AAMR regardless
of anti-ABO blood-type IgM/IgG antibodies before plasmapheresis. Careful
observation of anti-blood type IgG titers will be needed after transplantation.
Table 1.
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519 DOUBLE FILTRATION PLASMAPHERESIS
FACILITATES HLA ANTIBODY INCOMPATIBLE RENAL
TRANSPLANTATION, BUT IS LESS EFFECTIVE DURING
ANTIBODY RESYNTHESIS POST-TRANSPLANTATION
R. Higgins1, R. Hamer1, D. Briggs2, N. Krishnan1, S. Fletcher1, A. Short1,
D. Lowe2, K. McSorley1, Daniel Zehnder3
1
University Hospital, 2Histocompatibility Laboratory, UK Blood and
Transplant, 3Warwick Medical School
Introduction: We used double filtration plasmapheresis (DFPP) in antibody
incompatible transplantation (AIT). The use of DFPP has not been reported
extensively in HLA antibody incompatibility, and we review its efficacy.
Methods: 54 patients entered the AIT programme. 41 had 267 sessions of
DFPP, 1 had 10 sessions of plasma exchange, and 3 had 13 sessions of ABO
immunoadsorption. Some patients had more than one modality of treatment, 11
patients had no antibody removal.
Results:In patients treated with DFPP alone, the mean number of sessions pretransplant was 4.8, mean of 4.6 litres per session, total treatment 325 ml/kg.
Post-transplant, 18 received DFPP, for a mean of 3.5 sessions, mean 6.2 litres
per session, total treatment 309 ml/kg. Mean reductions in IgA, IgG and IgM
per treatment session were consistent with the plasma volume treated, 63.9%,
57.8%, 70.2% pre transplant, and 59.3%, 48.4% and 65.4% post-transplant.
70% of patients were transplanted with a flow cytometric (FC) relative median
fluorescence (RMF) >2.5, and 65% were transplanted with microbead DSA
mean fluorescence intensity (MFI) of >2000u. Failure to achieve negative
crossmatch was strongly related to the starting level of donor specific antibody
(DSA).
Patients who had a course of DFPP and who had complete data and no IVIg
administered were studied in more detail. Pre-transplant, in 21 patients, the
mean fall in IgG over the course of treatment was 70.0%, with a fall in FC RMF
25.7%, and fall in microbead MFI 52.6%. There was variation with levels in
some patients responding well, but others resistant to DFPP. Post transplant, in
8 courses of treatment administered during DSA resynthesis, IgG fell by a mean
of 45.3%, but the microbead MFI level rose by 41.2%, and no patient achieved
a reduction in MFI to <2000 by DFPP alone. Combined DFPP and rejection
treatment were associated with more adverse effects, including infections and
fluid shifts.
Discussion: Larger volumes of plasma were treated with DFPP than were
feasible with plasma exchange. Although graft survival was excellent, most
patients were transplanted with potentially damaging DSA levels, and DFPP
post transplant was unable to control rising antibody levels; we have phased
out the use of DFPP post-transplant. There is a need for improved methods of
DSA removal.
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520 ABO-INCOMPATIBLE RENAL TRANSPLANTATION
WITHOUT SPLENECTOMY OR RITUXIMAB – EXCELLENT
RENAL FUNCTION AND GRAFT HISTOLOGY
S. Flint1, M. Jose3, G. Kirkland3, D. Yip1, A. Landgren2, M. Finlay2,
S. Cohney1
1
Department of Nephrology, Royal Melbourne Hospital, 2Department of
Pathology, Royal Melbourne Hospital, 3Department of Nephrology, Royal
Hobart Hospital
Until recently ABO incompatible renal transplantation (ABOI) included
splenectomy and immunosuppression greater than administered in blood group
compatible transplantation. Since December 2005 we have performed 28
ABOI without splenectomy, using an immunosuppressive regimen similar to
that used in our compatible transplants with the exception of antibody removal,
and mycophenolate for 10-14 days pre-transplant. Four of 28 patients received
rituximab.
Three patients experienced early humoral rejection (AbMR) that resolved
clinically with treatment. In one case the AbMR was due to a concomitant
donor specific anti-HLA antibody (DSAb). Overall patient and graft survival is
100% after a median of 13 months (range 3 months to 29 months). 15 patients
have had their transplants in excess of 12 months. Here we present an analysis
of graft function and graft histology in this cohort; the latter based on review of
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all available post-transplant renal biopsies (n=57).
Graft function: Creatinine at 1, 3, 6 and 12 months indicates stable renal
function except for one patient with intermittent obstruction* and compares
favorably with donor renal function. Median creatinine is currently 140umol/L
(range 80-240), in comparison with a median donor creatinine of 110umol/L
(range 80-150). In all cases but one*, the differences in renal function between
donor and recipient are predominantly attributable to differences in gender and
body habitus (11 grafts were female to male and 4 male to female).
Graft histology: All patients underwent a biopsy at implantation with which
subsequent biopsies were compared. Protocol biopsies are scheduled at 3
months and 12 months, and all biopsies were assessed by Banff ’97 scoring
criteria.
Two of the patients with AbMR have had complete histological resolution
on 3 month biopsy, although one has mild (grade 1) CAN without transplant
glomerulopathy (TGP). The patient with DSAb has significantly improved
histology but in view of ongoing subclinical active rejection is receiving further
IVIG; this patient has mild early TGP.
In total, there are twenty-one “3 month protocol biopsies” and five “12 month
protocol biopsies” analysed to date. The remaining 31 biopsies were performed
for clinical indications (from day 2 to day 246 post-transplant). There was one
case of acute cellular rejection (ACR) (Banff 1B) and one of borderline ACR,
both on 3 month protocol biopsies and treated with additional corticosteroid. A
12 month biopsy from the latter patient showed no evidence of CAN.
No patient had TGP except for the patient with DSAb. This is in comparison
with the remaining 25 patients without AbMR, in which mild CAN was
reported in 4/18 three month protocol biopsies and in none of the twelve month
protocol biopsies.
C4d staining was observed in 26/57 post transplant biopsies and one implantation
biopsy (representing 13/28 patients), including all 3 with AbMR.
ABOI renal transplantation can be successfully performed without splenectomy
and rituximab and results in good function and graft histology.
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521 RESULTS OF A RANDOMIZED PROSPECTIVE STUDY
OF INDUCTION THERAPY WITH DACLIZUMAB VERSUS
THYMOGLOBULIN AMONG CROSSMATCH POSITIVE RENAL
TRANSPLANT RECIPIENTS
J. Locke, C. Simpkins, M.S. Leffell, A. Zachary, V. Collins, D. Warren,
D. Segev, A. Singer, M. Haas, R. Montgomery
Johns Hopkin University
Background: The introduction of protocols to desensitize recipients with
incompatible live kidney donors has been accompanied by an increased risk
of post-transplant acute rejection. Thymoglobulin, a polyclonal anti-human
thymocyte antibody preparation, has been shown to decrease the 1-year
incidence of acute rejection in renal transplant recipients. While this finding
is encouraging for renal transplant recipients in general, data on the use of
thymoglobulin as an induction agent in the highly sensitized patient population
are lacking. We report here interim results from a prospective, randomized
controlled clinical trial in our highly sensitized patient population comparing
renal transplant outcomes after induction with the anti-thymocyte agent,
Thymoglobulin, or an anti-human IL2 monoclonal antibody, daclizumab.
Methods: Adult, end-stage renal disease patients with donor-specific antiHLA antibody (DSA) against their only potential live donor were eligible
for this study. Patients were randomized to receive either Thymoglobulin or
daclizumab induction therapy just prior to transplant. The primary endpoint
was 6-month incidence of biopsy proven acute rejection [antibody mediated
(AMR) and/or cellular mediated (CMR)].
Results: 33 patients with at least 6-months of follow-up are currently enrolled
in this trial (16-Thymoglobulin; 17 daclizumab). There is no significant
difference between the two groups in mean crossmatch titer (14.0 vs. 9.9,
P=0.61), number of current HLA mismatches (5.7 vs.5.9, P=0.73), or repeat
mismatches (0.2 vs.0.2, P=0.98). The rate of acute clinical rejection at 6-months
is 56% in the Thymoglobulin arm, and 41% in the daclizumab arm (p=0.4), and
there is no statistically significant difference in the rate of clinical AMR or
CMR between the two treatment arms. However, there is an increased rate of
subclinical CMR in the daclizumab arm compared to the Thymoglobulin arm
(82% vs. 44%, p=0.02). Further, the severity of subclinical CMR is greater
among patients receiving daclizumab compared to Thymoglobulin, with a
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28% higher incidence of ≥2A rejection in the daclizumab arm. There are no
statistically significant differences at 6 months between the two treatment
arms with regard to patient and graft survival, infection, adverse drug events,
malignancy, delayed graft function, and length of stay.
Conclusion: The rate of acute rejection among crossmatch positive patients
is 2-4x higher than the non-sensitized kidney transplant recipient patient
population. While the results from our trial are preliminary, there appears to
be a reduction in both the incidence and severity of subclinical CMR among
patients receiving Thymoglobulin induction therapy compared to daclizumab.
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THE NEVER-ENDING ALTRUISTIC DONOR

M. Rees1, J. Kopke2, G. Hil3, W. Reitsma4, R. Pelletier5, J. Rogers6,
T. Sandholm7, A. Roth8, U. Unver9, R. Montgomery10
1
University of Toledo Medical Center, 2University of Cincinnati, 3National
Kidney Registry, 4New Jersey Sharing Network, 5Ohio State University,
6
Wake Forrest University, 7Carnegie Mellon University, 8Harvard University,
9
University of Pittsburgh, 10Johns Hopkins University
Introduction: We propose a non-simultaneous form of kidney paired donation
that starts with a living, non-directed donor (LND).
Methods: A paired donation matching algorithm was developed to allow for
LNDs to start potentially Never-Ending Altruistic Donor (NEAD) chains in
addition to closed loops of 2-, 3- and 4-way exchanges.
Results: In July 2007, a LND from Michigan traveled 1500 miles to donate a
kidney to a woman whom he had never met in Arizona. The following week,
the Arizona recipient’s husband donated one of his kidneys to a 32-year-old
woman in Ohio. The following month, the mother of this recipient traveled to a
city 3 hours away to donate her kidney to a patient whose incompatible donor
simultaneously gave a kidney to the fourth patient in the chain. Five months
later the fourth recipient’s incompatible sister donated a kidney to a patient in
Maryland whose incompatible donor initiated a chain of three transplants two
weeks later that ended with a recipient in North Carolina receiving a kidney.
This patient’s incompatible donor is now scheduled to initiate another chain
of three transplants in March 2008. Thus, one altruistic donor has allowed for
at least 8 people to be transplanted. In the first year of operation, an alliance
of 60 US transplant programs have partnered to perform 17 paired donation
transplants. Demonstrating the advantage of NEAD chains over classic paired
donation, 13 of 17 transplants resulted from altruistic donor-initiated chains.
Conclusion: In order to fully realize the potential of the above approach, one
must be willing to supplant two prevalent ideas: 1) that kidneys from altruistic
donors should be given to the top candidate on the deceased donor waiting
list, and 2) that paired exchanges must be done simultaneously. While there
are certain pitfalls to using non-simultaneous NEAD chains of transplants as
opposed to traditional “swaps” (i.e. the possibility that a donor could renege,
or the accumulation of type AB donors who are not likely to be able to begin
another chain), this proposed paradigm shift could result in a very significant
increase in both the number and quality of paired donation kidney transplants.

523 DONOR AND RECIPIENT ATTITUDES TOWARDS
ALTRUISTIC UNBALANCED PAIRED KIDNEY EXCHANGE
AND ITS POTENTIAL IMPACT ON LIVE DONOR
TRANSPLANTATION
L.E. Ratner, A. Rana, E.R. Ratner, V. Ernst, J. Kelly, D. Cohen, D. Kornfeld,
I. Wiener
Columbia University/New York-Presbyterian Hospital
Background: Altruistic Unbalanced Paired Kidney Exchange (AUPKE) utilizes
compatible live donor/recipient pairs (D/R) to exchange with incompatible live
D/R pairs to allow all recipients to receive a compatible donor kidney. There
has been concern about the potential coercive nature of AUPKE. However,
AUPKE has the potential to greatly increase the likelihood of paired kidney
exchanges, even at the single center level in the absence of large regional
or national sharing systems. Recently we performed a complex AUPKE to
facilitate a compatible live donor transplant for a patient (blood group O)
whose blood group AB husband was her prospective donor (Figure 1).
Purpose: 1) To determine the impact of AUPKE if practiced in its simplest

Figure 3
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524 IL-6R BLOCKADE IN EXPERIMENTAL AUTOIMMUNE
NEPHRITIS REDUCES PROTEINURIA AND IS ASSOCIATED
WITH TREGS IN THE DRAINING
LYMPH-NODE
G.Y. Zhang1, Y.M. Wang1, T. Polhill1, M. Hu1, D.C.H. Harris2, S.I. Alexander1
1
Centre for Kidney Research, Children’s Hospital at Westmead, 2Centre for
Transplantation and Renal Research, University of Sydney at Westmead
Millennium Institute. Westmead, NSW 2145. Sydney, Australia
Background: Heymann nephritis (HN) is an experimental autoimmune
model of glomerulonephritis induced in the Lewis rat by immunisation with
a crude renal tubular Ag (Fx1A). T cell depletion studies indicated that CD4
cells played a critical role in the pathogenesis of HN. Th17 cells have been
identified as a distinct lineage of CD4 cells and may play a decisive role in the
pathogenesis of autoimmune disease. IL-6 and TGF-β have been identified as
critical factors for Th17 induction. Data from mice with experimental multiple
sclerosis (EAE) suggests that IL-6 may be a major switch factor for reciprocal
induction of Th17 and Tregs.
Aim: To investigate if blocking IL6R can attenuate HN.
Methods: Rats were given anti IL-6R antibody or IgG control antibody iv
every 5 days (over 20 days) and immunized with Fx1A in CFA at day 2 after the
initial administration of antibodies. An additional control group was injected
with CFA only.
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form using ABO compatible, but non-identical donors (ABONI) at individual
centers. 2) To determine patients’ attitudes towards AUPKE to be able to
effectively encourage participation.
Methods: 1) Retrospective analysis of the UNOS data of live donor transplants
performed in 2005. 2) At initial evaluation, potential donors and recipients
were administered a survey regarding attitudes toward AUPKE. A 5-point
Likert Scale was utilized with the questions structured in the affirmative so that
a higher Likert Score supported participation in AUPKE.
Results: 1)1396 (22.8%) ABONI live donor transplants were performed in the
US in 2005 of which 91% of the donors were blood group O. 2) 53 potential
donors and 52 potential recipients completed the survey. Recipient survey
respondents were more likely than donors (p=0.002) to favor participation in
AUPKE in the absence of any advantage to themselves. However, a number
of circumstances increased the propensity to view AUPKE favorably for both
recipients and donors (p<0.05) (see figures 2 and 3 respectively) including if
the other individual in the D/R pair wanted to participate. Both cohorts felt
strongly that the decision to participate in AUPKE should be made jointly
(p<0.001 for both donors and recipients).
Conclusions: 1) AUPKE can have a profound impact on the number of live
donor renal transplants. 2) In its simplest form, utilizing ABONI donors
AUPKE can be performed at individual centers without requiring large sharing
networks or complex computer algorithms. 3) Blood group O recipients with
incompatible donors are likely to be the primary beneficiary of AUPKE. 4)
D/R attitudes are not static, and can be influenced in favor of participating in
AUPKE, particularly if there is a perceived benefit to the recipient. 5) Both
donors and recipients are more willing to participate in AUPKE if their intended
recipient or donor (respectively) are enthusiastic about participating. 6) Finally,
AUPKE reflects a major paradigm shift for live donation, converting a private
resource (the donor) to a shared or public one.
Figure 1
Figure 2

Wednesday 13 August 2008

Oral Abstracts

Results: Anti IL6R therapy significantly reduced proteinuria at week 6,
8, 10 and 12 HN. Proteinuria (mg/24 h/100g bodyweight) in control Ig
HN, anti-IL6RHN and CFA groups at Week6: 33±.36 ±11.24, 12.56 ± 2.4,
5.17 ±0.58; Week8: 357.1±67.03, 140.4± 43.85, 5.13± 0.5; Week10: 417
±40.28, 275.5 ±44.87, 5.8 ±0.52; Week12: 503.0 ±52.16, 355.0 ±66.58,
3.07 ±0.4 (p<0.05). Flow cytometry at Week 10 and 12 found equivalent
number of Foxp3+ Treg cells in spleens of all 3 groups but increased
Foxp3+ Treg cells in draining lymph nodes in IL6R/HN group (13.2%
±2.0) in comparison to IgG/HN group (10% ± 1.0) and CFA alone (8.5% ±
1.1). Immunohistochemistry showed reduced glomerular IgG deposition in
IL6R/HN group at Week10.
Conclusions: IL6-R blockade limits Heymann Nephritis and may potentially
influence the Treg/Th17 axis.
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525 SUCCESSFUL TRANSPLANTATION OF PATIENTS WITH
LOW LEVEL DONOR HLA SPECIFIC ANTIBODY WITHOUT
DESENSITIZATION TREATMENT
M.S. Leffell, J.E. Locke, J.A. Houp, R.A. Montgomery, A.A. Zachary
Depts of Medicine and Surgery, Johns Hopkins University School of Medicine
Donor HLA specific antibody (DSA) is a recognized risk factor for rejection
of renal allografts. However, solid phase immunoassays permit the detection
of very low levels of DSA for which the clinical relevance is not known.
We routinely treat patients with a positive flow cytometric crossmatch
(FCXM) due to DSA with our desensitization protocol. We report here the
successful transplantation, without desensitization, of 8 patients who had a
negative FCXM but who had DSA detectable by Luminex™ assay against
a panel of phenotypes. Eight patients comparably sensitized to third party
(non-donor) antigens only were used as controls. The two patient groups
were not significantly different in the degree of HLA mismatch or in their
sensitization history. Both groups included 6 primary grafts and 2 second
transplants (Tx). The low DSA patients included 6 female and 5 black
recipients compared to 4 females and 3 blacks in the control group. Both
recipient groups were treated with the same immunosuppression, except
for 4 patients in the control group who did not receive Thymoglobulin™.
The mean pre-Tx serum creatinine (SCr) was significantly higher (P=0.03)
among the low DSA patients (9.1±4.1) than in the control patients (5.0±1.3),
but, notably, at one month post-Tx there was no significant difference in the
SCr levels (1.5±0.6 and 1.2±0.3, respectively). SCr available for 5 patients
in each group at longer post-Tx times were also not significantly different,
1.3±0.4 and 1.2±0.3 (9.5 and 8.9 months, respectively). The mean MFI
for DSA was 1914±1406 pre-Tx, compared to 4085±5840 for third party
antigens in the low DSA group. None of the low DSA patients had any
significant increase in DSA by one month post-transplant. There have been
no graft losses in either group with follow-up times of 11.9 months (range
1-17) for the low DSA group and 13.8 months (range 4-23) for the control
group. Importantly, to date, there have been no rejection episodes among the
low DSA patients, compared to two rejection incidents among the controls.
These results suggest that low level DSA may not have an adverse effect on
early graft survival. Expanded, longitudinal studies are needed to determine
the long term impact.
Mean Values
Group

N

Low
DSA

8

Controls 8

Pre Tx
PRA

1 Mo
1 Mo Post
Mean
Follow- Max PreTx PreTx MFI
Rejection
Post TX
Tx MFI
FollowUp SCr
MFI *
for DSA
Episodes
SCr
for DSA
up (mos)

34.5±17.8 1.5±0.6 1.3±0.4 4085±5840 1914+1406 1758+1076
35.0±22.5 1.2±0.3 1.2±0.3 5278±5117

* Mean MFI to highest HLA phenotype
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NA

NA

0

11.9±4.9

2/8 (25%) 13.8±8.5
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526 TREATMENT AND PROGNOSIS OF LATE ONSET
HUMORAL REJECTION IN COMPARISON WITH EARLY
ONSET HUMORAL REJECTION IN KIDNEY TRANSPLANTS
D.J. Han, K.T. Park, S.C. Kim, J.J. Hong, E.J. Ahn
Asan Medical Center
With the advance of immunosuppressant and induction agents, incidence
of acute cellular rejection was decreased substantially, but acute humoral
rejection(AHR) has been diagnosed more than before due to improved
diagnostic study and increasing number of sensitized recipients. And treatment
of humoral rejection has not been established yet in spite of current success
with multimodal approach, especially for the late onset humoral rejection. So,
the purpose of this study is to compare early and late onset humoral rejection
in kidney transplants.
From Jan. 2003 to Apr. 2007, 45 kidney recipients having renal allograft
dysfunction were diagnosed as humoral rejection either by cross matching or
renal biopsy or serologic evidence at out institution. They were divided into
early and late group according to the onset of humoral rejection (within 3
months postoperatively).
Mean onset of humoral rejection was 9.1 day and 5.7 years respectively.
Cross matching was positive in 87.5% in early group and 19.0% in late group
(p<0.05). C4d marker on histology was positive in 37.5% and 70% respectively.
PRA was positive in 13 patients (54.2%) of early group and 1 patient (4.8%) of
late group. Female gender consisted of 80% in early and 42.9% in late group.
47% of female recipients in early group received their organs from offspring or
spouse donor, resulting in anamnestic reaction. And other donor and recipient’s
profiles were not different between the two groups. In early group, first
episodes of AHR were fully recovered in 96% of cases except one patient with
multimodal treatments like plasmapheresis, steroid pulse, immunoglobulin
and rituximab. Recurrent AHR was observed in two patients resulting in graft
failure and impaired renal function respectively. Finally, 87.5% of early group
remained in normal graft function. But, in late group only 2 recipients (9.5%)
showed full response to treatment and in 19 patients (90.5%) there were no
responses to multimodal treatment methods resulting in graft failure in 14 cases
(73.6%). Mean duration from diagnosis to graft failure was 21 months (1.1-102
months) and 4 recipients (19%) have experienced the episode of acute rejection
in early postoperative period.
AHR of early onset could be treated successfully with current multimodal
treatment and their prognosis was excellent. But humoral rejection of late onset
couldn’t be treated with current methods and the prognosis was also poor. It seems
to be different in pathogenesis from early onset AHR and more effective treatment
and risk factors of late onset humoral rejection should be sought in the future.

MINI-ORAL SESSION 18: IMMUNOSUPPRESSION 3:
TACROLIMUS, SIROLIMUS, EVEROLIMUS
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527 PHARMACOKINETICS (PK) OF TACROLIMUS FOR
A ONCE DAILY PROLONGED RELEASE FORMULATION
(ADVAGRAF®) VERSUS TWICE-DAILY (PROGRAF®) IN DE
NOVO KIDNEY TRANSPLANT RECIPIENTS IN A PHASE III
MULTICENTRE STUDY
N. Undre8, Z. Wlodarczyk1, M. Ostrowski2, M. Mourad3, B. Kramer4,
D. Abramovicz5, F. Oppenheimer6, D. Miller7, J. Dickinson8
1
Szpital Uniwersytecki im, 2Szpital Wojewodzki nr, 3UCL St-Luc University
Hospita, 4Klinikum der Universität Regensburg, 5Hopital Erasme, 6Hospital
Clinic I, 7Chris Barnard Memorial Hospital, 8Astellas Pharma Europe Ltd
Introduction: Advagraf® (ADV) is a prolonged release formulation of
tacrolimus to enable once daily administration. A previous Phase II study in
kidney transplant recipients has shown that the mean AUC of tacrolimus on
Day 1 following administration of ADV was approximately 30% lower than
that for Prograf (PRG); however, the exposure was comparable by Day 14. The
objective of this study was to further describe the PK of tacrolimus for ADV
versus PRG during the first 2 weeks post-transplant.
Methods: Thirty four patients (ADV n=17, PRG n=17), participating in a
Phase III study, provided four evaluable PK profiles. In all patients tacrolimus
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therapy as PRG or ADV was initiated at a pre-operative dose of 0.10 mg/kg/
day; the first post-operative dose was 0.2 mg/kg/day, with target whole blood
trough levels of 10 to 20 ng/mL. PK profiles (17 samples over 24 hours) were
obtained following the first post-operative administration of tacrolimus (Day 1)
and then on Day 3, Day 7 and Day 14. All samples were analysed using HPLC
with tandem mass spectrometric detection.
Results: The AUC0 24 mean values for ADV were 372 (Day 1), 437 (Day
3), 405 (Day 7) and 412 (Day 14) ng•h/mL. Corresponding values for
PRG were 447 (Day 1), 428 (Day 3), 335 (Day 7) and 339 (Day 14)
ng•h/mL. Dose normalised systemic exposure to tacrolimus for ADV on
Day 1 was approximately 81% compared to PRG. On Days 3, 7 and 14
AUC0-24 of tacrolimus for ADV compared to PRG was approximately
106%, 107% and 116% respectively. There was good correlation between
AUC0-24 and C24 for ADV and PRG (r=0.92 and r=0.87, respectively)
with similar slopes.
Conclusion: This study has confirmed that systemic exposure to tacrolimus for
ADV normalises to that of PRG within 3 days post-transplant and that the same
trough level monitoring concept can be used for both formulations.
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528 A POST-HOC ANALYSIS OF THE SAFETY AND
EFFICACY OF TACROLIMUS (PROGRAF) VERSUS A
“GENERIC FORMULATION” OF TACROLIMUS (TENACRINE)
AS PRIMARY IMMUNOSUPPRESSIVE THERAPY IN LRD
AND CAD, ADULTS AND PEDIATRIC RENAL TRANSPLANT
RECIPIENTS

529 PROSPECTIVE RANDOMIZED STUDY OF
PHARMACOGENETIC ADAPTATION OF TACROLIMUS
TREATMENT AFTER RENAL TRANSPLANTATION
E. Thervet1, M.A. Loriot2, S. Barbier3, M. Buchler4, B. Hurault de Ligny5,
G. Choukroun6, C. Legendre1, C. Alberti7, P. Beaune2
1
Department of Transplantation, Hopital Necker, 2Department of
Biochemistery, Hopital Europeen Georges Pompidou, 3Department of
Nephrology, CHU Rouen, 4Department of Nephrology, CHU Tours,
5
Department of Nephrology, CHU Cean, 6Department of Nephrology, CHU
Amiens, 7Department of biostatitics, Hopital Robert Debre
Introduction: Retrospective studies have demonstrated that cytochromeP450
3A5 (CYP3A5) polymorphisms are associated with tacrolimus (TAC) dose
requirements. CYP3A5 expressors (i.e. CYPA5*1 carriers) need a higher daily
dose to achieve therapeutic trough drug (C0) level. The aim of this study was to
demonstrate that the use of pharmacogenetic allows a better initial adaptation
of TAC treatment.
Patients and methods: This multicenter, prospective, randomized, open-label
trial included 280 de novo renal recipients randomized at day 0 to receive
TAC from day7 according to CYP3A5 genotype (group A, 0.075 mg/kg bid in
CYP3A5*1 carriers or 0.15 mg/kg bid in CYP3A5*3/*3) vs. a control group
with usual TAC daily dose (group B, 0.10 mg/kg bid). All patients received
also from day0 a biological induction, MMF and steroids. Primary endpoint
was the proportion of patients within therapeutic C0 (10 to 15 ng/ml) at day10.
33 patients were not analyze mainly because of the use of drugs which interact
with CYP3A.
Results: No significant difference was shown between group A vs. group B
for baseline characteristics. Genotype frequency was 79.8% CYP3A5*3/*3,
15.8% CYP3A5*1/*3 and 4.4% CYP3A5*1/*1. The mean TAC daily dose was
not different among the 2 groups (group A: 12.9[plusmn]3.4 vs. 15.3[plusmn]8
mg, p=NS). A significantly higher proportion of patients reached targeted
C0 at day 10 (43% vs. 26%, p=0.009). In CYP3A*1/*1, the mean C0 was
14,87[plusmn]2,35 in group A vs. 7,23[plusmn]2,35 in group B (p=0.035).
In CYP3A5*1/*3, the mean C0 were respectively 14.2[plusmn]1.4 vs.
11.8[plusmn]1.6 (p=0.26). In CYP3A5*1/*1, the mean C0 were respectively
13.7[plusmn]0.9 vs. 18.2[plusmn]0.8 (p=0.0002).
Figure 1.
Conclusion: This is the first demonstration that the prospective adaptation of
TAC daily dose according to CYP3A5 polymorphisms is associated with a
higher proportion of patients reaching the targeted C0. The clinical results are
being analyzed to determine if this pharmacokinetic improvement is associated
with clinical consequences.

POSTER BOARD NUMBER P3 – 391
530 THREE-YEAR EXPERIENCE WITH TACROLIMUS
ONCE-DAILY PROLONGED RELEASE IN KIDNEY,
LIVER AND HEART RECIPIENTS
J.P. Van Hooff1, R. Alloway2, P. Trunecka3, J-P. Squifflet4
1
University Hospital Maastricht, 2University of Cincinnati, 3IKEM, 4Clinique
Universitaires Saint-Luc
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily
formulation of tacrolimus with similar exposure and trough levels compared to
the well-established twice-daily formulation (Prograf®, PRO). Adult transplant
patients who had previously participated in European ADV Phase II de novo
(kidney and liver) or conversion studies (kidney and heart, PRO to ADV) were
entered into a follow-up open study to collect clinical data on acute rejection,
survival, safety and daily dose requirement in the maintenance phase.
Methods: Baseline assessments were made at study entry and all patients were
maintained on their original immunosuppressive regimen unless medical needs
necessitated otherwise. Any medication change was recorded as were adverse
events. Biopsy was only performed for suspected rejection. Tacrolimus whole
blood levels at 24 hours post-dose (Cmin) were measured every 3 months.
Efficacy was assessed according to patient and graft survival, and acute
rejection (graded for all indications as: none, mild, moderate, severe).
Results and conclusions: The full analysis set consisted of 240 patients: 47 de
novo liver, 47 de novo kidney, 67 kidney conversion and 79 heart conversion
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Tacrolimus (Prograf®) is a principal immunosuppressive agent used to prevent
allograft rejection in patients undergoing renal transplantation. Generic
formulations of Tacrolimus are available which may not be bioequivalent to the
original formula of Prograf® ,and therefore may be detrimental to patients.
This retrospective study compared the efficacy and safety of Prograf® with
Tenacrine®, a Generic formulation of Tacrolimus now used in Mexico in renal
transplant recipients.
Inclusion criteria included undergoing a first renal transplant and treatment
with Prograf® (n = 101) or Tenacrine® (n = 121) in a 3-year open-label,
prospective, randomized, controlled study.
Although the mean blood tacrolimus level in patients treated with Prograf®
did not change significantly over time, the mean blood tacrolimus levels were
lower in patients treated with Tenacrine® at 3 and 6 months post-transplant
when compared to baseline.
Approximately, twice as many patients receiving Tenacrine® developed acute
rejection compared with patients receiving Prograf® (11.8% versus 20.8%;
p=0.080). Although the statistical analysis showed a p-value, considered
as no significant, there is a tendency to develop more acute rejection in the
Tenacrine® group.
There was no difference in the development of acute rejection between living
and cadaveric renal transplants in patients treated with Prograf®. However,
patients undergoing cadaveric renal transplants were more likely to develop
acute rejection when compared to living renal transplants if treated with
Tenacrine® (75% of cadaveric versus 10% of living; p=0.04).
Patients receiving Tenacrine® had a median time to rejection of two months,
compared with a median time to rejection of five months in patients receiving
Prograf®.
These study suggest that use of Tenacrine® lead to poorer clinical outcomes in
renal transplant patients when compared to Prograf®.
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patients. 191/240 (79.6%) patients completed the 3-year follow up with
33/37/57/64 patients, completing across the separate studies. Decreases in
the mean daily tacrolimus dose and mean blood level with time were most
pronounced in de novo patients (see table). The mean total daily doses at 34-36
months were 4.5/5.9/5.0/4.8 mg, respectively.
Month
1-3
4-6
10-12
22-24
34-36

Liver
de novo
mg/kg
0.17
0.12
0.09
0.07
0.06

ng/mL
11.6
10.6
8.7
7.7
6.6

Kidney
de novo
mg/kg
0.15
0.12
0.10
0.09
0.08

ng/mL
11.6
9.9
8.9
7.8
7.6

Kidney
conversion
mg/kg
ng/mL
0.08
6.3
0.08
6.7
0.07
6.7
0.07
6.5
0.07
6.4

Heart
conversion
mg/kg
ng/mL
0.07
8.2
0.07
8.9
0.07
8.7
0.07
8.2
0.06
7.7

38/240 (15.8%) patients were withdrawn mostly for adverse events (13) or
withdrawal of consent (7). Kaplan-Meier 3-year patient and graft survival
estimates were 90.9%/100%/92.2%/95.7%. Acute rejection occurred in
4.3%/10.6%/0%/10.1% patients. Most rejections were mild to moderate with
the exception of 2 severe acute rejections in 2 heart conversion patients. Mean
creatinine clearance at 3 years was 89.8/61.3/77.6/78.3 mL/min. The adverse event
profile and efficacy were consistent with that historically observed with PRO.
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531 PRELIMINARY TWO-YEAR EFFICACY RESULTS FROM
A RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY OF
TWO DIFFERENT SIROLIMUS (SRL) REGIMENS VERSUS A
TACROLIMUS (TAC) + MYCOPHENOLATE REGIMEN (MMF)
IN DE NOVO RENAL ALLOGRAFT RECIPIENTS
S.M. Flechner1, S. Cockfield2, J. Grinyo3, G. Russ4, K.M. Wissing5,
C. Legendre6, J.B. Copley7, for the ORION Trial Investigators
1
Cleveland Clinic Foundation, Cleveland, OH, 2University of Alberta,
Edmonton, Alberta, 3Hospital Bellvitge, Barcelona, Spain, 4Queen Elizabeth
Hospital, Woodville South, Australia, 5Hospital Erasme, Brussels, Belgium,
6
Hôpital Necker, Paris, France, 7Wyeth Pharmaceuticals, Collegeville, PA
Purpose: To compare preliminary 2-year efficacy results from an open-label,
randomized, multinational trial of 2 SRL regimens versus TAC+MMF.
Methods: 451 renal transplant recipients were randomized to either Group
1: SRL (8-15 ng/mL, 12-20 ng/mL after week 13) + TAC (6-15 ng/mL) with
elimination at week 13 (n=155); Group 2: SRL (10-15 ng/mL through week
26, 8-15 ng/mL thereafter) + MMF (up to 2 gm/day) (n=155); or Group 3:
TAC (8-15 ng/mL through week 26, 5-15 ng/mL thereafter) + MMF (up to 2
gm/day) (n=141). Corticosteroids and daclizumab were given to all patients.
Because of increased acute rejection (AR) rates, Group 2 was terminated in
June 2006 (after all patients were accrued); data was collected for 30 days
beyond termination.
Results: With the exception of more females in Group 3, patient demography
was similar among groups. Group 2 had significantly higher biopsy-confirmed
AR (BCAR) rates compared with Groups 1 and 3, p<0.001 (Table). The majority
of these occurred during the first 6 months after transplantation (predominantly
in the first 3 months). SRL trough concentrations were subtherapeutic in a large
number of rejectors in Group 2. In Group 1, most ARs occurred within the first
6 months, but before TAC was eliminated. All ARs were mild to moderate,
although Group 3 had a higher incidence of grade II ARs. Rates of graft and
patient survival were similar among groups (see Table). Renal function was
similar between Group 1 and Group 3. The number of patients in Group 2 was
low because of group termination.
BCAR,a n (%)
Grade I (Mild)
Grade II (Moderate)
Patient survival, n (%)
Graft survival,b n (%)
Mean Nankivell GFR,
modified ITT, mL/min (n)
Mean serum creatinine,
modified ITT, mg/dL (n)

Group 1
(SRL+TAC-Elim)
20/148 (13.5)
15/20 (75.0)
5/20 (25.0)
147/155 (94.8)
145/155 (93.5)

Group 2
(SRL+MMF)
43/152 (28.3)*
33/43 (76.7)
10/43 (23.3)
147/155 (94.8)
147/155 (94.8)

Group 3
(TAC+MMF)
13/139 (9.4)
7/13 (53.8)
6/13 (46.2)
136/140 (97.1)
138/140 (98.6)

64.9 (118)

72.4 (10)

66.7 (110)

1.68 (123)

1.35 (10)

1.61 (112)

On-therapy; *p<0.001
b
Death censored
a

Conclusion: Preliminary results show excellent patient and graft survival.
Renal function was similar between groups 1 and 3. Adequate SRL exposure
appears to be essential early posttransplant to achieve low BCAR rates.
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532 MINIMIZATION OF IMMUNOSUPPRESSIVE DRUG
THERAPY AT 6 MONTHS AFTER RENAL TRANSPLANTATION:
EVEROLIMUS OR CYCLOSPORIN SUPERIOR TO
MYCOPHENOLATE SODIUM
I.J.M. ten Berge1, E. de Maar2, R. Press3, J. Homan van der Heide2,
H. de Fijter3, F.J. Bemelman1
1
Academic Medical Centre, Amsterdam, 2University Hospital, Groningen,
3
Leiden University Medical Cantre, Leiden
Chronic allograft nephropathy is the main cause of long term renal transplant
failure. The pathogenesis is complex involving amongst others nephrotoxic
drugs notably cyclosporin (CsA). Therefore we performed a randomized
multicenter trial to withdraw the calcineurin inhibitor (CNI) from a triple
maintenance immunosuppressive regimen at 6 months after transplantation
in a moderate risk population. Patients continued either on prednisolon (P)
and CsA, P and mycophenolate sodium (MPS) or P and everolimus (ELS).
All patients received induction therapy with basiliximab. Prior to withdrawal a
surveillance transplant biopsy was done to ensure that no subclinical rejection
was present before tapering the immunosuppressive regimen. Drug levels were
monitored calculating drug exposure using a Bayesian model with limiting
sample technique. Primary outcome was the degree of fibrosis and hyalinosis
in the 2 years protocol biopsies. Secondary endpoints were patient and graft
survival and surrogate markers for atherosclerosis. An interim analysis was
performed after inclusion of half of the patients. 264 patients were originally
enrolled at that time. 49 dropped out, 76 were still prior to conversion and in
26 the immunosuppression could not be tapered due to subclinical rejection in
their 6 months protocol biopsy. 113 patients were effectively randomized to
continuing cyclosporin (N=39, target AUC 3250 ƒÝg/l/hr), or MPS 2 x 720
mg (N=36) or ELS N=38, target AUC 150 ƒÝg/ml/hr). After conversion there
was 1 rejection in the ciclosporin arm (2%), versus 8 in the MPS arm (22%)
and none in the ELS arm. Mean plasma creatinin was 138 „b 14 ƒÝmol/l, 132
„b 25 ƒÝmol/L and 110 „b 10 ƒÝmol/ L in the ciclosporin, MPS and ELS arm
respectively. We conclude that an early switch to double therapy consisting of
P and either ELS or CsA is safe. In contrast, tapering at 6 months to double
therapy consisting of P and MPS bears a high risk of late, acute rejection.
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533 SIROLIMUS IS ASSOCIATED WITH WORSEN OUTCOME
COMPARED TO MYCOPHENOLATE MOFETIL IN HIGH
IMMUNOLOGIC RISK RENAL TRANSPLANT RECIPIENTS
RECEIVING TACROLIMUS COMBINED WITH ATG
INDUCTION
M. Durlik1, O. Tronina1, T. B±czkowska1, M. Klinger2, B. Rutkowski3,
A. Wiêcek4, M. Ostrowski5, L. P±czek6, J. Szmidt7, W. Rowiñski8
1
Dept. of Transplantation Medicine And Nephrology, 2Dept. of Nephrology and
Transplantation Medicine, 3Dept. of Nephrology, Transplantology and Internal
Medicine, 4Dept. of Nephrology, Endokrynology and Metabolic Diseases,
5
Dept. of General and Transplantation Surgery, 6Dept. of Immunology,
Transplantology and Internal Medicine, 7Dept. of General, Vascular and
Transplantation Surgery, 8Dept. of General and Transplantation Surgery
Introduction and aims: Results of kidney transplantation in high immunologic
risk are associated with increased rate of rejection and lower graft survival.
The aim of this multicenter, randomized, prospective study was to determine
optimal immunosuppressive regimen in this group of patients (pts).
Methods: 62 (30 males) high risk cadaveric renal transplant recipients, aged
15-55 years, were included in the study and followed-up for 36 months. High
immunologic risk was defined as retransplantation (2nd [n=34] or 3rd [n=l]
graft) or PRA > 25%. PRA range was 0-24% (n=28), 25-36% (n=23), and
>36% (n=11). HLA mismatches (MM) in class I (A + B) were 16.1, 26, 35.5,
11.4, and 4.8%, for 4, 3, 2, 1 and 0 MM, respectively and in class II (DR)
were 14.5, 5, and 26% for 2, 1 and 0 MM, respectively. Pts were randomized
to receive ATG (3 mg/kg; 4 doses) + Steroids + Tacrolimus (Tac) and either
mycophenolate mofetil (MMF) (n=40) or Sirolimus (Sir) (n=22). 1-year graft
and patient survival were estimated with Kaplan-Meier method. Renal function
(expressed as estimated GFR [eGFR calculated by Cocroft Gault’s formula]
was monitored for 24 months.
Results: Delayed graft function was observed in 35.5% pts. In 37% pts biopsy-

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Wednesday 13 August 2008

Oral Abstracts
proven acute rejection episodes were diagnosed (early [up to month 3] in 17%,
late in 20%), in 32.5% pts on MMF, and in 45.5% on Sir (NS). Significantly
higher cholesterol and trigliceryde levels, and significantly lower hemoglobine
and hematocrit were observed in Sir group. 8 kidney grafts were lost during
follow-up 5 and 3 in MMF and Sir groups, respectively. 4 patients were
converted from Sir to MMF due to thrombotic mieroangiopathy, 2 patients from
MMF to Sir due to neoplasia. Rate of infectious complications was comparable
in both groups. Two patients died during follow-up. Renal function was stable
in both MMF and Sir groups, with eGFR slope significantly more positive in
MMF group over 2 years after transplantation (p<0.045).
Conclusions: MMF with ATG induction proved more safe and efficacious than
sirolimus therapy in high immunologic risk kidney transplantation, resulting
in better graft function and lower incidence of adverse effects. Kaplan-Meier
estimates of l-year patient and graft survival showed a trend in benefit of
MMF.
Graft function (GFR mL/min [CC formula]), 1-year graft and patient survival
MMF group
Sir group

GFR at
Month 1
58.88±25.8
46.8±20.4

GFR at
Month 3
58.2±19
47±20.6

GFR at
Month 24
62.4±21
50.2±20.2

Graft survival
87.5%
81.8%

Patient
survival
95.5%
90.9%
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534 INFLUENCES OF IMMUNOSUPPRESSIVE AGENTS
ON GRAFT SURVIVAL: THE IMPACT OF DE NOVO CNI
MINIMIZATION COMBINED WITH SIROLIMUS
M.-K. Tsai, C-Y. Lee, I-R. Lai, R-H. Hu, P-H. Lee
Department of Surgery, National Taiwan University Hospital
A multivariate analysis was conducted to assess the impact of de novo sirolimus
therapy on graft survival. We collected 100 patients of renal transplantation
receiving sirolimus combined with a low-dose calcineurin inhibitor (CNI) (either
cyclosporine or tacrolimus) and 104 cases on CNI-based immunosuppressive
therapy from October 2000 to August 2007. Graft and patient survival rates
were estimated using the Kaplan-Meier method. Univariate analysis with the
log-rank test was used to examine the prognostic significance of recipient
age, gender, donor age, delayed function, donor type, HLA mismatch, SRL
therapy, CNI (CsA or TAC) and acute rejection in graft survival. Prognostic
significance of 6-month estimated GFR for graft survival was determined by
Cox¡¦s regression. Stepwise regression analysis was then applied to factors
with statistical significance in the univariate analysis to further determine the
independent effect of each factor. On univariate analyses, 6-month estimated
glomerular filtration rate (eGFR), acute rejection and sirolimus therapy were
significant for graft survival, and sirolimus therapy and tacrolimus therapy for
rejection-free survival. Mutivariate analyses identified 6-month eGFR as the
only one prognostic factor for graft survival. Acute rejection and sirolimus,
but not tacrolimus, therapy was significant for posttransplant renal function. In
conclusion, sirolimus de novo therapy brought about improved renal function
and graft survival of renal transplantation.
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Background: The high rate of side-effects, drug discontinuation and acute
rejection episodes seen in SRL based CNI-free immunosuppressive protocols
may largely be due to the ill-timed early initiation of SRL post-transplantation. To
avoid the well-known problems of mTOR-inhibitor based immunosuppression
in the early phase after transplantation, we designed a study where CNI-free
immunosuppression with SRL and mycophenolate mofetil (MMF) was started
2-3 weeks after renal transplantation following a short course of cyclosporine
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536 RESULTS OF A CALCINEURIN-INHIBITORFREE IMMUNOSUPPRESSIVE PROTOCOL IN RENALTRANSPLANT RECIPIENTS OF EXPANDED CRITERIA
DECEASED DONORS (ECD). 5-YEAR ANALYSIS
L.S. Re, M. Rial, D. Curcio, O. Guardia, J. Petroni, D. Casadei
Instituto De Nefrología De Buenos Aires
Introduction: The increasing number of patients on waiting lists and the
relatively stable organ procurement rate provide the groundwork for the use
of expanded criteria deceased donors. While calcineurin-inhibitors (CNI) are
excellent immunosuppressive drugs, their nephrotoxicity is largely responsible
for the lack of improvement in long-term graft survival.
Objective: The objective of this study was to analyze the results obtained with
the use of a calcineurin inhibitor-free immunosuppressive protocol (polyclonal
antibody induction, plus sirolimus, mycophenolate mofetil, and low doses of
steroids) in terms of graft and patient survival as well as post-transplant clinical
complications over a 5-year period.
Materials and methods: 75 kidney recipients of ECD performed between
01/01/01 y 01/05/05 were treated with Thymoglobulin induction for 7-14 days,
Sirolimus was adjusted to a level of 8-12 ng/ml during the first post-transplant
year and 6-8 ng/ml thereafter.
Results: Recipient age: 49.25 ± 18.5 years. Donor age: 56.25 ± 7.45 years.
Delayed graft function: 80%. 1-year acute cellular rejection: 15/75 (20%)
5-year actuarial patient survival: 85.7%. 5-year actuarial graft survival: 75.6%
5-year actuarial graft survival (death censored): 80.3%. 5-year creatinine level:
1.57 ± 0.34 mg/dl.
The incidence of post-transplant complications was low (arterial hypertension,
dyslipidemia, post-transplant diabetes, proteinuria, etc) and they were not
significantly different from that reported with other immunosuppressive
schemes.
Conclusion: The use of a calcineurin inhibitor-free protocol in renal-transplant
recipients of expanded criteria deceased donors was associated with excellent
graft and patient survival rates and a low incidence of adverse events in a
5-year follow-up period.
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535 DELAYED INTRODUCTION OF A CALCINEURININHIBITOR (CNI)-FREE, SIROLIMUS (SRL)-BASED
IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION
IS SAFE. PRELIMINARY RESULTS OF THE RANDOMISED,
MULTICENTER SMART TRIAL

(CSA) and MMF.
Methods: After ATG-F (9mg/kg bw.) induction and an initial 2-3 weeks
immunosuppression with CSA, MMF (2g/d) and steroids (ST), 141 low
risk renal transplant recipients were randomized to either continue on CSA
(target C0 200-250ng/ml), MMF (2g/d) and steroids or be converted to
CNI-free immunosuppression with SRL (target 8-12ng/ml) +MMF (1.5g/d)
and ST.
Results: Patient characteristics were comparable in both study arms. The
delayed introduction of SRL successfully avoided excess rates of wound
complications in the SRL arm. The rate of postoperative wound healing
problems was not significantly different in the SRL arm as compared to the
CSA arm (8 vs. 9%). The incidence of lymphoceles was 15% in the SRL arm
and 24% in the CSA arm. The early conversion did not result in an increased
risk of rejection during the conversion process. The rate of Banff 4 rejection
episodes from the time of conversion to 3 months was not significantly
different between the SRL arm 14% and the CSA arm 9%. Therapeutic SRL
levels were obtained within one week, reaching the intended target levels of
>8 ng/ml at day 7 after conversion (SRL trough 8.62±3.58 ng/ml). There was
no increased risk of infectious complications associated with the conversion
to SRL. However, CMV viremia, as a marker infection, was more frequent in
the CSA arm (28%) as compared to the SRL arm (6%). Although the overall
rate of adverse events was not significantly different between the study
groups, significantly more patients were withdrawn from the SRL arm 30% as
compared to the CSA arm 13%.
Conclusion: The preliminary results from this ongoing study show that the
delayed introduction of a CNI-free, SRL-based immunosuppression is equally
safe as compared to a CSA-based protocol in terms of surgical, immunological
and infectious complications. A well-timed, sequential use of SRL may
overcome problems observed with the de novo use of mTOR inhibitors.
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537 SAFETY AND EFFICACY OF EVEROLIMUS VS
MYCOPHENOLATE MOFETYL WITH CSA IN DENOVO LIVE
RELATED RENAL TRANSPLANTATION
R.K. Sharma, P.B. Vinod, A. Saxena, A. Gupta, R. Kapoor, A. Srivastava,
N. Prasad, A. Kumar
Department of Nephrology & Urology, Sanjay Gandhi Post Graduate Institute
of Medical Science
To compare the renal function, safety and efficacy parameters in everolimus vs
MMF group with cyclosporine at 1 year. This is a prospective non randomized
open label study in denovo live related renal transplant recipients. Total 60
patients above 18years and first renal transplant were included in the study
(30 in each arm). CsA was started on day -2 with 8 mg/kg/day in both groups
and tapered to achieve C2 level of 1-1.4 ƒÝgm/ml vs 1.7 ƒÝgm/ml at 1month
and 0.55 ¡V 0.65 ƒÝgm/ml vs 1.2 ƒÝgm/ml at 3 month and 0.35-0.45 ƒÝgm/
ml vs 1.0 ƒÝgm/ ml at 6 month and 0.25-0.35 ƒÝg/ml vs 0.8 ƒÝgm/ml at
12 months in Everolimus vs MMF group respectively. Everolimus was started
with 0.75 mg bid adjusted the dose to trough level of 3-8 ngm/ml. MMF dose
was started at 2 gm/day. Prednisolone 20 mg /day in both groups and reduced
to 10 mg /day by 3rd month of transplant. Renal functions were monitored
by serum creatinine and calculated GFR. The mean Serum creatinine (mg%)
at 1, 3, 6, 12 month of post transplant were 0.92±0.25; 1.0±0.12; 0.90±0.18;
0.91±0.11 in everolimus group vs 1.1±0.8; 1.2±0.34; 1.2±0.32; 1.23+0.67 in
MMF Gr respectively (NS).The mean GFR calculated at 12 month was 72±12
ml/mt/m2 (everolimus) vs 62±7.2ml/mt/m2 (MMF). The no: of patients with
BPAR at 12 month was 6 patients (20%) in the everolimus group and 8 patients
(26.6%) in the MMF group (P=NS). Graft loss occurred in 2 patients (6.6%)
in the everolimus group and 2 patients in the MMF group. Mortality was same
in both the groups-3.3% (1 patient in each gp). Side effect profile includes;
diabetes in 4 (13.3%) patients in everolimus group and 2 (6.6%) in the MMF
group. Dyslipidemia occurred in 6/30 (20%) in the everolimus group vs 5/30
(16.6%) in the MMF group .The average dose of CsA was 30 mg/day in the
evrolimus group compared to 150 mg/day in the MMF gp at 12month of
transplantation. The CsA requirement was five times less in the everolimus
group compared with MMF group at 12 month .The mean CsA drug level at 12
month was 0.55±0.08 ngm/ml in the everolimus group vs 0.85±0.21 ngm/ml in
the MMF group .The mean everolimus drug level at 12 month was 4.56±1.78
ngm/ml. The cost of therapy (calculated in US dollors) shows that everolimus
groups have significantly less cost compared to MMF group (555 vs 562 at
one month and 305 vs 417 at 3 month, 151 vs 331 at one year). There was no
significant difference in the serum creatinine level and calculated GFR at 1 year
of transplantation. The BPAR, graft loss and mortality were similar in the both
groups. The incidence of CMV infection or other viral infection were higher in
the MMF group. Exposure to CsA at 1 year was significantly less (1/5th dose)
in everolimus gp compared to MMF gp. This could have benefit in terms of
chronic CsA nephrotoxicity.
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everolimus arms of two 12-month, prospective, randomized studies (A2306,
A2307; n=493) in which patients received everolimus 1.5mg/day or 3.0mg/day
within 24h of transplantation, adjusted to target trough levels of 3–8ng/mL, in
combination with low-exposure CsA and steroids (with basiliximab induction
therapy in A2307). The primary endpoint for B201/B251 was efficacy, and for
A2306/A2307 it was renal function at 6 months; secondary endpoints included
adverse events (AEs) and serious adverse events (SAEs).
Results: In the pooled analyses, 167 (3.3%) of reported AEs in the MMFtreated group were associated with post-operative tissue regenerationrelated complications, such as wound infection, dehiscence and lymphocele
development, compared with 139 (2.2%) in the everolimus-treated group.
In both comparator groups, >85% of these AEs were classified as ‘mild’
or ‘moderate’. The two groups had comparable rates of wound infection,
dehiscence and lymphocele development (Table).
Conclusion: Tissue regeneration is comparable in the presence of everolimus
or MMF. The use of everolimus does not increase the post-operative risk of
delayed tissue regeneration.
2g/day MMF (B201/B251)
n=392
38 (9.7%)
14 (3.6%)
33 (8.4%)

Wound infection
Dehiscence
Lymphocele

Everolimus (A2306/A2307)
n=493
37 (11.4%)
30 (6.1%)
56 (7.5%)

MINI-ORAL SESSION 19: RENAL PATHOLOGY
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539 PITFALLS IN THE DIAGNOSIS OF CHRONIC ANTIBODY
MEDIATED REJECTION: LOSS OF PERITUBULAR
CAPILLARIES, WIDE SPECTRUM, AND TRANSIENT NATURE
OF C4D DEPOSITION
A.B. Collins, A.B. Farris, R.N. Smith, C.D. Adams, P.A. Della Pelle,
W. Wong, R.B. Colvin
Departments of Pathology, Medicine and Surgery, Massachusetts General
Hospital and Harvard Medical School, Boston MA 02114
The diagnosis of antibody mediated graft rejection is based on the extent of PTC
C4d deposition. However, recent studies have reported a loss of peritubular
capillaries in the setting of late graft dysfunction with fibrosis, and we have
commonly observed that the frequency of C4d+ PTC is less in CHR. In the
present study we performed single and two color immunohistochemistry for
capillary endothelium (CD34) and C4d. The PTC density was quantitated by
visual counts and compared to morphometry on digital virtual slides (Aperio).
These findings were correlated with graft function and extent of interstitial
fibrosis (trichrome morphometry). Cases studied were those classified
according to Banff 2007 as chronic antibody mediated rejection with transplant
glomerulopathy (CHR), transplant glomerulopathy with negative C4d (TG
C4d-), chronic calcineurin inhibitor toxicity (CNIT), and normal transplant
biopsies (NT). All of the CHR recipients tested had donor specific antibody (4
class I only, 5 class II only and 2 both).
Capillary Density/mm2

CD34/mm2

538 POST-OPERATIVE TISSUE REGENERATION IN RENAL
TRANSPLANTATION: COMPARABLE OUTCOME WITH
EVEROLIMUS OR MMF

Diagnosis

N

yrs post tx

CD34

C4d

%C4d+

CHR

15

8.7±5.7

233±124

117±122

43±31%

TG C4d-

7

13.9±12.6

165±138

0

0.006

R. Margreiter1, Š. Vitko2, J. Whelchel2, J.C. Magee2, H. Tedesco2, J. Eris2,
J. Pascual2, B. Kahan2, Z. Wang3, H. Sollinger2
1
Universitatsklinik fur Chirurgie, Innsbruck, Austria, 2On behalf of the B201,
B251, A2306 and A2307 Study Groups, and 3Novartis Pharmaceuticals
Corporation, East Hanover, United States
Introduction: Everolimus is a proliferation signal inhibitor that effectively
prevents acute rejection in renal transplant recipients. Its antiproliferative effect
has been shown to inhibit graft vasculopathy in cardiac allografts, and has been
a focus of interest during the early post-operative phase of tissue regeneration.
In this cross-study analysis, the influence of everolimus was compared with
mycophenolate mofetil (MMF), as part of a triple immunosuppressive regimen,
on the incidence of post-operative complications.
Methods: Pooled data from four prospective, randomized, renal transplantation
studies were compared: (i) the MMF arms from two 36-month, randomized,
parallel-group studies (B201, B251; n=392) in which patients received MMF
2g/day with standard-dose cyclosporine (CsA) and corticosteroids, and (ii) the

CNIT

6

5.2±3.2

243±185

0

n.s

NT

7

0.4±0.7

319±188

0

188

p vs NT
0.02

The PTC density was significantly decreased in the CHR group compared with
normal transplant biopsies (TG C4d-). Within the CHR group, the density of
C4d+ PTC correlated with the overall capillary density (p=0.001). According
to the new Banff C4d grades, one case was C4d1 (1-10%), 9 were C4d2
(10-50%) and 5 were C4d3 (>50%). However, there was a continuum of the%
of C4d+ capillaries from 1-89% and there was no obvious threshold that could
be applied to this group. Most had glomerular capillary wall C4d deposition
(83%). One case with class I DSA and TG had only 1% C4d+ but strongly
positive glomerular C4d deposition. One was more widespread by IHC and
one by IF. The% fibrosis correlated with the Cr at the time of biopsy (p=0.04).
C4d%+ and capillary density showed no statistically significant correlation with
Cr at the time of the biopsy or with the time post transplant. One question that
has been raised is the nature of TG with C4d-. This group also had a decreased
capillary density. Two cases had had prior acute humoral rejection and the TG

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Wednesday 13 August 2008

Oral Abstracts
was probably the residual of that episode. In 2 other cases the findings of CNIT
were typical and probably the cause of the TG. Three were idiopathic. One of
the CHR cases had a later biopsy with TG that was C4d-. Thus some cases of
TG C4d- are due to past episodes of antibody mediated glomerular injury.
We conclude that diagnosis of CHR by C4d staining has to take into account
the substantial decrease of capillary density and the wide range of positive PTC
down to a low percentage not normally considered diagnostic. C4d may be
transient and disappear or reappear in cases with TG, in keeping with the stages
of CHR previously proposed.
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540 EFFECTS OF MTOR-INHIBITION ON HYPOXIC
ADAPTATION BY HIF – PREFERENTIAL INFLUENCE
ON ERYTHROPIETIN REGULATION

541 EFFECTS OF PITUITARY ADENYLATE CYCLASE
ACTIVATING POLYPEPTIDE (PACAP) ON THE SURVIVAL,
MORPHOLOGY, APOPTOTIC SIGNALING AND OXIDATIVE
STRESS IN RATS SUBJECTED TO RENAL ISCHEMIA/
REPERFUSION
D. Reglodi1, P. Szakaly2, P. Kiss1, A. Lubics1, T. Magyarlaki3, A. Tamas1,
J. Nemeth4, A. Ferencz5, G. Weber5, B. Racz5
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PACAP was first isolated from the hypothalamus based on its cAMP-increasing
effect, but it has been shown in all parts of the central and peripheral nervous
system. The neuropeptide has well-known protective effects in the nervous
system, mainly through its antiapoptotic and antiinflammatory actions. A few
studies have shown that it is renoprotective in models of nephrotoxicity and
myeloma kidney injury. Our aim was to investigate the protective effects of
PACAP in rats subjected to different times of renal ischemia/reperfusion using
pathohistological analysis, Western blotting of apoptotic markers, biochemical
assay of oxidative stress and radioimmunoassay for measuring endogenous
PACAP. Rats received iv. saline or PACAP (100 μg) injection before renal
arteries were clamped for 15, 30, 45 or 60 minutes. Histological analysis 2 weeks
after survival showed that 15 or 30 min renal ischemia caused no morphological
changes in either group. Mortality increased after 45 and 60 min ischemia in
the controls with surviving rats showing severe tubular atrophy. However,
all PACAP-treated rats survived with normal or subtle renal morphological
alterations after 45 min ischemia, and only 1 rat died in the 60 min ischemic
group, where surviving rats displayed subtle focal tubular atrophy. Kidneys
were also further processed for examination of apoptotic signaling pathways
using Western blotting. Most marked effects were found in the expression of
mitochondrial antiapoptotic bcl-2: 45 and 60 min ischemia led to a marked
decrease, while PACAP treatment significantly increased the level of bcl-2.
Similar results were found with the MAP kinases: the antiapoptotic ERK was
increased while the proapoptotic JNK and p38 were decreased upon PACAP
treatment. Determining the levels of malondialdehyde and reduced glutathion
by biochemical assays revealed that levels of malondialdehyde were lower in
PACAP-treated rats that underwent 45 and 60 min ischemia. Furthermore, using
radioimmunoassay, the concentration of PACAP was determined in the kidney
tissue in young, old male and female rats before and after ischemia. PACAP
levels were significantly higher in young rats and were strongly reduced in
the cortex after short ischemic time, but an upregulation was observed a few
hours after longer ischemic times. Levels returned to baseline after 24 hours. In
summary, our results show that PACAP is endogenously present in the kidney
and the time-course of endogenous PACAP alterations may give further insight
to the role of PACAP in ischemia. Exogenously given PACAP prolongs the
ischemic time, increases survival rate and attenuates the pathomorphological
changes in a rat model of renal ischemia/reperfusion involving the upregulation
of antioxidant and antiapoptotic pathways.
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542 483 DONOR KIDNEY BIOPSIES: PREDONATION RISK
FACTORS AND HISTOLOGY
L. Kyllönen1, J. Kahu2, Ü. Kirsimägi2, K. Salmela1
1
Kidney Transplant Unit, Helsinki University Hospital, 2Clinic of Surgery,
Tartu University Hospital
Deceased donor quality is known to affect kidney transplantation outcome. Less
is known how donor risk factorsduring life are associated with the histological
findings in procurement biopsies.
Methods: We studied the influence of predonation risk factors on histology
of 483 deceased donor kidneys between 1995 and 2005. Mean age of the
donors was 45.9 ± 12.8 years (range 11-72). All biopsies were taken during
the donor operation and graded for this study according to the Banff criteria
by one pathologist. Clinical data were collected from hospital documents and
the national kidney transplantation registry. We analysed the cumulative effect
of risk factors on histological lesions. We also divided the donors according
to UNOS criteria to expanded (N=105) and non-expanded (N=378) criteria
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The Hypoxia-Inducible transcription Factor (HIF) and the kinase “mammalian
Target of Rapamycin” (mTOR) both represent key regulators in their field.
The former is the master regulator of oxygen dependent gene regulation,
enabling cells to adapt to a hypoxic environment. The latter is a central
controlling mechanism integrating influences of nutrients and mitogens to
cellular growth and proliferation. Both systems are of major importance in
tumour growth and wound healing, amongst many others. Recent data has
shown that both systems overlap, in that mTOR seems to activate HIF, yet the
mechanism and the biological relevance are unknown. mTOR inhibition is
increasingly being used in solid organ transplantation. A number of important
side effects, such as wound healing difficulties and posttransplant anemia,
represent relevant clinical problems. Furthermore, experimental data suggests
that ischemia tolerance is reduced under mTOR inhibition, which includes
early graft survival and cardiovascular events. Since HIF is involved in all
these processes, putative HIF repression by mTOR-inhibitors could partially
explain these unwanted effects.
We attempted to further characterise the regulation of HIF by mTOR, both
in cell culture and rodent models. Our studies confirm a profound effect of
mTOR inhibitors, such as everolimus on HIF activation amongst a broad panel
of cells, including primary and immortalised renal cells. However, these effects
are partially context- and cell-dependent. Interestingly, oxygen tension itself is
an important factor, in that HIF activation under severe hypoxia seems to be
completely independent of mTOR. HIF target genes such as VEGF or GLUT1
were moderately influenced by mTOR inhibition in cell culture. However, genes
regulated with a high amplitude, such as EPO and CA9 showed a pronounced
repression. Erythropoiesis is a classical function of HIF, which is mediated
by transcriptional regulation of the erythropoietin gene in the kidney, leading
to continuous EPO secretion. Therefore, we seeked to investigate the role of
mTOR inhibition in vivo. In rodents, pre-treatment with everolimus prior to
hypoxic (9% O2, 8 hours) exposure did not attenuate the expression of the HIF
targets VEGF or GLUT1 in any organ assayed, although pronounced effects on
the phosphorylation status of the downstream effector of mTOR, rpS6, were
observed. EPO, on the other hand, did show a significant reduction of mRNA
expression in the kidney by everolimus.
In conclusion, our data confirm and extend the previously demonstrated
effect of mTOR-inhibition on HIF, which appears to be a general cellular
effect. The regulation of HIF by mTOR seems to be most relevant at mild
hypoxia or even normoxia; which could enable a certain degree of oxygenindependent transactivation by HIF. Our data implicate that in severe tissue
hypoxia, mTOR inhibition may not influence HIF targets on a tissue level.
However, the influence of mTOR on EPO regulation possibly meets a clinical
correlate, which could at least partially explain the frequently observed
anemia in transplanted patients treated with mTOR inhibitors. This effect
would cause a relative deficit of circulating EPO, which would add to the
antiproliferative effect on the bone marrow and should encourage the use of
recombinant EPO.
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donors. Histological findings in these two categories were compared.
Results:
Table 1. Frequency of donor (N=483) risk factors
Risk factor
Smoking
Alcohol abuse
Hypotonia
Arterial hypertension
Resuscitation
Untreated hypertension
Aterosclerotic vascular disease
Ischemic heart disease
Oliguria

histological components of the Banff schema were positive only in solitary
cases.

%
61
25
23
19
16
9
7
6
4

Observed frequency of donor risk factors is shown in Table 1. Donor age was the
most significant risk factor affecting glomerulosclerosis (%GS), tubular atrophy
(ct), interstitial inflammation (ci), vascular intimal sclerosis (cv), arteriolar
hyalinosis (ah) and the composite CADI score in donor biopsy (Table 2.)
Cardiovascular causes of death and arterial hypertension affected the donors’
glomerular and vascular sclerosis and CADI but not the interstitial or
tubular compartment. Ischemic heart disease was correlated only with%GS.
Smoking was associated with cv and ah. Periods of hypotension affected
the tubulointerstitial compartment but otherwise the factors related to donor
management had no significant impact on biopsy findings. Alcohol abuse was
not a risk factor for donor kidney damage.
Donor creatinine was correlated only with CADI score (4 or higher), but not
with single histological parameters.
Table 2. Association of significant risk factors with donor histology.
Risk
factors,
P value
%GS
ct
ci
cv
ah
CADI

Age
< 0.0001
0.0115
0.0458
< 0.0001
0.0023
<0.0001

Dgn:
Trauma
vs other
0.0316
ns
ns
0.0004
0.0016
0.0013

Athero
sclerosis
ns
ns
0.0345
ns
0.0634
ns

Ischemic
heart
disease
0.0313
ns
ns
ns
ns
ns

Hypertension Hypo tonia Smoking
0.0004
ns
ns
0.0599
ns
0,006

ns
0.0386
0.0054
ns
ns
ns

ns
ns
ns
0.0222
0.0115
ns

An increased number of simultaneous risk factors resulted in higher scores of
CADI,%GS, ah, cv and ct. If no donor risk factors were present CADI 0 was
found in 63.6% of biopsies, if there were 2 or more risk factors only in 41%
(P = 0.033). Expanded criteria (UNOS) donors had significantly higher scores
of%GS, cv, ct, ah and CADI than non-expanded criteria donors.
Conclusions: The pre-existing histological injuries in donors with a number
of risk factors should be taken into account during allocation (old-for-old
programmes) and recipient management (minimal cold ischemia time, nonnephrotoxic schemas).
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543 DONOR BIOPSY HISTOLOGY AND RESULTS OF 833
DECEASED DONOR KIDNEY TRANSPLANTATIONS
L. Kyllönen1, J. Kahu2, Ü. Kirsimägi2, K. Salmela1
Kidney Transplant Unit, Helsinki University Hospital, 2Clinic of Surgery,
Tartu Univeristy Hospital
Expanded criteria donors are increasingly used for kidney transplantation. The
aim of our study was to examine what severity of lesions in the donor kidney
histology is acceptable for transplantation.
Methods: We evaluated baseline kidney biopsies (more than 7 glomeruli)
taken during the donor operation from 483 deceased donors (mean age 45.9
± 12.8, range 11-72). Kidneys from these donors were transplanted between
1995 and 2005 to 833 recipients. Follow-up time was from 2 to 12 years. The
biopsies were graded semiquantitatively according to the Banff classification
by one pathologist. Clinical data were collected from hospital documents and
the national kidney transplantation registry. The effects of each histological
parameter and the composite CADI on graft function as measured by calculated
(Cockcroft) creatinine clearance and survival was analysed. We also analysed
the histological findings by dividing the donors according to UNOS expanded
(N=105) and non-expanded criteria (N=378).
Results: The average number of glomeruli in biopsies was 16.4±6.7 (range
7 - 40). The mean percentage of sclerotic glomeruli was 3.5 (95% CI: 2.9 – 4.0,
range 0 – 43).
Table 1. Histological findings in 483 donor kidney biopsies. The remaining
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Banff 97 schema components
Vasc. intimal sclerosis (cv),%
Tubular atrophy (ct),%
Interstitial fibrosis (ci),%
Arteriolar hyalinosis (ah),%

0
70.8
96.1
87.4
80.3

1
25.1
3.9
12.2
9.7

2
3.9
0.2
9.3

3
0.2
0.2
0.6

CADI
%

0
45.5

1
33.5

2
13.7

3
4.8

≥4
2.5

Figure 1. CADI and 3-year Creatinine clearance
Donor biopsy variables (Table 1) did not significantly affect the graft survival.
In our material, concerning glomerulosclerosis, increasing the required number
of glomeruli did not make it a predictor of graft survival.
The 1 and 3 year creatinine clearances were significantly affected by CADI
(Figure 1), percentage of glomerulosclerosis and the other histological
parameters (cv, ct, ci, ah).
Rate of DGF was significantly higher in CADI >3 transplantations (52% vs.
28%). Singly, the histological variables of donor biopsy did not predict onset
of graft function. Expanded criteria (UNOS) donors had significantly higher
scores in vascular, tubular and glomerular injury and CADI. Transplantation
from these donors resulted in significantly worse graft survival.
Conclusion: In our deceased donor kidney transplant population donor
histology did predict the quality of graft function up to at least 3 years after
transplantation but did not predict graft survival.
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544 HEPARIN BINDING EPIDERMAL GROWTH FACTOR
(HB-EGF) IS DETRIMENTAL IN ISCHEMIA/REPERFUSION
INJURY (IRI)
H. van Goor1, G.M. Mulder1, W.N. Nijboer2, M.A. Seelen3,
W.B.W.H. Melenhorst1, L. Visser1, R. Khokha4, H.G.D. Leuvenink2,
R.J. Ploeg2, S.W. Sunnarborg5,
1
Department of pathology and medical biology, University Medical
Center Groningen, University of Groningen, Groningen, the Netherlands,
2
Department of surgery, University Medical Center Groningen, University
of Groningen, Groningen, the Netherlands, 3Department of nephrology,
University Medical Center Groningen, University of Groningen, Groningen,
the Netherlands, 4Ontario Cancer Institute, University Health Network,
Toronto, Canada, 5Department of Biochemistry and biophysics, University of
North Carolina School of Medicine, Chapel Hill, NC, USA
Background: Kidneys from living-related donors have a better long-term
survival than those from deceased donors, suggesting that ischemia is implied
in the pathogenesis of chronic transplant dysfunction (CTD). IRI causes
progressive deterioration of renal function. Regeneration may be accompanied
by fibrosis and lead to CTD. The Epidermal Growth Factor Receptor (EGFrec)
and its ligands are expressed along the nephron and involved in the development
of renal lesions. Mice overexpressing a dominant negative isoform of EGFrec
are protected from renal lesions during AngII infusion. We studied HB-EGF, a
ligand for EGFrec, in experimental and human IRI.
Methods: HB-EGF mRNA and protein expression were studied in rat kidneys
(n=6 per group) subjected to ischemia (45 min) and sacrificed at 30, 90 min,
6 hrs, 1, 4, 9, 14 or 21d after reperfusion. HB-EGF mRNA was determined in
cultured human tubular cells that were subjected to 36 hrs of hypoxia and 0, 2,
6, 12, 24, 48 hrs of reoxygenation. In human kidneys (Brain Dead (BD)=35,
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Living=20), HB-EGF mRNA and protein expression were studied at time of
donation (T1), after cold ischemia (T2) and after reperfusion (T3). HB-EGF-/and wild type mice (n=3-5 per group) were subjected to bilateral ischemia (30
min) and sacrificed at 1,5, 6 hrs, 1 after reperfusion to study the role of HBEGF in renal injury.
Results: In rat IRI, HB-EGF mRNA was 13-fold upregulated (P< 0.01) after
30 min, 90 min and 6 hrs of reperfusion, compared to sham rats. From 1 d
onwards, HB-EGF mRNA returned to control levels. HB-EGF protein was
expressed in distal tubules. From 30 min after reperfusion onwards de novo
expression of HB-EGF was detected in glomerular epithelial cells, proximal
tubules and arterial structures. One day after reperfusion the staining pattern
of HB-EGF returned to normal. In line with in vivo data, in cultured tubular
cells, HB-EGF mRNA was significantly increased (P< 0.05) after 2, 6, 12
and 24 hrs of reoxygenation. In human BD and living donor biopsies, HBEGF mRNA was significantly increased at T3, compared to T1 (P<0.001). In
human sections, predominant tubular expression of HB-EGF shifting from
cytoplasmatic expression at T2 to luminal expression at T1 and T3 was found.
HB-EGF-/- mice showed significantly less morphological damage after 6 hrs
(P< 0.05) and 1 day (P< 0.01) of reperfusion, compared to wild type mice.
Conclusion: Following IRI, HB-EGF is markedly upregulated in rat kidneys,
cultured human tubular cells, and human biopsies. Most importantly, HB-EGF-/mice are protected from renal damage. These results indicate that EGFrec
blockers might prove to be protective in the early phase of transplantation.
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545 ASSOCIATION BETWEEN DE NOVO DONOR SPECIFIC
HLA ANTIBODY, C4D STAINING IN RENAL GRAFT BIOPSY,
AND GRAFT OUTCOME

Antibody Category

N

C4d Positive
N (%)

Graft Failure
N (%)

None (ref)
Class I only
Class II only
Class I & II
NDSA

20
10
22
9
8

1 (5) (ref)
8 (80) (P<0.001)
13 (59) (P<0.001)
9 (100) (P<0.001)
2 (25) (P=0.12)

3 (15) (ref)
2 (20) (P=0.82)
9 (41) (P=0.06)
4 (44) (P=0.09)
1 (13) (P=0.86)

Figure. Graft survival according to DSA groups

Graft Failure or
SCr>4.0
N (%)
5 (25) (ref)
5 (50) (P=0.10)
13 (59) (P=0.03)
6 (67) (P=0.03)
1 (13) (P=0.40)

546 COMPARISON OF BIOPSY AND CLINICAL SCORE
SYSTEMS TO PREDICT OUTCOME OF EXTENDED CRITERIA
KIDNEY DONORS
A. Faenza1, G. Fuga1, M. Tsivian1, R. Bertelli1, F. Neri1, M. Scolari2,
G. Feliciangeli2, G.L. D’Arcangelo2, L. Ridolfi3, S. Stefoni2
1
Dept. of General Surgery And Transplantation, University of Bologna, 2Dept.
of Nephrology, Dialysis and Transplantation, University of Bologna, 3EmiliaRomagna Transplant Reference Center
Introduction: Advanced age, cerebrovascular death, hypertension, diabetes
and low calculated creatinine clearance are all risk factors in deceased kidney
donors. Subjects older than 50 with one or more risk factors or subjects older
than 65 without any of them are considered as suboptimal or marginal donors
and their kidneys all over Italy are rejected or accepted for single or double
transplantation following the Biopsy Score proposed by Remuzzi (J Am Soc
Nephrol 10,2591,1999). A different Score on simple clinical base has been
proposed by Nyberg (Am J Transpl. 3,715,2003). The aim of the present paper
is to verify whether the two Score systems can help predict the outcome of
renal transplantation.
Methods: We retrospectively analyzed the clinical records of donors and
recipients of kidney transplants of the last 4 years. Biopsy and Clinical Score
were correlated to the transplant outcome. End points assessed were Early
Kidney Function (primary non function, early good function for up to two
post-op dialyses or severe post-operative malfunction) and serum creatinine
at 1 and 6 months.
Results: In the last 4 years (2004-2007), 271 kidney transplantations were
performed at our centre, 151 of them using “ideal” donors and 120 using
“marginal” donors (102 as single and 18 as double kidney transplants). In
15 cases both kidneys and in 6 cases only one kidney from marginal donors
were discarded owing to a high Biopsy Score; in 3 other cases the organs
were discarded because the Biopsy showed a kidney disease. The Clinical
Score predicted well the outcome in terms of Early Graft Function and serum
creatinine at 6 months (p<0.001). The Biopsy Score did not prove such a
correlation since kidneys with 0, 1, 2, 3 or 4 total Score did not result in a
significantly different transplant outcome.
Discussion: Up to several years ago, a donor age over 60 and one risk factor
were sufficient to discard a kidney. The Biopsy Score era has given an essential
contribution to increase the donors’ pool with results not as good as ideal
donors kidneys, but still widely acceptable. Our study anyhow demonstrates
that a simple Clinical Score has a better predictive value of transplantation
results and suggests that the Biopsy should be performed in all marginal donors
but probably should be interpreted in a less mandatory manner.

POSTER BOARD NUMBER P3 – 408
547 CHRONIC TRANSPLANT GLOMERULOPATHY –;
CLINICAL AND PATHOLOGICAL CORRELATES
M. Durlik1, A. Perkowska-Ptasinska1, M. Ciszek2, T. Baczkowska1, A.
Chmura3, Z. Galazka4, L. Paczek2
1
Department of Transplantology and Nephrology, Medical University in
Warsaw, 2Department of Immunology, Transplantology and Internal Medicine,
Medical University in Warsaw, 3Department of General and Transplantation
Surgery, Medical University in Warsaw, Warsaw, 4Department of General,
Vascular, and Transplantation Surgery, Medical University in Warsaw,
Warsaw
Introduction: Chronic transplant glomerulopathy is one of the leading
causes of severe post-transplant proteinuria and graft loss. It may develop in a
response to several different injurious processes, such as humoral rejection or
thrombotic microangiopathy. In the majority of cases the etiology is obscure,
which excludes the possibility for targeted intervention. Our current knowledge
about risk factors for the development of TG, as well as factors affecting its
dynamics and prognosis is poor.
The aim of the study was to find pathological and clinical risk factors and
correlations of TG as well as parameters that influence the survival of grafts
with that pathology.
Materials and methods: We retrospectively reevaluated all 86 kidney
transplant cases with TG that have been recognized on the basis of indication

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

191

WEDNESDAY

Yong Cho1,2, J. Cicciarelli1,2, N. Kasahara1,3, M. Koss1,2, K. Houston1,
R. Mendez1,2, Ian Hutchinson1,2, Tariq Shah1,2
1
National Institute of Transplantation, 2USC School of Medicine, 3UCLA
School of Medicine
Background: Despite improved early graft survival, long-term kidney graft
loss rate has not been reduced. Both HLA antibodies and HLA donor specific
antibodies (DSA) have been detected and may be causal in chronic allograft
nephropathy (CAN) and, especially, in acute rejection. We evaluated the
association between DSA, C4d staining in transplant and graft outcome.
Materials and methods: During Sep 2004-Aug 2007, HLA antibody tests usng
the Luminex laboratory screen assay system were performed in 348 recipients.
Of these, Cd4 deposition was assessed in the biopsies of 69 recipients with
transplant dysfunction.
Results: In the 69 cases, 29 (42%) showed C4d negativity, 27 (39%) were
Cd4 positive, 6 (9%) were equivocal, and 6 (9%) not diagnostic. Fourty-nine
recipients (71%) with transplant dysfunction had HLA antibodies and 41
(59%) had DSA. The proportion of C4d positivity was significantly higher in
patients with DSA (Class I only, II only, and I & II) in comparison with patients
without post-transplant HLA antibodies (Table). The incidence of graft failure
(including current SCr≥4.0) in patients with class II antibodies (Class II only
or I & II) was significantly higher than that in patients without post-transplant
HLA antibodies (Table). In Figure, grafts of Class II DSA group continued to
fail beyond 2 years after transplantation when compared with other 2 groups
(None/NDSA or Class I only), however, the difference in graft survival between
Class II and None/NDSA group did not reach to statistical significant level
(log-rank P=0.32).
Conclusions: Significant association between C4d staining, de novo HLA
Class II antibodies and graft failure strongly suggests the importance of
post-transplant HLA antibodies. We propose that amelioration of CAN
graft loss depends on monitoring and identification of DSA and appropriate
immunosuppression of these antibodies.
Table. C4d positivity and graft outcomes according to DSA groups
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biopsy in Transplantation Institute since 1996. All the TG- as well as all preTG (previous) biopsies were histologically characterized according to Banff
classification including C4d positivity in PTC and in glomeruli. Pathological
and clinical data were subjected to detailed statistical analysis.
Results: C4d positivity was found in 52 biopsies (61%), among which in
33 (38%) C4d was present in both localizations. Among clinical parameters
univariate analysis revealed that younger recipient age and minimalization
of immunosuppression (drug withdrawal or suboptimal drugs dose/blood
level within 3-6 months preceding the biopsy) were associated with C4d
positivity in PTC (p =0,0053 and p=0,0365 respectively). In multivariate Cox
analysis diffuse PTC-itis (p=0.029, RR(95%CI) =3.349(1.131-9.919) and total
interstitial inflammation score (p=0.015, RR(95%CI) = 9.662 (1.784-52.329)
were found to have the negative impact on the graft survival. C4d positivity
in both analyzed localizations (PTC and glomeruli), the level of pre-Tx
sensitization, induction therapy with ATG or daclizumab, acute rejection and
C4d in previous (pre -TG) biopsies did not influence the survival of grafts with
TG.
Conclusions: In grafts with TG younger recipient age and minimalization of
immunosuppression are associated with C4d positivity. The survival of kidney
grafts with TG is significantly affected by the magnitude of inflammation in
interstitium and PTC, but not by C4d positivity in PTC and glomeruli.
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548 EXPRESSION OF INSULIN IN THE LIVERS OF
PREDIABETIC NON OBESE DIABETIC MICE MAY REDUCE
THE DEVELOPMENT OF TYPE I DIABETES
B. Ren, B. O’Brien, M. Byrne, A. Simpson
University of Technology Sydney
Type I diabetes (TID) is characterised by the autoimmune destruction of
the insulin-producing beta cells in the pancreas by the actions of CD4+ and
CD8+ T cells and macrophages infiltrating the islets. Many scenarios have
been suggested to prevent the progression of the disease by disrupting the
autoimmune process in the prediabetic state. Whilst no treatment has thus far
been successful the finding that antibodies and T cell clones directed against
a specific epitope of insulin in early diabetes has led to the suggestion that
treatment of early diabetes with insulin might have an immunomodulatory
effect in addition to its ability to allow the beta cells to rest. We have shown
that introducuction of furin-cleavable human insulin (INS-FUR) to the livers
of streptozotocin diabetic-Wistar rats (1) and non obese diabetic mice using
a lentiviral vector (HMD) has resulted in the reversal of diabetes. The aim
of the current study was to see if the introduction of a small amount of the
HMD/ INS-FUR vector to the livers of prediabetic NOD mice could prevent
the onset of T1D. The lentiviral vector was produced on 293T cells and purified
and concentrated by tangential flow filtration and ultracentrifugation (40,000g/
4h). Prediabetic female NOD mice (7 weeks old) were treated with the HMD/
INS-FUR vector (107 transduction units) (n=10) or saline (n=10), and mice
were monitored for changes in body weight and blood glucose levels. After
30 weeks, liver, pancreas, spleen, thymus and blood samples were harvested.
The spleen, thymus and pancreas were analysed for CD4+, CD8+, CD25+ and
T-regulated lymphocyte markers (Treg) subset CD4+/CD25+ expression by
immunofluorescence. Immunoperoxidase staining for insulin expression in the
liver and pancreas was also carried out. We examined sera for GAD 67 levels
in HMD /INS-FUR-pre-treated diabetic NOD mice and non obese resistant
(NOR) controls by western analysis.
Fifty percent of the mice that were pretreated with the HMD /INS-FUR vector
maintained normal blood glucose levels and weight, by comparison 80% of
the saline-pre-treated mice developed overt diabetes. CD25 and CD4+/CD25+
were significantly (P<0.05) higher in HMD/INS-FUR pretreated NOD mice
compared to saline-treated controls in spleen and thymus tissues. Pancreatic
T lymphocytes from saline pretreated NOD mice had a CD4:CD8 ratio of
1.17 ± 0.16 (n=10) compared with 1.79 ± 0.21 in HMD/INS-FUR pre-treated
NOD mice (P=0.037). In HMD/INS-FUR pre-treated NOD mice, we found
significant insulin-staining in the liver and pancreas and no obvious insulitis in
the pancreas. GAD 67 was not significantly different in HMD/INS-FUR pretreated mice, compared with controls. Liver function tests in HMD/INS-FUR
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pre-treated NOD mice were normal. These results indicate that it is possible to
reduce or eliminate insulitis and may have the potential to prevent the onset of
T1D in a proportion of NOD mice.

POSTER BOARD NUMBER P3 – 410
549 EFFICIENT AND LONG-LASTING ADENO-ASSOCIATED
VIRUS 8 (AAV8) VECTOR –MEDIATED TRANSGENE
EXPRESSION IN HEART TRANSPLANT MYOCARDIUM
J.J. Jokinen1, A.I. Nykänen1, K. Pajusola2, R. Tuuminen1, R. Krebs1,
J. Soronen2, K. Alitalo2, K.B. Lemström1
1
Cardiopulmonary Research Group. Transplantation Laboratory, 2Molecular
Cancer Biology Laboratory, Biomedicum, University of Helsinki and Helsinki
University Hospital, P.O. Box 21, FIN-00014 University of Helsinki, Finland.
Introduction: Heart transplantation offers an unique milieu to perform ex
vivo gene transfer during the cold preservation of the graft, but identification
and throughout characterization of safe and efficient gene transfer vector is
essential before pursuing to clinical applications. Adeno-associated virus
(AAV) vectors are excellent candidates for heart transplant gene therapy
because of their non-pathogenic nature, minimal immune and inflammatory
response and cardiomyocyte tropism. We compared the transgene expression
kinetics, efficiency and localization of the well-characterized AAV serotype 2
(AAV2) and the novel and efficient AAV8 in rat heterotopic heart transplant
model.
Material and methods: Heterotopic heart transplantations were performed
between syngeneic Dark Agouti (DA) rats. To investigate the kinetics and
efficiency of transgene expression, coronary arteries of the donor graft were
perfused with AAV2 or AAV8 vectors encoding firefly luciferase (AAV2-Luc
or AAV8-Luc, n = 6 per group, 1x1011 genomic copies). The recipients were
subjected to non-invasive bioluminescent in vivo imaging system (IVIS®,
Xenogen Corp, Alameda, CA, USA) at 2 days, and 1, 2, 3, 4, 8, and 12 weeks
after transplantation. Heart transplant transgene expression was quantified
with Living Image® 2.50 and IGOR® software (Xenogen Corp, Alameda,
CA, USA; WaveMetrics Corp, Lake Oswego, OR, USA). To localize the
transgene expression, donor grafts were perfused with AAV2 or AAV8 vectors
encoding enhanced green fluorescent protein (AAV2-EGFP or AAV8-EGFP, n
= 3 per group, 1x1011 genomic copies), and immunofluorescent stainings with
endothelial cell (RECA-1), smooth muscle cell (α-SMA) and cardiomyocyte
(T-CMC) markers were performed at 8 week time-point.
Results: Bioluminescent imaging revealed luciferase activity that mainly
localized to the heterotopic heart transplant of AAV-Luc perfused animals
(Figure 1, arrows). AAV2 transgene expression (Figure 2, dashed line)
increased gradually and peaked 4 weeks after transplantation whereas AAV8
transgene expression (Figure 2, solid line) continued to increase up to 12 weeks
after transplantation. AAV8-Luc perfusion resulted in ~4-times higher heart
transplant transgene expression than AAV2-Luc perfusion at 12 week time-point
(Figure 2, p = 0.025). Immunofluorescent stainings of AAV2-EGFP and AAV8EGFP-perfused grafts showed control gene expression in cardiomyocytes but
not in endothelial or smooth muscle cells.
Conclusions: Our results show that AAV vectors result in long-term transgene
expression in heart transplant cardiomyocytes, and the novel serotype AAV8 is
more efficient than AAV2. The low immunogenic nature of AAV-vectors makes
them ideal tools in future heart transplant gene therapy applications.
Figure 1.
Figure 2.
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550 CYCLIN KINASE INHIBITOR P21-MEDIATED IMMUNETOLERANCE: DIRECT AND INDIRECT EVIDENCE
M. Mehra, A. Khanna
University of Maryland,, Baltimore
Background: Since uncontrolled proliferation of T-cells is considered a
barrier to the induction of transplantation tolerance by T regulatory cells, we
hypothesized that there is a parallel between such aberrant proliferation and
cyclin kinase inhibitor p21 deficiency. We hypothesize that CD4+CD25+ T
regulatory cells and p21 expressing T cells as well as CD4+CD25- T regulatory
cells and p21-deficient T cells share similar proliferating properties relevant to
induction of immune tolerance.
Methods: Human CD4+CD25+ and CD4+CD25- cells were isolated from
normal healthy blood donors (n=6), p21-/- (n=9) and wild type mice (n=9).
Purification of Treg was confirmed by staining the cells with anti-CD4-FITC
and PE-coupled anti-CD25 antibody. These cells; CD4+CD25+, CD4+CD25alone or in combination were then activated with anti-CD3 with and without
cyclosporine (100 ng/ml). We also studied mRNA for FoxP3 in purified
CD4+CD25+, CD4+CD25- T cells from wild type and p21-/- mice and
human CD4+CD25+/- cells by real-time quantitative RT-PCR. We compared
proliferation and the expression of FoxP3 in CD4+ CD25+/CD25- cells with T
lymphocytes from wild type and p21-/- mice. We also compared the effect of
CD4+CD25+ and p21 expressing T cells on the proliferation of CD4+CD25and p21-/- T cells, respectively.
Results: The difference in proliferation (counts per minute, p<0.003)
among CD4+CD25+ (15236 1190) and CD4+CD25- (50317 974) T-cells
were proportionately similar to the difference in proliferation (p<0.001) of
lymphocytes from wild type (28206 2812) and p21-/- mice (49624 2164).
Similar to CD4+CD25- T cells, CD4+ T cells from p21-/- mice lacked FoxP3
gene expression. The analysis indicated that the number of T regulatory cells
in p21-/-mice were significantly (p<0.002) lower (2.6 0.8) than wild type mice
(14.5 1.6%,). T cells from wild type mice inhibited the proliferation of T cells
from p21-/- mice in a one way MLR assay similar to the effect of CD4+CD25+
T cells on the proliferation of CD4+CD25- cells. The proliferation of
CD4+CD25- T cells and p21-/- lymphocytes was resistant to the inhibition by
CsA. Gene expression of FoxP3, ILT3 and GITR supported these findings.
Conclusions: Expression of the cyclin kinase inhibitor p21 creates a milieu
consistent with an anti-proliferative and immunosuppressive effect of
CD4+CD25+ T-reg cells. These findings support the notion that p21 could be
used clinically in controlling allo-immune activation in an effort to prolong
graft survival.

POSTER BOARD NUMBER P3 – 412
551 REDUCED DEVELOPMENT OF TRANSPLANT
ARTERIOSCLEROSIS IN ADENOSINE DIPHOSPHATE (ADP)
RECEPTOR P2Y12-DEFICIENT RECIPIENT MICE
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552 THROMBOSPONDIN-1 (TSP-1) MEDIATES THE ANTIANGIOGENIC AND IMMUNOMODULATORY EFFECTS OF
RAPAMYCIN ON PANCREATIC ISLET ENDOTHELIAL CELLS:
RELEVANCE FOR ISLET TRANSPLANTATION
V. Cantaluppi1, S. Beltramo2, F. Figliolini2, G.M. Romanazzi2, L. Biancone1,
G.P. Segoloni1, G. Camussi2
1
Renal Transplantation Unit, University of Torino, 2Centre for Experimental
Medical Research (CeRMS), University of Torino
After the transplantation into the portal vein, a relevant percentage of pancreatic
islets fail to engraft into the liver as consequence of a poor vascular support.
Islet endothelial cells play a key role in the neo-revascularization processes by
forming a chimeric vascular tree with recipient vessels. The identification of
factors able to enhance neoangiogenesis may increase islet engraftment. Despite
the mTOR inhibitor rapamycin represents the central immunosuppressive drug
used in the Edmonton protocol for islet transplantation, it has been shown
to reduce the rate of beta-cell proliferation contributing to the progressive
dysfunction observed in islet graft recipients. In addition, rapamycin is known
to exert dual effects on islet endothelium inducing the simultaneous inhibition
of angiogenesis and the down-regulation of receptors involved in lymphocyte
adhesion and activation.
We evaluated by gene array analysis the mediators involved in the antiangiogenic effects of rapamycin on freshly purified human islets. In presence
of rapamycin, we found a significant decrease of pro-angiogenic factors such
as VEGF/Î±VÎ²3 integrin and the simultaneous increase of thrombospondin-1
(TSP-1) mRNAs. Thrombospondins are a family of five multidomain,
calcium-binding extracellular glycoproteins that are synthesized by a wide
variety of cells of both mesenchymal and epithelial origin. TSP-1 is a key
regulator of angiogenesis and it is markedly up-regulated in tissues following
ischemia-reperfusion injury, a common denominator of solid organ and cell
transplantation. Gene array data were confirmed at protein level by confocal
microscopy, western blot analysis and ELISA test of TSP-1 concentrations in
islet supernatants. The co-incubation with a blocking anti-TSP-1 polyclonal
antibody reduced the inhibitory effect exerted by rapamycin on endothelial
outgrowth from islets. Moreover, TSP-1 blockade resulted in a significant
increase of insulin secretion by rapamycin-treated islets in response to high
glucose challenge.
We also isolated endothelial cells from human islets to confirm the role of
TSP-1 in rapamycin-induced inhibition of angiogenesis. Rapamycin, at doses
similar to those detected in islet graft recipients (10-20 ng/ml) decreased
migration, proliferation and formation of capillary-like structures in vitro
when islet-derived endothelial cells were plated onto Matrigel-coated plates,
with consequent appearance of apoptosis. All these biological processes were
significantly reduced by co-incubation with a blocking anti-TSP-1 polyclonal
antibody. In vivo, TSP-1 blockade significantly reduced the anti-angiogenic
effect of rapamycin on islet endothelium xenotransplanted subcutaneously into
Matrigel plugs in SCID mice.
TSP-1 is also known to modulate the immune response to foreign antigens
by generating regulatory T cells (Tregs) through the specific binding of
CD47 antigen located on T cells. We found that TSP-1 blockade inhibited the
decrease of lymphocyte adhesion induced by rapamycin on islet endothelial

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

193

WEDNESDAY

Y. Matsumoto, K. Umemura
Department of Pharmacology, Hamamatsu University School of Medicine,
Hamamatsu City, Shizuoka 431-3192, Japan
Background: Transplant arteriosclerosis (TA) is characterized by an early
endothelial loss followed by a chronic inflammation, eventually leading to form
occlusive¦ neointima. The neointima is mainly composed of smooth muscle
alpha-actin (SMA)-positive cells in the grafted vessels. Although it is wellknown that adenosine diphosphate (ADP) receptor P2Y12 signaling cascade(s)
play a fundamental role and is pivotal for the full complement of platelet
activation, the role of the P2Y12 receptors in immune-mediated inflammation
and neointimal formation after transplantation is not well understood yet. We
therefore investigated the influence of P2Y12 receptor¦ deficiency (KO) on the
development of TA.
Methods: Fully MHC-mismatched carotid arteries from C3H/He (H-2k)
mice were orthotopically transplanted into Wild-Type (WT) or KO recipients
(C57BL/6 x 129S, H-2b). No immunosuppression was used. Grafts were
harvested at 8 weeks after transplantation, and the frozen cross sections were
processed for morphometry and immunohistology. Luminal occlusion was
calculated by the following equation: luminal occlusion (%) = intimal area/
(luminal area + intimal area) x 100. The number of CD45-positive leukocytes

or SMA-positive cells was examined by counting their nuclei counterstained
with 4’,6-diamidino-2-phenylindole (DAPI). Data are presented as mean ± SD.
The statistical evaluation was carried out using the Unpaired Student’s t-test.
Results: Morphometric analysis showed that the area of the graft intima was
significantly reduced in KO recipients when compared with WT recipients
(luminal occlusion: 23.2 ± 8.0% versus 44.9 ± 20.5% in KO and WT recipients,
respectively, n = 10, p<0.01). In addition, immunohistological analysis revealed
that the accumulation of CD45-positive leukocytes (24.4 ± 23.0 cells versus
61.9 ± 48.5 cells in KO and WT recipients, respectively, n = 10, p<0.04) and
SMA-positive cells (87.3 ± 51.7 cells versus 200 ± 144.7 cells in KO and WT
recipients, respectively, n = 10, p<0.03) in the graft intima was also significantly
decreased in KO recipients.
Conclusion: These experiments indicate that P2Y12 receptor deficiency
can effectively reduce the development of TA in the murine carotid artery
transplantation model, suggesting that P2Y12 receptor might play a role in the
development of TA (a manifestation of chronic rejection).
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cells through the modulation of surface molecules involved in lymphocyte
adhesion and activation.
In conclusion, TSP-1 significantly inhibited the anti-angiogenic effect of
rapamycin on islet endothelium. The conception of a therapeutic strategy
aimed to selectively block TSP-1 in the early period after transplantation may
enhance islet engraftment within liver sinusoids. Furthermore, our data suggest
a potential role of TSP-1 in the long term modulation of the immune response
therefore improving islet graft survival.
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553 IMMUNE CELL ACTIVATION COMPARING THREE
INDUCTION AGENTS (ALEMTUZUMAB, THYMOGLOBULIN
AND BASILIXIMAB) WITH TACROLIMUS, MYCOPHENOLATE
MOFETIL AND A RAPID STEROID WITHDRAWAL IN RENAL
TRANSPLANTATION
J. Holman, G. Harrison, K. Vandeputte, R. First, W. Fitzsimmons
R & D Department, Astellas Pharma U.S., Deerfield, IL, United States
Purpose: The ImmuKnow assay (iATP) provides a quantitative measure of
immune cell function. Previous studies have suggested an increased risk of
infection at low (< 250 ng/ml) or rejection at high (> 350 ng/ml) values. Prior
studies generally examined iATP values infrequently and inconsistently.
Method: We examined iATP values at Baseline, Day 14, Day 30, Day 60 and
Day 90 following transplant in a group of 474 adults randomized based on risk
profile: High Risk (HR=African American (AA), PRA>=20% or re-transplants)
were assigned to Campath (C1H) or to Thymoglobulin (Thymo). Low Risk
(LR=non-AA, PRA<20% or primary transplant) were assigned to C1H or
Basiliximab (Bas). Both C1H groups received 30 mg of C1H on day (D) 0; the
Thymo group received 4 doses of Thymo (1.5 mg/kg/d) on D0-4; the Bas group
received 2 doses of 20 mg of Bas on D 0-4. Only 1 gram of methylprednisolone
was given prior to discharge. Tacrolimus and Mycophenolate mofetil (MMF)
were used as maintenance immunosuppression. Occurrence of biopsyconfirmed acute rejection (BCAR) and any infection was correlated with iATP
values.
Results: There were no differences between groups in mean tacrolimus blood
levels or mean MMF doses. As expected C1H and Thymo resulted in profound
lymphocyte depletion. Lymphocyte counts were essentially unchanged in
Bas group. iATP values (ng/ml) decreased over time in all groups as shown
below. There were no differences between HR-C1H and Thymo. LR-C1H was
significantly lower than Bas at all post-transplant timepoints.
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HR

LR

C1H* N=70

Thymo N=69

C1H* N=164

Baseline

210**

251

271**

Bas N=171
242

Day 14

203

219

221

271***

Day 30

131

190

174

246***

Day 60

124

144

151

218***

Day 90

93

101

117

192***

*HR-C1H vs LR-C1H, repeated measures ANOVA, P=0.04
**HR-C1H vs LR-C1H, P=0.05
***LR-C1H vs LR-Bas, P=0.05

The incidence of BCAR and any infection by iATP value is shown below.
Treatment groups were combined for this analysis. Subjects were excluded if
clinical event occurred before Day 14 or subject had no iATP value prior to
clinical event.
Incidence of Clinical Event
Closest iATP Value Prior to Event*

BCAR

All Infection

0 – 250 ng/ml

10/341 (2.9%)

85/282 (30.1%)

251 – 350 ng/ml

4/44 (9.1%)

19/39 (48.7%)

>= 350 ng/ml

4/40 (10.0%)

22/48 (45.8%)

*For subjects without a clinical event their last iATP value used.

Summary: Immunosuppression results in a decrease in iATP value over time.
Depletional induction agents result in a greater decrease in iATP value than a
non-depletional agent. Although we show a positive correlation of iATP value
and incidence of BCAR, the cutpoint was lower than previously reported. The
positive correlation of iATP with incidence of any infection is in contrast to
previous reports.
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554 INFLUENCE OF MEDICAL IMMUNOSUPPRESSION ON
CMV-SPECIFIC T-CELL THERAPY: CONCLUSIONS FROM IN
VITRO- AND CLINICAL OBSERVATIONS
G. Brestrich3,2, S. Zwinger2, A. Röhmhild3,2, M. Hammer2, A. Kurtz3,2,
H-D. Volk2, P. Reinke3
2
Department of Medical Immunology- Charité- Universitätsmedizin,
3
Department of Nephrology- Charité- Universitätsmedizin
The cytomegalovirus (CMV) is a member of the beta-herpes family. After
primary infection the virus stays latent in the host and reactivates frequently.
In imunocompetent hosts these reactivations are controlled efficiently by
virus-specific CD4+ and CD8+ T-lymphocytes. In transplanted patients the
cellular immune response is diminished due to the applied immunosuppressive
therapy. Uncontrolled CMV-reactivations often manifest in the transplanted
organ leading to reduced graft and host survival. The incidence of CMVcomplications is strongly dependent on the type of transplantation ranging
between 5% in hemapoetic stem cell transplantation (HSCT) and 50% in lung
transplantation (LTX).
The adoptive transfer of in vitro manipulated CMV-reactive T cells is a
promising option to specifically strengthen the hosts’ immune response. It was
applied successfully in several clinical studies treating CMV-complications
after HSCT. To date, clinical trials concerning solid organ transplanted (SOT)
patients are missing as high levels of immunosuppression in this group affect
the generation of specific T-cell lines and their function in vivo.
In this study the influence of immunosuppressive drugs on the generation of
CMV-specific T-cell lines was analyzed. We used a HLA-type independent
protocol to generate T-cell lines against two immunodominant CMV proteins
pp65 and IE-1. Therefore, donor PBMCs were stimulated with overlapping
peptide pools of the both proteins. Next, specifically activated, IFN-ã secreting
T cells were selected and expanded. We analyzed 5 CMV seropositive healthy
donors and 10 kidney transplanted patients under standard immunosuppression.
Utilizing the protocol described we successfully generated both IE-1 and pp65
specific T-cell lines from all healthy and 8/10 immunocompromised donors.
Starting with 20 ml blood, T-cell lines achieved numbers > 5x107 after 4 weeks
of expansion. Comparing Phenotype, specific function, epitope diversity and
T-cell receptor beta repertoire revealed no significant differences between the
two groups.
With regard to the in vitro findings, a T-cell line specific for pp65 and IE-1
was generated under clinical conditions from a LTX-patient. The patient
suffered from a CMV-reactivation with indication of resistance to ganciclovir.
The patient was treated with two doses of 1x107/m2 specific T cells in a 4
week interval. Both infusions were well tolerated and increasing numbers of
pp65 and IE-1 specific T cells could be detected in the patients’ blood shortly
after infusion. Additionally, the viral load dropped significantly and patients’
condition advanced. After 5 weeks the viral load started to increase again going
along with a decrease of CMV-specific T cells. At this time point patients’
condition deteriorated and the patient died 4 weeks later by CMV-pneumonia.
We could show in this study, that the generation of functional CMV-specific
T-cell lines from blood of immunosuppressed donors is feasible using the
described protocol. Since its HLA-independence it is broadly applicable to
SOT patients suffering from CMV-complications. However data indicate that
in the LTX-patient the infused T-cells lost their function with time. This may
be due to the present immunosuppression that has negative effects of on the
T-cell function or survival. Dose escalating strategies have to be performed to
optimize the therapeutic success in these patients.

POSTER BOARD NUMBER P3 – 416
555 HOW DOES THE KIDNEY FIGHT BACK? THE ROLE
OF SERPINS IN RENAL ALLOGRAFT REJECTION
K. Heutinck1,2, I. ten Berge2, J. Hamann1, A. Rowshani2
1
Department of Experimental Immunology, 2Department of Internal Medicine,
Renal Transplant Unit, Academic Medical Center, Amsterdam, The Netherlands
Subclinical renal allograft rejection is defined as the presence of granzyme
positive lymphocytes leading to tubulitis. However, in sharp contrast to acute
clinical rejection, this does not immediately result in allograft dysfunction.
Subclinical rejection is common and is associated with the development
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of chronic rejection and long term graft failure. We recently showed that
serine protease inhibitor 9 (SERPINB9) is overexpressed by renal tubular
epithelial cells (TECs) during subclinical rejection. SERPINB9 specifically
inhibits granzyme B; the most important effector molecule during rejection.
Cytotoxic T lymphocytes (CTLs) are protected against self-induced apoptosis
via expression of this serpin. We hypothesized that SERPINB9 and related
serpins protect TECs against attacks of host inflammatory cells. We aimed to
investigate the role of serpins in renal transplantation.
The expression and regulation of several members of the serpin B family were
evaluated in HK-2 cells, a human TEC-line, and in primary human TECs.
The TECs were stimulated by several cytokines (TNFα, IFNγ, IL-1β, IL-6)
and toll-like receptor ligands (lipoteichoic acid, poly(I:C), LPS, imiquimod,
CpG, oligonucleotides) which are important inflammatory mediators during
rejection. Next, serpin expression was analyzed by quantitative RT-PCR and
Western blotting.
Resting HK-2 cells and primary TECs constitutively express several
members of the serpin family. Unexpectedly, serpin expression in HK-2 cells
was not affected significantly by the tested cytokines and TLR-ligands. On
the contrary, preliminary results in primary human TECs show that serpin
expression is regulated by these stimuli. SERPINB2, B6, B8 and B9 mRNA
levels were downregulated by interleukin-6. On the contrary, the mRNA levels
of SERPINB3, B8, and B9 were elevated due to stimulation of TLR3 with
poly(I:C). Moreover, SERPINB9 expression was also induced by IFNγ and
IL-1β.
Here, we demonstrate that several serpins are constitutively expressed by
TECs. In primary TECs, serpin expression is regulated by several cytokines
and TLR-ligands which are known to play a role in acute rejection. In contrast,
these stimuli did not influence serpin levels in HK-2 cells, suggesting that
this cell-line is not the best model to study serpin regulation. Currently, we
are performing cytotoxicity assays to unravel the function of serpins in renal
transplantation.

POSTER BOARD NUMBER P3 – 417
556 RAPAMYCIN INDUCES AUTOPHAGY IN ISLETS:
RELEVANCE FOR ISLETS TRANSPLANTATION

Rapamycin treatment
Blocking assay by 3-MA
for islets
Parental
1ng/ml of
mice
rapa
1ng/ml of 10ng/ml of
islets
+
rapamycin rapamycin
10mM
3-MA

10ng/ml of
rapa
+
10mM 3-MA

LC3-II/GAPDH ratio
(LC3-II expression by
Western blot)

0.50

0.44

0.73

% absorbance by
MTS assay (%) (islets
viability, recovery of
viability)

100
56.8±14.1 49.0±2.0
(control)

68.5±0.5

75.8±25.9

Assay

1.06

1.08

Conclusions: Our results demonstrate that rapamycin exerts the effects on islets
inducing autophagy and a down-regulation of islets viability. Therapeutically
targeting this novel pathway may yield significant benefits for long-term islet
graft survival.
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557 ACCELERATED RAT CARDIAC ALLOGRAFT FAILURE
IS PREVENTED BY ANTI-ICOS IMMUNOTHERAPY:
IMPLICATIONS FOR CONTROL OF CHRONIC REJECTION
L. Guo1, Y-X. Shan1, H-Y. Zhang1, H. Kimura2, M. Makuuchi3
1
The First Hospital of Ji Lin University, 2Department of Experimental
Surgery and Bioengineering, National Children’s Medical Research Center,
Tokyo, Japan, 3Department of Artificial Organ and Transplantation Surgery,
Graduate School of Medicine and Faculty of Medicine, University of Tokyo
In a DA (RT1a) to LEW (RT1l) rat model, inhibition of B7-CD28 co-stimulatory
signal blockade by adenovirus-mediated cytotoxic T-lymphocyte-associated
antigen 4 immunoglobulin (AdCTLA-4Ig) induces long-term acceptance of
cardiac allografts. However, allograft tolerance is incomplete and rejection
eventually occurs. In particular, donor-type skin grafting to recipients with
functional cardiac allografts causes accelerated heart rejection. Here, we reevaluated the combined effects of anti-ICOS antibody therapy, together with
AdCTLA-4Ig on allograft acceptance. To this end, the effect of anti-ICOS
on preventing accelerated cardiac rejection caused by donor-strain skin
grafting was examined, with or without AdCTLA-4Ig treatment. AdCTLA4Ig-treated recipients survive >100 days, and are characterized by ICOSpositive mononuclear cell infiltration and apparent vasculopathy. AdCTLA4IG treatment combined with anti-ICOS antibodies induced stable tolerance
without chronic rejection. Anti-ICOS therapy significantly reduced ICOSpositive inflammatory cell infiltration, and prevented accelerated cardiac
graft rejection following secondary skin grafting. Our results identify a
critical role for ICOS in chronic and accelerated cardiac allograft rejection,
and suggest a novel approach to prevent chronic rejection of vascularized
organ allografts.
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M. Tanemura1,3, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1,
T. Nishida1, Y. Sawa1,2, T. Ito1
1
Department of Surgery, Osaka University Graduate School of Medicine,
2
Medical Center for Translational Research, Osaka University Hospital,
3
Correspondence author: e-mail; tanemura@surg1.med.osaka-u.ac.jp
Objectives: Islet transplantation has recently become a clinical reality
from the results obtained by the adoption of the Edmonton protocol, which
is rapamycin-based glucocorticoide-free immunosuppressive regimen,
leading to insulin independence at 1 year in 90% of the treated patients with
Type1 diabetes. However, islets allograft recipients exhibit a gradual fall in
insulin independence with only 10% offinsulin at 5 years. This decline may
reflect drug toxicity of rapamycin on islet β-cell. The immunosuppressive
mechanism of rapamycin is based on selective blockade of the mammalian
target of rapamycin (mTOR) activation. Autophagy is an alternative cell death
pathway that is induced by mTOR inhibitors such as rapamycin and Rad
001. The relative contributions of autophagy in transplanted islets are poorly
understood. The aim of this study is to evaluate the effects of rapamycin in
islet such as autophagy induction, islet viability that may strongly affect the
engraftment of islets.
Materials and methods: Isolation of pancreatic islets: Male BL6 mice
were anesthetized. Subsequently, the bile duct was cannulated, and the
pancreas was inflated with 3ml of ET-Kyoto solution containing 1mg/
ml of collagenase. The inflated pancreas was removed and cleaned of its
lymphnodes, fat and bile duct. Tissue was digested with collagenase VIII
and purified on a discontinuous Ficoll gradient. Isolated islets were cultured
in complete RPMI-1640 culture medium. Western blot analysis: To detect
the accumulation of LC3-II (a LC3-phospholilated conjugate), which is a
good early maker of autophagy, Western blot analysis was performed. Fresh
mice islets (30islets/well) were incubated for 48 hr in culture medium in the
absence or presence of either 1 or 10 ng/ml of rapamycin. Subsequently,
the cells were lysed, protein samples were electrophoresed through a 15%
SDS/PAGE and then transferred to PVDF membrane. LC3-II in the lysate
was recognized by immunoblotting with anti-LC3 mAb (MBL). As the

loading control for the samples, protein expression of GAPDH in mice
islets was also detected. The relative protein expression of LC3-II in islets
was normalized by the LC3-II/GAPDH ratio. Islet viability assay: 30 cells
of fresh mice islets were cultured for 48hr with complete medium in the
absence or presence of either 1 or 10 ng/ml of rapamycin. Subsequently,
islet viability was determined using the colorimetric methyl tetrazolium
salt (MTS) Cell Titer 96 Aqueous One Solution cell proliferation assay
(Promega). The colorimetric reagent was added to each well, incubated for
2hr, and the absorbance values read at 490nm. Blocking assay of autophagic
signaling: To determine whether the rapamycin-treated islets had recovered
their viability, the rapamycin-treated islets were assessed by MTS assay in
the absence or presence of 10 mM 3-methladenine (3-MA), an inhibitor
of class III phosphatidylinositol 3-kinase, which has been shown to be an
inhibitor of autophagy.
Results: The results are summarized in the Table.
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558 IMMUNOREGULATORY EFFECTS OF A NEW S1P
AGONIST W-061 ON RAT SMALL BOWEL TRANSPLANTATION
J. Song1,3, T. Ito2,3, T. Nishida3, M. Nozawa3, J. Wei1
Department of General Surgery£¬Beijing Hospital, 2Department of
Complementary and Alternative Medicine, Osaka University Graduate School
of Medicine, 3Department of Surgery (E1),Osaka University Graduate School
of Medicine
Aims: To prevent immunologic respond of allograft, it is necessary to
administer systemic immunosuppressant to the recipient. A new S1P agonist
W-061 has the molecular structure which is completely different from FTY720.
The present study was performed to investigate the potency of W-061 in
treatment of allograft in SBTx.
Methods: Heterotopic total SBTx was performed from Wistar-Furth (WF) rat
to (WF x ACI) F1, or F1 to WF rats. Recipients was administered by a dose
3 mg/kg/day) for 14 days after SBTx. The recipient survival, histology and
subpopulation of lymphocytes in graft and target organs were evaluated.
Results: W-061 treatment significantly prolonged graft survival over 60
days in 3 out of 6 recipient of rejection group(53¡À17days, n=6) and over
100 days in 4 out of 6 recipients of GVHD group(86¡À29 days, n=6). W-061
strongly inhibited GVHD in histological study in comparison with untreated
control rats. W-061 significantly decreased the numbers of lymphocytes in PB
and target organs in GVHD group, as well as the infiltration T lymphocytes
subpopulations in the graft of rejection group. W-061 significantly decreased
the production of IFN-¦Ã in the target organs of different models in acute
GVHD or rejection phase.
Conclusions: A 14 days¡¯ treatment of W-061 inhibit the rejection as well as
GVHD, resulting in the prolongation of small bowel allograft survival.
1
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559 SIGNIFICANT DECREASE OF PLASMA ADAMTS13
ACTIVITY DURING ADVERSE EVENTS AFTER LIVER
TRANSPLANTATION
E. Okano1, S. Ko1, H. Kanehiro1, M. Matsumoto2, Y. Fujimura2, K. Tanaka3,
Y. Nakajima1
1
Department of Surgery, Nara Medical University, 2Blood Transfusion
Medicine, Nara Medical University, 3Institute of Biomedical Research and
Innovation
Background: ADAMTS13 was discovered as a key enzyme of thrombotic
microangiopathy (TMA) pathogenesis. ADAMTS13 specifically cleaves
multimeric von Willebrand factor (VWF) which is synthesized at the site
of vascular endothelial cell injury. Under physiological conditions VWF
is rapidly degraded by ADAMTS13. However, insufficient ADAMTS13
leads to formation of unusually large VWF multimers (UL-VWFM) which
have potent activity of platelet aggregation/microthrombosis, that results in
microcirculatory disturbance and organ dysfunction. Because the primary target
of major adverse events, including ischemia-reperfusion injury and rejection, is
vascular endothelial cell, ADAMTS13 and UL-VWFM may play a role in graft
dysfunction during these events even without TMA. The aim of this study was
to determine clinical implication of this enzyme in liver transplantation (LT).
Methods: Plasma ADAMTS13 and UL-VWFM were sequentially evaluated
before and after liver transplantation in six recipients without clinical signs
of TMA. ADAMTS13 activity was assayed by multimer and ELISA methods.
UL-VWFM was evaluated by vertical agarose gel electrophoresis.
Results: ADAMTS13 activity decreased markedly and rapidly in all recipients
from 75+-37% before LT to 22+-13 on day 1 after LT. The extent of decrease
depended on the severity of graft reperfusion injury. In a patient with steatotic
liver graft showed significant drop from 110% before LT to 9% on day 1. The
activity recovered gradually when the post LT courses were uneventful. There
were three episodes of acute rejection among six recipients. At the onset of
rejection, ADAMTS 13 activity decreased significantly to <3, 6, and 11%, and
increased after remission of rejection. Upregulation of UL-VWF was parallel
to decrease of ADAMTS13 activity.
Conclusions: Plasma ADAMTS13 activity decreases very frequently and
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markedly after LT. The kinetics of the enzyme was correlated with adverse events
including ischemia-reperfusion injury and rejection. These results suggest that
ADAMTS13 activity may be an useful indicator of graft dysfunction in liver
transplant recipients.
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560 POTENTIAL RISK OF PLATELET TRANSFUSION IN
VIEW OF SIGNIFICANT DECREASE OF ADAMTS13 ACTIVITY
AFTER LIVER TRASPLANTATION
S. Ko1, E. Okano1, H. Kanehiro1, M. Matsumoto2, Y. Fujimura2,
K. Tanaka3, Y. Nakajima1
1 Deaprtment of Surgery, Nara Medical University, 2 Transfusion Medicine,
Nara Medical University, 3 Institute of Biomedical Research and Innovation
Background: Various degrees of thrombocytopenia were commonly observed
after liver transplantation. Clinical studies demonstrated that thrombocytopenia
was associated with poor prognosis, while the mechanism is unclear.
ADAMTS13 was discovered as a key enzyme of thrombotic thrombocytopenic
purpura (TTP) pathogenesis. ADAMTS13 cleaves multimeric von Willebrand
factor (VWF) which is synthesized at the site of vascular endothelial cell
injury. Insufficient ADAMTS13 activity, as observed in TTP patients,
lead to formation of unusually large VWF multimer (UL-VWFM) which
is potent activator of platelet aggregation/microthrombosis, that results in
microcirculatory disturbance and serious organ dysfunction. In such situation
with decreased ADAMTS13 activity in TTP, platelet transfusion is thought to
be contraindication, because it further enhances platelet aggregation/thrombus
formation in organ microvessels and induces serious organ dysfunction.
Because liver transplant recipients often develop adverse events with vascular
endothelial injury including ischemia-reperfusion and acute rejection, excessive
production of UL-VWF and consumptive decrease of ADAMTS13 may occur
in the site of grafted liver. The aim of this study was to determine whether
thrombocytopenia and graft dysfunction with such local TTP like mechanism
is vital after liver transplantation (LT).
Methods: Plasma ADAMTS13 was sequentially assayed by multimer and
ELISA methods before and after LT in six recipients without clinical signs
of TTP. UL-VWFM was evaluated by vertical agarose gel electrophoresis.
Results: The mean value of ADAMTS13 activity before LT was 75+-37%,
and the values decreased significantly in all recipients after LT (the minimal
value after LT were 13+-11% during the first month after LT), while the
extent of decrease varied among recipients. There were five episodes of
severe thrombocytopenia with platelet count of 13,000 to 26,000/uL
in three recipients. During three of these episodes, marked decreases of
ADAMTS13 activity to 3, 8, and 15% were observed. Simultaneously,
upregulation of UL-VWFM was also associated. Because of the decreased
ADAMTS13 activity, we never transfused platelet during these events.
Thrombocytopenia in these recipients recovered after administration of
sufficient amount of fresh frozen plasma, which is currently an only source
of ADAMTS13 replacement.
Conclusions: Thrombocytopenia after LT was frequently associated with
significant decrease of ADMTS13 activity probably due to local TTP like
mechanism. Platelet transfusion may be dangerous and deteriorate liver graft
function when the ADAMTS13 activity is low. Our findings not only suggest a
novel mechanism of thrombocytopenia after LT, but also demonstrate critical
importance of ADAMTS13 monitoring in liver transplant recipients.
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561 DOES C4D COMPLEMENT SPLIT PRODUCT
EXPRESSION IN PERIOPERATIVE LIVER ALLOGRAFT
BIOPSIES REALLY PROVE THE ACTIVATION OF
RECIPIENT’S IMMUNOLOGICAL SYSTEM?
A. Mroz1, J. Pazik2, B. Lagiewska3, M. Pacholczyk3, M. Durlik2
1
Department of Gastroenterology And Hepatology, Medical Center For
Postgraduate Education, 2Department of Transplantation Medicine and
Nephrology, Transplantation Institute, Warsaw, 3Department of General and
Transplantation Surgery, Transplantation Institute, Warsaw
Background: The data concerning usefulness of C4d expression in differential
diagnosis of rejection in transplanted liver is conflicting. There is also debated
whether C4d deposits found in perioperative liver transplant biopsies have any
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impact on rejection in early post-transplant period. But here one can address
the question whether these deposits really express the activation of recipient
immunological response or are connected only with ischemic state as it was
proved in patients after partial hepatectomy procedures..
Aim: To compare C4d deposition in biopsies taken prior to and 30 minutes
after engraftment of liver transplant.
Patients and methods: The perioperative biopsies from 15 patients undergoing
liver transplantation were analyzed. The specimen were taken prior to and
30 minutes after engraftment and these biopsies were separately assessed
histologically as well as the expression of C4d in vessels were. This expression
was ascribed semiquantatively as 0 (no expression) to 3 (strong and diffuse
expression in portal and central veins endothelium).
Results: The C4d expression was found in 8 patients and in all but one case the
intensity of expression was exactly the same in pre and postreperfusal biopsies.
In one case C4d deposits appeared only in second specimen. 7 patients remained
C4d negative in both biopsies.
No correlation was shown between C4d expression and grade of ischemiareperfusion injury.
Conclusion: As we previously described C4d deposits are present in
perioperative biopsies. Nevertheless the expression seems to be exactly the
same in prior to transplantation and after the recipient’s circulation is instituted.
Taking it into account it is doubtful that C4d deposits really prove the activation
of recipient’s humoral immunological response and may simply reflect the
complement activation due to ischemic changes in transplanting organ. This
could be the reason of equivocal results investigating C4d expression in liver
transplant rejection.
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562 ALLOANTIBODY MEDIATED REJECTION (AMR) IN
LIVER GRAFTS: C4D STAINING AND DONOR SPECIFIC
AANTIBODIES (DSA) IN THREE PPOSITIVE CROSSMATCH
RECIPIENTS

563 MOUSE MAMMARY TUMOUR VIRUS - LIKE VIRUS
(MMTV-LV) IS PRESENT IN LIVERS OF A WIDE RANGE
OF HEPATIC CONDITIONS
W. Rawlinson1,2,3,5, H. Johal1,3, S. Riordan4, G. Scott1,3,5, R. Jones6,
1
Virology Research, POWH & UNSW Research Laboratories, Prince of Wales
Hospital, 2Virology Division, Department of Microbiology, SEALS, Prince
of Wales Hospital, 3School of Biotechnology and Biomolecular Sciences,
Faculty of Sciences, University of New South Wales, 4Gastroenterology
and Hepatology, Prince of Wales Hospital, 5School of Medical Sciences,
University of New South Wales, Sydney, AUS, 6Liver Transplant Unit, Austin
Hospital
Mouse mammary tumor virus (MMTV) is a hormonally regulated, oncogenic
virus, responsible for 95% of breast cancers in mice. Previous studies suggest
the human equivalent of MMTV, called MMTV-like virus (MMTV-LV)
may be important in the pathogenesis of primary biliary cirrhosis (PBC), an
autoimmune liver disease, and carcinogenesis. End-stage liver disease, as a
precursor to hepatocellular carcinoma is often indicated for liver transplantation.
We investigated the prevalence of MMTV-LV in liver tissue and explants from
Australian patients with various liver diseases resulting from different etiologies
(including PBC). The potential correlation between MMTV-LV presence
and cellular changes associated with liver disease and cancer progression,
namely p53 tumour suppressor protein accumulation and altered hormone
receptor expression (estrogen receptor-alpha and progesterone receptor), was
also examined. Polymerase chain reaction (PCR) on extracted DNA showed
MMTV-LV envelope (env) sequences were present in 25% (53/210) of liver
disease biopsies but not detected in normal liver tissues (0/20). Livers from
patients with PBC were positive for MMTV-LV at a prevalence of 12% (3/26)
whereas 22% (10/46) of explanted livers and 23% (42/138) of livers from
patients with other liver diseases were also positive for the virus, demonstrating
MMTV-LV is not limited to PBC and found in many non-cirrhotic and cirrhotic
liver diseases. A higher percentage of MMTV-LV positive tissues were positive
for p53 (84%) than MMTV-LV negative tissues (71%), with higher rates of
p53 detection in cirrhotic versus non-cirrhotic tissue, though the association
between MMTV-LV and p53 accumulation was not statistically significant
(p=0.08). None of the liver sections were progesterone receptor (PgR) positive
and no significant association between the virus and estrogen receptor-alpha
(ER-a) staining was noted.
This study shows that MMTV-LV is not limited to PBC, but found in many
non-cirrhotic and cirrhotic liver diseases, some with the potential to progress
to hepatocellular carcinoma (HCC). Further studies demonstrating the colocalization of the p53 protein with MMTV-LV in diseased liver tissues will
provide further insight into this association.

POSTER BOARD NUMBER P3 – 425
564 ARE POSTREPERFUSION SUBCAPSULAR WEDGE
BIOPSIES USEFUL IN PREDICTING GRAFT INITIAL POOR
FUNCTION AFTER LIVER TRANSPLANTATION?
A. Kocbiyik1, B. Demirhan1, S. Sevmis2, I. Budakoglu3, H. Karakayali2,
M. Haberal2
1
Baskent University Faculty of Medicine, Department of Pathology,
2
Baskent University Faculty of Medicine, Department of General Surgery,
3
Baskent University Faculty of Medicine, Department of Public Health
Preservation injury is a major contributing factor to primary allograft failure
or graft initial poor function after orthotopic liver transplantation (OLT). In
this study, we examine histopathological findings on routine postperfusion
biopsy (between graft reperfusion and the end of the surgery) specimens in
relation to the early graft function (within first week). From September 2001
to February 2008 a total of 217 OLTs were performed in our center. 129
liver biopsy specimens were excluded from analysis; because of poor quality
biopsy specimens, due to complication of surgery (biliary, hepatic artery
thrombosis,.) early mortality (< 1 month), small size graft, acute rejection.
Subcapsular postperfusion biopsies (from 88 patients) were reanalyzed and
histological lesions were graded. For analysis, grafts were grouped into 3
categories: good function (GF, 73 patients), initial poor function (IPF, 14
patients) and primary nonfunction (PNF, 1 patient). IPF was defined as an
alanine aminotransferase or aspartate aminotransferase level greater than
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T. Kozlowski, T. Rubinas, S. Zacks, R. Watson, J. Schmitz, K. Andreoni
University of North Carolina at Chapel Hill
As a follow up of our previous report defining histological and IF characteristics
of AMR, we present additional data supporting our description of novel C4d
staining of biliary sinusoids. Three liver recipients: alcoholic cirrhosis (P1),
HCV (P2), and PSC (P3) had positive crossmatch (pos XM) with greater
than 300 channel shifts (cs) for T and B cells. DSA levels and XM were
tested on POD2-3, and 7. P1 and P2 had neg XM on POD2. P3 had pos B
cell XM on POD3. All pts had pos XM on POD7 with C4d pos liver biopsy
(bx) within 40 days. P1 had a Class I B7 DSA that persisted despite IVIG,
Rituximab, and plasmapheresis (PP). Her graft showed severe cholestasis (all
pts had normal hepatic artery & portal vein flow with no mechanical biliary
obstruction). Multiple bx showed worsening AMR: cholangiolar proliferation,
centrilobular hepatocyte swelling, sinusoidal neutrophils, hepatocanalicular
cholestasis, and pos C4d staining along sinuosoidal endothelium. Pt refused
retransplantation and died on POD 114. P2 had Class I DSA strong T cell XM
on POD 13, and pos C4d stain with histological features of AMR on POD
33. Rituximab was given. P2 LFTs rapidly normalized post-op. She is doing
well 9 mos after transplant. P3 had strong T and B XM. He had several class
I DSAs that rapidly decreased, but a persistent Class II DSA despite IVIG,
Rituximab and OKT3. Multiple bx showed AMR with cellular component.
Transaminases were in 300-400. Bilirubin 13.6. Due to persistent AMR he
received 6 PP. Post PP XM and DSAs reveled decreased T cell flow. B cell
XM has decrease only to 332 cs. He has severe liver dysfunction with need
for retransplantation.
Most pts with pos XM become neg after tx with no clinical AMR. A pos XM on
day 2-3 may be a sign of rapid antibody response.
We postulate that sensitized liver transplant candidates should undergo XM
follow up at least for 7 days. Persistent Pos XM warrants bx for histology and
C4d. Treatment consist of IVIG, Retuximab and PP.
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1,500 IU/L during the first week. PNF was defined as death or re-OLT because
of hepatic insufficiency. There was only one patient for the last group. So the
other two groups were compared with each other for numerous morphologic
and clinical parameters. Istatistically there was no relationship between these
2 groups according to clinical data; bile-duct complication, donor (cadaver
or live-donor), graft volume, age and the type of stent. The histologic
parameters; neutrophilic infiltration of subcapsular region, hepatocellular
ballooning and macro-microvesicular fatty degeneration don’t seem to be
related to IPF. On the other hand neutrophilic infiltration of parenchyma,
hepatocellular necrosis were related to IPF (p<0.05). IPF rates are more in
cadavers (50%) than live-donors (8.5%). Preservation-reperfusion injury
(+2, +3 neutrophilic infiltration) was found 78.6% of the patients for IPF and
39.7% of the patients for GF. Subcapsular neutrophilic infiltration, which
is a sign of surgical hepatitis rather than preservation-reperfusion injury, is
not a morphologic changing that leads to advanced information about the
graft. Therefore, subcapsular wedge biopsies from liver allografts, which
were taken instead of tru-cut biopsies because of some complications for
instance bleeding, should be carefully examined for neutrophilic infiltration
of the parenchyma. Also presence of necrosis may be useful for defining
preservation-reperfusion injury.
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565 GRAFT PRECONDITIONING WITH LOW-DOSE
TACROLIMUS (FK506) AND NITRIC OXIDE INHIBITOR (AGH)
REDUCES ISCHEMIA/REPERFUSION INJURY AFTER LIVER
TRANSPLANTATION IN THE RAT
E. Matevossian1, N. Hüser2, D. Doll3, M. Werner4, A. Preissel5, M. Stangl6,
S. Thorban7
1
Department of Surgery, Transplantation, Klinikum rechts der Isar, Technical
University of Munich, 2Department of Surgery, Transplantation, Klinikum
rechts der Isar, Technical University of Munich, 3Department of Surgery,
Transplantation, Klinikum rechts der Isar, Technical University of Munich,
4
Department of Pathology, Klinikum rechts der Isar, Technical University
of Munich, 5Department of Preclinical Ressearch, Klinikum rechts der Isar,
Technical University of Munich, 6Department of Surgery, Transplantation,
Klinikum rechts der Isar, Technical University of Munich, 7Department of
Surgery, Transplantation, Klinikum rechts der Isar, Technical University of
Munich
Background/aim: Ischemia/reperfusion (I/R) injury in the early
postransplant period is closely associated with delayed recovery of graft
function, increased acute rejection, and late allograft dysfunction. Recent
evidence indicates that an increase in nitric oxide (NO) production after
liver transplantation is associated with I/R injury. Tacrolimus (FK506)
is a immunsuppressive drug that is a substrate of cytochrome P450
enzymes. The aim of this study was to demonstrate that low-dose FK506 in
combination with aminoguanidine (AGH) to reduction of nitric oxide level
has a hepatoprotective effect by reducing I/R injury-associated necrosis
after liver transplantation in the rat.
Materials and methods: Fortyone DA-(RT1av1) rats served as donors and
recipients for syngenic orthotopic arterialised liver transplantation (LTx) with
cold ischemia of 120 minutes and warm ischemia of 12 minutes (±1,2) in
microsurgical technique. They were divided into 4 groups: group I (controls
without pre-/tretment, n=6), group II (pre-/treatment with high-dose FK506,
n=11), group III (pre-/treatment with only AGH, n=13), and group IV (pre-/
treatment with lowe-dose FK506 in combination with AGH, n=11). On
postoperative days 1, 3, 5, 8 and 10 laboratory investigations and liver biopsies
for histopathological investigations had been performed.
Results: The level of transaminase (alanine amino transferase, ALT) in groups
I, II and III was significant highly on posttransplant day 3 as in group IV with
combinated pre-/treatment (p= 0.002, p= 0.001, p= 0.001). After low-dose
FK506 and AGH pre/-treatment in group IV, the I/R-induced liver necrosis rate
was reduced, and were significantly decreased.
Conclusion: We demonstrated that in the liver a combinated pre-/treatment
with lowe-dose FK506 and AGH to inhibition of inducible nitric oxide synthase
prevented I/R-induced injury of graft after liver transplantation in rat model.
The synergist administration of lowe-dose FK506 and AGH in transplant
patients should be performed with caution.
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566 AMANITINE INTOXICATION IN A PORCINE MODEL:
WHEN TRANSPLANT, WHEN WAIT FOR REGENERATION?
M. Schenk1, S. Rubitschek1, C. Thiel1, K. Knubben1, M.M. Morgalla2,
A. Etspüler3, A. Königsrainer1
1
University Hospital Tuebingen - General, Visceral and Transplant Surgery,
2
University Hospital Tuebingen - Neurosurgery, 3University Hospital
Tuebingen - Anaesthesiology
The toxin of Amanita phalloides causes liver failure by an irreversible inhibition
of RNA polymerase. This is often the case in not pre-injured livers with a high
regeneration potential. The clinical decision models for transplantation were
evaluated and new parameters were identified in a porcine model.
Intoxication was induced in 8 German Landrace pigs (32±2 kg) by an
intravenous application of 5mg or 10mg amanitine in deep anesthesia (fentanyl,
ketamine, midazolam). The animals were keep analogous to the human setting
of a maximum intensive care (respirator, invasive blood pressure monitoring,
hourly blood gas analysis, HES, NaCl, noradrenaline, electrolytes on demand).
The mean survival of the animals was 137 h (38,5-163,5 h). Liver synthesis
stopped and by the end of day 2, the PT of all animals was below 40%. Four
out of 8 animals spontaneously recovered as measured by an increase of the
PT above 80% on day 5. The serum activities of transaminases was at no time
predictive for liver regeneration. Values increased up to 2500 U/l for AST
in animals that spontaneously recovered. The increase of serum creatinine
above 106 μmol/l was observed in a transient way. In animals that recovered,
creatinine levels decrease whereas in animals with a fatal outcome kidney
failure became manifest.
In all animals with a regeneration of the liver, platelet count never dropped
below a limit of 300 *10^6 per ml. The difference clearly became predictive
(358 SD 54 versus 216 SD 56 10^6 per ml) on day 3, more than 24 hours before
the onset of regeneration seen by synthesis parameters.
The animal model confirmed most of the clinical observations. The platelet
count is an easy accessible parameter to help on the decision when to
transplant. On the background, that the role of platelets as stimulator for liver
regeneration is currently discussed, this observation may be directly related to
the mechanism.
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567 ROLE OF CASPASE-3 IN LIVER TRANSPLANT
COMPLICATIONS
T. Kyin1, A.N. Jeganathan2, R.N. Salomon1, H. Ashby-Richardson1,
H.M. Lee1, R.B. Freeman1
1
Tufts - New England Medical Center, 2Tufts Medical School
Background/introduction: Due to the growing demand for liver transplantation
coupled with limited donor organ availability, many transplant centers have
expanded their donor organ pool by procuring organs from extended criteria
donors, including donation from cardiac death (DCD). While these marginal
organs do confer some survival benefit, they are also associated with increased
rates of primary graft failure and complications such as biliary strictures. Biliary
epithelial cells (BEC) may be much more sensitive to ischemia/ reperfusion
injury (IRI) and more prone to apoptosis in the DCD scenario than hepatocytes
and other liver cell types. The purpose of our study was to analyze apoptotic
pathways in the setting of IRI, and to compare biliary tissue expression of
caspase-3, a central enzyme in the apoptotic pathway, in grafts from standard
donors with grafts from extended criteria donors.
Patients/methods: In a retrospective review of patients with available donor
gall bladder tissue, we identified 5 patients with post-transplant biliary
complications and compared them to 5 patients without post-transplant biliary
complications. These samples were matched for multiple variables including
age, gender, liver disease, and disease severity (MELD score). Donor gall
bladders in these 10 patients were removed 40-60 minutes after reperfusion
of the donor liver. Preserved gallbladder samples from these patients were
retrieved and stained with rabbit anti-cleaved caspase-3 antibody using
standard immunohistochemical techniques. Apoptosis was semi quantified by
counting the percentage of BECs that stained positive for caspase-3 under high
power magnification view.
Results: On average, 7.84% of BECs in samples obtained from patients without
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biliary complications stained positive for caspase-3. In contrast, 46.24% of
BECs in gallbladder samples obtained from patients who developed biliary
complications stained positive for caspase-3 (P<0.05). Caspase-3 activity was
not detected in the other cell types.
Conclusion: This data suggests that caspase-3 mediated apoptosis, which is
evident at a very early stage of reperfusion, is associated with development
of biliary complications weeks and months after transplantation. These
observations suggest that there are molecular pathways that incite/ trigger
biliary injury, resulting in clinical disease. These pathways could be potential
targets for intervention, thereby allowing better functioning and survival of
marginal liver grafts.
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568 IN VITRO ASSESSMENT OF ALLOREACTIVITY IN
LIVING RELATED LIVER TRANSPLANTATION

569 COMPARISON OF DE NOVO CYA-EVEROLIMUS
WITH CYA-AZA AND CYA-MMF IN PEDIATRIC HEART
TRANSPLANT PATIENTS
S. Schubert1, F. Berger1, N. Hiemann3, M. Huebler2, C. Knosalla2, R. Hetzer2,
H.B. Lehmkuhl3
1
Dept. of Congenital Heart Disease/Pediatric Cardiology, Deutsches
Herzzentrum Berlin, 2Dept. of Cardiothoracic and Vascular Surgery,
Deutsches Herzzentrum Berlin, 3Dept. of Cardiology, Deutsches Herzzentrum
Berlin
Introduction: Everolimus (Certican; Eve), acts as a m-Tor-inhibitor and may
improve acute rejection and cardiac allograft vasculopathy (CAV) in transplant
recipients. Only limited data are available about the clinical use in pediatric
patients. We studied the efficiency of Eve in pediatric heart transplant patients
in retroprospective study during 2004-2007.
Method: Patients were analyzed in regard to acute rejection (AR), CAV
after 1, 2, 5 years, renal function, survival and possible side-effects. Through
level monitoring was performed using mass spectrometry. Graft function was
analyzed with echocardiography, intramyocardial electrocardiogram (IMEG)
and heart catheterization.
Results: 13 pts. with CyA-Eve (A), 12 pts. with CyA-Aza (B), 16 pts. with
CyA-MMF (C) were included. Survival, Age, gender and weight were not
significant different in all three groups. Median posttransplant time was for 3.2
(A) vs. 8.1 (B) and 5,7 (C) years. Acute rejection during 1st year was significant
lower in pts. with CyA-Eve: 7% (A) vs. 23% (B) and 35% (C) (p=0.02). CAV
after 1 year were detected in 16% (B) patients and none of the other groups
(p=0.04). CAV after 2 years was detected in 7,7% (A), 41% (B) and 37% (C)
(p=0.004). After 5 years in 48% (B) and 56% (C) patients, where data was not
achieved CyA-Eve. CyA-blood level were comparable over the time: A: 101
(78-168) B: 125 (96-247) and C: 148 (91-293) ng/ml. Creatinine values: A:
0,67 (0,3–0.8), B: 0,92 (0.5–1,8) and C: 0,98 (0,53–1,54) mg/dl. Major side
effects of Eve were delayed wound healing and increased blood lipids and
triglycerides in two patients.
Conclusion: Everolimus was safe and well tolerated in pediatric patients.
It was significantly more effective in reducing the severity and incidence of
AR and CAV (up to 2 years) if compared with Aza or MMF. Wound healing
complications (15%) and high lipids were reasons to temporarily stop
medication in patients with de novo Everolimus. A 5-years follow-up is near
and may additional important information.
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570 POSTTRANSPLANT LYMPHOPROLIFERATIVE
DISEASE (PTLD) IN PEDIATRIC HEART TRANSPLANTATION.
INTERPLAY BETWEEN PRIMARY EPSTEIN-BARR VIRUS
INFECTION AND IMMUNOSUPPRESSION
S. Schubert1, H.B. Lehmkuhl2, P. Reinke3, M. Yigitbasi1, B. Schütz4,
R. Hetzer2, F. Berger1
1
Dept. of Congenital Heart Disease/Pediatric, Deutsches Herzzentrum Berlin,
2
Dept. of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum
Berlin, 3Clinic of Nephrology and Intensive Care Medicine, Charité
Universitätsmedizin Berlin, 4Clinic of Pediatric Oncology and Hematology,
Charité Universitätsmedizin Berlin
Introduction: PTLD is still a major complication in pediatric patients after
solid organ transplantation. Overall intensity of immunosuppression, EBV
mismatch or primary infection after transplantation may be a major risk factor
for the development of PTLD.
Method: The incidence, risk factors, and outcome of posttransplant
lymphoproliferative disease (PTLD) were examined for 150 children
undergoing pediatric heart transplantation.
Results: Incidence of PTLD was 8% (12 of 150). CyA-Azathioprine (Aza)
were associated with the development of PTLD in 8/12 as compared with
4 patients (CyA-MMF or CyA-Everolimus) (p=0.01). Three or more doses
of ATG were associated with an increased risk for PTLD (p=0.02). PTLD
was detected in lymph nodes (5), intestine (2), lung (1), tonsils (2) and eye
(2). Histology was a monomorphic B-cell lymphoma (7/12), a monomorphic
Burkitt lymphoma (4/12), polymorphic B-cell lymphoma, angiocentric
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U. Ekong, M. Yu, M. O’Gorman
Children’s Memorial Hospital, Northwestern University, Chicago, IL.
Background: With the success of solid organ transplantation has come the
realization that the post-transplant morbidity and mortality related to the use
of immunosuppressive medications. Induction of tolerance to the transplanted
organ would likely prevent these complications, however, the use of tolerance
induction protocols in solid organ transplantation will require assays that reflect
the immune alloreactivity of the recipient towards his/her donor.
Aim: To develop an in vitro method to detect immune alloreactivity of the
transplanted recipient towards his/her donor.
Methods: We developed a flow cytometry based mixed lymphocyte reaction
assay system, involving co-culture of peripheral blood mononuclear cells
(PBMC’s) from liver transplanted recipients (responder cells) with antigen
presenting cells, APC’s obtained from their living related donor (LRD
stimulator cells), APC’s from the other parent (OP stimulator cells) and APC’s
from 3rd party donors (TP stimulator cells). Surface activation marker (CD69,
CD25, and CD71) induction was measured in recipient CD4+ cells following 24
and 48 hour incubations with stimulator APC’s. The responses were compared
between recipient cells stimulated with: LRD-APC’s, OP-APC’s, and TPAPC’s. The recipient, donor, other parent and third party donors all had HLA
typing performed.
Results: Our preliminary observation indicate that stimulation of recipient T
cells with PBMC from the living related donor resulted in lower activation
marker induction in CD4+ recipient T-cells compared to the level of activation
marker induced following stimulation with PBMC from an unrelated 3rd party
donor; Fig 1 shows representative results of CD69.
Figure 1: median%CD4+CD69+ on y axis. 24 hour incubation. N=11.
To further investigate whether the decreased activation marker induction was
a result of both the recipient and donor being haploidentical or a true absence
of alloreactivity of the recipient towards his/her donor, we also looked at
activation marker induction following stimulation with OP APC’s. Our results
demonstrate decreased CD25 and CD71 induction following LRD stimulation
compared to OP and TP stimulation; Fig 2 shows representative results from
CD71.
Figure 2: median%CD4+71+ on y axis. 48 hour incubation.
Conclusion: PBMC obtained from liver-transplanted children exhibited lower
levels of activation in response to stimulation with APC’s obtained from their
living related donors compared to the responses obtained when stimulated with
APC’s from the second parent and unrelated 3rd party donors. This difference
is compelling and we are continuing to confirm these preliminary findings in a
larger number of transplant recipients.
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lymphoma (Liebow) and as reactive plasmacytic hyperplasia (early lesion),
respectively. PTLD was EBV positive in 10/12 patients and 50% had a
primary EBV infection after Tx. Risk factors in the comparison to patients
without PTLD were age at time of Tx, primary EBV infection after Tx, use
of Azathioprine and ¡Ý 3 doses of ATG. CMV mismatch and CMV infection,
rejection episodes and steroids were not risk factors. Despite reduction of
immunosuppression, treatment consisted of surgical procedures to remove
tumor masses (n=6), Rituximab (n=5), polychemotherapy (n=3), antiviral
(n=1) and autologous T-cell therapy (n=1). All patients demonstrated full
remission without death related to PTLD or treatment at 4.3 (1.6¨C6.8) years
median follow-up time.
Conclusion: Intense immunosuppression (ATG and Aza) was associated
with a significant increased risk of PTLD. Primary EBV infection after Tx
further accentuated this risk. Reduction of CyA blood level alone is not
reducing the risk of PTLD in combinative therapy with antimetabolites.
Identification of high-risk patients with screening protocols and frequent
EBV load measurments may lead to early PTLD-interventions, including
change and reduction of overall immunosuppression, pre-emptive antiviral
and antitumor therapies.
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571 PROGNOSTIC VALUE OF COMPUTERIZED
QUANTIFICATION OF LIVER FIBROSIS IN CHILDREN WITH
BILIARY ATRESIA BEFORE LIVER TRANSPLANTATION
L. Pape1, Ka. Olsson1, C. Petersen2, M. Melter3
Medical School of Hannover, Department of Pediatric Nephrology,
Hepatology und Metabolic Diseases, 2Medical School of Hannover,
Department of Pediatric Surgery, 3University of Regensburg, Department of
Pediatrics
Biliary atresia (BA) is the leading indication for liver transplantation during
childhood. Predictive clinical markers for the progression of liver cirrhosis
are lacking in accuracy. Therefore, we investigated the correlation between
histologically quantified fibrotic changes of the liver at the timepoint of Kasai
hepatic portoenterostomy and the clinical course of children with biliary
atresia.
Liver tissue was obtained at the time of the Kasai hepatic portoenterostomy
(HPE) in 53 children (median age 54 days, range 20 -122 days) with biliary
atresia. All liver biopsies were stained with PicroSirius Red. The images
were captured under polarization microscopy and the extent of fibrosis was
quantified by computerized analysis. The mean amount of fibrosis per number
of periportal fields (Vfib) and the Ishak score were individually calculated and
compared.
Mean Vfib was 3.9% (SD 3.8) and correlated positively with the risk of
early mortality in Pearson Correlation (R= 0.991, p< 0.001). However, this
did not correlate with the Ishak score (r=0.18, p= 0.21). Vfib was 6.5% (SD
4.1%) in children with early mortality as compared to 3.2% (SD 2.3%) in
those who survived during the observation time (p=0.01, ANOVA). A Vfib
> 3% predicted early mortality with a sensitivity of 61% and a specificity of
80%. Vfib was correlated with bilirubin 6 months after HPE (Bili6m) and a
significant elevation of Bili6m was found in those patients with Vfib ≥; 6. In
patients with a combination of Vfib > 3% and an increased serum bilirubin (>
20 μmol/l) after 6 months post HPE survival rate was significantly reduced
(58% vs 95%). This combination was highly predictive for mortality (odds
ratio 12.9, 95% Confidence Interval = 2.1 - 80.1, Pearsons chi-square-test
p= 0.002).
In conclusion, our data demonstrate that the computerized quantification of the
extent of periportal fibrosis at the time of HPE visualized by PicroSirius Red is a
valid marker in predicting the risk of death in children with BA. Therefore, this
method should be considered as an integral part of scoring systems predicting
the indication for liver transplantation in these patients and be subject of further
studies to evaluate, whether quantification of fibrosis in liver biopsies could
possibly be used as a follow up parameter after HPE.
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572 EBV SURVEILLANCE BY PLASMA RT-PCR AFTER
PAEDIATRIC LIVER TRANSPLANTATION
W. Hardikar1,3,4, Z-Z.D. Tham1, L. Crellin1, K. Lee2
1
Department of Gastroenterology, Royal Children’s Hospital,Melbourne,
2
Clinical Epidemiology and Biostatistics Unit,Royal Children’s
Hospital,Melbourne, 3University of Melbourne, 4Murdoch Children’sResearch
Institute
Background: EBV infection after liver transplantation (OLT) is the main
cause of post-OLT lymphoproliferative disease (PTLD), particularly in patients
who have not previously experienced EBV. At present, EBV monitoring and
pre-emptive modulation of immunosuppression is the mainstay of management
however the optimal method of monitoring has not yet been established. In
particular the significance of positive PCR in whole blood in patients who
are seropositive for EBV pre-OLT is uncertain. Recent studies suggest that
a positive plasma PCR is superior to whole blood assays as an indicator of
active EBV replication. We therefore sought to 1. Compare plasma PCR and
whole blood EBV PCR levels and 2. Determine the significance of active EBV
infection as defined by plasma PCR in our paediatric liver transplant recipients
using PTLD as an outcome measure.
Methods: The records of all children undergoing liver transplantation between
1995 and 2007 were reviewed for EBV status pre-OLT and EBV monitoring
post-OLT. Real time quantitative PCR (RT-PCR) of plasma and whole blood
samples using an in-house assay was performed in addition to EBV serology.
Primary infection was defined as the appearance of VCA-IgM or positive RTPCR plasma or blood in patients previously VCA-IgG negative. Sustained
infection was defined as + RT-PCR lasting longer than 6 months. PTLD was
diagnosed with standard criteria.
Results: Of 53 patients identified, 3 patients were excluded as they died within
1 month of transplantation. For the 50 remaining patients, 307 samples were
collected over a median of 45 months (range 5 months to 12 years). Of 114
paired whole blood and plasma samples, the specificity of plasma PCR was
98% (52/53) compared to whole blood while the sensitivity was 57% (35/61).
As expected plasma titres were always lower than whole blood titres. 25
patients were seronegative (group A) and 25 seropositive (group B) prior to
OLT. 13/25 of group A had a primary infection post transplant. 3/13 of group A
had a sustained infection and 1 of these developed PTLD and died. In contrast
only 1/25 of group B had a sustained infection and none developed PTLD.
Patients with sustained infection who did not develop PTLD had plasma viral
loads from 2x 103 to 2.5x106 copies/mL over a period of up to 35 months.
The patient with PTLD had viral loads from 3 x104 to 2.3 x109 only detected
4months prior to death.
Conclusions: Sensitivity of plasma PCR was inferior to whole blood PCR
however its significance in terms of EBV disease remains to be determined.
Sustained viremia is not predictive of PTLD.
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573 LIVING-RELATED DONOR LIVER TRANSPLANTATION
FOR CHILDREN WITH FULMINANT HEPATIC FAILURE IN
ISRAEL
R. Shapiro1, D. Shouval1, Y. Avitzur1, N. Bar- Nathan2, R. Steinberg1,
T. Shoenfeld1, Z. Ben-Ari2, R. Shamir1, E. Mor2
1
Schneider Children’s Medical Center of Israel, 2Rabin Medical center
Background: Conservative treatment fort fulminant hepatic failure (FHF) in
children is associated with high mortality rates, turning liver transplantation
into being the treatment of choice. Living-related donor liver transplantation
(LDLT) has been suggested as an alternative to cadaveric liver transplantation
in order to overcome the shortage of organ donors. However, experience with
LDLT in children with FHF is limited in the western world.
Objective: To present the experience with LDLT for children with FHF in a of
a major referral center in Israel.
Methods: The files of all children who underwent primary LDLT for FHF were
reviewed for demographic, clinical and laboratory parameters before and after
transplantation.
Results: During 1996-2007, thirteen children diagnosed with FHF
underwent primary LDLT at our center. The median age of the patients
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was 4 years (range 0.75-14 years), and the causes were acute hepatitis
A in 4 and unknown in 9. Short-term complications, documented in 12
children, included mainly hepatic artery thrombosis, which warranted retransplantation in 3 cases, and biliary leaks repaired either by surgery or by
invasive radiology. Three patients died during the first month after LDLT
of uncontrolled intraoperative bleeding (n=1), sepsis (n=1) and multiorgan
failure (n=1). Long term complications were less common, and included
ascending cholangitis and graft rejections. Patient survival rate was 69%
and 62% at 1 and 5 years, respectively. None of the donors had long term
complications.
Conclusions: Although the outcomes of LDLT in children with FHF seems
inferior to that in children after elective transplantations for chronic liver
diseases, the procedure is timely, life-saving and could reduce the dependence
on cadaveric donation in this setting.
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574 DEVELOPMENT OF ALLERGIC DISEASES FOLLOWING
ORTHOTOPIC LIVER TRANSPLANTATION IN CHILDREN

575 PREVALENCE OF CYTOMEGALO- AND ADENOVIRUSSPECIFIC T-CELLS IN CORRELATION TO VIRUSDNA AND -SEROLOGY BEFORE PEDIATRIC RENAL
TRANSPLANTATION
T. Ahlenstiel1, U. Sester2, M. Sester2, A. Heim3, L. Pape1
1
Medical School of Hannover, Department of Pediatric Nephrology,
2
University of the Saarland, Department of Nephrology, 3Medical School of
Hannover, Department of Virology
Introduction: Post-transplant immunosuppression leads to impaired
cellular immune defense resulting in increased risk for severe virus-induced
complications, e.g. by Cytomegalo- (CMV) and Adenovirus (ADV). Pretransplant virus-specific T cells might serve as prognostic marker for individual
risk to develop virus-induced diseases after transplantation.
Method: We investigated 31 children at the age of 1 to 16 years (median 13
years; 19 m, 12 f) listed for kidney transplantation. T cells were stimulated
with CMV and ADV antigen in vitro. Based on specific cellular activation and
induction of intracellular cytokines, the frequency of CMV- and ADV-specific
CD4-T cells was determined using flow cytometry. Viral load was quantified by
PCR. Serologic studies were performed for CMV.
Results: Pre-transplant prevalence of CMV-specific T cells (29%) correlated
with CMV-serology: Every CMV-seropositive child (9 out of 31) had detectable
CMV-specific T cells, whereas we have not found any CMV-specific T cells in
seronegative patients (22 out of 31). The frequency of CMV-specific T cells
showed interindividual variation and ranged between 0.1 and 7.3% of CD4positive T cells. The level of CMV-IgG-titers did not correlate with quantity
of virus-specific T cells. The single child with positive CMV-DNA-PCR also
showed CMV-specific T cells.
ADV-specific T cells was detected in 77% of our pediatric study group (24 out
of 31), among them three patients showed positive ADV-DNA-PCR. The level
of ADV-specific T cells ranged between 0.1 and 1.0% of CD4-positive T cells.
Conclusion: High prevalence of ADV-specific T cells suggested high
ADV-infection rate in early childhood, whereas the CMV-prevalence was
significantly lower in our pediatric study group. Children without sufficient
pre-transplant level of virus-specific T cells probably have an increased risk
for virus-induced complications after transplantation. Therefore virus-specific
T cells might serve as prognostic marker to estimate the individual risk for
post-transplant viral diseases. Pre-transplant level of virus-specific T cells is
probably helpful to optimize post-transplant monitoring, antiviral prophylaxis
and immunosuppression after transplantation. Further studies will have to
determine the minimal number of virus-specific T cells needed for effective
protection against viruses.
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576 ROLE OF HLA MATCHING IN ORGAN ALLOCATION:
BALANCE BETWEEN GRAFT SURVIVAL AND
SENSITIZATION IN PEDIATRIC KIDNEY TRANSPLANTS
L. Vu, L.A. Baxter-Lowe, J. Garcia, M. McEnhill, P. Stock
University of California, San Francisco
Background: Recent studies have questioned the necessity of HLA matching
in the kidney allocation system. Even though elimination of the HLA mismatch
criteria may shorten the deceased donor waiting time for children and create
equity among ethnic minorities, post-transplant sensitization for children who
will need re-transplantation is a rising concern.
Purpose: To determine the impact of HLA mismatching on rejection, graft
survival, and subsequent sensitization in pediatric kidney transplant recipients
in a regional allocation system that emphasizes donor quality rather than HLA
matching.
Methods: We studied patients less than 21 years of age who had kidney
transplant with dacluzimab induction immunosuppression between 1997
and 2006 at a single institution. Patient-related variables and outcomes
were ascertained by chart review. Survival analysis was used to determine
the risk factors for rejection and graft survival. Sensitization was defined as
development of Panel Reactive Antibody (PRA) > 0% in patients with pretransplant PRA of 0%.
Results: 172 patients were identified and median follow-up time was 3.9 years
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S. Kansal1,4, R. Heine1,3,4, K. Allen1,3,4, J. Pellegrini1,2, W. Hardikar1,2,3,4
Royal Childrens Hospital,Melbourne, 2Victorian Liver Transplant Unit,
3
Department of Paediatrics, University of Melbourne, 4Murdoch Children’s
Research Institute
Background: The prevalence of allergic diseases is increasing in Western
countries. In the Australian population 10% of 6-14 year old children
have eczema, 15% allergic rhinitis, 4-6% food allergies and 28% asthma.
Recent case reports have described the onset of difficult to manage
allergic conditions, such as peanut allergy and severe eczema, following
orthotopic liver transplant (OLT). It is unclear whether the development
of post transplant allergic conditions is due to the transfer of sensitized
donor T cells or alternatively loss of clonal control of oral tolerance in the
recipient.
Aim: To assess the development of de novo allergic disease and sensitization
in children after OLT.
Methods: Medical records of consecutive liver transplant recipients
(1995–2006) from a single center were reviewed for evidence of allergic
diseases before and after OLT. Criteria for diagnosis and grade of severity were
based on published guidelines. Data were also collected on donors, family
history of allergic disease in patients and immunosuppressant exposure.
Results: During the study period there were 51 liver transplants in children
in Victoria. Data were ascertained for 47 patients (23 males) with a mean age
of 4 years and 10 months at the time of liver transplant (range 7- 192 months)
for whom a minimum follow up of 1 year was available. In the pre-transplant
period, 2 (4.3%) had eczema, 3 (6.4%) had asthma, 1 (2.1%) had hay fever, 4
(8.5%) had food allergy and 3 (6.38%) had other allergies for example drugs
and tapes. Post OLT, there was a significant increase in the prevalence of
eczema 12 (25.5%) p < 0.007. The incidence of asthma 4 (8.1%), hay fever 2
(4.3%) and food allergy 5 (10.63%) was not significantly higher than for the
pre transplant period. However the incidence of all allergies was significantly
higher in the post transplant patients than in the general population. (p< 0.001
for eczema, p<0.007 for asthma and p< 0.04 for hay fever). Limited data on
allergic diseases was available in only 16 donors of whom 5/16 (31%) had a
history of mild asthma.
Conclusion: The significant increase in the incidence of eczema after transplant
together with the increased incidence of all allergies in post transplant
patients compared to non transplant patients suggest that factors relating to
transplantation may be important in the development of allergic diseases. The
mechanism of allergy sensitization or loss of tolerance is unknown and requires
further study.
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(interquantile range, 6 months to 9.6 years). Overall incidence of first episode
of acute graft rejection was 62%. The one- and five-year incidences of graft
survival were 91% and 79%. The Cox models identified common predictors
for graft failure and rejection: female gender, recipient’s age, and development
of post-transplant lymphoproliferative disorder (PTLD). However, patients
with one or two HLA-DR mismatches had 1.8 times greater hazard of rejection
than those with zero HLA-DR mismatch (p=0.02). The presence of either one
or two HLA-A mismatches and Hispanic race were independently protective
against both rejection and graft failure. (Table 1) The following variables did
not contribute significantly to model: cause of renal disease, blood type, time
on dialysis, donor type, donor’s race, and donor’s age. Overall incidence of
sensitization was 47% among 74 patients. HLA-mismatching did not play
a statistically significant role in post-transplant sensitization. Independent
predictors of sensitization included history of rejection (8.2, 0.002) and
recurrence of primary renal disease (32.2, 0.02).
Conclusion: HLA-DR mismatching is associated with increased risk of
rejection. Rejection is a strong predictor of both graft failure and post-transplant
sensitization. Including HLA-DR matching in the organ allocation system may
balance the concern for sensitization and graft survival in children receiving
kidney transplant. The ultimate decision to wait for HLA-DR match will be
dependent on the frequency of donors required to find an appropriate match.
Table 1. Independent predictors of graft failure and rejection
Graft Failure
Predictors

Rejection

Hazard ratio

p

Hazard ratio

p

1-2 HLA-A mismatch

0.3

0.04

0.5

0.02

1-2 HLA-B mismatch

3.8

0.3

2.2

0.09

1-2 HLA-DR mismatch

1.0

0.99

1.8

0.02

2.9

0.07

1.5

0.02

HLA antigen mismatch:

Gender: Female
Race: White (reference)
Black

1.4

0.7

1.4

0.2

Hispanic

0.1

0.02

0.6

0.02

Other

1.0

0.99

1.0

0.9

13 - 16 years

10.3

0.002

2.5

<0.0001

> 16 years

9.1

0.01

2.3

0.001

4.4

0.01

2.1

0.01

Age at transplant (years):

Results: Since 1999, the incidence of HAT among pediatric LT recipients has
increased 2-fold, and in parallel the number of LT performed for hepatoblastoma
has increased 3-fold (Figure). In addition to known HAT risk factors, such as
small donors and recipients, cytomegalovirus(+), ABO-incompatibility, and
split grafts, there is also an increased odds of developing HAT among recipients
transplanted for hepatoblastoma (OR 3.87, 95% CI 2, 7.5, p<0.001). Historically
HAT risk factors have been categorized as being associated with early or late
development of the complication. Interestingly, however, hepatoblastoma is
associated with a continuous and ongoing risk for the development of HAT
during the post-transplant period.
Conclusion: The incidence of HAT among pediatric LT recipients is
increasing, and parallels a rise in the number of pediatric patients transplanted
for hepatoblastoma. Hepatoblastoma is an important and previously unreported
risk factor for the development of HAT among pediatric LT recipients. Increased
vigilance in the care of these patients beyond the peri-transplant period is
warranted as HAT can develop at any time.

< 13 years (reference)

Rejection

11.7

0.006

PTLD

8.2

0.02

Donor gender: female

0.4

Renal disease recurrence

0.04

>0.2

> 0.2
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577 HEPATIC ARTERY THROMBOSIS AFTER PEDIATRIC
LIVER TRANSPLANTATION: IDENTIFICATION AND
CHARACTERIZATION OF A NOVEL RISK FACTOR
J. Locke, Z. Stewart, A. Singer, D. Warren, K. Schwarz, W. Maley,
R. Montgomery, A. Cameron
Johns Hopkin University
Background: Pediatric liver transplant (LT) recipients are at greater risk
than adults for the development of hepatic artery thrombosis (HAT). HAT is
associated with increased morbidity, graft loss, and patient mortality, and has
been attributed primarily to technical complications particularly in children in
whom small or split grafts are utilized. Despite technical improvements, there
has been a steady increase in the incidence of HAT among pediatric recipients.
The goal of this study was to identify and characterize additional occult factors
predictive of the development of HAT.
Methods: We analyzed outcomes of pediatric (<18-yrs) deceased donor
LT recipients reported to UNOS (1987-2006). Unadjusted and adjusted
logistic regression analyses were performed to identify factors predictive of
developing HAT.
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578 LONG-TERM OUTCOME OF RENAL TRANSPLANTATION IN CHILDREN BELOW 12 KG AT TRANSPLANTATION
U. Berg1, M. Herthelius1, J. Sandberg2, G. Tydén2
Division of Pediatrics, Dept. of Clinical Science, Intervention And
Technology, 2Division of Transplantation Surgery, Dept of Clinical Science,
Intervention and Technology, Karolinska University Hospital Huddinge
From 1982 to 2007, 195 transplantations (tx) were performed in children below
16 years of age at Karolinska University Hospital Huddinge. 44 (24 boys) of
those transplantations were done in children with a body weight <12 kg. Their
median age was 1.4 (range 0.4-3.7) years, body weight 9.4 (3.3-11.5) kg and
height 74 (53-85) cm, median height SDS –2.5. 65% received preoperative
dialysis half of them after bilateral nephrectomy and half because of too low
body weight to obtain an adult kidney graft. 79% received grafts from living
donors (LD). The underlying diseases were congenital in 39 (89%), obstructive
uropathies in 12 (10 urethral valves), dysplastic kidneys without obstruction
in 5, congenital nephrotic syndrome in 12, Drash syndrome in 6, others in 4
and 5 had acquired diseases, mostly postnatal cortical necrosis. The first 29
infants received cyclosporine-based and the last 15 tacrolimus-based triple
immunosuppression. No induction therapy was used.
Between 1982 and 1992, 4 children died, 2 because of generalized CMV
infection (before the prophylaxis era) and 2 after graft loss. After 1992 two
children died, one because of recurrent HUS and one because of nonEBVassociated lymphoma 12 years after tx. After 1992, graft survival was 93% after
10 years. Catch-up growth was seen during the first years after transplantation
from median height SDS of -2.5 at tx to –0.93 5 years after tx. Thereafter no
further increase in height was seen. 7 children had reached final height at last
investigation and the median height of the 5 boys was 171 cm and of the two
girls 168 cm. Mean GFR (clearance of inulin) was 75±28 ml/min per 1.73 m2
one year after tx, 53±22 5 years after and 45±14 10 and 15 years after tx.
We conclude that renal transplantation can be performed with excellent shortand long-term results in very small children.
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579 THE EFFICACY AND SAFETY OF VALGANCICLOVIR
VS. ORAL GANCICLOVIR IN THE PREVENTION OF
CMV INFECTION IN CHILDREN AFTER SOLID ORGAN
TRANSPLANTATION
Y. Avitzur1, E. Lapidus-Krol2, R. Shapiro1, M. Davidovitch3, E. Mor4, J. Amir2
Institute of Gastroenterology, Nutrition and Liver Diseases, 2Department of
Pediatrics “C” and 3Division of Nephrology, Schneider Children’s Medical
Center of Israel, and 4Department of Organ Transplantation, Rabin Medical
Center, Petah-Tikva, Israel
Infection with cytomegalovirus (CMV) can lead to severe consequences in
children after solid organ transplantation. Routine prophylactic treatment
with valganciclovir is common in adults but data to support its use in children
is scarce. The aim of this study was to compare the efficacy and safety of
valganciclovir vs. oral ganciclovir in a pediatric cohort.
Methods: Historical prospective analysis of all children who underwent
kidney (KTx) or liver transplantation (LTx) in our center between the years
2000-2007. Exclusion criteria included recipients with R-/D- serostatus, graft
loss or death within six month post transplantation, combined treatment with
acyclovir or lost to follow up. All children have received IV ganciclovir for
2 weeks and then oral ganciclovir (TID) before 2004 or valganciclovir (OD)
thereafter. Valganciclovir dose was determined by the following equation: 7 X
BSA X creatinine clearance. Treatment was given for 3 months in R+/D+/ –
recipients and for 6 months in R-/D+. Patients were followed for 1 year after
transplantation and efficacy and safety parameters were collected.
Results: 153 children underwent KTx or LTx between 2000-2007. 92 of them
fulfilled the inclusion criteria (25 LTx, 63 KTx, 4 combined LTx and KTx).
41 children have received oral ganciclovir and 51 valganciclovir. Both groups
were comparable in their demographic and transplant related history. In the
valganciclovir group 13.7% of the children have developed CMV infection/
disease vs. 19.5% in the ganciclovir group (95%CI, 0.2-2, P=0.57). Subanalysis according to graft type demonstrated a trend towards better efficacy of
valganciclovir compared to ganciclovir in LTx recipients (15% infection rate
vs.37% respectively, P-NS) but not in KTx recipients. Time-to-onset of CMV
disease or infection was comparable in both treatment groups; rates of acute
allograft rejection were slightly lower in the Valganciclovir group (3.9% vs.
9.8%). Risk factors for CMV infection included young age, serostatus of R-/D+
and liver graft. No significant side effects were noted in both groups.
Conclusions: As in adults, treatment with VAL is as efficacious and safe as
treatment with oral ganciclovir in children after KTx and LTx. There might be
some advantage for valganciclovir use in children after LTx but further studies
are needed to support this assumption.
1
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J. Foster1, S. Ratnapala1, G. Williams1, L. Mathieson1, A. Sharland2, B. Tuch1
1
Diabetes Transplant Unit, Prince of Wales Hospital and University of
New South Wales, 2Collaborative Transplantation Group, Bosch Institute,
University of Sydney
Xenotransplantation of porcine pancreatic tissue offers a conceivable approach
to overcome the shortage of human tissue available for transplantation. Fetal
porcine (FP) pancreatic tissue in the form of islet-like cell clusters (ICCs) offers
an advantage over neonatal and adult â-cells due to their resistance to adverse
effect of human inflammatory cytokines. The adoption of microencapsulation
technology adds further appeal to the clinical application of such therapy. Our
laboratory has previously demonstrated that FP ICCs will mature and function
when placed within barium alginate microcapsules (BAM) and injected intraperitoneally (IP) into diabetic SCID mice to normalise blood glucose levels
(BGL) for at least six months. Similarly, allotransplantation of barium alginate
encapsulated mouse insulin-producing cells into diabetic BALB/c mice
results in long-term normalisation of BGL. However, xenotransplantation of
microencapsulated FP ICCs into immunocompetent mice does not produce
such promising results.
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581 PROLONGED SURVIVAL OF MICROENCAPSULATED
NEONATAL PORCINE ISLET XENOGRAFTS IN IMMUNECOMPETENT MICE WITHOUT ANTI-REJECTION THERAPY
–IN VITRO CO-CULTURE WITH BONE MARROW AND
SERTOLI CELLS
H. Arefanian, D. Mok, K. Winton, R.V. Rajotte, G.S. Korbutt, G.R. Rayat
Alberta Diabetes Institute, Department of Surgery, University of Alberta
Background: Neonatal porcine islets (NPI) are an attractive alternative
source of insulin-producing cells for transplantation into patients with type
1 diabetes mellitus (T1DM). However, these islets could not immediately
reverse hyperglycemia in diabetic recipients due to their immature nature and
they are acutely rejected in diabetic recipients not receiving anti-rejection
therapy. Bone marrow and Sertoli cells could potentially enhance the survival
and function of NPI by providing growth factors and local immunoprotection
to NPI. Our objective therefore was to assess whether in vitro co-culture of
microencapsulated NPI with homologous bone marrow and Sertoli cells
could accelerate the maturation and prolong the survival of NPI in diabetic
recipients.
Method: NPI, bone marrow and Sertoli cells were isolated from 1-3 day old
Landrace-Yorkshire pigs. After 7 days of culture, NPI were placed in alginate
microcapsules and were cultured in HAM’s F10 media supplemented with
10% newborn pig serum alone, or in tissue culture plates with a monolayer of
bone marrow and/or Sertoli cells for 50 days with media changes every other
day. After 50 days of culture, 2000 microencapsulated NPI were transplanted
into the peritoneum of streptozotocin-induced diabetic (≥;25 mml/L) immunedeficient NOD.SCID and immune-competent BALB/c mice. Blood glucose
levels of recipient mice were monitored for 100 days post-transplantation
to assess graft function and grafts were considered functioning when blood
glucose levels decrease to 10 mmol/L.
Results: Transplantation of microencapsulated NPI into diabetic immunedeficient NOD.SCID or immune-competent BALB/c mice resulted in the
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580 XENOTRANSPLANTATION OF MICROENCAPSULATED
INSULIN-PRODUCING PIG CELLS

Aims: To investigate strategies to overcome the xenogeneic immune response
and following this, to characterise the nature of the xenogeneic immune
response in order to adopt more specific strategies to promote adequate function
of xenografts.
Methods: Incorporation of 0.3M mannitol into the microcapsule composition
(TAM) was attempted in order to decrease the capsule pore size. A porcine
endothelial cell line (13271) was placed within TAM capsules and transplanted
into C57/BL6 mice (2 x 106 cells/mouse) (n = 6); mice were killed at day 7
and cell viability and capsule overgrowth assessed. Co-encapsulation of FP
ICCs with human mesenchymal stem cells (MSC) was also investigated due to
the known immunoprotective properties of MSC. These were transplanted into
C57/BL6 mice (1 x 106 FP ICCs and 1 x 106 MSC/ mouse) and were killed at
day 7 and cell viability and capsule overgrowth assessed. FP ICCs encapsulated
within BAM were injected IP into C57/BL6 (n = 36) mice and mice killed
and capsules retrieved at days 1, 3, 7, 14, 21 and 30 post-transplantation (n
= 6). Analysis of the xenogeneic immune response in this model included
measuring FP ICC viability and insulin secretion and content, assessing
capsule overgrowth, measuring levels of porcine chemokines by real-time RTPCR and measuring levels of porcine C-peptide in the mouse sera. Levels of
murine peritoneal immune cells were measured by FACS analysis and murine
cytokines by multi-plex ELISA.
Results: The incorporation of mannitol into the alginate capsule did not
prevent the formation of cellular overgrowth surrounding the microcapsule.
Similarly, co-encapsulation of FP ICCs with MSC did not result in enhanced
graft function and prevention of capsule overgrowth. In all models, substantial
cellular overgrowth was present from as early as 7 days post transplantation.
It was further shown that insulin secretion and content and levels of porcine
C-peptide decreased from 1 day post-transplantation of FP ICCs encapsulated
within BAM. Increased levels of the porcine chemokines IL-8, MIP-1a,
HMGB1 and HSP90 co-incided with increased capsule overgrowth at day 14
post-transplantation.
Conclusion: Microencapsulation alone is not sufficient to overcome the
xenogeneic immune response. Further strategies must be developed and required
to be used in conjunction with microencapsulation such as manipulation of
capsule composition and/or transient immunosuppression.
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immediate reversal of hyperglycemia within 2 days post-transplantation.
However, NOD.SCID mouse recipients of microencapsulated NPI cultured
in HAM’s F10 media alone or with a monolayer of Sertoli cells showed
a gradual increase in blood glucose levels (from 11.0±0.2 to 16.1±0.2
mmol/L and 11.7±0.1 to 14.2± mmol/L, respectively) beginning at 72 and
86 days post-transplantation, respectively. NOD.SCID mouse recipients
of microencapsulated NPI co-cultured with a monolayer of bone marrow
alone or with Sertoli cells remained normoglycemic at 100 days posttransplantation. Similarly, all immune-competent BALB/c mouse recipients
of microencapsulated NPI co-cultured with a monolayer of Sertoli cells
alone or with bone marrow displayed long-term graft survival (40 days and
68 days post-transplantation, respectively) without administration of antirejection therapy. In contrast, BALB/c recipients of microencapsulated NPI
cultured in HAM’s F10 alone or with a monolayer of bone marrow had graft
survival of 25 and 28 days post-transplantation indicating rejection of the
NPI grafts.
Conclusion: Collectively, our results indicate that in vitro co-culture of
microencapsulated NPI with bone marrow and Sertoli cells is beneficial to the
maintenance of long-term function of NPI in vivo. Further research is required
to explore the potential of this strategy in preserving the function of NPI
xenografts in immune-competent recipients.
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582 TRANSPARENT IMMUNOISOLATIVE
MICROCONTAINERS FOR XENOTRANSPLANTATION
B. Gimi1,2, J. Kwon2, L. Liu1, B. Vachha1, J-B. Lee2
1
The University of Texas Southwestern Medical Center At Dallas,
2
University of Texas at Dallas
Xenografts can overcome the shortage of human sources of grafting, and
have been shown to replace or alter endogenous function in a wide range of
disease models. To date, polymer and micromachined capsules have been
used for the immunoisolation of xenografts. However, the clinical utility of
such encapsulation has been limited due to the inexact control over polymer
porosity and the difficulties in micromachining capsules that are sufficiently
small so as to support nutrition and oxygenation of encapsulated cells
as well as the inability of the micromachined capsules to access various
implant sites. To address these challenges, we have created a nanoliterscale cell-encapsulating microcontainer whose surface comprises nanoslots
for immunoisolation. The microcontainers are optically transparent so as
to facilitate image guided delivery and the evaluation of post transplant
xenograft function.
The microcontainer was fabricated from transparent SU-8 photoresist using
photolithography, comprising a hollow 200 x 200 x 200 micron cubic base,
and a lid. Thin SU-8 islands were recessed within the lid and milled with 25
nm nanoslots using focused ion beam milling so as to exclude large immune
complement compounds. MCF7-Luc-GFP human breast cancer cells were
loaded in the microcontainer base in the fluid phase using a syringe and a 30
Ga needle, and the microcontainer was closed with the nanoporous lid. Two
microcontainers were implanted subcutaneously and proximally in nude mice,
followed by fluorescence imaging immediately thereafter.
Cells within the microcontainer were viable for 1 d as evidenced by
fluorescence imaging of the GFP cells, providing preliminary evidence of
the feasibility of our approach for encapsulated cell therapy. Additionally it
was possible to detect fluorescence signal from the implantation site of the
microcontainers. Microcontainer transparency facilitated the evaluation of
cell viability and function and may be useful for image-guided implantation.
The small size of our microcontainers combined with the ability to generate
numerous nanoslots on its surfaces ensures sufficient oxygenation and
nutrition for the encapsulated cells while providing graft immunoisolation.
The 8 nl microcontainers can be easily deployed through the vasculature to
various locations within the body. The parallel lithography process resulted
in several microcontainers from a single process run; no mechanical breach
of the microcontainers was observed through the entire experimental
process.
Ongoing studies are expected to ascertain the optimal porosity that supports
immunoisolation and encapsulated-cell survival and function.
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583 MEASURING OXYGEN CONSUMPTION AS A
PREDICTOR OF ISLET CELL POTENCY PRIOR TO
TRANSPLANTATION
A. Pepper1
1
Multi Organ Transplantation Program, LHSC, 2University of Western
Ontario, 3Robarts Research Institute
Diabetes Mellitus is steadily becoming an epidemic not only in North America
but worldwide. Currently, only treatments are available for this continuously
growing disease, which still results in patients suffering from both microvascular
and macrovascular complications. However, the field of islet transplantation
seems to offer hope of curing type 1 diabetes. One of the major barriers to
successful islet transplantation is the pre-transplant viability assessment of the
isolated cells. Currently, there is no consensus on how to determine which islet
preparations are able to effectively reverse diabetes based on pre-transplant
metabolic function measurements. Presently, FDA protocol requires athymic
nude mouse bioassays for clinical islet transplants; however this assay is
costly, technically demanding and retrospective. Thus, we wish to explore the
hypothesis that O2 consumption rates (OCR) will serve as a pre-transplant
assessment of the metabolic potency of the islet isolation. By measuring
the Fractional Viability or FV (O2 consumption rates standardized to DNA
quantity) we have been able to develop a means to determine which preparations
of adult pig islets should be transplanted based on this value. Our preliminary
data shows that adult pig islets that have a FV over 300 nmol/min-mgDNA are
able to restore euglycemia in diabetic nude mice. Similarly, human islets with
a FV of greater that 1000 nmol/min-mgDNA are effective in reversing diabetes
in nude mice as well. By measuring the FV of our islet preparations in culture,
we have been able to conclude that the islets’ mitochondrial capacity and thus
viability significantly increases during a twenty-two day culture period. To
validate this finding we transplanted nude mice with adult pig islets cultured for
2 (n=4), 8(n=4), 15(n=4) and 22(n=3) days respectively. Our findings suggest
that pre-transplant culture selects highly viable porcine islets, resulting in an
increase reversal rate and more immediate normoglycemia response. We are
confident based on our future data regarding human and porcine islets, that we
can develop OCR thresholds which will allow the determination of which islet
preparation is most desirable for transplantation. Furthermore, it is anticipated
that the data we collect will lead to the development of a pre-transplant islet
potency protocol which will definitively assess which islet preparations will
reverse diabetes and will restore glycemic control in Type 1 diabetic patients.
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584 ADULT PORCINE SERTOLI CELLS SUPPRESS THE
XENOGRAFT RESPONSES TO PORCINE ISLETS IN RATS
MORE EFFECTIVELY THAN NEONATAL SERTOLI CELLS
D. White1,2, L. Copeman1, J. Melling1,2, C. Hasilo2
University of Western Ontario, 2London Health Sciences Centre
Purpose: This study was designed to evaluate the humoral immune responses
to xenotransplants of neonatal porcine islets, Sertoli cells or a mixture of these
two cell types in the rat. A comparison of the immune responses generated
when adult Sertoli cells were used in place of neonatal Sertoli was also done.
Methods: Female Lewis rats were transplanted with 400,000 neonatal or adult
porcine Sertoli cells, 2000 neonatal porcine islet equivalents or a mixture of
these two cell types. Transplants were done either under the kidney capsule
or into neovascularized subcutaneous autologous collagen pouches that had
been previously created by implanting polypropylene mesh chambers with
central Teflon rods 4 weeks pretransplant. No immunosuppression was given
at any time to the recipient animals. Weekly serum samples were collected for
5 weeks and rat anti-pig IgG responses were measured using flow cytometry.
All test sample fluorescence measurements were compared to a control serum
and data analysed as a ratio of maximum fluorescence of the test sample to
maximum fluorescence of the control.
Results: There was no significant difference in the rat anti-pig IgG response
when islets were transplanted into collagen pouches compared to under the
kidney capsule (peak immune response ratio (pirr) kidney 4.758±1.523 vs pirr
pouch 4.089±0.654). There was a significant decrease in this immune response
when neonatal Sertoli cells were transplanted into these two locations (pirr
kidney 5.375±0.874 vs pir pouch 1.151±0.783, p<0.01). Cotransplanting
1
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neonatal Sertoli cells with islets into collagen pouches did decrease the
generated immune response compared to transplanting islets alone however
this decrease failed to achieve statistical significance (pirr neonatal Sertoli
cells+islets 2.158±1.137). Rats transplanted with adult Sertoli cells alone
into collagen pouches failed to generate a measurable immune response
compared to their pretransplant levels (pretransplant ratio 0.049±0.011 vs pirr
0.0536±0.009). When adult porcine Sertoli cells were cotransplanted with
islets they were able to significantly decrease the generated immune response
compared with cotransplantation with neonatal Sertoli cells (pirr adult Sertoli
cells + islets 0.244± 0.139, p<0.0001). Grafts survive and produce insulin for
at least 126 days post transplant.
Conclusion: In the rat, transplanting porcine Sertoli cells into subcutaneous
autologous collagen pouches results in a decrease in the amount of anti-pig
IgG compared to transplanting under the kidney capsule. Adult porcine Sertoli
cells elicit no immune response when they are transplanted into collagen
pouches. Further, the immune response to porcine islets transplanted into
collagen pouches is significantly decreased when adult porcine Sertoli cells are
cotransplanted. Studies of cotransplanting adult porcine Sertoli cells and islets
in diabetic rats are in progress
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585 THE WESTRAN PIG: AN IDEAL AND SAFE DONOR
SOURCE FOR XENOTRANSPLANTATION
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586 ANALYSIS OF TRANSMEMBRANE FORM OF
COMPLEMENT REGULATORY PROTEINS SHOULD BE
EXPRESSED IN TRANSGENIC PIGS TO AVOID PERV
INFECTION
S. Miyagawa1, E. Okura1, M. Okumura1, M. Okabe2, A. Ishimaru1,
S. Nakatsu1, C. Kobayashi1, M. Fukuzawa1,
1
Osaka University Graduate School of Medicine, 2Research Institute for
Microbial Diseases, Osaka University
Transgenic pigs genetically engineered to overcome hyperacute rejection
following xenotransplantation via expression of human complement
regulatory proteins (CRP), such as DAF (CD55), have been produced by
many Institutes. However, it is possible that the pig endogenous retrovirus
(PERV) from transgenic pigs with CRP might become resistant to human
serum, as the graft acquires resistance due to viral particles produced from
the transgenic pig cell wall that express human CRP. In this study, we
investigated the effect of CRP on PERV neutralization and/or lysis by human
sera and formulated a new approach to avoid PERV that involves expression
of human CRP on PERV.
Methods: cDNAs corresponding to human DAFs were prepared as follows:
delta-short consensus repeat (SCR) 1 DAF (phosphatidylinositol (PI)-anchor),
and delta-SCR2 DAF (PI-anchor). The following transmembrane (TM) domains
were also constructed: HLA-G, modified influenza A virus hemaggulutinin
(HA), and MCP (delta-CYT form).
The PEC line was transduced by pseudotype infection with the LacZ gene and
the packaging signal of the murine leukemia virus (MuLV) under control of the
long terminal repeat of MuLV. The PEC lines were further infected with PERV
subtype B (PERV-B) to investigate PERV infectivity using a Lac Z pseudotype assay.
The cDNAs of modified DAFs were then transfected into the PEC/PERVB(Lac Z) lines using lipofection. Expression of each DAF on the cell
surface was verified by FACS analysis. Complement-dependent PEC lysis
was used to verify the complement regulatory function of the expressed
DAF. HEK293 cells were incubated with PEC culture supernatants with
or without human sera. The inoculated HEK293cells were stained for
histochemical analysis and the LacZ-positive blue foci were counted. The
rate of reduction in LacZ-positive cells following serum addition was then
calculated.
Results: I. While PERV from delta-SCR 2 DAF (without CRP function)
was not resistant to human serum, PERV from delta-SCR1 DAF (with CRP
function) showed a significant increase in resistance.
II. The DAF-blocking antibody assay indicated that PERV from the DAF
transfectants expressed DAF molecules on the surface of the retrovirus.
III. Inhibition of complement-dependent cell lysis was determined for each
PEC/PERV-B(Lac Z) line with TM-type DAF.
IV. While delta-SCR1 DAF (PI-anchor form) significantly inhibited the
reduction in Lac Z-positive cells following treatment with human serum, the
reduction in Lac Z-positive cells after exposure to human serum was inhibited
to a lesser degree by transmembrane (TM)-types of DAF: DAF-TM of HLA-G,
DAF-TM of modified HA, and DAF-TM of MCP [delta-SCR1 DAF >> HLA-G
> HA ¦ † CYT].
Conclusion: Induction of PERV resistance to human serum depends on the
form of the CRP tail. CRP/TM hybrids that do not associate with lipid rafts are
suitable for gene transduction
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1
The Centre for Transplant & Renal Research, Westmead Millennium
Institute, Westmead, 2Centre for Advanced Technologies in Animal Genetics
and Reproduction, University of Sydney, 3Living Cell Technologies, Virology
Laboratory, Hunters Corner, New Zealand
Aims: Inbred lines of minipig are possible donor sources for xenogenic
tissues and cells. However, the threat of Porcine Endogenous Retrovirus
(PERV) has raised concerns regarding the safety of xenotransplant therapies.
The Westran pig is a highly-inbred line with well charcterised features,
included a PERV burden, level of inbreeding and SLA homozygosity. To
further these findings, a thorough study of the xenozoonotic potential of the
Westran pig was conducted for evidence of both in vitro and in vivo PERV
transmission, the presence of potentially zoonotic viruses and assessment of
PERV-C in the line. PERV-C has been implicated in the generation of humantropic replication-competent PERV and as such should be absent in a line of
pigs used for human donor organs.
Methods: Stimulated and lethally irradiated Westran neonatal islet cell clusters
(NICCs) and peripheral blood mononuclear cells (PBMCs), and plasma were
co-cultured for a period of 24 weeks with the susceptible HEK293 cell line.
Retroviral release was assessed by C-type-RT activity and DNA and RNA
assessed weekly for evidence of productive infection in the presence or
absence of microchimerism. In vivo transmission of PERV from Westran
ICCs was assessed through the transplantation of 13 SCID mice for periods of
30-120 days. Infection in the absence of microchimerism was then assessed in
DNA and RNA of the transplanted mice. Expression of PERV in Westran and
commercial pig ICCs was detected by quantitative RT-PCR. PERV-C analysis
was conducted in parallel with PERV-A and B in Westran pig herd, representing
11 generations from the founding pair. Five suggested xenozoonotic exogenous
viruses; Pig cytomegalovirus (PCMV), Pig lymphotropic herpesvirus (PLHV),
Encephalomyocarditis (EMCV), Pig circovirus (PCV type2) and Hepatitis E
virus (HEV) were evaluated.
Results: The stimulation of the Westran NICCs and PBMCs resulted in no
increase in RT activity and no productive infection was detected at any point
in the co-cultures of NICCs, PBMCs or plasma. No in vivo transmission, in
the absence of microchimerism, was detected in any SCID transplanted with
Westran NICCs irrespective of graft duration. The level of PERV expression in
Westran NICCs was consistently lower than in NICCs from a commercial herd.
PERV-C was identified to be segregating in the early generations of the Westran
line, however the pair selected for establishment of a core line at generation
six were PERV-C “null”. As a result, all subsequent animals have been free
of the PERV-C envelope insert. Only PCV type2 was detected in the Westran.
Subsequent analysis has shown the incidence of the virus to be decreasing in
the herd.
Conclusions: Fortuitous decisions regarding selection of breeder has resulted

in the Westran pigs being free of PERV C. Hence, the Westran pig provides a
xenozoonotic herd that can be considered safe as a donor source of cells and
tissues for clinical xenotransplantation and suggests that it is possible to reduce
the risk of PERV infection through breeding..
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587 KNOCK DOWN OF TREG FUNCTION GENE
EXPRESSION BY SIRNA RESULTS IN REDUCED
SUPPRESSIVE POTENCY OF HUMAN TREG ON PORCINE
XENOGENEIC EFFECTOR T CELLS IN VITRO
L. Sun, S. Yi, J. Wu, P. O’Connell
CTRR Westmead Hospital
Background: Expanded human CD4+CD25+ T regulatory cells (Treg) are
capable of suppressing T cell-mediated porcine xenogeneic immune response
in vitro and this suppression was associated with upregulated expression of
Foxp3 and IL-10 in Treg. In this study RNAi technology was used to identify
the importance of the Treg function genes, Foxp3 and IL-10, in the human Treg
suppressive effect on the human to porcine xenogeneic effector T cell response
in vitro.
Methods: Expanded human Treg were transfected with small interfering RNA
(siRNA) targeting Foxp3 and IL-10 genes, respectively by lipofectamine 2000.
The transfection efficiency, and the level of corresponding gene and protein
expression were measured by fluorescent microscopy, FACS, real-time PCR
and Western-blotting. The siRNA transfected Treg were then cocultured with
porcine PBMC-stimulated human CD4+CD25- T cells for 4 days. After coculture, proliferation and xeno-cytotoxicity of porcine xenogeneic human
CD4+CD25- T cells were examined by WST-1 and Annexin V binding assay,
respectively.
Results: A 60% transfection efficiency in expanded Treg was achieved for the
both the Foxp3 and IL-10 siRNAs. Real-time PCR revealed a 63.4% reduction
in specific mRNA by siRNA targeting of Foxp3 genes in Treg compared to
control transfections. When Foxp3 siRNA transfected Treg were added to
human CD4+CD25- T cells there was a corresponding 55% reduction in the
suppression potency in response to porcine xenogeneic stimulation, when
compared to control transfected cells. Following transfection with IL-10siRNA, the mRNA was reduced by 61% and the suppression potency of the
Treg was reduced by 43.7% when compared to the negative control. Thus
the suppression potency of Treg was reduced after transfection with siRNA
for Foxp3 or IL-10 when compared with Treg cells transfected with control
siRNA.
Conclusion: Our results demonstrate that Foxp3 and IL-10 are important in the
Treg-mediated suppression on porcine xenogeneic effector T cells in vitro.
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588 INTRA- AND EXTRACELLULAR REMODELING
EFFECTIVELY PREVENT HUMAN CD8+ CTL-MEDIATED
XENOCYTOTOXICITY BY COEXPRESSION OF MEMBRANEBOUND HUMAN FASL AND PIG C-FLIPL
IN PIG ENDOTHELIAL CELLS
M. Tanemura1,3, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1,
T. Nishida1, Y. Sawa1,2, T, Ito1
1
Department of Surgery, Osaka University Graduate School of Medicine,
2
Medical Center for Translational Research, Osaka University Hospital,
Objectives: Overcoming cell-mediated immunity, especially of human CD8+
CTLs, is important for the success of long-term xenograft survival. Our
previous studies have reported that the cytotoxicity of human CD8+ CTLs
against pig endothelial cells (PEC) is highly detrimental and mediated in
major part by the Fas/FasL apoptotic pathway. To inhibit this strong CTL
killing, we have exploited the weapon by extracellular overxepression of a
membrane-bound human FasL that carries a deletion at the metalloproteinase
clearvage site. In addition, wa have demonstrated that intercellular
overexpression of pig c-FLIPlong (c-FLIPL), which are potent inhibitor of death
receptor-mediated pro-apoptotic signals, by virtue of blocking the signaling
pathway more upstream (before caspase-8 activation and release) can protect
PEC from human CTL-mediated killing. In the present study, we investigated
the cooperating effects of double remodeling of these molecules to prevent
CD8+ CTL-mediated xenocytotoxicity.
Materials and methods: Gene construction: cDNA encording the membranebound human FasL, which cannot be cleaved with metalloproteinase, was
subcloned into the site of pEF-BOS expression vector, which carried the
promoter of the human elongation factor 1α chromosomal gene. cDNA of

206

Oral Abstracts
pig c-FLIPL was subcloned into the EcoRI site of pCR3.1 expression vector,
which carried a CMV promoter. Gene expression: 20 μg of each plasmid were
cotransfected into PEC line by lipofection. The expression of membrane-bound
human FasL on PEC surface was assessed by FACS analysis. The protein
expression of pig c-FLIPL was detected by Western blot analysis. Protein
expression levels of pig c-FLIPL in PEC transfectants were quantified by Fluorchem image analyzer as expressed by arbitary units. Preparation of human
CD8+ CTLs: 10 to 15 X 106 cells of separated PBMCs were cocultured for 14
days with irradiated PEC in the presence of 50 U/ml recombinant human IL-2.
Subsequently, CD8+ CTLs were positively isolated by magnetic beads and
subjected to in vitro cytotoxicity assay as effector cells. In vitro cytotoxicity
assay: The cytotoxicity of human CTLs was assessed by 51Cr release assay,
employing parental PEC and PEC transfectants as target cells.
Results: Two single positive clones were isolated as follows: one had high
expression of FasL and other one is high expression clone of c-FLIPL. Three
double positive clones were established. The amelioration of CTL killing
against these PEC transfectants was subsequently assessed by comparison
with parental PEC, single positive and double positive PEC transfectants. The
results are summarized in the table.

Cells

Parental PEC
PEC-FasL
(single, high)
PEC-FLIPL
(single, high)
Double1 :Fas L (high)
+ FLIPL (low)
Double2 :FasL (low)
+ FLIPL (middle)
Double3 :FasL (middle)
+FLIPL (middle)

Protein expression in
PEC transfectants
membrane-bound
FasL
c-FLIPL
(Mean
(Arbitaly units)
fluorescence

% cytotoxicity by 51Cr
release assay (mean ± SD)
E/T
ratio=50:1

E/T
E/T
ratio=25:1 ratio=12.5:1

intensity)
not detected

6312(endogenous)

87.5±7.5

67.7±7.2

50.4±5.8

127

5669(endogenous)

31.8±4.2

21.6±3.2

12.5±5.3

not detected

29166

23.6±1.2

22.6±1.7

17.1±5.7

80.6

11649

55.2±7.5

33.2±3.5

18.4±5.5

33.1

19429

63.5±8.1

42.1±6.4

28.4±5.4

62.0

16595

42.2±1.6

26.7±3.0

13.7±6.4

Conclusions: The double remodeling with the overexpression of both
membrane-bound human FasL and c-FLIPL in xenograft cells effectively avoid
innate cellular responses against xenografts.
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589 IN VIVO CONTROLLING OF CELLULAR RESPONSE
TO PIG ISLET XENOGRAFTS BY ADENOVIRUS-MEDIATED
EXPRESSION OF EITHER MEMBRANE-BOUND HUMAN FASL
OR HUMAN DECOY FAS
K. Kawamoto1, M. Tanemura1, A. Saga1, H. Komoda1,2, Y. Fumimoto1,
T. Deguchi1, T. Machida1, Y. Sawa1,2, T. Nishida1, T. Ito1
1
Department of Surgery, Osaka University Graduate School of Medicine,
2
Medical Center for Translational Research, Osaka University Hospital
Objectives: Xenotransplantation of pig islets is a potential solution to the
shortage of human donor islets for the patients with type 1 diabetes. However,
pig islets may be rejected by cellular immune response, including CD4+ T cells,
CD8+ CTLs, macrophages, and NK cells. Our previous studies demonstrated
that human CD8+ CTLs are highly detrimental to pig islets and that adenovirusmediated transduction with both membrane-bound human FasL (mFasL),
which carries a deletion at the metalloprotease cleavage site, and human decoy
Fas antigen (decoy Fas), which lacks a death domain in its cytoplasmic region,
in pig islets effectively prevented human CD8+ CTL killing in an in vitro assay.
In this study, we assess the in vivo effectiveness of pig islets expressing these
molecules, employing a pig-to-rat xenotransplant model.
Materials and methods: Gene construction: cDNA encoding decoy Fas
was cloned into an expression plasmid containing CMV promoter, internal
ribosome entry site 2 (IRES2) gene, and enhanced green fluorescent protein
(EGFP). Subsequently, this expression unit was inserted into the adenovirusbased cosmid pAxcwit (Takara Bio, Otsu, Japan). Similarly, cDNA encoding
membrane-bound human FasL and the Discosoma sp red fluorescent protein
DsRed coding region were also subcloned into the cosmid pAxcwit. The control
adenovirus that contain EGFP gene without the human cDNA insert, was also
generated. The adenoviruses were amplified by infection of HEK-293 cells,
respectively. Preparation of pig islets: Adult pig pancreata were removed at a
slaughterhouse that handles young market weight pig. Pig islets were isolated
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by the modified Ricordi’s method. Gene expression: Freshly obtained adult pig
islets, resuspended in 500 μl serum-free HBSS, were exposed to adenovirus
encoding either human decoy Fas or membrane-bound FasL at a MOI of 30.
The expression of these molecules in pig islets were determined by FACS, using
appropriate mAbs. Transplant studies: Lewis rats were purchased from Oriental
Yeast (Tokyo, Japan). Recipient rats were rendered diabetic by intraperitoneal
injection of streptozotocin at a dose of 60 mg/kg, 7 days prior to pig islets
transplantation. Then the transduced pig islets were transplanted under the
kidney capsule of recipient rats. Rats were monitored every 6 hours for blood
glucose levels. The grafted kidney retrieved at day 3 posttransplantation was
subjected to immunohistochemical analysis, using anti-pig insulin antibody.
Results: Transduction efficiency and blood glucose levels of each group
were shown in Table 1. Both decoy Fas and mFasL were effective to improve
metabolic outcome of the recipient rats through 12 to 18 hours posttransplant
(p<0.05). Unfortunately, blood glucose levels of each group were not
significantly different after 24 hours posttransplant.
Discussion: Transplantation of pig islets expressing either human decoy
Fas antigen or membrane-bound human FasL effectively improved pig islet
xenograft survival and reduced serum blood glucose levels in recipient rats.
Therefore, the generation of transgenic pigs, overexpressing these molecules
may control innate cellular response to islet xenografts, creating a window of
opportunity for prolonged xenograft survival.
Table 1.
Pig islets

Mean fluorescent
intensity
(Transduction
efficiency)

Parental pig islets

endogenous

Mock islets
decoy Fas
transduced islets
mFasL
transduced islets

Blood glucose levels of recipients (mg/dl)

Xenograft
survival

12 hr

18 hr

24 hr

Day 3

430.5±38.8

462.2±52.4

478.6±42.1

rejected

Not determined

447.8±45.0

450.3±44.3

469.5±33.3

rejected

403 (81.4%)

186.6±18.7*

272.5±56.5*

458.3±36.9

79.5 (79.3%)

196.4±44.3*

304.3±42.9*

490.0±38.5

++
(survived)
++
(survived)

Each values are mean±SD (n=4). *; p<0.05 compared with mock.
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590 COMPARISON OF WHOLE BLOOD COAGULATION
ASSESSMENT USING THROMBOELASTOMETRY (ROTEM®)
BETWEEN HUMAN AND CYNOMOLGUS MONKEYS
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591 PROFILES OF GLYCOANTIGENS OF THE CELLS FROM
¿-1,3GT KNOCKOUT PIG
S. Miyagawa1, S. Takeishi2, A. Ishimaru1, E. Miyoshi1, M. Fukuzawa1
1
Osaka University Graduate School of Medicine, 2Gycomics Research
Laboratory, Moritex Co.
Species differences in glycoantigens are major obstacles to xenotransplantation.
Even after creation of the ƒ¿1,3 galactosyltransferase (GT) gene-knockout pig
(KO-pig), most non-Gal antigens remain on the surface of pig cells. However,
changes in glycoantigens of the KO-pig have not been thoroughly evaluated.
In this study, endothelial cells (EC) from KO-pigs were subjected to lectin blot
analysis, including a survey of non-Gal glycoantigens. The results were then
compared to those obtained for EC from wild-type pigs and human EC.
Methods: First, species differences between human and pig EC glycoantigens
were examined. Next, the differences between wild-type and knockout pig EC
glycoantigens were studied.
The following EC were studied: ƒ¿-Gal knockout (heterozygous and homozygous);
the ƒ¿-Gal homozygous knockout plus N-acetylglucosaminyltransferase-III
(GnT-III) transgenic; wild-type obtained from siblings of knockout animals;
and, human EC from HUVEC (Health Science Research Resources Bank,
Osaka) & HAOEC (AGC Techno Glass CO.,LTD.). Cells were cultured in
a gelatin-coated dish for several days. After centrifugation at 14,000G for 5
min, proteins in the supernatant were labeled with Cy3, applied to the lectin
array, scanned with an SC Profiler, and analyzed with an Array Pro Analyzer
(Moritex, Yokohama, Japan).
More than 40 different lectins were used in this analysis, including GSI-B4,
GSI-A4, GSIL-II, UEA-I, BPL, WFA, HPA, SBA, etc.
Results:
1. In the comparison between human and pig EC, pig EC exhibited stronger
signals for SBA, HPA, WFA, GSI-B4 and GSI-A4, while human EC showed
strong signals for UEA-1, MAL and ECA. Expression of ƒ¿1,2 fucose and
ƒ¿2,3 sialic acid are greater on human EC compared with pig EC. In constrast,
pig EC expressed high levels of both ƒ¿-Gal and terminal GalNAc.
2. A signal for GSI-B4 was observed in human EC, but signals for EEL were
not detected. These data indicate that the GSI-B4 signals observed in human
EC arise from ƒÀ-Gal expression.
3. EC from the KO-pig not only lost the GSI-B4 and GSI-A4 signals, but
expressed lower levels of SBA, HPA and BPL. Of note, EC from the KO-pig
had lower expression of terminal GalNAc, GalƒÀ1, 3GalNAc.
4. In contrast, SNA, SSA, and TJA-I were upregulated on EC from the KO-pig
compared with wild-type EC, suggesting higher expression of ƒ¿2,6Sia.
Conclusion: EC from the KO-pig vanished ƒ¿-Gal, and reduced terminal
ƒ¿-GalNAc. However, expression of both 2,3 and 2,6 sialic acid were
upregulated.
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M. Boldrin1, D. Bertini2, L. Spiezia2, S. Gavasso2, C. Radu2, F. Fante1,
C. Bulato2, E. Ancona1,3, P. Simioni2, E. Cozzi1,3
1
CORIT, 2Department of Medical and Surgical Sciences, 2nd Chair of Internal
Medicine, University of Padua, Padua, Italy, 3Department of Surgical and
Gastrointestinal Sciences, University of Padua, Padua, Italy
Introduction: Microvascular thrombosis, due to activation of clotting
cascade, is a key feature of the rejection process that takes place when pig
organs are transplanted into primates. Such coagulopathy is viewed by some
as the real barrier to the long-term survival of porcine xenografts in this
species combination. To date, little is known about qualitative characteristics
of clot formation in primates as far as strength, firmness and swiftness are
concerned. The present study is aimed at better understanding the differences
in blood coagulation between primate and human using thromboelastometry
(ROTEM®). This system appears to be an attractive tool for studying the
simultaneous and integrated effects of different components involved in the
dynamic process of clot formation such as plasma factors, platelets, leucocytes,
and red blood cells.
Materials and methods: We studied ROTEM profiles in 40 (15 males and 25
females; age range: 3-11 years) naïve cynomolgus monkeys from Mauritius,
China and Philippines and in 52 healthy human volunteers (22 males and 30
females; age range 20-60 years). Thromboelastometry (InTEM®, ExTEM®,
FibTEM®, NaTEM®) was performed from whole blood with the ROTEM®
coagulation analyser (Pentapharm, Munich, Germany). All samples were
analysed between 1-3 hours from collection. ROTEM® profiles were observed
for 60 minutes. Blood samples (1.2 mL) were drawn in syringes containing 1:10
(v/v) sodium citrate 3.8%. Four standard ROTEM® assays were performed
according to protocols supplied by manufacturer. The main parameters obtained
were clotting time (CT) [time (in seconds) from initiation of the measurement
until initiation of clotting]; clot formation time (CFT) [time (in seconds) from
initiation of clotting until a clot firmness of 20 mm is detected]; maximum clot

firmness (MCF) [the maximum amplitude (in mm) reached by the clot]; Area
Under Curve (AUC) [the area under the velocity curve]; and Alpha (α;) angle
[a tangent to the clotting curve through the 2 mm point]. Statistical analysis was
performed using unpaired t-student test.
Results: Data obtained in cynomolgus monkeys were reproducible and
consistent with the normal range observed in human healthy subjects. Some
important differences were, however, observed in primate blood. In monkeys
InTEM®, ExTEM®, FibTEM®, NaTEM® showed a hypercoagulable profile
as compared to humans. Mean CT and mean CFT were significantly lower in
primates (-25.7% and –55.5%, respectively) than in humans. MCF, α; angle
and AUC were significantly higher in primates than in humans (+23%, +21.5%
and +32%, respectively). Similar distribution and range in human and monkey
platelets were observed. In addition, fibrinogen levels in monkeys were lower
than in humans (145.4 mg/dl vs. 289.9 mg/dl).
Conclusion: Primate clot formation studied by ROTEM®, a novel technology
to study whole blood coagulation, is consistent with a higher prothrombotic
profile in primates as compared to humans. These differences do not appear to
be related to higher platelet counts or fibrinogen levels in monkeys. Together
these data suggest that, with regard to coagulation, xenotransplantation in cynos
represent a much more difficult situation than xenotransplantation in humans.
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MINI-ORAL SESSION 24: INTESTINAL TRANSPLANTATION
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592 EXPERIMENTAL SMALL BOWEL PRESERVATION
USING PACAP-38 CONTAINING UNIVERSITY OF WISCONSIN
SOLUTION
D. Reglodi , A. Ferencz , B. Racz , A. Tamas , J. Nemeth , K. Nedvig ,
K. Kalmar-Nagy3, O.P. Horvath3, G. Weber1, E. Roth1
1
University of Pecs, Medical School, Department of Surgical Research And
Techniques, 2University of Pecs, Medical School, Department of Anatomy,
3
University of Pecs, Medical School, Surgical Clinic, 4University of Debrecen,
Department of Pharmacology And Pharmacotherapy
The deleterious effects of cold ischemia and reperfusion are major problems
that affect clinical outcomes after intestinal transplantation. Despite its
overall acceptance as the first choice for organs, UW is unable to effective
preserve the bowel grafts. Pituitary adenylate cyclase-activating polypeptide
(PACAP) was originally isolated from ovine hypothalamic extracts. High
level of endogenous PACAP-38 can be detected in the intestine. The aims
of this study were to examine changes on endogenous PACAP values in
intestinal I/R model, and the efficacy of exogenous PACAP-38 on the
oxidative stress and tissue damage induced by small bowel cold preservation
and autotransplantation.
Intestinal ischemia/reperfusion (I/R) and autotransplanted groups were
established in Wistar rats (n=60). In I/R groups 1 hour (Group A), 2 hours
(Group B), and 3 hours (Group C) ischemia followed by 3 hours of
reperfusion was applied. In autotransplanted groups total orthotopic intestinal
autotransplantation was performed. Grafts were preserved in University of
Wisconsin (UW) solution for 1 (GI), 2 (GII), 3 (GIII), and 6 (GIV) hours and in
UW containing 30 ug PACAP-38 for 1 (GV), 2 (GVI), 3 (GVII), and 6 (GVIII)
hours. Reperfusion lasted 3 hours in all groups. Endogenous PACAP-38
concentration was measured by radioimmunoassay. To determine oxidative
stress parameters malondialdehyde (MDA), reduced glutathione (GSH), and
superoxide dismutase (SOD) were measured in tissue samples. Tissue damage
was analyzed by qualitative (Park¡¦s classification) and quantitative (software
Scion Image) methods on hematoxylin/eosin-stained sections. The level of
significance was set at p<0.05.
Concentration of endogenous PACAP-38 decreased during I/R compared to
sham. It was significant in Group B and C by the end of the reperfusion
periods. Value of tissue MDA increased in GI-GIV. Significant difference
was between GIV and GVIII (GIV: 128.2„b3.1; GVIII: 112.0„b2.1
uM/g). In GSH content significant different was between GIV and GVIII
(GIV: 289.7„b10.9; GVIII: 328.1„b11.8 uM/g). SOD activity decreased
significantly in GII and GIV. Better preservation of SOD was observed in
GV-VIII (GVIII: 205.1„b13.4 IU/g). According to Park¡¦s classification, the
highest grade of injury was observed in GIV (grade 5), whereas the lowest
grade of injury was found in GV (grade 0). In GI and GII histological
findings were corresponding to an injury grade 2, showing minor clefting
with the villus epithelium adjacent to the crypts intact. In GIII the injury was
grade 3 characterized by massive epithelial lifting and villus tip denudation.
In GIV the injury showed denuded villi, decellularization of lamina propria
and crypts. By contrast, in GV-VIII PACAP-38 ameliorated injury by the
end of reperfusion periods. Scion Image quantitative analysis has supported
these observations.
This is the first report demonstrating changes on endogenous PACAP-38
values in intestinal I/R model, and the efficacy of exogenous PACAP-38 on the
oxidative stress and tissue damage induced by intestinal autotransplantation.
PACAP-38-treatment exhibited a quality of intestinal preservation superior
to current clinical standard UW storage. The experimental setting used in our
study has several advantages to assess the quality of intestinal preservation.
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593 TNF ALPHA INHIBITORS REDUCE THE
INFLAMMATORY RESPONSE TO I/R INJURY IN A RAT
INTESTINAL TRANSPLANT MODEL
S. Kohler, G. Atanasov, U. Gerlach, A. Reutzle-Selke, P. Neuhaus,
J. Pratschke, A. Pascher
Surgery, Charité, Campus Virchow Clinic
Introduction: Ischemia/reperfusion injury is one of the major problems in
intestinal transplantation. We have evaluated the efficacy of TNF alpha inhibitors
to mitigate ischemia-/reperfusion injury in a rat small bowel transplant model.
Materials and methods: Small bowel transplantation was performed as an
orthotopic isogenic transplantation model in female Lewis rats. The graft
was flushed with UW and stored for 6 hours at 4°C before implantation.
There was no further treatment in the controls (C). The TNF-inhibitor groups
either received pentoxifylline (P) (25 mg/kg bw i.p., prereperf., PODs 1-5) or
etanercept (E) (1 mg/kg bw s.c.; prereperf., PODs 1,3,5,7). Tissue samples of
the proximal and distal small bowel were taken 20min, 12hrs, 7d, and 6mth
after reperfusion (each n=6 per time point and group) for histopathology
(HE) and immunohistology (CD4,CD8,CD25,ED1,ZO-1,HSP70). Samples
of the lung were stained for MPO. Statistics: multifactorial analysis/two-way
ANOVA, Bonferroni post-test.
Results: 7day- survival in the control group was 54,5%. TNF alpha inhibition
improved 7day-survival to 63,2% in the P treated group and to 66,7% in the group
treated with E, both without statistical significance. Survival beyond POD 7 was
100% in all groups. TNF alpha inhibition decreased I/R mediated inflammatory
response in both treatment groups significantly: immunohistologically assessed
graft and lymph node infiltration of CD4(+), CD8(+), and CD25(+)-T-cells, as
well as macrophages (see selected data in table1), and MPO stain of the lung
displayed significant reduction of inflammation over the whole observation
period. No significant differences could be found between both treatment
groups. However, graft damage and cellular infiltrates were significantly
enhanced in tissue of distal portions vs. proximal portions of the graft in all
groups. This difference even persisted after TNF alpha inhibition, however,
was reduced markedly (selected data table1).
Table 1:
Control

Etanercept (p-value) Pentoxifylline (p-value)

Cells/viewing field (VF) Cells/VF
CD 25
Proximal

Distal

ED 1
Proximal

Distal

Cells/VF

20 minutes

1.568

0.623 (<0.05)

0.413 (<0.01)

12 hours

2.216

0.837 (<0.001)

0.315 (<0.001)

7 days

1.693

0.468 (<0.01)

0.460 (<0.01)

6 months

0.688

0.257 (>0.05)

0.103 (>0.05)

20 minutes

5.165

1.086 (<0.001)

0.597 (<0.001)

12 hours

4.406

2.367 (>0.05)

0.685 (<0.001)

7 days

4.383

1.998 (>0.05)

0.955 (<0.05)

6 months

4.660

0.957 (<0.01)

0.328 (<0.001)

20 minutes

32.89

24.39 (<0.01)

20.45 (<0.001)

12 hours

42.54

22.63 (<0.001)

22.20 (<0.001)

7 days

37.80

18.79 (<0.001)

23.34 (<0.001)

6 months

41.23

45.58 (>0.05)

46.89 (>0.05)

20 minutes

53.90

35.69 (<0.001)

34.52 (<0.001)

12 hours

54.81

36.89 (<0.001)

32.28 (<0.001)

7 days

63.46

29.61 (<0.001)

27.35 (<0.001)

6 months

84.13

66.48 (<0.001)

55.31 (<0.001)

Discussion: I/R mediated inflammatory response after rat intestinal
transplantation is significantly reduced by TNF alpha inhibitors with regard to
short-term as well as long-term graft outcome. The distal portions of the grafts
were effected more severely by I/R injury. The presented findings may help to
ameliorate initial graft injury after I/R, which is believed to exert long-term
effects on graft outcome by activating innate immunity, thus contributing to
chronic allograft enteropathy.
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594 EXPERIMENTAL SMALL BOWEL TRANSPLANTATION
FROM NON HEART BEATING DONORS (NHBD):
A LARGE ANIMAL STUDY
M. Alessiani1, L. Cobianchi1, S. Zonta1, R. Ciccocioppo3, T. Dominioni1,
J. Viganò1, C. Filisetti1, E. Vicini1, A. Bottazzi2
1
University of Pavia, Department of Surgery, IRCCS Fondazione Policlinico
San Matteo, 2Anestesia and intensive care unit, IRCCS Policlinico San
Matteo, 3Department of internal medicine University of Pavia
Introduction: The shortage of organs in the last twenty years is stimulating the
development of new strategies to expand the pool of donors. The harvesting
of the graft from non-heart beating donors (NHBD) has been successfully
proposed for kidney and liver transplantation. To our knowledge, no studies are
available for small bowel transplantation using NHBD donors.
Aim of the study: in an experimental setting of small bowel transplantation,
we studied the feasibility of using intestinal grafts retrieved from NHBD.
Material and method: Twenty Large White piglets underwent total orthotopic
small bowel transplantation and were randomly divided as follow: group 1
(n=10) received grafts from NHBD; group 2 (n=10) received grafts from heart
beating donors (HBD). In group 1, the NHBD pigs were sacrificed inducing
the cardiac arrest by a lethal potassium injection. After 20 minutes (no touch
period = worm ischemia), they underwent cardiac massage, laparotomy and
aorta cannulation for flushing and cooling the abdominal organs. In group 2 the
cardiac arrest was induced at the time of organ cold perfusion. In both groups
immunosuppression was based on tacrolimus oral monotherapy. The animals
were observed for 30 days. The graft absorptive function was studied at day
15 using the D-xylose absorption test. Histological investigation included
EE microscopical analisys, immunohistological staining for CD4/CD8,
macrophage and dendritic cells. The complete profile of the MAP-kinase was
completed by western blotting.
Results: Two animals in each group died for technical complications and were
excluded from the study. The mean survival was 19 days in group 1 and 24 days
in group 2. Only 2 animals (25%) of the NHBD group 1 were alive at the end
of the study compared to 4 of the HBD group 2. The causes of death in both
groups were infection-related. The D-xylose absorption was significantly lower
in the NHBD group 1 compared to the HBD group 2 (pƒ¬0.05). The analysis
of cytokines profile in the serum reviled a significantly higher level of IL-1£],
TNF-£\. An increasing in the activation of p-38 and JNK MAPKs has been
detected compare to controls.
Conclusions: This study confirm that intestinal mucosa is very sensitive to
ischemic injury. When the intestinal graft is harvested from NHBD, the
infectious-related mortality is higher and the absorptive function of the graft
is lower Histology, cytokines profile and MAP-kines activation profile confirm
a higher grade of ischemic injury in the NHBD grafts that correlates with the
clinical data. Therefore this experimental study suggests that non-heart beating
donation may not be indicated for small bowel transplantation.
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Y. Ishikawa, A. Griesemer, A. Hirakata, J. Etter, A. Shimizu, K. Yamada
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: There are many unresolved obstacles to intestinal
transplantation that limit its applicability. These include inadequacy of
immunosuppression, lack of a reliable means to maintain functional barriers
to infection, and the insensitivity of currently available diagnostic assays
for rejection. In order to improve clinical outcomes and eliminate the comorbidities associated with chronic immunosuppression, the induction
of donor specific tolerance would be desirable, especially in the pediatric
population of intestinal transplantation recipients. In this study, we examined
the ability of the intestine to facilitate tolerance induction and analyzed
chimerism in the peripheral blood and both native and graft lymph nodes
following intestinal transplantation.
Methods: Five MGH-miniature swine received small intestine transplants, two
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596 RESCUE OF INTESTINAL FUNCTION IN PATIENTS
REFERRED FOR MULTIVISCERAL AND INTESTINAL
TRANSPLANTATION
E. Island, A. Manta, C. Lyssikatos, T. Kato, G. Selvaggi, J. Moon, D. Levi,
S. Nishida, A. Tzakis
University of Miami
Multivisceral and Intestinal transplantation have become excellent primary
treatments for many refractory intestinal disorders. However, transplantation
is often associated with significant morbidity due to the need for life long
immunosuppression. Herein we describe our experience with patients
referred for multivisceral or intestinal transplantation and treated with other
modalities. From 1994 to 2008 there were 701 referrals for intestinal or
multivisceral transplants, and 284 transplants were preformed. During the
same time period there were 38 patients rescued from transplantation. There
were 18 adult and 20 pediatric cases. Patient diagnoses included gastroschisis,
volvulus, Hirschsprung’s disease, NEC, Mesenteric thrombosis, tumors,
and other disorders. All patients were cared for by a multidisciplinary team
that included transplant surgeons, gastroenterologists, nutritionists, and
pharmacists. Rescue modalities included bowel rehabilitation with medical
management alone (17), surgical intervention followed by bowel rehabilitation
(10), surgical resection (6), and resection with auto transplantation (5).
Overall results were excellent; all patients demonstrated improvement in
their enteral intake and 10 patients (26%) are off TPN altogether. However,
there were 2 deaths due to septic complications in pediatric patients being
rehabilitated with short gut syndrome. In selected cases, multidisciplinary
care of complex intestinal patients has resulted in rescue of intestinal function,
and the avoidance of morbidities associated with transplantation and life long
immunosuppression.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

209

WEDNESDAY

595 TOLERANCE AND SUSTAINED PERIPHERAL
CHIMERISM FOLLOWING MHC MATCHED AND CLASS I
MISMATCHED INTESTINAL TRANSPLANTATION IN MGH
MINIATURE SWINE

across a minor-antigen mismatch and three across a class-I MHC mismatch, with
12-days of CyA. Chimerism was assessed by FACS analysis. The percentage
of donor cells was determined using class I specific antibodies and/or porcine
allele-specific antigen antibodies. Immunohistochemistry was performed to
determine the distribution of donor cells in the lymph nodes. CML assays were
performed to examine anti-donor responses across class I barriers. Regulatory
cells were detected using Foxp3 in the peripheral blood and lymph nodes.
Results: (1) Minor antigen mismatch: Both intestine grafts survived >120
days. Only minimal cell infiltrate was seen 1-2 weeks after cessation of
CyA. Recipient cells assessed by allele specific Abs migrated to the donor
mesenteric lymphnodes (LNs) as early as day 5 (15-25%). Greater than 15%
peripheral blood chimerism (donor cells) persisted greater than 60 days.
(2) Class-I mismatch: All animals accepted intestine grafts (163 days, 106
days and >90 days) following 12 days of CyA. Immunologically, all showed
donor specific unresponsiveness in vitro by CML by day 30. Although two
of the three animals had no signs of rejection throughout the experimental
period, one had a rejection crisis detected by graft biopsy at POD 66. At
this point, the level of Foxp3+/CD25+ cells in the graft mesenteric LNs
decreased markedly as compared to that at day 30. No signs of rejection
were noted at later time points. 5-10% of myeloid as well as lymphocyte
chimerism in the peripheral blood was observed in the first 2 weeks and then
gradually decreased, but was sustained at low levels for at least 3 months
after intestinal transplantation.
Conclusions: All intestinal transplants were accepted across both minormismatched and class I mismatched barriers with persistent myeloid and
lymphoid chimerism. To our knowledge, this is the first demonstration of
persistence of chimerism and tolerance induction to intestinal transplants in a
large animal. Studies to investigate the mechanisms of tolerance in this model
are currently in progress.
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597 TRANSPLANTATION OF THE STOMACH –
CLINICOPATHOLOGICAL OUTCOMES REVIEW
OF THE GASTRIC ALLOGRAFT INCLUDED IN
MULTIVISCERAL GRAFT
T. Kato, G. Selvaggi, S. Nishida, E. Island, D. Weppler, M. Velasco,
H. Takahashi, J. Gaynor, P. Ruiz, A. Tzakis
University of Miami
Background: Transplantation of the stomach has been done as part of
multivisceral transplantation at our institution. In this study, we review
our results of function, pathology and complications regarding the gastric
allograft.
Methods: A retrospective review of the recipients who received allograft
stomach as part of as part of the multivisceral graft.
Results: 146 patients received the stomach as part of the multivisceral graft
during 1994-2007. 124 received it with a standard multivisceral graft (liver,
stomach, pancreas and intestine) and 22 received it with a modified multivisceral
graft (stomach, pancreas and intestine). The gastric allograft was anastomosed
to the native esophagus (esophagogastrostomy) in 78 and to the small rim of the
native stomach (gastro-gastric anastomosis) in 68. All received pyloroplasty at
the time of transplant. 71 patients who received gastric allograft are currently
alive. The gastric emptying were normal to near normal in most cases except
for 3 cases who exhibit significant gastropalasis after the transplant both of
those cases had dysmotility disease as a cause of transplant. The rejection of the
gastric allograft was seen in xxx cases. All of those occurred concurrently with
the intestinal rejection. No isolated gastric rejection was seen. Significant gastro
esophageal reflux was seen in 10 patients. 8 of those had esophagogastrostomy
and 2 gastro gastrostomy. Fudoplication surgery was performed in 3 cases. No
anastomotic leak from the gastric anasomosis was seen in primary multivisceral
transplant; in 2 case, leak was seen after the second multivisceral transplant.
Conclusion: The gastric allograft as part of the multivisceral graft seemed to
show good emptying function. Gastric rejection seemed to be a rare occurrence
and other complication rate pertaining to the gastric allograft is rare as well.
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598 RECOVERY FROM LIVER DYSFUNCTION AFTER
ADULT ISOLATED INTESTINAL TRANSPLANTATION
WITHOUT LIVER GRAFTING
C. Zanfi1, A. Lauro1, M. Cescon1, L. Ansaloni1, G.L. Grazi1, A. Cucchetti1,
M. Ravaioli1, M. Zanello1, L. Pironi2, A.D. Pinna1
1
U.O Chirurgia Dei Trapianti Di Fegato E Muliorgano (Dir.:Prof. A.D
Pinna), 2Centro Riferimento Insufficienza Intestinale (Head:Prof .L.Pironi),
University of Bologna - Policlinico S.Orsola-Malpighi
Purpose: Indications for intestinal transplant with liver is the cohesistence of
liver and intestinal failure. Liver failure has been related to reversible liver
damage from bacterial translocation or total parenteral nutrition (TPN). The
etiology is still not clearly established but it is likely multifactorial; several
factors correlated with its occurrence include: duration of TPN therapy, length
of residual small bowel, presence of residual colon, composition of TPN
macronutrients hepatotoxic factors.). Impending or overt liver failure (which
is, according to Medicare coverage policy, one of the criteria that makes failed
TPN therapy) is defined by: increased serum bilirubin and/or liver enzyme
levels, coagulopathy, thrombocytopenia, splenomegaly, gastroesophageal
varices, stomal bleeding and liver fibrosis or cirrhosis at biopsy.
The aim of this study is to evaluate liver function recovery after isolated
intestinal transplantation in adults with irreversible intestinal failure.
Patients and methods: Over a 8 years period we performed 39 intestinal
transplantation in 38 adult patients: 29 received an isolated intestinal graft, 4 a
multivisceral graft without liver, and 5 a multivisceral graft with liver. Patients
were divided in 2 groups: the IF-Liver disease recipient group and the control
group; recipients for liver graft were not considered (5 patients). The first group
was composed by 16 recipients with pre-transplant liver dysfunction which
was considered when bilirubin was superior than 2 mg/dL (N.V.: 1.2) and/or
transaminases more than 100 IU/mL (N.V.:37/40); other inclusion criteria were:
TPN period > 3 months, no diagnosis of portal hypertension or cirrhosis. Two
patients had a biopsy-proven liver fibrosis. The control group was composed by
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17 patients without pre-transplant liver dysfunction.
Results: At discharge all patients recovered liver function normal values:
mean bilirubin blood level was 0.9 ± 0.96 mg/dL (range 0.3-1.6) and mean
transaminases was 26 ± 9/31 ± 18 IU/mL (range 10-44/27-65). After a mean
follow-up of 1618 ± 708 days (range 2605-227) only 2 patient has elevated
ALT without clinical signs of liver disease; one patient has high bilirubin level
(2.3 mg/dl) because he is affected by Gilbert’s syndrome but his liver is well
functioning. Pre-transplant liver disease didn’t impact on survival rates.
Conclusion: Liver disease associated with intestinal failure (IF-Liver disease)
is one of the main causes of death in patients with permanent intestinal failure.
Regression of IF-Liver disease can be achieved by combined liver-intestine
transplant or isolated small bowel transplant without liver grafting. In selected
cases isolated intestinal or multivisceral graft without liver can represent a “liver
salvage therapy” for early failing liver in patients with irreversible intestinal
failure: pre-transplant liver disease can regress after successful intestinal
transplantation and discontinuation of intravenous therapy if liver disease is
early referred. Pre-transplant liver disease isn’t a negative prognostic factor.
More Surgical Videos

599 BACTERIAL TRANSLOCATION IN ADULT INTESTINAL
TRANSPLANTATION
A. Cucchetti1, C. Zanfi1, M. Cescon1, L. Ansaloni1, A. Lauro1, A. Dazzi1,
M. Di Simone1, A. Bagni2, A. Siniscalchi1. A.D. Pinna1
1
Liver and Multiorgan Tranplant Unit (Dir.:Prof. A.D Pinna), 2Pathology ”F.
Addarii” Institute, University of Bologna - S.Orsola-Malpighi Hospital
Introduction: The application of small bowel transplantation (SBTx) is limited
by the relatively high rate of infectious complications that occurs; bacterial
translocation (BT) has been suggested as being responsible for the high rate of
infections associated with clinical transplantation.
Materials and methods: We reviewed 95 biopsies performed on 28 isolated
SBTx recipients in order to identify histological features predictive of BT
within the first month after transplantation.
Results: At least one episode of BT was observed in 13 patients out of 28 (46.4%);
occurrence of BT led to higher one-year mortality (38.5%) in comparison to
negative cases (6.7%; P=0.041). No clinical or surgical factors were found to
be significantly related to occurrence of BT. Of the 95 biopsies examined, 38
were followed by BT (40%): these biopsies showed a higher degree of mucosal
vascular alteration (Ruiz grade; P<0.05) and ischemia/reperfusion injury (Park/
Chiu grade; P<0.05) in comparison to negative cases; the presence of acute
cellular rejection was not found to be related to BT.
Conclusion: BT seems to be closely related to mucosal vascular alteration
and ischemia/reperfusion injury rather than acute cellular rejection; the
measurement of the degree of these histological features could identify patients
at high risk of potentially life-threatening infectious complications and death.

MORE SURGICAL VIDEOS
600 RENAL TRANSPLANT BIOPSIES: INTRODUCING THE
GLIDE PATH APPROACH AND SKEWER TECHNIQUE FOR
SAFE & EFFECTIVE BIOPSY PRACTICE
A.O. Mahendran, P.S. Veitch
Royal Free & University College London Medical School
Aim: Renal transplant biopsy remains the gold standard in the assessment of
parenchymal causes of graft dysfunction. As such it is a widely used procedure
amongst transplantation units. However, it is not without risk and traditionally
has been reserved to resolve clinical uncertainty over aetiology, usually in an
acute setting.
In our unit we have developed a biopsy procedure that prioritises patient safety
and comfort.
Our video demonstrates an accessible biopsy technique that harnesses the best
ultrasound technology to produce real time images of the needle passage. In
addition, the method encompasses two approaches to a transplant kidney ; the
glide path and the skewer technique. The use of either one is dependent on the
position of the graft.
We have devised an easy-to-follow two handed procedure that can be taught
effortlessly to transplant physicians and surgeons in training.
Method: The following pieces of equipment are essential for our method:
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• High resolution ultrasound machine with colour Doppler and a 7. 5MHz with
general purpose probe.
• A disposable, spring-loaded, automated 16 guage biopsy needle.
• A spinal needle for deep infiltration of tissues and renal capsule with local
anaesthetic.
The first step of the technique is imaging the graft and visualising the “no-go”
areas; renal medulla, any pole overlaid by bowel, areas around major vessels,
ureter and bladder.
The crux of the technique is in constant needle visualisation throughout the
procedure. This is facilitated by ensuring that both the needle tip and body
remain within the finite curtain of ultrasound emitted by the probe.
The glide path approach is based on the runway principle used in aviation to
guide an airplane to earth. The skewer technique is ideal for those kidneys that
are placed in the upright positions.
Results: Between January 2007 and January 2008, a total of 130 diagnostic and
105 protocol biopsies were performed. 3 biopsies were misses which yielded
no renal tissue. On average there were 18 glomeruli per core of biopsy tissue.
Two minor post-procedure complications were reported; transient haematuria
and an intracapsular haematoma. No graft was lost. In addition, 15 doctors
were trained successfully in the procedure.
Conclusion: In recent years we have witnessed an expanding role for transplant
biopsies. They have rapidly become an important management strategy in
patients with creeping creatinines, recipients of asystolic donor kidneys and in
protocol biopsies. The loss of a graft or serious complication following biopsy
is unpalatable. Therefore, it is imperative that a transplant unit has confidence
in its biopsy technique.
We have devised a procedure with a formidable safety profile, based on clear
guiding principles. The success of the technique has allowed our unit to
incorporate protocol biopsies into the routine follow-up of transplant patients.
This has significantly improved the early detection of graft dysfunction and
subsequent graft preservation.

601 OUR TECHNIQUE OF OBTAINING CUFF OF
INFERIOR VENA CAVA DURING RIGHT SIDED
RETROPERITONEOSCOPIC DONOR NEPHRECTOMY

602 LIVE DONOR KIDNEY TRANSPLANTATION
FOLLOWING EXTRACOPOREAL REPAIR OF RENAL ARTERY
ANEURYSM
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori,
S. D’Imporzano, L. Morelli, G. Amorese, F. Mosca.
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico,
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Aims: Complex vascular lesions, such as renal artery aneurysms, are usually
considered a contraindication for live kidney donation. We herein show the
video of a case of kidney transplantation from a live donor despite the presence
of a distally located renal artery aneurysm.
Methods: Kidney transplantation was performed on March 5th, 2008. The
LD, a 66 year old father, donated the right kidney to his 36 year old son.
During the pre-donation work-up the donor was incidentally discovered with
a renal artery aneurysm located the level of the primary bifurcation. Complete
investigation showed no other cardiovascular lesions, although a mild dilation
of the ascending aorta was noted. The dilated aortic segment showed no size
increment during a two year period of follow-up, during which intended
recipient did not match with any of the available deceased donors. Provided
that unilateral nephrectomy was not deemed detrimental for the progression
of cardiovascular disease, and that the potential donor would have required
repair of the renal artery aneurysm irrespective of his willing to donate we
decided that, if extracorporeal repair was satisfactory, it would have been
worth the effort to pursue live kidney donation. As defined by computed
tomography angiogram and arteriography, the right kidney was supplied
by two arteries The aneurysm originated from the superior renal artery
at the level of a trifurcation. The left kidney was completely normal either
anatomically or functionally. The right kidney was procured laparoscopically
(hand assisted technique), perfused with Celsior solution and maintained
between 0 and 4 Celsius degrees until transplantion. The renal aneurysm
was excised extracorporeally and reconstructed using a branched hypogastric
artery segment retrieved from the recipient. Each of the three renal branches
emerging from the aneurysm was reconstructed using microsurgical technique
with the aid of loop magnification. The kidney was eventually transplanted
into the right iliac fossa of the recipient. The same surgical team cared for all
surgical procedures (i.e. kidney procurement, extracorporeal vascular repair,
and KTx).
Results: The kidney was reperfused after 3 hours of cold storage. Reperfusion
was immediate and homogeneous. No significant haemorrhage was noted.
Urine production restarted promptly, with a urine volume of 4.500 cc during
the first 24 hours.
Conclusions: This video shows that, in well selected donors, renal artery
aneurysms may not be an absolute contraindication for live kidney donation.
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CONCURRENT ORAL SESSION 41: CARDIOVASCULAR AND
METABOLIC DISEASE IN RENAL TRANSPLANTATION
603 REDUCTION IN CARDIOVASCULAR DEATH RATES
AFTER KIDNEY TRANSPLANTATION IN ANZ
H. Pilmore1, H. Dent, S. Chang, S. McDonald, S. Chadban2
Auckland City Hospital, Auckland New Zealand, 2ANZDATA Registry
Background: Cardiovascular disease has been a leading cause of death and a
key impediment to successful long-term outcomes after kidney transplantation.
Strategies proven to reduce cardiovascular events in this context are lacking.
Methods: The ANZDATA (Australian and New Zealand Dialysis and
Transplant Registry) Registry was accessed to examine the causes of death
for all 3348 patients who died in Australia or New Zealand between 1980 and
2006 after receiving a kidney transplant. Annualised death rates and death
rates in 5 year time periods were examined. Poisson regression was used to
compare death rates over the time periods with adjustments made for multiple
confounders. In addition, the relative risk ratio (RR) for CVS death was
analysed in 12450 patients transplanted between 1991-2006 using multinomial
logistic regession.
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P. Modi, J. Rizvi, G. Rahul, G. Kadam, S. Patel, T. Amit
Institute of Kidney Diseases And Research Centre, Institute of Transplantation
Sciences
Purpose: To evaluate results of retroperitoneoscopic right side donor
nephrectomy.
Material and methods: Between September 2004 and February 2008 a
total of 270 retroperitoneoscopic donor nephrectomy were performed; 70
were on right side. Four ports were used for dissection and control of renal
pedicle; 10 mm camera port was placed at tip of 12th rib by open access,
followed by 5 mm port at posterior axillary line and 10 mm port at renal
angle. For stapler, a 12 mm port was placed at lateral border of eractor spina
muscle and 2 cm above the iliac crest. Renal artery was controlled by Hem
o loc clips while vein was controlled by Endo TA stapler. The kidney was
retrieved from iliac fossa.
Results: All procedures were completed without conversion to open surgery.
Eight donors had two renal arteries and 10 had two and one donor had four renal
veins. Cuff of inferior vena cava was obtained in all cases. Mean operative time,
blood loss and warm ischemia time were 124 minutes, 84 ml and 4 minutes and
35 seconds respectively. Intra-operative hemorrhage from inferior vena cava
(IVC) occurred in two patients and in both cases laparoscopic repair of bleeding
site at IVC was performed. Post operatively, mean analgesic requirement, time
to start orally and time to ambulation were 350 mg of Tramadol, 6.2 hours and
12.8 hours respectively. Mean hospital stay was 2.1 days. In recipients, mean
value of drop of serum creatinine on 1st post operative day was 2.5 mg/dL.
Delayed graft function was present in 4 patients. One year graft survival was
93%; two patients were lost.
Conclusion: Our technique of retroperitoneoscopic right sided donor
nephrectomy is safe and reliable method to obtain inferior vena cava cuff in

presence of single or multiple renal veins.
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Results: There is a significant reduction in the death rate since 1990 compared
to earlier eras with an ongoing reduction in the most recent decade (Figure
below); Incidence Rate Ratio (IRR) 0.54; p=0.000). In comparison, there is no
change in the rate of deaths from malignancy (IRR 1.18; p=0.287).

605 ANTIHYPERTENSIVE THERAPY FOR KIDNEY
TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW
AND META-ANALYSIS
N.B. Cross1,2, A.C. Webster1,2, P. Masson3, P. O’Connell4, J.C. Craig1,2
Centre For Kidney Research, Children’s Hospital At Westmead, 2School of
Public Health, University of Sydney, 3Royal Prince Alfred Hospital, Sydney,
4
Westmead Hospital, Sydney
Aims: To assess the relative effects of different classes of antihypertensive
agents on patient and graft survival, graft function, cardiovascular events,
acute rejection, proteinuria, blood pressure and anaemia in kidney transplant
recipients.
Data sources: A comprehensive search of MEDLINE, EMBASE, CENTRAL,
DARE, Science Citation Registry, reference lists of identified studies and
abstracts of conference proceedings.
Methods: We included randomised trials of any antihypertensive agent in
kidney transplant recipients which were administered for two weeks or more,
compared with placebo/no treatment or another class of antihypertensive agent.
Summary estimates of treatment effects were combined using a random effects
model and expressed as relative risks for dichotomous outcomes and weighted
mean difference for continuous outcomes, both with 95% CI.
Results: Data from a total of 60 trials of 76 intervention comparisons involving
3627 participants were retrieved. Indication for treatment varied: hypertension
25 trials (1407 participants), erythrocytosis six trials (111 participants), left
ventricular hypertrophy two trials (131 participants), and chronic allograft
nephropathy one trial (28 participants). In the majority (37 trials, 2291
participants), the indication was not provided or treatment was investigated
for effect on reducing concomitant cyclosporin use. Calcium channel blocker
(CCB) therapy was the most commonly allocated treatment (1612 participants,
49 trials), followed by ACE inhibitors (ACEi; 706 participants, 27 trials) and
angiotensin receptor-2 blockers (ARB; 367 participants, 16 trials). As trials
permitted use of additional agents to treat hypertension, similar blood pressure
control was achieved among all studied drug class comparisons.
Recipients allocated to ACEi, compared to placebo or no treatment had lower
GFR (WMD -6.0 ml/min, 95% CI -11.9 to 0.0), higher serum potassium (WMD
0.44 mmol/L, 95% CI 0.10 to 0.78) and lower haemoglobin (WMD -8.7 g/L,
95% CI -12.1 to -5.3). Recipients allocated to CCB, compared to placebo or no
treatment, had lower risk of graft loss (RR 0.71, 95%CI 0.53 to 0.94), higher
GFR (WMD 4.8 ml/min, 95%CI 1.9 to 7.6 ml/min) and lower creatinine (WMD
-6.5 mmol/L, 95%CI -11.9 to -1.1). Recipients allocated to CCB compared to
ACEi experienced less acute rejection (RR 0.61, 95%CI 0.46 to 0.82), had
higher GFR (WMD -10.6 ml/min, 95% CI 6.0 to 15.2), lower creatinine (WMD
-12.9 mmol/L, 95% CI -17.6 to -8.1), more proteinuria (WMD 0.28 g/24h, 95%
CI 0.10 to 0.47), less hyperkalaemia (RR 0.27, 95% CI 0.13 to 0.53) and higher
haemoglobin (WMD 11.5 g/L, 95%CI 7.2 to 15.8).
Conclusions: These data indicate that CCB should be favoured as first line
treatment in kidney recipients requiring antihypertensive treatment, and suggest
that CCB may prevent graft loss and improve graft function in kidney transplant
recipients, irrespective of indication. Further prospective randomised trials in
patients receiving newer immunosuppression regimens are required.

1

Factors associated with cardiovascular death after transplantation are: age over
45 years (RR 3.03, CI 1.15 – 8.0; p=0.025), diabetes as the cause of ESRF (RR
3.56; CI 1.52 – 8.35; p=0.0035) and presence of cardiovascular disease at the
onset of ESRF (RR 2.7, CI 1.47 – 4.97; p=0.0014).
Conclusions: The rate of death from cardiovascular disease appears to be
declining, in contrast to malignancy. Ongoing research is required to determine
the cause of this observation.

604 METABOLIC SYNDROME AND CARDIOVASCULAR
DISEASE RISK IN RENAL TRANSPLANT RECIPIENTS IN THE
ALERT TRIAL: EFFECTS OF STATIN TREATMENT
I. Soveri1, H. Holdaas2, A. Jardine3, N. Eriksson4, B. Fellström1
Department of Medical Sciences, Uppsala University Hospital, Uppsala,
Sweden, 2Rikshospitalet, Oslo, Norway, 3University of Glasgow, Glasgow, UK,
4
Uppsala Clinical Research Center, Uppsala, Sweden
Background: Metabolic Syndrome (MS) is a risk factor for cardiovascular
disease (CVD) and diabetes mellitus in the general population. Renal transplant
recipients (RTR) have unfavorable metabolic conditions, partly due to
immunosuppression.
Aim: To study MS as CVD risk factor in RTR. To investigate the effect of
fluvastatin treatment in CVD prevention in RTR with MS.
Methods: In total, 1708 stable RTR without diabetes mellitus in the ALERT
trial were randomized to treatment with fluvastatin or placebo. Follow-up was
7-8 years (ALERT-extension trial). MS was defined at baseline using ATPIII
definition. Major adverse cardiac event (MACE) was the primary study endpoint.
Results: In the ALERT study, 29% of the non-diabetic RTR had MS. MACE
risk was increased in RTR with MS [RR (95% CI)] 1.67 (1.27-2.20). RTR
with MS also had increased RR for non-fatal myocardial infarction (MI) 1.84
(1.20-2.88) and cardiac death 2.22 (1.44-3.42). Statin treatment was associated
with considerable reduction in cardiovascular event probability among RTR
patients with MS (Table).
Table. Cumulative 8-year probability of an event (%)
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MS and placebo

MS and statin

No MS and placebo

No MS and statin

MACE

27

14

12

10

Non-fatal MI

11

4.5

5

3.5

Cardiac Death

13

6

5

3.5

Conclusion: RTR with MS are at high risk for CVD. RTR with MS are easily
identifiable group of patients who benefit from statin treatment.
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606 GENETICS OF NEW-ONSET POST TRANSPLANT
DIABETES MELLITUS (NOPTDM)
I.V. Hutchinson1,2, J.W. Yang1,3, K Yamamoto1, S Takemoto1, G Burckart2,
T Shah1,2, V Pravica1,2, D.I. Min1,3
1
National Institute of Transplantation, Los Angeles, CA, 2University of
Southern California, Los Angeles, Ca, 3Western University of Health Sciences,
Pomona, CA
Background: The development of diabetes after transplantation is a significant
problem that dramatically increases patient morbidity and mortality. The
principle cause of NOPTDM is the use of diabetogenic drugs, especially
steroids and calcineurin inhibitors (CNIs), and yet only a proportion of
recipients develop the disease. This suggests an individuality in susceptibility
that may have a genetic component.
Patients and methods: Therefore we tested the association of known genetic
markers for type II diabetes (DM2) and mature onset diabetes of the young
(MODY) with NOPTDM in renal transplant recipients. NOPTDM was defined
as blood glucose >125 mg/dl at more than one time point, starting 30 days posttransplant. Patients were followed for at least 1 year after grafting. We identified
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117 patients with NOPTDM and 295 controls (never hyperglycaemic) from a
pool of 1153 patients transplanted between 01/01/2001 and 09/30/2005.
Results: Amongst the genes associated with NOPTDM were genes affecting
beta cell K-channel function (KCNJ11, p=0.008), insulin gene activation
(HNF1A, p=0.002) insulin response (IRS1, p=0.008) and regulatory feedback
of insulin action (TCF7L2, p=0.001). Each of these genes is responsive
to either NF-AT or glucocorticoid, and therefore influenced by CNIs or
steroids.
Conclusions: NOPTDM genes can be defined as follows: (1) the gene is
important in glucose homeostasis, (2) there are alleles of the gene that confer a
risk of diabetes and (3) the gene is directly susceptible to the immunosuppressive
drugs used to treat the patient. Given the strength of association, for example
TCF7L2 has an Odds Ratio of 13.72 (95% CI 3.13-60.21), genetic information
on the recipient may dictate the selection and dose of immunosuppressive
agents for individual recipients.

607 LATE STEROID WITHDRAWAL AND CARDIOVASCULAR
EVENTS IN KIDNEY TRANSPLANT RECIPIENTS

E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, M. Cardi2,
G. Mogilishetty1, M. Clippard1,
1
University of Cincinnati, 2The Christ Hospital
Background: Cardiovascular (CV) risk reduction has been a primary reason for
pursuing early corticosteroid withdrawal (ECSWD) in renal transplant (RTx).
To date, actual cardiovascular event (CVE) data (rather than CV risk) has not
been reported for ECSWD. Therefore, we analyzed and compared actual CVE,
CV-related survival, and overall patient survival in ECSWD (≤7 days) versus
chronic corticosteroid (CCS) therapy.
Methods: CVE and heart failure (HF) data were prospectively collected.
CVE were defined as sudden death, myocardial infarction, angina, and
cerebrovascular accident/transient ischemic attack. HF events were defined
as pulmonary edema or clinical HF diagnosis. Statistical analyses included
Student’s t-test, Cox Proportional-hazards Regression, and Kaplan Meier (KM)
survival estimates and time to CVE.
Results: Data on 693 RTx pts (471 ECSWD and 222 CCS pts) were analyzed.
Demographic data and results are presented in Table 1. Mean follow-up in all
pts was 1420 ± 958 days. No difference was observed in HF events between
groups (5.7% ECSWD v 6.8% in CCS group, p<0.57). CCS pts experienced
more CVE (27.5% v 13.4% in ECSWD), despite a higher proportion of preexisting cardiovascular disease (CVD) in ECSWD pts (15% v 7% in CCS).
CVE-free survival was numerically greater in ECSWD pts and approached
significance on KM analysis (Figure) (p<0.08). A trend toward better pt
survival by KM was observed for ECSWD (p<0.11).
Demographics and Results
group
CS Group (n=222) CSWD
(n=471)

p

Male

49%

60%

0.007

African American

27%

21%

0.08

Mean Age (yrs)

46.4 ± 12

48.7 ± 12.9

0.03

Pretxp FRS

7.8 ± 6.7

8.2 ± 7.4

0.49

Pretxp CVD

7%

15%

0.003

Pretxp DM

26%

31%

0.14

% pts w/ CVE

27.5%

13.4%

<0.0001

Mean #CVE/pt

1.6 ± 1

1.3 ± 0.6

<0.0001
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M. Arnol1, A.M. de Mattos2, J.S. Chung3, J.C. Prather3, A. Mittalhenkle3,
D.J. Norman3
1
Department of Nephrology, University Medical Center Ljubljana, Ljubljana,
Slovenia, 2Transplant Medicine, University of California, Davis, Davis,
California, USA, 3Transplant Medicine, Renal Transplant Program, Oregon
Health & Science University, Portland, Oregon, USA
Introduction: Cardiovascular events (CVE) are the leading cause of morbidity
and mortality in kidney transplant recipients. The adverse effects of long-term
therapy with steroids on cardiovascular risk factors have motivated increasing
interest in steroid withdrawal (SW). The objective of this study was to compare
the incidences of CVE (fatal and non-fatal cardiac and cerebrovascular events)
and all-cause mortality between patients who had undergone SW at 1 year posttransplant and control patients who continued on steroids.
Methods: The study cohort included 400 consecutive adult recipients of a kidney
transplant between January 1, 1993 and December 31, 1998 who qualified for
SW at 1 year after transplantation. Candidates for SW included those with no
more than 2 previous acute rejections, a stable serum creatinine of less than
2.0 mg/dl, and ability to tolerate full doses of azathioprine or mycophenolate
mofetil, and to maintain adequate levels of cyclosporine or tacrolimus. At 1 year
post-transplant 188 patients subsequently underwent SW, while 212 patients
continued on steroids. Cox proportional-hazards analysis was used to estimate
cardiac events (new-onset angina pectoris, acute myocardial infarct, coronary
angioplasty or by-pass surgery, or cardiac death), cerebrovascular events
(transient ischemic attack, cerebrovascular accident, carotid endarterectomy,
or death from a cerebrovascular event) and all-cause mortality hazard ratios
(HR) for patients who had undergone SW versus controls who continued on
steroids beyond 1 year.
Results: The average duration of follow-up was 61 months for the entire
cohort, with average follow-up of 63 months for SW group and 59 months
for control patients. There were 44 (11%) cardiac events, 18 (4.5%)
cerebrovascular events, and 41 deaths (10.3%). The composite outcome of
CVE and all-cause mortality was reached in 26 (13.8%) subjects who had
undergone SW and 50 (23.6%) controls (P = 0.013). In adjusted analyses,
SW was associated with decreased risk for the composite outcome (HR
0.46, 95% confidence interval [CI] 0.28-0.76, P = 0.003), cardiac events
(HR 0.48, 95% CI 0.28-0.84, P = 0.009), and all-cause mortality (HR 0.27,
95% CI 0.12-0.59, P = 0.001). There was no association of SW with the risk
for cerebrovascular events (HR 1.76, 95% CI 0.45-7.01, P = 0.42). Steroid
continuation was associated with increased body mass index, increased
frequency of newly-diagnosed hypertension, and higher cumulative rate of
new-onset diabetes mellitus when compared with SW (+0.50 ± 0.17 kg/m2
vs. -0.11 ± 0.18 kg/m2, 37.8% vs. 25.3%, and 8.0% vs. 1.1%, respectively;
P < 0.05).
Conclusion: In this retrospective analysis, SW at 1 year post-transplant was
associated with decreased risk for future CVE and all-cause mortality. Late
SW had a positive influence on some of the risk factors associated with
cardiovascular disease, specifically new-onset diabetes mellitus.

608 CARDIOVASCULAR EVENTS AND MORTALITY
IN RENAL TRANSPLANT RECIPIENTS: EARLY
CORTICOSTEROID CESSATION REGIMENS VERSUS
CHRONIC CORTICOSTEROID THERAPY

p < 0.08

Conclusions: RTx recipients receiving ECSWD experienced: 1) fewer CVE
and 2) a trend toward overall better pt survival. These differences in CVE and
pt survival do not present until at least 3 yrs PTx; therefore, require long term
follow-up to become evident.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

213

Wednesday 13 August 2008

Oral Abstracts

609 USE OF CARDIOPROTECTIVE MEDICATIONS IN
KIDNEY TRANSPLANT RECIPIENTS: PRELIMINARY
OBSERVATIONS FROM THE DETERIORATION OF KIDNEY
ALLOGRAFT FUNCTION (DEKAF) STUDY
B. Kasiske1,10, R. Gaston2, M. Cecka3, F. Cosio4, J. Grande4, F. Gourishankar5,
P. Halloran5, L. Hunsicker6, D. Rush7, A. Matas8
1
Hennepin County Medical Center, 2University of Alabama at Birmingham,
3
University of California at Los Angeles, 4The Mayo Clinic, 5University
of Alberta, 6University of Iowa, 7University of Manitoba, 8University of
Minnesota
Death with function causes half of late kidney transplant failure, and
cardiovascular disease (CVD) is the most common cause of death. Chronic
kidney disease is a CVD risk equivalent, justifying aggressive risk reduction
with blood pressure (BP) control, statins, aspirin, and liberal use of
angiotensin converting inhibitors (ACEI) and angiotensin receptor blockers
(ARB). DEKAF is an ongoing, prospective, multicenter, observational study
examining causes of kidney allograft failure at 7 transplant centers in the US
and Canada, with current enrollment of over 2000 subjects. We examined the
use of cardioprotective medications among patients transplanted after October
1, 2005 and completing at least 6 months follow-up, focusing on subgroups
with preexisting diabetes mellitus and/or CVD.
Medication use among patients with data from both 1 and 6 months
posttransplant.
Any BP medication
Beta blocker
Calcium blocker
ACEI or ARB
Statin
Aspirin

All (n=639)%
1 mo.
6 mo.
86
84
67
63
49
42
13
25
33
41
36
39

Diabetes (n=263)%
1 mo.
6 mo.
88
85
73
67
52
38
13
29
45
51
54
54

CVD1(n=205)%
1 mo.
6 mo.
91
88
80
74
46
39
12
28
52
57
60
58

Defined as coronary disease, peripheral vascular disease, MI, stroke, or heart failure

1
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Overall, 86% of all subjects were receiving antihypertensive therapy 30 days
after transplantation, and 84% were on drug therapy at 6 months. Similar usage
was noted among diabetics and patients with CVD, despite wide variability in
practice from center to center. The most commonly used BP medications were
beta-blockers, followed by calcium blockers, and both were used with the same
frequency at 1 and 6 months (Table). In contrast, the percentage of patients on
an ACEI or ARB doubled between 1 and 6 months, suggesting that physicians
may be reluctant to use these agents early after transplantation (a practice that
is not necessarily evidence-based); more than 70%, regardless of grouping, did
not receive ACEI/ARB therapy even at 6 months. Overall, fewer than half of
all patients were treated with aspirin, and only 60% with diabetes and/or CVD
received aspirin. Similarly, only half of patients with diabetes and/or CVD
received a statin at 1 and 6 months. These data indicate that current management
of kidney transplant recipients fails to utilize optimal CVD risk reduction
measures in a timely fashion, perhaps missing an opportunity to reduce longterm morbidity and mortality from CVD in this at-risk population.

610 NEW ONSET METABOLIC SYNDROME AFTER RENAL
TRANSPLANTATION: EFFECTS OF MAINTENANCE STEROID
THERAPY AND DIABETES
E.S. Woodle1, R.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1,
G. Mogilishetty1, S. Young1
1
Surgery, U of Cincinnati, 2Christ Hospital
Background: Corticosteroid therapy has been associated with several
metabolic effects that contribute to cardiovascular complications, osteoporosis
and increased post transplant (txp) infections complications. According to
NCEP ATP III guidelines, metabolic syndrome (MS) is a significant predictor
of cardiovascular events (CVE). The purpose of this study was to evaluate new
onset metabolic syndrome (NOMS) in renal txp patients (pts) receiving early
corticosteroid withdrawal (ECSWD) (≤ 7 days) versus chronic corticosteroid
therapy (CCS) and to identify risk factors associated with developing MS posttxp.
Methods: Prospective data collection on 682 renal transplant pts from 1997
to 2007 evaluating presence of MS at baseline, 6, 12, 24, 36, 48, and 60
months post-transplant. The NCEP ATP III criteria were used to define MS;
however, the WHO criteria of body mass index (BMI) > 30 kg/m2 was used
as an alternative to waist circumference. All patients evaluated were either on
CCS or ECSWD regimen. Analysis was completed on 3 separate groups: No
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pre-transplant diabetes (DM), pre-transplant DM type I, and pre-transplant DM
type II. All patients meeting the criteria for MS at baseline (pre-transplantation)
were excluded from the study. NOMS was defined as MS diagnosed at any time
point post transplantation.
Results: 365 patients (54%) without pre-transplant MS and were evaluated for
post-transplant NOMS. 79% were non-diabetics at time of transplant. Of these
non-diabetic patients 53% received CCS and 44% received ECSWD. Baseline
demographics between CCS and ECSWD were similar gender (more males in
ECSWD, p= 0.01). All characteristics that define MS were similar at baseline
between the two groups. Risk factors analyzed for NOMS in the univariate
and multivariate models included: Baseline BMI (stratified categorically:
<18.5, 18.5-24.99, ≥ 25-29.99, ≥ 30 kg/m2), TG, HDL, race, gender, age at
transplant, acute rejection (AR), chronic steroids, and diabetes mellitus (DM)
type. Significant factors (p<0.2) on univariate analysis for all patients included:
BMI (18.5 –24.9 kg/m2), ECSWD group, BMI (25.0-29.9 kg/m2), BMI > 30
kg/m2, and HDL. Of these variables, those that were significant in the final
multivariate model are listed below. Further analyses excluding diabetic
patients confirmed these results.
Rates of NOMS
DM Status
Non-diabetic pts
DM Type I pts
DM Type II pts
DM Type I and II pts

CCS (n)
53% (103)
43% (7)
69% (13)
60% (20)

ECSWD (n)
44% (186)
53% (19)
43% (37)
46% (56)

P-value
0.1
NS
0.1
NS

MVA for NOMS
Odds Ratio
0.9
2.3
4.6

Pre-txp HDL
Pre-txp BMI (25-29.9 kg/m2)
Pre-txp BMI (>30 kg/m2)

95% Confidence Interval
0.94-0.98
1.41-3.77
2.16-9.94

Conclusion: This analysis indicates that the primary risk factors for developing
NOMS are the degree of obesity and HDL pre-transplant. For each 1mg/dL
increase in pre-transplant HDL, there is a ten percent decrease in risk of post
transplant NOMS.

611 THE EFFECTS OF ROSUVASTATIN ON INSULIN
SENSITIVITY AND SECRETION IN NON-DIABETIC RENAL
TRANSPLANT RECIPIENTS
A. Sharif1,2, V. Ravindran2, R. Moore2, G. Dunseath3, S. Luzio3, D. Owens3,
K. Baboolal2
1
Russells Hall Hospital, Dudley, 2University Hospital of Wales, Cardiff,
3
Diabetes Research Unit, Llandough
Background: Previous studies by this group have examined the impact of
interventions to prevent the onset of new onset diabetes after transplantation
(NODAT). More recently statins have been demonstrated to have pleiotropic
effects beyond lipid-lowering. It is hypothesised that statins may delay the
onset of NODAT by improving insulin sensitivity and reducing the decline in
insulin secretion. The aim of this study was to analyse the effect of rosuvastatin
on insulin sensitivity and secretion in non-diabetic renal transplant recipients.
Methods: 20 non-diabetic renal transplant recipients were randomised to either
rosuvastatin 10mg or placebo daily for 12 weeks in a randomised, double-blind,
crossover study. Insulin sensitivity, first and second phase insulin secretion
was assessed at the end of each 12-week treatment period with a frequently
sampled, intravenous glucose tolerance test and meal tolerance test. After a
4-week washout, patients crossed over to the alternative therapy for a further
12 weeks and the investigations were repeated.
Results: Rosuvastatin was a safe and effective lipid-lowering agent, lowering
total cholesterol by 31% (p<0.001), LDL cholesterol by 48% (p<0.001)
and triglycerides by 19% (p=0.018) when compared to placebo. It also had
a significant anti-inflammatory effect, lowering C-reactive protein by 43%
(p=0.042). However no significant difference was observed in insulin sensitivity
or secretion (Table 1).
Table 1. Change in insulin sensitivity and secretion: placebo vs rosuvastatin
(mean ± standard error of the mean)
First-phase insulin secretion
(pmol/l.min)
Second-phase insulin secretion
(pmol/l.min)
Insulin sensitivity
(10-5min-1/ U/ml)

Placebo

Rosuvastatin

p value

2693 ± 365

2785 ± 455

0.875

67082 ± 8937

67393 ± 11748

0.983

4.8 ± 0.5

4.4 ± 0.6

0.580
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Conclusion: Short-term rosuvastatin was not associated with an improvement
in insulin sensitivity or secretion, despite significant lipid-lowering and antiinflammatory effects. Whether statins can attenuate the development of NODAT
in the long-term is questionable and not addressed by this study. This study
demonstrated no benefit of short-term statin therapy on glucose metabolism
post-transplantation and we should be cautious in advocating the pleiotropic
effects of statins post-transplantation in the absence of clinical evidence.

CONCURRENT ORAL SESSION 42: LIVER MALIGNANCY
612 DECREASING DISPARITY IN LIVER
TRANSPLANTATION AMONG WHITE AND ASIAN PATIENTS
WITH HEPATOCELLULAR CARCINOMA, CALIFORNIA,
1998-;2005
M. Daily1, A. Robbins2, C. Aoki3, M. Chen3, C. Troppmann1, J. McVicar1,
R. Perez1
1
University of California, Davis Medical Center, Department of Surgery,
2
California Cancer Registry, Public Health Institute, 3University of
California, Davis Medical Center, Department of Internal Medicine
Context: A preliminary study using national cancer surveillance data from
1998-;2002 suggested there were significant differences between non-Hispanic
whites (¡°whites¡±) and Asian/Pacific Islanders (APIs) in the use of liver
transplantation as a treatment for hepatocellular carcinoma (HCC).
Objective: To examine whether differences in liver transplantation between
white and API HCC patients were changing over time.
Design, setting, and participants: Population-based statewide cancer registry.
We obtained data on all HCC cases diagnosed in California between 1998 and
2005, but limited the study to white and API patients with non-metastatic HCC,
sized ¡Ü 5.0 cm (n = 1728).
Main outcome measures: Racial differences in odds of transplantation and
stage at diagnosis, as well as changes in these differences between 1998-;2003
and 2004-;2005.
Results: During 1998-;2003 (n = 1051), the odds of receiving a liver transplant
were 2.56 times higher for white patients than for API patients (95% confidence
interval [CI], 1.72 to 3.80 times higher), even after adjusting for age, sex,
marital status, year of diagnosis, TNM stage, and tumor grade. In contrast,
during 2004-;2005 (n = 677), there were no significant differences in the odds
of receiving a transplant (odds ratio for white vs API, 1.23; 95% CI, 0.77-;1.96).
The disappearance of a significant disparity coincided with changes in liver
transplantation policy between 2002 and 2004 that assigned priority points to
HCC patients (initially to stage I and II, then to stage II only). After the policy
changes, API HCC patients experienced a significant 17% relative increase in
stage II diagnoses, while white patients experienced no significant increase.
Conclusions: In California, there was a large and significant disparity in liver
transplantation among white and API patients with HCC during 1998-;2003,
but not during 2004-;2005. Changes in liver transplantation policy between
2002 and 2004 may have played a role in decreasing this difference.

D. Steffick1,2, R Freeman3, M Guidinger1,2, R Wolfe1,2, R Merion3,4
Arbor Research, 2SRTR, 3Tufts-New England Medical Center, and 4University
of Michigan
Introduction: Previous liver transplant survival analyses comparing the
efficacy of pre-transplant trans-arterial chemoembolization (TACE) with
radiofrequency ablation (RFA) have been subject to selection bias due to the
tendency to use RFA for single or smaller lesions. In order to reduce this source
of bias, the aim of this study was to examine the effect of TACE or RFA in HCC
candidates with single tumors only.
Methods: All US deceased donor liver transplant recipients between 5/1/2003
and 12/31/2005 with allocation exceptions for a single HCC lesion who
received either RFA or TACE exclusively as pre-transplant ablation therapy
were analyzed, with follow-up through 11/1/2007. Post-transplant survival was
estimated using Cox models, adjusted for recipient (age, gender, race, diagnosis;
creatinine, bilirubin, INR, and albumin at transplant; portal vein thrombosis,
1

614 ABLATION OF HEPATOCELLULAR CARCINOMA AS
A BRIDGE TO LIVER TRANSPLANT PROLONGS WAIT LIST
ELIGIBILITY
L. Lilly, D. Dubay, J. Kachura, G. Therapondos, D. Grant, P. Greig
University Health Network
Background: Ablation as a bridge to transplant in patients with hepatocellular
carcinoma (HCC) is widely utilized without significant data to support the
clinical efficacy. The purpose of this study is to measure the effect of ablation on
time to drop-off and overall survival in HCC patients listed for liver transplant.
Methods: Patients were stratified into ablation and no treatment groups based
upon interventions made while on the wait list. The ablation interventions
included both radiofrequency ablation (RFA) and percutaneous ethanol
injection (PEI). Patients with incidental tumors and those treated with TACE
were excluded. Cox proportional hazard regression analysis was performed to
assess time to drop-off probability.
Results: Between 1999 and 2006, 282 HCC patients were listed for
transplantation. There were 137 patients in the ablation group (117 RFA, 5 PEI
only, 15 both) and 145 patients in the no treatment group. The ablation group had
a lower MELD score (11 vs 13, p=0.005) and lower UNOS stage (2.4 ± 0.9 vs.
2.1 ± 0.8, p=0.03) but remained on the wait list twice as long as the no treatment
group (7.4 vs. 3.7 months, p<0.001). Ablation procedures were performed
with minimal morbidity. The overall drop-off rates were equivalent (23% vs.
24%, p=ns). Adjusting for UNOS stage, age and gender, the time to drop-off
analysis demonstrated an advantage for patients treated with ablation (p=0.05),
especially those listed longer than 6 months. The actuarial 12-month wait list
eligibility was 78% in the ablation group compared to 55% in the no treatment
group. There were no significant differences in the overall survival from the
time of listing or the post transplant survival in only those transplanted.
Conclusions: Ablation as a bridge to transplant is safe and significantly
prolongs wait list eligibility, especially in patients listed for longer than 6
months. Ablation does not impact overall survival or post transplant survival.
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613 DOES THE TYPE OF PRE-TRANSPLANT
ABLATIVE THERAPY AFFECT SURVIVAL AFTER
LIVER TRANSPLANTATION FOR PATIENTS WITH
HEPATOCELLULAR CARCINOMA (HCC)?

prior abdominal surgery, medical condition at transplant, life support), donor
(age, gender, race, cause of death, height, donation after cardiac death), and
transplant (partial liver, cold ischemia time, local or shared transplant) factors,
and level of RFA vs. TACE usage at the transplant center.
Results: 707 recipients (19% of HCC exceptions) had one lesion and RFA
or TACE ablation therapy (58% of all HCC recipients who had ablation
therapy). There was no difference in post-transplant survival for recipients
in centers that used only RFA, centers that used only TACE, and centers that
used both (100% RFA vs. 100% TACE [reference]: hazard ratio [HR]= 1.38,
p=0.36; combination of RFA and TACE vs. 100% TACE [reference]: HR=1.10,
p=0.77). Power analyses showed that this sample size had 95% power to detect
at least a 38% higher mortality than TACE and 80% power to detect at least
a 29% higher mortality than TACE. In a patient-level analysis (using actual
receipt of RFA and TACE rather than the center’s practice pattern), the HR for
RFA vs. TACE [reference] was 1.14 (p=0.52). A sample size of 2,292 would
be needed to detect a 15% difference in mortality risk between groups with
power of 80%.
Conclusions: In this national sample, powered to detect a relative mortality
difference between groups (i.e., hazard ratio) of 1.29 or larger, there was no
significant difference in the risk of post-transplant death within three years between
HCC recipients with one lesion who received ablation at centers that used RFA vs.
centers that used TACE. Further analyses of the effect of pre-transplant ablation
therapy on post-transplant outcome in patients with HCC is warranted.
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615 LIVING DONOR LIVER TRANSPLANTATION FOR
PATIENTS WITH HEPATOCELLULAR CARCINOMA
– EEFFECTS OF PRE-TRANSPLANT TREATMENTS
Y. Takada, T. Kaido, H. Egawa, S. Uemoto
Kyoto University
Purpose: In Japan, where deceased donor liver grafts are rarely available,
the role of living donor liver transplantation (LDLT) in the management for
hepatocellular carcinoma (HCC) has significantly evolved. However, given the
risks to the live donor, LDLT is indicated only for patients with HCC considered
unsuitable for resection or ablation therapies. Most recipients had a history of
non-transplant treatments, which were performed not as a bridge to transplant
or for downstaging but with intent for curative ablation. When they suffered
from uncontrolled recurrent HCC, they were referred for LDLT as a secondline treatment. In this study, effects of pre-transplant treatments on transplant
outcome were evaluated.
Patients and methods: Between February 1999 and August 2007, 144 patients
with HCC underwent LDLT. Of them, 105 patients (73%) displayed a history of
previous treatment for HCC using various non-transplant methods, including hepatic
resection, TACE, and RFA or ethanol injection (recurrent group). For the remaining
39 patients (27%) who had no history of pre-transplant treatment (primary group),
conventional treatment was not indicated because of advanced liver dysfunction in
most cases. The median follow-up period after LDLT was 32 months.
Results: 1) Overall patient survival rate at 5 years was 69%. Based on preLDLT imaging studies, 79 patients met Milan criteria (MC) and 65 did not.
Cumulative recurrence rates at 5 years were significantly higher for over-MC
than for within-MC group (32% vs. 8%, p<0.001). 2) The survival rates for
recurrent and primary groups were 69% and 69%, respectively (p=0.919). 3)
Of 105 patients in recurrent group, records of tumor stage at first diagnosis of
HCC were available for 92 patients. While 70 patients met MC, 22 patients
did not. Median period between first diagnosis of HCC and LDLT was 22
months (range, 2-168 months) in these 92 patients. At the time of LDLT, tumor
stage was up-staged in 30 patients (Group 1), down-staged in 6 (Group 2), and
unchanged in 54: 40 patients (Group 3) remained within MC and 16 (Group 4)
over MC. In the primary group, 26 patients met MC (Group 5) and 13 exceeded
MC (Group 6). The recurrence rates at 5 years were 29%, 25%, 3%, 36%, 0%,
and 34% in groups 1 to 6, respectively. Among 6 patients who were downstaged (Group 2), 5 patients are alive without recurrence at the median followup of 45 months (range, 28-85 months).
Conclusion: The survival rates were similar for recurrent and primary groups.
The recurrence rates after LDLT appeared to be associated with tumor stage
immediately before LDLT, irrespective of history of pre-transplant treatments.
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616 ELEVATED PREOPERATIVE NEUTROPHIL TO
LYMPHOCYTE RATIO PREDICTS OUTCOME IN PATIENTS
WITH HCC AFTER LIVER TRANSPLANTATION
K.J. Halazun, M.A. Hardy, A. Rana, D. Woodland, P. Witkowski, A. Seigal,
J. Emond
Columbia University - New York Presbyterian Hospital
Background: Orthotopic liver transplantation (OLT) has become the main
treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) as
it not only provides a cure for the cirrhosis, but also provides total neoplastic
clearance of the HCC. Although the initial results with OLT for HCC were
poor the emergence of the Milan has greatly improved prediction of successful
outcomes. The Milan Criteria, rely solely on the radiographic appearance of the
tumor, i.e size and number of lesions, but provide no measure of tumor biology.
Therefore, despite the adoption of Milan Criteria by UNOS, the recurrence rate
remains 20-30% in patients who fit these criteria. The neutrophil-lymphocyte
ratio (NLR) is an indicator of inflammatory status that has been previously
used as a prognostic indicator in primary colorectal malignancy and colorectal
liver metastases. The aim of this study was to establish whether NLR is able to
predict outcome in patients undergoing OLT for HCC.
Design: Retrospective analysis of the white cell and differential counts of 150
patients undergoing OLT for HCC between January 2001 and January 2007
at our institution. A NLR > 5 was considered to be elevated. Patients with
preoperative sepsis and missing blood results were excluded from the study.
Results: 118 males and 32 females were included with an overall recurrence
rate of 18% and 5 year survival of 60%. 13 patients (9%) had an elevated
NLR. Of the patients with raised NLR 62% developed recurrence compared
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to 14% of patients with normal NLR. The 5 year disease free survival for
patients undergoing OLT with high NLR was significantly worse than that
for patients with normal NLR (35% vs 75%, p<0.0001). Patients with high
NLR were also found to have poorer overall survival compared to patients
with normal (5year survival 31% vs 63%, p=0.006). Univariate analysis of
factors affecting recurrence revealed raised NLR, tumor grade, presence of
vascular invasion on explant pathology and a diagnosis other than hepatitis
B or C affected disease free survival. However, only a raised NLR remained
significant on multivariate analysis (HR=6.289, CI=1.703-22.226, p=0.006).
Patients categorised according to the Milan criteria with elevated NLR had
significantly poorer disease free survival that those with normal NLR who were
both inside and outside Milan (5 year survival 35% vs 87% vs 64%, p<0.0001
and p=0.03 respectively). Patients outside Milan who had high NLR fared
worst of all with a median disease free survival of <1 year.
Conclusion: Elevated NLR in patients who undergo OLT for HCC appears
to be a significant marker of increased risk for both tumor recurrence and
recipient death. Patients with high preoperative NLR who fit the Milan criteria
have much worse outcomes than those who have normal preoperative NLR and
who are within Milan Criteria. Preoperative NLR measurement may therefore
provide a simple method of identifying patients with a poorer prognosis and
may act as an adjunct to the Milan criteria in helping determine which patients
with HCC would benefit most from OLT.

617 THE IMPACT OF MELD ON PATIENT SURVIVAL AND
DISEASE FREE SURVIVAL IN PATIENTS RECEIVING LIVER
TRANSPLANT FOR HEPATOCELLULAR CARCINOMA
D. Moonka1, E. Castillo1, S. Kumer2, M. Abouljoud1, G. Divine1, S. Pelletier2
Henry Ford Health Systems, 2University of Michigan Medical Center
We combined data from two liver transplant centers to determine the impact of
the Model for End-stage Liver Disease (MELD) allocation system on survival
and disease free survival in patients listed for liver transplantation (OLT) for
hepatocellular carcinoma (HCC).
Methods: We evaluated a total of 172 patients listed for OLT for HCC. We
excluded patients who received live donation. 54 patients were listed in the
pre-MELD era and 117 in the MELD era. Patients were compared for standard
demographics and tumor characteristics. On an intention to treat (ITT) basis,
patients were compared for likelihood of transplant, therapy while on the list
(embolization or radio-frequency ablation (RFA)), time to transplant, patient
survival and tumor free survival. Survival comparisons were done with KaplanMeier analysis with log rank tests.
Results: There were no differences between the pre-Meld and MELD groups
in terms of age, incidence of hepatitis C, calculated MELD and the percent
of patients who met Milan criteria at time of listing (78% and 76%). 37 of 55
patients listed in the pre-MELD era received a transplant (67%) vs 106 of 117
patients (91%) in the MELD era (p < 0.001). 69% of pre-MELD patients and
51% of MELD patients received embolization or RFA (p=0.038). Patients who
did receive a transplant in the pre-MELD era waited a median of 258 days
vs 26 for those in the MELD era (p < 0.001). On an ITT basis, the 1, 3 and 5
year survival for patients in the pre-MELD era was 79%, 60% and 48% and
in the MELD era was 84%, 73% and 73% (p=0.055). On an ITT basis, the
1, 3 and 5 year tumor free survival in the pre-MELD era was 58%, 58% and
55% and in the MELD era was 83%, 74% and 70% (p=0.018). In patients who
received a transplant, there were no differences in overall survival or tumor
free survival. In patients who received OLT, the 1, 3 and 5 year survival was
92%, 84% and 67% in the pre-MELD era and 90%, 81% and 81% in the MELD
era (p=0.57). On explant, there was no difference between the pre-MELD and
MELD patients in total tumor burden (4.5 ± 2.8 cm vs 3.9 ± 2.5 cm) or the
likelihood of meeting Milan criteria (58% vs 67%). However, patients in the
pre-MELD era had more differentiated tumors (p=0.046).
Conclusions: The implementation of the MELD allocation system with its
exception for HCC did result in higher and more rapid rates of transplantation
with a nearly significant increase in overall survival (p=0.055) and a significant
increase in tumor free survival (p=0.018). However, despite the markedly
longer wait period for patients in the pre-MELD era, those who did receive
transplants had similar survival and recurrence free survival to patients in the
MELD era who received transplant. Patients in the pre-MELD era had more
differentiated tumors (p=0.046). These data support the hypothesis that the
longer wait periods of the pre-MELD era led to a drop-out of patients with
aggressive malignancy.
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618 MELD PRIORITIZATION FOR PATIENTS
WITH CIRRHOSIS AND SMALL UNRESECTABLE
HEPATOCELLULAR CARCINOMA HAS A MORE POSITIVE
IMPACT IN WAITING TIME AND POST TRANSPLANT
RECURRENCE FREE SURVIVAL THAN LIVING DONOR
LIVER TRANSPLANTATION
A.G. Villamil, O.A. Galdame, J.C. Bandi, P.C. Casciato, M. Reig,
V. Ardiles, E. de Santibañes, A.C. Gadano
Liver Transplantation Unit, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina
Introduction: A selected group of patients with cirrhosis and small
hepatocellular carcinoma (HCC) can be cured by liver transplantation. Yet,
organ shortage and long waiting time may preclude transplantation due to
disease progression.
Aim: To evaluate the impact of living donor liver transplantation (LDLT)
and MELD prioritization on pre and post LTx outcome of patients listed for
cirrhosis and HCC.
Patients and methods: 55 consecutive patients with small unresectable HCC
fulfilling the Milan Criteria (single nodule <5 cms or up to 3 nodules <3cms
without vascular invasion) and a normal chest CT and bone scan were listed
for LTx between Jan 2001 and Sept 2006. Outcome was analyzed in 2 different
time periods: Jan 2001-June 2005 (Group A, all patients were offered the
possibility of LDLT) and July 2005-Sept 2006 (Group B, all patients were given
a MELD score of 22 and an additional point every 3 months in the waiting list).
No differences in ethiology and severity of cirrhosis were observed between
groups. Results were also analyzed within Group A between patients with or
without an available living donor.
Results: In Group A only 7:32 patients had an adequate living donor and
received a LDLT. Median waiting time was significantly longer in Group A
compared with Group B (24.3 ± 10.3 vs 2.8 ± 1.6 months, p< 0.05). Within
Group A waiting time was significantly different between patients with an
adequate living donor compared with those without a living donor (6.8 ± 2.1 vs
27.8 ± 13.7 months, p<0.05). Recurrence free survival was lower for patients in
Group A compared to Group B (19/32 (59.3%) vs 19/23 (82.6%), p<0.05).
Results
Group
A (n=32)
A with LD
(n=7)
A without LD
(n=25)
B (n=35)

24.3±10.3

Died waiting
or "drop out"
from list
11/32 (34.3%)

6.8±2.1

0/7 (0%)

7/7

27.8±13.7

11/25 (44%)

2.8±1.6

2/23 (8.6%)

Waiting time
(months)

LDLT
7/32

Recurrence-free
Recurrence-free
survival from
survival from Tx
inclusion
19/32 (59.3%)
19/21(90.5%)
6/7 (85.7%)

6/7 (85.7%)

-

12/25 (48%)

12/14 (85.7%)

-

19/23 (82.6%)

1/12 (91.6%)

Conclusions: LDLT is a good alternative for patients with small HCC and an
adequate living donor, but low applicability results in a small impact in overall
recurrence free survival. MELD prioritization has a high efficacy, resulting in
short waiting time and high survival rates.

D. Moonka1, E. Castillo1, S. Pelletier2, S. Kumer2, M. Abouljoud1, G. Divine1
Henry Ford Health Systems, 2University of Michigan Medical Center
Hepatocellular carcinomas (HCC) detected in the explant after orthotopic
liver transplantation (OLT) are not infrequent. We reviewed our experience to
determine the tumor characteristics and patient outcomes of incidental HCC
and to determine if their incidence is declining.
Methods: We combined data from two liver transplant centers. A total of
970 patients who were not known to have HCC received a liver transplant.
51 patients were found to have an incidental HCC and these patients were
compared to 144 patients transplanted for known (nonincidental) HCC. Patients
were compared for preoperative characteristics, type of screening modality,
pathologic findings, survival and recurrence free survival. We also compared
the difference in frequency of incidental HCC in the pre-MELD (Model for
End-stage Liver Disease) and MELD eras.
Results: There was no difference in age and frequency of Hepatitis C infection
in patients with incidental vs nonincidental HCC. Patients with incidental HCC
were more likely to be African-American than patients with nonincidental HCC
1

620 THE PLACE OF LIVER TRANSPLANTATION
IN THE TREATMENT OF HEPATIC EPITHELOID
HAEMANGIOENDOTHELIOMA : REPORT OF THE
EUROPEAN LIVER TRANSPLANT REGISTRY (ELTR)
J. Lerut1, G. Orlando1, R. Adam2, V. Mazzaferro3, J. Klempnauer4, D. Mirza5,
E. Boleslawski6, A. Burroughs7, C. Fernandez Selles8, D. Jaeck9
1
St-Luc University Hospital, 2CHB Paul Brousse, 3Istituto Nazionale Tumori,
4
MHH Hannover, 5Q.E. Hospital, 6Hôpital Pitié Salpétrière, 7Royal Free
Hospital, 8Hospital Juan Canalejo, 9Hôpital Hautepierre
Background: Hepatic epitheloid haemangioendothelioma (HEHE) is a rare
low-grade vascular tumour. Its treatment algorithm is still unclear mainly due
to a lack of larger clinical experiences with detailed long-term follow-up .
Material and methods: 59 patients, reported to ELTR, were analyzed in order
to define the role of liver transplantation (LT) in the treatment of this disease.
Eleven (19%) patients were asymptomatic. Eighteen (30.5%) patients had
pre-LT surgical [hepatic (7 pts) and extra-hepatic (3 pts)] and/or systemic or
locoregional (10 pat) medical therapy. Ten (16.9%) patients had extra-hepatic
disease localization before or at moment of LT. Follow-up was complete for all
patients with a median of 92.5 (range 7-369) from moment of diagnosis and a
median of 78.5 (range 1-245) from moment of LT.
Results: The HEHE was bi-lobar in 96% of patients; 86% of patients had
more than 15 nodules in the liver specimen. Early (< 3 mo) and late (>3 mo)
post-LT mortality was 1.7% (1pat) and 22% (14 pat). Fourteen(23.7%) patients
developed disease recurrence after a median time of 49 mo (range 6-98).
Nine (15.3%) patients died of recurrent disease and five are surviving with
recurrent disease. One, 5 and 10 year patient survival rates from moment of
transplantation for the whole series are 93;83,72%. Pre-LT tumor treatment (n
= 18) (89;89 and 68% one, 5 and 10 year survival rates from moment of LT vs.
95;80 and 73% in case of absence of pre-LT treatment),lymph node invasion (n
= 18) (96;81 and 71% one, 5 and 10 year survival rates vs. 83;78 and 67% in
node negative patients) and extra-hepatic disease localization (n = 10) (90;80
and 80% one, 5 and 10 year survival rates vs. 94,83 and 70% in case of absence
of extra-hepatic disease) did not significantly influence patient survival whereas
microvascular (n = 24) (96;75,52% one, 5 and 10 year survival vs. 96;92,85%
in case of absence of microvascular invasion) and combined micro- and macrovascular invasion (n = 28) (90;72 and 54% one,5 and 10 year survival vs. 96;92
and 85% in case of absence of vascular invasion – p 0.03) did. Disease free
survival rates at one, 5 and 10 years post LT are 90;82 and 64%.The disease
free survival is not significantly influenced by pre-LT treatment, lymph node
status, extra-hepatic disease localization and vascular invasion.
Conclusion: The results of the largest reported transplant series in the treatment
of HEHE are excellent. Pre-existing extra-hepatic disease localisation as well
as lymph node involvement are not contraindications to LT. Microvascular or
combined macro-microvascular invasion significantly influence survival after
LT. LT therefore should be offered as a valid therapy earlier in the disease
course of these, frequently young, patients. Recurrent (allograft) disease should
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619 INCIDENTAL HEPATOCELLULAR CARCINOMA
AFTER LIVER TRANSPLANTATION: POPULATION
CHARACTERISTICS AND OUTCOMES

(22% vs 11%: p=0.014), they were more likely to be screened by ultrasound
(38% vs 8%: p<0.001) and they had a lower alpha-fetoprotein (258.1 ± 83.9
ng/ml vs 2157.8 ± 484.2 ng/ml: p=0.004). The liver explant of patients with
incidental HCC had smaller total tumor burden than nonincidental HCC (3.1 ±
3.5 vs 4.1 ± 2.6: p<0.001). Liver explant of patients with incidental HCC were
similar to nonincidental HCC in percentage of single lesions (66% vs 64%),
percentage that met Milan criteria (76% vs 64%), vascular invasion (8% vs
10%) and degree of histologic differentiation. Patients with incidental HCC
had 1 and 3 year survival of 78% and 67% and 1and 3 year recurrence free
survival of 90% and 87%. These were comparable to the 1 and 3 year survival
of 90% and 82% and the 1 and 3 year tumor free survival (91% and 84%) in
patients with nonincidental HCC. There were no differences in the number of
patients with incidental HCC transplanted in the pre-MELD and the MELD era
(5.34% vs 5.16%).
Conclusions: Patients with incidental HCC were more likely to be AfricanAmerican, to be screened by ultrasound and to have a lower AFP. Ultrasound
does not appear to be an appropriate modality of screening patients for HCC
while awaiting OLT. Incidental tumors differed from nonincidental tumors
only in total tumor diameter. Patients that are found to have an incidental
HCC have similar survival and recurrence free survival than those with
nonincidental HCC. The incidence of incidental HCC does not appear to be
declining in our experience.
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be treated aggressively as good long-term survivals can be obtained. Long-term
prospective follow-up multi-centre studies as well as the evaluation of antiangiogenic drugs are necessary in order to further optimize the treatment of this
rare vascular hepatic disorder.

Demographics and immunologic risk were similar between groups; however,
AA patients received significantly more deceased donor transplants (65%
versus 33%, p<0.0001).
Mean length f/u (days)

CONCURRENT ORAL SESSION 43:
RENAL LONG-TERM IMMUNOSUPPRESSION

Repeat txp
Deceased Donor

WEDNESDAY

2

3

4

Bela Rate/100 pt-yr (95% CI)

CsA Rate/100 pt-yr(95% CI)

Infections

4.0 (2.3-6.5)

7.1 (2.8- 14.6)

Neoplasms

3.0 (1.5-5.2)

3.0 (0.6-8.9)

Cardiovascular

0.5 (0.1-1.8)

3.0 (0.6-8.9)

Treated AR

3.0 (1.5-5.4)

3.2 (0.7-9.3)

Death or Graft Loss

1.0 (0.3-2.6)

2.0 (0.2-7.3)

622 AFRICAN-AMERICAN KIDNEY TRANSPLANT
RECIPIENTS UNDERGOING EARLY CORTICOSTEROID
WITHDRAWAL LONG TERM (5 YEAR) RESULTS SIMILAR TO
NON-AFRICAN AMERICANS
A.H. Rike1, R.R. Alloway1, R-A. Lee1, G. Mogilishetty1, P. Roy-Chaudhury1,
M.A. Cardi2, R. Munda1, J. Everly1, A. Tevar1, E.S. Woodle1
1
University of Cincinnati, 2The Christ Hospital
Background: African Americans (AA) have traditionally been considered
a high risk group for early corticosteroid withdrawal (ECSWD) after renal
transplantation. Our group and others have previously reported that short term
results (acute rejection, CV benefits, and survival) in AA were similar to nonAA. Long term (5 year) results have not been previously reported. The purpose
of this study was to examine the results of ECSWD regimens in a large group
of AA recipients compared to non-AA recipients with long-term follow-up.
Methods: Outcomes in 102 AAs were compared to 102 non-AAs who were
matched for age, gender, date of transplant, maintenance immunosuppression,
and induction. Patients were prospectively enrolled in one of several IRB
approved ECSWD trials (ie CSWD within 7 days posttransplant). Acute
rejection (AR) episodes were biopsy proven by Banff 97 criteria. Statistics
included chi square and Student’s t test.
Results: Results are reported as AA versus non-AA in table below.

218

p value
NS

14.7%

10.8%

NS

33%

<0.0001

11.8%

NS

83%

85.3%

NS

0.4 ± 0.6

0.3 ± 0.5

NS

Mean ∆ MDRD 6mth to 2yr (mL/min)

-4.1 ± 14.2

-1.8 ± 10.2

NS

Mean ∆ MDRD 6mth to 5yr (mL/min)

-14.2 ± 23.6

-9.4 ± 14.4

0.08

-14.5 ± 28.2

-22 ± 28.3

0.06

0.7 ± 1.6

-0.3 ± 1.6

NS

20.6 ± 50.2

-7.1 ± 59.7

0.0004
NS

Mean ∆ Scr 6mth to 5yr (ng/mL)
5

1328 ± 675

65%

Thymo Induction

F. Muelbacher , B. Charpentier , C. Larsen , M. Agarwal , F. Vincent
1
Univ. Klinik Für Chirurgie, General Hospital Vienna (AKH), 2Nephrologie,
Le Kremlin Bicetre Hospital, Le Kremlin Bicetre, France, 3Transplant
Surgery, Emory University, Atlanta, GA, 4Bristol-Myers Squibb Company,
Princeton, NJ., 5Transplant Svc, Univ Calif San Francisco, San Francisco, CA
Belatacept is a first-in-class T-cell co-stimulation blocker which inhibits
CD28 mediated T-cell activation and provides selective immunosuppression.
Belatacept is being evaluated in Phase 3 trials as CNI-free immunosuppression
in renal transplant. An interim report of an open-label long-term extension
(LTE) of the phase 2 trial is presented.
The Phase 2 trial design and results have been described previously. For the
LTE, Belatacept arms were dosed as either q4week or q8week maintenance
infusions of 5mg/kg; control patients received Cyclosporine (CsA), dosed to
target C0 levels (150-300 ng/ml). All patients continued to receive MMF and
steroids per protocol. Results for outcomes and serious adverse events (SAE)
are presented as incidence rates/100 patient-years of drug exposure. No formal
comparisons or statistical testing were applied.
128 of 218 original patients elected to participate in the LTE and remained on
their assigned treatment; 102 received Belatacept, 26 received CsA. Among
LTE patients enrolled, 92 (72%) patients remain (76/102, 75% Belatacept;
16/26, 62% CsA). Median follow-up from original randomization was 60
months (range 15 to 78 m). Results for SAE categories, acute rejection (AR),
and death/graft loss are shown (Table 1).
Through six years, belatacept continues to be safe with continued low rates
of acute rejection, death and graft loss as part of a long term- CNI-free
immunosuppression regimen in renal transplant. Phase III studies are ongoing.
Table 1. Efficacy Outcomes and SAE for Belatacept and CsA treated patients
for the period of LTE
1

Non-AA (n=102)

1234 ± 673

13.7%

DGF

621 LONG-TERM SAFETY OF BELATACEPT: 6 YEAR
RESULTS OF A PHASE II STUDY

AA (n=102)

Mean ∆ from pretxp to 5yrs
SBP (mmHg)
#BP meds
Total cholesterol (TC) (mg/dL)
Triglycerides (TG) (mg/dL)

5.8 ± 89

8.1 ± 108

4.4 ± 19.5

4.6 ± 10

NS

1 Yr Acute Rejection

18.6%

10.8%

NS

2 Yr Acute Rejection

21.6%

12.7%

0.09

5 Yr Acute Rejection

25.5%

13.7%

0.04

1 yr DC Graft Survival

98%

98%

NS

2 yr DC Graft Survival

93.1%

96.2%

NS

5 yr DC Graft Survival

91.2%

94.1%

NS

1 yr Patient Survival

97.1%

100%

0.08

2 yr Patient Survival

96.1%

98%

NS

5 yr Patient Survival

93.1%

96.1%

NS

CV Events (5 yr incidence)

15.7%

13.7%

NS

New Onset DM after Txp (NODAT)

14.7%

11.8%

NS

BK Nephropathy (5 yr incidence)

7.8%

5.9%

NS

Weight (kg)

Conclusions: This is the first reported experience with long term follow-up
following ECSWD in AA. Our findings demonstate that 5 year results in AA
renal transplant patients compared to non-AA are associated with 1) Similar
patient survival and death censored graft survival, 2) Similar serum creatinine;
however, MDRD estimates showed greater reduction at 5 years in AA patients,
3) Similar CVE, incidence of NODAT, TG, SBP (despite reduced medication
requirements in non-AA), and weight; however, TC was substantially increased
in AA. This study indicates that the long term risks and benefits of ECSWD are
similar between AAs and non-AAs.

623 CNI SPARING WITH MYCOPHENOLATE MOFETIL IN
DE NOVO RENAL TRANSPLANTATION: 3-YEAR RESULTS
FROM THE SYMPHONY STUDY
H. Ekberg1, H. Tedesco-Silva2, A. Demirbas3, S. Vitko4, J. Klempnauer5,
A. Gürkan6, R. Margreiter7, C. Hugo8, J. Grinyó9, U. Frei10,
Y. Vanrenterghem11, P. Daloze12, P. Halloran13
1
Lund University, 2Federal University Sao Paulo, 3Akdeniz University,
4
IKEM, 5Medizinische Hochschule Hannover, 6SSK Tepecik Hospital,
7
Universitätsklinik Innsbruck, 8FAU Erlangen-Nürnberg, 9Ciutat Universitaria
de Bellvitge, 10Virchow-Klinikum, 11KU Leuven, Leuven, Belgium, 12CHUM
Montréal, Montréal, Canada, 13University Alberta, Edmonton, Canada
Introduction: In the 1-year Symphony core study, a regimen with 2 g
mycophenolate mofetil (MMF) + low-dose tacrolimus (3-7 ng/ml) +
daclizumab + steroids resulted in significantly fewer acute rejections and better
glomerular filtration rate (GFR) compared with 2 g MMF + steroids and either
standard-dose cyclosporine (CsA; 150-300 mg/ml for 3 months, 100-200 ng/ml
thereafter), low-dose CsA (50-100 ng/ml) + daclizumab, or low-dose sirolimus
(4-8 ng/ml) + daclizumab.
Methods: 954 patients were included in the ITT population of an optional
additional 2-year follow-up. GFR data from 83% of patients included in the
follow-up (50% of the core ITT population) were available at 3 years.
Results: At inclusion into follow-up, 48%, 34% and 17% of patients received
standard- or low-dose CsA, tacrolimus or sirolimus, whereas about 25% had
been randomized to each regimen, indicating that follow-up patients had been
switched during the first year, particularly from sirolimus to tacrolimus. At 3
years, these values were 32%, 28% and 13%, respectively. At 3 years, 95% of
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the patients were still on MMF and 70% on steroids.
In the four arms, the mean GFR change over the 2nd and 3rd year was between
+1 and -3 ml/min. At 3 years, the low-dose tacrolimus arm still had the highest
GFR, although the difference was not significant (68 vs 62-65 ml/min, p =
0.10). Over the 2nd and 3rd years all arms had low rates of biopsy-proven acute
rejection (BPAR; 1-3%) and graft loss (3-6%). Non-fatal cardiovascular events
were rare (42 cases in total until month 36): 5.2% in the standard-dose CsA,
5.5% in the low-dose CsA 2.4% in the low-dose tacrolimus, and 4.6% in the
low-dose sirolimus group.
Conclusions: Observational follow-up results based on approximately half of
the core Symphony population indicate that during the 2nd and 3rd years renal
function was stable, BPAR and graft loss rates were low, and many patients
changed treatment regimen. The ITT arm with 2 g MMF + low-dose tacrolimus
+ daclizumab + steroids still resulted in highest renal function and lowest graft
loss at 3 years, but these differences were not statistically significant.

624 STABLE TROUGH LEVELS BUT SIGNIFICANT
REDUCTION OF THE AREA UNDER THE CURVE OF
TACROLIMUS IN RENAL TRANSPLANTED PATIENTS
CONVERTED FROM ASSOCIATED MYCOPHENOLATE
MOFETIL TO EQUIMOLAR DOSES OF ENTERIC-COATED
MYCOPHENOLATE SODIUM

625 TEN-YEAR FOLLOW-UP OF A MULTICENTRE KIDNEY
TRANSPLANT STUDY DISCLOSE HIGHER GRAFT SURVIVAL
AND BETTER RENAL FUNCTION IN TACROLIMUS THERAPY
B. Dominguez-Gil, J.M. Morales1, I. Vanrenterghem2, J.P. Squifflet3, B.
Suwelack4, F. Pietruck5, L. Wennberg6, S. Ball7, F. Mühlbacher8, J.P. Van
Hooff9, M. Fischereder10
1
Hospital Universitario Doce De Octubre, Madrid, Spain, on behalf of the
European Tacrolimus Study Group, 2University Hospital Gasthuisberg,
KU Leuven, Belgium, 3Centre Hospitalier du Sart Tilman, Liège, Belgium,

626 A THREE YEAR FOLLOW-UP STUDY OF STABLE
KIDNEY TRANSPLANT RECIPIENTS CONVERTED FROM
TWICE DAILY PROGRAF® TO ONCE DAILY ADVAGRAF
(EXTENDED RELEASE TACROLIMUS)
R. Alloway
for the Tacrolimus Extended Release Kidney Transplant Conversion Study
Group, University of Cincinnati, College of Medicine, Cincinnati, OH, USA
Purpose: To assess safety and efficacy three years following conversion from
tacrolimus twice daily (Prograf BID) to extended release tacrolimus (Advagraf,
previously Modified Release tacrolimus or MR) once daily (QD a.m.) in stable
kidney transplant recipients.
Methods: Seventy patients were enrolled in the pharmacokinetic (PK) portion
of the study (days 0-35). Sixty-seven patients were subsequently maintained
on Advagraf QD a.m. Patients were evaluated for Advagraf dosing and trough
levels, laboratory values, concomitant medications, graft survival, and adverse
events.
Results: The results of the PK portion of the study indicated that mg:mg
conversion from Prograf BID to Advagraf QD a.m. dosing resulted in equivalent
tacrolimus exposure in stable kidney transplant recipients. 66 patients agreed
to the extension portion of the study, and 51 patients completed the third year
of the study. Attrition was due to CNI toxicity, polyoma virus nephropathy,
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J.M. Puig1, M. Mir1, S. Hurtado1, M. Marin2, M. Ferrer3, M. Crespo1,
F. Barbosa1, C. Barrios1, E. Rodriguez1, J. Lloveras1
1
Hospital Del Mar. Nephrology Dept., 2Hospital Del Mar, Pharmacy Dept.,
3
IMIM, Pharmacology Dept.
Enteric-coated mycophenolate sodium (EC-MPS) is a delayed release
formulation of mycophenolic acid (MPA) developed to deliver MPA to the
small intestine with the aim to reduce the upper gastrointestinal (GI) tract
adverse-effects reported with the administration of mycophenolate mofetil
(MMF). The primary objective of this study is to compare the pharmacokinetics
(PK) of tacrolimus (TAC) and MMF with the PK of TAC and EC-MPS when
administered in either combination.
Methods: We studied a group of 32 long-term stable RT patients treated with
TAC and MMF without steroids. 53% were men. Age: 56.5±12.8y. Time
from RT: 5.5±4.8y. MMF doses: 1.02±0.43g/d. Target MPA Cmin: 1.5-4ng/L.
TAC doses: 4.7±2.5mg/d. Target TAC Cmin: 7-10ng/L. The PK parameters
considered for each drug were Cmin, Cmax, Tmax and the AUC calculated
by the trapezoidal rule. We first determined simultaneously the 12-hour
plasma TAC and MMF PK profile. Next, patients were switched from MMF
to equimolar doses of EC-MPS. After 30 days a new PK profile of TAC and
EC-MPS was carried out. TAC and EC-MPS doses remained unchanged
throughtout the study. No one patient was on rifampicin, acetyl salycilic acid,
antacids, ganciclovir or cholestyramine during the study period.
Results: Serum creatinine, proteinuria, serum albumin, leukocytes, hemoglobin,
platelets, and bilirrubin before and after conversion were without significant
differences. TAC Tmax, and Cmin were similar with MMF and with EC-MPS.
Howewer, TAC Cmax and AUC were 22% and 19% lower with EC-MPS
(p=0.0013). MPA Cmin, Cmax, and AUC were 28%, 36%,and 27% higher with
EC-MPS, and as expected, EC-MPS Tmax was significantly delayed. Neither
acute rejection episodes nor new-onset GI side-effects were observed and no
dose-adjustements were needed.
Conclusions: In long-term stable RT patients treated with TAC and MMF, if
MMF is converted to equimolar doses of EC-MPS, TAC AUC is significantly
reduced while TAC trough levels remain invariable. In addition, at equimolar
doses, EC-MPS provides significantly higher MPA AUC, Cmax and Cmin than
MMF. These PK discrepancies were without short term clinical significance i.e.
acute rejection, nephrotoxicity or new-onset G.I. adverse effects.

4Medizinische Klinik und Poliklinik D, Universitatsklinikum Munster,
Munster, Germany, 5Klinik für Nieren- & Hochdruckkrankheiten,
Universitätsklinikum Essen, Essen, Germany, 6Karolinska Institute Huddinge University Hospital, Huddinge, Sweden, 7University Hospital
Birmingham NHS Trust, Birmingham, United Kingdom, 8Allgemeines
Krankenhaus, Wien, Austria, 9Academic Hospital Maastricht, Maastricht, The
Netherlands, 10Medizinische Poliklinik – Innenstadt, Klinikum der Universität
München, München, Germany
The first European Phase III trial with tacrolimus conducted in the early
90´s clearly showed advantages for tacrolimus in terms of acute rejection
vs the original cyclosporin formulation. However, no advantages were seen
in survival rates. The present investigator-initiated, observational followup study collected data on patients included in the original cohort of 448
patients who participated in this large study and who were randomised to a
triple immunosuppressive regimen consisting of tacrolimus, azathioprine and
steroids (TAC/AZA/STER, n= 303) or cyclosporine, AZA and steroids (CSA/
AZA/STER, n=145). Efficacy and safety parameters assessed at follow-up
included: acute rejection; patient and graft survival; renal function, vital signs,
basic lab results and immunosuppressive regimen. The follow-up evaluation
included the assessment of patients 10 years after completion of the original
study.
Results: All assessments were conducted following the intent-to-treat
principles. A higher number of patients in the TAC than in the CSA group
remained on the randomised treatment at the 10-year assessment. While
Kaplan-Meier (K-M) estimates for patient survival at year 11 show comparable
(72% for tacrolimus vs 72% for CSA) results, K-M estimates for graft
survival demonstrate an advantage for the tacrolimus cohort (51% TAC vs
46% CSA). Graft half-life estimates (according to the method of Gjertson and
Terasaki) yielded overall results of 14.2 years (TAC) and 11.4 years (CS). In
both treatment groups, acute rejection was associated with inferior long-term
results. For patients with acute rejection, half-life estimates were 11.1 and 7.8
years for TAC and CSA, respectively, while in patients without acute rejection
half-lives were 19.2 (TAC) and 15.8 (CS) years. Mean serum creatinine after
10 years was significantly lower in the tacrolimus cohort vs the CSA group
(1.65mg/dL TAC vs 2.01mg/dL CSA, p<0.05). Mean glomerular filtration rates
(MDRD4 estimate) were 48.7 mL/min in TAC and 41.9 mL/min in CS. After
ten years of follow-up, mean daily dose of TAC was 4.3 mg (0.06 mg/kg) and
mean daily dose of CS was 160 mg (2.33 mg/kg). The corresponding mean (12
hour trough) levels were 7.6 mg/mL (TAC) and 120 mg/mL (CS). Patients in
monotherapy were 23% TAC vs 8% CSA. Also, TAC was associated with less
antihypertensive use, lower lipids levels while diabetes (post-trasplant) was
similar compared with CSA.
Conclusion: Analysis of this long term follow-up of a large study confirms
the benefits of a tacrolimus-based therapy. It also confirms the concept that
freedom from early acute rejection is associated with superior long term
results. In parallel, long term renal allograft function and cardiovascular profile
is remarkably good in TAC patients.
4
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HCV, lost to follow-up/LTFU (year 1), renal dysfunction, CAN/CNI toxicity,
bladder cancer, CNI toxicity, LTFU (year 2), and lung cancer resulting in death,
CNI toxicity, alopecia, proliferative GN, hyperglycemia, noncompliance with
protocol (year 3). Through three years, renal function remained stable.
Pre- Advagraf 1 Year PostBaseline
Conversion
N=70
N=62†

2 Year PostConversion
N=57†

3 Year PostConversion N
=51†

Mean Dose (mg/day)
Range (mg/day)

5.7
(1-19)

6.0
(1-17)

6.0
(1-18)

5.9
(1-16)

Mean Trough Conc. (ng/mL)
Range (ng/mL)
Mean Serum Creatinine (mg/dL)
Range (mg/dL)

6.6
(3-11.9)
1.4
(0.7-3.6)

6.5
(1.7-12.8)
1.5
(0.7-3.1)

6.6
(1.9-10)
1.5
(0.7-3.8)

6.7
(1.6-20)
1.6
(0.7-5.1)

† N = completers at each year

Patient and graft survival were 99% and 97% respectively at three years
post-conversion. Through three years, four biopsy confirmed acute rejection
episodes occurred in four patients: Grades IA (Day 727), IB (Day 235), IIA
(Day 163), and IIB (Day 466). One patient had multiple rejection episodes.
All episodes resolved with treatment. One patient died due to lung cancer. One
patient experienced graft loss due to polyoma virus infection.
Medication use for diabetes, hypertension, and hyperlipidemia at three years
was similar to usage at conversion. There have been twelve occurrences of
glucose intolerance (based on fasting plasma glucose ≥126 mg/dL). None of
these patients required insulin therapy and one required an oral hypoglycemic
agent. There were no patients with hemoglobinA1c ≥ 6%.
Conclusions: The three year data continues to support the safety and efficacy
of conversion from Prograf BID to Advagraf QD a.m. in kidney transplant
recipients.
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627 EFFICACY, TOLERABILITY AND SAFETY OF
MYCOPHENOLATE MOFETIL (CELLCEPT) + SIROLIMUS
(RAPAMUNE) AS MAINTENANCE THERAPY AFTER
CALCINEURIN INHIBITOR WITHDRAWAL IN LRD AND CAD,
ADYLTS AND PEDIATRIC RENAL TRANSPLANT RECIPIENTS.
(EXPERIENCE WITH 405 PATIENTS)
A. Holm, M. Hernandez, A. Camarena, L. Perez, M. Santos, M.A. Porras
UMAE HGCMN LA RAZA IMSS
In a 3-year open-label, prospective, randomized, controlled study, patients
maintained on MMF and a CNI were randomized 30-180 days after
transplantation to received MMF (1-2.0 g day) plus SRL (2-8 mg day, followed
by 1-2 mg/day; trough 5-10 ng/mL) and, discontinued the CNI (MMF/SRL
group) or to continued their current regimen (MMF/CNI group). All patients
received corticosteroids in low dose regimen (5-10mg day) and discontinued
after 12 months of transplant.
Antibody induction: Daclizumab-1mg/kg, divided in two doses (day-0 and
7) used in high risk LRD and CAD recipients. Efficacy endpoints included:
clinical data of all patients (baseline, 3, 6, 9, 12, 18, 24 and 36 months) and, the
proportion of patients with biopsy-proven acute rejection (BPAR), graft loss,
morbidity, death, and the percent change in measured glomerular filtration rate
(GFR; 99m Tc-MAG3).
Results: 405 randomized patients, within aged 24.7+-8.4 years, receiving
either MMF/SRL (n=220) or MMF/CNI (n=185) have completed 36 months
of follow-up. Baseline characteristics and measured GFR values were similar
in the treatment groups. Mean time post transplantation to randomization was
108+-72 vs 115+-65 days for MMF/SRL and MMF/CNI groups, respectively.
BPAR was seen in 14/220 (6.3%) MMF/SRL treated patients and 29/185
(15.7%) of those receiving MMF/CNI. Graft loss was experienced by 6/220
(2.7%) of those in the MMF/SRL group and, 18/185 (9.7%) of those in the
MMF/CNI group, p < 0.005. No patient in the MMF/SRL group and, 5/185
(2.7%) in the MMF/CNI group died. Patients receiving MMF/SRL had a
48.8+-10.2 ml/min of GFR at 1-year compared with 32.7+-5.4 ml/min in those
treated with MMF/CNI. SRL had minor side effects: dyslipidemias in 12/220
(5.4%) and slight proteinuria without presence of graft loss at 1-year; while
the proteinuria in the MMF/CNI was no significant. Safety outcomes were
generally similar in the treatment groups.
Conclusions: Our center is a Multiorganic Transplant Program, which
performed at least 140 kidney, 35 liver and 30 heart transplants per year. Based
on a 3-year experience in 220 patients with MMF/SRL maintenance therapy,
showed improvements in GFR, low acute rejection rate and low side effects.
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Final results will provide more definitive conclusions about the long-term
effect of these regimens on renal function, but it appears that maintenance
immunosuppression with MMF/SRL provides long-term graft protection and
is a safe (efficacy and tolerability) regimen.

628 INTERLEUKIN-2 RECEPTOR ANTAGONIST REDUCES
REJECTION RATES AND GRAFT LOSS IN LIVE-DONOR
KIDNEY TRANSPLANT RECIPIENTS
W. Lim, S. Chang, S. Campbell, S. Chadban, G. Russ, S. McDonald
ANZDATA Transplant Work Group, ANZDATA Registry, Adelaide SA,
Australia
Aims: The use of interleukin (IL)-2 receptor antagonist (IL2RA) in livedonor related kidney transplantation has been associated with a reduction in
acute rejection rates. However, the impact of IL-2RA induction in live-donor
kidney transplantation on renal function, graft and patient survival remains
unknown.
Methods: Using ANZDATA registry, all live-donor kidney transplant
recipients in Australia between 1991 and 2005 were analysed (n=2050).
Multiple organ grafts, recipients’ age <16 at time of transplant, recipients
on calcineurin-inhibitor and/or steroid-free regimens were excluded
from analyses. Induction therapy with monoclonal and polyclonal T celldepleting agents was also excluded. Outcomes analysed included the
presence of rejection at 6 months, graft and patient survival, and eGFR at
1 and 5 years. Confounding factors include donor and recipient variables
(including HLA-matching), as well as transplant year and type of initial
immunosuppression.
Results: The use of IL2RA reduced the risk of acute rejection in the first 6
months post-transplant in both univariate (odds ratio [OR] 0.44, p<0.0001)
and multivariate analyses (OR 0.49, p<0.0001). Late rejection >6 months posttransplant was similar in both groups. There was reduced graft loss at 5 years
(multivariate hazard ratio [HR] 0.61, p=0.03) and improved eGFR at 1 year
(unadjusted difference of mean 2.8ml/min, p<0.01) with the use of IL2RA in
live-donor transplantation. There was a non-significant trend towards reduced
death-censored graft loss, patient death and a superior eGFR at 5 years with the
use of IL2RA in the multivariate model.
Conclusions: The use of IL2RA in live-donor kidney transplantation improves
renal allograft outcomes independent of HLA-matching and the type of initial
immunosuppression.

629 FINAL RESULTS OF THE SPARE THE NEPHRON TRIAL
(CNI WITHDRAWAL TRIAL)
T.C. Pearson1, A. Patel2, J. Scandling3, H. Shidban4, M. Weir5, D. Patel6,
S. Mulgaonkar7
1
Emory University Hospital, 2Henry Ford Hospital, 3Stanford Univeersity,
4
National Institute of Transplantation, 5University of Maryland, 6Roche,
7
St. Barnabas Medical Center
Purpose: To evaluate the efficacy and safety of a maintenance
immunosuppressive regimen of mycophenoloate mofetil (MMF) and sirolimus
(SRL) after CNI withdrawal compared with that of MMF and a CNI in renal
allograft recipients.
Methods: This open-label, prospective, multicenter study, randomized 305
patients (maintained on MMF and a CNI) 30-180 days post-transplant to
receive either MMF (1-1.5 g BID) plus SRL (2-10 mg followed by at least 2 mg/
day; trough 5-10 ng/mL) and discontinue the CNI (MMF/SRL) or to continue
their current regimen (MMF/CNI). Antibody induction and/or corticosteroids
were administered according to individual center practice. Efficacy endpoints
included the proportions of patients with biopsy-proven acute rejection
(BPAR), graft loss, and death at 12 months, and the percent change in measured
glomerular filtration rate (GFR; cold iothalamate) from randomization.
Results: Mean time from transplant to randomization in both groups was 117
days. Baseline characteristics and measured GFR values were similar in the
treatment groups.
BPAR was reported in 8/123 (6.5%) MMF/SRL-treated patients and 9/126
(7.1%) receiving MMF /CNI. Graft loss occurred in 2/123 (1.6%) in the MMF/
SRL group and 3/126 (2.4%) in the MMF/CNI group.
Mean Percent Change (n) in Renal Function From Randomization (Baseline)
to Month 12
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Measured GFR
Calculated GFR
SCr
Calculated CrCl

MMF/SRL
25.8±75.0 (96)
7.1±23.0 (97)
-1.8±20.9 (99)
5.6±22.4 (99)

MMF/CNI
All Subjects
11.3±61.5 (100)
1.4±19.8 (104)
6.8±33.0 (105)
-0.5±23.2 (105)

MMF/TAC
4.7±54.4 (77)
0.4±19.1 (79)
9.2±35.1 (80)
-2.1±23.3 (80)

CrCl, creatinine clearance; SCr, serum creatinine

Conclusions: MMF-based maintenance therapy in combination with sirolimus
appears to be associated with improved renal function when compared with
MMF/CNI-containing regimens without increasing the risk of acute rejection
and is tolerated in almost 80% of patients.

CONCURRENT ORAL SESSION 44:
CMV AND OTHER VIRAL DISEASES
630 HUMAN CYTOMEGALOVIRUS ANTIVIRAL
RESISTANCE IN IMMUNOCOMPROMISED TRANSPLANT
RECIPIENTS

631 INVESTIGATIONS INTO THE PATHOGENESIS
OF CYTOMEGALOVIRUS-INDUCED TRANSPLANTARTERIOSCLEROSIS USING A HUMANIZED
MOUSE MODEL
S. Ensminger1, S. Abele1, M. Leis2, M. Wollin2, M. Weyand1, T. Stamminger2
Department of Cardiac Surgery, University of Erlangen - Nuremberg,
Germany, 2Institute for clinical and molecular Virology, University of
Erlangen - Nuremberg, Germany
Introduction: Recent findings have emphasised an important role of human
cytomegalovirus infection (HCMV) in the development of transplant
arteriosclerosis. Therefore, the aim of this study was to develop a human
peripheral blood lymphocyte (hu-PBL)/RAG-2(-/-)gc(-/-) mouse-xenograftmodel to investigate the immunological mechanisms of HCMV in the
progression of transplant arteriosclerosis.
Methods: Sidebranches from the internal mammarian artery were harvested
during CABG surgery, tissue-typed and infected with a clinical isolate of HCMV
(VR1814). In a next step size-matched sidebranches were implanted into the
infrarenal aorta of RAG-2(-/-)yc(-/-) mice. The animals were reconstituted with
approximately 5x107 peripheral blood mononuclear cells (PBMCs) 7 days after
transplantation. Human cell engraftment was measured by FACS and ELISA.
HCMV Infection was confirmed by RT-PCR and immunofluorescence. Arterial
grafts were harvested on day 40 after transplantation and histological analysis
was performed.
Results: Analysis of artery grafts after HCMV infection showed significant
amounts of viral DNA on days 7 and 14 after infection and immunohistochemical
analysis revealed IE-2 protein expression on endothelial cells of the artery
grafts. PBMC-reconstituted RAG-2(-/-) gc(-/-) animals showed splenic
chimerism levels ranging from 28-40% human cells. After reconstitution
with PBMCs RAG-2(-/-)gc(-/-) developed human leukocyte infiltrates in their
grafts and significant amounts of transplant arteriosclerosis. In addition our
first data using this model suggest that HCMV infection of the arterial graft
resulted in elevated levels of transplant arteriosclerosis. Arterial grafts from
unreconstituted RAG-2(-/-)gc(-/-) recipients showed no vascular lesions.
Conclusion: These data suggest that HCMV-Infection plays an important
role in the development of transplant-arteriosclerosis in a humanised mouse
arterial-xenograft-model.

1

632 A PROSPECTIVE STUDY OF VIRAL GENETIC
POLYMORPHISMS IN CMV GLYCOPROTEIN B AND
THEIR ASSOCIATION WITH CLINICAL AND VIROLOGIC
OUTCOMES IN PATIENTS WITH CMV DISEASE:
RESULTS FROM THE VICTOR STUDY
O. Manuel1, V. Emery2, A. Asberg3, A. Hartmann3, M. Pescovitz4, X. Pang1,
H. Rollag3, A. Jardine5, A. Humar1
1
University of Alberta Hospital, 2University College London, 3University of
Oslo, 4Indiana University, 5Univesrity of Glasgow
Background: It is unknown if specific viral polymorphisms affect in vivo
virulence in patients with CMV disease. Polymorphisms in the CMV UL55
gene encoding the glycoprotein B (gB), allow discrimination of four distinct
genotypes (gB1-4). We assessed the influence of gB genotypes on CMV disease
in a prospective cohort of patients with CMV disease.
Methods: Organ transplant recipients enrolled in an international trial
(VICTOR study) of CMV disease treatment (valganciclovir or intravenous
ganciclovir) were included. Quantitative and sensitive CMV gB genotyping
was performed using a real-time PCR at Day 0 (start of antiviral therapy) and
at days 3, 7, 14, and 21 after starting antiviral therapy. Mixed infection was
defined as CMV infection with more than one gB genotype in a single sample.
Results: 229 patients with CMV disease were analyzed. The prevalence of
gB strain types at day 0 was gB1 (28%), gB2 (14%), gB3 (14%), gB4 (6%)
and mixed-infection in 38%. Patients who were seropositive at the time of
transplantation were more likely to have mixed gB infection compared to
seronegative patients (41% vs. 12%, p=0.003). Mean baseline viral loads
were similar for different gB types but were higher for mixed vs. non-mixed
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J. Iwasenko1,3, G. Scott1,2,3,4, S. Chou5,6, W. Rawlinson1,2,3,4
1
Virology Research, POWH & UNSW Research Laboratories, Prince of Wales
Hospital, Sydney, AUS, 2Virology Division, Department of Microbiology,
SEALS, Prince of Wales Hospital, Sydney, AUS, 3School of Biotechnology and
Biomolecular Sciences, Faculty of Science, University of New South Wales,
Sydney, AUS, 4School of Medical Sciences, Faculty of Medicine, University
of New South Wales, Sydney, AUS, 5Medical & Research Services, Veterans
Affairs Medical Center, Portland, USA, 6Division of Infectious Diseases,
Oregon Health and Science University, Portland, USA
Immunocompromised transplant recipients are at high-risk for infection
with human cytomegalovirus (CMV) and life-threatening CMV-related
disease. Antiviral prophylaxis or treatment with ganciclovir (GCV), and now
valganciclovir (valGCV), has reduced the morbidity and mortality caused
by CMV, but antiviral resistant CMV strains still emerge and contribute to
CMV-related disease and adverse clinical outcomes in approximately 10% of
recipients. Even more problematic is the development of multi-drug (GCV,
foscarnet and cidofovir) resistance CMV, severely limiting the treatment
options for individuals infected with these strains. We have been investigating
CMV genotypes in Australian lung, liver and renal transplant recipients to
determine the prevalence, impact and changing patterns of antiviral resistant
CMV in treated immunocompromised patients. CMV-positive clinical
specimens were assessed for the presence of antiviral resistant strains by
genotypic analysis, where the genes that encode the CMV protein kinase
(UL97) and the viral DNA polymerase (UL54) are amplified by nested PCR
and sequenced to identify mutations known to confer antiviral resistance.
Previously unrecognized mutations identified in association with clinical
antiviral resistance are further characterized by transfer to an antiviral sensitive
CMV strain and subsequent phenotypic antiviral susceptibility analysis of the
recombinant virus.
Antiviral resistant CMV strains were identified in 34% (18/53) of patients
tested. Multi-drug resistant CMV strains containing mutations in both UL97
and UL54, or dual infections with single UL97 and UL54 variants (not always
at the same time point) were responsible for 13% (7/53) of infections. Nearly
half (47%) of the CMV strains containing mutations in UL97 and UL54 were
identified in lung transplant recipients, despite this group accounting for only
16% of patients studied. A previously unrecognized UL97 mutation (N597D)
identified in a heart transplant recipient was shown to confer moderate GCV
resistance on marker transfer analysis. ValGCV treatment reduced the viral load
to undetectable levels in this patient indicating that antiviral treatment can be
effective against moderately resistant CMV strains. A previously unrecognized
UL54 mutation (D485N) was also identified in a CMV strain from another heart
transplant recipient. This strain also contained a GCV-resistant UL97 mutation
(C603F) and UL54 mutation (P522S) that confers both GCV and CDV. The
D485N mutation occurs in a region of the UL54 DNA polymerase that is
invariant in antiviral sensitive strains and in proximity to other known GCV
and CDV resistance mutations, and marker transfer experiments are underway
to characterize the antiviral susceptibility of this mutation. Interestingly, a
different antiviral resistant strain/s with UL97 mutation C592G and UL54
mutation P522S was identified a year earlier in this patient, indicating ongoing
mixed CMV infections with differing profiles of multi-drug resistance.
Emergence of antiviral resistance remains a significant issue in
immunocompromised patients treated with antiviral agents and emphasizes the

relevance of regular antiviral resistance testing. Better understanding of the role
of individual and combined mutations in the susceptibility of CMV strains to
antiviral agents is improving diagnosis, assisting in patient management and
treatment and will improve outcomes for transplant recipients in the long-term.
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infections (4.36 vs. 4.16 log10 copies/ml; P=0.056). Time to viral eradication
was longer in mixed vs. non-mixed infections (median of 22.0 ± 2.0 vs.
19.0±1.0 days, respectively, p=0.06). Patients with mixed infection displayed
complex decay patterns but decay kinetics for all genotypes showed a bisphasic
response with a 1st phase half-life of ~0.7 days and a 2nd phase of ~3days.
1st phase declines were fastest for gB1 (p=0.0001 vs. gB2 and 4) while gB4
decline was slower than gB3 during the 1st phase. 2nd phase declines were
similar between gB1 and gB3 (3 days and 2.9 days) but were slower for gB2
and gB4 (3.45 days; p=0.01). In a multivariate model accounting for baseline
viral load, CMV IgG at baseline, ganciclovir resistance, and antiviral treatment
(valganciclovir or ganciclovir), mixed gB infection was a significant predictor
of failure of therapy at Day 21 (mixed vs. non-mixed OR 2.87; 95% CI: 1.38
to 5.95; P=0.005). No effect of gB genotype was seen on virological or clinical
CMV recurrence.
Conclusion: No specific strain of CMV based on gB genotyping appears to
confer a specific viral virulence advantage. However, mixed infection with
different gB genotypes is associated with higher viral loads and delayed
virological clearance suggesting a role for viral polymorphisms in influencing
in vivo viral fitness.
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633 DEMONSTRATION OF HHV-6 ANTIGENS IN BIOPSIES
OF KIDNEY TRANSPLANT RECIPIENTS WITH CMV
INFECTION
I. Helanterä1,2, R. Loginov2,3, P. Koskinen1, I. Lautenschlager2,3
1
Helsinki University Hospital, Dept of Medicine, Division of Nephrology,
2
Helsinki University Hospital, Transplant Unit Research Laboratory,
3
Helsinki University Hospital, Department of Virology
Introduction: In organ transplant recipients receiving immunosuppressive
medication, highly seroprevalent human herpesvirus-6 (HHV-6) reactivates
from latency during the first posttransplant weeks, often together with
cytomegalovirus (CMV) infection. Whereas CMV has been associated with
significant morbidity and enhanced rejection of organ transplants, the role of
HHV-6 after transplantation is less clear. CMV is able to persist in the kidney
allograft for a long period after viremia, and this persistence has been associated
with histopathological changes in the graft and inferior outcome. Although the
presence of HHV-6 in the renal allograft has been reported, not much is known
about the HHV-6 in the kidney. We examined the presence and the possible role
of HHV-6 and CMV in the biopsies of adult kidney transplant recipients with
previous CMV infection.
Methods: Frozen biopsy material for the retrospective detection of HHV-6
and CMV antigens was available from 22 adult kidney transplant recipients,
transplanted during 1992-2000 in the Helsinki University Hospital, who all
had had a previous CMV infection. Follow-up data of five years was analyzed.
The diagnosis of CMV infection was based on the standard CMV pp65
antigenemia test and viral cultures from blood and urine. CMV infections were
treated with i.v. gancyclovir. CMV and HHV-6 antigens were demonstrated in
frozen sections of kidney allograft biopsies using immunoperoxidase staining
and monoclonal antibodies against CMV pp65 and HHV-6B. The biopsy
histopathology was described according to Banff ’97.
Results: CMV infection was diagnosed mean 47±27 days after transplantation
by pp65-antigenemia in all except one patient, in whom CMV was detected
by viral culture from urine. Biopsies used for the detection of the viruses
were taken mean 327±364 after transplantation (range 30-1484). HHV-6
antigens were demonstrated in biopsies of 7/22 patients 18-1330 days after
symptomatic CMV infection (mean 215±346). HHV-6 antigens were located
in infiltrating leukocytes in the transplant of 6 patients, and in tubular epithelial
cells in two patients. A positive HHV-6 finding was not associated with
increased histopathological changes or reduced renal function at 5 years after
transplantation. CMV antigens were found in the biopsies of seven patients.
Only 1/7 of these biopsies demonstrated also HHV-6 antigens. Persistent CMV
antigens were demonstrated in the biopsies mean 93±74 after last positive
CMV finding from blood or urine.
Conclusions: HHV-6 antigens were commonly found in late kidney allograft
biopsies, suggesting that HHV-6 may persist in the kidney allograft. The nature
and clinical relevance of this finding remains to be elucidated.
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634 ORAL VALGANCICLOVIR AND INTRAVENOUS
GANCICLOVIR RESULTS IN COMPARABLE LONG-TERM
OUTCOMES IN TRANSPLANT RECIPIENTS WITH CMV
DISEASE: THE VICTOR STUDY
A. Åsberg1, M.D. Pescovitz2, A. Humar3, A.G. Jardine4, H. Rollag1,
H. Mouas5, A. Hartmann1
1
University of Oslo, 2Indiana University, 3University of Alberta, 4University of
Glasgow, 5F. Hoffmann-La Roche Ltd.
In the VICTOR-trial we previously showed that 21 days of oral valganciclovir
(900 mg twice daily) was non-inferior to intravenous ganciclovir (5 mg/kg twice
daily), in the treatment of CMV disease. Both arms further received maintenance
treatment with valganciclovir 900 mg once daily until Day 49. The present report
deals with long-term outcomes during one year of follow-up in the 321 enrolled
patients. The study population consisted of kidney (74.1%), heart (5.6%), liver
(7.2%), lung (5.9%) and other/combined (7.2%) recipients. Blood samples
were collected at days 0, 21, 49, month 3 and 6 and in case of recurrence for
central analyses of anti-CMV IgG titers (Abbott Architect), plasma viral loads
(Amplicor, cut-off 600 copies/mL) and genotypic ganciclovir resistance.
There were no significant differences in either viral clearance or resolution of
CMV disease between the two arms throughout the follow-up. Overall clinical
treatment success was 82.6% ay Day 21 and 91.1% at Day 49. The clinical
recurrence beyond Day 49 was 14.4% and the virologic recurrence was 28.6%.
Patients with persistent CMV viremia at day 21 were significantly more
likely to recur (absolute yearly risk: 23.2% [95% CI: 15.7-34.1%] vs. 9.6%
[6.3-14.7%]). Patients who were CMV IgG negative at day 0 had higher
recurrence rate: 8/29 (27.6% [15.6-48.6%]) vs. CMV IgG positive patients:
26/200 (13.0% [9.1-18.5%]; P=0.039, chi square). Lung transplant patients
were more likely to recur (37.5%) than kidney (14.4%), heart (6.3%) and liver
(0%) recipients. In a multivariable logistic regression analysis including viral
clearance at days 21 and 49, baseline viral load and CMV IgG serostatus (+
vs -), transplanted organ and treatment arm (valganciclovir vs ganciclovir),
the only independent predictor for recurrence was viral eradication at day 21
(Clinical recurrence: OR 3.9 [1.3-11.3], P=0.012; Virological recurrence: OR
5.6, [2.5-12.6], P<0.0001).
Five patients (2.0%) had resistant strains at baseline and eight more developed
resistance during treatment (NS). Seven out of 94 patients with viremia at day
21 had a resistance mutation (absolute risk: 7.4% [3.7-14.9%]) while those who
were positive at day 49 had a rate of 4/13 (30.8% [14.3-65.0%]).
Eleven (valganciclovir) and nine (ganciclovir) patients died during follow-up
(NS): twelve due to bacterial infections, eight were organ failures.
In conclusion, there were no differences in long term outcomes in transplant
patients initially treated with either oral valganciclovir or intravenous
ganciclovir for CMV disease. This supports the use of oral valganciclovir
for treatment of CMV disease. The data further indicates that the CMV IgG
status at start determines the response. Induction therapy should be given for at
least 21 days and viral load measured prior to reduction to maintenance dose.
Patients with persistent viremia at 21 days should continue on treatment doses,
but are not likely to have resistant mutations, whereas patients with viremia
at 49 days should be evaluated for resistance. These data support a patientspecific treatment regimen based on viral load at days 21 and 49, identification
of CMV resistance at day 49 and probably also baseline CMV IgG status.

635 DONOR-DERIVED DISEASE TRANSMISSION EVENTS
IN THE UNITED STATES 2006 – 2008: A REPORT FROM THE
OPTN/UNOS DISEASES TRANSMISSION ADVISORY GROUP
(DTAG)
M. Ison, J. Hager, V. McEwen, E. Blumberg, K. Carney, J. Cutler, M. DiMaio,
R. Hasz, L. Teperman, M. Nalesnik
OPTN/UNOS Diseases Transmission Advisory Group
Background: Donor-derived disease transmission is increasingly recognized
as a source of morbidity and mortality among transplant recipients. Policy 4.0
of the OPTN currently required reporting of donor-derived events.
Methods: All potential donor-derived transmission events (PDDTE) that were
reported to OPTN/UNOS and the DTAG through the patient safety system
were reviewed by the Group from January 1, 2006 - December 31, 2007 (Data
through May 31, 2008 will be presented at the meeting). Summary data were
prepared for presentation.
Results: Reports of PDDTE have increased from 7 in 2005, the first full year
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data was collected, to 60 in 2006, the first year that electronic submission was
available, to 97 in 2007. During the 2006-2007 period, there were 52 reports of
malignancy PDDTE with 7 (13%) documented transmissions and 3 attributable
deaths (Table 1; there were 72 reports of infectious diseases PDDTE with 14
(19%) documented transmissions and 6 attributable deaths (Table 2). Many of
the cases remain under investigation so documented transmission and deaths
may increase.
Conclusions: PDDTE are being increasingly reported to DTAG. Documented
transmissions occur in 13-19% of reports with 43% of confirmed transmissions
resulting in patient deaths. This likely under represents the true incidence and
impact of donor-derived infections.
Table 1. Potential Donor-Derived Malignancies Transmissions Reported to
DTAG
Disease

Reports in Donors

Breast Cancer
Colon Cancer
Glioblastoma Multiforme
Hepatocellular Cancer
Kaposi’s Sarcoma
Leukemia
Lung
Lymphoma
Metastatic Melanoma
Myeloid Sarcoma
Ovarian Carcinoma
Pancreatic Adenocarcinoma
Prostate Adenocarcinoma
Renal Cell Carcinoma
Renal Papillary Adenocarcinoma
Thyroid Cancer

1
1
3
1
1
1
7
3
2
1
1
1
2
24
1
2

Confirmed Cases
in Recipients
0
0
1
0
0
0
2
2
1
0
1
0
0
2
0
0

Attributable Deaths
in Recipients
0
0
1
0
0
0
2
0
0
0
0
0
0
0
0
0

Table 2. Potential Donor-Derived Infectious Diseases Transmissions Reported
to DTAG
Disease

Reports in Donors

Bacteremias*
Bacterial Meningitis
Candidemia
Chagas
Cryptococcus
Cytomegalovirus
EBV
Hepatitis B
Hepatitis C
HIV
Histoplasmosis
HTLV
Influenza A
Legionella
Listeria
Mycotic Aneurysm
Rocky Mountain Spotted Fever
Schistosomiasis
S. aureus in transport media
Strongyloides
Syphilis
Toxoplasmosis
Tuberculosis
West Nile Virus
Zygomycetes

3
1
1
4
2
1
3
6
9
7
3
1
1
1
1
1
1
2
1
2
2
6
8
5
1

Confirmed Cases
in Recipients
2
0
0
3
1
0
0
0
4
4
0
0
0
0
0
0
0
1
0
0
0
0
3
0
0

Attributable Deaths
in Recipients
2
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0

636 NO EXCLUSION OF HHV-8 INFECTED DONORS AND
RECIPIENTS FOR KIDNEY TRANSPLANTATION:
A FRENCH PROSPECTIVE NATIONAL COHORT
C. Frances , A-G. Marcelin , C. Legendre , S. Chevret , E. Dussaix ,
J. Lejeune4, A. Bigorie6, T. Schulz7, F. Agbalika4, C. Lebbe4
1
Hopital Tenon, 2Hopital Pitie, 3Hopital Necker, 4Hopital Saint Louis, 5Hopital
Paul Brousse, 6Drass D’ Ile-De-France, 7Hannover Medical School
Aims: The aim of this study was to appreciate the morbidity of HHV-8
infection, preceding or transmitted by the renal graft.
Methods: A prospective French national study was conducted from 2001 to
2006 (3 years of inclusion and 3 year of follow). Antibodies to HHV-8 latent
nuclear antigen were detected by indirect immunofluorescence (IF) in serum
samples collected just before transplantation from donors and kidney recipients.
Three groups were delineated according to the results: group A (HHV-8 +
patients before graft), group B (HHV-8 - patients transplanted with a HHV-8
+ donor) and group C (all other patients). HHV-8 serology of donors was
1

2

3

4

5

637 LONG TERM EXPERIENCE WITH THE USE OF
KIDNEYS FROM HCV POSITIVE DONORS INTO HCV
POSITIVE RECIPIENTS: A SPANISH COLLABORATIVE STUDY
B. Domínguez-Gil2, J.M. Morales1, N. Esforzado3, M.I. Delgado1, A. Andrés1,
J.M. Campistol3
1
Doce de Octubre Hospital, Madrid, Spain, 2Organización Nacional de
Trasplantes, Madrid, Spain, 3Clinic i Provincial Hospital, Barcelona, Spain
The use of kidneys from donors with a positive serology for HCV into HCV
(+) recipients still remains controversial. In 1990, our units adopted this policy,
subsequently modified in 1993, so these kidneys were limited to recipients with
a positive RNA HCV before transplantation.
The aim of the present analysis was to review the long-term safety of our policy.
Since January 1990 to February 2007, 474 HCV (+) patients with a negative
HbsAg and not treated with interferon received a kidney transplant in our units.
Three hundred and thirteen patients were transplanted from an HCV(-) donor
(Group 1) and 161 from an HCV (+) donor (Group 2).
Median follow-up time was 65 (IR 24-117) months. Remarkably, Group 2
showed a significantly higher donor age (46.6±13.6 versus 41.1±18.8 years;
p<0.0001) and recipient age (50.4±13.1 versus 44.9±14.6 years; p<0.0001), as
well as a worse HLA compatibility than Group 1. Immunosuppressive therapy
did not significantly differ between the two groups.
Main Outcome Results in HCV (+) Kidney Transplant Patients

5 year death-censored graft survival*
10 year death-censored graft survival*
5 year patient survival*
10 year patient survival*
Chronic liver disease**
Severe liver disease***

Group 1
HCV (-) donors
(N=313)
69.5%
58.4%
84.3%
73%
10.5%
5.5%

Group 2
HCV (+) donors
(N=161)
62.6%
45.1%
81.6%
70.4%
15.5%
7.9%

p
0.1433
0.1433
0.5631
0.5631
0.138
0.285

*Life table analysis **ALT > 2.5 times the upper normal limit for more than 6 months ***Signs of
hepatocelular insufficiency and/or portal hypertension

Notably, only 5 patients died because of a liver disease (3 in Group 1 versus 2 in
Group 2) and only 2 patients developed a hepatocarcinoma (both in Group 1).
In summary, no significant differences were observed in HCV (+) recipients
according to HCV serology of the donor, in terms of death censored graft
survival, patient survival and evolution of liver disease. Therefore, our
experience clearly demonstrates that the use of kidneys from HCV (+) donors
into HCV (+) recipients is a safe strategy in the long-term and a wise way of
using these kidneys, that otherwise would be lost at a moment of shortage.
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*Acinetobacter baumanii, Pseudomonas aeruginosa

controlled retrospectively using a lytic ELISA OrfK8.1. Blood samples were
collected every 3 months for quantitative HHV-8 viral load (groups A and B),
quantitative serology using a lytic ELISA OrfK8.1 (group A), detection of antiHHV-8 antibodies by 3 different methods. A seroconversion was defined by
emergence of anti-HHV-8 antibodies detected by two different assays. All the
statistic tests were performed using SAS (version 9.1) and R 2.5.1 softwares.
Results: The prevalence of HHV-8+ donors and recipients was 1.08% and
3.24% leading to include 161 recipients in cohort A, 64 in cohort B and
4,744 in cohort C. Compared to latent IF tested from donors, the sensibility
of the lytic ELISA OrfK8.1 was 39.4% and the specificity 98.2%. There was
no difference in terms of survival or graft loss in the 3 groups. Among group
A recipients, the cumulative incidences of Kaposi’s sarcoma (KS) and death
without KS were respectively 0.13 and 0.063 at 3 years after transplantation. In
multivariate analysis, only age > 53.5 years (p=0.025) and black skin (p=0.0054)
were associated with development of KS. Positive HHV-8 viremia was not
predictive of the development of KS although it was detected in 13/21 patients
with KS and in 10/140 patients without KS. Quantitative HHV-8 serology
showed a decrease of titers with time. Only 1 of the 64 recipients of the group B
developed a severe clinical HHV-8 primary infection with cytopenia, fever and
hemophagocytosis which was successfully treated with rituximab. Two other
patients developed KS with low HHV-8 viremia concomitantly to KS. Other
patients of group B did not have any clinical manifestations which could be
related to HHV-8 infection although a seroconversion to positive HHV-8 status
was documented in 24.8% of them.
Conclusions: The morbidity of HHV-8 infection during the first 3 years
after transplantation is low and does not justify actually to exclude HHV-8+
donors and recipients from kidney transplantation. Nevertheless, the long term
outcome of these patients is still uncertain.
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638 MULTIVARIATE ANALYSIS OF 81 LIVER TRANSPLANTS
(LT) FROM HTLV I/II DONORS – UNOS REGISTRY DATA
M.R. Marvin1, G.N. Brock2, R. Nagubandi1, K.V. Ravindra1, M. Eng1,
J.F. Buell1
1
Division of Transplantation, University of Louisville, Louisville, KY, United
States and 2Bioinformatics and Biostatistics, University of Louisville,
Louisville, KY, United States.
HTLV has been associated with leukemia/lymphoma and progressive
neurological disease. The purpose of this study was to evaluate the results of
LT using donors positive for HTLV.
An analysis of the UNOS database was performed and included all LTs
performed in the United States from 11/92-5/07. Donor, recipient, and organ
procurement logistical factors were evaluated. Statistics were performed using
SAS software.
There were 29,667 (-) and 81 (+) donors included in the analysis. Selected
variables are presented in table I.
UNOS data – Univariate Analysis

Local
Regional
National
Functional Status at Transplant
Well
Average
Poor
Functional Status at Last Follow Up Well
Average
Poor

HTLV (-)
(N=29667)
N
Percent
22102
75
3479
12
3168
11
1622
5
7114
24
21564
73
6401
22
1702
6
11383
39
5699
19
535
2
15445
56
2755
10
1119
4
Mean

Mean

p-value

DRI
Creatinine - Recipient
Bilirubin - Recipient
Age - Recipient
MELD
Age - Donor
Cold Ischemia Time

1.7
1.5
7.5
50.6
20.2
38.8
7.1

2.1
1.6
5.8
55.5
18.4
45.7
6.5

<0.001
0.7439
0.097
<0.001
0.0623
<0.001
0.3144

Variable
Race

Diabetes - Donor
Hypertension - Donor
Share Type

White
Black
Hispanic

HTLV (+)
(N=81)
N
Percent
41
51
30
37
9
11
10
13
35
43
29
36
13
16
39
48
34
43
24
30
10
13
44
57
14
18
7
9

p-value
<0.001

0.01
<0.001
<0.001

<0.001

0.002
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Variables affecting graft and patient survival along with survival curves are
depicted in the figures below.
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HTLV (+) grafts yield identical graft and patient survival with no significant
differences in functional outcome.
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639 ABSENCE OF NEUTROPHIL-MEDIATED RENAL
DYSFUNCTION AND TUBULAR CELL APOPTOSIS
FOLLOWING RENAL ISCHEMIA/REPERFUSION IN CXCR2-/MICE
M. Araki1,2, H. Kumon2, R. Fairchild1
1
Cleveland Clinic, 2Okayama University School of Medicine
Introduction: Ischemia/reperfusion (I/R) injury has a critical impact on
the outcome of organs transplant. The factors directing cell infiltration into
parenchymal tissues during I/R injury remain unclear. Previous studies from
this laboratory in a mouse model have shown rapid induction of neutrophil
chemoattractant chemokine expression and parenchymal neutrophil infiltration
shortly following reperfusion of ischemic kidneys. The goal of the current
study was to investigate the induction and role of chemokine receptors in this
model of renal I/R injury.
Methods: BALB/c wild-type and CXCR2-/- mice were anesthetized and the
renal hilum was clamped for 45 min while the temperature was maintained
at 32°C. At various times post-reperfusion, ischemic and control kidneys
were removed, whole cell RNA was prepared and tested for expression of
chemokine receptor genes by ribonuclease protection assay. Frozen sections
were prepared from kidneys and stained for the chemokines KC, MIP-2, and
for neutrophils and macrophages by immunohistochemistry. Serum creatinine
was measured each day post-reperfusion. In some experiments mice were
depleted of neutrophils by treatment with anti-Ly6G mAb and/or were treated
with goat anti-CXCR2 antiserum. Controls were treated with normal rat IgG or
normal goat serum. TUNEL assay was done to detect apoptosis.
Results: CXCR2 was the most highly expressed receptor in ischemic kidneys
with expression peaking 18 h after reperfusion. The ligands for CXCR2,
KC and MIP-2, were clearly present in the tubular epithelial cells 9 h after
reperfusion by immunocytochemistry. Renal dysfunction was abrogated in
CXCR2-/- mice as well as in wild-type animals depleted of neutrophils before
reperfusion. Treatment of wild-type mice with anti-CXCR2 antibodies at the
time of reperfusion resulted in extremely high serum creatinine levels 24-48
h after reperfusion followed by 100% loss in viability. This renal failure was
dependent on neutrophils as it was not observed in mice depleted of neutrophils
before renal ischemia and reperfusion.
Conclusions: CXCR2 plays an important role in kidney I/R injury. However,
the use of CXCR2 antagonists to attenuate neutrophil infiltration and the injury
following reperfusion should be carefully considered.
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640 IL-4 TREATMENT OF THE LIVER DONOR INDUCES
ALTERNATIVELY-ACTIVATED (TYPE 2) MACROPHAGES
AND CONVERTS LIVER TRANSPLANT REJECTION TO
ACCEPTANCE
C. Wang, S.S. Tay, A. Buchanan, J. Laurence, R. Allen, A. Sharland,
G. McCaughan, A. Bishop
Royal Prince Alfred Hospital And University of Sydney
Background: PVG strain rat liver transplants are accepted in low responder
DA strain recipients without requiring immunosuppression but rejected in
high responder Lewis strain recipients. We have previously shown that IL-4
treatment of the DA strain recipient converts acceptance to rejection and the
aim of this study was to examine the mechanism of this conversion.
Methods: PVG to DA liver transplants were compared with PVG to Lewis
transplants and PVG to DA liver transplants treated from day 3 to day 7 with
recombinant IL-4 (30,000 U/day i.p). In subsequent experiments, PVG donors
were treated with 5 daily injections of IL-4 (30,000 U/day i.p). and the liver
was transplanted to Lewis strain recipients. In separate experiments, the time
course of infiltration was measured by immunohistochemistry and the pattern
of expression of cytokine mRNA by quantitative real-time PCR
Results: IL-4-induced rejection of PVG livers in DA strain recipients was
associated with a marked increase in macrophage infiltration, but no detectable
differences in T cell infiltration or antibody deposition. Of interest, the
extensive macrophage infiltrate in IL-4-treated grafts was not associated with
increased iNOS expression but instead with a marked increase of the putative
immunosuppressive molecule indoleamine dioxygenase (IDO), suggesting
that the IL-4-induced macrophage infiltrate could consist of type 2 rather than
type 1-activated macrophages. Treatment of PVG donors with IL-4 led to a
marked infiltration with macrophages but little or no change in expression of
iNOS or TNF-alpha, markers of type 1 macrophages. In contrast there was a
massive increase in IDO (0.02¡Ó0.004 in untreated versus 196.6¡Ó117 in IL-4
treated). This suggested that IL-4 treatment of the donor induced macrophages
with a putative immunoregulatory phenotype that could prolong transplant
survival. Transplantation of IL-4-treated PVG livers to Lewis strain recipients
led to marked prolongation of survival of most recipients (19, 20, 91, >130,
>160„e2, MST >110) compared to untreated (10, 11„e2, 12, 13, 17, 19, MST
12)(p=0.001). Acceptance of IL-4-treated PVG livers in Lewis recipients was
compared with rejection of untreated PVG livers. There was little difference
in the pattern of infiltration or cytokine expression in the transplanted liver
however there was a rapid increase of IL-2 in the recipient spleen associated
with liver acceptance, similar to our findings in spontaneous acceptance of
unmodified PVG to DA liver allografts.
Conclusion: IL-4 treatment has opposite effects depending on whether it is
administered to the liver donor before transplantation or to the recipient 3 days
after transplantation. Alternatively activated (type 2) macrophages appear to be
closely associated with both phenomena, suggesting that they may induce very
early skewing of the immune response to acceptance rather than rejection.

641 IL-18 DEFICIENCY IN RECIPIENTS INDUCED EARLY
REJECTION OF MHC CLASS II-DISPARATE CARDIAC
ALLOGRAFT IN MICE

642 LYMPHOCYTE, BUT NOT PARENCHYMA-DERIVED
CXCL10 IS CRITICAL IN LIVER INNATE IMMUNE RESPONSE
AGAINST ISCHEMIA AND REPERFUSION INJURY
J. Kupiec-Weglinski, Y. Zhai, R. Busuttil
Dumont-UCLA Transplant Ctr
We have shown that CXCL10 (IP-10), the TLR4-IRF3 pathway activation
chemokine product, plays a key role in the mechanism of liver ischemia/
reperfusion injury (IRI). However, liver consists of cells derived from bone
marrow and parenchyma, both of which are known to produce CXCL10.
Hence, the question as to which liver cell type and resultant CXCL10 operate in
the innate response against IR is important for better elucidation of the disease
mechanism.
Aim: To study the impact of CXCL10 production by parenchymal vs. nonparenchymal cells on liver IRI cascade by employing: (1) bone marrow (BM)
chimeras; (2) T-cell deficient “nude” mice reconstituted with either WT or
CXCL10-deficient splenocytes.
Methods: Four groups (n=4-5/gr) of BM chimeras were created using syngeneic
CXCL10 KO and WT mice: 1) KO (BM donor)/WT (recipient); 2) WT/KO; 3)
WT/WT; 4) KO/KO. The chimeras were used at 6-8 wk after successful BM
engraftment, as determined by FACS. They were then subjected to liver partial
warm ischemia for 90 min, followed by 6 h reperfusion. Similarly, groups of
nude mice (n=4-5/gr), reconstituted with splenocytes (5x107 i.v.) from either
WT or CXCL10 KO donors were used at 7 days after cell infusion in the liver
warm IRI experiments.
Results: As expected, WT/WT mice suffered severe hepatocellular injury,
whereas KO/KO mice were protected against IRI, as shown by sALT levels
[Fig.1] and histology. Interestingly, WT/KO suffered severe IRI, comparable
with WT/WT, whereas KO/WT were protected. IR-induced liver proinflammatory response was restored in WT/KO, but remained suppressed
in KO/WT, as shown by qRT-PCR analysis of TNF-α, IL-1β, and IL-6. IRtriggered CXCL10 induction was partially restored only in WT/KO, but not
KO/WT livers. Furthermore, unlike WT, CXCL10 KO splenocytes failed to
recreate liver IRI in nude mice [Fig.1].
Conclusion: The lymphocyte- but not parenchyma-derived CXCL10 is critical
in triggering the innate immune response in liver IRI.
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H-T. Ko1,2, J-L. Yin1, B. Hambly2, V. Levidiotis1, J. Eris1, S. Chadban1
Department of Renal Medicine, Royal Prince Alfred Hospital, and
2
University of Sydney, NSW, Australia
Introduction: Chronic rejection remains the leading cause of late allograft failure.
Chronic allograft vasculopathy is the hallmark of chronic rejection, characterized
by diffuse, concentric intimal-hyperplasia of the coronary vasculature. IL-18 is a
pro-inflammatory, pro-Th1 cytokine that plays an important role in inflammatory
disorders and atherosclerotic disease. Blockade of IL-18 was found to be
protective against intimal-thickening in a murine atherosclerosis model. In this
study, we investigate the role of IL-18 in chronic cardiac allograft rejection in a
class II MHC-disparate murine heart transplant model.
Methods: Heterotopic cardiac transplants were performed: C57BL/6 and
IL-18-/- mice were recipients of B6.H-2bm12 heart grafts, (minor difference within
I-A MHCII antigens). A survival study was performed, assessed by palpation
of the heartbeat. In a second study, hearts were harvested at day 24 and 48
after transplantation (n=6 per group). Neointimal-hyperplasia was quantified
morphometrically in tissue sections stained with Verhoeff’s for elastin by
tracing the luminal area and the area bound by the internal elastic lamina.

1

Infiltration of immune cells and eosinophils were assessed by H&E. CD4+
and CD8+ cell infiltration were stained by immunhistochemistry. Depositions
of collagen and graft fibrosis were demonstrated by trichrome staining. Gene
expression of IFN-γ, IL-4, and IL-18 were determined by real-time RT-PCR.
Results: Survival study: 4/10 of IL-18-/- recipients experienced loss of heartbeat
within 30 days of transplant, versus nil in the B6 wild-type group (p<0.001).
1/7 of grafts in wild-type recipients experienced late graft failure at day 56.
Time point study: Significantly increased neointimal-hyperplasia was present in
IL-18-/- recipients versus wild-type at day 24 (p<0.01) but not at day 48. IL-18-/recipients showed significantly increased parenchymal cell infiltration and
collagen deposition, versus wild-type, at day 24 and 48 (all p<0.05). Eosinophils
were prominent within the infiltrate in IL-18-/- but not wild-type at day 24 and
48 (p>0.01). Infiltration of CD4+ and CD8+ leukocytes was significantly higher
in IL-18-/- recipients than in wild-type at day 24 (all p<0.05)., and CD8+ cells
in IL-18-/- recipients were significantly increased at day 48. Gene expression of
IFN-γ was decreased at day 24 and 48 (all p<0.01) and IL-4 increased in IL-18-/group at day 24 (p<0.05) compared with wild-type.
Conclusion: Deficiency of IL-18 in the recipient caused early graft failure in
this chronic rejection model, which was associated with a reduction in IFN-γ
expression but and increase in IL-4 expression and eosinophil accumulation. A
likely mechanism is that deficiency of IL-18 caused an imbalance of Th1-Th2
resulting in an active and deleterious Th2 immune response.
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643 IL-1β-DRIVEN ST2 EXPRESSION PROMOTES
MATURATION RESISTANCE IN RAPAMYCIN-CONDITIONED
DENDRITIC CELLS
A.W. Thomson1,4, H.R. Turnquist1, T.L. Sumpter1, A. Tsung1, A.F. Zahorchak1,
F.Y. Liew2, G.J. Nau3, D.A. Geller1,
T. E. Starzl Transplantation Institute And Departments of
Surgery,1Microbiology And Molecular Genetics,3And Immunology, 4University
of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Division of
Immunology, 2University of Glasgow, Glasgow, UK
Introduction: Tolerogenicity can be conferred on dendritic cells (DC),
-crucial regulators of T cells, by exposure to rapamycin (RAPA), a tolerancesparing immunosuppressant. Myeloid (m)DC generated in clinically-relevant
concentrations of RAPA (RAPA-DC) are phenotypically immature, particularly
deficient in CD86, and exhibit markedly inhibited T cell allostimulatory capacity.
Both in vitro-generated RAPA-DC and DC from RAPA-treated mice show impaired
responses to TLR4 and CD40 ligation. While poor stimulators of allogeneic CD4+
effector T cells, RAPA-DC enrich for potent alloAg-specific Treg. This contrasts
with control (CTR) mDC that favor non-Treg activation/expansion, especially
when mature. When pulsed with alloAg and infused systemically, RAPA-DC,
but not CTR-DC render alloAg-specific T cells hyporesponsive to donor and
promote indefinite organ allograft survival. By instilling maturation-resistance,
RAPA enables DC to act as ‘negative cellular vaccines’ with tolerogenic potential.
However, the mechanisms underlying the resistance of RAPA-DC to inflammatory
stimuli have not been defined. Our objective was to elucidate a molecular basis for
RAPA-induced DC maturation resistance.
Methods: RAPA administration was used to condition splenic DC in vivo and
bone-marrow derived DC in vitro. DC maturation was monitored by assessment
of costimulatory molecule expression, cytokine production, and allostimulatory
capacity. To identify negative regulators of maturation, microarray analysis and
quantitative RT-PCR was performed, and findings confirmed via Western and
flow cytometric analyses.
Results: In vitro or in vivo exposure of mDC to RAPA elicited de novo production
of IL-1β by otherwise immature DC (CD86lo). Importantly, IL-1β production
by RAPA-DC promoted overexpression of the IL-1 receptor family member,
ST2, and induced its surface expression. Surface ST2 acts as the receptor for
the Th2-polarizing cytokine IL-33 and has also been implicated as a negative
regulator of TLR signaling. Consistent with this regulatory function, RAPA-DC
with either inhibited IL-1β responsivity, and thus failing to upregulate ST2, or
generated from ST2-/- mice, exhibited increased maturity and allostimulatory
capacity, and were more responsive to TLR and CD40 ligation.
Conclusion: Pro-inflammatory stimuli often act in regulatory loops, in which
activation of the signaling downstream from their receptors causes the induction
of negative regulators of the same pathway. A novel aspect of our findings is
that, although RAPA-DC produce IL-1β, a potential inflammatory signal, they
upregulate ST2, remain immature and resistant to TLR stimulation. Thus, DC
conditioning with RAPA, and the consequent induction of ST2, establishes
a barrier to functional maturation of the cells, preserving their tolerogenic
phenotype. This decreases/minimizes any potential risk of host sensitization using
RAPA-DC as negative cellular vaccines. This work identifies a novel mechanism
by which a clinically-important immunosuppressant impedes the capacity of DC
to mature and consequently stimulate effector/adaptive T cell responses.

644 IL-21 ALTERS IMMUNE REGULATION AND PROMOTES
TH17 IN ALLORESPONSE
M Koulmanda, D. Hanidziar, Z. Fan, A. Kroemer, X. Xiao, T.B. Strom,
Departments of Surgery & Medicine, Harvard Medical School, Transplant
Research Center, Beth Israel Deaconess Medical Center, Boston, MA
Introduction: IL-21 prevents recruitment of naive T-cells to Treg phenotype
and simultaneously fosters commitment to pathogenic Th17 cells in vitro.
We hypothesized that IL-21 will promote allograft rejection by adversely
influencing the proportion of effector (Teff) to regulatory T-cells.
Methods: CD4+CD45.2+GFP- Teffs were isolated from both naive and TCRtransgenic anti-bm12 (ABM) foxp3gfp knockin (KI) B57BL/6 (B6) murine
models. CFSE-labeled naive Teffs were cultured 4 days with anti-CD3 and
CD3-depleted B6 splenic cells. ABM Teffs were stimulated with cognate
B6.C-H2-bm12 CD3-depleted splenic cells. CD4+GFP+ Tregs were isolated
from foxp3gfpKI naive CD45.1 and ABM mice (B6). Effects of IL-21 on the
cultures were analyzed by flow cytometry, after intracellular staining for IL-
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17A and IFNγ. In vivo, IL-21 was administered subcutaneously for 28 days in
RAG-/- DBA/2 skin recipients (B6) that were reconstituted with equal numbers
of naive Teffs (GFP-) and Tregs (GFP+) (B6).
Results: Mixed lymphocyte reaction CFSE histograms showed enhanced
stimulation of Teff proliferation by IL-21. When added to naive Teff-Treg
co-cultures, IL-21 blunted Treg-mediated suppression of CFSE-labeled Teff
proliferation. Moreover, IL-21 induced a prominent Th17 response (p<0.05).
However, in the in vitro transgenic system, Th17 cells were induced even in
the absence of IL-21. The addition of TCR-transgenic, but not naive Tregs,
suppressed Th17 response (p<0.05). In contrast, neither TCR-transgenic nor
naive Tregs suppressed Th17 induction in the presence of IL-21. IFNγ, highly
expressed by ABM Teffs cultured alone or with naive Tregs, was significantly
suppressed by ABM TCR-transgenic Tregs (p<0.05). The adverse effects of
IL-21 upon the allograft were confirmed in the DBA/2 to B6 skin transplant
model. The mean survival time of the allograft in the IL-21 treated hosts was 26
days (n=10) compared to 41 days in the untreated controls (n=10) (p<0.01).
Conclusion: IL-21 promoted commitment of naive alloreactive T-cells to the
Th17 phenotype and blunted the immunoregulatory effects of Tregs in vitro.
Consistent with these results, administration of IL-21 to skin allograft recipients
accelerated the transplant rejection.

645 INTERLEUKIN-13 SIGNALING THROUGH THE
INTERLEUKIN-13-RECEPTOR-ALPHA2 IS INVOLVED IN THE
INDUCTION OF TRANSFORMING GROWTH FACTOR-BETA1
PRODUCTION AND ORGAN FIBROSIS
S. Fichtner-Feig, G. Schiech, H-J. Schlitt, E.K. Geissler
Department of Surgery, University of Regensburg, Germany
To investigate the immunopathogenesis of organ fibrosis, a detrimental longterm complication of allograft transplantation, we analyzed bleomycin-induced
lung fibrosis and cardiac allograft transplantation-induced graft fibrosis in
mice. We could demonstrate that interleukin (IL)-13 is a major inducer of a
profibrotic pathway in chronic inflammatory responses leading towards organ
fibrosis and remodelling. In in vitro mechanistic studies, we found that IL-13
induces transforming growth factor (TGF)-beta1 in macrophages through
a two-stage process involving, first, the induction of a receptor formerly
considered to function only as a decoy receptor, IL-13-receptor-alpha2. Such
induction requires IL-13 and tumor necrosis factor (TNF)-alpha. Second, it
involves IL-13 signaling through IL-13-receptor-alpha2 to activate an AP-1
variant containing c-jun and Fra-2, which then activates the TGF-beta1promoter. Investigating this mechanism in vivo, using the bleomycin-induced
lung fibrosis, we found that IL-13, IL-13-receptor-alpha2, and TGF-beta1 were
upregulated on day 13 after initiation of the inflammatory response. We found
an increase in IL-13 expression in the bronchoalveolar fluid from 41.2±7.9pg/
ml on day 0 to 226.5±47.3pg/ml on day 13 and expression level of TGF-beta1
was 69.4±13.1pg/ml on day 0 and 682.4±63.6pg/ml on day 13. In concordance
with this increase in cytokine expression we detected an increase in the amount
of collagen deposited in the lung tissue from 374.9±31.0μg/lung on day 0 to
812.7±237.4μg/lung on day 24. Moreover the prevention of IL-13-receptoralpha2 expression by IL-13-receptor-alpha2 specific gene silencing led to
marked downregulation of TGF-beta1 production (977.6±57.8pg/ml in control
siRNA group vs. 315.2±26.1pg/ml in IL-13-receptor-alpha2 siRNA group,
p<0.01) and collagen deposition (824.1±257.3μg/lung in control siRNA group
vs. 471.9±61.7μg/lung in IL-13-receptor-alpha2 siRNA group, p<0.05) on
day 24 after initiation of the inflammatory response. Studying this pathway
in a mouse model of cardiac allograft transplantation-induced graft fibrosis,
we could demonstrate that the key players of the profibrotic pathway, namely
IL-13 (95.3±13.9pg/100μg allograft protein on day 0, 187.0±20.9pg/100μg
allograft protein on day 60, 303.4±46.5pg/100μg allograft protein on day 100),
IL-13-receptor-alpha2, and TGF-beta1 (39.5±10.7pg/100μg allograft protein
on day 0, 87.6±9.5pg/100μg allograft protein on day 60, 133.2±12.6pg/100μg
allograft protein on day 100) are being upregulated starting on day 60 following
cardiac allograft transplantation (FVB donor heart to DBA/1 recipient) with
increasing expression levels. In addition, the collagen content (50.5±19.1μg/
mg allograft protein on day 0, 105.3±26.6μg/mg allograft protein on day
60, 138.5±22.5μg/mg allograft protein on day 100) of the cardiac allografts
measured by sircol assay was significantly increased on day 100 after cardiac
allograft transplantation. These data are the first to describe the molecular
basis of organ fibrosis involving an IL-13-dependent induction of TGF-beta1
through the IL-13-receptor-alpha2. In addition, specifically targeting the IL-13-
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receptor-alpha2 proved to be an effective strategy to prevent organ fibrosis in
bleomycin-induced pulmonary fibrosis. The increasing expression levels of the
key players in this profibrotic program during chronic allograft rejection give
rise to the assumption that this pathway may be involved in graft fibrosis as a
complication of chronic allograft rejection. Therefore, IL-13-receptor-alpha2
could be specifically targetable to prevent TGF-beta1-mediated graft fibrosis.

646 INTERLEUKIN-21 RECEPTOR ON B-LYMPHOCYTES
IS UPREGULATED IN HIGHLY SENSITIZED RENAL
TRANSPLANT RECIPIENTS:A POTENTIAL TARGET
FOR DESENSITIZATION
R. Tavana, J. Tchervenkov, S. Liu
Department of Surgery, McGill University
Background: Renal transplant patients who are highly sensitized linger on the
transplant list due to HLA specific antibodies. Current desensitization protocols
are unreliable. Interleukin-21 is a type I cytokine that signals through a receptor
composed of the IL-21R and the common cytokine receptor gamma-chain
shared by the all known T-cell growth factors (TCGFs). IL-21 is a regulator of
anti-body production by B-cells (differentiation to plasma cells as well as for
immunoglobulin class switching) and acts as a co-stimulator of proliferation
and memory response in T-cells. We hypothesized that IL-21 could play a
role in antibody production by B-lymphocytes in sensitized renal transplant
recipients. We evaluated the effect of IL-21 on the anti-body production
capacity of B-cells and compared the expression IL-21 Receptor (IL-21R) on
peripheral B-cells in highly sensitized and non-sensitized patients on dialysis.
Methods: B-cells were isolated from peripheral blood of healthy individuals
by positively selecting B-cells with anti CD-19 magnetic beads (MACS). These
cells (purity >95%) were cultured in triplicate 96 plates and were stimulated
with mouse anti-Human CD40 monoclonal Ab (R&D), recombinant IL-21
or combination of both. Supernatants were collected after definite duration
and levels of IgG1 and IgM were measured by ELIZA. Patients (n=19) were
selected from the transplant waiting list based on PRA levels (non-sensitized
<5%, sensitized >50%). After consent, 1-2 ml of peripheral blood was taken
right before initiation of dialysis. After washing and Blocking, blood cells were
incubated with anti-CD19, anti-IL-21 antibodies and paraffin fixed after RBCs
lysis. IL-21R Expression was measured by Flowcytometry over FACScan
machine on the same day.
Results:
1. In-vitro Co-stimulation of B-cells with IL-21 and anti-CD40 increased IgG1
and IgM production significantly (p<0.02) compared with Anti-CD-40 or
IL-21 stimulation alone.
2. In-vitro stimulation of human B-cells with anti-CD40 Antibody alone or in
combination with rIL-21 results in increased expression of IL-21R.
3. The expression of IL-21R is significantly higher on B-cells in highly
sensitized patients compared to non-sensitized patients.(P=0.02)
Highly sensitized pt(HS)
Non-sensitized pt(NS)

647 SMALL BOWEL ALLOGRAFT REJECTION IS
ASSOCIATED WITH CCR6/MIP3A MEDIATED RECRUITMENT
OF HOST CELL INFILTRATION INTO LAMINA PROPRIA
Z. Zhang, Y. Lu, Z. Li, K. Chen, J. Fryer
Northwestern University, Feinberg School of Medicine
Inhibition of epithelial NFkB activation delays small bowel (SB) allograft
rejection possibly by downregulating of chemokine/cytokine production that
influences recruitment of host effector cells. While binding of macrophage
inflammatory protein-3 (Mip-3a), a NFkB dependent chemokine, to its receptor
CCR6 proves to be responsible for recruiting Memory/effector T cells immature
and dendritic cells (iDCs) into inflamed tissues, the role host CCR6 bearing
lymphocytes and iDCs in SB allograft rejection remains unknown. We utilized
a mouse model of SB transplantation, to test our hypothesis that recruitment
of CCR6 bearing host effector cell and iDCs into the Lamina Propria (LP)
of SB allograft through Mip3a/ CCR6 interactions are critical steps led to
SB allograft rejection and are initiated by MyD88 dependent TLR signaling.
SBs from wild type B6 and MyD88 knockout mice were transplanted into
B6 (isograft) or BALB/c (allograft) mice. We isolated epithelial cells and LP
leukocytes from the SB isografts and allografts on POD5, and evaluated Mip3a
mRNA expression by the real time quantitative PCR analysis and leukocytes
compositions by flow cytometry. We observed that the level of Mip3 mRNA
expression in the epithelial cells from SB isografts was similar to that of
normal non-transplanted SBs, while there was more 10 fold increased in Mip3a
mRNA expression in the epithelial cells of the SB allografts. Flow cytometrical
analysis of LP infiltrates revealed a 50% increase in the number of host CCR6
positive cells in SB allografts compared to the isografts, and more interestingly,
the proportion of host CCR6 bearing DCs was markedly increased from 12%
in SB isograft to 43% in SB allografts. Furthermore, we found that abrogating
MyD88 dependent TLR signaling by using SB from MyD88 knockout mice
markedly decreased infiltration of CCR6 bearing host lymphocytes and
minimized mucosal inflammation in the small bowel allografts compared to
wild type allografts at one week after transplantation. Taken together, TLR
signaling through graft derived MyD88 mediated recruitment of CCR6 bearing
host lymphocytes and iDC into the graft LP may be a critical mechanism in
small bowel allograft rejection.

CONCURRENT ORAL SESSION 46: CHIMERISM
648 AN IRRADIATION-FREE PROTOCOL FOR MIXED
CHIMERISM AND TOLERANCE THROUGH TREG-THERAPY
N. Pilat1, U. Baranyi1, C. Klaus1, E. Jaeckel2, N. Mpofu2, F. Muehlbacher1,
T. Wekerle1
1
Div of Transplantation, Dept of Surgery, Medical University of Vienna,
Vienna, Austria, 2Dept of Gastroenterology, Hepatology and Endocrinology,
Hannover Medical School, Hannover, Germany
Background: Routine clinical application of bone-marrow (BM) transplantation
for induction of tolerance by the concept of mixed chimerism is inhibited by the
requirement of cytotoxic host treatment by either irradiation or cytotoxic drugs.
Tregs have potent effects in autoimmune and allo-transplantation models, but
do not induce skin graft tolerance across MHC barriers on their own. Antigenspecific TCR-transgenic T cells retrovirally transduced to express FoxP3 exert
potent suppressor function in certain autoimmune disease models. However,
little is known about the ability of polyclonal FoxP3-transduced T cells to
suppress alloreactivity in wild-type transplantation models. We explored
whether treatment with polyclonal FoxP3 transduced Tregs leads to permanent
engraftment of clinically realistic doses of allogeneic BM and donor-specific
tolerance without irradiation or cytotoxic drugs.
Methods: MACS-separated C57BL/6 CD4+ cells were retrovirally
transduced to express FoxP3 and GFP under the control of an internal
ribosomal entry site. Regulatory function and phenotype were examined in
vitro in proliferation assays and by flow cytometry. Non-irradiated C57BL/6
recipient mice received 20x106 fully mismatched Balb/c bone marrow cells
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intensity of IL-21r exp (orange: HS, blue: NS)

4. There was a significant correlation between PRA level and expression of
IL-21 receptor on peripheral B-cells (r=0.6, p<0.05).
Conclusion: Il-21 and IL-21R may be an important cytokine interaction between
T and B-cells and antibody production in highly sensitized renal transplant
recipients. This may offer a novel target for desensitization protocols.
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(d0) under the cover of costimulation blockade (anti-CD154 mAb, MR1 d0
and CTLA4Ig d+2) and short-course rapamycin (d-1/0/+2). A separate group
of BMT recipients was treated in addition with 2-4x106 FoxP3-transduced
CD4 cells (d0, d+6). Multi-lineage chimerism and deletion of donor-reactive
T cells was followed by flow cytometry. Tolerance was assessed by grafting
donor and 3rd party skin.
Results: All mice receiving additional Treg treatment developed long-term
multilineage chimerism, whereas BMT recipients without Tregs uniformly
failed to do so (7/7 vs 0/7 at wk 19, p<0.01; e.g. 7.08% mean chimerism
among myeloid lineage at wk 12). Notably donor chimerism among T cells,
which is known to correlate with tolerance, was gradually rising in FoxP3Treg recipients. Treg treated recipients showed profound and specific deletion
of donor-reactive T cells in comparison to control group (1.87% vs 3.75%
for Vβ11+ P < 0.05, 0.86 vs 2.46 for Vβ5+ P < 0.01; 13 weeks after BMT)
and naïve B6 mice (1.87 vs 4.96 for Vβ11+ P < 0.05, 0.86 vs 1.72 for Vβ5+
P < 0.05). Notably, additional treatment with FoxP3-transduced Tregs led to
tolerance induction with this otherwise unsuccessful regimen (long-term donor
skin graft acceptance >100days in 7/7 mice in Treg-group vs 1/6 control group,
p<0.005).
Conclusions: These results demonstrate that polyclonal FoxP3-Tregs permit
engraftment of achievable allogeneic BM doses without cytotoxic recipient
treatment. FoxP3-Tregs lead to the induction of lasting mixed chimerism,
deletion of donor-reactive T cells and donor-specific skin graft tolerance in
an irradiation-free BMT protocol. Robust non-cytotoxic BMT regimens with
clinically obtainable BM doses have been elusive so far. We think that these
findings are an important step towards the development of non-toxic BMT
protocols.
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649 INFLUENCE OF CHIMERISM ON TOLERANCE AFTER
COMBINED HUMAN KIDNEY AND HEMATOPOIETIC CELL
TRANSPLANTATION
S. Busque1, J. Scandling2, J. Shizuru2, M. Sarwall5, S. Jones2, C. Benike3,
E. Engleman3, R. Lowsky2, R. Hoppe4, S. Strober2
1
Department of Surgery, Stanford University School of Medicine,
2
Departement of Medicine, Stanford University School of Medicine,
3
Depatment of Pathology,Stanford University School of Medicine,
4
Department of Radiation Oncology, Stanford University School of Medicine,
5
Deparment of Pediatrics, Stanford University School of Medicine
We studied 6 patients enrolled in a tolerance induction protocol with a goal of
complete immunosuppressive drug withdrawal after combined HLA- matched
kidney and hematopoietic cell transplantation. Donors received a 5 day course of
G-CSF 4-6 weeks before transplant surgery, and purified CD34+ hematopoietic
progenitor cells from the apheresis products were mixed with a fixed number
of donor CD3+ T cells (1x10^6) before cryopreservation. After transplantation
surgery, recipients were conditioned with 10 doses of total lymphoid irradiation
and 5 doses of rabbit anti-thymocyte globulin. Immediately after conditioning
(day 10), recipients were given an intravenous injection of the donor cells in the
outpatient clinic. Mycophenolate mofetil was given until day 30, and a tapering
course of cyclosporine until day 180. Five of 6 recipients developed chimerism
with at least 50% donor type cells among B cells, granulocytes, and/or NK
cells. One patient with rapid return of focal segmental glomerulosclerosis in
the transplant was treated with multiple plasmaphereses, and failed to develop
chimerism.Chimerism persisted for at least 6 months in 3 of the 5 recipients,
and all immunosuppressive drugs were either tapered to discontinuation or are
in the midst of tapering. The first patient has been off of all drugs for more than
2 years. Two chimeric patients with early immunosuppressive drug reduction
developed loss of chimerism associated with a rejection episode. Analysis of the
gene array profiles of PBMC of the first patient showed a “ tolerance” pattern,
and donor specific unresponsivesness in the MLR after drug withdrawal. In
conclusion,tolerance does not develop as soon as chimerism is established,
and drug withdrawal without allograft rejection episodes was feasible several
months after persistent chimerism. The results suggest that tolerance induction
in this protocol is an active and dynamic process.
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650 TOLERANCE INDUCTION IN A LARGE-ANIMAL
MODEL USING TOTAL LYMPHOID IRRADIATION AND
INTRATHYMIC BONE MARROW
P.J. Horton1, W.J. Hawthorne2, S. Walters2, T. Patel2, G.J. Stewart2,
R.D.M. Allen2, J.R. Chapman2
1
Division of Solid Organ Transplantation, University of Rochester Medical
Center, Rochester, New York, United States and 2Centre for Transplant &
Renal Research, Westmead Millennium Institute, Sydney, New South Wales,
Australia
Background: Immunological unresponsiveness of T-cells to alloantigen can
be induced by intrathymic injection of donor-specific antigen in small-animals.
Intrathymic tolerance to vascularised grafts in large-animals has not previously
been reported.
Methods: Twenty-six dogs were allocated into dog leukocyte antigen (DLA)
DP-matched pairs. Female recipients and male donors were preferred. Tissue
typing was based on restriction fragment length polymorphism. Recipients were
given total lymphoid irradiation (TLI), receiving 18Gy in 16 fractions (1.125Gy
each) over four weeks. After 6.75Gy, dogs underwent thoracotomy permitting
perithymic (n=4) and intrathymic (n=4) injection of donor bone marrow buffy
coat. Saline was injected in controls (n=5). Bone marrow engraftment outside
the thymus was prevented by further irradiation.
Fifty days post-thoracotomy recipients underwent bilateral native nephrectomy
and donor-specific kidney transplantation. Acute rejection was diagnosed by
serum creatinine >600μmol/L or urea >40mmol/L and histology. Full thickness
skin grafts followed >100 days post-RTx. Tissue samples were taken for
Y-chromosome polymerase chain reaction (PCR).
Results: Twelve female and one male recipient, aged 6-18 months, completed
the protocol. Control animals rejected kidneys after 8, 10, 23, 26 and 38
days. Intrathymic bone marrow recipients rejected after 27, 32 and 54 days;
one survived rejection-free for 288 days. Perithymic bone marrow recipients
survived rejection-free for 419, 199, 120 and 42 days (p=0.003). Recipients
surviving >100 days post-RTx accepted donor-specific and rejected DLA-DP
identical 3rd party skin grafts. PCR detected intrathymic chimerism but not
haematopoetic chimerism.
Conclusions: Fractionated TLI and either perithymic or intrathymic donorspecific bone marrow induced tolerance to allogeneic kidney and skin grafts.
This study demonstrates for the first time that tolerance to vascularised grafts
can be induced in large-animals using the intrathymic route.

651 INDUCTION OF ALLOREACTIVE CD4 TOLERANCE BY
CROSS-PRESENTATION OF DONOR MHC MOLECULES BY
RECIPIENT APC’
J. Kurtz1,2, L. Shubert2, S. LoCascio2, M. Sykes1
Transplantation Biology Research Center, Massachusetts General Hospital
and Harvard Medical School, 2Emmanuel College
The establishment of mixed hematopoietic chimerism across full MHC
barriers using a non-myeloablative regimen with costimulatory blockade (antiCD8 mAb and 3Gy total body irradiation on day-1 and 20x106 donor bone
marrow cells plus anti-CD154 mAb on day 0) induces rapid donor-specific
CD4 T cell tolerance. We have previously demonstrated a requirement for an
intrinsic CTLA-4 signal to recipient CD4 cells by B7.1/2 molecules expressed
by recipient and not donor hematopoietic APCs in order to tolerize alloreactive
CD4 cells.
In mixed chimeras prepared using this protocol, peripheral directly donorreactive CD4 T cells are deleted as early as one week post-BMT, and by 4
weeks are reduced to undetectable levels. To determine the fate of indirectly
alloreactive CD4 T cells, we created ‘syngeneic chimeras,’ whereby recipients
contain a small population of indirectly alloreactive transgenic CD4 T cells
specific for donor peptide/recipient class II MHC complexes. C5BL/6-CD45.1
received 3GY TBI and 4x106 BMC from C57BL/6-TEa TCR transgenic mice
(CD45.2+), which recognize a peptide of the I-E molecule presented by I-A.
Mice were allowed to rest until stable levels of transgenic CD4 cells were
established in peripheral blood (12 weeks). These synchimeras then received
allo-BMT with the above protocol with BMC that was I-E+ (B10.A), I-E(B10.S), or no BMT. At one week post-BMT, mice that received B10.A BMC
showed almost complete deletion of the indirectly alloreactive transgenic cells
(donor MHC-CD4+CD45.2+) in the peripheral blood (0.21%±0.19), whereas
mice that received either B10.S or conditioning alone did not (2.73%±1.56 and
1
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2.40%±.92, respectively). These data demonstrate rapid deletion of indirectly
alloreactive CD4 T cells, suggesting that recipient APC rapidly acquire donor
MHC molecules for processing/presentation on self MHC class II.
To further understand the mechanism by which peripheral directly alloreactive
CD4 T cells are tolerized, we hypothesized that recipient APC may ‘cross-dress’
wherein intact donor MHC molecules are transferred from donor to recipient
B7-expressing cells for presentation on their surface, where they interact with
recipient CD4 cells. C57BL/6-CD45.1 recipients that received B10.A (CD45.2)
BMT with the above protocol were sacrificed at 2, 4, and 7 days post-BMT,
and various splenocyte populations (B cell, myeloid DC, lymphoid DC) were
analyzed by flow cytometry. As early as 2 days post-BMT, a small, distinct
population of recipient B cells (CD19+ CD45.1+) was found to express donor
MHC class I and II molecules on their surface, as was a small percentage of
dendritic cells, although not as distinct. Similar data were obtained at 4 and 7
days post-BMT.
These data elucidate mechanisms by which BMT with CD40/CD154 blockade
induces donor-specific tolerance, and strongly suggest that interactions of
recipient APC with both indirectly and directly alloreactive CD4 T cells play
an important role.

652 REQUIREMENT FOR MHC CLASS I AND II EXPRESSION
ON HOST DENDRITIC CELLS TO TOLERIZE ALLOREACTIVE
CD8 CELLS DURING INDUCTION OF MIXED CHIMERISM

W.J. Hawthorne1, P.J. Horton2, M.L. Ferrara1, A.D. Griffin3, G.J. Stewart1,
R.D.M. Allen4, J.R. Chapman1
1
Centre for Transplant and Renal Research, Westmead Millennium
Institute, Sydney, New South Wales, Australia, 2Division of Solid Organ
Transplantation, University of Rochester Medical Center, Rochester, New
York, United States, 3Renal Transplant Unit, Princess Alexandra Hospital,
Brisbane, Queensland, Australia and 4Department of Surgery, Royal Prince
Alfred Hospital, Sydney, New South Wales, Australia
Background: Mixed hematopoietic chimerism depends on engraftment of
donor bone marrow and is associated with donor-specific tolerance.
Aim: To determine renal allograft survival in dogs treated with fractionated
total lymphoid irradiation (TLI) and donor-specific bone marrow
(DSBM).
Methods: Twenty-eight pairs of dog-leukocyte-antigen (DLA) DP-matched
spaniels were used. Tissue typing was based on restriction fragment length
polymorphism. Female recipients and male donors were preferred. Twentytwo dogs underwent TLI, receiving 18Gy in 16 fractions over four weeks.
Eighteen dogs had DSBM infused post-TLI (Group 1), while four dogs
received TLI alone (Group 2). Fifty days post-TLI recipients underwent
bilateral native nephrectomy and donor-specific kidney transplantation
(RTx) without immunosuppression. A control group received no treatment
prior to RTx (Group 3). Acute rejection was diagnosed by serum creatinine
>600μmol/L or urea >40mmol/L and compatible histology. Full thickness
skin grafts followed >100 days post-RTx. Tissue samples were taken for
karyotyping.
Results: Only dogs receiving >4x108 nucleated bone marrow cells/kg
recipient weight developed hematopoietic chimerism and tolerance. Seven
tolerant animals survived for median 974 days (range 185 to 1541) and
accepted donor-specific while rejecting DLA-DP identical 3rd party skin
grafts. Four dogs (22.2%) developed graft-versus-host-disease. Dogs
given TLI alone (Group 2) rejected the renal allograft after median 28
days (range 26 to 33) compared to 20 days (range 18 to 22) for control
animals (Group 3).
Conclusions: We have defined the parameters necessary to induce mixed
hematopoietic chimerism and tolerance to renal and skin allografts in DLA-DP
matched dogs without using immunosuppressive drugs.

654 DONOR BONE HARBORS HIGHEST CHIMERISM AND
IS SUFFICIENT TO PROMOTE ALLOGRAFT TOLERANCE
AFTER HETEROTOPIC HINDLIMB TRANSPLANTATION
M.J. Elliott, L.D. Bozulic1, D. Rahhal1, L. Adamson1, W-C. Huang2, H. Xu1,
Y. Huang1, W.C. Breidenbach3, and S.T. Ildstad1.
1
Institute for Cellular Therapeutics, Louisville, KY; 2Chang Gung Memorial
Hospital, Taipei, Taiwan; 3Kleinert, Kutz, and Associates Hand Care Center,
Louisville, KY
The requirement for immunosuppressive agents to prevent rejection has limited
the widespread clinical application of composite tissue allotransplantation
(CTA). An approach to induce transplantation tolerance and avoid the toxicity
associated with these agents would be significant. Chimerism established
with nonmyeloablative conditioning has been shown to induce tolerance to
organ transplants. However, whether acceptance of such a highly antigenic
tissue as CTA would occur in nonmyeloablatively conditioned recipients
remains controversial. In the present studies we evaluated the effect of
nonmyeloablative conditioning on the establishment of mixed chimerism
and CTA graft acceptance. Mixed allogeneic (ACI→WF) chimeric rats were
prepared by conditioning recipients with doses of total body irradiation (TBI)
ranging from 100 to 600 cGy on day 0 followed by anti-lymphocyte serum (5
mg) on day 10, FK-506 (1 mg/kg/day) days 0-10, and a single dose of anti-αβTCR mAb administered on day -3. Animals received 100 x 106 T-cell depleted
ACI bone marrow cells on day 1. An osteomyocutaneous flap was placed at
29 days in animals with chimerism ≥ 1%. Nine CTA acceptors were followed
for 6 months, then evaluated for chimerism in several hematopoietic tissue
compartments. Seven of the nine animals did not have detectable peripheral
blood (PB) chimerism. One animal had low donor PB chimerism (~1.33%) and
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BMT Section, Transplantation Biology Research Center, Department of
Surgery, Massachusetts General Hospital, Harvard Medical School
Objectives: Induction of mixed hematopoietic chimerism provides an approach
to achieving donor-specific tolerance. In the mouse, non-myeloablative
conditioning with anti-CD154 (CD40L) and 3Gy total body irradiation (TBI)
overcomes CD4 and CD8 cell-mediated resistance to allogeneic marrow
engraftment, permitting mixed chimerism induction. A requirement for host
dendritic cells (DC), CD4 cells, and MHC class II expression to tolerize
alloreactive CD8 cells has been demonstrated. Both indirectly and directly
alloreactive CD8 cells can prevent donor marrow engraftment when CD4 cells
are depleted. We hypothesize that the requirement for host CD4 cells and DCs
to tolerize alloreactive CD8 cells reflects three cell (CD4, CD8, and APC)
interactions occurring with CD40/CD40L blockade.
Methods: To generate recipient mice lacking expression of class I and II on
DCs, we used diphtheria toxin receptor (DTR)-transgenic mice which express
the primate DTR transgene under control of the murine CD11c promoter, so
that intraperitoneal (i.p.) administration of diphtheria toxin (DT) selectively
depletes CD11c+ DCs. B6 mice were lethally irradiated and reconstituted with
a mixture of bone marrow cells (BMC) from CD11c DTR and CIITa KbDb
class I and class II MHC-deficient B6 mice. Additional groups of mice were
reconstituted with a mixture of DTR and CIITa-/- or DTR and B6 BMC to
generate recipients with DCs lacking only class II expression or with wildtype DCs, respectively. In another experiment, we generated recipients lacking
expression of class I on host DC by reconstituting B6 mice with a mixture of
BMC from DTR and KbDb -/- or B6 mice. All mice received i.p. injections
of DT for two weeks beginning one day prior to allogeneic bone marrow
transplantation (BMT) with 3Gy TBI/anti-CD154. Chimerism was analyzed
by FACS.
Results: Seven of seven mice lacking class I and II expression on host DCs
rejected donor marrow by two weeks post-BMT. Rejection was prevented by
recipient CD8 depletion; all 4 of these mice were chimeric. Four of seven mice
lacking only class II on their DCs and 5 of 6 mice with wild-type DCs were
mixed chimeras at 2 weeks. In the second experiment, 7 of 9 mice lacking class
I expression on host DCs were mixed chimeras at 8 weeks compared to 4 of 5
mice with wild-type DCs.
Conclusion: These data suggest that in the absence of both MHC class I and
II expression on host DCs, allogeneic donor marrow was rejected by recipient
CD8 cells. However, when host DCs lacked only class II, donor marrow was
variably rejected, and when they lacked only class I, donor marrow was not
rejected by CD8 cells. Our data suggest the existence of a complex tolerance
pathway involving interactions of indirectly and directly alloreactive CD4 and
CD8 cells on recipient DCs that may pick up and present intact donor MHC
molecules.

653 CHIMERIC TOLERANCE INDUCED BY TOTAL
LYMPHOID IRRADIATION AND DONOR SPECIFIC BONE
MARROW INFUSION IN DLA-DP MATCHED DOGS
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1 had high PB chimerism (~73%) (not shown). With the exception of the latter
animal, when bone marrow from the transplanted donor bone was collected
and analyzed from 5 animals, significantly higher levels of donor chimerism
were observed in this compartment than in peripheral blood (P<0.01), draining
lymph node (P<0.05), thymus (P<0.05), and spleen (P<0.05). Significantly
higher levels of donor chimerism were also observed in the transplanted bone
vs. recipient native bone (P = .0358). A second donor skin graft challenge was
also accepted and did not result in rejection of the CTA. These results suggest
that homing of donor lymphocytes/stem cells to their native bone takes place
in the absence of lasting peripheral blood chimerism and that chimerism in
the bone is sufficient to induce donor-specific tolerance. Additional studies are
underway to determine whether transplanted vascularized bone graft provides
a vacant niche for donor stem cells, thereby providing a continuous tolerizing
source.
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evident in the spleens of transplanted animals.
Considering the favorable effects associated with Rapa administration,
AAsTreg were tested for their ability to induce transplant tolerance
employing the following protocol: B10 recipients of vascularized BALB/c
hearts received Rapa (1mg/Kg/d; d0-9) and 2x106 AAsTreg i.v. on d7. In
comparison to the untreated group (median survival time, MST=11d; n=14),
Rapa alone extended MST to 30 d (n=7), with no long-term graft survival.
AAsTreg under cover of Rapa exerted a profound tolerogenic effect: >80%
recipients exhibited long-term graft survival (MST>150d; n=6). This effect
was stronger than that achieved with polyclonal Treg administration: 40%
long-term survivors (MST=45; n=5). Moreover, the tolerogenic effect was
Ag-specific as AAsTreg selected against third party DC (C3H/HeJ) did
not prolong graft survival in comparison to the Rapa-only control group.
Significantly, heart graft survival was mediated via migration of infused
AAsTreg to graft-draining lymphoid tissues and the induction of alloreactive
T cell anergy.
Thus, combination of the anti-inflammatory properties of rapamycin with
AAsTreg administration, may represent an effective, clinically-applicable
approach to minimization of drug-based immunosuppression, and the induction
of long-term allograft survival.

656 DONOR CELL INFUSION WITHOUT
IMMUNOSUPPRESSION AS A NOVEL THERAPY FOR
INDUCTION OF DONOR-SPECIFIC TOLERANCE IN ISLET
CELL TRANSPLANTATION
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655 LONG-TERM ALLOGRAFT SURVIVAL IN
UNMANIPULATED HOSTS BY POST-TRANSPLANT INFUSION
OF DONOR-SPECIFIC REGULATORY T CELLS AND
RAPAMYCIN
G. Raimondi, T.L. Sumpter, B. Matta, D. Tokita, Z. Wang, A.W. Thomson
TE Starzl Transplantation Institute, University of Pittsburgh School of
Medicine, Pittsburgh, PA, USA, 15213
Long-term donor-specific acceptance of MHC-mismatched organ allografts
in unmanipulated hosts by administration of naturally-arising regulatory T
cells (Treg) remains an unmet goal. High frequency of alloreactive T cells and
pro-inflammatory condition are emerging as the two major hurdles preventing
induction of tolerance. We report the first demonstration of a toleranceinducing strategy based on post-transplant administration of allo-Ag-specific
Treg (AAsTreg) and rapamycin (Rapa), in a fully allogeneic, unmanipulated
mouse heart transplant model.
Enrichment of naturally-occurring AAsTreg represented the first step to
counteract the high frequency of alloreactive T cells. Selection of AAsTreg
was achieved by co-incubation of freshly-isolated CD4+CD25+ T cells with
donor bone marrow-derived dendritic cells (DC). This procedure rendered
a population with a conventional regulatory phenotype: Foxp3+, GITR+,
CTLA-4+, CCR7+, CD62L-. These cells potently inhibited in vitro effector
T cell proliferation at 1:20 and 1:40 Treg:T cell ratios. The suppressive
activity was Ag-specific; no significant inhibition was evident when effector
T cells were stimulated by third party DC. However, T cells isolated from
the spleen of graft recipients (d7 post transplant) were less susceptible to
AAsTreg inhibition. Such “resistance” was associated with the inflammatory
state arising from transplantation. This resistance to Treg suppression was
neutralized by Rapa administration, which also prevented graft infiltration
by effector T cells and favored endogenous Treg activity/expansion as was
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X. Luo, K. Pothoven, D. McCarthy, M. DeGutes, A. Martin, G. Xia, S. Miller
Northwestern University Feinberg School of Medicine
Background: In autoimmune models, peptide-pulsed splenic antigen presenting
cells that are chemically fixed with ethylcarbodiimide (ECDI) have been used
as a powerful and safe method to induce antigen specific T cell tolerance. ECDI
fixed donor cells for allo-antigen specific transplant tolerance has not been well
studied.
Material and methods: C57BL/6 mice were rendered diabetic by STZ. Kidney
subcapsular allogeneic islet transplant was performed 10 days after diabetes
stabilization (day 0). 1x108 ECDI-treated donor splenocytes were injected i.v.
either once (day -7) or twice (day -7 and day +1). Animals were analyzed for
graft outcome.
Results:Control mice receiving islet graft alone rejected the graft
between day 11 to day 18 (MST = 14 days, N=8). Mice receiving one
dose of ECDI-treated donor splenocytes (on day -7) showed similar graft
survival as controls (MST = 15 days, N=5). In contrast, mice receiving 2
doses of ECDI-treated donor splenocytes (on day -7 and day +1) showed
significant prolongation of graft survival with 72.7% functional grafts at
day 60 (N=11), and some remained functional >100 days. This protection
is donor-specific as mice receiving ECDI-treated SJL cells rejected Balb/c
islet grafts as controls (MST = 18 days, N=4). Immunohistochemistry
of protected grafts showed positive insulin staining within well-defined
islet architecture. Peri-islet infiltrates were composed of CD4+, CD8+,
and CD11c+ cells, with occasional Foxp3+ cells. Anti-donor antibody
production (IgG1,G2a,b, G3) was completely abolished in long-term graft
survivers. This tolerance was undisturbed by anti-CD25 antibody treatment
during maintenance stage, but could not be established if treatment was
given around the time of the first donor cell infusion. In addition, lack of
PD-L1 also impaired tolerance induction evidenced by using PD-L1-/- as
recpients.
Conclusion: 1. Multiple infusions of ECDI-treated donor splenocytes
significantly prolonged allo-graft survival in the islet transplant model. 2. The
protective effect is donor-specific and is dependent on regulatory T cells as well
as the PD-L1 signaling pathway. Therapy with ECDI-treated donor cells may
emerge to be a novel and potent agent for induction of donor-specific transplant
tolerance.
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ACUTE REJECTION AND HLA

658 SUCCESSFUL TRANSPLANTATION OF DONOR
SPECIFIC ANTIBODY POSITIVE, CROSSMATCH NEGATIVE
(AHG/FCXM)RENAL ALLOGRAFT RECIPIENTS

657 RENAL ALLOGRAFT OUTCOME AMONG RECIPIENTS
OF POSITIVE VS NEGATIVE CROSSMATCH COMBINED
LIVER-KIDNEY TRANSPLANTATION: UNOS DATA ANALYSIS

J. Lappin, J. Abraham, S. Katz, B. Kahan, E. McKissick, K. Hosek,
A. Hoover, B. Biedermann, R. Kerman, C. Van Buren
The University of Texas Medical School-Houston
Historically, the pretransplant (Tx) crossmatch (XM) alone was used to pair
immunologically appropriate donors and recipients (recips) for transplantation.
Recips were then transplanted following a negative (neg) donor-recipient antihuman globulin (AHG) XM and, more recently, following a neg, more sensitive,
flow cytometry XM (FCXM). In addition, the presence of HLA antibodies (Abs)
and their specificities can be identified in patient sera by Luminex and single
antigen bead technology. Would there be an increased immune and clinical risk
if the preTx evaluation yielded neg donor specific AHG and FCXMs albeit
in the presence of a positively identified donor-specific HLA Ab (DSA) in
patient sera? To address this question we prospectively transplanted 17 renal
allograft recips (14 with deceased and 3 with living related donors, including
5 ReTx and 12 primary recips, 8 females and 9 males; 6 of African American,
8 of Caucasian, 2 of Hispanic and 1 of Asian heritage). Immunosuppression
consisted of Thymoglobulin induction followed by Sirolimus (N=13),
Cyclosporine, Mycophenolate Mofetil (N=4) and Prednisone maintenance
therapy. No patients received preTx plasmapheresis. At one year post Tx there
was a 100% patient survival. One patient experienced a resolvable acute cellular
rejection while five patients (29%) experienced antibody mediated rejection
(AbMR). There were four graft losses with one due to a hypercoaguable
state and three immune losses to AbMRs (yielding an immune loss of 18%).
All three recips with AbMR and subsequent graft loss, occurred in African
American females and two of the three AbMRs were preceded by delayed graft
function (DGF). Two additional Caucasian female recips with immediate graft
function that also had AbMRs responded positively to therapeutic intervention.
The preTx DSA titers (1:2 – 1:32) and/or fluorescence intensities (8,486 ±
3,229) of Ab-DSA specific beads were not predictive of DGF, rejection or
graft loss. The presence of DSA in preTx neg AHG and FCXM recips did not
predict the clinical outcome. However, female recips may be at increased risk
for developing AbMRs and experiencing graft loss. In this study specifically,
African American females with DGF were at high risk (3X) of developing
AbMR and graft loss. To our knowledge this is the first report that patients with
neg AHG and FCXMs and positive DSAs can be successfully transplanted.
African American female recips who experience DGF could be treated more
aggressively (Ab reduction, anti-CD20 Ab, plasmapheresis) in this subset of
patients to guard against unresolvable AbMR and graft loss.

R. Parasuraman1, K.K. Venkat1, D. Moonka2, A. Yoshida2, A. Kappke3,
K. Brown2, M. Abouljoud2, D. Kim2
1
Division of nephrology, Henry Ford Hospital and 2Transplant Institute,
Henry Ford Hospital, Detroit, MI, United States
Successful combined liver kidney transplantation (CLKT) despite pre-transplant
positive cross match (+ CXM) has been reported implying immunoprotective
effect of liver allograft (LA) on renal allograft (RA). However, severe acute
humoral rejection with RA loss has been documented suggesting LA may not
always protect RA.
Aim: To examine the effects of pre-transplant + CXM on RA outcome in
CLKT.
Method: A total of 1401 CLKT recipients for whom CXM data available were
identified from UNOS data base from 1986–2006. Of these, 242 (17.3%) had
+CXM and data was analyzed for acute rejection rate and RA outcome. The
significant results are summarized below.
Variable

Negative CXM N
= 1159

Positive CXM N
= 242

p-value

Recipient: Female

374(32%)

136 (56%)

0.001

% Class I PRA

25.9±26.5

66.3±40.5

0.001

% Class II PRA

31.0±29.3

56.4±36.3

0.013

treated for rejection

69/606 (11%)

24/150 (16%)

0.026

Length of stay: Admission to
discharge

Days
28.8±33.2(N=838)

Days
37.3±46.0(N=155) 0.028

Results: The demographic and clinical data were similar between +CXM
and Negative CXM groups. The rejection rate was significantly higher and
the length of stay was significantly longer in +CXM group as shown in the
table. The RA survival rates were 8%, 7% and 6% lower at 1, 3 and 5 years
post transplant respectively among + CXM recipients. However, this did not
reach significance mostly due to small sample size (p=0.11). The inferior RA
outcome is seen during the initial few years after transplantation that disappears
after 9 years.

659 THE PRESENCE OF AN ANTIBODY COMPONTENT
IN ACUTE CELLULAR REJECTION DECREASES RENAL
ALLOGRAFT SURVIVAL
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Conclusion: In CLKT, pre-transplant +CXM can result in higher RA
rejection rate and longer length of stay in hospital. LA may not always confer
immunological protection to RA in + CXM CLKT and its true burden may be
under recognized since CXM is not routinely performed in all CLKT. Study of
antibody specificities or LA volume to determine the effect of +CXM on RA
outcome is essential.

M. Everly, J. Everly, P. Brailey, B. Susskind, L. Arend, A. Govil,
R.R. Alloway, P. Roy-Chaudhury, A. Tevar, E.S. Woodle
University of Cincinnati, Cincinnati, Ohio, USA
Background: Recent studies indicate that many acute rejection (AR) episodes
are not purely acute cellular rejection (ACR), but are mixed (i.e. contain humoral
aspects and ACR). Despite this new understanding of humoral involvement,
data regarding long term allograft survival in patients with mixed rejection
is unknown. The purpose of this study was to define the influence of humoral
components during AR (AMR or mixed) on graft survival.
Methods: Renal allograft recipients with AR by biopsy (bx) between 1/1/2003
and 8/1/2007 were evaluated for donor specific anti-HLA antibodies (DSA)
[Luminex platform/Labscreen single antigen beads] and C4d. All DSA were
de novo, i.e., not detected prior to transplantation. Bxs were graded by Banff
‘97 criteria (update 2003) for ACR and antibody mediated rejection (AMR).
Mixed AR included both AMR and ACR. AMR and mixed AR were treated
with apheresis, IVIg, rituximab, and/or thymoglobulin. Survival analysis was
performed by Kaplan Meier (STATA/SEv9.2).
Results: 48 patients with AR and DSA evaluation were analyzed: 30 were
classified as ACR, 8 AMR, and 10 Mixed. Demographics were similar between
groups. Median follow-up was 27.5 +/- 17.5 mos. Kaplan-Meier survival is in
Figure 1. Pts with AMR (p<0.001; Log-rank) or mixed AR had reduced graft
survival compared to ACR pts (p=0.002; Log-rank). GL was not observed in
31 pts with ACR.
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ACR
(n=31)

AMR
(n=8)

Mixed
(n=10)

p1

p2

Rejection Reversal, pts (%)

25 (83)

7 (88)

8 (80)

NS

NS

Recurrent Rejection, pts (%)

3 (10)

1 (12)

2 (20)

NS

NS

Overall GL, pts (%)

0

4 (50)

3 (30)

0.0009

0.0113

GL due to Chronic Rejection, pts (%)

0

3 (37)

2 (20)

NS

NS

GL due to Acute Rejection, pts (%)

0

1 (13)

1 (10)

NS

NS

Overall Graft Survival
(Kaplan-Meier: Log Rank)

100%

28.1%

64.3%

<0.001

0.002

p1 = ACR vs AMR, Fischers Exact; p2=ACR vs Mixed, Fischers Exact

Conclusions: Humoral involvement in AR has a profound negative impact
on graft survival. Therefore in all cases of rejection: (1) detection of humoral
components is essential to define a patient’s risk of graft loss, and (2) effective
treatment of the humoral component may reduce graft loss.

660 SERIAL MONITORING OF ANTI HLA-ANTIBODIES
IN LIVING RELATED RENAL ALLOGRAFT RECIPIENTS IN
EARLY POST-TRANSPLANT PERIOD AND CORRELATION
WITH PROTOCOL HISTOLOGY
M. Minz1, A. Yadav1, A. Sharma1, R. Minz2, K. Joshi3
Dept of Transplant Surgery, PGIMER, 2Dept of Immunopathology, PGIMER,
3
Dept of Histopathology, PGIMER
Introduction: The role of antibodies in rejection of solid organ allografts is
being increasingly recognized with development of improved techniques for the
characterization of anti-HLA antibodies. A large number of studies analyzing
the incidence of these anti HLA antibodies in past with patients with graft
dysfunction have proved the usefulness of their monitoring. However, none of
the studies have correlated presence of anti-HLA antibodies with changes in
protocol biopsies. The present study evaluated for appearance of Class I & II
anti HLA antibodies in immediate post renal transplant period, and correlated
it with simultaneous changes in histology in protocol biopsies done in the first
six months after transplant
Methods: Sera of 20 consecutive living related renal transplant recipients
[Mean age 31.0 + 8.8 yrs, M:F 13:7, Median Follow up of 6 months] were
screened for anti HLA class 1 and 2 antibodies by commercial ELISA
kits[GTI Inc., Waukesha, WI, USA] at 1, 3 and 6 months after transplantation.
The results of these tests were correlated with protocol biopsies and renal
function during the follow-up period. A total of 48 protocol biopsies were
performed. Immunosuppression comprised of Tacrolimus, Mycophenolate and
Prednisolone in all patients.
Results: Antibodies to class I was found in 25% of recipients included in this
study, and class II antibodies were found in 10% of recipients. The incidence
of acute rejection in these patients was similar to those who did not develop
antibodies after transplant [33.3% vs. 28.5%, p=NS]. Two patients in the
cohort had Type III Banff rejection which was associated with presence of
antibody. Changes of early chronic allograft nephropathy were seen in 2
patients. One of these patients had Class I antibodies in the serum. Serum
creatinine at 6 months in patients with antibody production was 1.2+0.6mg%
as compared to 1.4+ 0.4 mg% in those without anti-HLA antibody [p=NS].
Conclusions: Presence of anti-HLA antibody was associated with severe
rejection episodes and may predict development of chronic allograft
nephropathy.
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661 ANTIBODY-MEDIATED REJECTION IN RENAL
ALLOGRAFT RECIPIENTS TREATED WITH ALEMTUZUMAB
INDUCTION
J. Pascual, J.D. Pirsch, J.R. Torrealba1, A. Djamali2, Y.T. Becker, G. Leverson,
S.J. Knechtle, H.W. Sollinger, M.D. Samaniego2
Department of Surgery, Division of Transplantation, Department of Pathology
and 1Laboratory Medicine and 2Department of Medicine, University of
Wisconsin School of Medicine and Public Health, Madison, WI, USA
Alemtuzumab is a depletive agent used in induction therapy in kidney
transplantation (KT). Prevalence, risk factors and impact of antibodymediated rejection in alemtuzumab-treated patients is not well-known. From
2002 to 2005, 829 isolated KT in adults were performed at our institution.
Alemtuzumab induction was used in 613 of them, 602 without primary nonfunction. In addition to MMF and steroids, immunosuppression was based on
CsA (n=294), tacrolimus (n=187) or CNI-free (n=121). Tacrolimus patients
were younger, more sensitized and received more retransplantations. CNI-free
ones were older, more frequently received a cardiac dead donor kidney and
less frequently a living donor one. Delayed graft function was more frequent
in CNI-free patients.
Biopsy-proven acute cellular rejection (ACR) was diagnosed in 41 (6.8%)
patients, 13 of them before day 90th (early ACR) and 28 later (late ACR).
Biopsy proven C4d-positive AMR was diagnosed in 128 patients (21.2%), 58
early and 70 late cases. Donor age (HR 1.02, p=0.001), recipient age (HR 0.97,
p=0.001), peak PRA (HR 1.008, p=0.06) and HLA-B two mismatches (HR
1.57, p=0.02) were significant risk factors for AMR in the multivariate analysis.
Peak PRA (HR 1.017, p=0.001), pregnancies (HR 1.13, p=0.01) and CNI-free
treatment were risk factors for Early AMR, whereas donor age (HR 1.032,
p=0.001), recipient age (0.96, p=0.001), peak PRA (HR 1.017, p=0.001), CMV
D+R- status (HR 1.77, p=0.03) and time on dialysis (in months, HR 1.009,
p=0.02) were significant risk factors for Late AMR.
Post-rejection graft survival was similarly affected by all types of rejection
(Kaplan-Meier, all p<0.001 vs non-rejectors). Risk factors for graft loss in the
multivariate analysis were pretransplant diabetes (HR 1.61, p=0.01), ACR (HR
3.90, p<0.0001) and AMR (HR 3.83, p<0.0001). Post-rejection patient survival
was more affected by AMR (Kaplan Meier, early AMR p=0.001, late AMR
p=0.01, early ACR p=0.03, late ACR p=0.90, all vs non-rejectors). Risk factors
for post-rejection death in the multivariate analysis were recipient age (HR
1.06, p<0.001), pretransplant diabetes (HR 2.39, p<0.001), time on dialysis (in
months, HR 1.009, p=0.006) and AMR (HR 1.74, p=0.06).
AMR is very frequent (more than ACR) in alemtuzumab treated KT recipients,
and the reasons are not well-known. CNI-free regimens promote early AMR
episodes, whereas young recipients receiving old kidneys are predisposed to
late forms.

662 NON-HLA ANTIBODIES REACTIVE WITH
ENDOTHELIAL CELLS COULD BE INVOLVED IN EARLY
LOSS OF RENAL ALLOGRAFTS
C.R.D.S.C. Ronda1, D. Glotz5, E. Ianhez2, H. Rodrigues1, S.C. Ferreira1,
D.S.R. David2,3, C.S. Viggiani1, M.C. Castro2, J. Kalil1,4, N. Panajotopoulos1,4
1
Laboratory of Immunology, Heart Institute (InCor), School of Medicine,
University of São Paulo, 2Renal Transplant Unit of São Paulo, 3Division
of Pathology, University of São Paulo, 4iii – Institute for Investigation in
Immunology, Millenium Institute, Brazil, 5Departement of Nephrology and
transplantation, Hospital Saint-Louis, Paris, France
We investigated the presence of non-HLA antibodies in 11 patients who had
early loss of their transplanted kidney from irreversible humoral rejection
and 2 from renal venal thrombosis. The diagnosis was established based on
clinical and biopsy characteristics, as described in the Banff classification.
The absence of anti-HLA antibodies against the donor was ascertained at
transplant, at rejection, and before and after transplantectomy by the negativity
of crossmatches performed.
Eluates from the 13 renal allografts and patient’s platelet-absorbed sera were
negative by ELISA and were tested by flow cytometry against the endothelial/
epithelial hybridoma cell line EAHy.926. Non-HLA antibodies eluted from 9
rejected kidneys (by AHR) bound to EAHy.926. These non-HLA antibodies
were not detected in pre-transplant sera. However, 2 out of 4 pre-rejection sera
were positive against EAHy.926 and one showed a borderline reactivity.
Positive eluates were tested against frozen sections from 4 normal kidneys in
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order to define kidney structures to which they were reactive. Binding was
identified by indirect immunofluorescence method. Four out of 6 eluates tested
bound to the glomerulus and arterial endothelium with intense fluorescence but
not to the Bowman’s capsule and tubular epithelium, ruling out any possibility
that the eluates contained any anti-HLA antibodies. No polymorphism was
observed in eluates reactivity.
We evaluated retrospectively C4d in 7 kidney biopsy samples available (all
with positive eluates). All cases were negative, implicating involvement of
non-HLA and non-complement fixing antibodies.
Positive eluates were then tested with or without addition of an intravenous
polyvalent immunoglobulin preparation (IVIg) to ascertain the putative efficacy
of IVIg to block non-HLA antibodies binding to target cells. In all 9 cases,
addition of IVIg led to a strong decrease of non-HLA antibodies binding.
In conclusion, we have demonstrated that non-HLA antibodies may represent
a cause of humoral rejection and that addition of IVIg can block their binding
to the target cells. These are non-complement fixing antibodies and probably
recognize antigens of a non-polymorphic system in endothelial cells.

663 RISK FACTORS AND ASSOCIATIONS WITH
ALLOANTIBODIES IN TRANSPLANT GLOMERULOPATHY
H.S. Eng1,2, G. Bennett3, E. Tsiopelas3, S. Chang4, P. Bardy1,3,5, G.R. Russ1,2,3,4,
P.T.H. Coates1,2,3
1
Department of Medicine, University of Adelaide, SA, Australia, 2Department
of Nephrology and Transplantation Services, Queen Elizabeth Hospital, SA,
Australia, 3National Transplant Services, Australian Red Cross Blood Service,
SA, Australia, 4ANZDATA Registry, Queen Elizabeth Hospital, SA, Australia,
5
Department of Haematology-Oncology, Queen Elizabeth Hospital, SA,
Australia
Introduction: The pathogenesis of transplant glomerulopathy (TG) remains
controversial, with a rising evidence of alloantibody involvement. We
retrospectively studied the risk factors and the association of alloantibodies in
the development of TG.
Methods: All renal transplants (n=421) followed up in a single South Australian
transplant centre from 1 January 1990 to 31 December 2006 were studied.
Fifty-one biopsy-proven TG cases were identified. To assess the risk factors,
the TG group was compared with 62 grafts that were biopsy-proven without
TG (control group). IgG anti-HLA antibodies were defined by Luminex®
assays. IgG subclass (complement binding IgG1 and IgG3 subclass) of antiHLA antibodies were analysed using modified Luminex® assays.
Results:
Control (n=62)

Odds R, 95% CI, p value

37 (73%)

22 (35%)

4.8, 2.1-10.8, p<0.001

Death censored graft loss

25 (49%)

17 (27%)

2.5, 1.2-5.6, p=0.019

Graft survival after biopsy

16.5 months

32.6 months

p=0.08

Mean graft survival

80.5 months

80.8 months

p=0.99

Regraft rate

18 (35%)

10 (16%)

2.8, 1.2-6.9, p=0.02

6 months cellular rejection

8/19 (42%)

6/31 (19%)

p=0.09

6 months vascular rejection

4/19 (21%)

5/31 (16%)

p=0.66

6 months glomerular rejection

7/19 (37%)

1/31 (3%)

p=0.01

Glomerular rejection in the first 6 months post transplant was a predictor for
TG, vascular and cellular rejection were not. Other factors not statistically
related to TG included: recipient age, gender, race, pre-transplant current
and peak panel reactive antibody level (PRA%), donor source, age, gender,
delayed graft function, cold ischemia time, number of HLA A, B and DR
mismatch, 6 months acute rejection and immunosuppressive regimen at
induction. Pre-transplant sera from all TG patients and 43 of 62 patients from
control group were screened. 72% of TG patients had anti-HLA antibodies
compared to 33% in control group (p≤0.001). Presence of anti-HLA CI
antibodies was significantly associated with TG (Odds ratio 5.2, 95% C.I
2.2 – 12.5, p<0.001) but presence of anti-HLA CII was not (p=0.49). Donorspecific antibodies (DSA) were found in 25% of TG patients compared to 9%
of patients in control group prior transplantation (p=0.066). Post-biopsy sera
from 29 TG patients who did not have DSA pre-transplant were subsequently
screened. DSA were found in 17 (59%) of these patients. Eight TG patients
developed class I DSA (DSA-CI), 2 developed class II DSA (DSA-CII) and
7 developed both class I and class II DSA post-transplantation. TG patients
with DSA pre transplantation were diagnosed earlier than patients who

664 EVALUATION OF INTRA-GRAFT B-CELL SUBSETS
IN RENAL ALLOGRAFT REJECTION
M. Naesens,V. Zarkhin, N. Kambham, L. Li, S. Kwok, S. Hsieh,
O. Salvatierra, M. Sarwal
Stanford University
Background: Intra-graft CD20+ B-cell infiltrates in renal allograft acute
rejection (AR) correlate with aggressive clinical course and corticosteroid
resistance, an increased risk of graft loss, and independant of peritubular C4d
deposition. The refined lineages of B-cells that are pathogenic in this aggressive
rejection, and their trafficking to the graft, are largely unknown.
Aim: To study the phenotype, localization, migration and function of pathogenic
B-cells in graft rejection.
Methods: A Tissue microarray (TMA) was generated containing 7 normal
and 43 acute and chronic rejection nephrectomy samples from 50 patients
(9-68 years of age) and have only been used as a source of tissue to study
the distribution of different B-cell subsets in rejection. Immunohistohemical
studies (IHC) of TMA were performed for B-cell lineages (CD20, CD79a,
CD27, Pax-5, Bcl-6, Blimp-1, CD38, CD138); T-cells (CD3, CD4, CD8);
macrophages (CD68); chemokines and growth factors (CXCL12, CXCL13,
CXCR5, VEGF, STAT1); HLA-DR and C4d. Selected IHC stains including
CD20, CD38, CD138, CD21, CD27, CD79a, and C4d were performed on
37 renal allograft core biopsies from 28 patients (1-22 years age) with no
AR (controls; n=5), AR with (n=10), or without (n=22) graft loss, and the
results were correlated with specific clinical graft outcomes. XY chromosome
fluorescence in situ hybridization analysis was performed on 22 TMA sections
from male recipients of a female donor kidneys with CD20 stains performed
on consecutive sections to study the donor vs. recipient origin of infiltrating
B-cells.
Results: Two independant, pathogenic recipient derived B-cell subsets
were identified in rejecting renal allografts, without co-localization.
These are activated effector (CD20+/CD79a+/Pax-5low/Bcl-6-/Blimp-1-/
CD38-/CD138-) and memory B-cells (CD27+), with capacity for antigen
presentation (HLA-DR+), surrounded by CD4+ T-cells, and associated
with CXCL12/13, STAT1 and VEGF. These B-cell clusters do not correlate
with intra-graft C4d deposition or with detection of donor specific antibody.
A second group of B-cells are interstitial plasmablasts and plasma cells
(CD38+/CD138+/CD79low/Pax-5-/Bcl-6low/Blimp-1+/CD20-/HLA-DR-),
surrounding glomeruli and arteries. These cells correlate strongly with
circulating donor specific antibody, and to a lesser extent with intragraft C4d.
Both CD20+ B-cells and CD38+ cell subsets correlate with the recalcitrant,
steroid-resistant rejection, and CD20 positivity during rejection associates
with reduced graft survival. No B-cells and peritubular C4d+ were seen in
normal control tissue.
Conclusion: Two major recipient derived B-cell compartments populate
AR grafts. In response to donor antigen, naive B-cells undergo clonal
expansion and differentiation, developing either into memory and/or
effector cells for antigen presentation, or plasmablasts/plasma cells for
donor specific antibody production. Memory and chronically activated
CD20+ B-cell clusters may function as efficient antigen-presenting cells,
supporting aggressive T-cell mediated cellular rejection. CD38+ plasma
cells/plasmablasts characterize humoral rejection. These cells homing to
the graft in response to different chemokines and factors, such as CXCL12,
CXCL13, STAT1 and VEGF. As standard immunosuppressive rescue
therapy poorly depletes B-cells, scrutiny for these cells in AR and the
application of stratified B-cell lineage specific treatments may be necessary
to improve graft outcomes.
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TG (n=51)
Graft loss

developed DSA post transplantation (mean graft survival until biopsy 35
vs. 77 months, p=0.03). However, the timing of develop DSA did not affect
the graft survival in TG patients (mean 53 vs. 68 months, p=0.58). Five of 7
patients with DSA-CII and graft lost had complement binding IgG1 and IgG3
DSA-CII antibodies.
Conclusion: Transplant glomerulopathy is associated with 6 months glomerular
rejection and allosensitisation prior transplantation. More than 50% of TG
patients have DSA at any time, especially complement-binding IgG subclass
class II DSA are at high risk for graft failure.
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665 PROBABILISTIC MODELING OF CMV INFECTION
IN RENAL TRANSPLANTATION
P. Keown, S. Dmitrienko, R. Balshaw, R.J. Shapiro, P.A Keown
for the Biomarkers in Transplantation Team, University of British Columbia,
Vancouver, BC, Canada
Introduction: Cytomegalovirus (CMV) is the most common viral pathogen
following renal transplantation, and a major therapeutic challenge with profound
clinical and economic implications. CMV infection results in important direct
costs, and may incur indirect consequences and costs by increasing the risk of
acute rejection, by secondarily reducing the probability of graft and patient
survival, or by the combination of these events, although these effects are
uncertain.
Methods: This study employed multi-state time-dependent multivariate
modeling to examine the prediction, probability, consequences and treatment
costs of CMV infection and the relationship between CMV infection and
biopsy-proven graft rejection, graft loss and death after renal transplantation
using Canadian consensus guidelines for CMV management, as a basis for
comprehensive analysis of contingent consequences and costs.
Results: D+/R- patients received antiviral prophylaxis for 14 weeks; all but
D-/R- patients were monitored weekly for CMVpp65 expression; those with
¡Ý 4 cells/2x105 PMN received pre-emptive antiviral therapy; patients with
CMV syndrome or disease received antiviral treatment. Case incidences of
CMV viremia and syndrome in 270 sequential subjects were 27% (73/270)
and 9% (23/270) respectively and only 1% had CMV disease; 91% were
diagnosed in the first 6 months. BPAR occurred in 32/174 (18%) of patients
without CMV infection, 17/73 (23%) patients with CMV viremia and 5/23
(22%) patients with CMV syndrome/disease (p=0.6). Only 22 patients
experienced both events; in 4 subjects, CMV infection preceded BPAR
(mean: 62¡À26 range 32-85 days) while in 18 it followed the diagnosis and
treatment of BPAR (mean: 63¡À31, range 27-119 days). Time-dependent Cox
analysis showed that neither donor/recipient CMV risk stratum (p=0.204 for
BPAR, p=0.262 for graft loss and death) nor prior CMV infection increased
the probability of BPAR (HR=1.098, CI=0.332-3.633, p=0.878) or of graft
loss and death (HR=0.717, CI=0.224-2.299, p=0.576), but the risk of CMV
infection increased significantly following BPAR (HR=1.77, p=0.03). Mean
direct costs of CMV care were $2,256/patient, and ranged from $927/
patient in the D-/R- to $7,069/patient in the D+/R- strata. Extension of
antiviral prophylaxis to D+ (n=151, 56%), or D+ or R+ patients (n=200,
74%) increased estimated mean costs to $3,735 or $4,405/patient for an
absolute reduction to 4% in CMV syndrome or disease, an incremental cost
of $42,808 (range: $28,426-54,324) and $46,850 (range: $46,166-$48,000)
per case prevented.
Summary: Current consensus guidelines consequently appear highly costeffective in managing CMV infection; CMV infection does not increase the
risk of BPAR or graft failure, but BPAR significantly increases CMV risk
which merits consideration of prophylaxis.
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CONCURRENT ORAL SESSION 48:
TRANSPLANT SURGERY VIDEOS
666 MINIMALLY INVASIVE KIDNEY TRANSPLANTATION
(MIKT) – A 7-9 CM INCISION IS SUFFICIENT
P. Pfeffer, O. Øyen, T. Scholz, A. Hartmann
Rikshospitalet University Hospital, Oslo, Norway
Introduction: Minimally invasive surgery (MIS) has in recent years gained
widespread acceptance, and almost all abdominal procedures have now been
performed laparoscopically; including laparoscopic living donor nephrectomy
(LLDN). However, no MIS technique for kidney transplantation (KT) has been
described - untill recently.
Material/methods: A novel minimally invasive technique for kidney
transplantation (MIKT) has been developed; restricting to a 7-9 cm incision,
attempting minimal dissection/tissue trauma through the whole procedure. All
anastomoses are performed with the kidney placed in its intended position; a
fitting retroperitoneal pouch, lateral to the incision.
Twentyone patients were transplanted by MIKT (by a single surgeon) and
followed in a prospective manner, with matched controls.
Results:
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MIKT
n=21

[*: p < 0,05]
Skin incision length (cm)
Op. time (min)

Conventional KT
n=21

8,1* (7 - 9)

20,5 (17-23)

118* (95-140)

187 (130-270)

3

8

Complications requiring
Reoperations/Interventions
Stay in hospital (days)
Graft loss

8,2* (6-13)

12,4 (7-29)

0

1(rejection)

Discussion/conclusion: In experienced hands, KT may be executed safe and fast
through a minimal incision, similar to the one required for LLDN. Since our
first report of MIKT in nov. 2006, a partially video-assisted technique, through a
same-sized incision, has been presented by a South-Chorean group (July 2007).
Considering the rapid evolution of MIS during the last decade, there is little
reason to believe that KT in the future will be excluded from this development.
And there are substantial reasons to believe that the very well documented MISeffects on pain/recovery also apply to KT. Actually, MIS seems particularly
attractive in the immunosuppressed population, with significantly retarded
wound healing – and even more so with the recent introduction of potent
antiproliferative drugs.

667 RETROPERITONEAL PLACEMENT OF PANCREAS
GRAFT WITH PORTAL-ENTERIC DRAINAGE
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori,
S. D’Imporzano, G. Amorese, I. Mosca, F. Mosca
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico,
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Aims: Difficulties were reported in arterial reconstruction in pancreas
transplantation (PTx) with portal-enteric drainage (PED) especially in male
recipients with omental obesity. Furthermore, since the graft is usually located
intraperitoneally in a central position, graft accessibility for percutaneous biopsy
may also be problematic We have recently described a method for PTx with
PED, that circumvents these difficulties, in which the pancreas graft is located
in the retroperitoneal space behind the right colon mesentery (Transplantation
2005; 79: 1137-42.). We herein show the video of this technique.
Methods: Between April 20th 2001 and February 29th 2008 a total of 151
recipients were scheduled for PTx with PED. Pancreas were procured from heartbeating deceased donors en-bloc with liver and kidneys. No venous extension
graft was used, while a donor iliac artery bifurcation Y graft was employed
routinely. In the recipient, the abdomen was entered through a midline incision.
The right colon was hence mobilized, thus allowing exposure and dissection
of both the superior mesenteric vein (SMV) and the right common iliac artery
(CIA). The SMV was encircled as proximally as possible, usually where two
large ileal branches merge into the main trunk of the vein. The CIA was also
encircled as close to its aortic origin as possible. The venous anastomosis was
created end-to-side between donor’s portal vein and recipent’s SMV. The arterial
anastomosis was then created end-to-side between donor’s Y iliac graft (trimmed
as short as possible in order to avoid kinking of Y limbs after reperfusion) and
recipient’s CIA. Enteric drainage was obtained through a Roux-en-Y jejunal limb
brought to the right flank region through a window made in the avascular portion
of the right colon mesentery. The pancreas graft was eventually placed in the right
retroperitoneal space, being covered by the ascending colon and its mesentery.
Results: Retroperitoneal PTx with PED was carried out in 150 out of 151
recipients (99.3%), including 84 simultaneous pancreas kidney Tx (62 using
a cadaveric kidney and 22 a live donor kidney), 57 PTx alone and 9 pancreas
after kidney Tx, irrespectively of recipients’ body max index or size of superior
mesenteric vein. Arterial anastomosis was always performed with ease, despite
keeping the Y iliac artery graft extremely short. In a recipient of a pancreas
after kidney graft, systemic drainage was preferred to portal effluent due to
intraoperative diagnosis of liver cirrhosis. Relaparotomy rate was 15.3%. Two
recipients needed 2 relaparotomies, and 3 (2.0%) pancreas grafts were lost due
to thrombosis; no additional grafts were lost because of surgical complications.
One graft was lost due to arterial thrombosis 6 months after PTx. Percutaneous
biopsy was always possible. Overall, 20 biopsies were performed (75%
diagnostic) in 15 recipients. One-year patient and graft survival were 95.1%
and 88.3%, respectively.
Conclusions: The technique shown in this video has distinctive technical
advantages as compared to the “classical” method in which the graft is located
intraperitoneally.
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668 TECHNIQUE FOR RESTORED KIDNEY
TRANSPLANTATION(RKT) USING KIDNEYS REMOVED WITH
SMALL RENAL TUMOURS.
D. Nicol, J. Preston, S. Wood, D. Wall, V. Kanagarajah, A. Griffin
Princess Alexandra Hospital
We have recently reported the successful utilization of kidneys from patients
with incidentally detected small renal tumours(< 3cm) for transplantation(Nicol
et al BJU Int 2008. Following ex-vivo excision of the lesion and repair of
the parenchymal defect the kidney is transplanted into selected recipients.
These restored kidney transplants(RKT) appear a novel means of increasing
the possibility of transplantation for selected patients who may otherwise not
receive a transplant. To date we have performed 49 RKT with a median followup of 40 months. The kidneys were obtained from patients who had elected
to undergo ablative nephrectomy for small renal tumours after discussions
with their treating urologist of the alternative treatment options of partial
nephrectomy, percutaneous ablative techniques and observation. Recipients
were older patients with significant co-morbidities that may have prevented
them otherwise receiving a transplant following a rigourous informed consent
process outlining the risk of tumour recurrence(5%) as well as tchnical
complications including bleeding and urinary fistula. One graft failure occured
due to recurrent FSGS after 30 months and 4 patient deaths from unrelated causes.
The remaining transplants continue to function. Four patients experienced
technical complications requiring re-intervention. One patient developed
a calyceal fistula which was successfully repaired by open exploration with
nephrostomy drainage and ureteric stenting. An arteriovenous malformation
occured in another case. This was managed by selective embolisation without
compromise to graft function. A further 2 patients required re-exploration for
evacuation of haematoma. One recipient developed a small local recurrence 9
years following transplantation.To date the patient has declined intervention
and the tumour remains stable at 1.2cm after 18 months of observation.
In this video we demonstrate the donor nephrectomy procedure with the
subsequent ex-vivo surgery to excise the tumour. Repair of the parenchymal
defect including collecting system repair is then undertaken before
transplantation. Utilising standard techniques employed for partial nephrectomy
kidneys removed with small renal tumours appear a viable and novel source of
transplantation for selected recipients.

669 HAND-ASSISTED LAPAROSCOPIC LIVING DONOR
NEPHRECTOMY AND DISTAL PANCREATECTOMY FOR
SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT

670 HAND-ASSISTED SCOPIC LIVING DONOR
NEPHRECTOMY: A SINGLE CENTRE EXPERIENCE DURING
THE MINIMALLY INVASIVE ERA
P. Pfeffer, O. Øyen, M. Hagness, B.H. Lien
Surgical Dep., Rikshospitalet University Hospital, Oslo, Norway
Introduction: Since 1998 we have tried out various minimally invasive
procedures for living donor nephrectomy (LDN), including laparoscopic versus
retroperitoneoscopic - and strictly scopic versus hand-assisted techniques.
Several complications with the strictly laparoscopic tecnique (including two
intestinal perforations) urged us to explore alternative/safer approaches.
Material/methods: Since 2005, 95 hand-assisted procedures have been
performed, in most cases through a Pfannenstiel incision (7-9 cm). In the first
18 donors, the retroperitoneoscopic approach was used, (all left-sided). For
reasons explained below, we changed to laparoscopic/transperitoneal access
in the last 77 cases of this series, and 21 of these constituted our first rightsided nephrectomies. Lately, dissection/hemostasis with Ultracision has been
replaced by latest generation LigaSure.
Results:
Strict laparoscopic
2001-2004
n=63; all left-sided
Op. time (min.)
180 (110-295)
[Experienced surgeon]
Vascular lesions: 2
Periop. incidents
Conversions: 2
PCA-Analgesia
Postop. days 0+1
28,1 (0-77)
(Morphine Equiv.)
Total: 6 (10%)
Complications
Serious: 2 (intest. perf.)

Retroperitoneoscopic
Hand-assisted
n=18; all left-sided

Laparoscopic
Hand-assisted
n=77; left 56 + right 21

179 (130-240)

143 (100–185)

Conversions: 0

Conversions: 0

40,2 (10-87)

33,2 (4-79)

No major

No major

Conclusions: According to our experience during the minimally invasive era,
the hand-assisted and laparoscopic procedure is simpler, safer and faster.
Hand-assistance affords increased security, both towards vascular incidents
and gastrointestinal complications. Peroperative incidents are more easily
solved without conversion. The laparascopic approach utilizes a large premade
working space, while the retroperitoneoscopic space has to be created by
extensive stripping of the peritoneum.
The development has recently been facilitated by major technical improvements,
including ‘High Definition imaging’ and improved LigaSure, taking care of all
venous branches without clips.

671 NON-RELATED LIVING DONOR HORSESHOE KIDNEY
TRANSPLANTATION
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori,
S. D’Imporzano, L. Morelli, G. Amorese, F. Mosca
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico,
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Introduction: Horseshoe kidney (HK) is a rare renal congenital anomaly,
frequently associated with vascular and ureteral abnormalities. The increasing
organ shortage has led to consider using renal grafts with anatomical variations;
there are reports of cadaveric HK successfully transplanted en bloc into a single
recipient or splitted with each half transplanted into two separate recipients.
Use of divided HK from living donors has been described in only 7 cases, all
in related couples. We herein report the video of the first case of HK splitted
with a half harvested from a living donor and transplanted into a non-related
recipient (wife).
Case report: Kidney transplant was performed in November 2006 from a 55
year old donor to his 53 year old wife, who was diagnosed with polycystic
renal disease and underwent bilateral nephrectomy due to recurrent infectious
episodes, before to be listed. Preoperative donor ultrasonography revealed the
presence of a HK with no hydronephrosis or calculi. Renal function, assessed
by Tc99scintigram, was equally balanced in the two halfs, with a total glomerular
filtrate of 81 ml/min. The vascular supply, as evaluated by angio-CT and
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N. Akutsu1, M. Maruyama1, C. Iwashita1, K. Ootsuki1, K. Saigo1, T. Asano2,
T. Kenmochi1
1
Department of Surgery, Chiba-East National Hospital, National Hospital
Organization, 2Department of Surgery, Teikyo University Hospital
Background: It is seriously important for living donations to make safer
and to reduce operating stress. Laparoscopic surgery is though to be a useful
operating procedure for solving these problems. We have been performing
pure retroperitoneoscopic nephrectomy for living kidney donation to decrease
morbidity and reduce donor disincentives since April 2004. However, in
living donor operation for simultaneous pancreas and kidney transplants
(SPKTx), we had performed by open approach. In the last donation of SPKTx,
We started hand-assisted laparoscopic living donor nephrectomy and distal
pancreatectomy. In this presentation, we report a successfully completed handassisted laparoscopic living donor nephrectomy and distal pancreatectomy.
Patient and method: A 58-year old woman made kidney and distal pancreas
donation for her 25-year old daughter with severe type-1 diabetes mellitus
and diabetic renal failure. Her height was 160cm and weight was 55kg (body
mass index: 21.6%). In donor operation, the patient was placed in the supine
position rotated 30 degrees to the right. Placements of working ports were
as follows (one hand port (7cm); above umbilicus, three 12mm ports; (left
lateral abdomen, left subcostal abdomen and left lower abdomen)). First, we
performed left nephrectomy after dividing ureter with double clipping and
finally dividing renal artery and vein by ENDO GIATM (Covidien). Next, we
performed distal pancreatectomy. Resection position was above the left side
edge of portal vein.
Results and conclusions: Total operation time was 448 minutes (160 minutes
until nephrectomy and 382 minutes until distal pancreatectomy). An estimated
blood loss was 43 mL. A warm ischemia time of kidney was 150 seconds and
that of pancreas was 360 seconds. Renal and pancreatic functions in recipient

were so good that urine from transplant kidney and normalizing of blood sugar
were recognized immediately after transplantation. She discharged the hospital
without remarkable complications. In conclusion, we demonstrated that handassisted laparoscopic nephrectomy and distal pancreatectomy would have
advantages of safeness for donor and of transplant organ function for SPKTx.

Wednesday 13 August 2008
angiogram, consisted in two arteries and one single venous trunk on each side.
The HK lower poles were fused together in a parenchymal bridge at the level
of aortic carrefour and inferior vena cava, which was joined by an accessory
vein on each side. The urographic phase of angiogram revealed the presence
of a single ureter on the left side while the right ureter was duplicated, with
the two pelvis clearly separated. The HK was approached through a midline
laparotomy; the right half was isolated and a total selective vascular control
was achieved then the parenchymal junction was divided along its midline.
The transplant was performed in the right iliac fossa; the renal arteries and
the vein were anastomosed to the external iliac vessels, while the connection
between the ureter and bladder was obtained by an uretero-vesical anastomosis
according to Gregoire-Lich and intubated by a JJ stent. Postoperative course
was uneventful for either patients and no delayed complication has been noted
so far. One-year donor and recipient creatinine levels are 1.7 mg/dl and 1.3 mg/
dl, respectively.
Conclusions: When vascular and urologic anatomy are suitable, live renal
donation may still be considered even in the presence of a HK.

672 CONTROL OF BLEEDING COMPLICATION DURING
HAND-ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMY
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Z.A. Zarka, H. Haidar, A. Sadeq, H. Hayati
Saad Specialist Hospital
Background: Laparoscopic donor nephrectomy has gained wide acceptance
among transplant surgeons as it proved to be safe and provides similar graft
function to open nephrectomy. Minimally invasive donor nephrectomy can be
performed either totally laparoscopic or Hand-assisted. Hand-assisted donor
nephrectomy is thought to be safer in regards to immediate control of intraoperative bleeding. In this video we show clips of emergency intra-operative
arterial and venous bleeding during nephrectomy that were controlled by the
hand.
Method: DVD recording of all donor nephrectomy patients that had intraoperative bleeding were reviewed and representative clips were collected in
one DVD for presentation.
Results: This video demonstrates emergency intra-operative arterial and
venous bleeding during nephrectomy, and maneuvers used for the control of
bleeding by the surgeon’s hand. No patient required blood transfusion and blood
loss was minimal as control was immediate. Most bleeding was controlled by
compression only (either by the hand or by inserting a gauze) and dissection
was carried out uneventfully thereafter. Only one patient required conversion
to open, but with the surgeon’s finger controlling bleeding from the renal artery
stump as the team was preparing for the conversion.
Conclusion: Hand-assisted donor nephrectomy approach provides immediate
control of bleeding which allows the surgeon ample time to reassess the
situation and manage accordingly minimizing blood loss, the need for blood
transfusion, and the need to convert to open nephrectomy.

673 HAND TRANSPLANTATION: VIDEO DESCRIPTION OF
THE PROCEDURE AND SURGICAL TECHNIQUE FOR DONOR
LIMB HARVEST
B. Amirlak1, J. Ganz1, V. Gorantla2, R. Gonzalez2, C. Kaufman2,
W. Breidenbach2
1
Department of Plastic Surgery, Case Western Reserve University, Cleveland,
OH, USA, 2Christine M. Kleinert Institute of Hand and Microsurgery,
Louisville, KY, USA
Hand transplantation is a multifaceted procedure that involves a specialized staff
and support system. Because the limbs are not traumatized, the technical aspect
of hand transplantation may not be as difficult as a hand replantation. However,
hand transplantation can become increasingly complicated if the donor limb
is not harvested and prepared appropriately or if the recipient does not have
viable functioning tendons, vessels, and nerves. This presentation details the
steps, skilled personnel, and instruments required for upper extremity limb
harvest for transplantation. The video shown was recorded during our most
recent donor limb retrieval. It demonstrates the surgical technique for harvest
and preparation of the donor upper extremity. This presentation is based on
the information gathered from of the latest successful hand transplantation in
Louisville, KY, performed in November 2006.
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CONCURRENT ORAL SESSION 49: XENOTRANSPLANTATION
– PIG-TO-PRIMATE/IMMUNE RESPONSES
674 AVERAGE SURVIVAL GREATER THAN 50 DAYS WITH
EVIDENCE FOR BABOON THYMOPOIESIS IN PORCINE
THYMUS IN BABOON RECIPIENTS OF LIFE-SUPPORTING
GALT-KO PIG THYMOKIDNEYS
K. Yamada, A. Griesemer, Y. Ishikawa, At. Hirakata, S. Moran, P. Schule, H.
Iwaki,
S. Arn, A. Shimizu, D. Sachs
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: We have previously reported the initial results of pig-tobaboon thymokidney transplants from GalT-KO miniature swine using an
immunosuppressive regimen designed to facilitate the induction of tolerance.
Although the results were superior to results using hDAF thymokidneys, there
was a high rate of early post-operative complications, especially infections.
We have now investigated whether the elimination of steroids and whole body
irritation (WBI) from the treatment protocol would decrease the complication
rate in the perioperative period and enable the maturation of baboon T cells in
the porcine thymus at an earlier time point.
Methods: 7 baboons received thymokidney transplants from GalT-KO
miniature swine. The immunosuppressive regimen was based on the previously
published protocol, but we eliminated steroids and substituted Rituximab for
WBI. The regimen consisted of thymectomy before transplant, splenectomy
day 0, ATG, Rituximab, MMF and anti-CD154 mAb. Renal function was
assessed by serum creatinine levelsBaboon thymopoiesis in the pig thymus was
assessed by FACS and immunohistochemistry. Xenogeneic T cell responses
were assessed by cell-mediated lympholysis assays.
Results: One animal died due to a drug reaction at POD 18 with normal renal
function and no evidence of infection. The remaining 6 baboons showed
no signs of rejection although IgM deposition was observed, likely due to
preformed non-Gal nAb. There were no deaths due to rejection. Although
early infectious complications were not seen, late complications leading to
mortality were still observed, including systemic CMV infection (POD 28),
pleural effusions (POD 40, 57), ARDS with pulmonary hemorrhage (POD 49,
81) and acute myocardial infarction (POD 83). Three animals showed evidence
for early thymopoiesis in the pig thymus by FACS and immunohistochemistry.
CD4+/CD8+ thymocytes were seen in the thymic grafts, indicating that T cell
development was supported by the pig thymus. No animal had an anti-porcine
response on CML, with one animal regaining an anti-third party response by
day 49. The average survival of the steroid-free group was 51 days including
the animal with the drug reaction and 56 days excluding it, compared to 34.6
days in the previous regimen that included steroids/WBI.
Conclusions: A steroid-free and WBI free regimen designed for the induction
of tolerance across the pig-to-baboon xenogeneic barrier had fewer early
post-operative complications than previous regimens. Greater than 50-day
average survival of recipients of life-supporting xenogeneic thymokidneys was
observed without rejection. This regimen was associated with more advanced
baboon thymopoiesis in the porcine thymus at an earlier time point than was
seen with the previous regimen.

675 FUNCTIONAL ANALYSES OF CD55/HHO-1 TRANSGENIC
PIGS IN AN EX VIVO PERFUSION MODEL
W. Ramackers1, B. Petersen5, L. Friedrich2, A. Tiede3, R. Zimmermann1,
W. Schuettler1, S. Bergmann1, V. Broecker4, H. Niemann5, R. Schwinzer1,
M. Winkler1
1
Tranplant Laboratory, 2Dept. of Anesthesiology, 3Dept. of Hematology,
4
Institute of Pathology, Hannover Medical School, D-30625 Hannover,
Germany, 5Institute of animal genetics (FLI), Dept. of Biotechnology, 31535
Neustadt, Germany
Introduction: Although the hyperacute rejection (HAR) after pig-to-human
xenotransplantation can now be overcome by controlling complement
activation (i.e. by expressing human complement regulators), the acute
vascular rejection (AVR) is still an unsolved problem. Following pig to primate
kidney transplantation, endothelial cell activation and xenogenic activation of
the coagulation (XAC) system of the recipient leading to organ dysfunction
and disseminated intravascular coagulation (DIC) can be observed. Human
Hemeoxygenase-1 (hHO-1) is known to have anti-apoptotic and cell protective
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properties. Thus, the expression of hHO-1 on porcine endothelial cells
could have beneficial effects on organ survival after xenotransplantation and
could possibly interfere with XAC. In this study we analyzed porcine cells
and kidneys expressing the human complement regulator CD55 and the cell
protective protein hHO-1.
Methods: The protective effects of the transgenes against complementmediated attack were assessed by cytotoxity assays. Organ survival and
XAC following the contact of human blood with porcine endothelium, were
determined by using an ex-vivo perfusion circuit based on low dose heparin
mediated anticoagulation. Porcine kidneys were recovered following in situ
cold perfusion with HTK organ preservation solution and were immediately
connected to a perfusion circuit utilizing freshly drawn pooled human AB
blood.
Results: Porcine fibroblast transgenic for CD55/hHO-1 showed increased
resistance (up to 40%) against complement mediated attack than fibroblasts from
wildtype pigs. Survival of wildtype pig kidneys during organ perfusion with
human blood and addition of heparin was 42 +/- 26 min. Application of soluble
complement inhibition (C1-Inhibitor) prolonged organ survival to 126 +/- 72
min. XAC was observed with significantly elevated concentrations of d-Dimer
and thrombin antithrombin complex (TAT) combined with consumption of
fibrinogen and antithrombin. The histological analyses revealed numerous
microthrombi. In contrast, the perfusion of the CD55/hHO-1 transgenic porcine
kidneys was feasible for more than 240 min in all perfusion experiments
(without C1-Inhibitor). Although elevated levels of d-Dimer and TAT were
measured, no significant consumption of fibrinogen and antithrombin occurred.
In addition, no microthrombi were detectable histologically.
Conclusion: We conclude that the expression of CD55 and hHO-1 in porcine
kidneys can prolong organ survival and is able to interfere with XAC in this
ex vivo perfusion model. These results suggest that the expression of hHO-1 in
combination with CD55 could play an important role in xenograft protection.

676 IGVH GENES ENCODING XENOANTIBODIES TO
GALTKO XENOANTIGENS IN RHESUS MONKEYS
ARE RESTRICTED

F. Besenzon1, M. Seveso2, M. Vadori1, E. Bosio1, L. Cavicchioli3,
F. Calabrese4, N. Baldan5, L. Polito2, E. Ancona1,2,5, E. Cozzi1,2,5
1
Dept. of Surgical And Gastroenterological Sciences, University of Padua,
Padua, 2CORIT, Padua, Italy, 3Dept. of Public Health Comparative Pathology
and Veterinary Hygiene, University of Padua, Padua, Italy, 4Institute of
Pathology, University of Padua, Padua, Italy, 5Padua General Hospital,
Padua, Italy
Introduction: In the pig-to-nonhuman primate model, anti-pig antibodies are
responsible for Hyperacute Rejection (HAR) and Acute Humoral Xenograft
Rejection (AHXR). However, not all antibodies (natural or elicited) are
detrimental to the graft. In this study, we evaluated a group of primate recipients
of porcine renal xenografts showing long-term survival despite the presence of
high titer of anti-pig antibodies.
Materials and methods: Eight 5-year old nephrectomized females cynomolgus
monkeys (n=8) received a kidney from hDAF transgenic pigs (Novartis). All
recipients received GAS914 (Novartis), cyclophosphamide perioperatively,
cyclosporine A, mycophenolate sodium and steroids. In addition, the animals
received recombinant human activated protein C (rhaPC), (Xigris, kindly
provided by Eli Lilly, Florence, Italy) by continuous i.v. infusion, according
to different regimes. Due to the presence of very high anti-pig antibody titers,
prior to transplantation, all animals were exposed for 2 hours to extracorporeal
perfusion using the donor controlateral kidney. Sera taken before and after
transplantation were tested for their lytic activity on porcine aortic endothelial
cells (PAEC) and on porcine red blood cells (RBC). Isotypes of antibodies preand post-transplantation were evaluated by flow cytometry. Sera were analysed
for ability to induce expression of protective and anti-apoptotic genes such as
HO-1 and Bcl2 by Western blot analysis.
Results: Whilst in 4 primates the haemolytic anti-pig antibodies were reduced
by the pre-operative treatment, 4 primates presented high level of anti-pig
antibodies during all post-transplantation period. Nonetheless, these animals
survived for 8 to 24 days. It is of interest that one of these animals with good
graft function (Nr. 1792) survived for 24 days in the presence of high titer
anti-pig antibodies and kidney showing only grade I AHXR at euthanasia.
Moreover, the pre-transplant serum from this animal was able to induce HO-1
expression in PAEC more efficiently than sera from other animals, whilst no
differences were observed in Bcl2 induction. Following transplantation, 3 out
of 4 animals with high titers anti-pig IgM pre-transplant continued to produce
an IgM response in the absence of pig- specific IgG. In contrast, 3 out 4 animals
with low titers IgM pre-transplant elicited a low titer pig specific IgG response
in the post-transplant period.
Conclusions: The presence of high titer pre-transplant anti-pig IgM is not
necessarily associated with early graft rejection. Indeed, some subsets of
natural antibodies may increase expression of protective genes or even play an
immunomodulatory role.

678 B CELL PROLIFERATION AFTER Α-GAL EXPOSURE
REQUIRES THE PRESENCE OF ACTIVATED
T HELPER CELLS
T. Kandeva, S. Liu, J. Tchervenkov
McGill University Health Center, Montreal, Canada.
Background: Antibody-mediated rejection is central to ABO incompatible
transplantation as well as to Xenotransplantation. The xeno-antigen α-Gal has
a highly analogous carbohydrate structure to the human blood group antigens,
and both require memory B cell activation for antibody production.
We hypothesize that B cells reactive to the α-Gal xenoantigen require the
presence of fully activated T cells in order to survive and proliferate in vitro.
Materials and methods: Human CD19+ B cells, isolated from healthy donors,
were exposed to pig aorta endothelial cells’ membrane proteins, which express
the α-Gal epitope. After an incubation period of 48 hrs with different culture
conditions, their proliferation capacity was observed using the MTT assay
(ATCC Bioproducts, USA). The different in vitro culture conditions used were:
the addition of IL-4 (0.02mg/ml) and anti-CD40 receptor antibody (5mg/ml).
B cells proliferation was computed as a percentage of the proliferation of the
control group, which represents unstimulated B cells (B cells with culture
medium and IL-4 only)
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M. Kearns-Jonker1,2, I. Harnden2, K. Kiernan2, M. Gunthart1, J. Meisner2,
C. Gregory3
1
Childrens Hospital Los Angeles, 2USC Keck School of Medicine, 3University
of California at Davis National Primate Research Center
Galactoslytransferase-deficient (GalTKO) pig organs were developed to
provide a solution to the shortage of human organ donors. These organs do not
initiate hyperacute rejection but undergo acute humoral rejection mediated by
xenoantibodies directed at non-gal xenoantigens. The structure, specificity and
germline origin of these antibodies has not been determined.
Methods: Three rhesus monkeys were immunized with sixty million GalTKO
pig endothelial cells in order to induce high levels of xenoantibodies directed
at GalTKO xenoantigens. Pre-existing levels of anti-non-gal xenoantibodies
were significantly lower than anti-gal natural antibodies in rhesus monkeys. A
strong immune response directed at GalTKO xenoantigens was confirmed by
flow cytometry after immunization. Pre and post transplant peripheral blood B
cells were used to prepare IgG and IgM cDNA libraries for identification of the
IgVH genes encoding xenoantibodies.
Results: IgVH genes encoding anti-non-gal xenoantibodies were restricted to
the use of a gene most similar to human germline progenitor V3-21, a gene
that also encodes antibodies to carbohydrates. The CDR3 region is unique and
the J region is most similar to JH4 in 76% of the IgG sequences. The germline
progenitors encoding anti-non-gal xenoantibodies are also 91% similar to the
IGHV3-11 alleles that encode anti-carbohydrate xenoantibodies in primates
transplanted with either wild type and/or hDAF transgenic pig organs.
Expression of iGb3 synthase could not be detected by PCR in the GalTKO pig
cells used in this study, but could be confirmed in GalTKO mouse cells.
Conclusions: The anti-non-gal xenoantibody response is restricted to usage
of an IgVH repertoire known to encode antibodies to carbohydrates and
glycolipids.

677 HIGH TITER PRE-TRANSPLANT ANTI-PIG IGM IN
PRIMATES ARE NOT NECESSARILY ASSOCIATED WITH
EARLY PORCINE XENOGRAFT FAILURE
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Carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assay was
performed using the CellTrace™ CFSE Cell Proliferation Kit (Invitrogen).
Purified B cells were loaded with CFSE (5μM) in order to monitor their
proliferation profile. B cells were then seeded with purified T cells (1 B cell
per 2 T cells). T cells were either activated or not using anti-CD-3 (5 μg/mL).
Also, culture medium either included or not the α-Gal antigen at different
concentrations. Proliferation was analyzed after a 5-day incubation period
Results:

CFSE Dilution Assay
1 μg/mL Ag
Activated T cells

1 μg/mL Ag
Resting T cells

GTKO and GTKO/CD46 PBMC and PAEC, but there were no differences in
binding between WT and CD46 cells or between GTKO and GTKO/CD46
cells. CDC of WT PBMC and PAEC was significantly greater than of GTKO,
CD46, and GTKO/CD46 PBMC (WT 73%; GTKO 37%; CD46 30%; GTKO/
CD46 4%) and PAEC (WT 51%; GTKO 18%; CD46 1%; GTKO/CD46 0%)
(both p<0.05). Importantly, there was no lysis of GTKO/CD46 PAEC. After
activation of PAEC, although CDC was increased against WT and GTKO
PAEC, CD46 and GTKO/CD46 PAEC continued to demonstrate significant
resistance to lysis (WT 73%; GTKO 41%; CD46 5%; GTKO/CD46 0%).
In MLR, human PBMC and CD4+T cell responses to GTKO PBMC were
significantly less than to WT PBMC (p<0.05). The human PBMC and CD4+T
cell responses to PBMC from CTLA4-Ig transgenic pigs were significantly
reduced compared to the responses to non-CTLA4-Ig transgenic pig cells
(p<0.05). (Human PBMC 3H-thymidine uptake - WT 72,710, WT/pCTLA4Ig 30,625, GTKO 62,660, GTKO/pCTLA4-Ig 38,182. Human CD4+T cell
3
H-thymidine uptake - WT 90,636, WT/pCTLA4-Ig 34,450, GTKO 81,698,
GTKO/pCTLA4-Ig 55,385). The mean percent suppression of human PBMC
and CD4+T cell responses associated with pCTLA4-Ig expression was 40%.
Conclusions: (1) CDC of all 3 types of genetically-engineered PBMC and
PAEC was significantly lower than of WT PBMC and PAEC. (2) CDC was
significantly reduced by CD46 expression even after activation of PAEC,
lysis of GTKO/CD46 cells being significantly lower than of GTKO or CD46
cells. (3) The human T cell response to GTKO PBMC was weaker than to WT
PBMC, indicating that the GTKO pig may provide advantages with regard to
both humoral and cellular immunity. (4) Additional expression of CTLA4-Ig
significantly reduced the human T cell response, suggesting that organs from
GTKO/CD46/CTLA4-Ig pigs should provide considerable protection against
both the human humoral and cellular responses.

680 HUMAN CD47 ON PORCINE ANTIGEN PRESENTING
CELLS HAVE A POSSIBILITY OF PREVENTING T CELLMEDIATED XENOGRAFT REJECTION THROUGH
INHIBITORY SIGNALING TO SIRP ALPHA
The results from the MTT assays show that B-lymphocytes require both antiCD40 and IL-4 in order to proliferate in vitro, suggesting that B cells depend
on the presence of factors usually provided by activated T helper cells. This
finding is further confirmed by our CFSE dilution results, which suggest that
B cells are able to proliferate only in the presence of both activated T cells and
antigenic stimulation.
Conclusion: This finding may have clinical implications in offering novel
strategies at blocking proliferation, so as to reduce antibody production in
highly sensitized models.
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679 IN VITRO INVESTIGATION OF HUMAN CELLULAR AND
HUMORAL RESPONSES TO CELLS FROM GENETICALLYMODIFIED PIGS
H. Hara1, C. Long1, M. Ezzelarab1, P. Yeh1, S. Ball2, C. Phelps2, I. McKenzie3,
D. Ayares2, B. Loveland3, D.K.C. Cooper1
1
Thomas E. Starzl Transplantation Institute, University of Pittsburgh,
Pittsburgh, PA, USA, 2Revivicor, Inc., Blacksburg, VA, USA, and 3Austin
Research Institute, Melbourne, Victoria, Australia
Purpose: (1) To compare the antibody binding and complement-mediated
cytotoxicity (CDC) of human sera to pig peripheral blood mononuclear cells
(PBMC) and pig aortic endothelial cells (PAEC) from (i) wild-type (WT),
(ii) α1,3-galactosyltransferase gene-knockout (GTKO), (iii) human CD46
(homozygous) transgenic (CD46), and (iv) GTKO/CD46 (heterozygous) pigs.
(2) To compare the human T cell response to pig PBMC from (i) WT, (ii)
GTKO, (iii) pig cytotoxic T-lymphocyte antigen 4 (pCTLA4)-Ig transgenic,
and (iv) GTKO/pCTLA4-Ig pigs.
Methods: Pooled human serum was tested by flow cytometry for binding of
IgM and IgG (5% serum) and CDC (25% serum) to PBMC and PAEC from
WT, GTKO, CD46, and GTKO/CD46 pigs. PAEC from all 4 pig types were
activated by IFN-γ, and again tested for antibody binding and CDC. In MLR,
human PBMC and isolated CD4+T cells as responders were cocultured with
irradiated pig PBMC from WT, GTKO, CTLA4-Ig, and GTKO/CTLA4-Ig as
stimulators. The results were expressed as 3H-thymidine uptake.
Results: There was higher binding of IgM and IgG to WT and CD46 than to
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K. Ide, H. Ohdan, H.Tahara, T. Asahara
Hiroshima University
We have previously proven that genetic induction of human CD47 on porcine
cells provides inhibitory signaling to signal regulatory protein (SIRP) alpha
on human macrophages; this provides a novel approach to preventing
macrophage-mediated xenograft rejection. A recent report indicated that the
similar CD47-SIRP alpha system negatively regulates the functions of both
T cells and antigen presenting cells (APCs) in humans. We hypothesize that
the interspecies incompatibility of CD47 may also act as an additional barrier
of T cell-mediated xenograft rejection. We have analyzed the frequency and
proliferative activity of human T cells responding to either porcine or allogenic
APCs by using in vitro mixed lymphocyte reaction (MLR) assay with a CFSElabeling technique. Irradiated stimulator porcine or human peripheral blood
mononuclear cells (PBMCs) were cultured with CFSE-labeled responder
human PBMCs. By FCM analysis, the number of division precursors was
extrapolated from the number of daughter cells of each division and from the
mitotic events, and precursor frequencies in CD4+ and CD8+ T cell subsets.
Using these values, stimulation index (SI) was calculated. The frequencies of
alloreactive and xenoreactive CD4+ T cell precursors were almost identical,
4.5¦ }0.8% and 4.4¦ }0.9%, respectively (n=10-12, for each type of precursor).
However, the SI of xenoreactive CD4+ T cells was significantly higher than
that of alloreactive CD4+ T cells, indicating a more vigorous human CD4+
T cell response to xenoantigens than that to alloantigens per a single cell. In
the presence of human CD47-Fc(containing the extracellular domain of human
CD47 fused to the Fc portion of human Ig), the SI of xenoreactive CD4+ T cells
was significantly reduced to a level similar to that of alloreactive CD4+ T cells
(n=12, P<0.05), although the frequencies of their precursors were absolutely
uninfluenced. The frequencies of alloreactive and xenoreactive CD8+ T cell
precursors were also identical, i.e. 3.5¦ }0.3%, 3.9¦ }0.9%, respectively
(n=10-12). The SI of both alloreactive and xenoreactive CD8+ T cells did not
differ: however, that of xenoreactive CD8+ T cells was significantly suppressed
in the presence of human CD47-Fc (n=12, P<0.05). These results suggest
that the T cell responses to porcine cells are stronger than those to allogeneic
cells because of the interspecies incompatibility of CD47. Moreover, genetic
manipulation of porcine APCs to induce human CD47 expression might
attenuate human T cell-mediated xenograft rejection.
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681 RNA MICROARRAYS OF MACROPHAGES FROM
REJECTING ISLET GRAFTS IDENTIFY UNIQUE GENE
EXPRESSION AND PATHWAY ACTIVATION PATTERNS
FOLLOWING XENOGRAFT REJECTION
J. Wu, S. Yi, M. Vitalone, W. Hawthorne, K. Hucker, D. Simond, P. O’Connell
Center For Transplant & Renal Research, Westmead Millennium Institute,
Westmead Hospital
Background: Macrophages have been shown to be important in priming the
T-cell response and are direct effectors in xenograft rejection. Previously,
we have shown that pig primed and CD4+ T cell-activated macrophages are
able to migrate to and specifically destroy pig islet xenografts in mice. This
occurs without additional signaling from T cells, however, allograft primed
macrophages do not show the same specificity in graft recognition and
destruction. Our previous results also showed that xenografts microenvironment
provides additional signaling for macrophages activation, which are absent
following allotransplantation.
Aim: To identify the genes involved in macrophage recruitment, migration and
recognition which are specific for xenograft rejection.
Methods: Macrophages were isolated from rejecting neonatal pig islet cell
clusters (pNICC) xenografts (PM) and C57Bl/6 islet allografts (MM) in
NODSCID mice 12 days post reconstitution with 2x 106 Balb/c CD4+ T cells.
Macrophages isolated from the NODSCID mouse spleen (naïve, NM) were
used as controls. mRNA was extracted then amplified by Illumina TotalPrep
RNA Amplification Kit, producing biotin cRNA, which was hybridized on the
Illumina Sentrix® Mouse-8 (24K genes) bead-array. We compared both the
PM and MM back to NM for differential gene expression using Beadstudio
2.0 software. The differentially expressed genes were used in DAVID geneannotation engine for pathway activation analysis. Altered gene expression will
be tested by RT-PCR.
Results: DNA micro-array revealed the total number of differentially expressed
genes for MM and PM were 3157 and 445 respectively. The DAVID geneannotation engine analysis showed that immune cell activation and cytokine
production pathways were enriched and activated in both xeno- and allorejecting tissue models compared to naive controls; however these pathways
were activated to varying degrees in each model of rejection. The cytokinecytokine receptor interaction pathway and cytokine activity pathway were
specifically activated in the PM group (EASE score=2.04), whereas no change
was found from MM group. Various other pathways were activated to a greater
degree in the MM group than in PM group, such as metabolism (EASE=13.5 vs
1.8), immune related (EASE=4.9 vs 1.0) and G-protein binding (EASE=2.3 vs
1.0). Interestingly, TLR2 gene expression was specifically up-regulated in the
PM group and was absent from the MM group when compared with NM via
bead-microarrays. Furthermore, CXCL4 and TGFB-1 showed up-regulation
specifically in the MM group, but not in PM group. CXCL12 and CXCL17
were up-regulated and CCL8 were down-regulated in both xeno- and allograft
rejection.
Discussion: Microphages showed different gene expression patterns in
xenogeneic and allogeneic graft rejection which may reflect the different roles
played by microphages in two different processes. These studies should help us
identify the unique role microphage play in xenograft rejection.

HUMAN IMMUNE RESPONSES TO ISLET XENOGRAFTS

S. Safley, H. Cui, J. Avila, B. Holbrook, S. Cauffiel, M. Rigby, C. Weber
Emory University
Background: The long-term goal of our research is to enable islet transplants
in patients with Type 1 diabetes. The aim of this project was to analyze human
immune responses to porcine islet xenografts and human islet allografts in a
“humanized” mouse model.
Methods: NOD/Scid mice and NOD/Scids harboring a null mutation of the
common cytokine receptor γ; chain (γ; chain KO NOD-Scids, The Jackson
Laboratory, Bar Harbor, ME) were transplanted with neonatal or adult porcine
islets (6,000 islet equivalents) or human islets (6,000 islet equivalents) under
the renal capsule, and graft function was monitored by random blood glucose
levels. Human peripheral blood mononuclear cells (PBMC) were transferred
(i.v. or i.p.), and engraftment of human PBMC was documented by flow
cytometry of the murine recipient’s peripheral blood and spleen cells. Islet graft
destruction was evaluated histologically.
Results: Following transplantation under the renal capsule, adult porcine islets

CONCURRENT ORAL SESSION 50: MAINTENANCE
IMMUNOSUPPRESSION AND LONG-TERM COMPLICATIONS
683

RESULTS FROM THE PAN-EUROPEAN-HTX TRIAL

B. Meiser1, B. Reichart1, and all investigators2
1
Dept. of Cardiac Surgery, 2Depts. of Cardiac Surgery and Cardiology
Purpose: Nineteen centers from 6 European countries participated in the PanEuropean-HTx Trial. This prospective, centrally randomized investigator driven
trial (sponsored by Roche and Astellas) was initiated to compare Tacrolimus/
MMF versus (vs) cyclosporine/MMF. Unlike previous trials, MMF dosage was
adapted to MPA trough level measurements in all patients (pts).
Methods and materials: Altogether 201 pts entering the study were
randomized either to Tac/MMF/steroids (n=104) or CsA/MMF/steroids (n=97),
n=91 vs. n=96 received study medication. Mean donor age (years) was 34.9 vs
36.8, recipient age 53.6 in both groups, the male/female ratio (%) was 85/15
vs 80/20.
Results: Comparison of the one year follow-up data between the Tac/MMF vs
CsA/MMF group revealed: Survival of the treated pts.: 96% vs 92%, rejection
incidence per patient: 0.32 vs 0.46,% of pts. rejection free: 73 vs 55, mean
serum creatinine (mg/dl): 1.50 vs 1.53, blood, glucose (mg/dl): 114 vs 105,
systol./diastol. blood pressure (mmHg): 129/81 vs 133/83, cholesterol (mg/dl)
176 vs. 189. Mean MMF dose (g) after 1 year in the Tac vs CsA group was 1.9
vs 2.5, achieving mean MPA levels of 2.3 μg/ml in both groups.
Conclusions: The one year analysis indicates a similar, excellent survival in
both groups, tacrolimus treated pts had a lower rejection incidence, similar
creatinine, slightly higher blood glucose, lower cholesterol and lower blood
pressure than CsA treated pts.. Remarkably is the high percentage of pts.
completely free of rejection in both groups which might be due to the MPA
level adapted MMF application. Furthermore, the study confirms previous
observations in much smaller cohorts that CsA treated pts. need significantly
more MMF to achieve similar MPA trough levels.
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(API) reversed diabetes in streptozotocin (STZ)-diabetic NOD/Scid mice in 2
± 1 days (n=11), while neonatal porcine islets (NPI) reversed diabetes in 40 ±
14 days (n=10). API and NPI functioned for life in these immunoincompetent
NOD/Scids. Following transfer of human PBMC by either the i.v. or the i.p.
route, human CD4+ T cells, CD8+ T cells, and CD19+ B cells engrafted in γ;
chain KO NOD-Scids, but human macrophages, neutrophils, and eosinophils
did not engraft. When human PBMC and API were simultaneously transferred
to STZ-diabetic γ; chain KO NOD-Scids, the islet grafts were rejected in
9 days, correlating with the expansion of human CD4+ and CD8+ T cells,
but the islet grafts continued to function in control mice given no human
PBMC. When NPI were implanted, human PBMC were transferred after islet
grafts had reversed diabetes in all mice (>100 days). In these recipients, graft
rejection occurred >50 days post-transfer and correlated with the expansion
of human CD4+ and CD8+ T cells. Human islets were rejected within 40
days after transfer with human PBMC in γ; chain KO NOD-Scids, and also
correlated with expansion of human CD4+ and CD8+ T cells.
Conclusions: The results of our study show that human PBMC will engraft
in γ; chain KO NOD-Scids. We found that adult and neonatal porcine islets,
as well as human islets, will reverse diabetes in this murine model, and we
demonstrated that the transfer of human PBMC results in the resumption of
diabetes. Our study suggests that human CD4+ T cells, CD8+ T cells, and B
cells may be involved in rejection of porcine islet xenografts and human islet
allografts. In future studies, we plan to elucidate the phenotype and function
of human CD4+ and CD8+ T cells in islet graft rejection, as well as the role
of xeno-, allo- or islet-specific antibody. In addition, we will characterize the
mechanisms of rejection of islet allografts versus xenografts using this model.
We expect that this model will be useful in developing improved methods
to inhibit immune responses to islet xeno- and allografts, for example islet
immunoisolation (microencapsulation).
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684 DECREASE OF MAJOR CARDIAC EVENTS AND
HOSPITALIZATIONS IN DE NOVO HEART TRANSPLANT
RECIPIENTS RECEIVING EVEROLIMUS: RESULTS FROM
A 12-MONTH, MULTICENTER, RANDOMIZED TRIAL
COMPARING EVEROLIMUS WITH MMF
H. Lehmkuhl1, J. Arizon2, L. Almenar2, C. Magelli2, G. Gerosa2, S. Varnous2,
F. Musumeci2, M-F. Mattei2, J. Vanhaecke2, K. Mange3, G. Machnicki3,
U. Livi2
1
Deutsches Herzzentrum Berlin, Berlin, Germany, 2On behalf of the RAD
A2411 Study Group, 3Novartis Pharmaceuticals Corporation, East Hanover,
United States
Introduction: The risk of acute rejection and severity/incidence of cardiac
allograft vasculopathy is significantly reduced in heart transplant patients
receiving everolimus versus azathioprine. In this analysis, we compared major
adverse cardiac events (MACE; i.e. acute MI, CHF, PCI, CABG, AICD,
cerebral vascular accident or peripheral vascular accident) and the number
of hospitalization days due to MACE in heart transplant patients receiving
everolimus or MMF.
Methods: A 12-month, multicenter, randomized, open-label study was
undertaken in de novo heart transplant recipients. Patients were randomized to
everolimus (target C0 3–8ng/mL) with reduced-exposure CsA or MMF 1500mg
b.i.d. with standard-exposure CsA, both with steroids. The main endpoints
were renal function and efficacy. Data were captured on MACE leading to posttransplant hospitalization and hospital days due to MACE per 1000 patient
days of follow up were calculated. Bootstrapping was used to determine the
mean difference in number of hospital days due to MACE/1000 patient days
and 95% CI values.
Results: The safety population comprised 174 patients (91 everolimus, 83
MMF). Demographics were similar between groups. 14 (15.4%) everolimus
patients were hospitalized for a total of 65 days due to MACE (mean 4.6±2.9
days) and 18 (21.7%) MMF patients were hospitalized for 165 days (9.2±8.8
days). In the everolimus and MMF groups, respectively, there were 2.09 and
5.95 MACE hospital days/1000 patient days. Everolimus patients accounted
for 3.86 fewer hospital days due to MACE per 1000 days than MMF patients
(95% CI -7.8, -0.33). The ratio of MACE hospital days in the everolimus/MMF
groups was 0.35 i.e. everolimus patients experienced 65% fewer hospitalization
days than MMF patients after accounting for follow up.
Conclusions: Everolimus-based therapy was associated with fewer MACE
and with a 65% reduction in the number of hospital days for MACE versus
MMF by month 12 after heart transplantation. These preliminary findings
require confirmation, but everolimus may offer a benefit in light of the pivotal
prognostic role of coronary and peripheral vasculopathy in heart transplant
patients and the associated economic burden.
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months post-transplant, respectively. At 5 years post-transplant 12% were CKD
stage 4 or 5.
Risk of developing CKD stage 4 or 5 by 12 months post-transplant was higher
for those transplanted during the earlier years of the study (p<0.0001), for
those who received temporary haemodialysis or haemofiltration because of
postoperative acute renal failure within 30 days of transplant (odds ratio 2.5,
p=0.003), and for older recipients (p=0.002) and female recipients (odds ratio
2.7, p<0.0001). There was also a centre-specific effect (p<0.0001).
For those who survived at least one year post-transplant, there was a significant
difference in unadjusted long-term survival between those with CKD stage 4
or 5 at one year and those without (Figure 2, log-rank test p=0.019). Eight
year survival was estimated as 70% (95% CI 61-78) and 77% (95% CI 74-80),
respectively.
Conclusion: Renal function of heart transplant recipients is impaired early in
the post-transplant period, with 11% CKD stage 4 or 5 at 12 months posttransplant. Earlier transplant year, older recipient age, female recipient sex and
temporary postoperative renal replacement were associated with developing
CKD stage 4 or 5 within the first year post-transplant, and the risk also varied
between transplant centres. In unadjusted analysis, long-term survival was
inferior for those who develop CKD stage 4 or 5 in the first year compared to
those who do not.
Figure 1

Figure 2

685 CHRONIC KIDNEY DISEASE IN UK HEART
TRANSPLANT RECIPIENTS
R. Johnson, H.L. Thomas1, C.L. Murphy1, N.R. Banner2
NHS Blood and Transplant, 2Royal Brompton and Harefield NHS Trust
On behalf of the Steering Group, UK Cardiothoracic Transplant Audit
Background: Renal disease is a late complication of cardiothoracic
transplantation. We investigated the incidence of chronic kidney disease (CKD)
following heart transplantation in the UK.
Methods: Data on 1,732 first adult heart transplants in the UK, April 1996
to March 2007, were obtained from the National Transplant Database. Multiorgan, heterotopic and domino donor transplants were excluded from the cohort.
GFR was estimated using the 4 variable MDRD equation, and categorised
into National Kidney Foundation CKD stages at registration, transplant and
throughout the post-transplant period. eGFR data was only included if serum
creatinine was reported within 2 months of the relevant transplant anniversary.
Patients who survived the first post-transplant year were split into two groups:
those with eGFR<30ml/min/1.73m2 (CKD stage 4 or 5), and those with higher
eGFR at one year. Long-term survival was estimated using the Kaplan-Meier
method and compared between these two groups using the log-rank test. Risk
factors for developing CKD stage 4 or 5 at one year were identified using
logistic regression.
Results: Renal function changed very little between registration and transplant,
but deteriorated quickly following transplant (Figure 1). 3% of patients were
CKD stage 4 or 5 at time of transplant, rising to 7% and 11% at 3 and 12
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686 LONG-TERM IMMUNOSUPPRESSION WITH ANTICD25 MONOCLONAL ANTIBODIES IN HEART TRANSPLANT
PATIENTS
M. Cantarovich, N. Giannetti, J-P. Routy, R. Cecere, A. Papali, J. Barkun
Medicine, Cardiovascular and Thoracic Surgery and Epidemiology and
Biostatistics McGill University Health Center, Montreal, Quebec, Canada.
Purpose: To describe: 1- Safety of a long-term anti-CD25 mAb-based
immunosuppression strategy. 2- Efficacy of this strategy with respect to renal
function salvage.
Methods: 1- We describe 17 patients (64±7 years) who developed side-effects
secondary to either CNI (chronic kidney disease (CKD), n=10 patients) or to
Rapa (edema n=6 patients, lymphedema n=1 patient) and in whom conversion
to long-term anti-CD25 mAb was performed at 10±4 years post-HTx (range
3-16). Basiliximab, (20 mg iv at baseline and 4 days thereafter, then as needed)
was used in 3 patients and daclizumab (1.5 mg/kg/iv as needed) was used in
14 patients. The dosing interval was based on the CD25 saturation rate of
peripheral blood CD4 T-lymphocytes, measured q.2-weeks for 3-months and
monthly thereafter, aiming for <2% expression. Additional immunosuppression
included MMF and prednisone in the majority of patients. Endomyocardial
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biopsies were usually performed within 1-month after the discontinuation of
CNI or Rapa. 2- Of the 17 patients, the 10 who had developed CNI-induced
CKD were matched for age, gender and date of HTx with 10 HTx patients
whose renal function had remained stable.
Results: 1- Anti-CD25 mAb have been given over 17±13 months (range 2-32).
Based on the CD25 saturation rate, basiliximab was given every 2 months
and daclizumab every 2-3 months. Anti-CD25 mAb have been well tolerated.
Three patients died, 1 of perforated diverticulitis, 1 of acute renal failure (the
patient refused dialysis) and 1 of acute rejection (the patient refused a biopsy).
Side-effects secondary to Rapa resolved in all patients. 2- Table 1 depicts the
outcome of renal function in the 10 patients with CNI-induced CKD as well as
their matched cohort.
Table 1: Outcome of the creatinine clearance (mL/min)
Long-term antiCD25 mAb
Controls

1 month
post-HTx

6 months
pre-event

Event: CNI
3 months
discontinuation* post-event

6 months
post-event

Last visit**

74±16

50±22

37±12

42±13

42±15

41±14

72±12

72±31

70±27

68±27

67±30

65±27

*CNI were not discontinued in controls. This group was selected to compare the outcome of renal
function; **17±13 months (range 2-32) post-discontinuation of CNI and 15±10 months (range 3-31) in
controls.

The change in slope of the CrCl was +0.335 ml/min/month in patients in whom
CNI were discontinued, and -0.124 ml/min/month in controls (P=0.03).
Conclusion: Our results suggest that long-term anti-CD25 mAb-based therapy
has the potential to replace CNI- and Rapa-based immunosuppression. It is
crucial however that routine endomyocardial biopsies be performed in all
patients for surveillance of acute rejection. A randomized controlled trial is
required to confirm the benefits of this strategy.

687 LATE ONSET ANTIBODY-MEDIATED REJECTION
AND ENDOTHELIAL LOCALISATION OF VASCULAR
ENDOTHELIAL GROWTH FACTOR ARE ASSOCIATED WITH
DEVELOPMENT OF CARDIAC ALLOGRAFT REJECTION

E.R. Rodriguez1, W.M. Baldwin2, C.D. Tan1
Cleveland Clinic, 2Johns Hopkins University
Introduction: The single most important limiting factor to the longevity of
cardiac allografts is “coronary artery vasculopathy”. This process consists
of a cellular proliferative process which narrows the intima of the coronaries
and eventually leads to failure of the graft. The pathology of the lesion has
been compared to the pathology of coronary arteries in atherosclerosis. The
main distinction is the proliferative nature of the lesion in the intima of the
grafts. However the signals involved in this proliferative process are not well
understood.
Methods: The epicardial coronary arteries from 24 hearts were procured and
frozen in liquid nitrogen immediately after explanation of the heart from patients
undergoing orthotopic heart transplant. Six were from dilated cardiomyopathy
hearts without any evidence of coronary atherosclerosis. Six from patients
with severe coronary atherosclerosis, and 12 from patients with failed cardiac
allografts who were receiving a second transplant. Expression profiling was
studied by comparing these samples using Affymetrix HG-U133A expression
chips. Genes of interest were subsequently quantitated by RT-PCR, localized
in tissue samples by using antibodies to the protein encoded by these genes as
well as in Western blots.
Results: Expression analysis showed increased expression of Neuropilin 2,
ESDN and VEGFR2 in cardiac allograft coronary arteries. Immunofluorescence
demonstrated the abundant presence of these proteins in the neo-intimal
proliferative lesion of these arteries and not in the media of allograft
vasculopathy lesions.
Conclusions: This study shows that ESDN, Neuropilin 2 and its co-receptor
the Vascular Endothelial Growth Factor 2 are expressed in the neointimal of
coronary arteries with atherosclerosis and with allograft vasculopathy in a
differential manner. This differential expression may modulate the interactions
of VEGFR’s with other ligands that influence proliferation and migration of
smooth muscle cells into the intima.

1

689 IMMUNOFLUORESCENCE DETECTION OF
COMPLEMENT ACTIVATION PRODUCTS C4D AND C3D
CORRELATES WITH CARDIAC ALLOGRAFT DYSFUNCTION
AND DONOR SPECIFIC ANTIBODIES IN HUMAN HEART
TRANSPLANTS
C.D. Tan, R.C. Starling, G. Tsokos, D.O. Taylor, D. Pidwell,
G. Gonzalez-Stawinski, E.R. Rodriguez
Cleveland Clinic
Antibody mediated rejection in human heart transplantation is an
immunopathologic process in which activation of complement with formation
of the membrane attack complex results in allograft injury and dysfunction.
However activation of complement in heart transplants does not always result
in allograft dysfunction. The regulators of complement activation may play
an important role in protecting the allograft from injury despite activation of
complement.
Methods: We studied 1511 endomyocardial biopsies (EMBs) from 330
patients (age: 20-73 years, 266 males and 64 females). The number of years
after transplant was 1 year or less in 50 patients 1 to 5 years in 241 patients
and >5 years in 39 patients. The average number of EMBs studied per patient
was 5. Immunofluorescence showing deposition of complement activation
products C4d and C3d in linear pattern around capillaries was correlated
with the presence of Cardiac allograft dysfunction defined as one or more of
the following: 1. Systolic dysfunction defined as decreased cardiac output,
decreased ejection fraction, need for inotropic agents. 2. Diastolic dysfunction
defines as elevated filling pressures on right heart catheterization. 3. Sudden
cardiac death.
Results: Thirty eight of 333 (12%) of patients showed deposition of
complement. Group 1 included 19 patients with C4d and C3d deposits and
Group 2 included 19 patients who were positive C4d only). In Group 1 16/19
(86%) patients had concomitant allograft dysfunction and six of these patients
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J. Bayliss1, M. Bailey2, A. Leet3, N.M. Thomson1, C.A. McLean1,4
1
Department of Medicine, 2Department of Epidemiology and Preventative
Medicine, Monash University, 3Heart Transplant Service, 4Anatomical
Pathology, Alfred Hospital, Prahran, Victoria, 3181, Australia
Background: Improvements in cardiac transplant practice and
immunosuppressive treatment have done much to curb the incidence of
acute cellular rejection (ACR), however antibody-mediated rejection (AMR)
and cardiac allograft vasculopathy (CAV) remain prevalent. Recent studies
have shown that allograft rejection is governed by both allogeneic and nonallogeneic factors such as inflammation. Vascular endothelial growth factor
(VEGF) is a highly specific mitogen for endothelial cells (ECs) produced
by ECs and leukocytes. VEGF also acts as a monocyte chemoattractant
and increases the production of various proinflammatory mediators. Initial
studies have suggested that VEGF may play a specific role in not only
leukocyte trafficking, but in the augmentation of ACR and development of
CAV.
Methods: 152 endomyocardial biopsies from 76 heart transplant patients
undergoing orthotopic cardiac transplantation surgery between 1995 and 2000
were assessed. Using immunohistochemistry, we investigated the localisation
of VEGF protein to specific cell types during periods of ACR and AMR in the
first post transplant year and assessed the development of CAV.
Results: We showed a significant correlation between lymphocytic localisation
of VEGF protein and severe ACR (p<0.001). AMR positive biopsies taken
at twelve months post transplant showed significantly greater endothelial
localisation of VEGF that time-matched AMR negative biopsies (p=0.006).
When a subset of AMR positive biopsies with intravascular macrophage was
assessed the significance of the relationship with endothelial VEGF localisation
increased further (p<0.001). Diffuse endothelial expression of VEGF was also
associated with a 2.5-fold increase in the risk of developing CAV (p=0.001).
There was universal development of CAV in patients from whom twelve month
biopsies exhibited AMR with intravascular macrophage and endothelial VEGF
localisation (n=8).
Conclusions: We have shown that localisation of VEGF protein to the vascular
endothelium and intravascular macrophage during AMR is a highly significant
predictor of CAV. This study also highlights the potential pathogenic role of the
endothelial cell in late onset AMR and the development of CAV.

688 MICROARRAY ANALYSIS SHOWS THAT NEUROPILIN2,
ESDN, VASCULAR ENDOTHELIAL GROWTH FACTOR
RECEPTORS 1 AND 2 (VEGFR1 AND 2) ARE DIFFERENTIALLY
EXPRESSED IN PROLIFERATIVE CORONARY LESIONS
FROM ATHEROSCLEROTIC AND TRANSPLANT
VASCULOPATHY HUMAN ARTERIES

Thursday 14 August 2008
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died. In Group only 1 of 19 (5%) patients had dysfunction. There were no cases
of sudden death in Group 2. Donor specific antibodies were detected in 15/19
patients of Group 1 and only in 3/19 patients in Group2
Conclusions: A panel of C4d and C3d is more useful than C4d alone in the
evaluation of AMR. Presence of C4d and C3d correlates with cardiac allograft
dysfunction and DSA. The incidence of AMR in this cohort: 5%. AMR
can occur months to years after transplantation. The mere presence of C4d
complement deposition alone should not be equated with AMR.

levels (1.2±0.2 mg/dL vs. 1.7±0.3 mg/dL). MACE was correlated with stenotic
microvasculopathy (2.56 [1.36–1.81]; p=0.003) and total cholesterol levels
(1.01 [1.00–1.01]; p<0.001), while female gender (0.13 [0.03–0.59]; p=0.007)
and statin treatment (0.35 [0.13–0.97]; p=0.044) were found to lower the risk
for MACE.
Conclusions: CRP, total cholesterol and triglyceride levels do not seem to trigger
stenotic microvasculopathy. Statins decrease the risk for MACE independently
of cholesterol levels and should be considered in all HTx patients.

690 IS COMPLEMENT ACTIVATION WITHOUT ALLOGRAFT
DYSFUNCTION INDICATIVE OF “ACCOMMODATION”
IN HEART TRANSPLANT RECIPIENTS?
E.R. Rodriguez, C.D. Tan
Cleveland Clinic
The concept of “accommodation” has been used to refer to absence of injury
in the face of humoral immunity directed against an organ graft; however, the
mechanism(s) and concept of accommodation may extend much further. It has
been suggested that regulators of complement activation may play a role in
accommodation.
Methods: A cohort of 99 heart transplant recipients (81 men and 18 women)
with and average age of 52 years was studied. Biopsies were stained with C4d
and C3d as well as with antibodies to the regulators of complement activation
(RCA) CD55 or Decay Acceleration Factor (DAF) and CD59 Protectin.
Complement deposits were scored only if they were present in capillary pattern.
RCA’s were scored if present in granular pattern in capillaries or venules.
Results: Six of 99 patients showed activation of complement with deposition of
both C4d and C3d in capillaries. Only one of these six patient showed staining
for RCA’s. Four out of 99 patients showed deposition of C4d in capillary
pattern without staining for C3d. For out these four patients showed staining
for RCA’s. In addition 64 patients without any complement deposition showed
staining for CD55 and 44 showed staining for CD59.
Conclusion: In human heart transplants concomitant deposition of C4d and
C3d correlates with antibody mediated rejection and absence of staining for
CD55 or CD59
The presence of C4d deposits only does not correlate with antibody mediated
rejection, but in contrast it is associated with concomitant expression of either
CD55 or CD59 or both of these RCA’s
Patients without any evidence of complement deposits in the biopsy, often
show staining with either CD55 or CD59 or both.
Thus a protective role of the RCA’s may be present in humans which is part of
the accommodation mechanisms postulated in xenografts.

691 ROLE OF LIPIDS IN THE DEVELOPMENT OF STENOTIC
MICROVASCULOPATHY AFTER HEART TRANSPLANTATION
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N. Hiemann1, E. Wellnhofer1, C. Knosalla2, H. Lehmkuhl1, R. Hetzer1,
R. Meyer1
1
Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular
Surgery, 2Deutsches Herzzentrum Berlin, Department of Cardiology
Background: C-reactive protein (CRP) and elevated lipid levels have been
shown to increase the risk of epicardial vasculopathy after heart transplantation
(HTx). We tested the effect of lipids and CRP on the development of stenotic
microvasculopathy in biopsy, as novel prognostic factors for long-term
survival.
Patients and methods: In 9,713 biopsies harvested within the first posttransplant year from 873 patients (83% men, mean age 49 yrs) morphologic
alterations of endothelial cells and the media were studied by light microscopy
(thickening with/without luminal stenosis). Total cholesterol, triglyceride and
CRP levels were obtained during the first year post-transplant. End-point for
survival analysis was defined as major cardiac event (MACE: lethal myocardial
infarction, sudden cardiac death, graft failure).
Results: Stenotic microvasculopathy was present in 379 (43%) patients.
Endothelial disease (OR 1.96 [95%CI 1.38–2.78]; p<0.0001) and mild cellular
rejections (1.17 [1.12–1.22]; p<0.0001) were found to increase the risk
while statin treatment lowered the risk for stenotic microvasculopathy (0.68
[0.47–0.96]; p=0.029). No differences were found between patients with and
without stenotic microvasculopathy concerning total cholesterol (233±5 mg/
dL vs. 230±3 mg/dL), triglyceride (237±11 mg/dL vs. 235±7 mg/dL) or CRP
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692 VALIDATION OF AN ALGORITHM FOR DIAGNOSIS OF
CORONARY ARTERY DISEASE AND PREDICTING CARDIAC
EVENTS IN HIGH-RISK RENAL TRANSPLANT CANDIDATES.
J.J.G Lima1, L. Henrique Gowdak1, F.J. de Paula2, L.E. Ianhez2,
J.A.F. Ramires1, E.M. Krieger1
1
Heart Institute (InCor) University of São Paulo Medical School,, 2Renal
Transplant Unit, Hospital das Clínicas, University of São Paulo Medical
School.
Background: in a previous work (Hypertension 2003; 42:263) we showed that
coronary angiography (CA) was the best predictor of cardiac events in highrisk renal transplant candidates (RTC) compared to noninvasive testing. The
aim of the present work was to validate these results in a larger group of similar
individuals.
Methods: a strategy for diagnosis and risk assessment was applied in a group
of 228 RTC (56 ± 9 years old, 71% males, 66% Caucasians) to validate an
algorithm derivate from an initial study. Selection criteria were at least one of
the following: age > 50 years, diabetes and cardiovascular disease. Patients
underwent myocardial scans (SPECT) and CA, irrespective of symptoms and
were followed-up until death, renal transplantation or the occurrence of cardiac
events (sudden death, myocardial infarction, unstable angina, and heart failure).
Coronary artery disease (CAD) was defined as stenosis > 70%.
Results: the prevalence of CAD was 47% and 1/3 of patients with important
CAD were not detected by SPECT. The sensitivity, specificity and positive
and negative predictive values of SPECT for the detection of CAD were 70%,
74%, 69%, and 71%, respectively and 31 patients (13.6%) developed cardiac
events. The survival free of events in patients with normal and abnormal
scans did not differ (Log-Rank= 0.247, Fig. 1) and the differences remained
nonsignificant when we analyzed the results of fixed (Log-Rank= 0.30) or
reversible (Log-Rank= 0.14) defects separately. CAD, as defined by CA, was
associated with increased probability of cardiac events (Log-Rank= 0.001;
HR 1.90, 95% CI 1.29-2.92, Fig. 2). Multivariate analysis showed that
diabetes (p= 0.03; HR 1.58, 95% CI 1.06-2.45) and angiographically-defined
CAD (p=0.03; HR 1.69, 95% CI 1.08-2.78) were the independent predictors
of events.
Conclusion: the results validate our observations in a smaller number of RTC and
indicate that SPECT is not appropriate for the diagnosis of CAD or prediction of
cardiac events in high-risk RTC. CA was an independent predictor of events but,
because less than 50% of patients presented significant CAD, it seems premature
to recommend the test to all high-risk RTC. CA is necessary in many high-risk
RTC and better noninvasive methods are still lacking to identify with precision
those patients that will benefit from invasive procedures.
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693 COUNTERINTUITIVE ASSOCAITION BETWEEN
PRE-TRANSPLANT BODY MASS INDEX (BMI) DURING
HEMODIALYSIS TREATMENT AND 5-YEAR POSTTRANSPLANT MORTALITY IN 18,501 CKD PATIENTS
K.Kalantar-Zadeh1, E. Streja1, S. Bunnapradist2, J. Jing1, G.M. Danovitch2,
C. McAllister3,
1
Harbor-UCLA Harold Simmons Center for Kidney Disease Research and
Epidemiology, 2UCLA Kidney Transplant Center, 3DaVita Inc
Background: Conflicting results have been reported regarding the association
of BMI and graft and patient survival in renal transplant recipients (RTR). We
hypothesized that high pre-transplant BMI is NOT associated with greater
mortality in RTRs.
Methods: By linking the 5-year (7/2001-6/2006) national database of a large
dialysis organization (DaVita Inc) to the Scientific Registry of Transplant
Recipients (SRTR), we identified 18,501 DaVita maintenance hemodialysis
(MHD) patients, who underwent kidney transplantation in the USA. Quarterly
BMI data originated from the dialysis database, and mortality data from the
SRTR data.
Results: The 18,501 RTR patients were 47.3±14.2 years old and included
40% women and 24% diabetics. The pre-transplant BMI was 27.6±6.4 kg/m2.
Unadjusted and case-mix and malnutrition-inflammation complex syndrome
(MICS) adjusted survival analyses showed incrementally greater survival with
higher BMI>23 kg/m2 (see Figure):

Conclusions: A counterintuitive assocaition (or so-called “reverse epidemiology”)
was observed between pre-transplant BMI values during hemodialysis treatment
and post-transplant mortality, questioning the wisdom of weight reduction
recommendations for pre-transplant waitlisted MHD patients.

694 NT-PROBNP INDEPENDENTLY PREDICTS CVD AND
GRAFT FAILURE IN RENAL TRANSPLANT RECIPIENTS
L.H. Oterdoom1, R.M. van Ree1, A.PJ. de Vries1, R.T. Gansevoort1, W.J. van Son1,
J.J. Homan van der Heide1, P.E. de Jong1, R.O.B. Gans1 and S.J.L. Bakker1
1
Renal Transplant Program, University of Groningen and University Medical
Center Groningen, Groningen, Netherlands.
Manifest renal disease predisposes to cardiovascular disease (CVD). The
concept of cardio-renal interaction implies that the opposite is also true and
that cardiac dysfunction promotes development of renal dysfunction. Brain
(B-type) natriuretic peptide (BNP), is released by ventricular myocytes and
NT-proBNP is a cleaved product of BNP. It is unknown whether NT-proBNP
predicts CVD and graft failure (GF) in renal transplant recipients (RTR).
Outpatient-clinic RTR, who had a functioning graft ≥1 year, were invited to
participate between 2001-2003. CVD was defined as myocardial infarction,
CVA, well documented TIA, PTCA, CABG, and CVD mortality. CVD events
were retrieved by reviewing all electronic and paper charts until August 2007.
GF was also determined until August 2007 and defined as the return to dialysis.
NT-proBNP was determined using a sensitive immunoassay. Endpoints were
analysed with Cox-regression analyses in three groups: reference group below
the median and two groups above the median (equivalent to 3rd and 4th quartile).

NT-proBNP (median [IQR] 296 [131-669] pg/ml) was measured in 605
RTR (aged 51±12 years, 55% male) who were at a 6.0 [2.6-11.4] years posttransplant. Creatinine clearance was 62±22ml/min, 169 (28%) had proteinuria
>0.5g/24h, and systolic blood pressure was 152±23 mmHg. During follow-up
of 5.3 [4.7-5.7] years 78 had a CVD event and 42 suffered GF. In the reference
group of NT-proBNP (range: 13-294 pmo/l, n=301), 16 (5) had CVD and 8
(3%) suffered GF. In the 3rd quartile (296-667 pmol/l, n=152), 22 (15%) had
CVD (Hazard Ratio 6.2 [95%CI 3.5-11.0) and 13 (9%) suffered GF (HR:
3.5 [1.4-8.3]). In the 4th quartile (671-15392 pmol/l n=150), 40 (27%) had
CVD (HR: 6.2 [3.5-11.0) and 21 (14%) suffered GF (HR: 6.5 [2.9-14.7) (All
P≤0.001). After adjustment for age, sex, creatinine clearance, proteinuria,
systolic blood pressure, and time since transplantation, the 3rd quartile of
NT-proBNP predicted CVD (HR: 2.1 [CI 1.1-4.1], P=0.03), but the HR was
reduced to 2.0 [0.8-4.9], P=0.2) for GF. The 4th quartile showed a HR of 3.6
[1.8-7.0], P<0.001 for CVD and 2.8 [1.1-7.3], P=0.04 for GL in multivariate
analyses. Results remained similar after adjustment of CVD prior to inclusion
of the study.
NT-proBNP predicted CVD and GF independent of age, sex, renal function
and blood pressure in RTR. That NT-proBNP predicts GF suggests that there
is a cardio-renal interaction in RTR and that cardiac dysfunction leads to
accelerated graft dysfunction.

695 METABOLIC SYNDROME INCREASES RISK OF
MORTALITY IN RENAL TRANSPLANT RECIPIENTS.
A.P.J. de Vries1, L.H. Oterdoom1, R.M. van Ree1, W.J. van Son1, J.J. Homan
van der Heide1, P.E. de Jong1, R.O.B. Gans1, S.J.L. Bakker1
1
Renal Transplant Program, University Medical Center Groningen,
Groningen, Netherlands.
Many renal transplant recipients (RTR) suffer from the metabolic syndrome
(MS). It is unknown whether MS increases risk of mortality in RTR. We studied
MS (ATPIII criteria) in a cohort of 606 RTR, who had a functioning graft ≥1
year, with median [IQR] follow-up of 5.3 y [4.7-5.7]. MS was present in 63%
of RTR, of whom 77 (21%) died compared to only 19 (9%) in RTR without
MS (p<0.001). RTR with MS were older (53 vs 49y), more often female (50
vs 39%), had more often central obesity (72 vs 14%), hypertension (100 vs
95%), hypertriglyceridemia (84 vs 24%), low HDLc (83 vs 22%), and more
often impaired fasting glucose or diabetes (26 vs 1%, all p<0.001). RTR with
MS also had higher concentrations of fasting insulin (14 vs 9 pmol/L) and
CRP (2.5 vs 1.4 mg/mL), used more ACE inhibitors (37 vs 27%), statins (55
vs 40%), and had lower GFR (MDRD, 47 vs 53 mL/min, all p<0.001), whereas
urinary protein excretion (0.2 vs 0.2 g/24h), current smoking (21 vs 24%) and
immunosuppressive medication were similar. Figure 1 shows Kaplan Meier
survival plots for RTR with and without MS. The crude hazard ratio (HR) of
MS for mortality was 2.5 [1.4-4.1]. Age and sex adjusted HR was 2.2 [1.3-3.6].
The HR retained statistical significance (HR 1.8 [1.0-3.3]) after adjustment for
all MS criteria simultaneously. This did not change materially (HR 2.0 [1.1-3.9])
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after additional adjustment for GFR, insulin, proteinuria, smoking, CRP, and
medication. Our data show that RTR with MS have a two times higher risk for
mortality. Moreover, our data suggest that MS constitutes more than the sum
of its parts with regard to mortality. The risk is not conferred by impaired renal
function, hyperinsulinemia, proteinuria, inflammation, smoking, or medication.

696 EFFECT OF CANDIDATE HEALTH STATUS
ON INCREMENTAL YEARS OF LIFE FROM KIDNEY
TRANSPLANTATION
A. Leichtman1, K. McCullough2, P. Stock3, M. Stegall4, R. Wolfe2
Department of Medicine, Univ. of Michigan, 2Arbor Research Collaborative
for Health, 3Department of Surgery, Univ. of California San Francisco,
4
Department of Surgery, Mayo Clinic College of Medicine
Introduction: The projected incremental years of life that can be achieved
by receiving a kidney transplant v. remaining on dialysis (i.e. Life Years from
Transplant or LYFT) is under investigation in the United States as a potential
element of a national deceased donor kidney allocation system. Although
candidate age is a significant component in the LYFT calculation, additional
elements reflecting candidate health status contribute importantly to the LYFT
score. We report the distribution of LYFT scores by age range.
Methodology: The LYFT scores for adult kidney-alone transplant candidates
active on the national U.S. Organ Procurement and Transplantation Network
waiting list on 1/1/2004 and receiving an average non-expanded criteria donor
kidney were calculated. In the figure below the “whiskers represent the 5th and
95th percentiles, the box edges the 25th and 75th percentiles, and the line within
the box the median LYFT score.
Results: Median LYFT by age group ranged from 9.0 for kidney transplant
candidates between 18-30 years to 3.7 for candidates greater than 70 years of
age. The 5th-95th percentile for LYFT scores by age group ranged from 2.5-4.7
for candidates over 70 to 7.6-10.1 for candidates between 18 and 30.
1
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Discussion: Age is an important determinant, but not the sole important,
determinant of LYFT. Within each age grouping, there is considerable variance
in the projected incremental years of life that can be achieved by receiving a
deceased donor kidney transplant. LYFT can be the same for candidates with
as much as a 35 year difference in age. While age is an important determinant
of LYFT, other factors can be as important as 30 years of aging.
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697 PROSPECTIVE EVALUATION OF THE RISK BENEFIT
RATIO OF A VITAMIN D TREATMENT DURING THE EARLY
PERIOD AFTER RENAL TRANSPLANTATION
E. Thervet2, M. Courbebaisse1, J. Claude Couberbiellle1, J. Zuber2,
F. Martinez2, M. F. Mamzer2, C. Legendre2, G. Friedlander1, D. Prie1
1
Service d’explorations fonctionnelles, Hopital Necker, 2Department of
Transplantation, Hopital Necker
Introduction: It has been demonstrated that 25-OH vitamin D (25OHD) levels
are reduced in the large majority of renal transplant recipients (RTR) because
of reduced sun exposure, and steroid therapy. The aim of this prospective
randomized study was to investigate the risk benefit ratio of a correction of
25OHD during the early period after transplantation.
Patients and methods: All RTR in our center underwent a complete workup
including Ca, P, ionized (i)Ca, PTH, calcidiol, calcitriol, calciuria and
glomerular filtration rate (GFR) assessed by iohexol clairance at 3 months
(M3). The inclusion criteria were a serum concentration of 25OHD<30 ng/
ml and a iCa<1.35 mmol/L. Between 01/2006 and 09/2006, 49 patients were
randomized to receive 100.000 U of cholecalciferol (CLF) every other weeks
for 2 months (4 doses) and thereafter 100.000 U every two months. The
treatment was initiated at M4 (group A, n=23) or at M6 (groupe B, n =26) after
transplantation. Complete PCa workups were performed at M6, 8 and 12.
Results: No difference was found between the 2 groups regarding pretransplant characteristics and initial transplant evolution including steroid
therapy. Between M4 and M6, all patients normalize their 25OHD in group
A vs. no patient in group B (respectively 43.0±10.8 vs. 16.9±9.3, p<0.001).
Delayed treatment at M6 in group B normalizes the 25OHD concentration at
M8. Between M3 and M12, PTH significantly improved (106±121 vs. 75±57
pg/ml, p=0.03) without GFR modification. At M12, CLF treatment was not
associated with hypercalcemia or hypercalciuria (respectively 2.45±0.12
mmol/L and 0.33±0.27 mmol/mmol).
Conclusion: In RTR, 25OHD did not improve spontaneously between M4
and M6 after successful renal transplantation. A treatment by 400 000 U
of 25OHD allows a correction of vitD insufficiency, improve secondary
hyperparathyroidism, without 25OHD intoxication, hypercalcemia nor
hypercalciuria. The long term benefit of this treatment and the need for chronic
supplementation is currently being investigated.

698 STRATEGIES FOR DIAGNOSIS AND TREATMENT OF
CORONARY ARTERY DISEASE IN RENAL TRANSPLANT
CANDIDATES: IMPACT ON THE INCIDENCE OF POSTTRANSPLANT CARDIAC EVENTS.
J.J.G. Lima1, L.H.W. Gowdak1, F.J. de Paula2, L.E. Ianhez2, R.L. Arantes1,
E.M. Krieger1
1
Heart Institute (InCor) University of São Paulo Medical School,, 2Renal
Transplant Unit, Hospital das Clínicas, University of São Paulo Medical
School
Background: coronary artery disease (CAD) is a major cause of post-transplant
events in patients with chronic kidney disease (CKD). The best strategies for
pre-transplant diagnosis and treatment for these patients are controversial.
Methods: 831 CKD patients were evaluated for CAD before been admitted
to the waiting list for renal transplantation (Tx). High-risk patients (age >
50 y, diabetes and any cardiovascular disease alone or in combination) were
submitted to coronary angiography (CA) irrespectively of symptoms. All
other (low-risk) patients were first evaluated by myocardial scans and only
those with abnormal scans were also submitted to CA. All patients received
medical treatment according with the AST guidelines. Patients with significant
(> 70% stenosis) CAD were either kept on medical treatment or submitted to
intervention (surgery/angioplasty with nonpharmacological stent) prior to Tx
by decision of the study investigators. Survival curves were constructed using
the Kaplan-Meier method and compared by Log-Rank method.
Results: 580 patients completed pre-TX work-up and a first cadaver Tx was
subsequently performed in 167 patients. There were 25 post-Tx cardiac events
(myocardial infarction, unstable angina, heart failure and sudden death). The
incidence of cardiac events increased from 3% in the low-risk group to over
30% in patients with significant CAD (p< 0.01). Five-year event-free survival
was (Figure 1): low risk (N= 67) – 87%; high-risk, no significant CAD (N=
66) – 75%; high-risk, significant CAD, medical treatment (N= 23) – 55%; highrisk, significant CAD, intervention (N= 11) – 40% (p< 0.01 low risk versus
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significant CAD). The modality of treatment (medical/intervention) did not
alter the prognosis.
Conclusion: clinical risk stratification combined with CA is a powerful tool
to identify patients with increased probability of post-Tx cardiac events. CAD
strongly influences the prognosis. Coronary intervention did not alter the
prognosis of patients with significant CAD but the numbers are too small to
allow a definitive conclusion in that respect.

699 NATURAL HISTORY OF PARATHYROID HORMONE
(PTH) LEVELS IN THE FIRST YEAR POST KIDNEY
TRANSPLANTATION (TX)
R. Masterson, J. Beavis, S. Cohney, R. Walker
Royal Melbourne Hospital
Introduction and Aims: The impact of abnormal bone-mineral metabolism
pos t renal transplantation (Tx) is not well established and consequently
there is a lack of established guidelines determining the optimal level of
Ca 2+, P04& PTH in this patient population. The incidence of pre-Tx
parathyroidectomy varies with local practice but is reported to be associated
with low bone turnover, a higher incidence of fracture and potentially
increased vascular calcification post renal Tx. We carried out a retrospective
study to examine the natural history of PTH in the first year post renal Tx.
Methods: A single centre retrospective study of 61 renal allograft recipients
transplanted between January and December 2006 in whom 12 month (m)
clinical and biochemical follow up was available.
Results: Median
Pre Tx
3m post Tx
6m post Tx
12m post Tx
PTH (pmol/L) 12.5(0.4-180) 8 (0.8-32)
8 (0.6-38)
6.6 (3.4-30.6)
Ca2+ (mmol/L)
2.4 (1.9-2.9) 2.4 (1.5-3) 2.4 (1.5-3)
P04 (mmol/L)
0.87 (0.4-1.4)
0.9 (0.5-1.3)
0.9 (0.47-2.2)
Forty percent of patients had a pre-Tx PTH lower than KDOQI guidelines, with
18% having had a pre-Tx parathyroidectomy. Hyperparathyroidism (PTH > 2.5
times upper limit of normal) was present in 22% at 3m post-Tx, with 50% of
this group being hypercalcaemic (Ca2+ > 2.7 mmol/l). Of this hyperparathroid
group, 1 required parathyroidectomy at 12m for persistent hypercalcaemia & 1
received cinacalcet for 3m post Tx. In the overall group 25% were prescribed
calcitriol & 11.1% cholecalciferol.
Although 8 patients had a pre-Tx PTH > 65 pmol/L, in all cases the PTH fell
significantly post Tx: 81.9 (68-186) pmol/L (pre-Tx), 10 (4-32) pmol/L (3m)
& 7.7 (5.2 –31) pmol/L (12 m). One patient in this group received cinacalcet
for 3 months post Tx, 1 had calcitriol and none had a parathyroidectomy. The
median GFR at 12 m in the high PTH group (54 (36-91) mls/min) did not differ
significantly from the overall group (52 (27-102) mls/min).
Conclusion: A significant fall in PTH was uniformly observed post-Tx, even
in the setting of extreme pre-Tx hyperparathyroidism. The greatest fall in PTH
occurred within 3m of Tx, with no significant change in PTH thereafter, an
observation that may have implication for earlier intervention in the context
of persistent hyperparathyroidism and hypercalcaemia post Tx. Forty percent
had a pre-Tx PTH lower than KDOQI guidelines with a relatively high%
having parathyroidectomy. The long-term implications of this on post-Tx bone
and cardiovascular disease remain unknown. Post-Tx Ca2+ and P04 control
was better than previously reported, a factor potentially associated with the

relatively high percentage of patients prescribed Vitamin D.

700 ADVERSE EFFECTS OF HYPERURICEMIA ON RENAL
TRANSPLANT OUTCOME IN SEVERITY-DEPENDENT
MANNER
S.I. Min1, I.J. Yun2, J.M. Kang3, Y.J. Park1, S.K. Min1, E.M. Kim6, C. Ahn4,5,
S.J. Kim1,5, J. Ha1,5
1
Department of Surgery, Seoul National University College of Medicine,
2
Department of Surgery, Konkuk University College of Medicine,
3
Department of Surgery, Gachon University Gil Medical Center, 4Department
of Internal Medicine, Seoul National University College of Medicine,
5
Transplantation Research Institute, Seoul National University Medical
Research Center, 6Seoul National University Hospital Transplant Center
The effects of hyperuricemia on renal transplant outcome have been
controversial. We hypothesized that posttransplant hyperuricemia would
induce different effects on renal transplant outcome according to the severity.
Demographic and follow-up biochemical data were retrospectively collected on
244 consecutive renal transplant recipients. Follow-up biochemical parameters
were measured at the first and third month after transplantation and at intervals
of 6 months thereafter. Glomerular filtration rate (GFR) was estimated using
MDRD Study Equation 7 (eGFRMDRD). Hyperuricemia was defined as uric
acid (UA) level which was greater than 7.0 mg/dl in male and 6.0 mg/dl in
female and was persistent at least two consecutive follow-up. Recipients were
classified into normouricemia, mild hyperuricemia (Group 1, UA level <
8.0mg/dl) and moderate to severe hyperuricemia (Group 2, UA level ≥ 8.0mg/
dl). Compared to normouricemia, Group 1 had no significant difference in
graft survival rate, however, Group2 showed significantly reduced transplant
survival rate (P=0.003) (Fig. 1). In Cox proportional hazard analysis, UA level
≥ 8.0 mg/dl and episodes of acute rejection were significant risk factors for
graft survival. Interestingly, UA level ≥ 8.0 mg/dl had more significant impact
on graft survival than episodes of acute rejection (P = 0.012; HR 7.72; CI 95%
1.56-38.19 vs. P = 0.002; HR 3.77; 95% CI 1.61-8.79, respectively). In contrast
to normouricemia or Group1, Group2 showed persistent decrease in eGFRMDRD
throughout the follow-up. Twenty two patients (48.9%) of Group2 were treated
with UA lowering therapy (ULT) drugs. Those who had ULT showed better
transplant survival rate than those without treatment (P=0.02) (Fig. 2). ULT
also had a beneficial effect that halted the decline of eGFRMDRD (P<0.05). In
conclusion, hyperuricemia induces adverse effects on renal transplant outcome
in severity-dependent manner and moderate to severe hyperuricemia is an
important risk factor for renal transplant dysfunction. Therefore, strict control
of UA is warranted.
Fig. 1

Fig. 2
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701 THE FAMILIAL AMYLOIDOTIC POLYNEUROPATHY
WORLD TRANSPLANT REGISTER (FAPWTR) VIEW ON
LIVER TRANSPLANTATION FOR TRANSTHYRETIN
SYSTEMIC AMYLOIDOSIS DISORDERS
H.E. Wilczek, M. Larsson, B. Ericzon
Department of Transplantation Surgery, Karolinska University Hospital,
Karolinska Institute
Background: Transthyretin (TTR) systemic amyloidosis disorders can be
treated with liver transplantation (Ltx). The FAPWTR registers such patients
since more than 15 years, most of which have the Val30Met mutation. However,
patients with non-Val30Met mutations as well as new TTR mutations are
continuously added to the Registry. Recently, patients with non-TTR mutations
(ApoA1 renal amyloidosis and fibrinogen α-chain amyloidosis) have also been
reported to have undergone combined liver and kidney transplantation.
Results: As of December 2007, a total of 68 centres from 17 different countries
have reported patients to the Registry. Most transplants have been performed in
Portugal (n=637), France (n=165), Sweden (n=115), USA (n=77), UK (n=66),
Brazil (n=67) and Spain (n=60). Patients with more than 45 different variants of
TTR mutations have been transplanted, the most common being Val30Met (83%)
followed by Ser77Tyr, Thr60Ala and Tyr114Cys all 1-2% each. 1173 of the
FAP patients had the Val30Met TTR mutation, 165 patients had a nonVal30Met
variant, 10 were non-TTR variants and in 58 patients the information was missing
or unknown. A total of 1406 patients have undergone 1521 liver transplants. 36
patients have received a liver in combination with a kidney graft and 22 patients a
combined liver- and heart transplantation. 68 liver transplantations were done with
grafts from living related donors. Gastrointestinal and cardiovascular dysfunctions
appear more often in non-Val30Met than in Val30Met patients. Approximately
30-35% of the FAP patients are reported to have improved their sensory, motor,
g-i and nutritional status, while only 8% improved their cardiovascular status.
In the Val30Met group 236 patients (20%) died compared to 70 patients (42%)
in the non-Val30Met group (p<0.0001). The overall 10-year patient survival in
Val30Met patients was highly significantly better than in nonVal30Met mutations
(75.7% and 42.8%, respectively p<0.0001). This difference was also true when
comparing the survival between these groups from May 1998, when the first nonVal30Met mutation patient was reported to the Register. However, no significant
survival was observed when re-analysing the data with patients transplanted
during the last 6 years. Overall, cardiovascular related death dominated (26% of
the cases). In 24%, sepsis was reported as the main cause of death. Certain TTR
mutations appear to be important in relation to cardiac related deaths.
Conclusion: Ltx in patients with TTR amyloidosis disorders continues to save lives.
Val30Met and other TTR mutations differ clinically. NonVal30Met patients appear
more often to require combined liver-heart transplantation. The previously observed
highly significant post-transplantation survival difference between Val30Met and
non-Val30Met mutations has disappeared when analyzing the last 6 years, maybe
as consequence of improved pre- and post-transplantation patient management as
well as better selection criteria for the acceptance to transplantation.

702 HEREDITARY FIBRINOGEN A A ALPHA-CHAIN
AMYLOIDOSIS; PHENOTYPIC CHARACTERIZATION AND
THE ROLE OF LIVER TRANSPLANTATION
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N.D. Heaton1, J. O’Grady1, M. Rela1, B. Portmann1, J. Wendon1,
B. Hendry2, M. Buxton-Thomas3, N. Banner4, M. Benson5, A.J. Stangou1
1
Institute of Liver Studies & Amyloidosis Treatment Programme, King’s
College Hospital, London, U.K, 2Renal Medicine Department & Amyloidosis
Treatment Programme, King’s College Hospital, London, U.K, 3Nuclear
Medicine Department & Amyloidosis Treatment Programme, King’s College
Hospital, London, U.K, 4Cardiology and Cardiac Transplant Medicine,
Royal Brompton & Harefield Hospital, London, U.K, 5Amyloidosis Centre,
Department of Pathology and Laboratory Medicine, Indiana University
School of Medicine, Indianapolis, Indiana, USA
Background: Variants of fibrinogen A á-chain cause the commonest type
of hereditary renal amyloidosis (AFib) in the U.K. Variant fibrinogen is
produced in the liver, and solitary renal allografts fail within 1-7 years due to
progressive amyloidosis.
Patients and methods: We report the clinical features and outcome of 21
patients with AFib and National Kidney Foundation stage 3-5 chronic kidney
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disease (CKD) in association with renal amyloidosis, who were assessed for
combined liver and kidney transplantation (LKT). Median age of the patients
was 55 (49-69) years; 20 had the E526V variant and one had R554L.
Results: Coronary atherosclerotic disease was identified in 61.9% of cases,
and carotid and/or aortic atheromatosis in 57.1%. Vascular atheroma excised at
endarterectomy in one patient contained amyloid derived from purely variant
fibrinogen. Endomyocardial biopsies in 2 patients with the E526V the R554L
variants revealed fibrinogen amyloid. Cardiac parasympathetic and gut and
biliary autonomic neuropathy was identified in half the cases. Eight patients
have received LKT in the past 11 years, in 2 cases at stage 4 CKD preemptively
before haemodialysis. Six patients (cumulative survival 75.0 percent) are
alive and well with good dual allograft function, resolution of dysautonomia
and no progressive amyloidosis after a median 43.7 (range 11-132) months’
follow-up. In contrast to inexorable progression to ESRF in the natural course
of the disease, serial dynamic and static renal scintigraphy in the 2 cases of
pre-emptive LKT, demonstrated preserved function of the native kidneys with
stable contribution in the overall renal function by 13 and 20% respectively,
up to current 5 years posttransplant follow-up. Four of the explanted livers
were used successfully for subsequent domino LT in patients with cirrhosis and
hepatocellular cancer.
Conclusions: Hereditary fibrinogen amyloidosis is a systemic disease with
multivisceral, vascular, cardiac and neurological involvement. Hepatorenal
transplantation removes the sole source of variant amyloidogenic fibrinogen
and is curative, however, cardiovascular disease may confine successful access
to this option. The observed salvage of native kidney function post-LKT
encourages evaluation of pre-emptive solitary liver transplantation early in the
course of amyloid nephropathy to obviate progression to ESRF, requirements
for renal replacement therapy and kidney transplantation.

703 HEALTH-RELATED QUALITY OF LIFE AND
EMPLOYMENT STATUS OF LIVER TRANSPLANT PATIENTS
COMPARED TO THE GENERAL POPULATION
F.Åberg1, R.P. Roine2, A.M. Rissanen2, K. Höckerstedt1, H. Isoniemi1
1
Transplantation And Liver Surgery Clinic, Helsinki University Hospital,
2
Group Administration, Helsinki and Uusimaa Hospital Group
Health-related quality of life (HRQoL) is a comprehensive and currently
preferable outcome measure of medical interventions such as liver
transplantation (LT).
Aim: To compare HRQoL and employment status of LT patients with that of
the general population and in subgroups.
Material and methods: HRQoL was measured with the 15D instrument, which is
a validated, generic (non-disease-specific), 15-dimensional, self-administered
HRQoL instrument that can be used both as a profile and single index score
measure. The questionnaire was sent to all adult LT patients in Finland (401
patients) alive in June 2007. Response rate was 89% (353 patients). Results
were compared to 6050 age- and gender-standardized controls from the general
population.
Results: LT patients (mean age 55 years, range 20-82) had a slightly worse
HRQoL total score than the general population (mean 0.889 vs 0.907, P<0.001).
Although LT patients fared statistically significantly worse on most of the
15 dimensions of the HRQoL instrument, a clinically meaningful difference
between the patients and the general population was observed only on the
dimension of “usual activities” (Figure 1). Gender and retransplantation did
not alter HRQoL. Acute liver failure and older age at LT were independent
determinants of decreased HRQoL (P=0.03 and P<0.0001, respectively).
Mean HRQoL was worst during the first year after LT, then peaked during
posttransplant years 1-5, after which it deteriorated linearly along with longer
survival time in a similar manner to the HRQoL reducing effect of ageing itself.
44% of working-aged LT patients were employed at time of study, as compared
to 70% in the general population. Persons employed had better HRQoL than
those unemployed (difference in HRQoL score 0.07, P<0.0001 among LT
patients and difference in HRQoL score 0.04 among controls). 87% of patients
felt that their working-capacity had improved after LT compared to one week
before LT. Early retirement was the most common cause of unemployment
(56% of unemployed patients).
Conclusion: Mean HRQoL of LT patients is only slightly worse than that of the
general population. Older age, longer survival time and ALF decrease HRQoL.
CLD patients are accustomed to a chronic disease already before LT, while
ALF patients are often previously healthy with rapid disease-progression. Thus
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ALF and CLD patients experience posttransplant HRQoL very differently.
Employment is an indicator of HRQoL, and the association is more evident in
the LT population than in the general population.

* P < 0.05, ** P < 0.01, *** P < 0.001

706 PSYCHOSOCIAL RISK FACTORS AND THE IMPACT ON
PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION

704 HEALTH-RELATED QUALITY OF LIFE IN ADULT
TRANSPLANT RECIPIENTS MORE THAN 15 YEARS AFTER
ORTHOTOPIC LIVER TRANSPLANTATION.
T. Becker, L. Kousoulas , R. Bastian , T. Becker , M. Neipp , H. Barg-Hock ,
S. Jackobs1, C. Strassburg2, J. Klempnauer1
1
Medical School of Hannover. Department of General-, Viszeral- And
Transplantationsurgery., 2Medical School of Hannover. Department of
Gastroenterology, Hepatology and Endokrinology.
Background: With continuously rising survival rates following orthotopic
liver transplantation (OLT), health-related quality of life (HQOL) of long-term
adult transplant survivors becomes increasingly important.
Methods: Recipients more than 15 years after OLT were studied retrospectively.
HQOL in 104 long-term liver transplant recipients was assessed using the
Standard German Version of the 36-Item Health Survey (SF-36).
Results: Long-term liver transplant recipients revealed satisfactory HQOL
that was comparable to the general healthy population in three of eight SF-36
categories (physical pain, social functioning and mental health). Other SF-36
categories such as physical functioning, role physical, general health and
vitality were reduced. In contrast to patients living alone, married recipients
or recipients living in a close relationship revealed a significant improved
HQOL in numerous SF-36 categories such as role physical (p<0.005), physical
pain (p<0.005), vitality (p<0.005) and role emotional (p<0.005). Moreover
recipients with full or part-time employment revealed improved HQOL in
certain dimensions and especially in physical functioning (p<0.005) and role
physical (p<0.005).
Conclusions: More than 15 years after OLT, long-term survivors present
satisfactory HQOL comparable to the general healthy population. Occupational
rehabilitation and the presence of a stable familial environment are associated
with improved HQOL
1

1

1

1

The collected data was analysed in respect to known status of alcohol abstinence
or abuse.
Results: 1, 3 and five years afterLT the vast majority of patients (>80%)
displayed no or minimal fibrotic tissue degradation. These findings were
regardless of alcohol consumption post LT.
In the further course fibrosis rates increased among all patients, yet individuals
with known recurrence of abuse showed slightly more fibrosis. Contrastingly,
fatty involution was significantly more present in the group of patients with
known alcohol abuse starting as early as one year after LT (p < 0.01).
Survival was identical regardless of alcohol abuse 5 years after LT, however after
10 years abstinent patients did significantly better (82% vs. 68%; p = 0.017).
Conclusion: LT for alcohol induced liver cirrhosis offers excellent long term
survival with minimal histological alteration of hepatic parenchyma. However,
patients with recurrence of alcohol abuse experience significantly increased
risk of fatty involution and reduced survival.

1

705 LIVER TRANSPLANTATION FOR ALCOHOL-INDUCED
LIVER DISEASE – A 10 YEAR HISTOLOGICAL FOLLOW-UP
M. Schmeding, U.Neumann, R. Neuhaus, A. Kiessling, J. Pratschke,
P. Neuhaus
Charite University Hospital
Background: Alcohol induced liver cirrhosis (ALC) accounts for an increasing
number of patients on the waiting list for liver transplantation (LT). In contrast
to potentially recurrent virally or immunogenically induced liver disease the
primary cause of illness can be completely eliminated if patients refrain from
alcohol abuse after LT. However, if patients develop recurrence of alcoholism
after LT prognosis worsens significantly.
In this study we analysed the liver tissue biopsies of patients who had been
transplanted for ALC during a 10-year follow-up period, distinguishing between
patients with strict alcohol abstinence and those with known recurrence of abuse.
Patients and Methods: 271 patients with ALC who received liver
transplantation at our institution were included.
Biopsies were taken from each patient on a routine basis at specific time
points: one year, 3, 5, 7 and 10 years after LT. Specimen were analysed by an
experienced pathologist and graded concerning inflammation, rejection, fatty
involution, fibrosis or cirrhosis.

D. Sudan, L. Penkoski, J. Sorrell, W. Grant, J. Botha, A. Langnas
Univ Nebraska Med Ctr
Background: Substance abuse, poor coping skills, psychiatric illness, poor
social support and a history of non-compliance all raise concern in the pretransplant patient regarding the potential for non-adherence to medications and
postoperative follow-up. Very little is known however, about the prevalence and
impact of psychosocial factors on patient survival after liver transplantation.
Methods: A retrospective review was performed of all adult patients undergoing
primary liver transplantation between January 1, 2004 and December 31,
2004 (excluding patient’s with perioperative death or multi-organ transplant).
Psychosocial factors evaluated included a history of substance abuse, poor
coping skills, psychiatric diagnosis, adequacy of support system, and compliance.
Demographic variables were compared and patient survival evaluated by the
Kaplan Meier method. The impact of various risk factors was compared using
chi square analysis and survival curves compared using the log rank test.
Results: Sixty-nine patients were evaluated in this retrospective IRB approved
study, 43% of whom had no identified psychosocial risk factors during the
transplant evaluation. Substance abuse was identified in 29%, 24% had poor
coping skills, 35% had a psychiatric diagnosis, 13% had inadequate social
support, and 14% had a history of non-compliance. Multiple risk factors were
present in 10, 6 and 2 patients (3, 4 or all 5 risk factors), respectively. Patient
survival was 85% overall with mean follow-up of 3.3 + 0.96 years.
Conclusions: At least one risk factor is present in more than 50% of liver
transplant recipients at this center with substance abuse or psychiatric diagnosis
being most common and 16% of liver transplant recipients demonstrate 3 or
more risk factors. The evaluation process and postoperative support services are
adequately compensating for these risk factors since we could not demonstrate
any correlation between individual (or any group of) risk factors and patient
survival after primary liver transplantation.

707 THE IMPACT OF POOR ADHERENCE TO MEDICAL
REGIMEN IN LIVER TRANSPLANTATION (LT)
P. Burra1, G. Germani1, D. Canova1, M. Senzolo1, E. Perissinotto2, A. Masier1,
F.P. Russo1, M. Gambato1, U. Cillo3, G.C. Sturniolo1
1
Gastroenterology, Department of Surgical and Gastroenterological Sciences,
University of Padua, Italy, 2Department of Environmental Medicine and
Public Health, University of Padua, Italy, 3Surgical Unit, Department of
Surgical and Gastroenterological Sciences, University of Padua, Italy
Background: adherence to medical prescription in patients with liver
transplantation (LT) is mandatory to ensure patient and graft long term survival.
Aim: the aim was to evaluate adherence to medical regimen in patients before
and after LT, in order to identify risk factors of non adherence, by performing a
longitudinal prospective study.
Materials and methods: all consecutive patients in the waiting list who
attended our Liver Transplantation Unit in 2005-2006 were enrolled in the
study and followed up after LT. Before and at 6 and 12 months after LT, all
patients underwent anonymous questionnaire, locus of control test and blood
tests. Child-Pugh score and MELD were assessed before LT. T test, χ square
test, univariate and multivariate analysis were performed.
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Results: 134 liver cirrhotic patients in the waiting list were enrolled. Before LT
44%, 12.7% and 13.4% of patients were non adherent to therapy, to outpatient
visit and to requested blood tests, respectively. Non adherent patients, compared
to patients with good adherence, were younger (mean 52.1 vs 54 ys, p 0.09),
unmarried (96.6% vs 71.3%, p 0.06) and with external LOC (66.7% vs 40.5%,
p.04). 23 out of 134 (17.1%) patients underwent LT during the study period.
When univariate and multivariate analysis was performed, being divorced and
having a better MELD score were independent risk factors for non adherence
to medical prescriptions (OR, 95%CI ; OR, 95% CI). At 6 months after LT
15%, 20% and 10% of patients were non adherent to therapy, to outpatient
visit and to blood tests, respectively. These patients, compared to patients with
good adherence, presented better MELD at time of transplantation (mean 12.7
vs 16.9, p 0.04), were drinking alcohol (33.3% vs 5.9%, p 0.001) and referred
>3 side effects of immunosuppression therapy (66.7% vs 23.5%, p. 02). At 12
months after LT 60%, 50% and 50% of patients were non adherent to therapy,
to outpatient visit and to blood tests, respectively. These patients, compared to
patients with good adherence, were younger (mean 55.3 vs 61, p.05), presented
better MELD at time of transplantation (mean 13.3 vs 17.5), were drinking
alcohol (50% vs 0%, p.001) after liver transplantation and referred >3 side
effects of immunosuppression (83.3% vs 50%, p.02). Poor adherence after LT
was related with poor adherence before transplant in 50% of the cases.
Conclusions: Adherence to medical regimen is poor in patients in the waiting
list for LT but also at 12 months after LT. Being divorced and having a better
MELD score are independent risk factors for non adherence to medical
prescriptions in patients on the waiting list, side effects of immunosoppression
seem to be a risk factor of poor adherence after LT, therefore information and
education for those patients are badly needed.

708 DE NOVO MALIGNANCY FOLLOWING LIVER
TRANSPLANTATION – RETROSPECTIVE ANALYSIS OF 641
LIVER TRANSPLANTATIONS
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C. Graeb1, M. Franki1, M. Angele1, M. Rentsch1, M. Guba1, C. Wimmer1,
C.C.J. Bruns1, R. Zachoval2, K-W. Jauch1, F. Loehe1
1
Dept. of Surgery, 2Dept. of Medicine
Introduction: Development of de novo malignancy following liver
transplantation represents a main course of late mortality. The ongoing
improvement of both surgical technique and immunsuppressive regimens
has lead to an ongoing increase in long term patient survival. Therefore, the
individual patient’s risk for development of various forms of solid organ
malignancy has continuously risen. In addition, the patient’s underlying
disease, i.e. alcoholic cirrhosis, PSC, or various forms of hepatitis, may add to
the patient’s susceptibility to cancer. Here, we analyze both the incidence and
potential risk factors in our cohort of liver transplanted patients.
Method: Our retrospective analysis was based upon the peri- and postoperative
data bases (including the Munich Tumor Registry) of 537 patients in a total 641
liver transplantations.
Results: The cumulative risk for tumor development 20 years after
transplantation with a value of 19% lay significantly higher than in an age
matched cohort (9%). 49/537 pts. developed a total 74 tumors (excluding
pre-existent HCC) during a mean follow up of 9 years. Tumor prevalence
increased from 1.3% in the first year to 20% 15 years after transplantation.
The median time interval from transplantation to tumor development was 6
years (range 1-17 years). 19 pts. died as a result of malignancy, 30 pts. remain
alive following diagnosis. 11/19 patients (57,9%) died within 2 years following
transplantation. The most common tumours were basalioma (37%), squamous
cell skin cancer SCC (22%), LPD (7%), ENT malignancy (7%) and urogenitary
cancer (6%). The relative early development of basalioma (on average 52 mths)
in comparison to SCC (72 mths) was remarkable, as well as the observation
that squamous cell cancer (57%) was more common than adenocarcinoma
(37%). At the time-point of evaluation, no significant difference was detectable
with respect to the form of immunosuppression with comparative numbers of
patients treated with cyclosporine monotherapy (32%), CyA-steroids (14%),
tacrolimus monotherapy (37%)and tacrolimus-steroids (7%) Despite the fact
that cyclosporine had been used for a significantly longer time period (124
patient years) than tacrolimus (64 patient years), no difference was evident in
overall tumor incidence.
Conclusion: The more potent immunosuppressant tacrolimus seems to be
related to a higher incidence of postoperative malignancy. In our analysis,
the primary indication (alcoholic cirrhosis, PSC, and viral hepatitis) for liver
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transplantation was not related to a higher incidence for malignancy. The
cumulative tumor incidence following liver transplantation makes a continuous
surveillance of transplanted pts. necessary.

709 PREEMPTIVE VS. PROPHYLACTIC APPROACH TO
CYTOMEGALOVIRUS IN LIVER TRANSPLANTATION
G. Smallwood1, K. Kempton2, A. Stieber1, C. Fasola1, T. Heffron1
Emory University School of Medicine, 2Emory University Hospital
Cytomegalovirus (CMV) continues to be source of increased morbidity
and mortality in the solid organ transplantation. Currently valganciclovir
is FDA approved for CMV prevention in both heart transplant and kidney
transplantation. In the pivotal PV16000 registration trial, liver transplant
recipients, receiving valganciclovir, had an increase in tissue invasive CMV
disease. Although not approved, many transplant centers use valganciclovir for
CMV prophylaxis due to ease of patient compliance.
Aim: To compare the frequency of CMV viremia as determined by polymerase
chain reaction (PCR) between liver transplant patients being followed with a
preemptive strategy and treatment compared to patients taking valganciclovir
for 100 days as prophylaxis.
Methods: This is an IRB approved review of patients being followed for CMV.
Patients were routinely followed by weekly, serial blood draws for CMV by
polymerase chain reaction (PCR). Based on time transplanted, patients may
have received valganciclovir prophylaxis of 900mg daily or only monitored.
At time of seroconversion, patients were started on ganciclovir IV 5mg/Kg
Q12H and continued to be followed by PCR to monitor treatment. All patients
received the same immunosuppressive protocol which included daclizumab
induction. Outcomes were determined by rate of CMV viremia.
Results: Patients (n =119) receiving prophylactic valganciclvoir was similar
in race, gender, and age to the patients being followed preemptively (n=131).
CMV viremia within the first 3 months of transplant were similar between
groups [31.3%(41/131) vs. 26.8%(32/119); p=0.488]. Pre-emptive patients
seroconverted earlier [52.2± 37.9 days vs. 120.9 ± 91.3 days; p<0.001] but
had overall lower rates of conversion compared to the prophylactic group
[35.1%(46/131) vs. 49.6%(49.6%); p = 0.022]. The prophylactic group had
similar rates of viremia while on drug vs off drug [32/119 vs 27/119; p=0.4350).
High-risk (-/-) had similar rates of viremia (75% vs. 70.4%; p=0.843). Patients
taking valganciclovir had increased risk to develop viremia[RR 0.527 to
0.951;p=0.02] with decreased viremia free survival.
Conclusions: Use of prophylactic valganciclovir in liver transplant does not
prevent CMV viremia and break through viremia is not uncommon. Additional
multicenter work should be done with this agent in liver transplant.
1

CONCURRENT ORAL SESSION 53:
STEROID AVOIDANCE AND MYCOPHENOLATES
710 STEROID IMMUNOSUPPRESSION INDUCES CHANGES
IN THE GLUCOCORTICOID RECEPTOR
I. Hutchinson1,2, Y. Chen1,2, V. Pravica1,2
University of Southern California, 2National Institute of Transplantation
Introduction: Initial high dose steroid treatment of transplant recipients
induces changes in the cytoplasmic glucocorticoid receptor (cGR) that may
affect the mode of action of the drug. The cGR consists of functionally distinct
isoforms of the GR and chaperone molecules, including FK binding protein 5
(FKBP5), that modulate GR signaling. Normal sensitivity to steroids requires
expression of appropriate GR isoforms and the collaboration with FKBP5.
Gene transactivation requires the GR-α isoform and is inhibited by excessive
expression of the hGR-β isoform. Over expression of FKBP5 can attenuate
steroid sensitivity by restraining translocation of the GR from cytoplasm to
nucleus. We investigated the effect of bolus glucocorticoid (GC) treatment
on the structure of the cGR complex by measuring the levels of GR isoform
expression and FKBP5 transcription.
Methods: Peripheral blood mononuclear cells (PBMCs) were obtained before
renal transplantation and immediately after the initial methylprednisolone
treatment. Gene expressions of the GR-α, -β, -P isoforms and FKBP5 were
quantified by the simplex TaqMan relative quantification assay (Applied
Biosystems).
Results: Increased expression of FKBP5 (17.67+14.01 fold, mean+SD),
1
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GR-β (5.77+6.82 fold) and GR-P (2.98+4.53) were observed after steroid
bolus. The GR-β expression level is extremely low (1/500th) compared with
the GR-α isoform (GR-β/GR-α ratio =(1.96+1.89)x10-3:1), so the six-fold
increase GR-β expression after steroid bolus is small compared with GR-α
expression. By contrast, the GR-P isoform is relatively abundant (GR-P/
GR-α ratio =0.24+0.09:1), so the three-fold post-treatment increase may be
functionally relevant. Two individuals treated with 5mg dexamethasone for ten
years prior to transplantation had lower constitutional expression of GR-α (0.41
and 0.77 fold) and higher expression of GR–P (1.87 and 1.38 fold) compared
with the other patients. Early acute rejection episodes, within the first month
after transplantation, were not associated with the relative expression of GR
isoforms or FKBP5.
Conclusion: Steroid treatment, acutely with high doses and chronically with
low doses, alters the structure of the GR. In particular, the initial therapy with
high dose steroid may induce a steroid resistance phenotype by increasing
FKBP5 and GR-β expression. In chronic treatment (at least in two patients)
reduced expression of GR-β and increased expression of GR-P isoforms may
signal reduced steroid response. The modulatory role of the GR-P isoform
is not fully defined but may provide another dimension in understanding the
function of GR and the role of steroids in transplant immunosuppression.

711 STEROID AVOIDANCE AFTER RENAL
TRANSPLANTATION: RESULTS OF A PROSPECTIVE AND
RANDOMIZED TRIAL USING FRESENIUS ATG
D. Cantarovich, L. Rostaing, G. Mourad
for the FRANCIA study group. Nantes University Hospital, Nantes, France
Background: Steroid withdrawal after renal transplantation (Tx) is associated
with an increased incidence of acute rejection. We investigated the potential
effective role of Fresenius ATG in completely avoiding steroids from the day
of Tx.
Aim: seddomized and multicenter trial was designed in order to evaluate
the tolerability and efficacy of a sequential treatment based on Fresenius
rabbit anti-T lymphocyte serum (ATG), mycophenolate mofetil (MMF) and
cyclosporin (CsA), with and without concomitant corticosteroids (Cs), after a
first cadaveric renal Tx.
Patients and immunosuppression: This investigator origin protocol was
conducted in 6 french centers and included 204 patients. Central randomization
was done according to recipient’s age (> or <50 yrs) and cold ischemia time
(CIT; > or <24 hrs). Retransplants were not included. Three patients did not
received ATG and were excluded from analysis. Results included 201 patients,
99 in the steroid group (66% men; mean age 48 yrs, range 18-73) and 102
in the steroid avoidance group (71% men; mean age 48, range 19-69). ATG
was given at 9 mg/kg the day of surgery, followed by 4 doses of 3 mg/kg on
days 1, 3, 5 and 7. MMF was started the day of surgery at 1g/bid. CsA was
started on postoperative day 5 at 8 mg/kg, and doses were adjusted according
to standard C0 trough levels. 500 mg of Cs were given in all patients during
surgery, followed by standard maintenance doses in the steroid group and no
Cs at all in the steroid avoidance one.
Results: All patients were followed for at least one year. Mean CIT was similar
in both groups: (23 vs 22 hrs). Clinical tolerance of ATG was excellent in both
groups: the entire 5-day ATG course was given to 98% of patients in the steroid
group (one interruption on day 1 due to thrombocytopenia) and 96% in the
steroid avoidance one (2 interruptions on day 5 due to thrombocytopenia and
tachycardia). One case of acute serum sickness was observed (steroid avoidance
group).The number of severe side-effects did not differ in both groups (42 vs
46%). Four malignancies were observed: 3 in the steroid group and 1 in the
steroid avoidance one. CMV infections were 3% in the steroid group and 1%
in the steroid avoidance one. Acute rejection (all histologically confirmed) did
not differ during the first year: 14% in the steroid group and 22% in the steroid
avoidance one; rejection onset was significantly lower in the steroid avoidance
group (median 14 days) as compared to the steroid group (median 49 days).
Steroid-resistant rejections were not statistically different: 5% in the steroid group
vs 2% in the steroid avoidance group. One-year patient and graft survival was 99
and 96% in the steroid group and 97 and 94% in the steroid avoidance one.
Conclusion: This study demonstrates that Cs avoidance is possible and safe,
with excellent one-year results, in recipients of primary cadaver renal Tx under
an immunosuppressive regimen including Fresenius ATG, MMF and CsA.

712 NEW ONSET DIABETES AFTER TRANSPLANT IN
KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT
STEROID FREE MAINTENANCE IMMUNOSUPPRESSION
F. Luan1, D. Steffick2, S. Norman1, A. Ojo1
University of Michigan, 2Arbor Research Collaborative for Health
Background: New onset diabetes after transplant (NODAT) is a common and
serious complication of kidney transplantation. Steroid-free immunosuppression
has been shown to improve glucose homeostasis in some clinical trials. We
studied the risk of NODAT in kidney transplant recipients discharged without
maintenance steroids in national cohort of adult kidney transplant recipients.
Materials and Methods: Between January 1, 2004 and December 31, 2006,
a total of 29,534 adult solitary kidney transplant recipients without history of
diabetes mellitus prior to kidney transplantation and with available follow-up
information on their discharge immunosuppressive regimen were included.
Multivariate logistic regression analysis was used to compare the odds of
NODAT between recipients treated with steroid-free versus steroid-containing
maintenance immunosuppression regimen. NODAT was defined as a report of
diabetes mellitus at any time between transplant and 12/31/2007.
Results: The post transplant risk of NODAT was 15.8% (n=2,713) and 11.9%
(n=1,468) for deceased donor and living donor kidney transplant recipients
(p=<0.0001). After adjusting for 26 variables for the deceased donor (DD)
models and 18 for the living donor (LD) models , the adjusted odds ratio for
the development of NODAT was 0.68 (95%CI 0.61-0.76, p < 0.0001) for both
DD and LD kidney transplant recipients, respectively. In addition, among
recipients discharged on steroid-free regimen, the combination of cyclosporine
and mycophenolate mofetil maintenance regimen was associated with an OR of
0.83 (95% CI 0.71-0.97, p = 0.020) for DD and OR of 0.84 (95% CI 0.72-0.98,
p = 0.025) for LD kidney transplant, respectively, when compared to the
combination of tacrolimus and mycophenolate mofetil maintenance regimen.
Conclusions: Intention to treat steroids free maintenance immunosuppression
is associated with significantly lower risk of NODAT in both living and
deceased donor kidney transplant recipients.

1

713 IMPACT OF CENTER-SPECIFIC PATTERN OF USE OF
STEROID FREE MAINTENANCE IMMUNOSUPPRESSION ON
OUTCOMES IN LIVING DONOR KIDNEY TRANSPLANTATION
S. Norman1, F. Luan1, D. Steffick2, R. Wolfe2, A. Ojo1
University of Michigan, 2Arbor Research Collaborative for Health
Background: Steroid-free immunosuppression is increasingly utilized in living
donor kidney transplantation. U.S. transplant centers vary widely in their practice
of steroid-free immunosuppression. We examined the impact of transplant center
use of steroid-free maintenance immunosuppression on outcomes in a national
cohort of living donor kidney transplant (LDKT)recipients.
Materials and Methods: 39,728 U.S adult (age ≥18 years), solitary LDKT
recipients engrafted between January1, 2000 and December 31, 2006 were
stratified according to the level of maintenance steroid use at their transplant
center during the calendar year of their transplant. Patient and graft survival
were estimated with Cox regression models with adjustment for multiple
covariates including the use of induction therapy and other maintenance
immunosuppressive drugs.
Results: Table 1 shows the hazard ratios for the risk of graft failure or death for
recipients in transplant center with the specified level of maintenance steroid
use compared to the reference group of near universal use of steroids (>95% of
patients discharged on steroids).
1

Hazard Ratio
1-yr graft
1-yr patient
4-yr graft
4-yr patient

Percentage of Center’s Recipients Discharged with Steroid Maintenance at Time of Transplant,
Recipients Engrafted in 2000 to 2006
<0-19%
20-49%
50-64%
65-79%
80-89%
90-94%
95-100%
0.93
0.71*
0.63*
0.74*
0.77*
0.98
1.00
0.72*
0.74
0.71
0.66*
0.55*
0.84
1.00
0.97
0.81*
0.78*
0.89
0.88*
0.90
1.00
0.79*
0.68*
0.71*
0.82
0.78*
0.82*
1.00

* p-value <0.05

LDKT recipients in transplant centers that tended towards steroid free
maintenance regimens had lower risks of graft failure and death at both 1 and 4
years. Recipients in transplant centers that utilized steroids in <50% of recipients
were less likely to experience large weight gain (25kg or more) during the first
posttransplant year (OR 0.58, p <0.05) or to develop post transplant diabetes
(PTDM; OR 0.65 p < 0.05) than in centers utilizing maintenance steroids in >
95% of recipients).
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Conclusions: LDKT recipients in transplant centers with substantial and
selective utilization of steroid free maintenance immunosuppression regimens
(20-64% of their recipients) had better short and long-term patient and graft
survival rates when compared to recipients in transplant centers where < 20%
or > 95% of recipients were discharged on a steroid-containing regimen. In
addition, LDKT recipients in transplant centers with lower use of steroids had
lower risk for PTDM and less weight gain than recipients in centers with >95%
steroid use.

714 IMPDH ACTIVITY ON DAY 6 AFTER KIDNEY
TRANSPLANTATION IS SIGNIFICANTLY RELATED TO THE
RISK OF ACUTE REJECTION IN MMF TREATED PATIENTS
T. Van Gelder1, F. Sombogaard1, P. Glander2, W. Weimar1, K. Budde2,
R. Mathot \1
1
Erasmus Medical Center, Rotterdam, Netherlands, 2Charité University,
Berlin, Germany.
Introduction: Mycophenolic acid (MPA) –the active metabolite of MMF–
inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH).
Monitoring IMPDH activity, as a measure of the immunosuppressive effect of
MMF, could be a target to optimize MMF therapy. A previous study reported that
high pre-transplant IMPDH activity was associated with biopsy proven acute
rejection (BPAR) of the graft. So far, data on post-transplant IMPDH activity
and BPAR are not available. In this study we investigated the relationship
between IMPDH activity and risk of BPAR in renal transplant patients.
Methods: A cohort of 100 patients, transplanted between 4/06 and 9/07,
was prospectively monitored for pharmacokinetics (MPA plasma levels) and
pharmacodynamics (IMPDH activity) of MMF treatment. Patients received
triple immunosuppressive therapy, consisting of MMF, tacrolimus and steroids.
Blood samples were taken pre transplantation and on day 6 post transplantation
pre-morning dose and 0.5, 1, 2, 6 and 12h after MMF intake. The enzyme
activity of IMPDH in PBMCs was measured using a validated HPLC method.
IMPDH activity and MPA exposure was calculated as the area under the
activity or concentration–time curve (AUECact and AUCMPA) using a linear
trapezoidal rule. All acute rejection episodes were biopsy proven (Banff
classification grade IA or higher). This interim analysis includes patients with a
follow-up after transplantation of at least two months.
Results: Samples for IMPDH activity measurement were available from
78 patients (age 19-76 years) on day 6 (range 3-11) post transplantation.
In 16 (21%) of the patients a BPAR was documented within one year after
transplantation. The mean AUECact of patients with BPAR was significantly
higher compared to non-BPAR patients (401±294 and 255±155 h*ìmol/s/mol
AMP, p=0.017). No significant correlation was found between IMPDH activity
pre (51±26 vs. 53±41 h*ìmol/s/mol AMP; p=0.68) and at single time points
post transplantation compared to BPAR. The mean AUCMPA of patients with
BPAR was not significantly different to non-BPAR patients (48.5±23.9 and
52.1±38.9 h*mg/L; p=0.99).
Conclusion: In the largest patient series to date, IMPDH activity, measured
as AUECact on day 6, is significantly correlated with BPAR after renal
transplantation. Monitoring IMPDH activity is a promising and novel biomarker
to optimize MMF treatment in renal transplant patients.

715 EARLY STEROID WITHDRAWAL FOLLOWING RENAL
TRANSPLANTATION INCREASES THE RISK OF ACUTE
REJECTION: A META-ANALYSIS

THURSDAY

S. Knight1,2, L. Barcena1, P. Morris1
1
Centre For Evidence In Transplantation, Royal College of Surgeons of
England, 2Oxford Transplant Unit, Oxford, UK
Introduction: The morbidity related to long-term steroid therapy has led to
interest in withdrawal of steroids from immunosuppressant regimens following
renal transplantation. Previous systematic reviews have examined small
subsets of patients, and a number of recent trials provide greater longer term
information regarding the effects of steroid withdrawal. The present review is
the most comprehensive and up-to-date yet, providing information regarding
outcomes not previously reported.
Methods: A detailed literature search was performed using Ovid Medline and
Embase, the Cochrane Library and the Transplant Library from the Centre
for Evidence in Transplantation, which includes all randomised controlled
trials in organ transplantation from 1970 to the present day. All trials with a
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control arm receiving maintenance steroid therapy and a study arm in whom
steroids were withdrawn at any point following transplantation were included
in the review. Trials were assessed for quality using the Jadad scoring system.
Meta-analysis of extracted data was performed where appropriate using
the statistical software R. All data are reported as summary effect and 95%
confidence intervals.
Results: A total of 112 publications from 34 studies met the inclusion criteria;
these included a total of 5469 patients. Mean Jadad score was 2.2, with
only 13 studies (38%) scoring ≥; 3 (good quality). Steroid withdrawal (SW)
within 12 months of transplantation significantly increased the risk of acute
rejection (withdrawal within 7 days: RR 1.64, CI 1.41-1.91, p<0.0001; 7 days
to 12 months RR 1.82, CI 1.15-2.89, p=0.01) whilst there was no significant
increase in risk with SW after 12 months (RR 1.32, CI 0.69-2.54, p=0.40).
Creatinine clearance was significantly reduced with SW within 12 months,
although the magnitude of this reduction is small (2.98 ml/min, CI 1.29-4.66,
p=0.00005). Serum creatinine did not differ significantly. Patient survival was
unaffected by SW, but graft loss excluding death was significantly higher with
withdrawal from 7 days to 12 months post-transplantation (Hazard Ratio 1.52,
CI 1.06-2.18, p=0.02). Hypertension and hypercholesterolaemia were reduced
with SW within 12 months (RR 0.88, CI 0.81-0.96, p=0.002 and RR 0.77,
CI 0.70-0.85, p<0.0001 respectively). Serum cholesterol levels are reduced
by 0.39 mmol/L with SW within 12 months (CI 0.18-0.62, p=0.0004). Serum
triglycerides are reduced by 0.38 mmol/L (CI 0.28-0.48, p=0.0001) with SW
within 7 days, but not with later SW. Risk of new onset diabetes is reduced with
SW within 12 months (RR 0.70, CI 0.54-0.91, p=0.0009). Overall incidence of
infection and risk of CMV infection were unaffected, but the risk of leucopenia
is significantly increased when steroids are withdrawn (RR 1.80, CI 1.46-2.22,
p<0.0001).
Conclusion: Early steroid withdrawal (within 12 months) following renal
transplantation significantly increases the risk of acute rejection episodes, but
the effect on graft function and long-term graft and patient survival is minimal.
Significant reductions are seen in cardiovascular risk factors (hypertension,
serum cholesterol and triglycerides and diabetes) which may lead to a longerterm reduction in cardiovascular morbidity and mortality.

716 MYFORTIC VS. CELLCEPT: A LARGE, SINGLE-CENTER
COMPARISON
H. Sollinger, G. Leverson, B. Voss, J. Pirsch
University of Wisconsin Dept of Surgery/Division of Transplantation
Introduction: Myfortic (EC-MPS) was developed with the intent to reduce
the incidence of gastrointestinal side effects. In a pivotal Phase III study
involving patients undergoing de novo renal transplantation, efficacy, failure,
and adverse GI events were comparable between groups. Multi-center studies
addressing GI adverse events are hampered by the fact that GI adverse effects
are poorly standardized and so are the responses of the individual investigators.
Material and Methods: We performed a retrospective review of 2,216 patients
from DD, LRD, LURD or SPK between 2000 and 2006. 1,709 transplants
qualified for the study and were compared between a group receiving EC-MPS
and a group receiving mycophenolate mofetil (MMF). Post-initiation of MPA
therapy dose levels, post-transplant dose levels, and post-transplant e-GFR
levels were compared between groups using a Wilcoxon rank-sums test. Time
to first dose reduction, drug discontinuation, anti-diarrheal use, infection, acute
rejection, biopsy-proven acute rejection and graft loss were estimated using the
methods of Kaplan and Meier and compared between groups using a log-rank
test. Cox proportional hazards models were used to assess the impact of MPA
after adjusting for covariates that were thought to have an association with the
outcome of interest.
Results:
CellCept

Myfortic

N

1,111

598

Kidney graft survival

86.4%

84.4%

NS

Acute kidney rejection

31%

24.7%

0.0212

Biopsy-proven kidney
rejection

30.2%

21.9%

0.0004

Dose reduction

74.4%

64%

0.0001

Drug discontinuation

33.3%

27.9%

0.0130

Post-tx anti-diarrheal use

6.5%

3.6%

0.0132
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Infection

64.7%

59%

NS

Bacterial infection

36.4%

37.3%

NS

Viral infection

21.3%

19.5%

NS

Fungal infection

14.3%

9.4%

0.0091

Percentages listed are based on 2-yr Kaplan-Meier estimates. P-values are
based on a log-rank test
Conclusions: In this single-center retrospective analysis of 1,709 transplants,
EC-MPS was found to be associated with fewer adverse GI side effects requiring
dose reduction or discontinuation. This may have translated into the observed
significantly lower incidence of biopsy-proven rejection. EC-MPS patients
also have a trend toward a lower incidence of infections and a significantly
lower incidence of fungal infections. Based on these observations, EC-MPS
has become the IMPDH inhibitor of choice at this large center.

717 PHARMACOKINETIC AND PHARMACODYNAMIC
COMPARISON OF AN INITIALLY INTENSIFIED DOSING
REGIMEN VERSUS A STANDARD DOSING REGIMEN OF
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN
RENAL TRANSPLANT PATIENTS.
K. Budde1, W. Arns2, P. Glander1, C. Sommerer3, T. Ariatabar2, S. Kramer4,
K. Eichele4, W. Fischer4, M. Zeier3
1
Nephrology, Charité, Berlin, 2Nephrology, Köln-Merheim,
3
Nephrology, Heidelberg;, 4Novartis, Nuremberg, Germany
Objective: The aim of this prospective randomized trial was to investigate
whether an intensified dosing regimen of EC-MPS in comparison to a standard
dosing regimen will lead to higher MPA exposure and stronger inhibition of
inosine monophosphate dehydrogenase (IMPDH) early after transplantation.
Furthermore, we examined whether an initially intensified dosing regimen can
be administered without compromising safety.
Methods: In total, 75 de-novo kidney transplant recipients treated with
cyclosporine (CsA) were randomized to a standard EC-MPS regimen
(1440mg/d; n=36) or to an intensified EC-MPS regimen (2 weeks: 2880
mg/d; subsequent 4 weeks: 2160 mg/d; followed by 1440 mg/d; n=39). Full
12hr pharmacokinetic and pharmacodynamic profiles with determination
of IMPDH activity were taken on 6 different time points during the first 3
months.
Results: MPA exposure was significantly higher in the intensified regimen
on day 3 post-transplantation in comparison to the standard regimen (MPAAUC: 44.9 ± 15.2 vs. 31.8 ± 20.2 mg*h/L, p=0.022 and free-MPA-AUC: 2242
± 1526 vs. 1162 ± 1038 ug*h/L, p=0.002). Significant differences between
both regimens were also observed for both MPA-metabolites, MPAG and
AcMPAG (MPAG-AUC: 4424 ± 2102 vs. 2497 ± 937 mg*h/L, p=0.00002 and
AcMPAG-AUC 47.4 ± 49.2 vs. 26.6 ± 22.7 mg*h/L, p=0.036). Regarding the
pharmacodynamic parameters on day 3, initially intensified dosing resulted in
significantly lower IMPDH-activity compared to standard regimen (IMPDHArea effect curve (AEC): 33.2 ± 15.8 vs. 45.1 ± 19.4 (nmol/mg protein
*h)*h, p=0.03). During the first 3 months MPA exposure in the intensified
arm remained stable with decreasing MPA doses, while MPA exposure in the
standard arm increased over time, as expected.
An independent data review committee concluded that the overall safety profile
was comparable between both treatment arms. Most importantly, the intensified
dosing regimen did not lead to a higher risk of infections, gastrointestinal
disorders, or hematological side effects. Incidence of biopsy-proven rejections
was low in both arms.
Conclusion: Based on these data, an intensified dosing regimen of EC-MPS
in combination with CsA leads to a significantly higher MPA exposure and
significantly stronger inhibition of IMPDH early post-transplantation. Since it
has been shown that early adequate exposure is crucial for the clinical outcome,
this approach might be of clinical importance. Larger studies are needed to
prove the effect of an initially intensified MPA regimen on efficacy and safety.

718 RENAL FUNCTION AND INCIDENCE OF NODM
WITH ENTERIC-COATED MYCOPHENOLATE SODIUM
IN COMBINATION WITH REDUCED AND STANDARD
TACROLIMUS LEVELS: RESULTS OF A 6-MONTH
COMPARATIVE STUDY IN DE NOVO RENAL TRANSPLANT
RECIPIENTS
L. Chan1, M. Hart2, A. Andres3, K. Gugliuzza4, S. Bunnapradist5,
R. Parasumaran6
1
University of Colorado Denver, CO, USA, 2CSD Medical Center San Diego,
CA, USA, 3Hospital Universitario 12de Octubre, Madrid, Spain, 4University
of Texas Medical Branch Galveston, Texas, USA, 5University of California
Los Angeles, CA, USA, 6Henry Ford Hospital Detroit, MI, USA
This study investigated the safety and efficacy of enteric-coated mycophenolate
sodium (EC-MPS, myfortic) in combination with tacrolimus (tac) and
addressed the possibility to preserve renal function by reducing exposure to tac.
Methods: In a 6-month, multicenter, randomized trial, de novo renal transplant
patients (n=292) were randomized (1:1) to one of two treatment regimens, all
receiving basiliximab, EC-MPS 720 mg bid and steroids: Group A was treated
with low-dose tac (target troughs of 5-9 ng/mL, first 3 months, and 3-6 ng/mL,
subsequent 3 months), and Group B with standard-dose tac (10-15 ng/mL, then
8-12 ng/mL). Primary endpoint was the calculated Glomerular Filtration Rate
(GFR) at 6 months (Nankivell formula). Key secondary efficacy endpoint were
the incidence of treatment failure (biopsy proven acute rejection [BPAR], graft
loss or death), and the incidence of new onset of diabetes mellitus (NODM)
assessed by means of oral glucose tolerance testing and/or fasting glucose
measurements or by the need of use of hypoglycemic treatment. Results:
Baseline characteristics were comparable between Group A and B as was the
mean daily dose of EC-MPS (1296 and 1325 mg, respectively). In the intentto-treat (ITT) population, no significant difference in mean GFR was observed
between treatments (63.6 vs. 61.0 mL/min). However, since the compliance to
the pre-specified target tac levels was low and there was a poor differentiation
between the groups, a re-classification of patients consistently adhering to the
two tac ranges was performed; this population (n=158) showed that GFR was
significantly higher in patients with reduced tac levels compared to standard
tac concentrations (69.9 vs. 63.2 mL/min, p=0.038). Treatment failure was
observed in 14.6% and 11.3% of patients in Group A and B, respectively, with
a BPAR rate of 11% and 10%, respectively (ITT population). The incidence
of NODM was significantly lower in Group A than group B (17% vs. 30%;
p=0.016). The overall safety profile was comparable between treatments.
Conclusions: This 6-month study showed that EC-MPS in combination with
tac (standard or reduced doses) was overall efficacious and safe, with wellpreserved renal function. A clinically important lower incidence of NODM
in patients treated with EC-MPS with reduced tacrolimus was observed. In
patients where tac levels were consistently adhered to, better renal function
could be observed with reduced tac levels.

CONCURRENT ORAL SESSION 54: HISTOCOMPATIBILITY
719 HUMORAL RESPONSES TO DONOR HLA ANTIGENS
DURING ACUTE REJECTION ARE INDEPENDENT
PREDICTORS OF RENAL ALLOGRAFT LOSS
M. Everly1, J. Everly1, P. Brailey1, B. Susskind1, R.R. Alloway1, E.S. Woodle1
1
University of Cincinnati, Cincinnati, Ohio, USA
Background: Current data suggests that at the time of graft loss a many patients
have anti-donor specific HLA antibodies (DSA). However, little data exists
regarding the effect of de novo DSA at the time of acute rejection on graft loss.
Herein, we analyzed risk factors for graft loss including de novo DSA (detected
by single antigen bead assay) at the time of acute rejection.
Methods: Renal transplant pts with acute rejection by biopsy between
1/1/2003 and 8/1/2007 were evaluated for DSA [Luminex platform/Labscreen
single antigen beads]. All DSA were de novo, ie, not detected before renal
transplant. Acute rejection was defined by biopsy and Banff 97 criteria (update
2003). Univariate analysis defined variables with a p<0.25, which entered the
multivariate analysis. Multivariate analysis was performed by stepwise logistic
regression (STATA/SE v.9.2).
Results: Of 90 pts with acute rejection, 48 (53%) had DSA at diagnosis. Median
follow-up was 23.1 18.5 months post acute rejection. Univariate analysis of
risk factors for graft loss showed recipient age and gender, donor age and race,
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transplant type, AB mismatch, time to biopsy, acute rejection reversal rate, and
recurrent acute rejection to be insignificant. African American race, delayed
graft function, mean baseline serum creatinine above 2mg/dL, DSA, and repeat
transplants entered the multivariate analysis. In the multivariate analysis, DSA
and repeat transplant were significant. An interaction was noted between DSA
and repeat transplant (75% of the repeat transplants had de novo DSA). Thus,
two multivariate models were analyzed with Model 1 removing and Model 2
including repeat transplant. Multivariate analysis results: Model 1 – graft loss
was 5.5 times more likely in primary transplants with de novo DSA (p=0.047);
Model 2 – repeat transplants with de novo DSA were 16 fold increased graft
loss risk (p=0.035).

at higher risk for AMR, albeit reversible. Some pts’ DSA remained >105
subsequent to IVIG treatment for AMR yet maintained stable creatinine levels
and no sign of AMR. This robust desensitization protocol allows for tx of pts
with relatively high levels of DSA. Although longer term follow up is needed,
perhaps by using this protocol accommodation can be achieved with high
levels of DSA.

Risk Factors for Graft Loss: Multivariate Analysis Results
Variables
Odds Ratio
95% Confidence Interval
African American recipient race
4.8
0.82 – 28
Delayed graft function
7.8
0.89 – 68
Repeat transplant recipient
30
2.5 – 360
Baseline serum creatinine >2mg/dL
5.7
0.63 – 51
De novo DSA in primary transplant
5.5
1.02 – 29
recipient
De novo DSA in repeat transplant
16
1.22 – 209

A. Iniotaki1, I-S. Dokou1, H. Theodoropoulou2, M. Apostolaki1, A. Kostakis2,
J. Boletis2
1
National Tissue Typing Center, General Hospital of Athens, 2Nephrology
Department and Transplantation Unit, Laikon Hospital, Athens Greece
The aim of this study was to evaluate the immunological risk for humoral
alloreactivity development in renal transplant (RTx) recipients of an HLA class
II incompatible graft.
The development of de novo donor specific antibodies (DSA) was investigated
5.8±4.3 years post Tx in 643 RTx recipients using Luminex and single antigen
bead analysis. The patients were divided into two groups according to HLA
mismatched molecules (mm): Group A (n=486) patients with HLA class I and
II mm and group B (n=157) with only HLA class I mm. All patients had been
transplanted with a negative CDC-AHG and T/B Flow crossmatch. There was
no difference at the level of HLA sensitization before RTx between the two
groups.
De novo DSA post RTx were detected in 86/643 (13.4%) patients,76
(15.6%) from group A and 10 (6.4%) from group B (p=.003).Expansion of
alloreactivity to more than one HLA mm was found in 23/86(26.7%) cases.
We further analyzed the molecular specificity of DSA in group A patients. In
65/76 (85.5%) cases only HLA class II were found while HLA class I and II
DSA were present in 7 cases and HLA class I DSA only in 4 cases. The DSA
were directed against 63 HLA-DQ alleles,26 HLA-DR alleles,6 HLA-A, 6
HLA-B and 3 HLA-Cw alleles. DSA were detected earlier in patients who
had HLA antibodies before Tx (p=.013).Creatinine levels were significantly
higher in patients with DSA (2.1 mg/dl) in comparison to patients without
DSA (1.6 mg/dl) with p<.001.
We conclude that RTx recipients of HLA class II incompatible grafts are in
high immunological risk for development of de novo DSA post Tx and require
more intense follow up.

Conclusions: De novo DSA in acute rejection is an independent predictor of
graft loss. Additional studies are warranted to: 1) confirm the predictive ability
of DSA and 2) determine whether reduction/elimination of DSA will allow
improvements in graft survival.

720 SUCCESSFUL DECEASED AND LIVING DONOR KIDNEY
TRANSPLANTATION AFTER DESENSITIZATION THERAPY
IN THE PRESENCE OF DONOR SPECIFIC ANTIBODIES
(DSA): DETERMINATION OF ACCEPTABLE PRE- AND
POSTTRANSPLANT DSA LEVELS

THURSDAY

N. Reinsmoen, C. Lai, A. Vo, K. Cao, G. Ong, M. Naim, S. Jordan
Cedars-Sinai Medical Center
At our institution, desensitization protocols including high dose IVIG plus
rituximab (IVIG/R) have been shown to decrease anti-HLA antibodies and
improved rates of transplantation (tx) for patients (pts) highly sensitized to
HLA.
Aims: The aims of our study were to determine the strength of DSA that
would allow for successful tx after IVIG/R and to identify pts at higher risk for
antibody mediated rejection (AMR).
Methods: Pre and posttx sera from 16 pts highly sensitized to HLA with DSA
were tested. 8 pts received deceased donor txs; 8 pts received living donor
txs after desensitization with IVIG/R. Strength of DSA was determined by
single antigen (SA) luminex bead assay, standardized with quantiplex beads
(One Lambda, Inc) with results expressed as Standard Florescence Intensity
(SFI). T cell flow crossmatch (FXM) results were expressed as mean channel
shift (MCS) over background. AMR was determined by biopsy and C4d
deposition.
Results: Of 16 pts tested, 7 had neg pretx T cell FXM (<50mcs) with a mean
of 8,805 SFI for the highest DSA. 5 pts had FXM ranging from 78-192 MCS
with mean DSA levels of 55,869 SFI. No pts in either group had AMR. 5 pts
had FXM ranging from 242-333 MCS with mean DSA levels of 118,063 SFI.
3 of these pts experienced AMR. The mean MCS and DSA levels for pts with
AMR were significantly higher than pts without (p=<0.001). 8 pts had class II
DSA at the time of tx. The mean DSA level for the 2 with AMR was 213,428
as compared to 74,948 SFI for those with no AMR (p=<0.001). B cell FXMs
were not assessed due the interference of rituximab.
Posttx samples were obtained for all pts to follow DSA strength and specificity;
long-term data has been obtained for 11 pts. Two major patterns were observed.
For those pts without complications (N=7), DSA strength remained below 105
SFI and usually decreased to ~104 SFI by 5-8 weeks posttx for both class I and
II DSA. For 1 pt with DGF, DSA for DQ remained >105 and a gradual increase
in DR DSA was observed. For those pts with AMR (N=3), predominant
increases in class II DSA >105 SFI were observed. One of these pts was
treated preemptively with IVIG before a significant increase in creatinine was
observed. All three pts continue to have DSA ~105 SFI with stable creatinine
and no subsequent evidence of AMR. Patient and graft survival at 12 mo. were
both 100%.
Discussion: With this approach, ~63% of pts were transplanted with a positive
FXM. The results show that pts with DSA >105 and FCM > 200 MCS are
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721 HLA CLASS II MISSMATCHES IN RENAL
TRANSPLANTATION: IMMUNOLOGICAL RISK FOR
HUMMORAL ALLOREACTIVITY

722 CD20 ANTIGEN COATED BEADS FOR THE SELECTIVE
REMOVAL OF RITUXIMAB FROM SERUM PRIOR TO
CROSSMATCH
B. Book1, N. Higgins2, M. Pescovitz1
Indiana University School of Medicine, 2Clarian Health Partners
Rituximab (RIT), a human-mouse chimeric monoclonal antibody to human
CD20 currently used in transplantation, interferes with most cell-based
crossmatch techniques including complement dependent cytotoxicity and
flow cytometric B cell crossmatches. We have sought methods to remove RIT
interference by immunoabsorption. RIT has been reported to bind to a cyclic
peptide representing an extracellular epitope of CD20 composed of amino
acids 163-187. The cyclic CD20 peptide was synthesized with the addition
of an N-biotinyl-NH-(PEG)2-COOH conjugate to the ε;-amine group of the
lysine. The purified peptide was coupled to Dynal M-280 super-paramagnetic
polystyrene beads (Invitrogen, Carlsbad, CA) precoated with streptavidin
covalently attached to the hydrophobic surface. CD20 antigen coated beads
(6.7 X 105) were incubated with 100 μ;L of normal human serum (NHS)
containing 10 μ;g/mL RIT. Absorbed or unabsorbed sera were incubated with
human splenocytes. Cells were washed to remove unbound RIT. Binding of
human IgG was detected with fluoresceinated (FITC) goat F(ab)2 anti-human
IgG antibody (Jackson ImmunoResearch, West Grove, PA. The presence of
CD19 or CD20 on the B cells was detected with anti-CD19 or anti-CD20
coupled to phycoerythrin (PE) (Becton Dickinson, San Jose, CA). Samples
were analyzed by an Epics XL flow cytometer. Results are expressed as
median channel log green fluorescence for FITC, log red fluorescence for PE
and percent of positive cells for each. The percent positive CD20 cells (log
red fluorescence) was 72.7% in NHS, 1.24% for NHS containing 10 μ;g/mL
of RIT before absorption, and 75.6% after 5 absorptions with CD20 coated
1
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beads. Median channel of log red fluorescence detecting CD20 was 21.5 for
NHS, 0.457 for NHS containing 10 mg/mL of RIT before absorption, and
21.5 after 5 treatments thus indicating that the added rituximab was no longer
blocking the binding of the anti-human CD20 PE to the CD20 on the cell
surface. The percent positive log green fluorescence detecting anti-human
IgG was 0.98% in NHS, 83.1% for NHS containing 10 μ;g/mL of RIT before
absorption, and 4.96% after 5 adsorptions. Median channel of log green
fluorescence detecting anti-human IgG was 0.356 for NHS, 4.83 for NHS
containing 10 μ;g/mL of RIT before absorption, and 0.754 after 5 adsorptions
thus indicating that most of the added rituximab had been removed.
Alloantibody binding was not affected by absorption. With a pooled HLA
positive sera median channel of log green fluorescence was 4.83 before and
4.11 after 5 treatments. No change was seen in CD19 with binding median
channel of log red fluorescence was 4.26 (75.2% of cell positive) before and
4.53 (76.2% positive) after 5 treatments. This procedure shows rituximab
can be selectively removed from serum by immunoadsorption to allow for
crossmatching without drug interference and without loss of alloantibody.

with 1 (1.9%) patient having a PRA>90%. SRTR data for 2005 showed that
nationally 479 of 9914 transplants (4.8%) were in patients with PRA’s >80%.
During 2006-07 after the VCP, 62 deceased donor transplants were done,
with 9 sensitized (PRA>80%) patients (14.5%) receiving kidneys, with 6
(9.7%) patients having a PRA>90%, (p = 0.003 compared to SRTR national
data). The VCP was highly predictable of a negative final crossmatch. The
VCP eliminated the use of preliminary crossmatching and reduced the
number of final crossmatches performed with attendant cost savings of over
$100,000.
Conclusion: Initiation of a virtual crossmatch protocol using solid phase
histocompatibility techniques significantly increased access of sensitized
patients to kidney transplantation and was more cost effective. Utilization of a
virtual crossmatch may facilitate greater sharing of kidneys to improve access
to transplantation for highly sensitized recipients.

723 CLINICAL IMPORTANCE OF ANTI-HLA SPECIFIC
ANTIBODY CONCENTRATION IN PERFORMING
CALCULATED PRA AND VIRTUAL CROSSMATCHES
S. Vaidya
University of Texas Medical Branch
Background: Highly sensitized patients develop multi-HLA specific
antibodies. In this study we measured concentrations of anti-HLA antibodies
in multi-specific sera by converting fluorescence intensity (FI) into molecules
of equivalent soluble fluorocrome (MESF) units. This was used to determine
MESF units required for a positive T and B flow crossmatches (FLXM).
Methods: MESF values of negative controls and sera from patients devoid
of HLA antibodies were measured by FLXM and FlowPRA screening
beads. FI values of anti-HLA specific antibodies determined by FlowPRA
single antigen beads of highly sensitized patients were converted in MESF
units. In addition endpoint titers, MESF units and% PRA of 26 sera were
established.
Results: MESF analysis accurately predicted the outcomes of 100% of T
and B FLXM of sera with strong (MESF units>18,000) DSA. The predictive
values of T and B FLXM declined to 95% and 88% with weak DSA (6,000
MESF<10,000). End point titers of sera from highly sensitized patients ranged
from 1:512 to 1:8 with corresponding MESF values of 452,596 to 20,000 units.
However there was no statistical difference in PRA values among these sera
(95%-100%). We successfully transplanted 5 patients who had weak donorspecific HLA antibodies (MESF units >2,000). The graft survival at one year
was 100% and there was no evidence of DSA post transplant.
Conclusion: MESF analysis is both a time and cost efficient way of measuring
antibody strength. The strength of the antibody present in the sera of transplant
candidates is critical for crossmatch prediction.

724 A VIRTUAL CROSS-MATCH PROTOCOL
SIGNIFICANTLY INCREASES ACCESS OF HIGHLY
SENSITIZED PATIENTS TO DECEASED DONOR KIDNEY
TRANSPLANTATION
F. Wright1, A. Bingaman1, K. Murphy2, J. Palma-Vargas1, P. Foster1
1
Texas Transplant Institute, 2Southwest Immunodiagnostics Laboratory
Background: Patients with pre-existing anti-HLA antibodies (sensitized
patients) are more likely to have a positive cross-match with possible donors,
and have a lower likelihood of receiving a renal transplant with longer wait
times. A virtual crossmatch protocol (VCP) utilizing solid phase technology to
determine the specificity of anti-HLA antibodies should improve the probability
of identifying a cross-match negative compatible donor and increase access of
highly sensitized patients to kidney transplantation.
Methods: A VCP was initiated 10-1-2006 with solid phase HLA antibody
characterization for all sensitized patients on the wait list. Transplant rates for
the VCP period from 10-2006 through 9-2007 were compared with rates from
10-2005 through 9-2006 when only preliminary crossmatching was used for
screening sensitized patients. SRTR data from 2005 was used to determine
national transplant rates for sensitized patients.
Results: During 2005-06 prior to the VCP, 52 deceased donor transplants
were done, with 3 sensitized (PRA >80%) patients (5.8%) receiving kidneys,

725 FINAL CLINICAL TRIAL DATA EVALUATING THE
XM-ONE ENDOTHELIAL CELL CROSSMATCH TEST IN
PREDICTING EARLY REJECTION EPISODES IN RENAL
ALLOGRAFT RECIPIENTS.
A. Zachary1, A. M. Jackson1, D. Lucas1, J. Melancon1, M. Breimer2,
L. Rydberg2, J. Von Visger3, R. Pelletier3, S. Saidman4, W. WilliaJr4,
G. Klintmalm5, S. Coultrup5, J. Holgersson6, G. Tyden6, S. Holgersson6,
P. Grufman7
1
Johns Hopkins University, 2Sahlgrenska University Hospital, Goteborg,
Sweden, 3The Ohio State University Medical Center, Columbus, United States,
4
Massachusetts General Hospital, Boston, United States, 5Transplantation
Services, Baylor University Medical Center, Dallas, TX, United States,
6
Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden,
7
AbSorber, Stockholm, Sweden
Reports of antibody mediated rejection in the absence of HLA antibodies or
in HLA identical transplants have substantiated the importance of non-HLA
antigens in allograft rejection. An international clinical trial was conducted to
evaluate the clinical application of the XM-ONE endothelial cell crossmatch
test. The XM-ONE test detects antibodies reactive with donor-specific
endothelial cell antigens that escape detection in conventional lymphocyte
crossmatch assays. Endothelial cell precursors were isolated with magnetic
beads from donor peripheral blood and incubated with recipient serum. A
flow cytometric crossmatch procedure was performed, utilizing fluorescently
conjugated IgM- and IgG-specific secondary antibodies. The XM-ONE
test was performed pre-transplant, however, the results were not released
to the transplant physicians nor utilized in the decision to transplant. One
hundred and forty-seven renal transplant recipients from 6 transplant centers
were included in this evaluation. Composition of the study population was:
59% male, 41% female and 84% Caucasiod, 8% Black, and 1% Hispanic.
The majority of patients were transplanted with living donors (83%), were
primary transplants (86%), and had a PRA of less than 10% (77%). Patient
evaluation included solid phase HLA-specific antibody screening and clinical
follow-up at 3, 6, or 12 months post-transplant. A positive XM-ONE test
(IgM or IgG isotype) was detected in 24% (35/147) of the recipients prior to
transplant. The incidence of rejection was significantly higher in XM-ONE
positive patients (46%, 16/35) as compared to patients with negative XMONE results (12%, 13/112; p<0.00005). Rejection occurred within 14 days of
transplant in 37% of patients who had a positive XM-ONE result compared
to 5% of patients with a negative XM-ONE result. Moreover, the mean serum
creatinine levels were significantly higher in XM-ONE positive patients at
3 and 6 months post-transplant (p<0.05). The XM-ONE endothelial cell
crossmatch test provides an efficient method for determining the presence
and isotype of donor-specific endothelial cell-reactive antibodies that escape
detection in lymphocyte crossmatches and identifies recipients at greater risk
for rejection episodes.
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726 ANTIBODIESS TO HLA ELICITED BY PEPTIDES FROM
OTHER MOLECULES
P. Terasaki1, L. Morales-Buenrostro2, L. Marino-Vazquez2, J. Alberu2,
M Ravindranath1
1
Terasaki Foundation Laboratory, Los Angeles, 2National Institute of Medical
Sciences and Nutrition Salvador Zubiran, Mexico City
We had assumed that HLA antibodies are produced only in response to
immunization by HLA antigens through transfusions, pregnancies and
transplants. However, with the new luminex single antigen technology,
HLA antibodies are now detected in normal male donors who had not been
alloimmunized. Antibodies to HLA were found in as many as 44% of 432
Mexican male blood donors, 50% of 14 Japanese male laboratory personnel,
65% of 29 male laboratory personnel, and 64% of 11 male Asian- Indian
vegetarians. The last finding indicates that the stimulating agent is not in
the histocompatibility antigens of food from cattle, pigs or chickens. Most
remarkable is the specificities found were distinct and generally of low
frequency occurrence in the random population. The most frequent specificity
found was from 18% down to 10% in the following order: A3002, A3101,
B1512 (B76), B8201, CW1701, B1516, DPB1 0101. The ‘natural’ antibodies
are not ephemeral, but are consistently found in one individual as shown by 7
independent bleedings of some individuals as shown in the figure. Thus far,
unique peptides sequences found in B8201 were found in streptococci, and
CW1701 in herpes virus. Thus many microorganisms may share sequences
with the HLA molecule.
In conclusion, antibodies to HLA were found in normal males which had
probably been stimulated by infections from various environmental agents. These
antibodies may affect subsequent transplants from donors with these types.

727 A NON-ALLOGENEIC STIMULUS TRIGGERS THE
PRODUCTION OF DE NOVO HLA AND MICA ANTIBODIES.

THURSDAY

L.E. Morales-Buenrostro1, L.A. Marino-Vázquez1, A. Nguyen2,
P.I. Terasaki2, J. Alberu3
1
Department of Nephrology and Mineral Metabolism. Instituto Nacional
de Ciencias Medicas y Nutricion SZ, 2Terasaki Foundation Laboratory,
3
Department of Transplantation. Instituto Nacional de Ciencias Medicas y
Nutricion SZ
Background: In a previous study, we found that healthy people developed HLA
Abs after immunization against hepatitis B virus. The aim of this prospective
study was to establish if stimulation with influenza vaccine is capable of
triggering the production of HLA and MICA Abs.
Methods: We determined the presence of HLA and MICA Abs (de novo and
preformed Abs) in 3 groups of patients vaccinated against influenza: A) 42
healthy adults, B) 40 ESRD patients, and C) 25 KTx. Additionally, we followed
22 healthy unvaccinated people without exposure to sensitizing factor: D)
control group. Sera samples were collected at baseline (pre influenza shot),
at 1 week, and monthly up 6 months after immunization. HLA Abs were
assessed with Labscreen Single Antigen beads for Luminex. All samples of
each patient were tested simultaneously. A luminescence value higher than 500
was considered positive only if it was 3 times the baseline value. We analyzed
the data using Chi square, one way ANOVA test, and Logistic regression.
Results: The table shows the types of Abs in each group. Interestingly, we
found preformed Abs across all four groups, including the control group
(which is free of any known sensitizing factors). The proportion of de novo
Abs was higher in the group B and C. Multivariate analysis shows that the
only independent factor associated with development of de novo Abs was the
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presence of preformed Abs.
Conclusions: We observed a nonspecific immunologic response triggered by
external stimulus and it was not necessarily associated to the vaccine in people
previously sensitized.
Table. Distribution of antibodies by group.
Antibodies

Group A
Healthy n=42

Group B
ESRD n=40

Group C
KTx n=25

Group D
Controls n=22

HLA class I

0

3 (7.5%)

2 (8.0%)

0

HLA class II

1 (2.4%)

0

1 (4.0%)

0

0

4 (10.0%)

1 (4.0%)

0

MICA
HLA I & HLA II

0

0

1 (4.0%)

0

Any De Novo**

1 (2.4%)

7 (17.5%)

5 (20.0%)

0

Preformed HLA I*

21 (50.0%)

24 (60.0%)

17 (68.0%)

2 (9.1%)

Preformed HLA II*

8 (19.1%)

9 (22.5%)

16 (64.0%)

1 (4.5%)

Preformed MICA

17 (40.5%)

11 (27.5%)

6 (24.0%)

5 (22.7%)

Any Preformed*

28 (66.7%)

31 (77.5%)

22 (88.0%)

6 (27.3%)

**p=0.016 *p<0.001

CONCURRENT ORAL SESSION 55:
TOLERANCE AND T REGULATORY CELLS
728 COMBINE TGF-BETA/FC AND RAPAMYCIN FOR
REGULATORY T CELLS GENERATION AND ALLOGRAFT
TOLERANCE INDUCTION.
W. Zhang, D. Zhang, Y. Liu, Y. Tian, X.X. Zheng
Starzl Transplant Institute, Division of Plastic Surgery, University of
Pittsburgh School of Medicine
CD4+Foxp3+ T cells have been identified as regulatory T cells (Tregs) that
play important roles in the control of autoimmune and alloimmune responses.
Recent studies, including our own, demonstrate that TGF-β; can convert naïve
peripheral CD4+CD25- T cells into CD4+ CD25+ regulatory cells through
induction of Transcription Factor Foxp3 in context of TCR signaling and
costimulation. This may prove TGF-β; to be of critical importance in generating
regulatory T cells. However, TGF- β; is secreted in a latent form and active
TGF- β; is rapidly cleared from circulation. In this study, we test the hypothesis
that the combination of a long-lasting active form of TGF-β; ----TGF-β;/Fc
and Rapamycin will further shift the balance of transplant immunity toward
tolerance by strengthening the cadre of immunoregulatory T cells.
Methods: (1) For making TGF-β;/Fc fusion protein, all three Cystine in
the pro region of TGF- β; precursor were mutated to Serine by site-directed
mutagenesis and the mutant TGF-β; was fused to a mutant human IgG Fcγ;1
component which is incapable to direct ADCC and CDC activities. The
recombinant protein was produced in CHO cells, then western blot analysis
and in vitro bioassay were performed to determine the TGF-β;/Fc structure
and biological activity. (2) T cells and Naïve CD4+Foxp3- T cells from Foxp3
knock-in mice were stimulated in the presence of TGF-β;/Fc and Rapamycin.
The proliferation and differentiation of cells were measured by 3H-thymidine
incorporation and Flow cytometry. (3) The MHC mismatched DBA/2 Islets
were transplanted into C57BL/6 mice rendered diabetic by streptozotocin. The
recipients were treated with TGF-β;/Fc, Rapamycin or combination of them for
4 weeks and allograft function were monitored.
Results: (1) TGF-β;/Fc was expressed as two homodimers and one heterodimer.
Its circulating half-life in mice was 36 hours. TGF- β;/Fc inhibited IL-4
stimulated HT-2 cell proliferation in a dose dependent manner. (2) TGF-β;/Fc
and Rapamycin synergistically inhibited CD4+ or CD8+ T cell proliferation
and promoted the induction of CD4+Foxp3+ T cells. (3) In islet transplantation,
mean survival time of islet grafts was 19 days in control recipients (n=6) and 38
days in TGF-β;/Fc treated recipients (n=5). Rapamycin prolonged islet grafts
survival in 63% of recipients (n=8). Combined treatment with TGF-β;/Fc and
Rapamycin produced indefinite islet allograft survival in 83% cases (n=7).
Conclusion: We have produced the long-lasting active mutant TGF-β;/Fc
fusion protein. The TGF-β;/Fc is synergistic with Rapamycin to convert naïve
CD4+Foxp3- T cells into CD4+Foxp3+ Tregs. Short course of combined
TGF- β;/Fc and Rapamycin treatment promotes long-term islet allograft
engraftment.
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729 INDUCTION OF REGULATORY T CELLS
BY PERIOPERATIVE DONOR SPLENOCYTE
COTRANSPLANTATION IN ALLOGENIC PULMONARY
TRANSPLANTATION
S. Thissen1, B. Kruse1, G. Warnecke1, M. Avsar2, F. Länger3, V. Kaever4,
R. Baumann5, A. Haverich1, M. Strüber1
1
Division of Cardiac, Thoracic, Transplantation and Vascular Surgery,
Hannover Medical School, 2Division of Cardiac, Thoracic, Transplantation
and Vascular Surgery, Hannover Medical School, 3Institute of Pathology,
Hannover Medical School, 4Institute of Pharmacology, Hannover Medical
School, 5Department of Nuclear Medicine and Radiation Oncology, Hannover
Medical School
Purpose: Donor alloantigen infusion has been shown to induce T cell
regulation and transplant tolerance in small animal models. Here, we
wished to study the effect of a donor splenocyte infusion on the induction of
CD4+CD25+ regulatory T cells in a porcine allogenic lung transplantation
model. Procedures: Left-sided lung transplantation from MHC and gender
mismatched donors was performed in 20 adult minipigs. Intravenous
pharmacologic immunosuppression with methylprednisolone and tacrolimus
(Tac) was maintained for 28 postoperative days (POD). 6 animals additionally
received 1.5 Gy whole body and 7 Gy thymic irradiation on pre-operative day
one and a perioperative donor splenocyte cotransplantation (IRR+SpTx POD
0), the same protocol without irradiation was performed in another 5 animals
(SpTx POD 0). 3 animals received IRR and donor splenocyte infusion 28 days
before transplantation under and a 7 day course of tacrolimus (IRR+SpTx
POD -28). Another 6 animals received splenocytes 28 days before lung
transplantation without irradiation. Allograft survival was monitored by chest
radiographs and transbronchial biopsies (TBB). The immune phenotype was
monitored from peripheral blood samples and bronchoalveolar lavage fluid
(BALF) by FACS analysis. The suppressive potency of regulatory T cells was
tested in a mixed lymphocyte reaction (MLR).
Results: Transplant survival in the IRR+SpTx POD 0 group was significantly
prolonged compared to all other groups. All of these animals survived POD
178 without signs of acute rejection. CD4+CD25high+ T cells which are
supposed to be a lymphocyte subpopulation with a strong regulatory function
were increased in the SpTx POD 0 group, both in peripheral blood and BALF.
The presence of high levels of these regulatory T cells correlated with the
absence of acute vascular rejection in the animals of the SpTx POD0 group.
Purified CD25+ T lymphocytes suppressed MLR response to donor and to
third party antigen as well as control mitogen.
Conclusion: This data shows that miniature swine conditioned with preoperative irradiation and a donor splenocyte infusion develop long term
pulmonary allograft survival in the presence of high circulating levels of
regulatory T cells.

730 THE REQUIREMENT OF THE B7-H1 FOR
SPONTANEOUS ACCEPTANCE AFTER MOUSE LIVER
ALLOGRAFTING
M. Morita1, M. Fujino2, L. Xie2, Y. Kitazawa2, H. Kimura2, M. Azuma3,
X. Li2, A. Sugioka1
1
Fujita Health University School of Medicine, 2Laboratory of Transplantation
Immunology, National Research Institute for Child Health and Development,
3
Department of Molecular Immunology, Graduate School, Tokyo Medical and
Dental University
Programmed death-1 (PD-1), an inhibitory co-stimulatory receptor induced
on activated T, B, and myeloid cells, can modulate negative regulator of the
immune system. B7-H1 (PD-L1), a ligand of PD-1, is expressed on resting and
up-regulated on activated B, T, myeloid, and dendritic cells (DCs). PD-L1deficient mice developed more severe EAE and autoimmune hepatitis. These
results suggest that the PD-1/PD-L1 pathway acts as an important negative
regulator of immune response. Therefore, we investigated here a crucial
role of this pathway in establishing an immunological tolerance status after
mice liver allografting. B7-H1 was high expressed on the infiltration cells
in the mouse allografts, consistent with the results of the mRNA expression
assay. Strain of mouse (B10.BR, H-2Kk) liver transplanted into B10.D2
(H-2Kd) mice developed typical rejection pathologic changes and than
spontaneously repressed, permitting long-term survival of these allografts
similar to that of syngeneic grafts. Strikingly, blockade of the PD-1/PD-L1
pathway using anti-B7-H1 mAb in the same combination, was led to not only

server cell infiltration but also hemorrhage and necrosis, resulting no mice
survival beyond 12 days. Furthermore, the mRNA expression of the grafts
was assessed by quantitative real time reverse-transcription polymerase
chain reaction (qRT-PCR), revealing the increase of IFN-ƒÁ, TNF-ƒ¿, IL-2,
iNOS, and OPN mRNA expression in the antibody-treated group compare
to the control fs. Our data revealed that the expression of B7-H1 on graft
infiltration cells might play a critical role of the spontaneous acceptance in
mouse hepatic allografting.

731 NK CELLS RESTRAIN CD8 T CELLS DURING
TOLERANCE INDUCTION TO ISLET ALLOGRAFTS
R.G. Gill3, J.N. Beilke1, N.R. Kuhl2, L. Edwards2
University of California, San Francisco, 2University of Colorado Health
Sciences Center, 3University of Alberta/Alberta Diabetes Institute
Background: Previous studies indicate an unexpected role for NK cells in
facilitating tolerance induction to islet allografts following costimulation
blockade (anti-CD154). Other studies indicate that CD8 T cells can contribute to
costimulation blockade-resistant allograft rejection. Therefore, we determined
whether host CD8 T cells were a target of NK cell regulation during tolerance
induction in vivo.
Methods: The impact of NK cell function on alloreactive CD8 T cell reactivity
was analyzed in two ways:
(1) Analysis of allo-specific CD8 T cell receptor (TCR) transgenic (2C) T cell
reactivity in vivo: C57Bl/6 (B6; H-2b) TCR transgenic 2C mice (specific for
MHC class I Ld) were used as CD8 T cell donors. CFSE-labeled 2C T cells
(3xe7) were adoptively transferred into wild-type B6 hosts and monitored for
peripheral engraftment. Recipient mice then were challenged with BALB/c
(Ld+) spleen cells in the rear footpad and the 2C T cell response was monitored
in the draining lymph node. Challenged mice were otherwise untreated or were
treated with anti-CD154 (MR1), anti-NK1.1 (PK136), or combined anti-CD14/
anti-NK1.1 therapy.
(2) Islet allograft immunity and tolerance in CD8 knockout (CD8KO) recipient
mice. BALB/c islet allografts were grafted beneath the kidney capsule of
streptozotocin-induced diabetic B6 or B6CD8KO recipient mice. Recipients
were either untreated or treated with anti-CD154, anti-NK1.1, or combined
anti-CD154/anti-NK1.1 as above.
Results: (1) 2C T cell reactivity: 2C T cells reacted vigorously to BALB/c
(Ld+) spleen cells in vivo based both on total cell numbers and by CFSE
dilution within the draining lymph node. Anti-CD154 treatment alone resulted
in pronounced reduction of this response while anti-NK1.1 treatment alone
had little impact or led to a modest increase in the 2C response. Importantly,
combined anti-CD154/anti-NK1.1 treatment resulted in a marked increase in
the 2C response relative to anti-CD154 treatment alone.
(2) Islet allograft immunity/tolerance in vivo: Both B6 wild-type (9/9) and
CD8KO (6/6) mice acutely rejected BALB/c islet allografts (p = NS). AntiCD154 treatment resulted in long-term allograft survival in 10/13 wild-type B6
mice and in 6/6 CD8KO B6 mice. As previously reported, additional depletion
of NK1.1+ cells abrogated allograft prolongation facilitated with anti-CD154
in 6/6 wild-type B6 mice. Importantly, in recipients deficient in CD8 T cells
(B6 CD8KO), NK1.1+ cells were no longer required for long-term allograft
survival. That is, 7/9 BALB/c islet allografts survived >100 days in anti-CD154
treated CD8KO recipients despite additional depletion of NK1.1+ cells (p <
0.02 relative to B6 wild-type recipients).
Conclusions: Results indicate that anti-CD154 treatment restrains alloreactive
CD8 T cells in vivo and that NK1.1+ cells are necessary for this inhibition.
More importantly, CD8 T cells appear to be an essential target of regulation
by NK1.1+ cells. That is, in the absence of host CD8 T cells, regulation by
NK1.1+ cells is no longer required for achieving allograft prolongation. Thus,
it appears that one host MHC class I dependent pathway (NK1.1+ cells) is
necessary to regulate another MHC class I pathway (CD8 T cells) during
tolerance induction in vivo.
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732 DONOR-DERIVED TOLEROGENIC DENDRITIC CELLS
(DC) ARE REPROCESSED BY RECIPIENT DC TO DOWNREGULATE THE ANTI-DONOR RESPONSE AND PROMOTE
GRAFT SURVIVAL
S.J. Divito, W.J. Shufesky, Z. Wang, A. Montecalvo, A.E. Morelli
T.E. Starzl Transplantation Institute, Department of Surgery,
University of Pittsburgh
The discovery that maturation-resistant (MR) dendritic cells (DC) downregulate the anti-donor response heralded the potential use of MRDC for
therapy of transplant rejection. Although there is evidence that donor-derived
MRDC therapy prolongs allograft survival in murine models, it remains to be
elucidated whether these tolerogenic DC (i) interact directly with allospecific
T cells or (ii) are reprocessed by recipient antigen (Ag)-presenting cells for
indirect pathway presentation. Our study aimed to elucidate the mechanism
by which donor-derived MRDC down-regulate the anti-donor response in
vivo to prolong allograft survival in mice. We employed as prototypic donor
MRDC, bone marrow-derived DC treated with the active form of vitamin D3,
1α,25(OH)2 D3 (VD3-DC). Results: VD3-DC failed to up-regulate co-stimulatory
molecules in response to DC-maturation stimuli (LPS, CD40 ligation, DCmaturation cocktail) and adoptive transfer (i.v., d-7) of BALB/c-derived
VD3-DC prolonged significantly survival of BALB/c hearts in C57BL/6 (B6)
mice without additional immunosuppression. Utilizing 1H3.1 TCRtg CD4
T cells (specific for the BALB/c allopeptide IEα52-68 presented by IAb [B6]),
we demonstrated that donor-derived VD3-DC are reprocessed into alloAg by
recipient splenic DC which interact with anti-donor CD4 T cells via the indirect
pathway of allorecognition. Deficient activation of indirect pathway CD4 T
cells led to their peripheral deletion and resulted in outgrowth of CD4 FoxP3+
regulatory T cells. Reprocessing of donor-derived VD3-DC was performed
by recipient splenic CD8α+ and CD8– DC through phagocytosis of apoptotic
cell fragments, and resulted in alloAg presentation for up to 3 days following
administration of donor-derived VD3-DC. Interestingly, i.v. injected donorderived VD3-MRDC homed to splenic T cell zones but lacked the stimulatory
capacity necessary to directly prime either alloreactive CD4 (1H3.1) or CD8
(2C) TCRtg T cells. Our findings indicate that reprocessing of donor-derived
MRDC into alloAg by recipient DC in secondary lymphoid organs constitutes
a key mechanism by which DC-based therapies down-regulate alloimmunity
and prolong allograft survival.

733 LOCATION AND TIME DEPENDENT CONTROL OF
REJECTION BY REGULATORY T CELLS CULMINATES IN A
FAILURE TO GENERATE MEMORY T CELLS
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M.C.Gaspar, N. Jones, S. Luo, M. Laurent, B. Matthew, W. Kathryn
University of Oxford
Introduction: We have shown previously that adaptive CD25+CD4+ regulatory
T cells (Treg) suppress skin allograft rejection. However, the location of Treg
as they function in vivo and the mechanisms used to control donor-reactive T
cells remain ill-defined.
Methods: Treg were purified from tolerant CBA mice that had accepted a
donor-type cardiac allograft (C57BL/10; B10; H2b) following administration of
anti-CD154 mAb. 1x105 BM3 T cells (TCR-transgenic, H2Kb-reactive CD8+
T cells; H2k) were CFSE labelled and transferred alone or together with 5x105
Treg into syngeneic RAG-/- mice one day before transplantation of a B10 skin
allograft. The response of the BM3 T cells to skin allografts was visualised
using FACS (draining (dLN) and contralateral (cLN) lymph nodes, mesenteric
lymph nodes and spleen), immunohistochemistry and real-time PCR for proinflammatory genes (skin graft) 5, 10, 15 and 25 days after transplantation
(n=3/timepoint). Allografts transplanted onto naïve RAG-/- mice served as
control for real-time PCR analysis.
Results: Mice that received BM3 T cells alone showed clear priming by
10 days after skin grafting resulting in a dramatic increase in the number of
CFSE- BM3 T cells (> 7 cell divisions) in the dLN compared to those in the
cLN or in mice that did not receive a skin graft (50 fold increase). In contrast,
in mice that also received Treg the priming of the BM3 T cells in the dLN was
markedly attenuated. The suppression of T cell priming by Treg also resulted
in the absence of T cell infiltration into skin grafts and in a marked reduction
in the intragraft mRNA expression of IFN&#61543; (84 fold), perforin (19
fold), CCL5 (11 fold) and XCL1 (19 fold) by day 10 post-transplant compared
to grafts undergoing rejection (BM3 T cells alone). However, with time,
peripheral suppression waned and effector BM3 T cells were generated by day
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15 despite the presence of Treg, albeit in reduced numbers compared to mice
that had received BM3 T cells alone (957+/-737 compared to 3300+/-768
CFSE- BM3 T cells, respectively). The observed priming resulted in the
infiltration of BM3 T cells into skin grafts generating a ‘Tc1-like’ intragraft
gene expression profile similar to that seen during rejection. Despite effector T
cell infiltration, grafts were not rejected as intragraft effector cells were deleted
by Treg, that had also infiltrated skin allografts, which resulted in a marked
deficit in peripheral CD44+ BM3 memory T cells (2354+/-569 compared to
39434+/-19365 CD44+ BM3 T cells in the spleen from mice that had received
BM3 T cells alone).
Discussion: These data demonstrate for the first time that donor-reactive Treg
can suppress allograft rejection using distinct mechanisms at different sites in
vivo with the overall outcome of preventing the generation of donor-reactive
memory T cells. Extrapolation of these data to clinical transplantation suggests
that the identification of patients that have become “operationally” tolerant to
their foreign organ grafts will require a multi-faceted approach involving both
peripheral and perhaps more importantly analyses that focus on the transplanted
organ itself.

734 GRAFT-PROTECTIVE REGULATORY T CELLS
DEVELOP FROM FOXP3-NEGATIVE PRECURSORS IN VIVO
R. Francis, K. Wood, A. Bushell
Nuffield Department of Surgery, University of Oxford
Background & aims: Naturally-occurring FOXP3+CD4+ regulatory T cells
(Treg) play a crucial role in the prevention of autoimmunity. The ability to
generate similar populations of Treg against alloantigens offers the possibility
of preventing transplant rejection without the requirement for indefinite global
immunosuppression.
Pre-treatment of mice with a donor-specific blood transfusion (DST) combined
with anti-CD4 antibody generates alloreactive Treg with the capacity to prevent
rejection of cardiac, skin and islet allografts. The aim of this project was to
investigate whether these graft-protective Treg are derived from naturallyoccurring Treg or are generated by the peripheral conversion of non-Treg
precursors.
Methods: A novel cell sorting strategy was developed, based on the expression
of the cell surface markers CD25 and GITR, which yields a population of CD4+
cells that consistently contain ≤0.5% FOXP3+ cells by FACS. The purity of
sorted GITR−CD25− cells was confirmed using qRT-PCR for foxp3 mRNA.
T cell deficient CBA.RAG−/− mice were reconstituted with this sorted
population, devoid of naturally occurring Treg but containing potential effector
cells prior to tolerance induction with anti-CD4/DST. Control mice did not
receive anti-CD4 or DST. 28 days later, full thickness donor-type skin grafts
were performed. Spleen cells were isolated from additional cohorts of mice
given the same adoptive transfer but without skin grafting for analysis of
FOXP3 expression.
Results: In the absence of a skin graft, FOXP3+CD25+ T cells were readily
detected in both control and tolerised mice almost certainly reflecting
FOXP3 induction resulting from homeostatic proliferation. However, whilst
control mice rejected their skin grafts acutely (n=6, MST 19 days), mice
given the tolerance induction protocol accepted their grafts long-term (n=9,
MST>100 days).

Discussion: These data demonstrate that naïve CD4+ cells with the potential
to reject an allograft can undergo peripheral conversion into graft-protective
Treg following an alloantigen-dependent tolerising protocol. The fact that
skin grafts were not protected by FOXP3+ cells that arose in the absence

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Oral Abstracts
of alloantigen indicates a clear qualitative difference in the two FOXP3+
populations and emphasises the benefit of driving Treg selection using
alloantigen pre-treatment. Naturally-occurring Treg are scarce (≈5%
peripheral CD4+ cells) while the precursor frequency of alloreactive T cells
can be as high as 10%. Tolerance induction strategies that do not rely on
expansion of naturally-occurring Treg and are able to convert potential effector
cells into graft-protective Treg are very attractive for the establishment of
transplantation tolerance.

735 RAPID RECRUITMENT OF FOXP3+ REGULATORY
T CELLS INTO CARDIAC ALLOGRAFTS FOLLOWING
THE INDUCTION OF SPECIFIC UNRESPONSIVENESS TO
ALLOANTIGEN IN VIVO
M.C. Gaspar, N. Jones, A. Bushell, K. Wood
University of Oxford
Introduction: The early infiltration of regulatory T-cells (Treg) into the
allograft may protect the allograft from rejection. The aim of this study was
to determine the kinetics of Treg entry into cardiac allografts following the
induction of specific unresponsiveness to alloantigen in vivo and to assess the
impact of such cells on the expression of intra-graft pro-inflammatory genes
associated with the development of operational tolerance.
Methods: C57BL/10 (B10,H2b) cardiac allografts were transplanted into
naïve CBA (H2k) mice (grafts rejected with a median survival time (MST) of
8 days) or CBA mice that had received anti-CD4 mAb and a donor-specific
blood transfusion (DST) i.v. (‘pretreated mice’) 28-days before transplantation
(MST >100 days). Cardiac allografts transplanted into RAG-/- recipients (no
functional T or B-cells) were used as controls for activation of the innate immune
response after transplantation. Cardiac allografts were analysed 1,2,5,8 and
10-days after transplantation by real-time PCR analysis to determine the relative
mRNA expression of CD3, Foxp3 and a panel of different pro-inflammatory and
cytoprotective genes.
Results: Analysis of cardiac allografts from pretreated mice revealed a higher
level of chemokine and chemokine receptor mRNA expression 2-days after
transplantation, compared to that expressed in allografts transplanted into naïve
recipients. In particular, the expression of XCL1, CXCL9 and CXCL10 was
dramatically enhanced (276, 166 and 186-fold, respectively). The amplified
chemokine expression correlated with an increase in CD3 expression, indicating
that T-cells had infiltrated cardiac allografts earlier and in greater numbers in
pretreated mice compared to naïve recipients.
Interestingly, early T-cell infiltration correlated with an enhanced intragraft
mRNA expression of genes that have been associated with Treg phenotype
and/or function such as CCR5, CCR8, CD103, IL-2, IL-27p28, IFN&#61543;,
IDO, IL-10 and Foxp3 (by at least 10-fold). By 10-days after transplantation,
the difference in gene expression between grafts from pretreated and naïve
recipients was found to persist but was not as marked as at the earlier time
point.
Depletion of CD25+ T-cells from pretreated recipients by i.v. injection of a
depleting anti-CD25 mAb (PC61) 14-days before transplantation of a cardiac
allograft resulted in the rejection of the grafts that otherwise would have been
accepted (MST=27 versus >100 days). Analysis of these cardiac allografts
2-days after transplantation revealed a decrease in Foxp3 mRNA expression
when compared to pretreated recipients that had not received anti-CD25
mAb. Analysis of intragraft expression of other genes associated with Treg
phenotype and/or function that were enhanced in pretreated recipients 2-days
after transplantation in grafts from recipients that have been depleted of Tregs
is in progress.
Conclusions: We have shown that under conditions leading to long-term
cardiac allograft survival, alloreactive Treg that have been generated as a result
of anti-CD4 mAb+DST pre-treatment are recruited to the graft within 2-days,
before the priming and infiltration of alloreactive effector T-cells. We propose
that the rapid, increased expression of chemokines in the grafts of pretreated
recipients is important for the early recruitment of Treg that, via the expression
of CCR5 and CCR8, infiltrate the graft and suppress damaging effector T-cell
responses within the graft itself.

736 GENERATING ALLOGRAFT TOLERANCE BY BAFFDEPENDANT EXPANSION OF REGULATORY T CELLS
S. Walters, K. Webster, A. Sutherland, J. Groom, D. Liuwantara, E. Marino,
F. Mackay, J.Sprent, S. Grey
Garvan Institute of Medical Research
The B cell activation factor from the TNF family (BAFF) plays a critical role in
B cell function and survival. T cells have been shown to express BAFF receptors
suggesting that BAFF may also be important for T cell responses, however
this has not been investigated. We tested allograft responses in BAFF-Tg mice
and found that ~60% of mice accepted a full MHC-mismatched islet allograft
(BALB/c -> C57BL/6) for >100 days. In addition, BAFF-Tg mice also showed
delayed skin graft rejection. This tolerant phenotype was due to a T cell intrinsic
change in allo-responsiveness as shown by a failure of purified BAFF-Tg T
cells to reject an allograft in adoptive transfer experiments or to proliferate in an
MLR. However, BAFF-Tg T cells were not anergic per se as they proliferated
normally to antigenic stimulation in vitro and in vivo. Intriguingly, BAFF-Tg
mice harbored an increased frequency of FoxP3+ T regulatory cells (Tregs) in
the periphery as compared to Wild Type mice. Elimination of CD25+ T cells
restored normal allograft rejection to BAFF-Tg mice, demonstrating that the
increased number of Tregs were responsible for their altered allo-immunity.
In a second approach, BAFF-Tg T cells depleted of CD4+ CD25+ T cells by
FACS sorting were adoptively transferred to previously transplanted RAG-/recipients, and in this case the BAFF-Tg CD4+ CD25- T cells rejected their
allograft. Therefore we show for the first time that BAFF can drive the in vivo
expansion of Tregs that allow for immunosupression free allograft tolerance.
We next determined the mechanism by which BAFF was expanding Tregs.
We examined whether excessive BAFF was promoting Treg expansion in the
periphery by driving proliferation or enhancing survival and found neither to
be the case. However we found that BAFF promoted thymic Treg output. Since
BAFF can modify the APC activity of B cells we questioned whether the BAFF
expansion of Tregs was T cell intrinsic or B cell dependant. We found that
the BAFF receptors BR3 and TACI were present on Tregs in the thymus and
periphery however only in low levels. Signaling through BR3 activates the
NFkB2 pathway and consistent with the low expression of BR3, Tregs from
BAFF-Tg mice showed no increase in p100 to p52 processing compared to
Tregs from Wild Type mice, indicating BAFF was not expanding Tregs by a
direct interaction. To determine the role of B cells we generated bone marrow
chimeras using μMT bone marrow. This analysis revealed that in the absence
of B cells BAFF could not expand Tregs. Together these results demonstrate
that BAFF can play a complex role in the regulation of T and B cell immunity.
Excessive BAFF can drive a B cell dependant expansion of Tregs that promote
allograft tolerance. Therefore manipulating circulating BAFF levels may
provide a means to generate immunosuppression free allograft tolerance.

CONCURRENT ORAL SESSION 56: T CELLS AND NK CELLS
737 B CELLS PROMOTE GENERATION OF CD4 AND CD8
ALLOREACTIVE MEMORY T CELLS
Y-H. Ng, Q. Li, A. Marlowe, R. Hoffman, G. Chalasani
Starzl Transplantation Institute and The University of Pittsburgh
B cells and memory T cells are associated with treatment-resistant acute and
chronic allograft rejection. It is possible that B cells contribute to allograft
rejection by mechanisms other than alloantibody production since donor
specific antibodies often precede cellular rejection. We tested whether B
cells help generation of alloreactive memory T cells and promote allograft
rejection.
Methods and Results: Skin allograft rejection was compared between B-cell
deficient μ;MT and wild-type (wt) mice and was found to be similar in both
groups (MST 18 days, n=4/gp). Alloreactive effector and memory T cell
responses were measured by quantitating alloreactive IFNγ; producing T cells
at the time of rejection (effectors) and at 8 weeks after rejection (memory). As
expected, alloreactive effector T cell numbers were similar between μ;MT and
wt mice. However, alloreactive memory T cells in μ;MT mice were 12-fold
fewer in the CD4 and 10-fold fewer in the CD8 populations compared to wt
mice. Cytotoxic function of alloreactive memory T cells was measured by
testing in vivo allogeneic target cell lysis in μ;MT and wt mice at 8 weeks
after skin allograft rejection. Specific lysis of allogeneic targets in NK-cell
depleted μ;MT mice was 13±3% in comparison to 95 ± 2% in wt mice. These
findings suggest that the function of alloreactive memory T cells that were
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generated was significantly impaired in the absence of B cells. To address how
B cells promote generation of alloreactive memory T cells, the role of antigen
presentation by B cells was tested. Syngeneic mixed bone marrow chimeras
were created in irradiated μ;MT recipients by transplanting bone marrow from
μ;MT, wt and MHCko (lack MHC I & II expression on all cells) mice. B cells
but not other professional APCs in μ;MT+MHCko chimeras lacked expression
of MHC I & II and therefore, antigen presentation was specifically disrupted
in B cells. Skin allograft rejection was comparable between μ;MT+MHCko
and μ;MT+wt chimeras (MST = 17 days and 16 days, respectively, p = 0.6,
n = 5/grp). However, heart allograft rejection was significantly delayed in the
μ;MT+MHCko chimeras compared to μ;MT+wt chimeras (MST = 23 days and
15 days, respectively, p=0.03, n = 5/grp). Alloreactive memory T cells were
measured in chimeras at 8 weeks after skin allograft rejection and showed
significantly fewer memory T cells in μ;MT+MHCko chimeras (7-fold fewer
CD4, p = 0.02, and 5-fold fewer CD8, p = 0.003, n = 5/grp) than in μ;MT+wt
chimeras. These results show that in the absence of antigen presentation by
B cells, heart but not skin allograft rejection was significantly delayed and
development of alloreactive memory T cells was significantly impaired.
Conclusions: Development of alloreactive memory T cells but not effector T
cells is dependent upon B cells. Antigen presentation by B cells accelerates
heart allograft rejection and leads to development of alloreactive memory T
cells. These findings emphasize antibody-independent functions of B cells in
promoting alloimmune responses and highlight the need for B-cell targeted
therapies to improve long-term allograft survival.

738 IN VIVO TIME-LAPSE IMAGING OF NAÏVE T CELLS
CONVERSION TO REGULATORY T CELLS IN ALLOGRAFT
ISLET TRANSPLANTATION
M. Koulmanda1, Z. Fan1, J. Spencer2, Y. Lu1, T. Strom1, C.s Lin2
Dept of Medicine, Transplant Research Center, Beth Israel Deaconess
Medical Center, Harvard Medical School, 77Ave Louis Pasteur, Boston, MA
02115, 2Advanced Microscopy Program, Wellman Center for Photomedicine,
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
Purpose: To analyze the dynamic roles of effector T cells (Teff) and both
natural (nTreg), and induced (iTreg) regulatory T cells in allograft response of
untreated and tolerized islet allograft recipients through in vivo imaging.
Methods: nTreg (green+) from C57BL/6 Foxp3-GFP knock in (KI) mice
and naïve Teff (red +) from C57BL/6 DsRed tg x Foxp3-GFP KI mice, in
this hybrid mouse the induced expression of Foxp3 creates (red+, green+
chromophore expression -> orange iTregs) were purified and adoptively
transferred to C57BL/6 Rag1-/- recipients of DBA/2 (H2d) islets transplanted
under the kidney capsule. Untreated control and recipients tolerized with a 14
day course anti-CD154 + MR1 regimen were analyzed. In vivo flow cytometry
of circulating blood was performed on days 1- 7 & 14. In some cases, in vivo
confocal microscopy with three-dimensional imaging and reconstruction of the
graft was performed on post-transplant days 7 & 14 in order to analyze the
intensity and distribution of graft infiltrating Teff (red), iTreg (orange), and
nTreg (green) T cells. Mice were sacrificed on day 14 and flow cytometry of
spleen, peripheral lymph nodes (LN) and graft draining LN was preformed.
Results: In untreated hosts the MST was 14 days while grafts in tolerized hosts
survived more than 100 days before sacrifice. In this model, naïve Teff cells (Red),
nTreg (Green) and in vivo converted iTreg (orange) cells can be specifically
identified by in vivo imaging. In blood, conversion to the iTreg phenotype peaks
3-4 days post-transplantation. In tolerized mice, there were far more iTreg (orange)
and nTreg (green) in the grafts on both day 7 and 14 than in control mice. The
total cell numbers are much greater in control mice, with a predominant pattern
of graft infiltration by Teff (predominant). On day 14, iTreg were more prevalent
in spleen, lymph nodes and draining LN of tolerance induction mice (8-10% of
total DsRed+ cells) than control mice (2-4% total DsRed+ cells). Moreover, the
expression of Foxp3-GFP was higher per individual Foxp3-GFP+ iTreg cells in
samples from the tolerant as compared to control mice.
Conclusions: In vivo imaging is an invaluable tool to directly observe the
pattern of graft infiltration by Teff, iTreg and nTeg as well as study dynamics
of iTreg conversion in vivo. This tool can aid analysis of allograft rejection
and the effect of tolerance inducing regimens. The unique feature is the ability
to serially analyze in vivo the same subject to give a dynamic analysis of
the allograft response. The findings indicate that graft infiltrating iTreg and
nTreg are more abundant in tolerant than rejecting mice. It is notable that tire
in tolerant mice have enhanced foxp3 expression on a per cell basis than in
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rejecting mice, suggesting stronger graft protecting properties.

739 T-CELL HELP IS ESSENTIAL IN MEMORY B-CELL
ALPHA-GAL XENOANTIBODY PRODUCTION:IMPLICATIONS
FOR ABO INCOMPATIBLE AND XENOTRANSPLANTATION
S. Liu, J. Tchervenkov, T. Kandeva, R. Tavana
McGill University
Introduction: The interaction between preformed anti-Gal antibodies
(anti-Gal Ab) and α-gal epitopes is a major immunologic barrier in human
xenotransplantation. The α-gal epitopes are very similar structurally to human
blood group A and B. In recipients of ABO incompatible grafts, much of the
elicited anti-A and anti-B antibodies are in fact anti-Gal Ab capable of binding
to incompatible blood group antigen. Central to the production of anti-Gal Ab
is the presence of memory B-cells and the need for T-cell help in this process is
not very clear. B cells can present α-gal epitopes on the highly conserved MHC
class I like molecule CD1d to invariant Natural Killer T lymphocytes (iNKT).
We hypothesized that human iNKT cells can provide direct help for B cell antiGal Ab production through CD1d-restricted mechanism.
Methods: Glycolipid micelles with α-gal epitopes (α-gal glycolipids) were
extracted from swine red blood cells. 7.5X104 B cells were co-cultured with nonirradiated 15X104 CD4+ T cells for 4 days with α-Gal glycolipid stimulation.
After 4 days specific α-Gal glycolipid antigen stimulation, these cells were
washed and plated onto ELISPOT plates coated with Gal-BSA. This Assay
utilizes a specific antigen stimulation of B cells followed by an antigen-specific
ELISPOT for the detection of anti-Gal memory B cells that have differentiated
into antibody secreting cells (ASC) in vitro. 5X104 human CD19 B cells were
co-cultured with irradiated 15X104 CD4+ T cells in the medium containing 0.2
μg/ml of anti human CD3 antibody and 100 U/ml of interleukin (IL)-2 with or
without swine 1 μg/ml of RBC glycolipid for 12 days. Human CD4+ T cells
provide CD1d-dependent help to B lymphocytes for immunoglobulin production.
IgG and IgM released by B lymphocytes cultured with irradiated CD4+ T cells
with anti human CD3 antibody and in the absent α-Gal glycolipid in vitro. AntiGal antibody production was inhibited by anti-CD1d antibody. Values are the
mean OD from six independent experiments. P values are indicated above the
lines. Results for IgG are shown (IgM results are the same).

BT+ α-Gal BT+ α-Gal +anti-CD1d
Results: B cells produce anti-Gal antibodies only if they receive help from activated
T cells. These immune responses can be inhibited by anti-CD1d antibody.
Conclusion: T cell help is essential in B-cell anti-Gal Ab production.
Xenoantibody production can be blocked by inhibition of CD1d which suggests
that iNKT cells may be central to memory B-cell help.

740 ACCELERATED REJECTION OF ALLOGRAFTS
FOLLOWING HOMEOSTATIC PROLIFERATION OF T
CELLS DESPITE DISPROPORTIONATE EXPANSION OF
REGULATORY T CELLS
W. Wong, K. Brown, T. Tapmeier, V. Moxham, J. Karegli, S. Sacks
King’s College London
Homeostatic proliferation of peripheral lymphocytes becomes the main source
of new T cells in adults following thymic regression. This process is accelerated
in transplant recipients that are lymphopaenic as a result of immunosuppressive
therapy. Importantly, T cells that have undergone homeostatic proliferation
acquire the phenotype and functions of memory T cells. However, the fate of
the regulatory T cell component of the T cell population following homeostatic
proliferation has so far revealed contradictory results.
To determine the effect of homeostatic proliferation on Foxp3+ regulatory T
cells, we reconstituted RAG-/- mice with wild-type C57BL/6 splenocytes. The
proportions of Foxp3+ cells in wild-type spleens, and RAG-/- spleens 14 days
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following reconstitution, were analysed using flow cytometry. Surprisingly,
while only 0.73% + 0.16% CD4+ T cells from spleens of naïve animals also
stained positive for intracellular Foxp3 (n =10), 20.21% + 4.9% CD4+ T cells
from spleens of reconstituted RAG-/- mice were double positive, representing a
28 fold increase (n =6, p = 0.0002). To ascertain whether the increased numbers
of Foxp3+ T cells in the spleens of reconstituted RAG-/- mice compared with
wild type would infiltrate subsequent renal allografts and have a bearing on the
outcome of the alloresponse, immunohistochemistry was performed on BM12
allografts transplanted into WT or reconstituted RAG-/- recipients. Although
the level of CD4+ infiltration was similar in BM12 kidney grafts transplanted
into reconstituted RAG-/- or WT recipients, the level of Foxp3+ T cells was
more than 2 times higher in BM12 allografts transplanted into reconstituted
RAG-/- recipients (27.7+6.7 and 13.5+3.5 cells per HPF respectively, n = 4).
This is despite the fact that BM12 kidneys are rejected more rapidly by RAG-/reconstituted compared with WT mice.
Foxp3+ regulatory T cells have a greater ability to undergo homeostatic
proliferation compared with non-regulatory T cells. Despite this, rejection of
BM12 kidney grafts are accelerated, further supporting the notion that effector
T cells that have undergone homeostatic proliferation have enhanced “memory”
like functional capabilities and are therefore more difficult to regulate.

741 THE ROLE OF DONOR CD4 T CELLS WITHIN SOLID
ORGAN TRANSPLANTS IN GRAFT REJECTION
T.S. Win1, S. Rehakova1, K. Saeb-Parsy1, M. Negus1, M. Goddard2,
J.A. Bradley1, E. Bolton1, G.J. Pettigrew1
1
Department of Surgery, Addenbrooke’s Hospital, Cambridge, UK,
2
Department of Pathology, Papworth Hospital, Papworth, UK
Background: This study examines how donor CD4 T cells within heart
allografts contribute to the development of chronic allograft vasculopathy
(CAV), by providing help to recipient B cells for generating pathogenic
autoantibody.
Methods: B6 mice were transplanted with MHC II-disparate bm12 hearts. The
allo- and auto-antibody responses were quantified, and their contribution to
CAV assessed by serum transfer to B cell deficient recipients. The role of donor
CD4 T cells in providing help for autoantibody was tested by removing CD4
T cells from donor hearts before transplantation by three approaches: treating
with anti-CD4 depleting mAb, administering 1300Gy lethal irradiation, and
using RAG-/- bm12 donors.
Results: Bm12 heart grafts developed progressive vasculopathy and were
rejected slowly (MST 95 days, n=17). The contribution of antibody-mediated
effector mechanisms was confirmed by histopathological examination (fibrinoid
necrosis and vascular proliferation), by complement C4d staining, and by longterm graft survival and significantly reduced vasculopathy in B cell deficient
recipients. Surprisingly, no alloantibody was detected, but recipients instead
developed autoantibody. The autoantibody response was completely dependent
upon the provision of help from donor CD4 T cells; removing CD4 T cells from
donors lead to complete abrogation of autoantibody response. Furthermore,
C4d deposition was not detected in CD4 T cell depleted/deficient bm12
allografts. To confirm an effector role for autoantibody in CAV, B6 mice were
primed for humoral autoimmunity, but not for alloimmunity, by injecting highly
purified bm12 CD4 T cells prior to transplantation. Heart grafts developed
severe vasculopathy and were rejected more rapidly (MST 29 days, n=4,
p<0.01). Furthermore, the serum transfer of autoantibody to B cell deficient
recipients induced rejection (MST=40 days, n=4) and restored C4d deposition.
Autoantibody by itself is, however, not sufficient to cause graft rejection;
syngeneic grafts showed disease-free survival in the presence of autoantibody
(n=4), indicating that development of vasculopathy and rejection is dependent
upon synergy between humoral autoimmunity and cellular alloimmunity. Finally,
bone marrow chimeric recipients that lacked MHC class II expression specifically
on B cells did not develop autoantibody, demonstrating that transplantationinduced autoantibody response results from cognate interaction between donor
CD4 T cells and MHC class II of recipient B cells.
Conclusions: Our results demonstrate the novel finding that help for
autoantibody production is provided by graft-versus-host cognate recognition
of recipient B cell MHC class II by donor CD4 T cells. This autoantibody
contributes to the development of vasculopathy independently of alloantibody.

742 CD8+ MEMORY T CELLS ELICIT ACCELERATED
REJECTION THROUGH RAPID RECRUITMENT OF GR-1+
NEUTROPHILS TO THE ALLOGRAFT
N. Jones, M. Brook, M. Carvalho-Gaspar, S. Luo, K. Wood
University of Oxford
Introduction: Increasing evidence suggests that memory T cells (Tm) play
an important role in allograft rejection and may form a barrier to tolerance
induction. We have used TCR-transgenic mice (BM3; H2Kb-reactive CD8+ T
cells) to compare the response of naïve and memory BM3 T cells to allogeneic
skin grafts where the number, specificity and affinity of alloreactive naïve and
memory T cells was identical.
Methods: Naïve BM3 T cells were harvested from BM3 TCR-transgenic mice;
BM3 Tm were isolated from mice that had been primed with donor splenocytes
or a skin allograft. In all experiments 1x105 memory or naïve BM3 T cells
were transferred to syngeneic, immunodeficient RAG-/- mice the day before
H2Kb+ skin transplantation. The response of the memory and naïve T cells
was visualised using FACS (lymphoid tissues), immunohistochemistry and
real-time PCR for pro-inflammatory genes (skin graft).
Results: A comparison of the response of memory and naïve BM3 T cells to skin
allografts revealed that Tm rejected grafts with an enhanced kinetic (median
survival time (MST) of 16 days (naïve) and 26 days (memory); P=0.01).
Surprisingly, when the response of BM3 Tm to the skin allograft was evaluated,
we found that memory and naïve BM3 T cells proliferated to a comparable
extent. The percentage of Tm or naïve BM3 T cells that had undergone 4
(7.9±4.1 Vs 6.7±3.6%), 5 (8.9±4 Vs 10.6±5.5%), 6 (9.1±4.2 Vs 8.5±3.8%),
7 (7.7±6.4 Vs 8.9±2.5%) and 8 or more (20.4±18.7 Vs 37.1±33.1%) divisions
in the draining lymph nodes was not significantly different. Furthermore,
the resulting effector cells, whether derived from naïve or memory BM3 T
cells, infiltrated skin allografts with a similar kinetic (infiltration of skin grafts
between 5 and 10 days post transplant). The resulting graft infiltrating effector
cells were also found to induce a similar gene expression profile. However,
during accelerated rejection triggered by BM3 Tm and in marked contrast to
rejection triggered by naïve BM3 T cells, significant numbers of GR-1+ cells
(neutrophils) were recruited to the graft as revealed by immunohistochemistry.
To determine whether the enhanced recruitment of GR-1+ neutrophils to skin
grafts was responsible for the rapid rejection mediated by BM3 Tm mice, a
depleting anti-GR-1 mAb was administered to mice that had received naïve
or memory BM3 T cells and a donor skin allograft every 3 days for 27 days
post transplantation. We found that the anti-GR-1 mAb therapy attenuated graft
rejection mediated by Tm such that the rejection time was identical to that
triggered by naïve BM3 T cells in the absence of neutrophils (Tm+anti-GR1=MST of 30 days, naïve BM3+anti-GR-1=MST of 30 days; n=5-6/group).
Discussion: Tm are able to rapidly reject allografts through the enhanced
recruitment of GR-1+ neutrophils to the graft. These data extend our knowledge
of the function of alloreactive Tm in transplantation. Furthermore, we have
identified an under-appreciated role of neutrophils in transplant rejection and
suggest that the transient depletion/manipulation of GR-1+ cells may be of
therapeutic benefit in the control of rejection responses elicited by Tm.

743 ALLOGRAFT REJECTION IN ABSENCE OF SECONDARY
LYMPHOID ORGANS
C. Leduc, C. Daniel
INRS-Institut Armand-Frappier
In transplantation, the site of alloreactive response initiation is still a matter
of debate. Some have suggested that the organized structures of secondary
lymphoid organs (SLO) are absolutely required for T cell sensitization, whereas
others claimed that the graft itself could constitute an appropriate environment.
We investigated this issue in a murine model based on a single T cell clonotype
where direct and indirect allorecognition pathways can be independently
studied. Our previous studies showed that during direct responses, activated
alloreactive T cells were first detected inside the graft. We further investigated
whether alloreactive responses could be initiated in the absence of SLO.
The model used in the laboratory is based on a CD4+ T cell clone (2.102),
which recognizes I-Ep (MHC class II) molecules by the direct pathway
and mouse hemoglobin peptide Hb(64-76) presented by I-Ek molecules by
the indirect pathway. Purified CD4+ T cells from 2.102 TCR Tg mice were
adoptively transferred to splenectomized H-2k mice deficient for both α;β; T
cells and for lymphotoxin β; receptor. These mice, which lack lymph nodes and
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Peyer’s patches, were then grafted with donor tail skin.
Mice without SLO rejected their allograft but with a small delay in kinetics as
compared to mice with SLO. As expected, CD4+ T cells were detected massively
in the graft in the direct pathway at day 7. This infiltration is associated with an
IFN-γ; mRNA up regulation. How CD4+ T cells get activated in direct pathway
is still unclear. Is the graft environment itself sufficient to T cell activation
or is the development of lymphoid structures necessary? The presence of the
high endothelial cell restricted N-acetylglucosamine 6-O-sulfotransferase
mRNA, an enzyme involved in PNAd synthesis, in addition to the presence
of the CCL19 chemokine, suggest that lymphoid structures could be present in
the graft. Immunohistochemistry analyses are under investigation to determine
whether tertiary lymphoid organs developed in graft. Surprisingly, rejection by
the indirect also occurred in the absence of SLO. Because only inflammatory
cytokines and chemokines mRNA and almost no CD4+ T cells were detected in
the graft at that time, other organs were investigated for the presence of CD4+
T cells. Indeed, BrdU+CD69+CD4+ T cells were detected in the bone marrow.
Thus this primary lymphoid organ can also serve as a surrogate SLO where T
cell activation and proliferation occur before migration of these activated T cells
to the graft, as suggested by intra-graft chemokine receptors expression such
as CCR1, CCR3, CCR5 and CXCR3. Finally, different cellular mechanisms
seem to be implicated in each pathway as seen by a neutrophil infiltration in
the direct pathway and a macrophage infiltration in the indirect pathway. In
conclusion, although different sites of T cell activation and different effector
mechanisms, both pathways of allorecognition can lead to rejection in absence
of SLO.

744 THE ROLE OF NATURAL KILLER CELLS IN
LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV)
INDUCED CORONARY ALLOGRAFT VASCULOPATHY (CAV)

THURSDAY

J.Graham1, R. Wilkinson3, T. Hirohashi1, C. Chase1, J. Fishman3, J. Madsen1,
R. Colvin2, P. Russell1
1
Department of Surgery Massachusetts General Hospital, 2Department of
Pathology Massachusetts General Hospital, 3Division of Infectious Disease
Massachusetts General Hospital
Background: CAV is a major cause of death in cardiac transplant patients. In
this regard, understanding the pathogenesis of CAV has become a paramount
pursuit of the transplant community. Viruses have always been implicated in
CAV lesion formation, but the contribution of viral infection to the pathogenesis
of CAV remains unclear and anecdotal. Here we investigate the role of natural
killer (NK) cells in a novel example of LCMV-induced CAV. Importantly, the
well characterized anti-viral properties of NK cells make them relevant in this
discourse.
Methods: To isolate the contributions of NK cells, parental C57BL/6.RAG1-/(H2b) hearts were transplanted into (C57BL/6.RAG1-/- x BALB/c.RAG1-/-)
F1 (H2bxd) recipients. This system offers an uncontrived means with which
to eliminate B and T cell response while maintaining intact NK cell activity.
Four recipient groups were studied; 1) no treatment, 2) viral medium injection
(sham), 3) LCMV inoculation alone (mice were infected IP with 2.25 x 10e5
PFU of LCMV Armstrong strain) and 4) LCMV inoculation with anti-NK1.1
mAb administration to deplete NK cells. CB6F1.RAG1-/- recipients of
B6.RAG1-/- hearts were treated with PK136 (anti-NK1.1) at a dose of 200 mg
i.p. on days -6,+1 then once weekly thereafter. Recipients were sacrificed on
post-operative day 56 with beating hearts. A quantitative molecular assay for
LCMV in tissue at sacrifice revealed that infected hearts had a mean of 103,745
copies of LCMV/ng tissue RNA. Transplanted hearts were rapidly frozen and
sections were prepared from frozen tissue to determine the presence of CAV
formation.
Results: Only 1 in 11 untreated recipients developed lesions of CAV and none
of the 4 sham injected recipients did so. In contrast, 6 of 8 recipients infected
with LCMV developed distinct CAV lesions. Strikingly, none of the 8 mice
infected with LCMV and treated with anti-NK1.1 mAb developed CAV.
Conclusion: Our experiment demonstrates that LCMV can cause CAV, which
corroborates the clinical evidence supporting the possibility of virally induced
CAV. However more importantly, NK cell depletion was shown to abrogate
CAV lesion formation. Therefore, NK cells appear to mediate the development
of CAV induced by LCMV. We propose that LCMV infection causes non-self
peptide expression on the coronary graft endothelium leading to activation of
the NK cells, which in turn stimulate effector cells/cytokines to induce CAV.
Through the study of LCMV in our model we hope to clarify the role of
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the innate immune system and viral infection in the post-operative period.
Interestingly NK cells alone do not appear able to promote CAV, but rather
need another catalyst for stimulation. Our data demonstrates that viruses may
be germinal to the understanding of NK cell contribution to CAV and the
vascular biology of this disease.

745 NK CELLS REGULATE GRAFT-VERSUS-HOST DISEASE
AND CARDIAC ALLOGRAFT REJECTION BY LIMITING THE
ANTIGEN-DRIVEN EXPANSION OF CD4 T CELLS
M.N. Rivas, M. Hazzan, M.l Braun
Institute For Medical Immunology (IMI) – Université Libre De Bruxelles (ULB)
CD3-negative natural killer cells (NK) are granular lymphocytes capable of
producing inflammatory cytokines and killing malignant, infected or ‘stressed’
cells. We have recently observed a new role for NK cells in the control of the
proliferation of CD4 T cells under persistent antigenic stimulation. Adoptive
transfer of monoclonal anti-male CD4-positive T cells into sub-lethally
irradiated male recipients induced 100% mortality after one week. On the
contrary, non-irradiated mice survived indefinitely after transfer and did not
develop clinical sign of acute graft-versus-host disease (GVHD). Moreover, T
cells transferred into non-irradiated recipients did not expand or were rapidly
eliminated. Remarkably, T cells transferred into non-irradiated NK cell-deficient
hosts expanded extensively (15x10E6 cells after 28 days). Histology revealed
their capacity to mediate chronic GVHD-like lesions in these hosts. Transferred
T cells did not appear to develop a regulatory phenotype since they remained
Foxp3-negative and produced high amounts of IFN-g when stimulated in vitro.
Interestingly, even in the absence of NK, they were unable to promote acute
GVHD after transfer into irradiated recipients. These results highlight the
critical role played by NK cells in the control of antigen-dependent expansion
of CD4 T cells and the development of chronic GVHD.
The role played by NK cells in the control of T cell response was also investigated
in a vascularised cardiac allograft model. MHC class II-disparate Bm12 hearts
transplanted into C57BL/6 recipients underwent slow rejection (mst>50 days;
n=4). On the contrary, our preliminary results showed that the depletion of NK
cells by antibody treatment in this model accelerated the process of rejection
(mst=28 days; n=4). This observation is consistent with the hypothesis that the
control of alloreactive CD4 T cells by NK cells of the innate immune system
could limit the process of chronic rejection of solid organ transplants. We are
currently investigating whether the accelerated rejection process observed in
the absence of NK cells is the result of uncontrolled expansion of allograftspecific CD4 T cells.

CONCURRENT ORAL SESSION 57: CAN AND ANTIBODIES
746 CIRCULATING MARKERS OF ENDOTHELIAL
DYSFUNCTION INTERACT WITH PROTEINURIA IN
PREDICTING MORTALITY IN RENAL TRANSPLANT
RECIPIENTS
R.M. van Ree, L.H. Oterdoom, A.P.J. de Vries, J.J. Homan van der Heide,
W.J. van Son, G.J. Navis, R.O.B. Gans, S.J.L. Bakker.
Renal Transplant Program, University of Groningen and University Medical
Center Groningen, The Netherlands.
Proteinuria is associated with increased mortality in renal transplant recipients
(RTR). This association is considered the consequence of proteinuria reflecting
generalized endothelial dysfunction (ED). In RTR, however, proteinuria
is frequently a reflection of renal involvement. Both, soluble intercellular
adhesion molecule type 1 (sICAM-1) and soluble vascular cellular adhesion
molecule type 1 (sVCAM-1) are markers of ED. In this study, we investigated
whether markers of ED can help to recognize whether proteinuria is associated
with vascular involvement in RTR.
Outpatient RTR, who had a functioning graft ≥1 year, were invited to participate
between 2001-2003. Proteinuria was defined as urinary protein excretion ≥0.5
g/24hr. sICAM-1 and sVCAM-1 were measured by ELISA. Mortality was
analyzed using Cox-regression.
We measured sICAM-1 (median [IQR] 603 [514-721] ng/ml) and sVCAM-1
(952 [769-1196] ng/ml) in 606 RTR (aged 51±12 years, 55% male) at 6.0
[2.6-11.4] years post-transplant. Proteinuria was present in 169 (28%) RTR.
During follow-up for 5.3 [4.7-5.7] years, 95 (16%) RTR died.
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Figure 1. Interactions between proteinuria and (A) sICAM-1 and (B) sVCAM-1
concentrations on the risk of mortality. Ref. = reference.

747 ESTIMATION OF RENAL ALLOGRAFT HALF LIFE IN
COHORTS WITH DIFFERENT FOLLOW UP
D. Serón1, M. Arias2, J.M. Campistol3, D. Hernandez4, José Morales5,
Francesc Moreso6, Ana Sanchez-Fructuoso7
1
Hospital Universitari Bellvitge, 2Hospital de Valdecillas, 3Hospital Clinic,
4
Hospital Universitario de Canarias, 5Hospital 12de Octibre, 6Hospital
Universitari Bellvitge, 7Hospital Cínico San Carlos
Introduction: It is necessary to monitor graft and patient survival in cohorts
of patients transplanted at different time periods, to detect as early as possible,
the effect of different transplant policies on long term outcome. Modelling long
term graft failure has led to overestimation of real renal allograft half life. The
aim is to determine the minimum follow up using different statistical models to
accurately estimate renal allograft half life in patients with a functioning graft
at one year of follow up.
Patients and methods: Patients with a functioning graft at one year,
transplanted in Spain during 1990, 1994, 1998 and 2002 were followed until
December 2005. Real half life was calculated in the 1990 cohort since >50%
of patients lost their graft at the end of follow up. Additionally, exponential,
Weibull and Weibull method censoring the last 2 years of follow up were
employed to estimate renal allograft half life.
Results: During these 4 years a total of 6901 adult patients were transplanted
in Spain and 4842 accomplishing the inclusion criteria were enrolled. Of
these, 851 were transplanted in 1990, 1124 in 1994, 1512 in 1998 and 1355
in 2002.
Real half in 1990 was 14.2 years and estimated half life and its 95% confidence
interval according to the different statistical models are shown in the table.
Exponential
Weibull
Weibull
censoring last 2y
1990
15.8(14.2-17.5)
14.5 (13.4-15.6)
14.0 (13.1-15.0)
1994
18.2 (16.3-20.1) 15.3 (14.1-16.6) 13.6 (12.6-14.6)
1998
27.5 (24.0-31.0) 19.0 (16.9-21.1) 14.9 (13.4-16.4)
2002
57.5 (42.3-72.7) 27.8 (21.7-34.0) 18.0 (13.7-22.4)
P<0.0001
p<0.0001
ns
In order to estimate minimum follow up to obtain an accurate estimation of
mean half life, this parameter was estimated in the 1990 cohort considering
different follow up periods from 1 to 14 years. At least 9 year of follow up were

necessary to precisely estimated real half life in the 1990 cohort.
Conclusion: half life in patient with a functioning graft at one year can be
precisely estimated before 50% of patients have lost their graft provided these
patients are followed for at least 9 years.

748 DONOR-RECIPIENT AGE MATCHING DOES NOT
IMPROVE YEARS OF GRAFT FUNCTION IN DECEASED
DONOR KIDNEY TRANSPLANTATION
W. Lim, S. Chang, H. Dent, S. Campbell, S. Chadban, G. Russ, S. McDonald
ANZDATA Transplant Working Group
Aims: It is well established that donor and recipient age in kidney transplantation
affect graft and patient survival. The importance of age matching of deceased
donors and recipients in kidney transplantation and the impact on years of graft
function remains uncertain.
Methods: Using the ANZDATA registry, all deceased donor kidney transplant
recipients in Australia and New Zealand between 1991 and 2005 were
analysed (n=3888). Multiple organ grafts, donor and recipient age <16 years
at transplant were excluded. Outcomes analysed include overall graft loss,
death-censored graft failure (DCGF) and death with functioning graft (DFG).
We examined the associations of donor and recipient age with outcomes using
standard Cox and competing risk models. We estimated mean years of graft
function for donor-recipient age combinations with and without age matching.
Donor and recipient confounding factors were adjusted for in multivariate
models.
Results: There were no significant interactions between recipient and donor
age for all outcomes, indicating the associations of donor age with outcomes
was similar in younger and older recipients. Older donors were associated
with higher hazards of overall graft loss, DCGF and DFG at 1-8 years posttransplant (for donors >60 and recipients <55 years, adjusted hazard ratios [HR]
of 2.03 [95%CI 1.61,2.56], 2.62 [1.95,3.52], 1.49 [1.03,2.16] respectively;
p<0.05). Using standard Cox models, older recipients were associated with
higher adjusted hazards of overall graft loss and DFG, but with lower hazards
of DCGF (HR 0.60, 95%CI 0.46,0.79; p<0.01). When DCGF and DFG were
considered as competing events, the HR of older recipient age in competing
risk analysis were augmented but overall conclusions were similar between
the two methods (i.e. unadjusted HR of DCGF/DFG at 1-8 years for recipient
age ≥55 years using standard Cox and competing risk models were 0.60
[0.46,0.79]/3.10 [2.15,3.93] and 0.20 [0.14,0.28]/5.11 [3.58,7.30]). The
mean years of graft function obtained per patient for best (young-to-young
and old-to-old) and worst (young-to-old and old-to-young) donor-recipient age
combinations were similar, indicating no overall benefits of age matching (see
table).
Mean functioning graft years (up to 15 years’ follow-up)
Donor age group
Young

Old

Total

(a) Age cut-points: Recipient 55, donor 50 years
Young
Old

N=1806

N=887

11.44 (11.14, 11.74)

9.44 (8.94, 9.95)

Best age-match 9.08 (8.88, 9.73)

N=700

N=495

Worst age match

9.41 (8.94, 9.88)

7.16 (6.61, 7.71)

9.43 (8.94, 9.92)

(b) Age cut-points: Recipient 55, donor 60 years
Young
Old
Recipient age group

RTR who had proteinuria and high levels of sICAM-1 or sVCAM-1 were
at highest risk for death (Hazard ratio (HR)=2.2, P=0.003 and HR=2.9,
P=0.0001, respectively versus subjects without proteinuria and with low levels
of sICAM-1 or sVCAM-1, which were considered reference groups, both
with HR=1.0). Subjects with proteinuria but low levels of sICAM-1 (HR=0.9,
P=0.90) or sVCAM-1 (HR=0.9, P=0.80) had a risk comparable to the reference
groups. The same was true for subjects without proteinuria but high levels of
sICAM-1 (HR=1.1, P=0.80). For subjects without proteinuria but high levels
of sVCAM-1 (HR=1.5, P=0.10) there was an insignificant trend towards
increased risk (figure 1).
Both sICAM-1 and sVCAM-1 interact significantly with proteinuria in
predicting mortality in RTR. These results suggest that assessment of circulating
cell adhesion molecules can help to identify RTR in which proteinuria is
associated with vascular involvement.

N=2368

N=325

11.15 (10.88, 11.42)

8.30 (7.47, 9.12)

Best age-match 9.04 (8.48, 11.52)

N=981

N=214

Worst age match

8.93 (8.52, 9.34)

6.94 (6.08, 7.80)

8.62 (8.00, 9.23)

(c) Age cut-points: Recipient 50, donor 60 years
Young
Old

N=1880

N=252

11.14 (10.83, 11.44)

8.44 (7.52, 9.36)

Best age-match 9.10 (8.56, 9.63)

N=1469

N=287

Worst age match

9.68 (9.33, 10.03)

7.05 (6.29, 7.81)

9.06 (8.43, 9.70)

Conclusions: The associations of donor age with outcomes were similar in
younger and older recipients. Lower hazard of DFG in younger recipients was
counter-balanced by higher hazard of DCGF. Donor-recipient age matching did
not result in higher mean years of graft function.
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749 URINE MAGNETIC RESONANCE SPECTROSCOPY
(UMRS): PRELIMINARY OBSERVATIONS IN THE
DETERIORATION OF KIDNEY ALLOGRAFT FUNCTION
(DEKAF) STUDY

750 FOUR STAGES AND LACK OF STABLE
ACCOMMODATION IN CHRONIC ALLOANTIBODY
MEDIATED RENAL ALLOGRAFT REJECTION IN
CYNOMOLGUS MONKEYS

R. Gaston5, D. Rush1, R. Somorjai2, M. Cecka3, F. Cosio4, S. Gourishankar6,
J. Grande4, P. Halloran6, B. Kasiske7, A. Matas8
1
University of Manitoba, 2National Research Council Institute of
Biodiagnostics, 3University of California at Los Angeles, 4The Mayo Clinic,
5
University of Alabama at Birmingham, 6University of Alberta, 7Hennepin
County Medical Center, 8 University of Minnesota
DEKAF is an ongoing, prospective, multicenter, observational study of the
causes of renal allograft dysfunction and loss, conducted at 7 transplant centers
in the US and Canada, with over 1800 patients enrolled to date. At the first
sign of graft dysfunction or new-onset proteinuria a renal biopsy is obtained
to define clinico-pathological entities at their early stages before widespread
interstitial fibrosis and tubular atrophy (IF/TA) precludes identification of their
original etiology. In addition to traditional clinical, serological and pathological
studies, DEKAF will attempt to classify these entities with a novel non-invasive
method, UMRS.
For UMRS, samples are mixed with TSP/D2O. The 1H NMR spectra are
acquired on a 360 MHz Bruker spectrometer, aligned on the TSP peak, and
the water resonance is suppressed. The method for distinguishing patients
with and without inflammation, using the UMRS, is based on the multistage
Statistical Classification Strategy developed and used with success on MR,
IR, mass spectral and genomic data1. For the urine spectra, leave-oneout crossvalidation is used to identify maximally discriminatory spectral
subregions. The robust classifiers are based on least trimmed square regression
on the magnitude spectra.
Patients with a combination of acute inflammation and IF/TA have decreased
allograft survival compared to patients with IF/TA without inflammation.
As proof of concept that UMRS could accurately distinguish pathological
entities, we examined urines from patients with low Banff IF scores and
no inflammation (class 1: ci0 or ci1; ai=0; n=78) and compared these with
patients with low IF scores with inflammation (class 2: ci0 or ci1; ai>0; n=46)
(Study 1). We next analyzed patients with varying degrees of IF without
inflammation (class 1: ci>0; ai=0; n=63) and compared these with patients
with varying degrees of both IF and inflammation (class 2: ci>0; ai>0; n=39)
(Study 2). For either Study, the small sample sizes precluded a meaningful
splitting of the classes into training sets and independent validation sets.
The results are based on 6 subregions for both Studies, which satisfy the
necessary 5-10 sample to feature ratio, required for reliable classification
of unknown samples. The results show 87.2% accuracy for class 1, 87.0%
for class 2 (Study 1), and 90.4% for class 1 and 89.7% for class 2 (Study
2). Thus, sensitivity and specificity were well balanced for both Studies, but
more samples will be needed to stabilize the classification accuracies and
class assignment reliabilities.

R.N. Smith1, T. Kawai2, S. Boskovic2, O. Nadazdin2, D. Sachs2,
A.B. Cosimi2, R.B. Colvin1
1
Department of Pathology Massachusetts General Hospital, 2Department of
Surgery Massachusetts General Hospital
NATURAL HISTORY OF CHRONIC ALLOANTIBODY MEDIATED
REJECTION WITHOUT ENDURING ACCOMMODATION IN
CYNOMOLGUS MONKEYS
The etiology of chronic renal allograft failure in humans is unclear. Its diagnosis
both clinically and pathologically is difficult and confounded in humans by
non-immune mechanisms including recurrent disease, drug toxicity, transplant
ischemia, and hypertension. One cause is thought to be alloantibodies because a
substantial fraction of patients with chronic rejection have circulating antibodies
and deposition of C4d, which is associated with the later development of
transplant glomerulopathy and led us to postulate that C4d may predict later
chronic antibody mediated rejection (CAMR). To test this hypothesis we
have evaluated long-term renal allografts in Cynomolgus monkeys, treated
with mixed chimerism protocols without immunosuppression after 28 days.
To define the natural history of CAMR, we reviewed 417 specimens from
143 Cynomolgus monkeys with renal allografts, including the pathology and
C4d immunohistochemistry and correlated these data with DSA, analyzed by
flow cytometry of recipient alloantibodies against donor lymph node cells.
Pathological review was performed by Banff criteria. A subset of animals with
long-term survival made DSA (48%), were C4d positive (29%), developed
transplant glomerulopathy (TG) (22%), and chronic allograft arteriopathy
(CAA) (19%), all highly correlated (p<0.001). Acute cellular rejection, either
Banff type 1 or 2, did not correlate with alloantibodies, C4d deposition or TG,
however, endarteritis (Banff type 2) correlated with later CAA. A majority of
cases of TG were associated with alloantibodies, but a small subset of TG could
not be attributed to alloantibodies. Life table analysis showed that in long term
surviving animals the presence of alloantibody, C4d, TG, or CAA shortened
renal allograft survival by at least 58%, Table I.
Table I
N
Mean
SD Median SD
P Value
Antibody Negative
18
1056
222
770
79
Antibody Positive
22
348
56
274
18
P <.001
C4d Negative
24
950
185
755
282
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In future studies, independent validation sets will be used to assess the
diagnostic/prognostic capabilities of all eventual classifiers. We will also
obtain UMRS and corresponding classifiers for other entities (e.g. transplant
glomerulopathy). The non-invasive nature of urine MRS will allow for repeat
testing of individual patients to evaluate changes in the spectra and their
correlation with specific interventions and their outcomes.
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C4d Positive
TG Negative

22
23

303
964

43
186

256
755

33
282

TG Positive

23

287

42

230

35

P <.001

P <.001

CAA Negative
20
912
174
508
287
P value refers to either mean or median
We determined the time of first appearance of alloantibodies, C4d, TG, and
renal dysfunction in 18 cases with sufficient interval sampling, Table II and
identified four progressive stages of CAMR: 1) DSA, 2) deposition of C4d, 3)
transplant glomerulopathy, and 4) rising creatinine.
Table II
First Appearance
Ab
C4d
TG
Graft Loss
Days To
Mean
158
210
252
367
SD
145
180
165
217
Range
61-652
97-755
113-695
231-838
Cr at Days To Mean
1.4
1.9
2.2
5.8
SD
0.6
0.8
0.9
2.0
Range
0.9-2.9
1-3.5
1-3.7
2.3-9
These new findings provide strong evidence that CAMR develops without
enduring accommodation, progresses through four defined clinical pathological
stages and shortens renal allograft survival. In addition, our results emphasize
the importance alloantibody assays and C4d staining because these predict the
clinically silent progressive intragraft pathological changes that can ultimately
lead to graft loss from CAMR.
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751 ASSOCIATION BETWEEN DE NOVO DONOR SPECIFIC
HLA ANTIBODY, C4D STAINING IN RENAL GRAFT BIOPSY,
AND GRAFT OUTCOME.

752 THE PRESENCE OF DE NOVO DONOR SPECIFIC
ANTIBODY PREDICTS POOR ALLOGRAFT SURVIVAL IN
PATIENT WITH TRANSPLANT GLOMERULOPATHY

Y. Cho1,2, J. Cicciarelli1,2, M. Koss1, K. Houston1, R. Mendez1,2,
N. Kasahara3, I. Hutchinson1,2, T. Shah1
1
National Institute of Transplantation, 2USC School of Medicine, 3UCLA
School of Medicine
Background: Despite improved early graft survival, long-term kidney graft
loss rate has not been reduced. Both HLA antibodies and HLA donor specific
antibodies (DSA) have been detected and may be causal in chronic allograft
nephropathy (CAN) and, especially, in acute rejection. We evaluated the
association between DSA, C4d staining in transplant and graft outcome.
Materials and Methods: During Sep 2004-Aug 2007, HLA antibody tests usng
the Luminex laboratory screen assay system were performed in 348 recipients.
Of these, Cd4 deposition was assessed in the biopsies of 69 recipients with
transplant dysfunction.
Results: In the 69 cases, 29 (42%) showed C4d negativity, 27 (39%) were
Cd4 positive, 6 (9%) were equivocal, and 6 (9%) not diagnostic. Fourty-nine
recipients (71%) with transplant dysfunction had HLA antibodies and 41
(59%) had DSA. The proportion of C4d positivity was significantly higher in
patients with DSA (Class I only, II only, and I & II) in comparison with patients
without post-transplant HLA antibodies (Table). The incidence of graft failure
(including current SCr>4.0) in patients with class II antibodies (Class II only
or I & II) was significantly higher than that in patients without post-transplant
HLA antibodies (Table). In Figure, grafts of Class II DSA group continued to
fail beyond 2 years after transplantation when compared with other 2 groups
(None/NDSA or Class I only), however, the difference in graft survival between
Class II and None/NDSA group did not reach to statistical significant level
(log-rank P=0.32).
Conclusions: Significant association between C4d staining, de novo HLA
Class II antibodies and graft failure strongly suggests the importance of
post-transplant HLA antibodies. We propose that amelioration of CAN
graft loss depends on monitoring and identification of DSA and appropriate
immunosuppression of these antibodies.
Table. C4d positivity and graft outcomes according to DSA groups

M. Everly1, L. Arend1, A. Govil1, B. Susskind1, H. Al-Ghawi1, J. Everly1,
G. Mogilishetty1, R.R. Alloway1, E.S. Woodle1, P. Roy-Chaudhury1.
1
University of Cincinnati, Cincinnati, OH, USA.
Background: Recent studies indicate that renal transplant recipients with
chronic alloantibody production are at an increased risk of developing
transplant glomerulopathy (TG). Despite this association, many patients with
TG do not have peritubular capillary (PTC) deposition of C4d. The aim of this
study was to identify linkages between transplant glomerulopathy, the pattern
of C4d deposition, the presence of donor specific antibody (DSA) and allograft
survival.
Methods: 15 patients with evidence of TG on biopsy (in the absence of a
rejection episode in the previous 6 months) were included in this study. All
patients had to have a Banff 97 cg score >0. Donor specific anti-HLA antibodies
(DSA) [Luminex platform/Labscreen single antigen beads] and the pattern of
C4d deposition [glomerular (G) or peritubular capillary (PTC)] at the time of
the biopsy were assessed. All DSA were de novo, i.e., not detected prior to
transplantation. Survival analysis was performed by Kaplan Meier (STATA/
SEv9.2).
Results: TG was associated with the presence of DSA (53%). Of the DSA
specificities present, those directed against HLA class II predominated
(88%). The majority of patients had glomerular C4d deposition (73%). The
most common pattern was G+, PTC-, DSA- (33.3%). PTC C4d deposition
was limited to 3 patients only (20%). All 3 patients also had glomerular C4d
deposition and evidence of DSA. Graft loss in these patients with TG over
almost 2 years of follow up occurred exclusively in the DSA +ve cohort (see
Fig). Survival analysis of TG stratified by DSA positivity trended toward
statistical significance (log-rank, p=0.067).
Table 1: Relation of C4d Deposition to DSA in patients with Transplant
Glomerulopathy

Antibody
Category
None (ref)
Class I only

N

20

C4d Positive
N (%)

Graft Failure
N (%)

1 (5) (ref)

3 (15) (ref)

Graft Failure or
SCr>4.0
N (%)

TG (n=15)
C4d: G-, PTC-, DSA-, pt (%)

5 (33.3)

C4d: G-, PTC-, DSA+, pt (%)

2 (13.3)

C4d: G+, PTC-, DSA-, pt (%)

2 (13.3)

C4d: G+, PTC-, DSA+, pt (%)

3 (20.0)

C4d: G+, PTC+, DSA+, pt (%)

3 (20.0)

5 (25) (ref)

10

8 (80) (P<0.001)

2 (20) (P=0.82)

5 (50) (P=0.10)

Class II only

22

13 (59) (P<0.001)

9 (41) (P=0.06)

13 (59) (P=0.03)

Class I & II

9

9 (100) (P<0.001)

4 (44) (P=0.09)

6 (67) (P=0.03)

NDSA

8

2 (25) (P=0.12)

1 (13) (P=0.86)

1 (13) (P=0.40)

Figure. Graft survival according to DSA groups

Conclusions: Transplant glomerulopathy appears to be a heterogenous entity
with regard to the pattern of C4d deposition (G versus PTC), the presence of
DSA and the final clinical outcome. In particular, patients with TG and DSA (in
the absence of clinical and histological features of rejection) had an extremely
poor prognosis. We suggest that patients with transplant glomerulopathy who
also have DSA are at high risk of allograft failure. Interventions to suppress
DSA production may be indicated in these patients, even in the absence of
histological evidence of rejection.
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753 CLINICAL VALUE OF ROUTINE MONITORING OF
HLA ANTIBODY AND URINE PROTEIN AFTER RENAL
TRANSPLANTATION
H. Iwase1, T. Kobayashi2, A. Katayama2, S. Kohara3, T. Nagasaka3,
N. Goto3, T. Ueki4, Y. Kodera1, K. Uchida3, A. Nakao1
1
Nagoya University School of Medicine, Department of Surgery II, 2Nagoya
University School of Medicine, Department of Applied Immunology, 3Nagoya
Daini Red Cross Hospital, 4Masuko Memorial Hospital
Introduction: De novo production of HLA antibody has been reported
to be associated with poor prognosis due to chronic antibody-mediated
rejection. Although the practice of HLA antibody test has been advocated, no
recommendations for follow-up monitoring have been determined yet, including
how frequently, for what patients (all patients for screening or only patients
with renal dysfunction), what kind of methods and how specifically (specificity
of HLA antibody should be identified or not). Flow cytometry or luminex is a
powerful tool for scrutiny test, but requires special equipment and considerable
expense. The simple and costless assay for HLA antibody detection is ELISA.
The test for urine protein which reflects renal dysfunction is performed
everywhere. The purpose of this study was to assess the clinical value of HLA
antibody and urine protein monitoring after renal transplantation.
Methods: Total 297 serum samples were consecutively collected from renal
transplant recipients in 2004 and 2006. Mean+/-SD in recipient age and period
after transplantation were 44.7+/-11.6 and 8.3+/-6.5 years. All patients were
treated with maintenance immunosuppressive therapy. Paired sera were tested
for IgG antibody against HLA class I and II using ELISA (LAT-M). The status
of HLA antibody before transplantation was evaluated by the clinical record or
re-examined by flow cytometry (FlowPRA). Urine protein was determined to
be positive when dipstick protein reaction was +/- or over, which was nearly
compatible with a urine protein level of over 20mg/dL.
Results: 297 patients were divided according to the change of HLA Ab
and urine protein status between 2004 and 2006. Patients with continuing
positive urine protein test showed a significantly higher serum creatinine level
(2.13+/-1.31mg/dL) and deterioration over 2 years (&#8710;Cr: 0.36mg/dL).
In contrast, patients with positive to negative or negative to positive urine
protein test did not show any change of serum Cr. Only patients with de novo
production, sustained detection of HLA antibody and continuous positive urine
protein demonstrated significantly higher creatinine (2.31+/-0.67mg/dL) and
more marked deterioration over 2 years (&#8710;Cr: 1.26mg/dL). In contrast,
patients with de novo production and sustained detection of HLA antibody,
but with negative urine protein test did not show any deterioration of serum
Cr. Furthermore, negative change of HLA antibody status clearly stopped the
increase of serum Cr.
Conclusions: The positive change of HLA antibody and urine protein seems
to precede the increase of serum Cr. As it usually takes years to progress from
antibody production to irreversible renal dysfunction, a yearly routine HLA
antibody test for all patients is recommended. Considering cost-benefit and
availability, ELISA is the screening test of choice. When both de novo HLA
antibody and urine protein were detected, an attempt to reduce HLA antibody
to undetectable levels would be encouraged.

CONCURRENT ORAL SESSION 58:
ORGAN DONATION – PROGRESS AND CONTROVERSIES
754 DONATION PATTERNS IN 4 EUROPEAN COUNTRIES:
DATA FROM THE DONOR ACTION DATABASE
L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
Donor Action Foundation, 2Eurotransplant International Foundation
Study aims: To analyze heart-beating (HB) organ donation patterns in 4
countries using the Donor Action (DA) Program nationally, and identify areas
for improvement.
Materials: Retrospective Medical Record Review (MRR) of all Critical Care
deaths between Jan. 2006 and Dec. 2007 (n=18,118) in hospitals in Belgium,
Finland, France and Switzerland participating in DA’s Diagnostic Review
process. Upper age limit for medical suitability: 75 years. Data were entered to
the DA System Database for analysis.
Results: Of 6,561 patients (36.2% of all records) with no absolute contraindications to donation, 2,973 met pre-conditions for brain death (BD)
diagnosis (45.3%), 2,063 had signs of severe brain damage and 1,891
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met criteria for formal BD diagnosis (=potential donors). Belgium had
the highest number of patients with formal BD diagnosis (75.7%) and
Switzerland (57.4%, P<.0001) the lowest. Although donor identification
rates were uppermost in France (93.6%) with the least in Finland (47.7%,
P<.0001), Finland excelled in donor referral (93.9% of identified cases) vs.
only 63.8% in Switzerland (P<.0001), and excelled in family approach rates
(92.7%) vs. only 70.2% in France (P<.0001). Consent rates as a% of families
approached were superior in Belgium and Finland (89.5%) with the most
inferior in France (65.7%, P<.0001). Conversion rates as a% of potential
donors resulting in donation were higher in Finland (43.1%) and Belgium
(42.9%) and significantly lower in France (34.9%) and Switzerland (33.5%)
(P=.0187). Only Belgium had a non-heart-beating donation policy during
the study period, resulting in an addition of 11.2% donors to the country’s
donor pool.
Conclusions: The DA MRR proved to be an excellent tool to identify areas
of improvement within certain steps of the donation pathway, such as donor
identification, BD diagnosis, donor referral, family approach and obtaining
consent. Moreover, DA’s MRR has shown to be applicable in different countries
and environments and should be considered as a unique tool to measure and
compare countries’ donation performance.

755 LIVING LIVER DONATION: A QUESTION OF
CREDIBILITY
B. Ringe1, R. Strong2
1
Drexel University College of Medicine, 2University of Queensland
Living donor liver transplantation (LDLTx) is based on an act of altruism,
eventually turning a healthy volunteer into a patient. Informed consent is a
prerequisite for the candidate donor’s decision. Despite the fact that donor
safety is universally mentioned to be of prime importance, reliable data on
donor complications is not available – due to under-reporting, duplicate
reporting or false information. This is an update on living liver donor mortality,
to serve as an easy source of reference.
The authors reviewed the medical literature since 1989. To verify the accuracy
and source of information a certainty (C) level was assigned to each case: C1,
direct report by member representing the transplant program where the fatality
occurred; C2, indirect publication by author not involved in the care; and C3,
information based on verbal presentation or personal communication.
This update identified a total of thirty-three living liver donor deaths. Eight
fatalities each occurred in Europe and North America, five in South America,
ten in Asia, and two in Africa. Only 12 cases (36%) were classified as C1: donor
death directly reported by the transplant program involved. 64% of living liver
donor deaths mentioned or referred to in the transplant community were left
to speculation, including eight C2 and 13 C3 cases. Possible risk factors for
poor outcome are: preoperative medical conditions, psychosocial behavioural
abnormalities, right lobe donation, and postoperative surgical complications.
Based on an estimate of over 15,000 LDLTx performed worldwide, the
mortality rate is ranging from 0.08 to 0.22%.
Why is this information important? As long as LDLTx continues to play a
role for patients without access to deceased donor livers, i.e. in certain
geographic areas or with low MELD scores, it is unacceptable that the risk of
this procedure remains unclear. Short term, as well as long term outcomes of
all living donors need to be documented, including complications, abandoned
surgeries and mortality. As emphasized by the current and previous surveys,
the discrepancy between published and unpublished donor deaths has not
changed, and the dilemma of rumor versus facts prevails. All transplant
centers should be encouraged to report their own complications. It may appear
that the transplant community is not excited about these news, however, in
order to maintain informed consent and confidence in LDLTx it is imperative
that everyone knows the facts. If concerns for liability would be the reason
not to publish poor outcomes – how can we expect innovative techniques
in transplant surgery to be implemented in our clinical practice? This is a
question of credibility.
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756 SUSTAINED IMPACT OF THE DONOR ACTION
METHODOLOGY ON DONATION PRACTICES: A 7-YEAR
FOLLOW-UP IN 4 EUROPEAN COUNTRIES
L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
Donor Action Foundation, 2Eurotransplant International Foundation
Background: The Donor Action (DA) program offers Critical Care Units
(CCUs) all the necessary tools to optimize their donation processes, including
a standardized Medical Record Review (MRR) method and suggestions for
tailor-made improvement measures. This study aimed to measure the longterm impact of the implementation of the DA program in 4 European countries
(Finland, France, Poland, and Switzerland) where the program was piloted and
gradually implemented over a period of 7 years.
Methods: A total of 21,561 medical records from patients who had died between
Jan. 2000 and Dec. 2001 (n=2,782, pre-intervention phase) and between Jan.
2002 and Nov. 2006 (n=18,779, post-intervention phase) were collected from
81 hospitals (281 CCUs) and entered to the DA Database for analysis.
Results: 9,912 ventilated patients aged <81 years were reported to have no
absolute contraindications to donation on admission according to international
standard exclusion criteria. Although the% of patients with no contraindications
(theoretical potential) decreased from 51% in 2000-01 to 48.8% in 2006, the
identified/potential donor rate increased from 15.3% in 2000-01 to 31.7% in
2006 (+16.4%, P<.0001). Referral/identification rates increased from 88.5 to
97.3% (+8.8%). Whereas consent/family approach rates decreased from 77.9%
in 2000-01 to 66% in 2006, overall conversion rates of potential to actual donors
increased from 9.8% to 15.7% (+5.9%, P<.0001) because of significantly
improved identification and referral rates. The% of actual donors/total number
of deaths increased from 5.0% in 2000-01 to 7.6% in 2006 (+2.6%, P<.0001).
Conclusion: Whereas in the past the DA approach has proven to significantly
increase immediate post-intervention donation rates, the data presented
here demonstrates how this program’s sustained impact on donation rates is
the result of improved clinical practices within certain steps of the donation
pathway. Further efforts to increase consent rates will be needed to optimize
the conversion of potential to actual donors.

1

757 PAIRED AND ALTRUISTIC LIVING KIDNEY DONATION
IN THE UK: PAST, PRESENT AND FUTURE
R. Johnson1, C. Rudge1, J. Allen1, S. Fuggle1, A. Bradley2
1
UK Transplant, Bristol, UK, 2Dept of Surgery, University of Cambridge,
Cambridge, UK
Paired and altruistic living kidney donation became possible in the UK from
September 2006 following the introduction of a new legal framework for organ
and tissue donation. The regulatory authority for these types of transplant
resides with the Human Tissue Authority and national allocation schemes
have been established through UK Transplant which has responsibility for
overseeing matching and allocation arrangements.
Kidneys from altruistic, non-directed donors are allocated through the national
scheme for kidneys from donors after brain death (DBD) and since September
2006, 5 altruistic living donor transplants have been performed.
For paired donation, a new matching algorithm was developed. Initially, all
potential two-way exchanges are identified and possible exchanges are then
prioritised according to a points scoring system based on four factors: geographical
proximity between pairs (max 20 points), HLA sensitisation level of potential
recipient (max 50 points), HLA mismatch of potential transplant (max 15 points)
and, acting as a tie-breaker, donor-donor age difference (max 3 points).
The first pairs were registered in December 2006 and the first of a regular series
of three-monthly “matching runs” undertaken. The first two matching runs
were performed in April 2007 and July 2007, when 9 and 26 pairs respectively
had been registered. Each matching run identified one possible match between
two donor-recipient pairs. The four transplants proceeded successfully, with
kidneys, rather than donors, travelling between centres. A third matching run
in October 2007 identified no matches among 32 listed pairs, but in January
2008, three possible matches among 66 pairs were identified and two of the
exchanges are set to proceed.
The scheme has identified fewer matches than expected on the basis of
simulation studies that were undertaken when planning the scheme using
data on incompatible pairs identified in the UK in 2004-05. Unfortunately the
composition of the paired donation list has been less favourable than expected.
Of the 66 pairs listed in January 2008, 26 were ABO incompatible (ABOi),

33 were HLA incompatible (HLAi) and 7 were both HLAi and ABOi. Among
the ABOi pairs, there were 21 A donor, O recipient combinations, and no O
donor, A/AB HLA incompatible recipient pairs listed, thus making a match
impossible. Among HLAi pairs, the average level of recipient sensitisation
(calculated by comparing each patient’s unacceptable antigens with HLA types
of all blood group identical donors within a pool of 10,000 UK donors) was
very high at 82%, with 19 of the 40 pairs having a sensitisation level ≥95%.
In order to increase the transplant rate through paired donation in the UK, it
has been agreed that both 2 and 3-way exchanges will be considered in the
future. In addition, a protocol for domino paired donation is being developed
whereby altruistic non-directed donors will, where possible, donate to the
paired donation list to start a chain of additional transplants rather than donating
directly to recipients on the deceased donor transplant waiting list.

758 AMOUNT OF ANTIBODY, AS EXPRESSED BY
FLUORESCENCE INTENSITY, DOES NOT CORRELATE NOR
IS PREDICTIVE OF CROSSMATCH OUTCOME
R. Kerman, S. Katz, J. Lappin, E. McKissick, K. Hosek, N. Acorda,
B. Kahan, C. Van Buren
The University of Texas Medical School-Houston
UNOS has replaced panel reactive antibody (PRA) with a calculated PRA
(CPRA). The CPRA should result in a more standardized definition of patient
sensitization. Each transplant center can set criteria for indentifying and listing
unacceptable antigens either based upon the amount of antibody (Ab) measured
by the titer of donor specific HLA antibodies, DSA, or the fluorescence
intensity (FI) of the donor specific single antigen bead. It is unclear whether
Abs indentified by sensitive single antigen bead and solid phase assays (Flow
PRA and Luminex) correlate with and are predictive of a clinically relevant
end-point (a + FCXM).
We evaluated the PRA, DSA, bead specific Ag FI and FCXM reactivity of pretransplant (pre-Tx) sera from 219 recipients of a deceased donor renal allograft
to determine whether amount of Ab (measured by FI) predicts a (+) FCXM.
Patients with a (+) DSA, a (+) FCXM and pre-Tx class I PRA 80% (N = 103,
mean PRA of 91 6%) when compared to patients with pre-Tx PRA < 80% (N =
58, mean PRA 53 21%) had comparable mean FIs (7,407 4,305 vs 7,483 5,380),
FI ranges (1,000 20,243 vs 1,552 17,153) and median FIs (5,681 vs 5,670). The
class II comparisons were of the same pattern. Surprisingly, patients with a
(+) DSA, a (-) FCXM and pre-Tx class I PRA 80% (N = 22, mean 90 6%)
compared to patients with pre-Tx PRA < 80% (N = 36, mean PRA 50 18%) had
comparable mean FIs (6,758 4,841 vs 6,412 3,844), FI ranges (1,656 16,596
vs 2,162 11,637) and median FIs (5,924 vs 5,627). Again, the class II PRA
comparisons were of the same pattern. Of great interest is that the mean FI, FI
range and median FI of DSA (+)/FCXM (+) and DSA (+)/FCXM (-) are not
statistically different.
Because the mean FIs, FI ranges and median FIs of patients who are DSA (+)
and either FCXM (+) or (-) are not statistically different from each other the
amount of antibody (expressed as FI) can not be used to predict a (+) FCXM.
Other factors such as Ab avidity for the antigen epitope and consideration of
cross reactive Abs may contribute to predicting crossmatch outcome. Therefore,
since FI is not predictive of crossmatch results it should not be an acceptable
criteria for identifying clinically relevant donor specific HLA Abs or used for
listing unacceptable antigens as they relate to donor allocation schemes.

759 VOLUME-OUTCOME RELATIONSHIP IN THE
PROCUREMENT OF TRANSPLANTABLE ORGANS
J. Scalea MD1, J. Miller2, C. Alexander2, B. Philosophe MD1, R. Barth MD1,
S. Bartlett MD1, M. Cooper MD1
1
University of Maryland Medical Center Dept. of Surgery, Baltimore, MD
United States 2Living Legacy Foundation of Maryland, Baltimore, MD United
States
Background: Every year the numbers that die waiting for a transplant
continues to increase. Efforts at increasing the number of transplantable organs
have received international attention. Donor management protocols have been
developed and validated. An outcome advantage may exist if procurement
occurs at major transplant centers with staff dedicated to critical care ensuring
organ optimization and function.
Methods: Retrospective review of the transplant registry in a single OPO was
completed for a 12 month period. The cause of death (COD), conversion rate
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and number of organs transplanted per donor (OTPD) based upon referral center
was calculated. Two high-volume (HV), urban, academic transplant centers at
which the majority of donations occurred were compared to remaining centers
(LV). Student’s T-test was utilized to demonstrate significance.
Results: 120 donors yielded a total of 349 abdominal and thoracic organs.
Mean donor age was 41.2 yrs and 71.6% were male. COD was more likely
to be due to trauma at HV centers vs. LV (24 v 10), whereas CVA and CV
causes of death were more common at LV hospitals (20 v 10). Conversion rates
in HV centers v LV were 68% and 47% (p<0.001) The number of potential
donors that resulted in transplantable organs was higher (57/61) at HV centers
than at LV centers (53/61). Total number of organs transplanted from donors
at HV centers was also higher, 78.5% v. 65.4% at LV institutions. HV centers
yielded 3.40 OTPD compared to 2.41 at LV institutions (p=0.007). Eliminating
donors without transplantable organs from analysis, the OTPD was 3.64 for
HV centers and 2.84 for LV (p=0.02). Mean cold ischemia time (CIT) for livers
donated at HV centers was 6.25 hours (0.5-11.1) and 7.27 hours (4.9-11.9) at
LV centers (p=0.36). Mean CIT for kidneys was 13.82 at HV centers and 16.65
hours at LV institutions (p=0.13).
Conclusions: High volume transplant centers had an increased number of total
donors, an increased number of OTPD, and higher percentage of procured
organs that result in transplantation. Cold ischemia times are shorter for liver
and kidneys; however, these did not reach statistical significance. Intensive
care capabilities and the level of critical care training available in the donor
institution may be partially explanatory. The location of potential donor
management may impact upon donor numbers and organs from those donors
prompting consideration for transfer to HV centers.

760 INCREASING ORGAN DONATION FROM THE
EMERGENCY DEPARTMENT: A PRECIOUS RESOURCE
WASTED!
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P. Aubrey1,2, S. Arber2, J. Richardson1, S. Lister1, M. Tyler1, T. Tymkewycz1,
M. O’Brien1, R. Evans1
1
North Thames Donor Transplant Coordinators, 2Department of Sociology,
University of Surrey, Guildford
Background: The worldwide critical shortage of donor organs commands
that we do not have the margin to waste or ignore any department that has a
potential to supply organs for the purpose of transplantation. The majority of
organ donors are referred from the intensive care unit. This paper reports on
the findings of an audit of deaths undertaken in ten Emergency Departments
in North Thames Region. The audit itself was borne out of informal anecdotal
accounts from medical and nursing colleagues working in the Emergency
Department who suggested that there was a potential pool of organ donors
that were not being realised. The audit led to an educational programme for
Emergency Department staff
Method: Between October 2004 and December 2005 a retrospective audit of
deaths was undertaken within ten Emergency Departments. The audit findings
provided a basis to develop an education programme in each Emergency
Department within the region. This involved assessing the educational needs of
Emergency Department nursing and medical staff, and developing instructive
programmes aimed at helping key clinicians to identify potential donors.
Results: The Audit identified twenty potential organ donors from within
the ten departments. If these numbers were to be replicated over the thirty
one Emergency Departments, this would suggest as many as two potential
donors annually from each one. The educational programme for Emergency
Department staff resulted in a dramatic increase in the number of referrals from
North Thames Emergency Departments.
In 2003, there were 8 donor referrals, one donor and 3 solid organ transplants,
while in 2006 there were 24 donor referrals, 14 donors and 45 solid organ
transplants.
Summary: It is becoming increasingly clear that in order to address the current
shortage of organ donation, it is necessary to develop sound collaborative, multi
disciplinary educational developmental strategies in this area. Organ Donor
Transplant Coordinators play a fundamental role in ensuring all Emergency
Departments are delivered an efficient and effective organ donation education
programme.
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761 HEALTH STATUS AND RENAL FUNCTION EVALUATION
OF KIDNEY VENDERS: A REPORT FROM PAKISTAN
A. Naqvi, A. Rizvi, M.N. Zafar, E. Ahmed, B. Ali, K. Mehmood, B. Mubarak,
F. Mazhar
Sindh Institute of Urology And Transplantation
Introduction: Limited dialysis facilities and lack of cadaveric transplant
activity has lead to proliferation of unrelated commercial transplantation in
developing countries. Criteria for selecting unrelated donor may be less
stringent due to commercial interest. This may put donors at higher risk of
renal and cardiovascular disease. The main objective is to study health status
and renal function of kidney venders.
Patients and Methods
This study on 104 venders reports demographics, history, physical and
systemic examination, ultrasound findings, renal and liver function and GFR
by Cockcroft-gault. Results were compared with 184 age, sex and nephrectomy
duration matched living related donors controls.
Results: Comparison of venders vs controls showed mean age of 30.55±8.1
vs 30.65±7.85 (p=0.91) years, M:F of 4.5:1 vs 4.2:1 and nephrectomy period
of 33.89±30 vs 32.01±29.71 (p=0.60) months respectively. Of the venders
67% were bonded labourers earning <50$/month as compared to controls
where 68% were skilled labourers and self employed earning >100$/month.
History of venders revealed jaundice in 8%, stone disease in 2% and urinary
tract symptoms in 4.8%. Post nephrectomy findings between venders vs
donors showed BMI of 21.02±2.8 vs 23.02±4.2 (p=0.0001), hypertension in
17% vs 9.2% (p=0.04), serum creatinine (mg/dl) of 1.17±0.21 vs 1.02±0.27
(p=0.0001), GFR (ml/min) of 70.94±14.2 vs 95.4±20.44 (p=0.0001), urine
Protein/Creatinine of 0.150±0.109 vs 0.10±0.10 (p=0.0001), hepatitis C
positivity in 27% vs 1.0% (p=0.0001) and Hepatitis B positive 5.7% vs 0.5%
(p=0.04) respectively.
Conclusion: In conclusion, venders had compromised renal function suggesting
inferior selection and high risk for developing chronic kidney disease in long
term.

762 OUTCOMES OF PATIENTS SEEKING COMMERCIAL
RENAL ALLOGRAFT TRANSPLANTATION OUTSIDE OF
AUSTRALIA
L. Garry, J. Mawson, S. Chadban, C. George, R. Allen, J. Eris, D. Verran
Renal Transplant Programme
Introduction: Organ trafficking continues to be an issue for the transplant
community. Here we report on our experience with patients from within our
transplant service area who sought transplantation overseas.
Methods: Record review of 11 patients with end stage renal failure who have
sought commercial renal transplantation from 1/2001-2/2008.
Results: Demographics of the 11 patients were 9 male, 2 female with a median
age of 49(28-71) years. Causes of end stage renal failure were predominantly
glomuerulonephritis (7/11). To date 10 have been transplanted and one
was presumably transplanted but did not return from overseas (presumed
deceased). Countries where the renal allografts were purchased are- China 6,
Phillipines 3, Pakistan 1. Source of the donor was presumed deceased donor in
6 and live donor in 5. Information on donor demographics and peritransplant
course were unavailable or limited in most cases. Outcomes to date include
patient mortality-3/11(27%) from sepsis 1(pneumocystis pneumonia),
tumour 1(glomus tumour), unknown 1, and allograft loss in 1. Post transplant
complications requiring management on return of patients to Australia includedsepsis in 5 recipients (1 nocardia & cytomegalovirus, 1 cytomegalovirus, 1
cytomegalovirus & pneumocytis, 1 BK nephropathy, 1 aquisition of Hepatitis
B), major ureteric stricture requiring surgery 1, angioplasty transplant renal
artery 1. One patient has been followed for a kink of the transplant renal artery
[stable on serial imaging].
Conclusions: A small but steady number of patients, continue to seek and
purchase renal allografts outside of Australia against advice. This activity is
associated with a heightened morbidity and mortality rate for the recipient,
which physicians involved in the subsequent management of such patients
need to be aware of. The cessation of such activity would not only protect
donors but may be of benefit to recipients.
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CONCURRENT ORAL SESSION 59:
ISLET TRANSPLANTATION – ALTERNATIVE STRATEGIES
763 EFFECT OF NF-FÈB INHIBITON BY DHMEQ ON ISLET
TRANPLANTATION IN MICE
M. Watanabe1, K. Yamashita1, S. Matsumoto1, Y. Tsuruga1, T. Takahashi1, T.
Oura1, M. Ozaki1, K. Umezawa2, M. Matsushita1, S. Todo1
1
First Department of Surgery, Hokkaido University, Sapporo, Japan,
2
Department of Applied Chemistry, Keio University, Yokohama, Japan
Background: The transcription factor, nuclear factor (NF)-κB has been shown
to be involved in immediate islet graft loss by both non-immune-mediated
inflammatory and allo-immune responses. In order to attain a successful longterm engraftment, control of these responses is essential.
Aim: We examined the effect of a newly developed NF-κB inhibitor,
dehydroxymethylepoxyquinomicin (DHMEQ) in mice islet transplantation
(ITx).
Methods: Pancreatic islets of C57BL/6J (H-2b: syngeneic) or BALB/c (H-2d:
allogeneic) mice were isolated, purified and handpicked (1 IEQ=150 μm).
C57BL/6J recipient mice were rendered diabetic by streptozotocin (180 mg/
kg, i.p.). In the allogeneic ITx, either 600 or 300 islets were transplanted via
portal vein. Syngeneic 175 islets were transplanted as a marginal ITx model.
DHMEQ at a dose of 20 mg/kg was given i.p. once or twice daily for 14 days
after transplantation. Blood glucose levels (BGL) were monitored. Rejection
was considered when BGL exceeded 350 mg/dl for 2 consecutive time points.
Normoglycemia was defined when BGL became less than 200 mg/dl for 2
consecutive days.
Results: In the 600 islet allogeneic transplantation model, vehicle treated
control mice rejected allografts at a median survival time (MST) of 11
days (Fig. 1A). In contrast, daily and twice daily treatment with DHMEQ
significantly prolonged graft MST to 21 and >30 days (still surviving),
respectively (p<0.001 versus Control). Such effect was associated with
suppression of donor-antigen IFN-γ producing splenocytes and graft cellular
infiltration as examined on POD 9.
We then examined the effect of NF-κB inhibition on allogeneic ITx with reduced
istlet graft numbers. In the ITx model with 300 allogeneic islets, control grafts
did not survive at all, and the normoglycemic rate (NGR) was 0% (n=6). On
the other hand, once daily treatment with DHMEQ allowed a successful islet
engraftment (NGR: 100%) in all animals (n=6), and significantly prolonged
allograft MST to13 days (P<0.05).
In the syngeneic marginal ITx model, the NGR after transplantation 14.3% in
the control animals (Fig. 1B), whereas that of DHMEQ treated (once daily)
mice was significantly attenuated to 80% (n=6; p<0.01). Animals treated with
DHMEQ showed normal response, while control animals exhibited higher
BGL to the intraperitoneal glucose tolerance test which was performed at 14
days post-ITx.

Fig. 1A
Fig. 1B
Conclusion: A novel NF-κB inhibitor, DHMEQ prevented immediate islet graft
loss and prolonged islet allograft survival. With having both anti-inflammatory
and immunosuppressive properties, inhibition of NF-κB activation by DHMEQ
may become a new modality in ITx.

764 PPAR GAMMA MEDIATES THE PROTECTIVE EFFECTS
OF CARBON MONOXIDE IN ISLET TRANSPLANTATION
F. Rocuts, X. Zhang, F. Bach, H. Wang
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard
Medical School
Purpose: Exposing donor mice to carbon monoxide (CO) protects transplanted
islets from allogeneic immune rejection. We evaluated whether CO exerts its
protective effects by activating peroxisome proliferator-activated receptor
gamma (PPARg) in islets.
Methods: BABL/c islets were transplanted into C57BL/6 recipients rendered
diabetic by strepotozotocin injection (225mg/kg, i.p.). PPARg activation was
induced in islets by intravenously injecting the donor mice with two different
kinds of PPARg agonists, 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2, 0.3mg/
kg) and troglitazone (2mg/kg), respectively, 1 hour before islet isolation.
PPARg antagonist, 2-Chloro-5-nitro-N-phenylbenzamide (GW9662, 1mg/kg),
was used to block the activation of PPARg. Control animals received vehicle
only (2% DMSO). PPARg expression was detected by Western blot using
an anti-PPARg antibody. Cell apoptosis was quantified by flow cytometry.
Expressions of TNF-a and inducible nitric oxide synthase (iNOS) at mRNA
level were analyzed by real-time RT-PCR.
Results: Administering CO to the donor induced expression of PPARg, which
was observed rapidly after harvest and purification of the islets. Pre-exposure
an insulinoma cell line, bTC3 cells, to CO protected those cells from cytokines
(IL-1b plus INF-g)-induced apoptosis. Suppressing PPARg activation using
GW9662 abrogated the anti-apoptotic effect of CO by boosting expressions
of TNF-a and iNOS. Islets from vehicle-treated donors were rejected in 17.8 ±
4.4 days (n=5). Blocking PPARg activation in islets with GW9662 led to graft
rejection at 18.2 ± 3.5 days (n=3). In contrast, inducing PPARg activation with
15d-PGJ2 led to 3 of 4 (75%) grafts surviving >273 days in the recipients, the
other graft was rejected at 19 days. Similarly, administering troglitazone to islet
donors led to 50% of islet allograft (n=4) surviving long-term (>199 days) in
recipient mice.
Conclusion: Our results indicate that PPARg activation in the donor protects
islet allografts from immune rejection after transplantation. CO exerts its
protective effects at least in part by up-regulating PPARg.

765 A SIGNIFICANT CORRELATION OF DONOR PANCREAS
GENE EXPRESSION MORPHOLOGY WITH AND ISLET
FUNCTION
O. Sabek1, L. Truong2, L. Peterson3, D. Fraga1, A. Gaber1
Weill Medical College of Cornell, Deparatment of Surgery, The Methodist
Hospital, Houston, TX, 2Department of Pathology,The Methodist Hospital,
Houston, TX, 3Department of Public Health,The Methodist Hospital, Houston,
TX
Background: Enlarging the donor pool is severely limited, mainly because of
the poor function and high incidence of primary non-function of islets from
less than ideal donors. This study is aimed at identifying the morphological,
histopathological and the gene expression characteristics of the donor pancreas
as predictor for the outcome of human islet in- vivo function.
Methods: Islets were isolated from 39 human donor pancreata, and islet yield
was reported as islet equivalent per gram pancreatic tissue. In-vivo function of
islets from 39 isolations were further tested by transplantation into NOD-SCID
mice following short-term culture (<6 days). Biopsies from the 39 human
pancreata were obtained from the head section. Paraffin embedded sections
were evaluated after staining with H E, Trichome, Congo, and PAS. Correlation
between in vivo function (y/n) and BMI and positive histology (adipose tissue,
islet hypertrophy or hyperplasia) was done using Somers D tests for N=39
Pancreata. We also examined the gene expression of 5 of the pancreata using
high-density Affymetrix U133A Gene Chips® and Genespring software.
Results: Morphological characteristics such as the content of acinar and
interstitial adipose cells, islet hyperplasia, and islet hypertrophy per defined
area were found to have a significant reduction in in-vivo function (p= 0.003),
whereas BMI was not significant (p=0.44). Furthermore, in these isolation
Long cold ischemia was the only donor characteristic that correlated with a
significant reduction of in vivo function (Z=-1.95, p=0.011). Gene analysis of
Pancreata that yield non-function islets (3 out of 5) showed high relative levels
of expression of pro-inflammatory genes such as interleukin-1, toll-like receptor
4, T-cell activation NFKB-like protein1, as well as genes that is associated with
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insulin resistance such as SOCS-1 and 6 and nuclear factor of activated T-cells,
cytoplasmic (NFAT), calcineurin-dependent 1 and 2.
Conclusion: Morphological and Gene expression study of donor pancreata
can be very instrumental in predicting in vivo function in optimal and nonoptimal donor selection. The over-expression of pro-inflammatory and insulin
resistance related genes may results in reduced insulin secretion and lead to
islet destruction post-transplantation. Identifying and validating those genes
could allow the development of a potency assay for human transplantation
that would be very useful for screening human Pancreata before islet isolation
and clinical transplant and the possibilities of devising strategies for early
intervention to reverse the adverse effect of inflammation and ischemia on
the islet.

766 THE IMPORTANCE OF TRYPTIC-LIKE ACTIVITIES FOR
HUMAN ISLET ISOLATION

THURSDAY

D. Brandhorst, H. Brandhorst, O. Korsgren
Uppsala University Hospital – Department of Clinical Immunology
Objective: The insufficient characterization of the enzymes and the low
standardization of the enzymatic pancreas dissociation is exemplarily
illustrated by the difficulties that are associated with actual efforts to replace
Liberase HI by Serva collagenase NB1. Although Liberase HI seems to differ
from collagenase NB1 only with regard to thermolysin, that is replaced in
collagenase NB1 by neutral protease (NP), this seemingly minor change in the
protocol has caused major problems worldwide in terms of isolation outcome
and number of islet transplants performed worldwide. We hypothesize that
beside collagenase and NP/thermolysin a third enzyme may be required for
optimized islet release. The main objective of the present study was therefore
to characterize the importance of neutral protease, thermolysin and tryptic-like
activities for successful human islet isolation.
Materials and Methods: Crude collagenase was chromatographically purified
to obtain a blend consisting of Serva collagenase NB1 and different amounts
of tryptic-like activities. Tryptic-like activities (BAEE-U) were expressed as
the percentage of administrated collagenase activities (PZ-U). To evaluate
the effect of proteolytic activities, Blendzyme (Roche) was supplemented
with appropriate amounts of NP or thermolysin adjusted according to pilot
experiments. Rat and human research grade pancreata were processed with
current standard procedures.
Results: No significant differences were observed between the supplementation
of Blendzyme by NP or thermolysin regarding digestion time (25.5 ± 1.9 vs
28.5 ± 2.3 min), percentage of undigested tissue (15 ± 1 vs 22 ± 7%), purity
(53 ± 4 vs 55 ± 10%), islet equivalent number (IE) per gram (3660 ± 500
vs 2750 ± 1220 IE/g) and stimulation index (SI) (6.2 ± 0.1 vs 7.3 ± 0.8).
Tryptic-like activities for the digestion of human pancreata were adjusted
to 3 and 10% relative activity (BAEE-U/20 PZ-U/g) after performing pilot
experiments in rats suggesting that enhanced tryptic-like activities resulted
in an enormous acceleration of islet release from exocrine tissue without
affecting significantly rat islet yield, viability and posttransplant function in
diabetic nude mice.
Digestion time of human pancreata was significantly reduced by 25%
increasing relative tryptic-like activities from 3 to 10% (25 ± 0.8 vs 20 ± 1.5
min, p<0.01). The amount of embedded islets was reduced from 17 ± 4 to 11 ±
3% (NS) whereas islet yield (3840 ± 440 vs 4930 ± 290 IE/g, NS) and recovery
after purification (65 ± 6 vs 86 ± 5%, p<0.05) was enhanced. The percentage
of undigested tissue as well as islet purity were not influenced by increased
tryptic-like activities. Quality assessment of human islets revealed no reduction
of viability (99.9 ± 0.1 vs 95.3 ± 3.6%) or stimulation index (3.3 ± 0.6 vs 4.1
± 0.8).
Conclusions: Our preliminary experiments in human and rat pancreata
indicate that the presence of tryptic-like activities accelerates islet release
from acinar tissue reducing islet exposure to the harmful environment present
during pancreas digestion. Moreover, tryptic-like activities help to reduced the
detrimental effect of increased NP activity.
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EFFECT OF TRANSPORTATION ON HUMAN ISLETS

E. Jimenez-Vera1, L. Mariana2, L. Willia1, T. Kay3, P.T. Coates3,
P.J O’Connell1, T. Loudovaris2, W.J Hawthorne1
1
The Centre For Transplant And Renal Research, Westmead Millennium
Institute, 2St Vincent’s Institute, 41Victoria Pde, Fitzroy, 3065, Victoria, 3South
Australian
Introduction: Islet transplantation is a promising treatment for type 1 diabetes.
The limited availability of cadaveric human donor pancreata and the need to
concentrate expertise limits islet isolation to a few dedicated isolation centres.
In Australia this means that transportation of islets between institutions over
large distances is essential to provide a nation wide service. The aim of this
study was to assess the effects of transport on human islets between interstate
centres. A number of factors including quantity and quality of the islets prior to
and following transport were analysed.
Methods: Human islets were isolated using a modified Ricordi technique using
collagenase digestion and ficoll purification. Following culture, islets were
transported to the receiving centre by air and road, up to 48 hours post isolation.
The islets were sent at ambient temperature or slightly chilled with refrigerated
gel packs in 50-ml conical tubes and placed in a Styrofoam shipping box and
were received within 12 hours of being packed. Quality assessments were
performed at each centre at approximately the same time. The total number
(IEQs) and purity were determined, and flow cytometry was performed to
establish viability and the percentage of B cells in each shipped preparation.
Results: There was a significant exponential decay mean decrease 32.38% in
the number of IEQs after transportation. There was also a 68.86% increase in
the total number of dead cells which correlated with the decrease in the total
cell number. However, there was a 37.49% increase in the number of viable
B Cells with no significant difference in the number of B cells sent. This was
also reflected in the viability index remaining the same despite the loss of total
cell number.
Conclusion: Transportation of human islets to different sites in Australia
results in a decrease in the number of IEQs and viability. Factors responsible
include loss due to shipment time or conditions or injury sustained from organ
ischaemic time and the islet isolation process. Further studies to investigate the
numbers of variables that can lead to cell loss from transporting human islets
need to be assessed.

768 PREVENTION OF ISLET ALLOGARFTS BY COTRANSPLANTED HEPATIC STELLATE CELLS IS MEDIATED
BY TREG CELL LOCAL EXPANSION
H-R. Yang1, G. Jiang2, L. Wang1, J. Fung1, L. Lu1,2, S. Qian1,2
Department of General Surgery, Cleveland Clinic, 2Department of
Immuology, Lerner Research Institute, Cleveland Clinic
Transplantation of solid organs has successfully practiced in clinic for
decades, but the outcome of cell transplantation remains disappointing.
This is the case in experimental models. Thus, liver transplants in mice are
spontaneously accepted without the requirement of immunosuppression,
but hepatocyte grafts in the same combination are acutely rejection. These
observations suggest that non-parenchymal components may play a crucial
role in attenuation of anti-graft immune response. We have demonstrated a
profound T cell inhibitory activity of hepatic stellate cells (HpSC) in vitro,
as well as in vivo. Thus, co-transplant with HpSC effectively protects islet
allografts from rejection. To investigate the involved mechanisms, BALB/c
islets (300) mixed with 3 x 105 activated HpSC (B6) were transplanted into
STZ-induced diabetic B6 recipients. T cells were isolated from grafts and
lymphoid organs. On POD 8, a reduction of graft infiltrating CD4+ (30.7%)
and CD8+ T cells (31.3%) was seen in HpSC co-transplants, as compared
to islet alone. CD8+ T cells dropped &#61566;7 fold on POD 140, while,
CD4+/CD8+ ratio was increased from 0.5 on POD 8 to 2.0 on POD 140.
As to CD4+ T cells, co-transplant of HpSC was associated with a marked
expansion of Foxp3+ cell populations predominantly in grafts (41.2% vs.
25% in islet alone) and draining lymph nodes (LN) (35.1% vs. 15.4%),
compared to that in spleen (32.3% vs. 25.6%) and peripheral LN (27.1%
vs. 15.6%). The in creased incidence of Foxp3+ cells was seen on POD 12,
but returned to control levels in long-survival animals. Interestingly, about
40-50% of these Foxp3+ cells were CD25-. These results suggest that cotransplanted HpSC foster markedly expansion of Treg cells in grafts and
draining LN. To examine this in vitro, activated HpSC were cultured with
allogeneic CD4+ T cells at 1:10 ratio for 5 days, which elicited generation of
1
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CD4+CD25+FoxP3+ cells (13% vs. 5.5% in controls), with very few CD25Foxp3+ cells, which was different from what was seen in vivo. Addition
of HpSC expanded CD4+CD25+ cells into the culture of syngeneic CD4+
cells plus anti-CD3, resulted in marked inhibition of T cell proliferation in
a dose dependent manner. A similar effect was seen in an allogeneic MLR
culture. These FoxP3+ Tregs were expanded from na&iuml;ve CD4+CD25+
population in an IL-2 dependent manner, since depletion of CD4+CD25+
before co-culture only small potion of CD4+CD25+ T cells were generated,
and all of these cells are Foxp3-. This was confirmed by using purified
CD4+CD25+ T cells from Thy1.1+ congenic mice. In conclusion, cotransplant with HpSC can effectively protect islet allografts from rejection,
which could be mediated by expansion of CD4+CD25+FoxP3+ Treg cells in
the grafts and draining LN.

769 REAL-TIME COMPREHENSIVE HUMAN ISLET
ASSESSMENT IN VITRO USING FLUORESCENCE IMAGING
AND MICROFLUIDIC PERIFUSION SYSTEM
Y. Wang, J. Mohammed, T. Harvat, M. Qi, S. Wang, M. Enza, E. David,
J. Oberholzer
University of Ilinois At Chicago
Introduction and hypothesis: The Edmonton Protocol introduced in 2000
provided an increased interest in human islet transplantation as a new
promising treatment for Type I diabetes. Evaluation of islet quality pretransplantation is essential to ensure successful transplantation. However,
it has been difficult to predict islet in vivo outcomes based on the current
in vitro assays. In vivo evaluation using nude mice transplantation has only
retrospective value. Lacking reliable in vitro assays is one of main factors
for variable success rate. We hypothesize that simultaneously quantifying
mitochondrial integrity, dynamic insulin secretion, oxygen consumption,
and calcium influx during in vitro glucose stimulation will provide a
comprehensive analysis with a meaningful predictive value superior to
the individual assays. Our objective was to engineer a microfluidic device
to combine dynamic insulin secretion and fluorescence image for islet
functionality and viability that would allow for an accurate real-time analysis
prior to transplantation.
Approach: Three-layer of Polydimethylsiloxane (PDMS)-type microfluidic
devices with single or multiple-chamber were designed and fabricated for
simultaneous measurement of dynamic insulin secretion with digitized
fluorescence microfluorometry for measuring calcium signaling and
mitochondrial potentials.
Results: (1) In mice islet study, the device can be used for accurate detection
of biphasic calcium signal and insulin secretion simultaneously without flow
disturbance and has capability to image multiple-islets, unlike other designs
in which only a single islet can be observed; When measuring mitochondrial
potential, our results illustrate a physiological decrease in mitochondrial
potential preceding the actual insulin secretion. (2) 8 human islet preparations
have been assessed using the device and the in vivo results from nude mice
were used as the benchmark for the human islet potency. Our preliminary
results indicate that the multi-functional assessment can be used for
assessment of human islet functionality and predict in vivo outcomes. Highpotency islet preps that reversed diabetes in nude mice had better glucosestimulated calcium flux and insulin secretion, as well showed a normal
glucose dose dependant insulin secretion pattern, which was not observed in
the low-potency preps which failed to reverse diabetes. Interestingly, there
were no significant difference in insulin secretion as measured in standard
static glucose incubations between high-potency and low-potency group (SI
of high-potency group=2.07+/-0.78, SI of low-potency group=2.58+/-1.45;
P=0.532).
Conclusion: It is essential to develop a defined, accurate, real-time assessment
of beta-cell function based on beta-cell biochemical and metabolic signals that
can be used as a solid indicator of functional islet preparations for transplantation.
This microfluidic device allows us to assess islet function and integrates insulin
secretion with calcium influx and mitochondrial potential. We feel multiplexing
previously encouraging results into an all-in-one islet characterization device
will provide a complete and thorough analysis of islet function in an easy to use
format that can be adopted by many islet transplantation facilities and solve this
current clinical dilemma.

770 TREATMENT WITH EXENATIDE REDUCES CASPASE-3
ACTIVATION AND APOPTOSIS AND ENHANCES BETA CELL
SURVIVAL IN ISOLATED HUMAN ISLETS DURING CULTURE.
Z. Ao1, M. Meloche, E. Law, L. Dai, Z. He, D. Thompson3, G. Warnock, L.
Marzban2
1
Department of Surgery, University of British Columbia, Canada, 2Division
of Pharmacology, Faculty of Pharmaceutical Sci, University of British
Columbia, Canada, 3Department of Medicine, University of British Columbia,
Canada
Clinical islet transplantation is a promising approach for treatment of type 1
diabetes but is currently limited by loss of islets during both pre-transplant
culture period and following transplantation. Exenatide is a long acting
analogue of glucagon-like peptide-1 that has been shown to stimulate insulin
secretion and enhance beta-cell mass but the underlying mechanisms are not
fully understood. Exenatide has recently been approved as an anti-diabetic
drug for treatment of patients with type 2 diabetes and may also enhance betacell mass/function in islet grafts. In the present study, we sought to determine
whether exenatide treatment could reduce loss of beta-cells and improve
survival of human islets during pre-transplant culture period as a potential
approach to increase the yield of islets isolated from pancreatic donors. Freshly
isolated human islets from cadaveric donors were cultured in CMRL (5 mM
glucose, 10% fetal bovine serum, 37C) at different time points (1, 3, 5, or 7
days) in the presence or absence of exenatide (1 nM). At each time point, islets
were fixed in 4% paraformaldehyde and paraffin-embedded islet sections were
used for immunohistochemistry studies. Also, some islets were frozen and islet
lysates were used for measurement of cleaved caspase-3 by enzyme-linked
immunosurbent assay (ELISA). As expected, culture of human islets resulted in
loss of islet beta-cells in a time-dependent manner leading to a decrease in the
islet beta/alpha cell ratio during culture period (d0: 1.8 ± 0.3 vs. d7: 1.3 ± 0.2,
P<0.05) and an increase in the proportion of apoptotic (TUNEL-positive) islet
cells (d0: 3.4 ± 1.2% vs d7: 12.1 ± 2.4%, P<0.05). Treatment with exenatide
for 3, 5, or 7 days resulted in an increase in the islet beta/alpha cell ratio (+Ex:
1.6 ± 0.2%, P<0.05), intensity of insulin immunostaining and a decrease in the
proportion of TUNEL-positive islet cells (+Ex: 7.5 ± 1.5%, P<0.05). Double
insulin/TUNEL staining revealed that the majority of TUNEL-positive cells
were beta cells. This decrease in the number of TUNEL-positive beta cells in
exenatide-treated islets was associated with a marked decrease in the activation
of caspase-3 (34%) as assessed by ELISA performed on islet lysates as well
as double immunostaining for insulin and cleaved caspase-3. These findings
suggest that short-term treatment with exenatide reduces beta-cell apoptosis
in isolated human islets and decreases caspase-3 activation by a direct and/or
indirect mechanism leading to an increase in the yield of islet beta cells during
pre-transplant culture period.2690

771 FACTORS THAT INFLUENCE SUCCESSFUL CLINICAL
ISLET ISOLATION WHEN USING A GMP COLLAGENASE AND
NEUTRAL PROTEASE.
A. Posselt1, G. Szot, M. Lee1, J. Lang1, P. Koudria1, J. Bluestone1, P. Stock2
1
Diabetes Center and 2Department of Surgery, University of California San
Francisco, San Francisco, California, United States.
Background: In February 2007, the islet community was notified of a possible
bovine product contamination in the collagenase enzyme (Liberase HI) used
for human islet isolations. To eliminate this potential hazard, we successfully
adapted our human islet processing procedure to utilize a GMP Collagenase
NB1 and Neutral Protease NB (Nordmark/Serva). Here we describe what we
consider the most important factors for achieving reproducible and clinically
useable islet isolations.
Methods/Results: A standard isolation protocol involving controlled enzymatic
digestion followed by density gradient purification was used. Islets were
maintained in culture for 24-48h prior to transplantation. Eight of 10 (80%) of
isolations using the Nordmark/Serva Enzyme [table 1] were used for clinical
transplantation. In contrast, only 9 of 18 (50%) isolations using the Liberase HI
enzyme were adequate for clinical transplantation. The following factors were
identified as being important for ensuring a successful islet yield: 1) Donor
Age and Size: male donors 17-45 years of age who were tall (>180cm) and
heavy (>100kg), rather than all patients with high BMIs were preferred. 2)
Cold Ischemia Time, Transport and Preparation: Cold ischemia time was kept
at <9hrs; organs were maintained in UW solution during transport and were
trimmed immediately upon receipt by an experienced surgeon. 3) Enzyme
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perfusion: Pancreata were perfused with cold enzyme solution (6-10oC)
containing 11mM CaCl2 for 10-12 minutes while increasing pressure (80 psi
for 4 min., then 180 psi for 6-8 min). 4) Digestion/Dilution: DNAse (2.5 cc,
Pulmozyme) was added to a 600 mL Ricordi chamber and digestion was carried
out at 37oC. The digestate was diluted into RPMI containing 5.0% HSA at 4oC
while keeping the chamber temperature at 30oC for the entire dilution. Digest
was immediately centrifuged and pooled into dilution solution with 0.625%
HSA at 4oC.
Conclusions: Minor modifications to our islet isolation protocol have
demonstrated this GMP enzyme is as functional and viable as a related product
and can yield clinically useful isolations with greater efficacy.
Table 1. Islet Isolation Summary
Glucose Stimulation
Index

Transplanted IEQ

% Viability

Average

514,510

98.05%

3.20

Std. Dev.

140,606

0.02

2.54

Average

508,883

99.63%

4.04

Std. Dev.

115,815

0.00

5.20

Nordmark/Serva (n=8)

Roche Liberase HI (n=9)

CONCURRENT ORAL SESSION 60:
MECHANICAL CIRCULATORY SUPPORT
772 WEANING FROM LEFT VENTRICULAR ASSIST
DEVICES IN PATIENTS WITH IDIOPATHIC DILATED
CARDIOMYOPATHY: LONG-TERM RESULTS AND
PREDICTABILITY OF OUTCOME AFTER WEANING

THURSDAY

M. Dandel, Y. Weng, H. Siniawski, M. Pasic, E. Potapov, C. Knosalla,
H. Lehmkuhl, R. Hetzer
Deutsches Herzzentrum Berlin
Background: During mechanical unloading, clinical recovery which allows
reliable weaning from VADs is possible. After 13 years of weaning experience,
we evaluated the outcome of our weaned patients and searched for parameters
that are predictive for post-weaning cardiac stability and thus helpful for future
weaning decisions.
Methods: Among 82 patients weaned since 3/1995, a homogenous group of 35
patients with idiopathic dilated cardiomyopathy (IDCM) weaned from LVADs
were selected for evaluation. With regard to potential prediction of weaning
success we evaluated echocardiographic parameters obtained during final
¡°off pump¡± trials before VAD explantation, histological changes, duration of
mechanical support and duration of HF.
Results: The 8-year and 10-year post-weaning survival reached 78.1¡À8.2%
and 70.7¡À9.2%. Freedom from HF recurrence at 4 and 5 years after weaning
was 69.3 ¡À8.1% and 61.3¡À9.0%, respectively. Patients with post-weaning
cardiac stability were younger, history of HF and recovery time during
unloading shorter, LV short/long axis ratio lower (less spherical) and systolic
wall motion velocity higher (p< 0.05). For LVEF ¡Ý 45% at LV enddiastolic
diameter (LVEDD) ¡Ü 55mm the positive predictive value for ¡Ý 5 years
cardiac stability reached 87.5%. There was no HF recurrence during the first
4 years in patients with LVEF ¡Ý 45%, LVEDD ¡Ü 55% and history of HF
< 5 years. The time course of LVEF during the first 6 months also appeared
predictive for long-term stability after weaning. History of HF > 5 years
showed a predictive value of 90% for HF recurrence during the first 3 years.
Reduction in myocardial hypertrophy and fibrosis during unloading appeared
not predictive for post-weaning stability.
Conclusions: Off-pump LVEF and LVEDD, time course of LVEF during the
first 6 months after weaning and duration of HF are predictive for the outcome
after LVAD removal in IDCM patients. Patients¡¯ age, altered LV geometry,
low wall motion velocity and prolonged LVAD support until improvement (> 6
months) appeared to be risk factors for HF recurrence.
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773 ECHOCARDIOGRAPHIC PREDICTION OF SHORTTERM OUTCOME IN PATIENTS WITH IDIOPATHIC DILATED
CARDIOMYOPATHY REFERRED FOR TRANSPLANTATION
M. Dandel, R. Jasaityte, H. Lehmkuhl, R. Hetzer
Deutsches Herzzentrum Berlin
Objective: In the light of continuous prolongation of the waiting time on heart
transplantation (HTx) lists, the need for reliable predictors for the time course
of heart failure (HF) has become increasingly important.
To optimize HTx-listing decisions, we evaluated the prognostic value of
echocardiography including 2D strain imaging in patients with end-stage
idiopathic dilated cardiomyopathy (IDCM)
Methods: The study population comprised 32 consecutive stable IDCM patients
referred for HTx. At the baseline all underwent echocardiography including
radial, circumferential and longitudinal strain and strain-rate measurements.
Strain data were also used for quantification of systolic intraventricular
dyssynchrony. Echocardiographic parameters were tested for their value in
predicting the time course of HF during the following 6 months.
Results: During the first 6 months after inclusion in the study, 18 patients
(56.3%) remained stable; the other 14 showed severe cardiac deterioration
and finally underwent ventricular assist device implantation, although initially
there were no differences in left ventricular (LV) size or ejection fraction
(LVEF 20±7% vs. 22±3%) and also no significant differences in peak oxygen
consumption (VO2max) or NT-proBNP. However, at the baseline, patients who
remained stable had less altered diastolic function in comparison to those with
rapid HF progression: transmitral E/A-wave ratio 1.3±1 vs. 2.8±1,3 (p<0.001),
E-wave deceleration time (DT) 139±34.5ms vs. 102±17ms (p<0.05), strain rate
(SR) Am-wave 0.42±0.13/s vs. 0.22±0.11/s (p<0.001), SR Em/Am-ratio 1.4±0.8
vs. 3.1±2.7 (p<0.05) and also the systolic circumferential and longitudinal
dyssynchrony indexes were lower (p<0.05) in the group of unstable patients
(016±0.05 vs. 0.21±0.05 and 0.21±0.07 vs. 0.32±0.15, respectively). At certain
cut-off values, the transmitral E/A-wave ratio as well as the 2D-strain derived
circumferential dyssynchony index and the early diastolic strain rate (Em)
showed high predictive values (80%-92%) for cardiac stability over the next
6 months. Highest predictive values for rapid HF progression were found for
transmitral E-wave DT <100 ms and Em >0.3/s (80 and 84%, respectively).
Conclusions: In IDCM patients with similar LVEF (<30%), further cardiac
stability appeared related to the severity of alterations in LV systolic synchrony
and diastolic function. The high predictive values of transmitral flow and
2D-strain parameters for the short-term (<6 month) course of HF recommend
echocardiography as a valuable tool for guidance of HTx-listing decisions.

774 CONTINUOUS-FLOW VERSUS PULSATILE-FLOW
LVADS USED AS A BRIDGE-TO-TRANSPLANTATION
A. Watson1,2, P. Jansz2, E. Granger2, A. Farnsworth2, C. Axisa2, E. Kotlyar2, A.
Keogh1,2, C. Haryward2, P. Macdonald1,2, P. Spratt2
1
Transplant Program, Victor Chang Cardiac Research Institute, 2Heart &
Lung Transplant Unit, St Vincent’s Hospital
Introduction: Left ventricular assist devices (LVAD) are used most commonly
to ‘bridge’ patients with intractable heart failure to heart transplantation.
The aim of this study was to compare the survival of patients bridged with
continuous-flow LVAD to those supported with a pulsatile LVAD.
Results: Between March 1994 and February 2008, 44 patients awaiting heart
transplantation at our institution have required LVAD support for refractory
heart failure (n= 34), acute cardiogenic shock post AMI (n = 4) or postcardiotomy (n = 6). 23 patients received a continuous-flow VAD (Group 1:
17 Ventrassist, 6 Heartware) and 21 received a pulsatile VAD (Group 2: all
Heartmate).
The 2 groups did not differ significantly with regard to age, gender, cardiac
diagnosis or indication for support. Average duration of support was 262 +
50 days in Group 1 versus 162 + 27 days in Group 2 (p <0.05). 7 patients
died during LVAD support: 3 in Group 1 and 4 in Group 2. Causes of death
were multi-organ failure (3), stroke (2), infection (1) and pump malfunction
(1). Transplant-free survival at 1, 3 and 6 months was 96 + 4%, 91 + 6% and 91
+ 6% for Group 1 versus 91 + 6%, 91+6% and 80 + 11% in Group 2 (p = NS).
Post-transplant survival was excellent in both groups.
Conclusions: Continuous-flow LVADs provide excellent support when used as
a bridge-to-transplantation, with survival at least equivalent to older generation
devices.
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775 BEING AN ELDERLY VAD RECIPIENT: IS IT A
RISK FACTOR FOR DEATH DURING THE BRIDGE TO
TRANSPLANTATION AND POST-HEART TRANSPLANTATION
PERIOD?
A. Shafii, G. Gonzalez-Stawinski, K. Zeroske, M. Hanna, N. Smedira,
T. Buda, K. Hoercher, D. Taylor, R. Starling
The Cleveland Clinic Foundation
Background: Elderly heart failure individuals, like their younger cohorts who
are transplant candidates, may need mechanical circulatory support (VAD) to
be bridged to transplantation (BTT). The aim of this study was to determine
whether age at time of VAD placement impacts mortality during the BTT and
post- heart transplantation period.
Methods: A retrospective chart review was conducted on all VAD patients
listed for heart transplantation between 1997- 2006. Outcomes were compared
between older VAD patients ( ¡Ý 60 yrs of age, n = 89 ) and younger ones ( ¡Ü
59 yrs, n = 135). Kaplan-Meier method was used to analyze outcomes.
Results: Following, VAD implantation there was a trend towards more deaths
while BTT in the older VAD group when compared to younger VAD patients
(43.8% vs. 29.6%, p = 0.32). Mean time to death was 62 days for older
VAD patients compared to 100 days for younger VAD patients (p < 0.001).
When analyzing for actuarial mortality rate while BTT there was a direct
correlation between risk of death and age at which a VAD was implanted. Posttransplantation, both groups had similar 5 year survivals (p = 0.48); however
there was a trend towards greater deaths associated to sepsis in the older
patients (32% vs. 20%, p = 0.37).
Conclusion: There was a trend towards greater mortality in elderly VAD patients
during the BTT period; however if elderly VAD patients are successfully BTT they
may enjoy the same long-term survival benefits as younger BTT VAD patients.

777 USE OF ECMO SALVAGE FOR PRIMARY
ALLOGRAFT FAILURE FOLLOWING ADULT CARDIAC
TRANSPLANTATION
P. Jansz2, A. Watson1,2, A. Jackson3, A. Jabbour1,2, R. Pye3,4, E. Granger2,
D. Winlaw2,5, P. Macdonald1,2, P. Spratt2
1
Transplant Program, Victor Chang Cardiac Research Institute, 2Heart &
Lung Transplant Unit, St Vincent’s Hospital, 3Department of Anaesthetics, St
Vincent’s Hospital, 4Cardiothoracic Intensive Care Unit, St Vincent’s Hospital,
5
Department of Cardiac Surgery, The Children’s Hospital at Westmead
Introduction: Primary allograft failure (PAF) is the leading cause of death
within 30 days of cardiac transplantation. The aim of this study was to evaluate
the outcome of patients with PAF managed with veno-arterial ECMO.
Methods: Data were reviewed on 53 consecutive heart transplants performed
at our institution between 1st June 2005 and 31st January 2008. 9 patients (17%)
who required ECMO in order to wean from cardiopulmonary bypass (Group 1)
were compared with the remaining 44 patients in the cohort (Group 2).
Results: There were no significant differences in preoperative recipient
characteristics. Group 1 patients were more likely to receive hearts with
abnormal ventricular function on echocardiography prior to retrieval (4/9 vs
4/38, p=0.033). Eight (89%) patients requiring ECMO were weaned off support
following a mean of 91.3 hours, and seven were discharged alive (78%).
Median ICU stay was significantly longer in Group 1 (205.5 hrs, IQR 144.5
vs 74.0 hrs, IQR 49.6; p=0.003). There was a trend towards longer median
post-operative hospital stay in surviving Group 1 patients, however this did not
reach statistical significance (28.0 days, IQR 13.3 vs 15.0, IQR 12.0; p=0.09).
All seven survivors in Group 1 remain alive and well with normal ventricular
function after 479 days mean follow-up. There were no peri-operative deaths in
Group 2, however there were two late deaths due to acute rejection at 225 days
and sepsis at 500 days, respectively. In-hospital mortality was significantly
higher in Group 1 (2/9 vs 0/44, p = 0.026), however there was no difference in
late mortality (0/7 vs 2/44, p = NS). Kaplan Meier curves show significantly
superior survival for Group 2 patients (Figure 1) however, when plotted for
survival conditional upon survival to discharge, there is no significant difference
between the curves (Figure 2). Taken together, these data suggest that at least
short- to medium-term outcome for patients surviving ECMO may be expected
to be equivalent to those patients whose course is not complicated by PAF.

776 HEART TRANSPLANTATION IN ADULT PATIENTS WITH
EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
R-B. Hsu1, N-K. Chou1, N-H. Chi1, S-S. Wang1, F-Y. Lin1, S-H. Chu2
National Taiwan University Hospital, 2Far-Eastern Memorial Hospital
Objective: Donor shortage and improved heart failure management
increase the prevalence of patients with severe heart failure and mechanical
circulatory support to heart transplantation. There are numerous reports of
successful extracorporeal membrane oxygenation (ECMO) bridging to heart
transplantation in pediatric patients and the outcomes were variable. We sought
to evaluate the clinical outcome of heart transplantation in adult patients with
ECMO support.
Methods: Retrospective chart review.
Results: Between 1995 and 2007, 22 adult patients with severe heart failure
and ECMO support underwent heart transplantation at the authors¡¦ hospital.
Of these patients, 11 (50%) patients had a primary diagnosis of dilated
cardiomyopathy and 6 (27%) had coronary artery disease. Six patients (27%)
had previous cardiac operation. The median duration of ECMO support before
heart transplantation was 9.5 days (range, 1 to 48). Four patients underwent
combined heart and kidney transplantations. There were 8 in-hospital deaths.
Major postoperative complications occurred in 19 patients (86%): renal failure
requiring dialysis in 7, infection in 12, and neurological complication in 8
patients. Diagnosis of coronary artery disease, femoral ECMO, and no left
atrial decompression were associated with increased hospital mortality. The
1-year, 2-year, 3-year and 4-year patient and graft survival rates were 66.7 ¡Ó
10.3%, 60.0 ¡Ó 11.2%, 50.0 ¡Ó 13.1%, and 37.5 ¡Ó 14.6%.
Conclusions: Direct ECMO bridging to heart transplantation was associated
with high mortality and morbidity in adult patients, and the outcome was
especially poor in patients with diagnosis of coronary artery disease, femoral
ECMO, and no left atrial decompression.

1

Figure 1. Overall survival

Figure 2. Survival conditional on survival to discharge
Conclusions: The early implementation of veno-arterial ECMO for PAF was
associated with low early morbidity and mortality, and excellent long-term
outcomes. It has allowed us to expand our pool of potential donors by accepting
organs that would previously have been rejected.
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778 MECHANICAL CIRCULATORY SUPPORT AFTER
CARDIAC TRANSPLANTATION: THE MODERN ERA
L. Vargas, M. Hanna, G. Gonzalez-Stawinski, N. Smedira, T. Buda
Cleveland Clinic
Purpose: To determine the outcome of patients who underwent heart
transplantation and subsequently required mechanical circulatory support
(MCS) in the post –transplant period.
Methods: A retrospective chart review was conducted on 245 consecutive
heart transplants performed between January 2003 and December 2006 at
the Cleveland Clinic Foundation. Among these, 19 (7.7%) patients required
mechanical circulatory support following heart transplantation. Short- and
long-term outcomes were recorded.
Results: There were 13 men and 6 women, median age 43 years (11 to 69 years).
Among these 19 patients, 25 MCS devices were used. These included intraaortic
balloon pump (IABP) (n=11), extracorporeal membrane oxygenation (ECMO)
(n=12), and ventricular assist device (VAD) (n=2), one being biventricular VAD
and the other right VAD. The main indications for MCS were acute rejection
(n=3), right heart failure (n=4), and primary graft dysfunction (n=12). MCS
combinations included 4 patients with IABP + ECMO, 2 patients with VAD +
IABP, and 1 patient required support with VAD + ECMO. A total of 12 patients
were weaned from MCS (63%) and 7 patients died (36%), including a patient
who died intraoperatively while on ECMO. Support time ranged from 0.5 to
480 hours (20 days).
Conclusions: This retrospective analysis of patients who underwent cardiac
transplant and required post transplant mechanical circulatory support reveals
a high mortality rate. However, a good proportion of these can be weaned from
support with good outcomes.

779 USE OF EXTRACORPOREAL MEMBRANE
OXYGENATION IN ADULT SEVERE RESPIRATORY FAILURE
AS A BRIDGE TO RECOVERY OR BRIDGE TO LUNG
TRANSPLANT

THURSDAY

E. Granger1, A. Jackson2, P. Spratt3, P. Jansz4, M. Malouf5, A. Galnville6, J.
Cropper7, R. Pye8
1
St Vincent’s Hospital, 2St Vincent’s Hospital, 3St Vincent’s Hospital, 4St
Vincent’s Hospital, 5St Vincent’s Hospital, 6St Vincent’s Hospital, 7St Vincent’s
Hospital, 8 St Vincent’s Hospital
Background: The use of VV ECMO to treat respiratory failure in children
and infants is well established as a rescue therapy. The use of ECMO for adult
respiratory failure has previously demonstrated poor survival; however recent
experience suggests a valuable role and better outcomes in supporting the adult
patient with potentially reversible lung injury.
Objective: To review the results of veno-venous extracorporeal membrane
oxygenation (VV ECMO) in adult patients with severe acute respiratory failure.
Complications including renal failure, blood product transfusion, haemorrhage,
device thrombosis and technical failures will be analysed.
Design and Setting: Retrospective data was analysed from medical charts of
all patients receiving VV ECMO at a tertiary care adult transplant hospital.
From March 2004 to March 2008 15 patients with respiratory failure were
treated with VV ECMO after failure of conventional therapy.
Results: Overall hospital survival was 80%. The average duration of support
was 9.3 days (range 0.1 to 29 days). 80% patients were male, with the average
age of 38.3. Primary diagnoses included adult respiratory distress syndrome
(3, 100% survival), pneumonia(7, 86% survival), primary graft failure post
lung transplant(3, 100% survival) and late graft failure post lung transplant
(2, 0% survival). Only one patient developed bleeding complications on VV
ECMO requiring thoracotomy. Three patients were successfully bridged from
VV ECMO to lung transplant.
Conclusion: The use of VV ECMO in adult respiratory failure can achieve high
survival and low complication rates. The patients were selected on the basis of a
potential reversible lung injury refractory to conventional ventilation. In select
cases patients may be successfully bridged from VV ECMO to transplant.
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780 BRIDGING PATIENTS FROM VENO-VENOUS
EXTRACORPOREAL MEMBRANE OXYGENATION TO LUNG
TRANSPLANT – SURGICAL IMPLICATIONS AND LESSONS
LEARNED.
E. Granger1, P. Spratt2, P. Jansz3, A. Jackson4, A. Glanville5, M. Malouf6,
R. Pye7, M. Plitt8
1
St Vincent’s Hospital, 2St Vincent’s Hospital, 3St Vincent’s Hospital, 4St
Vincent’s Hospital, 5St Vincent’s Hospital, 6St Vincent’s Hospital, 7St Vincent’s
Hospital, 8 St Vincent’s Hospital
Background: Veno-venous extracorporeal membrane oxygenation (VV
ECMO) is an increasingly utilized therapy for adults with severe respiratory
failure that is refractory to conventional ventilation. Reports on the use
of ECMO as a bridge to lung transplant are rare, and the outcomes remain
poor. Many centers have considered ECMO to be a contraindication to lung
transplantation. We present 3 consecutive, successful cases in which ECMO
was used as a bridge to primary lung transplant. The surgical aspects of these
procedures and future implications will be discussed.
Objective: To review the results of bridging patients from VV ECMO to
bilateral sequential lung transplant. Complications including renal failure,
blood product transfusion, haemorrhage, device thrombosis, technical failures,
and anastomotic ischaemic injury will be analysed.
Design and Setting: Retrospective data was analysed from medical charts of
three patients receiving VV ECMO prior to bilateral lung transplant at a tertiary
care adult transplant hospital. From March 2004 to March 2008 15 patients with
respiratory failure were treated with VV ECMO after failure of conventional
therapy; three patients from this group were bridged to lung transplant.
Results: Overall hospital survival was 100%. The average duration of support
was 17.3 days (range 10 to 28 days). 100% patients were male, with the average
age of 19.6. Primary diagnoses included adult respiratory distress syndrome (1),
and influenza pneumonia(2). One patient required haemodialysis on ECMO
to correct acute hyperkaleamia, however all patients were free of multi-organ
failure. All patients were coagulopathic following surgery and required reexploration in the operating theatre combined with blood product replacement.
All patients required a tracheostomy for prolonged weaning from ventilator
support (average 27.7 days). The average length of hospital admission was 76
days. No anastomotic healing problems were encountered.
Conclusion: Patients can be successfully bridged from VV ECMO to lung
transplant. They must have single organ failure only and satisfy the criteria
otherwise for lung transplantation. Prominent surgical issues include massive
coagulopathy requiring re-opening of the thoracotomy in the operating theatre
and tracheostomy for prolonged ventilation.

THURSDAY – MINI ORAL ABSTRACTS
MINI-ORAL SESSION 25:
RENAL 6: LONG-TERM OUTCOMES AND COMORBIDITIES
POSTER BOARD NUMBER P4 – 390
781 OUTCOME OF HEPATITIS B, C INFECTION ON
TAIWANESE KIDNEY TRANSPLANT RECIPIENTS WITH
TACROLIMUS AND MYCOPHENOLIC ACID BASED
IMMUNOSUPPRESSANTS: A SINGLE CENTER STUDY
M-J. Wu1, K-H. Shu1, J-D. Lian2, C-R. Yang3, C-H. Cheng1, C-H. Chen1,
D-M. Yu1
1
Division of Nephrology, Taichung Veterans General Hospital, 2Division of
Nephrology, Chung-San Medical University Hospital, 3Division of Urology,
Taichung Veterans General Hospital
Hepatitis B and C are the most prevalent cause of chronic liver disease after
kidney transplantation (KTx). The aim of the present retrospective study was
to determine the outcome of tacrolimus and mycophenolic acid based regimen
for KTx recipients with hepatitis B, C infection. Among 232 patients, 14.7%
were HBsAg positive, and the other 9.5% patients were anti-HCV positive.
The overall 1-year, 3-year, 5-year patient survival rates were 99.6%, 97.7%,
and 96.5%, respectively. Chronic liver disease was an independent risk factor
for patient death and graft failure. Compared to patients without hepatitis B
or C infection, KTx recipients with hepatitis C infection, but not hepatitis B
infection, had poor long term graft survival rate. The overall prevalence rate
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of chronic liver disease was 18.5%. Hepatitis B and C infection significantly
increased the prevalence rate of chronic liver disease. The treatment of
lamivudine obviously reduced the development of hepatitis B related fulminant
hepatic failure. Post-transplant diabetes was diagnosed in 15.9% patients. The
logistic regression analysis revealed that hepatitis C infection, age, and first
month the blood trough level of tacrolimus were the independent risk factor for
post-transplant diabetes. In summary, we have demonstrated that tacrolimus
and mycophenolic acid based regimen is effective as a primary regimen in
KTx recipients with or without hepatitis B and C infection. KTx recipients
with hepatitis C, but not hepatitis B, infection may have poor long term graft
survival. The use of lamivudine can modify the natural course of hepatitis B
infection in kidney transplant recipients.

POSTER BOARD NUMBER P4 – 391
782 EPIDEMIOLOGY OF VARICELLA ZOSTER INFECTION
IN ADULT RENAL TRANSPALNT RECEPIENTS
M. Kaushik1, B. Swetha1, H.N. Leong2, K.P. Chan3, A. Vathsala1
Department of Renal Medicine, Singapore General Hospital, 2Department of
Internal Medicine, Singapore General Hospital, 3Department of Pathology,
Singapore General Hospital
Varicella zoster virus (VZV), a Herpes virus, presents with a wide spectrum of
disease in solid organ transplant recipients (TX). In adult recipients with prior
exposure to VZV, reactivation of latent virus, manifests either as dermatomal
Herpes Zoster (HZ) or as Disseminated Varicella infection with or without
visceral involvement (DVZ). Occurrence of primary VZV infection (PVZ)
in adult TX is less common, although associated with higher morbidity and
mortality. The present study examined the seroprevalence of VZV immunity
in an adult renal TX (RTX) population and evaluated the robustness of the
immunity and its relationship to the occurrence of VZV infection posttransplant.
497 adults, (2 re-transplants; 51.9% Males; 85.2% Chinese; mean age, 43.2
years; 79.4% Deceased Donor) transplanted between 1996 and 2007 constituted
the study population. All had been on follow-up for at least 1 year posttransplant and had undergone serological tests for VZV-IgM and IgG at 1 year
and annually thereafter. The mean follow-up period was 5.9 years. Occurrence
of HZ, DVZ and PVZ infections post-transplant and their outcomes were
documented and correlated with VZV serological status. RTX with persistent
VZV-IgG seroprevalence, unrelated to documented infections or exposure,
were defined as VZV-Immune.
Among 499 RTX, VZV-IgG seroprevalence was present at initial testing in
91.6% and was persistent in 99.8% of this cohort throughout the follow-up
period. In another 2.4%, VZV-IgG became seropositive only at subsequent
testing and was unrelated to VZV infections or exposure; although in 50%
of these, seropositivity persisted in the follow-up period, the remaining 50%
had only transient seropositivity. Overall VZV-IgM seropositivity was noted
in 11.2%; it was concomitant with VZV reactivation in 4% and unrelated to
infection or exposure in the remainder. Although transient in the majority,
notably, VZV-IgM seropositivity persisted on follow-up for >2 years in 26.8%
of this cohort. Overall, 92.6% had robust humoral immunity to VZV, 1.4% had
transient immunity while 6% were non-immune.
56 of 499 RTX (11.2%) developed 59 episodes of VZV infection (3 RTX
experienced 2 episodes each) at an interval of 34.2 months post-transplant.
57 (96.6%) episodes were reactivation infections (79.7% HZ, 16.9% DVZ)
occurring in VZV seropositive RTX. However, 3.4% of episodes were PVZ,
having occurred in VZV seronegative RTX. Although overall survival in
reactivation VZV was 100%, there was 50% mortality in the PVZ group,
1 seronegative RTX having succumbed to severe multi-organ, visceral
involvement, while the 2nd RTX successfully seroconverted to positive VZVIgG post-infection. The incidence of VZV infections was not significantly
higher in RTX receiving mycophenolate analogs (p=0.149).
These results demonstrate that VZV immunity is over 92% in adult RTX.
Despite the robust humoral immunity, VZV infections occurred in 11.7% of
VZV-Immune RTX. Reactivation VZV infections was 1.7-fold as common
as primary infections (2 episodes in 30 non-immune RTX, 6.7%). Although
reactivation infections have good outcomes, PVZ infections occurring in nonimmune RTX, appear to be associated with high mortality. Future studies
should evaluate the role of pre-transplant vaccination in VZV seronegative
patients in abrogating the severity of VZV infections post-transplant.
1

POSTER BOARD NUMBER P4 – 392
783 THE TEN YEARS FOLLOW UP OF KIDNEY
TRANSPLANTATION FROM HBSAG POSITIVE DONORS.
V. Sumethkul, A. Ingsathit, P. Leelasa-Nguan, S. Jirasiritham
Ramathibodi Hospital
HBsAg positivity is believed to preclude kidney donation. We examined the long
term outcome of KT from HBsAg+ donors to anti HBsAb+ recipients (Gr. 1).
The outcome of HBsAg+ recipients who received kidneys from HBsAg negative
donors were compared (Gr.2). End point was patient survival. 40 patients (14 in
Gr. 1 and 26 in Gr. 2) were enrolled. Anti-HBsAb ranged from 10 to >1000 mIU/
ml. Actuarial ten year survival was 90.9% and 72% for Gr. 1 and 2. One patient
in Gr.1 died (from acute MI) while ten in Gr. 2 died (3 hepatoma, 4 cirrhosis, 1
acute fibrosing cholestatic hepatitis, 2 stroke). No patient in Gr. 1 had HBsAg
seroconversion. Cox regression revealed that KT was significantly associated with
increased risk of death within 12 months after transplantation (RR=30;p=0.005)
and decreased risk of death thereafter (RR=0.03;p=0.005) for Gr. 2 but not for Gr.
1 (p=0.61). Our result shows no increase risk of liver disease ten years after KT
from HBsAg+ donors to recipients with anti-HBsAb+. Positive HBsAg in donors
can thus be allocated to immunized recipients.

POSTER BOARD NUMBER P4 – 393
784 IMPACT OF PRETRANSPLANT ANTIHCV ANTIBODY
STATUS AND TYPE OF IMMUNOSUPPRESSION ON
OUTCOMES IN RENAL TRANSPLANT RECIPIENTS
INFECTED WITH HEPATITIS C VIRUS
M. Minz1, A. Sharma1, A. Das2, Y. Chawla3
Dept of Transplant Surgery, PGIMER, 2Dept of Histology, PGIMER, 3Dept of
Hepatology, PGIMER
Introduction And Aims: HCV infection remains an important risk factor for
mortality and morbidity in the transplant recipients. This retrospective study
analyzed the impact of Hepatitis C antibody status; type of immunosuppression
in HCV infected renal allograft recipients on liver function, graft and patient
survival.
Methods: Between Feb 1998 to Aug 2007, 933 renal transplants were performed
at our centre. Out of these, 104 patients were identified to be harboring HCV
infection. 59 of these patients (Group I) were AntiHCV positive prior to
transplant and 45 patients (Group II) were found to be HCV RNA/antibody
positive in the post-transplant period. The patients transplanted in different eras
received different immunosuppression regimes. Complete follow-up data of
these patients was available for 72.3% (43/59) in Group I and 80%(36/45) in
Group II. Both the groups had a similar number of patients on cyclosporine
(62.8% vs 61.1%), tacrolimus (37.2% vs 38.8%) and MMF (58.1% vs 61.1%).
These patients were analyzed for difference in patient & graft survival by log
rank test. The risk of developing liver dysfunction in the post transplant period
(defined as SGOT/PT values 3 x normal) was also analyzed.
Results: The mean age was 35.1 + 10.4 and 32.4 + 10.4yrs, M:F 37:6 and
31:5, mean donor age was 41.5 + 10.9yrs and 41.2 + 13.1yrs and mean follow
up 29.4 + 24 mo (1-107.7 mo) and 32.6 + 24.2 mo (3.1-97.2mo) in Group I
and Group II respectively. The patients in Group I had received a significantly
higher number of blood transfusions as compared to patients in Group II
(6.2 + 5.7 vs 2.1 + 2.9) and significantly more number of dialysis prior to
transplantation (84.5 + 62. vs 33.8 + 43.2 vs) respectively. Liver function tests
– SGOT (22.6 + 16.1 vs 18.3 + 12.1and SGPT (24.2 + 28.9 vs 20.4 + 20.2) were
similar in the two groups in the pretransplant period respectively. The patient
and graft survival at 5years was similar 88.6% vs 82.3% [p=0.81] and 60.1%
vs 62.5% [p=0.75] in Group I and II respectively. The serum creatinine at last
FU was 1.38 + 0.6 vs 1.7+ 2.4 mg% [p=NS], SGOT 33.4 + 25.6 vs 38.3 + 47
and SGPT 39.3 + 46.7 vs 59.2 + 89 IU/L in Group I and II, respectively. Liver
decompensation occurred in four patients, two in each group at a mean duration
of 36.5mo.The risk of developing liver dysfunction was higher in patients
receiving tacrolimus vs. cyclosporine [Relative risk 1.7] and mycophenolate
vs. azathioprine[Relative risk 1.4].
Conclusions: Presence of HCV antibody does not offer any survival advantage
in HCV infected renal allograft recipients undergoing renal transplantation.
Patients on tacrolimus and mycophenolate are at higher risk of developing liver
dysfunction in the post transplant period.
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POSTER BOARD NUMBER P4 – 394
785 SIGNIFICANT IMPACT OF SERUM ADIPONECTIN
LEVELS ON INSULIN RESISTANCE IN NEW ONSET
DIABETES AFTER RENAL TRANSPLANTATION
K. Nishimura, Y. Yamauchi, N. Arichi, A. Okuno, S. Tokugawa, N. Fujii, Y.
Namba, H. Kishikawa, Y. Ichikawa
Hyogo Prefectural Nishinomiya Hospital
Aims: New onset diabetes after transplantation (NODAT) is increasingly
recognized as a serious complication in renal transplant recipients. Previous
studies have described incidence rates and predictors, however, the clinical
characteristics and mechanisms underlying this metabolic disturbance have
not been fully elucidated. Adiponectin (APN), a recently discovered adipocytederived protein, may be involved in type 2 diabetes mellitus pathogenesis based
on its relationship with insulin and glucose metabolism. The purpose of this
study was to analyze whether serum APN levels in renal transplant patients are
associated with insulin resistance and secretion for the development of NODAT.
Methods: A total of 98 previously non-diabetic patients who underwent renal
transplantation between 1997 and 2007 were enrolled. NODAT was defined
according to the Japan Diabetes Society guidelines based on results of an oral
glucose tolerance test (OGTT). Post-transplant homeostasis model assessment
for insulin resistance (HOMA-IR) and insulinogenic index (I-Index) values
were produced from OGTT-derived indexes. In addition, pre- and posttransplant serum APN and high-sensitivity C-reactive protein (hsCRP) levels
were measured.
Results: Twelve (12.2%) patients were diagnosed with NODAT and 86 (87.8%)
without (non-NODAT). For the NODAT patients, mean HOMA-IR (3.24) was
significantly higher than that for non-NODAT patients (1.35) (p=0.004), while
mean I-Index (0.41) was significantly lower (1.88) (p<0.001). In all patients, the
mean post-transplant serum APN level (16.8 ƒÊg/ml) was significantly lower
than the pre-transplant level (20.3 ƒÊg/ml) (p=0.009). Furthermore, mean preand post-transplant serum APN levels for NODAT patients were significantly
lower than those for non-NODAT patients (13.3 vs 21.0 ƒÊg/ml and 13.0 vs
16.4 ƒÊg/ml, p=0.01 and 0.027, respectively). In contrast, in regard to serum
hsCRP, there were no significant differences between NODAT and nonNODAT patients for both pre- (0.128 and 0.238 mg/dl, respectively) and posttransplant (0.566 and 0.402 mg/dl, respectively) levels (p=0.6347 and 0.0983,
respectively). There was a significant inverse correlation between mean posttransplant serum APN level and HOMA-IR (r=-0.223, p=0.0272) and a positive
correlation between follow-up duration after transplantation and HOMA-IR
(r=0.283, p=0.0047) for all patients, whereas none was seen between mean
post-transplant serum APN level and I-Index (r=0.085, p=0.4161), or between
follow-up duration after transplantation and I-Index (r=0.054, p=0.6067).
Conclusions: Our results indicate that serum APN levels are decreased after
transplantation and have a significant impact on insulin resistance, but not on
insulin secretion, for the development of NODAT in patients who undergo
renal transplantation.

POSTER BOARD NUMBER P4 – 395
786 BLOOD PRESSURE CONTROL IN RENAL TRANSPLANT
PATIENTS: ARE WE AGGRESSIVE ENOUGH?
G. Mourad 1, P. Esler 2, F. Vetromile 1, I. Szwarc 1, A. Mimran 2, J. Ribstein 2
Néphrologie, Transplantation et Dialyse Péritonéale, CHU Lapeyronie,
2
Médecine Interne et HTA, CHU Lapeyronie
Objective: In renal allograft recipients, best practice guidelines recommend
target arterial pressure <130/80 mmHg. Whether these values are achieved in
routine clinical practice is not known. The aim of this study was to analyze the
prevalence and identify factors associated with the presence of hypertension
(HT, ≥; 130/80 mmHg) in a large cohort of patients followed annually in our
center.
Methods: Blood pressure and renal function (glomerular filtration rate, GFR,
urinary 99mTC-DTPA clearance) were evaluated in 456 subjects, 66% male,
aged 51±12 yrs (mean ± SD) after a median follow-up period of 47 months
(range 47-335) post first-kidney transplantation (Tx).
Results: From the 456 subjects, only 33 (7.2%) were normotensivewithout
any antihypertensive treatment, 97 (21.3%) had well-controlled HT and 325
(71.5%) had uncontrolled HT. Among the 325 patients with uncontrolled HT,
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69 (15.1% of the whole population) had true resistant HT (at least 3 drugs
including 1 diuretic) whereas 257 could not be considered as resistant HT
since they received 2 or less antihypertensive drugs (1.3±0.8) . AS compared
to controlled HT, uncontrolled HT were slightly older (53±11 vs 50±12 yrs,
p=0.026) had received grafts from older donors (45±16 vs 38±16 yrs, p=0.001),
had lower GFR (51±21 vs 56±19 mL/min/1.73m²), and higher albuminuria (34
vs 19 μg/mL, p<0.001 after log-transformation) and fasting blood glucose
(5.85±2.61 vs 5.31±1.35 mmol/L, p=0.053). No difference was found for
gender, duration of dialysis before TX, delay after Tx, steroïd doses or type
of immunosuppressive treatment (cyclosporine vs tacrolimus). In multivariate
logistic regression analysis, using controlled HT as the reference category, the
presence of resistant HT was independently associated with higher body mass
index, albuminuria and higher donor age.
Conclusion: After kidney Tx, the main factor associated with persistent
hypertension is the inadequation of antihypertensive therapy. However, obesity,
albuminuria as well as older donor age are the main factors associated with true
resistant HT.

POSTER BOARD NUMBER P4 – 396
787 STRESS ECHOCARDIOGRAPHY FOR ASSESSMENT OF
RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF CARDIAC
OUTCOMES.
C.Hood1, J. Dunlop2, H. Pilmore3
The Alfred Hospital, 2Middlemore Hospital, 3Auckland City Hospital
Background: Pre-operative screening for coronary artery disease (CAD) is
recommended in high risk renal transplant candidates. Myocardial perfusion
studies are less invasive than coronary angiography but there are few studies
correlating the results of stress tests with subsequent decisions regarding
transplant listing and clinical events. In our programme, high risk patients
undergo yearly or two yearly stress echocardiography (SE) as assessment for
the active transplant list.
Aims: To evaluate the clinical utility of SE as a means of screening potential
renal transplant recipients.
Methods: Analysis of 210 SE undertaken for transplant assessment in high
risk patients was performed for the period October 2002 until Oct 2007 (185
dobutamine, 15 exercise). Patient records were analysed for the subsequent
development of cardiac events defined as angiographically proven significant
CAD (>70% stenosis), non-ST elevation myocardial infarction (NSTEMI),
ST-elevation myocardial infarction (STEMI), or new regional wall motion
abnormality on echocardiography.
Results: Of 210 tests, only 18 (8.6%) were positive. 155 (73.8%) tests were
negative. 37 (17.6%) of tests were equivocal or suboptimal. Mean follow-up
was 24.6 months. Of the 210 tests, 22 cases (10.5%) subsequently demonstrated
a significant cardiac event, as previously defined.
Positive tests: 75% of patients with a positive SE were declined listing for
transplantation on the basis of the initial test result alone or subsequent coronary
angiographic findings of severe CAD (>70% stenoses). 2 of these patients were
found to have significant but treatable CAD and were subsequently accepted
for listing after coronary artery stenting. 2 positive tests were considered
“false positives” for significant CAD as subsequent angiography revealed zero
or mild CAD only. 2 patients (12.5%) developed additional co-morbidities
contraindicating transplantation and further cardiac investigation was therefore
withheld. Therefore the positive predictive value of SE for significant cardiac
disease either precluding transplantation or requiring revascularisation was
85.7%. Of the 18 patients with a positive SE, 8 (44%) had reached a cardiac
endpoint or died within 24 months of follow up.
Negative tests: 155 patients had negative SE screening. Of these, 8 (5%)
experienced significant cardiac events within the next 24 months. The negative
predictive value NPV for screening SE was 94.8%. In comparison with patients
with a positive SE, there were significantly fewer cardiac events in those with
a negative SE (p<0.001).
Equivocal tests: 37 patients (17%) had equivocal tests. 13 of these were
further investigated with 2 being found to have significant CAD resulting in
the patients being excluded from transplantation.
Conclusion: Our five year experience of 210 SE tests has yielded 14 (6.6%)
positive or equivocal results that have ultimately resulted in the identification
of significant CAD and withholding of listing for transplantation. Negative
screening SE had a high NPV of 94.8% for cardiac events in the next 24
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months. The percentage of positive SE was low; however these patients had
a significantly worse outcome clinically suggesting that SE is a useful tool in
predicting CAD prior to transplantation.

POSTER BOARD NUMBER P4 – 397
788 POST TRANSPLANTATION DIABETES MELLITUS:
ROLE OF INSULIN-RESISTANCE AND PRO-INFLAMMATORY
CYTOKINES IN FIRST YEAR POST-TRANSPLANT
M. Carmellini1, V. Bonato2, A. Collini1, D. Cataldo2, G. Ruggieri1, L. Nigi2,
M. Bernini1, F. Dotta2
1
UOC Chirurgia dei Trapianti – Azienda Ospedaliera Universitaria Senese,
2
UOC Diabetologia – Azienda Ospedaliera Universitaria Senese
Post Transplantation Diabetes Mellitus (PTDM), a common complication of
kidney tranplant, has a negative impact on graft and patient prognosis. Age,
ethnicity, type 2 diabetes family history, and Hepatitis C were identified as non
modifiable risk factors of PTDM. Modifiable risk factors are type of immunesuppressive therapy, and overweight. Several study demonstrated that MCP-1
and IL-6, pro-inflammatory molecules, are involved in the pathogenesis of
type 2 diabetes. In a retrospective analysis, we found that 17% of 250 kidney
transplant recipients developed an altered fasting glucose (PTDM 12.2% and
impaired fasting glucose, IFG, 4.8%), interestingly with a major incidence in
first year post transplant. We aimed to evaluate the role of insulin-resistance
and proinflammatory molecules in PTDM and IFG.
Materials and methods: Fifty-three non diabetic consecutive patients were
included in this study, the day of renal transplantation. At the baseline the
following data were collected: age, sex, body mass index (BMI), prevalence
of overweight (BMI≥;25 Kg/m2), hepatitis C status, prevalence of diabetes
mellitus family history, prevalence of hypertension, dyslipidemia and smoke.
At follow up a blood sample was collected to determine glycaemia, lipid
profile, basal insulin, creatinine, and serum MCP-1 and IL-6. HOMA-IR and
QUICKI were calculated to determine insulin-resistance and insulin-sensitivity.
Type of immune-suppression (cyclosporine vs tacrolimus) and acute rejection
was evaluated at follow up. Patients were classified as PTDM, IFG or normal
glucose (NG).
Results: 9% of patients developed PTDM, il 28.3% IFG. PTDM and IFG
patients were older than NG (p<0.05 and p<0.03). In IFG patients HOMA-IR
resulted higher than in NG group (3.10±2.72 and 1.96±2.37 p=0.0082), while
QUICKI was lower (0.34 ± 0.03 and 0,36±0,03 p=0.0113). PTDM and IFG
prevalence was higher in tacrolimus-treated recipients than in cyclosporinetreated (p=0.002 and p=0.07). No differences were observed in proinflammatory molecules, MCP-1 and IL-6. Multivariate analysis confirmed
tacrolimus as independent risk factors for PTDM (p<0.02).
Conclusions: Our data confirm the role, in PTDM development, of known
risk factors, in particular age and tacrolimus treatment, during first year post
transplant. In our experience PTDM is only in part associated with insulin
resistance, which is a characteristic of IFG patients. In this patients insulin
secretion failure is necessary to develop PTDM.

POSTER BOARD NUMBER P4 – 398
789 REVERSAL OF METABOLIC SYNDROME POST-KIDNEY
TRANSPLANTATION IN CHRONIC CORTICOSTEROID
VERSUS EARLY CORTICOSTEROID WITHDRAWAL
REGIMENS
E.S. Woodle1, R-A. Lee1, A.H. Rike2, R.R Alloway1, J.J. Everly1, P. RoyChaudhury1, L. Cole1
1
Surgery, U of Cincinnati, 2Christ Hospital
Background: Prolonged use of steroids has been associated with several
metabolic side effects that can contribute to cardiovascular complications,
osteoporosis and increased post transplant infections complications. According
to NCEP ATP III guidelines, metabolic syndrome (MS) is a significant
predictor of cardiovascular events (CVE). The purpose of this study was to
evaluate the effects of maintenance corticosteroid therapy on rates of reversal
of pre-transplant (txp) MS in renal transplant patients (pts) receiving early
corticosteroid withdrawal (ECSWD) versus chronic corticosteroids (CCS).
Methods: Prospective data collection from 1997 to 2007 on 317 renal transplant
pts identified with MS at the time of transplant. Pts were evaluated post-

transplant at 6, 12, 24, 36, 48, and 60 months for presence of MS. The NCEP
ATP III criteria was used to define MS with WHO criteria of body mass index
(BMI) > 30kg/m2 used as an alternative for waist circumference. All pts met
the criteria for MS at the time of transplant. Time of MS reversal was defined
as the point in which criteria of MS was no longer met post transplantation
and remained reversed until the time of last follow-up. Statistics included chisquare, Student’s t-test, and Kaplan Meier time to event analysis.
Results:
317 pts had metabolic syndrome at time of transplantation and were evaluated
for reversal of MS. Of these 317 pts, 97 pts (31%) were in CCS regimen versus
220 pts (69%) in ECSWD regimen. Baseline demographics for MS were similar
between the two groups. There was no difference in the overall reversal rates of
MS (36% in CCS group v. 33% in ECSWD, p=ns). KM analysis of time to MS
reversal revealed no significant difference between ECSWD v. CCS patients.
Surprisingly, non-diabetic patients with CCS had a higher MS reversal rate than
non-diabetics with ECSWD. Analysis of HDL data indicates that corticosteroid
mediated increases in HDL were responsible for a significant portion of MS
reversal with non-diabetics.
MS Reversal Rates
All patients
Non-diabetic patients
DM Type I
DM Type II

CCS (n)
36% (97)
50% (60)
19% (16)
9% (21)

CSWD (n)
33% (220)
34% (123)
38% (21)
28% (76)

p-value
NS
0.03
NS
0.07

Conclusions: 1) A substantial proportion of patients (34%) experienced MS
reversal after kidney transplantation regardless of steroid therapy. 2) Pts with
pre-transplant DM Type II have significantly higher reversal rates of MS with
ECSWD. 3) Corticosteroid induced increases with HDL were responsible in
part for high MS reversal rates in non-diabetics receiving chronic corticosteroid
therapy.

POSTER BOARD NUMBER P4 – 399
790 DETERMINANTS OF BONE DENSITY IN RENAL
TX RECEPIENTS AND ITS CORRELATION WITH VIT D,
CALCIUM AND BISPHOSPHONATES – A SOUTH INDIAN
EXPERIENCE
P. Govindan1, G. Abraham1, B. Pratap1, M. Matthew2, S. Bhaskar2,
N. Leslie2, N. Fathima2
1
Sri Ramachandra University, Madras, India, 2Madras Medical Mission,
Madras, India
AIM: To correlate bone disease with Vitamin D therapy, bisphosphonates,
calcium and CKD duration.
METHODS: The study was conducted in two tertiary care centers in Chennai.
It consisted of 307 patients. Among this, males were 222(72%) and females
85(28%), diabetics numbered 109 (35.5%) and smokers number 76(24.8%).
Calcium containing phosphate binders and supplemental Vitamin D analogues
were being used by 111(36.2%) and 70 patients (22.8%), respectively.
Bisphosphonates were given to 64(20.8%) of the post transplant patients. The
bisphosphonates used were oral alendronate 70mg once a week. Injection
Palmidronate 60mg IV was given on discharge and followed up once in 6
months, along with oral 1,25-dihydroxy Vitamin D3 0.25mcg daily and calcium
carbonate 500mgOD. The baseline IS included prednisolone, azathioprine and
microemulsion form of cyclosporine (neoral). Lately, patients were converted
to mycophenolate mofetil, tacrolimus and rapamycin for rejection episodes
who were not included in the analysis.
Bone mineral density was measured by DEXA (Lunar IDXA system) at the
spine (L1-L4 mean density of 0.691g/cm2), neck of femur (mean density of
0.631g/cm2) and total body (mean density of 0.758g/cm2) within 15 – 45
days in 307 patients(first follow-up). A second and third follow-up was done.
This was correlated with anthropometry, various biochemical parameters,
CKD duration smoking, diabetic status, immunosuppressive therapy, dietary
habits and supplemental vitamin D and calcium therapy. The mean age of the
population was 44+/-12.7 years. The mean CKD duration was 19.4+/- 24.3
months.
RESULTS: Vitamin D therapy prior to transplantation increased femur
(p=0.013) and total body BMD (p=0.018). Prior calcium intake increased BMD
at spine (p=0.001), femur (p=0.00) and total (p=0.00). Bisphosphonate therapy
increased BMD at spine (p=0.001), femur (p=0.003) and total (p=.0.00).The
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mean ALP value was 112+/- 63.7IU which correlated negatively with BMD
at the spine (p=0.001), femur (p=0.00) and total (p=0.00). The longer CKD
duration prior to transplant showed greater loss of BMD in femur (p=0.013).
There was a positive correlation between BMI and BMD in spine (p=0.003),
femur (p=0.004 and total body (p=0.005). Ten patients sustained fractures; hip
joint replacement was done in 4 patients.
DISCUSSION: Renal transplantation is associated with osteodystrophy.
Osteopenia is frequent and the fracture risk is increased. Glucocorticoids
play a role by decreasing calcium absorption, increasing renal excretion
of calcium and reducing the secretion of sex hormones. They also inhibit
osteoblast differentiation and induce apoptosis in mature osteoblasts as
well as in osteocytes. Though glucocorticoids have a key role all other
immunosuppressives also contribute with the exception of mycophenolate
mofetil which is neutral with regard to post transplant bone disease.
In a developing country like India, avoiding steroids altogether from
the very beginning and steroid withdrawal later cannot be practiced in
organ transplant due to fear of rejection and the augmented cost of other
immunosuppression.
CONCLUSION: Calcium and vitamin D therapy pre-transplantation and
bisphosphonate therapy post-transplantation, prevented bone loss. BMI had
a positive correlation with BMD. Those with loss of BMD had higher ALP
values. The vintage of CKD correlated with a higher bone loss.
T-SCORE – SPINE

T-SCORE – FEMUR

TABLE 2 – Average biochemical Parameters at Baseline
VARIABLES

MEAN

S.Calcium1

8.60

Bicarbonate1

22.

Phosphorus1

3.2

iPTH1

112.6

eGFR1

74.72

S.Calcium 2

8.6

POSTER BOARD NUMBER P4 – 400
791 TRANSPLANT ERYTHROCYTOSIS: A DISAPPEARING
PHENOMENA?
B. Kiberd
Dalhousie University
Erythrocytosis is relatively common post kidney transplantation and may
have adverse consequences. This study examines whether erythrocytosis has
remained stable over time and explores the outcomes associated with this
condition.
This is a single center retrospective review of an incidence (transplanted from
1993-2005) and a prevalence cohort (cross section) of kidney and kidney
pancreas recipients. Predictors of erythrocytosis and hemoglobin levels and
patient and allograft survival were examined.
Erythrocytosis (defined as >170 g/L for >1 month) occurred in 59 of 511
recipients. Erythrocytosis occurred in only 8.1% of recipients transplanted
between 1997-2005 compared to 19.7% of recipients transplanted between
1993-1996 (p=0.0005). Independent predictors of erythrocytosis were prior
use of ACE inhibitors/ARBs (HR 0.172, 95% CI 0.042-0.734, p=0.017), male
gender (3.9, 95% CI 1.7-8.7, p=0.001), and use of mycophenolic acid agents
(0.49, 95% CI 0.25-0.97, p=0.041). Multivariate linear regression analysis of the
2 cohorts showed that ACEi/ARB use was associated with lower hemoglobin
levels. Patients with erythrocytosis had superior patient survival (HR for death
0.105, 95% CI 0.014-0.76, p=0.026) (see figure below), similar graft survival
but a trend for lower death censored graft survival (HR for graft loss 2.06,
95% CI 0.91-4.65, p=0.084). The comparison group were patients with graft
survival >1 year with a peak hemoglobin level >120 g/L but <170 g/L, and not
requiring ESAs. Most patients with erythrocytosis were eventually treated with
ACEi/ARBs and none required phlebotomy.
The incidence of erythrocytosis is falling and is likely related to greater use of
ACEi/ARB and possibly more antiproliferative immunosuppression. Patient
survival is excellent in those with erythrocytosis however long term graft
survival may be compromised.

MINI-ORAL SESSION 26:
IMMUNOSUPPRESSION 4: INDUCTION
T-SCORE – TOTAL BODY

POSTER BOARD NUMBER P4 – 401
792 RITUXIMAB INDUCTION IN HIGH RISK KIDNEY
TRANSPLANT RECIPIENTS MAY DECREASE THE
INCIDENCE AND SEVERITY OF RECURRENCE OF FOCAL
SEGMENTAL GLOMERULOSCLEROSIS.
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TABLE 1 – Age, CKD duration and IS dosage at baseline
VARIABLES

Mean

Std. Deviation

Age in years

44.0656

12.76285

CKDDuration in months

19.4109

24.37840

BMI in kg/m2

22.5156

4.05642

Pred mg/kg

0.4062

0.20822

Azo mg/kg

1.7420

0.57683

Neo mg/kg

2.7770

1.18662
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J. Sageshima, G. Ciancio, A. Fornoni, L. Chen, C. Abitbol, J. Chandar,
W. Kupin, D. Roth, G. Zilleruelo, G.W. Burke III
University of Miami, Miller School of Medicine
Background: Disease recurrence is a major obstacle of kidney transplant for
focal segmental glomerulosclerosis (FSGS). AntiCD20 antibody (rituximab)
has been used for nephrotic syndrome of native kidney. The significant
reduction of proteinuria in transplant recipients with FSGS recurrence was also
reported after rituximab use for posttransplant lymphoma. We hypothesized that
rituximab induction could alter the posttransplant course of FSGS recipients,
particularly in those patients with rapid progression to end-stage renal disease
who are higher risk of recurrence.
Methods: We compared the outcome of transplants for primary FSGS
treated with and without rituximab. From Jan. 2000 to Dec. 2003, 11 FSGS
patients (6-21 yo) received renal allografts along with our “standard”
immunosuppressive protocol, consisting of tacrolimus, mycophenolate,

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Oral Abstracts
corticosteroids, antithymocyte globulin and/or daclizubab. From Jan. 2004 to
Dec. 2007, 18 other FSGS recipients (7-24 yo) received rituximab in addition
to the “standard” immunosuppression. Posttransplant proteinuria was treated
with plasmapheresis (PP) and maintenance angiotensin blockade (AB).
Results: There was no adverse event related to rituximab infusion. The overall
incidence of posttransplant proteinuria was significantly lower in recipients
with rituximab induction (p < 0.05). Four recipients treated with “standard”
immunosuppression developed massive proteinuria (u-protein/creat. > 10)
immediately following transplantation; they responded poorly to PP and AB.
Four other recipients had moderate proteinuria. In contrast to this, of the 18
patients induced with rituximab, only 2 had massive proteinuria and 4 had mild
to moderate proteinuria which responded well to PP and AB. With a median
follow-up of 26 months, there was no significant difference of graft survival
between 2 groups (2-year survival: 81% without rituximab vs. 84% with
rituximab). A half of the graft loss was related to noncompliance.
Conclusion: While the mechanism of action is unclear, our observation
indicates that rituximab induction may decrease the incidence and severity of
recurrence of FSGS following kidney transplantation. A larger-scale study is
desirable to confirm this observation.

POSTER BOARD NUMBER P4 – 402
793 200 LIVING DONOR KIDNEY TRANSPLANTATIONS
UNDER ALEMTUZUMAB PRETREATMENT AND WEANING
OF TACROLIMUS MONOTHERAPY: 3 YEAR FOLLOW UP
H. Tan, J. Donaldson, A. Basu, M. Unruh, P. Randhawa, V. Sharma, C.
Morgan, J. McCauley, C. Wu, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Alemtuzumab has been used in off-label studies of solid organ transplantation.
We extend our report of the first 200 consecutive living donor solitary kidney
transplantations under alemtuzumab pretreatment with tacrolimus monotherapy
and subsequent spaced weaning to 3 years of follow up. We focused especially
on the causes of recipient death and graft loss, and the characteristics of rejection.
The actuarial 1, 2, and 3 year patient and graft survivals were 99.0% and
98.0%, 96.4% and 90.8%, and 93.3% and 86.3%, respectively. The incidence
of acute cellular rejection (ACR) at the following months was 2% <6, 9.0%
<12, 16.5% <18, 19.5% <24, 23.5% <30, 24.0% <36, and 25% <42. The mean
serum creatinine (mg/dL) and glomerular filtration rate (mL/min/1.73m2) at
1 and 3 years were 1.43+0.55 and 58.7+21.6, and 1.50+0.71 and 54.5+21.3,
respectively. 50 (25%) recipients had a total of 89 episodes of ACR. 88.7% of
ACR episodes were Banff 1, and of those, 82% were steroid-sensitive. Nine
(4.5%) recipients had antibody mediated rejection (AMR). 76.5% were weaned
to spaced dose (qod or less) tacrolimus monotherapy, and 94.4% were still
steroid-free from the time of transplantation. Infectious complications was low.
This experience confirms the 3-year efficacy of this approach.

POSTER BOARD NUMBER P4 – 403
794 ANTIBODY INDUCTION REGIMENS IN RENAL
TRANSPLANT PATIENTS DISPLAY DIFFERENCES IN TOTAL
T CELL AND B CELL BUT NOT T-REGULATORY CELL
RECOVERY- ASSOCIATION WITH REJECTION AND GRAFT
SURVIVAL
M.R. Carreño, P. Ruiz, H. Takahashi, T. Cordovilla, G. Ciancio, G.W. Burke,
A.Tzakis
Departments of Surgery and Pathology, University of Miami-L. Miller School
of Medicine,
Introduction: We evaluated early and long-term (two year) immunophenotypic
peripheral blood profiles in renal transplant patients receiving single agent
induction therapy with Thymoglobulin (T), Campath-1H (alemtuzumab) (C)
or Daclizumab (D) versus combined T and D (T-D) or T and C (T-C) with
steroid avoidance. The focus was to identify specific peripheral blood targets of
cytoablation that might help reduce the incidence of renal allograft dysfunction.
Methods: Patients used were enrolled in a single (T) (n=44), (D) (n=45), (C)
(n=64) or combined (T-D) (n=75) and (T-C) (n=75) induction protocols with a
mean follow-up of >1200 days and 457 + 131 days respectably. Maintenance
immunosuppression (IS) consisted of Tacrolimus and Mycophenolate but no
corticosteroids for C, T-D and T-C, in contrast to T and D which included
steroids. Flow cytometric assessment of percentage and absolute number
of several cell subpopulations including CD3, CD4, CD8, CD19, CD56/16,
CD4/25 bright (n T-regulatory cells) were measured pre-transplant and
thereafter serially in all patients.
Results: The recovery of CD4+ cells from cytoablation was more rapid within
the 1st, 4th and 8th months (24.7, 38.8, and 37.3% respectively) in the T-D vs.
the T-C group (1.6, 8.3 and 16.9%). The percent recovery, at 8th months, for
T (27.6%) and C (14.0%) were not different. No differences were found in the
nTreg recovery at 8 months in T-D (22.7%) and T-C (20.1%) vs. T (38.9%) and
C (20.3%). The earlier T cell recoveries were not associated with significantly
increased acute cellular rejections (T-D n=5 and T-C n=3) over the 1st year,
and not higher than (T n=5 and C n=5) in the previous study. The T-D group
had a minimal effect on B cells at 1 month (recovery 69.6%) in contrast to the
T-C (2.4%) and was within normal ranges by the 4th month. Humoral rejection
was not significantly different between T-D (n=3) and T-C (n=2) in the 1st year.
Patient and graft survivals at one year were T-D (96% and 94.6%, respectfully),
T-C (96% and 93.3%), T (95.1% and 92.9) and C (97.3% and 97.3%) in the
stand alone during the 1st year.
Conclusions: Cytofluorographic analysis of peripheral blood profiles in
renal transplant patients receiving various induction modalities revealed that
Campath has the most profound cytoablative long-term effects on overall
CD4+ T cells and B cells. Interestingly, nTreg cells are not comparably affected
by Campath and show recovery similar to other induction profiles. The rate
of rejections, graft and patient survival was not notably different between the
groups. These results raise the possibility that selective sparing of nTreg cells
by induction reagents may ultimately influence the capacity of the recipient
to manifest clinically apparent rejection episodes and this may facilitate
operational tolerance induction.

POSTER BOARD NUMBER P4 – 404
795 CALCINEURIN INHIBITORS-FREE
IMMUNOSUPPRESSION IN EXPANDED CRITERIA
DONOR KIDNEYS: COMPARISON BETWEEN TWO
INDUCTION ERAS.
L. Santiago Re, D. Curcio, S. Cuevas, J. Goldberg, M. Rial, D. Casadei
Instituto de Nefrología de Buenos Aires
Calcineurin inhibitor avoidance and antibody induction are the main
pharmacologic strategies to improve outcomes when using ECD kidneys
for transplantation. Our group reported previously the results of an
immunosuppressive protocol using rATG+ sirolimus+ MMF+ Pred. In
december 2005, we started to use Campath 1H (alemtuzumab) as induction
agent in ECD kidneys with the same maintenance therapy. In the present study
we report the comparative results between these two different induction eras.
Donor Age

rATG (n=41)
55.07 ± 4.36

P value
0.49
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Recipient age
DDS score
Remuzzi score
CIT (minutes)
DGF occurrence
DGF duration
1 yr-acute rejection
CNI conversion
Urinary tract infection
CMV infection
Hb level (g/dl)
Epo use
WBC (mm3)
G-CSF use
Cholesterol (mg/dl)
Statins use
Triglycerides (mg/dl)
Fibrates use
1-yr creatinine
1-year patient survival
1-year graft survival
1-year death censored graft survival

50.68 ± 15.10
19.65 ± 7.4
4.1 ± 2.3
1338 ± 546
17/41 (43.9%)
12.8 ± 13.5
7/41 (17.07%)
2/41 (4.87%)
16/41 (39.02%)
6/41 (13.9%)
10.6 ± 1.5
5/41 (10.8%)
6473 ± 1815
0/41
206 ± 29
21/41 (51.21%)
146±89
12/41 (27.8%)
1.50 ± 0.70
35/41 (85%)
33/41 (82%)
39/41 (95.12%)
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45.6 ± 19.35
22.54 ± 6.1
3.75 ± 2.7
1452 ± 834
18/25 (72%)
14.2 ±12.3
0/25
5/25
8/25
0/25
10.2 ± 2.9
19/25
4154 ± 1327
4/25
149 ± 57
9/25
131± 78
10/25
1.38 ± 0.65
23/25 (92%)
18/25 (72%)
20/25 (80%)

0.26
0.07
0.05
0.504
0.20
0.534
0.20
0.06
0.37
0.04
0.85
0
0.05
0.01
0.008
0.17
0.484
0.263
0.778
0.489
0.245
0.367

Campath 1H treatment was associated with a more frequent use of G-CSF, lower
levels of WBC, minor cholesterol levels and less incidence of CMV infection.
Both induction agents were associated with excellent 1-year outcomes in terms
of graft function and patient survival. Due to the fact that Campath 1H is less
expensive, it constitutes a cost-effective alternative to rATG as induction agent.
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796 A PROSPECTIVE RANDOMIZED TRIAL OF
ALEMTUZUMAB VERSUS RABBIT ANTI-THYMOCYTE
GLOBULIN INDUCTION IN KIDNEY AND PANCREAS
TRANSPLANTATION: MINIMUM 6 MONTHS FOLLOW-UP
A. Farney, R. Singh, J. Rogers, E. Ashcroft, E. Hartmann, L. Hart, W. Doares,
M. Gautreaux, P. Adams, R. Stratta
Wake Forest University
Alemtuzumab (Alem) and rabbit anti-thymocyte globulin (rATG) are the most
commonly used T-cell depleting induction agents in kidney (K) and pancreas
(P) transplantation (tx).
Methods: We conducted an IRB approved prospective randomized study
comparing single dose Alem (30mg) to alternate day rATG induction in Ktx and
Ptx patients (pts). Pts received FK and MMF. A risk stratification (PRA>20%,
re-tx, African Americans <40 years old) defined high immunologic risk and
determined steroid maintenance or elimination. Expanded criteria donors
(ECD) were included.
Results: Between 2/1/05 and 8/24/07 225 pts enrolled and 222 pts were
transplanted. Of 222 pts, 180 (81%) had Ktx alone, 38 (17%) KPtx, and 4
(2%) PAKtx. Of 180 Ktx alone, 152 (84%) were deceased donor, and 61 (34%)
were ECDs. Recipient age, race, re-tx, HLA match, PRA titer, ECDs, CMV
status, and immunologic risk were similar for Alem (n=113) and rATG (n=109)
groups.
Group(n) Ktx Ptx(KPtx) ECD Re-tx PRA(>20%)
Alem(113) 85 28(24)
33
12
34
rATG(109) 95 14(14)
28
10
32

Race(AA)
34
36

Low Immunologic Risk
72
71

Overall pt, Ktx, and Ptx survival are 96, 90, and 86% at 18 months median
follow-up. Actuarial survival rates, initial length of stay, delayed graft function,
steroid free rates, major infection, and incidence of PTLD (1 rATG pt) were
similar for Alem and rATG groups. Overall, treated acute rejection (AR)
occurred in 20 (18%) Alem pts compared to 30 (28%) rATG pts (p=0.11) and
biopsy proven rejection (BPAR) in 15 (13%) Alem pts compared to 26 (24%)
rATG pts (p=0.06). Amongst Ktx alone, treated AR occurred in 11 (13%) Alem
pts compared to 25 (26%) rATG pts (p=0.04) and BPAR in 9 (11%) Alem pts
compared to 21 (22%) rATG pts (p=0.06).
Group
Alem
rATG

1, 2 yr Pt
Survival
96, 95%
99, 98%

1, 2 yr Ktx
Survival
92, 88%
94, 88%

1, 2 yr Ptx
Survival
82, 82%
100, 88%

Treated AR

BPAR

CAN

20(18%)
30(28%)

15(13%)
26(24%)

19(17%)
32(29%)
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Only 1 Alem BPAR has occurred after 12 months. Total daily MMF doses were
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similar for Alem and rATG groups at 3 months (1570±460 mg vs 1670±510 mg).
Neupogen use was greater in the Alem group, 26 (23%), than in the rATG group
(14 (13%), p=0.03). Excluding PAK, chronic allograft nephropathy (CAN) was
observed in 19 (17%) Alem pts compared to 32 (29%) rATG pts. (p=0.04).
Conclusions: Alem and rATG induction both provide excellent 1 and 2 yr pt,
Ktx, and Ptx survival. Alem is associated with lower acute rejection rates and
less CAN, but requires increased Neupogen administration to help maintain
MMF dosing.
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797 IMMUNE RECONSTITUTION IN HUMAN RENAL
ALLOGRAFT RECIPIENTS TREATED BY SIROLIMUS OR
CYCLOSPORIN AFTER THYMOGLOBULIN INDUCTION
THERAPY
E. Morelon1, N. Lefrançois1, C. Besson2, J. Prévautel2, M.N. Kolopp-Sarda2,
M. Brunet1, J.L. Touraine1, L. Badet1, F. Touraine-Moulin2, C. Malcus2
1
Tranplantation Unit, Edouard Herriot Hospital, 2Immunology Unit, Edouard
Herriot Hospital
Background: Little is known regarding the impact of the maintenance
immunosuppressive regimen on the immune reconstitution following induction
therapy by depleting antibodies. The aim of this study was to compare the
peripheral blood lymphocyte subsets time course in ATG-treated patients that
received either cyclosporin A (CsA) or sirolimus (Sir) in a phase IV monocenter
randomized open trial.
Patients and Methods: Nineteen renal allograft recipients received a short
(4 days) initial dose of ATG, and were randomized to receive either 5mg/kg
CsA (n=10; CsA group [CsAG]) or Sir (J0-J1 15mg, J2 10mg and thereafter
5mg/d; n=9; Sir group [SirG]). All patients received mycophenolate mofetil
and steroids. Absolute CD3, CD4, CD8 T lymphocytes were enumerated by
flow cytometry (Flow-Count, FC500 Beckman-Coulter) every 3 days after
transplantation for 15 days and at D30, D90, D180 and D365. B, NK and
NKT cell count was assessed by the same method at day 0 and from D30 to
D365.
Results: Four patients were excluded for adverse events at week 3, month 2.5,
7, 8 and at month 2, 3, 6 and 8 in SirG and in CsAG respectively. Following
ATG induction, total lymphocytes, CD3, CD4 and CD8 cells were deeply
depleted without any difference between the 2 groups. From D5 to D30, a
gradually increase of every T cell subsets was observed in both groups but
was significantly higher in CsAG than in SirG. At D30, the mean values of
lymphocytes, CD3, CD4 and CD8 cells/L are 306±173 vs 157±76, 107±149 vs
35±44, 46±67 vs 13±18, 60±85 vs 23±29 in the CsAG and SirG respectively
(p<0.01). No difference between the two groups remains at later time points
(D30 to D365): both groups displayed stable reduced (by 50%) number of
total, CD4+, and CD8+ lymphocytes as compared with the initial values. NK
and NKT cells were similarly depleted from D30 to D180 in the 2 groups and
increased slightly at D365. B cell count was not affected by ATG induction in
the 2 groups.
Conclusion: ATG depletion is not different on CsA and Sir. However, the nature
of the maintenance regimen influences the kinetic of the immune reconstitution
that is delayed on Sir as compared with CsA. The intensity of the reconstitution
appears similar on the two drugs after the first month.
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798 5 YEAR OUTCOMES IN A RANDOMIZED TRIAL
COMPARING RABBIT ANTITHYMOCYTE GLOBULIN AND
BASILIXIMAB IN KIDNEY TRANSPLANT RECIPIENTS:
LINKING CLINICAL TRIAL DATA WITH REGISTRY DATA
D.C. Brennan1, M. Schnitzler2
1
Washington University in St. Louis, 2Saint Louis University
Background: A prospective, randomized, comparative, international clinical
study recently reported that induction treatment with rabbit anti-thymocyte
globulin was as safe as and more effective in preventing acute rejection in
deceased donor kidney transplant patients than basiliximab at 1 year. To assess
the 5 year long-term outcomes of patients enrolled in this study, we employed a
novel technique of linking clinical study records to registry data.
Methods: In the United States (US), transplant centers are mandated to
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enter solid organ transplant recipients’ clinical data into Organ Procurement
and Transplantation Network (OPTN) database. To obtain 5 year followup data, each US-enrolled patient was identified from the OPTN database
using date of birth, date of transplant, gender, and transplant center. Matches
were verified using recipient and donor human leukocyte antigen, blood
group and cross-referenced with Social Security Death records. Clinical
outcomes at 5 years were obtained from the OPTN database and compared
between groups.
Results: All US-enrolled patients (n=183) were matched uniquely to their
OPTN records. The 5 year cumulative incidence of acute rejection was
significantly lower in patients treated with rabbit antithymocyte globulin
group (15/91, 15.96%) than patients treated with basiliximab (28/92, 30.04%),
P=0.029. At 5 years, rabbit antithymocyte treated patients also had the lowest
composite endpoint of acute rejection, graft loss, and death than basiliximab
treated patients, 38.85% and 51.95%, respectively, P=0.037. There were no
differences in the incidences of opportunistic infections and post-transplant
malignancies between groups.
Conclusions: Using this novel approach, we observed that the 12 months
benefits of antithymocyte globulin over basiliximab induction were
sustained through 5 years follow up without the penalties of increase
risks of post-transplant complications. While most clinical studies provide
only short-term efficacy and safety results, this methodology provides an
efficient way to monitor long-term efficacy and safety of patients enrolled
in clinical studies.
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799 LONG-TERM IMMUNOLOGICAL EFFECTS OF ATG
INDUCTION THERAPY
R. Weimer1, S. Deisz1, H. Dietrich1, C. Süsal2, F. Renner1, S. Kamali-Ernst3,
W. Ernst4, W. Padberg5, G. Opelz2
1
Department of Internal Medicine, University of Giessen, 2Institute of
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar,
4
Dialysis Center, Langenselbold, 5Department of Surgery, University of
Giessen
We showed previously that rabbit ATG induction therapy induces a strong
decrease of CD4+ T cells, impaired CD28 expression and IL-2 secretion
up to 1 year posttransplant. To analyze long-term immunological effects of
ATG induction, we used sensitive intracellular cytokine analysis at 2 years
posttransplant in the same prospective study of 84 renal transplant recipients
(ATG, n=44).
ATG induction was associated with an increased frequency of severe
infectious disease (46% versus 23%, p=0.03) but not CMV disease. The
persistent decrease of CD4+ T cell counts (p<0.0001) 2 years after ATG
induction treatment coincided with significantly suppressed T cell functions
(T cell proliferation, p=0.01; intracellular CD4 cell cytokine responses: IL-2,
p=0.04; IL-10, p=0.004). Profoundly diminished CD4 cell IL-10 responses
were in part counterregulated by a significant increase in IL-10R expression
which was found on CD4+ T cells only (p=0.002). These associations
were confirmed by multivariate logistic regression. The occurrence of
severe infections was related to a low CD4/CD8 ratio (¡Ü0.5; p=0.002),
elevated CD8 cell counts (p=0.01) and low CD8 cell IL-2 production
(p=0.02). Interestingly, we found no long-term effects on production of the
lymphoma growth factors IL-6/IL-10, IL-4 responses, CD4 helper activity
or sCD30 levels.
Our data show that ATG induction is associated with long-term immunological
effects 2 years posttransplant. Decreased T cell proliferation, CD4 cell
counts and IL-2 responses may account for an increased risk of severe
infectious disease and of PTLD after ATG induction because of inadequate
T cell control. Previously shown beneficial effects of low CD4 cell IL-10
responses on graft outcome may provide long-term graft protective effects
after ATG treatment.
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800 ATG VERSUS BASILIXIMAB INDUCTION THERAPY
IN KIDNEY ALLOGRAFT RECIPIENTS RECEIVING A DUAL
IMMUNOSUPPRESSIVE REGIMEN: SIX-YEAR RESULTS
A. Pascher1, F. Ulrich1, S. Kohler1, S. Weiss1, S. Tullius2, P. Reinke3,
P. Neuhaus1, J. Pratschke1
1
Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow,
Berlin, Germany, 2Division of Transplant Surgery, Brigham and Women’s
Hospital, Boston, MA, United States, 3Dept. of Nephrology, Charité, Campus
Virchow,Berlin, Germany
Purpose: The aim of this prospective randomized study was the comparison
of efficacy and incidence of adverse events in two induction therapy regimens
(ATG versus basiliximab) in patients receiving a dual immunosuppression.
Methods: 120 recipients of first or second deceased donor kidney transplants
were prospectively randomized to receive either ATG (Fresenius) or
basiliximab (Novartis) as induction therapy. Dual immnosuppression consisted
of tacrolimus (Astellas) and methylprednisolone. CMV prophylaxis was not
applied on a regular basis. Statistical analysis was performed with Fisher’s
exact or chi-squared test, ANOVA or Mann-Whitney U test, Kaplan Meier
curves and log-rank test.
Results: Patient characteristics of populations treated with ATG versus
basiliximab were similar concerning average age (48 years), gender and
dialysis time prior to transplantation (78 vs. 82 months). Average donor age and
cold ischemia were also comparable (43 vs. 41 years and 832 vs. 852 minutes).
The actuarial 5-year patient survival for the ATG subpopulation is 91,7% in
comparison to 85% in the basiliximab group (n.s.). Analyzing graft survival
after 5 years, rates of 88,3% in ATG patients compared to 75% in the basiliximab
group can be observed (n.s.). The incidence of acute rejection episodes was
similar in both groups (ATG: n=20 vs. basiliximab: n=16). 18 (30%) patients
in the ATG group and 20 (33,3%) in the basiliximab group showed a delayed
graft function. Serum creatinine was not significantly different at 1 and 5 years
(ATG: 1,4±0,6 mg/dl and 1,4±0,8 mg/dl vs. basiliximab: 1,3±0,7 mg/dl and
1,5±0,9 mg/dl). Patients in the ATG group had a higher rate of CMV infections
(n=13 vs. n=3; p=0,05) and significantly more hematological complications
like anaemia, leukopenia and thrombocytopenia.
Conclusion: Comparing induction therapy with ATG and basiliximab, our data
shows similar patient and graft survival rates with slightly better results in the
ATG group. Patients treated with ATG had a higher rate of CMV infections and
more hematological complications.
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801 LOW DOSE THYMOGLOBULIN VERSUS SIMULECT
INDUCTION IN ADULT KIDNEY TRANSPLANT WITH CNI
TRIPLE IMMUNOSUPPRESSION: EFFICACY AND SAFETY
M.R. Laftavi1, S. Sharma1, L. FIng1, R. Koholi2, I. Min2, D.M. Danek1, J.
Tullock1, M. Dayton1, D. Dunn1, O. Pankewycz2
1
Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at
Buffalo
Significant improvements in patient and graft outcomes following kidney
transplantation have been made over the past decade. However, the role
of induction therapy in these advances remains uncertain. Moreover, the
type of induction therapy, whether lymphocyte depleting therapies such as
Thymoglobulin (TGL) or non-depleting agents such as anti-IL2R antibodies,
is also controversial. In the recent reports, full dose TGL (7-10 mg/kg) was
associated with higher rates of infection and cancer compared to anti-IL2R
antibody induction. In this retrospective study, we compare the efficacy and
safety of a lower dose TGL induction therapy (3-5mg/kg total dose, mean dose
= 3.64 mg/kg) to Simulect (SM) (20mg given 4 d apart) induction therapy.
Between 2000 and 2007, 355 kidney transplant recipients received TGL and
93 patients (Pt.)received SM for induction. Both groups received equal triple
immunosuppression therapy consisting of a calcineurin inhibitor, MMF and
low-dose prednisone. Demographic data including sex, donor type, age, race,
HTN, DM, PRA> 30% and HLA matching was similar in both groups. Mean
CIT was longer in TGL group (15+9 vs. 13+9 hours, p=0.04). Both groups
had equal hospital stays (TGL 8.3 vs. SM 7.6 days, p= 0.44) and delayed graft
function (TGL 28% vs. SM 26%, p= 0.49).
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Pt.1y Pt.5y Gft.1y Gft.5y Ca. BK virus Other infections
TGL

98%

88%

96%

87%

2

6

76 (21%)

SM

93%

85%

95%

90%

1

0

14 (15%)

p value

NS

NS

NS

NS

NS

NS

NS

Table I. Pt.=patient survival,Gft.=graft survival, y=year, Ca=Cancer, *Graft
survival is death censored.
Over the past 7 years, 43 patients in the TGL group and 14 patients in the SM
group died (p=0.44). Of the 43 deaths in the TGL group, 6 died from infection/
sepsis compared to 1 in the SM group (p= 0. 67). All deaths due to infection
occurred after 4 months post-transplant and 80% occurred after 2 years. Acute
graft rejection occured in 11% and 13% in TGL and SM group respectively
(p=0.6). Graft lost (death censored) occurred in 43 pts in TGL group compared
to 9 pts who received SM (p=0.51). Conclusion: low dose TGL and SM were
equally effective in promoting graft survival and preventing acute rejection.
There was no increased risk of death, infection or cancer in the low-dose (3-5
mg/kg total dose) TGL group.
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802 THYMOGLOBULIN DOSING INTENSITY AND
DENSITY: EFFECTS ON INDUCTION EFFICACY IN EARLY
CORTICOSTEROID WITHDRAWAL REGIMENS
E.S. Woodle1, R-A.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1,
P. Roy-Chaudhury1, A. Govil1, M. Clippard2
1
Surgery, U of Cincinnati, 2Christ Hospital
Thymoglobulin (TMG) induction reduces acute rejection (AR) risk in early
corticosteroid withdrawal (ECSWD) regimens in kidney transplantation (KTx).
However, inadequate data exists regarding dosing strategies (fixed versus CD3
based), intensity, and density of dosing on TMG efficacy. The purpose of this
study was to evaluate TMG dosing intensity and density on AR.
Methods: Data was collected prospectively in 334 pts who received TMG
induction and ECSWD. Variables with a p<0.20 entered the multivariate
(MVA) stepwise logistic regression model. TMG dose was 1.5 mg/kg. TMG
regimens were: fixed dosing (days 0,2,4,6) and CD3 based (dose given when
CD3+ cells > 25/ul).
Results: Data is presented as CD3 dosing/fixed dosing: Total # pts 194
/140, mean follow-up (days) 1526±699/898±609 (p<0.01). AR rate was
higher with CD3 based dosing (16%/8%, p<0.03). Univariate analysis
(UVA) of AR risk factors (gender, African American (AA) recipient race,
PRA >25%, delayed graft function (DGF), DR mismatches, diabetes, repeat
transplant) and TMG dosing data (dosing regimen type (fixed v CD3based), total dose (mg/kg), total dose by categories (£6 mg/kg and > 6 mg/
kg), and # of doses) was performed. Significant UVA factors (p<0.2) that
entered the MVA model are in the table below. In the final MVA model,
significant risk factors included CD3 dosing regimen and AA recipient race.
Additional MVA analyses that excluded DGF pts (33/334 pt) confirmed
these observations.
Odds Ratio

95% Confidence Interval

African American

UVA for AR

1.9

1.0-4.0

Repeat Transplant

1.8

0.8-4.3

Fixed dosing

0.4

0.2-0.9

Fixed dosing (total dose £6 mg/kg)

1.9

0.7-5.2

CD3 dosing

2.3

1.1-4.8

CD3 dosing (total dose >6 mg/kg)

3.0

1.3-7.4

Odds Ratio

95% Confidence Interval

CD3 dosing

2.5

1.3-6.1

African American

2.2

1.2-5.6

MVA for AR
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Conclusion: These analyses indicate that fixed TMG dosing which provides
greater dosing density is associated with decreased AR in ECSWD.
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803 EFFICACY OF A NOVEL RABBIT ANTI-HUMAN
LEUKOCYTE POLYCLONAL ANTIBODY IN PREVENTING
ACUTE RENAL ALLOGRAFT REJECTION IN NONHUMAN
PRIMATES
H. Xu1, Z. Liu1, A. Kirk2
1
Jinan City Central Hospital, 2Department of Transplantation, Emory
University Hospital, Emory University, Atlanta, USA
Thymoglobulin® is generated using thymocytes and thus has broad depleting
activity focused primarily on naïve T-cell populations. However, acute rejection
is mediated by activated T cells and monocytes. We have therefore developed
an anti-human leukocyte polyclonal antibody (newRALG) by immunizing
rabbits with activated lymphocytes and monocytes to specifically target these
activated cells. newRALG depletes lymphocytes and monocytes in vitro,
and targets multiple molecules on activating lymphocytes and monocytes to
a greater degree than thymoglobulin®. Surviving newRALG-treated human T
cells upregulate CTLA4, CD25, and Foxp3 molecules suggestive of regulatory
function. To evaluate the efficacy of newRALG in preventing allograft
rejection, rhesus macaques were treated with newRALG at 0, 1, 2.5, 5, or 20
mg/kg, and thymoglobulin® at 5mg/kg for 5 days. Fifteen animals underwent
renal transplantation. Lymphocyte and monocyte counts were decreased
following newRALG infusion, and reduced lymphocyte proliferative response
in MLR. The allograft survival in untreated monkeys (n=6) was 6.5±1.4 days.
Thymoglobulin® treated monkeys (n=3) rejected renal allografts between
11 to 27 days (mean=17±8.7). Monkeys treated with 2.5 mg/kg newRALG
rejected allograft in a mean of 16.7±10.8 days, and those treated with 5 mg/
kg rejected allograft in a mean of 26.3±7.1 days (p=0.01, vs thymoglobulin®).
Rabbit antibody was cleared within 14 days of infusion as determined by
FACS analysis of peripheral lymphocytes. Thus, newRALG inhibits rhesus
lymphocyte proliferation in MLR in vitro and in vivo, depletes monocytes
and lymphocytes including memory T cells in vivo, and significantly prolongs
renal allograft survival in rhesus. This strategy for generating memory selective
polyclonal antibodies may offer a better means of depleting alloreactive cells
than current, non-selective polyclonal strategies.
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804 POST-TRANSPLANT TUBERCULOSIS: SINGLE CENTER
EXPERIENCE FROM THE DEVELOPING WORLD
U. Hegde, K. Gogel, S. Gang, M. Rajapurkar
Muljibhai Patel Urological Hospital, Nadiad,Gujarat,India
Tuberculosis incidence is high in the transplant recipients especially in the
developing countries. Objective: The aim of our study is to study the prevalence
and to predict the risk factors for post-Transplant (Tx) Tuberculosis(TB)
Methods: This retrospective study is based on 498 renal allograft recipients
transplanted during the period January 2000 to December 2004. TB was
diagnosed AFB +vein fluid or tissue/histology suggestive of TB/ exudative
lymphocytic effusion/PUO with therapeutic response to anti-tubercular
therapy (ATT). Kaplan-Meier survival analysis and log rank statistics were
used to study the association between explanatory variables and post-Tx TB.
Cox proportional hazard model was used to measure the risk factors for TB in
the early (<18 Months) and late (>18 Months) post-Tx. period. The variables
considered were age, gender, donor type, MMF, HBV and HCV, DM, PTDM,
CMV, rejection and dialysis duration in months were analyzed using SPSS
Results: M/F: 388/110 with age 37.9 + 11.2 years .The prevalence of TB 12.85%
(64/ 498) over median (range) 39 (1, 90) months follow up. 46 had an early
while 18 had late onset post-Tx. TB. In the early TB; age (p=0.02) and other
than related donors (p=0.01) while in the late TB age (p=0.03), MMF (p=0.007),
PTDM (p=0.02) and duration of dialysis (p=0.04) were found to be the predisposing factors. No difference in the graft survival and patient survival in those
who suffered and not suffered the tuberculosis in the post transplant period.
Conclusion: Age, other than related donor in the early post-ttransplant period;
Age, MMF, PTDM, dialysis duration in the late post-transplant period were
pre-disposing factors for the occurrence of the post-transplant tuberculosis.
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805 HIGHER RISK OF TUBERCULOUS INFECTIONS AND
COMPLICATIONS IN HEPATITIS B OR C TRANSPLANT
RECIPIENTS THAN NON-CARRIER
B.Y. Choy, D. Yap, K.C. Tse, S.L. Lui, T.M. Chan, K.N. Lai
Department of Medicine
To determine the prevalence and risk factors for tuberculous infection (TB)
among the Chinese transplant recipients, we retrospectively analyzed all
renal transplant recipients who had been followed up in our centre from
1995 to 2007. Of the 436 patients, 21 patients (4.8%) were diagnosed to
have tuberculous infection. Seven patients were hepatitis B carrier and 3
were hepatitis C carrier. Seven patients were diabetic. The median interval
between transplant and diagnosis of TB was 89.5 months (range 3.8 to 247
months) and the mean age was 48.5 ± 8.3 years. Immunosuppressive therapy
consisted of triple therapy with cyclosporine A/tarcolimus, prednisolone
and azathioprine/mycophenolate mofetil. Hepatitis carriers were on double
therapy with omission of azathioprine. All except one hepatitis B carrier were
on lamivudine. Majority of patient had pulmonary involvement (71.4%).
Other site of involvement included disseminated disease 14.5%, laryngeal
9.5%, urological 9.5% and skin 9.5%. All patients were treated with standard
4 drugs regime with isoniazid, rifampicin, levofloxacin/moxifloxacin and
pyrazinamide/ethambutol with reduction to 2 drugs after 3 months if stable.
Doses of cyclosporine A /tarcolimus were adjusted according to serum level
and the treatment course was 9 to 12 months. Hepatitis B carrier status (OR
5.27, p<0.01), hepatitis C carrier status (OR 7.9, p<0.01) and DM (OR 3.65,
p<0.01) were independent risk factors for TB infection. Hepatitis B and C
carriers were also associated with higher liver related complications. Two
hepatitis B patients had flare up of the viral hepatitis needing replacement of
lamivudine with adefovir /entecavir. One hepatitis B patient had rifampicin
related hepatitis and another with rifampicin related thrombocytopenia. One
hepatitis C patient had isoniazid related hepatitis. Complications in noncarriers included gouty arthritis in two and isoniazid related neuropathy in
one. Two patients (1 hepatitis C and 1 non carrier) died due to uncontrolled
co-infections. All other patients recovered. In summary, tuberculous infection
was associated with significant morbidity and mortality in renal transplant
recipients. Hepatitis B and C carriers are more prone to TB infection
and development of liver related complications. Close monitoring of the
liver function and the level of viral replication of the hepatitis carriers are
important during the treatment course for proper diagnosis and treatment of
any liver dysfunction.

indication for transplantation (61.1% and 60.0% extrahepatic biliary atresia,
p=0.641). The rate of RSV infections did not differ between the PLT recipients
who received palivizumab and those who did not (8.3% and 10%, p=0.802);
however, the rate of RSV hospitalization did differ (0% palivizumab and 10%
no palivizumab, p=0.05). RSV infections manifested more frequently as a
LRTI in children who did not receive palivizumab prophylaxis compared to
those who did (75% and 0%, p=0.047). The mean hospital length of stay was
7.5 days (range, 3-13 days). Two children required admission to the intensive
care unit and mechanical ventilation; all required supplemental oxygen. There
were no deaths attributed to RSV.
Conclusion: This retrospective review suggests that palivizumab may prevent
progression of a RSV URTI to a LRTI and prevent hospitalization when
administered prophylactically in PLT recipients. To understand the full extent
of the benefit of palivizumab prophylaxis in this population prospective studies
are necessary.
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807 BENEFITS OF ISONIAZID CHEMOPROPHYLAXIS IN
RENAL TRANSPLANT RECIPIENTS
A. Naqvi, M. Hussain, R. Naqvi, S. Akhtar, F. Akhtar, E. Ahmed, A. Rizvi
Sindh Institution of Urology And Transplantation
Purpose: The incidence of post transplant tuberculosis is 15% in the
developing world. The aim of this study was to evaluate effect of Isoniazid
(INH) chemoprophylaxis on post transplant TB infection.
Methods: Four hundred and two patients were randomized and 187 received
INH prophylaxis at 300mg/day for one year and 215 without prophylaxis were
taken as controls prior to transplantation. Primary disease and co-morbidities
were similar in both groups. Immunosuppression was by triple drug. All
patients were followed for 1 year.
Results: The exposure risk factors in treated group A and controls group B
were, past TB 5.3% A vs 5.5% B, TB in close contacts 3.2% A vs 2.7% B,
acute rejection 10.1% A vs 10.2% B, smoking 12.7% A vs 9.6% B. At one
year follow-up 1 (0.62%) patient from group A and 10 (5.9%) from group B
developed TB. Site of TB was pulmonary in 9, joint in 1 and lymph node in 1.
The average duration of TB development was 32 weeks (range 11 64).
Conclusion: The study has shown that INH prophylaxis reduces post transplant
tuberculosis. Chemoprophylaxis may thus play an important role especially in
developing centres where TB is endemic.
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806 RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS
WITH PALIVIZUMAB IN PEDIATRIC LIVER TRANSPLANT
RECIPIENTS
A. Campbell1,2, N. Kerkar1
Mount Sinai School of Medicine, 2Abbott
Background: Respiratory syncytial virus (RSV) lower respiratory tract
infection (LRTI) in the post-transplant period is associated with significant
morbidity and mortality. Palivizumab, a RSV-specific monoclonal antibody,
has been shown to reduce the incidence of RSV hospitalization and the severity
of breakthrough disease in preterm infants with and without chronic lung
disease and infants with hemodynamically significant congenital heart disease.
As part of a comprehensive immunization program in pediatric liver transplant
(PLT) candidates and recipients at Mount Sinai, palivizumab (15 mg/kg IM
monthly during RSV season) was recommended for PLT recipients <4 years
of age beginning 2003.
Objective: To describe the impact of palivizumab prophylaxis on RSV
infections in PLT recipients at Mount Sinai School of Medicine.
Methods: Retrospective chart review of PLT recipients <4 years of age
transplanted between 01/01/2000 and 12/31/2005 was performed.
Results: 76 PLT recipients were identified; 36 received palivizumab
prophylaxis and 40 did not. Demographics did not differ between PLT
recipients who received palivizumab and those that did not with respect to
gender (55.6% and 60.0% female, p=0.814), race (63.9% and 57.5% nonwhite, p=0.150) mean age at transplant (0.94 years and 1.2 years, p=0.600) and
1

808 TRANSPLANTATION OF KIDNEYS FROM ANTI HCV
POSITIVE DONORS – RESULTS
A. Paul1, K. Nowak1, A. Gallinat1, F. Pietruck2, F. Saner1, O. Witzke2, J.
Treckmann1
1
University Hospital Essen, Clinic for General, Visceral and Transplantation
Surgery, 2University Hospital Essen, Clinic for Nephrology
Strategies for increasing the pool of kidney donors include acceptance of
donors with chronic infections like hepatitis c virus (HCV) infection. 5% of
all potential donors in Europe are positive for antibodies to HCV. Only few
centres in Europe include acceptance of kidneys of HCV positive donors
in their centre profile leading to the fact that most of the organs from HCV
positive donors in the Eurotransplant region are transplanted at the University
of Essen (Germany). The outcome of the recipients of kidneys of anti HCV
positive donors is analysed in this study.
Patients and Methods: Between September 2002 and May 2007 51 patients
(25 women, 26 men) were transplanted with kidneys of anti HCV positive
donors. 30 recipients had a chronic HCV infection before transplantation.
The remaining 21 recipients were HCV negative. 20 of them were
transplanted after HCV PCR was performed with negative result. One patient
(age 70) was transplanted with a PCR positive kidney and infected. All
patients signed an informed consent concerning the risk of new infection
and possible deterioriation of the underlying HCV infection. Peripoperative
data as well as data concerning graft function, liver function and serological
examinations (anti HCV antibodies, HCV PCR) were collected and
analyzed prospectively.
Results: Graft survival after one year was 87% and patient survival 95%.
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One patient was newly infected with HCV without actual consequences
concerning liver function but received a well functioning graft of a 25 year
old donor (s. patient and methods). Two patients with underlying HCV
infection showed deterioriation of liver function one without correlation to
transplantation one with genotype crossing. Of the 20 recipients without
HCV infection transplanted with kidneys of anti HCV positive donors with
negative HCV PCR none got infected. Mean waiting time of the study
group was 12 months shorter than mean waiting time in the Eurotransplant
region.
Conclusion: Acceptance of kidneys of anti HCV positive donors increases
the donor pool and is safe for recipients with chronic HCV infections. Also
recipients without HCV infection can be transplanted safely if PCR is negative.
In rare cases especially in old recipients HCV infection can be accepted as
consequence of transplantation.
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809 SYK, A NOVEL THERAPEUTIC TARGET FOR PTLD,
DRIVES EPSTEIN BARR VIRUS (EBV)+ B CELL LYMPHOMA
GROWTH AND SURVIVAL THROUGH ACTIVATION OF THE
PI3K/AKT PATHWAY

THURSDAY

O. Hatton1,2, S. Lambert1,2, M. Vaysberg1,2, J. Sharman3, S. M. Krams1,2, C. O.
Esquivel1, O. M. Martinez1,2
1
Department of Surgery/Division of Transplantation, Stanford University
School of Medicine, 2Program in Immunology, Stanford University School
of Medicine, 3Department of Medicine/Division of Hematology/Oncology,
Stanford University School of Medicine
Post-transplant lymphoproliferative disorder (PTLD)-associated Epstein Barr
Virus (EBV)+ B cell lymphomas are a serious, and often fatal, complication
of solid organ and bone marrow transplantation. Currently, therapeutic
options are limited and, apart from reducing immunosuppression, there is no
consensus regarding treatment strategies. EBV+ B cell lymphomas associated
with PTLD express several viral genes including latent membrane protein
2A (LMP2A). LMP2A mimics a constitutively active B cell receptor (BCR)
and provides survival signals to latently infected host cells in part by the
recruitment of the Syk tyrosine kinase and activation of downstream signalling
pathways, such as the PI3K/Akt pathway. We hypothesized that inhibition of
Syk activity would diminish growth of EBV+ B cell lymphoma lines derived
from patients with PTLD. Treatment with R406, an orally available inhibitor
of Syk, decreased proliferation and induced apoptosis of these lymphomas,
as assayed by 3H-thymidine incorporation and Annexin-V/PI staining,
respectively. Western Blot analysis for total Syk and autophosphorylated
Syk (Y525/526) revealed that Syk is constitutively activated in these
PTLD lines. Additionally, treatment with R406 led to a decrease in Syk
autophosphorylation at Y525/526, suggesting that Syk is the target of
the small molecule inhibitor R406. Syk is the tyrosine kinase exclusively
responsible for the phosphorylation of B cell linker protein (BLNK, SLP-65),
an important component of the BCR signalling pathway. Treatment of Ramos
cells, a human Burkitt’s lymphoma line, with R406 led to a decrease in the
phosphorylation of BLNK upon BCR ligation as determined by intracellular
staining. Together, these data verify that Syk is the target of R406. The PI3K/
Akt pathway plays a crucial role in cell growth and survival; in EBV+ B
cell lymphomas, activation of the PI3K/Akt pathway leads to, among other
things, secretion of the autocrine growth factor IL-10. Akt is constitutively
activated in EBV+ B cell lymphoma lines; however, treatment with R406
or Syk siRNA resulted in a significant decrease in levels of phosphorylated
Akt, as determined by Western Blot. Additionally, treatment of PTLD lines
with R406 or Syk siRNA led to decreased autocrine IL-10 production. These
data indicate that Syk mediates its effects on EBV+ B cell lymphoma growth
and survival in part through activation of the PI3K/Akt pathway. Thus, these
results provide mechanistic insight into how targeting Syk with inhibitors
such as R406 may serve as an effective therapeutic strategy for the treatment
of EBV-associated PTLD.
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810 GUIDELINES AND PHYSICIAN PRACTICES IN
RELATION TO VACCINATION OF BONE MARROW
TRANSPLANT (BMT) RECIPIENTS – THE AUSTRALIAN
PERSPECTIVE
A. Torda1, J. Alexander1, N. Gilroy2
1
Prince of Wales Hospital, Sydney, 2Westmead Hospital, Sydney
Background: Following BMT, not only are patients at risk of infection because
of immunosuppression, they also lose immunity acquired from previous
immunisation against vaccine preventable infections. As a result of this, bone
marrow transplant recipients need re-vaccination against a number of vaccine
preventable. The aim of this project is to review available guidelines for the
vaccination of bone marrow transplant recipients and examine knowledge of
and compliance with local guidelines in a local group of transplant physicians
and recipients.
Method: A questionnaire was administered to physicians involved in bone
marrow transplantation and bone marrow transplant recipients. This physician
questionnaire examined their knowledge of and practices in relation to
vaccination of BMT recipients. A questionnaire was also sent out to BMT
recipients to examine what vaccinations they had received and how these had
been organised.
Results: Two major international guidelines were most commonly used by BMT
physicians to guide their practice. There are no national Australian guidelines
specifically for this group of patients, and some hospitals have even developed
their own. In relation to vaccination practices, there was significant variation
amongst physicians. Most physicians felt that vaccinations were important, but
did not initiate them or have a system for ensuring that patient vaccinations
were carried out. Patient responses echoed this variability even more, and
confirmed that many patients had not received appropriate vaccination.
Conclusion: This study highlights the need for national post-BMT vaccination
guidelines in Australia. It also suggests that systems need to be developed
for ensuring that appropriate post-BMT vaccinations are actually performed
regularly.
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811 SILENCING OF HLA CLASS I EXPRESSION BY
LENTIVIRUS VECTOR-MEDIATED RNA INTERFERENCE
RESULTS IN RESISTANCE OF PRIMARY HUMAN CELLS TO
ALLOREACTIVE T CELL-MEDIATED CYTOTOXICITY
N. Kasahara1,2, N. Lemp1, K. Houston2, C. Rhodes2,S. Musa2, K. Haga1, R.
Stripecke1,3, R. Mendez2,4, C. Kruse5, J. Cicciarelli2,4
1
University of California Los Angeles (UCLA), 2National Institute of
Transplantation, 3Hannover Medical School, 4University of Southern
California (USC), 5Sidney Kimmel Cancer Center
Background: Recent advances in vector technology now allow the
possibility of genetically engineering graft tissues to express reduced
levels of HLA. Reducing HLA expression could help to overcome the
limitations imposed by polymorphisms which restrict availability of
suitable donors, complicate logistics of procuring and delivering matched
tissues and organs, and necessitate life-long immunosuppression. We
have previously shown that lentiviral vectors can be used to deliver short
hairpin RNAs (shRNA) that knock down HLA expression in a class- or
allele-specific manner in established human cell lines, and thereby allow
evasion from immune recognition by alloreactive T cells. Here we have
further characterized and quantitated the effects of dose-dependent gene
transfer and shRNA-mediated knockdown of HLA in human cell lines and
primary cells on their ability to be recognized by alloreactive cytotoxic T
lymphocytes (alloCTL).
Materials & Methods: Lentiviral vectors for shRNA targeting Class I-specific
and HLA-A0201 allele-specific sequences were employed to transduce 293T
human embryonic kidney cells and CD34+ human primary hematopoietic
progenitor cells. Transduced target cells were analyzed for sensitivity to
cytolysis by incubation with HLA A2-activated alloCTL at an E:T ratio of 10:1.
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Interferon-gamma production from the alloCTLs was measured by ELISA, and
viability of target cells was determined by MTS assay, annexin V staining, and
complement-mediated cytotoxicity assay.
Results: With higher multiplicities of infection (MOI=10-30), cell surface
expression of HLA-A2 and HLA-ABC was reduced in a dose-dependent
manner by 50% or >80%, respectively, compared to cells transduced with
control vector. Additionally, relative to target cells transduced with control
vector, target cells transduced with HLA-ABC shRNA and HLA-A0201
shRNA vectors induced 2.5- and 4.5-fold less interferon production from
alloCTL, respectively, and exhibited >2-fold enhanced resistance to alloCTLmediated killing (p<0.05). However, there were no significant differences in
survival of shRNA vector-transduced target cells compared to control vectortransduced cells after incubation with non-HLA-restricted LAK cells derived
from the same donor.
Conclusions: Reducing expression of HLA in a class- or allele-specific manner
may be as effective as utilization of powerful non-specific immunosuppressive
drugs, and would represent a fundamental shift in the concept of achieving
histocompatibility, by engineering the graft rather than immunosuppressing the
host. While efficient gene transfer to entire solid organs remains a technical
hurdle, application of this strategy can be readily envisioned for ex vivo
transduction of cellular transplants such as bone marrow and stem cells,
pancreatic islet cells, and keratinocytes.
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812 HUMAN PLASMACYTOID DENDRITIC CELLS INDUCE
PROFOUND HYPORESPONSIVENESS AND SUPPRESSIVE
CAPACITY IN ALLOGENEIC T-CELLS
H. Metselaar1, P. Boor1, S. de Jonge1, L. van der Laan2, J. Kwekkeboom1
Department of Gastroenterology and Hepatology, ErasmusMC -University
Medical Center, Rotterdam, The Netherlands, 2Department of Surgery,
ErasmusMC -University Medical Center, Rotterdam, The Netherlands
Background: A major barrier for induction of liver transplant tolerance in
humans is their large repertoire of allo-reactive memory T-cells, which rapidly
respond to allo-antigens, even when these are presented by non-professional
antigen-presenting cells. We investigated whether human plasmacytoid
dendritic cells (PDC) can induce hyporesponsiveness and suppressive capacity
in allogeneic T-cells containing memory T-cells.
Methods: Purified PDC from human blood, were stimulated with Toll-Like
Receptor (TLR)-7 agonist loxoribine (LOX) or TLR-9 ligand CpG A. After 20
hours, allogeneic T-cells containing CD45RA+ naïve and CD45RO+ memory
cells, were added. T-cell proliferation, cytokine production, CD25 and Foxp3expression were determined after 7 days. Hyporesponsiveness was assessed
in re-stimulations with LPS-matured monocyte-derived DC (MoDC), and
suppressive capacity was determined by adding graded numbers of PDCprimed T-cells to responder T-cells stimulated by mature MoDC, either derived
from the same donor as PDC, or from a third party.
Results: Toll-like receptor (TLR)-stimulated PDC primed allogeneic T-cells
to produce IL10 (CpG-PDC: 668±260 pg/ml; LOX-PDC: 715±369 pg/
ml). After stimulation with CpG-PDC or LOX-PDC 13±2% and 14±2%,
respectively, of allogeneic CD4+ T-cells acquired Foxp3 and CD25expression. CFSE-dilution showed that TLR-stimulated PDC induced
proliferation of CD4+Foxp3hi T-cells. No Foxp3hi T-cells were generated
when CD25+ T-cells were depleted from allogeneic T-cells prior to their
stimulation with PDC, showing that their enrichment was due to expansion
from pre-existing Treg. T-cells primed by TLR-stimulated PDC were
hyporesponsive upon restimulation with mature MoDC derived from the
same donor (90% decrease in proliferation compared with fresh T-cells),
and suppressed responder T cells stimulated by mature MoDC in a dosedependent and donor-specific fashion (55% inhibition of proliferation at
suppressor:responder ratio of 1:2). Suppression was abrogated by anti-IL10
receptor antibody.
Conclusion: TLR-stimulated human PDC induced profound hyporesponsiveness
nand suppressive capacity in allogeneic T-cells, including memory T-cells.
Cellular immunotherapy with PDC from donor blood may be considered as
a promising approach to silence the allo-reactive repertoire of liver transplant
recipients.
1
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813 HOST MHC CLASS I-DEPENDENT IMMUNITY IMPAIRS
ISLET XENOGRAFT PROLONGATION
F. Ramirez-Victorino1, J. Beilke2, R.G. Gill3
University of Colorado Health Sciences Center, 2University of California,
San Francisco, 3University of Alberta/Alberta Diabetes Institute
Background: Recent studies show an unexpected role for host MHC class
I-dependent immunity and NK cells in promoting islet allograft tolerance. In
this study, we determined whether induced islet xenograft prolongation also
showed a reliance on MHC class I-dependent pathways. In particular, we tested
whether NK1.1+ NK/NKT cells and/or CD8 T cells were required for the longterm (>100 day) survival of rat islet xenografts following a short course of
combined anti-CD154 plus anti-LFA-1 monoclonal antibody therapy.
Methods: 450 WF (RT1u) islets were grafted beneath the kidney capsule of
streptozotocin-induced diabetic C57Bl/6 (B6; H-2b), B6 NKT cell-deficient
CD1-knockout, or CD8 T cell-deficient CD8-knockout mice. Recipients
were either untreated or treated with combined anti-CD154 (MR1; 250 μ;g d
–1,2,7,9) plus anti-LFA-1 (KBA; 200ug d 0,1,7,14). In addition, some animals
were also depleted of NK1.1+ cells prior to transplant (PK136; 500ug d –1).
Long-term (>100 day) xenograft survival was confirmed by nephrectomy of
the graft-bearing kidney with subsequent return to hyperglycemia.
Results: WF rat islet xenografts were rapidly rejected in all untreated wild-type
B6, CD1-deficient, and CD8-deficient recipients (all rejecting within 13 days)
indicating that neither CD1-dependent NKT cells nor CD8 T cells are required
for rejection. In wild-type B6 mice, anti-CD154/anti-LFA-1 treatment resulted
in prolonged, but not indefinite xenograft survival (6/6 grafts rejecting in 62.3 ±
14 days). Such xenograft prolongation was not significantly enhanced in treated
CD1-deficient mice (6/9 grafts rejecting in 57.9 ± 12 days; p = NS). In contrast,
while anti-NK1.1 treatment itself did not prolong xenograft survival, adjunct
depletion of NK1.1+ cells greatly enhanced the efficacy of anti-CD154/antiLFA-1 therapy with 5/6 xenografts surviving >100 days (p = 0.015 relative to
anti-CD154/anti-LFA-1 therapy alone). Furthermore, anti-CD154/anti-LFA-1
therapy showed greater efficacy in CD8-deficient animals (6/6 xenografts
surviving >100 days; p < 0.01 relative to wild-type).
Conclusions: While previous studies show that the depletion of NK1.1+
cells inhibits islet allograft survival, this same approach greatly augments the
survival of islet xenografts. Thus, the role of NK1.1+ cells can play opposite
roles in the prolongation of islet allografts versus xenografts. Also, while CD8
T cells are not required for acute xenograft rejection, they do constitute a
resistance to induced xenograft prolongation in this model. Thus, both NK1.1+
cells and CD8 T cells represent MHC class I-dependent immune pathways that
can impede long-term islet xenograft prolongation.
1
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814 CD300A AND CD300C ON PLASMACYTOID DENDRITIC
CELLS ARE DOWN-REGULATED BY TLR7 AND TLR9 LIGAND
INDUCED TYPE I INTERFERON
D. Hart1, G. Clark1, X. Ju1, M. Zenke2
1
Mater Medical Research Institute, 2Institute for Biomedical Engineering,
Department of Cell Biology, Aachen University Hospital, Aachen, Germany
The success of transplantation relies on the ability to control immune responses.
The CD300 family of leukocyte surface molecules are immunoregulatory
glycoproteins that balance the immune response. In humans, there are 6
members of the family, CD300a-f. Both CD300a and CD300c are broadly
expressed on leukocytes, CD300b, d, and f are expressed on myeloid cells
and dendritic cells, whilst CD300e is restricted to monocytes. Plasmacytoid
dendritic cells (pDC) constitute a distinct population of DC in the peripheral
and secondary lymphoid organs. Human pDC numbers predict for the success
of haematopoietic stem cell transplantation and acute graft versus host disease
(GVHD). High numbers of pDC in a graft facilitate engraftment. In this study
we analysed the expression of CD300a and CD300c on pDC. After activation
with the ligands for Toll-like receptors (TLRs), particularly TLR7 and TLR9,
pDC secrete large amounts of type I interferons and differentiate into mature
DC, expressing co-stimulatory molecules and other cytokines. CD300a and
CD300c cell surface molecules are expressed by pDC and their expression was
down-regulated by CpG ODN binding TLR9. Because these CD300 molecules
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play important roles in regulating immune responses, we investigated their
contribution to pDC function in more detail. First, their down-regulation by
CpG-ODN was confirmed by real time PCR and RT-PCR for CD300a and
CD300c. Using the monoclonal antibody CMRF-35, to detect both CD300a
and CD300c, we demonstrated that both TLR7 and TLR9 ligands downregulated cell surface CD300a and CD300c. We showed that exogenous IFN-á
down-regulated CD300a/c expression in pDC. This suggested that the TLR
ligand induced down-regulation of CD300a/c might be an indirect effect and
in subsequent experiments, we added neutralizing antibody to IFN-á and found
that, it abolished the CpG-ODN induced CD300a/c down-regulation. The effect
of CD300a and CD300c activation on the function of pDC was investigated by
cross-linking CMRF-35 on pDC. This had no effect on CD80, CD83 and CD86
expression, but decreased MHC-II expression. Significant reductions in pDC
TNF-á and IL-6 production occurred after CMRF-35 cross-linking, however,
in marked contrast, CpG-ODN induced IFN was increased in pDC cross-linked
with CMRF-35. Thus the immune regulators CD300a and CD300c regulate the
cytokine production in pDC, whilst the pDC released cytokines regulated the
CD300a/c expression. This suggests that CD300 molecules may play a pivotal
role in fine tuning pDC driven immune responses. CD300a and CD300c are
also expressed on conventional DC (cDC). Our results indicate that these
molecules also regulate cytokine secretion by cDC. Thus members of this
family are likely to be important regulators for controlling transplant rejection
and might be useful therapeutic targets.
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815 T CELLS ACQUIRE HLA-G VIA TROGOCYTOSIS FROM
GENETICALLY MODIFIED HUMAN DENDRITIC CELLS
DURING ALLOIMMUNE ACTIVATION
B. Fedoric1,2, R. Krishnan1,2
The Queen Elizabeth Hospital, 2University of Adelaide
The Human Leukocyte Antigen (HLA-G) is expressed in the placenta and has
a role in protecting the foetal allograft from being rejected by the maternal
immune system. Immunomodulation mediated by HLA-G is predominantly
due to its interaction with its inhibitory ligands, ILT2 and ILT4 which belong to
the Immunoglobulin-like transcript (ILT) family of molecules. Recent studies
have reported that HLA-G can transfer to T cells via membrane cell fragments
by the process of trogocytosis using LCL cell lines expressing HLA-G.
Since dendritic cells (DC) are the major antigen presenting cells that initiate
allograft rejection, the ability of these cells to transfer HLA-G to allogeneic T
cells was investigated. Due to the low levels of HLA-G on human monocytederived dendritic cells, adenoviral gene constructs were used to transduce high
expression of the protein.
Adenoviral constructs containing the gene for the trans-membrane, HLA-G1
(ADV-HLA-G1), and the secreted, HLA-G5 (ADV-HLA-G5) isoforms were
used to transfect DC. Flowcytometry confirmed that DC expressed low HLA-G
and following transfection with ADV-HLA-G1, induction of cell surface
expression occurred (MFI of 3000 in HLA-G1 transfectants vs. 100 in control
transfectants). In addition, the HLA-G1 expressed on DC-transfectants showed
binding to ILT2-Fc (87% HLA-G1 transfected DC) indicating that the HLA-G1
was structurally functional. DC transfected with ADV-HLA-G5 and ADV-VB
(vector-blank) showed no detectable cell surface expression of HLA-G.
DC transfectants were then tested for their ability to transfer HLA-G to
allogeneic T cells using two different approaches. In the first approach, T
cells were pre-activated with IL2/PHA for 72 h prior to co-incubation with the
specific DC transfectants for 1 h at 370 C to allow for trogocytosis and then
stained with the anti-HLA-G mAb, 87G. Two colour flowcytometry analyses
showed that 10% of T cells expressed HLA-G upon co-incubation with HLA-G1
DC transfectants compared with 0.4% for ADV-HLA-G5 transfectants. Control
T cells that were not pre-activated were unable to acquire HLA-G1 from DC
transfectants. In the second approach, allogeneic T cells as responders were
cocultured with DC transfectants as stimulators in a ratio of 10:1 in a DC-MLR
and analysed for HLA-G transfer to T cells after 3 and 5 days, respectively.
Under these conditions, 22% of T cells acquired HLA-G from HLA-G1
transfectants compared to a baseline of 6% for HLA-G5 transfectants. HLA-G
acquired by T cells was observed as early as 1 h, peaked at day 3 and was
maintained at 5 days of culture. Functional assays of the T cells cocultured
with HLA-G1 transfectants demonstrated hyporesponsiveness to interleukin-2
(IL-2) stimulation (43% proliferation compared to control; p=0.05).
In conclusion, this study demonstrates that DC genetically modified to express
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only the transmembrane isoform of HLA-G were able to transfer to allogeneic
T cells via trogocytosis. In addition, allogeneic T cells that acquire HLA-G
by trogocytosis demonstrate hyporesponsiveness to IL-2 stimulation. These
observations suggest that genetically modified DC expressing HLA-G may
offer a novel approach to modify the alloimmune response to facilitate organ
allograft acceptance.
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816 ROLE OF HETEROLOGOUS IMMUNITY IN REJECTION
OF SKIN AND ISLET GRAFTS
B.F. de St Groth1, D. Gracey2, Y.W. Loh1
1
Centenary Institute of Cancer Medicine and Cell Biology, 2Prince of Wales
Hospital
The role of naïve versus heterologously primed T cells in graft rejection
mediated via the direct allorecognition pathway remains controversial. While
purified populations of either naïve or memory phenotype T cell receptor (TCR)
transgenic cells can reject skin grafts after transfer to immunodeficient hosts,
spontaneous or homeostatic proliferation of naïve T cells in the immunodeficient
environment generates activated T cells, making interpretation difficult. As
a direct test of the involvement of naïve versus memory cells in skin graft
rejection, we used a model in which 5C.C7 TCR transgenic T cells recognise
IAs, in addition to their primary specificity for moth cytochrome c (MCC) in the
context of IEk or IEb. The important feature of this model is that all endogenous
T cells remain naïve in 5C.C7 TCR transgenic mice on a RAG-/- background,
and transferred naïve 5C.C7 TCR RAG-/- cells do not undergo spontaneous
proliferation. Fully allogeneic H-2s skin grafts were accepted indefinitely by
5C.C7 TCR RAG-/- mice, but were rejected promptly after transfer of memory
but not naïve T cells from 5C.C7 TCR RAG-/- mice primed with MCC 2 months
earlier. On the other hand, H-2s skin grafts were rapidly rejected by AND TCR
RAG-/- mice, which share the 5C.C7 specificity for MCC-IE and IAs but have up
to 20% CD44hi memory cells as a result of ongoing spontaneous prolliferation.
Thus in these monoclonal models, memory but not naïve T cells can reject skin
grafts via the direct pathway of alloreactivity.
To understand why naïve T cells could not reject skin grafts, we studied
trafficking of dendritic cells (DCs) from skin grafts to draining LN where naive
T cells are situated. Skin from transgenic mice expressing GFP-tagged IAb was
grafted onto syngeneic H-2b and allogeneic H-2k hosts. No GFP-expressing
DCs could be detected in draining LN in either host. As a positive control,
subcutaneously injected DCs from GFP-tagged IAb mice were detected in
draining LN. As an additional control, the response of CFSE-labelled 5C.C7
TCR RAG-/- cells to H-2s skin grafts and subcutaneously injected H-2s DCs
was determined. T cells responded vigorously to injected DCs, but made no
response to skin grafts. Finally we isolated the cellular infiltrate from H-2s skin
grafts and showed that CD44hi 5C.C7 TCR cells from unprimed mice were
recruited into the grafts within 1 day.
These studies indicate that heterologously primed T cells are crucial in rejection
of skin grafts. We are now testing these findings in a second nonvascularised
graft model, in which pancreatic islets from H-2s donors are grafted under the
kidney capsule of H-2k hosts. Given the difficulty of inducing tolerance in
heterologously primed T cells, these data suggest that alternative strategies to
promote graft acceptance will be required for nonvascularised grafts.
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817 INDUCTION OF IMMUNOSUPPRESSIVE DENDRITIC
CELLS BY A NOVEL NUCLEAR FACTOR-KAPPA B
INHIBITOR, DHMEQ
T. Aoyagi1,2, K. Yamashita2, Y. Yanagawa3, R. Goto2, M. Ozaki2, K. Onoe3, K.
Umezawa4, S. Todo2
1
Gastroenterology Center, Surgery Division, Hakodate Municipal Hospital,
2
1st Dept of Surgery, Hokkaido Univ. School of Med., 3Division of
Immunobiology, Institute for Genetic Med. Hokkaido Univ., 4Dept of Applied
Chemistry, Faculty of Science and Technology, Keio Univ.
Background: Dendritic cells (DCs) have a potent property of antigen
presentation, and play a central role in activating the immune responses. An
ability of DCs to induce immunity or tolerance appears to be related to their
state of functional maturation., The transcription factor, nuclear factor-kappa
B (NF-κB) has been shown to be a key molecule in DCs upon maturation and
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Aim: We examined the effect of a novel NF-κB inhibitor,
DHMEQ on ex vivo induction of immunosuppressive DCs, and
assessed the immunosuppressive properties of these ex vivo
derived DCs in vivo using a mouse heart transplantation model.
Methods: DCs were propagated from BALB/c (H-2d) mouse bone marrow
with GM-CSF. DHMEQ (1-5 μg/ml) was supplemented during DC
generation or before stimulation with LPS or TNF-α. DC phenotype and
cytokine profiles were examined by flow cytometry and ELISA. Also, their
allostimulatory activity was assessed in vitro by a MLC. Ex vivo generated
C3H/HeJ (C3H: H-2k) DCs (3x106) with or without DHMEQ was given
i.v. to C3H mouse, and C57BL/6 (B6: H-2b) heart was transplanted 7 days
later. Allograft survival was examined without any immunosuppression.
Results: In contrast to the control DCs, DHMEQ-treated DCs expressed
lower CD40, CD86, and MHC class II antigen (I-Ad) following LPS and
TNF-α stimulation (Fig. 1A). This was associated with a dose-dependent
suppression of IL-12p40 (Fig. 1B) but not IL-6 secretion. Proliferation of
B6 T cells was inhibited by the DHMEQ-treated DCs as compared to the
mature DCs (Fig. 1C). Untreated mice rejected B6 hearts at a mean graft
survival time (MGST) of 11 days (no treatment: n=4). When transplant
recipient was pretreated with C3H DCs that were pulsed with B6 splenocyte
lysates during ex vivo generation, MGST was 15 days (control DC: n=6),
whereas injection of DCs generated in the presence of DHMEQ at 1 and 5
μg/ml significantly prolonged MGST to 20 (n=5, p<0.005) and 23 days (n=8,
p<0.005), respectively.

Conclusion: Inhibition of NF-κB activation by DHMEQ during ex vivo
generation significantly inhibits phenotypical and functional maturation of bone
marrow derived murine DCs. Such DCs acquire immunosuppressive properties
and prolong allograft survival in mice. Use of DCs generated under DHMEQ
supplimentation may become a new modality in immunosuppression.
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818 A NOVEL IMMUNOTOXIN HAS CYTOTOXICITY TO
CTLA-4 POSITIVE CELLS WITH SPECIFICITY
H. Cai1, Q. Huang1, L. Wan1, L. Chen1, L. Zeng1,2, H. Yang1, S. Li1, Y. Li1, J.
Cheng1, X. Lu1
1
Key Laboratory of Transplant Engineering and Immunology, Ministry
of Health, West China Hospital, Sichuan University,, 2Department of
Hematology, Ayliated Hospital of Medical College of Xu Zhou
Background: Activated T cells play central role in graft rejection. An
immunosuppressive strategy is to produce immunotoxin that could selectively
delete activated T cells. Cytotoxic T-lymphocyte antign-4 (CTLA-4) is
inductively expressed on surface of activated T cells and can function as a
target molecule for immunosuppressant.
Method: A novel immunotoxin called mST was constructed by fusing a poreforming antifungal peptide to the C-terminus of mouse-derived anti-CTLA4
single-chain fragment of variable antibody (scFv). The gene was expressed in
prokaryotic system E.coli M15 as well as eukaryotic system Pichia Pastoris
GS115. The cytotoxicity of mST protein was detected on cell model. The
mouse-derived anti-CTLA4 scFv (mS) was also prepared and used as a
control.
Results: In 1 liter of prokaryotic cell culture, we collected 0.1mg of soluble
mST protein from cytoplasm and refolded inclusion bodies separately. In 1 liter

of eukaryotic culture induced by 3% (V/V) methanol, we collected 1mg mST.
In vitro cytotoxicity assay showed that mST protein purified from prokaryotic
cytoplasm, inclusion bodies, and eukaryotic cytoplasm had killing rate of
44.0%(¡À3.8%), 45.0%¡À(10.1%), and 37.5%(¡À2.2%) to CTLA4-positive
lymphoma cell EL4 at concentration of 1¦ÌM, respectively. Furthermore, mST
protein did not display obvious killing to CTLA-4 negative cells CEM. At the
mean time, we found mS proteins produced by the same methods as mST did
not show cytotoxicity to cells.
Conclusion: Our results demonstrated that immunotoxin mST had significant
cytotoxicity to CTLA-4 positive cells. So it suggests that mST have possibility
as a novel immunosuppressant for deleting activated T cell selectively.
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819 THE ALLOGENEIC REACTION CAN INDUCE
GENERATION OF SEMI-MATURE REGULATORY DENDRITIC
CELLS THROUGH CYTOKINE SECRETION: MAJOR ROLE
FOR IFN GAMMA
A. Eljaafari7, Y-P. LI1, A. Farre2, D. Laurin3, J. Bernaud4, D. Rigal5,
P. Miossec6,
1
Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux, 2EFS
Rhone-Alpes, 3EFS Rhone-Alpes, 4EFS Rhone-Alpes, 5EFS Rhone-Alpes,
6
Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux,
7
Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux,
Centaure Group
Introduction:We have previously demonstrated that the alloresponse can
induce maturation and migration of immature dendritic cells (DC), through
cytokine secretion (Transplantation, 2004). We have also reported its action
on acute myeloid leukaemia blasts (Leukemia, 2006). Here we investigated its
impact on monocyte differentiation into DCs.
Methods: Blood monocytes were cultured for 6 days, either with supernatant
collected from major-histocompatibility Ag-mismatched mixed lymphocyte
reactions (MLR-Sn), or GM-CSF/IL4, as positive control. APCs were then
exposed to TNFalpha for two additional days to induce their maturation. As
negative control, Sn from HLA-identical MLR were used.
Results: Analysis of monocytes, at the phenotypical level, showed that, as
compared with HLA-identical MLR-Sn, HLA-mismatched MLR-Sn induced
in Mo-DCs(i) increased expression of CD54, CD40, HLA-DR, CD80 and
CD86 molecules, (ii) decreased expression of CD14, CD16 and other
Fcgamma Rs, and (iii) increased cell size and granulosity, at day 6. However,
further exposure to TNFalpha did not lead to maturation of these cells, as
assessed by absence of CD83 expression, and moderate increase in CD86 and
CD80. At the functional level, these cells were able to endocytose Dextran
at day 6, but secreted high levels of IL-10 and low levels of IL-12, at day 8.
Moreover, they were unable to elicit an allo-response, as assessed by CFSE,
intra-cellular IFNgamma, CD25, and CD28 staining. Finally, upon secondary
MLRs with these Mo-DCs, T cells expressed high levels of TGF beta, IL-10
and Foxp3, but no IL-2 mRNAs. Addition of GM-CSF/IL-4 to MLR-Sn
showed that the defect in maturation was not due to a lack in these cytokines,
but to the presence of an inhibitory factor, rather. Antibodies directed against
TNF-R, IL-6, and IFN gamma demonstrated that IFN gamma was the major
inhibitory factor, since able to restore both CD83 and CD80 expression.
Accordingly, when reciprocoal experiments were performed with addition
of IFN gamma to GM-CSF/IL-4, a similar pattern of semi-mature DCs was
observed.
Conclusion: The influence of IFN gamma on Tregs generation and function
has recently been reported by others. In support with these studies, our results
suggest a new mechanism by which IFN gamma can modulate the T cell
response. Indeed, we show that the alloreaction can lead to the generation of
semi-mature and regulatory DCs from monocytes, preponderantly through IFN
gamma secretion.
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820 AN INNATE MEMORY RESPONSE TO ALLOANTIGEN IN
RAG-/- MICE
D. Zecher, Q. Li, F. Lakkis
University of Pittsburgh, Depts. of Surgery and Immunology, Thomas E.
Starzl Transplantation Institute
Introduction: The adaptive immune system is both necessary and sufficient
for the acute and chronic rejection of solid organ allografts. Little is known,
however, about how the innate immune system triggers and perpetuates
allograft rejection.
Methods: Using Rag-/- mice, which are devoid of T- and B-cells, we
investigated the innate immune response to alloantigen in a footpad and ear
swelling experiment analogous to delayed-type hypersensitivity in wild-type
mice. We also asked whether the innate immune system is sufficient to cause
chronic rejection in a Rag-/- model of heterotopic heart transplantation.
Results: One week after priming Balb/c Rag-/- mice with allogeneic C57BL/6
(B6) Rag-/- splenocytes (allo), rechallenge with allo induced significantly
more swelling than challenge with syngeneic Balb/c Rag-/- splenocytes (syn),
peaking at 6h and gradually declining thereafter (footpad: allo vs. syn: 6h: 0.1
± 0.02 vs. 0.03 ± 0.01; 12h: 0.08 ± 0.01 vs. 0.01 ± 0.00; 24h: 0.06 ± 0.01 vs.
0.01 ± 0.01; all p<0.001). Challenge of immunized mice 4 weeks after priming
also resulted in a significant response to alloantigen (footpad: allo vs. syn: 6h:
0.16 ± 0.02 vs. 0.09 ± 0.01; 12h: 0.1 ± 0.01 vs. 0.05 ± 0.00; 24h: 0.07 ± 0.01
vs. 0.03 ± 0.01; all p<0.05). Challenge without prior sensitization resulted in a
significantly weaker response. We also found that the observed response was
not NK cell-dependent but that depletion of F4/80+Gr-1int macrophages led to
an abrogation of the swelling response. All results were comparable between
ear and footpad. To test whether sufficient priming or activation of the innate
immune system alone leads to graft pathology, Balb/c Rag-/- mice were either
left untreated or immunized with allo with or without complete Freund’s
adjuvant prior to performing an allogeneic B6 Rag-/- heart transplantation.
Analysis of the functioning hearts 50 days post-transplantation revealed no
histopathological evidence of either acute or chronic rejection when compared
to syngeneic control allografts.
Conclusion: These data provide evidence for a specific innate response
to alloantigen in Rag-/- mice that requires prior priming and is mediated by
macrophages. The data also suggest the presence of innate memory. Although
this innate response was not sufficient for the rejection of vascularized, solid
organ allografts, it is a reflection of early allorecognition events that contribute
to triggering the adaptive alloimmune response.
This work was supported by the German Research Foundation to D.Z. (ZE
835/1-1) and NIH grant AI/064343 to F.G.L.
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821 PROLONGED SURVIVAL OF COMPOSITE TISSUE
ALLOGRAFTS ASSOCIATED WITH POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISORDER IN A NON-HUMAN
PRIMATE MODEL
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R. Barth, E. Rodriguez, A. Nam, M. Stanwix, R. Bluebond-Langner,
C. Drachenberg, D. Kukuruga, S. Shipley, S. Bartlett
University of Maryland School of Medicine
Introduction: Composite tissue allotransplantation (CTA) has achieved
clinical advances in reconstructing soft tissue and bony defects. Despite
heavy immunosuppressive therapies, significant rejection episodes are still
encountered. We developed CTA models in non-human primates to investigate
immunosuppressive strategies to prevent rejection and prolong CTA survival.
Methods: Facial and fibular composite allografts (bone, muscle, skin) were
transplanted between mismatched cynomolgus monkeys. Facial CTAs were
heterotopically transplanted with anastomoses of the carotid artery, internal &
external jugular veins to femoral vessels. Fibular CTAs were heterotopically
transplanted into forearm defects. Immunosuppression consisted of 28 days of
continuous IV tacrolimus monotherapy followed by either tapered doses of IM
tacrolimus or conversion to oral rapamycin.
Results: Nine facial and 2 fibular CTAs were performed. Nine facial allografts
were transitioned to IM tacrolimus (n=6) or rapamycin (n=3) after 28 days of IV
tacrolimus monotherapy. Animals maintained on tacrolimus demonstrated mean
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survival of 113 days. One graft rejected after blood transfusion and 5 animals
had no rejection episodes but developed post-transplant lymphoproliferative
disorders (PTLD) (day 60-177) resulting in experimental endpoints. Genomic
analysis of PTLD tumors by short tandem repeat segments demonstrated donororigin in 3 of 4 animals. The origin of the fifth PTLD tumor is currently under
investigation. None of the animals had clinical evidence of rejection of skin,
bone, or muscle. Animals converted to rapamycin after 28 days of tacrolimus
developed rejection and graft loss on days 31 and 80, but did not develop PTLD.
Two fibular CTA transplants treated with tacrolimus therapy demonstrated no
evidence of PTLD (days 30+, 100+), but did not demonstrate prolonged skin
survival. Bone union of transplanted segments was radiologically confirmed
on day 70 and reflected viability of transplanted bone. Fibular CTAs contained
less than 5% of bone marrow cells compared to facial CTAs.
Conclusion: We have achieved predictable long-term survival of composite
tissue allografts in non-human primates. Tacrolimus monotherapy prevented
rejection of facial composite allografts, but was associated with donor-derived
PTLD development in a pattern more similar to bone marrow transplantation
than solid organ transplantation. Conversion to rapamycin failed to prevent
CTA rejection. Fibular composite allografts had minimal vascularized bone
marrow, and while tacrolimus monotherapy did not prevent loss of skin, no
PTLD tumors developed. This is suggestive of association between amount of
vascularized allogeneic bone marrow and PTLD development.
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822 USE OF CASPOFUNGIN AMONG RECIPIENTS OF LIVER
TRANSPLANTS WITH HIGH INDEX OF SUSPICION FOR
FUNGAL INFECTION.
C. Doria, C. Ramirez, A. Frank, C. Daskalakis, V. Kostaras, S. Vaccino,
R. Measley
Thomas Jefferson University Hospital
Introduction: This study is a retrospective analysis of death, adverse events
(AE), fungal infections, and hepatic function among recipients of liver
transplantation at high risk of fungal infection who received caspofungin
prophylactically.
Material and Methods: After reviewing data of 105 patients who had received
isolated liver transplant between January 2003 and April 2007, we identified
and analyzed 82 high-risk patients. High risk was defined by the presence of
at least one of the following: 1) re-operation 2) fever of unknown origin 3)
hypothermia 4) positive random culture for fungus at the time of transplant (bile
and/or ascites) 5) sepsis 6) use of vasopressors 7) re-intubation with mechanical
ventilation 8) prolonged intubation (>24 hrs) and 9) acute respiratory distress
syndrome. Exact conditional logistic regression was used to compare the risk
of death, AEs, and fungal infections in patients who received caspofungin,
other antifungals, and no antifungals. Analyses were performed with SAS 9.1
(SAS Institute Inc., Cary, NC).
Results: Patients were between 27 and 72 years old (mean = 55), with two
thirds male and three quarters white. Sixteen patients were received caspofungin
(11 prophylactically) and 32 received other antifungals (26 prophylactically).
Mortality and AEs are shown in table 1. There were no fungal infections among
the patients who received caspofungin prophylactically, three infections among
patients who received other antifungals (3/26 = 12%), and fourteen infections
among patients not treated prophylactically (14/45 = 31%). These infection
rates were significantly different across the three groups (p = 0.029), with
caspofungin and other antifungal prophylaxis comparable (p = 0.540), and both
better than no prophylaxis at all (estimated odds ratio OR = 0.15, p = 0.049, for
caspofungin versus no prophylaxis; OR = 0.29, p = 0.085, for other antifungal
versus no prophylaxis).
Conclusions: Caspofungin appears to be an effective prophylactic agent against
fungal infection when used in high-risk recipients of liver transplantation. There
is no apparent increase in risk of death or acute cellular rejection, although we
observed a significantly higher risk of AEs, especially acute renal failure (p =
0.001), in patients who received this agent.
Table 1.
No antifungal
therapy (N=34)
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Death, n (%)

6

(18)

5

(16)

2

(13)

1.000

Any adverse event
(AE), n (%)

13

(38)

20

(63)

13

(81)

0.011

Acute cellular rejection
(ACR), n (%)

5

(15)

6

(19)

3

(19)

0.865

Renal toxicity, n (%)

6

(18)

6

(19)

4

(25)

0.874

Acute renal failure,
n (%)

0

4

(13)

6

(38)

0.001

Hepatotoxicity, n (%)

1

(3)

6

(19)

2

(13)

0.089

Respiratory symptoms
n (%)

1

(3)

8

(25)

4

(25)

0.015

Congestive heart
failure, n (%)

0

1

(3)

0

0.585

* Prophylactic use: n=26 for other antifungals; n=11 for caspofungin.
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823 SIXTY LIVING DONOR LIVER TRANSPLANTATION FOR
WILSON DISEASE.
S. Gautier, O. Tsiroulnikova, E. Kim, A. Filin, E. Chekletsova, O. Malomooge
National Research Center of Surgery
The purpose of the study is to summarize the results of living donor liver
transplantation (LDLT) in patients with end stage liver cirrhosis due to Wilson
disease. Since December 1998 till December 2007 60 patients with verified
Wilson disease underwent 62 LDLT with right hepatic lobe. Twenty two
patients were adults (9 males and 13 females) with mean age 22.2±1.7 (18
– 47) years. Thirty eight patients were teenagers (17 males and 21 females)
with mean age 14±0.4 (9 – 17) years. All patients had Child C liver cirrhosis,
18 (30.0%) of them demonstrated urgent indications for transplantation. Ten
patients had different degree of Wilson neurological disturbances. Donors
were AB0-identical or compatible relatives of patients. Six patients had graft
weight to recipient body weight ratio (GWRWr) less than 0.8%. GWRWr in
other cases was 0.8% – 2.4%. Early mortality was observed once on the 19th
postoperative day due to spontaneous rupture of varicose veins in splenic hilus
and intraabdominal bleeding. All the rest recipients (98.4%) survived and were
discharged from hospital with good liver function including 6 recipients with
small-for-size grafts. Three patients died during the first year due to stroke (1)
and septic complications (2). One patient died after 18 mo. postoperatively
because of melanoma. Immunosuppressive protocol in 10 patients with Wilson
neurological disturbances included steroids and minimal doses of calcineurin
inhibitors due to their neurotoxicity. Eight recipients demonstrated normalization
of neurological status including 1 with severe neurological disturbances. In
2 other patients with severe neurological changes calcineurin inhibitors were
withdrawn and conversion to mycophenolate mofetil was performed. In one
of them the degree of neurological symptoms decreased. The other one died
after 3 years because of neurological deterioration. So, 48 (80.-%) of recipients
are alive with follow-up from 6 mo. to 9 years with good function of their
first grafts. Two recipients survived pregnancy and successful delivery. Two
patients were successfully retransplanted with other living related grafts after 3
and 6 years because of biliary complications and chronic rejection. The results
of LDLT for Wilson disease are generally good including patients with mild
neurological disturbances.
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824 MULTIDISCIPLINARY APPROACH FOR PATIENTS
WITH FULMINANT HEPATIC FAILURE IN THE ERA OF
LIVING DONOR LIVER TRANSPLANTATION
T. Shimamura1, T. Suzuki2, M. Taniguchi2, K. Yamashita2, M. Oota1,
H. Furukawa2, S. Todo3
1
Division of Organ Transplantation, Hokkaido University Hospital,
2
Department of Transplantation and Regenerative Medicine, Hokkaido
University, 3Department of General Surgery, Hokkaido University
Background: Liver transplantation (LTx) is a reliable therapeutic option for
patients with fulminant hepatic failure (FHF). However, due to shortage of
cadaveric organs and critical pretransplant condition, less than 50% of the
patients can undergo LTx in the Unites States, and perioperative neurological
deficits are still problems. Recently, apheresis technology has been developed.
In these circumstances, multidisciplinary approach including living donor

liver transplantation (LDLTx) is considered to be mandatory for the treatment
of FHF.
Patients and Methods: From September 1997 to December 2006, 93 FHF
patients were referred to our hospital. Twenty patients were not enrolled in our
treatment protocol due to many socio-medical reasons. The remaining 73 were
initially treated with extra-corporeal apheresis when the patients developed
stage II coma or higher. Apheresis therapy consisted of plasma exchange and
hemodiafiltration (filtration volume:12-96L/day) in order to remove middle
molecular-weight toxic substances such as cytokines. Intracranial pressure
(ICP) was monitored in patients with progressive brain edema, and the mild to
moderate hypothermic therapy (HT) were also carried out in those who had ICP
more than 20mmHg as a bridge until the operation. Liver transplantation was
indicated when the patients deteriorated despite of these treatments.
Results: Twenty-four out of the 73 patients (25.8%) recovered only through
apheresis. Remaining 49 were considered to be candidates for LTx, however,
28 died without transplant due to living donor unavailability, etc. Eventually,
21 patients underwent LDLTx (including 6 auxilliary transplantation cases)
with a mean period of 8.5 days after the onset of stage II coma. Among
transplanted patients, ICP monitoring was performed in 8 and HT was applied
perioperatively in 5 patients. One-year survival rate after LDLTx was 85.7%
(18/21). No neurological complications were observed in survivors. Among
those who could receive our protocol apheresis, overall survival rate reached
57.6% (42/73).
Conclusion: Apheresis therapy is effective not only as a conservative modality
but also as a bridge to LTx. Multidisciplinary approach including LDLTx can
improve the overall survival rate of patients with FHF.
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825 HEPATIC ANGIOSARCOMA (HAS): THE (LAST)
ABSOLUTE CONTRA-INDICATION TO LIVER
TRANSPLANTATION (LT) REPORT OF THE EUROPEAN
LIVER TRANSPLANT REGISTRY (ELTR).
J. Lerut1, G. Orlando1, R. Adam2, A. Burroughs3, M. Colledan4, F. Filipponi5,
J. Guggenheim6, Y. Grazadei7, D. Mirza8, F. Prevost9
1
St-Luc University Hospital, Brussels, 2Hôpital Paul Brousse, Paris, 3Royal
Free Hospital, London, 4Ospedali Riuniti, Bergamo, 5Ospedale Cisanello,
Pisa, 6CHU Nice, 7Universitätslinik, Innsbruck, 8 Q.E. Hospital, Birmingham,
9
Inselspital, Bern
Objectives: to define the place of LT in the treatment algorithm of HAS based
on a retrospective study from the European transplant experience.Background
data:
Methods: During the period 1985-2004, LT was done in 8 female and 11 male
pts having a mean age of 38±24.8 years. Main symptoms of HAS were weakness
(82%), upper abdominal discomfort or pain (59%), nausea (44%);main signs
were hepato-splenomegaly (82%), weight loss (56%) and anorexia (53%).Six
(37.5%) patients underwent neo-adjuvant treatment [chemotherapy (2x), TACE
(1x), TIPSS (1x), attempt of liver resection (1x), IFN-steroid-radiotherapy
(1x)]. Six patients had adjuvant therapy [chemo- (5pts) and /or radiotherapy
(2pt)]. Exact pre-LT diagnosis was available in 6 (37.5%) of 16 histological
documented patients. The remaining 10 patients were transplanted based on an
erroneous diagnosis of epitheloid haemangioendothelioma (EHE) (8 pts) and
hepatocellular cancer (HCC) (2 pts). Two (10.5%) pts had extra-hepatic disease.
Imaging was rarely conclusive. Indications for LT were giant invalidating
(painful) tumor (11/19 pts-58%), diagnosis of EHE (8/19 pts.-42%), HCC
and cirrhosis (2/19pts.-10%), and liver failure after liver resection done for
EHE (1/19pt- 5%).One (5.2%) patient had a small incidental HAS found in
the hepatectomy specimen. Pathology of the hepatectomy specimen showed
predominantly a multifocal diffuse pattern of HAS.
Results: Tumor recurrence was diagnosed at a mean delay of 6±2.7 mo (med. 5
mo, range 2-11). Mean patient survival was 8±5.9 mo (med. 7 mo, range 0-23).
One patient each died during the early (<3mo) post-LT period due to herpes
infection , graft non-function and sepsis. The remaining 16 patients ,including
the one with the incidentaloma, died of tumor recurrence.
Conclusions: This largest reported series clearly shows that HAS represents an
absolute contraindication to LT. Precise pre-transplant imaging and especially
histology is necessary in order to avoid spoiling of a scarce organ pool.
Differential diagnosis with other vascular tumors is of particular importance
in this context.
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826 SERUM CREATININE AND MELD SCORE
UNDERESTIMATE RENAL DYSFUNCTION IN
MALNOURISHED PATIENTS AWAITING LIVER
TRANSPLANTATION
D. Ranjan, P.P. McHugh, T.D. Johnston, R. Gedaly, H. Jeon
University of Kentucky
Background: To estimate risk of pre-transplant mortality, MELD score
weights serum creatinine (SCr) logarithmically to capture a patient’s degree of
renal dysfunction. At our center we also calculate creatinine clearance (CrCl)
using a 24 hour urine collection for all patients undergoing liver transplant
evaluation. We suspected that SCr of our malnourished patients fails to
reflect their renal dysfunction, putting them at a disadvantage in MELDbased liver allocation. In this study we estimated the derived creatinine (DCr)
using an inverse calculation of the Modification of Diet in Renal Disease
(MDRD) and Cockcroft-Gault (CG) equations. We hypothesized that renal
dysfunction is underestimated (demonstrated by a difference between DCr
and SCr) and inversely correlates with serum cholesterol, a surrogate marker
of malnutrition.
Methods: We reviewed clinical and laboratory data of patients who have
undergone or are listed for liver transplantation at our institution between
2004 and the present. CrCl was converted to GFR using previously established
cofactors, and used for inverse calculation of MDRD to achieve DCr. Similarly
DCr was achieved from inverse calculation in CG equation using measured
CrCl.
Results: We obtained data from 195 consecutive patients; 12 patients were
excluded for incomplete records or inaccurate collections. The median DCr
– SCr difference had an inverse correlation with decreasing cholesterol levels
– 0.75, 0.9, 1.35, and 2.64 using MDRD and 0.4, 0.45, 0.5, and 1.2 using CG
for patient groups with serum cholesterol level (mg/dL) breakpoints of 125,
100, 75 and 50 respectively. Those with cholesterol <150 (n=83) had a mean
DCr – SCr of 3 ±10.04, versus 0.95 ±2.25 for the group with cholesterol >150
(n=100; p=0.048).
Conclusion: There is a significant difference between measured SCr and
the DCr from measured CrCl in the context of the MDRD equation, and this
varies inversely with serum cholesterol. With severe nutritional depletion, the
disparity between MELD scores based on the two different creatinines could be
large and clinically important.

POSTER BOARD NUMBER P4 – 436
827 NOVEL CLINICAL MONITORING OF CELL MEDIATED
IMMUNITY (CMI) USING IMMUNKNOW® IN LIVER
TRANSPLANT RECIPIENTS PROVIDES OPTIMAL IMMUNE
SUPPRESSION AND IMPROVED OUTCOMES
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A. Sebastian, V. Kohli, Y. Huang, S-F. Li, Y. Yong, N. Jabbour, G. Sigle,
A. Gurakar, H. Wright
Integris Baptist Medical Center
The reduction of drug toxicity with immunesuppression minimization is
a current focus of long term patient management following solid organ
transplantation. Clinical monitoring of alloimmune T cell activation
status may optimize immunosuppression dosing and limit complications
resulting from overimmunosuppression. The goal of the present research
was to determine the impact of serial measurement of T cell activation on
immunosuppression use and post transplant complications following liver
transplantation.
Methods: Using the novel ImmuKnow® ATP assay (Cylex Inc), we monitored
T cell activation in 190 patients receiving transplants between 2002 and 2005.
Seventy-five (75) recipients were HCV+; the remainder (n=115), including
patients transplanted for autoimmune diseases, were HCV–. Dosing of
immunosuppressive agents, hospital readmission/length of stay, event-free
course of follow up, and the requirement for liver biopsy were evaluated
retrospectively.
Results: Results from three separate eras were compared: prior to use of the
ATP T cell activation assay (pre-assay era – 2002), during the period of initiation
of use (phase-in era – 2003), and the period in which monitoring with the ATP
assay became routine practice in our center (routine practice era – 2004-2005).
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Compared to 2002, the median tacrolimus trough levels at 6-12 months of
follow up in 2004-2005 decreased in both HCV– patients (8.0-10.0ng/mL
to 4.0-5.8ng/mL) and in patients with autoimmune disease (8.2-9.0ng/mL to
4.2ng/mL). The length of stay for hospital readmissions decreased by 53% and
41% for rejection and infection, respectively. The liver biopsy:transplant ratio
also declined from 1.28 in 2002 to 0.68 in 2005.
Conclusions: Our findings suggest that monitoring of CMI with the use of the
ImmunKnow® ATP assay may allow substantial, controlled immunosuppression
minimization without increasing the risk of rejection. Additional benefits may
include reduced length of hospital readmission due to rejection and infection,
and a reduced requirement for liver biopsy.

POSTER BOARD NUMBER P4 – 437
828 LONG-TERM COMPLICATIONS IN LIVER
TRANSPLANTATION FROM UNCONTROLLED NON-HEARTBEATING DONORS
J. Kim, , W.Y. Shin, K-S. Suh, H.W. Lee, N-J. Yi, J.Y. Cho, E.M. Kim,
K.U. Lee
Seoul National University College of Medicine, Department of Surgery
Background: Although uncontrolled non-heart-beating donors (NHBDs)
could represent the largest potential donor pool, the safety of uncontrolled
NHBD livers has not been proved yet. Thus, the purpose of the present study
was to investigate the type and incidence of long-term complications in liver
transplantation (LT) from uncontrolled NHBDs.
Patients and methods: Ninety-eight patients who underwent overseas LTs
from uncontrolled NHBDs in China between December 2001 and December
2004 were enrolled in this study. They were those who survived early
postoperative period and were followed-up at Seoul National University
Hospital in Korea. Eighty patients (81.6%) were male and 18 (18.4%) were
female. Mean age at the time of LT was 51.1¡¾0.83 (mean¡¾SEM) years,
with a range of 20 to 70 years. After LT, patients were followed-up for a
median time of 38.1 months.
Results: Fifteen patients (15.3%) died of cancer recurrence (n=8), hepatic
failure due to viral hepatitis (n=3), sepsis (n=3) or intracerebral hemorrhage
(n=1). Retransplantations were performed in 4 patients. Excluding operation
and hospital mortality, total patient survival was respectively 93.8%, 86.1%,
and 82.6% at 1-, 3- and 5-year. Eighty-one (82.7%) experienced one or more
complications. The most common complication was biliary complication
(n=24, 24.5%), followed by viral hepatitis, recurrence of primary cancer,
infectious complication and liver function abnormality of unknown cause.
Intrahepatic biliary stricture (IHBS) was the most common and serious
biliary complication (n=16, 66.7%). Among all patients with symptomatic
IHBS, two (12.5%) died of biliary sepsis, three (18.8%) underwent
retransplantation and the others had to receive repetitive interventional
therapies. Nineteen patients (19.4%) had post-LT viral hepatitis. Especially,
as many as five patients (5.1%) developed de novo HCV infection and one
of them died of fulminant hepatic failure. Twenty-six patients (26.5%)
experienced Clavien grade 3B or 4 complications, resulting in death,
retransplantation or residual diseases with high risk of death. Even when
cancer recurrences were excluded, 15 patients (15.3%) experienced high
risk long-term complications.
Conclusion: Although long-term survival of uncontrolled NHBD LTs was
acceptable, high risk long-term complications, such as IHBS and de novo
HCV, frequently developed, which are rare in conventional brain-dead donor
LTs. Therefore, patients who underwent uncontrolled NHBD LT should be
followed-up carefully.
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829 RENAL FUNCTION IN LIVER TRANSPLANT
RECIPIENTS: THE TRY STUDY.

830 ROLE OF DCD ORGANS IN SIMULTANEOUS LIVERKIDNEY TRANSPLANTATION

F. Saliba3, S. Karie1, N. Janus1, J. Dumortier2, V. Launay-Vacher1, Y. Calmus4,
C. Duvoux5, R. Lorho6, G. Deray1, G-P. Pageaux7
1
Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France,
2
Department of Digestive Diseases, Edouard Herriot Hopital, Lyon, France,
3
Department of Liver Disease and Liver Transplantation, Paul Brousse
Hopital , Villejuif, France, 4Department of Liver Transplantation, Cochin
Hopital, Paris, France, 5Liver Transplant Unit, Henri Mondor Hopital,
Creteil, France, 6Department of Liver Disease, CHU Pontchaillou, Rennes,
France., 7Liver Transplant Unit, Centre Hospitalier Universitaire (CHU)
Saint Eloi, Montpellier, France
Kidney disease (KD) is a common complication after liver transplantation
(LTx). Monitoring of renal function (RF) is particularly important in liver
transplant patients receiving calcineurin inhibitor that may have renal toxic
side effects. The TRY study aimed at determining the prevalence of KD in liver
transplant patients before transplantation (BT), at 1 month (1M), 1 year (1Y)
and 5 years (5Y) after LTx.
Methods: national, retrospective, multicenter observational study. RF was
assessed by Cockcroft-Gault (CG) and aMDRD formulae.
Results: 1508 patients (972 males, 536 females) were included from 15 centers.
The mean follow-up time post-LTx was 9.2 ± 3.4 years. Mean age and weight
BT were 48.2 ± 10.6 years and 70.8 ± 13.5 kg, respectively. The mean Body
Mass Index (BMI) was 24.7 ± 4.2 kg/m². The most common indications for
LTx were alcoholic cirrhosis (31.1%), hepatitis C (11.2%) and primary biliary
(5.8%) cirrhosis. The averages of biological data BT were: serum albumin
31.8 ± 6.9 g/L, total bilirubin 74.4 ± 99.2 mg/L, AST/ALT 211/178 UI/L,
haemoglobin 11.4 ± 2.2 g/dL.
Mean serum creatinine was 82, 115, 115 and 122 μmol/L BT, at 1M, 1Y and
5Y, respectively. Using CG formula, the mean creatinine clearance (CrCl) was
101, 67, 71 and 68 mL/min BT, at 1M, 1Y and 5Y, respectively. Using aMDRD
formula, the mean glomerular filtration rate (GFR) was 95, 66, 62 and 59 mL/
min/1.73m² BT, at 1M, 1Y and 5Y, respectively. Using CG formula, CrCl was
< 60 mL/min in 9, 43, 37 and 42% of the patients, respectively BT, at 1M,
1Y and 5Y. Using aMDRD formula, DFG was < 60 mL/min/1.73m² in 11,
48, 51 and 58% of the patients, respectively at each time of data collection
(cf. Table 1).
Conclusion: 5 years after LTx, 94, 58 and 5% of liver transplant recipients had
a GFR lower than 90, 60 and 30 mL/min/1.73m² (aMDRD), respectively. In
liver transplant patients with renal insufficiency at high risk for drug toxicity,
drug dosages should be adapted to RF and the use of nephrotoxic therapies
should be avoided whenever possible.
Table 1

W. Hewitt, H. Grewal, D. Willingham, J. Nguyen, B. Taner, T. Gonwa, A.
Keaveny, D. Harnois, C. Hughes
Mayo Clinic Jacksonville
Since the introduction of the model for end-stage liver disease (MELD) as a
prioritization system for listing patients for liver transplantation (LT) in the
United States in 2002, the number of simultaneous liver and kidney transplants
(SLK) has continued to increase. This redistribution of organs away from the
patients with renal failure alone raises significant concerns. Utilization of
donation-after-cardiac-death (DCD) allografts could assist in alleviating this
organ shortfall.
Methods: A retrospective review of all patients who received an LT at our center
from 04/2000 until 02/2007 was conducted. 1361 LTs were performed during
that time. Of these, 39 (2.9%) had a SLK transplant and 9 (0.7%) received
DCD organs. Technical allograft complications, patient and graft survival were
analyzed. The 9 DCD patients were compared to the 30 DBD LKT.
Results: In the SLK recipients 41.0% were diabetic, 48.7% required renal
replacement therapy (RRT) pre-transplant and 33.3% required RRT postoperatively. There was no difference in donor age, recipient age, MELD
score or cold ischemia time of the allografts between DCD vs. DBD SLK
groups. Wait time from listing to transplant was 91 ± 107 days (mean ± SD)
as compared to 64 ± 87 days for DBD vs. DCD, respectively. Mean follow-up
was 658 days (7 – 1821). There were 5 deaths in the DBD group and 1 death
in the DCD group. Length of stay was significantly longer in the DCD SLK
group. One-year graft survival for DCD vs. DBD kidney grafts was 88.9%
vs. 83.3%, respectively (p=0.15). One-year graft survival for DCD vs. DBD
liver grafts at 77.8% vs. 87.1%, respectively (p =0.11). The one-year patient
survival for DCD SLK was 88.9% compared to 83.3% with DBD SLK. No
ureteral complications were noted in either group. 2 out of 9 of the DCD livers
developed biliary complications and 0 out of 30 DBD livers had biliary issues.
56% of the DCD SLK group required RRT whereas only 27% required it in the
DBD group (p=0.11)
Conclusions: The use of DCD organs for SLK provides an attractive option to
help alleviate the pressure on an ever-expanding transplant waiting list. Despite
the higher incidence of delayed renal graft function and longer hospital stay, the
use of DCD donors provides comparable graft and patient survival and should
be considered for patients requiring SLK transplants.

CrCl mL/
min (CG) or
GFR mL/
min/1.73m²
(aMDRD)

Before LTx, n (%)

After LTx, n (%)
At 1M

At 1Y

At 5Y

CG

aMDRD

CG

aMDRD

CG

aMDRD

CG

aMDRD

< 90

617
(59.1)

689
(45.7)

1262
(83.7)

1268
(84.1)

1232
(81.7)

1391
(92.2)

1250
(82.9)

1422
(94.3)

< 60

142 (9.4)

163
(10.8)

651
(43.2)

719
(47.9)

553
(36.7)

772
(51.2)

637
(42.2)

870
(57.7)

< 30

14 (0.9)

20 (1.3)

45 (3.0)

57 (3.8)

21 (1.4)

28 (2.5)

61 (4.1)

75 (5.0)

0 (0)

3 (0.2)

3 (0.2)

4 (0.3)

1 (0.1)

2 (0.1)

15 (1.0)

19 (1.3)

< 15
and HD
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831 OUTCOME OF SAUDI AND EGYPTIAN PATIENTS
RECEIVING CADAVERIC LIVER TRANSPLANTATION
IN CHINA
N. Allam1, M. Al-saghier2, Y. Al-sheikh2, M. Al-sofayan2, H. Khalaf2, H.
Bahili2, M.Sebayel2, Y. Medhat2, H. Abdel-dayem2, A. Abdo2
1
National Liver Institute, Menofeya University, 2King Faisal Specialist
Hospital and Research Center, Saudi Arabia
Background: Because of long waiting list times in local liver transplant programs
in Saudi Arabia and because of unavailability of cadaveric liver transplantation
in Egypt, an increasing number of patients have been seeking transplantation
in foreign centers especially in China. They are especially attracted by the
lower costs in China as well as shorter waiting time compared to other foreign
centers. In this paper we describe the outcome of patients transplanted in China
and followed in one center in Saudi Arabia (King Faisal Specialist hospital and
Research Center (KFSH & RC) in Riyadh) and in Egypt.
Methods: All patients receiving liver transplantation in China from January
2003 to January 2007 who were followed post transplantation in the two
centers were included. Available preoperative data before traveling to China, all
available reports from China and their follow up charts after coming back were
retrospectively reviewed for relevant clinical and laboratory data. Mortality
and morbidity in this group of patients is described and compared to those
transplanted in KFSH & RC during the same period.
Results: Seventy four adult patients were included. Sixty were males while
fourteen were females. Their mean age was 54 years. Thirteen patients were
above 65 y. Forty-six patients were Saudi nationals, 27 were Egyptians and 1
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was Lebanese. Indications for liver transplantation were as follows: hepatitis
C cirrhosis (n=29); hepatitis B cirrhosis (n=13); cryptogenic cirrhosis (n=6);
hepatitis B and C co-infection cirrhosis (n=1), primary biliary cirrhosis (n=1)
and hepatocellular carcinoma (n=24). All patients were either on the KFSH
waiting list for liver transplantation or were denied liver transplantation in
KFSH or Egypt due to unsuitable medical condition such as old age or advanced
hepatocellular carcinoma (HCC). One year, 3-year and 5-year cumulative
patient survival rates were 83%, 62%, and 62% respectively compared to 92%,
84% and 71% in KFSH. Median survival time of the patients was significantly
less than that of those transplanted in KFSH (p=0.01). One year, 3-year and
5-year cumulative graft survival rates were 81%, 59%, and 59% respectively
compared to 90%, 84% and 71% in KFSH. Of the surviving patients, many
suffered from multiple other morbidities. Compared to the patients transplanted
in KFSH, the incidence of complications was significantly higher especially
biliary complications (p=0.01), sepsis (p=0.003), rejection (p=0.04), metastasis
(p=0.03) and acquired HBV infection posttransplant (p=0.02). In addition,
requirement of postoperative interventions (radiologic and laparotomy) as well
as hospital admissions, were significantly higher hence constituting a higher
burden on the resources of the hospital.
Conclusion: Our data shows clearly that there is a high mortality and morbidity
rate in Saudi and Egyptian patients receiving transplantation in China. This
could be related to poor selection criteria, long warm ischemia time, or poor
post transplant care. . Although cadaveric liver transplantation in China could
be an option for desperate Egyptian and Saudi patients with end stage liver
disease, patients and clinicians should be aware of the possible outcomes

patient set (mPP, n=42), the SCr in the early posttransplant period decreased
more rapidly in the YSPSL-treated patients than the placebo group (Figure 1)
and 78% of the YSPSL group achieved SCr <6.0mg/dL by day 5 posttransplant
compared to only 33% of the placebo group (p=0.004). Immediate graft
function was experienced in 81% of the patients who received only YSPSL IV,
in 67% of those who received both YSPSL IV and YSPSL to the donor organ,
and in only 40% of those who received placebo.
Conclusion: In this first double-blind, placebo-controlled phase I/II safety
and efficacy study in cadaveric renal transplant recipients, YSPSL was
found to be safe. Our data also suggest a potential benefit of YSPSL on early
renal function. Sponsor: Y’s Therapeutics.

Figure 1: Median serum creatine levels (normalized to post-operative Day 0
levels) over time in mPP patient set
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832 YSPSL (RPSGL-IG) FOR THE PREVENTION OF
DELAYED GRAFT FUNCTION (DGF): RESULTS OF DOUBLEBLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE I/
II SAFETY AND EFFICACY STUDY
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A.O. Gaber1, L.W. Moore1, S. Mulgaonkar2, B. Kahan3, V. Bowers4,
E.S. Woodle5, R. Alloway3, I. Bajjoka6, K. Butt7, S. Jensik8, N. Nezakatgoo9,
G. Klintmalm10, P. Patton11, R. Peddi2, D. Slakey13, G. Lipshutz14, A.
Wiseman15, E.C. Squiers16, S. Hemmerich17
1
Methodist Hospital, Houston TX; 2SBMC, Livingston NJ; 3Univ of Texas,
Houston TX; 4Lifelink, Tampa FL; 5Univ of Cincinnati, Cincinnati OH;
6
Henry Ford Hospital, Detroit MI; 7Westchester MC, Valhalla NY; 8Rush,
Chicago IL; 9Methodist Univ Hospital, Memphis TN; 10Baylor, Dallas TX;
11
Univ of Florida, Gainesville FL; 12CPMC, San Francisco CA; 13Tulane, New
Orleans LA; 14UCLA, Los Angeles CA and 15Univ. of Colorado, Denver CO,
16
Pacific Biodevelopment LLC, San Bruno CA; and 17Y’s Therapeutics, Inc.,
Burlingame CA.
Introduction: YSPSL (rPSGL-Ig) is a recombinant fusion protein of human
P-selectin ligand (PSGL-1) and an Fc fragment of human Ig. Studies in
several animal models have shown that YSPSL blocks the selectins and the
inflammation cascade following ischemic injury, thereby improving graft
function posttransplant. This clinical study was designed to assess the safety
and potential efficacy of YSPSL in preventing delayed graft function (DGF) in
patients receiving deceased donor kidney transplant.
Methods: This phase I/II study was conducted as a randomized double-blind
evaluation of two dosing strategies: a dose of 3.5mg/kg IV only (cohort 1,
n=15), and a dose of 1 mg/kg IV plus or minus a 10mg dose administered
directly to the donor organ prior to implantation (cohort 2, n=44). Endpoints
for analysis included incidence of dialysis within one week posttransplant and
early renal function parameters.
Results: No clinically significant adverse events related to drug administration
were identified. When all patients receiving YSPSL (n=39) were compared to
those who received placebo (n=20), the proportion of patients achieving a serum
creatinine (SCr) <6.0mg/dL by day 5 posttransplant was significantly higher in
the YSPSL group (74%) compared to placebo-treated patients (45%; p=0.043).
The incidence of DGF was 24% (11 of 45) in 13 of the 15 participating centers.
In the remaining two centers, DGF was declared in 64% (9 of 14) of the patients
enrolled. We determined to exclude those two sites for post hoc analyses due
to the skewed rate of DGF. Three additional patients were excluded from the
analysis due to technical complications. Within this “modified per protocol
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833 NK CELL AND T-CELL DELETION CAN ACHIEVE
TOLERANCE TO THE INNATE AND COGNATE IMMUNE
RESPONSE TO HTF TRANSGENIC SKIN GRAFTS
H. Gock 1,2, L. Murray-Segal 1, P. Cowan 1,2, A. D'Apice 1,2
Immunolgy Research Centre, St Vincent's Hospital Melbourne, Australia, 2
Department of Medicine, University of Melbourne, Australia
Background: An increase in H-transferase (HTF) activity occurs as a result
of increased substrate in Gal-transferase knock-out (KO) animals used in
xenotransplantation. The increase in HTF product was thought to be inert.
However, we have previously found that overexpression of HTF in transgenic
mice elicits (1) an innate immune response causing graft injury followed
by recovery and (2) a cognate immune response resulting in complete graft
rejection. Furthermore, the tempo of innate immune injury could be reduced by
incomplete NK cell inhibition (NK1.1 antibody treatment and Beige recipients)
and cognate immune-mediated graft destruction could be overcome by T-cell
inhibition (KT3 antibody treatment). We sought to further elucidate mechanisms
of the phenomenon and to investigate possible strategies to overcome.
Aims: (1) To investigate whether the innate immune injury could be negated by
(i) complete NK inhibition (ii) regrafting recovered HTF skin grafts in RAG-1
KO mice, (iii) using mannose receptor KO mice. (2) The test whether T-cell
sensitisation can occur and conversely whether sufficient anti-T-cell treatment
could induce tolerance.
Methods: (1) (a) WT and HTF skin were grafted side-by-side onto RAG-2/
ƒ×c double KO mice (n=11) and observed daily. (b) HTF skin was grafted
onto RAG-1 KO mice (n=9) and observed for 50 days. These grafts were then
removed and re-grafted onto WT recipients and observed. (c) WT and HTF
skin were grafted onto mannose receptor KO mice (n=3). (2) WT recipients of
WT and HTF skin were treated with KT3 and observed. An additional thirdHTF graft was added 100 days after the original graft.
Results: (1) (a) Graft injury was not observed in 6/11 RAG-2/ƒ×c recipients
and seen in the remainder to affect <50% surface area. (b) HTF grafts that
had recovered from injury in RAG-1 KO recipients completely rejected in WT
recipients when regrafted. However, the time to rejection was prolonged (18-30
days vs 12-16 days). (c) All HTF grafts rejected in the mannose receptor KO
recipients in the same timeframe as WT mice. (2) HTF grafts in KT3 treated
recipients were initially injured but recovered (day 10-14). However, 4 grafts
rejected at days 80-100. The remaining 3 survived indefinitely (>100days).
Rechallenge with a new HTF graft in these mice again underwent injury but
recovered to survive long term.
Conclusion: Overexpression of HTF could elicit an innate immune response
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resulting in graft injury which could be overcome in only some mice by
complete NK cell deletion. The mannose receptor does not appear to play a
role in the graft recognition. HTF grafts do not become tolerant after recovery
from innate immune-injury. Recipient treatment can induce tolerance to new
HTF grafts but not to innate immune injury.

POSTER BOARD NUMBER P4 – 442
834 CORD BLOOD TREGS CAN BE POOLED AND
EFFECTIVELY SUPPRESSIVE IN MIXED LYMPHOCYTE
CULTURES.
D. Figueroa-Tentori 1,2, R.C. Duggleby 1, S. Querol 1,2, J.A. Madrigal 1,2
1
Anthony Nolan Research Institute, London UK., 2 Royal Free And UCL
School of Medicine, London UK.
Regulatory T cells (Tregs) have shown in several models to be a good
therapeutic option to achieve tolerance in transplantation. However, Tregs are a
rare population, making it difficult to achieve the optimal cell numbers needed
in clinical settings to counteract the high numbers of alloreactive T cells. From
previous studies in hematopoietic stem cell transplantation (HSCT), some
groups have used successfully multiple unmatched cord blood (CB) units to
address the low nucleated cell numbers in the graft.
The aim of this study was to examine the feasibility of pooling Tregs isolated
from mismatch CB units and evaluate their suppressive ability in mixed
lymphocyte cultures (MLC).
Methods: The CD25 + populations were isolated from fresh CB mismatch
units using anti-CD25 directly conjugated microbeads (Miltenyi Biotec). Oneway fully mismatch MLCs were done and cultured in different ratios using
individual or pooled CD25+ populations for 6 days. Proliferation was measured
by [3H]-Thymidine incorporation.
Results: We find that pooled CB Tregs were suppressive in a dose dependent
manner (Tregs/effectors 1:5 ~50% suppression, 1:10 ~40% suppression,
p<0.05), showing a synergistic effect compared to individual Tregs suppression
(p<0.05). Pooled Tregs were anergic when stimulated with allo-PBMC’s
compared to CD25 negative fractions (p<0.005).
Conclusions: These results shows that CB Tregs can be pooled and maintain
effectively their individual suppressive properties as well as showing apparent
synergy in-vitro. Pooling of CB Tregs can be a good practical option with no
ex-vivo expansion needed to achieve the clinical cell numbers required for
immunotherapy. Further studies should be warranted to elucidate mechanism
of action and examine these results in in-vivo models.

POSTER BOARD NUMBER P4 – 443
835 MRI ASSESSMENT OF LIVER ISCHEMIA AFTER
INTRAPORTAL ISLET TRANSPLANTATION
E. Hathout, N. Sakata, A. Tan, N. Chan, P. Hayes, J. Mace, R. Peverini,
L. Sowers, R. Chinnock, A. Obenaus,
Loma Linda University
Background: Approximately 60% of islets fail to engraft following intraportal
islet transplantation. There is recent focus on embolization of the portal vein
by the islets themselves as a major cause for early graft loss. Transplanted
islets can obstruct portal vessels and compromise blood flow of surrounding
liver tissue. Resultant ischemia causes necrosis and/or apoptosis of liver
cells which, in combination with immediate blood-mediated inflammatory
reaction (IBMIR), leads to injury of the islet graft. Non life-threatening
micro-thrombosis may also occur as liver enzymes are usually elevated after
intraportal transplantation. Early graft failure is influenced not only by the islet
quality but also the condition of the transplant site. Thus, assessment of the
liver receiving the islet transplant is important to maintain a healthy islet graft.
In this study, we utilized a clinically applicable modality for the assessment of
the transplant site. If post-transplant ischemic liver changes are detectable by
MRI, the latter may serve as a noninvasive method to enhance the success of
clinical islet transplantation.
Methods: Balb/C female mice were used as donors and recipients.
Streptozotocin- induced diabetic mice were transplanted with syngeneic
islets (800 islet equivalent: IEQ) via the portal vein. We harvested the liver
at the time of transplantation (n=2), at 12 hours, 1, 2, and 3 days (early posttransplant stage, n=4) and 28 days after transplantation (late post-transplant

stage, n=4). We compared the findings of pre-fixed liver, MRI and histological
findings (hematoxylene and eosin and immunohistochemistry for insulin) at
each time point. MRI examination of liver specimens was performed by Bruker
Advance 11.7 T MRI (8.9-cm bore) with a 3.0 cm volume radiofrequency coil
(Bruker Biospin, Billerica, MA, USA). The conditions of MRI were T2 and
3D sequences: T2 sequences were examined for determination of changes in
the transplanted liver and 3D sequences aimed at assessment of the volume of
areas captured in T2 imaging.
Results: We could find ischemic / necrotic area of the liver at 12 hours after
transplantation from the findings of prefixed liver, and the necrosis became
more prominent 2 days after transplantation. Histological findings revealed
destruction of liver tissue and inflammatory cells at 12 hours with changes
becoming most prominent at 2 days after transplantation. MRI examination
reflected liver destruction which could be quantified from high intensity areas
on T2 sequences. The change was not seen in the whole liver and there was no
high intensity area on T2 by day 28. 3D imaging showed a significant increase
in the volume of ischemic / necrotic area at the early stage assessments.
Conclusion: Onset and reversibility of liver changes due to intraportal islet
transplantation are detectable using magnetic resonance imaging. We propose
that MRI, as a noninvasive monitor of graft-related ischemia, may significantly
enhance the outcome of clinical islet transplantation.

POSTER BOARD NUMBER P4 – 444
836 GENE EXPRESSION PROFILING OF HUMAN ISLETS
TO DETERMINE PREDICTORS OF CLINICAL ISLET
TRANSPLANT OUTCOMES
S.T. Grey 1,4 , A. Weinberg 1,4, M.J. Cowley 2, S.N. Walters 1,4,
W.J. Hawthorne3,4, A. Patel 3,4, E. Jimenez-Vera 3,4, L. Williams 3,4,
B. Tabor 2, W. Kaplan 2, P.J. O'Connell 3,4,
1
Gene Therapy and Autoimmunity Group, 2 Peter Wills Bioinformatics
Centre, Garvan Institute,, 3 The Centre for Transplant and Renal Research,
Westmead Hospital, Westmead, Australia, 4 The Australian Islet Transplant
Consortium
Islet transplantation has the potential to cure type I diabetes and prevent the
onset of diabetic complications. Despite these potential benefits, numerous
obstacles prevent the success of clinical islet transplantation. Indeed the natural
history of islet transplantation is a steady decline in graft function from a ~70%
1 year success rate to ~10% success rate at 5 years. Relatively little is known
about the underlying mechanisms of poor islet function post transplantation.
We hypothesise that some of the causes resulting in poor graft function relate
to islet intrinsic genetic factors present at the time of transplant, which then
impact upon later graft function. To examine this hypothesis we have prepared
mRNA from pancreatic islets isolated from 18 normal human cadaveric organ
donors. Islets were isolated for clinical transplantation for the Australian Islet
Transplant Consortium and a sample of each preparation was obtained for
mRNA extraction. We obtained an average mRNA yield of ~48.78μg with a
RIN ?8 for all samples. The gene expression profile of each individual islet
preparation was analysed on an Affymetrix HG-U133-Plus2 whole genome
array. We found that on average ~40% of all possible ProbeSets were expressed
by each islet sample, this compares to other tissues such as muscle and liver
where ~30% and 40% of all ProbeSets are expressed respectively. Moreover
we could determine that 11,000 of all possible ProbeSets were present in all
islet samples, ~25,000 ProbeSets were absent in all samples, and the remaining
~20,000 ProbeSets are present in at least one sample. Of the ~11, 000 present
ProbeSets, 2, 096 were unique to islet tissue (e.g. absent in liver or skeletal
muscle). Within this unique set, gene ontology analysis revealed an enrichment
of genes involved in protein transport and localization (p = 1.84E-06; 1.65E-06),
myoblast cell fate commitment (p = 0.000116), nucleic acid metabolism (p =
8.20E-05), primary metabolism (p = 0.000124) and secretion (p = 0.000367).
Thus our data reveals a cohort of genes that uniquely identify pre-transplant
islets at the molecular level. Further, we found that the inter-sample variability
of gene expression amongst individual islet preparations was very high; ~13%
of genes exhibited a ?5-fold change between samples whereas the median fold
change overall for all genes was 2.1. Of the 1, 058 most variably expressed
genes (standardised SD > 3), gene ontology analysis revealed many were
involved in glycolysis (p = 2.46E-05), response to wounding (p = 1.46E-18)
and inflammation (p = 3.52E-10). Thus, the variably expressed genes were
those most essential for beta cell metabolic function, cellular stress responses
and beta cell survival. We propose that preparation-specific variance in the
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expression levels of these critical genes should predict transplant outcomes. In
summary, we have established a methodology to analyse the transcriptome of
islets prior to transplantation. In further analysis islet gene expression profiles
will be compared against clinical transplant outcomes. Through this analysis
we aim to achieve a molecular algorithm to determine the suitability of an islet
preparation for clinical transplantation.

POSTER BOARD NUMBER P4 – 445
837 THE OUTCOME OF COMMERCIAL KIDNEY
TRANSPLANTATION: A QATARI STUDY ON PREOPERATIVE
AND POST-TRANSPLANT FOLLOW-UP RECORDS
OF PATIENTS HAVING COMMERCIAL RENAL
TRANSPLANTATION ABROAD
R.A.S. Fadhil, Y. Almoslamani, A. Alansari, O. Alani
Hamad Medical Corporation
Lack of donors in Qatar caused many ESRD patients to seek quick affordable,
live non-related renal transplants abroad. Qatar is a small gulf state with a
population of 1.5 million. It has a single nephrology and transplant unit within
Hamad Medical Corporation. Most of our patients were admitted to our centre
shortly after having commercial transplant abroad .This central (patients Data
Base) has enabled us to review the preoperative and the post-transplant followup records of all the transplant patients that were done abroad within the last five
years with no (lost to follow-up patients). Between 2003 and 2007, 91 patients (
34 female and 57 male ; 73 Qatari and 18 non Qatari ; mean age 46 + 32 years)
were Transplanted in Philippine (N=77), Pakistan(N=8), Egypt(N=2), Iran(N=
2), UK(N=1), China(N=1). The study showed a bad selection of patients;
17 patients had either relative or absolute contraindications to Transplant
Surgery, 11 patients died early in the post operative period, 8 of them had
absolute contraindication to transplantation. There was a high incidence of
post operative complications, including infections N=35, Urological N=13,
Surgical N=8, perigraft collections and lymphoceles N=18, immunological
N=7, cardiovascular N=4, peripheral vascular N=3. Many patients had more
than one complication N=18. The first year patient survival is 87.9%. The first
year Graft survival is 82.4%. On reviewing the literature, we sited 17 studies on
the outcome of commercial renal transplantation. Most of them coincide with
our findings of high mortality, poor selection of donors and recipients and high
incidence of serious unconventional complications. Some studies appraised
the long term results of commercial transplantation disregarding the lack of
information that they admit on the exact number of patients gone to transplant,
lost to follow-up patients, and lack of information on the early post operative
period. Commercial renal transplantation is a bad stigma to medicine; we should
resist the commercialization of the clean practice of organ transplantation which
could start by price tagging of the donated kidneys ;a policy that is called for
by many workers in this field, we should not underestimate the impact of this
endeavor on societies of different cultures and socio-economic status.

POSTER BOARD NUMBER P4 – 446
838 VOCLOSPORIN (ISA 247): THE PHASE 2 'PROMISE'
DE NOVO RENAL TRANSPLANT TRIAL DEMONSTRATES
EFFICACY AND AN IMPROVED SAFETY PROFILE ACROSS A
WIDE THERAPEUTIC RANGE

THURSDAY

S. Busque 1, R. Mateo 2, S. Kapur 3, E.L. Hartmann 4, G. Klintmalm 5,
M. Laftavi 6, A.O. Gaber 7
1
Stanford School of Medicine, Palo Alto, CA, 2 University of Southern
California, Los Angeles, CA, 3 Cornell New York Presbyterian Hospital, New
York, NY, 4 North Carolina Baptist Medical Center, Winston-Salem, NC, 5
Baylor University Medical Center, Dallas, TX, 6 Buffalo General Hospital,
Buffalo, NY, 7 The Methodist Hospital, Houston, TX
Background: Voclosporin (VCS) is a next generation calcineurin inhibitor
(CNi), developed using a pharmacodynamic approach for use in autoimmune
disease and solid organ transplantation. Voclosporin was previously shown
to be efficacious and well tolerated in stable renal transplant recipients
when compared to cyclosporine. A Phase 2b study (PROMISE) in de novo
renal transplant patients comparing voclosporin to tacrolimus was recently
completed.
Methods: PROMISE was a 6 month, randomized, multicenter, open-label,
concentration-controlled study comparing three oral voclosporin dosing groups
(low, mid, high dose) with initial dosing ranging from 0.4 to 0.8 mg/kg BID to
tacrolimus. De novo renal transplant recipients received induction therapy with
an IL-2r antibody, and maintenance treatment with mycophenolate mofetil
and steroids. Voclosporin and tacrolimus doses were titrated to target trough
concentrations. The primary efficacy parameter of the trial was non-inferiority
(in at least one dose group) in biopsy proven acute rejection (BPAR) at 6 months
as compared to tacrolimus. Secondary objectives included: proportion of
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patients with new onset of diabetes after transplant (NODAT), hyperlipidemia,
and hypertension; laboratory parameters; renal function; PK/PD relationships;
patient and graft survival. NODAT was defined by the 2003 ADA guidelines.
Results: 334 patients were enrolled and key results are listed below:
Randomization Group

BPAR

Patient/Graft
Survival

Nankivell GFR
(mL/min)

NODAT

Tacrolimus
(n=86)

5.8%

97.6%

69

16.4%

Low dose VCS (n=84)

10.7%

100%

71

1.6%*

Mid dose VCS (n=77)

9.1%

100%

72

5.7%

High dose VCS (n=87)

2.3%

98.8%

68

17.7%

considered as main risk factors for cancer in the renal transplant recipients.
Interestingly, ABO incompatible transplantation did not increase the risk of
cancer. The decline in incidence of post-transplantation malignancy since 1994
may be due to improvements in factors such as pre-operative cancer screening,
treatment and detection of viral infections, immunosupression regimes, patient
knowledge and life style. Alternatively, some cancers may not have occurred
within the post-transplantation period represented in the data set.
Figure 1 shows the incidence of post-transplantation malignancy

* p=0.031 vs. tacrolimus

At 6 months, the primary efficacy objective of non-inferiority in BPAR was
achieved in all three voclosporin treatment groups. In all groups, patient
and graft survival were excellent. The incidence of NODAT in the low dose
voclosporin group was significantly lower than the tacrolimus group, and was
numerically lower in the mid dose group. Despite a doubling of concentration
from the low to high dosing group renal function was similar in all 4 arms of
the study.
Conclusion: This large dose finding phase 2b study demonstrated that BPAR
was non-inferior to tacrolimus in all voclosporin treatment groups. While
efficacy appeared to be dose dependent and numerically better in the highest
dose voclosporin group, the safety profile was similar or better in all voclosporin
groups compared to tacrolimus. Kidney function was also excellent in all
treatment groups. These results support the continuing clinical development
of voclosporin.

MINI-ORAL SESSION 31: MALIGNANCY
POSTER BOARD NUMBER P4 – 447
839 RISK FACTORS AND INCIDENCE OF CANCER IN
RENAL TRANSPLANT RECIPIENTS REPORTED BY UNOS
BETWEEN 1988 AND 2006.
A.H. Jahromi, M. Morsy, J. Fronek, N. Kessaris
Renal Transplant Unit, St. Georges Hospital, London, UK.
Renal transplantation is the treatment of choice for most patients with endstage renal diseases because it confers survival and quality of life advantages
over dialysis. However, kidney transplantation is not without disadvantages,
as recipients are at increased risk of cardiovascular disease, infections as well
as cancer. The aims of this study were firstly to establish the relative risk of
cancer in the renal transplant recipients, and secondly to quantify how excess
risk varied within this population.
Methods: United Network for Organ Sharing (UNOS*) and Organ Procurement
and Transplantation Network (OPTN) data, as of February 25, 2008, were used.
The data included 234145 renal transplant recipients (M=140320, F=93825,
M/F=1.49) transplanted between 1988 and 2006. Relative Risk (RR) of cancer
was calculated for each risk factor.
Results: In total, 12120 (5.2%) recipients (M=8087, F=4043) developed
cancer during the study period. Male recipients had higher risk of developing
different cancers (RR=1.34). Of the reported cases, skin cancers (squamous
cell carcinoma, basal cell carcinoma and melanoma) constituted 34.1% of all
tumours and were the most common types of post-transplantation cancer. The
incidence of cancer in the recipients was increasing between 1988 and 1994, but
has been declining continuously ever since (Figure-1). Cancer was diagnosed
in 4079 patients (33.7%) who were up to 3 years post-transplantation, and in
4650 recipients (38.4%) who were 6 or more years post-transplantation.
Increased RR was found for age > 50 years (RR=2.03), white ethnic background
(RR=2.84) and previous history of cancer (RR=3.38, 581 cases out of 102759).
While different immunosupression regiments using Muromonab (RR=1.23),
Sandimmune (RR=1.05), Neoral (RR=1.16), Daclizumab (RR=1.42), Steroid
(RR=1.73) and Azathioprin (RR=1.63) were associated with increased risk
of cancer in the recipients, other regiments using ATG (RR=0.64), Gengraf
(RR=0.72), Tacrolimus (RR=0.63), Sirolimus (RR=0.66) and Mycophenolate
mofetil (RR=0.77) were associated with a reduction in the risk of cancer.
Incompatible donor-recipient ABO match had a RR of 0.89.
Conclusion: Age>50 years, white ethnic background, male gender,
immunosupression medications and history of pre-transplant malignancy were

POSTER BOARD NUMBER P4 – 448
840 PREVALENCE AND SIGNIFICANCE OF
LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID
ORGAN TRANSPLANTS
T. Jie, J. Beisse, J. Harmon, B. Peterson, C. Holman, D. Sutherland, A. Matas,
A. Humar
University of Minnesota
Introduction: Post-transplant lymphoproliferative disorders (PTLD) is
recognized as one of the lead causes of morbidities and mortalities in solid
organ transplant recipients. PTLD represents a collection of hematological
disorders that were not well characterized in literature.
Method: Retrospective review of single center solid organ transplant
experience.
Results: Among 10,171 patients received solid organ transplants at our center
between 1969 and 2007, 201 transplant recipients were diagnosed with PTLD
(17.4% < 18 years old and 62.4% man). The cumulative incidence of PTLD
in heart, lung, kidney, kidney and pancreas, pancreas, intestine, and liver
transplant recipients are 1.6%, 4.2%, 1.7%, 3.1%, 1.6%, 9.1%, and 2.1%
respectively. Subtypes of PTLD are as followed: 79.3% B cell lymphomas,
19.0% T cell lymphomas, and 1.7% Hodgkin’s disease. 26% patients had more
than one organ transplants. The onset of PTLD was 5.3 ± 0.4 (mean ± SEM)
years after transplant for patient with only one transplant, and 4.8 ± 0.7 years
after last transplant for patients with more than one transplant (p = 0.571).
The average immunosuppression exposure for patients with more than one
transplant was 17.5 ± 3.3 years, which is significantly longer than those with
only one transplant (p < 0.001). The interval of PTLD diagnosis was 5.2 ±
0.5 years and 6.7 ± 1.2 years after transplant in patients with B cell and T
cells lymphoma, not significantly different (p = 0.264). However, the average
survival for patients with T cell lymphoma is 4.8 months after diagnosis and
5-year survival of 26.2%, which is significantly worse then the average survival
of 4.5 years and5-year survival of 48.6% seen in patients with B cell lymphoma
(logrank p = 0.0129). Interestingly, despite lowering immunosuppression during
the treatment of PTLD, only 16% of patients with B cell lymphoma lost their
graft from rejections. In comparison, 50% of patients with T cell lymphoma
lost their grafts after the completion of oncological treatment.
Conclusion: PTLD is a heterogeneous group of hematologic malignancies
with distinctly characteristics and prognoses. T cell depleting induction therapy
may accelerate the onset of disease as more than 30% PTLD cases were
diagnosed within one year after transplant. The outcome of T cell lymphoma is
significantly worse than B cell lymphoma. Effective treatment of PTLD has yet
to be defined. Despite aggressive chemotherapy and severe immunosuppressive
state, graft los remains a major problem.
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841 RISK FOR NON-HODGKIN LYMPHOMA FOLLOWING
RENAL TRANSPLANTATION IS ASSOCIATED WITH
CURRENCY OF RECEIPT OF IMMUNOSUPPRESSION AND
REVERTS TO NORMAL ON CESSATION

842 THE INCIDENCE AND MANAGEMENT OF KAPOSIÏ¿½S
SARCOMA AFTER KIDNEY TRANSPLANTATION REPORTED
BY UNOS BETWEEN 1994 AND 2005

M. van Leeuwen1, C. Vajdic1, A. Webster2,3, S. McDonald2,4, M. McCredie5, J.
Stewart5, J. Amin1, J. Kaldor1, J. Chapman2,6, A. Grulich1
1
National Centre in HIV Epidemiology and Clinical Research, University
of New South Wales, 2Australia and New Zealand Dialysis and Transplant
Registry, Queen Elizabeth Hospital, 3School of Public Health, University of
Sydney, 4Disciplines of Medicine and Public Health, University of Adelaide,
5
Department of Preventive and Social Medicine, University of Otago, 6Centre
for Transplant and Renal Research, Millennium Institute, Westmead Hospital,
University of Sydney
Purpose: Non-Hodgkin lymphoma (NHL) occurs at markedly increased rates
following renal transplantation, as well as in other immunodeficient states, such
as in those with HIV/AIDS. This study examined the role of immunosuppression
and other risk factors for NHL in a large, population-based, Australian cohort
of renal transplant recipients.
Methods: Diagnoses of NHL in a cohort of 8,165 renal transplant
recipients during 1982 – 2002 were ascertained through probabilistic data
linkage between the Australia and New Zealand Dialysis and Transplant
(ANZDATA) Registry and the Australian National Cancer Statistics Clearing
House (NCSCH). Only cancers within the NHL rubrics ICD10 C82-C85
were included; post-transplant lymphoproliferative disorders (PTLD) of
uncertain malignant potential were excluded. Person-years of follow-up
were accrued from the date of transplantation until the diagnosis of NHL,
transplant failure, death, or last contact. Multivariate Poisson regression
was used to compute incidence rate ratios (IRR) for NHL during periods
of transplantation and dialysis, and for risk factors for NHL following
first transplantation only. Given the bimodal distribution of NHL over
time since transplantation, separate analyses were conducted to examine
risk factors for NHL less than two years (‘early’) and two or more years
(‘late’) following transplantation. Transplant recipients were classified as
having ‘potential primary EBV infection’ if the recipient was EBV antibody
negative and the donor was EBV antibody positive or of unknown EBV
status at the time of transplantation. Analysis of risk associated with antibody
use included exposure to the lymphocyte depleting agents OKT3 and ATG
only. To account for changes in immunosuppressive regimen over time, the
regression models included time-dependent covariates for exposure to the
major immunosuppressive agents.
Results: 130 diagnoses of NHL were recorded following transplantation
(212 cases per 100,000 person-years). Incidence was significantly
reduced (IRR 0.22, 95% CI 0.07 – 0.69, p=0.009) after transplant failure
and resumption of dialysis, returning to near pre-transplantation levels.
Independent risk factors for early NHL (n=32) during first transplantation
included potential primary EBV infection (IRR 3.97, 95%CI 1.90 –
8.33, p<0.001) and receipt of antibodies (IRR 2.48, 95%CI 1.19 – 5.13,
p=0.015). NHL occurring late after transplantation (n=79) was associated
with increasing age (IRR 1.02, 95%CI 1.01 – 1.04, p=0.007), greater time
since transplantation (p<0.001), and current use of calcineurin inhibitors
(IRR 2.66, 95%CI 1.38 – 5.12, p=0.004). For both early and late NHL,
the point estimate for tacrolimus was non-significantly greater than
that for cyclosporine when immunosuppressive agents were examined
individually.
Conclusion: Risk for NHL following transplantation reflects the currency of
receipt of immunosuppressive agents and returns to baseline on cessation of
immunosuppression. NHL has a distinct aetiological profile within and after the
first two years following renal transplantation. Early NHL appears to be driven
largely by primary EBV infection and the intensity of immunosuppression.
Late NHL was associated primarily with duration of immunosuppression.
The increased risk with use of calcineurin inhibitors- especially tacrolimus- is
consistent with previous reports.
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United Network for Organ Sharing, Post office Box 2484, Richmond, Virginia
23218, USA, 3Mayday University Hospital, 530 London Road, Surrey,
CR77YE, UK
Introduction: The primary aim of this study was to identify all cases of postkidney transplant Kaposi’s Sarcoma (KS) reported by the United Network for
Organ Sharing (UNOS) and to assess their management. The secondary aim
was to review the graft and patient survival.
Methods: Data on the incidence and treatment of KS in the US between 1994
and 2005 were retrieved and analysed by UNOS*.
Results: Based on Organ Procurement and Transplantation Network data as of
December 14, 2007, there were 57 (0.04%) reported cases of KS in 158,008
kidney transplant recipients. Of these, 43 (75.4%) patients were male. The
mean time to diagnosis was 728.1 days (SD=652, min=118, max=2817) after
transplantation.
Almost all patients (53, 93%) were receiving a calcineurin inhibitor and/or
an antimetabolite agent as maintenance immunosuppression. Upon diagnosis
of KS, management was as follows: immunosuppression was stopped for 7
(12.3%) patients, reduced for 40 (70.2%), not adjusted for 5 (8.8%) and not
reported for 5 (8.8%). Three patients were on Rapamycin at the time KS was
reported to UNOS. There were no data on radiotherapy or surgery.
Graft survival was 91.2% (52/57) and 56.6% (24/57) at one and 5 years
respectively. Patient survival was 98.2% (55/57) and 75.8% (27/57) at one and
5 years respectively.
Conclusions: UNOS data suggest that the incidence of KS in kidney transplant
recipients is low (0.04%) as compared to the rates of 0.5-5% found to be
associated with organ transplants general (Marcelin et al, 2007). With respect
to management, it is surprising only three patients were on Rapamycin as it
has recently been shown to be a particularly effective treatment in transplant
patients with KS (Stallone et al, 2005).
The patient survival rates described above seem to be better than US figures
published previously by the Israel Penn International Tumour Registry
(Hannaway et al, 2001), where patient survival was 88% and 66% at one and
five years respectively. This group described 63 patients, of which 52 had
kidney transplants that occurred between 1985 and 2001.

POSTER BOARD NUMBER P4 – 451
843 CHRONOLOGICALLY DIFFERENT INCIDENCE OF
POST-TRANSPLANT MALIGNANCY IN RENAL TRANSPLANT
RECIPIENTS; 25 YEARS EXPERIENCE IN KOREAN SINGLE
CENTER
M.S. Kim1,2, H.K. Chang1,2, M.K. Ju1,2, D.J. Joo1,2, S.J. Kim1,2, S.I. Kim1,2, Y.S.
Kim1,2, K. Park3
1
Department of Surgery Yonsei University College of Medicine, 2The
Research Institute for Transplantation Yonsei University College of Medicine,
3
Department of Surgery, Kwandong University Myongji Hospital
The incidence of malignancy in transplant recipients is known to be higher than
that of normal population. But the types of malignancies vary geographically
and relative risks compared with general population are also different country
by country. In this study, we investigated the incidence and characteristics of
malignancy after renal transplantation in single center.
A total 2,650 renal recipients who were operated from April 1979 to June
2007 were enrolled in this study. The accumulative and interval (per 3 years)
incidence of malignancy was calculated by post-transplant period. Synchronous
or metachronous malignancies were counted as different events.
A total 190 cases of post-renal malignancy among 177 recipients (6.73%) were
reported until June 2007. The post-transplant malignancy was detected from
6 months to 290 months after transplantation with mean duration of 112.6
± 66.0 months. As the post-transplant duration was prolonged, the interval
incidence of malignancy was extremely increased [figure1]. Skin cancer
(n=35,18.4%) was the most common, followed by thyroid cancer(n=25,13.2%),
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stomach cancer(n=22,11.6%), colorectal cancer(n=22,11.6%), urologic
cancer(n=19,10.0%), lymphoproliferative disorders (PTLD)(n=12,6.3%),
and Kaposi’s sarcoma(n=12,6.3%). Virus-related malignancy such Kaposi’s
sarcoma and cervix cancer developed in earlier post-transplant period, but on
the other hand urologic cancer, colorectal cancer and PTLD developed in late
post-transplant period [figure2].
Therefore, we should establish the strategies for post-transplant malignancy
based on characteristics of post-transplant malignancy in each country.
Figure 1

5-28 days). Mean follow-up interval was 24 months (range 2-66). At follow up,
4 patients were in remission and had significant improvement in neurological
status. Two retained their allograft with function that was at or near baseline.
Two were on dialysis. One patient died 38 days and another died 137 days after
diagnosis both with stable disease.
In conclusion, high-dose IV MTX in addition to decrease in immunosuppression
should be considered as a treatment option for CNSPTLD after kidney
transplantation.

POSTER BOARD NUMBER P4 – 453
845 RATES OF HUMAN PAPILLOMAVIRUS (HPV)-RELATED
CANCERS ARE INCREASED IN RENAL TRANSPLANT
RECIPIENTS AND RETURN TO LOW LEVELS ON CESSATION
OF IMMUNE SUPPRESSION.

Figure 2
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844 TREATMENT OF CENTRAL NERVOUS SYSTEM POST
TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH
HIGH DOSE IV METHOTREXATE
C. Kew1, A. Przekwas1, B. Nabors2, C. Palmer2,3, B. Julian2
1
Nephrology, University of Alabama at Birmingham, 2Neurology, University of
Alabama at Birmingham, 3Pathology, University of Alabama at Birmingham
Central nervous system post-transplant lymphoproliferative disorder
(CNSPTLD) is an uncommon complication of organ transplantation, and is
frequently associated with Epstein Barr Virus (EBV) infection and is especially
difficult to treat. The standard treatment for primary (non-transplant related)
CNS lymphoma is high-dose IV methotrexate (MTX). Few cases of CNSPTLD
in renal transplant recipients have been described in the literature. There is not
consistent treatment. We report our experience treating renal transplant patients
with CNSPTLD with IV MTX.
Between 07/31/92 and 12/24/02, 3105 kidney transplants were perfomed. Eight
kidney and 2 kidney pancreas transplant patients who developed CNSPTLD
were included (0.3%). Eight received tacrolimus and 2 received cyclosporine;
all patients received prednisone and mycophenolate. Six patients were treated
with IV MTX. Charts were retrospectively reviewed.
Time from transplantation to diagnosis of CNSPTLD ranged from 17-167
months (mean 74 months). On MRI all patients had contrast-enhancing lesions.
Brain biopsy revealed showed all to have B-cell lymphoma (2 polymorphous,
3 monomorphous, and 1 with mono- and polymorphous features). All 6 were
EBV+ on immunohistochemical staining. Five patients received IV MTX (dose
8 g/m2) alone and 1 patient received IV MTX plus whole brain radiation. All
received leucovorin 24 hours after MTX. All immunosuppression was reduced.
Mean from time of diagnosis to initiation of treatment was 11.1 days (range

A. Grulich1, M. McCredie2, M. van Leeuwen1, J. Amin1, J. Stewart2,
S. McDonald3, A. Webster4, J. Kaldor1, J. Chapman5, C. Vajdic1
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New South Wales, 2University of Otago, Dunedin, New Zealand, 3Australia
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for Tranplant and Renal Research, Westmead Millenium Institute, University
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Purpose: The International Agency for Research on Cancer classifies a
number of anogenital and oral cancers as being HPV-related. This study aimed
to describe incidence and risk factors for these cancers in a population-based
cohort of transplant recipients.
Methods: Diagnoses of HPV-related cancers in a cohort of 8,162 renal
transplant recipients during 1982-2002 were ascertained through probabilistic
data linkage between the Australia and New Zealand Dialysis and Transplant
Registry and the National Cancer Statistics Clearing House. HPV-related oral
cancers included cancers of the tongue (ICD10 C01-02), mouth (C03-C06),
tonsil (C09) and oropharynx (C10). HPV-related anogenital cancers included
those of the cervix (C53), vulva (C51), vagina (C52), penis (C60) and
anus (C21). Person-years (PY) of follow-up were accrued from the date of
transplantation until the first diagnosis of each specific cancer, death, or last
contact. Standardized incidence ratios (SIRs) were calculated using age-, sex-,
calendar year-, and state/territory-specific population cancer incidence rates.
Multivariate Poisson regression was used to compute incidence rate ratios
(IRR) for anogenital and oral cancers during periods of transplantation and
dialysis following graft failure, as well as risk factors following risk factors
during the period of first transplant function only.
Results: There were a total of 43 HPV-related cancers; 17 oral and 26
anogenital. The rate of oral cancer after transplantation was 27.6 per
100,000PY. SIRs were raised for cancers of the tongue (SIR 7.17, 95% CI
4.38-11.07), mouth (SIR 4.58, 95% CI 2.51-7.69) and tonsil (SIR 2.94, 95%
CI 0.80-7.52). During the period of first transplant function, oral cancer was
associated with a history of ever smoking (IRR 3.84, 95% CI 1.01-14.7),
increasing age in years (IRR 1.03 95% CI 0.99-1.08), and increasing years
since transplant (IRR 1.12, 95% CI 1.01-1.25). The rate of anogenital cancer
after transplantation was 69.9 per 100,000PY. SIRs were raised for cancers
of the cervix (SIR 2.49, 95% CI 1.33 – 4.27), vulva (SIR 24.5, 95% CI 14.6
– 38.8), vagina (SIR 15.57, 95% CI 4.24 – 39.85), penis (SIR 15.9, 95% CI
5.85 – 34.7) and anus (SIR 2.76, 95% CI 1.51 – 4.64). As there were only 5
cases, no analysis of risk factors was performed in men. In women, 21 cases
of anogenital cancer occurred after transplantation (83.2 per 100,000PY).
During the period of first transplant function, anogenital cancer in women was
related to increasing years since transplant (IRR 1.12, 95% CI 1.03-1.22) and
receipt of the anti-lymphocyte antibodies OKT3 or ATG (IRR 2.57, 95% CI
1.06-6.23). Of the 43 HPV-associated cancers all but 1 occurred in a period of
transplant function rather than in a subsequent period of dialysis (IRR 0.17,
95% CI 0.02-1.22).
Conclusion: HPV-associated cancers occur at increased rates in renal
transplant recipients. HPV-related cancer risk was raised only during periods
of transplant function, and returned towards baseline during periods of
dialysis subsequent to transplant failure. These data suggest that removal
or reduction of immune suppression may reverse the increased risk of HPVrelated cancer and highlight the importance of preventive vaccination in
this population.
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846 RISK OF CUTANEOUS MELANOMA DOES NOT
INCREASE OVER TIME AFTER RENAL TRANSPLANTATION

847 CANCER MORTALITY IN KIDNEY TRANSPLANT
RECIPIENTS

C. Vajdic1, M. van Leeuwen1, J. Amin1, S. McDonald2,3, M. McCredie4,
J. Stewart4, A. Webster2,5, J. Kaldor1, J. Chapman2,6, A. Grulich1
1
National Centre In HIV Epidemiology And Clinical Research, University
of New South Wales, 2Australia and New Zealand Dialysis and Transplant
Registry, 3Disciplines of Medicine and Public Health, University of Adelaide,
4
Department of Preventive and Social Medicine, University of Otago, 5School
of Public Health, University of Sydney, 6Millennium Institute, Westmead
Hospital, University of Sydney
Purpose: The incidence of melanoma is increased in solid organ transplant
recipients and people with HIV/AIDS. In both immune deficient populations the
highest risk estimates have been observed in Australian populations, suggesting
an interaction between immune deficiency and sun exposure. This study aimed
to explore the descriptive and analytical epidemiology of melanoma in a large,
population-based, Australian cohort of renal transplant recipients.
Methods: Diagnoses of melanoma in a cohort of 8,162 renal transplant
recipients during 1982¨C2002 were ascertained through probabilistic data
linkage between the Australia and New Zealand Dialysis and Transplant
(ANZDATA) Registry and the National Cancer Statistics Clearing House.
Person-years of follow-up were accrued from the date of transplantation until
the first diagnosis of melanoma, death, or last contact. Multivariate Poisson
regression was used to compute incidence rate ratios (IRR) for melanoma
during periods of transplantation and dialysis, as well as risk factors during the
period of first transplant function only.
Results: 82 melanoma diagnoses were recorded after transplantation (134 per
100,000 person-years). Incidence was significantly lower after resumption
of dialysis than during transplant function (IRR 0.18, 95% CI 0.04 ¨C 0.72,
p=0.015). Of the 74 cases with specified anatomic site, 55 (74%) were on
the head, neck, arms and legs, sites with more chronic sun exposure than the
trunk (n=19, 26%). Of the 40 cases with specified morphology, 24 (60%) were
superficial spreading melanoma, 5 (13%) were nodular and there were 1 each
of 11 other subtypes. During the first transplantation, melanoma (n=74) was
independently associated with increasing age (IRR 1.04, 95%CI 1.02 ¨C 1.06,
p=0.01), end-stage renal disease as a result of diabetic nephropathy relative to
glomerulonephritis (IRR 2.16, 95%CI 1.00 – 4.65, p=0.05), and receipt of the
anti-lymphocyte antibodies OKT3 or ATG (IRR 1.73, 95%CI 1.05 ¨C 2.83,
p<0.03). Risk was significantly lower among females (IRR 0.56, 95%CI 0.34
¨C 0.93, p<0.001), and non-significantly lower among non-Caucasians (IRR
0.15, 95%CI 0.02 ¨C 1.10, p=0.06) and those who resided at more southerly
latitudes at registration on ANZDATA (p=0.20); relative to latitudes <30¡ã
the IRR was 0.61 (95% CI 0.35 ¨C 1.05) for latitudes 30-36¡ã and 0.70 (95%
CI 0.38 ¨C 1.29) for latitudes ¡Ý36¡ã. Risk was also non-significantly lower
with increasing time since transplantation (p=0.47); relative to 0-5 years posttransplantation the IRR was 0.91 (95%CI 0.54 – 1.52) for 5-10 years and 0.61
(95% CI 0.27 ¨C 1.35) for ¡Ý10 years.
Conclusion: Risk of melanoma after transplantation is associated with
currency of immunosuppression but, unlike cancers with a viral association,
appears unrelated to cumulative immune suppression. We also found no
evidence of an association with exposure to specific immunosuppressive
agents, with the exception of antibodies. This is consistent with the finding of
excess melanocytic naevi across diverse groups of immunosuppressed patients,
including transplant recipients, those with HIV/AIDS and those treated with
chemotherapy. Risk of melanoma after renal transplantation appears related
to the currency and possibly the intensity of immune suppression. Our data
provide inconsistent evidence that sun exposure, an established risk factor in
the general population, is also important in the renal transplant population..

B. Kiberd1, C. Rose2, J. Gill2
1
Dalhousie University, 2University of British Columbia
Several large registry analyses have shown that the overall incidence of cancer
is significantly increased (2.5-3.6 fold higher) compared either to the general
or the dialysis populations. The increase in incidence is not uniform across all
cancers but the increase is believed to be due to immunosuppression. What is
not known is whether death from these cancers is increased to the same extent
in the kidney transplant population. Our hypothesis is that competing risks of
death from cardiovascular disease may diminish the fatality of malignancy in
this population. In keeping with this hypothesis patients with diabetes mellitus
would be expected to suffer less cancer death.
In an analysis of the UNOS database from 1995-2004, incidence rates for
mortality attributed to cancer were calculated per 100,000 patient years of
exposure with a first time functioning kidney transplant (n = 224,590). Rates
were stratified for age, gender and race. In comparison to SEER registry of US
cancer mortality rates, the overall incidence of cancer mortality per 100,000
person years is increased in the kidney transplant compared to the general
population (250 vs.198), greater in males recipients (285 vs.182 females),
and greater in African Americans recipients (249 vs. 196 whites). However
mortality rates were not uniformly increased in all age groups and were in fact
lower in the oldest age group; age 20-54 (50 general vs. 149 kidney transplant),
age 55-64 (368 general vs. 365 kidney transplant) and 65-74 (817 general vs.
592 kidney transplant). The figure below shows that kidney transplant recipients
with diabetes mellitus (DM TX) uniformly have lower cancer mortality rates
than non-diabetic recipients (Non-DM TX).
The findings are in keeping with the hypothesis that older and diabetic patients
suffer less from malignancy than is accounted for by incidence rates (likely
competing risks of death) but that the younger patients are at very high risk of
cancer mortality and may deserve greater surveillance.
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848 IS SCREENING FOR CERVICAL CANCER IN KIDNEY
TRANSPLANT RECIPIENTS COST-EFFECTIVE? THE COSTS
AND HEALTH BENEFITS OF SCREENING FOR CERVICAL
CANCER IN WOMEN WITH KIDNEY TRANSPLANTS
G. Wong¹, K. Howard², A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1
Centre for Kidney Research, The Children’s Hospital at Westmead, 2School of
Public Health, University of Sydney, NSW, Australia, 3Centre for Transplant
and Renal Research, Westmead Hospital, NSW, Australia
Background: Women with kidney transplants have a higher incidence for
cervical squamous neoplasia than women without a transplant. The optimal
cervical cancer screening strategies for this population, however, are
uncertain.
Aim: To estimate the costs and health outcomes for annual cytological cervical
cancer screening in women who had kidney transplants.
Methods: A Markov model was developed to compare the costs and health
outcomes in a cohort of women with kidney transplants aged 18-69, who
underwent cytological screening (conventional) compared to a cohort who
did not. A second comparison was made between annual screening using
liquid-based cytology and conventional cytology. Baseline prevalence data for
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cervical dysplasia, survival and cancer-specific mortality data were obtained
from the Australian and New Zealand Dialysis and Transplant (ANZDATA)
registry (1982 – 2006). Other information such as screening participation rates,
test performance and costs of the screening tool were sourced from published
literature in the general population. Unit costs for screening and treatment were
converted to the 2005 Australian dollars using the Medicare component of the
Consumer Price Index (CPI).
Results: The average costs for a program of annual screening for women
who had a kidney transplant were $2,761 for 50 years. The incremental costeffectiveness ratio (ICER) for annual conventional Pap screening compared
to no screening was $28,711 per life year saved (LYS), with a net gain in life
expectancy of 12.5 days. Using the newer liquid-based cytological screening,
the average costs for annual screening increased to $3453.5 and average
benefits increased from 15.0728 LYS to 15.0735 LYS. The incremental costs of
liquid-based screening compared to conventional cytological (Pap) screening
was $692.5, with an incremental benefit of only 0.26 days of lives saved.
The ICER for liquid-based screening compared to conventional cytological
(Pap) screening was over $1,000,000/LYS. The choice of screening was
most sensitive to the relative prevalence of disease, age at which screening
commenced, natural history of precancerous lesions, test specificity and costs
of the screening test. For example, reducing the relative disease prevalence
to half of the base-case estimates, increased the ICER from around $29,000/
LYS to over $600,000/LYS. Assuming the test specificity of conventional
cytological (Pap) screening decreased to only 50%, the ICER increased to over
$70,000/LYS.
Conclusion: Annual screening with conventional cytological (Pap) screening
in women with kidney transplants appears good value for money. The improved
test sensitivity and extra benefits obtained from liquid-based cytological
screening do not offset the additional costs of the newer test.

POSTER BOARD NUMBER P4 – 457
849 THE HEALTH AND ECONOMIC IMPACT OF HUMAN
PAPILLOMAVIRUS VACCINATION IN KIDNEY TRANSPLANT
RECIPIENTS
G. Wong¹, K. Howard², A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1
Centre for Kidney Research, The Children’s Hospital at Westmead, 2School of
Public Health, University of Sydney, NSW, Australia, 3Centre for Transplant
and Renal Research, Westmead Hospital, NSW, Australia
Background: Quadrivalent vaccine against human papillomavirus
HPV-6/11/16/18 for the prevention of high-grade cervical dysplasia is now
recommended for women and girls ages 9-26 in the general population.
It is uncertain whether vaccination in pre-pubertal girls prior to kidney
transplantation in combination with annual cervical cancer screening, is a costeffective healthcare intervention for women with kidney transplants.
Aim: To estimate the overall costs and health outcomes of HPV vaccination in
the setting of existing annual cervical cytological screening in kidney transplant
recipients.
Methods: We developed a static state-transition Markov model to simulate a
cohort of kidney transplant recipients (n = 1000, aged 18-69) who received pretransplant HPV vaccination (prior to HPV exposure) and post-transplant annual
conventional cytological (Pap) screening (commencing at age 18) compared to
a cohort who did not receive vaccination but were screened annually for cervical
cancer. Baseline prevalence data for cervical dysplasia, survival and cancerspecific mortality were obtained from the ANZDATA Registry (1982-2006).
Other information was sourced from the general population. Unit costs for
screening and treatment were converted to the 2005 Australian dollars.
Results: In the base-case analysis, assuming a sustained vaccine efficacy against
HPV infection, the average costs for a program of pre-transplant vaccination
plus annual screening over a period of 50 years were $3,032, and the average
benefits were 15.0578 LYS. The incremental cost-effectiveness (ICER) ratio of
pre-transplant vaccination plus annual screening compared to annual screening
alone was $59,363 per life year saved (LYS), with a net gain in life expectancy
of 1.9 days. Assuming vaccine efficacy waned over time and a booster shot was
required for the remaining cohort ten years after initial vaccination, the average
costs of vaccination plus annual screening increased to $7,817, and the average
benefits were15.0585 LYS. The ICER of pre-transplant vaccination plus annual
screening compared to annual screening alone increased to $843,471/LYS,
with a net gain in life expectancy of 2.2 days of life saved. Using a series of

one and multi-way sensitivity analyses, the model was most sensitive to age
at which screening commenced, cost of HPV vaccination, response to initial
vaccination and persistence of the vaccine efficacy. For example, the ICER
increased to $104,481/LYS with a starting age of 30 compared with an ICER
of $59,363/LYS at base-case (starting age at 18). Reducing the costs of initial
HPV vaccination from $400 to $200 decreased the ICER to just below $25,000/
LYS. Assuming vaccine efficacy waned over time, the ICER increased from
$60,000/LYS to over $100,000/LYS, with a reduction in the net gain in life
expectancy to just over 1.6 days.
Conclusions: Under the most optimistic assumptions where there is a
sustained and life-long vaccine efficacy against HPV infection, pre-transplant
HPV vaccination to HPV naïve individuals in addition to annual cervical
cytological screening commencing at age 18 is good value for money. Costeffectiveness of a HPV vaccination and annual cervical cancer screening
program in transplanted women is strongly dependent on the response to initial
vaccination, costs of the vaccine and persistence of the vaccine efficacy.

POSTER BOARD NUMBER P4 – 458
850 CANCER SCREENING PRACTICES BY TRANSPLANT
PHYSICIANS: WHAT DO PHYSICIANS SCREEN FOR AND
WHY?
G. Wong¹, A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1
Centre For Kidney Research, The Children’s Hospital At Westmead, 2School
of Public Health, The University of Sydney, NSW, Australia, 3Centre for
Transplant and Renal Research, Westmead Hospital, NSW, Australia
Background: Increased cancer risk is well established in the kidney transplant
population. Cancer screening, which detects early stage diseases and allows
effective curative treatment, reduces cancer-specific mortality and morbidity
in the general population. Despite the increased risk, little is known about
the current cancer screening practices by physicians caring for transplant
recipients.
Aim: To describe and determine the major factors influencing cancer screening
practices by kidney transplant physicians in Australia and New Zealand.
Methods: Questionnaires were electronically posted to all physicians, who
were in clinical practice and cared for adult transplant recipients, through
the Australia and New Zealand Society of Nephrology (ANZSN) contact
directory. The survey instrument assessed physicians’ knowledge of current
recommendations, attitude and practice behaviour of colorectal, breast and
cervical cancer screenings in the kidney transplant population.
Results: 132 (53.3%) out of the 250 invited members from the ANZSN took part
in the survey. Of all respondents, 88.6% offered breast, 90% offered cervical
and 85% offered colorectal cancer screening. The majority of participants
commenced screening at the recommended age (85%), used the recommended
screening tools (87.7%) and intervals (82.6%) for all three cancers. Over 90%
of respondents agreed breast and colorectal cancer screening should stop at
age 70. 55% of all respondents would continue screening for cervical cancers
using conventional Pap smear indefinitely. Most (89%) would not adopt the
newer liquid-based cytology and HPV DNA cervical screen. There was no
association between demographic factors such as age, gender, years of practice
in nephrology and the decisions to screen. Important factors considered by
clinicians when making cancer screening decisions were disease prevalence
(69.2% compared to 25.9% p< 0.001), disease-specific mortality benefits
(70.2% compared to 18.5% p <0.001) and screening test performance (47.1%
compared to 11.1% p = 0.01). Other factors such as the cost-effectiveness of
screening, life-expectancy and co-morbidities of transplant recipients were not
significant.
Conclusions: Despite the paucity of evidence for cancer screening in the
transplant population, transplant physicians generally agree screening is
acceptable and adopt screening practices recommended by current cancer
surveillance guidelines in the general population. The three most influential
factors affecting physicians’ decisions to screen for cancers are disease
prevalence, cancer-specific mortality benefits from screening and performance
of the screening tool. Other standard criteria for assessing the validity of
recommendations such as cost-effectiveness of screening, life expectancy
and competing risk of co-morbidities among transplant recipients were not
considered. Clinicians should be better aware and informed of the evidence
of benefits and harms that underpins the rationale behind screening guidelines
from professional groups.
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851 CTGF RELEASED BY APOPTOTIC ENDOTHELIAL
CELLS TRIGGERS FIBROGENESIS
P. Laplante, I. Sirois, M-A. Raymond, M-J. Hébert
University of Montreal
Apoptosis of endothelial cells (EC) is appreciated as a primary event in the
development of various fibrotic diseases, such as chronic allograft rejection,
systemic sclerosis and graft-vs-host-disease. Yet, the fibrogenic pathways
activated by apoptosis of EC have remained, until recently, ill defined. Two
important and concomitant phenotypic changes appear to be required for
development of fibrosis: differentiation of fibroblasts into myofibroblasts and
acquisition of a broad anti-apoptotic phenotype in fibroblasts/myofibroblasts.
The myofibroblast, a specialised and contractile type of fibroblast, is a
normal cellular constituent of healing tissues where it plays a central role in
ECM deposition and tissue contraction. In fibrosis, however, myofibroblasts
accumulate chronically due to a sustained state of resistance to apoptosis
and represent key players in generating the pathological tissue deformations
characteristic of fibrosis.
Here we demonstrated that caspase activation in apoptotic EC triggers
the release of fibrogenic mediators which in turn favour myofibroblast
differentiation. A comparative proteomic approach identified Connective
Tissue Growth Factor (CTGF) as a novel mediator released by apoptotic EC
downstream of caspase activation. Immunoblotting confirmed increased levels
of CTGF in medium conditioned by apoptotic EC (SSC) as compared with
medium conditioned by non-apoptotic EC. Also, fibroblasts exposed to SSC
immunodepleted of CTGF failed to differentiate, thus suggesting a pivotal role
for CTGF in this system. Use of gene deficient fibroblasts for Src, Fyn, Yes
and siRNA targetting Focal adhesion kinase or Pyk2, demonstrated that CTGF
induces myofibroblast differentiation through a Yes-Pyk2-Phosphatidylinositol
3-kinase (PI3K) dependent pathway. Collectively these results suggest that
apoptosis of EC presents an unrecognised potential towards CTGF production
and initiation of fibrosis.

POSTER BOARD NUMBER P4 – 460
852 ADVENTITAL VASCULAR PROGENITORS ARE MAIN
SOURCE OF CELLS FOR INTIMAL HYPERPLASIA IN
TRANSPLANT VASCULOPATHY

THURSDAY

P. Religa1, M. Grudzinska1, K. Bojakowski2, J. Soin2, Z. Gaciong2,
C. Soderborg-Naucler1
1
Karolinska Institutet, Stockholm, Sweden, 2Warsaw Medical University,
Warsaw, Poland
Transplant arteriosclerosis is the major factor of late organ dysfunction after
transplantation. The pathology involves inflammation of the vessel with
formation of the intimal hyperplasia consisting of smooth muscle cells (SMCs)
recruited into the vessel intima. The process results in a progressive narrowing
of the vessel lumen, partly due to a healing reaction in the intima.
Hypothesis: Smooth muscle cells contributing to the vascular narrowing are
in the large extension derived from grafts recipient. Evaluation of migration of
tissue progenitor cells from surrounding tissues was the aim of the study.
Methods: Infrarenal aorta was transplanted from female F344 to male
Lewis rats collected after different time points. Migration and activation of
host-derived SMCs and cells from surrounding tissue were analyzed by
immunohistochemistry and real-time polymerase chain reaction (PCR) for
SRY gene. The samples were analyzed by immunohistochemistry with respect
to cells present in the sections, such as: SMCs, endothelial cells, leukocytes and
activation of the cells (SM-actin, SM-myosin, von willebrand factor, CD45,
CD14, CD4, CD8, cyclinD1, PCNA). The samples were also analyzed by
electron microscopy. Phenotypic analysis of adventitial progenitor cells was
performed.
Results: Proliferating graft SMCs and infiltrating leukocytes were observed
in the intima and adventitia early after transplantation. The similar process
was observed also in the adjacent vessel, however in a lower extension. With
electron microscopy we observed also phenotypic modulation of medial SMCs
in the adjacent vessels. The cells from the adventitia were major source of
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intimal cells migrating to the intima in our model. FACS analysis indicated that
adventitial progentitor are sca1+.
Conclusion: The tissue progenitor cells from adjacent adventitia are important
source of cells for the formation of intimal lesion.

POSTER BOARD NUMBER P4 – 461
853 RENAL ISCHEMIA REPERFUSION INJURY
IS ABROGATED BY THE NOS COFACTOR
TETRAHYDROBIOPTERIN VIA MAINTENANCE OF NO
HOMEOSTASIS AND STRESS KINASE INHIBITION
R. Sucher1,2, P. Gehwolf2, R. Oberhuber2, M. Maglione1,2, E. Werner1,
P. Obrist1, S. Schneeberger1,2, R. Öllinger1,2, R. Margreiter1,2, G. Brandacher1,2
1
Department of General and Transplant Surgery, 2Daniel Swarovski Research
Laboratory
Purpose: Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide
synthases (NOS) and thus a critical determinant of NO production. BH4
depletion during cold ischemia leads to uncoupling of NOS and contributes
to reperfusion injury (IRI) due to increased superoxide formation. The role of
BH4 during warm ischemia, however, is still largely unknown.
Material and Methods: Ischemic renal injury was induced by clamping the
left renal artery for 45 min in male Lewis rats immediately after right-side
nephrectomy. Reperfusion was studied at R0 (no reperfusion), 15min (R1),
2hours (R2) and 7days (R3). Animals received either BH4(20mg/kg/BW) prior
to reperfusion (GroupI) or saline (GroupII). Sham operated animals served
as controls. Renal function was determined by plasma creatinine/urea. BH4
tissue levels were assessed by HPLC. Morphologic changes were quantified
by H&E histology. Peroxynitrite formation was assessed by nitrotyrosineimmunostaining and stress kinase (p38, JNK) activation was analysed using
phosphorylation specific antibodies.
Results: BH4 tissue levels were slightly increased after 45min warm
ischemia (1.0 to 1.6fold) up to two days (R1,R2) when compared to nonischemic controls. Additional BH4 treatment prior to ischemia significantly
improved renal function at all time points studied following reperfusion (all
p<0.001). Furthermore, BH4 reduced ischemia induced histologic damage
(increased inflammation, interstitial edema, hemorrhage, tubular atrophy and
focal areas of necrosis) and diminished peroxynitrite formation and hence
nitrotyrosine staining (R1-R3). Subsequently, stress kinase activation was
abrogated following BH4 treatment further limiting ischemia reperfusion
injury (p<0.01).
Conclusion: BH4 treatment significantly improves post-ischemic renal
function as well as histologic damage and might be a promising novel
therapeutic strategy in attenuating IRI via maintenance of NO homeostasis and
stress kinase inhibition in kidney transplantation.

POSTER BOARD NUMBER P4 – 462
854 DAMPENING OF ALLOIMMUNITY BY TOLL-LIKE
RECEPTOR 4 DESENSITIZATION
V. Nicolas, D.W. Virginie, L.J. François, P. Lemaitre, F. Lhomme,
M. Goldman, A. Le Moine
Institute for Medical Immunology Université Libre de Bruxelles
A single does of lipopolysaccharide (LPS) activates innate immunity through
the Toll-Like receptor (TLR) 4 whereas repeated injections of sublethal doses
desensitize animals, a process referred as endotoxin tolerance. During organ
transplantation, there is an early activation of innate immunity through the
recognition of endogenous and exogenous TLR ligands, a process considered
as boosting effector T cell differentiation and allograft rejection. Therefore, we
wondered if a prior LPS-desensitization could favourably influence the fate of
allograft. We observed that LPS-desensitization of both donors and recipients
significantly enhanced survival of male to female skin grafts, compared with
undesensitized control mice (p<0.05, Logrank test). Next, we tried to identify a
putative regulatory cell subtype by performing suppression assays of MLR and
polyclonal CD4+ and CD8+ T cell activation. Among desensitized splenocytes,
only CD11b+Gr-1+ cells were able to significantly suppress T cell proliferation
(CFSE dilution experiments and IFN-&#61543; production) whereas
CD11b+Gr-1+ cells from control animals did not. Transwell experiments
revealed that suppression was cell-cell contact-dependant. Moreover,
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alloreactive T cells only marginally responded to desensitized allogeneic
CD11b+ cells compared with undesensitized (thymidine incorporation and
IFN-&#61543; production). In vivo, LPS-desensitization increased the
percentage of CD11b+Gr-1+ cells up to 5 folds in bone marrow, spleen and
lymph nodes. Adoptive transfer of CD11b+ from LPS desensitized animals
to naïve female recipients significantly prolonged male skin graft survival
compared to untransferred controls (p<0.05, Logrank test). We conclude that
LPS-desensitization: (1) delays allograft rejection; (2) increases the number
of CD11b+Gr-1+ cells which are endowed with powerful cell-cell contactdependant immunosuppressive properties.

POSTER BOARD NUMBER P4 – 463
855 PROTECTION AGAINST RENAL ISCHEMIA INJURY IN
DNA-REPAIR DEFICIENT COCKAYNE SYNDROME MICE
R.W.F. de Bruin1, D. Susa1, J.R. Mitchell2, M. Verweij1, H.P. Roest1, S. van
den Engel1,
M. van de Ven2, I.M. Bajema3, J.N.M. IJzermans1, J.H.J. Hoeijmakers2,
1
Erasmus Medical Centre Rotterdam, Department of Surgery, 2Erasmus
Medical Centre Rotterdam, Department of Cell Biology and Genetics, 3Leiden
University Medical Centre, Department of Pathology
The premature aging symptoms of progerias with inborn errors in DNA repair
mechanisms, such as Cockayne syndrome, are thought to be due in part to
hypersensitivity to oxidative DNA damage caused by reactive oxygen species.
To assess the contribution of oxidative DNA damage to renal ischemia
reperfusion (I/R) injury, we tested the effects of congenital DNA repair
deficiency using a mouse model of Cockayne syndrome B (Csb-/- mouse) on
renal ischemia-reperfusion injury.
Renal I/R injury was induced by placing an atraumatic microvascular clamp
on the renal pedicle of the left kidney of Csb-/- or littermate control mice. After
reperfusion, the right kidney was removed. Mice were sacrificed at specified
time-points after reperfusion, and markers of kidney function, proliferation,
cell death, cell cycle and inflammation were determined.
Unexpectedly, we found that Csb deficiency was beneficial to survival and
kidney function following I/R injury. Mortality was significantly reduced
from 70% in controls to 40% in Csb-/- mice (p<0.01), and kidney function was
significantly improved. Acute tubular necrosis score was higher in control
mice on days 1 and 2 (p<0.05). Proliferation, as assessed by histology,
PCNA and KI-67 staining was significantly higher in Csb-/- kidneys in the
regenerative phase (days 1,2, and 3) following injury (p<0.05). Consistent
with increased proliferation, we found a reduced number of p21 positive
cells in Csb mice on day 2. Transcript levels of p-selectin and ICAM-1 were
significantly lower compared to controls at 6 and 24 hours after reperfusion,
respectively.
In conclusion, Csb-/- mice showed and increased resistance to renal I/R injury.
Our data suggest that certain types of unrepaired endogenous DNA damage
activate a stress response that preconditions against acute forms of stress such
as ischemic injury. Elucidation of this protective stress response may offer a
new approach to protect against renal ischemia reperfusion injury.

POSTER BOARD NUMBER P4 – 464
856 INTRACELLULAR SIGNALING PATHWAYS AS
TARGETS FOR THE PREVENTION OF ISCHEMIA/
REPERFUSION-INDUCED DAMAGE DURING SOLID ORGAN
TRANSPLANTATION
R. Sucher1, J. Smigelskaite1, P. Gehwolf1, A. Kuznetsov1, M. Hermann2,
C. Doblander1, M. Maglione1, T. Ratschiller1, G. Brandacher1, R. Margreiter1,
J. Troppmair1
1
Daniel Swarovski Research Laboratory, Dept. of General and Transplant
Surgery, Innsbruck Medical University, 2KMT Laboratory, Dept. of General
and Transplant Surgery, IMU
Pronounced changes in intracellular signaling are observed during ischemia
and reperfusion (I/R) in the context of solid organ transplantation. We are
only beginning to understand the underlying physiological activators and
the endpoints controlled by these signals. While genetic studies in mice
have underscored the profound effects altering key signaling molecules may
have on the outcome of I/R-induced organ injury (IRI), we have a much

better understanding of the role of the second messengers reactive oxygen
species (ROS) and Ca2+ in this process. In our work using isolated mouse
cardiomyocytes and a murine heart transplant model we noticed a significant
increase in the activity of mitogen-activated protein kinases (ERK, JNK, p38)
at the earliest time points after reoxygenation/reperfusion. These enzymes
play key roles in the control of cell death and thus constitute prime candidates
for possible regulators of IRI. In an attempt to establish a possible causal
relationship between altered intracellular signaling and the previously described
changes in mitochondrial ROS and Ca2+ we employed the cardiomyocyte cell
line HL-1 as well as non-myocytic cells. Using the latter our experiments
demonstrated that signaling through RAF-MEK-ERK controlled mitochondrial
ROS production, which otherwise resulted in mitochondrial Ca2+ overload and
apoptosis. In HL-1 cardiomyocytes undergoing hypoxia and reoxygenation
we observed that in these cells activation of p38 was responsible for the
increase in mitochondrial ROS and Ca2+ levels. Taken together, our data
demonstrate that MAPK signaling, which we found early after reperfusion
is critically involved in controlling ROS and Ca2+ levels and thus most likely
cardiomyocyte death. Modulating these pathways, which has become feasible
through the development of small molecular weight inhibitors may provide an
efficient means to interfere with the onset of IRI at a very early stage before
irreversible damage is set.

POSTER BOARD NUMBER P4 – 465
857 A NOVEL SIRNA-DELIVERY METHOD THROUGH
CORONAL ARTERY INFUSION OF DONOR HEARTS FOR
PREVENTING ISCHEMIA-REPERFUSION INJURY
X. Zheng, D. Chen, X. Zhang, M. Suzuki, N. Kobu, D. Lian, J. Jiang,
B. Garcia, A.M. Jevikar, W-P. Min
University of Western Ontario
Background: We have previously demonstrated that silencing inflammatory,
apoptosis and complement genes can prevent ischemia-reperfusion (I/R)
injury occurring in heart transplantation. However, the method for efficient
delivering siRNA into donor organ has not been established. This study
was designed to develop a new method to induce gene silencing by coronal
artery infusing with siRNA solution for prevention I/R injury in heart
transplantation.
Methods: Multiple siRNAs that specifically target TNFα, Caspase 8, and
C5a receptor (C5aR) genes were generated and selected. siRNA protection of
donor organs was evaluated in a rat heart transplantation model. Heart grafts
from Lawis rats were infused with siRNA solution via coronal artery and
preserved in HKT solution at 4 0C for 18 hrs, and subsequently transplanted
into syngeneic Lawis rats. Cardiac functions were assessed by heart beating
rate. Gene expression at mRNA level was determined by qPCR. The I/R injury
was assessed by immunohistochemistry.
Results: After donor heart perfusion with siRNA solution, siRNA was found
to enter the myocardial cells, indicated by the fluorescence emitted from the
dye labeled siRNA. The levels of TNFα, caspase 8 and C5aR genes were
significantly up-regulated in the grafts after ex vivo preservation for 18 hrs.
These up-regulated TNFα, caspase 8, and C5aR genes were significantly
knocked down by siRNA infusion. Using a siRNA infused organ as a donor,
the graft survival was significantly prolonged in heart transplantation. While
siRNA solution-treated heart grafts retained strong heartbeat up to the end point
of observation (>10 days), the control grafts lost function within 3 days. In
addition, an improved cardiac function was observed in the graft preserved
in siRNA solution. The protection of graft by siRNA solution is associated
with prevention of I/R injury. siRNA solution-treated organs exhibited almost
normal histological structures as well as less neutrophil and lymphocyte
infiltration, compared with control solution-treated organs.
Conclusions: This study developed a novel ex vivo siRNA delivery system
using coronal artery infusion, which can effectively silencing genes in donor
hearts and prevent cardiac I/R injury.
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POSTER BOARD NUMBER P4 – 466
858 INHIBITION OF TH17 CELLS REGULATES
AUTOIMMUNE DIABETES.
J. Emamaullee, J. Davis, L. Stanton, C. Toso, S. Merani, J. Shapiro
University of Alberta
Background: Type 1 diabetes (T1D) occurs following the T-cell mediated
destruction of the insulin-producing islet β;-cells within the pancreas. Recently,
a population of CD4+ T helper cells that secrete IL-17 (‘Th17’ cells) has
been specifically linked to autoimmunity, and high levels of IL-17 have been
associated with most autoimmune conditions. The impact of Th17 cells in T1D
is not known, but our group has determined that neutralization of IL-17 in the
NOD mouse, a model of T1D, significantly delays autoimmunity, suggesting
that Th17 cells play a role in this disease. It has recently been reported that IL-25,
a cytokine in the same IL-17 cytokine family, downregulates the development
of autoimmune inflammation mediated by Th17 cells in a mouse model of
multiple sclerosis. These data, combined with our previous work using antiIL-17, suggest that IL-25 therapy will control autoimmunity in T1D.
Results: A series of experiments were conducted to test IL-25 therapy in
diabetes prevention, remission, and recurrence in NOD mice. When IL-25
was administered at 1 μ;g/day for 25 days beginning at 10 weeks of age,
80% animals were free from diabetes at 6 months of age, vs. 10% of control
animals (P=0.007). Histological analysis of treated animals revealed an
absence of peri-islet infiltrates, which was in stark contrast to the obliterative
insulitis observed in control animals. As well, IL-25 treatment prevented the
formation of GAD65 autoantibodies and reduced the frequency of GAD65responsive autoreactive T-cells (P<0.001 vs control; ELISPOT). Interestingly,
administration of IL-25 at the time of diabetes onset resulted in remission from
diabetes in 82% of treated animals, versus 0% of control animals (P<0.001).
However, the remission was not always durable and hyperglycemia returned
after 7-10 days in some animals, even while IL-25 therapy was ongoing. In
the setting of recurrent autoimmunity following syngeneic islet transplantation,
control animals rejected their islet grafts in 4.2±0.8 days, while IL-25 treated
animals rejected their islets in 7.2±0.2 days (P=0.0013). Ongoing adoptive
transfer studies should reveal the mechanism of IL-25 mediated suppression
of autoimmune diabetes.
Conclusion: Our results suggest that further refinement of IL-25 treatment
regimens may lead to durable remission from new onset diabetes and prevent
recurrent β;-cell autoimmunity following islet transplantation.

POSTER BOARD NUMBER P4 – 467
859 A MULTICENTER RCT OF DECEASED ORGAN DONOR
PRE-TREATMENT WITH CORTICOSTEROIDS FOR THE
PREVENTION OF POSTISCHEMIC ACUTE
RENAL FAILURE
J. Wilflingseder , A. Kainz , C. Mitterbauer , C. Burghuber , P. Perco , T.
Meyer4, B. Mayer3, R. Langer5, R. Magreiter6, R. Oberbauer1,2
1
KH Elisabethinen, Linz, Austria, 2Medical University of Vienna, Austria,
3
Emergentec Biodevelopment, Vienna, Austria, 4Department of Nephrology,
University of Stanford, Palo Alto, CA, USA, 5Semmelweis University,
Budapest, Hungary, 6Medical University of Innsbruck, Austria
This randomized placebo controlled study seeks to elucidate whether pretreatment of deceased organ donors with corticosteroids before organ retrieval
will decrease inflammation in the donor kidney and will reduce the rate or
duration of postischemic acute renal transplant failure (ARTF). We have shown
previously, that inflammation of the donor kidney prior to transplantation is
among the main risk factors for ARTF (Hauser P et al. Lab Invest 2004, Kainz
A, AJT 2004).
The predetermined interim analysis of 210 recipients (calculated sample size
420) will be presented. This analysis includes genome-wide gene expression
profiles of donor kidney biopsies with subsequent systems biology approaches
such as transcription factors analysis, regulatory networks, and protein-protein
interaction data. Trajectories of GFR in the first week after engraftment will be
analyzed by mixed linear regression models for longitudinal data, the incidence
of ARTF, defined as more than one post-transplant dialysis will be analyzed by
Chi-square test.
At the time of abstract submission 27 randomly selected biopsy samples have
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been analysed. Unsupervised hierarchical clustering of experimental data
suggest a distinct molecular signature associated with reduction of inflammation
in the steroid group. Selection of twofold differentially downregulated genes
in the steroid group yielded 94 significant sequences that can be categorized
according to PANTHER ontologies into four main biological processes:
immunity and defense (p<0.001) protein modification (p<0.001), cell cycle and
control (p<0.003), cell proliferation and differentiation (p<0.003).
These preliminary genomics data suggest that inflammation was reduced by
steroid pre-treatment. The effect of this intervention on clinical endpoints of
ARTF will be presented in the interim analysis at the meeting.

POSTER BOARD NUMBER P4 – 468
860 DONOR ANGIOTENSIN II RECEPTOR TYPE 1
EXPRESSION CRITICALLY INVOLVES THE DEVELOPMENT
OF ACUTE REJECTION
M. Ogawa, J-I. Suzuki, M. Isobe
Tokyo Medical and Dental University
Backgrounds: Although angiotensin II receptor type 1 (AT1) mediates
inflammation, little is known about the roles of AT1 in the development of
cardiac rejection. Methods: To test the hypothesis that AT1 expression, either
on the donor hearts or recipient cells, plays a pivotal role in the development
of rejection, we established a murine heterotopic cardiac allograft model using
AT1a knockout (AT1aKO) (C57BL/6 background), C57BL/6 and/or BALB/c
mice. Total allomismatch combination was used to analyze graft survival
(acute rejection).
Results: The AT1aKO donor BALB recipient group significantly prolonged
graft survival compared to those of the B6 donor BALB recipient group
(AT1aKO/BALB; 28.71 +/- 16.75 days, B6/BALB; 8.14 +/- 0.40 days, p<0.05).
However, the BALB donor AT1aKO recipient group showed statistically
comparable survival to that of the WT donor WT recipient group (BALB/
AT1aKO; 7.33 +/- 0.33 days, BALB/B6; 7.13 +/- 0.23 days). 10% of the mice
in AT1aKO donor BALB recipient group showed graft survival more than 130
days, but not induced immunological tolerance with acceptance of the skin
graft from the donor strain.
Conclusion: Donor AT expression plays an important role as a mediator for
inflammation of heart transplantation. The donor AT regulation deeply involves
the development of acute rejection and the tissue distribution of the inhibitor
may be critical for the treatment of rejection.

STATE-OF-THE-ART SYMPOSIUM
CONCURRENT SESSION 33: UPDATE ON NEW
IMMUNOSUPPRESSIVE TRIALS IN TRANSPLANTATION
861 A PROSPECTIVE, RANDOMISED, PLACEBO
CONTROLLED,MULTICENTER STUDY OF THE EFFICACY
AND SAFETY OF RITUXIMAB AS INDUCTION THERAPHY
TOGETHER WITH TACROLIMUS,MYCOPHENOLATE
MOFETIL AND STEROIDS IN RENAL TRANSPLANTATION
G. Tyden1, L. Mjornstedt2, H. Ekberg3, G. Tufveson4
1
Karolinska University Hospital,Stockholm, 2Sahlgrenska University
Hospital,Gothenburg, 3University Hospital MAS,Malmoe, 4Academic
University Hospital, Uppsala
Purpose: There is an increasing evidence to suggest that B cells have a role
in otherwise classic T cell-mediated rejection by their ability to act as antigenpresenting cells and T cell activators. We therefore studied the efficacy and
safety of the monoclonal anti-CD20 antibody rituximab as induction therapy
in renal transplantation.
Methods: We performed a prospective, randomized, placebo-controlled
multicenter study of the efficacy and safety of rituximab as induction therapy,
together with tacrolimus, mycophenolate mofetil and steroids, for patients
undergoing renal transplantation. The primary end point was a composite
end point defined as treatment failure including the occurrence of any of the
following: biopsy-proven acute rejection, graft loss or death during the first
6 months following transplantation. Secondary end points were creatinine
clearance (Cockroft-Gault formula) at 6 months, incidence of infections and
incidence of rituximab-related adverse event.
Results: 140 patients were enrolled (44 LD and 96 DD) and of those 69
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rituximab patients and 68 placebo patients fulfilled the study. In all the patients
receiving rituximab there was a complete depletion of CD19/ CD20 cells at 3
and 6 months, while there was no change in the number of CD19/ CD20 cells in
the placebo group.There were 10 and 14 treatment failures in the rituximab and
placebo groups respectively. Thus there was one patient death and one graft loss
not related to rejection, in each group. There were 8 rejections in the rituximab
group (11.6%) versus 12 in the placebo group (17.6%). There were more early
C4d-positive rejections in the placebo group (4) than in the rituximab group(1).
Furthermore, there were more steroid-resistent rejections in the placebo group
(5) than in the rituximab group (2). However, none of these differences were
statistically significant.The creatinine clearance at 6 mos was 66 ml/min in
rituximab treated patients and 67 ml/min in the placebo group. There was
no difference in the number of bacterial infections, CMV infections, BKV
infections or fungal infections. Neither was there any significant difference in
the incidence of leucopenia and anemia or in the incidence of cardiac events.
Conclusion: We performed the first ever randomized, placebo-controlled study
of the efficacy and safety of rituximab in renal transplantation. There was a
tendency towards fewer and milder rejections during the first 6 months in the
rituximab group compared with the placebo group. Although induction with
one dose of rituximab induced a complete depletion of CD19/ CD20 positive
cells there was no increase in the incidence of infectious complications, cardiac
events, leucopenia or anemia and it appears safe therefore to conduct further
studies on the use of rituximab in transplantation.

862 OPTICEPT TRIAL: EFFICACY AND SAFETY OF
MONITORED MMF IN COMBINATION WITH CNI IN RENAL
TRANSPLANTATION AT 1 AND 2 YEARS
R. Bloom1, B. Kaplan, H-U. Meier-Kriesche, L. Shaw, T. Shah, D. Patel,
R. Gaston
1
University of Pennsylvania, 2University of Illinois, 3University of Florida,
4
University of Pennsylvania, 5National Institutte of Transplantation, 6Roche,
7
University of Alabama
Purpose: To compare the efficacy and safety of maintenance
immunosuppression with either a concentration-controlled or fixed-dose MMF
regimen in combination with standard or reduced level calcineurin inhibitor
(CNI) regimens in kidney recipients.
Methods: In a 2-year open-label, prospective, randomized, multicenter study,
720 single-organ kidney recipients received either: 1) concentration-controlled
MMF and reduced level CNI (MMFCC/CNIRL); 2) concentration-controlled
MMF and standard level CNI (MMFCC/CNISL); or 3) fixed-dose MMF (1 g
BID) and standard level CNI (MMFFD/CNISL). MMF dose adjustments were
made in the MMFCC arms to target MPA levels > 1.3 and 1.8 respectively
for patients on either cyclosporine or tacrolimus treatment. Antibody induction
and corticosteroids were administered according to center practice. Primary
endpoints included the percentage of patients with treatment failure (biopsyproven acute rejection [BPAR], graft loss, or death), and mean percent change
in calculated glomerular filtration rate (GFR; Nankivell equation) after 12
months. Safety endpoints were incidences of adverse events and serious
adverse events. Non-inferiority (α=0.05) of MMFCC/CNIRL vs. MMFFD/
CNISL for treatment failure was tested.
Results: 12- and 20-24 month data were analyzed for 720 participants; 82%
received tacrolimus. Baseline characteristics were similar among groups. At 12
months, noninferiority was established in the proportion of patients with treatment
failure among the 3 groups (90% CI -11.8%, 1.3% for MMFCC/CNIRLvs.
MMFFD/CNISL). Time to first acute rejection was significantly related to MPA
trough (p=.0114) and MPA AUC (p=.0171) measured before the rejection episode
when analyzed at 6 months. Despite significantly higher MMF doses but lower
CNI trough levels at most time points in those receiving MMFCC/CNIRL,
significantly fewer MMF withdrawals occurred in these patients vs. the other
treatment groups at both 12 and 20-24 months (p=.002 for each comparison at
each timepoint). Diarrhea within the first 90 days after transplant was significantly
associated with tacrolimus levels but not with MPA or cyclosporine levels. The
risk for diarrhea increased with higher tacrolimus levels.
Treatment failure at 12 months and BPAR at 12 and 20-24 months
MMFCC/CNIRL MMFCC/CNISL
MMFFD/CNISL
N
243
237
240
Treatment failure
55 (22.6%)
68 (28.7%)
67 (27.9%)
BPAR (12 m)*
15 (6.2%)
23 (9.7%)
23 (9.6%)
BPAR (20-24 m)*
16 (6.6%)
26 (11.0%)
24 (10.0%)
Graft loss*
5 (2.1%)
4 (1.7%)
4 (1.7%)

p value
A vs B/C
NS
NS

Death*
4 (1.6%)
2 (0.8%)
6 (2.5%)
Regression Analysis Model to Estimate Risk for First Diarrheal Episode within 90 Days
Trough level
Risk ratio
95% CI
p value
MPA
1.107
0.935, 1.311
.240
Tacrolimus
1.062
1.020, 1.106
.003
Cyclosporine
0.998
0.990, 1.007
.719
*Events are mutually exclusive because only 1st event counted/patient; MPA, mycophenolic acid.

Conclusions: The primary end point of the noninferiority of combining
concentration -controlled doses of MMF with low doses of CNI was met.
This study suggests that lower rejection and MMF withdrawal rates can be
accomplished with therapeutic drug monitoring of MPA.

863 A MULTICENTER, RANDOMIZED, DOUBLE
BLIND, PLACEBO-CONTROLLED TRIAL OF EARLY
CORTICOSTEROID CESSATION: FINAL FIVE YEAR REPORT
E.S. Woodle
University of Cincinnati
In five decades of renal transplantation, only three double blind trials of
corticosteroid withdrawal (CSWD) have been conducted, however, in each
CSWD was performed well after transplantation (>3monts). The final, five year
results of the first double blind, randomized placebo controlled trial of the early
CSWD in kidney transplant patients (pts) maintenance is presented.
Methods: CSWD (191 pts) was compared to chronic corticosteroid therapy
(CCS)(195 pts) under tacrolimus /mycophenolate therapy with thymoglobulin
(Thymo) or IL-2R antibody (Ab) induction. Prednisone dose in CCS pts was
reduced to 5mg/day at 6 months. The composite primary endpoint included
death, graft loss or severe acute rejection (AR) defined as AR requiring antibody
treatment or Banff 95 Grade >2B or Banff 97 Grade >2A. Blinding of patients
and investigators was maintained throughout the five year study period.
Results: Data are presented as CCS/CSWD. Differences were not observed
in demographic or immunologic risk data, or Thymoglobulin induction
69.7%/65.4% of pts. Primary endpoint (13.3%/15.7%);death (6.2%/5.2%),
death censored graft loss (3.6%/6.3%), and severe acute rejection (5.1%/7.9%)
were not different. Death to infection was higher with CCS (2.6%/ 0%, p=0.06).
Biopsy confirmed AR approached significance (10.8%/17.8%, p=0.06).
However, serum creatinine (1.5+0.8 / 1.6+0.7 mg/dl); calculated creatinine
clearance (60.2+20.5 / 57.1+20.2 ml/min and proportion of pts. with creatinine
clearance <40 ml/min (7.4% / 10.8%) were not different between groups.
Overall graft survival was similar, and a small increase in chronic allograft
nephropathy (CAN) (4.1%/ 9.9%, p=0.03) was noted in for cause biopsies.
CSWD provided cardiovascular risk/metabolic benefits including new onset
diabetes requiring insulin (13.5% / 2.1%, p=0.005); change in triglycerides (in
pts without hyperlipidemia at baseline (+26.1 / -69.0 mg/dl,p=0.001), and bone
disorders (fractures/avascular necrosis) (11.3%/4.7%, p=0.02).
Conclusions: After a five year blinding period, this study demonstrates that
early CSWD provides cardiovascular risk and bone disease benefits without
a significant effect in allograft survival or function compared to chronic
maintenance low-dose prednisone therapy at 5 mg/day.

864 TACROLIMUS ONCE-DAILY PROLONGED RELEASE
VERSUS TACROLIMUS TWICE-DAILY IN COMBINATION
WITH STEROIDS - A PHASE III MULTICENTRE LIVER STUDY
P. Trunecka1, O. Boillot2, J. Langrehr3, A.D. Pinna4, L. Fischer5, B-G.
Ericzon6, R. Troisi7, F. Bresadola8, J. Ortiz De Urbina9, W. Wall10
1
IKEM, 2Hôpital Edouard Hérriot, 3Klinik Tranplantationschirurgie, 4Policlinico
Sant’Orsola, 5Hepatobiliaere Chirurgie, 6Karolinska University Hospital
Huddinge, 7Departement Heelkunde, 8Clinica Chirurgica Universitaria, 9Unidad
de Trasplante Hepatico, 10London Health Sciences Centre
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily
formulation of tacrolimus with similar exposure and trough levels compared to
the well-established twice-daily formulation (Prograf®, PRO). This 12-month
study was designed to compare the efficacy and safety of ADV and PRO in de
novo liver transplant recipients.
Methods: The study was performed in 48 transplant centres and 16 countries.
This was a double-blind, double-dummy study with patients randomised 1:1 to
PRO or ADV. The first total daily dose was 0.1 mg/kg for PRO and 0.2 mg/kg
for ADV combined with a steroid taper (0-10 mg/day after Day 42). For both
treatment arms tacrolimus whole blood trough levels were targeted at 10-20
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ng/mL to Day 28, then 5-15 ng/mL to Day 90 and 5-10 ng/mL thereafter. The
primary end point was the event rate for biopsy proven acute rejection (BPAR,
per protocol set with non-inferiority comparison set at 15%) at 24 weeks with
a further 6-month extended open follow-up. Acute rejection, patient and graft
survival were also assessed at 24 weeks and 12 months. Adverse events and
safety parameters including renal function were recorded throughout.
Results: 234 PRO and 237 ADV patients received at least one dose of study
medication with 156/234 (66.7%) PRO and 150/237 (63.3%) ADV patients
completing the 12-month study. Key donor and recipient demographics were
similar. Mean daily tacrolimus dose and mean whole blood trough level for
PRO vs. ADV at Week 4 were 0.13 mg/kg and 10.7 ng/mL vs. 0.19 mg/kg and
11.5 ng/mL, and at Month 12 were 0.06 mg/kg and 8.1 ng/mL vs. 0.08 mg/kg
and 8.4 ng/mL. Kaplan-Meier patient survival at 12 months was 91% vs. 89%
and graft survival 86% vs. 85% (PRO vs. ADV). Similarly, 24-week BPAR
event rates were 29.3% vs. 32.6% (p=0.354). In the per protocol analysis
with major protocol violators excluded (PRO N=177 & ADV N=181),
BPAR events rates at 24 weeks were 33.9% vs. 35.9% (p=0.567; treatment
difference 95% CI -7.9%, 11.9% ) falling within the predefined 15% noninferiority margin. The 12-month BPAR event rate was 30.5% vs. 33.8%
(p=0.356). Mean creatinine clearance (Cockroft & Gault) at 12 months for
study completers was 82 vs. 78 mL/min and adverse event profiles were
similar for both regimens.
Conclusions: The study demonstrates that once-daily tacrolimus prolonged
release Advagraf® was well tolerated and is non-inferior, conferring similar
efficacy and safety profiles to the established twice-daily formulation
Prograf®.
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CONCURRENT ORAL SESSION 61:
LIVING DONOR RENAL TRANSPLANTS
865 TESTING WILLINGNES FOR LIVING KIDNEY
DONATION: AN OPTION FOR ALL PATIENTS?
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L. Kranenburg, W. Zuidema, W. Weimar, M. Hilhorst, J. IJzermans,
J. Passchier, J. Busschbach
Erasmus University Medical Centre
Purpose: This is the first large scale in-depth interview study done in patients
and potential donors who seem unwilling or unable to pursue living kidney
donation. By investigating these groups we explore whether further expansion
of the living kidney donation program is feasible.
Methods: We interviewed 90 patients on the waiting list for a kidney transplant
who seemed unwilling or unable to pursue living kidney donation, and
their potential donors (n = 54). We also included a comparison group of 53
patients and 51 donors who had planned to undergo living kidney donation/
transplantation in the near future. All respondents underwent an in-depth
interview by a psychologist about topics that could influence their willingness
to pursue living kidney donation, such as: information, communication and
risk perception.
Results: 82% of the patients on the waiting list are willing to accept the offer
of a living donor. Main reason given for not pursuing living kidney donation
was reluctance to discuss the issue with the potential donors. Notably, in the
comparison group, it was always the donor who initiated the communication
about donation. Both groups indicated that if no donor steps forward, one
is likely to interpret this silence as a refusal to donate. We found evidence
that this interpretation not always holds: over one third (20/54) of the
potential donors that we interviewed were in a pre-contemplation phase, open
to consider themselves as a potential donor. On the other hand, an in size
comparable group of potential donors (22/54), was reluctant about donation.
Main reasons for donor reluctance were 1) Fear for their own health, 2) The
specific relationship with the intended recipient, and 3) A lack of information
about living kidney donation.
Conclusion: The majority of patients on the waiting list are willing to accept
a living kidney donor, but are reluctant to discuss the issue of living donation
with their potential donors. If potential donors do not take up the issue
spontaneously, patients tend to interpret this as a refusal to donate. However,
this interpretation is not necessarily true. Therefore, offering those patients
professional assistance in finding a living kidney donor should be considered.
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866 TIME 0 LIVING KIDNEY DONOR BIOPSY: A VALUABLE
OPPORTUNITY TO CORRELATE PREDONATION CLINICAL
DATA WITH HISTOLOGICAL ABNORMALITIES.
E. Mancilla 1, J. Alberu2, F. Rodríguez 1, N. Uribe2, S. Aburto 1, M. Vilatobá2,
S. Magaña1, L. Morales2, B. Gabilondo2, C. Avila 1
1
Instituto Nacional de Cardiologia “ICh”, 2Instituto Nacional de Ciencias
Médicas y Nutrición “SZ”
Background: Living kidney donation is increasing rapidly worldwide to
partially offer a solution (or an alternative?) for the number of ESRD pts
waitlisted. In spite of properly following guidelines criteria for donor selection,
current reports identify unsuspected renal pathology by time 0-biopsy.
Purpose: Whether the findings in time 0-biopsies correlate with pre-donation
clinical data including renal function was explored in this study.
Methods: Kidney transplant database from two institutions were reviewed.
Time 0-biopsy started been performed routinely in recent years. Biopsies were
done in the kidney upper pole during the back-table (Bard® Magnum® Biopsy
System, gauge#16) and evaluated by 2 nephropathologist for: interstitial
fibrosis, tubular atrophy, arteriolar hialinosis, mesangial increase (MI) and
glomerulosclerosis (GS). Pre-donation data gathered from the donors were:
demography, body weight, BMI, Systolic/Diastolic BP, SCr, proteinuria, and
eGFR by Levey equation.
Results: At the time, a total of 231 time 0-biopsies of living donor
nephrectomy have been performed; 219/231 (94.8%) were adequate
specimens for pathologic analysis. Overall, 100/219 (45.6%) were absolutely
normal. The histological findings for the remaining 119 biopsies are shown
in Table 1. Clinical data is summarized in Table 2. On bivariate analysis,
significant correlation with interstitial fibrosis were: age (r=0.22, p=.001),
SCr (r=0.19, p=.005); Tubular atrophy with Diastolic BP (r=0.15, p=.03) and
proteinuria (r=0.20, p=.009); Arteriolar hialinosis with SCr (r=0.15, p=.02)
and eGFR (r= -0.16, p=.018); MI with BMI (r=0.13, p=.047); GS had no
significant correlation. Multivariate analysis failed to sustain the significant
associations found in the bivariate analysis, most likely due to a low event/
parameter relation.
Table 1. Time 0-biopsy (one or more abnormalities)
Histological Finding

n= 119

%

Interstitial Fibrosis

64

53.7

Tubular atrophy

29

24.3

Mesangial increase

26

21.8

Arteriolar hialinosis

23

19.3

GS

23

19.3

Table 2.
Age

35.4 ± 10

Gender F/M

127 (56.7%)

Weight (Kg)

66.27 ± 10.14

BMI

25.53 ± 2.99

Systolic BP (mmHg)

115.46 ± 9.2

Diastolic BP (mmHg)

73.5 ± 6.7

SCr (mg/dl)

0.91 ± 0.25

Proteinuria (mg/24 h)

70.25 ± 62.8

eGFR (ml/min)

96 ± 16.65

Conclusions. A significant correlation was established between time 0-biopsy
findings and clinical pre-donation parameters. Whether the existence of these
histological findings at the time of kidney donation might represent a higher
burden/risk for the remaining kidney ought to be evaluated during follow-up.
Certainly, in an era where the living kidney donation is expanded, we should at
least advice a closer surveillance of these donors in order to modify risk factors
that participate in kidney damage progression.
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867 THE ASSESSMENT OF ELDERLY DONORS AGED OVER
65 YEARS FOR LIVING RELATED KIDNEY TRASPLANTATION
BY 99MTC MERCAPTO-ACETYL-TRIGLYCINE (MAG3)
H. Ushigome1, K. Sakai1, T. Suzuki1, S. Nobori1, A. Yoshizawa2,
S. Sakamoto1, M. Okamoto2, N. Yoshimura1
1
Department of Transplantation and Regenerative Surgery, Kyoto Prefectural
University Graduate School of Medical Science, 2Department of Organ
Interaction Research Medicine, Kyoto Prefectural University Graduate
School of Medical Science
Background: Evaluating candidate donors for living donor kidney transplantation,
age is an important factor for excellent graft function and survival. Although
the survival of kidney grafts from elderly donors is considered to be inferior to
younger donors, clinically successful outcomes of kidney transplantation using
grafts from elderly donors have sometimes been seen. However, there is no
proper criterion for elderly donors of kidney transplantation.
Patients and Methods: From February 1994 to February 2008, 46 living
donor kidney transplantations from elderly donors aged over 65 years (mean
age 67.7 □} 3.5 years) were performed at Kyoto Prefectural University of
Medicine Hospital. 99mTc mercapto-acetyl-triglycine (MAG3) renal scan
was utilized for one of some preoperative assessments of all elderly candidate
donors. Then each of left and right kidney function was separately estimated
by effective renal plasma flow (ERPF) determined by the renography. Actual
graft survival and serum creatinine were analyzed at 1, 3, 5 and 10 years after
kidney transplantation.
Results: Renal function, as assessed by the serum creatinine level in patients
at 1 year after transplantation was correlated significantly with ERPF x donor/
recipient (D/R) body surface area (BSA). Actual graft survival at 1, 3, 5 and 10
years after kidney transplantation was 100%, 100%, 100% and 73%, respectively,
from donors with ERPF x D/R BSA > 180 ml/min and 96%, 78%, 58% and 58%,
respectively, from donors with ERPF x D/R BSA < 180 ml/min.
Conclusions: When ERPF x D/R BSA was sufficient, the survival of kidney
grafts even from elderly donors aged over 65 years was adequate. Our findings
indicate that age alone should not be regarded as an exclusion criterion
for kidney graft donation. When evaluating living donors before kidney
transplantation, ERPF x D/R BSA may be a more helpful parameter than age or
creatinine clearance for prediction of graft survival.

868 RENAL OUTCOMES IN AFRICAN-AMERICAN LIVING
KIDNEY DONORS
M. Cooper, A. Haririan, M. Weir, S. Jacobs, D. Klassen, S. Bartlett,
J. Nogueira
University of Maryland Medical Center
Living donor kidney transplantation (LDKT) has been encouraged as a source
of organs for transplantation. The transplant community has accepted the
procedure based upon a body of literature, with multiple studies as well as
a meta-analysis demonstrating a lack of long-term adverse health effects of
unilateral nephrectomy performed on a healthy individual. However, longterm safety has not been demonstrated with live kidney donation from AfricanAmericans, who are at increased risk for chronic kidney disease (CKD).
Methods: Upon institutional IRB approval, AALKD’s were identified
between 3/1/96 and 2/28/02 and invited to participate. A health questionnaire
on follow-up health care, interim medical history, and current medications
was administered. Height, weight and three blood pressures using a
standardized technique were completed. Urine and blood samples were
collected for measurement of urine albumin/microalbumin, urine creatinine,
and serum creatinine. Pre-donation serum creatinine-based estimation of
GFR was calculated using the abbreviated MDRD equation (MDRD-eGFR).
Continuous variables are reported as mean +/- standard deviation and were
compared using Student’s t tests. Categorical variables are reported as
absolute numbers and/or percentages and compared using 2x2 contingency
tables and chi-squared tests.
Results: 107 AALKDs were recruited. 39 subjects (36.4%) completed
evaluation at a mean of 7.1 +/- 1.6 (range 3.9-10.2) years post-donation. The
MDRD-eGFR was 72.1 +/- 16.3 (range 42-106) ml/min per 1.73m2, and 17.9%
of subjects had Stage 3 chronic kidney disease (eGFR 30-59).
SBP (mmHg)

120.8 +/- 14.5 (range 92-144)

DBP (mmHg)

79.7 +/- 9.3 (62-99)

SBP ≥ 140 or DBP ≥ 90 at GCRC visit

10 (25.6%)

Diagnosed with HTN prior to GCRC visit

8 (20.5%)

Current diagnosis of HTN (BP ≥ 140/90 mmHg at
GCRC visit or prior diagnosis of HTN)

16 (41.0%)

Undiagnosed HTN

8 (20.5%)

Microalbuminuria (30-300 mcg/mg creatinine)

6 (15.4%)

Macroalbuminuria (> 300 mcg/mg creatinine)

1 (2.6%)

Serum creatinine (mg/dl)

1.22 +/- 0.25 (range 0.8-1.7)

MDRD-eGFR <60 ml/min per 1.73m2 or
macroalbuminuria

8 (20.5%)

Diagnosed with diabetes mellitus

1 (2.6%)

The absolute and relative decrease in MDRD-eGFR from time of donation
to follow-up was 30.5 +/- 16.4 ml/min per 1.73m2 and 28.8%, respectively.
Subjects whose BMI was ≥ 35 kg/m2 (n=8) were found to have a greater
decrement in MDRD-eGFR than those with BMI < 35 kg/m2 (-40.1 +/- 7.3 and
28.3 +/- 17.1 ml/min per 1.73m2, respectively; p = 0.009).
Conclusion: AALKD’s may experience a high incidence of hypertension and
a substantial drop in MDRD-eGFR over several years following donation.
Obesity may increase the magnitude of renal decline. Further study is urgently
needed to determine the long-term risks of AALKD’s.

869 AFRICAN AMERICAN WOMEN AND OLDER PATIENTS
HAVE A GREATER DECLINE IN RENAL FUNCTION
FOLLOWING LIVING KIDNEY DONATION
M. Reza Laftavi1, S. Sharma1, R. Koholi2, J. Tolluck1, M. Danek1,
K. Paolini1, L. Fing1, M. Dayton1, D. Dunn1, O. Pankewycz2
1
Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at
Buffalo
Living donor kidney transplantation offers many advantages to the recipient.
Longer allograft survival, fewer postoperative complications and better
renal function are just some of the benefits of receiving living donor kidneys
compared to deceased donor organs. In contrast, the consequences to the
donor in terms of renal function are less well defined. Moreover, it is not
clear whether all donors share an equal risk to their renal function following
donation. In this study, we calculated the estimated GFR (eGFR) by the
MDRD formula in donors prior to and following renal donation. We compared
the percentage decline in renal function amongst various ages and other
demographic groups using individual patients as their own controls. Between
4/93 and 11/07, a total of 341 living donor transplants were performed in a
single center. Of these, 103 donor charts (38 men, 65 women) were available
for review. Donor characteristics were: 11 African American (AA), 94 white,
age 40.3 +/- 9.6 years of age and pre-op eGFR 93.3+/-17.7 ml/min. All
donors had normal blood pressures without medications, normal urinalysis
and normal urinary protein levels. On average, donors experienced a -34.7%
fall in eGFR to 59.8+/-10.9 ml/min determined 273 days post-transplantation.
A greater decline in eGFR was noted in the AA group -41% compared to
white patients -34% (p=0.03). The majority of the decline in the AA group
was accounted by AA women in whom the fall in eGFR was -46% compared
to AA men -31% and white women -34% (p=0.02). The percent decline in
eGFR was not different amongst the various age groups. However, donors >50
years old had a post-donation eGFR of 55.1 ml/min vs. 60.9 ml/min in those <
50 years old (p=0.03) reflecting the lower eGFR pre-donation (older 84.7 vs.
younger 95.2 ml/min, p=0.02). The percent decline in eGFR did not change
with time after donation (0-1 month 37%, 1-12 months 34%, >1year 30%).
These results suggest that renal function declines abruptly following kidney
donation in all patients but remains stable or improves afterwards. AA women
and older donors may have a higher risk because they experience a greater
immediate fall in eGFR and have a lower post-donation eGFR respectively.
Clearly, a larger and prospective study is required to assess the long term renal
functional decline in healthy living kidney donors.
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CONCURRENT ORAL SESSION 62:
EXPERIMENTAL LIVER TRANSPLANTATION
870 INSIGHTS INTO THE INTERACTION OF TISSUE CELLS
WITH INFILTRATING CD8+ T CELLS IN LIVER TRANSPLANT
TOLERANCE USING A TCR TRANSGENE APPROACH
G. Jiang1, Q. Zhang1, H-. Yang2, K. Brown1, J. Fung2, L. Lu1,2, S. Qian1,2
Department of Immunology, Lerner Research Institute, Cleveland Clinic,
2
Department of General Surgery, Cleveland Clinic
Liver allografts are spontaneously accepted without requirement of
immunosuppression in mice. The underlying mechanisms are not completely
understood. We hypothesized that it resulted from an abortive T cell response
within the liver due to hyporesponsiveness or apoptosis. To test this, we
examined the activation and fate of allo-Ag specific CD8+ T cells following
liver transplants (LTX) compared with heart transplants (HTX) that were
acutely rejected. Following transplantation [B10 (H2b)¡÷C3H (H2k)], CFSE
labeled CD8+ T cells (10x106) from Des TCR Tg mice (H2Kb specific)
were adoptively transferred into the recipients. Two days later, animals were
sacrificed for analyses of T cells in the grafts or draining lymph nodes (D-LN).
Host CD45+ leukocytes were quickly infiltrated following LTX. Among
CD3 population ƒî48% were CD4+ and ƒî52% CD8+. CD8+ T cells were
further increased thereafter in grafts and D-LN, associated with high INF-ƒ×
production. CD8+ T cells in the liver grafts rapidly reduced to 36% by POD
14, and to 12% POD 40. However, the incidence of CD4+ T cells remained
high. CFSE dilution assay and ELISPOT showed an active division of Des+
T cells in liver allografts either on POD 7 or 40. These Ag-specific CD8+ T
cells functioned well evidenced by IFN-ƒ× production in response to allo-Ag.
However, compared to HTX, the accumulation of Des+ cells in grafts was
significantly lower in LTX [9.6% (17x104/heart), and 0.59% (6.14¡Ñ104 /
liver)] on POD 7, and further dropped to 0.14% (3.14¡Ñ104/liver) on POD
40. The expended cohorts of adoptively transferred cells followed by their
elimination suggested elimination of Ag-specific CD8+ cells. To examine the
role of liver environment, graft CD45- non-parenchymal cells (NPC) were
isolated tested fro regulatory effect on Des+ T cell response. Liver allografts
showed significantly expansion of CD45- NPC, which were donor MHC class
I+ (H2b+), B7-H1+, TRAIL+ and low for CD40 and CD86. These cells did
not inhibit Des+ T cell proliferation in response to B10 spleen stimulation, but
significantly enhanced their death, which was dependent on B7-H1/TRAIL.
This was confirmed by using CD45- NPC from B7H1-/- or TRAIL-/- mice.
In conclusion, activated T cells in liver grafts may stimulate tissue cells to
express inhibitory and death inducing molecules, resulting in T cell death and
graft acceptance.
1

871 CYTOPROTECTIVE ACTION OF A CO-RELEASING
MOLECULE (CORM-3) IN A NOVEL MODEL OF PIG LIVER
ISCHEMIA/REPERFUSION INJURY
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E. Gringeri1, M. Vadori2,3, R. Motterlini4, C. Giacometti2, A. Stefani5, T. Pilla6,
E. Tognato3, U. Cillo1,2, D. Sacerdoti1,2, E. Cozzi7,3
1
Dept. of General Surgery and Organ Transplantation, 2Institute of Pathology,
Padua, Italy, 3CORIT, Padua, Italy, 4NPIMR, Harrow, UK, 5IZSV, Legnaro,
Italy, 6Dept. of Clinical Veterinary Sciences, Padua, Italy, 7Dept. of Surgical
and Gastroenterological Sciences, University of Padua, Padua, Italy
Introduction: Orthotopic liver transplantation is an established treatment
for end-stage liver disease. However, hepatic ischemia/reperfusion (IR)
injury, an unavoidable insult occurring to the graft as a consequence of
transplantation, often results in a higher incidence of acute/chronic
rejection. In this light, different surgical and pharmacological approaches
are under study to counteract IR injury and improve graft functionality.
Recently, the administration of carbon monoxide (CO) has been proposed
as a promising strategy to inhibit vasoconstriction and platelet aggregation,
and reduce inflammation and apoptosis in transplantation. In this study,
we examined whether the administration of CORM-3, a water soluble COreleasing compound, protects liver tissue from IR injury in a large animal
model.
Methods: Ten Landrace pigs (18-22 kg) were used for liver IR studies. Four
hour warm ischemia of the left hepatic lobe was obtained by clamping the left
hepatic artery and vein and occluding the left branch of the portal vein. The right
lobe maintained normal perfusion. Ischemia was followed by 4 h reperfusion. A
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single dose of 4 mg/kg CORM-3 was administered i.v. to five animals 30 min.
before onset of ischemia. Five untreated pigs served as controls. Biochemical
and hematological analyses were performed. Needle biopsies were obtained
prior to and after ischemia and, subsequently, hourly during reperfusion.
Edema, congestion, inflammatory cell infiltration and necrosis were evaluated
by semiquantitative histological examination (expressed as percentage of the
liver parenchyma involved). Apoptosis was detected by TUNEL and scored by
averaging the number of TUNEL positive cells/mm2. TNF-a amounts in liver
tissue omogenates were measured by ELISA.
Results: Following a 4 h ischemia, histological analysis revealed edema
(37%), congestion (30%), inflammatory cell infiltration (9%) and necrosis
(8%). Treatment with CORM-3 resulted in reduced edema (21%), congestion
(13%) and cellular infiltration (1%). Importantly, no necrotic areas were
present in CORM-3-treated animals at the end of ischemia. Liver necrosis
remained significantly lower in CORM-3 treated animals compared to
controls following 4 h reperfusion (18% vs. 60%). At this time point, the
group treated with CORM-3 had a lower incidence of TUNEL positive cells
compared to controls. A slight decrease in TNF-a levels in liver tissue of
treated animals was noticed. AST, ALT, ALP and bilirubin were not different
between groups. In addition, CORM-3-treated pigs showed a lower mean
systemic blood pressure following drug administration and throughout
the experiment.
Conclusions: This study has enabled the establishment of a novel model
to investigate liver IR injury in large animals. Administration of CORM-3
prior to inducing hepatic ischemia, attenuates the tissue damage occurring at
reperfusion, primarily by reducing necrosis and apoptosis.

872 EFFECT OF HYPOXIA/REOXYGENATION ON TRAILTRAIL RECEPTOR DR4 AND DR5 PATHWAY IN HUMAN
INTRAHEPATIC CHOLANGIOCYTES
Y.P. Li, L.L. Pang, L. Feng, N. Zhao, D. Long, L.L. Li, S.F. Li, C.T. Zhang,
L. Wei
Key Laboratory of Transplant Engineering and Immunology, Ministry of
Health, West China Hospital, Sichuan University
Ischemic-Type Biliary Lesion (ITBL) is one of the most serious complications,
associated with long-term prognosis of the recipients, and is unavoidable in
liver transplantation. The exact mechanism of human cholangiocytes injury
remains to be studied. We wondered whether TNF-related apoptosis-inducing
ligand(TRAIL)-mediated apoptosis can play some role in this course. This
study aims to investigate the effect of hypoxia and reoxygenation(H/R) on the
TRAIL -TRAIL Receptor DR4 and DR5 pathway for mechanism of ITBL and
liver injury.
Method: Setting cholangiocytes H/R model to mimic IRI of graft liver in
vitro. Normal cholangiocytes were exposed to hypoxia condition(1%CO2)
for 1 hour, then reoxygenated for 0,15,30,60,90min,2h,3h and 4h separately.
DR4, DR5 mRNA were measured by RT-PCR, and the protein were
detected by immunofluorescence. Moreover, cholangiocytes were hypoxia/
reoxygenated and treated with exogenous TRAIL in different concentrations
for 4h. Apoptosis of cholangiocytes were confirmed by FCM and MTT
analysis and compared with the apoptosis rate of hepatocytes under the same
condition.
Result: 1. H/R significantly increased DR4,DR5 expression after 1h hypoxia in
all time points of reoxygenation, compared with the low expression of DR4,DR5
protein and mRNA level of the normal cultured cholangiocytes, which peaked
on 90min(about 4 times higher than control group) after reoxygenation and
maintained until 240min(more than 3 times). DR5 expression of hepatocytes
also increased after 6h hypoxia, and reached the peak after 2h reoxygenation.
2. Exogenous TRAIL increased the sensitivity of the 2 kinds of cells to the
apoptosis and increased the apoptosis rate.
Conclusion: 1. H/R upregulated the DR4, DR5 expression of human
cholangiocytes and hepatocytes both on protein and mRNA level.
But the expression are earlier and higher in cholangiocytes than in
hepatocytes.2.Exogenous TRAIL increased the sensitivity of the 2 kinds
of cells for the TRAIL mediated apoptosis induced by H/R and enhance the
apoptosis rates£®These results suggested that the adoption of anti-apoptosis
drugs might become a new measure for prevention of the ITBL.
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873 INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE
(INOS) BY 1400W IMPROVES THE OUTCOME AFTER
TRANSPLANTATION OF FATTY PARTIAL LIVER GRAFTS
Z. Zhong 1, S. He 1,2, H. Rehman 1, X-P. Chen 2, G. Wright 1
1
Medical University of South Carolina, Charleston, SC, USA, 2 Tongji
Medical College, Huazhong University of Science and Technology, Wuhan,
China
Background & Aims: Hepatic steatosis is present in ~30% of potential
liver donors. Steatotic grafts are known to increase primary non-function
and therefore excluded for use in partial liver transplantation. This study
investigated if reactive nitrogen species (RNS) play a role in failure of fatty
partial liver grafts.
Methods: Fatty livers were induced in rats by feeding a high-fat high-fructose
(HFFr) diet (50% and 30% of total calories from corn oil and fructose,
respectively) for two weeks. Control animals received a low-fat low-fructose
(LFFr) diet. Hepatic triglyceride was ~9-fold higher in rats fed the HFFr diet
than those fed the control LFFr diet. Lean and fatty liver explants were reduced
in size ex vivo to approximately 1/3 and stored in the UW solution at 0-1oC for 2
h. 1400W (5╘ M), a specific iNOS inhibitor, was added to the storage solution
and the lactated Ringer post-storage rinse solution.
Results: Serum nitrite/nitrate level was 2-fold higher after transplantation of
fatty partial grafts compared to lean partial grafts, and 3-nitrotyrosine adducts,
an indicator of peroxynitrite formation, increased markedly in fatty partial grafts
compared to lean partial grafts. Serum alanine aminotransferase (ALT) was 65,
780, and 1420 U/L 24 h after sham operation or transplantation of lean and
fatty partial grafts, respectively. Serum bilirubin concentrations, an indicator of
graft function, increased from 0.1 mg/mL to 1.7 mg/mL after transplantation of
lean partial grafts and was increased to 9.3 mg/mL after transplantation of fatty
grafts. Hepatic cellular 5-bromo-2’-deoxyuridine (BrdU) incorporation was
25% in lean partial grafts but only 5% in fatty grafts at 48 h after transplantation,
indicating suppressed cell mitosis in the fatty grafts. Graft weight did not
increase in fatty partial grafts but increased by 64% in lean partial grafts. All
rats that received fatty partial grafts died within 4 days after transplantation,
whereas the 7 day-survival rate was 100% after transplantation of lean partial
grafts. 1400W largely blunted the increases of serum nitrite/nitrate and hepatic
nitrotyrosine adducts, prevented the elevation of serum ALT and bilirubin,
restored cell proliferation to 32% and weight gain to 66% in the fatty grafts.
The beneficial effect of 1400W on these preceding parameters coincided with
improved survival rates in animals receiving fatty grafts.
Conclusions: Taken together these results indicate that hepatic steatosis
increases RNS production after partial liver transplantation, leading to more
severe injury, poorer liver regeneration and lower graft survival. Therefore,
inhibition of iNOS could be a potential therapy to improve the outcome of
transplantation of fatty partial liver grafts (NIDDK).

874 DISTINCT GENE SIGNATURES LINKED TO ACUTE
PHASE INJURY AND TUMOR INVASIVENESS AFTER LIVER
TRANSPLANTATION USING SMALL-FOR-SIZE GRAFTS
– THE SIGNIFICANCE OF IP10 ON TUMOR INVASIONRELATED PROPERTIES AND TUMOR-ASSOCIATED
MACROPHAGE INFILTRATION
K. Man, C-M. Lo, K.T.P. Ng, Q. Cheng, K. Co Shih, Y. Chen, S-T. Fan
The University of Hong Kong
Background and objective: Acute phase small-for-size liver graft injury plays
important role on late phase tumor development and invasiveness after liver
transplantation. To develop novel therapies preventing tumor recurrence after
LDLT, it will be worthwhile to investigate the precise mechanism and potential
therapeutic targets. In the current study, we aim to study the gene expression
profiles associated with acute phase graft injury and tumor invasiveness at
early and late phase after liver transplantation using small-for-size grafts. The
potential candidate gene is identified for further functional studies.
Materials and Methods: Orthotopic liver transplantation was applied using
whole (100%) grafts (Group W) and small-for-size (50%) grafts (Group S) in a
rat transplantation model. The recipients were injected with hepatoma cell lines
(CRL1601, 2„e105) via the portal vein after reperfusion, and were sacrificed on
days 1, 3, 14, and 21 after transplantation for histological examination. Gene
signatures of acute graft injury (days 1, 3) and tumor recurrence (days 21) were
screened using cDNA microarray and confirmed by quantitative RT-PCR. Potential

gene candidate was selected for further functional studies to investigate its role
both in tumor progression and tumor associated macrophage mobilization.
Results: Early development of liver tumors and significantly larger tumor sizes
were noted in Group S, accompanied by invasive growth patterns, significant new
vasculature formation and tumor-associated macrophage infiltration. Distinct
gene panels linked to inflammatory responses and tumor invasiveness were found
in small-for-size liver grafts and/or the tumor developed in small liver grafts by
cDNA microarray screening. After confirmation by real-time RT PCR, the gene
IP10 was found over-expressed in the liver graft at early phase and in liver tumor at
late phase after liver transplantation. In vitro functional studies further confirmed
that IP10 promoted tumor invasive properties and angiogenesis. Consistent with
the animal study, IP10 also enhanced macrophage motility in vitro.
Conclusion: Distinct gene signature (over-expression of IP10) linked to acute
phase injury and tumor invasiveness in the small-for-size liver graft may
contribute to early tumor recurrence after liver transplantation. IP10 and its
downstream signals might be the potential therapeutic targets in the prevention
of tumor recurrence after liver transplantation using small-for-size graft.

CONCURRENT ORAL SESSION 63:
INDUCTION IMMUNUSUPPRESSION
875 ALEMTUZUMAB INDUCTION IN LIVING DONOR
KIDNEY TRANSPLANTATION: AN ANALYSIS USING THE
OPTN/UNOS DATABASE
S. Bunnapradist1, B.R. Madhira1, B. Anastasi1, T. Shah2, J. Gill1
UCLA Medical Center, 2National Institute of Transplantation
Background: Antibody induction using IL2 receptor antagonists (IL-2RA) is
common in living donor kidney transplantation (LDKTx). Recently, the use of
alemtuzumab is increasing in kidney transplantation. Our objectives were to
examine the use of alemtuzumab in LDKTx and to compare post-transplantation
outcomes between recipients who received either IL2-RA induction therapy or
alemtuzumab in the United States.
Methods: OPTN/UNOS data was used to identify all LDKTx performed in the
US from 2003 – 2006 where induction therapy with alemtuzumab or IL-2RA
(dacluzimab or basiliximab) was used. Follow-up was until November 2007.
The primary outcome was the incidence of acute rejection and graft survival.
The risk of graft loss was determined using Cox multivariate modeling.
Results: Of the 28,781 LDKTx identified, induction therapy was used in 19,
962 (69.4%). Among those receiving antibody induction, 2371 (11.8%) received
alemtuzumab and 8207 (41.1%) received an IL2-RA. The use of alemtuzumab
has increased over time (Figure 1). There were no clinically significant
differences in donor characteristics between those that received alemtuzumab
and IL2-RA, but the proportion of recipients with prior transplantation was
higher among recipients who received alemtuzumab.
The incidence of acute rejection at discharge was significantly lower in the
alemtuzumab group (0.6%) compared to the IL2RA group (4.3%), but was
similar by 1 year post transplant (alemtuzumab 9.1% IL2RA 8.3%). Compared
to the IL2-RA group, those in the alemtuzumab group had inferior overall graft
survival (Figure 2) and a higher adjusted relative risk of graft loss (HR 1.21,
95% CI 1.01-1.45). When the analysis was limited to re-transplant recipients,
the hazard of graft loss was 1.62 (0.98-2.67).
Conclusion: The use of alemtuzumab in living donor transplantation is
increasing in the United States. Analysis of OTPN/UNOS data revealed
that the risk of graft loss among patients that received alemtuzumab was
higher compared to those that received IL2-RA induction. The manner and
circumstances under which these agents are utilized may significantly impact
outcomes and requires further study.
Figure 1. Alemtuzumab use in Living Donor Kidney Tranplant (LDKTx) over time
1
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Figure 2.
Overall Graft Survival among LDTx receiving Alemtuzumab or IL2RA

876 12 MONTH RESULTS OF A MULTICENTER,
RANDOMIZED TRIAL COMPARING THREE INDUCTION
AGENTS (ALEMTUZUMAB, THYMOGLOBULIN AND
BASILIXIMAB) WITH TACROLIMUS, MYCOPHENOLATE
MOFETIL AND A RAPID STEROID WITHDRAWAL IN RENAL
TRANSPLANTATION
S. Woodle1, M. Hanaway2, S. Mulgaonkar3, R. Peddi4, G. Harrison5,
K. Vandeputte5, W. Fitzsimmons5, R. First5, J. Holman5
1
University of Cincinnati College of Medicine, 2University of Alabama, 3St.
Barnabas Medical Center, 4California Pacific Medical Center, 5Astellas
Pharma U.S.
Purpose: Induction therapy remains an important component of early
corticosteroid withdrawal (ECSWD). We sought to compare the safety and
efficacy of three induction agents (Alemtuzumab (C1H), Thymoglobulin
(Thymo) and Basiliximab (Bas) in renal transplantation, in combination
with tacrolimus (TAC), mycophenolate mofetil (MMF) with a rapid steroid
withdrawal.
Method: 474 adult patients were randomized and transplanted based on risk
profile: High Risk (HR=African American (AA), PRA>20% or re-transplants)
were assigned to C1H or to Thymo. Low Risk (LR=non-AA, PRA<20% or
primary transplant) were assigned to C1H or Bas. Both C1H groups received
30mg of C1H on day (D) 0; the Thymo group received 4 doses of Thymo
(1.5mg/kg/d) on D 0-4; the Bas group received 2 doses of 20mg of Bas on
D 0-4. Only 1 gram of methylprednisolone was given prior to discharge.
Tacrolimus and MMF were used as maintenance immunosuppression. Primary
endpoint was biopsy proven acute rejection (BCAR).
Results: No cases of CAN were seen through 12 mo. Mean results at 12 mo
are shown below. Adverse events are shown as% of patients with > 1 event
through 12 mo.
Parameter
BCAR (%)
Treated Rejections (%)
Antibody for Acute Rejection (%)
TAC Levels (12 mo mean, ng/mL)
MMF Daily Dosing (12 mo mean, mg/d)
Pt Survival (%)
Graft Survival (%)
All Infection (%)
All Malignancy (%)
All CMV Infection (%)
All BK Infection (%)
Total Lymphocyte (cells/mm3)
Creatinine Clearance (ml/min)
Serum Creatinine (mg/dL)
Study Discontinuation (%)

HR
C1H N=70
9.5
17.2
4.8
7.30
1647
98.6
97.1
41.4
2.9
10.0
2.9
928
60
1.6
12.9

Thymo N=69
13.0
17.4
8.0
7.26
1582
98.6
95.3
68.1*
0.0
13.0
8.7
974
55
1.5
4.3

LR
C1H N=164
2.5
5.6
1.9
7.41
1580
98.7
98.1
56.7
2.4
9.0
4.2
923
62
1.4
4.9

Bas N=171
19.6*
23.8*
9.2*
7.50
1650
98.7
95.1
57.9
1.8
8.1
2.3
1460
61
1.3
7.0

*P<0.05 for C1H vs Bas or Thymo
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Conclusions: In high risk patients C1H provides similar efficacy with fewer
patients with infection than Thymo. In low risk patients C1H therapy is
associated with fewer acute rejections and reduced use of antibody to treat
rejection, without an increase in infection.
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877 411 LIVING DONOR KIDNEY TRANSPLANTS USING
ALEMTUZUMAB PRE-CONDITIONING AND TACROLIMUS
MONOTHERAPY: 5 YEAR EXPERIENCE
H. Tan, J. Donaldson, A. Basu, M. Unruh, P. Randhawa, J. McCauley,
C. Morgan, C. Wu, N. Shah, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Introduction: We have previously reported the short-term results of
Alemtuzumab (Campath-1H) pre-conditioning with tacrolimus monotherapy
and subsequent spaced weaning in living donor kidney transplantation. We
report here our 5 year experience.
Methods: We performed 411 consecutive unselected living donor kidney
transplants (donor kidneys were removed laparoscopically) from 12/11/2002
to 11/26/2007 using 30 mg (0.5mg/kg) alemtuzumab and tacrolimus
monotherapy. At 6 months post-transplant and every 2 to 6 months interval,
we used clinical data (including ELISA antibody titers, Cylex T-cell activation
assay, and identification of donor specific antibodies) to wean tacrolimus when
possible (bid-->qd-->qod-->tiw-->biw-->qwk). The recipients included 5
HIV+, 35 pediatric recipients, and 60 re-transplants. The mean follow up was
843.1+478.7 days.
Results: Actuarial recipient survivals at 1-, 2-, 3-years were 98.4%, 95.6%,
and 92.7%, respectively. Graft survivals at 1-, 2-, 3-years were 97.6%, 90.4%,
and 85.4%, respectively. The mean creatinine (mg/dL) at 1-, 2-, 3-years were
1.46+0.62, 1.56+1.08, and 1.54+0.89, respectively. The mean GFR (mL/
min/1.73m2) at 1-, 2-, 3-years were 73.0+28.5, 71.8+28.8, and 68.9+28.6,
respectively. The cumulative incidence of acute cellular rejection (ACR) at 6-,
12-, 18-, 24-, 30-, 36-, 42-, and >42 months were 4.4%, 10.0%, 15.3%, 17.0%,
19.2%, 19.7%, 21.4%, and 22.1%, respectively. 23.4% of recipients had been
weaned to spaced-dose (qod or less) tacrolimus monotherapy. The incidence
of preweaning ACR was 10.5%, and postweaning was 24.9%. A total of 91
recipients had ACR. Most (>80%) episodes of ACR were Banff 1 and were
sensitive to steroid pulses. The degree of chronic allograft nephropathy score
(cg, ci, cv, and ct, with a maximal score of 12) in pts with ACR appeared,
as expected, to increase with time. The total CAN score for the 91 patients
with ACR at 6-, 12-, 18-, 24-, 30-, 36-, 42-, and >42 months were 2.2+2.0,
4.3+2.3, 3.4+2.0, 2.8+1.6, 4.1+1.2, 6.0+0.0, 5.1+1.8, and 8.3+2.1, respectively.
At least 82.7% of recipients were still completely steroid-free on tacrolimus
monotherapy from the time of transplantation.
Conclusion: This report represents the largest series to date of living donor
kidney transplantation under alemtuzumab preconditioning with tacrolimus
monotherapy and subsequent weaning and confirms the 5-year safety and
efficacy of this approach.

878 THYMOGLOBULIN INDUCTION IN LIVING DONOR
RENAL TRANSPLANT RECIPIENTS: UPDATE OF THE TAILOR
REGISTRY
A.O. Gaber1, A.J. Matas2, R.M. Fergusion3, S. Kapur4, D.C. Brennan5,
R.B. Stevens6, M. Schnitzler7, K. David8
1
The Methodist Hospital, Houston, TX, United States, 2University of Minnesota,
Minnesota, Minneapolis, MN, United States, 3Ohio State University Medical
Center, Columbus, OH, United States, 4NewYork-Presbyterian/Weill Cornell
Medical Center, New York, NY, United States, 5Washington University, St. Louis,
MO, United States, 6University of Nebraska Medical Center, Omaha, NE,
United States, 7Saint Louis University, St. Louis, MO, United States, 8 ProSanos
Corporation, Harrisburg, PA, United States
Introduction: The TAILOR (Thymoglobulin Antibody Immunosuppression in
Living Donor Recipients) Patient Registry was established to collect data in
conjunction with UNOS on the safety and efficacy of Thymoglobulin (Thymo)
induction in living donor (LD) renal transplant recipients. Excellent patient
and graft survival and low acute rejection rates were previously reported from
preliminary analyses of 610 TAILOR patients who had completed 12 months
of follow-up in 2006. We now report on a larger sample of patients enrolled in
the TAILOR registry through August 2007.
Methods: The following data are collected in TAILOR: Thymo dosing, dose
alterations, premedications and administration, viral prophylaxis, maintenance
immunosuppression, dialysis pre- and post-transplant, biopsy-proven (BPAR)
or clinically diagnosed rejection, severity and treatment of rejection, serious
adverse events (SAEs), infections, graft loss, and death. Graft and patient
survival rates were calculated by Kaplan-Meier survival analysis.
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Results: 2681 patients from 83 centers enrolled in TAILOR as of August 2007.
Data are presented here on 2243 patients (excluded patients: 322 received Thymo
post-reperfusion; 116 had cumulative Thymo dose <=1.5 mg/kg or >15 mg/kg).
Six and 12 month follow-up data were available for 1715 and 1464 patients,
respectively. Mean age was 46.5 ± 13.4 years, 60% of patients were male, 13%
were African-American, 13% had prior transplants, and mean peak PRA was
10.2%. Mean Thymo cumulative dose was 5.28 mg/kg (median total dose 5 mg/
kg). 89.3% received Thymo via central line. Unplanned dose interruption occurred
in 11.9% of patients, with leukopenia (11.1%) and/or thrombocytopenia (2.9%)
as common reasons for interruption. 2.1% of patients experienced delayed graft
function (i.e., dialysis within first week post-transplant). Mean serum creatinine at
post-operative day 3 was 1.97 ± 1.6mg/dL. Thymo was used as part of a steroid
minimization regimen (i.e., no steroids at discharge) in 36.2% of patients and as
part of a calcineurin inhibitor (CNI) avoidance regimen (i.e., no CNI at discharge)
in 2.6% of patients. 79.7% received valganciclovir as antiviral prophylaxis, 11.9%
received ganciclovir. Patient and graft survival rates were 99.1% and 98% at 6
months, and 98% and 95.9% at 12 months, respectively. The incidence of BPAR
was 8.8% (151/1715) at 6 months and 9.6% at 12 months (141/1464). BPAR
severity (Banff) was available for 76.2% (115/151) of 6 months BPAR episodes;
most were mild (56.5%; 65/115), followed by borderline 18.3% (21/115),
moderate (15.7%; 18/115), and moderate-to-severe (9.6%; 11/115). BPAR
severity was available for 81.6% (115/141) of 12 months BPAR episodes; most
were mild (60.0%; 69/115), followed by moderate (15.7%; 18/115), borderline
14.8% (17/115), and moderate-to-severe (9.6%; 11/115). Infection rates at 12
months were: 4.4% (64/1464) for CMV (no invasive disease), 0.3% (4/1464) EBV,
2.0% (29/1464) fungal, 23.1% (338/1464) bacterial, 4.9% (72/1464) viral, and
5.6% (82/1464) for other infections. PTLD occurred in 0.4% (9/2243) patients.
The overall incidence of SAEs prior to discharge was 3.5% (68/2243); only 11/68
SAEs were reported as either possibly or probably related to Thymo.
Conclusions: Thymo induction in LD renal transplantation is associated with
excellent one year outcomes and is safe as evident with the low infection rate.

879 20 YEAR FOLLOW-UP RESULTS OF A RANDOMIZED
CONTROLLED TRIAL COMPARING ANTI-LYMPHOCYTE
GLOBULIN-INDUCTION TO NO INDUCTION IN RENAL
TRANSPLANT PATIENTS
M. Cantarovich1,2, A. Durrbach2, M. Ladouceur1, C. Hiesse2, G. Benoit2,
B. Charpentier2
1
McGill Univesity Health Center, Montreal, Canada, 2Hopital de Bicetre,
Paris, France
Background: There is a need to report on long-term follow-up results of
randomized controlled trials in renal transplantation (Tx).
Purpose: To determine the impact of ALG-induction on long-term outcomes
post-renal Tx. Methods: Between January 1985 and January 1986, 123
consecutive adult patients received a deceased donor renal Tx at a single
institution. Patients were randomized into 2 groups (Gr.), Gr.1: 63 patients
(40±10 yr-old) received cyclosporine A (CsA), prednisone and azathioprine
(1.5 mg/kg/d); Gr.2: 60 patients (36±9 yr-old) received ALG (3 vials (100
mg/vial)/day for 14 days), CsA, prednisone and delayed initiation (45 days
post-Tx) of low-dose azathioprine (1 mg/kg/d). In both Gr., CsA was started
prior to surgery at a dose of 4 mg/kg/iv. Thereafter, CsA was given orally
and the dose was adjusted according to blood trough levels (150-250 ng/ml).
Patients did not receive CMV prophylaxis. Cold ischemia time did not differ
(Gr.1: 38±8 hr, Gr.2: 39±9 hr). There was no difference in HLA (A-B-DR)
matching (Gr.1: 2.4±1.1, Gr.2: 2.6±1.2).
Results: The incidence of acute rejection was lower in Gr.2 (28% vs. 75%,
P<0.0001). The incidence of CMV infection was 10% in Gr.1 and 18% in
Gr.2 (P=NS). The overall incidence of cancer was 22.2% in Gr.1 and 11.7%
in Gr.2 (P=NS). The incidence of lymphoma was 3% in Gr.1 and 5% in Gr.2
(P=NS)
Table 1. Short and long-term outcomes
Patient survival*
1 year
5 years
10 years
15 years
20 years

*P=NS

Group 1
100%
91%
83%
71%
64%

Group 2
100%
100%
88%
72%
54%

Graft survival*
Group 1
79%
67%
56%
43%
43%

Group 2
93%
75%
51%
47%
47%

Conclusion: The use of ALG-induction resulted in a lower incidence of
acute rejection and improved graft survival during the first year post-renal
Tx. Patient and graft survival at 20 year follow-up was not affected by ALGinduction. It remains to be determined whether long-term graft survival may
improve if current maintenance immunosuppressive strategies are used.

CONCURRENT ORAL SESSION 64:
BIOMARKERS OF ACUTE REJECTION
880 DIFFERENTIAL EXPRESSION OF BMP-7, TGFÂ1 AND
GRANZYME B DURING ACUTE REJECTION OF HUMAN
RENAL ALLOGRAFTS: A PLAUSIBLE MOLECULAR LINK
BETWEEN ACUTE REJECTION AND CHRONIC ALLOGRAFT
INJURY
T. Muthukumar, R. Ding, C. Snopkowski, C. Chang, B. Li, V. Sharma,
S. Seshan, D. Dadhania, M. Suthanthiran
Nephrology and Transplantation Medicine, Cornell University, New York, NY,
USA
Progressive loss of allograft function and ultimate graft failure remain one
of the great challenges of organ transplantation. A major cause for chronic
allograft injury (CAI) and graft failure is acute rejection (AR). The mechanistic
basis for acute rejection (AR) being a risk factor for CAI has not been resolved.
Better understanding of the molecular mechanisms responsible for CAI may
improve long-term outcome of kidney transplant recipients.
In experimental models, administration of bone morphogenetic protein-7
(BMP-7) reduces epithelial cell to mesenchymal transition (EMT), promotes
mesenchymal to epithelial transition (MET) and reverses interstitial fibrosis
(IF), and the balance between the pro-fibrotic TGFβ1 and the anti-fibrotic
BMP-7 determine whether EMT or MET is favored. Herein, we investigated
the hypothesis that acute rejection (AR) is associated with BMP-7 deficiency
whereas pro-fibrotic and other tissue destructive effectors are hyperexpressed.
We tested our hypothesis by measurement of urinary cell levels of mRNA for
anti-fibrotic BMP-7, pro-fibrotic TGFβ1 and tissue destructive granzyme B.
We obtained 78 urine specimens from 78 renal allograft recipients at the time of
diagnostic biopsies (N=28) or protocol biopsies (N=50), and measured urinary
cell mRNA levels using pre-amplification enhanced kinetic quantitative PCR
assays developed in our laboratory.
Urinary cell levels BMP-7 mRNA were lower in the urine specimens from the
AR group compared to the Normal Biopsy group whereas mRNA levels of
TGFβ1 and granzyme B were higher in the AR group than the Normal Biopsy
group (Table 1).
Table 1: Differential Expression of mRNA for BMP-7, TGFβ1 and granzyme
B during Acute Rejection
mRNA Type Acute Rejection (N=28)
median copies/ ug total RNA
BMP-7
279
TGF-β1
726500
Granzyme B 62600

Normal Biopsy (N=50)

P-Value

934
313000
3180

0.04
0.01
0.001

P- Values calculated with the use of Mann-Whitney test
We also found that the TGFβ1 to BMP-7 ratio favored EMT and was higher
in the AR group than the Normal Biopsy group (median ratio: 1635 vs. 438,
P=0.0002).

Scr (μmol/L)*
Group 1
155±45
144±44
190±163
146±46
128±47

Group 2
153±73
150±51
140±34
151±56
144±47

Our data demonstrate differential expression of anti-fibrotic BMP-7 and tissue
destructive granzyme B and pro-fibrotic TGFβ1 during an episode of AR. Our
observations that BMP-7 is down-regulated during AR and that the balance
between TGF-β1 and BMP-7 favors EMT over MET advances a plausible
molecular mechanism for the linkage between AR and CAI and proffers an
explanation for the deleterious impact of AR on the long-term outcome of
human renal allografts.
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881 TIM3 MRNA QUANTIFICATION IN THE PERIPHERAL
BLOOD AND URINARY SEDIMENT CELLS ALLOWS AN
ACURATE DIGNOSIS OF ACUTE REJECTION OF KIDNEY
ALLOGRAFTS.
R. Manfro, E. Aquino-Dias, G. Joelsons, F. Veronese, L.F. Gonçalves
UFRGS Medical School
Background: TIM3 is a molecule selectively expressed in cells of the Th1
phenotype. Its mRNA measurement in the peripheral blood and urinary cells
is a potentially useful tool for the non-invasive diagnosis of acute rejection
episodes of kidney allografts. The aim of the present study is to evaluate TIM3
mRNA expression in kidney biopsies, peripheral lymphocytes and urinary
cells of renal transplant patients aiming at the non invasive diagnosis of acute
rejection of kidney allografts.
Patients and Methods: mRNA was extracted from 111 graft biopsies and
concomitantly obtained from peripheral blood leucocytes and urinary sediment
cells of 100 kidney transplant patients. Fifty-eight were obtained from patients
with delayed graft function, 43 from patients with graft dysfunction and 12
from patients with normal protocol biopsies. According to the Banff 1997
classification biopsies were allocated in 6 diagnostic groups: (1) acute tubular
necrosis (ATN; n=33); (2) acute rejection in patients with ATN (ATN-AR;
n=25), (3) acute rejection (AR; n=17), (4) calcineurin inhibitor nephrotoxicity
(CIN; n=8), (5) chronic graft nephropathy (CGN; n=16) and (6) normal
protocol biopsies (PB; n=12). A real-time quantitative PCR technique (TaqMan
EZ RT-PCR, Applied Biosystems) was used for mRNA amplification and
quantification. A ROC curve was generated for choosing the cut-off for the
calculation of the diagnostic parameters of acute rejection.
Results: In the analyses performed in graft tissue patients with ATN-AR and
AR presented statistically significant increased amounts of TIM3 as compared
to the other groups. Similarly, in the peripheral blood TIM3 is overexpressed
in patients with rejection (ATN-AR and AR groups). The same pattern of
expression was observed in the analyses of the mRNA obtained from urinary
cells. (see table). Statistically significant correlations were observed between
the amounts in tissue and either peripheral blood and urinary cells (p < 0.01).
The sensitivities for the diagnosis of acute rejection were 97.4% and 93.0%,
specificities: 93.4% and 98.0%, predictive positive values: 90.5% and 96.3%;
negative predictive values: 98.2% and 96.1 and accuracies: 95.0% and 96%
respectively in the peripheral blood and urine.
Graft
Blood
Urine

ATN
1.04 ± 1.06
0.54 ± 0.56
0.48 ± 0.42

ATN-AR
214.2±13.1
171.9±80.7
156.8±85.4

AR
25.2±36.9
13.5±18.0
9.3±11.05

CIN
0.25±0.50
0.15±0.33
0.10±0.18

CGN
0.45±0.64
0.34±0.45
0.21±0.31

Protocol
0.03±0.05
0.03±0.06
0.02±0.04

Conclusions: TIM3 mRNA analyses in peripheral blood and urinary sediment
cells may provide an accurate non-invasive tool for the diagnosis of acute
rejection in kidney transplant recipients.

882 IDENTIFICATION OF POTENTIAL BIOMARKER FOR
ACUTE REJECTION OF RENAL TRANSPLANT IN URINARY
CELL PELLETS
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L. Ying, M. Naesens, A. Chen, T. Sigdel, S. Hsieh, H. Dai, S. Sosa
Stanford University
Purpose: Because of its noninvasive nature and ease of mRNA collection,
urine is a significant advancement for improved prediction, diagnosis and
prognosis of acute allograft rejection (AR). Previous single gene studies for AR
diagnosis in blood and urine have failed to conclusively diagnose all rejection
episodes due to the underlying molecular heterogeneity of acute transplant
rejection. We have identified a gene list specific to AR using microarray gene
profile analysis in biopsy and peripheral blood of pediatric kidney transplant
patients. In this study, we validated selected candidate genes in urine samples
from same patients.
Method: The genes to be tested in urine for rejection diagnosis were selected
by three strategies: highly statistically significant genes (q scores <5% by
statistical analysis of microarrays, and >2 fold change in rejection) from
previously conducted microarray studies (Affymetrix HU133plus2.0) on 71
peripheral blood samples (44AR, 27 stable, STA, unpublished), 51 kidney
transplant biopsy samples (32 AR, 19 STA unpublished), and known urinepresent genes obtained from data filtering in Ingenuity Pathway Analysis
(Ingenuity). Urine samples were collected from pediatrics transplant patients.
Total RNA was extracted from urine samples. Two independent urine sample
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sets were selected for qPCR validation consists of 89 samples from patients
with biopsy-proven AR (n=30), biopsy-proven stable grafts (STA n=40) and
BK virus infection (BK n=19, with no AR). The extracted total RNA was then
subjected to qPCR in 384-well plates using RT2 qPCR system (SuperArray).
Primers were selected from cDNA sequences of the chosen genes using Primer
3.0, a web-based software. 26 genes were chosen from array data to run qPCR
(12 from blood data, 15 from biopsy data, some of the genes known to be preset
in urine). qPCR were carried in RT2 qPCR Master Mix (SuperArray). Relative
gene expression levels of each gene were calculated using the comparative
delta-CT method and normalized to 18S ribosomal RNA. All samples were
tested in duplicates. Student T test was applied for statistical analysis. P<0.05
was considered significant.
Results: Of 26 genes tested, 5 genes were significantly up regulated in AR
comparing to STA (P< 0.03), all of which were originally selected from the biopsy
array data set. 4 of which (80%) were also differentially expressed between AR
vs BK (P<0.005), confirming the genes are specific to AR. Interestingly, the
expression level of 2 genes is even significantly lower in BK comparing to STA
(P< 0.004).
Conclusion: Urine is an excellent and non-invasive source for biomarker
discovery and clinical monitoring. Transplant rejection may be non-invasively
predicted by qPCR across 5 highly-selected genes. Further validation of these
genes set across an independent blinded set of rejection and stable samples
is underway to confirm the robustness and applicability of this gene-set for
outpatient clinical transplant monitoring.

883 LEUCOCYTE ELASTASE-Α;1PROTEASE INHIBITOR
COMPLEX – NEUTROPHIL DEGRANULATION MARKER
IN PLASMA AND URINE OF PATIENTS AFTER DECEASED
RENAL ALLOGRAFT TRANSPLANTATION. ASSESSMENT
OF INDUCING FACTORS AND IMPACT ON ALLOGRAFT
FUNCTION.
M. Zynek-Litwin1, J. Kuzniar1, Z. Marchewka2, W. Kopec1, M. Kusztal1,
D. Patrzalek3, P. Biecek4, A. Dlugosz2, M. Klinger1
1
Department of Nephrology and Transplantation Medicine, Wroclaw
Medical University, Wroclaw, Poland, 2Department of Toxicology, Wroclaw
Medical University, Wroclaw, Poland, 3Department of Vascular, General and
Transplantation Surgery, Wroclaw Medical University, Wroclaw, Poland,
4
Department of Genomics, Faculty of Biotechnology Wroclaw University
Introduction: Neutrophils (PMN) are mediators of ischemia/reperfusion (I/R)
injury following deceased renal transplantation (kTx). Leucocyte elastase
complex with α;1protease inhibitor (EL-α;1PI) is a PMN degranulation marker.
The study&#8217;s aim was to examine the influence of immune and nonimmune factors on plasma EL-α;1PI (pEL) and urine EL-α;1PI (uEL) levels,
and to assess the correlation between leucocyte activation and early posttransplant complications.
Patients and Methods: The study was performed on 24 kidney graft recipients
from deceased donors. Plasma and urine EL were analyzed 4 times in the first
week after kTx (in postoperative (PO) days 1, 3, 7) and in a distant period after
kTx. This was done by ELISA test.
Results: Plasma EL was significantly higher on 1st PO day (average (av):
314,2±; 225,45) then on days 3 and 7 (av. 191,2±; 125,16, p<0,001 and av.
99,62±; 80,3, p<0,0001 respectively), as well as in a distant measurement (av.
127,4±; 69,92, p< 0,001).
The highest uEL was observed on 3 PO day. Early uEL after kTx on day 1, 3
and 7 was markedly greater than in distant measurement (p<0,02; p<0,004 and
p<0,03 respectively)
There was no significant association between pEL as well as uEL and peak
panel-reactive antibodies (PRA) in the examined patients.
Significantly important positive correlation was observed between pEL on 1,
3, 7th PO days and overall A, B, DR mismatch (p<0,01; p<0,03; p<0,008). In
patients with mismatch number >3 the pEL markedly decreased between first
PO day (av.416,4±; 259,7) and 3, 7th PO days (av.249,2±; 146,5 and av.136,9±;
98,2; respectively) as well as distant measurement (p<0,03; p<0,004 and
p<0,01 respectively).
Urine EL in first PO day was significantly correlated with overall A, B, DR
mismatch number (p<0,02).
Study showed a correlation between cold ischemia time (CIT) and uEL on 1 PO
day (p<0,01). Significantly higher uEL excretion on 1st PO day was observed
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in patients with CIT >21,5h (av.:54,1±;26,8) than with CIT<21,5 h (av.:25,5±;
25,5) –; p<0,007.
Plasma EL on 1 PO day was significantly greater in patients with DGF
(av.472,6±; 230,6) than in those with IGF (av.258,4±; 201,4) – p<0,02. Urine
EL on first PO day was higher in DGF group (av.74,5±; 23,7) than in IGF group
(av.25,0±; 18,2) –; p<0,0007.
In patients with an early graft rejection episode uEL on 1 PO day was significantly
greater (av.:67,3±; 28,4) than in group without rejection (av. 29,8±; 24,4) – p<
0,009. Similarly, on 7 PO day there was a higher uEL in the graft rejection group
(av.113,6±; 93,9 and av.36,1±; 35,7 respectively) –; p<0,04.
Conclusions: PMN activation after kTx caused an increase of pEL and uEL
(max. pEL on 1 PO day). pEL level correlated markedly with an overall A, B,
DR mismatch. There was a significantly greater pEL in DGF patients. Urine
EL was markedly higher in patients with longer CIT. Greater uEL on 1 PO day
was observed in patients with early graft rejection. These findings suggest an
influence of ischemia/reperfusion-induced PMN degranulation on the kidney
graft function.

884 RELIABLE AND SIMPLE DIAGNOSIS OF RENAL
ALLOGRAFT REJECTION BASED ON URINARY
GRANZYME A
A. Rowshani3, M. van Ham1, K. Heutinck2,3, M. Strik1, T. Jorritsma1, E.
Remmerswaal2,
I. ten Berge3
1
Department of Immunopathology, Sanquin Research, Amsterdam, The
Netherlands, 2Department of Experimental Immunology, Academic Medical
Center, Amsterdam, The Netherlands, 3Department of Internal Medicine,
Renal Transplant Unit, Academic Medical Center, Amsterdam, The
Netherlands
Acute clinical rejection (ACR) is a serious complication of renal transplantation.
Early and rapid diagnosis is important to discriminate ACR from other causes
of graft dysfunction like acute tubular necrosis (ATN) and drug toxicity. A
sensitive and specific biomarker could help bypass renal biopsy which is the
current golden standard for the diagnosis of rejection.
We collected 120 urine samples from 44 recipients with biopsy confirmed
diagnosis of: ACR [19], acute tubular necrosis [8], subclinical rejection [8], or
stable graft function [9]. In 10 subjects with acute rejection we succeeded in
collecting urine samples longitudinally in time before the clinically manifested
and histologically proven rejection episode. Total RNA was isolated from urine
cell pellets, quantified and reverse transcribed to complementary DNA. Relative
mRNA expression levels of granzyme A (GrA), granzyme B (GrB), perforin
and SERPINB9 were measured. Afterwards, the results were normalized to the
internal control 18S-rRNA.
The relative urinary mRNA levels of the cytotoxic proteins GrA, GrB and
perforin were higher in patients with acute rejection compared to stable graft
function and ATN (p<0,014). Surprisingly, GrA levels were also significantly
elevated during sub-clinical rejection in comparison with stable function and
ATN (p<0,016). GrA levels in stable patients and in patients with ATN are
below the detection limit; therefore this marker is very specific for rejection
in contrast to GrB and perforin. Additionally, timely obtained sequential urine
samples showed an early rise in granzyme mRNA levels preceding the rise in
serum creatinine.

CONCURRENT ORAL SESSION 65: IMMUNOBIOLOGY/HLA
885 DOUBLE-NEGATIVE REGULATORY T CELLS BASED
THERAPEUTIC APPROACH TO PREVENT AND CURE TYPE I
DIABETES IN NOD MICE.
D. Zhang, W. Zhang, Y. Liu, Y. Tian, X.X. Zheng
University of Pittsburgh Medical Center
Accumulating evidence in supporting the existence of more than one
population of regulatory T-cells that function in immune responses. Further
characterization of the function and development of these regulatory T-cells
will contribute to our understanding of the intrinsic and extrinsic mechanisms
during an acquired process that maintain the peripheral tolerance.
Recently we have reported that proliferated CD4+ T-cells could convert to
CD4-CD8-CD3+ (DN) T-cells after either allogeneic or syngeneic mature
DC triggered proliferation, and IL-2 and IL-15 enhanced the conversion. The
converted DN T-cells were resistant to AICD and expressed a unique set of
cell markers and gene profile. Moreover, at a per cell base comparison, the
converted DN T-cells were more potent in suppressing alloantigen trigged
proliferation of na&#239;ve CD4+CD25- T-cells than na&#239;ve and
proliferated CD4+CD25+ Tregs in vitro.
In this study we further test the functional potential of the converted DN
T-cells in autoimmune diabetic NOD models. In an adoptive transfer model
of autoimmune diabetes, the adoptive transfer of T-cells or CD4+ T cells from
new onset diabetic NOD mice precipitated a rapid onset of diabetes in all NOD/
SCID recipients. In contrast, all NOD/SCID recipients received DN T-cells,
which were converted from CD4+ T-cells of new onset diabetic NOD mice,
alone remain diabetic free for up to 30 weeks post adoptive transfer. The cotransfer of DN T-cells with diabetogenic T-cells at 1: 1 ratio significantly delay
the onset of diabetes in NOD/SCID mice (P=0.0012). Thus, the DN T-cells
converted from diabetogenic CD4+ T-cells from new onset diabetic NOD
mice were capable of suppressing autoimmunity. Interestingly, the addition of
GAD65 peptide, a beta-cell specific antigen, in the conversion further enhanced
the suppressive function of DN T cells.
In a pre-diabetic NOD model, the adoptive transfer of 2 million DN T cells
(converted from CD4+ T-cells of NOD mice by co-culture with mature NOD
DC plus rIL-15 and GAD65 peptide in MLR for 6 days) into 5 weeks old prediabetic NOD female mice resulted in significantly delay of onset of diabetes.
Only 25% NOD female mice became diabetes at 22 weeks after DN T cell
transfer compare with 75% mice became diabetic in control group. Moreover,
a single transfer of 4 million DN T-cells converted from diabetogenic CD4+
T-cells reversed new onset of diabetes, albeit transient, in autoimmune new
onset diabetic NOD mice. We then combined low dose rapamycin with DN
T-cells in a MHC mismatched islet allograft model in spontaneous autoimmune
diabetic NOD recipients. The single transfer of 5 million DN T-cells plus 14
days low dose rapamycin (0.6mg/kg) treatment significantly prolonged islet
allograft survival in comparison with untreated group (MST 40 days vs. 6
days, p=0.002) and rapamycin alone treated group MST (40 days vs. 8 days,
p=0.002).
The results of using ex vivo CD4+ T-cells converted DN T-cells in NOD mouse
models support the concept and the feasibility of potentially utilizing this novel
cell-based therapeutic approach clinically for the treatment of autoimmune
type I diabetes.

886 THE CRITICAL ROLE OF CD4 T CELLS IN CD154
BLOCKADE-RESISTANT MEMORY CD8 T CELL ACTIVATION
AND ALLOGRAFT REJECTION IN SENSITIZED RECIPIENTS

Measurement of urinary GrA mRNA offers a sensitive and highly specific
non-invasive diagnostic tool for both acute and subclinical rejection. Urinary
GrA levels precede the rise in serum creatinine in case of ACR. Therefore,
detection of GrA in urine provides a useful tool to support the performance
of renal biopsy in order to detect both acute and subclinical rejection. The
timely initiation of anti-rejection treatment may lead to a better preservation of
allograft function in the long term.

J. Kupiec-Weglinski, Y.W. Wang, R. Busuttil, Y. Zhai
Dumont-UCLA Transplant Ctr
Background: The sensitized transplant recipients may undergo a
fulminant accelerated form of rejection, which is mediated by T celldependent mechanisms. These patients often experience increased rate of
early rejection episodes, which are difficult to control with currently used
immunosuppressive agents. Methods: In our model of cardiac graft rejection
in sensitized recipients, B6 mice are first challenged with B/c skin, followed
40-60 days later by B/c heart transplant (HTx). Unlike in naive hosts, HTx
rejection and alloreactive CD8 activation in this model are CD154 blockaderesistant. We first performed systemic analysis at the intragraft transcriptional
level by microarray to identify disparities in local immune responses in
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naive vs. sensitized hosts. Aiming to improve the efficacy of costimulation
blockade in the sensitization settings, we then determined the role of CD4
T cells in costimulation blockade-resistant alloimmune response by using
CD4 depleting (GK1.5) vs. CD4 blocking (YTS177) Ab, in conjunction
with CD154 blockade (MR1). Results: HTx harvested from groups of naive
(day 4-6), sensitized (day 2-4), control Ig or MR1 Ab treated mice (n=3/
gr) were subjected to microarray analysis. MR1 treatment suppressed HTx
expression of pro-inflammatory genes (IL-1 , IL-6, TNF-a), and T celltargeted chemokines (RANTES, Mig, CXCL10) early after HTx in naive, but
not sensitized recipients. Five groups of sensitized mice treated at the time of
HTx with: (1) control Ig; (2) MR1 [day 0]; (3) GK1.5 [day -1/+1]; (4) MR1
[day 0] + GK1.5 [day -1/+1]; (5) MR1 [day 0] + YTS177 [day -1/+1] were
contrasted. HTx were rejected promptly in <5 days in Gr. (1), (2) (3), but
survived ca. 30 days in Gr. (4) and (5). The CTL activation was determined by
FACS phenotyping at day 10 and 30. The simultaneous blockade of CD154
costimulation and CD4 help, but not a single blockade with MR1 Ab or antiCD4 Ab, was required to inhibit peripheral alloreactive CD8 activation in
sensitized mice. Additionally, CD8 activation in the absence of CD4 help
showed defective cytotoxic molecule profile, with suppressed perforin but
upregulated granzyme B expression at the graft site. Conclusion: CD154
blockade-resistant CD8 activation is critically dependent on CD4 T cells.
This study provides novel immunological basis to study the potential synergy
between adjunctive CD4 and CD154 targeted therapies to control accelerated
graft rejection in sensitized hosts.

887 DONOR-SPECIFIC ANTIBODIES ARE PRODUCED BY
B220+/CD20+/ CD5-/IGM+/IGD+ B CELLS REGULATED BY TH1
CYTOKINES: A STUDY USING A NOVEL MURINE MODEL OF
HLA SENSITIZATION

THURSDAY

G. Wu, Y. He, N-N. Chai, M. Toyoda, S. Jordan, A. Klein
Cedars-Sinai Medical Center
Objective: Anti-HLA antibodies are a major risk factor for antibody-mediated
rejection (AMR). However, the nature of anti-HLA-producing B cells and
the mechanisms that regulate their production are poorly understood. Lack
of appropriate animal models has been an obstacle in our research efforts to
quantify B cell production of HLA antibodies
Materials and Methods: We report a unique mouse model of HLA sensitization
in which anti-donor HLA antibodies are generated. This model involves skin
grafting from C57BL/6Tg/HLA-A2.1 mice to C57BL/6 mice. Due to the single
antigen difference, the recipient mounts a vigorous antibody response against
the donor specific HLA-A2 antigen.
Results: Low titers (1:10) of IgM antibodies reactive to HLA-A2 antigens
were detected in antisera produced at days 7-14 but not at days 21-28 posttransplantation (Ptx). High titers (1:100) of IgG2a antibodies were detected
in antisera at days 21 and 28 Ptx. Of interest was that the anti-HLA antibodies
not only reacted to HLA-A2 but also bound to a panel of class I (but not class
II) HLA antigens, as demonstrated in a Flow cytometric PRA assay. Thus,
the DSA generated in this model exhibited characteristics of panel antibody
reactivity that is usually observed in pre-sensitized transplant patients. On
the other hand, IgG1 PRA was absent in DSA samples harvested before days
21 Ptx, and occurred in less than 20% animals at day 28 Ptx, suggesting a
weak Th2 effect. The anti-HLA.A2 sera also exhibited complement-dependent
cytotoxicity against a HLA-A2-expressing human T-lymphoblast cell line.
Elevations of serum IGg2a PRA correlated with vigorous proliferation of
B220+/CD20+/CD5-/IgM+/IgD+B cells in the spleens. B cell depletion using
a mouse-anti-mouse CD20 antibody suppressed IgG PRA production. T cell
depletion by anti-CD3 antibody resulted in weakening of the IgM response and
a significant reduction in serum IgG PRA. Quantitative RT-PCR demonstrated
significant increases in mRNA expression of INF-γ and IL-2 but not IL-4 and
IL-10 in the spleens following primary immunization.
Conclusion: The data suggest that antibody responses to allogenic sensitization
are T cell-dependent. Th1 microenvironment may dictate the early phases of the
antibody responses while a Th2-dependent IgG1 response appears to follow amid
persisting alloantigen stimulation. DSA are produced by CD5- B cells expressing
a mature conventional B cell phenotype (B220+/CD20+/IgM+/IgD+). Suppression
of HLA antibodies can be effectively achieved by either B cell depletion by antiCD20 antibodies or T cell depletion by anti-lymphocyte sera.
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888 HUMAN REGULATORY T CELL THERAPY IN THE
PREVENTION OF TRANSPLANT ARTERIOSCLEROSIS
K.J. Wood, J. Wieckiewicz, S.N. Nadig, D.C. Wu, G. Warnecke, W. Zhang, S.
Luo, D. Taggart,
Transplantation Research Immunology Group, University of Oxford
Purpose: Transplant Arteriosclerosis (TA) is the main cause of chronic allograft
loss after allograft transplantation. Additionally, CD25hiCD4+ regulatory T
cells (Treg) have shown much promise in their ability to inhibit immunologic
effector responses in vitro and in rodent models. In this report, we detail the
capacity of ex vivo expanded human Treg to prevent TA in a clinically relevant
humanized mouse model.
Methods and Materials: Human T regulatory cells have been sorted and
expanded ex vivo with anti-CD28/anti-CD3 beads in the presence of high
doses of IL-2 and their phenotype and in vitro suppressive capacity was
assessed. Human arterial side-branches were procured from the internal
mammary artery of patients undergoing coronary artery bypass grafts. These
arterial segments were then transplanted into the abdominal aorta of RAG2/
commonãchain -deficient BALB/c (BALB/C DKO) recipients on day 0. On
post-operative day 1, allogeneic human peripheral blood mononuclear cells
(PBMC) +/-Treg, were adoptively transferred into transplant recipients. Thirty
days after transplantation, Elastin van Gieson staining was performed on the
grafted vessels to assess the degree of TA by measuring the percentage intimal
expansion (I.E.). Flow cytometric analysis of human CD45 stained splenocytes
confirmed human leukocyte chimerism.
Results: Sorted and ex-vivo expanded human CD25hiCD4+ retain phenotypic
characteristic of T regulatory cells and are highly suppressive in vitro. Human
arteries transplanted into BALB/c DKO mice reconstituted with human alloPBMC developed marked TA (n=8; mean% I.E.±SD= 45.53% ± 21.14). In
contrast, when transplanted mice were treated with PBMC + ex vivo expanded
Treg therapy, TA was significantly attenuated (n=6; mean% I.E.±SD=
12.45%±9.64; p=0.0013). As expected, TA did not develop in human arterial
grafts transplanted into BALB/C DKO mice that did not receive human alloPBMC (n=4).
Conclusions: Ex vivo expanded CD25hiCD4+ Treg can significantly reduce
the development of transplant arteriosclerosis in a clinically applicable
model of vascularized solid-organ transplantation. To our knowledge,
this is the first evidence showing the capacity of human Treg to prevent
arteriosclerosis in vivo.

889 A NOVEL DNA VACCINATION STRATEGY FOR
TRANSPLANTATION
A. Li, M. Hattori, J. Chen, O. Ojogho, Y. Iwaki, A. Escher
Loma Linda University
Background: We have previously described a DNA vaccine strategy that
ameliorates new-onset of autoimmune diabetes in NOD mice, and which
requires that plasmid DNA encodes the pro-apoptotic protein BAX and
a pancreatic β-cell antigen. Injection of the vaccine induces formation of
antigen-containing apoptotic cells in situ, recruits dendritic cells, and induces
CD4+CD25+foxp3+ regulatory T cells. Here, we investigated whether the same
strategy could be applied to prevention of skin allograft rejection in mice. We
hypothesized that induction of apoptotic cells near the allograft would promote
immunoregulation and increase graft survival.
Materials & Methods: Groups of C57/BL6 mice (n=8/group) received fullthickness skin allografts from BALB/c mice. All treated recipient mice received
a single injection of anti-lymphocyte immunoglobulin (ALG, 1.6 mg/20 gr
BW) at time of transplantation, followed by daily injections of rapamycin (1
mg/kg BW) for 4 weeks. In addition, selected groups received a weekly i.d.
injection of 50 μg plasmid DNA vector alone or coding for BAX. Allografts
were scored twice per week for rejection.
For immune analysis, draining lymph nodes of mice receiving ALG and
rapamycin alone and from mice vaccinated with BAX-encoding DNA were
taken 2 weeks after transplantation. Lymph nodes were cultured in presence of
inactivated splenocytes from C57/BL6 (recipient), BALB/c (donor), or DBA
(third party) mice as sources of antigens, and CD4+CD25+ cells were isolated for
proliferation assay. Quantitative PCR analysis of expression of selected genes
(Foxp3, Il-10, Tgf-β1, Tnf-α, Ifn-γ) was performed with skin allografts, cultured
lymph nodes, and CD4+CD25+ cells isolated from proliferation assays.
Results: Skin allograft survival. Untreated mice and mice receiving ALG and
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rapamycin alone with or without plasmid vector alone rejected skin grafts 1-2
and 5-6 weeks after transplantation, respectively. In contrast mice vaccinated
with plasmid DNA coding for BAX rejected the allografts 10-11 weeks after
transplantation. Quantitative PCR analysis. Expression of the selected genes
was consistently higher in the skin grafts of non-vaccinated animals. Similarly,
expression of Foxp3, Tgf-β1, and Tnf-α was higher in both cultured lymph
nodes and cultured CD4+CD25+ cells from non-vaccinated mice. In contrast,
increased expression of Il-10 and IFN-γ was observed in cultured lymph nodes,
but not in cultured CD4+CD25+ cells from the same animals. Proliferation
assay. CD4+CD25+ cells isolated from cultured lymph nodes of non-vaccinated
mice showed similar suppressing activities after stimulation with self, donor,
and third party antigens. In contrast, cells isolated from vaccinated mice showed
higher suppressive activity when stimulated with donor antigens.
Conclusion: Our results indicate that “pro-apoptotic” DNA vaccination can
be applied successfully not only to type 1 diabetes, but also to solid organ
transplantation. Injection of plasmid DNA coding for BAX appears to induce
a donor-specific immunoregulatory response that could contribute to increased
graft survival. We hypothesize that vaccination recruits dendritic cells that
process vaccine-induced apoptotic cells together with antigens from the
allograft. However, considering that expression of Foxp3, Il-10 and Tgf-β1
was consistently higher in non-vaccinated, immunosuppressed animals, other
mechanisms of tolerance induced by our DNA vaccination strategy are likely
to play a role in promoting graft survival.

CONCURRENT ORAL SESSION 66: COMPOSITE GRAFTS
890 FIRST FACE ALLOGRAFT IN HUMAN: A TWO YEARS
FOLLOW UP
E. Morelon1, S. Testelin3, P. Petruzzo2, L. Badet2, J. Kanitakis2, A. Eljafari4,
B. Lengele5, X. Martin2, B. Devauchelle3, J.M. Dubernard2
1
Transplantation Department, Hospices Civils de Lyon, INSERM U851,
2
Transplantation department, Hospices Civils de Lyon, 3University hospital,
Amiens, France, 4Unité mixte HCL Biomérieux, Lyon France, 5Catholic
University of Louvain, Brussels
The first human face allotransplantation was successfully performed in Amiens
(France) on November 27, 2005. We report outcomes up to two years after
transplantation.
The recipient was a 38 year-old woman who was mutilated and disfigured
by a dog bite on May 31th, 2005. She received a facial allograft (nose-lipschin) from a brain dead female donor. A vascularized sentinel donor skin
graft was performed under the recipient breast. Donor bone marrow was
infused on days 4 and 11 post transplantation to improve graft acceptance.
The immunosuppression protocol included Thymoglobulins as induction
therapy, tacrolimus, prednisone and mycophenolate mofetil. Sequential biopsy
specimens were taken from the sentinel skin graft, the oral mucosa and the
facial skin. Functional progress was assessed by tests of sensory and motor
function performed monthly.
The initial postoperative course was uneventful.
Sensitivity to light touch, as assessed with the use of static monofilaments,
and sensitivity to heat and cold had returned to normal at 6 months post
transplantation. Motor recovery was slower and labial contact allowing
complete mouth closure was achieved at 10 months. Psychological acceptance
of the graft progressed as function improved. Two episodes of acute rejection
occurred on days 18 and 214 post-transplant. Macroscopically the patient
developed erythema and oedema on both skin of face and sentinel flap and
oral mucosa. Biopsies revealed dense mononuclear cell infiltrates vacuolisation
of basal cells, occasional apoptotic keratinocytes. The two rejection episodes
were resolved with the combination of 3 boluses of 1 g prednisolone, increasing
tacrolimus and mycophenolate mofetil doses and topical immunosuppressants.
Extracorporeal photochemotherapy (EPC) was started at 10 months to prevent
recurrence of rejection without increasing the doses of the maintenance
immunosuppression. There have been no subsequent acute rejection episodes.
The main side effect of immunosuppressive regimen was a progressive renal
failure that resolved after the switch from tacrolimus to sirolimus at 14 months
post-transplant.
Conclusion: In this patient who underwent the first face transplantation, the
functional and aesthetic results 2 years after transplantation are satisfactory.

891 INTERNATIONAL REGISTRY ON HAND AND
COMPOSITE TISSUE TRANSPLANTATION
P. Petruzzo1, M. Lanzetta2, J.M. Dubernard1, R. Margreiter3, F. Schuind4, W.
Breidenbach5, J. Jablecki6, L. Landin7, P. Cavadas7
1
Department of Transplantation, 2Italian Institute of Hand Surgery, Monza
(Italy), 3Universitatsklinik fur Chirurgie, Innsbruck (Austria), 4Erasme
University Hospital, Brussels (Belgium), 5Kleinert, Kutz and Associates, and
Christine M. Kleinert Institute for Hand and Microsurgery, Louisville (USA),
6
Pododdzial Replantacji Konczyn, Szpital sw. Jadwigi Slaskiej w Trzebnicy,
Wroclaw (Poland), 7Pedro Cavadas Foundation at “La Fe” University
Hospital, Valencia, (Spain)
From September 1998 to February 2008 twenty-two male and two female
patients underwent 33 hand/forearm/digit transplantations (thirteen monolateral
and eight bilateral hand transplantations, two bilateral forearm transplantations,
one thumb transplantation). Patient average age was 32 years. Follow-up period
ranged from 3 months to 109 months.
The level of amputation was mostly at the distal forearm or wrist. Time since
hand loss ranged from two months to 30 years.
Immunosuppressive therapy included tacrolimus, mycophenolate mofetil,
rapamycin and steroids; polyclonal or monoclonal antibodies were used for
induction. Topical immunosuppression was administered in some patients.
Acute rejection episodes occurred in 85% of patients within the first year.
Rejection was completely reversible in all compliant patients.
Side-effects included opportunistic infections and metabolic complications. No
life-threatening complications or malignancies were reported.
All patients developed protective sensibility, 90% of them developed tactile
sensibility and 72% also a discriminative sensibility. Motor recovery enabled
patients to perform most daily activities.
Patient survival was 100%. Graft survival was 100% at one and two years.
Except for Chinese patients, current graft survival is 95.6% as only one
hand has been lost. While in 2006 it was reported that all but one Chinese
recipient have lost their grafts. In all cases the cause was non-compliance to the
immunosuppressive therapy due to abstention from therapy, long distance from
the transplantation centre, and unreported episodes of acute rejection.

892 MONITORING REJECTION IN HAND
TRANSPLANTATION BY A “DISTANT SENTINEL SKIN
GRAFT”
M. Lanzetta
Italian Institute of Hand Surgery
Background: Methods for monitoring rejection in human hand transplantation
include visual inspection of skin changes and histological analysis of biopsies.
Previous experimental studies have shown that skin allografts reject faster and
with a greater immune response than composite tissue allografts containing
skin. We aimed at using this differential rejection phenomenon to achieve
earlier detection of incoming rejection.
Methods: Three patients had their dominant right hand transplanted after
suffering a traumatic amputation respectively 4, 22 and 10 years before.
Additional full-thickness skin taken from the donor was simultaneously
transplanted onto the left hip area, and used both as a source for skin biopsies
and as an additional area for monitoring rejection (distant sentinel skin graft).
Immunosuppression included monoclonal antibody anti-CD25, FK506,
mycophenolate mofetil and steroids.
Findings: In Case 1 at 76 days postoperatively, the “distant sentinel skin graft”
showed an onset of rejection which was confirmed histologically. Clinical and
histological signs of rejection of the hand did not appear until day 83, when
appropriate systemic and topical therapy was started. The skin changes resolved
completely within 5 days at both locations. In Case 2 at postoperatively, the
additional skin rejected while the skin of the hand was free from rejection.
Immediate therapy reversed rejection of the monitor skin and prevented the
hand from developing any signs of rejection. In Case 3, early clinical signs of
rejection at the hip area were not reported by the patient, and within 72 hours
the hand joined the monitor island in showing signs of inflammation typical of
rejection. They were both treated successfully with salvage therapy.
Interpretation: These findings support previous experimental data showing
that skin alone rejects faster and more aggressively than composite tissues
containing skin. The earlier appearance of skin changes in the distant sentinel
skin graft compared to the hand permits a precocious start of rescue therapy
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minimizing tissue damages to the hand without interfering with rehabilitation
program. Routine biopsies can be taken from the distal sentinel skin graft
without disturbing the transplanted hand, minimizing aesthetic sequelae due
to visible multiple scars.

893 VASCULARIZED BONE MARROW TRANSPLANT AS
AN ALTERNATIVE TO CONVENTIONAL CELLULAR BONE
MARROW TRANSPLANTATION
I. Zegrea1, D. Zamfirescu1, I. Lascar1, E. Owen2, M. Lanzetta2, R. Bratianu1,
R. Sinescu1
1
Carol Davila Medical University, 2Microsearch Foundation of Australia
Vascularized bone marrow transplantation (VBMT), in comparison
with conventional marrow transplants, have the advantage of providing
a microenvironment and immediate engraftment of both mature and
progenitor hemopoietic cells at the time of transplantation in the absence
of immunomodulation or irradiation. Current protocols for bone marrow
transplantation involve removing the bone marrow component directly from
its donor microenvironment and then injecting such components into the
circulatory system of the recipient. This procedure is usually preceded by
either total or partial body irradiation, pharmaceutical immune suppression, or
both. The aim of the study was to follow the development of microchimerism
after allogeneic (VBMT) vs conventional bone marrow transplantation (BMT).
A VBMT model consisted of a donor (Brown Norway rat) femur that was
harvested with its nutrient vessels, anastomozed to the right femoral vessels
of the recipient (Lewis rat), and then placed subcutaneously in the epigastic
area. Cellular microchimerism was investigated in recipients of VBMTx
vs BMC. An intravenous infusion of BMC in suspension equivalent to that
grafted in the vascularized femur limb was administrated. Donor-derived
cells could be detected in VBMT recipients as long 60 days after cessation
off immunotherapy but not in recipients of i.v. suspension BMC grafting. In
the model of i.v. suspension BMC transplantation the number detected in the
recipient at the termination of therapy was very low 7 days later. A low level
of cellular microchimerism could be detected as long as 70 days after cessation
of therapy. VBMT provides a theoretical alternative to conventional cellular
bone marrow transplantation by addressing crucial clinical problems such as
failure of engraftment. With regard to future implications, it may be possible to
develop a new approach for bone marrow transplantation based primarily on a
surgical procedure (transfer of vascularized blocks of bone/marrow).

894 INVESTIGATION OF LYMPHOCYTE ADHESION AND
TRAFFICKING MARKERS IN REJECTION OF THE SKIN
COMPONENT IN HUMAN HAND ALLOGRAFTS
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S. Schneeberger5, T. Hautz1, B. Zelger2, G. Brandacher1, H-G. Mueller3,
A. Lee4, R. Margreiter1,
1
Dept. of General and Transplant Surgery, Innsbruck Medical University,
Austria, 2Dept. of Pathology, Innsbruck Medical University, Austria, 3Dept. of
Dermatology, Innsbruck Medical University, Austria, 4Div. of Plastic Surgery,
UPMC, Pittsburgh, PA, USA, 5Div. of Plastic Surgery, UPMC, Pittsburgh,
PA, USA and Dept. of General and Transplant Surgery, Innsbruck Medical
University, Austria
Introduction: Human Hand Transplantation has become a clinical reality
and good functional results have been achieved in most patients. The major
remaining obstacle for wider range clinical application is skin rejection. We
herein analyze eight key molecular markers of lymphocyte trafficking and
cellular as well as antibody mediated rejection in human hand transplantation.
Methods: One-hundred and thirty skin biopsies were taken from three bilateral
hand transplants recipients at and different time-points and graded as per
previously a published classification. Biopsies were further investigated by
immunohistochemistry (IHC) using antibodies for Lymphocyte FunctionAssociated Antigen (LFA)-1 = CD11a, Intercellular Adhesion Molecule
(ICAM)-1 = CD54, Selectin E = CD62E, Selectin P = CD62P, VE-Cadherin
= CD144, Human Leukocyte Antigen (HLA) II (DP, DQ, DR), Psoriasin =
S100A7, FoxP3 and C4d. Levels of expression were analysed according to a
4-graded classification (0, +, ++, +++) and interpreted in the light of clinical
courses, rejection as well as time after transplantation.
Results: Rejection ranged between grade 0 and IVa with an average score of
0.9. None of the markers investigated was consistently up-regulated in healthy
skin. Upon rejection, CD54, CD62E and CD62P staining in endothelial cells
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was significantly increased. Staining for CD62E correlated well with severity
of rejection. The majority of infiltrating lymphocytes were CD11a positive.
In biopsies taken at the onset of rejection, kerationcytes were highly positive
for CD11a. While CD144 was detected on endothelial cells, its expression did
not correlate with rejection. In contrast, FoxP3 positive T-cells were mainly
found in samples showing severe rejection. Psoriasin expression was observed
in keratinocytes in a basal and focal pattern and correlated well with rejection.
For C4d, no consistent staining pattern was observed indicating that antibody
mediated rejection did not play a role in these patients.
Conclusion: A pattern of molecular markers involved in lymphocyte trafficking
was found up-regulated upon skin rejection after hand transplantation. These
molecules represent promising targets for prophylaxis and treatment of rejection
in hand transplantation. FoxP3 expression indicates presence of T-regulatory
cells in the skin during advanced stages of rejection.

CONCURRENT ORAL SESSION 67:
SURGICAL DILEMMAS IN RENAL TRANSPLANTATION
895 ASSESSMENT FOR RENAL TRANSPLANTATION
IN THE UNITED KINGDOM AND IMPACT OF PATIENT
COMORBIDITY ON ACCESS TO THE WAITING LIST
D. Akolekar, J.L.R. Forsythe, G. Oniscu
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Introduction: This study evaluates the impact of comorbidity on access to the
kidney transplant waiting list and variations in the assessment practices among
transplant centres in the United Kingdom.
Material And Methods: 908 patients being assessed for renal transplantation
in 10 transplant centres across the UK were included in this prospective multicentre study. Sociodemographic and comorbidity data were prospectively
collected on a standard proforma over a nine month period from October 2006
to June 2007. Effect of various comorbid conditions on the likelihood of listing
and centre variations were ascertained using Chi square and Cox Proportional
analyses.
Results: 720 patients (80%) have at least one comorbid condition at the time
of assessment with wide centre variations. These include significant differences
in the incidence of ischaemic heart disease (p<0.0001) and diabetes (p<0.0001)
among the assessed patients. Overall 41% patients were assessed pre-emptively
but the proportion varies significantly between centres (p<0.001, Chi square test).
There are significant differences in the time from assessment to listing among
transplant centres even after adjusting for comorbidity and other sociodemographic
covariates (p<0.0001, Cox Regression analysis). On multivariate analysis the
other independent predictors of access to waiting list are ischaemic heart disease
(p=0.027) and smoking (p=0.003). Furthermore, at a given time comparable
patients are managed differently in different transplant centres.
Conclusion: This is the first prospective study demonstrating significant
variations in the assessment of patients for renal transplantation across the
United Kingdom leading to inequity in access to the waiting list. Comorbidity
alone does not explain centre differences. Uniform assessment guidelines are
required to ensure an equitable access to the renal transplant waiting list.

896 THE ORGAN SHORTAGE ON THE BALKANSPAKISTAN, THE PROMISING LAND!
Z. Popov1, S. Dohcev1, J. Masin2, I. Rambabova-Busljetic2, V. Pusevski2, O.
Stankov1, N. Ivanovski2
1
Department of Urology, Skopje Medical Faculty, 2Department of Nephrology,
Skopje Medical Faculty
Background: Underdeveloped cadaver renal transplantation and increase of
organ shortage stimulate some patients not only from the Balkan region to go
in the Far East to buy a kidney. Before it was India, but in the last years the
promising place is Pakistan. So the organ sale continues despite the all ethical
issues and dilemmas.
Patients and methods: 36 illegally transplanted patients in Pakistan (Lahore
and Ravalpindi) are followed during the last 16 months in our Department:
25 from Kosovo, 10 from Macedonia and one from Albania. The patients
are transplanted very quickly from the large pool of donors available. The
transplant team and the hospitals are identified and some data about the
transplant procedure, immunosuppression and HLA compatibility are sent.
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The immunosuppressive protocol included CyA, Pred and MMF. Most of the
patients did not pass the usual pretransplant workup and are not sent officially
to the Pakistan’s centers. 80% of them are HCV or HBsAg positive.
Results: 7 patients died, 16 had wound infections with postoperative hernias.
3 perirenal hematomas, 6 abscesses, 4 lymphocelles, and 4 urinary fistulas
are operated. Nephrectomy was done in 3 patients due to renal thrombosis.
9 have an active hepatitis C, 4 severe CMV diseases with gastrointestinal
bleeding, 3 steroid diabetes and 3 acute myocardial infarction. 9 had one or
more rejection episodes treated with steroid pulse therapy. Five have chronic
allograft nephropathy. Most of them have UTI with Pseudomonas or/and
Escherichia coli. The one year patients and graft survival rate is 80% and 68%,
respectively.
Conclusion: In conclusion, as many times before, the authors do not recommend
this type of transplantation not only from the ethical point of view, but also
from frequent medical and surgical complications which are life threatening.

897 FACTORS INFLUENCING THE NUMBER OF
HOSPITALIZATION DAYS IN THE FIRST THREE MONTHS
AFTER KIDNEY TRANSPLANTATION
M. Heemskerk1, A. Hemke1, B. Haase-Kromwijk1, A. Hoitsma2
1
Dutch Transplant Foundation, 2Radboud University Medical Centre
Nijmegen
Background: We analyzed the parameters that influence the number of
hospitalization days in the first 3 months after kidney transplantation.
Methods: We analyzed the 3 month follow-up for kidney transplants performed
in the Netherlands between 2000 and 2007 (n = 3317). We included both the
hospitalization days immediately after the transplantation as well as every
rehospitalization day in the first 3 months after transplantation. Patients were
included if they were alive with a functioning graft at three months after
transplantation. Cases were assumed “missing” if less than 5 hospitalization
days were reported.
Results: The mean number of hospitalization days during the first three months
after transplantation was 24.8 days (range 5-92) within the period 2000-2007.
A significant difference was shown in the mean number of hospitalization days
for the donor type: deceased donors (27.9 days) versus living donors (20.1
days). For the deceased donors, significantly more hospitalization days (2-4
days) were found for recipients who received kidneys from older donors,
recipients with a higher BMI, and recipients who received a non-heartbeating
donor kidney. For living donors significantly more hospitalization days (2-6
days) were found for older recipients, recipients with a higher BMI, recipients
with dialysis prior to the transplantation and recipients who received a kidney
from an unrelated donor. However, for both the deceased donor and living
donor transplants there was a significantly larger difference in hospitalization
days (maximum of 19 days for deceased and 12 for living donors) between
the different transplant centers. This center effect was present in each of the
identified donor type, donor and recipient age groups, dialysis, and in all but
one (due to small numbers) of the recipient BMI groups. The center effect thus
seems to be independent from the different characteristics described above.
Conclusion: From this analysis we conclude that the donor type (deceased
vs living) and the transplant center (and therefore the hospitalization policy)
are very strong, independent, parameters that influence the number of
hospitalization days in the first 3 months after kidney transplantation. Donor
and recipient age, recipient BMI, dialysis and donor type had a significant but
smaller effect.

898 HEALTH-RELATED QUALITY OF LIFE OUTCOMES
FOR KIDNEY DONORS DIFFER DEPENDING ON TYPE OF
LAPAROSCOPIC DONOR NEPHRECTOMY (PURE (P-LDN) VS.
HAND-ASSIST (HA-LDN))
M. Hughes, C. Jacobs, M. Hill, T. Jie, A. Rezcallah, T. Dunn, A. Humar,
D. Sutherland, A. Matas, R. Kandaswamy
University of Minnesota
Introduction: P-LDN offers the advantage of scar placement in a less
conspicuous area (supra-pubic) compared with HA-LDN. In addition, avoidance
of hand insertion allows for a smaller incision but whether this contributes to
greater post-donation quality of life remains unknown.
Methods: Since 1997, we have performed 558 HA-LDN and 141 P-LDN.

Choice of operation was at the discretion of the operating surgeon. Healthrelated quality of life (HQOL) scores were determined by SF-12 survey and
results were expressed as Physical Health Summary Scores (PCS) and Mental
Health Summary Scores (MCS). PCS included 1) physical functioning, 2) rolephysical, 3) bodily pain, and 4) general health. MCS included 1) vitality, 2)
social functioning, 3) role-emotional, and 4) mental health. RESULTS: Those
patients who underwent P-LDN were younger (P-LDN 40.0 10.4 years vs.
HA-LDN 41.9 10.4, p=0.03), thinner (25.0 3.6 vs 26.6 4.0, p<0.0001), and
more often donated the left kidney (92.2% vs 76.9%, p<0.0001). There were
no differences in gender (P-LDN 63.1% female vs HA-LDN 56.8%, p=0.2),
relation to recipient (63.8% vs 61.5%, p=0.6) or number of arteries (90.0%
single artery vs 84.0%). Length of stay was shorter for P-LDN (P-LDN 3.2
3.5 days vs. HA-LDN 3.3 1.7, p=0.04) with no significant differences between
groups in blood transfusion (p=0.2), infection (p=0.8), pulmonary embolism
(p=0.3), re-operation (p=0.8), or total in-hospital complications (p=0.4). There
were no differences between groups in kidney performance for the recipient as
measured by delayed graft function (P-LDN 2.8% vs. HA-LDN 2.9%, p=1.0),
5-yr graft survival (85.5% vs 89.7%, p=0.7), ureteral obstruction (10.6% vs
9.1%, p=0.6), or ureteral leak (4.4% vs 2.7%, p=0.4). Regarding HQOL,
Mental Health Summary Scores (MCS) were greater for those donors who
underwent P-LDN than for those who underwent HA-LDN (54.1 6.1 vs 52.1
6.1, p=0.009). Physical Health Summary Scores (PCS) were similar (P-LDN
55.0 6.1 vs 55.1 6.1, p=0.5).
Conclusion: Compared with HA-LDN, P-LDN results in greater mental healthrelated quality of life for donors without increasing donor risk, decreasing
physical health or adversely impacting allograft function.

899 SHOULD KIDNEY TRANSPLANTATION BE
CONSIDERED THE TREATMENT OF CHOICE FOR SYSTOLIC
HEART FAILURE IN PATIENTS WITH END STAGE RENAL
DISEASE?
R. Wali1, V. Mohanlal2, M. Weir1, S. Bartlett1
University of Maryland School of Medicine, 2Harbor Hospital, Baltimore,
MD USA
Among the spectrum of different cardiovascular disease events in dialysis
dependent patients, chronic heart failure (HF) is present in almost one-third
of patients and remains a common cause of morbidity and mortality. Due to
the lack of randomized studies in treatment of systolic heart failure (SHF) in
dialysis patients, at present these patients are treated on empirical basis without
established efficacy and safety.
Objective: Systolic heart failure (SHF) defined as symptom complex of heart
failure and left ventricular ejection fraction (LVEF) ¡Ü0.5 is associated with
an increased morbidity and mortality. To investigate mortality in dialysis
dependent patients with SHF after wait-listing while on dialysis and following
transplantation and to report on the effects of dialysis duration (co-morbidity)
on mortality after transplantation.
Design: Case-Control study of dialysis dependent patients that were waitlisted for kidney transplantation at University of Maryland Transplant Program
from March 2000 to December 2002. All patients aged over 18 years who had
established diagnosis of SHF were included in this analysis. Main outcome
measure was all cause mortality (ACM) and standardized mortality ratio
(SMR) against the dialysis and transplant patients without SHF. Results: A
total of 1700 patients were wait-listed during this period, and 438 patients had
history of more than one hospitalization for HF at the time of wait- listing. Fifty
seven percent (252/438) had SHF (LVEF ¡Ü0.5), 128/252 (51%) underwent
kidney transplantation; four patients were lost to follow-up during the first
three months, hence excluded from this analysis. Mean age was 58.8 years,
53% were blacks, 31% were females and 42% had diabetes mellitus. A total of
106 (42.7%) died during the mean follow-up of 3.3 years. ACM was 23.4% in
transplanted patient compared to 62.2% who continued to remain wait-listed
(log rank, p<0.0001). One-year mortality in transplanted patients was 14.5%,
and corresponding figures for those who remained on dialysis 42.4% (log
rank, p=0.003). Compared with dialysis and transplanted population without
SHF, the highest relative increase in mortality was in patients with LVEF <0.3
(Standardized mortality ratio 10.0 for SHF who underwent transplantation, 33.8
for those who continued on wait-list) and the lowest for general transplant and
dialysis population (2.4 and 6.8, respectively). The mean LVEF at the time of
transplant evaluation was 0.35, it increased to 0.49, and 0.53 at six and twelve
months, respectively, following transplantation. We conclude that mortality
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in dialysis patient with SHF is extremely high, and increases strongly with a
decrease in ejection fraction. Since kidney transplantation is associated with
increased longevity in dialysis population, this is more pronounced in those
with SHF. Hence, dialysis patients with SHF should be offered transplantation
at the time of diagnosis of SHF to prevent further deterioration in ejection
fraction. In addition, there should a public policy change to allow such patients
to have a priority score to prevent the prolonged wait-time as the best possible
chance of survival.

CONCURRENT ORAL SESSION 68: QUALITY OF LIFE
900 TRANSPLANTATION OF OLDER PATIENTS DOES
NOT IMPROVE SURVIVAL COMPARED WITH THOSE WAIT
LISTED. ANALYSIS OF 9,700 WAIT LISTED PATIENTS IN THE
UK
D. Ansell1, J. O;Neil2, R. Johnson2, D. Collett2, C. Dudley1
1
UK Renal Registry, 2UK Transplant
The survival benefit of receiving a kidney transplant over remaining on the
waiting list is often quoted from the American study by Wolfe. Recent USA
papers have also supported a survival benefit in the over 65s. In Europe survival
on dialysis is better than the USA across all age bands and survival benefit of
transplantation may not be as great. Using the same statistical methodology as
Wolfe, we have calculated the time to survival benefit by age group in the UK,
for patients receiving a deceased donor (DD) kidney transplantation over those
remaining on the waiting list.
Methods: 9739 adult patients listed for a DD first kidney only transplant
in the UK, 1995-2000, were analyzed. Patients were followed from date of
listing to Sept 2005 or death. Of the patients analysed, 6819 received a DD
transplant. Cox regression was used to analyze the combined effect of (age,
ethnicity, diagnosis, waiting time, on patient survival and to evaluate the time
to equal risk, equal survival, life years gained by transplantation for different
age groups. We also examined the effect of periods of suspension from the
waiting list (as a surrogate marker for comorbidity) on the survival benefit.
Results: Transplantation was of most benefit to younger patients with risk of
death at the time of transplant increasing with age, resulting in increasing time
to equal risk and equal survival with increasing age. In contrast to the USA,
UK patients aged over 65 years receiving a renal transplant did not show a
significant survival benefit.
[table1]

902 OLDER LIVING KIDNEY DONORS: SURGICAL
OUTCOME AND QUALITY OF LIFE

The survival benefit associated with receiving a DD transplant was similar for
whites, south Asians and Blacks with no reduced relative benefit seen in ethnic
minority groups.
Summary: In the UK patients aged over 65 years receiving a renal transplant
did not show a significant survival benefit. As well as age, the survival benefit
of transplantation varied by primary diagnosis and time spent suspended.

R. Minnee1, W. Bemelman1, B. Polle1, P. van Koperen1, S. ter Meulen2,
K.D. van der Pant2, F. Bemelman2, M. Idu1
1
Dept. of Surgery, Academic Medical Center, 2Dept. of Nephrology, Academic
Medical Center
Background: Older living donors remain controversial because of their
physiological decline in glomerular filtration rate and their increased
susceptibility of surgical complications. Little is known about the quality of life
(QoL) of this elderly group. The purpose of this study is to examine surgical
outcome and the QoL in older living donors.
Patients and Methods: All 105 consecutive living donors who underwent a
laparoscopic donor nephrectomy between June 2002 and February 2006 were
prospectively included in the study. Intra- and postoperative complications
were measured. QoL was recorded preoperatively and at several endpoints
postoperatively. Older donors were defined as fifty-five years and older.
Results: There were no significant differences in intra- and postoperative
complication rates and one year graft survival rate between both groups.
Elderly donors (N=34) had both a significant lower postoperative pain at rest
at day one compared to the younger group (p=0.019) as well as a lower total
pain score in the analysis for the whole follow-up period (p=0.002). Although
small solitary significant differences in Short Form 36 Health Survey (SF-36),
Multidimensional Fatigue Inventory-20 (MFI-20) and visual analogue scale
(VAS) measuring pain, between both groups were detected, in general QoL of
older donors was not different than of younger donors.
Conclusion: Although small solitary significant differences exist with respect to
pain, social functioning and mental health older donors have in general similar
surgical outcome and quality of life as compared to younger donors. There is
no need to exclude older donors in screening programmes for transplantation.

901 REMOVING FINANCIAL BARRIERS TO LIVING
ORGAN DONATION: BRITISH COLUMBIA PILOTS EXPENSE
REIMBURSEMENT

903 ESTABLISHING AN INDIGINOUS LIVE DONOR KIDNEY
TRANSPLANT PROGRAMME IN NIGERIA

Age band

N

18 – 34
35 – 44
45 – 54
55 – 64
65+

1956
2060
2464
2269
990

RR of death tx vs list
Equal survival
Equal risk (days)
** p< 0.001
(days)
0.3** (0.2-0.5)
0.4** (0.3-0.5)
0.5** (0.4-0.7)
0.7** (0.6-0.8)
0.9 (0.7-1.1)

34
126
158
186
190

82
279
362
480
581

Relative Risk
immediate
post tx
3.2
4.1
4.5
5.2
8.0

M.Y. Lorraine Gerard
Kidney Foundation of Canada, BC Branch
In British Columbia (BC), Canada (CAN) all organ transplantation surgery
occurs in Vancouver at one three transplant centres. The reality for living organ
donors is that regardless where they may live, if they are donating an organ to
a resident of BC, they must travel to Vancouver for their final assessments and
for their surgery. Most donors are advised to stay close by the transplant centre
for about a week following their hospital discharge; they are also advised to
refrain from returning to work for a period of up to eight weeks. The financial
impact to a living organ donor can be significant when travel, accommodation,
meals and loss of income are calculated. Both the Kidney Foundation of Canada
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(KFOC) and BC Transplant (BCT) believe that living organ donors should not
bear any costs associated with their donation.
In July 2006, the KFOC’s BC Branch and BCT launched the Living Organ
Donor Expense Reimbursement Program (LODERP) and as of the end of
February 2008 had reimbursed 140 donors or potential donors for their eligible
expenses. All donors are provided with the LODERP information through
their transplant social worker. Estimated expenses are pre-approved whenever
possible and donors complete an expense claim form which generates the
reimbursement cheque. Employer information is required to calculate the
potential loss of income. While the amount of reimbursement is higher for out
of province or out of country donors, the average reimbursement is far less than
was originally estimated.
Of the first 140 donors, 133 were kidney donors and 7 liver donors. The first
58 files have been closed with no further claims expected; these donors were
reimbursed between $56 – $3,719. Some travel costs, accommodation and
meal reimbursements were claimed by most donors. Only 29% claimed loss
of income and most claimed only a short wait period prior to their receipt of
government or employer benefits.
A study is currently underway to determine the impact of expense reimbursement
on living donation rates, donor perceptions about eligible expenses and
reimbursement rates and the potential for ongoing program funding. Healthcare
professionals involved in the program have already been interviewed and donor
interviews are scheduled to begin shortly.
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P. Lear1, S. Usman2
Southmead Hospital, 2Aminu Kano University Hospital
Three visits have been made to a west African teaching hospital to help set up
a locally provided kidney transplant service. The hospital (400 beds) provides
specialist surgical services to 25M, Moslem population. The city has a total
of 1200 hospital beds in three hospitals. Dialysis is not free and there are only
8 dialysis machines. During each visit two live donated kidney transplants
were performed with increasing independence of the local surgical team.
BTS/RA guidelines were followed for donor work up, where possible. Access
to CT (150Km away) was difficult due to the poor maintenance and renal
angiography was only available for two donors. Colour doppler ultrasound
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was offered as alternative imaging. 10 patient pairs were worked up to
preparation for surgery. Four patients were transplanted abroad. The visits
identified significant problems. Electricity power cuts are frequent (4 – 10
per day) and last 20 minutes or more. The theatre lights were old, had few
bulbs and could not focus. There is no back up power generator for the theatre
suite, but sunshine is plentiful. The air-conditioning is archaic. Anaesthetics
were given by nurses using Boyles machines, but two modern vaporisers
were bought for the final visit. Bore hole water in a large bucket and carbolic
soap was used for hand cleansing. The gowns and drapes were perforated
in many sites. The surgical instruments were crude but the sutures were of
European standard. Tissue typing is unreliable and written detail requires the
tests (including crossmatches) to be performed in Egypt. Cyclosporine is the
only ‘modern’ immunosuppressant , and levels are measured in another city:
the turnaround time is <24 hours. Luckily all the patients had BMIs of 20
– 22. There were no significant post-operative complications in donors or
recipients. They have all done well. Their care was funded by a generous
grant from the state governor and this covered all costs and drugs for 1 year
post transplant. Historical experience suggests that training African surgeons
in the UK will result in a skills drain, due to good opportunities in Britain
for career advancement. These options are now reduced by competition with
immigrant European medical staff. The available technology and facilities do
not prepare them for the limited resources back home and therefore this form
of training and mentorship is best provided by senior surgeons exporting
their expertise.

904 DUAL KIDNEY TRANSPLANTS FROM VERY OLD OR
VERY YOUNG DONORS; LONG TERM OUTCOMES AND
COMPLICATIONS
M.R. Laftavi1, R. Stephan1, R. Koholi2, A. Robino1, K. Paolini1, I.e Min1, M.
Dayton1, O. Pankewycz2
1
Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at
Buffalo
Introduction: The disparity between the supply of cadaveric donors and the
demand for organ transplants continues to grow steadily. In the USA, every
year 6700 patients (pts) die while waiting for an organ transplant. To increase
utilization of cadaveric organs we have expanded our acceptable criteria
to include very old (VO) or very young (VY) donors. For such donors we
transplanted both donor kidneys (Dual Transplant) into a single recipient. The
aim of this study is to evaluate the long term outcomes and complications of
dual kidney transplants from VO or VY donors.
Methods: From July 2001 to December 2006, 356 kidney (kd) transplants
were performed in our center. 22 pts received a dual ktx. 15 pts (mean age
68, range 60-78) received kds from VO (mean age 72, range 60-79) donors
and 7 pts (mean age 47, range 27-72) were transplanted from VY (mean age
17 months, range 2-36) donors. 74% of these kds were imported from outside
of our region after being deemed unacceptable by their local center due to the
quality (extreme age) of the donor.
Results: Three and 5 year pt survival rates were 95% and 82% respectively.
Three and 5 years graft (gft) survival rates (death censored) in the VO
donors were 94% and 94% and 85% and 68% in recipients of VY kidneys
respectively. Mean hospital stay was 6 days in both groups. One pt. (8%) in
the VY group and no pt. in the VO group experienced acute graft rejection.
In the VO group, one patient experience early graft thrombosis of both
kidneys, three pts experienced ureteral stenosis, one pt. developed urinary
leak and one pt developed a lymphocele after transplantation. Three gft
losses occurred in the VY gp: 1 due to lymphoma 11 mos post tx, 1 due
to HUS 7 mos post tx and one due to early thrombosis on POD 2. Four
pts experienced UTIs and 3 pts developed incisional subcutaneous seroma.
Mean serum creatinines for the entire group at 3 and 5 years were 1.23 and
1.38 mg/dl respectively. Mean eGFR at 3 and 5 years were 56.8 and 55.65
ml/min respectively.
Conclusion: Our study showed that using dual kidneys from cadaveric
donors that fall outside the general acceptance criteria for kidney donation
are a valuable resource and can maintain a good long term eGFR and provide
acceptable long term outcomes compared to conventional single kidney
transplant when properly placed.

CONCURRENT ORAL SESSION 69: XENOTRANSPLANTATION
– IMMUNOSUPPRESSION AND PERV
905 LOCAL EXPRESSION OF IMMUNOMODULATORY
MOLECULES INHIBITS XENOGENEIC RESPONSES IN VITRO
AND IN VIVO
D. Christiansen1, W. Mulley1, Y.Q. Li1, J. Wee1, N. Dodge1, F. Ierino1,2,
M. Sandrin1
1
University of Melbourne, 2Austin Health
Background: It is likely that transgenic expression of multiple
immunomodulatory molecules by a graft will be required to overcome cellmediated xenorejection. We examined the effects of local expression of several
immunomodulatory molecules by a porcine cell line (PIEC) on indirect murine
xenorejection responses in vitro and in vivo.
Methods: PIEC stable lines expressing IDO, CTLA4Ig, CD40Ig and IL10
as single immunomodulatory molecules, or expressing IDO in combination
with either of the others were generated. BALB/c mice were primed with
wild type PIEC, splenocytes were harvested for use as responder cells and
PIEC expressing immunomodulatory molecules were used as stimulators
in proliferation and cytokine assays. In vivo effects of modified PIEC were
examined in naïve and primed mice following cell transplantation under the
renal capsule or subcutaneously.
Results: Proliferation of primed BALB/c splenocytes was inhibited most
significantly by IDO compared with control cells (49%, p=0.02). In addition
both Th1 (interferon-gamma) and Th2 (interleukin-4 and interleukin-10)
cytokines were markedly inhibited in vitro by IDO expression. IL10 expressing
cells did not inhibit proliferation as potently (37%, p=0.03) whilst CD40Ig
lead to an increase in proliferative responses (59%, p=0.02). Co-expression of
CD40Ig, IL10 and CTLA4Ig with IDO resulted in further modest reductions in
proliferation compared with IDO expression alone. When transplanted under
the renal capsule of BALB/c mice, those grafts expressing IDO demonstrated
significantly lower levels of lymphocyte infiltration at days 7 and 14 than
control grafts and those expressing CD40Ig, CTLA4Ig or IL10 alone. Grafts
co-expressing IDO and a second molecule were no better protected than those
expressing IDO alone. Graft cell viability (PIECs) was reduced in some IDO
expressing grafts suggesting high levels of IDO expression may inhibit PIEC
viability, however, grafts co-expressing IDO-CTLA4Ig and IDO-IL10 were
not affected in this way. In the subcutaneous transplantation model, PIECCTLA4Ig grafts had significantly prolonged survival in naïve and primed
mice compared with controls. Survival was associated with an expansion of
CD4+25+ T-cells in naïve mice. Histology demonstrated significantly reduced
lymphocyte infiltration compared with controls.
Conclusion: IDO appears to be a potent molecule for protecting xenografts
from cell-mediated rejection responses activated via the indirect pathway. Coexpression of IDO with both CTLA4Ig and IL10 warrants further investigation.
Overall these findings support pursuing further studies, in larger animal models,
to determine whether increased IDO activity within the graft itself can attenuate
xenorejection responses.

906 TRANSDUCTION OF NEONATAL PORCINE ISLETS
BY AAV-CTLA-4-IG PROVIDED LOCAL PROTECTION OF
PORCINE ISLET XENOGRAFTS FROM HUMAN T-CELL
MEDIATED REJECTION IN VIVO
W. Wang, B. Ye, S. Liu, Z. Ye, Q. Tong, G. Zeng
Cell Transplant and Gene Therapy Center, 3rd Xiangya Hospital of Central
South University
Background: Cellular rejection of xenografts is predominantly mediated by
CD4+ T cells. CTLA-4 inhibits T-cell responses and regulates peripheral T-cell
tolerance. In this study we used AAV-CTLA-4-Ig transduced neonatal porcine
islet clusters (NPIs) to investigate whether CTLA-4-Ig produced by transfected
NPIs was able to provide local protection of porcine islet xenografts from
cellular rejection in a humanized mouse model.
Methods: NPIs were transduced with AAV-CTLA4-Ig-GFP (1013v.g/ml). The
transduction efficiency and CTLA4-Iggene and protein expression in NPIs
were assessed by fluorescent microscopy, RT-PCR and immunohistochemistry,
respectively. Static stimulation was performed to test transduced NPIs in vitro
function prior to transplantation. SCID mice were i.v. reconstituted with 1
x 108 human PBMC and made diabetes by strectozotocin. The humanized
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diabetic SCID mice were then transplanted with 2000 non-transduced or
CTLA-4-Ig transduced NPIs under left kidney capsule. After transplantation
levels of human IL-2, IFN-γ and TNF-α in peripheral blood were examined
by ELISA and xenograft survival was determined by BSL measurement and
histological analysis.
Results: AAV-CTLA-4-Ig transduced NPIs demonstrated high transduction
efficiency (>80%) and detectable expression of both CTLA-4-Ig mRNA and
protein with intact insulin secreting function. When transplanted to human
PBMC reconstituted diabetic SCID mice the CTLA-4-Ig transduced NPIs
normalized BSL 7 days after transplantation and remained intact with no
human cell infiltration for 59.1 ± 24.0 days after transplantation. In addition,
only low levels of human IL-2, IFN-γ and TNF-α were detected in these SCID
recipients. In contrast, humanized diabetic SCID recipients that received nontransduced NPIs remained hyperglycemic, showed high levels of human IL-2,
IFN-γ and TNF-α, and rejected their islet xenografts completely at day 12.7 ±
3.3 after transplantation. The NPI xenografts at rejecting time from these mice
were mainly infiltrated by human T cells.
Conclusion: This study demonstrates that AAV-CTLA-4-Ig was capable
of transducing NPIs efficiently thereby providing an approach to local
protection of porcine islet xenografts from human T-cell mediated cellular
rejection. It suggests a potential strategy for tolerance induction in clinical islet
xenotransplantation.

907 ADENOVIRUS-MEDIATED GENE EXPRESSION OF
HUMAN C-FLIPL PROTECTS PIG ISLETS AGAINST HUMAN
CD8+ CTL-MEDIATED CYTOTOXICITY
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M. Tanemura1, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1,
H. Komoda2, Y. Fumimoto2, T. Nishida1, Y. Sawa1,2, T. Ito1
1
Department of Surgery, Osaka University Graduate School of Medicine,
2
Medical Center for Translational Research, Osaka University Hospital
Objectives: Recent advantages in human allogenic islet transplantation have
established β-cell replacement therapy as a potentially viable treatment option
for individuals affected with Type 1 diabetes. However, the current shortage of
human islet donors limits the application of this treatment to the patient with
brittle Type 1 diabetes. Xenotransplantation of pig islets is a potential solution
to the shortage of human donor islets provided xengraft rejection is prevented.
Pig islets have precise advantages from glycobiological points, because they
lack α-gal epitopes. Therefore, short-term xenograft survival of these islets
may be successful by the reason of avoiding hyperacute rejection. However,
cell-mediated rejection, including NK cells, macrophages and CD8+ CTLs,
may represent another barrier preventing long-term xenograft survival. We
have demonstrated that human CD8+ CTLs display strong cytotoxicity against
pig islets. In this study, we assessed the cytoprotective effects of c-FLIPlong
(c-FLIPL), which are potent inhibitor of death receptor-mediated pro-apoptotic
signals, including Fas/FasL pathway, by overexpression of this molecule in
pig islets.
Materials and Methods: Pig islet isolation: Adult pig pancreata were
removed at slaughterhouse that handles young market weight pigs. Pig islets
were isolated by the Ricordi’s method. Construction of adenovirus vector:
The adenovirus vector, pAdex1CAwt regulated by CAG promoter, containing
the open reading frame of the human c-FLIPL gene was purchased from
RIKEN BioResource Center (Wako, Japan). The adenovirus was propagated
by infection of HEK-293 cells. Subsequently, adenovirus was purified on
a Cs/Tris gradient, separated into aliquots, and stored at -80 oC until use.
The “empty” control adenovirus that lack the human c-FLIPL insert, was
also amplified in a same manner as described above. Transduction of pig
islets by adenovirus vector: Freshly obtained adult pig islets represented
in 500μl serum free Medium-199 were exposed to adenovirus encoding
human c-FLIPL at a MOI of either 10 or 30 for 1hr at 37 oC. To identify the
expression of this molecule in pig islets, Western blot analysis was performed.
Generation of human CD8+ CTLs: PBMCs, freshly obtained from healthy
volunteers, were separated. These separated PBMCs were co-cultured for
14 days with the irradiated PEC monolayers in the presence of 50 U/ml
recombinant human IL-2. Subsequently, human CD8+ CTLs were positively
selected by magnetic beads and subjected to an in vitro cytotoxicity assay.
In vitro cytotoxicity assay and transplant studies: The cytotoxic activity of
human CD8+ CTLs against pig islets was assessed by a 51Cr release assay.
Furthermore, parental pig islets and transfected pig islets were transplanted
under kidney capsule of Lewis rats to prove the in vivo effectiveness of this
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molecule for the prolongation of pig islet xenograft survival. Subsequently,
immunohistochemical staining of insulin was performed to detect survived
pig islets.
Results: Results are summarized in the table.
Pig islets

□

Protein
Xenogfraft
% cytotoxicity by 51Cr
expression release assay (mean ± SD) survival in
in pig islets
transplant
studies
Adenovirus (Arbitaly
units by
Western
□
E/T
E/T
Day 3
blot)
ratio=50:1 ratio=25:1
□

Parental pig □ islets

11422

59.3 ± 15.9

47.6 ± 8.2

Rejected

MOCK islets 10 MOI
(control Ad 30 MOI
transfected
pig islets)

12532

64.0 ± 8.9

48.7 ± 14.8

Rejected

13531

59.0 ± 1.4

43.3 ± 5.5

N.D.

10 MOI

17105

30.5 ± 3.5

24.3 ± 1.6

+++ (Survived)

30 MOI

22276

23.6 ± 11.6

21.0 ± 11.0

N.D.

c-FLIPL
transfected
pig islets

N.D.: not done

Conclusion: Adenovirus-mediated gene expression of human c-FLIPL
effectively protected pig islets from human CD8+ CTL-mediated killing and
prolonged xenograft survival.

908 RAPAMYCIN PROMOTES THE ENRICHMENT OF
CD4+CD25HIFOXP3+ T REGULATORY CELLS FROM NAÏVE
CD4+ T CELLS OF BABOON THAT SUPPRESS ANTI PORCINE
XENOGENIC RESPONSE IN VITRO
M. Mohiuddin, A. Singh, K. Horvath
Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda MD, USA
The CD4+CD25+FoxP3+ regulatory T (Treg) cells play an important role in
regulating immune response. These Treg cells are present in peripheral blood
and lymphoid organs and have a high potential for immunotherapy in clinics.
Adoptive Cell transfer therapy using CD4+CD25+ cells has been shown to
prevent autoimmune diseases and has also induced transplant tolerance in
mice. Treg cells low frequency in peripheral blood will necessitate its ex-vivo
expansion to enable adaptive immunotherapy. Recently, it has been reported
that rapamycin, an immunosuppressive agent, inhibits T cell proliferation
while selectively increasing the number of Treg cells. Based on this additional
mode of action, rapamycin can be used to expand Treg cells for ex-vivo cellular
therapy in T-cell-mediated diseases and in transplantation. We have reported
the ex-vivo expansion of baboon Treg cells, using irradiated pig PBMC and
IL-2, and have demonstrated suppression of autologus CD4+CD25neg T-cell
proliferation in response to pig PBMCs. In present study, we have expanded
baboon CD4+ T cells in the presence or absence of rapamycin (0.1-10nM)
using irradiated pig PBMCs and IL-2 to enrich the regulatory T cells.
CD4+CD25+FoxP3+ Treg cells were increased up to two times in presence
of rapamycin as compared without rapamycin in cultures. However, a higher
dose of rapamycin (¡Ý10nM) considerably decreases the number of Treg cells.
Purified CD4+CD25+ Treg cells enriched from CD4+ cells in presence of
rapamycin were able to suppress the baboon anti-porcine xenogeneic immune
responses in vitro up to 90% at 1:1 ratio (T regulatory Cells: T effector cells)
and suppression ability exists even at 1:256 ratio whereas freshly isolated
natural Treg cells suppress only 70% at 1:1 and loose their suppressive
ability (>50%) at 1:16. We also examined the effect of rapamycin on cytokine
production in culture. The production of IL-4, IL-5, IL-6 and TNF-a was
increased in the culture supernatant containing rapamycin as compared to
cultures without rapamycin. However, IFN-g production and secretion was
significantly lower in rapamycin treated cells. Our results demonstrate that
the addition of rapamycin to the culture enrich the Treg phenotype and induce
functional regulatory T cells. This method may allow production of large
number of regulatory cells for the preclinical testing of Treg cell therapy in a
non human primate model.
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909 PERV FREE SWINE IN A DEFINED PATHOGEN FREE
HERD
W.E. Beschorner1,2, P.E. Kudlacek1, Y. Takeuchi3, T. Schieber4,
K.F. Lechtenberg2,4
1
Ximerex, Inc., Blair, NE USA, 2Swine Biomedical Resource Centre, LLC,
Oakland, NE USA, 3University London College, London, UK, 4Midwest
Veterinary Services, Inc., Oakland, NE USA
Objective: Xenotransplantation of pig tissues could provide functional
organs and tissues for many recipients. A major deterrent to using pig tissues,
however, is the presence of porcine endogenous retrovirus (PERV), defined as
three forms (A, B, C) in the porcine genome. Coculture studies with human
cells demonstrate the presence of the PERV within the human cells. While
no pathology or infection has yet been demonstrated in human recipients or
animal models, the possibility PERV could become a public health hazard from
PERV has led to extensive and prolonged suggested regulations by the FDA
for monitoring xenotransplant recipients. A herd of 22 defined pathogen free
(DPF) pigs was recently screened for PERV. One sow was found to be free of
all three forms of PERV. Thirteen additional pigs had only PERV-B. Based on
the relationship to the PERV free sow, 10 of the 13 have a 50 to 100% chance
to be heterozygous for PERV-B.
Materials and Methods: The DPF herd was developed for clinical
xenotransplantation over the past 20 years through selective breeding. The
pigs are maintained in isolation with extraordinary husbandry and regular
serological screening for more than 40 potential pathogens. Pigs from this
herd have been used in two clinical trials. PERV was not passed to human
cells in coculture tests. Blood from the 22 pigs was screened for PERV-A,
B, and C in the DNA by PCR using the appropriate probes for the envelope
gene. Additional studies included PCR for PERV gag-pol, and RT-PCR for
gag-pol RNA.
Results: One sow (22-10) was negative for PERV-A, B, and C and for gagpol DNA on repeated assessments. Thirteen additional pigs were PERV-A and
PERV-C negative, while being PERV-B positive. One pig was positive for
PERV-B and PERV-C. Based on the relationships of the pigs to sow 22-10, 10
pigs negative for PERV-A and PERV-C are believed to have a greater than 50%
probability of being heterozygous for PERV-B, including 7 pigs with a 100%
probability of being heterozygous for PERV-B.
Sow 22-10 was positive for RT-PCR when initially assessed for gag-pol RNA.
She had been bred with a boar that was positive for PERV-A and B. Four weeks
after farrowing the litter, her blood was RT-PCR negative.
Conclusion: Through selective breeding, it should be possible to eliminate
PERV from this herd of DPF pigs. The potential risk of a public health hazard
due to PERV would effectively be eliminated.

CONCURRENT ORAL SESSION 70: MTOR INHIBITION IN
CARDIOTHORACIC TRANSPLANTATION
910 BIOPSY-PROVEN ACUTE REJECTION AND RECURRENT
REJECTION IN DE NOVO CARDIAC TRANSPLANT
RECIPIENTS: SUPERIOR EFFICACY WITH EVEROLIMUS
H. Lehmkuhl1, G. Gerosa2, J. Arizon3, M. Viganó4, M-F. Mattei5, T. Dengler6,
Y. Li7, U. Livi8
1
Deutsches Herzzentrum Berlin, Berlin, Germany, 2Azienda Ospedaliera
di Padova – Università degli, Padova, Italy, 3Hospital Universitario Reina
Sofia, Córdoba, Spain, 4Policlinico S. Matteo – IRCCS Università degli Studi
di Pavia, Pavia, Italy;, 5CHU Hôpital de Brabois, Vandoeuvre les Nancy,
France, 6Univ.-Klinikum Heidelberg, Heidelberg, Germany, 7Novartis Pharma
AG, Basel, Switzerland, 8 Az. Osp. S. Maria della Misericordia, Udine, Italy
Introduction: The proliferation signal inhibitor (PSI) everolimus significantly
reduces the incidence of acute rejection and graft vasculopathy in cardiac
allograft recipients vs. azathioprine, due to its marked immunosuppressive and
anti-proliferative efficacy. Here we analyzed the immunosuppressive efficacy
of everolimus against the anti-metabolite MMF.
Methods: In a 12-month, multicenter, open-label trial, de novo heart transplant
patients were randomized to (i) everolimus (target trough level 3–8ng/mL)
with reduced-exposure cyclosporine or (ii) MMF 1500mg b.i.d with standardexposure cyclosporine. All patients received corticosteroids and the majority
received induction therapy. Primary endpoints were renal function and efficacy
(biopsy-proven acute rejection [BPAR] ISHLT ≥3A).

Results: The intent-to-treat population comprised 176 patients (92
everolimus, 84 MMF). Mean (SD) number of biopsies performed per
subject, considering time at risk, was identical between groups: 11.5 (5.2)
for everolimus and 11.2 (4.8) for MMF. 292 BPAR events were diagnosed
in the everolimus group vs. 339 events in the MMF cohort. Overall, 3.17
BPAR events/patient occurred in the everolimus arm, vs. 4.03 in the MMF
arm, a difference of 0.862 (P=0.037 [t-test]). Twenty-one (22.8%) patients
vs. 25 (29.8%) experienced BPAR ≥3A in the everolimus and MMF groups,
respectively (P=0.005 for non-inferiority), with 7/21 (33.3%) vs. 10/25
(40%) of these recipients suffering from recurrent rejection. The proportion
of subjects who developed recurrent rejection of any grade was significantly
lower for the concentration-controlled everolimus arm (62.0%) vs. MMF
(79.8%) (P=0.013, Fishers exact).
Conclusions: Everolimus-based immunosuppressive therapy in cardiac
transplant recipients offers excellent anti-rejection prophylaxis with numerically
fewer BPAR episodes, and statistically fewer recurrent BPAR events, compared
to MMF.

911 EFFICACY AND SAFETY OF EVEROLIMUS SWITCHING
IN HEART TRANSPLANT RECIPIENTS. A MULTICENTER
RETROSPECTIVE STUDY
N. Manito1, J.F. Delgado, M.G. Crespo, E. Roig, J.M.a Arizón, J. Segovia,
F. González, S. Mirabet, E. Lage
1
Hosp. Bellvitge, Hospitalet de Llobregat, Spain, 2Hosp. 12de Octubre,
Madrid, Spain, 3Hosp. Juan Canalejo, A Coruña, Spain, 4Hosp. Clínic,
Barcelona, Spain, 5Hosp. Reina Sofía, Córdoba, Spain, 6Hosp. Puerta de
Hierro, Madrid, Spain, 7Hosp. Marqués de Valdecilla, Santander, Spain, 8
Hosp. Santa Creu i Sant Pau, Barcelona, Spain, 9 Hosp. Virgen del Rocío,
Sevilla, Spain
Background: Everolimus (EVR), a proliferation signal inhibitor (PSI) with
immunosuppressive and anti-proliferative potential, significantly reduces the
risk of acute rejection and cardiac allograft vasculopathy (CAV) in cardiac
transplant recipients. EVR works synergistically with calcineurin inhibitors
(CNI) and thus allows the minimization of CNIs without compromising
efficacy.
Methods: The efficacy and safety of EVR has been assessed in this observational
retrospective study in 215 maintenance heart transplant recipients after 6 month
from EVR introduction in the Immunosuppressive regimen.
Results: The mean recipient age was 51.13 +/- 13,21; 84.7% males; mean time
since transplantation was 8.27¡Ó4.4 years. Main reasons for switching to EVR
were Nephrotoxicitiy due to CNIs (47%), CAV (33.5%) and Malignancies
(27.4%).
At baseline, 93.5% of patients were on CNI treatment, 70.6% of patients
were on Cyclosporine (CsA) – mean C0 121.55 ¡Ó 54.52 ng/ml – and 29.4%
on Tacrolimus (Tac) ¡V mean C0 8.07 ¡Ó 4.16 ng/ml -. Six months after the
initiation of EVR, only 57% of the patients were treated with CNI: 65.4% with
CsA – mean C0 84.16 ¡Ó 49.55 ng/ml – and 34. 6% with Tac – mean C0
5.35 ¡Ó 2.23 ng/ml -. Mean CsA C0 blood levels were reduced by 30.87%, 6
months after introduction of EVR. Mean EVR C0 blood levels at 1 week were
6.91¡Ó4.7 and at 6 months 5.54¡Ó2.4 ng/ml.
Renal function improved at 6 month post conversion to EVR (s-Creatinine:
Baseline, 1.79¡Ó0.77; Month 6, 1.68¡Ó0.97; p< 0.05). Blood pressure remained
stable during the observational period (Baseline 135.66 ¡Ó 21.08/83.77¡Ó12.15;
Month 6 136.64 ¡Ó 21.65/84.64¡Ó12.72 mmHg). Total cholesterol increased
from 179.47 ¡Ó 43.47 mg/dL to 188.19 ¡Ó 45.49 mg/dL p<0.05)
In 20.9% of the patients treatment with EVR was withdrawn due to: oedemas
40%, leucopoenia 13.3%, diahorrea 13.3%, dermatitis 11%, lung toxicity 6.6%
and other causes 15.8%. A total of 7 rejection episodes („d 3A ISHLT grade)
were recorded.
Conclusion: Switching immunosuppression to EVR is safe, with good
efficacy in maintenance heart transplant recipients. Renal function improved
significantly 6 months after conversion. EVR allows early reduction of CNI
exposure without significant loss of efficacy.

317

THURSDAY

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Oral Abstracts

912 IMMUNOSUPPRESSION WITH EVEROLIMUS IN
PEDIATRIC HEART TRANSPLANTATION
H. Lehmkuhl, S. Schubert, N. Hiemann, C. Knosalla, M. Dandel, M. Hübler,
F. Berger, R. Hetzer
Deutsches Herzzentrum Berlin
Introduction: Everolimus (Eve) prevents acute rejection in adult heart
transplant (HTx) recipients. Only limited data are available in pediatric patients.
Everolimus was introduced to the immunosuppressive protocol at our center in
June 2004. Therefore, we present the first study of pediatric heart transplant
patients with de novo use of cyclosporine A (CyA) in combination with Eve in
comparison to children receiving CyA in combination with either azathiprine
(AZA) or mycophenolate mofetil (MMF).
Methods: Pediatric HTx patients were analyzed with regard to acute rejection,
chronic graft vasculopathy (CAV) at 1 and 2 years after HTx, renal function,
PTLD, Ebstein-Barr-virus infaction, side-effects of their medication and
survival. Through level monitoring was performed using mass spectrometry.
Results: 11 patients with CyA-Aza (group A), 15 patients with CyA-Eve
(group B), 16 patients with CyA-MMF (group C) were investigated. Age,
gender, median age and body weight were not significantly different between
the groups. Median posttransplant time was 9.7, 2.9 and 5.4 years (groups A, B
respectively C). Rejection during the first year occurred in 30%, 0% (p=0.02)
and 49% of the patients (groups A, B respectively C). CAV at 12 months was
detected in 2/11 patients of group A and none of the other groups. CAV at 2
years was detected in 5/11, 1/15 and 6/16 (groups A, B respectively C). PTLD
occurred in 5/11, 1/15 and 2/16 patients (groups A, B respectively C) with
a median post-Tx manifestation after 3,6 years. In 3/15 patients, everolimus
was interupted during months 1 to 3 post-Tx because of wound healing
problems. Mean CyA-blood levels were comparable between the groups with
125 (96-247), 111 (78-218) and 148 (91-293) ng/ml at all post-HTx times.
Significant hyperlipemia was present in 3 patients with CyA-Eve. 2 children
on CyA-Eve were switched to CyA-MMF because of gastric problems and
insufficient target blood levels of both CyA and Eve (target Eve blood levels
3 – 8 ng/ml at all times).
Conclusions: Everolimus is safe and well tolerated in pediatric HTx patients,
with a lower incidence of acute rejection and CAV during the first 2 years
compared with patients receiving Azathioprine or MMF. The incidence of
PTLD is lower, if compared with CyA-Aza patients only. Wound healing
complications (20%) and enteral resorption problems were the major reasons
for interruption of everolimus use.

913 SAFETY AND EFFICACY OF STATIN THERAPY
IN PATIENTS SWITCHED FROM CYCLOSPORINE A TO
SIROLIMUS AFTER CARDIAC TRANSPLANTATION

THURSDAY

A. Zuckermann, A. Aliabadi, D. Dunkller, D. Zimpfer, S. Mahr, M. Grömmer,
M. Grimm
Dept. of Cardiothoracic Surgery, Medical University Vienna
Introduction: Statins are an established therapy against hyperlipidemia
after cardiac transplantation. However their interactions with CsA bear the
danger of rhabdomyolysis. Srl is a novel immunosuppressive drug that has
been used successfully in cardiac transplant patients. Yet it’s interactions
with statins are similar to CsA. Furthermore, Srl increases lipid blood
levels in transplant patients. The aim of the study was to evaluate the
safety and efficacy of statin therapy after switch from Csa- to Srl-based
immunosuppression.
Patients & Methods: 95 long-term patients were switched from Csa to Srl.
All patients received also MMF ± steroid therapy. Reasons for switch were
renal dysfunction (88%), graftvasculopathy (7%) and skin cancer (5%).
Average patient age at switch was 59.9±9.8 years and 92% were male. Patients
were switched 7.8±4.7 years after transplant. We retrospectively examined a
total period of 12 months before until 12 months after switch (total of 1088
patient-months). Safety evaluation consisted of regular measurements of
CK-levels as well as evaluation of incidence of rhabdomyolysis (CK>1000),
myositis (CK>500), CK elevation (>200)± myalgia. Moreover, hepatoxicity
(AST >100, ALT >140) was closely monitored. Efficacy analysis was
performed by serial blood lipid assessments (LDL, HDL, total cholesterol,
triglyzerides).
Results: 43(44%) of patients received atorvastatin, 28(29%) pravastatin
and 28 (27%) received other drugs or were converted from one statin to
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another or were therapy was paused. There were a total of 29 cases of CK
elevations (0.03 events/person-months (EPM). 19 cases were CK elevations
>200 without clinical signs (0.02 EPM), 9 cases of myositis (0.008EPM)
and 1 case of Rhabdomyolysis. Incidence of EPM was similar with between
atorvastatin (0.03) and pravastatin (0.02). Treatment consisted of reduction
or weaning of statins. Only four cases of hepatoxicity (0.003EPM) were
detected during follow-up. Most Lipid blood levels increased significantly
in the total patient population after switch (cholesterol: pre: 192.9±38.6 vs.
post:219.9±42.5, p<0.01; LDL: pre:107.9±35.6 vs. post:122.5±37.6, p<0.01;
Triglycerides: pre:178.3±88.2 vs. post:221.7±138.7, p<0.01). Only HDL
cholsterol remained unchanged (pre: 55.2±15.4 vs. post:56.3±13.3, n.s.).
Blood lipid levels increased significantly in patients no matter if they were
treated with either atorvastatin or pravastatin. Only in patients in whom statin
therapy was increased after switch (pre: 13.8±5mg vs. post 31.3±12.6mg;
p<0.01), blood lipid levels remained similar to pre-switch levels (cholesterol:
pre: 187.5±31.8 vs. post:221.6±59.8, p=0.07; LDL: pre:110.5±46.9 vs.
post:128.6±48.2,n.s.; Triglycerides: pre:175.4±82.2 vs. post:180.2±80.6,
n.s.).
Conclusion: Statin therapy after switch from Csa to Srl in long-term cardiac
transplant patients is safe. However, blood lipids increase significantly after the
switch unless statin therapy is increased. There were no differences in safety
and efficacy between atorvastatin and pravastatin.

914 IMPACT OF ACE-INHIBITOR AND ANGIOTENSIN
RECEPTOR BLOCKER THERAPY ON DEVELOPMENT OF
PROTEINURIA AFTER SWITCH TO SIROLIMUS IN CARDIAC
TRANSPLANT RECIPIENTS
A. Aliabadi, E. Pohanka, D. Dunkler, S. Mahr, M. Grömmer, E. Wolner,
M. Grimm, A. Zuckermann
Medical University of Vienna
Background: Switch to Srl due to renal impairment has been shown to be
effective and safe after cardiac transplantation. However there have been
reports of increased incidence of proteinuria (PU) after switch to Srl, associated
with a further decrease of renal function. ACEi/ARB are used to treat PU in the
non-transplant setting. The aim of this analysis was to examine if ACEi/ARB
therapy has an influence on development of PU after switch to Srl.
Patients & Methods: Sixty-one long-term cardiac transplant patients were
switched from CNI-based immunosuppression to Srl based IS 8.8±4.5 years
after transplantation. Concomitant IS consisted of MMF ±steroids. Pre- and
serial post-switch PU measurements were performed. Patients were divided
into two groups (ACEi/ARB group vs. conventional antihypertensive therapy
(CAT). Differences in development of PU and renal function were compared
between both groups.
Results: Fifty-five patients (89%) received anti-hypertensive medication. Of
these, 58% were treated with ACEi (n=32) and 4 (7%) patients received a
combination of ACEi/ARB. Overall PU increased significantly from pre-switch
0.13 g/d (range 0-5.7) to 0.23 (0-9.88) 24 months post switch (p=0.0024).
There was no difference in PU between the two groups before switch (ACEi/
ARB: 0.13 (0-5.7) vs. CAT: 0 (0-4.98; p=ns). After 24 months of follow-up
there was a significant difference between the two groups (ACEi/ARB: 0.18
(range 0-7.25) vs. CAT: 0.42 (0-9.88; p<0.05). Creatinin clearance (CC) was
similar before the switch in both groups (ACEi/ARB: 48.8ml/min (20.6-132.1)
vs. CAT: 40.6 ml/min (17.3-120.2; p=ns). After 24 months CC was better in the
ACEi/ARB group (58.8 ml/min (6.6-184.6)) compared to the CAT group (44.7
ml/min (10-84) p<0.05).
Conclusion: Development of proteinuria after switch to Srl can be significantly
reduced with the use of ACEi/ARB therapy. Antihypertensive therapy of
patients should be changed to ACEi/ARB before Srl is initiated.
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POSTER BOARD NUMBER P1 – 01
915 RECIPIENT-DERIVED ADJACENT ENDOTHELIAL
CELLS RECONSTRUCT THE STRUCTURE AND FUNCTION OF
REJECTED CORNEAL ALLOGRAFT

POSTER BOARD NUMBER P1 – 02
916 DONOR FACTORS AFFECTING CORNEAL
TRANSPLANTATION
D.J. Coster1, M. Philpott2, K.A. Williams1
1
Flinders University, 2Flinders Medical Centre
There can be no transplantation without donors and the status of the donor
tissue can affect graft survival. Australia is close to the top of the international
corneal donation table (fourth highest) with 48 corneal donations per year per
million population. The differences in donation rates and patterns of practice
around the world are striking and demand analysis if donation rates are to
increase. Examination of the pattern of eye banking practice in the Eye Bank
of South Australia (64 donations per year per million) reveals the complex
nature of the eye banking process. A large number of notifications yield a
small number of donors. Various factors account for the drop out. Once the
donations are procured, eye bank practices might affect the outcome of corneal
transplantation. However, donor age, cause of death, or the time in storage
(up to the accepted limits for a given corneal storage medium) do not affect
corneal graft survival. These findings have served to increase the size of the
potential donor pool, so that waiting times for corneal transplantation are
low and the majority of procedures are performed on an elective basis. With
an increased donor pool and more effective identification of donors, we are
rapidly approaching the point where there will be more donors than recipients.
This will present ethical issues not previously encountered.

LENTIVIRAL GENE TRANSFER TO THE RAT CORNEA

S.L. Brice1, L.A. Mortimer1, C. Tan2, D.S. Anson2, H.M. Brereton1 and
K.A.Williams1
1
Department of Ophthalmology, Flinders University, Adelaide Australia;
2
Department of Genetic Medicine, Women’s and Children’s Hospital,
Adelaide, Australia.
Background: The leading cause of human corneal graft failure is irreversible
rejection. The cornea is ideal for gene transfer because it can be treated ex vivo
prior to transplantation to prevent graft rejection. Lentiviral vectors provide
stable, long term gene expression and have minimal immunogenicity.
Aims: To explore the use of monogenic and multigenic lentiviral vectors in the
rat cornea as a method of gene delivery.
Methods: VSVG-pseudotyped HIV-1 lentiviral vectors were constructed. All
expression cassettes were driven by the simian virus type 40 early promoter.
Two monogenic lentiviral vectors were constructed. One such vector, LVCD4scFv, encoded a secreted protein, an anti-CD4 scFv antibody fragment
and the other LV-eYFP, encoded the intracellular reporter gene, enhanced
yellow fluorescence protein (eYFP). A multigenic lentiviral vector, LVCD4scFv_F2A_eYFP, was assembled which contained the anti-CD4 scFv
and eYFP. Genes were linked by a self-cleaving 2A sequence derived from a
picornavirus. A furin cleavage site was situated upstream of 2A for removal of
the remaining residues attached to the second protein in the cassette. The furin
2A (F2A) sequence enabled expression of both genes by a single promoter. To
monitor gene expression, HEK-293A cells and rat corneas were transduced
with the lentiviral vectors. Anti-CD4 scFv expression was measured using
flow cytometry on rat thymocytes and eYFP expression was assessed using
fluorescence microscopy.
Results: Anti-CD4 scFv expression analysis: HEK-293A cells were transduced
with the lentiviral vectors and flow cytometry on rat thymocytes was performed
to detect the anti-CD4 scFv in the culture supernatant. After 6 days in culture,
HEK-293A cells transduced with LV-CD4scFv and LV-CD4scFv_F2A_eYFP
had produced 17 ng/ml and 47 ng/ml of anti-CD4 scFv respectively. Rat
corneas were transduced with LV-CD4scFv_F2A_eYFP and organ cultured in
vitro. After 6 days in organ culture, 29 ng/ml of scFv was detected in the culture
supernatant. EYFP expression analysis: HEK-293A cells were transduced
with lentiviral vectors and eYFP expression was observed using fluorescence
microscopy. EYFP was expressed by 27% of the HEK-293A cells transduced
with LV-eYFP, whilst eYFP was expressed in 2% of HEK293A cells transduced
with LV-CD4scFv_F2A_eYFP. Rat corneas were transduced with lentiviral
vectors and organ cultured in vitro for up to 6 days. Fluorescence microscopy
revealed that LV-eYFP transduced corneas showed eYFP expression in 50%
of the corneal endothelium (n=3) and that one out of five rat corneas that were
transduced with LV-CD4scFv_F2A_eYFP showed detectable eYFP expression
in the corneal epithelium. No eYFP expression was detected in the endothelium
of any of the LV-CD4scFv_F2A_eYFP transduced corneas.
Conclusion: The presence of the F2A sequence did not affect the expression of
anti-CD4 scFv. Anti-CD4 scFv is the first gene in the expression cassette and
is situated before the F2A self-cleaving sequence. However, the F2A sequence
may be affecting expression of the second gene in the expression cassette,
because eYFP expression was lower in HEK-293A cells and rat corneas
transduced with LV-CD4scFv_F2A_eYFP compared with LV-eYFP.

POSTER BOARD NUMBER P1 – 04
918

DEMENTIA AS AN EXCLUSION TO TISSUE DONATION

A. Jack1, N. Nuttall2, L. Hirst3
1
Queensland Eye Bank, 2Queensland Eye Bank, 3Medical Director
Queensland Eye Bank, Queesland Eye Institute
The risk of transmission of potentially fatal infectious diseases from donor
to recipient via tissue transplantation cannot practically be eliminated, but
must be minimised. Careful screening of potential and actual donors is the
major available tool to achieve this. Screening usually involves investigation
of patient medical records and histories for not only diagnoses, but
risk factors or markers for disease as well. Dementia is one such marker
identified by tissue banks as it is one of the few indicators of CreutzfeldtJakob Disease (CJD). However, CJD accounts for only a very small and
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N.Q. Gong1, U. Pleyer2, T. Ritter3,4, E. Knop2, X.P. Chen1
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College,
Huazhong University of Science And Technology,Wuhan,China, 2Department
of Ophthalmology, Charit¨¦ ¨C University Medicine Berlin, Germany,
3Institute of Medical Immunology, Charit¨¦ ¨C University Medicine Berlin,
Germany, 4Regenerative Medicine Institute, National University of Ireland,
Galway, Ireland
Objective: To determine corneal allograft endothelial cell (EC) replacement
and the origin of the regenerative ECs in response to rejection, and to deduce
new strategy to clinical human corneal transplantation.
Methods: The rejection kinetics of untreated corneal allografts was observed
in a MHC class I/II disparate DA-Lewis combination. The EC integrity
of rejected allografts was compared with that of normal corneas. Then the
transparency recovery of the rejected grafts was analyzed. The recovering
grafts were collected at different time point after rejection for EC staining to
clarify the EC replacement and the origin of the regenerative cells. To elucidate
the influence of treatment on EC replacement, adenovirus-mediated nerve
growth factor (AdNGF) was transfected into the grafts before transplantation.
The rejection kinetics and EC integrity of the treated grafts were documented
after transplantation and compared with that of untreated cases.
Results: All corneal allografts without treatment were rejected and their ECs
shed. The rejected corneas recovered clear gradually. The re-constructed graft
endothelium was covered by recipient-derived ECs raised from the adjacent
host cornea but not from circulation-derived ECs. The AdNGF gene therapy
protected the grafts against transplanted-trauma, and altered the rejection
kinetics and the EC integrity.
Conclusions: Recipient-derived adjacent ECs reconstruct the structure and
function of rejected corneal allograft, different from other kind of grafts. EC
replacement represents a reparative response to injury rather than a constant
mechanism of tissue maintenance dependant on the tissue-specificity and the
milieu where the graft survives. Initiation of host-derived EC proliferation,
protection of graft ECs, inducing EC chimerism of graft and recipient, and
surgery approach improvement could contribute to the corneal allograft.
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decreasing percentage of dementia cases in Australia. Disease processes
that are believed to be non-infectious in origin, and therefore safe in a tissue
transplantation context, such as Alzheimer’s and vascular dementia, cause
the vast majority. In addition, dementia as a diagnosis is extremely common
in the potential donor population. The current screening strategy employed
by the Queensland Eye Bank (QEB) involves the exclusion from donation
of individuals in which there is any uncertainty about the aetiology of their
dementia, and this decision is often based on limited information. In 2007,
of the 4053 death notifications received by QEB, 3575 were not considered
suitable for donation, many because of dementia. This demonstrates that
QEB uses a conservative risk management procedure and while it approaches
a zero risk of CJD transmission, it also causes the exclusion of individuals to
a level which is out of proportion to the prevalence of CJD in the potential
donor population in Australia.

POSTER BOARD NUMBER P1 – 05
919 DONOR REGISTERS AND EYE DONATION; FUTURE
USE AND COMPARISON WITH ORGAN DONATION
P.W. Madden
Queensland Eye Institute, 41Annerley Road, South Brisbane. QLD 4101.
Australia.
Context: Many countries have registers to allow individuals to record their
intent or consent for organ donation following death and these usually also
have provision to include donation of eyes and tissues. There are many
more eye donors compared with organ donors e.g. 5 to 1 in Australia.
This means that Eye Banks are usually the largest users of registers, but
government campaigns to support registers often focus on organ donation
because of the chronic shortage of organs. Furthermore: campaigns may
not adequately address the concerns and fears of eye donors; the primary
age group may differ between eye and organ donation; and the method of
approach is usually by telephone which may require different use of the
register.
Objectives: To review the way in which the Australian Organ Donor Register
(AODR) and other registers are, 1) being used for potential eye donors and how this
differs from organ donation. 2) To assess how information from registers should
best be used with next of kin of potential eye donors. 3) How use of registers may
change with this sector and 4) how the use of registers could be improved.
Design: Statistics of the proportion of matches on organ donor registers for
those to be approached for eye donation was reviewed and this was compared
with similar available information on potential organ donors.
Results: National statistics were not readily available in Australia. The
percentage of potential donors who were registered on the AODR, where
the next of kin were approached, varied between Australian states. The
percentage relied upon the degree of deliberate selection for registrants e.g.
< 11% in Queensland were registered whereas in South Australia over 50%.
In the UK the proportion approached was almost one third and this was the
same as with organ donors, which suggests little selection. In Queensland
the percentage of registered potential donors over 65 years old was even
lower than for those of younger age, despite the majority of donors arising
from the older group. It was noted that surgeons often express a preference
for younger donors, even though there has been no demonstrated increase
in outcomes.
Conclusions: Registers can have value to aid consent, but the proportion of
those registered is generally low without deliberate selection. Some Eye Banks
already select heavily based on registration status. Selection is expected to
increase along with a rise in consent registration, especially with older donors.
Eye Banks should have written policy to: always check available registers of
notified cases; follow these cases in preference to non-registered cases; advise
donor families of the register record and the method of such interaction; review
statistics of the success of using the register. Use of registers for eye donation
differs to that of organ donation, but good management of both sectors will be
beneficial to all donation for transplantation.
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CONCURRENT ORAL SESSION 72: STEM CELLS
POSTER BOARD NUMBER P1 – 06
920 APPROACHES TO AVOIDING IMMUNE RESPONSES
TO REPEATED INJECTIONS OF ALLOGENEIC UMBILICAL
CORD TISSUE-DERIVED CELLS
B. Lutton1, P. Cho1, E. Hirsh1, K. Ferguson1, A. Teague1, N. Chi2,
S. Goldman2, D. Messina2, S. Popma2, D. Sachs1, C.A. Huang1
1
Massachusetts General Hospital, 2Centocor R&D Inc.
Cellular treatment for repairing diseased tissues is a promising clinical strategy.
Using porcine umbilical cord tissue-derived cells (pUTC) obtained from the
Massachusetts General Hospital swine leukocyte antigen (SLA) -defined
miniature pigs, we previously demonstrated that these cells can induce an
immune response under certain conditions. Although a single subcutaneous
injection of SLA-mismatched pUTC did not induce a detectable immune
response, when injected in an inflamed region, injected repeatedly in the same
region at one month intervals or stimulated with IFN-¦Ã prior to injection,
pUTC were immunogenic. Since clinical cellular repair strategies may involve
repeat dosing of cells to achieve a lasting therapeutic benefit, in the current
study we examined approaches to avoid an immune response to repeated
injections of SLA-mismatched pUTC. pUTC derived from umbilical cords
of SLAdd miniature swine were injected subcutaneously into SLA-disparate
animals. Two animals were injected twice, in a separate site, with one month
between injections. Four animals received two injections of pUTC in the same
site with the second doses at 3 month (n=2) and at 6 month (n=2) time intervals.
Four animals received immunosuppression prior to injections one month apart
consisting of either Prednisolone at the time of the second dose (n=2). or
Prednisolone plus Cyclosporine A at the time of both doses (n=2). To assess
for sensitization, animals were evaluated by flow cytometry for detection of
serum allo-antibody (SLAdd IgG) in vitro. Animals injected twice without
immunosuppression either in a separate site one month apart or in the same site
up to 6 months apart demonstrated rapid SLAdd IgG production within a week.
Delayed and decreased IgG production was observed in one of two animals that
received repeated injections of pUTC one month apart with Prednisolone at
the time of the second dose, while no SLAdd IgG could be detected in animals
receiving repeated injections of pUTC one month apart with Prednisolone
and Cyclosporine A administration at each dose. To assess for sensitization in
vivo, a pUTC haplotype-matched SLAdd skin graft was placed at least 30 days
following the second pUTC injection. Visual assessment and histopathological
analysis of grafts demonstrated an accelerated tempo of rejection in animals
that produced SLAdd IgG following the second dose of pUTC, while animals
that received Prednisolone and Cyclosporine A administration at each dose
showed rejection identical to na&iuml;ve control animals. In this study it was
confirmed that the primary injection does not induce a measurable immune
response as assessed by standard immunological methods. However, repeated
subcutaneous injection of pUTC into a disparate site or delayed administration
of pUTC in the same site for up to 6 months elicits a rapid secondary immune
response and accelerated graft rejection, suggesting that animals are sensitized
by the first injection. The observed immune responses were successfully
prevented by concurrent immunosuppression with each dose of pUTC. These
studies may provide important considerations and guidelines for clinical
protocols utilizing cellular therapies.

POSTER BOARD NUMBER P1 – 07
921 DONOR DERIVED MESENCHYMAL STEM CELLS AND
THEIR SUSCEPTIBILITY TO IMMUNOSUPPRESSANTS
M. Hoogduijn1, M. Crop1, S. Korevaar1, A. Peeters1, A. Balk2, L. Maat2,
W. Weimar1, C. Baan1
1
Dept of Internal Medicine, Erasmus Medical Center, 2Thorax Center,
Erasmus Medical Center
Introduction: Mesenchymal stem cells (MSC) are present at many body sites
and have tissue repair and immunosuppressive capacities. They have potential
for various therapeutic applications, such as repair of injured organs and
control of allograft rejection. We isolated MSC from human cardiac allografts
before and after transplantation and investigated their origin and susceptibility
to immunosuppressants.
Methods: MSC were expanded from atrium tissue before heart transplantation
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922 NOVEL APPROACH FOR IDENTIFICATION OF
KERATINOCYTE STEM CELLS
W.L. Olszewski1,2,3, E. Sinkiewicz-Darol1, A. Domaszewska1, M. Zaleska1,
1
Department of Surgical Research & Transplantology, Medical Research
Center, Polish Academy of Sciences, Warsaw, Poland 2Central Clinical
Hospital, Ministry of Internal Affairs, Warsaw, Poland 3The Norwegian
Radiumhospital- Rikshospitalet, Oslo, Norway
Rationale: We documented that human skin preserved in anhydrous
pulverized sodium chloride for months and transplanted to skin mice and
humans is taken by the recipient (Transplantation 2006; 81: 1583-1588).
The grafts were characterized by aggressive proliferation of keratinocytes
(KC) seen on immunohistochemical section stained for BrdU. Clinically
there was evident hyperkeratosis. We also noticed that dehydration in
sodium chloride stopped proliferation of keratinocytes, and subsequent
rehydration and transplantation brought about restarting of mitoses. This
model allowed to identify cells that first undergo mitosis after contact with
the recipient. The question arouse whether these cells might be the sporelike stem cells?
Materials & methods: Fragments of normal human leg skin harvested during
elective vascular surgery were preserved in anhydrous pulverized sodium
chloride. After 7 to 30 days they were rehydrated, the epidermis was separated
and KC were isolated. They were cultured for 7 and 21 days. Viability of
cultured KC was tested in Live/Dead Viability/Cytoxicity test. BrdU was added
to culture medium. Flow cytometry was used for characterization of mitotic
cells.
Results: The morphological shape of KC was totally preserved. Cells from
all 5 epidermal layers could be identified. Among the whole population single
large cells resembling by shape those from stratum spinosum and granulosum
revealed full enzymatic activity. No cells with other shape revealed this
property. Since in culture KC change their shape it was not possible to
objectively identify their site of origin. These cells slightly incorporated
BrdU whereas other KCs did not. Further identification of this population
is needed.
Conclusions: Preservation of KC in anhydrous pulverized sodium chloride
doesn’t stop some single cells’ to display enzymatic activity upon setting
in culture. The descibed method may help to identify KC of highest
capacity providing progenies probably belonging to the so called spore-like
stem cells.

POSTER BOARD NUMBER P1 – 09
923 INTERSTITIAL CELLS EXPRESSING THE CARDIAC
DIFFERENTIATION MARKER GATA4 INCREASE
FOLLOWING TRANSPLANTATION BUT DO NOT
CONTRIBUTE TO CARDIAC REGENERATION
A. Dedja1,2, T. Zaglia3, C. Candiotto3, S. Bracco3, E. Ancona1,2,4,
S. Schiaffino3,5, S. Ausoni3, E. Cozzi1,2,4
1Dept. of Surgical And Gastroenterological Sciences – University of Padua,
2CORIT, 3Dept. of Biomedical Sciences, 4Padua General Hospital, 5Venetian
Institute of Molecular Medicine
Introduction: The heart is a terminally differentiated organ and is unable
to regenerate after tissue damage. In the last years, several studies have
been performed to identify a suitable stem cell population for a cell-based
regenerative therapy. The cardiogenic properties of adult extra-cardiac and
cardiac stem cells have been considered, but there are still conflicting results
about their ability to provide an efficient de novo cardiogenesis. Recent studies
have demonstrated the possibility to convert adult cells of mesenchymal origin,
such as pericytes and skin fibroblasts, into differentiated specialized cells, such
as myoblasts, neurons and cardiomyocytes.
Material and Methods: Cardiac interstitial cells were studied both in the
native heart and in heterotopically transplanted cardiac allografts in the rat.
Sprague-Dawley wild type (n=35) and GFP+ transgenic rats (n=35) were used
as heart donors and recipients, respectively. In this model, previously used by
our group to study cardiac regeneration mediated by extra-cardiac circulating
progenitor cells, transplanted hearts undergo immunological rejection, ischemiareperfusion damage and progressive atrophy. Heart allografts were retrieved 15
(n=26) and 90 (n=9) days after surgery and tissue sections were analyzed by
immunofluorescence using specific antibodies for cell differentiation markers.
Results: In native hearts we identified a considerable population of GFP+
interstitial cells expressing GATA4 and MEF2C, two transcription factors
expressed in cardiomyocytes during development and adulthood. These cells
were predominantly cardiac fibroblasts and pericytes. In addition, a minor cell
population co-expressed GATA4 and the stem cell marker nestin (8 cells/section)
and may therefore represent an endogenous cardiac stem cell population.
The number of GATA4+ cells increased up to 5-fold in cardiac allografts, as
compared to normal hearts, but did not convert into mature cardiomyocytes.
The majority of GATA4+ cells proliferated as fibroblasts and myofibroblasts of
remodelling tissue. The number of GATA4+/nestin+ cells was also significantly
higher in the allografts (45 cells/section in 15 days allografts). However, we
never identified small GATA4+ interstitial cells co-expressing markers of
cardiac maturation, such as sarcomeric proteins. Interstitial cells, isolated from
both native hearts and cardiac allografts, were cultured and stimulated with
5-azacytidine, dexametasone, adult and embryonic cardiac tissue extracts. In
no case did we observe differentiation into cardiomyocytes or smooth muscle
cells.
Conclusion: Adult hearts home interstitial cells that already express
early markers of cardiac differentiation but are refractory to spontaneous
differentiation into cardiomyocytes. We aim at devising molecular strategies
to allow their conversion into specialized cardiac cells using cardioinductive
factors, as reported for fibroblasts of other sources.

POSTER BOARD NUMBER P1 – 10
924 EVALUATION OF AN HEPATOCYTE CELL LINE
DERIVED FRON HUMAN AMNION STEM CELL
I. Tabei1, T. Nakahara2, O. Ishiwata3, Y. Ishida1, A. Ohyama4,5, K. Yanaga1,
H. Ishikawa2,4
1Jikei University School of Medicine Deparment of Surgery, 2Nihon Dental
University Dept. of Embryology and Regenerative Medical Science, 3Ishiwata
Gynecological and Oncological Hospital, 4Nihon Dental University
Laboratory of Regenerative Medical Science, 5ALOKA CO.,LTD
Aim: Although liver transplantation has become the ultimate therapy for
hepatic failure patients, the lack of absolute donor organ has yet to be solved.
One solution is the development of transplantable hepatocytes. The metabolic
characteristics of hepatocytes (HEAC-2L cell) derived from the human amniotic
membranes is clarified. Also the cells were transplanted into chemically
induced liver failure rats (CILFR) to confirm function and adaptation. This
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and from endomyocardial biopsies taken up to 6 years after transplantation.
After expansion in culture, the MSC were phenotypically and functionally
examined. Pre-transplantation heart MSC were exposed in vitro to therapeutic
doses of the immunosuppressive drugs tacrolimus, MPA and rapamycin,
whose targets are expressed in MSC, and toxicity, apoptosis, proliferation,
differentiation and immunosuppressive characteristics examined.
Results I: MSC isolated from endomyocardial biopsies from the human
heart taken up to 6 years after transplantation were of donor origin; we found
no evidence for recipient MSC in endomyocardial biopsies. There was no
change in MSC phenotype, immunosuppressive capacity or cardiomyogenic
differentiation ability after heart transplantation, but MSC showed reduced
adipogenic and increased osteogenic differentiation capacity.
Results II: In culture, treatment of pre-transplantation MSC with therapeutic
concentrations of tacrolimus, MPA and rapamycin did not induce toxicity or
apoptosis. MSC proliferation was not affected by tacrolimus, but was strongly
inhibited by MPA and rapamycin. The immunosuppressants furthermore
affected MSC differentiation; tacrolimus and MPA reduced osteogenic
differentiation, whereas rapamycin induced adipogenic differentiation. Preincubation of MSC with the immunosuppressants had no effect on the capacity
of MSC to inhibit mixed lymphocyte reactions.
Conclusion: MSC of donor origin remain present in donor hearts at least 6
years after transplantation. Their functionality changed after transplantation,
possibly caused by effects of immunosuppressive medication. These results
demonstrate that heart-resident MSC are responsible for repair processes of the
heart for at least several years. Side effects of immunosuppressants may relate
to their effects on transplanted and patients’ own MSC.
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material was focused to solve ethical problems in producing hepatocyte from
human origin materials.
Methods: From human amniotic membrane of early embryo, colonies of
small spherical cell were cultured and collected as human amniotic membranestem cell (HEAC-2 cell). Further differentiation in a circumfusion apparatus
an hepatic cell line (HEAC-2L) was derived. HEAC-2L cells were cultured
in collagen type 1 to characterize. Also CILFR were produced by carbon
tetrachloride. HEAC-2L cells were transplanted into the spleen to observe the
blood serum levels of prothrombin time (PT). ammonium (Anm) and bilirubin
(TBil) as well as survival rate.
Results: HEAC-2L cell have contact inhibition, showed long term stable
phenotype. Within the collagen sponge 3-dimention culture the cells produced
albumin, a typical characteristic of an hepatocyte. Transplanted into the spleen
of CILFR, it improved PT, Anm and TBil. Also survival rate improved from
33 to 85%.
Conclusion: An albumin producing hepatocyte cell line was successfully
derived from human amniotic membrane. With less ethical problems compared
to ES cell, this resource may make an ideal material for artificial organ and cell
transplantation.

POSTER BOARD NUMBER P1 – 11
925 CHEMOKINE EXPRESSION IN INFARCTED
MYOCARDIUM AND COGNATE INTERACTION WITH
CHEMOKINE RECEPTORS EXPRESSED IN MESENCHYMAL
STEM CELLS
K. Atkinson1, K. Kollar1, G. Brooke1, C. Blair2, I.M. Ahmed2, M.P. Feneley2
Mater Medical Research Institute, 2Victor Chang Cardiac Research Institute
The ability of a therapeutic cell therapy to aid the recovery of heart muscle is of
great significance, as heart muscle shows poor recovery after acute myocardial
infarction and morbidity and death are common. Mesenchymal stem cells
(MSC) are adult-derived cells that have multipotent lineage potential and an
immuno-privileged status with therapeutic potential for repair of tissue injury.
They have been shown in preclinical studies to improve myocardial function
after infarction (1). Bone marrow-derived MSC migrate to sites of inflammation
in preference to bone marrow (3). However, the molecular mechanisms for
this are currently unknown (2, 3, 4). After myocardial ischaemia chemokines
including CXCL12 (stromal cell-derived factor [SDF-1]). macrophage
inflammatory protein (MIP) -1α/β, interleukin (IL) -8, CX3CL1 (fractalkine)
and CCL5 (RANTES) are released and their expression is up-regulated in the
heart (2).
We have utilised a murine myocardial infarction/reperfusion model and
extensively analysed chemokine expression by flow cytometry and qRT-PCR.
Expression of CXCL12, CCL4, CCL5, CCL8, CCL19, CCL25 and CCL27
was significantly up-regulated at 24 hours after myocardial infarction, thus
identifying an important time point for potential therapeutic intervention with
MSC. Furthermore, we have shown that MSC express surface and cytoplasmic
chemokine receptors for CXCR4 (the receptor for CXCL12) CCR1, CCR7,
CCR9, CCR10 and CCR11. Thus, MSC express specific chemokine receptors
for the up-regulated chemokines, suggesting binding pairs which could
be important in controlling preferential MSC migration and lodgement in
infarcted myocardium. Upon treatment with IFN-γ, MSC showed to have
up-regulated receptor expression of CXCR4, CCR1, CCR3 and CCR11 at
the mRNA level, proposing increased migration efficiency of MSC. MSC
migration will be tested further using peptide agonists and antagonists in vivo
and in vitro.
Another pathway which we postulate important in MSC migration is CD44
and its receptor hyaluronic acid (HA). We have shown that the expression of
CD44H isoform is expressed in MSC. CD44KO/GFP mice have been developed
and will be used to test further the CD44/HA pathway in MSC migration to
ischaemic myocardium.
1
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926 EXPRESSION OF MARKERS CHARACTERISTIC
FOR HUMAN KERATINOCYTE STEM CELLS UNDER THE
INFLUENCE OF HUMAN LYMPH AND SERUM
A. Domaszewska1, M. Zaleska1, W.L. Olszewski1,2,3
1
Department of Surgical Research & Transplantology, Medical
Research Center, Polish Academy of Sciences, Warsaw, Poland 2Dept. of
Transplantation Surgery, Central Clinical Hospital, Ministry of Internal
Affairs, Warsaw, Poland
3
The Norwegian Radiumhospital-Rikshospitalet, Oslo, Norway
Previous study performed in our department, using ELISA method, revealed a
large number of growth factors, cytokines and chemokines in the human lymph
fluid. Moreover, we found that leg skin expressed more cells with stem cells
antigens in comparison to other regions. Progenitor/stem cell populations of
epithelium are known to reside in the small-sized cell population. Small-sized
cells demonstrated the highest colony-forming efficiency, and a highest longterm proliferative potential. This observations prompted us to study the effect
of lymph on proliferation potential of human epidermal cells in vitro.
Aim: To study the effect of human peripheral lymph and serum on the number
of keratinocyte stem cells detected in the in vitro culture. The expression of
markers characteristic for human keratinocyte stem cells, colony-forming
efficiency, and long-term proliferative potential allow us to determine the
differences between observed cells populations.
Methods: Skin sections were stained using monoclonal antibodies against:
p63, CD29 (ß-integrin) as well as CD34 and were analyzed using confocal
microscopy and compared with healthy control. Keratinocytes were isolated
from three parts of human extermity of different proliferative potential: sole,
foot and groin. Cells were cultured in various concentrations of lymph and
serum (100%, 50%, 20% of lymph and the same dilutions of serum). Lymph
contained IL -1, IL- 6 TNF-α, KGF, EGF, VEGF, TIMP -1, TIMP-2 at levels
significantly higher levels than serum. Control cells culture were conducted in
medium RPMI with 5% fetal bovine serum. To identify cytokines responsible
for KC proliferation IL- 6, TNF -α, KGF and VEGF were blocked with
neutralizing antibodies. After 1 and 7 days of culture the phenotypes were
studied using monoclonal antibodies against CD34, p63 (stem cells). CD29
(transient daughter cells) using confocal microscopy. Furthermore, the colony
– forming cells were observed and proliferative potential was measured by
detection of the markers of differentiation Ki67 and PCNA in confocal
microscopy. Additionally BrdU incorporation rate was estimated after 7 days
of culture using flow cytometry analysis.
Results: Seven day lymph culture revealed increased number of p63 and CD29
positive cells compared with cells cultured in RPMI with 5% FCS. There were
no differences in expression of CD34 marker. Moreover, there was increased
number of dividing cells in cultures supplemented with lymph.
Colony-forming efficiency was the highest in cultures with 20% lymph
concentration.
Conclusion: Cells cultured in lymph expressed increased number of stem cells
markers and the proliferating rate was also increased. Lymph cytokines and
growth factors are participating in keratinocyte proliferation and are probably
responsible for high number of presumptive keratinocyte stem cells.

POSTER BOARD NUMBER P1 – 13
927 EFFECT OF AUTOLOGOUS BONE MARROW STEM
CELLS MOBILIZATION ON INFRACTED CARDIAC
FUNCTION
Z. Shen1, G. Yu2, Y. Hu3, M. He4, H. Huang5, Y. Yu6
1The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University, 4The First Affiniatied Hospital of Soochow University, 5The First
Affiniatied Hospital of Soochow University, 6The First Affiniatied Hospital of
Soochow University
Objectives: To study the effect of mobilization of autologous bone marrow
stem cells on cardiac function after myocardial infarction.
Methods: 20 healthy Taihu Meishan swines were divided into four groups
randomly to create the model of myocardial infarction. A group: control, B
group: injected G-CSF for 5 days 3 hours after myocardial infarction. C group:
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injected G-CSF for 5 days 1 week after myocardial infarction. D group: injected
G-CSF four weeks after myocardial infarction. Changes of indexs of cardiac
function were observed with MRI,Doppler£¬ VEGF and TGF-©¬ levels of
blood serum were detected in different period after mobilized.
Results: Compared with other groups£¬left ventricular function was
significantly improved in B group.
Conclusions: Mobilization of autologous bone marrow stem cells immediately
after myocardial infarction was effective£¬ feasible and safe to thearpy
ischemic heart disease.

928 TIME-WINDOW OF TRANSPLANTING AUTOLOGOUS
BM-MSCS TO TREAT MYOCARDIAL INFARCTION
Z. Shen1, S. Guo2, M. He3, Y. Chen4, P. Jiao5, H. Huang6
1The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University, 4The First Affiniatied Hospital of Soochow University, 5The First
Affiniatied Hospital of Soochow University, 6The First Affiniatied Hospital of
Soochow University
Background: Myocardial infarction (MI) remains a major healthcare problem.
Although modern medical therapy has improved its outcome, the mortality
and morbidity rates are still very high. Recently, stem cell therapies have been
proposed as an alternative for the treatment of MI on the basis of the damaged
cells’replacement or enhanced regeneration of vessels. The aims of this study
were to assess the consequence of the delay between injury and autologous bone
marrow mesenchymal stem cells (bMSC) transplantation on the cardiac function
in the swine model of MI and to explore the corresponding mechanism.
Methods: Thirty healthy Taihu Meishan swines were randomized into six groups
(n=5). Myocardial infarction models were then established by embolization
in the distal end of the left anterior descending branch (LAD) with a gelatin
sponge through cardiac catheter. 30 milliliter bone marrow was aspirated from
the postero-superior iliac spine and bMSCs were isolated and cultured for
transplantation. swine¡¯s hearts were acquired 8 weeks after transplantation,
Ultrasound cardiography, Magnetic resonance imaging and immunochemistry
were performed to detect the cardiac function and bMSCs engraftment
Results: Compared with the control group, indexes of cardiac function
including EF, LVEDD, LVESD, infracted size, vascular density and VEGF
levels were improved in experimental groups underwent bMSCs transplantation
2 and 4 weeks after MI, and the improvement was more obvious in the group
underwent transplantation 4 weeks after MI than that underwent transplantation
2 weeks after MI .There were more engraftment cells in the group underwent
transplantation 4 weeks after MI than other groups and no engraftment cells in
the group underwent transplantation 3 hours after MI.
Conclusions: The therapeutic effect of bone marrow mesenchymal stem cells
transplantation 4 weeks after MI is superior to that of 2 weeks and 3 hours after
MI, the results strongly suggest that the optimal time window for stem cell
therapy is after the early phase of the ischemic injury.
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929 BONE MARROW MONONUCLEAR CELL FRACTION
CAN RETARD/STABILIZE PROGRESSION OF CHRONIC
KIDNEY DISEASE IN RATS
M. Abbud-Filho1,2, H. Caldas1, I. Fernandes1, H. Ramalho1,2, M.A. Baptista1,
D. Braile1,
R. Kawasaki1, E. Bertelli1, E. Bertolli1
1
Medical School of Sao Jose do Rio Preto, 2Instituto de Urologia e Nefrologia
The therapeutic potential of adult stem cells in the treatment of chronic diseases
is becoming increasingly evident over the last few years. In the present study,
we sought to assess whether the infusion of bone marrow derived mononuclear
cells (MoSC) and mesenchymal cells (MSCs) could reduce/stabilize the rate of
progression of chronic renal failure (CRF) in rats.
Methods: We used the 5/6 renal mass reduction model to induce chronic renal
failure in male Wistar rats. Renal function was assessed by measurements of
serum creatinine (sCr). creatinine clearance (Clcr). and 24h proteinuria (PT24h)
at baseline, days 60 and 120 after surgery. MoSC and MSCs were obtained
from bone marrow aspirates and separated by the Ficoll-Hypaque method.

POSTER BOARD NUMBER P1 – 16
930 RENAL PROGENITER LIKE TUBULAR EPITHELIAL
CELLS CUTUED FROM INITIAL URINE INCLUDING THE
EXFOLIATED CELLS FROM TRANSPLANTED KIDNEYS
R. Hattori1, T. Yamamoto1, T. Sugaya2, E. Noiri3, M. Gotoh1
1Department of Urology, Nagoya University School of Medicine, 2Center for
Developmental Biology, Kobe, 3Department of Nephrology, Tokyo Univesity
School of Medicine
Object: Mitotic cells are known to appear in post -ischemic kidneys and
contribute to the recovery of renal function and structural restoration of
tubules. We successfully isolated these progenitor cells from the initial urine
of transplanted kidneys.
Material and Method: The urine sample including exfoliated cells was
collected from 14 living related kidney transplant patients. The initial urine
during 60 minutes after vascular declamping was washed within DEM-10%
FBS and was cultured in DEMN/F-12-10% FBS with supernatant of mouse
menchymal cell culture and some supplements.
Results: The primary culture of tubules with high proliferation was successful in
11 out of 14 patients (78.6%).&#12288; The cultured cells showed cobblestone
appearance and characteristics of proximal or distal tubular cells and collecting
duct cells. And the cultured cells expressed Pax2 or Pax8 as immature cell
markers relating the kidney development by Western blot method. Flow
cytometry analysis showed the high rate (0.33%) of side population cells.
Sixty-eight percent of the primary culture cells showed dome formation after
2 week culture.
Conclusion: A high percentage of progenitor tubular epithelial cells were
cultured from the initial urine in transplanted kidneys. These exfoliated cells
possess characteristic features as progenitor like epithelial tubular cells of selfrenewal, multipotent differentiation and high rate of side population cells. The
cultured cells may possibly contribute to the future development of cell therapy
for renal regeneration.

POSTER BOARD NUMBER P1 – 17
931 MAGNETIC RESONANCE INFLUENCED (MRI) OVARIAN
ORGAN FREEZING AND TRANSPLANT FOR IATROGENIC
STERILITY OF CANCER THERAPY.
M. Mihara, S. Tainosho
Department of Plastic And Reconstructive Surgery, University of Tokyo
Background: Chemotherapy and radiotherapy are essential for treatment of
cancer in children and young adults, but these methods often result in testicular
failure or reduced ovarian function. One problem in this area is that the ovum
is structurally weak, compared with sperm, and the pregnancy rate after frozen
ovum storage is very low. Ovarian preservation might be performed before
cancer therapy and, in particular, may offer hope for preservation of fertility in
young women with cancer.
Method: We hypothesize that this is due to instability of blood flow, and to examine
this possibility we have focused on the vascular system and cryopreservation of
5 rats and 2 cynomolgus monkey with MRI, magnetic resonance influenced,
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After a 12 to 14 day culture period, 1.5x106 MSCs and the same amount of
MoSC were injected intra renal parenchyma in the remanent kidney of rats with
CRF at day of surgery.
Results: In the control group, at day 120, the results were sCr= 1.31 ± 0.5mg/
dl, Clcr= 0.64±0.35ml/min, and PT24h= 140 ± 57.7mg/24h. Rats treated with
MoSC at day 120 had sCr=0.81 ± 0.20mg/dl, Clcr= 1.05 ± 0.26ml/min, and
PT24h= 61 ± 46.5mg/24h, while rats injected with MSC had sCr=0.95 ±
0.1mg/dl, Clcr= 0.68 ±0.24ml/min, and PT24h=119.2 ± 50.0mg/24h. Analysis
of the progression to CRF did show that treatment significantly reduced the rate
of decline in Clcr after treatment with MoSc (Control: – 0.0049 ± 0.0024ml/
min/day vs MSC: -0.0013 ± 0.0017ml/min/day vs MoSC: +0.0002 ± 0.0016ml/
min/day; p= 0.017). PT24h tended to be lower in treated groups. Histological
scores of chronic damage were not different but distinct patterns of chronic
lesions were observed in treated rats.
Conclusion: Our results did show that progression of CRF in rats could be slowed/
stabilized by intra renal parenchyma injection of MoSC. A trend toward reduction
in the progression rate of CRF was also observed with injection of MSC.
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whole organ freezing method. We are examining the potential of this technology
in transplantation and cryopreservation of the ovary.
Result: We attempted transplantation of a vascularized ovary following a certain
period of cryopreservation. The endocrine function of the ovary and the potential
for pregnancy were permanently re-acquired following these procedure.
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932 SYNCHRONOUS PROLIFERATION PROFILE OF THE
NAIVE LIVERS AND ENGINEERED LIVER TISSUES UNDER
THE KIDNEY CAPSULE
K. Ohashi1, T. Kohei2, T. Yokoyama3, H. Kuge3, A. Yoshioka2, Y. Nakajima3,
T. Okano1
1
Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s
Medical Univeristy, 2Department of Pediatrics, Nara Medical University,
3
Department of Surgery, Nara Medical University
Background: Liver tissue engineering is a new and emerging field in which a
functional liver system is created in vivo using isolated hepatocytes. Our group
has recently been established an approach to create liver tissues under the kidney
capsule that undergo active regenerative growth similar to that observed with
the naive liver. It would be essential to elucidate the proliferation profile of the
engineered liver tissues because such information could assess the functional
and structural importance as a liver. For this reason, this study was undertaken
with mice that had been engineered liver tissues under the kidney capsule to
investigate the start, peak and termination of hepatocyte proliferation of the
naive livers and engineered liver tissues.
Method: Donor hepatocytes were isolated from transgenic transgenic mice
bearing the human alpha 1-antitrypsin (hAAT) reporter gene (provided by Dr.
Bumgardner, Ohio State Univ.). Two million hepatocytes were re-suspended
in Basement Membrane Matrix gel (Matrigel, rich with laminin and collagen
type IV). By transplanting the hepatocyte suspension under the kidney capsule
space, liver tissues were created to the wild type mice (syngenic to the donor).
At day 70 of the experiments, 2/3 partial hepatectomy (PH) was performed
to provide liver regeneration stimulus. For the analyses of cell proliferation,
we administered 5-bromo-2-deoxyuridine (BrdU) for a period of 24 hours
at different timing after hepatectomy (from day 0 to day 5). In each mouse,
the BrdU labeling indices (LI) of the naive livers and the engineered liver
tissues were histologically determined separately by counting a total of 1000
hepatocytes.
Results: All the recipient mice receiving hepatocyte transplantation showed
persistent serum hAAT levels by the time of PH, confirming that engineered
liver tissues under the kidney capsule had been functionally stable. By the
assessment of BrdU LI of the hepatocytes in the naive livers, the proliferation
started at the 1st post-PH 24-hour period, peaked at the 2nd period, and
terminated at the 5th period. In the engineered livers, the hepatocyte
proliferation started at the 2nd post-PH 24-hour period, peaked at 3rd period,
and terminated at 6th period. The peak BrdU LI values of the naive livers and
engineered livers were 56.2 } 6.3% and 54.3 } 7.5%, respectively (statistically
insignificant).
Conclusion: Although there was a 24-hour delay in the proliferation profile
of the engineered liver tissues, the present studies clearly showed that the
naive livers and the engineered livers carried out synchronous regenerative
process after hepatectomy. This data highlighted the functional and structural
importance of the engineered tissues that support entire regenerative
process. In all, the present studies demonstrate that liver tissues with high
regenerative capacity at similar levels to the naive liver can be engineered
at a heterologous site.
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933 GENERATION OF HUMANIZED ANIMAL LIVERS USING
STEM CELL TRANSPLANT
J. Locke, Z. Sun, D. Warren, T. Sheets, H. Holzer, M. Shamblott,
R. Montgomery, A. Cameron
Johns Hopkin University
Objective: Animal organs engineered to be chimeric for human cells have
the potential to contribute significantly to new developments in the field of
transplant surgery, including the study of human specific diseases such as
hepatitis C, treatment for in-born errors of metabolism, and development of
a renewable source of transplantable organs via modified xenotransplantation.
We sought to use human stem cells (HSC) to populate livers in mice and rats
for applications in transplant surgery.
Methods: SCID mice and rats underwent liver injury with either carbon
tetrachloride exposure or partial (50%) hepatectomy. Animals received
intrasplenic injection of 5 x 105 fluorescently labeled HSCs. Spleen and liver
were assessed at 2, 7, 15, and 30 days after transplant for the presence of HSCs,
and for markers of human hepatocyte differentiation.
Results: HSCs migrate to and engraft in animal liver after splenic injection
only under conditions of hepatic injury. HSCs are detectable at 2-days and are
in abundance at 1-week after transplant (Figure 1A&B). HSCs persist in rodent
liver long-term (> 1 month). and once engrafted in animal liver differentiate
into functional human hepatocytes as assessed by the production of human
α-FP and human albumin (Figure 1C).
Conclusions: We developed a novel animal model in which hepatic injury
and HSC transplantation leads to the generation of chimeric humanized
animal organs. We are currently using our model to study molecules capable
of preventing hepatits C re-infection after liver transplantation, and as an
alternative to whole organ transplantation for treatment of in-born errors of
metabolism.
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934 CHANGE TO A CALCINEURIN-INHIBITOR FREE
IMMUNSUPPRESSION – SAFETY AND EFFECTS TO BLOOD
PRESSURE PROFILE
A-E. Lison1, V. Eilts1, F.A. Zantvoort1, H.-G. Wullstein1, G.F. Hillebrand2,
J. Gossmann3, H-G. Kachel3, E. Jochum4, H-G. Hartmann5
1
Klinikum-Bremen-Mitte, 2Klinikum Großhadern, Universität München, 3KfH
Nierenzentrum Frankfurt, 4Krankenhaus der Barmherzigen Brüder Trier,
5
Gemeinschaftspraxis Innere Med/Nephrologie Saarbrücken
Introduction: Calcineurininhibitors must be seen critical caused to the
big spectrum of side effects. But they are still used as basic therapy in
organtransplantation.
However, there are possible influences to cardiovascular morbidity and mortality
and at least to the survival of graft and patient. To improve the long-term
survival of graft and recipient a randomised, prospectively, two arms study was
done in five german centers. Patients after kidney transpantation got a different
immunsuppressive treatment, calcineurin-inhibitor based immunsuppression
and mycophenolate mofetil (MMF) based immunsuppression. These two arms
were compared.
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935 EARLY STEROID WITHDRAWAL (DAY 6) AFTER RENAL
TRANSPLANTATION, LONG-TERM RESULTS
M. Gallichio, O. Elbahloul, J. Jaber, D. Conti
Albany Medical College
Maintenance steroid therapy is associated with significant morbidity. We report
our long-term experience with early (day 6) steroid withdrawal (SW) after
renal transplantation. Between 3/03 and 9/05, 125 patients enrolled in a SW
protocol. Immunotherapy for all recipients included: Thymoglobulin (rATG)
induction on days 1-5 (mean total dose 4.3 mg/kg). Prograf dosed to achieve
a 12-hour trough level of 6- 10ng/ml until 3 months when the daily dose was
decreased by 50% and targeted to a level of 2- 3ng/ml thereafter, Cellcept
500 mg BID and prednisone on days 0-6 (total dose 1000 mg). Rapamune
therapy was initiated on day 6, concomitant with prednisone withdrawal, at
3 mg/day (no loading dose) and dosed to target a 24-hour trough level of
7- 10 ng/ml. Recipient demographics were as follows: mean age 46 years,
male 63%, Caucasian 82%, deceased- donor 70%, primary transplant 92%,
diabetes 38%.
The mean follow-up at 12/1/07 is 43 months (27-57). Patient and allograft
survival at one-year was 100% and 98% respectively. Ten patients (8%)
have suffered an acute rejection episode. 90% developed within 2 weeks of
transplantation. Long-term actual patient and allograft survival, as of 12/1/07, is
96% and 89% respectively. Mortalities were due to cardiovascular events (n=4,
at 20, 21, 30 and 40 months). and infection (n=1 at 49 months). Non-mortality
etiologies of graft loss included; chronic nephropathy in 4 patients at 20, 22,
26 and 30 months (3 directly related to non-compliance). recurrent disease in 2
recipients at 11 and 35 months, infection in 2 patients at 11 and 20 months and
cardiogenic shock in 1 recipient at 11 months. Mean serum creatinine levels at
6 (n=125). 12 (n=122). 24 (n=116). 36 (n=87) and 48 (n=40) months were 1.5,
1.5, 1.5, 1.4, and 1.5 mg/dl respectively.
This immunosuppressive regimen provides effective immunotherapy in renal
transplant recipients. The rate of acute rejection was only 8% and one-year
graft survival was 98%. Furthermore, 3 ½ year patient and renal allograft
survival is excellent and serum creatinine levels have remained stable longterm. Induction with rATG followed by maintenance Rapamune, Prograf and
Cellcept therapy safely provides for the early discontinuation of steroids after
renal transplantation.

POSTER BOARD NUMBER P1 – 22
936 RAPID DISCONTINUATION OF CORTICOSTEROID IN
KIDNEY TRANSPLANTATION: A JAPANESE SINGLE CENTER
EXPERIENCE
N. Shimoda, K. Morita, K. Hotta, K. Nonomura
Hokkaido University Hospital, Department of Urology
Introduction: Corticosteroid is commonly used as an immunosuppressive
therapy after renal transplantation, while it is associated with considerable side
effects including hypertension, hyperlipidemia, diabetes mellitus, osteopenia,
cataracta and cosmetic disfigurement. The aim of this study is to investigate the
effects of rapid discontinuation of corticosteroid on graft outcome and posttransplant complications.
Methods: Twenty five patients underwent live donor kidney transplantation
under induction immunosuppression with basiliximab, tacrolimus and
mycophenolate mofetil. In addition, the patients were administered
methylprednisolone for 3 days (250mg on day0, 125mg on day1, 2 in adults and
125mg on day0, 40mg on day1, 2 in children). Corticosteroid was completely
discontinued after 3 POD. Exclusion criteria were: ABO incompatible, presensitized transplantation and retrasnplantation. Mean follow-up period was
26 months (range: 2-41). Study end points were to determine graft survival
and function, acute rejection and complications. All allograft rejections were
diagnosed by persistent elevation of serum creatinine and were confirmed by
allograft biopsy.
Results: There was no graft loss during follow-up periods. A total of 6
(24.0%) patients had experienced an acute rejection (Banff grade 1b: one
patient, Borderline Change: 5 patients). All rejections could be treated by
methylprednisolone pulse therapy and/or deoxyspergualin administration,
following continuous oral methylprednisolone administration. Mean serum
creatinine and creatinine clearance at 1 year after transplantation were 1.15 mg/
dl and 52.3ml/min/1.73m2. One patient with severe leukocytopenia resumed
oral methylprednisolone due to cessation of mycophenolate mofetil.
Conclusions: Renal transplantation utilizing a rapid discontinuation of
corticosteroid protocol appears to be safe and effective, without increasing the
risk of acute rejection or graft loss in short-time post-transplant period.

POSTER BOARD NUMBER P1 – 23
937 IMPACT OF STEROID WITHDRAWAL ON THE IMMUNE
RESPONSE OF RENAL TRANSPLANT RECIPIENTS
R. Weimer1, S. Deisz1, H. Dietrich1, F. Renner1, C. Süsal2, S. Kamali-Ernst3,
W. Ernst4, W. Padberg5, G. Opelz2
1
Department of Internal Medicine, University of Giessen, 2Institute of
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar,
4
Dialysis Center, Langenselbold, 5Department of Surgery, University of
Giessen
Superior kidney graft outcome has been described after steroid withdrawal in a
large prospective study within the CTS. To analyze effects of steroid withdrawal
on clinically relevant immune parameters of Th1/Th2, B cell and monocyte
responses, we assessed CD4 helper activity, sCD30, immunoglobulin-secreting
cell formation, neopterin and intracellular cytokine production in a prospective
randomized study of 84 renal transplant recipients (CsA/Aza, CsA/MMF,
Tacr/Aza; steroid tapering not earlier than 6 months posttransplant) at 2 years
posttransplant.
Two-year graft function was better in patients off steroids (creatinine clearance:
62±7 versus 47±4 ml/min, p=0.03). Lower steroid dosage was significantly
related to lower systolic and diastolic blood pressure (p<0.0005 and p=0.002,
respectively). and lower serum lipid levels (cholesterol, p=0.002; triglycerides,
p<0.0005).
Multivariate logistic regression showed that steroid-free therapy was
independently associated with enhanced T cell proliferative capacity (CD69
expression; p=0.004) and CD4 cell IL-4 responses (p=0.07; p=0.03, univariate
analysis). which was previously shown to predict a low risk of acute rejection.
Enhanced CD4 cell IL-2 production on steroid-free treatment (p=0.02,
univariate analysis) could not be confirmed in the multivariate analysis.
Logistic regression, however, confirmed a downregulated IL-2R (CD25;
p=0.02, univariate; p=0.01; logistic regression) and CD40 expression on B
cells (p=0.03, univariate and logistic regression) in steroid-free patients. MMF
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Methods: Primary aim were safety, tolerability as well as calcineurininhibitor associated side effects like hypertension. Corticosteroides were
permitted in both arms. Patients became randomised (1: 2 ratio CNI: MMF).
Patients had to be transplanted at least one year ago, graft-function had to be
stable (serum-creatinine >2,5mg/dl) at the beginning of the study. 59 KTX
were included.
Results: There were no more rejections neither in the early nor in longer follow
up after change to calcineurin-inhibitor free treatment. No graft was lost since
beginning of the study. Kidney transplanted patients with MMF based treatment
achieved stable graft-function with improved serum-kreatinine (mean: 1,66 to
1,51 mg/dl) and creatinine-clearance.
Significant improvement of mean arterial blood pressure (MAD) was found
from day 84 on. So it was the case with a surrogat parameter consisting of
MAD and the daily dose of antihypertensive medication.
Conclusion: This study shows, that change to calcineurin-inhibitor free
immunsuppression is possible and safe without increased risk for graft and
patient. A positive effect on blood pressure profile could be acertained in patients
treated with MMF only. Establishment of an easy transposable and regulated
switching-sheme with closmeshed controls in the early phase stood the test
during the study for both, patients and physcian. The present results indicate
that there is a possibility for our patients to change immunsuppressive regime
and to reduce CNI associated side effects. So, CNI associated cardiovascular
and nephrotoxic outcomes can possibly be prevented. Traditional regimes
ought to be substituted by an individual, well matched medication for each
patient. This interesting therapeutic alternative with MMF ought to be used as
early as possible.
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compared to Aza showed only a minor effect on B cell CD25 downregulation
(p=0.05; logistic regression). Steroid-free treatment had no impact on monocyte
activation, CD4 helper activity, sCD30 levels and immunoglobulin-secreting
cell formation.
Compared to healthy controls, only patients on steroid-free immunosuppression
showed decreased IL-2R (CD25) and CD40 expression on B cells (p<0.0005
and p=0.005, respectively) together with decreased IL-6R expression on
monocytes (p=0.02). Patients on steroid treatment, however, exhibited even
higher IL-2R (CD25) expression on CD4 cells than healthy controls (p=0.02).
Our data show that steroid-free maintenance immunosuppression enhances
T cell proliferation but provides graft protective immunological effects via
suppression of IL-2R (CD25) and CD40 expression, and enhanced CD4 cell
IL-4 production. Upregulation of IL-2R and the B cell costimulatory pathway
by steroids might result in B cell responses against the graft during periods of
infection-induced IL-2 release.

POSTER BOARD NUMBER P1 – 24
938 SUCCESSFUL STEROID WITHDRAWAL AFTER LONGTERM ADMINSTRATION IN RENAL TRANSPLANT PATIENTS
N. Amada, H. Kikuchi, I. Haga, T. Fukumori, A. Sato, T. Sato
Sendai Shakaihoken Hospital
Objective: Prolonged administration of steroids is associated with
numerous side effects, which may have a negative impact on long-term
patient and graft survival in renal transplant recipients. These days, steroids
can be reduced or even withdrawn in these patients under treatment of other
concomitant prominent immunosuppressive agents such as calcineurin
inhibitors or anti-metabolites. This study evaluated the effect of steroid
withdrawal after long-term administration on stable functioning renal
transplant recipients.
Patients and Methods: Between April 2000 and October 2006, steroid
administration was safely withdrawn in 47 patients with stable graft function
for more than 1 year after renal transplantation. The period between renal
transplantation and steroid withdrawal varied from 12 to 234 months (median:
114 months). Steroids were withdrawn over a period of more than 2 months
from 5 mg prednisolone-equivalent daily maintenance dose either by reducing
the dose or every other day administration. We followed their clinical course
after steroid withdrawal for 16 to 94 months (median: 51 months). We also
investigated the current steroid doses of all 274 outpatients who had undergone
renal transplantation in our hospital between July 1977 and October 2006. Since
some patients receive methylprednisolone, it was converted to prednisoloneequivalent doses.
Results: Twelve patients out of 47 had to resume steroid administration
at 3 to 55 months (median: 13.5 months) after withdrawal, 10 (21%)
due to acute rejection with/without recurrent glomerulonephritis, 1 due
to treatment for subacute thyroiditis, and the other due to accompanying
cessation of azathioprine for ovarian cancer, respectively. Thirty-five
patients have maintained stable graft function for 12 to 90 months (median:
49 months) after steroid withdrawal confirmed by follow-up. Laboratory
data shows that the serum total cholesterol and HDL-C levels decreased
significantly; however, there were no changes in body weight, systemic
blood pressure, triglycerides or HbA1c level after steroid withdrawal. At
present, only one patient of the 47 had to resume hemodialysis due to
the chronic deterioration of the renal graft function at 262 months after
transplantation, including a period of 31 months of steroid withdrawal and
35 months of steroid re-administration thereafter. Current steroid doses
(prednisolone-equivalent) of the 274 outpatients at our hospital are as
follows: The number of patients for withdrawn, < 5 mg, 5mg, > 5 to 10
mg, and > 10mg per day is 38, 20, 155, 57, and 4, respectively. Although
steroid doses are administered per body and are not adjusted by body
weight, 213 out of 294 (77.7%) are maintaining stable renal graft functions
with ≤ 5 mg prednisolone per day.
Conclusion: Although further follow-up is necessary to evaluate the
effectiveness to prevent serious adverse events, steroids may be safely
withdrawn in renal transplant patients with stable graft functions, even after
long-term administration, and it is effective to decrease serum cholesterol
levels.
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POSTER BOARD NUMBER P1 – 25
939 THE FUNCTION OF TRANSPLANTED KIDNEY
AFTER EIGHT YEARS OF TACROLIMUS (PROGRAF)
IMMUNOSUPPRESSION WITH DISCONTINUATION OF
CORTICOIDS
M. Kuman, P. Studenik, V. Mejzlik, J. Ondrasek, P. Nemec
Center of Cardivascular Surgery And Transplantation
Introduction: The first 18 patients treated with Prograf at our centre were
subject to long-term follow-up.
Patient group: 18 patients, of whom 5 women and 13 men, after the first
kidney transplant, recieved immunosuppressant treatment with tacrolimus,
corticoids and, on randomised basis, either with azathioprine from 1999 to 2001
(9 patients, i.e. 50%). or with mycophenolate (9 patients, i.e. 50%). Corticoid
treatment was discontinued at four months post-transplant. Patients were
monitored for eight years. Two of the monitored patients were later transferred
from Prograf to Neoral (cyclosporine A) due to neurotoxicity. 16 patients, i.e.
89%, continued on Prograf therapy. All patients with functioning graft at year
eight were on Prograf and corticoidfree.
Objective: To establish long-term patient survival and quality of function of
the kidney graft.
Results: 15 patients completed the eight-year follow up – the survival rate
being 83.3%. Three patients with functional graft died before the end of the
follow up period – 16.6% mortality
(lx colorectal carcinoma, lx Grawitz tumor, lx lung embolia ). Kidney grafts
ceased to function and haemodialysis treatment was renewed in two patients
only, i.e. in 11.1%. (both IgA nephropathy). 13 kidney grafts, i.e. 72%, were
functional after eight years of transplant. Rejection episodes (all in first
year) were also documented (7 episodes on the total, i.e. 39%, of which
5 corticosensitive, i.e. 28%, and 2 corticoresistant, i.e. 11%, ). More in the
branch using azathioprine (corticosensitive 33% of all patients in the branch,
corticoresistant 22%). The quality of graft function was assessed by trends in
values of creatininemia (at year eight 132.8 ± 31.7 umol/l) and glomerular
filtration (at year eight 1.275 ± 0.37 ml/s ).
Conclusion: The follow up has shown that immunosuppression with
Prograf, with early discontinuation of corticoid treatment, in combination
with mycophenolate mophetil brings from the long-term point of view
very good survival and transplanted kidney function results and benefits
transplant patients.

POSTER BOARD NUMBER P1 – 26
940 THE EMERGENCY OF NEPHROTOXICITY: A
REVERSIBLE ADVERSE REACTION OF IVIG THERAPY IN
RENAL TRANSPLANT PATIENTS
C. Callender, C. Thompson, A. Hernandez
Howard University
Background: Steroid avoidance and reduced dose calcineurine inhibition
regimens have been possible by the use of potent induction agents. At Howard
University Hospital Transplant Center, we have adopted the use of Campath1H induction which allows us to use low dose Prograf, MMF and steroid
avoidance as maintenance immunosuppression.
Since May 2003, we have performed 46 kidney transplants following this
regimen. During this period we have recognized an increased rate of acute
antibody mediated rejection of 6.5%. (It was zero previously). In this
setting, the initial therapy used at our center is IVIG. Blood Urea nitrogen
and serum creatinine elevation following IVIG administration is a well
recognized adverse event that has been described in the literature when
IVIG is used to treat autoimmune diseases. The package insert reports a
10% incidence of this adverse reaction. This presentation however, in the
face of an already impaired renal function in renal transplantation is rarely
addressed.
Objective: We describe three cases of IVIG administration followed by
a reversible elevation of BUN and Serum creatinine as high as 88 and 8.8,
respectively.
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Clinical Course:

POSTER BOARD NUMBER P1 – 28
942 TOXIC TACROLIMUS BLOOD LEVELS WITH
RIFAMPICIN ADMINSTRATION IN A RENAL TRANSPLANT
RECIPIENT

POSTER BOARD NUMBER P1 – 27
941 STEROID-FREE MAINTENANCE THERAPY – NOT
APPROPRIATE FOR EVERYONE, BUT WORTHWILE FOR
MANY
K. Lopau, F. Swoboda, C. Wanner
University of Wuerzburg
Introduction: Steroid free immunosuppression (IS) after kidney transplantation
(KTx) is still considered critical due to reports of increased rejection episodes
(AR) after steroid weaning. Since 1998 we have performed routinely
prednisolone withdrawal after 12 months without AR >Banff °Ia under the
coverage of MMF combined with tacrolimus or cyclosporin-microemulsion.
Herein we report our experience with this late steroid-tapering comparing
outcomes and side effects of patients on three different immunosuppressive
regimens.
Methods: All patients gave informed consent for data collection aand analysis
before extraction of their follow-up data out of the centre-database. We analyzed
57 pts receiving Tac+MMF and compared them to 84 pts with CsA+MMF and
94 pts receiving CsA+MMF+prednisolone (Pred). All pts were transplanted
between 1998 and 2004 and had at least 12 months graft survival. Pts received
Tac only in case of a second transplant, PRA´s >30% or severe CsA-related
side effects.
Results: All groups were comparable concernig most donor and recepient
variables (age, gender, diabetes, type and duration of dialysis, living-donation,
donor age, CIT etc). CsA-pts had less HLA-mismatches compared to both other
groups. S-creatinine at discharge was comparable. After 5.8 yrs of follow-up
S-Crea was significantly lower at 12 and 24 months in both steroid-free groups,
thereafter differences diminished. S-Crea at year 5 was 2.0 vs 2.0 vs 1.9 mg/
dl (Tac vs CsA vs steroids). The same pattern was observed when using eGFR
as surrogate. Graft loss occured in 4 vs 5 vs 14%. Biopsy-proven AR were less
frequent in CsA-pts compared to both other groups (13.1 vs 21.1 vs 29.8%).
Incidences of major cardiovascular events and death did not differ significantly.
There was a trend for post transplant diabetes appearing more often in the
steroid group (14 vs 13 vs 18%). Blood pressure as well as infections and
cancer incidences were comparable between groups.
Conclusion: Tailored immunosuppression employing a calcineurin inhibitor
together with MMF in pts without higher-graded AR is highly successful
with very low incidences of graft loss in the long term. This approach leads
to similar graft function compared with pts on steroids and low incidences of
cardiovascular events, diabetes, infections and death after 5 years. However
these results have to be confirmed in larger studies with longer follow-up.

POSTER BOARD NUMBER P1 – 29
943 ANALYSIS OF ALLOSPECIFIC T CELLS IN
KIDNEY TRANSPLANT PATIENTS ON VARIOUS
IMMUNOSUPPRESSIVE PROTOCOLS
M. Gasser1, I. Tsaur1, B. Avilez1, J. Lutz2, M. Grimm1, K. Lopau3, A. Thiede1,
U. Heemann2, A. Chandraker4, A.M. Waaga-Gasser1
1
University of Wuerzburg, Department of Surgery I, 2University of Munich,
rechts der Isar, Department of Nephrology, 3University of Wuerzburg,
Department of Nephrology, 4Transplantation Center, Brigham and Women’s
Hospital, Harvard Medical School
Chronic allograft dysfunction remains a major clinical problem in organ
transplantation. Morphologically it is characterized by changes suggestive
of an alloantibody mediated mechanism such as glomerulopathy and
vasculopathy or by non-specific changes such as interstitial fibrosis and tubular
atrophy. Alloantigen dependent as well as -independent factors contribute to
the pathogenesis of these changes. In this study we analysed allospecific T
cells from the peripheral blood of kidney transplant patients under different
immunosuppressive protocols with or without chronic allograft dysfunction.
107 renal allograft recipients of our renal transplant clinic were screened
at least six months after transplantation. All patients were on a calcineurinbased immunosuppressive protocol consisting of cyclosporine (CsA) /
mycophenolate mofetil (MMF) /steroid, tacrolimus (Tac) /mycophenolate
mofetil (MMF) /steroid, or CsA/steroid. Patients had to be mismatched for one
or more of the five canditate HLA-DR antigens for which synthetic peptides
were available (DR1, DR2, DR3, DR4, and DR7). Patients with biopsy proven
chronic allograft nephropathy (CAN) with an elevated serum creatinine level
of ≥ 1.6 mg/dl were compared with patients with stable allograft function
(serum creatinine <1.6 mg/dl. T cell lines were generated from peripheral
blood lymphocytes of renal transplant recipients against donor-derived HLADR peptides presented by self APC. T cell lines generated from patients
with CAN produced significantly IFN-γ, while those generated from stable
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Discussion: It has been theorized that the use of Sucrose or Maltose in the
IVIG solution are the culprits for the development of a “Manitol like osmotic
nephrosis”. In these cases we use Carimune ® NF, Nanofiltered, human IVIG
and reconstituted with D5W or Normal Saline, avoiding the use of the sugars
considered implicated in the tubular toxicity.
Conclusion: Rather than the osmolality of the IVIG, we consider that other
mechanisms may also be implicated in the etiology of these events. We
consider these adverse events completely reversible and they are apparently
dose dependent.

M. Halim, T. Ai-Otaibi, M. Nampoory, T. Said, P. Nair
Hamed Alessa Organ Transplantation Center
Induction of the hepatic cytochrome P450-3A4 system and intestinal
P-glycoprotein is an unavoidable consequence of rifampicin (Rif) administration
which require substantial increase in tacrolimus (Tac) dose when given
concurrently. Chronic diarrhea is known to precipitate Tac toxicity irrespective
of it’s cause in renal transplant recipients.
A 28 years old lady had a second renal transplant when she was 15 years old which
is functioning well. She was maintained on prednisolone, azathioprine and Tac.
She has close relatives infected with tuberculosis. She was started on isoniazide
prophylaxis and Tac was maintained on therapeutic levels (5-7 ng/ml).
She developed intermittent fever, night sweating, nausea, vomiting, chronic
diarrhea, and loss of weight. Detailed investigations didn’t show definite
diagnosis. Mantoux skin test was border-line positive and antituberculous
drugs including Rif were started 7 months later. She continued to
have significant symptoms requiring multiple drugs to be controlled
(omeprazole, antacids, metoclopramide, loperamide, acetaminophen and
ondasetron hydrochloride). During the first four months of antituberculous
treatment she had very high Tac blood levels requiring successive dose
reduction from 7mg/day up to 0.5mg every other day with rise of serum
creatinine from 100 to 140umol/l. Tac was changed to low dose sirolimus
and renal function gradually improved to its baseline while still on Rif
treatment.
We conclude that chronic diarrhea may cause toxic Tac blood levels even
in presence of Rif, this would be possibly due to its significant enzyme
inhibitory effect.
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patients produced IL-10 associated with a low proliferation index in response
to donor-derived mismatched HLA-DR allopeptide in vitro. Moreover,
significantly more CD4+CD25+Foxp3+ T cells were found in stable patients
on Tac and MMF as compared to patients on CsA and MMF. Interestingly,
higher gene expression profiles of CD4, CD25, CTLA-4, Foxp3, and IL-10
were observed in those patients. Taken together a Th1 (IFN-γ) alloimmune
response is deleterious and promotes chronic graft damage, while a Th2
(IL-10) response seems to be associated with a lower incidence of chronic
allograft nephropathy. An immunosuppression based on tac and MMF seems
to favour CD4+CD25+Foxp3+ T cells and to allow long-term engraftment
with stable renal function.

POSTER BOARD NUMBER P1 – 30
944 PHARMACODYNAMIC CHARACTARISTICS OF RENAL
TRANSPLANT RESIPIENTS
T. Kuzuya1, T. Kobayashi2, A. Katayama2, Y. Miwa2, T. Nagasaka3,
K. Uchida3, K. Yamada1
1
Department of Hospital Pharmacy, Nagoya University School of Medicine,
2
Deaprtment of Applied Immunology, Nagoya University Gradually School of
Medicine, 3Kidney Center, Nagoya Daini Red Cross Hopital
Aims: Inhibition of cytokine production is the main immunosuppressive
effect of carcineurin inhibitor, which is widely used in organ transplantation.
Pharmacodynamic (PD) assay can directly determine the drug efficacy and is
considered to be a realistic monitoring method of providing a more appropriate
dosing regimen to each patient. However, such monitoring is not available
at present. The purpose of this study was to elucidate the value of PD assay
and to assess its clinical applicability. We examined an inhibitory effect of
cyclosporine (CsA) on mitogen-induced cytokine mRNA expression in whole
blood and evaluated the extent of inter-individual variations of PD and clinical
efficacy for PD index.
Methods: Written informed consent was obtained from renal transplant
patients who participate in this study (n=50). The study protocol was approved
by the Ethics Committee of the Nagoya University Hospital. Five different
concentration mixtures of CsA (0-800 ng/ml) were added to whole blood from
pre-transplant patients before taking immunosuppressive drugs to determine
the relationship between CsA concentrations and the inhibitory response of
cytokine (IL-2, 4, 6, 10, INF-g, TGF-b, TNF-a) production. The degree of
inhibition observed at the different CsA concentrations was estimated by a
50% inhibitory concentration (IC50) which was determined by variable slope,
non-linear regression curve fitting. Quantification of each cytokine mRNA
expression in the presence of PMA and Ca ionophore was performed by reverse
transcription polymerase chain. An endogenous housekeeping gene (b-actin)
was also quantified to normalize the results and comparative threshold cycle
method was used to quantify samples.
Results: Cytokine mRNA expressions except for TGF-b were declined in
relation to an increase in CsA and the relationships could describe by the
inhibitory sigmoid Emax model. Each value of IC50 of cytokine showed high
specificity among the patients (IL-2, 4, 6, 10, INF-g, TNF-a; 156 } 54, 166 }
68, 165 } 64, 147 } 42, 191 } 68, 164 } 46 mg/mL) and correlated with those
of other cytokines. Acute rejection and cytomegalovirus infection occurred in
9 and 10 patients, respectively. There are no relationship between the value of
IC50 of each cytokine and these events.
Conclusion: PD assay using cytokine mRNA semi-quantification in whole
blood is a simple, reliable and reproducible method of evaluating the individual
variations in drug sensitivity. After transplantation, as patients are generally
treated with multiple immunosuppressive agents, only single drug monitoring
of sensitivity would be insufficient to provide the information on optimal dosage
in consideration of overall patient condition. However, there is a possibility
that such PD assay as a sensitivity test can be used for design of dosing regimen
and/or drug selection before transplantation.
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945 THE EFFECT OF GRAPEFRUIT JUICE ON
SERUM CONCENTRATION AND BIOAVAILABILITY OF
CYCLOSPORINE IN KIDNEY TRANSPLANT PATIENTS
A. Mehrsai, G. Pourmand, M. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: To estimate the effects of concurrent administration of grapefruit
juice, a known inhibitor of drug metabolism, on pharmacokinetics of
cyclosporine in transplant patients.
Materials: This is a randomized crossover clinical study performed in the renal
transplant unit. On two study occasions 15 kidney transplant patients who had
been transplanted at least 6 months before and had stable kidney function
and using cyclosporine, received either 250cc grapefruit juice or water at the
time of drug ingestion and 2 hours later. Systolic and diastolic blood pressure,
serum concentration of cyclosporine, 3 and 11.5 hours after its ingestion were
measured. Bioavailability was calculated using specific formula.
Results: Grapefruit juice increased peak (778.01 +- 241.5 vs. 595.3 +146.47 p<0.005) and least (280.9 +- 78.5 vs. 234.6 +- 45.5 p< 0.01) serum
concentration of cyclosporine and its bioavailability (15.6 +- 8.2 vs. 11.1 +- 3.6
p< 0.05). Changes in blood pressure were not significant.
Conclusions: Grapefruit juice inhibits the metabolism of cyclosporine, which
may be explained by the inhibition of cytochrome P450 enzymes in the gut wall
and to a lesser extent by inhibition of these enzymes in the liver. This interaction is
of potential clinical importance in terms of mechanism, side effects and dosing.

POSTER BOARD NUMBER P1 – 32
946 SIROLIMUS DOSE REQUIREMENT AND
THE SIGNIFICANCE OF CYP3A5,MDR1 GENETIC
POLYMORPHISMS
T.K. Saha1, S. Durugkar1, G.K. Gadikota1, K. Ramanjaneyulu1, V. Kiran2,
Q. Hasan2
1
Dept. of Nephrology, Kamineni Hospitals, 2Dept. of Genetics, Kamineni
Hospitals
Introduction: Dose requirement of various immunosupressants varies in
different races. Present study was done to determine the dose required to
achieve therapeutic trough level of Sirolimus and to find out any correlation
between CYP3A5, MDR1 genetic polymorphisms with the dose requirement
of Sirolimus in Indians.
Methods: Sirolimus was started in chronic allograft nephropathy patients.
Sirolimus treated patient’s trough level was done to monitor target level. Target
trough level was set as 3-8ng/ml for patients treated with Prenisolone, CNI/MMF
& Sirolimus, whereas it was set as 6-12ng/ml if patients were on 2 drugs with
Prednisolone & Sirolimus. Sirolimus level monitoring was done by Microparticle
Enzyme immuno assay technique. The target trough level for Sirolimus and the
dose (daily dose and dose per kg body weight) required achieving trough level of
Sirolimus were noted. Serum creatinine and other biochemical and hematological
parameters were noted.CYP3A5 and MDR1 genetic polymorphism was done
in patients willing to undergo these tests. Different mutations of these genes
were compared with the dose requirements of patients. Patients on Diltiazem,
Rifampicin and Fluconazole were excluded from the study.
Results: Total 39 patients treated with Sirolimus were studied. 30 patients
received three immunosuppressants. Their average dose requirement was
1.99±0.51mg/day, 0.031mg/kg/day; the average level achieved was 5.29±2.41ng/
ml and the average creatinine was 2.0±1.04mg/dl. 9 patients were on two drugs.
They required 1.92±0.70mg/day,0.026±0.008mg/kg/day,the level achieved was
7.28±1.20 ng/ml and the average creatinine was 2.13±0.97 mg/dl. Out of total 39
patients 16 patients genetic analysis could be done. 11 patients had heterozygous
mutated CYP3A5 gene, 4 had homozygous normal and one had homozygous
mutated CYP3A5 gene. There was no significant (p= 0.7052) difference in dose
requirement in mg/kg/day in these three CYP3A5 gene variation. 9 patients
had CT Polymorphism of MDR1 gene, 4 had CC polymorphism another 3
had TT polymorphism. There was no significant (P=0.983) difference in dose
requirement in mg/kg/day in MDR1 gene variation.
Conclusion: Indians require approximately 2 mg daily dose of Sirolimus to
achieve therapeutic drug level. CYP3A5 and MDR1 genetic polymorphisms
did not differ in dose requirement in this small pilot study in Indians.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Monday 11 August 2008

Poster Abstracts
POSTER BOARD NUMBER P1 – 33
947 IMMUNOSUPPRESSIVE DRUGS AND NEW ONSET
DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION
IN RECIPIENTS OF HISPANIC ORIGIN

POSTER BOARD NUMBER P1 – 34
948 ABBREVIATED AUC OF CYCLOSPORINE IDENTIFY
MORE ADEQUATELY THAN RECOMMENDED C2
CONCENTRATION VALUE THE PATIENTS AT RISK
OF ACUTE REJECTION DURING THE INDUCTION OF
IMMUNOSUPPRESSIVE THERAPY AFTER KIDNEY
TRANSPLANTATION.
P. Troncoso, M. Ortíz, S. Vilches
P Universidad Católica De Chile
Introduction: Monitoring of Cyclosporine (CsA) is critical during the induction
of immunosuppressive therapy. In this period sub therapeutic exposure to CsA
is associated to high risk of acute graft rejection. The area under the curve of
concentration versus time (AUC) continues to be the gold standard to quantify
drug exposure. Although most of the centers have incorporated C2 (2 hour post
administration CsA) for dosing changes, our unit is still using an abbreviated
AUC model which includes C1, C2 and C6 concentration levels. The objective
of this study was to compare both strategies of CsA monitoring in the immediate
period after kidney transplantation.
Methods: The study included all CsA concentration levels (CEDIA plus,
Roche®) obtained during the first 30 days after kidney transplantation in 89
consecutive receptors induced with CsA (Neoral) and steroids. Abbreviated
AUC was calculated by the formula: 196+0.82x (C1) +0.96x (C2) +9,53x
(C6). A value between 5500 to 6000 ngxh/ml was considered to be in the
therapeutic range. For comparison purposes a value of C2 ≥ 1500 ng/ml was

POSTER BOARD NUMBER P1 – 35
949 A COMPARISON OF RADIOIMMUNOASSAY VERSUS
MASS SPECTROSCOPY IN MONITORING OF EVEROLIMUS
LEVELS
S. McGinn1, A. Caswell1, A. Jackson1, T. McGee1, D. Chesher1, R. Caterson1,
J. Ray2
1
Royal North Shore Hospital, 2St Vincent’s Hospital
Long term calcineurin inhibitor use in transplant recipients (CNIs) has
been correlated with nephrotoxicity and reduced long term graft survival.
Consequently CNI-sparing protocols have been developed using agents such
as everolimus the proliferation signal inhibitor/mammalian target of rapamycin
inhibitor (mTORi). Everolimus is extensively metabolized resulting in several
hydroxylated and demethylated metabolites. These can interfere with the
standard immunoassay used for measuring trough drug levels and hence
given the small range allowed for clinical dose adjustment (3-8ng/ml) and in
particular 5-8 ng/ml for those at increased risk of rejection, the aim of this study
was to assess the safety of the fluorescence polarization immunoassay (FPIA)
for the measurement of everolimus concentrations in whole blood against the
gold standard mass spectroscopy (LC-MS).
Methods: Whole blood samples were taken from renal transplant patients
attending outpatient department at Royal North Shore Hospital between
April and July 2007. and everolimus trough levels were measured using both
immunoassay (Innofluor, Certican Assay System) and mass spectroscopy.
Results from the FPIA were compared with LC-MS using regression analysis,
while the distribution of the differences in everolimus concentrations with the
two methods was assessed using Bland Altman approach.
Results: One hundred and ten samples were analysed from thirty patients. The
cost of analysis by FPIA was $3316.5 (AUD) versus $16500 (AUD) by LCMS. The everolimus levels ranged from 1-22 ng/ml (FPIA) and from 0-18.9
ng/ml (LC-MS). Regression analysis showed a good correlation with multiple
correlation coefficient of 0.95. However using Bland Altman plot, trough levels
were consistently higher with FPIA method, the mean difference was 1.1 ng/ml
higher with a standard error of 0.1 ng/ml (P < 0.001) suggesting interference
from metabolites.
Conclusion: Everolimus trough levels measured by FPIA are cost efficient but
consistently higher than those measured by Mass Spectroscopy. Consequently
interpretation of levels by FPIA should be made cautiously in those patients
who are at increased risk of rejection
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P.W. Baron1, R. Ben-Youssef1, O. Ojogho1, J. Weissman1, E. Franco1, A.
Kore1, J. Limjoco1, M. DeLeon2, Z. Cordero-MacIntyre2
1
Transplantation Institute and 2Center for Health Disparities Research, Loma
Linda University, California, United States.
Background: Calcineurin inhibitors (CNI) are established risk factors for newonset diabetes mellitus posttransplant (NODM). However, the diabetogenic
effect of sirolimus (SLR) and mycophenolate mofetil (MMF) is still
controversial. We studied the incidence of NODM under different CNI-based
regimens in Hispanic kidney transplant patients.
Method: Data of 139 primary kidney transplant Hispanic patients performed
between Jan 1998 and Dec 2002 were reviewed. WHO/ADA criteria were used
to diagnose NODM. We excluded 37 patients due to pretransplant diabetes
mellitus. The remaining 102 patients were divided into 2 groups: 37 received
FK (Group A) and 65 received cyclosporine (CsA) (Group B). We studied the
incidence of NODM, noncompliance, acute rejection, BK virus and CMV
infection, patient and graft survival. Median follow-up was 71 mo (20-114).
Antibody induction therapy was used in 28 FK (75.7%) and 32 CsA (49.2%)
patients. All patients received steroids plus MMF or sirolimus.
Results: The groups were comparable for age, gender, BMI and family history
of diabetes mellitus. Infection and noncompliance rates were similar in both
groups. NODM occurred in 13 Group A, and in 8 Group B patients (p=0.006).
NODM incidences among surviving patients at 6 mo, 1, 3, and 5 y were 24.3%,
27%, 38.2%, and 25% in Group A, and 7.7%, 10.2%, 13%, and 14.9% in Group
B (p = 0.02, 0.03, 0.006, and 0.36 at 6 mo, 1, 3 and 5 y, respectively). SLR was
used in 6 FK and in 5 CsA patients: 4/6 FK-SLR patients developed NODM,
while only 1/5 CsA-SLR patients did. Mean SLR level was 14.685.27 ng/mL in
FK-SLR, and 12.423.42 ng/mL in CsA-SLR (p=0.13). This level was 13.75.5
ng/mL in the 4 FK-SLR-NODM patients, and 18 ng/mL in the only CsA-SLRNODM patient. MMF was used in 31 FK (83.8%) and 60 CsA (92.3%) patients.
Nine (29%) FK-MMF, and 7 (11.7%) CsA-MMF patients developed NODM
(p=0.04). 5-y patient and graft survival were 97% and 59.5% in Group A, and
98.3% and 76.9% in Group B (p=0.27 and 0.02, respectively).
Conclusion: Immunosuppressive drugs are associated with variable
diabetogenic rates in Hispanics. However, the overall incidence of NODM
was lower, and graft survival was better with the CsA-based regimens.
Prospective studies are needed to establish a consensus regarding the choice of
immunosuppression in Hispanics.

also considered therapeutic. Biopsy proven acute rejection episodes (BPAR)
were contrasted with the immediately previous C2 and AUC values. Changes
in doses were done considering only AUC studies as it is usual in our unit.
Results: 20 patients were receptors of living donor kidneys and 46 were
females. Initial induction dose of CsA was 8,26 ± 1,58 mg/day. A total of 248
abbreviated AUC studies were done during this period and 40 of them (16%)
were under the therapeutic range. When the analysis of these studies included
only C2 level 164 (66%) were under the therapeutic value (p<0.001). In
addition, the analysis of all concentration levels showed that the peak of CsA
was in C2 in 54,5% of the studies and in C1 in 45,5%. Five patients had
BPAR during the study period and all of these patients were out of the AUC
therapeutic range. The average C2 in those patients was 1127 ± 383 with a
range of 710 to 1740 ng/ml. On the other hand, the analysis of AUC studies
in the therapeutic range showed that the average C2 was 1156 ± 276 ng/
ml with a range of 632 to 1859 ng/ml (p=0.84). C1 did not show either any
difference between patients with BPAR and those in the therapeutic range
according to the AUC. Only two patients experienced clinical CsA toxicity
during the study period.
Conclusions: In this series, abbreviated AUC monitoring during the induction
of immunosuppressive therapy was associated to a low incidence of CsA
toxicity and identified more adequately than C2 patients at risk of acute
rejection. Recommended C2 concentration levels for this period were achieved
in less than a half of the studies though most of them were related to therapeutic
AUC range.
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950 IMPACT OF TIMING OF MEAL INTAKES ON THE
THERAPEUTIC DRUG MONITORING OF CYCLOSPORINEMICROEMULSION ADMINISTRATION IN STABLE RENAL
TRANSPLANT RECIPIENTS – IS C2 LEVELS MANAGEMENT
THE OPTIMAL MONITORING METHOD IN STABLE RENAL
TRANSPLANT PATIENTS?

952 AN OPEN LABEL SINGLE CENTRE PILOT STUDY TO
CORRELATE THE PRETRANSPLANT C 2 BLOOD LEVEL (2HR
POST SINGLE DOSE) OF TACROLIMUS AS A PREDICTOR OF
POST TRANSPLANT TACROLIMUS DOSE IN DENOVO RENAL
TRANSPLANTATION PATIENTS

S. Ohtsuka1, K. Uchida2, T. Nagasaka2, N. Goto2, A. Katayama3,
T. Kobayashi3, A. Nakao3
1
Toyohashi Municipal Hospital, 2Nagoya Daini Red Cross Hospital, 3Ngoya
University School of Medicine
Background & Purpose: C2 levels monitoring of Cyclosprine-microemulsion
(Neoral) has been published as an effective and method for optimally
individualizing therapy for de novo and maintenance renal transplant patients.
However, there was a serious problem related to the existence of low or slow
absorbers causing malabsorption. The aim of this study was to evaluate the
change of variability in C2 levels, C2/dose ratio, coefficient of variation (CV%)
of intra-patients and clinical outcomes with comparing the effect of various
timings of food intakes on variations in Cyclosporine levels in stable renal
transplant patients.
Methods: 10 patients (age 43 }12) were enrolled in this study. Five kidney
transplantations were from cadaver donors, 5 from living donors. The time that
had elapsed from after the transplant to the initiation of this study was 3.3 }2.1
years. All patient received Neoral-based triple therapy (Neoral + Steroids +
MMF). Cyclosporine blood concentrations were measured by FPIA method
(AxSYM analyzer). Dose adjustment of Neoral was made according to levels
of AUC0-4 sparse-sampling that estimated using 2 sampling points (C1 and
C2) once a month. The maintenance phase AUC0-4 was set at 2,000ng hr/ml.
The time differences were selected two patterns, as following.
# Pattern 1: drug administered (within 10 minutes) after meal
# Pattern 2: drug administered immediately (within 10 minutes) before meal
At first, all patients were enrolled in pattern 1 during 3months. Secondary, they
were enrolled in pattern 2 next during 3 months.
Results: C2 levels were 489 }248 (241-845) in pattern 1 (3 times measurements)
and 558 }82 ng/ml (435-670) in pattern 2.
Results of mean CV% of intra-patients of C2/dose were 48.5% in pattern1 and
pattern 2 was 13.7% (p=0.008, CV% of pettern 1 vs pattern2).
The peak of Neoral often came to C2 with pattern 2. Moreover, absorption
pattern (C1/C2) was different also in the same individual depending on the
meal timing. No patient suffered from chronic rejection or nephrotoxicity
during the study.
Conclusions: The absorption pattern of Neoral in the individual is different
depending on the meal timing, Neoral should be monitored under the same
meal timing. Especially, Neoral administered immediately (within 10 minutes)
before meal pattern might be more appropriate timing of C2 monitoring
administration than drug administered after meal.

1

A. Sharma1, M. Minz1, V. Shetty2
Dept of Renal Transplant Surgery, PGIMER, 2Medical Advisor, Biocon
Limited
Introduction: Tacrolimus is being increasingly used as a preferred calcineurin
inhibitor for prophylaxis of rejection in organ transplant recipients. One
of the problems associated with use of tacrolimus is a great inter-individual
variability in dose requirement. Currently, there is no method to predict the
dose requirement for an individual patient in the pretransplant period and the
drug is started at a uniform dose in all the patients which places the patients at
increased risk of underdosing or toxicity. The present study evaluated whether
a single pretransplant peak tacrolimus blood level (2hours post dose) could
predict the trough level obtained after transplant and help in establishing post
transplant dose of tacrolimus.
Methods: This was an open label, nonrandomized, single arm, single centre,
pilot study conducted in 20 patients undergoing renal transplantation. All
patients received a single dose of Tacrolimus (Tacrograf, Biocon, India) at the
dose of 0.1mg/kg/dose and blood level for tacrolimus was estimated 2 hr post
dose (C2 level) 4-7 days before transplantation. All patients were started on
0.2mg/kg/day of tacrolimus one day before transplant. After transplant, the
patients underwent trough level monitoring on 2nd, 5th, 10th, 15th & 30th day
of posttransplant days and additionally whenever indicated. The pretransplant
peak tacrolimus level was correlated with the trough levels obtained and with
the dose requirement after transplant.
Results: 20 patients were included in the study. Mean age 35.2+ 8.9 yrs, M:
F 16: 4, Mean body weight 55.4+ 10.2 kg. The mean peak level of tacrolimus
in the pretransplant period was 24.6 + 17.4 (Range 4.85-69.46) ng/ml. The
mean first trough level obtained 48 hours after transplant was 11.0 + 5.9 (Range
3.7 – 22.07) ng/ml. There was a strong positive correlation [r=0.62] between
the peak value obtained before transplant and trough level after transplant.
There was a large variation in dose requirement at the end of two weeks in
these patients with the dose ranging 0.05-0.42 mg/kg/day with a mean of 0.26
+ 0.11mg/kg/day. There was a good negative correlation between peak level
obtained before transplant and dose requirement at the end of second week [r=
-0.57]. A peak level of more than 30 ng/ml could identify 80% (4/5) patients
who achieved trough levels more than the desired range and all patients (4/4)
with a peak level of less than 10ng/ml had subtherapeutic levels in the first
week after transplant.
Conclusions: A strong correlation could be observed between peak levels done
before transplant with the trough levels and dose requirement after transplant
Measurement of a single peak level before transplant presents a simple strategy
to identify patients at risk of underdosing or developing toxicity.
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951 MYCOPHENOLATE-ASSOCIATED DIARRHEA:
DOES IT AFFECT CYCLOSPORINE-A C-2 LEVELS?
COMPARATIVE STUDY IN 41 PATIENTS. TRANSPLANT UNIT,
HOSPITAL GENERAL SAN JUAN DE DIOS, GUATEMALA
CITY, CENTRAL AMERICA

953 LOWER SERUM C0 AND C2 LEVELS OF CYCLOSPORIN
A IN RENAL TRANSPLANT PATIENTS ON MYCOPHENOLATE
MOFETIL (MMF)

R.A. Garcia-Gallont, M. Toledo, A. Sojuel
Transplant Unit, Hospital General San Juan De Dios
Abstract: Mycophenolate (MMF/MPS) – associated diarrea is common, and
may hypotetically interfere with Cyclosporin A (CyA) absorbtion. To assess
this in a group of patients on a triple-drug immunosuppressive regimen (CyA,
MMF or MPS, and steroids). CyA blood levels 2 hours post oral intake (C-2,
were measured in 20 patients suffering this type of diarrhea, and in a control
group (n=21) without diarrhea. C-2 levels dropped significantly in 75% of
patients with diarrhea (n=15). but only in 38% (n=8) of the control group
(p=0.039). We conclude, that in the given setting, where CyA is frequently
used in association with MMF or MPS, C-2 levels must be watched closely if
patients develop diarrhea, to stay within therapeutic levels for CyA.
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N.C.T. Kong, A.G. Halim, Z. Soehardy1, M. Rozita1 and C.Y. Loo1.
Department of Medicine, National University of Malaysia, Kuala Lumpur.
Serum C2 levels of cyclosporin A (CsA, ‘Neoral’) are the most consistent
predictor of CsA AUC. The CONCERT consensus – performed in the era
of steroids-CsA -azathioprine, had recommended target serum C2 levels of
1500-2000, 1500, 1300, 1100, 900, and 800 ng/mL for months 1, 2, 3, 4-6, 7-12
and >12 post-transplantation respectively. We report our experience with lower
C0 and C2 targets with the steroids-CsA-MMF regimen in 15 patients (11 males,
4 females) with a mean age of 39.9 11.7 years and a mean duration of follow-up
of 22.7 18.4 months. Our target C2 levels were 1000-1200, 800-1000, 700-800
and 500-700 ng/mL for 1-3, 4-6, 7-12 and >12 months respectively. C0 and
C2 levels were categorized into 3 time periods: 1-3 months, 4-6 months and
7-12 months post transplantation. There were 3 biopsy-proven acute rejection
episodes, all precipitated by infection. There were no significant increases in
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serum creatinine levels (p=0.61, Table) on follow up. 68.4% patients were
free of any acute rejection episodes up to 64 months post transplant (Figure).
Thus we conclude that with our current immunosuppressive regimen which
incorporates MMF, both Co and C2 levels lower than recommended are safe and
spares chronic CsA nephrotoxicity.
1-3 months
106.7 29.2
239.1 77.3
1065.0 233.5

Creatinine (umol/L)
C0 (ng/mL)
C2 (ng/mL)

4-6 months
104.3 27.5
184.2 564.0
956.7 183.8

7-12 months
116.6 40.8
177.3 49.7
878.5 192.3

> 12 months
118.2 40.9
143.8 96.5
808.3 203.7

954 IS CALCINEURIN INHIBITOR METABOLISM ALTERED
IN POST RENAL TRANSPLANT RECIPIENT WITH END STAGE
RENAL FAILURE DUE TO ADULT POLYCYSTIC KIDNEY
DISEASE
D.M. Little, R. Manecksha, N. Pervez-Aslam, M. Eng, M. Ponnusamy,
D.P Hickey
Beaumont Hospital
Calcineurin inhibitors, cyclosporine (CyA) or tacrolimus (tac) are the primary
immunosuppresants used post renal transplant. Both are metabolised in the
liver by cytochrome P450 enzyme system. Patients with end stage renal failure
(ESRD) due to adult polycystic kidney disease (APCKD) frequently have
associated liver cysts. We retrospectively reviewed data from 134 consecutive
adult renal transplants in 133 recipients with ESRD due to APCKD to determine
if they were more susceptible to calcineurin inhibitor toxicity in the immediate
period post renal transplant.
Materials and Methods: Between Jan 1997 and December 2006, 134 patients
(66 males and 67 females) with APCKD were transplanted in a single centre.
1 patient died on the first post-operative day and was excluded from analysis.
Immunosuppression was achieved using a combination of mycophenolate (1g
daily). steroids and either cyclosporine (Neoral 5mg BID) (n 54) or tacrolimus
0.15mg/kg loading dose X2 followed by 0.1mg/kg (n 80). Pre-operative
abdominal ultrasound confirmed liver cysts in 45 patients, 24 received
cyclosporine and 21 tacrolimus. All 133 patients had negative hepatitis B and
C serology. Post-operative 12 hour drug trough levels were recorded on Days
3, 7 and 14 post transplant using either Integra 800 EIA assay for cyclosporin
or MEIA Abbott for tacrolimus. Liver function tests (LFTs) were also measured
pre-operatively and at the same time intervals.
Results: Patients immunosuppressed with cyclosporine who had documented
liver cysts pre-operatively tended to have significantly higher levels of
cyclosporine levels in the immediate post-operative period compared to those
with no liver cysts. This trend was also evident in patients immunosuppressed
with tacrolimus but the number of patients with sustained high levels of
tacrolimus declined by 14 days post-operatively (Figure 1) There was no
significant alteration in LFTs in patient s with cystic liver disease and high
calcineurin inhibitor levels.
Conclusion: Patients with APCKD tend to be more prone to developing
calcineurin inhibitor toxicity in the early period post transplant. This trend is
more evident in the subgroup of patients immunosuppressed with CyA and tac
who have documented liver cysts. We recommend dose reduction in APCKD
patients undergoing renal transplant immunosuppressed with cyclosporine.
Liver cysts 45
No liver cysts 40
CyA >300ng/mL
Tac > 14ng/mL
Figure 1

Day 3
71%
81%

Day7
63%
67%

Day 14
67%
38%

Day 3
52%
82%

Day7
43%
41%

Day 14
62%
47%

955 DILTIAZEM AS A FK506-SPARING AGENT IN KIDNEY
TRANSPLANT RECIPIENTS: PROSPECTIVE SELF-CONTROL
CLINICAL TRIAL AND PHARMACOKINETIC STUDY
C. Wang1, S. Chen1, J. Li2, L. Liu1, X. Wang2, Q. Fu1, L. Teng1, C. Xiao1,
L. Chen1, M. Huang2,
1
Kidney Transplant Department, Organ Transplant Center, The First Affiliated
Hosp, 2School of Pharmaceutical Science, Sun Yat-sen University
Background: FK506, a first-line immunosuppressant with poor oral
bioavailability, is a substrate of Cytochrome P450 (CYP3A) and P-glycoprotein
(P-gp). The calcium-channel blocker Diltiazem is a well-known inhibitor of
both CYP3A4 and P-gp. We have used Diltiazem as CsA-sparing agent since
1991 in over 1,000 kidney transplant recipients and applied it to FK506-based
regimens since 1999 in over 300 patients. A prospective self-control clinical
trial and pharmacokinetic study were conducted to quantitatively assess the
FK506-sparing effect of Diltiazem in kidney transplant recipients.
Methods: Kidney transplant recipients on FK506+MMF+steroid regimen
were recruited and Diltiazem (30mg tid) was added. Trough whole blood
concentration of FK506 was monitored afterwards so as to adjust the FK506
dose accordingly. Renal function, liver function, blood cell counting, urine
analysis and adverse events were recorded in routine follow-up clinic. Intentionto-treat (ITT) analysis is applied to these results. Pharmacokinetic study was
conducted in participants with good compliance and volunteered to receive the
tests. In this sub-group, the day before and 14 days after adding Diltiazem, 2ml
venous blood sample was drawn 1 minute before, 0.5, 1, 1.5, 2, 3, 4, 6, 9 and
12 hours after taking the morning dose of FK506. Whole blood concentration
of FK506 was measured by liquid chromatography-tandem mass spectrometry
(LC/MS/MS). and then two profiles of pharmacokinetic indexes (C0, Cmax, Tmax
and AUC0-12h) were adjusted by the corresponding FK506 doses and compared.
Results: From Jan 2006 to Jan 2008, 88 kidney transplant recipients (67 males
and 21 females) between 17 to 61 years old were recruited 1 to 103 months
post-transplant. Ten patients (11.36%) withdrew from the study for hypotension
(7 cases, 7.95%) and transaminase elevation (3 cases, 3.41%). Six episodes
(6.82%) of biopsy-proved acute rejection was documented over the followup period of 1-25 months (median time: 11 months) and were all reversed by
Methylprednisolone impulse therapy. Serum creatinine level remained stable
when compared to baseline (118±37ng/ml vs. 124±44ng/ml, p>0.05). FK506
dose decreased from 0.11±0.05mg/kg to 0.07±0.03mg/kg (p<0.01) while the
concentration maintained steadily within target ranges. Ten patients (7 males
and 3 females) of 36±11 years old joined the pharmacokinetic study sub-group.
Their body weight was 60±10 kilograms and remained constant throughout
the 15 days. After using Diltiazem for 14 days, the dose-adjusted peak
concentration (Cmax/Dose) significantly increased from 286.1±128.1ng/ml/kg/
mg to 409.2±127.3ng/ml/kg/mg (p<0.05). while the area under the curve (AUC012h) significantly increased from 1703.4±597.1 ng·h/ml/kg/mg to 2559.1±821.7
ng·h/ml/kg/mg (p<0.05). Dose-adjusted trough concentration (C0/Dose) and
peak time (Tmax) were not significantly different from baseline (p>0.05).
Conclusion: Intentionally applying Diltiazem to kidney transplant recipients
could increase FK506 exposure and decrease the FK506 dose needed for a
certain target level; thus may reduce the expense on immunosuppressant. Its side
effects, though usually mild and reversible, should be taken into consideration
when deciding to add it as a FK506-sparing agent.

POSTER BOARD NUMBER P1 – 42
956 EVALUATING THE CLINICAL IMPACT OF A CHANGE IN
TACROLIMUS IMMUNOASSAY
T. Cavanaugh1, J. Martin1, V. Culp1, N. Parrish1, S. Rudich2, G. Neff2
1James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati,
OH, 2Transplant Services, The University Hospital, Cincinnati, OH
Background: Due to a narrow therapeutic window, tacrolimus (TAC) is
an immunosuppressive agent that undergoes extensive and routine drug
therapeutic monitoring in transplant patients. Patient specific therapeutic
ranges take into account individual factors and the relationship between side
effects and effectiveness demonstrated by specific assay results in clinical
practice over time. A recent change the immunoassay technology used by our
local laboratory required an analysis and re-establishment of patient specific
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TAC ranges. Fluorescence polarization immunoassay (FPIA) technology,
which measures TAC and its metabolites, had been used for several years. New
technology, the cloned enzyme donation immunoassay (CEDIA) measures the
parent TAC compound, as well as approximately 37% of one metabolite, is
currently being implemented. For two weeks, the laboratory is reporting both
assay results. The purpose of this study is to evaluate the correlation between
the FPIA and the CEDIA laboratory values and to determine how that impacts
clinical decision making.
Methods: A list of liver transplant patients receiving TAC at our institution over
the two weeks since the change in assay techniques was generated. Laboratory
TAC values for the FPIA and CEDIA assays were collected. Descriptive
statistics, as well as simple linear regression and a t-test were used to evaluate
the reported TAC concentrations.
Results: Sixty-two TAC concentrations reported with both FPIA and CEDIA
were collected from 20 liver transplant patients. The mean results for TAC
concentration with FPIA were 7.85 ± 4.50mcg/L and CEDIA 9.37 ± 5.74 mcg/
mL (p = 0.11).The mean percent change in TAC concentrations was 21.6% ±
29.4% and the mean absolute difference was 1.52 ± 2.01 mcg/L. Sequential
daily TAC measurements demonstrated extensive intra-patient variability in the
range from minimum to maximum values of 12.70% to 155.14% corresponding
to absolute differences of 0.7 to 4.9 mcg/L (mean 11.0% ± 28.2% and 0.65 ±
1.37). There was no evident ratio or other applicable mathematic relationship
identified to guide the development of new patient specific ranges. A high degree
of correlation of FPIA and CEDIA TAC levels was determined by simple linear
regression, R2 = 0.86. Despite this, based upon current patient specific target
ranges or ± 30% from the FPIA result, a clinically different decision would
have been made if the FPIA value had not been reported 45% of the time.
Conclusion: Change in TAC immunoassay technology resulted in considerable
intra- and inter-patient variability causing difficulty with interpretation of results
for purposes of clinical decision making. Nearly half of the time, a different
clinical decision would have been made based on the new level. It will take time
to establish the relationship between the new assay values and patient outcome.
Further analysis of the potential impact of these changes is warranted.

non-expressers. Median time post-transplant was 4.26 years (range 0.6-17.8); 12
were female and 30 male; median age was 46 years (range 26-75). Ethnic groups:
2 Asian, 1 Black, 32 Caucasian and 1 other. When the first blood concentration
was measured on day 4 after switching 1/4 (25%) CYP3A5 expressers and 5/38
(13%) were below the target range. None of the expressers and 9 of the nonexpressers (24%) were above target (Figure). 6 months following switch, dose
normalized sirolimus blood concentrations for the CYP3A5 expressers were
clustered at the lower end of the range for CYP3A5 non-expressers (median 147
ng/mL/mg/kg (range 99.6-220) vs 225 (81-524); p=NS).
Discussion: In this small study the range of dose-normalised sirolimus blood
concentration for CYP3A5 expressers lay within the range observed for
CYP3A5 non-expressers. The potential utility of a pharmacogenetic approach
to dosing sirolimus would be to identify the optimal initial dose to prevent
under-exposure prior to optimization in respose to therapeutic drug monitoring.
The regimen employed here with a loading dose delivered the target range for
the CYP3A5 expressers but led to higher than planned exposure in a number
of CYP3A5 non-expressers. Recently, practice has evolved to aiming for lower
target blood concentrations of 5-10 ng/mL in late-stage transplant recipients
with omission of a loading dose. The regimen from this study, with a loading
dose, would deliver this target for CYP3A5 expressers and lower initial doses
without a loading dose would run the risk of under-exposure in this patient
group with increased risk of rejection at the time of switching.
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957 THE INFLUENCE OF CYP3A5 GENOTYPE ON BLOOD
SIROLIMUS CONCENTRATIONS FOLLOWING SWITCH
FROM A CALCINEURIN INHIBITOR

958 DENOVO POST-RENAL TRANSPLANT INFLAMMATORY
BOWEL DISEASE SUCCESSFULLY TREATED WHILE ON
MYCOPHENOLATE MOFETIL

I. MacPhee, M. Moreton, D.W. Holt
St. George’s, University of London
Background: Genotyping at the single nucleotide polymorphism CYP3A5*1
predicts whether individuals will express cytochrome P4503A5. Individuals
with at least one wild-type CYP3A5*1 allele are expressers while CYP3A5*3
homozygotes do not synthesise the functional protein. CYP3A5 expressers
require two-fold higher doses of tacrolimus to achieve target blood
concentrations. Published studies on sirolimus have generated conflicting
results.
Methods: A sub-group of patients from a multi-centre randomized controlled
trial of switching patients from calcineurin inhibitor therapy to sirolimus at least
6 months after renal transplantation consented to entry to a pharmacogenetic
sub-study. Calcineurin inhibitor was discontinued and on the next day a loading
dose of 12 mg sirolimus was given followed by 4 mg daily. The dose was then
adjusted to a target blood concentration of 8-16 ng/mL. The study received
ethical approval and subjects gave written informed consent.
Results: Of the 42 patients recruited there were 4 CYP3A5 expressers and 38

M. Halim, T. Al-Otaibi, M. Nampoory, P. Nair, T. Said, M. Samhan
Hamed Alessa Organ Transplantation Center
Background: Prevalence of inflammatory bowel disease (IBD) post transplant is
affected by the immune tolerance and modality of immunosuppression used (1).
Mycophenolate mofetil (MMF) may have a promoting effect in developing
post transplant IBD, Crohn’s disease-like pattern (2,3). in spite that MMF is
reported to be a reasonable alternative in treating Crohn’s disease for patients
who do not tolerate azathioprine (4).
Case summary: A 39 years old Omani gentleman had chronic renal failure due
to advanced nephrosclerosis.
He was on hemodialysis for 9 months till he received live unrelated renal
transplant.
He was on prednisolone, MMF and tacrolimus which is changed to sirolimus
when he developed diabetes mellitus two months post-transplant.
Five months post-transplant, he developed recurrent attacks of bloody diarrhea
and ischiorectal abscesses complicated by anal fistulae not responding to routine
surgical treatment (incision and drainage); when he was on prednisolone 10mg/
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959 HIGHER DOSE OF ENTERIC COATED
MYCOPHENOLATE SODIUM (EC-MPS) IN KIDNEY
TRANSPLANTATION; TOLERABILITY, EFFICACY AND
PHARMACOKINETIC CORRELATION.
M. Nampoory1, T. Said1, A. Shihab-Eldeen2, T. Al-Otaibi1, K.V. Johny3,
M.A. Halim1, M.P. Nair1, M. Al-Mousawi1
1
Hamed Al-Essa Organ Transplant Center, 22Department of Pharmacology,
Faculty of Medicine, Kuwait University, 3Department of Medicine, Faculty of
Medicine, Kuwait University
Introduction: EC-MPS in regular dose is known to improve mycophenolic acid
(MPA) related gastrointestinal (GI) symptoms with therapeutic equivalence to
mycophenolate mofetil (MMF) in kidney transplant recipients (KTRs). The
aim of the study is to assess the effect of higher dose of EC-MPS on its efficacy,
tolerability and pharmacokinetic properties.
Patients and Methods: Twenty two KTRs were randomly selected to
receive either 50% increased dose of EC-MPS 1080 mg bid (study group,
n=10) or regular dose of MMF 1000 mg bid (control group, n=12) in
addition to prednisolone and cyclosporine as triple immunosuppressive
therapy. Rejection in the first 3 months post transplant was taken as a
parameter of efficacy while GI disorders, hematological abnormalities and
presence of infections over 6 months were used to assess tolerability. A
severity score system was used to assess GI disorders. Pharmacokinetic
profiles were performed in 6 patients in each group to compare MPA trough
concentration (C0). maximum concentration (Cmax). time to maximum
concentration (Tmax) and area under the concentration curve (AUC) of
both drugs.
Results: Four patients in EC-MPS group had acute rejection versus one in
MMF group. None of them lost the graft. Eight patients (80%) on EC-MPS
versus 6 patients (50%) on MMF developed GI symptoms with severity
index of 0.32 versus 0.11 respectively. Dose reduction due to adverse
events was attempted 1.4 times/patient for patients on EC-MPS versus 0.42
for patients on MMF. AUC was 39 ug.h/ml for EC-MPS group versus 23
ug.h/ml for MMF group (p=0.004). C0 (1.59 versus 0.69 ug/ml, p=0.049).
Cmax (9.87 versus 5.85 ug/ml, p = 0.011) and Tmax (2 versus 1 hour, P
= 0.001) were significantly higher in EC-MPS compared to MMF groups
respectively.
Conclusion: Higher dose of EC-MPS was associated with reduced tolerability
and efficacy. Higher AUC and/or Cmax in the study group could be the reason
for increased adverse events.

POSTER BOARD NUMBER P1 – 46
960 MYCOPHENOLIC ACID MONITORING IN RENAL
ALLOGRAFT RECIPIENTS ON MMF/ENTERIC COATED MPS
THERAPY
R.K. Sharma, G. Sreedas, S. Mehrotra, A. Saxena, A. Gupta
Sanjay Gandhi Post Graduate Institute of Medical Science
MMF, a prodrug of mycophenolic acid (MPA). is a highly effective
immunosuppressant. Enteric coated mycophenolate sodium (EC-MPS –
Myfortic). a formulation for delivering MPA was developed with the aim of
improving MPA – related upper GI adverse events. Pharmacokinetic difference
exists between the two molecules due to functional enteric coating, leading
to delayed delivery of MPA as compared to MMF. The present study aims
to detect (1) the pharmacokinetic difference between MMF and EC-MPS by
the plasma time curve of MPA (2). compare side effects and efficacy of the 2
molecules, (3) drug interaction with concomitant immunosupression. 250 live
related renal allograft recipients were started on MMF and 73 patients on ECMPS (Myfortic). The clinical profile of these patients, their tolerance to MPA
and serial renal function were studied and 12 hour MPA-AUC was done in
15 patients (9 on EC MPS and 6 on MMF) with stable graft function. Blood
samples were taken in EDTA tubes immediately before the administration of the
drug (C0). at 30 min (C30). 75 min (C75). 2h (C2) ,4 hour (C 4h) ,6 h, 8h and
12 hours. The concentrations of plasma MPA was measured by EMIT method.
EC-MPS demonstrated the typical pharmacokinetic profile of an enteric coated
formulation with a delayed release of MPA compared to MMF. Patients on ECMPS had a higher (C0) level of MPA and delayed peak compared to patients
on MMF, although the 12 hour AUC was comparable in both groups .The AUC
ranged from 30-60mg.h/L. No single value could predict the 12 hour AUC. By
regression analysis, abbreviated AUC (0-4). limited sampling strategy using 2
samples (C30, C4) for EC MPS (r = 0.968, r²= 0.937) and 3 samples (C0, C30
and C4) for MMF could predict AUC (0-12) (r = 0.968, r²= 0.937). The mean
AUC of the patient groups studied were as follows – Myfortic + CsA = 32.4±
6 μg/ml, MMF + CsA = 42.3±14.3 μg/ml, Myfortic +Tac = 78.4± 19.8 μg/ml.
With CsA both EC-MPS and MMF showed comparable AUC, but there was
delayed Cmax with EC-MPS. With Tacrolimus and EC-MPS, Cmax and AUC
of MPA were almost double that of CsA and EC MPS. The side effect profile
revealed that MPA related GI side effects were more common with MMF (45%)
than EC-MPS (6%).Herpes zoster was observed in 20% patients with MMF
and 6% patients on EC-MPS.CMV disease developed in about 12% patients
on MMF and 5% in EC-MPS. Cutaneous fungal infection occurred in 15%
patients on MMF and 20% patients on EC-MPS. Neutropenia was observed in
25% patients on MMF and 17% patients on EC-MPS. The incidence of acute
rejection in the MMF group was 15% compared to 8% in EC-MPS group. EC
MPS formulation is associated with less incidence of hematological and gastric
side effects & had less evidence of acute rejection episodes.

POSTER BOARD NUMBER P1 – 47
961 DOES DOSING OF MYCOPHENOLATE MOFETIL 500 MG
QID VS 1000 MG BID IMPACT EFFICACY AND TOLERABILITY
AFTER RENAL TRANSPLANTATION
J. Oberholzer6, M. Campara1, J. Thielke2, T. Ommert3, H. Herren4,
P. West-Thielke5, E. Benedetti7, B. Kaplan8
1University of Illinois At Chicago, 2University of Illinois At Chicago,
3University of Illinois At Chicago, 4University of Illinois At Chicago,
5University of Illinois At Chicago, 6University of Illinois At Chicago,
7University of Illinois At Chicago, 8University of Illinois At Chicago
Mycophenolate mofetil (MMF) reduces the incidence of acute rejection
(AR) episodes and improves outcomes of kidney transplant (KTx) recipients.
However, this agent is often associated with adverse events that may require
dose reduction, interruption or withdrawal of therapy. Several investigators
have noted that MMF dose reduction (<2 g/day) may be associated with
suboptimal outcomes in KTx patients. In this retrospective data analysis,
we examined if MMF dose reduction, extending dosing interval to 500 mg
QID or conversion to mycophenolate sodium salt has had any effect on AR,
tolerability, graft survival and glomerular filtration rate (GFR) in KTx patients
vs those receiving standard dose MMF.
Between 01/99 and 12/06, 641 adult, KTx recipients will be reviewed. We
present preliminary data on 64/641 patients; 14 non-MMF patients were
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day, MMF 500mg twice/day, and sirolimus 4mg/d with trouph level 7.6ng/dl.
Colonoscopy showed multiple erythematous lesions in the rectum and sigmoid
colon with aphthous ulcers and erosions.
There was mild chronic lymphoplasmacytic cell infiltration of the lamina
propria with cryptitis and non-caseating granulomatous lesions (figure1). There
was no evidence of acid fast bacilli or viral infections and CMV antigenemia
was negative.
He was diagnosed to have IBD, Crohn’s disease-like pattern.
He was treated with steroids and 5-aminosalicylic acid (5-ASA) in addition
to a course of ciprofloxacin and metronidazole. Later, he required a course of
infliximab.
He was continued on the same doses of MMF (500mg/d) and sirolimus (4mg/
day with trouph level of 7.6ng/dl) .
He became asymptomatic and rectal lesions healed within one month of
treatment.
Tow years later, he was asymptomatic and maintained on the same
immunosuppressive treatment and 5-ASA with normal graft function.
Conclusion: IBD disease can develop in renal transplant recipients
in spite of immunosuppressive therapy especially when MMF is used
which can be successfully treated without discontinuing this important
immunosuppressive drug.
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excluded and 9 were switched to alternate therapy. All patients received
induction with either thymoglobulin, daclizumab or basiliximab. Steroid free
maintenance with calcineurin inhibitors and MMF was used in 39/64 cases.
Group A was the dose reduction group and Group B received standard dose
MMF. Data for all Groups, including Group C (500 mg QID) and Group D
(mycophenolate sodium). is still being collected and will be available at the
time of presentation.
AR rate, GFR and overall graft survival at 6 and 12 months post-transplant is
shown in the table. As previously described, significant difference was noted in
the rates of early AR (22% vs 57%, p 0.049).
Our preliminary results show that the patients in the MMF dose reduction
Group experienced a higher rate of AR. Final conclusions are pending
completion of data collection at which time we hope to show whether
this effect translates into the extended interval dosing Group and the
mycophenolate sodium Group.
Preliminary Results
African American
Female
Age at Transplant
AR within 6 months
AR 6-12 months
GFR at 6 months
GFR at 12 months
Overall Graft Survival
Overall Patient Survival

Group A n=18 (n,%)
3 (16.7)
9 (50)
42.1 (16.1)
4 (22.2)
2 (11.1)
55.1 (14.8)
64.55 (16.4)
18 (100)
17 (94.4)

Group B n=21 (n,%)
12 (57.1)
9 (42.9)
46.1 (14.3)
12 (57.1)
1 (4.8)
56.31 (18.8)
61.64 (20.3)
20 (95.2)
21 (100)

p-value
0.412
0.049
0.586
0.839
0.681
NS
0.462

POSTER BOARD NUMBER P1 – 48
962 IMPDH – INHIBITION AS A KEY MARKER IN RENAL
TRANSPLANTATION
M. Raggi1, M. Stangl1, S. Siebert1, S. Thorban1, D. Abendroth2
Klinikum Rechts der Isar, TU-München, 2Universitätsklinikum Ulm
Introduction: Interpatient variability, changes of pharmacokinetic parameters
over time and drug interactions make the systemic exposure of mycophenolic
acid (MPA) unpredictable at a fixed-dose regimen. There is evidence for a
relationship between pharmacokinetic parameters, the in-/decrease of the
AUC, and the co-medication of calcineurin-inhibitors. In this multicenter,
prospective, longitudinal trial we have investigated the value of therapeutic
drug monitoring for MPA in correlation to inhibition of Inosin-MonophosphatDehydrogenase (IMPDH) in kidney transplant recipients.
Patients and Method: 68 renal transplant recipients receiving 720 mg of ECMPS twice daily and concomitant ciclosporin/tacrolimus provided a total of
114 pharmacokinetic profiles for IMPDH. By application of an IMPDH assay
(TDM, 2000). enzyme activity was investigated in isolated lymphocytes from
renal transplant recipients at predose and at 30min, 60min, 2h, 4h, at week 1,
2 and 3 months after transplantation (n=68, gender 32 f/34m; mean age: 53
years). MPA concentrations were measured by a validated HPLC method in
150 plasma samples collected at the identical time points.
Results: Patients with infection either bacterial or viral as well as patients on
dialysis were excluded from the study. Finally 22 Patients were left and divided
in two groups. Patients with rejection (G I, n=11; gender 5f/6m; mean age: 44
years; FK= 5/CyA= 6) showed a significant lower Inhibition of IMPDH starting
in week 1 (day 3-5) irrespective the used dosage of CNI. The corresponding
group (G II n=11; gender 5 f/6m; mean age: 53 years; FK= 5/CyA= 6) without
rejection showed significant (p<0.006) higher inhibition rates at week 1 and
2, but no differences in MPA values. The MPA values for week 1 and 2 were
lower in G II. There was no correlation between IMPDH-Inhibition and MPA
levels at all timepoints of the protocol. All patients w./o. rejection and with low
inhibition showed a high trough level of CNI. There was no difference between
both CNIs applied.
Conclusion: The data show that the measurement of the biological response
provides a useful adjunct to traditional therapeutic drug monitoring of MPA.
This will be helpful for preventing rejection episodes especially because the
discrimination between the patients suffering from a rejection and patients with
no immunological problems was possible as early as in week one and was
seen in general before clinical signs of rejection were visible. The therapeutical
potential of MPA may be optimized especially under the aspects of CNI
optimized/free immunosuppressive regimens.

1
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POSTER BOARD NUMBER P1 – 49
963 A REAL LIFE REFLECTION OF MYCOPHENOLATE
SODIUM USAGE IN TURKISH RENAL TRANSPLANT
POPULATION; AN INTERIM ANALYSIS
A. Uslu, T. Arinsoy1, S. Mir, I. Titiz, F. Gonenc, A. Celik, A. Turkmen,
S. Apaydin, S. Kacar, N. Guvence
1Gazi University Faculty of Medicine, 2SB Bozyaka Research and
Educational Hospital, 3Ege University Faculty of Medicine, 4Haydarpasa
Numune Hospital, 5Yukses Ihtisas Hospital, 69Eylul University Medical
School, 7Istanbul University Istanbul Faculty of Medicine, 8Istanbul
University Cerrahpasa Faculty of Medicine, 9SB Tepecik Research and
Educational Hospital, 10SB Etlik Ihtisas Hospital
Objectives: Myfortic® is an enteric coated mycophenolate sodium (EC-MPS)
formulation developed for acute rejection prophylaxis in renal transplant
patients. It has been shown before in clinical trials that EC-MPS is an effective
treatment option for kidney transplant recipients. This is the first observational
EC-MPS study and also the first country based renal transplant study in Turkey
with a large patient number. The primary objectives of the study were to
evaluate patient and graft survival, the incidence of rejection and graft function.
The secondary objectives were to evaluate the patient compliance and side
effects of EC-MPS in renal transplant patients who were switched from MMF
to EC-MPS in equimolar doses or in whom EC-MPS was added to therapy.
Methods: 460 renal transplant patients who received EC-MPS as an adjunct
therapy with/without CNIs or mTOR inhibitors ± steroids, from 23 Turkish
transplant centers, were enrolled in this prospective, observational study. 252
(160 de novo, 92 maintenance) of them completed the follow up period and
were included in this interim analysis. Vital parameters, efficacy and safety
were monitored on 1, 3, 6 and 12th months.
Results: 85 (33.7%) of the 252 patients received cadaveric kidney transplants.
Mean age of the patients were 31.6±13 and%57.9 were females. 94 (%61)
patients received induction treatment with interleukin-2 receptor antagonists
(Basiliximab or Daclizumab). In graft function analysis no change was observed
in 3, 6 and 12 month blood creatinine, urea, BUN and GFR levels (p=0.05,
p=0.126, p=0.202 and p=0.970, respectively). Acute rejection was seen in 14
patients (8 de novo (%5); 6 maintenance (%7,6) and mean time to rejections
were 2.29±1.09 and 8.67±8.02 months, respectively. Major adverse events:
anemia/thrombocytopenia
increase of liver enzymes
gastrointestinal symptoms
Infection
Leucopenia

de novo
16.9%
16.3%
13.1%,
15%
10%

maintenance
43.5%
26.1%
31.5%
14.1%
8.7%

There was one graft loss due to BKV nephropathy and CMV infection and 3
deaths due to cerebrovascular accident, respiratory failure and glioblastome
multiforme. 47 (%29,3) de novo and 25 (%27,1) maintenance patients needed
mycophenolate dose adjustment. 104 de novo (65%) and 38 (41%) maintenance
patients could use full dose of EC-MPS (1440mg/day). gastrointestinal complaints
were recorded in 16 (%15,3) and 11 (%28,9) of the patients in this group.
Conclusion: In our opinion; EC-MPS is an effective adjunct therapy for kidney
transplant patients, successfully preserves renal function in maintenance
patients, has a high patient compliance and is well tolerated according to this
real life reflection.

POSTER BOARD NUMBER P1 – 50
964 CNI MINIMISATION WITH 2 G MYCOPHENOLATE
MOFETIL – WHAT HAVE WE LEARNED FROM THE
SYMPHONY STUDY?
H. Ekberg1, C. Bernasconi2, P. Halloran3
Lund University, 2F. Hoffmann-La Roche Ltd, 3University of Alberta
Introduction: The efficacy of calcineurin inhibitor (CNI) -based
immunosuppression has been hampered by chronic nephrotoxicity associated
with these agents. The CNI-minimisation studies that had been performed
before the inception of the Symphony study had reported some positive results,
but there was a clear need to find the optimal balance between reducing toxicity
and maintaining efficacy. The Symphony study was therefore designed to
determine whether the use of mycophenolate mofetil (MMF) and daclizumab
in conjunction with low doses of CNIs or sirolimus may be beneficial compared
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965 OMISSION OF AZATHIOPRINE AND MYCOPHENOLATE
MOFETIL IN IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY
TRANSPLANTATION
M. Taherimahmoudi, G. Pourmand, A. Mehrsai, M. Nikoobakht
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: In this study effects of reduction and omission of cellcept and
azathioprine (AZA) in standard immunosuppressive regimen on acute rejection
,chronic rejection and graft survival has been evaluated.
Methods: During 1989-2005,1000 kidney transplantations has been
performed in our center, 105 of them, has been followed up 1-10 years (mean
5 years). All patients received cyclosporine A (CsA). cellcept or AZA and
maintenance prednisolone. But with the onset of GI complication, hepatic
toxicity or leukopenia, some alternations in Immunosuppressive regimen
was considered and patients were divided to 4 groups. Group 1 (15 patients)
developed severe, resistant leukopenia ,GI complications or hepatic injury,
so AZA and cellcept were discontinued permanently. Group 2 (38 patients)
developed leukopenia ,hepatic injury or GI complications at 3 mg/kg AZA
or 2gr cellcept which were reduced to 1mg/kg Aza or 1 gr cellcept. In
group 3, all 21 patients received AZA with the dose of 3 mg/kg without any
complication. In group 4 (31 patients) received cellcept 2gr daily without any
complication.
Results: Mean creatinine level was 1.32, 1.24, 1.31, 1.38 mg/dl in each group
respectively. There was no significant difference between mean age ,gender
and serum creatinine level in 4 groups .Age and sex had no effect on acute or
chronic rejection within 4 groups .
- Acute rejection was reported 4 ,2,4,4 patients of each group, respectively (non
significant )
-rejection and graft loss was observed in 3 cases only in group 1 (significant)

Conclusions: In our study significant increase of chronic rejection was observed
only in group 1 .No significant association between acute rejection and groups
was observed. So if side effects due to cellcept or AZA observed, cellcept 1gr
daily or a minimal dose of AZA (1mg/kg) with CsA and prednisolone can
prevent leukopenia, hepatic toxicity or GI complications without any significant
rise in incidence of acute or chronic rejection and graft loss.

POSTER BOARD NUMBER P1 – 52
966 AN EPIDEMIOGICAL, MULTICENTER, CROSSSECTIONAL STUDY TO ASSESS THE PREVALENCE OF
GASTROINTESTINAL DISORDERS IN MAINTENANCE
RENAL TRANSPLANT PATIENTS TREATED WITH
AN IMMUNOSUPPRESSIVE REGIMEN INCLUDING
MYCOPHENOLIC ACID (MPA)
M.C. Rial1, E. Maggiora2, M. Vazquez3, J. Pefaur4, M. Espinosa5
Instituto de Nefrologia Nephrology, BsAs Argentina, 2Sanatorio Mitre, BsAs
Argentina, 3Sanatorio Parque, Rosario Argentina, 4Hospital Barros Luco,
Santiago Chile, 5Hospital del Salvador, Santiago Chile
Introduction: Gastrointestinal (GI) disorders in maintenance renal transplant
patients treated with mycophenolic acid (MPA) are particularly important
due to the fact that they may lead to dose reductions or to discontinuation
of MPA therapy, which in turn have been shown to increase the incidence
of acute rejection and graft loss. An epidemiological, multicenter, crosssectional study was performed to assess the prevalence of GI disorders
and the GI symptom burden (GSRS questionnaire) in maintenance renal
transplant patients treated with an immunosuppressive regimen including
MPA.
Materials and Methods: From a total of 500 patients (pat) enrolled in
Argentina and Chile, 498 pat were analyzed, 209 received MMF and 289
Enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Data were
retrieved with a one visit record form including demographics, transplant
background, immunosuppressive treatment details and GSRS questionnaire.
Data were analyzed using descriptive statistics. T test and Chi square test were
used to compare both treatment groups.
Results: All baseline data were similar for both arms, except: retransplant rate:
MMF: 16/209 (8%) and EC-MPS: 57/289 (27%) (p=0.042); years post tx: MMF:
4.79±3.85, EC-MPS: 3.49±3.64 (p=0.001) and years of MPA: MMF: 3.49±2.56,
EC-MPS: 2.21±1.53 (p=0.001). The therapeutic combinations observed were:
MMF+CsA: 88 pat (42%). MMF+Tac: 61 pat (29%). MMF+Sirolimus: 42
pat (20%) and EC-MPS+CsA: 99 pat (34%). EC-MPS+Tac: 123 pat (43%).
EC-MPS+sirolimus: 52 pat (18%). other patients received a combination with
everolimus or only MPA+ steroids.
The prevalence of GI symptoms was 32% in the overall population (MMF:
34%, EC-MPS: 31%; p=ns). however a significantly higher proportion of
patients on EC-MPS were on full MPA dose (MMF: 31%, EC-MPS: 44%,
p=0.005). In patients on reduced MPA dose, the average dose (percentage
of full dose) was higher with EC-MPS, regardless of the CNI type: MMF
1542/2000 mg/day (77% of full dose) + CsA vs. EC-MPS 1190/1440 mg/day
(83%) + CsA; MMF 1324/2000 mg/day (66%) + Tac vs. EC-MPS 1101/1440
mg/day (76%) + Tac.
The GSRS scores were comparable in both treatment arms. A GSRS sub
analysis was additionally performed according to creatinine levels (> or
< to 1,5 mg/dl). In patients with creatinine levels >1,5 mg/dl (n=210) the
abdominal pain score was lower with EC-MPS vs. MMF (1,63 vs 1,89 –
p<0.05). The other items of GSRS questionnaire showed a positive trend in
favor of EC-MPS.
Conclusions: The prevalence of GI symptoms and the GI symptom burden
evaluated by GSRS were comparable between MMF and EC-MPS. However,
a larger proportion of patients on EC-MPS were treated with full MPA dose vs.
MMF. In addition, patients on reduced doses of EC-MPS received higher doses
of MPA than those on reduced doses of MMF. The abdominal pain score was
significantly lower in the population with creatinine levels >1,5 mg/dl treated
with EC-MPS.
1
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with standard-dose cyclosporine-based immunosuppression.
Methods: The Symphony study was the largest ever prospective study in
de novo solid organ transplant patients, designed to provide robust data
on the relative benefits of the four regimens tested. A total of 1645 kidney
recipients were enrolled from 83 sites in 15 countries for the one-year core
study comparing a standard regimen of 2 g MMF + cyclosporine + steroids
with regimens comprising 2 g MMF + daclizumab + steroids and low doses of
either cyclosporine, tacrolimus or sirolimus. Approximately half of the patients
were subsequently enrolled into an optional, observational, follow-up study of
additionally 2 years.
Results: The results at 1 year showed that the regimen based on MMF + lowdose tacrolimus resulted not only in significantly improved renal function,
but also in a significantly lower rate of acute rejection compared with the
other regimens. The benefits on renal function and acute rejection were also
confirmed by sub-analyses of the data stratified for country (e.g. with all donors
being living or deceased donors) or for various ages of the recipients. Similarly,
when rejectors and non-rejectors were analysed separately, the same pattern
remained, with MMF + low-dose tacrolimus having superior renal function,
not only in rejectors but also in non-rejectors. Graft survival was highest in the
MMF + low-dose tacrolimus group, and patient survival was excellent in all
treatment groups.
In the follow-up study, many patients changed their immunosuppressive
regimen (in particular, switching from sirolimus to tacrolimus). but the vast
majority (95%) remained on MMF at 3 years. In all groups, graft and patient
survival rates remained high, and acute rejection rates were low during the
second and third years. The MMF and low-dose tacrolimus arm still had the
highest GFR, although the difference was not statistically significant.
Conclusions: The Symphony study, the largest ever prospective study
performed in de novo solid organ transplantation, has provided robust and
valuable data on the efficacy and safety of CNI-minimisation regimens.
Most significantly, 2 g MMF + low-dose tacrolimus was shown to be
highly efficacious, without the negative effects on renal function that were
commonly reported in patients receiving standard CNI regimens. As a result
of the Symphony study and other data, 2 g MMF + low-dose tacrolimus has
become the gold standard immunosuppressive regimen in de novo kidney
transplant recipients. New standards in clinical transplant research have been
set, and the Symphony study will serve as the benchmark for future studies
in transplantation.
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967 RENAL FUNCTION IMPROVEMENT IN PATIENTS WITH
MAINTENANCE IMMUNOSUPPRESSION WHO INITIATE
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS)
A. Sánchez-Fructuoso1, J.C. Ruiz San Millán2, M. Rengel3, J.M. Morales4,
I. Beneyto5, V. Torregrosa6, C. Cantarell7
1
Hospital Clínico San Carlos, 2Hospital Marqués de Valdecilla, 3Hospital
Gregorio Marañón, 4Hospital 12de Octubre, 5Hospital La Fe, 6Hospital
Clinic, 7Hospital Vall d´Hebron
Introduction: Although the safety and efficacy of the new entericcoated mycophenolate sodium (EC-MPS) are comparable to those of the
mycophenolate mofetil (MMF). it still needs a lot of evaluation of its use in
routine clinical practice.
Objective, research design and methods: The aim of the current study was
to examine prospectively in routine clinical practice the efficacy and safety of
EC-MPS in 726 stable renal transplant patients at 1, 3, 6, and 12 months after
its initiation.
Data are presented at the end of the study (12th month).
Results: Mean age was 53±13 years, 56% males.
The main causes for the switch to EC-MPS were GI intolerance to MMF (44%; due
principally to diarrhea -30%-, abdominal pain -20%- or dyspepsia -17%-). chronic
nephropathy (16%; toxicity attributed to calcineurin inhibitor drugs (CNI) -11%and chronic rejection -5%-). or others (40%; from which 14% were for prevention
in order to reduce or suspend the dosage of CNI -10%- or steroids -3%-).
90% started with EC-MPS after the first post-transplant month (median time of
the transplant: 6.1 years).
Basal plasma through levels (PTL) of mycophenolic acid (MPA) taken after
conversion to EC-MPS increased from 2.0 ng/ml to 2.9 ng/ml at 12 months
(p<0.001). And this occurred even having received slightly lower than
equimolar doses of MPA (711 mg/d vs 648 mg/day, p<0.005). CsA and Tac
doses were also significantly reduced (163 mg/d vs 142 mg/d of CsA, p<0,001
and 5.1 mg/d vs 3.9 mg/d of Tac).
Before conversion, the evolution of creatinine clearance showed a negative
slope, reflecting a progressive deterioration of renal function, (p<0.005).
whereas after conversion the slope showed positive (p<0.05). indicating an
improvement in renal function.
CsA (169.04 mg/d basal to 142.91 mg/d at 12 months, p<0,001) and Tac (5.18
mg/d basal to 3.93 mg/d at 12 months, p<0,001) doses decreased along the study.
10.0% of patients quit the treatment with EC-MPS with 5.3% due to GI toxicity.
85 patients with GI intolerance to MMF were converted to EC-MPS: Among
these patients, 80% tolerated EC-MPS and more than 40% patients tolerated
well the drug up to doses more than 720 mg-d.
Conclusions: Treatment with EC-MPS results in significant changes in renal
function, reversing the progression of renal deterioration after 12 months after
beginning EC-MPS treatment. This may be attributed to the lowering of the
dose of CNI and/or a better immunosuppressive efficacy of EC-MPS, because
of an improvement in the GI tolerability and drug absorption.
The increased basal PTL of MPA and good tolerability could have been part of
the reasons for the CNI dose reductions.
There are patients with MMF intolerance that can be treated with full doses of ECMPS. EC-MPS tolerability has been good with a low rate of GI adverse effects.
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968 SIGNIFICANCE OF PK STUDY OF MPA IN RENAL
TRANSPLANTATION. A META-ANALYSIS AND PK STUDY
K. Yoshida1, M. Kobayashi2, Y. Miyashita2, Y. Takeuchi3, M. Arima2,
K. Yago2, T. Hirayama1, F. Obata4, M. Ikeda1, F. Noguchi1
1
Kitasato University Urology, 2Kitasato University Hospital Pharmacology,
3
Kitasato University Nephrology, 4Kitasato University Immunology
Purpose: Mycophenolate mofetil (MMF) is now widely used immunosuppressant
in renal transplantation (RTX). To avoid rejection and adverse events, monitoring
mycophenolic acid (MPA) level is recommended, but pharmacokinetics (PK)
monitoring of MPA is still controversial. We studied the relationship between
PK parameters of MPA and clinical event in RTX by meta-analysis, and
investigated PK parameters of RTX patients in our institute.
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Materials & Methods: A) META-ANALYSIS; We picked up papers by
MEDLINE and Cochrane Library (1996 to 2006) using eighteen terms related
to MPA, and investigated about 1) PK parameter and clinical outcome (acute
rejection (AR) and adverse event (AE). 2) target concentration of MPA, 3)
sampling point and frequency of monitoring, 4) method of measurement, 5)
induction and maintenance dose control. B) PK STUDY; We conducted PK
study of the RTX patient in our institute after obtaining patient fs consent under
control of our ethical committee. Blood sampling was done on 7 days, 1 month
and 3 months post transplant at before (C0) and 0.5 (C0.5). 1 (C1). 2 (C2). 3 (C3).
4 (C4). 6 (C6). and 8 (C8) hours after MMF administration. MPA concentration
was measured by HPLC, and data was analyzed by SPSS ver. 15.
Results: A) META-ANALYSIS; We finally choose eleven papers from 286
selected papers, and combined data. Significant relation was observed between
C0 & AUC of MPA and AR & AE (p<0.05). Significant increase of AR incidence
was occurred in the group of MPA AUC0-12 less than 30 ug h/ml (p<0.05). The
numbers of blood sampling points were between once to eight times to control
MPA concentration estimation. MPA was measured by HPLC in six papers out
of eleven. B) PK STUDY; We collected 205 blood samples from eleven living
and four cadaver RTX patients. Cyclosporine was used in five, and tacrolimus in
ten patients. PK parameters of MPA in those patients were C0; 4.5+/-2.5 ug/ml,
AUC0-12; 84.5+/-37.7 ug h/ml. AR was recognized in two patients and AE was
observed in 21 (such as anemia and CMV infection). Two AR were recognized
in the patients of both AUC0-12 less than 40 ug h/ml and C0 less than 1.3 ug/
ml. C0 was different in the patients of using cyclosporine from tacrolimus. AE
(anemia) was observed in 5 patients out of 6 who showed AUC0-12 more than
100 ug h/ml. From our PK study, calculated AUC0-12 estimation using the
result of C0 and C3 MPA measurement was recommended (r2=0.931).
Discussion: Significant relation was observed between PK parameters and AR
& AE in RTX by meta-analysis, suggesting efficacy to perform PK study of
MPA in RTX. From our results of PK study of MPA in RTX patients, the target
concentration of more than 1.3 ug/ml as C0 and 40 ug h/ml as AUC0-12 to avoid
AR may be recommended. AUC0-12 of less than 100 ug h/ml may also have to
maintain to avoid AE such as anemia. To estimate AUC0-12 from less frequent
sampling points, two points of C0 and C3 measurements of MPA were effective.
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969 OUTSTANDING GRAFT SURVIVAL AFTER INCLUSION
OF MYCOPHENOLATE MOFTIL IN INITIAL 114 RENAL
TRANSPLANTATIONS: SINGLE CENTER STUDY FROM
NORTHWESTERN PART OF INDIA
L.C.S. Laxmichand1, V. Malhotra2, D. Agarwal3, V. Khandelia4, J.H. Hota5,
V.K. Binwal6
1Institute of Renal Scincies, Sms Hospital,Jaipur, 2Institute of Renal Scincies,
Sms Hospital,Jaipur, 3Institute of Renal Scincies, Sms Hospital,Jaipur,
4Institute of Renal Scincies ,Sms Hospital,Jaipur, 5Institute of Renal Scincies,
Sms Hospital,Jaipur, 6Institute of Renal Scincies, Sms Hospital,Jaipur
Initial 114 renal transplants from live related donors were performed from
Jan 1999 to Feb. 2008 at SMS Hospital, Jaipur a tertiary care Hospital of
North West Rajasthan. Recipients were 104 males and 10 females, age
ranged between 16-50 years. Amongst Donors 22 were males & 92 females,
their ages were between 20 to 60 years. In 61 renal transplant; parents were
the donors and the rest include 26 siblings, 24 spousal and 3 second degree
relatives. All recipients received cyclosporine and prednisolone. Fiftynine
patients received azathioprine and 55 patients received mycophenolate mofetil.
Acute graft rejections were treated with 3 cycles of I.V. methylprednisolone.
HLA matching & cross matching were done. All patients were negative for
crossmatching. HLA matching was: 0 antigen matches in 10 cases, 1 in 31
cases, 2 in 58 cases, 3 in 12 cases & 4 in 3 case. Urological complications
occurred in 10 cases consisting of 8 urinary leaks, 2 ureteral stenosis. In 2 cases
renal artery thrombosis took place. Out of 114 patients 17 expired, sepsis being
the main cause of death in 15 patients followed by preumonia, CMV infection
& hepatic failure due to hepatitis-C.
Overall patients survival for last 9 years were 85%, for last 3 years 87% and there
was much improved graft survival in last 2 & 1 years 91%, 100% respectively.
The mycophenolate mofetil was started as third immunosuppression replacing
azathioprine after 2005, resulted in less number of acute rejection episodes and
excellent graft & patient survival in last 2 years which reached to 100% in the
year 2007.
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970 AZATHRIOPRINE IS BETTER THAN MYCOPHENOLATE
MOFITIL IN LONG TERM KIDNEY GRAFT FUNCTION.
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971 TWELVE MONTH FOLLOWUP OF GASTROINTESTINAL
(GI) CO-MEDICATION DISCONTINUATION OR REDUCTION
IN RENAL TRANSPLANT PATIENTS AFTER CONVERSION
FROM MYCOPHENOLATE MOFETIL (MMF) TO
MYCOPHENOLATE SODIUM (EC-MPS)
P. Bolin, P. Vos, P. Sullivan, S. Gerkin, K. Parker
Brody School of Medicine, East Carolina University
Purpose: To evaluate if successful discontinuation or reduction of GI comedication use is sustainable 12 months after conversion from MMF to ECMPS.
Methods: Fifty-four renal transplant patients on a GI co-medication were
recruited from a single center cohort of 93 patients who had successfully
converted from MMF to EC-MPS in a previous study. These patients were
placed on a protocol to reduce or discontinue their GI co-medication.
Additional follow up was conducted at one year. At baseline, patients on twice
a day GI co-medication were reduced to daily dosing and at 30 day visit further
reduced to PRN. Patients on daily dosing at baseline were reduced to PRN.
All patients were given pocket diaries to record GI co-medication use and
potential cost savings. Assessments for GI symptoms were performed using
Gastrointestinal Symptom Rating Scale (GSRS). Gastrointestinal Quality of
Life Index (GIQLI) and Psychological General Well-Being Index (PGWBI)
at each visit.
Results: Successful discontinuation or reduction of GI co-medication
was achieved in 42 (78%) patients after 30 days and maintained through
day 90. There was no significant change in assessments from baseline to
day 30 or 90 despite discontinuation or reduction in GI co-medication.
Twenty-four patients (44%) were taking Proton Pump Inhibitors (PPIs) and
30 (56%) were taking H-2 blockers at enrollment. Twelve month follow
up demonstrated sustained improvement in 32 (91%) of these patients. A
balanced reduction of both PPIs and H-2 blockers was observed. Estimated
cost savings per patient for H-2 blockers are $925-$1850 and PPIs are
$1861-$3722 annually.
Conclusion: This study supports successful long term minimization of GI
co-medications in maintenance renal transplant patients after conversion
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D. Sirivongs, U. Toimamueang, C. Pongskul, S. Reungjui
Khon Kaen University, Faculty of Medicine
Background: Azathrioprine have been replaced by mycophenolate mofitil
in 3-drug regimen of KT for a decade, but it is still used in many centers
in developing countries. To analyze outcome of KT patients with Aza
compared with ones with MMF, we performed a retrospective analytic
study.
Methods: We reviewed 204 renal transplant recipients who had the operations
performed at our facility during 1990-2007 and who had received a primary
immunosuppressive protocol consisting of CSA, steroid and azathioprine
(AZAgr; 51 patients) or CSA, steroid and MMF (MMFgr; 153 patients). Only
adult primary renal transplant recipients aged between 15 and 60 years were
included. All cases received kidneys from cadaveric donors. The study was
based on the long-term follow-up data of these renal transplant recipients.
Comparative analyses included graft survival rates, rejection (acute and
chronic). PTDM and opportunistic infection.
Results: The overall frequency of acute rejection episodes was not
significantly different between both groups. Graft survival rate was: 50%
survival in AZAgr was 59 mo. compared to 48 mo. of MMFgr (p=0.0000).
Four cases of AZAgr showed serious bone marrow suppression compared
to 2 cases of MMFgr. No significant differences were encountered
between the two groups regarding post-transplant diabetes mellitus, DGF,
or serious bacterial infections. Conclusion: AZA is still be a choice of
immunosuppressive drugs for KT, but may need a preventive measure for
bone marrow suppression. The survival outcome of AZAgr is quite good
and significant better than MMFgr. AZA should be reconsidered as a good
immunosuppressive drug for KT.

to EC-MPS. These data suggest that after conversion to EC-MPS renal
transplant patients can successfully reduce or discontinue GI co-medication
without worsening of symptom burden, while maintaining their health-related
quality of life and overall well-being. Considering graft survival rates of 72%
at 5 years this could translate into significant long term savings for renal
transplant patients. In addition, avoidance of GI co-medication is important
considering the multiple potential complications recently described in this
class of medication.
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972 50% OF THE RENAL TRANSPLANT PATIENTS THAT
CAN NOT REACH THERAPEUTIC MYCOPHENOLIC ACID
LEVELS WITH MMF BECAUSE OF GI INTOLERANCE,
ACHIEVED THERAPEUTIC LEVELS WITH EC-MPS.
J.M. Puig, M. Mir, S. Hurtado, O. Rap, M. Crespo, C. Barrios, F. Barbosa,
C. Estadella, E. Rodriguez, J. Lloveras
Hospital Del Mar, Nephrology Dept
Mycophenolic acid (MPA) trough levels are significantly related to acute
rejection incidence, but also to gastrointestinal (GI) and hematological
toxicity. At equimolar doses, enteric-coated mycophenolate sodium (ECMPS) may provide significantly higher MPA area under the curve (AUC). and
Cmin than mycophenolate mofetil (MMF). The study objective is to analyse
whether stable RT patients treated with tacrolimus (TAC) or cyclosporine
(CsA) and MMF with persistently MPA Cmin levels below the therapeutic
window (1.5ng/ml-4ng/ml) because of GI intolerance, could reach the desired
level with equimolar or higher EC-MPS doses.
Methods: Due to the high intraindividual variability in the MMF
absorption profile, we defined MPA undertherapeutic levels as Cmin
under 1,5ng/ml in at least two of the last five level measurements ie:
at least 40% of the time below the therapeutic window. We studied 40
long-term stable RT patients. 61% men. Age: 53.4±13.4y. Time from RT:
2.5±3.6y. Deceased donor: 95%. Second RT: 15%, highly sensitized: 10%.
Induction treatment: policlonal antibodies: 28%, OKT3: 5%, Daclizumab:
59%, TAC: 87%, CsA: 13% and steroids: 100%. Maintenance treatment:
TAC+MMF: 97%, CsA+MMF: 2.5%, steroids: 23%. Target levels: TAC:
7-10ng/ml, CsA C2: 600-850ng/ml, MPA: 1.5-4ng/ml. All patients were
switched from MMF to equivalent EC-MPS doses. After the conversion,
EC-MPS dose was increased by 50% in those patients that still were under
the therapeutic level in two o more controls, provided that there were no
GI side effects and leukocyte count was over 4000. Those patients that still
were under the desired level despite increasing doses, EC-MPS was further
increased by 180mg/d.
Results: When MMF maintenance dose was switched from 0.75±0.39g/d
to the equivalent 0.54±0.22g/d of EC-MPS, 11/40 patients (28%) reached
the objective with MPA levels of 2.58±2.1ng/ml. When EC-MPS dose
was rised by 50% (0.81±0.37g/d). other 9/29 patients (31%) achieved and
tolerated MPA levels of 2.63±2.3ng/ml. Of the remainig 20 patients no one
tolerated any further increment without appearence of GI side-effects. After
rising the EC-MPS dose by 50%, there was a non significant trend towards
a drop in the number of leukocytes, hemoglobin and platelets. In no case
this drop lead to lowering EC-MPS doses or treatment withdrawal. No acute
rejection episodes were observed and no dose-adjustement of TAC or CsA
was needed.
Conclusions: In long-term stable RT patients with subtherapeutic MPA levels
because of GI adverse-effects, 28% achieve therapeutic levels after equivalent
dose conversion from MMF to EC-MPS. An additional 31% of the remaining
patients, reach the desired levels after increasing EC-MPS dose by 50% without
new-onset GI side effects.
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973 USE OF MYCOPHENOLATE SODIUM AND MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS
P.F. Fernandes, G. Silva Junior, J.P. Ferreira Silva, M. Uchoa Mota,
S. Albuquerque Andrade, C. Oliveira, J.B. Evangelista Junior
Renal Transplant Unit, Walter Cantidio University Hospital, Federal
University of Ceara
Background/Objectives: Therapeutic equivalence of mycophenolate sodium
and mycophenolate mofetil has been established in randomized trials. The aim
of this study is to analyze the use of enteric coated mycophenolate sodium
(MPS) and mycophenolate mofetil (MMF) in renal transplant recipients.
Methods: This is a case-series study, conducted a study from July 2007 to January
2008, including 21 renal transplant recipients in Brazil. It was investigated the
occurrence of biopsy-proven acute rejection (BPAR). infection, gastro-intestinal
side effects, graft loss, rejection and the need for drug discontinuation or dose
reduction. Descriptive statistical analysis was done.
Results: It was included 21 patients, with an average age of 45 years
(range 21-68 years); 12 were male. The immunosuppressive regimens were
Prednisone/MMF/FK (7 cases). Prednisone/MPS/FK (11 cases). Prednisone/
MPS/Ciclosporine, Prednisone/MPS/FK and MPS/Ciclosporine (1 case each).
BPAR was observed in 4 cases (2 in Pred/MMF/FK regimen, 1 in Pred/MPS/
FK regimen); three had graft loss (1 primary non-function in Pred/MMF/FK
regimen, 1 renal artery thrombosis in Pred/MPS/Ciclosporine regimen, 1 renal
vein thrombosis in Pred/MPS/FK regimen). Gastro-intestinal side-effects were
observed in 5 cases (3 using MPS, 2 using MMF). Infection occurred in 8
cases, being more frequent in patients using MPS.
Conclusion: These are the first data regarding the use of MPS in our unit. MPS
seems to be as safe as MMF in renal transplant recipients. Further studies are
required to better establish the main differences in using these medications in
immunosuppressive regimens.
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974 ANALYSIS OF CONVERSION FROM MYCOPHENOLATE
MOFETIL TO ENTERIC-COATED MYCOPHENOLATE
SODIUM (EC-MPS, MYFORTIC) IN RENAL TRANSPLANT
PATIENT USING PATIENT-REPORTED OUTCOMES
W. Arns1, K. Budde2, B. Nonnast-Daniel3, K. Eichele4, W. Fischer4,
P. Petersen5, D. Scholz5, H. Sperschneider5, L. Fricke5, P. Reinke2
1
Cologne General Hospital, 2Berlin University Charite Berlin, 3University
Hospital Nuernberg, 4Novartis Pharma Nuernberg, 5on behalf of the MyLife
study group
Background: The benefit of converting renal transplant recipients with
gastrointestinal (GI) complaints from mycophenolate mofetil (MMF) to
enteric-coated mycophenolate sodium (EC-MPS) has been evaluated using
patient-reported outcomes. To our knowledge, no validated data are available
including either patients with or without GI complications before conversion.
Methods: A multi-center, open-label, prospective study was undertaken in
MMF-treated renal transplant recipients. Patients were converted to equimolar
EC-MPS. At baseline and Visit 2 (6–8 weeks post-baseline). patients completed
the Gastrointestinal Symptom Rating Scale (GSRS). Gastrointestinal Quality of
Life Index (GIQLI) and Psychological General Wellbeing Index (PGWBI). At
Visit 2, patients and physicians completed the Overall Treatment Effect (OTE)
scale for GI symptoms and health-related quality of life (patients only).
Results: Of 196 patients enrolled, 100 experienced GI complications at
baseline. These patients revealed significant improvement for GSRS, GIQLI
and PGWBI total scores as well as for the OTE scale between baseline and
Visit 2 (all p<0.001, except p<0.01 for PGWBI). Mean improvement in GSRS
score (-0.43) exceeds the assumed minimally clinical important difference
in the GSRS score of 0.33. Primary endpoint analysis, i.e. change of GSRS
in the total population revealed no significant differences, however, the total
population improved in GIQLI and OTE scales (p<0.001).
Conclusion: This study supports that converting patients with GI complaints
to EC-MPS significantly reduces GI-related symptom burden and improves
patient health-related quality of life. Moreover, this study indicates that the
entire population might benefit from conversion in terms of quality of life and
OTE for GI symptoms.
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975 THE EFFICACY AND SAFETY OF TAILORED
MYCOPHENOLATE THERAPY BASED ON BODY WEIGHT
AND MYCOPHENOLIC ACID TROUGH LEVELS IN ASIAN
RENAL TRANSPLANT RECIPIENTS.
T. Kee, A. Vathsala
Singapore General Hospital
Introduction: At our centre, a higher incidence of leukopenia and CMV
infections were seen with fixed dosing [1g twice daily (BD) ] of mycophenolate
mofetil (MMF) compared to azathioprine treated renal transplant recipients
(RTX). A dosing protocol based on body weight (10mg/kg/dose) was utilised
between 2003 and 2006. Therefore, we compared in de novo RTX, the safety and
efficacy of MMF fixed (FD) versus tailored dosing (TD) based on body weight
with subsequent titration to mycophenolic acid trough level (MPA-C0).
Methods: The study population consisted of 63 RTX (26 TD-RTX, 37 FDRTX; Weight 56.2 kg [range 37-93 kg]) on cyclosporine (adjusted to 2-h post
dose (C2) of 1,200-1,500 ng/mL for the first month and 1,000-1,200 ng/mL up
to six months). corticosteroids and MMF. The starting MMF dose was 10mg/
kg/dose BD and 1g BD for TD and FD-RTX respectively. Subsequent doses
were adjusted to clinical events or to MPA-C0 of less than 4 ng/mL for TDRTX. MPA-C0 were obtained at day 7, 14, 30 and monthly thereafter.
Results: All TD-RTX received deceased donor kidneys (compared to
27% [n=10/37] of FD-RTX) and 1 recipient per group were CMV D+/R-.
Prophylaxis was pre-emptive in 88.5% [n=23/26] of TD-RTX and universal in
67.6% [n=25/37] of FD-RTX. Mean initial MMF dose for TD-RTX and FDRTX were 9.6±1.2 mg/kg/dose and 17.0±4.6 mg/kg/dose respectively (TD vs.
FD-RTX; p<0.005). During 6-month follow-up, 61.5% (n=16/26) of TD-RTX
vs. 43.2% (n=16/37) of FD-RTX had dose reductions (p=0.15). Frequency of
adverse events prompting dose reductions between TD-RTX and FD-RTX were
similar (50% [n=13/26] vs. 40.5% [n=15/37]; p=0.45). Between TD and FDRTX, adverse events included rejections (15.4% [n=4/26] vs. 8.1% [n=3/37];
p=0.37], CMV disease (15.4% [n=4/26] vs. 8.1% [n=3/37]; p=0.37], bacterial
infections (42.3% [n=11/26] vs. 40.5% [n=15/37]; p=0.88). cytopenias (7.7%
[n=2/26] vs. 18.9% [n=7/37]; p=0.21) and gastrointestinal complications (0 vs.
10.8% [n=4/37]; p=0.08). Compared to initial MMF dose, dose used in FDRTX was significantly reduced at 6 months to 14.7±5.5 mg/kg/dose (p=0.01)
whereas doses used in TD-RTX was not significantly different (8.1±2.2 mg/
kg/dose at 6 months; p=0.22). Withdrawal of MMF occurred in 1 FD-RTX
at 3 months post-transplantation for CMV disease. Within TD-RTX, MPA-C0
were maintained below 4 ng/mL (1.8±0.7 ng/mL to 2.6±1.2 ng/mL) during
follow-up. C2 levels were also similar between TD-RTX and FD-RTX except
at 4 (1,010±331 ng/mL vs. 1,235±349 ng/mL; p=0.03) and 6 months (871±266
ng/mL vs. 1,048±181 ng/mL; p=0.01) post-transplantation. At six months,
calculated glomerular filtration rate were similar between TD-RTX and FDRTX (48.1±19.6 ml/min/1.73m2 vs. 47.2±12.4 ml/min/1.73m2; p=0.8).
Conclusions: Only 57% of FD-RTX could be maintained on 1g BD for six months
without adverse events in an Asian RTX population. In contradistinction, TDRTX who were dosed by body weight and subsequently titrated to MPA-C0 had
similar outcomes to FD-RTX. Refinements in a titrated dosing strategy may further
optimise mycophenolate use in a population with wide variations in body weight.
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976 MMF 500 GENERIC FORMULATION IN KIDNEY
TRANSPLANTATION
B. Abdallah 1-2, I. Helal 1, M. Ounissi 1, M. Cherif1, R. Goucha1,
E. Abderrahim 1, A. Klouz2, M. Lakhal2, Y. Gorgi3, A. Kheder 1
1Department of Internal Medicine A Charles Nicolle Hospital,
2Pharmacovigilance department Charles Nicolle Hospital, 3immunology
laboratory department Charles Nicolle Hospital
Introduction: The Introduction of mycophenolate mofetil (MMF) has proven
to be effective in the prevention of acute rejection in renal transplant recipients.
However his prohibitive cost renders its long-term use in countries with limited
income.This 6-month single center, prospective, randomized and open-label
study instigated the efficacy and safety of a new MMF generic formulation
(MMF 500 developed by Medis – Tunisia) compared with Cellcept (Hoffman
La Roche Switzerland) renal transplant recipients.The study enrolled 18
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977 LONG-TERM OUTCOME OF MYCOPHENOLATE
MOFETIL ADDITION TO CALCINEURIN-INHIBITORBASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT
RECIPIENTS WITH BIOPSY PROVEN CHRONIC GRAFT
DYSFUNCTION
M. Durlik1, A. Urbanowicz1, E. Blazik1, E. Wazna1, A. Perkowska1, T.
Cieciura1,
A. Kwiatkowski2, Z. Galazka3
1
Transplantation Institute, Dept. of Transplant Medicine and Nephrology,
Warsaw Medical University, 2Dept. of General and Trasnplant Surgery, 3Dept.
of General, Vascular and Trasnplant Surgery
Introduction: Chronic graft dysfunction, a major cause of late renal graft
loss, is promoted in part by prolonged exposure to calcineurin inhibitor (CnI).
Mycophenolate mofetil (MMF) addition improves renal function in short term.
Long term outcome and safety profile still awaits verification.
Aim: Evaluation of long term MMF effect on renal graft function in recipients
with biopsy-proven graft dysfunction, treated with cyclosporine (Cs) or
tacrolimus (Tac). with further continuation, reduction or withdrawal of CnI.
Methods: 109 recipients with declining renal function were included, after
addition of MMF to Cs (n=96) or Tac (n=13) at month 72 and 13 posttransplant
for Cs and Tac, respectively. CnI was reduced (Group R, n=50 for Cs, n=6 for
Tac). withdrawn (Group W, n=28 for Cs, n=4 for Tac) or not changed (Group
C, n=18 for Cs, n=3 for Tac). Slopes of GFR (estimated with short MDRD
[eGFR]). along with proteinuria, lipid profile, mean blood pressure (MAP) and
antihypertensives were recorded for 4-6 month run-in, and followed-up for 1
(n=109) to 3 years (n=60).
Results: MMF improved renal function in all groups (eGFR slope [mL/month]
-1.462 1.52 vs. -0.098 1.16, p<0.0001). independently of CnI used or group (R,
W, C) effect. Proteinuria and lipids level did not change after MMF addition,
however total cholesterol was lower in Tac treated recipients (212.2 vs. 179.8,
p<0.002, for Cs and Tac, respectively). MAP lowered similarly in both CnI
groups (102 6.3 vs. 98.4 6.8, p<0.006). with no change in antihypertensives
use (2.82 vs. 2.62 and 1.84 vs 2.0 in Cs and Tac group, respectively). Use
of antihypertensives tended to be lower in Tac group. 7 reversible rejection
episodes were observed exclusively in Cs group (3, 2, and 2 in Group R, W,
and C,respectively).
Conclusions: MMF added to CnI-based immunosuppressive regimen stably
improves transplanted kidney function in long-term, as does blood pressure
control in recipients with chronic graft dysfunction independently of CnI type
or its further continuation. Risk of late rejection concerns only Cs treated
patients, it does not exceed 10% independently of further continuation of Cs.
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978 A OPEN-LABEL, PROSPECTIVE RANDOMIZED TRIAL
TO COMPARE TOLERABILITY AND OUTCOME FOR TWO
FORMULATIONS OF MYCOPHENOLATE
Y. Qazi1,2, S. Takemoto3, R. Mateo1, J. Alameda1, C. Romero1, S. Schroff1,
A. Tsirunyan3, T. Shah2,3
1University of Southern California, 2MOTC, St Vincents Medical Center,
3National Institute of Transplantation
Two formulations of mycophenolate have essentially replaced Azathioprine, and
made antiproliferatives (AP) a cornerstone of maintenance immunosuppression.
However, data comparing their relative efficacy in denovo patients are lacking.
For instance, little is known, to what extent side effects such as gastrointestinal
irritation or anemia warrant dose reductions. The objectives of this study were
to compare the efficacy and tolerability of these formulations over a six month
period.
Methods: A total of 111 subjects were enrolled at two institutions to receive
either mycophenolate mofetil (MMF) or Enteric coated mycophenolic acid
(EC-MPA) with a calcineurin inhibitor (tacrolimus or cyclosporine). steroids
and induction. Target dosages were 1000 mg BID for MMF and 720 mg BID
for EC-MPA. Doses were reduced if white blood count fell below 4,000 cells
per ml or if a patient developed gastrointestinal or other side effects that might
be attributable to the AP. A composite endpoint of rejection, graft loss and death
was used to compare efficacy with rates calculated using the Kaplan Meier
produce limit method and significance by log rank. Chi-square was used to test
for significance in the percentage of patients receiving full dose AP and the
association of complications prior to dose change.
Results: Dose reductions occurred in 40% (n=44) of enrolled patients. Clinical
events occurring at significant rates prior to dose reduction included delayed
graft function (9% vs. 0% with no dose reduction, p=0.01). diarrhea (11% vs.
0%, p=0.005). urinary tract infection (14% vs. 0%, p=0.002). and anemia (7%
vs. 0%, p=0.03). The table below illustrates the percentage of patients on full
dose AP during the four clinic follow-up visits. Patients receiving EC-MPA
more likely tolerated full dose AP compared to MMF, with the difference
statistically significant through 3 months. The percentage of patients reaching
the composite rejection endpoint at the 6 month time point was similar (15%)
for the two arms of the study.
Conclusions: This prospective randomized comparison of two anti-proliferative
formulations indicates patients receiving enteric coated mycophenolic acid more
likely tolerated full intended doses compared to those receiving mycophenolate
mofetil. This better tolerability can have positive effects on clinical outcomes
besides facilitating compliance.
Percentage of patients on full dose antiproliferative
EC-MPA
MMF
P

Week 2
90.7
75.6
0.047

Month 1
90.4
69.2
0.007

Month 3
84.3
57.8
0.004

Month 6
75.0
56.4
0.074
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979 BILIARY HEMORRHAGE AFTER REMOVAL OF
EXPANDABLE METALLIC STENT DURING LIVER
TRANSPLANTATION
S. Narumi, K. Hakamada, Y. Toyoki, M. Nara, S. Yoshihara, M. Sasaki
Department of Surgery, Hirosaki University School of Medicine
Introduction: The self-expandable metallic stent (SEMS) has become a
common device for palliative treatment of malignant biliary obstructions or
benign strictures. Despite the ease in the placement of SEMSs, their removal
has been reported to be very difficult. Here, we report a case with primary
sclerosing cholangitis (PSC) who developed massive hemorrhage after
intraoperative removal of a SEMS.
Case: Possible living donor liver transplantation was considered for a
49-year-old female with PSC. However, her general condition did not meet
the criteria for liver transplantation; therefore, she was referred back to her
primary physician. Two years later, she developed jaundice, and multiple
SEMSs were placed by her primary physician, one of which was placed
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patients from February to august 2007 divided in 2 groups: 8 pts in G1 received
MMF 500 and 10 pts in G2 received Cellcept. Their demographics data were
similar: respectively mean age (y) 36.7 + 7.1 and 33.3±11.7, sex M/F: 2/6
and 5/5, mean age donor 42.6 +11.9 and 43.6±3.9, mean HLA mismatchs 2.7
±1.1 and 3.3 ±1.4, cadaveric donors 25% and 20%, warm ischemia time 40.2±
11.9 and 38.7± 10.5 minutes.All patients received 2 gr. daily of MMF500 or
Cellcept in combination with tacrolimus at an initial dosage of 0.15 mg/Kg/day
and prednisolone.
Results:
Acute creat Diarrhea Infection AUC*day 7AUC*day 30
rejection6 months Nb
(μmol/l)
G1
1
120.7±24.4
2
6
25.9
34.1
G2
1
100.4±16.8
3
9
27.5
27.1
P
NS
NS
NS
NS
NS
NS
AUC is expressed In ng/ml/h
The graft and patient survival at months were at 100% in the 2 groups In
conclusion, These results indicated that the use of MMF500 provided safe and
effective immunosuppression compared with cellcept. However as the duration
of the study was short, these results need to be confirmed in long term.
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across the papilla of Vater. She was evaluated rapidly, and underwent living
donor liver transplantation. During the operation, the common bile duct was
examined and an incision was made. A stent was found firmly embedded
in the bile duct. Each wire of the SEMS was pinched and then successfully
pulled out one by one. Finally, all parts of the SEMS were removed. Before
creating the Roux-en-Y limb, hemorrhage from the remnant bile duct was
confirmed by examination of the duodenum and bile duct stump. The bile
duct was sewn internally with monofilament stitches and compressed for
10 min. Finally, hemostasis was brought about and transplantation was
completed successfully.
Conclusion: Despite some reports regarding successful endoscopic removal of
SEMSs, its removal in patients with coagulopathy is risky. SEMSs should not
be placed in patients for liver transplantation.

POSTER BOARD NUMBER P1 – 66

Of the veins that presented a common trunk 15.5% there was a common trunk
formed by the middle hepatic vein and two left hepatic veins. In 6.7%, there
was a common trunk formed by the middle hepatic vein, the left hepatic vein,
and a vein from segment IV. In 2.2%, there was a trunk formed by four veins:
a middle hepatic vein, two left hepatic veins, and one independent vein from
segment VIII.
The veins of the segment I formed a common trunk that has a diameter ranging
from 0.5 to 0.7 centimeter.
The mean of dorsal hepatic veins entering the vena cava was 11, however up to
28 were noted on one occasion.
Conclusions: 1- Compared with studies performed in Japan and US hepatic
vein anatomy has similar variations in our ethnic group
2- The only difference see in our ethnic group was the presence of 3 right
hepatic veins all largest than 0.5cms which has not been previously described
in the literature.

980 “BILE LEAK AFTER ADULT RIGHT LOBE SPLIT
LIVER TRANSPLANTATION: ARE TOPICAL SEALANTS
EFFECTIVE?”
L. Toti, M. Attia, T.M. Manzia, I. Lenci, B. Gunson, J. Buckels, D.F. Mirza,
A.D. Mayer, S.R. Bramhall, S.J. Wigmore
Liver Unit – Queen Elizabeth Hospital – University of Birmingham – UK
Background: Bile leaks are a frequent complication of adult split liver
transplantation. We compared surgical complications in patients who
had the cut surface of the liver treated with a fibrin-collagen sponge
(Tachosil®) and patients in whom the cut surface of the liver was treated
with fibrin glue.
Methods: Two consecutive cohorts of 16 patients undergoing adult right lobe
split liver transplant were compared. In the first cohort the liver was treated
with Tachosil® fibrinogen-thrombin-collagen sponge patches and in the second
the liver surface was treated with fibrin glue. Blood usage and post operative
complications were documented.
Results: Blood usage in both groups was equal. Patients in whom the cut
surface of the liver was treated with Tachosil® had significantly fewer bile
leaks (1 of 16) compared with those where fibrin glue was used on the cut
surface (7 of 16) (p<0.03). There were some differences in biliary anastomotic
techniques used in the two groups but 7 of 8 leaks arose from the cut surface
only and 1 from both the surface and anastomosis.
Conclusions: Using a fibrinogen-thrombin-collagen sponge patch such as
Tachosil® may reduce bile leaks from the cut surface of adult right lobe split
liver transplants.

POSTER BOARD NUMBER P1 – 67
981 SURGICAL ANATOMY BY CORROSION CAST OF THE
HEPATIC VEINS IN COLOMBIA SOUTH AMERICA
E. Lozano Marquez
Universidad Nacional De Colombia Departamento De Cirugía Y Morfología
Background: To determine if the surgical anatomy of the hepatic veins among
Colombians is similar to the one described in the literature.
Materials & Methods: 50 normal livers ,mean age 30 (age 5-50) obtained
from autopsies were studied.
The hepatic veins were injected retrogadely from the vena cava with colored
acrylic resin .After hardening of the acrylic resin ,the livers were corrosioned
in caustic soda.
Results: The 90% of the right hepatic vein drains segments VI and VII, and
several parts of segments V and VIII. The middle hepatic vein always drains
segments IV and V, and to some extent segment VIII. In 10% the middle hepatic
vein also drained segment VI. The left hepatic vein drains segments II and III;
in 12%cases, it also drained segment IV.
The right hepatic vein was single in 82% casts and double or more in 18%. 12%
had an accessory right hepatic vein parallel to the main right hepatic vein; in
6%, there were three right hepatic veins all of which were > 5mm.
64% have no ramification within 1 centimeter from the inferior vena cava; 22%
have one vein within less than 1 centimeter and 14% have two veins within 1
centimeter.
The middle and left hepatic veins presented a common trunk in 90% of our
cases,while in 10% the middle and left hepatic veins were independent.
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982 THE EFFECTS OF MICROSURGICAL BACK WALL
SUPPORT SUTURE TECHNIQUE IN LIVING-DONOR LIVER
TRANSPLANTATION
S. Miyagi, Y. Enomoto, N. Kawagishi, S. Sekiguchi, Y. Akamatsu,
K. Fujimori, S. Satomi
Transplantation, Reconstruction And Endoscopic Surgery, Tohoku University
Objectives: Microsurgical reconstruction of hepatic artery is the essential
but challenging technique in liver transplantation (LTx). Especially on living
donor, compared with cadaveric donor, hepatic artery is short, the intimal
damage is severe, and usable vessel grafts are limited. So, sometimes it
is difficult to used conventional reconstruction technique, twist technique
that turned over the hepatic artery. To overcome these difficulties we
performed back wall support suture technique with double needle sutures.
The purpose of this study is to examine the effects of this technique using
ultrasonography.
Methods: From July 1991 to January 2008, we performed 118cases of
living-donor LTx (LDLTx). In the 88cases, we used conventional twist
technique. In the 30cases, we used back wall support suture technique. To
put it briefly, we placed two sutures at the deepest, most difficult points in
the artery for backside support. Each stitch was placed from inner side of
the arterial wall to outer side with double needle sutures. We performed
ultrasonography every day after LDLTx and examined pulsatile index (PI:
peak systolic-end diasto!ic/mean velocities) and resistive index (RI: peak
systolic-end diastolic/peak systolic velocities) on 1, 5, 7 and 14 days after
operation.
Results: Total ratio of hepatic artery thrombosis (HAT) was 7.6% (9/118).
In the conventional twist technique group, HAT occurred in eight patients
9.1% (8/88). On the other hand, in the new technique group, it occurred
only one patient 3.3% (1/30). This patient had intimal dissection in recipient
original artery. So there is no case of HAT that was associated with arterial
reconstruction in new technique group. PI in the conventional group versus
in the new technique group on 1, 5, 7 and 14 days after operation was 1.380,
1.852, 1.204 and 1.006 versus 1.550, 1.606, 1.570 and 1.347 respectively. RI
in the conventional group versus in the new technique group on 1, 5, 7 and 14
days after operation was 0.772, 0.776, 0.598 and 0.577 versus 0.722, 0.735,
0.739 and 0.694 respectively. The values of PI on 14 day and RI on 7 and 14
days in the new technique group were significantly higher than those in the
conventional group.
Conclusion: We think that our technique allows for safe intimal adaptation,
because it didn ft need turning over of the artery and all stitches are carried
from inside to outside. In conclusion, this back wall support suture technique
might contribute to more satisfactory results.
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983 BILIARY RECONSTRUCTIONS AND COMPLICATIONS
AFTER ADULT LIVING DONOR LIVER TRANSPLANTATION –
FEASIBILITY OF DUCT-TO-DUCT RECONSTRUCTION WITH
T-TUBE EXTERNAL STENT

984 EARLY RESULTS OF BILE DUCT RECONSTRUCTION
WITHOUT STENT FOR LIVER TRANSPLANTATION
M. Haberal1, H. Karakayali1, S. Sevmis1, G. Moray1, C. Aydogan1, A. Torgay2,
G. Arslan2
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Anesthesiology
Biliary complications are some of the most important problems in liver
transplantation (LT). Although T tubes and stents are widely used for routine
biliary reconstruction in LT, which lead to complications, and there is no proof
that they are beneficial on healing. In this report, we describe our results of
biliary reconstruction without stenting in both deceased and living-donor
LT. Two hundred and twelve LTs were performed between January 2001 and
January 2008 at our center. Before December 2006, we used different drainage
techniques for biliary reconstruction including T tubes, straight feeding tubes,
and transhepatic catheters. Since December 2006, we have performed biliary
reconstruction without a drainage catheter for both deceased and living-donor
LT. After December 2006, 70 LTs (44 males, 26 females; median age, 25.2 ± 20.7
years; range, 0.5 to 60 years) were performed, the results of which were reviewed
retrospectively. Thirty-four of these 70 recipients were children, 17 of them were
under the age of 1 year at the time of LT. Thirteen recipients received a wholeliver graft, 24 received a right lobe graft, and 33 received a left-lateral lobe or left
lobe graft. Biliary reconstruction was performed with a duct-to-duct anastomosis
in 51 recipients and with a Roux-en-Y hepaticojejunostomy in 19. Fifty-two of
the 70 grafts had single bile duct, 14grafts had 2 bile ducts, 3 grafts had 3 bile
ducts, and 1 graft had 4 bile ducts. Biliary leak was seen in 3 recipients, and biliary
stenosis was seen in 8 during the follow-up 7.7&#61617;4.7 months (range, 1
to 16 months). All complications were treated with interventional radiological
approach. Five recipients died, and remaining 65 (93%) recipients are alive in
this series. We conclude that biliary reconstruction without using a stent is safe
for both deceased and living-donor LT, even for the pediatric recipients
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985 LATE VASCULAR COMPLICATIONS AFTER LIVINGDONOR LIVER TRANSPLANT
M. Haberal1, S. Sevmis1, F. Boyvat2, H. Karakayali1, G. Moray1, A. Torgay3,
C. Aydogan1, G. Arslan3
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Radiology, 3Baskent
University Faculty of Medicine, Department of Anesthesiology
The aim of this study was to assess the late vascular complications (which occurred
> 6 months after transplant) in 168 living-donor liver transplants (LDLTs) in
165 recipients (93 pediatric, 72 adult, 114 males, 51 females) at our center
between September 2001 and January 2008. These 168 LDLTs were analyzed
retrospectively. The mean age of the pediatric recipients was 6.5 &#61617; 5.4
years (range, 2 months to 17 years). and the mean age of the adult recipients
was 41.3 &#61617; 12.6 years (range, 18-66 years). The vascular complications
were identified by Doppler ultrasonography; then, the diagnosis was confirmed
by computerized tomography angiography and conventional angiography. We
observed hepatic arterial (HA) stenoses in 2 (1.1%). an HA aneurysm in 1
(0.6%). portal vein (PV) stenoses in 4 (2.2%). PV aneurysms in 3 (1.7%). and
hepatic vein (HV) stenoses in 2 recipients (1.1%). At the time of diagnosis, 2 HA
stenoses, 1 PV stenosis, and 1 HV stenosis recipient had complication-related
symptoms such as elevated liver function test results and ascites. HA aneurysm
recipient was admitted to the hospital with massive upper gastrointestinal
bleeding. In 1 recipient with PV aneurysm, portal vein thrombosis occurred
23 months after diagnosis. The remaining 6 recipients were asymptomatic.
All late vascular complications were treated successfully using interventional
radiological approaches except 1. A PV aneurysm with a thrombosis was
treated with anticoagulant therapy. We did not encounter any radiology-related
complications. None of the patients required surgery. Mean follow-up period
after treatment of complications was 18.6 &#61617; 13.3 months (range, 3 to 37
months). At the time of this writing, all recipients (100%) are alive with normal
liver functioning. In conclusion, our vascular complications rates during the
late post-operative period after LDLT are acceptable. Late arterial and venous
complications may be managed by angioplasty and endovascular stenting with
no significant effect on mortality at our center.
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T. Kobayashi, Y. Sato, S. Yamamoto, H. Oya, Y. Hara, T. Watanabe, H. Kokai,
K. Hatakeyama
Division of Digestive and General Surgery, Niigata University
Objectives: Biliary complications are one of the important issues to be addressed
after living donor liver transplantation (LDLT). Our previous preliminary study
showed duct-to-duct biliary reconstruction (hepaticohepaticostpmy) with
T-tube external stent (HH-T) may decrease biliary complications compared to
other biliary reconstructions. The aim of this study is to analyze the feasibility
of duct-to-duct biliary reconstruction with a T-tube external stent after adult
LDLT based on long-term follow-up.
Methods: From March in 1999 to January in 2008, 79 LDLTs were performed
in our institution. Among these, we retrospectively evaluated 63 primary adult
LDLTs survived more than one month. We compared the incidence of bile leaks
and biliary strictures in three groups of patients; those who had Roux-en-Y
hepaticojejunostomy biliary reconstruction (HJ) (n=18). those who had duct-toduct hepaticohepaticostomy with external stents except a T-tube (HH) (n=26).
and those who had duct-to-duct hepaticohepaticostomy with a T-tube external
stent (HH-T) (n=19). Bile leaks were defined as the leak by cholangiography
or presence of bile juice in the free abdominal cavity. Biliary strictures were
defined as the strictures by cholangiography or dilatation of intrahepatic bile
duct with/without elevation of biochemical liver test. Median follow-up was
longer in HJ group (63, range: 4.5-105 months) than others (32, range: 2.5-93
months in HH group and 25, range: 1.5-59 months in HH-T group) (p=0.04).
Results: The overall incidence of biliary complications (bile leaks and biliary
strictures) and patient survival were 46% and 75%. Patient characteristics (age,
gender, MELD score, Child-Pugh score, donor age, graft type (right lobe or
left lobe). graft-to-recipient weight ratio, cold/warm ischemic time, operation
time, blood loss, hepatic artery thrombosis, and cytomegarlovirus infections)
were not different in three groups. Only the incidence of ABO incompatibility
was higher in HH-T group (42%) than others (0% in HJ group, 8% in HH
group) (p=0.0007). Bile leaks were observed in eight patients (44%) in HJ
group and nine patients (33%) in HH group, and one patient (5%) in HH-T
group (p=0.02). Biliary strictures were observed in four patients (22%) in HJ
group and 12 patients (46%) in HH group, and four patients (21%) in HH-T
group (p=0.12). Overall biliary complications were observed in 10 patients
(56%) and 15 patients (58%). and four patients (21%). respectively (p=0.03).
All patients of bile leaks were treated by continuous drainage and 15 (83%) of
them were resolved. However, three grafts and patients (one in HJ group and
two in HH group) were lost because of sepsis after bile leaks. 10 patients (56%)
of biliary strictures were managed with endoscopic treatment. Especially, 64%
of strictures in HH and HH-T groups were managed endoscopically. 4 patients
(22%) of strictures were managed with percutaneous transhepatic approach. 4
patients (22%) of strictures were managed with operative treatment.
Conclusions: Biliary reconstruction using HH-T may be effective to prevent bile
leaks after LDLT and lead to reduce the incidence of overall biliary complications.
However, HH-T did not decrease the incidence of biliary strictures in this retrospective
long term follow-up study. Endoscopic management was main treatment for biliary
stricture after duct-to-duct biliary reconstruction after adult LDLT.
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986 NON-STENTED DUCT TO DUCT ANASTOMOSIS IN
LIVER TRANSPLANTATION: A SAFE METHOD
A. Jafarian1, M. Moeeni2, M.A. Mohagheghi1, J. Salimi2, A. Aminian1,
A. Rabbani1
1Imam Khomeini Hospital Complex- Tehran University of Medical Sciences,
2Sina Hospital- Tehran University of Medical Sciences
Introduction: Biliary complication has been named Achilles’ tendon of
liver transplantation. Common bile duct (CBD) anastomosis is an important
technical step of the procedure. Several techniques have been used since the
introduction of liver transplantation.
Materials & Methods: 11 liver transplantations were performed from October
2006 to December 2007. After evaluation of Oddi sphincter with number 3 and
4 Bakes dilator, duct to duct anastomosis was performed in 10 patients using
separate 6/0 PDS sutures. Choledochojejenostomy was done in one patient
with diseased CBD.
Results: There were 2 early postoperative mortalities, one due to primary non
function and another with hepatocellular carcinoma and pulmonary sepsis. The
remaining 8 patients (M/F=5/3) with mean age of 41.7 years were followed
for a mean of 6 months. We had only one biliary leakage in a patient with
early hepatic artery thrombosis diagnosed at fourth week. No other biliary
complication or canalicular enzymes abnormality occurred.
Conclusion: Non-stented end to end CBD anastomosis is a safe method for
biliary reconstruction in liver transplantation with lower morbidity. Monitoring
of bile quality could be replaced with other clinical and laboratory findings.
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987 LATE SURGICAL OPERATIONS IN LIVER TRANSPLANT
RECIPIENTS
K. Zieniewicz1, W. Patkowski1, T. Wroblewski1, M. Fraczek1, W. Kupis2,
Z. Jabiry-Zieniewicz3, R. Paluszkiewicz1, P. Bojarski4, P. Nyckowski1,
M. Krawczyk1
1Dept. of General, Transplant & Liver Surgery, Medical University of
Warsaw, 2Dept. of Thoracic Surgery, Institute of Tuberculosis and Lung
Diseases, 3Dept. of Gynecology and Obstetrics, Medical University of
Warsaw, 4Dept. of Neurosurgery, Medical University of Warsaw
Liver transplant (LTx) recipients sometimes require surgery for various reasons
unrelated directly to the transplantation procedure.
Aim: analyzis of the incidence of late operations, indications and impact on
survival.
Materials & Methods: clinical records of 580 consecutive LTx patients
operated on in the period 1994 -2007 were retrospectively reviewed and
statistically analyzed to compare the subpopulations.
Results: 32 patients (5,5%). 11 males: 21 females, age 19-58, mean 40,2,
underwent late operations performed at least 3 months post LTx. Mean period
after LTx was 24 months (range 3 – 120 months). 37,5% procedures occurred
within 1 year postransplant. The variety was very wide: in 7 patients (22%)
operations were performed for gynecological indications, 4 patients (12,5%)
underwent the abdominal or inguinal hernia repairs, 3 patients (9%) underwent
neurosurgical operations unfortunately with fatal outcome, 4 patients (12,5%)
– for late septic complications and 11 (34%) – were operated on for oncological
diseases including melanoma, HCC recurrence in lungs and liver, thyroid
cancer and esophageal cancer (colon bypass performed). 1 patient after liver
and kidney transplantation underwent total hip replacement. 6 patients have
two or more late operations.18 procedures (56%) were performed by the
transplant surgery team and all occurred in the same facility as the transplant.
The majority of operations were related to the initial disease or to the
complications of immunosuppression. 22 patients (69%) are still alive in good
general condition.
Conclusions: Late operations are relatively rare among liver transplant
recipients, but their variety is very wide. Oversight by the transplantation team
may have an important impact to the favourable outcome.
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988 THE USE OF RECIPIENT SUPERFICIAL FEMORAL VEIN
AS A VENOUS GRAFT FOR PORTAL VEIN RECONSTRUCTION
IN A RIGHT-LOBE LIVING DONOR LIVER TRANSPLANT
PROCEDURE
K. Sato, S. Sekiguchi, T. Watanabe, Y. Akamastu, N. Kawagishi, A. Sato,
K. Fujimori, S. Satomi
Advanced Surgical Science And Technology Division, Department of Surgery,
Tohoku University School of Medicine
Aims: In living donor liver transplantation (LDLT). the presence of portal
vein thrombosis (PVT) in the recipient is frequently regarded as a relative or
absolute contraindication by most groups because of the poor outcomes and
high mortality rates in addition to the technical difficulties. To reconstruct
the portal vein (PV) of a right-lobe liver graft (RLG) using an interposition
graft from the splenomesenteric junction, a sufficient length of vascular graft
is required. In the absence of venous grafts from a deceased donor, a venous
graft must be obtained from the LDLT recipient. A single external iliac vein or
internal jugular vein graft coming from the recipient may sometimes be short
as a jumping graft for PV reconstruction. Therefore, we have used the recipient
superficial femoral vein (SFV) to reconstruct the PV because the size of the
SFV makes it an excellent natural size match for the PV.
Methods: A total of 40 adult LDLT using RLG was performed at Tohoku
university hospital. Of these, 33 patients were reconstructed PV by single endto-end anastomosis with right or left portal vein of the recipient. 3 patients
were transplanted RLG with two separated portal veins and reconstructed
by double anastomoses using both right and left portal vein of the recipient.
The remaining 4 patients were required venous graft for portal reconstruction,
including complete occlusion of the main PV (n=3) that was demonstrated
prior to LDLT and sclerotic portal vein with partial thrombosis (n=1). In all 4
cases, we adopted the use of SFV derived from recipient as an interposition or
jumping graft from the splenomesenteric junction to the graft PV.
Results: The 1-, 3-, 5-year patient survival in 40 right-lobe LDLT patients was
90.4, 86.1, and 72.2%, respectively. None of the patients were died due to PVT.
There were 2 cases of anastomotic PV stenosis, which were suspected by clinical
manifestation and then demonstrated by portography, one in portal reconstruction
without venous graft and the other with SFV graft. Both cases were treated
successfully by balloon angioplasty. Of the 4 patients with portal reconstruction
using SFV graft, one died 2 months posttransplanatation due to multiple organ
failure associated with multiple liver abscess, although the adequate portal inflow
was maintained. Another patient revealed partial occlusion of a SFV graft with
residual thrombosis after a 10-month follow-up computed tomogram portography
(CTP). Although complete occlusion of a SFV graft in this patient was confirmed
by a 15-month follow-up CTP, portal inflow was maintained due to developed
collateral vessels from the splenomesenteric junction into the intrahepatic PV
with 28 months follow-up. The remaining 2 patients revealed excellent patency
of main PV trunk by CTP with 37 and 55 months follow-up, respectively.
Conclusions: The recipient SFV is an excellent size match for the PV
reconstruction as a long interposition or jumping conduit when the venous
system from the deceased donor is not available. The indication for LDLT in
patients with complete PVT should be carefully decided before transplantation
in terms of the portal reconstruction.
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989 THE EFFECTS OF THE TIMING FOR HARVESTING
VASCULAR GRAFT FOR VENOUS RECONSTRUCTION FROM
RECIPIENT ON INTRAOPERATIVE BLOOD LOSS IN LIVING
DONOR LIVER TRANSPLANTATION
K. Sato2, T. Iwane1, S. Sekiguchi2, N. Kawagishi2, Y. Akamastu2, S. Miyagi1,
I. Takeda1, K. Fujimori2, A. Sato2, S. Satomi2
1
Tohoku University Hospital, 2Advanced Surgical Science and Technology
Division, Department of Surgery, Tohoku university school of medicine
Aims: Liver transplantation has been associated with significant blood loss.
The recipient hepatectomy in living donor liver transplantation (LDLT) differs
from the deceased donor liver transplantation in that the maximum length of
the hepatic artery, portal vein and hepatic duct (hilar dissection) and the inferior
vena cava (IVC) have to be preserved. Blood loss usually predominates during
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990 FURTHER UNDERSTANDING OF ISCHEMIC-TYPE
BILIARY LESIONS BY RESEARCH ON MECHANISM OF
ISCHEMIA/REPERFUSION INJURY IN RAT BILIARY TRACT
Y.P. Li, N. Zhao, L. Feng, Y.S. Li, L.L. Pang, L. Wei, S.F. Li,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
The most troublesome biliary complications after liver transplantation is the
ischemic-type biliary lesions (ITBL). with an incidence varying between 5%
and 15%. Several risk factors for ITBL have been identified, and ischemiarelated injury (IRI) is the main risk factor. This study is to investigate the
mechanism of ischemia/reperfusion injury in rat biliary tract.
Methods: Male Wistar rat were devided into sham group and biliary tract IRI
group (n=27/group). The liver was prepared as for graft removal during liver
transplantation. At the completion of this procedure, the liver was isolated from
all vascular supply except for the main hepatic artery, the extrahepatic peribiliary
plexus and the portal vein. Then the biliary tract was suffered from long-term
ischemia/reperfusion injury. Liver tissues and serum samples were harvested
at 4h, 1d, 2d, 1w, 2w, 3w,4w, 5w and 6w after operation. The morphology,
function, pathophysiology and immunology were observed and detected by HE
stain, Massion stain, PAS stain, serum enzyme detection, IHC and RT-PCR.
Results: Rats developed biochemiacal signs of cholestasis exlusively after
complete arterial depribation of bile ducts. Compared with sham group, IRI
group had significant higher level of ALT, AST, ALP, GGT and TB after
operation, but all of them completely resolved at 6 weeks postoperation.
Cholangiocyte proliferation and the number increase of biliary tract were
obseved beginning at 1 week, up to peak at 4 weeks and returned to be normal
at 6 weeks. At 1 week, fibrosis became detectable as thin deposites around
proliferative bile ducts, and increased along with the bile ducts proliferation.
Myofiroblasts (MFB) were around the proliferative bile ducts from 1 week

postoperation. At later time points, moderate inflammatory infiltrates were
present in portal tracts. Compared with sham group, the expression of ICAM-1,
VEGF and TGF-¦Â1 of cholangiocytes in IRI froup were significantly higher.
Besides, we detected the RRLT, homologous to mouse RAE-1 family of
proteins, but had no positive expression.
Conclusions: Cholangiocyte proliferation resulted from IRI is a compensation
to impaired bile function. However, its proliferation maybe some different with
normal cholangiocyte, lead to high expression of certain molecules and finally
results in fibrosis, stenosis and increased chance to be attacted by immune
reaction. If we can find an appropriate opportunity to give interventions, maybe
we can ease or improve ITBL after liver transplantation.

POSTER BOARD NUMBER P1 – 77
991 TECHNIQUE AND RESULTS OF BILIARY
RECONSTRUCTION WITH DUCT-PLASTY IN ORTHOTOPIC
LIVER TRANSPLANTS.
S. Nishida, A. Tekin, A. Maki, E. Akpinar, J. Moon, D. Levi, G. Selvaggi,
E. Island, T. Kato, A. Tzakis
University of Miami, Miami Transplant Institute
Backgrounds: End-to-end bile duct reconstruction without T-tube has become
one of the preferred methods for biliary reconstruction in liver transplantation.
Biliary complication including late phase biliary strictures has been reported in
this method. We present the technique and results of bile duct-plasty including
spatulated end-to-end bile duct reconstruction and cuff reconstruction using the
common bile duct and cystic duct.
Methods: Between April 2007 and February 2008, 20 patients (26 – 68 years
old) underwent orthotopic liver transplantation with biliary reconstruction with
duct-plasty. Spatulated end-to-end bile duct reconstruction was performed
for15 patients. Cuff reconstruction using the common bile duct and cystic duct
was performed for 3 patients. Combination of spatulation of bile duct and cuff
reconstruction using the common bile duct and cystic duct was performed for
2 patients. Running anastomosis with 6-0 PDS was performed for all patients.
Neither a biliary stent tube nor T-tube was used.
Results: No biliary leakage was observed within the early postoperative
period (post operative day 0-30). No stenosis of the bile duct anastomosis
was observed during this time. So far, no late biliary stenosis was observed
(40-329 post operative days). Complications unrelated to the surgical technique
including one cholestatic recurrent hepatitis C and one graft failure secondary
to infection were observed. MRCP or ERCP was performed in 2 cases due to
elevated liver function test and all the results were negative for biliary stricture
or leakage. Current blood works showed as follows: median total bilirubin 0.9
mg/dL, direct bilirubin 0.1mg/dL, AST 33U/L, ALT 33 U/L, ALKP105U/L,
and GTTP 61U/L.
Conclusions: Biliary reconstruction with bile duct-plasty (including spatulated
end-to-end bile duct reconstruction, cuff reconstruction using the common bile
duct and cystic duct and combination of these) represents a safe technique of
bile duct reconstruction and leads to a low technical complication rate after
liver transplantation. Further follow up and randomized prospective studies are
needed to confirm our results.

POSTER BOARD NUMBER P1 – 78
992 THE USE OF A MODIFIED HEPATOJEJUNOSTOMY IN
LIVER TRANSPLANTATION.
B.Gala Lopez, J. Copo Jorge, O. Clausell Wong, R. Sarría Duvergel,
F. Gonzalez Castillo, S. Sainz Lopez, J. Gonzalez Escobar, D. Perez
Transplant Division, Hermanos Ameijeiras Hospital
Biliary complications are a major concern in liver transplantation. Several
strategies have been developed to avoid such complications, especially when
small caliber structures are involved.
We describe the use of a modified hepatojejunostomy previously described
by the authors in liver transplant settings. The technique was used in 3 adult
patients undergoing whole cadaveric liver transplantation, in which the donor
bile duct presented with a diameter below 3 mm.
The hepatojejunostomy was performed as follows: The jejunal free limb of
a Roux-in-Y was opened through its anterior wall with a lineal incision. The
stump of the bile duct was introduced into the jejunal lumen through and
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the dissection of the native liver. In the absence of venous system from deceased
donors, right liver without middle hepatic vein transplant procedure sometimes
needs the additional surgical procedure such as harvesting an autologous vein
for vascular reconstruction from the recipient. In such a patient, the additional
procedure sometimes contributes to progressive coagulopathy and cause
unexpected bleeding from the abdomen. Therefore, we analyzed our cases to
determine the optimal timing for harvesting an autologous vascular graft from
the patient in terms of intraoperative blood loss (IBL).
Methods: A total of 51 adult LDLT was performed at Tohoku university hospital.
Of these, 26 patients were not required venous graft for vascular reconstruction
(group A). The remaining 25 patients were performed LDLT using a venous graft
that was obtained superficial femoral vein (SFV) from the recipient; 12 patients
had undergone SFV extraction after hilar dissection and liver mobilization
from retro-hepatic area with preserving IVC were complete (group B). and 13
patients underwent SFV extraction immediately after hilar dissection without
liver mobilization to avoid progressive coagulopathy (group C).
Results: The actual 1- and 3-year patient survival was similar between the
3 groups (84.8%, 78.9% in group A, 90.9%, 90.9% in group B, and 92.9%,
84.4% in group C, respectively). The median warm ischemic time for the 3
groups was similar (58 min in group A, 53 min in group B and 44 min in group
C, respectively). but the median cold ischemic time (CIT) for group B (173
min) was significantly longer than that for group A (95 min) and group C (112
min). Although the median IBL for group C patients (176 mL) was similar to
that for group A patients who had not undergone SFV extraction (174 mL/kg).
the median IBL for group B (381 mL/kg) was significantly higher than that for
other 2 groups. In group B patients, the additional hemostatic procedure further
aggravated coagulopathy and significantly prolonged not only the time from
skin incision to liver graft implantation (633 min) but also the total operation
time (1041 min) to control bleeding from the abdomen in addition to the SFV
harvesting site, compared with other two groups (453, 861 min in group A and
457, 870 min in group C, respectively). however the average operation time in
group C patients was similar to that in group A in spite of SFV preparation.
Conclusions: The timing for undergoing SFV extraction in LDLT patients has
effects on IBL associated with consumptive coagulopathy and operation time
including CIT. Based on our experiences, we conclude that SFV preparation for
vascular reconstruction should be performed before liver mobilization from the
retro-hepatic area to minimize IBL in LDLT.
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opposite opening. Sutures were applied to the end of the stump interiorly,
involving the entire bile duct wall and the jejunal mucosa and submucosa, over
a silicone stent. The jejunal external wall close to the entering site of the bile
duct was fixed to the later, and the jejunal anterior opening was finally closed.
All 3 patients showed uneventfully recovery after a 36 months followup with no evidences of stenosis. We offer this technique for the surgeon’s
armamentarium, to be used when a very thin bile duct presents. Yet, further
studies involving larger series may be required to ensure total validity.

POSTER BOARD NUMBER P1 – 79
993 SINGLE ORIFICE VEIN RECONSTRUCTION FOR
MULTIPLE HEPATIC VEINS IN LIVING DONOR ADULT LIVER
TRANSPLANTATION USING A LEFT LIVER GRAFT
Y. Yamauchi1, T. Noritomi1, K. Mikami2, S. Hoshino1, T. Shinohara1,
Y. Takahashi1, N. Noda1, N. Yamamoto1, T. Maekawa2, Y. Yamashita1
1Fukuoka University School of Medicine, 2Fukuoka University Chikushi
Hospital
Background: For maximum use of small liver grafts, most draining veins
in donor graft should be reconstructed. We describe the usefulness of single
orifice reconstruction for the multiple hepatic veins in living donor adult liver
transplantation.
Methods: Six patients who underwent living donor adult liver transplantation
using the left liver plus caudate lobe grafts were reviewed. A wide and single
venous orifice was created by gathering the left, middle or its tributaries such as
segment 4, and/or short hepatic vein using a conduit vein graft and a patch vein
grafts. This single, newly-created orifice was then anastomosed to the common
trunk created in the recipient fs hepatic veins.
Results: The mean graft volume standard liver volume ratio (GV/SLV) was
33.5% (26.5 – 41%). Of 6 liver grafts, four included the middle hepatic vein
trunk. Another included only the middle hepatic vein tributaries (without
middle hepatic vein trunk). In 3 grafts, a significantly-sized short hepatic
vein was connected with the left hepatic vein concurrently with the middle or
segment 4 hepatic veins to make a single orifice using a conduit vein graft. In
another 3 grafts without significantly-sized tributaries and short hepatic veins,
two adjacent hepatic vein trunks (left and middle hepatic veins) were simply
connected together using the septoplasty technique. The redundant vascular
cuff was further added to elongate the orifice. The diameter of the new hepatic
vein tract after venoplasty was larger than that of before venoplasty. Hepatic
vein waveforms of all grafts showed the biphasic or triphasic pattern and graft
congestion was not observed immediately after venoplasty. No graft was lost
due to hepatic venous outflow block with the mean follow-up of 14 months.
Conclusions: The short-term results of our technique were satisfactory. Our
techniques can simplify graft-to-recipient cava anastomosis and might be useful
to avoid hepatic venous stenosis. Long-term outcome of our technique remained
unclear, further follow-up is necessary to confirm the feasibility of this method.

POSTER BOARD NUMBER P1 – 80
994 AUXILIARY PARTIAL ORTHOTOPIC LIVER
TRANSPLANTATION FROM LIVING DONOR FOR PATIENT
WITH ADULT-ONSET TYPE II CITRULLINEMIA
S.H. Joo1, B.S. Kim, J.I. Lee, S.H. Lee, S.M. Lee, H.C. Park
1
Kyung Hee University, 2Kyung Hee University, 3Kyung Hee University,
4
Kyung Hee University, 5Kyung Hee University, 6Kyung Hee University
Introduction: Adult-onset type II citrullinemia (CTLN2) is one of inborn
errors of metabolism in the liver. CTLN2 is an autosomal recessive disorder
characterized by recurrent encephalopathy with hyperammonemia due to
highly elevated plasma levels of citrulline and ammonia, and is ascribed to
a deficiency of argininosuccinate synthetase in the liver. We report a case of
patient with type II citrullinemia who were treated successfully with auxiliary
partial orthotopic liver transplantation (APOLT) from living donor. Case
report: This patient was a 27-year-old Korean man who diagnosed as CTLN2
3 years ago. He was 178 cm in height and 60kg in weight. He has been treated
by low protein diet and oral administration of L-arginine, sodium benzoate,
kanamycin, and branched amino acids. However, his plasma ammonia level
did not decrease, and frequent irritability and consciousness disturbance were
developed. Despite the medical treatments his condition failed to improve,
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therefore he underwent partial liver transplantation using a left lobe graft from
his 25 year – old sister. The estimated volume of donor’s right lobe was 800ml
compare to 180ml of the left. We eventually decided to perform APOLT using
the left lobe of liver of the donor. Actual graft volume was 200g and the graft
– to- recipient weight ratio (GRWR) is only 0.33%. The patient’s extended
left lobe (including caudate lobe) was resected. The left lole graft (segments
2–4) was transplanted orthotopically and the recipient’s right portal vein was
narrowed by surgical clipping. The postoperative course was uneventful,
and the neurological symptoms were resolved. The plasma concentrations of
ammonia were upper normal limits, so only low protein diet (50g/day) was
supplied without any specific medication. The estimated computed tomography
volume of graft on postoperative day 14 was 220 ml. In conclusion, APOLT
can be a life saving and effective treatment for patients with adult-onset type
II citrullinemia, especially those who have no chance of receiving a deceased
donor graft or who have candidate donors with insufficient graft volume.
Careful monitoring of portal flow to the graft is important for detecting delayed
graft dysfunction.

POSTER BOARD NUMBER P1 – 81
995 TRANSHEPATIC DILATION OF ANASTOMOTIC AND
NONANASTOMOTIC BILIARY STRICTURES WITH CUTTING
BALLOON IN LIVER TRANSPLANT RECIPIENTS
F. Boyvat1, C. Aytekin1, H. Karakayali2, A. Harman1, S. Sevmis2,
M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent
University Faculty of Medicine, Department of General Surgery
Purpose: To assess the outcome of a transhepatic dilation, using combined
cutting balloon and conventional balloon to manage anastomotic and
nonanastomotic biliary strictures in liver transplant recipients.
Materials and Methods: Between 2001 and 2008, 217 liver transplants (172
living donor, 45 deceased donor) were done at our center. Twenty patients
with a biliary obstruction were treated with combined cutting balloon and
conventional balloon. Seven of these 20 patients had anastomotic stenoses
and the rest had nonanastomotic stenoses. Percutaneous biliary drainage was
done, and an internal-external biliary drainage catheter was routinely inserted.
Cutting balloon dilation was followed by conventional balloon dilation, which
was 1 mm to 2 mm larger than the cutting balloon. The diameter of the cutting
balloon changed from 5 mm to 8 mm.
Results: The technical success was considered to be less than 20% stenoses
after several dilations. The mean number of balloon dilation sessions needed for
anastomotic stenoses was 2.1 and for nonanastomotic stenoses, this number was
3.2. Recurrent strictures developed in 4 patients in the anastomotic group and
in 9 patients in the nonanastomotic group, which is why repeated interventions
were needed. Major hemobilia was observed in 1 patient; this patient was treated
with embolization. Self-limiting minor hemobilia occurred in 6 patients.
Conclusions: Percutaneous treatment using a cutting balloon angioplasty
protocol was more successful in anastomotic strictures than it was in
nonanastomotic strictures (intrahepatic). More balloon dilation sessions and
longer catheter drainage times were required for nonanastomotic strictures.

POSTER BOARD NUMBER P1 – 82
996 SIMULTANEOUS MULTIPLE PERCUTANEOUS LARGEPROFILE PLASTIC STENTS FOR RESISTANT BILIARY
ANASTOMOTIC STRICTURES AFTER LIVER TRANSPLANT:
PRELIMINARY REPORT
F. Boyvat1, S. Sevmis2, U. Ozyer1, A. Harman1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent
University Faculty of Medicine, Department of General Surgery
Purpose: To evaluate the management of biliary anastomotic strictures with
simultaneous multiple plastic stents for complicated liver transplants.
Materials and Methods: Between 2001 and 2008, 217 liver transplants (172
living donor, 45 deceased donor) were done at our center. The study included
4 female and 5 male patients (mean age, 25 years; age range, 11-46 years)
with recurrent biliary anastomotic stenoses in whom prior balloon dilation and
single plastic stent placements had failed. Percutaneous biliary drainage was
done first, and then 2 plastic stents were placed percutaneously through 1 tract
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997 HEPATIC ARTERY COMPLICATIONS AFTER LIVER
TRANSPLANT, MANAGED WITH PERCUTANEOUS GRAFTCOVERED STENTS
F. Boyvat1, U. Ozyer1, S. Sevmis2, G. Moray2, C. Aytekin1, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent
University Faculty of Medicine, Department of General Surgery
Purpose: To assess the feasibility of graft-covered stent placement for treating
hepatic artery stenoses (HAS). hepatic artery thromboses (HAT). and hepatic
artery bleeding after liver transplants.
Materials and Methods: Between 2001 and 2008, 217 livers (172 livingdonor, 45 deceased-donor) were transplanted at our center. Six children and
4 adults (mean age, 28.8 years) had transplant-related hepatic artery problems
after their transplant. These problems were treated with graft-covered stents.
Endovascular treatment indications for these patients were HAT (n=5). HAS
(n=3). and active bleeding from the hepatic artery (n=2). Covered stents were
placed 0 to 7 days postoperatively in 7 patients, 8 to 30 days postoperatively in
2 patients, and more than 30 days postoperatively in 1 patient.
Results: Technical success was achieved in 9 of the 10 endovascular
procedures. Five ruptures were seen before dilatation of the hepatic artery.
Only 1 patient required surgical intervention. The other patients were managed
with graft-covered stents. Continuous thrombolysis for 2 days was necessary
in 1 patient to lyse the thrombus. Follow-up ranged from 1 month to 5 years.
Three patients with patent hepatic arteries died during follow-up; the causes of
death were unrelated to the hepatic artery intervention. One stent was occluded
at 11 months without any clinical findings. In 1 patient, 75% stenosis was found
angiographically at 2-year follow-up; a percutaneous transluminal angioplasty
was done.
Conclusion: Graft-covered stent placement in the hepatic artery is technically
feasible. Graft-covered stent placements, specifically, can be done safely and
effectively during the early postoperative period.

POSTER BOARD NUMBER P1 – 84
998 TREATMENT OF ARTERIAL STEAL SYNDROME IN
LIVER TRANSPLANT RECIPIENTS
F. Boyvat1, U. Ozyer1, S. Sevmis2, A. Harman1, C. Aytekin1, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent
University Faculty of Medicine, Department of General Surgery
Purpose: To describe the effect of splenic or gastroduodenal artery embolization
in liver-transplant patients with arterial steal syndrome.
Materials and Methods: Between 2001 and 2008, 217 livers (172 livingdonor, 45 deceased-donor) were transplanted at our center. Of these, 20
patients (14 male, 6 female; mean age, 23 years; age range, 3-52 years) had
graft ischemia diagnosed on the basis of clinical, laboratory, ultrasonographic,
and angiographic findings. To determine diagnostic criteria, steal syndrome
was defined as diminished hepatic arterial flow caused by a shift of hepatic
arterial flow to the splenic or gastroduodenal artery. Treatment consisted of
coil embolization of the midsplenic (n=12) or gastroduodenal artery (n=3).
or both the midsplenic and gastroduodenal arteries (n=1) and embolization of
midsplenic artery with an Amplatz plug device (n=4). Biochemical parameters
were checked at 1, 7, and 30 days after the procedure.
Results: Nineteen patients improved clinically within 24 hours of the procedure

with significant changes in the biochemical parameters. Before treatment, mean
alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels
were 148.05 U/L, 85.43 U/L, and 6.77 U/L, respectively. The first day after
treatment, the mean alanine aminotransferase, aspartate aminotransferase, and
total bilirubin levels were 105.12 U/L, 56.92 U/L, and 5.23 U/L, respectively.
In 1 patient, no biochemical or clinical improvement was observed immediately
after embolization; however, 3 weeks later, the patient’s biochemical parameters
returned to normal levels.
Conclusions: Conventional angiography has a crucial role in diagnosing and
treating arterial steal after liver transplant.

POSTER BOARD NUMBER P1 – 85
999 THE NEW METHOD OF TIME-LAG LIGATION FOR
PORTOSYSTEMIC SHUNT USING CABG OCCULUDER FOR
ADULT LDLT
H. Kokai, Y. Sato, S. Yamamoto, H. Oya, H. Nakatsuka, T. Kobayashi,
T. Watanabe, K. Takizawa, K. Hatakeyama
Division of Digestive And General Surgery, Niigata University Graduate
School of Medical And Dental Science
We have already reported an useful method of time-lag ligation of portosystemic
shunt for the steal of portal venous flow without laparotomy after living donor
liver transplantation (LDLT). However its method was by a manual ligation
and somewhat invasive. In this study, we reported a less invasive and easy new
time-lag ligation by CABG occuluder for a patient who had an end-stage liver
failure with portal hypertension and the internal mesenteric vena-left testicular
vein (IMV-LTV) shunt.
We performed a LDLT for a 57-years old man who had end-stage type C liver
cirrhosis with hepatic encephalopathy and Hepatocellular carcinoma within
Milan criteria. We used the right hepatic lobe for graft, and it had enough size.
(graft volume was 733g, and GRWR was 1.22.) He had portal hypertension,
and his IMV was expanded for a 2cm caliber and about 3 times wider than
the portal vein. There was hepatofugal blood flow from the IMV to the left
renal vein via the IMV-LTV shunt. We tried to clump of the IMV, then the
portal vein pressure (PVP) became excessive high from 25.5 to 32.5cmH2O.
So we declumped the IMV, and encircled the IMV with CABG occuluder, a
surgical device that is used to clump of the clonally artery in bypass operation,
and it was passed outside the body through the abdominal wall. Additionally,
continuous portal injection of Prostagrandin E1 (PGE1) was started for the
control of PV flow. We ascertained that the PV flow increase effect of PGE1
by temporary interruption of it for test. On POD5, the PV flow decreased, so
we clumped the IMV by clump of the CABG occuluder without re-laparotomy,
then the PV flow was improved, while the PVP increased little. Post operative
course was smooth and he discharged from our hospital on POD23.
An excessive portal hypertension leads to an excessive shear stress and prevent
a graft liver regeneration after liver transplantation, therefore a management
for the excessive portal hypertension immediately after inplantation is very
important to lead to physiological graft liver regeneration. Additionally,
portosystemic shunt decreases might portal venous flow after enlarged graft
and sometimes become a cause of portal thrombus or graft liver atrophy. The
technique of time-lag ligation of portosystemic shunt by CABG occuluder
might be both easy and useful without invasive re-laparotomy.

POSTER BOARD NUMBER P1 – 86
1000 USING SPLIT LIVER FOR RETRANSPLANTATION
IS A SAFE PROCEDURE: THE FIRST EXPERIENCES OF
REGENSBURG
T-U. Tsui, C. Zülke, M.N. Scherer, H.J. Schlitt, A. Obed
Department of Surgery, University of Regensburg Medical Center
Splitting the liver is one of current procedures to expend the organ
availability for transplantation. Encouraging results have been obtained
in showing that the short-term and the long-term results of using split
livers are comparable with those using whole grafts. However using the
split liver for retransplantation remains controversial. Since the technical
complexity and the potential risks in the increase of surgical complications,
split liver is generally not considered for the retransplantation. Here we
report the first three cases of using right split liver (Seg V-VIII± SegI) for
retransplantation in patients with severe sclerosing cholangitis and bile duct
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(percutaneous tracts were between 8F to 12F). The sizes of the 2 plastic stents
were 16F (n=3). 20F (n=5). or 22F (n=1).
Results: Indwelling stents remained in place for a median of 3 months.
Biochemical parameters in these patients were checked at 1 week, 1 month, and
3 months intervals. Also, Doppler ultrasound was routinely done at the same
time intervals. In 2 patients, the plastic stents were removed endoscopically
because of cholangitis. In 7 patients with internal plastic stents, no cholangitis
or obstruction was observed.
Conclusions: Sequential percutaneous insertion of 2 plastic biliary stents
through 1 percutaneous access site effectively treats anastomotic strictures that
occur after liver transplant. This technique lets the clinician place a large-profile
internal stent through a single small percutaneous hole. The technique has a high
success rate; however, more studies with longer follow-ups are necessary.
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necrosis in two cases and patient with thrombosis of hepatic artery in one
case. Between 2005 and 2006, 11 of 90 recipients experienced allograft
failure that required retransplantation. Eight of 11 allograft failures were
associated with sclerosing cholangitis and bile duct necrosis. Two of these
patients received split liver retransplantation. The graft weight/recipient
weight ratios were 1.27%, 1.41% and 1.24% respectively. Venoplasty with
large caval patch was performed in the reconstruction of hepatic venous
outflow of the split livers in two cases. Reconstruction of middle hepatic
vein outflow and caval anastomosis using standard technique in one case.
Hepaticojejunostomy were performed in patients with bile duct necrosis.
Hepaticocholesdochostomy was performed in patient with hepatic artery
thrombosis. In comparison with using the whole graft, the cold ischemic
time was slightly longer in using split liver (14hrs and 14hrs52min).
There were not differences in terms of warm ischemic time, primary bile
production and total operation time. In addition, the initial graft functions
were comparable in both using split livers and using whole grafts. No acute
rejection episode was observed in using split livers. In conclusion, split
liver retransplantation can be performed safely in selected patients in order
to further expend the organ availability.

POSTER BOARD NUMBER P1 – 88
1002 MASSIVE HEMOBILIA AFTER PERCUTANEOUS
CHOLANGIOGRAPHY TREATED BY SUPERSELECTIVE
EMBOLIZATION IN A LIVER TRANSPLANT RECIPIENT
I. Boin1, M. Camargo2, W. Oliveira2, M. Leonardi1
1
UNIT OF LIVER TRANSPLANTATION – Unicamp, 2Faculty of Medical
Science – HC – Unicamp
Hemobilia is a rare but potentially life-threatening cause of upper or lower
gastrointestinal bleeding. It is most frequently a result of iatrogenic trauma.
Transarterial embolization is considered the first line of intervention to stop the
bleeding for most causes of hemobilia. In the transplanted liver, this has only
been reported in ten cases. We reported a 56-year-old liver transplant patient
who was submitted to percutaneous transhepatic cholangiography as part of
cholestasis investigation, and developed massive hemobilia 3 days later. He
presented with delay lower gastrointestinal active bleeding and hypovolemic
shock. Confirmatory diagnosis and treatment was achieved through selective
angiography and embolization. There were no rebleeding, abscess formation
or allograft necrosis in a 6 month follow up. Transcatheter embolotherapy is
recommended as initial treatment to control serious iatrogenic hemobilia even
in transplanted liver patients.

POSTER BOARD NUMBER P1 – 87
1001 EXPERIMENTAL STUDY OF ABSORBABLE AND NONABSORBABLE VASCULAR ANASTOMOSIS IN GROWING
VESSELS. A TOOL FOR CLINICAL DECISIONS.
M. Uribe1,2, V. Bianchi1, A. Gallego1, M. Dib1, P. Fluxá1, M. Capetillo1,
A. Mercado1, F. Valenzuela1, S. Cavallieri1,2
1Surgical Research Unit University of Chile Hospital del Salvador, 2Liver
Transplantation Program Clínica Las Condes – Hospital Luis Calvo
Mackenna
Introduction: Vascular anastomoses in growing vessels, as used in pediatric
organ transplantation, are influenced by surgical technique and suture material
used. Absorbable suture has shown to allow growing of arterial anastomoses
with fewer stenosis rates. The aim of this study was to compare absorbable with
non-absorbable suture material in end-to-end vascular anastomoses in growing
lambs.
Materials and Methods: Six 4-week-old lambs weighting between 10-20
kg were anesthesiated. Bilateral primary end-to-end continuous running
anastomoses of femoral arteries and veins using 6/0 absorbable Polydiaxonone
(PDS) and 6/0 nonabsorbable Polypropylene (Prolene) were performed. After 6
months animals were euthanized. Vessels were excised and burst-tested to 300
mmHg. Stenosis was defined as decrease in 50% or more of the anastomotic
site. Vessels were evaluated macroscopically, histologically and by contrast
angiography by specialists in a blind fashion. Fisher Test was used. P < 0.05
was considered significant*.
Results: Median original weight was 13 kg, and increased to 37,5 kg (range
28-48). Stenosis and tissue reaction are shown in Table 1. Burst testing caused
no disruption. Neither aneurysm nor dilatation of the anastomotic site was
observed by angiography in any vessel. Suture material was observed in
vessels of both groups.
TABLE 1. Stenosis and tissue reaction of vessel anastomoses.
Artery

Stenosis

Artery

Vein

Vein

Prolene

PDS

Prolene

PDS

4/6

2/6

0/6

0/6

33%*

100%

100%

100%

0%

0%

0%

Tissue

No/Mild

Reaction

Mod/Severe 67%*

Comments: In this study, we used each animal as its own control. Arteries and
veins of both groups were resistant to burst test and showed no aneurysm or
dilatation. PDS showed less arterial stenosis and no or only mild inflamatory
reaction in those vessels. There were no differences in parameters studied
in veins in either group. PDS is a better alternative for a running vascular
anastomosis in this model.
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1003 FEASIBILITY OF AUXILIARY PARTIAL LIVING DONOR
LIVER TRANSPLANTATION FOR FULMINANT HEPATIC
FAILURE AS AN AID FOR SMALL FOR SIZE GRAFT – SINGLE
CENTER EXPERIENCE
T. Kobayashi, Y. Sato, S. Yamamoto, H. Oya, H. Kokai, K. Hatakeyama
Division of General And Digestive Surgery, Niigata University
Objectives: Auxiliary partial orthotopic liver transplantation (APOLT) or
heterotopic auxiliary partial liver transplantation (HAPLT) was initially
indicated as a potentially reversible fulminant hepatic failure. Kyoto group
expanded the indication of living donor APOLT for fulminant hepatic failure
and non-cirrhotic metabolic liver disease as an aid for small-for-size grafts to
support the function of implanted graft during the early post-operative period.
However, long-term survival was not observed in patients of fulminant hepatic
failure.
Methods: From March in 1999 to January in 2008, 79 living donor liver
transplantations (LDLT) were performed in our institution. We started
auxiliary partial living donor liver transplantation for fulminant hepatic
failure on May in 2002. From then, Five patients (three female and two male)
underwent auxiliary partial LDLT (3 cases of APOLT and 2 cases of HAPLT)
for fulminant hepatic failure. All of them received small for size graft. The
definition of small for size graft in this study is an actual graft-to-recipient
weight ratio (GRWR) of less than 1.0%. Etiology of fulminant hepatic failure
was HBV in one, Wilson fs disease in one, and unknown origin in three.
Three were acute type and two were subacute type. Median age was 45
(range;14-54) years old. Blood type was identical in all cases. Left lobe graft
was used in four cases and right lobe graft was used in one cases. Median
GRWR was 0.74 (0.42-0.85). Median follow up was 42 months (range; 3
days -70 months)
Results: Three of five (60%) patients were alive (42, 67, 70 months). We
lost two cases. One patient was lost at post-operative day three because
of cytomegalo virus pneumonia and one patient was lost at 10 months
after APOLT because of sepsis. Overall complications were seen in four
patients (relaparotomy of hemostasis in two, biliary strictures in one, and
hemostasis and biliary strictures in one case). There were no vascular
complications. Controlled acute rejection was observed in one case,
which achieved free of immunosuppression after sufficient recovery of
the native liver.
Conclusion: Auxiliary partial living donor liver transplantation may be a
choice as an aid for small for size graft in fulminant hepatic failure.
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1004 MANAGEMENT OF SUBCAPSULAR HEMATOMA
OF THE GRAFT AFTER LIVING DONOR LIVER
TRANSPLANTATION

1006 PROLONGED COLD ISCHEMIC TIME IS A RISK
FACTOR FOR BILIARY STRICTURES IN DUCT-TO-DUCT
BILIARY RECONSTRUCTION IN LIVING DONOR LIVER
TRANSPLANTATION.
J.M. Chun, J.B. Park, J.M. Kim, G.O. Jung, K.U. Jung, H.J. Park, H.T. Jung,
S.J. Kim, J.W. Joh, S.K. Lee
Sungkyunkwan University School of Medicien Samsung Medical Center
Duct-to-duct (DD) anastomosis is a widely accepted procedure for biliary
reconstruction in living donor liver transplantation (LDLT). However, biliary
complication (BC) rates in LDLT recipients have been reported to be as high as
20~30% or more. In this study, we examined various potential risk factors for
biliary stricture (BS) that occurs in the context of DD reconstruction in a single
active transplant center. Enrolled in this study were adults who underwent
their first LDLT with DD reconstruction between August 2002 and May 2007
(n=283). BSs were defined as anastomotic strictures that required interventions
or operative procedures to be corrected. We reviewed retrospectively the
medical records of recipients, including medical history, surgical procedures,
and progress, and analyzed risk factors of BS with the Kaplan Meier method.
BS occurred in 58 of the 283 recipients (20.5%). The mean follow-up period
was 24.4 months post-transplantation (SD=16.5). The univariate analysis
revealed that recipient age (p=0.032). bile duct size (p=0.003). biliary
reconstruction surgeon (p=0.023). perfusion solution (p=0.001). cold ischemic
time (CIT) (p<0.001). biliary leakage history (p<0.001). and acute rejection
episode (p<0.001) were significant risk factors. In the multivariable analysis,
CIT (p<0.001). biliary leakage history (p=0.002). and acute rejection episode
(p=0.013) were significant risk factors for BS. A CIT cut-off value of 71 minutes
was calculated using the minimum p-value approach with correction by the
Miller and Siegmund method (p=0.0186). In conclusion, efforts for reducing
CIT are recommended in order to lower the incidence of BS in LDLT.

POSTER BOARD NUMBER P1 – 93
1007 LONG-TERM ASSESSMENT OF ENDOSCOPIC AND
INVASIVE RADIOLOGY TREATMENT FOR BILIARY
STRICTURES AFTER LIVER TRANSPLANTATION

POSTER BOARD NUMBER P1 – 91
1005 SPLIT LIVER TRANSPLANTATION (SLT) BETWEEN
TWO ADULTS. THE EXPERIENCE OF “OCTOBER 12”
UNIVERSITY HOSPITAL.
J. Fundora, A. Moreno, J.C. Meneu, B. Perez, M. Abradelo, A. Gimeno,
C. Jimenez, V. Barra, S. Jimenez, E. Moreno
Doce De Octubre University Hospital
Introduction: The split of the liver was created to expand the donor pool. In
1989, Bismuth et al, described the first SLT between two adults. Two years
later, In Spain, we performed the first SLT between two adults in our country.
The aim of this study was to show our recipients and grafts results about this
procedure.
Methods: We designed a prospective study. We included the recipients of
graft from SPLT between two adults, between April 1991 to September
2006. Among 25 splitting of the liver graft, in 8 cases we used it between
two adults recipients. In 7 of 8 cases, splited right and left lobe. In only
one case used the segments II-III and I-IV-V-VI-VII-VIII, in the other
recipient.
Results: The mean of the age and weight was 56±18 yo and 58±1,86 kgr,
respectivily. The mean of Graft Recipient Weight Ratio (GRWR) was 1,39±0,7.
We made a in situ partition in 87,6%. At the admission, 76,5% of the recipients
was C Child -Pugh score. The most frecuent etiology was HCV cirrhosis.
About the complications, Hepatic artery trombosis 3 patients (18,8%).
hemoperitoneum 1 patient (6,2%). fluid coleection 1 patient (6,2%).The 1 year
recipient and graft survival was 75% and 68
Summarize:%. The SLT between two adults is a complex but possible
procedure ,in references transplant center and It might possible to increase
the do

S. Eisner1, A. Belinki2, A. Geller3, E. Shaharabani1, Z. Ben-Ari4, M. Kniznik2
and E. Mor1
Department of Transplantation1, Invasive Radiology Unit2, Department of
Gastroenterology and the Liver Institut, Rabin Medical CenterPetah-Tiqwa,
affiliated with Sackler School of Medicine, Tel-Aviv University, Israel
Biliary strictures (BS) after liver transplantation (LTx) are responsible for
considerable morbidity and mortality. Endoscopic (ERCP) and invasive radiology
(PTC) procedures are the mainstay for treatment of BS while surgical approach is
reserved mainly for patients who failed the non-surgical measures. We evaluated
the long-term results with non-surgical procedures to treat BS after LTx.
Material and Methods: A retrospective review of our data-base including 270
adult LTx recipients was done searching for patients with biliary strictures.
BS were categorized into 3 types: common bile duct (CBD) (type-1). major
hepatic duct ± CBD (type-2) or intra-hepatic stricture (type-3). Patients with
anastomotic strictures were treated first conservatively by dilatation of an
internal (with ERCP) or an external stent (PTC). The procedure was repeated
as needed until reaching good radiographic result or was stopped if there was
no response. When failed, patients with anastomotic stricture underwent Rouxen-Y hepaticojejunostomy (HJ) or in cases with intrahepatic stricture patients
were listed for re-transplantation. Good result was defined as normalization of
liver function tests (LFT) at 6-months follow-up. Partial response was defined
as slightly impaired LFT at the same interval and failure was defined as a need
for surgical repair, retransplantation or patient death.
Results: Forty-one patients (15.1%) developed BS including 10 who had a bile
leak preceding the development of BS. Of the 26 patients with type-1 stricture,
2 underwent surgical repair by HJ; one patient survived and another patient who
was operated with severe cholestasis and sepsis died after surgery. The other 24
were managed by non-surgical approach of whom 11 (45.8%) achieved good
result and 3 had a partial response; one of them died 1-year later and the other
2 are alive at 2.5 and 3 years. Of the remaining 10 patients in whom the nonsurgical procedure failed 3 died from complications related to the procedure
and 7 underwent delayed HJ of whom 4 patients survived and 3 died. Of the 8
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J-H. Ryu, S.G. Lee, S. Hwang, K-H. Kim, C. Ahn, D-B. Moon, K. Song,
T. Ha, K. Kim, N. Choi
Division of HBP Surgery and Liver transplantation, Department of Surgery,
University of Ulsan College of Medicine and Asan Medical Center
Subcapsular hematoma of the graft is a serious complication of liver
transplantation (LT). and there has been no discussion in the literature about
optimal management except in sporadic case reports. The aim of this work
is to review our experience of subcapsular hematoma in living donor liver
transplantation (LDLT) and to introduce our management strategy. Among the
1473 cases of adult-to-adult LDLT between February 1997 and November
2007, there have been 5 cases of subcapsular hematoma. Two of these developed
after percutaneous liver biopsy and the other 2 developed after percutaneous
transhepatic biliary drainage (PTBD). Two developed immediately after the
procedure, whereas the other 2 developed 8 and 12 days after the procedure,
respectively, due to rupture of a pseudoaneurysm. Another one case developed
immediately after LDLT without any procedure. Our management strategy
was as follows; after performing dynamic computed tomography for initial
diagnosis, these 3 steps were taken: 1) hepatic arteriography and selective
embolization of bleeding focus; 2) pigtail catheter drainage (PCD) of
subcapsular hematoma; and 3) hepatic vein stenting if there was a sign of
outflow disturbance due to compression by a large hematoma. All 5 of our
patients recovered from the insult of subcapsular hematoma. In conclusion,
our results indicate that patients who develop subcapsular hematoma after
LDLT can be treated nonsurgically
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patients with type-2 stricture, 5 patients achieved good long-term result and 3
patients who had a partial response died at follow-up from rec. hepatitis C at
2.5,3 and 4 years. Of the 7 patients with type-3 stricture, 3 patients responded
well to the non-surgical procedure, 1 underwent re-transplantation and survived
and another 3 patients died of septic complications. The overall long-term
success rate with non-surgical approach to treat post-transplant BS was 48.7%.
The overall graft loss and death rate directly related to BS was 26.8%.
Conclusions: Minimally invasive non-surgical procedures to treat bile duct
strictures after liver transplantation achieve long-term success in only half
of the patients. Earlier surgical intervention to repair anastomotic strictures
might reduce mortality related to septic complications following the more
‘conservative’ measures.

POSTER BOARD NUMBER P1 – 94
1008 THE MORPHOLOGIC ANALYSIS OF ACCESSORY
ARTERIAL SOURCES OF CAUDATE LOBE
K. Branzaniuc1, P. Matusz2, C. Copotoiu1, L. Azamfirei1, S.M. Copotoiu1,
A.M. Pusztai2, E. Hordovan2
1University of Medicine And Pharmacy, 2University of Medicine And
Pharmacy
Reconsidering of the fundamental knowledge of liver intraparenchymal anatomy
is imposed by the intense development of transplant surgery. The caudate lobe
(CL) is considered by most anatomists like a distinct volume of parenchyma.
The objective of this study was to realize the correlations between the modalities
of intraparenchymal distribution of the elements from the afferent and efferent
pedicles of the CL, its external morphologic aspect and the own segmentation
of CL parenchyma, which allows better surgical practice of hepatic resection
and transplant.
Material and Method: The corrosion casts (150). were created by the injection
of the vasculo-ductal systems with plastic mass, followed by the corrosion of
the hepatic parenchyma with hydrochloric acid.
Results: In 7% of the cases we revealed the presence of supplementary sources.
In 5% of the cases the right medial division is vascularized by the right accessory
hepatic artery, originated from the superior mesenteric artery. In this case, from
the right branch of the HAP originates only the posterior branch. In 2% of the
cases, the left medial division is vascularized by the left gastric artery. In these
cases from the left branch of the HAP originate only the lateral branch. The
revealed accessory hepatic arteries are destined only the medial divisions. In
11% of the cases the medial branch originates from the right branch of the HAP,
and in 7% of the cases it continues the terminal part of the left branch of the
HAP. Five morphological types of arterial vascularization of the liver have been
noted. Most important were: type II (1,33%) (2/150) in which the medial branch
proceeds from the accessory left hepatic artery; type V (5,33%) (8/150) in which
the anterior branch originates from the accessory right hepatic artery.
Discussions: These correlations allow the assessment of the principal aspects
of intraparenchymal distribution of the vasculo-ductal elements only based on
the examination of the quantitative development of the parenchymal parts of
CL at the visceral aspect of the liver.
Conclusion: The current study will prove the fact that CL is actually “a little liver”,
based on the same principles as is based the liver on the whole (“the big liver”).

POSTER BOARD NUMBER P1 – 95
1009 SURGICAL TECHNIQUE TO AVOID HEPATIC VENOUS
OBSTRUCTION IN PARTIAL AND FULL PEDIATRIC LIVER
TRANSPLANTATION
T. Heffron1, D. Solis1, T. Pillen2, G. Smallwood1, R. Romero1
1Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Background: Liver transplantation is the treatment of choice for end stage liver
disease. In the pediatric population, the development of innovative techniques
has allowed more transplants to be performed reducing time and mortality in
the waiting lists. Reduced size, split and living related transplants have become
the alternative to relieve the shortage of organs in the pediatric population
with end stage liver disease, but in the other hand, these types of grafts are
associated with a higher incidence of hepatic vein outflow obstruction. The
size of the anastomotic orifice, the length and orientation of the vessels, and
the positioning of the graft are key determinants in maintaining patency of
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the reconstructed hepatic vein. Others centers previously has described an
incidence of hepatic venous obstruction as high as 20% when using recipients
hepatic veins for the anastomosis. We described our technique in this series
and showed its efficacy avoiding hepatic venous obstruction in pediatric liver
transplantation.
Methods: A total of 202 consecutive pediatric liver transplants, have been
performed at Children’s Healthcare of Atlanta by a single surgeon. A triple
hepatic venoplasty was performed in the recipient IVC to create an adequate
outflow orifice in all recipients with partial liver transplantation. If two or more
orifices were found on split and living related donor livers, a venoplasty was
performed to create a single wide common orifice for anastomosis. No fixation
sutures to any hepatic ligament was done.
Patients with any clinical finding suggesting venous outflow obstruction
(ascites, splenomegaly, abdominal distention) were studied with ultrasound or
venogram.
Results: Liver transplants performed include 109 whole liver transplants
(%). 39 left lateral lobes (%). 29 left lobes (%). 24 living related (%) and
1 right lobe graft in 178 patients. In our series, no hepatic veins outflow
obstruction was found based on ultrasound, clinical findings or venogram.
Our 1 and 3 year graft survivals were 82.3% and 77.6% for whole livers and
80.2% and 72.5% for partial size livers. Patient survival at 1 and 3 years
were 90.3% and 82.1% for whole size livers and 90% and 86% for partial
livers.
Conclusion: A wide venoplasty at the recipient venous site with a single short
wide orifice is the most appropriate method for hepatic vein anastomosis to
prevent stenoses and to assure an adequate outflow for proper graft function
and survival. The technique is feasible, easy, straightforward, and has led to
excellent outcomes.

CONCURRENT ORAL SESSION 77: PANCREAS
POSTER BOARD NUMBER P1 – 96
1010 IS SYSTEMIC VENOUS DRAINAGE THE EXPLANATION
FOR HYPERINSULINEMIA IN PANCREAS-GRAFT
RECIPIENTS?
M. Hartmann1, M. Bertoluci2, M.C. Guterres1, L. Diogo1, D. Saitovitch1,
S. Gullo-Neto1, M. Falavigna1, L. Kroth1, M.A. Traesel1
1
Sao Lucas Hospital- Porto Alegre- Brazil, 2Clinicas Hospital- Porto AlegreBrazil
Hyperinsulinemia has been associated to systemic venous drainage as a
reconstruction technique in pancreatic transplantation. The hypesinulinemia
may be associated with dyslipidemia and insulin resistance (IR) and
metabolic syndrome. However, it may be the case that IR would be
responsible, at least in part, for the observed hypersinsulinemia. The
prevalence of IR in patients submitted to this reconstruction technique as
well as the beta cell functional status is not clearly known. The aim of this
study is to evaluate glycidic metabolism after systemic venous drainage
of pancreatic graft through fasting measurements of insulin, glucose,
C-peptide, glucosilated hemoglobin as well as HOMA, oral glucose
tolerance test and the corresponding curve of insulinemia. We analyzed 30
patients after the systemic venous drainage of the graft (23 SPK, 2 PAK,
5PTA). All of them were insulin-independent. The results (mean values and
standard deviation) are the following: Glycemia: 85.7 (+/- 14.2) mg/dl;
isulinemia 17.8 (+/- 8.6) mU/l; C-peptide 3.4 (+/-1.7) ng/ml; glucosilated
hemoglobin: 6.0 (+/- 0.7)%. The HOMA index identified two groups of
patients: those who were insulin-resistant (n=20) and those who were not
(n=10). Both groups had adequate glucose levels control despite of the
differences in IR. Also, the levels of basal insulin and the measurements
after the oral glucose challenge were higher in the IR group. These results
show that hyperinsulinemia is not an universal finding among pancreas
recipients submitted to systemic venous drainage of their grafts. It may be
associated to the IR itself. Also, the data show that functional status of beta
cells was good enough to surpass the IR, when it is present.
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1011 IDO – A NEW REJECTION-MARKER IN SIMULTANEOUS
PANCREAS AND KIDNEY TRANSPLANTATION

POSTER BOARD NUMBER P1 – 98
1012 PREVENTION OF PANCREAS GRAFT THROMBOSIS
USING LOW-MOLECULAR-WEIGHT HEPARIN
P. Schenker, O. Vonend, A. Wunsch, M. Schaeffer, L-C. Rump, R. Viebahn
Ruhr-University-Bochum
Background: Simultaneous pancreas-kidney transplantation is the current
treatment of choice for patients with type I diabetes and end stage renal disease,
resulting in good short and long term patient and graft survival. Vascular graft
thrombosis (VGT) after pancreas transplantation is the main cause of early
graft loss. Low-molecular-weight heparins (LMWH) have been proved to be
as safe and effective in preventing thromboembolism as unfractionated heparin
(UFH).
Methods: 188 consecutive pancreas transplantations were performed between
January 2000 and December 2006. A retrospective study has been carried out
in order to compare the safety and efficacy of once daily fixed dose LMWH to
dose adjusted intravenous UFH.
Results: 58 patients receiving LMWH and 129 receiving UFH were
identified. One patient was excluded since lepirudin was used. There
were 7% (4/58) VGTs in the LMWH and 17% (22/129) in the UFH group
(p=0.047). The mean time between transplantation and VGT was 4.2 ± 2.5
days in LMWH and 5.6 ± 7.7 days in UFH receiving patients. The frequency
of major bleedings requiring relaparatomy was not significantly different
in the groups related to LMWH and UFH, respectively (6.9% vs. 7.8%).
One year patient and pancreas graft survival was 98.9/89.6% in the LMWH
and 97.8/74.4% in the UFH group. Donor and recipient characteristics
were similar.
Conclusion. The once daily fixed dose low-molecular-weight heparin is
safe and effective for initial prophylaxis of graft thrombosis after pancreas
transplantation. There is no benefit of dose adjusted intravenous heparin
application.

POSTER BOARD NUMBER P1 – 99
1013 SIMULTANEOUS PANCREAS-KIDNEY
TRANSPLANTATION: A TEN YEARS FOLLOW-UP ANALYSIS
FROM CLINICS HOSPITAL OF MEDICAL SCHOOL OF
UNIVERSITY OF SAO PAULO, BRAZIL
R. Meirelles1, T. Bacchella1, C. Cocuzza2, F. Makidisi1, V. Rocha-Santos1,
E. David-Neto2, W. Nahas2, L. Ianhez2, M. Srougi2, M. Machado1
1
Disciplina de Transplante de Figado do Hospital Das Clínicas Da FMUSP,
2
Disciplina de Urologia do Hospital Das Clínicas Da FMUSP
Introduction: The pancreas transplantation is the only treatment that provides
euglicemia and normalizes serum levels of glycosylated hemoglobin in type I
diabetic patients [4] The transplantation of pancreas improves quality of life
by promoting independence of exogenous insulin and preventing secondary
complications of diabetes type I.
Aim: Our objective is to present the initial experience and patients follow-up
undergoing to SPK in our institution.
Patients and Methods: During the period June 1997 to December 2007, 50 type
I diabetes and end stage renal disease patients were submitted to SPK. Pancreatic
graft implantation was performed in the right iliac fossa with systemic venous
drainage and bladder or enteric drainage. Most enteric drainage and all drainage
conversion were performed by Roux Y duodenojejunostomy. Immunossuppression
protocol used was polyclonal antibodies or monoclonal anti-receptor for
interleukin-2 induction followed by calcineurin inhibitor (Tacrolimus). associated
with mycophenolic acid (Mycophenolate) and corticosteroids.
Results: Patients, pancreatic and renal transplants 1 year survival were 89.12%,
87.07% and 86.71%, respectively. Patients, pancreatic and renal transplants 5
years survival were 81.04%, 81.04% and 81.04%, respectively. Early patient
death main cause was sepsis secondary to pancreatic graft thrombosis. Late
patient death primary cause was cardiovascular event. Early pancreatic graft
loss main cause was venous thrombosis. Mainly late pancreatic graft loss was
due to chronic rejection The most frequent complication in the immediate
postoperative period was abdominal wall infection Bladder drainage conversion
rate to enteric drainage was 18.18%. The most frequent late complication was
CMV infection (18%).
Conclusion: SPK remains the most effective treatment for type I diabetic with
end stage renal disease patients. One and five year patients and pancreatic
grafts survival were similar to US pancreas transplantation programs.

POSTER BOARD NUMBER P1 – 100
1014 SONOGRAPHIC CONTRAST MEDIA CONTRIBUTION IN
PANCREAS TRANSPLANTATION ASSESSMENT
R. Meirelles2, A. Marcelino 1, C. Cocuzza3, E. David-Neto3, L. Ianhez3,
T. Bacchella2, M. Srougi3, M. Machado2, G. Cerri1
1
Disciplina de Radiologia do Hospital Das Clínicas Da FMUSP, 2Disciplina
de Transplante do Hospital Das Clínicas Da FMUSP, 3Disciplina de Urologia
do Hospital Das Clínicas Da FMUSP
Introduction: Pancreatic transplantation is the long-term therapeutic option
for maintaining normoglycemic status in patients with type 1 diabetes mellitus.
Sonographic contrast medium allows to evaluate tissue perfusion but there are
no studies comparing this parameter in normal and pathologic pancreatic grafts
in the literature at the time of this writing. The importance of assessment of
graft perfusion and the potential role of contrast-enhanced sonography with
microbubbles in this regard were the reasons for this research. The study
conducted at the Instituto de Radiologia do Hospital das Clínicas da Faculdade
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D. Abendroth, M. Marzinzig
Center of Surgery, University of Ulm
Introduction: Pancreas rejection after transplantation is best monitored by
the serum creatinine of the simultaneously transplanted kidney from the same
donor. A specific pancreas graft marker for rejection would be desirable for
monitoring isolated pancreas allografts.
Material and Methods: In 24 patients after successful simultaneous
pancreas and kidney transplantation, serial values of indoleamine 2,3
dioxygenase (IDO). IL-10, TNF-α, Neopterin (NPT). sHLA were determined
(sera samples) beginning on day 0 and over a follow up period of at least 12
weeks. Rejection was diagnosed by the clinical term and the day of treatment
with antirejection medication (steroid bolus, polyclonal Ab). Kidney function
was controlled by daily serum-creatinine and pancreas function by fastened
blood sugar.
Results: 11 out of 24 patients experienced a total of 13 rejection episodes
(2x pancreas/11x kidney and pancreas) within the first 3 months after
transplantation. Baseline values of proinflammatory mediators (IDO, TNF-α,
neopterin) showed a rise during rejection (IDO: 7,9 + 1,3 μM to 17,6 + 3,4
μM, sig.; TNF: 2,7+1,5 to 43,2+25 pg/ml, sig.; NPT: 37,8+19,2 to 354+108
nmol/l n.s.). In parallel, immunologic markers like sHLA and IL-10 showed
a similar profile (IL-10: 13,2+3,1 to 87,1+23,8 pg/ml n.s.; sHLA: 1,8+ 0,6
to 5,9+1,0 ug/ml, sig.; values given as x+SEM, p<.05 for all parameters,
rejection vs. baseline). IDO was the only parameter showing an early
detection of rejection as well as the grade of balance between inflammation
and immunsuppression.
Conclusion: There was a correlation of the determined markers with the clinical
course of rejection, best represented by IDO, however none of the parameters
was pancreas-specific. IDO as a new parameter was most sensitive in diagnose
of rejection and further outcome.
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de Medicina da Universidade de São Paulo between November, 2004 and
September, 2006 had the following
Objectives: A) to establish patterns of graft vascularization in normal patients
and in those with suspected abnormalities; B) to compare grayscale mode and
contrast-enhanced sonographic findings with clinical status, laboratory results,
and need for exogenous insulin; C) to define the role of contrast-enhanced
sonography with microbubbles in the evaluation of pancreatic transplantation.
Materials and Methods: Twenty-six patients underwent a total of 30
sonographic examinations with microbubbles, 20 (66.7%) men and 10 (33.3%)
women. Age range was 25 to 51 years, with a mean of 40 years (+ 7.3 years).
Time elapsed between transplantation and imaging ranged from 1 day to 63
months (median, 24 months). Using grayscale mode, pancreas was assessed for
echogenicity, dimensions (both quantitatively and qualitatively) and contours.
Following intravenous contrast medium administration, time for enhancement
of the pancreatic graft, pattern and intensity of enhancement were documented.
A classification system based on grayscale and contrast-enhanced sonographic
findings was designed, with the following categories: normal perfusion pattern,
acute changes (rejection, pancreatitis or thrombosis) and chronic changes
(chronic rejection).
Results: There was a statistically significant association between echogenicity
and clinical status (p=0.010); echogenicity and need for exogenous insulin
(p=0.021); dimensions (qualitative criteria) and clinical status (p=0.011);
dimensions (qualitative criteria) and need for exogenous insulin (p=0.028);
pattern (p=0.024) and intensity of enhancement versus clinical status
(p=0.039). There was also statistically significant association between need
for exogenous insulin and graft perfusion (p=0.014). and sonography-based
diagnosis (p=0.001).
Conclusion: The study provided patterns of vascularization in normal pancreatic
grafts and in patients with suspected abnormalities. Distinction of normal and
abnormal pancreatic grafts was possible using echogenicity and qualitative
analysis of graft size on grayscale mode. Contrast-enhanced sonography with
microbubbles also contributed to differentiation between normal and abnormal
pancreatic grafts, using pattern and intensity of enhancement and perfusion of
the graft during the arterial phase.

POSTER BOARD NUMBER P1 – 101
1015 ACTIVATION OF PANCREASTIC STELLATE CELLS IN
THE FIBROTIC PROCESS OF GRAFT IN RAT MODEL
Y.P. Li, Y.S. Li, L.L. Li, T.C. Zhang, D. Long, N. Zhao, L.L. Pang, Z.P. Zhen,
Y.C. Huang, S.F. Li,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
Our previous study based on statistic data of 240,000 cases about solid organ
transplantions from OPTN/UNOS suggested that pancreas transplantation
alone (PTA) was one of the highest and earlist graft dysfunction occurred
organ even with the committed HLA mismatch and informed treatment of
immunosuppressive agents. The characteristic of dysfunction is mainly fibrosis
and lack the effective intervention due to its mechanism has not been throughly
identified. Reseaches on chronic pancreastitis and pancreatic cancer found that
actived pancreastic stellate cells (PSC) can induce the fibrotic process. The aim
of this study was to probe the role and mechanism of PSC with pancreastic
fibrosis in rat atopic PTA acute rejection model.
Method: Rat atopic PTA (SD-Wistar) were performed without
immunosuppressive treatment and graft were harvested in 1d, 3d, 5d and 7d
postoperation. The pathomorphological changes, the fibrotic extent (Masson
staining Sirius red staining) and indicators of activated PSC on mRNA and
protein level (RT-PCR immunohistochemistry) were conducted including
-SMA, desmin, collagen I.
Result: The fibrosis of pancreas graft could be found in 3d postoperation,
aggravated in 5d and almostly become fibrotic in 7d. The fibrotic area extended
from interstitial substance to parenchymatous tissue. The number of acinus was
decreased, and the architectonic of lobulous was destroyed along with the fibrotic
process. The fibrosis stained positively for Sirius red and collagen <st2: place w:
st=on>type I.</st2: place> Sirius red staining was associated with -SMA-positive
cells. And the similar consequence could be seen in desmin-positive cells.
Conclusion: We found that actived PSC was the main source of graft fibrosis on
rat PTA acute rejection model. It suggested that inhibited actived PSC might be
one of available prevention and treatment measure for chronic graft dysfunction.
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1016 TREATMENT WITH VITAMIN A ATTENUATED THE
FIBROSIS OF RAT PANCREAS GRAFT
Y.P. Li, Y.S. Li, L.L. Li, Y.C. Huang, N. Zhao, L.L. Pang, L. Wei, Z.P. Zhen,
S.F. Li, L. Feng,
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
Our previous results suggested PTA was one of highly and early graft
dysfunction occurred model, and actived PSC was the main source of graft
fibrosis. Studies on vitamin A (VitA) in vitro showed that vitamin A could
inhibit PSC activation in pancreatic fibrosis model caused by alcohol. The aim
of this study was to explore whether Vit A could alleviate the graft fibrosis in
rat PTA model.
Method: Rats atopic PTA (SD-Wistar) were performed without
immunosuppressive treatment and divided into two groups: control group and
Vit A group (4000IU/kg.d; intragastric administration). Graft pancreas were
harvested in 1d, 3d, 5d, 7d postoperation. The pathomorphological changes,
the fibrotic extent (Masson staining Sirius red staining) and indicators of
activated PSC on mRNA and protein level (RT-PCR immunohistochemistry)
were studied including -SMA, desmin, collagen I, and statistical analysis were
applied.
Result: The graft fibrotic process could be found in 3d postoperation,
aggravated in 5d and almost become fibrotic in 7d in both groups.The extent
in Vit A group was significantly improved in the fibrotic extent, number of
acinus and the architectonic of lobulous in every time-point. All difference was
significant in 5d and 7d comparing with control group (P<0.05).
Conclusion: Vitamin A could significantly alleviate the fibrosis and protect
acinus and architectonic of lobulous in rats atopic PTA acute rejection model.
Vitamin A might be used as supplemental drug for delay and decrease graft
fibrotic process in clinical pancreas transplantation.
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1017 EFFECTS OF OCTREOTIDE ON THE ACTIVED
PANCREATIC STELLATE CELLS IN EXPERIMENTAL
PANCREAS GRAFT FIBROSIS
Y.P. Li, L.L. Li, Y.S. Li, D. Long, L.L. Pang, N. Zhao, C.T. Zhang, L. Feng,
S.F. Li,
Key Laboratory of Transplant Engineering and Immunology, Ministry of
Health, West China Hospital, Sichuan University
Our previous results suggested that graft pancreas was one of highist and earlist
graft dysfunction occurred organ in PTA even with committed HLA mismatch
and informed treatment of immunosuppressive agents, and actived PSC was
the main source of pancreatic fibrosis. Octreotide is widely used to prevent
and treat complications after clinical pancreas transplantation. But it is unclear
whether octreotide can play role in the graft fibrosis. The aim of this study was
to investigate the effect of octreotide in the perioperative course of fibrotic
process of transplanted pancreas both in vitro and in vivo.
Method: Isolated PSC from SD rat and cocultured with different dose (2.5, 5,
10, 20, 40ng/ml) octreotide for 24h, 48h and 72h seperately. PSC proliferation
was assessed by MTT. The expression of -SMA, desmin and collagen I of
PSCs were determined by western blotting of cell lysates. Rat atopic PTA
(SD-Wistar) were performed without immunosuppression treatment and
divided into two groups: control group and Oct group (0.01mg/kg.bid;
subcutaneouly). Graft pancreas were harvested in 1d, 3d, 5d, 7d postoperation.
The pathomorphological changes, the fibrotic extent (Masson staining Sirius
red staining) and indicators of activated PSC on mRNA and protein level (RTPCR immunohistochemistry) were studied including -SMA, desmin, collagen
I. Finally, statistical analysis were applied.
Result: Octreotide markly inhibited PSC activation and proliferation in vitro
with effective concentration range range frome10 to 40ng/ml in 48h and 72h.
The expression of -SMA, desmin and collagen I of PSCs significantly decreased
(P<0.05). Inflammatory infiltration was clearly relieved in Oct group and the
extent was lightly improved in the fibrosis, number of acinus and architectonic
of lobulous, although the differences were not significant comparing with
control group (P>0.05). And the expression of -SMA, desmin and collagen I
also were not significant decreased (P>0.05).
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Conclusion: Octreotide can effectively inhibit PSC activation and proliferation in
vitro as well as degree of inflammatory inliltration, but not the noticeably relieved
in the fibrotic process of pancreas graft in rat PTA acute rejection model.
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1018 TRANSIENT DIABETES MELLITUS DUE TO
TACROLIMUS TOXICITY IN A SIMULTANEOUS PANCREASKIDNEY TRANSPLANT RECIPIENT

↑ Tacrolimus withdrawn
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1019 SURVIVAL OF PANCREAS ALLOGRAFTS DESPITE
PARTIAL THROMBOSIS OF THE Y-GRAFT USED FOR
ARTERIAL RECONSTRUCTION
C. Margreiter1, W. Mark1, M. Maglione1, D. Wiedemann2, R. Sucher1,
R. Öllinger1, H. Maier1, M. Freund3, R. Margreiter1, F. Aigner1
1
Dept.of General and Transplant Surgery, Innsbruck Medical University,
2
Dept.of Heart Surgery, Innsbruck Medical University, 3Dept.of Radiology,
Innsbruck Medical University
Background: A complex system of arterial anastomoses between the
gastroduodenal, splenic (SA) and superior mesenteric artery (SMA) exists.
During pancreas transplantation arterial reconstruction between the SA
and SMA is performed by using a donor iliac Y-graft. Graft thrombosis is
still responsible for up to 10% of graft losses. The aim of this study was to
investigate arterial vascularization of the pancreas with special regard to the
anastomoses within the pancreatic head.
Material and Methods: Ten pancreas grafts considered not suitable for
transplantation were removed and a canula was inserted into the splenic artery
and the SMA ligated. Angiography was performed with 5, 10 and 15 ml of
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1020 SOLITARY LIVING RELATED ORTHOTOPIC PARTIAL
PANCREATIC TRANSPLANTATION WITH DUCT TO DUCT
DRAINAGE OF PANCREATIC JUICE FOR TYPE I DIABETES
MELLITUS
Y. Sato1, S. Yamamoto1, H. Oya1, T. Kobayashi1, H. Kokai1, K. Hatakeyama1,
M. Hirota2
1First Dept. of Surg., School of Medicine, Niigata University, 2Dept. of Surg.,
Prefectuaral Muikamachi Hospital
In this study, we reported a complete solitary living related orthotopic partial
pancreatic transplantation (LROPPT) with duct to duct drainage of pancreatic
juice. (Case) A 29-year old man, who has suffered from type I diabetes
mellitus at 2 years after his birth, underwent LROPPT on 2007 August 9th.
He had hypoglycemia for several times per week. His preoperative HbA1c
was 8.4%. He has little diabetic complications of 2 degree of nephropathy
with albuminuria and slight neuropathy. The donor was a 57-year old his
father, whose preoperative 75gOGTT and ivGTT revealed normal pattern.
(Immunosuppression) In this case, we choose the new immunosuppresion of
steroid free-protocol with intraportal infusion of donor specific antigen, which
enable both rapid reduction of immunosuppression and macrochimerism of
donor type of CD56+T cell in the graft liver. Induction of immunosuppression
was by both thymoglobulin (1.5mg/kg) on day0, 4 and intraportal
administration of donor leukocyte on day 0, 4, 7, 10 after transplantation.
An each time of volume of Donor specific leukocytes separated from donor
whole blood using Cellsorba EX (Asahikasei Co. LTD) ,which has been used
as leukocyteapheresis therapy with leukocyte removal filter for ulcerative
colitis, was about 40ml. Count of leukocytes was almost of 1-5x108.
Maintenance of immunosuppression was by FK506 and MMF. (Operative
Procedure) Donor was performed hand-assisted distal pancreatectomy with
spleen. The pancreas was cut left side of portal vein that remnant pancreas
was a half of whole pancreas by the CT volumetry. The pancreatic duct was
repaired by the ligation and transfixing suture. The pancreas wad closed by
fish mouse with 6-0 prolene. Operative time was 5 hours and 18 min and
intraoperative hemorrhage was 75 ml. Recipient was explored by upper
abdominal L-shaped incision. Distal pancreatectomy with spleen with the
enough expose of both splenic vein and artery, and main pancreatic duct.
Both the splenic vein and the arterial anastomosis was made, thereafter,
pancreatic duct to duct anastomosis was made by 6-0 PDS with pancreatic
duct stent. The pancreatic duct stent lead to extra abdomen through Papilla
Vater and duodenum. Pancreatic tissue was anastomosis by 6-0 prolene using
fibrin-glue. Afterthat, absorbed thin mesh was rolled around the pancreatic
anastomosis with fibrin-glue. The operative time was 10hr 10min and the
blood loss was 435ml. Patient discharged without a pancreatic leakage and
vessel thrombosis 16th days after transplantation.
Conclusion: LROPPT is a complete physiologic procedure. In Japan, almost
of donor is marginal donor aged above 50 years old. The portal drainage might
be comfortable for the stress of the partial pancreatic graft.
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S. Wright, J. Jamboti, H. Rhodes
Fremantle Hospital
Severe hyperglycaemia in a Simultaneous Pancreas-Kidney (SPK) transplant
recipient is sine qua non of pancreatic allograft failure. Tacrolimus is a known
cause of pancreatic βcell toxicity leading to decreased insulin production.
We report a case where in Diabetes Mellitus with severe hyperglycaemia
resulted from Tacrolimus toxicity and resolved with its withdrawal. The role of
Tacrolimus toxicity should be considered in all SPK transplant recipients who
become diabetic with low C-peptide levels.
The patient is a 38 year old Caucasian male who received a SPK transplant
in 2000. His immunosuppression consisted of Tacrolimus, Mycophenolate
Mofetil and Prednisolone. His transplant grafts had functioned well with blood
glucose levels between 5-8mmol/L and a stable serum creatinine of 130μmol/L
until August 2007 (Graph). His other medical history included recurrent urinary
tract infections and ischaemic heart disease.
He presented in October 2007 with a two week history of feeling unwell
with polydipsia, polyuria, anorexia and vomiting. His blood glucose level at
presentation was 71mmol/L and serum creatinine 189μmol/L. He underwent an
urgent ultrasound of pancreas and kidney allografts with doppler flow studies,
which showed good blood flow to the grafts and no evidence of pancreatic
vein thrombosis. C-peptide and insulin levels revealed lack of endocrine
pancreas graft function. This was attributed to high Tacrolimus levels and he
was switched to Cyclosporin. Following this his blood glucose levels improved
with restoration of C-peptide and insulin production.
In SPK transplant recipients who present with Diabetes Mellitus, Tacrolimus
toxicity should be considered as a reversible insult to the pancreatic βcells.
Graph – Blood Glucose Levels

contrast medium. In addition we retrospectively analyzed 15 patients with
radiologically (multisliced CT) proven thrombosis of the SMA with stable
graft function.
Results:
Angiography
showed
excellent
perfusion
of
the
pancreaticoduodenal arcade via anastomoses in all cases after ex-vivo
injection of 5 ml of contrast medium into the splenic artery only. All 15
patients analyzed had normal graft function and sufficient perfusion of the
pancreatic head.
Conclusion: This study demonstrates that the whole pancreas is sufficiently
perfused by the splenic artery only through a complex system of
intraparenchymal anastomoses. This finding can be important not only for
pancreas transplantation but also for all kinds of pancreatic surgery.
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1021 APPLICATION OF FIBRIN SEALANT ON THE
PANCREATIC SURFACE DURING TRANSPLANTATION: A
PROSPECTIVE RANDOMISED SINGLE CENTRE TRIAL
P. Pfeffer, O. Øyen, B.H. Lien, B. Lien
Rikshospitalet University Hospital, Oslo, Norway
Background: Excellent results, with long term insulin-independency, have
in recent years been achieved by pancreas-Tx, particularly by simultaneous
kidney-Tx (SPK). However, pancreas-Tx represents a major surgical trauma
with a high rate of postoperative complications, particularly bleedings and
leakage of serous fluids (lymph/transudation/exocrine secretions).
We wanted to investigate whether the use of a fibrin sealant (“tissue glue”)
on the pancreatic surface could reduce bleedings and/or serous leakage; and
thereby the rate of complications/reoperations. This is the first randomised trial
addressing this issue.
Material/Methods: During 2003-2007 42 pancreas recipients [39 SPK/1 PTA
(Pancreas-Tx Alone) /2 PAK (Pancreas- After Kidney-Tx) ] were randomised
(1: 1) to the application of fibrin sealant or not. The fibrin sealant (Tisseal) was
sprayed on the whole pancreatic surface, after revascularisation and hemostasis
– i.e. under reasonably dry conditions. In the postoperative phase, drains were
removed when secretion was below 50-100 ml/day. These parameters were
recorded: Duration of drainage; total drainage volume; s-amylase values;
transfusions; complications/reoperations/interventions; stay in hospital.
Results:
[mean]
Duration of drainage (postop. days)
Total drainage volume (ml)
Max. s-amylase (U/l)
Reoperations (pancreas-related)
Transfusions (units of SAG-blood)
Stay in hospital (days)

Fibrin sealant +
n=19
2,2
1338
285
11 reop. in
4 pts (21%)
1,8
17

Fibrin sealant ÷ (ctr)
n=23
3,0
1509
251
6 reop. in
4 pts (17%)
1,7
18

Conclusion: Our randomised trial has not revealed any effect of using fibrin
sealant spray on the pancreatic surface after revascularisation; neither on serous
secretion/drainage volume, nor on complications.
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1022 ANALYSIS FOR THE CAUSES OF GRAFT FAILURE AND
MORTALITY IN 91 PANCREAS TRANSPLANTS
D.J. Han, S.C. Kim, K.T. Park, J.J. Hong, E.J. Ahn
Asan Medical Center
The purpose of this study is to improve the graft survival rate by analyzing the
causes of graft failure and mortality after pancreas transplants.
91 pancreas transplants have been performed from July 1992 to October 2007.
The cases were divided into four eras by immunosuppression protocols: Era
1 (July 1992 Dec. 1996, n=12) cyclosporine (CsA). azathioprine (AZA).
steroid (PD) and OKT3 induction; Era 2 (Jan. 1997- Jan. 1999, n=11)
tacrolimus (Tac). AZA, PD and OKT 3; Era 3 (Feb. 1999-July 2004, n=24)
Tac, mycophenolate mofetil (MMF). PD, and IL-2 receptor antibody induction;
Era 4 (Apr. 2004-present, n=44) Tac+MMF maintenance, PD early withdrawal,
thymoglobulin induction. They consisted of PTA (41%). PAK (7%) and SPK
(52%). 82 patients were transplanted from deceased donors and 9 patients
from living donors. Median follow up duration was 55.9 months (range 1 180
months).
Graft survival rates at 2 year by eras were 18%, 64%, 88% and 80%
respectively and patient survival rates at 2 year were 60%, 90%, 92% and 96%
respectively. Overall graft and patient survival of PTA/PAK were inferior to
that of SPK, but 3 year graft and patient survival of PTA/PAK since era 3
were slightly better than that of SPK (graft; 78% vs 76, patient; 96% vs 88%,
p>0.05). The graft failure rate from era 1 to 4 were 92%, 64%, 17% and 23%
respectively and acute rejection (AR) rate by eras were 75%, 64%, 42% and
25% respectively. The causes of graft failure were rejection (34%). anastomotic
leak (16%). thrombosis (9%). graft pancreatitis (9%). noncompliance to drug
13% and death with functioning graft (DWFG) (19%). Immunological graft
failures have decreased by eras (50%, 18%, 8%, 2% each) and technical failure
rate by eras were 42%, 18%, 4% and 7% respectively. But other causes like
noncompliance, DWFG have persisted by eras (0%, 27%, 4%, 14%) and 4
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cases of noncompliance in young PTA recipients and 2 cases of suicide were
experienced in our series. Overall mortality rate was 16.4% and mortality by
eras were 42%, 27%, 13% and 9%. The causes of mortality were mainly due
to sepsis in (40%). bleeding (13.3%). suicide (13.3%). anoxic death (13.3%)
and others (20%).
Immunological and technical graft failure has been markedly decreased, but
other causes such as noncompliance, DWFG has been a problem. Therefore,
in addition to precautious immunologic monitoring, noncompliance from
medication or psychological problem and DWFG from already developed
diabetic complication should be considered as important factors for preoperative
screening and postoperative care.
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1023 INITIAL EXPERIENCE ON PANCREAS
TRANSPLANTATION IN IRAN
S. Nikeghbalian, S.P. Ostad, H. Salahi, A. Bahador, K. Kazemi,
S.M.R. Nejatollahi, M. Dehghani, S.A. Malek-Hosseini
Shiraz Organ Transplantation Center
Hyperglycemia is the most important factor in the development and
progression of the secondary complications of diabetes. The only treatment that
have been demonstrated to influence the progression of these complications
is normalization or near normalization of glycosylated hemoglobin levels
either by intensive insulin therapy or beta cell replacement therapy with
pancreas or islet transplantation. Pancreas transplantation is superior to islet
transplantation and intensive insulin therapy with regard to the efficacy of
achieving glycemic control, and its beneficial effects on diabetes secondary
complications. Pancreas transplantation started in Iran in May 2006. Until
March 2008, 37 pancreas transplantations (26 males,11 females) have been
performed at Shiraz Namazi hospital (21 SPK, 3 PAK and 13 PTA). The mean
age of patients was 31.86 years (+/- 9.38) with a range of 16 to 50 years. The
most common indications for transplantation was diabetic nephropathy (62%)
followed by diabetic retinopathy and hypoglycemic unawareness (35%).
Surgical techniques were pancreaticoduodenal allograft with exocrine entericdrainage and portal venous drainage. Daclizumab has been used for induction
of immunosuppression and baseline immunosuppression has been achieved
with Tacrolimus, Mycophenolate Mofetil and Prednisolone. Acute rejections
have been treated with intravenous bolus of Methylprednisolone. Early death
(within 1 month) occurred in one patient due to pulmonary emboli. One patient
expired 2 months after transplantation due to fungal pulmonary infection. One
patient went under pancreatectomy due to surgical complications and 3 patients
had immunologic transplant rejection after 4 to 6 months post transplantation.
32 patients (86.4%) are alive with normal functioning pancreas. Pancreas
transplantation is now performed on a regular basis at Shiraz Namazi hospital
and further experience will improve patients’ survival and quality of life.
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1024 C2 MONITORING FOR THE EVALUATION OF DIABETIC
GASTROPARESIS
W.D. Schareck1, A. Püschel1, R. Wacke2, M. Gock1, E. Klar1
1Dept. of Surgery, University of Rostock, Germany, 2Institute of Clinical
Pharmacology, University of Rostock, Germany
The indication for combined pancreas-kidney transplantation (PNTX) is type
I diabetes with end-staged renal disease. This therapy is additionally effective
in secondary diabetic complications as especially neuropathy including
autonomic neuropathy. Therefore we questioned whether a regression of
diabetic gastroparesis could be detected with resorption kinetics of orally
applicated immunosuppression.
Methods: From 10/2003 to 8/2004 we performed in our center consecutively
10 PNTX´s immunosuppressed with single shot ATG, Ciclosporine A
(microemulsion mCsA ). MMF and steroids. One week after transplantation
AUC 0-12h (C0,C1,C2,C3,C4,C6,C8,C10,C12) was calculated for mCsA.
With a mean AUC of 4431 ± 2400 ng/ml x h, the concentration maximum
(Tmax) was measured after 3 hours (C2 582 ± 308 ng/ml, C3 590 ± 353 ng/
ml ).
Results: In the postoperative course after 4 years, 3 patients had to be switched
to another immunosuppressive regimen (2 tacrolimus, 1 sirolimus) one patient
died. Of the remaining 7 patients with mCsA therapy 4 patients are alive: 3 of
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them have excellent pancreas and kidney graft function with mCsA and MMF,
1 patient is insulin-dependent with good kidney function. Controlling the CsApharmacokinetics 4 years after PNTX revealed an AUC of 3604 ± 851 ng/ml
x h and showed a shift of mean Tmax from C3 (496 ± 119 ng/ml) to C2 (716
± 99 ng/ml ).
Conclusion: These results demonstrate an improved gastrointestinal resorption
thus indicating the amelioration of existing autonomic neuropathy. Neoquadruple therapy with mCsA reveals sufficient immunosuppression in PNTX.
In the long-term course mCsA pharmacokinetics are able to evaluate the course
of diabetic gastroparesis.

Figure 1. Piggy back venous reconstruction
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1025 SURGICAL STRATEGIES IN THE USE OF SMALL
PEDIATRIC DONORS FOR SIMULTANEOUS PANCREAS AND
KIDNEY (SPK) TRANSPLANTATION
H.G. Illanes, C.M. Quarin, R. Maurette, C. Piña, L. Reniero, H. Domingo,
C. Casadei
Instituto de Nefrología de Buenos Aires
Pediatric donors are underutilized in pancreas transplantation due to a possible
inadequate cell mass and increased risk of technical complications. We describe
our different surgical approaches to deal with pediatric donors. Between
September 2006 and February 2008, 45 SPK were performed in our institution,
4 of them were from pediatric donors.
Case 1: A pediatric pancreas and en-bloc kidney were transplanted into an
adult recipient.
The 3 year-old donor weighted 18 kg and the recipient was a 41 year-old female
and weighted 36 kg with a BMI of 14. The recipient was a brittle Type 1 diabetic
uremic with a deteriorated general condition including malnourishment. Up
to the present, 10 months post transplant, she has sustained excellent graft
functions and increased her BMI to 19.
Case 2: A single kidney and pancreas from a 12 year-old- donor with inborn
neurological disorder were transplanted to a 31 year-old-female type 1
diabetic uremic patient. The donor and recipient’s weight were 25 and 50 kg
respectively. 9 months post transplantation, the recipient is euglycemic with
normal renal function.
Case 3: An en-bloc dual kidneys-pancreas from a 5 year-old (25 kg) donor was
implanted in a 28 year-old-male (49 kg) recipient. In this case, the liver was not
retrieved, hence en-bloc kidneys, pancreas, duodenum, abdominal aorta (AA)
and inferior cava vein (ICV) were utilized. The pancreas did not require arterial
reconstruction. A portocaval shunt was made for venous pancreas drainage into
the donor ICV. The proximal end of the donor ICV was anastomosed to the
recipient ICV in a piggy back fashion. The donor distal AA was anastomosed
end-to-side to the right common iliac artery (RCIA). The pancreas was enteric
drained and the ureters were extravesically implanted. 5 months after the
transplant, the patient is off dialysis and insulin.
Case 4: An en-bloc dual kidneys-pancreas from an 18 month-old pediatric
(9.6 kg) donor was transplanted in a 30 year-old-female (60 Kg) pre-emptive
recipient type 1 diabetic. Donor operation and the back table dissection were
similar to case 3. During the recipient’s surgery, the proximal end of the donor
AA was anastomosed to the recipient RCIA. The donor RCIA was included
in the graft in order to preserve a right kidney polar artery. 4 months after
transplantation, patient is euglycemic with normal renal function.
Conclusion: We observed that pancreas and kidney transplantation from
donors with less than 25 kg shows excellent short term-outcomes. It seems
that these donors reach the metabolic demand of adult recipients. No
technical failures were displayed with these challenging donors. As far
as we know, this is first time that such a small donor (case 4) and these
complex techniques (case 3 and 4) has been described in the transplantation
literature.
Table 1.
Graft

Weight
Donor

Recipient

Kidney & Pancreas

18

36

En Bloc Double Kidneys
& Pancreas

25

50

En Bloc Dual Kidneys-Pancreas

25

49

En Bloc Dual Kidneys-Pancreas

9.6

60
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1026 PSYCOPATHOLOGICAL ASSESSMENT OF A SAMPLE OF
PATIENTS CANDIDATES FOR TRANSPLANTATION’
U. Boggi6, A. Calderone1, A. Armani2, S. Rinaldi3, A. Romano4, G.E. Costa5,
M. Mauri7, G.B. Cassano8
1
Psychiatrist, 2Psychiatrist, 3Psychiatrist, 4Psychiatrist, 5Medical Doctor,
6
Surgeon, 7Psychiatrist, 8Psychiatrist
Background: transplant is an important surgical intervention inducing distress
and anxiety. Psychiatric evaluation of organ transplant candidates is now
routinely proposed. This study purposed to assess the psychological evolution
in patients having received psychological and/or psychiatric assistance before
the transplantation.
Objective: To evaluate the prevalence of major psychiatric Disorders (Axis
I) and personality disorders (Axis II) in a sample of 227 patients candidates
transplantation
Methods: 227 consecutive transplant candidates were psychically evaluated as
part of the preoperative protocol. All patients were examined by a psychiatrist
using the MINI-International Neuropsychiatric Interview (MINI) (Sheehan
e coll., 1998) for mental disorder and a structured diagnostic interview for
personality disorder (SCID II) (First e coll., 1997).
Results: 57.7% (131) of the sample was male, mean age 41.62 („b9,7). with a
prevalence of married subjects (55%). with high school certificate (38%) and
dependent job (36,5%). Diabetes Mellitus type I complicated represents 78%
of the sample, while 22% is affected by a kidney disease. The age of onset of
the pathology was 16.4 („b9.7) for the diabetes and 28 („b11.2) for a kidney
disease.
A total of 30.8% of the sample met criteria for at least one Axis I disorder,
namely for Depression 13.8% (9.8%, lifetime, 4% current) for Anxiety disorder
10.1% (3.5% Panic Disorder lifetime, 1.3% panic disorder current, 0.45% panic
paucisintomatic lifetime, 4.85% agoraphobia current).
The most frequently observed axis II disorder was obsessive-compulsive
(20.25%). followed by Paranoid (5%). Oppositive (3.1%). Istrionic and
Depressive (1.75%). at the last Borderline and Avoidant (1.3%).
Discussion: These preliminary data indicate that Mood disorders are frequent
among individuals candidates for transplantation, their prevalence being much
higher than in the general population. The causes for the association between
chronic disease and mood disorders at present are not known, but we suppose
that psychophysical distress and pharmachologic treatment may contribute to
the development of psychiatric disorders.
There is a significant association between personality disorder and kidney
disease supporting the impact of somatic chronic disease in axis II disorders .
Implications of these findings for the pre-transplant psychological and
psychiatric evaluation are to be discussed.
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1027 INCREASED INCIDENCE OF BONE FRACTURES IN
BLADDER-DRAINES VS ENTERIC-DRAINED SIMULTANEOUS
PANCREAS-KIDNEY TRANSPLANT RECIPIENTS
O. Olaitan, J.A. Zimmermann, P. Mohan, W. Shields, J.G. Rodriguez,
D.P. Hickey
Beaumont Hospital
Introduction: Several pre and post-transplant factors are known to contribute
for the higher incidence of osteopenia-relatedfractures in both trabecular and
cortical bone after simultaneouspancreas-kidney (SPK) recipients, including
diabetic condition,dialysis, renal insufficiency, hyperparathyroidism, low
boneturnover and steroid use; however, the influence of chronicmetabolic
acidosis and its related calcium metabolism derangementsecondary to bladder
drainage of the duodenopancreatic graft hasnot been reported as a risk factor.
Patients and Methods: To support our observation, we performed
aretrospective study with all 80 SPKs performed at our institution from1992
to 2005. 37 cases were bladder-drained (BD) with a conventional sideto side
extraperitoneal duodenocystostomy for control of pancreaticexocrine fluid and
43 had an enteric drainage (ED) through aduodenoileostomy. Both groups had
comparative demographic features interm of sex, age, time in dyalisis, length
of the diabetic condition.There were not patients treated with biphosphonates
post-transplant. Allcases received a calcineurin-inhibitor based quadruple
immunosupressivetherapy.
Results: Four recipients with bone fractures were identified in the ED group
(9.3%) and ten cases in the BD group (27%) with a statisticalsignificance.
Comparable patient and graft survival were found in bothgroups. All pancreas
grafts except one had endocrine function at the timeof the fracture, and all
BD recipients were on oral sodium bicarbonatereplacement. The average from
the time of the transplant to the time ofthe fracture was 62.1 months (12-120)
for the BD group compared to 15months (12-24) for the ED group. The most
common site for fractures wasankle long bone (30%) followed by radius (20%).
femur (20%). calcaneus (10%). middle foot (10%) and forefoot (10%) in the
BD group; the mostcommon fractured bone in the ED group was the femur
(50%). followed bythe ankle (25%) and the middle foot (25%).
Conclusions: We found bladder-drained SPKs to have a triple-foldincidence
of bone fractures when compared to enteric drained recipients.Osteoporosis is
prevalent in the pre-transplant population waiting for akidney or a SPK and in
the post-transplant population regardless of theorgan involved, thus they are at
increased risk of bone loss. Acceleratedosteopenia post-transplant is therefore
expected as the cause for a highfracture rate in SPK recipients (as high as 49% in
some series). Withcomparable demographics and immunosuppressive regimes
employed for bothSPK recipient groups, we found statistically and clinically
significantthe higher incidence of bone fractures in the BD group, making
thissubset of patients at particular risk for this condition and thereforefor the
need of increased surveillance. Attention must be paid tostrictly correct both
metabolic acidosis and to improve bone fitness bothpharmacologically and
with physiotherapy in this fragile population.
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1028 QUALITY OF LIFE AND SPECTRUM
SYMPTOMATOLOGY IN POTENTIAL RECIPIENTS LISTED
FOR PANCREAS TRANSPLANTATION
U. Boggi, A. Calderone, S. Rinaldi, A. Armani, A. Romano, G.E. Costa,
S. Augusto
Psychiatrist
Background: The Spectrum Project aims to define subthreshold and
atypical conditions not sufficiently characterized in the current diagnostic
nomenclature.
Objective: The objective of this study was to assess the quality of life (QoL) and
the spectrum symptoms in patients candidates to renal-pancreas transplantation.
This study compared the prevalence of mood and panic spectrum features and
quality of life in candidates to transplantation with kidney disease and diabetes
mellitus.
Methods: The study was conducted at the University Hospital of Pisa. All
patients were examined using self-report Structured Clinical Interview for the
Spectrum of Panic Disorder (SCI-PAS) and for the spectrum of Mood Disorder
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(SCI-MOOD). QoL was measured using the ‘Quality of life Enjoyment and
Satisfaction Questionnaire-SF (QlesQ) ’.
Results: Mean score of MOODS-SR-LF was 32.7 (± 21.5) in the total sample,
37.4 (± 23.0) for the female group and 29.1 (± 19.7) for the male group. In
patients with diabetes mellitus type I mean score was 33.0 (± 21.1). while in
patients with kidney disease was 30.9 (±22.1).
Mean score of PAS-SR-LF was 18.5 (± 16.2) in the total sample, 24.8 (± 18.2)
for the female group and 13.7 (± 12.6) for the male group. In patients with
diabetes mellitus type I mean score was 18.5 (± 15.6). while in patients with
kidney disease was 18.1 (±17.7).
Mean score at QLesQ was 44.6 (±8.5). 44 (±8.4) in patients with diabetes and
46.6 (±8.4) in patients with kidney disease.
Conclusions: The total score on the mood and panic spectrum was higher in
subjects with Diabetes Mellitus compared to those with kidney disease.
Total score on QLesQ was lower nearly significantly in patients with diabetes
mellitus, indicating a worse impairment of quality of life in those patients.
The Q-LES-Q score in the overall sample was considerably lower than the
community norm but similar to that of Major Depressive Disorder patients.
We believe that early onset of diabetes mellitus may contribute to the
development of higher mood and panic spectrum psychopathology by means
of the stigma and the associated psychological and physical suffering in
individuals who are affected by a chronic disease. This appear to influence also
quality of life of these subjects.
Subtreshold and atypical symptoms deserve attention for an optimal and
complete management of this particular population of patients.
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1029 ENTERIC CONVERSION AFTER BLADDER DRAINAGE
IN PANCREAS TRANSPLANTS: TWO STEP APPROACH
D.J. Han, S.C. Kim, K.T. Park, J.J. Hong, E.J. Ahn
Asan Medical Center
In spite of urologic and metabolic complication, bladder drainage (BD) is
still preferable option in pancreas transplantation alone (PTA) or pancreas
after kidney transplant (PAK). The method of exocrine diversion in
pancreas allograft continues to be controversial due to the advantages versus
disadvantages of bladder versus enteric drainage. So, the purpose of this
study is to analyze the clinical outcomes of BD and enteric conversion (EC)
in pancreas transplants.
Among 68 pancreas transplantation from January 1999 to December 2007, BD
was performed in 41 patients (25 PTA, 4 PAK, 12 SPK including 2 living donor
SPK). 4 cases (9.7%) were excluded due to early death of the patient or early
graft failure within 1 year, yielding an analysis of 37 patients. All the recipients
with BD were maintained with oral bicarbonate to prevent metabolic acidosis
and were monitored with checking urine amylase.
Of 37 recipients with functioning pancreas graft (BD). adverse effects of
BD like hematuria (n=9). reflux pancreatitis (n=6). UTI (n=9) and metabolic
acidosis (n=4) were experienced, but which were well tolerated and
managed with medication. For recurrent and poorly tolerated complications,
6 enteric conversions (16.2%) were performed. The indication for enteric
conversion (EC) were graft pancreatitis with minor leak (n=3). recurrent
reflux pancreatitis (n=1). recurrent UTI (n=1) and pancreatic duct obstruction
(n=1) in segmental pancreas transplant treated by pancreaticojejunostomy at
pancreas tail. Mean duration of EC from transplantation was 21.3 months
(8-60 months). Mean operation time was 91minutes (80-115min) and no
surgical morbidity or mortality was observed related to EC. In all patients,
initial problems associated with BD were completely resolved maintaining
pancreatic function. No graft rejection following enteric conversion was
found and long-term renal and pancreatic function was not affected by the
enteric conversion.
EC after pancreas transplantation is an effective and safe procedure with
low morbidity and mortality rates. To maximize benefits of BD in terms of
pancreatic monitoring and to minimize the adverse effects of BD, a strategy
of two-step approach of primary bladder drainage followed by timely enteric
conversion would be appropriate in PTA, PAK patients and in a selected group
of SPK patients at least until an effective diagnostic tools monitoring pancreas
allograft be found.
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1030 EFFECTIVE CONTINUOUS ARTERIAL THROMBOLYSIS
AFTER PANCREAS TRANSPLANTATION
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1031 SIMULTANEOUS KIDNEY AND PANCREAS
TRANSPLANTATION AT A UNIVERSITY, GENERAL HOSPITAL
IN ARGENTINA.
S. Hyon, R. Groppa, N. Heredia, L. Costan, O. Campi, C. Giudice, L. Barcan,
L. Litwak, L. Algranati, P. Argibay
Pancreas And Kidney Transplantation Program, Hospital Italiano De Buenos
Aires
Introduction: Simultaneous pancreas and kidney transplantation (SPK) is an
established therapy for type 1 diabetes with end-stage renal disease and has
increased the survival of patients from 50% to above 80% at 5 years. Objective.
To describe the results of SPK at a teaching, general hospital based in a nonUS, non-European country.
Methods: Sixty two consecutive SPKs were performed at a single, multiorgan
transplant center in type-1 diabetic patients with end-stage renal insufficiency.
Recipient characteristics were: men, 33; women, 29; mean age at transplant,
33.0 +/- 5.0 years; mean time of diabetes pretransplant, 21.5 +/- 5.1 years;
mean time of dialysis pretransplant, 39.9 +/- 25.2 months. All organs were
obtained from heart-beating cadaveric donors with a mean age of 23.7 +/- 7.5
years. All pancreatic grafts were placed intraperitoneally with systemic venous
anastomosis and exocrine drainage to the bladder in the first 22 cases, and the
small bowel in the following 40. Pancreas and kidney cold ischemia times were
11.0 +/- 1.8 h, and 14.1 +/- 2.1 h, respectively. Immunosuppression was induced
with antilymphocytic globulin or daclizumab. Maintenance was done with a
three-drug protocol, lately with tacrolimus, steroids, and mycophenolic acid.
Results: All patients had immediate pancreatic graft function with insulin
independence. Mortality within 3 months post-transplant was 1.6% (1/62). HbA1c
stayed within normal range throughout follow-up (7.8% vs. 5.3% pre- vs. posttransplant, respectively). Mean creatinine at 1 year was 1.1 mg/dL. Four kidneys
were lost (1, primary non-function; 3, venous thrombosis). One patient from the
last group underwent a kidney re-transplant with a living donor, with continuous
pancreas function. Another patient returned to hemodialysis 7 years after SPK due
to kidney loss from rejection, with preserved pancreas function. Five pancreases
were lost from thrombosis (2, arterial; 3, venous). Patient, pancreas, and kidney
1-year survival rates were 91%, 85%, and 88%, respectively; while 5-year
survival rates were 87%, 76%, and 79%, respectively, with 17 patients in this
series surviving over 5 years post-transplant and 4 over 10 years.
Conclusions: SPK at our center may offer type 1 diabetic patients with endstage renal disease high probabilities of avoiding the use of exogenous insulin
and dialysis in the mid-term and the long-term post-transplant. Although
an important number of patients has not yet been achieved, the results are
comparable to larger, international transplant centers.

1032 ACUTE REJECTION AFTER SIMULTANEOUS KIDNEYPANCREAS TRANSPLANTATION WITH DIFFERENT
IMMUNOSUPPRESSIVE REGIMENS.
S. Hyon, R. Groppa, L. Algranati, N. Imperiali, C. Giordani, G. Gallo,
C. Mombelli, N. Heredia, L. Costan, P. Argibay
Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos
Aires
Introduction: Simultaneous kidney and pancreas transplantation is an
established therapy for type-1 diabetes mellitus with end-stage renal disease.
However, a precise immunosuppressive regimen has not yet been well
defined.
Objective: To assess the rate of acute rejection after simultaneous
kidney-pancreas transplantation in two groups of patients with different
immunosuppressive regimens.
Patients and methods: Forty four type-1 diabetic patients with end-stage
renal disease undergoing simultaneous kidney and pancreas transplantation
were included in this study. All organs were located intraperitoneally with
arterial anastomoses to the common iliac artery and venous anastomoses to the
external iliac vein. Exocrine drainage were established with the bladder (n=22)
or the jejunum (n=22). A historical group (Group A, n=15) received induction
immunosuppression with monoclonal or polyclonal anti-T cell antibodies
and maintenance therapy with cyclosporine, prednisone and azathioprine or
mycophenolate. A more recent group (Group B, n=29). were induced with
anti-thymocytic antibodies or daclizumab, and maintained with tacrolimus,
prednisone and mycophenolate. No significant differences were observed
regarding donor or recipient characteristics between both groups, including
age, time of dialysis and time of diabetes pretransplant, cold ischemia time
and mismatch.
Results: The rate of acute rejection for groups A and B were 57% and 24%,
respectively. Within group B, those patients who received daclizumab for
induction had an acute rejection rate of 30% (all responsive to steroid therapy).
while those receiving thymoglobulin had no episodes of rejection. CMV
infection was only observed in the group treated with thymoglobulin (rate,
33%). At one-year, survival rates for patient, pancreas and kidney were 91%,
85% and 88%; at 5 years 87%, 76% and 79%, respectively; one-year creatinine
for groups A and B were 1.2 +/- 0.2 mg/dL vs. 1.2 +/- 0.3 mg/dL, respectively;
HbA1c was 5.5 +/- 0.5% vs. 5.3 +/- 0.2%, respectively.
Conclusion: The use of newer, more potent immunosuppressive drugs
determined a reduction of acute rejection episodes in patients undergoing
simultaneous kidney and pancreas transplantation. However, no differences
were observed in the immediate and the long-term post-transplantation.
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1033 INTRAPYLORIC INJECTION OF BOTULINUM TOXIN
A AMELIORATES DIABETIC GASTROPARESIS SYMPTOMS
AND QUALITY OF LIFE IN PANCREAS TRANSPLANT
PATIENTS
M. Maglione, G. Brandacher, R. Öllinger, M. Biebl, W. Mark, H. Weiss,
R. Margreiter
Department of General and Transplant Surgery, Innsbruck Medical
University, Innsbruck, Austria
Background: Diabetic gastroparesis (DGP) represents a chronic gastrointestinal
disorder defined by delayed gastric emptying in the absence of mechanical
obstruction. However, following successful simultaneous or sequential
pancreas kidney transplantation DGP remains a major concern in one third
of these patients. In diabetic patients refractory to prokinetic and anti-emetic
medication alternative options like intrapyloric injection of botulinum toxin A
(BoTx) were recently reported. However, results regarding BoTx therapy in
these patients still remain contradictory. Here we report on the application of
this treatment option in four pancreas transplant recipients.
Methods: All four patients (three males) suffered from severe and persistent
gastroparesis following successful transplantation with stable graft function.
Cardinal symptoms of gastroparesis like nausea, vomiting, early satiety,
bloating and abdominal pain were quantified by the Patient Assessment of
Gastrointestinal Symptom (PAGI-Sym©) Severity Index before injection and
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S. Nobori, M. Okamoto, T. Suzuki, K. Sakai, A. Yoshizawa, H. Ushigome,
S. Sakamoto, N. Yoshimura
Kyoto Prefectural University of Medicine
Backgrounds: Venous thrombosis remains an important non-immunological
cause of pancreatic graft loss. We report a case of successful continuous arterial
thrombolytic therapy of venous graft thrombosis.
Methods/Results: A 54-year-old male with insulin dependent diabetes mellitus
received a cadaveric pancreas transplant alone in the right iliac fossa with enteric
exocrine drainage and standard vascular anastomosis. Immunosuppression
consisted of induction with basiliximab and maintenance therapy with tacrolimus,
mycophenolate mofetil and steroid. Nafamostat mesilate was used for prophylactic
anticoagulation therapy. Six days after transplantation, venous graft thrombosis
developed with normal graft function and mild increase of serum pancreatic enzyme.
Doppler ultrasonography and enhanced computed tomography showed partial venous
graft thrombus in splenic and mesenteric vein. After failed systemic anticoagulation,
selective catheter thrombolysis was started with continuous urokinase infusion at
the graft artery and systemic heparinization. Arterial thrombolysis achieved the
complete recover of venous outflow in 9 days without any complication.
Conclusions: Graft rescue was achieved by continuous arterial thrombolysis
of venous graft thrombosis.
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during follow up. Likewise Quality of life (QoL) was assessed by the Patient
Assessment of Gastrointestinal Disorders Quality of Life (PAGI-QoL©) Index.
Total score varies from 0 to 5. To exclude other possible underlying causes
gastric emptying was determined by X-ray and scintigraphic examination prior
to BoTx treatment. BoTx therapy consisted of up to 100U which were injected
equally distributed over the four quadrants of the pylorus. A first control X-ray
was performed 24 hours later.
Results: Substantial therapeutic effects were evident within two weeks
following BoTx injection in all patients. While the mean symptom score before
BoTx injection was 3.5 (range 3.14 – 4.44) after the treatment it decreased to 0.8
(range 0.3 – 1.8). Similarly the PAGI-QoL© Index decreased from 2.8 (range
2.37 – 3.24) to 1.1 (range 0.24 – 2.44). The first patient reported a consistent
decrease of clinical symptoms paralleled by an improvement in QoL after a
total of 120U BoTx applied within two gastroscopies. The second and the third
patient required a second injection (each 100U) due to recurrent symptoms
after two and ten months, respectively. Finally, the forth patient experienced
significant ameliorations of both, symptoms and QoL, after just a single BoTx
injection of 100U. After a mean follow up of 320 days all treated patients are
doing well and display considerable improvements of all cardinal symptoms
and even more important conspicuous amelioration of their reported QoL.
Conclusion: Intrapyloric BoTx injection represents a safe and straight forward
treatment option for pancreas transplant patients suffering from severe and
persistent DGF and should therefore be considered if they are refractory to
prokinetic and anti-emetic medication.

POSTER BOARD NUMBER P1 – 120
1034 MICROSURGICAL TECHNIQUE IN SIMULTANEOUS
PANCREAS-/KIDNEY TRANSPLANTATION OF THE RAT –
CLINICAL EXPERIENCE AND REVIEW OF LITERATURE
E. Matevossian1, N. Hüser2, T. Brill3, S. Thorban4, M. Stangl5
Department of Surgery, Transplantation, Technical University, Munich,
2
Department of Surgery, Transplantation, Technical University, Munich,
3
Department of Preclinical Research, Technical University, Munich,
4
Department of Surgery, Transplantation, Technical University, Munich,
5
Department of Surgery, Transplantation, Technical University, Munich
Background: The special quality of technique and immunologic findings in
combined pancreas-/kidney transplantation (PNTx) requires experimental
basic research. Therefore standardized and reproducible transplantation models
which reflect technical and immunologic aspects are necessary. In this article
an experimental model with microsurgical aspects of the combined PNTx will
be described, in detail following clinical transplantation.
Material and Methods: For the syngenic transplantation model Lewis- (RT)
rats were used to differentiate immunologic aspects after rejection from
surgical technical artefacts. After organoprotective hypothermic perfusion the
donor received en-bloc pancreatectomy with duodenal segment/aortic patch
with mesenterial artery and nephrectomy on the right side with aortic and cava
patch. The arterial and venous revascularization of the heterotopic transplanted
pancreas in the recipient was performed using the aorta with mesenterial artery
and vena cava inferior with portal vein. The exocrine drainage of the pancreas
took place over the segment of the duodenum which has been transplanted in
side-to-side technique to the jejunum of the recipient. The kidney has been
transplanted over the aorto-cava segment end-to-side below the artery and vena
renalis of the recipient. The ureter was anastomosed to the bladder by patchtechnique. The donor operation took 60 (±14.0) minutes and the transplantation
90 (±17.5) minutes. After transplantation serum parameters have been controlled
daily. Biopsies for histopathology were taken on day 5,10 and 12.
Results: All 12 recipients survived the combined PNTx without serious
surgical complications. In one recipient on postoperative day 10 a thrombosis
of the portal vein segment of the transplanted pancreas occured, which lead to
organ failure. The blood glucose levels were normal on the 3. postoperative
day on. From histopathologic point of view the transplanted pancreas organs
appeared like normal pancreas tissue on postoperative day 8. The transplanted
duodenal segment showed slight villous atrophy. The origin in situ pancreas
organ of the recipient with vascular exclusion showed total necrosis on day
5 after transplantation. The transplanted kidneys were well perfused, and no
vascular complications occured. The anastomosis between ureter and bladder
was leakproof in all recipients.
Conclusion: The transplantation model for combined PNTx presented is easily
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reproducible and associated with a low mortality and postoperative complication
rate. Excellent graft function and graft survival rates are achievable due to the
simplified operation technique and the short operation time. This transplantation
model may thus represent high clinical relevance as to answer surgical and
immunologic questions within the scope of basic research.
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1035 RENAL RETRANSPLANTATION IN SIMULTANEOUS
PANCREAS KIDNEY TRANSPLANT RECIPIENTS
W. Shields, F. Al-Nooh, D. Olaitn, A. Zimmerman, J.G. Navas, P. Mohan,
D. Little, D. Hickey
National Centre of Renal And Pancreatic Transplantation, Beaumont Hospital
Objective: To examine renal retransplantation after graft loss in simultaneous
pancreas kidney (SPK) transplant recipients.
Methods: A retrospective study was conducted on all patients with SPK
transplants at a single centre in Ireland between 1992 and 2008. Timing of
transplant, duration of functioning renal graft, timing of graft failure, panel
reactive antibody (PRA). cause of graft failure, timing of second renal
transplant, outcomes, and technical aspects of the surgery were recorded for
analysis.
Results: In our centre, eight SPK patients underwent renal retransplantation
after the failure of their renal graft. Cause of graft failure in all patients was
chronic allograft nephropathy. All patients underwent transplant nephrectomy
at the time of transplantation and received deceased donor kidneys. Kidneys
were allocated purely on ABO compatibility only. Kidneys were transplanted
into the left iliac fossa utilizing synthetic vascular grafts in three of the eight
patients. All patients continued on their previous immunosuppression regime
with a perioperative increase in intravenous corticosteroids. All kidneys
functioned immediately and have normal renal function at follow-up (6 months
to seven years). No deterioration in pancreatic function was noted at followup.
Conclusion: Renal retransplantation represents an effective treatment option in
SPK patients who lose their first kidneys. The procedure can be accomplished
without risk to the pancreatic graft.
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1036 CURRENT STATUS OF TRANSPLANT NEPHRECTOMY
IN ONE INSTITUTION
M. Nakatsuka1, A. Colquhoun, M. Posner, M. Behnke
1
Virginia Commonwealth University Health System, 2Virginia Commonwealth
University Health System, 3Virginia Commonwealth University Health System,
4
Virginia Commonwealth University
Aims: The role of transplant nephrectomy after failure of kidney transplantation
is still debatable.The routine removal of the asymptomatic allograft may not
be recommended because of risks associated with transplant nephrectomy.We
reviewed current status of transplant nephrectomy in our institution.
Methods: 844 cases of kidney transplants were reviewed from 1995 to 2006
from data bank. Number of cases who underwent transplant nephrectomy were
evaluated.
Results: Among 193 cases of graft failure (24.2%).82 cases (mean age of
41.2) underwent transplant nephrectomy. 82.9%) were black and 79.3% were
cadeveric kidney transplants. Graft loss < 1 yr (all of them within 1 month)
were 14 (7.2%) and 9 cases among them underwent nephrectomy. More than
81% of patients underwent transplant nephrectomy because of chronic allograft
nephropathy with pain/fever/infection/hematuria or thrombocytopenia. 7 cases
underwent transplant nephrectomy due to acute rejection.
Conclusion: We presented our data of transplant nephrectomy .24.2%
of our kidney transplants ended up to have transplant nephrectomy.
We believe it is necessary to remove the kidney if the patient present with
hematuria,fever,tenderness and swelling over the allograft, infection or tumor
development in the kidney in addition to chronic allograft nephropathy. Gross
specimen of removed kidney usually showed severe inflammatory changes.
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1039 DOPAMINE TREATMENT IN BRAIN-DEAD DONOR
RATS IMPROVES KIDNEY FUNCTION EARLY AFTER
TRANSPLANTATION AND REDUCES RENAL INFLAMMATION

J. Thompson, Y. Chu, J. Glass, S. Brown
VAMC And University of Kentucky
Despite recent advances in conditioning and prophylaxis, there still is no
consistently reliable way to treat and/or prevent aGVHD and preserve GVL.
Recently characterized cytokines involved in inflammatory signaling pathways
offer new experimental and potentially clinical approaches to improve GVHD
outcome. Because the p19 dimer of IL-23 is a critical component in the
induction of inflammatory Th17 cells, we investigated its role in stem cell
transplantation. BALB/c mice received 8.5 Gy TBI followed by transplantation
of 10 x 106 bone marrow (BM) plus 2.5 x 106 T containing spleen cells (SCs)
from syngeneic, allogeneic wild type (WT) C57BL/6 (B6) or allogeneic p19-/mutant donors. In the first experiment, 21/24 (87.7%) of the BALB/c mice
transplanted with WT B6 cells died by the end of the experiment (21 days)
in contrast to only 7/24r (24.1%) of those transplanted with p19-/- cells. In a
second experiment, BALB/c mice transplanted with B6 or p19-/- cells were
autopsied on days 7 and 14. Simonsen’s ratio of spleen to body weight and
histology, particularly of the bowel, confirmed aGVHD in the WT mice. In
a third experiment 10/10 mice transplanted with B6 cells died by day 14 and
all 10 of the p19-/- animals survived. By day 54, 7 of these 10 had developed
clinical and histological signs of cGVHD. When either WT B6 or p19 KO
mice were transplanted with BALB/c BM + SCs, there was no difference in
the incidence or severity of aGVHD. Furthermore, p19 KO animals were no
more radio-resistant to 8.5 Gy TBI than WT B6. In conclusion, BALB/c mice
transplanted with IL-23p19 deficient cells develop aGVHD less frequently and
less severely than those transplanted with WT B6 cells. The survivors develop
cGVHD. Although we have not yet tested for GVL, historically there is a strong
positive correlation between cGVHD and GVL.

S. Hoeger1, B. Yard1, A. Reisenbuechler1, U. Goettmann1, W. van Son2,
M. Seelen2, R. Waldherr1, P. Schnuelle1,
1Department of Nephrology, University Hospital Mannheim, University of
Heidelberg, 2Department of Nephrology, University of Groningen
Introduction: Brain dead is associated with hemodynamic changes in the
micro-circulation and with tissue inflammation. Since donor dopamine
treatment improves transplantation outcome after renal transplantation in
human, we tested in an animal model if this treatment affects renal function
and inflammation in donors and recipients.
Methods: Brain death was induced in F344 rats for 6 hrs in all experiments.
Dopamine (10μg/kg/min) was given from the onset of brain death for 6
(DA 6) or 3 hours (DA 3). Untreated ventilated non brain dead (NBD) and
brain dead (BD) animals served as controls. Kidneys were transplanted into
bilaterally nephrectomized recipients. Serum creatinine was measured both
in donors and recipients. Leukocyte infiltration was assessed 10 days after
transplantation.
Results: In BD donors serum creatinine was not significantly different between
dopamine treated and non-dopamine treated rats. One day after transplantation
mean serum creatinine in recipients that received an renal allograft from BD
vehicle treated rats was 1.7± 0.9, while in recipients receiving a renal allograft
from dopamine treated BD or from NBD rats serum creatinine was significantly
reduced (0.8 ±0.4 (DA 3). 0.8± 0.2 (DA 6) and 0.8 ± 0.5 (NBD). (P<0.05)
). Ten days after transplantation, the number of infiltrating monocytes was
significantly lower in grafts obtained from dopamine treated and from NBD
rats (P<0.05). A reduced infiltration in these grafts was confirmed by Banff 97
classification.
Conclusions: Administration of dopamine to brain dead donors improves
early renal function after transplantation and reduces renal inflammation.
Hence this may explain the salutary effect of donor dopamine treatment in
renal transplantation.
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1038 MICROCHIMERISM AND RENAL TRANSPLANTATION:
DOUBT STILL PERSISTS
G. Pourmand1, A.R. Mehrsai1, M.R. Nikoobakht1, M. Taherimahmoudi1,
B. Nikbin2
1Urology Research Center,Tehran University of Medical Sciences,
2Department of Immunology, Faculty of Medicine, Tehran University of
medical Sciences,Tehran,Iran.
Objectives: The Presence of donor leukocytes in recipients of organ allograft
has been shown even several years after transplantation. However, it remains
unclear whether this donor cell microchimerism plays an effective role in
allograft acceptance or is simply a consequence of immunosuppression
condition in recipients.
Materials & Methods: In this study we retrospectively evaluated the Peripheral
Blood Microchimerism (PBM) after renal transplantation in 32 male-to-female
recipients of living (unrelated) and cadaveric donor renal transplants. Using
a Nested Polymerase Chain Reaction (Nested-PCR) amplification specific
for SRY region of the Y chromosome, microchimerism was detected with
sensitivity up to 1: 1000000. According to the presence of PBM recipients
were classified into microchimeric and nonmicrochimeric group, and then
acute and chronic rejection episodes, type of allotransplant (living or cadaveric
donor). recipient and donor age at transplantation, previous male labor or blood
transfusion, allograft function (serum creatinine level). and body mass index
were compared between two groups.
Results: Among 32 recipients 7 (21.9) were positive for PBM in multiple
testing at different post-transplantation times. All microchimeric recipients
had been received kidney from living-unrelated donors. Regarding to other
parameters mentioned above significant difference was not observed. In
addition, acute rejection rate in microchimeric group was 3 (42%) versus 4
(16%) in nonmicrochimeric recipients (not significant).
Conclusion: Our results demonstrate better establishment of microchimerism
after living donor kidney transplantation. But, concerning true effect of
microchimerism after renal transplantation doubt still persists; and it seems that
microchimerism alone has no major protective role in renal allograft survival.
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1040 THE EFFECT OF LOW LEVEL HE -NE LASER
RADIATION (4 J/CM2) 632.8 NM ON THE SECRETION OF
EFFECTIVE CYTOKINE ON CHRONIC GRAFT REJECTION –
AN IN VITRO STUDY
A. Mehrsai1, M. Afsharpad1, G. Pourmand1, B. Nikbin2, H. Wahhabaghai1,
M. Taherimahmoudi1
1Urology Research Center,Tehran University of Medical Sciences,
2Immunology department; Medical Faculty,Tehran University of medical
sciences, Tehran, Iran
Introduction: Basically Chronic graft rejection is a type four hypersensitivity
process, also known as delayed type hypersensitivity (DTH).the role of
cytokines secreted from T cell lymphocytes is known in this process. Among
these cytokines the biggest role belongs to TGFâ and IL2. Many studies on
the effect of low level lasers on DTH have been published, but not many
studies have focused on mechanism of low power lasers effect on DTH
which is also the mechanism of chronic graft rejection. If low level lasers
are able to decrease the level of cytokines effective on this process, then it
is possible to use this device to prevent chronic graft rejection either alone
or combined with routine treatmentsto gain less side effects than routine
treatments. This study was designed to evaluate the effect of low level laser
on the amount of cytokines secreted by T cells after stimulation by foreign
antigens in vitro.
Method and Materials: Human Peripheral Blood Mono nuclear Cells were
cultured; the cells were divided into 4 groups (case1, case2, control1, control2).
Control 1 group was the base group and the cells did receive neither stimulation
nor irradiation. Group control 2 just was stimulated by PHA, group case 1
started receiving irradiation prior to stimulation and case 2, started receiving
irradiation after the stimulation. Both case groups were irradiated by the same
laser device and on days 3, 5 and 8 the level of the cytokines were checked in
all the groups and later was analyzed.
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Results: Our results showed that low level irradiation can decrease the level
of cytokines which are known to be stimulator for chronic graft rejection (IL2,
IL12, and INFã. (The changes were significant but there was no significant
difference between our two case groups.
Discussion: Although this study suggests the successful role of low level
lasers on preventing chronic graft rejection by affecting the cytokines
known to have strong role on this process, before using these devices as a
treatment in clinic, further experimental studies and dosage determination
are required.
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1041 EFFECT OF PRE-TRANSPLANT LEVEL AND POSTTRANSPLANT SERIAL CHANGE OF SOLUBLE CD30 ON THE
INCIDENCE OF BIOPSY-PROVEN ACUTE REJECTION AFTER
KIDNEY TRANSPLANTATION
K.H. Huh1,2, M.S. Kim1,2, S.I. Kim1,2, Y.S. Kim1,2, M.K. Ju1,2, H.J. Ahn3,
H.K. Chang1,2, D.J. Joo1, S.J. Kim1, K. Park3
1
Department of Surgery and 2The Research Institute for Transplantation,
Yonsei University College of Medicine, Seoul, Korea 3Department of Surgery,
Kwandong University Myongji Hospital, Goyang, Korea
Serum level of soluble form CD30 (sCD30) might be used as a marker of
immunologic status of pre-transplant recipient. We analyze effect of pretransplant level and post-transplant change of sCD30 on the incidence of
biopsy-proven acute rejection prospectively.
One hundred sixty-one recipients, who underwent kidney transplant from
March 2006 to June 2007, were enrolled in this study. Measurement of serum
sCD30 level was performed using enzyme-linked immunosorbent assay kit
(Bender MedSystems, CA, U.S.A.) at pre-transplant 1 day, post-transplant 1-2
days, 5-6 days and 14 days.
Mean score of pre-transplant sCD30 was 109.7 ± 60.0 U/ml, which was not
correlated with conventional immunologic status parameters such as panel
of reactivity antibodies (PRA). previous history of positive lymphocyte
cross matching and organ transplantation. The sCD30 was rapidly
decreased after transplantation; mean score of sCD30 at post-transplant
1-2 days, 5-6 days and 14 days were 50.1 ± 34.7, 28.0 ± 27.3 and 14.3 ±
17.6 U/ml respectively. The post-transplant serial change of sCD30 level
was not affected by the pre-transplant sCD30 level. The slow decrement
of sCD30 after transplantation was related with deceased donor, high (>2.0
mg/dl) serum creatinine level at post-transplant 7 day and delayed graft
function. High pre-transplant sCD30 group (≥ 100 U/ml, n=82) showed
significantly higher incidence of biopsy-proven acute rejection (17.1%,
14/82) than low sCD30 group (5.1%, 4/79) (p=0.016). The slow decrement
of sCD30 level after transplantation did not cause a significant difference
in incidence of biopsy-proven acute rejection in separated and combined
analysis[figure1].
Pre-transplant sCD30 level, not post-transplant change of sCD30 level, is
related with the incidence of biopsy-proven acute rejection.
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1042 CLINICOPATHOLOGICAL REVIEW IN ALLOGRAFT
NEPHRECTOMY
H-C. Park, S-J. Park, J-H. Jang, B-S. Kim, S-H. Joo,
Department of Surgery, Kyung Hee University College of Medicine, Seoul,
Korea
Purpose: Allograft nephrectomy is not necessary in all cases of transplant
failure. This procedure should be reserved for the symptomatic cases. The
aim of this study was to evaluate the causes and complications of allograft
nephrectomy.
Materials and Methods: Among 326 kidney transplantations performed at our
center between 1978 and 2007, 39 patients underwent allograft nephrectomy.
The patient records were reviewed for allograft nephrectomy indications,
morbidity, mortality and pathologic causes. Allograft nephrectomy was
performed by the extracapsular or intracapsular route.
Results: A total of 39 (11.9%) allograft nephrectomies were performed in 27
(69%) male and 12 (31%) female patients. Mean age at nephrectomy was 40.9
years (range, 26 to 59). The mean interval between kidney transplantation and
nephrectomy was 6.7 years (range, 1 day to 16.8 years). Allograft nephrectomy
was performed by the extracapsular route in seven cases and intracapsular
route in 32 cases. The pathologic causes of allograft nephrectomy were chronic
rejection in 29 cases (74.4%). acute rejection in five cases (12.8%). accelerated
rejection in three cases (7.7%). and graft vessel thrombosis in two cases (5.1%).
There were one wound infection and two injuries of the iliac vessels. One patient
died of sepsis. The interval from transplantation to allograft nephrectomy was
more than 12 months in most patients (74.4%).
Conclusions: In our study, chronic rejection was the major pathological cause
of allograft nephrectomy. The incidences of allograft nephrectomy due to acute
and accelerated rejection were 12.8% and 7.7%, respectively. We suggested that
early detection and aggressive treatment of acute rejection might be considered
to lower the incidence of allograft nephrectomy after kidney transplantation.
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1043 DOES MICA ANTIGEN INFLUENCE ON CELLULAR AND
VASCULAR REJECTION IN KIDNEY TRANSPLANTATION?
M. Kato1, T. Kinukawa1, R. Hattori2, Y. Tsuji1, M. Tsuyuki1, N. Kohriyama3
1
Chukyo Hospital, 2Nagoya University, 3Fujita Health University
Introduction and Objective: MHC class 1-related chain A (MICA) antigens
are polymorphic genes and are expressed on endothelial cells, dendritic cells,
fibroblasts, and epithelial cells, but not on peripheral-blood lymphocytes.
MICA has been reported to be recognized by specific antibodies in sera of
transplanted patients. Recent paper suggested that sensitization against
MICA was associated with poorer allograft survival. Few reports mentioned
pathological aspects on MICA so far.
Methods: To evaluate the clinical significance of allo-antibodies (HLA and
MICA antibodies) developed after kidney transplants, 31 patients who lost
their kidney grafts were tested for post-transplant antibodies by LABScreen
single antigen test and preserved biopsy samples were also re-stained for this
study. All the patients had been transplanted between 1984 and 1993 at single
center. Theses patients followed over 10 years and the sera had been collected
at approximately 2-month intervals throughout the transplant from the original
transplant date. Biopsies were taken dependent on the clinical data. The patients
sera had been stored at -20 C by the test. Graft survival of 5,10,15 years are
77%, 56% and 42%, respectively.
Results: Of 31, 21 patients lost their graft by chronic rejection with alloantibody by first screenig using PRA test. 12 of 21 patients developed donor
specific antibodies @ (57%). On the other hand, in 1of 15 control patients @
(7%) maintaining good renal function over 10 years, donor specific antibody
was detected (P=0.0058) Although MICA antibodies were found in several
cases with chronic rejection, C4d staining was negative in PTC and glomerulus
of available biopsy samples. Interestingly, one rejected case showed MICA
antibody titer increased before graft failure and that HLA antibody was
continuously negative for this period. Biopsy sample before graft failure
showed mild acute cellular rejection and vascular rejection.
Conclusions: In conclusion, these data shows MICA antigen may induce
cellular and vascular rejection on renal transplantation. HLA and MICA
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antibodies are usually present before kidney graft failure, and their development
post-transplantation is possibly causally related to the failure of most of living
donor kidney transplants.

CONCURRENT ORAL SESSION 79: ACUTE REJECTION –
HLA/AMR
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M. Zynek-Litwin1, J. Kuzniar1, Z. Marchewka2, W. Kopec1, M. Kusztal1,
B. Szymanska2, D. Patrzalek3, P. Biecek4, M. Klinger1
1Department of Nephrology And Transplantation Medicine, Wroclaw Medical
Universit, 2Department of Toxicology, Wroclaw Medical University, Wroclaw,
Poland, 3Department of Vascular, General and Transplantation Surgery,
Wroclaw Medical University, Wroclaw, Poland, 4Department of Genomics,
Faculty of Biotechnology Wroclaw University
Introduction: Low molecular proteins are established markers of
kidney graft function. The peritransplant events modify serum and urine
α;1microglobulin (α;1M). β;2microglobulin (β;2M) as well as neutrophil
gelatinase-associated lipocalin (NGAL). interleukin18 (IL-18) release.
The mechanism of those protein concentration changes is not completely
clear in an early period after kidney transplantation (kTx). The aim of the
study was to seek correlations between neutrophils (PMN) activation (ELα;1PI complex) and classic (α;1M, β;2M) as well as novel (NGAL, IL-18)
kidney graft tubulo-intestinal injury markers measured in blood and urine
of deceased renal allograft recipients.
Patients and methods: The study was performed on the 24 kidney graft
recipients from the deceased donors. The plasma and urine EL-α;1PI were
analyzed 3 times in the first week after kTx (on postoperative (PO) days 1, 3,
7) by ELISA test. The other kidney injury markers in serum and urine were
measured similarly on days 1, 3, and 7. NGAL, IL-18 and β;2M were measured
by ELISA test. Serum and urine α;1M test was done by nephelometric
method.
Results: There was an important positive correlation between plasma ELα;1PI (pEL) and serum NGAL on 1 and 3rd PO day (p<0,02 and 0,002
respectively).
Strong correlation was observe between urine EL-α;1PI (uEL) on 1st PO day
and serum NGAL on day 3 and 7 (p<0,03 and p<0,001 respectively).
Urine EL on 1 PO day correlated with urine NGAL on 3 and 7 PO day (p<0,009
and p<0,001 respectively).
There was no important association between EL-α;1PI (in plasma and urine)
and IL-18 level in serum and urine.
A positive association was found between pEL on the first PO day and serum
α;1M on days 3, 7 (p<0,04 and p<0,01 respectively) and between both markers
on 3 PO day (p<0,01).
A correlation was observed between uEL on 1st PO day and serum α;1M on 1,3
and 7th PO day (p<0,01, p<0,01 and p< 0,02 respectively).
Urine EL on 1 PO day remained in a positive correlation with urine α;1M on
7th PO day (p<0,04).
A positive association was found on day 3 between pEL and serum β;2M
(p<0,02).
Urine EL on 1 PO day correlated with serum β;2M on 1, 3 and 7 PO days
(p<0,01, p<0,001, p<0,002 respectively).
There was a significant association between pEL on 1 PO day and urine β;2M
on 1,3 and 7 PO days (p<0,003, p<0,003, p<0,04 respectively).
The association between pEL and urine β;2M was observed on 3 PO day
(p<0,04).
Urine EL on 1 PO day correlated with urine β;2M measured on PO day 1 and 7
(p<0,007 and p<0,04 respectively).
Conclusions: Serum and urine NGAL concentration significantly correlated
with plasma and urine EL-α;1PI –; marker of PMN activation in early period
after kTx. Similarly, there was important association between other lipocalin
family protein – α;1M as well as low molecular protein β;2M and EL-α;1PI.
No such correlation has been found between serum and urine IL-18 and PMN
degranulation marker EL-α;1PI.

1045 CELL SENESCENCE AT THE TIME OF KIDNEY ACUTE
ANTIBODY MEDIATED REJECTION: COULD PREDICT
FUNCTION OUTCOME?
L.E. Morales-Buenrostro3, M. Arvizu-Hernandez1, M. Vilatoba1, E. Mancilla4,
N. Uribe-Uribe2, C. Avila-Casado5, J.L. Gonzalez2, B. Gabilondo1,
R. Correa-Rotter3 and J. Alberu1.
1
Transplantation; 2Pathology; 3Nephrology, Inst. Nal. de Ciencias Medicas y
Nutricion SZ; 4Transplantation and 5Pathology, Inst. Nal. de Cardiologia ICh,
Mexico
Body: Late vs. early acute antibody mediated rejection (AAMR) episodes are
associated with worse kidney function/graft survival. Whether cell senescence upon
development of AAMR contributes to this outcome was explored in this analysis.
Methods: KT databases from 2 Institutions were reviewed. Biopsies (bx)
performed due to acute graft dysfunction from 01/2000 to 03/2007 were
analyzed. Bx fulfilling morphological criteria of pure AAMR (n=17) were
reviewed by 2 board-certified renal pathologists. Immunoperoxidase staining
for p16INK4a was performed in paraffin embedded tissue, available in 9 of the
17 bx. Immunoreactivity for p16INK4a was only considered positive if nuclear
expression was observed to avoid false-positive results due to background
staining. Average number of positive cells/HPF was calculated in every case.
AAMR events were treated in accordance to current standards. Patient, biopsy
and donor data are shown in the Table.
RECIPIENTS/BIOPSES n=17
Age at KT
Gender F/M
time to AAMR (weeks)
AAMR grade 1/2/3
n of bx w/p16ink4a
Nuclear expression of p16 cells/HPF
Graft loss
*eGFR before AAMR
*eGFR (nadir) during AAMR
*eGFR at last visit
* eGFR before AAMR/last visit
time from AAMR to last visit (weeks)
DONORS
LD/DD
Gender F/M
age
*Levey equation

< 3 mo
32.1 3.5
2/6
3.2 3.6
0/8/0
4
12.2 11.3
1
48.5 7.6
24.8 5.6
56.7 18
12.5 25.9
143.9 94.1

> 3 mo
32.6 4.6
5/4
167.2 131
0/8/1
5
59.8 51.3
1
43.7 4.6
20.3 7.6
30.7 10.8
-13.7 12.3
69.635.1

P
ns

0.58
0.51
0.004
0.023
0.057

5/3
5/3
36.7 4.3

8/1
3/6
39 3.7

0.53

0.003
0.116

AAMR cases were grouped according to the time of presentation as early (<3
mo) or late (>3 mo).
Conclusions: Even though the number of biopsies analysed for p16INK4a was low,
it is evident that the number of cells expressing this marker of cell senescence
was higher in bx of late AAMR.This finding may suggest the presence of prior
injuries to the AAMR episode.The significantly lower eGFR in the late AAMR
group may translate a reduced capacity of the repairing process to sustain
nephron function.
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1046 IMPORTANCE OF CD4 DEPOSITION IN ACUTE
HUMORAL REJECTION
S. Sevmis1, B. Demirhan2, H. Karakayali1, B. Bilezikci2, N. Savas3,
M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery,
2Baskent University Faculty of Medicine, Department of Pathology, 3Baskent
University Faculty of Medicine, Department of Gastroenterology
Acute humoral rejection (AHR) should be considered in patients with renal
allograft dysfunction, as it can develop at any stage of the posttransplant course.
In this study, we review the diagnosis, treatment, and outcomes of 8 patients.
There were 8 patients (4 women, 4 men; mean age, 32 &#61617; 16.7 years)
who underwent renal transplant (RT) at our center who were later diagnosed as
having AHR at mean of 19.6 months (range, 6 days to 74 months) after RT. AHR
was diagnosed via allograft dysfunction and allograft biopsy. Allograft biopsy
showed a strong, diffusely distributed endothelial staining pattern of CD4 in
the peritubular capillaries. The results of a pretransplant lymphocyte subset
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analysis, and the results of panel reactive antibody were normal. All patients
were treated with plasma exchange. AHR occurred in the early postoperative
period (< 3 months) in 3 patients and in the late postoperative period (> 3
months) in 5 patients. Before treatment, the patients’ mean serum creatinine
level was 2.4 &#61617; 0.6 mg/dL (range, 1.4-3.4 mg/dL) and after treatment,
the mean serum creatinine level was 1.9 &#61617; 0.6 mg/dL (range, 0.9-2.9
mg/dL). All patients were treated successfully except 1. In that patient, a graft
nephrectomy was performed 17 days after RT owing to total vascular occlusion
of the graft. One patient returned to hemodialysis 3 months after treatment, and
retransplatation was performed 2 months later. At the time of this writing, the
remaining 6 patients are alive with good graft functioning at a mean follow-up
of 14.1 &#61617; 6.3 months (range, 7-25 months). In conclusion; widespread
CD4 deposition in the peritubular capillaries, as demonstrated by renal allograft
biopsy, is an important characteristic for the diagnosis of AHR. In the patients
studied, several plasma exchange treatments were effective in resolving AHR.
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1047 CASE REPORT: PRETRANSPLANT SEROLOGICAL
NEGATIVITY AND HYPERACUTE REJECTION IN KIDNEY
RETRANSPLANTATION
I.M. Titiz1, G. Isitmangil1, H. Tozkir2, I. Kilicaslan3, G. Gumrukcu1, F.
Turkmen1,
G. Tellioglu1, B. Yigit1, I. Berber1
1
Haydarpasa Numune Research And Educational Hospital, Renal
Transplantation and Immunology Unit, Istanbul, Turkey, 2Trakya University,
Medical Faculty, Department of Medical Biology, Edirne, Turkey, 3Istanbul
University, Istanbul Medical Faculty, Department of Pathology, Istanbul,
Turkey
Hyperacute rejection (HAR) occurring within minutes after transplantation are
due to the presence of preformed antibodies to donor organ antigens.
A 35 year-old male patient, awaiting kidney retransplantation has been performed
hemodialysis for 13 years. His original disease is chronic glomerulonephritis.
He has not had a history of either smoking or diabetes mellitus. He was
immunosuppressed with mycophenolate mophetyl and steroid before surgery
and was given anti-timosit globulin (ATG) during the operation. He has been
grafted from cadaveric donor age-matched, ABO blood type-matched with
22 hour cold ischemia time. Before the operation the complement-dependent
cytotoxicity cross-match assay was negative and also flow cytometric crossmatch (FCXM) was negative. Furthermore ELISA-PRA class I and class II
results were all negative serologically. This patient has undergone hyperacute
rejection. PRA class I has become positive 3 months after the retransplantation.
Antibodies were occurred against A1, A11, A25, A26, A29, A34, A36, A66,
and B65 antigens.
Pathologically hematoxylen eosin (HE) staining is indicating HAR and also
C4d is focally positive at peritubular capillary area.
This case is important to show that although all immunological markers are
negative in pretransplantation period, it may be possible to undergo a hyperacute
rejection and further assays may be necessary to avoid the HAR.
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1048 THE IMPACT OF DIFFUSE C4D BIOPSY STAINING AND
SERUM DONOR SPECIFIC HLA ANTIBODIES ON KIDNEY
TRANSPLANT GRAFT SURVIVAL
R. Vaughan2, S. De Freitas1, N. Mamode1, R. Nortley1, R. Hangartner3,
J. Else4, O. Shaw2, P. O’Donnell3
1Department of Transplantation, Guy’s Hospital, 2Clinical Transplantation
Laboratory, Guy’s Hospital, 3Department of Histopathology, Guy’s Hospital,
4Department of Histopathology, St George’s Hospital
Introduction: Both C4d positive staining and serum donor specific antibodies
are thought to confer a higher risk of graft failure in kidney transplant
recipients.
Methods: This was a retrospective single centre study review outcomes in
all adult kidney transplant recipients who had had a kidney Transplant biopsy
taken between April 2003 and October 2006 at Guy’s Hospital. The C4d stain
was introduced in 2003 and therefore outcomes were evaluated according
to C4d status and the presence of donor specific antibodies. The presence of
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staining and the pattern of this as well as kidney function at a pre-biopsy
baseline, the day of the biopsy, six months post biopsy, one year post biopsy
and then yearly thereafter was collected. The abbreviated MDRD was used.
If several biopsies had been performed in one patient the incident biopsy was
taken as the first to show C4d positive staining. For the C4d –ve patients the
first biopsy was taken as the first biopsy after 2003. This group have never
had C4d stain detected but have not had any biopsies performed prior to 2003
re-stained.
Results: One hundred and seventy three patients had not had C4d stain detected
on their biopsies. The biopsies were reviewed by an external Histopathologist
from a separate centre and 45 cases with diffuse (>50%) C4d stain confirmed
using paraffin sections and polyclonal antibodies. One case was then excluded
due to detection on a biopsy post graft failure giving a diffuse C4d group of
n=44.
Outcomes differences looked at were between those patients with diffuse
(>50%) C4d staining, and those whose biopsies had been negative for C4d.
The Kaplan-Meyer transplant survival curves from time of transplantation (in
months) were significantly different for these two groups (p=0.006, MantelCox and Breslow). In the C4d+ve group there were 14 graft failures within 1
year of biopsy. Of the 12/173 C4d –ve group had graft failure and only 6 within
a year of the biopsy.
Overall positive DSA was also associated with worse graft survival irrespective
of whether C4d staining was positive (p=0.016). There were eight patients who
had biopsies that were consistently C4d –ve but had +ve DSA +ve. Three out
of eight developed graft failure.
An analysis of change in eGFR over time from either a pre-biopsy baseline or
the day of the biopsy did show a greater reduction in function in the C4d+ve
group however due to the excess of graft loss in this group this did not reach
statistical significance as the those with End Stage Renal Failure (ESRF) are
removed from this analysis which relies on numerical values.
Summary: Graft survival was significantly worse in the patients under follow
up at Guy’s Hospital with a kidney transplant whether outcome was looked
at according to diffuse C4d staining on biopsy or Donor Specific antibodies
detection in the serum.
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1049 LOW-DOSE RITUXIMAB TO SALVAGE RENAL
TRANSPLANTS FROM REFRACTORY ANTIBODY-MEDIATED
REJECTION
J. Kanellis1, W. Mulley1, F. Hudson2, B. Tait2, A. Skene3, J. Dowling3, P. Kerr1
1
Department of Nephrology, Monash Medical Centre, Clayton, Australia
3168, 2Victorian Transplantation and Immunogenetics Service, Parkville,
Australia 3052, 3Department of Pathology, Monash Medical Centre, Clayton,
Australia 3168
Recent reports suggest that treatment with the monoclonal anti-CD20
antibody, Rituximab (Rtx) may improve renal graft survival in antibody
mediated rejection (AMR); however optimal dosing for this indication
is unknown. We examined the efficacy of a single low dose (500mg) of
Rtx for treatment of refractory AMR in order to limit significant infective
complications associated with conventional dosing regimens (375mg/m2).
Rtx was used in seven consecutive patients who had refractory AMR as
judged by ongoing biopsy evidence of AMR after 4 weeks of standard
therapy consisting of pulse methylprednisolone and plasma exchange with
low dose IVIg (100mg/kg) (PE/IVIg). All patients received Tacrolimus and
Mycophenolate Mofetil. AMR was defined as 1) characteristic histology
on biopsy (Banff criteria). 2) graft dysfunction and 3) presence of a donor
specific anti-HLA antibody (DSAb). B-cell counts (CD19) and serum
creatinine (SCr) were monitored. PE/IVIg was ceased in all cases after
Rtx dosing. The average follow-up since Rtx dosing is 16.8 months (range
5.3-28.9 mths). All patients still have functioning grafts (100% 12 month
graft and patient survival). with current mean SCr levels (156±17ìmol/L)
significantly lower than mean peak rejection levels (514±355ìmol/L)
p=0.05. CD19 counts fell to zero and remained <5x106/L for >6 months
in all patients. DSAbs remain detectable by Luminex Flow Beads in all
patients despite stabilization of SCr. Two of 7 patients developed an
infective complication post Rtx dosing. One patient developed bacterial
pneumonia requiring hospital admission whilst a second patient developed
CMV viraemia and later BK nephropathy which has not led to significant
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graft dysfunction. Hence, infectious complications are far less than those
reported for multiple standard dose regimens in similar patient groups.
Large clinical trials are required to confirm the efficacy of Rtx in treating
AMR as well as optimal dosing. Standard dosing is based on oncology
treatment regimens which are likely to be excessive for AMR in patients
already markedly immunosuppressed. Our data suggests single low-dose
Rtx for refractory AMR results in excellent patient and graft survival and
leads to low rates of serious infective complications in the short-term.

1050 INFLUENCE OF CYTOKINE GENE POLYMORPHISMS
ON THE DEVELOPMENT OF ACUTE AND CHRONIC
REJECTION IN ROMANIAN RENAL TRANSPLANTATION
RECIPIENTS
I. Constantinescu1, D. Vasile1, D. Nedelcu1, M.A. Toader1, M. Zaharia1,
M. Harza2, B. Stefan2, A. Iordache2, B. Serbanescu2, I. Sinescu2
1
Centre For Immunogenetica And Virology, Fundeni Clinical Institute, 2Centre
For Urology, Dialysis And Renal Transplantation
Both donor and recipient cytokine genotype influences the development of
acute rejection after renal transplantation
Purpose: Acute allograft rejection remains an important cause of morbidity after
kidney transplantation and has been shown to be a crucial determinant of longterm graft survival. Although rejection is mediated by recipient lymphocytes,
both donor and recipient factors contribute to the local environment that
influences the nature, severity, and duration of the rejection response. Cytokine
gene polymorphisms are important factors involved in the outcome of renal
transplant recipients and in this study is designed to explore the impact of
donor cytokine and cytokine gene polymorphisms on acute rejection after renal
transplantation.
Methods: A total of 138 related donors and renal allograft recipients were
selected according to the presence or absence of graft rejection in the first
month after transplantation. DNA was genotyped using the polymerase
chain reaction with sequence specific primers. Associations were assessed
using contingency table analysis and the [chi]2 test. The Invitrogen Cytokine
Genotyping Kit is a PCR-based method designed to detect polymorphisms
of thirteen cytokine genes. The Invitrogen Cytokine Genotyping Kit
consists of various combinations of lyophilized primer mixes that are used
to amplify genomic DNA using a 96 well tray. Setup includes mixing a
reaction buffer with a human genomic DNA sample and Taq polymerase,
dispensing the mixture to the 96 well tray, capping and then thermal cycling.
After cycling is complete, the PCR products are loaded onto a 2% agarose
gel for electrophoresis. After electrophoresis the ethidium bromide gel is
photographed and interpreted using a worksheet for specific application
patterns.
Results: Polymorphisms at position – 174 of the donors IL6 gene was associated
with the incidence and severity of recipients acute rejection (62,3%). Acute
rejection was not influenced by recipient IL6 genotype. In some pairs donor
IL4 gene polymorphisms at position – 590 was also associated with acute
rejection within one month after kidney transplantation (13,1%).
IL 10 gene polymorphisms at position 1082 in some of the donors (24,6%) was
correlated with rejection episode in recipients, but the intensity of the acute
rejection was not so strong as in the other cases. Acute rejection episodes were
not influenced by recipient IL4 and IL10 genotypes. All pairs were matched
for HLA DR
Conclusions: Our study identifies donor IL6, IL4 and IL10 polymorphisms as
a major genetic risk factor for the development of acute rejection after renal
transplantation.
This provides evidence that donor-derived cytokines play a major role
in determining outcome after transplantation, and will contribute to the
development of the therapeutic algorithms to predict individuals at particularly
high risk of acute rejection.

1051 ANTI-BODY MEDIATED REJECTION DIAGNOSED ON
CLINICAL AND HISTOPATHOLOGICAL GROUNDS MEETS
ONLY RARELY THE FULL REVISED BANFF 97 CRITERIA.
I. ten Berge1, S. Adhin1, P. Kuin2, S. Florquin3, N.J. Lardy2, F.J. Bemelman1
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Sanquin,
Amsterdam, Dpt of HLA diagnostics, 3Dpt Pathology, Academic Medical
Centre, Amsterdam
Acute anti-body mediated rejection (AMR) is accompanied by rapid detoriation
of renal function. Histological signs of (AMR) vary from relatively mild to
fulminant allograft destruction. None of the clinical and histopathological
symptoms are specific. According to the Revised Banff 97 criteria, a definitive
diagnosis of humoral rejection can be made, when, apart from histopathological
changes, the renal biopsy is positive for C4d and donor specific antibodies
(DSA) can be detected.With only two of the three criteria AMR is suspected.
However, C4d positivity can be focal, diffuse, weak or strong, possibly
depending on the type of antibodies used and the type of tissue. Variation in
the techniques to detect DSA is even wider. In this single center retrospective
study we aimed to define the percentage of patients treated for AMR that met
the official Revised Banff 97 Criteria for (suspicion) of AMR.
From January 2004 to July 2007 21 patients were treated for AMR diagnosed
on clinical and histological grounds with anti-thymocyte globulins (ATG) and
plasmapheresis. Serum and renal tissue was available in 19/21 patients. 108
pre and posttransplantation sera were evaluated with a Luminex Screening
and Single Antigen technique. When DSA were detected, CDC and FACs
crossmatches were repeated. Complementary C4d staining was performed,
when needed. Positivity was defined as more than 75% staining of the
peritubular capillaries.
Results: 71 van de 108 sera were positive in the Luminex Screening. DSA MHC
Class I and/or Class II could be detected in 7 patients. 2 out of 7 showed C4d
positivity. 2 patients without DSA were positive for C4d. There was a complete
overlap in detection of DSA in the FACs cross match and the Luminex.
Renal allografts were lost in 5 patients. Only one of these patients met the
criteria for AMR. Two met the criteria for suspicious for AMR.
We conclude that only a minority of patients with a diagnosis of AMR on
clinical and histopathological grounds met the Revised Banff 97 Criteria for
AMR or suspicious for AMR. There was no surplus value of the FACs cross
match.
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1052 CLINICAL IMPLICATIONS OF THE MONITORING OF
ANTI-HLA ANTIBODIES AFTER KIDNEY TRANSPLANTATION
M.C.R. Castro1, P. Souza1, N. Panajotopoulos2, D. David3, C. Ronda2,
H. Rodrigues2, F. Agena1, L.E. Ianhez1, E. David-Neto1, J. Kalil2,
1
Urology Division- Kidney Transplant Unit, 2Laboratory of Immunology –
Heart Institute, 3Pathology Division
Aim: To follow systematically anti-HLA antibodies (Abs) after renal
transplantation and to evaluate their association with acute rejection, C4d
staining and graft survival.
Methods: Between July/05 and July/06, 926 sera from 111 transplanted
patients (pts) who completed 12mo FU or lost the graft were analyzed. Sera
were collected before transplantation, at days 7, 14, 30, 60, 90, 180, 360 posttransplant (PTx) and during acute rejection episodes (AR). Donor-specific
antibodies (DSA) were detected by flow cytometry (FXCM) and NIH-CDCAGH technique. Panel reactive antibodies (PRA) were analyzed using ELISA
methods; AR were classified by Banff 97 criteria (updated in 2003). C4d
staining was performed on frozen biopsies.
Results: Pre-transplant PRA was >1% in 23 pts (21%). 11 of them had
PRA>50%. Pts were classified in 5 groups according to PTx PRA: Group A
(n=88): no evidence of Abs pre and PTx; group B (n=8): non-sensitized pts
who developed Abs de novo; Group C (n=6): sensitized pts who remained at
the same PRA level; Group D (n=13): sensitized pts who decreased PRA level
and Group E (n=4): sensitized pts who increased PRA levels during the 1st
yr. Groups C, D and E received more ATG than groups A and B (p=.001). AR
occurred in 30/111pts (27%). Groups with appearance or increase of the PRA
after transplantation presented 3 to 5 times more rejection episodes: B=62,5%;
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C=66,7%, E=75% vs A=21,3% (p<.001) and D= 7,7% (p<.02). Group A,
which had no Abs pre and PTx, had lower Banff scores than the other groups
(p=.03). Group A had also lower rates of C4d positivity on AR biopsies (6% x
75%, p<.001). Among pts with AR, 43,3% had Abs which appeared/increased
during the AR episode, and 77% of them were DSA. The overall incidence of
antibody-mediated rejection was 11,7%. One-year censored graft survival was
lower in patients with AR, especially in those with AMR. The presence of AR
(p<.05). C4d+ (p=.02) and DSA (p<.05) where risk factors for graft loss.
Conclusion: Our data suggest that monitoring of anti-HLA Abs after kidney
transplantation may be a useful tool to evaluate the risk of antibody-mediated
responses, and has also prognostic implications in terms of graft survival.

with the CD4+ helper T cells, providing a favorable situation for activation of
both cell types, each of which are involved in cellular and humoral reactions,
respectively. On the other hand, HLA antibodies were detected in 4 (15%) of
the CD4+ cases and in 5 (19%) of the CD4- cases. Twelve cases (46%) of the
CD4+ cases did not produce any HLA antibody. With regard to CD19, HLA
antibodies were detected in 3 (23%) of the 13 CD19+ cases and in 5 (38%) of
the CD19- cases. Six cases (46%) of the CD19+ cases did not produce any HLA
antibody. These results suggested that number of CD4 helper T cells and B cells
in renal allograft did not correlate directly with the HLA antibody production.
We are continuing this approach to know whether cellular accumulation in
allograft induces future humoral immune response.
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1053 CHEMOKINES AND CHEMOKINE RECEPTORS IN
RENAL TRANSPLANTATION
L.T. Saber1, J.C.O. Crispim2, R.A. Duarte3, C.P. Soares3, R.S. Costa4,
J.S. Silva2, C.T. Mendes-Júnior5, E.A. Donadi5
1Renal Transplant Unit, Hospital Das Clinicas, University of São PauloRibeirão P, 2Department of Biochemistry and Immunology, FMRP-USP,
Brazil, 3Department of Clinical Analysis; School of Pharmaceutical Sciences,
UNESP, University of São Paulo State., 4Department of Pathology, FMRPUSP, Brazil., 5Division of Clinical Immunology, FMRP-USP, Brazil
Chemokines are potent mediators of leukocyte to the site of inflammatory
processes, which are produced constitutively or upon activation by a variety of
different cell types in renal tissue, including infiltrating leukocytes, endothelial
and tubular epithelial cells, fibroblasts, and mesangial cells. The potential
relationship between the expression of the chemokines IP-10, MCP-1 and
respective receptors CCR5 and CXCR3 with histological and clinical features
was investigated in specimes renal allograft at the time acute rejection (AR)
and chronic allograft nephropathy (CAN) and compared with biopsies no signs
rejection.
Patients and Methods: Fifty-one renal specimens (7 with acute rejection
and 11 chronic allograft nephropathy, and 33 with no signs of rejection were
immunohistochemically evaluated for MCP-1, IP-10, CXCR3 and CCR5
Results: Chemokine and chemokine receptor expression was observed mainly
in mononuclear cells infiltrating the interstitium and tubulointersticial area. In
the group as a whole, IP-10 expression was detected in 21 cases (41.2%). 8
out of 18 exhibited AR and CAN, and the remaining 13 exhibited no signs
of rejection. CXCR3 expression was detected in 26 cases (51%). 9 out of 18
exhibited AR and CAN, and the remaining 17 exhibited no signs of rejection.
MCP-1 expression was detected in 12 cases (23%). 5 out of 18 exhibited AR
and CAN, and the remaining 7 exhibited no signs of rejection. Considering
only patients with AR the expression of MCP-1 was significantly increased
(p<0.0415). CCR5 expression was detected in 23 cases (45.1%). 10 out of 18
exhibited AR and CAN, and the remaining 13 exhibited no signs of rejection.
Conclusion: Renal allograft exhibiting AR showed increased MCP-1
expression; however, no significant differences were observed regarding the
IP-10, CXCR3 and CCR5 expression in rejection and non-rejection groups.
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1054 CORRELATION ANALYSIS AMONG SERUM ANTI-HLA
ANTIBODIES, CD4+, CD8+, AND CD19+ CELLS IN RENAL
ALLOGRAFTS.
F. Obata1, K. Yoshida2, Y. Takeuchi2, M. Tsuchida2, T. Endo2, S. Baba2
1Kitasato University School of Allied Health Sicences, 2Kitasato University
School of Medicine
Objective: To know the correlation between humoral and cellular rejections
of renal allograft.
Methods: Anti HLA-class I and -class II IgG antibodies in the serum of renal
allograft patients were detected by flow cytometry using PRA screening beads
(Flow-PRA). CD4+, CD8+, and CD19+ cells in the biopsy specimens of renal
allografts were detected by reverse transcriptase-PCR (RT-PCR).
Results and Discussion: Thirty-four patients who were positive for any one
of CD4, CD8, or CD19 were subjected to correlation analysis. Among the 26
cases of CD4+, 9 (35%) were CD8+, and 11 (42%) were CD19+. Thus, in these
cases, CD8+ killer T cells and B cells resided in renal allografts concomitantly
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1055 PERITUBULAR CAPILLARY ENDOTHELIAL
INDOLEAMINE 2,3-DIOXYGENASE (IDO) IN HUMAN RENAL
ALLOGRAFTS: CORRELATIONS WITH HUMORAL AND
CELLULAR REJECTION AND LATE GRAFT PATHOLOGY
R. Smith1, P. Della Pelle1, A.B. Collins1, L. Cornell2, W. Wong3, T. Tatsuo
Kawai4, C. Cook5, D. Sachs4, A.B. Cosimi4, R.B. Colvin1
1Department of Pathology, Massachusetts General Hospital, 2Department
of Pathology, Mayo Clinic, 3Department of Medicine, Massachusetts
General Hospital, 4Department of Surgery, Massachusetts General Hospital,
5Department of Surgery, Ohio State University
Indolamine 2, 3-dioxygenase (IDO). induced by IFNγ in endothelial and
dendritic cells, can inhibit the allogeneic immune response. Induction of IDO
has been documented in endothelial cells of accepted murine kidney and heart
allografts, but little is known about its expression in human renal allografts.
Here we test the hypothesis that endothelial IDO in 97 human renal allografts
might correlate with resistance to antibody-mediated rejection. Transplant
biopsies, classified by Banff criteria including C4d staining, were stained by
immunohistochemistry with a monoclonal antibody (Serotec).
Diagnosis
Acute Graft Injury
Acute Cellular Rejection
Acute Tubular Injury
Acute Humoral Rejection (AHR)
Acute Cellular and Humoral
Rejection
Chronic Graft Injury
Chronic Humoral Rejection (CHR)
Transplant Glomerulopathy, NOS
Chronic Calcineurin Inhibitor
Toxicity
Interstitial Fibrosis & Tubular
Atrophy, NOS
Stable/No Pathology
Accommodation (DSA+/C4d+; No
Pathology)
No Diagnostic Abnormality
Donor Kidney (one hour)
Donors
Total

% Positive
C4d

% Positive
TG Status

N

% Positive
Cases

0
0
100
100

0
0
0
0

11
2
9
5

45%
0%
11%
0%

100
0
0

92
100
0

13
5
2

31%
80%
50%

0

0

5

0%

100

0

5

100%

0

0

30

13%

0

0

10
97

40%

Endothelial IDO was not observed in normal control kidneys. Stable grafts
without pathology or C4d, including 30 protocol biopsies, were usually
negative for IDO in PTC (13% positive). Among cases with positive C4d,
endothelial IDO was present infrequently in acute humoral rejection (11%).
absent in mixed cases of acute cellular and humoral rejection, present in the
some of cases of chronic humoral rejection (31%). and was uniformly and
strongly expressed in cases with C4d but without rejection (accommodation)
(100%). In C4d negative cases, acute cellular rejection, endothelial IDO was
expressed in PTC (45%). and arterial endothelium in Banff type II rejections.
Infiltrating cells were also focally positive. IDO expression was not identified
in two cases of acute tubular injury. In late graft injury without C4d, IDO was
more common in cases with transplant glomerulopathy than in those showing
only interstitial fibrosis and tubular atrophy without glomerulopathy (80% vs
0%). Two of the positive TG cases had prior C4d+ CHR. Among donor biopsies
IDO was variable (40%) with the strongest expression from a donor with
subarachnoid hemorrhage. In addition, one of two cases of chronic calcineurin
inhibitor toxicity was positive (50%).

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Monday 11 August 2008

Poster Abstracts
Conclusions: These data show frequent presence of peritubular, glomerular and
arterial endothelial IDO expression in human renal allografts. Among those with
antibody mediated pathogenesis, the strength and frequency of IDO correlated
inversely with the severity of chronic graft injury (accommodation > AHR >
CHR). Other apparent stimuli include acute cell mediated rejection, presumably
via IFNγ, and donor status. Detection of induced IDO expression provides a
novel and potentially useful marker of endothelial status in the graft.
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K.V. Ranga1,2, S. Sathyan2, V. Patel2, P. Niezgorski1, A. Lally1, M. Brown1,
J. D’Avella1, D. Hull1
1Hartford Hospital, 2University of Ct Health Center
Incidental biopsies, as we would like to define, are renal biopsies performed
during the course of other surgical procedures related to the renal allograft.
For transplant programs that do not routinely perform protocol biopsies, these
‘incidental’ biopsies may offer a means of monitoring for sub clinical rejections
in their allografts. Some of these biopsies may even happen to be done in the
first few days post-transplant, before most scheduled protocol biopsies, offering
a unique look into the histology of the allograft.
This was a retrospective study performed by chart review of all renal transplants
performed at our institution from 2002 to 2007. All these patients received
standard triple immunosuppression with Tacrolimus, Mycophenolate mofetil
and steroids, with IL-2 receptor antibody induction in the majority of patients,
and lytic induction for the pancreas recipients and some ‘high-risk’ kidney
recipients. Thirty three patients
(M: F = 21: 13, median age 46 years) who underwent abdominal surgery had
incidental renal allograft biopsies performed, at a median of 17 days post
transplant (range: 1 to 225 days). Biopsies were performed depending on
preference of surgeon. Of those biopsied, 7 were operated for repair of urine
leaks, 8 for wound dehiscence, 10 for marsupialization of lymphoceles, 3
for questionable blood flow on ultrasound, 3 for evacuation of hematomas,
and 1 each during exploratory laparotomy in a febrile simultaneous pancreas
and kidney (SPK) reciepint, and during graft pancreatectomy. Of the 33
biopsies performed, 4 patients (8.25%) were reported to have acute cellular
rejection (Banff Class II in 1 patient, and class I in 3 patients) and 1 patient
had c4d positivity with no ACR and normal renal function. A small number
of patients had mild interstitial fibrosis and tubular atrophy. The incidence of
acute rejection in this cohort of patients is greater than the incidence of acute
rejections demonstrated by indicated biopsies in our patient population, thus
making a case for protocol surveillance biopsies.
We conclude that incidental biopsies are important in assessing allograft
histology in programs that do not perform protocol biopsies routinely. In those
patients that do not receive an incidental biopsy by a certain period of time,
protocol biopsies may be recommended for allograft monitoring.
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1057 ABNORMAL PROFILE OF C-PEPTIDE AND PROINSULIN
IN NONDIABETIC KIDNEY TRANSPLANT RECIPIENTS:
IMPACT OF RENAL FUNCTION, STEROID TREATMENT AND
HYPERLEPTINEMIA.
A. Kagan, R. Sarafian, N. Haran, L. Leschinsky, J. Rapoport
Department of Nephrology And Hypertension, Kaplan Medical Center
Rehovot And Faculty of Medicine, Hebrew University, Jerusalem
Abnormal profile of C-peptide and proinsulin in nondiabetic kidney transplant
recipients: impact of renal function, steroid treatment and hyperleptinemia.
Alexander Kagan, MD; Ruth Sarafian, RN, BA; Nurit Haran PhD; Ludmila
Leschinsky MD, PhD and Jayson Rapoport MB, BS, FRCP, Department of
Nephrology and Hypertension, Kaplan Medical Center Rehovot and Faculty of
Medicine, Hebrew University, Jerusalem
Background: Factors associated with kidney transplantation, including renal
functional impairment, glucocorticoid and calcineurin inhibitor therapy,

1058 TRANSPLANTATION OF A KIDNEY WITH A RENAL
CELL CARCINOMA AFTER LIVING DONATION: A CASE
REPORT
A. Ghafari
Urmia University of Medical Sciences
Abstract: Transmission of cancer is a serious risk in organ transplantation.
We present a case of renal cell carcinoma (RCC) in a kidney obtained from
a living donor. A 48-year-old mother was evaluated for donation to her
12-year-old daughter. Donor renal ultrasound, intravenous pyelography, and
angiography were normal. A 5 _ 5 mm nodule found on the surface of the
kidney during harvesting was totally excised before transplantation. The
histology revealed RCC with free margins at 2 weeks after transplantation.
The immunosuppressive drugs consisted of cyclosporine, mycophenolate
mofetil, and prednisolone.
The graft function remained stable. Donor and recipient are without evidence of
tumor recurrence at 24 months after transplantation. This experience indicated
that donor kidneys with small, incidental RCC may be managed with excision
and transplantation, without tumor recurrence in recipients who are informed
of the potential risks of recurrence and metastases.
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1056 INCIDENTAL BIOPSIES: AN ALTERNATIVE TO
PROTOCOL BIOPSIES IN RENAL ALLOGRAFT RECIPIENTS?

hyperleptinemia and insulin resistance may affect the synthesis, secretion,
circulating levels and clearance of beta cell pancreatic hormones such
as insulin, C-peptide and proinsulin. This issue has not been extensively
investigated in nondiabetic transplant kidney patients (Tx). and may have an
important bearing on the development of post-transplant diabetes mellitus
(PTDM).
Subjects and methods. The study population was selected from 47
subjects: 21 normal subjects (Ns) and 26 kidney transplant (Tx) patients.
16 Tx and 16 Ns matched by gender, age, BMI, hematocrit levels, serum
concentrations of glucose, albumin, cholesterol, C-reactive protein were
studied. In addition, 15 males: 5 Ns, 5 cyclosporine-A (Tx-CsA) and 5
tacrolimus (Tx-FK) treated were studied prospectively from 08.00 to 16: 00
while fasting. Most Tx patients received triple immunosupressive therapy
including calcineurin inhibitors (Tx-FK or Tx-CsA). anti-metabolites
(mycophenolate mofetil or azathioprine) and steroids (prednisone). Tx
were divided into two groups: cyclosporine-A-treated (Tx-CsA, n=9)
and tacrolimus-treated (Tx-FK, n=7). Fasting serum levels of insulin,
C-peptide and cortisol were measured by a chemiluminescent enzyme
immunoassay. Fasting serum proinsulin and leptin concentrations were
measured by radioimmunoassay. Insulin resistance was calculated using
the homeostasis model assessment.
Results: 50% of Tx (8/16) compared to 12.5% of Ns (2/16) exhibited increased
fasting serum C-peptide levels (>1320 pmol/l). 68% of Tx (11/16) compared to
6% of Ns (1/16) showed increased fasting serum proinsulin levels (>9.4 pmol/l).
Corresponding fasting values of insulin, C-peptide and proinsulin decreased
steadily with time (08.00 versus 16.00). Serum proinsulin concentrations in
Tx- FK were markedly higher throughout the fast than those of Ns and TxCsA, but there was no statistical difference between Tx-CsA and Ns. Serum
concentrations of C-peptide and proinsulin, but not insulin, were significantly
correlated with serum leptin, cortisol and glomerular filtration rate (GFR)
levels in all subjects and in Tx.
Conclusions: We found that renal functional impairment, hyperleptinemia,
steroids and calcineurin inhibitor treatment lead to increased circulating levels
of proinsulin and C-peptide, especially in the Tx-FK group. We suggest that
fasting C-peptide and proinsulin levels are better markers of pancreatic ï ¢-cell
function in Tx patients then insulin.
The relationship observed between increased serum levels of leptin and beta
cell polypeptides in nondiabetic transplant kidney patients Tx requires further
evaluation.
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1059 RENAL RE-TRANSPLANTATION: IS IT JUSTIFIED?
S. Moniri, M. Samhan, T. said, M.R.N Nampoory, P. Nair, T. Al Otaibi,
I. Al-Mezairai, M. Al-Mousawi
Member of Mesot
Introduction and Objectives: there is a dispute about the justification of
renal re-transplantation in the presence of organ shortage, and the concept
that patients who have lost a transplanted kidney are widely recognized as a
high risk for re-transplantation. This is a retrospective study of the outcome
of renal re-transplantation (Re-Tx) and to find out if renal re-transplantation
is justified.
Patients and Methods: Between 1993 and December 2006, 646 kidney
transplantation procedures were performed in our centre, 39 of these (6%) were
Re-Tx. The medical records of these patients were reviewed. They were 19
males and 20 females, aged 10 to 62 years (mean 36 years). nine of them were
children. Kidney grafts were obtained from 16 living and 23 cadaveric donors.
Induction immunosuppression was with ATG in 28, and with anti-Interleukin-2
receptor antibodies in 5 recipients.
Results: patients were followed up for 12 months to 134 months. Post
transplantation complications were in the form of: 14 instances of surgical
complication, 12 episodes of acute rejection, and 2 cases of malignancy. Four
recipients died with functioning graft at 4 months to 62 months after Tx. Seven
more grafts were lost at one day to 84 months after Tx secondary to renal vessel
thrombosis in 3, chronic dysfunction in 3, and graft infarction secondary to
antiphospholipid syndrome in one recipient.
Conclusion: It was observed in the present series that renal Re-Tx is associated
with recipient survival rates which are similar, and graft survival rates which are
10-13% lower than those in primary Tx. These results are still quite reasonable
to justify renal re-transplantation.
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1061 VISFATIN, NEW ADIPOCYTOKINE IS PREDOMINANTLY
RELATED TO INFLAMMATION/ENDOTHELIAL DAMAGE IN
KIDNEY ALLOGRAFT RECIPIENTS
J. Malyszko, J. Malyszko, E. Koc- Zorawska, M. Mysliwiec
Medical University, Department of Nephrology and Transplantation,
Bialystok, Poland,
Visfatin, a ubiquitous adipokine, firstly described in 2005, was found to be
selectively upregulated in the adipose tissue and have insulin-mimetic effects. It
has been reported that visfatin is associated with endothelial damage in chronic
kidney disease. We investigated plasma visfatin levels (using commercially
available kits) in 100 clinically stable kidney allograft recipients.
We assessed visfatin markers of coagulation: TAT (thrombin-antithrombin
complexes). prothrombin fragments 1+2; fibrinolysis: tPA (tissue plasminogen
activator). PAI-1 (plasminogen activator inhibitor). PAP (plasmin-antiplasmin
complexes); endothelial function/injury: vWF (von Willebrand factor).
thrombomodulin, ICAM (intracellular adhesion molecule). VCAM (vascular
cell adhesion molecule). inflammation: hsCRP, TNFá and IL-6.
Visfatin is significantly higher in kidney allograft recipients than in healthy
volunteers. Visfatin did not differ significantly between diabetic and non-diabetics,
hypertensives and normotensives, patients with and without coronary artery
disease and between males and females. Type of immunosuppressive regimen
(CSA vs tacrolimus or MMF vs azathioprine) did not affect visfatin levels. In
univariate analysis, visfatin correlated positively with prothrombin fragments
1+2, VCAM, creatinine, hsCRP and negatively with albumin. In multivariate
analysis, only VCAM was an associate of visfatin in kidney allograft recipients.
Visfatin related to markers of inflammation may represent a novel link between
inflammation and adipocytokines in studied patients.
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1060 SIGNIFICANTLY HIGH RATE OF COMORBIDITY IN
RENAL TRANSPLANT RECIPIENT CANDIDATES WAITING
FOR MORE THAN 10 YEARS
Y. Watarai, A. Kawaguchi, S. Maru, R. Ishikawa, N. Taniguchi
Kushiro City General Hospital
Purpose: Candidates on the renal transplant waiting list wait for significantly
long time, 18 years in average, in Japan and they are assumed to have increasing
numbers of comorbidity during dialysis period. Transplant centers need to
ensure that their candidates are acceptable for transplantation when the organ
becomes available. We have evaluated the renal transplant waiting list in our
institute.
Methods: 18 out of 20 candidates on our waiting list, mean age of 49.8 (28-60)
and duration on hemodialysis of 11.2 years (1-22 years). were evaluated 1)
complete blood tests, 2) chest X ray, 3) echocardiography and cardiac stress
testing, 4) measurement of Pulse wave velocity (PWV) and Ankle blood pressure
index (ABPI). 5) Plain CT scan with 3D reconstruction of the calcification of
aortic and iliac artery by maximum intensity projection.
Results: All candidates revealed normal chest X ray, echocardiography and
cardiac stress testing. CT scan showed severe aortic calcification in 8 candidates
(44%) in which the calcification occupied all around the aorta, and partial aortic
calcification in 7 (39%). But all candidates had non calcified iliac artery site to
make vascular anastomosis possible. However, 13 candidates (72%) showed
significantly high PWV in average of 1601 sec, and one showed significantly
low ABPI which consequently required the interventional treatment for the
external iliac artery occlusion. One candidate showed ventricular tachycardia
which needs ablation treatment. One candidate revealed thrombocytopenia
which was due to liver cirrhosis by hepatitis C infection. Finally 3 candidates,
which all had more than 10 years of dialysis history, were not acceptable for
transplantation at the time of evaluations and 2 have been treated successfully.
Among 18 candidates, 7 had more than 10 years dialysis history and 43% of these
candidates had comorbidity which was not acceptable for transplantation.
Conclusions: Screening especially of cardiovascular and peripheral vascular
disease is mandatory on the renal transplant candidate who is on waiting list
for more than 10 years.
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1062 IMPACT OF COLD ISCHEMIA TIME ON RENAL
ALLOGRAFT OUTCOME FROM YOUNG DONORS
D. Hernández1, S. Estupiñán2, G. Pérez Suárez3, M. Rufino4, J.M. GonzálezPosada5, D. Luis6, P. Delgado7, D. Marrero8, A. Rodriguez9, A. Torres10
1
Nephrology Section and Research Unit. Hospital Universitario De Canarias.,
2
Nephrology Section. Hospital Universitario De Canarias., 3Nephrology
Section.Hospital Universitario De Canarias., 4Nephrology Section.Hospital
Universitario De Canarias., 5Nephrology Section and Research Unit .Hospital
Universitario De Canarias., 6Nephrology Section. Hospital Universitario De
Canarias., 7Research Unit. Hospital Universitario De Canarias., 8Nephrology
Section. Hospital Universitario De Canarias., 9Nephrology Section.Hospital
Universitario De Canarias., 10Nephrology Section and Research Unit.
Hospital Universitario de CanariasHospital Universitario De Canarias.
Background: The chronic allograft loss, particularly those from deceased donors,
continues to occur at an unacceptable high rate. Prolonged cold ischemia time (CIT)
is associated with delayed graft function (DGF) and both conditions have been
related to a poorer long term transplant outcome. However the effect of CIT on longterm allograft survival in KT from younger donors has not been well established.
Methods: We investigated the predictive value of CIT exposure on long-term
death-censored graft loss in 829 KT recipients from younger donors (<50 yr)
that were performed in our center between 1991 and 2005. According to our
median CIT (19hr). we compared clinical data of patient with CIT exposure
shorter or longer than 19 hr. Cox regression model was used to determine the
relative impact of CIT on the transplant outcome.
Results: Overall death-censored graft failure rate was significantly higher in
CIT>=19 hr group versus CIT<19 hr group (26 versus 16.5%; P=0.002). Significant
differences were also observed when patients with primary non-functioning graft
were excluded (21 versus 14%; P=0.020) and in patients who received tacrolimus
plus mycophenolate mofetil (12 versus 4%; P=0.05). By multivariate Cox
analysis, CIT was independently associated with death-censored graft loss with
a 20% increase for every 5 hr of CIT [relative risk (RR) 1.04; 95% Confidence
interval (CI): 1.01-1.1; P=0.021]. Likewise, graft loss risk significantly increased
in CIT>=19 hr group versus CIT<19h group (RR 1.5; 95%CI: 1.1-2.1; P=0.023).
Conclusion: Prolonged CIT is an independent predictor of graft survival in
KT from younger donors. Efforts by minimizing CIT (<19hr) should improve
significantly transplant outcome in this population.
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1063 DOES DONOR NEPHRON MASS HAVE ANY IMPACT ON
GRAFT SURVIVAL?
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1064 PERIOPERATIVE MARKERS OF OXIDATIVE STRESS
CORRELATE WITH LONG TERM OUTCOME AFTER KIDNEY
TRANSPLANTATION
J. Mayer1, S. Stracke2, F. Keller2, S. Kolodziej1
Viseral- & Transplantation Surgery, 2Nephrology
The negative effect of oxidative stress on early kidney allograft function is well
known. Little data exists on the correlation between perioperative oxidative
stress and long term function in allograft kidney transplantation. We therefore
analysed markers of oxidative stress measured at and shortly after reperfusion
in allograft kidney recipients and correlated them with clinical long term
follow-up data.
Clinical data from 39 kidney recipients were obtained at least 60 months after
transplantation (mean follow-up 69.3 months). Of these, 13 had an impaired
allograft kidney function (creatinine >200 μmol/l) and 26 a good allograft
function (creatinine <200 μmol/l).
Some perioperative markers of oxidative stress were significantly
different in patients with an impaired allograft function after 5 years:
Thiobarbiturate reactive substances (TBARS). a marker of lipid
oxidation, were higher in the systemic circulation at reperfusion and in
the allograft vein five minutes after reperfusion. These patients also had
more free thiols in their venous blood preoperatively and higher levels of
4-Hydroxynonenal (4HNE). another product of lipid peroxidation, at 30
minutes after reperfusion.
In patients with an impaired long term kidney allograft function, higher
perioperative markers of oxidative stress both in the allograft vein and
the systemic circulation can be found. The suggested association between
increased perioperative oxidative stress and poorer long term function
in kidney transplantation stresses the relevance of this perioperative
phenomenon.

1

1065 NGAL (NEUTROPHIL GELATINASE-ASSOCIATED
LIPOCALIN) AND CYSTATIN C COULD PREDICT RENAL
OUTCOME IN PATIENTS UNDERGOING KIDNEY
ALLOGRAFT TRANSPLANTATION- A PROSPECTIVE STUDY
J. Malyszko1, U. Lebkowska2, E. Koc-Zorawska1, A. Lebkowska2,
J. Malyszko1, W. Lebkowski3, M. Gacko4
1
Medical University, Department of Nephrology and Transplantation,
2
Medical University, Department of Radiology, 3Medical University,
Neurosurgical ICU, 4Medical University, Department of Vascular Surgery and
Transplantation
Parikh et al. [Am J Transplant.2006] in a small group of kidney transplant
recipients reported that urinary NGAL may represent early, predictive
biomarker of delayed graft function, another model of ischemia-reperfusion
injury. Unfortunately, creatinine is an unreliable indicator during acute
changes in kidney function. Mishra et al. (Lancet 2005) highlighted value of
NGAL (neutrophil gelatinase-associated lipocalin) as a novel marker for early
detection of acute renal failure. Because of its small molecular size (25kDa)
and resistance to degradation, NGAL is readily excreted and detected in urine
as cystatin C. Therefore, the aim of the study was to assess whether NGAL and
cystatin C could predict renal outcome in 35 consecutive patients undergoing
kidney allograft transplantation in a single center.
Serum, NGAL (ANTIBODYSHOP, Gentofte, Denmark). cystatin C (Dade
Behring, Germany) were evaluated before, and after 1, 3, 6, and 10 days after
kidney transplantation using commercially available kits. Serum creatinine was
assessed at the same time. ANOVA or Kruskall-Wallis ANOVA for repeated
measurements were used in statistical analysis.
We found a significant fall in serum NGAL, as early as after 1 day following
kidney transplantation (409.9±104.4 ng/ml, vs 319.9±107.4 ng/ml, p<0.001,
baseline vs day 1, 283.8±102.8 ng/ml, p<0.0001 vs day 3, 200.2±99.8 ng/mL,
p<0.0001 vs day 6, 238.2±111.9 ng/ml vs day 10). Serum cystatin C decreased
significantly 3 days after transplantation, Before transplantation serum NGAL
was related to creatinine (r=0.45,p<0.001). cystatin C (r=0.52,p<0.001).
At each time point serum NGAL was related positively to serum creatinine,
and negatively to urine volume. In 4 patients we observed a delayed graft
function, in all these patients we did not observe a fall in serum NGAL and
cystatin C (mean serum NGAL before transplantation 442.2 ±32.1 ng/ml, at
day 10 421.5±73.1 ng/ml, NS). At any time serum NGAL and cystatin C were
significantly higher in patients with delayed graft function when compared to
patients without delayed graft function.
Our findings may have important implications for the clinical management of
patients undergoing kidney transplantation. The “window of opportunity” is
narrow in delayed graft function to distinguish between acute rejection and
CNI nephrotoxicity and time is limited to introduce proper treatment after
initiating insult. Therefore, NGAL needs to be investigated as a potential early
marker for delayed graft function, especially in the upcoming setting of early
dialysis treatment or antirejection therapy.
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1066 HYPERURICEMIA IS A MEDIATOR OF ENDOTHELIAL
DYSFUNCTION AND INFLAMMATION IN RENAL
ALLOGRAFT RECIPIENTS
M. Boratyñska, A. Karbowska, M. Kusztal, M. Klinger
Dept. af Nephrology and Transplantation Medicine, Wroclaw Medical
University, Wroclaw, Poland
Hyperuricemia is common in renal transplant recipients treated with
calcineurin inhibitors. Experimental studies suggest that uric acid induces
glomerular hypertension, microvascular disease and renal interstitial
fibrosis. Hyperuricemia is also an independent risk factor of cardiovascular
complications. The mechanism by which uric acid injures renal allograft and
cardiovascular system is still unclear.
The aim of this study was to assess the influence of serum uric acid level on
biomarkers of endothelial dysfunction and inflammation in renal allograft
recipients.
Material and Methods: The study entailed 78 adult, renal transplant
recipients (at age 19-70 years) with stable graft function (serum creatinine
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H. Wahhabaghai
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: Functioning nephron mass (number of nephrons in grafted kidney)
is one of the nonimmunologic factors that may have some impact on long- term
graft survival.
The aim of this study was Impact of Donor Nephron mass on recipient graft
outcome.
Methods: During 1989 – 2005, 1000 renal transplants was carried out at our
center. 217 of them were studied and followed for an average of 8 years. All
patients received grafts from living donors. Weight of grafted kidney (donor
nephron mass) and also recipient BMI were measured at the time of operation
in all cases. Nephron mass index (NMI) was defined as the ratio of donors’s
nephron mass to recipient’s BMI. This ratio was calculated for all 217 cases.
Associations between variables was tested by logistic regression and pearson
correlation .The analysis was performed with the SAS system and Splus
statistical software.
To evaluate the graft function, serum creatinine, acute and chronic rejection
episodes were determined.
Results: Mean NMI was 8.07 (±0.2) and mean creatinine level was 1.43 (±0.4)
mg/dL. There were 32 cases (14.7%) of acute rejection, managed successfully
with antithymocyte globulin (ATG) in 28 cases. Four patients lost their graft.
There were five cases of graft loss due to chronic rejection. Using Pearson
correlation, we found no association between NMI and mean serum creatinine
level. Logistic regression showed significant relation between NMI and acute
rejection (P < .05).with odds ratio of 2.0. There was no significant correlation
between NMI and chronic rejection.
Conclusion: The less NMI, The higher acute rejection.However, in long term,
no significant correlation between graft survival and NMI was found. Also,
mean creatinine level was not significantly different in patients regardless of
their NMI was found.
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level 0.7 – 1.4 mg/dl). The patients were transplanted between 2003 and
2006. Exclusion criteria were abnormal renal function, proteinuria, diabetes
mellitus, BMI above 30 and inflammation. The immunosuppressive protocol
consisted of CsA or tacrolimus and azathioprine or mycophenolate mofetil
and prednisone. The patients were divided into 2 groups: group I- 48 patients
with hyperuricemia (serum uric acid level 7.72±1.33 mg/dl) and group II
– 30 patients with normal uric acid level 5.48±0.92 mg/dl (control group).
Markers of endothelial function and inflammation were assessed in both
groups: plasma resistin level, CD146 (novel adhesion molecule) and soluble
vascular cell adhesion molecule-1 (sVCAM-1). These markers were measured
by enzyme immunoassay.
Results: No significant differences existed in demographic data between groups
of patients with and without hyperuricemia, such as age, gender, cause of renal
failure, number of HLA mismatches, DGF and number of episodes of acute
rejection per patient. Hypertension was observed in 85,4% of patients from
hyperuricemia group and 82% without hyperuricemia. Hypercholesterolemia
and hypertriglicerydemia were found in 45,8% of patients with hyperuricemia
and 56,6% with normal uric acid level.
The examined biomarkers were elevated in the group of patients with
hyperuricemia. Plasma resistin level was higher in hyperuricemic patients
than in control group (7.15±2.42 ng/ml vs 6.29±2.76 ng/ml). and tended to
be higher in women (7.83 ng/ml) than in men (6.58 ng/ml). Also sVCAM-1
was significantly higher in hyperuricemic patients (1126±371 ng/ml) when
compared to patients with normal uric acid level (955±269 ng/ml) P<0.03.
Resistin level correlated significantly with sVCAM-1 (P<0.01). CD146 was
elevated in patients with hyperuricemia (389.7±150 ug/ml). In control group
CD146 was 330±117 ug/ml.
Conclusions: Hyperuricemia mediates endothelial dysfunction and
inflammation and by this pathway may contribute to chronic allograft injury
and cardiovascular events in renal allograft recipients.
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1068 CHARACTERISTICS OF KIDNEY ALLOGRAFT
SURVIVORS WITH MORE THAN 10 YEARS FOLLOW-UP
A. El Agroudy, S. Al Arrayed, A. Al Arrayed, S.Ghareeb, E. Fareed
Salmaniya Medical Complex
Background/Aim: To study the characteristics and the predictors of survival
in Bahrani renal transplant recipients with an allograft that functioned for more
than 10 yr.
Methods: Sixty three patients underwent renal transplantation between 1979
and 1997. Of these, 37 had functioning allografts for more than 10 yr (range,
10–28). Characteristics of the patients, data on graft survival, and determinants
of outcome were obtained by reviewing all medical records.
Results: The mean age at time of transplantation was 30.7±14 years. The
donor source was 25 related and the mean age was 30.4±7 years. Thirty
three patients received their first graft. Thirty three were cyclosporine (CsA)
treated while 4 patients were primarily immunosuppressed by steroids and
azathioprine and 21 patients received induction therapy. Acute rejection
episodes occurred in 7 patients (58%). out of them 2 experienced two
acute rejection episodes. At most recent follow-up (March 2008). the mean
serum creatinine was 137±34 mmol/l. A history of cancer was noted in one
patient whereas; hypertension was (54%) and diabetes mellitus in 20.5%.
We compared the surviving group with the non surviving group at the
same time of transplantation and found that the independent determinants
of long-term graft survival were incidence of acute rejection episodes and
histopathological findings of CAN.
Conclusions: We concluded that renal transplantation even in its earliest years
and despite the numerous complications have provided 10 or more years of
near normal life to patients with end stage renal disease. Patients on CsA-based
immunosuppression clearly didn’t show any significant benefit on long-term
graft survival than patients on azathioprine and steroids.
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1067 RISK FACTORS FOR LONG-TERM GRAFT LOSS IN
KIDNEY TRANSPLANTATION: EXPERIENCE OF A MEXICAN
SINGLE-CENTER.
B. Aguilar1, R. Bernal, R. Mondragon
1
Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico
ISSEMyM
Background: There is not enough information regarding risk factors for renal
graft loss in Mexico and Latin America.
Aim: The purpose of this study was to analyze risk factors associated with graft
loss in our renal transplant program.
Pathients And Methods: Clinical records of 176 patients with renal
transplantation performed between August of 1982 to October of 2007 in
Centro Medico ISSEMyM were reviewed. Clinical and laboratory variables
were recorded, as well as the final patient and renal function status. Survival
rates were analyzed by Kaplan-Meier method; mortality risk by multivariate
Cox’s proportional hazard model.
Results: After ten years of follow-up, 156 patients were alive and 20 were
dead and all had functioning graft at the time of their dead. Patient survival
rates at 1, 5 and 10 years were 94%, 91%, and 89% respectively while the
graft survival rate at 1, 5 and 10 years were 96%, 97% and 99% respectively.
Twelve subjects lost their graft, 5 due to chronic graft nephropathy, 3 due
to infectious complications, 2 due to acute vascular rejection, and two due
to vascular thrombosis. Twenty subjects died with a functioning graft,
9 due to infections, five due cardiovascular complications, four due to
metabolic complications and two due to cancer. In the univariate analysis,
the following were significantly associated (p < 0.05) with graft loss:
delayed graft function, acute rejection episodes, vascular and infectious
complications. In the multivariate analysis, only acute rejection predicted
graft loss.
Conclusions: Some factors are related to graft lost like type of donation, HLAhaplotipe, delayed graft function, And the main cause of graft failure was acute
rejection. The mortality risk to the transplant patients was related to infectious
complications.
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1069 IMPACT OF SLOW GRAFT FUNCTION ON RENAL
ALLOGRAFT OUTCOME AND FUNCTION.
R. Bernal1, R. Mondragon, B. Aguilar
1
Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico
ISSEMyM
Introduction: Kidney transplant patients can be divided into three groups,
according to the initial graft function. Slow graft function (SGF) or immediate
graft function (IGF) according to whether the day 5 serum creatinine was
higher versus lower than 3 mg/dL, respectively.
Aim: The purpose of this study is to analyze the impact of graft function on the
first days after the transplant and their impact in the long term renal outcome.
Results: SGF patients showed worse graft survival, above higher incidence
of acute rejection and lower renal function than IGF patients, although few
reports have analyzed outcomes in these groups. We analyzed the impact
of SGF on graft survival, first-year renal function, and incidence of acute
rejection in 176 renal transplant patients. Creatinine was significantly worse
at 12 months for SGF than for IGF patients (1.9 +/- 0.8 mg/dL, 1.5 +/- 0.5
mg/dL, respectively; P < .05). The acute rejection rate was higher among the
SGF than the IGF group (P < .05). Graft survival was better among IGF than
SGF patients.
Conclusions: Kidney transplant recipients who develop SGF have a worse
outcome than patients with IGF, similar to DGF patients. SGF patients show
worse graft survival, worse renal function, and higher acute rejection rates than
IGF patients, despite not needing dialysis
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1070 SERUM NEUTROPHIL GELATINASE-ASSOCIATED
LIPOCALIN AS A MARKER OF EARLY FUNCTION OF RENAL
TRANSPLANTS
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1071 THE IMPACT OF DELAYED GRAFT FUNCTION ON
ACTUAL GRAFT SURVIVAL IS EQUALLY BAD IN DECEASED
DONOR KIDNEY TRANSPLANTS FROM EXPANDED
CRITERIA DONORS AND STANDARD CRITERIA DONORS.
J. Tchervenkov1, M. Cantarovich2, P. Metrakos1, S. Paraskevas1, D. Baran2,
M. Fernandez1, P. Chaudary1
1
Department of Surgery,McGill University,Montreal,Canada, 2Department of
Medicine, McGill University, Montreal, Canada
Introduction: Renal Transplant waiting lists continue to grow. The use of
expanded criteria donors (ECD) will increase the donor pool, but their use
is still limited because of poorer graft survival compared to standard criteria
donors (SCD). We assessed the impact of immediate renal function on renal
graft survival in recipients of SCD and ECD.
Methods: All Cadaveric renal transplants (n=335) performed at our center
between 1990 and 2002 were included. Immunosuppression included induction
with Thymoglobulin (83%). Mycophenolate Mofetil (51%). Azathioprin (47%).
Tacrolimus (55%). or Cyclosporine Neoral (45%) and Methylprednisolone.
ECD was defined according to UNOS criteria. All other donors were considered
as SCD. Delayed graft function (DGF) was defined as anyone who required a
form of dialysis immediately after the kidney transplant. Slow graft function
(SGF) was defined as a functioning kidney with the serum creatinine drop of
<20% in the first 24hrs after the transplant. Imediate graft function (IGF) was
defined as a functioning kidney with a serum creatinine drop >20% in the first
24hrs after the transplant. Data for graft survival is Non-Death Censored Actual
Graft Survival.
Results: Seventy two of the 335 pts (21.5%) were ECD. IGF was present in
54.7% of pts vs SGF 16.2% and DGF 29.1%. In SCD, the SGF and DGF rates
were 15.3% and 23.4% respectively. In ECD, the SGF and DGF rates were 19.4
and 50% (p<0.02). Actual graft survivals at 1 and 5yrs was 86.3% and 70.4%
respectively and although ECD pts had a slightly lower 5year graft survival
(72.6% vs 62.5%) this was not significant (p=0.13). Pts with IGF had a much
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L. Kyllönen1, M. Hollmén1, J. Merenmies2, K. Salmela1
1
Kidney Transplant Unit, Helsinki University Hospital, 2Tissue Typing
Laboratory, Finnish Red Cross
NGAL (neutrophil gelatinase-associated lipocalin) is proposed to be a
marker of acute renal tubular injury. We wanted to test that hypothesis
in serum samples of our kidney transplant recipients. Sixty consecutive
adult, dialysis dependent patients undergoing deceased donor kidney
transplantation (TX) were prospectively enrolled between September 2007
and January 2008. Serum samples were drawn pre TX and 1, 3 and 7 days
post TX. S-NGAL ELISA was performed with a commercial kit and as
recommended by the manufacturer.
Twenty-three (38.3%) patients had delayed graft function (DGF). The preTX s-NGAL concentrations did not significantly differ in patients who
developed DGF (594 ng/ml) compared to those with early function (EF)
(561 ng/ml). S-NGAL concentrations at day 1 post-TX were significantly
higher among patients with DGF (mean 466 ng/ml, range 253 to 651 ng/
ml) compared to those with EF (mean 325 ng/ml, range 81 to 638 ng/ml).
p=0.00057. The significant difference persisted in samples drawn at 3 and
7 days post TX.
The mean change of s-NGAL from pre-TX to day 1 (Δ-NGAL) was –236 in
EF and –129 ng/ml in DGF patients (p=0.0017). As the day 1 samples were
drawn on the first morning after TX, samples were taken from 2 to 20 hours
after TX. The Δ-NGAL in samples taken <12 hours after TX was significantly
larger in EF (-232 ng/ml) than in DGF patients (-91 ng/ml) (p=0.008). whereas
in samples taken >12 hrs after TX it was -241 ng/ml in EF and -176 ng/ml in
DGF patients (N.S).
In conclusion, high serum NGAL concentrations early after TX are associated
with renal dysfunction and NGAL determination provides a novel predictor
of DGF.

better actual graft survival at 5yrs compared to SGF and DGF (83.5%vs74.1%
vs 45.4%). DGF had an equally bad impact on actual 5yr graft survival in SCD
and ECD (42.6%vs 50%). Donor age or cold ischemia time had no effect on
5year actual graft survival in SCD or ECD except for cold ischemia >18hrs in
ECD recipients.
Conclusion: DGF has a strong detrimental impact on 5year graft survival.
There is a higher rate of DGF in ECD vs SCD kidneys. The detrimental impact
on 5year actual graft survival is equal in SCD and ECD kidneys. Minimizing
DGF should be our goal in deceased donor kidney recipients.
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1072 RECOVERY OF GRAFT FUNCTION EARLY POST
TRANSPLANT DETERMINES LONG-TERM GRAFT SURVIVAL
IN DECEASED DONOR (DD) RENAL TRANSPLANTS.
J. Tchervenkov1, M. Cantarovich2, S. Paraskevas1, P. Metrakos1, D. Baran2,
M. Hussanaian1, M. Fernandez1
1
Department of Surgery, McGill University, Montreal, Canada, 2Deapartment
of Medicine, McGill University, Montreal, Canad
Introduction: Kidneys show remarkable resilience and can recover function
even after prolonged periods of delayed graft function. We looked at the
impact of both early graft function and the rate of renal function recovery in
the first 3 months after transplantation, on long term graft survival in DD renal
transplants.
Methods: All Cadaveric renal transplants (n=583) performed at our center
between 1990 and 2007 were included. Immunosuppression included
induction with Thymoglobulin, Mycophenolate Mofetil or Azathioprin,
Tacrolimus or Cyclosporine and Methylprednisolone. ECD was defined
according to UNOS criteria. All other donors were considered as SCD.
Delayed graft function (DGF) was defined as anyone who required a form of
dialysis immediately after transplant. Slow graft function (SGF) was defined
as a functioning kidney with the serum creatinine drop of <20% in the first
24hrs after the transplant. Immediate graft function (IGF) was defined as a
functioning kidney with a serum creatinine drop >20% in the first 24hrs after
the transplant. Recovery of renal function (RFR) was expressed as either
the best creatinine clearance in the first 3months post-renal transplantation
(BCrCl-3mos) as calculated using the Caulcroft-Gault formula or as a
percentage of actual versus expected (as calculated from the donors’ CrCl
at procurement). Data for graft survival is Non-Death Censored Graft
Survival.
Results: 140 pts (23.6%) were ECD. IGF was present in 50.3%, SGF in
19.8% and DGF 29.1%. Overall graft survival at 1 and 5yrs was 87.8% and
74% respectively. Pts with IGF had a 5yr graft survival of 85%, whereas
pts with SGF and DGF had a survival of 76% and 54% respectively
(p<0.02). There was no difference in our cohort on the impact of early
graft function and 5yr graft survival between ECD and SCD kidneys. The
only difference is that ECD kidneys had twice the DGF rate (49 vs 23%
p<0.001). RFR also had an impact on 5yr graft survival and projected halflife. BCrCl -3mos of <30ml/min had a 1 and 5yr graft survival of 47 and
34%; BCrCl-3mos of 30-39ml/min had a 1 and 5yr survival of 92 and 72%;
BCrCl-3mos of 40-49 ml/min had a 1 and 5yr survival of 98 and 85%;
BCrCl-3mos of >50 ml/min had a 1 and 5yr survival of 96 and 82% and the
half-lives were 10mos, 9.5yrs, 13.5yrs and 13yrs respectively (p<0.0001).
Similarly a recovery within 90% of expected CrCl in the first 3mos posttransplant was associated with a graft survival at 1 and 5yrs of 94 and 81%;
a recovery of 70-90% was associated with a survival at 1 and 5yrs of 91
and 65%; a recovery of <70% was associated with a survival at 1 and 5yrs
of 63 and 51%. The half-lives were 12.5 vs 10.5 vs 5.5 yrs respectively
(p<0.0001).
Conclusion: Early Graft function in the first 3mos has a significant impact on
long term graft survival after DD renal transplantation.
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1073 A MODIFIED QUANTITATIVE SUBJECTIVE GLOBAL
ASSESSMENT OF NUTRITION FOR PATIENTS ON THE RENAL
TRANSPLANT WAITING LIST
A. Demýrag, G. Kantarci, M. Kalayci, B. Ekcý, T. Gulcelýk, O. Gokce
Yeditepe Univ Hospital
Subjective Global Assessment (SGA) is widely used and validated method for
identifying and classifying malnutrition. It has been thought that this semiquantitative feature restricts the SGA’s reliability and precision. Recently,
in effort to asses nutritional status a modified quantitative subjective global
assessment systems have been devised in which scores are assigned for items
or components of the SGA. This prospective study evaluated both conventional
and quantitative SGA systems.
Method: Using the components of the conventional SGA, we operated a fully
quantitative scoring system consisting of seven variables: weight changes,
dietary intake, gastrointestinal symptoms, functional capacity, comorbidity,
subcutaneous fat, and sign of muscle wasting. Each component was assigned a
score from 1 (normal) to 5 (very severe). The sum of all seven components in this
malnutrition score lies between 7 (normal) and 35 (severely malnourished). To
evaluate nutritional status patients on renal transplantation waiting list, mid-arm
circumference (MAC). body mass index (BMI) and laboratory parameters were
used. Twenty-seven patients (9 women and 18 men) were randomly selected
from the waiting list. Patient’s age were between 16 and 62 years (43,1±11,6)
and on hemodialysis for between 1 month and 196 months (55,9±44,9).
Results: Correlation coefficients between the malnutrition score and duration
of hemodialysis (r=+0.72). sex (r=+0.44). total iron binding capacity (r= -0,44)
were significant, whereas the conventional SGA had significant correlation
only with duration of hemodialysis (r=+0.42).
Multiple regression analysis showed a significant correlation between
malnutrition score and the combination of duration of hemodialysis, sex, total
iron binding capacity (r=0.77, p<0.001).
Conclusion: The quantitative SGA scoring system may be better than the
conventional SGA to evaluate patients on the waiting list. More comparative
studies are required to confirm the validity of this scoring system in nutritional
evaluation of renal transplant candidates.
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1074 CLINICAL RELEVANCE OF PRE-TRANSPLANT
ADIPONECTIN LEVELS FOR PREDICTION OF NEW-ONSET
DIABETES AFTER TRANSPLANTATION
A. Kazory, C. Courivaud, S. Mercier, S. Kury-Paulin, E. Toussirot,
G. Zanetta, A. Penfornis, J-M. Chalopin, G. Dumoulin, D. Ducloux
University of Franche-Comte
Background: Adiponectin is an adipose-specific protein with insulinsensitizing and anti-atherogenic properties. It is not known if pre-transplant
plasma adiponectin levels can be used to predict new onset diabetes after
transplantation (NODAT).
Methods: We performed a case-control study to evaluate the potential role of
adiponectin as a risk factor for NODAT independent of obesity, and then to
find a threshold for identification of high-risk patients. Forty nine patients with
NODAT were compared to 49 transplant patients (controls). matched for age,
gender, body mass index at the time of transplant, and the calcineurin inhibitor
agent used for immunosuppression. Adiponectin levels were also measured in
thirty five healthy subjects with normal renal function.
Results: Adiponectin levels were significantly higher in pre-transplant
patients compared with healthy subjects (13.9 +/- 5.8 μg/ml vs. 9.5 +/- 4.2
μg/ml; p<0.0001). In multivariate analysis, higher plasma adiponectin level
was protective against NODAT (incidence rate ratio 0.86 [95% CI 0.78-0.95],
p=0.002). All patients with adiponectin levels ≤; 7 μg/ml (8.2%) developed
NODAT. This corresponds to a positive predictive value of 100%. None of
the patients with adiponectin values ≥; 22 μg/ml (7.1%) developed NODAT.
For a threshold of 10 μg/ml (27.6%). more than one third of patients
developed NODAT; the adjusted incidence ratio was 4.29 [95% CI 1.62-11.47]
(p=0.004).
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Conclusion: Low pre-transplant plasma adiponectin levels are associated with
a higher risk for subsequent development of NODAT. These results suggest that
a threshold of 10 μg/ml can identify high-risk patients for whom preventive
interventions might be employed.
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1075 C-REACTIVE PROTEIN AS A PREDICTOR OF
PROGNOSIS FOLLOWING RENAL TRANSPLANTATION FOR
DIABETIC END STAGE RENAL DISEASE
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy3
1
Cairo University, Division of Nephrology, Department of Medicine, 2Cairo
University, Department of Urology, 3Cairo University, Department of Clinical
Pathology
Aim of Study: To analyze the impact of an elevated C-reactive protein (CRP)
on outcome following renal transplantation for diabetic ESRD.
Method: Retrospective analysis of a prospectively gathered dataset. 70 patients
with CRP measurements taken immediately prior to the surgery
were included in this study. Patients were followed up at the outpatient clinics
withregular blood tests, including blood sugar, kidney function tests, serum
cholesterol,tumor markers carcinoembryonic antigen (CEA).and liver function
tests.In addition, regular chest abdominal sonography and echocardiography
were performed. Patients were followed up a minimum period of 1 year post
renal transplantation at the time of study (range 1.5 years.The data examined
included patient demographics;number of rejetions; preoperative CRP; postoperativemorbidity/mortality
Results: A CRP value above 10 mg/l was taken as elevated.
Results: Pre-operative CRP was elevated (!10 mg/l) in 54 (77%) patients.
The number of ischemic cardiac episodes in patients with an elevated CRP
was 19months (95% CI 7.5 !31.2 months) compared to 42.8 months (95% CI
33.2 !52.5 months) for those with a normal CRP, p#0.0044.The results of a
multivariable analysis of the predictors of survival showed that an elevated
CRP (p#0.032) as well as uncontrolled diabetes, elevated LDL cholesterol
predicted for poorer overall survival.
Conclusions: This study showed that an elevated CRP level,measured before
surgery, is present in a significant proportion of patients with diabetic end stage
renal patients. This is found to predict for a poor survival outcome in patients
who had kidney transplantation performed. The inflammatory response, as
reflected by CRP, is the only factor that can be modulated pre-operatively in
these patients and this may lead to the use of novel therapies among this group
of patients in the future.
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1076 POST-TRANSPLANT DIABETES MELLITUS: A SINGLE
CENTER EXPERIENCE
A. Ghafari1, V. Modaess
1Urmia University of Medical Sciences, 2Urmia University of Medical
Sciences
Introduction: Post-transplant diabetes mellitus (PTDM) has been increasingly
recognized as an important post-transplantation complication and a significant
contributor to inferior recipient outcomes. In this study, we assessed the
incidence of PTDM and the factors that are associated with the development
of this complication.
Patients and Methods: All adult patients (n = 1350) who were regularly followed
at a single kidney transplant outpatient clinic were included in a cross-sectional
study between April 2005 and February 2006. Among them 644 (47.7%) pts
had no history of DM prior to transplantation and enrolled in to study. Data was
extracted from the patient’s charts at the hospital. Demographic information
and details of medical history were collected at enrollment when information
about age, gender, etiology of end stage renal disease (ESRD) and presence of
DM in first-degree relatives were obtained. Among pts 97% received their graft
from living donors. The immunosuppressive protocols included cyclosporine
A, azathioprine or Mycophenolate mofetil and prednisolone.
Statistical Analysis: Statistical analysis was carried out using the SPSS 10.0
software. Continuous variables were compared using Student’s t-test and
categorical variables were analyzed with the chi-squared test or the Fisher
exact test, as appropriate.
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1077 VIABLE YIELD OF ISLETS FROM ISCHEMIC PORCINE
PANCREATA IS IMPROVED USING TWENTY-FOUR HOUR
HYPOTHERMIC MACHINE PERFUSION PRESERVATION .
M.J. Taylor1,3, S. Baicu1, E. Greene1, A. Vazquez1, J. Brassil2.
1
Cell and Tissue Systems, N. Charleston, SC, USA, 2Organ Recovery Systems,
Des Plaines, IL, USA. 3Dept. Surgery, Medical University of South Carolina,
Charleston, SC. USA.
Objectives: Pancreas (Px) procurement for islet isolation and transplantation
(Tx) is hindered due to concerns for the detrimental effects of post-mortem
ischemia. Perfusion/preservation technology has recently been reported to
improve the recovery of islets after 24h hypothermic machine perfusion
(HMP) of porcine Px prior to islet isolation [1]. This technology is now
applied to pig Px subject to a warm ischemia time (WIT) prior to HMP and
islet isolation.
Methods: Pancreata in anesthetized Domestic Yorkshire pigs (25-30 kg) were
surgically removed and the superior mesenteric artery and celiac trunk were
cannulated using a proprietary seal-ring cannula.The splenic vessels and other
arterial branches were ligated to allow uniform perfusion through the gland ex
vivo. Px were assigned to one of four preservation treatment groups: Controls
– processed immediately with minimum cold ischemia (<1h) [G1, n=7]. Static
Cold Storage-flushed with cold UW-Viaspan and stored at 2-4ºC for 24h with
no prior WIT [G2, n=9], Hypothermic Machine Perfusion (HMP) -perfused on
a LifePort® machine with KPS1 solution at 2-6ºC and low pressure (10mmHg)
for 24h either immediately after procurement (no WIT) [G3, n=7], or after
30 min WIT in situ [G4, n=7]. Islet isolation was then accomplished by
ductal distension of the gland with liberase enzyme, normothermic digestion
and density gradient purification. Standard, accepted product release criteria
were used including islet quantification and islet function using the glucose
stimulated insulin secretion assay.
Results: The measured degree of glandular edema was 0%; -2.79±0.71%;
138±18.6% and 127±21.5% for the groups respectively. Islet yield normalized
by the weight of digested pancreas was markedly different between the
treatment groups: G1=1673.6±697.8 IEQ/g; G2=1239.1±290.4 IEQ/g;
G3=3113±555 IEQ/g and G4=1840.6±317.3IEQ/g. The increased yield in the
HMP group G3 over the static cold storage in UW-Viaspan was statistically
significant (p<0.05). Functionally, the islets from each experimental group
were equivalent and not significantly different to controls (G1) with insulin
stimulation indices of G1=4.6±1.3; G2=2.5±0.4; G3=2.8±0.4 and G4=4.2±0.4.
However, insulin content (ng/ml/IEQ) was different between the treatment
groups with the highest insulin content in islets harvested from HMP Px (G3)
=11.8±3.8 compared with G1=8.5±3.7,G2=4.8±1.0 and G4=6.6±1.1. Dithizone
staining for islets showed a consistently more uniform digestion of the Px from
G3 and G4 compared with G1 and G2, with greater separation of the tissue and
less entrapped islets.
Conclusion: HMP for 24h is well tolerated leading to moderate edema but no
loss of function of the harvested islets. The edema appears to aid in enzymatic
digestion producing a greater yield and purity of islets compared with Px
subjected to 24h of static cold storage. The salutary effects of HMP are also
manifest after prior warm ischemia of the donor Px.
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1078 INCIDENCE OF THE METABOLIC SYNDROME IN
KIDNEY TRANSPLANTATION
H. Kishikawa, N. Arichi, Y. Namba, K. Nishimura, Y. Ichikawa
Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Hyogo,
Japan
Objectives: Metabolic syndrome (MS) was recently reported to be a risk factor
for cerebrovascular disease (CVD). which is one of the leading causes of death
following kidney transplantation. However, little is known about the incidence
and impact of this syndrome in those patients. We investigated the prevalence of
MS in kidney transplantation patients and assessed its development following
that procedure by determining plasma Adiponectin levels and results of an oral
glucose tolerance test (OGTT).
Methods: We conducted a cross-sectional study of 94 patients with stable
graft function who underwent kidney transplantation between January 1999
and October 2008. Those with diabetes at the time of transplantation were
excluded. The presence of MS was determined using National Cholesterol
Education Program Adult Treatment Panel III (NCEP-ATP III) criteria with
body mass index used in place of waist circumstance. In addition, plasma
Adiponectine level was measured and a 75g oral glucose tolerance test (OGTT)
performed. A homeostatic model assessment of insulin resistance (HOMA-R)
was calculated using the following formula: fasting BG x fasting SI/405. In
addition, insulinogenic index (I-Index) was calculated as ¦¤SI (30’-0’) /¦¤BG
(30’-0’).
Results: A total of 14 (14.9%) out of 94 patients suffered from MS at a mean
time of 46.7 months (range 1-106) after the transplantation. The rates of
incidence of obesity (BMI > 25). triglycerides (TG) ¡Ý 150mg/dL, high-density
lipoprotein (HDL) < 40mg/dL in men or <50 mg/dL in women, systolic blood
pressure (SBP) ¡Ý 130mmHg or diastolic blood pressure (DBP) ¡Ý 90mmHg,
and fasting glucose (FBG) > 100mg/dL were 8.5%, 78.7%, 33.0%, 7.4%, and
22.3%, respectively. Age at transplantation, gender, end-stage renal disease
(ESRD) duration, HLA mismatch, and immunosuppressive regimen were not
significantly different between the MS and non-MS group, whereas BMI at
the time of transplantation was significantly greater in the MS group (23.4+/3.24 vs. 20.1 +/-2.50, p< 0.0001). In addition, the nadir creatinine (Cr) level,
and Cr at 1 year after transplantation, and Cr at the final observation were not
significantly different between the groups, while plasma Adiponectin level was
significantly lower in the MS group (11.95+/-5.13 vs. 17.71+/-8.47, p=0.0158).
Furthermore, the I-index values was similar, whereas HOMA-R was greater in
the MS group (2.598 +/- 1.918 vs. 1.340 +/- 0.934, p= 0.0002).
Conclusions: In this cross-sectional study, 14.9% of the subjects suffered from
MS following kidney transplantation. The level of Adiponectin was lower in
those with MS and found to be negatively correlated with insulin sensitivity in
kidney transplant recipients. We concluded that a low Adiponectin level may
correlates with the prevalence of MS in kidney transplantation in association
with impaired insulin sensitivity.
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1079 RELATIONSHIP BETWEEN SERUM PARAOXONASE
ACTIVITY AND ADIPOKINES LEVELS IN RENAL
TRANSPLANTED PATIENTS
L. Locsey1, I. Seres2, F. Sztanek2, L. Szabo3, L. Asztalos3, D.G. Paragh2
1
B.Braun Avitum 10. AKD , 2I.Dept.Med. DEOEC ,Univ Debrecen, 3I.Surg.
Dept. DEOEC ,Univ.Debrecen
Increased oxidative stress and inflammation are associated with atheroscle rotic
coronary disease in renal transplanted pts.HDL-associated paraoxonase
(PON1) prevents LDL-C from oxidation providing protection against athero
– sclerotic and coronary artery disease.Previous studies shown that serum
leptin,adiponectin concentrations are elevated in pts with chronic kidney
disease.
Aim: our aim was to investigate the connection between serum para
-oxonase activity ,renal function ,adiponectin and leptin levels in renal
transplanted pts.79 transplanted pts (38 males,41 females,age: 49,01 +/-14,00
ys) were included in the study.We examined in fasting serum creatini -ne
cystatin C,homocysteine,CRP,glucose and lipids.Serum PON1 activity
was determined spectrophotometrically.Serum adiponectin and lipid levels
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Results: Among 644 non DM patients enrolled to the study 350 (54.35%) were
male. Mean age was 41.34 ± 13.8 year (range 12-82). PTDM developed in 66
patients (10.2%). among PTDM patients 36 were female and 40 were male (P =
0.172). Patients divided in three groups according to age: age< 40 year, 40<60
and age > 60. Prevalence of PTDM were 3.8%, 15.6% and 20.3% among
different age groups respectively (P< 0001). PTDM developed in 8.3% of
patients with and in 10.3% without past history of CMV infection (P = 0.825).
PTDM developed in 10.2% of patients receiving first transplant versus 10.2%
receiving second or more transplant (P = 0.957). Among all patients 85 had
history of DM in first degree relatives, PTDM developed in 17 (20%) 0f them
versus 8.8% in patients without history of DM in first degree relatives (0.003).
Patients divided in to three groups according to pretransplant dialysis duration:
preemptive (16 ). one to 23 months (444). and more than 24 months (184).
PTDM occurred in 25%, 9.9% and 9.8% respectively (P = 0.143).
Conclusions: the older age at the time of transplantation and family history of
DM were the main predictors for developing PTDM.
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were measured by ELISA method.Our pts had hypercholesterolaemia,high
LDL and ApoB levels and paralel with improved renal function decreased
cystatin C and homocysteine levels (p<0.001).We devided our pts into two
group accor -ding to BMI.In obes pts (BMI>30kgm2 n=14) was siginificantly
higher LDL (p<0.05) and leptin concentrations (58.06 vs.15.16 ng/ml,p<0.01)
than in malnourished pts (n=9).We not found significant difference between
serum adiponectin levels (15,12 vs.17,34 ug/ml) and PON1 activity (91,45
vs. 101.20U/L) in obese and malnourished renal transplanted pts.Between
serum leptin concentrations and PON1 activity was not significant negative
corre lation.After transplantation was significant negative correlation
between serum PON1 activity and improved renal function (p < 0.01 ).In
dyslipidaemic ,obes transplanted pts have high LDL,leptin concentrations
and paraoxonase activity not significant correlation between leptin ,adipo
nectin and CRP levels.With improved renal function significant increased
serum PON1 activity.
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1080 NEW ONSET DIABETES (NODAT) AFTER KIDNEY
TRANSPLANTATION IN AUTOSOMAL DOMINANT
POLYCYSTIC KIDNEY DISEASE (ADPKD).
R. Irene, R. Walker, C. Shlomo, M. Rosemary
Department of Nephrology, Royal Melbourne Hospital
Introduction and Aims: NODAT is an important complication of solid
organ transplantation Recognised risk factors in kidney transplants include
increased age, obesity, family history of diabetes, high dose steroid, CMV,
Hepatitis C and tacrolimus based immunosuppressive regimens. Several
recent publications have reported ADPKD as a risk factor for NODAT. We
examined the incidence of NODAT and impaired glucose tolerance (IGT)
in patients with ADPKD compared with a matched control group in our
transplant population.
Methods: A single center case controlled retrospective study examined the
incidence of NODAT and IGT in 65 renal allograft recipients with ADPKD
compared to those without ADPKD transplanted in the period January 2000
and October 2007. NODAT definition: (WHO definition) random blood
glucose (RBG) estimations ≥ 11.1 mmol/L on two separate days > six weeks
post transplantation. IGT definition: RBG ≥ 7 mmol/L and < 11.1 mmol/L on
two separate days > six weeks post transplantation and/or post intravenous
methylprednisolone. Patients on oral hypoglycaemic medication or insulin
were classified as NODAT, regardless of blood glucose. Graft losses and
deaths (n=2) within 3 months of transplantation were excluded. Intergroup
comparisons were analysed with a paired student’s t-test. The Control group
(n=63) were matched for gender and year of transplantation. Known diabetics
pre-transplantation were not included.
Results: (Mean values +/-SD)
Control

n

ADPKD

n

p value

Age (years)

50.2 +/- 8.5

63

52.1 +/- 8.1

63

n.s

Male: Female

35: 28

63

35: 28

63

n.s

Follow-up (months)

92.5 +/-73.2

63

85.8 +/- 74.8

63

ns

Weight at Tx (kg)

69.8 +/-13.6

63

77.0 _/- 14.9

63

p =.005

Height (cm)

166.8 +/- 11.2 63

172.2 +/- 9.2

63

p <.005

BMI (kg/m2)

25.0 +/- 3.7

63

25.9 +/- 3.9

63

n.s

Weight 1yr post Tx (kg)

73.0 +/- 15.7

48

79.0 +/- 13.2

45

p <.05

ΔWeight 1 year (kg)

4.9 +/- 7.7

48

4.1 +/- 8.4

45

n.s.

There were no differences between groups in the incidence NODAT: IGT.
For ADPKD the numbers were 9: 8 (Total=17) and for Controls 8: 11 (Total
=19) respectively. Only 2 ADPKD patients and 1 control group patient were
on insulin. There were no differences in ethnicity, Δ weight over 1 year post
transplant, immunosuppression regimen (prednisolone dosages and Tacrolimus
levels). There was no difference in number of acute rejection episodes requiring
intravenous methylprednisolone, either for the whole groups or those who
developed either NODAT or IGT.
Conclusions: This study in a cohort of Australian patients found no evidence
to suggest ADPKD is a risk factor for NODAT
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1081 ABNORMAL GLUCOSE HOMEOSTASIS WITHIN FIRST
SIX MONTHS POST KIDNEY TRANSPLANTATION
S. Norman, F. Luan, D. Cibrik, A. Ojo
University of Michigan
Background: Abnormal glucose homeostasis is common in renal transplant
recipients (RTRs) and associated with poor clinical outcomes. We studied the
evolution of abnormal glucose homeostasis within 6 months after a kidney
transplant using sequential standardized oral glucose tolerance test (OGTT).
Materials and Methods: Between October 1, 2006 and February 28, 2008, 60
non-diabetic RTRs underwent sequential standard 2-hour OGTT at 10 weeks
and 6 months post transplantation as part of institutional cardiovascular risk
stratification protocol. The demographic and clinical parameters were compared
among the three groups of patients according to 2 hours post challenge glucose
levels at 6 months: normal (< 140 mg/dl). impaired (140-199 mg/dl) and
diabetic (>200 mg/dl). The fasting glucose levels and 2 hours post challenge
glucose levels at 2 time points were compared. Univariate, including ANOVA,
χ2 test and McNemar for paired proportion, and logistic regression analysis
were utilized.
Results: The cumulative incidence of new onset diabetes after transplant
(NODAT) was 15.0 and 16.6%, respectively, at 10 weeks and 6 months
after kidney transplantation while cumulative incidence of impaired glucose
tolerance (IGT) increased over the same time period (from 15.0% to 20.0%).
There was good correlation between 0 and 2 hours glucose levels at 6 months
(Pearson correlation coefficient = 0.502, p<0.0001). However, fasting glucose
levels underestimate the seriousness of early abnormal glucose homeostasis at
both 10 weeks and 6 months. Univariate analysis showed that fasting glucose
levels prior to the transplant, first three days and 10-12 weeks post transplant
were significantly different among the groups. Logistic regression analysis
revealed fasting glucose levels at 10-12 weeks as only predictor of abnormal
glucose homeostasis at 6 months.
Conclusions: OGTT is more sensitive in identifying impaired glucose
homeostasis within 6 months of kidney transplantation. Fasting serum glucose
concentration alone misses a significant proportion of early impaired glucose
homeostasis in the kidney transplant population.
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1082 RELATIONSHIPS OF SOCIO-CULTURAL AND DIETARY
FACTORS TO OBESITY AND RENAL HEALTH
S. Madhere, C. Callender, A. Campbell, E. Clark.
Howard University
Previous research has identified obesity as a precursor to renal disease. As
obesity threatens to reach epidemic scale in the United States, it is important
to examine concomitant factors that may foster such a health risk. It is equally
crucial to determine whether those factors can also influence kidney function
through additional pathways.
The present study explores the relationships of renal health to truncal obesity
as well as socio-cultural and dietary factors. Levels of creatinine, urine protein
and urine glucose were recorded to assess renal health. Socio-cultural factors
include sex, income, and cultural leverage. Cultural leverage was based on
self-report of the degree of access and influence a person has when dealing
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While the model correctly classified 87.1% of the cases, only body-mass
emerged as a significant predictor of diabetic status. The odds-ratio associated
with this variable was 1.1 (95% CI ranging from1.01 to 1.20). Our results
suggest that obesity stands as the more reliable contributing factor to diabetes.
By contrast, the inflammatory response, if measured through interleukin-6
among human subjects, may not be as powerful a mechanism in the emergence
of diabetes, as it reported is among animals.
This research investigation is part of a larger study entitled, “A Research
Center to Reduce Health Disparities in End Stage Renal Disease”, that is
funded by The National Center on Minority Health and Health Disparities,
Grant #1P20MD000512-04. Principle Investigator: Clive O. Callender,
MD, Co-Principal Investigators: Alfonso Campbell, Jr., PhD and Jules P.
Harrell, PhD

Predictors

1084 IMPACT OF POSTTRANSPLANT DIABETES MELLITUS
ON GRAFT FUNCTION AND SURVIVAL AFTER RENAL
TRANSPLANTATION IN THAI POPULATION.

Indices of Renal Health
Glucose

Protein

Creatinine

Obesity

.43*

.27*

.19*

Stress

.21*

.24*

.25

Emotional Eating

.17*

.13

.36*

Meat Consumption

.05

.14

.09

Vegetables

-.13

-.14

-.11

Fast-food

.09

.18

.19*

Income

-.11

-.15

-.05

Leverage

.18

.09

.24*

Total Variance Accounted for
(Eta-squared)

.32*

.19*

.35*

• p < .05
This research investigation is part of a larger study entitled, “A Research Center
to Reduce Health Disparities in End Stage Renal Disease”, that is funded
by The National Center on Minority Health and Health Disparities, Grant
#1P20MD000512-04. Principle Investigator: Clive O. Callender, MD, CoPrincipal Investigators: Alfonso Campbell, Jr., PhD and Jules P. Harrell, PhD
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1083 OBESITY AND INFLAMMATION: THEIR RESPECTIVE
ROLE IN PREDICTING THE EMERGENCE OF DIABETES IN
HUMAN SUBJECTS
S. Madhere, C. Callender, A. Campbell
Howard University
The link between Type II diabetes and obesity has been predicated on the effect
of increased liver triglycerides on insulin sensitivity. But recently, it has been
proposed that obesity is responsible for a state of low-grade inflammation
which tends to enhance insulin resistance (Shoelson et al., 2006). The evidence
for this is an increase in the expression of pro-inflammatory cytokines such as
interleukin-6 (Hirosumi et al., 2002). After demonstrating that Jun kinases may
serve as a trigger to obesity-induced inflammation in a mouse model, Solinas et
al. (2007) argued that the regulation of JNK1 might be useful to the treatment
of diabetes.
The present study tests whether a single or a dual pathway links obesity and
diabetes in human subjects. The study was conducted with a sample of 31
African American participants, five of whom had been clinically diagnosed
as diabetic. A measure of interleukin 6 was obtained for each participant.
This biomarker of inflammation was supplemented by a subjective report
of bodily pain, using items from the Health Perception Scale F36 (Ware,
2000). Body-mass index was also recorded. Logistic regression was used
in order to predict diabetic status as a function of IL6, bodily pain, and
body-mass.
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A. Ingsathit, S. Rattanasiri, P. Chatchaipun, S. Jirasiritham, V. Sumethkul
Faculty of Medicine, Ramathibodi Hospital
Introduction: Posttransplant diabetes mellitus (PTDM) is a major complication
after kidney transplantation. We examined the impact of either condition on
death-censored graft and patient survival in Thai population.
Materials and Methods: A cohort of consecutive ESRD patients who
underwent first kidney transplantation at a single center, university based
hospital during June 1995 to December 2006 were examined. We studied the
outcomes of 494 KT recipients that included 62 PTDM patients (12.5%; Gr1).
63 patients with DM as underlying disease (12.7%, Gr2) and 369 non DM
patients (Gr3) in a single center during a 10-year period. Diagnostic criteria
of PTDM include: fasting blood glucose levels higher than 126 mg/dl on
two separate occasions or the requirement of glucose-lowering medications
(insulin or oral hypoglycemic agents). Primary end point was the deathcensored graft survival rate. Secondary end point was the patient survival
rate. Graft failure was defined as when recipients returned to hemodialysis.
Cox’s regression with time-varying covariates was used to determine the
prognostics factors. Risk factors for PTDM were assessed by mean of multiple
logistic regression analysis models. A p value less than 0.05 was considered
as statistical significant.
Results: Among 494 recipients during study period, 62 recipients developed
NODM. The median follow-up time was 5.2 years (range: 0.2-10.0 years).
The estimated incidence of PTDM was 3.7/100 patients/year. The overall
DM-free survival rates at 1, 5, and 10 years were 91.1%, 82.8%, and 79.3%
respectively. Tacrolimus-based immunosuppressive regimen were used in 49
(11.6%) recipients and the average prednisolone used per day were 9.73 + 3.35
mg/day. Only recipient’s age was significantly able to explain development of
PTDM. We found that recipients whose age were older than 40 years were
1.83 (95%CI: 1.06-3.15) times more likely to have PTDM than recipients
aged 40 years or younger. However, recipient’s gender, type of donor,
HBV seropositive status, HCV seropositive status, duration of dialysis, and
tacrolimus use were not associated with the risk for development of PTDM.
Ten year actuarial graft survival was 78.5% for Gr. 1, 81.7% for Gr. 2 and
74.3% for Gr. 3 (P = 0.335). And the actuarial 10 year patient survival of Gr1
was not significantly different compared with Gr2 and Gr3 (92.2% VS 96.4%
and 86.4%) (p=0.136).
Discussion: The rate of development of PTDM was lesser than previous reports.
Low proportion of tacrolimus used and low cumulative dosage of prednisolone
used in our practice may explain this finding. No significant difference in deathcensored graft survival and patient survival in renal recipients who develop
PTDM compared with recipients with history of DM before transplantation or
control patients.
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with major social institutions. We examined dietary habits such as inclusion
of vegetables in a person’s meals, consumption of red meat, and a reliance on
take-out or fast-food. Two psychological variables, relevant to eating behavior,
were also taken into account: daily stress and reactive emotional eating.
Data were collected from a sample of 88 African Americans, part of a much
larger group recruited for a comprehensive study on transplant education
(MOTTEP). The average age of participants was 47 years. The statistical
analysis was conducted in several stages. First, the pertinent dimensions of diet
were derived from factor-analysis of a 51-item instrument, using maximumlikelihood procedures. Second, a correlation matrix was obtained for all
variables in the study. Finally, multivariate analysis of variance was used to
analyze the relationships between the set of independent predictors and the
three measures of kidney function.
Details of the analysis are summarized in the table below. It is worth
noting that sociocultural and dietary factors together could explain 35%
of the variance in creatinine level, 32% in urine glucose level, and 19%
in urine protein level. Significant predictors for creatinine were (in order
of their contribution based on the value of eta-squared): emotional eating,
sex, obesity, cultural leverage, and fast-food habit. Obesity turned out to be
the significant predictor for urine glucose, with marginal contribution from
emotional eating and cultural leverage. Level of urine protein was dependent
on obesity only.
Correlations of Various Indices of Renal Health with Sociocultural and Dietary
Factors.
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1085 METABOLITES PATTERNS IN KIDNEY TRANSPLANT
PATIENTS

1086 NEW ONSET POSTTRANSPLANT DIABETES MELLITUS
IN HISPANIC KIDNEY TRANSPLANT RECIPIENTS

M. Carmellini3, H. Stenlund1, M. Calderisi2, A. Vivi2, M. Tassini2,
G. Valensin2, M. Cocchi4, J. Trygg1
1
Chemistry Department Umeå University, Sweden 2NMR Center University
of Siena, Italy 3Department of Surgery and Bioengineering, Siena, Italy
4
Chemistry Department University of Modena and Reggio Emilia, Italy
NMR spectroscopy is an analytical platform for biological matrices; it enables
the quick generation of spectral profiles of low molecular weights metabolites.
Metabonomics is a system approach used to investigate the metabolic profile
by multivariate data analysis tools.
The goal of this work is the identification of the dynamic biopatterns (individual
patient recovery trajectories) related to the recovery progress in kidney
transplant patients, by 1H-NMR spectroscopy. Urine samples of 14 trasplanted
patients, with deceased donor kidney, were collected during the graft recovery
period of 15gg after trasplantation, along with clinical data (glucose, dialysis,
diuresis, drug therapy).
Urine NMR measurements were carried out on a Bruker DRX 600 MHz Avance
spectrometer. The samples were measured at pH 2.50 ± 0.02.
Clinical data have been analyzed by means of Principal Components Analysis
(PCA). Cluster Analysis (CA). while 1H-NMR spectroscopic data have been
analyzed by means of O-PLS-DA (Orthogonal PLS Discriminant Analysis).
The diuresis data has been studied by PCA. The first two components loadings
plot shows a clear trend from the first days to the last one (fig. 1).

P.W. Baron1, R. Ben-Youssef1, E. Franco1, J. Weissman1, W. Baqai2, A. Kore1,
M. DeLeon2, Z. Cordero-MacIntyre2 and O. Ojogho1.
1
Transplantation Institute and 2Center for Health Disparities Research, Loma
Linda University, California, United States.
Background: Tacrolimus (FK) is less commonly used in Hispanic patients
due to anticipated higher risk of new-onset diabetes mellitus posttransplant
(NODM). We analyzed the incidence of NODM and the outcome of Hispanic
patients treated with FK or cyclosporine (CsA).
Method: Data of 139 Hispanic patients who underwent primary kidney transplant
between Jan 1998 and Dec 2002 were reviewed. We used WHO/ADA criteria for
NODM diagnosis. 37 patients were excluded due to diabetes mellitus pretransplant.
The remaining 102 patients were divided into 2 groups: 37 received FK, and 65
received CsA. We analyzed NODM incidence, acute rejection (ACR). BK virus
and CMV infection rates, patient and graft survival. Median follow-up was 71
mo (20-114). All patients received FK or CsA plus steroids, MMF or rapamycin.
Antibody induction therapy was used in 28 FK (75.7%) and in 32 CsA (49.2%)
patients. ACR was initially treated with steroid and/or anti-thymocyte globulin.
Results: NODM incidences among surviving patients at 6 mo, 1, 3, and
5 y were 24.3%, 27%, 38.2%, and 25% with FK, and 7.7%, 10.2%, 13%,
and 14.9% with CsA (p=0.02, 0.03, 0.006, and 0.36 at 6 mo, 1, 3, and 5 y,
respectively). 4/13 (30.8%) NODM FK patients and only 1/8 (12.5%) NODM
CsA patients received rapamycin (p=0.34). BK virus infection was seen in 4
FK and in 2 CsA patients. CMV infection was seen in 1 FK and in 2 CsA
patients. Noncompliance was recorded in 3 FK and in 2 CsA patients. ACR
rate was 43.2% (16/37) in FK and 27.7% (18/65) in CsA (p=0.1). 5-year graft
and patient survival were 59.5% and 97% in FK, and 76.9% and 98.3% in CsA
(p=0.02 and 0.27, respectively).
Table 1. Patients characteristics and outcome
FK (n=37)
34.615.6
24.75.5
12 (32.4)
16 (43.2)
13 (35.1)
94.6/56.8

Age (y)
BMI (Kg/m2)
DM family history, n (%)
5-y ACR, n (%)
5-y NODM incidence, n (%)
1/5-y graft survival (%)

Figure 1
The dialysis data matrix is structured as time vs. patients (presence/absence
data array). A cluster analysis (complete linkage and percent disagreement)
was chosen to study this type of data.
For therapy data it is possible to build an unfolded 3 way data array; PCA give
the most interesting results, showing relations between patients and drugs, for
each drugs it is possible to see how dosage changed with time.
The Q residual from a PCA on glucose data showed that the sample 1325 it is
an outlier: in fact the glucose value for 1325 was very low on day 0, very high
on day 1 and day 2.
Referring the graft kidney recovery as a discrete two-stage progress, O-PLSDA analysis of NMR spectroscopy data (mean centered data, Pareto scaled).
allow us to estimate a joint intra-person effect that is representative for the
majority of the individuals.

Figure 2
It is moreover evident that patients 1317 didn’t produce similar O-PLS effect as
the others (they show an opposite trajectory) and patient 1325 show only one
stage, that is doesn’t show a clear direction (figure 2). The OPLS profile (biopattern) for all the patients has been tested/validated for all samples.
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CsA (n=65)
31.317.5
26.26.8
16 (24.6)
18 (27.7)
8 (12.3)
100/72.3

p-value

0.006
0.02

MeanSD=, NS=
Conclusion: The incidence of NODM was significantly higher in the FK
group. Patients treated with CsA had lower ACR rate and better graft survival.
Is the higher incidence of NODM contributing to worsening the long-term graft
survival in Hispanic patients treated with FK? Large prospective studies are
needed to guide the use of calcineurin inhibitors in Hispanics.
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1087 THE EFFECT OF SMOKING ON KIDNEY GRAFT
FUNCTION
V. Müller1, P. Gombos1,2, R. Korbely1,2, R. Langer2
1Semmelweis University Department of Pulmonology, 2Semmelweis
University Department of Transplantation and Surgery
Chronic graft loss represents the major problem after transplantation. Smoking is
a well known, however often neglected risk factor of chronic kidney damage.
A survey was conducted among 402 randomly selected kidney graft recipients,
which included questions about smoking habits, Fagerström test of nicotine
dependence. Parallel CO measurement was performed. Clinical data in smokers
and non smokers were compared.
Twenty five% of kidney graft recipients continued smoking after transplantation.
Demographic data did show only difference between smokers and non smokers
in age at transplantation, showing, that smokers receives their grafts at younger
age. Posttransplant kidney function assessed by serum creatinine was not
different in the two groups 1 month after transplantation. Three years after
engraftment significantly decreased serum creatinine was present in the smoker
group. Decline of kidney function correlated with smoking intensity.
Smoking is a preventable risk factor of kidney damage after transplantation.
Effective tobacco dependence treatment is advised in this group of patients as
smoking cessation might contribute to longer preservation of graft function.
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1088 INFLUENCE OF ANGIOTENSINOGEN (AGT)
M235T GENOTYPE AND INSERTION/DELETION (I/D)
POLYMORPHISM OF ANGIOTENSIN-CONVERTING ENZYME
(ACE) GENE ON GLUCOSE METABOLISM IN KIDNEY
TRANSPLANT RECIPIENTS
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1089 DIFFERING INCIDENCES OF POST TRANSPLANT
DIABETES MELLITUS DEPENDING UPON DEFINITION
R. Higgins, M. Lambie, N. West, S. Fletcher, A. Anwar, P. Harrison,
M. Clamp,
University Hospitals of Coventry And Warwickshire
Post transplant diabetes mellitus (PTDM) is a common complication of
transplantation with a significant morbidity and mortality associated, but the
incidence rates vary between studies from 6.5% to as high as 46%. Some of
the variation is due to different definitions used, although an international
consensus group has now published guidelines. To ascertain the incidence in
our centre, we conducted a retrospective audit of all renal transplants between
1998 and 2007.
Data was extracted from the computer system covering all transplants on age,
ethnicity, weight, diabetic status at time of transplant, glucose levels, diabetic
treatment, immunosuppression and outcome. Two or more glucose levels
between 7.1 and 11.1 were defined as impaired glucose tolerance (IGT) and
over 11.1 as PTDM. As 44 patients were transferred at 6 months to another
centre, these were excluded from outcome data.
298 patients with a mean age of 47 (19-76) were included with 83.6% White,
11.4% South Asian and 4.7% Black.
Population (actual
number)
Mean Age

Normal glucose
40.6%
(121)
43

IGT
33.6% (100)
49

Diabetic pre-transplant
8%
(24)
50.2

PTDM
17.8% (53)
51.2

The outcomes were slightly worse in the PTDM group compared with the
normal glucose group – graft functioning 78.7% vs 85.7%, graft failed 4.3% vs
9.5%, patient died 17.0% vs 4.8%.
Of the PTDM group, 19 patients (6.4% of the total) started hypoglycemic
treatment at a median of 68 days (range 6-1399) with 15 starting sulphonylureas,

POSTER BOARD NUMBER P1 – 176
1090 GLUCOSE METABOLISM DISORDERS IN RENAL
TRANSPLANT RECIPIENTS
L.M. Obregon, M.F. Taylor, H. Petrone, M. Baran, M.E. Menna
CRAI Sur CUCAIBA
Objectives: evaluate carbohydrate metabolism in renal transplant patients.
Materials and Methods: we evaluated adult kidney transplant recipients that
fulfilled these criteria of inclusion: more than six months from the transplant,
stable renal function, no rejection in the last 90 days, no infectious episodes or
associated diseases (myocardial infarction, vascular complications, etc.) that
required hospital admission, without diabetes diagnosis (pre transplant diabetes
or post transplant diabetes). and women who were not attending pregnancy,
that acceded to participate in the study. Clinical data were considered: age,
sex, time from transplant, type of donor, circumference of waist, relation waist/
hip, BMI and dose of steroids. An oral glucose tolerance test (OGTT) was
performed, as well as a fasting plasma glucose (FPG) and insulin, HbA1c and
creatinine determination. In addition, we did a retrospective analysis of the
FPG values. Patients were divided in two groups, according to whether they
presented or not altered FGP (GI and GII respectively). We took as reference
values American Diabetes Association’s (ADA’s) ones and we considered as
significant a value of p<0,05.
Results: 40 renal graft recipients were evaluated. By means of OGTT, 3
cases of intolerance to oral glucose (7,5%) and one case of diabetes (2,5%)
were diagnosed. A 62,5% (n=25) presented two or more altered FGP (GI).
When we compared them to the group with normal FGP (GII). we observed a
significant difference in the circumference of waist (94.36 vs 86.41 cm) and a
non significant tendency to higher values of plasma glucose two hours after the
test in the GI. No differences in the other variables were found.
Conclusions: OGTT is a simple test, available and accessible in developing
countries like ours. In our study a 10% with abnormal results were detected. It is
important to consider the historical values of FPG, frequently underestimated,
since it was altered in a 62.5% of these patients. These are significant results in
the prevention of future cardiovascular complications.

POSTER BOARD NUMBER P1 – 177
1091 NEW ONSET DIABETES AFTER TRANSPLANTATION IN
AN AUSTRALIAN COHORT – INCIDENCE AND ASSOCIATED
FACTORS
C.N. Naresh, K. Wyburn, J. Eris, G. Whitman, S. Chadban
Department of Renal Medicine, Royal Prince Alfred Hospital, and University
of Sydney, Australia
Background: New Onset Diabetes After Transplantation (NODAT) is
associated with inferior patient and graft survival after kidney transplantation.
Uncertainty about incidence and causative factors exists and significant
variation between centres is evident. We sought to estimate the incidence and
determine clinical factors associated with the development of NODAT at week
10 after kidney transplantation in an Australian centre.
Methods: Prospective observational cohort study conducted at a tertiary care
university hospital from January 2005 to December 2007. All non-diabetic
patients undergoing kidney transplantation and local follow-up were recruited.
Immunosuppression was determined by the treating physician and at initiation
included steroids in all cases, a monoclonal IL-2Rα receptor antibody (n=
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B. Grandtnerova1, O. Krizanova2
Transplant Centre, Faculty Hospital Martin, 2Institute of Molecular
Physiology and Genetics, Slovak Acedemy of Sciences
Objective: to assess the frequency of I/D polymorphism of ACE gene and
AGT M235T genotype and its impact on glucose metabolism in patients after
kidney transplantation.
Patients and Methods: Medical records of 53 adult Caucasoid patients
covering a period 4th month – 4 years after Tx were included in a retrospective
analysis. Immunosuppression consisted either of CsA (10 Ps) or Tac (39 Ps) or
Rapa (4Ps). All Ps were treated with mycophenolate mofetil or sodium and 10
mg of prednisone. Evaluated groups did not differ in acute rejection episode
incidence and methylprednisolon treatment. PCR-RFLP was used to detect
gene polymorphisms.
Results: Frequencies of ACE gene II: ID: DD genotypes were 34%: 36%: 30%
and TT: TM: MM genotypes of AGT 26%: 47%: 27%. Highest fasting glucose
level was significantly different in TT homozygous individuals in comparison
to MM genotype (mean ± SEM= 8.62 ± 0.78 vs 6.62 ± 0.31 mmol/l, p < 0.05).
differences between I/I vs D/D were not statistically significant (8.31 ± 0.65 vs
7.2 ± 0.43 mmol/l, p= 0.15). Highest HbA1c level was significantly different
in carriers of at least one T allele in comparison to MM genotype (7.67 ± 0.27
vs 6.94 ± 0.26%, p < 0.05). differences between I/I vs D/D were not significant
(7,4 ± 0,2 vs 7,3 ± 0,3%).
Conclusions: Our results suggest influence of RAS polymorphisms on
glucose metabolism after kidney transplantation. Carriage of at least one T
allele (M235T) of AGT was linked to increased fasting glycaemia and HbA1c
during the follow up. If proven in a larger study, prospective genotyping of
RAS on the waiting list could help to further individualization of posttransplant
immunosuppressive strategy, with a special regard to metabolic syndrome, e.g.
steroid avoidance or minimalization.

1

3 starting insulin, 1 starting a biguanide and 5 subsequently converted
to insulin. The mean age was 51.2, the mean HbA1c was 6.8, and the mean
Tacrolimus levels over the first 3 months were 12.7 vs 12.5 for the normal
glucose population. Of these 19 patients, 6 had their hypoglycemic treatment
successfully withdrawn, leaving 4.4% of the total group on treatment. In the
group diagnosed as having PTDM, only 15 of 33 had their HbA1c checked, with
a mean value of 6.1 (4.5-8.2).
This audit demonstrates the significant difference in calculated incidence of
PTDM depending upon the definition used. Our rates range from 17.8% for 2
or more random glucose levels over 11.1 at any time post transplant, contrasting
with lower rates from other units who excluded glucose levels from a variable
time post transplant, to 6.4% for those requiring treatment, to 4.4% for those
remaining on treatment.
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94). a calcineurin inhibitor (n=104). plus mycophenolate (n=92) or a mTOR
inhibitor (n=13). Participants were subjected to a 2-hour oral glucose tolerance
test (OGTT) at 10 weeks post-transplantation, except for those receiving oral
hypoglycaemic agents or insulin. Primary outcome measure was NODAT,
defined by requirement for hypoglycaemic therapy or a positive OGTT (fasting
blood glucose > 7.0 mmol/L or a 2-hour glucose > 11.1mmol/L). A multivariate
analysis of clinical factors associated with NODAT was undertaken.
Results: 134 patients were recruited; 3 incurred early graft loss and 131 were
included. 48 participants (36.6%) developed NODAT. Tacrolimus usage was
strongly associated with NODAT, ORadj 6.54, χ2 = 37.55 (6df). p <0.0001
(95%CI 2.38 – 17.98). This increased risk was independent of recipient age,
hepatitis C status, weight at the time of transplantation, body mass index &
weight gain at 10 weeks post-transplantation. NODAT was observed more
often in patients treated with tacrolimus compared to cyclosporin (58.3% vs
21.8%; p = 0.0008).
Variables
N
OR
95% CI
χ2
p Value Pseudo R2
At the time of Renal Transplantation
Impaired OGTT*
8
3.17
0.72 – 13.94
2.44 0.12
0.01
Age >50 years
69
1.88
0.91 – 3.89
2.96 0.09
0.02
BMI > 25
80
0.96
0.46 – 1.98
0.01 0.9
0.0001
Hepatitis C positive
3
0.68
0.06 – 7.78
0.01 0.8
0.0006
Tacrolimus use
63
3.35
1.59 – 7.81
10.61 0.001
0.06
Cyclosporin A use
41
0.44
0.19 – 1.01
4.01 0.05
0.02
At 10 weeks post Renal transplantation
Weight gain (≥4Kg increase)
51
0.19
0.08 – 0.45
16.92 <0.0001 0.1
Receiving Tacrolimus
60
6.25
2.83 – 13.77
23.01 <0.0001 0.1
Receiving Cyclosporin A
32
0.40
0.16 – 1.0
4.21 0.04
0.02
BMI>25
82
0.75
0.36 – 1.56
0.58 0.4
0.003
Tacrolimus use ◊
60
6.54
2.38 – 17.98
37.55 <0.0001 0.3
Cyclosporin A use◊
32
0.15
0.04 – 0.51
33.31 <0.0001 0.2
*Impaired OGTT is defined as 2-hour post prandial BGL > 7.8 mmol/L
◊Adjusted for HCV status, Age & weight at transplantation, BMI & weight gain at 10 weeks

Conclusions: NODAT was extremely common and strongly associated
with the use of tacrolimus, either as initial therapy or following switch from
cyclosporine or mTOR. This rate is higher than in other published reports and
reasons for this require exploration. Risk of NODAT should be considered in
initial choice of calcineurin inhibitor.

POSTER BOARD NUMBER P1 – 178
1092 ORAL FRUCTOSE LOAD INDUCED HYPERURICEMIA
IN RENAL TRANSPLANT PATIENTS TREATED
WITH TACROLIMUS- OR CYCLOSPORINE BASED
IMMUNOSUPPRESSION
M. Nowicki, A. Zawiasa, I. Kurnatowska, J.F. Morawska
Medical University of Lodz, Dept. Nephrology, Hypertension And Kidney
Transplantation
An increase in the prevalence and incidence of hyperuricemia and gout over
the past few decades coincided with a substantial increase in the consumption
of fructose-sweetened soft drinks and fructose. Acute oral administration
of fructose results in a rapid increase in serum levels of uric acid through
accentuated degradation of purine nucleotides and increased purine synthesis.
Hyperuricemia has been implicated in the pathogenesis of both cardiovascular
and renal disease and is a common finding in organ transplant patients where
it was found to adversely affect graft function. Hyperuricemia is also a well
known adverse effect of cyclosporine A. Data regarding the effect of tacrolimus
have been contradictory.
The aim of the study was to compare the effect of an acute oral fructose load
on serum uric acid, plasma lipids and blood pressure in stable (mean GFR 55
ml/min). long-term (5.1±;4 years post-Tx) kidney transplant patients treated
with cyclosporine- or tacrolimus-based triple (CNI+MMF+prednisone)
immunosuppressive protocol (25 patients in each group). All patients received
75 g of fructose per os and the blood was withdrawn for biochemistry at
baseline and after 60, 90, 120 and 180 minutes.
Both groups did not differ with respect to age, BMI, time after Tx, GFR, and
plasma lipids. In both groups a significant increase of serum uric acid was
observed after an oral fructose administration (from 456±;84 to 494±;91
μ;mol/l in CyA treated and from 438±;104 to 470±;109 μ;mol/l in Tac treated
patients) (p<0.001 in both groups). The maximal increase of serum uric acid
was observed 90 minutes after fructose intake (to 495±;97 and 484±;109
μ;mol/l, respectively). Plasma total, LDL and HDL cholesterol did not change
after the fructose load in both groups but there was a significant increase of
plasma triglycerides from baseline in both groups (0.23±;0,30 vs 0.19±;0,24
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mmol/l, respectively, p=0.02). Blood pressure tended to be lower at baseline in
Tac than in CyA treated patients (mean arterial pressure 103±;14 and 97±;16
mmHg, respectively, p=0.1) but no change of blood pressure was recorded after
the fructose intake in both groups.
Conclusion: Oral fructose intake causes an acute rise of serum uric acid and
triglycerides in kidney transplant patients that is similar in both Cya and Tac
treated patients.

POSTER BOARD NUMBER P1 – 179
1093 USEFULNESS OF ORAL GTT IN PREDICTING AND
MANAGING DM ON RENAL TRANSPLANT RECIPIENTS IN A
SOUTH INDIAN HOSPITAL SETTINGS
G. Abraham1, R. Chandran2, N. Fathima2, M. Mathew2, S. Soundarajan2
1
Sri Ramachandra University, Chennai, 2Madras Medical Mission, Hospital,
Chennai
Aim: To evaluate the usefulness of GTT, hip and waist ratio as a tool for
screening the risk of NODAT.
Patients & Methods: Study included non diabetic (M – 57, F-20) renal
transplant recipients from January 2005 to June 2007 with mean age of 36.9
years. All the patients were inducted with Basiliximab or Daclizimab, base
line IS with prednisolone (0.5mg/kg) – Aza/MMF/CSA/FK506/Rapamycin.
Prednisolone was reduced to 2.5 to 7.5mg in 6 months. Family H/O diabetes
and Pre and post transplant weight recorded. Oral GTT was done with Glucose
75mg before and within 8 to 30 days after transplantation (serum creatinine
stabilized to ≤ 1.5mg/dl). Based on GTT patients were grouped as normal, IGT
and diabetes. Hip and waist ratio taken for all patients on before discharge from
hospital and 2 months later. The population included Indian- 33, Srilankan –
10, Nepalese – 19, Tanzian – 10, and Seychelles – 5.
Results: Out of 77 patients, 12 patients (15.5%) developed NODAT and 21
(27.2%) developed IGT. 22 patients had BPAR of various BANFF grades
requiring Inj. Methyl Prednisolone. Normal GTT (Pre Tx) in 56 (Male – 42,
female – 14). abnormal (IGT) in 21. Out of the 56 patients who had normal
GTT (pre Tx). post Tx normal GTT in 39 (69.6%). IGT in 7 (12.5%) and DM
requiring therapy in 10 (17.8%) Among 21 patients with IGT (pre Tx). DM
developed in 2 (9.52%) and IGT in 12 (57.1%).
IMMUNOSUPPRESENT REGIMENT:
Cyclosporine/MMF/Steroids
Tacrolimus/MMF/Steroids

No. of Pts
57
20

No. of DM
6 (10.52%)
6 (30%) p<0.05

Hip waist ratio was 0.97 in 39 patients with normal GTT (men 29 and women
10) and those who developed DM 0.95 (men 09 and women 03) which
was not significant. Pre and Post transplant weight of these patient showed
insignificance in predicting NODAT.
Conclusion: The oral GTT was useful tool in diagnosing DM early and IGT.
More patients in Tacrolimus group developed DM. Hip waist ratio is not
predictive of development of DM or IGT. Pre and post weight is not predictive
of development of DM or IGT. Steroid free immunosuppression is costly in
Indian subcontinent, hence this data helped in modifying immunosuppressive
therapy, dietary regimen, exercise for NODAT patients.

POSTER BOARD NUMBER P1 – 180
1094 RENAL TRANSPLANT OUTCOME IN DIABETIC
PATIENTS
F. Jawad, R. Shaikh, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Objectives: To compare one year’s outcome of diabetics subjected to renal
transplantation (RTx) with matched non-diabetics as controls.
Methods: All diabetics, with a first live related RTx from October 1994 to April
2007 were included. A control group comprised of non-diabetics, matching
with respect to time of transplant, sex, age, pre Tx dialysis period and post Tx
immunosuppressive regime. The variables studied were one-year patient and
graft survival, acute and chronic rejection episodes, systemic infections and
wound status.
Results: There study included 55 diabetics (Group 1) and 55 non-diabetics
(Group 2). having undergone Tx surgery within a span of 3 months of each
other. There were 46 males and 9 females in each group, with a mean age of
40.9±7.5 and 39.7±6.7 years respectively. In Group 2 Hypertension was the
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1095 STEADY AND STRICTLY LINEAR RISE IN BODY MASS
INDEX AMONG RENAL TRANSPLANT RECIPIENTS AT UCLA
FROM 2002 TO 2006
S. Bunnapradist1, B.R. Madhira1, J. Gill1, M. Low2, G. Danovitch1,
K. Kalantar-Zadeh2
1
UCLA Kidney Transplant Program, 2Harbor-UCLA Harold Simmons Center,
Los Angeles and Torrance, CA
Background: Obesity is on the rise both in the general population and among
renal transplant recipients (RTRs) and may lead to technical problems during
the transplantation surgery and immediate post-operative era. Since California
has one of the highest obesity incidence and prevalence rates in the nation, we
examined the rate of increase in body mass index (BMI) in the 21st century
among RTR in UCLA.
Methods: We collected data from all adult RTRs between January 1997 and
December 2007 in the UCLA kidney transplant center.
Results: A total of 2,396 RTRs were identified at UCLA between 1997
and 2007; 67% were deceased donor transplants, 22% living related and
11% living unrelated. RTR age was 46.7±3.5 yrs; 59% were men, 63%
White, 7% Black and 10% Asian. The baseline BMI, available in 994
RTRs on the day of transplant from 2002 to 2006, was 25.9± 5.2kg/m2
(mean±SD). A strictly linear and steady increase in BMI was noticed across
5 years of observation (r=0.99, p<0.0001) with this regression equation:
BMI=0.39*YEAR-766.

Conclusions: Among UCLA RTR at the dawn of the 21st century, the baseline
BMI shows a strikingly constant and significant increase of 0.39 kg/m2 per
year. The clinical and public health implications of this constant increase in
baseline weight at transplant on the outcomes of kidney transplantation need to
be examined in longitudinal studies.

POSTER BOARD NUMBER P1 – 182
1096 DISCREPANCIES OF BODY MASS INDEX AT THE TIME
OF KIDNEY TRANSPLANT ACROSS GENDER, RACE AND
TRANPLANT TYPE AT UCLA
S. Bunnapradist1, B.R. Madhira1, J. Gill1, M. Low2, G.M. Danovitch1,
K. Kalantar-Zadeh2
1
UCLA Kidney Transplant Program, 2Harbor-UCLA Harold Simmons Center,
Los Angeles and Torrance, CA
Background: Conflicting results have been reported regarding the association
of body mass index (BMI) and graft and patient survival in renal transplant
recipients (RTR). We hypothesized that significant baseline BMI discrepancies
across gender, races/ethnicities or donor status may be a relevant factor to that
end.
Methods: We collected data from all adult RTRs between January 2002 and
December 2006 in the UCLA kidney transplant center.
Results: A total of 1368 RTRs at UCLA were performed at that time. RTR
age was 46.7±3.5 yrs; 60% were men, 56% White, 17% Black and 16% Asian.
Mean Pre-transplant dialysis time was 1,371±1,265 days (median: 848, IQR:
472-1,784]. Using electronic data record the baseline BMI, available in 993
RTRs on the day of transplant, was 25.9±5.1 kg/m2 (mean±SD).
Donor type Overall

Men

Women

Whites

Blacks

Asians

Living

25.7±4.8

26.5±4.2

24.6±5.4

25.5±4.7

28.2±5.0

24.5±4.4

Others
26.2±5.6

Deceased

26.1±5.2

26.4±5.4

25.6±5.1

26.2±5.1

27.2±5.9

24.2±4.1

25.7±5.2

Conclusions: Hence, among Black and female RTRs at UCLA, a living renal
transplant was associated with 1.0 kg/m2 higher BMI than deceased transplant,
whereas in Whites an opposite trend (0.7 kg/m2 lower BMI) was observed.
Asians RTR have the lowest BMI compared to other races. Longitudinal studies
need to examine whether the found discrepancies have significant clinical and
public health implications in RTR outcomes.

CONCURRENT ORAL SESSION 82: SURGICAL
COMPLICATIONS
POSTER BOARD NUMBER P1 – 183
1097 SURGICAL COMPLICATIONS AFTER KIDNEY
TRANSPLANTATION (KT) IN CHILDREN: AN
OBSERVATIONAL SPANISH STUDY
R. Vilalta, M. Navarro, J. Govantes, I. Zamora, G. Ariceta, A. Luque,
A. Vila, A. Muriel, F.J. Burgos, J. Pascual
For the Spanish Paediatric Kidney Transplant Survey
Abstract Document: Surgical complications are not very frequent in
children receiving a renal allograft. We have reviewed all the pediatric
KidneyTransplantKT performed in Spain during the year 2004 followedup for one year, to assess the prevalence of vascular, urological and wound
complications. During the study period, 65 patients (<18years.) received a KT
and one a kidney-liver in the 7 Spanish pediatric KT units. Mean donor age
was 19.8±13.4 years, 58 (88%) were deceased donors and 7 living donors.
Mean pre-harvesting SCr was 0.8. The cause of donor death was trauma in
63% of cases. Recipient age was 12.3±5 years, 61% were males, mean BMI
was 19 kg/m2, peak PRA was 12.4±25.9%, time on dialysis had been 12±23.8
months and 23% were retransplantations. Urinary tract anomalies were present
before transplant in one third of cases. Immunosuppression was always based
on Tacrolimus or CsA, MMF and steroids. Sirolimus was never used initially.
Double J ureteral stent was used in 8 cases (12%). Six patients (9%) showed
delayed graft function and 7 (11%) acute rejection episodes.
Surgical complications are detailed in the table.
Complication

n

%

CI (95% )

Wound problem (Non-infectious)

3

4,5

1-13

Wound infection

0

Perigraft fluid collection

10

15,2

8-26

Lymphocele

4

6,1

2-15

Hematoma

5

7,6

3-17

Urinoma

1

1,5

0-8

Vascular

6

9,1

4-21

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

375

MONDAY

cause of renal failure in 25 cases, stone disease in 7, Glomerulonephritis in
3 and 20 with unknown etiology. The pre-Tx dialysis period was 12.5±10.5
and 9.7±4.6 months, in-group 1 and 2 respectively. Hypertension was
present in 50 diabetics and 45 non-diabetics. The acute and chronic rejection
episodes of the two groups had no significant difference. Post Tx infections
were similar in the two groups with urinary tract infections having the
highest frequency (24 in Group-1 and 20 in Group-2). Wound infection and
dehiscence was significant in the diabetic patients (17 and 4 respectively)
with 5 wound infections in Group 2. Three patients from Group 1 suffered
an acute myocardial infarction. There was no cardiovascular morbidity
in Group 2. One-year graft survival was 84% and 94% in Group 1 and 2
respectively. One-year patient survival was 89.6% and 94% in the two groups
respectively.
Conclusion: One-year graft and patient survival was similar in the diabetic
and non-diabetic control subjects. Wound infection and dehiscence were more
in diabetic subjects.
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Arterial or venous Thrombosis

4

6,1

2-15

Renal artery stenosis

1

1,5

0-8

Iliac artery thrombosis

1

1,5

0-8

Urinary leak

2

3,0

0-11

Bladder

1

1,5

0-8

Ureteral or ureterovesical

1

1,5

0-8

Urinary Stenosis/Obstruction

6

9,1

3-17

Ureteral or ureterovesical

4

6,1

2-15

Pyeloureteral

2

3,0

0-11

The incidences complications were not significantly different to those observed
in the adult population during the same period in Spain. Vascular thrombosis
was more frequent in children (6.1 vs 3% in adults). Seven grafts (10.6%) were
lost during the first year ;the most frequent cause was vascular thrombosis
(n=4). Patient survival was 100%. Surgical complications in children are
frequent after KT, and adequate prophylactic measures are encouraged, to
prevent vascular and urological problems.
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1098 SUCCESSFUL RENAL TRANSPLANTATÝON
AFTER ENDOVASCULAR STENT PLACEMENT OF TASC
(TRANSATLANTÝC INTER-SOCÝETY CONSENSUS) TYPE B
AORTOÝLÝAC OCCLUSÝVE DÝSEASE
A. Demýrag, G. Kantarci, M. Kalayci, B. Ekcý, T. Gulcelýk, O. Gokce
Yeditepe Univ Hospital
The occurrence of aortoiliac lesions with renal transplantation is an increasingly
common combination that causes problems regarding operative strategy and
indications for aortoiliac reconstruction and renal transplantation. Staged or
simultaneous surgical repair of aortoiliac lesions with renal transplantation
is possible at reasonable risk. Renal transplantation after repair of aortoiliac
occlusive disease with traditional prosthetic vascular grafts has been shown
to be effective.
Interventional radiology continues to rapidly evolve, most notably with the
advancement of PTA/stent placement of aortoiliac lesions. Trials continue to
support the trend toward the use of endovascular aortic stent grafts in patients
with TASC type A, B, C and D aortoiliac lesions. Literature data are still scarce
regarding renal transplantation after endovascular stent placement of TASC
type B aortoiliac lesions. Here, we describe the first renal transplant in a patient
with disabling claudication and TASC type B aortoiliac disease which treated
with an endovascular aortoiliac stent graft (figure 1). ABI (ankle-brachial
index) before and after the stent placement were 0.6 vs. 1.2 respectively.
No intraoperative difficulties were encountered. At 1 year follow-up, the
transplanted kidney is functioning well with a normal serum creatinine level
of 1.2 mg/dl, and the patient has no worsening of peripheral vascular disease
with ABI 1.28 (figure 2). We recommend that percutaneous intervention can be
recommended for patients with TASC type B aortoiliac disease and the presence
of an endovascular aortoiliac stent not be a contraindication to perform a renal
transplantation.

Figure 1 Endovascular aortoiliac stent graft before renal transplantation.
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Figue 2 Duplex ultrasonography transplanted kidney

POSTER BOARD NUMBER P1 – 185
1099 DONOR AGE AFFECTS IMMEDIATE BUT
NOT LONGTERM SURVIVAL FOLLOWING KIDNEY
TRANSPLANTATION
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy
1
Cairo University, 2Cairo University, Department of Urology, 3Cairo
University, Department of Clinical Pathology
Organ shortage has resulted in an increased use of elderly related donors
(>55years) for kidney transplantation (RTx). The aim of this study is to
re-examine, in a modern era of transplantation, the effect of donor age on
outcomes following RTx. In addition, we compared the effect of old donor
kidneys onoutcomes following transplantation between young and old
recipients.
Methods: Data was collected in a prospective clinical database on 79 patients
receiving live kidney transplantation between January 1998 and October 2005.
Donor and recipient age were analyzed as continuous and categorical variables.
Univariate and multivariate regression analysis were performed investigating
donor and recipient age, ischemia time, recipient gender, hepatitis C infection,
CMV status for both donor and recipients, year of transplantation,and original
renal disease. Postoperative outcomes were assessed by development of
acute tubular necrosis, length of hospital stay, postoperative serum creatinine,
development of rejection, calcineurine drug toxicity, graft failure, and patient
survival.
Results: As expected, postoperative creatinine was predicted by ischemia
time. When the influence of donor and recipient age was examined, we found
that an increased donor age was associated in univariate analysis with the max
postoperative serum creatinine, calcineurine toxicity and degree of oliguria.
This association held true in multivariate analysis for BUN,serum creatinine
and GGT levels. Recipient age was associated in univariate analysis only
with increased max ALT, an associationthat did not persist upon multivariate
regression analysis. Combining older donor kidneys with young (<40 years) or
old >55 years) recipients resulted in identical peri-operative outcomes. Graft
and patient survival was identical between patients receiving from old or young
donors. Combining old donors and old recipients did not result in worsened
ong-tem survival.
Conclusion: The use of old donor kidneys for RTx is associated with increased
indices of reperfusion injury and calcineurine toxicity in the immediate
postoperative period. However, recipient survival is not affected by the age of
the donor, and the age of the recipient receiving the older donor kidney does not
affect short or long-term results. This study provides evidence for the safety of
using older kidney grafts.
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1100 NON HEARTBEATING KIDNEY DONATION AT GROOTE
SCHUUR HOSPITAL: RESULTS 2006-2007

POSTER BOARD NUMBER P1 – 187
1101 DGF RISK INDEX (ACCORDING SRTR) FAILS TO
PREDICT DGF REAL INCIDENCE IN A MONOCENTRIC
EXPERIENCE WITH VERY OLD CADAVERIC DONORS.
E. Bertoni, M. Salvadori
Renal Unit Careggi University Hospital
The DGF Risk Index (0-18, with 0 being the lowest risk of DGF) was derived
from an analysis of deceased donor renal transplants by SRTR and was based
upon five predictor variables independently associated with DGF: donor age, cold
ischemia time, recipient race, cause of death and prior kidney transplantation.
Aim of this study was to verify whether the predicted probability of DGF fit
well in the case of very old kidney donors, as in our regional program.
Our regional program has the highest number of cadaveric donors in Italy and
oneof the highest in Europe (40.9 actual donors p.m.p.). mostly because of old
donors (>60yrs). We divided our donors in 3 periods according era (91-96 (A).
97-02 (B). 03-08 (C) ) and evaluated for each period the incidence of donors
>60 yrs, the predicted probability of DGF for such donors according the DGF
Risk Index above mentioned and the observed DGF.
Overall we had 638 cadaveric renal transplantation, 126 in period A, 253 in
period B, 259 in period C. Donors over 60 yrs were respectively 6.5%, 30%,
39.8%; p<0.0001. The observed overall DGF incidence increased by era (19%,
26.5%, 30.9%; p<0.01).Transplants with DGF Risk Index ³ 7 were respectively
16/126, 107/253 and 128/259; p<0.0001. According to SRTR DGF Risk Index,
a score ³ 7 bears a probability of DGF of 0.79 (CI 0.75-0.81). In our patients

POSTER BOARD NUMBER P1 – 188
1102 COLD PRESERVATION INDUCES A STRONG
ADDITIONAL DAMAGE IN GRAFTS FROM BRAIN-DEAD
DONOR RATS
B. Yard, S. Hoeger, K. Petrov, A. Reisenbuechler, R. Waldherr, P. Schnuelle,
Department of Nephrology, University Hospital Mannheim, University of
Heidelberg
Brain death and cold preservation are both alloantigen-independent risk factors
which could deteriorate the graft. In the present study we addressed to what
extent these alloantigen-independent factors could accelerate the hurtful effects
of each other.
Experiments were performed in the allogeneic Fisher-Lewis rat model. Brain
death (BD) was induced in F344 rats and duration of brain death was 6 hrs in all
experiments. Either with or without 24 hours of cold preservation (Cp) grafts
were transplanted into Lewis recipients. Living donor animals (LD) served as
controls. In order to evaluate renal inflammation, the transplanted kidneys were
harvested after 10 days.
Combination of brain death and cold preservation accelerated renal inflammation
and the number of TUNEL-positive cells. Infiltrating cells (ED1+ and MHCII+)
and cytokines (e.g. VEGF, IL-10) were significantly increased in grafts from
brain dead rats which were subjected to Cp compared to directly transplanted
grafts or grafts from LD donors.
The data indicate that cold ischemia time should be minimized in grafts from
deceased donors to prevent drastic aggravation of graft injury.

POSTER BOARD NUMBER P1 – 189
1103 IMPACT OF DONOR AGE IN A STANDARD DONOR
POPULATION ON THE PRESENCE OR ABSENCE OF DELAYED
GRAFT FUNCTION IN OUR CENTER- RETROSPECTIVE
ANALYSIS
M. Kandarpa1, S. Subramanian1, S. Aure1, K. Samindla1, R. Raja1, R. Zaki2,
S-C. Kung1
1
Kraftsow Division of Nephrology, Albert Einstein Medical Center, 2Division
of Transplantation, Albert Einstein Medical Center
Delayed graft function (DGF) is a principal factor affecting one-year graft
survival. It is well known from previous studies that kidneys from standard
donors have better long-term outcomes.
We sought to find out if donor age was an important determinant of DGF in the
standard donor population pool.
We did a retrospective analysis of standard kidney transplant cadaveric donors
and attempted to find out if there was a correlation between the donor age and the
presence or absence of DGF. We included all the patients who received a single
kidney from a standard donor as defined by UNOS in our center from 2003 to
2005. Patients who were lost to follow up, patients who received dual kidneys
from standard donors and those that received bloc single organs were excluded.
Data from a total of 188 patients were included in this retrospective analysis.
We found that there was a significant correlation (p = 0.010) between a younger
donor age and the absence of delayed graft function in the recipient. Of interest
recipient’s age did not have a statistically significant impact (p = 0.699) on the
presence or absence of DGF.
This study suggests that kidney from a standard donor population, the donor
age has a significant impact on the presence or absence of DGF. The reason for
this is unclear, further study is needed.
Correlation between Donor age and DGF
DGF (N=53)
No DGF (N=135)
P Value
Mean Age (±SD)
41.33 ± 12.33
35.60 ± 14.11
0.010
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E. Muller, D. Kahn
University of Cape Town
Background: A non heart beating kidney donation programme was started in
January 2006 at Groote Schuur Hospital. The current head injury policy is to
withdraw treatment in patients with irreversible brain damage and a Glasgow
Coma Scale under 5T. The objective of the non heart beating policy is to
address this group of patients as potential donors.
Method: After consent is given for organ donation, the patient is extubated
while the surgeon who will do the procurement stands ready in theatre.
If the patient has a cardiac arrest within a 2 hour time span, the patient is
taken to theatre immediately after death and the organs are retrieved. If the
patient does not arrest in that time span, the procedure is abandoned. After
procurement the cold ischaemic time is kept as short as possible. Recipients
with no previous transplants and low antibody status are used. Initially standard
immunosuppression with Cyclosporin, Azathioprine and Medrol was used from
day 1. Subsequently the policy in the unit has changed and Simulect induction
therapy is now being used, with Cyclosporin started on day 3-5.
Results: In the time period between January 2006 and December 2007, 7
referrals for non heartbeating kidney donation were made to the Transplant
Coordinators at Groote Schuur Hospital. All the donors were male patients with
an average age of 31. The cause of death was gunshot wounds in 3 cases, a
stab wound in 1 case, suicide in 1 case and motor vehicle accidents in 2 cases.
Consent for donation was given in 6 cases. Of the 6 cases, 2 did not arrest in the
2 hour time span; 1 patient had an unexpected cardiac arrest before extubation,
but was successfully procured in theatre within 30 minutes; and 3 patients
arrested within the 2 hour period after extubation.
Of the 8 kidneys harvested, 2 kidneys could not be used because they were
from a AB-blood group donor and there were no suitable recipients available.
Six kidneys were transplanted with an average cold ischaemic time of 12 hours.
Five patients required dialysis in the first week, 4 in the second week, 2 in
the third week and none in the fourth week post transplantation. Renograms
were done on 5 patients in the first week, 2 in the second week and 2 in the
third week. Four of the patients required a biopsy in week 2 or 3 and 2 of
these patients had subsequent treatment with pulsed Medrol. One patient had
a wound infection as well as a post-operative Klebsiella pneumonia. Four
patients were discharged on day 17, one on day 31 and one on day 63 after
severe complications with sepsis and pneumonia. All patients had functioning
grafts on discharge.

with such score the observed DGF rate was 37.5%, 32.7%, 42.9% according
the period. DGF observed rate was almost the half of DGF predicted rate.
The DGF Risk Index do not predict the real DGF rate in the case of old donors.
This fact may be ascribed to several factors. A regional allocation program may
have several advantage with respect to a national one. Donor management in
ICU, shorter cold ischemia time, higher surgeon skill in retrieval and transplant
such kidneys, better management of immunosuppressant drugs cause that data
from a large national cohort can’t fit to a regional program.
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1104 CYSTIC CHANGES OF THE BREAST IN A FAMILY WITH
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
(ADPKD)
A. Ghafari
Urmia University of Medical Sciences
Background: There is no report of cystic changes of the breast in ADPKD.
We describe three members of a family with multiple bilateral breast cysts in
association with ADPKD.
Case Report: A 21-year-old girl referred to our center for evaluation of
bilateral breast masses. On breast examination there were no dysmorphic
or abnormal cutaneous findings, the patient had a 30×30×50 mm mass
in her right and a 20×20×20 mm mass in her left breast. On the family
history her paternal grandfather and her brother died due to renal failure.
Her 59-year-old father and two sisters have done renal transplantation
because of end stage renal disease due to ADPKD. One of her sisters was
evaluated for bilateral breast masses two years after renal transplantation
and multiple bilateral breast Cysts confirmed by mammography and
ultrasonography. The patients refused aspiration of the cyst and accepted
to be followed up and had no problem until now. Another transplanted
sister has also same bilateral breast Cysts. With the known family history
of ADPKD, an abdominal and breasts ultrasonography was obtained for
possible association and showed renal cortical cysts, a small liver cyst and
multiple bilateral breast Cysts leading to the diagnosis of asymptomatic
ADPKD. Aspiration of breast cysts was considered but she refused it and
accepted to be followed up. In her 6th month of follow-up cysts persist,
inducing some pain in her right breast.
Conclusion: To our knowledge this is the first report of familial occurrence of
multiple bilateral breast Cysts in association with ADPKD.

POSTER BOARD NUMBER P1 – 191
1105 GRAFT FUNCTION IN HAND ASSISTED
RETROPERITONEOSCOPIC DONOR NEPHRECTOMIES WITH
MULTIPLE ADHESIONS
M. Hossain, C. Kirby, J. Fronek
St George’s Hospital Department of Renal Transplantation
Introduction: In the absence of national guidelines, a retrospective audit
was undertaken to review the current renal transplant immunosuppression
regime. There was a perception that the new Tacrolimus target level (8–10ng/
ml) introduced in May 2007 was too low and more rejections observed. Our
current maintenance protocol includes prednisolone, Mycophenolate Mofetil
and Tacrolimus.
Methods: All transplant recipients (Feb 2003-Oct 2007) were reviewed for the
highest C0 (trough) Tacrolimus level achieved within 7 days post-transplant.
Tacrolimus level of 10ng/ml was considered a cut-of as it represents the highest
target in the current protocol. Rejection episodes within the first 10 days posttransplant were recorded.
Results: This audit included 277 renal transplant recipients. Tacrolimus
levels were ≥;10ng/ml (high group) in 223 (80.5%) and <10ng/ml (low
group) in 54 (19.5%) recipients. Of the low group, 11 (20.4%) had rejection
compared to 22 (9.9%) of the high group (p=0.03). There was a difference
between recipients with high and low Tacrolimus levels with respect to GFR
(MDRD) levels at one year post-transplant, with a mean of 36.7±21.2 in
31 recipients with high Tacrolimus levels compared to 40.7±24.5 in 246
recipients with low Tacrolimus levels (p=0.4). Lower GFR levels (31.1±22.5)
in rejecting compared with non-rejecting (41.4±24.1) recipients observed
(p=0.02).
Conclusion: Trough Tacrolimus level <10ng/mL was associated with more
rejection episodes. The authors feel that the current Tacrolimus target, 8-10ng/
mL is low and needs revision. While rejection and high Tacrolimus level have
adverse effects on the GFR at 1 year, this was not statistically significant when
comparing Tacrolimus level groups (sample size).
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1106 DESFERRIOXAMINE DECREASES ISCHAEMIA
REPERFUSION INJURY TO THE KIDNEY
R. Stokes, K. Cheng, J. Gunton
Garvan Institute of Medical Research
A common phenomenon following whole kidney transplantation is primary
non-function in recipients. This is due to hypoxia followed by reperfusion and
various other stressors. Acute Tubular Necrosis (ATN) with damage to tubular
epithelial cells is the mechanism which contributes to this acute deterioration
of renal function. Desferrioxamine (DFO). an iron-chelator is a non-toxic
stabilizer of HIF1-alpha, which is a transcription factor required for a protective
response to hypoxic insult. We hypothesised that giving Desferrioxamine prior
to organ retrieval would reduce the severity of ischaemia reperfusion injury by
increasing protein levels of the anti-apoptotic transcription factor HIF-1alpha.
Aim: To investigate whether increasing Desferrioxamine (DFO) decreases
renal ischaemia-reperfusion injury.
Methods: C57bl/6 mice were exposed to renal ischaemia-reperfusion injury.
The insult was achieved by temporarily clamping the renal arterial supply to
the left kidney for 7 minutes. One week later, the right kidney was surgically
removed and saved for histological analysis. Two days later the mice were
euthanased. Plasma was collected for urea and creatinine for analysis of residual
renal function. The left kidney was also collected for histological analysis.
Two groups were used (1) control mice given a saline intraperitoneal injection
prior to clamping and (2) mice given a single DFO injection intraperitoneally
prior to injury.
Results: Desferrioxamine treated mice had markedly lower urea and creatinine
levels than controls. Control mice had an average Urea of 40.6±10.8 versus
DFO 9.7±2.0 (4.2-fold higher in controls, p<0.03). Control mice had an average
Creatinine of 91.3±26.6 compared to DFO 14.4±3.1 (6.3-fold difference,
p<0.03). Consistent with this, histological analysis showed markedly less
damage and cell death in the DFO-treated mice compared to the controls. This
data shows that DFO significantly reduces the degree of kidney damage caused
by ischaemia-reperfusion injury.
Conclusions: DFO markedly decreased ischaemia-reperfusion injury, and
histological damage to the kidney. Increasing HIF1-alpha via DFO treatment
of either the donor or the transplant recipient, or both may reduce the frequency
and severity of ATN after kidney transplantation. This in turn has potential to
improve human kidney transplant outcomes.

POSTER BOARD NUMBER P1 – 193
1107 DONOR RISK FACTORS FOR DELAYED
GRAFT FUNCTION (DGF) IN CADAVERIC RENAL
TRANSPLANTATION (RTX)
A. Amoroso1, R. Giraudi2, M. Meucci3, F. Fop2, P. Magistroni1, R. Bosco4, R.
Giacometti1, S. Roggero1, P. Stratta5, G.P. Segoloni2
1
Regional Transplantation Center of Piedmont, 2Nephrology, Dialysis
and Transplantation- University of Turin, 3Hospital of Aosta, 4Regional
Procurement Center- Hospital San Giovanni Battista, 5Nephrology and
Transplantation- University of Novara
Introduction and Aims: Delayed graft function (DGF). defined as the need
of dialysis within one week following rTx, is a common post-transplant
complication. The usual rate of DGF is 10% to 40% and depends on many
variables.
The purpose of this study is to evaluate donor risk factors for DGF, to determine
which therapeutic strategies are correct to prevent DGF in the setting of donor
management and to evaluated some pre-transplant recipient risk factors.
Methods: In this retrospective study, all primary deceased donor, between
January 2000 and December 2006, were identified in Oracle database of the
Regional Transplantation Centre of Piemonte and Valle d’Aosta. We analyzed
562 consecutive donors from 32 Intensive Care Units (ICU) and 1073 renal
recipients transplanted in the two big Centres.
Regarding donor, DGF was compared with age, sex, cause of death, body
max index (BMI). history of hypertension and diabete, renal function, days
in ICU, central venous pressure, blood pressure, hypotensive period, cardiac
resuscitation, use of catecholamine, cold ischemia time (CIT) and renal biopsy,
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1108 MANAGEMENT AND LONG-TERM OUTCOMES OF
WOUND-HEALING COMPLICATIONS ASSOCIATED WITH
RAPAMYCIN
T. Taner, P. Dean, N. Tran, M. Stegall
Mayo Clinic
Background: Steroid– and calcineurin inhibitor-sparing immunosuppression
regimens are increasingly being used in allograft recipients to avoid long-term
toxicities of these agents. Rapamycin, with its unique mechanism of action, has
been used to facilitate these regimens. One of the well-documented side-effects
of rapamycin is its interference with wound healing, mostly attributed to its
inhibitory impact on fibroblast proliferation and angiogenesis. Although there
is ample evidence for impaired wound healing in patients receiving rapamycin,
little has been reported regarding the management and long-term outcome of
these wounds.
Methods: Forty five solid organ transplant recipients at our institution
developed wound-healing complications while receiving rapamycin, as part of
either de-novo or maintenance immunosuppression, between 1999 and 2006.
A retrospective analysis of risk factors (obesity, diabetes, smoking history,
hypoalbuminemia). treatment modalities and outcomes over a one-year followup period was performed.
Results: Among 45 patients with one or more wound-healing complications,
there were 26 incidences of cellulitis/superficial wound infection, 25
superficial wound dehiscences, 12 incisional herniae, 10 perigraft fluid
collections and 8 fascial dehiscences. Body mass index (BMI) over 25 kg/
m2 was the single most common risk factor (n=36 or 80%); while serum
albumin levels (mean=3.6 ± 0.5 g/dl). history of diabetes (n=18) or smoking
(n=24) did not appear to be significantly associated with development of
complications. 25 patients required surgical intervention, while the rest were
managed with traditional or vacuum-assisted dressing changes. Rapamycin
was discontinued in 16 patients due to refractory wound complications.
Whereas 37 patients (82%) had complete resolution, four had persistent
healing problems at the end of one-year follow-up and four were excluded
as they either lost follow-up or allograft was removed due to rejection.
Among the former 37, only 12 (32%) required discontinuation of rapamycin.
Furthermore, of the four non-healers, all had been off rapamycin for at least
one-year at the time of last evaluation and were all noted to have BMI>25
(mean 33.5 ± 8.3).
Conclusion: Wound-healing complications associated with rapamycin can
be effectively managed with different modalities, although healing is often

prolonged. In our series, treatment did not require discontinuation of rapamycin
in most cases; conversely switching to alternative immunosuppressives did not
always alter the outcome of complications.

POSTER BOARD NUMBER P1 – 195
1109 EMBOLIZATION OF IATROGENIC ARTERIOVENOUS
FISTULA AFTER RENAL TRANSPLANT BIOPSY.
P. Schenker1, M. Bülles1, O. Vonend2, E. Mielke3, L. Heuser3, R. Viebahn1
1
Ruhr-University-Bochum, Department of Surgery, 2Ruhr-University-Bochum,
Department of Nephrology, 3Ruhr-University-Bochum, Department of
Radiology
Backround: Biopsy related vascular injuries in renal transplants are rare,but
they can lead to significant clinical symptoms. Some case reports describes
transcatheter embolization for treatment of arteriovenous fistula (AVF) after
renal transplant biopsy, other publications reports a high complication rate after
embolization of AVFs. We evaluated the incidence of AVFs after renal biopsy
and assessed the use of superselective
embolization (coiling) fot treatment.
Methods: A retrospective study was performed of all biopsy-related vascular
injuries in renal transplants treated with transcatheter embolization over a
period of 5 years .
Results: Between January 2002 and February 2007 434 renal biopsies were
performed. Out of these, 25 patients with symptomatic AVFs were identified.
Indications for embolization were persistent macroscopic hematuria (n=9).
large intrarenal pseudoaneurysm (n=4) and renal transplant dysfunction
(n=12) after rejection was excluded. In all patients transcatheter embolization
was performed with GDC or tornado microcoils. Mean time of angiographic
intervention was 123 (71,5) minutes with a mean volume of contrast medium
of 41,9ml. Technical success was achieved in 100% of cases. There where
no serious complications. Only two minor complications were documented
due to a coil application in the extern iliac artery and in a renal segmental
artery, without haemodynamically relevance in both cases. Clinical symptoms
disappeared in all patients. Serum creatinine levels decreased significantly
(p<0,05) in 18 of 25 (72%) patients 1 week after embolization.
Conclusion: Transcatheter embolization (coiling) is a safe and effective
endovascular technique to treat biopsy-related vascular injuries in renal
transplant patients.

POSTER BOARD NUMBER P1 – 196
1110 INFLUENCE OF DELAYED GRAFT FUNCTION AFTER
HAND ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMIES
R. Minnee1, W. Bemelman1, K. Donselaar van der Pant2, J. Booij3,
S. ter Meulen2, I. ten Berge2, D. Legemate1, F. Bemelman2, M. Idu1
1
Dept. of Surgery, Academic Medical Center, 2Dept. of Nephrology, Academic
Medical Center, 3Dept. of Nuclear Medicine, Academic Medical Center
Introduction: The hand assisted laparoscopic donor nephrectomy (HALDN)
is an alternative for a total laparoscopic donor nephrectomy. The presence of a
hand in the abdomen has several advantages including the ability to use tactile
feedback, less kidney traction, rapid kidney removal and shorter warm ischemic
time. Shorter warm ischemia time is associated with a reduced frequency and
severity of delayed graft function of the renal allograft. The objective of this
study was to evaluate the results of the first 200 consecutive HALDN in out
institution and to investigate the occurrence of delayed graft function and
associated factors.
Patients and Methods: All 200 consecutive living donors who underwent a
laparoscopic donor nephrectomy between January 2002 and July 2007 were
prospectively included in the study. Delayed graft function was defined as the
need for dialysis within the first postoperative week. 99mTc-MAG3 renography
was performed in all donors prior to donor nephrectomy.
Results: The mean (± SD) donor operative time was 177 ± 41 minutes and
the mean (± SD) hospital stay for donors was 4.8 ± 1.9 days. No conversions
were necessary; intraoperative complications and postoperative complications
occurred in 10 donors (5%). respectively 24 donors (13.5%). In 14 recipients
(7.0%) there were urological complications i.e., obstruction in 10 and leakage
in 4. One-year graft survival was 95%. Delayed graft function was diagnosed
in 12 patients (6%). Two risk factors for delayed graft function were identified:
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for donor over 50 yrs. In recipients, DGF was compared with age, sex, BMI,
current and historical panel reactive antibodies (PRA%). number of transplants,
patient hospidalization.
Results: The incidence of DGF is 30% and DGF is a significant factor in
long-term patient and graft survival (p<0,005). Predictive donor factors
are: age (60,3±13,1 ys in DGF transplants vs 46,8±18,2 ys in non-DGF
transplants, p<0,05). cause of death (cerebrovascular accident vs trauma,
p<0,05). history of hypertension (58% vs 29%, p<0,05). renal function
evaluated with Cockcroft formula (84,4±37,6 vs 99,1±39,5, p<0,05) and
with renal biopsy (2,4±1,1 mean score vs 2,2±1,2, p<0,05). BMI in female
gender (27,2±5 vs 23,3±3,7, p<0,05). No differences in the incidence of
DGF is noted for: donor sex, hypotension, cardiac arrest, history of diabetes.
Donor employement of catecholamines results in less incidence of DGF
(p<0,05)
As in literature, prolonged CIT is associated with increased DGF: (19,4 ± 4,9
hours in DGF transplants vs 18,1± 5,2 in non-DGF transplants, p<0,05).
In recipients the occurrence of DGF is associated with age (54,1±10,7 ys
in DGF recipients vs 48,5±12,9 ys in no DGF recipients). BMI in female
gender (24,1±3,9 vs 22,4±3,6). current and historical PRA% (15,3±24,9% vs
11,8±23,2%/5,8±17,1% vs 3,2±12,0%). previous transplants, prolonged patient
hospitalization (31,8±30,6 vs 19,2±30,6, p>0,05).
Conclusions: DGF remains a common complication in cadaveric renal
transplant and is important because it increases risk of graft loss and patient
survival; in order to reduce incidence is mandatory a close cooperation between
all the specialists involved in the multidisciplinary process of organ donation,
in particular between anesthetists, immunologists, surgeons and nephrologists.
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lower counts per second on time to peak activity (Tmax; corrected for BMI)
during renal donor scintigraphy (odds ratio 6.04, 95% confidence interval (CI):
1.24-29.45) and multiple renal veins (odds ratio 15.33, 95% CI: 2.96-79.02).
Conclusion: HALDN is a safe procedure regarding donor morbidity rates
and graft survival. The correlation between low counts per second on Tmax
during renal donor scintigraphy and delayed graft function may represent
hyperfiltration injury of a relatively small donor kidney. When renal donor
scintigraphy shows asymmetric function between both kidneys, one should
keep in mind that transplanting a kidney with low counts per second op Tmax
bears an increased risk of delayed graft function.

the incidence of lymphoceles and wound problems for patients starting de novo
on sirolimus based immunosuppression. Using this program wound healing
problems are similar or less than that reported with other immunosuppressive
combinations.
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1111 SCREENING FOR FUNCTIONAL ASYMMETRY IN
POTENTIAL LIVING KIDNEY DONORS
N. Suh, H. Lau, H. Pleass, B. Nankivell, P. O’Connell, J. Chapman, R. Allen,
B. Ryan
Westmead Hospital
All potential living renal donors are thoroughly and systematically assessed
to ensure the safety of the donor and the recipient prior to transplantation.
The means of assessment varies according to local practice, however, much
emphasis is placed on anatomical factors when determining which kidney is to
be donated. As such, procurement of the left kidney is preferred by surgeons.
We have reviewed our experience of routine assessment for renal functional
asymmetry with Tc-99m DTPA renal scintigraphy in 124 consecutive live
donors between 2003 and 2007 at our transplant centre. We found that in 13%
of our donors, renal function was significantly asymmetrical and that the left
kidney showed greater function. We believe that routine renal scintigraphy
provides a more comprehensive profile of the potential donor whose altruistic
intentions should not be rewarded by harm.
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1112 A SYSTEMATIC APPROACH TO MINIMIZING WOUND
PROBLEMS FOR DE NOVO SIROLIMUS TREATED KIDNEY
RECIPIENTS.
S.M. Flechner, H.Y. Tiong, A. Wee, L. Zhou, B. Lane, B. Mastroianni,
K. Savas, D. Goldfarb, C. Modlin.
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation,
Cleveland, OH, USA
Purpose: Posttransplant lymphoceles and wound healing problems are reported
with greater frequency in kidney recipients given de novo sirolimus. We report
a program to reduce these problems based on the use of patient selection; closed
suction drains, and altered wound closure techniques.
Methods: Consecutive series of adult kidney-only recipients given antibody
induction followed by de novo sirolimus, mycophenolate mofetil, and steroids
were compared. Group 1- 103 patients transplanted with a weight restriction <32
kg/m2; retroperitoneal closed suction drains placed at surgery (Jackson-Pratt or
Blake); multilayer non-absorbable sutures, and no loading dose of sirolimus.
Sirolimus was introduced day 0-5 at 5mg. Group 2- A control group of 204 patients
were transplanted, many with BMI >30 kg/m2, with no drains, and various suture
techniques. All records and imaging studies were reviewed for delayed wound
healing and fluid collections greater than 3.0 cm after drain removal.
Results: There was no significant difference in recipient demographics
between Group 1 and 2 groups, including mean age (47.8 vs. 48.4). BMI
(25.7 vs. 26.6). males (63.1% vs. 68.1%). whites (69.9% vs. 78.9%). deceased
donors (50.5% vs. 50%). Retransplants (8.7% vs. 7.3%). and diabetics (27.9%
vs. 28.4%). Median day drain removal was 18. There was a significant (P
<0.0001) reduction in lymphoceles identified, treated, and treated by surgery
in patients with closed suction drains (Table 1). In addition there was a
significant reduction in total (P=0.0054) and non-operative (P=0.0095) wound
healing problems. Multivariate analysis demonstrated a dramatic reduction in
lymphoceles in drained patients (OR 0.33; 95%CI .181-.596; p<.0001); while
acute rejections (OR 3.14). DGF (OR 1.54). and age (OR 1.16) increased the
risk. Similarly, there was a significant reduction in all wound healing problems
in drained patients (OR 0.48; 95%CI .236-.997; p<.005).
Conclusions: A program of patient restriction by BMI, closed suction drains,
altered surgical technique, and no loading dose of sirolimus dramatically reduces
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Number (%)
Lymphocele identified
Total treated
Operative drainage
Wound Problems Total
Non Operative
Operative repair

Group 1 Drained
N=103 (%)
23 (22.30)
5 (4.8)
2 (1.9)
8 (7.8)
3 (2.9)
5 (4.8)

Group 2 Undrained
N=204 (%)
95 (46.7)
50 (24.5)
29 (14.2)
40 (19.6)
29 (14.2)
11 (5.4)

Totals
N=307
118 (39.3)
55 (18.3)
31 (10.3)
48 (15.6)
32 (10.4)
16 (5.2)

P Value
0.0002
<0.0001
<0.0001
0.0054
0.0095
0.76

1113 HAND-ASSISTED RETROPERITONEOSCOPIC
DONOR NEPHRECTOMY: CLINICAL OUTCOMES OF 170
CONSECUTIVE CASES AND COMPARISON WITH OPEN
DONOR NEPHRECTOMY
N. Ichimaru1, Y. Kakuta1, T. Abe1, M. Okumi1, R. Imamura1, T. Yoshioka2, N.
Fujimoto3, Y. Isaka1, S. Takahara1, A. Okuyama1
1
Osaka University, 2Sumitomo Hospital, 3Osaka Koseinenkin Hospital
Introduction: Although the advent of laparoscopic donor nephrectomy has
had a positive effect on the donor pool, there is still some concern about the
increased morbidity and safety of the laparoscopic donor nephrectomy.
Aims: To determine whether hand-assisted retroperitoneoscopic donor
nephrectomy (RDN) is a safe and effective procedure, the clinical results of
RDN were compared with that of ODN.
Patients and Methods: From September 2001 to February 2008, RDN was
performed in 170 consecutive patients at our hospitals. All patients were followed
longitudinally with office visits. Perioperative and postoperative data for these
RDNs, including postoperative kidney graft function, operative time, blood loss,
and complications, were compared with those of open donor nephrectomies
(ODNs) performed between January 1999 and December 2001.
Results: Conversion to open surgery was needed in four cases (renal vein
injury in 1, lumber vein injury in 1, peritoneum injury in 1, and diaphragm
injury in 1). The average warm ischemia times were 3.6 minutes (range 1.0-8.5
minutes) and 2.9 minutes (range 2.3-5.5 minutes) in the RDN and ODN groups,
respectively (P = NS). The mean donor operative time for RDN (238 min)
was significantly longer than that for ODN (192 min, P < 0.01). The mean
blood loss for RDN (158ml) was significantly less than that for ODN (280ml)
(P < 0.01). No transfusion was needed. There was no significant difference
between the groups in number of doses of analgesics administered after the
operation. Perioperative and early postoperative major complications occurred
in 12 recipients (7%) in the RDN group and consisted of lymphocele in 6 (4%).
ureteral complication in 3 (2%). and delayed graft function in 3 patients (2%).
All of these complications were treated successfully. No postoperative major
complications were occurred in donors. The mean recipient serum creatinine
concentrations did not differ among the groups (P = NS).
Conclusions: The RDN is a safe and effective procedure for donors, and
recipient fs graft function is similar to that after ODN. Although the benefits of
RDN have been demonstrated, further long-term studies of graft function and
patient survival are needed.
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1114 SITE AND TIMING OF HAND ASSISTANCE ARE KEYS
FOR SUCCESSFUL RETROPERITONEOSCOPIC LIVE DONOR
NEPHRECTOMY
M. Yashi1, T. Yagisawa2, A. Nukui2, N. Ishikawa2, N. Miyamoto2, Y.
Sakuma2,T. Fujiwara2, O. Muraishi1
1
St. Luke fs International Hospital, 2Jichi Medical University Hospital
Introduction: Hand assistance in laparoscopic surgery has been widely applied
method for live donor nephrectomy, because the meticulous fingers action
enables to dissect the renal vessels easier and to control accidental bleeding.
In addition, reducing warm ischemia time (WIT) by a rapid extraction through
the hand-port device is an important advantage. However, when used in the
retroperitoneal approach, the hand movement is limited due to the small
retroperitoneal space. We introduce our method for the hand assistance to
realize an effective retroperitoneoscopic surgery.
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1115 EVALUATION OF VOLUME OVERLOAD AND BODY
COMPOSITION IN HYPERTENSIVE RENAL TRANSPLANT
PATIENTS
A. Saxena, R.K. Sharma, A. Gupta, N. Prasad, A. Kual
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical
Science
After transplantation, it is expected that the transplanted kidney would restore
near-normal renal function and correct nutritional abnormalities arising from
pre-transplant renal insufficiency. Therefore, evaluation of nutritional status
and body composition is a must in post transplant patients.
Objectives: To evaluate body composition, volume expansion, relationship
of hypertension with body water, nutritional depletion and dry weight in post
renal transplant patients using bioelectrical impedance analysis (BIA).
BIA parameters of 100 well nourished, clinically non edematous post
transplant patients (TP) were compared with 16 male patients on maintenance
hemodialysis (MHD) and 60 healthy controls. BIA parameters included dry
weight, total body water (TBW). extracellular water (ECW). intracellular water
(ICW). extracellular fluid (ECF). plasma, interstitial fluid (IF). fat free mass
(FFM). fat mass (FM). body cell mass (BCM). muscle mass (MM). protein,
mineral, calcium, glycogen, potassium.
Results: There was significant difference in all the parameters of TP and
control and TP and MHD patients.
TP and Controls: TP had significantly low body weight, BMI and fat compared
to controls. TP had significantly higher ECF, plasma and IF. Because of higher
ECW fat free mass. There was significant difference in the systolic (120.8±13.0
and 116.2±6.6) and diastolic (80.5±8.0 and 77.0±3.0) blood pressure.
TP: Dry weight derived from BIA was significantly less than the actual weight
of TP (p=0.000). Transplant patients were divided into groups based on GFR
(low GFR <40 ml/min n=33 and High GFR >40 ml/min n=67). Patients
with low GFR had low body weight (53.0/61.5). dry weight (50.1/58.7).
BCM (21.3/23.1). FFM (42.8/48.3). TBW (30.0/34.4). ICW (46.7/51.3).
MM (19.8/23.4). protein (9.1/10.1). mineral (3.1/3.6). ECM (21.3/23.1).
potassium (101.3/119.5). calcium (855/987). glycogen (388/438.7) and ECS
(4.36/5.01) compared to patients with higher GFR. Patients with low GFR
had higher ECW. When patients were grouped according to blood pressure
(controlled BP<120/80 n=47, High BP >120/80 mmHg n=53) it was found
that patients with controlled blood pressure had higher GFR (47.2 ml/min
p=0.001) than those with high BP (40.80ml/min). To find out relationship
between fluid overload & requirement for antihypertensive drugs (AHD).
patients were divided into two groups (one AHD n=32, more than one AHD
n=68). It was found that patients on one AHD had significantly lower TBW
(30.9±3.9/34.1±4.3). ECW (15.1±2.9/17.2±2.53). ICW (15.7±3.4/17.4±4.9).
plasma (3.2±0.62/3.6±0.52) and IF (11.2±2.19/11.2±1.84) than those on more
than one AHD.
MHD and TP: MHD patients had significantly higher (p=0.000) TBW, ECW

ECW/TBW, ECW/ICW. ECF, PF, IF, FFM but low ICW and fat.
Conclusion: In clinically non-edematous transplant patients, nutritional deficit
and volume expansion can be picked up by BIA. Transplant patients should be
evaluated for expanded volume for better control of blood pressure using BIA.
Since there is a close
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1116 MODIFIED SURGICAL TECHNIQUE IN LIVING KIDNEY
TRANSPLANTATION
S.C. Park1, K.H. Yang2, Y.S. Won1, I.S. Moon1
1Kangnam St. Mary’s Hospital, The Catholic University of Korea,
2Sanggyepaik Hospital, College of Medicine, Inje University
Usually, the transplanted kidney is placed into the right retroperitoneal iliac
fossa through a right abdominal surgical skin incision. The skin incision may
be oblique or inverted J-shaped known as the ¡°hockeystick¡±. Roughly,
oblique or curvilinear incision, parallel to the inguinal ligament, known
as the ¡°pelvic Gibson incision.¡±, which is also extended medially to the
midline, just above the pubis is used. The most common incision for kidney
transplantation in our center is a paramedian incision which is parallel to
rectus abdominis muscle and extends medially to the midline, just above
the pubis symphysis (¡°hockeystick¡±). which is recent years has become
increasingly popular for kidney transplantation. Nowadays, the minimal
invasive surgery is popular in various field of surgery and the patients who
concerned the cosmetic effect are increasing. We make the skin incision
at lower right abdomen from laterally below the anterior superior iliac
spine to the midline just above the pubis in five young unmarried women
whose BMI were below 25 and there were no anatomical variation. The
lower transverse abdominal skin incision compared with the usual hockeystick incision suggested more favorable cosmetic result and more easily
hidden and there is no difference in postoperative various factors including
clinical pathway of renal function comparing with other routine renal
transplant patients.
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1117 THE OUTCOME OF RENAL TRANSPLANTATION IN 28
PTIENTS RECEIVING KIDNEYS WITH MULTIPLE RENAL
VESSELS
A. Mehrsai, G. Pourmand, M. Nikoobakht, M. Taherimahmoudi,
H. Wahhabaghai
Urology Research Center,Tehran University of Medical Sciences
Objectives: To study the renal Transplantation outcomes in the patients that
received kidney from kidneey donor with multiple renal vessels, the receipient
were followed for 16 years.
Materials & Methods: In a 16 years period (1989-2005). 1000 renal
transplantation was carried out at our center. In 28 cases the transplanted kidney
had multiple renal vessels. The patients had been followed up for average of 8
years. Serum creatinine level, vascular complications, graft survival and patient
survival had been studied .
Results: In 3 cases grafted kidneys had 3 arteries and one vein, 3 cases had 2
arteries and 2 veins, one case had 2 arteries, one vein and 2 ureters and finally 21
cases had 2 arteries and one vein. The mean cold ischemic time was 78 minutes
(50-143). The surgical technique employed, Included: 1- Anastomosis of graft
arteries and veins followed by anastomosis of common trunk to recipient iliac
artery and vein.2- Anastomosis of graft arteries or veins separately to recipient
iliac vessels. No venous or arterial thrombosis occurred. 4 cases developed
acute rejection managed successfully with Antithymocyte Globulin (ATG)
.No graft loss was seen. Mean creatinine level was 1.4 mg/dl. 2 patients were
expired due to sepsis and myocardial infarction. The grafted kidneys functioned
normally in both cases at the time of death .
Conclusions: Multiple arteries or veins had no adverse effect on graft survival.
Hence due to shortage of organ donors, Using kidneys with multiple vessels
are justified.
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Methods: We performed 57 retroperitoneoscopic live donor nephrectomies,
including 14 right-sided and 43 left-sided procedures according to the basic
principle of transplantation, namely, leaving the better-functioning kidney
in the donor. The hand port device (LapDisc) was placed through a 6.5 cm
incision vertically extending the inner port sequentially after the kidney and
renal vessels almost mobilized by pure retroperitoneoscopy using 3 ports.
Thereafter, the ureter which is just placed under the hand port is completely
dissected by an open procedure. The renal vessels were transected using
EndoGIA under the pure retroperitoneoscopy and the kidney removed through
the hand port.
Results: Hand-assisted retroperitoneoscopic surgery was accomplished
in 55 of the 57 donors (96.5%). The median operative time, WIT, blood
loss, and renal vein length were 244 minutes, 179 seconds, 130 ml, and
18 mm, respectively. No delayed graft function was observed. Histological
validation revealed only minor cortical damages: bleeding or ischemia, in
11 kidneys (19.3%). which did not have any harmful influences on graft
function.
Conclusions: The technical and functional outcomes were acceptable, and our
strategic hand assistance made the surgery easier and safer. The site and timing
of hand assistance we devised more than make up for the disadvantage of a
small working space in retroperitoneoscopic procedure.
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1118 VENOUS THROMBOEMBOLISM IN LIVE KIDNEY
DONORS – A PROSPECTIVE STUDY
J. Wadström, A. Biglarnia, M. Johansson, D. Bergqvist
Department of Surgery, Uppsala University Hospital
Aim: To evaluate risk factors for venous thromboembolism (VTE) and deep
vein thrombosis after living donor nephrectomy in a centre using extensive
preoperative screening and perioperative venous duplex scan.
Material and Methods: In 130 consecutive living kidney donors (laparoscopic
105, open 25) thrombophilia screening and pre- and postoperative
ultrasonographies were performed. Donors were followed prospectively for at
least 3 months. All donors received prophylaxis with the low molecular weight
heparin enoxaparin and compression stockings. Donors with increased risk
received the double dose of enoxaparin and the prophylaxis was continued for
6 weeks. Donors with venous thrombosis at discharge duplex also received
prolonged prophylaxis.
Results: The frequency of thrombophilia was similar to what can be expected
in the Swedish population (four with factor V Leiden, one each with protein
S deficiency, prothrombin gene mutation and anticardiolipin antibodies).
Preoperative duplex was normal. Three donors had small postoperative deep
vein thrombosis. Twelve donors (9,2%) received an intensified and prolonged
prophylaxis. No further thromboembolic complications developed in three
postoperative months.
Conclusion: With the present protocol for preoperative evaluation,
perioperative duplex screening and prophylaxis, the risk of postoperative
venous thromboembolism is low after living donor nephrectomy. Given that
9,2% had risk factors or developed deep vein thrombosis and the extraordinary
situation where an operation is performed on a healthy person who has no
therapeutic benefit and the low incidence of VTE in the present study, we
recommend the presented approach to be implemented more broadly and that
further studies should be performed in larger cohorts.
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1119 VASCULAR PROTECTION OF ISCHEMIC
POSTCONDITIONING IN ACUTE RENAL ISCHEMIAREPERFUSION INJURY BY UP-REGULATION EXPRESSION
OF DECAY-ACCELERATING FACTOR
T. Tang1, W. Wang2, S. Cui1, P. Zhang2, L. Zhang2, H. Bu2
1Affiliated Hospital of North Sichuan Medical College, NanChong, P.
R. China, 2Key Laboratory of Transplant Engineering and Immunology,
Ministry of Health, West China Hospital, Sichuan University, Chengdu, P. R.
China
Introduction: Complement activation during ischemia-reperfusion injury (IRI)
is an important reason that impacts vascular endothelium integrity after kidney
transplantation. Recent evidences showed that ischemic postconditioning
(Pos-con) may obviously lessen vascular injury on the acute renal IRI. We
explored the hypothesis that the Pos-con protects vascular endothelium, at least
in part, through inhibiting down-regulation of complement inhibitors decayaccelerating factor (DAF). CD59, or/and membrane cofactor protein (MCP).
Methods: After right nephrectomy, the acute IRI model was established as
described before. 30 Wistar rats were randomized into 3 groups: IRI, Poscon (6 cycles of 10 sec ischemia and 10 sec reperfusion before reperfusion)
and control. After 24h reperfusion without control, the blood samples were
taken through the vena cava and the renal samples were taken too. The mRNA
and protein expression of DAF, MCP and CD59 were examined by real-time
PCR, western blot and immunohistochemistry, and C3d deposition in tissue
will be detected by immunofluorescence, further vascular endothelial integrity
destruction was also observed by histological examination. In addition,
blood urea nitrogen (BUN) and serum creatinine (Scr) values were measured
commercially by quantitative colorimetric assay by Antec Diagnostics.
Results: Compared with Pos-con and control, the mRNA transcription/protein
expression of DAF and C3 deposition in the IRI group were significantly
decreased and increased evidently, respectively (P<0.05, n=10). and the BUN/Scr
of IRI group were increased remarkably (P<0.01, n=10). However, no statistical
difference of DAF expression, C3d deposition and BUN/Scr values between PosCon and control has been found. Moreover, the injury of kidney was attenuated and
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the pathological scale was reduced significantly in the Pos-Con group compared
with IRI group (P<0.05, n=10). Of interest, the mRNA and protein expression of
MCP and CD59 among all groups have not statistical difference.
Conclusion: These observations provide evidence that down-regulation of
DAF, not CD59 or MCP, plays a key role in complement-mediated vascular
endothelium dysfunction resulted by IRI, and this cytolysic effect would be
inhibited, at least in part, through Pos-Con.
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1120 MODIFIED APPROACH TO MINI-INCISION LIVE
DONOR NEPHRECTOMY: A SAFE PROCEDURE THROUGH A
SMALLER INCISION
1121 L. Wales1, N. Hakim1, T. Dosani1, N. Mustafa1, R. Canelo1, V. Papalois1
The West London Renal And Transplant Centre, 2The West London Renal
And Transplant Centre, 3The West London Renal and Transplant Centre, 4The
West London Renal and Transplant Centre, 5The West London Renal and
Transplant Centre, 6The West London Renal and Transplant Centre
Objective: To determine operative parameters and complications, using a
modified approach to mini-incision live donor nephrectomy.
Methods: 161 consecutive live donor procedures performed at the West
London Renal and Transplant Centre between October 2005 and January 2008,
using a modified approach to open mini-incision live donor nephrectomy, were
included in the study. Patient demographics, intra-operative parameters and
post-operative complications were prospectively recorded.
Results: Mean donor age was 43.2±11.6 years, with an average body mass
index of 27.1±5.1. Right-sided donor nephrectomies were performed on
16 patients (9.9%) and 26 donors (16%) were found to have multiple renal
arteries. Median incision length was 7.0cm (range, 3.5-15cm). Average
operative time was 120 minutes (range, 50-265 minutes). with a median blood
loss of 120mL (range, 20-500mL) and an average warm ischaemia time of 4.3
minutes (range, 1.5-10 minutes). Three patients (1.9%) required peri-operative
blood transfusions. There were no other intra-operative complications, no reexplorations and no donor deaths. Ten patients (6.2%) developed minor postoperative complications, but no patients developed chronic wound pain, over
a median follow-up period of 14 months (range, 1-28 months).
Conclusion: This prospective series demonstrates that a modified approach to
open mini-incision live donor nephrectomy can result in a smaller incision length
whilst maintaining patient safety, and has few post-operative complications.
1
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1122 VASCULAR RECONSTRUCTION PRIOR TO KIDNEY
TRANSPLANTATION IN PATIENTS WITH SEVERE
ATHEROSCLEROSIS
J. Szmidt, Z. Galazka, S. Nazarewski, T. Grochowiecki, T. Jakimowicz,
B. Solonynko
Department of General, Vascular And Transplant Surgery, Medical University
of Warsaw, Poland
Atherosclerosis or severe calcification of recipient iliac arteries is considered
contraindication for kidney transplantation. On the other hand it is common
in end stage renal disease patients on dialysis. Nowadays, since renal
transplantation is increasingly successful, extended indications are accepted
on the waiting list including patients with severe atherosclerosis. This requires
vascular procedure prior or during kidney transplantation.
The aim of the study was to present our experience with aorto-iliac reconstruction
prior to kidney transplantation.
There were eight atherosclerotic, uremic patients refereed to our Department as
a candidates for kidney transplantation. All were refused waiting list inclusion
due to occlusive lesions of iliac arteries or distal part of the aorta. There were
7 male and 1 female, age 45-62 years, all current or past smokers. Preoperative
assessment consisted of Doppler ultrasound and angio-CT scan.
Reconstruction of blood supply was performed with aorto-bi-iliac in 5, aortobi-femoral in 2 and ilio-femoral graft in 1 patient under general anesthesia.
There was no major postoperative complications. Patients were discharged and
placed on a special waiting list.
Six of them received kidney allograft including one living-related
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transplantation. All procedures were made with transplanted kidney artery
anastomosis to the side of the prosthesis. No patient developed signs of arterial
graft infection. In postoperative period there was no arterial or renal allograft
related complications except delayed kidney function in 2 cases.
Remaining two patients are still on waiting list 4 and 6 months after vascular
procedure.
Adequate vascular reconstruction in uremic patients with severe atherosclerotic
lesions of iliac vessels allows safe and durable kidney transplantation.

1123 DETECTION OF LOCAL METABOLIC CHANGES AFTER
INCREASING RENAL ISCHEMIA IN PIGS
A.K. Keller1, T.M. Jorgensen2, L.H. Olsen2, L.B. Stolle3
1Institute of Clinical Medicine, Aarhus University, Denmark, 2Department
of Urology, Aarhus University Hospital, Denmark, 3Department of Plastic
Surgery, Aarhus University Hospital, Denmark
Purpose: Vascular complication after renal transplantation causing initially
only partial renal ischemia can be difficult to discover in time to save the
kidney. Our aim was to design an animal model of gradually increasing renal
ischemia and investigate whether microdialysis could detect the subsequent
metabolic changes.
Microdialysis is based on simple diffusion over a semipermeable membrane.
It is a minimally invasive technique for monitoring of local metabolism or
drug distribution. Clinically it is used in reconstructive surgery for detection of
postoperative ischemia in free microvascular flaps.
Materials and methods: Eight pigs of 37 kg were used. Two microdialysis
catheters were placed, one in the lateral renal cortex and one just outside the renal
capsule. During steady state conditions, baseline measurements were obtained for
two hours. Then five repeated injections of 100μ-Polyvinyl alcohol (PVA) particles
were administered through an angiographic catheter placed in the renal artery in
order to make a gradual decrease of the renal arterial blood flow, monitored by
a flow probe. There was one hour between each injection. Every thirty minutes
the microdialysis samples were collected and analyzed for glucose, glutamate,
glycerol and lactate. GFR was continuously estimated by 51Cr-EDTA.
Results: GFR, renal blood flow and all metabolites measured by microdialysis
remained stable during baseline (ANOVA: p>0.05). The first injection of 26
mg PVA particles caused within thirty minutes a reduction of the blood flow to
40±13% of the baseline flow (t-test: p<0.001 vs. baseline) and significant changes
of cortical lactate and glutamate as well as extracapsular glutamate as indicators
of the resulting ischemia. Cortical glucose changed 60 minutes after baseline.
Furthermore we demonstrated a strong correlation between decrease in renal
blood flow and change in concentrations of metabolites. This was in particular
seen when the flow is depicted on a logarithmic axis. The association was
strongest for lactate (R=0.95, p<0.001). glucose (R=0.94, p<0.001) and
glutamate (Cortical: R=0.93, p<0.001; Extracapsular: R=0.93, p<0.001).
Conclusion: We present a model of acute stepwise reduction of the renal blood
flow by injection of PVA particles and demonstrate that microdialysis can be
suitable for monitoring of local metabolic changes in the kidney. An early
warning of ischemia is provided – with possible improvement of survival of
transplanted renal grafts suffering from postoperative ischemia.
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1124 MICRODIALYSIS FOR DETECTION OF
POSTOPERATIVE ISCHEMIA IN EXPERIMENTAL RENAL
TRANSPLANTATION
A.K. Keller1, T.M. Jorgensen2, K. Ravlo1, T.K. Nielsen1, L.H. Olsen2,
L.B. Stolle3
1Institute of Clinical Medicine, Aarhus University, Denmark, 2Departmant
of Urology, Aarhus University Hospital, Denmark, 3Departmant of Plastic
Surgery, Aarhus University Hospital, Denmark
Purpose: Vascular thrombosis is a feared and devastating complication
after renal transplantation because it most often leads to loss of the renal
graft. Furthermore it can be difficult to monitor the primary non functioning
kidney graft – a situation which is clinically important in children. A previous
published article has shown that microdialysis is a fast and reliable detector of
renal ischemia in a porcine model. However this has only been demonstrated
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1125 INFLUENCE OF PERIOPERATIONAL ACID-BASE
BALANCE AND ION DISORDERS ON GRAFT FUNCTION IN
KIDNEY TANSPLANTATION
K. Tejchman1, L. Domañski2, T. Sulikowski1, M. Romanowski1, J. Sieñko1, K.
Ciechanowski2, M. Ostrowski1
1Department of General Surgery And Transplantation, Pomeranian Medical
University, 2Department of Nephrology, Transplantology and Internal
Diseases, Pomeranian Medical University
The study&#8217;s purpose was analysis of influence of acid-base and ion
balance disorders during 30 minutes of reperfusion and 4 hours after operation
on graft early function in patients after kidney transplantation.
The examined group consisted of 53 recipients: 32 men, 21 women in
average age 47&#61617;14 years. Arterialised blood samples for analysis
in each patient were taken 9 times during operation using catheter placed in
arteriovenous fistula: 0, 1, 3, 5, 10, 15, 20, 25, 30 minutes after unclamping
renal vessels and fingertip capillary blood 1, 2, 3, 4 hours after last stich
on the wound was placed. Every of those 13 measurements consisted
data about temporary acid-base balance state, which was evaluated on the
basis of common parameters: pH, pCO2, [HCO3-], BE, sO2c and TCO2.
9 intraoperational test were extended by ion concentrations (Na, K, Ca).
glycaemia, hematocrite, lactates concentrations and vital parameters
(expiratory pCO2, O2 saturation, heart rate, blood pressure, tidal volume
and rate) recorded with Ohmeda 5250 RGM and Dräger Sulla 909V/
Julian apparatus. Blood samples were analysed using Corning 278 and
248 apparatus. Assay of graft function was based on parameters of urine
output, serum concentrations of creatinine, urea, uric acid and ions (Na,
K). which were analysed during postoperative hospitalization and 1-year
observation. Additional parameters like blood morphology, urinalysis,
serum concentration of glucose, aminotransferases, ions (Cl, Ca, P) were
also taken into consideration. Statistical significance was analyzed using
repeated-measures ANOVA followed by Tukey post-hoc test as well as U
Mann-Whitney&#8217;s and Spearman&#8217;s ranges correlation tests.
The analysis showed increasing parameters of metabolic acidosis with
compensative blood and expiratory pCO2 growth. Dynamics proved to be
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in a normal healthy kidney in situ. The aims of this study was thus to make a
model of transplantation in order to see how much warm and cold ischemia
would affect the subsequent microdialysis measurements after reperfusion.
Furthermore we evaluated if the technique could still detect induced
postoperative ischemia.
Materials and methods: Sixteen pigs with a weight of 57±3 kg were used. In
the left kidney one microdialysis catheter was placed superficially in the lateral
renal cortex and one was fixated with a 5-0 suture outside the kidney, on the
lateral side of the renal capsule. After two hours of baseline measurements the
kidney was removed and subjected to warm ischemia for 5 minutes and cold
ischemia for 145 minutes. The kidney was subsequently reanastomosed end
to end in situ, reperfused for five hours and randomized into two groups: one
subjected to total occlusion of the renal artery and one group with controls.
After additionally two hours the experiment ended. Throughout the study the
local renal metabolism was monitored by microdialysis, with samples changed
every thirty minutes.
Results: One pig from the controls was excluded due to thrombosis of the
renal artery 240 minutes after reperfusion. In this case the microdialysis
measurements showed early detection of ischemia.
Mean arterial blood pressure, temperature, systemically glucose and lactate
did not differ significantly between the two groups during the 690 minutes the
experiment lasted (ANOVA, p>0.15).
Significant changes of glucose, glutamate, glycerol and lactate in the renal
cortex and of glutamate and glycerol on the renal capsule were seen during
induced postoperative ischemia compared to the period of reperfusion, while
no changes were seen over time in control pigs. (ANOVA on Ranks; p<0.05 for
ischemia and p>0.05 for controls)
Conclusion: In a porcine model of renal transplantation we found microdialysis
a reliable and early detector of induced postoperative ischemia, while no
metabolic changes were observed in the control group without ischemia. In the
future, microdialysis may be a valuable tool for postoperative observation of
transplanted kidneys in selected cases.
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repeatable phenomenon independently from initial values, correlating with
risk of graft loss and renal function. Some alterations in vital parameters
were observed, especially in circulatory response. Analysis of postoperative
acid-base balance also showed increasing parameters of metabolic acidosis
corresponding with initial state and course of reperfusion. Ion balance was
characterized by higher stability, notwithstanding potassium concentrations
dynamics also showed repeatable alterations. Basing on analysed group there
was unable to separate acid-base and ion balance disorders as an independent
risk factor of function worseing, however they seem to have predictive value in
the course of kidney transplantation.
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1126 LIVING DONOR RENAL TRANSPLANTATIONS THAT
USES PURE TRANS-ABDOMINAL LAPAROSCOPIC DONOR
NEPHRECTOMY ~ SINGLE CENTER EXPERIENCE ~
K. Kozaki, K. Yuzawa
Department of Organ Transplantation, Mito Medical Center
The increased acceptance of laparoscopic nephrectomy (LN) has been a
driving force for living donor renal transplantation (LRTx). Since organ
donors undergo an operation without any physical benefit for them, donor
safety and preservation of graft function must be respected. Not to harm
a graft function in the LRTx, in principle we shorten graft ischemic time,
namely preservation time as much as possible. Therefore the parallel
operation of donor and recipient is performed generally in Japan, and the
graft kidney is transplanted after perfusion and cooling promptly. As a result,
although graft preservation time shortens, either waiting time under general
anesthesia of donor or recipient arise till both donor and recipient get ready
for starting operation. In April 2006, renal transplant program has been
started in our center. In our center, since the reduction of patient fs waiting
time under general anesthesia and the purpose of using the operation room
effectively, recipient enters in the same operating room after donor operation
end and donor return to the ward. Therefore renal graft was preserved for
about 4 hours. In addition, donor nephrectomy was performed by pure transabdominal laparoscopic procedure and used UW solution as preservative
solution. In Japan, there are extremely few transplant centers performing
LRTxin this procedure.
Objective: To investigate efficacy of this procedure in LRTx.
Methods: FFrom April 2006 to December 2007, 22 LRTx were performed
by pure trans-abdominal laparoscopic procedure in our center. To investigate
time of immediate diuresis and postoperative day 1, 7 and 28 transplant kidney
function in recipients, and to investigate complications of perioperative period
in donor.
Results: Mean warm ischemic time was 6.9 min, mean total ischemic
time was 234.2 min, immediate diuresis was occurred in all recipients
and mean time of immediate diuresis was 10.6 min. Postoperative mean
plasma creatinine value in recipient was 5.00 (mg/dl) on POD 1, 1.36
on POD 7 and 1.42 on POD 28. No patients needed hemodialysis after
transplantation. No complication occurs in donor, and although surgical
complications including postoperative hemorrhage, lymphocele and
urinary extravasation occurred in recipients, all recipients get good renal
function so far.
Conclusions: FIn 2006, we mailed to 124 centers, and 100 (80.6%) centers
responded. These centers carried out 695 living donor nephrectomies. In
these centers, 52 (52.0%) centers performed total 589 LN donors. In 589 LN
donors, 2 had life-threatening complications by bowel injury and bleeding and
both survived. In 589 laparoscopic donated recipients, 1 case was reported
as primary nonfunction and 28 (4.8%) recipients needed hemodialysis after
transplantation because of delayed graft functions Moreover, according to
this nationwide total investigation about living donor LN in Japan, mean
warm ischemic time was 7.0 min, mean total ischemic time was 96 min and
mean time of immediate diuresis was 13 min. In comparison with this survey,
no postoperative hemodialysis and good posttransplant renal functions in all
recipients and no complications in donor by our procedure, which is excellent
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procedure in LRTx.
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1127 OUTCOME OF LAPAROSCOPIC LIVE DONOR
NEPHRECTOMY IN 2007: NATIONAL SURVEY OF
TRANSPLANTATION CENTERS IN JAPAN
K. Yuzawa1, K. Kozaki1, M. Shinoda2, K. Fukao3
1
National Hospital Organization Mito Medical Center, 2University of Tsukuba,
3
Chiba Rousai Hospital
In Japan, the number of cadaveric kidney available for transplantation has
not increased and the number of living donor has increased. Laparoscopic
nephrectomy (LN) for live kidney donation offers an alternative for a less
invasive surgical access, better cosmetic, and a shorter hospital stay for donor.
In many countries, the increased acceptance of LN has been a driving force
for live donor kidney transplantation. Outcome of LN in live donors must be
surveyed nationwide.
In this study, we surveyed 138 Japanese kidney transplantation centers to
investigate current status of live donor LN, including morbidity, mortality, and
various methods in the donors underwent nephrectomies.
Of 138 centers, 106 (76.8%) responded. These centers carried out 822 live
donor nephrectomies. In these centers, 48 (45.3%) centers performed LN. In
all donors underwent nephrectomies in all responded centers, 623 (75.8%)
donors had LN and 199 (24.2%) had open nephrectomies. In 47 centers, 23
were performed hand-assisted (HA) LN, 18 non-HA, 3 both HA and non-HA,
and 3 laparoscope-assisted. And 17 centers carried out peritoneal approach, 26
retro-peritoneal and 4 both.
In 623 LN donors, 2 had life-threatening complications by colon injury and
bleeding, and both survived. Blood transfusions were performed in 5 (0.8%)
donors. Open conversions in LN were 8 (1.3%). Minor complications not
requiring long-hospital stay were reported in 10 (1.8%). The mortality of LN
was 0. On the other hand, in 623 recipients, 1 case was reported as primary
non-function. 13 (2.1%) recipients needed hemo-dialysis after transplantation
because of delayed graft functions. Urinary tract complications were noted in
13 (2.0%) recipients.
We surveyed all kidney transplantation centers in Japan for 6 years on LN.
LN increases steadily in Japan. In donor complications, the incidence of blood
transfusion and that of open conversion decreased progressively. Organ donors
underwent an operation have no physical benefit, but the results of this survey
showed the validity of LN in live donor renal transplantation. This survey
presents current status from which complete informed consent can be taken
from donors.
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1128 NON-IMMUNOLOGICAL DONOR FACTORS AND THEIR
INFLUENCE ON KIDNEY FUNCTION FOLLOWING THE
KIDNEY TRANSPLANTATION
L. Bena1, J. Rosenberger1, I. Zezula2, R. Roland1
1
Transplantcenter of Teaching Hosp L Pasteur Kosice, 2Faculty of Natural
Sciences of Universty of PJ Safarik Kosice
Objective: To analyse the influence of donor age, age-related diseases, factors
related to donor brain death, management, perfusion and preservation factors
on the offset of kidney function following the transplantation. Comparing
the influence of antigen–independent factors of deceased and living kidney
donors on the offset of kidney function following the transplantation and
assess possibilities of affecting the offset of kidney function by modification
of affectable donor factors.
Material and Methods: We analysed 279 consecutive donor-recipient pairs
transplanted in Transplantcentre Kosice during the period of 1995-2005.
Data were statistically treated by ordinal regression, the offset of kidney
function (IGF – immediate graft function, SGF – slow graft function, DGF
– delayed graft function, PNF – primary non-function) was a dependent
variable, independent variables were as follows: CIT, WIT II, cold storage
solution type, donor age, donor-recipient age difference, donor sex,
existence of extended donor acceptance criteria, diagnosis leading to the
brain death and donor management. Diuresis in the first eight hours after
the transplantation, administration of dopamine, calcium channels blockers
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Creatinine

GFR ml/min

5th day

3.7 ±2,6 mg/dl

37.65±45.34

15th day

1,9 ±1,3 mg/dl

59.94±42.10

30th day

1.7 ±1.2 mg/dl

63.16±44.42

P< 0.05

P < 0.05

Results from color Doppler IR and IP and parameters from contrast-enhanced
sonography are reported in Table II at different scheduled times of study.
T0

T1

T2

p

P

(mean +/- SD)

(mean +/- SD)

(mean +/- SD)

T0 vs T1

T0 vs T2

T1 vs T2

IP

2,14±0,98

1,96±0,79

1,60±0,73

-

-

-

IR

0,83±0,13

0,77±0,12

0,73±0,10

-

0,02*

-

5,64±10,8

61,48±10,89

65,78±5,92
-

-

-

TTP

14,87±3,71

16,34±7,27

16±5,35

-

-

-

RBV

3925,86±1715,59 6423,97±4146,57 7332,11±3976

0,05*

0,02*

-

RBF

71,03±13,79

80,23±12,26

85,49±7,27

0,01*

0,00*

-

T/2

60,22±15,13

72,64±38,84

79,61±37,55

-

0,03*

-

Peak

We obtained moreover a significant correlation between T/2 value at T0 from
contrast sonography and GFR (ml/min) at 30th day post transplant (p< 0.014).
Conclusion: Our data support a role of contrast-enhanced ultrasound with
SonoVue in the evaluation of early function and complication of kidney
transplants and suggest also from contrast sonography a possible prognostic
index for mid term renal function.
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1129 CONTRAST-ENHANCED ULTRASOUND WITH
SONOVUE IN THE EVALUATION OF FUNCTION AND
COMPLICATIONS OF KIDNEY TRANSPLANTS
L. Benozzi1, G. Cappelli1, D. Bonucchi1, D. Davoli1, A.M. Savazzi1,
A. Albertazzi1, P. Torricelli2, M.G. Montecchi2, A. Grossi2, P. D’Alimonte2
1
Nephrology, Dialysis And Kidney Transplantation. Policlinico Hospital –
Modena, 2Radiology Department – University Hospital, Modena – Italy
Introduction and Aims: Purpose: To compare data from contrast-enhanced
sonography versus routine color Doppler ultrasound and resistance index value
(IR) in the study of kidney transplanted patients.
Methods: From December 2006 to August 2007 we performed both routine
color Doppler ultrasound and contrast enhanced sonography at 5th (T0). 15th
(T1) and 30th (T2) day post transplant on 15 patients who had undergone kidney
transplantation. Graft function was daily monitored by standard parameters,
immunosuppresion was controlled by therapeutic drug monitoring and in 4/15
patients a kidney biopsy was performed due to acute graft dysfunction.
Patients data: 13 males and 2 females, aged from 17 to 70 years (mean:
49,5yrs). weight from 47 to 98 kg (mean 70,5 Kg); 4/15 were transplanted
from living donor, while 11/15 from cadaveric donor (a double kidney in one
case). Immunosuppressive therapy was based, after a basiliximab induction,
on a triple regimen with methylprednisolone tapering, calcineurin inhibitors
(11/15 cylosporin, 4/15 tacrolimus) and mycophenolate mofetil (13/15).
Color Doppler ultrasound: evaluated kidney morphology and vascularisation
by color Power Doppler on principal, interlobar and arcuata arterial vessels,
providing systolic peak (MAS m/sec). diastolic peak (MIN m/sec). resistance
index (IR) and plasticity index (IP)
Contrast-enhanced ultrasound with SonoVue (5 ml i.v.) was used to assess
arterial inflow in the interlobar artery and renal cortex using a time-intensity
curve (TIC) software analysis to obtain perfusion parameters. Time to peak
intensity (TTP) between these two vascular territories was determined so as
peak level (Peak). regional blood volume (RBV). regional blood flow (RBF)
and time to half of peak intensity (T/2).
Results: According to post grafting renal function evolution patients were
divided into three groups:
10/15 with a standard kidney function as control group (group C); 2/15 with a
delayed graft function (biopsy proven in one case) (group ATN); 3/15 with an
acute rejection (3/3 biopsy proven, 1/3 steroid resistant) (group AR)
Mean creatinine and GFR for all pts on study is reported in following table I:

p

POSTER BOARD NUMBER P1 – 215
1130 COMPARISION OF PREVALENCE OF PULMONARY
ARTERY HYPERTENSION IN PRE AND POST RENAL
TRANSPLANT RECIPIENTS
G. Abraham1, D. Lunawat1, M. Mathew2, S. Bhaskar2
Sri Ramachandra University Hospital, 2Madras Medical Mission Hospital
Objective: The aim of this study was to compare the prevalence of pulmonary
artery hypertension in a cohort of patients with end stage renal disease prior to
and following renal transplantation along with other variables.
Methods: This was a retrospective study of renal transplant recipients whose
pulmonary artery pressure was compared pre and post transplantation, in a
tertiary care centre in South India. Of the 425 renal transplantations performed
over 2001 to 2007, 124 patients had their Doppler Echocardiographic findings
available. The data analysed included the hypertensive, diabetic and the
smoking status of the patient along with their BUN, Creatinine, GFR (by
Nankivell formula). Hemoglobin, Hemodialysis duration, AV fistula+/-,Urine
albumin, BMI and most importantly the echocardiographic findings both pre
and post transplant – the pulmonary artery pressure, ejection fraction. Statistical
analysis was performed using SPSS for Windows and t-test, chi-square test and
ANOVA were used.
RESULS: There were 72%males and 28% females with mean age of
43.3+_13.02 years. Out of this 87% were hypertensives, 30% were diabetics
and 4% smokers. Statistical analysis revealed a significant decline in
pulmonary artery pressure (PAP) following renal transplantation (p<0.05). PAP
had no significant correlation with a patient’s hypertensive, diabetic, smoking
status, age, gender, BUN, Creatinine, GFR, Hemoglobin, Hemodialysis
duration, AV fistula, Urine albumin. It was noticed that BMI had a significant
correlation (p<0.05) with Pre-transplant PAH. Of the 72% patients with nil
Pre-PAH (<=35mmof Hg). 68% remained nil following transplantation, 2%
developed mild PAH, 2% moderate PAH. Of the 14% patients with mild PrePAH (>35and<=45mm of Hg). 9% developed nil PAH, 4% mild PAH,1%
moderate PAH following transplantation. Amongst the 11.3% patients with
moderate pre-PAH (>45and<=55mmof Hg). 6.5% had nil, 2.4%mild and
2.4% moderate PAH post transplantation. Out of the 3.2% who had severe
pre-PAH (>60mmof Hg).0.8% had nil, 1.6% moderate and 0.8% severe PAH
post transplantation. There were no patients with moderately severe PAH in
the study (>55and<= 60mm of Hg).
Conclusion: The findings of our study reveal that pulmonary artery
pressure declines in ESRD patients after renal transplantation as compared
1
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and furosemide following the transplantation were the factors assessed on
the recipient side.
Results: In 46% of cases IGF or SGF following the transplantation was present,
in 42% temporary dialysis treatment was needed because of DGF and in 12%
primary non-function was registered being more frequent in first years of
studied period of time (16% vs 11% in 1995-1997 vs 2003-2005, no statistical
significance). Donor mean age was 37,46y. (5-70y.). 75,99% of donors were of
male sex, mean CIT was 17h24m (5h00m – 30h40m). mean WIT II was 41m
(15m – 1h35m). UW or HTK solution was used in 52,19% of procedures, in
26,16% of all cases donor was more than 5y. older than the recipient, in 13,98%
of all the cases kidney from female donor was transplanted into the male
recipient. On the recipient side, in 66,08% diuresis was present immediately
following the surgery, in 19,04% dopamine was administered, in 29,04%
calcium channels blockers were administered and in 77,77% furosemide was
administered.
Conclusion: In multivariate analysis, no correlation between donor age
and offset of kidney function was found, though statistically non-significant
prevalency of DGF comparing to IGF/SGF is present in the donor age group
>50y. Presence of extended criteria in donor appraisal as well as cause of
donor brain death or donor management itself did not reach statistically
significant level, but in multivariate analyses combining more independed
variables in ECD importance of short CIT as well as of age-matching started
to be of significance when dealing with offset of kidney function following
the transplantation. More studies comparing given and many others nonimmunologic parameters among transplant centers are needed in the future
to create more sophisticated algorithm for the allocation of kidney for the
transplantation.

Monday 11 August 2008

Poster Abstracts

prior to it. This emphasizes the fact that excessive pulmonary blood flow
is involved in the disease pathogenesis which again could be related to
various factors.
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1131 THE EVALUATION OF THE EFFECT OF DONOR’S AGE
WITH DIAGNOSED BRAIN DEATH AND RECIPIENT’S AGE ON
THE INCIDENCE OF DELAYED FUNCTION OF RENAL GRAFT
A. Caban, G. Oczkowicz, G. Budzinski, K. Zagalski, W. Wystrychowski,
L. Cierpka
Dept.of General, Vascular And Transplant Surgery, Silesian Medical
University
Abstract: Delayed graft function (DGF). interpreted as the necessity of
carrying out a dialysis during the first week after renal graft, remains an
incompletely explained issue. Based on multi-centre analyses, older age
of donor is a relevant aggravating factor. However, more and more often
obtaining kidneys from donors aged over 60 years is not always correlated
with the rise of incidence of DGF episodes. Nonetheless, such studies are
frequently loaded with error resulting from the heterogeneity of groups in
particular study centres and they lead to ambiguous findings. The aim of our
study has been the analysis of the effect of donor’s and recipient’s age on the
incidence of DGF in the material from our clinic. Our study has involved 436
renal recipients from 218 donors with diagnosed brain death. The necessity
of dialysis during the first week was the basis for the qualification of each
recipient for DGF group. Donors’ age and recipients’ age, the difference
between them among both groups as well as a possible correlation with the
incidence of DGF were compared. DGF has been recorded in 135 (31%)
recipients. Mean age in this group was 41.2 ± 12.8 years whereas in the group
featuring a good renal function it was estimated to 38.9 ± 11.6. No statistically
significant difference for recipients’ age between both groups has been
observed. Similarly, no correlation was demonstrated between recipient’s
age and DGF incidence as well as between donor’s age and delayed renal
function. Correlation between the incidence of DGF and the absolute value
of age difference (R = 0.19, P < 0.05) was observed. In the group of organ
recipients from older donors R-Spearman coefficient was 0.20 (p = 0.01). In
contrast, in the group of organ recipients from younger donors this coefficient
was lower (R = 0.17) but still statistically significant (p = 0.04). The age
difference between donor and recipient did not correlate with the number of
dialyses (R = -0.004, p = 0.96). Nevertheless, when it exceeded a 10-year
threshold the number of dialyses was statistically significantly higher (5.6 ±
3.8 vs. 3.7 ± 3.0, p < 0.05 ).
Conclusions: Donor-recipient age difference, particularly if it exceeds 10
years, and also in such cases when a donor is older than a recipient, is an
essential factor that increases the risk of DGF occurrence. In this group of
patients a delayed graft function is also associated with the necessity of the
application of significantly greater amount of haemodialyses during an early
postoperative period.
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1132 COMPLICATIONS OF LIVING DONOR NEPHRECTOMY
OF LIVING – ONE CENTER EXPIERIENCE
P. Domagala1, M. Bieniasz1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1,
M. Wszola1, J. Trzebicki3, M. Durlik2, W. Rowinski1, A. Chmura1
1Medical University of Warsaw, Department of General Surgery
And Transplantology, 2Medical University of Warsaw, Department
of Transplantology And Nephrology, 3Medical University of Warsaw,
Department of Anaesthesiology And Intensive Care
Background: Kidney transplantation from living donors is associated with
excellent graft and patient survival. The attention of transplantation teams
is focused on the graft and its recipient, as well as on the safety and wellbeing of healthy donors and is directed at minimizing the number of donor
complications.
The aim of this study was to analyze the perioperative complications of living
donor nephrectomies in our center.
Patients and method: The records of 46 live kidney donors operated on
between 2004 and 2007 were reviewed. Mean donor age was 39 years (range
25 – 57). The donors were predominantly female (61%). Mean hospitalization
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time was 8 days (range 4 – 22 days). Open nephrectomy was performed in all
cases, usually left-sided (78%). Donors were followed up during hospital stay
to assess perioperative complications. Ultrasonography was performed prior
to discharge.
Results: Twenty complications were diagnosed in 18 (39%) donors (see table
below). There were no deaths or thromboembolism. We noted no hemorrhage
in the postoperative period.
Complication
Major complications
intraoperative hemorrhage
Minor complications
wound infection
retroperitoneal haematoma
urinary tract infections
mild hypertension

Number (%)
1 (2%)
6 (13%)
3 (6%)
3 (6%)
1 (2%)

Conclusion: Nephrectomy in living kidney donors is a safe procedure burdened
however by a range of predictable surgical complications.
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1133 HAND-ASSISTED LAPAROSCOPIC DONOR
NEPHRECTOMY OF THE RIGHT OR LEFT KIDNEY: A
RANDOMISED CONTROLLED TRIAL
I. ten Berge1, R.C. Minnee2, W.A. Bemelman2, F.J. Bemelman1, D.J. Gouma2,
M.M. Idu2
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of
Surgery, Academic Medical Centre, Amsterdam
Aims: The (hand assisted) laparoscopic approach (HLDN) is an accepted
method in live kidney donations. The benefits are decreased postoperative pain
and morbidity, a shorter convalescence for the donor and a better postoperative
cosmetic result. Most centers prefer to use the left kidney for live kidney
donation because of the longer renal vein. It has never been addressed which
kidney can be used best for live kidney donation, in terms of operating time,
morbidity, reconvalescense and transplant survival.
Methods: From April 2002 to September 2006, 60 HLDN were performed.
Donors were randomly assigned to undergo either a right- or left-sided
donornephrectomy. Primary outcome parameters were operating time and
length of hospital stay. Secondary parameters were donor morbidity, conversion,
warm ischemia time, blood loss, graft survival and urological complications.
Results: There were no conversions and no major morbidity. The median blood
loss was respectively 60cc (range 10-1000) and 55cc (range 25-1200) for left
and right-sides donornephrectomies. Median operating time for HLDN was 180
minutes (range 110-274) in the left group versus 150 minutes (range 88-221) in
the right group (p=0.027, odds ratio 1.02 (95% CI: 1.00-1.03) ). Median hospital
stay was 4 days (range 2-7) in both HLDN groups. Warm ischemia time was
3 minutes in both groups. Median operating time for transplantation was 138
minutes (range 90-265) in the left group and 148 minutes (range 104-300) in
the right group (p= 0.38). The surgical re-intervention rate due to a urological
complication for respectively left-sided and right-sided harvested grafts were
2% and 4% respectively (p=0.55, Chi2-test). One year graft survival rate was
91% in the left group versus 96% in the right group (p=0.55, log rank).
Conclusions: Operating time of HLDN of the right kidney is 30 minutes
shorter than HLDN of the left kidney. There are no differences in morbidity
of donor and acceptor, hospital stay and transplant survival in HLDN of either
the right or left kidney.
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1134 HAND ASSISTED LIVNG DONOR NEPHRECTOMY
AT KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE,
STOCKHOLM, SWEDEN
H. Gjertsen, A. Sandberg, G. Tyden, B-G. Ericzon
Karolinska University Hospital, Huddinge
Introduction: Living donor kidney transplantation accounts for about 50% of
the total number of renal transplantations in our center. From 1999 through
2005, 75 out of 220 living donor nephrectomies (LDN) were performed with
laparoscopic technique (LLDN). In June 2005 we introduced the technique
of hand assisted retroperitoneoscopic nephrectomy (HARS) for our living
donors.
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1135 HAND-ASSISTED TRANSPERITONEAL LAPAROSCOPIC
LIVE DONOR NEPHRECTOMY: A SINGLE CENTRE
EXPERIENCE
I. Butt, C. Vallance, C. Clayton, M.S. Melbridge, V.C. Nathan, W.S. McKane,
P. Brown, A.T. Raftery, B.M. Shrestha
Sheffield Kidney Institute
Introduction: Laparoscopic live donor nephrectomy is being increasingly
practised. It reduces the disincentives to live kidney donation and is associated
with less post-operative pain, shorter hospital stay, early return to work and
better cosmesis. The purpose of the study was to assess the impact of handassisted laparoscopic live donor nephrectomy (HLLDN) on donor and recipient
outcomes and compare these with the established technique of open donor
nephrectomy (ODN).
Methods: Over a period of 7 years, commencing 2000, 75 live donor
nephrectomies (HLLDN = 35, and ODN = 40) were performed. Data was
retrieved from a prospectively maintained departmental computer database and
case notes. HLLDN was performed through transperitoneal and ODN through
retroperitoneal flank approaches.
Results: Donor age (HLLDN 42 ± 11 vs. ODN 43 ± 10 years) and sex (HLLDN
17 males, 18 females vs. ODN 15 males, 25 females) was similar in both groups.
The total anaesthetic time was longer in HLLDN group (267 ± 52 vs. 174 ±
42 minutes, p <0.001). The mean serum creatinine of the donors at discharge
and at 1 year was higher in the HLLDN group (116 ± 22 vs. 101 ± 21 μmol/l,
p<0.05 and 115 ± 21 vs. 103 ± 20 μmol/l, p<0.05, respectively). which would
correlate with higher body mass index in the HLLDN group (28 ± 3 vs. 26 ± 3
kg/m2, p<0.05). The recipient serum creatinine at discharge and at 1 year was
similar in both groups (140 ± 88 vs. 147 ± 66, p=0.72 μmol/l and 128 ± 52
vs. 146 ± 41 μmol/l, p=0.17, respectively). Duration of post-operative hospital
stay was shorter in the HLLDN group (3.7 ± 1.1 vs. 6.4 ± 1.4 days, p<0.001) as
was time to return to work (6.0 ± 1.6 vs. 12.5 ± 4.7 weeks, p<0.001). Delayed
graft function was observed in 4 of the HLLDN group in comparison to 3 of
the ODN group. No significant post-operative complications occurred in the
HLLDN group. Three patients required conversion to an open procedure due to
dense adhesions between the kidney and perinephric fat. All three were athletic
young males.

Conclusions: HLLDN is a safe alternative to ODN. We have observed distinct
advantages over ODN with respect to shorter hospital stay, early return to work
and cosmesis without compromising graft function.
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1136 RENAL TRANSPLANTATION FROM THE LIVING
DONORS/PATIENTS WITH SMALL RENAL CELL CARCINOMA
OR URETERAL CARCINOMA (AUSTRALIA AND JAPAN
EXPERIENCES)
M. Mannami1, R. Mannami1, N. Mitsuhata2, M. Nishi3, K. Nannba4,
Y. Tsutsumi5, S. Fujita6, N. David7
1
Uwajima Tokushukai Hospital, 2Kure Kyosai Hospital, 3Kagawa Rosai
Hospital, 4Rokumeisou Pathology Center, 5Fujita Health University,
6
University of Florida, 7University of Queensland
Materials and Methods: Since March 1993, sixty five kidney allografts were
obtained from 65 patients (57 small renal cancers, 8 ureteral cancers) after
extended discussion of treatment modalities at Princess Alexandra hospital
Brisbane, Australia, Uwajima Tokushukai Hospital, Ehime, Japan, Uwajima
municipal hospital, Ehime, Japan, and Kure Kyosai hospital, Hiroshima, Japan.
All patients agreed to undergo simple total nephrectomy. The lesions were
removed on the back table, and the kidneys were transplanted into 64 recipients
(one recipient received twice).
Results: There was one recurrence of renal cell cancer 9 years after
transplantation. The patient remained stable under observation for 18 months.
There was one recurrence of ureteral cancer in the transplanted kidney 15
months after kidney transplantation, treated with partial resection of the
tumor at the patient fs request. The patient developed fatal squamous cell lung
cancer three years later. Eight patients (6 renal cancers, 2 ureteral cancers)
died from unrelated illnesses. Three other grafts lost function 7 months and 6
years following transplantation (2 renal cancers and one ureteral cancer). All
remaining grafts continue to function with median and mean follow-ups of 25
and 32 months.
Discussion: Based on our experience we believe that in case where nephrectomy
is performed for small, localized, incidentally detected small renal cancer or
ureteral cancer, the kidney should be considered for transplantation to carefully
selected patients. In countries where deceased donors are scarce, these kidneys
will be a last resort for patients on the kidney transplant waiting list.
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1137 REVIEW OF JAPANESE PRACTICE FOR SMALL RENAL
CELL TUMORS: ESTIMATION OF NUMBER OF GRESTORED
KIDNEY TRANSPLANTATION H FROM THE PATIENTS WITH
SMALL RENAL CELL TUMORS IN JAPAN.
Y. Tsutsumi1, M. Mannami2, R. Mannami2, N. Mitsuhata3, M. Nishi4,
K. Nannba5, S. Fujita6
1
Fujita Health University, 2Uwajima Tokushukai Hospital, 3Kure Kyosai
Hospital, 4Kagawa Rosai Hospital, 5Rokumeisou Pathology Center,
6
University of Florida
Background: Restored kidney transplant (RKTx) has a great potential to
increase available renal allografts. In this study, we estimated the number of
RKTx from the kidneys with small renal cell tumors (RCC) in Japan, according
to the questionnaire sent to the representative hospitals.
Material and Methods: Questionnaire was sent to 10 various hospitals,
representing Japanese hospitals including 2 universities, asking the numbers of
all RCC cases, partial resection cases for RCC patients, and tumor size of each
case in 2004 -2006. The incidence rate of renal cell carcinoma in Japan was
estimated based on the cancer registry of Hiroshima prefecture, and we applied
it to estimate the number of possible RKTx.
Results: All RCC surgical cases were 613 in 10 hospitals, of those the
number of T1a cases (tumor size: not more than 4.0 cm) was 283 (46.2%).
112 underwent partial resection out of 283 T1a cases (41.9%). Expected rate
of total nephrectomy for T1a RCC patients out of all RCC patients is (283 –
112) /613 = 27.9%. According to the cancer registry of Hiroshima prefecture,
estimated surgical cases of RCC in Japan is expectedly 6660 yearly. The annual
number of total nephrectomy for T1a RCC cases is 6660 X 0.279 = 1858.
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Methods: All HARS nephrectomies were performed by one single surgeon.
Access and hand port position was via pfannenstiel incision.
Results: Since the introduction till the end of February 2008, 73 out of 84
LDN were performed with HARS. 42 HARS operated donors were female
and 31 male, with an average age of 49 years. 62 left sided and 11 right
sided nefrectomies were performed, where 67 kidneys had single artery,
and 6 had two or more arteries. Mean operation time was 148 minutes
compared to 244 minutes in the LLDN. In the first 10 HARS operations
mean operation time was 168 minutes, compared to 144 minutes in
the last 63. None were converted, but four peroperative incidents were
experienced, one clip failure on a lumbar vein, and three failures with
the vascular stapler, where two times clips blocked the stapler suture
at the kidney side of the vein, and one technical failure of the stapler,
where the stapler clips did not close when dividing the artery. No severe
postoperative complications were experienced, but three donors developed
wound infection and two more had wound haematoma in the pfannenstiel
incision. We had three early graft losses, two due to venous thrombosis
and one due to ischemia, but none were believed to be associated with
the nephrectomy technique. One venous thrombosis was in a right kidney.
Two recipients experienced delayed graft function, one was in need of
reoperation early due to bleeding, and the other was from the donor with
clip failure of a lumbar vein.
Conclusion: So far HARS in our hands is a fast and safe procedure. Compared
to LLDN, we experienced reduced operation time together with the advantage
of retroperitoneal access. Failure of clips and vascular stapler with potential
bleeding complications emphasizes the advantage and increased security of a
hand assisted technique.
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Discussion: Estimated number of renal allograft for Restored kidney
transplantation is up to around 2000 yearly. This can be a great source of donor
organ for the patients who are longing for the renal transplantation. The number
is 10 times of current cadaveric renal allograft number in Japan.
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1138 URINARY LEAKAGE IN RENAL TRANSPLANT
PATIENTS
A. Gurkan1, S. Kacar2, C. Varýlsuha1, C. Karaca2, F. Akman2, S. Tilif1
1
GOP Hospital Organ Transplantation Center, 2Kent Hospital Organ
Transplantation Center
Purpose: Urinary leakage is of the most difficult complication to deal with in
the renal transplantation procedure. We examined the factors effecting urinal
leakage in our renal transplant patients.
Patients and Methods: During the time period between Nov. 2005 and Feb.
2008, 138 renal transplantations have been performed in Izmir Kent Hospital
and Istanbul G.O.P Hospital. 94 (68.1%) of these patients are live-related
and 44 (31.9%) deceased donor transplantations. Mean age of the donors and
recipients were 45.7 and 38.4, respectively. 84 (60.9%) of the patients were
male. All urinary anastomosis were performed by the method of Lich-Gregoir.
Double-J tube was used in 81 (58.7%) of them. 13 (9.4%) of the patients had
multiple arteries which were anastomosed with double barrel manner. The
relation between urinary leakage and certain factors such as acute rejection,
acute tubular necrosis, recipient gender, delayed graft function, usage of ATG,
donor gender, number of arteries, warm ischemia time, cold ischemia time,
usage of double-J catheter, donor type, donor age, recipient age and vascular
complication were analyzed in this study. Chi-square and student-t tests were
applied for statistical analysis.
Results: All the patients were followed-up during the study. 2-year graft and
patient survival were 100%. 16 (11.6%) and 3 (2.1%) patients have experienced
acute rejection episodes and acute tubular necrosis, respectively. 6 (4.3%)
patients had vascular complications whose have been treated properly. 10
(7.2%) urinary leakages were seen in this series. Only the application of double-J
catheter and donor age (p= 0.025) were found to be statistically different in
effecting urinary leakage. Urinary leakage rate was 2.5% (2 patients) in the
patients whom urinary anastomosis had been performed via double-J catheter
insertion and 14,0% of the patients in whom double-J catheter was not used
(p= 0.016). In the double-J group, one of the leakages was seen postoperative
15th day, probably due to severe acute rejection episode. Both leakages were
treated with suturing the hole. Mean donor age was found to be 45.2 in the
patients whom urinary leakage was not seen, while 52.1 in the patients with
urinary leakage.
Conclusion: Although donor age was found to be one of the two factors
effecting urinary leakage; insertion of double-J catheter was the only one, which
the surgeon could be able to affect the course of the procedure. So, we suggest
the insertion of double-J catheter in all renal transplantation procedures.

thrombosis.
Conclusion: This study suggests that a reduced dose of enoxaparin in conjunction
with aspirin is a reasonably safe and effective option for thromboprophylaxis in
the peri-transplant period.
Demographics of study population
Age
Male
Caucasian
Living donor recipients
Delayed graft function
Enoxaparin dose
Post-op day enoxaparin started
Number days enoxaparin continued

55.1 ± 14.7 yrs (19-77)
67%
93%
73%
13%
0.42 ± 0.11 mg/kg/day
1 ± 0.7
10.4 ± 8.3 (1-30)

Indication for anticoagulation
Hypercoaguable state
Prior allograft thrombosis
Mechanical heart valve
Atrial fibrillation
Unknown or miscellaneous

49%
4%
22%
29%
11%

Bleeding complications
Major bleeding
Hemoglobin fell by ≥ 2 g
Minimum 2 units PRBC transfused
Perinephric hematoma
Incidence
Requiring drainage
Other bleeding complications
Retroperitoneal hematoma
Hematuria
Re-exploration

13%
11%
4%
9%
2%
2%
4%
0%
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1140 EN BLOC LIVER AND KIDNEY TRANSPLANTATION
FOR CHILDREN
T. Kato, E. Island, J. Chander, G. Selvaggi, M. Velasco, A. Tzakis
University of Miami
Background: En bloc liver and kidney transplantation can be used for children
who require simultaneous liver and kidney transplant.
Methods: Retrospective review of three children who received en bloc bilateral
kidney and liver graft at our institution.
Results: Patient’s ages were 1.5, 9 and 12 years. Diagnosis was polycystic kidney
and hepatic fibrosis in 2. Primary oxalosis in the other. Liver and bilateral kidneys
were harvested en bloc. Arterial inflow was from the recipient’s infra renal aorta.
Suprahepatic vena cava of the donor was anastomosed to the recipient in a
piggyback fashion. Age of donor was 4 yo, 5 yo and 10 mo. Imunosuppression
regimen included tacrolimus, steroids and daclizuab. All three recipients are alive
and well at 7 years, 5 years and 8 months from the transplant. Posttransplant liver
and kidney function were excellent in all three of them. No surgical complication
has been seen. Liver rejection was seen in two of them.
Conclusion: En bloc liver and kidney transplant can be safe and effective
option for children who require simultaneous liver and kidney transplant.
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1139 LOW DOSE ENOXAPARIN AND ASPIRIN FOLLOWING
KIDNEY TRANSPLANTATION IN PATIENTS AT RISK FOR
BLEEDING OR THROMBOSIS
R. Shapiro, K. Sperling, N. Shah, C. Wu, A. Basu, H. Tan, J. McCauley,
F. Bontempo
University of Pittsburgh School of Medicine
Background: Renal transplantation in patients with a hypercoaguable state
or on chronic anticoagulation is a potentially difficult clinical challenge. A
number of strategies have been tried to reduce the risk of thrombosis, but they
have yielded conflicting results. Some approaches have been associated with a
high incidence of significant bleeding.
Methods: We reviewed the medical records of 45 high-risk patients transplanted
at our institution over the past 5 years who were treated with low dose aspirin
and low dose enoxaparin post-operatively.
Results: There were no cases of allograft thrombosis. There was a 13.3%
incidence of major bleeding in patients receiving a mean daily dose of 0.42
mg/kg of enoxaparin and 81 mg of aspirin, although no patients required
re-exploration for bleeding. One patient (2.2%) developed a deep venous
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1141 FACTORS INDUCING IMMEDIATE RENAL FUNCTION
IN TRANSPLANTATION ENGRAFTING RENAL GRAFTS
FROM CARDIAC DEAD DONORS
K. Hayakawa, H. Sasaki, M. Kusaka, T. Maruyama, R. Shiroki, A. Sugitani,
K. Hoshinaga
Fujita Health University
Introduction: In renal transplantation engrafting kidneys donated after cardiac
death (DCD). the incidence of delayed graft functions (DGF) is common
compared to that of brain dead donors. This phenomenon chiefly depends on the
unstable renal circulation of DCD donors before cardiac death; however in certain
number of patients, we have immediate graft function (IGF) achieved even under
such poor conditions. The objective of this study is to evaluate the contributable
factors for IGF in renal transplantation engrafting kidneys from DCD donors.
Patients and Methods: From January 1983 to February 2008, we recovered
409 kidneys from DCD donors at our center. Among them, 24 grafts have
never had graft function. In this study, we enrolled 385 kidneys, which could
recover functions with or without hemodialysis after transplantation. Kidneys
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1142 DONOR AGE AND WARM ISCHEMIC TIME ARE RISK
FACTORS FOR PRIMARY NON-FUNCTION IN RENAL
TRANSPLANTATION ENGRAFTING KIDNEYS FROM
CARDIAC DEAD DONORS
K. Hayakawa, H. Sasaki, M. Kusaka, T. Maruyama, R. Shiroki, A. Sugitani,
K. Hoshinaga
Fujita Health University
Introduction: In renal transplantation engrafting kidneys donated after cardiac
death (DCD). the incidence of delayed graft functions and primary nonfunctions (PNF) are not rare compared to that of brain dead donors.
In this study, we investigate the outcome of transplantation engrafting kidneys
from DCD donors and evaluate the risk factors for PNF.
Patients and Methods: In this study, 409 kidneys recovered from DCD donors
at our center were enrolled. Kidneys were procured from DCD donors using
in situ regional cooling technique. After procurements, all kidneys were cold
preserved. Grafts were classified into 2 groups; having graft function or PNF.
As risk factors for PNF we employed donor age, cause of death, donor serum
creatinine on admission, donor serum creatinine immediately before donation,
recipient age, warm ischemic time (WIT) and total ischemic time (TIT).
Results: Twenty-four grafts have never recovered the functions after
transplantations (PNF: 5.9%). and among the other 385 grafts (functioning
graft: FG). 57 grafts had immediate function without post-transplant
hemodialysis (13.9%) and 328 grafts recovered the functions with posttransplant hemodialysis (80.2%).
Between PNF and FG, there was no significant difference except WIT (P<0.05)
when the mean values were compared. @On the other hand, the multivariate
logistic regression model to test associations with PNF indicated that donor
age and WIT over 35 minutes were selected as significant risk factors using
stepwise method (p=0.03, <0.01).
Conclusion: Donor age and WIT over 35 minutes are significant independent
risk factors for PNF in transplantation from DCD donors.

CONCURRENT ORAL SESSION 83: PRESERVATION
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1143 LIMITED PENETRATION OF PERFLUOROCARBON
IN PANCREAS PRESERVED BY THE TWO-LAYER METHOD
FOR ISLET TRANSPLANTATION DEMONSTRATED BY
19FLOURINE MAGNETIC RESONANCE SPECTROSCOPY AND
HEAD SPACE GAS CHROMATOGRAPHY
A. Agrawal1, P-W. So, P. Martin, P. Steve, F. Barry, D. Brian
1
Royal Free Hospital, 2Hammersmith Hospital, 3Royal Free Hospital, 4Royal
Free Hospital, 5Royal Free Hospital, 6Royal Free Hospital
Introduction: The mechanism of action of the two-layer method (TLM) of
pancreas preservation remains unclear. Direct measurements of pO2 in the

core of TLM-preserved pancreas have yielded conflicting results. The degree
of penetration of perfluorocarbon (PFC) into the substance of pancreas during
TLM storage has not been established.
Materials and Methods: Segments of porcine pancreas (7.5 cm in length)
were preserved either in University of Wisconsin solution (UW) alone
or in TLM for 24 hours and then studied using a Varian INOVA 9.4T MR
spectrometer. Tissues were suspended in UW solution and an external standard
of PFC was introduced for quantitation. Four consecutive transverse images
of 4mm thickness were obtained using a spin-echo sequence: repetition time
(TR) of 1s, echo time (TE) of 20ms, field of view (FOV) of 45 x 45cm, matrix
size 256 x 128 and 4 averages. 19F MRS was then performed with the same
parameters. For head space chromatography 500mg of pancreatic tissue was
transferred to 50ml Pyrex vials containing 2g anhydrous magnesium sulphate.
The bottles were placed in a microwave oven and heated for 90s at 200°;C to
volatilize the PFC. One ml of headspace was analyzed in a gas chromatograph
equipped with a flame ionization detector.
Results: 19F MRI/MRS – In transverse 19F MR images of the porcine pancreas
after 24h storage in TLM, PFC phantom was readily detected but no fluorine
signal was obtained from the pancreas. 19F MR spectra typical of PFC were
not obtained from either UW- or TLM-preserved pancreas with non-localized
19F MRS. GC-FID – The mean concentration of PFC in TLM pancreas (n=6)
was 0.011nl/g (SD ±0.006). not significantly different from the background
concentration (0.012nl/g, SD ± 0.006) in UW pancreas (n=6, p = 0.42).
Conclusion: There is no evidence of penetration of perfluorocarbon in pancreas
preserved by the two-layer method and the mechanism of action of the TLM
remains speculative.
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1144 THE ADDITION OF ADENOSINE TO UW: DOES IT HELP?
C. Corps1, M. Shires2, D. Crellin2, R. Smolenski3, J. Pratt2, J.P.A. Lodge1
St. James’s University Teaching Hospital, 2LIMM, Leeds University,
3
Harefield Hospital, Imperial College London,
Introduction: ATP precursors are often added to preservation solutions in the
belief that once the organ is reperfused the precursors will help to build ATP
back up more quickly, so returning the organ back to its original metabolic
state.
Adenosine is added to University of Wisconsin Solution (UW) to overcome
this lack of nucleotides with the theory that it will be available at reperfusion
for the reformation of ATP. But Adenosine has a short half in blood (<1
second). so in practice will it be available for use following reperfusion
or will it have been broken down further? During hypothermic organ
preservation Adenosine Triphosphate (ATP) degrades rapidly to form
adenosine diphosphate (ADP) and adenosine monophosphate (AMP).
Although these are not able to diffuse across the cell membrane, when AMP
is dephosphorylated to the nucleoside adenosine by 5’-nucleotidase, this can
freely diffuse across the cell membrane leading to a total absence of adenine
nucleotides in the cell.
This work studied ATP and it’s metabolites during preservation of the rat
liver using UW, which contains Adenosine, or either Histidine Tryptophan
Ketoglutarate (HTK) or a new phosphate based preservation solution, LS,
under development at our institution, neither of which contains Adenosine.
Methods: Livers were perfused and at various time points, tissue samples were
analysed for ATP and metabolites by HPLC.
Results: Although the addition of adenosine to UW did correspond to the
expected significant difference in overall adenosine levels, at no time did it
correspond to higher levels of ATP during preservation. Similarly the addition
of adenosine to LS did not cause a corresponding significant increase in ATP
levels.
After less than 4 hours any advantage in concentration of the adenosine in the
UW has disappeared, which was probably due to the adenosine having a short
half life and being broken down to its metabolites.

1
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were procured from DCD donors using in situ regional cooling technique.
After procurement, all kidneys were simply cold preserved. Grafts were
classified into 2 groups; without post-transplant hemodialysis (IGF) or with
post-transplant hemodialysis (DGF). As risk factors, we employed donor age,
cause of death, donor serum creatinine on admission, donor serum creatinine
immediately before donation, recipient age, warm ischemic time (WIT) and
total ischemic time (TIT).
Results: Fifty-seven grafts had IGF after transplantations (14.8%). and the
other 328 grafts revealed DGF. Among several factors associate with donation
and transplantation, serum creatinine less than 2.0 mg/dl immediately before
donation, TIT less than 6 hours and recipient age less than 25 years old are
significantly different between IGF and DGF respectively (p<0.05). The
multivariate logistic regression model to test associations with IGF indicated
that serum creatinine level than 2.0 mg/dl immediately before donation,
recipient age less than 25 years old and TIT less than 6 hours were selected as
associate risk factors by stepwise method (P<0.01).
Conclusion: Kidneys from DCD have a chance to achieve immediate graft
function, if donated under condition of good serum creatinine level, short TIT
and transplanted to young recipient.
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Discussion: Therefore for cadaveric transplantation, when the ischaemic time
is usually greater than 4 hours the levels of adenosine in the tissues will not
be any higher in UW than those tissue perfused with HTK or LS. Only in live
donor transplants where the cold ischaemic time is short may there be some
advantage to the addition of adenosine.
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1145 HISTOLOGICAL COMPARISON OF LIVER TISSUE
PRESERVED IN UW COMPARED TO TISSUE PRESERVED IN A
NOVEL SOLUTION
C. Corps1, M. Shires2, S. McKenzie1, D. Crellin2, J. Pratt2, J.P.A. Lodge1
1
St. James’s University Teaching Hospital, 2LIMM, Leeds University,
Introduction: Histological analysis of rat liver tissue during preservation and
following reperfusion was done to compare the efficiency of a novel solution,
LS, under development at our institution.
Methods: Livers were perfused with either LS or the “Gold Standard” of
preservation solutions UW (University of Wisconsin solution). Tissue samples
were taken and stored in gluteraldehyde at time zero and 5 minutes, 1, 4 and 24
hours after the start of preservation.
Other livers were stored in the same way for 24 hours, but no samples were
taken from them during preservation. These livers were then reperfused
with rat blood and placed on an Isolated Perfused System and underwent
reperfusion on this system for 2 hours. After this period liver samples
were taken and placed in gluteraldehyde for histological analysis. All the
samples were analysed using two different histological stains: PAS and
Gordon and Sweet.
Results: Glycogen disappears from hepatocytes of livers preserved in LS at
a slower rate than hepatocytes of livers preserved in UW, with glycogen still
being present after 24 hours when preserved with LS but not seen with UW.
Following 2 hours reperfusion, glycogen can be seen in many hepatocytes
originally perfused with LS, whilst very little is seen in those perfused with UW.
Due to the large amount of cell shrinkage seen in UW preserved livers reticulin
is seen to breakdown quickly and takes a long time to reform following
reperfusion. In LS perfused livers there is a relatively small change in cell
volume during perfusion and a correspondingly low amount of reticulin
breakdown and following reperfusion reticulin is reformed quicker than with
UW perfused tissue.
Discussion: These results show that histologically LS preserves the liver as
well as UW or even better. Following reperfusion of the liver the damage that is
done to the reticulin is reversed more quickly in LS preserved liver than in UW
preserved liver and the glycogen is also seen to build up again more quickly
in LS preserved liver. This means that the improvements seen in liver tissue
preserved in LS over those seen in UW are followed through to reperfusion.
LS can therefore be believed to be as good a preservation solution as the Gold
Standard of UW.
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1146 METABOLIC AND BIOCHEMICAL ANALYSIS OF
HEARTS PRESERVED IN DIFFERENT PRESERVATION
SOLUTIONS.
C. Corps1, M. Attia1, D.J. Potts2, J.P.A. Lodge1
1
St. James’s University Teaching Hospital, 2Department of Biological Science,
University of Leeds,
Introduction: A solution has been under development at our institute, based on
Phosphate-Buffered Sucrose, which has shown good preservation for kidneys
and livers. This work used a refined version of this solution to be used in heart
preservation and compared it to solutions which are already widely used.
Method: Hearts were mounted initially mounted in a Langendorff configuration
for a washout and equilibrium period, during which cannulation of the left
atrium took place. Hearts were then flushed with 15ml of the preservation
solution and left at 4˚C to be reperfused 6 hours later in a Langendorff working
heart model for 15 minutes followed by working perfusion for 30 minutes.
For the measurement of the enzymes the initial 1.5ml of the coronary effluent
was collected immediately after the storage period and tested for Creatine
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Phosphokinase (CPK) and Lactate Dehydrogenase (LDH). The hearts were then
dropped immediately into liquid nitrogen in order to measure the Adenosine
Triphosphate (ATP). Lactate and Creatine Phosphate (CP).
Spectrophotometric analysis was used to assess both the release of CPK and
LDH into the coronary effluent, and the level of ATP, Lactate and CP in the
frozen heart tissue.
Results: Table 1:
Solutions

CPK (IU/L)

LDH (IU/L)

Lactate (μM)

ATP (μM)

CP (μM)

PBSH (n=6)

18.9 ± 2.8

26.4 ± 3.6

5.7 ± 0.4

1.7 ± 0.4

2.2 ± 0.4

STH (n=8)

19.9 ± 4.0

31.0 ± 3.3

7.5 ± 0.5

0.8 ± 0.2

0.7 ± 0.2

UW (n=7)

41.0 ± 4.9

42.1 ± 3.2

7.8 ± 0.9

0.3 ± 0.1

1.3 ± 0.5

CS (n=8)

22.9 ± 2.4

20.4 ± 7.8

6.5 ± 0.5

0.9 ±0.2

2.2 ± 0.7

Conclusion: High energy phosphate compounds, including ATP and CP, are
markers of energy preservation within the cardiac muscle after preservation.
The higher the level of these compounds the better the quality of the organ
preservation, as the more energy remaining in the heart the higher the possibility
that it will start working again. ATP was found to be higher in heart preserved
in PBSH than in any other solution, and this reached significance over the UW
preserved hearts. Overall these results, coupled with better haemodynamic
recovery (not shown). show that PBSH is at least as effective in cardiac
preservation in the rat model of 6 hours cold ischaemia, as the other widely
used solutions tested.
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1147 OH-RADICAL SCAVENGERS AND IRON CHELATOR
IMPROVE POSTHYPOXIC CELLULAR INTEGRETY IN
GLYCINE-PRESERVED RENAL TUBULUES
M.K. Schilling1, M.R. Moussavian1, J.E. Slotta1, O. Kollmar1, M.D. Menger2,
1
Department of General, Visceral, Vascular and Pediatric Surgery, and
2
Institute of Clinical and Experimental Surgery, University of Saarland,
D-66421Homburg/Saar, Germany
Introduction: Cellular stress during reoxygenation is a common phenomen in
solid organ transplanation. Reperfusion and reoxygenation are characterized by
production of reactive oxygen spezies (ROS) and free radicals. Furthermore,
multiple substances like benzoat (BA). salicylate (SA). manitol (MAN).
tocopherol (TF). superoxide dismutase (SOD). catalse (CAT). ascorbid acid
(ASS) and desferroxamine (DFO) protect against free radicals. We studied
in tubular segments of rat kidney cortex (ITS) at 1mM concentrations of
scavengers and 0.1-1mM iron chelator during the posthypoxic recovery
period.
Materials and Methods: All tubules were suspended in Ringer’s solution
containing 5mM glycine and were oxygenated for 30min with 95% O2 and
5% CO2. There after, the ITS were gassed for 30min with 95% N2 and 5%
CO2, followed by a 60min reoxygenation period with 95% O2 and 5% CO2.
Untreated tubules served as controls (=100%). To investigate the oxidant
activity, membrane leakage and lipid peroxidation were measured by the
loss of the marker enzymes lactate dehydrogenase (LDH) and glutamate
dehydrogenase (GLDH) and the development of thiobarbituric acid reactive
substances (TBA-RS) in the solutions. Cell function was quantified by
gluconeogenesis (GNG) and intracellular potassium accumulation (K+).
Results: DFO, TF, ASS and BA significantly decreased the loss of marker
enzymes (LDH, GLDH). Cell function was also supported by MAN, TF, ASS
and DFO. BA improved K+ accumulation but had no marked effect on GNG.
Nevertheless, the observed protection by the hydroxy radical scavengers BA
and MAN indicated that even in glycine-protected reoxygenated tubulues
hydroxy radical (OH.) formation has deleterious effects. This hypothesis was
supported by similar effects of DFO: reduction of free tissue iron (Fe). released
by heme proteins, by the iron chelator DFO could have diminished the catalytic
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reaction of Fe on OH. formation via Fenton`s reaction.
Conclusion: Antioxidants in the storage solution confer protection against
reoxygenation damage. The most effective antioxidant was the iron chealator.
DFO, which was effective in the solution buffer. Suppression of reperfusion injury
in solid organ transplantation could be obtained by antioxidant therapy. However, it
is unclear how best to deliver the antioxidants to the site of oxyradical generation.
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M.K. Schilling1, M.R. Moussavian1, J.E. Slotta1, O. Kollmar1, M.D. Menger2,
1
Department of General, Visceral, Vascular and Pediatric Surgery, and
2
Institute of Clinical and Experimental Surgery, University of Saarland,
D-66421Homburg/Saar, Germany
Introduction: The reduction of peroxide radicals (O22-) by superoxide radicals
(O2-.). catalysed by iron ions (Fe2+) leads to the formation of hydroxy radicals
OH., a highly reactive biological oxidantive which may contribute to oxidant
stress in reoxygenated renal tissue.
We studied in tubular segments of rat kidney cortex (ITS) the effect of free
iron ions (Fe2+/Fe3+). hemoglobin (hb) and intact erythrocytes on reoxygenation
damage. We demonstrate that apart from the ischemic damage, additional tissue
injury evolves as a result of reoxygenation.
Materials and Methods: All ITS were suspended in Ringer’s solution
containing 5mM glycine and oxygenated for 30min with 95% O2 and 5%
CO2, followed by a 30 minutes period with 95% N2 and 5% CO2, and final
reoxygenation with 95% O2 and 5% CO2 for 60 minutes. Untreated tubules
served as controls (=100%). In the first series, different concentrations of free
hb were added to the incubation medium. In the second series, we examined
the effect of intact erythrocytes. To investigate the oxidant activity, membrane
leakage and lipid peroxidation were measured by the loss of the marker
enzymes lactate dehydrogenase (LDH) and glutamate dehydrogenase (GLDH)
into the medium and the development of thiobarbituric acid reactive substances
(TBA-RS). Cell function was analysed using gluconeogenesis (GNG) and
intracellular potassium accumulation (K+).
Results: Hb exerted cytotoxic effects indicated by significantly increased
enzyme leakage rates, lipid peroxidation and a significantly raised cell function,
(P<0.05) in ITS during extreme hypoxia and subsequent reoxygenation.
Moreover, we found that toxicity of both Fe2+ and Fe3+ ions increased with
rising concentration. However Fe2+ showed a higher tissue toxicity than Fe3+.
Conclusion: Our data clearly demonstrate a massive cytotoxic effect of free hb
in ITS, which critically depended on the reduction state of the iron ions.

POSTER BOARD NUMBER P1 – 234
1149 SIGNALING PATHWAY ON THE EFFECT OF
OXYGENATED WARM PERFUSION PRIOR TO COLD
PRESERVATION OF THE LIVER GRAFTS FROM NONHEART BEATING DONORS, AND THE ADDITIVE EFFECT OF
EDARAVONE
Y. Kobayashi, Y. Akamatsu, T. Iwane, A. Nakamura, S. Satomi
Division of Advanced Surgical Science And Technology, Graduate School of
Medicine, Tohoku University
Background and Aim: We reported that oxygenated warm perfusion prior to
cold preservation (pre-perfusion) improved energy metabolism and decreased
apoptotic cells in the grafts from non-heart beating donors (NHBD). previously.
In this study, we investigated the efficacy and molecular mechanisms of preperfusion and the additive effect of free radical scavenger, Edaravone (Ed).
Method: Rat liver ex vivo perfusion model was used. Liver grafts from Wistar
Rats were divided into four groups. HB group: grafts from heart beating
donor. NHB group: grafts from NHBD. PRE group: grafts from NHBD and
perfused prior to cold preservation. ED group: grafts from NHBD and perfused
with Ed containing buffer at pre-perfusion. Warm ischemic time was 30 min.
Oxygenated Klebs-Hensereit buffer at 37 °C was perfused via portal vain
during pre-perfusion for 30 min. and reperfusion for 60 min. Bile production
during reperfusion and ALT in perfusate were measured. MDA, MAPK family
and apoptosis were examined in liver tissues.
Result: Bile production in ED group was higher than that in NHB group. ALT

Parameters
HB group
NHB group
PRE group
Bile production
42.27±2.98
19.28±4.01†
21.87±9.311†
(μl/g/h)
TUNEL positive
3.65±1.69
110.08±52.09†
63.79±25.04†
cells (counts/mm2)
ALT (IU/l)
0.12±0.07
3.88±1.63†
1.22±0.40**†
MDA content
0.307±0.013
0.328±0.019
0.244±0.020**
(μmol/g protein)
*: P < 0.05 vs. NHB group **: P < 0.01 vs. NHB group †: P < 0.01 vs. HB group

ED group
24.46±4.422*†
39.83±14.86**†
1.29±0.42**†
0.239±0.022**

Table 2: p-JNK and p-p38 MAPK activity (Western Blot)
HB group
NHB group
PRE group
ED group
p-SAPK/JNK
0.24±0.18
1.08±0.59
0.38±0.12**
0.37±0.14**
(p-JNK/β-Actin)
p-p38 MAPK
0.45±0.27
0.53±0.34
0.25±0.13*
0.23±0.13*
(p-p38 MAPK/βActin)
The relative band intensities were expressed as the ratio of the protein of interest to beta-Actin. Results
were expressed as the means ± S.D.
*: P < 0.05 vs. NHB group **: P < 0.01 vs. NHB group
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1150 PROTECTIVE EFFECT OF GLYCERYL TRINITRATE
AND CARIPORIDE IN A MODEL OF DONOR HEART
PRESERVATION: ACTIVATION OF ERK 1/2 PATHWAY
J. Kwan2, L. Gao2, P. Macdonald1, M. Hicks1
St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: Demonstration of the association of pharmacological pre- and
post-conditioning with activation of pro-survival kinase pathways such the
p42/p44 extracellular signal-related MAP kinase (ERK 1/2) and the PI3K/
Akt pathways at reperfusion has provided a paradigm shift in the approach to
myocardial protection. We have previously demonstrated that inclusion of
preconditioning agents such as the nitric oxide donor, glyceryl trinitrate (GTN)
and the sodium hydrogen exchange inhibitor, cariporide (Car) in Celsior, a
commercially available storage solution, significantly improved post-storage
function in an isolated working heart model of donor heart preservation after 6
hours hypothermic storage1. The aim of the present study was to examine the
extent to which the ERK 1/2 and PI3K/Akt pathways were activated by these
agents.
Methods: Pre-arrest indices of cardiac function were measured in isolated
working rat hearts after 25 minutes. Hearts were arrested and stored for 6 hours
at 2-3°C in Celsior alone or Celsior supplemented with either 0.1 mg/ml GTN,
10μM Car alone or in combination. After storage, hearts were remounted on the
perfusion apparatus and indices of cardiac function were remeasured. Hearts
were then bisected and frozen in liquid nitrogen for Western blot analysis or
fixed for imunohistochemical processing.
Results: The values in the following table are post-storage recovery as
percentage of pre-arrest values (mean ± SEM) :
1

Heart Rate
Coronary Flow
(beats/min)
(ml/min)
None; 8
48 ± 12
31 ± 12
GTN; 9
94 ± 8*
70 ± 8*
Car; 6
115 ± 6*
82 ± 3*
GTN + Car; 6
95 ± 6*
85 ± 3*
P < 0.05 vs unsupplemented Celsior control.
Supplement; n

Aortic Flow
(ml/min)
15 ± 8
42 ± 7*
66 ± 4*
60 ± 5*

Cardiac Output
(ml/min)
22 ± 9
52 ± 7*
70 ± 3*
68 ± 3*

The observed improved post-storage function of hearts stored in Celsior
supplemented with glyceryl trinitrate and cariporide alone or in combination
was associated with: i) an increase in phosphorylation status of ERK 1/2, ii) an
increase in phospho Bcl2 (Ser87). an anti-apoptotic marker and downstream
substrate of ERK 1/2, iii) a decrease in pro-apoptotic cleaved (activated)
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1148 HEMOGLOBIN INDUCES CYTOTOXIC DAMAGE OF
GLYCINE-PRESERVED RENAL TUBULES

and tissue MDA content were reduced in PRE and ED group (table 1). p-JNK
and p-p38 MAPK were also reduced in PRE and ED group (table 2). In contrast,
pre-perfusion and addition of Ed did not influence the ERK activity. TUNEL
positive cells in ED group were fewer than that in NHB group (table 1).
Conclusion: Oxygenated perfusion prior to cold preservation improves
the viability of grafts from NHBDs as represented in improvement of bile
production, release of transaminase, and down regulation of JNK and p38
MAPK pathway was involved in these effects. Addition of Ed to pre-perfusion
led to increasing bile production and reducing in cell death. Pre-perfusion was
suggested to be promising strategy in liver transplantation from NHBD, though
further investigation should be necessary.
Table 1
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caspase 3 (P < 0.01 all celsior supplements vs unsupplemented Celsior for each
protein) and iv) no increase in phosphorylation status of Akt.
Conclusions: GTN and cariporide alone or in combination are able to activate
the ERK 1/2 pro-survival pathway. Importantly for the logistics of clinical
cardiac procurement, the heart need only be exposed to the protective agents at
the time of arrest and hypothermic ischemic storage obviating the need for pretreatment of the donor or treatment (of the recipient) at reperfusion.

MONDAY

POSTER BOARD NUMBER P1 – 236
1151 SUCCESFUL TRANSPLANTATION OF ALLOGENEIC
AND XENOGENEIC ARTERIAL GRAFTS PRESERVED IN
PULVERIZED SODIUM CHLORIDE
M. Gewartowska1, M. Maksymowicz1, H. Doleżyczek1, W.L. Olszewski1,2
Department of Surgical Research and Transplantology, Medical Research
Center, Polish Academy of Sciences, Warsaw, Poland 2Norwegian Radium
Hospital, Oslo, Norway
Arterial graft patency is limited by a process of rejection at the site of
implantation. In our previous methods dehydrated studies skin fragments
preserved for 10 months and transplanted to SCID mice were taken by
recipient.
Aim: To establish a method of successful aortic preservation for long time
periods with unchanged morphological structures and low allogeneic and
xenogeneic reactivity.
Methods: Freshly obtained fragments of rat aorta were fixed in anhydric
sodium chloride and stored at 4oC up to 3 months. Cryosections of desalinated
aortic samples were evaluated on histology using H/E method, trichrome and
Gomori staining and immunohistochemical staining for CD 31, factor VIII
and actin. Group 1.Syngeneic and allogeneic transplantations of rat aorta were
performed in a LEW to LEW or BN to LEW combination. Specimens were
collected 1 year after transplantation. Histological evaluation was the same as
before grafting. In group 2, fragments of small arteries of a diameter of 2-4 mm
obtained from the amputated human legs were transplanted to LEW rats as in
group 1. Histological evaluation was carried out with use of mAbs against rat
and human endothelial cell, lymphocyte and macrophage antigens.
Results: Group 1.H/E staining showed preserved anatomical structure of aortae
after storage in NaCl. No significant differences between NaCl fixed and nonfixed aortae in staining against CD 31, factor VIII, actin and trichrome were
found. The orthotopically transplanted aortae did not evoke local recipients
reaction and pulsated up to 1 year after transplantation. Moreover, we did
not observe significant cellular infiltrates around the graft after subcutaneous
implantation of fixed aorta. The tensile strength of harvested specimens did not
differ from controls. Group 2. Grafts were remaining pulsating over a period of
3 months. Only minor peri-graft infiltrates composed of rat ED1 (macrophage)
cells. Grafts retained their structure and human CD31 on endothelial cells.
Conclusions: Perfectly preserved anatomical and molecular structure of
transplanted aortae stored at 4oC for months, indicate that dehydration in
anhydric NaCl may be considered as a novel method for preservation of arterial
grafts. Moreover, limited allo- and xenogeneic reactivity of recipient to the
graft may protect against mechanical weakning of the pulsating graft.
1

POSTER BOARD NUMBER P1 – 237
1152 DANSHEN PROTECTS KIDNEY GRAFTS FROM
ISCHEMIA/REPERFUSION INJURY AFTER EXPERIMENTAL
TRANSPLANTATION
A. Nickkholgh1, X. Guan1, G. Dei-Anane1, H. Bruns1, R. Liang1,
M-L. Gross2, M. Kern2, J. Ludwig3, M.W. Büchler1, P. Schemmer1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Dept. of
Pathology, Ruprecht-Karls University of Heidelberg, 3Central Laboratory,
Ruprecht-Karls University of Heidelberg
Introduction: Ischemia/reperfusion injury (IRI) remains one of the major
problems in transplantation. Substances with low overall toxicity that can
ameliorate IRI are desperately needed. Hence, we investigated the effect of
the traditional Chinese medicine Danshen (DS, Salvia miltiorrhiza) on IRI in
experimental kidney transplantation (eKTx).
Methods: Sprague-Dawley rats underwent eKTx. Two groups were infused
with 1.5ml DS 10 minutes before organ harvest or transplantation while
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controls received the same volume Ringer solution. After 20h of cold storage
in HTK, eKTx was performed.
Blood and tissue samples were collected 6h after reperfusion. BUN, creatinine,
LDH, ALT and tubular damage (TDI). caspase-3 (CI) and heat shock protein
indexes 72 (HI). superoxide dismutase (SOD). inducible nitric oxide synthase
(iNOS) and tumor necrosis factor (TNF) á were assessed.
Results: Donor preconditioning with DS (DS-d) significanty decreased BUN,
creatinine, LDH and AST to 91%, 97%, 65% and 97% of controls while
preconditioning of the recipient (DS-r) decreased values to 80%, 82%, 69%
and 58%, respectively (p<0.05). TDI and CI decreased significantly in both
groups (DS-d: 96% and 67%, DS-r: 83% and 75% of controls; HI and SOD
increased significantly (DS-d: 143% and 173%, DS-r: 166% and 194% of
controls). Further, iNOS and TNF á decreased (DS-d: 84% and 61%, DS-r:
79% and 67%) after DS.
Conclusions: Preconditioning of both donors and recipients with DS reduces
IRI and thus improves graft function in eKTx.

POSTER BOARD NUMBER P1 – 238
1153 SUCCESSFUL SOLID ORGAN TRANSPLANTATION
FROM BRAIN DEATH BY SALMONELLA ENCEPHALOPATHY
Y.S. Han, D.L. Choi, M.S. Kim, E.J. Jang, J.Y. Park, J.H. Mun
Daegu Catholic Medical Center, Catholic University of Daegu, School of
Medicine
Systemic donor infections are largely contraindication to cadaveric organ
donation for transplantation due to fear of transmitting the pathogenic
organisms to the immunosuppressed recipients. Especially, Salmonella species
infection, because of virulence, tendency to adhere to endothelial surfaces, and
the ability of spread hematogenously to other sites, render a donor undesirable.
However, We experienced successful organ transplantation from donor with
negative culture after administration of adequate antimicrobial therapy.
A 53-year old man was transferred to our hospital for decision of brain death
and organ donation. The patients had an encephalopathy following infection of
Salmonella Group D as the cause of brain death. The donor was treated until
blood cultures were negative. Cetotaxime was used for over 14 days in the
intensive care unit. The liver and two kidneys were procured. All recipients
are alive with excellent graft function at 12 months following transplantation.
The question is whether recipients are infected by grafts from the donors even
though all them are given prophylactic antibiotic therapy. Our experience
suggests that donor with Salmonella infection under proper treatment can be
considered for transplantation.

POSTER BOARD NUMBER P1 – 239
1154 PREDICTIVE PRESERVATION: TOWARD AN EVIDENCEBASED ORGAN RETRIEVAL STRATEGY
L. Hostert1, J. Pratt2, S. McKenzie1, D. Potts3, P. Lodge1
1
Department of Organ Transplantation Leeds Teaching Hospitals, 2Leeds
Institute of Molecular Medicine, 3University of Leeds
In renal transplantation the choice of preservation strategy for the various
donor types is not evidence based. This study is a first attempt to match the
efficacy of preservation fluids to the period of cold ischaemia using an in-depth
assessment of functional parameters. The aim of this work is to investigate the
effects of preservation fluids over time to predict which fluid should be used in
any particular clinical scenario, so- called “Predictive Preservation”.
Male Wistar rat kidneys were flushed with a preservation solution (PBS140, LS,
SLS, HOC or UW) and were stored at 4oC for 0-72 hours (n = 6/group). The
kidneys were then maintained for 2 hours on an optimised ex vivo reperfusion
circuit at 37oC. Physiological analyses of reperfusion fluid and urine were
performed at 30 minute intervals to assess ischaemia/reperfusion injury (I/RI)
to components of the nephron.
Using the optimised ex vivo model, preservation with LS produced significantly
improved urine flow rate, GFR and% Na+ reabsorption (29, 44 and 25%
increase respectively) when compared to organs preserved in PBS140, HOC
or UW (P<0.05) after 24 hours of preservation. Compartmental assessment
suggested LS attenuated tissue damage in the glomerulus, the proximal tubules
and the collecting system that was supported by histological observation. Using
percentage contribution analysis the data showed differential effects of time on
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1155 TOLERANCE OF THE COLD PRESERVATION OF LIVER
GRAFT IS LIVER MASS DEPENDENT
Y.L. Gu1, J.F. Schlaak2, U. Rauen3, A. Paul4
1Department of General, Visceral And Transplantation Surgery, 2Department
ofGastroenterology and Hepatology, University Hospital of Essen, 32Institute
of Physiological Chemistry, University Hospital of Essen, 4Department of
General, Visceral And Transplantation Surgery
Aims: Due to the shortage of donor livers, partial liver transplantation is
currently being used more and more frequently. The mechanisms of primary
graft non-function and factors affecting liver regeneration after small-for-size
(SFS) liver transplantation are not completely understood. The aim of the
present study was to assess the effect of cold ischemia time on postoperative
liver injury and graft regeneration after SFS liver transplantation using a rat
model.
Methods: Inbred male Lewis rats (250-300g) were subjected to 70% liver
resection as donors and the partial liver grafts were then transplanted into
recipients. Livers were preserved with an HTK (histidine-tryptophanketoglutarate) solution at 4°C for 5 hours (group A, n=5) or 8 hours (group
B, n=7) before transplantation. Full-size liver transplantations with 19 hours
cold ischemia were performed on a control group (group C, n=4). The animals
were sacrificed on postoperative day 7. Survival rate, liver function and
changes in the graft recipient body weight (GRBW) ratio of the recipients were
investigated.
Results: All animals in group A survived. Prolonged time of cold preservation
(8 hours) was associated with a statistically significant decrease of animal
survival in comparison to animals with 5 hours cold ischemia after SFS liver
transplantation (42.86% vs. 100%, p<0.05). All animals receiving a full-size
liver with a cold ischemia time of up to 19 hours survived. The initial GRBW
ratios of the recipients in group A and B were 1.49% ± 0.14% and 1.50% ±
0.12%, respectively (p>0.05). whereas on postoperative day 7 the GRBW ratio
was significantly lower in group B than in group A (4.27% ± 0.21% vs. 4.68%
± 0.38%, p<0.05).
Conclusions: The animal survival and the graft regeneration were significantly
reduced after only 3 hours prolongation of the cold storage for a small-forsize graft, suggesting that the small-for-size grafts are particularly sensitive
to cold storage injury. The cold preservation time of a full-size graft could be
almost 4 times longer than a SFS graft, indicating that the duration of the cold
preservation of liver graft is liver mass dependent.

POSTER BOARD NUMBER P1 – 241
1156 IMPROVED CORTICAL MICROCIRCULATION OF
PORCINE KIDNEY GRAFTS USING POLYSOL FOR WASH-OUT
AND COLD STORAGE PRESERVATION
M.C.J.M. Schreinemachers1, B.M. Doorschodt1, R.H. Tolba2, T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands,
2House of Experimental Therapy, University Clinic of Bonn, Germany
Background: The most widely used preservation method for kidney grafts
is cold static storage (CS) using the University of Wisconsin solution (UW).
To date, new preservation solutions have not been able to clearly improve
preservation quality of grafts. The aim of this study was to compare Polysol

(PS). a recently developed low viscosity preservation solution based on the
colloid Poly-Ethylene-Glycol, and UW solution for CS of porcine kidney grafts.
Furthermore, we evaluated real time parameters of cortical microcirculation,
pre-retrieval, at 10 minutes post-reperfusion and 7 days posttransplant at
sacrifice using the novel Oxygen-To-See (O2C) laser Doppler flowmetry and
remission spectroscopy system.
Methods: German Landrace pigs underwent left nephrectomy directly after
assessment of cortical microcirculation using the O2C. Kidneys were washed
out with PS or UW followed by 20 hr CS in PS and UW, resp. Thereafter,
the contralateral kidneys were removed prior to reimplantation of the
preserved kidneys. Ten minutes after reperfusion, the cortical microcirculation
was assessed. Renal function was measured daily. Prior to removal of the
kidney grafts for histological evaluation seven days posttransplant, cortical
microcirculation was reassessed and animals were sacrificed.
Results: All animals survived for 7 days. In the PS group, improvement of
microcirculation was seen as expressed by higher capillary blood flow, higher
blood flow velocity and higher tissue oxygen saturation values at 10 minutes after
reperfusion (capillary blood flow p<0.001, blood flow velocity p<0.001, tissue
oxygen saturation PS 88.9% vs UW 79.3%, p<0.05) as well as 7 days posttransplant
compared to the UW group (capillary blood flow p<0.001, blood flow velocity
p<0.001, tissue oxygen saturation PS 82.0% vs UW 66.6%, p<0.001). Overall, PS
preserved grafts showed improved recovery of renal function demonstrated by lower
posttransplant serum creatinine and blood urea values in the PS group in comparison
to the UW group (p=0.041 and p=0.048 resp.). Also, peak-creatinine and peak-urea
values were lower in PS preserved grafts (peak-creatinine, PS 4.79 ± 0.59 mg/dl,
UW 13.01 ± 2.86 mg/dl, p=0.004 and peak-urea, PS 81.5 ± 14.3 mg/dl, UW 225.8
± 60.2 mg/dl, p=0.015). At sacrifice, creatinine clearance rates in the PS preserved
grafts were significantly higher than in the UW group (33.09 ± 2.7 ml/min, vs.
12.30 ± 8.7 ml/min, p=0.046 resp.). Glomerular shrinking and tubular injury were
less pronounced in the PS group, compared to UW. Also, less inflammatory cell
infiltrates were present in the cortical region of PS preserved grafts.
In conclusion, using Polysol, cortical microcirculation was better preserved
and renal function was improved after 20 hr CS preservation compared to UW
solution. This study in a clinically relevant large animal model, suggests for
the first time since the introduction of UW solution that a new preservation
solution resulted in clearly improved preservation quality of kidney grafts.

POSTER BOARD NUMBER P1 – 242
1157 PRESERVATION OF KIDNEY GRAFTS WITH
THE AIRDRIVE, A NOVEL DISPOSABLE SYSTEM FOR
OXYGENATED PERFUSION
M-C. Schreinemachers1, B.M. Doorschodt1, T.M. van Gulik1, R.H. Tolba2
1Academic Medical Center, University of Amsterdam, The Netherlands,
2House of Experimental Therapy, University Clinic of Bonn, Germany
Body: Recently, a disposable machine perfusion (MP) system for preservation
of kidney and liver grafts has been developed, named the Airdrive (AD). This
air-pressure driven, hypothermic perfusion system allows for oxygenated
pulsatile MP during the entire preservation period.
The aim of the study was to assess MP preservation with the Airdrive using
the new low-viscosity perfusion solution Polysol (PS-AD) in comparison with
cold storage (CS) using Polysol solution (PS-CS) or University of Wisconsin
(UW-CS) as controls.
Methods: German Landrace pigs (18-32 kg) underwent left nephrectomy.
Kidneys were thereafter flushed with either UW (n=6) or PS (n=6) followed by
20 hr CS using UW or PS, respectively. Machine perfused kidneys were flushed
using PS followed by 20 hr of MP (n=6). Pulsatile perfusion was performed
with a mean arterial pressure of 20 mmHg at a temperature of 2-6 C. After
preservation, all kidneys were autotransplanted and the contralateral kidneys
removed. Renal function was assessed daily. Seven days posttransplant, animals
were sacrificed and the kidney grafts removed for histological analysis.
Results: All animals survived for 7 days. Overall, an improved recovery
of renal function was seen in both the PS-AD group and the PS-CS group
compared to the UW-CS group. Also, peak creatinine and peak urea values
were lower in PS preserved grafts for both MP and CS (peak creatinine (mg/
dl). PS- AD: 3.58 0.81, PS-CS: 4.79 0.59, UW-CS: 13.01 2.86, p=0.003, and
peak urea (mg/dl). PS-AD: 67.2 10.7, PS-CS: 81.5 14.3, UW-CS: 225.8 60.2
mg/dl, p=0.013). Mean posttransplant creatinine clearance rates were higher in
the PS-AD and PS-CS groups at all timepoints with significant differences at
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cold ischaemic damage in the different nephron compartments. In effect, the
cumulative data rank scores showed that from 24 to 48 hours, LS was optimal,
but not at either extreme. At time 0, PBS140 was best, and beyond 48 hours,
SLS or PBS140 was optimal.
In conclusion, a global assessment of functional parameters has enabled an
in-depth assessment of fluids used in experimental renal cold storage. The data
suggests different fluids should be applied where a short (living donation).
or longer (cadaveric) cold ischaemic time is anticipated, i.e. Predictive
Preservation. Importantly, all fluids which best protected the kidney from I/
RI were based on PBS140 and outperformed UW across the duration of cold
ischaemia. To diminish I/RI and maximise post-transplant functional recovery,
we advocate an evidence-based approach to preservation be developed in the
future and that consideration be given to PBS based preservation for clinical
renal transplantation.
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posttransplant days 2 and 7 (Creatinine clearance at day 7 (ml/min): PS-AD:
33.4 2.1, PS-CS: 33.1 2.7, UW-CS: 12.3 8.7, p=0.021). Histological evaluation
showed less glomerular damage, less tubular injury, less inflammatory cell
infiltrates and less edema in the machine perfused grafts compared to the cold
stored grafts. Also, grafts cold stored in Polysol showed better preservation of
structural integrity than UW preserved grafts.
Conclusions: Renal function after 20 hr of preservation was significantly
improved with both MP using the recently developed Airdrive MP system as
well as CS using Polysol as compared to UW-CS in a large animal model.
Structural integrity was better preserved using oxygenated pulsatile perfusion
compared to both PS-CS and UW-CS groups. This study in a large animal model
demonstrates significant higher quality preservation of oxygenated machine
perfusion of heart-beating kidney grafts using the Airdrive in combination with
Polysol, as compared to cold storage.

POSTER BOARD NUMBER P1 – 243
1158 IMPROVED RENAL FUNCTION OF WARM
ISCHEMICALLY DAMAGED KIDNEYS USING POLYSOL
M-C. Schreinemachers1, B.M. Doorschodt1, M.M. Idu1, R.H. Tolba2,
T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands,
2University Clinic of Aachen, Aachen, Germany
Background: The gold standard for preservation of warm ischemically damaged
kidneys is cold storage (CS) using Histidine-Tryptophane-Ketoglutarate
(HTK) solution. Recently, a new low-viscosity perfusion preservation solution,
Polysol (PS). was developed. The efficacy of PS has been proven in different
small and large animal organ preservation models. In a previous study using
a porcine renal autotransplantation model, the preservation of heart-beating
donor kidneys using PS resulted in improved renal function compared to the
University of Wisconsin solution.
The aim of this study was to assess the efficacy of PS for the preservation of
NHBD kidney grafts in a porcine autotransplantation model compared to HTK
solution and a uninephrectomy group as control.
Methods: Pigs (25-30 kg) underwent left nephrectomy after clamping the
renal vessels for 30 minutes. Kidney grafts were washed out with PS (n=6)
or HTK (n=6) and cold stored for 20 hr at 4 C. After the preservation period,
the contralateral kidney was removed and the preserved kidney was implanted
heterotopically. Pigs which underwent uninephrectomy served as non-ischemic,
non-transplanted controls (Uni, n=4). Renal function was assessed daily for
seven days, after which time animals were sacrificed and the kidney grafts
removed for histological analysis.
Results: All animals survived for 7 days. All PS-CS preserved grafts showed
immediate function, as demonstrated by urine production within 24 hours after
reperfusion as compared to 3 out of six grafts in the HTK-CS group. Overall,
the PS-CS group showed improved renal function compared to HTK-CS (serum
creatinine, area under the curve (AUC). p<0.01 and blood urea, AUC p<0.05,
resp.). Blood urea values of the PS-CS group (AUC) did not differ from the Uni
group. Serum creatinine peak-values were lower in the PS-CS group compared to
the HTK preserved grafts (p<0.0001). but higher when compared to Uni controls
(PS-CS vs Uni, p<0.0001 and HTK-CS vs Uni, p<0.0001; peak creatinine
(umol/l). PS-CS 629.8 ± 64.8, HTK-CS 1016 ± 39.6, Uni 170.8 ± 27.1). In
addition, peak-urea values provided a similar outcome. Histological evaluation
of the warm ischemically damaged grafts showed less tubular damage, less
edema, less inflammatory cell infiltrates and less necrosis in the PS-CS preserved
grafts compared to grafts washed out and preserved using HTK.
Conclusion: Application of the new Polysol solution for wash out and
CS preservation of warm ischemically damaged kidney grafts resulted in
significantly improved renal function and structural integrity when compared
to wash out and CS preservation using the current clinical standard HTK.

POSTER BOARD NUMBER P1 – 244
1159 EVALUATION OF FUNCTIONAL AND BIOCHEMICAL
EFFECTS OF WARM ISCHEMIA ON KIDNEY GRAFTS USING
AN OPTIMIZED PORCINE EXPERIMENTAL MODEL
M. Morsy, M. Hossain, M. Nortley, N. Kessaris, R. Chang.
Renal Transplant Unit, St George’s Hospital, London, UK
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Introduction: Warm ischemia negatively affects the outcome of organ
transplantation. The length of warm ischemia time (WIT) is difficult to
determine in clinical setting. Therefore, it can be difficult to assess the
damage sustained by the organs and predict their viability. We report our early
experience in developing an optimized porcine experimental model to assess
the effect of warm ischemia on kidney grafts.
Material and Methods: Twelve female wild-white pigs were included in
this study after obtaining a project license (PPL70/6580-UK). Additionally,
3 pigs (controls- 0 WIT) were used to optimize the surgical procedures
including surgical approaches, contralateral nephrectomy timing and ureter
exteriorization. The pigs were randomized into 4 groups (3 pigs/each) according
to the length of WIT; 30, 45, 60 and 90 minutes. The left kidney was exposed in
situ to WI by clamping the renal artery. A T-tube was inserted in the ureter and
exteriorized in the groin to check the urine before the contralateral nephrectomy.
A microdialysis needle was inserted in the cortex 30 minutes before clamping.
Microdialysis samples were collected every 15 minutes before and during
WI for glucose, lactate, pyruvate and glycerol analysis. The left kidney was
then reperfused. The contralateral kidney was kept in situ until the left kidney
function was approved by (T tube urine, ~7 days). The contralateral kidney
removal was performed after exposing it to the same WIT as the left kidney
in the same animal with microdialysis sample collection. Then, it was coldperfused in a pulsatile machine. The pig was kept alive for a week to assess the
function of the left kidney (urine output and serum potassium and creatinine).
Results: There was positive correlations between WIT and glycerol and lactate
concentrations (R2=0.779 and 0.105) with significant increase in the mean
change from baseline; 50, 29.33, 38.06, 119.53, 136.4, 128.2, 144.7 umol/L
for glycerol and 1.26, 1.86, 4.66, 3.82, 3.67, 2.87, 2.57 mmol/L for lactate at
0, 15, 30, 45, 60, 75 and 90 minutes WIT respectively. There was a negative
correlation between WIT and glucose and pyruvate concentrations (R2=0.909
and 0.807) with significant decline from baseline; 2.5, 1.89, 1.05, 0.84, 0.13,
0.03, 0.06 mmol/L for glucose and 64.4, 36.93, 24.6, 5.53, 3.58, 3.2, 1.9 umol/L
for pyruvate at 0, 15, 30, 45, 60, 75 and 90 minutes WIT respectively.
The perfusion flow was significantly lower and the resistance was higher at
60 and 90 minutes WIT compared to 0 and 30 minutes at pre-set 40 mmHg
pressure and 2-5Co. The glycerol and lactate concentration declined constantly
while there was no change in glucose and pyruvate during machine perfusion.
There was no observed delayed graft function with good urine output in all
groups.
Conclusions: We devised an optimized porcine experimental model to evaluate
the effect of WIT on the kidney function. It enabled evaluation of microdialysis
markers. It enabled utilizing the contralateral kidney in WIT and cold ischemia
studies. Although the number of animals is small, it demonstrated a trend of
change in microdialysis markers and perfusion parameters.

POSTER BOARD NUMBER P1 – 245
1160 NITRIC OXIDE SYNTHASE (NOS) COFACTOR ACTIVITY
OF TETRAHYDROBIOPTERIN (BH4) IS ESSENTIAL IN
ATTENUATING MICROVASCULAR REPERFUSION INJURY
FOLLOWING MURINE PANCREAS TRANSPLANTATION
M. Maglione1, R. Oberhuber1, P. Hengster1,2, M. Hermann2, W. Mark1, P.
Obrist3, G. Werner-Felmayer4, E.R. Werner4, R. Margreiter1, G. Brandacher1
1
Department of General and Transplant Surgery, Innsbruck Medical
University, Austria, 2Center for Islet-Cell Transplantation, Innsbruck Medical
University, Austria, 3Institute of PathologyKrankenhaus St. Vinzenz, Zams,
Austria, 4Division of Biological Chemistry, Biocenter, Medical University of
Innsbruck, Austria
Purpose: Tetrahydrobiopterin (BH4) is not only an essential cofactor for nitric
oxide synthases and thus a critical determinant of NO production but also a
strong antioxidant. In this study we compared the recently shown protective
effect of BH4 supplementation previous to organ retrieval with supplementation
of 4-amino-tetrahydrobiopterin (ABH4). a pteridin analogue with similar
chemical redox behaviour but no cofactor activity.
Material and Methods: Male syngeneic C57BL6 mice, were used as sizematched donor and recipient pairs. Cervical heterotopic vascularized pancreas
transplantation was performed with a modified no-touch technique. Pancreatic
grafts were subjected to 16h prolonged cold ischemia time (CIT) and different
treatment regiments: untreated (I). BH4 50mg/kg i.m. prior to organ reperfusion
(II) and ABH4 50mg/kg i.m. prior to organ reperfusion (III). Non transplanted
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CONCURRENT ORAL SESSION 84: INFECTIOUS DISEASE –
BACTERIAL, FUNGAL AND OTHER INFECTIONS
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1161 IS PREOPERATIVE INTRAVESICALLY APPLIED
ANTIBIOUTIC SOLUTION EFFECTIVE IN THE PROPHYLASIS
OF URINARY TRACT INFECTION COMPLICATIONS OF
RENAL TRANSPLANTATION
M. Salehipour1, H. Jalaeian2, H. Salahi1, A. Bahador1, S. Nikeghbalian1, K.
Kazemi1, M. Nejatollahi1, M. Dehghani1, A. Malek-hosseini1
1Shiraz University of Medical Sciences, 2Ipswich Hospital, QLD, Australia
Background: Urinary tract infection (UTI) is a major cause of morbidity and
mortality in renal transplant recipients. The effect of intravesically applied
antibiotic solution in the prevention of infectious complications of renal
transplantation is still controversial. The aim of this study was to evaluate the
efficacy of intravesical Amikacin for the prophylaxis of the post transplant UTI
within the first three months after kidney transplantation.
Methods: In a prospective, randomized controlled trial, two hundred consecutive
renal transplant recipients were randomly allocated to two 100 study groups.
The bladder was filled preoperatively with saline solution containing Amikacin
(1 gr in Adults or 30 mg/kg in children) in the test group, and with saline
solution only in the controls. Patients were followed up for three months after
the transplantation. Post operative urinary tract infection was defined based
on a urine culture with a bacterial count of 100,000 CFU per mL of urine, or a
positive nitrate test. Factors such as gender, age, the underlying kidney disease,
receiving the first graft or subsequent retransplantation, and the source of graft
(living-related, unrelated, or deceased donor) were analysed.
Results: The overall incidence of UTI was significantly lower in the test group (25%
vs. 49%; p=0.0007). In addition, male patients, adults, first kidney graft recipients,
patients with ESRD due to glomerulonephritis, having renal transplantation for
the first time, or those patients from the test group receiving a living-related graft
have significantly lower episodes of UTI than their control counterparts. (p<0.05)
Ecoli was the most common organism causing UTI (28.9%).
Conclusion: The addition of Amikacin to the bladder irrigation fluid could
have significant effects on the overall incidence of UTI in the first three months
after the kidney transplantation.
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1162 INFECTIOUS COMPLICATIONS IN PATIENTS WITH
KIDNEY TRANSPLANTATION: LONG-TERM FOLLOW-UP
RESULTS
C. M. Kang1, T.Y. Koo1, G-H. Kim1, C.H. Lee1, O.J. Kwon2
1
Hanyang University Hospital, Department of Internal Medicine, 2Hanyang
University Hospital, Department of Surgery
Background: Kidney transplantation (TX) has become a well-established,
highly successful therapy for end-stage renal disease and is more widely
accessible now than in previous decades. The risk of any infection is much

greater in the immunosuppressed transplant population than in general
population. Although the current infection-related one-year mortality has been
reduced to less than 5%, infectious complications (Cx) remain serious threats
to successful outcomes following transplantation. This study was undertaken
to investigate current epidemiology of bacterial, viral and fungal infections in
renal transplant recipients and to identify the risk factors for their occurrence.
Patients and Methods: Clinical data were retrospectively analyzed from 534
recipients who underwent kidney TX from February 1986 to September 2006.
Antimicrobial prophylaxis included preoperative 1st generation cephalosporin
and trimethoprim/sulfamethoxazole and isoniazid for post-transplant six months.
Immunosuppressive regimens were cyclosporine or tacrolimus, prednisolone,
and mycophenolate mofetil or azathioprine. The infections were grouped into
4 categories; infection within 1 month after transplantation, infection between
1 to 6 months after transplantation, infection between 6 months to 1 year after
transplantation and infection later than 1 year after transplantation.
Results: 251 recipients (47.0% of total) had 390 episodes of infectious Cx.
Most patients (86.8%) suffer 2 or less episodes of infection. No opportunistic
infections due to cytomegalovirus (CMV). tuberculosis (Tbc). pneumocystis
carinii, or fungi, occurred within 1 month after TX. The skin and soft tissue
(40.7%) infection was the most common over all post-transplant periods, and
the most common causative organism was virus (55.2%). Among the bacterial
infections, the urinary tract (UTI) (43.0%) was the most common sites of
infection. The causative organisms of UTI were E.coli (41.5%) and coagulase
negative staphylococcus (19.5%). Pneumonia occurred in 25 patients; seven
of them had prior history of steroid pulse therapy for acute rejection, and
two patients expired. In viral infections, varicella-zoster virus was the most
frequent organism. 28 patients (16.9%) developed CMV diseases, and 32% of
CMV diseases had tissue invasive diseases. 24 patients had post-TX Tbc. None
of them died of Tbc or its Cx. Overall mortality after kidney TX was 8.0% and
infection-related mortality was 3.2%. Female sex associated with infectious
Cx occurring after kidney TX and ATG therapy for acute rejection and age
at kidney TX (¡Ã40 years) were associated the risk for infection within one
month. Steroid pulse therapy was associated with the risk for UTI and bacterial
infection between 1 to 6 month after TX.
Conclusion: Infectious complications are the important cause of morbidity
and mortality in the post-transplant period. Strategies to reduce the infectious
complications are necessary for the successful kidney transplantation outcome.
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1163 SIGNIFICANCE OF POSITIVE URINE CULTURES
DURING THE IMMEDIATE POST-TRASNPLANT PERIOD IN
RENAL TRANSPLANT RECIPINETS. RETROSPECTIVE STUDY
M. Koukoulaki1, I. Baraboutis2, E. Platsouka3, V. Papastamopoulos2, V.
Hadjiconstantinou1, O. Paniara3, A. Skoutelis2, S. Drakopoulos1
1Transplant Unit, Evangelismos, General Hospital of Athens, 25th
Department of Internal Medicine – Division of Infectious Diseases,
Evangelismos, General Hospital of Athens, 3Department of Microbiology,
Evangelismos, General Hospital of Athens
Purpose: Urinary tract infections are the commonest cause of bacterial
infection in renal transplant recipients. Epidemiology study the immediate
post-transplant period raises special interest because immune suppression
treatment includes different agents and patients are in hospital environment.
Purpose of the present retrospective study is to audit urinary tract infections the
first post-transplant month and identify potential risk factors.
Patients and Methods: During the period of September 2002 till September
2007 renal transplant recipients who had complete data on urine culture and
urinalysis the first post-transplant month were included in the study. All
recipients except for the induction therapy and triple immune suppressive
regimen, were treated with prophylactic antibiotics with cephotaxim (third
generation cephalosporin) for 10 days and then ciprofloxacin for six weeks.
Results: 116 renal transplant recipients of mean age 50,6±9,7 years old and
male gender 74,1% (86/116) were studied. During the follow-up period of one
month, 50 positive urine culture were identified which were derived from 38
(38/116, 32,7%) renal transplant recipients, of whom 27 presented only one
positive urine culture. Urinalysis identified pyuria in 18 recipients with positive
urine culture which was considered as presentation of urinary tract infection.
More specifically pathogen microbes were Gram positive bacteria (22/50,
44%) with commonest pathogen Enterococcus faecalis, Gram negative bacteria
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animals served as controls (IV). After 2h of reperfusion intravital fluorescence
microscopy was used for analysis of graft microcirculation by means of functional
capillary density (FCD) and capillary diameters (CD). Quantitative assessment
of parenchymal damage was analysed by histology (H&E) and by performing
nitrotyrosine-immunostaining to determine peroxynitrite formation.
Results: Following prolonged CIT only pancreatic grafts treated with BH4
prior to retrieval (II) displayed NOS stabilization and hence markedly higher
values of FCD and CD compared to non treated animals (I) (p<0.01 and
p<0.05 respectively). In contrast, pre-treatment of donor animals with ABH4
(III) did not improve FCD or CD levels. However, parenchymal damage as
well as peroxynitrite formation were significantly attenuated in grafts of both
treatment regiments (p<0.05). Acinar haemorrhage and fat necrosis as well as
peroxynitrite formation were significantly reduced by BH4 treatment compared
to ABH4 (p<0.05).
Conclusion: The protective effect of BH4 supplementation prior to organ
procurement on microcirculation relies on its NOS cofactor activity rather than
on its antioxidative capacity. BH4 might therefore be a novel, promising agent
to attenuate IRI in clinical solid organ transplantation.
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(17/50, 36%) with commonest pathogen Pseudomonas aeruginosa and finally
fungus (11/50, 22%) (three cases with Candida albicans and eight with Candida
non-albicans). Mean time of identification of positive urine culture 14±4,7
days post transplantation. Preliminary statistical analysis revealed significant
relation of positive urine culture with female gender (Pearson x2, p=0,043) and
cold ischemia time (non-parametric test Mann Whitney U, p=0,005). Further
analysis of urinary tract infection presented with pyuria did not show significant
relations with the parameters examined.
Conclusions: Positive urine cultures were observed in 32,7% of renal transplant
recipients with commonest pathogens Enterococcus faecalis and Pseudomonas
aeruginosa. These findings demonstrate significant relation with female gender
and cold ischemia time.
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1164 ETIOLOGICAL AGENTS OF FUNGAL INFECTIONS
IN PATIENTS AFTER SOLID ORGAN TRANSPLANTATIONS
(SOT) – FUNGAL STRAINS AND THEIR SUSCEPTIBILITY TO
ANTIFUNGAL DRUGS.
A. Chmura2, I. Netsvyetayeva1, E. Swoboda-Kopec1, D. Kawecki1, M.
Sikora1, S. Blachnio1, E. Stelmach1, M. Durlik3, L. Paczek4, M. Luczak1
1Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of
General Surgery and Transplantation Medical University of Warsaw, 3Dept.
of Transplantation Medicine and Nephrology Medical University of Warsaw,
4Dept. of Immunology Transplantation and Internal Medicine
Fungal infection is one of the severe complication in patients undergoing solid
organ transplantations.
Aim: The aim of the study was to evaluate species distribution and antifungal
susceptibilities of fungal isolates taken from patients after – SOT.
Material and methods: The study included samples of urine, blood, systemic
fluids and the swabs of the post-operative wounds, haematomas, drains taken
from patients after kidney, liver or simultaneous pancreas-kidney transplantation
hospitalized in Institute of Transplantation Medicine, Medical University of
Warsaw and Department of General and Transplantation Surgery, Medical
University of Warsaw in 2005 – 2007. All cultured specimens were isolated by
using Sabouraud medium with antibacterial protection using chloramphenicol
and gentamicin (bioMerieux, France or Oxoid, England). Yeast-like fungi was
incubated on CHROMAgar Candida Medium (Becton Dickinson ®) and identified
by using biochemical, automatic test ID32C (bioMerieux). Susceptibility of the
strains to the antifungal agents: amfotericin B, itraconazol, fluconazol, voriconazol
was tested using E-test (AB Biodisk) on RPMI agar plates (Biolife®).
Results: The positive cultures were obtained in 662 samples from 402 patients
receiving immunosuppressive therapy. There were cultured 267 isolates of
Candida albicans, 223- Candida glabrata, 39 strains of C. parapsilosis, 37 – C.
krusei and 35 ofTrichosporon asahii, 20- Saccharomyces cerevisiae, 9 strains
of Cryptococcus neoformans 5 – C. lipolytica, 6 strains of C. lusitaniae and 4
of C. sake, 5 strain of C. quilliermondii, 3 – C rugosa and and 9 molds from
Aspergillus fumigatus species. From cultured strains 37.3% was naturally
fluconazole resistant and 0.5% amphotericin B resistant. The acquired resistant
to fluconazole was presented by 10 isolates, to itraconazole- 26, to voriconazole2 and to amphotericin B by 3 isolates.
Conclusions: 1. The most numerable groups of isolated fungal species in
patients after SOT were Candida albicans- 40% of all isolates and Candida
glabrata- 33,7%. 2. Molds were cultured less often and they were found only
in 1.4% of positive cultures. 3. More than one third of isolated fungi were
resistant to fluconazole.
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1165 NEW THERAPEUTIC OPPORTUNITY IN MANAGMENT
OF INFECTION BY MULTIRESTENT GERMS IN PATIENTS
UNDERGOING SOLID ORGAN TRANSPLANTATION. ROLE OF
A NEW TETRACICLIN TIGECICLINE
G. Ferretti1, M. Rossi2, G. Novelli2, L. Poli2, G. Mennini2, S. Ferretti2,
C. Mancini3, G. Raponi3, C. Ghezzi3, F. Pugliese4
1
Azienda Policlinico Umnerto I Dip. Malattie Infettive, 2Centro Trapianti Di
Organo, 3Servizio Di Microbiologia, 4Unita’ Intensiva Post Trapianto
The management of infections by multiresistent bacteria in patients undergoing
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solid organ transplant now be regarded as one of the greatest challenges in
these patients.
The pathogens in particular (Staphylococci, Enterococci spp and Klebsielle
spp) are very often with variability from center to center germs more frequently
isolated in such patients.
And ‘understandable then as the possibility of using a new antibiotic active
against these pathogens, with excellent tolerability and pharmacology no
interference with drugs that would normally take these patients which represents
Tygeciclinal for infettivologo managing such patients an excellent ally.
Materials and Methods: ten patients have been included in the study
undergoing transplantation of solid organ (6 liver, 2 kidney, lung 2) who
have contracted in the first week after transplantation systemic or localized
infections incurred in 8 paz. by Enterococci spp and two patient with
kidney transplant by Klebsiella spp. The enterococci isolates showed a high
resistance to both glicopeptidi that although to a lesser extent to linezolid
while all had a mic <0.25 mgL to tigecycline. The two isolates of klebsielle
spp had a good sensitivity and a carbapenem excellent sensitivity to
tigecycline.
In all patients was used as a loading dose of 100 mg followed by a double dose
of 50 mg daily for cycles 12-14 days total.
Results: In all patients was obtained sterilization of biological specimens
after 3-5 days of initiation, the fever has regressed in 3 ° 4 ° day therapy
simultaneously improving the symptoms, in all patients was obtained healing
clinic. side effects more frequently found was nausea (3 paz) short-lived 1-2
days regressed during the therapy.
Comment: the management of infections borne pathogen in patients
transplanted multi the possibility of using a new antibiotic with therapeutic
efficacy is documented for a weapon infettivologo more available.
However, the therapeutic choice should always be done whenever possible
on the basis of isolation microbiological to use best features of the new
drug. Tigecycline on the basis of our experience, even if limited, offers
interesting therapeutic possibilities for the treatment of infections by
difficul germs in such difficult patients with the good tolerability and little
or no interference with other drugs commonly given to these patients but
we must remember always the Spectrum action of this drug in order to
avoid easy enthusiasm.
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1166 URINARY TRACT INFECTIONS ASSOCIATED WITH
URETERAL STENT IN RENAL TRANSPLANT RECIPIENTS
A. Asderakis, M. Ranganathan, M. Akbar, M. Ilham, R. Chavez, N. Kumar,
Transplant Unit, University Hospital of Wales, UK
Background: Stenting of the ureter is commonly performed during the time of
renal transplantation in order to avoid early ureteric complications. However, it
predisposes to infections. These infections in the immunosuppressed transplant
recipients pose a significant threat to the graft and to the patient and are a
reason for repeated admissions.
Aim: Our study aimed to investigate the incidence of infections associated with
stenting in renal transplant recipients.
Material and Methods: A retrospective analysis of 100 consecutive renal
transplant recipients who received their graft in a period of one year with
median follow up period of 6 months post-transplant. The incidence of urinary
tract infections was recorded and associated with the use of indwelling stents.
Results: The patients median age was 46 (19-71 years). 75 patients received
organ from deceased donors while 25 from live donors. 79 patients had stents
and 18 patients had no stent. Three patients had vascular thrombosis that
required early nephrectomy and were excluded from the study. There were
2 cases of ureteric stenosis (following stent removal, one required surgical
correction and the other was treated radiologically) and no cases of urinary leak.
The incidence of Urinary Tract Infections (UTI) was significantly higher in the
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stent compared to the non-stent group (70% vs 39% p=0.02). New episodes of
UTI following the removal of the stent were more common in patients who had
infection while having a stent as compared to infection-free stented patients
(54% vs 30% p =0.04).
Conclusion: Ureteric stents help to reduce early postoperative ureteric
complications (leak and stricture) in kidney transplantation but increase the
likelihood of UTI. Infection while having a ureteric stent was associated with
high recurrence rate of UTI even after removal of the stent.

1167 INFECTIOUS COMPLICATIONS AFTER INDUCTION
THERAPY WITH LOW-DOSE RITUXIMAB IN LIVING-DONOR
KIDNEY TRANSPLANTATION.
H. Nishida, H. Ishida, H. Shirakawa, T. Shimizu, K. Omoto, D. Toki, S. Iida,
M. Setoguchi, K. Tanabe
Tokyo Wemen’s Medical University
Anti-CD20 antibody (rituximab) is becoming the standard for induction
therapy in non-splenectomized ABO-incompatible, as well as highly sensitized
kidney transplantation, at our department. However, the influence of rituximab
therapy on the risk of infections remains uncertain. In this study, we evaluated
the infectious complications after induction therapy with low-dose rituximab
in kidney transplant recipients.
Fifty-three patients with donor-specific anti-HLA antibodies and/or anti-blood
type antibodies were treated with rituximab prior to renal transplantation from
2005 to 2006. Of these, 33 underwent ABO-incompatible kidney transplantation
(ABO-iLKT) and 6 of the 33 ABO-iLKT recipients underwent splenetomy at
the time of operation. The total study population included 10 cytomegalovirus
(CMV) Ab-negative patients and 43 CMV Ab-positive patients. The
immunsuppressive regimen consisted of tacrolimus, mycophenolate mofetil
(MMF). methylprednisolone and basiliximab. Rituximab (200 or 500mg/
body) was given to all 53 patients as a single dose, a few days before the
transplantation. We investigated the incidence of bacterial, fungal and viral
infections in the study population.
There were 7 episodes of bacterial infections in 6 patients, including urinary tract
infections (4). pneumonia (1). surgical wound infection (1). and atheroma (1).
There were no episodes of fungal infections. There were 41 episodes of viral
infections in 34 patients, including CMV infection (34). influenza (2). zoster (2).
adenovirus infection (1). verruca vulgaris (1). and HCV reactivation (1). Seven
of the 10 CMV Ab (-) recipients who were CMV antigen positive developed
prolonged CMV infection. However, the CMV antibody status in these 7 patients
became positive after CMV infection. None of the patients developed any lifethreatening infectious disease, and all could be cured by conservative treatments.
These data suggest that there is no trend toward increase in the severity of
infectious complications with the use of low-dose rituximab as induction
therapy in kidney transplantation. We conclude that rituximab is an effective
and safe anti-rejection therapy for immunologically high-risk recipients.
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1168 CLUSTER OUTBREAK OF PNEUMOCYSTIS
PNEUMONIA (PCP) AMONG KIDNEY TRANSPLANT PATIENTS
WITHIN A SINGLE CENTER
N. Arichi1, N. Fujii, H. Kishikawa, H. Shiina, M. Igawa, Y. Ichikawa
1
Hyogo Prefectural Nishinomiya Hosipital, 2Hyogo Prefectural Nishinomiya
Hosipital, 3Hyogo Prefectural Nishinomiya Hosipital, 4Shimane medical
university hospital, 5Shimane medical university hospital, 6Hyogo Prefectural
Nishinomiya Hosipital
Background: Pneumocystis pneumonia (PCP) is a life-threatening opportunistic
infection that occurs in immunocompromised hosts and associated with a high
mortality rate that ranges between 29% and 50% in kidney transplant recipients.
PCP is relatively rare after kidney transplantation and there are few known
reports about its occurrence as an epidemic. In present study, we analyzed the
risk factors for PCP development in kidney transplant recipients.
Methods: Between 1973 and January 2008, 441 patients underwent kidney
transplantation at Hyogo Prefectural Nishinomiya Hospital. A total of 10 petitents
suffered from PCP in our hospital during past 35 years. 9 of those PCP cases were
clustered within the 7 month period from June 2007 to January 2008. We studied the
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1169 PULMONARY TUBERCULOSIS POST KIDNEY
TRASPLANT PROSPECTIVE STUDY 1997-2007
C.R. Miranda
Essalud
Lung Tuberculosis is a very big health problem that affects our population and
is a priority at health politics in our country. We did a prospective study of
266 kidney trasplants patients from cadaveric donor with a follow up of 66
months of average from 1997 to 2006. We did interviews, clinical test and
X Rays of lung of every one of our patients with the clinical history, cultures
for Mycobacterium tuberculosis in sputum, and gastric juice, We report
every clinical suspect of specific process for tuberculosis for unknown fever,
lost of weigth, nocturnal sweeting, positive PPD and history of previous
tuberculosis contact. All the patients received profilactic treatment of 200mg of
Isoniazida dayly for 12 months post trasplant and Piridoxine 50 mg daily. The
patientes received de protocol induction with linfoglobulina, ciclosporine and
metilprednisolona. Between inmunosupressor therapy received Ciclosporina,
micofenolato of mofetil and prednisone. The men group was of 47.37% (126)
and the women was 52.63% (140). Age average at the moment of transplant
was 37.63 years. We report 16 cases (6%) of diagnosis of tuberculosis, wich
only six cases were confirmed with positive culture at 60th day. Ten cases were
diagnosis based in clinical findings, two of them without therapeutic answer
and 8 with answer to treatment with: Isoniazide, rifampicine, pirazinamide,
etambuthol and negative culture. Th incidency of TBC in transplant in our
country is lower comparative with other countries like Egypto, India, Turky
and Pakistan. This results are probably for the profilactic measures and the
educational level of our transplant population. Our treatment with isoniazida for
a year have diminished dramaticaly the the incidency of TBC in our transplant
population. Our conclusion is that incidency of TBC post transplant is going to
be under stimated and we must consider the clinical features as like a positive
culture of M. tuberculosis. At the same time the incidency of TBC could and
must diminish in our countries with more carefuly evaluation of donor and
receptor, like the social enviroment that is a big concern in our society.
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1170 BLOOD INFECTIONS IN THE EARLY POSTOPERATIVE
COURSE AFTER LIVER TRANSPLANTATION.
G. Aguirre-Avalos1,2, M.A. Covarrubias-Velasco2, R.M. Chávez-Ramírez1,
C. Reynoso-Lomeli1, R.I. Guzmán-Lázaro1, F. López-Cisneros1,
R. Gutierrez-Valdez1, R. Hernández-Vidales1, L.C. Rodríguez-Sancho2,
H. Coronado-Magaña1
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risk factors for the development of PCP and prophylaxis in transplanted patients.
Results: Of the 10 patients who developed PCP, 7 cases occurred as outpatients
and other 3 as inpatients. The mean time between transplantation and PCP
diagnosis was 32.1 }27.5 months, with 3 cases occurring within the first 3
months after transplantation, while 1 occurred at 6 months and the other 6 more
than 1 year after transplantation. The cumulative incidence rate rose during
the first 3 months after transplantation. Further, the mortality rate was 33.3%
and all cases showed rapid progress. A clustering of transplant patients within
a single center suggests the possibility of human-to-human transmission,
however, we didn ft find any important relationships among our patients. We
compared patients who developed PCP with those who didn ft develop PCP.
There were no significant differences in regard to gender, rejection episodes,
episodes of virus infection, and use of a calcineurin inhibitor (CNI). Patients
with PCP showed a higher mean age at transplantation (46.9 }11.8 vs 34.0
}11.1, p=0.003) and longer mean duration of dialysis (146.3 }120.0 vs 51.3
}66.6, p<0.0001). Since the outbreak of PCP in the patients within 7 months,
all the patients have received primary prophylaxis with TMP-SMX and no
occurrences of PCP have been noted.
Discussion and Conclusions: We found the risk of PCP in kidney transplant
recipients to be associated with age at transplantation and duration of dialysis.
The mortality rate in our study was nearly the same as other reports, while
early detection and appropriate treatments for PCP were shown to be important.
Prophylaxis with TMP-SMX administration is necessary during the first 3 to
6 months after transplantation, which is the time period that showed the high
incidence rate of PCP.
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1
Intensive Care Unit, Hospital Civil de Guadalajara., 2Transplant Unit,
Hospital Civil de Guadalajara., 3Universidad de Guadalajara.
Background: Orthotopic Liver Transplantation (OLT) patients have increased
risk for infectious complications. Blood infections (BI) is a major source of
morbidity and mortality in OLT recipients. The present study determined the
rate of BI in the early postoperative course of OLT.
Methods: From July 1998 to December 2004, all patients who underwent OLT
admitted to a 14-bed medical and surgical adult Intensive Care Unit (ICU) were
monitored for BI.
The blood-culture (BC) specimens were collected in BD BACTEC.
Identification and susceptibility to antimicrobial agents was determined using
the MicroScan and Sensititre system.
Results: Of 101 admissions to the ICU after OLT, 78 (77%) patients had at least
one set of BC samples. The rate of BI was 14% per 100 admissions. Of 152 BC,
16 (10.5%) were positive. One episode of BI was present in 8 (73%) patients and
3 (27%) had more than one episode. The median period between ICU admission
and the acquisition of BI was 3 days. Gram-negative microorganisms were the
most frequently isolated. E. coli, E. aerogenes and P.aeruginosa were the tree
most frequently isolated pathogens. There were 1 episode with polymicrobial
BI. All patients received perioperative prophylaxis.
Mortality rate for patients with BI was of 45%. The mean length of ICU stay
was 11 days.
Conclusion: BI in OLT patients are associated with significant rate of death.
Most BI occur within in the first week after transplantation.
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1171 ANALYSIS OF FEBRILE EPISODES IN POST LIVER
TRANSPLANT RECIPIENTS DURING POST-OPERATION
HOSPITALIZATION
S.I. Kim1, Y.J. Kim2, Y.H. Jun3, H. Jeong4, Y.R. Kim5, S.C. Park6,
I.S. Moon7, D.G. Kim8, M.D. Lee9, M.W. Kang10
1The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2The
Catholic University of Korea, Kangnam St. Mary’s Hospital, 3The Catholic
University of Korea, Kangnam St. Mary’s Hospital, 4The Catholic University
of Korea, Kangnam St. Mary’s Hospital, 5The Catholic University of Korea,
Kangnam St. Mary’s Hospital, 6The Catholic University of Korea, Kangnam
St. Mary’s Hospital, 7The Catholic University of Korea, Kangnam St. Mary’s
Hospital, 8The Catholic University of Korea, Kangnam St. Mary’s Hospital,
9The Catholic University of Korea, Kangnam St. Mary’s Hospital, 10The
Catholic University of Korea, Kangnam St. Mary’s Hospital
Background: Fever is a common clinical occurrence in liver transplant
recipients; infections being the predominant etiology. However, the
exact etioloies of fever could not differentiable from infectious and noninfectious causes. And the severity is not clear in clinical settings. We
analyzed febrile episodes to find the clues that were strongly related
to mortality.
Methods: One hundred seven consecutive liver transplant recipients of
Kangnam St. Mary’s hospital were analyzed retrospectively. Fever was
defined as more than 37.4 oC by axillary temperature and lasting more than
one hour.
Results: Among them, 29.9% (32/107) patients had 40 episodes of fever during
post-transplant hospitalization. Infectious causes were documented in 72.5%
(29/40) of cases and non-infectious 27.5% (11/40). Non-infectious causes were
4 bleeding, 2 rejection, 2 hematoma, 1 procedure related, and 2 unknown.
There was no case of infectious complication without fever. Ten patients
were died and 50% (5/10) of death were related to infectious complications.
We compared the patients between survival (n=24) and death (n=5) who had
episodes of infectious fever. There were no significant differences in age (48.4
vs 50.4 year-old). operation time (648.2 vs 708.0 min). white blood cell count,
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MELD score, Child-Pugh score, and the body temperature between two groups.
Time intervals between the point of fever and the point of administration or
change of antibiotics (756.7 vs 1062.4 min). and duration of administration
of immune suppressive agents (2,504.8 vs 5,290.0 min) were not significantly
different, however the odd ratio were 5.3 and 5.3 with univariate logistic
regression analysis.
Conclusion: In case the post-transplant recipients have fever presumed by
infectious disease, administration of appropriate antibiotics as soon as possible
and discontinuation of immune suppressive agents as possible seemed to
improve the survival.
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1172 FUNGAL INFECTIONS IN LIVING DONOR LIVER
TRANSPLANT RECIPIENTS: 9 YEARS SINGLE CENTER
EXPERIENCE
S.I. Kim1, Y.J. Kim2, Y.H. Jun3, Y.R. Kim4, J.Y. Choi5, S.K. Yoon6,
I.S. Moon7, D.G. Kim8, M.D. Lee9, M.W. Kang10
1The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2The
Catholic University of Korea, Kangnam St. Mary’s Hospital, 3The Catholic
University of Korea, Kangnam St. Mary’s Hospital, 4The Catholic University
of Korea, Kangnam St. Mary’s Hospital, 5The Catholic University of Korea,
Kangnam St. Mary’s Hospital, 6The Catholic University of Korea, Kangnam
St. Mary’s Hospital, 7The Catholic University of Korea, Kangnam St. Mary’s
Hospital, 8The Catholic University of Korea, Kangnam St. Mary’s Hospital,
9The Catholic University of Korea, Kangnam St. Mary’s Hospital, 10The
Catholic University of Korea, Kangnam St. Mary’s Hospital
Background: Fungal infection remains one of the most significant infectious
complications following living donor liver transplantation (LDLT). We analyzed
the frequency and type of fungal infections according to the post-transplant
periods and risk factors related to morbidity and mortality of fungal infection.
Patients and Methods: We analyzed 208 living donor liver transplant
recipients from May 1996 to August 2005 at a single center.
Results: Mean age was 48.3 and male was predominant (M/F=148/60).
Infectious complications were developed in 76.9% (160/208) of patients and
the fungal infections were developed in 7.7% (16/208) of patients. Total 351
infectious episodes of 160 patients were analyzed. Among them, 19 episodes
were diagnosed as fungal infection. Aspergillus spp. (47.4%) was most common
and followed by Candida spp. (36.8%). Within 1 month after transplantation,
Candida spp. (6/11) was the most common pathogen, between 2-6 months,
Aspergillus spp. (5/7) was the most common. The most common type of infection
was pneumonia (36.9%). followed by intra-abdominal infection (21%). primary
fungemia (21%). and catheter related infection (5.3%). Our study showed the
operation time (p=0.007) was the significant risk factor for fungal infection
while age, amount of transfusion, MELD score, serum creatinine, total bilirubin,
INR, re-operation, renal failure at post-operation, and the rejection were not
significant. The overall mortality of fungal infection was 43.8% (7/16).
Conclusion: Fungal infections in liver transplant have resulted in mortality of 43.8%.
Candida infection was common in the first month after LDLT, while mortality cases
were more common after that period by aspergillosis. Our data showed operation
time was the only statistically significant risk factor for fungal infection.
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1173 LATE ONSET PNEUMOCYSTIS PNEUMONIA IN
PATIENTS RECEIVING RITUXIMAB FOR ANTIBODY
MEDIATED RENAL TRANSPLANT REJECTION
S. Cohney1, M. Yong2, E. Shelton1
Department of Nephrology, Royal Melbourne Hospital, Parkville, Australia
3050 2Department of Infectious Diseases, Royal Melbourne Hospital,
Parkville, Australia 3050
Rituximab is a monoclonal antibody targeting the CD20 molecule on B cells
and is being used on an increasing basis in solid organ transplantation and
other areas of nephrology, despite the absence of any trial data. In addition,
Rituximab does not target the antibody producing plasma cells. A contributor
to the expanding “off label” use of Rituximab has been the relatively low
morbidity associated with its use in thousands of lymphoma patients over
many years. However, reports are now emerging of an increased incidence of
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1174 EARLY COLONIZATION OF URINARY TRACT AND
RISK OF URINARY TRACT INFECTION IN TRANSPLANT
RECIPIENTS
E. Ahmed, F. Noman, N.H. Jaffery, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Introduction: Urinary tract infection is the commonest bacterial infection in
Renal transplant recipients. Early post-operative colonization of urinary tract
may be a risk factor for subsequent infections.
Objective: To evaluate the role of early post-operative bacteriuria in the development
of future symptomatic urinary tract infections in renal transplant recipients.
Patients and Methods: A prospective cohort of patients transplanted between
January and December 2004 were studied. Urine cultures were taken twice in
first ten days post-transplant from all patients (surveillance culture). For the next
6 months follow-up urine cultures were obtained periodically from all patients on
OPD visits and whenever urinary tract infection was suspected on clinical grounds.
Result: 107 patients, 85 Male and 22 Females were followed.14 (13.3%) had
positive surveillance culture. In the follow-up period, 36 (33.6%) patients
developed symptomatic infection. Ten (71%) out of 14 in surveillance culture
positive group, and 26 (28%) out of 94 in negative surveillance culture group
(RR =2.5, 95% C.I 1.6 – 4.1, P=0.002). Females did not show a higher incidence
of UTI compared to Males (36.7% vs 33%). D.J stenting and its duration did
not increase the risk of symptomatic infection.
Conclusion: Early post transplant urine culture positivity is a risk factor for
subsequent UTI, whether treating this will decrease the risk needs further
evaluation.
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1175 CRYPTOCOCCAL MENINGITIS OCCURING TO
PATIENTS SUBJECTED TO A RENAL TRANSPLANT:
DIAGNOSTIC AND THERAPEUTIC PARTICULARITIES
RELATING TO ONE CASE.

H. Skhiri, L. Jaafoura, T. Dalila, A. Sabra, H. Kamel, F. Mouna, B. Samia,
F. Ameur, B. Nasr, E. Mezri
Tunisian Nephrology Society
Cryptococcus is an opportunistic fungic infection to be met particularly
between the second and the sixth post-graft months (the period of maximum
Tcell immune dysfunction).
Meningo encephalitis is its most frequent manifestation with an acute mortality
rate reaching 100% with patients not yet taken in charge. The rate is around
20% despite antifungic treatment
We report a case of Cryptococcal neuro-meningitis occurring to one 42 yearold female patient with a kidney transplant out of 72 patients engrafted at the
Monastir hospital-university center over eight years (1999-2007).
It‘s noteworthy that this infection had been developed in the four years
subsequent to the graft.
The case evolution for this woman was adverse: deceased five days following
the start of a treatment based on Amphotericin B and 5-Fluorocystosin.
The Cryptococcal neuro-meningitis symptoms are not specific.
The symptoms for such infection have to be sought out in order to be diagnosed
and treated precociously.

CONCURRENT ORAL SESSION 85: IMMUNE MONITORING
AND MOLECULAR DIAGNOSIS
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1176 THE COMPARISON ANALYSIS WITH ACUTE
CELLULAR REJECTION AND VARIOUS LIVER
DYSFUNCTIONS USING GENE EXPRESSION PROFILING
T. Asaoka, S. Marubashi, K. Dono, N. Hama, C. Chim, S. Kobayashi, Y.
Takeda, H. Nagano, K. Umeshita, M. Monden
Department of Surgery, Graduate School of Medicine, Osaka University,
Osaka, Japan
Backgrounds: Recent advances in immunosuppressive therapy have
dramatically enhanced the survival of solid organ transplantation.
Nevertheless, acute cellular rejection (ACR) still remains a major challenge
in liver transplantation. In addition, recurrent hepatitis C (CRC). reperfusion injury, infection and drug toxicity caused by administration of
immunosuppressive drugs also contribute to graft failure. Histological
evaluation of liver biopsy is the gold standard for diagnosing these
various conditions, but it is often difficult to diagnose ACR after liver
transplantation.
Purpose: The aim of the present study is to establish a strategy based on gene
expression profiling to more accurately discriminate acute rejection from
various other liver dysfunctions.
Materials and Methods: We analyzed 35 graft liver biopsy samples
obtained from living-donor liver transplant recipients. Among them, 13
samples were pathologically diagnosed as ACR (moderate/mild; 5/8)
according to Banff criteria, whereas 13 samples were diagnosed as other
dysfunction without ACR (CHC/IRI/drug induced; 5/5/3) and 9 samples
were protocol biopsies without liver dysfunction (ACR group/Non-ACR
group/Protocol group: 13/13/9). A part of liver biopsy samples were frozen
and stored at -80C. Prior to the gene profiling analysis, we followed the
patients and confirmed that those pathological diagnoses matched the
clinical course of the patients. We used an oligonucleotide microarray
covering 44,000 human probes (Agilent; DNA Chip Research Inc, Tokyo).
For validation of microarray results, RT-PCR was performed on selected 5
genes. In our study, we furthermore adopted the Ingenuity computational
pathway analysis (IPA) to identify regulatory networks of differentially
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viral and opportunistic infections following Rituximab. Until now there have
been no reports of specific infectious complications relating to its use in renal
transplantation.
Here we report the onset of Pneumocystis pneumonia (PCP) in two patients nearly
three years after receiving their renal transplant, both of whom had received
rituximab for refractory antibody mediated rejection (AbMR). In 2004, a 59 year
old female received a transplant from her husband against whom there was a
donor specific anti-HLA antibody associated with a positive cytotoxic crossmatch.
Despite “desensitization” with plasma exchange and high dose immunoglobulin
(IVIG) pre-transplant she developed early AbMR. She received a single dose of
Rituximab 500mg, plasma exchange and IVIG, with complete resolution of the
AbMR both clinically and histologically. At 6 months her immunosuppressive
therapy consisted of mycophenolate sodium 360mg mane/180mg nocte, tacrolimus
0.5mg bd and prednisolone 5mg daily and at this time her PCP prophylaxis (daily
Bactrim) was ceased. She remained well for the next 2½ years but in mid 2007
presented with a respiratory illness confirmed microbiologically as PCP infection.
Likewise a 52 year old female recipient of a cadaveric renal transplant in 2005
developed severe acute AbMR requiring plasma exchange, IVIG, and a single
dose of 500mg Rituximab. Although she also completed a 6 month Bactrim course
for PCP prophylaxis, it was not until 2 years and 8 months after administration of
Rituximab in 2007 that she presented with clinical PCP infection.
All patients in our centre receive at least 6 months PCP prophylaxis with
Bactrim unless there are contraindications. Since 2000, we have managed
over 450 renal transplant recipients with only 1 other case of PCP, occurring
in a patient whose immunosuppressive therapy was increased for late rejection
without reinstitution of PCP prophylaxis. The two individuals described here
are amongst 10 patients who have received Rituximab for AbMR developed a
late infectious complication of PCP at a time when their immunosuppressive
therapy was no different from other renal transplant recipients.
This report alerts transplant clinicians to the possibility of late opportunistic
infections in patients who have received Rituximab and highlights the need for
randomised clinical trials to establish the efficacy (or otherwise) of Rituximab
in treating and preventing AbMR in areas of nephrology and transplantation.

MONDAY

Monday 11 August 2008

Poster Abstracts

expressed genes.
Result: We identified about 2,000 genes which were differentially
expressed between three groups. Hierarchical clustering demonstrated
almost good separation of each groups. This clustering revealed that there
were specific gene expression pattern underlying in ACR. The data from
RT-PCR validation confirmed an impression from the microarray data.
Biological interactions using the IPA tool demonstrated several genetic
networks targeted by ACR.
Conclusion: We found gene expression patterns associated with ACR. Our
findings suggest that gene expression profiling may be useful in diagnosing
ACR after liver transplantation.

POSTER BOARD NUMBER P1 – 262
1177 IMMUNE MONITORING IN LIVER TRANSPLANT
PATIENTS WITH COMBINED MYCOPHENOLATE MOFETIL
AND LOW DOSE CALCINEURIN INHIBITOR THERAPY
S. Beckebaum1,2, Z. Yu1,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos1, A.
Radtke1, G. Gerken1, V.R. Cicinnati1,2
1
Department of Gastroenterology and Hepatology, University Hospital Essen,
Germany, 2Department of General, Visceral and Transplantation Surgery,
University Hospital Essen, Germany, 3Department of Surgery, Beijing
Tongren Hospital, Capital University of Medical Sciences, Beijing, China,
4
Institute of Immunology, University Hospital Essen, Germany
Background: Long term complications of calcineurin inhibitors (CNI) have a
major impact on morbidity of liver transplant recipients. Immunosuppressive
drugs are regularly used in combination to reduce the adverse effects of each
individual drug.
Aim: To investigate the impact of combined mycophenolate mofetil (MMF)
and low dose CNI therapy on T cell function in vivo and in vitro.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from
32 liver transplant recipients at baseline and 12 months after conversion to
MMF/low dose CNI regimen. T cell frequencies, phenotype and expression of
activation markers were analyzed by flow cytometry. In in vitro studies, freshly
isolated PBMC from healthy volunteers were treated with mycophenolic acid
(MPA). cyclosporine A (CsA). tacrolimus (Tac) and combined CsA/MPA or
Tac/MPA to assess the effect on T cell proliferation, expression of activation
markers and of nuclear factor of activated T cell (NFAT) -regulated cytokines.
Results: Combined MMF and low dose CNI therapy in vivo leads to a
reduction of the percentages of CD8+ and CD8+CD56+ T cells, to inhibition
of T cell activation and to an increase of circulating FOXP3+CD25+CD4+
regulatory T cells (Treg) as compared to CNI monotherapy. MPA stops the
cell cycle of activated T cells at G0/G1 phase in vitro; whereas MPA and CNI
each individually inhibit the expression of T cell activation markers, and this
effect is enhanced by combined exposure to MPA and CNI. Low doses of
CNI strongly inhibit interleukin (IL) -2, IL-4, IL-10 and interferon (IFN) -γ;
production by T cells in vitro.
Conclusions: Combined MMF and low dose CNI administration has synergistic
effects by a) decreasing the percentages of circulating NKT and cytotoxic T
cells, b) increasing the number of circulating Treg cells, c) blocking the T cell
proliferation and d) decreasing NFAT-regulated gene and activation marker
expression in T cells. Immune monitoring may facilitate optimization of the
immunosuppressive regimen with minimization of drug related adverse effects
without increasing the risk of cellular rejection.
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1178 CLINICAL UTILITY OF THE NOVEL METHOD OF
IMMUNOSUPPRESSION MONITORING (IMMUKNOW ASSAY)
IN CYTOMEGALOVIRUS INFECTIONS IN KIDNEY AND
PANCREAS TRANSPLANT RECIPIENTS
P. Kadambi, R. Harland, M. Josephson
The University of Chicago
Cytomegalovirus (CMV) infection is the most common viral infection in solid
organ transplant recipients. Patients are at highest risk of developing CMV
infection if they are CMV seronegative and receive an organ from a seropositive
donor (D+). The recipients could also be infected by reactivation of their own
CMV or by transmission of a different strain of virus from a D+. The overall
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degree of immunosuppression may play a role in this infection.
The current tests used to detect CMV that are sensitive and specific are the
pp65 antigenemia test and the Polymerase Chain Reaction (PCR) test to detect
the viral DNA.
The Cylex ImmuKnow (IK) assay was approved by the FDA for detection of
cell-mediated immunity in immunosuppressed patients. Immune responses are
reported in ng/ml of ATP and divided into strong (≥525). moderate (226-524)
or low (≤225) categories. In theory, patients in the low group are generally
more immunosuppressed and hence might be susceptible to opportunistic
infections.
Six patients that had CMV infection at our institution in 2007 were identified.
Of them, 4 received kidney transplants, and 2 received pancreas transplants
alone. Two patients received induction with thymoglobulin and the rest with
an IL2 receptor antagonist. Four patients fell in the high risk group (D+/R-) for
CMV, and the other 2 were in the intermediate risk group. We use the PCR test
to diagnose CMV, and the threshold for detection is <2500copies/mL of blood.
The test is obtained when there is clinical suspicion of CMV infection. Patients
were treated with intravenous ganciclovir (5/6) and valganciclovir (1/6) for 3
weeks, and reduction in immunosuppression. No secondary prophylaxis with
valganciclovir was used.
We obtained IK values after the CMV infection was diagnosed and serially
followed the values during the course of the infection. The mean IK value of
patients during the infection (PCR positive) was
51.08 ±36.17, and 186.45 ±127.22 when the PCR was negative (p=0.001).
In most cases the IK value prior to the onset of CMV was not known. The
values were consistently low in patients during active CMV infection
indicating depressed immunity, and improved during periods when CMV was
undetectable.
Perhaps the IK assay could be utilized prospectively after transplantation to
determine which patients may be at risk for CMV and other opportunistic
infections and optimize the immunosuppression accordingly to prevent these
infections.

POSTER BOARD NUMBER P1 – 264
1179 DETECTION OF CD4+ CELL IMMUNE ACTIVITY IN
UTERUS GRAFTED PORCINE PERIPHERAL BLOOD WITH
IMMUKNOW ASSAY
Y. Jin1, W. De Faria1, P. Tryphonopoulos1, H. Takahashi1, D. Avison1,
A.G. Tzakis1, P. Ruiz1,2
1
Dept of Surgery,University of Miami, 2Dept of Pathology, University of
Miami
Aim: ImmuKnow assay introduced by Cylex Inc is a useful assay to assess
immune competency in human transplant recipients. The aim of this study was
to determine whether this assay has the research applications for transplant
animal model. MHC class-I and II matched or full MHC mis-matched uterus
transplanted porcinis were included in this study.
Methods: We adopted ImmuKnow assay to measure CD4+ cell immune
activity in PHA stimulated porcine peripheral blood pre- and post- uterus
transplantation. Recipient to donor immune reactions were determined with a
modified ImmuKnow assay in some cases.
Results: We found that the beads coated with anti-Human CD4 antibody
had cross reaction with porcine CD4+ cells, but the optimal dosage of
PHA stimulation for porcine was higher than that for Human. The data
collected from 14 pre-transplant porcinis showed ATP level variations
from 162.2 ng/ml to 559.49 ng/ml, with an average of 305 ng/ml ±110ng/
ml. High responses to PHA stimulation had the correlation with strong
immune reactivity against donor in most of the post-transplant tests. On
the other hand, high PHA responses were not always associated with graft
rejections.
Summary: In this study, we demonstrated that ImmuKnow assay has valuable
application for animal transplant model as well.

POSTER BOARD NUMBER P1 – 265
1180 IN VIVO LABELING OF ACTIVATED T-CELL WITH
QUANTUM DOTS CONJUGATED ANTI-CD25 ANTIBODY
REVEALS REJECTION IN THE MOUSE SKIN GRAFT MODEL
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1181 TRANSPLANTATION AND MONITORING THE HIGHLY
SENSITIZED HEART PATIENT.
M. Lopez-Cepero1, M. Weston2, D. Rinde-Hoffman2
LifeLink Foundation, 2LifeLink Health Institute
The use of plasmapheresis (PP) and IVIG has been reported by an increasing
number of transplant programs to be beneficial in the transplantation of highly
sensitized renal patients. This approach was followed to transplant highly
sensitized heart patients.
Our study thus far includes 63 recipients of orthotopic heart transplants that
had a Flow PRA > 10%. The cause of sensitization included transfusions,
pregnancies, VAD, previous transplants and immunizations. All patients
underwent PP and received 20g IVIG immediately prior to transplant. Class I
and II% PRA and antibody specificities were determined by Flow Cytometry
using single antigen coated beads. Flow T and B cell crossmatches were done
prior to and after PP. Results were expressed in quantitative MESF shifts.
Post transplant, these patients were followed at time of biopsy for quantitative
determination of donor specific antibodies (DSA’s) with antigen coated beads
and/or Flow T and B cell crossmatches. The effect of immunosuppressive
therapy on cell mediated immunity was followed using the Immuknow assay
(Cylex).
Forty one% (26/63) of patients had a positive FCXM prior to PP. Fifty nine% of
patients had a negative FCXM prior to PP. Of those patients that were positive,
PP removed DSA’s in 46% (12/26) of the cases. However, 54% (14/26) of the
patients after PP still had a positive FCXM. Out of 63 patients, 13 patients
have died. Nine of these had a negative FCXM prior to PP. These patients
did not develop DSA’s and died of different causes including: primary non
function, non compliance, bacterial pneumonia and sepsis. The other 4 patients
had a positive FCXM prior to PP and causes of death include: GI bleed, sepsis,
respiratory distress and pulmonary embolism. Seven% of sensitized heart
patients show graft coronary vasculopathy when compared to 11% in an age
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and disease match control group.
Our study shows that pre-operative plasmapheresis and IVIG in sensitized
patients awaiting heart transplantation is effective with no difference with
controls in occurrence of rejection and graft survival at 3 years. We also have
shown that sensitized patients with Class II antibodies are more susceptible to
rejection; however there was not a significant difference in graft survival in
this group. When compared to a well matched control group of patients, the
sensitized group that had plasmapheresis and IVIG prior to transplant, had no
significant difference or even less graft coronary vasculopathy. These results
and those of others are very encouraging in the use of plasmapheresis and
IVIG with close post transplant monitoring to transplant the highly sensitized
patient.
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1182 PERFORMANCE OF A FULLY AUTOMATED SIROLIMUS
ASSAY ON THE SIEMENS DIMENSION VISTA ® CLINICAL
CHEMISTRY SYSTEM
T. Wei, A. Posey, C. Schaible
Siemens Healthcare Diagnostics Inc.
Background: Monitoring sirolimus (Rapamune®, Wyeth Laboratories) in
whole blood is a standard practice during immunosuppressive therapy for
transplant patients. We describe the initial performance of a fully automated
immunoassay for sirolimus* in whole blood on the Siemens Dimension Vista
system.
Methods: A whole blood sample (8.5 μL) is automatically lysed, incubated first
with antibody β−galactosidase conjugate and later with chrome particles coated
with a sirolimus analog. Sirolimus in the sample forms immuno-complexes
with the antibody conjugate, and the excess molecules of antibody conjugate
are bound by the chrome particles, which are magnetically separated from
the supernatant. The supernatant containing the sirolimus-antibody conjugate
complexes is then transferred to a photometric cuvette where the enzyme tag is
detected using a chromogenic substrate.
Results: Analytical sensitivity is 1.2 ng/mL. The method is linear to 30 ng/mL
and calibration is stable for 30 days. Repeatability and within-lab reproducibility
on patient pools were 2.5 and 3.9%CV at 30.3 ng/mL, 1.9 and 2.5%CV at 20.2
ng/mL, 4.0 and 4.9% at 10.2 ng/mL, and 7.0 and 12.9% at 4.7 ng/mL sirolimus
respectively per the CLSI EP10-A3 protocol. Split sample correlation (n=100)
between the Dimension Vista method (DV) and the Dimension® sirolimus*
method (DM) gave a Passing-Bablok regression fit of: DV = 1.03×DM +
0.5, r=0.984, range = 1.3 – 29.5 ng/mL. Metabolite cross-reactivity was 45,
14, and 61% for 39-O-demethyl, 16-O-demethyl, and 12-hydroxy sirolimus,
respectively. No significant cross-reactivity was detected in samples spiked
with 120 ng/mL tacrolimus, 2000 ng/mL CSA, 400 ug/mL MPA or 1000ug/mL
MPAG. No significant interference (<10%) was found for 60 mg/dL bilirubin,
1000 mg/dL triglyceride, 500 IU/mL rheumatoid factor, type I and II HAMA,
and 25 g/dL total protein.
Conclusion: This method provides accurate, reproducible, and fast
measurements of sirolimus on the Dimension Vista system.
*Product under development – not available for sale.
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1183 A REVISED NO-PRETREATMENT IMMUNOASSAY FOR
CYCLOSPORINE ON THE SIEMENS DIMENSION® CLINICAL
CHEMISTRY SYSTEM
T. Wei, S. Kramer,
Siemens Healthcare Diagnostics Inc.
Background: Therapies combining lower dosages of cyclosporine with other
immunosuppressant drugs to reduce nephrotoxicity require more sensitive
methods for its therapeutic monitoring. We describe an improved, automated
immunoassay for cyclosporine on the Dimension system.
Methods: A whole blood sample (5 μL) is automatically lysed, incubated first
with antibody β−galactosidase conjugate and later with chrome particles coated
with a cyclosporine analog. Cyclosporine forms immuno-complexes with
the conjugate, and the excess conjugate molecules are bound by the chrome
particles. The chrome-conjugate complexes are then magnetically separated
from the supernatant, which contains the cyclosporine-antibody conjugate
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H-Y. Lee1, K. Bang3, H. Ro2, J. Yang4, Y.H. Park5, K.W. Kang1, C. Ahn2
1Department of Nuclear Medicine, Seoul National Universiy, College of
Medicine, 2Department of Internal Medicine, Seoul National Universiy,
College of Medicine, 3Department of internal medicine, Eulji University
College of medicine, 4Department of Internal Medicine, Gachon University
of Medicine and Science, 5Department of Surgery, Gachon University of
Medicine and Science
Material and Method: The tail skins from Balb/c (allograft) and B6 mice
(isograft) were transplanted on the back of Five B6 mice (female, 6 weeks
old). A day after transplantation, 75 ug of quantum dot (Qdot 655, Invitrogen)
conjugated anti-CD25 antibody was intravenously injected to mice. Fluorescent
imaging was daily acquired until 8 days after transplantation using optical in
vivo imaging system (IVIS Lumina, Xenogen).
To confirm the fluorescence signal from activated T-cell, the tail skin from
B6.CHbm12 and Balb/c were transplanted on B6 mouse, which underwent
thymectomy and CD8 T-cell depletion. After the skin graft, the mouse followed
the same protocol as above. Also we applied the same method to evaluating the
effect of Tacrolimus (Astellas. co). We measured the counts of skingraft from
each image. Then, mice were sacrificed, and immunohistochemistry (IHC) was
performed to correlate their pathologic results with the fluorescent imaging
between the allo- and isografted skin.
Result: Quantum dot conjugated anti-CD25 was more accumulated on the
allograft than isograft. When comparing the photon counts, allograft was
significantly brighter than isograft (allograft: 5.4E-5¡¾3.4E-6, isograft:
3.6E-5¡¾1.3E-6, p<0.05). Comparing with IHC, the number of activated T-cell
was correlated with the counts on image. Quantum dots were located on stained
activated T-cells.
On the skin graft with MHC II mismatch, there was no abnormal signal was
detected (MHC II mismatch 1.8E-5, allograft: 6.7E-5). Also, there was less
signal intensity on the allograft with Tacrolimus, compared with the allograft
without Tacolimus (With Tacrolimus: 3.8E-5¡¾4.8E-6, Without Tacrolimus:
5.4E-5¡¾3.4E-6 p<0.05).
Conclusion: Activated T-cell was labeled in vivo using quantum dot conjugated
anti-CD25 antibody. We could evaluate the rejection of skin graft with noninvasive optical imaging.
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complexes. The supernatant is then transferred to a photometric cuvette where
the enzyme tag is detected using a chromogenic substrate.
Results: Analytical and functional sensitivity are 9.5 and 25 ng/mL, respectively.
The LoB and LoD are 15.0 and 22.5 ng/mL, respectively, based on a study per
the CLSI EP-17A protocol. The method is linear to 500 ng/mL. Repeatability
and within-lab reproducibility on patient pools were measured to be 5.9 and
7.3%CV at 82.5 ng/mL, 4.2 and 6.1%CV at 132.2 ng/mL, 3.5 and 4.3%CV at
219.4 ng/mL, and 3.6 and 3.9%CV at 369.2 ng/mL cyclosporine respectively
per the CLSI EP5-A2 protocol over a 20 day testing interval. Split sample
correlation between the revised method (rCSA) and the existing method (CSA)
gave a linear regression fit of: rCSA = 1.035×CSA – 6.5, r=0.994, n =184,
range = 19 – 468 ng/mL. Cross-reactivity with metabolite AM9 was <2%. No
significant cross-reactivity was detected in samples spiked with 100 ng/mL
tacrolimus, 5000 ng/mL rapamycin, 200 ug/mL MPA or 400 ug/mL MPAG. No
significant interference (<10%) was found for 60 mg/dL bilirubin, 1500 mg/dL
triglyceride, 500 mg/dL cholesterol, 500 IU/mL rheumatoid factor, type I and
II HAMA, 4 g/dL and 12 g/dL of total protein.
Conclusion: The revised method showed significant precision improvement
at the analyte concentrations below 100 ng/mL, and provides accurate and fast
measurements of cyclosporine on the Dimension system.
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1184 DIFFERENTIAL EFFECT OF DITHIOTHREITOL (DTT)
ON ANTI-A/B IGM, IGG AND IGA ANTIBODIES
L. West, M. Jeyakanthan, S. Senthilselvan
University of Alberta
Introduction: Reliable measurement of IgG isotype anti-A or anti-B antibodies
is crucial in ABO-incompatible transplantation, but detection of IgG anti-A/B
activity is often masked by the agglutinating IgM antibody. DTT seems to
selectively inactivate IgM leaving IgG intact and it is widely used to measure
anti-A/B IgG titre determined by antiglobulin technique. However its effect
specifically on anti-A and anti-B antibodies has not been explored. The purpose
of this study was to evaluate the effect of DTT on anti-A/B IgM, IgG and IgA
antibodies.
Methods: Serum samples from volunteers of different ABO-blood types (A=2,
B=2,O=12) were tested for anti-A and anti-B IgM, IgG and IgA by ABOELISA. Antibody levels were retested after incubation of serum with 0.005M
DTT at 37C for 30 minutes. ELISA measurements were done at least three
times on each sample pre and post DTT treatment. The effect of DTT on antiA/B IgM, IgG and IgA was evaluated by comparing mean OD values for each
sample, and the overall effect on samples from this cohort of people was also
evaluated.
Results: Following DTT treatment, residual anti-A IgM was detectable in
samples from 6 of 16 people; only 1 sample had residual anti-B IgM. There
was no change in anti-A IgG with DTT, but sera from 2 people had significant
reduction in anti-B IgG. Sera from 9 people had detectable anti-A and anti-B
IgA after DTT treatment. There was no significant amount of anti-A/B IgM
detectable when the entire cohort was analysed as a group, and also there was
no significant change in anti-A/B IgG. Both anti-A and anti-B IgA on the other
hand were detectable at a significant level after DTT treatment.
Conclusions: Our data demonstrate that overall, DTT treatment effectively
inactivates anti-A/B IgM leaving anti-A/B IgG intact but the variability among
different people cannot be ignored. These data suggest it is likely that sera from
ABO-incompatible transplant recipients may differ in the response to DTT,
and erroneous quantitation of IgG antibodies may lead to mismanagement or
unnecessary treatment. We intend to explore all possibilities of developing a
simple but reliable method to quantitate anti-A/B IgG and IgA which may aid
in development of efficient clinical protocols for the management of ABOincompatible transplant recipients.
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1185 THE IMPROVEMENT OF TRANS-VIVO DTH ASSAY AND
ITS EVALUATION IN IMMUNOLOGICAL STATUS IN HEART
TRANSPLANT RAT
T. Xu1, X. Zhang, X. Qu, H. Ye, W. Bai, X. Wang
1
Peking University People’s Hospital, 2Peking University People’s Hospital,
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Peking University People’s Hospital, 4Peking University People’s Hospital,
Peking University People’s Hospital, 6Peking University People’s Hospital
Trans-vivo DTH is an approach to measure the status of cell-mediated
immunity, which is believed to be correlated with the immunological mode
of patient after transplant. We conducted this experiment with a novel and
improved trans-vivo DTH assay. The PBMCs and allergens from subjects were
transferred into the footpads of mice. Measurements of footpad thickness were
obtained immediately prior to injection and 24 h after injection with a dial
thickness gauge. The swelling that occurs within 24 h after injection serves as
an index of the subjects¡¯ immunological status to the specific antigen. But the
precision of dial thickness gauge is considered to be relatively low, and could
be interfered by many factors. We use Universal Toolmaker Microscope to
replace dial thickness gauge, and compare the test-retest reliability of the two
methods. Finally, we compare this improved Trans-vivo DTH assay with MLC
and IL-2 mRNA level (measured by RT-PCR) to investigate its evaluation on the
immunological status in heart transplant rat. A total of 20 C57BL/6 male mice
were enrolled in this experiment. The ipsilateral mouse footpads were measured
with universal toolmaker microscope and dial thickness gauge. The error of
duplicate measurement and coefficients of reproducibility were calculated and
compared. There were 4 groups: A, Control group (5); B, Shum operation group
(20); C, Isotransplant group (20); D, allotransplant group (20, F344 to Lewis).
The improved Trans-vivo DTH assay were performed in the 1st¡¢4th¡¢7th¡¢11th
days after operation. The error of duplicate measurement and the coefficients of
reproducibility of universal toolmaker microscope£¨0.007 and 0.008£©were
lower than those of dial thickness gauge (0.049 and 0.053 respectively). The
test-retest reliability of universal toolmaker microscope was greater than dial
thickness gauge. Significant footpad swelling occurred in the Group D after
injection with PBMC+ alloantigen but not in Group B and C (averaging about
0.036mm) after operation, and the peak swelling responses in Group D were
observed in the 11th day post operation (averaging about 0.790mm). Further
research also demonstrates that a significant difference between Group D and
other groups in the 4th day post operation (as determined by ANOVA).The level
of IL-2 mRNA was elevated except the Group A. The peak levels of Group B and
C were observed in post operation, and then gradually declined. The IL-2 mRNA
level of Group D increased till rejection. We also found that there was significant
difference between Group B and other groups in 4th day post operation, but not
between Group C and D until the 8th day.The data may demonstrate that the
IL-2 mRNA level was related to acute rejection, but it is prone to be influenced
by many factors. There were no differences between groups in MLC assay. We
improved Trans-vivo DTH assay by use of the universal toolmaker microscope,
instead of dial thickness gauge. According our research result, we believe that
the improved Trans-vivo DTH assay is an effective method in evaluating the
immune status of patient after transplantation.
3
5
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1186 THE EMIT® 2000 SIROLIMUS ASSAY* ON THE
V-TWIN®/VIVA E® ANALYZERS
K. Ryzewski, H. Yau, A. Dominowski, Y.F. Zheng, Y. Yang, N. Morjana
Siemens Healthcare Diagnostics Inc.
Objective: Sirolimus (Rapamycin, Wyeth) is a potent immunosuppressive
drug used in patients undergoing organ transplantation. It has a narrow range of
safe and effective therapy therefore, therapeutic drug monitoring is absolutely
necessary in patients on Sirolimus. A new Emit Sirolimus Assay is currently
being developed on the V-Twin®/Viva E® Analyzers. The proposed assay
design was evaluated here. Methods: Imprecision was evaluated using three
levels of sirolimus-spiked whole blood according to CLSI EP5-A2. Recovery
was studied by spiking sirolimus into whole blood at concentrations that span
the assay range. Linearity was assessed using patient specimens. Calibration
stability was assessed by testing three levels of whole blood controls over a
30-day period. Accuracy was evaluated with specimens from renal transplant
patients and compared to LC/MS/MS and the Abbott IMx Sirolimus Assay using
linear regression. Cross-reactivity with sirolimus metabolites was assessed at a
concentration of 25 ng/mL in the presence and absence of sirolimus. The effect
of common interferences was assessed by spiking the interferents into whole
blood in the presence of 5 and 20 ng/mL sirolimus.
Results: Within run imprecision CVs were 11.9% for level 1 (5 ng/mL), 3.7%
for level 2 (12.6 ng/mL) and 6.0% for level 3 (29 ng/mL). Total imprecision
CVs were 15.5%, 7.4% and 9.2%. Spike recovery of Sirolimus into whole blood
was within 10% of the expected values. The assay linearity range is between
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1187 SENSITIVE FORENSIC MEDICINE METHODS ALLOW
TO DETECT DONOR DNA IN RECIPIENT BLOOD FOR YEARS
AFTER KIDNEY TRANSPLANTATION
J. Rutkowska1, B. Interewicz1, R. Ginak1, A. Rydzewski1,2, M. Świętek2, A.
Dominiak1, M. Durlik1,2, W.L. Olszewski 1,2,3
1
Department of Surgical Research & Transplantology, Medical Research
Center, Polish Academy of Sciences, Warsaw, Poland 2Central Clinical
Hospital, Ministry of Internal Affairs, Warsaw, Poland 3The Norwegian
Radium Hospital-Rikshospitalet, Oslo, Norway
After organ transplantation passenger cells and cellular debris from ischemia
and rejection damaged cells disseminate in recipient and in most part are
being taken up by macrophages and dendritic cells (DC). The most important
question is whether donor DNA may be incorporated into recipient cell genome
in the process of the so called “illegitimate DNA incorporation” a frequent
phenomenon in nature. A subsequent question would be the presumptive effect
of donor DNA on the rejection process.
Aim: To search for donor DNA in recipient tissues and cells after allogeneic
transplantation and immunosuppression.
Materials: Recipient’s blood samples were collected before and after kidney
transplantation 1, 14,28,90, 180, 360 and 720 days and genomic DNA was
isolated using Nucleospin kit (macharey-Nagel). Quantification of DNA was
performed in capillary cuvettes on GeneQuant (Amersham Pharmacia Biotech).
The short tandem repeats analysis (STR) was applied. The investigated
loci were: phospholipase A2- HUMPLA2A1 (AAT) n, cytochrome P450
HUMCYARO (AAAT) n and D1S80. This type of analysis is used in forensic
medicine.
Results: Donor cytochrome P450 or HUMPLA2 or D1S80 genes were detected
in recipient blood cells up to 2 years after kidney transplantation. Positive
results were observed in all investigated patients, 24hr after grafting in 3 out
of 3pts and in 4 out of 4 pts after 14 days, in 28 out of 28 after 28, in 2 out of
2after 90, in 3 after 180, in 1 after 1 and in 2 out of 2 after 2 years. All patients
remain under further follow-up.
Conclusions: Donor DNA can be detected in recipient blood cells 2 years after
kidney transplantation. The question as to whether the detected donor DNA
was contained in the surviving donor cells or in a form of apoptotic or necrotic
bodies in recipient phagocytes or was incorporated into recipient cell genome
remains to be answered. The role of donor DNA in recipient cells in rejection
or acceptance is not clear, although we know from animal experiments that it
is detected in recipient dendritic APCs (antigen presenting cells). Most recent
study documents presence of donor DNA in nuclei of recipient APCs. The
comparison of clinical course of transplant and level of donor DNA have so far
not been carried out because of a low number of patients.
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1188 STIMULATION INDEX FOR PCNA MRNA EXPRESSION
IN PERIPHERAL BLOOD AS A PREDICTIVE INDICATOR OF
OVER-IMMUNOSUPPRESSION
T. Kobayashi1, M. Niwa1, Y. Miwa1, A. Katayama1, M. Haneda2, T. Kuzuya3,
T. Nagasaka4, T. Ueki5, K. Uchida4, A. Nakao6
1
Nagoya University School of Medicine, Department of Applied Immunology,
2
Nagoya University School of Medicine, Department of Immunology, 3Nagoya

University School of Medicine, Department of Hospital Pharmacy, 4Nagoya
Daini Red Cross Hospital, 5Masuko Memorial Hospital, 6Nagoya University
School of Medicine, Department of Surgery II
Introduction: Although the use of multiple immunosuppressive agents has
recently reduced acute rejection, drug-induced toxicity and infection due to
over-immunosuppression occasionally become a serious problem. Change
from uniform treatment to individualized therapy is highly desirable. However,
therapeutic drug monitoring is generally performed only in dose adjustment
of calcineurin inhibitors. No assay for evaluating overall patient condition is
available at present. We have attempted to develop a simple and reliable method
of speculating the immunosuppressive state of recipients. Our attention was
focused on proliferating cell nuclear antigen (PCNA). which is synthesized in
early G1 and S phases of the cell cycle, and expected to reflect the proliferation
capacity of T lymphocytes under the immunosuppressive condition. The
purpose of this study was to assess the feasibility and clinical applicability of
PCNA mRNA monitoring after renal transplantation.
Methods: Heparinized blood samples were collected from recipients
successively until 3 months after renal transplantation. Within 24 hours after
withdrawal, 1 mL of whole blood was incubated overnight at 37 C with and
without PMA/Ca ionophore stimulation. Extracted mRNA was applied to real
time RT-PCR for the semi-quantification of PCNA mRNA. Immune function
was expressed as T cell proliferation capacity which was calculated as a
stimulation index (SI = PCNA mRNA with stimulation/PCNA mRNA without
stimulation). SI values were compared with clinical outcome such as rejection
and infection episodes.
Results: Mean and SD values of SI in recipients were 5.6+/-2.1 at pretransplantation, 3.0+/-1.3 at 1 week, 2.9+/-0.9 at 2 weeks, 3.7+/-2.3 at 3 weeks
and 5.8+/-3.0 at 4-12 weeks. SI values in healthy volunteers are significantly
higher (10.8+/-5.0) than those in transplant recipients. Eight (72.7%) among 11
recipients with SI below 2.0 during the early post-transplant course developed
cytomegalovirus or herpesvirus infection. In contrast, only 3 (14.3%) of 21
recipients with continuously high SI (>2.0) showed CMV infection. SI for
PCNA mRNA expression seemed to be closely related to immunosuppressive
state of recipients and preceded viral infection episodes. Relation between SI
values and acute rejection episodes could not be evaluated, because incidence
of acute rejection within 3 months was very low (<10%).
Conclusions: PCNA mRNA monitoring in peripheral blood can be utilized to
give a caution for over-immunosuppression as a simple immune function assay.
Such immune function monitoring would be essential in providing optimal
immunosuppressive therapy to each transplant recipient.

POSTER BOARD NUMBER P1 – 274
1189 ALLOREACTIVITY IN LIVER AND KIDNEY
TRANSPLANT RECIPIENTS
M. Lindemann1, H. Klinkenbusch1, C. Saure1, O. Witzke2,
C. Valentin-Gamazo3, S. Beckebaum3,4, V.R. Cicinnati4, T. Philipp2,
C.E. Broelsch3, H. Grosse-Wilde1
1
Institut für Immunologie, 2Klinik für Nephrologie, 3Klinik für Allgemein-,
Viszeral- und Transplantationschirurgie, 4Klinik für Gastroenterologie und
Hepatologie, Universitätsklinikum
Background: Whereas HLA compatibility between donor and recipient clearly
impacts on graft survival in kidney transplantation, it appears as minor relevant
in liver transplantation. “Tolerogenic” properties of the liver are one possible
explanation for this phenomenon.
Aim: To analyze if in-vitro alloreactions differ between liver and kidney
tranplant recipients.
Methods: In 15 liver and 10 kidney transplant recipients interferon-γ und
granzyme B ELISpots were performed prior to transplantation, at week 2-3,
week 4-6, month 3, month 4, and month 6 post transplantation (n=95 interferon-γ
and n=116 granzyme B ELISpots, respectively). At each time alloreactivity
was determined against the donor and 3 HLA-DR different controls.
Results: Mononuclear cells of recipients after liver vs. kidney transplantation
displayed significantly (p<0.05) less interferon-γ production against donor
cells prior to and at week 4-6 post transplantation (Figure). On the contrary,
comparable alloreactivity against donors was observed from month 3 to 6
after liver and kidney transplantation. Similarly, a decreased interferon-γ
production was detected against 3 HLA-DR controls prior to and initially post
transplantation. However, granzyme B production did not differ after liver and
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1.5-30 ng/mL. The calibration curve is stable for at least 2-weeks. A total of
54 specimens were evaluated. The assay showed the following comparisons:
V-Twin = 1.26*LC/MS/MS + 1.86; correlation to LC/MS/MS, r = 0.94; V-Twin
= 1.07*Abbott + 2.9; correlation to Abbott, r = 0.92. The cross-reactivity
of sirolimus metabolites: 41-O-demethyl, 7-O-demethyl, 11-hydroxy, 32,
41-O-didemethyl was 38%, 15%, 4%, and 52%, respectively. No interference
of >+/-10% was observed with the endogenous interferences, hematocrit
or HAMA. The interference of the co-administered drugs Cyclosporine,
Tacrolimus, MPA or MPAG was within +/-10%. The reagents are stable onboard the V-Twin analyzer for at least 30 days.
Conclusion: The new Emit Sirolimus assay will provide good assay
performance and accurate determination of Sirolimus in whole blood samples.
* Product under development - not available for sale.
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kidney transplantation.

Figure: In-vitro alloreactivity of liver and kidney transplant recipients (LTX
and NTX, respectively) against donors.
In our cohort containing 3 HLA-identical donor/recipients pairs (2 liver, 1
kidney) no effect of HLA compatibility on in-vitro alloreactivity could be
observed. Comparing immunosuppressive drug therapy after liver and kidney
transplantation (cyclosporine A, tacrolimus, rapamycin, mycophenolate mofetil,
and prednisone). average dosages were lower after liver transplantation. Thus,
drug therapy appears as unlikely to cause diminished alloreactivity after liver
transplantation. In summary, the data indicate that alloresponses in liver
transplant recipients are reduced up to week 4-6 post transplantation.
Conclusions: Reduced in-vitro alloreactivity in liver transplant recipients
could be caused by the severity of underlying disease and surgery. Thereby,
an impairment of immunocompetence could lead to decreased alloreactivity in
liver transplant recipients.
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1190 PERFORMANCE OF A FULLY AUTOMATED
CYCLOSPORINE EXTENDED RANGE ASSAY ON THE
SIEMENS DIMENSION VISTA® CLINICAL CHEMISTRY
SYSTEM
T. Wei, Y. Yue, A. Baylis, E. Nuzzaci, J. Mizzer, D. Clark, T. Pankratz
Siemens Healthcare Diagnostics Inc.
Background: Cyclosporine Extended Range (CSAE) monitoring has been
shown to better correlate with AUC (area under the curve) than trough
monitoring and adequately estimates oral adsorption in transplant patients.
We describe the initial performance of a fully automated immunoassay for
cyclosporine extended range assay* in whole blood drawn at 2 hours post-dose
on the Siemens Dimension Vista System.
Methods: The method employs the same reagents as used in the Dimension
Vista CSA method. A whole blood sample (1.1 μL) is automatically lysed,
incubated first with antibody b-galactosidase conjugate and later with chrome
particles coated with cyclosporine A. Sample cyclosporine forms immunocomplexes with the antibody conjugate, and the excess conjugate is bound by
the chrome particles, which are magnetically separated from the supernatant.
The supernatant containing the cyclosporine -antibody conjugate complexes
is then transferred to a photometric cuvette where the enzyme tag is detected
using a chromogenic substrate.
Results: The assay range is 350-2000 ng/mL. Time to first result is about
13 minutes. Calibration is stable for 30 days. Repeatability and within-lab
reproducibility on whole blood patient pools and control materials from More
Diagnostics were measured to be 1.8 and 2.7%CV at 1691 ng/mL, 2.3 and
3.6%CV at 1030 ng/mL, 3.4 and 4.4% at 653 ng/mL, and 4.7 and 5.5% at 483
ng/mL cyclosporine respectively per the CLSI EP 5-A2 protocol over a 20 day
testing interval. Split sample correlation (n= 116) between the Dimension Vista
method (DV) and the Dimension method (DM) gave a linear regression fit of:
DV = 0.92*DM + 38, r=0.990, Sy/x= 43, range = 349 – 1765 ng/mL.
No significant cross-reactivity was detected in samples spiked with 100 ng/mL
tacrolimus, 5000 ng/mL sirolimus, 200 ug/mL MPA or 400 ug/mL MPAG. No
significant interference (<10%) was found for 60 mg/dL bilirubin, 1500 mg/dL
triglyceride, 500 mg/dL cholesterol, 500 IU/mL rheumatoid factor, type I and
II HAMA, and 12 g/dL total protein.
Conclusion: This method provides accurate, reproducible, and fast
measurements of extended range cyclosporine on the Dimension Vista system.
*Product under development – not available for sale.
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P. Van De Berg1, N. Nikolaeva1, S-L. Yong1, E. Remmerswaa1,
A. Rowshani2, K. Donselaar2, F. Bemelman2, R. van Lier1, I. ten Berge2
1
Dept. of Experimental Immunology, Academic Medical Center, 2Renal
Transplant Unit, Academic Medical Center
Discriminating patients who are at low risk for acute allograft rejection
from those who are at high risk would allow to adjust the amount of
immunosuppressive drugs individually. Here, we tried to find T cell properties
of transplant-recipients that can predict the risk of acute rejection episodes
pre-transplantation. IL-7 is important for the initiation and perpetuation of an
immune response and polymorphism in the IL-7Rα gene is correlated with the
clinical outcome of bone marrow transplantation. Therefore, it can potentially
be used as marker to predict the risk of an acute rejection.
We included patients with and without a rejection after transplantation.
Lymphocytes of recipients, collected before transplantation, were CFSE
labeled and stimulated in a mixed lymphocyte culture by either donor spleencells or HLA mismatched 3d party lymphocytes. FACS analysis was performed
after staining with CD3, CD8, CD4 and IL-7Rα.
The precursor frequency of alloreactive CD4+ and CD8+ T cells measured
before transplantation was higher in rejectors than in non-rejectors. In patients
who later experienced acute cellular rejection, the precursor frequency of
alloreactive CD8+ T lymphocytes could not significantly be decreased by
blocking CD8 mAb. These same patients showed pre-transplantation higher
IL-7Rα expression on their alloreactive CD4+ and CD8+ T cells than nonrejectors.
Based on the ability to down regulate IL-7Rα expression after stimulation,
recipients may be identified before transplantation as being at low risk for
developing an acute rejection episode. To further increase the chance of having
an immunological uncomplicated course after transplantation a transplant
donor can be selected to which they mount a low affinity CD8 response of low
precursor frequency.
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1192 IN SITU QUANTITATIVE IMMUNOPROFILING
OF REGULATORY T CELLS USING LASER SCANNING
CYTOMETRY
H. Takahashi, P. Ruiz, C. Ricordi, A. Miki, A. Mita, S. Barker, A. Tzakis,
H. Ichii
University of Miami
Introduction: Cytofluorographic analysis enables to analyze suspended cell
populations quantitatively. On the contrary, quantitative in situ analysis (i.e. in
a tissue sections) is difficult because of a lack of objective methodology. Laser
scanning cytometry (iCys; CompuCyte) is recently developed methodology
that utilizes fluorescence-based quantitative measurements on tissue sections
or other cellular preparations at a single-cell level. The purpose of this study
was to develop objective quantitative immunoprofiling of regulatory T cells
(T regs) on formalin-fixed/paraffin embedded (FPE) biopsy sample from
transplanted allograft using iCys.
Methods: We analyzed the population of CD4 (+) Foxp3 (+) T regs among
the entire CD4 (+) T cells and the entire T cells (the total of CD4 (+) and CD8
(+) ) in human intestinal allograft biopsy samples to evaluate the usefulness of
iCys. Two unstained sections of four μm in thickness were prepared from the
routinely processed FPE tissue. After deparaffinization and blocking, primary
antibodies (Foxp3 and CD4) were incubated on one section. Foxp3 and CD4
were labeled by Alexa Fluoro 488 (Alexa488) and 647 (Alexa647) using
polymer HRP and catalyzed signal amplification. Propidium iodide (PI) counter
staining was performed to visualize nuclear. On the other section, CD8 and
CD4 were labeled by Alexa488 and Alexa647 using the same protocol. Data
acquisition was performed using iCys. Determination of nucleated cells was
achieved by recognizing PI signals. Alexa488 (Foxp3 or CD8) and Alexa647
(CD4) integrals in section were acquired at a single-cell level.
Results: The nuclear signal of each cell was well determined by the PI signal.
The signal intensity of Alexa488 and Alexa647 was sufficient to analyze
by iCys. Figure A and B show an example of intestinal allograft biopsy
which histologically showed indeterminate for acute rejection with mild
lymphoplasmacyitc infiltrate. Distribution of the integrals of Alexa488 and
Alexa647 on the section in which Foxp3 and CD4 were labeled was visualized
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1193 HMGB1 AND IDO AS PREDICTIVE MARKERS IN RENAL
TRANSPLANTATION
D. Abendroth1, M. Marzinzig1, J. Kaden2
1Center of Surgery, University of Ulm, 2Vivantes Hospital Friedrichshain,
Berlin
High mobility group box 1 (HMGB1) is a nuclear factor (NF) released as
an early mediator of inflammation and destruction. We compared results of
indolamine 2,3 deoxigenase (IDO) with HMGB1 in renal transplantation to
estimate which parameter is the more predictive tool for diagnosis of rejection.
Furthermore, we evaluated the role of HMGB1 in delayed graft function.
Material and methods: Sera from 4 different groups of patients after renal
transplantation (Gr.I, triple drug, no rejection=10; Gr.II, induction treatment
with ATG-F, no rejection, n=10; Gr.III, rejection, n=10; Gr.IV, delayed graft
function, n=10) were used for measurements. Estimation of HMGB1 was
performed by using an enzyme immunoassay, IDO by using a uv detection
method.
Results: There was a statistical difference (p<0.001) between the group I and
IV for IDO as well as for HMGB-1 (IDO: 5,5+1,85 μM vs. 17,93+4,27μM;
HMGB-1: 3,23+1,28 ng/ml vs. 5,65+1,08ng/ml) showing the effects of delayed
graft function. The days until creatinine dropped < 200μmol/l were 4,4+2,7
(dialysis n=0) compared to Gr.IV with 12,2+5,8ng/ml (dialysis n=3+1,6).
IDO was higher in delayed function because of the inflammation potency of
the dialysis treatment. Concerning rejection, there was a statistical difference
(p<.001) for HMGB-1 for rejection between group I and II compared to III
(3,23+1,28; 3,03+0,98 and 6,69+3,4ng/ml). These findings were more accented
with IDO (5,5+1,85; 3,2+1,13 and 22,4+5,4 μM). There was a beneficial
behaviour for the ATG-F group for both parameters showing the lowest values
compared to all other groups.
Conclusion: There was a positive correlation of HMGB1 and IDO in the state
of rejection and delayed graft function. HMGB1 was more pronounced in
DGF compared to IDO, which was the more sensitive parameter for rejection.
Elevated HMGB1 levels might indicating the ongoing activated innate immunity
via TLR4. The role of HMGB-1 as a predictive marker has yet to be evaluated.
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1194 IMPACT OF IMMUNOSUPPRESSIVE TREATMENTS
ON ENDOTHELIAL BIOMARKERS AFTER KIDNEY
TRANSPLANTATION

H. Vacher-Coponat1,2, G. Al-Massarani2,3, P. Paul2,3, Y. Berland1,
F. Dignat-George2,3, L. Camoin-Jau2,3
1
Nephrology and transplantation unit, AP-HM, Hopital Conception,
2
Hematology unit, AP-HM, Hopital Conception, 3INSERM UMR-S608,
Université de la Méditerranée Aix-Marseille 2
Background: Endothelial dysfunction has been reported in haemodialysis and
kidney transplanted patients and can be enhanced by immunosuppressive therapy.
Circulating endothelial cells (CEC). endothelial microparticles (EMP) and
sVCAM-1 have provided information on endothelium activation and/or damage.
Material and Methods: The objective was to compare the impact of two
immunosuppressive regimens (CsA/Aza vs Tac/MMF) on the kinetics of CEC,
EMP and sVCAM-1 levels during the first year post-graft for 52 haemodialyzed
patients by reference to 50 healthy controls donors.
Results: One-year post transplant (M12). CEC, EMP and sVCAM-1 levels
were significantly lower than before graft regardless of the treatment. While
EMP counts reached normal values, CEC and sVCAM-1 levels were still
significantly higher than in controls at M12. When compared to the Tac/
MMF treated group, earlier improvement of EMP and lower CEC counts
were observed in patients treated by CsA/Aza. We further investigated
possible relationships between endothelial markers and clinical history such as
cardiovascular diseases (HCVD) and cytomegalovirus infection. At M12, the
CEC and EMP levels decreased significantly only in patients without HCVD.
Also, higher levels of EMP were observed after CMV infection.
Conclusion: As evaluated through non invasive circulating endothelial
markers, renal transplantation decrease endothelial alteration with a more
pronounced effect in patients treated by CsA/Aza. This may reflect the reduced
cardiovascular risk after kidney transplant but also provide early markers
reflecting persistence of vascular injury in transplanted patients.
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1195 DIRECT CYTOKINE MEASUREMENT IN URINE
AND PLASMA IN A RAT MODEL OF CHRONIC KIDNEY
REJECTION
U. Christians3, W. Schöning1,3, A. Frazer-Abel2, G. Puhl1, V. Schmitz1,
1Dept. of Transplantation Surgery, Charite Campus Virchow, Humboldt
University at Berlin, 2Complement Laboratory, National Jewish Medical and
Research Center at Denver, CO, USA, 3Dept. of Anesthesiology -Resaerch
and Development, University of Colorado at Denver, Health Science Center,
CO, USA
Background: Up to now cytokines were mostly indirectly measured as
cytokine mRNA expression in tissues by RT-PCR. Recently, a novel ‘direct’
cytokine measurement for rat urine and plasma samples based on antibodybeads-Luminex™-technology has become commercially available. We present
first results of sequential urine and plasma cytokine analysis during the
development of experimental chronic kidney rejection (CR).
Material and Methods: Using the well established Fisher to Lewis CR model,
24-h-urine and plasma samples of 10 rats (250-300g BW at transplantation)
were collected pre-transplantation and every two weeks post-transplantation
over a 6 months period.
500μl of urine samples were concentrated by filter-centrifugation using 10kDa
Millipore Microcon centrifugal filter units™, whereas 25 μL of plasma samples
were diluted five times. Lincoplex™ multiplex-antibody-bead-Kits and a
Luminex™ 100IS device were used to measure the following cytokines: IFN-g,
IL-10, IL-12, IL-18, IL-1a, IL-2, IL-4, IL-6, MCP-1, RANTES, TNF-a.
Results: Histological analysis revealed clear signs of CR at time of harvest 6
months post-transplantation.
Significant differences in Cytokine excretion over 24 h in urine compared to
pre-transplantation were found for IL-18, IL-1a, RANTES and MCP-1. Plasma
levels of IL-18, IL-1a, IL-2, RANTES and MCP-1 also showed significant
differences vs. pre-transplantation.
Conclusion: The above-mentioned inflammatory Macrophage and T-Lymphocyte
cytokines were easily measurable with minimal volumes of plasma and urine.
Our results also contribute to an evolving discussion about interpretation of
mRNA derived conclusions concerning cytokine actions in CR.
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and CD4 (+) cell population was gated (Fig. A: R4). The population of T reg
(Fig. A: R5) among CD4 (+) T cell was 13.7% (Fig. A: R5/R4). Distribution of
the integrals of Alexa488 and Alexa647 on the section in which CD8 and CD4
were labeled was visualized (Fig. B). The population of CD4 (+) T cell (Fig. B:
R4) among the total of CD4 (+) and CD8 (+) T cells (Fig. B: R5) was 20.9%
(Fig. B: R4/ (R4+R5) ). Accordingly, the population of T reg among the entire
T cells was 2.9%.
Conclusion: iCys and signal amplified immunofluorescent staining allowed
objective quantitative immunoprofiling of in situ T reg populations, with precise
quantitative analysis at a single-cell level on FPE section. Combined analysis
of various immunoprofiling enables to investigate more detailed analysis on
the in situ T reg profiling. This objective method can be applied on the biopsy
sample from various transplant organs.
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1196 NK CELL ALTERATIONS CORRELATE WITH RENAL
FUNCTION AND IMMUNOSUPPRESSIVE REGIMEN IN
KIDNEY-TRANSPLANTED PATIENTS
H. Vacher-Coponat1,2, T. Legris1,2, C. Brunet2, M.L. Lyonnet2, V. Moal1,
R. Purgus1, M. Indreies1, F. Dignat-George2,3, Y. Berland1, P. Paul2,3
1
Nephrology and Transplantation unit, Hopital Conception, AP-HM,
2
Hematology unit, Hopital Conception, AP-HM, 3INSERM UMR-S 608,
Université de la méditerranée Aix Marseille 2
Background: NK cells represent the first line of immune defense against viral,
tumoral or allogenic challenge, in particular in patients with T cell deficiency.
Still, in contrast with hematopoietic transplantation, evaluation of their
alloreactive, anti-infectious or anti tumoral potential is poorly documented
in organ transplantation. The impact of immunosuppressive drugs, designed
to target activated T cells, on post transplant NK cell reconstitution may
indeed have implications with regards to the immune potential of long term
transplanted patients.
Methods: We first conducted a multivariate and comparative retrospective
analysis of variables that affect lymphocyte subsets counts in a cohort of 237
hemodialyzed patients analyzed both before graft and during the first year post
kidney transplant. These patients were included in a randomized trial comparing
quadritherapies including rabbit anti-thymocytes induction (ATG). prednisone
in association with either Tacrolimus/mycophenolate mofetil (Tac/MMF) or
Cyclosporine/Azathioprine (CsA/Aza). Two control groups, undialyzed uremic
patients and healthy control donors, were evaluated.
The impact of treatment on NK cell phenotypical and functional features was
further analyzed one year post transplant in relation with renal function.
Results: A 32% decrease in NK cell counts was observed in hemodialyzed
patients awaiting graft in reference to age and sex matched healthy
controls. Early post graft NK cell depletion observed after ATG treatment
was followed by differential reconstitution of NK cell counts in the 2
therapeutic arms. At one year post transplant, the better NK cell counts
reconstitution observed in the Tac/MMF group (median, 147 versus 45 in
CsA/Aza, p<0.0001) was associated with a 10% increase in renal function
(evaluated by MDRD clearance, p=0.02). As observed in undialyzed
uremic patients, lower renal function was associated with lower NK cell
counts in the Tac/MMF group (r= 0.3854, p <0.0001). This selective effect
of immunosuppressive treatment was also associated with enhanced NK
cell cytotoxicity in the Tac/MMF group (% K562 target lysis, median,
25-75 percentile: CsA/Aza 5.6, 0.9-18.9 versus Tac/MMF 32, 17.11-49, p
<0.0001) and specific phenotypic features that affect the NK cell subsets
defined by expression of NK receptors such as NKG2D, CX3CR1, CD122
and CD244/2B4.
Conclusions: End stage renal diseased patients already have a defect in the
NK cell compartment, which is worsened after graft in patients under CsA/
Aza immunosuppressive regimen. In contrast, association of Tac/MMF favors
NK cell reconstitution one-year post graft, in association with better kidney
graft function. These data may have implications to optimize use of immune
suppressive drugs and improve graft and patient’s survival. Some associations
may indeed both limit rejection while preserving the innate immune response
potential against infections and tumors in long-term immunosuppressed
patients.

POSTER BOARD NUMBER P1 – 282
1197 COMPARISON OF CYTOKINE PROFILE BETWEEN PREAND POSTTRANSPLANTATION 1ST YEAR
I.M Titiz1, G. Isitmangil1, G. Tellioglu1, F. Turkmen1, H. Tozkir2, S. Gulle1,
T. Ozgezer1, B. Yigit1, I. Berber1
1
Haydarpasa Numune Research and Educational Hospital, Renal
Transplantation and Immunology Unit, Istanbul, Turkey, 2Trakya University,
Medical Faculty, Department of Molecular Biology, Edirne, Turkey
Background: Cytokines are immune mediators indicating proinflammatory
or immunosuppressive state. A balance of cytokines normally exists between
these two states. In this study we aimed to compare cytokine levels between
pre- and postop 1st year patients who had been immunosuppressed by
CyA+MMF+steroid therapy regimen.
Methods and Subjects: We determined IL-1alpha, TNF-alpha, IFN-gamma,
IL-10 and TGF-beta concentrations among totally 77 blood samples by ELISA
(RayBiotech, Inc) performed according to manufacturers’ instructions. Group 1
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(n=35) included kidney transplant patients at postoperative 1st year and Group
2 included the same blood samples (n=35) which were studied preoperatively.
All were lymphocyte cross-match negative by both complement-dependent
cytotoxicity assay and flow cytometry technique. Group 3 contained 7 healthy
subjects.
Results: There was no graft loss at postoperative 1st year after renal
transplantation. Seroconversion rates from preoperative period to postoperative
1st year were as follows for each cytokine separately: For IL-10 from negative
to negative 94.28%; from positive to negative 5.71%. For TGF-beta from
negative to negative 88.57%; from negative to positive 2.85%; from positive
to negative 8.57%. For IL-1alpha from negative to negative 54.28%; from
negative to positive 22.85%; from positive to positive 5.71%; and from positive
to negative 17.14%. For IFN-gamma from negative to negative 85.71%; from
negative to positive 11.42%; from positive to positive 5.71%; from positive to
negative 2.85%. TNF-alpha was negative in all included cases. All cytokines
were negative in the control group.
Conclusion: We conclude that routine pre- and posttransplant cytokine
monitoring by ELISA offers early risk assessment that is crucial for proper
immunosuppression and for antirejection therapy choice.

POSTER BOARD NUMBER P1 – 283
1198 A SIMPLIFIED METHOD USING ATP
AND A LUMINOMETER FOR ASSESSMENT OF
IMMUNOSUPPRESSION IN TRANSPLANT PATIENTS
A. Assounga, S. Omarjee
Dept of Nephrology, University of KwaZulu-Natal and Laboratory of
Immunology, Doris Duke Medical Research Institute, Durban, South Africa.
To prevent transplant rejection patients are subjected various combinations of
immuno suppressive agents that may have addictive synergistic antagonistic
effect. Furthermore additional co-morbid condition (ie: CMV, HIV infection)
may further alter patient’s immune condition. Currently most monitoring
methods measures levels of individual drugs. Recently a method using CD4
cells was developed by Cylex to measure immune response through ATP levels
detected by a luminometer. In this study we have applied a simplified method
using peripheral blood mononuclear cells (PBMC) and tested kidney transplant
patients.
Method: PBMC were separated from 30 transplant patients and five control
blood samples by ficoll hypaque gradient centrifugation. 100ul of cells in culture
medium were plated in triplicate on white opaque 96 well microtitre plates and
incubated for 15-18 hours with phytohemagglutinin (PHA 25μg/ml) in a 37º C/
CO2 incubator. The assay plate was assembled so as to include an ATP standard
in duplicate that was prepared by serial dilutions to concentrations of 1000ng/
ml, 100ng/ml, 10ng/ml and 1ng/ml. The Promega CellTiter-Glo Luminescent
Cell Viability assay which signals the presence of intracellular ATP by using the
luciferin/luciferase enzyme reaction was used. The amount of intracellular ATP
present was measured with the Turner Biosystem luminometer in relative light
units (RLU). ATP concentration in PBMC wells was calculated and compared
the published literature values. .
Results: ATP results reported in nanograms of ATP per milliliter were
determined by constructing a standard curve. The measure of the functional
ability of PBMCs’ response to the PHA challenge in vitro demonstrated
lower ATP values in the immune compromised patients as compared to the
healthy controls. The patient’s immune statuses according to ATP levels were
comparable to Cylex published values. PBMC of patients or controls showed
various increases in ATP following exposure to PHA
Conclusion: These preliminary results demonstrate that the use of ATP
bioluminescence together with a luminometer for assessing immune function
is simple and sensitive assay and has possible application to assist in the
management of immunosuppression in kidney transplant patients.

POSTER BOARD NUMBER P1 – 284
1199 IN SEARCH OF NON-INVASIVE MARKERS FOR
CAUSE OF GRAFT DYSFUNCTION AFTER RENAL
TRANSPLANTATION
R. Naqvi1, Z. Imani1, S. Ali1, K. Fatima1, S. Batool1, M. Mubarak1, J. Kazi1,
R. Muzzafar1, A. Naqvi1, A. Rizvi1
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Conclusion: The findings of our study are of importance when designing studies
using the cytokine gene expression profile as a marker for graft dysfunction in
setting of renal transplantation.

POSTER BOARD NUMBER P1 – 285
1200 PHARMACODYNAMIC MONITORING OF DE NOVO
RENAL TRANSPLANT RECIPIENTS UNDERGOING
CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS IN
COMBINATION WITH MYCOPHENOLATE
K. Budde1, J. Nolting1, P. Glander1, N. Gauer1, M. Naik1, A. Sefrin2, M. Mai1,
J. Klupp3, H-H. Neumayer1, P. Reinke2
1
1Medizinische Klinik m.S. Nephrologie, Charité Universitätsmedizin Berlin
Campus Mitte, Germany, 22Medizinische Klinik m.S. Nephrologie und
Internistische Intensivmedizin, Charité Universitätsmedizin Berlin Campus
Virchow Klinikum, Germany, 33Centrum für Chirurgische Medizin, Charité
Universitätsmedizin, Berlin, Germany
Pharmacodynamic monitoring has been shown to be a possible tool to
measure immunological response in patients receiving immunosuppressive
therapy after transplantation (TX). We investigated pharmacodynamic
(Pd) markers in 61 de novo renal transplant recipients after TX to identify
early changes in the immunological activity of the recipients during
conversion from cyclosporine to everolimus (EVR). All patients received
mycophenolate sodium maintenance therapy. Immunosuppressive induction
therapy included basiliximab (pre-TX and day 4). corticosteroids, entericcoated mycophenolate sodium and cyclosporine A (CsA). After month
4.5 patients were randomized to continue on CsA (controls) or to proceed
with everolimus. Pharmacodynamic monitoring included measurement
of the expression of intra-T cell cytokines (IL2, TNFa). T cell activation
markers (CD25, CD71) and lymphocyte proliferation from whole blood
by FACS. The activity of IMPDH in isolated peripheral mononuclear cells
was measured by HPLC. All markers were investigated pre-TX, at day 3,
10, 28 and at month 3, 4.5, 6, 7.5. Immediately after TX we observed a
significant (p<0.001) decrease in IMPDH activity (-52%). IL2 (-62%) and
TNFa production (-68%). CD71 (-78%) and CD25 expression (-94%) and
lymphocyte proliferation (-92%). Proliferation, CD25 and CD71 levels

continuously recovered in part until M4.5 (p<0.001). The conversion from
CsA to EVR was associated with a significant (p≤;0.004) reduction of
IMPDH activity leading to a significant (p≤;0.003) difference of IMPDH
activity between groups. The EVR treated group tended to have lower
lymphocyte-proliferation (-45%) after conversion (n.s.). CD71 expression
was significant (p≤;0.002) lower in the EVR group when compared to
controls. A further normalisation of CD25 (p≤;0.001). CD71 (p≤;0.001) as
well as TNFa (p≤;0.01) and proliferation (p≤;0.05) was observed in the
control group. IL2 remained unchanged in both groups.
Conclusion: Investigation of PD markers may lead to a better understanding
of immunosuppressive therapy after renal transplantation. We observed
differences between two immunosuppressive treatments with these markers.
Prospective research activities might link clinical events like infections and
rejection to distinct pharmacodynamic parameters.

POSTER BOARD NUMBER P1 – 286
1201 IN VIVO IMAGING SYSTEM (IVIS). A NEW TECHNIQUE
FOR LYMPHOID FUNCTIONAL INSPECTION
L-J. Xu1, W-N. Zhang1, H-M. Zhou1, J-M. Huang1, X-K. Pei2, C. Liu2,
Z-H.K. Chen1
1Instiute of Organ Transplantation, Key Lab of Ministry of Education/
Ministry of Health of China, Tongji Hospital, Huazhong University of Science
And Technology£¬Wuhan£¬430030,China, 2Organ Transplantation Center,
2nd Affiliated Hospital of PLA General Hospital, Beijing, 100091
Objective: To evaluate the veracity and sensitivity of In Vivo Imaging System
(IVIS) for inspection of lymphoid function especially in vivo.
Methods: (1) In Vitro Experiments: Mouse melanoma cells (B16-F10-luc-G5)
in 100ul media were seeded into a 96 well plate by 1: 2 serial dilutions from
10,000 cells (well #1) to 78 cells (well #8). The plate was imaged with IVIS
(IVIS Lumina 100, Xenogen) to evaluate its sensitivity for luminescence.
Mixed lymphocyte culture (MLC) system consisted of total lymphocytes
(as effect cell) and tumor cells (B16-F10-luc-G5, as target cell). and it was
divided into 3 groups: Group1, at a 20: 1 effector: target ratio (5×104 total
lymphocytes: 2.5×103 tumor cells) in each well; Group2, at 10: 1 effector:
target ratio (2.5×104 total lymphocytes + 2.5×103 tumor cells) in each well;
Control group, only tumor cells 2.5×103 in each well. After twenty-four hours’
culture, 1×D-luciferin working solution (150 ug/ml) was added to cells just
prior to imaging, and then plate was imaged with IVIS for 60s, the intensity
indicated the sensitivity of IVIS for lymphoid functional inspection in vitro. (2)
In Vivo Experiments: Ten Bablc mice, with melanoma cells (B16-F10-luc-G5)
(1×105 in 100ul) injected subcutaneously into the right dorsal region near
the thigh, were randomly divided into experimental group (n=5) and control
group (n=5). CD4+CD25+ regulatory T cells suspension (1×106 in 100ul)
(which suppresses immune responses against tumor, namely down-regulates
lymphocytes’ function and prolongs tumor survival) was given to each mouse
after tumor cells implantation on Day0 in experimental group, while media
(100ul) was given to control group. Tumor growth is monitored by in vivo
imaging (luminescence detection by IVIS) and caliper measurement at Day0,
Day3, Day5, Day7 and Day9.
Results: (1) In vitro: As few as 78 tumor cells were detectable. A strong
correlation between number of tumor cells and bioluminescence (R2=0.99) was
also demonstrated. In MLC system, there was significant difference (P<0.01) of
mean photon count [photon/ (cm2.ser.s) ] between Group1 and Control, Group2
and Control [ (6.98E+03) ±66.0 vs (4.24E+05) ±5354.1, (1.15E+05) ±1070.8
vs (4.24E+05) ±5354.1]. Moreover, with few cells, effector: target ratio at 10
¦ 1 was appropriate for lymphoid functional inspection by IVIS. (2) In vivo: A
strong correlation (R2=0.94) between mean bioluminescence and mean tumor
volume was also demonstrated. There was significant difference (P<0.01) of
tumor luminescence [mean photon count, photon/ (cm2.ser.s) ] detected by IVIS
between two groups in Day3, Day5, Day7 and Day9 [ (2.36E+05) ±2270.8 vs
(1.12E+05) ±1820.1, (2.57E+05) ±3070.0 vs (1.12E+05) ±2090.7, (3.00E+05)
±4352.8 vs (2.40E+05) ±3515.2, (1.31E+06) ±11852.3 vs (1.18E+06)
±11530.8]. Moreover, tumor dynamic morphology could be monitored by IVIS
when it is invisible.
Conclusion: Compared with conventional methods, with high veracity and
sensitivity, IVIS System should be recommended as an effective method for
lymphoid functional inspection especially in vivo.
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Sindh Institute of Urology and Transplantation (SIUT). Karachi, Pakistan.
Objective: Hyperexpression of some non invasive markers have been studied
previously in setting of acute rejection in renal allograft recipients and
necessitated to confirm the observation in larger sample size.
Methods: We at our institution isolated RNA from urine samples, reverse
transcribed to cDNA and proceeded with doing kinetic (Real Time) Quantitative
PCR. We studied 5 genes i.e. 18S, Granzyme B, Perforin, TGF β and FOX
P3, on all urine samples collected on day 1, day 7, 3 months and 6 months
post transplant, and at time of graft dysfunction. Clinical setting includes acute
rejections, UTIs, CMV, CAN and DGF.
Results: Between July 2007 – Feb 2008, 135 samples from 50 consecutive
transplant recipients processed for above mentioned genes.
We noticed high level expression of cytokines from both cytotoxic and
regulatory T cells on first day post transplant, which showed declining pattern
of these genes on day 7 and 3 months post transplant. (Table). We were also
able to demonstrate again rising expression of GB, Perforin and FOX P3 with
acute rejections. Results of these findings will be analysed and presented.

Tuesday 12 August 2008

Poster Abstracts

TUESDAY – POSTERS ABSTRACTS
CONCURRENT ORAL SESSION 86: BONE MARROW TISSUE
POSTER BOARD NUMBER P2 – 01

TUESDAY

1202 COSTIMULATION AS A GVHD PROPHYLAXIS
H.R. Cho1,2, B. Kwon2,3, J.S. Lee2,4, R.J. Kim2
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea,
3Department of Biological Science, University of Ulsan, Ulsan, Ulsan,
Korea., 4Department of Internal Medicine, Ulsan University Hospital, Ulsan,
Ulsan, Korea
We previously demonstrated that in vivo engagement of CD137, a member of
TNF receptor superfamily, can delete alloreactive CD4+ T cells through the
induction of activation-induced cell death (AICD), thus preventing chronic
GVHD in the DBA/2unirradiated (C57BL/6 x DBA/2)F1 (BDF1) chronic
GVHD model. In this study, we further showed that in vivo engagement of
CD137 was highly effective in triggering AICD of donor CD8+ T cells as well
as donor CD4+ T cells in the C57BL/7unirradiated BDF1 acute GVHD model.
Even though CD137 stimulation facilitated lethal GVHD in mice preconditioned
with a higher dosage of total body irradiation, CD137 stimulation rather
completely prevented acute GVHD without impairing donor cell engraftment
in mice preconditioned with a lower dosage of total body irradiation (200
rad). Further analysis showed that engrafted donor T cells followed by CD137
stimulation did not exhibit alloreactivity to host alloantigens, including skin
graft, further demonstrating that CD137 stimulation completely removed
alloreactive donor T cells from the mature donor T cell pool transferred into
the host. Interestingly, however, CD137 stimulation heightened a GVL effect.
Our result suggest that CD137 stimulation increase the activity of donor T cells
against weak tumor antigens, while deleting donor T cells responding to strong
alloantigens. In sum, CD137 stimulation may be used as a GVHD prophylaxis
in a parent-into-F1 GVHD setting.

POSTER BOARD NUMBER P2 – 02
1203 COMPARISON OF CHIMERISM INDUCTION AFTER
DONOR BONE MARROW TRANSPLANTATION INTO
DIFFERENT RECIPIENT COMPARTMENTS
M. Siemionow, E. Sonmez, A. Klimczak
Cleveland Clinic
Purpose: This study was designed to evaluate the efficacy of different routes
of BMC transplantation on development of donor specific chimerism across
major histocompatibility complex barrier under 7-day alpha-beta-TCR/CsA
treatment protocol.
Methods: Thirty two BMC transplantations were performed between ACI
(RT1a) donors and Lewis (RT11) recipients. In 8 groups (n=4 of each group)
each receiving 100x10 6 BMC, following BMC delivery routes included:
intravenous (Groups 1 and 2), intraosseus (Groups 3 and 4), renal intracapsular (Groups 5 and 6) and intra-testicular (Groups 7 and 8). Groups 1,3,5,7
(controls) received BMC transplantation without immunosuppression, whereas
groups 2,4,6,8 received BMC transplantation under 7 day alpha-beta-TCR/
CsA protocol. Flow cytometry monitored immunodepletion and donor specific
chimerism for MHC class I for T-cells, B-cells and monocyte/granulocyte
antigens.
Results: All animals survived without development of graft-versus-host
disease up to 35 days. In summary: As early as 7 day post-transplant in intratesticular and renal intra-capsular transplanted groups under alpha-betaTCR/CsA therapy, chimerism was supported predominantly by T-cells, and
monocyte/granulocyte populations. During follow-up period at day 35 posttransplant, chimerism declined in all transplanted groups. In treatment groups
chimerism decreased by 49% after intravenous, 22% after intraosseus, 78%
after intracapsular, and 85% after intra-testicular BMC delivery.
Despite the fact that the highest level of chimerism decline was found after intratesticular and intra-capsular BMC transplantation, total level of chimerism was
still superior compared to intraosseus and intravenous BMC transplantation,
and was assessed as follows: 13.27% (intra-testicular), 22.71% (intra-capsular),
11.46% (intraosseus), 7.49% (intravenous) respectively.
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All animals are still under observation in good condition and long-term results
also will be presented.
Conclusion: Our observations indicate that chimerism induction and
maintenance is superior when BMC is delivered into privileged environment
(intraosseus) or to barrier carrying organ such as renal intra-capsular and intratesticular BMC delivery compared to standard intravenous injection. This study
has proven that BMC transplantation into immuno-privileged compartment
may be a preferred method of transplantation and currently studies are carried
out testing its efficacy in composite tissue transplantation models.

POSTER BOARD NUMBER P2 – 03
1204 ALLOGENEIC BONE MARROW TRANSPLANTATION:
CLINICAL OUTCOME AND ANALYSIS OF RISK FACTORS
FOR MORBI-MORTALITY
I. Helal, A. Byzun, J-P. Rerolle, E. Morelon, H. Kreis, M-F. Bruneel-Mamzer
Department of renal transplantation, Necker Hospital. Paris-France
Bone marrow transplantation (BMT) has become a widely used therapy for
malignant and nonmalignant diseases. Despite the associated high risk of
toxicity, with high morbidity and mortality rates. The present study evaluated
the clinical outcome and analysis risk factors for morbidity and mortality in
patients undergoing allogeneic BMT.
We performed a retrospective cohort study including all patients who had
received allogeneic BMTs at Necker Hospital from March 1991 to May 2002.
These patients were reviewed to determine their baseline characteristics, the
development of co-morbidity conditions, and mortality rates at one year. ARF
is defined by the doubling of the baseline serum creatinine concentrations.
Analysis was made using Chi-square test for qualitative parameters and non
paired student’s t test for continuous variables.
One hundred and one patients aged 34 ± 11.8 years on average were included
in our study. The majority of patients (95/101: 95%) had received cyclosporine
prophylaxis and overall 67 patients (66.3%) developed an acute graft-vhost disease (GVHD). Only 12 of the 101 patients (11.9%) developed a
venoocclusive disease (VOD).
Of the 101 patients 40 (39.6%) were admitted to intensive care, mainly for septic
choc in 14 cases (35%) and acute respiratory failure in 11 cases (27.5%).
Of the 101 patients, 58 (57.4%) had ARF corresponding to an incidence of
2.6% per week during the first year following BMT. The peak frequency of
ARF occurred during the second week (29. 3%).The recourse to haemodialysis,
a proof of the severety of ARF, was necessary in 12 cases (20.7%).
The overall mortality rate for the 101 allogeinic BMT was 35.6% at the end
of the first year.In multivariate analysis, only the aminoglycoside use (p=0.02,
RR=0.31), admission to the intensive care unit (p < 10-3, RR=7.29) and the
development of ARF (p=0.001, RR=8.97) were independent predictors of
mortality.
Conclusion: We conclude that ARF is a common complication of allogeneic
BMT. It is of early onset, of multifactorial origin and often associated with
iatrogenic complications. As the prognosis is rather grim, it is very important
that those associated factors be identified for an effective prevention of
this disease.

POSTER BOARD NUMBER P2 – 04
1205 MICROSURGICAL MODELS FOR VASCULARIZED
BONE MARROW ALLOTRANSPLANTS IN RATS
D. Zamfirescu1,2, I. Lascar1, E. Owen2, M. Lanzetta2, R. Bratianu1,
R. Sinescu1, I. Zegrea1
1
Carol Davila Medical University, 2Microsearch Foundation of Australia
It has been suggested that a limb allotransplant can be consider as a vascularized
bone marrow transplant (VBMT). A VBMT is a live and continuous source
of donor bone marrow cells (BMC) in their own environment (stromal
cells, hematopoietic cytokines) that continuous seeding BMC and homing
in recipient tissues and may be responsible for partial tolerance to MHC
antigens. The aim of this work was to familiarize with some experimental
animal models used in the research field of Composite Tissue Allografts
(CTAs) that can be used as vascularized bone marrow models. All these
animal models are vascularized allotransplants from Brown Norway to Lewis
rats. A total 92 procedures were done: orthotopic (n = 60) and heterotopic (n =
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5) limb transplantation, femur transplantation (n = 5), limb and contralateral
femur transplantation (n = 5), knee transplantation (n = 5), tail transplantation
(n = 5), and sternum transplantation (n = 2). All animals received drug
therapy (FK506, MMF and Prednisone) for 8 weeks, then treatment was
ceased entirely. The average success rate of transplantation was 84.57%. This
study demonstrated that vascularized bone marrow transplants could be a
reliable new method for bone marrow transplantation based on this surgical
approach. It is proposed that the transfer of VMB could be a better technique
than cellular bone marrow transplantation.

POSTER BOARD NUMBER P2 – 05
1206 IMMUNOLOGICAL EVALUATION OF THE EARLY POST
TRANSPLANT PERIOD IN PEDIATRIC BONE MARROW
ALLOTRANSPLANTATION

1207 ISOLATION OF CD4/CD8 DOUBLE POSITIVE HUMAN
REGULATORY T CELLS, IN THE SKIN OF A BONE MARROW
TRANSPLANTED PATIENT SUFFERING
FROM GVHD
A. Eljaafari1, M. Michallet2, A. Farre3, C. Ferrand4, J. Kanitakis5, J. Bernaud6,
C. Malcus7, P. Tiberghien8, D. Rigal9, P. Miossec10
1
Edouard Herriot Hospital, Immunogenomics Unit HCL BioMerieux
,Centaure group, 2Edouard Herriot Hospital , Hematology Dept, 3EFS RhoneAlpes, Lyon, 4EFS France Comté, 5Edouard Herriot Hospital , Dermatology
Dept, 6EFS Rhone-Alpes, Lyon, 7Edouard Herriot Hospital , Immunology
Dept, 8EFS France Comté, 9EFS Rhone-Alpes Lyon, 10Edouard Herriot
Hospital, Immunogenomics Unit
Introduction: Whereas regulatory T cells have been isolated among CD4+,
CD8+, or CD4/CD8 double negative sub-populations in the human, the
existence of CD4/CD8 double positive regulatory (DP) T cells is still unknown,
as opposed to the mouse.
Methods: Skin biopsies were performed in a patient suffering from graftversus-host-disease(GVHD), following HLA-identical BMT. Skin infiltrating
T cells were isolated by culture with 25 UI/ml rhIL-2, for two weeks.
Results: At day 14 of culture, we isolated a double positive CD4/CD8 T cell
population which expressed an oligoclonal V beta T cell repertoire. These cells
specifically recognized recipient, but not donor or third-party APCs in proliferation
assays. Anti-HLA class I mAbs blocked the allo-response. Following stimulation
with recipient APCs, the cytokine profile of CD4/CD8 DP T cells showed
moderate levels of TGF beta, high levels of IL-10, intermediate levels of IL-4,
but no IL-2 secretion. This regulatory T cell clone expressed low levels of FoxP3
mRNAs, which specifically increased upon allogeneic stimulation with recipient
APCs. Finally, the T cell clone was able to inhibit the response of third party T
cells that were stimulated with recipient, but not with donor, or third party APCs.
Conclusion: We have identified for the first time, CD4/CD8 double positive
regulatory T cells, in humans. Interestingly, we show at the clonal level, that
these cells are specific for an HLA-class I-restricted minor histocompatibility
antigen, which induces their regulatory function.

POSTER BOARD NUMBER P2 – 07
1208 CAMPATH LYMPHODEPLETION ALLOWS REDUCED
INTENSITY CONDITIONING TO ESTABLISH DURABLE
MIXED CHIMERISM IN PATIENTS WITH SICKLE CELL
DISEASE
M.J. Elliott 1, S. Ildstad1, A. Cheerva 1, C. Dampier 2, S. Bertolone 1, D.
Tollerud 1, G. Herzig 1, R. Herzig 1
1
Institute for Cellular Therapeutics, University of Louisville, 2St. Christopher
Hospital for Children, Philadelphia, PA
Bone marrow transplantation is the only curative therapy for patients with sickle
cell disease (SCD) and thalassemia. Sensitization due to transfusion therapy
has been a significant barrier in the establishment of chimerism in patients with
SCD. Higher intensity conditioning has been required to achieve successful
engraftment. We recently found that humoral immunity is the dominant barrier
in sensitization to alloantigen. As a result, we developed a conditioning approach
to tolerize B cell as well as T cell immunity. Two cycles of Campath-1H (antiCD52) were administered to deplete B-cells and T-cells when preconditioning
recipients for bone marrow transplant, with the rationale to remove memory B
cells induced to undergo homeostatic proliferation by the first round of therapy.
Patients were conditioned with Campath-1H (cycle 1: 10 mg/day; day -53 to -50
and cycle 2: 7 or 8 mg/day -24 to -21, respectively), fludarabine (30 mg/m2 day
-5 to -3), 200 cGy TBI (day -1), peripheral blood hematopoietic cell infusion
day 0, followed by cyclosporine and mycophenolate mofetil (MMF) (day -1
to > 6 months). Patient 1 is an eight-year-old African American female who
experienced multiple pain crises and episodes of acute chest syndrome. She had
been extensively treated with transfusion therapy and hydroxyurea pre-transplant.
She received 14.5 x 106/kg CD34 cells, 43.5 x 106/kg αβ-TCR cells and 6 x 106/
kg facilitating cells from her HLA-identical sibling donor with SCD trait. She
showed 5% donor engraftment on day 17 and 78% donor engraftment on day 30.
Her HgbA has remained over 50% through day 754 post-transplant, with donor
chimerism consistently > 20%. She has been asymptomatic since her transplant
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H. Abdelrazik1, G. Morreale2, E. Lanino2, P. Terranova2, L. Scarso2,
B. Cappelli2, D. Di Martino2
1
Cairo University, 2Istituto Giannina Gaslini
Successful hematopoietic progenitor cell transplantation requires rapid and
complete transfer of the donor hematopoietic and immune systems to the host.
The kinetics of immune reconstitution following various modes of transplant
have been previously studied and found to be impaired for up to several years.
Most of the studies showing delayed immune reconstitution post bone marrow
transplantation (BMT) have focused on long term reconstitution and outcome
of the transplant. Only a few, have looked at immune reconstitution in children
in the early (First 100 days) post-transplant period. Studies have shown that
immune reconstitution is accelerated following autologous transplant when
compared to allogeneic transplant. In the allogeneic setting, graft-versus-host
disease (GvHD) and immune-suppressive therapy may interfere with recovery
of the immune system and strategies which diminish GvHD also retard immune
reconstitution.
To compare the different settings of allogeneic BMT;19 matched unrelated
pediatric donor transplants with mean age of 9.6yrs (1.5-18yrs) and 13
familial allotransplantation with mean age of 6.7yrs (0.5-14yrs) were
evaluated for Immunological Reconstitution during the first 90 days posttransplantation. Immunoglobulin assay levels, T-cells and its subsets, B
cells and natural killer (NK) cell numbers were assessed by flowcytometry
at different time points; engraftment time, day+30, day+60 and day+90
posttransplat. Immunoglobulin (Ig) diversity was determined using heavy
chain determining region 3 (HCDR3) fingerprinting. Two variable heavy
chain (VH) gene families (VH3 and VH6) were amplified by nested PCR
and visualized on 6.5%polyacrylamide gel by silver staining. Fingerprinting
for Ig HCDR3 was also done before transplantation for both the donor and
the recipient in order to monitor whether the patient engrafts with the same
memory of the donor. Pretransplant CD34 counts, neutrophil and platelet
engraftments were also considered.
The natural limb of the immune system seems to play the major role of body
defense during the early post-transplant period. NK cells and neutrophil
counts showed the highest significant differences between patients who had
a familial donor than patients who had Matched Unrelated Donor (MUD),
however most of the tested elements; B-cell counts, Ig levels and T cell counts
showed significant differences. Immunoglobulin fingerprinting showed that
patients were engrafted with the same diversity pattern as the donors while
there was no correlation between the immunoglobulin assay levels and the B
cell number and diversity. Incidence of acute GVHD did not differ between
the two groups. Although the intensity of the immunsuppression didn’t differ
between the two groups, it did affect the diversity and immunoglobulin
production of the B cells.
Familial transplanted patients had a more rapid immune reconstitution
until Day 30 post transplant after which there was no statistical significant
differences recognized between both groups. Thus after the first 30 days
Familial transplantation is comparable with MUD transplantation regarding
Immunological reconstitution and incidence of GvHD
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and her immunosuppression has been discontinued. Patient 2 is a nine-year-old
African American male who had suffered multiple pain crises and two episodes
of acute chest syndrome prior to transplant. He had been treated with red cell
exchange transfusions since August 1999. He received HLA-identical mobilized
product, processed to deplete T-cells and B cells, from an HLA identical sibling
donor with SCD trait. The graft contained 5.24 x 106/kg CD34 cells, 0.55 x 106/
kg αβ-TCR cells and 0.35 x 106/kg FC. The patient has remained transfusionindependent, with HgbA > 50% and chimerism levels at > 25% through > 608
days post-transplant. His immunosuppression has also been discontinued. Both
patients have been asymptomatic since their transplant. Neither experienced graftversus-host disease. These data suggest that targeting of adaptive B-, as well as
T-cell reactivity in sensitized recipients allows a significant reduction in intensity
of conditioning to establish chimerism in treatment of sickle cell disease.
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1209 DEPLETION OF CD16+ CELLS LEADS TO INCREASED
SURVIVAL OF CFSE-LABELED PERIPHERAL BLOOD STEM
CELLS IN RHESUS MACAQUES
A. Kirk, A. Charafeddine, K. Hamby, C. Larsen, L. Kean
Emory University
The induction of donor chimerism after non-myeloablative conditioning
and hematopoietic stem cell transplantation has potential utility for inducing
immune tolerance to subsequently placed solid organ allografts. However, one
of the potential barriers to success of chimerism-based approaches may be the
large number of donor stem cells required to evade early rejection responses.
Our previous work in mice has suggested that natural killer (NK) cells play
an important role in early rejection, and that transient NK depletion leads to
10-20x increased efficiency of stem cell engraftment.
We have now developed a system to study this problem in non-human primates,
and to test the effect that NK cell depletion has on survival of transplanted
cells in this clinically relevant translational model. We have established a
method to collect large quantities of peripheral blood stem cells (up to 1x1010
nucleated cells and 5x108 CD34+ cells after leukopheresis) and to efficiently
label these cells with the fluorescent marker, CFSE (>95% of cells labeled with
>95% post-labeling viability). CFSE+ cells can then be adoptively transferred,
allowing us to monitor trafficking and survival of multiple cell populations (eg.
CD45+ leukocytes, CD34+ stem cells, CD4+ and CD8+ T cell subpopulations,
CD20+ B cells, and CD16+ NK cells).
We have performed leukopheresis, CFSE labeling and autologous adoptive transfer
on 4 recipients and have monitored the trafficking of labeled cells to the peripheral
blood, the lymph nodes and the bone marrow after transfer. In addition, we have
adoptively transferred CFSE+ cells into 6 unrelated, MHC mismatched animals, half
of which had been previously depleted of NK cells (using the anti-CD16 antibody
3G8). We have found that depletion of CD16+ cells led to as much as a 10-fold
survival advantage of adoptively transferred cells within one week of transplant,
and that this survival advantage was found in multiple hematopoietic lineages.
We are currently expanding on these results to determine if NK depletion gives a
similar advantage in the setting of increased MHC matching, and if the increased
stem cell survival that occurs in the setting of NK depletion will ultimately lead to
increased chimerism after nonmyeloablative bone marrow transplantation.

was further stabilized with a plastic cylinder shaped to fit into the vertebral
canal. Vertebral bodies L4-Th8 were stored for 37h14min±36min in 1-4°C cold
Custodiol solution and transferred to a class 10,000 GMP clean room. Cubes
of 1-2cm were irrigated with medium containing saline, albumin, DNAse
and gentamicin, and grinded in a bone marrow machine (Biorep Technology)
housed in a class II bio-safety cabinet. Cells were collected through stainless
steel sieves (425, 180u). Additional cells were eluted during 2 rounds of
agitation using a bone marrow tumbler. Cells were pooled, filtered (500, 200u)
and collected using a bone marrow collection kit. &#8232;
Results: The modified technique allowed for rapid and reproducible retrieval
of vertebral bodies. Most cells (71.9±12.5%) were eluted directly from the
crushed bone, whereas 22.3% and 5.5% were eluted after the first and second
rounds of tumbling, respectively. Larger lumbar vertebrae yielded about 1.6
times the cells of thoracic vertebrae. A total WBC number of 5.37±1.24E+10
and CD34+ cell count of 5.71±1.78E+10 was retrieved. WBC and CD34+
cell viability were 94.3±4.7 and 98.9±0.7% respectively. A distinct population
of CD45- CD34- CD105+ CD73+ mesenchymal stem cells constituted
approximately 0.05% of nucleated cells. Cell yields correlated well with age
but not body weight.
Conclusion: A modified procedure for VB retrieval was established while avoiding
instabilization of the donor body. Bone marrow cell isolation with consistently
high yields and cell viability can be performed in a GMP environment.
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1211 CONSENT TO BONE MARROW TRANSPLANTATION:
A CONVENIENT FICTION?
C. Scanlan
Centre for Values, Ethics and the Law in Medicine (VELiM), University of Sydney
Legal and ethical doctrines of consent are essential components of contemporary
medical practice. These doctrines assume that a competent patient can make a
choice from a series of treatment options (including having no treatment) after
having been sufficiently/adequately informed by their clinician of the risks
and benefits of the proposed treatment(s). These assumptions remain largely
unquestioned in the literature, in health policy, and in practice guidelines.
We conducted a qualitative study of the experience of patients who had
undergone autologous haematopoietic stem cell transplantation (ASCT),
and the experience of their lay carers. Insights from the study fundamentally
challenge common conceptions of consent and choice in medical care.
Participants said they had ‘no choice’ but to consent to ASCT, because the
only alternative for them was death, and for them death was not an option.
They talked about there being a ‘correct’ course of treatment for them, which
evolved with their clinical circumstances and that this dictated what had to be
done. These results suggest that in clinical circumstances such as these, consent
should not be conceptualised as an authorisation based on information delivered
and received in order to allow choice. Instead, the paradigm should shift to the
understanding that patients are consenting to an ongoing relationship of mutual
trust and obligation with their doctor.

CONCURRENT ORAL SESSION 87: PRE-CLINICAL
IMMUNOSUPRESSION
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1210 VERTEBRAL BODY RETRIEVAL AND BONE MARROW
CELL ISOLATION FOR TRANSPLANTATION
S. Schneeberger1, V.S. Gorantla1, L.R. Moore2, B. Pulikkottil1, T.E. Starzl3,
A.W.P. Lee1, A.D. Donnenberg2
1Division of Plastic Surgery, UPMC, 2UPCI Hematopoietic Stem Cell
Transplantation Program, 3Thomas E. Starzl Transplantation Institute
Introduction: Donor bone marrow (BM) cell infusion has been successfully
incorporated and promotes the opportunity for reducing maintenance
immunosuppression in recently described treatment protocols organ and composite
tissue transplantation. The best source for BM cells in deceased donors is vertebrae.
Methods: We have performed five vertebral body retrievals after perfusion
with Custodiol in deceased donors and performed vertebral BM preparation
in a GMP environment. Removal of soft tissue was performed using a Versajet
system and an angled oscillating saw allowed for retrieval of the vertebral
bodies while the remaining appendixes helped stabilizing the body. The spine
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1212 EFFECTS OF ALKALOID SINOMENINE ON CD4+ T
LYMPHOCYTES OF HUMAN PERIPHERAL BLOOD
IN VITRO
Y. Wang1, Z. Luo, G. Qin, J. Li
1The Second Affiliated Hospital, University of South China, 2The Second
Affiliated Hospital, University of South China, 3The Second Affiliated
Hospital, University of South China, 4The Second Affiliated Hospital,
University of South China
To evaluate the immunosuppressive effects of alkaloid sinomenine (SIN) on
CD4+T lymphocytes through the study of effects of SIN on the proliferation
and intracellular Ca2+ concentration and the expression of CD69 and apoptosis
of CD4+ T lymphocytes of human periphory blood in vitro.
Establishment of the CD4+T lymphocytes model of human peripheral blood:
The proliferatiosd CD4+T lymphocytes suspension were divided averagely
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1213 DEFICIENCY IN THE RECALL RESPONSE OF THE
SUPPRESSOR CD8 T CELL GENERATED IN THE ABSENCE OF
THE CD4 T CELL HELP
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu
University
Background: The suppressor CD8 T (Tsupp) cells generated in the tolerant
animal has reported to be efficient for the engraftment in the allogenic organ
transplantation. Tsupp cells are reported to be generated in the recipients made
tolerant by the Cyclophosphamide (CP)-induced tolerance (CPIT) conditioning,
which is the mixed chimerism based tolerance induction regimen. Recent
study reported that the CD4 T cell ghelp h is required for CD8 memory T
cell generation under virus infection, and the ghelpless h CD8 memory T cell
generated in the absence of CD4 T cell help is deficient for its expansion in the
secondary stimulation. In this study, we asked the requirement of CD4 T cell
help for the generation of T supp cells in the tolerant animals.
Method: DBA/2 (H-2d, CD45.2) and BALB/c (H-2d, CD45.1 and CD45.2)
were used the donor and the recipients. Recipient mice were treated with CPIT
conditioning, which comprise the 100 millions of donor splenocyte (SC) on day
0 and 200mg/kg CP on day 2. Recipients were received donor skin graft (SG)
at 2 weeks to confirm the donor SG tolerance. Donor mixed chimerism in the
recipients was also examined by flow cytometry. Recipients were treated with
anti-CD4 mAb on day -4, day 0, and then weekly, when indicated (helpless
Tsupp mice). Secondary CD45.2 BALB/c recipients received CD8 sorted T
cells from the CD45.1 primary mixed chimeras. Those recipients received
donor DBA/2 heart graft (HG) within 2 days, and grafts survival was evaluated.
The Suppressive function in the mixed lymphocyte reaction was also assessed

in vitro. Distributed CD45.1 positive primary recipient CD8 T cells in the
secondary CD45.2 BALB/c recipients were assessed by flow cytometry.
Results: Permanent donor skin grafts acceptance along with the stable donor
mixed chimerism was observed in the primary recipient after the CPIT treatment.
The helped and helpless Tsupp showed equivalent suppressive function in
vitro. Donor DBA/2 HG was permanently accepted in the secondary BALB/c
recipients, that received ghelped h Tsupp from primary mixed chimeras. In
clear contrast, donor DBA/2 HG were rejected in the secondary recipients,
which received ghelpless h Tsupp from primary mixed chimeras treated with
CPIT conditioning with CD4 depletion. Consistent to the HG survival, CD45.1
positive ghelped h Tsupp cells from tolerant recipients was clearly detected in
the secondary recipients. However, ghelpless h Tsupp cells from CD4 depleted
recipients were found smaller percentage in the secondary CD45.2 recipient,
suggesting helpless Tsupp undergo death by activation-induced cell death upon
secondary stimulation.
Conclusion: CD8 suppressor T cells were generated in the mixed chimeras.
Our results indicated that the Tsupp cells generated in the absence of CD4
T cell help was ineffective to suppress donor HG rejection because of its
deficiency in recall response.
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1214 NVP-AEB071 PHARMACOKINETICS: EFFECT OF
METABOLIC INHIBITION WITH KETOCONAZOLE
A. Slade1, J.M. Kovarik1, A. Huang1, P. Chandler2, R. Schmouder1
1
Novartis Pharmaceuticals Corp., East Hanover, NJ and 2Covance, Inc,
Dallas, TX.
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively
blocks early T lymphocyte activation via inhibition of protein kinase C.
AEB071 is metabolized by CYP3A4 and is currently under development for
the prophylaxis of organ rejection and treatment of autoimmune diseases. As
AEB071 has potential for replacing CNIs and may be combined in future
immunosuppressant regimens with other CYP3A4 substrates, a drug-interaction
study was conducted with ketoconazole to quantify the pharmacokinetics (PK)
under metabolic inhibition.
Methods: Using an open-label, two-period, single sequence design, single
doses of 50 mg AEB071 were administered to 18 healthy volunteers alone
and in combination with steady-state ketoconazole (200 mg bid X 7 days).
PK samples were collected during both treatment periods through 72 h postdose. LC-MS methodology was used to quantify AEB071 and ketoconazole
concentrations with a quantification limit of 3 ng/mL and 10 ng/ml respectively.
Results: All doses were well tolerated with a total of 13 adverse events reported
by 9/18 subjects. The most common reported adverse events were headache (3)
and nausea (2); none of them serious or severe. When dosed in combination
(See figure below),

AEB071 Cmax increased 2.5-fold from 285 ± 128 to 678 ± 189 ng/ml; AUC
increased 4.6-fold from 1666 ± 808 to 7378 ± 3011 ng*h/ml; and the elimination
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into 5 groups at random whose cell concentration was 5¡Á105 and volume was
10 ml: 1) Group contrast: No medicine was added to cell culture medium; 2)
Group CsA: CsA solution whose final concentration was 50ng/ml was added
to cell culture media; 3) Group genistein: Genistein solution whose terminal
concentration was 50¦Ìmol/L was added to cell culture medium; 4) Group
low-concentration SIN: SIN solution whose terminal concentration was 10
¦Ìmol/L was added to cell culture media; 5) Group middle-concentration SIN:
SIN solution whose terminal concentration was 200¦Ìmol/L was added to cell
culture media; 6) Group high-concentration SIN: SIN solution whose terminal
concentration was 1000¦Ìmol/L was added to cell culture media.
Results: 1.The cell proliferation inhibition ratios(%) (1)¡¢Group blank
contrast:0.00¡À0.00;(2)¡¢Group
CsA:72.62¡À0.85;(3)¡¢Group
lowconcentration SIN:2.25¡À1.58;(4)¡¢Group middle- concentration SIN:
27.65¡À1.65;(5)¡¢Group
high-concentration
SIN:40.12¡À1.08.
2.The
data of intracellular Ca2+ fluorescent intensity estimated by FCM, which
represented intracellular Ca2+ concentration:(1)¡¢Group blank contrast:
11.00¡À0.20;(2)¡¢Group CsA:11.90¡À0.27;(3)¡¢Group low-concentration SIN:
11.30¡À0.26;(4)¡¢Group middle-concentration SIN: 7.57¡À0.15; (5)¡¢Group
high-concentration SIN:6.00¡À0.10. 3. The expression of CD69 in differently
treated CD4+Tlymphocytes estimated by FCM(%): 1) Group contrast:
87.42¡À0.96; 2) Group genistein: 36.53¡À1.17; 3) Group low-concentration
SIN: 85.46¡À1.52; 4) Group middle-concentration SIN: 62.45¡À1.09; 5) Group
high-concentration SIN: 43.70¡À0.62. The expression of CD69 of group lowconcentration SIN was little changeable in contrast to that of group contrast
(P>0.05). the expression of CD69 of Group middle-concentration SIN, Group
high-concentration SIN, Group genistien decreased gradually, and the expression
of CD69 of group genistein was the lowest than that of other groups (P<0.05).
4. The apoptosis in differently treated groups of CD4+T lymphocytes estimated
by FCM: 1) Group contrast: 1.70¡À0.30; 2) Group genistein: 21.17¡À1.21; 3)
Group low-concentration SIN: 1.83¡À0.19; 4) Group middle-concentration
SIN: 6.90¡À0.30; 5) Group high-concentration SIN: 10.17¡À0.32.
Conclusions: The study of the immunosuppressive value of SIN in the CD4+T
lymphocytes model of human peripheral blood suggests that this medicine
has remarkable efficacy in immunotherapy. The immunosuppressive efficacy
of SIN is probably based on inhibiting of the proliferating and intracellular
Ca2+ concentration evaluation and the expression of CD69 and the apoptosis
of CD4+T lymphocytes of human peripheral blood in vitro. The efficacy is
concentration-responsively. SIN may be a potential Chinese medicine for
immunosuppression therapy in transplantation.
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half-life was prolonged from 5.9 ± 1.7 to 10.6 ± 2.5 hours. Based on the mean
change in AUC, this interaction is classed as “moderate”. The increase in
AEB071 blood levels is similar to or less than that seen with other
immunosuppressants used in transplantation, for example, following a similar
study design, ketoconazole elicits a 4-fold increase in cyclosporine exposure,
but an 11-fold increase in sirolimus exposure.
Conclusion: The transplant clinician should be aware that the combination of
strong inhibitors of CYP3A4, such as ketoconazole with AEB071 results in a
moderate increase in systemic AEB071 exposure.
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1215 NVP-AEB071: EFFECT OF MILD AND MODERATE
HEPATIC IMPAIRMENT ON AEB071 PHARMACOKINETICS
A. Slade1, C. Liu1, J.M. Kovarik1, T. Dumortier1, R. Preston2, R. Schmouder1
1
Novartis Pharmaceuticals Corp, East Hanover, NJ and 2University of Miami,
Miami, FL.
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively
blocks early T-cell activation via selective inhibition of protein kinase C (PKC).
AEB071 is currently under development for the prophylaxis of organ rejection
and treatment of autoimmune diseases. AEB071 is extensively metabolized,
in part by CYP3A4. To measure the effect of hepatic insufficiency on the
pharmacokinetics of AEB071, a study was conducted in patients with mild or
moderate hepatic impairment.
Methods: In this open-label, parallel group, single dose study, eligible
subjects were stratified by their Child-Pugh classification; mild (Class A) or
moderate (Class B) prior to receiving a single, 50 mg, oral dose of AEB071.
Standard laboratory assessments, ECGs and pharmacokinetic (PK) sampling
was conducted throughout the study and follow-up periods. PK samples
were taken through 96 hours post dose. For PK comparison, two historical,
50 mg single dose healthy volunteer studies A2210 (n=22) and A2101 (n=6)
were used.
Results: A total of 12 subjects, 6 each mild or moderate hepatic impairment
were enrolled. There were no clinically relevant changes in laboratory or vital
sign assessments and all doses were well tolerated. There was 1 adverse event,
headache reported.

As shown above, the mild group demonstrated higher variability with a mean
Cmax of 311 ng/ml and AUC(all) of 2134 ng*hr/mL, compared to the healthy
volunteers (265 ng/mL and 1501 ng*hr/mL). The 30% difference in exposure
is likely due to the inherent variability of AEB PK and the small sample size of
6 patients. This interpretation is supported by the results of the moderate group,
in which a mean Cmax of 235 ng/mL and AUC of 1349 ng*hr/mL is similar to
that of healthy controls.
Conclusion: Hepatic impairment, up to Child-Pugh classification B
(moderate) has no clinically relevant effect on the pharmacokinetics of
AEB071. These data support the further development of AEB071 in hepatic
transplantation.
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1216 NVP-AEB071 MAXIMUM TOLERATED DOSE: SAFETY
AND TOLERABILITY OF A NOVEL T-CELL ACTIVATION
INHIBITOR
A. Slade1, T. Jung1, T. Dumortier1, G. Stingl2, M. Seiberling3, J. Wilmer4,
R. Schmouder1
1
Novartis Pharma AG, Basel, Switzerland, 2Medical University of Vienna,
Austria, 3Swiss Pharma Contract, Allschwil, Switzerland, 4CANTEST,
Vancouver BC, Canada
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively
blocks early T-cell activation via selective inhibition of protein kinase C
(PKC). AEB071 is currently under development for the prophylaxis of organ
rejection and treatment of autoimmune diseases. To assess the maximum
tolerated dose of AEB071, single (SD) and multiple dose (MD) studies were
conducted in healthy volunteers and psoriasis patients. Studies from 10-500
mg SD and 25-200 mg MD showed that these doses were well tolerated
as previously reported. Herewith we report on the results of higher dose
studies.
Methods: Three separate, double-blind, placebo controlled studies were
conducted. Subjects were randomized to receive either AEB071 or placebo.
Single doses of 750, 800 or 1100 mg AEB071 or placebo were administered to
24 healthy volunteers. Multiple doses of 300 mg or 400 mg AEB071 or placebo
were administered to 21 subjects, twice daily, for 14 days. Standard laboratory
assessments, ECGs and vital signs were collected throughout the dosing and
follow-up periods.
Results: 38 adverse events (AEs) were reported by 16/24 subjects in the
SD cohorts; one was an SAE (sinus arrest) that resolved spontaneously. 77
AEs were reported by 15/21 subjects in the MD cohorts. There were no
clinically relevant changes in laboratory assessments. A transient increase
in heart rate (sinus tachycardia) and liver function tests were noted at
the highest doses; 1100 mg SD and 400 mg MD AEB071, respectively.
Two subjects discontinued 400 mg bid treatment, one for persistent AEs
and the other for a protocol violation. Otherwise, all patients completed
treatment.

As shown in the table above, 6/6 subjects receiving a single 1100 mg dose of
AEB071 presented with nausea, 4 of whom vomited. Similarly, 4/10 subjects
receiving multiple, 400 mg, doses of AEB071 presented with nausea and
multiple incidence of vomiting.
Conclusion: AEB071 800 mg SD and 300 mg MD for two weeks were well
tolerated. GI intolerance at higher doses of 1100 mg SD and 400 mg bid
MD limit these AEB071 dosings. These data support further development of
AEB071 in transplantation at doses up to and including 300 mg bid.
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1217 STUDY EVALUATING A NEW GENERATION OF
RABBIT ANTI-HUMAN LEUKOCYTE POLYCLONAL
ANTIBODY IN COMBINATION WITH ANTI-CD20
RITUXIMAB IN A NONHUMAN PRIMATE MODEL OF SKIN
ALLOTRANSPLANTATION
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1219 A PILOT STUDY ON SUBLINGUAL AND RECTAL
ADMINISTRATION OF TACROLIMUS
A. Van de Plas1, J. Dackus2, M. Christiaans2, L. Stolk1, K. Neef1,
J. Van Hooff 2
1
Dept of Clinical Pharmacy, 2Subdivision Nephrology of the Dept of Internal
Medicine, Maastricht University Medical Centre, The Netherlands
Introduction: Tacrolimus has a narrow therapeutic index and high variability of
its pharmacokinetics. Oral bioavailability is relatively low and highly variable
(25%(4-93%)). Sublingual and rectal administration of tacrolimus were studied
in six kidney transplant patients before transplantation as part of our search for
a non-oral formulation. Reams et al. recently reported therapeutic blood levels
after sublingual administration of tacrolimus in lung transplant patients. Rectal
administration of tacrolimus has not been published yet.
Objectives: Investigation of sublingual and rectal administration of tacrolimus
to humans.
Methods: Sublingual administration: Three kidney transplant patients were
treated with 0,04 mg/kg tacrolimus s.l. two days before transplantation and 0,1
mg/kg one day before transplantation. A capsule with tacrolimus was opened
and the content was dispersed under the tongue. The patient was told not to
swallow during 15 minutes and afterwards the saliva was spit out and the
mouth was rinsed with 250 ml water.
Rectal administration: Three kidney transplant patients were treated rectally
with 0,23-0,27 mg/kg tacrolimus in suppositories two days before transplantation
and 0,1 mg/kg tacrolimus orally one day before transplantation.
Blood samples of all patients were taken at t= 0, ¼, ½, 1, 2, 4, 8, 12 and 24 hours
post dose. Whole blood tacrolimus levels were analyzed by HPLC and tandem
mass spectrometry (LOQ = 0.05 μg/l). Compounding of the suppositories was
performed according to GMP rules.
Results:
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1218 EFFECTS OF THE NEW IMMUNOSUPPRESSIVE AGENT
AEB071 ON HUMAN IMMUNE CELLS IN VITRO
K. Budde1, M. Matz1, U. Weber1, M-F. Mashreghi2, J. Ladhoff3, S. Kramer4,
H.H. Neumayer1
1
Department of Nephrology; Universitaetsmedizin Charité, Berlin,
Germany, 2DRFZ; Berlin, Germany, 3Institute of Medical Immunology;
Universitaetsmedizin Charité, Berlin, Germany, 4Novartis Pharma;
Nuernberg, Germany
The novel immunosuppressive agent AEB071 is currently being evaluated for
its capability to prevent rejection after kidney transplantation as a potential
replacement for calcineurin inhibitors. AEB071 is a selective protein
kinase C inhibitor and has been shown to be well tolerated in humans. Its
immunosuppressive efficacy could be demonstrated in several transplantation
models. We here present in vitro studies based on PBMC from healthy
volunteers (n=6) that contribute to the understanding of AEB071 effects on
human lymphocyte activation, proliferation and NK-cell activity. Additionally
the effect of AEB071 on human DC maturation and their capacity to stimulate
allogeneic T-cells was studied.
We were able to show that mitogen-stimulated T-cell-proliferation rates are
significantly reduced after AEB071 administration. Also mitogen-induced
T-cell activation characterized by expression levels of surface markers ICOS,
CTLA-4, CD71, CD25, Ox40, PD-1 and CXCR3 could be significantly
inhibited by AEB071 treatment. In contrast the T-cell stimulatory capacity of
AEB071-treated mature Mo-DC is not reduced and AEB071 administration
does not prevent LPS-induced Mo-DC maturation defined by expression levels

Figure 1. Tacrolimus blood levels (μg/l) against time postdose (hours). SL1,
SL2, SL3; s.l. administration, PO1, PO2, PO3; oral administration.
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P. Wang1, Z. Liu1, X. Wang1, P. Yun1, Y. Jia1, H. Xu1, A. Kirk2
1
Jinan City Central Hospital, 2Department of Transplantation, Emory
University Hospital, Emory University, Atlanta, USA
We have generated new rabbit anti-human leukocyte polyclonal antibody
(newRALG) by immunizing rabbits with activated lymphocytes and
monocytes to specifically target these activated cells. The newRALG blocks
multiple surface molecules such as costimulatory molecules and cytokine
receptors on both activated lymphocytes and monocytes, and inhibits acute
renal allograft rejection in rhesus macaques. To evaluate the effects of
newRALG in combination with monoclonal anti-CD20 antibody Rituximab
in preventing allograft rejection, rhesus macaques were treated with 5 doses
of newRALG at 5 mg/kg with or without 2 doses of Rituximab at 10 mg/
kg (day -1 and posttransplant day 7). Thirteen animals underwent skin
allotransplantation. Peripheral blood lymphocyte and monocyte counts were
decreased dramatically, and the depletion of peripheral CD4+ and CD8+
cells as determined by FACS was observed after newRALG infusion. FACS
analysis revealed undetectable peripheral blood CD20+ lymphocytes following
Rituximab infusion. The allograft survival in untreated monkeys (n=4) was
7.5¡À0.58 days. Rituximab treated monkeys did not demonstrate prolongation
of skin allograft survival (n=2, mean=8¡À0). Monotherapy with newRALG at 5
mg/kg moderately prolonged rhesus skin allograft survival ranged from 10 to 11
days (n=3, mean=10.7¡À0.6 days), and those treated with combination therapy
(newRALG and Rituximab) rejected skin allograft in a mean of 15.5¡À0.7
days (n=2). In additional experiments, two monkeys received rapamycin at 1
mg/kg/day and pre-transplant donor specific bone marrow infusion via portal
vein 7 days before transplantation and treated with combined therapy with
newRALG and Rituximab after transplantation. Both monkeys rejected skin
allograft within 7 days after transplantation. Thus, newRALG depletes rhesus
monocytes and lymphocytes in vivo, and moderately prolongs skin allograft
survival. Rituximab monotherapy does not prolong skin allograft survival.
newRALG in combination with Rituximab significantly prolongs skin allograft
survival in rhesus. The effects of high dose newRALG therapy in combination
with Rituximab and post-transplant specific donor bone marrow infusion in
preventing skin allograft rejection are currently under investigation.

of markers CD83, CD40, CD80, CD86, B7-DC and HLA-DR. We additionally
evaluated the effect of AEB071 on the lytic activity of human NK-cells and
were able to show that the new immunosppressive agent significantly inhibited
their cytotoxic activity in vitro.
AEB071 has a clear and strong impact on T-cell activation and proliferation,
NK-cell activity, but not DC-maturation and therefore functions T-cell
and NK-cell specific via PKC inhibition, and is thus a highly promising
immunosuppressive agent.
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Figure 2. Tacrolimus blood levels (μg/l) against time postdose (hours). R1, R2,
R3; rectal administration, PO1, PO2, PO3; oral administration.
Discussion: To our surprise tacrolimus was hardly absorbed after sublingual
administration. A possible explanation for the results contradictory with the
study of Reams et al. could be that in the study of Reams et al. patients were
not told not to swallow and to spit out saliva and rinse the mouth. Therefore
oral intake of tacrolimus can not be excluded. After rectal administration of
suppositories in a dose of 0,23-0,27 mg/kg tacrolimus, blood levels seemed to
be comparable with blood levels after oral administration of 0,1 mg/kg. Peak
blood levels occurred later and the absorption period seems to be prolonged
after rectal in comparison with oral administration.
Conclusion: In this pilot study tacrolimus was hardly absorbed after sublingual
administration. After rectal administration in suppositories tacrolimus is well
absorbed. These results indicate that sublingual administration of tacrolimus
is no but rectal administration probably is a useful alternative for oral
administration. Further investigation is warranted in order to establish correct
dose and pharmacokinetic parameters for rectal administration.
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1220 PHARMACOKINETIC PROFILE OF CP-690,550 IN DE
NOVO RENAL ALLOGRAFT RECIPIENTS
S. Krishnaswami1, S. Busque2, J. Leventhal2, S. Steinberg2, G. Klintmalm2, D.
Brennan2, V. Chow1, P. Gupta1, S. Menon1, N. Lawendy1, C. Wang1, G. Chan1
1
Pfizer, Inc., 2A3921009Study Group
Background: CP-690,550 (CP) is an orally active inhibitor of Janus kinase,
currently in Phase 2 trials for kidney transplantation and autoimmune diseases.
Objective: To characterize the CP-690,550 pharmacokinetic (PK) profile in de
novo kidney transplant patients enrolled in a 6-month, Phase 2, randomized,
open-label, multicenter, active comparator-controlled, parallel group study.
Methods: Plasma samples were collected in patients receiving 15 mg (N=19)
and 30 mg (N=20) of CP-690,550 twice daily (BID) using a combination of
sparse (predose samples on Days 1, 3, and 14 and Months 1, 3, and 6 posttransplant) and dense (samples at 0.5, 1, 2, 4, 8, and 12 hours post-dose on
Days 1 and 3 in approximately 40% of the patients) sampling strategies. PK
data were analyzed using noncompartmental techniques, where possible, and
population modeling techniques.
Results: The absorption of CP-690,550 on Day 1 post-transplant was decreased
with variable time to peak concentration (Tmax) between 1 and 12 hours postdose. The PK profiles on Day 3 showed rapid and consistent absorption, and
rapid elimination (Table 1), consistent with historical healthy-volunteer data.
While increases in median area under the curve (AUC0-t) estimates were
roughly dose proportional, Cmax increases tended to be less than proportional
between 15 mg and 30 mg BID. Over the 6-month period, geometric mean
trough concentrations of CP-690,550 were 17 ng/mL and 32 ng/mL for the 15
mg and 30 mg BID doses, respectively, and were highly variable (coefficients
of variation [CV] of ~100%). Concentrations at 4 hours post-dose showed
higher correlation with AUC0-t (r=0.92) than the trough concentration (r=0.63).
Table 1: Noncompartmental PK estimates of CP-690,550 on Day 3
Parameter

Cmax (ng/mL)

Dose (mg BID)

15

30

15

30

15

30

15

N$

6

9

6

9

6

9

5

9

176
(33)

258
(51)

NC

678
(48)

1141
(36)

3.5
(13)

3.5
(31)

Mean
(%CV)
Median
(range)

Tmax (h)

NC

AUC0-t (ng.h/mL)

Half life (h)
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1221 THE EFFECT OF CP-690,550, A JANUS KINASE
INHIBITOR, ON QTC INTERVAL AND BLOOD PRESSURE: A
CONCENTRATION-RESPONSE ANALYSIS OF PHASE 1 DATA
S. Krishnaswami, P. Gupta, J. French, J. Cook, D. Gruben, G. Chan
Pfizer, Inc.
Background: CP-690,550 (CP) inhibits Janus kinase 3 with nanomolar potency,
and is currently in Phase 2 development for preventing allograft rejection in
kidney transplant recipients. Recent experience with select investigational
immunosuppressive agents has shown unexpected effects on vital signs (eg,
FTY720 on heart rate). To support the ongoing Phase 2 program in kidney
transplantation, a concentration-response analysis was performed to evaluate
the effect of CP on QTc interval and blood pressure (BP) collected in singleand multiple-dose Phase 1 studies.
Methods: Time-matched ECG and corresponding plasma CP concentration
data were pooled from 2 studies. Data included in the concentration-QTc
analysis were derived following single doses of placebo and 0.1 mg to 100
mg CP in 94 healthy subjects and following multiple doses (up to 14 days)
of placebo, 5 mg to 50 mg twice daily and 60 mg once daily in 58 psoriatic
patients. BP and corresponding plasma CP concentrations were pooled from 3
studies. Data included in the concentration-BP analysis were derived from the
same 2 studies used in the QTc analysis and an additional study that employed
multiple doses (up to 14 days) of placebo and 15 mg twice daily in 33 healthy
subjects. Concentration-QTc and concentration-BP analyses were conducted
using the mean of triplicate ECG and BP measurements, where available, at
baseline and at various time points during treatment. Mean Cmax at the highest
single (100 mg) and multiple (50 mg BID) doses utilized in these analyses
exceed that of the highest dose evaluated in Phase 2 kidney transplant studies.
Results: The Fridericia correction adequately rate-corrected the QT interval data
(QTcF). Linear mixed effects models (with additive inter-individual random
effects on intercept and slope and additive residual error) were used to describe
the data. The slope (drug-effect) was essentially zero (estimate: -0.0023, 90% CI
[-0.0077, 0.0031]). At mean steady-state Cmax of the highest therapeutic dose, a
mean QTcF change of -0.5 msec (90% CI [-1.6, 0.6]) is predicted, a value well
below the 5 msec threshold of potential clinical significance (ICH E14 Guidance).
The concentration-BP models yielded slope estimates of 0.0016 (-0.0013, 0.0045)
for diastolic and 0.0018 (-0.0022, 0.0058) for systolic BP. At mean steady-state
Cmax of the highest therapeutic dose, the predicted mean changes are 0.3 mm
(-0.3, 0.9) for diastolic and 0.4 mm (-0.4, 1.2) for systolic BP.
Conclusion: Concentration-response analyses of pooled Phase 1 data suggest
no unexpected, clinically relevant changes in QTcF interval or BP at therapeutic
concentrations of CP.
Future Direction: Additional concentration-response analysis on heart rate is
being performed. Long-term studies are needed to confirm the BP findings in
the patient population.

30

173
260
1
2
656
1234
3.6
3.3
(84-264) (56-434) (0.5-2) (0.5-4) (239-1211) (286-1618) (2.8-3.9) (2.4-5.9)

BID – twice daily; NC – not calculated; $ − Subjects with at least 3 samples within a dosing interval

A one-compartment model with exponential inter-individual error (additive
residual error on log-transformed concentrations) best described the PK
profile of CP-690,550. Population estimates (% relative standard error) of oral
clearance (CL/F), volume (V/F) and absorption rate were 22.7 L/h (8%), 116
L (15%) and 1.1 h-1 (29%), respectively. Inter-individual variability (%CV) in
CL/F was 43%. There were no obvious trends between individual CL/F values
and body weight, gender, race, or age. Model-based AUC estimates were in good
agreement with the noncompartmental estimates (bias -5% and imprecision
15%). CL/F estimates showed time dependency with an approximately 25%
lower CL/F at Month 6 compared with earlier time points.
Conclusions: After the early post-transplant period, CP-690,550 showed rapid

414

absorption, rapid elimination, and dose proportional AUC in renal allograft
recipients. Correlation with clinical outcomes will be required to understand
the clinical relevance of the observed inter-patient variability and the timedependent changes in exposure.
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1222 A SINGLE DOSE OF TM-1 SUPPRESSES THE
DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS
J. Ma, .-Y. Tsui, M. Vogel, A. Obed, H. Schlitt
Department of Surgery, University of Regensburg Medical Center
Transplant arteriosclerosis is one of main features of chronic allgraft rejection
that significantly affects the long-term outcome of solid organ transplantation.
In the study, we examined the therapeutic potentiality of a newly generated
recombinant protein containing a cell penetrating peptide and a truncated form
of heme oxygenase-1 (TM-1) in a rat aorta transplantation model. The cell
penetrating peptide could pass through the wall of blood vessel. The positive
signals for cell penetrating peptide-mediated delivery of target protein were
detected in whole endothelial and smooth muscle cell layers of blood vessels.
The newly generated TM-1 could significantly enhance the heme oxygenase
activities in a hypothermic condition at five minutes after delivery. Intraluminal
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application of TM-1 significantly suppressed the development of transplant
arteriosclerosis in aorta allografts using BN rats as donors and LEW rats as
recipients. In contrast, the aorta treated with control protein showed severe
intimal proliferation and luminal narrowing. The infiltrating leukocytes
including CD45, CD4, ED-1 cells were significantly less in TM-1-treated aorta
allografts as compared with control protein-treated allografts. Sera levels of
anti-donor antibodies were significantly diminished in rats bearing TM-1-treated
allografts. In addition, suppressive effects of TM-1 were associated with less
IL-17A production in allografts in early and late phases after transplantation. In
conclusions, the newly generated TM-1 protein represents a novel agent for the
treatment of transplant arteriosclerosis in clinical organ transplantation.
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1223 EFFECT OF MTOR INHIBITOR ON DYSLIPIDEMIA IN
HEART TRANSPLANT RECIPIENTS RECEIVING STATINS. IS
THERE ANY DIFFERENCE BETWEEN SIROLIMUS
AND EVEROLIMUS?

CONCURRENT ORAL SESSION 88: IMMUNOSUPPRESSION –
PHARMACOKINETICS
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1224 THE EFFECT OF LIVER REGENERATION ON
CYCLOSPORINE PHARMACOKINETICS
D. Kahn, L. Lodewijk, A. Mall, W. Spearman, E. Shepherd
University of Cape Town/Groote Schuur Hospital
In liver transplantation, the liver can be injured as a result of ischaemia,
reperfusion, rejection and infection. The transplanted liver responds by
undergoing liver regeneration. We know that cyclosporine is metabolised via
the cytochrome P450 system and that cytochrome P450 is down-regulated
during liver regeneration. In this study we investigated the effect of liver
regeneration on cyclosporine pharmacokinetics.
Male Long Evans rats weighing 250-300gm were randomly assigned to either
2/3 partial hepatectomy (PH) or sham operation (SH). Cyclosporine (5mg/
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1225 TACROLIMUS PHARMACOKINETICS IS IMPAIRED
IN LIVER REGENERATION
D. Kahn, L. Lodewijk, A. Mall, W. Spearman, E. Shepherd
University of Cape Town/Groote Schuur Hospital
Ischaemia, reperfusion, rejection, infection and drug toxicity are all potential
causes of injury to the graft in liver transplantation. This injury results in a
regenerative response in the liver graft. Tacrolimus is metabolised via the
Cytochrome P450 system, and liver regeneration is associated with downregulation of cytochrome P450. We therefore investigated the effect of liver
regeneration on the pharmacokinetics (PK) of tacrolimus.
Male Long Evans rats weighing 250 - 300 gm were randomly assigned to either
66% partial hepatectomy (PH) or sham operation (SH). Tacrolimus (0,2 mg/kg)
was administered orally at 0, 24 and 96 hours postoperatively. Blood samples were
taken at 0, 1, 2, 4, 6, 12 and 24 hours and the Tacrolimus PK profiles calculated.
The following PK parameters were calculated: AUC, Cmax, Co, and t1/2.
PK studies undertaken immediately after PH and SH, showed higher AUC,
Cmax and Co in the PH group (188 vs129; 20 vs11; and 10 vs 2.9,respectively).
Similarly the PK studies undertaken at 96 hours after PH and SH, showed
higher AUC, Cmax and Co in the PH group (169 vs 94; 18 vs 7; and 4.3 vs
2.3, respectively. In the animals subjected to PH, the AUC, Cmax, and Co were
higher at 0 hours compared to 96 hours postoperatively (188 vs169; 20 vs 18
and10 vs 4.3, respectively).
In conclusion, the PK parameters were higher in the PH group compared to
the SH animals.The impaired metabolism of Tacrolimus in the PH group was
probably related to the down-regulation of Cytochrome P450 associated with
liver regeneration. This has important implications in patients transplanted
with marginal livers.
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1226 THE EFFECT OF LIVER REGENERATION ON
RAPAMYCIN PHARMACOKINETICS
D. Kahn, L Lodewijk, A. Mall, E. Muller, W. Spearman
University of Cape Town/Groote Schuur Hospital
In liver transplantation, the donor liver is susceptible to many forms of injury,
including ischaemia, reperfusion, rejection and infection. The liver responds to
injury by undergoing liver rgeneration. Several of the new immunosuppressive
agents are known to modify the regenerative response. In this study we
investigated the effect of liver regeneration on the pharmacokinetic (PK)
profile of rapamycin (RAPA).
Male Long Evans rats weighing 250-300gm were randomly assigned to either
two-thirds partial hepatectomy (PH) or sham operation (SH). Single bolus
doses of RAPA were administered orally at 0, 24 and 96 hours postoperatively.
Blood samples were taken at 0,1,2,4,6,12 and 24 hours after the dose of RAPA
and used to measure RAPA levels. These were used to calculate the following
PK parameters: AUC, Co, Cmax, and T1/2.
The PK profiles (AUC, Cmax and Co) at 24 hours after PH and SH were the
same (63 vs 64; 5.3 vs4.5; and 1.5 vs 1.8, respectively). The PK parameters
(AUC, Cmax and Co) at 96 hours in the PH and SH groups were also similar
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M.J. Paniagua, M.G. Crespo-Leiro, D. Perez, C. Naya, Z. Grille, S. Albiñana,
M. Outeda, J.A. Rodriguez, F. Estevez, A. Castro-Beiras
Hospital Juan Canalejo
Mammalian target-of-rapamycin inhibitors (mTORi) are increasingly used in heart
transplant (HT) recipients. Dyslipidemia is a side effect associated to mTORi but
the magnitude of this effect, when they are used in combination with statins, is less
known and it is also not well known if there are differences between the 2 mTORi
currently available for clinical use: sirolimus (SIR) and everolimus (EVE).
Aim: To asses changes in lipid levels in HT recipients who received treatment
with everolimus or sirolimus, each of them in combination with statins.
Method: Retrospective analysis of lipid profile in HT recipients treated with
statins and mTORi. Each recipient received statin therapy with pravastatin,
fluvastatin or atorvastatin. Variables: Type of mTORi: SIR or EVE; Total
cholesterol (TC), triglycerides (TG) and HDL cholesterol (HDL) were assessed
before (time 0) and at 6 and 12 months after initiation mTORi therapy. Statistical
analysis: student t test for paired samples comparing lipid levels at 6 and 12
months to basal (time 0).
Results: 52 HT recipients (92.3% male, mean age 57.9 ± 7.4 years) treated
with mTORi, SIR (n= 43) and EVE (n=9) were analyzed. Follow-up time:27 ±
19 months. TC and TG increased significantly in patients received SIR group
but not in EVE group. TC at 0, 6 and 12 months were 174 ±20.4, 213±35 and
212 ± 38 p<0.001 for SIR group vs 195 ±37, 221.2±47 and 215 ± 11.5 p=NS for
EVE group. TG at 0, 6 and 12 months were 136 ±53, 173±74 (p<0.01) and 164
± 80.5 (p<0.03) for SIR group vs 159 ±141.7, 164±56.7 and 132.52 (p=NS)
for EVE group. No differences between 0 and at 6 and 12 months were found
regarding HDL neither SIR nor EVE groups.
Conclusions: In our series of HT recipients receiving statins, mTORi therapy
is associated with a significant increase of TC and TG at 6 and 12 months
if the mTOR used is SIR while this is not observed with EVE. Although the
smaller sample size of EVE group could limit scientific evidence our results,
it seems reasonable to better study these differences between this two mTORi
in a ranzomized trial.

kg) was administered orally at 0, 24 and 96 hours postoperatively. Blood
samples were taken at 0,2,4,6,12 and 24 hours after each dose of cyclosporine
and the following pharmacokinetic parameters calculated: Co, Cmax, Tmax,
AUC and T1/2.
The pharmacokinetic profile at 96 hours postoperatively showed higher
AUC in the PH group (5963 vs 4001), higher Cmax in the PH group (360
vs 263), and higher Co in the PH group (235 vs 173). The pharmacokinetic
profile immediately after PH or SH showed higher AUC in the PH group (4754
vs3350), and a higher Co in the PH group (88 vs72). After PH, the AUC,Cmax
and C0 were all lower in the pharmacokinetic studies done at 0 hours compared
to 96 hours (4754 vs 5963, 172 vs 360, and 88 vs 235, respectively). There
was minimal change in pharmacokinetic parameters after SH at 0 and 96 hours
postoperatively.
In conclusion, liver regeneration results in impaired metabolism of cyclosporine,
presumably as a result of its effect on cytochrome P450. This would impact on
cyclosporine monitoring in patients with compromised liver grafts.
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(186 vs 149; 7.6 vs 8.2; and 5.7 vs 4.3, respectively). The PK parameters were
higher at 96 hours after PH compared to 24 hours (186 vs 63; 7.6 vs 5.3, 5.7
vs 5.7, respectively).
In conclusion, RAPA pharmacokinetics were not modified by the
regenerative response.
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1227 HYPERBARIC OXYGEN THERAPY REDUCES
ISCHAEMIA PRESERVATION AND REPERFUSION INJURY IN
LIVER TRANSPLANTATION
N.Q. Tran, C. Christophi, V. Muralidharan
University of Melbourne, Department of Surgery, Austin Health, Studley
Road, Heidelberg, VIC 3084
Background: A major cause of suboptimal donor organ function after liver
transplantation is ischaemia, preservation and reperfusion injury (IPRI).
Hyperbaric oxygen therapy (HBO) therapy has multiple mechanisms which
may improve IPRI. This project examines the effect of HBO on IPRI in a rat
model of liver transplantation.
Methods: Male inbred Lewis rats were used for syngeneic liver transplantation.
Donor organs were stored at 4oC for 24 hours for severe IPRI. HBO therapy
was administered twice daily with matching controls for all groups until
animals were killed and livers removed at either 12, 24 or 48 hours after
transplant. Assessment of the effect of HBO on IPRI was performed using
histopathological, quantitative stereological and immunohistochemical
methods to quantify hepatocyte necrosis, proliferation and apoptosis.
Results: HBO therapy significantly reduced the percentage volume of hepatic
necrosis at 12 hours (2.38 ± 0.41% vs. 18.74 ± 1.79%, P<0.001), 24 hours
(3.81 ± 0.51% vs. 10.46 ± 2.61%, P<0.001) and 48 hours (3.43 ± 0.86% vs.
8.48 ± 1.34%, P<0.05). Concurrently, HBO therapy reduced apoptosis at 12
hours (1.59 ± 0.17% vs. 6.41 ± 0.37%, P<0.001), 24 hours (1.41 ± 0.10% vs.
4.80 ± 0.22%, P<0.001) and 48 hours (1.04 ± 0.08% vs. 2.38 ± 0.23%, P<0.05).
Hepatocyte proliferation was found to significantly increase at all time points
with HBO treatment, (12 hours: 4.45 ± 0.26% vs. 1.00 ± 0.08%, P<0.05; 24
hours: 7.38 ± 0.18% vs. 2.93 ± 0.19%, P<0.01; 48hrs:18.86 ± 0.74% vs. 8.58
± 0.46%, P<0.001,).
Conclusion: HBO therapy administered immediately following liver
transplantation improved IPRI with a significant reduction in hepatocyte
necrosis and apoptosis. It also independently stimulated the proliferation of
hepatocytes, accelerating recovery.
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1228 MODULATION OF ACUTE CELLULAR REJECTION
BY HYPERBARIC OXYGEN THERAPY IN A RAT MODEL OF
LIVER TRANSPLANTATION
S. Gan, V. Muralidharan, C. Christophi
Department of Surgery, University of Melbourne Austin Health
Background: Acute cellular rejection is a common cause of post-transplantation
morbidity. Hyperbaric oxygen (HBO) therapy has been shown to favourably
alter immune responses and may be useful in the early post transplantation
period.
Aim: This study investigates the effect of HBO therapy on rejection in a rat
model of liver transplantation.
Methods: Male inbred Dark Agouti and Lewis rats were transplanted to create
severe or mild rejection. HBO was administered twice daily for one, three and
seven days after transplantation, after which rats were killed and liver tissue
collected for histopathology. The total number of infiltrating cells, and both the
number and percentage of T cells (CD3+) were assessed in the periportal and
perivenous regions using immunohistochemistry. A survival study in the severe
model was conducted over 14 days with HBO and matching controls.
Results: A significant survival benefit was found using twice daily HBO
administration in the severe model, with mean survival time of 289 ±
17.2 hours vs 234 ± 5.5 hours in controls (p = 0.01). We have previously
determined that the Banff scoring system is not sufficiently sensitive for this
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rat model; control and treated animals in both the mild and severe rejection
models received a score of severe rejection and the maximum Rejection
Activity Index score of 9. Therefore, we used infiltrating cell counts as a
method to quantify the effect of HBO. In the severe model, HBO produced a
significant reduction in the total number of infiltrating cells at Day 1 (24 ± 2
vs 31 ± 3 cells, p = 0.036) and Day 7 (198 ± 11 vs 275 ± 19 cells, p = 0.001)
in the perivenous region. CD3+ cell numbers were found to be significantly
reduced at Day 3 in both periportal (49 ± 5 vs 56 ± 4 cells, p = 0.025) and
perivenous regions (14 ± 1 vs 22 ± 2 cells, p = 0.002), and at Day 7 in the
perivenous region alone (86 ± 6 vs 124 ± 10 cells, p = 0.002). Percentage
CD3+ cells at Day 3 in the periportal (31 ± 1 vs 36 ± 1 cells, p = 0.007)
and perivenous regions (22 ± 1 vs 28 ± 2 cells, p = 0.002) was found to be
decreased by HBO treatment. In the mild model at Day 7, both T cell number
and total infiltrating cell counts in the periportal region (322 ± 20 vs 385 ± 20
cells, p=0.004; 551 ± 32 vs 619 ± 26 cells, p=0.008), and in the perivenous
region (54 ± 3 vs 67 ± 3 cells, p=0.001; 96 ± 4 vs 113 ± 5 cells, p=0.007) were
found to be decreased by HBO therapy.
Conclusion: HBO therapy after liver transplantation reduces inflammatory cell
infiltration in perivenous and periportal regions. In particular T cell infiltrates
were found to have been decreased. Acute rejection was attenuated by HBO
administration, producing an overall survival benefit. This therapy may
potentially provide therapeutic benefits.
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1229 CONVERSION TO EVEROLIMUS MONOTHERAPY
DOES NOT AFFECT HCV AND CMV STATUS IN LIVER
TRANSPLANTATION
P. Simone1, P. Carrai1, S. Petruccelli1, A. Precisi2, L. Baldoni1, J. Ducci1,
L. Coletti1, G. Tincani1, G. Catalano1, F. Filipponi1
1
Liver Transplant Unit, 2Laboratory
Aim: We prospectively investigated the impact of conversion to everolimus
(EVL) on cytomegalovirus (CMV) and hepatitis C virus (HCV) status in
maintenance liver transplantation (LT).
Materials and methods: Adult, consenting recipients of LT from a deceased
donor with a minimum follow-up of 12 months were included. EVL was
introduced at 0.75 mg b.i.d. with overnight withdrawal of antimetabolites and
a 50%-per-week reduction of CNI to a complete stop after 4 weeks. Steroids
were kept at pre-switch levels. EVL target levels were between 3 and 8ng/mL
(RIA). Viral status was assessed in HCV positive patients by means of HCVRNA at baseline (-day 1 before EVL initiation), week 1, 2, 3, 4, month 2, 3,
4, 5, and 6. CMV status was assessed with CMV-DNA assay in all patients at
baseline, month 3 and 6. Efficacy evaluable (EE) patients were those on EVL
monotherapy at 6 months.
Results: Forty patients (mean age 54.9±11 years; M/F=28/12) were enrolled
at a mean of 45.5±31.2 months post-l LT. Native disease was HCV-related
in 15 patients (37.5%) with 13 (86.6%) HCV-RNA positive at baseline
(mean log 6.2±0.7). Indications for conversion were deteriorating renal
function in 36 (90%), CNI-related peripheral neuropathy in 3 (7.5%), and
microangiopathy in 1 (2.5%). Six months after conversion, patient and graft
survival were 100%. The treatment success rate was 75% with 30 patients
on EVL monotherapy (±steroids as necessary). Incidence of biopsy-proven
acute rejection (BPAR) was 15% (6/40). Ten patients (25%) were treatment
failures: 1 patient (2.5%) required conversion to prior treatment for BPAR;
3 patients (10%) needed CNI reintroduction for BPAR; 3 (7.5%) patients
required EVL withdrawal for worsening HCV-related graft hepatitis;
1 patient (2.5%) required EVL withdrawal for acute cholangitis; and 2
patients (5%) withdrew consent to EVL due to persistent pruritus and oral
ulcers, respectively. In the 30 EE patients successfully converted to EVL
monotherapy at 6 months, mean EVL dosage was 1.7 ± 0.9 mg/day and mean
EVL trough level 4.6±1.9 ng/mL. In such patients no CMV reactivation was
observed as per clinical and laboratory parameters. In HCV-RNA positive
patients successfully converted to EVL monotherapy mean change in log
viral load at 6 months was 0.2, i.e. from a mean of 6.2±0.7 at baseline to a
mean of 6.4±0.5 at month 6 (Table).
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Table: HCV-RNA by follow-up visit.
Evaluable
patients

Mean log

Mean change
from baseline

Baseline

13

6.2 ± 0.7

-

Week 1

13

6.3 ± 0.6

0.1

Week 2

12

6.4 ±0.6

0.2

Week 3

12

6.3 ± 0.6

0.1

Week 4

11

6.1 ± 0.6

-0.1

Month 2

9

6.3 ±0.6

0.1

Month 3

8

6±0

-0.2

Month 4

8

6.2 ± 0.4

0

Month 5

8

6.3 ± 0.4

0.1

Month 6

8

6.4 ± 0.5

0.2

Conclusions: Based on our data, conversion to EVL monotherapy is not
associated with change in CMV and HCV viral load in LT patients.
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1230 EPSTEIN-BARR VIRUS SPECIFIC CELLULAR
IMMUNITY IN PAEDIATRIC LIVER TRANSPLANT
RECIPIENTS

Figure: Time course of EBV immunity in two treatment groups of paediatric
liver transplant recipients
Conclusion: This finding indicates a mechanism how a reduced dose of
corticosteroids could lead to the prophylaxis of PTLD.
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1231 EFFICACY OF MINIMAL DOSAGE OF CALCINEURIN
INHIBITOR FOR THE RECIPIENTS WITH PREOPERATIVE
RENAL DYSFUNCTION IN LIVING DONOR LIVER
TRANSPLANTATION
S. Marubashi, D. Keizo, C.W. Kim, T. Asaoka, N. Hama, S. Kobayashi,
Y. Takeda, H. Nagano, K. Umeshita, M. Monden
Department of Surgery, Osaka University Graduate School of Medicine
Calcineurin inhibitor (CNI) is the main immunosuppressive agent (IS)
and necessary for liver transplant. However, its renal toxicity is one of the
greatest concerns and should be carefully monitored especially in patients
with preoperative renal dysfunction. Although renal-spare IS protocol in early
postoperative period is quite important, the standard protocol has not been
established yet.
Objectives: To evaluate the efficacy of minimal dosage of CNI as an induction
IS for the recipients with preoperative renal dysfunction in living donor liver
transplant (LDLT).
Patients and methods: Among 67 patients with end-stage liver disease who
underwent adult-to-adult LDLT between 1999 and 2006 in our hospital, 18
patients (26.9%), who had preoperative creatinine clearance (CCr) less than
50 ml/min, entered this study. Low dose CNI (Cyclosporin A (CsA), C0:
100-150ng/ml or tacrolimus (FK), 5ng/ml) combined with mycophenolate
mofetil, corticosteroids, and basiliximab was used for the first 3 months in
6 recipients (L-bas group). As control groups, normal dosage of CNI (CsA
250-350 ng/ml, FK 10-15 ng/ml) was used in 11 patients (N group), and low
dose CNI as L-bas group without basiliximab was used in 3 patients (L group).
Postoperative renal function, incidence of acute cellular rejection (ACR),
patient survival, and other clinical data were compared among these groups.
Results: Preoperative demography was similar among three groups.
Preoperative CCr was similar among three groups (37.1 }10.0, 44.9 }2.5, 34.4
}10.6 ml/min in L-bas, L, N group, respectively). Incidence of ACR was similar
among three groups (40%, 33%, 35%, in L-bas, L, N group, respectively). No
recipient developed renal failure in L-bas group, while one (9%) did in N group.
patient survival at 1 year in L-bas group was 100%, while patient survival at 1
year was 58.3% in N group, and 66.7% in L group. [figure1]
Conclusions: Our renal spare protocol using minimal dosage of CNI as an
induction IS was safe and might be effective for the recipients with preoperative
renal dysfunction in LDLT.
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1232 SIROLIMUS FOR RESCUE OF STEROID AND ANTITHYMOCYTE GLOBULIN RESISTANT RECURRENT ACUTE
REJECTION AFTER LIVER TRANSPLANTATION. REPORT OF
ONE CASE
A. Demýrag, M. Kalaycý, B. Ekci, O. Gökce
Yeditepe Univ Hospital
Acute liver allograft rejection episodes refractory to antilymphocyte
preparations almost inevitably progress to transplantation loss. Sirolimus
(SRL) rescue therapy for refractory rejection in renal transplantation has been
reported in the literature but information regarding rescue therapy for refractory
rejection in liver transplant scarcely. To reverse ongoing rejection processes,
we administered SRL after failure of conventional immunosuppressive
regimens including full courses of antilymphocyte sera. Compared with the
calcineurin inhibitors, SRL has different mechanisms of action and side effects
profile. Thus, this drug offers significant potential advantages over other
immunosuppressive agents. SRL inhibits the signal of interleukin 2 at a postreceptor level, inhibiting lymphocyte proliferation and fibroblast proliferation.
It also has antineoplastic and antifungal effects.
We report a 26 years old man who underwent OLT due to hepatits C related
liver failure, experiencing a biopsy-proven recurrent acute rejection (AR)
following 2 weeks after transplant. The patient initially received two 20-mg
doses of basiliximab (days 0 and 4 after OLT) followed by tacrolimus (0.15
mg/kg/day; 10-15 ng/mL target trough levels), steroids (methylprednisolone
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M. Lindemann1, E. Liapakis1, M. Wallot2, H. Grosse-Wilde1
1
Institut für Immunologie, Universitätsklinikum Essen, 2Kinderklinik,
Bethanien Krankenhaus Moers, Germany
Background: In paediatric liver transplant recipients the infection with Epstein
Barr virus (EBV) is associated with a severe complication, the occurrence of
post transplant lymphoproliferative disease (PTLD).
Aim: To analyze the therapy effects on cellular in-vitro reactions towards EBV.
Methods: Children were randomized to receive two different doses of
methylprednisolone (15 vs. 60 mg/m2, n=16 vs. n=18) starting from the time of
transplantation. In addition, they were treated with the same dose of cyclosporine
A and Basiliximab. To detect EBV specific cellular reactions interferon-γ
ELISpots were performed prior to and five times post transplantation. Here,
cryopreserved peripheral blood mononuclear cells (PBMC) of the recipients
were stimulated by autologous EBV transformed B cell lines (B-LCL, n=65 vs.
n=64). Pre-incubation of 4 x 105 PBMC was performed for two days in round
bottom microtiter plates; then the cells were incubated for two further days in
ELISpot plates.
Results: In the group receiving 15 mg/m2 methylprednisolone EBV specific
interferon-γ production was 8-fold higher at day 28 post-transplantation
(p=0.008, two-way ANOVA, Figure). Thus, the dose of methylprednisolone
had a significant influence on the strength of cellular immunity towards EBV.
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1 g intraoperatively followed by tapering doses) and mycophenolate mofetil
(MMF) 1 g every 12 h. Steroid resistant acute rejection episodes did not
respond anti-thymocyte globulin treatment. The patient was rescued with SRL,
not experiencing AR again. MMF and steroids were continued and tacrolimus
treatment was stopped, without experiencing severe complications. SRL is a
new and safe immunosuppressive agent for rescue in patients with OLT and
recurrent AR.
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1233 COMBINED MYCOPHENOLATE MOFETIL AND
MINIMAL DOSE CALCINEURIN INHIBITOR THERAPY IN
STABLE LIVER TRANSPLANT PATIENTS IS NEPHRO- AND
HEPATOPROTECTIVE
V.R. Cicinnati1,2, Z. Yu2,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos2, A.
Radtke2, G. Gerken1, S. Beckebaum1,2
1
Department of Gastroenterology and Hepatology, University Hospital Essen,
Germany, 2Department of General, Visceral and Transplantation Surgery,
University Hospital Essen, Germany, 3Department of Surgery, Beijing
Tongren Hospital, Capital University of Medical Sciences, Beijing, China,
4
Institute of Immunology, University Hospital Essen, Germany
Background: Calcineurin inhibitor (CNI)-related nephrotoxicity significantly
contributes to chronic renal failure after liver transplantation (LT).
Methods: In this prospective study, LT patients with renal dysfunction were
randomized to either receive mycophenolate mofetil (MMF) followed by
stepwise reduction of CNI with defined minimal CNI-trough levels (MMF
group) or to continue their maintenance CNI dose (control group). Immune
monitoring was performed in a subgroup of the patients.
Results: In the MMF group (n=50), renal function assessed by serum creatinine
improved >10% in 62% of patients, was stable in 36% and deteriorated >10%
in 2% after 12 months compared with baseline values. Mean serum creatinine
levels (+/- SD) significantly decreased from 1.90+/-0.44 mg/dL to 1.61+/-0.39
mg/dL and the corresponding calculated glomerular filtration rate significantly
increased from 48.7+/-14.1 mL/min to 57.6+/-16.9 mL/min over a 12-month
follow-up period. Blood presssure and levels of liver enzymes significantly
decreased. In the control group (n=25), there were no significant changes with
respect to the investigated parameters. The MMF group had significantly lower
numbers of circulating cytotoxic T cells compared with the controls; whereas
regulatory T cells significantly increased.
Conclusions: Combined MMF and minimal dose CNI therapy after LT is
nephro- and hepatoprotective, and may also promote allograft tolerance.
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1234 MANAGEMENT OF LIVING DONOR LIVER
TRANSPLANT PATIENTS USING TWICE-DAIRY 4-HOUR
INTRAVENOUS CYCLOSPORINE THERAPY
K. Sato, Y. Kobayashi, S. Sekiguchi, N. Kawagishi, Y. Akamatsu,
K. Fujimori, S. Satomi
Advanced Surgical Science And Technology Division, Department of Surgery,
Graduate School of Medicine, University of Tohoku
Aims: Oral administration of cyclosporine (CsA) is the currently favored
route of administration in most liver transplant (LT) centers. However, in
some LT patients with poor oral absorption during the early period after LT,
or clinically illness who were unable to take medicine orally such as severe
immunosuppression-associated leucoencephalopathy, intravenous CsA (IV
CsA) is the only alternative option to achieve and maintain therapeutic blood
levels. In this study, we evaluated our experiences with 4-hour intravenous CsA
administration in living donor LT (LDLT) patients.
Methods: From October 1998 to January 2008, 86 LDLTs were performed in
85 patients (46 adults and 39 children) at our institution. Of these, 73 patients
received Tacrolimus (Tac) via a nasogastric tube immediately after LDLT, and
12 patients intravenous CsA twice daily at a dose of 3 mg/kg/day as a 4-h
continuous infusion, for the following indications: insulin-treated diabetes
mellitus (n=7), hepatitis C virus infection (n=4), QT prolongation (n=1). 13
(17.8%) of 73 Tac-based patients were switched to CsA because of Tac-related
side effects. Of these, 5 patients were switched to intravenous CsA because they
were unable to take the drug orally due to severe Tac-related complications.
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The remaining 6 patients switched to oral CsA administration because they
were well enough clinically to take the drug orally. Among them, we evaluated
a total of 14 patients (11 adults and 3 children), including 12 patients with
induction therapy and 2 with conversion therapy within 2 weeks after LDLT,
who were given a 4-h IV CsA at an initial dose of 3 mg/kg/day.
Results: The type of graft using in LDLT was right (n=10) and left liver (n=4).
Of these, 5 patients were reconstructed bile duct using an external biliary stenttube. The median actual graft volume/recipient standard liver volume (GV/
SLV) was 47.5% (31.3 -71.8%), which corresponded to 0.94 (0.57-1.41) of
the graft weight/body weight (GW/BW) ratio. Of 14 patients, 2 patients died
within 1 year of LDLT, due to multiple organ failure. The median duration
of IV CsA administration was 19 days. Stable and adequate blood CsA
concentrations were achieved by 4-h IV CsA administration in 14 patients after
LDLT, compared to blood levels after the conversion from IV CsA to oral CsA
(FIGURE). Of several factors that affects blood CsA concentration, only GW/
BW ratio (r = .743, P < .0001) showed significant correlations with initial blood
CsA concentration. No adverse effects were observed after IV CsA. However,
1 of 14 (7.1%) patients developed acute cellular rejection (ACR) during IV
CsA therapy, whereas 4 patients developed ACR after conversion from IV CsA
to oral CsA.
Conclusions: Stable and adequate blood CsA concentrations were achieved by
4-h IV CsA administration at the early stage after LDLT. In our cases of LDLT,
the initial blood CsA level could be predicted by the transplanted liver graft
and recipient body weight. Therefore, our findings suggest that the immediate
administration of a 4-h IV CsA at an initial dose of 3 mg/kg/day would be
practical and effective for routine clinical use.
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1235 STEROID RESISTANCE ACUTE REJECTIONS AFTER
LIVER TRANSPLANTATION
C. Aydogan, S. Sevmis, H. Karakayali, S. Pehlivan, H. Akkoc,
M. Haberal
Baskent University Faculty of Medicine, Department of General Surgery
Liver transplantation is the definitive treatment for the end stage liver disease.
Although effective immunosupressants are available, steroid resistance acute
rejection (SRAR) can be encountered.
Between September 2001 and January 2008, 212 adult and pediatric liver
transplantations were perfomed from both cadeveric and living related donors
at our center. All patients received tacrolimus based immunosuppressive
therapy. Steroids were tapered in 3 months. Liver biopsy was performed for
confirmation of acute rejection after vascular or biliary complications were
excluded. High dose methylprednisolone was administered for acute rejections.
Acute rejection was defined as SRAR if there was no response to steroids.
After confirming SRAR by second biopsy; the patients received Antithymocyte
globulin (ATG) for10- 14 days with ganciclovir prophylaxis. Acute rejection
was detected in 70 patients (32.8%). SRAR were detected in 9 of 70 patients
(12.8%).Seven patients were male and 2 were female. While 6 patients were
pediatric, 3 were adult. The mean age of the patients were 14.6 &#61617;
10.7 years (range 5-32 years).The mean follow up period of SRAR patients
were 19.4 &#61617;19.1 months (range 5-53 years).The mean time from
transplantation to SRAR was 77.3 &#61617; 66.9 days (range 20-181 days).
SRAR therapy was successful in 7 patients (77.7%) and 2 patients did not
respond therefore advanced to chronic rejection. They required retransplantation
at 7th and 8th month after first transplantation but they died due to sepsis and
sudden cardiac arrest at 12nd and 32nd day after retransplantation. Mean total
bilirubin, Aspartate aminotransferase and Alanine aminotransferase levels
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decreased from 12.6&#61617;9.5 mg/dl, 171.6&#61617;132.1 IU/L, and
266.7&#61617;235.2IU/L to 2.4 &#61617; 2.3 mg/dl, 45.7&#61617;30.5
IU/L, and 56.3 &#61617; 28.8 IU/L respectively. Minor side effects were
observed in 6 patients. We did not encounter serious infections and pulmonary
edema. In conclusion; according to our experience ATG can be considered as a
good therapeutic option in SRAR with acceptable side effects.
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1236 LOW-DOSE MYCOPHENOLATE MOFETIL USE
REDUCES RISK OF LATE ACUTE REJECTION IN ADULT
LIVING DONOR LIVER TRANSPLANTATION
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1237 MTOR INHIBITORS IN LIVER TRANSPLANTATION
– THE BUDAPEST PRACTICE
I. Fehervari, Z. Gerlei, L. Kobori, D. Gorog, B. Nemes, Z. Mathe
USN Transplantation And Surgical Dept
Aim: To investigate the results of conversion from CNI based immunosuppression
to mTOR based immunosuppression after liver transplantation. There were 26
pts between 2003 -2007 converted. The causes of conversion were: progressive
renal insufficiency in 16 cases, de novo tumor in 4 cases and planned conversion
in 6 pts, transplanted with known or incidental liver tumors.
Results: Median conversion time was 20 month after transplantation (2-97
month) in whole group. In renal insufficiency group the median was 14
month. Comparing the serum creatinine levels at the time of conversion
(mean 163μ;mol/l ±;88 μ;mol/l) and 2 months after conversion (mean 123
μ;mol/l ±;63 μ;mol/l) we found significant (p=0.01)improving but no change
in glucose intolerance or diabetes. Side effects were: mucosal ulcerations in
3 cases-requiring hospitalizations in one case. Also peripheral edema was
found in 5 cases. In 6 patients we found severe anemia but relation to mTOR
inhibitors is not clear because on consecutive IFN+ RBV treatment of HCV.
Conclusions: On bases of our investigations the mTOR inhibitors seems to
be safeand probably have place in liver transplant immunosuppression in a
stepwise treatment

1238 THE IMPACT OF EVEROLIMUS MONOTHERAPY ON
RENAL FUNCTION IN LIVER TRANSPLANTATION
P. De Simone1, A. Precisi2, S. Petruccelli1, L. Baldoni1, P. Carrai1, J. Ducci1, E.
Balzano1, G. Catalano1, F. Filipponi1
1
Liver Transplant Unit, 2Laboratory
We investigated retrospectively the impact of conversion from calcineurin
inhibitors (CNI) to everolimus (EVL) monotherapy on renal function (RF)
in liver transplant (LT) recipients. Between January 2006 and July 2007, 70
consenting recipients (51 M, 19 F; mean age 55.9±11 years) from a deceased
donor were enrolled into a program of conversion to EVL monotherapy at a mean
interval of 45±35.9 months from transplantation (range 7÷192). Indications for
conversion were deteriorating RF in 63 (90%). Efficacy failure was defined
as persistence of CNI, EVL discontinuation, death, graft loss, loss to followup, and need for dialysis at 6 months. Six months after switching, 53 efficacy
evaluable patients (75.7%) were on EVL monotherapy and their mean change
of creatinine clearance (CrCl) from baseline (-day 1 before EVL introduction)
to endpoint (6 months) was 6.3±11.1 mL/min (range: 8.6÷50.4) (Table 1).
Breakdown analysis revealed that the mean change of CrCl was 7±11.2 mL/
min (range -4.8÷50.4) for the 35 patients with baseline CrCl between 21 and
60 mL/min vs. 4.9±10.9 mL/min (range-8.6÷36.6) for patients with baseline
CrCl ≥61 mL/min (p=ns) (Table 1). On univariate and multivariate analyses the
clinical variables correlated with the greatest probability of improvement were
age (p=0.006) and baseline CrCl (p=0.008) (Table 2).
Table 1: Mean baseline and endpoint CrCl in efficacy evaluable patients
converted to EVL monotherapy.
CrCl group
≥20 mL/min
20÷40 mL/min
41-60 mL/min
61-80 mL/min
≥81 mL/min
≤60 mL/min
≥61 mL/min

# patients (%)
Mean baseline
Mean endpoint
Mean change
53 (100)
59.4±21.9 mL/min
66.1±25.3 mL/min
6.3±11.1 mL/min
7 (13.2)
34.9±4.5 mL/min
39.8±4.3 mL/min
4.9±6.8 mL/min
28 (52.8)
55.5±5.5 mL/min
57.5±9.9 mL/min
7.5±12.1 mL/min*
12 (22.6)
68.4±6.7 mL/min
69.6±7.3 mL/min 1.5±4.5 mL/min*, **
6 (11.3)
105.34±31.8 mL/min 114.5±45.5 mL/min 11.6±16.8 mL/min**
35 (66)
49.1±7.7 mL/min
57.2±11.5 mL/min
7±11.2 mL/min
18 (34)
81.6±26 mL/min
85.6±34.2 mL/min
4.9±10.9 mL/min

*p = 0.049 by Mann-Whitney test; **p =0.031 by Mann-Whitney test.

Table 2: correlation analysis between change in CrCl at 6 months and selected
patients’ clinical variables.
Baseline CrCl
Age
Interval from transplantation
Type of baseline CNI (CsA vs. TAC)
Use of antimetabolites
Sex
Native disease (HCV vs. non-HCV)

Univariate
0.0005
0.0028
ns
ns
ns
ns
ns

Multivariate
0.006
0.008
ns
ns
ns
ns
ns

Based on our data conversion from CNI to EVL monotherapy is successful in
75.7% of cases. The improvement in RF is correlated in a continuous rather
than categorical way with age and baseline CrCl. These data support preemptive minimization of CNI in the post-transplant course in order to delay the
decline in renal function.
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1239 SAFETY AND EFFICACY OF CONVERSION
TO EVEROLIMUS MONOTHERAPY
P. De Simone1, P. Carrai1, A. Precisi2, S. Petruccelli1, E. Balzano1,
L. Coletti1, L. Baldoni1, J. Ducci1, G. Catalano1, F. Filipponi1
1
Liver Transplant Unit, 2Laboratory
Aims: We investigated retrospectively the safety and efficacy of conversion
from calcineurin inhibitors (CNI) to everolimus (EVL) monotherapy in liver
transplant (LT) recipients.
Materials and methods: Retrospective analysis of prospectively collected
clinical data of patients undergoing conversion to EVL monotherapy at any
time point during follow-up. Efficacy failure was defined as persistence of CNI,
EVL discontinuation, death, graft loss, loss to follow-up and need for dialysis
at 6 months.
Results: Between January 2006 and July 2007, 70 recipients (51 M, 19 F;
mean age 55.9±11 years) from a deceased donor were enrolled into a program
of conversion to EVL monotherapy at a mean interval of 45±35.9 months from
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C-L. Chen, A. Concejero, C.C. Wang, S.H. Wang, Y.W. Liu, C.H. Yang,
C.C. Yong
Liver Transplant Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center
Background and objective: Mycophenolate mofetil (MMF) used in a tripledrug regimen decrease both early and late acute rejection rates. The impact
of low-dose MMF on acute rejection episodes has not been well described
in living donor liver transplantation (LDLT). Our objective is to present our
experience in low-dose MMF in adult LDLT.
Patients and methods: To investigate the risk of early acute (rejection <6
months) and late acute (rejection >6 months) rejections, we analyzed the
records of adult pimary LDLT recipients (n=153), between January 1999-June
2007, with hepatitis B virus (HBV) (n=92), hepatitis C virus (HCV) (n=26),
both hepatitis B and C viruses (HBCV) (n=8) or a non-viral (n=27) primary
cause of liver disease who received continuous MMF+tacrolimus+steroid or
MMF+cyclosporine+steroid for at least 6 months immediately post transplant
using our low-dose MMF regimen (<3 gm/day).
Results: The mean starting dose of MMF was 500 mg, twice a day. The
tacrolimus dose was 0.01-0.18 mg/kg; and the cyclosporine (C2) trough
levels were maintained at 800-1200 for the first 6 months and 640-960 for
up to 1 year. Steroid, started as methylprednisolone 20 mg/kg intra-operative,
was tapered and discontinued within 6 months. Basiliximab induction was
given in 123 recipients. Ten recipients discontinued MMF due to side-effects.
The rates of early acute rejection episode in HBV, HCV, HBCV, and nonviral groups were 18.5%, 30.8%, 25.0%, and 33.3%, respectively; whereas,
the rates of late acute rejection episode were 3.3%, 3.8%, 12.5%, and 11.1%
respectively. Kaplan-Meier analysis showed freedom from acute rejection
rates of 98.6%, 95.6%, 84.4%, 75.3%, and 64.5% at 6-months, 1-, 2-, 3-, and
5-years, respectively.
Conclusion: Triple-drug therapy for around 6 months, using low-dose MMF,
may offer a better treatment strategy to avoid the consequences of acute
rejections in adult LDLT.
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transplantation (range 7÷192). Indications for conversion were deteriorating
RF in 63 (90%). Native disease was HCV-related in 28 (40%); HBV-related
in 18 (25.7%); alcohol-related in 10 (14.3%); primary biliary cirrhosis in 4
(5.7%); acute liver failure in 3 (4.2%); cholangiocarcinoma in 2 (2.8%);
polycystic liver in 2 (2.8%); cryptogenic cirrhosis, idiopathic liver fibrosis and
sclerosing cholangitis in 1 (1.4%) each. Six months after switching, 53 patients
(75.7%) were treatment success (Table 1). Complications included 5 cases of
worsening HCV-related graft hepatitis (Table 1 and 2) in patients on baseline
CsA-based immunosuppression. Biopsy was performed in all such cases and
confirmed recurrent HCV graft hepatitis (mean grade 11.6; mean stage 2.4).
Retrospective analysis revealed that all such patients had overexposure to EVL
as per a mean trough level of 15.5 ng/mL 7 days after drug initiation; were
genotype 1 and had failed to respond to previous anti-viral treatment (Table 2).
Upon withdrawal of EVL all patients but one returned to baseline liver function
test values.
Table 1: 6-month results.
Variable
Efficacy (%)
Efficacy failure (%)
BPAR
Death
Worsening HCV-related graft hepatitis
Oral ulcers (consent withdrawal)
Acute cholangitis
Intractable pruritus (consent withdrawal)
Need for dialysis
Proteinuria >1 gr/24 hr
BPAR (%)
CNI reIntroduction
EVL dose adjustment
Steroid boluses and resumption of pre-switch regimen
Mean RAI score (±SD)
Mean days after EVL introduction (±SD)
Complications (%)
Hyperlipemia
Oral ulcers/stomatitis
Worsening HCV-related graft hepatitis
Pruritus
Acne
Low tract urinary infection
Erythema
Shingles
Pharyngitis
Urticaria
Persistent headache
Eczema
Psoriasis
Oral abscess
Cholangitis

53 (75.7)
17 (24.3)
4 (5.7)
1 (1.4)
5 (7.1)
3 (2.8)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
6 (8.6)
3 (4.3)
2 (2.8)
1 (1.4)
7 (0.6)
70 (14.1)
19 (27.1)
14 (22.5)
5 (7.1)
4 (5.7)
3 (3.9)
2 (2.8)
2 (2.8)
2 (2.8)
1 (2.5)
1 (2.5)
1 (2.5)
1 (2.5)
1 (2.5)
1 (2.5)
1 (2.5)

Table 7: main clinical characteristics of the patients with worsening HCVrelated graft hepatitis after EVL introduction.
Sex
Age
Interval from LT
(months)
Baseline
immunosuppression
Baseline CsA-ME daily
dosage (mg/kg)
Baseline log HCV-RNA
Viral genotype
EVER starting dosage
(mg/day)
EVER trough level at 7
days (ng/mL) (RIA)
7-day log viral load
Grade (Ishak)
Stage (Ishak)
Previous attempt at
antiviral treatment
post-LT
Endpoint liver function
tests (AST/ALT after
EVL withdrawal)

1
M
65

2
M
68

3
M
64

4
M
59

5
M
42

25

49

16

15

36

CsA-ME,
MMF

CsA-ME

CsA-ME

CsA-ME

CsA-ME

110 mg (1.5)

100 (1.7)

150 (2)

150 (2)

125 (1.6)

7
1

7
1

6
1

7
1

7
1

1.5

1.5

1.5

3

3

12

15.1

15.5

18

17

7
12/18
3/6

7
12/18
1/6

6
11/18
3/6

7
12/18
2/6

7
11/18
3/6

Yes/failed

Yes/failed

Yes/failed

Yes/failed

Yes/failed

Within range

Within range

>2 upper limit

Normal

Normal

Conclusions: Based on our data, conversion to EVL monotherapy is safe and
effective. However, inadvertent EVL overexposure may be associated with
hepatitis flares in non-responder, HCV-RNA-positive patients on baseline
CsA immunosuppression. Strategies to reduce the risk of EVL overexposure
need to be implemented to expand to this category of patients the benefit of
antiproliferative immunosuppression.
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1240 INDICATIONS AND MANAGEMENT OF M-TOR AFTER
LIVER TRANSPLANTATION
R. Charco1, G. Sapichosin1, C. Dopazao1, A. Escartin1, J.L. Lazaro1,
L. Castells2, M. Caralt1, I. Bilbao1
1
Department of HBP Surgery and Transplants. Hospital Vall d’Hebron,
2
Department of Hepatology. Hospital Vall d’Hebron
Aim: To asses our experience with the use and management of m-TOR after
liver transplantation (LT).
Material: From 1988 to 2007, 783 LT has been performed in 725 patients. Fifty
one patients (7%) received immunosuppression with m-TOR: Rapamicine 36
and everolimus 15. Mean age was 54.8 years old (r:24-70). Indication of use,
time between LT and introduction of m-TOR, eficacy, side effects and survival
were analysed .
Results: Indications were: refractory rejection in the context of renal
insufficiency 20 (39%), renal insufficiency 5 (10%), other side effects of
CNI 6 (12%), extended HCC in the explanted live 7 (14%), HCC recurrence
in the follow-up 7 (14%) and the novo tumour 3 (6%). Mean time between
LT and m-TOR were 18 ± 29 months with a median of 3 months (r:10 days122months). Mean follow-up after conversion was 12 months (r: 1-65), with
a median of 7. Half of the patients converted for refractory rejection, resolved
the event. Four required re-LT, 3 progresed to chronic rejection and 3 died
due to non resolved rejection, overimmunosuppression and sepsis. Of 19
patients with renal insufficiency at time of conversion, 10 (52%) resolved.
Three out of 7 patients with extended HCC, died and 4 out of 7 patients with
recurrent HCC, died. The 3 the novo tumour were operated and are perfectly
healthy. Half of the patients presented side effects related to m-tor: diarrhea
in 4 (8%), hematologic complications in 5 (10%), dyslipemia in 22 (43%),
and infection in 8 (16%). Ten patients (20%) developed acute rejection after
conversion. Nineteen patients (33%) discontinued drug: 9 due to ineficacy, 4
due to resolution of the cause, 3 due to intercurrent surgery and 3 due to advers
event. Actuarial survival postconversion is 55% and 15% at 1y and 3y.
Conclusion: m-TOR are indicated in critical and irreversible situations where
other immunosuppressants have failed: in the early period for refractory
rejection or as prophylaxis for recurrence of extended tumors; in the late period
for patients with serious side effects of CNI.
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1241 IMMUNOSUPPRESSION AND RENAL DYSFUNCTION IN
LIVER TRANSPLANTATION
F. Nolasco, A.C. Ferreira, S. Sampaio, A. Baptista, E. Monteiro,
A. Martins, E. Barroso
Hospital Curry Cabral
Renal dysfunction is a common complication of orthotopic liver transplant
(OLT). Long term use of cyclosporine A (CyA) or tacrolimus (FK) can lead
to nephrotoxicity. The introduction of Mycophenolate Mofetil (MMF) and
sirolimus seems to improve renal function on these patients.
The aim of this retrospective study was to determine the incidence of renal
complications (acute and chronic) in hepatic transplants and its association
with immunosuppression.
Clinical data included age, gender, aetiology for hepatic failure, presence of
diabetes mellitus, hypertension, hepatitis B and C infection, renal dysfunction
pre transplant (RD pre), defined by Glomerular Filtration Rate (GFR) ¡Ü60
ml/min or serum creatinine (Scr) ¡Ý1.5mg/dl, and immunosuppression.
Laboratorial data included serum creatinine (Scr) at day 1, 7, 21, month 6 and
every year. The GFR was determined by Cockcroft-Gault equation. We studied,
retrospectively, from September 1992 to March 2007, 708 OLT recipients, 82
being re-transplanted. Mean age 44 ¡À12.6 years, 64% males, 17% diabetic,
18.8% with hypertension, 19.9% with C hepatitis and 3.8% B hepatitis, 30.7%
with amyloidotic polyneurophaty. Renal dysfunction pre transplant was known
in 21.6%. Mean follow-up was 3.6 years (0- 15). Mean transplant survival was
75% at 12 months and 69% at 3 years. 152 patients died. Uni and multivariate
analysis (Spearman and binary regression) were performed and a p<0.05 was
considered significant.
Acute Renal Failure (ARF) occurred in 33.8% of the patients and the
development of Chronic Kidney Disease (CKD) according to KDIGO definition
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was observed in 50% of the population: 50.2% had CKD stage 3, 29% with a
GFR ¡Ü45ml/min, 9% had CKD stage 4 and 5.6% CKD stage 5d, by the time
of the study.
Concerning immunosuppression, almost all were treated initially with a
calcineurin inhibitor (CI), associated to an anti metabolite. Sirolimus was
employed in 10.6% particularly those with renal dysfunction (r=0.16, p<0.001).
At the time of this study, 46.4% of the population was on CyA, associated with
azatioprine or MMF, 44.7% were on FK mostly associated with MMF and
8.9% on sirolimus.
On univariate analysis, permanent renal dysfunction, GFR ¡Ü45 ml/min,
was positively correlated with the use of Azatioprine (r=0.130, p=0.001),
CyA (r=0.123, p=0.003) and sirolimus (r=0.163, p<0.001) and was inversely
correlated with the use of tacrolimus (r=-0.125, p=0.002) and MMF (r=-0.163,
p<0.001). On multivariate analysis, renal dysfunction was positively correlated
with CyA (p<0.01) and sirolimus (p=0.008) and inversely correlated with the
use of MMF (p<0.01).
In univariate analysis, mortality was correlated with the use of azatioprine
(r=0.093, p=0.025). The use of FK had a favourable impact (r=-0.095,
p=0.018). On multivariate analysis, mortality was correlated with the use of
azatioprine (p=0.021).
In conclusion, in this population, some immunosuppressors are associated with
worst outcome. The use of FK and MMF seems to have better outcome in what
concern to renal function in contrast to CyA and Azathioprine. Sirolimus may
be important in preventing further progression of renal failure.

MELD
at transplantation

18 (6-40)

24 (6-40)

Number of patients needing renal replacement therapy
pre-transplant

6 (4,4%)

4 (7%)

Number of patients needing renal replacement therapy
post-transplant

42 (31%)

18 (31%)

Days of renal replacement therapy post transplant
(in patients needing renal replacement therapy)

25,5 (1-206)

12,5 (1-149)

The duration of renal replacement therapy was shorter in patients receiving
individualized CNI delay and MMF in the MELD era compared to patients on
standard immunosuppression with CNI in the pre-MELD era.
Summary and conclusion: Our data show that perioperative renal failure
remains a severe problem for LTX patients as one third needed renal
replacement therapy. Although our patients had a higher MELD score at
time of transplantation in the MELD era than in the pre- MELD era, no
increase in need of renal replacement therapy was found. On the contrary,
we found that patients who needed renal replacement therapy after LTX
were shorter on dialysis in the MELD era than in the pre-MELD era. This
may be due to our change in standard immunosuppression in the MELD era
from a CNI based therapy to an individualized CNI delay combined with
MMF for patients with preexisting renal insufficiency and/or perioperative
renal failure. A prospective, randomized trial will be started to confirm
these data.
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S. Farkas1, A. Doenecke1, A. Schnitzbauer1, M. Scherer1, M. Loss1,
G. Kirchner3, B. Banas2, A. Obed1, H-J. Schlitt1
1Dep. of Surgery, University Clinic of Regensburg, 2Dep of Nephrology,
University Clinic of Regensburg, 3Dep. of Internal Medicine 1, University
Clinic of Regensburg
Background: MELD score based liver allocation selects for patients with renal
dysfunction prior to liver transplantation (LTx). Furthermore transplantation
of extended criteria donor organs is associated with increased rates of renal
dysfunction. CNI therapy induces chronic renal dysfunction and other
complications. Long-term outcomes, including patient quality of life and survival
are thereby compromised. Reduced-CNI regimens are intensely investigated to
reduce nephrotoxic effects, while simultaneously preventing early graft loss.
Mycophenolate mofetil (MMF)-based CNI minimisation allows prevention of
negative side effects of CNIs. The ReSpECT trial showed a benefit of reducing
CNI in kidney transplantion without compromising graft survival.
We investigated the impact of the MELD allocation system on perioperative
kidney function of LTx recipients. Moreover, due to the MELD allocation, we
changed our standard immunosuppressive regimen from previously starting
CNIs at day 1 to an individualized CNI delay replaced by MMF in patients
with increased risk of kidney failure or actual need for renal replacement
therapy. CNI delay was continued until kidney function recovered, i.e. renal
replacement therapy was no longer necessary or occurrence of documented
rejection.
Material and methods: LTx patients from 2004-2006 (pre-MELD era)
were compared to recipients allocated during the MELD era (2007) at the
transplant center of the University of Regensburg/Germany. For analysis of
the two patient cohorts the MELD score was also calculated retrospectively
for patients in the pre-MELD era. We investigated the MELD score at the
time of transplantation, the pre- and postoperative need for renal replacement
therapy. Furthermore we investigated if the individualized CNI delay for
patients with acute renal failure had a beneficial effect on the duration of renal
replacement therapy.
Results:
pre-MELD era
136 patients
Median (Range)

MELD era
57 patients
Median (Range)

1243 CLINICAL EVOLUTION OF LIVER TRANSPLANT
PATIENTS IN MAINTENANCE PHASE DURING THE
FIRST 6 MONTHS AFTER CONVERSION FROM MOFETIL
MYCOPHENOLATE TO ENTERIC-COATED SODIUM
MYCOPHENOLATE DUE TO GASTROINTESTINAL
COMPLAINTS
M. Miras, J. Egea, C. Marín, A. García, A. Minguela, F. Carballo, P. Parrilla
Liver Transplant Unit, Hospital Univ. Virgen De La Arrixaca, CIBERehd
Background and objective: Enteric-coated sodium mycophenolate (EC-MPS)
in gastro-resistant tablets is a new formulation of mycophenolic acid which
delivers drug directly in the bowel. This may reduce gastrointestinal adverse
effects. In previous clinical trials, EC-MPS has demonstrated similar efficacy
and safety to mofetil mycophenolate (MMF) in de novo patients converted
from MMF.
Methods: Clinical data from liver transplant recipients receiving MMF for
more than one year who were converted to EC-MPS due to gastrointestinal
complaints was retrospectively collected. Data from 20 patients followed-up
during a maximum of 6 months after EC-MPS initiation is presented. Visits
were conducted at the moment of conversion (baseline), and after 1, 3 and
6 months.
Results: Mean age (±SD) was 53±10 years, 75% men. The main reason for
transplantation was alcoholic cirrhosis (70%), followed by hepatitis C (30%).
At baseline visit, all patients received treatment with cyclosporine, which was
reduced during follow up (baseline dose and levels of 179 mg/day and 90 ng/ml
versus 143 mg/day and 86 ng/ml at 3 months [p=0.017 for paired differences
in levels], and 85 ng/ml at 6 months). The EC-MPS administered dose was 720
mg/day in all cases. The prevalence of gastrointestinal complaints at baseline
visit was: diarrhoea, 60% (92% moderate-severe), abdominal discomfort, 60%
(58% moderate), abdominal pain, 45% (44% moderate-severe), flatulence,
40% (38% moderate-severe), nauseas, 20% (25% moderate), dyspepsia, 20%
(all mild). After 3 months of treatment with EC-MPS, only 2 patients (10%)
displayed moderate diarrhoea as gastrointestinal complaint. The evolution of
renal function was good, serum creatinine was significantly reduced and 24-h
creatinine clearance increased (creatinine: 1.78±1.6 mg/dl baseline vs 1.30±0.3
mg/dl at 3 months, p=0.002; creatinine clearance: 72.8±18 ml/min vs 79.6±13
ml/min, p=0.001). No significant differences were found between 3 and 6
months visits.
Conclusion: The conversion from mofetil mycophenolate to enteric-coated
sodium mycophenolate in liver transplant recipients with gastrointestinal
complaints reduces tolerability problems and improves renal function in the
first three months, with no changes at six months after conversion. A reduction
in anticalcineurin dose requirements is also observed.
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1244 SODIC MYCOPHENOLATE IN LIVER TRANSPLANT
PATIENTS WITH GASTROINTESTINAL COMPLICATIONS
G. González, B. Pulido, G. Bravo, A. Martinez, B. Bellido, S. Artacho,
S. Diez Canedo, D. Usero, S. Martinez, P. Lopez
HH. UU. Virgen del Rocío. Seville; Spain
Introduction: Mycophenolate mofetil (MMF) causes gastrointestinal (GI) side
effects in approximately 40% of patients, making necessary to modify the dose
or to discontinue treatment, increasing the risk of rejection.
Myfortic®, enteric-coated mycophenolic acid sodium salt is directly absorbed
in the small intestine. Its formulation provides an adequate exposure to the
active ingredient and reduces the undesirable GI effects.
Objective:
• To reduce the GI side effects of MMF by using Myfortic® in liver transplant
patients.
• To obtain a safe and effective immunosuppressive regimen using Myfortic® in
monotherapy or in combination with calcineurin inhibitors (CNI) or mTOR
Material and methods: 17 patients with intolerance to MMF or who had
discontinued its use due to undesirable effects were included.
Data on MMF intolerance were collected and its evolution in time after
Myfortic® introduction was studied.
Different variables were recorded: CNI dose and levels, MMF/Myfortic®
doses and levels, lipid profile, markers of liver function, white blood cells and
uric acid.
These variables were recorded at: visit prior to conversion, starting day, and
months: 1, 3 and 6. Rejection episodes were collected.
Results: 17 patients analyzed: 14 males (mean age 53.5 years), 3 females (mean
age 57.7 years).
16 patients required conversion to Myfortic® due to GI complications:
diarrhea (76.5%), anorexia and vomiting (5.9%), nervousness related
to taking MMF (5.9%), anorexia and diarrhea (11.8%). 17.6% received
MMF monotherapy (due to renal dysfunction), and 5.9% received MMF
plus Sirolimus, 58.8% plus tacrolimus, and 17.6% received MMF plus
cyclosporine.
Daily doses of CNIs prior to conversion: Tacrolimus 3.1±2.6 mg (levels
7.2±3.05 ng/mL), Cyclosporin 75.0±25.0 mg (levels 26.0±5.1 ng/mL).
The MMF doses administered to patients are shown in Table 1.
MMF DOSES
Valid

Frequency

Valid percent

No MMF

4

23.5

500mg/12h

7

41.2

500mg/8h

3

17.6

250mg/8h

1

5.9

750mg/8h

1

5.9

500mg/24h

1

5.9

Total

17

100.0

Table 1. MMF doses before switching to treatment with Myfortic®
• One month after conversion: 63.6% of patients presented no GI complication;
at 6 months, 66.7%.
• At month 1, 18.2% presented sporadic diarrhea; at 6 months, 11.1%.
• Patients continued with diarrhea at month 1, 18.2%; at 6 months, 11.1%
At 6 months, 11.1% presented epigastralgia and pyrosis as the only
complication.
No significant changes were observed in the remaining studied variables.
No patient experienced rejection episodes.
Myfortic® treatment was discontinued in two patients due to dyspnea and due
to nervousness related to the fact of taking the drug.
Conclusions: The use of Myfortic® in liver transplant patients with GI
complications resulting from the chronic use of immunosuppressive agents
(CNI and MMF) is effective as it significantly reduces the incidence of such
complications.
Myfortic® therapy is safe as no rejection episode or liver function impairment
have been reported during the study period.
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1245 OUTCOMES OF 4-HOUR INTRAVENOUS
CYCLOSPORINE A IN LIVING DONOR LIVER
TRANSPLANTATION
T. Hibi, M. Tanabe, K. Hoshino, Y. Fuchimoto, S. Kawachi, H. Obara,
M. Shinoda, N. Shimojima, Y. Morikawa, Y. Kitagawa
Department of Surgery, Keio University School of Medicine
Background and aims: Several randomized trials have revealed the
advantages of tacrolimus over cyclosporine A microemulsion (CsAME) in cadaveric liver transplantation; however, the dose of CsA-ME is
determined by its trough level in most of the series. Recently, CsA-ME
administration by C2 monitoring has been described to show equivalent
immunosuppressive efficacy with acceptable morbidity and the selection
of calcineurin inhibitor remains controversial. Meanwhile in living donor
liver transplantation (LDLT), small graft size, intestinal congestion due
to extensive operative time, and external biliary diversion all affect the
bioavailability of CsA-ME and the data from Western countries cannot
be simply extrapolated. This study was aimed to evaluate the outcomes
of 4-hour intravenous cyclosporine A (CsA-IV) protocol in the early
postoperative period of LDLT.
Material and methods: From 1997 through 2007, 53 adult patients
underwent LDLT. They were divided into 3 groups, CsA-IV (n = 9),
tacrolimus (Tac, n = 20), and CsA-ME (n = 24), according to the
immunosuppression protocol. The medical records were retrospectively
reviewed to compare the dosage, rejection rate, adverse events, and
prognosis among the groups.
Results: Male: female = 31: 22; median age [range], 48 [21-64] years; inhospital mortality rate, 15%; median postoperative hospital stay [range],
68 [31-256] days; median follow-up [range], 35[5-114] months; overall
5-year survival rate, 76%. No significant difference in patient background,
operative procedures, and long-term prognoses was observed among the
3 groups. In the CsA-ME group, patients with biliary output > 200 ml/
day had a significantly low chance of reaching the target peak level. The
area under the curve (AUC) at 3 days posttransplant revealed a remarkable
difference between the CsA-ME and the CsA-IV group. Compared to the
random distribution of the C2 levels of the CsA-ME group, the C4 levels of
the CsA-IV group was nearly identical and the AUCs of each patient could be
superimposed. Acute cellular rejection was significantly higher in the Tac and
the CsA-ME groups (15% and 17%, respectively) compared with the CsA-IV
group (0%, P < 0.05). Patients in the Tac group showed higher incidence of
renal toxicity compared with the other 2 groups, although the difference did
not reach statistical significance. Infection rate was comparable among the 3
groups. The difference between the initial and the maintenance dose around
7POD was the largest in the Tac group (40%) compared with the CsA-IV and
the CsA-ME groups (5% and 10%, respectively). The Tac and the CsA-ME
groups also required more frequent dose changes to achieve the target trough
level compared to the CsA-IV group.
Conclusions: The pharmacokinetics of CsA-ME is complicated by the
external biliary diversion and its immunosuppressive effect is unpredictable
in LDLT compared to the deceased donor. CsA-IV does not require enteral
absorption and demonstrates minor individual dose variance; thus permits
easier control in the early postoperative period. The immunosuppressive
efficacy of CsA-IV appears to be equivalent to Tac with less nephrotoxicity.
Short-term outcomes of CsA-IV were promising and it may become a rational
alternative in LDLT.
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1246 SAFETY AND EFFICACY OF ENTERIC COATED
MYCOPHENOLATE SODIUM (EC-MPS) IN COMBINATION
WITH BASILIXIMAB (BSX) INDUCTION, TACROLIMUS (TAC)
WITH OR WITHOUT CORTICOSTEROIDS (CS) IN ADULT
LIVER TRANSPLANTATION (OLT)
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1247 COMPLETE CORTICOSTEROID (CS)-AVOIDANCE
IMMUNOSUPPRESSION (IS) REGIMEN WITH BASILIXIMAB
(BSX) INDUCTION AND TACROLIMUS (TAC) IN ADULT LIVER
TRANSPLANTATION (OLT)
C. Doria1, C.B. Ramirez1, A. Frank1, V. Navarro2, S. Herrine2, S. Rossi2,
M. Chaballa3, S. Vaccino1, Y. Kang4, I.R. Marino1
Departments of 1Surgery, 2Medicine, 3Pharmacology, and 4Anesthesiology,
Thomas Jefferson University Hospital, Philadelphia, PA U.S.A.
Background: Corticosteroids have remained a standard part of post-transplant
IS; however, they have been shown to cause long-term adverse effects, such as
susceptibility to infection, obesity, hypertension, hyperlipidemia, diabetes, etc.
They have also been implicated in accelerating Hepatitis C virus re-infection
post-OLT. The primary aim of this study is to assess the efficacy and safety of
a completely CS-free IS regimen in adult OLT by comparing graft and patient
survival rates, rejection rates and treatment for rejection between recipients
treated with and without CS. The secondary objectives are to compare the
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1248 REPLACEMENT OF CALCINEURIN INHIBITORS WITH
MMF IN PATIENTS AFTER LIVER TRANSPLANTATION: A
PROSPECTIVE RANDOMIZED TRIAL
U.P. Neumann, M. Schmeding, A. Kiessling, R. Neuhaus, P. Neuhaus
Charité, Virchow Clinic
Side effects related to long-term immunosuppressive therapy with calcineurin
inhibitors (CNI) are a major cause for morbidity and mortality in patients after
liver transplantation (OLT). Several studies have proven the beneficial effect
of CNI sparing in combination with introduction of mycophenolate mofetil.
The aim of this study was to prove the feasibility of CNI withdrawal and
replacement with MMF.
Overall 146 patients a minimum of 6 months after OLT were included
in this prospective randomized trial. Patients received their maintenance
CNI treatment (n=71, controls) or stepwise replacement of CNI with MMF
(MMF group, n=75) within 3 months. Renal function, blood pressure, and
cardiovascular combinations were monitored prior to study entry and every 3
months thereafter. Follow up was 24 months in all patients. Liver biopsies were
performed routinely.
A complete cessation of CNI in the MMF group was possible in 50/75
patients. Incidence of histological proven rejection was 10.7% in the MMF
group compared to 1.4% in controls. None of the patients developed a steroid
resistant rejection. None of the patients showed signs of chronic rejection or
ductopenia. All rejections occurred after complete cessation of CNI treatment.
Renal function significantly improved in the MMF group (p<0.01). In contrast
creatinine levels increased in the control group. This effect was pronounced
in patients with impaired renal function (creatinine levels > 1.3mg/dl) at
study entry (p<0.05). 8 patients of the control group showed a fast significant
deterioration of renal function during the study and were switched to MMF
monotherapy to avoid chronic dialysis. We could not identify changes in blood
pressure and cardiovascular complications between groups.
Replacement of CNI with MMF after OLT is safe and feasible. However, in
1/3 of the patients a complete cessation of CNI was not possible. None of the
patients developed a severe complication. The replacement of CNI with MMF
significantly improved renal function.
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C. Doria1, C.B. Ramirez1, A. Frank1, V. Navarro2, S. Herrine2, S. Rossi2,
M. Chaballa3, S. Vaccino1, Y. Kang4, I.R. Marino
CB Ramirez1, C Doria 1, A Frank 1, V Navarro 2, S Herrine 2, S Rossi 2, M
Chaballa 3, S Vaccino1, Y Kang 4, IR Marino
Departments of 1Surgery, 2Medicine, 3Pharmacology, and 4Anesthesiology,
Thomas Jefferson University Hospital, Philadelphia, PA U.S.A.
Methods: From February 2006 to December 2007, 40 adult OLT recipients were
included in our prospective, randomized trial (CS=20 vs no-CS=20). All patients
received BSX induction (20mg intra-operatively and day 4), Tac (0.1mg/kg/
day), and EC-MPS (720mg BID). Patients randomized to CS cohort received
methylprednisolone 1gm IV intra-operatively followed by prednisone taper to
20mg PO QD and weaned off at 6 months. Quality of life (QoL) was assessed preOLT (baseline), 3 and 6 months post-OLT using the Gastrointestinal Quality of Life
Index (GIQLI), a 36-item questionnaire evaluating the impact of GI symptoms,
emotional status, physical and social function, and stress of medical treatment.
Score range: 0-144 (higher score=better QoL). Gastrointestinal (GI) intolerance
was assessed at the discretion of the physician to be related to EC-MPS therapy.
Results: Mean age of patients was 53±9.4 years, with 1:4 female/male ratio
and 33/40 (83%) white. EC-MPS was initiated at a mean time of 5 days postOLT (mean duration = 12±4.2weeks; mean daily dose at 1, 2 and 3 months =
1224±322mg, 1247±371mg, and 1158±413mg). Mean Tac trough levels were
10±4.8ng/ml, 8.5±3ng/ml, 8.5±4.4ng/ml at 1, 3 and 6 months, respectively.
Six patients were switched to cyclosporine micro-emulsion (CsA-ME) due
to neurotoxicity. No significant difference in 1 year graft (84.4%) and patient
(90%) survival was observed across groups; 1 biopsy-proven CS-responsive
rejection occurred in each group. EC-MPS dose was maintained at 720mg BID
in 16/40 (40%) patients; however, it was reduced in 18/40 (45%) patients: 9
patients for GI intolerability, 8 patients for leukopenia, 1 patient for both GI
intolerability and leukopenia. Mean duration of GI intolerability and leukopenia
was 2.7 weeks and 3.1 weeks, respectively. GI intolerance for 6/9 patients
resolved upon dose reduction; leukopenia resolved in 5/8 patients. EC-MPS
treatment was either discontinued (2/40=5% patients) or withheld (4/40=10%
patients) due to infection or change in IS. Upon improvement of adverse events
6/22 patients had EC-MPS dose increased to baseline. No CMV or difference
in bacterial infection rate was observed. Clinical improvement in GIQLI was
observed across groups from baseline (mean score = 79.8) to 6 months (mean
score=107.1), p<0.0001. All subscales were statistically significant from
baseline to 3 and 6 months except for stress of medical treatment from baseline
to 3 months (p= 0.06).
Conclusion: EC-MPS, BSX, Tac /CsA-ME in a CS or no-CS IS regimen is
effective and safe with improvement in QoL in adult OLT. Long term follow-up
and a greater number of subjects are necessary to further validate this conclusion.

incidence of steroid-related complications, and Hepatitis C recurrence between
recipients treated with and without CS.
Methods: A 2-year, prospective, randomized trial of CS or no-CS IS regimen
with BSX at 20mg IV intra-operatively and POD 4, Tac at 0.1mg/kg/day and
EC-MPS at 720mg BID was performed on 40 patients (CS=20; No-CS=20).
The CS cohort received methylprednisolone at 1gm IV intra-operatively
followed by prednisone taper to 20mg PO QD and weaned off within 6 months.
Hepatitis C virus (HCV) patients had HCV PCR pre-OLT, .5, 1, 3, 6 months
post-OLT. Protocol liver biopsies were performed at baseline, 2 weeks and 6
months post-OLT and/or when clinically indicated.
Results: One patient in no-CS cohort was excluded from the analysis due to
graft failure secondary to hepatic artery thrombosis leading to re-transplantation
within 2 weeks of primary OLT. Patient characteristics were matched between
groups for age, sex, ethnicity, MELD score, Cold and Warm Ischemia Time,
and diagnosis. HCV was the primary etiology for OLT (CS:12; no-CS:14).
Mean duration on CS was 186 days (median 151 days). Tac target trough levels
were 8-10ng/ml. Six patients were switched to cyclosporine micro-emulsion
(CsA-ME) due to neurotoxicity. Mean follow up time was 12.3 ± 5.9 months
(range 3-23.4 months). No significant difference was observed between groups
for incidence of Acute Cellular Rejection (CS:1; No-CS:1), histologic HCV
recurrence (CS:5; no-CS:8), bacterial infection (CS:10; no-CS:10), CMV
and malignancy (none). Kaplan-Meier 12-month patient (CS: 88.89%; noCS: 91.67%) and graft (CS:88.89%; no-CS: 80.21%) survival rates were not
statistically significant (p=0.9, p=0.5, respectively). There were 2 deaths with
functioning grafts due to Adult Respiratory Distress Syndrome (no-CS:1) and
intracerebral bleeding (CS:1). Graft loss from HCV recurrence (time from OLT
12.7 months) was observed in the no-CS group. No significant difference was
observed for new onset DM, hypertension, hypercholesterolemia, and weight
gain during follow-up.
Conclusion: Complete CS-avoidance IS regimen with BSX, Tac/CsA-ME and
EC-MPS is safe and effective in adult OLT recipients. Longer follow-up and an
increased number of subjects may be needed to fully assess this conclusion.
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1249 POSTOPERATIVE IMMUNOSUPPRESSANT-FREE
FOR VERY SICH PATIENTS UNDERGOING LIVER
TRANSPLANTATION
C-F. Lee, T-J. Wu, H-S. Chou, K-M. Chan, W-C. Lee
Chang-Gung Transplantation Institute, Chang-Gung Medical Center,
Chang-Gung University
Introduction: Very sick liver cirrhotic patients are immuno-compromized.
Organ transplantation for very sick patients has a high mortality because
postoperative immunosuppressive agents may further compromised immunity
and result in profound sepsis. In this study, post-transplant immunosuppressive
agents are suspended for very sick patients to improve the outcome of liver
transplantation.
Materials and methods: Five very sick patients, 2 males and 3 females,
who underwent liver transplantation were included in this study. Two
patients had hepatitis C-, one patient had hepatitis B-, and two patients
had hepatitis B+C-related liver failure. Among these patients, two patients
had whole liver, one had size-reduced liver, one had split liver, and one
had living donor liver transplantation. The administration of postoperative
immunosuppressive agents was according to the number of CD4+ and CD8+
lymphocytes.
Results: The mean age of the patients was 54.4+5.7 years. The MELD score
was 33.6+10.7. Before liver transplantation, 3 patients had bacterial infection
under antibiotic control. The percentage of CD4+ and CD8+ lymphocytes were
13.2+6.7% and 5.7+2.3%, respectively. According to low number of CD4+
and CD8+ lymphocytes, postoperative immunosuppressive agents were not
administrated for 44.2+27.1 days. Postoperatively, 2 patients had CMV and
bacterial infection, and 3 patients had CMV, bacterial and fungal infection.
Immunosuppressive agents were administrated until AST and ALT were
elevated slightly and CD8+ lymphocytes were more than 10%. Among these
patients, 4 patients were survived and one patient who had a marginal donor
liver died of sepsis.
Conclusion: Postoperative immunosuppressive agents can be fully suspended
to prevent uncontrolled infection for very sick patients undergoing a liver
transplantation. The number of CD4+ and CD8+ lymphocytes can be used as a
guide for immunosuppressant administration.
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1250 BASILIXMAB INDUCTION WITH DELAYED
TACROLIMUS IN ADULT LIVER TRANSPLANTATION
– IS THERE A RENAL PROTECTIVE EFFECT?
S. Iyer, A. Yu, S. Chang, V. Lee, K. Madhavan
National University Hospital
Introduction: Basiliximab, a chimeric monoclonal antibody directed against
the alpha-chain of the interleukin 2 receptor (CD25), has been evaluated as an
induction therapy for liver transplant recipients, with the aims of decreasing
acute rejections, rapid steroid withdrawal and delaying calcineurin inhibitors.
In this study, we assessed the efficacy of basiliximab in combination
with a delayed tacrolimus-based regimen for renal protection after liver
transplantation.
Methods: We instituted use of Basiliximab induction and delayed tacrolimus
in immunosupression protocol from Jan 2000.The study group (group I)
consisted of 20 recipients who received induction IV Basiliximab 20mg (Day
0, 4) with steroids and introduction of tacrolimus on day 8. The control group
(group II) included 20 patients with early tacrolimus and steroids prior to
Jan 2000. The patient profiles, perioperative data were compared. Creatinine
clearance was compared pretransplant and post transplant at several time
intervals (1, 2, 3, 4 weeks, 3 months, 6 months and 1 year). The tacrolimus
dose and the serum levels were compared at 2, 6 weeks, 6 months and 1 year
post transplant.
Results: The mean age, gender, Childs-Pugh status, indication for transplant
was similar in both groups. There were no differences in the operative time,
cold and warm ischemia time, blood transfusion in both groups (p>0.05). Pre
preoperative creatinine clearance was 81.9 and 88.3 ml/minute respectively
(p=0.5). There were no significant differences in creatinine clearance in the 2
groups at all time points post transplantation. There was no difference in acute
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cellular rejection rates, post transplantation diabetes mellitus, hypertension and
renal insufficiency at the end of one year follow up. Moreover there was no
difference in the tacrolimus levels and tacrolimus dosage in the two groups up
to one year of follow up.
Conclusion: Basiliximab induction has no added advantage to prevent early
renal dysfunction by delaying the introduction of tacrolimus. It doesn’t reduce
the dose requirement of tacrolimus without increasing graft rejection and
infection. This study questions the role of routine basiliximab induction in
orthotopic liver transplantation in adults.
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1251 DE NOVO USE OF MTOR INHIBITOR EVEROLIMUS
IN COMBINATION WITH MYCOPHANOLATE SODIUM
IN PATIENTS UNDERGONE ORTHOTOPIC LIVER
TRANSPLANTATION
E. Antoniou1, D. Dimitroulis1, D. Mantas1, M. Flessas1, K. Labathariou2,
N. Nikitakis1, P. Paraskeva1, D. Karoussos, K. Tsinari, A. Kostatkis
1
Laikon University Hospital -2nd Surgical Department, 2Laikon University
Hospital - Anaesthetic Department
Introduction: We present the results from our new liver transplant centre using
the combination treatment of everolimus (mammalian target of rapamycin
-mTOR- inhibitor) (Certican) and mycophanolate sodium (MPS - Myfortic), as
de novo anti-rejection treatment after orthotopic liver transplantation (OLTx).
Methods: Eight out of thirteen patients who had an OLTx in our centre,
between July’06 – January ’08, received the above treatment. Six of them had
hepatocellular carcinoma (HCC), one had acute hepatic failure due to epitheliod
haemangioendothelioma (EHE), and one had PBC and a single kidney with
borderline renal function. All patient received de novo anti-rejection therapy
with everolimus (1.5mg bid), MPS (720mg bid) and prednisolone (10mg bid),
except the one with single kidney and PBC cirrhosis, who received half dose of
Myfortic due to low white cell count.
Results: All patients had an improving liver function, coming almost to
normal by the end of the first week, after starting the above treatment. Five out
of eight patients had liver cirrhosis due to viral hepatitis and hepatocellular
carcinoma (HCC). One had PBC cirrhosis and HCC. The patient with EHE
died on the 14th postoperative day (POD) already being in the ward, due
to cardiac arrest. Another one who had HCV cirrhosis, HCC (8cm) and
portal vein thrombosis, although recovered well after her OLTx, developed
massive brain haemorrhage on the 8th post-operative day (POD) and died.
The one with PBC and single kidney, had also everolimus dose reduced to
half after the first week, due to very high everolimus level (22ng/ml). This
patient had two episodes of acute rejection, first treated effectively with
high dose of steroids, second, was a steroid resistant rejection clinically,
although liver biopsy did not supported the clinical findings of rejection.
This patient converted to Tacrolimus, keeping Everolimus and steroids,
3 months after OLTx, with very good response. Five out eight continue
the above combination therapy and two of them have already been treated
for more than one and a half year. The remaining three have been treated
for 2-5 months postransplant. Three out of seven had a moderate acute
rejection and treated effectively with high dose of steroids for three days.
None presented any side effect due to this treatment, and no hepatic artery
thrombosis or wound healing problems noticed. Survival range is between 2
-17 months. Everolimus blood level (Cmin) in all patients has been between
4.5 to 7.1ng/ml.
Conclusion: Everolimus has been mainly used in renal transplantation and only
in few centres in OLTx, as late conversion from CyA or FK. To our knowledge,
it is the first time of de novo use of everolimus and MPS combination, in OLTx
patients with long term survival. Although the number of patients is small, the
results show that the above immunosuppression combination can safely be used
in OLTx patients, especially in those with malignancy and/or renal impairment.
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1253 EFFICACY OF THERAPY OF RECURRENT HEPATITIS
C VIRUS INFECTION AFTER LIVING DONOR LIVER
TRANSPLANTATION IN EGYPT
A. Salah1, M. El-Mansy2, S. Zakaria1
Cairo University, 26th October University
In Egypt, hepatitis C viral (HCV) infection genotype 4a is a major health
concern with a reported prevalence as high as 24.3%. It has been closely
associated with schistosomiasis. HCV recurs in nearly all patients after liver
transplantation (LT) and is associated with progressive fibrosis and graft loss.
Treatment of recurrent HCV in liver transplant is controversial.
Objective: To evaluate the efficacy of pegylated interferon alpha 2b (PEG-IFN)
and ribavirin therapy of recurrent HCV after living donor liver transplantation
(LDLT) in Egypt.
Methods: We retrospectively investigated the clinical progress and
management of recurrent HCV in 32 patients who underwent living donor
liver transplantation in Egypt from August 2003 to August 2007. Twenty six
patients were males. The median age was 47 +/-7 (39-65) years. All patients
had 1) a positive test for HCV- RNA in serum; 2) alanine aminotransferase
(ALT) >45 UI/mL; and 3) a liver biopsy showing chronic hepatitis without
rejection in the previous 2 months. Patients received PEG-IFN (1.5 microg/
kg/week) and ribavirin (800-1,000 mg/day) for 12 months. Follow-up was
based on biochemical (ALT), virological (RNA-HCV), and histological (liver
biopsy) examinations. Follow-up lasted a minimum of 6 months after the end
of antiviral therapy. Sustained virological response (SVR) was achieved in 7

1
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1254 DEPRESSIVE SYMPTOMS, HOST IMMUNITY, AND
SURVIVAL IN HEPATITIS B AND/OR C PATIENTS EVALUATED
FOR ORTHOTOPIC LIVER TRANSPLANTATION
J. Steel1, T. Clark Gamblin, M. DeVera, P. Fontes, J.W. Marsh,
K. Chopra
1University of Pittsburgh School of Medicine, 2University of Pittsburgh
School of Medicine, 3University of Pittsburgh School of Medicine,
4University of Pittsburgh School of Medicine, 5University of Pittsburgh
School of Medicine, 6University of Pittsburgh School of Medicine
Objective: Increasing evidence is accumulating regarding the association
between depressive symptoms and increased morbidity and mortality in the
general population as well as across several chronic diseases. The aims of
the present study were to: (1) assess the prevalence of depressive symptoms
in patients diagnosed with hepatitis B and C awaiting orthotropic liver
transplantation; (2) test the association between depressive symptoms and host
immunity; and (3) begin to explore possible associations between depressive
symptoms, graft injury, and survival
Methods: A prospective study of 23 patients with hepatitis B and/or
C-related chronic liver disease who were being evaluated for orthotopic
liver transplantation were recruited between April to September 2003.
Patients were administered the Center for Epidemiological StudiesDepression (CES-D) scale. Immune system markers including IL-4, IL-5,
TNF-ƒÑ, IFN-ƒ×, and Natural Killer (NK) cell number and activity were
collected at baseline. Sociodemographic and disease-specific data was
gathered from the patients¡¦ chart. Survival was measured from date of
diagnosis to death.
Results: At the time of evaluation, 40% of patients reported depressive
symptoms in the clinical range of the CES-D. Of the 23 patients, 44% had
received a transplant at 5-year follow-up. The patients who did not receive a
transplant reported a higher level of depressive symptoms (CES-D score=18)
when compared to those patients who were transplanted (CES-D mean
score=15). At 5-year follow-up, only 54% of those who reported depressive
symptoms in the clinical range of the CES-D were still living whereas only
72% of patients who reported depressive below the clinical cut-off of the
CES-D were still alive. Although not statistically significant, patients with
depressive symptoms in the clinical range, had lower levels of NK number [75
versus 107] and activity [11.7 versus 15.9], lower levels of IL-4 (0.02 vs. 0.04)
and higher counts of CD4 (37 s 34), CD8 (22 vs. 18), and TNF-ƒÑ (7.5 vs.
2.5) when compared to patents who reported depressive symptoms below the
clinical range of the CES-D. A trend toward significance (p=0.13) was found
in patients who reported depressive symptoms in the clinical range in regard
to portal vein inflammation at the second biopsy subsequent to transplant (0.75
vs. 0.17).
Conclusion: Preliminary data suggests a high prevalence of depressive
symptoms in patients diagnosed with hepatitis B and C awaiting liver
transplantation. Although not statistically significant, a potentially clinically
significant difference may exist in regard to survival and host immunity.
It is unclear if depressive symptoms and host immunity may play a role in
the inflammation process. Further research concerning the prevalence and
association between depressive symptoms, immunity, and survival is warranted.
Psychological evaluation and treatment should be included in standard of care
for patients awaiting liver transplantation.
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B. Nashan1, M. Sterneck1, D. Benten2, L. Renders3, A. Lohse2, L. Fischer1
1
University Hospital Hamburg Transplantcenter, 2University Hospital
Hamburg Department of Medicine, 3University Hospital Schleswig Holstein,
Department of Nephrology
Background: Treatment of HCV reinfection after orthotopic liver
transplantation (OLT) with interferon (IFN) and ribavirin (RIB) is poorly
tolerated and sustained biochemical and virological response (SVR) rates are
low. Therefore, prognostic factors have to be defined and treatment modalities
need to be optimized.
Patients and methods: We retrospectively analyzed 31 OLT recipients with
HCV reinfection treated with Peg-IFN alpha-2b (1-1.5 mg/kg BW) and RIB
(start dose: 800-1000 mg/day) for 48 weeks. In 15 of these patients, RIB
dosage was adjusted according to blood level monitoring (HPLC; target level
8-12 μmol/l). In the remaining 16 patients, RIB dose was adjusted according
to the degree of anemia.
Results: SVR was achieved in 7/31 patients (23%), with significantly higher
SVR in patients with genotype 2 or 3 (4/8; 50%) compared to patients with
genotype 1 or 4 (2/23; 9%); p=0.029. Early virological response (EVR defined
as negative HCV-PCR or 2-log decrease, 12 weeks after initiation of therapy)
was highly predictive for SVR. No patients without EVR achieved SVR despite
continued treatment until week 48 (100% negative predictive value). Only 5/13
patients with EVR did not achieve end-of-treatment response or had relapse
after completion of antiviral therapy (EVR with 62% positive predictive
value for SVR). In 15 patients with RIB drug monitoring, 155 serum levels
were determined which resulted in adjustment of RIB dosage in 13 patients.
However, RIB drug level monitoring did not result in improved SVR rates or
reduction of side effects; in particular, the need for erythropoietin was similar
in both groups.
Conclusion: Like in non-transplant patients, infection with HCV genotype
2/3 and EVR are predictive factors for SVR in OLT recipients with HCV
reinfection. RIB drug level monitoring did not improve SVR nor reduce side
effects of treatment.

(22%) patients. A total of 20 (63%) patients had normalized ALT levels at the
end of therapy. Inflammatory portal and lobular score declined significantly
in patients with SVR (P < 0.05) but not in non-responder patients. Fibrosis
did not change significantly in either group. SVR was significantly associated
with low gamma-glutamyltransferase GGT (P = 0.04) and HCV-RNA levels
(P = 0.03), a virological response at 12 weeks (P = 0.002) and patient’s
compliance (P = 0.04). Six (19%) patients were withdrawn prematurely due
to adverse effects.
Conclusion: Therapy with PEG-IFN and ribavirin achieved SVR and a
significant histological improvement in 22% of living donor liver transplant
recipients with recurrent HCV. Management of post-recurrent cirrhotic change
is crucial for graft and patient survival. We think customized protocols are
needed for every situation of recurrent hepatitis C.
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1255 HEPATITIS B IMMUNOGLOBULIN AND LAMIVUDINE
FOR HEPATITIS B PROPHYLAXIS AFTER LIVER
TRANSPLANTATION
S. Sevmis1, N. Savas2, U. Yilmaz2, F. Ozcay3, H. Karakayali1,
M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery,
2Baskent University Faculty of Medicine, Department of Gastroenterology,
3Baskent University Faculty of Medicine, Department of Pediatry
Recurrence of the hepatitis B virus (HBV) after liver transplantation (LT) is a
major risk factor affecting graft and patient survival. Short-term (ie, 1-2 years)
HBV reactivation rates following LT range between 3% and 15%. Using
combination prophylaxis, outcomes of LT for HBV-related liver disease have
been improved to levels comparable with non-HBV recipients. This study
presents the results (ie, longer than 1 year) of combination prophylaxis with
hepatitis B immunoglobulin (HBIG) and lamivudine. Between September
2001 and January 2008, 55 patients with HBV underwent LT at our hospital,
34 of these patients were followed for more than 12 months. Their outcomes
were analyzed retrospectively. Our combination protocol includes lamivudine
(100 mg PO/day beginning the day after surgery) and HBIG (10 000 IU
IV during the anhepatic phase, 2000 IU/day IV during the first week after
surgery, 2000 IU IV/month from the first to the 12th postoperative month).
Using our dosage of HBIG, the anti-Hbs Ab serum titer was maintained
at approximately 100-150 IU/mL. The female: male ratio was 7:27. Two
patients were children. The mean age of patients was 43±13.1 years (range,
4 to 65 years). Eleven patients received grafts from cadaveric donors, and
23 received grafts from living donors. The mean MELD score was 18.7
&#61617; 5.5. Four patients had HDV coinfection, and 12 recipients had
concomitant hepatocellular carcinoma. All patients were given steroids and
low-dose tacrolimus for immunosuppression. Steroid treatment was stopped
at the end of the third month. Four patients died of causes unrelated to HBV
13, 15, 23, and 30 months after LT. At the time of death, their HBsAg was
negative, and serum titers of anti-Hbs Ab were 35.3, 56.4, 79.6, and 123
IU/mL. The mean follow-up was 26.8 &#61617; 8.1 months (range, 12-47
months). HBsAg became positive 16 months after LT in one patient; the
remaining 29 patients had negative evidence of HBsAg. In 9 patients, the
serum titer of anti-Hbs Ab was 0; in the remaining 20 patients, it was 69.2
&#61617; 133 IU/mL (range, 8-468 IU/mL). In conclusion, our combination
protocol with HBIG and lamivudine is a safe and effective treatment modality
for HBV prophylaxis after LT. Initial long-term follow-up of this protocol
shows satisfactory outcomes.
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1256 LOW-DOSE HEPATITIS B IMMUNE GLOBULIN
COMBINED WITH LAMIVUDINE IS SUCCESSFUL FOR
PROPHYLAXIS AGAINST HEPATITIS B RECURRENCE AFTER
ORTHOTOPIC LIVER TRANSPLANTATION
M.N. Toosi1, A. Jafarian2, M. Moini2, A. Najafi3, Z. Ahmadinegad4,
M. Salimi2, F. A. Ardalan5, A. Rabani2, A. Mohagheghi2, S. Irajian2
Departments of 1Internal Medicine, 2Sugery, 3Anestesiology, 4Infectious
disease, and 5Pathology, Liver Transplantation Group, Tehran University of
Medical Sciences, Tehran, Iran
Background: Chronic hepatitis B virus (HBV) infection is leading cause
of end-stage liver disease in Asia. Orthotopic liver transplantation (OLT)
for patients infected with HBV had been identified as having important
limitations because of reinfection of allograft by HBV. Introduction of
high-dose hepatitis B immune globulin (HBIG) and nucleoside analogues
helped in development of strategies to prevent graft reinfection. To get a
better regimen for HBV prophylaxis after OLT, combination of HBIG
with lamivudine was introduced. No consensus exists concerning dosage
and duration of prophylactic HBIG for prevention of HBV recurrence after
OLT.
Method: We report the follow-up of combination prophylaxis with lowdose HBIG and lamivudine in four cases of HBsAg positive liver transplant
recipient. Our prophylaxis therapy to prevent HBV recurrence was combination
of Lamivudine plus subcutaneous and Intramuscular HBIG10,000 IU/daily for
five days and 5,000 IU/daily for ten days without any dose of IV HBIG. HBIG
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administrations were continued by IM HBIG 2,500 IU/weekly for last of the
year. Our objectives were patient survival and tolerance, graft survival, HBV
recurrence, HBIG requirement and HbsAb titers.
Results: Two men and 2 women HBsAg positive post HBV necrotic cirrhotic
patients were undergone OLT. Pre-transplant HBV viral loads were negative
with amplicore PCR method threshold of 200 copies/ml, with negative HbeAg
and lamivudine therapy in all patients. One patient was positive for anti-HDV
antibody. All patient tolerated well the rout of injections with no major problem.
In 14th day after transplantation, HBsAb titer received to >2,000 mIU/ml in
all patients. Other results of follow up are in table. The patients were HBV
recurrence free during the follow up. Marked reduction in overall requirement
of HBIG was produced.
Conclusion: In post HBV cirrhotic patients with negative HBV DNA before
transplantation, low-dose subcutaneous/IM HBIG and lamivudine is safe,
low cost, and highly effective prophylactic regimen in prevention of HBV
recurrence after liver transplantation.
Gender/Age (yr)

F/37

M/30

F/46

M/46

Blood group

A+

A+

B+

O+

Duration of follow up

60 mo.

48 mo.

12 mo.

3mo.

HDV status

negative

negative

positive

negative

12 mo after OLT

412

180

1000

n/a

24 mo after OLT

122

negative

n/a

n/a

Negative HBsAg report

12 mo

12 mo

12 mo

short follow up

Time of HBIG discontinuation

24 mo

24 mo

HBIG

continue

Immunosupressive protocol

Neoral cellcept prednisolon

prograf cellcept prednisolon

Acute rejection (during 1st yr)

yes

yes

HBsAb titters (mIU/ml)

no

no
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1257 PREDICTIVE FACTORS OF OUTCOME IN PATIENTS
TRANSPLANTED FOR HEPATITIS B
S. Beckebaum1,2, Z. Yu1,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos1, A.
Radtke1, G. Gerken2, V.R. Cicinnati1,2
1
Department of General, Visceral and Transplantation Surgery, University
Hospital Essen, Essen, Germany, 2Department of Gastroenterology and
Hepatology, University Hospital Essen, Essen, Germany, 3Department of Surgery,
Beijing Tongren Hospital, Capital University of Medical Sciences, Beijing,
China, 4Institute of Immunology, University Hospital Essen, Essen, Germany
In this study, we aimed 1) to investigate the impact of variables on graft
and patient survival in hepatitis B virus (HBV)-infected liver transplant (LT)
recipients and 2) to identify factors associated with a higher risk of graft
cirrhosis at 5 years post-LT. A total of 104 chronically infected HBV patients
(76% male, mean age of 49 &#61617; 10,8 years) transplanted between
September 1992 and November 1997 were considered for this study. The
overall 5 year patient and graft survival was 79,8% and 72.1%, respectively.
All patients had cyclosporine A (CSA, n=58) or tacrolimus (TAC, n=46) based
immunosuppressive regimens. Univariate and multivariate Cox’s proportional
hazards regression analysis indicated that recipient age and recipient BMI
at LT and immunosuppression with CSA correlated with decreased patient
survival. Older recipient age and higher recipient body mass index (BMI)
at LT were associated with worse graft survival. In the log rank test,
significant risk factors for graft cirrhosis within 5 years were qualitative and
quantitative detection of HBV DNA and antiviral therapy at LT; significant
posttransplant factors included biliary stenoses due to anastomotic strictures
or ischemic type biliary lesions, hepatitis B recurrence, nucleos(t)id analogue
monoprophylaxis (without hepatitis B immunoglobulin) and short term (<1
year) mycophenolate mofetil therapy. In conclusion, our study has shown
that various recipient factors at LT as well as post-transplant virological
status, antiviral prophylaxis, biliary complications and immunosuppressive
regimen are related to the outcome of HBV recipients. Prospective studies are
warranted to define the “optimal” immunosuppression in patients transplanted
for hepatitis B.
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1258 EFFICACY OF LAMIVUDINE MONOTHERAPY
FOLLOWING ONE-YEAR COURSE OF HEPATITIS B
IMMUNOGLOBULIN IN PREVENTING HEPATITIS B
VIRUS RECURRENCE AFTER LIVING DONOR LIVER
TRANSPLANTATION
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1259 MINIMAL COSTS AND EFFICACY OF
IMMUNOPROPHYLAXIS IN HBV TRANSPLANTED PATIENTS
– EXPERIENCE IN THE ROMANIAN PROGRAM OF LIVER
TRANSPLANTATION
S. Iacob1, D. Hrehoret2, B. Dorobantu2, E. Gangone2, R. Iacob1, L. Gheorghe1,
I. Popescu2
1
Fundeni Clinical Institute, Gastroenterology And Hepatology Center,
2
Fundeni Clinical Institute, General Surgery and Liver Transplantation Center
Background: HBV in transplant patients has been associated with good
outcomes and the challenges are primarily focused around optimizing
prophylactic regimens with hepatitis B immune globulin (HBIg) and
minimizing related costs. HBIg is an expensive therapy, and there are wide
practice variations at different institutions.
Aim: To evaluate the efficacy and costs of the prophylactic regimen consisting
of lamivudine (100 or 200mg/day) and HBIg administered in order to keep the
anti-HBs between 50-100 IU/L.
Methods: We included in the study 42 patients (69% with hepatic cirrhosis
secondary to HBV+HDV coinfection and 31% with HBV infection alone)
that underwent OLT between 2000 and 2007. Chi-squared and T-Student test
were used to compare the qualitative and quantitative variables. Survival was
estimated using the Kaplan Meier method.
Results: There were 27 men and 15 females with a mean age at OLT of 47.2±8
years. HBV DNA was negative (<200 copies/mL) before OLT in 97.4% and
HBeAg was negative in 92.1% of patients. HBV recurrence rate (positivity of
HBsAg after initial negativity) was 4.8% after a mean of 1.2±0.85 years. The
3 year survival rate was 75.8%. No death was due to HBV recurrence and no
patient required relisting or retransplantation for recurrent HBV infection. The
total mean cost for HBIg and lamivudine was 10977.13 EUR and the mean
cost for patient per month of survival was 826.08 EUR. Patients with HBV
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1260 REAL-TIME ELASTOGRAPHY AND HISTOLOGICAL
EVALUATION IN PATIENTS WITH RECURRENT HEPATITIS C
FOLLOWING LIVER TRANSPLANTATION
S. Iacob1, L. Gheorghe1, R. Iacob1, G. Becheanu1, V. Herlea2, D. Hrehoret2,
C. Gheorghe1, I. Popescu2
1
Fundeni Clinical Institute, Gastroenterology And Hepatology Center,
2
Fundeni Clinical Institute, General Surgery and Liver Transplantation Center
Background: HCV infection invariably recurrs after liver transplantation and
at least 50% of recipients develop histologic evidence of recurrent disease
within 1 year posttransplant. Yearly protocol liver biopsies are currently the
adopted strategy in HCV patients in order to detect progression of fibrosis and
to initiate on time antiviral therapy. Noninvasive evaluation of liver fibrosis is
now under evaluation in chronic hepatitis C.
Aim: A pilot study to evaluate the clinical value of real-time elastography in
patients with histologically mild posttransplant recurrent hepatitis C has been
conducted.
Methods: Patients with histologically proven hepatitis C underwent
transcutaneous ultrasound elastography (SonoElastography mode, HITACHI
EUB-6500). All patients underwent liver biopsies the same day after
elastography evaluation and METAVIR score was used to assess the degree
of inflammation and stage of fibrosis. Ninety-four elastography images were
analyzed using Adobe Photoshop 7. The mean intensity of colors red, blue,
green were measured using a semi-quantitative method. Analysis of histograms
for each color of the sonoelastography images was performed for quantifying
the elasticity of liver tissue. In order to investigate the predictive role of
sonoelastography for diagnosis of hepatitis, the c-statistic parameter was used.
Results: There were analyzed 8 patients (3 females and 5 males), with a mean
age of 51.75 ± 4 years. All patients had mild histologic liver disease (A0-A2 and
F0-F2) on liver biopsy. Necroinflammation grade A1 and A2 was diagnosed in
case of green colour >146.3, with a Se=44.8% and Sp=100% and c-statistic=0.63,
and blue colour <90.7, with a Se=32.1%, Sp=100% and c-statistic=0.7. For fibrosis
stage 2 the following results were obtained: green colour >157.8, Se and Sp=100%,
c-statistic=1; blue colour >102.2, Se=100%, Sp=58.6%, c-statistic=0.74.
Conclusion: Necroinflamation can be estimated with high specificity using
real time elastography but the analysis might be of better clinical usefulness
in assessing fibrosis, possibly contributing to selection of patients best suited
to undergo liver biopsy. Larger validation studies of the method, including all
stages of fibrosis, are needed.
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1261 HCV RECURRENCE ON PROTOCOL LIVER BIOPSIES
AFTER LIVER TRANSPLANTATION
P. Burra1, E. De Martin1, M. Senzolo1, M. Guido2, A. Masier1, C. Ferronato1,
M. Gambato1, G. Germani1, G. Zanus1, U. Cillo1
1
Department of Surgical and Gastroenterological Sciences, 2Institute of Pathology
Background: Histological HCV recurrence is accelerated following LT with
the development of cirrhosis up to 30% after 5 years.
Aim: To evaluate the progression of fibrosis on protocol liver biopsies in
patients transplanted for HCV cirrhosis.
Methods: Patients transplanted (1999-2005) for HCV cirrhosis who underwent
protocol liver biopsies consecutively performed at our Gastroenterology Unit
at 6, 12, 24 and 36 months after LT were included. Histological stage of fibrosis
(S) was evaluated according to Scheuer (score 0-4). The fibrosis progression
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N. Kawagishi, A. Nakamura, T. Iwane, I. Takeda, S. Miyagi, K. Satoh,
Y. Akamatsu, S. Sekiguchi, S. Satomi
Division of Transplantation, Reconstruction And Endoscopy
Background and purpose: Prophylaxis of recurrent hepatitis B virus (HBV)
using hepatitis B immunoglobulin (HBIG) after liver transplantation is costly
and it has some limitations. We report the efficacy of lamivudine (LAM)
monotherapy following one-year course of HBIG plus LAM after LDLT.
Methods: Out of 111 LDLT, we had 11 patients with chronic hepatitis B before
Tx and 3 recipients whose donors were anti-HBc antibody positive. Ten out of
11 chronic HB patients had LAM, 1 patient had adefovir in addition to LAM,
and 1 patient had no nucleoside analogue before Tx. HBV DNA was detected
in 4 patients at the time of Tx. Until the second day, total 30,000 units of HBIG
was administered and then the level of anti-HBs Ab was maintained around
150 IU/l for one year by monthly administration of HBIG. After 1 year, HBIG
was stopped to use. LAM (100mg) was administered daily from just after Tx,
and it was continued throughout this study. One recipient out of 3 anti-HBc Ab
positive donors, who had transplanted in 1993, had no prophylaxis. Other two
recipients of anti-HBc Ab positive donor had the same prophylaxis of chronic
hepatitis B patients. The mean follow-up period was 42 months.
Results: Two out of 14 recipients, including one who did not receive
prophylactic therapy, had HBV recurrence [HBs Ag (+), HBV DNA (+)]. One
recurrent recipient, who had our prophylactic protocol, treated with entecavir
because of YMDD mutant 3 years after Tx. Two recipients were dead; one was
due to liver abscess 3 years after Tx and the other was due to recurrence of HCC
3 years after Tx. The other 12 recipients were alive and in good conditions.
One recipient, who had HB hepatitis transmitted by an HBc Ab(+)donor, was
administered LAM and adefovir, and the HBV DNA became negative.
Conclusion: LAM monotherapy after one-year course of HBIG plus LAM is
feasible and cost-effective in terms of the preventing HBV recurrence.

monoinfection received lamivudine pre-OLT in a significantly higher percent
(80%) compared to HBV+HDV infection (21.1%, p=0.01) and also HBIg in
the anhepatic phase (86.2% HBV vs 46.2% HBV+HDV, p=0.006). The time to
HBsAg negativity after OLT was shorter in HBV+HDV infection (51.8±55.8
days) compared to HBV infection (73.3±65.1 days), but did not reached
statistical significance (p=0.47). There was no difference regarding survival or
costs between HBV and HBV+HDV.
Conclusion: In our transplant center HBV recurrent infection was low and
achieved with minimal costs. There was no significant difference regarding
survival or costs between HBV and HBV+HDV coinfection, although there is
a trend to a more rapid negativation of HBsAg in coinfected patients.
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rate (FPR) was expressed as fibrosis unit per month (FU/mo) and compared
over 3 periods (6-12; 12-24; 24-36 months after LT).
Results: 38 patients underwent 4 serial liver biopsies following LT, follow-up
24-95 months. Overall, at 6, 12, 24 and 36 months after LT, S 3 or 4 was seen
in 0%, 5.3%, 10.5% and 15.8% of patients (p=0.05, 6 vs 36 months), S (mean
value) was 1.18, 1.18, 1.59, 1.83 (p= 0.009, 6 vs 36 months) respectively; FPR
was 0.01, 0.04 and 0.02 FU/mo, respectively. 28/38 (74%) of patients were on
tacrolimus and 10 (26%) on cyclosporine. Low dose of steroids were given to
21/38 (55%) patients. (14 at month 1, 2 at month 3 and 4 at month 6 after LT).
1 patient was treated with boluses of steroids for acute rejection following 1
month after LT. The progression of fibrosis at 36 months after LT was similar
in patients taking or not steroids. 8/38 (21%) underwent antiviral therapy, at 6,
12, 24 and 36 months after LT, S 3 or 4 was 0%, 12.5%, 25%, 50% of treated
patients and 0%, 3.3%, 6.6%, 6.6% of non-treated patients (p=0.002 at 36 mo),
S was 1.37, 1.62, 2.12, 2.75 in treated patients (p=0.04) and 1.13, 0.98, 1.45,
1.58 in non treated patients (p=0.003).
Conclusion: The progression of fibrosis due to HCV recurrence following LT
is overall accelerated between the 1st and 2nd year compared to the early or
later period after LT. Low dose of steroids does not significantly increase the
fibrosis progression. A lower stage of fibrosis and a slower progression is seen
in patients who do not need antiviral therapy.
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1262 OUTCOME OF 100 CONSECUTIVE PATIENTS WITH
CHRONIC HEPATITIS B TRANSPLANTED IN A SINGLE
CENTER: EFFICACY OF SHORT-TERM, LOW DOSE
HBIG + LAMIVUDINE (LAM) IN PREVENTING DISEASE
RECURRENCE
L. Lilly, N. Girgrah, G. Therapondos, E. Renner, I. McGilvray, P. Greig,
M. Cattral, D. Grant, G. Levy
University Health Network
Background: The routine use of HBIG in combination with nucleos(t)ide
therapy has dramatically reduced the incidence and mortality of recurrent
hepatitis B virus (HBV) following liver transplantation (LT). However, the
most efficacious and cost-effective protocol has yet to be determined.
Aims: To describe the results of an HBIG/LAM protocol in consecutive
patients transplanted for chronic HBV in a large transplant program.
Patients and methods: From Sept 1998 through March 2007, 100 patients
with chronic HBV underwent LT in our center. 60 had hepatoma complicating
their cirrhosis. Twelve had developed lamivudine resistance (LAM-R) prior to
transplant, and were already on ‘rescue’ nucleotide therapy at the time of LT;
of the remaining 88, all had serum HBVDNA levels <5pg/ml or <1E4copies/
ml on no treatment (20%) or on LAM monotherapy (80%). 5/88 received LAM
only following transplant; all are alive and free of recurrence; the remaining
83 received LAM + one year of HBIG afterwards: first dose (2000IU) given
IV during the anhepatic phase, followed by one dose daily for seven days (IV,
then IM with normalization of INR), an IM dose weekly for three weeks, and
then monthly x11. Anti-HBs titers were not measured. HBsAg and HBVDNA
were measured q3m and prn for one year, and then q6m or prn thereafter. Mean
followup is 47m.
Results: 11 patients have died, 5 <3m after transplant, and 6 beyond 3m, one of
a stroke at 7m, two of recurrent hepatoma (9m and 22m), two of sepsis (11m and
47m) and one of melanoma at 94m. None had recurrent HBV. 4 patients have
developed recurrent HBV (HBsAg (+) with detectable HBVDNA), at 1, 7, 15,
and 24m following LT. The patient with immediate recurrence had HBVDNA
<5pg/ml 3 months prior to LT, but had a rapidly rising ALT immediately going
into surgery, so likely had LAM-R pre transplant; the patient who recurred at
7m had received only 1 month of HBIG treatment. All patients with recurrence
are alive; three are currently HBVDNA negative on LAM plus nucleotide
therapy.
Conclusions: Patients with HBV have excellent survival following LT, with no
graft or patient losses due to recurrent HBV. A low-dose HBIG/LAM protocol
has proved extremely effective (failure rate <5%) in preventing recurrent HBV,
and the short course of low dose HBIG, the absence of anti-HBs monitoring,
and the use of LAM monotherapy make it less costly and cumbersome than
many other protocols currently in use.
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1263 IMMUNOSUPPRESSIVE MINIMIZATION TO ACHIEVE
EFFECTIVE TREATMENT OF RECURRENT HEPATITIS C IN
LIVER TRANSPLANTATION
W-C. Lee, C-F. Lee, T-J. Wu, H-S. Chou, K-M. Chan
Chang-Gung Medical Center, Chang-Gung University
Introduction: Hepatitis C virus (HCV)-related liver cirrhosis is a major
indication of liver transplantation. Recurrence of hepatitis C after liver
transplantation is universal. Post-transplant HCV recurrence accelerates liver
fibrosis and leads to cirrhosis. How to treat recurrent HCV effectively is an
important issue.
Materials and methods: Thirty patients, 19 males and 11 females, undergone
liver transplantation for HCV-related liver cirrhosis from 2001 to 2007, were
included. Recurrence of HCV was diagnosed by elevation of HCV RNA
and liver transaminoferases. Treatment of HCV was conducted by pegylated
interferon and ribavirin once upon HCV recurrence was diagnosed.
Results: All 30 patients were positive for anti-HCV antibody. Ten patients had
hepatocellular carcinoma. Seventeen patients had decreased liver transplantation
and 13 had living donor liver transplantation. When liver transplantation was
performed, their mean age was 53.2+6.5 years and mean MELD score was 18.7+8.8
with a range from 6 to 40. Eight patients who were negative for HCV RNA before
transplantation did not have HCV recurrence. All other 22 patients had HCV
recurrence and 21 patients received anti-HCV treatment. The immunosuppressive
regimen consisted with tacrolimus, MMF and steroid. Tacrolimus were minimized
to keep trough blood tacrolimus level within 5 ng/ml. The dosage of MMF was only
250mg twice a day. Steroid was discontinued within 3 months. HCV recurrence
was treated by pegylated interferon every other week and ribavirin, 200-400 mg/
day. Nineteen patients (86.4%) were treated for HCV recurrence with 2 months
after liver transplantation. The mean duration for pegylated interferon treatment
was 9.6+4.4months. Till now, the end-of-treatment viral response rate was 66.7%
(14/21) and sustained viral response (SVR) rate was 61.1% (11/18). Ten of the 14
patients who had viral response had acute rejection during or end of HCV treatment.
All acute rejection was treated by pulsed and recycling steroid successfully.
Conclusion: The SVR in this study is comparable to the treatment results
of no-transplant patients. Minimization of immunosuppression and reducing
dosage of pegylated interferon and ribavirin to prevent treatment withdrawn
can achieve a high SVR.

POSTER BOARD NUMBER P2 – 63
1264 PEGYLATED INTERFERON AND RIBAVIRIN:
INTERFERON FOR HCV INFECTION IN KIDNEY
TRANSPLANTATION REVISITED
Y. Yamauchi1, N. Fujii1, A. Okuno1, N. Yoshimura2, S. Takahara3,
Y. Ichikawa1, T. Akiyama4
1
Hyogo Prefectural Hospital, Nishinomiya, 3Osaka University Hospital
Background: Although newer immunosuppressant therapies have led to
longer survival for kidney transplant recipients, liver disease caused by chronic
hepatitis C virus (HCV) infection has become more prevalent. Clinical trials of
interferon have been conducted, however, it failed to achieve a sufficient antiviral effect and also caused graft dysfunction.
Objectives: The aim of the present study was to elucidate the efficacy and
tolerance of low-dose pegylated interferon and ribavirin in long-term kidney
transplant recipients with chronic HCV infection.
Methods: This was a single-center longitudinal interventional study. The
subjects were outpatients enrolled in the kidney transplant center of Hyogo
Prefectural Hospital Nishinomiya, Japan, with stable graft function and an
estimated glomerular filtration rate (eGFR) of 30 ml/min/1.73 m2 or greater.
A liver biopsy was performed in all cases, followed by low-dose pegylated
interferon and ribavirin combinational therapy. Pegylated interferon-alpha 2b
was administered subcutaneously at a dose of 0.25 μ;g/kg/week for the first 4
weeks, then dosed up to 0.5 μ;g/kg/week. Ribavirin was started at 200 mg/day
with dose titration to achieve an optimal serum concentration of 2000-3000 ng/
ml, which was measured at weeks 1, 2, 4, and 8. Complete blood counts and
blood chemistry tests were performed at every visit. HCV-RNA was measured
every 4 weeks until week 12 and every 12 weeks thereafter.
Results: At the end of February 2008, we enrolled ten subjects (6 males, 4 females;

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Poster Abstracts
mean age 61.4 } 9.3 years) with a mean eGFR of 52.1 } 23.3 ml/min/1.73 m2. The
post-transplant period was 19.9 } 9.7 years. Although half of the subjects showed
normal ALT values, all had biopsy-proven hepatitis. Median baseline serum HCVRNA was 1700 KIU/ml [interquartile range, 830-4400 KIU/ml]. Eight subjects
had HCV genotype 1b and the other two had 2a. On week 12, ALT returned to
a normal level in all except for one case and four subjects (genotype 1b/2a =
2/2) showed a remarkable decrease in HCV-RNA in the order of two digits for
a median value at week 12 of 7.0 KIU/ml [1.5-640 KIU/ml]. In contrast, three
(38%) subjects with genotype 1b did not show a significant decrease in HCVRNA. The concentration of ribavirin only reached 1469 } 765 ng/ml, because of
its adverse effect of hemolytic anemia. Graft function was preserved in all subjects
throughout the first 3 months (week 12 eGFR, 55.7 } 17.0 ml/min/1.73 m2).
Conclusions: Low-dose pegylated interferon and ribavirin given to kidney
transplant patients with HCV infection was effective and tolerable, especially
for those with genotype 2a. A long-term evaluation should be conducted and a
more effective regimen for HCV genotype 1b is needed.

CONCURRENT ORAL SESSION 93: LIVING DONOR LIVER
TRANSPLANTATION
POSTER BOARD NUMBER P2 – 64
1265 PREVENT SMALL-FOR-SIZE SYNDROME USING DUAL
GRAFTS IN LIVING DONOR LIVER TRANSPLANTATION

POSTER BOARD NUMBER P2 – 66
1267 THE IMPACT OF THE PRIMARY LIVER DISEASE
ON THE EARLY OUTCOME OF LIVING RELATED LIVER
TRANSPLANTATION: A STARTING PROGRAM
E. Hammad1, I. Marwan1, E. Soliman1, H. Konsowa2, T. Yassin1
Surgery Department, National Liver Institute, Menoufiya University, Egypt,
2
Paediatric Department, National Liver Institute, Menoufiya University, Egypt
Background and aim: Living related liver transplantation (LRLT) has gained
wide acceptance in Egypt where cadaveric transplantation is not yet allowed.
Many factors have been noted to impact the outcome of liver transplantation.
Age, sex, underlying liver disease, hepatitis viral infection, immunosuppressive
regimen, coagulopathy and metabolic derangements can influence the outcome of
liver transplantation.The aim of this work is to study the effect of the primary liver
disease on the early outcome of the patients who underwent LRLT in the National
Liver Institute, Menoufiya University during the early phase of the program.
Patients and methods:This study included 20 cases of LRLT (14 children
and 6 adults).They were HCV cirrhosis(6), biliary atresia(5), Budd Chiari
syndrome(3), Byler disease(2), congenital hepatic fibrosis(2), hepatoblastoma(1)
and HCC(1) patients.The demographic data,the operative details,the early
postoperative course and regimen of immunosuppressant and the incidence of
complications were documented.
Conclusion: The results of transplantation were better in the paediatric
age group.The state of the portal hypertension should be considered for the
optimum GRWR.For successful outcome selection of the donor and recipient
should consider the socioeconomic and cultural status of the parties involved.

1
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1266 EVALUATION OF 368 LIVING RELATED LIVER
DONORS: SINGLE CENTER EXPERIENCE
N. Allam1, M. Al-Sofayan2, A. Helmy3, H. Al-manna4, M. Faguih4,
M. Neimatallah5, Y. Al-quaddy5, Y. Medhat2, A. Abdo2, M. Sebayel2
1
Hepatology,National Liver Institute, Egypt, 2Liver Transplantation, King
Faisal Institute and Research center, 3Gastroenterology, King Faisal Institute
and Research center, 4Pathology,King Faisal Institute and Research center,
5
Radiology,King Faisal Institute and Research center
Background and aims: Organ shortage has been the ongoing obstacle to
expand liver transplantation world-wide including Saudi Arabia. Living donor
liver transplantation (LDLT) was hoped to improve this shortage. The aim of
the present study was to analyse the results of the evaluation for a large pool of
potential living donors at our center.
Methods: From April 2001 to June 2007, a total of 44 living donors liver

1268 PRESENT STATUS AND PROSPECTS OF LIVING DONOR
LIVER TRANSPLANTATION (LDLT) IN EGYPT
H. Abdeldayem1, M. Bahaa2, N. Alam1, E. Salah1, A. Helmy1
National Liver Institute, 2Ain Shams University
Background: In Egypt, because cadaveric liver transplantation is not allowed
by law and hampered by religious beliefs and cultural traditions, liver
transplantation is restricted to LDLT.
Objective: To evaluate the results of LDLT programs in Egypt and to study
the prospects in the setting of high prevalence of HCV infection in the general
population.
Methods: Reports from four major centers of liver transplantation in Egypt
were reviewed during the period from August 2002 to February 2007.
Results: A total number of 326 LDLT cases were performed. While adult cases
were 285, pediatric cases were 41. In the adult group, the main indication was

1

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

429

TUESDAY

L. Yan, Z. Chen, B. Li, Y. Zeng, T. Wen, J. Zhao, W. Wang, M. Xu
Division of Liver Transplantation, West China Hospital, West China Medical
School
Background: The growing gap between the number of patients waiting
for transplantation and available organs is still the main issue facing the
transplant community. The major limitation of adult-to-adult living donor liver
transplantation (LDLT) is the small-for-size problem because of the concern of
donor safety. We report preliminary experiences for preventing small-for-size
syndrome using dual grafts from one right lobe without the middle hepatic vein
and one left lateral segment in adult-to-adult LDLT.
Methods: 110 cases of adult-to-adult LDLT were performed in West China Hospital
of Sichuan University from Jan 2002 to Aug 2007, and there were sixteen smallfor-size (SFS) grafts in all grafts. Dual grafts LDLT was performed for six patients
with end-stage liver disease, consisting of 5 cases from one right lobe without the
middle hepatic vein and one left lateral segment, and one case from two left lobes.
Results: All living donors underwent a full recovery from the operation without
persistent complications. Four recipients died of multiple organ dysfunction
syndrome (MODS) induced by sepsis and one recipient was performed retransplantation owing to hepatic failure and three recipients were performed
selective and transplenic artery embolization or splenic artery ligature for
small-for-size syndrome in the recipients with SFS grafts. All recipients with
dual grafts displayed good graft function and a majority of grafts showed
normal triangularshape regeneration of their respective liver grafts. Only one
left lateral segment occur atrophy, graft hepatectomy didn’t be required.
Conclusion: Dual grafts from one right lobe without the middle hepatic vein
and one left lateral segment in adult-to-adult LDLT can prevent the small-forsize problem and yet secure the safety of the donors.

transplantation were performed at our institution (37 patients had a right lobe,
1 had a left lobe and 6 had left lateral grafts). 368 potential donors were worked
up according to a step-wise evaluation protocol. Their age ranged from 18 to 60
years, with 75% in the third and forth decades. Female: male ratio was 77: 291.
They were all first and second degree relatives of the patients.
Results: Only 44 (11%) were accepted for donation and 324 (89%) were
rejected. 37% were excluded either at initial screening due to high body
mass index (15%), or in the first step of evaluation due to incompatible blood
group (3%), positive hepatitis serology (7%),elevated liver enzymes (12%).
6% were rejected due to miscellaneous systemic diseases. In 13% of cases,
the evaluation was aborted due to recipient conditions and in 5% because of
socioeconomic reasons. 20% were rejected because of abnormal anatomy
and 5% due to insufficient volume as determined by CT volumetry. In 14%,
abnormal histopathology primarily abnormal fat content was the reason for
rejection. Liver density was estimated by CT imaging before liver biopsy and
the results were in agreement with the finding of steatosis (ƒÛ agreement=29.2,
p=0.001).
Conclusion: There is no doubt that LDLT has helped in alleviating the severe
shortage of cadaveric organs in Saudi Arabia. However suitable living donors are
not easy to find especially right lobe donors. Our initial evaluation is effective in
eliminating a large number of unsuitable donors. However, the donor evaluation
process indeed remains to be a large burden on the resources of our program.
Estimation of liver density by CT is useful since marked hypodensity would
imply significant steatosis and hence avoid unnecessary biopsy.
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hepatitis C related cirrhosis (88%), other indications included: hepatocellular
carcinoma (4%), hepatitis B related cirrhosis (3%), Budd Chiari Syndrome
(3%), primary sclerosing cholangitis (1%) and hemochromatosis (1%). In the
pediatric age group: congenital biliray atresia represented the main indication
(87.5%), other indications included: hepatoblastoma (5%), Bylar disease (5%)
and congenital hepatic fibrosis (2.5%). There were two reported donor mortality
(0.6%). Relaparotomy was mandatory in 6 donors. The overall recipient
survival was 68.8%. While biliary complications occurred in 95 recipients
(29.1%), vascular complications occurred in 33 cases (10.1%).
Conclusion: LDLT in Egypt is associated with reasonable outcomes; yet, it
carries considerable risks of mortality and morbidity to healthy donors, it lacks
cadaveric back up, and associated with other difficulties including financial
coverage, availability of suitable donors and technical difficulties in some
cases. We hope that efforts to legalize cadaveric organ donation in Egypt will
succeed in the near future
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1269 BILIARY RECONSTRUCTION AND COMPLICATIONS
AFTER LIVING-DONOR LIVER TRANSPLANTATION
R. Saidi, P. Kennealey, N. Elias, D. Ko, T. Kawai, H. Yeh, J. Markmann,
A.B. Cosimi, M. Hertl
Massachusetts General Hospital, Harvard Medical School
Background: The technique of biliary reconstruction is remains controversial
in living-donor liver transplantation (LDLT). The objective of this review was
to assess the incidence of biliary complications after LDLT .
Methods: Thirty patients underwent LDLT between 1997 and 2007. The type
of allograft was the right lobe in 14, left lobe in 4, and left lateral sector in 12
patients. There were 18 adults and 12 pediatric recipients. The mean followup was 48 months (range 6-120 months). Biliary complications were initially
treated by endoscopic and/or radiological modalities.
Results: Biliary reconstruction was achieved with Roux-en-Y
choledochojejunostomy in 17 patients (Group I), and choledochocholedochostomy
in 13 patients (Group II). A external biliary stent was placed in all patients
(expect one) in Group I and reconstruction over a T-tube was done in 6/13 of
patients in Group II. Twenty five (83.3%) patients had one biliary anastomosis
and the remaining 5 (16.7%) had multiple anastomoses (one in Group I and
four in Group II).
The overall incidence of biliary complications was 30%.; 29.4% in Group I and
30.8% in Group II. The incidence of biliary leakage was 23.5% for Roux-en-Y,
and 15.4% for Group II (p>0.05). However, the incidence of biliary stricture
was significantly higher in Group II (15.4%) compared to Group I (5.9%) (p<
0.01). In Group II, biliary complications occurred equally in patients with and
without T-tube stenting. Overall, 93.3% of the strictures were managed with
endoscopic treatment alone. One patient in each group needed revision of the
biliary anastomosis.
Comparison between two biliary reconstruction methods
Biliary Anastomosis

Bilary stent/
Biliary
t-Tube
Complications

Biliary
Leak

Biliary
Stricture

Need
anastomotic
revision

Roux-en-Y
choledocho-jejunostomy
(n=17)

94.1%
(n=16)

29.4%
(n=5)

23.5%
(n=4)

5.9%
(n=1)

5.9%
(n=1)

duct-to-duct
choledochocholedochostomy
(n=13)

46.2%
(n=7)

30.8%
(n=4)

15.4%
(n=2)

15.4% *
(n=2)

7.7%
(n=1)

* p<0.01

Conclusions: Although there was a higher rate of biliary stricture in the
choledochocholedochostomy group, we feel that because of physiologic
bilioenteric continuity, comparable incidence of leakage, and easy endoscopic
access, duct-to-duct reconstruction represents a feasible technique in LDLT.
The endoscopic approach has been shown to be a first-line therapy for the
management of biliary complications after LDLT. Placement of T-tubes did not
appear to be beneficial.
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1270 POSTOPERATIVE COMPLICATIONS IN LIVE LIVER
DONORS AFTER PARTIAL HEPATECTOMY FOR LIVER
TRANSPLANTATION
R. Saidi, P. Kennealey, N. Elias, D. Ko, T. Kawai, H. Yeh, J. Markmann,
A.B. Cosimi, M. Hertl
Massachusetts General Hospital, Harvard Medical School
Introduction: Donor safety is the first priority in living donor liver
transplantation (LDLT). We evaluated the postoperative morbidity after partial
hepatectomy for LDLT in our unit.
Method: Thirty patients underwent LDLT between 1997 and 2007 at our
institution. This represented approximately 8% of the total liver transplant
experience during that period.
The type of graft was the right lobe (segments 5-8) in 14, left lobe (segments
1-4) in 4, and left lateral sector (segments 2 and 3) in 12 patients. There were 18
adults and 12 pediatric recipients. Mean donor age was 36 years (26-57).
The mean follow-up was 48 months (range 6-120 months). Complications were
classified according to Clavien’s system: grade I, deviation from the normal
postoperative course but without the need for therapy; grade II, complication
requiring pharmacologic treatment; grade III, complication with the need for
surgical, endoscopic or radiological intervention (IIIa/b: without/with the
need for general anesthesia); grade IV, life-threatening complication requiring
intensive care; grade V, death.
Results: No deaths occurred. Overall 8 (26.6%) patients experienced a total of
14 postoperative complications. Mean length of hospitalization was 7.5 days
(5-12 days).
Donor complications based on graft type were as follows: left lateral sector
(16.7%), left lobe (25%), and right lobe (35.7%). Type of and grade of
complications are summarized in the Table below.
The experience was divided into two periods 1997-2001 (15 patients) and
2002-2007 (15 patients). Overall complications during 2 periods were 40%
and 13.3%, respectively (p<0.001). The incidence of grade III complication
also decreased significantly, 63.6% vs 33.3 (p<0.01).
Grade of Complications:
n(%)
I: 4 (28.6%)
II: 1 (7.1%)
IIIa: 7 (50%)

IIIb: 2 (14.3%)
IV: 0
V: 0

Complications (1997-2001)
(n)
atelectasis (2),
superficial phlebitis (1)
Ileus (1)
Biloma (3),
perihepatic fluid collection (1),
pleural effusion (1),
GI bleeding (1)
wound dehiscence (1)
0
0

Complications (2002-2007)
a
0
peripancreatic fluid collection (1)

ventral hernia (1)
0
0

Conclusion: Partial hepatectomy in living donors has a learning curve which
appears to approximate is about 15 cases. This learning curve is not restricted
to the surgeons performing the procedure but involves all areas of peri- and
postoperative patient care. Our experience emphasizes that LDLT can be safely
provided by active liver transplant programs performing only modest number
of LDLT.
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1271 MULTIPLE BILE DUCT ANASTOMOSES WITHOUT
STENT IN LIVING-DONOR LIVER TRANSPLANT
M. Haberal1, G. Moray1, S. Sevmis1, H. Karakayali1, A. Torgay2, G. Arslan2
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Anesthesiology
It is unclear whether presence of multiple bile ducts in the graft increases the
risk of biliary complications after living-donor liver transplant (LDLT). In this
study we analyzed multiple bile duct anastomoses in LDLT. Since 2006, we
did not any drainage catheter for bile duct reconstruction, and after that time 57
LDLT were performed at our center. Eighteen (31.5%) of these 57 recipient’s
graft had multiple bile ducts, which were analyzed retrospectively. There were
12 male, 6 female, with mean age 30.9&#61617;22 years (range, 8 months to 54
years). Biliary reconstruction was performed with a duct-to-duct anastomosis in
13 recipients and with a Roux-en-Y hepaticojejunostomy in 5. Fourteen of the
18 grafts had 2 bile ducts, 3 had 3 bile ducts, and 1 had 4 bile ducts. In 4 grafts
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with 2 bile ducts, 2 separate anastomoses were performed. In the remaining
10 grafts with 2 bile ducts, we create a single orifice at the back-table. In two
grafts with 3 bile ducts, 2 neighboring ducts were sutured together, other bile
duct anastomosed separately. In remaining graft with three bile ducts, 3 bile
ducts were sutured together. In last graft with 4 bile ducts, 2 neighboring ducts
were sutured together, remaining 2 bile ducts were anastomosed separately.
Two biliary leakages and 1 billiary stenosis occurred in this series, which were
treated with interventional radiological approach, successfully. In the mean
follow-up 7.3&#61617; 4.1 months(range, 1 to 15 months), 1 patient died 3
months after liver transplant due to pulmonary emboli, remaining 17 patients
(94.4%) are alive with normal liver functioning. In conclusion, although our
follow-up period was short, the presences of more than one bile duct in the
graft do not appear to increase billiary complications after liver transplant in
our series.
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1272 POSTSURGICAL COMPLICATIONS IN LIVINGRELATED LIVER DONORS
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1273 COMPARISON OF SCINTIGRAPHIC FINDINGS
OF LEFT LOBE GRAFTS TO RIGHT LOBE GRAFTS
IN LIVING-DONOR LIVER TRANSPLANTATION
A. Gencoglu1, S. Sevmis2, A. Aktas1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Nuclear Medicine,
2Baskent University Faculty of Medicine, Department of General Surgery
Aim: The aim of this study was to compare the perfusion and function of left
liver lobe grafts to right liver lobe grafts using hepatobiliary scintigraphy during
the early postoperative period in patients receiving liver transplants from the
living-related donors.
Material and methods: Fifty-one liver transplant recipients were
investigated. Twenty-four patients (10 men, 14 women) received left/
extended left lobe grafts, and 27 patients (23 men, 4 women) received right
lobe grafts from living-related donors. A graft-to-recipient weight ratio was
calculated for each patient. In all recipients, hepatobiliary scintigraphy was
done 7 to 10 days after the transplantation. The hepatobiliary scintigraphy
was performed after an intravenous injection of 1.85 MBq/kg Tc-99m
mebrofenin. A large-field-of-view dual-head gamma camera with a low-
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1274 SCINTIGRAPHIC COMPARISON OF CADAVERIC
LIVER GRAFTS AND LIVER GRAFTS FROM
LIVING-RELATED DONORS
A. Gencoglu1, S. Sevmis2, A. Aktas1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Nuclear Medicine,
2Baskent University Faculty of Medicine, Department of General Surgery
Aim: The aim of this study was to compare the scintigraphic findings of
liver grafts during the early postoperative period in patients who received
grafts from living-related donors versus in patients who received grafts from
cadaveric donors.
Material and method: Thirty-five liver transplant recipients were included
in the study. Fifteen patients (6 women, 9 men; mean age: 43±18.07years;
mean cold ischemic time: 5.88±0.86 hours) received liver grafts from
the cadaveric donors. Twenty recipients (6 women, 14 men; mean age:
30.35±20.15 years) received grafts from the living-related donors. A
hepatobiliary scintigraphy was done in all recipients 7 to 10 days after the
transplantation. The hepatobiliary scintigraphy was performed after the
intravenous injection of 1.85 MBq/kg Tc-99m mebrofenin. A large-field-ofview dual-head gamma camera with a low-energy all-purpose collimator
was used to acquire the images. To test graft perfusion, data were recorded
every second for 1 minute and to evaluate the parenchymal function, data
were recorded every 30 seconds for 40 minutes in a 64×64 matrix. Perfusion,
hepatocyte uptake and excretion of the grafts were evaluated visually. A
graft liver biopsy was carried out in patients with abnormal scintigraphic
findings.
Results: Hepatobiliary scintigraphies during the early postoperative period
showed normal perfusion and function in 14 of 15 grafts (93.33%) from
cadaveric donors. However, 1 out of 15 grafts had diminished perfusion
and function. In that graft, a liver biopsy demonstrated hepatocyte damage/
cholestasis. During the early postoperative period, 18 of 20 grafts (90%)
from living-related donors had normal results on scintigraphy. However, 2
of 20 grafts in this group showed diminished perfusion and function due to
hepatocyte damage/cholestasis.
Conclusion: These scintigraphic findings indicate that perfusion and function
during the early postoperative period in liver grafts from cadaveric donors are
as good as those in grafts from living-related donors.
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H. Karakayali1, S. Sevmis1, F. Boyvat2, Y. Ekici1, R. Shahmazov1,
S. Pehlivan1, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery,
2Baskent University Faculty of Medicine, Department of Radiology
The crucial prerequisite to performing living-donor liver transplantation
procedure is a minimal morbidity and mortality risk to the healthy living donor.
In this study, we evaluate living related liver donor.
From September 2001 to January 2008, we performed 168 living-donor liver
transplantations in our transplantation center. For each patient, we collected
data from charts, and the Ba&#351;kent University Liver Registry and found
the following: of 168 donors, 99 were male and 69 were female, with a mean
donor age of 35.2 &#61617; 9.3 years (range, 20-56 years); 125 (74.2%) were
first-degree relatives, 29 (17.3%) were second-degree relatives, and 14 (8.3%)
were spouses. We performed 28 (16.74%) left hepatic lobectomies, 62 (37.13%)
left lateral segmentectomies, and 78 (46.1%) right hepatic lobectomies. The
mean percentages of remnant liver to the donor’s total liver volume for right
and left lobectomies were 41.7% and 67.8%. The mean length of patients’
postoperative hospital stay was 7.4 &#61617; 3.1 days (range, 3-16 days). There
was no postoperative mortality. Eleven complications (6.5%) occurred in 8 of
the 168 donors (4.7%); these were biliary leak (n = 3), biliary stenosis (n = 1),
wound infection (n = 2), incisional hernia (n = 1), portal vein thrombosis (n =
1), pulmonary thromboembolism (n = 1), deep venous thrombosis (n = 1), and
intraabdominal collection (n=1). For the donor with portal vein thrombosis, the
vein was recanalized, and the patient recovered without treatment. This same
donor also developed a bile leak from the cut liver surface and an incisional hernia.
Most complications were treated with radiologic interventions. In conclusion,
donor safety should be the primary focus in living-donor liver transplantation.
More experience, improved surgical techniques, and meticulous donor evaluation
will help minimize morbidity and mortality for living liver donors.

energy all-purpose collimator was used for image acquisition. To test graft
perfusion, data were recorded every second for 1 minute. To evaluate the
parenchymal function, data were recorded every 30 seconds for 40 minutes
in a 64×64 matrix. Perfusion, hepatocyte uptake and excretion of liver grafts
were evaluated visually.
Results: The mean graft-to-recipient weight ratio was 1.63%±0.57% in
recipients who received the left lobe grafts. This value was 1.29%±0.27% in
the right lobe graft recipients. There was no statistically significant difference
between the 2 groups in terms of graft-to-recipient weight ratio(p>0.05). On
hepatobiliary scintigraphies, normal scintigraphic parameters were found
in 25 of 27 right lobe graft recipients during the early postoperative period.
However, in this group, 2 of 27 grafts showed diminished perfusion and
function. In 19 of 24 left liver lobe graft recipients, the results of hepatobiliary
scintigraphies were completely normal. In 3 of 24 recipients in this group,
scintigraphy demonstrated a hypoactive area in the liver grafts due to minor
vascular problems; however, the other areas of the grafts had normal perfusion
and function. Similar to the right lobe grafts, the 2 left lobe grafts showed
abnormal perfusion and function on scintigraphy.
Conclusion: In the light of these scintigraphic findings, we conclude that
although they may have some minor vascular problems, left liver lobe grafts
have perfusion and function as good as right lobe grafts during the early
postoperative period in living-donor liver transplant recipients who have
sufficient graft-to-recipient weight ratios.
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1275 THE IMPACT OF ٱGALL-IN-ONEٱH MDCT
FACILITATING 3D VIRTUAL VENOGRAPHY AND
CHOLANGIOSCOPY ON LIVING DONOR LIVER
TRANSPLANTATION
J. Yamanaka, S. Saito, T. Sugimoto, Y. Iimuro, N. Kuroda, T. Hirano,
T. Okada, Y. Asano, N. Uyama, J. Fujimoto
Hyogo College of Medicine
Background/aim: In living donor liver transplantation (LDLT), accurate
assessments of liver graft volume and anatomical variation are mandatory
for preoperative planning of safe donor hepatectomy and successful recipient
implantation. Conventional planimetry has been used to estimate the resected and
residual liver volumes, although considerable volumetric error has been observed.
In addition, the volumetric evaluation of hepatic venous drainage is essential to
avoid liver graft and donor residual liver congestion. We previously reported the
efficacy of virtual hepatic resection using three-dimensional (3D) image analysis
software based on hepatic circulation (Hepatology 2005;41:1297-1304). The aim
of this study was to evaluate the impact of multidetecter CT (MDCT) scan based
simulation on the preoperative planning of living donor liver transplantation, with
special reference to hepatic venous drainage and variation in biliary anatomy.
Methods: Between May 2001 and December 2007, 161 individuals, including 6
living donors, underwent preoperative hepatectomy simulation. The simulation
software (Hitachi Image Processing System, Version 0.7a), which was developed
by the Department of Radiology, Hyogo College of Medicine (Nishinomiya,
Japan) and Hitachi Medical Corporation. The software was programmed to
reconstruct functional 3D anatomy and to calculate liver graft volume based
on portal perfusion. Briefly, 3D images of the portal vein, hepatic vein, hepatic
artery, bile duct, and liver parenchyma were reconstructed by a region-growing
technique and were overlapped to create the integrated 3D images. Clipping of
the proposed portal branch prompted volumetric calculation of the corresponding
liver graft volume. The predicted graft volume was compared with the actual
weight. Moreover, we applied our simulation algorithm to the hepatic venous
system for volumetric estimation of the hepatic vein branch drainage area.
Virtual cholangioscopy was also used to estimate hilar bile duct anatomy.
Results: Of the 161 patients enrolled in the study, 151 (94%) had complete
simulation data and received liver resections subsequently. Poor quality
images were obtained in 10 patients with dyspnea and could not be used for
the simulation. Simulation revealed a significant correlation (r=0.96; p<.001)
between the predicted and actual liver resection volumes, with mean discrepancy
of 9.3 „bƒn6.0 mL. The drainage area by the inferior right hepatic vein and
middle hepatic vein tributaries was quantified to achieve reconstruction of the
corresponding venous branch. The application of virtual cholangioscopy allowed
detailed visualization of 3D biliary anatomy and facilitated intraoperative
dissection in case with variant right posterior duct arising from left hepatic duct.
Conclusions: Hepatectomy simulation system in 3D allowed for volumetric
estimation of liver graft and hepatic venous drainage area. Virtual cholangioscopy
was also useful for detailed evaluation of biliary anatomy. This virtual method
may contribute to the preoperative planning of safe donor hepatectomy and
successful graft implantation based on the functional anatomy.
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1276 THREE RIGHT HEPATIC VEINS RECONSTRUCTION
USING CADAVERIC ILIAC VEIN IN RIGHT LOBE
LIVING-DONOR LIVER TRANSPLANTATION
S.C. Park, Y.S. Won, I.S. Moon, D.G. Kim, M.D. Lee, E.K. Kim
The Catholic University of Korea, Kangnam St. Mary’s Hospital
In case of various right hepatic vein anatomy, the hepatic vein reconstruction is
one of the surgically challenging techniques. The right inferior hepatic vein is
the most common hepatic vein abnormality during right lobe living donor liver
transplantation. But, the three accessory right hepatic veins is a rare case of
abnormal right hepatic veins. We had experienced 1 case of unusual right hepatic
vein reconstruction in 247 partial liver transplantations using right lobe in our center.
Here, we report our surgical case. The donor’s right lobe has one main right hepatic
vein and three accessory hepatic veins at lower liver border, so the restoration of
three accessory hepatic veins to inferior vena cava was made after forming one
conduit from the three accessory hepatic veins using cadaveric iliac vein
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1277 VARIOUS PORTAL VEIN RECONSTRUCTIONS IN RIGHT
LOBE LIVING-DONOR LIVER TRANSPLANTATION IN ADULT
S.C. Park, I.S. Moon, D.G. Kim, M.D. Lee
The Catholic University of Korea, Kangnam St. Mary’s Hospital
The anatomical variations of the portal vein in right liver lobe for partial liver
transplantation are common. In case of various right portal vein anatomy, the
technical modifications for various portal vein are necessary and one of the
surgically challenging techniques. We had experienced unusual portal vein
reconstructions in 247 partial liver transplantations using right lobe in our
center since Jan. 2000 to May 2006.The portal vein anatomy of right liver lobe
during donor operation were examined. The portal vein anatomy of the right
lobe graft is variable and can be changed by donor surgery, e.g. according to cut
margin of the right lobe graft. 34 cases of 18 cases of interposition graft. The
surgical techniques for portal vein reconstructions were analysed according to
it’s anatomy. The portal vein anatomy was defined as proposal of Dr. Chen. The
graft portal vein anatomy (type 1) was 213 (86.2%) and type 2 in 18(7.3%),
type 3 in 14(5.7%) and type 4 in 2(0.8%). Most of type 1 portal vein was
reconstructed with end to end direct anastomosis between portal veins. In 6
cases of poor inflow from recipient portal vein because of portal vein stenosis
and/or thrombosis, jump graft using cadaveric iliac vein or autogenous iliac
vein from superior mesenteric vein or coronary vein were used. In the 18 type 2
portal vein anatomy cases, the venoplasty to make common ostium on the graft
surface was made for end-to end anstomosis. 14 cases of type 3 portal vein
anatomy, 13 ¡°Y-shaped autogenous portal vein graft¡± was made on the graft
for end to end anastopmosis. In 1 case of type 3 and 2 cases of type 4 portal vein
anatomy, separate portal vein anastomosis was performed. The interposition
graft using autogenous rt. external iliac vein in one case. The four cases of
cryopreserved cadaveric iliac vein interposition from coronary vein, superior
mesenteric vein in portal vein thrombosis patients.
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1278 A COMPARATIVE STUDY ON THE PEDICTABILITY
OF CT VOLUMETRY IN LIVING DONOR LIVER
TRANSPLANTATION
D.H. Jung, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, T.Y. Ha,
G.W. Song, E.J. Lee, E.S. Yang
Department of Surgery, Division of Hepatobiliary Surgery and Liver
Transplantation, University of Ulsan College of Medicine and Asan
Medical Center
Backgrounds: Accurate prediction of the functional mass of both graft and
remnant livers is essential for proper donor selection and optimal recipient
outcome in adult living donor liver transplantation (LDLT). The objectives of
this study is to evaluate accuracy for determining lobar liver volumes using
a multi-detector CT scanner in potential donors undergoing LDLT and to
compare predictability of CT volumetry between right and left lobe.
Methods: During the period from January 2005 to December 2006, 472 donors
who underwent hepatectomy for LDLT in our center were included this study.
359 patients underwent right lobectomy and 113 patients underwent extended
left lobectomy. Multi-detector CT was preoperatively performed all patients.
The estimated volume of the grafts in two-demensional image was compared
with actual graft weight.
Results: In right lobectomy group, preoperatively measured right lobe volume
was 779 ± 133 mL and actual graft weight was 692 ± 107 g. There was
significant agreement between preoperatively measured right lobe volume and
actual graft weight at surgery in right lobectomy group (r=0.838). In extended
left lobectomy group, preoperatively measured left lobe volume was 372 ± 92
mL and actual graft weight was 384 ± 82 g. There was significant agreement
between preoperatively measured left lobe volume and actual graft weight at
surgery in extended left lobectomy group (r=0.841). Error ratio <=(estimated
liver volume – actual graft weight)/actual graft weight * 100> was 12.9 ± 10.3%
and – 2.7 ± 11.6% for right lobe graft and extended left lobe graft, respectively.
Conclusions: The relationship between the estimated CT volume and actual graft
weight was linear. The preoperatively measured volume of right lobe is substantially
larger than the intraoperative actual graft weight. The preoperatively measured
volume of left lobe is smaller than the intraoperative actual graft weight.
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1279 PATIENT CONDITION ADAPTIVE PASS SYSTEM
(PCAPS) IN MANAGEMENT OF LIVING DONOR LIVER
TRANSPLANTATION

1280 BILIARY RECONSTRUCTION UNDER
MIRCROSURGICAL TECHNIQUE: ANSWER TO
THE ACHILLES’ HEEL IN LIVING DONOR LIVER
TRANSPLANTATION?
C-L. Chen, A. Concejero, T.S. Lin, C.C. Wang, S.H. Wang, Y.W. Liu,
C.H. Yang, C.H. Yong, Y.C. Chinag
Liver Transplant Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center
Objective: Our objective is to describe our institutional experience with
routine biliary reconstruction using microsurgical technique in living donor
liver transplantation.
Patients and methods: From March 22, 2006-October 3, 2007, 72 grafts
were transplanted in 70 patients (including 2 dual graft transplants). All biliary
reconstructions were done under microscope by a single microvascular surgeon
who also did the hepatic artery reconstruction under microsurgical technique.
Except for biliary atresia, duct-to-duct reconstruction was performed. Stents
were not used. The records were analyzed retrospectively. The outcomes using
microsurgical technique were compared with a historical cohort using the last
71 grafts (70 patients) done by conventional method before March 2006.
Results: The indications for transplant were hepatitis B and/or C cirrhosis
with/without hepatocellular carcinoma (48), biliary atresia (13), alcoholic
cirrhosis (4), Wilson¡¦s disease (2), urea cycle disorder (1), glycogen storage
disease (1), and Alagille syndrome (1). The grafts used included 54 right and
4 left lobes, 13 left lateral and 1 extended left lateral segments. The minimum
follow-up among surviving recipients was 4 months. There were single ductto-duct (37), 2-in-1 ductoplastied (9), 3-in-1 ductoplastied (1), 2-to-2 (4), and
2-to-1 (1) anastomoses, and Roux-en-Y hepatico-jejunostomies (18). The
average graft duct sizes were 4.4 mm for a right lobe and 3.2 mm for a left
lobe single duct orifice, and 2.1 mm for multiple duct orifices. There was no
relationship between occurrence of biliary complications and number of duct
openings or liver lobe used. Most complications occurred during the first 15
cases which can be inferred as the learning curve phase. The complication rate
in the first 15 cases was 46.7%; whereas 15% in the next 20 cases, and 5.7% in
the last 35 cases. Overall complications included 9 bile leaks and 3 strictures.
Comparing the use of microsurgical technique with the conventional method,
the mean graft duct opening was smaller (2.8 mm vs 3.4 mm), and the ducts
which underwent ductoplasty reconstructions were also smaller. Considering
the learning curve and smaller duct openings, the overall complication rate
over time in the microsurgical group (8.9%) was significantly lower than the
conventional method (21.9%).
Conclusion: Bile duct reconstruction in small graft duct opening „T3 mm is
technically demanding. Routine use of microsurgical biliary reconstruction is a
technical innovation that may lead to decreased complications in the long-term.
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1281 THE INOVATION OF HEPATIC ARTERIAL
RECONSTRUCTION IN LIVING DONOR LIVER
TRANSPLANTATION
F. Zhang, L. Lv, X. Wang, X. Li, L. Kong, B. Sun, G. Li, F. Cheng
Liver Transplantation of The First Affiliated Hospital of Nanjing Medical
University
Objectives: Microsurgical hepatic artery reconstruction has become an essential
technique in living donor liver transplantation (LDLT) and helps in decreasing
the risk of hepatic arterial thrombosis (HAT) during arterial reconstruction.
However, microsurgical reconstruction of a hepatic artery poses significant
challenges to microsurgeons, such as vessel-size discrepancy between the
graft and recipient hepatic arteries. We have reported herein our technique for
hepatic artery reconstruction using a graft with tiny arteries (diameter < 1.5
mm) to decrease the postoperation complication of hepatic artery, which is an
obvious discrepancy from the recipient hepatic artery.
Methods: Since January 1995, 94 cases of living-donor liver transplants have
been performed in our center. In this report, we retrospectively analyzed 9 cases
using grafts with tiny arteries. Donor artery branch to create a patch or straight
to reconstruction in LDLT was performed to increase inflow since 2002.
Results: All donors were discharged without any vascular complications. One
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T. Yamada1, K. Tanaka1, K. Uryuhara2, S. Kaihara2, J.P. Raj3, T. Nakata4,
S. Tsuru4, M. Munechika5, Y. Iizuka4
1Institute of Biomedical Research And Innovation, Transplantation Division,
2Kobe City Medical Center General Hospital, Transplantation Division,
3Mount Elizabeth Hospital, 4The University of Tokyo, School of Engineering,
5Waseda University
The Patient Condition Adaptive Path System (PCAPS) is a new dynamic
method of monitoring a patient fs clinical course during hospitalization while
at the same time allowing and monitoring medical treatment that is being
instituted according to the patient fs changing condition.
The PCAPS is essentially an electronic medical chart comprising, 1) a process
chart, 2) a unit sheet, 3) a master file and 4) a data analyzer.
The process chart allows a complete overview or gbird fs eye view h of a
patient receiving his treatment. It defines the clinical state of the patient at
any given point of time during his stay and the effect of the treatment that is
given at that same point of time. In effect, the process chart appears like an
galgorithm h.
In progressing along this galgorithm h, the patient thus has to satisfy certain
clinical criteria. This allows the patient a comprehensive overview of his
treatment that he has been through and what he may go through should there
be or not any complications. At the same time other medical and paraclinical
staff have access to the process chart and can easily understand the preceding
clinical course and subsequent plans for the patient.
The Unit Sheet component of PCAPS incorporates details of medical treatment
and is linked to a prescription system and the patient fs medical record. Both
the Process Chart and the Unit Sheet provide us with a visual comprehensive
overview of the patient. By applying the PCAPS to patients in the postoperative
course following liver transplantation, we can evaluate our knowledge and
experience more effectively. More importantly, we can establish standards of
clinical care in liver transplantation.
Currently, daily hospital charts evaluating the clinical status of the patient
cannot be applied to patients requiring special care following the onset of
complications. In contrast, any patient can be monitored with our PCAPS
without exception. Every patient fs data is collated and can then be evaluated
to ensure a high level of quality care.
The Data Analyzer component allows us to readily perform a cost benefit
analysis both in our institution as well as to benchmark ourselves against other
institutions.
We have reviewed the clinical outcomes and perioperative courses of 150
patients following living donor liver transplantation in Kyoto University and
Kobe City Medical Center General Hospital. Our initial experience with PCAPS
for liver transplant patients is that it is able to both structure and standardize the
clinical processes very well.
We would like to present the data from PCAPS in patients with biliary
complications following living donor liver transplantation. Currently there is
much controversy and hence debate pertaining to biliary complications because
of its high incidence and the fact that its cause and prevention are unknown.
In conclusion we will show that our Patient Condition Adaptive System can
improve the quality of postoperative management of liver transplant patients
as well as evaluate the possible causes of complications and help us take
preventive measures.
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donor experienced bile leakage from the dissection plane of the liver, which was
treated by draining the abdominal cavity. Two patients with branch and seven
with branch patch anastomosis survived without evidence of HAT during 32
months (ranging from 11 to 72 months) of follow-up. One recipient died due to
a cytomegalovirus infection 11 months following LDLT. Both techniques were
successfully rescued by reanastomosing the HA. There was not statistically
significant.
Conclusions: Our arterial reconstruction technique has enabled the
reconstruction of tiny arteries and eliminated problems of diameter discrepancy.
This technique can be adapted for living donor liver transplantation without
increasing donor complications.
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1282 THE USE OF INTRATHECAL MORPHINE FOR
POSTOPERATIVE PAIN RELIEF AFTER LIVING DONOR
RIGHT HEPATECTOMY
I.H. Kim1, J. Ko2, S.J. Choi3, M.S. Gwak4, G.S. Kim5, J.W. Joh6, S-K. Lee7
Dept of Anesthesiology And Pain Medicine, Samsung Medical Center, 2Dept
of Anesthesiology And Pain Medicine, Samsung Medical Center, 3Dept of
Anesthesiology And Pain Medicine, Samsung Medical Center, 4Dept of
Anesthesiology And Pain Medicine, Samsung Medical Center, 5Dept of
Anesthesiology And Pain Medicine, Samsung Medical Center, 6Dept of
Surgery, Samsung Medical Center, 7Dept of Surgery, Samsung Medical Center
Introduction: The condition of healthy patients makes tolerance to pain
particularly low in the living donor population, and thus, it is necessary to
find an analgesic technique that provides effective pain relief while ensuring
donor safety. A single dose of intrathecal morphine, administered immediately
before surgery, may be a useful and safe alternative in obtaining prolonged
postoperative analgesia especially when the safety of epidural catheter is
still in question in living liver donors. This prospective, randomized study
compared, after right lobe liver resection and over a 72-h follow-up period,
the efficacy and safety of single-dose intrathecal morphine combined with
intravenous patient-controlled analgesia (IV-PCA, fentanyl) with an IV-PCA
alone.
Methods: Forty adult patients undergoing right donor hepatectomy were
randomly allocated into two groups: intrathecal morphine + IV-PCA group
(ITM group, n=20) and IV-PCA-only group (Control group, n=20). In the ITM
group, morphine sulfates 400 μg in 0.9% saline solution 4 mL was intrathecally
administered before general anesthesia. A visual analog scale (VAS) at rest and
when coughing was used for pain assessment and respiratory rate, SpO2, and
IV-PCA and supplementary demerol consumptions were assessed at 2, 4, 6, 8,
10, 12, 18, 24, 30, 36, 42, 48 56, 64, and 72 h after surgery. Side effects such as
nausea, vomiting, pruritus, sedation, respiratory depression, and hypotension
were evaluated.
Results: As measured by the VAS, patients in the ITM group had significantly
less pain at rest and when coughing for up to 30 h and 24 h, respectively (P
<0.05). The time to receive first rescue demerol was significantly longer in
the ITM group (45.7 ± 23 h vs. < 1 h; P < 0.001). Cumulative postoperative
consumptions of IV-PCA and demerol until postoperative 72 h were
significantly less in the ITM group (P < 0.001). There were no significant
differences in sedation, nausea, vomiting, repiratory rate and SpO2 between
the groups. The incidence of pruritus was significantly higher in the ITM group
(50% vs. 5%; P < 0.01).
Conclusions: In conclusion, preoperative single-shot intrathecal morphine
injection combined with IV-PCA provides effective postoperative pain control
and may be considered as an alternative method of pain control in patients
undergoing living donor right hepatectomy.
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1283 INTRAHEPATIC BILIARY ANATOMY DERIVED
FROM RIGHT GRAFT ADULT LIVE DONOR LIVER
TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2,
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1
Department of General and Abdominal Surgery, Johannes Gutenberg
University Hospital, Mainz, Germany, 2Department of General, Visceral,
and Transplantation Surgery, University Hospital Essen, Essen, Germany,
3
Department of Diagnostic and Interventional Radiology, University Hospital
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The successful management of the bile duct in right graft adult
live donor liver transplantation requires knowledge of both its central (hilar)
and distal (sectorial) anatomy. The purpose of this study was to provide a
systematic classification of its branching patterns in order to enhance clinical
decision-making.
Patients and methods: We analyzed 3-dimensional CT-imaging reconstructions
of 139 potential live liver donors evaluated at our Institution between January
2003 and June 2007.
Results: 1) Fifty four (n=54 or 38.8%) donor candidates had a normal (classic)
hilar and sectorial right bile duct anatomy (type I), 2) Seventy eight (n=78 or
56.1%) cases had either hilar or sectorial branching abnormalities (types II or
III), 3) Seven (n=7 or 5.1%) livers, a mixed type (IV) of a rare and complex
central and distal anatomy was encountered.
Conclusions: We believe that the classification proposed herein can aid in the
better organization and categorization of the variants encountered within the
right-sided intrahepatic biliary system.
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1284 PERIPHERAL ANATOMY OF THE RIGHT HEPATIC
DUCT A NEW SYSTEMATIC CLASSIFICATION EXPERIENCE
FROM ADULT LIVE DONOR LIVER TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2,
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1
Department of General and Abdominal Surgery, Johannes Gutenberg
University Hospital, Mainz, Germany, 2Department of General, Visceral,
and Transplantation Surgery, University Hospital Essen, Essen, Germany,
3
Department of Diagnostic and Interventional Radiology, University Hospital
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The peripheral intrahepatic biliary anatomy, especially at the
sectorial level on the right side, has not been adequately described. The purpose
of our study was to systematically describe this complex anatomy, and to make
it clinically applicable.
Patients and methods: We analyzed 3-dimensional CT-imaging reconstructions
of 139 potential live liver donors evaluated at our Institution between January
2003 and June 2007.
Results: 1) Eighty nine (64%) donors had a normal right bile duct
sectorial anatomy, 2) In the other 50/139 (36%) cases, we observed an
abnormal sectorial branching pattern, 3) 45 of the 50 abnormalities were
trifurcations, while the remaining ones were quadrifurcations, 4) in 22/50
(44%) of abnormalities, a linear branching pattern (types B1/C1) and
an early segmental origin off the right hepatic duct (types B3/C3) were
present (this finding being of particular danger when performing a right
graft hepatectomy) 5) in two cases, a mixed type (B6/C6) of a rare complex
anatomy was seen.
Conclusions: Our proposed classification of the right sectorial bile duct system
clearly displays the “area at risk” encountered while performing right graft
ALDLT and tumor resections involving the right lobe of the liver.
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1285 ANATOMICAL CLASSIFICATION OF THE PERIPHERAL
RIGHT HEPATIC DUCT – EARLY IDENTIFICATION OF A
PREVENTABLE SOURCE OF MORBIDITY AND MORTALITY
IN ADULT LIVE DONOR LIVER TRANSPLANTATION
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1286 HEPATIC HILAR AND SECTORIAL VASCULAR AND
BILIARY ANATOMY IN RIGHT GRAFT ADULT LIVE LIVER
DONOR TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2,
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1
Department of General and Abdominal Surgery, Johannes Gutenberg
University Hospital, Mainz, Germany, 2Department of General, Visceral,
and Transplantation Surgery, University Hospital Essen, Essen, Germany,
3
Department of Diagnostic and Interventional Radiology, University Hospital
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The aim of this study was to analyze vascular and biliary
variants at the hilar and sectorial level in right graft adult living donor liver
transplantation.
Methods: From January 2003 to June 2007, 139 consecutive live liver donors
underwent 3-D CT reconstructions and virtual 3-D liver partitioning. The portal
(PV), arterial (HA) and biliary (BD) anatomy was evaluated.
Results: The hilar and sectorial biliary/vascular anatomy was predominantly
normal (70-85% and 67-78%). BD and HA showed an equal incidence
(30%) of hilar anomalies. BD and PV had a nearly identical incidence of
sectorial abnormalities (64.7% and 66.2%). The most frequent “single”
anomaly was seen centrally in HA (21%) and distally in BD (18%). A
“double” anomaly involved BD/HA (7.2%) in the hilum, and HA/PV and
BD/PV (6.5% each) sectorially. A “triple” anomaly involving all systems
was found at the hilum in 1.4% of cases, and at the sectorial level in 9.4%
of instances. Simultanous central and distal abnormalities were very rare.
13.7% of all donor candidates had normal hilar and sectorial anatomy
involving all three systems. A simultaneous central and distal “triple”
abnormality was not encountered. A combination of “triple” hilar anomaly

POSTER BOARD NUMBER P2 – 86
1287 ANALYSIS OF HEPATIC STEATOSIS AFTER PEDIATRIC
LIVING DONOR LIVER TRANSPLANTATION
K. Wakayama1, M. Taniguchi1, T. Shimamura2, T. Suzuki3, K. Yamashita1, H.
Furukawa3, S. Todo1
1Department of General Surgery, Hokkaido University, 2Division of Organ
Transplantation, Hokkaido Universty, 3Department of Organ Transplantation
and Regeneration, Hokkaido University
Background and aim: It is well known that hepatic steatosis recurs after
liver transplantation in adult patients with pre-existing Non-Alcoholic Fatty
Liver Disease(NAFLD). Moreover, it has been recently reported to occur after
transplantation even in adult patients without pre-existing NAFLD. In pediatric
liver transplantation, however, the actual situation of hepatic steatosis after
liver transplantation is unknown. Herein, we investigated the hepatic steatosis
in pediatric transplant cases at our center.
Patients and methods: From July 1998 to May 2007, forty pediatric patients
underwent living donor liver transplantation (LDLT) at our center. Biliary
atrasia was the most common indication (27 cases) for transplantation.
Diagnosis for steatosis was obtained from liver biopsy specimens after
transplantation. Liver biopsies were performed when the possibility of
rejection was raised clinically. This included unexplained increases in
liver enzyme level. Significant steatosis was defined as steatosis >5%, and
subdivided into mild (5-33%), moderate (>33-66%), and severe (>66%).
Recipient characteristics, risk factors for post-transplant steatosis, change
of post-transplant liver numbers, and histological changes of steatosis were
analyzed.
Result: The post-transplant steatosis was observed in 24 cases (62%),
mild in 15 cases (38%), moderate in 3 cases (8%), and severe in 6 cases
(16%), respectively. The mean time to diagnose steatosis was 16.6 post
operative day. The mean cumulative steroid consumption in 4 weeks after
transplantation was significantly larger in steatosis group(41.7mg/kg) than in
non-steatosis group(28.4mg/kg). The levels of T-Bil, AST, and gamma-GTP
revealed no significant change between the two groups during 8 weeks after
transplantation. Histologically, 7 cases showed improvement or disappearance
of steatosis within two years after transplantation. In 2 cases whose diagnoses
were Methylmalonic aciduria and Byler fs disease, histological findings
demonstrated the persistent severe steatosis and the progression to liver
cirrhosis, respectively.
Conclusion: Transient hepatic steatosis caused by steroid was observed at
early period after LDLT in two thirds of pediatric cases. In patients with Byler
fs disease and Methylmalonic aciduria, the progressive hepatic steatosis should
be paid attention after pediatric LDLT.
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1288 DONOR PORTAL VENOPLASTY FOR SEGMENT 4 IN
RIGHT LOBE LIVING DONOR LIVER TRANSPLANTATION
H-L. Fan, S.M. Kuo, T.W. Chen, J.C. Yu, C.B. Hsieh
Tri-Service General Hospital
Segment 4 branch of portal vein rarely comes from right portal vein. Once it is
encountered during right lobe living donor liver transplantation, it is mandatory
to reconstruct this branch for the proper function of the rest of liver in donor.
A simple procedure of direct end-to-end anastomosis between the stump of
segment 4 branch and of right portal vein is described in 3 out of 40 donors
from May 2005 to March 2008. During the right lobectomy in the donor, a
sufficient length of stump of right portal vein was preserved and venoplasty
was performed for the size match of anastomsis.
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Objective: The purpose of this study was to determine the impact of our
classification on right graft ALDLT outcomes.
Methods: Three dimensional CT reconstructions were used to classify the hilar
and sectorial biliary anatomy of 71 consecutive live liver donors. Four possible
clinical types were defined, based on the normal (N) or abnormal (A) features
of the corresponding hilar / sectorial ducts: type I: N/N; type II: N/A; type III:
A/N and type IV: A/A. An analysis of the operative outcomes based on the
donor anatomy was subsequently performed.
Results: Type I was encountered in 47.9% of cases, type II in 29.6%, type
III in 19.7%, and type IV in 2.8%. The highest incidence of biliodigestive
anastomoses was observed with type III (50%) and type IV (100%) variants.
Type I was associated with the highest incidence of single anastomoses (single
versus multiple p= 0.001) and of single bile duct biliary anastomoses (single
versus multiple p= 0.004). Type III was associated with more multi-duct
reconstructions when compared with types I and II (p= 0.002 and p=0.05,
respectively). There were no significant differences in early (p= 0.08) or late
(p= 0.33) biliary complications, or deaths of biliary etiology (p= 0.55) among
the four types.
Conclusions: Complex biliary anatomy in the right liver graft usually
requires biliodigestive anastomoses and is often associated with complicated
biliary reconstructions. The precise delineation of the intrahepatic biliary
anatomy provided by our clinical classification contributed to acceptable
postoperative morbidity and mortality, especially for grafts at highest
anatomical risk.

with “triple” sectorial normality was found in 2 cases (1.4%). A central
“triple” normality associated with a distal “triple” abnormality occurred in
7 livers (5%).
Conclusions: Our data showed a variety of “horizontal” - hilar or sectorialand “vertical” - hilar and sectorial- vascular and biliary branching patterns,
providing a comprehensive assistance in surgical decision-making for right
graft hepatectomies.
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1289 A CASE OF PYOGENIC SPONDYLODISCITIS CAUSED
BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
(MRSA) AFTER LIVING DONOR LIVER TRANSPLANTATION
J.S. Kim, D.J. Kim, I.G. Kim, J.P. Jung, H.J. Kim, S.E. Chon, J.Y. Jeon,
S. Lee, S.J. Hyun
From Departments of Surgery, Hallym University College of Medicine,
Methicillin-resistant Staphylococcus aureus (MRSA) infection frequently
complicates the postoperative course of liver transplant recipients. It has been
well described that MRSA associated bacteremia, pneumonia and surgical
site infection are common. But, MRSA infection manifesting as pyogenic
spondylodiscitis is very rare. To our knowledge, pyogenic spodylodiscitis due
to MRSA in lumbar spine after living donor liver transplantation (LDLT) has
not been previously reported. Here, we report a 50-year-old man developed
pyogenic spondylodiscitis caused by MRSA after LDLT. Our patient underwent
LDLT for HBV related cirrhosis in February 2004. Immnosuppressive
treatment was administered with basiliximab, tacrolimus, corticosteroids
and mycophenolate mofetil. He discharged on postoperative 28th day with
uncomplicated course. At one week after discharge the patient was readmitted
for abdominal pain and septic condition. Bile leakage at the anastomosis site
was found by endoscopic retrograde cholangiopancreaticography (ERCP) and
managed successfully with endoscopic nasobiliary drainage (ENBD). The
culture of drained fluid showed MRSA and he was treated with vancomycin
for 4 weeks. These treatment resulted in resolution of the infection. However,
one month later the patient presented with severe back pain. At this time, MRI
showed massive spondylodiscitis of lumbar 2-3 spine and paraspinal abscess
formation. Our patient was treated by surgical debridement and primary bone
graft. MRSA was cultured from the abscess specimen. Postoperatively, the
patient received intravenous vancomycin for 4 weeks and revealed satisfactory
outcome with no neurological sequelae. Presently he is followed up without
rejection and other complications.

POSTER BOARD NUMBER P2 – 89
1290 EARLY REGULAR CHECK-UP OF BILIARY STRICTURES
BY ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY FOR
DUCT-TO-DUCT BILIARY RECONSTRUCTION AFTER ADULT
LIVING DONOR LIVER TRANSPLANTATION
T. Kobayashi1, Y. Sato1, S. Yamamoto1, H. Oya1, H. Kokai1, K. Shioji2,
K. Hatakeyama1
1Division of General And Digestive Surgery, Niigata University, 2Division of
Digestive Disease, Niigata University
Objectives: Biliary strictures (BS) are one of the important issues to be
addressed after living donor liver transplantation (LDLT). Duct-to-duct
biliary reconstruction allows the performance of endoscopic retrograde
cholangiography (ERC) for evaluation and management of BS. However,
operative biliary management is sometimes required. From September 2006,
we started regular check-up of BS by ERC within six month after removal of
external stents in duct-to-duct biliary reconstructed adult LDLTs. We examined
feasibility of the routine post-operative ERCs for BS after adult LDLT.
Methods: From March in 2000 to January in 2008, 54 LDLTs with duct-to-duct
reconstruction with external stents were performed in our institution. Among
these, we retrospectively evaluated 45 primary adult LDLTs survived more
than one month. We separated those cases to two groups; the early cases (from
03/2000 to 08/2006, n=34) and the late cases (from 09/2006 to 01/2008, n=11) and
compared the incidence of BS and success rate of endoscopic treatments in these
two groups. BS was defined as the strictures by cholangiography or dilatation of
intrahepatic bile duct with/without elevation of biochemical liver test. Median
follow-up of the late cases (8.0 months) was shorter than that of the early cases
(38.5 months) (p=0.0003). Characteristics of the recipients (age, gender, donor
age, MELD score, Child-Pugh score, ABO incompatibility operation time, blood
loss, number of biliary anastomoses) were not different in those two groups.
Results: Overall incidence of BS was 36% (16/45). The incidence of BS was
32% (11/34) in the early cases and 45% (5/11) in the late cases. There was
no difference of the incidence of BS in these two groups (p=0.18). BS was
successfully treated by endoscopic management in four of five (80%) in the late
cases and three of 11 (27%) in the early cases (p=0.049). Endoscopic-relatedcholangitis developed in one patient in the early cases. Nine patients with failed
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endoscopic therapy were converted to percutaneous or surgical treatment.
Two patients in the early cases required operative biliary reconstructions.
No surgical treatments were not required in the late cases. Median follow-up
period between removal of the biliary stents and diagnosis of BS were 67 days
in the late cases and 165 days in the early cases (p=0.047).
Conclusions: It was longer period to diagnose BS in the early cases. Early
postoperative regular check-up of BS by ERC for duct-to-duct biliary
reconstructions may be effective to avoid surgical interventions after adult LDLT.
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1291 LIVING-DONOR LIVER TRANSPLANTATION WITH
TRANSIENT PORTOCAVAL SHUNT AND SPLENECTOMY
FOR A SMALL-FOR-SIZE GRAFT AND BLEEDING GASTRIC
FUNDAL VARIX
Y. You, S.K. Lee, K.K. Lee, J.H. Park, C.A. Oh, D.G. Kim, E.K. Kim
The Catholic University of Korea
Background: Excessive portal venous inflow has been known as the
determining factor for hepatic injury in small for size graft in living-donor liver
transplantation. Partial diversion of portal inflow to the systemic circulation
by portocaval shunt has been reported as a promising treatment modality to
prevent patient from small-for-size syndrome. Initial hyperperfusion injury
to the graft would be the most dreadful component in the living-donor liver
transplantation. In addition, splenectomy itself is not only a method to decrease
portal flow, but also a treatment for the gastric fundal variceal bleeding.
Methods: We performed living–donor liver transplantation with transient
portocaval shunt and splenectomy for small-for-size graft in a 50 year-old
male who suffered from hepatitis B virus related liver cirrhosis with a bleeding
gastric fundal varix, which was intractable to endoscopic control. The height
and weight of recipient, donor(spouse) was 177 cm, 88kg and 160 cm, 48 Kg
respectively. Graft to recipient body weight ratio(GRWR) was 0.65. During
surgery, left portal vein was used for temporary portocaval shunt and the
right portal vein was anatomosed to the graft portal vein. After all vascular
anastomoses completed, an endoloop(OpenLoop®) was placed around
portocaval shunt without tightening, and the knot pusher was taken out of the
abdominal cavity placed in a silastic drain tube. Concomitant splenectomy was
performed. 24 hours after transplantation, the loop placed around portocaval
shunt was tightened as a bedside procedure.
Results: The recipient had an uneventful postoperative course and was
discharged with normal graft function 26 days after transplantation.
Conclusion: Living-donor liver transplantation with transient portocaval shunt and
splenectomy could be an acceptable surgical treatment strategy for patient with
end-stage liver disease with small-for-size graft and bleeding gastric fundal varix.

POSTER BOARD NUMBER P2 – 91
1292 EOSINOPHILIC INFILTRATION OF DONOR LIVER
K-H. Ko, S.G. Lee, K.M. Park, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon,
T.Y. Ha, K.W. Song, D.H. Jung, J.H. Ryu, H.J. Lee, J.I. Park, K.W. Kim,
N.K. Choi
Division of HBP Surgery and Liver transplantation, Department of Surgery,
University of Ulsan College of Medicine and Asan Medical Center
In Korea, Cadaver Donor is rare, Living Donor Transplantation(LDLT) is
essentail for End-stage Liver disease. The quality of Living donor is important
for postoperative recovery of recipient and safety of donor. There are rare
report about using donor liver with eosinophilic infiltration. We performed
Rt. lobe LDLT on February 2007, using with eosinophilc infiltration of donor
Liver. In LT donor work-up, pre-op CT shows multifocal ill-defined low
attenuation lesion,such as eosinophilic infiltration. In MRI, two ill-defined
T2 high signal lesion(less than 1cm) showed at Liver S6,8. But, those lesion
were not detected on US, Hepatic, Mescenteric Doppler. The important point is
those were migrating lesion on CT scan and CBC and diffentail count showed
eosinophilia 8%. After transplantation, we checked CT scan on POD 1 day,
and the eosinophilc lesion were not detected in recipient side. We followed
up CT scans for 3 months post-operatively and no abnormal lesion detected in
transplant liver, and donor is recovered safely. Conclusively, in view of short
term follow up, liver donor with eosinophilc infiltration can be safely used for
Liver graft in LDLT. But long term follow up is needed.
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1293 CLINICAL ANALYSIS OF GRAFT FAILURE AFTER
ADULT LIVING DONOR LIVER TRANSPLANTATION
K.K. Lee, D.G. Kim, S.K. Lee, I.S. Moon, M.D. Lee
The Catholic University of Korea
Introduction: Graft failure after liver transplantation remains an important
cause of graft loss and leads to patient death or retransplantation, resulting in
lower survival rate. The purpose of this study was to evaluate the epidemiologic
and cause of graft failure and find out the risk factors influencing graft failure
after adult living donor liver transplantation (LDLT).
Method: We analyzed 286 patients among 330 patients who underwent adult
LDLT from May 1999 to Jan. 2008, in which was consisted of 28 patients in
graft failure group and 258 patients in control group. The patient with graft
failure was divided to two groups according to period of graft failure, early
failure, before discharge after transplantation and later failure, after discharge.
Result: There was no significant difference between two groups in preoperative
and operative factors. The 11 patients were suffered from early graft failure
and their causes consisted of 7 in vascular problem and 4 in graft dysfunction
and the only one patient survived after retransplantation. The late graft failure
occurred in 17 patients and the biliary complications including biliary leakage
or strictures were the main causes of failure in 9 patients, and other causes
consisted of hepatic artery or vein stenosis and TACE complication for
recurrent HCC. Among them, the 4 patients survived after retransplantation,
and 1 patient died of graft dysfunction in spite of retransplantation.
Conclusion: The main causes of graft failure after LDLT originated from
technical problem and to prevent the graft failure, meticulous surgical technique
is required. After graft failure, considering retransplantation is important to
increase the survival rate.

1294 HEPATIC INFLOW INFLUENCE UPON PORTAL VEIN
COMPLICATIONS IN PEDIATRIC LIVING DONOR LIVER
TRANSPLANTATION
S. Shibasaki1, M. Taniguchi1, T. Shimamura2, T. Suzuki3, K. Yamashita1,
M. Ohta2, H. Furukawa3, S. Todo1
1
Department of General Surgery, 2Division of Organ Transplantation,
3
Department of Organ Transplantation and Regeneration, Graduate School of
Medicine, Hokkaido University, Sapporo, Japan
Background/aim: Portal vein (PV) complications in pediatric living donor
liver transplantation (LDLT) are often asymptomatic in the early stages after
transplantation and can be serious enough to lead to graft failure. There have
ever been few reports on hepatic inflow as risk factors for PV complications in
LDLT. The aim of this study is to investigate the influence of hepatic inflow and
to predict patients at risk for these complications.
Material/method: From Septembar 1997 to April 2007, 40 pediatric patients
underwent LDLT at our center. Portal venous and hepatic arterial flows after
reperfusion and PV diameter were analysed.
Results: PV complications were identified in 6 patients (15%), and occurred in
lower age (the group with PV complications vs. the group without PV complications:
0.95 ± 0.4 vs. 5.3 ± 5.3 yr, p<0.001) and lower weight (7.6 ± 1.3 vs. 18.6 ± 14.3
kg, p<0.001). None suffered graft failure. Smaller PV diameter in recipient, larger
donor-recipient PV diameter ratio, lower portal venous flow and higher hepatic
arterial flow after reperfusion were risk factors for PV complications (Table.1).
In the analysis of 21 patients under two years of age, smaller PV diameter in
recipient, larger discrepancy of PV diameter, and higher hepatic arterial flow were
risk factors, too. Portal venous flow was also tended to be low.
Conclusion: PV size and hepatic inflow influence upon PV complications.
Patients under two years of age were a high risk group of PV complications.
Small PV size, great discrepancy in PV diameter between donor and recipient,
low PV flow, and high HA flow were risk factors for PV complications.

N
Recipient
HA diameter (mm)

(3) noncomplications
(1)
(2) noncomplications complications
(under
2 year-old)
6
34
15
3.5 ± 0.6

3.6 ± 0.9

3.4 ± 0.6

(A)

(B)

p=0.774

p=0.637

(B)
p=0.006

9.3 ± 1.8

9.1 ± 1.5

8.9 ± 1.3

p=0.698

p=0.576

2.8 ± 1.0

1.4 ± 0.5

1.7 ± 0.4

p=0.018

p=0.044

141.0 ± 75.7
54.9 ± 22.7
3.1 ± 2.2

240.3 ± 93.6
28.6 ± 17.6
12.8 ± 14.1

196.4 ± 48.1
29.6 ± 17.6
9.8 ± 6.9

p=0.019
p=0.013
p=0.103

p=0.058
p=0.013
p=0.032

Table.1 univariate analysis of hepatic inflow and vascular size
(A) is comparision between (1) and (2) using the Student’s t-test
(B) is comparision between (1) and (3) using the Student’s t-test
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1295 A SINGLE CENTER EXPERIENCE OF 1000 RIGHT LOBE
LIVING DONOR LIVER TRANSPLANTS
T.Y. Ha, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, G.W. Song,
D.H. Jung, J.H. Ryu
Asan Medical Center
Background and purpose: Right lobe living donor liver transplantation
(LDLT) has been increasingly performed for adults with end-stage liver
disease. However, its application to the seriously ill patients as acute liver
failure or acute-on-chronic liver failure is still controversial due to justification
of subjecting a healthy donor to the risk of life-threatening surgery. This study
was aimed to evaluate 1,000 adult right lobe LDLT in a single center whether
the early outcome is comparable to cadaveric whole-size liver transplant.
Method: One thousand consecutive adult right lobe LDLTs performed between
15th July 1997 and 8th October 2007 were retrospectively reviewed especially
for in-hospital mortality of recipients and major donor complications. One
thousand right lobe liver grafts consisted of 72 right lobes (without middle
hepatic vein reconstruction), 20 extended right lobes (with middle hepatic vein
trunk), 902 modified right lobes (with reconstruction of middle hepatic venous
tributaries) and 6 modified extended right lobes (with reconstruction of distal
middle hepatic vein trunk and segment 8 hepatic vein). The median follow-up
period was 31 (range, 3-123) months.
Results: Recipients’ age ranged from 17 to 69 years. Graft-to-recipient weight
ratio ranged from 0.56 to 1.69% (mean 1.03 ¡¾ 0.25, median 1.03). MELD score
ranged from 4 to 40 (mean 20.0 ¡¾ 9.1, median 18). According to UNOS urgency
category, there were 57 status I, 143 status IIa, 116 status IIb, and 684 status
III. Among 1000 recipients, 44 could not return to home because of in-hospital
mortality. There was neither mortality nor life-long disability in donors.
Conclusion: Despite the complexity of right lobe LDLT procedure, the
standardization of the technique of procedure and the surveillance of the posttransplant dynamic change of the partial graft have improved the results of this
operation comparable to the full-size cadaveric donor liver transplants.

POSTER BOARD NUMBER P2 – 95
1296 CAUSES OF REJECTION OF POTENTIAL LIVING
DONORS FOR LIVING-RELATED LIVER TRANSPLANTATION
M. Mihaila1, L. Micu1, C. Ruscanu1, A. Berbec1, I. Popescu2, M. Voiculescu1
1Fundeni Clinical Institute, Center of Internal Medicine-Nephrology,
2Fundeni Clinical Institute, Center of General Surgery and Liver
Transplantation
One of the most important problems in liver transplantation programs is
represented by the shortage of organs due to the increasing number of patients
on the waiting lists, which is not matched by an increase of available cadaveric
donors. For this reason many patients die while awaiting a liver transplant. In
order to better cope with this growing problem, living donor liver transplantation
programs have been developed.
The aim of the study is to evaluate the most frequent causes that lead to the
rejection of potential living donors from donating a liver fragment.
Material and methods: In the Center of Internal Medicine of Fundeni
Clinical Institute, 34 potential donors were evaluated between 2003-2007 in
order to establish the possibility of donating a liver fragment for 13 patients
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PV diameter (mm)
Donor
PV diameter (mm)
the PV size’s ratio of donor
to recipient
Hepatic inflows after reperfusion
PV flow (ml/100g/min)
HA flow (ml/100g/min)
PV/HA flow ratio

(3) noncomplications
(1)
(2) non(A)
complications complications
(under
2 year-old)
3.7 ± 1.0
7.5 ± 2.6
5.7 ±1.4
p<0.001
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with end stage liver disease. The standard protocol of investigations was
applied including compatibility of the ABO system, normal psychological
and psychiatric examinations, absence of liver or systemic disorders, as
well as hepatic volume. We performed biological, hematological, virological
and imagistic examinations (CT scan for hepatic volumetry, angio- and
cholangioMRI, angiography for evaluating hepatic vascularization), liver
biopsy, psychological, cardiological and neurological examinations.
Results: Of the 34 potential liver donors, only 9 (26.47%) were considered
elligible for donation. 7 patients (20.58%) were found to be HBV carriers, 1
patient (2.94%) presented multiple hepatic cystic masses, 1 (2.94%) presented
lung tumor, 3 patients (8.82%) presented macrovesicular steatosis > 20% at
liver biopsy, 5 pts (14.7%) were rejected after psychological evaluation, in 3
patients (8.82%) hepatic volumetry contraindicated donation due to the risk of
small-for-size syndrome, 1 patient (2.94%) presented an anatomical variant of
the hepatic artery which did not allow for hepatic resection, and 4 (11.76%) had
biological profiles which suggested Wilson disease.
Conclusions: It is important to underline the fact that for each recipient for living
donor liver transplantation it is usually necessary to evaluate several potential
donors. The screening of potential donors is costly and time-consuming, while
medical contraindications of donation are frequently encountered.

liver failure, necessitating support with artificial ventilation, multiple
vasopressive agents, and continuous veno-venous hemodiafiltration. After
a liver biopsy demonstrated submassive liver necrosis, he was listed for
transplantation as a status 1A, and received a full-size liver transplant from
a deceased donor eleven days after his liver resection. Following a stormy
post-transplant course, with major difficulties to close the abdominal
wound, the patient was finally discharged from the hospital after 79 days.
Eight months later, he has fully recovered from his liver and kidney failure
as well as peritonitis.
This is the first description of a living donor who received a successful
liver transplant. There are four additional living liver donors mentioned in
the medical literature: three died, and in one the outcome is unknown. Our
own patient is the only documented survivor, so far. This case demonstrates
that even in supposedly healthy living donors postoperative complications
cannot be completely prevented. Although liver failure is rare in these
patients, timely transplantation may need to be considered as the only lifesaving treatment.
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1297 PROSPECTIVE EVALUATION OF DUCT-TO-DUCT
BILIARY RECONSTRUCTION IN ADULT LIVING DONOR
LIVER TRANSPLANTATION
T.Y. Tsui, M.N. Scherer, M. Loss, A. Doenecke, H.J. Schlitt, A. Obed
Department of Surgery, University of Regensburg Medical Center
Background: Biliary reconstruction remains the Achilles’ heel of adult living
donor liver transplantation (LDLT). This study aims to investigate the feasibility
of duct-to-duct hepaticocholedochostomy in LDLT.
Methods: Perioperative data from thirty consecutive LDLT aiming at ductto-duct reconstruction of the biliary tract using a continuous suture technique
were prospectively collected. Nineteen recipients (63.3%) had one graft bile
duct. Eleven recipients (36.7%) had two or three graft bile ducts. The median
follow up was 30 months
Results: The overall biliary complication rate was 23.3%. Two recipients
developed biliary stricture (6.7%) and two recipients (6.7%) presented with
biliary leakage in early posttransplant phase (< 90 days). One recipient suffered
from bilioma (3.3%) and two recipients (6.7%) presented with biliary stricture
in later posttransplant phase (>90 days). No correlation was found between
the number of graft bile ducts and the incidence of biliary complications. No
biliary complication-associated necessity for re-transplantation or mortality
was observed. On multivariate analysis, no single risk factor associated
with biliary complication could be identified. All biliary complications were
successfully treated with Roux-en-hepaticojejunostomy and/or with endoscopic
interventions.
Conclusion: Duct-to-duct hepaticocholedochostomy represents a safe and
feasible procedure for biliary reconstruction in LDLT. Recipients may be
benefit from aggressive management of biliary complications with Roux-enhepaticojejunostomy as compared to repeated endoscopic interventions in
early posttransplant phase.
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1298 LIVER TRANSPLANTATION OF A LIVING DONOR
B. Ringe, G. Xiao, D. Sass, J. Reynolds, W. Meyers
Drexel University College of Medicine
Postoperative liver failure has been identified as a rare complication after living
donor liver resection. According to a recent review of the literature the outcome
is usually fatal. Although liver transplantation was attempted in a small number
of patients, no survivor has been reported, so far. This is a case report of a living
donor who was rescued with liver transplantation.
A 22-year old healthy male underwent a right hemihepatectomy including
segments 5-8 for a patient suffering from cystic fibrosis. After an uneventful
early recovery he had an exploratory relaparotomy four days later for clinical
signs of acute abdomen. We found a gastric perforation with peritonitis,
eventually leading to septic shock with acute renal and subsequent
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1299 RISKS AND BENEFITS OF LIVING DONOR LIVER
TRANSPLANTATION
B. Ringe, R. Petrucci, J. Reynolds, D. Sass, G. Xiao
Drexel University College of Medicine
Living donor liver transplantation (LDLTx) was introduced to alleviate organ
shortage, and to help patients who have no chance of receiving a deceased
donor organ. The procedure has always been under intense scrutiny because
of concerns for the safety of the donor. To assess the risks and benefits of
LDLTx we have reviewed our own experience with 26 pairs of donors and
recipients.
26 adults (age 19-54 yr; 15 m/11 f) completed evaluation as living donors,
including assessment of preoperative medical and psychosocial risk factors
by an independent hepatologist, psychologist, and social worker. 27% had
no medical, 62% no psychosocial, and 19% no combined risks. Overweight,
hypercholesterolemia, smoking, and history of alcohol or illicit drugs were
the most frequent conditions identified preoperatively. Postoperative recovery
was completely uneventful in 11 donors. Complications were observed in 15
patients, and graded as 1 (7), 2a (2), 2b (4), 4a (1), and 4b (1), according to the
modified Clavien classification (2006). A death from illicit drug overdose was
not related to surgery performed 57 days earlier. One donor received a liver
transplant for multi organ failure and sepsis secondary to gastric perforation,
and is alive after 8 months. Eighteen right, one left, and 7 left lateral lobe
grafts from 18 genetically and 8 emotionally related living donors were
transplanted into 14 adults (age 22-58 yr) and 11 pediatric recipients (age 5
mo - 18 yr; one retransplant). Indications were chronic end stage liver disease
in adults (mean MELD 14, waiting time 188 d), and in 8 children (mean PELD
11, waiting time 40 d); four pediatric patients had acute hepatic failure, and
were transplanted within 2-10 d after listing on status 1. 17 of 25 recipients are
alive (follow up 8 mo - 5 yr), including 10/11 children. Two of the mortalities
were related to the technique of LDLTx (small for size syndrome and hepatic
artery rupture).
What can be learned from this single center analysis? It is important to
document all risks and complications accurately. Ideally, living donors
should be completely healthy. In our experience, 81% of liver donors had at
least one risk factor which may have contributed to some of the postoperative
complications. However, except one, all major complications occurred in
low risk donors. On the recipient side there is no doubt that LDLTx had
significant benefits in patients with low MELD scores, selected tumors, and
in children, including acute hepatic failure. LDLTx should not be performed
in patients with high MELD scores, especially since they are prioritized
to receive deceased donor organs. Sufficed to say, but LDLTx is a delicate
balance. By violating the principle of primum non nocere there will always
be an unpredictable risk for the donor. Any risk-benefit calculations involving
both donor and recipient will not help to answer the question as to where to
draw the line.
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1300 EVALUATION OF 368 LIVING RELATED LIVER
DONORS: SINGLE CENTER EXPERIENCE
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1301 LIVING DONOR LIVER TRANSPLANTATION USING A
GRAFT FROM SITUS INVERSUS DONOR
J.M. Chun, J.M. Kim, G.O. Jung, J.B. Park, H.T. Jung, H.J. Park, K.U. Jung,
S.J. Kim, J.W. Joh, S.K. Lee
Samsung Medical Center, Department of Surgery
Several reports have shown uneventful outcomes after liver transplantation
performed in recipient with situs inversus and three cases of deceased donor
of situs inversus undergoing liver transplantation were reported.we report a
case of LDLT using a graft from situs inversus donor with successful result.
In the recipient operation, the Glissonian pedicles were cut intrahepatically
as high as possible using high hilar dissection technique and right hepatic
vein was obtained long enough to perform hepatic vein anastomosis without
tension. The reversed right hepatic vein(hepatic vein on the left side of vena
cava)of donor was anastomosed directly to the right hepatic vein of recipient
without vascular modifications and then donor portal vein was anastomosed to
the confluence of right anterior branch and right posterior branch of recipient
portal vein in an end to end fashion. The reversed right hepatic artery of donor
was anastomosed to the recipient right hepatic artery using a microvascular
technique and thereafter intraoperative Doppler examination was performed
to evaluate the vascular flow and patency. Biliary reconstruction was
achieved using a duct to duct choledochocholedochostomy and no stent
was placed. The graft function was excellent postoperatively and the patient
presented in satisfactory condition at his last follow up, 6 months after liver
transplantation.

1302 SUCCESSFUL USE OF EXTENDED CRITERIA DONOR
GRAFTS WITH LOW TO MODERATE MACROVESCICULAR
STEATOSIS IN PATIENTS
WITH BIOCHEMICAL MELD SCORE LESS THAN 26
F. Frongillo1, A.W. Avolio1, E. Nure1, R. Barbarino1, G. Pepe1, V. Perilli2,
Salvatore Agnes1
1
Catholic University of Rome, Dpt of Surgery - Transplantation Service,
2
Catholic University of Rome, Dpt of Anaesthesiology
Background: Today, liver transplantation cannot be performed without the use
of extended criteria donor (ECD) grafts. Characteristics of ECD grafts include,
age higher than 60, use of iv narcotics until brain death, long Intensive Care
Unit stay, history of malignancy, and steatosis. Even if, a precise definition of
extended-criteria donors remains elusive, liver grafts are frequently discarded
for orthotopic liver tranplantation (OLT) due to steatosis. Few papers on donor
liver steatosis have been published as yet. Steatosis could be microvescicular
or macrovescicular. Macrovesicular steatosis, is the most relevant in terms of
unfavourable outcome due to primary non function or primary dysfunction.
Patients and methods: From January 2000, all referred donors at our institution
were considered potentially transplantable and they were all surgically
evaluated using inspection and biopsy (wedge-biopsy and ago-biopsy). To
have a unique point of view, when possible, we utilized the same pathology
service. We basically avoid to transplant steatotic grafts in patients with severe
decompensation of liver function as represented by high MELD score (≥26).
We defined steatotic liver grafts when steatosis rates higher than 5%.
A typical graft with moderate steatosis without fibrosis.
Results: We observed 30 donor grafts with steatosis higher than 5%.13 grafts
(43%) show macrovesicular steatosis affecting more than 50% of the hepatocytes
and were discarded. 2 grafts (7%) with macrovescicular steatosis equal to 35%
and 47%, were discarded by our Unit, and transplanted by other Italian centres.
The graft with 35% steatosis had favourable outcome, the one with 47% steatosis
did not, and required urgent re-transplant because of primary non function. The
remaining 15 grafts (50%) were transplanted in spite of their steatosis.
Regarding the 15 grafts transplanted at our institution 7 grafts (23%) had a
macrovesicular steatosis between 5% and 10%; 6 recipients are still alive and
one (the patient who received a fatty liver for urgent retransplant) died for
sepsis after primary dysfunction. 4 grafts (13%) had steatosis between 10% and
15%; all the recipients are still alive and without complications. 2 grafts (7%)
had a steatosis between 15% and 30%; both the recipients ar alive and without
complications. 2 grafts (7%) were transplanted with microvesicular steatosis
beetwen 40% and 50%, in absence of macrovesicular steatosis; both recipients
are alive and well.
Conclusions: In summary, the carefull use of ECD grafts with low to moderate
steatosis but without fibrosis, cannot be precluded, especially if particoular care
is reserved to avoid additional risk factors related to the recipient.
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1303 RISK FACTORS OF ACUTE CELLULAR REJECTION
IN ADULT LIVING DONOR LIVER TRANSPLANTATION:
POSITIVE LYMPHOCYTOTOXIC CROSS-MATCH IS NOT
A RISK FACTOR
J.M. Chun, G.O. Jung, J.M. Kim, K.U. Jung, H.T. Jung, H.J. Park, J.B. Park,
S.J. Kim, J.W. Joh, S.K. Lee
Samsung Medical Center, Department of Surgery
Background: The influence of lymphocytotoxic crossmatch on acute cellular
rejection in adult living donor liver transplantation (LDLT) has not been
well examined. In this study, we evaluated the risk factors of acute rejection
including positive lymphocytotoxic cross-match.
Method: Between June 1997 and June 2007, consecutive adult 382 recipients
who underwent 1st LDLT, were enrolled in this study. Clinical factors including
recipient age, relation of donor, primary indications of transplantation, MELD
score, graft to recipient body weight ratio (GRWR), donor age, human leukocyte
antigen mismatch, lymphocytotoxic cross-match, cold ischemic time, induction
immune suppression and incidence of biliary complication and CMV infection
were analyzed for possible risk factors by Kaplan Meier Method.
Results: Among 382, 32 recipients were positive in lymphocytotoxic cross-
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N. Allam1, M. Al-sofayan2, A. Helmy, M. Al-saghier, Y. Medhat,
H. Khalaf, A. Abdo, M. Sebayel
1
National Liver Institute, Menofeya University, 2King Faisal Specialist
Hospital and Research Center
Background and aims: Organ shortage has been the ongoing obstacle to
expand liver transplantation world-wide including Saudi Arabia. Living donor
liver transplantation (LDLT) was hoped to improve this shortage. The aim of
the present study was to analyse the results of the evaluation for a large pool of
potential living donors at our center.
Methods: From April 2001 to June 2007, a total of 44 living donors liver
transplantation were performed at our institution (37 patients had a right lobe,
1 had a left lobe and 6 had left lateral grafts). 368 potential donors were
worked up according to a step-wise evaluation protocol. Their age ranged
from 18 to 60 years, with 75% in the third and forth decades. Female: male
ratio was 77: 291. They were all first and second degree relatives of the
patients.
Results: Only 44 (11%) were accepted for donation and 324 (89%) were
rejected. 37% were excluded either at initial screening due to high body
mass index (15%), or in the first step of evaluation due to incompatible blood
group (3%), positive hepatitis serology (7%),elevated liver enzymes (12%).
6% were rejected due to miscellaneous systemic diseases. In 13% of cases,
the evaluation was aborted due to recipient conditions and in 5% because of
socioeconomic reasons. 20% were rejected because of abnormal anatomy
and 5% due to insufficient volume as determined by CT volumetry. In 14%,
abnormal histopathology primarily abnormal fat content was the reason for
rejection. Liver density was estimated by CT imaging before liver biopsy and
the results were in agreement with the finding of steatosis (ƒÛ agreement=29.2,
p=0.001).
Conclusion: There is no doubt that LDLT has helped in alleviating the severe
shortage of cadaveric organs in Saudi Arabia. However suitable living donors
are not easy to find especially right lobe donors. Our initial evaluation is
effective in eliminating a large number of unsuitable donors. However, the
donor evaluation process indeed remains to be a large burden on the resources
of our program. Estimation of liver density by CT is useful since marked
hypodensity would imply significant steatosis and hence avoid unnecessary
biopsy.
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match. Median follow-up duration was 28.0 months (0~93). And 56 recipients
underwent one more acute rejection episodes. In univariate analysis, positive
lymphocytotoxic cross-match was not significant risk factor of acute rejection
(p=0.625), while HCV (p=0.003), low MELD score (p=0.011), and no induction
of anti-IL-2 receptor antibody (p=0.034) were revealed as risk factor for acute
rejection. In multivariate analysis by Cox-Regression hazard model, younger
recipient age (p=0.030, HR 0.965, CI 0.935~0.997), HCV (p=0.003, HR 0.268,
CI 0.112~0.642), lower MELD score (p=0.006, HR 0.956, 0.926~0.987) were
significant risk factors.
Conclusion: Positive lymphocytotoxic cross-match is not risk factor for acute
cellular rejection.

POSTER BOARD NUMBER P2 – 103

TUESDAY

1304 OUTCOME OF CANDIDATE EVALUATION IN ADULTTO-ADULT LIVING DONOR LIVER TRANSPLANTATION IN
JAPAN: FROM THE COORDINATOR’S POINT OF VIEW
E. Soeda1, M. Tanabe2, S. Kawachi2, H. Obera2, M. Shinoda2, T. Hibi2,
Y. Kitagawa2
1
Keio University Hospital, 2Department of Surgery, School of Medicine,
Keio University
Purpose: In 2004, the Japanese National Insurance began to cover medical
expenses for Adult-to-adult Living Donor Liver Transplantation (A2ALL) and
the number of transplant candidates increased. However, not all candidates
could receive A2ALL for a variety reasons. We report the outcome of candidates
evaluated in one of the metropolitan university hospitals in Tokyo, Japan. This
university is a major hospital with a special interest and experience in ABO
blood type incompatible living donor liver transplants.
Methods: The records of consecutive 170 candidates from 2003 to 2007 were
reviewed and analyzed.
Outcome: Of the 170 candidates (mean age=51.6,), 41 (24.1%) underwent
A2ALL and 129 (75.9%) did not. The primary diagnoses established were
Hepatitis B and/or C (108, 63.5%), alcoholic liver cirrhosis (20, 11.2%),
fuluminant hepatitis (15, 0.9%). Seventy one candidates had HCC (71, 65.7%),
beyond Milan criteria (52.1%). Of the 129 candidates, 107 were unsuitable
for A2ALL, 15 went overseas and 7 went other Japanese hospitals to receive
liver transplants. The main reasons identified for those who did not receive
A2ALL were 1) too late for transplant (46, 42.9%), 2) no donor (31, 28.9%), 3)
other reasons such as considered social factors preferred deceased donor liver
transplant (11, 10.2%).
Conclusion: In Japan, only one-forth of candidates underwent A2ALL.
Because of the difficulty of finding a suitable living donor, about half cases were
assessed too late for A2ALL. As a clinical transplant coordinator, facilitating
meaningful communication among those patients and patients’ family to make
the right decision at the right time, it was very important to not miss the chance
of a potentially life saving liver graft. An increase in organ donation from
deceased donors in Japan is an urgent requirement.
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1305 INDICATION OF PREOPERATIVE LIVER BIOPSY
IN DONOR EVALUATION FOR LIVING DONOR LIVER
TRANSPLANTATION
Y. Koshizuka, T. Suzuki, M. Taniguchi, K. Yamashita, T. Shimamura,
T. Kamiyama, M. Matsushita, H. Furukawa, S. Todo
First Department of Surgery, Hokkaido University, Sapporo, Japan.
Background: Living donor liver transplantation (LDLT) has become an
acceptable alternative for orthotopic liver transplantation to resolve donor
shortage. As donor safety should be the primary consideration, accurate
assessment for donor evaluation is critical to ensure a successful outcome for
both donor and recipient. Preoperative liver biopsy for donor candidates whose
liver was suspicious of hepatic steatosis or liver dysfunction by preoperative
examination is generally accepted. However, there are arguments both for and
against the routine preoperative liver biopsy for donor evaluation.
Aim: The aim of this study is to investigate an expansion of the indication for
preoperative liver biopsy in donor evaluation.
Material and method: Between October 1997 and February 2007, one hundred
eighty six donor candidates who had completely passed preoperative evaluation
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by laboratory tests, imaging, and psychosocial examination, hospitalized
in our institution to undergo donor operation. Preoperative liver biopsy was
performed only for donor candidates whose liver were suspicious of hepatic
steatosis or liver dysfunction by preoperative examination. The outcome of
donor candidates was analyzed.
Results: Of 186 donor candidates, one hundred seventy six underwent
successful hepatectomy for living donation. There was no donor mortality.
Ten donor candidates, who did not undergo liver biopsy before operation,
were cancelled their operation. Of these, five donor candidates were cancelled
because of abnormalities in liver function, or symptoms of common cold.
Abnormalities in liver function test were caused by taking medicine,
constitutional jaundice, and alcohol drinking. Other 5 donor candidates were
cancelled by the findings of laparotomy. Intraoperative liver biopsy showed
hepatitis in 4 cases, and the peritoneal dissemination of a gall bladder
cancer was revealed by laparotomy in one case. In 4 donor candidates,
two cases, whose recipient was diagnosed primary biliary cirrhosis (PBC),
were suspicious of PBC. Of 10 donor candidates who cancelled their
operation, 2 cases were old donor more than 50 years old. Conclusion:
For the donor candidates whose recipient’s primary disease is autoimmune
hepatitis including PBC or the old donor candidates more than 50 years old,
preoperative liver biopsy should be considered.
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1306 GASTROINTESTINAL BLEEDING WITH ANTIPLATELET
MEDICATION IN SEVERE PORTAL HYPERTENSIVE PATIENT
AFTER LIVING DONOR LIVER TRANSPLANTATION: A CASE
REPORT
J.W. Park1, J.H. Kim2, W.B. Kim3, S.D. Suh4, S.Y. Choi5
Department of Surgery, Korea University Guro Hospital, 2Department of
Internal Medicine, Korea University Guro Hospital, 3Department of Surgery,
Korea University Guro Hospital, 4Department of Surgery, Korea University
Ansan Hospital, 5Department of Surgery, Korea University Guro Hospital
Background: Hepatic artery thrombosis is a catastrophic complication after
liver transplantation leading to graft failure. For this reason, antiplatelet
medication should be started at early postoperative day especially in living
donor liver transplantation.
Case presentation: A 56-year old male patient with hepatitis B virus related
and alcoholic liver cirrhosis underwent living donor liver transplantation.
The donor was his daughter. He was suffering from severe refractory ascites
and intermittent spontaneous bacterial peritonitis. There were no significant
comorbidities such as diabetes mellitus, hypertension, hypercholesterolemia,
etc. He received massive transfusion because of severe bleeding during
operation. But, his vital sign was stable perioperatively. He began to recover
rapidly without any abnormal findings after liver transplantation. We started
anticoagulation prophylatic therapy with low molecular heparin from
immediate postoperative day and examined liver graft by color Doppler
sonogram at first and third postoperative day. His hepatic artery flow was
good with normal resistive index. At 5th postoperative day, we started
oral antiplatelet medication with overlapping intravenous low molecular
heparin according to protocol. Next day, his hemoglobin decreased abruptly
from 15g/dl to 7.9g/dl with stable vital sign. We found gastrointestinal
bleeding by esophagogastroscope over duodenal third portion suggesting
jejunojejunostomy site. We managed this patient conservatively with packed
RBC transfusion and stopped any anticoagulant therapy. After 3 days, he
recovered to normal hemoglobin level. Color Doppler sonogram showed good
hepatic artery flow with normal resistive index at postoperative one month.
He discharged without any anticoagulant prophylactic medication from that
event and had a good graft function at out-patient department. This was our
first adult living donor liver transplantation.
Conclusion: Gastrointestinal bleeding should be considered in massive
transfused patient with antiplatelet medication at early postoperative period
and we suggest that antiplatelet medication for prevention of hepatic artery
thrombosis can be hold with caution in low risk patient.
1
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1307 DONOR COMPLICATION AND SATISFACTION
ASSESSMENT AFTER LIVING DONOR LIVER
TRANSPLANTATION USING RIGHT LOBE GRAFT
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1308 CLINICAL OUTCOMES AFTER LIVER
TRANSPLANTATION (OLT) FROM LIVING DONORS ARE
COMPARABLE TO THOSE FROM DECEASED DONORS
M. Almarastani, A.W. Khan, A.A. Abdulkareem
King Abdulaziz Medical City
Background: Living donors offer expansion of the donor pool in the era of
donor shortage. The donor shortage is a serious problem in the third world
countries. The aim of this study is to determine if the outcomes of OLT from
deceased livers are comparable to those from living one.
Material and methods: A retrospective review of liver transplant recipients
from deceased and living donor at a single transplant center was performed.
Patient demographics, liver function tests, length of stay, complications, and
patient outcomes were reviewed. Comparisons between groups were done
with Chi-square test and two samples Student t-test with p value < 0.05 being
significant.
Results: Between January 2002 and December 2006, 82 patients underwent
OLT. 25 were from living and 57 from deceased donors. The mean age of
recipients in the living group was 53.24+/- 9.48 years and 53.33+/- 10.79 years
for deceased group (p=0.96). There were 76% males in the living versus 63%
in the cadaveric group. None of the living group underwent re-transplanted
compared with two patients (3%) of the deceased group. The follow up
period was between 2002- 2007, during this period 84% of living related liver
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1309 CLINICAL OUTCOMES AFTER LIVER
TRANSPLANTATION (OLT) FROM LIVING DONORS ARE
COMPARABLE TO THOSE FROM DECEASED DONORS
M. Almarastani, A.W. Khan, A. Abdulkareem
King Abdulaziz Medical City
Background: Living donors offer expansion of the donor pool in the era of
donor shortage. The donor shortage is a serious problem in the third world
countries. The aim of this study is to determine if the outcomes of OLT from
deceased livers are comparable to those from living one.
Material and methods: A retrospective review of liver transplant recipients
from deceased and living donor at a single transplant center was performed.
Patient demographics, liver function tests, length of stay, complications, and
patient outcomes were reviewed. Comparisons between groups were done
with Chi-square test and two samples Student t-test with p value < 0.05 being
significant.
Results: Between January 2002 and December 2006, 82 patients underwent
OLT. 25 were from living and 57 from deceased donors. The mean age of
recipients in the living group was 53.24+/- 9.48 years and 53.33+/- 10.79 years
for deceased group (p=0.96). There were 76% males in the living versus 63%
in the cadaveric group. None of the living group underwent re-transplanted
compared with two patients (3%) of the deceased group. The follow up
period was between 2002- 2007, during this period 84% of living related liver
transplant patients were still alive versus 86% in the deceased group. There
was two out of twenty-five patients (8%) in the living group developed primary
non function versus three out of fifty-seven patients (5%) in the deceased
group. None of the living group had hepatic artery complications versus one
patient (1.7%) in the deceased group. Biliary complications requiring surgery
developed in 12% of the living group versus none in the deceased group. None
of the living group patients had portal vein complication versus one patient in
the cadaveric group. The mean length of stay in the living group was 26+/15.73 days versus 22.62+/-17.65 days in the deceased group (P= 0.4). 4% of
the living group SGOT>2000 vs 56% in the deceased group9 (p<0.05), and 4%
of the living group SGPT>2500 vs 28% in the deceased group (p<0.05). The
mean peak value of total bilirubin in the living was 140.45+/-81.32 mmol/l
versus 175.41+/- 167.19 mmol/l in the deceased group (p=0.37). The mean
peak value of INR in the living was 2.46+/-0.86 versus 2.72+/-1.42 in the
deceased group (p=0.44).
Conclusion: In our series, the biliary complication rate was higher in the
living group, but otherwise there were no significant differences in the other
complication, length of stay, and graft function between liver transplant
patients from living and cadaveric donors. This data suggests that using livers
from living does not place patients at significantly increased risks of morbidity
and mortality. Liver transplantation from living donors provides a safe source
of livers to expand the donor pool in the third world.
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M.K. Ju1,2, K.H. Choi1, K.H. Huh1,2, D.J. Joo1, S.J. Kim1, J. Choi1, M.S.
Kim1,2, S.I. Kim1,2, Y.S. Kim1,2
1
Department of Surgery and 2Transplantation Institutes Yonsei University
College of Medicine, Seoul, Korea
Risk of donor mortality and morbidity is major obstacle in living donor liver
transplantation. The goal of this study is to assess unexpected complications
and satisfaction after donation process.
Methods: Fifty-five adult living donors who underwent right (n=45) or
extended right lobectomy (n=10) for living donor liver transplantation between
September 2005 and December 2007 were enrolled in this retrospective study.
The mean age of donors was 32.1 ± 10.5 years old (16-52 years old). The mean
follow-up time for the donors was 12.3 months (2–26 months).
Result: Majority of donor type were related donor (33 offspring and 6 siblings),
and spouse and unrelated donor was 6 (10.9%) and 10 (18.2%), respectively.
Mean donor operation time was 440.1 ± 86.6 minutes (362 ~ 645 minutes). Only
one donor was needed transfusion during operation. There was no operation
mortality. Sixteen complications (29.1%) were occurred within 1 month after
operation. Wound complication required secondary closure (7/55; 10.9%) was
most common complication in this study. The bile leakage was another major
complication of donor (5/55, 9.1%), and gastric ulcer bleeding (n=3), portal
vein stricture (n=1), post-operative atelectasis (n=1) and major depressive
disorder (n=1) were followed. Only one patient with bile leakage was need
the operative management, but the others were well controlled by medical or
interventional management. The hospital days of donors with post-operative
complication was significant longer than donors free complication (18.1 ± 6.5
days versus 13.5 ± 3.9 days)(p=0.015). In risk factor analysis for occurrence of
donor complication, we could not define the significant risk factors. There was
no difference of complication rate by demographics and donor type. Especially,
degree of donor hepatectomy that was expressed by residual volume ratio (<
35% or ≥ 35%) was not related with complication rate (p=0.287). We could
obtain the reply about current status of 33 donors. Twenty-five donors (25/33;
78.8%) were satisfied with their donation, however, 19 donors (19/33; 57.6%)
felt the change of daily life after operation. Unexpectedly, more than half of
donors were satisfied with their surgical wound (20/33; 60.6%).
Conclusion: Though there was no donor mortality, the overall complication
rate after adult right lobe donation for liver transplantation was 29.1% in
our center experience. More careful and meticulous surgical techniques for
lowering donor complication are required.
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1310 A CHANGE IN BILIARY ANASTOMOTIC TECHNIQUE
LEADS TO A SIGNIFICANT IMPACT ON COMPLICATIONS
FOLLOWING ADULT LIVING DONOR LIVER
TRANSPLANTATION (LDLT)
A.A. Moss1, K.L. Mekeel1, K.S. Reddy1, M.E. Harrison2, D.D. Douglas2,
H. Vargas2, E. Carey2, T. Byrne2, D.C. Mulligan1
1
Division of Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ, United
States and 2Division of Transplant Medicine, Mayo Clinic Arizona, Phoenix,
AZ, United States
Up to 60% of patients (pts) undergoing LDLT develop biliary complications,
most within the first 3 months postoperatively (PO).
We describe a change in anastomotic technique that significantly decreased the
incidence of biliary complications at our center. This retrospective is a longitudinal
cohort analysis of 77 LDLT completed at our institution since 2001. For the first
59 LDLT, the biliary anastomosis, either duct-to-duct (49) or Roux-en-Y (10)
reconstruction, were completed with a running absorbable suture (Group I). Since
2006 all our LDLT to date (16) have been completed with a running posterior line
and an interrupted anterior row of stitches also using absorbable sutures (Group II).
Since then, the rate of biliary complications (leak and stricture), has significantly
decreased. In Group I bile leaks occurred in 44% of pts and strictures in 63%,
many of the leaks occurring after endoscopic balloon dilatation of strictures. Pts
in Group II had a 6% incidence of both biliary leaks and strictures (p=0.0068 and
p=0.0001 respectively) (Table 1). The mean follow-up was 47 months for Group
I and 8 months for Group II. In both groups most biliary complications occurred
within 3 months PO, with a median of 22 days for leaks and 75 days for strictures.
If we exclude the first 20 pts of our series as a learning curve, bile leaks occurred
in 41% (16/39) in Group I and 6% in Group II. Biliary strictures occurred in 67%
(26/39) in Group I and 6% in Group II, (p=0.0068 and p=0.0001 respectively)
with a mean follow-up of 35 (Group I) and 8 months (Group II).
In conclusion, employing a biliary anastomotic technique using a combination
of running and interrupted sutures significantly decreases the incidence of early
biliary complications in LDLT.
Table 1
Biliary Leak
Biliary Stricture

Group I (Running)
(n=59)
26 (44%)
37 (63%)

Group II (Interrupted)
(n=16)
1 (6%)
1 (6%)
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1312 FUNCTIONAL CAPACITY OF HUMAN ISLETS SHIPPED
LONG DISTANCES
V. Vaithilingam1, T. Romagnoli2, J. Oberholzer2, B. Tuch1
Diabetes Transplant Unit, Prince of Wales Hospital/University of New South
Wales, Sydney, Australia and Division of Transplantation, 2University of
Illinois at Chicago, USA
Background: Human islets produced at an Isolation Centre are shipped to
researchers, usually taking short periods of time to arrive at their destination.
The Diabetes Transplant Unit in Sydney as part of the Chicago Project has
received human islets from Chicago. The aim of this preliminary study was to
investigate the functional capacity of these islets.
Methods: From September to November 2007, two human pancreatic islet
preparations, each consisting of 100,000IEQ, were sent from the University
of Illinois at Chicago to Sydney in CMRL at room temperature. The islets
arrived day 4 post-isolation, and were cultured for a further 2 days before being
encapsulated in 2.2% barium alginate (Transplantation 2007; 83: 1440-7). On
day 11-13 post-isolation, the encapsulated islets were transplanted into the
peritoneal cavity of streptozotocin-diabetic NOD/SCID mice in aliquots of
3000, 2000 or 1000 IEQs. Blood glucose levels (BGLs) and weights of the
animals were monitored and oral glucose tolerance tests (OGTTs) performed on
animals that normalized BGLs. Blood was also collected for human C-peptide.
Results: Viability of the encapsulated islets, as assessed by the fluorescent
markers CFDA and PI, was 80-85%, and the average capsule diameter 588
± 12.μm. In the first preparation, normalization of BGLs was achieved in all
6 animals that received 3000 IEQs within 24 hours of transplantation, and
subsequent OGTTs were normal. In the 2nd preparation, normalization of BGLs
was achieved with both 3000 and 2000 IEQs, but not 1000 IEQs, within 4 days
of transplantation. This critical number of encapsulated IEQs is similar to the
number of unencapsulated human islets required to normalize BGLs of diabetic
immunodeficient mice reported in the literature.
Conclusion: These data indicate the transportation of islets from Chicago to
Sydney does not significantly deteriorate their functional capacity.
1

p value
0.0068
0.0001
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1311 BILIARY COMPLICATIONS IN ADULT TO ADULT
LIVING DONOR RIGHT LOBE LIVER TRANSPLANTS
– LONG TERM RESULTS
A. Cotterell1, R. Fisher1, D. Maluf1, R. Stravitz2, R. Sterling2, V. Luketic2,
A. Sanyal2, M. Shiffman2, M. Posner1
1
Department of Surgery, Virginia Commonwealth University, 2Department of
Medicine, Virginia Commonwealth University
Living donor right lobe liver transplantation provides a functional graft for
adults with end stage liver disease and is one means of alleviating the severe
shortage of donor organs. However, biliary complications are a major cause of
morbidity following this procedure. This report compares the incidence of biliary
complications following Roux en Y versus duct to duct reconstruction. Between
June 1998 and June 2005, 75 patients underwent 77 adult to adult living donor right
lobe liver transplants. A Roux limb was used routinely until September 2000, when
a duct to duct anastomosis was adopted if technically feasible. Of 50 procedures
involving Roux en Y reconstruction, 15 patients (30%) experienced biliary
complications including 8 cases of biliary anastomotic strictures (one requiring
surgical revision), 3 cut surface leaks requiring intervention, 1 anastomotic leak,
1 anastomotic obstruction and 1 excluded segmental duct. Additionally, 5 patients
experienced episodes of cholangitis unrelated to strictures. Of 27 patients with
duct to duct reconstruction, 9 patients (33%)experienced biliary complications
including 6 anastomotic strictures (4 requiring surgical revision), 2 anastomotic
leaks, 1 cut surface leak requiring intervention and 1 excluded segmental duct.
The incidence of biliary complications after adult to adult living donor right
lobe liver transplantation is approximately 30% regardless of the method used
for biliary reconstruction. A duct to duct biliary anastomosis is an acceptable
alternative to Roux en Y reconstruction if technically feasible.
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1313 EVIDENCE FOR INDUCED EXPRESSION OF HLA CLASS
II ON ISOLATED HUMAN PANCREATIC ISLETS: POSSIBLE
MECHANISM FOR HLA SENSITIZATION IN TRANSPLANT
RECIPIENTS
B. Naziruddin1,2 , A. Jackson1,2, J. Connolly1,3, S. Matsumoto1,3, H. Noguchi1,3,
N. Onaca2, M.F. Levy2
1
Institute of Biomedical Studies, Baylor University, Waco, Tx; 2Baylor
Regional Transplant Institute, 3Baylor Institute for Immunology Research
Objective: Pancreatic islet transplantation is a promising treatment for labile
type 1 diabetes mellitus. However, recent reports have shown that islet transplant
recipients develop antibodies to donor HLA class I and class II antigens. Since
human islets do not express HLA class II normally, mechanisms underlying
induction of the alloimmune response are unclear. We hypothesized that under
inflammatory conditions islets will have induced expression of HLA class II
that leads to HLA sensitization.
Method: Human islets isolated from cadaveric donors were divided into two
groups. Group 1 was cultured at 37 ºC for 48 hours as control; Group 2 was
cultured at 37 ºC in presence of 1000 U/ml TNF-α and 100 U/ml IFN-γ for 48
hours to simulate inflammation. After treatment islets were analyzed for the
expression of HLA class II using Real-time PCR (CIITA, HLA DRα and β
chain), immunofluorescence (anti-insulin and HLA class II), and flowcytometry
(anti-HLA class II). Furthermore, HLA class II antibody (DR7) positive serum
from an islet transplant patient was also tested by flowcytometry. Prior to
testing, the serum was cross absorbed with DR7 negative islets to remove nonspecific antibody binding.
Results: Real-time PCR analysis for gene transcripts of HLA-DRα, CIITA,
and HLA-DRβ1 showed 2.41, 5.94, and 1.24 fold increase respectively under
the treated conditions when compared to control. Fluorescent imaging analysis
revealed that islet cells express minimal HLA class II molecules on their
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surface, while the simulation of inflammation increased surface expression
dramatically especially on insulin positive beta cells. Flowcytometric analysis
confirmed the results obtained from imaging. Patient serum containing antiHLA DR7 bound to class II matched islet cells from Group II showing binding
of both IgG and IgM.
Conclusion: It is known that islets are subjected to inflammation during the
peri-transplant period. We conclude that inflammation leads to induction of
donor specific HLA class II molecules on islets. This increased expression may
contribute to the development of alloimmune response, which in turn could
lead to destruction of the islet graft. Minimizing post-transplant inflammation
will lead to prolongation of islet graft survival.
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1315 SHORT-TERM INFUSION OF LOW MOLECULAR
WEIGHT DEXTRAN SULFATE (LMW-DS) IS WELL
TOLERATED IN HUMANS AND INCREASES ENDOGENOUS
EXPRESSION OF ISLET PROTECTIVE HEPATOCYTE
GROWTH
FACTOR (HGF)
P. Schmidt1, C. Magnusson1, O. Korsgren2, B. Nilsson2
TikoMed AB, 2Division of Clinical Immunology, Uppsala University
Introduction: Low Molecular Weight Dextran Sulfate (LMW-DS) attenuates
all parts of the instant blood-mediated inflammatory reaction and is a candidate
drug to prevent early post-transplantation islet graft destruction. An open
single centre study in healthy volunteers was conducted to study LMW-DS
pharmacokinetics, safety and tolerability in humans. The effect of the drug on
endogenous release of various growth factors was also evaluated.
Materials and methods: 34 healthy volunteers, 20 men and 14 women,
were enrolled. In part A of the study, 6 subjects received LMW-DS as one
i.v. bolus dose of 1.5 mg/kg followed by a 20 minutes i.v. infusion of 3 mg/

1
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1316 LATE EPSTEIN BARR VIRUS REACTIVATION IN ISLET
TRANSPLANT RECIPIENTS
P. Cure1, C.B. Leitão2, A. Pileggi1, T. Tharavanij3, D.A. Baidal1, D. Mineo1, K.
Bernetti1, T. Froud1, C. Ricordi1, R. Alejandro1
1
Diabetes Research Institute, University of Miami, 2Endocrine Division of
Hospital de Clínicas de Porto Alegre, RS, Brazil, 3Department of Medicine,
Thammasat University, Pratumthani, Thailand
Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis,
is among the most frequent viral infections occurring after transplantation
being associated to graft dysfunction/rejection and increasing in morbidity
and mortality in this population. In EBV sero-positive (IgG>IgM) solid organ
transplant recipients, the incidence of EBV reactivation might be as high as
~60%. In islet transplantation, all potential recipients must be EBV sero-positive.
Prophylaxis with valganciclovir is given for 3 months after transplantation
and EBV PCR in peripheral blood is measured at least every 6 months as per
protocol. Long-term immunosuppression represents a risk for EBV reactivation,
with the additional risk of post-transplant lymphoproliferative disease (PTLD).
To date, no cases of EBV reactivation and clinical disease have been reported
in the literature in patients following islet transplantation under an Edmontonlike immunosuppressive regimen.
Herein we present the incidence of late EBV-reactivation in recipients of islet
transplantation (IT) under the Edmonton-like protocol. A total of 23 subjects,
16 islet transplant alone (ITA) and 7 islet after kidney (IAK) recipients were
included. Four patients (ITA= 2, IAK n= 2) were excluded due to short-term
follow up (<800 days). Patients were divided in cases (n=4) and controls (n=15)
based on EBV infection detected by PCR. Total time in months since initiation of
immunosuppression (IS) after kidney or islet transplant was calculated. The two
groups were compared in terms of overall exposure to maintenance IS 3 months
prior to EBV detection measured by trough levels of sirolimus and tacrolimus
(24 and 12 hour, respectively) as well as in terms of Hemoglobin A1c.
EBV-reactivation was observed in 4/19 (21%) patients (ITA n=1, IAK n=3).
Two IAK cases had a second recurrence after successful treatment and negative
EBV-PCR (total EBV episodes = 6). Total time on IS was longer in patients
with EBV (126.4±50.5 vs 67.3±32.7 months, p=0.005), but time after IT was
not different between groups (46.6±16.2 vs 52.7±18.9 months, p=NS). No
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T. Ikemoto1, T. Ito5, A. Jackson4, M. Shimoda3, H. Noguchi1,
B. Naziruddin3, Y. Yasunami5, S. Matsumoto1,2, L.F. Marlon2,3
1
Baylor Institute for Immunology Research, 2Baylor All Saints Islet
Laboratory, 3Baylor University Medical Center, 4Baylor University,
5
Department of Regenerative Medicine and Transplantation, Faculty of
Medicine, Fukuoka University
Background: Islet cell transplantation (ICTx) is one of the promising therapies
for type 1 Diabetes Mellitus. However, it has limited use due to certain issues
like the difficulty to convert to normoglycemia with islets from single donor
pancreas. Compared to North America or European countries, there is a severe
organ donor shortage in some countries such as Japan. If it is possible to ship
islets internationally, these severe shortages might be solved. It has already
been shown that it is possible to ship islet within short distance. However, it is
still unclear whether international shipping of islet is safe and effective.
Purpose: The purpose of this study is to evaluate the safety and efficacy
of shipping islets internationally (from USA to Japan) and to evaluate the
efficiency of various islet cell containers.
Method: Three pancreata were procured for this study from January to
February 2008. All pancreata were preserved by the two-layer method and
isolations were performed at our institute based on the Ricordi method. Isolated
islets were packed in gas-permeable and nongas-permeable bags (both form
Baxter) and shipped by air to Japan. Cell numbers, recovery rate, viability,
purity, potency based on static incubation method were investigated.
Results: Mean shipping time was 53.6 ±3.5 hours. Overall mean
numbers,viability,purity of pre-shipping were 34,852 IEq, 92± 2.6%, 48.5±
11.3%. The same parameters post-shipping were 8705 IEq, 92.4± 1.5%,
37.6± 3.3%. Recovery rate of islets post-shipping in gas-permeable bags were
significantly high compared to that in nongas-permeable bags (19.6± 16.4% vs.
60.9± 7.2%, P<0.05, t-test).
Conclusion: Long distance international shipping of islets is possible. It will
be more advantageous when gas-permeable bags were used. This could lead to
a new possibility of islet transplants in countries with limited organ donors and
islet isolation technology by using islets from an international remote center.

kg (simulating the procedure of islet transplantation). Monitoring of activated
partial thromboplastin time (APTT) in whole blood was used to estimate and
control the plasma concentration and results from part A were used to calculate
a dosage regimen in the subsequent part B. Here, 24 subjects were divided into
four groups and received the same treatment as in part A plus a continuous
i.v. infusion of LMW-DS for 5 hours to reach one target APTT per group; 10s
above baseline (i.e. ~35s), 60s, 100s and 150s, respectively. 4 subjects were
given 5000 IU heparin as a reference treatment. Safety, including haemostasis
parameters, was evaluated prior to proceeding to a higher target APTT-level.
Plasma was collected continuously during the infusion and was analysed
for APTT, additional safety markers and the presence of 6 different growths
factors.
Results: In all evaluated subjects receiving LMW-DS, the mean peak APTT
was 187s (SD+/-37s, n=29), obtained at the end of the 20 minutes infusion.
In part B, the predetermined target levels of APTT were reached and kept
without extensive dose corrections. After the 5hrs20min LMW-DS infusion,
the subjects in the highest dose group (target APTT=150s) were back at APTTlevels below 75s within 60 minutes. There was a good correlation between
APTT measured in whole blood and in plasma. Plasma levels of Hepatocyte
Growth Factor (HGF) were increased 100-fold within 20 minutes of infusion
start and persisted more than 8 hours in the two highest dose groups (target
APTT=100s and 150s).
Conclusion: The study demonstrated that LMW-DS, at doses that maintain
APTT at up to 150s for 5h20min, safely could be infused without affecting
the platelet count or revealing other signs of increased bleeding risk.
Pharmacokinetics was determined and confirmed to be favourable from a
safety perspective. Bed-side monitoring of APTT in whole blood was shown to
be a suitable technique to monitor the LMW-DS plasma concentration. Based
on previously published in vivo data, we propose that the endogenous release
of islet protective HGF could be an additional beneficial effect of LMW-DS
during the first critical hours after transplantation.
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differences were observed in overall IS levels of sirolimus (11.7±0.4 vs 11.5±2
ng/ml) and tacrolimus (4.8±0.2 vs 4.6±0.3 ng/ml) between case and control
groups. Similarly, no differences in levels 3 months prior to EBV-reactivation
(or equivalent time in controls) were found. HbA1c was similar (5.9±0.4 vs
6.0±0.6%). Clinical symptoms included chronic fatigue (n=5), glucose instability
(n=1) or no symptoms (n=1). Notably, 4 IAK recipients had history of dialysis,
three of which developed EBV reactivation (NS). In all cases, reduction of IS (at
least 10%) and valganciclovir therapy were required. No PTLD was observed.
Late EBV-reactivation may occur after IAK and less frequently after ITA. Long
term IS therapy may increase the risk of EBV infection/reactivation. We did
not observe any relationship between occurrence of EBV and other variables
(immunosuppressive drug levels and HA1c). Furthermore, direct relationship
between EBV reactivation/infection and islet graft dysfunction/rejection cannot
be established at this point. In recipients of IT, long term follow-up should
include EBV-DNA PCR at least twice a year and/or as clinically indicated.
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1317 IMPROVED LONG-TERM HEALTH RELATED QUALITY
OF LIFE AFTER ISLET TRANSPLANTATION: A 6-YEAR
FOLLOW-UP STUDY
T. Tharavanij1,2, A. Betancourt3, S. Messinger1,4, P. Cure1, C.B. Leitao1,
T. Froud1,5, C. Ricordi1,5, R. Alejandro1,6
1
Diabetes Research Institute, University of Miami, Miami, Florida, USA,
2
Department of Medicine, Thammasat University, Pratumthani, Thailand,
3
Departments of Psychiatry and Behavioral Science, University of Miami,
Miami, Florida, USA, 4Department of Epidemiology and Public Health,
5
Department of Surgery, 6Department of Medicine
Objective: To evaluate long-term effects of islet transplantation (ITx) on health
related quality of life (HRQoL) and to outline possible influential factors.
Research design and methods: Forty ITx recipients completed 344 Health
Status Questionnaires (HSQ 2.0) and 384 Diabetes quality of life questionnaires
(DQoL) between 1996-2007. Assessments were performed pre-ITx, then every
3 months after the first infusion for 18 months and every 6 months thereafter.
The mean follow-up post-ITx was 26±19.5 (3-72) months. Clinical and
metabolic variables, medications and adverse events were recorded.
Results: Sustained improvement in DQoL-impact score was observed at all
time-points post-ITx (increment of 6±3 to 15.5±3, p<0.05). Similarly, worry
and satisfaction scales were significantly better than pre-ITx evaluation for
most time-points. Four-out-of-eight HSQ 2.0 scales demonstrated a significant
improvement at several time-points (increment of 5±2 to 17±4, p<0.05).
Longitudinal analysis, after adjustments for potential confounding factors,
showed sustained improvement in impact scale up to 72 months (increment of 6±2
to 11±3, p<0.05). Longer diabetes duration, higher insulin dosage and occurrence
of adverse events had negative effects on HRQoL. Single islet infusion or islet
after kidney transplant (IAK) recipients showed the lowest values in HSQ 2.0. In
contrast, patients on exenatide therapy had significantly higher HSQ 2.0 scores.
Conclusions: ITx is associated with long-term improvement in HRQoL.
Exenatide usage had a positive effect while single islet infusion, IAK
transplantation, longer diabetes duration, higher insulin dosage and adverse
events had a negative impact on HRQoL scores.
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1318 LONG-TERM METABOLIC AND HORMONAL EFFECTS
OF EXENATIDE ON ISLET TRANSPLANT RECIPIENTS WITH
ALLOGRAFT DYSFUNCTION
T. Froud, R.N. Faradji, S. Messinger, P. Cure, A. Pileggi, D. Mineo, T.
Tharavanij, A. Mendez, C. Ricordi, R. Alejandro
Clinical Islet Transplant Program, Diabetes Research Institute, University of
Miami Leonard M. Miller School of Medicine, Miami, FL, United States
Context: The initial success of Islet Transplantation (ITx) is followed by graft
dysfunction (GD) and insulin reintroduction. Exenatide, a GLP-1 agonist,
increases insulin and decreases glucagon secretion and has potential for β-cell
regeneration. To improve functional-islet-mass, exenatide treatment was given
to ITx recipients with GD.
Objective: Assess metabolic and hormonal effects of exenatide in GD.
Design: Prospective, single-arm, 12-month duration.
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Patients or other participants: Eleven type-1-diabetes recipients of ITx with GD.
Interventions: Exenatide injection.
Main outcome measures: HbA1c, weight, insulin requirements and mixedmeal tolerance-test (MMTT; with/without exenatide given before test) at
baseline, 3, 6 and 12 months after initiating exenatide.
Results: Baseline MMTT showed postprandial hyperglycemia and
hyperglucagonemia. Daily exenatide treatment resulted in improved glucose,
increased amylin and decreased proinsulin as assessed by MMTT. Glucagon
responses remained unchanged. Exenatide administration 1-hr before MMTT
showed decreased glucagon and glucose at 0-min and attenuation in their
postprandial rise. Time-to-peak glucose was delayed, followed by insulin,
proinsulin, amylin and C-peptide; indicating glucose-driven insulinsecretion.
Five subjects completed 12-month follow-up. Glucose and glucagon suppression
responses after MMTT with exenatide were no longer observed. Retrospective
3-month analysis of these subjects revealed higher and sustained glucagon
levels that did not suppress as profoundly with exenatide administration,
associated with higher glucose levels and increased C-peptide responses.
Conclusions:
Exenatide
suppresses
the
abnormal
postprandial
hyperglucagonemia and hyperglycemia observed in GD. Changes in amylin
and proinsulin secretion may reflect more efficient insulin processing. Different
degrees of responsiveness to exenatide were identified. These may help guide
the clinical management of ITx recipients.
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1319 OPTIMISING HUMAN SERUM FOR CLINICAL ISLET
ISOLATION
M. Ståhle, A. Andersson, O. Korsgren
Clinical Immunology and Transfusion Medicine, University Hospital,
Uppsala, Sweden
Background: Human serum is regarded as the preferred supplement throughout
the process of clinical islet isolations and culture. However, for safety and
regulatory purposes, mainly related to the risk of transferring infections to the
recipient, many centers involved in clinical islet programs are required to use
human albumin instead. The risk depends on the quality of the test used to
detect pathogens and the epidemiology of the donors. Today the risk of viral
contamination of blood components has been dramatically reduced as a result
of extensive testing of blood donors for different infectious disease markers.
However, the appearance of new pathogens in the population escaping even
the most advanced detection protocols remains a major concern. Pathogen
inactivation (PI) may provide a way to protect from both known and as yet
unidentified agents.
Aim: In many European countries, the Intercept technology is routinely used
for pathogen inactivation of platelets and plasma for clinical use. Intercept
uses small molecules of psoralen which can pass through cell membranes and
capsids. Here, the psoralens bind to the helical regions of the nucleid acid.
When UV-A light (300-400 nm) is applied, the psoralens crosslink to the DNA
and RNA, both free and in the genome, thus blocks both transcription and
replication. It has so far not been tested for inactivation of human serum. The
aim for this study was to evaluate the use of this method on human serum used
for culture of human islets of Langerhan.
Method: Whole blood from normal Swedish donors was allowed to coagulate
and the serum was collected and treated with the Intercept system (PI) or
not (control). Both groups of serum complement inactivated (57Co, 30 min).
Human islets of Langerhan were cultured with PI serum or control serum
(10%) for 4 days under standard conditions (37°C and 5% CO2) including a
medium exchange on day 2.
Result: There was no difference between the two groups in terms of insulin
stimulation index (dynamic glucose challenge) or the amount of ATP compared
with ADP in the cells (energy content in the cells). Likewise, no difference was
found in expression of insulin, IL-6, IL-8, Tissue Factor and MCP-1.
Conclusion: Our results demonstrate that PI provides a solution to an important
safety and regulatory problem in modern cell therapy. PI exerts no negative
impact on the islets and may provide a solution allowing the use human serum
in clinical islet transplantation. A major advantage of PI is that it, due to its
mechanism of action, eliminates also unknown emerging pathogens for which
tests do not exist today.
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1320 EFFECT OF IN VITRO TREATMENT OF ISOLATED
HUMAN ISLETS WITH HUMAN ALPHA1-ANTITRYPSIN
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1321 ISLET ALONE, ISLET-KIDNEY, AND ISLET AFTERKIDNEY TRANSPLANTATION IN ARGENTINA
S. Hyon, M. Barbich, R. Groppa, L. Gimeno, L. Grosembacher, P. Martinez,
R. Marenchino, N. Imperiali, L. Algranati, P. Argibay
Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos
Aires
Introduction: Islet transplantation may be used as an alternative treatment for
type-1 diabetic patients with metabolic instability and inadequate response to
insulin therapy.
Objective: To describe the results with islet transplantation in the pre- and
post-Edmonton Protocol era at a single pancreas and islet transplant center.
Patients and methods: Twenty seven islet transplants were performed in this
series. Twenty were done as simultaneous islet-kidney transplants (SIK), 1
was an islet after kidney (IAK) transplant, and 6 were islet transplants alone
(ITA). Recipients for SIK were type-1 diabetic patients on dialysis due to endstage renal disease who were not eligible for simultaneous vascularized grafts.
An IAK was performed in a diabetic patient who showed loss of pancreatic
graft function following a simultaneous kidney and pancreas transplant done
in France several years earlier. Immunosuppression and peritransplant care for
both SIK an IAK patients were based on the University of Giessen protocol
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1322 SUCCESSFUL SHIPPING OF HUMAN PANCREATA
AND ISOLATION OF PANCREATIC ISLETS BY REMOTE
ISOLATION CENTERS — AN AUSTRALIAN PERSPECTIVE
C. Milner1,4, C. Drogemuller1,4, C. Russell1,4, T. Loudovaris2,4,
W. Hawthorne3,4, T. Kay2,4, P. O’Connell3,4, G. Russ1,4, P. Coates1,4
1
The Queen Elizabeth Hospital, Adelaide, 2Tom Mandel Islet Program,
St. Vincent’s Hospital, Melbourne, 3Center for Transplant and Renal Research,
Westmead Millenium Institute, Sydney, 4Australian Islet Consortium
In North America and Europe the use of central islet processing centers has been
promoted amongst various islet transplantation programs to maximise expertise
in islet isolation. Based on overseas success the Australian Islet Transplant
Consortium adopted this model. Since the inception of the Consortium in 2006,
the Adelaide Transplant Center has shipped pancreata interstate to either of the
Australian islet isolation centers in Melbourne or Sydney. This allows the islet
isolation expertise to be concentrated in these centers, and the isolated islets to
be utilized in specialized transplant units outside of the isolation centers. Islets
from these shipped pancreata, as well as islets from pancreata not procured in
Adelaide, have been successfully returned to Adelaide.
Method: The quality and quantity of islets produced at remote isolation centers
was evaluated. Human pancreata were shipped from Adelaide (n=32) or
Darwin (n=2) by commercial airlines to the Melbourne (n=25) or Sydney (n=9)
isolation centers. Pancreata were shipped using the Two-Layer-Method (TLM)
to Melbourne (25), or preserved with University of Wisconsin (UW) solution
to Sydney (9). The islets were isolated using a modified Ricordi method, after
initially using Roche Liberase®, and lately using Serva® Collagenase and
Neutral Protease. Product release tests for the islets (quantity, purity, viability
index, sterility and stimulation index) were performed at the isolation center,
and at the islet receiving center when adequate islets were received.
Results: Between July 1st 2006 and December 31st 2007 a total of 34 donor
pancreata were procured and shipped from Adelaide, (14M; 20F; age 53.5
years; BMI 27.5). The average time from cross clamp to airport departure was
4hr 7min (Melbourne) and 3hr 12min (Sydney), followed by an additional
2 hr for transportation to Melbourne or 3hr 30min to Sydney, resulting in
total shipping time of <8 hours. One islet preparation was used for an islet
transplant, while 30 of the remaining 33 pancreata produced islets for research.
An additional 5 pancreata sourced from elsewhere had islets returned to
Adelaide (total returned = 35). The average islet yield was 176,940 (range
23,000-366,000), with a purity of 73% (range 45-90%). We have previously
shown that the yield of islets using the TLM with a Cold Ischemic Time (CIT)
of >6 hours is comparable to the yield of islets without using the TLM and
having a short CIT (average 3hr 19mins). However without the TLM and a CIT
of >6hrs, the islet yield was on average 50% less than yields where the TLM
was used. All returned islet products passed the sterility test except one which
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Alpha1-antitrypsin (A1-AT) is a serine protease inhibitor that possesses antiinflammatory properties. In mouse islets, A1-AT treatment protects beta cells
from isolation-associated apoptosis and reduces cytokine-induced cell loss.
When administered to mice, monotherapy with A1-AT prevents diabetes onset
in the NOD model, prolongs graft survival in islet allograft transplantation and
induces strain-specific allograft tolerance. The effect of A1-AT treatment on
isolated human islets in vitro has not been reported. In the present study, we
evaluated the effect of A1-AT on human islets. Islets from five donors were
exposed to clinical grade A1-AT from either of two sources (Prolastin® and
Aralast) each containing comparable elastase inhibitory activity but different
anti-inflammatory properties, as established using human blood cytokine
production assays. Human islets were isolated by semi-automated method
and purified with density gradients. Hand-picked human islets were cultured
for 48-72 hours in the presence of increasing concentrations of A1-AT (0.05
to 0.5 mg/ml, 6-replicate wells) under constitutive culture conditions, and
in the presence of IL-1beta plus interferon gamma, which mimic the early
inflammatory and pro-apoptotic environment that follows human intrahepatic
engraftment. Functional assessments included morphology, cell loss, insulin
content, insulin release, cell viability, cytokine and chemokine secretion,
gene expressions and in vivo beta-cell function following transplantation into
streptozotocin-induced diabetic mice.
Although islets incubated with Prolastin® produced significantly less
constitutive IL-6 and IL-8 secretion and exhibited reduced interferon gamma
gene expression, there was no significant difference in morphology, cell loss,
insulin secretion, insulin content or viability. Prolastin® treatment did not
improve transplantation of human islets into diabetic mice. In contrast, islets
incubated with Aralast produced significantly less constitutive IL-8 (> 50%
reduction) and IL-6 (> 70% reduction). Also, in cytokine-stimulated islets,
Aralast improved morphology and significantly reduced IL-6, IL-8, MCP-1
and nitric oxide levels.
In conclusion, the effects of in vitro A1-AT treatment on human islets suggest
that the protective activity of A1-AT is independent of protease inhibition. The
addition of A1-AT may offer cytoprotection during cadaveric islet isolation.
Furthermore, in light of the safety record of A1-AT in humans, A1-AT pre- and
post-treatment may be beneficial for islet graft survival during transplantation
in humans.

(including the use of steroids). Three patients with brittle diabetes and normal
kidney function received 1, 2 and 3 sequential islet transplants, respectively,
under the Edmonton protocol (steroid free, sirolimus, low-dose tacrolimus, and
daclizumab immunosuppression). Recipient mean age was 42.8 +/- 6.2 years.
Cold ischemia time for pancreas was 7.6 +/- 2.4 h, while kidney cold ischemia
time in SIK cases was 9.3 +/- 2.5 h. Islets were obtained after liberase digestion
of the exocrine tissue in a Ricordi chamber and transplanted without previous
culture into the portal circulation (n=21) or the omentum (n=6). In every case,
90% viability was obtained. Mean islet equivalent number was 6,649.5 +/4,093.3 per kilogram of recipient weight.
Results: Islet graft survival (defined as C-peptide levels =/>0.5 ng/dL) for
intrahepatic transplants at 1-week, 2 months, and 1 year were 57.1%, 35.7%,
and 21.4%, respectively. Mean HbA1c and creatinine at one year were 6.4%
and 1.4 mg/dL, respectively. Post-transplant episodes of hypoglycemia were
reduced in 76%. Mean insulin requirement pre- vs. post-transplantation was
50.4 +/- 5.7 IU/d vs. 44.1 +/- 3.8 IU/d, respectively. One patient with ITA had
an intrahepatic bleeding that required red blood cell transfusion. The presumed
cause of graft failure in the patients with ITA was the insufficient islet mass.
Conclusions: Although in this series none of the patients achieved insulin
independence, all of them evidenced a marked improvement of the metabolic
control, with fewer and less severe episodes of hypoglycemia. Continuing
investigation in the field of islet transplantation worldwide will define its real
role in the treatment of patients with diabetes.
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grew Candida albicans, which was also confirmed at the isolation center. All
islets samples had 100% viability at the isolation centers, and all endotoxin
levels tested were acceptable.
Conclusions: In Australia where centers are geographically remote, donor
pancreata can be received at isolation centers using commercial airlines
with an acceptable CIT to allow successful islet isolation. Viable islets can
be successfully returned to interstate centers using commercial airlines.
Shipped islets have met islet cell quality, quantity and sterility criteria for
transplantation.
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1323 USE OF ACETAMINOPHEN LEVEL TESTING DURING
MIXED MEAL STIMULATION IN ISLET TRANSPLANT
RECIPIENTS USING EXENATIDE
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C. Ricordi1,2, R. Alejandro1,4
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4
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Background: Following the approval of exenatide (Exn) its use in islet
transplant recipients with graft dysfunction was commenced at this institution.
Long term diabetes has the risk of neuropathic complications and gastroparesis,
and Exn has the effect of delaying gastric emptying. This study evaluated the
effect of Exn on gastric emptying during mixed meal testing (MMT) in this
unique population.
Methods: 12 subjects that had received at least one islet infusion and had been
taking exn for more than 3 months were included. 1000 mg of acetaminophen
(Acet) were co-administered with the 12 oz liquid mixed meal stimulus and
levels of glucose, insulin, c-peptide and acetaminophen were measured up to
5 hours post ingestion.
Results: Evaluation of Acet levels during MMT without Exn, demonstrated a
typical emptying pattern in 6 subjects (group 1) and an abnormal pattern in 6
subjects (group 2). Peak Acet levels occurred ≤120 mins in group 1 compared
to ≥180 mins in group 2. Mean peak Acet levels were 92±17.8 and 34.7±28.3
pg/ml in groups 1 and 2 respectively. Mean time to peak was 105±16.4 and
270±118.5 mins in groups 1 and 2 respectively. The administration of Exn
resulted in delayed gastric emptying overall, mean time to peak without Exn
162.5±74.0 mins, with Exn 245±69.9 mins, however subanalysis of groups 1
and 2 demonstrated delay in peak Acet more pronounced in subjects with a
pre-existing normal empyting pattern. Mean time to peak (group 1) without
exn 162.5±16.43, with exn 280.0±49.0 mins and in group 2: without Exn
270.0±118.5, with Exn 230.0±79.7 mins
Discussion: In this small group of subjects the frequency of pre-existing
abnormal gastric emptying was high (50%). Exenatide caused a significant
delay in liquid gastric emptying in subjects that had a normal pattern of gastric
emptying but not in subjects that had pre-existing delay. The significance of
this finding and its contribution to glycemic control remain to be elucidated.
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1324 SUBCUTANEOUS TRANSPLANTATION OF EMBRYONIC
PANCREAS AND NON-INVASIVE IN-VIVO IMAGING IN MICE
WITH TYPE 1 DIABETES
S. Gunawardana, R. Benninger, S. Head, D. Piston
Vanderbilt University
Islet transplantation, a promising treatment for type 1 diabetes, has many
limitations. It requires millions of donor islets, initial invasive surgery and
lifelong immuno-suppressive therapy. Success is low due to graft rejection;
poor vascularization; and difficulty to monitor graft viability in-vivo. We
have developed a strategy with the potential to overcome all these problems.
This technique includes minimally-invasive transplantation of mouse
embryonic pancreatic tissue expressing green fluorescent protein(GFP) into
the subcutaneous space of recipients with diabetes, and non-invasive in-vivo
monitoring of transplants using two-photon excitation microscopy(TPEM).
This strategy, if successful, can be easily customized for human patients using
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stem cell-derived islet-like cell clusters.
Using embryonic pancreata instead of mature islets has many advantages.
Embryonic tissue, being immune-privileged, can survive better within a
foreign host. Being a built-in source of angiogenic factors, embryonic tissue
can achieve successful vascularization even in a site with poor vascularization
potential. Furthermore, an embryonic pancreatic bud, not much larger than
an islet, can develop into a mature endocrine pancreas inside the recipient,
eliminating the need for many donor islets. Unlike traditional transplantat sites,
subcutaneous tissue is superficial and easily-accessible, eliminating the risks
and inconveniences in initial invasive surgery, and can be used repeatedly if
necessary. Transplants can be placed in a minimally invasive manner with
minute incisions and no sutures.
Current success rate of transplantation therapy is low. A major difficulty
in finding and addressing problems is the lack of techniques to monitor
transplant development in-vivo. There are no suitable techniques in
humans, and the techniques used in research animals are invasive, involving
chronic instrumentation or repeated surgery. Confocal microscopy often
used for imaging transplants involves high laser intensities that cause
tissue damage. The ideal transplant-monitoring technique should be
painless, non-invasive, and not harmful to live tissue. Imaging GFPexpressing subcutaneous transplants by TPEM is such a technique. Our
donor embryonic pancreata come from mice expressing GFP under
regulation of the insulin-1 promoter, causing beta cells to emit bright green
fluorescence. TPEM can produce optical sectioning up-to 1 mm depth
inside the tissue, and causes minimal photo-damage. With TPEM we can
detect subcutaneously transplanted GFP-expressing embryonic pancreata
non-invasively from the skin surface.
We have successfully transplanted embryonic pancreata subcutaneously into
several recipient strains, and optimized imaging parameters for non-invasive
in-vivo graft-monitoring with TPEM. Preliminary data show survival,
vascularization, and differentiation of transplants into insulin-containing
islet-like structures; and considerable improvement of blood glucose
homeostasis in diabetic mice. Provided these transplants can permanently
reverse diabetes, this technique would eliminate many problems in current
transplantation therapy. We hope to test its success at a larger scale in several
models of type 1 diabetes, determining whether subcutaneously transplanted
embryonic pancreata can a)survive within non-immune deficient hosts
without immuno-suppression; b)achieve vascularization comparable to renal
subcapsular transplants; and c)reverse diabetes, with or without facilitation
techniques to help their survival. In light of recent advances in stem cell
research, this technique, if successful, would be applicable towards human
transplantation therapy, and would pave the way towards a much greater
transplant success rate.

POSTER BOARD NUMBER P2 – 124
1325 C5A INHIBITORY PEPTIDE COMBINED WITH
GABEXATE MESILATE IS A CLINICALLY AVAILABLE
CANDIDATE FOR PREVENTING THE INSTANT BLOODMEDIATED INFLAMMATORY REACTION
K. Tokodai1, M. Goto1.2, T. Imura2, N. Ogawa1, K. Fujiori3, Y. Kurokawa2,
H. Okada4, S. Satomi1
1Division of Advanced Surgical Science And Technology, Tohoku University,
Sendai, Japan, 22Tohoki University Biomedical Engineering Research
Organization, Tohoku University, Sendai, Japan, 33Division of Surgical
Oncology, Tohoku University, Sendai, Japan, 44Choju Medical Institute,
Fukushimura Hospital, Toyohashi, Japan
Background: The instant blood-mediated inflammatory reaction (IBMIR),
characterized by activation of both the coagulation and complement cascades,
is one of the main obstacles to successful islet engraftment. We have thus
far shown that a low molecular weight dextran sulfate efficiently attenuates
xenogeneic IBMIR triggered by porcine islets (Transplantation:2004:77:741
-747). No attractive protocol, however, is clinically available yet. Therefore
the aim of the present study was to examine whether complementary peptide
against an active region of C5a, proved to be safe due to extremely low
molecular mass, in combination with clinically available anti-coagulant could
provide an effective protocol for suppressing IBMIR.
Methods: Three islet equivalents/g of syngeneic rat islet grafts were
transplanted intraportally into 6 pairs of streptozotocin-induced diabetic rats.
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Islets from the same donor were transplanted to each pair and for each pair,
one rat was treated with C5a inhibitory peptide (bolus: 4 mg/kg, continuous
infusion: 0.42 mg/kg/hr for 3 days) in addition to a continuous intravenous
infusion of gabexate mesilate (2 mg/kg/hr) 30 minutes prior to islet infusion
and up to 1 hour after the infusion. The other recipient was injected with
equivalent amount of saline and served as a control. Two rats were treated
with the same dose of gabexate mesilate. The curative rate, the duration to
normoglycemia, insulin amount in the liver of the recipients, and in vivo
glucose tolerance tests were evaluated.
Results: The curative rate was remarkably improved (100% vs. 33.3%,
p=0.005) and the duration to normoglycemia in cured animals was significantly
shortened in treated group (12.2 }1.4 vs. 25.0 }0.0, p=0.039). Two rats only
received the gabexate mesilate did not restore normoglycemia during the whole
study period. No difference was observed between the groups in terms of
glucose tolerance (AUC:p=0.85, Kg:p=0.35). However, insulin amount in the
liver was considerably higher in treated group than that in control group (18.0
}3.2 vs. 12.0 }1.0 ng/IEQs p=0.14). Notably, the increase of body weight in
the recipients was not affected by treatment (the increase rate of body weight:
128.6 }1.2% vs. 127.7 }3.3%, p=0.80), suggesting that C5a inhibitory peptide
combined with the gabexate mesilate is considered to be free from the side
effect.
Conclusions: These data suggest that C5a inhibitory peptide combined with
gabexate mesilate could be an attractive drug candidate, without side effects,
to control the detrimental innate immune responses induced in clinical islet
transplantation.

1326 A NOVEL PREDICTIVE METHOD FOR ASSESING THE
QUALITY OF ISOLATED PANCREATIC ISLETS USING
A SCANNING ELECTROCHEMICAL MICROSCOPY
M. Goto1, H. Abe1, T. Ito-sasaki1, M. Goto1, A. Inagaki1, N. Ogawa2,
K. Fujimori3, Y. Kurokawa1, T. Matsue4, S. Satomi2
1
Tohoku University Biomedical Engineering Research Organization, 2Division
of Advanced Surgical Science and Technology, Tohoku University, 3Division
of Surgical Oncology, Tohoku University, 4Graduate School Environmental
Studies, Tohoku University
Aims: The current standard methods for evaluating islet potency are not useful
in clinical islet transplantation. Furthermore, most tests are relatively subjective
and time-consuming. Therefore, establishment of reliable and rapid methods
enabling accurate prediction of islet quality is warranted.
Methods: In the present study, we have evaluated the respiratory activity
using a scanning electrochemical microscopy (SECM), glucose stimulated
respiratory activity, glucose stimulated insulin release, ADP/ATP assay, levels
of insulin/DNA, and Trypan blue exclusion test as predictive methods for the
ability of isolated rat islets which were exposed to various degrees of heat
shock stress (0, 40, 50, 60, 80 seconds) to cure Streptozotocin-induced diabetic
syngeneic rats.
Results: Although glucose stimulated respiratory activity, basal respiratory
activity, ADP/ATP ratio, and glucose stimulated insulin release was
significantly correlated to the outcome of transplantation into diabetic rats
(p<0.0001, <0.0001, <0.0001, and 0.002: ƒÏ=0.80, 0.71, -0.66, and 0.53,
respectively), there was no correlation between islet transplantation outcome
and insulin/DNA ratio, and Trypan blue exclusion test. The glucose stimulated
respiratory activity in islet preparations that could cure diabetic rats was
significantly higher than in those unable to cure diabetes (1.94 }0.18 vs. 0.57
}0.07: p<0.0001). Rat islets with the glucose stimulated respiratory activity
more than 1.5 consistently cured diabetic rats, whereas rat islets with a value
less than 1.5 hardly cured any rats (p<0.0001). Notably, the predictive rate
for curing diabetic rats was 91% when glucose stimulated respiratory activity
was employed.
Conclusions: A measurement of the glucose stimulated respiratory activity
using a SECM technique is a novel method that could be applied as a rapid and
potent predictor for the outcome of clinical islet transplantation.

1327 ADENOSINE HAS AN INHIBITORY EFFECT ON
NKT CELLS FACILITATING TO PREVENT EARLY LOSS
OF TRANSPLANTED ISLETS IN ASSOCIATION WITH
ENGRAFTMENTS
T. Nitta1, N. Matsuoka1,2, T. Itoh1, T. Mera1, A. Kinjo1, M. Nakano1,2,
Y. Yamashita2, Y. Yasunami1
1
Dept of Regenerative Med and Transplantation, Fukuoka University, 2Dept of
Gastroenterol Surg, Fukuoka University
The limited success in achieving insulin-independence of a single IDDM
recipient from one donor hampers clinical application of pancreatic islet
transplantation. One of the major reasons for this includes early loss of
transplanted islets in association with engraftments. Previously, we have
shown that NKT cells play an essential role in the early loss of transplanted
islets in the liver of mice (JEM 202:913, 2005), which prompted us to screen
drugs which have already been introduced in clinics and have an inhibitory
effect on NKT cells. Here we demonstrate that adenosine fulfills the criteria.
A single injection of adenosine (ip, 5mg/kg) at the time of islet transplantation
ameliorates hyperglycemia of STZ-diabetic mice (C57BL/6) receiving 200
syngenic islets, which otherwise remained hyperglycemic by 60 days after
transplantation. Two hundreds is a number of islets isolated from a single
mouse pancreas. In the liver of @diabetic mice receiving islets and treated with
saline as a control, hepatic NKT cells become activated and Gr-1+CD11b+
cells (neutrophils) accumulated into the liver by 6 hours after transplantation
with up-regulation of their IFN-ƒÁ production, essential for early loss of
transplanted islets. In marked contrast, a single injection of adenosine (ip,
5mg/kg) at the time of islet transplantation down-regulates IFN-ƒÁ production
not only of NKT cells but Gr-1+CD11b+ cells in the liver receiving islets,
although accumulation of Gr-1+CD11b+ cells was similarly seen. IFN-ƒÁ
production of NKT cells in the liver of mice treated with iv administration of
ƒ¿-Galactosylceramide, a synthetic ligand of NKT cells was down-regulated
by a single injection of adenosine. Inhibitors of adenosine transporter on the
cellular membrane such as dipyridamole (persantin) and S-(4-nitrobenzyl)-6thioinosine (NBTI) have similar effects to adenosine with respect to prevention
of early loss of transplanted islets. The beneficial effect of adenosine was also
the case in diabetic mice (C57BL/6) receiving allogeneic islets (BALB/c) when
alloimmune rejection was prevented by anti-CD4 antibody. These findings show
that increased level of extracellular adenosine has an inhibitory effect on NKT
cells facilitating to prevent early loss of transplanted islets. Thus, adenosine has
a potential to increase the success rate of clinical islet transplantation when the
beneficial effect of adenosine holds true in humans.

POSTER BOARD NUMBER P2 – 127
1328 PREDICTION OF LONG-TERM CLINICAL
OUTCOME BY VIABLE DUCTAL CELL MASS IN ISLET
ALLOTRANSPLANTATION
H. Ichii, A. Miki, A. Mita, S. Barker, T. Yamamoto, Y. Sakuma, L. Inverardi,
R. Alejandro, C. Ricordi
Diabetes Research Institute, University of Miami
Background: Recent improvements in islet isolation and immunosuppression
have allowed transplantation of human islets of Langerhans to become a viable
treatment for patients with long-standing type 1 diabetes mellitus (T1DM).
However, improving long-term islet graft function is highly desired in current
clinical trails. It is well known that human islet preparations includes a
substantial amount of non-endocrine cells as well as endocrine cells. Ductal
cells could be potentially beneficial for islet survival and expansion of
islet cell mass, but could also adversely affect islet survival due to the proinflammatory cytokine/chemokine production. We have developed a method
for the assessment of fractional beta and ductal cell viability and content, using
FACS and Laser scanning cytometer (iCys). Objective of this study was to
examine whether transplanted viable ductal cell mass affect clinical outcomes
in islet allotransplantation.
Methods: Nineteen islet preparations transplanted in Diabetes Research Institute,
University of Miami were retrospectively assessed. Beta-cell and ductal cell
viability were assessed by FACS using a four-color analysis (7-AAD, Newport
green, TMRE, CA19-9). Beta-cell and ductal cell content were assessed using
iCys. Viable beta-cell Equivalent Number/kg (vbetaEQ/kg recipient weight) and
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viable ductal cell Equivalent Number/kg (vdEQ/kg) were calculated using the
formula (islet beta-cell content x beta-cell fractional viability x IEQ/kg, Viable
beta-cell Equivalent Number/kg x%ductal cell /%beta-cell) and compared to
clinical outcomes (exogenous insulin requirement). Recipients were divided
into two groups based the change of insulin requirement between 3 months
and 2 years after the last transplantation. (Group 1, n=5, insulin requirement
increased; Group 2, n=7, decreased or no change)
Results:Average transplanted islet mass was 576,122±177,570IEQ, 9,395±2,577
IEQ/kg, 2,766±1,199 vbetaEQ/kg and 1,793±1,156 vdEQ/kg. Beta-cell content
and beta-cell fractional viability were 43±12 and 68±16%, respectively. Ductal
cell content and viability were 12± 6.8 and 80± 8.8%. Three out of 5 in Group
1 and 4 out of 7 in Group 2 became insulin independent. In transplanted Islet
mass and viable beta-cell mass, there was no significant difference between two
groups (Group I vs. Group 2; 8,552±1,740 vs. 10,020±2,830 IEQ/kg, p=0.29;
2,533±1,066 vs.3,027±1,261 vbEQ/kg, p=0.48, respectively). However,
viable ductal cell mass in Group2 was significantly higher than that in Group1
(2,303±993, 976±795 vdEQ/kg, p=0.027, respectively).
Conclusions: The recipients received higher amount of viable ductal cell
mass showed significantly better long-term graft function. Our data suggest
that integrated assessment of ductal cell mass as well as viable beta-cell mass
might be assistance in developing the strategy to improve long-term islet graft
function.
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1329 LOWER EXPRESSION OF ANTI-OXIDANT ENZYMES IN
HUMAN BETA CELL ACCOUNTS FOR THE VULNERABILITY
TO REACTIVE OXYGEN SPECIES
A. Miki, C. Ricordi, A. Mita, S. Barker, R-D. Molano, L. Inverardi,
A. Pileggi, H. Ichii
Diabetes Research Institute
Objective: Recent reports have showed wide variations in beta-cell content
of human islet preparations, which appears substantially lower when
compared to the „d80% reported in rodents. Reactive oxygen species (ROS)
such as hydrogen peroxide, free radical, and superoxide have been reported
to be noxious to human islets. During islet isolation, islets are exposed to
ROS, causing to islet cell injury. As a defense mechanism, human tissues
have antioxidant enzymes, such as catalase and superoxide dismutase (SOD).
In this study, we examined the expression of these antioxidant enzymes
in cell subsets from human islet preparations, in relation to the change of
cellular composition observed during islet cell processing and following
transplantation.
Materials and methods: Single human islet cell preparations (Accutase
Dissossiation method) were double-stained with anti-catalase, anti-SOD1
or anti-SOD2 antibody, along with either anti-C-peptide, anti-Glucagon,
anti-Somatostatin or anti-CK19 antibodies, to quantify the expression of
antioxidant enzymes selectively into beta-, alpha-, delta- and ductal cells.
Human islets cultured with or without H2O2 (50£gM) for 24 hours were
assessed to examine the ROS-mediated vulnerability of each cell subset.
Cellular composition in pre-isolation pancreatic tissue samples was analyzed
by confocal microscopy, while cell subpopulation analysis of isolated islets
and renal sub-capsular islet grafts (diabetic nude mice) was performed using
an iCys/LSC.
Results: Intracellular catalase expression in alpha- and ductal cell was
significantly much higher compared to beta cells and delta cells, which
appeared negative. However, there was no significant difference in SOD1
and SOD2 expression among beta-, alpha-, delta- and ductal cell. H2O2
significantly reduced the beta/alpha cell ratio compared to islet without H2O2
(beta/alpha = 1.20 vs. 0.78, P<0.05). The beta/alpha cell ratio significantly
decreased following each step of islet cell processing and transplantation
(Pancreas vs. Post-Isolation vs. Post-Transplantation: 3.58 vs. 1.52 vs. 1.02,
P<0.05).
Conclusion: Absence of any significant catalase expression in human betacells was associated with an increased vulnerability against oxidative stress,
which was paralleled by a beta-cell loss during islet isolation and following
transplantation. Prevention of beta-cell oxidative stress before and after
islet transplantation may be of assistance to improving clinical transplant
outcomes.
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1330 A REAPPRAISAL OF THE PASSENGER LEUKOCYTE
MODEL OF ISLET ALLOGRAFT IMMUNOGENICITY
R.G. Gill1, J. Beilke2
1University of Alberta / Alberta Diabetes Institute, 2University of California,
San Francisco
Background: Donor-derived antigen presenting cells, or ‘passenger
leukocytes’, can play a major role in triggering islet allograft rejection. This
concept has implied that ‘direct’ (donor APC dependent) antigen presentation
predominates in initial islet allograft immunity. However, ‘indirect’ (host APC
dependent) CD4 T cells are known to contribute to allograft rejection. In the
current study, we tested this long-standing passenger leukocyte model by
determining the relative role for donor MHC expression, donor APCs, and host
CD4 T cells for islet allograft rejection.
Methods: Streptozotocin-induced diabetic BALB/c (H-2d) recipient mice
were grafted with 400-450 islets from either wild-type C57Bl/6 (B6, H-2b), B6
MHC class II-deficient (C2D), or B6 MHC class I (β2m-/-) and class II (C2D)
double deficient mice. In some cases, donor-derived passenger leukocytes were
depleted using five days of 95% O2 culture prior to transplant. Analysis of such
cultured islets indicated undetectable levels of remaining donor-derived CD45+
cells. Finally, recipients were sometimes depleted of either CD4 or CD8 T cells
during the peri-transplant period with monoclonal antibody treatment (GK1.5
and 2.43, respectively).
Results: If donor APCs are required to directly activate host CD4 T cells,
then donor-derived APCs should require MHC class II expression. However,
C57Bl/6 (B6) MHC class II-deficient (C2D) islet allografts (n=8) were
acutely rejected in allogeneic BALB/c recipients within three weeks, a
time course comparable to wild-type C57Bl/6 islets (n=10). B6 MHC I/
II double-deficient islets were uniformly accepted >100 days in BALB/c
mice (7/7), indicating that donor MHC expression could be rate limiting
for allograft rejection. Furthermore, rejection of C2D islet allografts was
CD4 T cell-dependent; anti-CD4 antibody treatment prevented rejection
of both C2D and B6 islet allografts (5/9 versus 6/9 grafts surviving > 100
days, respectively, p < .02). Rejection of C2D islets was also CD8 T cell in
that anti-CD8 treatment resulted in long-term survival of C2D islets in 5/12
recipients (p < 0.05).
Importantly, the rejection of C2D islets was nevertheless donor APC-dependent.
Pretreatment of either C2D or B6 islets in 95% O2 culture to eliminate donor
APCs resulted in long-term allograft acceptance (>100 days in 5/5 versus 4/4,
respectively).
Conclusions: The finding that the rejection of C2D allografts is CD4 T cell
dependent strongly suggests that ‘indirect’ (host APC dependent) antigen
recognition can play a significant role in triggering islet rejection. Conversely,
the findings that CD8 T cells and donor MHC expression also are important
for allograft rejection supports a role for ‘direct’ alloantigen recognition.
Importantly, CD4 T cell dependent rejection of C2D islets remains donor APC
dependent in vivo.
Taken together, these results suggest that ‘passenger leukocytes’ are not
merely the source of ‘direct’ donor antigen presentation to initiate immunity
but can also be an important source of donor antigen for the indirect pathway
of allorecognition. These results further imply that donor APCs, rather than
islet parenchymal cells, are an important source of antigen for such indirect
recognition in vivo.
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1331 POTENTIAL REGULATORY EFFECT OF
NICOTINAMIDE ON EARLY ISLET FAILURE FOLLOWING
INTRAPORTAL TRANSPLANTATION

POSTER BOARD NUMBER P2 – 131
1332 EXPRESSION OF CELL DEATH AND INFLAMMATORY
MEDIATORS IN HUMAN ISLETS POST ISOLATION
P. Campbell, L. Mariana, G. Jhala, S. Fynch, T. Loudovaris, J. Allison,
H. Thomas, T. Kay
St. Vincent’s Institute
Allogeneic human islet transplantation replaces the insulin producing beta
cells and corrects the blood glucose levels in type 1 diabetic recipients,
replacing the need for daily insulin injections. Islets are exposed to a number
of insults during the isolation procedure including mechanical stress,
hypoxia, temperature variations and enzyme impurities. These insults may
lead to functional impairment resulting in loss of viable beta cell mass. We
hypothesize that beta-cell damage and death before, during and after islet
isolation and transplantation are factors affecting the number of islets required
to achieve insulin independence. Using human islets from the Tom Mandel
human islet transplant program we aim to determine if expression and/or
activation of genes involved in inflammation and cell death correlate with
islet function after transplantation. The inflammation -regulated molecules
class I MHC and Fas were detected on the islet cell surface by flow cytometry,
but there was no significant difference in these levels 3, 24 or 48 hours post
isolation. This indicates that the types of stress experienced by islets during
the isolation procedure do not change the levels of class I MHC or Fas. Real
time PCR using RNA isolated from human islets revealed very low levels
of expression of members of the Bcl-2 family that regulate apoptosis by
controlling mitochondrial integrity. Molecules predicted to improve transplant
engraftment including insulin, and anti-apoptotic Bcl-XL and Bcl-2, were

POSTER BOARD NUMBER P2 – 132
1333 DEFINING THE IMMUNE RESPONSE LEVELS IN
ISLET ALLOTRANSPLANTATION BY THE IMMUNE CELL
FUNCTION ASSAY IMMUKNOW™ CYLEX®
D. Mineo2, P. Cure1, D.A. Baidal1, T. Froud1, G. Selvaggi1, A. Khan1,
N.S. Kenyon1, L. Inverardi1, C. Ricordi1, R. Alejandro1
1
Diabetes Research Institute, Miller School of Medicine, University of Miami,
Florida, USA and also 2Department of Internal Medicine, School of Medicine,
Tor Vergata University of Rome, Italy
Immunosuppressive management in islet transplantation is mainly based on drug
blood levels, metabolic parameters and clinical course. None of them is completely
reliable in preventing rejection, infections or toxicity-related side-effects.
Immuknow™ by Cylex® is a simple and FDA-approved test, currently used
to modify immunosuppression in solid organ recipients. It detects the immune
cell function of immunosuppressed patients by measuring the ATP levels of
phytohemagglutinin-stimulated CD4+ T-lymphocytes, thus defining 3 zones
of immune response, as strong (>525ng/mL), moderate (226-524) and low
(<225), significantly correlated with clinical outcomes: rejection, graft stability
or infections/side-effects, respectively.
To define the immune response in islet transplantation by the Immuknow™
assay, to help in managing graft stability and reduce the immunological risk.
We studied 26 islet recipients with functioning allografts in different
immunosuppressive protocols. A total of 152 samples, corresponding to at
least 2 immunological tests for each patient during a 20-month follow-up
period, were analyzed. Clinical status was evaluated at the time of the test
and recipients categorized in groups according to graft function or episodes of
infections or side-effects.
Recipients with stable islet grafts showed ATP levels (mean±SD) of 211±48ng/
mL, those with graft dysfunction of 340±95ng/mL while those with infections
or toxic side-effects of 73±33ng/mL (the same patient may having different
clinical events during follow-up).
Statistical analyses showed significant correlations between ATP values and
either leukocytes (r=0.40 p<0.01), CD4+ T-lymphocytes (r=0.42 p<0.01) and
fasting plasma glucose (r=0.26 p<0.05).
This retrospective observational study has defined the immune response values
in islet transplantation. ATP levels for islet graft stability (211ng/mL) were
lower than for solid organs transplant (249ng/mL) but similar to the ones for
whole pancreas transplantation, (194ng/mL).
Immuknow™ Cylex® assay can be of utility in islet transplant recipients, to
reduce the risk of rejection, infections or side-effects.
Figure: Immune response levels in Islet Transplantation
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S-J. Kim1,2, D-Y. Jung1, S-K. Lee2, J-W. Joh2, J-M. Chun2, G-O. Jung2,
J-M. Kim2, U-J. Kyung2, H-J. Park2, H-T. Jung2
1
Transplantation Research Center, Samsung Biomedical Research Institute,
Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department
of Surgery, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea
Intrahepatic human islet transplantation has been raised as a potential cure
for diabetes mellitus, especially in patients with type 1 diabetes. However,
early graft failure following intraportal islet transplantation represents a
major obstacle for successful islet transplantation. Islets exposed to blood are
subject to an immediate blood-mediated inflammatory reaction (IBMIR) that
involves the activation of coagulation and complement systems. Therefore, we
examined beneficial effect of nicotinamide (NIC) to prevent IBMIR-induced
islet destruction in a model of syngeneic islet transplantation in STZ-induced
diabetic C57BL/6 mice.
Chemically induced C57BL/6 diabetic mice underwent intraportal syngeneic
islets transplantation with various doses, such as 250, 300, 350, and 400 IEQ.
Nonfasting serum glucose levels were evaluated after transplantation of islets
cultured with or without 10 mM NIC. To the confirm islet function following
intraportal islet transplantation, intraperitoneal glucose tolerance test (IPGTT)
and hepatectomy were carried. After 3 and 24 hours of islet transplantation, the
effects of NIC were evaluated by blood cell count, monocyte chemoattractant
protein-1 (MCP-1) serum level, and immnohistology.
NIC-treated islet transplantation via intraportal vein promoted to decrease high
blood glucose level in syngeneic diabetic C57BL/6 recipients. In addition, 15
days posttransplantation, the function of islet grafts was higher in NIC treated
group than in the untreated. Among the various islet doses, recipient infused
with 300 IEQ was exhibited markedly difference of the effect of NIC treatment
on glucose tolerance. 1 day after islet 300IEQ transplantation, islets treated
with NIC were significantly well-granulate (p = 0.001), NIC-treated islet grafts
also showed the decrease of serum MCP-1 concentration in comparison with
those of the control. In the long-term survival graft (> 100 days), about 80% of
liver was removed and then diabetes was recurrent.
These findings clearly demonstrate that NIC may function to prevent prompting
the deterioration of the islet grafts in syngeneic mouse model.

observed at elevated levels in islets that normalised blood glucose in diabetic
scid mice, while those predictive of poor graft outcome, including proapoptotic Bim and Puma, were elevated in islets that did not normalize blood
glucose in mice. These data suggest that pro- and anti-apoptotic members of
the Bcl-2 family may be useful as predictive markers of islet function after
transplantation.
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1334 ZINC TRANSPORTER EXPRESSION IN ISOLATED
HUMAN ISLETS: HIGH VARIABILITY IN BETA CELL
SPECIFIC ZNT8 EXPRESSION

1335 AN INCREASE IN HOST FOXP3+ REGULATORY T CELLS
IS ASSOCIATED WITH ABROGATION OF AUTOIMMUNITY
AND ISLET GRAFT SURVIVAL IN NOD MICE

C. Drogemuller1,6, C.R. Milner1,6, D.M. Mohanasundaram1,6, A. Kupke1,6, D.J.
Torpy1,2,6, C. Murgia3, W. Hawthorne4,6, T. Loudovaris5,6, G.R. Russ1,6, P.T.H.
Coates1,6
1
South Australian And Northern Territory Islet Program, The Queen Elizabeth
Hospital, 2Department of Endocrinology, Royal Adelaide Hospital, 3INRAN
(National Research Institute on Food and Nutrition), 4Center for Transplant
and Renal Research, Westmead Millenium Institute, 5Tom Mandel Islet
Program, St Vincent’s Hospital, 6Australian Islet Transplant Consortium
Background: β-cells within the pancreatic islet contain the highest
concentration of zinc (Zn) in the human body. Large quantities of Zn are
required to form the zinc-insulin crystals in the secretion vesicles of these cells.
Exocytosis of these vesicles and release of insulin into the circulation occurs
in response to elevated glucose levels. Zn ions cross biological membranes
aided by a set of specialized proteins grouped into two families based on
their structural and functional features. ZRT/IRT-related proteins (ZIP)s are
members of the Solute Carrier Family 39A (SLC39A) while Solute Carrier
Family 30A (SLC30A) comprise the mammalian ZnTs. The primary role of
ZIP proteins is to mediate Zn uptake from the extracellular environment or
from intracellular vesicles into the cytoplasm. In contrast proteins belonging
to the ZnT family were predominantly responsible for Zn efflux from the
cytoplasm towards intracellular vesicles, the extracellular space and to
specific metalloproteins. The Zn transporter gene ZnT8 is expressed primarily
by β-cells of the pancreatic islet and is required to transfer Zn into insulin
secretory vesicles. ZnT8 is found in the membrane of insulin secretory
granules and at the plasma membrane and is thought to play a crucial role in
insulin synthesis, secretion and storage. A single-nucleotide polymorphism in
the gene for ZnT8 was also recently identified as a critical marker for type 2
diabetes risk.
Aim: To compare Zn transporter expression levels between different human
islet isolations.
Materials and methods: Human pancreatic islets from ten pancreatic donors
(age 51±15yrs, BMI 24.3±3.4) were separated by the Ricordi method. RNA
was isolated using Qiagen® RNA kit, prior to reverse transcription and
real time PCR analysis using gene specific Taqman® primers and probe. A
polyclonal antibody to ZnT8 was raised in rabbits and tested on human islet
preparations.
Results: The unique polyclonal antibody to ZnT8 recognises mouse, rat and
human protein expressed in pancreatic islets as well as being functional in
Western Blot. RNA was purified from ten individual human islet isolations
and reverse transcribed for Q PCR analysis. Relative expression levels of
seven Zn transporter genes, ZIP1, ZIP6, ZIP7, ZIP14, ZnT4, ZnT6 and ZnT8
were determined. Little or no expression of ZIP6, ZnT4 and ZnT6 was seen
in any of the preparations. There was a 16 fold difference between the highest
and lowest expression level of ZIP1 in the ten separate isolations, a 6 fold
difference for ZIP 7, a 41 fold difference for ZIP14 and a 25 fold difference for
ZnT8. Although ZIP14 had the largest fold difference it was ZnT8 that showed
the greatest variability between isolations. ZIP1 and ZnT6 expression levels
correlated (r2= 0.8) as did ZIP6 and ZIP7 (r2= 0.83) when compared between
the different isolations. There was no significant relationship to glucose
induced insulin stimulation (Average Stimulation Index 1.66±0.91) between
islet preparations.
Conclusion: Human pancreatic islet preparations expressed a range of Zn
related transporter genes. The antibody to ZnT8 showed cross reactivity with
human islet tissues. Of the transporter genes expressed, ZnT8 gene expression
showed the greatest variability between preparations.

Q. Shi, D.L. Farber, D.W. Scott, S.T. Bartlett
Department of Surgery, University of Maryland School of Medicine,
Maryland, USA, 21201
Objective: We have developed a novel protocol for promoting long-term
acceptance of semi-allogeneic islets in diabetic NOD hosts using antilymphocyte serum (ALS) treatment coupled with injection of donor pancreatic
lymph node-derived (PLNC) CD4 T cells from non-diabetic donors. However,
it is not known the precise phenotypic and functional CD4 subset that mediates
long-term islet graft survival, and whether donor or recipient FoxP3 regulatory
T cells are required for the observed effects.
Methods: Diabetic NOD.NON/Thy1.1+ mice treated with 0.2 ml ALS QOD for
one week were used as recipients. Two islet transplant groups were analyzed:
1. ALS/PLNC group: received 500 fresh islets from diabetes-resistant NOR/
Thy1.2+ donors with intraportal infusion of 3×107 purified NOR PLNC-derived
CD4+CD25- T cells and 2. ALS-alone group: received 500 NOR islets without
PLNC. Some of ALS/PLNC mice were sacrificed normoglycemic at 30 days
post-transplant, while ALS-alone recipients were hyperglycemic by day 20,
indicating islet graft loss and were subjected to immediate flow-cytometric
and histologic analysis. We analyzed the frequency of FoxP3 expression on
CD4 T cells from spleen, pancreatic-draining and non-draining lymph nodes
by flow cytometry. Donor T cells were distinguished from recipient T cells
by Thy1.2 and Thy1.1 expression respectively. Sections of graft-bearing livers
were stained with H&E and anti-insulin.
Results: Co-administration of CD4+CD25- T cells of PLNC in ALS-treated hosts
resulted in dramatic long-term survival of islet grafts with a MST of 93 days
for NOR islets. However, ALS treatment alone was ineffective in preventing
graft loss with a MST of 20 days for NOR islets. We found a significant
enhancement of FoxP3+ T cells in spleen and draining pancreatic nodes in ALS/
PLNC recipients (17%-18%) compared to the ALS-only recipients (6%-11%).
An increased number of FoxP3+ T cells among chimeric donor CD4 T cells was
also observed from prior to transfer (4%) compared to post-transfer (7%). Graft
histology revealed pristine islet grafts and an absence of cellular infiltration in
ALS/CD4+CD25- recipients.
Conclusion: These results demonstrate that an increase of FoxP3 expression in
host CD4 T cells is associated with long-term islet graft survival in ALS/PLNC
treated NOD mice, and suggests that the presence of donor T cells in chimeric
hosts with long-standing islet grafts may be required for that increased FoxP3
expression in the host compartment.
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CONCURRENT ORAL SESSION 96: CULTURE ON ISLETS
POSTER BOARD NUMBER P2 – 135
1336 HYPERGLYCEMIA IN VITRO UP-REGULATES
GROWTH-RELATED CELL CYCLE PROTEINS OF ADULT
MOUSE PANCREATIC ISLETS
S. Hsu, B.R.S. Hsu, S.H. Fu
Chang-Gung Medical Center, Div of Endocrinol and Metabol
In order to study the changes of cell cycle proteins of adult pancreatic islets
during metabolic adaptation, we cultured isolated islets of 12 week-old male
B6 mice in RPMI-1640 complete medium containing either 5.5 mM or 20 mM
glucose. At 0, 1, 3 and 7 days of cultivation, islets were homogenized to prepare
cytosol for PAGE and Western blotting using antibodies against β-actin (housekeeping), p27kip1 (G1/G0 checkpoint), cyclin D1 (G1/S), cyclin B1 (G2/M),
and FoxM1. The cell cycle proteins were expressed as the ratio of band density
of each protein over that of β-actin of the same batch of islet cytosol. At day
1, protein p27 of islets cultured in 5.5 mM and 20 mM glucose was 0.48±0.11
(n=4) and 0.63±0.10 (n=6), respectively, when comparing with that of day
0. Meanwhile, B1 of islets cultured in 5.5 mM and 20 mM glucose elevated
7.01±5.46 times and 11.58±6.19 times at day 1. Proteins D1 and FoxM1 of
islets cultured in 5.5 mM and 20 mM glucose medium were 1.01±0.24 and
1.18±0.23, and 0.98±0.22 and 1.00±0.32, respectively, at day 1 when compared
to that of day 0. At day 3, proteins of p27, B1, D1 and FoxM1 of islets cultured
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in 5.5 mM (n=4) and 20 mM (n=5) glucose were 0.84±0.24 and 0.84±0.12,
3.07±1.47 and 17.16±9.14, 1.77±0.34 and 1.24±0.35, 0.36±0.12 and 0.69±0.23,
respectively, when comparing with that of day 0. Furthermore, at day 7,
proteins of p27, B1, D1 and FoxM1 of islets cultured in 5.5 mM (n=5) and 20
mM (n=7) glucose were 1.20±0.45 and 1.09±0.29, 3.15±1.07 and 14.83±9.31,
0.83±0.27 and 1.26±0.30, 0.45±0.14 and 1.08±0.53 when compared to the
corresponding mean of that of day 0, respectively. In conclusion, (1) adult
mouse islets response to in-vitro cultivation with rapidly reducing p27 and
markedly increasing growth-related protein B1, (2) gradual elevation of p27
along with cultivation days was accompanied with gradual decrease of growthrelated proteins B1, D1, and FoxM1, (3) high glucose medium attenuates p27
elevation but enhances B1 and FoxM1 elevations. Our data suggested that
growth-related proteins of adult mouse islet response rapidly to proliferation
stimuli such as glucose and in-vitro cultivation.

POSTER BOARD NUMBER P2 – 136
1337 ANTI-PRO-INFLAMMATORY EFFECTS OF SIROLIMUS
SUPPLEMENTATION TO THE PRE-TRANSPLANT CULTURE
MEDIA ON HUMAN ISLET PREPARATIONS

POSTER BOARD NUMBER P2 – 137
1338 THE INFLUENCE OF A CURRENT STYLE OF CULTURE
ON THE QUALITY OF ISOLATED PANCREATIC ISLETS
H. Takahashi1, M. Goto1,2, N. Ogawa1, Y. Saitoh1, K. Fujimori3,
Y. Kurokawa2, H. Doi1, S. Satomi1
1Division of Advanced Surgical Science And Technology, Tohoku University,
Sendai, Japan, 2Tohoku University Biomedical Engineering Research
Organization, Tohoku University, Sendai, Japan, 3Division of Surgical
Oncology, Tohoku University, Sendai, Japan
Objectives: Although one of the key factors of Edmonton protocol is
transplanting fresh islets just after islet isolations, it has recently been reported
that the outcome of islet transplantation with short-period culture could be
comparable. This could be based upon the different culture media applied in
each institution. To clarify the influence of a current style of culture on isolated
pancreatic islets, in the present study, fresh islets were compared to those
cultured with several current fashions in terms of islet quality including not
only viability but also inflammatory mediators expressed on the islets.
Materials and methods: The islets isolated from rats were cultured for 48 hours
with CMRL including 10% serum, CMRL including 0.5% human serum albumin
(HSA), and Miami medium including 0.5% HSA as one of the current most
established media. The influence of culture on islet integrity was evaluated by
survival rate of islets during culture and visual scoring. The influence of culture
on islet function and viability was examined by ADP/ATP test, Insulin/DNA
content, glucose stimulation test and transplantation of islets to homogeneous
rats. The influence of culture on the expression of inflammatory mediators in the
islets was examined by western blotting assay for tissue factor (TF) which is the
initiator of detrimental instant blood-mediated inflammatory reactions (IBMIR).
Results: Although the survival rate was similar in all groups, the visual scoring
was lower in Miami medium. Stimulation index in glucose challenge test was
higher in fresh islets than the others (fresh;17.89 }4.93, serum;13.69 }5.44,
HSA;5.36 }1.60, Miami;2.69 }0.82: p=0.02). Insulin/DNA revealed the same
tendency as glucose challenge test (fresh;1.02 }0.07, serum;0.83 }0.11, HSA;0.52
}0.07, Miami;0.37 }0.08: p=0.0005). ADP/ATP ratio was lower in both fresh and
serum group than the others (fresh;0.047 }0.021, serum;0.054 }0.017, HSA;0.086
}0.004, Miami;0.084 }0.026: p=0.38), suggesting that the apoptotic islets are
relatively lower in both fresh and serum group. Most importantly, the expression
of TF on the islets was considerably lower in fresh group, suggesting that a
current style of culture could enhance TF-dependent IBMIR after transplantation.
In transplantation, blood glucose level normalized earliest in a fresh group, and
the serum group showed a good result in the culture group.
Conclusions: In conclusion, isolated islets without prior culture is beneficial to
the transplantation under a current style of culture. Further improvements are
required to optimize a substitute for serum supplement.

POSTER BOARD NUMBER P2 – 138
1339 PROLACTIN SUPPLEMENTATION TO PRETRANSPLANT CULTURE MEDIA IMPROVES BETA CELL
SURVIVAL ON HUMAN ISLET PREPARATIONS
T. Yamamoto1, C. Ricordi2, A. Mita2, A. Miki2, Y. Sakuma2, R.D. Molano2, A.
Fornoni2, L. Inverardi2, A. Pileggi2, H. Ichii2
1
Fujita Health University, 2Diabetes Research Institute, University of Miami
Objectives: Apoptosis are induced in pancreatic islets during islet proceeding
and transplantation. It is critical to prevent the islets from the apoptosis in
culture prior to transplantation for improving islet transplantation outcomes.
Previous studies demonstrated that PRL has cyto-protective effect on insulinproducing cell lines and pancreatic islets in streptozotocin (STZ) treated mice.
In this study, we examined the effect of human recombinant prolactin (rh-PRL)
supplementation to the culture media, to determine whether it could exert
b-cell-selective proliferation and cyto-protection on human islet preparations.
Materials and methods: Pancreatic islets were isolated from 11 donors (Age
40.1 }3.5, Gender 7 males and 4 females, BMI 28.6 }1.5, CIT 646.8 }67.1min).
The purified islets were cultured in Miami defined medium supplemented with or
without 500ug/l of rhPRL for 48 hours. Non-b-cell- and b-cell-specific fractional
viability and cellular composition were assessed by FACS and LSC. Islets were
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A. Mita1,3, C. Ricordi1,4,5, A. Miki1, S. Barker1, R. Haertter1,
Y. Hashikura2, S-I. Miyagawa3, L. Inverardi1, H. Ichii1,4,5
1Diabetes Research Institute, University of Miami Leonard M. Miller
School of Medicine, 2Transplantation Center, Shinshu University School of
Medicine, 3Department of Surgery, Shinshu University School of Medicine,
4DeWitt Family Department of Surgery, University of Miami Leonard M.
Miller School of Medicine, 5Jackson Memorial Hospital Transplant Institute,
University of Miami Leonard M. Miller School of Medicine
Background: Improved islet isolation techniques and immunosuppressive
regimens have made islet transplantation a therapeutic option for patients with
type 1 diabetes mellitus. This success is likely attributable in part to the noble
immunosuppression protocol. Sirolimus (SRL) plays a critical role in facilitating
steroid-free immunosuppression, in conjunction with low dose tacrolimus, in
current islet transplantation. Although several studies have investigated the
effects of sirolimus on islet cells, conflicting results have been reported. In this
study, we assessed the effects of sirolimus supplementation in culture media on
human islet preparations, focusing on the anti-pro-inflammatory aspects.
Methods: After purification, human islet preparations were divided into four
groups: pure (purity >90%) SRL+ (30ng/ml); pure SLR- (0ng/ml); impure (purity
40-60%) SLR+ and impure SLR-. All groups were cultured in Miami-defined
medium 1 with or without sirolimus for 3 days and assessed regarding glucose
stimulated insulin release, fractional ƒÀ-cell viability, and ƒÀ-cell and macrophage
content within human islet preparations. Cytokine/chemokine production from
islet preparations and sorted pancreatic ductal cells were also examined.
Results: Stimulated insulin release in impure SRL+ group was significantly
increased when compared to impure SLR- group (static incubation index: 1.9 } 0.4
and 1.1 } 0.3, respectively, p=0.024), as previously reported, but not in pure SRL+
group. Although fractional ƒÀ-cell viability showed no significant differences, ƒÀcell survival during culture significantly increased in impure SRL+ group when
compared to impure SLR- group (133.6 } 24.2% control, p=0.015). However, both
fractional ƒÀ-cell viability and ƒÀ-cell survival during culture were comparable
in pure SRL+ group. TNF-ƒ¿, IL-1ƒÀ, MCP-1 and MIP-1ƒÀ production from
impure SRL+ group significantly decreased when compared to impure SLRgroup (64.4 } 7.3% control; p=0.003, 79.0 } 4.3% control; p =0.003, 55.9 } 18.8%
control; p = 0.049 and 60.9 } 9.8% control; p=0.007, respectively). Furthermore,
TNF-ƒ¿ and MIP-1ƒÀ production from sorted ductal cells significantly decreased
in SRL+ group (59.2 } 10.3% control; p=0.007, 33.5 } 14.3% control; p=0.004,
respectively). The number of macrophages contained in islet preparations
significantly decreased in impure SRL+ group when compared to impure SRLgroup (55.9 } 27.0% control; p = 0.048), but not in pure SRL+ group.
Conclusions: Sirolimus improved not only stimulated insulin release, but also
ƒÀ-cell survival during culture in impure human islet preparations. In addition,
sirolimus reduced the quantity of macrophages contained in the human islet
preparations, and cytokine/chemokine production especially from ductal cells
which exist more in impure human islet preparations than in pure ones. Although
many investigators have paradoxically reported the effects of sirolimus on
human islet preparations, reconsidering the variability in the purity of human
islet preparations used in those experiments could more adequately elucidate
the discrepancies and allow a better comparison with these results. The antiinflammatory effects of sirolimus, also appear beneficial to islet cells in culture
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exposed to following compounds to induce apoptosis 1h after treatment with or
without rhPRL; S-nitroso-N-acetyl-dl-penicillamine (SNAP), hydrogen peroxide
and cytokine cocktail (CTK;IL-1ƒÀ+TNF-ƒ¿+IFN-ƒÁ). Islet potency was
assessed in vivo by transplantation into diabetic immunodeficient nude mice.
Results: The relative islet b-cell content and relative viable b-cell mass in PRL
group were significantly higher than control group. All transplanted mice achieved
normoglycemia in both groups and there was no significant difference in days of
diabetes reversal and Intraportal glucose tolerance test (IPGTT) between control
and PRL groups, indicating PRL treatment did not alter islet function.
Conclusion: PRL treatment improves b-cell-specific viability and survival in
human islets. The development of novel b-cell-specific cytoprotective strategies
will be of assistance in improving islet transplantation.

POSTER BOARD NUMBER P2 – 139

TUESDAY

1340 EFFECTS OF INSULIN-LIKE GROWTH FACTOR-1 AND
AGE ON PORCINE NEONATAL PANCREATIC CELL CLUSTERS
J-H. Juang1, C-H. Kuo2, B.R-S. Hsu1
1
Division of Endocrinology and Metabolism, Chang Gung University and
Memorial Hospital, 2Department of Biological Science and Technology,
National Chiao Tung University
Islet transplantation has led to insulin independence in humans with type 1
diabetes mellitus. However, a large number of islets are needed to achieve
normoglycemia. To overcome this supply problem, islet tissues from neonatal
pigs have been considered for xenotransplantation. Unfortunately, it takes a
long period to cured diabetic nude mice after transplantation with the porcine
neonatal pancreatic cell clusters (NPCCs). To shorten the latent period
between transplantation of these cells and the reversal of hyperglycemia, we
investigated the effects of insulin-like growth factor-1 (IGF-1) and donor age
on transplantation of NPCCs.
To test whether IGF-1 can modulate the proliferation and differentiation of the
NPCCs, those isolated from 1- to 3-day-old pigs were cultured with IGF-1. The
stimulation index was not significantly different between the NPCCs cultured with
or without IGF-1 at 1, 2 or 4 weeks. Furthermore, at 4 weeks after transplantation
with 300 NPCCs to nondiabetic nude mice, the insulin content of the grafts were
comparable in the recipients of NPCCs precultured with or without IGF-1.
To know whether the NPCCs isolated from 1-month-old pigs (I-B) are functioning
better than those isolated from 1- to 3-day-old pigs (I-A), we compared their
characteristics and effects on transplantation. Soon after isolation, I-B was larger
than I-A. After 6-day culture, I-B contained more insulin than I-A. However, the
stimulation indices of I-A and I-B during static incubation were not significantly
different. Furthermore, both I-A and I-B had no first or second phase of insulin
secretion during perifusion study. Three hundred and 2000 cultured NPCCs were
transplanted to nondiabetic and diabetic nude mice, respectively. In nondiabetic
mice received I-A or I-B, their insulin content and beta-cell mass of the graft at 4
weeks after transplantation were comparable. In diabetic recipients with I-A or I-B,
the blood glucose decreased after transplantation and normoglycemia was achieved
at 8 weeks. Their insulin content of the graft at 3 months was not different.
Our data indicate that: (1) isolated NPCCs cultured with IGF-1 had no beneficial
effects on their in vitro function and transplantation; and (2) NPCCs isolated
from 1- to 3-day-old and 1-month-old pigs had different characteristics but
similar effects on transplantation.

POSTER BOARD NUMBER P2 – 140
1341 IMPROVED HUMAN ISLET QUALITY USING STEROID
WITH EXENDIN-4 FOR PRE-TRANSPLANT CULTURE
A. Miki, C. Ricordi, T. Yamamoto, S. Barker, I. Luca, H. Ichii
Diabetes Research Institute
Objective: Definition of optimal culture conditions for isolated human islets
should aim at providing sufficient oxygen and nutrients in order to allow
for recovery from isolation-induced damage, and preventing islet mass loss.
A wide space for improvements still exists in the methods currently utilized
for pre-transplant culture of human islets. Steroid is known to have an antiinflammatory function to reduce the cytokine/chemokine production from
various cells. However, the effects of steroids during culture on islet cells
have been controversial. Exendin-4 is a GLP-1 analog, which was reported to
enhance the glucose induced insulin secretion and improve clinical outcomes
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in islet transplantation. We examined the cyto-protective and functional effects
of steroid and exendin-4 on human islet cells during pre-transplant culture.
Materials and methods: Human islet isolations were performed using
automated method at Diabetes Research Institute of University of Miami. After
isolation, islets were cultured under following conditions (Group I, Miami
defined medium (MM1); Group II, MM1with 2uM methylprednisolone (MP);
Group III, MM1 with 2uM MP and 10nM exendin- 4). Beta cell fractional
viability, cellular composition, multiple cytokine assays, multiple protein
assays and perifusion were performed.
Results: Fractional beta cell viability of Group II and III were better than
Group I (106.4 } 2.7%, 105.1 } 3.7% control, p<0.05).). Islet beta-cell
content in of Group II (27.1 } 1.0%) and Group III (31.4 } 1.0%) were
higher than Group I (32.7 } 1.8%). In multiple cytokine assays, TNF-alpha,
IL-1, MCP-1,IL-6 and IFN-gamma were significantly lower in Group II
(71.2 } 32.6%, 51.5 } 23.2%, 66.7 } 20.2%, 20.3 } 5.3%, 53.8 } 16.8%,
control respectively, p<0.05) and Group III (68.9 } 14.1%, 63.1 } 22.9%,
66.7 } 20.2%, 24.6 } 6.9%, 55.2 } 14.9% control respectively, p<0.05) when
compared to Group I. In multiple protein assay, Erk-2 was significantly
decreased, insulin secretion in Group III was recovered to be comparable to
Group I in perifusion assay.
Conclusion: Steroid supplementation into culture medium significantly
decreased the cytokine/chemokine production and increased the Erk-2
expression, probably leading to increase the beta cell viability. In addition,
Exendin-4 ameliorated the insulin secretion suppressed by steroid. The use of
steroid and exendin-4 during culture may be a useful strategy in improving islet
transplantation outcomes.

POSTER BOARD NUMBER P2 – 141
1342 EFFECTS OF PITUITARY ADENYLATE CYCLASEACTIVATING POLYPEPTIDE (PACAP) ON HUMAN ISLETS
H. Ichii, Y. Sakuma, A. Miki, T. Yamamoto, A. Mita, S. Barker, R.D. Molano,
L. Inverardi, A. Pileggi, C. Ricordi
Diabetes Research Institute, University of Miami
Selected reagents may provide desirable and effective cyto-protection for
islet cells during processing, increasing islet yield and/or viability. Pituitary
adenylate cyclase-activating polypeptide (PACAP) is an islet substance
serving as an intra-islet amplifier of glucose induced insulin secretion similar
to exendin-4. It has been reported that systemic administration of PACAP
maintained beta-cell mass, delayed the onset of hyperglycemia and resulted
in cyto-protection from glucose toxicity. PACAP increases glucose-stimulated
insulin release in vitro and in vivo. In this study, the effect of PACAP on islet
cells was tested before and after transplantation.
Methods: Human islets were cultured in the presence or absence of PACAP
(10-9 10-14M) for 48 hours. Beta cell viability was assessed by FACS,
cellular composition analysis was performed by iCys/LSC and glucosestimulated insulin secretion was tested. In vivo, islets were transplanted
beneath the kidney capsule of streptozotocin-STZ diabetic nude mice.
Glycemic and insulin levels were assessed by glucose tolerance test
(IVGTT) in presence or absence with PACAP (Peptide International; 1.3
nmol/kg).
Results: There were no significant differences in terms of beta-cell viability
and cellular composition in between islets cultured with or without PACAP.
However, glucose stimulated insulin secretion significantly improved in islets
cultured with PACAP, compared to controls (stimulation index: 2.8 vs. 1.8,
respectively; P<0.05). Treatment of recipient mice with PACAP resulted in
a beneficial effect on insulin secretion (2.2 vs. 1.9 mU/l,) following IVGTT.
However, no significant difference in glucose level was observed during
follow-up.
Conclusions: Our study indicated that PACAP maintained islet viability
and beta-cell content during culture, as well as improved insulin secretion
both in vitro and in vivo. However, blood glucose levels during an IVGTT
were not affected. Because of the known effect of PACAP on blood pressure,
local treatment may be preferable and could be further considered in islet
transplantation.
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POSTER BOARD NUMBER P2 – 142
1343 THE CULTURE MEDIUM INCLUDING OXYGEN
NANO BUBBLES IS PRESENTED TO IMPROVE THE
VIABILITY OF ISLET CELLS FROM NON-HEART BEATING
DONOR PANCREAS

1345 DECLINE IN NATIVE KIDENY FUNCTION IN LIVER
TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH BKV
VIRUS INFECTION
P. Ferrari4 , M. Salama1, N. Boudville2, D. Speers3, G. Jeffrey1
1
Department of Gastroenterology/Hepatology, Sir Charles Gairdner Hospital,
Perth, 2Department of Nephrology, Sir Charles Gairdner Hospital, Perth,
3
PathWest, Laboratory Medicine, Sir Charles Gairdner Hospital, Perth,
4
Department of Nephrology, Fremantle Hospital, Perth
BK virus (BKV) infection is an established cause of allograft dysfunction
in renal transplant recipients. The relationship between BKV infection and
chronic kidney disease (CKD) post orthotopic liver transplant (OLT) has been
poorly investigated. The aim of this study was to determine the prevalence of
BKV infection, its relationship to CKD and renal function loss over time in
OLT recipients.
Prevalence of BKV viruria and viraemia were studied in 41 post OLT patients
after a mean 6.5±4.7 years post-transplantation. Renal function was assessed
using estimated glomerular filtration rate (eGFR) calculated from the yearly
serum creatinine levels using the MDRD formula and by 51Cr-EDTA clearance
(nGFR) at the time of viral studies. Polymerase chain reaction was performed
for detection of BKV DNA in urine and plasma.
BKV viruria was present in 24.2% of patients, but none of these OLT recipients
had detectable BKV viraemia. Isolated positive urine cytology for decoy cells
was found in another 9.7% patients. CKD defined as eGFR <60ml/min/1.73m2
was found in 83% of OLT recipients, but only in 56% when nGFR was used.
The yearly decline in eGFR was -6.9±17 and -9.2±18 ml/min per year in BKV
viruria positive and negative patients, respectively (P=0.39). There was no
relationship between the presence or absence of BKV viruria and either nGFR,
current eGFR, yearly decline in eGFR, number and type of immunosuppressive
agents or aetiology of liver failure.
In the setting of established BK virus reactivation, immunosuppression without
kidney injury seems insufficient to cause BKV viremia and nephropathy, and
it appears that the most probable pathways for the development of BKV
nephropathy requires a second-hit such as kidney inflammation, kidney
ischemia, or donor-recipient human leukocyte antigen mismatch.

POSTER BOARD NUMBER P2 – 145
CONCURRENT ORAL SESSION 97: BK POLYOMA VIRUS
POSTER BOARD NUMBER P2 – 143
1344 A SINGLE CENTRE EXPERIENCE ON APPLICATION
OF CADAVERIC POLYCYSTIC KIDNEYS FOR
TRANSPLANTATION
D. Nicol, H. Rhee
Transplant Unit
Increasing incidence of end stage renal failure (ESRF) is compounded by
the limited number of available organs for transplantation. We report our
experience with transplantation of cadaveric kidneys from patients with
autosomal dominant polycystic kidney disease (ADPKD), as an option for
selected patients with end stage renal failure.
All files from deceased donors in Queensland, Australia, in the period of
1994-2007 were reviewed to identify 5 donors with ADPKD. Data on recipients
of polycystic kidneys was retrieved from the Australia and New Zealand
Dialysis and Transplant (ANZDATA) registry.
Nine patients were transplanted with follow up ranging from 6 months to
11.5 years. Two grafts failed due to vein thrombosis and chronic allograft
nephropathy, both of which were unrelated to natural progression of ADPKD.
The remaining 7 grafts all continue to function. Follow up scans of two
patients demonstrated progressing cystic disease, whilst another showed
regression.
Kidneys from deceased donors with adult polycystic kidney disease and
acceptable renal function can be considered for transplantation. Uncertainty
regarding the longevity of these kidneys and long term risks mean that they
should be offered to carefully selected patients who would not otherwise be
able to receive a transplant.

1346 INITIATION OF A SCREENING PROTOCOL FOR
POLYOMA VIRUS RESULTS IN A DECREASED RATE OF
OPPORTUNISTIC NON-BK VIRAL DISEASE IN RENAL
TRANSPLANT RECIPIENTS
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
BK nephropathy (BKN) develops in 2-5% of renal transplant patients and
is recognized as a serious complication that is associated with a high rate of
graft dysfunction and loss. In an attempt to decrease our rate of BKN, in Jan.
2006, we initiated a serum screening policy for all newly transplanted patients
with recipients undergoing monthly blood testing for polyoma determination
by PCR. Patients with a positive PCR underwent a reduction in baseline
immunosuppression which was either a discontinuation or 50% daily dose
reduction in mycophenolate mofetil (MMF). Between Jan 1, 2006 and Feb 28,
2007, 66 renal transplants were performed at our center (Group A). Serum PCR
became positive for polyoma in 11 patients (17%). Mean time to positive PCR
post-transplant was 5 months (2-9).Following discontinuation (n=5) or 50%
reduction (n=6) in MMF dosing, 10/11 patients became negative for polyoma
detection by PCR and no case of BKN has developed. To identify if a positive
polyoma PCR served as a marker for over-immunosuppression and risk for
opportunistic infection, we examined the rates of CMV and EBV disease
in Group A patients compared to the prior 66 consecutive renal transplant
recipients at our institution in whom monthly polyoma screening PCR was not
obtained (Group B, Dec.1, 2004-Dec 31, 2005). Immunotherapy for recipients
in both groups consisted of Thymoglobulin induction followed by maintenance
therapy with prograf, MMF and prednisone or rapamune. Recipients in both
groups received prophylactic therapy with valcyte for the first 90 days posttransplant. Demographics were similar between the 2 groups with respect to
age, gender, ethnicity and deceased vs. live-donor transplant. In addition, there
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H. Nagata1,2, M. Ito1, T. Yamamoto1,2, R. Ito3, Y. Iwanaga4
1
Fujita Health University, 2Diabetes Research Institute Nagoya, 3University of
Nebraska Medical Center, 4Kyoto University Transplant Unit
Background: The consumption of oxygen has been recognized as an important
element of isolated islets. We evaluated whether the Nano-bubble oxygen
solution improves cell viability under the cell culture.
Materials and Methods: Nano-bubble refers to ultra-fine oxygen gas bubble
of diameter less than 10ƒÊm (1ƒÊm=1/1,000,000 m). We applied gNagano-shizuku h produced by Royal Electric Co., Ltd., in collaboration with
REO Research Institute and the Naga Group. It already commercialized as
a healthy drinking water in Japan. The Nano-bubble water was mixed with
conventional culture medium 0, 5,10,30,50,90%, respectively. The pancreas
was procured from non-heart beating retired pigs. The pocine pancreas
transported with two layer method and isolated using the Kyoto isolation
method.
The viability of islet was assessed after purification (day 0) and after 1,
7 and 28days of culture. The selected islets were dissociated for the single
cell. The single cell suspensions are incubated with Newport Green PDX
acetoxymethylether (NG) and Tetramethylrhodamine ethyl ester (TMRE).
After washing, the cells are stained with 7-aminoactinomycin D (7-AAD). The
samples are analyzed using a FACScan cytometer. The beta cell composition of
islet also analyzed using cellular antibodies. And beta cell viability index was
calculated using ICHII-method.
Result: 50% of Nano-bubble group was maintained viability more than 80%
after 28days culture.
Conclusions: The oxygen nano-bubbles solution may improves that the
adaptive capability of islet cells against into apoptosis among the cell culture
procedures.
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were no differences between the groups in regards to primary (D+/R-) CMV
epidemiologic risk, 26% in Group A and 24% in Group B.
Opportunistic viral infection developed in 5 (8%) group B patients (4
CMV, 1 EBV)) and no group A patient. CMV disease in group B patients
manifested as 1 case of CMV colitis and 3 cases of CMV syndrome. In
addition, 1 group B patient suffered from disseminated EBV disease
(tonsillitis, hepatitis).
In summary, monthly screening for polyoma virus by PCR in renal transplant
recipients, with an associated decrease in immunotherapy, effectively prevents
the development of BKN. Furthermore, this screening protocol served as
an effective marker for over-immunosuppression and was associated with a
decreased incidence of other opportunistic viral disease.
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1347 MONTHLY SCREENING FOR POLYOMA VIRUS
RESULTS IN AN ELIMINATION OF BK NEPHROPATHY AND
PRESERVATION OF RENAL FUNCTION
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
BK nephropathy (BKN) is recognized to be a serious complication after
renal transplantation and is associated with a high rate of allograft failure.
In 219 patients transplanted at our center between Jan. 2002 and Nov. 2005,
there were 11 cases of biopsy proven BKN (5%). In an attempt to decrease
our rate of BKN in Jan. 2006, we initiated a serum screening policy for
all newly transplanted patients with recipients undergoing monthly blood
testing for polyoma determination by PCR. Patients with a positive PCR
underwent a reduction in baseline immunosuppression which was either
a discontinuation or 50% daily dose reduction in mycophenolate mofetil
(MMF). Serum PCR was repeated monthly and any patient with a 25%
increase in serum creatinine from baseline underwent a renal transplant
biopsy.
Between Jan 1, 2006 and Feb 28, 2007, 66 renal transplants (26 live-donor
and 40 deceased donor) were performed at our center. Immunotherapy
consisted of Thymoglobulin induction in all recipients, mean total dose
of 4.6mg/kg, followed by maintenance therapy with prograf, MMF and
prednisone (n=13) or a steroid-free regimen of prograf, MMF and rapamune
(n=53). Serum PCR became positive for polyoma in 11 patients (17%), 4
in the maintenance steroid- treated group (31%) and 7 in the steroid-free
recipients (13%). Mean time to positive PCR post-transplant was 5 months
(range 2-9 months). Following discontinuation or reduction in MMF dosing,
10/11 patients became negative for polyoma serum detection by PCR within
6 months. The mean time to a negative PCR was 4 months, range 2-6 months.
Renal transplant dysfunction, 25% increase from baseline serum, developed
in only one patient (9%) two months after discontinuation of MMF therapy.
Renal transplant biopsy in this recipient showed acute rejection. The serum
creatinine returned to baseline in this patient after steroid therapy, however,
the serum polyoma PCR remains positive. No other positive PCR recipient
required a biopsy. Mean serum creatinine values for these 11 patients at one
month post-transplant, time of initial positive polyoma PCR, 3 (n=11), 6
(n=11) and 12 months (n=6) after immunotherapy reduction was 1.5, 1.4,
1.5, 1.4, and 1.5 mg/dl respectively.
A trend towards a higher rate of positive serum polyoma PCR in
maintenance steroid- treated patients compared to steroid-free regimen
recipients was identified. Monthly screening for polyoma virus by PCR for
early detection, with associated immunosuppressive regimen reduction, is
an effective way to prevent BKN. In addition, this screening protocol is
associated with a low rate of acute rejection and preservation of excellent
renal function.
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1348 RETRANSPLANTATION AFTER RENAL ALLOGRAFT
LOSS TO POLYOMA VIRUS-ASSOCIATED NEPHROPATHY
(PVAN)
M.R.N. Nampoory1, T. Said1, T. Al-Otaibi1, A.S. Pacsa2, M.P. Nair1,
M.A. Halim1, M. Balaha1, M. Samhan1, M. Al-Mousawi1
1
Hamed Al-Essa Organ Transplant Center, 2Department of microbiology,
faculty of medicine
Introduction: Polyomavirus-associated nephropathy (PVAN) is an emerging
cause of kidney transplant failure affecting 1-10% of patients. Limited data exists
concerning retransplant in patients who lost their first graft due to PVAN.
Patients and methods: Live donor retransplantation was done in four
recipients who lost their grafts due to PVAN at a mean of 10 months after
graft failure. Graft nephrectomy was done in all except one who was negative
for viraemia and viruria and did not require dialysis prior to transplantation.
Induction immunosuppression was given for thee patients (2 monoclonal and
one polyclonal antibody). Post transplant immunosuppression was similar
to the current center policy during the first three months (Prednisolone,
Mycophenolate and either tacrolimus in three or cyclosporine in one patient).
Immunosuppression was tapered over the next 3 – 9 months to the minimum
that keeps normal graft function. Follow up to detect virus reactivation in blood
and urine was done monthly for the first 3 months then every 3 months for the
first year using polymerase chain reaction (PCR).
Results: The follow up period was 3, 6, 15 and 50 months post transplant
with mean serum creatinine 85 umol/l. All patients tolerated reduction of
immunosuppression without rejection episodes. Viral reactivation was observed
in two patients one turned negative and the second remained viruric on further
reduction of immunosuppression.
Conclusion: Reduced immunosuppression in retransplantation of patients
who lost their first graft due to PVAN remains to be an option with low virus
reactivation rate.
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1349 BK VIRUS ASSOCIATED HEMOPHAGOCYTIC
SYNDROME IN A RENAL TRANSPLANT RECIPIENT
K. Charfeddine, S. Yaich, S. Zagdane, D. Hssairi, M. Masmoudi, J. Hachicha
Hedi Chaker Hospital University
Introduction: Hemophagocytic syndrome (HPS) is a life threatening
hematological disorder in immuno compromised patients. Reactive HPS is
observed in patients with systemic infection, neoplasia or auto immune disease.
Various infectious agents have been associated with the development of HPS,
including viruses. We report here a case of BKV – associated HPS.
Case report: A 29 – year – old male with end – stage renal disease secondary to
chronic glomerulonephritis, received a kidney allograft from a living unrelated
donor. His immunosuppression consisted of mycophenolate mofetil (MMF),
Tacrolimus and corticoteroids without induction therapy. The graft functioned
immediately with a 101 μmol/l serum creatinin on day 15.
11 months later, he presented fever, pancytopenia and a raising of serum
creatinin (s.creat) to 398 μmol/l. We found no clinical evidence of infection,
urine and blood cultures were negative. Cytomegalovirus virus (CMV)
antigenemia was positive and gancyclovir treatment was instaured. Graft
ultrasound showed no abnormality. A graft biopsy on day 7 found an acute
rejection with viral inclusions. Gancyclovir was continued and corticosteroid
pulses were instaured. Ten days later, CMV antigenemia was negative but his
pancyopenia was worsening (white blood cells = 500 /mm3, platelets level
= 62 000 /mm3). Bone marrow aspiration was negative. Thus, we prescribed
granulocyte growth factor witch leads to rising WBC count to 4900 /mm3.
One month later, allograft function was worsening and s.creat rises to 828
μmol/l and hemodialysis was started. Concomittely to rising of s.creat, the
patients develops again fever with pancytopenia (WBC: 400 /mm3, platelet
level: 18 000 /mm3, hemoglobin: 3 g/dl). CMV antigenemia was negative,
liver enzymes level was normal. Ferritinemia level was at 2890 ng/ml and
triglycerid level at 2,7 mmol/l. Urine sample was positive for decoy cells, BK
virus viremia chain was at 5.1 log10 copies/ml. He underwent a second graft
biopsy witch showed lesions suggestive of overt BKV nephropathy.
A bone – marrow aspiration was suggestive of HPS and the bone – marrow
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biopsy disclosed typical features of hemophagocytosis. We reduced MMF and
tacrolimus doses by half, but renal function was worsening and the patient
return to dialysis.
Conclusion: Reactive HPS is rare after renal transplantation and must be
suspected when fever and pancytopenia are associated especially in patients
with viral infections. HPS was usually associated with CMV infections. In
future, we must expected for BK virus.
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1350 LEFLUNOMIDE IMPROVES ALLOGRAFT
DYSFUNCTION IN BK-POLYOMA VIRUS NEPHRITIS IN
RENAL TRANSPLANT RECIPIENTS

POSTER BOARD NUMBER P2 – 150
1351 IMPACT OF PROPHYLACTIC CIPROFLOXACIN
ADMINISTRATION ON BK POLYOMA VIRUS REPLICATION
M. Koukoulaki, T. Apostolou, V. Hadjiconstantinou, S. Drakopoulos
Transplant Unit, Evangelismos, General Hospital of Athens
Purpose: BK virus has emerged as a potential pathogen in renal transplantation,
leading to irreversible renal allograft dysfunction. Early diagnosis and appropriate
treatment are decisive steps in prognosis of graft survival. Treatment choices include
modification of immune suppression or administration of anti-viral agents. In vitro
evidence suggests that fluoroquinolones inhibit polyoma virus DNA replication
and viral cycle by interacting with the subunit of gyrase and helicase activity.
Patients and methods: We studied prospectively 32 de novo renal transplant
recipients of median age 48.5 years old (range 22 – 76) (male: female, 23:9)
for a period of 12 months with sequential samples of urine and blood tested
for BK virus with real-time polymerase chain reaction. All recipients received
induction therapy (Basiliximab: 18, Daclizumab: 14) and triple immune
suppressive regimen with calcineurin inhibitor (cyclosporine: 19, tacrolimus:
13), mycophenolate mofetyl and corticosteroids. Prophylactic antibiotic
treatment was administered as follows: third generation cephalosporin,
cefotaxim for ten day and subsequently ciprofloxacin for six weeks. Recipients
with concurrent positive urine cultures of pathogens resistant to quinolones
were converted to beta-lactamic antibiotic.
Results: During the period of follow-up of the first two months nine recipients

Month
Plasma Positive Samples
(No -%)
Median Plasma Viral load*
(range)
Urine Positive Samples (No
-%)
Median Urine Viral load*
(range)

0

1

3

6

9

12

3 - 9,4

6 - 18,7

9 - 28,1

7 - 23,3

0-0

3 - 12

2,35
(1,3-3,1)

2,56
(1,6-3,9)

2,73
3,4
(0, 8-3,6) (1,90-5,1)

9 - 28,1

9 - 28,1

10 - 31,2

7 - 23,3

9 - 31,1

6 - 24

2,57
3,17
(1,0 – 6,9) (0,7-7,6)

4,36
(1,1-9,7)

3,52
(1,4-7,5)

3,32
(0,8-5,7)

4,98
(2,4-7,4)

3.08
(2,8-5,7)

*log10 viral load, No: number,%: percentage
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1352 THE ROLE OF SERIAL BKV PCR ASSAY IN KIDNEY
TRANSPLANTATION
S.H. Kim1,3, H.E. Yoon1, Y.K. Kim1, S.C. Park2, B.S. Choi1, Y.S. Kim1,
I.S. Moon2, B.K. Bang1, S.Y. Kim1, C.W. Yang1
Department of 1Internal Medicine and 2Surgery, College of medicine,
The Catholic University of Korea, Seoul, Korea, 3Department of Internal
Medicine, College of Medicine, Chungang University, Seoul, Korea,
Background: BK virus nephropathy (BKVN) is one of leading causes of renal
allograft dysfunction and related with immunosuppressant. The goal of this
study was to investigate natural course of BK virus (BKV) using BKV DNA
polymerase chain reaction (PCR) assay after transplantation.
Methods: We measured BKV DNA PCR assay in plasma and urine at
pretransplant, then weeks 1 and 2, month 3, 6 and 9 post-transplant in kidney
transplant recipients.
Results: The median age at transplantation was 41 year (range: 22-58 year),
median HLA mismatch was 3(1-6) (n=38). Transient viruria was occurred 5.3%,
10.5%, 18.4%, 15.8%, 13.2% and 5.3% patients at pretransplant, weeks 1 and
2, month 3, 6 and 9 post-transplant, respectively. And viruria was significantly
increased in FK506 treated group compared to CsA treated group at weeks 2
post-transplant (9 patients in FK506 treated groups vs 0 patients in CsA treated
groups, p=0.029). BKV viremia was occurred 4 patients within 6 months after
kidney transplant. In the all four patients, the load of viremia was decreased
or disappeared after consequential reduction of immunosuppressant and their
renal function were well preserved. None of these patients developed biopsy
proven BK nephropathy during the follow-up period.
Conclusion: The BKV viremia and viruia is transient occurred and decreased
or disapperaed after reduction of immunosuppressant.

POSTER BOARD NUMBER P2 – 152
1353 BK VIRUS INFECTION IN RENAL TRANSPLANT
RECIPIENTS: DIAGNOSIS AND RISK FACTORS ANALYSIS
G. Tu, T. Zhu, Q. Tang, M. Xu, R. Rong
Department of Urology, Zhongshan Hospital, Fudan University, China
Objective To investigate methods of diagnosis and risk factors of BK virus
infection in renal transplant recipients.
Methods 92 patients received renal transplantation in our center were
undertaken BK virus detection and presence of decoy cells in urinary sediment,
urine, and serum BKV-DNA. Epidemiological features and risk factors of BK
virus infection were analyzed.
Results Among 92 patients, decoy cells were found in 29(31.5%) patients. The
median time for the first detection of decoy cells was 18.3 months after surgery.
The sensitivity and specificity of decoy cells to diagnose BK virus infection were
67.7% and 86.9% respectively. 22(23.9%)patients were diagnosed as BK viruria at
a median of 16.3 months after surgery, and 9(9.8%)recipients at a median of 39.5
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D. Samarapungavan, R. Kosuri, G. Reddy, B. Rai, I. Khan
William Beaumont Hospital
Immunosuppression reduction alone has limited success in improving renal
function and avoiding progressive graft failure in patients with established
graft dysfunction from BK-Polyoma nephritis (BKN). We present outcomes
of 13 transplant recipients who developed clinically relevant BKN after
basiliximab induction, with Cellcept and prednisone maintenance. One patient
was on sirolimus, twelve received tacrolimus.
Diagnosis was established either by a positive biopsy (n=3), or clinically in
the setting of an otherwise unexplained drop in GFR (by a mean of 26 ml/min)
in conjunction with both BK viruria and viremia (n=7), or a drop in GFR with
significant viruria (≥ 15 million copies) alone (n=3). The mean tacrolimus
level at the time of diagnosis was 6.9 ng/mL (Abbott IMX). No patient had
received more than 2 gm of Cellcept/day. Mycophenolic Acid levels were
available on 11 patients (mean-3.13 μg/mL, range 0.5-11.9; 4 patients were
>3.5 μg/mL, 4 patients were <1.5 μg/mL). Mean time to diagnosis of BKN
after transplant was 14 months (range 2-72).
Treatment consisted of changing Cellcept to leflunomide, with a loading dose
of 100mg/day for 3 days, then 40mg/day; targeting trough levels of the active
metabolite teriflunomide to ≥40,000ng/mL. Tacrolimus levels were optimized to
target trough levels of 4-6 ng/mL (Abbott IMX) or 3-5 ng/mL (LC/MS/MS).
Mean follow-up is 11 months (range 1-19). One patient developed acute rejection
(that responded to therapy) due to non-compliance after improvement in BKN,
and another received empiric pulse methylprednisolone for a rise in creatinine in
the setting of urosepsis. One patient died of an unrelated cause with good graft
function. Side effects did not limit drug usage and resolved with dose adjustments.
Mean LFL dose and levels were 49 mg/day and 57,000 ng/mL respectively.
All patients show an excellent response with decline in viral loads (90% drops
in viruria at a mean of 4 months) and improved GFR (at a mean of 8 months,
range 1-15) as demonstrated in figure 1 and figure 2.

had received for three weeks ciprofloxacin and 23 recipients were on treatment
with ciprofloxacin for six weeks. The incidence of BK viremia and viruria were
not affected by administration of ciprofloxacin (table). The was an increasing
tendency with a peak the third post-transplant month and subsequently declined.
Viral load (log10) in urine showed significant difference (Mann-Whitney U test,
p=0,045) between measurements on the first and the third post-transplant month
that may be attributed to concurrent administration of ciprofloxacin during the
collection of samples the first post-transplant month.
Conclusion: In this study it was observed that ciprofloxacin does not protect
from BKV re-activation. However ciprofloxacin may exert an influence on
BKV replication and viral load.
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months after surgery. Decoy cells were associated with a significantly higher rate of
graft dysfunction. Of 9 renal recipients diagnosed as BK viremia, 8 demonstrated
graft dysfunction. Risk factors of BK virus infection were analyzed by Logistic
regression which implied that immune induction and patients without hemodialysis
were high risk factors. Whereas, immunosuppressive regimen¦ primary kidney
disease and post-surgery infections were found no significant differences.
Table 1 Comparison of decoy cell and BKV-DNA detection facility
BKV-DNA(+)
21
10

Decoy cell(+)
Decoy cell(-)

BKV-DNA(-)
8
53

Table 2 Impact of BK virus infection on graft function
A
Decoy cell(+)
Decoy cell(-)
B
Urine BKV-DNA(+)
Urine BKV-DNA(-)
C
Serum BKV-DNA(+)
Serum BKV-DNA(-)

Normal function

Graft disfunction

χ2

P value

12
45

17
18

7.61

0.006

16
41

15
20

2.12

0.145

1
54

8
29

9.83

0.003

Conclusion BK virus infection is a common complication of renal
transplantation.The infection of BK virus may result in graft dysfunction.
Detection of decoy cells and BKV-DNA in urine samples may lead to early
diagnosis of BK virus infection.

Results: A total of 2014 transplants were done at our institute between
01/95 to 11/07 which included 1134 renal; 424 liver;87 - pancreas; 231
heart; 138 lung transplants. A total of 13 patients had positive (mean age
49) BK virus urine and or serum titers (10 kidney, 1 lung, 2 heart/kidney,
1- kidney/pancreas). The overall incidence was 0.6% for our program with
an incidence of 1.1% for kidney, 1.1% for kidney/pancreas, 0.9% for heart
and 0.7 for lung transplants. All patients received alemtuzumab induction.
The mean creatinine 6 months prior to and at the time of diagnosis was
3.8 and 3.2 respectively. Treatment included elimination of antiproliferative
drugs and minimization of calcinurin inhibitors. All viremia were followed
by serial testing. The mean creatinine was 3.0 six months after the initial
diagnosis.
One renal transplant patient had mild rejection and there were two renal graft
losses. In two thoracic transplants we used the immune cell function assay
(Immuknow) to direct the immunosuppression modulation. The heart/kidney
patient is in need of a kidney re-transplantation and immunosuppression is
actively being reduced.
Conclusions: BK virus infection is low in our patient population with minimal
graft rejection stimulated by down-regulation of immunosuppression. We
believe that the immune cell function assay may provide valuable insight into
appropriate immunosuppresion modification in patients who are at higher risk
of graft loss following immunosuppressive down regulation
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1354 SURVEILLANCE FOR POLYOMA VIRUS (BK):
A USEFUL STEP TO AVOID NEPHROPATHY
W.M. Bennett, L. Meyer, J. Aman, T. Batiuk
Legacy Transplant Services, Portland, OR, USA
Renal infection with BK virus is known to be associated with poor allograft
survival and a clinical picture difficult to distinguish from rejection. Diagnosis
at the time of renal dysfunction frequently leads to graft loss despite reduction
of immunosuppression.
We followed 58 consecutive recipients prospectively for BK infection with
plasma and urine PCR at 1, 2, 3, 6, and 12 months post transplant. Standard
immunosuppression was thymoglobulin (3 mg/kg) induction followed by
tacrolimus, mycophenolate mofetil and 0.1 mg/kg prednisone. When plasma
PCR was > 2.6 log copies, mycophenolate was stopped or reduced until there was
no detectable viral load. The plasma PCR became positive in 11 patients (19%)
at a mean of 1.82 months (1-5) post transplant. Viremia resolved in 3 months or
less in 9 of 11 patients with no antiviral therapy. There were 2 patients with urine
PCR > 7 log copies who never developed positive plasma PCR and no patient
had viremia without > 7 log copies viriuria. Two patients had biopsy proven
rejection episodes during reduced immunosuppression and 2 patients developed
viremia following anti-rejection treatment. There was no graft loss due to
rejection. Surveillance biopsies at 8 weeks in all patients showed no evidence of
BK nephropathy histologically or with SV40 staining. Patient survival was 98%
and graft survival was 95% with no graft lost to BK nephropathy.
Conclusion: Active surveillance for BK virus with prompt reduction of
immunosuppression can prevent graft loss due to BK nephropathy.
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1355 BK VIRUS DETECTION AND MANAGEMENT
AT A TRANSPLANT INSTITUTE
M. Marvin, R. Nagubandi, R. Kadiyala, M. Eng, J. McConnell, R. Ouseph,
J. Gleason, J. Buell
Division of Transplantation, Dept. of Surgery, University of Louisville,
Louisville, Kentucky, United States.
Objective: The incidence of BK virus has ranged from 1 to 4.6%. The presence
of viremia appears to predict allograft nephropathy and eventual graft loss. Our
aim is to evaluate the incidence and management strategy at our institution.
Method: Retrospective review of all transplants performed from 01/05 to
11/07 was done. All patients with BK positive urine and or serum titers were
identified. Patient demogrphics, allograft biopsy, immunosuppression and
outcomes were examined for these patients.
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1356 CIDOFOVIR AND CIPROFLOXACIN FOR BK
NEPHROPATHY AFTER KIDNEY TRANSPLANTATION
M. Razavian, K. Wyburn, L. Garry, D. Verran, R.D.M. Allen, J. Eris,
S. Chadban
Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia
Background: Polyoma BK virus (BK) is a highly prevalent DNA virus that
causes BK nephropathy (BKN) in 1-10% of kidney transplant recipients and
probably related to over immunosuppression. Graft dysfunction is usual and
graft loss is not uncommon. The optimal therapeutic strategy has not been
defined. We report our experience of 6 consecutive cases of BKN.
Method: Retrospective analysis of 6 patients with biopsy proven BKN, treated
with a protocol of reduction in immunosuppression (calcineurin inhibitor
reduction/cessation +/- reduction in anti-proliferative agent), IV cidofovir
0.25mg/kg every 2 weeks for 6 doses, followed by oral ciprofloxacin 250mg
daily until clearance of BK DNA from serum.
Results: The six patients were transplanted between 2003 and 2007. Five
patients were male and median age was 43.5 years (range 24-75). Immunesuppression at time of transplantation included steroids (n=6), tacrolimus
(n=3), cyclosporine (n=3), mycophenolate (n=5), basiliximab (n=4) and
thymoglobulin (n=1). Five patients had been treated for acute rejection with
pulse steroids (n=5) and T cell depleting antibodies (n=1). Mean baseline
creatinine after transplantation was 112μ;mol/L (range 95- 210μ;mol/L) after
transplantation. BKN was diagnosed at median time of 8 months (range 4-18
months) after transplantation by PCR and biopsy (EM or immune staining
for BK). Median creatinine at time of diagnosis of BKN was 230μ;mol/L
(range 150-350μ;mol/L). Following therapy outlined above, all patients had
improvement (n=5) or stabilization (n=1) in renal function. Five patients were
followed for 6 and 12 months after initiation of therapy. Mean creatinine at
6 months was 200μ;mol/l (125-260μ;mol/L) and at 12 months 180μ;mol/L
(120-225μ;mol/L). There was 1 graft loss 8 weeks into treatment for BKN due
to renal artery thrombosis. Treatment was well tolerated and all patients were
able to complete treatment. There were no episodes of acute rejection during
follow-up.
Conclusion: In our experience a reduction in immunosuppression, coupled with
IV cidofovir, and followed by low dose ciprofloxacin in cases with persistent
BK viraemia, resulted in improvement and maintenance of function in grafts
with biopsy proven BKN. This treatment was well tolerated and warrants
evaluation in a randomised controlled trial.
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1357 CROSS-SECTIONAL STUDY OF BK VIRUS INFECTION
IN KIDNEY TRANSPLANT RECIPIENTS. A SINGLE CENTRE
EXPERIENCE
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1359 PRESENCE OF BK VIRURIA IN HEART TRANSPLANT
PATIENTS
S. Palekar1, C. Slavov1, S. Akbar1, L. Mele2, S. Pardi2
Division of Nephrology and Transplantation Newark Beth Israel Medical
Center., 2Division of Cardiac Transplantation Newark Beth Israel Medical
Center.
Introduction: BK virus (BKV) also known as Polyomavirus hominis 1, is a
human polyomavirus in the Papovaviridae family. It is a small, non-enveloped
virus with an icosahedral capsid and a core of circular double-stranded DNA.
By adulthood 70% of the population have serologic evidence of prior infection.
The relation between BK viral shedding and nephropathy is still unclear in nonrenal solid organ transplant patients. The purpose of our study was to conduct
a prospective study that would test for the presence of BK viruria and viremia
in Orthotopic Heart Transplant (OHT) recipients when their GFR suddenly
declined below 60mL/min on routine follow-up visits.
Method: We tested all patients presenting to the heart transplant service
between May and July 2007 who fit the following criteria: s/p OHT and a sudden
decrease in GFR to below 60mL/min unexplained by hemodynamic changes or
medications that would affect renal function (ACEI, ARBs, diuretics). Patients
testing positive for viruria (PCR assay) were then tested for BK viremia (PCR
assay). Medical records were reviewed for the type of immunosuppression and
other medications or events that would impact the GFR.
Results: Twenty-two patients met the inclusion criteria for the study. 7 out of 22
(32%) patients were found to have BK viruria. In 5 out of 7 patients the BK viruria
was above 10,000 copies/mL. Our report focuses on these 5 patients. 3 patients
were within the first 3 months after transplant, while 2 out of 5 were within the
3 to 12 month period. All patients had steroid induction and were on Tacrolimus
maintenance regimen. At the time of diagnosis 1 patient was on low dose Prednisone,
Tacrolimus and Mycophenolate; 2 were on Tacrolimus and low dose prednisone; 1
was on Tacrolimus and Mycophenolate, and 1 patient was on Tacrolimus alone. In
the Tacrolimus alone patient, Mycophenolate had been discontinued 4 weeks prior
for gastroenterological intolerance. None of the patients had detectable viremia.
The level of BK viruria detected was between 50,000 copies/mL to greater than 39
million copies/mL. 3 out of 5 patients had BK viruria above 1 million copies/mL.
Conclusion: BK viruria is present in a substantial number of non-renal solid
organ transplant patients that have had cardiac transplantation. It can be seen
with diverse immunosuppressive regimens and may be a marker of excessive
immunosuppression. Interestingly, no BK viremia was found raising the
possibility of a lower rate of viral replication.

1
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1358 ABDOMINAL AORTIC ENDOANEURYSMORRHAPHY
IN A RENAL TRANSPLANT RECIPIENT
R.M. Rosete-Liquete, M.A. Mejes
National Kidney and Transplant Institute
Repair of abdominal aortic aneurysm in a renal transplant patient presents an
important technical challenge since the allograft is placed at risk of irreversible
renal damage due to warm ischemia. We report a case of a 61-year old male
previously diagnosed with chronic kidney disease secondary to hypertensive
nephrosclerosis who underwent living donor kidney transplantation last March
2002 and was diagnosed three years later with a progressively enlarging (4 cm
to 7 cm) infrarenal saccular aneurysm. He was maintained on cyclosporine 100
mg twice daily, mycophenolate mofetil 500 mg twice daily and prednisone
5mg a day with a pre-operative serum creatinine level of 1.1 mg/dL. Patient
subsequently underwent endoaneurysmorrhaphy using a 16 mm PTFE tube
graft with cross clamping below the native kidney renal arteries and just above
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1360 REDUCTION OF IMMUNOSUPPRESSION IN OHT
PATIENTS WITH BK VIRURIA
S. Palekar1, C. Slavov1, S. Akbar1, L. Mele2, S. Pardi2
Division of Nephrology and Transplantation Newark Beth Israel
Medical Center, Newark, New Jersey, United States, 2Division of Cardiac
Transplantation Newark Beth Israel Medical Center, Newark, New Jersey,
United States
Introduction: The relation between BK virus replication and nephropathy
is still unclear in non-renal solid organ transplant patients. We conducted a
prospective study to determine if a reduction in the degree of immunosuppression
in Orthotopic Heart Transplant (OHT) patients with BK viruria would lead to
a decline in the viral load; and also whether the use of two immunosuppressive
agents concomitantly would influence the viral load.
Method: We tested all patients presenting to the heart transplant service
1
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S.K. Lim, Y.L. Thye, C.M. Wong, T.C. Keng, Y.B. Chong, C.Y. Loo, S.Y. Tan
Renal Unit, Department of medicine,University Malaya Medical Centre
Introduction: Although discovered over thirty years ago, BK polyomavirus
(BKV) was not shown to be associated with clinical disease until two decades
later. BKV infection has now emerged as an important cause of allograft
dysfunction and loss in kidney transplant recipients. This is closely linked to
the usage of more potent immunosuppressive agents such as tacrolimus and
mycophenolate mofetil in recent years. The prevalence of BKV nephropathy
(BKVN) is estimated to be 5% to 10% in renal transplant recipients. In
Malaysia, there is currently no epidemiological data of BKV infection and
disease in our local transplant population
Objectives: To outline the prevalence of BKV infection and nephropathy
among renal transplant recipients in University Malaya Medical Centre.
Methods: This is a cross sectional study which recruited renal transplant
recipients who consented to participate in the study. Blood and urine of all
patients were sent for quantitative BKV by Polymerase Chain Reaction (PCR).
Renal function is determined using standard assays on sera collected from
patients. Demographic and clinical data are collected using a questionnaire.
For patients with BKV viraemia i.e. plasma BKV PCR > 4 log copies/ml and
renal dysfunction i.e. rise in serum creatinine by 20% above baseline, allograft
biopsy is performed to confirm presence of BKVN.
Results: There were a total of 56 patients in our preliminary analysis and their
median age was 42.5 years. Thirty nine patients (70%) were male and 17 were
female. Majority of the patients were Chinese (66%) followed by Malays (20%)
and Indians (13%). Fifty percent of the patients were living-related renal transplant
recipients while the others were cadaveric recipients. The median duration posttransplant was 69 months and majority of them (91%) had immediate graft
function. Only 3 out of 56 patients (5.4%) were found to have low grade BKV
viraemia as determined by PCR (100, 170 and 260 copies/ml respectively) and
none of them had raised serum creatinine of more than 20% above baseline.
Therefore, graft biopsy was not performed in these 3 patients but the blood
BKV PCR and renal function were monitored closely. None of them received
monoclonal antibody at induction or received antilymphocyte globulin as antirejection therapy. There were 3 patients who were given antilymphocyte globulin
(Atgam) for steroid resistant acute rejection but none of them had positive BKV
PCR. Most of the patients (50%) received cyclosporine, mycophenolate mofetil
and steroids as triple immunosuppressive therapy and another 23% of patients
were treated with tacrolimus, mycophenolate mofetil and steroids.
Conclusion: Our preliminary results suggest that the prevalence of BKV
infection and disease among our renal transplant recipients is relatively low.
However, the number of patients is small and we are extending the study to
include more patients to determine local prevalence of BKV infection in out
transplant population. The low prevalence rate, if confirmed, may be related to
several issues including our choice of immunosuppresion which usually does
not include the combination most frequently associated with BKVN.

the common iliac bifurcation lasting for 49 minutes. The inferior mesenteric
artery was simultaneously re-implanted to the PTFE graft after converting
to a partial side clamping of the aorta. No additional procedure such in situ
renal perfusion or shunts were done to protect the allograft simplifying the
surgical procedure. Post-operatively, highest creatinine level was 1.3 mg/dL
with cyclosporine level maintained at 400-600 ng/ml. No renal replacement
therapy was necessary during the recovery period. Therefore, standard repair
of infrarenal abdominal aortic aneurysm can be carried out without additional
renal protective procedures by experienced hands.
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between May and July 2007 who fit the following criteria: s/p OHT and a
sudden decrease in GFR to below 60mL/min. Patients testing positive for
viruria (PCR assay) were then tested for BK viremia (PCR assay). 22 patients
met the inclusion criteria for the study. 7/22(32%) patients were found to
have BK viruria. In 5/7 patients the BK viruria was above 10,000 copies/
mL. 5/7 patients with BK viruria were followed for Tacrolimus drug levels,
serum creatinine/GFR and the drug regimens before and after diagnosis of BK
viruria. Upon diagnosis the immunosuppressive regimen was adjusted by either
stopping Mycophenolate in the patients who were on it and or by decreasing
the Tacrolimus doses. Prednisone was either stopped or the dose decreased. BK
viruria evaluation was repeated at a mean of 61 days after the initial diagnosis
for follow-up.
Results: All of the 7 patients diagnosed with BK viruria had Tacrolimus and
steroid induction. At the time of diagnosis 5/7patients had BK viruria above 10,000
copies/mL. At the time of diagnosis 1 patient was on triple therapy (Prednisone,
Mycophenolate, Tacrolimus), 2 were on Tacrolimus and low dose prednisone,
1 on Tacrolimus and Mycophenolate and 1 patient was on Tacrolimus alone.
3/5 patients had BK viruria above 1 million copies/mL. The level of BK viruria
detected was between 50,000 copies/mL and greater than 39 million copies/
mL. At the time of diagnosis Mycophenolate was discontinued in all patients
receiving it, the Tacrolimus dose was decreased in 4/5 patients and prednisone
was decreased in 1 patient and stopped in another. At follow-up 2/5 patients had
cleared the virus, while 2/5 patients remained positive for BK viruria though the
levels reduced by a factor of at least 1 log. These 2 patients corresponded to the
patients with the highest viral load. Meanwhile 1 patient was not retested. No
BK viremia was detected. At follow-up all patients had an improvement in their
GFR/serum creatinine. 2/5 returned to a GFR above 60mL/min.
Pt B & E had BK viruria<10,000 copies/mL
Conclusion: Prompt intervention to decrease the degree of immunosuppression
at the time of initial diagnosis of BK viruria in OHT patients can lead to
eradication of the virus. Our results suggest that the type of immunosuppressive
regimen used did not predispose to a significantly higher level of BK viruria at
diagnosis; rather viral loads greater than 1 million copies/mL were associated
with failure to clear the virus. We suspect that there was a correlation between
BK viral replication and renal function as the GFR/serum creatinine improved
in all patients at follow-up.
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1361 LACK OF EFFICACY OF CIDOFOVIR IN THE
TREATMENT OF BK VIRUS POSITIVE RENAL TRANSPLANT
RECIPIENT’S: ONE TRANSPLANT CENTER’S EXPERIENCE
S. Palekar, J. Madigan, S. Akbar, C. Flores
Division of Nephrology and Transplantation Newark Beth Israel Medical
Center, Newark, New Jersey, United States
Introduction: BK Virus associated nephropathy is a commonly recognized
cause of acute and chronic renal allograft dysfunction. Detection of BK viremia
and / or viruria may be an occult sign of excessive immunosuppression.
Current opinion suggests that decreasing the dose and / or frequency of
immunosuppression may be effective. However, some patients may require
immunosuppression withdrawal or nucleoside analogs such as Cidofovir. The
purpose of our study was to show that Cidofovir is an ineffective therapeutic
modality for BK virus infection.
Method: At our renal transplant center we retrospectively looked at a case
series of 22 patients who were found to have persistent BK viruria and/
or viremia. An extensive chart review was performed observing patient
demographics, induction and maintenance immunosuppression regimens, the
number and dosage of Cidofovir treatments, and living versus deceased donor
transplantation.
Results: 22 patients were found to have persistent BK viruria and / or viremia. 17/22
(77%) patients were males and the average age was 49 years (17–71 years). All
patients were more than one year post-transplant. 9/22 (41%) were African American,
6/22 (27%) were Hispanics, 5/22 (23%) were Caucasian, and 2/22 (9%) were Asian
Indian. 12/22 (55%) transplant recipients had a deceased donor, while 10/22 (45%)
had living donors. 13/22 (59%) had received induction with Thymoglobulin, while
8 had received Daclizumab, and 1 patient received Basiliximab. 8/22 were on a
maintenance regimen comprising of Prednisone, Tacrolimus and Mycophenolate,
2/22 were on Prednisone, Mycophenolate and Cyclosporine, 7/22 were on only
Prednisone and Tacrolimus, 2/22 were on only Mycophenolate and Tacrolimus,
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2/22 were on Sirolimus and Prednisone and 1 was on Sirolimus, Prednisone and
Mycophenolate. BK viruria ranged from less than 500 copies/mL to greater than
39 million copies/mL, while BK viremia ranged from none detected to 754,000
copies/ mL. The number of Cidofovir treatments ranged from 3 to 16, with the
mean of 8 treatments, with appropriate renal dosing (0.25mg/kg-0.5mg/kg). Despite
numerous treatments there was no significant decrease in the degree of BK viruria.
7/22 (32%) patients had an increase in the degree of BK viruria despite multiple
Cidofovir treatments. 9/22 (41%) patients had a decrease in the BK viremia, while
18/22 (82%) had no detected BK viremia at final follow-up; and 4 had persisting
viremia. No correlation could be made between the degree of BK viruria and the
induction or maintenance regimens. Both African Americans and Caucasians were
equally predisposed to BK viruria with greater than 39 million copies/mL.
Conclusion: Multiple treatments with Cidofovir to eradicate BK viruria were
ineffective. 32% of the patients had an increase in the degree of BK viruria
despite treatment with Cidofovir. None of the patients had undetectable urinary
BK viral load. No significant risk factors could be alluded to, that would
predispose to persistent viruria. However, Cidofovir was effective in decreasing
the degree of BK viremia. We suggest a further larger and prospective trial to
decipher whether persistent BK viruria in the absence of viremia should be
treated and if so, what level of viruria is of concern.
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1362 BK VIRAL LOAD IN RENAL TRANSPLANT RECIPIENTS
WITHOUT CLINICAL NEPHROPATHY
S.C. Tang1, A.Y. Leung2, T.M. Chan1, W.K. Lo1, Y.L. Kwong2, K.N. Lai1
Divisions of 1Nephrology and 2Haematology, Department of Medicine,
The University of Hong Kong, Queen Mary Hospital, Hong Kong
Polyoma BK virus (BKV)-associated nephropathy (PAN) occurs in up to 9%
of kidney transplantation in which half will have impaired graft function due
to reactivation of BKV infection in the transplanted kidney. PAN occurs most
commonly in the first two years after transplantation and is associated with a
rise in serum BKV DNA. Little is known about whether BKV DNA is present in
renal transplant recipients without clinical features of nephropathy. Quantification
of serum BKV DNA levels using real-time quantitative polymerase chain
reactivation (Q-PCR) was performed in 23 first-time kidney transplant recipients
(9 males; mean age, 53.9±13.5 y; mean serum creatinine, 103±25.4 umol/L) who
had normal serum creatinine (below 140 umol/L or 1.58 mg/dL) within 3 years of
transplant and were receiving an immunosuppressive regimen comprising steroid,
calcineurin inhibitor, and mycophenolate. The frequencies of BK viral load in 4
log orders are shown in the table. Only 1 patient had 1.2x104 copies/mL.
Yrs after Tx
0-1 year (N=5)
1-2 years (N=6)
2-3 years (N=12)
Overall (N=24)

undetectable
3 (60%)
2 (33%)
8 (67%)
13(57%)

BKV DNA (copies/mL)
< 102
< 103
< 104
3 (60%)
4 (80%)
4 (80%)
3 (50%)
5 (83%)
6 (100%)
11 (92%)
12 (100%)
12 (100%)
17(74%)
21(91%)
22(96%)

> 104
1 (20%)
0 (0%)
0 (0%)
1
(4%)

We conclude that among renal transplant recipients with stable and good
graft function during the first 3 posttransplant years, around half of them had
undetectable circulating BKV DNA, and 90% had levels < 103 copies/mL. BK
viral load is independent of the duration of transplantation.
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1363 IS ABO-INCOMPATIBLE RENAL TRANSPLANTATION
A RISK FACTOR FOR BK VIRUS INFECTION OR
NEPHROPATHY?
T. Ueki1, A. Katayama1, K. Uchida2, T. Nagasaka2, T. Kobayashi3, A. Itoh1
1
Masuko Memorial Hospital, 2Ngaoya Daini Red Cross Hospital, 3Nagoya
University School of Medicine
Introduction: BK virus nephropathy (BKVN) is a troubling onset complication
of renal transplantation, which may affect upwards of 8% of allografts in the
current era of immunosuppression. Risk factors for the development of this
condition appear to be a history of acute rejection, anti-rejection therapy
(particularly the number of corticosteroid pulses) and possibly increased donor/
recipient HLA mismatching. However, no studies have demonstrated that
ABO-incompatible renal transplantaion(ABOi LDRT) is a risk foctor for BK
virus infection or BKVN due to over-immunosuppression.
Method: We have performed ABOi LDRT in 88 patients (60 patients received
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Cyclosporine based regimen and 28 patients received Tacrolimus based
regimen) since 1993. To minimize the risk of humoral rejection, we performed
a splenectomy 2 weeks before transplantation, eliminated anti-A and/or anti-B
antibodies by double-filtration plasmapheresis (DFPP), and administered a
potent immunosuppressive regimen consisting of cyclophosphamide, antiCD25 monoclonal antibody, calcineurin inhibitor and prednisolone. The
calcineurin inhibitor dose was adjusted by monitoring AUC0-4 target values.
We have performed BK virus follow-up in all patients since 2005. BK virus
DNA detection in blood samples was performed using the quantitative real time
polymerase chain reaction (PCR) technique. The primers used for this assay are
specific for BK virus and have been designed to accommodate mutated strains.
The range of detection is 1x1000 copies/ƒÊL.
We investigated the incidence of BK virus infection between ABOi LDRT and
ABO-compatible renal transplantation group (n=120).
Results: The incidence of BK virus infection after transplantation was 1.1% (1/88)
in the ABOi LDRT group as compared with 5.0% (6/120) in the ABO-compatible
renal group (p=0.127). The incidence of acute rejection during the first 3 months
after transplantation was 18.2% @(8 cellular, 1 combined type and 7 antibodymediated rejection) in ABOi LDRT group, as compared with 20.8% (25/120) in
the ABO-compatible group (p=0.634). Graft survival rates were similar in both
groups (95.6% vs 96.3%) at 1 year (p=0.296). There are 4 patients with BKVN in
ABO-compatible renal group, but no patient in ABOi LRT group.
Conclusion: Although total immunosuppression might be generally potent in
ABOi LDRT, Our center protocol of ABO-incompatible renal transplantation
is not a risk factor for BK virus infection or BKVAN.
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P. Acott1, H. Mouas2
1
IWK Health Centre, Halifax, Canada, 2F. Hoffmann-La Roche Ltd, Basel,
Switzerland
Introduction: BK virus-associated nephropathy (BKVN) develops in 1-10% of
renal transplant patients and often leads to permanent allograft dysfunction and/
or loss. A key factor in the development to BKVN pathogenesis is the “net state
of immunosuppression”, but other factors, including allograft inflammation, acute
rejection and drug toxicity, may contribute as well. In order to investigate whether
mycophenolate mofetil (MMF) is a risk factor for BKVN, a cumulative review of
all BK-related cases reported in patients treated with MMF was carried out.
Methods: The Roche global safety database was searched using MedDRA
version 10. The following search terms were used: BK virus infection;
polyomavirus-associated nephropathy; and human polyomavirus infection. In
addition, the following text strings were used: BK; PVAN; polyoma; and PV.
Results: A total of 84 cases were retrieved from 19 countries, including 21
cases from the USA, 17 from Germany, and 14 from Japan. The average age
of patients was 48 years (range 1.7 to 76 years), and approximately two-thirds
of patients were male. The use of additional immunosuppressive agents was
reported in the majority (93%) of cases and anticipated in all. There was variation
in the reported criteria for diagnosis of BKVN, and only 51 cases (61%) were
confirmed by renal biopsy. In 17 cases (20%) evidence of BK viruria only was
reported, while 16 cases (19%) were unconfirmed. Allograft loss was reported in
only two of the 51 biopsy-proven cases of BKVN. Clinical suspicion of rejection
was reported in 36 cases, and 20 cases provided pathological information about
acute or chronic rejection prior to or at time of diagnosis of BKVN. Confirmed
BKVN occurred on average 249 days (median 181 days) after the first dose
of MMF was administered. The reports originated from the following sources:
53 (63%) from clinical trials; 22 (26%) from literature cases; and 9 (11%)
spontaneous reports. Amongst the clinical trial reports, 42 cases originated from
Roche-sponsored studies in a total of 5712 patients. This represents a BKVN
prevalence of 1.4%, which is below the rate seen in many clinical studies.
Conclusions: The incidence of biopsy-confirmed BKVN in patients receiving
MMF was low. Based on the results of this cumulative review, MMF does
not seem to play a major role in the development of BKVN. Based on in vitro
findings that mycophenolate reduces BK virus replication and considering the
proven benefit of MMF in preventing allograft rejection and steroid pulsing
in the first year post renal transplant, the use of MMF may even be protective
against the emergence of BKVN.

1365 COLLAPSING FOCAL SEGMENTAL
GLOMERULOSCLEROSIS DUE TO POLYOMAVIRUS
INFECTION IN A KIDNEY TRANSPLANT PATIENT:
SEROLOGICALLY, IMMUNOHISTOCHEMICALLY
AND ULTRASTRUCTURALLY VERIFIED CASE
A. Colak1, B. Demirhan1, E. Baskin2, N. Haberal1, M. Haberal3
1Baskent University Faculty of Medicine, Department of Pathology, 2Baskent
University Faculty of Medicine, Department of Pediatrc Nephrology,
3Baskent University Faculty of Medicine, Department of General Surgery
Background: The availability of potent immunosuppressant drugs has resulted
in an increasing incidence of viral infections in solid organ transplantation. Of
particular interest is the occurence of polyomavirus allograft nefropathy. This
affects%5-10 of kidney transplant recipients and is associated with a high risk
of premature graft loss.
Case: 12 year-old-girl with end stage renal failure secondary to VUR was
followed-up with continous ambulatury peritoneal dialysis and hemodialysis for
3 years. She underwent renal transplantation from a deceased donor in July 2007,
in our center. The 4th month of transplantation she was admitted to our hospital
with fever and cough. Patient was thought to have a urinary tract infection.
However, renal biopsy was done because of high suspicion of renal allograft
rejection. Renal biopsy did not show any sign of acute rejection. Biopsy of the
transplant kidney of this patient showed segmental and global collapse of the
glomerular capillaries, marked hypertrophy and hyperplasia of podocytes. The
biopsy revealed that the interstitium was infiltrated by numerous lymphoÂ¬cytes.
Tubular epithelial cells had severe injury and severe reactively changes. The light
microscopy findings which is pointing to collapsing glomerulopathy induce us to
suggest about the possible presence of polyoma virus infection in renal allograft
although there was no significant inclusions in tubule cells. A few number of
tubular epitelial cells were positive by SV 40 antigen-antibody (which reacts with
BK virus) in the immunohistochemical staining.
In the mean while, the patient’s urine was sent for polyoma DNA detection by
PCR, which was reported positive for BK virus. Electron microscopy showed
intranuclear viral particles.
Cidofovir treatment was started for BK virus infection and Tacrolimus was
discontinued and steroid dose was decreased. After discontinued of the
immunosuppression, with antiviral treatment with cidofovir, renal function
was stabilized.
Conclusion: The role of post-transplant factors such as immunosuppressive
medication, immunological injury, microvascular disease and infection in the
pathogenesis of collapsing focal segmental glomerulosclerosis (cFSGS) is also
not well known. Collapsing glomerulopathy is a morphologic variant of FSGS
characterized by segmental and global collapse of the glomerular capillaries,
marked hypertrophy and hyperplasia of podocytes, and severe tubulointerstitial
disease. The cause of this disorder is unknown, but nearly identical pathologic
findings are present in idiopathic collapsing glomerulopathy has been associated
with polyomavirus and treatment with cidofovir. Polyomavirus reactivation
can occur in the kidneys transplant recipients. The effects of PV reactivation on
long-term transplant kidney function are not known.
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1366 BK VIRUS INFECTION IN ASSOCIATION WITH
POST-TRANSPLANT UROTHELIAL CARCINOMA
H-H. Wang1, Y-J. Chiang1, P-C. Lai2, Y-C. Tian2, S-H. Chu1, K-L. Liu1
1
Department of Urology, Chang-Gung Memorial Hospital, 2Department of
Nephrology, Chang-Gung Memorial Hospital
Background: We treated two kidney recipients with urothelial carcinoma and
BK virus infection. We report our experiences and discuss their association.
Objectives: BK virus infection after transplantation has been associated
with graft failure. The association with malignancies are controversial. More
evidence on immunohisochemical staining and viral DNA had been reported.
Subject and methods: BK virus workup was performed for kidney recipients
in our hospital under the condition of hematuria and acute deterioration of renal
function. Two BK virus infected recipients were diagnosed urothelial caricinoma.
We reviewed their history and report our treatment and the disease course.
Results: Two patients received kidney transplantation at Mainland China and
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returned to our country. They had persisted painless hematuria. BK virus was
identified in their urine and cystoscopic workup showed synchronous bladder
and upper tract TCC. They received bilateral native nephroureterectomy and
transurethral resection of bladder tumors followed by intravesical chemotherapies.
We reduce their immunsuppresants to minimal and shift to Sirolimus based
regimen. Both patients had no recurrence on three-month follow up and graft
remained functional. In our center, the incidence of urothelial carcinoma in BK
viruremia recipients was much higher than control. Immunohistochemical stains
in the tumors were negative of BK virus in these two patients.
Conclusion: There are more clues suggesting that BK virus infection may relate
to malignancies. We have detected higher incidence of urothelial carcinoma in
BK virus infected kidney recipients. We should modify our protocol for tissue BK
virus staining and correlate to RTPCR to establish more evident association.
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1367 MONITORING CELLULAR IMMUNITY IN THE
TREATMENT OF BK VIRUS INFECTION AFTER KIDNEY
TRANSPLANTATION: TWO CASE REPORTS
R. Olsson1, A. Sedigh1, A-K. Lidehäll2, M. Engstrand1,2, J. Henriksson1,
A-L. Hammarin3, G. Tydén1, O. Korsgren2, L. Wennberg1
1
Department of Transplantation Surgery, Karolinska University Hospital,
Huddinge, Stockholm, 2Department of Clinical Immunology, Uppsala
University, Uppsala, and 3Department of Virology, The Swedish Institute for
Infectious Disease Control, Stockholm, all in Sweden.
Background: BK virus associated kidney allograft nephropathy (BKVAN)
is regarded as an important cause of graft dysfunction or loss. Overimmunosuppression is considered to be the major cause of BKVAN and the
most commonly applied treatment is reduction of the immunosuppression.
Consequently, a way to monitor the degree of immunosuppression and the specific
immunological reactivity to BK virus would be of significant importance.
Materials and methods: In an ongoing clinical study at our center, preemptive
treatment of BK virus infection is evaluated as a mean to avoid subsequent
BKVAN. Therefore, all kidney transplant recipients are monitored for BK
viremia (defined as >10 000 viral copies/ml). In patients diagnosed with BK
viremia, and therefore treated with a reduction of the immunosuppressive
treatment, T cell reactivity to BK virus was determined at diagnosis and after
1 month. Briefly, after in vitro stimulation with BK virus-specific protein
(protein T), the number of CD8+ T cells producing IFN γ was determined
with FACS, and expressed per ml blood. In addition, the degree of cellular
immunosuppression was analyzed with the ImmuKnow® assay (Cylex Inc.,
Columbia, MD, USA) and the viral load was determined by quantitative PCR.
Results: Case 1: A 45-year-old male with terminal kidney failure due to
nefrosclerosis, who received his first cadaveric kidney. Five months posttransplantation the creatinine suddenly increased from 149 μmol/l to 178
μmol/l. At the time, he was maintained on tacrolimus (trough level 5 ng/ml),
mycophenolate mofetil (1 g daily) and prednisolone (10 mg daily). BK viremia
was discovered (84 000 copies/ml) and mycophenolate mofetil was therefore
discontinued. At diagnosis, the recipient had no BK virus specific CD8+
T-lymphocytes. One month later the creatinine had decreased to 126 μmol/l and
the recipient had developed BK virus specific T-lymphocytes (600 CD8+cells/
ml). Furthermore, the BK viral load was markedly decreased (19 000 copies/ml).
In contrast, the results of the ImmuKnow® assay indicated a progressive overimmunosuppression (427 and 123 ng/ml ATP, respectively). Case 2: A 53-yearold male with chronic kidney failure due to IgA-nefritis, who received his 3rd
kidney. One year after transplantation, the creatinine increased to 141 μmol/l and
BK viremia (80 000 copies/ml) was observed. At the time, immunosuppression
was with tacrolimus (trough level 5 ng/ml), mycophenolate mofetil (2 g daily)
and prednisolone (10 mg daily). At diagnosis, ImmuKnow® showed a moderate
ATP production (340 ng/ml), and we could not detect any BK virus specific
lymphocytes. One month after reducing tacrolimus (trough level 3-5 ng/ml) and
mycophenolate mofetil (1 g daily), the creatinine was stable (143 μmol/l) and
ImmuKnow® showed a similar ATP production (297 ng/ml). However, there was
no longer any BK viremia (5 600 copies/ml) and we were now able to detect the
appearance of BK virus specific lymphocytes (935 CD8+ cells/ml).
Conclusions: In our hands, the Immuknow® assay does not properly reflect
the clinical course or the degree of immunosuppression during treatment of
BK viremia. In contrast, preliminary data indicate that monitoring BK virus
specific T cells might be a more useful clinical tool.
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1368 A NOVEL REAL-TIME PCR ASSAY FOR THE
DETECTION AND QUANTIFICATION OF HUMAN
POLYOMAVIRUS BKV AND JCV
K.K. Iwaki1, Y. Qazi2, M. Smogorzewski2, J. Garcia-Gomez1, K. Matsuda3, Y.
Iwaki1,4
1
USC Metic Transplantation Laboratory, 2Department of Nephrology, USC
Keck School of Medicine, 3Division of Infectious Disease, Children Hospital
of Los Angeles, 4Department of Urology, Pathology and Surgery, USC Keck
School of Medicine
The polyomavirus, BK virus (BKV) and JC virus (JCV), are becoming
increasingly recognized as clinically important pathogens particularly in
transplant recipients. Recent studies have shown polymerase chain reaction
(PCR) to be an effective tool for detecting polyomavirus in a range of
clinical samples. A major obstacle, however, in the development of a reliable
and consistent PCR-based assay has been the large number of intraspecies
polymorphisms in the nucleotide sequences of naturally occurring strains of
BKV and JCV. The goal of this study was to identify an evolutionarily stable
genetic target and to develop of a more robust real-time PCR assay for the
detection and quantification of BKV and JCV in clinical samples.
Amino acid and nucleotide sequences from more than 10 species of
polyomavirus were compared and evaluated for areas where: <a> the product
of the nucleotide sequence was placed under strict biological restrictions in
terms of form and function, <b>the product of the sequence was necessary for
efficient viral replication and infection, <c> the amino acid sequence was highly
conserved within the genus polyomavirus, and <d> the interspecies variation in
nucleotide sequence was sufficient for accurate species discrimination.
A stable, conserved region within the C-terminus of the VP2/3 gene of the
polyomavirus was elucidated and determined to be an effective and resilient
target. A real-time PCR based assay was developed, which targeted the
hydrophobic alpha-helix region within the C-terminus of the VP2/3 gene.
Specificity of the assay was confirmed by testing against known amounts of
cloned BKV DNA and JCV DNA. The assay allowed specific and reliable
quantification of 8 copies of viral DNA.
In conclusion, our novel molecular diagnostic assay would be very useful to
monitor polyomavirus in transplant patients.

CONCURRENT ORAL SESSION 98: CAN – CELL AND
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1369 CYSTATIN C AS A RELIABLE MARKER OF KIDNEY
FUNCTION IN RENAL TRANSPLANT PATIENTS
B. Geramizadeh1, N. Azarpira, M. Ayatollahi, M. Aghdai, R. Yaghoobi,
M. Banihashemi, Z. Malekpour
1
Transplant Research Center, Pathology Department, 2Transplant Research
Center, 3Transplant Research Center, 4Transplant Research Center,
5
Transplant Research Center, 6Transplant Research Center, 7Transplant
Research Center, 8Transplant Research Center
Introduction: Serum creatinine (sCr) is the most commonly used biochemical
parameter for evaluating the kidney function, but, due its limitations, it is not
the ideal marker for glomerular filtration rate (GFR). Serum Cystatin C (sCyC)
appears to be an endogenous marker of GFR.
Purpose: To assess the use of sCyC as a marker of renal function in kidney
transplant patients, we compared it with sCr and with creatinine clearance
(CrC) in a 24-hour urine specimen.
Methods: Among 60 patients (62.8% men, 37.2% women) undergoing kidney
transplantation (average age: 44.87 ± 13.37 years) we determined at 1, 3, 5, and
7 days after kidney transplantation: sCr (using the Jaffe colorimetric method),
sCyC (ELISA method), and Cr clearance with a 24 hours urine specimen.
Results: During the first 5 days following transplantation, there was a
progressive decline in sCr levels. In the first 5 days post transplantation we
couldn’t find good correlation between CrC and sCyC, but after 7 days there
was a good correlation between CCr and sCyC which is easier to perform and
it doesn’t need 24 hour urine specimen collection.
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Conclusion: sCyC is an endogenous marker of GFR. Its limitations relate
to its being affected by high doses of steroids in the first days following
transplantation. After a week post transplantation, it is correlated with CrC in
a 24-hour urine. So after a week post renal transplantation sCyC is a reliable
marker of kidney function.
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1370 COMPARISON OF GLOMERULAR FILTRATION
RATE ESTIMATION BETWEEN CREATININE CLEARANCE,
CREATININE BASED EQUATIONS AND CYSTATIN C BASED
EQUATIONS IN KOREAN RENAL TRANSPLANT RECIPIENTS

Characteristics

2

3

1

1

1

N=37

Range

Age (yr)

44.13±9.36

27-60

Male [n(%)]

18 (48.64)

Weight (kg)

58.14±10.44

38.8-80.8

Height (cm)

163.86±9.28

144.1-182.0

Body surface area (m2)

1.62±0.17

1.24-1.89

Creatinine (mg/dl)

1.05±0.34

0.6-2.4

Cystatin-C (mg/l)

1.26±0.41

0.69-2.69

Table 2. Bias, precision, accuracy and relative difference of creatinine and
cystatin C estimates

Bias Precision

Accuracy
Relative
Paired
Correlation (%) within difference
t- test
coefficiency
(P value)
(%)
30% 50%

51Cr-EDTA GFR 71.83±20.41
Creatinine
clearance

76.20±20.78

3.96

12.52

0.66

0.817

33.33 55.56

9.03

Estimates using creatinine
Abbreviated
MDRD

76.97±21.03

5.14

12.96

0.021

0.805

81.08 94.59

10.28

IDMS traceable
MDRD

72.42±19.79

0.59

12.57

0.778

0.805

86.49 97.30

3.76

Walser

70.87±19.29 -0.96

13.83

0.675

0.759

86.49 94.59

1.94

12.12

0.018

0.816

83.78 89.20

11.10

Cockcroft-Gault 76.77±19.38

4.94

Jelliffe-2

76.80±21.69

4.97

14.24

0.041

0.773

81.08 91.89

10.82

Gates

87.96±20.97

7.14

13.70

0.003

0.781

81.08 89.18

13.31

Nankivell

88.15±24.67 16.32

16.65

<0.001

0.743

62.16 83.78

27.21

Salazar

53.30±20.89 -18.52

35.53

0.003

-0.480

32.43 56.76

-7.97

-0.02

Estimates using cystatin C
MacIsaac

69.06±18.98 -2.77

15.67

0.289

0.686

83.78 94.59

Le Bricon

70.62±17.50 -1.21

15.27

0.632

0.686

78.38 94.59

3.06

Orebro

71.41±22.44 -0.42

17.09

0.882

0.686

75.68 91.89

2.19
11.16

Filler

77.11±22.68

5.28

17.32

0.072

0.682

72.97 94.59

Larsson

69.44±26.10 -2.38

20.86

0.491

0.622

70.27 86.49

-0.79

Grubb

70.80±29.97 -1.03

22.79

0.784

0.650

67.57 91.89

-1.27

Hoek

64.31±18.03 -7.52

15.40

0.005

0.686

81.08 94.59

-7.04

Rule

64.20±19.49 -7.64

15.98

0.006

0.680

81.08 94.59

-7.67

Bias, mean difference between the actual measured GFR and the estimated GFR
Precision, standard deviation of the difference between the measured and estimated GFR
Accuracy, proportion of GFR estimates within 30% and 50%
Relative difference, percent difference from the measured GFR
All values expressed as ml/min/1.73m2; 51Cr-EDTA, 51Cr-Ethylene diamine tetraacetic acid.
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1371 BLOCKADE OF ADVANCED GLYCATION IN CHRONIC
ALLOGRAFT DYSFUNCTION
M. Baumann, C. Jianxing, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R.D. Isar, TU Munich
Background: Advanced glycation end products (AGEs) induce oxidative stress
and inflammation by activating the receptor of AGE (RAGE). Evidence exists
that AGEs are present in chronic kidney disease and RAGE-blockade improves
renal function in diabetes models. We hypothesize that RAGE-blocker improve
renal transplant function.
Methods: Fisher 344 kidneys were orthotopically transplanted into Lewis
recipients. Recipients were treated with placebo, an unspecific RAGE-blocker
(aminoguanidine 100mg/kg/day), specific RAGE-blocker (pyridoxamine
50mg/kg/day) and angiotensin II type 1 receptor blocker (AT1RB; candesartan
5mg/kg/day) over 24 weeks posttransplantation. Each group consisted of 8
rats. Before harvesting 24-h proteinuria was determined. Intra-arterial blood
pressure and renal blood flow was measured under isoflurane anesthesia and
renal vascular resistance was calculated.
Results: RAGE-blockade did not reduce proteinuria nor was glomerulosclerosis
reduced as compared to controls. Blood pressure and renal blood flow were
significantly reduced by the AT1RB candesartan (P<0.05) and renal vascular
resistance tended to be lower after RAGE-blockade (P=0.08). Heart weight/
body weight ratio was lowered by all treatments (P<0.05).
Conclusion: RAGE-blockade does not ameliorate transplant-related
proteinuria. As cardiac hypertrophy is reduced by this treatment and renal
vascular resistance shows a tendency to be ameliorated by RAGE-blockade,
a beneficial cardiovascular rather than direct renal effect may be suggested in
this animal model.
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Y. Yeo , D.H. Moon , D.J. Han , S.B. Kim , J.S. Park , S.K. Park
Division of Nephrology, 1Department of Internal Medicine, 2Department
of Nuclear Medicine and 3Department of Surgery, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, South Korea
Background: Accurate measurement of glomerular filtration rate (GFR) is
critical for the successful management of kidney transplant recipients. Since
reference methods to measure GFR cannot be easily implemented, numerous
equations based on creatinine have been developed to estimate GFR. However,
these equations have not been shown to be reliable in renal transplant
recipients. We aimed to compare the performance of creatinine clearance,
creatinine based equations and cystatin C based equations in Korean renal
transplant patients.
Methods: We measured 51Cr-EDTA clearance as a reference GFR in 37
stable kidney transplant recipients. For accurate measurement of GFR, 6
plasma samples were taken at 10, 20, 30, 60, 180 and 300 minutes after 50μCi
51
Cr-EDTA bolus injection. Serum creatinine was measured by rate-blanked
compensated kinetic Jaffe assay. Because the creatinine concentration measured
by compensated kinetic Jaffe assay was traceable to an isotope dilution mass
spectrometry (IDMS) determination, we estimated GFR using the IDMS
traceable MDRD equation in addition to the abbreviated MDRD equation.
(Vickery et al. Nephrol Dial Transplant (2006) 21:2439-2445). Cystatin C
was measured by particle enhanced immunonephelometric method. GFR was
estimated using 13 creatinine based equations and 8 cystatin C based equations
as well as creatinine clearance. The bias, precision, accuracy within 30% and
50%, relative difference and agreement of each methods were compared.
Results: The mean 51Cr-EDTA GFR was 71.83±20.41 ml/min/1.73m2. Each
GFR equation correlated significantly with 51Cr-EDTA GFR. Abbreviated
MDRD equation overestimated GFR significantly (P=0.021) with a bias
of 5.14 ml/min/1.73m2 and an accuracy within 30%, 50% of 81.08%,
94.59% respectively. The IDMS traceable MDRD equation had the highest
accuracy (accuracy within 30%, 50% of 86.49%, 97.3% respectively) with
a bias of 0.59 ml/min/1.73m2 and a precision of 12.57 ml/min/1.73m2. The
Walser equation based on creatinine also showed high accuracy (accuracy
within 30%, 50% of 86.49%, 94.59% respectively) with a bias of -0.96 ml/
min/1.73m2. Among the cystatin C based equations, the MacIsaac equation
had the highest accuracy (accuracy within 30%, 50% of 83.78%, 94.59%
respectively) with a bias of -2.27 ml/min/1.73m2 and the least relative
difference of -0.02%. Creatinine clearance had the lowest accuracy (accuracy
within 30%, 50% of 33.33%, 55.56% respectively) with a bias of 3.98 ml/
min/1.73m2
Conclusion: Among the various GFR equations, IDMS traceable MDRD
equation was the most accurate equation for GFR in Korean renal transplant
recipients. The cystatin C based GFR equations, especially MacIsaac method
exhibits similar diagnostic characteristics to the IDMS traceable MDRD
equation.
Table 1. Patient characteristics
1

Mean±SD
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1374 SERUM LEVEL OF PLASMINOGEN ACTIVATOR
INHIBITOR-1 (PAI-1)IS SUPERIOR TO SERUM CREATININE
OR EGFR TO PREDICT HISTOLOGICAL CHRONIC
ALLOGRAFT DAMAGE INDEX OF RENAL ALLOGRAFTS

R. Thuraisingham, E. VIllar, M. Varagunam, M. Yaqoob
Barts and The London NHS Trust
Introduction: Dialysis requiring delayed graft function (D-DGF) is an
independent predictor of long-term renal transplant survival. More recently non
dialysis requiring delayed graft function (ND-DGF) as defined by a creatinine
reduction ratio between days 1 and 2 (CRR2) of < 30% has been shown to have
similar outcomes to D-DGF. We applied this definition in our cohort of patients
to examine outcomes.
Methods: All transplants between 1996 and 2004 at our centre were assessed
of which 361 were included in this study (mean age of 44 (range 17-73), 66%
male). Patients were divided into 3 groups: IGF (immediate graft function;
CRR2 >30%), D-DGF and ND-DGF. Follow up was for a mean of 4.2 years
(SE + 0.06).
Results: IGF accounted for 36% of patients, D-DGF 22% and ND-DGF
42%. CRR2 was inversely correlated with serum creatinine on day 7 (r
=-0.673 p <0.001), day 30 (r=-0.377 p <0.001), day 90 (r=-0.256) and
day 365 (r=-0.186 p=0.008). Risk of graft loss was significantly different
between the groups with D-DGF > ND-DGF > IGF (shown below), having
adjusted for recipient age and sex, donor age and sex, HLA mismatches and
immunosuppression.
Conclusion: Our study shows that CRR2 influences long-term graft outcomes.
Unlike the original description however, patients with ND-DGF carried
an intermediate risk and hence could be considered as early as Day 2 for
calcineurin inhibitor sparing treatment regimens.

H.R. Chang1,2, J.D. Lian1, S.F. Yang2, C.C. Lin3, M.C. Wen4, Y.S. Hsieh3
Division of Nephrology, Department of Internal Medicine, Chung Shan
Medical University Hospital, Taichung 402, Taiwan, 2Institute of Medicine,
Chung Shan Medical University, Taichung 402, Taiwan, 3Institute of
Biochemistry and Biotechnology, Chung Shan Medical University, 4Division
of Pathology, Taichung Veterans General Hospital,
Background: Plasminogen activator inhibitor-1 (PAI-1) has been recognized to
play an important role in renal fibrosis. We conduct this study to examine whether
serum PAI-1 is with a role predicting chronic allograft nephropathy (CAN).
Methods: A total of consecutive 50 cadaveric kidney transplant recipients
receiving graft biopsies were enrolled. The pathologic diagnosis of the graft
biopsies were acute tubular necrosis (ATN; n=12), borderline rejection (BR;
n=7), acute rejection (ACR; n=12), CAN (n=11), polyomavirus nephropathy
(PVN; n=3) and others (n=5; glomerulopathy, n=4; calcineurin inhibitor
nephropathy, n=1). The serum level of PAI-1 of each patient and chronic
allograft damage index (CADI) score of each graft were determined.
Results: The distribution of CADI score in all patients was 4 (0-10) (median
and range) and in each group was ATN 0.5 (0-4), BR 2.0 (1-4), ACR 4.0 (2-8),
CAN 5.0 (4-10), PVN 7 (4-8) and others 2 (0-8). The distribution of serum
PAI-1 level in the ATN group was 9.38 (2.35-14.52) ng/ml, in the BR group
was 10.09 (0.61-18.06) ng/ml, in the ACR group was 11.08 (2.32-20.68) ng/ml,
in the CAN group was 14.51 (3.66-21.12), in the PVN was 14.79 (13.94-21.94)
and in the others group 16.35 (4.05-21.01) ng/ml. The CADI score is associated
with the serum PAI-1 activity (r=0.405, p=0.003) and is inversely associated
with serum creatinine (r=-0.348, p=0.011) but not with eGFR (p=0.124).
Conclusion: Serum PAI-1 level is superior to serum creatinine and eGFR to
predict CADI score, the quantitative score of CAN.

TUESDAY

1372 THE CREATININE REDUCTION RATIO BETWEEN
DAYS ONE AND TWO (CRR2) IS AN EARLY
INDEPENDENT PREDICTOR OF POOR LONG TERM RENAL
GRAFT SURVIVAL

1

POSTER BOARD NUMBER P2 – 174
1375 PREDICTING THE IDEAL SERUM CREATININE OF
RENAL TRANSPLANT RECIPIENT BY SIMPLE FORMULA:
BASED ON THE BALANCE BETWEEN METABOLIC
DEMANDS OF RECIPIENTS AND RENAL MASS SUPPLY FROM
DONORS

POSTER BOARD NUMBER P2 – 172
1373 MAST CELLS TRYPTASE IN PATIENT AFTER
RENAL TRANSPLANTATION
M. Barczyk1, M. Mysliwiec2, M. Kalinowski1, M. Rowinski1, S. Brzosko2
1
Dep. Nephrology And Transplantology, Specialized Hospital Bialystok, 2Dep.
Nephrology And Transplantology, Medical Univesity Bialystok
Mast cells are involved in the pathogenesis of interstitial fibrosis, acute
renal transplant rejection and chronic allograft nephropathy. The aim of
this study was to evaluate MC tryptase concentration in serum of 58 renal
transplant recipients in different time after transplantation in relation to
the graft function. We found for the first time that patients after kidney
transplantation had much higher serum tryptase concentration than
healthly controls and we demonstrated positive correlation between serum
tryptase concentration and Hgb, Hct, Rbc count and hepatic cells damage.
We were not able to show any direct correlation between serum tryptase
concentration and graft function. Clinical relevance of this findings demand
further investigation.
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C-K. Oh1, B.M. Lee1, J.H. Kim1, H. Kim1, S.I. Kim2, Y.S. Kim2
1Ajou University School of Medicine, 2Yonsei University College of Medicine
Background: Serum creatinine (Scr) is the most useful and frequently used
test to estimate the graft function after kidney transplantation. Our previous
study demonstrated that the independent predictors of recipient post-transplant
Scr included the ratio of graft weight to recipient body weight, the ratio of graft
weight to recipient body surface area (BSA), and the ratio of graft weight to
recipient body mass index (BMI).
Methods: This prospective analysis about the impact of the balance between
metabolic demands and renal supply on the post-transplant Scr of recipient was
conducted and previously reported. We plotted the scattered graph by X-axis of
the independent predictors of Scr by linear regression and Y-axis of recipient
Scr. To generate the predictive formula of Scr, we calculated a statistical fit line
of the plotted cases using a fit method of linear regression, and two regression
prediction lines for the upper and lower 95% confidence interval. Each line was
converted into the predictive formula.
Results: Scr=-0.0033*(Graft weight(g)/Recipient BSA(m2))+1.75. Under
95% confidence, the Scr ranges from -0.0033*(Graft weight(g)/Recipient
BSA(m2))+1.07 to -0.0033*(Graft weight(g)/Recipient BSA(m2))+2.44.
Scr=-0.1049*(Graft weight(g)/Recipient body weight(kg))+1.72, which
ranges from -0.1049*(Graft weight(g)/Recipient body weight(kg))+1.06 to
-0.1049*(Graft weight(g)/Recipient body weight(kg))+2.37.
Scr=-0.0158*(Graft weight(g)/Recipient BMI(kg/m2))+1.56, which ranges
from -0.0158*(Graft weight(g)/Recipient BMI(kg/m2))+0.75 to -0.0158*(Graft
weight(g)/Recipient BMI(kg/m2))+2.26.
Conclusions: Prediction of post-transplant Scr could be determined by
measuring the graft weight as well as the recipient weight and height. When
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recipient’s Scr is significantly higher than that predicted by the formula, a
clinician should suspect the possible underlying graft injuries.
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1377 ANGIOPOIETINS AND TIE2¡¯S EXPRESSION
IN THE RAT RENAL ALLOGRAFT WITH CAN

POSTER BOARD NUMBER P2 – 175
1376 ASSOCIATION OF TGF-β1 AND VEGF GENE
POLYMORPHISMS WITH CHRONIC ALLOGRAFT
NEPHROPATHY AND GRAFT SURVIVAL IN RENAL
TRANSPLANT RECIPIENTS

TGF-β1

C-509→T polymorphism
C/C

C/T

T/T

No CAN

38 (19.0)

112 (56.0)

50 (25.0)

CAN

5 (23.8)

10 (47.6)

6 (28.6)

0.706

p-value

TGF-β1

p-value

T/T

T/C

C/C

40 (20.0)

113 (56.5)

47 (23.5)

CAN

5 (23.8)

10 (47.6)

6 (28.6)

0.705

p-value

0.476

0.524

1.000

p-value

p-value

T allele

C allele

0.483

0.518

0.476

0.524

1.000

p-value

C-2578→A polymorphism
C/C

C/A

A/A

No CAN

111 (55.5)

71 (35.5)

18 (9.0)

CAN

13 (61.9)

8 (38.1)

0 (0.0)

0.467

p-value

VEGF

T allele
0.530

T869→C polymorphism

No CAN

VEGF

C allele
0.470

C allele

A allele

0.733

0.268

0.810

0.190

0.356

p-value

C405→G polymorphism
C/C

C/G

G/G

No CAN

33 (16.5)

101 (50.5)

66 (33.0)

CAN

5 (23.8)

9 (42.9)

7 (33.3)

* Data were analyzed by Fisher’s exact test

0.588

C allele

G allele

0.418

0.583

0.452

0.548

0.743

POSTER BOARD NUMBER P2 – 177
1378 ROLE OF ERK2 IN TGF-¦Â-INDUCED EPITHELIALMESENCHYMAL TRANSITION OF HUMAN RENAL
PROXIMAL TUBULAR EPITHELIAL CELLS AND CHRONIC
ALLOGRAFT NEPHROPATHY
X.L. Chen, Z. Ding, Z.S. Chen, N.Q. Gong
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College,
Huazhong University of Science And Technology
Objective:
Transforming
growth
factor-¦Â
(TGF-¦Â)-induced
epithelial¨Cmesenchymal transition (EMT) in renal tubular epithelial cells
is thought to contribute to chronic allograft nephropathy(CAN). However,
the underlying signaling mechanism remains largely unknown. This study
investigated the role of extracellular signal-regulated kinase-2 (ERK2) activation
in EMT process in renal tubular epithelial cell line (HK-2) and CAN.
Methods: HK-2 cells were transfected with adenovirus-mediated antisense
ERK2 (Adanti-ERK2) and then stimulated with 10ng/ml TGF-¦Â. The
expression level of mesenchymal markers£¨¦Á-SMA and vimentin£©and
epithelial markers (E-cadherin) were assessed by immunofluorescence. Cell
migration was measured by Boyden chamber. Furthermore, a series of human
specimen of living-related kidney allografts with biopsy-proven CAN were
detected by immunohistochemistry.
Results: TGF-¦Â induced a time-dependent EMT characterized by de novo
expression of ¦Á-SMA and vimentin, loss of E-cadherin and increased
migratory property. Transfection with Adanti-ERK2 was able to attenuate
TGF-¦Â1-induced EMT changes in HK-2. The detection of kidney specimen
demonstrated the expression of increased ¦Á-smooth muscle actin (¦Á-SMA)
and vimentin coupled with reduced E-cadherin, confirming the presence of
EMT in CAN. Concomitantly, the up-regulation of TGF-¦Â was co-localizes on
the tubular epithelium with sites of EMT, and the expression of phosphorylated
ERK2-positive cells was markedly increased.
Conclusions: The results suggest the important role of ERK2 in the progression
of TGF-¦Â1-induced EMT and provide a novel therapeutic avenue against CAN.
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C-D. Kim, J-H. Cho, S. Huh, H-M. Ryu, J-Y. Choi, H-J. Choi, H-J. Choi,
S-H. Park, Y-L. Kim
Division of Nephrology, Department of Internal Medicine, Transplantation
and Vascular surgery, Kyungpook National University School of Medicine,
Daegu, 700-721, Korea
Purpose: Transforming growth factor-β1 (TGF-β1) has been associated
with the promotion of renal allograft interstitial fibrosis and thereby
chronic allograft nephropathy (CAN). Vascular endothelial growth factor
(VEGF) has been shown to contribute to cytoprotection of the graft after
kidney transplantation. We investigated the influence of single nucleotide
polymorphisms (SNPs) of the TGF-β1 (C-509T and T869C) and the VEGF
gene (C-2578A and C405G) on graft survival and the development of
CAN.
Methods: Genotyping was carried out using a real-time polymerase chain
reaction which was performed on the LightCycler480 in 221 Korean renal
transplant recipients and 148 healthy controls. According to the typical biopsy
proven appearances of CAN or chronic calcineurin inhibitor nephrotoxicity,
the recipients were separated into the CAN (n=21) and the No CAN (n=200)
groups.
Results: The genotype frequencies of the SNPs were in Hardy-Weinberg
equilibrium. The distributions of genotypes and alleles did not differ between
recipients and controls. No significant differences were observed in the
genotype distributions and allele frequencies between the CAN and the No
CAN groups (Table 1). On the basis of the linkage disequilibrium coefficients
between polymorphisms, which indicated that investigated polymorphisms of
TGF-β1 (D′=0.98) and VEGF (D′=0.78) were in tight linkage, haplotypes were
reconstructed. However, there were no significant differences in the frequencies
of the reconstructed haplotypes between the two groups. There were no
statistically significant effects of TGF-β1 and VEGF gene polymorphisms on
graft survival.
Conclusion: This study demonstrates that four selected SNPs of the TGF-β1
and the VEGF genes are not associated with an increased risk of development
of CAN and graft survival in renal transplant recipients.
Table 1. TGF-β1 and VEGF genotype distributions (%) and allele frequencies
in 200 recipients without CAN and 21 with CAN

Y.P. Lu, X. Ma, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University
Objective: Angiopoietin-1 and Angiopoietin-2 are both ligands for the
endothelium- specific tyrosine kinase Tie2. Previous studies have indicated
that the mutual regulations of Ang1, Ang2 and Tie2 play a significant role
in chronic cardiac allograft vasculopathy. We investigated the expressions of
Ang1, Ang2 and Tie2 and their roles in rat renal allograft with chronic allograft
nephropathy (CAN) in this study.
Methods: Renal transplant following the procedure of Kamada with our
modification was orthotopically performed by using Fisher (F344, RT1lv1)
rats as both donor and recipient in autograft group. Fisher and Lewis (LEW,
RT1l) were used as donor and recipient in allograft group, respectively. The
allograft group was treated with CsA 10mg.kg-1.d-1*10d. At 4w, 8w, 12w
post-transplant, SCr was measured and the pathologic changes were assessed
according to Banff 97 criteria. The expression of mRNA(¦¤ct) and protein of
Ang1, Ang2 and Tie2 was determined and localized by real-time fluorescence
quantitative PCR and by immunohistochemistry.
Results: The elevation of SCr and the pathologic changes of CAN were observed
in all the allografts at 8w and 12w. The expression of Ang1 and Ang2 was localized
in epithelial cells and endothelium of vascular bundles of glomeruli, and Tie2 was
specifically expressed in endothelium of vessels both in auto- and in allografts at
all the time points post transplant. At 4w, the difference of mRNA expression of
Ang1, Ang2 and Tie2 between 2 groups was not significant (p>0.05). Comparing
with the autografts, the mRNA expression of Ang1 was decreased significantly at
8w and 12w post-transplant (p<0.05), and the mRNA expression of Ang2 and Tie2
were increased significantly (p<0.05). These changes of the expression of all the 3
genes showed a significant correlation with the Banff score in the allografts.
Conclusions: This study for the first time shows that the abnormal expression
and mutual regulations of Ang1, Ang2 and Tie2 are likely to play an important
role in the development of CAN in rat renal allografts.
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1379 CHARACTERIZATION OF CHRONIC RENAL
ALLOGRAFT DYSFUNCTION BY HUMAN SERUM
PROTEOMIC ANALYSIS

1381 URINARY C3 EXCRETION IS NOT A GOOD
PROGNOSTIC INDICATOR OF RENAL ALLOGRAFT
OUTCOME

Y. Gao, K. Wu, Y. Xu, H. Zhou, W. Zhang, Z.C. Chen, X. Lin, W. He,
F. Wang, Z. Fang
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of
Science And Technology
Backgroud: Most late renal allograft failure is attributed to chronic allograft
dysfunction, but this is a clinicopathological description and not a diagnosis,
and its pathogenesis and treatment are largely unknown. The purpose of
this study was to apply techniques for identifying chronic renal allograft
dysfunction biomarkers in human serum using two-dimensional differential ingel electrophoresis (2-DE DIGE), and characterizing the protein biomarkers
using matrix-assisted laser desorption/ionization (MALDI) to study the
pathogenesis and treatment strategy of chronic allograft dysfunction.
Method: Serum samples were divided into 5 groups: acute reject, chronic
allograft dysfunction, healthy volunteers, chronic renal function failure and
long-term stable renal function. serum samples were first chromatographed
using an immunoaffinity HPLC column, to selectively remove albumin,
immunoglobulins, transferrin, haptoglobin, and antitrypsin. Then they were
processed using the immunoaffinity column. Differential protein analysis was
performed using DIGE. These spot features were excised, trypsin digested, and
analyzed by MALDI.
Result: A total of 34 differential protein spot features were found. These spot
features included apolipoprotein A-I precursor, selenium-binding protein 1,
complement C4-A precursor, complement factor H-related protein 1 precursor,
complement component C9 precursor, vitamin D-binding protein precursor,
plasma retinol-binding protein precursor, clusterin precursor, hornerin, et al.
Conclusion: These biomarker candidates may provide the basis for
understanding the pathogenesis and treatment strategy of chronic allograft
dysfunction further.

K.M. Brown1, S.H. Sacks1, N.S. Sheerin2
1
Department of Nephrology and Transplantation, Guy’s Hospital, King’s
College London, 2School of Clinical Medical Sciences, Newcastle University
Murine studies have shown a key role for local C3 secretion in renal allograft
rejection. We know that increased levels of C3, both intact and activated, are
found in the urine of patients with glomerulonephritis, however, there is little
information relating to transplantation. This study prospectively investigated
the impact of acute inflammatory events on urinary C3 concentration as well as
the influence of urinary C3 on the incidence of graft dysfunction.
A cohort of adult transplant recipients (n=88) who received a renal allograft
between June 2003 and January 2005 were recruited from the out-patient clinic
based at Guy’s and St Thomas’ Hospital NHS Foundation Trust. Patients were
prospectively followed for an average of 336.2 days (range; 41 to 708 days)
post-transplantation or until allograft failure with return to dialysis. Urine and
serum samples were collected at the following time-points:
(a) Baseline - 2 weeks post-transplantation or when graft function was achieved,
whichever was the latest.
(b) Stable function - 3 months and 12 months post-transplantation, with no
evidence of graft dysfunction.
(c) Event-related - when there was evidence of acute graft dysfunction due to
rejection, infection or drug (cylosporin / tacrolimus) -induced toxicity.
Prospective analysis of renal transplant recipients revealed that episodes
of graft dysfunction (rejection, infection or CNI-induced toxicity) tended to
correlate with increased urinary C3 compared to baseline samples taken at
onset of graft function and at 3 and 12 months post-transplantation. However,
there was no significant correlation between urinary C3 concentration and
graft function (measured by serum creatinine and eGFR). Donor-recipient
demographics (ethnicity, cause of ESRF and C3F/S allotype), as well as time
post-transplantation, significantly influenced urinary C3 levels.
Despite the identification of several factors that significantly affect urinary C3
levels, this study indicates that urinary C3 excretion is not a good prognostic
indicator of renal allograft outcome.
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1380 LOCAL PRODUCTION OF C3 IS NOT A RISK FACTOR
FOR RENAL ALLOGRAFT FUNCTION
K.M. Brown1, S.H. Sacks1, N.S. Sheerin2
Department of Nephrology and Transplantation, Guy’s Hospital, King’s
College London, 2School of Clinical Medical Sciences, Newcastle University
Murine studies have shown a key role for local C3 secretion in renal allograft
rejection. In humans a structural polymorphism exists in the C3 gene that is
based on the reactivity of the HAV4-1 monoclonal antibody. Donor-recipient
pairs who are mismatched at the C3 HAV4-1 locus provide a unique setting for
the quantification of donor specific C3 in the recipient circulation. Previous
studies suggested that secretion of HAV4-1+ C3 increased during episodes of
acute rejection in the early post-operative phase. This study investigates how
donor C3 allotype, and the relationship of locally secreted C3 influences late
graft outcome.
We determined the HAV4-1+/- allotype of 427 pairs of adult kidney donors and
recipients transplanted at Guy’s Hospital from 1993-2002 and then related the C3
HAV4-1+/- polymorphism status to demographic and clinical outcome data. As
a secondary analysis serum samples were collected from patients in this cohort
who were still attending the renal transplant clinic in 2004 (n=89). Double ligand
ELISA was used to quantify HAV4-1+ C3 and total C3 in these samples.
Analysis of Caucasian recipients identified 93 C3 HAV4-1-/- recipients receiving
a C3 HAV4-1+ kidney and 147 C3 HAV4-1-/- receiving C3 HAV4-1-/- kidneys.
Kaplan-Meier analysis of graft survival suggested a trend for improved outcome
of the C3 HAV4-1+ donor group, although the data was non-significant (p=0.19,
log rank test). HAV4-1+ C3 was detectable in serum samples collected from
these patients up to 8 years post-transplantation. However, serum C3 HAV4-1+
concentration did not show a significant correlation with serum creatinine as an
estimate of graft function (r2<0.001, p=0.89).
Ongoing genetic analysis will determine the role of complement protein
polymorphism analysis as predicators of transplant outcome. This study would
suggest that the quantity of C3 protein produced within the graft does not
correlate with function.

1
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1382 HORNERIN AND GALECTIN-7 ARE PROMISING
BIOMARKERS FOR CHRONIC ALLOGRAFT NEPHROPATHY
K. Wu, Y. Xu, Y. Gao, H. Zhou, Z.K. Chen
Institute of Organ Transplantation, Key Laboratory of Organ Transplantation,
Ministry of Public Health, Ministry of Education, Tongji Hospital, Tongji
Medical College, Huazhong University of Science A
Chronic Allograft Nephropathy (CAN) remains the leading cause of renal
graft loss after the first year following renal transplantation. Identifying
potentially protein biomarker associated with CAN could improve recipient
care by allowing CAN to be diagnosed non-invasively and promptly. Three
patient groups were defined on the basis of allograft function, clinical course,
and allograft biopsy result: CAN group (n=4), chronic renal failure group
(n=4) and stable transplant group (n=4, renal transplant patients with normal
renal function more than one year after transplantation). The control group
included 4 normal volunteers. We attempted to identify novel biomarkers
associated with CAN by analyzing serum proteins using differential ingel electrophoresis (DIGE), and characterizing the protein biomarkers
using tandem mass spectrometry (MS/MS). Serum samples were first
chromatographed using an immunoaffinity HPLC column, to selectively
remove albumin, immunoglobulins, transferrin, haptoglobin, and antitrypsin.
Differential protein analysis was performed using DIGE. A total of 40 protein
spot-features were found to be different among these groups. These spot
features were excised, trypsin digested, and analyzed by MALDI/TOF/TOF.
We identified 2 unique proteins that were increased and 2 unique proteins
that were decreased significantly in CAN. Western blot analysis confirmed
increased levels of 1 protein and decreased levels of 1 protein in the CAN
samples. In an independent series of serum samples from 15 patients with
CAN, 15 stable transplant patients, 15 chronic renal failure patients and
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15 normal volunteers, increased level of Hornerin and decreased level of
Galectin-7 were found to be associated with CAN. The results suggest that
affinity column enrichment and 2-D DIGE can be used to identify numerous
proteins differentially expressed in serum from patients after transplantation.
These two proteins have been described as playing important role in human
immune system. And the novel role of Hornerin and Galectin-7 identified
provide a potential means of diagnosing CAN by non-invasive methods
and also provide potentially important information about the development
and management of CAN and possible potential targets future therapeutic
strategies in the prevention of CAN.

POSTER BOARD NUMBER P2 – 182
1383 CYSTATIN C OUTPERFORMS CREATININE-BASED
EGFR IN ADULT RENAL TRANSPLANTATION
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1384 THE USEFULNESS OF SELECTED URINARY
PROTEINS LEVELS MEASUREMENT AND PATHOLOGICAL
EXAMINATION IN THE PREDICTION OF LONG–TERM
RENAL TRANSPLANT FUNCTION
M. Durlik1, T. Cieciura1, E. Nowacka-Cieciura1, A. Perkowska-Ptasinska1,
M. Sawosz1, T. B±czkowska1, O. Tronina1, A. Urbanowicz1, M. Pacholczyk2,
M. Cieciura3
1Departament of Transplantation Medicine And Nephrology, Medical
University of Warsaw, 2Departament of Transplantation General And
Transplantation Surgery, Medical University of Warsaw, 3University of
Information Technology
Chronic allograft dysfunction is the leading cause of renal loss one year after
transplantation. There is still a need to find some biomarkers identifying
recipients with the high risk of premature renal transplant dysfunction. The
aim of the study was to evaluate the usefulness of selected urinary proteins
measurement and pathological examination in the prediction of chronic kidney
disease (CKD) staging five years after protocol or diagnostic renal allograft
biopsy.
Methods: 65 renal allograft recipients, between third month and third year after
transplantation with preserved graft function at least one year after biopsy were
included into the study. The Cockcroft–;Gault formula was used to estimate
initial and final glomerular filtration rate (eGFR C–;G). Beta2–;microglobulin,
alpha1–;microglobulin, albumin, immunoglobulin G (IgG) and total protein
concentrations were obtained from the second morning urine specimen (just
before the biopsy) and calculated per 1 gram of creatinine excreted in urine
(Ucr). Pathological examinations of graft specimens were done according
to Banff&#8217;97 schema. All data along with recipient age, time after
transplantation, serum creatinine level (Scr), and its change over period of 2
months prior to biopsy as well as e–;GFR were taken for analysis. Statistical
calculations were performed using MANOVA and Stepwise Discriminant
Analysis (SDA).
Results: We were able to predict chronic kidney disease staging five years after
biopsy in 86.15% of cases. Our methodology has allowed to correctly identify
75% (3 of 4), 95% (19 of 20), 84.62% (22 of 26), 77.78% (7 of 9) and 83.33%
(5 of 6) patients with chronic kidney disease stage 1, 2, 3, 4, and 5 respectively.
Percentages of totally (0.6884) and focally (0.4804) sclerotized glomeruli as
well as urinary excretion of IgG calculated per 1 gram of Ucr (0.5781) were
highly indispensable parameters. Nevertheless, initial eGFR (1.6942) but not
Scr (0.0948) was the most indispensable parameter.
Conclusion: Advanced statistical analysis of selected urinary protein levels and
pathological parameters taking into consideration initial eGFR may be useful
in prediction of long-term renal transplant function as well as in identifying
recipients with the high risk of premature graft loss.

CONCURRENT ORAL SESSION 99: CAN – SURVIVAL AND
TREATMENT
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1385 MANAGEMENT OF CHRONIC ALLOGRAFT
NEPHROPATHY WITH SIROLIMUS -A SOUTH INDIAN
EXPERIENCE
G. Abraham1, V. Sundaram1, V. Sundaram2, V. Sathiah1, M. Mathew3,
S. Bhaskar3
1
Sri Ramachandra University Hospital, 2Sundaram Hospitals, 3Madras
Medical Mission Hospital
Objectives: The aim of this study was to evaluate the efficacy of conversion
from Calcineurin Inhibitors to a rapamycin based immunosuppressive regimen
in renal transplant recipients who had allograft dysfunction in a South Indian
Population
Methods: This was a retrospective analysis of renal transplant patients who
were randomly initiated on rapamycin in a tertiary care centre in South India.
Overall seventy five of the 398 renal transplants performed over a five year
period 2002-2007 were converted from a Calcineurin based immunosuppression
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R. Cervantes1, R. Nanra1, P. Trevillian1, A. Gillies1, P. Mcelduff2,
S. Carney1, B. Jones1, M. Heer3, G. Reeves4, A. Hibberd3
1Department of Nephrology, John Hunter Hospital, 2Hunter Medical
Research Institute, Newcastle, Australia, 3Transplant Unit, Division
of Surgery, John Hunter Hospital, Newcastle, Australia, 4Hunter Area
Pathology Services, Dept. Immunology, John Hunter Hospital, Newcastle,
Australia
Background: Cystatin C has been advocated as a more reliable marker of
GFR than creatinine based methods for estimating native kidney function.
The data evaluating Cystatin C performance in estimating GFR changes in
stable renal allografts is controversial. Also the use of steroids in transplant
recipients may affect Cystatin C level and hence its reliability as a marker of
GFR.We have examined the reliability of Cystatin C to predict GFR, both
in single samples, and serially in the same transplant recipient over a 5 year
period.
Methods: 17 patients with stable renal function (51Cr EDTA GFR range
30-90 ml/min, mean: 53 ml/min/1.73m2) were followed with prospective,
annual 51Cr EDTA GFR (71 measurements over 5 years). Comparative
annual Cystatin C levels were measured retrospectively from stored
serum samples using immunonephelometric assays (Dade-Behring). Serial
estimates of eGFR (Cockcroft-Gault, MDRD, Nanra) and the reciprocal of
Cystatin C (1/Cys C) were compared with 51Cr EDTA GFR. Multilevel
linear regression models were used to estimate change over time for each
measure and to estimate the correlation of 51Cr EDTA GFR with the other
measures within and between subjects. Additional models were fitted
to estimate the impact of BMI, age gender and prednisone use on these
associations.
Results: Although 51Cr EDTA GFR did not change (-2.6 X10-3, p=0.223),
serum creatinine levels showed steady increase over the 5 years period
regardless of correction for age and weight (change= 1.6X10-2, p<0.001).
1/Cystatin C change also remained stable (change= -1.9X10-5 p= 0.152).
Correlation coefficients between 51Cr EDTA GFR and 1/Cystatin C, MDRD,
Nanra and Cockcroft-Gault eGFRs were 0.77, 0.68, 0.62 and 0.60 respectively.
Over the 5 year period the “r” value of change in 51Cr EDTA GFR compared
with 1/Cystatin C, MDRD, Nanra and Cockcroft-Gault were 0.73, 0.63, 0.64
and 0.66 respectively.
In a multilevel model adjusting for the repeat measures on individuals, 1/
Cystatin C measures maintained the highest correlation (as measured by R2)
with 51Cr EDTA GFR for both within individuals effects (R2=0.37 vs 0.22 for
Nanra, 0.25 for MDRD and 0.30 for Cockcroft-Gault) and between individuals
effects (R2=74 vs 0.42 for Cockroft-Gault, 0.55 for Nanra and 0.64 for MDRD).
Adjustment for BMI, gender and age did not alter the association between 51Cr
EDTA GFR and 1/CysC.
Inclusion of prednisone in the regression models did not show any effect
either on Cystatin C levels or creatinine based GFR estimates either within
individuals or between individuals.
Conclusions: 51Cr EDTA GFR remains the gold standard for GFR measurement
in renal transplants. Cystatin C is an acceptable clinical alternative and
retains validity over the early post-transplant life of the graft. On the other
hand,creatinine-based eGFRs appear to give a spurious decline in eGFR with
time and this may be related to altered creatinine handling by the nephron in

aging renal transplants.This problem is not seen with Cystatin C.
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to rapamycin whihch included patients with chronic allograft dysfunction,
chronic allograft injury and malignancy. The data analysed included serial
rapamycin levels, serum creatinine, eGFR by nankivel formula, lipid profile,
haemoglobin and serum pottasium levels. Statistical analysis was performed
using students t test and kaplen Meyer survival curve was used to predict
probability of survival among patients on sirolimus.
Results: Male patients formed majority of the study sample (74.6%).The mean
age patients was 39.6+_12.2yrs. Diabetic nephropathy was the predominant
cause (36%) of ESRD. Sataistical analysis revealed a significant improvement
in GFR of 14.6 ml and decrease in pottassium by 0.7mmol/L after initiation
of rapamycin. There were no significant differences in terms of lipid profile,
platelet count, hemoglobin and urine albumin levels. Rapamycin was stopped
in one patient due to hypokalemic nephropathy and in another patient due to
delayed wound healing.
Discussion: To our Knowledge this is the first study to provide information
on the conversion from a CNI to rapamycin based immunosuppression in
cohort of Indian patients who recieved renal transplant .The findings of
our study confirm that rapamycin based immmunosuppressive regimen
improves renal function and graft survival with minimal side effects in
comparison to CNI based immunosuppression. Withdrawal of CNI also
resulted in slowing the progression of chronic allograft injury. Rapamycin
based therapy with elimination of CNI is safe and results in improved renal
function.
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1386 THE EFFECTS OF ROSUVASTATIN ON 51CR-EDTA
MEASURD GLOMERULAR FILTRATION RATE AND
URINARY ALBUMIN EXCRETION IN NON-DIABETIC RENAL
TRANSPLANT RECIPIENTS
A. Sharif1,2, V. Ravindran2, R. Moore2, K. Baboolal2
1
Russells Hall Hospital, Dudley, 2University Hospital of Wales, Cardiff
Background: Hyperlipidaemia contributes to chronic allograft injury,
leading to eventual graft loss. Emerging literature from the general
population suggests statin treatment has pleiotropic and renoprotective
properties. This raises the possibility of using statin therapy to attenuate
chronic allograft injury in renal transplant patients. This study aimed to
assess the change in 51Cr-EDTA measured glomerular filtration rate (GFR)
and urinary albumin excretion after short-term rosuvastatin treatment in
renal transplant recipients.
Methods: Twenty patients were recruited into a randomised, double blind,
placebo controlled, crossover study. 51Cr-EDTA GFR and urinary albumin
excretion was assessed after 12 weeks of either rosuvastatin or placebo before
patients crossed over to the opposite table and the investigations repeated after
12 weeks. Clinical and biochemical investigations were conducted at the end
of each 12-week period.
Results: Rosuvastatin was a safe and effective lipid-lowering agent, lowering
total cholesterol by 31% (p<0.001), LDL cholesterol by 48% (p<0.001)
and triglycerides by 19% (p=0.018) when compared to placebo. It also had
a significant anti-inflammatory effect, lowering C-reactive protein by 43%
(p=0.042). However there was no difference in creatinine, estimated GFR,
51
Cr-EDTA derived GFR or urinary albumin excretion between rosuvastatin
and placebo (Table 1).
Table 1 – Change in renal indices between placebo and rosuvastatin (mean ±
standard error of mean)
Placebo

Rosuvastatin

Change

p value

Creatinine (mmol/l)

112 ± 5

109 ± 5

- 3%

0.100

Est. GFR (ml/min)

61 ± 3

63 ± 3

+ 3%

0.102

51Cr EDTA GFR (ml/
min)

61 ± 3

62 ± 4

+ 2%

0.612

2.3 ± 0.8

3.3 ± 1.0

+ 43%

0.274

Albumin/Creatinine
Ratio

Conclusions. Short-term rosuvastatin treatment does not affect renal allograft
function, despite a significant lipid-lowering and anti-inflammatory effect.
Whether long-term treatment slows the decline of GFR remains unanswered.
The renoprotective properties of statins remain speculative and we should
hesitate from advocating benefits without evidence from large, clinical studies
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specifically designed to answer this question.
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1387 PREEMPTIVE LIVING-DONOR RENAL
TRANSPLANTATION: THE OUTCOME AND CLINICAL
ADVANTAGES
O.J. Kwon1, T.S.W. Yu2, J.Y. Kwak3, C.M. Kang4
1
Transplantation Center, Hanyang University Hospital, 2Transplantation
Center, Hanyang University Hospital, 3Transplantation Center, Hanyang
University Hospital, 4Transplantation Center, Hanyang University Hospital
Background: Kidney transplant recipients have a higher quality of life
and consume fewer health care resources compared to patients on dialysis.
However, optimal timing of transplantation has been controversial. Recent
studies have clearly demonstrated that preemptive renal transplantation is
associated with better graft survival, lower complications, and cost-effective
option. We evaluated the differential effects on long-term outcomes according
to dialysis type and duration, or no dialysis.
Materials and methods: We retrospectically analyzed 499 cases of first living
donor kidney transplantations performed in our center from Jan. 1990 to Jan.
2007. We exclude retransplantation cases(n=32), follow up loss (n=60), and
deceased donor transplant(n=20) among 611 renal transplants. We evaluated
and compared with 3 groups according to graft survival rates, acute and chronic
rejection rates, postoperative complication rates, and delayed graft function rate.
Results: The mean duration of follow up was 95.23¡¾54.35 months. Among
499 cases, 81 cases were preemptive renal transplantation, and 418 cases (HD:
343 cases, PD: 75 cases) were performed transplantation after dialysis. The
immunosuppressant regimens were cyclosporine/ tacrolimus, azathioprine/
MMF, and steroid with or without antiCD25 antibody according to the period.
The mean duration of dialysis was 29.73¡¾36.46 months. The characteristics of
3 groups were not significant differences in risk factors, such as recipient’s and
donor’s age, sex distribution, HLA matching degree, and the cause of ESRD.
The 1, 5, 10 year graft survival rate were 97.50%, 89.45%, 79.40% in preemptive
renal transplantation group, respectively and those of the dialysis groups(HD, PD)
were 91.11%, 77.55%, 69.08%, respectively (p=0.0322). The differential effect
of pretransplant dialysis either by hemodialysis or peritoneal dialysis was not
significant. However, the graft survival rates of hemodialysis group was higher
than peritoneal dialysis group and it is not significant in statistically (p=0.6056).
The duration of dialysis (hemodialysis or peritoneal dialysis), according to 12
months, was not associated with graft survival rate(p=0.2424). The complication
rate of preemptive renal transplantation group was lower than dialysis groups,
such as infection, delayed graft function rate, and acute rejection rate.
Conclusions: The preemptive renal transplantation without initiation of
dialysis is as safe as conventional transplantation with better graft survival
rates and lower complication rates. It has major advantage of avoiding the
inconvenience, and cost of dialysis. This improved survival might be the
consequence of patient selection or the reduced severity of co-morbid diseases
associated with avoidance of uremia and dialysis. We suggest that preemptive
renal transplantation can be the optimal mode of renal replacement therapy for
medical and socioeconomic reasons.
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1388 THE FIRST YEAR RENAL FUNCTION AS PREDICTOR
OF LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER
KIDNEY TRANSPLANTATION
I. Helal1, E. Abderrahim1, F.B. Hamida1, M. Ounissi1, S. Barbouche1,
R. Bardi2, Y. Elgorgi2, F. Elyounsi1, T.B. Abdallah1, A. Kheder1
1
Department of Nephrology-Charles Nicolle Hospital, 2Laboratory of
immunology-Charles Nicolle Hospital
This study examined the impact of graft function, at the end of the first year
after kidney transplantation (KT), on the long-term graft survival. The role of
serum creatinine (Scr) and other variables as predictors of graft survival were
analyzed in 235 adult kidney transplanted patients. Patients were divided into
three groups (G1, G2 and G3) according to their Scr at the end of the first year
following KT; G1: Scr < 100 μmol/l, G2: 100 μmol/l &#61603; Scr &#61603;
150 μmol/l and G3: Scr > 150 μmol/l.
The annual rate of graft loss was of 0.7% (CI, 95%: 0.63-0.77) in G1, it is lower
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than those of 2.1 (2.02-2.18, p<0.0001) and 6% (5.74-6.26, p<0.0001) observed
in G2 and G3, respectively. Regression analysis showed the role of recipient
age, at the time of KT, and Scr level, at the end of the first year after KT, as
independent predictors of graft loss. Graft survival was not influenced by any
of other studied parameters including age of donor, year of KT, warm ischemia
time, history of acute tubular necrosis and acute rejection. We conclude that
one-year creatinine value predict long-term renal graft survival, it represents a
simple practical tool to identify recipients with high risk for late graft failure.

POSTER BOARD NUMBER P2 – 188
1389 CAN SERIAL EGFR, BODY MASS INDEX PREDICT
RENAL ALLOGRAFT SURVIVAL IN SOUTH ASIAN PATEINTS
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1390 CHLAMYDIA PNEUMONIAE INFECTION IN PATIENTS
AFTER KIDNEY TRANSPLANTATION TREATED WITH
SPIRAMYCIN
S. Fesolowicz1, A. Kwiatkowski1, M. Wszola1, E. Podsiadly2, K. Ostrowski1,
M. Durlik3, L. Paczek4, S. Tylewska-Wierzbanowska2, W. Rowinski1,
A. Chmura1
1
Department of General and Transplantation Surgery, 2National Institute
of Hygiene, 3Department of Transplantation Medicine and Nephrology,
4
Department of Immunology, Transplantology and Internal Diseases
Previous research pointed to a significant role of C. pneumoniae infection in
the development of chronic renal allograft dysfunction, liver chronic rejection
and vasculopathy of the transplanted heart. The aim of the study was to
evaluate the C. pneumoniae presence prior to and after kidney transplantation
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1391 LONG TERM RENAL AND METABOLIC OUTCOMES
AFTER CONVERSION FROM CNI-BASED THERAPY TO
SIROLIMUS IN RENAL TRANSPLANT RECIPIENTS WITH
ALLOGRAFT DYSFUNCTION
R. Swaminathan1,2, A. Irish1
Royal Perth Hospital, 2University of Western Australia
Background: Long term calcineurin inhibitor (CNI) therapy in renal transplant
recipients (RTRs) is associated with allograft dysfunction. The long term renal
and metabolic outcomes following conversion from CNI to the mTOR inhibitor
Sirolimus (SRL) in RTRs with allograft dysfunction remains uncertain.
Aim: To compare the renal and metabolic outcomes of continuing CNI therapy
versus conversion to SRL in RTRs with allograft dysfunction and biopsy
proven CNI toxicity &/or chronic allograft nephropathy (CAN).
Methods: A retrospective comparison of the eGFR (absolute and rate of change),
metabolic (lipids, glycemic control, proteinuria) and clinical outcomes in 60
RTRs with biopsy proven CNI toxicity &/or CAN.
Results: 41/60 patients were converted to SRL (SG) and 19/60 were continued
on CNI (CG) at the same or reduced dose according to clinicians’ discretion.
The mean SRL level was 7.3 mcg/l (95% CI 6 .6-8.1) with a mean dose of
1.7mg/day (95% CI 1.42 - 2) at 12 months post conversion.
There was no difference in age, duration of CNI exposure (7 vs.6 years),
eGFR (33 vs.39ml/min), proteinuria, diabetes or histological findings based on
Bannf”97 criteria between the groups, at the time of biopsy. The rate of fall of
eGFR during the 12 months preceding the biopsy was similar in both groups
(-1 ml /min/month).
However, there was significant improvement in the measured and slope of
the eGFR between the groups after conversion. At 12 months the mean eGFR
improved from 39 to 48.5ml/min (SG) vs. 33 to 39.4ml/min (CG) and the
difference in the slopes of the eGFR was 2.3 (SG) vs. 1.2 (CG) ml/min/month.
(P=0.02). After a mean follow-up of 32 months, the eGFR was 51.2 ml/min
(SG) vs. 34.2 ml/min (CG), p=0.02. 2/41(SG) vs. 4/19 (CG) reached ESRF
after a median of 18 months.
The mean protein: creatinine ratio (PCR) was significantly higher after
conversion in the SG, (21.6 vs.118.4mg/mmol (p=0.001) with no significant
change in CG.
7/41 SRL patients discontinued therapy due to new onset nephrotic range
proteinuria which was associated with a preconversion PCR of >40mg/mmol
(P=0.001).
In the SG, but not the CG, the glycated haemoglobin (6.1% vs. 6.7%, p=0.03)
and the mean triglyceride level (1.7 vs. 2.4mmol/l, p=0.005) deteriorated post
conversion, associated with an increase in the lipid lowering and anti- diabeteic
medications. There was also less use of anti-hypertensives including ACE-I
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G. Abraham, M.A. Ali, M. Mathew, N. Fathima, S. Saravanan, S. Varun,
N. Lesley
Sri Ramachandra Medical College and Research Institute, Madras Medical
Mission Hospital, Chennai, India
Background: There is limited data on long-term allograft survival in South Asian
patients in the era of modern immunosuppressive therapy. This retrospective
analysis was undertaken to see the graft survival based on serial eGFR,
immunosuppressive therapy, BMI and other confounding factors in patients who
have undergone renal transplantation in a tertiary care in South India.
Materials and patients – We retrospectively analyzed the outcome of all
patients who underwent primary renal transplantation with a graft from a
living and deceased donor in a tertiary care center between 2001 and 2006.
We performed 303 renal transplants (3 cadaveric and 300 live). The group was
made up of 212 male and 92 female patients, with a mean age of 42.74 ±
13.03 years. Among the 303 renal transplant recipients, 89 were diabetic, 234
were hypertensive, 18 had coronary artery disease and two underwent coronary
artery bypass grafting. One recipient was positive for Hepatitis B, 17 were
positive for Hepatitis C and none of them were HIV positive. Acute rejection
episode occurred in seventy-nine transplant recipients and seven were back
on hemodialysis. The HLA matching showed 202 complete mismatches in the
A loci, 198 in the B loci and 86 in the DR loci. Zero mismatching in the A,
B and DR loci were 13, 7 and 14 respectively. Mismatching of two to four
antigen at A, B and DR loci were 85, 95 and 173 respectively. Our baseline
immunosuppressive therapy consisted of prednisone, micro-emulsion form of
cyclosporine A, tacrolimus, mycophenolate mofetil, azathioprine or rapamycin.
Ninety-three transplant recipients received basiliximab as induction therapy
of which 27 had multiple doses, 102 received daclizumab of which two had
multiple doses, and seven patients had anti-thymocyte globulin single dose.
Results: Mean graft survival after transplantation is 6.38 ± 0.11 in years, graft
survival at one year is 95.7%, two is 92.72%, three is 91.72% and five year are
89.21%. Mean creatinine value for graft survival is 1.24 ± 0.59 and for graft not
surviving is1.74 ± 0.94 and it is statistically significant. (p <0.001). Mean BMI for
the graft survival at 1 year is 21.63 ± 2.29, graft not surviving is 26.59 ± 3.18, and
it is statistically significant. (p <.0.05). Mean eGFR for the graft survival is 61.50
± 17.40 and graft not surviving 43.73 ± 13.65 and it is statistically significant.
Conclusion: In conclusion, this analysis has shown that serial eGFR, body
mass index are significant predictor of survival following renal transplantation
in south Asian patients. Utilizing this information, interventions can be initiated
to improve the outcome of patients with kidney transplantation.

and to determine the role of spiramycin therapy in patients after kidney
transplantation.
Material and methods: The study group consisted of 50 patients (25 pairs)
who received kidney transplants from cadaveric donors. One of the two
kidneys from one donor was transplanted to a patient randomised to spiramycin
(dose of 2x3milion U/day orally for 3 months) (group S) and the other was
transplanted to a patient assigned as control (group C). Markers of infection
were assessed on day 1 post transplantation and 3 months later (average=94
days). All (n=50) patients were examined for bacterial DNA presence in
peripheral blood leukocytes using real-time PCR and titers of serum anti C.
pneumoniae IgG and IgA antibodies using microimmunofluorescence (MIF).
C. pneumoniae infection was diagnosed as C. pneumoniae DNA presence in
peripheral blood leukocytes or positive antibodies in both classes.
Results: C. pneumoniae infection was initially diagnosed in 14 patients
from group S and in 8 patients from group C (p=ns) after 3 months in 12
and 9 patients respectively (p=ns). Conversion from positive to negative C.
pneumoniae status occured in 7 patients from group S and one patient from
group C (p=0,04). Conversion from negative to positive C. pneumoniae status
occured in 5 patients from group S and 2 patients from group C (p=ns).
Conclusions: The results suggest a possible role for spiramycin treatment
of in C. pneumoniae infection in kidney allograft recipients. C. pneumoniae
infection diagnosis and treatment should be considered as a routine at every
patient awaiting transplantation.
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and ARBs post conversion.
Conclusions:
1. Improvement in renal allograft dysfunction was significantly greater after
conversion to SRL compared with CNI continuation and this benefit was
maintained after a mean follow up of nearly 3 years.
2. Pre-conversion PCR >40mg/mmol predicted post conversion nephrotic
range proteinuria which limited therapy in nearly 20% of patients.
3. Conversion to SRL was associated with a worsening lipid profile and
glycaemic control requiring additional therapy, but a reduced need for
antihypertensives.
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1392 MANAGEMENT OF CHRONIC KIDNEY DISEASE
AFTER RENAL TRANSPLANTATION. IS IT DIFFERENT FROM
NONTRANSPLANT PATIENTS?
S. Jiménez-Alvaro, R. Marcén, J.L. Teruel, A. Fernández, J. Pascual,
J.J. Villafruela, J. Villacorta, *F.J. Burgos, J. Ortuño
Departments of Nephrology and *Urology. Hospital Ramón y Cajal. Madrid
Background: The Kidney Disease Quality Initiative (K/DOQI) of the National
Kidney Foundation has published guidelines for the diagnosis and management
of chronic kidney disease (CKD). Renal transplant recipients frequently have
CKD and complications similar to patients with native kidney disease. There are
few publications comparing the management of these two population groups.
The purpose of the present study was to compare the management of CKD
complications between renal transplant recipients and nontransplant patients.
Patients and methods: 83 renal transplant recipients (RTR) with CKD stage
4T and 5T were chosen for the study. The mean age was 57.8±13.0 years, 36
male and 47 female, the follow-up after transplantation was 114±77 months.
The control group (CG) consisted of 83 native CKD patients matched by CKD
stage followed at the predialysis outpatient clinic.
Results: There were no differences between the groups in serum hemoglobin
(12.0±1.6 in RTR vs 12.3±1.5 g/dl in CG; NS), prevalence of anemia, Hb <11g/
dl, (18% vs 19%; NS) and patients treated with erytopoiesis-stimulating agents
(42.1% vs 40.3%), but serum ferritin levels were higher in RTR (181±159 vs
114±108 ng/ml; p=0.003). Blood pressure was similar in both groups and 83%
RTR and 66% had systolic blood pressure higher than 130 mmHg. However
more patients were treated with either ACEI or ARA in the transplant group
(43.4% vs 8.0%; p<0.001). LDL-cholesterol was lower in the transplant
recipients (109±30 vs 120±40 mg/dl; p=0.049) and a higher percentage was
on statin treatment (44.5% vs 27.8%; p=0.046). Serum calcium was higher in
transplant recipients (9.6±0.8 vs 8.9±0,7 mg/dl; p<0.001) and phosphate was
lower (3.9±0.9 vs 4.3±1.1; p=0.019) and there were no differences in iPTH
blood levels (248±290 vs 272±27 pg/ml; NS).
Conclusions: The management of renal transplant recipients is not worse than
that at nontransplant patients. However, in both populations some parameters
are far from the target recommended by the guidelines.
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1393 IT IS INDEED POSSIBLE TO SLOW THE PROGRESSION
OF RENAL ALLOGRAFT CHRONIC DISEASE AND
TO ACHIEVE THE REMISSION OF A PROGRESSIVE
NEPHROPATHY
X. Rocca, M. Espinoza, P. Herrera, E. Reynolds, E. Lorca, O. Espinoza,
E. Roessler, J. Hidalgo, F. Gonzalez.
Department de Nephrology, Universidad de Chile, Hospital del Salvador,
Santiago, Chile
Successful treatments of progressive kidney disease are those that retard the
decrease of the glomerular filtration rate.
Several factors participate in the progressive loss of glomerular filtration of
renal allografts; one of them could be the nephrotoxicity related to calcineurin
inhibitors. It is desirable to search therapeutic interventions capable of improving
the adverse prognosis of the chronic kidney disease of the allograft.
Prospective, open label clinical trial in 24 kidney transplant patients with
more than 3 months of evolution (range 141-4249 days), progressive kidney
function deterioration and a graft biopsy showing interstitial fibrosis and
tubular atrophy. Immunosuppressive treatment: cyclosporine, ketoconazole
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and steroids associated or not to azathioprine or mycophenolate mofetil. After
an IRB approved written consent form signed by the patient, cyclosporine was
switched to sirolimus in a two weeks period until achieving a trough blood
sirolimus concentration of 6-15 ng/ml.
Using Student’ T and Wilcoxon* tests, we compared selected clinical and
laboratory variables in the annual period before and after the drug switch
(Table). We did not observe any graft rejection episode. No patient or graft was
lost in the follow up. Mean daily enalapril equivalent dose in the 12 month of
follow up was 6.6 mg.
Slope of the decreasing GFR
Crockoft-Gault (1/(ml/min/year)
MDRD equation (1/(ml/min/year)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Doses of antihypertensive /patient
Cholesterol total (mg/dL)
Triglycerides (mg/dL)
Doses of hypolipemic /patient
Proteinuria (mg/dL)
Hematocrit (%)

Baseline Period

Post Switch Period

p

-6.93 ± 10.08
-6.54 ± 9.17
129.1 ± 20.2
78.6 ± 12.9
2.0 ± 1.7
209 ± 51
196 ± 118
0.17 ± 0.38
13.7 ± 17.3
37.3 ± 5.3

5.03 ± 9.10
8.14 ± 14.04
122.1 ± 16.1
76.6 ± 11.5
1.8 ± 1.5
219 ± 49
239 ± 135
0.43 ± 0.50
40.9 ± 90.4
38.1 ± 5.3

0.0008
0.0017
0.0060
0.1285
0.242*
0.4270
0.0049
0.030*
0.009*
0.4133

The switch of cyclosporine to sirolimus in kidney transplant patients with
decreasing GFR and a graft biopsy showing interstitial fibrosis and tubular
atrophy changes the natural history of the progressive nephropathy of the graft.
It is feasible to control proteinuria with enalapril or other similar drugs. It is
necessary to conduct trials using clinical end points to definitively validate this
therapeutic intervention.
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1394 CLINICAL ATTITUDES ON CHRONIC GRAFT
DYSFUNCTION: THE ICEBERG STUDY
J.M. Grinyó1, N. Saval2, S. Gatell2, J.M. Campistol3, on behalf of the
ICEBERG STUDY group
1
Hospital Universitari de Bellvitge, Barcelona, Spain, 2Medical Department
Novartis Spain, 3Hospital Clinic de Barcelona, Spain
Purpose: Renal impairment after transplant is associated to a greater risk of
death. It is of interest to asses how and how early or late the diagnosis is made,
in what way the clinician perceives the severity of the graft dysfunction and the
measures adopted after the diagnosis.
The primary objective was to asses the prevalence of chronic graft dysfunction
(CGD) in renal transplant patients; secondary objectives comprised: method
of diagnosis, characteristics of CGD and its evolution in time, current
immunosuppressive treatment and if the diagnosis of CGD lead to changes in
the immunosuppressive treatment.
Methods: National, multicenter, observational, cross-sectional study including
872 renal transplant patients with an at least two year follow-up and a
functioning graft. Patient, transplant and five cross-sectional visits data were
collected. Clinicians were asked if they considered that the patient had CGD
and also objective criteria were applied (objective criteria: serum creatinine >2
mg/dl or MDRD<50 ml/min).
Results: 872 patients were analyzed, 62% male, 98,7% Caucasian, mean
age 54 years (SD 13 years). Ethiology of end stage renal failure: 32,7%
chronic glomerulonephritis, 19,8% unknown, 12,4% polycystic disease, 7,6%
chronic pielonephritis, 8% diabetes, 5,9% hypertension, 15,7% other. Mean
(SD) transplant evolution 8,2 (5,1) years. Mean (SD) donor age 42 years.
CGD could be diagnosed according to investigators’ criteria vs. objective
laboratory criteria. CGD was diagnosed in 35% of the patients according to
the investigators’ criteria and in 55, 5% of the patients according to objective
criteria. In 40% of the patients that were diagnosed of CGD by objective criteria
the clinician had not considered this diagnosis (see table 1). Graft biopsy was
performed in 31% of patients with investigators’ criteria of CGD. The presence
of proteinuria conducted to a biopsy more than a rise in serum creatinine. Time
from transplant to biopsy was greater in patients with antiproteinuric treatment
(p=0,032). Immunosuppressive treatment changes were not associated to
biopsy histological data. The creatinina slope showed a direct relationship with
the total number of treated acute rejections (Pearson’s r: 0,12; p<0,001).
Conclusions: The prevalence of CGD in renal transplant patients is between
35-55%, depending on the type of criteria applied (investigator’s or objective).
Around of 40% of patients diagnosed of CGD by objective criteria had not
been diagnosed by the investigator. Proteinuria is the main indication for
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biopsy. Nephrologists are more sensitive to glomerular disease than to renal
impairment itself. Antiproteinuric treatment delays the conduct of renal biopsy.
Changes in the immunosuppressive treatment due to presence of CGD are
performed late and unsatisfactory.
Table 1: Concordance among criteria (Investigator’s vs. objective):
Investigator Criteria Yes
Investigator Criteria No

Objective Criteria
Yes
283 (92.8%)
199 (35,3%)

Objective Criteria
No
22 (7,2%)
364 (64,7%)

Kappa index (IC95%): 0,51 (0,45 a 0,56)
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1395 STATIN THERAPY IS ASSOCIATED WITH A LOWER
RATE OF DECLINE OF RENAL FUNCTION IN KIDNEY
TRANSPLANT RECIPIENTS
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1396 SPIRONOLACTONE AMELIORATES FOCAL
GLOMERULOSCLEROSIS IN EXPERIMENTAL
CHRONIC ALLOGRAFT NEPHROPATHY IN RATS
F. Waanders1, H. Rienstra2, J. Rozing2, G. Navis1, H. van Goor3,
J-L. Hillebrands1
1
University Medical Center Groningen, Dept . Internal Medicine, Div.
Nephrology, 2University Medical Center Groningen, Dept . Cell Biology section Immunology, 3University Medical Center Groningen, Dept . Pathology
Background: Chronic allograft nephropathy (CAN) is the leading cause of
long-term renal graft loss. CAN is characterized by proteinuria and decreased
renal function associated with focal glomerulosclerosis (FGS), interstitial
fibrosis (IF), tubular atrophy and transplant arteriopathy. So far, no effective
therapy is available to prevent CAN.
There is increasing evidence that aldosterone plays a significant role in
renal damage via the non-epithelial mineralocorticoid receptors (MR).
Spironolactone, a competitive aldosterone antagonist, administered prior to the
induction of renal ischemia/reperfusion injury prevented loss of renal function,
proteinuria and oxidative stress. In this study we investigated whether MR
blockade by spironolactone ameliorates the development of CAN.
Methods: Renal transplantations (Tx) were performed in the Dark Agouti
(DA)-to-DA (isograft) and DA-to-Wistar Furth (allografts) combinations. After
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1397 PROTOCOL BIOPSIES: AN ANALYSIS OF A SINGLE
CENTER EXPERIENCE
L. Saber1, J.C. Crispim2, R.S. Costa3, T.M.P. Garcia1, M.E.P. Nardim1,
V.A. Muglia1
1
Renal Transplant Unit, Hospital Das Clinicas, University of São PauloRibeirão Preto, São Paulo, Brazil., 22-Department of Biochemistry and
Immunology, FMRP-USP, Brazil, 3Department of Pathology, FMRP-USP,
Brazil
Chronic allograft nephropathy (CAN), as a result of both immunological and
non-immunological factors, is the most prevalent cause of late kidney allograft
losses. In this context, calcineurin inhibitor (CNI) nephrotoxicity has been
identified to play a major non-immunological role, as demonstrated by Nankivell
et al. in protocol biopsy studies. In this study, we evaluated 57 prospective,
protocol kidney biopsy specimens, from 49 patients, of mean age of 38.3 years,
including 41 recipients of organs from deceased donors, taken at different time
points from 1 to 26 months after transplantation (mean time 8.95months),
for evidence or not of protocol biopsy utility. Written informed consent was
obtained from all patients. The initial protocol consisted of biopsies obtained
at 1, 3, 6, 12 and 24 months, but due to technical difficulties were grouped in
months 1 to 6, 7 to 12 and 13 to 26. All biopsies were evaluated according to
97 Banff criteria. IL-2R blockage was performed as induction in 28 patients
(62.2%) and 44 (89.8%) patients were in use of CNI at the time of biopsy.
Only one patient had previous acute rejection and 70.4% presented delayed
graft function (DGF), defined as the need of hemodialysis during the first week
post-transplant. Twenty-one biopsies (BX) were performed at the first 6 months
post-transplant, with a mean serum creatinine of 2.67mg%: 14 presented CNI
nephrotoxicity evidence and 8 had already presented CAN. These findings led
to CNI dose reduction in 6 and sirolimus (SRL) conversion in 9 patients. From
month 7 to 12 we could evaluate 19 BX (mean serum creatinine 1.74mg%), 7
of them with CAN and 4 with CNI nephrotoxicity, leading to SRL conversion
in 7 and CNI reduction in 4 patients. From month 13 to 26, 17 BX were
evaluated (mean patient serum creatinine 1.93mg%): 10 with CAN and 4 with
CNI nephrotoxicity, leading to SRL conversion in 8 and CNI dose reduction
in 1 patient. No subclinical rejection was detected. Three patients presented
post-biopsy time-limited bleeding and the mean hospitalization time required
was 2.8days. In conclusion, 82.5% of all studied biopsies showed CAN and/
or CNI nephrotoxicity, which allowed us to perform therapeutic adjustment in
71.43% patients, either SRL conversion in 48.98% or CNI dose reduction in

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

469

TUESDAY

A. Assounga, S. Harparshad, N. Madala
University of Kwazulu-Natal and Inkosi Albert Luthuli Central Hospital
Background: Statins have proven ability as antilipidaemic agents as well
benefit on cardiovascular survival in transplant patients. The pleiotropic
effects on renal function in renal allograft patients is still undetermined. A
retrospective study was done to determine the effect of statin therapy on renal
allograft function.
Method: We monitored all transplant patients who were on statin therapy for
more than a year. We determined their renal function before, during and after
commencing statin therapy. Statin treatment was initiated based according to
guidelines for cardiovascular protection. Serum creatinine and eGFR were
analysed before and after the introduction of statins. A total of 73 patients
were studied including those who had become dialysis requiring. The average
monthly change in eGFR was compared before and after commencing statins
using a Chi-square test.
Results: The average creatinine 18 months before starting statins was 160.13
μmol/l versus an average creatinine of 172.22 μmol/l 24 months after starting
statins .The average eGFR 18 months prior to starting statin therapy was 53.40
ml/min. The average eGFR when starting statins was 49.43 ml/min. This
represented a decline in renal function of 0.22 ml/min/month over 18 months.
The eGFR 12 and 24 months after commencing statins was 52.67 ml/min and
49.06 ml/min respectively. The rate of decline after starting statins was 0.015
ml/min/month over a 24 month period. There was a statistically significant
reduction in the rate of decline of eGFR after starting statins (p value < 0.0001).
A total of 4 out of 73 patients developed graft failure within 24 months .
Conclusion: Statin therapy in our setting was associated with a lower rate of
decline of renal function in renal allograft patients within 2 years of starting
therapy.

Tx the rats received 5 mg/kg CsA s.c. for 10 days and at day 14 unilateral
nephrectomy of the autologous kidney was performed. Treatment with 20 mg/
kg spironolactone (+) or vehicle (-) was given daily by oral gavage and started
at 2 days prior to Tx. 4 groups were included: isografts- (n=8), isografts+ (n=8),
allografts- (n=9) and allografts+ (n=9).
Before and every 2 weeks after Tx systolic blood pressure and renal function
were measured. Rats were sacrificed at 12 weeks and kidneys removed for
histological analyses.
Results: All isografts survived until the end of the experiment. Of the allografts
treated with vehicle 3 animals had to be sacrificed prematurely but in the
spironolactone treated allografts only 1 animal. The survival curves reached a
borderline significant difference (p=0.07). The allografts developed proteinuria
which was decreased after spironolactone treatment (77±28 mg/day vs 41±10
mg/day; p=0.06). In the isografts, urinary protein excretion remained at preTx
levels (<10 mg/d). Both the allografts and isografts showed a significant
decrease of creatinine clearance after 12 weeks. Spironolactone did not affect
systolic blood pressure.
Compared to the isografts, the allografts showed prominent development of
FGS and IF. FGS in allografts was significantly ameliorated by spironolactone
(100±37 vs 47±17 A.U., p<0.05), without having effects in the isografts (1±1
vs 1±2 A.U). However, spironolactone did not affect the development of IF.
Conclusion: MR blockade by the aldosterone antagonist spironolactone
ameliorates proteinuria and FGS in an experimental rat model for CAN.
However, spironolactone has no effect on IF development in this model. We
propose that the observed glomeruloprotective effect of spironolactone might
result in improved graft survival. It should be evaluated whether spironolactone
is a useful adjunct therapy to attenuate CAN.
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22.45% of patients. Therefore, we may conclude that despite its financial and
time consuming cost, protocol biopsy is an important tool in the post-transplant
management.
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1398 SIMVASTATIN TREATMENT FAILS TO INHIBIT
CHRONIC ALLOGRAFT NEPHROPATHY IN RAT WHEN
STARTED AFTER TRANSPLANTATION
J. Savikko1, P.K. Koskinen1,2, N.K. Malmström1, J.M. Rintala1, R. Tuuminen1,
1
University of Helsinki, 2Department of Nephrology, Helsinki University
Central Hospital
Background: The role of statins in prevention of chronic allograft nephropathy
(CAN) is still unclear. We examined the effect of an early start of simvastatin
treatment in a rat renal transplantation model of CAN.
Methods: Allograft recipients were treated with a suboptimal dose of
cyclosporine A (1.5 mg/kg/d s.c.) which allows acute rejection and CAN to
develop. Simvastatin 2 mg/kg/d was started eight days after transplantation
(n=3) and was diluted in PEG and given orally using orogastric tube.
Control group received an equal amount of vehicle (n=3). Syngrafts with no
immunosupression served as an additional control group (n=3). Grafts were
harvested 90 days after transplantation for histopathological analysis.
Results: Simvastatin treatment did not statistically inhibit the development
of CAN changes quantitated as chronic allograft damage index (CADI) score
(mean values: control vs. treated 5.3 vs. 6.3). The mean values of the CADI
score components were: fibrosis (1.7 vs. 1), inflammation (1 vs. 1.3), tubular
atrophy (1 vs. 0.7), mesangial matrix increase (0 vs. 0), glomerular sclerosis
(1 vs. 1.7), intimal thickening (0.7 vs 1.7). Syngrafts displayed nearly normal
glomerular and tubular structure.
Conclusions: Simvastatin treatment failed to show a beneficial effect on
CAN when started 8 days after transplantation. However, our preliminary data
indicate that donor treatment of simvastatin may possess a protective effect.
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1399 BENEFICIAL EFFECTS OF CANDESARTAN ON
REDUCTION IN PROTEINURIA IN PATIENTS WITH
FAVORABLE RENAL ALLOGRAFT FUNCTION
M. Okumi1, N. Ichimaru1, T. Moriyama2, T. Abe1, R. Imamura1, Y. Kojima3, Y.
Isaka4, A. Okuyama1, S. Takahara4
1
Department of Urology, Osaka University Graduate School of Medicine,
2
Health Care Center, Osaka University, 3Soryukai Inoue Hospital,
4
Department of Advanced Technology for Transplantation, Osaka University
Graduate School of Medicine
Background: Recently, in non-transplant patients with chronic kidney disease
(CKD), blockade of the renin angiotensin system with an angiotensin-converting
enzyme (ACE) inhibitor or angiotensin II type-1 receptor blocker (ARB) has
been shown to reduce proteinuria and delay the progression of CKD. Although
it has been shown that the use of the ARB in kidney transplant patients is safe
and effective with regard to the control of hypertension, the effect of the ARB
on urinary protein excretion and renal function in patients with unremarkable
allograft function remains unclear. The aim of this study was to evaluate the
efficacy and safety of the ARB candesartan on proteinuria and renal function in
kidney transplant patients.
Methods: 75 patients with stable allograft function were included into a
prospective study at least 6 months posttransplantation. The patients were
treated with increasing doses of Candesartan. The initial dose of 0 to 8 mg/day
was increased at 2 months intervals up to a maintenance dose of 12 mg/day for
a total of 12 months, while monitoring tolerability in individual cases. Efficacy
was evaluated on the basis of urinary protein level by 24-hour protein excretion,
accompanied by evaluation of safety through analysis of blood pressure (BP),
serum creatinine, rennin, and aldosterone levels.
Results: After 12 months of therapy with candesartan, 69 cases were analyzed.
Doses of candesartan were safely increased from the baseline level of 2.5 mg/
day to 10.8 mg/day on average. Significant decreases were seen in systolic BP
from 125.9 to 121.7 mmHg at 12 months (p<0.003) and diastolic BP dropped
insignificantly from 79.4 to 77.6mmHg at 12 months. Protein level in 24-hour
urine decreased from 298.5 to 215.2mg/day significantly (P = 0.03), while no
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changes were noted in serum creatinine level or estimated eGFR level. While
renin level increased significantly from 5.7 pg/ml to 9.7 pg/ml (P < 0.0007),
aldosterone level maintained.
Conclusions: It is concluded that candesartan reduces systolic BP and
proteinuria in kidney transplant patients without inducing a serious worsening
in renal function. These findings suggest that the treatment with candesartan
exerts kidney protective effects in renal transplantation patients with regard to
the control of proteinuria.
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1400 THE CLASSIFICATION OF DETERIORATING RENAL
GRAFT FUNCTIONS AFTER THE SERUM CREATININE
VALUE SURPASSED THE POINT OF NO RETURN
Y. Kato, K. Iwado, K. Kai, K. Nanmoku, A. Sannomiya, I. Koyama,
T. Tojimbara, I. Nakajima, S. Fuchinoue, S. Teraoka
Department of Surgery ‡V, Tokyo Women’s Medical University
Purpose: The transplanted renal graft is mortal yet and its end stage is still
unclear. We have analyzed the behavior of serum creatinine (s-Cr) values of
patients with renal grafts that survived longer than three years, both functioning
and lost. Last year we reported that the s-Cr 3.0 mg/dl could be the point of no
return of renal graft function mainly by observing s-Cr values of functioning
grafts. We have further investigated the subsequent patterns of time series s-Cr
values of the lost grafts after their s-Cr exceeded 3.0 mg/dl.
Method/material: We performed 1332 living/deceased renal transplantation
between 1985 and 2000. After excluding death with functioning graft cases
and those with inadequate s-Cr data, 126 cases that had been lost were studied.
All the s-Cr values taken later than 1 year after transplantation were examined.
They were divided into three groups according to the time needed for the s-Cr
value to rise up form 3.0 to 6.0. Group A (n=31; 25.6%): in less than 6 months,
Group B (n=47; 38.8%): from 6 to 18 months and Group C (n=43; 35.5%): in
more than 18 months. Linear regression analysis was applied to the time series
s-Cr values of each group and the mean increment of s-Cr value in 3 month
were figured out.
Result: That increment in Group A was 1.16 mg/dl/3month (p<0.001), that
in Group B, 0.622 mg/dl/3month (p<0.001) and that in Group C, 0.162 mg/
dl/3month (p<0.001), respectively.
Conclusion: The steady increase of s-Cr more than 3.0 mg/dl could indicate
the deteriorating renal graft function. Roughly speaking, the graft might be lost
within 6 month if the increment of s-Cr in 3 month after it exceeded 3.0 is more
than 1.2 mg/dl/3month. On the other hand, it might continue functioning more
than 18 month if that increment is less than 0.2 mg/dl/3month.
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1401 A STEROID-FREE MANAGEMENT STRATEGY FOR
CHRONIC TRANSPLANT GLOMERULOPATHY, USING
RITUXIMAB IN SELECTED PATIENTS
D. Anthony1,2, J. Galliford1, K.Y. Shiu1,2, H.T. Cook1,3, P. Brookes4,
M. England3, K. Chan1, A. Warrens1,2, D. Taube1
1
Imperial College Kidney And Transplant Institute, West London Renal and
Transplant Centre, 2Department of Immunology, Imperial College London,
Hammersmith Hospital, 3Department of Histopathology, Imperial College
London, Hammersmith Hospital, 4Tissue Typing, Hammersmith Hospital
Background: Transplant glomerulopathy (TG) is a form of chronic antibodymediated rejection. Other than a report showing 12 month stabilisation in
3/4 patients after introduction of steroids, tacrolimus and MMF, there is little
guidance on treatment. We report a steroid-free regimen used in 16 patients
with chronic TG, tubular atrophy and interstitial fibrosis, diagnosed in the
context of progressive allograft dysfunction.
Methods and results: 7 patients who presented on azathioprine and
prednisolone ¡À ciclosporin were changed to tacrolimus [12 hr trough levels
5-7 ng/L (LCMS)] and MMF [12 hr trough levels 1.5 ¨C 3.0 mg/ml]; steroid
doses were not increased. 6/7 had positive C4d immunostaining on ¡Ý25% of
peritubular capillaries and/or glomerular endothelium. 3/7 stabilised rapidly
and remain stable 18 months later. 2/7 stabilised but then deteriorated 6-9
months later and 2/7 failed to respond. All 4 had ongoing TG on repeat biopsy;
3 were administered two doses of Rituximab, 1g IV two weeks apart. Of these,
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2 continued to deteriorate and reached ESRF within 6 months. The 3rd (the
only patient with C4d-negative TG) appears to have stabilised 3 months later.
There were no serious adverse events. One patient with hepatitis C presented at
13 months with an acute hepatitis that resolved spontaneously.
9 other patients, on optimal doses of tacrolimus and MMF at diagnosis,
received Rituximab straight away. 6/9 stabilised rapidly. 4 of these had C4dnegative TG and all remain stable 6 months later. One patient, with longstanding chronic obstructive pulmonary disease, developed pneumonic
consolidation 2 months post-rituximab which completely resolved after
appropriate anti-infective therapy. The other 2 had C4d+ TG; one remains
stable 2 years later. The second, with pre-existing bronchiectasis, presented
with chest sepsis 9 months post-rituximab, which resolved after appropriate
anti-infective therapy; this patient suffered fatal myocardial infarction 6
months later. 3/9 (all with C4d+ TG) failed to stabilise after rituximab and
reached ESRF within 6 months.
On analysis of the whole group, eGFR at presentation was highly significant in
predicting graft stability at 3 and 6 months [38.4¡À8.5 mls/min vs. 22.2¡À7.5
mls/min; p=0.004]. Comparing the responses of those administered rituximab
(12 patients), all 5 patients with C4d-negative TG remain stable at the time of
follow-up (3-6 months), whereas only 2/7 of those with C4d+ TG were stable
at 3-6 months (p<0.01). Data on the presence of donor specific antibodies will
be presented.
Conclusion: It is possible to stabilise renal function in TG, without steroids,
by optimising oral immunosuppressive therapy and using rituximab in selected
patients. This is the first report of efficacy of rituximab in TG and overall it
appears to be safe with few side effects; although numbers are small, our data
suggests those with C4d-negative- may respond better than those with C4dpositive TG. Successful treatment in both groups appears to depend on early
diagnosis (eGFR >30 mls/min).

1402 DURATION OF DELAYED GRAFT FUNCTION IS
AN IMPORTANT PREDICTOR OF ONE YEAR SERUM
CREATININE
J. Dominguez1,2, F. Lira1, R. Rebolledo1, P. Troncoso1, C. Aravena2,
M. Ortiz1, R. Gonzalez2
1
Pontificia Universidad Catolica De Chile. Santiago, Chile, 2Hospital Sotero
del Rio. Santiago, Chile
One year Serum Creatinine (SCr) has been shown to be a very good surrogate
end point for kidney allograft survival. The purpose of this study is to evaluate
the importance of different factors on one year SCr in a series of kidney
transplant from two centers.
Methods: Two hundred and sixty consecutive renal transplants performed
between 1997 and february 2007 with at least one year follow-up were
included. Mean age at transplantation was 40 ± 13, 55% were male, 19%
living donors, 96% of the patients received a CyA based immunosuppressive
protocol. Factors considered for analysis were: donor and recipient age and
sex, number of transplants, Panel Reactive Antibodies, Total number of HLA
mismatches, Cold Ischemia Time (CIT), 6 month Acute Rejection (AR)
rate and presence and duration of Delayed Graft Function (DGF) defined as
the need of postoperative dialysis and time to last post transplant dialysis.
Multiple regression analysis were performed for one year S Cr, AR rate
and duration of DGF. All calculations were performed on the Stat View®
software.
Results: Mean one year SCr was 1.46 ± 0.5, 6 month AR rate was 22% and
DGF rate was 26% with a mean duration of 3 ± 8 days (range 0-38). Multiple
regression analysis identified female recipient sex, decreasing donor age,
absence of AR within 6 months and decreasing DGF duration (but not DGF
rate) as giving lower one year S Cr (p <0.05). Analysis of AR showed that
the only significant factor affecting AR rate was duration of DGF. Finally
prolonged CIT was associated with a longer duration of DGF.
Conclusions: We confirm that one year SCr is affected primarily by well
known factors such as the incidence of AR, donor age and female recipient sex.
However we have identified the number of days on post transplant dialysis as
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1403 VERY LATE CONVERSION TO SIROLIMUSBASED IMMUNOSUPPRESSION VERSUS CALCINEURIN
INHIBITOR MINIMIZATION FOR TUBULAR ATROPHY/
INTERSTITIAL FIBROSIS AND CALCINEURIN INHIBITOR
NEPHROTOXICITY IN RENAL TRANSPLANTS
T. Kee, Y.M. Chin, A. Vathsala
Singapore General Hospital
Objectives: Tubular atrophy/interstitial fibrosis of renal transplants (RTX)
and calcineurin inhibitor (CNI) nephrotoxicity can be treated either with a
switch from a CNI to a Sirolimus (SRL) based immunosuppression or CNI
minimization (CNIM). Others have reported that switch to SRL leads to
improved allograft function and histology than CNIM when performed within 5
years after transplantation. We report the efficacy and safety of these strategies
when performed beyond 5 years after transplantation.
Methods: Twenty-seven RTX who experienced allograft dysfunction with
biopsies showing either TA/IF or CNI nephrotoxicity were either abruptly
switched from cyclosporine to SRL (SRL; n=11) or had cyclosporine dose
reduced to achieve a 2-hour cyclosporine level of 400-600 ng/mL in association
with a mycophenolate derivative (CNIM; n=16). The loading dose of SRL was
6-20 mg with a subsequent maintaining dose titrated to a target trough level of
8-10 ng/mL. Follow-up was for 12 months after conversion.
Results: At conversion, SRL and CNIM groups did not differ significantly with
respect to baseline renal function (serum creatinine (Cr); 215.2±56.3 μmol/L
(SRL) vs 222.2±72.8 μmol/L (CNIM); p=0.8) or time after transplantation
(127.8±55.9 months (SRL) vs 110.0±31.0 months (CNIM); p=0.35). However,
after one year of treatment, a 18.9±15.3% increase from baseline Cr (p=0.01)
was seen in 72.7% (n=8/11) of SRL versus a 6.5±5.9% increase in Cr (p=0.04)
for 37.5% (n=6/16) of CNIM. No difference in proteinuria between SRL and
CNIM was seen at conversion (0.2±0.3 g/d vs 0.4±0,7 g/d; p=0.3) and after
conversion (0.9±1.1 g/d vs 0.3±0.4 g/d; p=0.06). Infections occurred in 63.6%
(n=7/11) of SRL vs 12.5% (n=2/16) of CNIM during follow-up (p=0.006) but
no rejections, graft loss or patient death was seen.
Conclusions: After 5 years post-transplantation, switch to SRL may not be as
effective as CNIM and are associated with an increased rate of infections.
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1404 ARTERIAL STIFFNESS AND PROTEINURIA AFTER
KIDNEY TRANSPLANTATION
M. Baumann, C. Pan, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R.D. Isar, TU Munich
Background: Cardiovascular mortality is major cause of death after kidney
transplantation. Arterial stiffness as measured by aortic pulse wave velocity
(aPWV) is an accepted risk factor for blood pressure independent cardiovascular
mortality. The role of aPWV in renal transplant patients in context with their
renal glomerular and tubular function remains uncertain. Therefore we aimed
to investigate in stable renal transplant patients for aPWV, estimated glomerular
filtration rate (eGFR) and proteinuria.
Methods: In sixty-nine stable renal transplant recipients aPWV was measured
in duplicate using the Complior. GFR was estimated using MDRD (Modification
of Diet in Renal Disease) and logarithmic albumin-creatinine ratio (logACR)
were determined by morning spot urine. Adjusted correlations were performed.
Results show median±standard deviation.
Results: Mean age was 50.6±14.1 years with an eGFR of 43.6±16.2 ml/min
and a logACR of 2.28±0.42. Systolic blood pressure was 142.4±22.7 mmHg
and aPWV 8.9±2.2 m/s. LogACR positively correlated with aPWV including
adjustment for age, eGFR, heart rate and height, (r=0.32; P<0.05). The relation
between eGFR and aPWV did not reach statistical significance after adjustment
for age, logACR, heart rate and height (r=0.26; P=0.08).
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a new and significant factor affecting one year SCr. On the other hand AR rate
is also affected by DGF duration which in turn is conditioned by longer CIT.
Every effort should be made to decrease DGF duration in order to improve one
year S Cr and possibly graft survival.

Tuesday 12 August 2008

Poster Abstracts

Conclusion: Albuminuria and aortic stiffness show a significant association in
renal transplant patients, suggesting an interaction between transplant function
and systemic vasculature. This relation is less clear for eGFR and aortic
stiffness, mirroring the data evident in patients with chronic kidney disease.
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1405 HYPERTENSION AFTER RENAL TRANSPLANTATION
– AN INDIAN EXPERIENCE
D.S. Deepak1, V. Sakhuja2
1
Dept of Nephrology,Medical Division,Command Hospital (Chandimandir),
India, 2Dept of Nephrology, Postgraduate Institute of Medical Education and
Research, Chandigarh, India
Hypertension after renal transplantation is quite common. The prevalence
has been reported to be 20-80% in various studies.Multiple factors have been
thought to be responsible for development of hypertension following renal
transplantation .
Aim: To analyse the prevalence and risk factors associated with development
of hypertension in renal transplant recipients.
Methods: A retrospective analysis of 324 renal transplant recipients from
Jan 1995 to May 2001 at a tertiary care nephrology and transplant centre
was carried out. The renal transplant recipients predominantly being live
donors(319 in number-98.5%), followed up for at least six months, were
selected. Hypertension was defined as a blood pressure of >140/90 mm of
Hg.Risk factors like age and sex of the recipient& donor,relationship with
donor, type of immunosuppression, details of surgical procrdure,severity of
pretransplant hypertension, HLA match, number of donor arteries, number of
acute rejection episodes were studied. The stastical analysis was carried out
using chi square test and multiple logistic regression model.
Results: Out of 324 renal transplant recipients,268(82.7%) were males and
56(17.3%) were females. The commonest underlying cause for end stage renal
disease was noted to be Chronic Glomerulonephritis present in 215(66.4%).
253 recipients (78.3%) were on cyclosporine based triple drug immuno
suppression and rest were on azathioprine and prednisolone at time of last
follow up. The patients had a mean followup of 27.93+_18.52 months(6-80
months) after renal transplantation. Hypertension was found to be present in
278(85.8%) patients, out of which 229(82.4%) were males and 49(17.6%)
were females.The majority of patients(66.7%) developed hypertension within
first two weeks following renal transplantation and the prevalence peaked
to93.1% at 3 months post transplantation. Out of 278 patients who developed
hypertension after renal transplantation ,180(64.8%) patients required two
or more drugs for control of blood pressure after renal transplantation.
Parent donor[ odds ratio-2.40,(95% confidence interval-1.21-4.75)
,p<0.01], severity of pretransplant hypertension(>1 antihypertensive drug
to control blood pressure)[ odds ratio-2.28(95% confidence interval-1.134.61),p<0.05] and body weight of renal transplant recipient(>55 kgs) [odds
ratio-1.5,(95% confidence interval-0.80-2.83),p<0.05] were the factors
found to be significantly associated with development of hypertension in
a renal transplant recipient .However left kidney implantation with end to
end anostomosis of donor renal artery to internal iliac artery of recipient
had a negative association with respect to development of hypertension
after renal transplantation[ odds ratio-1.53(95% confidence interval-1.224.77),p<0.05].A total of 5(1.5%) transplant recipients were detected to have
Transplant Renal Artery Stenosis.
Conclusion: 85.8% renal transplant recipients were found to have hypertension.
The main factors associated with development of hypertension after renal
transplantation were- parent donor, severity of pre-transplant hypertension in
the transplant recipient and weight of the renal transplant recipient. However
surgical procedure comprising of a combination of left kidney implantation
with end to end anostomosis of donor renal artery to recipient’s internal iliac
artery was found to be negatively associated with development of hypertension
after renal transplantation.The prevalence of Transplant Renal Artery Stenosis
was quite low.
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1406 THE EFFECTIVENESS OF A RENAL TRANSPLANT
CLINIC IN DISPENSING HEALTHY LIFESTYLE ADVICE: A
SURVEY OF PATIENTS
R. Naik
Royal Berkshire Hospital
Introduction: Several lifestyle choices are known to be important determinants
of mortality in renal transplant recipients. This is particularly the case for
lifestyle factors which impact upon cardiovascular risk, as this is the most
common cause of death among transplant patients. Smoking not only increases
cardiovascular risk but also adversely affects graft survival. The UK Renal
Association has published guidelines on the lifestyle advice which should be
offered to all renal patients, including transplant patients.
Renal transplant patients attend clinics in secondary care more frequently than
other patient groups, and hence may attend their primary care doctor less often.
Thus roles which are traditionally taken on by primary care doctors - advice
about exercise, offering help to stop smoking - need to be taken up by doctors
on the clinic.
The aim of this study was to determine not just if healthy lifestyle advice is
being offered in the transplant clinic, but if it is effective. We also looked at
rates of vaccination against Influenza and Pneumococcus - again, often thought
of as the role of primary care.
Methods: Questionnaires were handed out at clinics.
Results: 9% of respondents smoked, of whom 25% felt they had not been
advised to stop, and 50% felt they had not been offered help to stop. 33% of
patients took no regular exercise; only 30% felt they had been advised to take
more. One patient admitted to alcohol consumption above the recommended
weekly limit. 15% of patients had not received the Influenza vaccine, and 37%
had not received the Pneumococcal vaccine.
Conclusions: Lifestyle advice was reasonable, but there was room for
improvement. A readiness on the part of clinic doctors to prescribe aids to
smoking cessation may help, as may printed reminders to discuss smoking and
exercise on clinic pro-formas. Improved communication between secondary
and primary care is needed to raise vaccination rates.
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1407 FRAMINGHAM RISK ASSESSMENT BY ACTUAL
CARDIOVASCULAR EVENT DATA IN RENAL TRANSPLANT
RECIPIENTS
E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, M. Cardi2,
G. Mogilishetty1, S. Safdar2, J. Durbin1
1University of Cincinnati, 2The Christ Hospital
Background: Framingham risk score (FRS) predicts cardiovascular (CV) risk
in the general population, but may underestimate CV risk in kidney transplant
(txp) patients (pts). FRS has not previously been validated by prospective
cardiovascular event (CVE) data collection in kidney txp pts. The purpose of this
study was to validate FRS with actual observed CVE data in kidney txp pts.
Methods: CVE data was collected at routine intervals in our kidney txp
pts and entered in a cardiovascular risk database. FRS was calculated from
baseline to 7 yrs posttransplant (PTx). Individual FRS factors of age, sex,
smoking, diabetes mellitus (DM), high-density lipoprotein (HDL), total
cholesterol (TC), and blood pressure (BP) were evaluated for their ability
to predict actual CVE occurring after kidney txp. Pts with coronary artery
disease (CAD) were excluded from the FRS analysis. CVE were defined as
sudden death, myocardial infarction, angina, and cerebrovascular accident/
transient ischemic attack. FRS factors were evaluated by Cox proportional
hazards in univariate (UVA) and multivariate (MVA) models.
Results: 693 renal txp pts were evaluated from 1997-2007. Demographics
and FRS data are presented in Table 1. Mean follow-up was 1420 ± 958 days.
123 patients (18%) experienced a CVE PTx. FRS decreased significantly
from preTx to 7 yrs PTx (p<0.05). FRS was significantly correlated with CVE
(p< 0.01) in the UVA model. MVA results for individual FRS factors are in
Table 2.
Table 1:
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Male

56%

African American

23%

Mean Age

47.9 ± 12.7

Pretxp CAD

12.3%

Pretxp FRS (% 10 Yr Risk)

8.1 ±7.3

FRS 1 Yr (% 10 Yr Risk)

7.8 ±7.2

FRS 2 Yr (% 10 Yr Risk)

8.2 ±6.8

FRS 3 Yr (% 10 Yr Risk)

7.1 ±6.1

FRS 5 Yr (% 10 Yr Risk)

7.6 ±6.2

FRS 7 Yr (% 10 Yr Risk)

7.2 ±5.8

Table 2:
MVA of CVE
SBP>160mmHg

Odds Ratio

95% Confidence Interval

p

4

1.03 - 15.4

0.04

DM

3.5

2.1 - 5.7

0.0001

Smoking

2.4

1.4 - 4.06

0.002

TC>240mg/dL

2.3

1.06 - 5.07

0.04

HDL>40mg/dL

0.6

0.34 - 0.93

0.03

Conclusions: Individual component risk factors of the FRS were each
demonstrated to be statistically signficant predictors of CVE in kidney txp pts.
This study presents the first correlation of FRS with actual CVE data collected
prospectively in kidney txp pts.
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1408 TRADITIONAL VERSUS NONTRADITIONAL RISK
FACTORS FOR CARDIOVASCULAR EVENTS IN KIDNEY
TRANSPLANT RECIPIENTS

MVA for CVE
Chronic CS
DM
HDL

Odds Ratio
2.7
2.8
0.97

p
<0.001
<0.001
0.02

Conclusions: Strongest predictors of CVE included CCS, HDL, and DM.
Other factors, including FRS, acute rejection, MDRD, BP, preTx CAD, and
smoking were predictive only in the UVA. Since FRS does not include CS
therapy, incorporating CS therapy as a risk factor may improve the predictive
ability of FRS in the renal txp population.

1409 RELATIONSHIP BETWEEN ARTERIAL STIFNESS,
CARDIOVASCULAR DISEASE AND METABOLIC
ALTERATIONS AFTER KIDNEY TRANSPLANTATION
L. Locsey1, L. Szabo2, R. Fedor2, A. Dan1, L. Asztalos2
B.Braun Avitum 10AKD, 2I.Surg.Dept.DEOEC ,Univ.Debrecen
The arterial stiffness is an independent predictor cardiovascular risk fac tor,the
associated aging,hypertension and cardiovascular disease.The aug- mentation
index (AIx)and pulse wave velocity (PWV) are early markers for atherosclerotic
vascular changes.We examined 81 males ,64 females (45,3+/- 11,2 ys)renal
transplanted pts,measured systolic,diastolic blood and pulse pressure (PP)and
AIx ,PWV with TensioClinic(TensioMed) arteriograph and cardiovascular risk
was assessed by echocardiography and ultrasonography of carotid arteries.The
thickness of left ventricular wall,the ejection frac- tion and stenosis of carotid
arteries were measured.We investigated is fas-ting serum creatinine,cystatin
C,homocysteine,CRP,iPTH ,lipids and CaxP le-vels. The serum cystatin C was
2,1+/-0,2 mg/l,homocysteine 15,2+/-2,6umol /l, with hypercholesterolaemia,high
LDL and ApoB levels.After transplantation significantly increased BMI,FM and
VFA (p<0,01).The AIx increased 20% of men,and 37% of females (AIx <10%).
PWV increased in 43% of men,34% of fema les (>10m/s).PP was pathological high
12-12% of pts.The PWV was siginificantly related to age(r=0.52),thickness of the
ventricular wall(r=0.46).PP ,BMI,systolic and diastolic blood pressure correlated
positively but modestly with PWV.The was significant relationship between AIx80
and systolic (r=0.42),diastolic (r=0.39) blood pressure and PP (r=0.33).Ejection
fraction negatively correlated with PWV and AIx.There was strong association
between carotid arteries stenosis and PWV,AIx80.All pts with greater than 10m/s
had carotid stenosis.The pathological high AIx80 (>10%) and PWV (>12m/s)
can be found high BMI,FM,VFA and increased PP,systolic,diastolic blood
pressure,MAP with dyslipidaemia ,high Ca x P (> 4,4),iPTH (>160 pmol/l).
The arteriograph an objective ,non-invasive ,convenient method for the early
diagnosis and follow -up atherosclerosis.

1
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1410 RELATIONSHIP BETWEEN VISCERAL FAT SURFACE
AND CARDIOVASCULAR COMPLICATIONS AFTER RENAL
TRANSPLANTATION
L. Locsey1, B. Borbas1, B. Szlanka1, I. Menes1, A. Dan1, L. Szabo2,
L. Asztalos2
1
B.Braun Avitum 10AKD, 2I.Surg.Dept. DEOEC ,Univ.Debrecen
After renal transplantation significant increased BMI ,FM .In chronic dialysed
programme increased the aging ,accelarating atherosclerosis and malnourished
complications. Aims of study: relationship between change of body different
compartment (fat and water) and cardiovascular complications (blood and
pulse pressure,cardiac events, arterial stiffness). We are investigated dialysed
pts 79 males, 56 females (67,12 +/-7,26 years) and renal transplanted 81
males, 64 females (45,51 +/- 11,27 years). Blood pressure and cardiac events
measured with CardioTens (Meditech 04), arterial stiffness with arteriograph
(TensioClinic-TensioMed). Bioimpedancia analysis (BIA) was performed
with multifrequential BIA analyser (InBody 720 –BIOSPACE). We compared
the LAP–lipid accumulation product–waist(cm) x serum triglyceride (mM/l)
and waist/hip ratio in malnourished, and obes pts in dialysis programme and
after renal transplantation. After renal transplantation cystatin C,homocysteine
concentrations were 2,1 vs 5,2 mg/l and 15,21 vs. 23,78 umol/l. Dialysed pts have
hypertriglyceridaemia, in transplanted pts were high hypercholesterolaemia,
LDL and ApoB levels. In dialysis programme was 9,87% malnourished pts,with
decreased FM (4,9-12,6kg), visceral fat surface area less --26,9 + 12,8 cm2
than normal. In obes dialysed pts were 29,87%, increased FM (26,89 +/- 6,71
kg), and VFA (92,78 –296,45cm2).Transplanted pts increased BMI, in 63,14%
FM,VFA (98,67–278,14 cm2). LAP was 72,22 +/- 13,74 cm x mM/l (<21kg/
m2 BMI), and 227,15+/- 41,78 cm x mM/l (BMI >30kg/m2). In obes pts was
frequently arythmia ,non dipper hypertension and negative diurnal index, and
pulse pressure increased higher (>70 mmHg) in 38% of dialysis pts ,and 24% of
transplanted pts. The augmentations index (AIx) increased in dialysed female
60%, after transplantation only 18% (> 10%).The pulse wave velocity (PWV)
was higher in dialysed males 25%, after transplantation 10% (> 12m/s). In obes
pts increased significantly BMI ,FM and VFA,with increased LAP and waist/
hip ratio increased blood and pulse pressure with cardiac events.
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E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, G. Mogilishetty1,
M. Cardi2, M. Clippard, R. Munda1
1University of Cincinnati, 2The Christ Hospital
Background: The Framingham risk score (FRS) has underestimated
cardiovascular (CV) risk in renal transplant (txp) patients (pts). Evaluation
of additional factors may provide a means for enhancing risk prediction. The
purpose of this study was to evaluate FRS and other txp-related factors for
observed CV events (CVE) in kidney txp pts.
Methods: CVE data is regularly updated in our cardiovascular risk database.
CV risk factors (renal function (fxn), pretxp coronary artery disease (CAD),
diabetes mellitus (DM), acute rejection (AR), blood pressure (BP), lipids, and
corticosteroids (CS)) are assessed at baseline, 6 mths, and yearly posttransplant
(PTx). FRS factors included age, sex, smoking, DM, high density lipoprotein
(HDL), total cholesterol (TC), and blood pressure (BP). Renal function was
assessed using MDRD equation. HF events were defined as pulmonary edema or
clinical HF diagnosis. CVE included sudden death, myocardial infarction (MI),
angina/unstable angina or cerebrovascular accident (CVA)/transient ischemic
attack (TIA). Statistical analyses included Chi square, Student’s t-test, Univariate
(UVA) and multivariate analyses (MVA) using Cox proportional-hazards.
Results: Data from 693 pts were analyzed. 471 pts received early CS withdrawal
(ECSWD) (≤7 days) and 222 pts received chronic CS (CCS). Overall, 123 pts
(17.7%) experienced a CVE PTx. Mean follow-up in all patients was 1420 ±
958 days. Demographics included: 56% male, 23% African Americans, and
mean age 47.9 ±12.7 yrs. In the MVA for HF events, patients with DM were
2.8 times more likely to have a HF event (p<0.04). In the UVA for CVE, FRS,
DM, CAD, MDRD, CS, smoking, AR, high-density lipoprotein (HDL), and BP
were significant. However, in the MVA for CVE, only CS, DM, and HDL were
significant (Table).
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1411 LIPIDEMIC PROFILING IN RENAL TRANSPLANT
RECIPIENTS. A PROSPECTIVE STUDY
M. Koukoulaki1, D. Pistolas1, K. Balaska1, T. Apostolou1, C. Vlachopoulos2,
E. Kyristi1, V. Hadgiconstantinou1, C. Stephanadis2, S. Drakopoulos1
1
Transplant Unit, Evangelismos General Hospital of Athens, Greece, 21st
Department of Cardiology, University of Athens, Hippokrateio General
Hospital of Athens, Greece
Introduction: Immunosuppression has a direct impact on lipidemic profiling
of renal transplant recipients that affects in the long term the cardiovascular
risk. Atherosclerosis is a systematic disease of the vessels and patients with a
single clinical manifestation of atherosclerotic lesions have increased risk of
identification of atherosclerotic lesions at multiple sites.
Patients and methods: We studied 50 patients, non-diabetic, with end-stage
renal disease who received a renal allograft. 37 were male and 13 female of
mean age of 47.5±9.7 years old. Triplex ultrasonography of carotic arteries was
performed prior to transplantation and one year later. Parameters of lipidemic
profiling were also monitored before transplantation, and subsequently
on the first, third, sixth and twelfth month post-renal transplantation.
Immunesuppressive protocol included induction therapy and triple regimen
with calcineurin inhibitor, mycophenolate mofetyl and corticosteroids.
Recipients were not administered statins or other lipid lowering drug.
Results: Cholesterol, HDL and triglycerides present statistically significant
increase post transplantation (one way ANOVA, P<0.001) (table). Mild
atherosclerotic lesions at carotid arteries were found in 50% of renal transplant
recipients prior to transplantation. One year post-transplantation, 18% of renal
graft recipients did not present atherosclerosis, 54% had mild atherosclerotic
lesions and 28% present significant stenosis. Statistical analysis showed
significant change of carotid stenotic lesions (paired t-test, p=0.0013).
Conclusions: In this study it was shown that the majority of renal transplant
recipients during the first post-transplant year presented mild or significant
atherosclerotic lesions at the carotid arteries which represented extensive
atheromatosis including coronary arteries and increase of cardiovascular risk.
Month
Cholesterol
HDL
Triglycerides

0
169.56±44.04
44.2±11.28
144.2±9.82

3
211.46±44.22
52.12±13.29
182.58±8.28

6
201.56±35.29
53.0±14.42
175.36±9.71

12
198.64±41.05
54.84±16.25
147.76±7.77
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1412 PREOPERATIVE CARDIOVASCULAR SCREENING
PROVIDES NO SURVIVAL BENEFIT FOR PATIENTS PLACED
ON THE RENAL TRANSPLANT WAITING LIST
R.K. Patel1, P.B. Mark1, N. Johnston2, R. McGeoch2, M. Lindsay2, H. Dargie2,
A.G. Jardine1
1
BHFGCRC, University of Glasgow, Glasgow, UK, 2Department of
Cardiology, Western Infirmary, Glasgow, UK
Purpose: Premature cardiovascular (CV) death is increased in patients with
ESRF. The benefits and predictive value of pre-transplant cardiac assessment
and intervention remain uncertain. We therefore examined its the importance
on clinical outcome.
Methods: We prospectively examined 300 patients with ESRF who underwent
pre-transplant cardiac investigation with ECG, standard Bruce exercise testing
(ETT) and cardiac MRI to assess left ventricular dimensions. Patients with
high index of suspicion of coronary artery disease (CAD) underwent coronary
angiography and percutaneous coronary intervention (PCI) if indicated.
Results: Of the 222 patients accepted onto the renal transplant waiting list;
80 patients were transplanted during the follow-up period and 31 died (7
following transplantation). Successful transplantation was associated with
improved survival (transplanted mean survival 4.50.6 years vs not transplanted
4.11.4 years; p<0.0001). 74 patients of wait listed patients underwent coronary
angiography; 56 (25.2%) had no or mild CAD and 18 (8.1%) significantly
obstructive CAD. 15 patients (6.8%) were treated by PCI. There was no
apparent survival difference between patients who underwent PCI or CABG
(n=15), compared to those who underwent angiography without intervention
or no angiography (p=0.90; Figure 1) despite higher perceived risk of CAD
in patients referred for angiography based on clinical history and non invasive
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test results. For patients placed on the transplant waiting list, univariate Cox
regression analyses demonstrated older age at screening, past medical history of
IHD, cerebral vascular disease (CeVD) or hypertension and ETT performance
as factors significantly associated with death. Multivariate analysis revealed
older age, history of diabetes, IHD and CeVD and ETT performance as
independent predictors of death.
Conclusion: Pre transplant CV screening provides prognostic information for
patients placed on the renal transplant waiting list. However, if the aim is to
identify and treat CAD, it provides no benefit.
Figure 1
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1413 ISCHEMIC HEART DISEASE (IHD) IS THE MAJOR
CAUSE OF DEATH IN RENAL TRANSPLANT RECIPIENTS
I. Kim, V. Chestuhin, B. Mironkov, M. Gontuar, N. Tomilina
Research Institute of Transplantology And Artificial Organs
The aim of this study was to determine the prevalence and risk factors of
IHD, its influence on the outcome of renal transplantation and the efficacy of
coronary revascularization.
We analyzed the data of 479 renal transplant patients (males- 332, females147, age 38,69 ±11,2 years). The follow-up period was 72,78 ± 46,72 mo after
transplantation. Diabetes mellitus was found in 68 recipients. Multivariate
analysis was used to estimate the independent relation between IHD and its
risk factors.
IHD was present in 14,8% of all patients (71 from 479); in 12,7% recipients it
was found de novo during 32,4 ±18 mo after transplantation. 10-year patient
survival rate was 39% in IHD group and 75% in patient without coronary
artery disease (p<0,0001). Age>45 year, gender, diabetes, hyperlipidemia,
infections, left ventricular hypertrophy and renal transplant dysfunction were
defined as risk factors of de novo IHD. Coronary artery disease was found to
be independently associated only with age (p<0,009), gender (p<0,00001) and
hyperlipidemia (p<0,0058).
34 renal transplant recipients with IHD were undergoing percutaneous
transluminal coronary angioplasty (PTCA) with stenting and 2- coronary artery
bypass grafting (CABG). Follow-up after revascularization was 23mo (2 to
74). 7 PTCA-treated patients required subsequent revascularization during 3-6
mo. All of them had coronary stenting with bare metal stents. Long-term effect
(>12 mo) was defined in 71% patients. There was only one case of myocardial
infarction after revascularization. 1 recipient died of cardiac failure during 38
mo after repeated revascularization. 3 PTCA-treated patients died after 28, 96
and 146 mo of oncology, hepatic cirrhosis and cerebrovascular disease. 8-year
patient survival rate was 91% in CABG- and PTCA- treated group and only
38% in patients with usual course of IHD (p<0,0001).
Conclusion: IHD is found in 14,8% of renal transplant recipients and in
12,7% patients it was defined as de novo disease. Coronary heart disease is
independently associated with age>45 year, gender and hyperlipidemia.
Coronary revascularization may be used as effective method of management in
renal transplant recipients with IHD.

POSTER BOARD NUMBER P2 – 213
1414 ENDOVASCULAR REPAIR AS FIRST-CHOICE
TREATMENT OF ABDOMINAL AORTIC ANEURYSM IN
KIDNEY TRANSPLANT RECIPIENTS
J. Szmidt1, Z. Galazka1, O. Rowinski2, T. Jakimowicz1, L. Romanowski
1Department of General, Vascular And Transplant Surgery, Medical
University of Warsaw, Poland, 22nd Department of Radiology Medical
University of Warsaw, Poland
Improved long term survival of kidney transplant recipients contributed to
increase number of incidence of abdominal aortic aneurysm (AAA) in this
group of patients. Open aneurysmectomy is technically difficult and burdened
with high risk of ischemic injury to transplanted kidney upon cessation of
aortic blood flow.
The aim of the study was to present results of endovascular AAA exclusion by
stentgraft implantation in patients after kidney transplantation.
In our Department since 1998 593 patients with AAA were treated
endovasculary. In this group eight (1,34%) were kidney transplant recipients.
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Time between kidney transplantation and AAA management was from 3 to 19
years. In 5 patients graft’s renal artery was anastomosed in end-to-end fashion
to hypogastric artery, in remaining patients end-to-side to external iliac artery.
Aneurysm diameter were 50 mm to 76 mm. Commercial bifurcated stentgrafts
were used (Zenith, Excluder and PowerLink). All procedures were performed
under epidural anaesthesia. All patients were followed-up with CT-scan
performed postoperatively, in 3-rd, 6-th, 12-th month and annually thereafter
according to Eurostar protocol. Kidney function was assessed two times a year.
Successful AAA exclusion (without any endoleak) and preserved flow to
transplanted kidney was confirmed on completion angiogram in all patients.
Temporary deterioration of transplanted kidney function was observed in two
patients, one of them required transient haemodialysis. In follow-up there was
one stentragft limb thrombosis contralateraly to transplanted kidney in 9-th
month after stentgraft implantation that required femoro-femoral by-pass.
In one patient there was endoleak type I treated successfully with proximal
extension. The mean observation period was 33 months (range 9-68 months).
Endovascular treatment of AAA in kidney transplant recipients is safe and effective
method and can be performed without serious impairment of graft function.

cholesterol (HDL-C) and triglycerides (TR), whereas its safety by determination
of liver enzymes (ALT, AST), LDH, CPK, serum creatinine and blood levels of
immunosuppressive drugs (cyclosporine, tacrolimus, everolimus, sirolimus),
over the follow-up period of 18 }6 months.
Results: A significant reduction of TC and LDL-C blood levels by 25%
and 34% respectively was observed during the first month of treatment with
ezetimibe (TC: 230 }34 ¨172 }29 mg/dl and LDL-C:147 }25 ¨87 }22 mg/dl)
(p<0.001). Although the TC and LDL-C blood levels of patients on ezetimibe
monotherapy showed the same degree of reduction, they remained well above
target levels. The renal function of all patients remained stable over the followup period (Cr: 1.7 }0.5 ¨1.5 }0.5mg/dl), whereas no changes on the blood
levels of immunosuppressive drugs were observed. The liver enzymes, LDH
and CPK remained normal in all patients apart from a diabetic patient who
developed rabdomyolysis. Apart from gastrointestinal symptoms in 2 patients,
no other side - effects were observed.
Conclusion: Combination of ezetimibe with statins represents an effective and safe
regimen for treatment of persistent hyperlipidemia of renal allograft recipients.
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1415 OUTCOME OF KIDNEY TRANSPLANTATION IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS: IMPACT OF
ROUTINE PRE TRANSPLANT CORONARY ANGIOGRAPHY
AND REVASCULARIZATION
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1416 EZETIMIBE IS EFFECTIVE IN THE TREATMENT
OF PERSISTENT HYPERLIPIDEMIA OF RENAL ALLOGRAFT
RECIPIENTS
E. Savvidaki, A. Benou, M. Roumeliotou, K. Fourtounas, P. Kalliakmani,
E. Papachristou, D. Goumenos, J.G. Vlachojannis
University Hospital of Patras
Introduction: Ezetimibe is a hypolipidemic agent acting via inhibition of
cholesterol absorption from small intestine. The effectiveness and safety
of long-term administration of ezetimibe was estimated in renal allograft
recipients with persistent hyperlipidemia.
Materials and methods: Sixty-seven renal allograft recipients with posttransplantation hyperlipidemia resistant to statins were included in the
study. All patients were treated by ezetimibe (10mg/day) alone (n=11) or in
combination to statins (n=56). The effectiveness of the drug was estimated
by determination of total cholesterol (TC), LDL cholesterol (LDL-C), HDL
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1417 48 MONTHS RESULTS OF A SPANISH MULTICENTRE
DATABASE: LEADING CARDIOVASCULAR DISEASE AFTER
RENAL TRANSPLANTATION
B. Dominguez-Gil , J.M. Morales1, R. Marcén2, D. Del Castillo2,
M. González-Molina2
1
Hospital Universitario 12de Octubre, Madrid, Spain, 2Grupo Forum Renal
With the aim to evaluate cardiovascular disease after kidney transplantation
(KTx) patients in Spain in the actual immunosuppressive era.
Methods: We analyzed the results of 2600 KTx patients during years 2000-2002
in 14 Spanish units, most of them, from cadaveric donors.
Results: Donors and recipient age were 46.9 ± 17 and 49.7 ± 13.7 years,
63% men, 16% were retransplanted and 12.5% hyperimmunized. The most
frequent immunosuppressive protocol was Tac+MMF+St. Acute rejection
rate at 1 year was 14.8%. Graft survival at 48 months was 85.6% (death
censored), and 80.7% (death non censored). The first cause of graft loss
was death with functioning graft during the first three years, and chronic
allograft nephropathy at the 4th year. Mean serum creatinine was 1.57mg/
dl during the first three years 1-3 and 10.83 mg/dl at the fourth year. Mean
proteinuria was 0.4 g/d at the 1st year, 0.5 g/d at the 2nd and 3rd year
and 1.27 g/d at the 4th year. 12.7% of patients had proteinuria at month
48. Patient survival at four years was 91.7%.The first cause of death
was cardiovascular disease (specially, IHD and PAD) at 1st, 2nd and 3rd
year (36, 36.7 and 39.4%). Cox regression analysis showed that time on
dialysis (HR=1.96, CI=1.24-3.10, p=0.004) and renal function impairment
(HR=1.52, CI=1.30-179, p<0.0001) were independent risk factors for graft
loss at 4th year. Moreover, multivariate analysis showed that recipient age
was the most important predictor of mortality (HR=2.5, CI=1.72-3.78,
p<0.0001) whereas acute tubular necrosis (HR=1.5, CI=1.07-2.36, p=0.02)
and renal function impairment (HR=1.3, CI=1.11-1.53, p=0.001) where
other independent risk factors.
Notably, the use of statines at 12 months was a protective factor for patient
survival at 48 months (HR=0.48, CI=0.28-0.83, p<0.001).
Conclusion: Death with functioning graft was the main cause of graft loss
during the first three years after transplantation in Spain. Nevertheless, at the 4th
year chronic allograft nephropathy was the leading cause of graft loss. Despite
of the age of recipients, patient survival was excellent. The most important
cause of death was cardiovascular disease. Recipient age and concomitant
pathology at the moment of transplantation could be related to these results.
Therefore, in this way it would confirm that the statines could be useful. It is
necessary to make a big effort to control cardiovascular risk factors, before and
after transplantation.
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S. Gang, B. Kalani, K. Gohel, U. Hegde, M. Rajapurkar
Muljibhai Patel Urological Hospital
Introduction: Coronary artery disease (CAD) is the leading cause of morbidity
and mortality in type 2 diabetic patients undergoing renal transplantation. These
patients have a high incidence of silent CAD. We wanted to investigate the outcome
of type 2 diabetic patients who had undergone routine coronary angiography
prior to transplantation and if deemed necessary coronary revascularization.
Methods: Between March 2002 and May 2007, 46 type 2 diabetic patients
underwent living donor kidney transplantation. There pre transplant work
included dobutamine stress echocardiography and coronary angiography. 14
patients (8 coronary artery bypass grafting and 6 percutaneous interventions)
underwent coronary interventions prior to transplantation. Mean age was 50.5+
5.7 years and 89% were males. Mean follow-up since kidney transplant was
28.8 + 20.1 months.
Results: 1, 3 and 5 year graft survival in patients who did and did not undergo
pre transplant revascularization was 92%, 78%, 78% and 87%, 71%, 68%
respectively. The patient survivals in these groups were 92%, 78%, 78 and
90%, 75%, 71% respectively. The cause of death was sepsis in 7, cardiovascular
disease in 6 and pancreatitis in 1.
Discussion: Routine coronary angiography in type 2 diabetic patients shows
high incidence of silent CAD. Pre transplant coronary interventions possibly
offer an opportunity to transplant these patients. Limitation of this study is that
there is no control arm that was medically managed.
Conclusion: Type 2 diabetic patients can undergo successful kidney
transplantation after pre transplant coronary revascularization.
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1418 ADDITION OF SPIRONOLACTONE TO DUAL
BLOCKADE OF RENIN ANGIOTENSIN SYSTEM (RAS)
DRAMATICALLY REDUCES SEVERE PROTEINURIA IN
RENAL TRANSPLANT PATIENTS: AN UNCONTROLLED
PILOT STUDY AT SIX MONTHS
E. Gutierrez, J. González, E. Ramirez, E. Merida, M.J. Gutierrez,
E. Morales, M. Praga, A. Andres, J.M. Morales
Nephrology Department, Hospital 12de Octubre, Madrid, Spain
Background: Experimental and clinical data strongly suggest that aldosterone
may contribute to proteinuria and progressive renal disease. In fact, antagonist
of aldosterone seems to be effective controlling proteinuria in native kidneys.
However there is no information in renal transplant patients a population in
whom the presence and the amount of proteinuria are risk factors for graft loss,
cardiovascular disease and death.
The aim of the study was to evaluate if the addition of an antagonist of
aldosterone, spironolactone, provide an additional antiproteinuric effect to
the angiotensin converting enzyme inhibitor (ACEI) and angiotensin type 1
receptor antagonists (ARB).
Methods: We evaluate in 9 renal transplant patients (serum creatinine < 3 mg/
dl) the six-month effects of spironolactone (25 mg/d) on severe proteinuria in
spite of the treatment with ACEI (Enalapril or captopril) plus ARB (Losartan
or Valsartan). Patients also received cation-exchange resins and they were
carefully controlled (mainly renal function and serum potassium) in the renal
transplant outpatient clinic, every week in the first month and twice a month
thereafter.
Results: The most important data are showed in the [table 1]
The reduction in proteinuria (in seven patients more than 50%, mean 61.6%))
was early and sustained at six months with mild non-significant deterioration of
renal function. Notably, nobody presented severe hyperkalemia.
Conclusions: This pilot study demonstratred that Spironolactone dramatically
decreased severe proteinuria in patients treated with ACEI plus ARB without
significant changes on renal function or serum potassium. Therefore, it suggest
that triple blockade of RAS is feasible in selected renal transplant patients to
reduce proteinuria, although caution to avoid severe hyperkalemia is required.
Finally, prospective and randomized studies testing the use of Spironolactone
with or without ACEI /ARB after renal transplantation are mandatory.

that were significant in the final model included: DM (OR 3.2, CI 2.0-4.9)
and CS (OR 3.2, CI 2.0-4.9. (table below). Significant factors for pt survival
on UVA that entered the MVA model included: pre-txp DM, statin therapy
group, DD, CS, delayed graft function, and DR mismatching > 0. Factors that
were significant in the final model included: DM, male gender, and CS. Statin
therapy approaches significance in the final multivariate model for decreasing
the risk of CVE (p=0.07) and death rates (p=0.08).
Mean Length of Follow Up (Days)
AR Rate
CVE Rate
Overall Pt Survival

Statin Therapy
(n=293)
1282±779
13%
15%
95%

No Statin Therapy
(n=345)
1603±1040
12%
21%
90%

p value
<0.01
0.70
0.05
0.02

MVA for CVE
Odds Ratio
2.8
3.2

Pretxp DM
CCS

95% Confidence Interval
1.8-4.3
2.0-4.9

Conclusion: This analysis indicates that CS therapy increases CVE and death
rates. Statin therapy offers a means for reducing cardiovascular risk in patients
receiving corticosteroids.
Kaplan Meier Estimates for Time to CVE Stratified by Statin Use and
Steroid Group
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1419 STATIN THERAPY AND CORTICOSTEROID
THERAPY IN KIDNEY TRANSPLANTATION: EFFECTS ON
CARDIOVASCULAR EVENT AND DEATH RATES
E.S. Woodle, R.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1, A. Govil1,
J. Durbin2,
1
Surgery, U Of Cincinnati, 2Christ Hospital
Body: Statin therapy has previously been shown to reduce acute rejection (AR)
risk in cardiac transplant (txp) recipients. Moreover, statin therapy also reduces
risk for cardiovascular events (CVE) in the general population. The purpose of
this study was to evaluate the effects of statin therapy on AR, CVE, and patient
survival in kidney txp recipients.
Methods: Patients were categorized based on statin therapy post-txp versus
no statin therapy. Univariate analysis (UVA) and multivariate analysis (MVA)
were conducted by stepwise logistic regression (STATA v9.2) to determine
significant risk factors for AR, CVE, and patient (pt) survival. Kaplan Meier
time to event analysis was conducted for overall pt survival and CVE rates.
Results: 638 renal txp pts were analyzed from 1997-2007 (46% received statin
therapy v. 54% with no statin therapy). Demographic data (not shown) and
AR rates were similar between groups. Statin therapy post-txp was associated
with increased pt survival (95% versus 90%, p < 0.02). CVE occurred
significantly less in pts on statin therapy versus those not on statin therapy
(p < 0.05). There was no difference in infectious complications between the
groups. Individual risk factors for CVE evaluated by UVA and found to be
insignificant included: current PRA > 25%, HDL < 40 mg/dL, AA recipient
race, age and gender. Significant factors for CVE on UVA that entered the MVA
model included: pre-txp diabetes (DM), statin therapy, repeat txp, deceased
donor (DD), corticosteroid therapy (CS), and DR mismatching > 0. Factors
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1420 EFFICACY AND SAFETY OF VYTORIN FOR
THE TREATMENT OF DYSLIPIDEMIA IN RENAL
TRANSPLANT PATIENTS
H.E. Yoon, B.J. Hyoung, S.Y. Lee, H.S. Hwang, Y.J. Jeon, B.S. Choi,
Y.S. Kim, B.K. Bang, C.W. Yang
Kangnam St Mary’s Hospital, The Catholic University of Korea
Background: Dyslipidemia affects the majority of renal transplant patients,
and is associated with cardiovascular events and premature graft loss. Despite
of treatment with statin, many patients do not achieve the target goal of LDLcholesterol and need additional lipid-lowering agents. Ezetimibe/simvastatin
(Vytorin) is a dual cholesterol-lowering therapy that inhibits the intestinal
absorption (ezetimibe) and synthesis (simvastatin) of cholesterol.
Methods: The efficacy and safety of ezetimibe/simvastatin in renal transplant
patients with dyslipidemia were assessed in an open-label, nonrandomized,
prospective study. Seventy-five renal transplant patients received the combination
tablet of ezetimibe 10mg and simvastatin 10mg daily. Concentrations of
fasting lipid panels, liver enzymes, serum creatinine, and C-reactive protein
(CRP), protein-creatinine ratio from a random urine sample (UPC), and trough
concentrations of cyclosporine (CsA), tacrolimus (FK506) or sirolimus (SRL)
were measured before and after the initiation of ezetimibe/simvastatin.
Results: 60 patients (80%) showed good compliance on ezetimibe/simvastatin
for 60 days (range 20-76). The concentrations of total cholesterol, triglycerides
and LDL-cholesterol decreased significantly by 33.2%, 25.9%, and 47.1%
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respectively. There were no significant changes in the concentration of HDLcholesterol, liver enzymes, serum creatinine and CRP, UPC, and trough
concentrations of CsA, FK506 or SRL. Eight patients (10.7%) stopped
ezetimibe/simvastatin because of myalgia, two patients (2.7%) because
of elevated concentration of liver enzymes, two patients (2.7%) because of
dizziness, and one patient (1.3%) because of skin rash.
Conclusions: The ezetimibe/simvastatin combination therapy is safe and
effective for the treatment of dyslipidemia in renal transplant patients without
changes in the concentration of immunosuppressants or renal allograft function.

POSTER BOARD NUMBER P2 – 220
1421 EZETIMIBE TREATMENT AS A GREAT TOOL
FOR CONTROL OF HYPERLIPEMIA IN RENAL TRANSPLANT
RECIPIENTS

Basal

3m

6m

p

TC

C
A

231±50
239±45

177±37*
203±33

179±42*
180±38**

<0.0001*
0.001**

HDL

C
A

61±19
54±15

56±15
51±14

54±16*
50±13**

<0.0001*
0.008**

LDL

C
A

133±42
144±40

93±37*
114±34

93±37*
97±32**

<0.0001*
0.001**

TG

C
A

211±125
212±73

163±71*
186±80

161±79*
156±76**

<0.0001*
0.020**

ApoA1 C
A

160±38
154±33

155±34
153±32

155±34
146±28

0.090
0.225

ApoB C
A

114±26
122±26

91±27*
102±21

93±24*
94±24**

<0.0001*
0.004**

A/C: alone/combined with statins. Basal: pre-ezetimibe. 3m and 6m: 3
and 6 months post-ezetimibe.
Conclusions: Ezetimibe is a safe and effective therapy for dyslipemia
in renal transplantation. It improves lipid profile at 3 and 6 months
post-treatment in combined therapy with statins and at six months in
monotherapy. Ezetimibe decreases the apoB too, a proinflammatory, but
no modifies the serum CRP.

1422 IMPORTANCE OF WAIST/HIP (W/H) RATIO
EVALUATION IN RENAL TRANSPLANTED PATIENTS
M.F. Taylor, L.M. Obregón, H. Petrone, M. Barán, M.E. Menna
CRAI Sur CUCAIBA
Objectives: Evaluate the importance of W/H ratio measurement in renal
transplanted patients.
Materials and methods: patients that followed the following inclusion criteria
were evaluated: more than 6 months since transplant, stable renal function
without rejection in the last 90 days, without hospitalization,infectious episodes
or complications, without diabetes diagnosis before or after transplant, by
fasting glucemia, women that were not pregnant who agreed to participate in
the study. Clinical data (age, smoking, time since transplant, donant type, sex,
waist circumference, w/h ratio, BMI and steroids dose) were considered. An
oral glucose tolerance test (OGTT) was performed, an overnight fasting plasma
glucose level, creatinine and insulin determinations, HbA1c. A retrospective
analysis of values was carried out. Patients were divided into two groups
according to altered values in W/H ratio (Group I and group II). As reference
values, we took into account WHO (World Health Organization). A value of
p 0.05 was considered significative. Chi square test and two tail student test
were used.
Results: 31 patients were evaluated. 80.64% had increased W/H ratio (group
I). This group presented significantly higher values of glucemia in time 0
and, after two hours in OGTT. We also observed BMI higher values. In the
retrospective analysis of FPG values, greater frequence of altered FPG in group
I. A correlation between W/H and FPG were observed. No differences were
observed in age, smoking, time since transplant, donant type, sex, steroids
dose, creatinine levels, fasting insulin determinations and HbA1c .
Conclusions: W/H ratio measurement is very simple and of great usefulness in
renal transplanted population, specially in developing countries, such as ours,
where it does not exist great availability for many laboratory determinations.
This simple measurement is a good parameter to evaluate insuline resistence in
this group of patients. Prevalence is very high and frequently infravalorated.
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1423 AMBULATORY BLOOD PRESSURE MONITORING
(ABPM) AND TARGET ORGAN DAMAGE IN KIDNEY
TRANSPLANTATION
F. Margulis, R. Schiavelli
Servicio De Nefrologia Y Trasplante Renal, Hospital Argerich
The prevalence of hypertension in patients with kidney transplantation is highly
elevated (60-80%). Several studies have demonstrated that ABPM is a useful,
more advantageous and efficient technique than the measurement of BP in the
office and correlates better with target organ damage. This is a useful technique
too for the diagnosis of white coat hypertension (WCH).
For this reason we have made a retrospective study to evaluate the prevalence
of hypertension and WCH, the changes in circadian rhythm and its possible
relationship with target organ damage.
Material and methods: A total of 210 patients (127 males) mean age 39 ±
13 years and mean serum creatinine 1,6 ± 0.5 mg/dl were analysed, they were
assigned to immunosuppresant treatment with cyclosporin, mycophenolate
mofetil and prednisone (n=136), tacrolimus, myco phenolate mofetil and
prednisone (n=46), sirolimus and prednisone (n=21) and azathioprine and
prednisone (n=7), all of them were studied by ABPM 33 ± 48 months after
transplantation without any antihypertensive treatment. ABPM was recorded
noninvasively with an Accutraker II over 24 hr on a regular working day.
Patients were defined as hypertensive (HT) when mean daytime BP was higher
than 130/80 mmHg and non-dippers (ND) those patients whose mean sleeping
BP was 10% less than mean walking BP or rose during sleep. Patients who had
office blood pressure greater than 130/85 and mean daytime BP lesser than
130/80 mmHg was defined as WCH.
Trans-thoracic m-mode echocardiograms were performed by a single operator
who was blinded to the other results. LV mass was calculated according to the
Penn convention and corrected for body surface area to produce the LV mass
index (LVMI).
Independent Student´s t or Mann-Whitney test were used and P values < 0.05 were
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A. Sanchez-Fructuoso2, I. Perez-Flores1, N. Calvo3,
M.A. Moreno de la Higuera4, M. Giorgi5, S. Anaya6, A. Barrientos7
1
Hospital Clinico San Carlos, 2Hospital Clinico San Carlos, 3Hospital Clinico
San Carlos, 4Hospital Clinico San Carlos, 5Hospital Clinico San Carlos,
6
Hospital Clinico San Carlos, 7Hospital Clinico San Carlos
Aims: To evaluate the efficacy and safety of ezetimibe as monotherapy
or combined treatment for hyperlipemia in renal transplant recipients. To
investigate the effect of ezetimibe in the inflammation state and the ability to
modify levels of proinflammatory lipoproteins in these patients.
Methods: One hundred and forty patients who received ezetimibe during
six months at least in our renal transplant unit were included. Fasting lipid
profile [total cholesterol (TC), low-density lipoproteins (LDL), high-density
lipoproteins (HDL), triglycerides (TG), apolipoprotein B (apoB) and
apolipoprotein A1 (apoA1)], immunosuppressive therapy, inflammation state
[C-reactive protein (CRP)], body mass index (BMI), patient demographics
[age, sex, left ventricular hypertrophy (LVH), diabetes mellitus], fasting
glucose, renal function (serum creatinine and urea, creatinine clearance),
creatinine kinase (CK), liver function test were collected pre- and three, six
and twelve months post-ezetimibe therapy.
Results: Twenty-four patients (20%) were on ezetimibe after statins withdrawing
due to adverse reactions and 112 renal transplantation received ezetimibe after
failing statins in control of fasting lipid profile according to NCEP III lipid
guidelines were included. The average age was 53 years (range 25-77) and
66% were male. Main comorbid conditions were: DM 12%, LVH 68%, cardiac
disease 18%, hepatic disease 15% and chronic obstructive lung disease 14%.
The maintenance immunosuppression was: tacrolimus 45%, cyclosporine
25% and inhibitors mTOR 30%. The average serum creatinine was 1.5 mg/
dL and calculated GFR by Cockcroft –Gault was 53 ml/min. There was a
positive correlation between apoB and CRP in all patients (r 0.42, p<0.0001).
Seven patients (5%) received combined treatment had to be discontinued
due to adverse event (myalgias with elevations CK in 5, diarrhea in 1 and for
elevated cost in 1). There were no differences in serum levels of CRP pre- y
post-ezetimibe. We did not find any relationship between immunosuppression
drugs type and levels and the ezetimibe.
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considered to be statistically significant. Results are expressed as mean ± SD.
Results: WCH was found in 13% of transplant patients, the prevalence of HT
has increased after transplantation (62% to 77%) and 57% of all transplant
patients had alteration of circadian rhythm. The loss of circadian rhythm was
seen in both HT (53%) and NT (71%).
The HT group had greater LVMI (160,7 ± 44 vs 140 ± 47 gr/m2 p< ,004) and
lesser renal function (60,8 ± 17 vs 71,1 ± 22 ml/min p< ,0001) than NT group.
Significant differences were found with respect to the alteration of circadian
rhythm in relation to left ventricular mass index (LVMI) 162 ± 46 vs 146,1 ±
34 gr/m2 (p< .01) and graft function 61,7 ± 16 vs 67,2 ± 19 ml/min (p< .03)
between ND and dippers respectively.
When the relationship between alteration of circadian rhythm with LVMI and
graft function were analyzed, we did not find any significant differences in the
normotensive group but we did in the hypertensive one.
Conclusion: The prevalence of WCH in our patients was lesser than in general
population and the ABPM was useful to defined the alteration of circadian
rhythm and its relationships with organ damage in HT patients.
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1424 CARDIOVASCULAR RISK FACTORS AND THEIR
MANAGEMENT IN RENAL TRANSPLANT RECIPIENTS
X. He1, Y. Zhao1, A. Johnston1, I.A.M. MacPhee2 on behalf of the
Pan-Thames Renal Audit Group
1
Clinical Pharmacology, William Harvey Research Institute, Barts and the
London School of Medicine and Dentistry, University of London, 2Cellular
and Molecular Medicine: Renal Medicine, St. George’s, University of London
Background: The commonest cause of premature death in the renal transplant
population is cardiovascular disease. This retrospective study aimed to identify
conventional cardiovascular risk-factors and their modification in a cohort of
229 renal transplant recipients from a group of transplant units in a single city
who were transplanted in 1999 with five years of follow-up.
Methods: Data on all adult patients transplanted in the calendar year 1999
were collected into an Access database by one clinical research nurse who
visited all of the units. Cardiovascular risk factors at the time of transplantation
were recorded with annual measures of blood pressure (mean of 3 values
closest to annual review), lipid profile and eGFR. A blood pressure standard
of < 130mmHg/< 80mmHg was introduced by the UK Renal Association in
2002. There are no formal standards for lipid management in renal transplant
recipients so those used for the general population were employed.
Results: 23% had a previous cardiovascular event. Five year graft survival
was 84% and death censored graft survival was 94%. Mean eGFR was
around 50 mL/min/1.73m2 for the whole study period. Only 30-40% of
patients achieved the target systolic blood pressure of <130 mmHg and fewer
than 10% had diastolic BP <80mmHg. The mean number of antihypertensive
agents was between 1.7 and 1.9. Use of ACE-inhibitors or Angiotensin-II
receptor blockers and statins increased over the follow-up period. Mean
blood pressure for 41 patients who were on no anti-hypertensive therapy was
130±15/79±9mmHg. Only 8 (20%) had systolic pressure less than 130mmHg.
The percentage of patients with total cholesterol < 5.0 mmol/L increased from
45% to 70% over the follow-up period. Mean LDL was 2.8 mmol/L in 2000
and 2.4 mmol/L in 2005. For the 75 patients not on lipid lowering therapy,
TC at each visit were 4.8±0.9(2.5-7.6) mmol/L, 4.7±0.9(3.1-6.9) mmol/L,
4.6±0.9(3.0-6.9) mmol/L, 4.6±0.9(2.5-7.0) mmol/L, 4.6±0.9(2.8-7.1) mmol/L
and 4.6±0.9(2.1-6.9) mmol/L, respectively, with 30 (40%)having total
cholesterol less than 5 mmol/L. Aspirin was prescribed for approximately
30% patients.
Discussion: In this cohort, over 50% of patients failed to meet the Renal
Association blood pressure targets in spite of a mean of around two
antihypertensive agents per patient. This suggests that there is scope for
increasing the number of agents in an attempt to reach targets in modifying
conventional cardiovascular risk factors. In contrast, achievement of lipid
targets through statin use was more successfully achieved.
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1425 SUCCESSFUL RENAL TRANSPLANTATION AFTER
PERIPHERAL AND CEREBRAL VASCULAR DISEASE
J. Bittar, P. Arenas, C. Chiurchiu, W. Douthat, J. de Arteaga, J. de la Fuente,
G. Paladini, R. Colla, P. Massari
Hospital Privado - Centro Medico De Cordoba
Pretransplant cardiovascular disease is a known risk factor for patients survival
after renal trasnplantation. Patients with cardiac and peripheral vascular disease
are frequently excluded from waiting lists. The post-transplant outcome in
patients with cardiovascular disease (CVD) is not well know in South America.
The purpose of this single center retrospective study was to compare patient
and graft survival of patients with cardiac disease (CD) and patients with
cerebrovascular and peripheral vascular disease (CPV) and indentify factors
associated to CDV outocome. From a total of 758 renal transplants done from
1986 to 2004, 19,39% (147) were identified as CVD. Of them, 116 (78,9%)
were CD and 31 (21,1%) were CPV. There were more diabetics in CPV (25,8%
vs 8,6%) and predominantly male (87,9% vs 63,7%) than CD [p= 0,008 and
p= 0,009]. Inmunosupression was based on CNIs and MMF in most cases.
The donors age were 35,7 15,1 years and 41,9 17,1 years in CD and CPV
respectively (p= 0,05). Late acute rejection (> 6 months) were more frequent
in CPV than CD: 6,4% vs 0,86% (p= 0,05) and they had more incidence of
graft thrombosis: 9,6% vs 0,9% (p= 0,01) respectively. Patient survival for 1, 3
and 5 years was 94,6%, 90,8% and 89,6% in control patients. Patient survival
for 1, 3 and 5 years was 93,8, 92,6% and 92,6% in CD vs 72,6%, 72,6% and
63,5% in CPV (p<0.001). Graft survival for 1 and 5 years was 83,8%, 69,2%.
Graft survival at 1 and 5 years was 86,9% and 75,4% in CD vs 73,9% and
61,6% in CPV (p=0,05). Sepsis was the main cause of death in both groups,
but its prevalence was higher in CD: 75,0% vs 70,0% respectively (p=0,006).
Cardiovascular death was 12.5% and 30% in CD and CPV respectively.
Coxs multivariated analysis showed that recipient age [RR 1,10(1,04-1,16)]
(p=0,0003); CPV 1,83(1,56-1,94)](p=0,02) and serum creatinine at year [RR
and [RR 3,20 (1,21-8,87)](p=0,003) were an independent risk factor for patient
survival. Diabetes was not independently associated risk factor.This series
shows that patients with pretrasplant heart disease have a similar outcome
than controls in terms of patient and graft survival and that only those with
previous clinically symptomatic peripheral and cerebrovascular disease have
significantly lower graft and patient survival.
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1426 BLOOD PRESSURE CONTROL IN RENAL TRANSPLANT
PATIENTS: ARE WE AGGRESSIVE ENOUGH?
F. Vetromile2, P. Fesler1, I. Szwarc2, A. Mimran1, J. Ribstein1, G. Mourad2
1
Department of Internal Medicine and Hypertension, CHU Lapeyronie,
2
Department of Nephrology, Transplantation And Peritoneal Dialysis, CHU
Lapeyronie
Objective: In renal allograft recipients, best practice guidelines recommend
target arterial pressure <130/80 mmHg. Whether these values are achieved in
routine clinical practice is not known. The aim of this study was to analyze the
prevalence and identify factors associated with the presence of hypertension (HT,
≥; 130/80 mmHg) in a large cohort of patients followed annually in our center.
Methods: Blood pressure and renal function (glomerular filtration rate, GFR,
urinary 99mTC-DTPA clearance) were evaluated in 456 subjects, 66% male,
aged 51±12 yrs (mean ± SD) after a median follow-up period of 47 months
(range 47-335) post first-kidney transplantation (Tx).
Results: From the 456 subjects, only 33 (7.2%) were normotensive without
any antihypertensive treatment, 97 (21.3%) had well-controlled HT and 325
(71.5%) had uncontrolled HT. Among the 325 patients with uncontrolled HT,
69 (15.1% of the whole population) had true resistant HT (at least 3 drugs
including 1 diuretic) whereas 257 could not be considered as resistant HT
since they received 2 or less antihypertensive drugs (1.3±0.8). AS compared
to controlled HT, uncontrolled HT were slightly older (53±11 vs 50±12 yrs,
p=0.026) had received grafts from older donors (45±16 vs 38±16 yrs, p=0.001),
had lower GFR (51±21 vs 56±19 mL/min/1.73m²), and higher albuminuria (34
vs 19 μg/mL, p<0.001 after log-transformation) and fasting blood glucose
(5.85±2.61 vs 5.31±1.35 mmol/L, p=0.053). No difference was found for
gender, duration of dialysis before TX, delay after Tx, steroïd doses or type
of immunosuppressive treatment (cyclosporine vs tacrolimus). In multivariate
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logistic regression analysis, using controlled HT as the reference category, the
presence of resistant HT was independently associated with higher body mass
index, albuminuria and higher donor age.
Conclusion: After kidney Tx, the main factor associated with persistent hypertension
is the inadequation of antihypertensive therapy. However, obesity, albuminuria as
well as older donor age are the main factors associated with true resistant HT.
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1427 CORRELATION OF PULMONARY HYPERTENSION
WITH EGFR, DIABETIES, SMOKING, HD, PD IN A COHORT
OF RENAL TRANSPLANT RECIPIENTS FROM SOUTH INDIA

CONCURRENT ORAL SESSION 101: DONOR ALLOCATION
AND ETHICS
POSTER BOARD NUMBER P2 – 227
1428 LEGAL ASPECTS OF ORGAN TRANSPLANTATION IN
ITALY
P. Bruzzone
University of Roma “La Sapienza”
Informed consent is of paramount importance in any field of surgery, both from
the ethical and the legal point of view.
As far as organ transplantation is concerned, potential recipients are fully
informed before entering the waiting list. However, according to the Italian
law, they have to sign another informed consent form before entering the
operating rooms. It is the personal opinion of this author that not only the
recipients should be informed of the quality of the donor and of the particular
organ/s they are going to receive, but also that before entering the waiting list
they should accept or refuse the future possibility of receiving an organ from a

POSTER BOARD NUMBER P2 – 228
1429 ETHICAL ASPECTS OF LIVING DONOR LIVER
TRANSPLANTATION
P. Bruzzone
University of Roma
Living donor liver transplantation is still associated with some donor risk.
Mortality ranges from 0.3% to 1% and morbidity from 15% to 67%. After
donation, liver does not regenerate to 100% of its predonation mass. The
regenerative capacity and long-term health consequences of such a resection
are still unknown.
The technical requirements of performing and maintaining an ALDLT are
higher than in case of deceased donor transplantation or PLDLT.The graft-torecipient weight ratio should be sufficiently large to provide enough hepatic
mass and avoid small-for-size syndrome.A living donor should not be used for
a salvage operation in situations in which 1-year patient mortality is greater
than 20%.
Living donors should be uses only for UNOS-approved transplantation and
thus only for recipients with a physiological Model for End-Stage disease
(MELD) score of <25 or >15.
Patients with a MELD<15 may have a greater mortality risk with ALDLT than
if they would have waited for a full-sized deceased donor organ, while patients
with MELD>25 may be too debilitated or need a larger hepatic mass.
Donor only benefit is increased self-esteem, although in some countries financial
compensation is tolerated. There are some recipient benefits. Particularly, the
waiting time is reduced. This can be important for patients with blood group
O or A, with malignant liver tumors (advanced HCC: stage T3 and T4a and
low-grade primary malignancies other than HCC limited to the liver, such as
hemangioendotheliomas,small in stature, with acute hepatic necrosis and in
certain U.S. regions of allocation. Some non-neoplastic patients may even be
transplanted too early!
Strict requirements must be fulfilled both from the ethical and legal point of view.
Living donor transplantation must be performed in a center of medium to large
size. Minimum yearly volume should be 50 to 100 OLTx,including 10% to 30%
segmental tx within a comprehensive department of surgery performing 2000
or more general surgery cases, 50 hepatectomies, 20 pancreaticoduonectomies
and 10 complicated biliary cases annually, with mortality rates <5% and
complication rates<15-20% in standard liver resection surgery.
Each surgeon should have received a full training (including a fellowship
in visceral organ transplantation), should perform at least 30 major hepatic
surgery cases and 20 liver transplants (including pediatric and segmental
transplants) yearly and must have an impeccable surgical record and
outstanding ethical behaviour.
The transplant center should avoid unnecessary liver donations, pursuing
cadaver organ donation and a split liver transplant program for adults
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1430 IMPROVING CONSENT VIA PATIENT SUPPORT
GROUPS
Y. Kattoah
Kfshrc - Jeddah
Purpose: Consent for organ donation is a significant challenge in Saudi Arabia
with families reluctant to agree to cadaveric or living donation, preferring to
obtain kidneys abroad. The rate of Saudis leaving the country to obtain organs
has increased significantly and in 2006, 646 unrelated living kidney transplants
were performed outside the Kingdom while only 220 living related and 151
cadaveric transplants were performed inside the country.
Method: A qualitative approach was used, consisting of personal interviews to
survey potential donors and families before and after attending a support group.
Many factors influence decision making, including fear of effects of donation
on the living donor, and lack of understanding about the process. To address
this, our program has organ donors visit dialysis patient support groups to share
experiences.
These groups provide an avenue for mutual support and exchange of
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G. Abraham1, D. Lunawat2, M. Mathew2, N. Fathima2, S. Soundarajan2,
V. Sundaram2
1
Sri Ramachandra University, Chennai, 2Madras Medical Mission, Hospital,
Chennai
Objective: The aim of this study was to compare the prevalence of pulmonary
hypertension in a cohort of patients with end stage renal disease prior to and
following renal transplantation along with other variables.
Methods: This was a retrospective analysis of renal transplant recipients whose
pulmonary artery pressure was compared pre and post transplantation, in a tertiary
care centre in South India. Of the 425 renal transplantations performed over 2001 to
2007, 124 patients had their Doppler Echocardiographic findings available. The data
analysed included the hypertensive, diabetic and the smoking status of the patient
along with their BUN, Creatinine, GFR (by Nankivell formula),Hemoglobin,
Hemodialysis duration, AV fistula+/-,Urine albumin, B.M.I and most importantly
the echocardiographic findings both pre and post transplant – the pulmonary artery
pressure, ejection fraction. Statistical analysis was performed using SPSS-Windows
software and t-test, chi-square test and ANOVA were used.
Results: There were 72%males and 28% females with mean age of 43.3+_13.02
years. Out of this 87% were hypertensives, 30% were diabetics and 4%
smokers. Statistical analysis revealed a significant decline in pulmonary artery
pressure(PAP) following renal transplantation(p<0.05).PAP had no significant
correlation with a patient’s hypertensive, diabetic, smoking status, age ,gender,
BUN, Creatinine, GFR, Hemoglobin%, Hemodialysis duration, AV fistula,
Urine albumin.It was noticed that BMI had a significant correlation with Pretransplant PAH. Of the 72% patients with nil Pre-PAH(<=35mmof Hg), 68%
remained nil following transplantation, 2% developed mild PAH, 2% moderate
PAH. Of the 14% patients with mild Pre-PAH(>35and<=45mm of Hg), 9%
developed nil PAH, 4% mild PAH,1% moderate PAH following transplantation.
Amongst the 11.3% patients with moderate pre-PAH(>45and<=55mmof
Hg), 6.5% had nil, 2.4%mild and 2.4% moderate PAH post transplantation.
Out of the 3.2% who had severe pre-PAH(>60mmof Hg),0.8% had nil, 1.6%
moderate and 0.8% severe PAH post transplantation. There were no patients
with moderately severe PAH in the study(>55and<= 60mm of Hg).
Conclusion: The findings of our study reveal that pulmonary artery pressure
declines in ESRD patients after renal transplantation as compared prior to it.
This emphasizes the fact that excessive pulmonary blood flow is involved in
the disease pathogenesis which again could be related to various factors.

so called “marginal” or “Extended criteria donor” and/or a Non Heart Beating
Donor (NHBD).
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information between those closest to the problem. Scheduling former donors
and their families to speak at support groups provides an opportunity for
patients and family members to learn complex and challenging information
ranging regarding the donation process through the first hand experiences of
other Saudis who have gone through the process.
Results: By allowing potential donors families the opportunity to address their
concerns on an informal basis in a support group, we are improving perceptions
and practice regarding organ donation.
Conclusion: While the program is still relatively new, notable progress has
been made and combined with a coordinated multidisciplinary approach
committed to promoting living organ donation within the Kingdom, has seen
positive results with more families appearing receptive to the possibility of
living donation after meeting with prior donors and their families in these
patient support groups.
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1431 ACCIDENTAL HIV TRANSMITTED INFECTION FROM
HIV+ CADAVERIC DONOR IN HIV- RECIPIENTOF KIDNEY
TRANSPLANTATION:MANAGEMENT AND FOLLOW-UP
E. Bertoni, M. Zanazzi, A. Rosati, M. Salvadori
Renal Unit Careggi University Hospital
No accidental donor transmitted HIV infection in kidney transplantation
has been up to now described in literature. Aim of this report is to describe
the main concerns encountered after accidental HIV transmission in kidney
transplant recipient.
A 27 old female affected by ESRD for chronic glomerulonephritis on waiting
list for kidney transplantation, was transplanted on february 14, 2007 in our
center. Two other patients (kidney and liver) had been elsewhere transplanted
by the same donor. The patient had an immediate recovery of renal function
with fast decrease of serum creatinine. Her immunosuppressive treatment was
IL-2R blockers, cyclosporine microemulsion, mycophenolic acid and steroids.
5 days after transplantation the donor serum resulted HIV+ at control test by
tissue bank. All transplanted patients resulted contaminated.
An immediate HAART regimen was started with lopinavir/ritonavir, lamivudine,
fuzeon. Due to several genotype mutations the virue resulted resistant to the
above mentioned therapy. Two recent new drugs not yet on the market in Italy
(TMC 114 and TBC 125) were added. Main problems encoutered beside the
ethical and psychological ones, were the virus resistance and the powerful
interference with cyclosporine. After change in HAART regimen the virus
replication became undetectable. Cyclosporine dose was reduced to 10/20
mg every other day (0.5 mg/kgs) to obtain a C0 of 150-200 ng/ml. Eleven
months after transplantation virus replication is still undetectable,the GFR is
84 ml/min, serum creatinine is 0.7 mg/dl, 24 hours proteinuria is about 100 mg.
CD4+ count has been stable above 600/mmc. No acute rejection verified. Main
post-transplantation complications were usual for a normal kidney transplant
recipient,e.g. a CMV pneumonia (recovered with ganciclovir therapy), diabetes
mellitus and cataract.
In this case report, a fatal human mistake caused three organ recipients to be
infected by HIV. We can only argue that such contamination can sporadically
happen worldwide. No case is yet reported in literature. We would like to
stress the huge ethical and psychological problems arisen by such condition.
On the contrary, by the transplant point of view, the problem can be rather
easily afforded. Main concerns are the HAART and its interaction with
calcineurin inhibitors. Data coming from a number of centers offering renal
and liver transplants to stable HIV+ patients suggest graft and patient survival
comparable to those for non-HIV infected recipients.
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1432 WHAT DOES A DIAGNOSIS OF BRAIN STEM DEATH
MEAN TO FAMILY MEMBERS WHO ARE APPROACHED
ABOUT ORGAN DONATION?
T. Long, M. Sque, J. Addington-Hall
University of Southampton
Brain death, whether it be brain stem death [UK] or whole-brain death [USA]
is a prerequisite for most cadaveric organ donation. Understanding how brain
death is perceived by bereaved family members approached about organ
donation, its significance and acceptability to them, are therefore important
issues to explore as biomedicine moves to expand the range of end of life
technologies that, potentially, blur the demarcation between life and death.
To explore the concept of brain stem death and what it means to family
members who are in receipt of this diagnosis the present study asked: i)
What does the diagnosis of death, which is based on brain stem testing,
mean to those family members who are asked to consider donating the
organs and tissues of a deceased relative? and ii) How do family members
understand this concept? To address these questions a secondary analysis
of 28 transcripts, from two primary datasets, was carried out, applying
Charmaz’s approach to grounded theory. Datasets consisted of interviews
with family members who had agreed to donate the organs of a deceased
relative.
The core pattern developed during analysis is defined as: Conflict
Rationalisation, a process whereby family members and health professionals
appeared to engage in a series of practical and psychological activities aimed
at rationalising real or potential emotional and cognitive conflict resulting from
a brain based diagnosis of death, whilst being faced with the physical image of
a live body. Conflict rationalisation appeared to be how family members and
health professionals’ processed this paradoxical death, a death which, as it is
brain-based, is contrary to received conventional opinion. These findings are
summarised and interpreted in the substantive theory of ‘Paradoxical Death’.
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1433 THE DONOR FAMILY - RECIPIENT LINK:
A COMFORT OR A HAZARD?
A. Barnwell
Australian Red Cross Blood Service
For donor families and transplant recipients, the belief that psychic, social and
biological qualities are transferred with organs may lead to emotions ranging
from natural curiosity to a compelling desire for contact. Recipients often
experience an overwhelming sense of gratitude coexisting with sympathy for
the grieving family and an inability to reciprocate in a meaningful way. Both
parties face challenges in meeting the needs of each other within legislative
boundaries.
Analysis of the patterns of correspondence between the families of 183 deceased
donors and 714 transplant recipients identified the frequency, patterns of flow
and commonalities in dialogue.
Letters from recipients were received by 68% of donor families. Common themes
include gratitude and the impact on their lives. Two thirds of the recipient group
have not expressed their gratitude personally. The desire for correspondence
remains unfulfilled for 32% families. Only 14% of donor families corresponded
regularly with recipients, the majority being parents of donors.
Receiving personal letters from recipients is highly valued and described as
comforting and reassuring. Given that only 2% donor families indicated a
preference not to hear from recipients; donation agencies play a vital role in
providing the infrastructure necessary to facilitate the exchange of anonymous
correspondence.
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1434 UNRELATED LIVING DONATION IN SOUTH AFRICA:
LEGISLATION AND CHALLENGES
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1435 HYPOTHERMIC PRESERVATION RESULTS IN
PROFOUND PROTEOLYSIS IN VASCULAR ENDOTHELIAL
CELLS: INFLUENCE OF DOPAMINE PRE-TREATMENT
B. Yard, B. Rudic, S. Hui, N. Ponnelies
Vth Medical Clinic, Medical Faculty Mannheim, University of Heidelberg
Prolonged hypothermia, as occurs during solid organ transplantation, severely
affects post transplantation organ function. Proteolysis is one of the deleterious
events that have been implicated in preservation injury of organ allografts.
This strongly affects graft quality and hence immediate organ function. Since
donor catecholamine treatment improves transplantation outcome after renal
transplantation, the present study was conducted to examine the influence
of dopamine (DA) pre-treatment on hypothermia induced proteolysis in
endothelial cells subjected to prolonged cold storage.
Untreated human umbilical vein endothelial cells (HUVEC) were highly
susceptible to cold storage, which was reflected by morphological changes,
loss of viability and by significant changes in the cellular proteome. DA
pre-treatment completely prevented cell death during cold storage. Western
blot analyses demonstrated a time dependent up-regulation of calpain 1
and 2 during cold storage, which could be prevented by addition of EDTA
to the preservation solution. DA pre-treatment abolished auto-proteolysis
of calpain 1. Analysis of ubiquitin and ubiquitinilated proteins revealed a
significant increase in both – free ubiquitin and ubiquitinilated conjugates
after cold storage. This was not prevented by DA pre-treatment. Neither
proteasome - nor calpain inhibitors prevented cell death during cold storage
of endothelial cells.
In conclusion, these findings suggest that DA-pre-treatment might inhibit
proteolysis during organ preservation. Although activation of the calpain
and ubiquitin pathways occur during cold storage, neither of these pathways
are directly involved in cell death. Our data may explain the salutary effect
of donor DA treatment on transplantation outcome and may contribute to
comprehend the mechanisms underlying hypothermic organ preservation
injury

1436 A SIMPLE AND TRANSPARENT KIDNEY ALLOCATION
SYSTEM BASED ON HLA-IDENTITY AND A 1-1-1 HLA-A,
-B AND -MISMATCH
M. Heemskerk1, E. de Buijzer1, F. Claas2, I. Doxiadis2, B. Haase-Kromwijk1,
G. Haasnoot2, J.H. van der Heide3, W. Weimar4, A. Hoitsma5
1
Dutch Transplant Foundation, 2Leiden University Medical Centre,
3
University Medical Centre Groningen, 4Erasmus Medical Centre Rotterdam,
5
Radbout University Medical Centre Nijmegen
Recently (Transplantation. 2007;83:1207-1213), a kidney allocation system
based on HLA-DR identity was described to be a simpler and more equitable
way of kidney allocation. The authors described HLA-DR matched renal
transplantation to have a superior graft survival compared to HLA-DR
mismatched grafts. They hypothesised that with an exclusive HLA-DR matched
allocation system all kidneys could be regionally allocated.
We tested this hypothesis in an allocation algorithm were 1416 kidneys, from
708 Dutch donors from the period 2004-2006, were offered to a non-exhaustive
waiting list, starting with the 1014 Dutch patients on the 1-1-2004 waiting list.
We assumed the Netherlands to be one transplant region. All HLA antigens
were typed on split level. Simulation of an exclusive HLA-DR matched kidney
allocation showed that 13% of the 1416 kidneys could not be matched to a
patient. As an extra rule, one HLA-DR with maximally one HLA-A and one
HLA-B mismatch (1-1-1-mismatch) was allowed when no HLA-DR matched
patient kidney combination was available. This additional rule reduced the
percentage of non-transplantable kidneys to 2%. We questioned whether this
modification would have resulted in worse graft survival.
We analysed five year graft survival (death censored) after heart beating kidney
transplantation in the Netherlands between 1990 and 2005 with Kaplan-Meier
curves and a Log rank test. We included 1-1-1-mismatched pairs (n= 511) and
HLA-DR split matched pairs (N = 1305). Excluded from the analysis were
highly immunized patients, patients within the acceptable mismatch program,
patients younger than eighteen years, donors younger than five years, combined
transplants, and retransplants.
At 5 years after kidney transplantation, graft survival was 79% for HLA-DR
matched patient donor pairs and 77% for pairs with a Haplomatch, which is not
significantly different (p = 0.2).
We compared these results with those in a larger cohort within the Eurotransplant
region (n = 22090). Both cohorts were similar, except that HLA typing was on
broad level and three year follow up was analysed in the Eurotransplant cohort.
Graft survival was 84% for pairs with a 1-1-1-mismatch. Full house matched
pairs (89%; p<0.000) and HLA-DR matched pairs with a single HLA class I
mismatch (86%; p=0.013) had superior graft survival. HLA-DR matched pairs
with more HLA class I mismatches did not have significantly different graft
survival rates compared to 1-1-1-mismatched pairs (p > 0.1).
Including 1-1-1-mismatched transplants in a kidney allocation system based
on HLA-DR identity can lead to a simpler, faster and a more equitable way of
kidney allocation, without affecting superior transplant results.
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1437 OPTIMAL UTILIZATION OF HTLV I/II POSITIVE
ORGANS A NATIONWIDE SURVEY
M.R. Marvin1, R. Nagubandi1, G.N. Brock2, K.V. Ravindra1, M. Eng1,
J.F. Buell1
1
Division of Transplantation, Dept. of Surgery, University of Louisville,
Louisville, KY, United States and 2Bioinformatics and Biostatistics, University
of Louisville, Louisville, KY, United States
Objective: We recently presented data from the UNOS database that
demonstrated no significant difference in graft or patient survival between
HTLV I /II (+) and (-) liver recipients. Several Organ Procurement Organizations
(OPO) including our own, do not offer HTLV I /II positive organs while many
others find it difficult to place them. Despite this, the number of HTLV (+)
organs is increasing with 31 utilized in 2006 alone. This prompted us to evaluate
the practical difficulties in placing these organs so as to improve utilization of
these high risk life saving organs.
Method: A telephone/email survey of all the 65 OPOs in USA was done over
a 2 month period from October to November 2007.
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A. Michaelides
Netcare Transplant Division
Aim: Unrelated living donation (URLD) has been performed in South Africa
for more than 10 years. However, URLD accounts for less than 3% of our
national renal transplants, as opposed to related living donation (RLD)which
accounts for 36%. In an effort to understand this, close attention was paid to the
challenges and legislation surrounding this process.
Method: The national renal transplant statistics, as collated by the Organ Donor
Foundation of South Africa, was analyzed from January 2001-December 2006.
This legislation and policy guidelines were studied and a comparison made
with the United Kingdom. A retrospective analysis of potential donors who did
not complete the process was performed.
Results: A total of 1860 renal transplants were performed during this 6 year
period. 1131 (60%)renal transplants were from cadaver donors. This includes
simultaneous kidney-pancreas transplants. 675 (36.6%) were from related
living donors and 54 (2.9%)were from unrelated living donors. Legislation
is thorough and protective of both the donor and recipient, but the process
is slow moving and understaffed. Donors who withdrew from the process
cited a variety of reasons, predominantly stress, medical unsuitability and
frustration due to delays by the authorization process. The process in South
Africa takes approximately 3 months as opposed to 10 days in the United
Kingdom.
Conclusion: URLD accounts for less than 3% of our national transplant
statistics, and this figure could probably increase with improvements in the
authorization process. A time frame of 3 months is considered excessive.
Addressing the patients’ stress through extensive education and counseling
should impact positively on the need for unrelated organ donation.
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Results: Of the 65 OPOs, 42 responded. All screen patients for HTLV I/II with
ELISA. 38 centers confirm with repeat ELISA, 27 confirm with Western Blot
and 6 centers do not pursue further. 36 of the 42 centers offer the HTLV I/II
positive organs. There were a total of 231 positive donors in the past 5 years of
which organs from 109 donors (47.2%) were placed.
27 centers offer all the organs while 15 offer one or more organs selectively
based on accepting centers. None have been able to place the pancreas. Only
liver and kidney were commonly accepted. Several centers noted a high false
positive rate.
Based on the UNOS regional analysis data, 43% of the organs are utilized
in NY state alone. Many OPOs did not know which particular centers accept
these organs and consequently spend a lot of time and effort in order to
place them. A majority wanted to have a list of transplant centers that accept
these organs.
Conclusions: HTLV I/II organs are being underutilized. Moreover, our prior
analysis of UNOS data shows that these life saving organs are shared more
nationally than loco-regionally which is associated with a poorer outcome.
Increased knowledge of successful HTLV (+) donation and the centers that are
willing to utilize these organs in the appropriate setting will help expand the
donor pool and decrease mortality on the waiting list.

Through a review of evidence and new allocation arrangements, well matched
transplants continue to be provided for younger patients while the emphasis on
HLA matching decreases with increasing patient age.
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1438 TAILORING HLA MATCHING FOR PATIENTS
THROUGH NATIONAL KIDNEY ALLOCATION
R. Johnson1, C. Rudge1, L. Mumford1, S. Fuggle1, J. Fosythe2
1
UK Transplant, Bristol, UK, 2Royal Infirmary of Edinburgh, Edinburgh, UK
Since national kidney allocation schemes were introduced in the UK and
elsewhere, HLA match between donor and recipient has remained an important
criterion in the selection of recipients for transplant. In 1995, development
work was undertaken for the UK Kidney Allocation Scheme and this included
investigation of the role of HLA matching in allocation.
In the UK, HLA match has long been an important consideration in allocation
of kidneys from donors after brain death (DBD). This has resulted in
excellent HLA match grades in kidney transplants for all patients, regardless
of age: in 2003-2005, 72% of kidney transplants from DBD had no more
than 2 HLA-A+B+DR mismatches, and this figure ranged only between 70
and 74% across all adult age groups. In this era, median waiting times to
transplant were two years for young adults increasing to three years for the
oldest patients.
Analyses to inform decision-making about new allocation arrangements
included a review of the influence of HLA mismatch on transplant outcome.
This lead to a redefinition of HLA mismatch (mm) into four levels, based on
a risk-adjusted Cox regression analysis of five-year transplant survival (deaths
with function treated as failures):
1 - 000 mm [baseline level – relative risk (RR) = 1.0]
2 - (0 DR mm with < 2 B mm) [RR=1.06, 95% CI 0.87-1.30]
3 - (0 DR mm with 2 B mm) or (1 DR mm with < 2 B mm) [RR=1.22, 95%
CI 0.99-1.49]
4 - (1 DR mm with 2 B mm) or 2 DR mm), [RR=1.41, 95% CI 1.11-1.80]
These results suggested that there is no significant benefit of HLA matching
in terms of transplant outcome, provided the fourth level of graft mismatch
is avoided. However, another reason to HLA match is to avoid the recipient
developing antibodies to mismatched donor antigens, thus making
retransplantation more difficult due to higher levels of sensitisation.
Taking these considerations into account, the new UK Kidney Allocation
Scheme introduced in April 2006 prioritises 000 HLA-A, B, DR mismatched
patients and well-matched paediatric patients, does not routinely consider
level 4 mismatched grafts for any patient and, through a new points
scoring system where points for age and HLA match are combined, gives
HLA match a greater weight for younger patients than for older patients.
The rationale is that the younger the patient is, the more likely they are
to require a retransplant in the future and the greater their need to avoid
sensitisation.
Eighteen months after the introduction of the scheme, its effect, and in particular
the impact of the age/HLA points, is apparent.
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1439 HLA MATCHING IN KIDNEY ALLOCATION: REVISED
CRITERIA IMPROVE EQUITY OF ACCESS TO TRANSPLANT
S. Fuggle1, R. Johnson1, L. Mumford1, C. Rudge1, J. Forsythe2
UK Transplant, Bristol, UK, 2Royal Infirmary of Edinburgh, Edinburgh, UK
HLA matching has been considered an important factor in deceased donor
kidney allocation in the UK for many years. However, there are many
criteria to consider in allocation and over-emphasis on HLA matching
disadvantages patients with rare HLA types. The new national kidney
allocation scheme introduced in the UK in April 2006 includes features
to improve equity of access to transplantation for patients throughout
the UK. One feature was to revise the definition of an HLA match, by
defaulting antigens that are rare (frequency of <2%) in the donor pool to
more common, related antigens based on serological and sequence data.
For example HLA-A36 is found in 0.2% patients on the transplant list
and in 0.05% UK donors. By mapping A36 to the serologically related
specificity, HLA-A1, HLA-A36 patients are ‘matched’ to HLA-A1 donors,
which represent 18% of the donor pool. HLA-A36 positive donors are
only matched to HLA-A36 patients. 3 HLA-A, 16 HLA-B and 4 HLADR specificities are defaulted in the 2006 allocation algorithm. Simulation
studies of transplant activity predicted that by adopting this approach the
transplant rate in difficult to match patients would increase, for example
by 14% for ethnic minority patients.
Results from the 18 month review of the allocation scheme show that
antigen defaulting has been a factor in patient selection in 192 of 1431
(13%) kidney transplants performed. A single HLA-DR default was
most likely to have influenced allocation (131 cases, 68%) and HLA-B
antigen defaults in 49 cases, (26%). In 11 (6%) transplants resulting from
defaulting, at least two antigen defaults contributed to the recipient being
selected for transplant.
While HLA antigen defaulting was a factor in 13% of transplants overall, this
rate varied significantly among patient subgroups. Most noticeably there was
variation according to patient ethnicity. 10% of transplants for White patients
involved defaulted antigens but this figure was 18% in Asian patients and
48% in Black patients (p<0.0001). The overall number of transplants in ethnic
minority patients increased by 17% in the first year of the 2006 allocation
scheme compared with the previous year.
Antigen defaulting was of benefit to patients with longer rather than shorter
waiting times (p=0.0005), patients who are calculated to be difficult to HLA
match (p=0.002) and to patients of blood groups B and AB rather than O and
A (p=0.04).
While retaining HLA match as an important criterion in kidney allocation,
the UK 2006 kidney allocation scheme strives to achieve equity of access
to transplant for difficult to match patients by defaulting rare antigens to
more common counterparts. The results of the first 18 months of the scheme
demonstrate that this approach is achieving increased access to transplant for
ethnic minority and other difficult to match patients.
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1441 A SURVEY OF COGNITIVE, INTENTION AND BEHAVIOR
OF THE LIVING DONORS AND GENERAL POPULATION
IN LIVING ORGAN DONATION
Objective: To investigate the living renal transplant donors about cognitive,
intention, behavior situation, and contrast with whom refused to be living
organ donor and willing to be living organ donor in general population. Discuss
the impact factors of decisions relevant to living organ donation in general
population.
Method: Designed the questionnaire on cognitive, intention, behavior of living
organ donors. Undergraduate anonymous surveys from July 2007 to February
2008 among 35 cases of live donor kidney transplantation in our center, 21cases
of general population refused to be living donor well 73 cases will in medical
centre. The living donors also assess mental state with SCL-90 Symptom
Rating Scale at the same time.
Results: Living kidney donors are overall psychological normal. Male:female
ratio is 1.06£º1,those aged below 38 accounted for 60% ,under high school
qualifications are 62.86%, 88.57% of the manual; and those who consciously
on living organ donation and transplantation than understanding is 82.58%,
the organ donation more positive effect is 97.14%, 62.86% donors think that
the most important factors to be an organ donor is whom they will donate to;
48.57% donors hope that their parents will be the receptors;and 45.71% of
them hope that will be their children; 85.71%donors think that is wrong to
ask for compensation; 64.29% donors are opposed to organ trading; the act of
organ donation get high grade in moral evaluation from 75.71% donors;2.86%

POSTER BOARD NUMBER P2 – 241
1442 ARE ETHNIC PATIENTS STILL DISADVANTAGED FROM
RECEIVING RENAL TRANSPLANTS?
R. Naik, D. Meredith, M. Mohteshamzadeh, E. Vaux, L. Barker
Royal Berkshire Hospital, London Road, Reading, RG15AN
Introduction: Renal transplantation for patients with end stage renal failure
should be available to all patients regardless of ethnicity. There is however
a serious shortage of organs for transplantation and there are in the United
Kingdom over 7000 patients awaiting renal transplants. Previous reports have
suggested that ethnic patients (Asian Indian and Pakistani) who have more
kidney failure are less likely to get transplants compared to Caucasian patients.
Efforts have been made to improve this with more education and appointments
of specific coordinators in some units to facilitate transplantation. The aim of
our study was to assess whether the transplant needs of an increasing ethnic
population were being met.
Methods: We reviewed the ethnicity of all patients on Haemo or peritoneal
dialysis at the Royal Berkshire Hospital who are currently on the transplant
waiting list. We also assessed the ethnicity of patients who had received renal
transplants and compared these figures with the ethnic distribution in the
general population.
Results: The county of Berkshire, England (population 800,090), is
predominately Caucasian (88.7%) with Asian (6.8%) and Black (2%) residents
making up the largest of the minority groups. There are currently 350 patients
receiving dialysis of whom 52 patients (15%) are from the Asian population.
156 patients are currently on the transplant waiting list of whom 32 (20.5%) are
ethnic. 10 out of 156 patients (6.4%) are black. Of the 325 transplant recipients,
262 (86%) are Caucasian, 37 (11%) are Asian and 8 (2%) are Black.
Asian patients are the least likely to receive a Living Related Donor Transplant
(14% compared to 22% of Caucasian and 25% of Black patients). A total of 38
grafts have failed to date, with average graft survival being longest in patients
of Asian ethnicity. Of the 21 deaths in the group, 19 were Caucasian, 2 were
Black, and none were of Asian origin.
Conclusion: This data supports recent publications which suggest
that patients of Asian ethnicity are least likely to receive living related
donors or find a match for a cadaveric graft within a predominantly white
population. Asian patients are over represented in the dialysis population
and in the transplant waiting list. Whilst this is due in part to the availability
of suitable blood group or HLA matches, there is still a reluctance amongst
Asians to become kidney donors due to cultural or religious objections,
which needs urgent addressing on a local and national level. However,
our data suggests that once transplanted, Asian patients appear to have a
relatively long graft survival with the lowest incidence of post transplant
mortality.
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M. Shapiro
Touro University College of Medicine
Discussions regarding the appropriate allocation of organs have sought to
balance the ethical principles of equity (Justice in a Rawlsian sense) and utility.
Recent US proposals to shift the balance in a utilitarian direction, such as the
current proposal to use “net life survival benefit” or “life years from transplant”
in a new kidney allocation schema have been met with consternation, and cries
of injustice. Such a system might create winners and losers, and make more
explicit who would receive a transplant and who would not. While this is
likely true, to suggest that such a system is unjust is to misunderstand both the
appropriate application of equity, and to imply that the appearance of fairness
is more important than fairness itself.
The goal of transplantation of any organ is to save lives, and improve the
quality of life. In order for that to occur, there must be a utilitarian basis for
any transplant. Thus, to prioritize allocation based on who is most likely to die
waiting (as MELD does) is only of value if those patients have a reasonable
expectation of survival post-transplant. Similarly, there is little question that a
kidney transplant that functions for ten years is of more value, and should take
precedence, over that which survives one week. If one accepts that premise,
then whether a month or a year or five years is an appropriate threshold is
merely quibbling over details.
It has been suggested that the current US kidney allocation system, based
primarily on waiting time, is more just than one based on predicted net
survival benefit. This presupposes several facts, none of which are without
serious question. These include the notion that patients have equal access
to the waiting list, patients have equal survival while waiting, and that all
patients have an equal right to be transplanted. This also approaches the
problem from the perspective of the potential recipient, without regard to
the perspective of the organ, organ donor, or donor family member. One
might hypothesize, and data suggest, that the donor family would have the
expectation that their gift be used in the most utilitarian manner, to “do the
most good.” This requires a judgment be made as to how long a particular
recipient will survive, pre-, peri- and post-transplant, and take primarily those
factors into account in allocation.
Equity is important in organ allocation, but only to the extent that one is
comparing like groups of patients, When differences in utilitarian outcomes
can be demonstrated between disparate groups, utility should prevail, and
differences in priority between such disparate groups is not un-just.

donors think that living organ donation do harm more than benifit. 47.83%
women of non organ donor refuse to donate their organs ,so do 28.57%man,
38.10% refusers think that organ donations will cause serious health problom,
just 33.33% think that the most important factors to be an organ donor is
whom they will donate to;they think about 2.25 fators average when they make
decision about organ donation,61.90% of them think the most important fator
is their own health in future,61.90% of them agree organ trading. Compare
with the kiney donors;54.05% of who willing to be living organ donors ask for
compensation; the most accepted form of compensation in these three groups is
to provided with comprehensive health insurance or Organ Transplant priority
right.
Conclusion: In general population ,the process of decision making to free
reward live organ donation is also the process of balancing gains and losses;
most of living organ donors or who willing to donate their organ agree that
they will be benefit from the living organ transplantation more than loss. So
to enhance public understanding of organ donation and organ transplantation,
to improve the surgical results of both receptor and donor, strengthen the
community recognition and insurance to organ donor may be expanded the
pool of free reward donation, and prevent organ trading.
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1443 DONOR ANTIGENIC SPECIFICITY CD4+CD25+TREG
CELLS INDUCE IMMUNE TOLERANCE OF ALLOGRAFT
KIDNEY TRANSPLANTATION IN RATS
S. Gu1*#, C. Huang2*, J. Zheng3#, Y. Zhang2, J. Li2, Q. Wang2, J. Feng2,
Y. Xiao2, H. Huang3, M. Unoki1
1
School of Rehabilitation Sciences, Seirei Christopher University,Hamamatsu,
Japan, 2Xinqiao Hospital, Third Military Mcdical University, Chongqing,
China, 3Faculty of Medical Lab,Science, Third Military Mcdical University,
Chongqing, China, *S GU and C HUANG contributed equally to this work.
#Corresponding authors.
Objective: It is confirmed that CD4+CD25+Treg cells have the potent
suppressive effect not only on responder T cells either directly via cell contract or
secretion of IL-10 and TGF-ƒÀ1 or alternatively by influencing the stimulating
APC but also on B cell Ig response directly via cell contact. Meanwhile, the
important role of CD4+CD25+Treg cells played in transplantation immunology
tolerance in human were take into account initially. However, there are little
evidence to realize the role of CD4+CD25+Treg cells to induce transplantation
tolerance in vivo. This study was designed to utilize donor antigenic specificity
CD4+CD25+Treg cells to induce allograft transplantation tolerance of
kidney transplantation in rats and to study the dose-effect relationship of
CD4+CD25+Treg cells tentatively in vivo.
Methods: To establish allograft kidney transplantation animal models with
F344 rats as donors and Lewis rats as recepients; Separating CD4+CD25+Treg
cells from splenic cells of Lewis rats and inducing phenotype of donor antigenic
specificity in vitro; According to the quantities of CD4+CD25+Treg cells inject
through tail vein in the operation of allograft kidney transplantation, models
were divided into four experiment groups: group1 i2X105 j Ageoup2 i5X105 j
Ageoup3 i1X106 j Ageoup4 i2X106 j ini=12 j.
Results: The models without injection as controls (n=12); The mean survival
time was the highest in group3 (27.3 }4.6)d and the lowest in controls (12.3
}4.6)d. The mortality rate was highest in controls(83.3%)while all models
survival in group 1X106 15 days after operation; The function of transplanted
kidney were exert the most sable in group3. The semi-quantitative scores
of histopathology had statistical difference between controls with group3
iP<0.05 j.
Conclusions: It can be tentative confirmation that donor antigenic specificity
CD4+CD25+Treg cells could induce immune tolerance of allograft kidney
transplantation in rats and 1X106 should be the right single dosage.

POSTER BOARD NUMBER P2 – 243
1444 FOXP3+ REGULATORY T-CELLS PLAY A DOMINANT
ROLE OVER RORGAMMA+ TH17-CELLS IN DECEASED
DONOR KIDNEYS
C. Baan1, A. Peeters1, J. van de Wetering1, J. IJzermans2, W. Weimar1
1
Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The
Netherlands, 2Surgery, Erasmus MC, University Medical Center Rotterdam,
The Netherlands
Th17 cells and regulatory T-cells (Tregs) have an interactive relationship
mediated by IL-6 and TGF-ß. Both cell types are involved in the reactivity
against alloantigens and in response to tissue injury. Here, we studied the Th17Treg network in zero biopsies of kidneys from living donors with relatively
short ischemia-reperfusion times and from deceased donors with brain death
related inflammation and prolonged cold ischemia-reperfusion times
Biopsies from deceased (n=13, > 14 h cold ischemia) and living (n=14, < 2 h
cold ischemia) donors were studied at the end of cold storage and after 20-30
min reperfusion.
In deceased donor kidneys higher mRNA expression levels of CD3 were
measured compared to living donor kidneys demonstrating that more T-cells had
infiltrated these allografts (p=0.04). Moreover, in deceased donor kidneys the
expression levels of TGF-ß, which acts as a differentiation factor for FOXP3+
regulatory T-cells, was abundantly present (p=0.005) compared to living donor
kidneys. Likewise, FOXP3 mRNA was detected at significantly higher levels in
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deceased than in living donor kidneys (p=0.001). In contrast, in biopsies from
deceased donor kidneys the mRNA levels of RORgamma, the transcription
factor that directs IL-17 transcription, was significantly lower than in samples
from living donors (p<0.001).Concurrently, no induction of the RORgamma
inducing cytokines (IL-6, TNF-a, IL-21) and IL-17 was measured.
In conclusion, the high mRNA expression levels of CD3, TGF-ß and FOXP3 in
deceased vs living donor kidneys suggests that regulatory T-cells, but not Th17
cells play a role in controlling tissue injury resulting from the pathophysiologic
events inherent to deceased donation.

POSTER BOARD NUMBER P2 – 244
1445 EX VIVO GENERATED TREG AMELIORATE
TRANSPLANT ARTERIOSCLEROSIS BY INHIBITING
EFFECTOR CELL PRIMING AND GRAFT INFILTRATION
R.S. Francis1, G. Warnecke2, S.N. Nadig1, G. Feng1, K.J. Wood1, A.R. Bushell1
1Nuffield Department of Surgery, University of Oxford, UK, 2University of
Hannover, Germany
Background and aims: Naturally-occurring FOXP3+CD4+ regulatory T cells
(Treg) play a crucial role in the control of self-directed immune responses.
Similar populations of Treg have also been shown to suppress alloimmune
responses, offering the potential to prevent transplant rejection without the
requirement for indefinite global immunosuppression.
We have developed an in vitro culture system that is able to generate
graft-protective Treg from naïve CD4+ T cells. CBA (H2k) CD4+ T cells
are conditioned for 14 days in the presence of allogeneic B6 (H2b) bone
marrow-derived dendritic cells (BMDCs) and interferon-γ (IFN-γ).
Following this protocol, the conditioned T cell population (Tcon) are
enriched for FOXP3+ cells and are able to prevent skin graft rejection by
a defined CD4+ effector population following adoptive transfer into T cell
deficient mice. The aim of this research was to ask whether Tcon can also
control the development of transplant arteriosclerosis using a relevant
mouse model of vasculopathy.
Methods: T and B cell deficient CBA.rag−/− mice were reconstituted with
1×105 naïve CBA CD25−CD4+ effector T cells (Teff) with or without 4×105
Tcon on day -1. The following day, a B6.CD31−/− aortic interposition graft
was performed. CD31−/− grafts were used so that the degree of endothelial
repopulation could be assessed histologically as a marker of graft damage.
On day 30, the animals were sacrificed and the spleen and graft harvested for
histological, functional and phenotypic analysis.
Results: Mice that received Tcon and Teff had significantly reduced
arteriosclerotic lesions compared to mice that received Teff alone (luminal
occlusion 11.7±13.1% vs 29.7±14.5%; p=0.04). Significantly, in mice
reconstituted with Teff alone the donor CD31−/− endothelium was entirely
replaced by CD31+/+ recipient endothelial cells reflecting an active immune
response against the graft. However, co-transfer of Tcon completely prevented
this endothelial repopulation.
To investigate the mechanisms by which Tcon attenuated transplant
arteriosclerosis, we analysed graft infiltrating cells by histology and splenic T
cells by FACS and IFN-γ ELISpot. Strikingly, the frequency of primed donorreactive IFN-γ secreting CD4+ cells was reduced from 170±16 per 1×105 in
mice that received Teff alone to 48±15 per 1×105 in mice that also received
Tcon (Figure 1). This correlated with CD4+ T cell infiltration into grafts, which
was markedly reduced in the presence of Tcon.
Figure 1: Frequency of donor-reactive IFN-γ-secreting CD4+ cells
a) Representative ELISpot well images
b) Enumerated spots per 1×105 input cells
Discussion: These data indicate that the mechanisms by which ex-vivo generated
regulatory T cells control transplant associated vasculopathy include a reduction
in both effector cell priming and infiltration into the graft. These data emphasise
the potential of ex-vivo generated regs to control not only acute allograft rejection
but also vascular changes associated with chronic allograft dysfunction.
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1446 CD4+ T LYMPHOCYTES TRANSFER TOLERANCE
INDUCED BY PORTAL VENOUS INJECTION
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1447 BYSTANDER REGULATORY T CELLS PLUS SUBOPTIMAL IMMUNOTHERAPY CONTROLS ALLOGRAFT
REJECTION
A. Bushell, K. Wood
Nuffield Department of Surgery
Background and aims: Strategies that lead to the development of specific
populations of regulatory T cells (Treg) could provide an active immunological
solution to allograft rejection and promising protocols exist for Treg generation/
expansion both in vivo and ex vivo. Whilst it is not clear at present which will
offer the greatest clinical benefit, one attractive approach would be to induce
antigen-driven Treg in the patient prior to transplant to provide immediate control
of rejection responses. This can be achieved in the mouse by pre-treatment with
donor-specific blood transfusion plus anti-CD4 antibody, but this approach is
only practical clinically in the setting of living donor transplantation. To address
this limitation, we have previously shown that bystander Treg generated by
challenge with unrelated protein antigen in an analogous protocol can prevent
allograft rejection in adoptive transfer models. The aim of this study was to
ask if Treg functioning through bystander mechanisms can influence allograft
rejection in primary transplant recipients.
Methods: CBA mice (H2k) mice were pre-treated with 200μg of IgG2a antiCD4 antibody (YTS 177.9) on days -28 and -27 plus 500μg of human gamma
globulin (HGG) on –day -27 and re-challenged with HGG on day -1 which is
essential for elaboration of Treg function. These mice were then transplanted

POSTER BOARD NUMBER P2 – 247
1448 PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL
BY EX VIVO EXPANSION OF SELECTED FOXP3-TRANSDUCED
CD4 REGULATORY T CELLS
M. Hu1, Y.M. Wang1, G.Y. Zhang1, D. Watson1, J. Fletcher1, T. Polhill1,
I.E. Alexander2, S.I. Alexander1
1
Centre for Kidney Research, 2Gene Therapy Research Unit, Children’s
Hospital at Westmead, University of Sydney, NSW, Australia
Background: Treg mediated immunoregulation plays an important role in the
induction and maintenance of transplantation tolerance. Manipulating Tregs
has significant therapeutic potential in transplantation. Retroviral gene transfer
of Foxp3has converted naïve CD4+ T cells toward a regulatory T cell phenotype
similar to that of naturally occurring CD4+ Tregs.
Aim: We investigated a strategy to expand the proportion of antigen specific Tregs
by retroviral gene Foxp3-transduced Tregs that are capable of suppressing effector
T cells and prevent cardiac allograft rejection across an MHC mismatch.
Methods: Retroviral supernatant was harvested from packaging cells 72 h after
transfection of pFoxp3/MIGR1/GFP+. Naïve BALB/c CD4+ T cells were cultured
in the coated anti-CD3 Ab plate with rIL-2 for overnight and transduced with
Foxp3/MRGR1/GFP viral supernatant then stimulated with irradiated C57BL/6
splenocytes for another 3 days. GFP+ cells were sorted at day 5 after transduction
and adoptively transferred to each SCID mouse received C57BL/6 and third
party B10.BR heterotopic cardiac allografts, then these mice were reconstituted
with 5×106 BALB/c splenocytes at 104 days after adoptive transfer.
Results: The study demonstrated that ex vivo expanded Foxp3-transduced
CD4+ Tregs specifically prolonged C57BL/6 cardiac allograft survival (n =
4) with MST >300 days, while retaining the ability to reject third-party B10.
BR cardiac allografts (n=2) at average 137 days post transplantation. In vivo
flow cytometry analysis showed that antigen specific Foxp3-transduced CD4+
T cells significantly expanded in SCID mice with C57BL/6 cardiac allografts,
compared to SCID with third party B10.BR cardiac allografts. Foxp3transduced CD4+ Tregs were increased in SCID mice with C57BL/6 cardiac
allografts (1.2%±0.4) more than in mice with B10.BR third party cardiac
allografts (0.8%±0.3) relative to total CD45+ cells after 8 days adoptive transfer.
Moreover, the proportion of transduced cells significantly increased from to
2.1%±0.6 at day 106 to 7.5%±3.2 at day 196 after reconstitution BABL/c cells
in SCID mice with C57BL/6 cardiac allografts (p=0.005). This compared to
0.4% at day 106 after reconstitution and 2.3% at day 196 after reconstitution
in a SCID mouse that had already rejected B10.BR cardiac allografts. Further,
a higher percentage of CD127 low CD4+ T cells in splenocytes of SCID mice
received C57BL/6 allografts (16.3% ± 4.4) was observed, compared with
splenocytes of SCID mouse, which had rejected 3rd party B10.BR allograft
(9.7%) and naïve BALB/c (11.3%) at 196 days after reconstitution BALB/c
cells. This suggested that the antigen specific allograft itself is crucial for the
maintenance of tolerance in vivo. Splenocytes from SCID mice with C57BL/6
cardiac allografts showed reduced proliferation and reduced IFN-γ production in
response to the stimulator C57BL/6 strain (PI=5.2+/-0.6, p<0.05) (34.3+/-12.9
spots, p<0.05) compared with the third-party B10.BR (PI=6.8+/-0.5, p<0.05)
(72.8+/-32.6 spots, p<0.05).
Conclusions: Ex vivo expanded Foxp3-transduced CD4+ Tregs are capable of
suppressing effector T cells and specifically prolonged cardiac allograft survival.
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F. He, Z. Chen, S. Xu, M. Wu, M. Cai
Institution of Organ Transplantation, HUST
Objection: A portal venous injection of allogeneic donor cells is known to
prolong the survival of subsequently transplanted allograft. In this study we
analysis the role of T lymphocytes in transferring tolerance induced by portal
venous injection.
Methods: C57BL/6 (B6) mice were used as donors. 7 days after portal venous
injection of irradiated B6 splenocytes into BALB/c mice, the splenocytes of
the recipient were isolate and CD4+, CD8+T lymphocytes were magnetically
sorted respectively using an auto MACS cell sorter. The sorted CD4+ (CD8+) T
lymphocytes were then transfused into another BALB/c mice followed by heterotopic
implantation of a B6 heart allograft. A C3H heart allograft and normal BALB/c were
used as controls. The rejection and survival of the allograft were observed.
Result: when transfusion with CD4+T lymphocytes from BALB/c mice
treated with a portal injection of B6 splenocytes, the subsequent transplanted
B6 allograft was survival longer than C3H allograft. Similar results were
not observed for normal BALB/c or BALB/c with transfusion with CD8+T
lymphocytes from BALB/c mice treated with a portal injection of B6
splenocytes (data show in figure 1).
Conclusion: This finding indicates that CD4+T lymphocytes, but not CD8+T
lymphocytes, play an important role in transferring tolerance induced by portal
venous injection and this tolerance is antigen-specific.
Figure 1 Survival posttransplant of each groups
A: Donor: B6 mice Recipient: BALB/c mice receiving transfusion with
CD4+T lymphocytes from BALB/c mice treated with a portal injection of
B6 splenocytes
B: Donor: C3H mice Recipient: BALB/c mice receiving transfusion with
CD4+T lymphocytes from BALB/c mice treated with a portal injection of
B6 splenocytes
C: Donor: B6 mice Recipient: BALB/c mice receiving transfusion with
CD8+T lymphocytes from BALB/c mice treated with a portal injection of
B6 splenocytes
D: Donor: C3H mice Recipient: BALB/c mice receiving transfusion with
CD8+T lymphocytes from BALB/c mice treated with a portal injection of
B6 splenocytes
E: Donor: B6 mice Recipient: Normal BALB/c
F: Donor: C3H mice Recipient: Normal BALB/c

with fully vascularised B.6 (H2b) hearts on day 0 either with no further treatment
or were given 25μg of CTLA4-Ig (Abatacept, Orencia) i.v. on days 0 and +1.
Graft outcome was determined by palpation.
Results: Though present at the time of transplant, bystander Treg were unable
to control primary cardiac allograft rejection (MST 8 days, data not shown).
However, adjunctive CTLA4-Ig therapy resulted in prolongation of cardiac
allograft survival (MST~50 days in two separate groups). Importantly, mice
treated with CTLA4-Ig alone rejected their grafts at essentially control rates
(MST 13 days, n=5). Thus, when combined with minimal immunosuppression,
in vivo generated bystander Treg can influence graft outcome.
Conclusion and significance: Treg can be generated in vivo by antigen
challenge combined with immunomodulation but alloantigen in the clinical
setting is possible only in limited situations. The optimised use of specified
protein antigens may provide an alternative route to in vivo Treg generation
and when combined with Treg-sparing immunosuppression may offer a route
to operational transplantation tolerance.
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1449 ALLOANTIGEN ACTIVATED NAIVE CD4+CD25+FOXP3+T
REGULATORY CELLS EXPRESS CD8; A MARKER OF NEWLY
ACTIVATED ANTIGEN SPECIFIC T REGULATORY CELLS
N.D. Verma, K.M. Plain, M. Nomura, G.T. Tran, R. Boyd, N. Carter,
C. Robinson, C. Wang, G.A. Bishop, S.J. Hodgkinson, B.M. Hall.
Faculty of Medicine, University of NSW, and Department of Gastroenterology,
University of Sydney, Sydney NSW 2006, NSW, Australia
Natural CD4+CD25+Foxp3+T regulatory cells can be activated in vitro by
alloantigen and IL-2, and used to induce tolerance to specific donor bone marrow
and allografts. We have found that both IL-2 and IL-4 induce alloantigen specific
CD4+CD25+Foxp3+T regulatory cells, in that after 3-4 days culture with alloantigen
and IL-2 or IL-4 these cells can suppress rejection at a ratio of 1:10 with naïve
CD4+T cells. Fresh naïve CD4+CD25+Foxp3+T regulatory cells only suppress
at a ratio of 1:1 and not at 1:10 and do so in a non antigen specific manner. In
characterizing the activated CD4+CD25+Foxp3+T regulatory cells, we observed
that within 3-4 days of culture between 11 and 30% of cells also expressed CD8,
whereas the starting population had less than 1% CD8+T cells. These CD8+cells
also expressed CD4 and CD25 and were amongst the Foxp3 expressing cells. We
considered this was de novo induction of CD8 on the original CD4+CD25+Foxp3+T
regulatory cells. This study examined if the minor CD4+CD8+CD25+Foxp3+T cells
contained the antigen specific regulatory T cells.
DA rat CD4+CD25+Foxp3+T regulatory cells were cultured with fully allogeneic
PVG stimulator cells and IL-2. After 4 days in culture, the suppressive
capacity of these cells was compared to populations depleted of CD8. The
CD4+CD8+CD25+Foxp3+T cells could not be directly tested as in vivo the mAb
to CD8 opsonizes cells it binds to. The antigen specific potency was tested by
transfer of 5x105 activated Tr, together with 5x106 naive CD4+T cells, to irradiated
DA hosts grafted with either PVG or third party Lewis grafts. Severe rejection
was prevented in 8 of 9 rats with PVG grafts but in none of 5 rats with third party
Lewis grafts. Controls given 5x106 naïve CD4+T cells rejected PVG grafts in
10-20 days (n=12) and 7 of 10 Lewis grafts were rejected in 9-26 days. However,
5x105 naïve fresh CD4+CD25+T cells mixed with 5x106 naïve CD4+T cells failed
to prevent rejection with 7 of 8 animals rejecting in 8-14 days, similar to controls
given 5x106 naïve CD4+T cells alone. Depletion of the CD8+CD4+CD25+T cells
from the IL-2 activated CD4+CD25+T cells removed their capacity to suppress as
transfer of 5x105 of these cells with 5x106 naïve CD4+T cells resulted in rejection
of 4 of 5 PVG grafts in 10-22 days, only one becoming tolerant. We are examining
the cytokine/cytokine receptor expression of CD4+CD8+CD25+T cells compared
to IL-2 and alloantigen activated naïve CD4+CD25+Foxp3+T cells.
These studies suggest that within days of naïve CD4+CD25+T cell activation,
antigen specific clones may express CD8 and this may be a marker to select
antigen specific regulatory cells for further ex vivo expansion.

POSTER BOARD NUMBER P2 – 249
1450 ANTIGEN SPECIFIC T REGULATORY CELLS FROM
TOLERANT HOSTS EXHIBIT PHENOTYPES SIMILAR TO
CELLS THAT WERE ACTIVATED IN VITRO AND USED TO
INDUCE TOLERANCE
N.D. Verma, K.M. Plain, M. Nomura, C. Robinson, G.T. Tran, R. Boyd,
S.J. Hodgkinson, B.M. Hall.
Immune Tolerance Group, University of NSW, Sydney, Australia
Aims: To examine phenotype and in vitro reactivity of T regulatory cells (Tr)
from rats made tolerant by adoptive transfer of IL-2 and IL-4 activated T
regulatory cells.
Background: Natural CD4+CD25+T cells that express Foxp3, regulate immune
response with no antigen specificity, whereas the CD4+CD25+Tr that mediate
transplant tolerance are antigen-specific, but require ongoing activation
by specific antigen and cytokines from activated T cells. How non-antigen
specific naïve CD4+CD25+Tr develop into antigen specific Tr is unknown. We
found either IL-2 or IL-4, but not other Th1 or Th2 cytokines, activate naïve
CD4+CD25+Foxp3+Tr cultured with alloantigen. IL-2 activated CD4+CD25+Tr
expressed IFN-γ receptor (R) and IL-5 but not IFN-γ or IL-5 receptor α mRNA.
IL-4 induced CD4+CD25+Tr had a reciprocal profile with increased expression
of IL-5Rα and IFN-γ, but not IL-5 and IFN-γR mRNA. These activated
CD4+CD25+Tr showed enhanced capacity to suppress rejection of specific
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donor, but not third party allografts upon transfer to adoptive hosts. This
study compared the peripheral lymphocytes in hosts where tolerance had been
induced by either IL-2 or IL-4 alloactivated CD4+CD25+T cells to examine if
their CD4+CD25+T cells continued to have different phenotypes.
Methods: CD4+CD25+T cells from naïve DA rats were activated in vitro with
fully allogeneic PVG stimulator cells supplemented with IL-2 or IL-4. They
were transferred to irradiated DA rats that were grafted with PVG or Lewis heart
allografts and restored with naïve CD4+T cells. Both IL-2 and IL-4 activated
cells induced tolerance to the specific PVG but not the third party Lewis. We
examined the peripheral lymphocytes from long-term tolerant hosts.
Results: Both groups of tolerant hosts had normal numbers of CD4+CD25+T
cells (5-7% of CD4+ T cells). CD4+CD25+T cells from adoptive hosts restored
with IL-2 activated CD4+CD25+T cells had high expression of IFNGR and
IL-5 mRNA but not IL-5Rα. Those given IL-4 activated CD4+CD25+T cells
expressed IL-5Rα but no IL-5 mRNA. CD4+CD25+Tr hosts given IL-4, but
not IL-2, activated CD4+CD25+Tr responded to IL-5 in MLC with significantly
higher proliferation. This is consistent with the finding of IL-5Rα mRNA
expression on IL-4 activated CD4+CD25+Tr and shows that IL-5Rα has a
functional role in maintaining these cells. CD4+CD25-T cells from these
tolerant rats had normal reactivity to donor specific or third party alloantigens
in MLC indicating they were not clonally deleted.
Conclusion: This study showed that there are two lineages of alloantigen
specific activated CD4+CD25+Tr that persist in the adoptive host and may
contribute to long term tolerance. The persistence of the phenotypes observed
after short-term culture suggests there may be two separate pathways of
activation and that both can mediate long term tolerance. These regulatory cells
do not deplete donor reactive clones of CD4+CD25-T cells.

POSTER BOARD NUMBER P2 – 250
1451 FOXP3, CD11B AND CD57 - LOOKING FOR MARKERS
OF SUPRESSOR SUBSET OF CD8+CD28- CELLS FROM RENAL
ALLOGRAFT RECIPIENTS
A. Korecka1, A. Duszota1,2, P. Wierzbicki2, M. Niemczyk2, J. Wyzgal2, M.
Durlik2, A. Chmura2, A. Gorski2, L. Paczek2, G. Korczak-Kowalska1,2
1Department of Immunology, Faculty of Biology, University of Warsaw,
2Transplantation Institute, The Medical University of Warsaw
The induction of transplant tolerance is one of the main aims of clinical
transplantation. Suppressor CD8+CD28- T cells (Ts) are important for the
development and maintenance of immune tolerance to allografts. CD8+CD28population is very heterogeneous and Ts subset is postulated to be FoxP3+.
Recently, CD11b and CD57 markers were also proposed to be characteristic
for Ts subpopulation. Although immunosuppressive drugs are used to prevent
acute allograft rejection, they can also inhibit Ts population and therefore
interfere with transplant tolerance achievement.
The aim of this study was to evaluate the level of CD8+CD28- cells and the
expression of FOXP3, CD11b and CD57 markers among this population in
renal allograft recipients.
Blood samples were obtained from patients with stable renal allograft function or
with chronic rejection that were under CsA or RAPA treatment and from healthy
volunteers. Peripheral blood mononuclear cells were stained with monoclonal
antibodies conjugated with fluorochromes and analyzed by flow cytometry.
The CD8+CD28- population level was higher in patients than in healthy
individuals. Less than 1% of CD8+CD28- cells had FOXP3 marker and the level
of CD8+CD28-FOXP3+ cells was decreased both in patients with stable allograft
function and with chronic rejection. CD8+CD28- cells from patients treated with
CsA showed lower amount of FOXP3 marker. The level of CD8+CD28-CD11b+
and CD8+CD28-CD57+ cells was higher in patients than in healthy controls. We
observed increased CD57 marker expression on CD8+CD28- cells, but there was
no increase in CD11b marker level. CD8+CD28-CD11b+ cells level increased
due to the higher CD8+CD28- cells number.
We did not observe any significant differences in CD8+CD28- cells level or
CD11b, CD57 and FOXP3 expression between patients with stable allograft
function and with chronic rejection. The FOXP3 molecule level decreased after
transplantation, especially in patients treated with CsA. The possible reason
for that could be inhibited activation of T cells by immunosuppressive drugs
or diminished Ts subset level. The CD57 molecule, presented on majority of
CD8+CD28- cells, may be the Ts subpopulation marker, but the increased
expression of this molecule and the higher number of CD8+CD28- cells

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Poster Abstracts
might be the result of chronic alloantigen stimulation. We can assume CD11b
molecule is not a Ts subset marker because we did not observe any changes in
its expression after transplantation.

POSTER BOARD NUMBER P2 – 251
1452 INCREASED CD4+CD25+FOXP3+ REGULATORY T CELLS
IN TOLERANCE INDUCED BY PORTAL VENOUS INJECTION

POSTER BOARD NUMBER P2 – 252
1453 PREFERENTIAL DISTRIBUTION OF FOXP3+
REGULATORY T CELLS IN COMPOSITE TISSUE
ALLOGRAFTS
M.J. Elliott 1, B. Swearingen 1, D. Rahhal 1, L. Adamson 1, W.C. Huang 2,
S. Atay 1, W. Breidenbach 3, S. Ildstad 1
1
Institute For Cellular Therapeutics, Univeristy of Louisville, USA, 2Plastic
and Reconstructive Surgery, Chang Gung Memorial Hospital, Taiwan,
3
Christine M. Kleinert Research Institute, Louisville, Kentucky, USA
Background: More than 30 hand transplants have been performed.
Despite initial concerns, graft acceptance has been achieved with standard
immunosuppression.
Hypothesis: Regulatory T cells (Treg) have been implicated in the maintenance
of tolerance. Treg express the transcription factor FoxP3. Peripheral blood
Treg have skin homing receptors to aid their translocation to CTA and assist
in cutaneous immunity. This study evaluated whether FoxP3+ Treg infiltrate
specific CTA tissue compartments.
Materials and Methods: An ACI WF MHC-disparate rat model was utilized.

POSTER BOARD NUMBER P2 – 253
1454 PROLONGATION OF HEART-ALLOGRAFT SURVIVAL
AFTER LONG-TERM EXPRESSION OF SOLUBLE-MHC CLASS
I-ANTIGENS AND VIL-10 IN THE LIVER BY AAV-PLASMID
MEDIATED GENE TRANSFER
A. Doenecke, E. Frank, M. Scherer, E. Geissler, H. Schlitt
University of Regensburg Medical Center
The essential prerequisite for successful gene therapy in vivo is an effective
and long-lasting transfer of the desired gene into the respective cell type or
tissue. Over the last decades, many different methods have been developed
for this purpose. The use of plasmid DNA seems to be a good alternative to
the commonly used viral vectors, since its large scale production is simple,
and side effects are low. Unfortunately, most reports describe only short-term
expression in vivo, probably due to the lack of genomic integration in the target
cell. This problem can possibly be addressed by the use of adeno-associatedvirus plasmids (AAV-plasmids), where the coding sequences are cloned
between the AAV-specific ITRs. Here we report our results after allogeneic
heart transplantation, which followed AAV-plasmid mediated gene transfer of
the rat soluble MHC class I-antigen RT1.Aa and vIL-10 in the „high“-responder
DA to Lewis rat-strain combination.
Results: A high and stable long-term expression was achieved by in vivo
transfection of the liver using AAV plasmids. Serum levels over 1000 ng/ml
of soluble RT1.Aa and over 300pg of vIL-10, respectively, were achieved.
Expression levels remained high for up to several months. A mean prolongation
of heart allograft survival of 1 to 2 days was demonstrated after transfection of
either RT1.Aa, or vIL-10.

POSTER BOARD NUMBER P2 – 254
1455 CARBON MONOXIDE PREVENTS REJECTION OF
CARDIAC ALLOGRAFTS VIA ACTIVATION OF HIF1Α;
M.N. Thomas1,3, T. Macdonald3, E. Csizmadia3, F. Bösch2, F.H. Bach3,
L.E. Otterbein3, B.Y. Chin3
1
General Transplant Surgery, Medical University of Munich, Germany,
2
Medical University Innsbruck, Austria and 3Transplant Center, Beth Israel
Deaconess Medical Center, Harvard School of Medicine, Boston,
MA 02215, USA
Carbon monoxide (CO) at low concentrations can reduce the development
of acute and chronic rejection of allografts. One mechanism of protection
involves preventing the actute inflammatory response and oxidative injury
following transplantation. The mechanism(s) by which CO imparts protection
is still unclear. One mechanism that we have elucidated in limiting ischemia/
reperfusion injury involves CO-induced stabilization of hypoxia inducible
factor 1α; (HIF1α;). We tested the hypothesis that HIF1α; activation in the
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F. He, Z. Chen, M. Cai, S. Xu, M. Wu
Institution of Organ Transplantation, HUST
Background and aims: A portal venous injection of allogeneic donor cells
is known to prolong the survival of subsequently transplanted allograft. But
the underlying mechanisms remain to be clarified. In this study we examined
the proportions and function of CD4+CD25+Foxp3+ regulatory T cells (Treg
cells) in a tolerance modal induced by portal venous injection of alloantigen.
Methods: Irradiated C57BL/6 (B6) splenocytes were transfused into BALB/c
mice though portal vein. 7 days after portal venous injection, the proportions of
CD4+CD25+Foxp3+ regulatory T cells (Treg cells) were examined in blood,
liver and spleen. CD4+CD25+ Treg cells were isolated from BALB/c mice
treated with a portal injection of B6 splenocytes using an auto MACS cell
sorter. These isolated Treg cells were adoptive transfused into another BALB/c
followed by heterotropic implantation of B6 or C3H (third party) heart
allograft. Implantations of B6 heart allograft to normal BALB/c were used
as control group. The survival of the heart allograft was analyzed by KaplanMeier Estimator. Ex vivo alloantigen-specific CD4+CD25- T cells proliferation
responses were assessed by cocultured CD4+CD25- T cells isolated from B6
mice with Treg cells from normal BALB/c or BALB/c mice treated with a
portal injection of B6 splenocytes.
Result: After portal injection of alloantigen, CD4+CD25+Foxp3+ Treg
proportions in liver, spleen and peripheral blood were increased significantly
compared with normal BALB/c mice (date show in figure 1). Treg cells
isolated from BALB/c mice treated with a portal injection of B6 splenocytes
suppressed antigen-specific CD4+CD25- T cells proliferation ex vivo (PVI:
38.2%±3.4%,n=6; Control: 78.9%±4.4%,n=6; P<0.01). Adoptive transfusion
of Treg cells isolated from BALB/c mice treated with a portal injection of B6
splenocytes prolonged B6 and C3H heart allograft compared with control group.
But the B6 allograft had the greatest mean survival among the 3 groups. (Control:
(3±1) days, n=6; C3H: (21±3) days, n=6; B6: (40±4) days, n = 6) (figure 2)
Conclusion: CD4+CD25+Foxp3+ regulatory T cells are increased in tolerance
induced by portal venous injection of alloantigen. This kind of Treg plays an
important role in promoting antigen-specific tolerance.
Figure 1 Proportions of CD4+CD25+Foxp3+ regulatory T cells (Treg cells)
are increased in portal venous injective BALB/c (PVI) than in normal BALB/c
(Normal). CD25+FoxP3+ Treg were gated from a CD4+subset of CD3+T cells.
Figure 2: Survival curve of the three groups. Adoptive transfusion of Treg cells
isolated from BALB/c mice treated with a portal injection of B6 splenocytes
prolonged B6 and C3H heart allograft compared with control group. The B6
allograft had the greatest mean survival among the 3 groups.

WF rats were conditioned with 600 cGy total body irradiation on day -1,
transplanted with 100x106 T cell depleted bone marrow from ACI rats on day
0, and treated with tacrolimus (FK506) (days 0 to 10) and one dose of antilymphocyte serum (day 10). Mixed chimerism was evaluated by flow cytometry
on day 28. Rats with 1% chimerism underwent modified hind limb CTA on day
29. Animals were analyzed for FoxP3+ cell infiltrates in different compartments:
spleen, lymph node, bone marrow and skin at 6 months. RESULTS: The
percentage FoxP3+ cells in spleen, lymph node, and bone marrow in rejecters
(33.8, 34.2, 54.8%, respectively) and acceptors (46.1, 49.4, 47.4%) of CTA
was not significantly different. Both were significantly lower compared to
naive controls (83.9%, 68.7%, 61.3%). The skin of treated rats analyzed for
infiltrating CD4+/CD25+/FoxP3+ Treg showed a significantly higher level of
FoxP3 expressing cells (33.4 cells/HPF and 46.5 cells/HPF) in the transplanted
skin of CTA acceptors compared to naïve donor or host skin (0 cells/HPF).
Discussion: CTA is becoming a viable treatment option in patients with large
tissue and limb defects. Understanding the factors that contribute to graft
acceptance will allow focused approaches to modulate their role in posttransplantation therapy. The preferential presence of FoxP3+ Treg in skin of
CTA may partially explain why acceptance of CTA has been more readily
achieved than previously predicted. Functional studies are underway to
corroborate the findings that Treg are present in skin. These data may have
significant implications in the interpretation of clinical biopsy results since
some cellular infiltrates (FoxP3+) may not herald rejection.
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graft would prevent rejection. Employing a strong mismatch model of heart
heterotopic allograft transplantation in mice (BALB/c to C57BL/6) we
show that administration of exogenous CO attenuates graft rejection and
the development of arteriosclerotic lesions. Recipients only were exposed
to 250ppm CO or air for one hr prior to transplantation and then 1 hr daily
thereafter. Rejection was assessed by palpating heartbeat and quantitation
of intimal hyperplasia histopathologically 2 weeks post transplant. Airtreated mice showed signs of rejection as measured by intimal hyperplasia
of the aortas by 13-15 days postoperatively, which was not observed in CO
treated hearts. Examination of tissue sections showed significant increases
in T aggressive cell infiltrates in air-treated controls, which was significantly
reduced in CO-treated mice. We observed a statistically significant survival
benefit of transplanted hearts with CO vs air; with air-treated animals
rejecting by day 8 while the hearts in CO-treated animals survived until day
12. CO induced a marked enhancement in Treg (Foxp3) positive staining
in the aortas of CO-treated treated animals, which was significantly less in
air-treated animals. Administration of PC61, an antibody selective for Treg
(CD4+/CD25+), reversed the protection afforded by CO to that observed in
air-treated controls. Additionally, we observed a greater number of monocyte/
macrophage (m&#966;) infiltrates in CO-treated mice vs air. Employing a
conditional macrophage specific knockout mouse for HIF1α; (lyz-HIF1α;/-cre-lox) we tested the role of macrophage-specific HIF1α; expression in
recipients. Air-treated lyz-HIF mice showed similar graft survival vs wildtype littermates. The ability of CO to impart protection as that observed
in wild-type littermates was lost in lyz-HIF recipients. Taken together, our
studies suggest that one mechanism by which CO enhances graft survival is
through HIF1α; stabilization in macrophages.
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1456 UPREGULATING CD4CD25FOXP3 T CELLS IN
PANCREATIC LYMPH NODES AND INCREASING TGF-BETA
PRODUCTION IN DIABETIC NOD MICE BY ADJUVANT
IMMUNOTHERAPY
L. Tian1, H. Yi1, B. Tian1, J. Hao1, Y. Zhang1, T. O’Brien2, D. Sutherland1, B.
Hering1, Z. Guo1
1
Department of Surgery, University of Minnesota, 2Department of Veterinary
Population Medicine, University of Minnesota.
Regulatory T cells play a key role in controlling or maintaining selftolerance. In this study, we investigated whether adjuvant immunotherapy
with Complete Freund’s adjuvant (CFA) up-regulates CD4+CD25+FoxP3+
regulatory T cells and increases TGF-beta in diabetic NOD mice. Spontaneous
diabetic NOD mice were treated with a single dose of CFA at 0.1 mg alone or
with CFA and exendin-4, a potent analog of Glucagon-like peptide-1. Blood
glucose level was monitored and CD4+CD25+FoxP3+ regulatory T cells in
the peripheral blood, spleen, thymus, and pancreatic nodes will be measured.
Reversal of diabetes was not achieved in mice that treated with insulin only.
However, 5 of 13 (38%) diabetic NOD mice became normoglycemic from 9
to 42 days (mean 25±14 days) after the CFA treatment; and 12 of 14 (86%)
diabetic NOD mice became normoglycemic from 4 to 106 days (mean: 35±29
days) after CFA and exendin-4 treatment. One week after CFA treatment, the
percentage of CD4+CD25+FoxP3+ regulatory T cells among the total CD4+
T cells of peripheral blood and thymus were 8.5±2.7% and 1.3±0.7% in
CFA-treated NOD mice; and 5.9±1.8% and 1.0±0.4% in control NOD mice.
However, the number of CD4+CD25+FoxP3+ regulatory T cells in spleen
and the pancreatic lymph nodes of CFA-treated NOD mice were significantly
increased, as compared with control diabetic NOD mice. The percentages
of CD4+CD25+FoxP3+ regulatory T cells among total CD4+ T cells in the
spleen and pancreatic lymph nodes were 12.8±2.7% and 10.9±2.0% in CFAtreated NOD mice; and 8.2±0.6% (P<0.05) and 6.7±1.1% (P<0.05) in control
NOD mice. The percentage of CD4+CD25+FoxP3+ regulatory T cells in the
total CD4+ T cells in the pancreatic lymph nodes was 15.0±1.2% in control
nondiabetic NOD mice, 14.8±1.7% in diabetic NOD mice 5 weeks after
CFA and exendin-4 treatment; and 7.8±1.0% in diabetic NOD mice with
exendin-4 alone treatment. The number of CD4+CD25+FoxP3+ regulatory
T cells was significantly and persistently increased in the pancreatic lymph
nodes of diabetic NOD mice after CFA treatment. Fifteen to seventeen weeks
after treatment, the mean level of CD4+CD25+FoxP3+ regulatory T cells in
pancreatic lymph nodes of NOD mice was 13.3±2.3%, which was significantly
higher than the mean level in the peripheral blood (4.6±0.9%, <0.01), thymus
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(2.4±2.3%, P<0.01), and spleen (8.5±2.4%, P<0.05). All 8 NOD.scid mice
that received lymphocytes from control diabetic NOD mice developed
diabetes at 5 weeks post-adoptive transfer. However, diabetes developed in
only 1 of 7 NOD.scid mice at 5 weeks (P<0.05) after receiving lymphocytes
from CFA-treated NOD mice. Furthermore, diabetes only developed in 1 of
7 NOD.scid mice at 5 weeks (P<0.05) following co-transfer of lymphocytes
from diabetic NOD mice with lymphocytes from CFA-treated NOD mice.
The concentration of TGF-beta in the sera was 7.6±1.6 ng/ml in diabetic
NOD mice; 18.1±9.7ng/ml in nondiabetic NOD mice; and 45.9±26.4ng/
ml in CFA treated NOD mice. Our results demonstrated that adjuvant
immunotherapy with CFA ameliorates autoimmunity in diabetic NOD mice
by regulating CD4+CD25+FoxP3+ regulatory T cells and increasing TGFbeta production.

POSTER BOARD NUMBER P2 – 256
1457 LIVER DENDRITIC CELLS RESIST THE EFFECTS OF
RETINOIC ACID AND TRANSFORMING GROWTH FACTOR-B
FOR THE INDUCTION OF FOXP3+ REGULATORY T CELLS
A. Thomson1,2, D. Tokita1, C.S. Gandhi1, T. Sumpter1
1University of Pittsburgh, Starzl Transplant Institute, Dept of Surgery,
2University of Pittsburgh, Dept of Immunology
Transplanted livers are better tolerated compared to other organs. This may
reflect interactions between dendritic cells (DC) and Foxp3+ regulatory
T cells (Treg) within the liver. CD103 expression on DC correlates with de
novo induction of Foxp3 in T cells. Furthermore, Foxp3 expression in T
cells is elevated in the presence of transforming growth factor-b (TGF-b)
and retinoic acid (RA), both of which are produced in the liver. This study
evaluates CD103 expression on liver plasmacytoid (p) and myeloid (m) DC
and the potential of liver DC subsets to induce Foxp3 expression in T cells
in the presence of TGF-b&#61472;and RA. Magnetically isolated pDC and
mDC from livers and spleens of C57BL/10 mice and evaluated for CD103
expression by flow cytometry. pDC or mDC were co-cultured with CFSElabeled allogeneic (BALB/c) CD4+CD25- T cells. After 4 or 5d of co-culture,
T cells were assessed for CFSE dilution and intracellular Foxp3 expression by
flow cytometry. rhTGF-b&#61472;and either all trans or cis-RA were added
to co-cultures. Both mDC and pDC from the liver expressed higher levels
of CD103 compared to spleen pDC or mDC, with the highest expression of
CD103 found on liver mDC. pDC, compared to mDC, from either the liver
or the spleen were poor inducers of Foxp3 expression in CD4+CD25- T cells.
TGF-b enhanced the induction of Foxp3 in T cells co-cultured with splenic
pDC, but not liver pDC. The effects of TGF-b were further enhanced when RA
(either all trans or cis) was added to CD4+CD25- T cells when splenic pDC
but not liver pDC were used as stimulators. TGF-b&#61472;and TGF-b with
RA also enhanced Foxp3 induction in CD4+CD25- T cells when either spleen
or liver mDC were used as stimulators, though splenic mDC were superior
inducers of Foxp3 in CD4+CD25+ T cells. Our data show that liver mDC and
pDC are poor inducers of Foxp3 in T cells, even in the presence of TGF-b and
RA. These data suggest that the inherent tolerogenicity of liver DC subsets may
be independent of de novo induction of Treg.

POSTER BOARD NUMBER P2 – 257
1458 TOLERANCE TO RAT LIVER ALLOGRAFTS AFTER
TOTAL LYMPHOID IRRADIATION IS MEDIATED BY
CD4+CD25+FOXP3+ T REGULATORY CELLS AND THE
APOPTOSIS OF INTRAGRAFT CD4+ T CELLS
S. Krams1, M. Fujiki1, C. Esquivel1, O. Martinez1, S. Strober2,
1
Surgery, Division of Transplantation, Stanford University, 2Medicine,
Stanford University
Aim: We previously reported that total lymphoid irradiation (TLI) induces
tolerance to rat liver allografts with increased CD4+CD25+ T cells in the
peripheral blood of long-term surviving recipients. Both TLI and liver
allotransplantation have been reported to contribute to the expansion of
regulatory T cells (T reg) and tolerance. In this study we examined the
mechanism of TLI-induced tolerance to liver allografts.
Methods: Lewis recipients were transplanted either with syngeneic Lewis
(Syn) or allogeneic DA livers (Allo) and were left untreated or received
8 doses of 240 cGy of TLI after transplantation. Graft infiltrating cells
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were isolated and stained with Annexin V to quantitate apoptotic cells. T
reg cells (CD4+CD25+Foxp3+ cells) in the blood, spleen and graft were
measured by flow cytometry Specific alloresponsiveness was determined
by MLR and adoptive transfer of splenocytes to naive recipients of heart
allografts.
Results: TLI prolonged liver allograft survival, with 88% of recipients
surviving >100 days without any evidence of chronic rejection. At day
7 post-transplant, CD4+CD25+Foxp3+ cells in the graft were increased
in the Allo TLI group as compared to the Allo control group (Allo+TLI
10.8% vs. Allo 6.6%). Intragraft CD4+CD25+Foxp3+ cells remained
increased in the graft (day 35) and spleen (day >100) in the Allo TLI group.
Furthermore, apoptotic CD4+ cells were detected in markedly higher
numbers in the Allo TLI group as compared to the Allo group (AnnexinV+/
CD4+; Allo+TLI 35.9% vs. Allo 14.0%). Apoptotic infiltrating cells were
not observed in the Syn TLI group. CD4+CD25+ cells isolated from the
spleen of Allo TLI recipients (day >100) inhibited the alloresponse of naive
Lewis splenocytes to DA splenocytes in MLR, whereas CD4+CD25 -cells
increased the alloresponse. Importantly, adoptive transfer of splenocytes
from day >100 Allo TLI recipients prolonged the survival of donor, but
not third-party heart grafts (MST; 33 days TLI vs.18 days control; p<0.01).
Importantly, depletion of CD4+CD25+ cells from transferred splenocytes
abrogated this prolongation (MST; 16 days). Cardiac graft survival was
not prolonged by the transfer of splenocytes from day 35 recipients of
allo TLI.
Conclusion: TLI induces tolerance to liver allografts via a mechanism
involving concomitant apoptosis of CD4+ cells and the accumulation of
CD4+CD25+Foxp3+ Treg cells that persist in the spleen >100 days after
transplant.
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1459 BENEFICIAL EFFECT OF CANDESARTAN FOR
PREVENTING RENAL INTERSTITIAL FIBROSIS THROUGH
PAI-1 AND TGF-BETA SUPPRESSION
A. Ishikawa1, M. Tanaka2, Y. Ishibashi3, T. Fujita3, T. Kitamura1
1Department of Urology, Faculty of Medicine, The University of Tokyo,
2Growth Factor Division, National Cancer Center Research Institute,
3Department of Nephrology and Endocrinology, Faculty of Medicine, The
University of Tokyo
Introduction and objective: To elucidate the mechanism of renal preservation
effect of angiotensin II receptor blockers (ARBs), we carried out the following
study using cyclosporine (CyA) nephrotoxic rats.
Methods: Ten-week-old male Wistar rats were divided into four groups (five
animals each). Group 1 received a medium only. Group 2 received 30 mg/kg/
day (i.e. experimentally nephrotoxic dose) of CyA only. Group 3 received both
30 mg/kg/day of CyA and 10 mg/kg/day of candesartan (CAN), one of ARBs.
Group 4 received 10 mg/kg/day of CAN only. Drugs were given orally once a
day for fourteen days. On the fifteenth day, after blood sampling, kidneys were
removed and processed for Western blotting (WB), reverse transcriptionalpolymerase chain reaction (RT-PCR), and immunohistochemistry (IHC) to
examine PAI-1 and TGF-beta expression.
Results: Plasma PAI-1 levels of groups 1-4 were 22 }8, 37 }11*, 27 }10, 23
}9 (0-50) ng/ml respectively (* p<.05 vs. Group 1). WB, RT-PCR, and IHC
demonstrated that PAI-1 and TGF-beta were up-regulated in group 2, and
down-regulated in group 3.
Conclusions: Our present study suggested that PAI-1 and TGF-beta might play
important roles in nephrotoxic side effect of CyA and renal preservation effect
of ARBs. ARBs would contribute to prevent renal interstitial fibrosis through
PAI-1 and TGF-beta suppression.

1460 THE ROLE OF THE KIDNEY IN THE SYSTEMIC
ELIMINATION OF SELECTED CYTOKINES AND
GROWTH FACTORS
M. Nowak1, Z. Wlodarczyk2, A. Wyczalkowska-Tomasik1, L. Paczek1
Transplantation Institute, Warsaw, Poland, 2University Hospital,
Bydgoszcz, Poland
Study goal: The aim of the study was to assess the role of kidney in systemic
elimination of cytokines (IL-6) and growth factors (PDGF, TGF-B) by
comparison of their concentrations and gene expression in renal artery and vein,
peripheral vein and urine. A mathematical model of elimination of investigated
proteins from systemic circulation was elaborated.
Material and methods: 30 kidney donors were included into the study.
Samples were obtained during harvesting procedure. 10 healthy volunteers
served as controls. Serum levels of investigated proteins were estimated using
immunoenzymatic method (ELISA). Real-Time Polymerase Chain Reaction
(RT-PCR) method was used to evaluate gene expression of investigated
proteins in mononuclear blood cells.
Results: Increased peripheral blood concentrations of all investigated proteins
comparing to the control group were observed: IL-6 – 330-fold, PDGF 25-fold
and TGF-B 12-fold. Renal IL-6 uptake
ratio (UR) amounted to 6.6%, elimination ratio (ER) amounted to 6.4% and
pass ratio (PR) amounted to 0.2%. PDGF ratios amounted to 5.1%, 5.0% and
0.1% and TGF-B ratios amounted to -9%, -9% and 0%, respectively. Mean
IL-6 gene expression was higher in renal artery comparing to vein. Differences
in TGF-B and PDGF genes expressions were not significant.
Conclusions: Kidney donors have increased serum concentrations of cytokines
and growth factors. The kidney takes part in the elimination of IL-6 and PDGF
from systemic circulation. The kidney does not take part in the elimination of
TGF-B. Mononuclear blood cells producing IL-6 are retained by the kidney.
The above phenomenon was not observed regarding to PDGF and TGF-B.

1
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1461 AUGMENTED EARLY IMMUNE RESPONSE AFTER
TRANSPLANTATION OF GRAFTS FROM AGED DONORS
C. Denecke1, X. Ge1, D. Bedi1, I. Kim1, A. Jurisch1, J. Pratschke2,
P. Neuhaus2, S. Tullius1
1Div of Transplant Surgery, BWH, 2Dept of Surgery, Charite, Berlin,
Germany
The discrepancy between demand and supply requests an increased utilization
of older organs for transplantation. Advanced donor age may not only be
associated with physiological impairments but also with a modified immune
response of the recipient. We hypothesized a more potent early immune
response following the transplantation of elderly donor organs and analyzed
the immune response in a mouse heart transplant model.
Young B6 mice received heart allografts from 3, 12 and 18mths old bm12 donors.
Recipients immune response and intragraft changes were analyzed. Elderly,
non-manipulated hearts contained overall significantly elevated frequencies of
CD4+and CD8+ T-cells and DCs (CD11c+) (18mths vs. 3mths: CD4+: 2.77%
vs. 1.35%, CD8+: 3.90% vs 1.71%, CD11c+: 46.1% vs.11.8%, p<0.05).
Following engraftment of 18mths old heart grafts numbers of activated DCs
(CD11c+I-Ab+and CD11c+CD40+) had significantly increased in recipients
spleens (day 14:p<0.05). In parallel, frequencies of effector/memory phenotype
T-cells (CD4+CD44highCD62Llow and CD8+CD44highCD62Llow)
were significantly elevated with increasing age (3 vs. 12 vs, 18mths:
CD8+CD44highCD62Llow :6.7% vs. 8.4% vs. 12.2%, respectively, p< 0.01). In
parallel, Tregs (CD4+CD25+FoxP3+) were also elevated (3 vs. 12 vs, 18mths:
2.9%vs.9.6%vs.11%,p<0.05). T-cell alloreactivity as measured by IFN?production increased with donor age (3mths vs. 12mths vs.18mths: 24.4±1.5
vs 74.4±21.9 vs. 73.2±7.8 IFN?-producing spots/5x106 cells, p<0.05). Mixed
Lymphocyte Reaction (MLR) at day 14 revealed a gradual incline in splenocyte
proliferation with advancing donor age (p=0.0002) underlining an enhanced
immunogenicity of older organs.
Immunohistochemical staining confirmed augmented CD4+ and CD8+ T-cell
infiltrates in 18mths old heart grafts, emphasizing an intensified immune
response associated with the engraftment of older organs.
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In summary, old native heart transplants contain an overall increased cellularity
with higher numbers of passenger leukocytes contributing to an increased
immunogenicity.. Following transplantation, a more potent DC and T-cell
activation and intragraft T-cellinfiltration was observed in elderly organs
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1462 INTENSIFIED INNATE AND ADAPTIVE IMMUNE
RESPONSE AFTER DCD TRANSPLANTATION FROM AGED
DONORS
C. Denecke1, I. Kim1, D. Bedi1, A. Jurisch1, X. Ge1, K. Kotsch2, J. Pratschke3,
P. Neuhaus3, S. Tullius1
1Div of Transplant Surgery, BWH, 2Dept of Med. Immunology, Charite,
Berlin, Germany, 3Dept of Surgery, Charite, Berlin, Germany
Introduction: Organs from DCD donors are increasingly utilized for
transplantation. We evaluated the outcome, recovery and the recipient’s
immune response of young and old DCD organs in an experimental model.
Methods: Young (3 months) and old F-344 donor rats (18 months) were
anesthesized, ventilated and monitored. Following withdrawal of the ventilator,
asystole was awaited;kidneys were engrafted into bilaterally nephrectomized
LEW recipients after a warm ischemia time of 45min. To test organ recovery,
DCD organs were followed under the protection of a contralateral native kidney
in an additional set of experiments.
Survival and recovery: By 10 days survival in DCD recipients was reduced by
50% independent of donor age compared to LD controls. H&E staining confirmed
extensive acute tubular necrosis of > than 80% in DCD kidneys. However, all
DCD recipients with a supportive contralateral native kidney in place for 4 weeks
survived long-term, demonstrating a potential for recovery after tubular injury.
In vitro analysis: 24hrs after transplantation recipients of old DCD
grafts showed significantly elevated numbers of activated CD4+CD25+Tcells and NK-cells (CD161+TCR-) in draining lymph nodes (p<0.05).
Significantly elevated frequencies of activated DCs (OX62+ClassII+ and
OX62+CD86+) were detected at that time (p<0.05). Moreover, recipients of
old DCD grafts responded with an enhanced IFN? production (ELISPOT;
p<0.01) and upregulated intragraft gene expression (TNF?, TGF-?;p<0.05).
Immunohistochemical staining revealed significantly more intragraft NK/NKTcells (CD161+) in old DCD kidneys (p<0.05).
By day 10, frequencies of effector T-cells (CD4+CD45RC-), activated DCs
(OX62+ClassII+), B-cells (CD45RA+ClassII+) but also CD4+CD25+FoxP3+
T-cells had increased in DCD recipients (p<0.05). Old DCD kidneys
demonstrated a significantly stronger intragraft gene expression of IFN? and
IP10 and higher numbers of graft infiltrating CD4+ T-cells and NK/NK-Tcells
(CD161+) as assessed by IH (p<0.05).
Conclusion: In conclusion, DCD organs have a high potential to recover
after extensive ATN and DGF. Engraftment of elderly DCD organs elicited
an intensified early innate and adaptive immune response. Clinically, DCD
recipients may benefit from a modified immunosuppression.

POSTER BOARD NUMBER P2 – 262
1463 EVIDENCE THAT THE GRAFT PLAYS AN IMPORTANT
ROLE IN MAINTAINING TOLERANCE TO DONOR
ALLOANTIGENS
M. Hara1, E. Chosa1, A. Watanabe1, T. Shimizu1, M. Tomita1, T. Ayabe1,
M. Yano1, R. Sekiya1, K. Wood2, T. Onitsuka1
1Department of Cardiovascular, Thoracic And General Surgery, Faculty of
Medicine, University of Miyazaki, Japan, 2. Nuffield Department of Surgery,
University of Oxford, UK
Background: Dissecting the mechanism of transplantation tolerance is one of
the ways to investigate the role of regulatory T cell in controlling rejection.
Treatment with a depleting anti-CD4 mAb at time of transplantation (day-1,
0) induces tolerance to vascularized cardiac allografts. When the primary heart
graft is removed 50 days after transplantation, tolerance to donor alloantigen
is maintained for 130 days even in the absence of the primary heart graft. The
mechanism of maintenance of tolerance without antigen has not been elucidated.
We have shown that administration of either anti-CD25 or anti-CTLA4 ab
induces rejection of the second graft. The question is whether anti-CD25 and
anti-CTLA4 ab induce rejection of the second graft without first graft removal.
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Methods: C57BL/6 hearts were transplanted into the neck of a recipient C3H
mice treated with the depleting anti-CD4 mAb treated (YTA 3.1 0.05mgx2,
day-1,0 iv). The primary heart graft was removed or leaved at day 50. A second
heart graft was transplanted into the recipient fs abdomen at day 100 and graft
survival was evaluated.
Results: The second heart graft was accepted in a strain fashion (MST=100 vs
third party MST=16). Administration of either anti-CD25 ab (PC61; 0.25mgx1,
d97 iv) or anti-CTLA4 ab (4F10; 0.25mgx3, d100,103,106 ip) induced rejection
of the second graft (MST= 71, 11, respectively). @However, administration of
either anti-CD25 ab or anti-CTLA4 ab could not induce rejection of the second
graft without first graft removal.
Conclusion: Graft itself plays an important role in maintaining tolerance.

POSTER BOARD NUMBER P2 – 263
1464 CYCLOSPORIN A PROMOTES EPSTEIN-BARR VIRUS
INFECTED HUMAN B CELL TRANSFORMATION ASSAYED BY
THREE CORRELATED ASSAY METHODS
D. Ranjan, C. Chen, T.D. Johnston, H. Jeon, R. Gedaly, P. McHugh
University of Kentucky
We have reported that Cyclosporin A (CsA) has direct effect in promoting EpsteinBarr virus (EBV) transformation of human peripheral blood B-lymphocytes. In
this paper we report that CsA promoted EBV infected human B cell transformation
as assayed by three methods of colony number counting, cell number counting,
and 3H-thymidine incorporation. At first, we tried to find the correlation between
the three methods in EBV infected human B cell transformation, and found that
they are convenient and correlate with each other and only vary in the degree
when transformed cells are compared to the controls. We found that in the EBV
infected B cells, there were 27 +/-4 colonies/well (n=12, +/- SE) in the experiments
after 4 weeks of culture. The number of transformed cells was at 33708+/- 990
cells/well (n=12, +/- SE). In correlation with the transformed colony and cell
numbers, 3H-thymidine incorporation of the EBV-B cells were at high rate,
at 12763 +/- 368 CPM/well (n=12, +/- SE). Whereas, the non infected B cells
had 0 in colony number, 4250 +/- 185 cell number and 152 +/- 22 CPM/well in
3H-thymidine incorporation respectively. Based on these experiments, the three
assay methods were then applied to CsA treated and non treated EBV-infected
human B cells to investigate if CsA treatment promotes EBV infected human B
cell transformation. We found that CsA treatment increased colony formation
from control of 28 +/- 4.5/well to 49 +/- 4.3 (colonies /well) (n=5, p<0.05); CsA
treatment increased cell number from control 33025 „b 1900 to 50925 +/- 4194
(cells/well)(n=5, p<0.05); CsA treatment increased 3H-thymidine incorporation
from control 12481 +/- 1341 to 26514 +/- 5464 (CPM/well) (n=5, p<0.05). In
conclusion, CsA promotion of EBV-B cell transformation is clearly indicated
in the three correlated assay methods in the in vitro model of post-transplant
lymphoproliferation disorder (PTLD).
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1465 PROTEIN KINASE C-DELTA (PKC-D) AS DONOR
FACTOR DETERMINING ALLOGRAFT REJECTION
H.R. Cho1,2, B. Kwon2,3, C.W. Nam1, Y.W. Nah1
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea,
3Department of Biological Science, University of Ulsan, Ulsan, Ulsan, Korea
PKC-d plays a critical role in proliferation and apoptosis of various types of
cells. In this study, we examined the role that PKC-d plays in target organs
or cells in alloimmune responses, using three experimental model systems.
First, we showed that, in the C57BL/6C3H vessel transplant model, there
was an increased neointima hyperplasia and inflammation in PKC-d-deficient
allografts compared with wild-type allografts. Marked upregulation of
molecules involved in chemotaxis and T cell activation was observed in PKCd-deficient allografts. Second, in the C57BL/6 (H-2Kb)C3H.SW (H-2Kb)
minor histocompatibility antigen-mismatched cardiac allograft model, PKC-ddeficient cardiac allografts exhibited more severe vasculopathy, inflammation,
and damage of cardiac muscles. Results from RT-PCR analysis were in
agreement with histopathological data in that there was markedly increased
expression of molecules involved in chemotaxis, costimulation, inflammation,
tissue remodeling, and cell adhesion. Finally, PKC-d-deficient C57BL/6
recipients that received bone marrow and T cells from C3H.SW donors had

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Tuesday 12 August 2008

Poster Abstracts
more severe loss of body weight and intestinal damage, and lower survival rate
than did wild-type littermates, indicating that deficiency of PKC-d in recipients
deteriorates acute graft-versus-host disease (GVHD). Taken together, our
results clearly indicate that PKC-d functions as a host factor determining
allograft rejection.
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1466 THE ANTI-INFLAMMATORY EFFECT OF CO
RELEASING MOLECULES IS NOT PERPETUATED BY
INDUCTION OF HEME OXYGENASE 1
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1467 THE EFFECT OF IMMUNO-SUPPRESSANT DRUGS
ON INNATE IMMUNITY
A. Bakran2, L. Hopcraft1, M. Howse2, S.W. Edwards1
1School of Biological Sciences, University of Liverpool, Crown Street,
Liverpool, L697BZ, 2Royal Liverpool and Broadgreen University Hospitals,
Prescot Street, Liverpool, L78XP
Introduction: Patients who undergo renal transplantation receive immunosuppressive drugs designed to down-regulate T-lymphocytes (T-cells) which
mediate acute rejection episodes. Whilst immuno-suppression increases the
risk of viral infections, bacterial infections are even more common in these
patients, despite any obvious direct effects on innate immune cells that would
normally combat these pathogens. This observation suggests that innate
immunity is likely to be impaired during immuno-suppressive therapy, but few
investigations to date have focussed on the effect of such drugs on cells of the
innate immune system. The aim of this study was to determine whether the
commonly prescribed immuno-suppressive drugs elicited any direct in vitro
effects on the functions of the neutrophil, an important component of the innate
immune response.
Methods: Neutrophils were isolated from heparinized venous blood from
healthy volunteers by a one-step isolation method on Polymorphprep. Cells were
incubated at 37°C in RPMI 1640 medium (+HEPES, +10% pooled human AB
serum) in the absence (control) or presence of a variety of immuno-suppressant
drugs (or their solvent vehicle) at concentrations representing “peak” and
“trough” serum levels following administration. After 30 min pre-incubation,
changes to neutrophil function were determined by measurement of reactive
oxygen species (ROS) following activation of the respiratory burst measured
by luminol and isoluminol-dependent chemiluminescence respectively, and
stimulation by the phorbol ester, PMA.
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1468 THE ERK2 SIGNAL TRANSDUCTION PATHWAY
MODULATES EPITHELIAL-MESENCHYMAL TRANSITION OF
HK-2 CELL ACTIVATED BY CONNECTIVE TISSUE GROWTH
FACTOR
N. Gong, Z. Ding, X. Chen, Z. Chen
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College,
Huazhong University of Science And Technology
Objective: Accumulating data show epithelial-mesenchymal transition (EMT)
plays important role in the progress of chronic allograft nephropathy. To
date, the effect of connective tissue growth factor (CTGF) on EMT has been
explored but the underlying mechanism still remains unclear. In the present
study, extracellular signal-regulated kinase 2 (ERK2) pathway was blocked by
anti-sense adenovirus-mediated ERK2 (Adanti-ERK2) gene therapy in a model
of EMT activated by CTGF in a HK-2 cell line culture system.
Methods: (1) The HK-2 cells were transfected by Adanti-ERK2 with
multiplicity of infection (MOI) 50, 100 and 200, and then followed by green
fluorescence for 2 days observation. The alive cells ratio was calculated for
optimal MOI for the further work. (2)The cultured HK-2 cells were divided
into four groups: empty control group (no gene transfer); vector control
group (transfected with Ad-LacZ); CTGF-treated group (treated with CTGF
at a final concentration of 5 ng/ml); and Adanti-ERK2 therapy group (cells
were transfected with Adanti-ERK2 and then treated with CTGF). Cells were
collected at 72h and then immunohistochemistry and western-blot were used
to detect the expression of E-Cadherin£¬Vimentin, ¦Á-SMA and ERK2. In an
additional series, boyden chamber was used to detect the migration capability
of HK-2 cells in each group at 1d, 3d and 5d.
Results: (1) Compare with the control group, over 95% HK-2 cells expressed
green fluorescence after transfection of Adanti-ERK2 with MOI 100 for 48h.
The alive cell ratio had no difference in the four groups at 48h; (2) Compared
with the empty control group and vector control group, more Vimentin,
¦Á-SMA, ERK2 and less E-Cadherin expressed in the CTGF-treated group
at 72h. No significant difference of expression of E-Cadherin, Vimentin and
¦Á-SMA was observed between the Adanti-ERK2 therapy group and the empty
control and vector control group, as well as the expression of ERK2 in AdantiERK2 therapy group was down-regulated markedly. (3) the migration capability
of HK-2 didn’t show difference in all four groups at day 1. From day 3, the
transited cells raised and migrated through the filter pores of boyden chamber
to the opposite side in the CTGF-treated group. At day 5, the transformed cells
in the opposite side of filters in CTGF-treated group were markedly more than
other groups (P<0.05). No difference of migration capability of HK-2 cells
among the Adanti-ERK2 therapy group, the empty control and the vector
control group (P>0.05) was obtained.
Conclusion: CTGF is one potent factor to activate EMT of HK-2 but the effect
is modulated by ERK2 signal transduction pathway. Adanti-ERK2 gene therapy
could be the candidate for the investigation of chronic allograft nephropathy.
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B. Yard, S. Hui, C. Bergstrasser, S. Hoeger
Vth Medical Clinic, Medical Faculty Mannheim, University of Heidelberg
Heme oxygenase-1 (HO-1) exert anti-inflammatory effects via heme
degradation and subsequent generation of carbon monoxide (CO). Since
CO itself is able to up-regulate HO-1 expression, perpetuation of the antiinflammatory effects is expected. We investigated how CO releasing molecules
(CORM), i.e. CORM-3, influence the expression of adhesion molecules and if
HO-1 mediated perpetuation was involved.
CORM-3 consistently inhibited the expression of VCAM-1 and E-selectin on
TNF-α; stimulated human umbilical vein endothelial cells (HUVEC), while for
ICAM-1 this was not observed in each line tested. CORM-3 did not influence
initial NFkappaB activation by TNF-α;, however, NFkappaB activation was
diminished after 4 hrs and completely lost after 24 hrs. CORM-3 was also
able to down-regulate VCAM-1 expression, even when added to HUVEC that
were prior stimulated for 24 hrs with TNF-α;. In this case, down-regulation of
VCAM-1 was not completely paralleled by a decreased NFkappaB activation
and VCAM-1 mRNA expression. Induction of HO-1 occurred in a dose and
time depended manner and was mediated by Nrf-2. Neither in HO-1 – nor in
Nrf-2 siRNA transfected HUVEC, was the efficacy of CORM-3 lost to downregulate VCAM-1 expression. In Nrf-2 siRNA transfected HUVEC however
HO-1 was no longer induced by CORM-3.
In conclusion our study demonstrates that CORM-3 mediated anti-inflammatory
effects are independent of HO-1 up-regulation. Although CORM-3 most
likely exerts its effect by inhibition of sustained NFkappaB activation, downregulation of VCAM expression also seems to be regulated post-translationally.
CORM-3 might have a potential clinical use to resolve ongoing inflammation
as occurs during ischemia/reperfusion and organ transplantation.

Results: Under these experimental conditions, the majority of the drugs tested had
no significant effect on the magnitude or kinetics of the respiratory burst. These
included prednisolone (100-1000 ng/mL), 6-mercaptopurine (50-150 ng/mL,
the active ingredient of azathioprine), rapamycin (0.1-1000 ng/mL), ciclosporin
(200-1000 ng/mL) and tacrolimus (0.1-1000 ng/ml). However, mycophenolic acid
(MPA, the active ingredient of mycophenolate mofetil) resulted in a significant
dose-dependent inhibition of ROS production (p<0.05) measured by either
luminol or isoluminol which measure total and secreted ROS, respectively.
Conclusions: Clinically relevant concentrations of MPA markedly impaired
production of ROS by neutrophils. The NADPH oxidase which regulates ROS
production plays a key role in the anti-bacterial mechanisms of neutrophils.
This suggests that bacterial infections in renal transplant patients may result
from direct suppression of innate immunity by immuno-suppressive drug
regimes containing mycophenolate mofetil. At present, we cannot exclude the
possibility that other immune-suppressants that did not affect ROS production,
may elicit some other effects on neutrophil function. Alternatively, suppression
of T-cells may indirectly affect neutrophil function in vivo via deficiencies in
cytokine production, which are known regulators of innate immunity. This
work, however, provides the first direct evidence that T-cell targeted immunosuppression may directly lead to enhanced susceptibility to bacterial infections
via inhibition of neutrophil function.
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1469 MODULATION OF URETERIC SMOOTH MUSCLE
CONTRACTILITY BY UROPATHOGENIC E.COLI (UPEC)
A. Bakran1, R. Floyd2, C. Winstanley3, S. Wray2, T. Burdyga2
Royal Liverpool University Hospital, 2Department of Physiology, University
of Liverpool, 3Division of Medical Microbiology and GU Medicine, University
of Liverpool
Introduction: Urinary tract infection is a common cause of morbidity pre and
post-transplantation. Ascending urinary tract infections can cause abnormal
ureteric functioning but little is known about the mechanisms causing this
modulation. UPEC produce cytotoxic necrotizing factor (CNF-1) which
triggers inflammation and apoptosis of urothelial cells 1. CNF-1 has also been
shown to directly activate Rho-GTPases. There are however, no studies of this
interaction in live ureteric tissue.
Aims: In the present study, we investigated how UPEC’s expressing CNF-1 can
modulate phasic and agonist induced contractions in human and rat ureters.
Methods: Phasic contractions evoked by electrical field stimulation (EFS)
and stimulation by high-potassium and the cholinergic agonist carbachol
have been investigated in the presence and absence of UPEC. Ureters were
lumenally exposed to UPEC’s J96 or C536 or a control strain of K12 E.coli
for 3 hours to study the effects on contractility. Sham loading procedures were
performed using physiological saline. Tetraethylammonium (TEA) 1mM
which specifically inhibits Ca-activated potassium channels was used to study
tissue excitability.
Results: Ureters exposed to UPEC’s J96 and C536 showed no overall
decrease in the amplitude of phasic contractions induced by electrical field
stimulation compared to sham and untreated controls but excitability of
the tissues was markedly reduced. The impaired excitability was reversed
by application of 1mM TEA which selectively inhibits BKCa channels.
Carbachol-induced contractions were significantly increased in tissues
exposed to UPEC’s when compared to high-potassium induced controls.
Sham and K12 e.coli treated tissues showed similar high-potassium and
carbachol responses to untreated ureters. Application of the rho-kinase
inhibitor H1152 to UPEC exposed ureters, caused a reversal in the
elevations in carbachol-induced contractions which mimicked responses
seen in control ureters.
Conclusions: Our studies show for the first time the effects of UPEC’s on
the intact contractile machinery of whole live ureters. These studies show that
short exposures to UPEC’s can modulate the excitability of smooth muscle
via a mechanism involving BKCa channels. Furthermore, there are additional
effects of UPEC’s which our studies suggest are mediated in part by rho-kinase
activation. Previous studies suggest that this may be as a result of CNF-1
secretion which constitutively activates the Rho-GTPases; RhoA, Rac1, and
Cdc42 2.
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1470 CELLULAR CHANGES IN SPLEEN OF TRAUMA
DONORS UNDERGOING PROLONGED RESUSCITATION
W.L. Olszewski1,2,3, A. Wluka1, M. Zaleska1, M. Durlik1,2
Department of Surgical Research and Transplantology, Medical
Research Center, Polish Academy of Sciences, Warsaw, Poland, 2Dept. of
Transplantation Surgery, Central Clinical Hospital, Ministry of Internal
Affairs, Warsaw, Poland, 3The Norwegian Radiumhospital-Rikshospitalet,
Oslo, Norway
The morphological and functional condition of spleen of trauma donors has so
far not been thoroughly studied. Donor spleen is frequently used as a source
of lymphocytes for in vitro histocompatibility tests. The knowledge on the
response of spleen and other lymphoid organs to trauma and infections remains
rudimentary.
Aim: To study the cellular composition of the functional areas of human spleen
in trauma patients undergoing prolonged resuscitation.
Material and methods: Twenty spleen specimens from trauma patients,
unsuccessfully resuscitated, serving as organ donors were used. Patients
received routine treatment including fluid replacement, antibiotics, and
pressure-regulating drugs. Phenotypes of cells in various functional regions of
spleen were identified using monoclonal antibodies to T and B lymphocytes,
1
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macrophages, migrating and follicular dendritic cells. Responsiveness to
microbial antigens was studied in culture. Normal spleens obtained from
patients with abdominal trauma and intraoperatively ruptured spleen served
as controls.
Results: Immunohistochemical evaluation. Spleens were depleted of
lymphocytes and erythrocytes. Cell density was 3-5-times less than in controls.
The white pulp contained few CD3 (CD4 and CD8) cells around the arterioles.
There were few CD123 dendritic cells. The CD34 expression on endothelial
cells was downregulated. A number of dendritic-like cells contained cellular
debris. Red pulp had few erythrocytes. The responsiveness of splenocytes
to E.coli, LPS and CpG in a 24 h culture was 5-times less than in controls.
Staph. epidermis did not stimulate splenocytes. Only a few bacteria were
phagocytyzed.
Conclusions: Trauma patients in terminal stages reveal depletion of
splenocytes and their low responsiveness. This observation may partly explain
the mechanism of immune deficiency in traumatized patients and point to the
necessity of mobilizing the stores of immune cells (BMC?). The low in vitro
responsiveness of trauma donor splenocytes may be wrongly interpreted as low
reactivity to recipient transplantation antigens.
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1471 SPLEEN DENDRITIC CELL-ENRICHED POPULATION
INNATE REACTION TO TRANSPLANTATION AND
BACTERIAL ANTIGENS
W.L. Olszewski1,2, J. Stanislawska1, M. Maksymowicz1, M. Moscicka1,
M. Zaleska1
1
Department of Surgical Research and Transplantology, Medical Research
Center, Polish Academy of Sciences, Warsaw, Poland, 2Norwegian Radium
Hospital, Oslo, Norway
Transplants are accompanied by infections that enhance allogeneic reaction
(heterologous immunity) and accelerate rejection.
Aim: To determine ability of bacterial and allogeneic antigens to stimulate
splenic DC.
Methods: DCs were isolated from rat spleen and incubated with
E.coliDH5αpEGF, S.epidermidis, LPS and DNA of E.coli for 24h and isolated
after i.p. E.coliDH5αpEGFP and S.epidermidis, LPS and bacterial DNA for 6
days. Allo- and syngeneic heart, skin and BMC were transplanted. Phenotypes
of cells were identified on flow cytometry.
Results: In culture stimulation of rat splenic DC by E.coli, S.epidermidis,
LPS and CpGDNA caused increase in class II-positive cells and decrease in
percentage of ED1, B cells and OX62 DC. LPS decreased frequency of OX62
and NK cells. In vivo stimulation by E.coli, S.epidermidis, LPS and CpGDNA
increased percentage of class II-positive cells. S.epidermidis decreased ED1,
OX62 and B cell populations. Syn- and allogeneic heart, skin and BMC
transplants caused increase in class II –positive, ED1 and W3/13 cells. OX62
cells did not react, whereas the B cell frequency rose only after allogeneic
transplantation. Mixed culture of DC and donor PBM showed stimulation
of both populations. In vitro and in vivo bacterial stimulation brought about
expression of TLR and Hsp and MLR of DC with donor PBM culture expression
of Hsp 90 but not TLR. Recipient DC produced IFN-γ upon stimulation with
LPS and skin but not heart and BMC. Microbial and allogeneic stimulation did
not increase IL-12.
Conclusions: Bacteria and their components cause decrease of OX62 and
expression of TLR and Hsp. Allogeneic antigens do not evoke evident innate
reaction.
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1472 REVISITING THE ORIGIN OF INTRAGRAFT
FIBROBLASTS: EVIDENCE FOR HETEROGENEITY OF
FIROBLASTS IN CARDIAC ALLOGRAFTS EXPERIENCING
CHRONIC REJECTION
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1473 INTRAGRAFT FIBROBLAST-DERIVED MCSF AND
MCP-1 PARACRINE LOOPS REGULATE MACROPHAGE
RECRUITMENT IN CARDIAC ALLOGRAFTS DEVELOPING
CHRONIC REJECTION
G.D. Wu, Y. He, H. Wang, A. Klein
Cedars-Sinai Comprehensive Transplant Centre, 8635W. 3rd St., Suite 590W,
Los Angeles, CA 90048. U.S.A
Objective: Macrophage colony-stimulating factor (MCSF) is known as
a macrophage survival factor which facilitates monocyte-to-macrophage
maturation and proliferation. MCP-1 is a chemoattractant that mediates
monocyte migration. In previous studies, we have found that intragraft
fibroblasts isolated from rejecting cardiac allografts produce high levels of
MCSF and MCP-1. The current study investigated the effects of MCSF and
MCP-1 paracrine loops produced by intragraft fibroblasts (IF) in monocyte/
macrophage migration and proliferation.
Materials and methods: Intragraft fibroblasts derived from heart allografts
undergoing chronic rejection were examined for production of a panel of pro-
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1474 INFLUENCE OF SYSTEMIC HTK PRECONDITIONING
OF DONORS IN RAT LIVER TRANSPLANTATION
V. Ariyakhagorn1,2, V. Schmitz1, P. Olschewski1, P. Neuhaus1, G. Puhl1
1
Charité Campus Virchow, Department of General Visceral and
Transplantation Surgery, Berlin, Germany, 2Chiangmai University,
Department of Surgery, Chiangmai, Thailand
Introduction: Outcome of liver transplant patients has dramatically improved
over the last decades. Since preservation damage has a significant influence
on subsequent organ function, organ preservation protocols should be further
optimized. Many protective strategies have been shown to be effective against
ischemic injury in animal models. In our study we investigated a protocol
foreseeing intravenous systemic preconditioning of the donor using the wellestablished preservation solution HTK in a model of rat liver transplantation.
Methods: Rats were divided into two groups. In the study group, 15 minutes
prior to organ procurement, donors were preconditioned with systemic
intravenous infusion of warm HTK (0.01ml/g body weight). The same amount
of saline was given in the control group. After organ procurement with cold
HTK, livers were stored at 4ºC for 6 hours and reflushed with cold saline
prior to implantation. Recipients were sacrificed after 4 hours, 2 and 5 days
following transplantation to obtain liver function parameters (Bilirubin, ASAT,
ALAT, LDH) and histology. For each time point in each group a total of 6 liver
transplantations were performed (total number 36).
Results: Four hours after transplantation, serum transaminases ASAT
(1900±1200U/L; p= 0.015), ALAT (789±330U/L; p=0,005) and LDH
(5938±4415; p=0.035) were significantly lower after HTK preconditioning
compared to the control group (ASAT: 3800±1900/ ALAT: 2500±1100/
LDH: 17380±10346U/L). However, at later time points (2 and 5 days),
values normalized and there was also no difference in regard of serum
bilirubin during the entire observation period. Survival was 100% for both
groups. For all time points, based on a semiquantitative score from 0-3, liver
endothelial cells were less damaged following donor pre-treatment with HTK,
whereas hepatocellular damage did not differ microscopically between the
groups.
Discussion: Our data shows that in a rat liver transplantation model,
preconditioning of the donor with HTK has a beneficial influence on the negative
effects of ischemia/reperfusion injury. Reduction of histological damage and
enzyme release were found at an early period after transplantation without any
adverse reaction to either the donor or the recipient animals. Further studies are
warranted to elucidate the exact mechanisms.
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G. Wu, H. Wang, Y. He, A. Klein
Cedars-Sinai Comprehensive Transplant Centre, 8635W. 3rd St., Suite 590W,
Los Angeles, CA 90048. U.S.A
Objective: A major development in fibrosis research is the recognition that
myofibroblasts, which are considered as the terminally-differentiated scarcontracting cells can originate from several distinct progenitor cells. The
development of this new concept warrants a critical investigation into the
progenitor source of intragraft fibroblasts, which was once considered to only
be phenotypically mesenchymal.
Materials and methods: A rat model of allograft fibrosis involving the use of
a male F344 rat as the recipient of cardiac allograft from a female LEW rat was
studied. The cellular sources of intragraft fibroblastic cells (IFC) were qualified
using qPCR detection of Y chromosome using DNA primers specific for the
sry gene. The phenotype of IFC was studied using cell surface markers with
flow cytometry and quantitative real time PCR. Myofibroblast differentiation
potential was examined in fibroblast cultures.
Results: qPCR demonstrated that approximately 70% of IFC isolated from
chronically rejecting cardiac allografts was sry+, indicating that the majority of
intragraft fibroblasts are of recipient origin whereas the minority but considerable
numbers of IFC were donor-derived fibroblasts. The population of intragraft
fibroblastic cells includes both a CD45+ and a CD45- subset. The CD45+ subset
expressed a phenotype CD34/CD45/αSMA/Collagen-1, which is consistent with
the description of fibrocytes. The CD45- subset expressed a phenotype typical
of conventional fibroblasts. Dramatic changes in the proportions of CD45+
and CD45- IFC was observed in fibroblast cultures. About 60% of intragraft
fibroblastic cells were CD45+ at 24 hours in cultures and the positive cells
decreased to 30% at day 4, 10-15% at day 7 and <1% at day 14 of cultures while
CD45-negative fibroblasts increased inversely and proportionally, indicating
that either the CD45+ IFC rapidly transit to CD45- fibroblasts or alternatively,
massively undergo apoptosis while the CD45- cells proliferate swiftly. In
fibroblast cultures stimulated with FGF2 and TGF-β, the CD45+ fibroblastic cells
exhibited differentiation potential to become αSMA-expressing myofibroblasts.
On the other hand, the CD45- intragraft fibroblasts readily expressed high levels
of stress filaments containing α-actin, indicating that these cells may derive from
mesenchymal progenitors of bone marrow origin.
Conclusion: Taken together, the data demonstrate that intragraft fibroblasts
are heterogeneous in origin. They may come from cardiac resident fibroblasts
or/and recipient-derived progenitors. The latter may originate from CD45+
fibrocytes or/and CD45- mesenchymal progenitors from the bone marrow. The
donor-type myofibroblasts, on the other hand, may result from transition from
vascular endothelia or cardiomyocytes under persistent tissue hypoxia during
chronic rejection.

inflammatory / fibrosis cytokines, including MCSF and MCP-1. The effects of
MCSF and MCP-1 produced by IF, and consequential monocyte/macrophage
migration and proliferation were studied using a fibroblast-macrophage coculture system and a siRNA inhibition assay.
Results: Quantitative real-time PCR demonstrated that fibroblasts from
chronically rejecting allografts significantly increased expression of MCSF
as well as MCP-1 when compared with that from isografts control (p<0.01,
respectively). In serum-free condition culture, PDGF, a fibrogenic cytokine
abundantly present in chronic rejection was able to up-regulate MCSF and
MCP-1 expression by IF (p<0.05 and 0.01 respectively). In co-cultures,
intragraft fibroblasts were able to activate the macrophage cell line RN8383,
as demonstrated by significant increases in expression of MCP-1 receptor
CCR2 and MCSF receptor c-fms. The MCSF paracrine effect on macrophage
proliferation was antagonized by treatment of the IF with siRNA against
MCSF. On the other hand, treatment of the cultures with siRNA MCP-1
resulted in suppressed MCP-1 secretion by IF and decreased CCR2 expression
by RN8383 cells, resulting in significant decrease in chemotactic migration of
the macrophages (p<0.05).
Conclusion: Mononuclear cell infiltration and fibroproliferation in chronicallyrejecting allografts are regulated by a complex network of pro-fibrogenic/
inflammatory cytokines. This mechanistic study suggests that a pathway
involving PDGF, MCSF, MCP-1 and their receptors play an important role in
the pathogenesis of chronic rejection.
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1475 BENEFICIAL EFFECTS OF HYPERBARIC OXYGEN
PRETREATMENT ON MASSIVE HEPATECTOMY IN AN
EXPERIMENTAL RODENT MODEL
H. Mori1, M. Shimada2, G. Nowak1, B-G. Ericzon1
1
Division of Transplantation Surgery, CLINTEC, KAROLINSKA
INSTITUTET, Karolinska University Hospital Huddinge, Stockholm, Sweden,
2
Department of Surgery, The University of Tokushima Graduate School,
Tokushima, Japan
Background: The purpose of this study was to investigate the impact of
hyperbaric oxygen (HBO) pretreatment in an extensive hepatectomy model, a
surrogate model of small-for-size graft, using rats.
Methods: (Experiment I) Rats were divided into the following four groups:
HBO (-), HBO-1D (day), HBO-3D, and HBO-5D. Samples were taken after
the completion of HBO pretreatment and the following parameters were
evaluated; RT-PCR and immunohistochemical staining for heat shock protein
(HSP 70 and HO-1); biochemical parameters; and liver weight to body
weight ratio (Lw/Bw ratio). (Experiment II) Rats were divided into four as
follows; 70% hepatectomy (Hx), 70%Hx-HBO, 90%Hx, and 90%Hx-HBO
group. Samples were taken 12, 24, 48 and 72 hours after hepatectomy and the
following parameters were investigated: biochemical analysis; Lw/Bw ratio;
PCNA labeling index; and survival.
Results: (Experiment I) The expression of HSP70 mRNA was significantly
increased in the HBO-3D group compared with the HBO (-) group (P<0.05).
HSP70- and HO-1-positive hepatocytes were significantly increased in the
HBO-3D group compared with the HBO (-) group (P<0.05). (Experiment II)
Transaminases were significantly decreased in both 70% and 90%Hx-HBO
groups compared with Hx alone group (P<0.05). The Lw/Bw ratio and PCNA
labeling index of the 90%Hx-HBO group were significantly increased compared
with the 90%Hx group, 24, 48 and 72 hours after hepatectomy (P<0.05). The
survival rate in the 90%Hx-HBO group was significantly higher than that in the
90%Hx group (P=0.01).
Conclusions: HBO pretreatment had beneficial effects in an extensive
hepatectomy model in rats via the induction of HSP70 and HO-1.

POSTER BOARD NUMBER P2 – 275
1476 PROTECTION OF PANCREATIC ISLETS FROM
IMMUNE-MEDIATED DESTRUCTION BY OVEREXPRESSION
OF DOMINANT NEGATIVE HUMAN FAS IN BETA CELLS
K. Graham, H.E. Thomas, L. Mariana, T.W. Kay
St Vincent’s Institute, 9Princes Street, Fitzroy, 3065, Australia
Protection of islet beta cells from immune-mediated destruction is important
in the goal to improve islet transplantation outcome. Both allogeneic and
autoreactive cytotoxic T lymphocytes can use the Fas death receptor as
a mechanism of killing beta cells. While global deficiency of Fas leads
to dysregulated immune homeostasis in mice and humans, blocking Fas
only on beta cells has potential for prevention of immune-mediated beta
cell damage. We developed a model where dominant negative human Fas,
derived from a patient with autoimmune lymphproliferative syndrome, is
overexpressed in beta cells under control of the rat insulin promoter (RIPhFas). Several studies using different approaches have suggested that
preventing Fas-FasL interaction on beta cells has only a modest effect on
beta cell destruction and type 1 diabetes. Surprisingly, our RIP-hFas mice
are significantly protected from spontaneous type 1 diabetes. Fas can be
cleaved from the cell surface and evidence suggests this occurs in RIPhFas mice. Soluble Fas is detectable by ELISA in supernatants of RIP-hFas
islets cultured in vitro. Preliminary evidence suggests that antigen-specific
CD8+ T cells labelled with CFSE proliferate in the pancreatic lymph node
and islets of RIP-hFas mice, but the number of divisions that these cells
undergo may be reduced. We hypothesize that production of mutant Fas in
beta cells and its release into the local environment has inhibitory effects on
immune cells. Our data suggest that systemic administration of soluble Fas
or encapsulation of islets in the presence of soluble Fas are strategies that
may be employed in islet transplantation without the need for transgenic
islets. Therapeutics based on members of this receptor family (eg TNF
receptors) are in clinical use.
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1477 PREVENTION OF KIDNEY ISCHEMIA-REPERFUSION
INJURY: ROLE OF P38 MAP KINASE INHIBITION
P. Gehwolf1, N. Fischler1, R. Oberhuber1, C. Margreiter1,2, R. Öllinger1,2, S.
Schneeberger1,2, G. Brandacher1,2, J. Troppmair2, R. Margreiter1,2, R. Sucher1,2
1
Daniel Swarovski Research Laboratory, 2Department of General and
Transplant Surgery, Innsbruck Medical University
Introduction: Ischemia (I) and reperfusion (R) causes complex changes to
the graft during solid organ transplantation. Cell death, metabolic alterations
and inflammation result in impairment of short- and long term function. Cells
respond to extracellular signals by transmitting intracellular instructions to
coordinate appropriate responses. The group of mitogen activated protein
kinases (MAPKs) was implicated through aberrant activation in many settings
including I/R-associated organ damage. Although MAPKs are known as critical
proteins in cell signaling their role during I/R is controversially discussed.
Material and methods: To asses intracellular signaling and kidney function a
rat ischemia reperfusion model was used. Ischemic renal injury was induced by
clamping the left renal artery for 45 min in male Wistar rats immediately after
right-side nephrectomy. Reperfusion was studied at R0 (no reperfusion), 15min
(R1), 2hours (R2) and 7days (R3). Sham operated animals served as controls.
Renal function was determined by plasma creatinine/urea. MAPKs (ERK,
JNK, p38) activation was analysed using phosphorylation specific antibodies.
Results: In summary, reoxygenation was characterized by a dramatic
increase in the activity of ERK (p<0.05, JNK (p<0.05) and p38 (p<0.0001)
during early reperfusion. This was associated with a significant raise in
creatinine and urea. Data suggest that the use of small molecular weight p38MAPK inhibitors (SB 203580 and SB 239063) have a beneficial effect on
the ischemia reperfusion injury, showing a decrease in creatinine and urea as
assessed 24 hours after reperfusion.
Conclusion: Renal I/R injury is associated with a significant increase in MAPK
activity. Isolated p38 MAPK inhibition during ischemia improves kidney
function suggesting that p38 may provide a promising target for ameliorating
reperfusion injury.
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1478 TOLL-LIKE RECEPTOR 4 MEDIATES HEPATOCYTE
APOPTOSIS AND ACUTE LIVER FAILURE AFTER
INTRAPERITONEAL D-GALACTOSAMINE/LPS IN MICE
T. McKenzie1, J. Lillegard1, J. Luebke-Wheller3, G. Brunn3, S. Nyberg2
Department of Surgery, Mayo Clinic, 2Department of Transplant Surgery,
Mayo Clinic, 3Department of Transplantation Biology, Mayo Clinic
The purpose of this study was to elucidate the mechanistic role of TLR4 in the
development of D-galactosamine (GaIN)/lipopolysaccharide (LPS) induced acute
liver failure. TLR-mutant (C3H/HeJ) mice with non-functional TLR4 and TLR4
wild-type control (C3H/HeN) mice were studied after intraperitoneal injections of a
lethal dose of GaIN/LPS (1000mg/kg and 250mcg/kg) simultaneously (n=8/group).
Animals were electively sacrificed at 6 hours post injection of GaIN/LPS. Liver
injury was assessed by examining gross morphology, histopathology, quantifying
apoptosis using in situ terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling assay (TUNEL) stain, and measuring serum ALT measurement
at 6 hours. Clinical status was determined both prior to injection and 6 hours post
injection. We found that hepatic injury of the mutant animals with non-functional
TLR4 was greatly attenuated when compared to wild-type controls. 6 hours post
injection of GaIN/LPS, the mutant mice were clinically healthy, without evidence
of illness. In contrast, wild-type controls appeared moribund with limited activity
and minimal response to stimuli. Mean ALT levels of TLR4 deficient mice and
wild-type controls were 707 and 6006 U/L, respectively (p<0.001, normal 7-55
U/L). The wild-type control livers appeared non-viable on gross exam, while the
TLR4 deficient livers appeared grossly normal. Consistent with previous studies,
massive hemorrhage and necrosis were seen on histologic examination of the wildtype control livers by hematoxylin and eosin staining. Microscopic examination
of TLR4 deficient livers demonstrated minimal hepatic parenchymal damage,
consistent with this group’s lower levels of serum ALT and non-impaired clinical
status. TUNEL stain demonstrated a decreased number of apoptotic nuclei among
the TLR4 deficient mice when compared to wild type control mice, 88.0 +/- 41.2
and 185.1 +/- 39.8 TUNEL positive nuclei/40x field, respectively (p=0.01). The
1
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percent TUNEL positive nuclei of total nuclei for each group was 14.6 and 29.4%,
respectively (p=0.01). Furthermore, the TLR4 deficient livers displayed less
inflammatory cell infiltrate. The present study demonstrates the marked decrease
of hepatocyte apoptosis and attenuation of acute hepatic failure in mutant mice
with non-functional TLR4 when compared to wild-type controls. Apoptosis and
parenchymal damage of TLR4 mutant livers after GalN/LPS suggests another,
possibly direct, secondary pathway of injury. In conclusion, TLR4 is implicated as
a pivotal receptor in GaIN/LPS induced apoptosis and acute liver failure in mice.
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1479 SIALIC ACID DYNAMICS BEFORE AND AFTER
COLLAGENASE ISOLATION OF PANCREATIC ISLETS WITH
POTENTIAL IMMUNOLOGICAL EFFECTS
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1480 NK CELL STIMULATORY RECEPTORS AND LIGANDS
ARE INDUCED IN LIVER ALLOGRAFTS EARLY POSTTRANSPLANTATION
S. Krams, M. Fujiki, M. Zhuo, L-E. Wai, C. Esquivel, O. Martinez
Transplant Immunobiology Lab, Division of Transplantation, Department of
Surgery, Stanford University
Background: Numerous studies suggest a role for NK cells in acute and
chronic allograft rejection. NK cells express a variety of stimulatory receptors
that, upon binding to their ligands, activate and/or regulate effector function.
However, the expression and functional significance of NK cell stimulatory
receptors and ligands in the alloimmune response remain unclear. Tumor
necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is known to
be expressed by NK cells in the liver and can participate in effector function.
Similarly, NK cells are a major source of IFNγ early post-transplant. The aim
of this study was to determine the expression of receptors that can stimulate
effector function of NK cells and their ligands post-transplantation.
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1481 PROPAGATION OF A UNIQUE V 1-BEARING T CELLS
CLONE WITHIN GRAFT INFILTRATES OF HUMAN LIVER
TRANSPLANTATION TOLERANCE-IMMUNOPRIVILEGED
LIVER SPECIFIC ?Y. Li1, Y. Tanaka2, J. Pirenne3, N. Minato2, T. Koshiba1
Innovation Center For Immunoregulation Technologies And Drugs, Graduate
School of Medicine, Kyoto University, 2 Department of Immunology and
Cell Biology, Graduate School of Medicine, Kyoto University, 3 Abdominal
Transplant Surgery Department, University Hospital Leuven
Background: TCRVƒÂ1 ƒÁƒÂT cells (VƒÂ 1 cells) was reported to function
as suppressors against allo-response during normal pregnancy and therefore, to
be responsible for fetomaternal tolerance. We reported that VƒÂ 1 cells, which
represent a minor subset of T cells in normal individuals, predominate over
VƒÂ 2bearing T cells (VƒÂ 2 cells) in peripheral blood of tolerant patients after
liver transplantation (LTx) (Am. J. Transplant, 2004, 4: 2118). This implies
that there may be a common feature between fetomaternal tolerance and Ltx
tolerance (Transplant Immunol, 2007, 17: 94). We further examined LTx
tolerant patients for VƒÂ 1 cells/VƒÂ2 cells (VƒÂ 1/VƒÂ 2) ratio and sequence
in VƒÂ 1 TCR chains in graft infiltrates. To elucidate whether VƒÂ 1 cells
are responsible for immunoprivilege of LTx, highly immunogenic intestinal
Tx (ITx) was studied in addition. (Method) Protocol biopsy was performed in
patients whose grafts were functioning well despite the absence of or minimum
immunosuppression after LTx (N= 9) and intestinal Tx (ITx) (N=4) (GrTol). Total RNA was extracted to synthesize cDNA. V ƒÂ1 and V ƒÂ2 gene
expressions were quantified by real-time PCR, and CDR3 sequence in V ƒÂ1
TCR chains was analyzed. The results were compared to those of removed
graft as a result of chronic rejection (Gr-CR N= 7) and normal liver i. e. donor
zero biopsy (Gr-Nor N=6) in LTx and native intestines of the patients (Gr-Nat
N=3) in ITx. Sampling of intestinal grafts and native intestines was repeated
twice within one year interval since the number of the ITx patients was small.
Results: LTx; VƒÂ 1/V ƒÂ2 ratio was the highest in Gr-Tol, compared to those
in Gr-CR and Gr-Nor (Gr-Tol, Gr-CR, and Gr-Nor; 0. 074 } 0. 063, 0. 012 } 0.
015, and 0. 021 } 0. 043. Gr-Tol vs. Gr--Nor, p<0. 05, Gr-tol vs. Gr-CR, p<0.
01). All the 9 recipients in Gr-Tol exhibited a common sequence among several
CDR3 sequences of VƒÂ1 cells. In Gr-Tol, this sequence predominated over
other sequences in 6 of 9 recipients. In contrast, the identical sequence which
all the recipients in Gr-Tol was not observed in any recipient of Gr-CR, while it
was observed in 5 of 6 samples in Gr-Nor. However, in Gr-Nor, this sequence
predominated over other sequences in only 1 sample. ITx; Unlike LTx, there
was no difference between Gr-Tol and Gr-Nat with respect to VƒÂ 1/V ƒÂ2
1
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S. Hyon2, L. Gimeno2, C. Bernard2, P. Argibay2
Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos
Aires, 2Instituto de Ciencias Basicas y Medicina Experimental, Hospital
Italiano de Buenos Aires
Introduction: Host immune response has precluded clinical islet transplantation
from becoming a consistent therapy for type 1 diabetes. Enzymatic and mechanical
digestion of pancreatic tissue for islet isolation may affect the molecular
structure of cell surface. Sialic acid is a nine-carbon monosaccharide with a great
natural diversity, being N-acetyl neuraminic acid the most common form. It is
ubiquitously distributed on the surface of cells and certain microorganisms and
may play a crucial immunological role in a variety of biological settings.
Objective: To assess the presence of a variety of sialic acid molecules in the
endocrine as well as the exocrine tissue of whole pancreas and the potential
modifications occurring upon isolation of pancreatic islets.
Methods: Fresh pancreas and pancreatic islets were obtained from 6 to 8 weekold, male C57BL/6 mice. Tissue and cells were fixed in Bouin’s solution and 4%
formalin; paraffin embedded, and cut in 4-micron thick slices. The presence of
different terminal N-acetyl forms and other monosaccharides were assessed by
specific ligands. For this purpose, lectins used were Aleuria aurantia, Erithrina,
Maakia amurensis, Sambucus nigra agglutinin, Peanut agglutinin, sWGA, WGA,
VVL, GNL, GSL-II, and lotus; revealed with the fluorescent dye FITC and
observed under a fluorescence microscope. Mice colon and nervous tissue were
used as positive controls while negative controls were done with PBS. Results.
No changes were observed for WGA, VVL, GNL, GSL-II, or lotus on pancreatic
islets and acinar cells before and after the isolation process. However, the following
modifications were observed: sialic acid with alpha 2-3 and alpha 2-6 unions were
lost both from islets and acini; sialic acid alpha 2-6 galactose unions were preserved
on islets but lost on acinar tissue; galactosyl (beta 1-3) N-acetyl galactosamine
was detached from islets but not from acini; and terminal N-acetyl glucosamine
without sialic acid were lost from both islets and acinar cells as revealed by Maakia
amurensis, Sambucus nigra, Peanut agglutinin, and sWGA lectins, respectively.
Conclusions: Enzymatic and mechanical factors occurring during islet
isolation produce changes on the molecular structure of endocrine as well as
exocrine pancreatic tissue. This phenomenon may cause a critical effect on the
immunogenicity of cells obtained for transplantation.

1

Methods: Lewis recipients were transplanted either with fully allogeneic donor
DA rat livers or syngeneic Lewis rat livers. The stimulatory receptors, NKp30,
NKp46, NKG2D were analyzed by quantitative real-time PCR (q-PCR). TRAIL
receptor expression was evaluated by flow cytometry and q-PCR. We cloned
two rat NKG2D ligands (RAE-1L and Rat RAE-1 like transcript (RRLT)) and
graft expression of these ligands was analyzed by q-PCR. IFNγ expression and
production were determined by both q-PCR and ELISA.
Results: NKp30 expression is detected very early post-transplant and is
specifically increased in allografts by the first day post-transplant. NKp30
mediates NK cell interaction with dendritic cells and contributes to induction
of IFNγ. The stimulatory receptors NKp46 and NKG2D are increased in
allografts, but not syngeneic grafts, by day 3 post-transplant and expression
strongly correlated with IFNγ levels in both the graft and periphery. TRAIL
expression on NK cells is upregulated in allografts on day 3 but is diminished
by day 7 post-transplant. RAE-1L expression is silent in the liver and is not
increased post-transplantation. However, expression of the NKG2D-ligand,
RRLT is induced in the liver post- transplantation and is specifically increased
in liver allografts at day 7 post-transplant.
Conclusion: Our data demonstrate the concomitant expression of NK
stimulatory receptors and induction of the RRLT ligand early post-transplant.
These data suggest that NK cells are activated early in liver allografts, and
may be a functional link between innate and adaptive immunity posttransplantation.
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ratio. Any common sequence was observed among patients in Gr-Tol.
Conclusions: A unique V 1 T cell clone propagated within tolerant liver graft but
not tolerant intestinal graft. We hypothesize that this propagation is liver-antigenselected and associated with a mechanism of immunoprivilege of liver Tx.
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1482 IMMUNOCOMPETENCE OF CANINE HEMATOPOIETIC
CHIMERAS WITH LONG-TERM RENAL ALLOGRAFTS
P.J. Horton1, W.J. Hawthorne2, T. Patel2, S. Walters2, G.J. Stewart2,
R.D.M. Allen2, J.R. Chapman2
1University of Rochester Medical Center, , 2Centre for Transplant & Renal
Research, Westmead Millennium Institute,
Background: We developed a pre-clinical model of mixed hematopoietic
chimerism (MC) using 18Gy fractionated total lymphoid irradiation (TLI) and
unfractionated donor bone marrow (BM) to induce tolerance in dogs. TLI alone
can suppress the immune system long-term
Aim: To study immune responses in canine hematopoietic chimeras that had
accepted renal allografts from dog-leukocyte antigen (DLA)-DP matched, class
II compatible BM donors for more than one year without immunosuppression.
Materials and methods: Five female hematopoietic chimeras were compared
to their five male DP-matched donors and also to five male and five female DPmatched 3rd party dogs. Techniques used included flowcytometric analysis of
lymphocyte subsets, lymphocytotoxicity assay (LCA) and mixed lymphocyte
culture (MLC). Delayed type hypersensitivity (DTH) testing was also
performed using a standard panel of antigens including tetanus, streptococcus,
tuberculin, candida, trichophyton and proteus.
The four hematopoietic chimeras and the donors were inoculated intraperitoneally
with macerated intra-peritoneal lymph nodes taken from DP-matched 3rd party
dogs. Each dog received three lymph node inoculations injected at two weekly
intervals. LCAs were performed before and after each inoculation.
Results: There was no difference between the complete blood counts and
differential cell counts measured in peripheral blood taken from the four groups
of dogs. Lymphocyte staining for CD3, CD4, CD8a, CD8b, CD21, CD45,
CD45RA and class II antigen was not different. Lymphocytes from tolerant dogs
proliferated normally in response to mitogens and stimulation by alloantigen.
DTH testing revealed normal wheel and flare response in three out of four
hematopoietic chimeras. The immune response in the fourth dog was relatively
reduced but still present. Each lymph node inoculation contained median 5. 1
x108 cells (range 1. 5 to 12. 9). All dogs were sensitized after one lymph node
inoculation and the humeral response as determined by the dilution titer was
greater in three out of the four female chimeras that their respective male donor.
Conclusion: No evidence of an impaired immune response was found in the
hematopoietic chimeras more than one year following the TLI. The absence of
donor-specific alloantibody supports the assertion that true tolerance had been
induced in chimeric dogs.
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1483 EFFECT OF DONOR BONE MARROW CELLS INFUSION
ON ALLOIMMUNIZATION AND KIDENY ALLOGRAFT
OUTCME
B. Nikbin1, A. Amirzargar1, M.H. Nicknam1, G. Pormand2, A. Mehrsai2,
M. Taheri2, E. Rad1, M. Seraji2, M. Moheydin1, G. Solgi1
1Molecular Immunology Research Center, Faculty of Medicine, Tehran
University of Medical Sciences, 2Urology Research center, Sina Hospital,
Tehran University of Medical Sciences
Objectives: The aim of this study was to investigate the role of donor bone
marrow cells infusion in post transplantation anti-HLA antibody induction and
outcome of kidney allograft patients.
Methods: a total of 40 living unrelated donor primary kidney transplant; 20
recipients with Donor Bone Marrow Cells infusion (2. 1× 109 ±1. 3×109
MNCs/body including 3. 5× 107 ±1. 6×107 CD34+ progenitor cells) and 20
without infusion as control, were entered into study and followed prospectively
for one year. Both groups received the same baseline immunosuppressant
consisting triple drug regimen (cyclosporine A, MMF and prednisolone). WBC
cross match, Panel Reactive Antibody and HLA-DNA typing were performed
for all patients before transplantation. Pre and post transplant sera samples (day
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14, 30, and 90) were screened for the presence of anti-HLA class I and class II
antibodies, and subsequently antibody specificity was determined for positive
patients by ELISA method.
Results: All patients from both groups had a negative pre-transplant WBC
cross match. A lower incidence of acute rejection (AR) (30% vs. 40%), and
less post-transplant percentage of PRA (27. 2% vs. 36. 7%), as well as lower
average serum creatinine in patients with AR (2. 41 vs. 4. 0 mg/dl during first
3 months post operatively, P=0. 13) were found in DBMI patients compared
to controls.
Almost all patients with AR had a pre-transplant anti-HLA antibody in both
groups. On the other hand about 50% in DBMI and 36. 3% in control had
pretransplant antibodies without acute rejection. Post transplant antibody
production and episodes of acute rejection was the same in both groups.
The presence of post transplant Donor Specific antibody (DSA) in patients with
acute rejection was nearly the same in DBMI and control groups (33. 3% vs.
37. 5% respectively). A significant correlation was found between AR and DGF
in control patients (P=0. 005).
Conclusions: Despite the small number of patients, the lower number of
infused cells, and shorter period of follow up (meanly one year), our results
indicate that DBMC infusion didn’t sensitize the recipients and additionally it
has some tolergenic effects on anti donor immunity.

POSTER BOARD NUMBER P2 – 283
1484 IMPACT OF CREG MATCHING AND INCIDENCE OF
ANTI-HLA DONOR SPECIFIC ANTIBODY IN TOLERANT
LIVER RECIPIENTS AND CONTROLS
R. Cirocco, P. Tryphonopoulous, D. Weppler, K. Tomaki, J. Moon, D. Levi,
G. Selvaggi, C. Ricordi, P. Ruiz, A. Tzakis
University of Miami School of Medicine
In an attempt to understand the role of pharmacological immuno-supression
in liver transplant tolerance, we followed twenty-two tolerant transplant
patients that were weaned off of immuno-suppresive drugs and thirty controls
(on immunosupresive drugs) The recipients were studied ten years post liver
transplantation. The patients were analyzed for their HLA Cross Reactive
antigen Group (CREG) match (donor and recipient). In addition, we looked
for the presence of donor specific anti-HLA antibodies. These findings may
elucidate why certain patients are tolerant (i. e. off immunosuppressive
therapy) and others are not (controls on immuno-suppressive drugs). HLA
matching is thought not to improve graft survival. In the CREG analysis most
HLA-B and HLA-C antigens fell into expected groups representative of a
normal population. In the tolerant recipients 12 had both HLA-A antigens
in the A-1 CREG with 22 donors having both alleles in the A-1 CREG
versus the controls, 19 in the A1, 8 in the A-2 and ten had one antigen in
both A-1 and A-2 CREGS. These data demonstrated a difference with a
significance of p = 0. 02. All the other CREG analysis were not significant.
In the tolerant recipients; two produced anti-HLA donor specific antibodies
out of ten demonstrating any anti-HLA antibodies (20%). In the controls
fifteen demonstrated anti-donor specific HLA antibodies out of twenty-five
producing anti-HLA antibodies (60%). In conclusion: 1) The matching
of liver recipient and donors for CREGS may improve graft survival, 2)
The tolerant recipients produce less anti-donor HLA antibodies than the
controls, and 3) It is surprising that in these transplant patients, the lack of
immunosupression resulted in a blunted or reduced humoral response i. e.
less anti-HLA antibody production in general as compared the immunosuppressed recipients, demonstrating true long term tolerance to mismatched
HLA antigens on the graft.
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1485 TOLERANCE INDUCTION TO ABO BLOOD GROUP
ANTIGENS BY USING AUTOLOGOUS LYMPHOCYTES
ENGINEERED TO EXPRESS THE COGNATE ANTIGEN

POSTER BOARD NUMBER P2 – 285
1486 A CELL-BASED APPROACH TO THE MINIMISATION OF
IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION
M. Schulze1, J.A. Hutchinson1, B.G. Brem-Exner1, P. Riquelme1, D. Roelen2,
A. Sotnikova1, L. Renders1, E. Geissler3, U. Kunzendorf1,
F. Fändrich1
1University Hospital of Schleswig-Holstein, Kiel, Germany, 2Leiden
University Medical Center, the Netherlands, 3Regensburg University
Hospital, Regensburg, Germany
Transplant Acceptance-inducing Cells (TAICs) are a type of immunoregulatory
macrophage with the capacity to specifically suppress allogeneic T cell responses.
Five recipients of kidney transplants from living donors were preoperatively
treated with TAICs in a Phase-I clinical trial. Following transplantation, these
patients received ATG induction therapy in combination with tacrolimus and
steroid immunosuppression. Over the course of the subsequent twelve weeks,
steroids were withdrawn and tacrolimus therapy was minimised. Three of the
six patients were able to tolerate low-dose tacrolimus monotherapy and one

POSTER BOARD NUMBER P2 – 286
1487 ECONOMIC IMPACT OF TOLERANCE INDUCTION
BY COMBINED KIDNEY AND BONE MARROW
TRANSPLANTATION
T. Kawai, D. Sachs, T. Spitzer, N. Tolkoff-Rubin, M. Sykes, M.L. Farrell,
R. Colvin, A.B. Cosimi
Massachusetts General Hospital
Background: The primary benefits anticipated following successful induction
of allograft tolerance are avoidance of the complications of long-term
immunosuppression and prevention of chronic rejection. We have previously
reported successful induction of renal allograft tolerance in recipients of HLA
mismatched combined kidney and bone marrow transplantation (CKBMT).
No evidence of chronic rejection has been observed in these recipients after
immunosuppression-free periods of 1 to 4 years. In the current study, we have
evaluated the longer-term economic impact of this approach.
Method: The conditioning regimen for CKBMT included cyclophosphamide,
thymic irradiation, anti-CD2 mAb, and a calcineurin inhibitor, which was
discontinued after 9-12 months. 18 stable renal transplant recipients receiving
ongoing triple or double drug immunosuppressive therapy with compatible
follow up times were compared with the four tolerant recipients. Tolerant
patients and stable patients on maintenance immunosuppression were also
comparable with respect to their age, their original disease and donor-recipient
histocompatibility.
Results: The perioperative charges for CKBMT were approximately $90, 000
higher than those for conventional living donor kidney transplantation. After
9-12 months, continuing medications in CKBMT recipients included only
occasional over-the-counter analgesics. In contrast, the stable conventionally
treated were taking an average of 8 pills daily. These included treatments
required for de novo diabetes (11%), hypertension (67%), hyper lipidemia
(22%) and gastro-intestinal symptoms/prophylaxis (78%) in addition to their
maintenance immunosuppression. These needs resulted in annual maintenance
charges of over $15, 000/year/allograft recipient and do not include unmeasured
costs related to issues such as quality of life or absences from employment.
Conclusion: Even with this admittedly expensive approach to tolerance
induction, the overall medical costs for conventional kidney transplantation
with ongoing immunosuppression and treatment for complications will exceed
the cost of tolerance after approximately 5 years.

POSTER BOARD NUMBER P2 – 287
1488 PROPAGATION OF COMMON MARMOSET MONKEY
(CALLITHRIX JACCHUS) DENDRITIC CELLS (DC) USING
GROWTH FACTOR MOBILISED DC PRECURSORS AND
IDENTIFICATION OF STABLY IMMATURE DC FOR PRETRANSPLANT CELLULAR IMMUNOTHERAPY
S. Prasad1,2, S. Kireta1, E. Leedham1, G. Russ1,2, P. Coates1,2,3
1
Transplant Immunology Laboratory, Department of Nephrology and
Transplantation Services, The Queen Elizabeth Hospital, Woodville,
Australia, 2Department of Medicine, University of Adelaide, Adelaide,
Australia, 3Center for Stem Cell Research, University of Adelaide, Adelaide,
Australia
Background: Pre-transplant treatment with donor immature DC in small animal
models prolongs allograft survival in the absence of immunosuppression, but
requires further evaluation in non-human primates (NHP) before clinical
application. The common marmoset is a New World NHP. Due to its small size
(<400g) and easy breeding, It has lower maintenance requirements and costs
compared to larger NHP, while retaining substantial immunological similarities
with humans. We characterised marmoset DC to identify potentially tolerogenic
DC subsets for transplant studies in this novel model.
Methods: Sequence-based genotyping of Caja-MHC DRB was performed on
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H. Ogawa1, T. Kobayashi2, A. Onishi3, M. Iwamoto4, Y. Miwa2, D. Liu2,
K. Kadomatsu2, U. Galili5
1Obihiro University of Agriculture And Veterinary Medicine, 2Nagoya
University School of Medicine, 3National Institute of Agrobiological Sciences,
4Prime Tech LTD, 5University of Massachusetts Medical School
Objectives: ABO-incompatible transplantation is performed worldwide
because of donor paucity and availability of living donors with mismatched
ABO blood group antigen. Despite removal of anti-A or anti-B antibodies
prior to transplantation and immunosuppression, graft rejection can occur by
antibodies elicited against the incompatible blood group antigen. We have been
developing a gene therapy method to induce tolerance to B cells that produce
antibodies to carbohydrate antigen by using autologous lymphocytes engineered
to express the cognate antigen (Blood 2003, 101: 2318; Transplantation 2004,
77: 366; Gene Therapy 2004, 11: 292). The objective of this study is to
elucidate the efficacy of the method in inducing B cell tolerance to ABO blood
group antigens.
Method: Using Nucleofector (Amaxa), mouse spleen lymphocytes and
baboon peripheral blood lymphocytes were co-transfected with human A
or B (A/B) transferase and human H transferase genes, which encode the
gene synthesizing blood group A/B antigen and O antigen, respectively.
The transfected lymphocytes were in vitro cultured, and the expression of
A/B antigen on the lymphocytes was analyzed by flow cytometry. In order
to induce tolerance to A/B antigen in mice, the transfected lymphocytes were
intravenously administered into syngeneic mice 4~5 h post transfection. The
injection was repeated 4 times in 3-4 day intervals. Then, the mice were weekly
immunized 4 times with human blood type A/B red cell membranes, and the
production of antibodies against A/B antigen was analyzed by ELISA.
Results: Mouse lymphocytes expressed A/B antigen following the transfection
with both of H transferase and A/B transferase genes but not with A/B transferase
gene alone. The proportion of cells expressing the antigen was approximately
2% of the viable cells cultured in vitro for 24 h (65% viability). Control mice
intravenously administered with mock-transfected lymphocytes developed antiA/B antibodies in high titers following the immunizations with human red cell
membranes. In contrast, the mice received lymphocytes engineered to express
A/B antigen were tolerant to the antigen. In baboon, approximately 15% of
transfected lymphocytes expressed A/B antigen in vitro with 90% viability 24
h post transfection. Tolerance induction in baboon is currently under study by
injecting the transfected lymphocytes back to the own circulation.
Conclusions: We could induce tolerance to B cells with specificity to ABO
antigens in mice. Further studies in baboons and/or other suitable experimental
animals may enable us to apply this method for clinical ABO-incompatible
transplantation.
This work is supported by a Grant-in Aid for Scientific Research (18380162)
from MEXT, Japan.

patient was withdrawn from all immunosuppression for over eight months.
No acute or delayed adverse events were associated with the infusion of
TAICs. Although these data do not prove that pre-transplant TAIC treatment
is beneficial, they are encouraging, in that they suggest that TAICs promote
a state of alloantigen-specific hypo-responsiveness, or prope tolerance, which
might allow safe minimisation of pharmacological immunosuppression.
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our colony (n=45) to facilitate donor-recipient pairing. Recombinant human
granulocyte-colony stimulating factor (rhG-CSF; 10mcg/kg for 5 days)
was administered to mobilise peripheral blood (PB) monocytes and CD34+
stem cells (38 mobilisations, 10 animals). DC were propagated in-vitro
from unmobilised (n>15) and G-CSF mobilised (n>25) CD14+ monocytes
using interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating
factor (GM-CSF). Myeloid precursors were expanded from CD34+-enriched
populations (n=6) using fms-like tyrosine kinase 3 (flt3-L), stem cell factor
and thrombopoeitin, then differentiated in IL-4/GM-CSF. Maturation stimuli
included TNF-α ± prostaglandinE2, lipopolysaccharide, and CD40Ligand.
The DC growth-factor flt3-L (100mcg/kg for 10 days) was used to mobilise
myeloid DC in-vivo (7 mobilisations, 5 animals). Cells were characterised by
morphology, surface marker phenotype, endocytic capacity, allostimulatory
capacity in mixed lymphocyte reaction (MLR), and NFkB/RelB mRNA
expression, to establish DC-like features and maturation status.
Results: Twenty-six genotypes involving 14 Caja-DRB alleles (including 2 new
alleles) were described. DRB mismatching predicted in-vitro allo-reactivity.
Monocyte yield from unmobilised animals was insufficient (< 150, 000/ml PB)
for detailed study. rhG-CSF treatment caused a 2-26 fold-rise in monocytes
and 4-16 fold-rise in CD34+ stem cells. Monocyte-derived DC (MODC)
yield was 0. 8-1 million/ml of rhG-CSF mobilised PB. CD34+-enriched
cultures gave rise to a myeloid precursor population, with 4-7 fold expansion
of cells by 4 weeks (5-15 million/ml mobilised PB). In-vitro propagated DC
exhibited typical morphology. MODC had immature characteristics. Lowlevel co-stimulation molecule expression, high endocytic capacity, weaker
allostimulatory ability and minimal increase in RelB expression were observed
despite exposure to various maturation stimuli. In contrast, stem-cell derived
DC had higher expression of mature DC surface markers which increased
further with maturation stimuli, and greater allostimulatory capacity. In-vivo
treatment of marmosets with flt3-L induced a 35-93 fold rise in PB myeloid DC
by day 14. Freshly isolated, flow-sorted myeloid DC had typical morphology
and were mildly stimulatory in MLR. However, the final yield was less than
MODC (0. 4-0. 9 million/ml mobilised blood). Based on stable immaturity,
MODC were chosen for in-vivo testing of tolerogenic ability. Two million
immature MODC from rhG-CSF mobilised donors were given intravenously
to two DRB-mismatched recipient monkeys, without side-effect. Durable (>
4weeks) donor-specific hyporesponsiveness developed in 1 recipient, based on
MLR and interferon-gamma production. .
Conclusions: Marmoset DC display many functional similarities to human DC
and can be differentiated in-vitro from in- vivo mobilised precursors to produce
sufficient numbers of candidate immature DC for further cellular tolerance
studies in this unique, cost- effective new primate model.

POSTER BOARD NUMBER P2 – 288
1489 IMMUNOSUPPRESSIVE EFFECT OF TOTAL LYMPHOID
IRRADIATION USED IN TOLERANCE INDUCTION
PROTOCOLS IN DOGS
P.J. Horton 1, W.J. Hawthorne 2, T. Patel 2, S. Walters 2, G.J. Stewart 2,
R.D.M. Allen 2, J.R. Chapman 2
1 University of Rochester Medical Center, 2 Centre for Transplant & Renal
Research, Westmead Millennium Institute
Background: We developed pre-clinical models of mixed hematopoietic
chimerism (MC) and intrathymic tolerance in dogs using fractionated total
lymphoid irradiation (TLI) and donor bone marrow (BM) inducing tolerance
to renal and skin allografts. TLI alone can suppress the immune system longterm.
Aim: To study the immunosuppressive effect of the TLI protocol in outbred
dogs given unmatched renal allografts and inbred spaniels given dog-leukocyte
antigen (DLA)-DP matched, class II compatible renal allografts.
Materials and methods: Outbred mongrel and inbred English springer spaniel
dogs were used. Fourteen dogs underwent median width field TLI, receiving
18Gy in 16 fractions delivered over four weeks using a designated 6MV linear
accelerator (Phillips Sl75) emmitting gamma irradiation from a gold source.
The mantle field extended from the back of the skull to the 10th rib. The
abdominal field extended between the 11th and 12th rib to the base of the tail.
Penumbral shielding limited beam divergence and field overlap. Elbow and
knee joints were outside irradiation fields. Native kidneys were shielded. Half
treatments were given posterior-anterior and half anterior-posterior. X-rays
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ensured shielding remained adequate. Monitor units were adjusted for growth.
Twenty-nine dogs, including those given TLI underwent bilateral native
nephrectomy and renal transplantation. Mongrel dogs received unmatched
renal allografts while spaniels received renal allografts from DLA-DP-matched
dogs. Tissue typing was based on restriction fragment length polymorphism.
Five mongrels (Group 1) and six spaniels (Group 3) received no treatment pretransplantation. Five mongrels (Group 2) and nine spaniels (Group 4) received
TLI pre-transplantation. Four spaniels (Group 5) received no treatment pretransplantation but received renal allografts from DLA-DP matched donors that
had undergone TLI and recipient BM infusions. Serum creatinine >600μmol/L,
urea >40mmol/L and renal histology confirmed acute rejection.
Results: Graft survival in mongrel dogs was not prolonged by TLI; median
7 days (range 5 to 8) (Group 1) compared with 8 days (range 6 to 11) (Group
2). Spaniels receiving DLA-DP matched renal allografts (Group 3) rejected
allografts slower than mongrels (Group 1) (p=0. 002). TLI prolonged graft
survival of DLA-DP matched renal allografts; median 20 days (range 18 to 22)
(Group 2) compared with 26. 5 days (range 10 to 38) (Group 4) (p=0. 005). One
dog in groups 2 and 4 was excluded for arterial thrombosis. Renal allografts
from DLA-DP matched chimeric donors were rejected at a similar rate to DLADP matched grafts; median 20 days (range 14 to 25) (Group 5).
Conclusion: DLA-DP matching prolonged graft survival. TLI only prolonged
graft survival in dogs receiving DLA-DP matched grafts. Survival of DLA-DP
matched kidneys from chimeric dogs was not prolonged.

POSTER BOARD NUMBER P2 – 289
1490 EVALUATION OF TOLEROGENIC EFFECT OF DONOR
SPLENOCYTES AND DELAYED CALCINEURIN INHIBITOR IN
A PRIMATE MODEL OF KIDNEY TRANSPLANTATION
V. Benseler, P. McKenzie, L. Weston, J. Watson, M. Dahlke,
H-J. Schlitt, A. Hennessy, K. Allman, A. Bishop, R.D.M. Allen
Collaborative Transplant Group, University of Sydney & Royal Prince Alfred
Hospital
Donor splenocytes in combination with a delayed course of calcineurin
inhibitors (CNI) is a strong protocol to induce donor-specific tolerance in
rodents and has the potential to be used in deceased donor transplantation.
Heavy initial immunosuppression, particularly with CNI and steroids, is
thought to inhibit induction of tolerance. In the clinical setting however, this
regimen might be associated with early graft loss from acute rejection and
graft-versus-host disease (GvHD).
Aim: To evaluate the safety and efficacy of intra-portal infusion of unfractionated donor specific splenocytes in a preclinical primate model of kidney
transplantation (KT) with delayed introduction of cyclosporin A (CsA).
Methods: Preliminary pharmacokinetic studies with CsA and mycophenolate
mofetil (MMF) provided appropriate trough levels of both drugs. Eight adult
female outbred baboons received ABO-matched MHC-mismatched KT from
four adult male donors. All recipients received MMF from days 0-10. The
four control baboons commenced CsA from day 0. They were compared with
four study baboons who received intra-portal donor splenocytes at time of
transplantation and CsA from 72 hours. KT was life-supporting for 2 pairs.
Target trough CsA was 1000 ng/ml till day 50 in both groups after which CsA
dose was weaned progressively to cease on day 90. Splenocyte distribution
was assessed by whole-body-scan after radioactive labelling with 111InOxime. Allograft rejection and function were assessed by histology, duplex
ultrasonography, serum creatinine and nuclear scans.
Results: All allografts functioned at the conclusion of the operative procedure.
One control kidney was lost on day 3 for technical reasons and no kidney was
lost from early rejection in either group. Target CsA levels were achieved.
Weekly core biopsies and duplex ultrasound findings were comparable for
control and study animals with evidence of progressive rejection from day
14. The remaining three control kidneys, including two life-supporting
procedures, survived 60-85 days. Two life-supporting study animals were lost
to overwhelming pyelonephritis day 36 and 59 and two study animals were
followed for >200days without GvHD.
Conclusions: This translational study in non-human primates demonstrated that
donor specific splenocytes and delayed CsA are not associated with increased
risk of early kidney transplant rejection or GvHD. However, it failed to induce
donor-specific tolerance in this rigorous immunological model.
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1491 NEONATAL INJECTION OF ALLOGENEIC LIN-/C-KIT+
FETAL LIVERCELLS INDUCES OPERATIONAL TOLERANCE
TO CARDIAC ALLOGRAFTS
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1492 MODULATION OF ACUTE AND CHRONIC ALLOGRAFT
REJECTION VIA ORAL APPLICATION OF ALLOANTIGEN
CODING DNA
S. Ensminger1, A. Bushell2, K. Goldmann3, M. Weyand1, B. Spriewald3
1
Department of Cardiac Surgery, University of Erlangen – Nuremberg,
Germany, 2Nuffield Department of Surgery, University of Oxford, U. K. ,
3
Department of Medicine 5, University of Erlangen – Nuremberg, Germany
Introduction: Nowadays the major effort in transplant immunology is the
development of immunomodulatory protocols that help to achieve long-term
allograft survival. One promising approach is the pre-treatment of transplant
recipients with donor MHC (major histocompatibility complex) –alloantigen
under favourable immunological conditions. Therefore, the aim of this study
was to develop a strategy for oral delivery of MHC-antigen coding genes via
DNA-chitosan nanoparticles to induce longterm allograft survival.
Methods: Chitosan, the deacetylated form of Chitin, is an inert, nontoxic polycationic biopolymer that can be coacervated with DNA to form
nanoparticles. Mice were treated with Kb-nanoparticles and anti-CD4 mAb
for two consecutive days. 40 days later CBA (H2k) recipients recieved a
fully MHC-mismatched C57BL/6 (H2b) cardiac allograft. Survival of cardiac
allografts was assessed by daily palpation and intestinal uptake of nanoparticles
was analysed by immunofluorescence and RT-PCR.
Results: First, we could demonstrate that nanoparticles remain stable
throughout intestinal transport. They were taken up in the small bowel where
the target gene was expressed in the Peyer’s patches and mesenteric lymph
nodes. Oral treatment with Kb-nanoparticles resulted in a significant increased
cardiac allograft survival. Moreover combination of a non depleting anti-CD4

POSTER BOARD NUMBER P2 – 292
1493 RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV2/8)
EXPRESSING INDOLEAMINE 2, 3-DIOXYGENASE (IDO) IN
RAT LIVER TRANSPLANTATION
J. Laurence 1, C. Wang 1, 2, S. Cunnigham 2, 4, J. Earl 4, M. Zheng 2, 4, G.
Mccaughan 3, R. Allen 1, I. Alexander 2, 4, A. Sharland 1, A. Bishop 1, 3
1
Collaborative Transplantation Research Group, Bosch Institute, University
of Sydney, NSW, Australia, 2 Gene Therapy Research Unit, Children’s
Medical Research Institute, Westmead, NSW, Australia, 3 AW Morrow Liver
Immunobiology Laboratory, Centenary Institute, Sydney, NSW, Australia, 4
Children’s Hospital at Westmead, Westmead, NSW, Australia
Aims: To evaluate transduction of the rat liver with rAAV2/8 vectors expressing
transgenes under the control the human alpha 1-antitrypsin promoter and to test
a potentially immunomodulatory vector in a normally rejecting (PVG>LEW)
rat liver allotransplant model.
Methods: Using a rAAV2/8 vector expressing GFP (rAAV2/8_GFP), the kinetics
of expression and optimal dosing for transduction of PVG strain rat livers was
determined. A rAAV2/8 vector encoding for the IDO gene (rAAV2/8_IDO)
was constructed and tested by its ability to induce tryptophan catabolism and
kynurenine production in vitro and in vivo. PVG strain donor rats were injected
via the portal vein with rAAV2/8_IDO two weeks before transplantation into
LEW strain recipients to determine if allograft rejection could be ameliorated.
Results: By means of the rAAV2/8_GFP vector, it was determined that a dose of
1013 vector genomes was required to attain widespread hepatocyte transduction.
Not before two weeks after vector administration was high-level gene expression
achieved. The rAAV2/8_IDO vector was able to induce tryptophan catabolism and
kynurenine production by Huh7 hepatoma cells. The function of the rAAV2/8_
IDO vector was validated in vivo by confirming tryptophan catabolism both in
untransplanted PVG animals and in isograft (PVG>PVG) recipients where serum
tryptophan was 64. 5±5. 3μM in recipients of livers transduced with rAAV2/8_
GFP and 28. 9±5. 7μM in recipients of livers transduced with rAAV2/8_IDO (p=0.
001). LEW recipients of PVG liver allografts pre-treated with the rAAV2/8_IDO
vector had a median survival time (MST) of 12 days, whilst recipients of allografts
pre-treated with rAAV2/8_GFP had a MST of 13 days (p=0. 38). Both groups
displayed similar histological features of acute cellular rejection.
Conclusions: rAAV2/8 vectors produced highly efficient hepatocyte
transduction in vivo and provide a gene therapy tool for use in transplantation
models. However, gene therapy using IDO was unsuccessful in prolonging rat
liver allograft survival.

POSTER BOARD NUMBER P2 – 293
1494 INDUCTION OF TOLERANCE AFTER LONG-TERM
TREATMENT OF HUMAN ENDOTHELIAL CELLS WITH
EVEROLIMUS?
G. Koehl3, K. Lehle1, L.A. Kunz-Schughart2, S. Hirt1, T. Puehler1, C. Schmid1,
1 Department of Cardiothoracic Surgery, 2 OncoRay - Center for Radiation
Research in Oncology, Medical Faculty Carl Gustav Carus, TU Dresden,
Fetscherstr. 74, PF86, D-01307 Dresden, Germany, 3 Department of Surgery,
University of Regensburg
Cardiac allograft vasculopathy (CAV) is characterized by intimal hyperplasia
as a result of endothelial cell (EC) injury. The anti-proliferative and antiinflammatory properties of mTOR inhibitors (e. g. everolimus) were used
to treat CAV. Our study evaluated the specific impact of everolimus on EC
regeneration and conservation of its function.
Patient-derived human saphenous vein EC (HSVEC) were incubated with
therapeutic concentrations of everolimus. The proliverative activity and the
inflammatory response of the cells were analyzed.
Treatment of HSVEC with mTOR inhibitors dose-dependently reduced EC
proliferation by about 40%, while apoptosis or cytotoxicity was not induced.
However, after long-term cultivation of HSVEC with 10 nM everolimus and
repeated transfers into the next generation under immunosuppression resulted
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L. West, M. Jeyakanthan, K. Tao
University of Alberta
Introduction: We previously showed that injection of neonatal mice with
fully allogeneic fetal liver cells (FLC) results in long-term acceptance of both
donor-specific and unrelated cardiac allografts as adults. A mechanistic role for
CD4+CD25+Foxp3+ regulatory T cells has been implicated in graft survival in
this model. The purpose of this study was to identify specific cell populations
in the FLC tolerizing inoculum that induce non-donor-specific cardiac allograft
acceptance.
Methods: BALB/c (BALB, H-2d) FLC from day 12-14 fetal pups were sorted
by magnetic cell separation and the purity of sorted cells was assessed by flow
cytometry. Neonatal C3H/He (C3H, H-2k) mice were injected iv with either Lin/c-Kit+ or Lin+/c-Kit- BALB FLC, followed at 6-8 weeks of age by heterotopic
transplantation of C57BL/6 (B6, H-2b) cardiac grafts. Untreated C3H controls
received B6 cardiac grafts. All cardiac grafts were monitored for long-term survival;
grafts surviving longer than 60 days were considered as long-term survivors.
Results: Purity of Lin-/c-Kit+ cells was over 90% and – Lin+/c-Kit- cells
contained less than 3% of c-Kit+ cells. While long-term graft survival was
achieved in 6 of 8 recipients in the
Lin-/c-Kit+ group, acute rejection occurred in all 8 recipients in the Lin+/c-Kitgroup and all 6 recipients in the untreated group.
Conclusions: This study demonstrates that Lin-/c-Kit+ cells isolated from
FLC, when injected into fully MHC-mismatched neonatal mice, induce
non-donor specific cardiac allograft acceptance. These data suggest that less
differentiated cell populations within the FLC inoculum are responsible for
the alterations in neonatal immunity that result in graft acceptance as adults.
We are further investigating the underlying mechanisms by which Lin-/c-Kit+
cells induce the regulatory T cells that mediate non-donor specific cardiac
allograft acceptance. Further refinement of this strategy may offer a useful tool
for transplant situations in which time constraints preclude consideration of
donor-specific tolerance induction, as in cardiac transplantation.

mAb with Kb-nanoparticles resulted in long term allograft survival. Untreated
controls acutely rejected their grafts around day 7.
Conclusion: These data show oral delivery of MHC-antigen coding genes via
DNA-chitosan nanoparticles resulted in significantly prolonged allograft survival.
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in a regeneration of cell growth. In addition, long-term treatment with high
concentrations of everolimus did not induce the basal and TNF-induced
expression of cellular adhesion molecules (CAM). Thus, the drug per se did not
stimulate EC. Surprisingly, everolimus inhibited the synthesis of interleukin-6
(IL-6).
In summary, dose-dependent inhibition of proliferation might explain a delayed
reendothelialization of injured EC layers. However, long-term treatment
induced a regeneration of cell growth. In addition, therapeutic concentrations
of everolimus did not contribute to the endothelial activation during CAV.
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1495 LIVER SUPPRESSOR FACTORS SPECIFIC TO
AUTOIMMUNITY IN LIVER TRANSPLANTATION
S. Goto1,2, T. Nakano1, L.W. Hsu1, C.Y. Lai1, S. Kawamoto3, K.C. Chiang4, T.
Goto4, K. Ono3, S.V. Lynch5, C.L. Chen1
1
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology,
Graduate School of Advanced Sciences of Matter, Hiroshima University,
4
Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences,
Josai International University, 5The Queensland Liver Transplantation
Service (QLTS)
For past 15 years at QLTS (Brisbane) and Liver Transplant Program,
Chang Gung Memorial Hospital-Kaohsiung Medical Center (Taiwan), we
have investigated the diagnostic and therapeutic potentials of various liver
suppressor factors (LSFs) induced by orthotopic liver transplantation (OLT).
Recent proteomic approach allows us to target on specific molecules of LSFs
underlying the common mechanism between experimental and clinical liver
allograft tolerance. Especially, a new insight has been given into our study
since we found that post-transplant autoimmune responses with high titer of
anti-nuclear antibodies against histone H1 and high mobility group box 1
(HMGB1) play an important role in induction of liver allograft tolerance in
OLT rats and clinical drug-free OLT patients. Our previous studies showed
that either treatment of recipient rats with commercially available histone H1
polyclonal Ab or immunization with calf thymus histone H1 could prolong
allograft survival in heterotopic heart transplantation. We have also reported
that the blockade of histone H1 modulated dendritic cells toward tolerogenic
status, decreased the cytotoxicity of lymphokine activated killer and natural
killer cells, and induced CD4+CD25+ T-cells. For further analysis of this
mechanism, we generated an immunosuppressive histone H1 monoclonal Ab
(16G9 mAb). From phage display peptide library, we have selected one peptide
(designated SSV) that binds directly to 16G9 mAb. The binding of SSV to
16G9 mAb was inhibited by histone H1. Furthermore, SSV binds to serum of
both tolerogeneic OLT rats and clinical drug-free OLT patients, and the binding
to SSV was also inhibited by histone H1. Immunization of mice with SSV
induced immunosuppression in serum, suggesting that SSV was an epitope
responsible for the immunosuppressive activity of 16G9 mAb. Peptide SSV
binding will allow us to establish a novel diagnostic and therapeutic strategy
in transplantation.
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1496 TH2 DEPENDENT ALLOANTIBODIES SPECIFICALLY
MODIFY RECIPIENT IMMUNE RESPONSE TOWARD
TOLERANCE AND ATTENUATION OF CHRONIC REJECTION
N. Semiletova1, D. Edberg1, X-D. Shen1, D. Feldman1, M. Ghobrial2
1
UCLA Medical School, CA, 2Methodist Hospital, TX
Cardiac transplanted recipients treated with soluble MHC class I chimeric
proteins developed specific tolerance. It was characterized by the deviation of
alloantibody (alloAb) responses and predominant expression of Th2 dependent
anti-donor IgG1 and IgG2c immunoglobulins. This study further examines the
immunoregulatory effect of Th2 alloAb on inhibition of chronic rejection (CR)
in the MHC disparate cardiac allografts.
Methods: ACI recipients of WF hearts were treated with alloIgG1 and
alloIgG2c enriched serum (1 mL, i. v. ) from tolerant syngeneic recipients.
Whole body irradiation (130R) was used to create temporary CD4 deficiency.
Results: In vitro: Endothelial cells (ECs) is a first target for alloAb and most
affected by CR. RNA turnover assay demonstrated that allogeneic serum (ACI)
directly inhibits metabolic activity of IFN-γ activated donor (WF) ECs. Mixed
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lymphocyte reaction (MLR) was performed on LN T cells from naïve ACI
rats (responders) stimulated with syngeneic, donor or third-party splenocytes
in the presence of naive or modulated MHC class I serum. MHC-induced,
but not naïve, serum significantly blocked ACI proliferative responses to WF
stimulation. In vivo: Whole-body γ-irradiation creates temporary peripheral
CD4 lymphopenia. CD4 lymphopenic ACI hosts treated with syngeneic
alloIgG1/IgG2c enriched serum demonstrated long-term survival of WF
hearts for more then 120 days (MST=11314. 14, n=13). Sera from animals
treated with high-dose CsA, which contains minimal alloAb levels, modestly
prolonged allograft survival to MST of 51±11 (n=6) days. Treatment of not
irradiated hosts with either naïve or MHC class I modulated serum cased
delayed rejection (MST=40+15 & 58+21, respectively). Transfer of alloIgG1/
IgG2c has specific effect, ACI recipients of BN hearts promptly rejected
grafts (ACI-BN; n=2, MST 16+1. 5). Therapy with alloIgG1/IgG2c abrogated
CR in MHC disparate grafts. CR–free recipients demonstrated upregulated
IgG2b serum alloAb and IgG and IgM deposits on the graft vascular intima.
Heart tissue had a diminished number of apoptotic cells. WB analysis showed
upregulation of antiapoptotic proteins (BcL-2/BcL-xL) and decreased
production of p50 subunit of NF-B in compare to grafts with high-level of
CR. CR-free grafts after allo-IgG1/IgG2c therapy were free of CD3+ cells and
had medium level of CD4+ infiltration.
Conclusion: Transfer of alloIgG1/IgG2c-enriched serum develops specific
tolerance and abrogates CR. Presence competent CD4 cells cancels effect
of alloIgG1/IgG2c therapy. Th2 dependent alloAb can directly inhibit ECs
metabolic activity. These in vitro and in vivo novel findings have important
clinical implications for inhibition of chronic rejection in transplant
recipients.
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1497 INDUCTION OF DONOR-SPECIFIC TRANSPLANTATION
TOLERANCE BY ALLOANTIGEN-PRIMED MONOCYTEDERIVED PROGENITOR CELLS COMBINED WITH LOWDOSE IMMUNOSUPPRESSION
Z.F. Yang, P. Ngai, Y. Liu, M.N.P. Ng, C.K. Lau, W.Y. Ho, R.T.P. Poon,
S.T. Fan
The University of Hong Kong
Background: Transplantation tolerance is the ultimate goal in the field of organ
transplantation. The present study was designed to investigate a combined
strategy of alloantigen primed monocyte-derived progenitor cells (PCMOs)
and low-dose immunosuppression in the induction of cardiac transplantation
tolerance.
Methods: PCMOs were isolated from DA spleen, and cultured with IL-3,
M-CSF in the presence or absence of LEW antigen. Adult male DA (RT1a)
and LEW (RT1l) rats were used as donors and recipients in a rat heterotopic
heart transplantation model. The cultured PCMOs were injected into recipient
rats immediately after transplantation. RAD001 (a rapamycin derivative) was
administered at the dose of 5 mg/kg/day oral feeding for 1 week either alone or
in combination with PCMO injection.
Results: The non-treated cardiac allografts were rejected within 7 days. PCMO
injection prolonged allograft survival to 12 days, whereas low-dose RAD001
prolonged allograft survival to 11 days. When combining PCMOs with RAD001,
half of the allografts developed indefinite allograft survival. The injected
PCMOs were identified in the allograft, spleen and mesenteric lymph nodes of
recipients. Histological study revealed normal cardiac structure on day 7 with
the combined treatment, whereas the non-treated allograft displayed extensive
areas of necrosis at the same time point. In the long-term surviving animals,
nearly normal cardiac structure was retained. Immuno-fluorescent staining
detected reduced number of CD4+, CD8+ and CD68+ cells in the allografts
with the combined treatment, compared with non-treatment group and groups
with PCMO or RAD001 treatment on day 4 after treatment. Flow cytometry
analysis revealed an increased number of CD4+CD25+Foxp3+ regulatory T
(T-reg) cells in the blood, thymus and lymph nodes in the group with combined
treatment, whereas there was no obvious change in the number of T-reg cells in
the spleen.
Conclusion: When combined with low-dose immunosuppression, alloantigen primed PCMOs could induce long-term cardiac allograft survival
by the generation of T-reg cells and subsequent induction of transplantation
tolerance.
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1498 THE EFFECT OF SELECTED IMMUNOSUPPRESSIVE
DRUGS: CSA, FK506, MMF AND RAPA ON CD8+CD28- CELLS
LEVEL IN MIXED LYMPHOCYTE CULTURE (MLC)
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1499 BLOCKING B7-CD28 CO-STIMULATORY PATHWAY
INDUCED IMMUNE TOLERANCE AND PROLONGED
ALLOGRAFT SURVIVAL
S. Xiong, J. Chen, P. Yu, X. Yang, Q. He
Dept. Immunology, Shanghai Medical College, Fudan University
The interaction of T cell CD28/CTLA-4 receptors with B7 on antigenpresenting cells (APCs) represents an important co-stimulatory pathway
in T cell activation or anergy. Our previous study indicated that recipients
immunized with allogenic donor immature dendritic cells (DCs) or resting B
cells could induce specific immune tolerance and prolong allograft survival.
The possible mechanism for those observations is that the expression of B7
molecules is either at a low level or lacking on these APCs. Then we tried
to investigate whether blockade of B7 molecules on donor splenocytes with
a B7 antisense peptide (B7AP), could have the same effect using a murine
pinna cardiac allograft experiment model. Results showed that B7AP treatment
did not influence the expression of B7 molecules on C57BL/6 splenocytes
but dose-dependently inhibited the mixed lymphocyte reaction by up to 38.
4%. The recipients (BALB/c) immunized with B7AP-pretreated C57BL/6
splenocytes induced a specific immune hypo-response (43% versus control)
and notably prolonged survival of the C57BL/6 cardiac allograft by up to
20. 3 days. When bone marrow transfusion (BMT) was performed 3 days
after B7AP-treated C57BL/6 splenocytes injection, a long-lasting allogenic
chimerism was observed with the rate as 3. 6% even on day 100 post BMT.
And the survival of allgenic cardiac grafts was maintained over 100 days in
recipients. Another strategy, a B7AP-exCD40L fusion protein, consisting of
both B7AP and exCD40L (extracellular portion of CD40L) was also used to
treat donor splenocytes and built an allo-hypo-response state. Combining with
BMT in such a state also generated an over-100-days allogeneic chimerism and
an over 100-days survival of cardiac allografts. Therefore, mixed chimerism
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1500 EFFECTS OF ATORVASTATIN ON RENAL ACUTE
REPERFUSION INJURY FOLLOWING ISCHAEMIA WITH
FOCUSES ON APOPTOSIS, INFLAMMATION AND OXIDATION
IN A RAT MODEL
J. Haylor1, K.P.G. Harris2, H. Waller2, M.L. Nicholson2, B. Yang2
Sheffield Kidney Institute, University of Sheffield; 2Department of Infection,
Immunity and Inflammation, University of Leicester, United Kingdom.
HMG-CoA reductase inhibitors may have beneficial effects on renal injury
independent of lowing lipid effects, although the underlying mechanism
is not fully defined. We examined the changes of apoptosis, inflammation,
oxidation and renal structure in a rat model of 45 minutes ischaemia (45mI)
and 4 hours reperfusion (45mI/4hR) with uninephrectomy (Unx) and the
effect of 10 mg/kg atorvastatin (45mI/4hR+AT) administered intravenously
after clamping the renal artery (before reperfusion). Caspase-3 activity (pmol
AMC liberated/min/μg protein) in kidneys was gradually increased from Unx
(0. 0020 ± 0. 0003), 45mI (0. 0034 ± 0. 0003) to 45mI/4hR (0. 0041 ± 0.
0004), but decreased by addition of AT (0. 0030 ± 0. 0001, p<0. 05). 12 kD
active caspase-3 protein significantly increased by 45mI, while the change of
17 kD active caspase-3 occurred after 4hR. Apoptotic cells (per 400× field)
in both tubular (1. 2 ± 0. 2 vs. 2. 3 ± 0. 2) and interstitial areas (0. 7 ± 0. 3
vs. 1. 9 ± 0. 4), necrotic cells (1. 2 ± 0. 5 vs. 4. 3 ± 1. 2) and ED1 positive
inflammatory cells (1. 4 ± 0. 4 vs. 5. 4 ± 1. 2) were significant decreased by
AT compared with 45mI/4hR alone. In addition, protein carbonyl in kidney
tissues (nmol/μg protein) was significantly enhanced by 45mI (0. 44 ± 0. 03)
and eliminated by 4hR with (0. 28 ± 0. 01) or without AT (0. 28 ± 0. 01). The
score of tubulointerstitial damage was gradually raised from Unx (0. 43 ± 0.
08), 45mI (1. 3 ± 0. 06) to 45mI/4hR (2. 89 ± 0. 06), all p<0. 01; but reduced
by AT (2. 14 ± 0. 18, p<0. 05). There were no significant differences in the
level of serum triglyceride, cholesterol and creatinine between the groups with
or without AT. In conclusion, caspase-3 activation, apoptosis, inflammation
and oxidation were involved in renal ischemia and I/R injuries. AT might
modulate these processes and improve reperfusion tolerance in the kidney,
but its long-term impact on renal function following I/R injury remain to be
determined.
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1501 INHIBITION OF DENDRITIC CELL DIFFERENTIATION
AND MATURATION BY SOLUBLE FACTOR (S) PRODUCED BY
LIVER STELLATE CELLS
C-C. Hsieh1, H-R. Yang2, G. Jiang1, J. Fung2, S. Qian1,2, L. Lu1,2
1
Deaprtment of Immunology, Lerner Research Institute, Cleveland Clinic,
2
Department of General Surgery, Cleveland Clinic
Tolerogenic property of the liver has been demonstrated by spontaneous
acceptance of liver allografts in many species, as well as tolerance to antigens
that are delivered through portal vein. The involved mechanisms are not
completely understood. It has been noticed that liver allografts are accepted in
mice, but hepatocytes transplants in same combination are acutely rejection,
suggesting a crucial role of liver non-parenchymal components (NPC) in
protecting parenchymal cells from immune attacks. We have focused on
hepatic stellate cells (HpSC) which showed potent immune suppressive
activity. Co-transplant with HpSC effectively protected islet allografts from
rejection. We hypothesize that liver NPC may modulate immune response
via inhibition of liver dendritic cells (DC) which are known of bone marrow
(BM) origin. In this study, DC were propagated from B6 BM cells with
GM-CSF for 5 days. Irradiated HpSC isolated from B6 mouse liver were
added at the beginning into the culture at HpSC : DC progenitor ratio of
1: 20. The differentiation, maturation and function of propagated DC were
determined by characterizing their surface molecule expression and T cell
stimulatory activity at the end of culture. The results showed that addition
of HpSC markedly blocked the differentiation of DC from BM precursors
(most cells remained in CD11b+CD11c- precursors stages). The incidence of
CD11c+ cells was 7% vs. 41. 6% in normal DC culture (without HpSC). The
presence of HpSC also prevented maturation of CD11c+ DC, as evidenced
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A. Korecka1, K. Bocian1, J. Wyzgal2, G. Korczak-Kowalska1,2
1Department of Immunology, Faculty of Biology, University of Warsaw,
2Transplantation Institute, The Medical University of Warsaw
Among immunosuppressive drugs we can distinguish calcineurin inhibitors
that act by blocking cytokine production (cyclosporine A – CsA and tacrolimus
– FK506) and cell division inhibitors (mycophenolate mofetil – MMF
and rapamycin – RAPA). The achievement of transplant tolerance seems
to be dependent of the presence and action of regulatory cells, including
CD8+CD28- suppressor lymphocytes (Ts). The examination of influence of
immunosuppressive drugs on regulatory cells level is essential for transplant
immunology.
The aim of this study was to determine how the selected immunosuppressive
drugs: CsA, FK506, MMF and RAPA affect the level of CD8+CD28- cells in
Mixed Lymphocyte Culture (MLC).
Mononuclear cells were obtained from peripheral blood of healthy volunteers
and were cultured in MLC in the presence or without investigated drugs.
After six days CD8+CD28- cells level was evaluated using monoclonal
antibodies conjugated with fluorochromes and analysed by flow cytometry
(FACSCalibur).
We observed that obtained data can be grouped into two subsets. In some
cultures with drugs the level of CD8+CD28- cells decreased significantly
but there was no decline in other cultures. This phenomenon concerns to all
investigated drugs despite of their different mechanism of action.
There are two possible explanations. The effect of immunosuppressive drugs on
CD8+CD28- lymphocytes can vary with different alloantigens configurations
in MLC. It can be dependent on individual variations in drug responses. In the
other hand, population of CD8+CD28- cells is very heterogeneous. It contains
both suppressor cells and cells without regulatory properties. It is possible that
examined drugs affect only one of these subsets and the change in CD8+CD28cells number is due to the ratio of suppressor cells to non-suppressor cells
within CD8+CD28- population.

approach, by treating with B7-CD28 costimulatory blockade could effectively
induce an allograft tolerance in mice.
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by low expression of CD40, CD80 and CD86, but high of B7-H1. The
inhibitory effect appeared to be mediated by soluble factor (s) produced by
HpSC since addition of the HpSC culture supernatant provided comparable
inhibitory activity. Culture of allogeneic CD4+ T cells with DC propagated
in the presence of HpSC elicited poor proliferative response in a 3d MLR
assay, with low IL-2 and IFN-ƒ× production. This was associated with high
expansion of CD25+Foxp3+ T cells (10. 9%, compared to 6. 7% in T cells
stimulated by normal DC, which was associated with vigorous proliferation
and high IL-2, IFN-ƒ× production), suggesting that HpSC inhibited DC
were capable of inducing Treg cells. In conclusion, liver tissue cells, such as
HpSC markedly inhibit DC differentiation and maturation, suggesting that
the tolerogenic property of liver DC may not be intrinsic, but is altered by the
microenvironmental factors in the liver.
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1502 FACE TRANSPLANT SURVIVAL IS PROMOTED BY
DONOR BONE MARROW CELLS AND PRESENCE OF
REGULATORY CD4+/CD25+ T-CELL
M. Siemionow, A. Klimczak, M. Unal, Y. Demir
Cleveland Clinic
Purpose: We have formerly achieved functional tolerance in fully MHC
miamatched rat facial allotransplantation model under cyclosporine-A
(CsA) monotherapy. In this study we tested the effect of donor bone marrow
transplantation (DBMT) under short-term alpha-betaTCRmAb and CsA 7-day
protocol on development of chimerism, allograft survival, and presence of
regulatory T-cells in face allograft model across MHC barrier.
Methods: Thirty six hemiface allotransplantation were performed between
LBN (RT1l+n) donors and LEW (RT1l) recipients in 6 groups (6 rats each).
Controls: Group 1 isograft and Group 2 allograft without treatment, Group 3
received intraosseous DBMT only. Groups 4, 5 and 6 received alpha-betaTCR/
CsA 7-day therapy. Additionally Groups 5 and 6 were augmented with
intraosseous DBMT of 35x106, and 100x106 of bone marrow cells (BMC)
respectively. Before transplantation BMC were stained with PKH dye to
evaluate engraftment and migratory process of donor BMC.
Flow cytometry assessed immunodepletion of T–lymphocytes, donorspecific chimerism for MHC class I (RT1n) antigens and presence of
regulatory T-cells CD4+/CD25+. Grading of graft rejection was assessed
by H+E staining.
Results: Isograft controls survived indefinitely, whereas controls without
immunosuppression rejected transplanted allograft within 5 to 8 days. Group
3 treated with only DBMT accepted transplant up to 13 days. Median survival
time (MST) of facial allograft (Group 4) under alpha-betaTCR/CsA therapy
was 35 days. In both Groups 5 and 6 augmented with donor BMC MST was
48 days. However, the longest survival time in Groups receiving 35x106 or
100x106 BMC was 465 and 498 days respectively. In long-term survaivals
split tolerance was found as presented by acceptance of skin and intact ear and
rejection of hair components.
PKH-positive cells of donor origin were present within lymphoid organs
and skin of recipients. In rejected allografts T-cell chimerism declined <1%,
and B-cell chimerism was at 4. 5% of CD45RA/RT1n. In contrast, in longterm survival animals T-cell chimerism was 2%-4% (RT1n) during followup period and B-cell chimerism reached 12. 4% CD45RA/RT1n at day 465
post-transplant. At day 7 post-transplant, regulatory CD4+/CD25+ T-cells
initially were detected at 1. 8%, however in long-term survivals reached 4. 0%,
whereas rejected allografts reveled 2. 2% of CD4+/CD25+ T-cells at the time
of euthanasia.
Conclusion: Long-term face allograft survival was achieved under 7-day
alpha/beta-TCRmAb/CsA protocol augmented with DBMT without chronic
immunosuppression. Long-term allograft acceptance was supported by
development of regulatory T-cells and maintenance of donor T-cell and B-cell
chimerism.
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1503 FATE AND INTERACTIONS OF TOLERIZING CELLS IN
NEONATES
L.J. West, R.A. Bascom, K. Tao
Departments of Pediatrics, Surgery and Immunology, University of Alberta,
Edmonton, Canada.
Introduction: and Methods: Injection of neonatal mice with either allogeneic
fetal liver cells (FLC) or semi-allogeneic adult F1 splenocytes (F1SpC) induces
acceptance of donor-type and third-party heart grafts in adults; regulatory T
cells (Tregs) have been implicated in both models. To understand the early
events of tolerance induction we studied the fate and cellular interactions of
injected CFSE-labeled cells in host organs by confocal microscopy using
monoclonal antibodies for specific cell surface markers. Injected cells were
tracked for six days after injection.
Results: The fate of injected cells depended not only on their nature but
also on the host organ examined. F1SpC persisted over 6 days in thymus
and spleen but not in liver. FLC were greatly reduced or absent by day
6 in all organs examined. Both F1SpC and FLC were rare in thymus
compared to spleen, consistent with thymic entry being gated. In the
thymus, both F1SpC and FLC appeared to interact with cortical epithelial
cells and cortico-medullary junction dendritic cells (DC) suggesting they
may undergo positive and negative selection respectively. Many F1SpC
appeared to survive both positive and negative selection processes, possibly
because they expressed appropriate functional T cell receptors. In contrast,
the immature allogeneic FLC, which contain few if any functional T cell
receptors, fragmented in the thymic cortex and were detected in host
macrophages and DC. The fate of F1SpC and FLC also differed in host
spleen. F1SpC colonized the developing neonatal spleen before arrival of
the bulk of host T cells. F1 T cells were detected in the PALS and B cells in
the immediate surrounding follicular regions, and were thus positioned for
immune regulation and tolerance induction. Three days post-injection, both
host and donor (F1) Foxp3-expressing cells were seen in close association
with one another and with host DC. In contrast, in the allogeneic model
many of the FLC appeared to be fragmented three days after injection. Some
allogeneic FLC could be seen in intimate association with host CD8+ T cells
suggesting they were being killed. As early as day one post-injection, host
DC containing FLC fragments were seen adjacent to host T cell, suggesting
indirect antigen presentation may play an important role in Treg development
in this tolerance model.
Conclusion: The fate of tolerizing cells and their interactions with host cells
differ significantly between the allogeneic and semi-allogeneic models of
neonatal tolerance, suggesting different events leading to Treg induction.
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1504 EFFECT OF EARLY WITHDRAWAL OF A FIRST
ALLOGRAFT ON SURVIVAL OF A SECOND VASCULARIZED
GRAFT. EXPERIMENTAL MODEL OF TOLERANCE?
P. Troncoso, G. Olivares, C. Parra
Pontificia Universidad Católica De Chile
Introduction: The critical role of the receptor alloimmune response is the main
determinant of transplanted grafts. Experimental observations have shown
us that interrupting the immune response during this process may increase
survivals of subsequent grafts. The objective of the study was to develop an
animal model to test this strategy.
Materials and Methods: Male Lewis rats were used as receptors and Brown
Norway as graft donors. Skin was used as first grafts and heterotopic heart as
seconds grafts. Animals in the experimental groups underwent extraction of a
first skin graft in predetermined periods of time after the implant and the second
transplant was performed 30 days after the first one. The graft was controlled in
a daily fashion with digital examination of heart beat. The absence of beating
was considered rejection.
The design included the following 5 groups:
Control Group (CG): Lewis rats with a Brown Norway heart transplant and no
other intervention. (First set rejection). Group 1: Lewis rats with a skin graft
and a heart transplant after 30 days (Second set rejection). Group 2: Lewis
rats with a skin graft, withdrawal during the third day and a heart transplant
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after 30 days. Group 3: Lewis rats with a skin graft, withdrawal during the
second day, and a heart transplant after 30 days. Group 4: Lewis rats with
a skin graft, withdrawal during the first day and a heart transplant after 30
days. Both cellular and humoral acute rejection components were analyzed
according to the classification of the International Society for Heart & Lung
Transplantation (ISHLT).
Comparisons were made using a variance analysis and the multiple comparison
test of Bonferroni.
Results: Mean graft survivals were: CG: 8 days ± 0, 82; Group 1: 6 days ± 0,
5; Group 2: 6 days ± 0, 58; Group 3: 8 days ± 1 and Group 4: 7 days ± 1, 53.
There was a tendency towards increased survival of the grafts or at least to be
equal to that of the CG when the skin allograft was removed earlier (Groups
3 and 4). However, this difference was not statistically significant (p = 0, 8).
In addition, there was a tendency in groups 1 and 2 to present moderate to
severe cellular rejection compared to groups 3 and 4. On the other hand, in
CG and group 1 a total of 5 cases presented rejection with humoral component
compared to groups 2, 3 and 4 in which only 3 cases presented this kind of
rejection.
Conclusions: Though this strategy was not associated to tolerance the graft
survival of some experimental groups and the intensity of histological rejection
were different from those of a second set type. This model needs to be more
explored.
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S. Qi1, A. Ma1, Z. Wang1, L. Liu1, D. Xu1, E. Massicotte2, M. Dupuis2,
P. Daloze3, H. Chen1
1Research Center, CHUM, Notre-Dame Hospital, University of Montreal,
2Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.
, 3Department of Surgery, Hôpital Notre-Dame, University of Montréal,
Montreal, Canada
Exploring new immunosuppressive strategies to induce donor-alloantigenspecific hyporesponsiveness is an important challenge in transplantation.
CD4+CD25+ regulatory T (Treg) cells have been known to play an
important role in transplantation and autoimmune diseases. In this study, our
study aimed at whether adoptive transfer of CD4+CD25+FoxP3+ regulated
T cells could prolong survival of totally MHC-mismatched composite
facial allografts in rats and mice. The composite facial allotransplantations
including the ear and scalp were performed by the anastomosis of the
external carotid arteries, external jugular veins and facial nerves from
Brown Norway (RT1n) to Lewis (RT1l) rats and isotransplantation between
Lewis rats. In rats, isograft controls and allograft controls did not receive
adoptive transfer Treg cells. Allografts in treatment group were adoptively
transferred with donor-specific Treg cells on day -3, day 0 and day 7. All
groups did not administer any other immunosuppressants. Function to face
allografts was evaluated clinically. In vitro, evaluation of donor-specific
tolerance was performed by mixed lymphocyte reaction on day 6 after
transplantation. In mice, allograft control group, from C57BL/6J (H-2b)
to BALB/c (H-2d) mice, did not receive any therapy. Donor-alloantigenspecific Treg cells were administered in allograft treating group at day
-3, 0 and 7. All allograft controls rejected their grafts within 5 to 7 days
after transplantation. Facial allograft group under the Treg cells transfer
protocol showed prolongation of the allograft survival with mean survival
time (MST) of 13. 7 „b 3. 4 days in rats, and 13. 0 „b 2. 2 days in mice,
compared with untreated allograft control (MST of 6. 2 „b 0. 2). The
mixed lymphocyte reaction assay at day 6 after transplantation revealed
that regulatory T cells display suppressive function in cell dose-dependent
and donor-antigen-specific manners. Adoptive transfusion of ex vivo donor
alloantigen-induced CD4+CD25+FoxP3+ regulated T cells may represent a
new strategy for preventing allograft rejection after transplantation.

1506 ABSENCE OF MHC CLASS II ANTIGEN EXPRESSION
IN THE TOLERIZING INOCULUM IMPAIRS ALLOANTIBODY
PRODUCTION IN NEONATALLY-TOLERIZED MICE WITH
ACCEPTED CARDIAC ALLOGRAFTS
L. West1, K. Tao1, L. Mai2
1University of Alberta, 2University of Toronto
Introduction: We previously showed that injection of allogeneic fetal liver
cells (FLC) into neonates induces acceptance of donor-type and third-party
cardiac grafts in adults. Mechanisms of operational tolerance in this model
appear to involve non-specific Treg cells. In this study, C3H neonates (H-2k)
were treated with FLC from MHC-deficient mice to investigate the role of MHC
antigen expression on induction of cardiac graft acceptance and production of
alloantibodies.
Methods: C3H neonates were injected iv with 15x106 FLC from C57BL/6
(B6; H-2b), class II deficient [B6/II-], or class I&II deficient [B6/I-II-] mice. At
8 weeks, treated and untreated mice received heterotopic B6 cardiac allografts.
After 60 days of graft survival, sera were assessed by flow cytometry for
anti-B6 antibodies.
Results: Mice treated as neonates with B6 (n=6), B6/II- (n=9) and B6/I-II(n=9) FLC accepted B6 cardiac grafts as adults with median survival time
(MST) >60 days; graft MST in untreated mice (n=9) was 9 days. Production
of various IgG isotypes in mice with cardiac grafts varied with the different
treatments. Generally, B6 FLC-treated mice had significantly higher antibody
levels than untreated mice, B6/II- and B6/I-II- FLC-treated mice. The level
of IgG1 in mice treated with B6/II- and B6/I-II- FLC was 5-fold lower than
in untreated mice and 15-fold lower than in B6 FLC-treated mice. The level
of IgG2a in mice treated with B6/II- and B6/I-II- FLC was 10-fold lower than
in untreated mice and 2-fold lower than in B6 FLC-treated mice. The level
of IgG3 was 5-fold higher in B6 FLC-treated mice than all other groups. No
difference was observed in IgG2b production.
Summary: Preliminary results suggest that expression of MHC class II antigen
in the tolerizing inoculum is not essential for neonatal induction of cardiac graft
acceptance, but appears to play a role in alloantibody production, particularly
IgG1 and IgG3, which are important in many humoral rejection responses. The
intact MHC class II molecules in B6 FLC may sensitize recipients such that
transplantation of B6 cardiac grafts results in elevated antibody production
even higher than in mice not treated as neonates. It is notable that neither
the presence or absence of tolerizing inoculum MHC class II antigens, nor
alloantibodies after transplant, had a discernible effect on cardiac allograft
MST in this model.
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1507 DONOR SENSITIZATION AS A NEW APPROACH FOR
IMMUNOMODULATION. STUDY IN A COMPOSITE TISSUE
TRANSPLANTATION MODEL
M. Siemionow, M. Hivelin, S. Nasir, A. A Klimczak, L. Krokowicz
Plastic Surgery Department-Cleveland Clinic
Introduction: New protocols are needed for tolerance induction in composite
tissue allograft (CTA). It is well documented that bone marrow transplantation
induces donor–specific immune-tolerance through the creation of mixed
chimerism. Donor sensitization with the recipient bone marrow before
transplantation is a new approach to induce immunotolerance. We studied the
effect of donor sensitization on the immune response, for vascularized skin
allografts.
Methods: Twenty groin flap transplantations were performed in 4 experimental
groups of 5 animals each. Allograft transplants were performed between
presensitized ACI donors and Lewis (LEW) recipients. The ACI (RT1a) donor
rats were presensitized with Lewis (RT1l) bone marrow (80x 106 cells) and
these donors received áâ-TCR and cyclosporine (CSA) treatment therapy
before transplantation. At either 24 hours or 72 hours after sensitization, the
vascularized skin allografts (VSA) were transplanted to Lewis (RT1 I) recipients.
Group I and II were the control groups without immunosuppressive treatment
after transplantation and 24 to 72 hours of presensitization respectively. In
group III, and IV, animals received áâ TCR and CSA protocol for 7 days after
transplantation, with the same duration of presensitization as in group I and
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II. Assessment included flap viability, flow cytometry for chimerism, and
immunohistochemistry.
Result: In the control groups (group I, II) VSA were acutely rejected within
2 to 10 days post transplant. The mean survival of VSA was 82 days in Group
III and 73 days in group IV, with longest survival of 115 days. Donor specific
chimerism in peripheral blood was estimated by presence of T and B cells.
Total chimerism levels for Group III at day 7, 21, 35 and 63 were 4. 93%, 1.
75%, 2. 46%, 1. 45% respectively and Group IV 3. 6%, 2. 37%,
1, 87%, and 0. 48% respectively.
Conclusions: Donor presensitization with the bone morrow cells of the
recipient modifies the recipient’s responsiveness and extends survival of
vascularized skin allografts, under short-term protocol of áâ-TCR monoclonal
antibodies and cyclosporine (CSA) therapy.

CONCURRENT ORAL SESSION 106: IMMUNOLOGY AND
ALLOGRAFT REJECTION
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1508 THE FISHER-LEWIS KIDNEY TRANSPLANTATION
MODEL AS TOOL TO INVESTIGATE TRANSPLANT-RELATED
CARDIOMYOPATHY
M. Baumann, J. Chang, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R. D. Isar, TU Munich
Background: Cardiovascular mortality is major cause of death after kidney
transplantation. Thus, cardiovascular protection is a major concern in
transplant patients. However, information from animal models about cardiac
characteristics after kidney transplantation is lacking.
Therefore we investigated in a model of chronic allograft injury cardiac
structure and function.
Methods: Fisher 344 kidneys were orthotopically transplanted into Lewis
recipients. Recipients were treated with placebo, angiotensin II type 1 receptor
blocker (AT1RB; candesartan 5mg/kg/day) over 24 weeks posttransplantation.
Untreated matched-Lewis rats were used as healthy untransplanted controls.
Each group consisted of 8 rats. Echocardiography was performed at 24 weeks
posttransplantation measuring ejection fraction, fractional shortening and
left ventricular mass in triplicate. 24-h proteinuria was determined and after
harvesting heart weight/body weight ratio (HW/BW) measured.
Results: Renal transplant recipients demonstrated 24 weeks posttransplantation
significantly reduced ejection fraction (58. 9±3. 2% vs. 70. 7±2. 1%) and
fractional shortening (29. 8±2. 0% vs. 38. 3±2. 0%) and increased HW/BW and
left ventricular mass (7. 7±0. 2cm3 vs. 6. 7±0. 2cm3) as compared to healthy
controls. HW/BW and left ventricular mass (7. 7±0. 2cm3 vs. 6. 8±0. 2cm3) were
significantly ameliorated by AT1RB as compared to placebo-treated transplant
recipients. In parallel, reduction of proteinuria was evident after AT1RB.
Conclusion: The Fisher-Lewis kidney transplantation model results in
cardiac hypertrophy and reduced cardiac function. AT1RB normalizes cardiac
hypertrophy without improving the functional state. This demonstrates that the
Fisher-Lewis renal transplantation model can be used to investigate transplantrelated cardiomyopathy.
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1509 REQUIREMENT OF LFA-1 DE-ACTIVATION FOR
CARDIAC ALLOGRAFT REJECTION
N. Hüser1, M. Stangl1, V. Aßfalg1, M. Semmrich2, B. Holzmann1,
M. Laschinger1
1
Department of Surgery, Division of Transplantation, 2Department of Cell and
Molecular Biology, Immunology Section
Background: The leukocyte-specific integrin LFA-1 is considered to be
important for immune responses leading to organ transplant rejection.
Regulating the affinity of LFA-1 for its ligand ICAM-1 is known to be crucial
for its function. However, the importance for de-activating LFA-1 remains
largely unknown. A mutant mouse that locks LFA-1 in an active state (LFA1d/d) provides the unique opportunity to explore the function of LFA-1 deactivation in the multifaceted immune responses leading to the rejection of
cardiac allografts in vivo. We investigated the involvement of active LFA-1 in
the proliferation and effector function of allo-reactive T cells as well as its role
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in the recruitment of leukocytes into the allogeneic cardiac graft in a murine
model of heterotopic cardiac transplantation.
Methods: Allogeneic donor hearts were transplanted heterotopically into
wildtype or mutant mice expressing LFA-1 that cannot be de-activated (LFA1d/d). Mixed lymphocyte reactions were performed to study the influence of
LFA-1 de-activation on T cell proliferation. Histology and flow cytometry were
applied to analyze graft infiltrating leukocytes. Cytokine or chemokine levels
in the graft were determined by RT-PCR and ELISA.
Results: Defect in LFA-1 de-activation ameliorates graft survival in LFA1d/d recipient mice. A key event in graft rejection is its infiltration by allogenprimed T cells. Constitutively active LFA-1 hinders activation and proliferation
of allo-reactive T cells. We found expression of the chemokines CXCL10/
IP-10 and CCL5/RANTES to be markedly reduced in grafts of LFA-1d/d
recipients. This defect translates into a low number of CD4 and CD8 T cells
detected in the transplanted heart. Furthermore, leukocyte subsets initiating the
inflammation at early stages of graft rejection are not efficiently recruited into
cardiac allografts of LFA-1d/d hosts. The reduced amount of TNFα and IFNγ
in the allograft seems to account for this defect.
Conclusions: Constitutively active LFA-1 negatively affects different
immunological events inducing or controlling graft-specific responses. Thus,
regulating LFA-1 de-activation appears to be vital for allograft rejection, opens
new possibilities to specifically interfere with immune responses and could
encourage the development of novel therapeutic approaches to promote graft
survival.
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1510 IGG-MEDIATED HYDROLYSIS OF COAGULATION
FACTORS IS ASSOCIATED WITH A REDUCED RISK
OF CHRONIC ALLOGRAFT NEPHROPATHY IN RENAL
TRANSPLANTED PATIENTS
O. Thaunat1, B. Wootla2, C. Legendre3, A. Nicoletti2, S. Lacroix-Desmazes2
1
Service de transplantation et d’immunologie clinique, Hopital Edouard
Herriot, 2Centre de recherche des Cordeliers, INSERM UMRS872, 3Service de
Transplantation Renale, Hopital Necker
Background: We have previously identified IgG endowed with hydrolytic
properties against coagulation factors in various inflammatory diseases.
Uncontrolled activation of the coagulation cascade by the stressed
endothelium of the graft is believed to play an important role in the
pathophysiology of chronic allograft nephropathy (CAN), a major cause of
late allograft failure.
Objective: To investigate whether hydrolytic IgG are detectable in renal
transplanted patients and whether they are associated with a reduced risk of CAN.
Material and methods: Case-control study using the sera and the graft
biopsies from the biocollection of the renal transplantation department of
Necker hospital. Ten patients with CAN lesions on the 2-years graft biopsy
were randomly retrieved from the database and compared to 10 matched
patients that displayed a normal histology at the same time point.
The presence of hydrolytic IgG in the serum of renal transplanted patients was
tested by incubating patients IgG with coagulation factors VIII, IX, VIIa and
prothrombin.
The hydrolysis of a fluorescent synthetic substrate (PFR-MCA) was used to
quantifyed the hydrolytic activity of patients IgG, 3 months and 2 years posttransplantation.
Results: Circulating IgG from renal transplanted patients are endowed with
hydrolytic properties towards coagulation factors VIII and IX that was reliably
quantified by the measure of the hydrolysis of (PFR-MCA).
Elevated hydrolysis rate of PFR-MCA by circulating IgG correlated with
the absence of CAN lesion on protocol graft biopsy performed 2 years posttransplantation. Low rates of PFR-MCA hydrolysis, measured 3 months posttransplantation, were predictive of CAN at 2 years down the lane.
Conclusions: High levels of circulating IgG endowed with serine protease-like
activity are associated with a reduced occurrence of CAN in renal transplanted
patients.
PFR-MCA hydrolysis by circulating IgG appears as an early risk marker for
CAN.
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1511 IMMUNE ACTIVE EFFECTS OF CHEMOKINE RANTES
ON HUMAN PERIPHERAL MONONUCLEAR CELLS
X. Gu1, H. Zhao2, J. Yang1, G. Zhou1, S. Gu1, T. Gu2
1Affiliated Hospital of Yangzhou University, 2University of Louisville
Objective To investigate the proliferation and phenotypes of peripheral
mononuclear cells (PMNC) stimulated by recombinant human RANTES
(rhRANTES) and the mechanisms involved.
Methods: PMNC was stimulated by various concentrations of rhRANTES
and/or anti-CD3 mAb and intervened by PDTC and CTLA4Ig. Scintillation
counter was used to count the cpm of proliferation cells and flow cytometry
was used to detect the phenotypes of lymphocytes.
Results: rhRANTES was capable of directly stimulating purified human
PMNC proliferation and two peaks occurred with rhRANTES concentration of
100 ng/ml and 5000 ng/ml respectively. The proliferation of PMNC stimulated
by rhRNATES was significantly higher than that in the presence of anti-CD3
mAb (P < 0. 05). The immune active effects of rhRANTES could be inhibited
by PDTC or CTLA4Ig in a dose dependent manner. RANTES treatment of
PMNC in vitro increased the level of cell surface CD25 and decreased the
CCR5 expression. But it did not influence the ratio of CD4/CD8 and CD28
expression of lymphocytes.
Conclusion: RANTES is an important stimulatory mediator in human PMNC
activation. This special signal works depending on the activation of IL-2 signal
pathway, CD28 costimulatory pathway and nuclear factor-¦ÊB, but independent
of CD3 activation.
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M. Kloc, B.L. Bass, O.A. Gaber, R.M. Ghobrial
The Methodist Hospital and The Methodist Hospital Research Institute
Immuno-Biology Laboratory
Background: The immune response in allograft rejection involves a
cascade of molecular events leading to the formation of immunological
synapses between T cells and the antigen-presenting cells. The migration
and activation of T cells and the formation of immunological synapse are
critically dependent on the re-polarization and extensive reorganization of
T cell cytoskeleton: microtubules and intermediate filaments, and T cell
receptors (TCR) clustering. Thus one of the novel approaches to eliminate or
attenuate allograft rejection would be the inhibition of the polarization and
reorganization of T cell cytoskeleton.
Methods: We have developed an in vitro and in vivo assay using Xenopus
oocytes as a model system to study the structural role of various RNAs in actin
and cytokeratin filament formation and the maintenance of the cytoskeleton
organization and architecture. In in vitro assay the synthetic Texas Red
labeled VegT RNA containing whole ORF and 21 nucleotides of 5’ UTR was
mixed with recombinant human cytokeratin19 (Biodesign International) in
cytokeratin assembly buffer (5mM Tris-HCl, 5mM ?-mercaptoethanol, pH 7.
0) and incubated for 30 min and 1-2 hr at room temperature. In in vivo assay
the same RNA and cytokeratin or antisense deoxyoligonucleotides against
Fatvg RNA were delivered into Xenopus oocytes and incubated 30 min or
overnight. Subsequently the whole cells or aliquots of the assembly reactions
were incubated with anti-cytokeratin FITC conjugated antibody or Rhodamine
conjugated phalloidin and immediately observed under the fluorescence
microscope.
Results: Previously we found that noncoding (Xlsirts) and coding (VegT)
RNAs function in maintaining the integrity of the cytokeratin network
in Xenopus oocytes. Destruction of these transcripts with antisense
deoxyoligonucleotides disrupts cytoskeleton in a transcript-specific manner.
Analysis in live cells using molecular beacons showed that these RNAs
are integrated into the cytoskeleton. These findings demonstrated a novel
structural role of coding and noncoding RNAs in the organization of the
cellular cytoskeleton and architecture. In assembly reaction incubated for 30
min-1hr we observed the presence of aggregates of Texas Red labeled VegT
RNA and cytokeratin. Some of these aggregates showed also the presence

POSTER BOARD NUMBER P2 – 312
1513 PRIOR SENSITISATION LIMITS LONG TERM
ALLOGRAFT SURVIVAL ACROSS A MAJOR MHC MISMATCH
AFTER PRUNING ALLOREACTIVE T CELLS.
D. Watson1, M. Hu1, G. Zhang1, Y.M. Wang1, M. Sartor2, J. Fletcher1,
S.I. Alexander1
1
Children’s Hospital At Westmead, 2Millenium Institute Westmead
We have demonstrated prolonged skin allograft survival across a major
MHC mismatch following the pruning of alloreactive T cells based on their
proliferation following allo-stimulation. Memory T cells are known to be a
major barrier to transplantation tolerance. Therefore the aim of this study
was to examine the effects of memory on the proportion of allo-stimulated
dividing cells and allograft survival in the pruning model. Our hypothesis
was that stimulating memory cells would result in an increased number of
cells that would proliferate and that this would be a more effective pruning
strategy to remove alloreactive T cells. In a mixed lymphocyte culture (MLC),
naive BALB/c (naive MLC) or memory BALB/c (memory MLC) responder
splenocytes were stained with CFSE and stimulated with irradiated C57BL/6
donor splenocytes. Memory BALB/c splenocytes were generated by isolating
spleen cells from BALB/c mice that had been grafted with and that had
rejected their donor C57BL/6 allografts (Median Survival Time (MST), 20d,
n = 4). Flow cytometry at Day 5 of the MLC indicated an increase in the
number of proliferating cells in the memory MLC (46%), compared to the
naive model (12%). At day 6 of the MLC, SCID mice were injected with
allo-stimulated non-dividing (ND) or dividing (D) CD4+ T cells from the
naive or the memory MLC. SCID mice were grafted with C57BL/6 (donor),
BALB/c (self) and B10. Br (third party) allografts. SCID mice reconstituted
with allo-stimulated ND CD4+ T cells from the naive MLC demonstrate
prolonged survival of their donor C57BL/6 allografts (MST > 65d, n = 4),
while rejecting third party B10. BR allografts (MST, 21d, n = 4) (p = 0. 0100).
However, mice reconstituted with allo-stimulated ND CD4+ T cells from the
memory MLC rapidly rejected both their donor C57BL/6 (MST, 17. 5d, n =
4) and third party B10. Br allografts (MST, 13d, n = 4) (p = NS). Histology of
C57BL/6 skin grafts demonstrated increased cellular infiltrates at day 8 posttransplant for mice reconstituted with ND CD4+ T cells from the memory
MLC. Interestingly IFN-gamma production measured using Elispot analysis
demonstrated a significant increase for memory ND cells (115. 7 +/- 0. 88
spots per 200, 000 cells) compared to naive D cells (49. 5 +/- 6. 76 spots per
200, 000 cells) (p = 0. 0004) in response to stimulation with donor C57BL/6
cells, indicating the persistence of memory cells within the ND population.
While the pruning method is an effective strategy to prolong allograft
survival in mice reconstituted with naive ND CD4+ T cells, this was not the
case for allo-stimulated ND CD4+ T cells from the memory MLC. This data
indicates that while there is an increased proportion of proliferating cells in the
memory MLC potentially increasing the number of alloreactive cells pruned,
memory cells are maintained within the allo-stimulated ND population, and
consequently rejection is observed. This study emphasizes the importance
of developing strategies for tolerance induction in transplantation that can
specifically account for memory T cells.
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SYNAPSE

of short cytokeratin filaments, which we interpret as an initial step in
cytokeratin filament polymerization. In assembly reaction incubated for 1-2
hr we observed the presence of long cytokeratin filaments, which emanated
from the foci containing the aggregates of VegT RNA and cytokeratin. None
of these were present in control samples. In in vivo assay we found that VegT
RNA speeds up the formation of cytokeratin filaments and incorporation of
newly made cytokeratin filaments into pre-existing cytokeratin network,
and the antisense oligonucleotide-mediated destruction of Fatvg RNA
hyperpolymerizes cytokeratin and actin.
Conclusions: VegT RNA is able to bind unpolymerized cytokeratin and
induce its polymerization into filaments in vivo and in vitro, and Fatvg RNA
is needed to maintain the proper organization and cellular architecture of
actin and cytokeratin filaments. The study of structural RNAs involved in the
polarization and the maintenance of cytoskeleton in naïve and activated T cells,
and the interference with these functions will ultimately lead to attenuation of
graft rejection.
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1514 EXPRESSION OF ARGINASE 1 (ARG1), THE
ALTERNATIVE ACTIVATED MACROPHAGES MARKER IN
RAT MODEL OF CARDIAC TRANSPLANTATION
Y. Chen1, Y. Liu1, Z. Yuan1, J. Lamb2, P.K.H. Tam1
1Department of Surgery, The University of Hong Kong, 22Department
of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies,
University of Edinburgh
Introduction: Macrophages infiltration is often correlated to the grafts lose
especially in acute phase of transplant rejection. Meanwhile, the polarization
capacity of the macrophages activation suggested the heterogeneity of two
subpopulations, namely classical activated macrophage and alternative
activated macrophage (AAM) might co-exist inside the grafts. The later
one has been suggested maintaining anti-inflammation activity and also
produced TGF-beta1. Arg1 is one of the markers of AAM. In this study,
the expression of Arg1 in grafts and the effect of PPAR-gamma agonist
rosiglitazone (Rosi) in Arg1 expression were investigated in our rat model
of cardiac transplantation
Materials and Methods: Heterotopic cardiac transplantations were performed
using F344 to Lewis as donor and recipient. The acute rejection was prevented
by 10-day course of cyclosporine A (CsA). The Rosi was applied along the
course of transplantation (CsA+Rosi). The grafts rejection and Arg1 expression
was examined at 30 days and 120 days after transplantation by histology and
immunohistochemistry analysis
Results: In normal and syngeneic transplant heart, Arg1 immune positive
(Arg1+) cells were barely detected. At 30 days after transplantation,
when compared between rejected and survived grafts, the total number of
macrophage (ED1+ cells) was much higher in the rejected grafts then that in
survived grafts. Simultaneously, Arg1+ cells were great increased in rejected
grafts, they were located around the vessels and intra myocytes space.
Arg1+ cells can also be detected in necrosis area. In contrast, the number
of Arg1+ cells was much less in survived grafts and mainly situated near
the blood vessels. In the grafts survived more than 120 days, the ED1+ cells
was reduced and the Arg1+ cells mostly found in occluded blood vessels at
outer layer and neointimal area. The Rosi treatment largely increase the grafts
survival time, beside the reduction of ED1+ cells, the number of the Arg1+
cells was 50 to 80% less then that in CsA alone group. In some necrosis
area in this group, only few of Arg1+ cells can be detected. Similarly, in the
grafts over 120days in CsA + Rosi group, the number of Arg1+ cells was also
much lower than that in CsA group. Furthermore, using adjacent section, we
showed the colocalization of Arg1 and CD163 (ED-2, another AAM marker)
inside the grafts and the expression of TGF-beta1 was also found colocalized
with Arg1+ cells.
Conclusion: Our data suggested the present of alternative activated macrophage
in chronic rejection grafts, which positively correlated to the grafts rejection. In
grafts vasculopathy, the present of the cells which produce higher level of TGFbeta might aggressive the vessels occlusion. Rosi treatment reduced the Arg1+
cells may explain the beneficial effect of the treatment in this experimental
transplantation model
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1515 HUMAN MONOCYTES REPRESENT A COMPETITIVE
SOURCE OF INTERFERON-ALPHA IN PERIPHERAL BLOOD
H. Hackstein, W. von Wulffen, L. Hansmann, G. Bein
University of Giessen
Interferon-alpha (IFN-á) has a critical role in anti-viral immunity and
plasmacytoid dendritic cells (pDCs) have been demonstrated the principal
IFN-á source after Toll-like receptor (TLR) 7 and 9 stimulation. Little is known
about the contribution of pDC-independent IFN-á sources to total IFN-á
production capacity of human peripheral blood. Using an array of pathogen
associated molecular patterns (PAMPs), Poly (I: C)/Dotap represented the
second strongest IFN-á stimulus in total PBMC. Poly (I: C)/Dotap induced
three times more IFN-á, when compared to TLR7-stimulation (R848) and four
times less, when compared to TLR9-stimulation. Dotap (mediator of cellular
uptake) dramatically increased Poly (I: C)-induced IFN-á production. Sorting
experiments and ELISpot assays revealed that monocytes and not myeloid
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DCs are the main IFN-á source after Poly (I: C)/Dotap stimulation. ELISpot
analyses demonstrated the highest IFN-á spot numbers after Poly (I: C)/
Dotap stimulation. Although pDCs produced highest IFN-á levels per cell,
monocytes represent a competing IFN-á source in total PBMC due to their
high frequency.
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1516 ROLE OF TH1/TH2 CYTOKINES IN KIDNEY
ALLOGRAFT REJECTION
M. Karczewski1, J. Karczewski2, M. Glyda1
1
Szpital Wojewodzki w Poznaniu, 2Uniwersytet Medyczny w Poznaniu
Background: One of the major issues the contemporary kidney transplantation
faces is rapid diagnosis and prevention of the acute allograft rejection (AR),
which occurs in approximately 20% of patients, significantly shortening the
time of allograft survival. Crucial mediators of immune reaction leading to AR
are cytokines. Understanding the role of those proteins in the AR process may
improve survival of kidney transplants. The aim of this project was to examine
the relation between the profile of serum Th1/Th2 cytokines and incidents of
AR in patients after kidney transplantation.
Patients, Materials and Methods: The project included 44 patients
undergoing kidney transplantation. During the three-month period following
the surgery AR was diagnosed in 11 patients. Diagnosis was based on
clinical signs, Doppler study and biopsy. Patients were treated with various
immunosuppressives. Pretransplantation epidemiological and clinical
characteristics of non-rejection (NONAR) and rejection (AR) patients were
examined in order to ensure that patient populations in NONAR and AR groups
were, in fact, similar. Serum samples were collected 1 day before and 2, 7, 14
and 30 days after transplantation. Each sample was tested for concentrations
of IL-2, IL-4, IL-5, IL-10, IFN-ã, TNF-á, using Human Th1/Th2 Cytokine
CBA Kit (BD Biosciences Pharmingen, USA) by means of flow cytometry.
Data were analyzed by Mann-Whitney U, Wilcoxon’s signed rank test and ÷2
test using the Spss v. 15 (SPSS, USA). Values were considered statistically
significant when p<0. 05.
Results: NONAR and AR patients did not show significant differences in
baseline characteristics (p>0, 05). The mean plasma cytokine concentration
levels in AR and NONAR patients were: IFN-ã pretransplantation 4, 53±1,
1 vs. 2, 64±0, 4 pg/mL (p=0, 000003); 2 days posttransplantation 4, 53±1, 1
vs. 2, 64±0, 4 pg/mL (p=0, 003); 7 days posttransplantation 8, 02±1, 7 vs. 6,
12±1, 3 pg/mL (p=0, 002); 14 days posttransplantation 9, 42±1, 7 vs. 6, 58±1,
2 pg/mL (p=0, 00002); 30 days posttransplantation 9, 98±2, 3 vs. 6, 29±1, 5
pg/mL (p=0, 000003), respectively; IL-10 pretransplantation 6, 87±0, 4 vs.
3, 69±0, 8 pg/mL, (p=0, 000001); 2 days posttransplantation 7, 40±0, 6 vs.
3, 95±0, 8 pg/mL (p=0, 000001); 7 days posttransplantation 8, 44±0, 9 vs.
6, 17±0, 7 pg/mL (0, 000002); 14 days posttransplantation 10, 42±1, 4 vs.
7, 44±0, 9 pg/mL (p=0, 000002); 10, 77±1, 5 vs. 6, 31±0, 8 pg/mL (p=0,
000001), respectively. Cytometric analysis also showed slightly higher IL-4
plasma levels in NONAR patients up till 7 days posttransplantation (p>0,
05), followed by a drop in concentration in NONAR patients and continuous
increase in AR patients (IL-4 30 days posttransplantation 4, 06±0, 9 vs.
2, 31±1, 2 pg/mL (p=0, 0002), respectively). No significant differences in
plasma levels of IL-2, IL-5, IL-10, TNF-á between the two groups were
observed (p > 0, 05).
Discussion: Higher pretransplantation levels of IFN-ã and IL-10 observed
in AR patients indicate the ongoing non-detected, probably non-specific,
inflammatory processes able to intensify the immune response directed
against the transplanted organ and leading to its acute rejection. Therefore,
increased pretransplant levels of both cytokines can be considered as
risk factors increasing the probability of AR incidents. On the contrary,
higher level of IL-4 prior to the transplantation and shortly afterwards
can have protective effect upon the graft. However, prolonged increased
production of IL-4 after transplantation can also increase the number of
AR incidents.
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1517 “PRUNING OF ALLOREACTIVE T CELLS PREVENTS
PANCREATIC ISLET ALLOGRAFT REJECTION ACROSS AN
MHC MISMATCH
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1518 CD10: A POTENTIAL NON-HLA ANTIGEN IN RENAL
TRANSPLANTION
T. Polhill1, Y.M. Wang1, G.Y. Zhang1, B. Howden1, X-M. Chen3,
C. Pollock3, D.C.H. Harris2, S. Alexander1
1
University of Sydney at Children’s Hospital, Westmead, 2Centre for
Transplant and Renal Research, University of Sydney at Westmead Hospital,
Westmead 2145, 3Department of Medicine, University of Sydney at Royal
North Shore Hospital, St Leonards, 2065
Background: CD10 (neutral endopeptidase (NEP)) is expressed highly in
the glomerulus. Alloantibodies against CD10 cause a severe form of neonatal
membranous glomerulonephritis. This occurs in rare cases of maternal CD10
deficiency, by feto-maternal transfer of antibodies against CD10, which bind to
fetal CD10. We aim to create a mouse model of antigen-specific renal disease.
One strategy employed to provoke an immune response is renal transplantation
in a setting where the only genetic difference between donor and recipient is
non-HLA linked, namely the CD10 gene.
Methods and Results: We obtained mice heterozygous for the CD10 knockout,
created on a C57BL/6 background by targeted deletion of Exon 13 of the CD10
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1519 A NOVEL ROLE OF NUCLEAR PROTEIN, HISTONE H1
ON TRANSPLANTATION IMMUNOLOGY
L-W. Hsu1,3, S. Goto1,2, T. Nakano1, C-Y. Lai1, S-H. Chen3, K-C. Chiang4,
T. Goto4, C-H. Yang1, C-C. Wang1, C-L. Chen1
1Department of Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical
Center, 2Department of Surgery, Iwao Hospital, Yufuin, Japan, 3Department
of Chemistry, National Cheng Kung University, Tainan, Taiwan, 4Kazusa
Institute for Drug Discovery, Josai Internation University, Kisarazu, Japan
We previously demonstrated that liver allograft tolerance is associated with the
immunosuppressive activity of anti-histone H1 autoreactive antibodies (Abs)
induced in the serum of liver transplantation. Furthermore, we and others have
shown that nuclear proteins such as histone H1 and high mobility group box
1 (HMGB1) play an important role in maturation of DCs although the precise
mechanisms are still unknown.
In the present study, we focus on the significance of histone H1 on DCs in terms
of the intracellular signaling pathway of DCs. Initially, we confirmed the DCspecific morphology of cultured cells in our assay system, and that most of histone
H1-translocating cells expressed a rat DC lineage marker OX62. Subseqeunt
immunostaining and immunoblot studies demonstrated that histone H1 was detected
in cytoplasm and culture supernatants upon the activation of DCs. Furthermore, the
addition of histone H1 to DCs instead of adding with endotoxin upregulated major
histocompatibility complex class II (MHCII), the CD80 and CD86 surface markers
of DCs and the activation of MAPKs (p38 and ERK1/2) and IκBα. On the other
hand, histone H1 blockage by anti-histone H1 Ab downregulated the intracellular
activation of mitogen-activated protein kinases (MAPKs) (p38), IκBα and NF-κB
of DCs, and inhibited DC activity in the proliferation of CD4+ T-cells. We have also
shown that either treatment of recipient rats with commercially available histone
H1 polyclonal Ab or immunization with calf thymus histone H1 could prolong
allograft survival in heterotopic heart transplantation.
These results suggest that the translocation of histone H1 from nuclei to cytoplasm
and the release of their own histone H1 are necessary for the maturation of DCs
and the activation for T-lymphocytes. Therefore, immunosuppressive therapy
with anti-hitsone H1 Ab or immunization of recipients with histone H1 prior
to transplanataion may have a great potential to be novel immunosuppressive
therapies in organ transplantation.
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1520 MONOCYTES PRIMED WITH INTERFERON-Γ
DIFFERENTIATE INTO MATURATION-ARRESTED
REGULATORY DENDRITIC CELLS THAT INDUCE T CELL
HYPORESPONSIVENESS
D. Rojas1,2 , R. Krishnan1,2
1
Transplantation Immunology Laboratory, Basil Hetzel Institute, The Queen
Elizabeth Hospital, Woodville and 2Department of Medicine, The University
of Adelaide, South Australia.
Interferon-γ (IFN-γ) is a pro-inflammatory cytokine that activates T cells
and induces the proliferation of T-helper 1 (TH1) cells that cause allograft
rejection. Paradoxically, cardiac allografts transplanted in IFN-γ deficient mice
as recipients are rejected rapidly in contrast to wild type mice. This observation
suggests that IFN-γ has a potential role in regulating immune responses that
lead to allograft rejection. We hypothesised that IFN-γ may act on dendritic
cells (DC) which are the major antigen presenting cells that initiate allograft
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M. Hu1, W.J. Hawthorne2, J.M. O’Hara2, K. Hucker2, J. Wu2, S. Yi2,
D. Watson1, G.Y. Zhang1, Y.M. Wang1, M. Sartor3, P.J. O’Connell2,
S.I. Alexander1
1
Centre for Kidney Research, Children’s Hospital at Westmead, 2National
Pancreas Transplant Unit, Westmead Hospital, 3WICR, Millennium Institute
Westmead, University of Sydney, NSW, Australia
Background: Islet transplantation is now a clinical therapy for diabetes.
However successful transplants appear to have a limited survival. One of
the potential causes is T cell mediated allorecognition. We have previously
reported that “pruning” of alloreactive CD4+ T cells based on their proliferation
prolongs skin allograft survival across an MHC mismatch.
Aim: In this study our aim was to establish whether “pruning” of alloreactive
CD3+ T cells protects pancreatic islet allograft from rejection.
Methods: Responder BALB/c (H-2d), splenocytes stained with CFSE were
stimulated with irradiated C57BL/6 (H-2b) splenocytes in a mixed lymphocyte
reaction (MLR). At day 5, cells were sorted into dividing and non-dividing CD3+
T cells based on fluorescent CFSE staining, then adoptively transferred into
SCID mice (BALB/c background). At 42 days of reconstitution, streptozotocin
inducted diabetic SCID mice were transplanted with C57BL/6 pancreatic islets
under their right renal capsule. Successful islet function was defined by a BSL<10
mmol/L and allograft rejection by a BSL>16 mmol/L. Flow cytometry analysis
was performed for cell phenotype in the MLR, and following reconstitution.
Results: SCID mice reconstituted with non-dividing CD3+ T cells demonstrated
prolonged pancreatic islet allograft survival (MST>100 days) compared to the
dividing group (MST = 8 days) (p = 0. 0022). In vitro flow cytometry analysis
after 5 days MLR showed that 58% ± 2. 3 of BALB/c CD3+ T cells were
dividing while 42% ± 2. 3 were non-dividing CD3+ T cells. Both dividing and
non-dividing CD3+ T cells contained CD4+ and CD8+ T cells. As expected, the
dividing CD3+ T cells had higher levels of activation markers such as CD69
and CD25 than in the non-dividing CD3+ T cells. In vivo equivalent number
of dividing and non-dividing CD3+ T cells was detected in peripheral blood
(PB) of SCID mice 16 days after reconstitution. The percentage of CD3+/
CD45+ was 7% ± 1. 9 in SCID mice receiving dividing CD3+ cells and was
9% ± 0. 9 in SCID mice receiving non-dividing CD3+ T cells. Tregs as defined
by CD4+CD25+ were equivalent between both groups. However γδ T cell
expression was higher in PB (10% ± 3. 6) and spleen (12. 1% ± 8. 6%) of longterm pancreatic islet allograft surviving SCID mice (>100 days post transplant)
compared with naïve mice including BALB/c (1 – 5%), and SCID mice with
dividing CD3+ T cells at the time of rejection (2. 7% ± 0. 9%).
Conclusions: Pruning of alloreactive T cells allows long-term pancreatic islet allograft
survival across an MHC mismatch in a mouse model. The high number of γδ T cells
observed, suggest that this may contribute to the mechanism of graft acceptance.

gene (C Gerard, Boston). By Western blotting, we confirmed the absence of
CD10 protein in homozygous knockout offspring using a polyclonal CD10
antibody. No offspring of CD10-homozygous knockout female mice crossed with
heterozygous males spontaneously develop renal disease, after investigation of
colocalisation of anti-CD10 and anti-IgG under fluorescence microscopy; urine
protein and creatinine; and renal morphology under light microscopy at 14 days of
age. Additionally, renal disease cannot be induced in pups by immunising female
mice with renal extract containing CD10. Preliminary results from transplantation
show by electron microscopy that a wild-type kidney transplanted into a CD10immunised, CD10-/- female provokes antibody deposition in the donor kidney.
Conclusions: CD10 deficiency in mice as compared to humans does not lead to
neonatal immunisation and transfer of disease. However differences in CD10
expression may lead to alloantibody responses in transplantation.
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rejection. Therefore we examined the effect of IFN-γ on DC differentiation and
allostimulatory capability.
Monocytes were primed with IFN-γ at the time of DC differentiation with IL4
and GMCSF for 5 days and compared with un-primed cells as controls. The
maturation of the IFN-γ DC were performed by treatment with TNF-α for 2
days. Phenotypic analysis by flowcytometry of the IFN-γ-primed monocytes
demonstrated typical DC differentiation with IL4/GMCSF as indicated by
the loss of CD14 and the expression of DC-SIGN similar to un-primed cells.
However, upon maturation with TNF-α, the IFN-γ DC demonstrated a profound
downregulation in the expression of the maturation marker CD83 (76-94%
inhibition of positive cells) and CD86 (62-71% inhibition of MFI) compared to
unmodified DC. Furthermore, Rel B mRNA analysis of IFN-γ DC showed an
87% (p=0. 0005) inhibition compared to unmodified DC confirming that these
cells were maturation-arrested. Interestingly, IFN-γ DC showed a 95% (p=0.
0002) reduction in interleukin-12 (IL-12) mRNA compared to unmodified DC.
Moreover, IFN-γ DC as stimulators in the DC-MLR induced allogeneic T cell
hyporesponsiveness compared to unmodified DC (27, 500 +/- 1800 cpm vs 9400
+/-1300 cpm, respectively; p=0. 00004). To ascertain the mechanism of T cell
hyporesponsiveness in the MLR, allogeneic T cells were cocultured with IFN-γ
DC and assessed for FoxP3 expression by flowcytometry. Surprisingly, IFN-γ
DC generated approximately 3-fold reduction in FoxP3+ T cells compared to
unmodified DC (31. 5% +/- 10. 5% vs%13. 5 +/- 4%, p=0. 01). While the
priming of monocytes with IFN-γ modified the DC phenotype and function,
treatment of DC post-differentiation demonstrated no regulatory effects.
In conclusion, the immunomodulatory effect of IFN-γ is mediated by the
suppression of DC maturation. The induction of T cell hyporesponsiveness by
IFN-γ DC is not likely to be governed by suppressive mechanisms involving
FoxP3+ T regulatory cells however, T cell anergy due to the downregulation of
CD83 may be contributory to the effect.

POSTER BOARD NUMBER P2 – 320
1521 INCREASED EXPRESSION OF TRANSGLUTAMINASE
(TG2) IN THE FISHER-TO-LEWIS RAT MODEL OF CHRONIC
ALLOGRAFT NEPHROPATHY
B.M. Shrestha, I. Butt, M. Delbridge, B.E. Wagner, A.T. Raftery,
M. El Nahas, T. Johnson, J.L. Haylor
Sheffield Kidney Institute
Introduction: Chronic allograft nephropathy (CAN), the leading cause of
renal allograft loss, involves expansion of the extracellular matrix (ECM) and
is associated with tubular atrophy, interstitial fibrosis, glomerulosclerosis and
obliterative arteriolopathy. Transglutaminase (TG2) is believed to be central to
this expansion by crosslinking proteins through the formation of å (ã-glutamyl)lysine dipeptide bonds that causes accelerated ECM deposition and resistance
to proteolytic clearance. The aim of this study was to investigate the activity
and distribution of TG2 and å (ã-glutamyl)-lysine in the Fisher-to-Lewis (F-L)
rat model of CAN.
Methods: Under isoflurane anaesthesia, donor kidneys obtained from Fisher
rats (allograft) (n=7) or Lewis rats (isograft) (n=5) were transplanted into
Lewis rats (N=12) using end-to-side anastomosis employing aortic and inferior
venacaval conduits. Total renal TG2 activity was measured using the [14C]
putresceine incorporation assay. TG2 protein and its cross-linked product å
(ã-glutamyl)-lysine were detected by immunofluoresence (FITC/DAPI) and
quantified by image analysis.
Results: F-L allografts were hypertensive (systolic BP 124 ± 11 vs. 159
± 11 mmHg, p<0. 05) and proteinuric (37 ± 17 vs. 303 ± 80 mg/24h, p<0.
05) with a lower creatinine clearance (1. 57 ± 0. 19 vs. 0. 62 ± 0. 18 ml/min,
p<0. 05) than Lewis-to-Lewis (L-L) isografts. Masson’s trichrome staining
showed an increased expansion of the ECM in the F-L allografts together with
tubular atrophy and tubular dilatation. Electron microscopy confirmed the
changes of CAN in the allografts. Kidneys from the F-L allografts had higher
transglutaminase activity (0. 41 ± 0. 03 vs. 1. 09 ± 0. 13 nmol/h/mg protein,
p<0. 05) than the L-L isografts. Immunofluoresence showed a marked increase
in FITC/DAPI ratios for both TG2 protein (glomeruli: 2. 1 ± 0. 2 vs. 64. 5
± 17. 6, p<0. 001; interstitium: 3. 2 ± 0. 4 vs. 13. 7 ± 1. 6, p<0. 001) and å
(ã-glutamyl)-lysine (glomeruli: 2 ± 0. 4 vs. 21. 7 ± 2. 7, p<0. 01; interstitium:
0. 4 ± 0. 1 vs. 37. 9 ± 17. 1, p<0. 05) in the F-L allografts.
Conclusions: An increased expression of renal TG2 and å (ã-glutamyl)-lysine
was observed in both glomeruli and the renal interstitium in the F-L rat model of
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CAN. This therefore provides a suitable model for interventional studies using
TG2 inhibitors to treat CAN based on the successful use of these compounds
in slowing the development of renal scarring in other animal models of chronic
renal failure.

POSTER BOARD NUMBER P2 – 321
1522 MURINE DENDRITIC CELLS (JAWS II) EXPRESSING
SOLUBLE CTLA4IG PROLONGS FIRST AND SECOND SET
SKIN GRAFT SURVIVAL
F. Ierino1,2, W. Mulley1, N. Dodge1, Y.Q. Li1, D. Christiansen1, M. Sandrin1
1University of Melbourne, 2Austin Health
Genetically engineered Dendritic cells (DCs) expressing immunomodulatory
molecules have potential therapeutic application in transplantation.
Aims: Prime mice with a murine DC cell line (JAWS II) expressing CTLA4Ig
and determine the in vitro (proliferation assays) and vivo (skin graft)
immunological effects.
Methods: The mouse DC cell line, JAWSII (C57/BL6) was transduced with
lentivirus to express either soluble CTLA4Ig or green fluorescent protein
(GFP control protein) These transduced DCs were then used to immunise
BALB/c mice in vivo. After 7-10 days, splenocytes from immunised mice
were used in proliferation assays against C57/BL6 (donor) and CBA (3rd
party) stimulators. Mice also received skin grafts from C57/BL6 and CBA
mice donors. Two months later, mice that had rejected their grafts were
re-transplanted with C57/BL6 (donor) and CBA (3rd party) skin grafts to
determine whether second-set rejection could be inhibited, and whether
systemic immune modulation had resulted from the priming with DC.
Splenocytes from mice primed with JAWSII-CTLA4Ig had a significantly
lower stimulation index (SI) to C57BL6 compared with JAWSII-GFP (45%
reduction, p=0. 008) at day 3 and 28% reduction, p= 0. 07, at day 4. Third
party responses were not significantly different, confirming the response was
specific. There was an increase in ratio of CD4+25hi T-cells in the JAWSIICTLA4Ig C57B6/CBA cultures compared to JAWSII-GFP. In vivo, there was
specific prolongation of C57/BL6 skin graft survival in the JAWS-CTLA4Ig
primed mice in both the first set (Figure: Left panel) and second-set rejection
responses (Figure Right panel).
The peripheral blood of mice injected with JAWSII-CTLA4Ig expressing DC
and control DC, are being examined for markers of Regulatory T cells.
Conclusion: These studies confirm the potent effects of modified DC in primary
and secondary responses, and that systemic modulation of T cell responses are
established. The mechanism of this regulation is under investigation.

POSTER BOARD NUMBER P2 – 322
1523 CD4+ Ô CELL IMMUNE FUNCTION IN RENAL
TRANSPLANT RECIPIENTS UNDER SPECIFIC
IMMUNOSUPPRESSIVE PROTOCOLS
A. Iniotaki1, A. Vitoraki1, M. Darema2, I. Synodinou2, A. Kostakis2,
J. Boletis2, M. Apostolaki1
1National Tissue Typing Center, General Hospital of Athens, 2Nephrology
Department And Transplantation Unit, Laikon Hospital, Athens Greece
The evaluation of the status of CD4+ T cell immune function in renal
transplant (RTx) recipients may be useful in order to optimize the
immunosuppression. In this study, intracellular adenosine triphosphatase
(ATP) levels were evaluated in 392 clinically stable RTx recipients and 104
volunteers blood donors that were used as control population (NC). Blood
samples (n=451) were collected at various post Tx intervals and ATP (ng/
ml) levels were measured in CD4+ Ô cells following stimulation with PHA
in whole blood culture. Regarding the immunosuppressive protocols 287
patients, were separated in 4 groups: group A (n=125) who received MMF/
CsA/MP, group A1 (n=40) who received MMF/CsA, group B (n=97) who
received MMF/Fk/MP and group B1 (n= 15) who received MMF/Fk. ATP
levels were tested for the ability to discriminate patients from controls
using receiver operating characteristic (ROC) curve. Analysis of variance
–ANOVA with Tukey s correction was used for multiple comparisons.
The patients (n=392) had significantly lower levels of intracellular ATP with
cut-off value 314 ng/ml compared to NC (p=. 005). Intracellular ATP levels
were found significantly lower in group A1 (284. 6 ng/ml) in comparison with
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group A (354. 5 ng/ml) p=. 009. Creatinine levels were significantly lower (p=.
0019) in group A1 patients (1. 4 mg/ml) comparatively to group A patients (1.
6 mg/ml). Mean time post RTx was significantly higher for group A1 (8. 2y)
and B1 (4. 4y) compared to group A (7. 2y) and B (2. 4y) patients (p=. 050 and
p=. 016 respectively).
The above results indicate that MP withdraw in clinically stable RTx recipients is
followed by suppression of T cell immune status and has no effect on graft function

POSTER BOARD NUMBER P2 – 323
1524 EARLY GROWTH RESPONSE (EGR)-1 AND ITS TARGET
GENES CORRELATES WITH LUNG GRAFT FUNCTION IN
RATS

POSTER BOARD NUMBER P2 – 324
1525 LONG TERM ACCEPTANCE OF FULL MHC DISPARATE
LUNG ALLOGRAFTS IN MINIATURE SWINE IS NOT
PERTURBED BY EXPOSURE TO DONOR ANTIGEN
T. Shoji1, H. Sahara1, A. Aoyama1, A. Muniappan1, D. Guenther1, J. Wain1,2, S.
Houser1, M. Bravard1, J. Madsen1,3, J. Allan1,2
1
Transplantation Biology Research Center, Massachusetts General Hospital,
2
Division of Thoracic Surgery, Massachusetts General Hospital, 3Division of
Cardiac Surgery, Massachusetts General Hospital
Background: We have previously reported that long-term acceptance of MHC
disparate lung allografts in miniature swine can be achieved using an intensive
12-day course of tacrolimus. To determine whether the state of graft acceptance
would be perturbed by exposure to donor antigen following transplantation,
skin grafts were placed on animals with viable lung graft long term.
Methods: Six of SLAdd (Id/IId) swine were transplanted with full MHC
SLAaa (Ia/IIa, n=3) or SLAcc (Ic/IIc, n=3) lungs. All recipients were treated
with a 12-day course of high-dose tacrolimus (0. 15 mg/kg/d, POD0-11).
Recipients with long term graft acceptance (>350d) underwent skin grafting
with frozen donor skin, donor MHC-matched (minor antigen-mismatched)
skin, and fully mismatched SLA skin bearing third-party class I plus thirdparty class II antigens.

POSTER BOARD NUMBER P2 – 325
1526 THERAPEUTIC STRATEGY FOR COUNTERACTING
COMPLEMENT IN T CELL ACTIVATION
W. Zhou, Q. Peng, K. Li, C. Farrar, R. Smith, S. Sacks
King’s College London
Our previous studies in murine acute rejection and in the analysis of human
long term graft outcome have shown that local production of C3 in donor
organs appears to be a major determinant of graft survival. In addition, we have
shown that APCs prepared from C3-/- mice have reduced ability to stimulate
alloreactive T cells in vitro and in vivo. We envisage that complement activation
at the surface of APCs will lead to enhanced allo-stimulatory capacity of those
cells and/or provide essential help for T cell stimulation at the immunological
synapse. Conversely, we propose that therapeutic overexpression of complement
regulator will lower the alloreactive T cell stimulatory capacity of APCs in
favour of immune suppression/tolerance.
We first assessed if APT070, a membrane–localising complement regulator
can inhibit murine complement activation and bind to murine bone marrow
dendritic cells (DCs). Using a haemolytic assay, we show that APT070
(20&#61549;g/mL) inhibits >75% of complement mediated cell lysis. Using
immunochemical staining and flow cytometry with anti-human CD35 mAb, we
show that APT070 efficiently binds to DCs.
We next determined if APT070 treatment modulates DC activation and their
function in alloreactive T cell stimulation. APT070 (20&#61549;g/mL) or
control molecule (APT544) was added to the DC culture medium, from the
beginning of BM cell culture, with repeated addition every two days. We show
that compared to control molecule treated DCs, APT070 treated DCs exhibit a
tolerogenic cytokine profile with a lower IL-12 and higher IL-10 production;
when co-cultured with naïve allogeneic CD4 T cells, they elicit significantly
lower T cell responses measured by IFN-γ; production and thymidine uptake.
Our findings showing that APT070 treatment reduces the alloreactive T cell
stimulatory capacity of donor DCs may have therapeutic potential for targeting
the alloreactive T cell response in allograft rejection.

POSTER BOARD NUMBER P2 – 326
1527 HOST ENDOTHELIAL AND MESENCHYMAL
CHIMERISM IN EXPERIMENTAL CHRONIC ALLOGRAFT
NEPHROPATHY
J.L. Hillebrands1, H. Rienstra1, M. Boersema2, A. Zandvoort1,5, A. Smit-van
Oosten5, J. Rozing1, H. van Goor3, G.J. Navis4
1
University Medical Center Groningen, Dept. Cell Biology – Immunology,
2
University Medical Center Groningen, Dept. Pathology & Laboratory
Medicine, Div. Medical Biology, 3University Medical Center Groningen,
Dept. Pathology & Laboratory Medicine, Div. Pathology, 4University Medical
Center Groningen, Dept. Internal Medicine, Div. Nephrology, 5University
Medical Center Groningen, Central Animal Facility
Background: Vascular and interstitial remodeling are hallmarks of chronic
allograft nephropathy (CAN). Vascular remodeling (transplant arteriopathy)
is characterized by occlusive neointima formation resulting from uncontrolled
smooth muscle cell (SMC) proliferation. Interstitial remodeling is characterized
by myofibroblast recruitment and proliferation culminating in interstitial
fibrosis. Both transplant arteriopathy and interstitial fibrosis supposedly lead to
deterioration of graft function. The origin (graft vs. host) of neointimal ECs and
SMCs as well as interstitial myofibroblasts in CAN still is a matter of debate.
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O. Yoshida, M. Yamane, S. Yamamoto, S. Toyooka, T. Ohto, Y. Sano
Okayama University Graduate School of Medicine Depertment of Cancer And
Thoracic Surgery
Background: Primary graft dysfunction (PGD) caused by ischemia reperfusion
injury (IRI) is a major clinical problem after lung transplantation. Early growth
response (EGR)-1 is a transcription factor induced by various stimuli including
hypoxia and reoxigenation. It regulates the expression of proinflammatory cytokine,
adhesion molecules and other genes pertinent to inflammation, coagulation and
proliferation associated with IRI. EGR-1 is known to play roles in IRI. Changes in
the levels of transcripts for EGR-1 and the target genes for the duration of reperfusion
have not yet been investigated. We examined the correlation of the pulmonary graft
function and gene expression patterns of Egr-1 and its target genes.
Methods: Sprague-Dawley rat lungs were harvested and stored at 4 centigrade
degrees for 3h or 18h followed by left lung transplantation and reperfusion
for up to 4h. Transplanted lungs were assessed with blood gas analyses
after ligation of right pulmonary artery, and then harvested and stored at -80
centigrade degree. Transcript levels of EGR-1, ICAM-1, IL-1beta, MIP-2 and
PAI-1 in lung tissues were analyzed with semi-quantitative RT-PCR.
Result: Compared with 18h cold preserved lung, 3h cold preserved lung
displayed significant higher oxygenation during 4h of reperfusion. RT-PCR
revealed that prolonged cold preservation induced more relevant upregulation
of EGR-1 mRNA in the lung tissues after transplantation. Maximum levels
of EGR-1 transcript were observed after 1h of reperfusion regardless of cold
preservation length. Cold ischemia alone did not induce mRNA for EGR-1 and
target genes. PAI-1 and MIP-2 mRNA expression increased for up to 4hours in
long time preserved lungs. Significant change in ICAM-1 mRNA level was not
observed during observation time regardless of preservation time.
Conclusions: The patterns of changes in mRNA levels of EGR-1 and target
genes after transplantation were various and related with the severity of IRI and
prolonged cold preservation. Target genes may have other regulatory pathways
such as a signal from tissue damage, negative feedback of cytokines and other
MAPK cascades and so on.

Results: 5 of the 6 recipients maintained their grafts long term (>350d). Isolated
lesions of obliterative bronchiolitis (OB) were occasionally seen on open lung
biopsy, and donor-specific hyporesponsiveness on MLR and CML assays was
consistently observed. The other recipient rejected its graft on POD 103 with
histologic findings of OB. 5 animals with long term graft acceptance underwent
skin graft and all 5 animals rejected donor skin grafts in 18, 20, 22, 22, 23 days,
respectively. Nonetheless, all animals continued to maintain their lung grafts
without pathological change following skin grafting. After skin grafting, MLR
and CML responses against donor-type cells were not increased.
Conclusions: After exposure to donor antigen following transplantation, the
lung grafts themselves remained stably engrafted without histologic or clinical
evidence of progression of rejection.
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We therefore determined the origin of ECs, SMCs and myofibroblasts in an
experimental model of CAN in rats.
Methods: Dark Agouti (DA) allografts were transplanted to human
Placental Alkaline Phosphatase (hPAP) transgenic F344 rats. hPAP F344
rats constitutively express hPAP in nucleated cells which can be detected by
hPAP-specific immunostaining. DA isografts served as controls. Recipient
rats received ciclosporin (5 mg/kg) on the first 10 days after transplantation.
Contralateral nephrectomy was performed 10 days after transplantation. Renal
function was determined before transplantation and 4, 8 and 12 weeks after
transplantation. Recipients were sacrificed 12 weeks after transplantation or
earlier in case of poor condition. Grafts were processed for histological analysis
and severity of transplant arteriopathy, glomerulosclerosis and interstitial
fibrosis was determined. Furthermore, host EC, SMC and myofibroblast
chimerism was determined by specific immunofluorescent staining using the
following antibodies: RECA-1 (ECs), 1A4 (á-smooth muscle actin [SMCs/
myofibroblasts]), MN4-91-6 (DA MHC class I) and anti-hPAP (transgene).
Results: Compared with isografts, allografts presented with severe CAN
characterized by glomerulosclerosis, tubular atrophy, transplant arteriopathy
and interstitial fibrosis. These histological changes were associated with
reduced renal function as indicated by proteinuria and reduced creatinine
clearance. Graft survival was inversely correlated with the severity of
transplant arteriopathy. Immunolabeling for hPAP, DA MHC class I and
smooth muscle actin revealed graft origin (co-expression DA MHC class I and
smooth muscle actin) of virtually all neointimal SMCs in allografts. Similar
results were obtained for neointimal ECs. However, host EC-chimerism
was detected in peritubular and glomerular capillaries; 62% of glomeruli in
allografts contained host-derived ECs (RECA-1+hPAP+; ~2 host ECs/chimeric
glomerulus/cross-section). Staining for smooth muscle actin revealed increased
numbers of cortical interstitial myofibroblasts in allografts (vs. isografts),
indicative of interstitial fibrosis. Immunolabeling for hPAP, DA MHC class I
and smooth muscle actin revealed presence of both graft- and recipient-derived
interstitial myofibroblasts. Quantitative analysis revealed 53% of interstitial
myofibroblasts to be of host-origin.
Conclusions: Neointimal SMCs and ECs in CAN are graft-derived indicating
that endothelial repair as well as neointima formation in graft arteries are
mediated by cells residing within the graft. In contrast to vascular remodeling
in the larger arteries, the development of interstitial fibrosis involves both
graft- and host-derived myofibroblasts. These results suggest that interstitial
myofibroblasts are derived from distinct cell lineages, which may separately
or in concert contribute to interstitial fibrosis in CAN. We propose that hostderived mesenchymal progenitor cells are a putative target for therapeutic
intervention. Reduced mesenchymal progenitor cell recruitment is expected to
attenuate interstitial fibrosis resulting in prolonged graft function.

POSTER BOARD NUMBER P2 – 327
1528 SPIRONOLACTONE AMELIORATES FOCAL
GLOMERULOSCLEROSIS AND TRANSPLANT
ARTERIOPATHY IN EXPERIMENTAL CHRONIC ALLOGRAFT
NEPHROPATHY IN RATS
J-L. Hillebrands2, F. Waanders1, H. Rienstra2, J. Rozing2, A. Zandvoort1,4, A.
Smit-van Oosten4, G.J. Navis1, H. van Goor3
1
University Medical Center Groningen, Dept. Internal Medicine, Div.
Nephrology, 2University Medical Center Groningen, Dept. Cell Biology –
section Immunology, 3University Medical Center Groningen, Dept. Pathology
& Laboratory Medicine, Div. Pathology, 4University Medical Center
Groningen, Central Animal Facility
Background: Chronic allograft nephropathy (CAN) is the leading cause of
long-term renal allograft loss. CAN is characterized by histopathological
changes including focal glomerulosclerosis (FGS), interstitial fibrosis, tubular
atrophy and transplant arteriopathy (neointima formation). No effective therapy
is available to prevent CAN. Increasing evidence indicate that aldosterone
plays a significant role in renal damage via the non-epithelial mineralocorticoid
receptors. The aldosterone antagonist spironolactone has been shown to
attenuate renal ischemia/reperfusion injury in rats. In this study we determined
the efficacy of spironolactone in attenuating CAN after experimental renal
transplantation in rats.
Methods: Renal transplantation was performed in the allogeneic Dark
Agouti-to-Wistar Furth rat strain combination. Dark Agouti-to-Dark Agouti
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isografts served as controls. Transplanted rats received ciclosporin (5 mg/kg
BW) on the first 10 days after transplantation. 14 days after transplantation,
nephrectomy of the remaining host kidney was performed. Recipients received
either spironolactone (20 mg/kg BW) (+) or vehicle (-) daily by oral gavage
till the end of the experiment. Treatment started 2 days before transplantation.
4 experimental groups were included: 1) isograft- (n=8), 2) isograft+ (n=8),
3) allograft- (n=9) and 4) allograft+ (n=9). Before, and every 2 weeks after
transplantation systolic blood pressure and urinary protein excretion were
determined. Grafts were retrieved 12 weeks after transplantation and processed
for histological analyses (i. e. glomerulosclerosis, interstitial fibrosis,
macrophage infiltration, transplant arteriopathy).
Results: Isografts (both + and -) survived until the end of the experiment.
Spironolactone improved allograft survival rates (p=0. 07, borderline
significance, group 3 vs. 4). Isograft recipients did not develop proteinuria. In
contrast, allograft recipients developed clear proteinuria which was attenuated
by spironolactone (77±28 mg/day [group 3] vs. 41±10 mg/day [group 4];
p=0. 06). In time, spironolactone did not affect systolic blood pressure in both
isograft and allograft recipients. In contrast to isografts, allografts presented
with prominent glomerulosclerosis and interstitial fibrosis. Spironolactone
significantly attenuated severity of focal glomerulosclerosis in allografts
(100±37 A. U. [group 3] vs 47±17 A. U. [group 4], p<0. 05) however without
affecting interstitial fibrosis. Reduced focal glomerulosclerosis in allografts
from spironolactone-treated recipients was accompanied by reduced glomerular
infiltration with ED-1+ macrophages (p<0. 05, group 3 vs. group 4). Allografts
presented with severe neointima formation which was significantly reduced
(p<0. 05) by spironolactone.
Conclusion: Blockade of mineralocorticoid receptors by the aldosterone
antagonist spironolactone ameliorates proteinuria, focal glomerulosclerosis and
transplant arteriopathy but not interstitial fibrosis in an experimental rat model
for CAN. We propose that the observed glomerulo- and vasoprotective effects
of spironolactone might result in improved graft survival on the long-run.

POSTER BOARD NUMBER P2 – 328
1529 EXPLORATION OF THE ROLE OF B7H4 IN CHRONIC
ALLOGRAFT VASCULOPATHY
J. Popoola, J. Yang, M. Sayegh, A. Chandraker
Brigham And Women’s Hospital, Children’s Hospital and Harvard Medical
School
Introduction: The specific roles and significance of the newer co-stimulatory
pathways such as B7H4 (B7S1 or B7X) are not entirely clear. B7H4 is of
particular interest in the context of transplantation because of its ubiquitous
expression. It is speculated that the co-stimulatory regulation of T cells by
B7H4 is influenced by the activation status of B cells and that BTLA may act
as a putative ligand.
Methods: Unmodified wild-type C57BL/6 recipients of BM12 class II
mismatched heterotopic cardiac transplants were used as a model of chronic
allograft rejection. The treatment group received anti-B7H4 monoclonal
antibody (mAb) or B7H4 fusion protein while the control group received
IgM mAb administered on days 0, 2, 4, 6, 8 and 10. Graft survival and
histopathological change were compared and assessed at 8 weeks. In-vitro
studies were carried out at 21 and 56 days and assessed by flow cytometry
for temporal variation and phenotypic differentiation of the activation status,
regulatory T cell markers and effector cell generation to dissect the mechanisms
of action of anti-B7H4 in the setting of development of chronic allograft
nephropathy.
Results: A class II mismatch was used to assess the effect of inhibiting the
B7H4 pathway in a chronic rejection model. Graft survival was not significantly
shortened in the presence of a class II mismatch in untreated wild type
mice (MST=53. 7+/-5. 6, n=7) compared to treatment with B7H4 antibody
(MST=51+/-6. 3, n=5), or B7H4 fusion protein MST=54+/-2. 3. Histology
however showed a greater degree of cellular infiltration (haematoxylin and eosin
staining), fibrous change (trichrome staining) and vasculopathy (elastin staining)
signifying worsened chronic damage. Characterisation of the cellular infiltrate
by immunohistochemistry showed a predominance of T cells (CD4+, CD8+)
and macrophages (CD11b+) within the allograft. B7H4 was demonstrable in
the interstitium of the IgM control treated animals with a particular locale for
the vascular endothelium by immunofluorescence and confocal microscopy.
To further confirm the presence of B7H4 on cardiac vascular endothelium we
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1530 COMPARTMENTALIZATION OF PLATELET DERIVED
CD154: IMPLICATIONS FOR CLINICAL CORRELATION.
A. Kirk1, A. Charafeddine1, T. Weaver1, D. Maynard2, W. Gahl2
Emory University, 2National Human Genome research institute-National
institues of Health (NIH)
CD154 plays a crucial role in allograft rejection by serving as the ligand for
CD40, an activation molecule on APCs. Platelets have recently been found as
a major storage compartment of CD154, and platelet-derived CD154 has been
shown to be sufficient to support rejection in vivo. We sought to determine the
mechanism of CD154 release from platelets. There are two types of secretory
granules in platelets: alpha and dense granules. Serum and platelets from
Hermansky-Pudlak syndrome (HP, lacking dense granules), and grey platelet
syndrome patients (GP, lacking alpha granules) were obtained. Serum samples
(from clotted blood containing products of platelet degranulation) from GP had
no CD154 (0+/-0pg/ml, n=3) while normal serum was rich in CD154 (10, 038
+/- 3637pg/ml; n=71). However, HP patients had normal serum CD154 (11,
405+/-4, 779pg/ml; n=3). Sucrose gradient alpha granule enriched subcellular
fractions from normal platelets had higher levels of CD154 than the cytosolar
fractions (6200 vs 254 pg/ml respectively). Platelet cytosol from alpha granule
deficient platelets surprisingly also had high levels of CD154 (>50, 000 pg/
ml), indicating that CD154 is present in platelets lacking alpha granules but
cannot be released upon thrombus formation. Finally, an immuno-Electron
microscopy using gold labeled anti-CD154 antibodies shoed alpha granule
decoration of normal human platlets. With alpha degranulation required for
CD154 release, plasma but not serum would represent ambient/physiologic
CD154. Serum CD154 has been associated with several inflammatory disease
processes, but serum, a product of clot, is not reflective of in vivo conditions;
rather, plasma is. Blood from normal humans (n=100) was thus studied
under varying collection circumstances including serum, platelet containing
plasma, and platelet free plasma. CD154 was not found in plasma (non-clotted,
representative of physiologic in vivo conditions), but was only evident when in
vitro platelet activation was present. Indeed, serum CD154 levels were merely
correlated with platelet count (p<0. 0001), and changed with changes in platelet
1

content and in vitro activation. We conclude that platelet CD154 release is an
alpha granule mediated process that is dependent on activation such as that
involved in thrombus formation. Under physiologic circumstances in the
absence of platelet activation, CD154 is not a normal soluble blood component.
This mechanism of release is consistent with a regulated, locally responsive
delivery of CD154 providing APC stimulation at sites of trauma.

POSTER BOARD NUMBER P2 – 330
1531 EXPLORATION OF THE ROLE OF THE NOVEL B7
FAMILY MEMBER B7H4 IN CHRONIC REJECTION
J. Popoola, J. Yang, A. Vidhyadharan, M. Sayegh, A. Chandraker
Brigham And Women’s Hospital And Harvard Medical School
B7H4 (B7S1 or B7X) is a member of the B7 family which includes (B7. 1,
B7. 2, B7-H3, ICOS, PD-L1 (B7-H1), PD-L2 (B7-DC). The specific role
and significance of B7H4 in solid organ transplants in the context of other
costimulatory pathways remains unclear. It is speculated that the co-stimulatory
regulation of T cells by B7H4 is influenced by the activation status of B cells
with BTLA being a putative ligand.
Unmodified wild-type C57BL/6 recipients of bm12 class II mismatched
heterotopic cardiac transplants (model of chronic allograft rejection). The
treatment groups received anti-B7H4 monoclonal antibody (mAb) or B7H4
fusion protein while the controls received IgM mAb administered on days 0,
2, 4, 6, 8 & 10. Graft survival, histology & in-vitro studies (flow cytometry,
proliferation assays, elispot & luminex) were carried out at 3 & 8 weeks.
Results: Graft survival was similar in controls, anti-B7H4 mAb or B7H4 fusion
protein treated (MST=53. 7+/-5. 6, n=7), (MST=51+/-6. 3, n=5), MST=54+/-2.
3, n=3) respectively. At 3 weeks there was increased damage to the interstitial
compartment compared to wild type. By 8 weeks, histology showed worse fibrosis
mean 80 vs 50 vs 57% and vasculopathy 80 vs 63 vs 55% in antiB7H4mAb vs
controls vs B7H4 fusion protein. Expression of B7H4 was demonstrable on
interstitium & vascular endothelium by immunofluorescence of donor allografts
from control animals, anti-B7H4 mAb resulted in reduced donor allograft
expression. The effect on the alloresponse was assessed by MLR average cpm
21032+/-2657 vs 10814 +/-4326 in anti-B7H4 mAb treated vs controls. B7H4
blockade, did not influence the number of regulatory T-cells (CD4+CD25+FoxP3+)
in the periphery. Additionally, unlike anti-PDL1 mAb, anti-B7H4 did not lead to
reduction in conversion of TGF-B induced regulatory T cells in-vitro. At 8 weeks
the effector-memory population was (18. 5+/-1. 5 vs 15+/-1. 8%) of the CD4 T
cell population (15+/-0. 9 vs 11. 7+/-1. 3%) of the CD8 population in anti-B7H4
mAb treated vs controls. There was up-regulation of both the Th1 (IFN-γ;) & Th2
(IL-4, IL-5) cytokine response verified by ELISPOT and increased production of
1L12 p40/70 by LUMINEX in the antibody treated group. B7H4 expression is
demonstrable on cardiac derived cultured endothelial cells un-stimulated ex-vivo.
Blockade of B7H4 accelerates changes of allograft vascuolpathy and fibrosis. Its
predominant effects appears to be mediated through its parenchymal expression
and its absence appears to lead to an enhanced alloimmune response. B7H4 may
serve as a potential therapeutic target for enhancing acceptance of donor grafts by
manipulation of the donor graft tissue.

POSTER BOARD NUMBER P2 – 331
1532 THE NKG2D RECEPTOR AND LIGAND ARE INDUCED
AFTER TRANSPLANTATION.
S. Krams, M. Zhuo, M. Fujiki, K. Piard-Ruster, O. Martinez
Stanford University School of Medicine
Background: Studies by our group and others suggest a role for NK cells
in acute and chronic allograft rejection. Indeed we have demonstrated that
calcineurin inhibitors do not block NK cell function. NKG2D is a C-lectin
type molecule expressed by NK cells and subsets of NKT and T cells. NKG2D
functions as a stimulatory receptor on NK cells and as a co-stimulatory
receptor on CD8+T cells. Interestingly, expression of NKG2D is induced by
DNA damage and cellular stress. The objective of this study was to determine
the expression and functional significance of NKG2D interactions after liver
transplantation.
Methods: We have cloned the rat homologue of NKG2D and developed
reagents to detect NKG2D expression in rat blood and tissue by quantitative
real-time PCR (q-PCR). Additionally two ligands of NKG2D have been
cloned, rat RAE-1L and rat RAE-1 like transcript (RRLT). Tissue expression of
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isolated and cultured endothelial cells from murine hearts un-stimulated ex-vivo
and showed expression of B7H4 having confirmed that these cells maintain the
phenotypic characteristics of uncultured vascular endothelium by both flow
cytometry and confocal visualization of the cytospan passaged cells. Treatment
with anti-B7H4 mAb resulted in loss of B7H4 parenchyma expression on donor
allografts in-vivo. The expression of B7H4 on haemopoietic cells remained at
similar levels in both the naive and in the recipient
Mixed lymphocyte reaction proliferaton assays from splenocytes cultured for
4 days gave an average cpm of 21032+/-2657 compared to 10814 similarly
with CFSE based proliferation assay – (1. 13+/-0. 21: 0. 44+/-0. 17, p
value =0. 01) in anti-B7H4 mAb treated recipients compared to controls.
Interestingly blockade of the B7H4 pathway did not significantly affect the
number of regulatory T cells (CD4+CD25+FoxP3+) in the periphery or within
in the allograft target tissue using FoxP3 staining by immunohistochemistry
compared to IgM controls. Additionally while anti-PDL1 mAb reduces the
conversion of TGF-B induced regulatory T cells, anti-B7H4 does not lead to a
similar effect. The effector memory population at 8 weeks was (18. 5+/-1. 5 and
15+/-1. 8) of the CD4 T cell population and of the CD8 population (15+/-0. 9
versus 11. 7+/-1. 3) in the anti-B7H4 mAb compared to IgM controls. Similarly
the CD4 effector: CD4 FoxP3+ regulatory cell ratio was increased in the antiB7H4 treated recipients 1. 9: 1. 6. There was up-regulation of both the Th1
(IFN-γ;) and Th2 (IL-4, IL-5) cytokine response verified by ELISPOT further
exploration of the cytokine mileu by LUMINEX showed increased production
of 1L12 p40/70 but reduced IL6 in the antibody treated group.
Conclusion: Here we present novel data exploring the potential role of
the co-stimulatory pathway B7H4 in the development of chronic allograft
vasculopathy. B7H4 serves as a negative co-stimulatory pathway in the context
of chronic allograft rejection. Its predominant effect appears to be through an
influence its expression on the endothelial parenchymal tissue and its influence
on the effector cell population and its blockade results in up regulation of the
cytokine response potentially providing a window for involvement of cells of
both the innate (macrophages) and adaptive (T cells) immune system. B7H4
may serve as a potential therapeutic target for enhancing acceptance of donor
grafts by manipulation of the donor graft tissue.
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NKG2D and its ligands was analyzed in rat liver allografts (DA&#8594;Lewis)
and syngeneic grafts (Lewis &#8594;Lewis) by q-PCR. A rat NK cell line
(RNK-16) that expresses NKG2D was used to confirm functional interactions
of NKG2D with expressed ligands.
Results: Ectopic expression of both RAE-1L and RRLT stimulated RNK16
cells to produce IFNγ; (as determined by ELISA) and trigger cytotoxic activity.
Further we show using an experimental model of rat liver transplantation, that
NKG2D expression is increased in allografts, but not syngeneic grafts, by day
3 post-transplant and expression strongly correlated with the IFNγ; levels in
both the graft and periphery. The NKG2D ligand RRLT is silent in normal liver,
induced upon liver transplantation, and specifically increased (25. 8 ± 6. 1 fold)
in allografts by day 3 post-transplant.
Conclusion: Our data indicates that the “stress’ associated with transplantation
induces the expression of NKG2D ligands. Further since NK cells are refractory
to standard immunosuppressive drugs, and NKG2D interactions induce IFNγ;
production and killing, therapeutics specifically aimed at this receptor or its
ligands may prove beneficial after transplantation.
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1533 DIFFERENTIAL IMMNOLOGICAL BEHAVIOR OF
ENHANCED GREEN FLUORESCENCE PROTEIN (EGFP)
MINOR HISTOCOMAPTIBILITY ANTIGEN WITH A SPECIAL
REFERENCE TO SKIN ISOGRAFTING AND SPECIFIC
REGULATON OF LOCAL GRAFT-VERSUS-HOST REACTION
H. Kimura1, M. Miyamoto1, P. Xuan-Chao1,2, Y. Sugawara2, M. Makuuchi2,
D. Ying-Bing2, N. Fuji-Funeshima1, R. Haba1, Y. Hattori1, X-K. Li1
1
National Research Center For Child Health & Development, 2Graduate
School of Medicine and Faculty of Medicine, Tokyo University
Backgrounds: Although enhanced green fluorescence protein (EGFP) is widely
used as a molecular tag in cell biology, it has become evident that transgenic or
transduced EGFP behaves itself like minor histocompatibility antigen (s). Thus
it appears that an in vivo application of cell, tissue and organ transplantation
becomes limited. Furthermore immunological behavior of EGFP as minor
histocompatibility antigen in various major histocompatibility antigen complex
(MHC) backgrounds is not fully understood.
Methods: Employing two lines of EGFP transgenic rats, e. g. , Green-F344 Tg
(RT11) and Green DA Tg (RT1 a), and its F1 hybrid with non-transgenic rat,
behavior of EGFP-transgenic antigen (s) as minor histocompatibility antigens
was investigated.
Accordingly immunological behavior of EGFP-transgenic skin isografts or
EGFP-transgenic lymphocytes was examined in normal F1 hybrid rats. In
the latter system EGFP-specific suppression of local graft versus host (GvH)
reaction, i. e. , in vivo equivalence to cytotoxic assay in vitro, was developed.
Results: In skin isografting model all EGFP-positive (Green DA x F344)
F1 donor skin isografts were rejected by non-transgenic (DA x F344)F1
recipients (MST: 12 days). In sharp contrast, none of (DA x GreenF344)
F1 donor skin was rejected by the same F1 recipients. This non-responder
phenotype of F1 hybrid to EGFP transgenic F1 skin isograft was not altered
even after immunization of normal F1 with EGFP expressing F1 APC such
as green DCs. Nevertheless once normal F1 hybrid rats were sensitized with
EGFP, regardless of (Green DA x F344)F1 or (DA x Green F344)F1 origin,
the sensitized F1 recipients resisted to local and systemic GvH reaction
induced by EGFP-expressing parental T lymphocytes. Thus (DA x F344)
F1 hybrid that had been sensitized with EGFP antigen, regardless of the
EGFP origin, i. e. , (Green DA x F344)F1 or (DA x Green F344)F1, strongly
resisted to GvH reaction induced by Green DA T cells and Green F344 T
cells, respectively.
Conclusions: Evidence is provided that differential immunological behavior
of EGFP-transgenic minor histocompatibility antigen occurs in vivo. Thus
immune responses to EGFP-minor histocompatibility antigen (s) become
apparent to EGFP-specific suppression of local GvH reaction induced by
EGFP-transgenic T cells only after EGFP-specific sensitization. However this
was not the case where test skin isografting was applied in spite of extensive
sensitization protocols.
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1534 A NOVEL THERAPEUTIC STRATEGY THAT REMOVES
ACTIVATED T CELLS EXTENDS GRAFT SURVIVAL IN PRESENSITISED RECIPIENTS
S. Jurcevic, R.E.G. Hargreaves, N.J. Gardner, S.H. Sacks, C.A. Farrar
King’s College London, Dept. Nephrology & Transplantation, Guy’s Hospital,
UK
Memory T cells with their rapid and efficient response to antigen re-challenge and
long-term persistence are a crucial component of adaptive immunity. However,
when re-activated upon encounter with a transplant, these cells play a central role
in causing and perpetuating tissue damage. Furthermore, current treatments which
efficiently control the naive T cell response, have limited effects on primed T cells.
We have developed a treatment based on a combination of antibodies specific for
molecules expressed by activated T lymphocytes to selectively remove these cells.
This approach, which we termed multi-hit therapy, leads to the cumulative binding
of antibodies to the activated T cell targets and results in a striking prolongation of
skin graft survival in pre-sensitised recipients in a stringent skin transplant model.
We propose that CD8- and CD70-specific antibodies in our therapy bind
activated, CD8+ T cells (multiple hits), thus reaching a threshold for Fc-mediated
depletion. Similarly, CD70- and CD154-specific antibodies target the activated
CD4+ T cell responders. Rapamycin functions to limit the T cellresponder
pool size. This combination of four reagents (CD8-, CD154-, CD70-specific
antibodies and rapamycin) had striking effects on skin graft survival in the presensitised HY (male to female transplant) model, with median survival time
(MST)= 84 days compared to untreated control MST=9 days.
Importantly, this was associated with the removal of graft-specific HYtetramer+ CD8+ T cells in sequential tail bleeds post-transplantation.
Furthermore, this multi-hit therapy approach allows a flexible approach with
the potential for the replacement of individual reagents as long as the final
combination adequately targets the activated responder T cell population.
Indeed, replacing CD154- with CD25-specific antibody maintained the potent
effects of the multi-hit approach on HY skin graft survival in pre-sensitized
recipients (MST >100 days).
The ability to alter the antibody combination in the multi-hit therapy whilst
maintaining selectivity for activated target cells has important implications for
future therapeutic strategies.

POSTER BOARD NUMBER P2 – 334
1535 NKP30-MEDIATED INTERACTIONS BETWEEN
NATURAL KILLER CELLS AND DENDRITIC CELLS INDUCE
IFN-GAMMA PRODUCTION BUT NOT CYTOTOXICITY
L-E. Wai, O. Martinez, S. Krams
Dept of Surgery/Division of Transplantation and Program in Immunology,
Stanford University
Background and Aims: There is considerable interest in using dendritic cells
(DC) to induce transplant tolerance, with animal studies showing prolonged
heart and pancreatic islet allograft survival following treatment with immature
DCs (iDC). Natural killer (NK) cells can mediate both maturation and killing
of iDCs, which has implications in tolerance induction. Indeed we and others
have demonstrated that NK cells infiltrate solid organ allografts early after
transplantation. Moreover, calcineurin inhibitors do not block NK cell function.
The aim of this study was to investigate the role of the rat NK cell stimulatory
receptor, rNKp30, in the interaction of NK cells with DCs.
Methods: Wildtype and rNKp30-transfected RNK-16 cells (rat NK cell line)
were co-cultured with rat bone marrow-derived DCs. IFN-gamma production by
NK cells was analyzed by ELISA and flow cytometry. To determine if the cellular
interactions are contact-dependent, transwell assays were performed. Cytotoxicity
was measured using a flow cytometry-based assay. In addition, degranulation by
NK cells was determined by CD107a surface expression and granzyme B release.
The presence of putative rNKp30 ligands on DC was determined by analyzing
the binding of rNKp30-Fc fusion proteins with flow cytometry.
Results: Flow cytometry on DC with an rNKp30-Fc fusion protein, as compared
to a control Fc fusion protein, indicated the presence of rNKp30 ligand (s) on
the surface of DCs. The ligand (s) is likely a protein since trypsin treatment
of the DCs prevented rNKp30-Fc binding. Co-culture of rNKp30+, but not
rNKp30-, NK cells with either immature or mature DC resulted in significant
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IFN-gamma production. This interaction requires direct cell contact. However,
both rNKp30- and rNKp30+ NK cells demonstrated similar cytotoxicity against
DC, with iDC being more susceptible to killing than mature DC, suggesting that
killing is mediated by receptors other than rNKp30. As a control, both rNKp30and rNKp30+ NK cells kill YAC-1 targets to the same extent. Further, after
co-culture with DC, NK cells demonstrate increased surface expression of the
degranulation marker CD107a and decreased intracellular levels of granzyme
B suggesting the NK cells have undergone degranulation.
Conclusions: NK cells interact with DC in a cell contact-dependent manner
and rNKp30-rNKp30 ligand interactions are important for inducing IFNgamma production by NK cells. In contrast, NK cell degranulation and killing
is mediated by other NK cell stimulatory receptor (s). Studying the involvement
of different NK cell receptors in NK-DC crosstalk will help us elucidate the
role of innate immunity in allograft rejection, and could lead to new targets for
tolerance induction.
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1536 CHRONIC KIDNEY ALLOGRAFT REJECTION IN F344
TO LEW RATS: RELATIONSHIP OF ALLOANTIBODIES, C4D
DEPOSITION AND GLOMERULOPATHY/INTIMAL FIBROSIS.

POSTER BOARD NUMBER P2 – 336
1537 CHIMERIC SOLUBLE MHC CLASS I PROTEINS CAN
INDIRECTLY PRIME RECIPIENT CD4 CELLS AND INDUCE
SPECIFIC REGULATORY CELLS THAT INHIBIT THE
DEVELOPMENT OF CHRONIC REJECTION
N.V. Semiletova1, D.M. Feldman1, X-D. Shen1, D. Edberg1, M.R. Ghobrial2
UCLA Medical School. 2Methodist Hospital, TX.
MHC class I soluble chimeric proteins (pMHC) that represent donor
immunogenic epitops at α1-helical region on the recipient background able to
modulate immune response toward donor specific tolerance. Tolerant recipients
demonstrated attenuated levels of cardiac graft transplant vascular sclerosis
(TVS). Tolerant hosts demonstrated a restricted alloreactive T cell repertoire,
strong up-regulation of Th2 dependent IgG1 and IgG2c alloantibodies, and
accumulation of CD4+CD25+IL10+ cells at the graft site. This study investigated
the role of pMHC in the development of T regulatory cells (T-regs).
Methods: Irradiated (130R) ACI hosts of WF hearts were injected with
1
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1538 IL-4 HAS TOLEROGENIC AND ALLOGENIC EFFECTS:
IT ACTIVATES CD4+CD25+ T CELLS TO INDUCE SPECIFIC
TRANSPLANT TOLERANCE AND PROMOTES REJECTION,
EFFECTING CD4+CD25-T CELLS TO EXPRESS CD25 BUT NOT
FOXP3.
K. Plain1, N. Verma1, C. Robinson1, G. Tran1, R. Boyd1, S. Hodgkinson1,2, B.
Hall1
1University of NSW, 2Liverpool Hospital
Th2 responses, especially IL-4, have been associated with transplant tolerance
induction. Whilst administration of IL-4 can in some cases delay rejection,
Th2 cells induced by IL-4 effect graft rejection. To examine how IL-4 may
have such diametrically opposed actions we examined the effect of IL-4 on
alloimmune responses by CD4+, CD4+CD25-, CD4+CD25+T cells from both
naïve and transplant tolerant animals.
Responses of naïve and specific transplant tolerant DA cells against fully
allogeneic PVG stimulators were examined. Tolerance in DA to PVG heart
grafts was induced by a short course of cyclosporine. In this model, tolerance
is maintained by CD4+CD25+ Treg cells. We have previously shown that in
culture with PVG alloAg, IL-4 primes naïve or tolerant CD4+T cells to rapidly
effect both PVG and third party Lewis allograft rejection when transferred to an
irradiated adoptive host. This contrasts to freshly isolated tolerant CD4+T cells
that transfer specific tolerance. Paradoxically, IL-4 induces a Th2 response that
effects rejection, and breaks tolerance.
Culturing naïve CD4+CD25+Foxp3+ cells with IL-4 and alloAg has a very
different effect on naïve and tolerant cells. Naïve Treg are activated to become
alloAg specific suppressor cells that can suppress the reconstitution of PVG,
but not third party Lewis, graft rejection at ten-fold lower cell numbers than
fresh naïve Treg. Fresh naïve Treg suppress rejection at 1: 1 ratio with naïve
CD4+T cells, whereas those activated with IL-4 and donor alloAg suppress at
1: 10. With tolerant CD4+CD25+T cells, the opposite effect was observed in
that after culture with IL-4 and PVG alloAg they failed to transfer tolerance
even at a ratio of 1: 2. However at this ratio they partially suppressed Lewis
rejection. Both naïve and tolerant CD4+CD25+T cells cultured with IL-4 and
alloAg proliferated to PVG or other stimulators, and retained high levels of
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W. Carmen1, L. Erickson1, F. Pan1, I-C. Hong1, T. Yamada1, L. Wu1,
J. Ding1, G. Crew1, K. Tamura1,2, H. Jiang1,2
1
Astellas Research Institute, 2Department of Medicine, Northwestern
University
Chronic transplant glomerulopathy and intimal fibrosis are common causes
of chronic transplant dysfunction of unknown pathogenesis. To determine
the possible contribution of the humoral immune response, we assessed the
relationship of alloantibody titers to C4d deposition/graft gene expression and
to measures of glomerulopathy and intimal fibrosis during the development of
chronic kidney allograft rejection in the F344 to LEW rat model. MM: Kidneys
of F344 rats were orthotopically transplanted into bilaterally nephrectomized
LEW recipients treated with a brief dose of FK506. Blood and 24 hr urine
samples were collected once a week for determination of creatinine and allospecific antibodies. Kidney grafts were harvested on day 6, 30, or 90 after
transplantation and subjected to histologic (Banff criteria), RT-PCR (C4d) and
immunohistological (C4d) analysis.
Results: 80% of kidney grafts in F344 to LEW recipients with functional and
histological changes of chronic rejection showed a high Banff classification
for both glomerulopathy and intimal fibrosis on day 90 after transplantation.
These recipients were associated with detectable levels of allospecific IgM and
IgG at week 2 and strikingly higher levels at week 5. C4d staining was mainly
localized in the glomeruli and the peritubular capillaries of graft kidneys. The
staining intensity of C4d deposition was low, medium and highest on days
6, 30, and 90 after transplantation, respectively. This pattern was consistent
with the mRNA expression of intragraft C4 in the same time intervals. The
remaining recipients with lower Banff classification of glomerulopathy and
intimal fibrosis demonstrated low serum alloantibodies and C4d deposition.
Conclusion: Our results suggest that C4d is a hallmark of humoral responsemediated chronic kidney rejection in the rat.

syngeneic splenic CD4+; CD8+; CD4+CD25+ cells (107 cells >95% purity; iv)
from tolerant pMHC or high-dose CsA treated cardiac hosts. Indirect priming
of CD4 recipient’s cells were tested with BM generated DC in vitro.
Results: In vitro: pMHC can inhibit CD4 cells ability to recognize antigen
(Ag). DCs loaded with pMHC were injected into hind footpads of ACI
recipients. CD4 from post-lethal LN did not proliferate against donor (WF)
or third-party (BN) Ag. Recipient DC loaded with pMHC can directly block
proliferation of naïve ACI CD4 cells against donor Ag but failed to inhibit of
activated CD4 cells. MHC chimeric therapy induces CDR3 size restriction in
hosts spleen cells. Vgenes 10, 12, 18 were limited when expression of V 8. 1 and
5 were upregulated. pMHC therapy increased population of CD4CD25FoxP3
cells in spleens of treated rats. LN T cells from tolerant pMHC and longterm surviving CsA treated rats inhibited proliferation of ACI naive cells
against WF (750+100 1600+200 3H-TdR cpm/min), but not third-party BN
(3200+500; P <0. 001) Ag. In vivo: T-regs activity from pMHC and CsA rats
was confirmed by their ability to prolong WF graft survival (>120 d) in ACI
hosts (n=17 and 8, resp. ). However, only pMHC induced T-regs abrogated
TVS, (NI=15+5) with only 26+6% of vessels affected. In contrast, allografts of
secondary ACI hosts treated with CsA-induced T-regs, exhibited severe TVS.
Attenuated chronic rejection was associated with diminished level of cytotoxic
T cells. Surprisingly, both CD4 and CD8 subsets induced long-term survival
of secondary test grafts (>100 days). However, only the CD4+ T-reg prevented
TVS (NI=19+5, 21+6% of vessels), as compared to CD8+ T-reg (NI=40+9 in
50+15% of vessels). Alloantibody analysis showed up-regulation IL-4/IL-12
dependent IgG1 and IgG2c.
Conclusion: Soluble chimeric MHC class I proteins can indirectly prime
recipient CD4 cells, moreover, recipient DC loaded with chimeric MHC
protein can inhibit proliferative response of naïve CD4 cells. Therapy with
soluble MHC chimeric molecules generate CD4 and CD8 regulatory cells that
prolong graft survival, but only CD4+ cells prevent TVS. This CD4+ T-reg may
be responsible for long-term graft maintenance through its unique ability to
control anti-inflammatory and alloantibody responses.
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expression of both CD25 (>95%) and Foxp3 (70-80%) indicating there was not
loss of Treg phenotype.
Naïve and tolerant CD4+ cells cultured with IL-4 and alloAg had increased
proliferation compared to controls without IL-4. This was associated with a
massive up-regulation of CD25 expression (72-85% CD25+ with IL-4 compared
to 25% CD25+ when cultured with IL-2 and 12% CD25+ in control cultures) but
the majority of these CD25+ cells were Foxp3-, suggesting these were activated
effectors. Both tolerant and naïve CD4+CD25- T cells cultured with IL-4 and
alloAg for 3 days became 75% CD4+CD25+ of which <2% were Foxp3+.
Thus, the effect of IL-4 on Treg cells is important in induction but not
maintenance of tolerance. In parallel, IL-4 massively activates CD4+CD25-T
cells to express CD25 but not Foxp3 and to effect rejection. These different
actions may explain the variable effects of IL-4 on tolerance induction.

CONCURRENT ORAL SESSION 107: KIDNEY
TRANSPLANTATION SURGERY – DONOR SURGERY
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1539 USE OF PELVIC KIDNEY FOR LIVING
TRANSPLANTATION. CASE REPORT AND REVIEW OF THE
LITERATURE
K. Charfeddine, S. Zagdane, S. Yaich, M. Masmoudi, D. Hssairi, J. Hachicha
Department of Renal Transplantation
Introduction and Aim: The word-wide shortage of cadaveric kidneys for
transplantation has result in a tendency to extend the indication for procurement
from cadaveric donors and increased our reliance on living donors. We report
the use of a pelvic kidney for living-related renal transplantation.
Methods: A 58-year-old man with history of end-stage renal disease presented
for renal transplant evaluation. Her other medical problem was medically treated
hypertension. He weighed 85 kg and the rest of her physical examination was
unremarkable. The donor was unremarkable, except for a palpable left-side pelvic
kidney which has been discovered by an ultra sound examination confirmed the
presence of a normal right kidney. The pelvic kidney provided 39% of the overall
renal function. The angiographic examination demonstrated the presence of three
renal arteries arising from the aorta and the common iliac artery, two renal veins
draining into the inferior vena cava and a single ureter. Immunologically, the
donor and recipient were ABO compatible, had a 3/6 HLA antigen match and
B and T-cell cross-match negative. Upon completion of this lenghly evaluation;
living related transplantation of the pelvic kidney was performed.
Results: The donor nephrectomy was performed through a transperitoneal lower
mediane incision. A right sided incision was used for the recipient surgery. The
donor vessels were anastomosed end-to-end to the recipient external iliac vein
and artery with nonabsorbable sutures, and the graft promptly produced urine.
The ureter was stented prior to reimplantation, using a tunneled modified Lich
neocystomy. Postoperative, tacrolimus, MMF and corticosteroids were used for
immunotherapy. The recipient’s serum creatinine fell from 64 mg/to 48 mg/l
by the second post operative day, and 9 mg/l at 1 month after transplantation.
At two years post transplantation, the graft function was excellent and serum
creatinine level was maintained at 10 mg/day.
Conclusions: transplantation of the pelvic kidney is technically feasible, and
therefore individuals with pelvic kidneys should be considered as extended
renal donors.

POSTER BOARD NUMBER P2 – 339
1540 THE SERIES LIVING DONOR RENAL
TRANSPLANTATIONS THAT USES PURE LAPAROSCOPIC
DONOR NEPHRECTOMY ~SINGLE CENTER EXPERIENCE~
K. Kozaki, K. Yuzawa
Department of Organ Transplantation, Mito Medical Center
Not to harm a graft function in the living donor renal transplantation (LRTx),
in principle we shorten graft ischemic time, namely preservation time as
much as possible. Therefore we perform the parallel operation of donor and
recipient generally, and the graft kidney is transplanted after perfusion and
cooling promptly. As a result, although graft preservation time shortens,
either waiting time under general anesthesia of donor or recipient arise till
both donor and recipient get ready for starting operation. From April 2006

514

renal transplantation has been started in our center. In our center, since
the reduction of patient’s waiting time under general anesthesia and the
purpose of using the operation room effectively, recipient enters in the same
operating room after donor operation end and return to the ward. In our
country, there are extremely few transplant centers performing the renal
transplantation in this procedure. As a result, renal graft was preserved for
about 4 hours. In addition, donor nephrectomy was performed by pure transabdominal laparoscopic procedure and used UW solution as preservative
solution.
Objective: To investigate efficacy of this procedure in LRTx.
Methods: FFrom April 2006 to December 2007, 22 LRTx were performed by
pure trans-abdominal laparoscopic procedure. To investigate time of immediate
diuresis and postoperative day (POD) 1, 7 and 28 transplant kidney function.
Results: Mean warm ischemic time (mWIT) was 6. 9 min, mean total ischemic
time (mTIT) was 234. 2 min, immediate diuresis (IU) was occurred in all
patients and mean time of immediate diuresis (mIUT) was 10. 6 min.
Postoperative mean plasma creatinine value was 5. 00 (mg/dl) on POD 1, 1. 36
on POD 7 and 1. 42 on POD 28. No patients needed hemo-dialysis (HD) after
LRTx.
Conclusions: FAccording to nationwide total investigation in our country
about live donor laparoscopic nephrectomy in 2006, mWIT was 7. 0 min, mTIT
was 96 min and mIUT was 13 min. In 589 laparoscopic donated recipients, 1
case was reported as primary nonfunction and 28 (4. 8%) recipients needed HD
after LRTx because of delayed graft functions. In comparison with this survey,
no postoperative HD and good posttransplant renal functions in all patients by
our procedure, which is excellent procedure in LRTx
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LAPAROSCOPIC DONOR NEPHRECTOMY
S. Kacar 1, A. Gurkan 2, C. Varýlsuha 3, C. Karaca 3, S. Tilif 2
1
Private Kent Hospital, Izmir, TURKEY, 2 Private Gaziosmanpasa Hospital,
Istanbul, TURKEY, 3 SSK Tepecik Training Hospital, Izmir, TURKEY
Aim: Laparoscopic donor nephrectomy (LDN) has gained popularity
throughout the world recently. Although LDN has many advantages over
open donor nephrectomy such as early recovery, less long-term postoperative
complications, better cosmesis and shorter hospital stay for the donors. The aim
of this paper is to compare the first 30 and the last 100 cases.
Method: 130 living laparoscopic donor nephrectomies have been performed
between November 2000 and February 2008 by the same surgical team. All the
procedures were performed via transperitoneal approach.
Results: The mean duration of the donor surgery was 183 min (max 420, min
75). The mean warm ischemia time was 2 min 44 sec (4 min 14 sec in the first
30, and 2 min 17 sec in the last 100 donors). In 7 patients right sided, in 123
patients left sided nephrectomy was performed. Laparoscopic nephrectomy
was converted to open procedure in eight donors (6, 1%), all of them in the first
30 donors. In the last 100 cases there is no conversion. Intraoperative bleeding
(3 major, 1 minor bleeding) was the most common cause for conversion. The
other reasons were diffuculty in disection in 3 patients, and technical in 1
patient. Postoperative urinary complications were seen in 7, 7% (16, 6% in the
first 30, and 5% in the last 100 donors), vasculary complications in 6, 9% (16,
6% in the first 30, and 4% in the last 100 donors)of the patients. Lengths of
hospital stay of the donors was 1, 9 days.
Conclusion: Laparoscopic donor nephrectomy was preferred in more and
more patients, as experience grew, due to the charm of short hospital stay, less
postoperative pain, scar and incision morbidity. In our transplantation clinic,
as our surgeons gained experience in various laparoscopic general surgery
procedures in the last ten years, LDN was started first with selected patients,
than on routine basis.
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1541 RIGHT KIDNEYS AND DELAYED GRAFT FUNCTION:
CLINICAL IMPLICATIONS.
H. Vacher-Coponat1, V. Moal1, R. Purgus1, M. Indreies1, T. Legris1,
Y. Berland1,2
1
Nephrology and transplantation unit, AP-HM, Hopital Conception,
2
Université de la méditerranée Aix-Marseille 2
Background: Cold ischemic time (CIT) and delayed graft function (DGF)
are associated with transplant outcome. Having one of the shortest CITs of
transplant centers in France, we analyzed the relevant risk factors on DGF in
our center.
Methods: Risk factors for DGF were retrospectively evaluated by multivariate
analysis for all kidneys transplanted between June 2004 and April 2006 in
our center. Impact of four courses of organ allocation on CIT and DGF were
compared.
Results: Relevant DGF risk factors were CIT (OR = 1. 15, p=0. 002), lower
donor creatinine clearance (OR = 1. 33, p= 0. 002), hemodialysis duration
(OR= 1. 28, p= 0. 011), and kidney harvested on the right side (OR= 5. 56, p=0.
012). Local kidneys not in the national sharing program were transplanted with
a CIT of 12. 45 h and a DGF rate of 14. 7%. The sharing program increased CIT
2 fold and DGF 3. 6 fold. This increase concerned not only priority recipients
but also recipients of local kidneys used after the cancellation of a priority, due
to positive cross match.
Conclusion: Procurement of right kidneys is a new DGF risk factor. CIT is
a known risk factor, which is inevitably prolonged with the national sharing
program whether the kidneys are grafted or not in priority recipients.
Considering the independent impact on DGF of CIT and of kidney side, we
suggest using right kidneys locally in the first instance and providing left
kidneys for sharing.

1542 UNUSUAL COMPLICATIONS FOLLOWING LIVING
DONOR NEPHRECTOMY
J. Akoh1, S. Stacey
1
Plymouth Hospitals NHS Trust, 2Plymouth Hospitals NHS Trust
Introduction: The living donor programme was re-established in January
2003, with the appointment of a living donor transplant co-ordinator, resulting
in the introduction and meticulous assessment of all potential living donors
in conjunction with local and national guidelines. The aim of this study is to
highlight unusual complications following living donor nephrectomies within
a single centre.
Method: During the period 305 people completed the staged assessment
process for potential kidney donors resulting in 56 nephrectomies (52 open
and 4 laparoscopic hand assisted). All patients were followed up at 6 weeks
and then discharged to regular yearly visits with their designated nephrologists.
All complications were entered prospectively into a database used for this
analysis.
Results: Forty three (77%) had a left donor nephrectomy, whereas thirteen
(23%)had a right nephrectomy. There were 22 males and 34 females. Donor
average length of hospital stay was 5 days (median 4). Forty six (82%) had
no complications and those seen in the remaining 10 (18%) are shown in the
table below:
Complication
Haemorrhage requiring blood transfusion
Ileus
Incisional hernia
Testicular Pain (orchidectomy)
Chronic Pain
Lymphoma

Number
6
2
1
1
1
1

Two individuals presented with severe upper gastrointestinal bleeding, one
from seven small gastric ulcers managed conservatively and the other from
a duodenal ulcer requiring surgical intervention. Both were on non steroidal
ant-inflammatory agents (NSAID). A patient demanded orchidectomy to treat
severe testicular pain following a right donor nephrectomy.
Discussion: NSAIDs should be used with caution in patients after donor
nephrectomy. To prevent neuropathic pain following the anterolateral
extraperitoneal approach, dissection close to the subcostal neurovascular bundle
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1543 HAND-ASSISTED RETROPERITONEOSCOPIC LIVINGDONOR NEPHRECTOMY: 106 CONSECUTIVE LEFT AND
RIGHT SIDED CASES
N. Kessaris, J. Fronek
StGeorge’s Hospital
Background: This is a report of 106 consecutive donors nephrectomies
using hand assisted retroperitoneoscopic live donor nephrectomy (HARS).
Extraperitoneal approach seems to be safer than transperitoneal as less
dissection is required. Our Unit has therefore adopted this technique for both
right and left living-donor nephrectomies.
Methods: All living-donor nephrectomies performed since the intoduction of
HARS in 2005, were included in this study. Data were collected prospectively.
In 10 cases the right kindey was retreived. The operation is performed in the
manner described by Wadström et al 2002, with minor modifications.
Results: The mean age of the donors was 46 years (20-65, median 45), the
mean body mass index was 24. 75 (20-35, median 26). One donor had a double
vena cava, six donors had retroaortic left renal vein and 40 donors had complex
anatomy (multiple vessels or ureters). One of the operations was converted
to open. The average operating time was 107 min (65-175 min, median 95).
The mean warm ischaemic time was 104 seconds (40-300, median 90 sec).
Moreover, the mean estimated blood loss was 40 ml (0-440, median 20 ml)
and the mean postoperative hospital stay was 44 hours. All of the donors
demostrated rapid recovery and had no major complications except two
incisional hernias and one wound infection. The mean serum creatinine on
admission was 83mmo/L (57-130, median 82) and at the time of discharge
from hospital 120mmol/L (83-170, median 118). All donors will have long
term follow up. All transplanted kidneys had immediate function except two
(none of these two were related to the nephrectomy).
Conclusions: The HARS is a very safe way of performing living-donor
nephrectomy with minimal morbodity and fast recovery. Since the introduction
of this technique, the number of potential living donors has increased.

POSTER BOARD NUMBER P2 – 344
1544 DO PERINEPHRIC ADHESIONS AFFECT DONOR’S
MORBIDITY OR RECIPIENT’S OUTCOMES?
M. Hossain, C. Kirby, J. Fronek
St George’s Renal Transplantation Unit
Background: We report of 106 consecutive donors nephrectomized with using
the Hand Assisted RetroperitoneoScopic live donor nephrectomy (HARS)
between Jan 2005 and Mar 2008. Extraperitoneal approach seems to be safer
than transperitoneal as less dissection is needed. Risk of conversion to an open
procedure is the presence of perinephric adhesions.
Methods: All living-donor nephrectomies performed using the HARS
were included and followed prospectively. In 10 cases the right kindey was
retreived. We present a series of those who underwent HARS and were found
intraoperatively to have perinephric adhesions. Donors morbidity and operation
complexity as well as recipient’s outcomes are described.
Results: Out of 106 cases 12 were found to have adhesions (11. 3%) all male. The
mean (SD, range) age was 51. 9 (53, 35-64)years, operative duration 149. 8 (35. 1,
75-192)minutes and blood loss 119 (142. 3, 0-500) mls. Anatomically, there were
5 cases with simple anatomy, with 7 cases with complex anatomy (3 with 2 artery,
1 vein; 3 with 1 artery, 2 vein; 1 with 2 artery and 2 vein). One operation was
aborted as the adhesions found were considered so dense, as to render the kidney
unretrievable and 1 other procedure was converted to an open retrieval due to
bleeding from a gonadal vein. All other operations were performed successfully.
Discussion: Nephrectomy on donor with perinephric adhesions has got
significantly higher blood loss and duration, although non of the donors received
a blood transfusion. There is no significant difference in donors hospital stay,
morbidity and recipients graft function. We believe HARDN can be extended
to cases with adhesions with no impact on donor or recipient.
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should be avoided. Extensive assessment of a potential living kidney donor did
not detect a low grade B-cell lymphoma in the donated kidney. Diagnosis was
made due to the fortuitous development of renal vein thrombosis resulting in
transplant nephrectomy on day zero.
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1545 THE OUT COME OF KIDNEY TRANSPLANTS WITH
MULTIPLE RENAL ARTERIES.

1547 LIMB SALVAGE IN NON-TRANSPLANTATION AND
TRANSPLANTATION POPULATION

M.R. Alam1, A. Khanam1, S.A. Khan2, M. Salauddin1, H. Rahman1,
H.U. Rashid1
1Dept of Nephrology, BSM Medical University, 2Dept of Urology, BSM
Medical University
Objective: To determine whether the use of kidney allograft with multiple
renal arteries adversely affects post transplant out come and complications.
Background: Transplantation of kidney with multiple renal arteries is generally
avoided. The disadvantages of multiple vessel graft includes technical difficulty
to anastomose, longer warm ischaemia and hence increased incidence of ATN,
early graft dysfunction, various urologic and vascular complications.
Methods: We reviewed the records of 35 living related adult kidney transplants
done at our centre over a period of 3 years (from January 2005 to December
2007).
We divided the study population into two groups: Group A –20 Patients with
single renal artery and group B-15 patients with multiple renal arteries.
Single, end to side anastomosis was done with recipient’s external iliac artery.
All patients were placed on conventional immunosuppressant in the post
operative period. We compared the incidence of post transplant complications
like ATN, Hematoma, technical obstruction of ureter, Urine leak, lymphocele,
sloughed ureter, graft nephrectomy etc. between two groups.
Result: Of the 34 patients; 20 patients (57%) had single renal artery
and 15 (43%) had multiple renal arteries. In group-A: 1 (5%) developed
hematoma, 1 (5%) technical obstruction of ureter, 1 (5%) ATN, 1 (5%)
developed sloughed ureter and 1 (5%) patient required graft nephrectomy
for coagulation necrosis.
In group B, hematoma was found in 2 (13% patients, technical obstruction of
ureter in 1 (6%) urine leak in 3 (20%), ATN in 3 (20%) sloughed ureter in 1
(6%) patients and 1 (6%) required graft nephrectomy.
In Kidneys with multiple renal arteries, only the incidence of ATN, Urine leak
and technical obstruction of ureter was higher compared to single artery grafts,
which were also not significant statistically.
Conclusion: Although kidney grafts with multiple renal arteries carry a
relatively higher incidence of some complications, even then it should not be
avoided, because post transplant out come and complications are comparable
with single artery grafts.

P. Pootracool1, J. Fletcher2, R. Allen2, J. Chapman2, H. Pleass2, J. Swinnen2,
M. Vicaretti2
1Department of Surgery, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand 10400, 2Westmead Hospital, Sydney, Australia
Objective: To assess the current incidence of limb salvage, and survival in
non transplantation and transplantation group following lower extremity
revalascularization and follow up during 6 months to one year. In addition
cumulative limb salvage in 2, 4, 6 years were studied in Westmead Hospital
during the last 17 years.
Material and methods: In a retrospective review in Westmead Hospital
from 1988-2005 of lower extremity revascularization in dialysis patients and
functioning kidney transplantation or combined kidney-Pancreas transplantation
for chronic critical limb ischemia (such as foot gangrene, nonhealing ulcer, rest
pain) and disabling claudication. Follow up within 6 months to one year and
cumulative limb salvage in 2, 4, 6 years, graft patency were studies
Results: Between January 1988-December 2005, total 44 patients (84 limbs) in
chronic critical limb ischaemia (CLI) and disabling claudication with end stage
renal disease included the patients who had history of Kidney transplantation/
Kidney-Pancreas transplantation with functional or non functional of kidney
graft were analyzed.
Four of the patients had short distance claudication (walking distance 50to
100 metres). Previous revascularization was 27. 3% which same side 50%,
contralateral side 50% and previous minor amputation was 31. 7% which same
side 24. 4%, contralateral side 7. 3%. Most of the patients were males 75% with
a mean ± SD age of 58 ± 8. 9 years, and 25% were females with a mean ±SD
age of 51 ± 13. 3 years. Age was not statistic significant difference between
two groups.
A total 126 procedures were performed during presentation and follow-up for
treatment of the primary disease. Revascularization procedure was 55. 5%
which 32. 5% surgical revascularization, 23% endovascular intervention. Minor
amputation 22. 2%, major amputation 16. 7%, lumbar sympathectomy 5. 5%.
There was no mortality rate in 30-days postoperative but in 6 months follow
–up mortality rate 4. 5%, major amputation 8. 3% (below knee amputation 6%,
above knee amputation 2. 3%). Limb salvage in 1, 2, 4 and 5 year was 82. 9%,
79. 5%, 78. 4%, and 76. 1% respectively.
From the result of this study, transplantation patients had better outcomes in
limb salvage, major amputation, and mortality rate than the patients dependent
dialysis. Limb salvage rate in transplantation group was 90. 2% in total one to
five year
Discussion: From this study, our 30- day primary graft patency was 96%. In this
study, the mortality rate at 4 year was 9. 1% which improving in revascularization
outcome of historical experience. This result can be explained by age of the
patients in this group younger than previously published results and 54. 5%
of patients in this group had transplantation which 22. 7% combined kidney
– pancreas transplantation, 31. 7% kidney transplantation alone. Thus, in this
study limb salvage, mortality and amputation rate in transplantation group were
better outcome than non-transplant group. In addition, simultaneous kidney
and pancreas transplantation can be touted as a therapeutic advance for type I
DM. It can improve survival rates and limit many DM-related complications.
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1546 SEQUENTIAL CHANGES IN COAGULATION AFTER
RENAL TRANSPLANTATION – A THROMBOELASTOGRAM
STUDY
D. Kahn, J. Timmermans, G.H.C. Dolmans
University of Cape Town/Groote Schuur Hospital
Chronic renal failure (CRF) is associated with complex alterations in
coagulation. The changes in coagulation which occur after renal transplantation
have been studied only to a limited extent. The thromboelastogram (TEG)
provides a global assessment of whole blood clotting. In this study, sequential
changes in coagulation after renal transplantation were investigated using
the TEG in eight patients. The controls included normal healthy controls
(n – 6), and patients on haemodialysis (n = 5), on peritoneal dialysis (n = 6)
and long-term after transplantation (n = 7). The TEG parameters measured
included the R-time, K-time, alpha angle and the maximum amplitude
(MA).
The TEG parameters pre-transplantation demonstrated a hypercoagulable state.
There was a trend towards normal coagulation immediately post-transplantation
(days 2-4) and a return to hypercoagulability thereafter, compared to the normal
controls. There was no difference in the TEG parameters between the patients
long-term after transplantation and the normal controls. The dialysis patients
were also hypercoagulable.
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1548 DOES CLAMPING OF DISTAL PART OF ILIAC
ARTERY DURING TRANSPLANTATION IMPROVING THE
REPERFUSION OF TRANSPLANTED GRAFT
M. Romanowski1, L. Domañski2, L. Szyd³owski3, A. Kempiñska3,
J. Sieñko1, T. Sulikowski1, K. Tejchman1, K. Safranow2, M. Ostrowski1
1Clinic of General And Transplantation Surgery, 2Clinic of Nephrology,
3Department of Forensic Medicine
Does the termovision imaging can help surgeon to assessing reperfusion
transplanted kidney, does clamping of distal part of iliac artery improving the
reperfusion of transplanted graft, does shorten time of reperfusion have an
influence on early and late function after transplantation.
60 kidneys from idem cadaveric donors were divided for 2 groups. Clamping
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of distal part of iliac artery for 5 minutes after vascular anastomoses
were completed was the only differences between groups. We observed
reperfusion and recorded by termovison camera. The thermovision
camera was focused on the renal parenchyma. The images acquired over
the operation area were recorded intraoperatively using a thermovision
camera ThermaCAMTM SC500 which detects infra-red radiation and
records digital images with surface temperature distribution of tested
objects. During the reperfusion of every graft we made 100 thermographic
scans each acquired in one second interspaces. We started the recording
at the moment of removal of the arterial forceps (end of rewarm time).
The outcoming graph of thermoemission changes of the graft was nearly
continuous this way.
The computerized system of image analysis enables to choose the method of the
radiation and temperature analysis (along a given line on a given surface) and
to present the obtained results in the form of a text or a diagram. To estimate the
emission of radiation from the area studied, one can also used such parameters
as highest and lowest or the average temperature inside a chosen isotherm.
Kidneys function was analyzed by creatinine and BUN level and diuresis (
follow up 6 months).
Conclusion: The registered initial and continuous images of the kidney
reperfusion enable to compare temperature distribution and make a qualitative
analysis of the efficiency of reperfusion. It is non-contact method that does not
disturb during operation and it is saving for graft.
These data demonstrate the reperfusion in a new digitally imaging and additional
clinical study will help us to develop of this technology in investigative
practice.
Claping of distal part of iliac artery cut down of reperfusion time but is not
correlated with creatinine, BUN level and diuresis.
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1550 ENDOVASCULAR LIGATURE OF PRIMARY
COMPLICATED AV FISTULAS WITH AMPLATZER VASCULAR
PLUG
F. Boyvat1, A. Harman1, F. Karakayali2, U. Ozyer1, G. Moray2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent
University Faculty of Medicine, Department of General Surgery
Purpose: Here, we report the first use of an Amplatzer vascular plug to close
dysfunctional or complicated primary arteriovenous fistulas.
Materials and Methods: From January 2007 to February 2008, 4 patients
with primary arteriovenous (AV) fistulas, presented at our institution with arm
swelling and long segment venous occlusion (n=1) and ischemic steal syndrome
(n=3). Two fistulas were brachiocephalic and the other 2 were radiocephalic
fistulas. Because of arm swelling and cellulitis around the anastomosis of the
AV fistulas, surgical ligation was not preferred for these patients. Ultrasoundguided venous access was gained, and a vascular sheath was guided toward the
arterial anastomosis. We used fluoroscopy and real-time ultrasound to visualize
the Amplatzer vascular plug, and placed the plug exactly at the origin of the
venous site. Two Amplatzer plugs were used in 3 patients, and 1 Amplatzer
plug was used in 1 patient.
Results: Complete thrombosis of the venous site of the AV fistula was
obtained in all patients. No migration of the Amplatzer vascular plug or arterial
complication related with embolization was observed. The patients’ preembolization symptoms diminished significantly after closure of the fistulas.
Conclusions: These cases underscore the importance of the Amplatzer vascular
plug as a precise occlusion device for AV fistulas. The end result is similar to
surgical ligation of an AV fistula. It has been our experience that the device is
easy to use and has a high rate of technical success.
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1549 RENAL FUNCTION IN RENAL TRANSPLANT
RECIPIENTS WITH RENAL ARTERY STENOSIS DURING NINE
YEAR FOLLOW UP
H. Ronald1, S. Laime, J. van Ampting, J. Beutler, G. Stapper
1
University Hospital Utrecht, 2University Hospital Utrecht, 3University
Hospital Utrecht, 4University Hospital Utrecht, 5University Hospital Utrecht
Purpose: The aim of this prospective clinical study was a nine year follow
up of renal function in renal transplant patients with (Peak systolic velocity
¡Ý 200cm/sec) and without a significant renal artery stenosis. In addition, the
difference in number of rejections between these two groups is determined.
Methods: Nineteen adult renal transplant patients, with significant renal
transplant artery stenosis (peak systolic velocity ¡Ý 200cm/s) diagnosed by
Duplex ultrasound, were compared to eighty-one adult recipients without
renal artery stenosis (peak systolic velocity < 200cm/s). These two groups,
matched by age, gender, time and type of renal transplantation, were followed
during a period of nine years post-transplantation. The peak systolic velocity
(PSV) in the renal transplant artery, pulsatility index (PI) and resistance index
(RI) were measured at least one year post- transplantation. Furthermore,
serum creatinine was followed twice a year during the period of 9 year follow
up. After nine years the recipients with renal artery stenosis (PSV ¡Ý 200cm/
sec) underwent the second duplex-Doppler for evaluation of renal artery
stenosis.
Results: Serum creatinine was increased over nine years in group of patients
with renal artery stenosis (PSV ¡Ý 200cm/sec) more rapidly than the control
group (PSV < 200cm/sec). However, the difference was insignificant.
Furthermore, neither significant difference in the number of rejections has been
found between the two groups.
Conclusion: PSV ¡Ý 200cm/sec with a normal RI or PI does not affect the
outcome of renal function after 9 years of follow up. It could be concluded
that an angiography and successive angioplasty in these patients seem not to
be useful.

1551 PTFE GRAFT RECONSTRUCTION OF THE EXTERNAL
ILIAC ARTERY IN KIDNEY TRANSPLANT RECIPIENTS WITH
SEVERE ATHEROSCLEROSIS
R.M. Rosete-Liquete, A. Jordan-Casupang
St. Luke’s Medical Center
Background: Arteriosclerosis and calcification of iliac arteries are common
in patients on dialysis especially those with diabetes mellitus. In such cases,
thrombendarterectomy of the hypogastric artery is usually sufficient to provide
adequate blood supply to the renal graft. However, in rare cases, severe
atherosclerosis of the iliac arteries make effective endarterectomy impossible
hence the simultaneous PTFE (polytetrafluoroethylene) graft reconstruction of
the external iliac artery which we will describe here.
Patients and Methods: Between January 1988 and December 2007, 8/845
(1%) kidney transplantations required a vascular graft reconstruction of the
external iliac artery due to severe arterioscleroses of the iliac vessels making
direct anastomosis precarious. All recipients were diagnosed to have diabetes
nephropathy. Segmental resection of the external iliac artery was done and
replaced with a 6mm PTFE anastomosed end-to-side to the common iliac artery
and end-to-end to the distal end of the external iliac artery. Renal scintigraphy
was done within the first postoperative week when indicated. Post transplant
allograft status was monitored by serial serum creatinine measurement and
urine output. The mean follow-up was 29. 6 (range: 6-114) months.
Results: All the kidney allografts functioned immediately and six patients who
had renal scintigraphy during the immediate post transplant period showed
adequate graft perfusion. There were no infections related to PTFE placement.
Two cases underwent evacuation of hematoma but this was not associated with
PTFE graft anastomosis. Serum creatinine decreased within the first week
for all the patients. There were two mortalities at 2-months and 2-years post
transplant due to sepsis although both still had good graft function. One-year
survival rate was 87. 5%
Conclusions: Severe atherosclerosis is not a contraindication for kidney
transplantation. Vascular reconstruction during kidney transplantation can be
performed and can impact survival and kidney function. Moreso, it is a safe
option when performed under experienced hands.
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1552 ANGIOPLASTY AND STENTING OF ARTERIAL
STENOSIS AFFECTING RENAL TRANSPLANT FUNCTION
P. Pappas1, G. Zavos2, S. Kaza1, P. Leonardou1, E. Theodoropoulou3,
J. Bokos2, J. Boletis3, T. Karatzas4, A. Kostakis4
1
Department of Radiology, Laiko General Hospital, Athens, Greece
2
Transplantation Unit, Laiko General Hospital, Athens, Greece 3Department
of Nephrology, Laiko General Hospital, Athens, Greece 4Second Propaedeutic
Department of Surgery, University of Athens, Medical School, Athens, Greece
Aim: To evaluate the efficacy of percutaneous angioplasty and stenting
(PTAS) in cases of artery stenosis of the transplanted kidney or proximal iliac
artery stenosis causing graft dysfunction and/or increase of the arterial blood
pressure.
Materials and Methods: Between January 1999 and June 2007, we evaluated
24 patients who had undergone renal transplantation, newly presented with
refractory hypertension and graft dysfunction; signs of possible renal transplant
artery stenosis. Color Doppler Ultrasonography (CDU) and Magnetic Resonance
Angiography (MRA) preceded the intraarterial angiographic investigation,
with false negative results in 18. 2% and 13. 6% of patients, respectively. In
two out of the 24 patients angiography did not reveal arterial stenosis affecting
the transplanted kidney. Two patients had severe ipsilateral iliac artery stenosis
and the remaining 20 had transplant artery stenosis. Successful angioplasty and
stenting was performed in these 22 patients.
Results: The method was technically feasible in 100%. The procedure-related
morbidity was 0%. During the follow-up period (range 3 to 104 months), two
patients died with normal renal graft function, two suffered transplant failure,
while the remaining 18 still have normal graft function and easily controlled
hypertension.
Conclusions: Percutaneous angioplasty and stenting in cases of arterial
stenosis affecting the renal transplant function is a safe and effective procedure.
Even more, the strong clinical suspicion must lead the patient to angiographic
investigation regardless of the results of other imaging approaches.
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1553 EARLY THROMBOTIC COMPLICATIONS IN KIDNEY
TRANSPLANT RECIPIENTS
W. El Kady, L.W. Moore, S. Patel, A.O. Gaber.
The Methodist Hospital, Houston, TX
Background: Venous thrombosis is a known complication in kidney transplant
patients, occurring in about 5. 1%. With significant emphasis on decreasing
lower venous thrombosis, these rates have been declining. However, upper
limb thrombosis appears to be increasing in kidney transplant patients.
Aim: The purpose of this evaluation was to assess the incidence and the factors
associated with the occurrence of upper limb or lower limb deep venous
thrombosis or pulmonary embolism in kidney transplant patients.
Methods: We reviewed electronic and physical charts of 139 patients who
received their kidney allograft in the period between September 2005 till
December 2007. We evaluated donor and recipient characteristics and
demographics, extended donor criteria, creatinine, sodium and central venous
pressure, early and delayed graft function, induction therapy and recipient age,
sex, race, transplant site, central venous access, posttransplant blood transfusion,
length of hospital stay, complete blood count, and changes in recipient body
mass index to determine the factors associated with thrombotic events.
Results: The mean patient age was 51 years (range, 22-80). Thrombotic events
occurred in 14 patients (n=19 events); mean 1. 3 ± 0. 5 events with 5 patients
having more than one event. The mean age for patients who had thrombosis
was 58 years (range 39-80; P<0. 03).
Lower extremity thrombosis occurred in 10 (5. 9%) patients. Lower extremity
DVT was ipsilateral to the side of transplant in 5 (50%) patients and was
contralateral in 3 (30%). Two (20%) patients had a bilateral venous thrombosis.
The mean time to lower extremity thrombosis was 90 days. Blood transfusion
was a significant risk factor in patients with lower extremity thrombosis (P <
0. 04).
Upper limb venous thrombosis occurred in 9 (6. 4%) patients. PICC line was
inserted in 6/9 (66. 6%) patients who had upper limb thrombosis (P< 0. 01).
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The incidence of venous thrombosis was high in patients who had delayed
graft function (DGF, P<0. 02), posttransplant blood transfusion (P<0. 01) or
prolonged posttransplant hospital stay (P< 0. 0001).
Conclusion: Recipient age and factors requiring blood transfusion, PICC lines,
prolonged hospitalization and the occurrence of delayed graft function are high
risks for venous thrombosis in kidney transplantation. Furthermore, upper limb
thrombosis may be as prevalent as lower limb thrombosis. Minimization of
these factors and use of appropriate antiplatelets may be of help in decreasing
the incidence of venous thrombosis.
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1554 FATAL CATASTROPHIC ANTI-PHOSPHOLIPID
SYNDROME FOLLOWING RENAL TRANSPLANTATION
A-M. Craven1, S. Campbell1, D. Johnson1, N. Isbel1, C. Hawley1,
V. Kanagarajah2, D. Mudge1, D. Nicol2, J. Preston2
1
Department of Renal Medicine, Princess Alexandra Hospital, 2Department of
Transplantation Surgery, Princess Alexandra Hospital
“Catastrophic Anti-phospholipid Syndrome” (CAPS) is a fulminant, often lethal
form of the Anti-Phospholipid Syndrome first defined in 1992. Characterised by
arterial and venous thromboembolism in multiple organ beds, it has a mortality
rate of almost 50%. The clinical picture is dominated by small vessel occlusions
with rapid development of multi-organ failure, severe thrombocytopenia,
haemolytic anaemia, disseminated intravascular coagulation and the systemic
inflammatory response syndrome, manifested as adult respiratory distress
syndrome. We report on the development of CAPS in a patient in the days
immediately following renal transplantation and the fatal outcome.
Mr. H was a 64 year old aboriginal man from a rural area who presented to
his nephrologist with end stage renal failure. Investigations at the time of
presentation showed bilaterally small, echogenic kidneys on ultrasonography
and nephrotic range proteinuria. He had a positive lupus anti-coagulant (LAC),
but no known clinical thrombotic events. The cause of his renal failure was
uncertain. A biopsy was not performed. He commenced on peritoneal dialysis
and remained on this modality for two years prior to transplantation.
At day 8 post living unrelated renal transplantation, the patient developed
worsening renal impairment and thrombocytopaenia in the setting of a very
high anticardiolipin antibody (ACLA) titre. Despite intravenous heparin, a 5
day course of intravenous immunoglobulin and ongoing daily plasma exchange,
the patient’s renal function continued to deteriorate. He became increasingly
thrombocytopaenic, and had evidence of thrombo-embolic events in other
organs with rapid atrial fibrillation and cardiac ischaemia, skin involvement
and ultimately ARDS. He died 24 days post renal transplantation. His family
declined an autopsy.
Discussion: Although not proven with biopsy evidence, a diagnosis of
CAPS in this case was made on the basis of thrombocytopaenia, markedly
elevated ACLA and suspicion of thromboembolism in at least two organs.
Several studies have shown an increased incidence of ACLA and LAC in
patients with end stage renal disease compared with the general population.
However the pathogenecity of these antibodies in the renal failure population
remains unclear. To our knowledge this is the first documented case of CAPS
precipitated by organ transplantation. Consideration should be given to the use
of prophylactic anti-coagulation in those patients with high antibody titres in
the early post transplant period.
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1555 AN UNUSUAL CAUSE OF ANURIA TEN YEARS AFTER
SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION
S. Nangia, E. Saad,
Medical College of Wisconsin
Case: A 48-year-old female underwent SKPT in 1997. Ten years later
she presented with a three days history of nausea, vomiting, loose stool
and anuria. She had base line serum creatinine of 1. 1mg/dl. On physical
examination she was severely dehydrated, markedly hypotensive and had
mild left lower quadrant abdominal pain. Her serum creatinine was 6. 2mg/
dl. Her pancreatic function was normal with the following levels: glucose
93mg/dl and serum amylase 38mg/dl. A renal ultrasound scan showed
mild pelvicaliectasis with no apparent change from a previous study two
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1556 UNUSUAL CAUSE FOR TRANSPLANT URETERIC
OBSTRUCTION
T. Dighe, S. Shivde, J. Date, V. Gorde, P. Joshi
Deenanath Mangeshkar Hospital & Research Center, Erandawane, Pune,
India
Introduction: Urological complications are the most common type of posttransplant surgical problems. Transplant ureteral stenosis occurs in 3. 1–10.
2% of patients after renal transplantation. The diagnosis is usually made by
ultrasound and radiography with contrast media. Now a days most (95%) have
been treated by percutaneous nephrostomy, with or without stenting. We here
present a case where ureter was obstructed due to encasement in dense scar
which did not responded to the PCN and antegrade stenting and has to be
surgically explored.
Case Report: A 24-year-old man underwent live related renal transplantation
with mother as donor.
Transplantation done one and half month back and was with uneventful
recovery. He developed recurrent UTI and was treated with appropriate
antibiotics. one month post transplant he presented with colicky pain over
the right iliac fossa and decreased urine output. There was hydronephrosis of
transplanted kidney on ultrasound. We elected to perform a transplant puncture
for antegrade pyelography which showed lower ureteric stricture. It was dilated
endoscopically followed by stent insertion. On follow up stent was removed
but RGP showed again lower ureteric stricture. On open exploration he showed
ureter incorporated in dense scar tissue which was released till the extravesical
ureterocystostomy. The post-operative course was uneventful. Ultrasound
showed no evidence of hydronephrosis and serum creatinine remained stable.
Discussion: The most frequent urological complications include ureteral
stenosis, urinary fistula, renal artery stenosis and lymphocele formation. Most
often these complications occur within 3 months after transplantation. Ureteral
stenosis affects 3. 1–10. 2% of patients after transplantation]. Usual causes of

ureteral stenosis are post-operative oedema, ureteral torsion or compression
(e. g. from haematoma or lymphocele), and different implantation techniques.
Endourological means to treat such situations are usually successful but due
to uncommon etiology in our case we have to explore the patient to treat the
situation.
Conclusion: We here present a rare cause of obstruction in transplanted kidney
which may not be treated by endourological means and needs exploration to
treat it completely

POSTER BOARD NUMBER P2 – 357
1557 EFFECTIVENESS OF PREOPERATIVE HYDROSTATIC
DILATATION OF CONTRACTED BLADDER FOR KIDNEY
TRANSPLANTATION
J-H. Choi1, W-I. Park, J-M. Kong, J-H. Jeong
1
Maryknoll Hospital, 2Maryknoll Hospital, 3Maryknoll Hospital, 4Maryknoll
Hospital
Purpose: Chronic renal failure patients may have contracted bladder which
is the result of disuse atrophy and fibrosis of bladder mucosa and muscle.
Contracted bladder brings many difficulties to conduct ureteroneocystostomy
in kidney transplantation. So many authors have suggested that preoperative
bladder augmentation using intestine and ureter etc. could have increased
success rate in kidney transplantation. These methods, however, have been
studied in pediatric transplantation in most cases and known to have many
complications associated with medical and surgical treatments. Since the
late 1960s, a hydrostatic dilatation of bladder used as a treatment in patients
with urgency, urge incontinence, interstitial cystitis and bladder tumor. We
applied this method to dilatate the bladder in recipients who had contracted
ones.
Methods: In our hospital, we did 462 kidney transplantations from August,
1990 to December, 2007. Among them, we attemped the hydrostatic dilatation
of bladder in 27 patients with contracted bladder less than 100cc in capacity.
We inserted 18Fr-3 way Foley catheter and instilled 50-100cc normal saline
gravitationally in 80cmH2O without any kinds of anesthesia. We repeated it
from 5 to 10 times daily. We started this procedure to the patients 7 day before
operation and ceased it at least 2 day before operation.
Results: Predilatation volume ranged 60-100cc (average 86. 3cc) and
postdilatation volume did 100-250cc (average 198. 2cc). There was no
complication associated with hydrostatic dilatation of contracted bladder and
ureteroneocystostomy. Double J catheter was not applied in our series. There
was no loss of transplanted kidney.
Conclusion: Our results suggest that pretransplant hydrostatic dilatation of
contracted bladder can make ureteroneocystostomy more easier and increase
success rate of kidney transplantation.
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1558 URETEROSCOPIC MANAGEMENT OF UROLOGICAL
COMPLICATIONS AFTER RENAL TRANSPLANTATION
M. Nikoobakht, A.R. Mehrsai, G.R. Pourmand, M.R. Taherimahmoudi
Urologu Research Center, Tehran University of Medical Sciences
Purpose: To determine the feasibility, safety, and efficacy of diagnostic and
therapeutic ureteroscopy in renal allograft ureters.
Materials and Methods: We reviewed 1560 consecutive renal allograft
performed between June 1989 and February 2002. Of these, 28 patients (1. 8%)
had indications for endoscopic procedure of the allograft ureter. Six patients
had obstructive ureteral calculi with a history of failed ESWL, 3 had suspected
ureteral strictures, nine had upward migrated ureteral stents and 10 had ureteral
stricture at ureteroneocystostomy sites. The ureters have been anastomosed to
the bldder using the leadbetter politano (6) and lich – GreGoire (22) methods
of the ureteric implantation.
Ureteroscopies were performed with semirigid 9. 8F wolf ureteroscope.
Results: Identifying and cannulating the transplant ureteral orifice was
successful in 19 (68%). Four of the ureteral calculi (67%) were removed with
ureteroscope. Seven of the migrated stent (78%) were retrieved. Four of the
patients with ureteral strictures (40%) had successful ureteral dilatation and
a double J ureteral catheter insertion. Diagnostic ureteroscopy was successful
in all cases.
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years prior. Doppler sonography showed normal arterial waveforms.
Patient was aggressively resuscitated with crystalloids. There was no
improvement in her urine output. A renal biopsy was performed and did
not show any significant pathological changes. No rejection was evident
on the biopsy. A CT scan of the transplanted kidney showed moderate
degree of hydronephrosis and swelling around the kidney. An antegrade
nephrostogram demonstrated a corkscrew like configuration of the proximal
ureter with neither opacification of the more distal ureter nor the urinary
bladder. A percutaneous nephrostomy tube was placed and a copious
amount of urine returned. . The patient was taken to the operating room.
At laparotomy the kidney was found twisted 180º around its pedicle. The
torsion was straightened and a nephropexy of the kidney to the left colon
and the anterior abdominal wall was performed. Post operatively her serum
creatinine went down to 0. 9mg/dl and she was discharged from the hospital
with excellent allograft function.
Discussion: Renal transplant torsion around its pedicle is a rare technical
complication of intraperitoneal renal transplantation. Intraperitoneal
placement of SKPT is technically easier compared to extra peritoneal
placement. However, intraperitoneal location allows more transplant mobility
that increases the risk of torsion. One of the diagnostic difficulties of renal
torsion is its lack of specific clinical features. A high level of suspicion is
needed to diagnose renal transplant torsion since it may mimic rejection,
ureteric obstruction as well as venous thrombosis. Imaging studies play a
crucial role in torsion diagnosis. Renal ultrasound is not as sensitive as CT
scan in detecting this problem. Once the diagnosis is made, nephropexy
to the anterior abdominal wall is indicated. Prophylactic nephropexy of
intraperitoneally placed transplanted kidney is warranted to prevent torsion
of the transplanted kidney. To our knowledge, this is the first case of
simultaneous kidney-pancreas transplant recipient who developed torsion of
the transplanted kidney ten years after transplantation.
Conclusion: Transplant torsion should be considered in the differential
diagnosis of acute renal failure and anuria particularly in simultaneous kidneypancreas transplant recipients with intraperitoneal kidney. It is extremely
important not to be committed to one diagnosis but rather explore other
diagnoses especially if there is inadequate response to therapy or if additional
data becomes available.
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Complications were one urinary leakage and one symptomatic urinary tract
infection.
Conclusion: Transplant ureteral endoscopy was safe and effective for
the management of urological complication after renal transplantation.
Ureteroscopy is technically demanding in these patients. One should consider
ureteroscopy as an alternative to percutaneous and antegrade modalities, as
these methods carry significant morbidity.
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1559 MANAGEMENT OF URETERAL UROLOGIC
COMPLICATIONS: EXPERIENCE AFTER 700 KIDNEY
TRANSPLANTATION
M. Taherimahmoudi, G. Pourmand, A. Mehrsai, M. Nikoobakht
Urology Research Center, Tehran University of Medical Sciences, Tehran,
Iran
Objectives: To evaluate the incidence, diagnosis, management, surgical
technique, outcome and risk factors of ureteric urologic complications after
kidney transplantation.
Materials and Methods: Since 1989-2002, among 700 kidney transplanted
patients, 200 patients were successfully completely followed up for 1-13
years, by clinical examination, graft sonographic study, biochemical and if
indicated isotope scanning of the renal graft (DTPA scanning). All transplanted
ureters were stented and received the same immunosuppressive protocol as
routine. Those who proved to have ureteral complications were first referred
for endourologic intervention, and if failed referred for surgical repair. This
study didn`t included extra ureteral obstructive cause, like lymphocele or other
pelvic collections.
Results: 14 among 200 patients (7%), were developed ureteric complications.
M/F ratio =10/4. ureter stenosis (6), ureteric fistulae (5) and ureter obstruction
(3). All of them initially treated by percutaneous nephrostomy (PNS) and if were
possible antegrade JJ stenting. Those who failed conservative approach, were
referred for surgical intervention (10 patients = 3 ureter obstruction + 4 stenosis+
3 fistulae). (3) cases managed by Boari`s flap, (3) by ureteroureterostomy
with native ureter, (3) by pyeloureterostomy with native ureter and (1) by
ureteroneocystostomy. One case failed to respond (ureteroureterostomy) and
was managed with proper outcome by Boari`s flap. Among 14 patients, 10
were diabetics, 12 had previous history of CMV infection and 5 had acute
rejection episodes.
Conclusion: Post kidney transplantation ureteral complications are easily
diagnosed and can conservatively manage by expertise radiologists. Those
with prolonged DM, previous acute rejections and/or CMV infection, are better
to be referred to surgical repair using native ureters.
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1560 CONSERVATIVE SURGERY IN RENAL CELL
CARCINOMA IN TRANSPLANTED KIDNEYS
J.A. Pereira, J.R. Andrade, L.C. Pinheiro, A. Pena, A. Martins, E. Barroso
Curry Cabral – Hospital
The frequency of malignancy in organ transplant recepients is estimated
to be 100 times higher than that in genaral population. The transplant
patiens have an incidence 15 times higher of renal cell carcinoma than the
general population.
We present two clinical cases of renal carcinomas in transplanted kidneys.
Diagnosis were made in 15 and 19 years post-transplant by routine
ultrasonography. the tumors are unifocal with 45mm and 15mm capsulated
and low stage (t1). The resection of the mass (nephron-sparing surgery)and of
a layer of the tissue surrounding the tumour was perfomed, without vascular
controle or hypothermia. 12 months after surgery the patients are alive, without
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disease recurrence and with good renal function.
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1561 UROLOGICAL COMPLICATIONS IN RENAL
TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 10
YEARS.
M. Aragon1, B. Aguilar, R. Mondragon, R. Bernal
1
Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico
ISSEMyM, 4Centro Medico ISSEMyM
Introduction: Urological complications are a cause of graft loss or morbidity
in 2 to 20% patients.
Aim: : The purpose of this study was to review the incidence and management
of all urological complication in our center.
Patients and Methods: A retrospective study of the hospital charts of 176
consecutive transplanted patients was performed in order to analyze the
ureteral complications and their management. Between August of 1983 to
October of 2007, 176 renal transplantations were performed at the Centro
Medico ISSEMYM. The ureter from the kidney graft was inserted into the
bladder according to the technique of extravesical implantation described by
Lich-Gregoir, and based in the criteria of the surgeon the insertion of a transient
ureteral stent in 90% of the patients.
Results: Urological complications occurred in 9/176 renal transplantations
(5%). Anastomotic urine leakage was the most frequent, follow by ureteral
estenosis. The mean time to appearance of these complications was 6 months.
All cases were managed surgically. The most frequent surgical repair was
ureterovesical reimplantation (n=8), ureteroureteral end-to-end anastomosis
(native ureter-ureter transplant, n=1). The insertion of the transient ureteral
stent was no related to infectious complications. No mortality related to any of
the urological complications were reported.
Conclusion: The rate of complications observed in this retrospective analysis
is similar to the experience of other studies. If the classical extravesical ureteral
bladder implantation is to remain an attractive technique due to its simplicity,
the surgical team at the training center should be aware of all the means to
prevent any ureteral complications, such as the choice of another implantation
technique and/or insertion of a transient ureteral stent.
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1562 UROLOGICAL COMPLICATIONS AFTER KIDNEY
TRANSPLANTATION: EXPERIENCE OF OVER 1000
TRANSPLANTS
A. Faenza1, M. Tsivian1, R. Bertelli1, F. Neri1, G. Cavallari1, B. Nardo1, G.
Fuga1, S. Stefoni2
1Transplant Center of Bologna, University of Bologna, Italy, 2Dept. of
Nephrology, Dialysis and Transplantation, University of Bologna, Italy
Introduction: Urinary fistulas and stenoses are the most common complications
after kidney transplantation that may require surgical revision.
The aim of this study is to assess retrospectively the incidence of and risk factors
for early (within 30 days) or late major urological complications (stenoses and
fistulas) after kidney transplantation in the experience of the transplant center of
Bologna.
Methods: The study population comprised 1142 consecutive patients who
underwent kidney transplantation between January 1990 and September 2007.
End points considered were early and late urological complications (stenoses
and fistulas). The variables considered in multivariate and univariate analyses
were: recipient’s age, sex, etiology of renal failure, number and type of kidney
transplant (first/second and single/double/combined with other organs), cold
ischemia time, type of urinary reconstruction (uretero-cystostomy vs ureteroureterostomy), stent positioning, donor’s cause of death, sex, age, serum
creatinine and clearance, presence of graft polar arteries, acute rejection and
post-operative graft function.
Results: Out of 1142 transplants 100 (8. 7%) patients experienced 107
urological complications: 85 (79. 4%) early (56 fistulas, 29 stenoses) and 22
(20. 5%) late (7 fistulas and 15 stenoses).
Multivariate analysis for all complications revealed significant association
with male sex of the recipient (p=0. 00, HR=2) while first kidney transplant
was protective (p=0. 00, HR=0. 4). Male gender both of the recipient and of
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the donor was significantly associated with early fistulas (p=0. 01, HR=2. 5
and p=0. 02, HR=2, respectively). First (vs second) kidney transplantation had
a protective effect on early stenoses (p=0. 01, HR=0. 27). Late fistulas were
associated with anastomosis stenting (p=0. 03) in a univariate analysis but non
in a multivariate one. Multivariate analysis for late stenoses did not demonstrate
any significant association with the considered variables; however the late
stenoses cases had a significantly higher recipient and donor age (p<0. 05) and
a lower donor creatinine clearance (p<0. 05). Other parameters considered did
not reach statistical significance.
Discussion: In our experience the incidence of urinary complications have
not decreased in the last years and remains a major issue in kidney transplant
recipients. In this study, the type of urinary anastomosis, stenting, cold
ischemia time, presence of polar arterial branches and type of transplant
did not influence the incidence of urinary fistulas and stenoses. Our data
confirm that older recipients and organs from older donors, especially of male
gender, and re-transplants are to be considered risk factors for urological
complications. The present analysis cannot suggest any modification of the
actual surgical strategy in order to prevent urological complications in kidney
transplantation.
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J. Pascual1, F.J. Burgos2, J. Zamora3, A. Muriel3, N. Plana3
1
Servicio de Nefrología, Hospital Ramón Y Cajal, 2Servicio de Urología.
Hospital Ramón y Cajal, 3Unidad de Bioestadística, Hospital Ramón y Cajal
The different pathophysiology underlying the appearance of ureteral and
ureterovesical junction leaks and ureteral or pyeloureteral stenoses after
kidney transplantation (KT) may support different risk factor profiles for each
anatomical localization. Ureter ischemia and anastomotic problems, specially
healing problems may be respectively the main underlying processes in the
two groups of leaks. We have tested this hypothesis in 1341 adult isolated
KT performed in 26 Spanish units during 2004 and followed-up for 1 year.
Mean donor age was 48. 4±17. 3 years, 97. 2% were deceased donors, mean
recipient age was 51. 1±13. 5 years, 59% were males, mean BMI was 25.
3 kg/m2, peak PRA was 8. 5±19. 9%, time on dialysis had been 33. 5±36.
1 months and 13. 4% were retransplantations. Immunosuppression included
steroids (99%), MMF (92%), Tacrolimus (66%), CsA (18%), and sirolimus
(9%). Double J ureteral stent was used in 35% of cases for a mean of 21
days. Delayed graft function was observed in 37. 4%, acute rejection in 16.
5% and graft loss in 8. 6% and death in 3%. Urinary leaks developed in 5.
7% and urinary stenosis in 5. 5%. The leaks were localized in the ureter in
4. 4% and in the ureterovesical anastomosis in 1. 3%. In the multivariate
logistic regression analysis, ureteral leak was associated with donor age (OR
1. 027, p=0. 004), the absence of double J stent (OR 0. 455 if used, p=0.
023), and the use of cyclosporine as opposed to tacrolimus (OR 2. 058, p=0.
02). Bladder leaks were associated again to the absence of double J stent
(OR 0. 250 if used, p=0. 06) and the use of sirolimus (OR 3. 53, p=0. 019).
Regarding stenoses, ureteral ones were associated to donor age (OR 1. 04,
p=0. 0001), warm ischemia time (OR 1. 016, p=0. 03), and direct ureteral
reimplantation (OR 2. 67, p=0. 012). The use of ureteral stent also protected
against pyeloureteral stenosis (OR 0. 288, p=0. 046), but had no effect on
ureteral stenoses.
Ureteral leaks and stenosis, of ischemic origin, develop more frequently
with advanced age kidneys. Other pro-ischemic factors such as the use of
cyclosporine or prolonged warm ischemia time are also related with ureteral
leaks and stenoses respectively. Contrarily, bladder leaks are more related with
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1564 UROLOGICAL COMPLICATIONS OF RENAL
TRANSPLANT IN A LIVE RELATED TRANSPLANT
PROGRAMME AT SIUT
A. Rizvi, A. Hashmi, H. Askari, M. Hussain, A.S. Hasan, A. Naqvi
Sindh Institute of Urology And Transplantation
Introduction: The incidence of urological complications after kidney
transplant ranges from 3 to 14%. Some of these are so severe that they end up
in graft loss. The main objective of this study is to review retrospectively the
urological complications in living related kidney transplants.
Patients and Methods: It is a retrospective study of renal transplantation
which was done at SIUT between November 1985 and August 2005. All the
urological complications encountered were recorded. Ultrasonography, renal
scintigraphy, antegrade pyelography, CT scan and MR angiography were the
main diagnostic tools.
Results: 1448 patients were transplanted during this period. Out of these 97
(6. 7%) patients had developed urological complications like urinary fistulae
in 21 (1. 5%) patients, distal ureteral necrosis in 5 (0. 4%) patients, ureteral
stenosis in 13 (0. 95) patients, renal calculi in 2 patients while 3 had ureteric
calculi, symptomatic vesico-ureteric reflux in 13 (0. 9%) patients, lymphocele
requiring intervention in 35 (2. 5%) patients and bladder outlet obstruction
in 5 (0. 4%) patients. All complications were treated either conservatively or
surgically. No graft or patient was lost due to urological complications.
Conclusion: Many complications may occur after kidney transplant. Prompt
diagnosis with high index of suspicion and a combination of endourological
and open reconstructive techniques may play a major role in minimizing
urological complications.
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1565 LACK OF VARIATION IN SERUM CREATININE
VALUES BETWEEN CENTRAL STUDY LABORATORY AND
CLEVELAND CLINIC IN KIDNEY TRANSPLANT RECIPIENTS
K.C. Mange1, H. Tedesco2, T. Johnston2, G. Zibari2, Y. Li1 Z. Wang1.
1
Novartis Pharmaceuticals, East Hanover, NJ, United States and 2On behalf
of the A2309Study Group.
Background: Recalibration of laboratory serum creatinine assays to the
Cleveland Clinic laboratory standard may improve the accuracy of GFR
estimation using the abbreviated MDRD equation. It is unknown what value, if
any, this may have for kidney transplantation.
Methods: RAD001A2309 is a 24-month, multicenter, randomized, openlabel study of the efficacy and safety of concentration-controlled everolimus
with reduced-exposure cyclosporine microemulsion (CsA-ME, Neoral) vs
enteric-coated mycophenolate sodium (myfortic) with standard-exposure
CsA-ME in 833 de novo renal transplant recipients. Blood samples from
469 enrolled subjects were selected from the studys central laboratory that
were representative of the distribution of serum creatinine at any timepoint.
These residual samples were sent to the Cleveland Clinic Laboratory, which
was blinded to the serum creatinine values recorded by the central laboratory.
Treatment assignment remains blinded to the clinical team and data were
pooled across treatment groups.
Results: 464 residual blood samples were available from the 469 selected
subjects. There was a mean difference in serum creatinine of 0. 835mg/dL
between the laboratories) (lower for the central laboratory versus the Cleveland
Clinic Laboratory), equivalent to a mean difference in eGFR that was 0. 186mL/
min/1. 73m2 lower for the central laboratory.
Conclusions: 1) The RAD001A2309 central laboratory has, on average,
little variation in serum creatinine from the Cleveland Clinic laboratory, with
differences being clinically irrelevant; 2) The level of variation will need to
be explored across different NKF categories of chronic kidney disease to
determine if the lack of difference is maintained over the full range of renal
function.
Serum Creatinine
(mg/dL)

Cleveland Clinic (CC)
Value
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1563 DIFFERENT RISK FACTORS ARE ASSOCIATED
TO DIFFEENT ANATOMICAL LOCALIZATION OF
URINARY TRACT LEAKS AND STENOSES AFTER KIDNEY
TRANSPLANTATION

the wound healing problems promoted by sirolimus. The use of ureteral stent
prevents both types.

Tuesday 12 August 2008
Minimum
Median (50%)
Maximum
Mean
Std Deviation
95% CI for Mean
eGFR mL/min/1. 73m2
Minimum
Median (50%)
Maximum
Mean
Std Deviation
95% CI for Mean
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0. 300
2. 980
18. 450
3. 790
3. 091
[3. 507, 4. 072]

0. 622
3. 083
16. 923
3. 802
2. 979
[3. 530, 4. 074]

-0. 322
-0. 103
1. 527
-0. 012
0. 112

3. 370
23. 785
348. 350
34. 478
31. 400
[31. 613, 37.
342]

3. 300
22. 750
137. 500
33. 643
27. 895
[31. 098, 36.
188]

0. 070
1. 035
210. 850
0. 835
3. 505
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1566 10 YEARS SINGLE CENTER EXPERIENCE IN KIDNEY
TRANSPLANTATION CHALANGED BY ABNORMAL GRAFT
VASCULAR ANATOMY
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, B. Stefan,
D. Tacu, E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni
Clinical Institute
Purpose: The aim of this study was to evaluate 10 years transplant experience,
using normal pedicle kidney and borderline vascular graft.
Material and Methods: From June 1997 until March 2008, 855 renal
transplantations (710 living and 145 cadaver, 807 adults and 48 pediatric
transplants) have been performed in our center, with an average of 81/year
(116 in 2007). In all cases, general preoperative evaluation, immunological
and vascular anatomy study was performed. Standard minimal lombotomy
nephrectomy technique was preferred. 266 cases (31%) had vascular graft
anomalies, 165 abnormal arteries and 101 abnormal veins.
Results: No major complications appeared in 710 nephrectomies. Minor
complications were: renal artery spasm, bleeding, minor respiratory
complication, pneumothorax, illeus, bladder voiding problems, UTI. Longterm complications were: persistent wound pain, parestezia and wound hernia.
Quality of life after surgery was assessed using SF 36 Health Survey Test and it
was normal. Special anastomotic techniques were used as followed: double T-T
anastomosis – 96 cases, T-L anastomosis – 9 cases (cadaver donors), combined
anastomosis – 3 cases; single trunk made by two branches – 27 cases and we
used the epigastric artery in 4 cases. 26 minor aberrant vessels were excluded,
feeding a minor area of parenchyma. Cava patch was used in 32 cases (11
from cadaver donors). Abnormal venous drainage was managed by classical
T-L anastomosis to the external iliac vein. Graft function was 96% – one year,
84% – 5 years and 80% – 10 years.
Conclusions: General evaluation, immunological and renal pedicle
assessment was a must. The living donor nephrectomy respected in our
center the international accepted morbidity. No major complication appeared.
Mortality was 0. Vascular anomalies of renal pedicle were founded in 31% but
transplantation was performed due to special anastomotic techniques which
did not significantly increase the ischemia time and vascular complications.
Accepting the borderline vascular donor the number of transplantation could
increase with 30%.

mean corticosteroid dose, and nutritional status were noted between the two
groups.
Early diagnosis and intervention improved the prognosis; 18. 1% (2 out 11)
of those operated on within 24 hours died; 50% (5 out 10) died after delayed
intervention. (p< 0. 05).
Excision of the lesion with end- ileostomy + transverse colon mucous fistula (right
colon perforations) or end-colostomy plus sigmoid colon mucous fistula (left
colon perforations) were performed. The incidence and outcome of posttransplant
colonic perforations were associated with the intensity of immunosuppression.
Conclusions: Colon perforation is a dramatic complication in immunosuppressed
renal transplant recipients. Prompt diagnosis and treatment are critical; a high
index of suspicion, urgent investigation, prompt surgical intervention and
attention to the nutritional status are essential for survival.

POSTER BOARD NUMBER P2 – 368
1568 IMPACT OF EARLY ADVERSE EVENTS ON
KIDNEY GRAFT SURVIVAL IN THE MODERN ERA OF
TRANSPLANTATION
C. Süsal, B. Döhler, M. Sadeghi, J. Ovens, G. Opelz
Dept. of Transplantation Immunology, Univ. of Heidelberg
Abstract Document: In a prospective multi-center study, in which 23 centers
are participating, we are examining the impact of serum factors on graft outcome.
We also collect information on clinical events that occur during the early phase
after transplantation. Here we analyzed the association of early adverse events
with graft survival. All transplantations were performed after 2001.
Altogether, 1437 patients were studied. Primary non-function during the first
24 hours was reported in 314 patients, acute tubular necrosis (ATN) in 360
patients, an acute rejection episode during the first 3 months in 285 patients,
and an infection during the first 3 months in 181 patients.
Recipients with primary non-function, ATN, or acute rejection showed 3-year graft
survival rates (± standard error) of 79±3%, 81±2%, and 81±3%, respectively. These
rates were significantly lower than the 93±1%, 94±1%, and 92±1% rates found in
1117 patients with primary function, 1067 patients without ATN, and 1131 patients
without rejection, respectively (log rank p<0. 001 for all 3 comparisons). The 3-year
graft survival rate in 80 patients without primary function who also experienced
an acute rejection during the first 3 months was a poor 67±7%, as compared to a
95±1% rate in 904 patients with primary function and without acute rejection (p<0.
001). Importantly, however, neither primary non-function nor early rejections or
ATN had an impact on 3-year graft survival if good graft function with a serum
creatinine of <130 umol/L was observed at the end of the 3rd month (>94% 3-year
graft survival for all three adverse events). Infection during the first 3 months also
had a significant impact on 3-year graft survival (with infection: 86±3% vs. without
92±2%, p=0. 024). A remarkable 3-year graft survival rate of 97±1% was observed
in 386 patients in whom none of the 4 early adverse events were reported.
Our results indicate that, even in the modern era of transplantation, prevention,
early diagnosis, and consequent treatment of early adversary events, such as
primary non-function, ATN, rejection, and infection, are of great importance
for good outcome.
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1567 COLONIC PERFORATIONS AFTER RENAL
TRANSPLANTATION: RISK FACTORS ANALYSIS.
A. Faenza, F. Catena, L. Ansaloni, L. D’Alessandro, R. Bertelli, A. Pinna
St Orsola- Malpighi University Hospital
Background: Perforation of the colon is a rare and dramatic complication in kidney
transplanted patients (high risk population for end-stage renal failure, maintenance
therapy with dialysis before transplantation and chronic immunosuppression)
Methods: 1651 consecutive renal transplants performed between 1976 and
2007 at the St Orsola- Malpighi University Hospital, Bologna, ITALY.
21 recipients (1. 2 percent) experienced 21 episodes of colonic perforations, 7
of which (33. 3 percent) were fatal. The medical records and clinic charts of
each person were analyzed for variables between those who survived and those
who died of the colon perforation.
Results: Significant differences in patients characteristics, laboratory findings,
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1569 VACUUM-ASSISTED CLOSURE THERAPY (VACT) IN
THE MANAGEMENT OF WOUND INFECTION FOLLOWING
RENAL TRANSPLANTATION: A SINGLE CENTRE
EXPERIENCE
I. Butt, V.C. Nathan, M.S. Delbridge, D. Throssell, W.S. McKane,
A.T. Raftery, B.M. Shrestha
Sheffield Kidney Institute, Herries Road, Sheffield, S57AU, UK
Introduction: Wound infection in the setting of an immunosuppressed state
such as after renal transplantation (RT) causes significant morbidity from
sepsis, prolongs hospital stay and is expensive. Vacuum-assisted closure therapy
(VACT) is a new technique of management of wound based on the principle of
application of controlled negative pressure. The aim of this study was to assess
the efficacy of VACT in the management of wound infection following RT.
Methods: This is a prospective study of a cohort of 237 consecutive RTs
performed over a period of 5 years, where the data were retrieved from a
prospectively maintained computerised database and case-notes.
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Results: 11 of 250 (4. 4%) patients developed deep wound infection following
RT leading to cavitations and dehiscence with copious discharge, which
refused to heal with conventional treatment. All 11 cases were treated with
VACT. The VACT system was removed after a median of 9 (range 3-120) days
when discharge from the wound ceased. Six patients were discharged home
with portable VACT device and managed on an outpatient basis, where the
system was removed after a median of 7 days (range 3-116) days. The median
hospital stay after initiation of VACT was significantly shorter (4, range 2-12
days) than on conventional treatment prior to VACT (11, range, 5-20 days).
Complete healing was achieved in all cases. No complications related to VACT
such as haemorrhage and intestinal fistulae were observed in this series.
Conclusions: The use of VACT is an effective and safe adjunct to conventional
and established treatment modalities for the management of deep wound
infection and dehiscence following RT.

POSTER BOARD NUMBER P2 – 370
1570 INFECTIOUS AND NONINFECTIOUS SURGICAL WOUND
COMPLICATIONS AFTER KIDNEY TRANSPLANTATION (KT)
IN ADULTS: A MULTICENTER RISK FACTOR ANALYSIS
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1571 SYMPTOMATIC LYMPHOCELES AFTER KIDNEY
TRANSPLANTATION – MULTIVARIATE ANALYSIS OF
RISK FACTORS AND OUTCOME AFTER LAPAROSCOPIC
FENESTRATION
A. Pascher1, F. Ulrich1, S. Weiss1, S. Kohler1, S. Tullius2, P. Reinke3,
P. Neuhaus1, J. Pratschke1
1Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow, Berlin,
Germany, 2Division of Transplant Surgery, Brigham and Women’s Hospital,
Boston, United States, 3Dept. of Nephrology, Charité, Campus Virchow,
Berlin, Germany
Introduction: Lymphocele formation is a common complication after kidney
transplantation. The aim of this study was the analysis of incidence, risk factors
and treatment outcome.

POSTER BOARD NUMBER P2 – 372
1572 SURGEON YURII VORONOY (1895-1961) – A PIONEER
IN THE HISTORY OF THE CLINICAL TRANSPLANTOLOGY:
IN MEMORIAM AND ON THE 75TH ANNIVERSARY OF THE
FIRST HUMAN KIDNEY ALLOGRAFT
E. Matevossian1, D. Doll2, Y. Snopok3, J. Nährig4, S. Thorban5,
M. Nichitailo6
1
Department of Surgery, Transplantation, Technical University of Munich,
2
Department of Surgery, Transplantation, Technical University of Munich,
3
National institute of Transplantology, Academy of Medical Sciences, Kiev,
Ukraine, 4Institute of Pathology, Transplantation, Technical University of
Munich, 5Department of Surgery, Transplantation, Technical University of
Munich, 6National institute of Transplantology, Academy of Medical Sciences,
Kiev, Ukraine
Objective/Aim: Organ transplantation plays a common and important
part in the clinical medicine of today and is an effective cure in most of
organ failures occuring. Its´ history and development has been a stony and
challenging path. After pioneeristic experimental works done by Jaboulay
and Carrel in Lion an the beginning of the XX century. In 1933, a Soviet
surgeon Yurii Voronoy (Kherson, Ukraine) performed as pioneer the first
human allograft transplantation of cadaveric kidney, using 6 hr anoxic
kidneys to be reimplanted into the medial thigh. In the classic account by
David Hume of the pioneer kidney transplants done in Boston, he gave
credit to the surgeon Voronoy, as being the first to perform an allograft
kidney transplant upon a human being. The aim of this historical overwiew
article was to descript, what is known of this history and can now be
reviewed.
Results: In spit of this priorithy in human kidney transplantation, the life and
works of Voronoy have attracted little attention in the Western hemisphere.
The original article of Voronoy`s first kidney transplantation published in the
Spanish journal is brief in its account of the transplantation, but more detail
of this case was given in a recent Soviet review. Our article shows that not
only had Voronoy carried out a first human kidney transplant from a cadaver,
but also that he had some insight into the immunologic characteristics of graft
rejection.
Conclusion: These milestones of organ transplantation associated to the
broadening of knowledge in the field of surgical technique, preservation of
allografts and immunological aspects of acute rejection. Thus, Voronoy has a
major place in the history of transplantation and the specialy history of human
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J. Pascual1, F.J. Burgos2, J. Zamora3, A. Muriel3, N. Plana3
Servicio De Nefrología, Hospital Ramón Y Cajal, 2Servicio de Urología,
Hospital Ramón y Cajal, 3Unidad de Bioestadística, Hospital Ramón y Cajal
The surgical complication profile after KT is being modified by the increasing
donor and recipient age and co-morbidity, and the use of anti-proliferative
immunosuppressive drugs that alter tissue healing. To assess prevalence and risk
factors for such complications, we have performed an observational study in 26
units including patients who received a KT during 2004 and were followed-up for
1 year (n=1434). Multiple organ transplants (n=41) and patients with insufficient
data (n=52) were excluded, so the final studied population comprised 1341
KTs, including 16 double KTs. We classified wound complications in I) noninfectious, two subgroups (a) not-requiring surgical repair, supra-aponeurotic
and (b) requiring surgical repair, dehiscence or incisional hernia; II) infectious,
either superficial or deep infra-aponeurotic. Mean donor age was 48. 4±17. 3
years, 97. 2% were deceased donors, mean recipient age was 51. 1±13. 5 years,
59% were males and 13. 4% retransplantations. Initial immunosuppression
included tacrolimus (66%), CsA (18%), or sirolimus (9%). Overall wound
complications developed in 10. 8% of patients: 6% had non-infectious wound
problems (3. 5% did not require surgical repair and 2. 5% required it), and 4.
8% wound infections. In the multivariate logistic regression analysis, detected
risk factors for a non-infectious wound problem not requiring surgery were short
height (OR 0. 96, p=0. 006) and treated acute rejection (OR 2. 41, p=0. 01). For
those requiring surgical repair: recipient age (OR 1. 07, p=0. 004), body mass
index [BMI] (OR 1. 04, p=0. 021), warm ischemia time (OR 1. 03, p=0. 002).
For wound infection: donor age (OR 1. 032, p=0. 002), peak PRA (1. 016, p=0.
003), use of sirolimus (OR 2. 44, p=0. 019), treated acute rejection (OR 2. 16,
p=0. 016) and delayed graft function (OR 1. 92, p=0. 027).
In the investigation of risk factors for wound complications it is important
to distinguish those not requiring surgical repair from those requiring it,
and analysing separately wound infections. In this Spanish large series,
sirolimus use increases wound infections, but does not increase non-infectious
complications. Advanced donor and recipient age and obesity are the other
significant factors, with different impacts in each subgroup.
1

Methods: In a retrospective study we analyzed 426 patients who underwent
kidney transplantation between January 2002 and December 2006. After
basiliximab induction recipients received triple immunosuppressive therapy
with either tacrolimus or cyclosporine combined with mycophenolate mofetil
and methyiprednisone. Patients were analyzed for donor factors, incidence and
symptoms of lymphocele, demographic and clinical variables and treatment
outcome. Statistical analysis was performed with Fishers exact or chi-squared
test, ANOVA or Mann-Whitney U test, univariate analysis and the multivariate
Cox proportional regression model.
Results: The incidence of lymphocele was 9, 85% (n=42) in our population.
Patients with lymphocele were older and had a higher BMI. There was no
significant difference in donor characteristics. Diabetes, acute rejection
episodes and tacrolimus therapy were significant risk factors in univariate
analysis. After multivariate testing only diabetes confirmed its significance.
Laparoscopic fenestration was performed in 24 patients with a mean
lymphocele size of 7, 8±2, 9 cm. Creatinine levels at the day of lymphocele
diagnosis were significantly higher in patients with lymphocele treated
surgically (3, 2±0, 7 vs. 1, 7±0, 6 mg/dl), whereas albumin levels were
significantly decreased (2, 7±0, 2 vs. 1, 6±0, 5 g/dl). Both parameters
returned to a range comparable to other patients at the end of treatment.
Two patients presented with a recurrence after fenestration and underwent
a secondlaparoscopic procedure. All other patients were treated successfully
without additionalmorbidity.
Conclusion: Diabetes is a major risk factor for lymphoceles after kidney
transplantation, while acute rejection episodes and tacrolimus use play a minor
role. An increase of creatinine and decrease of albumin serum levels might be
able to indicate lymphocele formation. Laparoscopic fenestration is a safe and
effective treatment option.
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kidney allograft. In addition to his pioneering first kidney allograft operation
upon a human being, which has been briefly noted in the literature of the
Western world.
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1573 BOWEL OBSTRUCTION CAUSED BY SCLEROSING
PERITONITIS OCCURED AFTER A KIDNEY
TRANSPLANTATION: TWO CASE-REPORTS.
H. Skhiri, T. Dalel, J. lamia, H. Kamel, F. Mouna, A. Sabra, B. Samia,
F. Ameur, B. Nasr, E. Mezri
Tunisian Nephrology Society
Sclerosing peritonitis (SP) is a serious complication of chronic ambulatory
peritoneal dialysis (CAPD). It’s carecterized by thickening of peritoneum
that can enclse some or all of the small or large bowel. The most common
complication of SP is the partial or complete bowel obstruction.
We report two cases of bowel obstruction due to SP following long-term CAPD
and that have both occurred after a kidney transplantation.
1est case: occlusif syndrom that has occurred 3months after kidney
transplantation and in which the patient was in CAPD for 5 years than in
hemodialysis for 3 years. Diagnosis was a ileo-colic invagination
2sd case : occlusif syndrom that has occurred 4months after kidney
transplantation and in which the patient was in CAPD for2 years;diagnosis was
a volvulus of grele intestine.
Eventheless it was described a recovery of gastrointestinal function after renal
transplantation in a patient with sclerosing peritonitis secondary to continuous
ambulatory peritoneal dialysis due to immunosuppressive agents used after
kidney transplantation.
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1574 LONG-TERM NUTRITIONAL INTERVENTION OF
POST TRANSPLANT PATIENTS – VISCERAL PROTEIN,
BIO IMPEDANCE ANALYSIS (BIA), AND CLINICAL: AN
OVERVIEW.
V. Jaynthi, N. Vijayashree, G. Abraham,
Department of Nutrition and Dietetics, Madras Medical Mission, Chennai, India
Introduction: Assessment of the patient’s nutritional status enables the clinician and
dietitian to identify those at nutritional risk. Appropriate techniques of nutritional
assessment can detect nutritional deficiency in the early stage of development in
renal transplant recipient so that appropriate nutrition can be given. BIA and DEXA
scan are commonly used technique to assess nutritional status of renal transplant
recipients. The present study was undertaken to correlate the biochemical parameters
and Bioimpedence Impedance Analysis among post-renal transplant Patients.
Methodology: 138 post-renal transplant patients (66. 67% Diabetic, 53%
Hypertensive, 88% Nonvegeterians, 22% vegetarians) were randomly selected
and their BIA and bio chemical parameters, clinical status were analyzed.
Results: The mean value of visceral protein was found to be less among the
selected population (Albumin-3. 1 g/dl, Total Protein-%. 27g/dl). Calcium
found to be 8. 2 mg/dl. The mean Hemoglobin levels were 8. 2 g/dl. The lipid
profile analyzed showed normal mean values of total cholestrol-140. 3 mg/dl,
Triglycerides-90mg/dl, HDL-42mg/dl, LDL-80. 3 mg/dl respectively.
The average BMI of the Selected patients was 22. 7, in which 39% were over
weight with the average of 28. 4 and 15% were underweight with average BMI
of 17. 2. From the BIA it was identified that 68. 2% of the patients were having
higher percentage of body fat (mean-32. 83%). The percentage of patients who
were having lesser fat percentage was 15. 9%. While assessing the Total Body
Water (TBW) it was found that 44. 9% patients TBW was below the normal
levels (mean-38. 34). 15. 9% were overloaded with water percentage of 60. 39.
Nutritional deficiencies like zinc 50%, Niacin 30%, Essential fatty acids 25% were
clinically observed. Dehydration was found in 44. 9% of the selected population.
Conclusion: This study gives an overview of the post transplant patient’s
nutritional intervention is necessary for a long-term period to lead a healthy life.
Obesity, hyperlipidemia, lower visceral proteins, zinc, niacin, Essential fatty
acid deficiencies were found to be common among post transplant patients.
Bio impedance analysis is very useful and meticulous method along with other
methods to enable the nutritionist to educate, to provide appropriate nutritional
support to the post transplant patients.
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1575 SEVERITY OF LIVER DISEASE, RATHER THAN
AETIOLOGY, REFLECTS BLOOD LEVELS OF FAT SOLUBLE
VITAMINS IN ADULTS AWAITING LIVER TRANSPLANTATION
W. Abbott-Johnson1, P. Kerlin1, A. Clague2, R. Cuneo3
1
Princess Alexandra Hospital, 2Queensland Health Pathology Service,
3
Department of Medicine, University of Queensland
Although malnutrition is common in advanced liver disease, there are limited
data on levels of fat soluble vitamins in various diseases. The aims of this study
were to 1) determine levels of fat soluble vitamins in patients assessed for liver
transplantation 2) compare levels in hepatocellular and cholestatic disease 3)
relate vitamin levels to aetiology, biochemical (albumin and bilirubin) and clinical
indicators of disease severity (Child-Pugh and MELD scores). Plasma retinol,
serum 25-hydroxycholecalciferol and plasma vitamin E and were measured in 107
(76 males) consecutive patients, mean age 47 (16-64) years. Child- Pugh classes
were A (26), B (42) and C (38). Diseases were hepatocellular 74, cholestatic 22
and other etiologies 11. Deficiencies of retinol, 25-hydroxycholecalciferol and
vitamin E were present in 75% (< 1.0 μmol/L), 66% (< 50 nmol/L) and 3% (<
11 μmol/L) of patients. Concentrations of retinol and vitamin E were lower in
hepatocellular than cholestatic disease, (0.4 (0.01-1.6) versus 0.8 (0.2-2.2) μmol/L,
P = 0.0004 and 21 (7-61) versus 29 (6-54), P = 0.014 μmol/L respectively).
25-hydroxycholecalciferol concentrations were similar (42 (11-110) versus 46.5
(26-96) nmol/L, P = 0.065) and Child-Pugh score was higher in hepatocellular
disease than cholestatic (9 (5-14) versus 7 (5-11), P < 0.0001). For the whole
group, levels of retinol, 25-hydroxycholecalciferol and vitamin E were inversely
related to Child-Pugh score, MELD score and bilirubin, and directly to albumin.
Using multivariate regression analysis, fat soluble vitamin levels were reflected by
albumin and disease severity rather than etiology. There was a high prevalence of fat
soluble vitamin deficiencies (particularly retinol) in patients with advanced disease.
Vitamin levels were more closely related to disease severity than aetiology.

POSTER BOARD NUMBER P3 – 02
1576 ADVANCED GLYCATION END-PRODUCTS (AGES)
IN DEVELOPMENT OF ISCHEMIC AND DILATED
CARDIOMYOPATHY IN PATIENTS WITH DIABETES
MELLITUS TYPE 2 (DM)
M. Zakliczynski1, J. Nozynski1, D. Konecka-Mrowka1, B. Nikiel2,
J. Mlynarczy-Liszka2, D. Lange2, M. Zembala1
1
Silesian Center For Heart Disease, Zabrze, Poland, 2Comprehensive Cancer
Center M. Sklodowska-Curie Institute Branch, Gliwice, Poland
Background: Abnormal glycemia in diabetic subjects accelerates a process of
non-enzymatic conjugation of glucose with proteins, nucleic acids and lipids,
resulting in AGEs formation. AGEs are thought to be a reason of heart muscle
stiffness and impairment of its mechanical function. The aim of the work was
morphological evaluation of AGE in the left ventricle of the heart in patients
with diabetes type 2, and establishing the role of AGE in development of
ischemic (ICM) and dilated cardiomyopathy (DCM) in diabetic patients.
Material: The diabetes group consisted of 11 hearts explanted in patients with ICM
(ICM+DM group) and 8 hearts from DCM patients (DCM+DM group) undergoing
orthotopic heart transplantation (OHT). Two comparative subgroups were
composed of hearts explanted from OHT recipients without DM – 41 patients with
ICM and 41 with DCM. The groups were homogenic according to patients age and
DM2 duration. All tissues were fixed and processed routinely to paraffin-wax. The
localization of AGE was detected immunohistochemically, intensity was marked
with a semiquantitative scale in cardiomyocytes, fibroblasts, capillaries, arterioles
and arteries (two independent observers, double blind study). Additionally, the
score sale for contractile cells (AGECardiocyt) and all left ventricular constituents
(AGETOTAL) were calculated. The statistical analysis was based on nonparametric
statistical tests (Mann-Whitney test and Spearman rank correlation).
Results: The cytoplasmic positive reaction in cardiomyocytes was predominantly
diffuse-granular (mixed type) in both DM groups, whereas comparative groups
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represented predominantly lack of reaction or diffuse cytoplasmic pattern. These
dependences were statistically significant. ICM and DCM groups did not differed
in the staining pattern as both DM2 groups. Moreover, there was no statistical
differences in the reaction intensity neither between ICM and DCM, nor between
ICM+DM vs. DCM+DM, whereas practically all myocardial constituents and
cells showed higher intensity range in DM groups compared with corresponding
nondiabetic groups. The only difference between ICM+DM and DCM+DM was,
that AGE accumulation was significantly more pronounced in capillaries of patients
from ICM+DM group, while DCM+DM group AGE occurred predominantly in
large arteries. There was no significant correlation between the AGE intensity or
scores with patients age, whereas diabetes duration correlated significantly and
strongly with the staining intensity in subendocardial and subepicardial myocardial
layers and with AGECardiocyt and AGETOTAL, only in ICM+DM2 group.
Conclusions: The deposition of AGE in left ventricular myocardium is
enhanced by DM, both in ICM and DCM. Different localization of AGE in
coronary vessels of patients with ICM and DCM suggest etiology dependent
differentiation of its role in heart failure development.

POSTER BOARD NUMBER P3 – 03
1577 CARDIOCYTE NUCLEAR CHROMATIN DENSITY
CORRELATES WITH TRANSPLANTED HEART LEFT
VENTRICULAR MASS
M. Zakliczynski, J. Nozynski, D. Konecka-Mrowka, R. Przybylski,
M. Zembala
Silesian Center For Heart Disease
Background: Cardiocyte hypertrophy is accompanied by polyploidy, seen as
a decrease in chromatin density in enlarged nucleus. Repeated biopsies of a
transplanted heart offer the possibility of dynamic evaluation of these phenomena.
The aim of the work was the evaluation of cardiocyte nuclear chromatin density in
a transplanted heart during long-term follow-up. Material encompassed myocardial
biopsies taken in the first week, first month and then on an annual basis up to year
ten after surgery. Only biopsies with no rejection were considered (grade “0” ISHLT
– 122 biopsies). The control group consisted of seven donor hearts specimens.
Methods: The optical density – mean gray level – of cardiomyocyte nuclear
chromatin was evaluated. Correlations of this index with nuclear area, and with
left ventricle ultrasound measurements were determined. Statistical correlation
analysis was performed.
Results: The chromatin mean gray level showed a decrease with the passage of
time, and correlated positively with the interventricular septum thickness, the
left ventricle posterior wall diameter and the left ventricular mass. The analysis
of individual periods showed a significant positive correlation of the mean
grey level with the cardiocyte nuclear surface in the 3rd, 4th and 9th year after
transplantation, thereby suggesting the occurrence of polyploidy within that
time. The significant negative correlation of these values (1 week and 1 year)
indicate normalization of early cardiocyte hypertrophy.
Conclusions: With the passage of time chromatin condenses, leading to pyknosis.
The activity of cardiocyte chromatin correlates with left ventricular hypertrophy.
The compensatory cardiomyocyte polyploidy is a periodical phenomenon.

POSTER BOARD NUMBER P3 – 04
1578 ANALYSIS OF THE IMPACT OF CELSIOR®
PRESERVATION SOLUTION ON CARDIAC TRANSPLANT
OUTCOMES: A 5-YEAR RETROSPECTIVE CASE STUDY
P. Macdonald1,2, J. Kuo1, P. Jansz1, F. Junius1, E. Grainger1, P. Spratt1
1
St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: The quality of donor heart preservation plays a critical role in
determining myocardial function after heart transplantation and therefore,
the overall success of the procedure. Many preservation solutions, both
commercially and locally formulated solutions, are used in the different
cardiac transplant centres. The optimal preservation solution is yet to be
established. The aim of this study was to assess the impact of two different
cardiac preservation solutions, Celsior and aspartate-supplemented St Thomas

POSTER BOARD NUMBER P3 – 05
1579 ACCELERATED CARDIAC ALLOGRAFT REJECTION
AND GRAFT LOSS AMONG CIGARETTE SMOKERS, ROLE OF
INFLAMMATION, OXIDATIVE STRESS AND TISSUE REPAIR
MOLECULES
M. Mehra, A. Khanna, J. Xu, C. Baquet,
University of Maryland, Baltimore
Background: Cigarette smoke exposure before and after among cardiac
transplant recipients is associated with the development of cardiac allograft
vasculopathy and excess risk of allograft loss. However, pre-transplantation
exposure to tobacco and its impact on cardiac transplantation outcomes has not
been adequately studied. We undertook this animal study to discern the early
consequences of tobacco smoke exposure in cardiac donors or recipients with
emphasis on alloimmune mediators of graft outcome.
Methods: Allogeneic heterotopic heart transplantations were performed (n=
18) using histocompatibility mismatched rat strains, Wistar Furth (WF) and
Lewis (LEW), as donors (D) and recipients (R). Exposure to tobacco smoke
occurred using a novel smoke inhalation device, for D and recipient R rats at
a dose of four cigarettes a day for five days a week for at least 1-month. We
monitored allograft survival by a heart palpation scale. Unexposed allografts
(n=3) and isografts (n=3) were used as controls. No animals were exposed
to immunoprophylaxis. IL-6, TNF-ƒÑ, IL-10 and IFN-ƒnƒ× expression were
ascertained from donor rat splenocytes while intragraft gene expression of
MMP-2, Granzyme B, Perforin and TNF-ƒnƒÑ was studied post-transplantation
using Real Time PCR assay., the results are expressed as relative fold expression
with respect to ƒÒ-actin.
Results: These effects of cigarette smoke exposure was associated with a
markedly shortened allograft survival (D and R smokers 6.7 ¡Ó 0.33 days,
Donor smoker 4.0 ¡Ó 1.7 days and Recipient smoker 7.3 ¡Ó 4.1 days). The
survival of either donor or recipient rats exposed to tobacco was similar
or decreased compared to untreated allogeneic animals. Chronic tobacco
exposure to the donor and recipient strains resulted in a marked increased
expression of pro-inflammatory cytokines (expressed as Mean ¡Ó SEM,
relative fold expression compared to rats without smoke exposure; IL-6
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CONCURRENT ORAL SESSION 109: CARDIAC
PRESERVATION AND EXPERIMENTAL
HEART TRANSPLANTATION

solution, on post-transplant outcomes of heart transplant recipients.
Methods: This was a retrospective case study using a historical control group
for comparison. A total of 101 consecutive heart transplant patients were
reviewed (Celsior, n= 51; control, n= 50). The initial 50 patients in the 5-year
study period, between September 2002 and August 2007, constituted the Control
group in which all donor hearts were preserved in aspartate-supplemented St
Thomas’ Hospital solution. The subsequent 51 patients formed the Celsior
group, in which all hearts were stored in Celsior preservation solution. Data
from various databases and patient’s clinical notes were used to compare the
post-operative outcomes achieved in the 2 groups.
The study groups were evenly matched for most donor and recipient base line
characteristics, including donor and recipient ages and donor heart ischemic
times., however, the Celsior group did contain a higher proportion of female
donors (52 vs 24%, p<0.05). Also, patients in the Celsior group were in more
advanced heart failure at the time of transplantation (NYHA Class IV, 66 vs
42%, p<0.05).
Results: Both groups demonstrated excellent 30 day survival rates and did
not differ (98±0%). There was a trend towards better one year survival in the
Celsior group (93±4% vs 90±4%), though this difference was not statistically
significant. Median time to ICU discharge was 3 days in the Celsior group and
4 days in the control group (p=ns). Patients in the Celsior group demonstrated
a significantly higher rate of spontaneous return to sinus rhythm post transplant
(82 vs 55%, p<0.05). Need for mechanical support post transplant was similar
between the 2 groups (Celsior vs control; 32 vs 34%, p=ns). Celsior patients
had better renal function (eGFR 57±25 vs 46±21 ml/min, p<0.05) and a trend
towards better pulmonary gas exchange (PaO2/FiO2 298±119 vs 262±82,
p=0.08) at 24 hours post-transplant.
Conclusions: Excellent post-transplant outcomes were achieved with both
preservation solutions, however storage of the donor heart in Celsior solution
was associated with higher rates of spontaneous return to sinus rhythm and better
recipient renal and lung function early post-transplant. These improvements
in outcome were observed in the face of more adverse donor and recipient
baseline characteristics in the transplants where Celsior was used.
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(15.82 ¡Ó 0.58), TNF-ƒÑ (11.21 ¡Ó 0.63), IFN-ƒ× (9.65 ¡Ó 1.58) and a
significant decreased expression of IL-10 (0.83 ¡Ó 0.18) mRNA expression
in splenocytes. Besides the increased inflammation, smoke exposure also
resulted in increased circulating levels of cotinine, a metabolite of nicotine.
In rejected allografts derived from smoke exposed donor, recipient or both,
mRNA expression of MMP-2, Granzyme B, perforin and TNF-ƒÑ mRNA
was markedly increased as compared to those animals that were untreated and
rejected without cigarette smoke exposure. Histopathological analysis reveals
3B to 4 rejection grades among smokers compared to 1 or 2 among untreated
rejecting allografts.
Discussion: Our findings show that tobacco exposure in cardiac donors and
recipients is associated with pro-inflammatory cytokine upregulation that
results in heightened allo-immune activation and accelerated allograft loss.
This allograft loss is mediated by marked activation of alloimmune and
inflammatory molecular mediators. These findings may provide insight into
the danger theory of alloimmune activation and urge caution in the use of
donors with chronic exposure to tobacco as well as development of strategies
for supplementation of appropriate treatments in the absence of cessation of
smoking among transplant recipients.
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1580 ADENOVIRAL EXPRESSION OF HUMAN HYPOXIAINDUCIBLE FACTOR-1¦Á WITHOUT ODD DOMAIN IN
MYOCARDIAL CELL EFFECTS ON ISCHEMIA REPERFUSION
INJURY
Y.P. Li, L. Wei, J. Shan, J. Lu, D. Long, L. Feng
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
The allograft will exposure to hypoxia during ischemia reperfusion (IR)
procedure in heart transplantation, which is a major nonimmunologic
factor implicated in pathogenesis of chronic graft dysfunction. In
response to hypoxic conditions, cells upregulate the activity of hypoxiainducible factor 1 (HIF-1) which mediates the transcription of a number
of genes against hypoxia. However, it was reported that Cyclosporin A
(CsA) which is a widely uesed immunodepressant inhibits the activity of
HIF-1¦Á, so the ability against IR injury of allograft may be decreased.
Whether overexpression of HIF-1¦Á in heart will effect on the IR injury
as well as alteration of immunological factors are little known. HIF-1 is
a heterodimer composed of an oxygen-regulated subunit known as HIF1¦Á and a constitutively expressed HIF-1¦Â subunit. In normoxia, HIF-1¦Á
protein is rapidly degraded via ubiquitination and proteasomal digestion by
an oxygen-dependent degradation domain (ODD). The function of HIF-1 is
represented by HIF-1¦Á.
In this study, we deleted the nucleic acid sequence coding for ODD domain
in human HIF-1¦Á gene, then transfected the human HIF-1¦Á¦¤ODD gene by
adenovirus into myocardial cell of rat in vitro which is treated with or without
CsA. After hypoxia-reoxygenation-induced injury, we examined the expression
patterns and activities of transgenes, degree of apoptosis, cell histomorphology
and alteration of immunological factors. These results suggest that adenoviral
expression of human HIF-1¦Á¦¤ODD domain can help cells adapt to hypoxia
and may effect on long-term graft survival rate.
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1581 STUDY ON THE PRESERVATION WITH CO
(PCO=5000HPA), RESUSCITATION, AND HETEROTOPIC
TRANSPLANTATION OF AN ISOLATED RAT HEART
K. Seki , Y. Yoshida , N. Hatayama
Kanagawa University, 2Kanagawa University, 3Kanagawa University
We succeeded in an experiment in which tardigrades were desiccated using
perfluorocarbon (PFC), an inert fluid that has been used in liquid breathing
and as artificial blood for mammals since about the 1960s, and then they were
exposed to high pressure at 6,000MPa for resuscitation. We decided to work
on an experiment to preserve an isolated mammal organ by immersing it in
this desiccated PFC. It was thus demonstrated that after an isolated rat heart
was dry-preserved for 24 hours in an environment with 400 hPa of partially
pressure CO2 within a hyperbaric environment compressed at 2000hPa and
then was resuscitated, it could be heterotopically transplanted into a recipient
1
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rat, and the reproducibility thereof was verified. When the isolated rat heart was
aeration-dried at 100 hPa of partially pressure CO2 after being immersed in
PFC, the preservation time could be extended to 72 hours. In this experiment,
aiming for a further extension of the preservation time, CO was added as a
substitute gas in place of CO2 in a gas mixed with oxygen. Inbred rats LEW/
SsN Slc (¦ ‰, 6 weeks old) that were developed for organ transplantation
by Japan SLC Inc. were used as a donor and a recipient. After an isolated
heart of the donor rat was created, it was exposed to a gas mixture such as
PO2=200hPa and PCO=1800hPa, and PO2=2000hPa and PCO=5000hPa in a
2ATA high-pressure chamber, and was preserved in a refrigerator at 4¦ ‹C. We
herein present our findings which demonstrate that significant reproducibility
has been verified. The heart was removed from the refrigerator 24 hours later,
and a heterotopic heart transplantation was performed in the right neck of the
recipient rat, and the pulsating of the transplanted heart was detected by an
electrocardiogram.

CONCURRENT ORAL SESSION 110: CLINICAL HEART
TRANSPLANTATION
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1582 KIDNEY AFTER EXTRARENAL TRANSPLANTATION
– THE IMPACT OF ALEMTUZUMAB INDUCTION
R. Shapiro, A. Basu, H.P. Tan, C. Morgan, V. Sharma, D. Blisard, J.
Donaldson, P.S. Randhawa, A. Marcos, T.E. Starzl
Thomas E. Starzl Transplantation Institute, University of Pittsburgh
Background: Calcineurin inhibitor nephrotoxicity in extrarenal allograft
recipients can lead to end stage renal disease and the need for kidney
transplantation. We sought to evaluate the role of alemtuzumab induction in
this population.
Patients and methods: We evaluated 144 patients undergoing kidney
transplantation after extrarenal transplantation between 5/18/1998 and
10/8/2007. 72 patients transplanted between 1/15/2003 and 10/8/2007
received alemtuzumab induction and continued their pre-transplant
immunosuppression. 72 patients transplanted between 5/18/1998 and
7/21/2007 did not receive alemtuzumab induction. Mean recipient age was
52.1 ± 16.6 years, and mean time after extrarenal transplantation was 8.1 ±
4.7 years. There were 133 (92.4%) adults and 11 (7.6%) pediatric patients.
35 (24.3%), 16 (11.1%), 87 (60.4%), and 6 (4.2%) had undergone previous
heart, lung, liver, or multi-visceral transplantation, respectively. There were
100 (69.4%) deceased (mean cold ischemia time 24.7 ± 7.9 hours) and 44
(30.6%) living donors.
Results: Mean follow-up was 35.7 ± 30.7 months, 23.3 ± 15.0 in the
alemtuzumab and 48.1 + 36.9 months in the non-alemtuzumab groups.
1 year Survival%

3 Year Survival%

Overall

91.5%

75.3%

Alemtuzumab Group

93.0%

78.9%

Non-Alemtuzumab Group

90.0%

72.4%

Overall

88.1%

71.4%

Alemtuzumab Group

93.0%

75.2%

Non-Alemtuzumab Group

83.3%

67.0%

Overall

1.4 ± 0.7 mg/dl

1.5 ± 0.9 mg/dl

Alemtuzumab Group

1.3 ± 0.5 mg/dl

1.3 ± 0.7 mg/dl

Non-Alemtuzumab Group

1.5 ± 0.8 mg/dl

1.6 ± 1.0 mg/dl

Patient

Graft

Mean Serum Creatinine

Conclusion: Alemtuzumab induction in patients undergoing kidney after
extrarenal transplantation represents a reasonable immunosuppressive
strategy.
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1583 EVALUATION OF EVEROLIMUS PHARMACOKINETIC
IN ORTHOTOPIC HEART TRANSPLANTATION FROM
CURRENT CLINICAL PRACTICE
J.M. Arizón, C. Segura, M.D. Aumente, B. Tejada, M. Cardenas
Hospital Universitaria Reina Sofia
Background and objective: Everolimus is a immunosuppressor drug that has
been recently introduced to prevent acute and cronic cellular rejection of solid
organ transplantation. The aim of this study was to report our experience with
everolimus in heart transplant patients, assesing pharmacokinetic parameters
from current clinical practice.
Methods: Retrospectively therapeutic drug monitoring of everolimus was
performed in 6 de novo heart transplant. Everolimus dosing adjustment was
made to achieve Cmin>3ng/ml. All patients also received corticosteroids
and cyclosporine, with or without antilymphocyte induction. Samples were
obtained before the morning drug intake to measure Cmin for everolimus.
Blood sampling to characterize the AUC was performed at 0, 0.5, 1, 2, 3, 4,
6, 8 and 12 hours postdose. Dosage, Cmin (ng/ml), Tmax (h), Cmax (ng/ml),
AUC0-12(ng.h/ml), Cavg (ng/ml) were also determined. Everolimus levels
were determined by Fluorescence Polarization Immunoassay (FPIA, TDx).
Results: Interindividual pharmacokinetic variability was high, specially Cmax
which ranged from 7.8ng/ml to 16.77ng/ml. The AUC mean was 88.9ng.h/ml
(69.35ng.h/ml-119.31ng.h/ml). This data can be considered similar to reference
values published by Kovarik in a study of 634 heart transplant recipients.
Cmin was the kinetic parameter which correlated best with AUC (r=0.855,
r2=0.73, n=6). The mean dose to achieve therapeutic drug levels (3-8ng/ml)
was 0.62mg/12h.
Conclusion: Interindividual pharmacokinetic variability with everolimus
is high. Cmin is the kinetic parameter which correlates best with AUC. Our
results agree with literature data in heart transplantation patients
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1585 BK VIRUS NEPHROPATHY IN THE NATIVE KIDNEYS
OF A PEDIATRIC HEART TRANSPLANT RECIPIENT
R. Chinnock1, S. Sahney1, P. Yorgin1, C. Zuppan1, N. Kanbaum2, D. Cutler1
Loma Linda University, 2Stanford University
Human BK-Polyoma virus (BK virus) is acquired by respiratory or enteric route
during childhood. The virus may remain latent in the uroepithelium. However
in renal transplant recipients it may be reactivated, and is an important cause
of graft dysfunction and graft loss. Although BK virus nephritis in the native
kidneys is rare, there have been case reports of its occurrence in native kidneys
of adult patients with non-renal transplants.
We report a case of BK nephropathy in a seven and a half year old heart
transplant recipient. The patient received his first heart transplant at 18 months
of age, and the second heart transplant at 6.75 years of age. Prior to the second
heart transplant, his serum creatinine was 0.9mg/dL (estimated GFR 70ml/
min/1.73m2). He developed acute renal failure following heart transplant
surgery and was hemodialysed for three days. At discharge, his serum creatinine
was 1.0 mg/dL (estimated GFR 62 ml/min/1.73m2). Eight months following
the second heart transplant the patient presented with acute deterioration of
renal function, with a serum creatinine of 3.6mg/dl (estimated GFR 16mL/
min/1.73 m2). His blood was positive for 200,000,000 copies of BK virus by
quantitative polymerase chain reaction. Renal biopsy showed typical features
of BK virus nephropathy, and the renal tissue stained positive for SV40.
Treatment with Cidofovir, IVIG and reduction of immunosuppresion did not
halt the progression to renal failure. This patient is receiving maintanence
hemodialysis and is currently awaiting kidney transplant.
To our knowledge this is the youngest reported patient with BK virus
nephropathy in the native kidney. We recommend that immunosuppressed
children, and pediatric recipients of non-renal transplants with rising serum
creatinine should have BK virus PCR testing, and a renal biopsy performed if
there is sufficient suspicion.

1
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1584 INFLUENCE OF CYCLOSPORINE ON EVEROLIMUS
CONCENTRATIONS IN DE NOVO HEART TRANSPLANT
PATIENTS

1586 HOW TO USE SIROLIMUS IN ORDER TO INCREASE
SURVIVAL IN HEART TRANSPLANT RECIPIENTS?
M. Zakliczynski, J. Nozynski, M. Zembala
Silesian Center For Heart Disease
Aim of the study was to assess an impact of sirolimus used as a part of
immunosuppressive therapy on survival of orthotopic heart transplantation
(OHT) recipients.
Material and methods: We performed a retrospective case-control study
involving all 60 OHT recipients receiving sirolimus (study group), and 60
matched individuals treated without sirolimus (control group). In almost a half
of pts. sirolimus was used for a short period of time early after transplant,
or introduced late after procedure. However, we identify 31 pts. in whom
sirolimus was introduced before the 3rd year post-transplant, and continued
for at least 3 years, or till the end of observation (28M/3F, 45±11y/o, ischemic
c-pathy in 15 pts.). Majority of them received a combination of sirolimus and
low-dose cyclosporine-A, which was replaced with mycophenolate mofetil
3 years post transplant (at the end of the observation 21 pts. were without
calcineurin inhibitor). They were confronted with their matches from control
group (28M/3F, 44±11y/o, ischemic c-pathy in 17 pts.). We compared survival
time and time free from death from particular causes. Significance was assessed
using log-rank test and chi-square test, when applicable.
Results: Average follow-up was 2138±1192 days in study group and 1949±1221
days in control group (2169±650 vs. 1872±987 days, respectively in substudy).
14(33%) deaths occurred in study group and 25(42%) in control group
(p=0.032) – 5(16%) deaths in study subgroup vs. 14(45%) deaths in control
subgroup (p=0.028). Survival time was significantly longer both in the whole
study group and subgroup when compared with matched controls (p=0.044 and
p=0.019, respectively). The same trend was observed when a time free from
non-cardiac death was compared (p=0.036 and p=0.022, respectively).
Conclusion: Long-term therapy with sirolimus prolongs survival in heart
transplant recipients. This effect is related to the decreased probability of noncardiac death in this group of pts.
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J.M. Arizón, C. Segura, D.D. Aumente, B. Isla, M. Cardenas
Hospital Universitario Reina Sofia
Background and objective: Everolimus is a novel immunosuppressant
intended for use with cyclosporine in acute rejection prophylaxis following
heart transplantation. Both agents are primarily metabolized by CYP3A4
isoenzyme located in gastrointestinal enterocytes and the liver. In this context, it
is essential to characterize the mutual influence of cyclosporine and everolimus
on each other`s concentrations.
Methods: Case report of four de novo heart transplant patients. We compared
morning trough whole-blood levels (Cmin) and 2h post-dosis level (C2) of
cyclosporine versus Cmin and C2 of everolimus measured at 1 to 3 days
intervals during first month post-transplant. Cyclosporine and everolimus
levels were determined by Fluorecesce Polarization Immunoassay (FPIA,
Axsym and TDx respectively).
Results: A graphical assessment of this interaction was observed in four
patients. All patients were on induction with baxiliximab, cyclosprorine,
corticosteroids and everolimus. No drug that could interact with everolimus
kinetic behaviour was used. In all cases an increase in everolimus blood
levels was observed, as cyclosporine blood levels were increasing. This fact
made to stop everolimus dose intake for 1-2 days and the dose was reduced
after that. However, the increase of everolimus levels was highly variable
between patients, ranging Cmin from 8.15ng/ml to 17.11ng/ml, and C2 from
19.39 to 31.8ng/ml. This suggests a possible dependence of the simultaneous
cyclosporine levels found in each patient. Anyway, in all cases everolimus
dose-reduction was evident with an average dose by 3-fold (from 0.75mg/12h
to 0.25mg/12h).
Conclusion: These results suggest that the dosing of everolimus needs to be
adjusted to take account the increase of cyclosporine levels when cyclosporine
co-administered. Given the wide variability in the magnitude of this drug
interaction, both everolimus and cyclosporine blood concentration need to be
carefully monitored.
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1587 SURVIVAL BENEFIT IN HEART TRANSPLANT
RECIPIENTS WITH CORONARY ARTERY DISEASE
CONFIRMED IN ANGIOGRAPHY RECEIVING SIROLIMUS
M. Zakliczynski, M. Swierad, M. Maruszewski, M. Zembala
Silesian Center For Heart Disease
Aim of the study was to assess efficacy and safety of sirolimus used in heart
transplant recipients in order to prevent development of transplanted heart
coronary artery disease (TxCAD) confirmed in coronary angiography.
Material and methods: We performed a retrospective case-control study
involving all 60 heart transplant recipients receiving sirolimus in a number
of combination with other immunosuppressive drugs (study group), and 60
matched individuals after heart transplantation treated without sirolimus
(control group). TxCAD was diagnosed in elective coronary angiography in
9 pts. from study group (8M/1F, 44±11y/o, ischemic c-pathy in 4 pts.) and 15
individuals from control group (15M, 47±7y/o, ischemic c-pathy in 8 pts.). We
compared time to develop significant TxCAD and death caused by TxCAD,
and all-cause death in pts. with TxCAD. Significance was assessed using logrank test and chi-square test, when applicable.
Results: Significant TxCAD (critical coronary lesions, myocardial infarction
or death) was observed in 5(56%) pts. receiving sirolimus and 11(73%) without
sirolimus (p=NS). Time to develop significant TxCAD was comparable. There
were 2(22%) deaths in sirolimus group and 8(53%) in control group (p=NS).
Survival time was significantly longer in pts. receiving sirolimus (p=0,02).
None of deaths in study group was caused by TxCAD compared with 6(40%)
deaths in controls (p=0,09). Time free from death caused by TxCAD was
significantly longer in study group (p=0.023).
Conclusion: Sirolimus prolongs survival in heart transplant recipients with
TxCAD confirmed in coronary angiography.
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1588 SIMULTANEOUS HEART AND KIDNEY
TRANSPLANTATION FROM A SINGLE DONOR
R-B. Hsu1, N-K. Chou1, N-H. Chi1, S-S. Wang1, F-Y. Lin1, S-H. Chu2
National Taiwan University Hospital, 2Far-Eastern Memorial Hospital
Objective: There are no guidelines to establish the indications and
contraindications for a simultaneous heart and kidney transplantation. We
report our single-institutional experience with simultaneous heart and kidney
transplantation.
Methods: Retrospective chart review.
Results: Between 1995 and 2006, 13 patients with co-existing end-stage heart
and renal failure underwent simultaneous heart and kidney transplantation at
the authors¡¦ hospital. Heart failure was secondary to dilated cardiomyopathy
in 5 patients, ischemic cardiomyopathy in 3, cardiac allograft vasculopathy in
2, and congenital heart disease, cardiac allograft failure, and acute myocarditis
each in 1. Renal failure was secondary to glomerulonephritis in 6 patients, heart
failure in 2, cyclosporine nephropathy in 3, hypertension in 1, and systemic
lupus erythematosus in 1. Eight patients were in UNOS status IA and 5 patients
in UNOS status II before transplantation. The 30-days mortality rate and inhospital mortality rate were 15% and 38%. Of 8 patients in UNOS status IA, 7
patients have lived beyond 30 days and 3 (38%) beyond 1 year. Of 5 patients
in UNOS status II, 4 patients have lived beyond 30 days and 4 (80%) beyond
1 year. Patients in UNOS status IA had high rates of previous cardiac surgery,
cardiac allograft rejection, and major renal allograft complications.
Conclusions: Although simultaneous heart and kidney transplantation
continues to be a viable option for patients with co-existing end-stage heart and
renal failure, the results do not match those of isolated heart transplantation.
The clinical outcomes were not satisfactory in UNOS status IA patients with
previous cardiac surgery.
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1589 USE OF EVEROLIMUS FOR LATE COMPLICATION
AFTER HEART TRANSPLANTATION
N. Fukushima, G. Matsumiya, S. Kogaki, Y. Sawa
Osaka University Hospital
Background: A proliferation signal inhibitor (PSI), everolimus (EVL)
provides attractive options in patients with cardiac allograft vasculopathy
(CAV), malignancies and renal dysfunction, or in patients intolerant to other
immunosuppressive agents. We reported 8 patients to be given the EVL for late
complications after heart transplantation (HTx).
Patients and methods: Eight cardiac transplant recipients (3.8 to 44.0 years
old; 6 male 2 female) received EVL since 0.6 to 14.1 (a mean 6.6) years
after HTx. The reasons for the use of EVL were CAV in four, post-transplant
lymphoproferative disorder (PTLD) in three, severe diarrhea in one and renal
dysfunction in one (Two cases were overwrapped).
Results: No patients died from 5.2 to 37.0 (a mean 17.7) months after using
EVL. Intravascular ultrasound (IVUS) showed no progression of CAV in two
and mid regression of CAV in two. Although one case experienced temporal
recurrence of PTLD, all three cases are completely free from PLTD between
and after occurrence of PTLD. Severe diarrhea completely stopped soon after
switching mycofenolate to EVL. Serum creatinine decreased from 3 to 1.4 mg/
ml after switching cyclosporine to EVL.
Summary: everolimus seems safe for heart transplant recipients with late
complications and may improve long-term survival.
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1590 IMPROVEMENT OF RENAL FUNCTION AND
ITS ASSOCIATED FACTORS IN HEART TRANSPLANT
RECIPIENTS AFTER EVEROLIMUS INTRODUCTION
L.A. Bonet1, J.A. Moro López1,2, L. Martinez-Dolz1, I. Sánchez-Lázaro1,
J.A. Ramón-Llin1, A.S. Sanz1
1
Heart Failure And Transplant Unit. Cardiology. UH La Fe, 2Research
Foundation. UH La Fe.
Objective: to prospectively assess the evolution of renal function in
heart transplant (HT) patients and the potential factors associated with its
improvement after the introduction of a proliferation signal inhibitor (PSI) in
the treatment
Patients and method: 56 HT patients who sequentially receive Everolimus to
either withdraw (77%) or reduce the calcineurin inhibitor. The demographic
and analytical variables prior to the change were analyzed. Renal function was
determined by plasma creatinine levels and by the glomerular filtration rate
calculated using MDRD. A favorable change above 10% in these parameters
was defined as renal function improvement.
Results: the sample mean age was 52±9 years. 93% were males and the mean
BMI was 27±4. 43% underwent transplantation for dilated cardiomyopathy,
39% for ischemic cardiopathy. Prior to the change, 75% presented hypertension,
34% diabetes, 69% hypercholesterolemia, and 12% hypertriglyceridemia. 61%
were ex-smokers. Mean plasma creatinine before change was 1.75±0.5mg/dl,
with a GFR of 47.2±18ml/min. Change was due to renal dysfunction in 67% of
the cases and presence of tumors in 32%.
45 patients have received treatment for at least 6 months. Concerning the renal
function basal values, significant improvement is observed both in plasma
creatinine (1.92±0.7 vs 1.67±0.6; p=0.02) and in glomerular filtration (43.9±17
vs 52.5±23; p=0.003). Improvement was obtained in 32 patients.
Basal
creatinine
(mg/dl)

Basal
MDRD
(ml/min)

Creatinine
6m
(mg/dl)

MDRD
6m
(ml/min)

No improvement (N=13)

1.83±0.5

43.5±13.5

2.2±0.5

34.6±12.9

Improvement (N=32)

1.95±0.8

44.2±18.9

1.4±0.5

59.7±22.4

0.6

0.9

0.0001

0.0001

P

No differences between groups were observed in the analysis of the characteristics
prior to the change of treatment as far as age at HT, reason for HT, age at
change of treatment, time HT-change, drug replaced, BMI, gender, presence
of cardiovascular risk factors at change, plasma levels of cholesterol and its
fractions, triglycerides, hemoglobin, white blood cell count, or platelet count.
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After 12 months of treatment (n=30), improvement significantly persisted as
shown by the repeated measures ANOVA.
Conclusions: the use of a PSI drug to replace a calcineurin inhibitor or
to complement this one at low doses, allows obtaining renal function
improvement at 6 months which is maintained for the first year after
therapeutic change. None of the studied variables was shown to be useful to
predict this improvement.
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1591 SAFETY PROFILE OF EVEROLIMUS AS A RESCUE
THERAPY FOR LONG-TERM HEART TRANSPLANT
RECIPIENTS: EXCLUDING THE HARM, WHILE WAITING
FOR EFFICACY

1592 CARDIAC MRI ASSESSMENT OF LV FUNCTION
IN PATIENTS POST CARDIAC TRANSPLANTATION: A
COMPARISON WITH GATED BLOOD POOL IMAGING
C. Hamilton-Craig1,2, W. Strugnell1, T. Parry1, H. Bartlett3, R. Slaugther2
Cardiovascular MRI Research Centre, 2Department of Cardiology,
3
School of Mathematical Sciences, Queensland University of Technology
Purpose: To determine if cardiac MRI (CMRI) could replace Gated Blood
Pool Imaging (GBPI) for annual assessment of left ventricular (LV) function in
the on-going review of patients post-cardiac transplantation.
Methods: Forty-nine post-cardiac transplant patients presenting for annual
review underwent LV functional assessment with GBPI and CMRI. LV
ejection fractions obtained from the two methods were compared and limits of
agreement determined.
Results: The mean EF (plus and minus two standard deviations) was 58.3%
±18 for GBPI and 57.6% ± 18 for CMRI.
Conclusions: Assessment of left ventricular ejection fraction with CMRI
is comparable to GBPI in post-heart transplant patients. CMRI also allows
quantitative volumetric analysis of ventricular volumes and assessment of wall
motion and valvular function. As is now accepted in native heart assessment,
CMRI should be considered a “gold standard” for post-transplant volumetric
and functional evaluation and offers information over-and-above traditional
imaging modalities.

1

POSTER BOARD NUMBER P3 – 19
1593 TREATMENT OF LATE HUMORAL REJECTION WITH
ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB;
A SINGLE CENTRE EXPERIENCE
H. Hayes1, C. Wood, L. Dembo1, G. O’Driscoll1,2
1
The Advanced Heart Failure & Cardiac Transplant Service, Royal Perth
Hospital, Perth, Western Australia, 2School of Medicine, University of Notre
Dame, Fremantle Western Australia
Background: Humoral or vascular rejection is a B cell-mediated production
of immunoglobulin (Ig) G antibody against a transplanted organ that results
in immune complex deposition on the vascular endothelium, activation of
the complement cascade, production of endothelial dysfunction and regional
ischaemic injury.
Method: 4M, age 42.3 ± 6.2 years with dilated cardiomyopathy in 3 cases and
aortic valvular disease in the other, underwent orthotopic cardiac transplantation.
One patient was bridged to transplant after 156 days with a Heartmate XVE
left ventricular device. HLA antibodies measured as a percentage of the panel
reactive pre transplant with the patient’s serum, was 41%, 76%, 0% and 0%
respectively. The prospective flow cytometric cross match was negative for
T and B cells for all patients prior to transplant. Post transplant at 65 months,
47 months, 22 months and 90 months respectively, the diagnosis of humoral
rejection based on allograft dysfunction, circulating HLA or DSA antibody
and rejection morphology on allograft biopsy was made and the patients were
treated with Rituximab.
Results: Rituximab, a chimeric humanized monoclonal antibody directed
against the pan-B cell surface molecule, CD20 was administered intravenously
at a dose of 375mg/m2 for four weeks. All patients were on triple therapy
immunosuppressant maintenance which included calcineurin inhibitors,
antiproliferative agents, mTOR inhibitors and prednisolone. Following
rituximab treatment, all patients improved with resolution of their symptoms
of cardiac failure. This improvement has been maintained for 48 months,
10 months and 5 months respectively of follow-up. One patient presented
11 months following administration of rituximab with acute haemodynamic
compromise secondary to severe right failure and died.
Patient Characteristics
Patient

Age

Age

HLA Antibodies
pre Transplant

1

45

M

2

45

M

3

33

4

46

Immunosuppression

Rituximab
post Transplant

41%

CyA/MMF/Prednisolone

65 months

76%

CyA /MMF/Prednisolone

47 months

M

0%

CyA/MMF/Sirolimus

22 months

M

0%

CyA/Everolimus/Prednisolone

90 months
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L. Potena, F. Fabbri, G. Magnani, F. Coccolo, F. Fallani, M. Masetti, A.
Russo, G. Arpesella, F. Grigioni, A. Branzi
Cardiovascular Department, University of Bologna
In several countries, everolimus is registered for the prevention of acute
rejection in de novo heart transplant (HT) recipients. Clinical and experimental
studies additionally suggested a potential effect in prevention of cardiac
allograft vasculopathy (CAV) and neoplasm, and in facilitation of cyclosporine
minimization protocols. Thus, many transplant centers use the drug off label by
substituting azathioprine, mycophenolate or even cyclosporine with everolimus
as a rescue therapy for maintenance HT recipients with severe comorbidities.
While prospective trials documented the drug safety profile in de novo patients,
sparse safety data are available for everolimus use as a rescue therapy. In this
report, we compare the occurrence of drug-related adverse effects between
patients receiving everolimus in de novo vs. long-term patients shifted from
another immunosuppressant.
All patients treated in our center with everolimus for at least 6 months, in
addition to low-dose cyclosporine and prednisone, were included in the study.
We analyzed change in glomerular filtration rate (GFR) from baseline to 6 and
12 months of everolimus therapy, and occurrence of peripheral edema, pleural/
pericardial/lymphatic effusions, and infections needing specific antimicrobial
therapy.
Fifteen patients were treated de novo, and 30 received everolimus 4.6±3.5
years after transplant. Shifted patients were older (62±5 vs. 49±12 y; P<0.01)
with a lower prevalence of females (13% vs. 46%; P=0.01), and with worse
baseline GFR (37.7±11.5 vs. 60.8±25.2 ml/min/1.73m2; P<0.01) as compared
with de novo. Reasons for shifting to everolimus were: CAV (30%), renal
insufficiency (57%), and neoplasm (13%). Of these, one CAV patient died
suddenly, and one with severe renal insufficiency died for sepsis. After 12
months, no difference in everolimus levels was noted (6.4±2.3 vs. 6.6±2.0
ng/ml: P=0.8), but trough cyclosporine was lower in maintenance patients
(91±30 vs. 65±29 ng/ml; P=0.01). In de novo patients, after an initial
worsening trend at 6 months (from 60.8±25.2 to 52.5±13.2 ml/min/1.73m2;
P=0.2), GFR remained stable at 12 months (50.6±19.1 ml/min/1.73m2). In
shifted patients, GFR remained stable for the entire follow-up (37.8±11.5 vs.
38.6±13.8 vs. 36.7±13.8 at baseline, 6, and 12 months respectively; P=0.7).
Pleural/pericardial/lymphatic effusions were restricted to de novo patients
(n=4; 27%), while peripheral edema was noted only in maintenance patients
(n=8; 27%). The incidence of relevant infection was similar between the two
groups (17±7 vs. 13±9%; P=0.8).
These prospective observational data suggest that, despite the higher burden
of comorbidities, shift to everolimus as a rescue therapy in long term HT
recipients seems to have a similar safety profile as compared with the use of
the drug in de novo patients. Extreme cyclosporine minimization may favor
everolimus safety profile in these patients. The long-term efficacy of this
strategy remains to be proven, but it appears unlikely if undertaken in severely
ill patients.
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Conclusion: Rituximab provided rapid and full resolution of symptoms and
objective evidence of allograft dysfunction in this patient group. There was
no toxicity or complications following rituximab therapy. Patients successfully
treated for humoral rejection with rituximab still require careful revaluation as
the B-cell population can rebound with time.
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1595 DIAGNOSIS OF TOXOPLASMOSIS IN A
SERONEGATIVE AND TREATMENT-RESPONSIVE
HEART TRANSPLANT RECIPIENT
M. Unlukaplan1, B. Celasun1, S. Sengel2, A. Sezgin3, B. Demirhan1
Baskent University Faculty of Medicine, Department of Pathology, 2Baskent
University Faculty of Medicine, Department of Infectious Diseases, 3Baskent
University Faculty of Medicine, Department of Cardiovascular Surgery
Toxoplasma gondii infections in heart transplant recipients are generally
seen as acquired infections of the immunocompromised sero-negative patient
from an exogenous source, usually the donor organ. We report a 19-yearold heart transplant recipient who developed a collapse of heart functions,
28 days after the transplantation. Histopathological examination of the
endomyocardial biopsy revealed T. gondii infection. After the appropriate
medical therapy regimen, the patientâ€™s ejection fraction recovered
dramatically. The control endomyocardial biopsy of the patient revealed
any histopathologic sign of T. gondii infection or acute rejection. In both
preoperative and postoperative serologic tests of the recipient, T. gondii IgG
values were negative. Altough a seroconversion of T. gondii IgG/M was not
detected, a two fold rise was significant in the titer of IgG. Unfortunately the
serologic status of the donor was not known, but the recipient of liver of the
same donor is known to have an infection-free course. However, the heart
transplant recipient died on the 65th day of transplantation because of other
reasons. Our case demonstrates that the histological diagnosis of T. gondii
is precious for recovery. In conclusion, T. gondii infection should be kept
in mind while interpreting endomyocardial biopsies of transplanted heart.
It is significant to distinguish its histopathologic symptoms from a possible
rejection because the therapy of these two entities are completely different
and depends on the pathologic diagnosis.

1
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1594 CLINICAL PROFILE IMPROVEMENT AND SAFETY
OF THE CONVERSION TO EVEROLIMUS (EVE)
IN HEART TRANSPLANT (HT) RECIPIENTS:
A MULTICENTER ANALYSIS
N. Manito1, E. Kaplinsky1, I. Vallejos2, J. Roca1, V. Brossa3, S. Mirabet3,
F.P. Villa2, E. Roig2
1
Heart Transplant Program, Hospital de Bellvitge, Barcelona, Spain,
2
Heart Transplant Program, Hospital Clinic, Barcelona, Spain,
3
Heart Transplant Program, Hospital de Sant Pau, Barcelona, Spain
Background: EVE is a non-nephrotoxic immunosuppressive drug with antiproliferative properties. Its utilization may reduce the incidence of graft vascular
disease (GVD) and also exhibits antitumoral effects. EVE allows minimization
or withdrawal of calcineurin inhibitors (CNIs) in HT recipients.
Methods: We present a multicenter retrospective analysis in maintenance HT
recipients switched to EVE. Aim of this work was to assess the clinical impact
and safety after 12 months (m) from EVE conversion.
Results: 62 patients (81% male) of mean age 59±11 years and mean time
after transplantation 5,9±4,03 years were switched to everolimus-based
immunosuppression because the presence of renal function impairment (RFI)
in 28 patients (45%), GVD in 17 (27,4%), cancer in 6 (9,6%), sirolimus
intolerance in 3 (4,8%), refractory rejection in 2 (3,2%), CNI neurotoxicity in
2 (3,2%) and other reasons in 4 (6,4%).
Initial immunosuppression was based on cyclosporine in 36 cases (58%),
tacrolimus in 20 (32%) and sirolimus in 6 (10%). In addition, prednisone was
present in 51 patients, mycophenolate mofetil in 48, azathioprine in 5 and
sodium mycophenolate in 4.
EVE mean initial dose / first through level was 1,39±0,29 mg/day and 5,8±3,67
ng/ml. Mean EVE doses (mg/day) and concentrations(ng/ml) at 6 (n: 46) and
12 m (n: 37) were: 1,38±0,37 / 5,9±2,5 and 1,33±0,69/ 6,3±2,6. Analytical
parameters during the 12 m follow up showed a significant serum creatinine
reduction and HDL-LDL cholesterol increase:
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Item (units)

Base
(n=62)

6m
(n=46)

12 m
(n=37)

P
6 m vs base

P
12 m vs base
0.0007

Creatinine (mg/dl)

1.8±0.7

1.5±0.5

1.5±0.4

<.0001

Cholesterol (mg/dl)

181±28

201±79

189±37

NS

NS

HDL (mg/dl)

55±20

63±25

67±23

0.2426

0.0198
0.0028

LDL (mg/dl)

91±24

91±31

106±20

0.0337

Triglycerides (mg/dl)

154±83

146±74

155±88

NS

NS

Platelets (109/L)

212±59

204±45

205±54

NS

NS

13±2

13±1.4

13±1.3

NS

NS

Haemoglobin (g/dl)

CNI withdrawal was performed in 28 patients with RFI., Glomerular Filtration
Rate (GFR) measured by MDRD improved (ml/minute/1,73m2): baseline
45±17 to 6 months 56±13 (p < .00001), to 12 months 55±15 (p = 0.0131). Mean
previous cyclosporine and tacrolimus doses (mg/day) and concentrations (ng/
ml) were: 159±73,3 / 124,73±51,86 and 2,06±1,08 / 4,31±2,07.
There were 11 infections, 4 rejection episodes and 2 deaths (1 non-cardiac
and 1 GVD-related). EVE related toxicity was present in 36 episodes: oedema
(n:12), transitory RFI (n: 9), diarrhoea (n:5), oral aphtas (n:5), pericardial
effusion (n:2), pneumonitis (n:1), anasarca (n:1) and 1 peripheral venous
thrombosis.
Conclusion: EVE conversion in maintenance HT recipients is safe and
improves renal function. CNI withdrawal in patients converted to EVE for RFI
improved GFR. Safety and efficacy parameters for GVD and tumors requires
a larger experience.
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1596 PREVALENCE OF RENAL DYSFUNCTION IN HEART
TRANSPLANT PATIENTS IN MAINTENANCE TREATMENT.
THE ICEBERG STUDY
F. González1, J.M. Arizón2, S. Gatell3, N. Saval3, on behalf of the ICEBERG
study group
1
Hosp. Marqués De Valdecilla, Santander, Spain, 2Hosp. Reina Sofía,
Córdoba, Spain, 3Novartis Farmacéutica, S.A.
Introduction: Renal impairment after transplant has a high impact in the graft
and/or patient survival. Since its cause is complex and multiple actors are
involved, it is important to know the prevalence, severity and factors that may
have influence, in order to help in its prevention or at least, in the instauration
of a treatment as soon as possible. Also, it is important to evaluate the little
changes in renal function because they can mean a severe renal impairment in
a middle-long term period.
Methods and materials: This is a national, multicenter, observational, crosssectional study including 243 cardiac transplant patients in maintenance
treatment for at least two years. The primary objective was to asses the
prevalence of renal dysfunction in maintenance cardiac transplant patients
and the secondary objectives was to determine the characteristics of renal
dysfunction, its evolution and the current immunosuppressive treatment and if
the diagnosis of renal dysfunction lead to any changes in the immunosuppressive
treatment.
Results: 243 patients were analyzed, 81% male, 99% caucasian, age 59 years
(SD 12 years). Etiology of cardiopathy that originated the transplant was mainly
coronary disease, 40.33%; idiopathic, 38.27%, valvulopathy, 5.35% and other
reasons, 16.05%. Mean time since transplantation was 7.7 ± 4.0 years. Renal
dysfunction (RD) could be diagnosed according to clinical criteria vs. objective
laboratory criteria (Serum Creat >2mg/dl and/or GFR <50 ml/min). Taking into
account objective criteria 32.5% (79/243) of the patients present RD. Mean
serum creatinine was 2.2 ± 0.6 mg/dl.
Conclusions: The incidence of Renal dysfunction in this population of
heart transplant patients is 32.5%. No renal biopsy has been performed. The
proteinuria determination in not used as current practice. Complete data will be
available to be presented in the Congress.
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1597 CAN THE EUROSCORE PREDICT MORTALITY
AFTER CARDIAC TRANSPLANT?
A. Saito, M. Quantz, N. McKenzie, B. Kiaii, S. Swinamer, G. Fisher, R.
Novick
London Health Sciences Center
Background: The European System for Cardiac Operative Risk Evaluation
(EuroSCORE) is frequently used to predict outcomes following cardiac surgery.
EuroSCORE has been validated in multiple trials, however there is no current
evidence evaluating its value in cardiac transplant patients. This study examines
the use of EuroSCORE in predicting outcomes following cardiac transplantation.
Method: Between June 2001 to October 2007, 83 patients underwent orthotopic
heart transplantation at our institution. Data was complete on 78 patients and they
represent the study group. The additive and logistic EuroSCOREs were calculated.
The following variables were analyzed: 30-day, in- hospital and overall mortality;
hospital Length of Stay (LOS), Intensive Care Unit LOS; prolonged ventilation
requiring tracheostomy, mechanical support (Intra-Aortic Balloon Pump, ExtraCorporeal Membrane Oxygenation), acute renal failure requiring hemodialysis,
chronic renal failure, peak creatinine, and delayed sternal closure.
Observed 30-day, in-hospital, and overall mortality were compared to predicted
mortality as determined by additive and logistic EuroSCORE. The calculated
scores were analyzed with hospital LOS, ICU LOS, and postoperative
morbidities. The calculated values were described as mean (95% Confidence
Interval:CI) and p<0.05 is deemed as of statistical significance.
Results: The observed 30-day mortality rate was 12.8% (10/78), and overall
mortality rate was 25.6% (20/78). Predicted mortality by additive EuroSCORE
was 8.81% (CI 8.08-9.53), and logistic EuroSCORE was 18.39% (CI
14.86-21.92). Sixty-four patients (82%) were classified as high-risk (additive
EuroSCORE >5); in this high risk group the observed 30-day mortality was
14.1% (9/64), and overall mortality was 26.6% (17/64). EuroSCORE predicted
mortalities were 9.6% (additive) and 21.5% (logistic). Comparison of mean
logistic EuroSCOREs between survivors and non-survivors was lower in the
overall survivors than non-survivors (16.2 vs 24.9, p=0.03, CI 0.8-16.6). The
patients with acute renal failure had higher logistic EuroSCOREs than those
without (26.6 vs 16.1, p=0.01, CI 2.2-18.7). There was no correlation between
logistic EuroSCOREs and hospital LOS (r=0.194) or ICU LOS (r=0.285). For
the co-mobidities of prolonged ventilation, mechanical support, chronic renal
failure, peak creatinine, and delayed sternal closure, there was no statistical
significant difference in EuroSCORE between the patients who had these
morbidities and those who did not.
Conclusion: This study reiterates that patients presenting for cardiac
transplantation, even those deemed to be at ¦ glow risk¦ h represent a
challenging cohort. The logistic EuroSCORE was able to identify patients
at higher risk that were undergoing cardiac transplantation as well as those
more likely to develop renal failure. EuroSCORE does not predict the length of
stay or other complications. The logistic EuroSCORE may prove useful when
discussing the risks of transplantation with patients. However, further studies
with a larger sample sizes are warranted.

1598 PRELIMINARY EXPERIENCE ON CONVERSION FROM
CALCINEURIN INHIBITORS TO EVEROLIMUS IN CARDIAC
TRANSPLANTATION MAINTENANCE TREATMENT
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1599 VENTRICULAR FIBRILLATION IN THE PATIENT
IMPLANTED WITH A CONTINUOUS FLOW LEFT
VENTRICULAR ASSIST DEVICE – CASE REPORT
C. Axisa, P. Jansz, E. Granger, C. Hayward, A. Keogh, E. Kotlyar, A. Tay, P.
Macdonald, P. Spratt
St. Vincent’s Hospital Sydney
Introduction: Ventricular Fibrillation is a life threatening rapid irregular heart
rhythm where the ventricles do not contract effectively and the heart fails to
pump blood into the arteries and systemic circulation. If Ventricular Fibrillation
is left untreated death results within a few minutes.
We report a case where a patient implanted with the VentrAssistTM continuous
flow left ventricular assist device (LVAD) experienced Ventricular Fibrillation
without loss of consciousness for substantial time periods and maintained
LVAD flows above 3.0 Litres per minute (L/min) throughout the episode.
Case report: Patient was a 66 year old male with Ischemic Dilated
Cardiomyopathy. While the patient was at home his implantable cardiac
defibrillator (ICD) fired nine shocks within a few minutes. The patient
presented to the local hospital emergency department. An Electrocardiograph
was performed which confirmed a rhythm of Ventricular Fibrillation. The
patient was conscious with device flows of 4.0 L/min. Antiarrthymic drugs
and intravenous fluids were administered and patient was transferred to the
LVAD implanting hospital. On arrival to the coronary care unit at the LVAD
implanting hospital the patient was externally cardioverted to a paced rhythm.
The patient had been in Ventricular Fibrillation for 4.5 hours without loss of
consciousness. Patient had been supported by the LVAD for 129 days at the
time of the event and is currently awaiting heart transplantation.
Results and discussion: The VentrAssist system is preload dependent and after
load sensitive. In the setting of Ventricular Fibrillation the patient is severely
compromised with no cardiac output and there is increased risk of ventricular
suck down from the continuous flow device. Despite these obstacles the
VentrAssist system continued to provide circulatory support to the patient.
This was a significant finding of the VentrAssist system. The patient ICD delivered
six bursts of Antitachycardia Pacing (ATP) and nine shocks but was unsuccessful
in terminating the Ventricular Fibrillation. Hence, irrespective of other technology
the VentrAssist system continued to provide circulatory support.
Conclusion: Implantation with the VentrAssist continuous flow LVAD
improves hemodynamic status and enables survival during life-threatening
episodes of Ventricular Fibrillation.

E. Lage, J.A. Sánchez-Brotons, J.M. Sobrino-Márquez, R. Hinojosa,
A. Martínez
Cardiology Dept., Virgen Del Rocio Univ. Hospital, Sevilla, Spain
Introduction: Everolimus (Eve) has been used after cardiac transplantation
both in initial and later maintenance therapy. We present our initial experience
with Eve as maintenance therapy after cardiac transplantation.
Methods: We retrospectively included all those patients converted from
calcineurin inhibitors to Everolimus from September 2006 to October 2007 in
our centre. We analyzed their basal clinical characteristics, indications for the
conversion into Eve as well as beneficial and adverse effects observed.
Results: A total of 16 cardiac receptors were included. Reasons for conversion
into Eve were: Allograft vasculopathy (n=8), renal failure (n=4) and Sirolimus
toxicity (n=4). Treatment with Eve was initiated a mean of 79.8±52.7

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

531

WEDNESDAY

POSTER BOARD NUMBER P3 – 24

months after transplant (range: 10-163). Mean initial dose was 1.4±0.2 mg
(range: 1-1.5), and maintenance 1±0.31 mg (range: 0.5-1.5). Mean time of
follow-up was 7.28±3.22 months (range: 0.5-13). Side effects observed were
hypertriglyceridemia, hypertension and edema.
Only one out of four patients included due to Sirolimus intolerance did not
tolerated Eve. Renal dysfunction did not get worse in any of the 4 patients that
received Eve for that reason. No cases of allograft vasculopathy were observed.
Conclusions: Renal function seems to get stabilized after conversion to Eve in
those patients with previous progressive renal dysfunction. Security profile was
proven in all the patients although conclusions can not be established regarding
allograft vasculopathy evolution.

Wednesday 13 August 2008
POSTER BOARD NUMBER P3 – 26
1600 THE INCREASINGLY COMPLEX HEALTH CARE
ENVIRONMENT OF CARDIAC TRANSPLANTATION:
A ROLE FOR THE NURSE PRACTITIONER
C. Wood1, H. Hayes1
Advance Heart Failure and Cardiac Transplant Service, Royal Perth
Hospital, Western Australia
Background: In the last 25 years cardiac transplantation has become the
accepted treatment modality for patients with end stage heart failure. This paper
aims to demonstrate how the implementation of the nurse practitioner role
within the designated area of the West Australian Cardiac Transplant Service
can improve clinical outcomes and augment the services offered to patients
and their families whilst promoting the efficacy of cardiac transplantation in a
world of the “shrinking dollar.”
Key points: There are manifold challenges to be met when delivering nursing
care to patients before and after cardiac transplant. The cardiac transplant
domain provides diverse opportunities for the advanced practice nursing
role where the nurse must combine the skills of clinical expert with educator,
coordinator, researcher, manager and administrator.
Results: Implementation of the role is demonstrated in terms of professional
autonomy and accountability, legislation, extended academic qualifications
and scope of practice. The Nurse Practitioner - Cardiac Transplant provides
and coordinates outpatient health care to individuals throughout the transplant
process. The nurse practitioner has increased clinical responsibilities and
emerges as an independent practitioner who delivers quality, cost effective
patient care.
Conclusion: The role of the nurse practitioner is currently evolving in Western
Australia to meet the needs of this increasingly complex patient population.
Extending and empowering the nurse practitioner role will require evidence based
research that demonstrates enhanced effectiveness in meeting the needs of cardiac
transplant patients and communicate to the nursing profession and other health
care providers the difference the role makes in terms of clinical outcomes.
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Conclusions: Functional exercise capacity, lung function and quality of
life improved significantly over the first 3 months in LTx recipients who
participated in a structured PR program at our institution. This data provides
a benchmark for comparisons to be made with other centres and program
structures.
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1601 PULMONARY REHABILITATION FOLLOWING
LUNG TRANSPLANTATION
G.I. Snell1, P.E. Munro1, B. Button1, M. Bailey2, A.E. Holland1,3,
1
The Alfred Hospital, 2Monash University, 3La Trobe University
Background: Pulmonary rehabilitation (PR) following lung transplant (LT) is
regarded as part of best practice management, however the optimal duration
and composition of PR programs for LTx recipients is unknown.
Objective: This study aimed to describe changes in functional outcomes of LTx
recipients who participated in our standard outpatient post LTx PR program.
Methods: A prospective, repeated measures design was used. Functional
exercise capacity (six minute walk distance -6MWD), lung function (FEV1,
FVC) and quality of life (SF 36) were assessed at one, two and three months
following LTx. Following discharge, all subjects attended a one hour outpatient
group exercise training class three days per week until 12 weeks post LTx and
six education sessions facilitated by the multidisciplinary team. Patients with
post-operative complications (mechanical ventilation, major myopathy) were
excluded. Data were analysed using descriptive statistics and ANOVA with
repeated measures.
Results: 60 consecutive LTx recipients between Sept 2003 and March 2005
were assessed for inclusion. 36 (50% male) subjects, 81% bilateral LTx, mean
age 46 ± 14 years were recruited and completed the study. The most common pre
LTx diagnoses were cystic fibrosis (33%) and chronic obstructive pulmonary
disease (31%). Significant improvements were demonstrated in 6MWD (451
± 16m to 545 ± 16m, p<0.001), FEV1 (72 ± 4% to 81 ± 4%, p<0.0001), FVC
(74 ± 4% to 78 ± 4%, p<0.0001) and all SF36 domains, p<0.05. The greatest
changes in 6MWD and lung function were seen between one and two months.
Four SF36 domains (physical functioning, role functioning- physical, role
functioning- emotional and social functioning) significantly improved between
month two and three, p<0.01.
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1602 CAN PRETRANSPLANT CONDITION OF RECIPIENTS
PREDICT OUTCOMES AFTER LIVING-DONOR LOBAR LUNG
TRANSPLANTATION?
Y. Sano1, T. Oto1, M. Yamane1, S. Toyooka1, M. Okazaki1, H. Date2
Okayama University Graduate School of Medicine, Department of Cancer
And Thoracic Surgery, 2Kyoto University Graduate School and Faculty of
Medicine, Department of Thoracic Surgery
Background: Due to the shortage of brain-dead donors, living-donor lobar
lung transplantation (LDLLT) accounts for nearly two-thirds of the lung
transplantation cases in Japan. Although there have been no incidences of
donor mortality following lobectomy for LDLLT at our institution, we believe
that LDLLT should be performed under strictly limited circumstances.
Purpose: The purpose of this study was to evaluate the impact of the
pretransplant condition of a patient on LDLLT outcomes during the early
postoperative period.
Patients and methods: This single-center, retrospective study was conducted
on 47 patients (37 female and 10 male), aged 6–55 years (median: 30 years),
who underwent LDLLT between October 1998 and May 2008 at Okayama
University Hospital. Of these, 9 patients were children. The underlying
diagnoses of these patients included pulmonary arterial hypertension
(n = 15), interstitial pneumonia (n = 12), bronchiolitis obliterans (n = 8),
lymphangioleiomyomatosis (n = 4), and bronchiectasis (n = 3). The five-year
actuarial survival rate after LDLLT was 88.6%. However, 3 patients died during
this period; 1 just before the transplant procedure in the operating room and 2
after the transplant procedure in the ward.
Results: All patients were dependent on continuous oxygen inhalation, of
which 19 (40.4%) were admitted in the ICU before transplantation. Among
all patients with end-stage lung diseases (n = 31), 25 (80.6%) were grade V
according to Hugh-Jones classification, and the remaining 6 (19.4%) were
grade IV at the time of transplantation. Of these, 5 (16.1%) were ventilatordependent, and another 5 required noninvasive positive pressure ventilation.
Nineteen (61.3%) patients were steroid-dependent. Among patients with
pulmonary hypertensive diseases (n = 16), 12 (75%) were NYHA class
IV, and the remaining 4 (25%) were class III at the time of transplantation.
Patients with idiopathic pulmonary arterial hypertension were being treated
with high-dose intravenous epoprostenol (average dosage: 60.2 ng/kg/min)
and inotropic agents. All procedures were performed under cardiopulmonary
bypass.
As mentioned before, two patients died post transplantation in the hospital due
to severe acute rejection and bronchopulmonary aspergillosis. In addition, a
patient died just before the transplant procedure in the operating room owing to
pulmonary hypertensive crisis with massive bleeding. The underlying diseases
of these patients included idiopathic interstitial pneumonia, bronchiolitis
obliterans, and idiopathic pulmonary arterial hypertension. The pretransplant
status of these patients was not severe compared with the other recipients. In
fact, two patients were classified as grades V and IV according to Hugh-Jones
classification, and the third was NYHA class III. Although all of them were
steroid-dependent, none were ventilator- or noninvasive positive pressure
ventilator-dependent. In addition, none of these patients were admitted in the
ICU before transplantation.
Conclusions: Although the pretransplant condition of the recipients was
quite severe, a strong relationship between the pretransplant condition and
the outcomes during the early postoperative period after LDLLT was not
observed.
1
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1603 LUNG TRANSPLANTATION IN PULMONARY FIBROSIS:
CHALLENGING EARLY OUTCOMES COUNTERBALANCED
BY SURPRISINGLY GOOD OUTCOMES BEYOND 15 YEARS.
D. Keating, B. Levvey, T. Kotsimbos, H. Whitford, G. Westall, T. Williams,
G. Snell
Lung Transplant Service, Alergy, Immunology And Respiratory Medicine,
Alfred Hos
Introduction: Interstitial lung disease (ILD) has been reported as having a
poor outcome following lung transplantation (LTx). This has been based on the
difficulties involved in getting ill recipients to LTx and challenging early post
operative outcomes. We looked at the results in our institution over the last 18
years to assess longer term outcomes for this cohort.
Method: A retrospective chart review was carried out of all ILD LTx recipients
(February 1990-February 2008). Outcomes for ILD patients with respect to
single and double lungs were compared with all other LTx patients over the
same time period and ISHLT registry data.
Results: From a total of 585 LTx, 90(15%) were ILD (53 single LTx, 27
bilateral LTx). There were 67(74%) Idiopathic Pulmonary Fibrosis (IPF),
9(10%) were sarcoidosis, 9(10%) were lymphangioleiomyomatosis and 5(6%)
had other indications. The mean age in the ILD cohort was 52yrs (range 34-69),
and the actuarial survival at 1, 5, 10, 15 and 18 yrs compares to all other LTx
performed (77 Vs X, 51 Vs X, 42 Vs X, 28 Vs 22, 28 Vs 20). For the IPF cohort
the actuarial survival at 1, 5, and 10 yrs appears superior to ISHLT registry
data (76 Vs 72, 50 Vs 44, 34 Vs 20 respectively). There was equivocal survival
between single (n=47) and double (n=23) LTx at 1, 5, and 10yrs (78 Vs 68%,
49 Vs 50%, 29 Vs 50%). The incidence of BOS (as a cause of death) is low at
7% compared to 63% for other LTx indications.
Conclusion: Our LTx figures for ILD compare favourably to LTx for other
diseases and international standards, this appears to be related to a lower BOS
mortality. In addition, survival from single LTx is as successful as double
LTx both in the short term and longer term. Consideration should be given to
utilising more single LTx procedures to maximise the allocation of donor lungs
and decrease the high mortality on waiting lists associated with IPF.

preliminary results demonstrate the safety of this technique.

CONCURRENT ORAL SESSION 113: EXPERIMENTAL LUNG
TRANSPLANTATION
POSTER BOARD NUMBER P3 – 31
1605 ASSOCIATION OF FLOW-RATE AND ARTERIAL
BLOOD GAS MEASUREMENT IN EX-VIVO EVALUATION OF
THE LUNGS FROM DONATION AFTER CARDIAC DEATH
DONOR
S. Hori, T. Oto, S. Otani, S. Yamamoto, T. Kakishita, M. Okazaki, O. Yoshida,
M. Yamane, S. Toyooka, Y. Sano
Cancer And Thoracic Surgery, Okayama University
Background: Donation after cardiac death (DCD) has a potential to solve
the shortage of donor lungs. Assessment of the lungs from DCD donor before
transplant is important, therefore evaluating lungs by means of Ex-vivo lung
perfusion or simple blood flush have been proposed. However, the optimal
flow rate of the perfusate during ex-vivo evaluation remains unclear. This study
aims to investigate the effect of flow rate on the measurement and determine
the minimal flow rate acceptable for lung evaluation avoiding its adverse effect
on the graft.
Methods: Ex-vivo lung evaluation circuit was established using a pig as
a deoxygenator. Lungs with 6 hours warm ischemia (DCD-group) and no
ischemia (Control-group) was evaluated (n=7 in each) in a various condition of
the flow rate (ranged from 0.1 to 1.2 L/min).
Results: In the Control-group, PO2 of the effluent perfusate was stable (ranged
from 495 to 563 mmHg) regardless of the flow rate. In the DCD-group, PO2
was stable (ranged from 39.9 to 47.8 mmHg) when the flow rate was more than
0.5 L/min, whilst that increased up to 237 mmHg (at 0.1 L/min) when the flow
rate was less than 0.5 L/min.
Conclusions: The flow rates of 0.5L/min. in minimum seemed necessary for
Ex-vivo DCD lung evaluation. Further transplant model is needed to validate
the results.

POSTER BOARD NUMBER P3 – 30
1604 LUNG TRANSPLANTATION FROM DONORS WITH
CARDIAC DEATH – INITIAL EXPERIENCE IN NSW

POSTER BOARD NUMBER P3 – 32
1606 BLOOD MONOCYTE DIFFERENTIATION INTO
AIRWAY DENDRITIC CELLS IS CONTROLLED BY MYD88
FOLLOWING ORTHOTOPIC LUNG TRANSPLANTATION
S. Sugimoto, M. Okazaki, J. Lai, D. Kreisel, A. Gelman
Washington University School of Medicine
In lung grafts ischemia-reperfusion (I/R) signals rapidly induce the recruitment
and differentiation of host monocytes into macrophages and dendritic
cells. The nature of these I/R signals are antigen-independent but have been
hypothesized to initiate Toll-like receptor (TLR)-mediated signaling pathways
that are thought to potentiate alloimmune responses. We asked if MyD88, an
adaptor molecule critical for TLR-mediated inflammatory responses, regulated
monocyte differentiation in a novel mouse model of vascularized orthotopic lung
transplantation. Orthotopic left lung transplants were performed in the following
syngeneic combinations: CD45.1+ B6 Æ CD45.2 + MyD88-/- and CD45.1+ B6 Æ
CD45.2+ B6 (WT). 24 hrs later recipient-derived dendritic cell (DCs: CD45.2+
CD11c+ CD11bhi IAblo-hi) and macrophage (Macs: CD45.2+ CD11c- CD11blo
IAblo) numbers were assessed in bronchial lavage (BAL) by FACS analysis.
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L.C. Yap, A. Hamilton, I.M. Ahmed, P. Spratt, P. Jansz, A. Farnsworth, E.
Granger, P. Macdonald, A.R. Glanville
St Vincent’s Hospital, Sydney
Introduction: Donation after cardiac death (DCD) has potential to expand the
current limited donor pool in Australia. We illustrate the challenges of starting
such a programme and show our early results.
Methods: Institutional guidelines were created to encompass potential ethical
and legal issues with DCD lung transplant, and an education programme initiated
for hospital staff and donor coordinators. Initially all donors had elective
withdrawal of ventilation (Maastricht III) in ITU or the operating room. No
donor treatment of any kind was permitted. Our technique involved inflation of
the lungs with FiO2 0.4 after re-intubation. Chest was opened simultaneously
with the abdomen and lungs were assessed prior to flushing antegrade and
retrograde with cold Celsior/GTN mix. Implantation and postoperative
management was as per our standard protocol for all lung transplants.
Results: Since November 2007 we transplanted lungs from 3 DCD donors
with a mean age of 46(range 33-56). Cause of death was traumatic head injury
(n=1) and subarachnoid haemorrhage (n=2). The 3 recipients had a mean age
of 42 (range 22-61). Indications for lung transplant were emphysema, primary
pulmonary hypertension and late graft failure after lung transplant.
Mean time to asystole after withdrawal of treatment was 14 minutes (range
10-19). Mean warm ischaemic time was 22 minutes (range 12-31). Mean total
ischaemic time was 231 minutes (range 184-275).
Early function was excellent with mean PO2 on the 1st postoperative day of
100 (range 64 to 136) on FiO2 0.4. Mean length of ITU stay was 6 days (range
3-10) and time to discharge 30 days (range 25-36). There was no mortality.
Conclusions: Our initial experience in this new venture to expand our donor
pool taught us some key principles in setting up such a programme and our
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Compared to the BAL of WT recipients, MyD88-/- recipients had comparable
numbers of Macs (10297±945/ml vs. 11419±1016/ml; p=0.4) but significantly
fewer DC’s (5563±677/ml vs. 2891±341/ml; p<0.05) in lung graft airways that
were of recipient origin. Lower numbers of newly differentiated lung graft
DCs was coincident with the appearance of higher numbers of undifferentiated
monocytes (CD115+F4/80+Gr1lo CD11c-) in the lung graft airways of MyD88-/recipients as compared to WT recipients (254±80/ml vs. 1341±435/ml; p<0.01).
We also analyzed monocyte differentiation in allogeneic lung recipients by
comparing the fate of adoptively transferred CD45.2+ CD11b+ IAb- Ly6Chi Gr1bone marrow monocyte precursors (MPs) from either MyD88-/- or WT mice in
CD45.1+ B6 mice that received Balb/c lung grafts. As in the syngeneic graft
combinations, adoptively transferred MyD88-/- MPs were similarly defective
at differentiation into DCs in lung allografts. In conclusion these data show
that MyD88 regulates graft-infiltrating monocyte differentiation and suggests
a mechanism by which TLR signaling pathways control adaptive responses in
lung allografts through controlling monocyte fate.

CONCURRENT ORAL SESSION 114: SIROLIMUS
POSTER BOARD NUMBER P3 – 33
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1607 EARLY VERSUS LATE CONVERSION OF 100 HIGH RISK
RENAL TRANSPLANT RECIPIENTS FROM CALCINEURINE
INHIBITORS TO SIROLIMUS – LONGTERM FOLLOW UP –
KUWAIT EXPERIENCE
M.A. Halim, T. Al-Otaibi, K.V. Johny, M.R.N. Nampoory, M.H. Hamid, T.
Said, P. Nair, I. Al-Muzairai, M. Samhan
Hamed Alessa Organ Transplantation Center
Conversion of stable renal transplant recipients (RTR) from calcineurin
inhibitors (CNI) to sirolimus (SRL) is safe and effective while this step is
still under investigation for recent and high risk RTR. We studied the long
term effect of early and late conversion of high risk RTR maintained on CNI,
mycophenolate mofetil and steroid immunosuppressive regimen to SRL,
mycophenolate mofetil (MMF) and steroid on the graft and patient outcome.
Over about 4 years, the first 100 subjects converted to SRL in our center were
prospectively observed. The main indications for conversion were rejection,
CNI toxicity, CNI elimination and ATN (90% had biopsy diagnosis before
conversion). Candidates with severe bone marrow suppression were excluded.
Mean age was 37.5(13-70) years including 14% pediatric and 9% geriatric age
group. Mean BMI was 28.99(8.0). Grafts from deceased donors were 40%.
Sixty percent were having 4-6 HLA mismatches. Biopsy proven total acute
rejection and steroid resistant rejection were documented in 31% and 14%
respectively prior to conversion. Mean follow up period after conversion was
45.3 months (20.3- 65.8). Forty five subjects started SRL within one month of
transplantation (mean 0.5 month, range 0-0.97 month) - (group A). Fifty five
subjects started SRL later (mean 21.9, range 1-124.2 months) - (group B). No
significant differences were noticed between the groups in the demographic
features.
Subsequent total acute rejection and steroid rejection episodes were 17% and
10% respectively without significant difference between the groups. Proteinuria
>2gm/day, leucopenia, hypercholesterolemia and hypertriglyceridemia
increased significantly after conversion in both groups (p 0.001, 0.0003,
0.0001 and 0.0001 respectively). The patient and graft survival were 95% and
90% respectively without significant differences between the groups. Serum
creatinine and calculated creatinine clearance (MDRD formula) significantly
improved after conversion in both groups (p < 0.0001). Incidence of oedema
and lymphocele were significantly higher in group A (p 0.0001). Incidence of
discontinuation of SRL was 27% mainly due to bone marrow suppression and
wound complication. The main side effects and complications of SRL were
documented as generalized edema (n = 36), gastrointestinal (n = 34), headache
(n = 20), lymphocele (n = 17), mucocutaneous (n = 14), interstitial pneumonia
(n = 2) and wound dehiscence (n = 7). Infection episodes were significantly
high in both groups mainly respiratory(n = 49)and gastrointestinal (n = 36).
We conclude that early and late conversion from CNI to SRL was effective in
high risk RTR during long-term follow up. High incidence of discontinuation
of SRL was mainly due to drug complications and side effects. This was
aggravated by the high exposure to MMF. Lower dose of MMF is advisable
when combined with SRL. RTR with multiple medical problems may not be
the best candidates for SRL/MMF/steroid regimen.
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1608 SIROLIMUS-BASED CALCINEURIN INHIBITORSPARING IMMUNOTHERAPY, 6-YEAR RESULTS
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
The Immunosuppressive efficacy of Sirolimus (SIRO) has stimulated efforts to
limit calcineurin inhibitor (CNI) exposure in SIRO treated patients. We report
our 6-year experience, patients enrolled between 5/01 and 8/02, with a CNIsparing protocol in 50 consecutive primary renal transplant recipients. Patient
characteristics were as follows: mean age 46 years, male 64%, caucasian 80%,
deceased-donor 54%, diabetes 40%. Recipients were treated with a triple drug
regimen consisting of SIRO, tacrolimus and prednisone. SIRO dosing was
adjusted to target a trough level of 10 ng/ml. Tacrolimus dosing in the first
three months was targeted to trough levels of 8-12 ng/ml. At 90 days tacrolimus
dosing was decreased by 50% with subsequent maintenance dosing targeted to
a trough level of 3 ng/ml.
The mean follow-up at 12/1/07 was 72 months (64-79 months). At 90 days
post-transplant the mean SIRO trough level was 10.9 ng/ml (6-21) and the
mean 12-hour trough tacrolimus level was 8.4 ng/ml (4.4-13.3). Subsequent to
tacrolimus dose reduction at three months the mean trough tacrolimus level at
6 months was 3.1 ng/ml (1.7-6.5).
Patient and allograft survival at 1-year was 98%. Long-term actual patient and
allograft survival, as of 12/1/07, was 82% and 72% respectively. Mortalities
were due to cardiovascular events (n=5, at 13, 16, 30, 36 and 48 months),
infection (n=2, at 8 and 42 months), malignancy (n=1, at 45 months), and
unknown causes (n=1, 49 months). Five additional grafts have been lost to,
chronic nephropathy at 28, 58 and 68 months, recurrent disease at 66 months
and BK nephropathy at 44 months. There have been no graft losses to acute
rejection. Acute rejection developed in 5 patients (10%), with all episodes
ocurring within 14 days of transplantation. No acute rejection episodes
have been identified more than 90 days post-transplant when CNI dosing
was reduced. Mean serum creatine levels at 12 (n=49), 24(n=47), 36(n=45),
48(n=41), 60(n=37) and 72(n=21) months were 1,5, 1.5, 1.5, 1.6, 1.6, and 1.6
mg/dl respectively.
This SIRO, CNI-sparing and steroid regimen provided potent immunotherapy
for primary renal transplant recipients. The incidence of acute rejection was
only 10%. In addition, subsequent to reduced prograf dosing and target levels,
acute rejection did not occur. Furthermore, 6-year renal allograft survival is
excellent and serum creatinine levels have remained stable long-term. SIRO
maintenance immunotherapy safely allows for a 50% reduction in tacrolimus
dosing and levels at three months.

POSTER BOARD NUMBER P3 – 35
1609 DIFFERENT PROFILE OF GENE EXPRESSION OF
CYTOKINES IN PERIPHERAL BLOOD MONONUCLEAR
CELLS OF TRANSPLANT RECIPIENTS TREATED WITH
M-TOR INHIBITOR AND CALCINEURIN INHIBITOR
M. Niemczyk, J. Egarska, M. Pawowska, J. Wyzga, M. Ciszek, L. Pczek
Medical University f Warsaw, Transplantation Institute
Aims: To determine how sirolimus (SRL), in comparison to calcineurin
inhibitors (CAI), influences gene expression of cytokines: interleukin 1 beta,
tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma),
and interleukin 10 (IL-10) in peripheral blood mononuclear cells (PBMC) of
transplant recipients.
Material and methods: Twenty-two patients (13 kidney and 9 liver transplant
recipients), in which: CAI was replaced with SRL (n=11); SRL was introduced
additionally to CAI (n=7); or SRL was replaced with CAI (n=4), were recruited.
PBMC were obtained before and after modification of immunosuppression.
Real-time polymerase chain reaction was used for quantitative assessment of
expression of investigated genes.
Results: During therapy with SRL+/-CAI, the pro-inflammatory genes
expression was increased, and IL-10 gene expression was decreased, in
comparison to treatment with CAI. In subgroup of patients with malignancy
as the reason of liver transplantation, gene expression of TNF-alpha and IFNgamma was higher when SRL+/-CAI was used in comparison to treatment with
CAI. Patients with viral infection receiving SRL+/-CAI had higher expression
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of pro-inflammatory genes than during therapy with CAI.
Conclusions: Transplant recipients during therapy with SRL+/-CAI have
increased gene expression of Th1 cytokines, and decreased gene expression of
Th2 cytokine, IL-10, in PBMC, compared to treatment with CAI. This effect
is also present in subgroups of patients with malignancy or viral infection, and
may be beneficial in these patients.

POSTER BOARD NUMBER P3 – 36
1610 DE-NOVO CALCINEURIN INHIBITOR MINIMIZATION
IN COMBINATION WITH SIROLIMUS FOR RENAL
TRANSPLANTATION: A SINGLE CENTER’S REPORT
OF 100 CASES
M-K. Tsai, C-Y. Lee, I-R. Lai, R-H. Hu, P-H. Lee
Department of Surgery, National Taiwan University Hospital
Chronic nephrotoxicity of calcineurin inhibitors (CNIs) causes irreversible
renal dysfunction and shortens renal transplant survival. We conducted a
retrospective cohort study to test a hypothesis that de-novo CNI minimization
combined with sirolimus improves graft survival of renal transplantation. From
October 2000 to August 2007, we performed 100 cases of renal transplantation
with de-novo CNI (either cyclosporine or tacrolimus) minimization combined
with sirolimus. The initial target trough level for cyclosporine (CsA group:
33 patients) was between 100 to 200 ng/mL, and that for tacrolimus (TAC
group: 67 patients) between 4 to 8 ng/mL. Sirolimus was given by a loading
dose of 6 mg plus 2 mg/day for maintenance. The mend follow-up period was
45.0+/-25.1 months. The incidences of delayed function were 23.8% (16/67)
for the TAC group and 15.2% (5/33) for the CsA group. The 1-year rejectionfree survival and 5-year graft survival and 5-year patient survival rates were
94.87%, 87.72% and 98.61%, respectively. Fifteen patients stopped taking
sirolimus because of major infection (3 patients), liver enzyme elevation (3),
urinary leak (2), incisional hernia (1), lymphocele (1), deep vein thrombosis
(1), joint pain (2), patient decision (1) and malignancy (1). No interstitial
pneumonitis was noted in this series of patients, but 7 patients had pneumonia
with good response to antibiotics. One patient had wound disruption and graft
incarceration, which eventually lead to graft loss. In conclusion, de-novo CNI
minimization combined with sirolimus brought about good rejection-free graft
survival and patient survival of renal transplantation.

POSTER BOARD NUMBER P3 – 37
1611 LONG-TERM FOLLOW-UP OF SIROLIMUS (SLR)
MONOTHERAPY IN KIDNEY TRANSPLANT PATIENTS

Parameter
Mean (Standard Deviation)

Baseline

6 months

GFR (Nankivell) (mL/min)

58.3 (18.1)

58.5 (19.2)

59.6 (20.9)

GFR (MDRD-4) (mL/min)

48.7 (18.8)

48.0 (19.6)

48.6 (20.9)

12 months

Serum creatinine (μmol/L)

153.4 (65.3)

153.2 (69.0)

153.9 (77.4)

Systolic Blood Pressure (mmHg)

128.9 (14.6)

128.7 (14.5)

129.1 (15.7)

Diastolic Blood Pressure (mmHg)

74.2 (6.1)

73.9 (7.4)

73.4 (7.7)

Glycaemia (μmol/L)

5.6 (1.4)

5.6 (1.6)

5.8 (2.0)

Body weight (Kg)

68.3 (10.8)

67.3 (9.2)

67.9 (9.9)

Proteinuria (mg/24h) (Median)

115.5

147.0

159.0

Cholesterol (μmol/L)

5.4 (1.2)

5.4 (1.1)

5.5 (1.2)

Triglycerides (μmol/L)

1.9 (1.3)

1.9 (1.3)

2.0 (1.1)

POSTER BOARD NUMBER P3 – 38
1612 SUCCESSFUL CONVERSION TO SIROLIMUS IN
CALCINEURIN INHIBITOR(CNI) TOXICITY INDUCED GRAFT
FAILURE COMBINED WITH HEAVY PROTEINURIA
Y.K. Son, Y.H. Shin, J.K. Kim, S.S. Lee, K. Hur
Bong Seng Memorial Hospital
Sirolimus has been shown to be as effective as CNI in maintaining allograft
without causing nephrotoxicity. Otherwise, sirolimus might aggravate the
proteinuria after renal transplantation and some reports do not recommend
the sirolimus in case of heavy proteinuric graft. However, we report a case of
successful conversion to sirolimus in calcineurin inhibitor(CNI) induced graft
dysfunction combined with heavy proteinuria.
The present case of human renal allograft recipient documents the utility of
switching from CNI to sirolimus therapy for a patient experiencing ongoing
biopsy proven CNI toxicity and heavy proteinuria induced by presumed CNI
toxicity.
The patient described herein underwent maintenance therapy with CsA/MMF/
Steroid for 3months after renal transplantation.
He was complaining to edema and poor urine volume. He was oliguric with a
urine output less than 500ml per day (Proteinuria > 6g/day) and uremic with a
serum creatinine(sCr) value above 4.3mg/dl.
Graft biopsy showed intact glomeruli and tubules with cytoplasmic isometric
vacuolation, focal flattening and several casts consistent with acute CNI
toxicity.
Although heavy proteinuria, CsA was switched to the sirolimus to treat biopsy
proven CNI toxicity. Within 2 weeks the patient´s sCr value decreased to
1.4mg/dl and urine output returned to greater than 2000ml per day (proteinuria
< 1.5g/day).

POSTER BOARD NUMBER P3 – 39
1613 IMMUNOSUPPRESSION BASED ON M-TOR INHIBITORS
WITHOUT STEROIDS OR CALCINEURIN INHIBITORS IN
RENAL TRANSPLANT RECIPIENTS
A. Franco, E. Cotilla, S. Roca, L. Jimenez, J. Sanchez, J. Olivares
Hospital General Alicante
The aim of this study was to study the evolution of renal function and proteinuria
of 28 renal transplant recipients with m-TOR based immunosuppression
without calcineurin inhibitors or steroids.
This study was prospective and observational.They were 14 males and 14
females, aged 49,2±± 12,1 years. The therapy on m-TOR without calcineurin
inhibitors nor steroids was 13,2 ±15,4 months postransplant. The follow- up
was at least 12 months, mean 23,2 ±9,4 months (ranged 13-39).
Conversion to mTOR was performed within two weeks., due to histological
nephrotoxicity (18 cases), gingival hypertrophy (2cases), postransplant diabetes
(2 cases), de novo haemolytic-uremic syndrome (1 case) and Kaposi sarcoma
(1 case). Four recipients received no calcineurin inhibitors nor steroids since
the first day after transplantation.
Patients improved the renal function ,mean GRF increased from 40.8 ±15,6ml/mn
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R. Pinto1, M. Arellano2, A. Franco3, J.C. Ruiz4, Y. Armendariz5, E. Granados5,
J.M. Campistol2
1
H Curry Cabral, Lisboa, Portugal, 2H Clínic, Barcelona, Spain, 3H
Universitario, Alicante, Spain, 4H Marqués de Valdecilla, Santander, Spain,
5
Wyeth Farma
Background: Sirolimus (SRL) offers an alternative to CNIs as a maintenance
immunosuppressive drug. Usually, the SRL monotherapy (without steroids) in
kidney transplant recipients is the result of a reactive situation. The aim of
this study was to analyze the safety of SRL monotherapy in kidney transplant
recipients.
Methods: Ongoing retrospective study performed in N=97 patients from 4
sites from Spain and Portugal, all of them followed at least 12 months. The
analysis included acute rejection rate and other assessments at 4 and 12 months
after SRL monotherapy initiation.
Results: Mean time after SRL monotherapy start was 6.5 years (95%CI:
5.7; 7.2), and mean trough level was 10.3 ng/mL (9.8; 10.8). Reasons to
start monotherapy included treatment optimization (53.8%), minimization
(23.7%), cancer (9.7%), chronic allograft nephropaty (CAN; 8.6%). There
was not any acute rejection episode either at 6 or 12 months after treatment
initiation. The haemoglobin increased significantly (p=0.020) from 12.1 g/dL
(1.9) at baseline in a mean of 0.27 g/dL (1.3) after 12 month-treatment. There
were no statistically significant differences in the rest of parameters [table1].
There were 4 deaths (cerebrovascular accident and progression of cancer) and
3 graft failures. The most frequently reported related adverse event was mouth
ulceration (8 patients).
Conclusions: These preliminary data obtained from an ongoing selective

population show that long-term maintenance SRL monotherapy in kidney
transplant recipients is safe in terms of immunological risk.
Table 1
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to 44.6 ±16.9 at 6 months and 49.9 ±18.0 at 12 months (p=n.s), while creatinine
decreased from 1.86 ±0.6 mg/dL to1.72 ±0.6 and 1.60 ±0.5 at 6 and 12 months
(p=n.s,T-student). The 24 h proteinuria increased from 234 mg/24h(89-280) to
280(86-731) at 6 months and 210(66-1162)) at 12 months (p=n.s Wilcoxom,).
Most of the adverse effects such as Kaposi sarcoma, hemolityc uremic syndrome,
gingival hypertrophy disappeared after conversion, but .postransplant diabetes
had no change.
One patient died due to abdominal sepsis at 20 months with a functioning
graft. One patient was switched to FK due to dermical rush. During the followup no acute rejection episode was observed .Concomitant therapies were:
hypolipemics in 16 of 27 patients (59,3%), erythropoietin and angiotensinconverting enzyme innibitors in 5/27 patients (18,5%).
At the end of the follow-up,16 of 27 patients (59,3%),were on m-TOR
monotherapy and 11 of 27 (40.7%)with micophenolate.
The present study supports the safety and efficacy of calcineurin inhibitors
and steroid withdrawal in selected renal transplant recipients with m-TORbased immunosuppression to solve adverse effects due to calcineurin
inhibitors or steroids.
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1614 PULMONARY TOXICITY INDUCED BY SIROLIMUS
T. Matuck, F. Miloski, M. Graciano, L. Morgado, M.E. Gouveia, D. Carvalho
Hospital Geral De Bonsucesso
Introduction: Sirolimus is an immunosuppressive agent used increasingly
in kidney transplant recipients for initial and long-term maintenance therapy.
It is also being used as maintenance therapy in patients following with
chronic allograft nephropathy to stop the use of the calcineurin-inhibtor and
avoid nefrotoxicity. Pulmonary toxicity has been recognized as a potential
complication associated to this medication.
Objective: To report a case of intersticial pneumonitis and organizing pneumonia
associated with the administration of sirolimus after renal transplant:
A 58-year-old African American woman, who underwent a cadaveric renal
transplant 57 months before. Initially she received, as immunosuppressive
regimen, tacrolimus, mycophenolate mofetil and prednisone, but 10 months
before hospitalisation the tacrolimus was discontinued and sirolimus
was introduced, as there was a graft biopsy suggesting chronic allograft
nephropathy. She was hospitalised presenting a 4-week history of dyspnea
and cough. Fever appeared only 3 weeks later, when dyspnea worsened. She
also referred hyporexia and weight loss during this period. Chest radiography
and CT scan revealed bilateral ground-glass alveolar infiltrate, suggesting
intersticial pneumonitis and organizing pneumonia. She was initially treated
with antibiotics for atypical pneumonia with no response. Bronchoscopy
was performed and bronchoalveolar lavage (BAL) culture was negative for
bacteria and fungus and cytology revealed marked lymphocytosis. Arterial
blood gas studies showed severe hypoxemia with mild respiratory alkalosis.
Hematology was without leucytosis and the biochemistry showed only
hypercholesterolemia, while creatinine and urea remained normal. One week
after the initial treatment, sirolimus was discontinued, as the hypotesis of
pneumonities secondary to the drug was suspected. Fever, dyspnea, fatigue
and lung infiltrates resolved rapidly when sirolimus therapy was stopped.
After two weeks a high resolution chest CT scan showed a good radiologic
evolution, but her chest X-ray and CT scan resolved completely only 6
months later.
Conclusions: The temporal relationship between sirolimus exposure and
onset of pulmonary symptoms in the absence of infectious causes and other
alternative pulmonary disease suggested that sirolimus was the cause of the
pulmonary changes. The associated clinical and radiological improvement
after it was discontinued confirmed a causal relationship. Because the use of
sirolimus in kidney transplantation has become more widespread, clinicians
must remain vigilant to this potential pulmonary complication.
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1615 A FOLLOW-UP AFTER CONVERSION THERAPY
FROM CALCINEURIN INHIBITOR(CNI) TO LOW DOSE
SIROLIMUS(SRL) IN RENAL TRANSPLANTATION
RECIPIENTS
M. Yu, T. Zhu
Zhongshan Hospital, Fudan University
Purpose: To Evaluate the short-term efficacy and safety of conversion therapy
from Calcineurin Inhibitor(CNI) to Sirolimus(SRL) in renal transplantation
recipients, finding the appropriate SRL trough blood level for Chinese.
Methods: In a prospective study, we evaluated the short-term efficacy
and safety parameters in 19 renal transplantation recipients who had been
operated for 4 months to 10 years. They were switched from CNI to SRL for
allograft dysfunction. A kidney biopsy was done in 12 of the patients prior
to conversion, and showed either chronic allograft nephropathy (n=3) or CNI
nephrotoxicity (n=9). Conversion was abrupt. The patients received SRL at a
starting dose of 3mg/d twice, then 2mg/d£¬ target trough blood level 4-7ng/
ml, with CNI withdrawal in the evening before starting SRL. The concomitant
immunosuppression remained unchanged. Patient data were recorded at
baseline(Day 0), and at month 1, 3, 6, 9, 12 post-conversion.
Results: After a mean post-conversion follow-up of 7.8¡À3.4 months, the
survival of the patients and grafts was 100%. One patient had to stop SRL due
to financial limitations. No acute rejection was found. No significant change in
hepatic function, while dyslipidemia was induced in three patients and major
pneumonia was observed in one. One patient required erythropoietin therapy
because of the low hemoglobin level. De novo proteinuria of >1g/day appeared
in another one. There was significant amelioration of the renal function with
Creatinine Clearance increasing from 47.0¡À15.0 baseline to 55.3¡À16.9 ml/
min post-conversion(P<0.001).
Conclusion: Conversion from CNI to low dose SRL in renal transplantation
patients with allograft dysfunction was associated with improved renal function.
It decreased the appearance of side reaction such as anemia, dyslipidemia,
hepatic dysfunction and medical expense as well. So the conversion therapy
is feasible and safe in short term. Long-term follow-up will be necessary to
confirm the preliminary data.

POSTER BOARD NUMBER P3 – 42
1616 EARLY CONVERSIO CNI-BASED TO SIROLIMUS-BASED
TRIPLE IMMUNOSUPRESSION IN PATIENTS WITH CHRONIC
CNI TOXICITY: A PROSPECTIVE PROTOCOL BIOPSY
MANDATED STUDY
A. Uslu1, H. Töz3, F.A. Taþlý2, A. Nart1, S Þen4, A. Nart1, M. Doðan1,
T. Þahin2, H. Postacý2
1
Izmir Teaching Hospital Organ Transplantation Center, 2Izmir Teaching
Hospital Department of Pathology, 3Ege University Medical Faculty
Department of Nephrology, 4Ege University Medical Faculty Department of
Pathology
Background: There is emerging consensus on conversion from calcineurin
(CNI)-based regimens to proliferation signal inhibitor (PSI)-based protocols
for the prevention of progressive graft dysfunction due to CNI toxicity.
Methods: 31 primary renal transplant patients were enrolled in this doublecenter study. Eligible patients were those having zero-hour biopsy and
completed at least twelve months of follow-up after transplantation with
current deteriorating graft function indicative of chronic CNI toxicity on biopsy
specimen. Fast conversion protocol, being defined as complete withdrawal of
CNI drug in two weeks, was attempted.
The primary endpoint of this study was the assessement of renal function by
mGFR and renal histology by protocol biopsy at one year of conversion.
Results: The mean follow-up after conversion was 21.6 months. The
difference between mean GFR before conversion and at the last followup (40.8¡À2.36ml/min vs 53.8¡À2.96ml/min, p<0.000) was significant,
indicating a sustained improvement in graft function. The change in CAN
scores between conversion period and the first year of follow-up (-0.38¡À0.27)
was indicative of a mild but unsignificant progression. Multivariate
regression analyses revealed three independant factors (SCr<2.34¡À0.16mg/
dl, mGFR¡Ý40.6¡À3.0ml/min and CAN score<3.1¡À0.3 at conversion) with
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significant impact on mGFR and CAN score one year after conversion. The
incidence of acute rejection and the patient and graft loss was 0% in this
group.Moreover, SCr and mGFR was improved in 21 of the 29 patients
(%72), remained stable in 4 (%14) and decreased in 4 (%14) patients.Study
drug was withdrawn in two patients due to severe infections. The most
frequent adverse event was abnormal lipid profile observed in 23 patients
(%74) after conversion.
Conclusion: Late conversion protocol from CNI- to SRL,particularly in
patients with mGFR¡Ý40.6ml/min and mild CAN is safe and having excellent
graft outcomes
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1617 CONVERSION FROM TADCROLIMUS TO SIROLIMUSBASED PROTOCOL IN RENAL TRANSPLANT RECIPIENTS: A
LONG-TERM COMPERATIVE STUDY
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1618 INCREASED FREQUENCY OF ANGIOEDEMA UNDER
COMBINED TREATMENT WITH MTOR – AND ACEINHIBITOR IN KIDNEY TRANSPLANTED PATIENTS
M. Duerr, P. Glander, F. Diekmann, H-H. Neumayer, K. Budde
Nephrology, Charité University Hospital
Angioedema is a potential life threatening swelling of the face, lips mouth and
throat. The pathology is driven through inflammatory mediators that cause
dilatation and increased permeability of capillaries additionally. The etiology is
unknown, but under treatment with ACE-I a frequency of 0,1-0,5% developing
angioedema is described in literature, but also may rapid develop with ARBs.
Because we observed some cases of angioedema we therefore screened our
electronic patient database for all cases of angioedema under mTOR-therapy
systematically. We identified 112 patients receiving both ACE-I and mTORtherapy (169 patient treatment years). Out of these 27 discontinued ACEtherapy, of whom six patients (4,5%) developed angioedema after a mean period
of 98 days (17-255d) under combined therapy. For control group we found 73
patients receiving ARBs and mTOR-I combined (124 patient treatment years).
No event of angioedema was reported in control group.
Five patients developed angiodema after initiation of mTOR-therapy, although they
had been on ACE for 2,75 years (1,3-3,9y) already before the onset of symptoms
started. One patient developed angioedema 255 days after initiation of ACE-I while
he had been on Sirolimus for 430 days. All patients recovered rapidly after steroid
bolus (n=3) and stop of ACE-I therapy (n=6). After the event of angioedema in four
out of six patients, treatment with ARBS was initiated instead.
Conclusion: Angioedema occurs with a frequency of approximately 4,5%
under combined therapy with mTOR and ACE-I. Therefore the preferential use
of ARBs in patients under mTOR-therapy could be justified.
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1619 TREATMENT WITH SIROLIMUS RESULTS IN LESS
WEIGHT GAIN AFTER KIDNEY TRANSPLANTATION
F. Diekmann1, J. Rovira2, M. Arellano2, J.T. Burke3, Y. Brault3,
J.M. Campistol2
1
Nephrology, Charité Campus Mitte, Berlin, Germany, 2Nephrology and Renal
Transplantation, Hospital Clínic, Barcelona, Spain, 3Wyeth Research, Paris,
France
Immunosuppressive treatment after kidney transplantation has been associated
with undesirable weight gain and obesity. Sirolimus (SRL), as the archetypal
inhibitor of the mTOR pathway, has demonstrated in experimental models
significant downregulation of this critical regulatory pathway of nutrient
signalling and cell growth.The aim of this analysis was to evaluate if treatment
with SRL results in less weight gain compared with conventional calcineurin
inhibitor-based treatment.
Methods: Data on body weight and body mass index was pooled from four
de novo randomized prospective kidney transplant trials. 1421 patients were
included in the study and were randomized at transplantation to receive
either a conventional immunosuppressive treatment consisting of a CNI, an
antimetabolite (MMF or Azathioprine) and steroids or sirolimus plus either
CsA or an antimetabolite and steroids. Data were analyzed at 1, 6, 12, 24
months post-transplant.
Results: Results on renal function and transplant outcome were reported earlier
(Groth et al. Transplantation 1999; Kreis et al. Transplantation 2000; Kahan et
al. Transplantation Proceedings 2003). Of the 1421 patients 586 completed the
study phase of two years. At baseline patient weight in the CNI-based and the
SRL-based groups were 74.6±17.2 and 75.0±16.5 kg. The mean weight gain
was 8.6±8.6 vs. 5.8±9.3 kg after 24 months in the CNI and the SRL group
respectively (p<0.001). Mean BMI at baseline was 25.7±5.1 and 25.6±4.7.
The mean increase of BMI after 24 months was 3.0±3.0 vs.2.0±3.2 (p<0.001).
In a multivariate analysis significant risk factors related to BMI change were:
Ethnic origin, treatment based on SRL or CNI, cumulative steroid dose,
baseline triglycerides, recipient age and gender.
Conclusions: SRL-based treatment is associated with significantly less weight
gain after kidney transplantation. This could have clinical implications, since
obesity is an important risk factor for insulin resistance and for cardiovascular
diseases, which are the main cause of death after kidney transplantation.
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R. Rahamimov1, A. Yusim2, J. Winkler1, T. Mashraki2, U. Gafter1, E. Mor2
1
Department of Nephrology, and 2Department of Transplantation, Rabin
Medical Center, Petah-Tiqwa affiliated with Sackler School of Medicine
Tel-Aviv University, Israel
Sirolimus has been advocated in patients with chronic allograft nephropathy
to replace the traditional calcineurine-inhibitor protocols. We conducted a
comparative study to assess the efficacy of conversion from tacrolimus to
sirolimus in recipients with renal dysfunction.
Material and methods: Twenty-nine of 60 designed study population
were enrolled in a randomized open label prospective manner to stay on
Tacrolimus-based protocol (Tac) with MMF and steroids or to change to
Sirolimus-based protocol (Sir) with the same medications. The inclusion
criteria included patients who were > 6-months after transplant with stable
serum creatinine levels (Cr.) ranging between 2-3 mg/dL with no clinical
evidence of rejection. To exclude any vascular or uro-mechanical problem
Renal Doppler ultrasound was performed before enrolment. All patients were
followed every 3-month up to 3 years or until return to dialysis with serum
Cr. and 24-hr. urine protein (U-Pr). Statistical method: A Person Chi square
and Fisher Exact Test were used to compare the two groups for age, sex,
time from transplant, serum Cr. and U-Pr at enrolment. These parameters
were included in a stepwise Cox regression model to compare graft survival
between the two groups.
Results: The study was discontinued by the researchers before the designed
number of patients (60) were enrolled with literature reports advising not to
use Sir in patients with advanced renal impairment and proteinuria. Three
patients from the control arm were excluded from analysis (two refused their
randomization and one who was found with RCC at enrolment). Twenty-six
patients (11 - Tac arm, 15 - Sir arm) completed a median follow-up of 31
months (7-44 months). At enrolment the two groups were not different by age,
sex and interval after transplant (median 31 months). The mean Cr. and U-Pr at
base line and follow-up were not different between the two groups (table). In
intention to treat analysis graft survival at 36 month were 52% in the Tac group
and 72% in the Sir arm (p=ns). In the Cox regression model the parameters
affecting survival were Cr. (<0.02) and Ur. protein (p<0.02) at base line but not
the immunosuppressive protocol.
Conclusion: Progression of recipients with moderate degree of renal
insufficiency after transplant to graft failure depends mostly on the severity of
functional changes and not on the immunosuppressive protocol.
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1620 THERAPY OF CALCINEURIN INHIBITOR-INDUCED
THROMBOTIC MICROANGIOPATHY IN RENAL
ALLOGRAFTS
N.C.T. Kong1, C.Y. Loo1, A.G. Halim1, M. Rozita1, S. Rashidi1, K.S. Phang1
1Faculty of Medicine, National University of Malaysia, Kuala Lumpur,
Malaysia
Although thrombotic microangiopathy (TM) is a well recognized albeit rare
complication of calcineurin inhibitor (CNI) therapy, its treatment is not well
established. We report a case of tacrolimus (Tac)-induced TM and propose a
course of treatment for this entity.
Mr MN, a 32 year old teacher developed ESRD due to obstructive uropathy and
hypertension and was commenced on CAPD in June 2006. In March 2007, he
received a kidney donated by his spouse. Basiliximab and methylprednisolone
(MP) were used for induction followed by prednisolone-Tac-mycophenolate
mofetil. He was discharged 10 days post-surgery with a serum creatinine of 95
umol/L and a daily urine output of 5-7 L. On follow-up, his serum creatinine
vascillated between 120-145 umol/L depending on hydration status and serum
Tac levels were kept within therapeutic ranges. On the 95th day post-transplant,
his serum creatinine rose steeply from 132 to 162 umol/L despite euvolaemia.
Physical examination was unremarkable and his blood pressure was 117/63
mmHg, lying and standing. Results of the usual investigations were all within
normal limits. However, echodoppler ultrasound of the graft showed a rise
in the resistive index from 0.68 (first week post-transplant) to 0.8. IV pulse
methylprednisolone (500 mg daily x3 days) was commenced whilst awaiting
results of the urgent graft biopsy and Tac was reduced. Graft biopsy showed 9
glomeruli, 4 of which demonstrated capillary occlusion by microthrombi. The
tubules, interstitium and other blood vessels were normal and C4d staining
was negative. A diagnosis of thrombotic microangiopathy (TM) consistent with
CNI nephrotoxicity was made.
Tacrolimus was substituted with sirolimus. The 3-day course of pulse IV MP
was completed. Plasmapheresis daily for 3 days was instituted followed by IV
Gammaglobulins at 10 gm daily for 3 days. Aspirin and dipyridamole were
also added. His serum creatinine held at 162 umol/L for 2 days then dropped
progressively to 126 umol/L by 2 weeks post- and 114 umol/L by 50 days postevent. At last review in February 2008, his serum creatinine was 123 umol/L.
Given our extensive experience with this sequential protocol for the remissioninduction treatment of severe lupus nephritis, we are emboldened to propose
that this may indeed be a reasonable solution for CCNI-induced TM. Early
diagnosis is the key to success.
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1621 RETROSPECTIVE COMPARATIVE ANALYSIS OF
CYCLOSPORINE AND SIROLIMUS BASED TRIPLE DRUG
IMMUNOSUPPRESSION
A.K. Gupta1, V. Verma1, S. Jasuja1
1
Apollo Hospitals, Delhi
Introduction: Calcineurin toxicity significantly contributes to chronic allograft
dysfunction. We retrospectively analyzed patients who were shifted from
cyclosporine-MMF- steroid to sirolimus (SRL)-MMF-steroid regimen.
Methods: There were total of 16 patients. Repeated measure ANOVA design
was done to find significant difference between s. creatinine at conversion and
six time points 2, 7, 30, 91,182 and 365 days post conversion. Patients were
divided into 3 sub groups: period of post transplant at conversion (less than or
equal to 200 weeks (n=11) v/s more than 200 weeks (n=5)); diabetics (n=7) v/s
non diabetics (n=9); and pre-conversion s. creatinine (less than or equal to 2.2
(n=10) v/s more than 2.2 mg/dl (n=6)).
Results: Mean (±SD) donor age was 40.14 ± 13.4 years; mean post
transplant weeks at conversion 109.81 ±13.92; mean post transplant lowest
s. creatinine (in 2 weeks) 1.5 ± 0.33 mg/dl; mean s. creatinine at conversion
2.17 ± 0.76 mg/dl, mean s. creatinine post conversion: 2 days 2.02 ± 0.73;
7 days 1.81 ± 0.44 ; 30 days 1.74 ± 0.46 ; 91days 1.74 ± 0.55;182 days
1.73 ± 0.81 ; 365 days 1.78 ± 0.64 ; and s. creatinine at last follow up 1.94
± 1.16 mg/dl. Mean s. cholesterol was 188.31 ± 50.5 mg/dl(all patients
were on statins pre as well as post conversion). On repeated measure
ANOVA analysis all values of s. creatinine post conversion (2,7,30,91,182
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and 365 days) were significantly lower as compared to s. creatinine at
conversion (p<0.05).Mean s. creatinine at conversion and all time points
post conversion was significantly lower in less than or equal to 200 weeks
group as compared to more than 200 weeks group. Intra group comparison
showed that significantly lower s. creatinine at 30,91,182 & 365 days in less
than or equal to 200 weeks and at 7,30 & 91 days in more than 200 weeks
group when compared to s. creatinine at conversion. Mean s. creatinine in
diabetics at conversion and all time points post conversion was higher than
in non diabetics but could not reach statistical significance (p=0.27). Intra
group comparison revealed significantly lower s. creatinine at 91 & 182 days
in non diabetics and at 7, 30, 91, 182 & 365 days in diabetics as compared s.
creatinine at conversion. Mean s. creatinine in group with s. creatinine more
than 2.2 mg/dl at conversion remained significantly higher at all time points
post conversion as compared to group with s. creatinine less than or equal
to 2.2 mg/dl.S. creatinine was significantly lower at 91, 182 days in group
with s. creatinine less than or equal to 2.2 and at 7,30,91,812 & 365 days in
group with s. creatinine more than 2.2 mg/dl post conversion as compared to
s. creatinine at conversion in intra group analysis.
Conclusion: SRL-MMF-Steroid regimen significantly improves graft function.
Better results are achieved with early change over from cyclosporine to SRL.
Diabetics have significantly higher s. creatinine as compared to non diabetics
and appear to benefit more from SRL based regimen.

POSTER BOARD NUMBER P3 – 48
1622 A REVIEW OF FIVE YEARS OF EXPERIENCE WITH
SIROLIMUS IN RENAL TRANSPLANT PATIENTS AT INKOSI
ALBERT LUTHULI HOSPITAL, DURBAN,
SOUTH AFRICA
A. Assounga, S. Maharaj
Dept of Nephrology, University of KwaZulu-Natal, Inkosi Albert Luthuli
Hospital, Durban South Africa
Background: Evidence of sirolimus associated nephrotoxicity has recently
gained focus. To assess the impact of this potential problem, we performed
a retrospective audit on renal transplant patients receiving sirolimus at Inkosi
Albert Luthuli Hospital from 2003 until 2007.
Method: Medical records of transplant recipients were analysed.
24 hour urine protein excretion (UPE) and estimated glomerular filtration
rates(eGFR) prior to initiation of sirolimus(baseline) and at their last clinic
visit were compared. Patients were sub-categorised according to their specific
indications for switching to sirolimus therapy.
Results: 30 patients were included. Average follow-up was 25 months.
Indications for use of sirolimus were: Group 1:Ciclosporin induced biochemical
toxicity(n= 6), Group 2: Chronic allograft nephropathy(n= 6), Group 3:Severe
gum hypertrophy(n= 9), Group 4: Post transplant diabetes(n= 4), Group
5:Calcineurin inhibitor(CNI) induced histologic nephrotoxicity(n= 2) and
Group 6:CNI associated malignancy(n= 3).
Average UPE rate and eGFR prior to starting sirolimus were 0.44 ± 0.08 g/24
hrs and 50.1±3.1 ml/min respectively, compared to 0.94 ± 0.2 g/24 hrs and
52.1±4.8 at an average follow up of 25 months.
On subgroup analysis, eGFR was increased/unchanged in groups 1(47.3 vs.
51.16 ml/min) and 4(60.0 ml/min vs. 60.0 ml/min) when compared to baseline,
but decreased in groups 2(47 vs. 27.6ml/min), 3(51.3 vs. 42.2ml/min), 5(54.0
vs. 29.5ml/min) and 6(60.0ml/min vs. 56.5ml/min).
UPE rates increased in groups 2(0.30 vs 1.44g/day), 3(0.39 vs. 1.55g/day)
5(0.08 vs. 0.77g/day) and 6(0.17 vs. 0.53g/day) compared to baseline, but
was unchanged in groups 1(0.25 vs 0.25g/day) and 4(0.23 vs 0.21 g/day).
Combining the latter 2 groups, most patients(80%) received sirolimus within 1
year of transplantation, whereas only 2 patients(10%) received the drug within
one year of transplantation in the former groups combined.
Conclusion: Overall, sirolimus therapy was associated with an improvement
eGFR but an increase in UPE rates. Maximum benefit was achieved when
patients were switched to sirolimus within the first transplant year.
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1623 EXCELLENT RESULTS OF EARLY STEROID
WITHDRAWAL LOW DOSE TACROLIMUS
IMMUNOSUPPRESSION IN LIVING DONOR KIDNEY
TRANSPLANTATION
W-C. Lye
Centre For Kidney Diseases
We present our 10-year, January 1996 - December 2005, single centre
propectively collected outcome results on an early steroid withdrawal, low
dose tacrolimus based immunosuppression in low immunologic risk living
donor kidney transplantation. Induction therapy consisted of either 2 doses
of basiliximab given 4 days apart or 2 doses of daclizumab, 1 mg/kg body
wt, given 2 weeks apart. I.v. methylprednisolone 500 mg/day was given for
3 days beginning on day 0. Oral prednisolone was administered at a dose
of 30/day for 3 days, 20 mg/day for 3 days, 15 mg/day for 3 days, 10 mg/
day for 3 days and continued on 5.0 mg/day until day 30 post transplant.
Tacrolimus was started at a dose of 0.2 mg/kg body wt the night before the
transplant, tacrolimus dose was adjuested to maintain the trough level at 8-12
ug/L for the first 3 months, 5-8 ug/L from 3-12 months and 4-6 ug/L onwards.
Mycophenolate was given at a dose of 750 mg b.i.d. for the first 3 months and
reduced to 500 mg b.i.d. later. Protocol biopsy was performed at day 10 post
transplant, all suspected acute rejection episodes were biopsied. The 1-year
acute rejection rate, 1-, 5- and 10-years patient and graft survival rates were
studied. A total of 210 patients, mean age; 55.3±12.1 years (range 8-78 years),
males:female; 136:64 were studied. Diabetes mellitus was the cause of endstage renal disease in 60% of patients. Subclinical rejection was detected in 5%
of patients on protocol biopsy but was not treated if there was no rise in serum
creatinine. The 1-year biopsy-confirmed acute rejection and steroid-resistant
rejection rates were 10% and 2% respectively. The 1-, 5-, and 10-years death
censored graft survival rates were 99%, 95% and 90% respectively. The 1-,
5- and 10-years patient survival rates were 100%, 92% and 85% respectively.
De novo diabetes mellitus occurred in 7% of patients at 1-year. 5/210 patients
developed malignancy, 4 were PTLDs. In conclusion, early steroid withdrawal,
low dose tacrolimus and mycophenolate based immunosuppression with antiIL2 receptor induction therapy is an effective immunosuppression regimen
with minimal complications for living donor kidney transplantation.
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1624 DRIED BLOOD SPOT MEASUREMENT: APPLICATION
IN TACROLIMUS MONITORING USING LIMITED SAMPLING
STRATEGY AND ABBREVIATED AUC ESTIMATION

1625 TACROLIMUS AND TIBOLONE: A POSSIBLE DRUG
INTERACTION OF WHICH TRANSPLANT CLINICIANS
SHOULD BE AWARE
C.J. Clark, D.W. Mudge, C.M. Hawley
Nephrology Department, Princess Alexandra Hospital, Brisbane
Tibolone is a synthetic steroid increasingly used as a hormone replacement
therapy. It is known to have only weak interactions with the cytochrome P450
enzyme system. We report a case in which a patient who underwent renal
transplantation six years previously developed acute renal failure ten days after
starting tibolone. The likely cause of the acute renal failure was tacrolimus
toxicity, as her tacrolimus level increased from 5 μg/l to 17 μg/l. She displayed
symptoms of toxicity including fine tremor and anxiety. Both the serum
creatinine and the tacrolimus levels returned to normal within two weeks of
ceasing tibolone therapy, and the symptoms resolved. We believe this was a
significant drug interaction of unknown mechanism.
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1626 CONVERSION FROM CYCLOSPORINE TO
TACROLIMUS BASED IMMUNOSUPPRESSION THRAPY IN
RENAL TRANSPLANT RECIPIENTS
L. Bäckman
Transplant Institute
Body: This is an an interim analysis of an investigator-driven multicenter trial in
renal transplant recipients: the Prospective Quality of life Renal Transplantation
Switch Study; Tacrolimus-based immunosuppression (PQRST study).
Patients and methods: Patients included in the trial were initially treated
with cyclosporine-based immunosuppression after renal transplantation. They
experienced cyclosporine- or steroid-related side-effects, such as hypertension,
hyperlipidemia, hypertrichosis, or other adverse reactions and were converted
to a tacrolimus-based immunosuppressive regimen (n = 76). Steroids were
subsequently discontinued between 3 and 6 months after the conversion.
Follow up ranged from 2 to 24 months.
Results: One patient died from a PTLD 7 months after the conversion. This event
was however not felt to be related to the change in immunosuppression. There
have been no acute rejection episodes and no other grafts were lost. As of today
19/31(60%) patients, who have completed at least 6 months, are successfully
weaned off steroids with the remaining patients in this process. No patient
experienced an acute rejection episode. The blood pressure and the need for
antihypertensive medication decreased. No patient developed de novo diabetes or
other serious side effects related to the conversion. Three patients were withdrawn
from the trial because of bleeding, depression, and proteinuria. However, none
of these adverse events were felt to be directly related to the change of the
immunosuppressive regimen to tacrolimus based immunosuppression.
In conclusion, conversion from cyclosporine to tacrolimus-based
immunosuppressive therapy was safe and well tolerated and may improve the
cardiovascular risk profile after kidney transplantation.
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1627 CLINICAL AND HISTOLOGICAL ANALYSIS OF
CHRONIC TACROLIMUS (TAC) NEPHROTOXICITY IN RENAL
ALLOGRAFTS
T. Shimizu1, H. Ishida1, K. Omoto1, H. Shirakawa1, T. Tokumoto1, K. Tanabe1,
Y. Yamaguchi2
1
Tokyo Women’s Medical University, 2Department of Pathology, Kashiwa
Hospital, Jikei University School of Medicine, Chiba, Japan
Aim of study: Tacrolimus (TAC) is an effective primary immunosuppressive
agent in kidney transplantation. Chronic nephrotoxicity due to TAC in kidney
transplant patients was reported to be similar to that of cyclosporin A (CYA).
However, the severity and influence of chronic TAC nephrotoxicity are not
fully elucidated, the clinico-histological characteristics of chronic TAC
nephrotoxicity in kidney transplants were studied.
Patients and methods: We studied retrospectively the clinico-histological
profiles of fifteen transplant patients under TAC-based immunosuppression,
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C.Y. Cheung1, J. van der Heijden2, K. Hoogtanders2, M. Christiaans2,
K.F. Chau1, C.S. Li1, J. van Hooff 2, L. Stolk2
1
Queen Elizabeth Hospital, Hong Kong, 2University Hospital Maastricht, the
Netherlands
Dried blood spot sampling and high-performance liquid chromatographytandem mass spectrometry (HPLC-MS), has been developed in monitoring
tacrolimus levels. Our center favors the use of limited sampling strategy and
abbreviated formula to estimate the AUC0-12. However, it is inconvenient
for patients because they have to wait in the center for blood sampling. We
investigated the application of dried blood spot method in tacrolimus level
monitoring using limited sampling strategy and abbreviated AUC estimation
approach. Duplicate venous samples were obtained at each time point (C0,
C2 and C4). To determine the stability of blood samples, one venous sample
was sent to our laboratory immediately. The other duplicate venous samples,
together with simultaneous fingerprick blood samples, were sent to the
University of Maastricht in the Netherlands. Thirty six patients were recruited
and 108 sets of blood samples were collected. There was a highly significant
relationship between AUC0-12 estimated from venous blood samples and
fingerprick blood samples (r2=0.96, p<0.0001). Moreover, there was excellent
correlation between whole blood venous tacrolimus levels in the 2 centers
(r2=0.97; p<0.0001). The blood samples were stable after long distance
transport. Dried blood spot sampling can be used in centers using limited
sampling and abbreviated AUC0-12 strategy as drug monitoring.
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who were diagnosed as chronic TAC nephrotoxicity by allograft biopsies
showing a characteristic arteriolopathy (PAS-positive hyaline thickening
in small arteries), which underwent at Tokyo Women’s Medical University
between January 2004 and December 2005. Mean age of their recipients was
37.3 years old and they consisted of 11 males and 4 females. The mean age of
their donors was 59.4 years old.
Results: The diagnoses of chronic TAC nephrotoxicities were done at an
average of 54.7 months postoperatively. The severities of arteriolopathy were
moderate in 8 cases and severe in 8 cases. The mean dosage of TAC at the time
of diagnoses was 0.054 mg/kg. Mean trough level of the whole blood TAC
was 5.09 ng/mL which was recognized within so called recommended level.
The moderate to severe arteriosclerosis of medium sized arteries were seen in
twelve (80.0%).
Conclusion: The existence of moderate to severe arteriosclerosis in medium
sized arteries would have the potential of causing chronic TAC nephrotoxicities,
rather than the TAC dosage and the trough level of the whole blood TAC.
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1628 TACROLIMUS ONCE-DAILY PROLONGED RELEASE
VERSUS TACROLIMUS TWICE-DAILY IN COMBINATION
WITH MMF AND STEROIDS – A PHASE III MULTICENTRE
RENAL STUDY
B. Banas, B. Krämer1, B. Charpentier2, L. Bäckman3, H.T. Silva Junior4, G.
Mondragon5, E. Cassuto-Viguier6, G. Mourad7, R. Sola8, E. Ancona9,
J. Ortuno Mirete10
1
University of Regensburg, 2Hôpital Bicêtre, 3Sahlgrenska University
Hospital, 4Fundacao Oswaldo Ramos – UNIFESP, 5Instituto Mexicano de
Transplantes, 6Service de Nephrologie, 7Hôpital Lapeyronie, 8Servicio de
Nefrologia, 9Azienda Ospedaliera di Padova, 10Servicio de Nefrologia
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily
formulation of tacrolimus with similar exposure and trough levels compared to
the well-established twice-daily formulation (Prograf®, PRO). This 12-month
study was designed to compare the efficacy and safety of ADV and PRO in de
novo renal recipients.
Methods: The study was performed in 74 transplant centres and 22 countries.
This was a double-blind, double-dummy study with patients randomised
1:1 to PRO or ADV. Patients received a daily tacrolimus dose of 0.2 mg/kg
combined with MMF 2 g/day (1 g/day after Day 14) and steroid taper (0-5 mg/
day after Day 84). The first dose of PRO or ADV was given within 12 hrs prior
to reperfusion. MMF was also started pre-operatively. For both treatment arms
tacrolimus whole blood trough levels were targeted at 10-15 ng/mL to Day 28,
then 5-15 ng/mL to Day 168 and 5-10 ng/mL thereafter. The primary end point
was the event rate for biopsy proven acute rejection (local BPAR, per protocol
set with non-inferiority comparison set at 10%) at 24 weeks with a further
6-month extended open follow-up. Acute rejection, patient and graft survival,
and creatinine clearance (Cockroft & Gault) were also assessed at 24 weeks and
12 months. Adverse events and safety parameters were recorded throughout.
Results: 336 PRO and 331 ADV patients received at least one dose of study
medication with 275/336 (81.8%) PRO and 257/331 (77.6%) ADV patients
completing the 12-month study. Reasons for withdrawal were similar in both
arms. Key donor and recipient demographics were not significantly different
except for mean HLA-DR mismatch with higher risk for ADV (0.9) vs. PRO
(0.8, p<0.01). Mean daily tacrolimus dose and mean whole blood trough level
at Week 4 for PRO vs. ADV were 0.16 mg/kg and 12.9 ng/mL vs. 0.21 mg/kg
and 12.2 ng/mL, and at Months 10-12 were 0.08 mg/kg and 9.0 ng/mL vs. 0.10
mg/kg and 8.8ng/mL. Kaplan-Meier patient survival at 12 months was 98%
vs. 97% and graft survival 93% vs. 92% (PRO vs. ADV). Similarly, 24-week
local BPAR event rates were 14.9% vs. 18.7% (p=0.239); central blinded
review rates were 14.5% vs. 18.2% (p=0.230). In the per protocol analysis
with major protocol violators excluded (PRO N=291 & ADV N=280), local
BPAR events rates were 15.8% vs. 20.3% (p=0.182; treatment difference
4.5%; 95% CI -1.8%, 10.9%) and central 15.1% vs. 19.6% (p=0.165; 95%
CI -1.6%, 10.8%) falling slightly outside the predefined 10% non-inferiority
margin. When adjusted for HLA-DR mismatch non-inferiority was established
for PRO and ADV for local BPAR event rates (treatment difference 1.9%;
95% CI -4.4%, 8.3%). Creatinine clearance was similar for both arms (mean
at 12 months 67 mL/min in both arms) and adverse event profiles were similar
for both regimens.
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Conclusions: The study demonstrates that once-daily tacrolimus prolonged
release Advagraf® was well tolerated, conferring similar efficacy and safety
profiles to the established twice-daily formulation Prograf®.
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1629 EFFICACY AND SAFETY OF IMMUNOSUPPRESSION
BASED ON TACROLIMUS OR CYKLOSPORINE IN PATIENTS
AFTER KIDNEY TRANSPLANTATION –
A RANDOMIZED PROSPECTIVE STUDY
M. Slupski, Z. Wlodarczyk, M. Tomczak, M. Masztalerz
Department of Transplantation And General Surgery, Collegium Medicum
Nicolaus Co
Objective: The aim of this research was to evaluate the effectiveness and
safety of cni-based immunosupression.
Methods: 150 de novo renal transplant patients were randomized to tacrolimus
(tac group) or cyclosporine microemulsion with mycophenolic acid or
azathioprine and steroids.
Results: There is no statistical difference in 12-month neither in graft and
patient survival nor serum creatinine levels. Steroid-sensitive rejection rate
was higher in cyclosporine group: 20.78% vs. 31.51% (p<0.05). A tendency to
anaemia was observed in tac group: average hemoglobin level after 6 months
was lower in tacrolimus group: 12.3 vs. 12.9 (p=0.047). Bilirubin and AspAT
levels were lower in tacrolimus group (p=0.003. Patients in tacrolimus group
have lower cholesterol and trigliceryds serum levels (p=0.0002).
Conclusion: No differences in renal function during 12-month were observed.
In tacrolimus group we observed ten more cases of aneamia, whereas in
cyclosporine group lipid metabolism and liver function disturbance occurred
more frequently.
Tacrolimus group

Cyclosporine group

p

12 month graft survival

95.59%

96.97%

n.s.

12 month patient survival

98.53%

96.97%

n.s.
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1630 THE EFFECT OF CONVERSION FROM CYCLOSPORINE
TO TACROLIMUS IN RENAL ALLOGRAFT RECIPIENT WITH
HYPERLIPIDEMIA
S. Lee, J.E. Park, S.Y.C. Choi, K-H. Jung, J-Y. Moon, C-G. Ihm, T-W. Lee
Dept.of Nephrology, School of Medicine, Kyunghee University
Background: Calcineurin inhibitors improved the clinical course after
kidney transplantation. However, they have been implicated in contributing
to increased cardiovascular risk. We evaluated the change of blood lipid
and glucose levels and the deterioration of renal function according to the
conversion from cyclosporine to tacrolimus in renal allograft recipient with
hyperlipidemia.
Methods: In our single-center prospective study, 23 adult renal recipients
who were receiving cyclosporine-based regimen with serum total cholesterol
greater than 200 mg/dL more than 1 year after transplantation and minimal
dose of steroid (5 mg or less a day) were enrolled. Cyclosporine was replaced
by tacrolimus. Blood pressure, fasting lipid profile, glucose and HbA1c were
measured at baseline and at 3, 6, 12 months after conversion. The change of
estimated GRF was also compared using data recorded from 1 year before and
after conversion.
Results: There was a significant improvement in total cholesterol (205.5 +/24.3 to 186 +/- 29.6 mg/dL, P < 0.01)) and low-density lipoprotein cholesterol
(119.6 +/- 20.1 to 109.1 +/- 16.8 mg/dL, P < 0.01) after conversion. No new
onset or worsening of diabetes mellitus was observed after conversion. There
were no significant differences in HDL cholesterol, triglycerides, fasting blood
glucose and HbA1c levels.
The deterioration of renal function was significantly stabilized with tacrolimus
(change of eGFR -7.3 +/- 13.5 mL/min under cyclosporine versus -2.9 +/- 13.4
mL/min under tacrolimus).
Conclusion: Our study susggests that conversion to tacrolimus may be
preferable over cyclosporine for chronic maintenance immunosuppression in
renal recipient with hyperlipidemia because it improves cardiovascular risk
factors and leads to stabilization of transplant function.
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1631 FIVE YEARS FOLLOW-UP OF RENAL TRANSPLANT
RECIPIENTS ON ADVAGRAF MONOTHERAPY: A SINGLE
CENTRE EXPERIENCE
M. Christiaans1, M. Gelens1, N. Undre2, M. Mullens1, J. van Hooff1
1
Departement of Internal Medicine, University Hospital Maastricht,
The Netherlands, 2Astellas, London, UK
Introduction: The immunosuppressive protocol for low and intermediate
immunological risk renal transplant recipients in our centre consists of
tacrolimus and low dose corticosteroids. In non-rejectors corticosteroids are
withdrawn within the first 3 months. Therefore almost 70% of our patients
are on one drug, only tacrolimus, as maintenance therapy (ref: Boots et al.
Transplant Int. 2001; 14: 370-83).
Our centre participated in a open label, multicentre study in which stable renal
transplant patients were converted from twice daily formulation of tacrolimus
(Prograf) into a once-daily formulation of tacrolimus prolonged release
(Advagraf).
In this analysis we present the 5-year clinical data of our patients on Advagraf
monotherapy.
Methods: Clinical and laboratory data such as immunosuppressive therapy,
serum Creatinine (median and range), and causes of death, graft failure or
treatment failure were prospectively collected. Time data are given relative
towards time of conversion, unless otherwise stated.
Results: Thirty-two patients on Advagraf monotherapy were included.
Patient characteristics at inclusion were: age 54 year, range 21-64 yr, time
posttransplant 4.6 yr, range 1.3-11.2 yr, serum creatinine 141micromol/L,
range 79-203micromol/l, and donor type: postmortal n=20; living n=10 (4
related,6 unrelated).
Patient survival is 97%. One patient died because of lung cancer with a good
functioning graft (month 28).
There were 4 treatment failures: 2 patients withdraw their consent (resp at month
3 and 6). In the other two patients their immunosuppression was changed (month
24 recurrent squamous cell skin cancer and month 22 recurrent disease).
Graft survival censored for death and treatment failure is 100%.
There were no acute rejections.
In 4 patients serum creatinine increased slowly (10-30%).The cause was in 2
patients a biopsy proven recurrence of IgA nephropathy; in the 2 other patients
the cause is (still) unknown.
Conclusion: In low – and intermediate immunological risk renal transplant
patients with stable renal function 4 years after transplantation on Prograft
monotherapy, conversion towards a single dosage of Advagraf in the morning
as their only immunosupressant, 5-year patient survival is 97% and 5-year graft
survival censored for death and treatment failure 100%.

36 months.
Results: Our population consisted of 70% males, 53% African American (AA),
43% Caucasian and 42% diabetic. Mean transplant vintage was 7.5 years. An
improvement in total cholesterol, LDL cholesterol and Cystatin C was seen in
each TAC group over the course of 36 months compared to CsA group.
Conclusion: Results seen in the multi-center trial at 12 months were sustained
in our single center trial at 36 months. Improvement in renal function was
maintained at 36 months in patients converted from CsA to TAC. These
data suggest that reduced TAC dosing provides long term improvement in
cardiovascular risk factors to renal transplant patients. These benefits were seen
in a cohort of patients who were 53% AA and 42% diabetic and more than 7
years post transplant.
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1633 A RETROSPECTIVE REVIEW OF TACROLIMUS
LEVELS IN RENAL TRANSPLANT RECIPIENTS AND GRAFT
REJECTION
M. Hossain, D. Magrill, M. Morsy, N. Kessaris, R. Chang
St George’s Renal Transplantation Unit
Introduction: In the absence of national guidelines, a retrospective audit
was undertaken to review the current renal transplant immunosuppression
regime. There was a perception that the new Tacrolimus target level (8–10ng/
ml) introduced in May 2007 was too low and more rejections observed. Our
current maintenance protocol includes prednisolone, Mycophenolate Mofetil
and Tacrolimus.
Methods: All transplant recipients (Feb 2003-Oct 2007) were reviewed for the
highest C0 (trough) Tacrolimus level achieved within 7 days post-transplant.
Tacrolimus level of 10ng/ml was considered a cut-of as it represents the highest
target in the current protocol. Rejection episodes within the first 10 days posttransplant were recorded.
Results: This audit included 277 renal transplant recipients. Tacrolimus levels
were ≥;10ng/ml (high group) in 223(80.5%) and <10ng/ml (low group) in
54(19.5%) recipients. Of the low group, 11(20.4%) had rejection compared to
22(9.9%) of the high group (p=0.03). There was a difference between recipients
with high and low Tacrolimus levels with respect to GFR (MDRD) levels at
one year post-transplant, with a mean of 36.7±21.2 in 31 recipients with high
Tacrolimus levels compared to 40.7±24.5 in 246 recipients with low Tacrolimus
levels (p=0.4). Lower GFR levels (31.1±22.5) in rejecting compared with nonrejecting (41.4±24.1) recipients observed (p=0.02).
Conclusion: Trough Tacrolimus level <10ng/mL was associated with more
rejection episodes. The authors feel that the current Tacrolimus target, 8-10ng/
mL is low and needs revision. While rejection and high Tacrolimus level have
adverse effects on the GFR at 1 year, this was not statistically significant when
comparing Tacrolimus level groups (sample size).
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P. Bolin, R. Mirza, P. Sullivan, D. Holbert, K. Parker
Brody School of Medicine, East Carolina University
Purpose: To determine the effect of conversion from Cyclosporine (CsA)
to Tacrolimus (TAC) based therapy on cardiovascular risk factors and renal
function at 36 months assessed by cholesterol, low density lipoprotein (LDL)
and Cystatin C.
Methods: OPTIMA, a 12 month randomized, open label, multi-center study of
323 stable renal transplant recipients currently receiving CsA were randomized
1:1:1 to continue CsA (50-250ng/mL); or convert to reduced TAC (3.0-5.9ng/
mL) or standard TAC (6.0-8.9ng/mL). Improvement in total cholesterol
(p<0.004) and LDL cholesterol (p<0.004) was observed in both TAC groups
compared with CsA group at 12 months. Renal function improved in the
reduced TAC group compared to CsA (p<0.001). Sixty patients from our center
completed the 12-month OPTIMA trial and were followed for an additional
2 years to determine if these benefits could be sustained for 3 years. Patients
were assessed for renal function and cardiovascular risk factors at year 24 and

1634 COST EFFECTIVENESS COMPARISON FOR
TWO IMMUNOSUPPRESSIVE REGIMENTS IN KIDNEY
TRANSPLANTATION
H. Vacher-Coponat1, M. Indreies1, V. Moal1, R. Purgus1, J.F. Moussi1, B.
Dussol1, P. Brunet1, Y. Berland1,2
1
Nephrology and transplantation Unit, AP-HM, Hopital Conception,
Marseille, France, 2Centre d’investigation clinique, AP-HM, Hôpital
Conception, Marseille, France, 3Université de la méditerranée Aix-Marseille
2, Marseille, France
Background: Used since the 1990s, tacrolimus (Tac) and mycophenolate mofetil
(MMF) became the principal immunosuppressive drugs used in transplant
centers. Their superiority for acute rejection prevention, but not in term of
renal survival, has been showed when compared with the more older molecules
cyclosporine (CsA) and azathioprine (Aza). Rates of acute rejections (AR)
having diminished these last years for more than 40% to about 10% for various
causes, we have evaluated the real impact of this expensive drugs today. So, we
have conduced a randomized trial for compare two sequential quadritherapies
associating rabbit anti-thymocytes, steroids, anticalcineurine and antimetabolic
drugs (Cisclosporine microemulsion associated with Azathioprine (CsA/Aza)
or Tacrolimus with Mycophenolate Mofetil (Tac/MMF)). We report here the
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cost-efficiency analysis for this two immunosuppressive regiments
Patients and methods: 289 patients were included in this prospective, openlabel, randomize, monocentric study after written consent. The primary end
point was the rate of clinical suspected acute rejections during the first year,
with an expected rate to 25% in the CsA/Aza group and an envisaged reduction
risk to 50% with Tac/MMF
Results:
Acute Rejection
Clinically suspected
patients number
events number
Biopsy confirmed
Patients number
total
Kidney death
Patient death
Creatinine (mmol/l)
DGFe (MDRD)
Hemoglobin (g/dl)
Delayed Graft Function
Treatment at M12
CsA/Tac posology (mg/J)
Aza/MMF posology (mg/J)
Withdrawal/switch CsA/Tac
Withdrawal/switch Aza/MMF
Cost for immunosuppressive drugs (day)
Antimetabolic agents (€ /j)
anticalcineurine (€/j)
Secondary effects
CMV Diseases
Cancers
Skin
PTLD
Miscellaneous
Diabetes at M12 (Treatment)
Total de novo
Treated with insulin
HbA1C >6%
HTA (treated) at M12
Hyperlipidemia at M12
Treated with statins
Cholesterol (mg/l)
LDL (g/l)
Triglycerids (g/l)

CSA/Aza
nb (%)

Fk/MMF
nb (%°

p

21(14,4%)
26

11 (7,7%)
13

ns
ns

21(14.4%)
23
6 (4.1%)
2 (1.4%)
148.9 ±55.59
47.7 ±1.4
12.8 ±1.7
23.4%

8 (5.6%)
9
10 (6.9%)
4 (2.8%)
134.9 ±56.08
52.7 ±1.4
13.4 ±1.6
30.9%

<0.05
<0.02
ns
ns
0.044
0,0106
0.008
ns

234.2 ±5.9
83.9 ±8.9
5.11%
17.2%

5.8 ±0.2
1263 ±61.1
5.51%
16.4%

NA
NA
ns
ns

7.97 ±0.38
10.25 ±0.31

0.54 ±0.06
15.17 ±0.72

<0.0001
<0.0001

27.6%
5
2
2
1

39.6%
3
1
1
1

0.034
ns

8%
4.80%
41.5%
86.86%

12.61%
5.88%
44%
74.22%

ns
ns
ns
<0.01

56.93%
2.10 ±0.48
1.27 ±0.78
1.59 ±0.87

41.41%
2.04 ±0.43
1.35 ±1.32
1.57 ±1.00

<0.02
ns
ns
ns

Conclusions: The primary end point, clinical suspected acute rejection, was not
significantly different between the two groups. With Tac/MMF, renal function
was improved for 5 ml/min and the biopsies confirmed acute rejection rate was
slightly lowered. These results are obtained with more CMV infections and an
additional cost of 320 € (480$ US) each month. So, with rabbit antithymocyte
induction, CsA/Aza remains a valid alternative to more expensive treatments
Tac/MMF.
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1635 LONG-TERM CARDIOVASCULAR RISK IN RENAL
TRANSPLANTED PATIENTS RECEIVING CALCINEURIN
INHIBITORS DRUGS: EXPERIENCE OF A SINGLE CENTER
I. R. Vicente1, J.V. Torregrosa1, J. Cantoni2, F. Oppenheimer1,
J.M. Campistol1
1
Renal Transplant Unit. Department of Nephrology and Renal Transplant.
University Clinic Hospital, 2Bioclever. Barcelona
Introduction: Cardiovascular (CV) pathology is the first cause of death after
kidney transplantation. The estimated CV risk usually used in the general
population is not usefull to the transplant recipient. The objective of this study
is to know the risk factors that contribute to the high CV in our area.
Methodology: This is a retrospective study of patients receiving calcineurin
inhibitors with a follow-up of 5 years. We collected epidemiologic and clinical
data related to CV (familiar and personal history, medication, blood pressure,
and metabolic profile) before and after transplantation and immunosuppressive
therapy, renal function and graft and patient survival. Univariant analysis
of Cox, the Bonferoni test and multivariate analysis (automatic method for
selection of variables “stepwise”, for logistic method “Likelihood “ and “wald”
test) were applied (SAS vs 9.1)
Results: 189 patients with a mean age of 50.8 ± 16,03 years were included
(62.23% males). The mean follow up was 98.81 ± 89.13 months. 12.7% had pre
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transplant CV disease. The incidence of CV events after transplantation was of
15.34% (18 with ischemic heart disease, 6 with cerebrovascular disease and 9
with peripheral vascular disease). We find that age, etiology of renal disease,
CV disease, arterial hypertension, vascular calcification, hyperlipidemia and
obesity, and levels of glycoside hemoglobin before transplantation, were
significantly related to CV risk after transplantation. During the follow-up,
new-onset diabetes mellitus (NODM), renal function, use of the antiplatelet,
lipid- lowering and antihypertensive drugs, and levels of lipids and uric acid,
were significantly related to CV risk. Immunosuppressive therapy and arterial
hypertension (43,39% had a good control of blood pressure) did not show
statistical significance relation with CV risk.
Conclusion: In transplanted patients receiving anticalcineurinic drugs, renal
function, lipid profile and NODM are the main modificable CV risk factors.

CONCURRENT ORAL SESSION 116: EVEROLIMUS
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1636 EVEROLIMUS-ASSOCIATED PNEUMONITIS
J. Otton1, C. Hayward1, A. Keogh1, E. Kotlyar1, P. Macdonald1, M. Malouf1,
A.R. Glanville1
1
Heart and Lung Transplant Unit, St Vincent’s Hospital, Sydney
Although pulmonary toxicity from sirolimus was first reported in 2000, the
biochemically homologous everolimus has been thought to be free from this
side effect. Indeed, everolimus has been proposed as an alternative agent to
sirolimus in some cases of sirolimus pulmonary toxicity.
We report two cases of acute onset and one case of sub-acute onset
pneumonitis in association with everolimus therapy for heart transplantation
immunosuppression. Serum everolimus levels were within or below
typical therapeutic range at the time of onset of pneumonitis. In each case
marked dyspnoea manifested as the primary symptom and was mirrored by
hypoxia and the radiological appearance of bilateral pulmonary interstitial
infiltrates on chest x-ray and computed tomography. The pneumonitis
was associated with a normal white cell count but raised serum c-reactive
protein. Symptoms and imaging improved or normalised after cessation
of everolimus.
Investigations for alternative diagnoses were negative. The bronchoalveolar
lavage (BAL) in the two acute cases showed an increased neutrophil count in
the absence of a significantly raised lymphocyte count. Culture of the BAL was
negative as was indirect fluorescent assay (IFA) and serology for viruses and
other respiratory pathogens. Left ventricular function on echocardiography and
endomyocardial biopsies were normal.
Pt

Age

Time from Everolimus Time to
transplant level
onset

Time to
recovery

Negative investigations
for other causes

1

32

3 days

7.9 ng/ml

2 weeks

2 weeks

BAL, IFA, serology,
echocardiogram,
endomyocardial biopsy

2

69

13 years

2.8 ng/ml

2 weeks

8 weeks

BAL, IFA, serology,
echocardiogram,
endomyocardial biopsy

3

60

15 years

5.5 ng/ml

6 months

3 months

Echocardiogram,
endomyocardial
biopsy.

We consider that these cases provide evidence to support an everolimusinduced pneumonitis based on the temporal course, radiographic features and
absence of other causative factors despite extensive investigation. We conclude
that everolimus-induced pneumonitis should be considered as part of the
differential diagnosis of pulmonary infiltrates and dyspnoea in the transplanted
patient receiving everolimus therapy.
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1637 METABOLIC CHANGES FOLLOWING CONVERSION
FROM AN ANTICALCINEURINC BASED THERAPY TO AN
EVEROLIMUS BASED ONE. A SINGLE CENTER EXPERIENCE
J. Morales, M. Ayala, A. Fierro, C. Herzog, L. Calabran, E. Buckel
Centro de Trasplante Clínica Las Condes
Everolimus (EVL) a mammalian target of rapamycin antagonist has been
recently introduced into solid organ transplantation either associated to
low dose of anticalcineurincs (CNI) or replacing them in order to avoid
nephrotoxicity and chronic allograft nephropathy. Due to molecular similarities
with Sirolimus it has been expected the same incidence of metabolic changes
and adverse events; this is intensively investigated at the present time. We
studied retrospectively recipients of kidney allograft converted from CNI to
EVL during a 12 months period. Patients received a standard dose of EVL
starting with 1.5 mg/day, afterwards titrating the dose in order to get trough
levels in the range of 3 to 5 ug/ml. Patients effectively achieved mean EVL
trough levels of 5.2 ug/ml, 4.0 ug/ml and 4.5 ug/ml at 1, 6 and 12 months
respectively. One year following conversion calculated creatinine clearance
increased from 57 to 63 ml/min and proteinuria did not change. Fasting blood
glucose levels decreased significantly following conversion to EVL. During
the same time period no significant changes were observed in body weight,
body mass index, serum albumin, cholesterolemia, triglyceridemia, HDL
cholesterol, LDL cholesterol, lowering lipid medication requirements, blood
magnesium and uric acid. We conclude that EVL does not negatively influence
different nutritional parameters.
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1638 EVEROLIMUS-BASED SEQUENTIAL
IMMUNOSUPPRESSION IN EXTENDED-CRITERIA DONORS
RENAL TRANSPLANTATION: ONE-YEAR RESULTS OF AN
OBSERVATIONAL STUDY

HPK2
TX n
ECD n (%)

POD 25
20
13 (65)

30
20
13 (65)

90
19
13 (68)

180
17
13 (76)

210
12
9 (75)

365
10
8 (80)

543±174
5.5±2.6
1.74±.87

269±162
7.9±3.7
1.51±.65

264±97
9.2±3.1
1.61±.42

285±115
9.2±2.7
1.57±.37

266±96
9.8±1.9
1.75±.42

282±72
7.8±1.9
1.89±.44

Drugs levels are ng/ml; SCr is mg/dl - ECD: Extended Criteria Donors
After one year, one pt is off CyA (85 years old donor) and one is off steroid
(PTDM); the mean daily doses of drugs are: Ev 1.3 mg, CyA 67 mg and steroid
3.8 mg.
Conclusions: In a cohort of grafts with a high proportion of ECD donors, the
sequential HPK2 protocol gave satisfactory results. This drug combination is
easy to handle, since Ev and CyA target levels are reached within 10 days after
switch. In our serie, WHP don’t seem to be linked to Ev. The slight increase in
SCr after six mos could be explained by drugs levels above the target and/or by
the increasing prevalence of ECD donors over time. Increasing our case-load
and closer tapering of drugs will allow a comparison of these different factors.
Protocol biopsy around 9-12 mos could address the question of sub-clinical
rejection.
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1639 THE RISK OF WOUND HEALING COMPLICATIONS IS
COMPARABLE IN PATIENTS TREATED BY EVEROLIMUS
VERSUS MPA IN THE EARLY PHASE AFTER KIDNEY
TRANSPLANTATION
C. Legendre5, M-C. Moal1, E. Cassuto2, L. Rostaing3, F. Berthoux4,
F. di Giambattista6, J. Dantal7
1
Hôpital La Cavale Blanche, Brest, France, 2Hôpital Pasteur, Nice, France,
3
Hôpital de Rangueil, Toulouse, France, 4Hôpital Nord – CHU, Saint Etienne,
France, 5Hôpital Necker, Paris, France, 6Novartis Pharma SAS, RueilMalmaison, France, 7Hôpital Hôtel Dieu, Nantes, France
Introduction: The proliferation signal inhibitor (PSI) sirolimus has been
associated with delayed tissue regeneration following initial transplant surgery.
After the introduction of everolimus (EVL), a PSI with a more favorable
pharmacokinetic profile, markedly fewer post-surgical complications have
been observed in de novo cardiac transplantation compared with mycophenolic
acid (MPA). We report here a post-hoc analysis of the incidence and type of
wound healing complications in kidney transplant patients randomized to EVL
or MPA during the first 4 weeks post-transplant.
Methods: CALLISTO was a multicenter, open-label, 12-month study in de
novo deceased-donor kidney transplant patients at protocol-specified risk of
delayed graft function (donor age >55 years, cold ischemia time ≥24 hours
and <40 hours, or second/ subsequent transplant). For the first 4 weeks posttransplant, patients were randomized to receive (a) EVL initiated ≤48 hours
post-transplant at a starting dose of 1.5mg/day, adjusted to target trough level
3-8ng/mL, with low-exposure cyclosporine (CsA; C2 target 500-700ng/mL) or
(b) MPA according to local practice with standard CsA (C2 target 1100-1500ng/
mL). All patients received steroids and anti-IL-2 receptor induction. Wound
healing complications were classified as fluid collection, wound dehiscence
or urine leak.
Results: 65 EVL and 74 MPA patients were recruited. Demographics were
similar, including risk factors for wound healing complications (recipient age
57.3±10.5 years versus 58.4±9.9 years; BMI 24.0±3.4kg/m2 versus 24.6±3.5kg/
m2, respectively). EVL exposure was within target range of 3-8ng/mL. Mean
MPA dose at week 4 was 1427±175mg/day. Mean CsA C2 at week 4 was
854±213ng/mL and 1105±281ng/mL in the EVL and MPA groups, respectively.
Biopsy-proven acute rejection occurred in 3 EVL patients (4.6%) and 1 MPA
patient (1.4%) by week 4. Study drug was discontinued due to wound healing
complications in 1 EVL patient (1.5%) and 2 MPA patients (2.7%). Wound
healing complications reported as serious adverse events within 4 weeks
occurred in 2 (3.1%) and 4 (5.4%) patients in the EVL and MPA groups,
respectively. Overall, wound healing complications reported as adverse events
were distributed equally between groups at 4 weeks (Table).
Conclusions: EVL with low-exposure CsA or MPA with standard-exposure
CsA as initial immunosuppression after kidney transplantation are associated
with a similar profile of wound healing complications.
Incidence at week 4
Wound dehiscence
Urine leak
Total wound healing complications
Fluid collection on protocol ultrasound

Everolimus (n=65)
0 (0.0%)
2 (3.1%)
14 (21.5%)
18/49 (36.7%)
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MPA (n=74)
2 (2.7%)
3 (4.1%)
17 (23.0%)
19/55 (34.5%)
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L. Benozzi, D. Bonucchi, G. Cappelli, F. Ravera, D. Davoli, V. Albertazzi,
Z. Gissara, G. Mori, A. Albertazzi
Nephrology, Dialysis and Kidney Transplantation. Policlinico Hospital –
Modena
Introduction and aims: According to Everest Study, suggesting the usefulness
of high-dose everolimus (Ev) in combination with low-dose Cyclosporine
(CyA), we started an observational, not randomized, single center study
aimed to protect patient (pt) and graft (G) against early and late transplant
complications. Due to the increasing utilization of extended criteria donors
(ECD), it is very hard to face at once delayed graft function (DGF), acute
rejection (AR), wound healing problems (WHP), chronic allograft nephropathy
and long-term CNI toxicity.
Methods: HPK2 includes basiliximab on POD 0 and 4, Mycophenolic Acid
720 mg bid from POD 0 till switch to Ev (maximum overlap allowed 7 days),
delayed Cyclosporin A (CyA) at 2 mg/kgBW bid since serum creatinine (SCr)
is < 3 mg/dl (target C2 around 1000 ng/ml). On POD 21 Ev is started (0.75
mg bid) and targeted to TLC between 8-10 ng/ml, while CyA is reduced to C2
around 350 ng/ml. Steroid is started at 16 mg/day, after a 500 mg bolus during
surgery and 200 mg on POD 1. Steroid is tapered to 4 mg/day within 45 days.
After 6 mos, target levels are 6-8 for Ev and 250 for CyA C2.
ECD donors accounted for 13/20 G: 6 double G with a mean Karpinsky score
(Ks) of 4.5 and 7 single G (mean Ks 2.7).
Here we present results of 20 pts followed-up for a mean of 12 mos (range
3-25). Outcomes were Ev TLC, CyA C2 and SCr from POD 25 to 365, pts and
G survival, drop-outs, prevalence of post-transplant diabetes (PTDM).
Results: Four out of 24 patients were excluded before switch to Ev because
of WHP. We observed 3 DGF (15%), 4 biopsy proven AR (3 Banff 1a and 1
Banff 1b) at 7,70,90 (drop-out) and 100 POD (20%). Two acute miocardial
infarctions (1 fatal after 3 mos) occurred (Pts survival 95%); death-censored G
survival was 95%. PTDM occurred in 3 pts (15%).
High protection K2 - Drugs levels and graft function by Post-Operative Day
(POD) after transplantation

C2 CyA m±sd
Evero m±sd
SCrm±sd

Wednesday 13 August 2008

Poster Abstracts

POSTER BOARD NUMBER P3 – 66

WEDNESDAY

1640 MULTI-CENTER, OPEN-LABEL, PROSPECTIVE,
RANDOMIZED, PARALLEL GROUP STUDY INVESTIGATING
AN EVEROLIMUS-BASED CNI-FREE REGIMEN IN
COMPARISON TO A CYCLOSPORINE-BASED STANDARD
THERAPY IN DE NOVO RENAL TRANSPLANT PATIENTS
(ZEUS STUDY)
K. Budde1, J. Klempnauer2, W. Arns3, C. Sommerer4, P. Reinke5,
U. Eisenberger6, W. Fischer7, S. Kramer7, F. Pietruck8
1
Nephrology, Charité, Berlin, Germany, 2Department of Visceral and
Transplantation Surgery, Hannover Medical School, Hannover, Germany,
3
Cologne General Hospital, Merheim Medical Centre, Cologne, Germany,
4
Department of Nephrology, University Hospital, Heidelberg, Germany,
5
Department of Nephrology and Internal Intensive Care, Campus Virchow
Clinic, Charité University Medicine, Berlin, Germany, 6Department of
Nephrology and Hypertension, University Hospital of Bern, Switzerland,
7
Novartis, Nuernberg, Germany, 8Department of Nephrology, University
Hospital, School of Medicine, Essen, Germany
The ultimate aim of immunosuppressive therapy in transplantation is to
provide an efficacious regimen while minimizing non-immune toxicities.
By combining synergistic drugs, it may be possible to reduce the exposure
to individual agents and therefore avoid adverse effects whilst maintaining
favorable clinical outcomes. Until now, no therapy has been recognized
as being efficient in the prevention of long-term allograft loss due to
chronic allograft dysfunction (CAD) reflecting an unmet medical need in
transplantation. Therefore, the use of antiproliferative drugs like Everolimus
in combination with the withdrawal of CNI has become an interesting concept
in treating calcineurin inhibitor toxicity leading to chronic slow deterioration
of renal allograft function.
Therefore, the purpose of the here presented ZEUS study was to assess whether
an Everolimus-based CNI-free regimen is as safe and well-tolerated as the
Cyclosporine-based standard regimen but results in a better renal function.
This 1-year, prospective, open-label, randomized, parallel group, controlled
study compared the efficacy, safety and tolerability of an immunosuppressive
regimen with Everolimus and EC-MPS to that of Cyclosporine (CsA) and ECMPS in renal allograft recipients.
The study population consisted of a representative group of 300 de novo
kidney transplant recipients. For the first 4.5 months post transplantation, all
patients were treated with Basiliximab as induction therapy, CsA, EC-MPS
and corticosteroids. 4.5 months post-transplant patients were randomized
1:1 to either a) (n=150) continue the current regimen of CsA and EC-MPS
(720mg BID) or b) (n=150) to convert from CsA to Everolimus over a 4
week period and continue with Everolimus (adjusted according to trough
levels of 6-10 ng/ml) and EC-MPS (720mg BID). Corticosteroids were
prescribed according to center practice with a minimum dose of 5 mg/day.
The efficacy of the two treatment arms was assessed by the determination
of Glomerular Filtration Rate (GFR), calculated according to Nankivellmethod (primary endpoint), Cockcroft-Gault method, and MDRD method,
Serum creatinine and slope of creatinine and rejection episodes (treated
and biopsy proven), graft loss, death, lost to follow up, as well as treatment
failure as a composite endpoint. The patients will be followed-up for safety
and graft survival for additional 4 years. At the ICTS we will present the
data on the primary and secondary endpoints, safety and efficacy of 285
randomized patients.
In summary, the ZEUS study results are adequate for investigating the influence
of different immunosuppressive regimens with or without CNI on short- and
long-term renal function. Our data – which will be presented at ICTS - will
contribute to the knowledge about CNI-free regimens in renal transplantation.
Furthermore, the study will shead some light to the important question about
the time point of switching the immunosuppressive regimen from a CNI-based
to a CNI-free therapy.
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1641 EFFICACY AND SAFETY OF EVEROLIMUS
WITH LOW DOSE CYCLOSPORINE A COMPARED
WITH MYCOPHENOLATE MOFETIL AND FULL DOSE
CYCLOSPORINE A IN DE NOVO RENAL TRANSPLANT
RECIPIENTS
G. Miserlis, V. Papanikolaou, G. Vergoulas, N. Antoniadis, I. Fouzas, D.
Vrochidis, A. Papagiannis, G. Imvrios, D. Giakoustidis, D. Takoudas
Organ Transplant Unit,Hippokration General Hospital, Thessaloniki, Greece
Proliferation signal inhibitors (mTOR inhibitors) are used in combination with
calcineurin inhibitors for acute rejection prophylaxis and prevention of chronic
rejection in renal transplantation.
The purpose of the study was to evaluate and compare the efficacy and safety
of two different immunosuppressive protocols (Group A: steroids, everolimus,
reduced dose CsA, basiliximab vs. Group B: steroids, MMF, full dose CsA,
basiliximab) in de novo renal transplant recipients (RTR).
The analysis included 74 RTR (Group A: 33 pts, Group B: 41 pts) transplanted
between January 2005 and March 2007. Recipients and donors mean age
were 44.5 and 57.8 years respectively. Sixteen patients (48.5%) from group
A and 27 pts (65.9%) from group B had received the kidney allograft from
deceased donors. Everolimus and CsA starting dose in group A were 2mg/d
and 2mg/KgBW/d while MMF and CsA dose in group B were 2g/d and 5mg/
KgBW/d respectively. The mean (±SD) GFR was higher in group A than in
group B patients (60.3±14.7 vs 51.3±15.8 ml/min/1.73m2 ,p<0.05) six months
post transplantation. There was not noticed any significant difference of GFR
between the two groups 1 and 12 months after transplantation. Serum creatinine
and urine albumin did not differ significantly between the two groups 1, 6 and
12 months post transplantation. Total and LDL cholesterol were statistically
significant increased in RTR on immunosuppressive regimen with everolimus
at 6 and 12 months after transplantation. (T-cholesterol of group A, 6 and 12
months post transplantation: 278.48±70.98mg/dl and 259.29±84.67mg/dl vs
T-cholesterol of group B: 217.37±76.39mg/dl and 202.6±59.21mg/dl, p<0.05
and LDL of group A, 6 and 12 months post transplantation: 187.66±56.97mg/
dl and 178.47±50.31mg/dl vs LDL of group B: 131.39±35.58mg/dl and
126.18±30.54mg/dl, p<0.05). The incidence of biopsy proven acute rejection
(BPAR) was 12.1% (4 pts) in group A vs 22% (9pts) in group B. CMV infection
occurred in 3 RTR of group A and in 5 of group B. Everolimus trough levels
ranged from 3.35 to 9.18ng/ml in group A. CsA dose was reduced by 27.5%
and 31.3% at 12 and 18 months post transplantation in group A and this was
resulted in reduction of CsA C2 levels by 38.21% and 45.5% at the same time
intervals. In conclusion, although mTOR inhibitors are associated with several
class specific adverse reactions (hyperlipidemia), concentration-controlled
everolimus therapy of de novo renal transplant recipients provide effective
protection against rejection with good renal allograft function when used in
combination with reduced dose CsA, steroids and basiliximab.
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1642 EARLY DIAGNOSIS OF HEPATIC ARTERY THROMBOSIS
AFTER LIVER TRANSPLANTATION WITH AN ICGCLEARANCE NON-INVASIVE TECHNIQUE
F. Saliba, E. Levesque, S. Benhamida, P. Ichaï, D. Azoulay, R. Adam,
D. Castaing, D. Samuel
Hopital Paul Brousse, Centre Hépato-Biliaire, Université Paris Sud, Unité
INSERM N°785, Villejuif-FRANCE
Hepatic artery thrombosis (HAT) is a life threatening complication that occurred
in 2 to 12% of liver transplant recipients. The diagnostic performance of Dopplerultrasonography (D-US) is reported to be excellent with 91% sensitivity. False
positive results, i.e. non-visualization of flow, are considered to be a limitation of
this exam and an angiography or a CT angio-scan is usually required.
Methods Indocyanine green clearance (Cl-ICG) is used to measure the hepatic
function and the hepatic blood flow. Recently, with the LiMON® system, the
Plasma Disappearance Rate of Indocyanine Green (PDR-ICG) assessment is
available by a non-invasive pulse-densitometric method. Serial daily D-US and
PDR-ICG measurements were performed after liver transplantation. For each
measurement, 0.25 mg/Kg of ICG was given through a peripheral vein.
In a routine screening of 72 liver transplant recipients for PDR-ICG (299
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measurements), D-US revealed in seven patients a complete stop of blood
flow in the hepatic artery. The characteristics of these 7 patients, PDR-ICG
and angiography results are shown in the table. In patients 4 to 7, the presence
of HAT (early post-OLT), confirmed by angiography, was associated with
extremely low values of PDR-ICG. Moreover, the treatment of hepatic artery
thrombosis (surgical repair or retransplantation) was followed with a PDR-ICG
increase. In one delayed HAT after OLT, the same result was obtained. In the
three other patients (patients 1 to 3), the HAT diagnosis has been eliminated
either by angiography (patient n°1), CT angio-scan (patient n°2) or by a second
D-US showing the presence of flow in the hepatic artery the following days
(patient n°3). In these three cases, the PDR-ICG remained normal.
Conclusion In this report, we suggest that Green Indocyanine elimination
reflected by the PDR-ICG as measured by a non-invasive technique, may be of
major help in the diagnosis of HAT when the D-US is difficult to interpret and
allow a rapid salvage decision.
Patient
Age / Gender
Etiology of Liver
Disease
Absence of flow on
D-US (days post LT)
ASAT/ALAT (IU/l)
Total Bilirubin (μmol/l)
Gamma GT (IU/l)
Prothrombine time (%)
PDR-ICG (%/min)
Angiography results

1

2

3

4

5

6

7

46/M

/M

45/M

49/M

28/F

32/M

63/M

Acute
Liver
Failure

FAP

FAP

Day 2

Day 22

Day 2

253/378 4079/2281 287/237
578
25
69
43
50
595
15
50
75
9.5
0.4
1.1

35/56
18
59
66
8.7

HBV
HCV
Alcoholic HCV
cirrhosis
Cirrhosis
Cirrhosis cirrhosis
+ HIV
+ HIV
Day 2

Day 3

Day 4

512/589
20
33
42
24

65/163
43
125
69
28.9

21/45
29
103
84
17.2

No HAT

Day 3

HAT

PDR-ICG: Plasma Disappearance Rate of Indocyanine Green, HAT: Hepatic Artery Thrombosis
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1643 COMPARISON OF RADIOIMMUNOASSAY VERSUS
MASS SPECTROSCOPY IN MONITORING OF EVEROLIMUS
LEVELS

1644 EVEROLIMUS WITH LOW TACROLIMUS DOSE IS AN
EFFECTIVE AND SAFE IMMUNOSUPPRESSIVE REGIMEN IN
RENAL ALLOGRAFT RECIPIENTS
E. Savvidaki, D. Goumenos, K. Fourtounas, P. Kalliakmani, E. Papachristou,
A. Belas, J.G. Vlachojannis
University Hospital of Patras
The significant improvement of the short-term graft survival, observed in renal
transplantation over the last decades with the development of new and effective
immunosuppressive agents, is not followed by improvement of the long-term
graft survival. One of the leading causes of graft loss is the development of
chronic allograft nephropathy that is related to long-term administration of
calcineurin inhibitors (CNIs). Everolimus, a proliferating signal inhibitor
targeting on m-TOR, is a non-nephrotoxic new immunosuppressive drug. The
combination of everolimus with low cyclosporin dose (target C2 blood levels
200-250ng/ml) represents an effective and safe regimen followed by better
preservation of renal function than regimens using higher doses of cyclosporin.
In this study the effectiveness and safety of combination of everolimus with
low tacrolimus dose (target trough levels 3-5ng/ml) is investigated.
Fourteen renal allograft recipients, 8 males and 6 females, aged 42„b11 years old
were included in the study. All patients received induction therapy with basiliximab
and combination of methylprednisolone, tacrolimus and mycophenolate mofetil
(MMF) (850„b400 g/day). MMF was replaced by everolimus after a mean
period of 20 months because of the development of significant side-effects
(leucopenia and gastrointestinal intolerance). In 7 patients the tacrolimus dose
remained unchanged after the commencement of everolimus (trough blood
levels 8„b1 ng/ml) for a period of 12„b5 months and then it was reduced by
50% (trough blood levels 4„b1 ng/ml). In the rest 7 patients low tacrolimus dose
was used from the beginning of everolimus administration. Everolimus blood
levels were maintained between 3 and 8 ng/ml over the period of treatment of
18„b13 months. No rejection episodes were observed in patients treated with
higher or lower tarcolimus doses. A significant improvement of renal function
was observed in 7 patients treated with higher tacrolimus dose after reduction
of the dose (calculated GFR (MDRD6) 44„b17 ¡÷ 51„b18 ml/min, p=0.005).
Furthermore a trend towards improvement of glomerular filtration rate was
noted in the 7 patients treated by low tacrolimus dose from the beginning of
everolimus administration (GFR 61„b24 ¡÷ 67„b21 ml/min). Overall the renal
function of 14 renal allograft recipients was significantly improved during the
period of treatment with everolimus (GFR 52„b22 ¡÷ 61„b25 ml/min, p=0.01).
Leukopenia disappeared and gastrointestinal intolerance showed remission in
all patients after MMF discontinuation. No serious side-effects were observed
with everolimus. The drug was discontinued only in 1 patient because of skin
infection. Antilipemic agents were necessary in 12 of 14 everolimus treated
patients because of increase of triglykerides, Total and LDL cholesterol by 24%,
27% and 41% respectively. In 3 patients anemia (Hb<12g/dl) was observed that
was managed by administration of erythropoetin.
In conclusion, everolimus with low tacrolimus dose represents an effective and
safe therapeutic regimen leading to improvement of renal function of renal
allograft recipients and it is not followed by serious side-effects.
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1645 CLINICAL EXPERIENCE IN THE FIRST YEAR AFTER
CONVERSION TO AN EVEROLIMUS-BASED COMBINATION
REGIMEN IN RENAL TRANSPLANT RECIPIENTS
J.C. Ruiz1, A. Sánchez-Fructuoso2, M. Rengel3, D. Ramos4, J.J. Plaza5,
S. Zárraga6, A. Andrés7, P. Errasti8, A. Fernández9
1
Hospital Universitario Marqués De Valdecilla, 2Hospital Clínico San
Carlos, 3Hospital Gregorio Marañón, 4Hospital La Fe, 5Fundación Jímenez
Díaz, 6Hospital Cruces, 7Hospital 12 de Octubre, 8Clínica Universitaria de
Navarra, 9Hospital Ramón y Cajal
Introduction: While clinical trials have shown the efficacy of everolimus
(EVL) in combination with CsA, there is little experience in other combinations
or with complete calcineurin inhibitor (CNI) elimination, in rutine clinical
practice. We describe the clinical experience in a large series of patients (from
23 transplant centers in Spain) converted to EVL in stable phase and the followup for the 12-month period after conversion.
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S. McGinn1, A. Caswell1, A. Jackson1, T. McGee1, D. Chesher1, J. Ray2
1
Royal North Shore Hospital, 2St Vincent’s Hospital
Long term calcineurin inhibitor use in transplant recipients (CNIs) has
been correlated with nephrotoxicity and reduced long term graft survival.
Consequently CNI-sparing protocols have been developed using agents such
as everolimus the proliferation signal inhibitor/mammalian target of rapamycin
inhibitor (mTORi). Everolimus is extensively metabolized resulting in several
hydroxylated and demethylated metabolites. These can interfere with the
standard immunoassay used for measuring trough drug levels and hence
given the small range allowed for clinical dose adjustment (3-8ng/ml) and in
particular 5-8 ng/ml for those at increased risk of rejection, the aim of this study
was to assess the safety of the fluorescence polarization immunoassay (FPIA)
for the measurement of everolimus concentrations in whole blood against the
gold standard mass spectroscopy (LC-MS).
Methods: Whole blood samples were taken from renal transplant patients
attending outpatient department at Royal North Shore Hospital between
April and July 2007. and everolimus trough levels were measured using both
immunoassay (Innofluor, Certican Assay System) and mass spectroscopy.
Results from the FPIA were compared with LC-MS using regression analysis,
while the distribution of the differences in everolimus concentrations with the
two methods was assessed using Bland Altman approach.
Results: One hundred and ten samples were analysed from thirty patients.
The cost of analysis by FPIA was $3316.5(AUD) versus $16500(AUD)by LCMS. The everolimus levels ranged from 1-22 ng/ml(FPIA) and from 0-18.9
ng/ml(LC-MS). Regression analysis showed a good correlation with multiple
correlation coefficient of 0.95. However using Bland Altman plot, trough levels
were consistently higher with FPIA method, the mean difference was 1.1ng/ml
higher with a standard error of 0.1ng/ml (P < 0.001) suggesting interference
from metabolites.
Conclusion: Everolimus trough levels measured by FPIA are cost efficient but
consistently higher than those measured by Mass Spectroscopy. Consequently
interpretation of levels by FPIA should be made cautiously in those patients
who are at increased risk of rejection

POSTER BOARD NUMBER P3 – 70

Wednesday 13 August 2008
Methods: 429 stable renal transplant patients, who initiated EVL in clinical
practice, were reviewed in a prospective, longitudinal, observational study with
cross sections at basal, and 1, 3, 6, and 12 months after EVL initiation. Results
are presented at the end of the study (12th month).
Results: Mean age of patients at conversion was 57¡À13 years (23¨C80) and
68% were male. Mean time since transplant was 7.9¡À5.7 years (0.3¨C26.0).
13.8% of patients had at least one previous failed kidney transplant.
Main indications for the introduction of EVL were: the diagnosis of a malignant
neoplasm (37.1%), nephrotoxicity & chronic allograft nephropathy (26.1%), and
elective prevention (26.3%). 96% of patients were under a CNI-based regimen.
At the end of the follow-up period CNI had been eliminated in 83% of patients,
being EVL the main immunosuppressor. In 11 cases (2.5%) an acute rejection
was reported but in all cases this was Banff-tipe I (a or b) and steroid sensitive
Before conversion a trend to progressive renal function deterioration was evident
(p=0.04), after conversion a trend to a better renal function, at 12-months,
(p=0,002) was observed. This findings were also seen in the sub-group of
patients converted due to chronic allograft nephropathy. The improvement in
renal function was more evident in those patients converted during the first
3 years after transplantation. In patients with proteinuria ¡Ý500mg/day at
baseline there was no improvement in renal function. However in those cases
with proteinuria <500mg/day, even in patients with a creatinine clearance ¡Ü
40ml/min there was an improvement in renal function.
Transplant recipients demonstrated a manageable toxicity profile. In 21.0%
of patients was eliminated. Edema (18%), hematologic (15%) and renal/graftrelated (27%) causes were the most frequent causes for withdrawal.
During the study 12 patients died, (2.8%). Mortality was due mainly to
neoplasia (11; 2.6%). Graft loss occurred in 35 patients
Conclusions: This study shows the patterns of use and the efficacy and safety of
EVL in rutine clinical practice in Spain. Conversion with complete elimination of
CNI is the most frequently used strategy and this study shows that it is safe with a
very low rejection rate. The benefits on renal function should probably be attributed
to the reduction of CNI nephrotoxicity. Nevertheless the presence of proteinuria
pre-conversion is a predictor of bad outcome of renal function. Early conversion
(during the first three post-transplant years) seems to be more beneficial.
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1646 ASSESSMENT OF EVEROLIMUS IN MAINTENANCE
RENAL TRANSPLANT RECIPIENTS: THE ASCERTAIN STUDY
H. Holdaas1, K. Midtvedt1, D. Seron2, P. O’Connell3, C. Thiagrajan4,
R. Fassett5, J. Dantal6, R. Sharma7, E. Cole8, J. Chapman3, L. Rostaing9
1
Rikshospitalet, Oslo, Norway, 2Ciutat Sanitaria I Universitaria De Bellvitge,
Hospitalet de Llobregat, Barcelona, Spain, 3Westmead Hospital, Westmead,
Australia, 4Devaki Hospital Limited, Chennai, India, 5Launceston General
Hospital, Launceston, Australia, 6Hopital Hotel Dieu, Nantes Cedex, France,
7
Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India,
8
Toronto General Hospital, Toronto, Canada, 9CHU de Rangueil, Toulouse
Cedex 4, France
Background: Calcineurin inhibitors (CNI) contribute to chronic allograft
nephropathy (CAN) and are also associated with an adverse cardiovascular risk
profile. Everolimus, a proliferation signal inhibitor (PSI) immunosuppressant
with an anti-proliferative potential may allow for minimization or
discontinuation of CNI exposure in renal transplant recipients. This ongoing
study was undertaken to evaluate the effect of everolimus on renal function,
measured as glomerular filtration rate (mGFR), and atherosclerosis, assessed
by carotid intima media thickness (IMT).
Design: ASCERTAIN is a 24-month, open-label, multicentre, randomized,
controlled study in which maintenance renal transplantation patients are
randomized to one of three parallel treatment groups: continuation of current
immunosuppressive regimen without everolimus (Group A); initiation of
everolimus (C-0h 8–12ng/mL; initial dose 4mg/day) with discontinuation of CNI
(Group B); or initiation of everolimus (C-0h 3–8ng/mL; initial dose 3mg/day)
with reduction of CNI blood levels by 70–90% (Group C). CNIs (tacrolimus or
cyclosporine) and adjunctive therapies (mycophenolate mofetil or azathioprine)
are used according to local centre practices with patients stratified by centre to
ensure similar numbers in each group. All groups receive steroids.
Objectives: The primary objective is to compare mGFR at 24 months.
Secondary objectives are to compare the groups at 24 months in terms of
patient and graft survival, the progression of CAN (protocol biopsy findings)
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and atherosclerosis (ultrasonography), biopsy-proven acute rejection (BPAR),
safety (including hypertension, hyperlipidaemia and diabetes), and drug blood
levels (everolimus C-0h, cyclosporine C-2h, tacrolimus C-0h).
Population: A total of 398 patients (65.8 male; mean age = 48.9 years) from
71 centres worldwide, at a mean of 5.5 ± 4.1 years after transplantation, were
enrolled between February 2005 and August 2007. Key inclusion criteria
were: age >18 years, primary or secondary renal transplant >6 months ago,
unchanged immunosuppressive regimen for the previous 3 months, and renal
impairment defined as GFR 30–70mL/min/1.73m2. Last patient last visit will
be in August 2009, with data available in the fall of 2009.
Discussion: ASCERTAIN is a pivotal study that will assess the feasibility of
clinically relevant CNI reduction/discontinuation in renal maintenance patients,
and its impact on renal function and cardiovascular risk.
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1647 LONG-TERM BENEFITIS OF MTORI CONVERSION
ON RENAL FUNCTION IN STABLE RENAL TRANSPLANT
PATIENTS
J.C. Ruiz1, A. Sanchez-Fructuoso2, C.G. Alamillo1, I. Pérez-Flores2,
G. Fernandez-Fresnedo1, N. Ridao2, T. Giménez1, N. Calvo2, A. Barrientos2,
M. Arias1
1
Hospital Universitario Valdecilla, Santander, Spain, 2Hospital Clinico
Universitario, Madrid, Spain
Introduction: The use of mTOR inhibitors (mTORi) is a real option in the
management of renal transplant patients but their role has not been clearly
established and their unique toxicity profile has delayed its large scale
utilization. We describe our experience with conversion to mTORi in two
Spanish transplant centres.
Patients and methods: Between Oct-98 and Dec-07 279 renal transplant
patients were converted from a calcineurin inhibitor (CNI) to an mTORi
for different indications after the third month postransplant.(128, 46% to
Rapamycin [SRL] and 151, 54% to Everolimus [EVE]). We analyze our results
with respect to indications of use, drug-tolerance and impact of conversion on
renal function and proteinuria.
Results: Median postransplant time of conversion was 81 months and indications
were: chronic allograft nephropathy (40%), malignant neoplasms (36.5%) and
less frequently cardiovascular disease (10.5%) and others (13%). In 59 cases
(21%) the drug had to be prematurely eliminated and the main reasons for
that were: non-infectious pneumonitis (3.2%), severe infection (2.9%), renal
function deterioration (2.2%), dermal eruption (2.2%), proteinuria (1.8%) and
anemia (1.1%). Dermal eruption was more frequent in patients taking EVE (3.3
vs 0.8%) and pneumonitis in those receiving SRL (3.9 vs 2.6%) although the
differences were not statistically significant. In 62% of cases drug elimination
was made in the first three months after initiation.
In the whole group renal function was progressively deteriorating with a mean
loss of 3.7 mL/min (eGFR-Cockcroft formula) in the year before conversion
(p=0.04) whereas in the year following conversion this parameter increased
by 2.1 mL/min (p=0.01). Long-term analysis of renal function was performed
in the 28 patients that reached 4 years of follow-up. In this subgroup eGFR
increased from 38.9±3.9 to 56.7±3.3 mL/min and in the 17 patients followed
for more than 5 years eGFR increased from 33.8±5.0 to 64.9±5.6 mL/min.
With respect to proteinuria in the whole group, mean values where 0.55±.0.06
g/24h at conversion and 1.00±0.13 g/24h one year after conversion. The
predictors for the development or increase of proteinuria were: the presence
of proteinuria at the moment of conversion (>0.5 g/24h; OR 21.9, CI95%:
6.4-74.4) and late conversion considered as that preformed beyond the third
year postransplant (OR 4.8, CI95% 1.1-20.7).
Twenty three patients lost their grafts (9.8%) and 16 dead during follow-up
(6.8%)
Conclusions: Conversion to mTORi in renal transplant patients is followed by a
clear long-term benefit in terms of renal function improvement in our series and
it should be considered a realistic therapeutic option. Nevertheless this benefit
can only be obtained in those patients who tolerate the drug in the long-term.
An adequate selection of candidates to conversion is essential to maximize this
benefit, especially with respect to proteinuria and time after transplantation.
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1648 EVEROLIMUS AS PRIMARY IMMUNOSUPPRESSANT IN
STABLE KIDNEY TRANSPLANTS WITH CNI ELIMINATION: A
SUCCESSFUL STRATEGY
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1649 EVEROLIMUS (EVE)IN MAINTENANCE TREATMENT
IN RENAL TRANSPLANT RECIPIENTS SWITCHED FROM
CALCINEURIN INHIBITORS (CNI)
M. Rengel, A. Mossé, Ú. Verdalles, S. Abad, A. Vega, E. Verde
Hospital General Universitario “Gregorio Marañón”
Everolimus is a proliferation signal inhibitor utilized in combination with CNI as
immunosuppression therapy. This approach resulted in excellent efficacy when
EVE is combined with reduced exposure to CNI. The present paper reports the
results with patients who were switched from CNI to EVE, allowing cessation of
CNI related toxicities and maintaining efficacy. From february 2005, 120 cadaver
kidney grafted patients (82 men and 38 women), were switched from CNI to
EVE. The age of patients was 55 15 years, with 8.5 6 (1-23) years follow-up
period. The basal immunosuppressant was Prednisone, Mycophenolate Mofetil
(MMF)/ Mycophenolic acid (MPA) and Neoral Cyclosporine/Tacrolimus.
Everolimus blood levels were maintained between 3-5 ng/ml. CNI was stopped

POSTER BOARD NUMBER P3 – 76
1650 USE OF EVEROLIMUS IN DE NOVO RENAL
RECIPIENTS: INITIAL EXPERIENCE IN THE GREEK
POPULATION
D. Vrochides, V. Papanikolaou, G. Imvrios, A. Papagiannis, D. Giakoustidis,
I. Fouzas, N. Antoniadis, G. Vergoulas, G. Miserlis, D. Takoudas
Organ Transplant Unit, Aristotle University, Thessaloniki, Hellas
Although everolimus has proven to be as clinically efficacious as MMF, there
are reports that proliferation signal inhibitors have resulted in poor tolerability.
This study aims to report the experience of a Greek transplant center using either
everolimus or MMF in de novo renal transplant recipients. In this retrospective
study a cohort of 40 patients who received everolimus after renal transplant
was matched for 10 descriptive parameters with a cohort of another 40 patients
who received MMF. The primary endpoint was renal function measured by
creatinine and its clearance as well as wound dehiscence and opportunistic
infections. The mean creatinine clearance for month 3 was 61.03 ± 16.99 ml/
min and 60.99 ± 8.03 for the living related recipients on everolimus and MMF
respectively. The mean creatinine clearance for month 3 was 71.24 ± 12.61 ml/
min and 62.61 ± 20.24 for the cadaveric recipients on everolimus and MMF
respectively. In addition, the incidence of wound dehiscence was 33.34% and
3.92% and the incidence of CMV infection was 8.33% and 17.64% for the
same two groups respectively.
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1651 PROLONGED EFFECTS OF EVEROLIMUS ON WOUND
HEALING IN EXPERIMENTAL INTESTINAL ANASTOMOSES
M. Willems1, J.A. van der Vliet1, B. de Man2, J. van der Laak3, R. Lomme2,
H. Thijs2
1
Radboud University Medical Centre Nijmegen, vascular and transplantation
surgery, 2Radboud University Medical Centre Nijmegen, Surgical Research
Laboratory, 3Radboud University Medical Centre Nijmegen, department of
Pathology
Introduction: Minimizing cyclosporine and steroid exposure has been the main
reason to introduce mTOR inhibitors, such as Everolimus, in transplantation
surgery, the ultimate goal being reduction of side effects of the post-transplant
poly-drug regime. However, the use mTOR inhibitors in the solid organ
recipient, has shown a worrying increase in surgical complications, which
warranted further investigation. In an animal model of bowel anastomoses that
is frequently validated for measurement of wound healing, Everolimus proved
to have a negative, dose related effect on early wound healing. The duration of
the effect is not known because previous experiments were limited to the first 7
days after operation. Here, we have investigated the effect of Everolimus over
a longer postoperative period.
Materials and methods: Three groups of 48 Wistar rats received a daily oral
dose of Everolimus of 1 mg/kg (E-1)or 2 mg/kg (E-2), or saline (controls) form
the day of operation onwards. In each rat a resection of 1 cm ileum and 1 cm
colon was performed, and end-to-end anastomoses were constructed using 8
interrupted sutures. On day 7, 14 and 28 the animals were killed and wounds,
also those in the fascia, were analysed for mechanical (bursting pressure BP,
breaking strength BS and histological (collagen) parameters.
Results: In both ileum and colon, a diminished (p<0,05 vs controls) BP was
seen in the E-2 group after 7 days. The ileal BS at 14 days did not significantly
differ between groups. However, after 28 days, ileal BS was significantly lower
in both groups that received Everolimus (p=0,0001). In colon anastomoses a
significantly reduced BS was seen in both experimental groups after 7 (p<0,0001
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A. Sanchez-Fructuoso1, J.C. Ruiz2, I. Pérez-Flores1, C.G. Alamillo2,
N. Ridao1, R. Palomar2, N. Calvo1, J. Ruiz-Criado2, M. Arias2, A. Barrientos1
1
Hospital Clinico Universitario, Madrid, Spain, 2Hospital Universitario
Valdecilla, Santander, Spain
Introduction: Everolimus (EVL) was approved as immunosuppressive drug
in 2005 but almost all clinical trials before approval were in combination with
Cyclosporin A (CyA), for that reason experience in conversion with calcineurin
inhibitor (CNI) elimination was very limited. We report the combined experience
of two renal transplant centres in conversion of stable transplant patients from a
CNI-based regimen to an EVE-based regimen for different indications.
Patients and methods: Between Mar/05 and Dec/07 155 patients were
converted from a CNI to EVL with rapid and complete elimination of CNI (98
patients in HCM and 57 in HUMV). All patients were converted in the same
way (Initial dose between 2 and 4 mg/day of EVL divided in two doses and half
dose of CNI until EVL through level in the desired range and then suspension).
EVL through levels were measured at 4 and 8 days after initiation and then
monthly up to three months and every three months thereafter.
Results: Indications for conversion were: Chronic allograft nephropathy/CNI
nephrotoxicity (36.8%), malignant neoplasm (29.0%), cardiovascular disease
(16.8%), and other reasons in 13.5% of patients. In 6 patients (3.9%) conversion
was performed as a preventive strategy in the first year postransplant in order to
minimize the long-term CNI toxic effects. Two thirds of patients were males.
Mean age at conversion was 55.8±12.6y and median time from transplant to
conversion was 78 months (range 3-286m). Approximately the same proportion
of patients were under CyA and Tacrolimus. Mean initial dose was 2.94±0.7 mg/
day and mean through levels at four days were 9±5.4 ng/mL (range: 1.8-28.5).
In 92.4% this first level was over 3 ng/mL and in 78.6 over 5 ng/mL. Mean time
to CNI complete elimination was 5 days (p25-75 4-8 days).
EVL had to be prematurely eliminated in 33 patients (21.3%) due to drug
intolerance/toxicity (8.9%), poor graft evolution (5.1%), severe infection
(1.9%) or other reasons (5.2%). Among drug toxicity, dermal eruption (3.2%)
and non-infectious pneumonitis (2.6%) were the most frequent reasons for EVL
withdrawal. Median time for EVL suspension in this subgroup was 3.7 months
(p25-75 1.4-11.1m). Among poor graft evolution the reasons were proteinuria
(2.6%), deterioration of renal function (1.9%) and acute rejection (0.6%).
Renal function was analyzed in the 87 patients with a functioning graft and continuing
on EVL at twelve months postconversion. Creatinine clearance (Cockcroft-Gault
formula) significantly improved at six months (57.0±21.4 vs 59.9±23.4 mL/min;
p=0.001) but that difference decreased at 12 months (58.3±22.9mL/min; p=0.15)
Conclusions: Conversion to EVL with complete suspension of CNI is a safe
procedure in terms of risk of graft rejection. Approximately 10% of patients do
not tolerate EVL due to drug toxicity and in an additional 10% of it must be
eliminated for different reasons, specially poor graft evolution. This might be
reduced with a more adequate selection of candidates. Progressive deterioration of
renal function before conversion was apparently detained with this intervention.

using an abrupt conversion protocol. CsA /Tac treatment was stopped after the
morning dose and EVE was started at 1.0 mg/day. MMF/MPA-based therapy
was continued as well as prednisone while target EVE trough blood levels (3-5
ng/ml) were achieved. At 1 year, graft and patient survival was 100% and there
was no acute rejection. Blood pressure remained unchanged and there were not
changes in glucose metabolism. Lipids increased silghtly during first 3 months
after EVE treatment. Proteinuria appears in patients with previous glomerular
lesion. GFR improved in 55% of patients.
Conclusion: Conversion of renal transplant recipients from CNI-based
immunosuppressive regimen to EVE in renal transplant recipients is safe and
affect slightly to lipid metabolism.
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for E-1 and E-2) and 14 (p< 0,0001 for E-1 and E-2) days, if compared to the
controls. After 28 days the effect remained non-significant, although average
values were still lower. Hydroxyproline content and concentration were
measured after 7 days and show a dose dependent decline. The difference
between the experimental groups and control group was significant (p< 0,05),
the difference between E-1 and E-2 for ileum and colon anastomoses was not
significant. Histological parameters did not show any apparent differences
between groups. Fascial wounds were less strong in both experimental groups
at all three points measured.
Conclusion: Everolimus interferes with wound repair. Fibroblast collagen
synthesis and deposition of new collagen fibers are essential to the proliferation
phase of normal wound repair. Most likely, impaired cellular proliferation
is responsible for the effect seen here. Even after 4 weeks, wound strength
appears to remain below normal. Such a prolonged effect may have clinical
consequences and cause surgical morbidity. The possibility of prevention
of surgical complications, or diminishing the negative effect, is an exciting
incentive for further investigation.

POSTER BOARD NUMBER P3 – 78

WEDNESDAY

1652 A SHORT DELAY IN ADMINISTRATION OF
EVEROLIMUS RESULTS IN NORMALIZED WOUND HEALING
IN A RAT-BOWEL ANASTOMOSIS MODEL
M. Willems1, T. Hendriks2, B. de Man2, R. Lomme2, J.A. van der Vliet1
1
Radboud University Medical Centre Nijmegen, vascular and transplantation
surgery, 2Radboud University Medical Centre Nijmegen, Surgical Research
Laboratory
Introduction: Everolimus, used in post-transplant medical therapy, is
related to an increased incidence of surgical complications in the early
postoperative phase. In previous experiments the negative effect on wound
healing of Everolimus was demonstrated in a dose dependent fashion.
While the interest in Everolimus in transplantation surgery is mainly
based on attempts to decrease side effects, this is considered an important
phenomenon. Delaying the administration of Everolimus might prevent
surgical complications as shown in other drug studies. In this study, we have
analysed the effect of delayed administration of Everolimus after bowel
resection and anastomoses in the rat, a model that is frequently validated for
measurement of wound healing.
Materials and methods: In 143 male Wistar rats a resection of 1 cm
ileum and 1 cm colon was performed, and end-to-end anastomoses were
constructed using 8 interrupted sutures. Thirteen rats per group started
Everolimus after 0, 1, 2, 3 or 4 days postoperatively, in an orally daily dose
of 1 mg/kg (groups E1-0, E1-1, E1-2, E1-3 and E1-4). Five other groups
of rats received Everolimus in a daily dose of 2 mg/kg (E2-0, E2-1, E2-2,
E2-3, E2-4). A control group existed of 13 rats. On day 7 the animals were
killed and analysed using mechanical tests (bursting pressure BP, breaking
strength BS), biochemical tests (collagen content and gelatinase activity) and
histological parameters.
Results: Mean BS of the ileum after 7 days in the control group was 99
± 47,2 g. A significant decrease of strength was seen in the E2-0 group
(p<0,001). BS of the ileum reached control values after a delay of
administrating Everolimus of 3 days in the low dose, and 4 days in the high
dose group. BS of the colon followed the same pattern. BP of the ileum in
the control group was 261 ± 75 mm Hg, this was significantly lower in the
E1-0 group as well as the E2-0 group (p<0,05). More importantly, a very
significant difference was seen in precentage of the anastomoses bursting
outside the suture line, representing a stronger anastomosis. All the groups
of rats using Everolimus had a significantly lower percentage of bursting
outside the suture line (p<0,0001). The colon anastomoses showed a similar
pattern. In the groups of delayed strength a decreased collagen disposition
was noted.
Discussion: Delaying administration of Everolimus until the third postoperative
day clearly diminishes wound-healing disturbance in colon and ileum
anastomoses of the rat. In the post-transplantation poly drug regime, delaying
the administration of mTOR inhibitors could be of important clinical benefit.
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1653 CONTRIBUTION OF THE LIVER TO ELIMINATION OF
PRO-INFLAMMATORY CYTOKINES AND GROWTH FACTORS
FROM PORTAL CIRCULATION
D. Porowski1, A. Wirkowska1, M. Pacholczyk2, L. Paczek1
1
Transplantation Institute, Department of Immunology, Transplantology
And Internal Diseases, Medical University of Warsaw, Warsaw, Poland,
2
Transplantation Institute. Department of General and Transplant Surgery,
Medical Universiy of Warsaw, Warsaw, Poland
Study goal: To evaluate the contribution of liver to elimination of cytokines
and growth factors from portal circulation. Additionally, a mathematical model
of liver elimination of cytokines and growth factors was designed. The design
of the elimination ratio was based on definition of the first pass effect and
existing formula of drug extraction ratio.
Material and methods: 20 liver transplant donors and 20 patients with endstage liver failure, were included into the study. Their blood was collected
during surgery from portal vein, hepatic vein, artery and peripheral vein.
Concentrations of cytokines and growth factors were determined using
ELISA.
Results: In donors, significantly lower levels of IL-6, TNF-alpha, HGF, and
TGF-beta were detected in portal vein compared to liver vein. In cirrhotic
patients, there were no significant differences in levels of IL-6, TNF-alpha,
and TGF-beta between portal and hepatic vein. However, significantly
higher level of HGF in liver vein compared to portal vein was observed. The
observations were proven by values of the designed elimination ratio. In donors
the elimination ratio was between 0.2 and 0.4, and in recipients between -0.5
and 0.1. Positive values suggest predominance of intra-liver elimination over
synthesis of these mediators. Negative values suggest predominance of intraliver synthesis over the elimination.
Conclusions: Healthy liver takes part in elimination of growth factors and proinflammatory cytokines in humans. In cirrhotic liver, the elimination ability is
disturbed. However, cirrhotic liver is able to produce some cytokines and growth
factors, therefore impacts the profile of mediators and their concentrations in
circulation.

POSTER BOARD NUMBER P3 – 80
1654 THE NEW STRATEGY OF LIVER TRANSPLANTATION
FROM MARGINAL DONORS USING SERINE PROTEASE
INHIBITOR
S. Miyagi, A. Okada, S. Tsukamoto, K. Fujimori, S. Satomi
Advanced Surgical Science And Technology, Tohoku University
Objectives: The purpose of this study is to establish the safety manner of
procurement of liver grafts from marginal donors such as non-heart-beating
donors (NHBD).
Materials and methods: Male Wistar rats were divided into five groups: i)
HB group, livers were retrieved from heart-beating donors; ii) NHB group,
livers were retrieved from uncontrolled NHBD that were experienced apnea
induced agonal condition; iii) NM group, retrieved the same manner as
NHBD pretreated with nafamostat mesilate (NM) (0.2mg/kg/hour); iv) PG
group, retrieved the same manner as NHBD pretreated with prostaglandin
I2 (PG) (33ng/kg/hour, for 30min.); v) NM+PG group, retrieved the same
manner as NHBD pretreated with NM and PG. After 1hr cold preservation,
those were transplanted according to the Kamada methods. We examined
AST, ALT, LDH, IL-1beta, TNF-alpha and thromboxane B2 (TXB2) 24hours
after transplantation. And we also performed histological examination using
an electron microscope.
Results: The number of survivals on 9 days after liver transplantation from
group i) to v) was 9/9, 0/9, 1/9, 1/9, and 3/9. The values of AST 24hours
after transplantation in the HB, NHB, NM, PG and NM+PG groups were
3446¦ }1810, 5316¦ }985, 5914¦ }789, 5323¦ }1158, and 4193¦ }1019
respectively. The values of ALT 24hours after transplantation in the HB,
NHB, NM, PG and NM+PG groups were 3842¦ }902, 9126¦ }2001,
9878¦ }790, 7268¦ }1644, and 7354¦ }2889 respectively. The values of
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LDH 24hours after transplantation in the HB, NHB, NM, PG and NM+PG
groups were 6644¦ }1902, 20758¦ }7631, 16068¦ }5095, 17802¦ }9977
and 14062¦ }4714 respectively. The values of IL-1beta 24hours after
transplantation in the HB, NHB, NM, PG and NM+PG groups were
2895¦ }2240, 4257¦ }5514, 4444¦ }6547, 4199¦ }5016, and 3544¦ }2877
respectively. The values of TNF-alpha 24hours after transplantation in the
HB, NHB, NM, PG and NM+PG groups were 2854¦ }3322, 5765¦ }3537,
5244¦ }4072, 3879¦ }4101, and 2817¦ }3472 respectively. The values of
TXB2 24hours after transplantation in the HB, NHB, NM, PG and NM+PG
groups were 2982¦ }2648, 4807¦ }3776, 4511¦ }2685, 3123¦ }2592 and
2903¦ }2477 respectively. In the NM+PG group all of those values are slightly
lower than those in the NHB group, but there are no significant differences
between those groups. On the histological exam, in the NM+PG group the
sinusoidal endothelial cells were well preserved.
Conclusion: The strong serine protease inhibitor, NM, and PG supported
sinusoidal endothelial cells. This method is promising strategy on liver
transplantation from marginal donors.
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1655 EARLY EXPRESSION OF HGF, IL-6, TGF-BETA 1 AND
TGF-BETA 2 IN SYMPTOMATIC INFECTION IN PATIENTS
WHO HAVE UNDERGONE LIVER TRANSPLANTATION

1656 THE GASTRIC SUBMUCOSA AS THE SAFER
AND REPEATABLE SITE FOR THE CELLULAR
TRANSPLANTATION
K. Takeshita1, N. Kakihara2, S. Naka3, H. Ishibashi4
Minami Shiga Clinic, 2Kyoto Second Red Cross Hospital, Department of
Surgery, 3Shiga University of Medical Science, Department of Surgery,
4
Notogawa Hospital, Department of Surgery
In order to establish a safely repeatable method for cell-transplantation avoiding
serious complications, such as portal thrombosis in the case of hepatocellular
transplantation into the portal vein, we tried liver-cell transplantation into the
submucosal layer of stomach wall.
Hepatocytes were isolated from the Lewis rats by a two-step collagenase
perfusion method. Final hepatocyte suspension contained 2x107 viable
hepatocytes in 1 ml of 0.2% collagen gel solution. Recipient rats underwent
20% partial hepatectomy and the hepatocyte suspension (2x107 cells) was
injected into the submucosal layer at the anterior wall of stomach. Rats were
sacrificed and histologically examined at days 1, 3, 7, 30, and 180. The most
of transplanted hepatocytes were remained in submucosal layer until day 7.
The PAS positive cells were observed at the peripheral area of the transplanted
hepatocyte-mass. The survived hepatocytes made clusters in the submucosa on
day 30, and BrdU positive cells were observed. The transplanted hepatocytes
proliferated and reconstructed the liver-tissue like structure in the gastric
submucosa on day 180.
The gastric submucosa is easily and repeatedly accessible by the gastroendoscope. Thus, these results suggest that the gastric submucosa is a possible
site for the safely repeatable cell-transplantation, using endoscopic injection.

1
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1657 NO SEPTICAL COMPLICATIONS IN AN ANHEPATIC
PIG MODEL WITH PROLONGED SURVIVAL
A. Etspueler1, C. Thiel2, K. Knubben2, K. Unertl1, M. Morglla3,
A. Koenigsrainer2, M. Schenk2
1
University of Tuebingen, Department of Anethesiology, 2University of
Tuebingen, Department of General, Visceral And Transplant Surgery,
3
University of Tuebingen, Department of Neurosurgery
Introduction: Despite the progress in intensive care therapy the acute liver
failure (ALF) has still a high mortality. Due to a depression of the immune
system the risk of septical complications increases during anhepatic survival
time. Aim of the present study was to investigate the course of inflammatory
parameters in an anhepatic pig model.
Methods: 20 female pigs of the German landrace (30-35kg) underwent a
total hepatectomy under fully sterile conditions. Animals were kept under
deep narcosis with pressure controlled ventilation and received intensive care
therapy including volume substitution with sodium chloride 0.9% and glucose
20%, hydroxyethylstarch 6%, fresh frozen plasma and erythrocyte units. All
animals received daily 2g Ceftriaxon. Blood samples were taken every eight
hours in order to measure leucocytes, TNF-α; and IL-6. Body core temperature
was recorded continuously by a rectal tube. Endotoxin (LPS) was measured by
a modified LAL-Assay.
Results: All pigs died due to multi organ failure after a median of 49.5 ± 20.1
hours. Clinical signs of sepsis were not noticed in any case. Body temperature
and leucocytes remained stable until death at 37.3 ± 0.93°C and 22661 ± 5645/
μl (normal up to 22000/μl), respectively. Values of IL-6 and TNF-α; showed no
increase over the critical value of 1000 mg/L and 1000 ng/L. Endotoxin levels
remained at the detection limit and increased the last 20 hours before exitus.
Conclusion: In our anhepatic pig model no direct or indirect signs of
septical complications were observed. It can be postulated that a “protective
hepatectomy” could prevent septical complications in ALF-syndrome.
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K. Dudek1, K. Koziak2, M. Kotulski1, J. ¯urakowski1, K. Zieniewicz1,
M. Krawczyk1
1
Department of General, Transplant And Liver Surgery, Medical University
of Warsaw, 2Department of Internal Medicine, Hypertension and Angiology,
Medical University of Warsaw
Early septic complications are still a deciding factor for successful recovery
in patients who have undergone orthotopic liver transplantation. Therefore,
monitoring liver function parameters plays an important role in post-operative
treatment, where it can be used in the early diagnosis of post-surgical
complications.
Aim: 1) to measure standard liver function parameters and the levels of
expression for selected cytokines in patients exhibiting symptoms of infection
after orthotopic liver transplantation.
Materials and methods: The study was carried out on thirty patients who
had received orthotopic liver transplants. The patients were divided into two
groups: SI-0 consisted of those patients who showed no symptoms of infection,
and SI-1 of those who did. Standard liver function parameters were measured,
including ALT, AST, bilirubin and prothrombin time. The levels of expression
of the following cytokines were also determined: HGF, IL-6, TGF-ƒÒ1 and
TGF-ƒÒ2.
Gene expression in circulating lymphocytes was determined two hours before
surgery, 24 hours after re-perfusion, and two, six and ten days after surgery.
mRNA was isolated from the lymphocytes using the PAXgene Blood RNA
Tube test kit (Qiagen). Reverse transcription was carried out, followed by RealTime PCR.
All results were statistically elaborated using the SAS System ver. 8.02 software
package (SAS Institute,Cary NC, USA).
Results: 1) There were no significant differences in standard liver function
parameters between the two groups of patients. 2) There were no significant
differences in the levels of expression for the cytokines in question between the
two groups of patients.
Conclusions: 1) Although monitoring standard liver function parameters
provides diagnostically valuable information on the condition of the patient,
it cannot be used to determine the extent of systematic infection in patients
showing signs of infection after liver transplantation. 2) Determining gene
expression levels in circulating lymphocytes is a very sensitive method which
can be used to monitor the condition of patients who have undergone liver
transplantation. 3) The levels of expression of HGF, IL-6, TGF-beta 1 and
TGF-beta 2 and IL-6 in circulating lymphocytes is are not specific enough
to diagnose transitory post-surgical complications such as symptomatic
infection.
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1658 HISTOLOGICAL STUDIES IN VARIOUS MODELS OF
ACUTE HEPATIC FAILURE
M. Schenk1, K. Knubben1, C. Thiel1, M.H. Morgalla2, A. Etspüler3,
A. Königsrainer1,
1
University Hospital Tuebingen – General, Visceral and Transplant Surgery,
2
University Hospital Tuebingen – Neurosurgery, 3University Hospital
Tuebingen – Anaesthesiology
Objective: Several animal models have been developed for evaluation of acute
hepatic failure. A differentiation of liver damage and regeneration is needed to
evaluate the different models.
Methods: In 12 German landrace pigs (30-35 kg) hepatic failure was induced
by acetaminophen 1g/kg b.w. (n=6), amanitin 0,15 mg/kg b.w. (n=2) or 0,35
mg/kg b.w. (n=2) or extended liver resection (n=2) with 3h hypoxia of the
remaining segments. Hemalum-Eosin and immunohistochemistry staining
(Ki67 for regeneration and TUNEL-apoptosis staining) were performed in
liver biopsies taken every 24 hours. Albumin, ALT, AST and liver depending
clotting factors were measured every 8 hours.
Results: Liver biopsies of acetaminophen induced liver failure showed massive
centrolobular necrosis 24 to 48 hours after intoxication which was confirmed
by a significant decline of PT and albumin and a worsening clinical course. In
the liver of surviving pigs a diffuse Ki67 expression in all over the periportal
fields (positive cells per field: 24h: 5, 48h: 27 and 72h: 93) and a focal apoptosis
was shown.
After amanitin intoxication liver necrosis was seen between 48 and 72 hours, 24
hours later compared to acetaminophen. In animals with low toxin administration
20% Ki67-positive hepatocytes were observed 96h after intoxication, which
leads to a functional recovery of liver depending clotting factors. In animals
with high amanitin dosage, less than 5% Ki67-postive hepatocytes and massive
congestion were observed. Disseminated apoptosis was detected.
In the resection model, liver architecture in the remaining tissue was restored
within 3 days after injury. No signs of liver cell necrosis were observed.
Conclusions: Maximum necrosis and localisation of liver damage and the
potential of regeneration is specific to the mechanism of liver injury. This fact
must be taken into consideration before therapeutic strategies and liver support
devices will be tested.
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1659 THE DAMAGE ASSOCIATED MOLECULAR PATTERN
MOLECULE [DAMP] HMGB1 ENHANCE TLR AND RAGE
EXPRESSION ON HEPATIC STELLATE CELL (HSC),
STIMULATES ACTIVATION AND PROLIFERATION
X. Liang1,2,3, A.M. Farkas3, M.T. Lotze2,3, M.E. DeVera1,2
Starzl Transplantation Institute, 2Department of Surgery, 3Hillman Cancer
Institute, University of Pittsburgh
Activation of HSC, the major profibrogenic cell type in the liver, is associated
with severe hepatitis C virus (HCV) recurrence after liver transplantation
(LTx). We previously showed that levels of HMGB1, a DAMP molecule,
decrease with time after LTx. HMGB1 is released by necrotic cells as well
as activated macrophages and hepatocytes during oxidative stress and chronic
inflammation, a milieu that exists in the HCV-infected liver. We hypothesized
that HMGB1 would promote HSC activation and examined its effects on
the expression of toll-like receptor TLR4, TLR9 and receptor for advanced
glycation end-products (RAGE) [All receptors for HMGB1], receptors which
may play a role in fibrogenesis.
Methods: Human HSC were obtained from non-parenchymal cells isolated
from portions of donor or resected livers using collagenase perfusion and
Percoll density centrifugation under an IRB approved protocol. HSC were
cultured overnight in complete RPMI medium then stimulated with HMGB1
(10£gg/ml), LPS (1£gg/ml), IFN£^ (100IU/ml), and TGF-£] (4ng/ml) for
48 hours. HSC proliferation was measured by MTT while their activation
was assessed by alpha-smooth muscle actin expression detected by indirect
immunofluorescence (IF) staining and Western blot as well as by NF-£eB
translocation measured by single cell immunofluorescent imaging analysis.
TLR 4 and RAGE expression were also assessed by IF.
Results: HSC expressed high levels of alpha-smooth muscle actin expression
in response to HMGB1 (++), LPS (++), TGF-£] (+++) and IFN-ƒ× (+). IF
staining demonstrated low-level expression of TLR 4 and RAGE in quiescent
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HSC. HSC activation with LPS, TGF-£], and HMGB1 all significantly induced
TLR 4, TLR9 and RAGE expression (LPS > TGF-£] > IFN£^). Compare to
no stimulation control, HSC proliferation was increased more than 2.5 folds
after stimulated by HMGB1 and other stimuli. NF-£eB nuclear localization
was demonstrated with HMGB1, LPS and TGF-£] stimulation, while STAT1
signaling occurred with IFN£^ stimulation.
Summary: HMGB1 markedly stimulates HSC activation through NF-£eB
signaling and induces TLR 4, TLR9 and RAGE expression. Strategies to limit
HMGB1 release in chronic inflammatory states in the liver may be a novel
means to slow down fibrosis progression in patients with hepatitis C in the
transplant setting.
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1660 PROLONGATION OF COLD PRESERVATION
DRAMATICALLY DECREASES THE SURVIVAL RATE AND
SYNTHESIS FUNCTION AFTER SMALL-FOR-SIZE LIVER
TRANSPLANTATION IN THE RAT
Y. Gu1, O. Dirsch, Q. He, U. Dahmen
1
Department of General, Visceral And Transplantation Surgery, University
Hospital of Essen, Essen, Germany, 2Institute of Pathology, University
Hospital of Köln, Köln, Germany, 3Department of General, Visceral And
Transplantation Surgery, University Hospital of Essen, Essen, Germany,
4
Department of General, Visceral And Transplantation Surgery, University
Hospital of Essen, Essen, Germany
Aims: The aim of the present study was to assess the influence of cold ischemia
time on small-for-size liver transplantation using a rat model.
Methods: Inbred male Lewis rats were subjected to 50% or 70% liver resection
in donors and the partial liver grafts were transplanted into recipients. Grafts
were preserved with Ringer’s solution at 4 degrees for 3 hours and 5 hours
before transplantation, respectively (n=10/group). Animals were sacrificed on
postoperative day 7. Study outcomes included survival time and liver function
were investigated.
Results: Transplantation of a 50% partial liver graft underwent 3 hours cold
ischemia were well tolerated by all animals. Prolonging the period of cold
preservation to 5 hours was associated with an obvious decrease of animal
survival (60%). Transplantation with a 30% liver graft underwent 3 hours
cold ischemia reduced the survival rate significantly as compared to 50% liver
transplantation (50% vs. 100%, p<0.05). Prolonging the cold preservation of a
30% graft (5 hours) dramatically decreased the survival again (30%, p<0.05).
Total protein and fibrinogen levels were significantly decreased in recipients
with 5 hours cold ischemia compared to recipients with 3 hours cold ischemia
in both 50% partial liver Transplantation group and 30% liver transplantation
group, p<0.05).
Conclusions: Sustained periods of cold preservation significantly impaired the
animal survival and synthesis function of the grafts. Cold ischemia tolerance of
the liver grafts is associated with the liver mass.
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1661 APOPTOSIS IS NOT THE MAIN RESPONSIBLE BY
ISCHEMIA-REPERFUSION INJURY AFTER HUMAN
LIVER TRANSPLANT
H. Noujaim1, E.F.S. Montero2, C. Ribeiro1, V.L. Cappellozzi3, R. Gomes1,
L. Curvello1, M. De Miranda1, F. Crescentini1, M. Casagrande1, T. Genzini1
1
HEPATO - Hospital Beneficencia Portuguesa De São Paulo, 2UNIFESP,
3
LAB IMINUNO-HISTOQUIMICA - FMUSP
Introduction: Apoptosis is a key mechanism of reperfusion injury in normal
liver; however, the pathway of cell death in steatotic grafts after liver transplant
(LTx) is unknown.
Purpose: to analyse the cold ischemia and warm reperfusion (CI/WR) using
steatotic and non steatotic grafts after LTx.
Patients and methods: this is a prospective study performed between May/02
and Feb/08. Liver biopsies were collected 2 hours after graft reperfusion in 115
LTx performed in 112 patients. The biopsies were assessed for the following
histological features (hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3),
portal inflammation (degree 0 - absent, I- mild, II- moderate, III– severe),
parenchymal neutrophilic infiltration (degree 0- absent, I –rare around zone 3,
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II-moderate in zone 3, III- since zone 3 to1) and presence of apoptotic cells;
steatosis was classified in macro and/or microvesicular, and its degree classified
as absent, mild (<30%), moderate (30to59%), severe(≥60%). Apoptosis was
assessed by the apoptosis index (TUNEL and Caspase-3 cleaved assays).
The 115LTx were divided according to their steatosis degree in 4 groups:
absent –ASG (n=36), mild –MSG (n=36), moderate- MoSG(n=26), severe –
SSG(n=17). Macrosteatosis were predominantly present in mild – G1(n=10)
and moderate+severe- G2+3 (n=12), and microsteatosis in mild-G1 (n=29) and
moderate+severe- G2+3 (n=24), and 4 cases presented macro and microsteatosis
simultaneously. Preservation solutions, cold ischemia time (CIT),surgery
time and grafts functions were assessed during the 7 days after LTx by serum
levels of AST, ALT, GGT, Bilirubine, Protrombin time and creatinine. Results
significant when p<0.05.
Results: There was no difference among the groups when comparing
preservation solutions, CIT and surgery time. Comparing among the 4 groups
(ASG, MSG, MoSG, SSG), the SSG had significant increase of AST level (2nd
day LTx) p-0.02 and creatinine level (2nd to 7th day LTx) p-0.04.
No LTx
Suzuki score (2+3)
neutrophilic infiltration
(II + III)
Apoptosis index (TUNEL)
Apoptosis index
(Caspase-3 cleaved)

MSG(n=36)
6%

MoSG(n=26)
13.5%

SSG(n=17)
20%

ASG(n=36)
8%

p
0.3

42%

55%

68%

56%

0.4

0.23±0.12

0.26±0.11

0.20±0.12

0.23±0.10

0.5

0.14±0.11

0.17±0.10

0.19±0.11

0.15±0.10

0.6

Apoptosis index (TUNEL assay and caspase-3) were in macrosteatosis
group: G1-0,23±0,11 and G2+3 -0,16±0,09,(p=0.4) and G1-0,17±0,12
and G2+3-0.14±0,09 (p=0,8),respectively and in microsteatosis group:
G1-0.23±0.11 and G2+3- 0.27±0.12,(p=0.4) and G1-0.13±0.11 and G2+30.18±0.11(p=0.2).
Conclusion: Although there was no significant difference among the groups,
severe steatosis was associated with increased parenchymal neutrophilic
infiltration and decreased apoptosis index (TUNEL) when comparing with
other degrees. Isolate macrosteatosis (degree moderate and severe) had lower
apoptosis index than those of G1 or non-steatotic grafts´ while microsteatosis
(>30% fat) had increased apoptosis indexes. This study demonstrates, therefore,
that apoptosis is not the main mechanism of CI/WR injury in human LTx using
grafts with severe and macrosteatosis.

CONCURRENT ORAL SESSION 118:
XENOTRANSPLANTATION
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1662 INDUCTION OF DIABETES IN RHESUS MONKEY WITH
PANCREATECTOMY AND LOW-DOSE STREPTOZOTOCIN
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1663 PIG PANCREATIC ISLETS TRANSPLANTATION
IN SPONTANEOUSLY DIABETIC DOGS
M. Bacqué2, A.G. Abalovich1, D. Grana3, J. Milei4
Escuela de Ciencia y Tecnología de la Universidad Nacional de San Martín,
Argentina- ININCA, Fac. Medicina and Department of Transplantation,
Hospital de Clínicas, Fac.Medicina, UBA, 2Department of transplantation,
Hospital de Clínicas Fac.Medicina UBA, 3Instituto de Investigaciones
cardiológicas, Fac. Medicina, UBA, Conicet, 4Instituto de investigaciones
cardiológicas, Fac. Medicina UBA, Conicet
Pig islets xenotransplantation represents an attractive way of resolve the human
organ shortage problem.
Porcine islets are frequently considered in xenotransplantation because they
produce insulin similar to the human´s insulin.
To avoid immediate rejection of porcine cells, many strategies are being
developed, between them, we find the microencapsulation.
In this protocol, in preclinical phase, we implanted microencapsulated adult
porcine islets in alginate-polylisine, to insulin-dependent diabetic dogs. We
hypothesized that porcine islets act as insulin sensors and improve the metabolic
control of the disease, even though the diabetes is not completely cured.
Methods: Pancreases were obtained from the slaughterhouse, from animals
weighing 100-150 kg. The islets were isolated by collagenase digestion without
using purification.
The encapsulation technique was a modification of Sun´s method.
Isolated islets (150.000 IE) were mixed with 1.6% low viscocity alginate
(Keltone ®,UK).The alginate solution was converted into droplets using an air
driven droplet generator.
Microcapsules were cultured in RPMI supplemented 10% BFS in 5% CO2
atmosphere and 37ºC during 36 hs before implantation.
Islets with a viability count below 80% with trypan blue test, were discharged.
Animals: The five dogs were in well health status and with diabetes mellitus
of at least one year of evolution. All animals were being treated witn glargine
insulin. Under sedation, microcapsules were implanted. Insulinemia basally
and every-3 months and glycosiled hemoglobin basally and every-4 months
were registered in peripheral blood. In the follow-up, the glycemia was
registered twice a day, 3 hours after morning and night meals with blood
glucose monitoring system.
Results: In the first dog, it was observed an immediate reduction of the insulin
dose of 19%, and a new decrease of 12% in the 5 months follow-up.
In the second dog, after the immediate decrease in 20% of the basal dose, at
6 months the dog was almost insulin-independent, with a dose of 20% of the
original dose.
In the other three dogs, after implantation the insuline dose show a mean
diminution of 10%.The insuline needs were also reduced after a follow-up of 5
or 6 months in 10 to 20%.
Animals who reached in their follow-up the glycolized hemoglobin control
showed a decrease of 8 to 15%.
All the owners subjectively claimed that their animals are now enjoying a
1
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Objective: This study is to develop and assess a standard technique for induction
of diabetic rhesus monkey with C-peptide negative, and establish available
insulin strategy, which would significantly benefit preclinical investigation
of islet transplantation and new drug treatment for Type 1 diabetes mellitus
(T1DM).
Methods: Four rhesus monkeys were obtained from Chengdu Ping’an
Experimental Animal Reproduction Center. Normal pancreatic function was
confirmed by the intravenous glucose tolerance test (IVGTT). Each two
monkeys were assigned into two groups. Group 1: total pancreatectomy to
induce T1DM; Group 2: 75% partial pancreatectomy combined with low-dose
(15mg/Kg) streptozotocin (STZ). Spiral CT of the pancreas and eyeground
examination were carried out before and after the operation. Fasting and
postprandial blood glucose (BG) levels were monitored twice daily after the
operation and the last STZ injection via finger or toe. Different types and
doses of insulin were administered twice daily in order to maintain fasting BG
<200mg/dL. Throughout the experimental period, the animals were regularly
assessed for food intake, water intake, urine, blood hematological parameters,
serum biochemistry, insulin, C-peptide and glycated hemoglobin.

Results: The fasting BG increased significantly (>400mg/dL) with reduced
insulin and negative C-peptide in serum in two groups after operation, and
no apparent adverse effects were observed. One monkey didn’t develop
diabetes after 75% pancreatectomy plus injection with 15mg/Kg STZ, and was
given 3 more doses of STZ, which did induce diabetes. Except for C-peptide
and insulin, clinical parameters associated with T1DM of monkeys showed
no significant difference with normal status. During the exogenous insulin
treatment, hypoglycemia was happened for two times about 1 hour after
Humulin® N (1.78U/kg/day) injection; but was not happened during treated
with Humulin® R (1.25 U/kg/day) and LANTUS® Insulin Glargine Injection
(1.43 U/kg/day) or porcine insulin (1.07U/kg/day Insulin Injection and 2.14U/
kg/day Protamine Zine Insulin Injection).
Conclusions: The results showed that total pancreatectomy could successfully
result in T1DM in rhesus monkeys. STZ injection after 75% pancreatectomy
may be a safer and reproducible method, while the dose of STZ showed
interindividual variation. Porcine insulin is a safe and economical application
to control the blood glucose for diabetic rhesus monkey before islet
transplantation.
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better quality of life.
Discussion: The changes in the five dogs, with better metabolic control
and reduction of insulin requirements, let us propose the pig islets
microencapsulation as a way of achieve the metabolic control without the risk
of the immunosupression.
The time of insulin secretion, allows us think in the need of implant only one or
two doses per year. We hypothesized that the improvement at 6 months, could
be due to neogenesis from exocrine tissue microencapsulated with the islets.
This could have important clinical implications if acinar tissue could facilitate
the neogenesis
Although these results are preliminary, they permit a different vision about
microencapsulated pig islet xenotransplantation to cure or ameliorate the type
I diabetes.
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1664 TRANSCRIPTIONAL PROFILING IN PORCINE AORTIC
ENDOTHELIAL CELL INDUCED BY INFLAMMATORY
STIMULATOR
Y. Hye-Jun, J-S. Kim, S.Y. Hwang*
Department of Biochemistry, Hanyang University & GenoCheck Co. Ltd.,
Sangrok-gu, Ansan, Gyeonggi-do 426-791
Gene expression microarrays is the key technology can easily determine
the expression of thousand of genes. For successful development of
xenotransplantation, it is particularly important to study the biology and
molecular characteristics of porcine aortic endothelial cells (PAECs) treating
human cytokines in order to discover xenotransplantation-related expression
genes. We developed pig oligonucleotide 13K microarray chips for elucidating
xenotransplantation-related genome in PAEC. Quality control has been done
from several cells based on various conditions. We analyzed differentially
expressed transcriptomes PAEC treated with hydrogen peroxide (H2O2; 40
uM), human tumor necrosis-alpha (hTNF-α; 20 ng/ml), Lipopolysaccharide
(LPS; 10ug/ml) and pig interferon gamma (pIFN-γ; 100ng/ml).
We selected three time points (1hr, 6hr, 24hr) for VCAM-1 expression using
real–time PCR. Total RNA isolated from PAEC that treated with H2O2, hTNF-α,
LPS and p IFN-γ was used for the synthesis of fluorescence for microarray.
There was a distinct difference in the expression level of these genes between
H2O2, hTNF-α, LPS and pIFN-γ of PAEC. Our results should be validated for
elucidating their clear role and functions of xeno-immune response.
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1665 GENERATION OF HUMAN A20 GENE TRANSGENIC
PIGS BY SOMATIC CELL NUCLEAR TRANSFER
M. Oropeza1,2, B. Petersen1, E. Lemme1, A. Lucas-Hahn1, A-L. Queisser1,
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2
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Introduction: Xenotransplantation is considered as a promising strategy
to close the growing gap between demand and availability of appropriate
human organs. While the hyperacute rejection response can already be reliably
controlled, the acute vascular rejection (AVR) remains a major hurdle for
longterm survival of xenografts in a porcine-to-primate organ transplantation.
The human A20 (hA20) gene exhibits both anti-apoptotic and anti-inflammatory
properties in endothelial cells (Transplantation 82: 36-40, 2006) and could thus
prevent endothelial cell activation leading to AVR and subsequent xenograft
destruction.The goal of this project is to produce hA20-transgenic pigs with
improved features in xenotransplantation.
Materials and methods: The hA20-expression vector driven by the ubiquitous
CAGGS hybrid promoter (chicken β;-actin-/ rabbit β;-globin) with an IRESneomycin resistance cassette (9.1 kb) was transfected into porcine fetal
fibroblasts (PFFs) derived from German Landrace porcine fetal explant cultures.
Transfection of 3 x 106 cells was accomplished at 450 V and 350μF with 10
μg plasmid DNA. G418-resistant (800 μg/mL) cell clones were screened by
PCR with hA20 specific primers for hA20-integration. Somatic cell nuclear
transfer (SCNT) was performed as recently described (Cloning Stem Cells 7:
35-44, 2005).
Results: A total of 80 cell clones were hA20-positive in PCR screening from
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4 rounds of transfection after a 14 days G418 selection period. Thirty positive
cell clones were re-selected for 14 days with G418. Four of these cell clones
were used as donor cells for SCNT. Immediately after SCNT, reconstructed
embryos were transferred to 10 synchronized recipient sows (~80 reconstructed
embryos per recipient). Ultrasound examination on days 23-25 of pregnancy
confirmed established pregnancies in 7 of 10 recipient sows. Two pregnant
animals were sacrificed on day 30 of pregnancy and a total of 8 fetuses were
isolated. PCR and Southern Blot analysis showed integration of the hA20 gene
in 6 of 8 fetuses. RT-PCR analysis conducted on transgenic PFFs derived from
hA20-positive fetuses demonstrated mRNA expression of the hA20-gene. Six
out of 16 piglets born recently showed integration of the hA20-gene and were
healthy at the time of birth.
Conclusions: The hA20-vector can be integrated in PFFs and hA20 transgenic
PFFs can successfully be used in SCNT to produce transgenic offspring. The
selection method for transgenic PFFs needs to be optimized to ensure that all
donor cells used for SCNT carry the transgene. Further analysis will focus on the
expression patterns and biological function of hA20 in transgenic piglet organs.
Another approach will be to introduce an endothelial specific promoter active
in pigs to target expression of hA20 to the endothelial cell layer. Providing
the endothelial cells with a higher anti-apoptotic potential could decrease their
susceptibility to cell death.
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We have produced genetically engineered pigs by heterozygous knockout of α1,3-galactosyltransferase gene (GalT-KO) and co-expression
of two transgenes, human decay-accelerating factor (hDAF) and
N-acetylglucosaminyltransferase III (GntIII), using the technology of somatic
cell nuclear transfer (SCNT; Takahagi et al., 2005). Cells collected from
these pigs were used to generate homozygous GalT-KO cells by means of
spontaneous mutation phenomenon of heterozygous GalT-KO cells during
cultivation, i.e. loss of heterozygosity. Then homozygous GalT-KO pigs have
been successfully cloned by SCNT (Fujimura et al., 2008). Natural breeding
of the heterozygous GalT-KO pigs also gave rise to three homozygous GalTKO pigs. The objective of the present study was to investigate the possibility
of cloning the homozygous GalT-KO pigs by SCNT as an alternative approach
for the preservation of those animals.
Primary cultures of preadipocytes (Tomii et al., 2005) were established from
two of the homozygous Gal T-KO pigs at 6 month old (DK3-1, male and
DK3-2, female) and cryopreserved by routine procedures. Using these cells
as nuclear donors and in vitro matured oocytes as recipient cytoplasts, cloned
embryos were produced as described previously (Kurome et al., 2006). Cloned
embryos were transferred into the oviducts of estrus synchronized recipient
gilts after in vitro culture for 1- 2 days.
Transfer of the 547 cloned embryos reconstructed with the donor cells from
DK3-1 into 6 recipients gave rise to 6 pregnancies (100%). Although two
miscarried at 30 and 21 days of gestation, one recipient farrowed 3 piglets,
including one stillborn piglet (Production efficiency: 3.3%, 3/92). The other
3 recipients are due in March, 2008. Two to 4 fetuses were confirmed by
transabdominal ultrasound examination in these recipients, respectively. When
176 cloned embryos derived from DK3-2 were transferred into 2 recipients,
both became pregnant, and two stillborn piglets were delivered.
Homozygous knock-out of the GalT gene was confirmed in all of the cloned
pigs obtained by PCR and PCR-Southern (Takahagi et al., 2005). These data
demonstrated that GalT-KO pigs can be efficiently produced by SCNT, hence
cloning technology is suggested to be a feasible option for clinical application
of the GalT-KO pigs.
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1667 ANTI-CD40L ANTIBODY NOT CTLA4IG TREATMENT
PROLONGED SURVIVAL OF XENOGENIC ISLET GRAFTS
INDEFINITELY
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1
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Research Center, 4Department of Pathology, Asan Medical Center, University
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Pancreatic islet transplantation can cure insulin dependent diabetes
mellitus (IDDM). However, the shortage of the donor graft is one of the
major limiting factors in clinical application of islet transplantation. In
this perspective, the porcine pancreatic islet can be used as an alternative
donor source. In this study, we compared the effect of anti-CD40L (MR1)
antibody with CTLA4Ig on preventing islet xenograft rejection in pig to
mouse model. The pig islets were isolated from CMS miniature pig and
5,000 IEQ were transplanted underneath the kidney capsule of C57BL6/J
mouse rendered diabetic by streptozotocin. The mean survival day of the
graft without treatment was 15 „b 2 days. Immunohistochemical analysis
of the rejected graft showed infiltration of CD4+ and CD8+ T cells into
the graft from 3 days post transplantation (DPT). To control the rejection
process, the transplanted mice were injected i.p. either with 50 ug/mouse
of CTLA4Ig, 7 times every other day or with 500 ug/mouse of antiCD40L (MR1) antibody for 5 consecutive days from DPT 0. The MR1treated graft, but not CTLA4Ig-treated, survived longer than 200 days
with well controlled blood glucose level in 8 out of 8 transplanted mice.
Immunohistochemical analysis showed intact insulin containing graft
with infiltration of CD4+ and CD8+ T cells in peri-islet space in MR1treated recipient. Of note, approximately 40% of the infiltrating CD4+ T
cells were Foxp3+. Whereas, in CTLA4Ig treated mice, the graft site were
infiltrated with CD4+ and CD8+ T cells without insulin staining cells and
only 2~3% of CD4+ T cell expressed Foxp3. The ratio of CD4+FoxP3+
T cells in splenocytes and peripheral blood mononuclear cells from MR1
treated recipient was not significantly different from CTLA4Ig treated
mice. Conclusively, targeting CD40-CD40L signal pathway rather than B7CD28 pathway is more beneficial in preventing pig to mouse islet xenograft
rejection by inducing Tregs in the graft site.
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1668 ALPHA1,3-GALACTOSYLTRANSFERASE KNOCKDOWN
IN COMBINATION WITH LOW-DOSE GAL ALPHA(1-3)GAL
BINDING LECTIN CONFERS PORCINE ENDOTHELIAL CELL
RESISTANCE TO AB/COMPLEMENT MEDIATED CYTOLYSIS
BY PI3K/AKT-DEPENDENT HO-1 UP-REGULATION
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1669 EVALUATION OF CULTURED NEONATAL PORCINE
SERTOLI CELLS AND THEIR EXPRESSION OF
IMMUNE-PRIVILEGE RELATED MOLECULES IN VITRO
Z.Z. Yin, F. Hu, L. Wang, L. Xie, Y. Xiang, G. Chen, S. Chen
Institute of Organ Transplantation of Tongji Hospital, Huazhong University of
Science And Technology, Tongji Medical College
Background: Sertoli cells (SCs) protect co-grafted allogeneic and xenogeneic
islets from immune destruction and reverse diabetes in immunocompetent and
autoimmune animals. SCs are thought to confer immune privilege to the testes,
probably by producing cytokines that act locally to inhibit immune response.
But the mechanisms underlying immune privilege are not well understood. In
this study, SCs isolated and identified from 10 to 15 day-old landrace testes
were evaluated the biology and detected the expression of immune privilegerelated molecules in vitro.
Methods: Testes were harvested from 10 to 15 day-old landrace pigs. SCs were
successfully prepared by a modified two-step enzymatic digestion method with
collagenase type V, trypsin and DNase I, then cultured in DMEM/F12 with 5%
FBS at 37¡æ,5% CO2 atmosphere, and then identified by electron microscope.
As a specific SCs marker, Sox9 was detected by both immunocytochemistry
and reverse transcription-polymerase chain reaction (RT-PCR). Viability and
apoptosis of cultured cells were measured by flow cytometry with annexin V
and propidium iodide. The viability of long-term cultured porcine SCs was
detected by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrasodium bromide
(MTT). With RT-PCR, we investigated some immune privilege-related
molecules expressed on the SCs, such as Fas ligand (FasL), transforming
growth factor ¦Â (TGF-¦Â1, TGF-¦Â2, TGF-¦Â3), clusterin, CD46, CD59, DAF
and Bcl-2. Additionally, clutserin and Bcl-2 expressed on cultured SCs were
also measured by western bolt.
Results: With the identification, the purity of SCs isolated by our modified
methods were accounted more than 90%. In this culture system, viabilities
were more than 95% assayed by trypan blue exclusion dye. The self apoptosis
and necrosis rate of SCs was 4.73£¥¡À1.70£¥ after 3 days culture. The viability
of SCs were found to be the highest at the seventh day of culture, however,
after being cultured for 21 days, the viability began to reduce rapidly. Sox9
was found to be expressed on our cultured SCs.The expression of FasL on the
neonatal SCs was weakly positive or nearly negative, whereas, TGF-¦Â1, TGF¦Â2, TGF-¦Â3, clusterin, CD46, CD59, DAF were strongly positive, but the
Bcl-2 was negative. By western blot, we confirmed that clusterin was indeed
expressed and the Bcl-2 was absent, although it was found to be expressed on
the tissue of testis.
Conclusions: Our modified two step method had a yield and purity similar
to previous reports measured with one step method, but the viability was
much better than it. Sox9 as specific cell marker for identifying SCs could
clearly identify transplanted SCs in heterotopic sites. These immune privilegerelated molecules may be useful for future investigate the mechanism of the
immuneprivileged sites.
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Background: A major barrier to clinical xenotransplantation is preformed
xenoreactive natural antibodies (XNA) found in higher primates which react
to Gal¦Á(1,3)Gal (¦Á-Gal) epitopes found on lower species. Accommodation of
organs to xenogeneic recipients involves upregulation of cytoprotective genes
and resistance to complement dependent cytotoxicity (CDC).
Methods: To develop methods of increasing these organ-protective effects, we
established an in vitro CDC model utilizing human serum as the source of XNA
and porcine endothelial cells (pEC) as targets.
Results: Using this system we demonstrated that downregulation of ¦Á-Gal
epitopes by siRNA silencing of ¦Á1,3-galactosyltransferase (¦Á-GT) led to
marginal protection (62%~85%) from CDC while combined treatment with
Griffonia simplicifolia isolectin B4 (GS-IB4) at low concentration (2&micro;g/
ml), led to complete protection (¡Ö100%). However, GS-IB4 alone, only upto
24 &micro;g/ml, began to achieve a significant protective effect against CDC.
Interestingly, SiRNA silencing and GS-IB4 mediated effects were not associated

with inhibition of IgG, IgM or C3c binding to cells, but with significant
decreased E-selectin expression and cytoprotective gene HO-1 upregulation.
PI3K inhibitor LY294002 could block the elevation of HO-1 protein expression
and reverse the protective effect of SiRNA and GS-IB4 against CDC.
Conclusion: These data support the use of combination approaches targeting
independent accommodation mechanisms to synergistically enhance donor
organ survival in a xenogeneic setting.
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1670 RESISTANCE OF PORCINE SERTOLI CELLS
TO XENOREACTIVE ANTIBODIES MEDIATED
COMPLEMENT LYSIS
Z.Z. Yin, L. Wang, Y. Xiang, L. Xie, F. Hu, G. Chen, S. Chen
Institute of Organ Transplantation of Tongji Hospital, Huazhong University
of Sc
Background: Sertoli cells£¨SCs£© contain immunoprivilege properties
which allow them to survive as allografts and to protect the co-transplanted
islets from rejection. We have shown previously that neonatal porcine sertoli
cells£¨NPSCs£© express clusterin and complement regulatory proteins,
such as CD46, CD59 and DAF. Prior to the transplantation of NPSCs
into humans, it is necessary to determine whether they can also protect
themselves from humoral injury mediated by xenoreactive antibodies
and complement. ¦Á-Gal has been detected in the porcine testis, however,
whether it expresses on NPSCs is still unknown. Thereby, we examine
¦Á-Gal expression on our isolated NPSCs and the binding capability
with preformed xenoreactive antibodies. Furthermore, an in vitro model
was used to assess whether NPSCs could resist xenoreactive antibodies
mediated complement lysis.
Methods: SCs were isolated from testes of 10 to 15 day-old landrace
pigs. ¦Á-Gal expression on SCs was measured by RT-PCR, FACS and
cytoimmunofluorescence. The binding of human serum IgG and IgM with
SCs was assayed by FACS and cytohistochemistry. After the incubation of the
cultured SCs with 20% human B serum in vitro, the cellular lysis and cytotoxicity
assay were detected with Cyto Tox-ONETM Homogeneous Membrane
Integrity Assay and MTT method, and then activation of the complement
cascade was examined by immunohistochemistry and immunofluorescence.
The SV40-porcine endothelium cells line (SV40-PED) was served as control
cells. Finally, the expression of clusterin on either sertoli cells or the SV40PED cells was detected by RT-PCR and western blot.
Results: ¦Á-Gal expression was found on SCs by FACS and
cytoimmunofluorescence, which was confirmed at mRNA level by RT-PCR.
The binding of human serum IgM and IgG with SCs was 24.59¡À9.85 and
9.91¡À1.25 (mean fluorescence intensity) respectively, while the binding
with SV-40 PED was 46.45¡À4.75 (P<0.05, vs. SCs) and 12.99¡À1.26.
After incubation with 20% human serum, cellular lysis ratio of the SV40PED was 53.13%¡À14.53%, while lysis ratio of the SCs was significantly
lower (24.38%¡À0.50%, P<0.01), the viability of SCs and SV40PED were 98.73%¡À18.84% and 52.43%¡À8.08%, respectively. With
immunohistochemistry and immunofluorescence, C3 and C4 were found
binding on both the SCs and SV40-PED cells, however, C5b-9 was only
detected on SV40-PED cells. With RT-PCR, mRNA of clusterin, CD46, CD59,
and DAF were all found to be expressed on both SCs and SV40-PED cells.
Among these proteins, clusterin expression on sertoli cells and SV40-PED cell
line was further confirmed by Western Blot.
Conclusions: ¦Á-Gal was expressed on NPSCs, and the SCs could bind
with the human serum IgM and IgG. In vitro, Compared with the SV40PED, NPSCs could resist xenoreactive antibodies of human serum mediated
complement lysis by preventing the C5b-9 formation. Furthermore, expression
of clusterin, CD46, CD59 and DAF between NPSCs and SV40-PED has no
difference, however, the binding of IgM with NPSCs was significantly lower
than SV-40 PED. Therefore, we presumed that NPSCs resisted xenoreactive
antibodies mediated complement lysis may associated with their lower binding
of the xenoreactive IgM.
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1671 SURVIVAL OF NEONATAL PIG ISLETS IN DIFFERENT
CULTURES
M.G. Lopez-Santos2, B. Ramírez-González2, O. Ramirez-Espinosa2,
L.M. Dorantes-Álvarez3, H. Astudillo de la Vega2, R.V. González-Salas1,3
1
Departamento de cirugía, Facultad de Medicina Universidad Nacional
Autónoma de México, 2Laboratorio de Xenotrasplantes Hospital Infantil
de México “Federico Goméz”, 3Departamento de Endocrinología Hospital
Infantil de México “Federico Gómez”
Xenotransplants can be an alternative for the treatment of diabetes mellitus,
because of the lack of human donors, therefore the importance to improve the
quality of purification, viability and functionality of the islets so they can be
used in future transplants. The main goal of this study was to determine the
optimal conditions of viability and functionality of the cell culture (islets of
langerhans) for a period of time of 24 h and outside optimal culture (37oC
/ 5%CO2). Here we used the pancreas of neonatal pigs (age 7 days), the
purification of the islets was determined by enzymatic digestion (Liberase
H) cultivated at 48 h/37oC/5%CO2. For this study we used different kind
of medium (F-10/Alb, F-10/SFB, RPMI) and three different levels of
temperature at (25oC, 4oC and 37oC without CO2). The viability of the
culture was determined with Acridine Orange / Propidium iodide (AO/PI) and
the functionality with static stimulation of glucose (SGS) at several times 0, 6,
9, 12, and 24 h. The results show that at normal temperature (25oC) and using
medium F-10/Alb, after 12 h, we obtain viability between 90-95% of total
and a productivity of insulin above of 70 μIU/ml/h. With this obtained data,
we keep the islets in optimal functionality an viability for the transplant in a
period of no less than 12 h.
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1672 FUNCTIONALITY AND VIABILITY AFTER ENZYM
DISAGGREGATION OF NEONATAL PIG ISLETS.
B. Ramírez-González2, M.G. López-Santos2, L.M. Dorantes-Álvarez3,
A.L. Rodríguez-Ventura2, O. Ramírez-Espinosa2, H. Astudillo de la Vega2,
R. Valdés-González1,2
1
Departamento de Cirugía, Facultad de Medicina Universidad Nacional
Autónoma de México, 2Laboratorio de Xenotrasplantes Hospital Infantil
de México “Federico Gómez”, 3Departamento de Endocrinología Hospital
Infantil de México “Federico Gómez”
The islets of Langerhans posses a system of vascular communication and
paracrine on point communications those are critical in cellular relationship,
regulation, production and hormone secretion. The distribution of every cell
point settles in a specific microenvironment depending the cellular age.
In this study we describe the cellular micro organization of the main types of
cellular pig islets (age between 7 to 30 days) as well as their functionality while
being isolated and disaggregated in an in vitro system.
The disaggregated islets at 48 h were presented with a parameter of stimulation
1(IS1) of 2.42 ± 0.49 and IS2 of 0.70 ± 0.06 with an insulin production (PI)
of 12.62 ± 1.15 and 5.66 ± 1.26 μUI/ml/h respectively. Meanwhile, the intact
islets show an IS1 of 20.82 ± 0.7 with a PI 137.50 ± 4.18 and an IS2 of 21.37
± 2.81 with a PI of 121.4 ± 21.34 μUI/ml/h. The viability post-trypsin was
greater than 95% in all cases. At 24 h, viability was of 94 ± 3.86% and 89.54 ±
4.97% in the intact and disaggregated islets respectively, without presenting an
important variation at 48 h of culture.
The results of the immunofluorescence of those pigs (30 days) show 61% of
positive cells of insulin, a 28% for glucagons and a 5% for somatostatine.
In pigs (7 days) show a 45% of insulin, an 18% for glucagon and a 3% for
somatostatine. Evidently it exists an important difference of functionality
between disaggregated islets and non disaggregated islets, so we conclude
that the percentage decreases probably because of the importance of the
intercellular unions.
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1673 XENOVIROLOGY LABORATORY ORGANISATION:
TASKS AND ISSUES
O. Garkavenko, D. Nathu, S. Wynyard, P. Tan, R. Elliott
Living Cell Technologies Ltd, New Zealand
Xenotransplantation is an emerging technology that aims to alleviate the
shortage of human donors. Pigs are considered to be the most suitable donors.
One of the main concerns in the field is the risk of cross-species infection from
donor to recipient.
Diagnostic laboratories concerned with xenovirology must be able to perform
several key tasks. This includes the establishment of reliable and sensitive
assays for the detection of porcine infectious agents as well as the development
of strategies for donor safety evaluation, source herd maintenance and recipient
follow-up. Laboratories can expect to progress through two distinctive stages.
The first, focused primarily on research and development, comprises such
tasks as the identification, evaluation and establishment of a donor herd
and the development of a monitoring strategy for source herd maintenance.
The following criteria should be considered essential for the establishment
of a donor herd: the absence of xenotransplantation important pathogens
and favourable PERV characteristics (absence of an infectious PERV, low
PERV copy number). Diagnostic assays for recipient follow-up must also be
developed. The second stage is the conversion of the research laboratory to a
medical diagnostic laboratory and its certification. The unique characteristic
of a xenovirology laboratory is the synergy of knowledge and skills from
veterinarian and human medical diagnostics as well as the ongoing search for
new infectious agents and improvement of modern techniques for donor and
recipient surveillance.
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1674 WESTRAN PIGS: A UNIQUELY INBRED COLONY
SUITABLE FOR XENOTRANSPLANTATION
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1675 EFFECT OF INTRATHYMIC INOCULATION WITH
MESENCHYMAL STEM CELLS ON DISCORDANT RODENT
CARDIAC XENOGRAFT REJECTION
Z. Shen1, Z. Zhu2, M. He3, X. Zhu4
The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University, 4The First Affiniatied Hospital of Soochow University
Objective: This study was designed to investigate the effect of ntrathymic
inoculation with MSCs on the the recipient immunoloregulation and on the
discordant rodent Cardiac Xenograft Rejection with the model of guinea pig to
rat xeno- transplantation and to explore the mechanisms behind.
Materials and methods: BMSCs of guinea pig were expanded to third
passage, then inoculated into thymuses gland of rats. After inoculation, we
observed the change of CD4+CD25+ T regulatory cells in rats. Donors(guniea
pig) and recipients (SD rat) were divided into four groups. Group A (Control
group); Group B (injection with CVF); Group C (IT inoculation with MSCs);
Group D (CVF injection plus IT inoculation with MSCs).The grafted heart
mean survival time (MST), the proliferation of mixed lymphocyte reaction
(MLR) ,the expression of GATA-3,CCR3 and the pathology of xenograft were
observed.
Results: The blood CD4+CD25+ regulatory T cells were higher in experiment
groups compared with control group, the stimulator index of MLR in group
C much lower significantly than group Control, the expression of GATA£3,
CCR3 of Group D were highest and the MST of group D were the longest
among the four groups.
Conclusions: CVF injection plus IT inoculation with MSCs could prolong the
survival time of rats with xenograft.
1
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1676 INDUCTION OF IMMUNOTOLERANCE BY MIXED
XENOGENEIC CHIMERA WITH MACROPHAGES
CLEARANCE
Z. Shen1, Y. Zhu2, M. He3
The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University
Objectives: In this study, we aimed to investigate whether macrophages
clearance could help to establishment mixed chimeras then, we explore the
mechanisms of immunotolerance in xenotransplantation induced by establishing
the guinea pig to rat mixed chimeras model with a non-myeloabalative
preparative regimen.
Methods: Recipient SD rats were conditioned with sublethal whole body
irradiation (WBI), administered with intraperitoneal injection of cytoxan(CTX),
then treated with clodronate-encapsulated liposomes before guinea pig bone
marrow cells were infused .Rat spleen and liver Blood and bone marrow
cells were collected to examine macrophage depletion and the percentage
of labeled guinea pig bone marrow cells, Mixed lymphocyte reaction
(MLR) was also performed. then divided randomly into 6 groups: group
I£¨control£¬n=5£©¡¢group II£¨cobra venom factor(CVF), n=5£©¡¢group
III£¨CVF+ clodronate-encapsulated liposomes, n=5£©¡¢group IV£¨CVF+
BMC, n=5£©¡¢group V£¨CVF+ BMC + blank liposomes, n=5£©¡¢group
VI£¨CVF+ BMC + clodronate-encapsulated liposomes, n=5£©.The survive
time of xenograft was measured and the histopathologic observation was
carried out after the graft arrest. The changes of IgG were detected before heart
transplantation and graft arrest by flow cytometry.
Results: Clodronate-encapsulated liposomes treatment resulted in complete
depletion of both liver Kupffer cells and splenic macrophages Macrophages
depletion increase the percentages of infused labeled guinea pig bone marrow
cells in the rat blood Recipient SD rats were specifically tolerant to the guinea
1
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K. Moyle1, D.M. Simond1, P. Holyoake2, C. Moran2, P.J. O’Connell1,
W.J. Hawthorne1
1
The Centre for Transplant & Renal Research, Westmead Millennium
Institute, Westmead, NSW, 2145, 2University of Sydney, Faculty of Veterinary
Science, NSW, Australia
Introduction: The highly inbred Westran pig (WTP) colony is being further
developed and characterised in order to meet the immunological & inherent
safety criteria for clinical xenotransplantation.
Method: These isolated miniature pigs have been inbred for eleven successive
generations with breeding directed by pig size, genetic markers and ABO
blood group. Assessment of genetic and immunological homogeneity
was performed using ABO blood grouping, mixed lymphocyte reaction
(MLR), lymphocytotoxicity assay (LCA), monitoring of hyperpolymorphic
microsatellite (HPM) markers and sequence-genotyping of the swine leucocyte
antigen complex (SLA=MHC). Genomic DNA was extracted & PCR fragments
analysed to identify relevant genetic loci & to sequence MHC class I & II on
a Licor sequencer.
Results: A total of 985 live pigs have been bred from 11 generations of full
sibling matings. Current 11th generation pigs reach an average adult weight
of 67.9kg + /- 4.0kg at 12months of age. All are blood group O with negative
MLR’s and LCA across the colony. There are no differences between WTP
across MHC SLA class I 6, 7, 14 & class II DQA, DQB, DRA & DRB loci,
however, all WTP display a heterozygous SLAI-1RFLP pattern. This level of
functional inbreeding has been confirmed by microsatellite analysis of highly
polymorphic markers, which show that 52 of 53 chromosomally dispersed
markers were fixed by the 9th generation. This level of fixation was consistent
with 19 to 20 generations of full-sibling inbreeding. The calculated inbeeding
coefficient at generation 10 was 0.98159. Same sex and female to male
skin grafts between sibs are accepted long term and third party donor skin
is rejected. However due to inbreeding fertility rates decreased with the 8th
generation having 3.3 (SD ± 1.45, Range 1-6) live births. However, we have
counteracted this problem and in 2007 produced an average litter size for the
tenth generation pigs of 4.5 (SD ± 2.06, Range 1-9) live births.
Conclusion: Westran pigs are of a suitable size for transplantation into patients
are blood group O and homozygous for 7 SLA loci. Variation at the SLA-1 locus

appears due to gene duplication or an artifactual amplification from a closely
related locus (SLA-5), thus SLA-1 is also homozygous. HPM analysis suggests
a highly inbred core herd approaching genetic identity at 98% inbreeding.
This is a unique colony which is ideal to assess aspects of transplantation and
xenotransplantation processes without the need for immunosuppression.
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pig as certified by MLR assay. Group VI showed the longest mean survival
time of cardiac xenograft .The level of IgG was increased slightly in every
group after heat transplantation, but the increase of group VI was slower than
other groups.
Conclusions: (1) Depletion of macrophages with clodronate-encapsulated
liposomes can improve guinea pig chimerism in sublethally irradiated rats.
(2) Mixed xenogeneic chimera can significantly prolong discordant xenograft
survival time after using Chinese Cobra Venom Factor (CVF) in guinea pig to
rat model.
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1677 PRODUCTION AND CHARACTERIZATION OF PIGS
TRANSGENIC FOR HUMAN HEMEOXYGENASE-1 BY
SOMATIC NUCLEAR TRANSFER
W. Ramackers2, B. Petersen1, A. Lucas-Hahn1, D. Herrmann1, W.A. Kues1,
S. Bergmann2, W. Baars2, J.W. Carnwath1, R. Schwinzer2, M. Winkler2,
H. Niemann1
1
Institute of animal genetics, Dept. of Biotechnology, D-31535 Neustadt,
Germany, 2Transplant Laboratory, Hannover Medical School, D-30625
Hannover, Germany
Introduction: The hyperacute rejection after porcine-to-human
xenotransplantation can now be reliably overcome either by transgenic
expression of complement regulating factors (done in this study) or by
knocking out the gene for α1,3-galactosyltransferase in pigs. The next
immunological hurdle is the acute vascular rejection (AVR) primarily caused
by endothelial cell activation. Human Hemeoxygenase-I (hHO-1) is known
to have anti-apoptotic and cell protective properties. Thus, the expression
of hHO-1 on porcine endothelial cells could have beneficial effects in a
xenotransplantation setting. Here we describe transgenic pigs with expression
of CD55 and hHO-1.
Methods: Fibroblasts were obtained by an ear punch from a CD55
transgenic female pig and were cultured in vitro (Kues WA et al. 2005
Biol Reprod 72:1020-1028). Cells reaching confluency of 70-80%,
were detached with EDTA/trypsin and subsequently transfected by
electroporation at 450V/350 μF with a vector coding for hHO-I driven by
the SV40 promoter. Transfected cells were selected for resistance against
G418 (800 μg/ml) for 14 days. Resistant cell clones were screened for
integration of the vector by PCR. One positive cell clone was selected for
somatic nuclear transfer.
In total, 205 reconstructed embryos were transferred to two synchronized
peripuberal German Landrace gilts which gave birth to nine live piglets,
all with normal birth weights. The expression of the transgenes (CD55 and
hHO-1) was determined by flowcytometry and Western blot in endothelial
cells and peripheral blood lymphocytes. The expression pattern of the
transgenes in different organs was shown by immunostaining, RT-PCR and
Northern blot.
Results: PCR and Southern blot analyses revealed that all of the offspring had
integrated the vector in their genome. Six transgenic animals were sacrificed
for further characterization. In these animals, the expression of CD55 and
hHO-1 in peripheral blood lymphocytes and cultured endothelial cells was
shown by flowcytometry and Western blot. In addition, though all animals were
cloned from the same cell clone, variations in the expression pattern and levels
could be observed in immunostaining, RT-PCR and Northern Blot. The animals
showed only weak expression of hHO-1 in most of the xenorelevant organs like
heart, kidney and liver.
Conclusion: These results show that hHO-1 in combination with CD55 can
be expressed in transgenic pigs. These results are encouraging and warrant
further studies on endothelial cell activation and the biological function of
hemeoxygenase-I in the context of xenotransplantation.
This study was funded by the Deutsche Forschungsgemeinschaft Ni 256/ 22-1,
-2, -3.
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1678 XENOGENEIC CHIMERAS SUPPRESS THE ACTIVATION
OF DONATOR ENDOTHELIAL CELLS BY DECREASING THE
EXPRESSION OF ICAM -1 AND VCAM-1
Z. Shen1, M. He2, Z. Liu3, H. Huang4, Y. Chen5
The First Affiniatied Hospital of Soochow University, 2The First Affiniatied
Hospital of Soochow University, 3The First Affiniatied Hospital of Soochow
University, 4The First Affiniatied Hospital of Soochow University, 5The First
Affiniatied Hospital of Soochow University
Objective: To observe the effects of the rat bone marrow mesenchymal stem
cells£¨BM-MSCs£© on the prolixferation of mouse lymphocyte in a co-culture
system. Then explore the mechanisms of tolerance in xenograft induced by
establishing the rat BM ¨CMSCS to mouse mixed chimeras model with a nonmyeloabalative preparative regimen.
Methods: A co-culture system with or without rat BM-MSCs was established
to observe the result.
Results: In the co-culture system, the OD value of the co-culture system and
the expression of ICAM-1 and VCAM-1 of the co-culture system with rat BMMSCs is lower than that without rat BM-MSCs£¨P <0.05£©.
Conclusions: The rat BM-MSCs can suppress the prolixferation of mouse
lymphocyte in the co-culture system. Non-myeloablative conditioning regimens
for xenogeneic BM-MSCs transplantation can successfully establish rat BM
¨CMSCS to mouse mixed chimeras model. Mixed chimeras can suppress
xenogeneic lymphocytes proliferation. Xenogeneic chimeras can suppress the
activation of donator endothelial cells ¨C decrease the expression of ICAM -1
and VCAM-1
1
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1679 A SURVEY OF THE ATTITUDE OF SCIENTISTS
TOWARD XENOTRANSPLANTATION
S-Y. Yen1, S-M. Lee2, C-F. Tu3, S-M. Tang4, J. Tapsoba5
1
Graduate Institute of Management of Technology, Feng Chia University,
2
Graduate Institute of Management of Technology, Feng Chia University,
3
Animal Technology Institute Taiwan, 4Financial & Economical Law, Asia
University, 5Department of Applied Statistics, Feng Chia University
The progress in the pharmaceutical biotechnology and the genetic engineering
such as the genetic modification of animal and the cloning of animal has
triggered the development of research on xenotransplantation. While
potential benefits may be derived from the therapeutic technology, many
concerns including moral, ethical and legal issues and public health risks are
often raised. The paper presents the results of a questionnaire based survey
study of the attitude of scientists involved in biotechnical research toward
Xenotransplatation in Taiwan. The study population consisted of the employees
of the Animal Technology Institute in Taiwan (ATIT). The institution
consists of 210 scientists involved in research on veterinary medicine and
biotechnology. The study sample is composed of 91 participants that were
randomly selected from the population and each participant voluntarily
completed a twenty-item questionnaire.The data from the survey was analyzed
using SPSS 13.0 statistical software. The Cronbach’s alpha coefficient that
measures the overall consistency of the questionnaire was 0.689 indicating a
good reliability. A principal component analysis revealed seven factors that
jointly accounted for 67.63% of the overall variation in the measures. The age
of the respondents ranges from 20 to 63 years and 75% were younger than
47 years old. Fifty participants are female (55%) and the majority of them
are married (60%). Twenty-seven were Buddhist and many (43.8%) did not
have any religious belief. 35.2% had master’s degree or doctorate and 34.1%
completed their studies with a bachelor degree. 65.2% of the participants
agreed that using organs harvested from genetically modified pig for human
recipients was risky. However, most of them (55.6%) disagreed that clinical
studies on xenotransplantation should be banned through legislation. 92.3%
agreed that ethics and morality should be considered when developing the
xenotransplantation treatment. 85.4% thought that genetic modification of
animal organs should not violate ethical and moral rules. A clear majority
(95.6%) believed that animal welfare should be respected in any research
on xenotransplantation. 85.2% thought that xenotransplantation can be more
benefic than harmful to human society and 94.3% believed that it would solve
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the problem of human organ shortages. The nonparametric Kruskal-Wallis
test was used to detect variables that might have influenced opinions and it
turned out that gender and education did (p-value smaller than 0.05). The
survey highlighted a high level of awareness of xenotransplantation among
the respondents. Despite concerns over ethics, morals and animal welfare, the
majority of them had favorable opinions on the technology.
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1680 REVERSE XENOTRANSPLANTATION: HUMAN TO PIG
LIVER TRANSPLANTATION
G. Xiao1, O. Devon1, M. Pakerev1, R. Huneke2, W. Meyers1
Department of Surgery, Drexel University College of Medicne, 2University
Animal Labarotary Resources, Drexel University College of Medicine
Introduction: The first step of this study is to establish the feasible model of
liver transplantation from human to pig. Eventually, the successful creation of
this unique model will allow us to test a panel of experimental medications
without subjecting human to potential side effects and to avoid potential human
morbidity and mortality.This study is approved by IRB.
Methods: Selection of human donor liver, which is not suitable for human liver
transplantation secondary to variable reasons, is based on size-matching, preexisting liver disease, overall hepatic function, and liver biopsy. A Yorkshire
pig weighing greater than 60 kg is premedicated, intubated, and anesthestized.
Two grams of methylprednisolone is given to the pig intravenously 10 minuts
before incision. The abdomen is entered using midline incision combined
with bilateral subcostal incisions. The pig liver has significant amount of
liver parenchyma embedded the whole inferior vena cava (IVC), even 10 to
12 cm below the portal hepatis level. This special anatomy makes piggy-back
technique impossible. We used traditional liver transplant technique without
bypass, a small cuff of liver parenchyma is left on the infrahepatic IVC during
the transection. We kept lower IVC transection plan as high as possible to
benefit the later lower IVC anastomosis so that we do not have to use venous
graft as interposition in case human liver lower IVC can not reach the pig IVC.
The hepatic artery, common bile duct, and portal vein are dissected, ligated and
divided close to liver hilum. The suprahepatic IVC is clamped and three hepatic
veins were dissected and transected closed to liver. The pig liver is removed,
small cuff of liver tissue which is wrapped up the lower IVC is dissected off
IVC, leaving at least 8 mm free edge for lower IVC anastomosis. The human
liver implantation is performed in the following order: suprahepatic IVC,
infrahepatic IVC, portal vein anastomosis.
Results: To date, we have performed two successful human to pig liver
transplants. Three anastomoses were completed and the human liver appeared
well-perfused.
Conclusion: This new promising technique and model of reverse liver
xenotransplantation from human to pig may be a reasonable approach to
produce and maintain a functioning human liver for early analysis of medication
metabolism, drug accumulation, and dose escalation toxicity.
1
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A. Plege, W. Ramackers, K. Borns, M. Winkler, R. Schwinzer
Transplant Laboratory, Hannover Medical School, Germany
Objectives: Triggering of programmed death 1 receptor (PD-1) by its ligands
PD-L1 or PD-L2 delivers negative signals thereby downregulating T cell
activation. Thus, transgenic expression of human PD-L1 in pig cells and tissues
is regarded to be an approach to prevent T cell reactivity after pig to human
xenotransplantation. Recent data suggest that pig PD-L1 is able to functionally
interact with human PD-1 (Jeon et al., Xenotransplantation, 14:236, 2007)
implying that endogenous porcine PD-L1 could as well be a target for
immunomodulation after xenotransplantation. It was the aim of this study to
assess the expression patterns of PD-L1 and PD-L2 in the pig.
Methods: Expression of porcine PD-L1 and PD-L2 was analyzed on mRNA
level by semi-quantitative RT-PCR. RNA was isolated from cultured cells
(PBMC: peripheral blood lymphocytes, B cell lines, endothelial cells) as
well as from tissue samples (thymus, lymph nodes, spleen, heart, liver, lung,
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1682 REFINED ANAESTHESIA AND PERIOPERATIVE
CARE IN A PRECLINICAL TRANSPLANTATION MODEL WITH
PRIMATES
G.M. De Benedictis1, F. Fante2, L. Bellini1, E. Tognato2,3, M. Boldrin2,
A. Dedja2,4, L. Ravarotto5, E. Ancona2,4,6, R. Busetto1, E. Cozzi2,4,6
1
Dept. of Clinical Veterinary Sciences, Padua, Italy, 2CORIT, Padua, Italy,
3
Dept. of Pathology and Veterinary Hygiene, Padua, Italy, 4Dept. of Surgical
and Gastroenterological Sciences, Padua, Italy, 5IZSV, Legnaro, Italy, 6Padua
General Hospital, Padua, Italy
Introduction: Improving safety and efficacy of anaesthesia is a critical aspect
of transplantation research with animals. Appropriate management allows
minimization of the risk of potential adverse events, which may considerably
impact the ultimate outcome of the study. With the aim of refining the procedure
in our primate transplantation model, in this series we introduced adjustments
to the anaesthesic protocol without modifying the selection of the drugs used
for anaesthesia.
Materials and methods: Forty-nine cynomolgus monkeys (3-7 kg) were
used in a xenotransplantation model as recipients of hDAF-transgenic pig
kidney. Based on the anaesthetic protocol animals were divided into 3 groups.
The different cocktails of drugs included sedation with ketamine 10 mg/kg
i.m., buprenorphine 0.01 (Groups A and C) or 0.02 (Group B) mg/kg i.v. and
induction with midazolam i.v. (1, 0.5 or 0.2 mg/kg respectively Group A, B, C)
and propofol to effect. Anaesthesia was maintained with isoflurane in oxygen
with (Group A) or without (Groups B and C) propofol continuous rate infusion
(CRI). During surgery, heart rate, ECG, pulse-oxymetry, non invasive blood
pressure, respiratory rate, capnometry, end-tidal isoflurane were measured. To
prevent perioperative hypothermia, animals were covered with lambskin and
transported in insulated transport cages warmed by hot water-bags; heat and
humidity exchanger, isothermic blanket and heating pads were used to reduce
intraoperative heat loss. Prewarmed fluids were used both for i.v. infusion and
for flushing the abdominal cavity.
Results: All animals arrived to the operating room with mild hypothermia. In
Groups A and B mean oesophageal temperature remained almost unchanged
during anaesthesia (35,7°C and 35,4°C, respectively). In Group C, temperature
increased gradually from 35,6±0,6°C to 37,2±0,9°C and was 36,6±0,7°C at the
end of the anaesthesia. Extubation time was compared in 10 animals from Group
A and 10 animals from Group B and C with similar mean body temperature
during surgery. After propofol CRI/isoflurane anaesthesia, the extubation
time was 18.67±8.04 min., while in animals receiving only isoflurane it was
6.98±0.36 min. The mean intraoperatory body temperature was analysed for
each animal and correlated to the extubation time. Interestingly, the reduced
body temperature was significantly correlated with a longer recovery time
(r2=0.4145).
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1681 EXPRESSION PATTERNS OF THE NEGATIVE
COSTIMULATORY MOLECULES PD-L1 AND PD-L2 IN
PORCINE CELLS AND TISSUES

kidney). PD-L1, PD-L2 and ß-actin mRNA was amplified by specific primers.
PD-L1:ß-actin and PD-L2:ß-actin ratios (densitometric units) were calculated
to determine the expression intensities of PD-L1 and PD-L2.
Results: PD-L1 and PD-L2 mRNA was readily detected in porcine PBMC. In
vitro activation of the cells by mitogen stimulation resulted in significant upregulation of PD-L1 and PD-L2 mRNA. B cell lines expressed less PD-L1 than
the entire PBMC population suggesting preferential expression in T cells and
monocytes. Primary endothelial cells isolated from pig aorta weakly expressed
both, PD-L1 and PD-L2. Studying PD-L1 and PD-L2 mRNA in tissue samples
from pig lymphoid organs revealed strong expression in lymph nodes, spleen,
and thymus. In addition, PD-L1 and PD-L2 mRNA was found in tissue samples
from kidney, heart, liver and lung. Markedly enhanced levels were detected in
kidneys which had been perfused with human blood using an ex vivo perfusion
circuit, suggesting up-regulation in response to endothelial cell activation.
Conclusion: PD-L1 and PD-L2 show very similar expression patterns in the
pig. Since PD-L1 and PD-L2 are differentially expressed in mice and humans
the function of these molecules might not be identical in different species.
The strong basal expression of PD-L1 and PD-L2 in various tissues and the
observation that further up-regulation is possible supports the assumption that
the two molecules are interesting endogeneous regulatory elements of the pig
to modify human T cell responses after xenotransplantation.
This work was supported by the DFG (Research Unit “Xenotransplantation”,
FOR 535).
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Conclusion: A more effective management of anaesthesia and faster
recovery were obtained by modifying the dosages of drugs administered,
whilst guaranteeing the maintenance of an optimal anaesthesia depth. Our
findings indicate that a higher oesophageal temperature during surgery is
always correlated with a shorter recovery time. Continuous monitoring of
the experimental procedures may allow the identification of possible areas
of refinement that may contribute to enhance the scientific outcome and the
ethical profile of complex experimental animal models.
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1683 ENHANCEMENT OF HUMAN CHIMERISM IN PIGS
THROUGH INHIBITION OF FETAL PORCINE NATURAL
KILLER CELLS
W.E. Beschorner1, P.E. Kudlacek1, T. Schieber2, K.F. Lechtenberg2
Ximerex, Inc., Blair, NE USA, 2Midwest Veterinary Services, Oakland, NE
USA
Objective: A major barrier to transplantation of pig tissue is vigorous rejection
of the xenograft. For diseases such as type 1 diabetes, autoimmunity may also
contribute to loss of the graft. Our program has developed the production of
chimeric donor pigs as a way to induce immune tolerance to the pig tissue.
Tolerance is induced outside of the patient and before transplantation, sparing
the patient considerable risk. The technology is supported by growth of human
cells within fetal pigs, generation of functional suppressor cells, and production
of CD4+/foxP3+ T regulatory cells. Large animal proof of principle includes
prolonged survival of pig aorta and pig hearts within sheep and two independent
trials of pig islet tissue into diabetic monkeys. In the diabetes studies, 5 of 6
monkeys showed prolonged survival and function of porcine islet cell clusters
without evidence of rejection, up to 222 days post transplant. They received no
anti-rejection drugs.
A technical challenge for the use of chimeric donor pigs is the difficulty in
generating sufficient chimerism within the pig. It is estimated that chimerism
needs to be greater than 0.3% to generate sufficient T regulatory cells for a
70 kg human recipient. While variable, typically chimerism less than 0.05%
is observed. Many procedures have been explored to enhance chimerism,
including fetal pig infusion of growth factors, accessory cells, different sources
of hematopoietic stem cells, and post-natal boosting with donor lymphocytes.
It was hypothesized that resistance to human cell engraftment is due to innate
immunity in the fetal pig. Here the natural killer cells were inhibited by
injecting antibodies to porcine NK cells into fetal pigs along with the human
hematopoietic cells.
Materials and methods: Human bone marrow and human cord blood from
a commercial source were processed for injection into fetal pigs at 45 days
gestation. Monoclonal antibodies were added to the fetal pig inoculum,
including anti-pCD16 and anti-pCD11R3 (Serotec), 100 ug/pig. Fetal pigs
received 1x107 bone marrow cells or 4x107 cord blood cells. Controls
consisted of sows in which the injected fetal pigs did not receive the antibodies.
At 7 weeks after birth, blood from the pigs was evaluated for the presence
of chimerism by PCR. Chimerism was quantified with flow cytometry using
antibodies specific for human lymphocytes.
Results: At 7 weeks of age, two of the three pigs injected with human cord blood
cells and anti-pig NK antibodies were chimeric, with 0.14 and 1.1% chimerism.
Of the five pigs injected with human marrow cells and anti-pig NK antibodies,
all were chimeric, with 0.15, 0.16, 0.34, 0.40, and 1.5% chimerism.
Conclusion: Inhibition of the fetal pig NK activity with antibodies to porcine
CD16 and porcine CD11R3 appeared to enhance the human chimerism within
the pigs. NK cells are known to contribute to hybrid resistance in hematopoietic
stem cell transplants and resistance to human stem cell engraftment in SCID
mice. NK cell inhibition in the fetal pig should enhance the generation of
specific T regulatory cells in donor pigs.
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1684 ENCAPSULATED SINGLE PORCINE ISLET CELLS
CONFER LONG-TERM IN VIVO FUNCTION
I. Stuiver
MicroIslet, Inc.
Sufficient tissue yield is a constant problem in the field of islet transplantation.
Clusters of islet cells have been shown to be highly functional in both xeno
and allo transplantation models and tissue specimens containing islet of
low mass, are not considered suitable for transplant. Disposal of this tissue
results in a significant loss in the islet yield and in many instances insufficient
mass for transplantation. Most islets from humans, rats and mice contain a
significant outer-layer of collagen, thus provides an increased opportunity
for intact islet isolation. Alternatively, porcine islets are encapsulated with a
thin or non-existent collagen membrane. At most, 50% of the islet is covered.
This leads to preparations that are more fragmented than those typically
found in other animals. Little evidence is available that indicate whether
fragmented or single-celled preparations function. A series of experiments
were conducted that tested whether encapsulated single celled or fragmented
preparations of porcine islets functioned in streptozotocin induced diabetic
mice.
Here we demonstrate that islets that have been triturated to be fragmented or
single cells can render diabetic mice normoglycemic for 190 days or longer. The
ability to use fragmented islets or single cells derived from the islet increases
the yield of useable transplant material by 30-50%. A series of experiments
were conducted that tested whether encapsulated single celled or fragmented
preparations of porcine islets functioned in streptozotocin induced diabetic
mice. In the first study, encapsulated single cells outperformed controls by 70
days. In the follow-up study, 50% of the animals in the broken islets and 25%
of the animals dosed with single cells were normoglycemic at day 290. Of the
control animals transplanted with complete islets, 100% had grafts failed by
day 215. In the subsequent dose response study, 1.5 and 3K IEQ single celled
doses performed 50% longer than 0.75K IEQ per mouse and 25% longer that
the 1.5K control arm.
These results imply that single and broken pig islet cell populations can
adequately produce insulin and promote long-term normoglycemia in a diabetic
in vivo setting. One question of significant interest is does the encapsulation
create an environment such that the cells are proximal enough so hormonal
cross-talk by insulin, glucagon and others can occur? Can this hormonal crosstalk also mediate a glucose responsive single cell? These and other questions
are currently being explored.
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1685 XENO-TRANSPLANTATION OF SKELETAL MYOBLAST
FOR ATTENUATION OF HYPERINSULINEMIA AND
HYPERGLYCEMIA
L. Ye1, K.O. Lee2, L-P. Su3, W.C. Toh1, H.K. Haider4, P.K. Law5, W. Zhang3,
E.K.W. Sim6
1
National University Medical Institutes, National University of Singapore,
Singapore, 2Department of Medicine, National University Hospital,
Singapore, 3National Heart Center, Singapore, 4Department of Pathology
and Lab Medicine, University of Cincinnati, Ohio, USA, 5Cell Transplants
Singapore Pte. Ltd, Singapore, Singapore, 6Department of Surgery, National
University of Singapore, Singapore & Gleneagles JPMC Cardiac Center,
Brunei Darussalam
Aim: Type 2 diabetes mellitus is characterized by hyperglycemia resulted
from insulin resistance: the impaired suppression of liver glucose output
and stimulation of muscle and adipose tissue glucose uptake in response to
insulin The study investigates the feasibility and efficacy of intra-muscular
transplantation of human skeletal myoblast (hSkM) for attenuation of
hyperglycemia and improvement of insulin sensitivity using a mouse model of
type 2 diabetes mellitus.
Methods: KK Cg-Ay/J mice (KK mice, an animal model of Type II diabetes
mellitus) aged 14-16 weeks after screening (fasting glucose> 6.5 mmol/L
and glucose > 13 mmol/L at 2-hour of fasting glucose tolerance test (GTT))
were divided into two groups (n=16 each group): KK group-1: receiving basal
medium only, and KK group-2: receiving hSkM transplantation. C57BL mouse
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was used as normal control to receive hSkM transplantation. Cells were intramuscularly transplanted into the skeletal muscle of KK and C57BL mice with a
transient cyclosporine treatment. Fasting GTT was performed at before and 12
weeks after treatment. HbA1c and fasting serum adiponectin, cholesterol (TG),
insulin and triglyceride (TG) were determined.
Results: Histochemical study demonstrated extensive survival of hSkMs
in the skeletal muscles of all animals receiving hSkM transplantation at
12 weeks. The nuclei of hSkM integrated into host muscle fibers. Fasting
GTT showed significantly reduced glucose (mmol/L) (0 hour = 5.84± 0.73,
0.5 hour= 12.69± 1.39, 1 hour= 13.6± 1.71, 2 hour = 7.26± 0.83) was
achieved in KK mice received hSkM transplantation as compared with KK
control mice (0 hour=7.32± 0.48, 0.5 hour= 17.47± 1.13, 1 hour=21.07±
1.61, 2 hour=14.96± 1.79). KK mice receiving hSkM transplantation
had reduced HbA1c, Chol, insulin, and TG, and reduced decreasing of
adiponectin. AKT activity assay showed improved AKT activity in KK
group-2 as compared with KK group-1. No hypoglycemia was found in
C57BL mouse.
Conclusion: These data suggested that hSkM transfer therapy attenuated
hyperglycemia, hyperinsulinemia, and improved glucose tolerance in a Type 2
diabetes mouse model. This approach may be served as an alternative treatment
for muscular insulin resistance of type 2 diabetes mellitus.
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1687 ASSESSMENT OF ACUTE REJECTION IN INTESTINAL
TRANSPLANT PATIENTS USING A PANEL OF MINIMALLY
INVASIVE ASSAYS
P. Tryphonopoulos, P. Ruiz, D. Weppler, R. Cirocco, M. Carreno, J. Vargas,
Y. Jin, A. Sornaraj, A. Berlanga, T. Kato, G. Selvaggi, A. Tzakis
University of Miami
Background: Intestinal transplantation is used for the treatment of intestinal
failure. The graft can be monitored for acute rejection early post transplantation
through a temporary ileostomy that we use for endoscopy / biopsies. Following
closure of the ileostomy access to the graft can be limited. Moreover, the patient
often leaves at some distance from the Transplant Center and cannot come
readily for a graft endoscopy and biopsy. The measure of serum citrulline on a
dried blood spot that the patient can mail to the Transplant Center has yielded
promising results and can serve as a warning of possible acute rejection if its
value drops below 13 umoles/Lt; however the level of specificity for detecting
acute rejection is not optimal. A panel of surrogate markers alongside citrulline
could serve to refine and improve specificity in detecting acute rejection
episodes, the latter which notably contribute to late graft loss.
Methods: Since March 2007, we studied blood or stool samples of 17 patients, 4
adults and 13 pediatrics who had undergone an intestinal (n=2) or multivisceral
(n=15) transplant. Ten of these patients presented 14 rejection episodes during
this period of time (mild n=5, moderate n=5 and severe n=4). We monitored
the intestinal graft function with 5 different tests, from the peripheral blood:
Perforin, Granzyme B, Serum citrulline, Cylex Immunoknow assay, or from
the feces: Calprotectin.
Results: During the rejection episodes: There was a significant increase of the
fecal calprotectin levels, a significant decrease of the serum citrulline levels
and an increase of the lymphocyte reactivity (Cylex).
Conclusions: Monitoring of the small bowel graft function with a panel of
minimally invasive assays may allow an early detection and a timely treatment
of a rejection episode.

1686 BENEFICIAL EFFECT OF LONG-TERM CULTURE
OF NEONATAL ISLET CELL CLUSTERS (NICCS)
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1688 THE NOVEL NF-~ ÈB INHIBITOR,
DEHYDROXYMETHYLEPOXYQUINOMICIN (DHMEQ)
PREVENTS LOCAL AND REMOTE ORGAN INJURY
FOLLOWING INTESTINAL ISCHEMIA/REPERFUSION
IN RATS
T. Suzuki1, K. Yamashita1, W. Jomen1, S. Ueki1, T. Aoyagi1, M. Fukai1,
H. Frukawa1, K. Umezawa2, M. Ozaki1, S. Todo1
1
Dept. of Surgery, Hokkaido University, 2Dept. of Applied Chemistry, Keio
University
Background: Nuclear factor-ƒÈB (NF-ƒÈB) regulates the expression of several
genes involved in inflammation, the immune response, apoptosis, cell survival
and proliferation. Many of these same genes are activated during ischemia/
reperfusion (I/R) injury. Here, we examined the anti-inflammatory efficacy
of a newly developed NF-ƒÈB inhibitor, dehydroxymethylepoxyquinomicin
(DHMEQ), in the intestinal I/R injury model of rats.
Method: Intestinal ischemia was induced by occluding the superior mesenteric
artery for 60 min. The experimental animals were divided into 2 groups:
untreated group, control; treated group, DHMEQ-treated (20 mg/kg). DHMEQ
were administered intraperitoneally at 60 min prior to clamping and 5 min
prior to reperfusion. Animal survival rates, intestinal tissue blood flow (ITBF),
serum levels of TNF-ƒ¿ and interleukin (IL)-6, and the histopathology of both
the intestine and lung were analyzed.
Results: The DHMEQ-treated animals exhibited higher values of ITBF and
suppression of TNF-ƒ¿ and IL-6 production, resulting in marked prolongation
of their survival times. Histopathological findings obtained by examining
tissues from control animals revealed severe intestinal mucosal damage and
disruption of the lung alveolar architecture accompanied by hemorrhage and
marked neutrophilic infiltration. These findings were significantly ameliorated
in DHMEQ-treated animals.
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E. Jimenez-Vera, D. Simond, K. Moyle, J. O’Hara, P.J. O’Connell,
W.J. Hawthorne
The Centre for Transplant and Renal Research, Westmead Millennium
Institute, Westmead Hospital, Westmead, NSW 2145, Australia
Introduction: As a means to treat patients suffering type 1 diabetes,
transplantation of porcine neonatal islet cell clusters (NICC) have the potential
to be used as a source for xenotransplantation. NICCs are used within the first
week following isolation; however, we do not know if outcomes will improve
by culturing the islets before transplantation or if extended culture is possible
to allow for pooling of preparations for clinical transplantation. In this study
we aimed to determine which NICC culture time point was optimal for in vivo
functional outcome.
Method: Pig pancreases from 1-3 day old pigs were used to isolate NICCs
using mechanical and enzymatic digestion. NICCs were cultured for up to 5
weeks post isolation at 37°C, 5% CO2. Each week for 5 weeks the number of
IEQ were determined, FACs analysis, static stimulation, Insulin:DNA ratio,
ATP activity, ethidium bromide and acridine orange viability staining, and
mouse transplants, were performed.
Results: Despite maintaining appropriate culture conditions there was an
significant loss in the number of IEQs over time p-values = 0.0001. There
was no significant difference at any other time point in the other parameters
investigated due to the high variability in number of NICCs cultured in each of
the experiments. However, preliminary diabetic mouse transplant data indicate
NICCs functioned better after they were cultured for two or more weeks post
isolation compared with results achieved after only one week of culture.
Conclusion: In these preliminary studies we have found that there was a
decrease in the number of NICCs over time. However, NICCs transplanted at
week one had poorer in vivo function than those transplanted following 2, 3
and 4 weeks of culture. Further experiments are required to investigate which
culture point achieves the optimum in islet numbers and function.
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Conclusion: DHMEQ effectively prevented both intestine and lung injuries in
rat intestinal I/R models. This agent may possess a good potency for clinical
application in various pathological settings including intestinal I/R and/or
inflammatory acute lung injury.
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1689 ASPERGILLUS-INDUCED SPONDYLODISCITIS AFTER
MULTIVISCERAL TRANSPLANTATION
U. Gerlach, S. Kohler, O. Guckelberger, J. Pratschke, P. Neuhaus, A. Pascher
Charite, Universitaetsmedizin Berlin, Campus Virchow Klinikum
Although the incidence of spondylodiscitis is rare, it has increasingly
been described in patients with low immunity, most commonly due to
immunosuppression, malignancy or chemotherapy.
We report on a case of fungal spondylodiscitis after multivisceral-transplantation
(MVTX). A 25-year old male patient suffering from short bowel syndrome
due to congenital intestinal malrotation and multiple abdominal operations
underwent MVTX and kidney transplantation (stomach, duodenum, pancreas,
liver, intestine, right kidney and adrenal gland) in June 2007. Baseline
immunosuppression consisted of tacrolimus and steroids with thymoglobulin
and infliximab added as induction therapy. The patient experienced one episode
of fungal pneumonia caused by aspergillus fumigatus which was treated with
Caspofungin and Voriconazole for 21 and 46 days, respectively, until complete
recovery was achieved.
Due to recurrent lumbalgy and limited mobilization, an MRI was performed
which revealed a spondylodiscitis between the lumbar vertebral bodies L2
and L3. Intervertebral disc puncture provided negative results. Considering E.
faecium and Aspergillus fumigatus as potential pathogens, calculated antibiotic
and antifungal treatment (Linezolid and Voriconazole) was offered. The patient
was discharged 3 months after transplantation.
He was re-admitted 2 weeks later for aggravating lumbalgy and rising CRP-levels
and a progressive spondylodiscitis was diagnosed radiographically. Surgical
restoration including dorsal stabilization and reconstruction with autogenous
iliac crest graft was performed immediately. Microbiological samples taken
intraoperatively gave evidence to invasive fungal infection with Aspergillus
fumigatus. Consequently we initiated a triple antifungal treatment consisting
of Caspofungin, Voriconazole and liposomal Amphotericin B, concomitant to a
triple antibiotic regimen (Tigecycline, Ceftazidim and Metronidazole).
The patient achieved a very good response clinically and microbiologically and
remained symptomfree afterwards. He was discharged 3 weeks later. At present,
8 months after transplantation and 5 months after spinal surgery, there is a
complete absence of clinical symptoms and significant signs of inflammation.
Spondylodiscitis caused by fungal infection is a rare but serious complication
after solid organ transplantation. Early surgical treatment should be considered
in the event of irreversible disc destruction and limited mobilization due to
intolerable pain.
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1690 TRANSFUSION SUPPORT IN INTESTINAL
TRANSPLANTATION
S. Shariatmadar1, M.E. Barron2, A.G. Tzakis3
University of Miami Miller School of Medicine/Jackson Memorial Hospital,
Dept. of Pathology, 2Dept. of Anesthesiology, 3Dept.of Surgery
Introduction: The current literature lacks information on the transfusion
requirements of patients undergoing intestinal transplantation (ITX). We report
on the intraoperative blood product utilization and the incidence of RBC
alloimmunization in 73 ITX patients.
Methods: Medical and transfusion records were reviewed in 73 consecutive
patients who underwent ITX from 3/94 to 5/07. Thirty-nine were adults (age
range: 19-61 yrs), 34 were pediatric (age range: 7 mos.-17 yrs). Blood samples
for serologic investigation were submitted to the transfusion service no later
than 4 hours prior to initiation of surgery. The incidence of clinically significant
RBC alloantibodies pre-transplant and subsequent transfusion requirements
during surgery were evaluated.
Results: All patients received irradiated and CMV negative/leukoreduced
cellular products during transplantation.
Total Intraoperative Utilization
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PRBCs (Units)

FFP (Units)

PLTS (dose)

Mean

Range

Mean

Range

Mean

Range

Average Blood
Loss (ml)

Pedi (n:33)

2.4

0.5-9

0.8

0-5

0.1

0-1

618

Adult (n:31) receiving
<10 PRBC Units

3.9

1-8

1.0

0-8

0.0

0-1

1434

Adult (n:8) receiving
>10 PRBC Units

21

11-44

13

6-26

0.75

0-2

10387

A 17 year old pediatric patient re-transplanted for acute rejection required 26
units PRBCs, 30 units FFP, and 2 doses of platelets during surgery. Eight adults
(20%) required extensive transfusions secondary to technical and anatomic
difficulties attributed to multiple prior abdominal surgeries. The diagnosis
in these included Gardner’s syndrome with extensive desmoid tumors, short
bowel syndrome secondary to trauma, and venous thrombosis from protein
C deficiency. Hemostasis was achieved in all cases and ITX successfully
completed. One of 73 patients (1.3%) had a clinically significant RBC
alloantibody (anti-Kell) prior to re-transplantation. The patient was successfully
managed with Kell-negative PRBCs during surgery.
Conclusion: This is the first reported large consecutive series of blood
utilization in isolated intestinal transplantation. Successful ITX is associated
with minimal blood loss in most patients with an average of 2.4 units PRBCs
in the pediatric and 3.9 units in the adult population with minimal component
use. Patients with extensive desmoid tumors and short gut syndrome secondary
to trauma with a history of multiple prior surgeries were identified as being a
high utilization group with larger PRBC use and markedly increased need for
FFP. RBC alloimmunization remains rare in this expanded series of patients as
initially reported.
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1691 THE PREVALENCE OF VASCULAR C4D DEPOSITION IN
INTESTINAL ALLOGRAFT BIOPSIES.
E. Lerut1, J. Pirenne2, K. Geboes1, D. Monbaliu2, N. Ectors1
Dept Morphology and Molecular Pathology, University Hospitals Leuven,
2
Dept Abdominal Transplant Surgery, University Hospitals Leuven
Aim: In renal and cardiac transplantation, C4d deposition is accepted as an
in situ marker for acute antibody-mediated rejection. Several correlations
with a less favourable prognosis have been described. Literature data on the
prevalence and significance of C4d deposition in intestinal allograft biopsies
are sparse.
Methods: Between October 2000 and March 2008, 8 patients (6
female/2male, mean age 36 years, range 2-57 years) underwent an intestinal
transplantation (combined liver-intestinal (n=3), isolated intestinal (n=3),
combined kidney-intestinal (n=1), multi-visceral (n=1) transplantation).
Allograft biopsies were taken as part of a standardized clinical follow-up
or depending on clinical indication. Out of all intestinal allograft biopsies
(n=208; 0-2539 days post-transplantation), 159 biopsies had high-quality
frozen tissue available, which was immunohistochemically stained for C4d.
For each biopsy the presence of mucosa (lamina propria) and submucosa
was noted. C4d positivity in the capillaries of the lamina propria was
scored as ‘negative’, ‘focally positive’ (<5% of the capillaries positive), or
‘positive’ (>5% of the capillaries positive). C4d positivity in the submucosal
vasculature was scored as ‘negative’ or ‘positive’. Correlations with clinical
and morphological data were studied.
Results: In the lamina propria, capillaries were C4d negative in 83 biopsies
(52.2%), focally positive in 34 biopsies (21.4%) and positive in 41 biopsies
(25.8%) (1 biopsy (0.6%) without assessable mucosa). The submucosal
microvasculature was C4d positive in 77 biopsies (48.4%) and negative
in 42 biopsies (26.4%) (40 biopsies (25.2%) without submucosal tissue).
When only biopsies consisting of both mucosa and submucosa were studied
(n=118), 35 biopsies (29.7%) were C4d negative in both levels and 29
biopsies (24.6%) were C4d positive in both levels (45.7% showed other
combinations of positive/focal positive/negative in the lamina propria and
positive/negative in the submucosa) (X2 p≤0.0001). C4d positivity was
observed in early as well as in late post-transplantation biopsies. Although
some degree of C4d positivity was observed in biopsies of all 8 patients,
an acute rejection (clinically highly suspected and biopsy-proven) was
only diagnosed in 2 patients. In those 2 patients, who were tested for the
presence of donor specific antibodies, 1 was found positive and 1 negative.
Subclinical acute cellular rejections (clinically stable allografts with
1
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histological features of acute cellular rejection) were not present in our
patients.
Conclusion: In our unicentric cohort of intestinal allografts (n=8),
immunohistochemical C4d deposition was present in the majority of biopsies
without a clear correlation with allograft function or the presence of donor
specific antibodies. A strong correlation between C4d positivity in the lamina
propria and the submucosa was seen. To assess the impact of C4d deposition in
the lamina propria and submucosa on graft function and/or outcome, a larger
cohort with longer follow-up data is needed.
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1692 EARLY HUMAN FETAL PANCREAS AS A THERAPY FOR
DIABETES

1693 TRANSGENIC EXPRESSION OF THREE ANTIOXIDANT
ENZYMES PROTECTS MOUSE ISLETS FROM PROINFLAMMATORY CYTOKINES IN VITRO AND PROLONGS
ISLET ALLOGRAFT SURVIVAL
T. Mysore, T. Shinke, N. Fisicaro, L. Murray-Segal, P. O’Connell, A. d’Apice,
P. Cowan
Immunology Research Centre, St. Vincent’s Hospital, Melbourne,
National Pancreas Transplant Unit, Westmead Hospital, Sydney
Background and aim: During islet isolation and transplantation, reactive
oxygen species (ROS) are generated within beta cells by several mechanisms
including the action of pro-inflammatory cytokines (PIC). Because islet grafts
are poorly equipped to deal with ROS, we produced transgenic C57BL/6 mice
expressing the antioxidant enzymes glutathione peroxidase (Gpx-1), CuZn SOD
and extracellular SOD under the control of the mouse H-2Kb (MHC Class I)
promoter. We have previously used these mice to show that co-expression of
the 3 enzymes improves the function of marginal islet isografts. The aim of the
current study was (i) to further explore the mechanism of this protective effect by
examining the resistance of transgenic islets to PIC in vitro, and (ii) to determine
whether transgene expression prolonged islet allograft survival in vivo.
Methods: (i) 100 handpicked islets from triple-transgenic (TG) and wild type
(WT) control mice were incubated for 72 hrs with combinations of PIC (50
U/ml IL-1β, 1000 U/ml TNFα, 1000 U/ml IFNγ). Culture supernatants were
assayed for nitrite using Griess reagent. Islet viability was assessed by the MTT
assay and expressed relative to untreated islets. (ii) 450 handpicked islets were
transplanted under the kidney capsule of diabetic CBA-RIP-Kb mice. Islet
graft function was checked by measuring the blood glucose levels (BGLs) of
recipient mice on alternate days until graft rejection (BGL >15 mmol/l).
Results: (i) Accumulation of nitrite was significantly lower in TG versus WT
islets under all three conditions, indicating that transgene expression inhibited
ROS generation. The viability of WT islets was reduced to 53 ± 5.0% by IL-1/
TNF, 19 ± 2.4% by IL-1/IFN, and 8.0 ± 0.4% by IL-1/TNF/IFN treatment. The
corresponding viability of TG islets was 54 ± 2.1% (not significant versus WT),
60 ± 3.0% (P<0.001), and 20 ± 1.2% (P<0.02). (ii) In the transplantation model,
TG islet graft survival was significantly prolonged compared to WT islet grafts
(mean time to graft rejection 21 days versus 15 days, P<0.03).
Conclusion: Transgenic islets were significantly protected from PIC toxicity,
but only when IFNγ was a component of the cytokine cocktail. We hypothesise
that this is at least partly due to upregulation of transgene expression by IFNγ
activation of the H-2Kb promoter. Transgenic expression of the antioxidants
also delayed the rejection of fully allogeneic islet grafts in mice. Investigation
of the mechanisms by which these antioxidants mediate their effects on islet
allograft survival is underway. Overall our results indicate that balanced
expression of antioxidant enzymes protects mouse islets against oxidative
and cytokine-mediated injury. This approach may be useful in both allo- and
xenotransplantation.

POSTER BOARD NUMBER P3 – 120
1694 A NEW SPONTANEOUSLY DIABETIC TRANSGENIC
(SDT) MOUSE LINE: A USEFUL RECIPIENT FOR ISLET
TRANSPLANTATION
T. Mysore, L. Murray-Segal, A. d’Apice, P. Cowan
Immunology Research Centre, St. Vincent’s Hospital, Melbourne
Background: Chemically-induced diabetic mice have been used for many
years as recipients in islet transplantation studies. However, diabetogenic
chemicals such as streptozotocin have several disadvantages: (i) cytotoxic
effects outside the pancreas, which may result in mortality or affect immune
responses; (ii) variable degrees of hyperglycemia, which may affect the
reproducibility of diabetes reversal; and (iii) incomplete deletion of beta cells,
which may recover sufficiently to mask suboptimal performance of islet grafts.
Spontaneously diabetic mice offer a useful alternative, but often suffer from
poor health or fertility. In a separate project to develop doxycycline-inducible
expression of angiogenic factors in mouse beta cells, we noticed that mice in
one transgenic line were polyuric, and further investigation revealed that they
were spontaneously diabetic. The mice, on a C57BL/6 background, contained
two transgenes: the Tet-On transactivator rtTA2 under the control of the RIP7
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B. Tuch1, W. Wu1, K. Brands1, E. Colvin1, J. Sung1, L. Williams1, R. Lock2,
R. Wang3
1
Diabetes Transplant Unit, Prince of Wales Hospital, 2Children’s Cancer
Institute Australia for Medical Research, 3University of Western Ontario
The use of human fetal pancreatic tissue may provide an alternative source of
tissue for transplantation as a therapy for type 1 diabetes. Human fetal pancreas
has a remarkable capacity to grow and differentiate in vivo and has been shown
to reverse diabetes in rodents (Transplantation 1988; 46: 608-11). However,
it is known that human fetal pancreas obtained from the 2nd trimester of
gestation is immunogenic and is rejected after transplantation. Tissue obtained
from earlier stages might prove to be immune privileged, as has been shown
for other tissues.
In this study we determined the immunogenicity of human fetal pancreatic
tissue obtained from the 1st trimester of gestation in a humanized mouse
model, a NOD/SCID mouse injected with 5 x 106 human peripheral blood
mononuclear cells (PBMCs). A microarray study of immunoregulatory
gene expression in 1st and 2nd trimester human fetal pancreas also was
undertaken. Finally, experiments were conducted to determine the fate of the
1st trimester tissue if it was maintained in the humanized mice long enough
for it to mature.
The analysis of transplanted human fetal pancreata revealed a significantly
decreased immunogenicity of the 1st trimester tissue. The 1st trimester grafts
3 weeks after injection of PBMCs showed only limited cellular infiltration and
contained numerous insulin positive cells, whereas 2nd trimester tissue was
completely infiltrated and rejected. The%age of CD45+ human cells was 26 ±
7 vs 43 ± 5% (P < 0.05) in 1st and 2nd trimester grafts respectively. Most of
the CD45+ cells were T cells, with CD8 > CD4 but no differences between the
trimesters. Grafts analysed as late as 8 wk after injection of PBMCs survived
in 11% of mice. Humanization was confirmed at this time, but most of the mice
developed either a, lymphoproliferative disorder or graft-vs-host disease. To
reduce the chance of these adverse events occurring, PBMCs were obtained
from EBV-ve donors, with 50% long-term survival of the grafts.
Normalization of blood glucose levels was achieved in the streptozotocindiabetic mouse grafted with 1st trimester human fetal pancreases, both nonhumanized and humanized.
An analysis of immunoregulatory genes expressed in 1st and 2nd trimester
human fetal pancreas by microarray demonstrated the upregulation of several
key immunoregulatory genes in the 2nd trimester tissue, especially HLA class
II, CCL19, C3, B7-H4, IL22Rá1 and TNFSF10. This might account for the
reduced immunogenicity of the younger tissue.
Our results provide a first indication that the use of 1st trimester human fetal
pancreas for transplantation might increase the survival of the grafts and might
decrease the requirement for immunosuppressive drugs.
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beta cell-specific promoter, and human VEGF-A under the control of the Tetresponsive element (TRE). The aim of the current project was to characterise
these mice as potential islet graft recipients.
Methods: The non-fasting blood glucose level (BGL) of the spontaneously
diabetic transgenic (SDT) mice and wild type (WT) littermate controls was
determined weekly. Mouse pancreata were harvested for measurement of
insulin content by ELISA and expression of rtTA2 and VEGF-A by RT-PCR
and Western blot. 400 handpicked islets from C57BL/6 (syngeneic) WT mice
were transplanted under the kidney capsule of SDT male mice. Islet graft
function was monitored by measuring BGL on alternate days for 35 days, at
which point the graft-bearing kidney was removed.
Results: Diabetes in both male and female SDT mice was predictable and early
in onset (mean BGL 29.5 ± 1.7 and 27.3 ± 5.2 mmol/L, respectively, at 4 wks;
WT 7.2 ± 2.1 mmol/L; P<0.01 versus WT). By 16 wks of age, diabetes remained
severe in male mice (29.6 ± 1.2 mmol/L) but was milder in female mice (18.6 ±
3.4 mmol/L). All SDT mice showed normal fertility, appeared healthy apart from
polyuria, and could be maintained beyond 35 weeks of age without parenteral
insulin. Pancreatic insulin content was lower in 10 wks old SDT mice (2.43 ±
0.71 ng/mg protein) than in WT mice (6.62 ± 3.46 ng/mg protein). Pancreasspecific expression of rtTA2 was shown by RT-PCR and Western blot; however,
human VEGF-A could not be detected even after doxycycline treatment of the
mice. In the transplantation model, syngeneic islet grafts (n=4) maintained
normoglycemia for the length of the experiment (35 days), and recipients
returned to hyperglycemia after removal of the graft-bearing kidney.
Conclusions: The SDT mice offer several advantages as islet transplant
recipients because they reproducibly and spontaneously develop diabetes
without overt detrimental effects. Our hypothesis is that specific over-expression
of the transcription factor rtTA2 in beta cells disrupts the processing and
secretion of insulin in particular or beta cell functions in general. Investigation
of these potential mechanisms is underway.
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1695 BETA CELLS IN TRANSPLANTED ISLETS ISOLATED
FROM YOUNG DONORS CAN REPLICATE WITH OR
WITHOUT EEXENDIN-4 TREATMENT
L. Tian1, H. Yi1, T. O’Brien2, D. Sutherland1, B. Hering1, Z. Guo1
Department of Surgery, University of Minnesota, 2Department of Veterinary
Population Medicine, University of Minnesota
The outcome of islet autotransplantation in pediatric patients was better than
the adolescent patients. One of the possible mechanisms is that beta cells in the
transplanted islets from young donors have the capability of regeneration. In this
study, we investigated whether beta cells in the transplanted islets isolated from
young donors can replicate in syngeneic diabetic mice and whether exendin-4
(a glucagon-like peptide-1 analog) treatment can enhance beta cell replication.
Donor islets were isolated from 8 week-old C57BL/6 mice. Diabetes in the
C57BL/6 recipient mice was induced by streptozotocin. Diabetes was diagnosed
when the nonfasting blood glucose level was >400 mg/dl on at least 2 consecutive
days. Total 100 or 150 islets were transplanted under the right kidney capsule of
each diabetic C57BL/6 mouse. Islet graft function was monitored by measuring
the blood glucose level. These recipient mice were given bromodeoxyuridine
(BrdU) at 100 mg/kg/day or BrdU and exendin-4 at 10nM/kg/day. All recipient
mice achieved normglycemia after transplantation. When 100 islets were
transplanted, the average days before achieving normglycemia were 10 days in
exendin-4 treated mice (N=10); and 16 days in control mice (N=11). When 150
islets were transplanted, the average days before achieving normglycemia were
7 days in exendin-4 treated mice (N=9); and 10 days in control mice (N=5).
At 4 weeks posttransplantion, nonfasting blood glucose level was 139±14 mg/
dl in exendin-4 treated mice, and 161±20 mg/dl in control mice that receiving
100 islets. Nonfasting blood glucose level was 112±19 mg/dl in exendin-4
treated mice, and 116±22 mg/dl in control mice that receiving 150 islets.
Nephrectomy was performed to remove islet grafts for insulin and BrdU double
immunofluorescence staining. Both insulin+ and BrdU+ beta cells in the islet
grafts were found in mice with and without exendin-4 treatment. An average
of 7.2 1.8% both insulin+ and BrdU+ beta cells were detected in the untreated
islet grafts. However, both insulin+ and BrdU+ beta cells significantly increased
in inexendin-4 treated islet grafts with an average of 16.2±5.9% insulin+ and
BrdU+ beta cells in islet grafts (P<0.01). Our data indicated that beta cells in
the transplanted islets isolated from young donors can replicate and exendin-4
treatment can enhance beta cell replication.
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1696 ENHANCEMENT OF DIABETES REVERSAL IN BALB/C
ATHYMIC NUDE MICE WITH OPTIMAL RATIOS OF ADULT
PORCINE ISLETS OF LANGERHANS TO ADULT PORCINE
SERTOLI CELLS
C.P. Hasilo1, G. Vilk1, C.W.J. Melling1,3, A. Pepper1, A. MacGillivary1,
A. Sverzhinsky1, C. Gall1, D.M. Siroen1, K. Grise1, D.G. White1,2,3
1
Multi-Organ Transplant Program, London Health Sciences Center, London,
Ontario, Canada, 2Department of Xenotransplantation, Robarts Research
Institute, London, Ontario, Canada, 3Department of Pathology, The
University of Western Ontario, London, Ontario, Canada
Islet transplantation is a viable cell replacement therapy with great potential
to effectively cure type 1 diabetes mellitus (T1DM). Several limitations have
prevented islet transplantation from emerging as a standard of care for T1DM.
The supply of high quality donor pancreata and harsh immunosuppressive drug
regimes are two major obstacles that need to be overcome to progress the field.
Sertoli cells (SC) can provide an immune privilege to the islets of Langerhans
when co- transplanted, thus bypassing the need for immunosuppression. The
complexity of the immune reaction in animals with an intact immune system
prompted us to test out the benefits of varying ratios of islets to SC in diabetic
balb/c athymic nude mice. These mice have an intact innate immune system
(antibodies, NK cells, dendritic cells, Bcells, etc.) but an absence of adaptive
immunity (Tcell deficient). We set out to determine an optimal range for the islet
to SC ratio for the combined cell therapy and examine if there exists a functional
threshold to the number of adult porcine SC that may be combined with the
adult porcine islets (islet equivelents; IE) and still reverse diabetes. Transplants
consisted of 4,000-8,000IE islets under the left kidney capsule alone or in
combination with Sertoli cells. The initial test consisted of a comparison of a
1:5,000 ratio of islets to SC with a high dose of 8,000IE and 40x106 Sertoli cells.
None of the mice receiving the dose of 1:5,000 reversed (n=4) during the study,
compared to 75% in the 8,000IE alone group (3/4 mice). We then established
that 1:5,000 may effectively be too great a ratio of islets to Sertoli cells and set
out to test the effect of varying the ratio on the rates of diabetes reversals. Three
groups of islet to Sertoli cell ratios of 1:2,000, 1:200 and 1:20 using a standard
dose of 4000IE adult porcine islets to prevent excessive volume loading causing
hypoxia of the cells, combined with varying amounts of adult porcine Sertoli
cells (corresponding to 8x106 SC, 8x105 SC, and 8x104 SC, respectively).
The resulting non-fasting blood glucose values demonstrated dose-dependent
rates of diabetes reversal of 25% (1/4 mice), 50% (2/4 mice) and 75% (3/4
mice) corresponding to the ratios of 1:2,000, 1:200 and 1:20, respectively (n=4
per group). Nephrectomizing the graft-bearing kidney in the mice achieving
normoglycemia showed reversion to hyperglycemia. Maintenance of weight as
an indicator of health status followed a similar pattern in all mice transplanted
with islets and SC; mice demonstrated healthy weight gain upon reversal of
diabetes and those that did not reverse did not drop in weight as is characteristic
of diabetic balb/c athymic nude mice. Furthermore, even the mice that do not
reverse their diabetes show better maintenance of weight when co-transplanted
with SC (n=4) than those that did not reverse with islets alone (n=2). Taken
together the results of this study demonstrate optimal ratios between 1:2000 and
1:20 islets to SC with enhanced maintenance of animal health when combining
adult porcine islets and SC.
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1697 ULTRAPURIFIED ALGINATE-BASED MICROCAPSULES
FOR IMMUNOPROTECTION OF HUMAN ISLET
ALLOGRAFTS IN TYPE 1 DIABETES MELLITUS (T1DM)
G. Basta, L. Racanicchi, P. Montanucci, C. Santi, R. Calafiore
University of Perugia
Staircase-like declining long-term success of human islet allografts in totally
immunosuppressed T1DM patients, according to Edmonton/ITN mandates
validation of alternative approaches for islet grafts immunoprotection, so as to
obviate recipient’s general immunosuppression, as well as establishment of new
insulin producing cell sources. As to the former, immunoisolatory microcapsules,
enveloping individual islets could represent a potential solution to this specific
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problem. Alginic acid (AG)-based microcapsules have encountered, so far, a
series of technical problems, mainly due to low purity grade of the constituent
polymers that have seriously hampered their application for transplant. In our
laboratory we have generated a method for AG ultra-purification, and obtained
a “clinical grade” product, to be used for human as well as nonhuman islet
cell microencapsulation. Such AG is being approved for clinical use in the US
(IND submitted). Using this product, complexed with poly-L-ornithine (PLO)
as an aminoacidic poly-cation coat, we have initiated our own phase-1 pilot
clinical trial of intraperitoneal AG/PLO encapsulated human islet allografts
into 4/10 nonimmunosuppressed patients with long-standing T1DM, upon
approval by the Italian Ministry of Health. Out of 4 patients, 3 have been
grafted intraperitoneally, under local anesthesia and echography guidance,
while patient#4 has been implanted by abdominal laparoscopy, under general
anesthesia, with the encapsulated islets being deposited beneath the liver and the
spleen. Grafted islet mass ranged from 400,000 to 1,000,000 islet equivalents
IEQ per patient. All cases showed graft response in terms of either appearance
of prior inexistent serum C-peptide (CPR) levels, both in basal (range: 0.4-1.2
ng/ml) and after glucagon test (1 mg i.v.) (range: 0.9-2 ng/ml), or significant
decline of HbA1c levels at 6 mo. post-TX, or reduced daily exogenous insulin
requirements (transient complete insulin withdrawal was obtained only in
pt.#4). Most importantly, microcapsules prevented allosensitization in all
recipients, with anti-HLA Class I and II antibodies resulting negative, unlike
reported for pharmacologically immunosuppressed islet allograft recipients.
In conclusion and preliminarily, our microcapsules formulated with “clinical
grade” AG and PLO were shown to immunoprotect human islet allografts and
prevent patient’s immunosensitization without immunosuppression. Further
adjustments in islet mass dosing per patient could result in stable insulinindepencency in the treated cases to come.
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1698 EFFECT OF HEPARIN ON EARLY ISLET FAILURE
AFTER INTRAPORTAL TRANSPLANTATION IN SYNGENEIC
AND ALLOGENEIC MODEL

1699 DEDIFFERENTIATION OF HUMAN PANCREATIC
ISLETS SEEDED ONTO 3D-SCAFFOLDS
G. Sundaram, V. Vaithilingam, J. Lees, W. Wu, C. Wu, H. Zreiqat, B.E. Tuch
Diabetes Transplant Unit, Prince of Wales Hospital/University of New
South Wales, Sydney and Tissue Engineering and Biomedical Research Unit,
University of Sydney
Attempts to expand the number of beta cells in islets have been attempted by
culturing the islets in a two-dimensional (2D) system. The insulin positive
cells dedifferentiate, losing insulin expression and enhancing expression of
the ductal/progenitor marker, CK19 and mesenchymal marker, vimentin. It is
known that mouse islets function more efficiently in a three-dimensional (3D)
than a 2D system. We hypothesized, therefore, that there is an advantage in
placing human islets in a 3D environment. For this reason, we seeded human
islets onto 3D scaffolds made of polylactic-glycolic acid (PLGA), which are
available for clinical use. Before transplanting the seeded scaffolds, we wished
to determine whether it would be beneficial to culturing them in vitro.
Human islets in aliquots of 4000 or 8000 islet equivalents (IEQs) were
seeded onto 3D porous scaffolds of PLGA of dimensions 8 x 8 x 3 mm and
with a pore size of 300 μm. Degree of attachment, survival, morphology
and characterization of the cells by immunofluorescent analysis for insulin
(endocrine marker), CK19 and vimentin (mesenchymal marker) were analysed
at 2h, 24h, 3d and 7d post-seeding.
The islets readily attached to the scaffolds, with the cells migrating from the
spherical islets onto the surface of the scaffolds. The cytoplasm diminished in
size and the nuclei become slightly smaller, but the nuclear:cytoplasmic ratio
increased. Many of the cells died after the first day of culture, with the surviving
insulin positive cells dedifferentiating into cells that expressed CK19. The
percentage of insulin positive cells diminished from 66% at 2hr to 35% at 1 day
with a smaller reduction to 29% by 7 days. Conversely, the percentage of CK19
positive cells increased from 22% at 2 hr to 53% at day 7. The percentage of
mesenchymal cells remained constant throughout at 20%.
In summary, human islets seeded onto a 3D scaffold and then cultured
dedifferentiate, just as the islets do when cultured in a 2D environment. There
is no advantage in culturing human islets seeded onto 3D scaffolds for > 24
hours since many of the cells do not survive. How human islets seeded onto 3D
scaffolds and transplanted behave remains to be determined.
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1700 EFFECTS OF SYSTEMIC IMMUNOSUPPRESSION
ON ISLET ENGRAFTMENT AND FUNCTION INTO A
SUBCUTANEOUS BIOCOMPATIBLE DEVICE
A. Pileggi1, S. Marzorati1, N. Bocca1, R.D. Molano1, A.R. Hogan1, M. Doni1,2,
L. Cobianchi1,2, L. Inverardi1, C. Ricordi1
1
University of Miami Miller School of Medicine - Diabetes Research
Institute, 2Department of Surgery, Fondazione IRCCS “San Matteo” Hospital
University of Pavia, Italy
Recent data suggests that immunosuppressive agents may adversely affect the
engraftment and the function of transplanted islets. Tacrolimus (Tac) is known
for its diabetogenic and toxicity leading to progressive islet cells dysfunction.
Also sirolimus (Sir) may adversely affect islet engraftment and compromise
ß-cell function.
Aim of the study was to explore the effect of Sir and Tac immunosuppression
(IS) on islets implanted into a subcutaneous (SC), prevascularized device. To
avoid the confounding elements of rejection and autoimmunity, we used a
syngeneic transplant model in rats.
A biohybrid device was implanted subcutaneously in Lewis rats 40 days prior
to islet transplantation to allow prevascularization of the site. To test the effects
of the drugs on islet engraftment, animals received a 40-day treatment with
Tac (daily SC at 1.0mg/kg), Sir (oral 3.0mg/kg on days 0, 1, 2 and every other
day thereafter) alone or in combination. Controls received no treatment. An
additional experiment used the same immunosuppressive protocol in animal
with established syngeneic islet graft function (>40 days). For both group we
performed a 40-day washout period. Nonfasting glycemia (<200mg/dL) and
intravenous glucose tolerance tests (IVGTT) were performed to monitor graft
function over time.
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S-J. Kim1,2 , D-Y. Jung1, S-K. Lee2, J-W. Joh2, J-M. Chun2, G-O. Jung2, J-I.
Moon2, J-M. Kim2, U-J. Kyung2, H-J. Park2, H-T. Jung2
1
Transplantation Research Center, Samsung Biomedical Research Institute,
Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department
of Surgery, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea
In clinical transplantation, the instant blood-mediated inflammatory reaction
(IBMIR) is a major factor contributing to the poor initial engraftment of the islets.
Tissue factor (TF), MCP-1 and other inflammatory mediators trigger an injurious
thrombotic/inflammatory reaction, engaging the coagulation and complement
systems, platelets and PMNs, when islets come in contact with blood in the portal
vein. As an anticoagulant, heparin which possesses substantial anti-inflammatory
properties has been in widespread clinical uses. We therefore studied the effects
of heparin to prevent IBMIR-induced islet destruction following intraportal islet
transplantation in syngeneic and allogeneic mouse model.
Chemically induced C57BL/6 diabetic mice underwent intraportal syngeneic
and allogeneic mice islets transplantation (300 and 350 IEQ, respectively).
Nonfasting serum glucose levels were evaluated in islet transplant mice; the
islets were cultured with 10 mM NIC (or without), and saline or heparin (10
unit) with islet was infused. After 3 and 24 hours of islet transplantation, the
effects of heparin were evaluated by blood cell count, monocyte chemoattractant
protein-1 (MCP-1) serum concentration, and immnohistology.
Islet transplant recipients infused with heparin (10unit) became
normoglycemic after syngeneic and allogeneic islet transplantation (300 and
350 IEQ, respectively), and the difference was significantly exhibited when
compared with the NIC-treated or untreated. After 3 hours of intraportal islet
transplantation, platelet consumption and MCP-1 concentration were rapidly
increased, while heparin treatment induced slightly to decrease, but not
significant. After 24 hour, necrosis of liver was not serious in heparin-treated
graft compare to the control graft. In addition, islet cells in the heparin-treated
graft were morphologically well-granulate (control vs heparin; 40% vs 75%,
p<0.05), and stained by nitrotyrosin, biomarker of oxidative stress, less than
those of the control group (p=0.02).
These observations indicate that heparin might play an important role to prevent
prompting the deterioration of the islet grafts in syngeneic and allogeneic
mouse models.
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While, 3/4 recipients achieved and maintained normoglycemia long-term
after transplantation in the control group. Animals under any IS regimen did
not reverse diabetes during the 40-day treatment when started at the time of
islet transplantation. Graft dysfunction was not reversible after withdrawal
of the IS. In the Sir group, only 1/3 animals had transient graft dysfunction
during IS treatment that resolved during the washout period. We observed a
persistent significant difference in glucose clearance during IVGTT between
control group and animal under FK (p=0.048 under IS; p=0.0016 after
washout).
In the animal with established graft function, graft dysfunction (elevation
of nonfasting glycemic values) was observed during the IS treatment, and
dysfunction persisted after washout in 2/3 and 3/3 of the animals treated with
Tac and Sir+Tac, respectively. In the Sir group, only 1/3 animals had transient
graft dysfunction during IS that resolved during the washout period. Significant
differences in glucose clearance during IVGTT were measured in the Tac group
and in the Tac+ Sir group before and after IS, when compared to controls
(p=0.008 Tac; p=0.004 Tac+Sir).
Our data underlines the potential toxicity of Sir and Tac on islet grafts also in
the context of islet cell transplanted into a biohybrid device.
Our data indicates that Sir and Tac have profound deleterious effects on islet
cell engraftment and function, which may hinder the success of implantation
into biohybrid devices. Non-diabetogenic IS protocols should be considered
for a clinical application of islet transplantation into biohybrid devices.
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1701 ANCHORING OF GROWTH FACTORS TO SURFACEIMMOBILIZED HEPARIN ON PANCREATIC ISLETS;
IMPLICATIONS FOR STIMULATING ISLET ANGIOGENESIS
P.U. Magnusson1, S. Cabric, U. Johansson
1
Dep of Clinical Immunology, 2Dep of Clinical Immunology, 3Dep of Clinical
Immunology
In pancreatic islet transplantation, early revascularization is necessary
for long-term graft function. We have recently shown in in vitro and in
vivo models that modification with surface-attached heparin protects
the islets from acute attack by the innate immune system of the blood
following intraportal islet transplantation. In the present study, we have
investigated the ability of an immobilized conjugate composed of heparin
to bind the angiogeneic growth factors VEGF-A or FGF-2 as a means
of attracting endothelial cells (ECs) in order to induce angiogenesis an
revascularization.
The capacity of growth factors to bind to immobilized heparin was evaluated
using a quartz crystal microbalance with dissipation monitoring (QCM-D)
technique and ELISA. VEGF adherence to the surface of heparin-coated islets
and the coating of islets with ECs were visualized by confocal microscopy. The
proliferation of ECs on heparinized surfaces in the presence of VEGF was also
evaluated using a thymidine incorporation assay.
QCM-D and ELISA demonstrated considerable binding of VEGF and FGF to
heparin- coated surfaces, and binding of VEGF was further verified by confocal
microscopy. Covering islets with heparin also increased the adhesion of ECs to
the islet surface. ECs cultured on heparinized surfaces showed 2-fold reduced
proliferation in basal conditions but responded equally upon VEGF stimulation
as corresponding control. Also, ECs cultured on heparin-coated glass surfaces
exhibited induced focal adhesion and stress fiber formation.
Immobilized heparin on the islet surface may be a useful anchor molecule for
achieving complete coverage of the islets with growth factors such as VEGF
and FGF, ultimately improving islet revascularization and engraftment in
pancreatic islet transplantation.
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1702 GENERATION OF FUNCTIONAL NEOISLETS OF
LANGERHANS FROM SURGICAL RESECTED PANCREATIC
TISSUE
Y-M. Shyr
Taipei Veterans General Hospital
Objective: Type 1 diabetes is a degenerative disease in which the destruction of
£]-cells leads to persistent hyperglycemia. Although islet cell transplantation holds
promise for the treatment of diabetes, shortage of donor remains a major drawback.
The aim of this study is to generate functional insulin-producing neoislets from
adult human pancreatic cells taken from surgically-resected pancreas tissue.
Research design and methods: Procedures were developed to isolate ƒÒcell stem cells from 57 surgically-resected pancreas tissues. The cells were
cultured and propagated in conditioned medium and then differentiated in
Matrigel. The successfulness of culture of functional neoislet was determined
by morphological and immunofluorescent study, characteristic pancreatic islet
gene expression, and glucose-induced C-peptide secretion.
Results: The pancreatic stem cells grew in conditioned medium and showed
islet-like clusters when transferred to Matrigel. Immunofluorescent labeling
of cultured pancreatic neoislet cells was immunopositive for neural stem cell
marker nestin, duct cell marker CK19, and endocrine cell marker such as
C-peptide, glucagon, and Pdx1. The expressions of pancreatic islet markers
were also confirmed by RT-PCR. The neoislets secreted C-peptide in response
to glucose stimulation. The neoislet cultured from soft pancreas parenchyma
had significant higher success rate.
Conclusions: We conclude that the isolated pancreatic stem cells had
differentiated into neoislets and showed characteristics of functional endocrine
cells. The present study describes an alternative source and improved method
for obtaining a constant supply of large numbers of neoislets from adult human
pancreatic tissue.
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1703 THE IMPACT OF DONOR, PROCUREMENT, AND
ISOLATION FACTORS ON PANCREATIC ISLET PURITY, AND
INTEGRITY
O. Sabek1, L. Peterson2, D. Fraga1, A.O. Gaber1
1
Deparatment of Surgery, The Methodist Hospital, 2Public Health Research,
The Methodist Hospital
Background: For islet transplantation to become a successful therapy
for diabetes, it must be possible to routinely transplant a sufficient mass of
purified viable islets isolated from one well-matched donor pancreas to one
diabetic recipient. To define donor and isolation parameters in our center, we
retrospectively analyzed 341 pancreases and the outcome of their isolation with
emphases on islet yield, purity and integrity. Continuous measures of isolation
yield in units of equivalents per gm, purity, and integrity were normalized
to range [0, 1]. Non-parametric Somers D tests were performed to quantify
association between yield and age, Caucasian(y/n), alcohol intake(y/n), illicit
drugs(y/n), blood type A(y/n), blood type O(y/n), Rh+(y/n), CMV+(y/n), and
hepatitis+(y/n), height(m), weight(kg), BMI, IBW, hospital time (h), ventilator
time (h), max(glucose), min(glucose), well perfused (y/n), cold ischemia(h),
pre-digestion pancreatic weight(gm), pancreatic gm digest percent, collagenase
concentration, distention volume, digestion time (min), whole/cut distention,
and 38 binary (y/n) variables for known medications. Significant univariate
predictors were then used in maximum likelihood multivariate models to fit a
2-parameter beta distribution of the yield variables.
Results: Modeling results suggest that for islet equivalents per gm, the
following variables were significant predictors: log pancreas pre-digestion
weight (g), (Z=-2.11, p=0.04), log distension volume (Z=-2.84, p=0.01), well
perfused (Z=-2.00, p=0.05), CMV (Z=2.17, p=0.03), and anti-arrhythmia
medication (Z=2.94, 0.00). For purity, significant predictors were log ventilator
time (Z=-1.98, p=0.05), and log digestion time (Z-2.15, p=0.03). Finally, for
integrity, significant predictors were log hospital stay time (Z=2.22, p=0.03)
and log cold ischemia time (Z=-1.95, p=0.05).
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Conclusion: Identifying donor and isolation variables vary from one center to
another, which can be the result of donor management and isolation technique.
As it is important for each center to identify the effect of donor and isolation
variables within their center, the emphasis should be placed on donor management
and evaluating potential therapies within the context of clinical trials.
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1704 A META-ANALYSIS OF THE IMPACT OF THE
TWO-LAYER METHOD OF PRESERVATION ON HUMAN
PANCREATIC ISLET TRANSPLANTATION
A. Agrawal, K. Gurusamy, S. Powis, D. Gray, B. Fuller, B. Davidson
Royal Free Hospital
Background: There are conflicting reports about the effectiveness of
perfluorocarbons used in the two-layer method (TLM) of pancreas preservation
for human islet transplantation. The mechanism of action is unclear and the
optimal role of this method uncertain.
Design: a systematic review of the literature regarding mechanism of action of TLM
and a meta-analysis of the evidence that TLM improves islet isolation outcomes.
Data Sources: Pubmed, CENTRAL, EMBASE, Science Citation Index and
BIOSIS were searched electronically in May 2007.
Methods: After selecting the relevant human trials for meta-analysis data
relating to donor variables, study design, primary and secondary islet isolation
outcomes were extracted. Publications that explained the mechanism of action
of TLM were chosen from this search for a systematic review.
Results: Electronic searches identified seven unique citations, describing
eight human studies that were eligible for the meta-analysis. When comparing
TLM with preservation in University of Wisconsin (UW) solution, there was
a statistically significant higher islet yield (WMD 946.22, 95% CI 485.4 to
1407.04) in the TLM group. The number of transplantable preparations obtained
was not significantly different (OR 1.56, 95% CI 0.96 to 2.54) between the two
groups. The rate of successful islet isolations for marginal organs was higher
in the TLM group (OR 6.69, 95% CI 1.80 to 24.87). Improved oxygenation
and preservation of cellular bioengertics is thought to be the main underlying
mechanism although no single mechanism has yet been confirmed.
Conclusion: There is currently no clear evidence that the TLM is beneficial in
human islet transplantation. It may improve the preservation of marginal organs.

POSTER BOARD NUMBER P3 – 131
1705 THE INFLUENCE OF BRAIN DEATH ON TISSUE
FACTOR EXPRESSION IN THE PANCREATIC TISSUE AND
ISOLATED ISLETS IN RATS

POSTER BOARD NUMBER P3 – 132
1706 CURRENT STATUS OF ISLET TRANSPLANTATION
FROM NON-HEART BEATING DONOR IN JAPAN~ F A REPORT
FROM JAPAN PANCREAS ISLET TRANSPLANTATION
REGISTRY
T. Saito1, K. Ise1, M. Gotoh1, S. Satomi2, S. Uemoto3, T. Kenmochi4, T. Itoh5,
Y. Kuroda6, Y. Yasunami7, S. Teraoka8
1
Fukushima Medical University, 2Tohoku University, 3Kyoto University,
4
National Hospital Organization Chiba-East Hospital, 5Osaka University,
6
Kobe University, 7Fukuoka University, 8Tokyo Women Medical University
Objectives: The program of islet transplantation in Japan, which was
characterized by islet isolation from non-heart-beating (NHB) donors and
national covering system for donation, isolation, and transplantation, had been
started in 2004. Here, we summarize three years outcome of the islet isolation
and transplantation outcomes in Japan.
Materials and methods: Seven transplantation centers (Tohoku, Fukushima,
Chiba, Kyoto, Osaka, Kobe, and Fukuoka) have been enrolled as a national
team for islet isolation and transplantation. At the beginning, recipients were
limited only for patients who had no history of kidney transplantation. From
September 2006, we expanded the program for IAK (islet after kidney)
recipients maintaining stable renal function with limited steroid use (below
10mg/day). Candidates for recipients were selected according to candidate
evaluation system conducted by three diabetologists. Selection and listing
criteria for transplantation includes regional priority, ABO blood type, previous
islet transplant who can be insulin-independent, and a longer waiting time.
Isolation and purification procedures of islets from pancreas are performed
according to an individual protocol in each institute. Immunosuppression is
based on sirolimus/tacrolimus combined with basiliximab induction. Two
or three times consecutive infusions of >5,000 IE/kg were planned for each
recipient until achievement of insulin independency.
Results: One hundred fifty seven recipients are currently registrated. Sixty
five isolations and 34 transplants were performed in 18 IDDM recipients
including 2 IAK recipients. All but one donors (64/65) were NHB. Intervals
between each transplantation ranged from 8 to 954 days (mean 242 days). All
recipients were free from severe hypoglycemic episodes after transplantation.
Of 18 recipients, all cases had partial function (C-peptide >0.3 ng/ml) at 1 year
after transplantation, but 5 cases had graft loss (C-peptide <0.3 ng/ml) 3 years
after transplantation. Three of these recipients attained insulin-independence
with good glycemic control at any point during follow-up period for 14, 79,
and 215 days, however, all of these required insulin again. The other recipients
are currently followed up with minimal dose of exogenous insulin. Mean levels
of HbA1c before transplant and at 1 year after 1st, 2nd and 3rd transplant were
8.8, 7.1, 6.5, and 6.3%, respectively. The renal function remains stable in 17
recipients including 2 IAK cases, however, one recipient who had borderline renal
function (IIIa – IIIb) became renal failure and underwent renal transplantation.
Diabetic retinopathy remains stable in 16 recipients, but progressed in 2
recipients. Diabetic neuropathy remains stable in 16 recipients, and improved in
2 recipients. Nine severe immunosuppression-related events including anemia,
diarrhea, oral ulcer and bacterial infections were treated successfully.
One procedure-related event of intra abdominal bleeding needed open
hemostasis without transfusion.
Conclusion: Islet transplantation from NHB donors can successfully restore
long-term endogenous insulin production and glycemic stability in non-uremic
IDDM as well as IAK recipients. Persistent islet function provides protection
from severe hypoglycemia and improved levels of glycated hemoglobin.
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Y. Saito1, M. Goto1,2, K. Maya2, N. Ogawa1, K. Fujimori3, Y. Kurokawa2,
S. Satomi1
1
Division of Advanced Surgical Science And Technology, 2Tohoku University
Biomedical Engineering Research Organization, 3Division of Surgical
Oncology
Background: It has been revealed that tissue factor (TF) in the islets is identified
as the main trigger of the instant blood-mediated inflammatory reaction, and
low expression of TF in the graft is correlated with high C-peptide values after
clinical islet transplantation. However, the crucial procedures that directly
induce TF remain to be determined. In the present study, we therefore focused
upon the influence of brain death (BD) on TF expression in the pancreatic
tissues and isolated islets.
Methods: BD was induced in male Lewis rats weighing 250¦ `300g by
inflation of a Fogarty catheter placed intracranially. The rats were mechanically
ventilated for 6h until removal of the pancreas. The expression of TF protein
in the pancreatic tissues was examined by western blotting assay. mRNA
expression of TF in the isolated islets was analyzed by real-time PCR assay (BD
n=5, control n=8). The influence of BD on the isolation outcome was evaluated
by the islet yield and purity (BD n=11, control n=10). Islet viability and function
were assessed by ATP/DNA test and respiratory activity measurement using a
scanning electrochemical microscopy system (BD n=5, control n=6).
Results: TF protein levels in the pancreatic tissues were similar between
the groups. However, TF mRNA in the isolated islets of BD group was
significantly higher than that of control group (TF/GAPDH BD;0.169¦ }0.033,
control;0.119¦ }0.041: p=0.04). Islet yield was considerably lower

(BD;2110¦ }231IEQ, control;2390¦ }528IEQ: p=0.19), and purity was
significantly lower in BD group than control group (BD;87.7¦ }7.5%, control
97.0¦ }2.6%: p=0.002). Unexpectedly, ATP/DNA ratio and respiratory
activity were comparable between the groups (ATP/DNA BD;51.6¦ }12.8,
control;59.1¦ }3.47:
p=0.20,
respiratory
activity
BD;2.39¦ }0.55,
control;2.58¦ }0.19: p=0.45).
Conclusions: Although BD per se was not enough for inducing TF expression
in the pancreatic tissues, BD combined with subsequent warm ischemia
(isolation procedures) remarkably up-regulated TF mRNA expression in the
isolated islets, suggesting that BD is of great importance as an initiator of TF
induction in the islet grafts. The present study demonstrates that the expression
of inflammatory mediators rather than islet viability is more susceptible to BD.
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1707 THE MITOCHONDRIAL K-ATP CHANNEL OPENER,
DIAZOXIDE, IMPROVES ISLET ISOLATION OUTCOME IN
MICE COLD ISCHEMIA MODEL
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Y. Wang, M. Qi, S. Wang, T. Harvart, L. Rodriguez, C. Groh, E. Marchess,
J. Oberholzer
University of Ilinois At Chicago
Introduction and hypothesis: Human islet transplantation is a promising
treatment alternative for Type I diabetes. One of main reasons for variable
success rate is lacking good quality islets and insufficient amount to reverse
diabetes. Ischemia-reperfusion injuries and isolation stress including enzymatic
and mechanical contribute the islet damage. Diazoxide, a mitoKATP channel
opener, has been extensively investigated for its impact on preconditioning
against myocardial and neuron ischemia-reperfusion injuries, but not on the
pancreas ischemia model and islet isolation process. Therefore, the aim of the
present study is to investigate the islet protection of this compound in rodent
pancreas ischemia model and the impact on the islet outcomes.
Approach: (1) Mice cold ischemia (CI) model was established by vascular
flush with UW solution or other agents through lower abdominal aorta and then
organ preserved in 4 oC for 6, 10, 14 hours. (2) Groups: 150μM Diazoxde+
8ml UW; 8ml UW alone, and 150μM Diazoxide +8ml UW+ 100μM 5-HD (a
specific mitoKATP channel blocker). (3) After cold storage, islets were isolated
and purified by standard methods. (4) Isolated islets were assessed by islet
yield, glucose-stimulated insulin secretion(SI), calcium signal, mitochondrial
potential changes, and confocal mitochondrial morphology.
Results: (1) in 6 hrs CI model, Diazoxide group has significant higher islet
yields compared to UW alone (237.5+/-25.6 vs.108.7+/-48.3; p<0.05), when
added 5-HD, Diazoxide effect dramatically diminished, 117.3+/-33.1. (2) In
10 hrs CS model, Diazoxide group islet yield still is better than UW alone
(95.5+/-16.7 vs. 47.5+/-27.5; p<0.05), but in 14 hrs CI model, Diazoxide did
not show its protection (54+/-2.8 vs. 49.5+/-16.2; p>0.05). (3) SI of Diazoxide
group is 3.67+/-0.51 vs. SI of UW 2.28+/-1.67; p<0.05. Interestingly, SI of
Diazoxide+5-HD is 5.47+/-2.29. (4) Glucose stimulated calcium influx and
mitochondrial potential change is well preserved in Diazoxide group compared
to UW group. (5) Mitochondrial morphology assessment using confocal image
indicate that Diazoxide group has less fragmentation, swelling, and aggregation,
and normal distribution.
Conclusion: our results show the pharmacological mitoKATP opening protects
against ischemia damage and mimics ischemia preconditioning, probably
through mitochondrial protection. Since plasma KATP channels of beta-cells
have similar structure, it is expected that Diazoxide also have effect on plasma
KATP ,but with different affinity and may explain the 5-HD and diazoxide
combined group preserves insulin secretion capacity but without improved islet
yield. To our best knowledge, it is first investigation of Diazoxide effect on
the pancrease ischemia-reperfusion and islet outcomes. However underlying
physiological and pathological signaling events are still needed to be elucidated
and in vivo evaluation of Diazoxde-treated islets in animal model has to be
investigated.

POSTER BOARD NUMBER P3 – 134
1708 ANALYSIS OF DONOR AND ISOLATION RELATED
VARIABLES ASSOCIATED WITH VIABLE BETA-CELL INDEX
H. Ichii, A. Miki, A. Mita, S. Barker, T. Yamamoto, Y. Sakuma, A. Khan,
L. Inverardi, R. Alejandro, C. Ricordi
Diabetes Research Institute, University of Miami
Backgrounds: The results of clinical islet transplantation have greatly
improved due to the introduction of more efficient methods for the separation
of islets and more effective immunosuppressive strategies. Improved islet
isolation has been key to the evolution of this procedure. Suitable selection of
donors and isolation methods is critical for successful human islet isolation and
transplantation. Donor and isolation related factors for efficient islet isolation
have been examined and identified using the analyses based on islet yields.
These identified factors have been helpful for improving the efficiency of
human islet isolation. However, the quality of islets, such as beta-cell content
and viability was not taken into consideration in many analyses. We have
recently reported that beta-cell content in islet and beta-cell fractional viability
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as well as transplanted islet mass had a good correlation with clinical islet
transplantation outcomes. Therefore, to identify donor and isolation related
factors for better islet quality is highly desired.
Aims: In the present study, we have analyzed donor and isolation related
factors for efficient islet isolation based on beta-cell content, beta-cell fractional
viability and viable beta-cell Index.
Methods: Between 2004 and 2006, seventy-six human islet isolations processed
for transplantation in Diabetes research institute, University of Miami,
retrospectively analyzed. Univariate regression analyses were performed to
identify donor and isolation related factors associated with beta-cell content,
fractional beta-cell viability and viable beta-cell index. Beta-cell content were
assessed by using LSC /iCys and beta-cell fractional viability was assessed by
FACS within 24hors after isolation. Viable beta-cell index were calculated by
the following formula (beta-cell content x beta-cell fractional viability x islet
yields).
Results: Beta-cell content was significantly associated with donor height
(r2 =0.228; p=0.047), digestion time (r2 =0.279; p=0.015), Fatty pancreas
(p=0.038) and female donor (p=0.007). Fractional beta-cell viability was
significantly associated with cold ischemia time (r2 =0.287; p=0.012), total
collection volume of media (r2 =0.316; p=0.006) and firm pancreas (p=0.023).
Viable beta-cell index was associated with cold ischemia time (r2 =0.240;
p=0.037) and total collection volume of media (r2 =0.316; p=0.006). Two-layer
method did not show any associations with beta-cell content, fractional betacell viability or viable beta-cell index.
Conclusions: These data indicate that beta-cell content and viability are
affected by independent donor and isolation related factors, which are difficult
to identify by the analysis based on only islet yield. A sequential integrated
approach to assess potency of islet cell products could be of assistance in
improving islet transplant outcomes.

POSTER BOARD NUMBER P3 – 135
1709 31PHOSPHORUS MAGNETIC RESONANCE
SPECTROSCOPY TO ASSESS MITOCHONDRIAL FUNCTION
IN RAT PANCREAS PRESERVED BY TWO-LAYER METHOD
A. Agrawal1, A. Bainbridge, B. Fuller, B. Davidson
1
Royal Free Hospital, 2University College Hospital, 3Royal Free Hospital,
4
Royal Free Hospital
Introduction: Several centres have reported improved islet isolation outcomes
with this preservation technique. Reports of success with single donor islet
transplants and marginal donors have also been attributed, either partially or
wholly, to the employment of the two-layer method. However, despite two
decades of experimental and clinical application the precise mechanism of the
two-layer method remains a mystery.
Methods: 38 Male Sprague-Dawley rats underwent pancreas procurement (with
associated spleen and duodenum, which was securely ligated at both ends). The
pancreas thus retrieved was maintained in either cold Marshalls solution (M)
or at the interface of perfluorodecalin and Marshalls solution that had been
pre-saturated with oxygen (two layer method – TLM). Pancreases maintained
in TLM were assigned to one of two groups: TLMs – no further oxygen was
bubbled through the solution; TLMc – oxygen was bubbled (0.5 litre/hour)
through the solution for 20min at intervals of 1 hour. The preservation solution
was randomly assigned immediately following extraction. The solutions were
kept between 4°C and 6°C during the entire experiment. Phosphorus (31P)
magnetic resonance spectroscopy (MRS) was performed continuously during
the period of 1 hour to 3 hours following extraction (TR = 10s; Averages =
256). To improve signal to noise, pancreases were scanned 2 at a time. Thus
group numbers for the experiments were: M = 6; TLMs = 6; TLMc = 7. Spectra
were fitted using AMARES as implemented in the jMRUI software package.
The following metabolite ratios were calculated and plotted against time from
extraction: Inorganic phosphate (Pi) / g - nucleotide triphosphate (g-NTP), Pi /
b-NTP. To facilitate comparisons between groups, these data were interplotted
linearly and the area under each curve for each experiment was calculated
between 1 hour and 2.75 hours following extraction. Grouped data was then
compared using ANOVA with t-tests used for pairwise comparisons.
Results: There was no difference between the groups in the mean value of
Pi/g-NTP and Pi/b-NTP measured between 0.5 and 1 hours from procurement
(ANOVA; p > 0.3 and p>0.2 respectively). The data for the area under the
Pi/g-NTP and Pi/b-NTP curves between 1hr and 2.75 hours from extraction are
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shown in the table. The grouped mean areas for both Pi/g-NTP and Pi/b-NTP
curves were significantly different between the groups (ANOVA; p < 0.001
and p< 0.002 respectively). The marshals group was significantly different to
the TLM groups for both Pi/g-NTP and Pi/b-NTP (see table). No significant
differences were seen between the TLM groups.
Conclusions: There was no difference between the groups for Pi/g-NTP and
Pi/b-NTP at the start of the experiment. A larger area under the Pi/g-NTP and
Pi/b-NTP vs time curves indicates increasing Pi/g-NTP and Pi/b-NTP over
the course of the experiment. The data indicate that both Pi/g-NTP and Pi/bNTP increased in the Marshalls group during the first three hours following
procurement, presumably due to decreased NTP and consequently increased
Pi. In contrast, Pi/g-NTP and Pi/b-NTP levels were maintained using TLM in
both TLMs and TLMc which did not differ.

POSTER BOARD NUMBER P3 – 136
1710 SUITO-INDEX FOR ASSESSMENT OF ENGRAFTED
ISLET MASS IN CLINICAL ISLET TRANSPLANTATION
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1711 THE EFFECT OF ANESTHETIC ADMINISTRATION
ROUTES ON FUNCTION OF RAT ISLET ISOLATION
J.Y. Kim1, J-I. Lee1, J.H. Jeong1,2, Y. Fang1,2, Y.S. Kim1,2
The Research Institute for Transplantation, 2BK21 Team of Nanobiomaterials
for Cell-Based Implants, Yonsei University College of Medicine, Seoul, Korea
Introduction: Intraperitoneal (IP) administration of anesthesia is most
commonly used for rodent islet isolation. When inhaled volatile agent is
used in rodents, many problems such as high cost and technical difficulty of
keeping airway are still present. Although diethyl ether is preferred because
of simplicity and low cost, but it has explosive nature and potentially irritates
both animal and researchers. In this study, we explored the possibility of using

1
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1712 HYPEREMIC ISLETS, A POSSIBLE EXPLANATION FOR
POOR YIELDS IN HUMAN AND PORCINE ISLET ISOLATION
D.E. Hilling, E. Bouwman, J.K.R.A. Rijkelijkhuizen, H.A.M. Töns,
O.T. Terpstra,
Department of Surgery, Leiden University Medical Center, Leiden, The
Netherlands
Background: Transplantation of islets of Langerhans can restore insulin
production in patients with type 1 diabetes. Although procedures have been
improved, islet isolation is still associated with considerable loss of endocrine
tissue and unpredictable, highly variable islet yields in both humans and pigs.
When studying histological characteristics of human and porcine pancreases in
relation to islet isolation, a remarkable high number of hyperemic islets (HI’s)
was encountered, a phenomenon that has not been described in detail before.
HI’s are characterized by dilatation of different magnitudes of islet blood vessels
and are sometimes associated with hemorrhages extending in the surrounding
exocrine tissue. The aim of the present study was to determine the frequency
of HI’s in pigs and humans, the occurrence of HI’s in relation to the amount of
endocrine tissue and the possible relevance for islet isolation outcome.
Methods: 150 porcine pancreases were harvested in different slaughterhouses.
The population consisted of a juvenile group (6-12 months) of 69 animals
and an adult group (>12 months) of 81 animals. Islet isolation was performed
in 50 animals of the adult group. Human pancreases were obtained from 86
multi-organ donors. Donor ages ranged from 16-69 years. Islet isolation was
performed in 28 cases.
Tissue samples were stained using the Aldehyde Fuchsine-Halmi technique.
For determination of the endocrine content, all islets (except the HI’s) in a
tissue area of 1 cm2 were assessed. The endocrine area density was determined
by summation of all calculated (πr2) islet areas and expressed as percentage of
the total area. The presence of HI’s was scored semi-quantitatively. Pancreases
were allotted to categories based on the presence and severity of the HI’s
found.
Results: In humans we found HI’s in 48% of the pancreases. In the affected
pancreases an average (±SD) of 4.0±2.4% (range 1.3-9.5) of the assessed islets
was hyperemic. In pigs, HI’s were found more frequently in juvenile than in
adult pigs (in 64% versus 31% of the pancreases, p<0.001). In both humans
and pigs, a significant increase (p<0.001) in endocrine content was found in
the most severely affected pancreases. The higher endocrine content could be
a consequence of islet expansion, possibly by vasodilatation, edema or both.
When this higher endocrine content was taken into account and isolation results
were expressed as ratio of yield and content, we found a trend towards lower
yields in the most-affected pancreases in both humans and pigs.
Conclusions: In humans and pigs a substantial amount of the pancreases contain
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Baylor All Saints Islet Laboratory, 2Baylor Research Institute, 3Baylor
University Medical Center, 4Institute of BIomedical Studies, Baylor University
Introduction: Assessment of engrafted islet mass is important for evaluation
of clinical islet outcome. Previously we have shown that fasting C-peptide
and blood glucose were correlated after islet transplantation and the angle of
fitting line of such correlation reflected engrafted islet mass (1). We developed
a simple formula; Fasting C-peptide [ng/dl] divided by fasting blood glucose
(mg/dl) minus 63 multiplied by 1500 to get engrafted functional islet mass.
This formula was designed for normal non-diabetic person resulting in 100.
SUITO index = C-peptide/(Blood glucose – 63)x1500. The purpose of this
study is to evaluate the relationship between mean SUITO index and insulin
independence after islet transplantation using brain-dead organ donors.
Method: Six pancreata were procured for this study between November 2005
and January 2008. All pancreata were preserved by the two-layer method.
Five islet isolations were performed at Baylor research institute and one islet
isolation was performed at remote center. All islet isolations were performed
based on the Ricordi method. Six islet preparations were transplanted into 3
type 1 diabetic patients at Baylor University Medical Center. Each patient
received two islet transplantations. Medications including immunosuppression
were based on the Edmonton protocol. SUITO index was calculated using data
between POD 3 and 30. Insulin requirements after islet transplantation were
compared with pre-transplantation levels and categorized more than half, less
than half and insulin free.
Results: Among the three patients, the SUITO index and insulin requirement
after the fist islet transplantation were 7.9 ± 1.3; more than half, 16.9 ± 4.4;
less than half and 24.6 ± 8.9; less than half respectively. All of SUITO indices
were less than 26 and none of the patients achieved insulin independence.
All three patients received second islet transplantation. After the second islet
transplantation the mean SUITO index in each patient was 52.1 ± 8.5, 43.2 ±
3.0, and 52.6 ± 7.3. All the three patients achieved insulin independence.
Conclusion: The mean SUITO index of greater than 26 between POD 3 and 30
could predict insulin independence after islet transplantation using brain dead
organ donors. SUITO index is useful in the estimation of islet engraftment and
a tool for consideration of additional islet transplantation.

intramusclar (IM) anesthesia for rodent islet isolation procedure.
Method: Lewis (male, 250~350g) was anesthetized using the combination of
ketmaine (75mg/kg)+xylazine (K/X, 5:2) or zoletil (30mg/kg)+xylazine (Z/X
3:2). These drugs were injected through IM or IP route. To shot IM drugs, we
have invented a specially designed restrainer. Lag time required to lose deep
pain by negative pedal withdrawal responses (supposed as deep anesthesia)
were measured in order to compare between K/X and Z/X. Islets of each
group were isolated and function was examined within 30 minutes. Glucose
challenging test (100mg/dl, 400mg/dl, 100mg/dl, 1 hour each) was performed
with each group of prepared islets. Additionally, to compare the effect of
anesthetics on primary islet and RIN-5F cell line, we investigated the viability
of RIN-5F by MTT assay of the each combination and the amounts of insulin
from RIN-5F with ELISA.
Result: Compared to IP route, lag time to deep anesthesia was significantly
reduced [K/X (IM: 313±66 sec versus IP: 371±84 sec): Z/X (IM: 206±76
sec, IP: 245±92 sec)] with IM route. Yield of isolated islets by IM route was
significantly improved [K/X (IM: 1530±242 ea, IP: 1245±149 ea) and Z/X
(IM: 1136±226 ea, IP: 511±154 ea)]. Function of fresh islet with IM route
was better kept than of IP, which was expressed by stimulation index. The
viability and the insulin secretion of RIN-5F treated with anesthetic agents (eg.
ketamine, zoletil, xylazine alone and combination of K/X and Z/X) showed
time-dependent decrease.
Conclusion: For rodent islet isolation experiments, IM route for anesthesia is
simple and better way compared to IP route in the aspect of time and islet yield.
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HI’s, a phenomenon that has not been described before. In veterinary literature it is
widely recognized that electric stunning induces a rise of blood pressure resulting
in hemorrhages of different extent, which most likely explains the finding of HI’s.
The fact that only a small fraction of the islets is visually abnormal, suggests that
HI’s are only an indicator of the detrimental effects of blood pressure rise. Although
the results in humans are preliminary, our data suggest that this could explain the
generally experienced difficulties in obtaining islets from either humans or pigs.
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1713 ISCHEMIC PRECONDITIONING IMPROVES ISLET
RECOVERY AFTER PANCREAS COLD PRESERVATION
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A.R. Hogan1, A. Pileggi1, M. Doni1,2, M.M. Ribeiro1, R.D. Molano1, L.
Cobianchi1,2, J. Molina1, E. Zahr1, C. Ricordi1, R.L. Pastori1
1
University of Miami Miller School of Medicine – Diabetes Research
Institute, 2Department of Surgery, Fondazione IRCCS “San Matteo” Hospital
University of Pavia, Italy
Increasing evidence supports the beneficial effects of ischemic preconditioning
(IPC) of organs on subsequent ischemia. IPC may result in the activation of
cytoprotective ‘survival’ pathways resulting in improved organ preservation.
The aim of this study was to assess the effects of IPC of the pancreas on islet
cell recovery after cold preservation.
Using a rat model to test the effects of IPC, the pancreas was deprived of
perfusion (celiac artery and superior mesenteric artery occlusion) for 10
minutes followed by a reperfusion period of 10 minutes, prior to 18 hours of
cold preservation. Islet isolation was performed after cold ischemia.
Glands undergoing IPC yielded significantly higher numbers of islets than
controls (890±270 IEQ vs. 662±152 IEQ, respectively; p=0.012). Islet cell
loss after overnight culture was used as a surrogate indicator of islet quality:
a significantly greater proportion of islets were recovered from IPC-treated
pancreata, when compared to controls (48±12% vs. 33±10%, respectively;
p=0.00045). In vivo functional status, assessed by reversal of diabetes in mice
after islet transplantation, demonstrated comparable function between IPC and
control groups. Preliminary microarray genomic analysis of pancreatic tissue
revealed a significant differential expression of 602 unique mRNA strands
within IPC pancreata compared to only 95 unique mRNA strands within
non-IPC pancreata (fold change >2; p<0.05). Proteomic analysis revealed a
significant differential expression for at least 5 proteins (fold change >1.5;
p<0.05), within the IPC group versus controls.
One of the limitations of clinical islet transplantation is the inability to obtain
a sufficient number of islets from one donor pancreas to reverse diabetes in a
recipient. Our data indicates that IPC of the pancreas prior to cold preservation
is associated with improved islet cell recovery after cold ischemia. The use of
IPC of the pancreas may represent a viable therapeutic intervention to increase
success of islet transplantation from a single donor. A better understanding
of the underlying mechanisms of IPC-mediated cytoprotection in this model
may be of assistance in developing targeted interventions to maximize organ
utilization for transplantation.

POSTER BOARD NUMBER P3 – 140
1714 EFFECTS OF PANCREAS COLD ISCHEMIA ON ISLET
FUNCTION AND QUALITY
A. Pileggi1, M.M. Ribeiro1, A.R.. Hogan1, R.D. Molano1, J. Embury2,
H. Ichii1, L. Cobianchi1,3, A. Fornoni1, C. Ricordi1, R.L. Pastori1
1
University of Miami Miller School of Medicine - Diabetes Research Institute,
2
Department of Pathology, University of Florida College of Medicine,
Gainesville, FL, USA, 3Department of Surgery, Fondazione IRCCS “San
Matteo” Hospital University of Pavia, Italy
The success of islet transplantation depends upon the quality and number of
islets transplanted. Several variables contribute to the reduction of islet mass
and quality that can be obtained from a donor pancreas.
We used a rat model of pancreas cold preservation to assess its effects on islets.
Glands were surgically retrieved in UW and stored for 3hrs (Short) or 18hrs
(Long) cold ischemia time (CIT).
Islet yield was significantly lower in Long-CIT (868.3¡Ó235.8 IEQ/rat; n=14)
than Short-CIT group (1,560.8¡Ó528.4 IEQ/rat; n=12; p=0.00004), as well
as islet recovery after overnight culture 55¡Ó20% (n=12) vs. 82¡Ó13% (n=7;

568

Poster Abstracts
p=0.005). Islet cell viability after isolation was significantly reduced in the
Long-CIT group (p<0.04). Reversal of diabetes following transplantation of
suboptimal islet grafts occurred earlier in the Short-CIT group than LongCIT (10.2¡Ó8.6 vs. 22.4¡Ó6.0 days; n=5/group). All animals in Short-CIT
and 80% (4/5) in the Long-CIT group achieved euglycemia. Freshly isolated
islets showed a significant increase of JNK (2.45¡Ó0.99 vs. 1.0¡Ó0.4; p=0.016)
and p38 (1.92¡Ó0.63 vs. 1.0¡Ó0.61; p=0.047) phosphorylation in LongCIT compared to Short-CIT, respectively. Histopathological assessment of
the pancreas showed significantly higher injury score overall (2.4¡Ó0.9 vs.
1.7¡Ó1.3; p=0.004) and particularly acinar (2.4¡Ó0.9 vs. 1.6¡Ó0.3; p=0.004).
Proteomic analysis of pancreatic tissue led to identification of 5 proteins
consistently differentially expressed (cut-off range „d1.5) between Short and
Long-CIT.
Cold ischemia of the pancreas significantly affects both islet cell yield and
potency (viability and function) paralleled by increased phosphorylation of
stress kinases. Better understanding of the molecular pathways involved in this
phenomenon will be of assistance in defining targeted interventions to improve
organ utilization in the clinical arena.

CONCURRENT ORAL SESSION 123: ENZYME AND
GRADIENTS
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1715 COLLAGENASE PENETRATES HUMAN PANCREATIC
ISLETS FOLLOWING STANDARD INTRADUCTAL
ADMINISTRATION
P. Johnson1, S. Hughes1, C. Partridge2, D. Gray1, S. Cross1
1
Islet Transplant Research Group, Nuffield Department of Surgery, University
of Oxford, Oxford, UK, 2Oxford Centre for Diabetes, Endocrinology and
Metabolism, University of Oxford, Oxford, UK
Background: To optimise human islet isolation, it is important to improve
our understanding of the collagenase digestion phase. Considerable research
has been undertaken to improve the reproducibility, purity and stability of
collagenase. However, even with an optimal collagenase blend, the technique
used for administrating collagenase into the pancreas needs to enable delivery
of collagenase to the islet-exocrine interface without it entering the islets. The
aim of this study was to characterise collagenase distribution in relation to
islets in infused human pancreases.
Methods: Human pancreases were retrieved from multi-organ donors (age
range 19-61 years) with appropriate consent and ethical approval. Tissue
samples were taken from the pancreatic neck, body and tail regions before and
after collagenase infusion by manual syringe-loading (n=10) or recirculating
perfusion (n=8), and snap frozen in liquid nitrogen. Frozen sections (8mm
thick) were immunolabelled for collagenase, insulin, CK19, collagen VI and
CD31. Intra- and peri-islet collagenase was assessed by confocal microscopy in
double- or triple-labelled sections, with 47±5 islets assessed per section.
Results: Collagenase labelling was widespread throughout the pancreas,
associated with collagen VI and adjacent to CK19-labelled ducts. Collagenase
was found within 67±2% of islets (“intra-islet”), associated with capillaries
(CD31-positive). Intra-islet collagenase labelling was observed in 70±3% of
islets in the pancreatic tail, compared to 58±2% and 53±2% of islets in the
body and neck, respectively (p<0.05 tail vs neck), and was more prevalent in
islets with diameters >150μm (98±1% of islets >150μm vs. 52±2% of islets
<150μm, p<0.05). There was no difference in intra-islet collagenase labelling
between perfused and syringe-loaded pancreases (65±3% vs 69±3%, ns).
Conclusions: This study shows that collagenase penetrates the islet interior
during infusion procedures currently used routinely in most human islet
isolation facilities. This finding has potentially important clinical implications.
First, intra-islet collagenase may result in islet fragmentation either by
enzymatic digestion of the internal structural framework of the islet or simply
as a result of the pressure effects of fluid entering between the islet cells. Islet
fragmentation in turn can lead to low islet yields and islet dysfunction. Second,
the transplantation of islets that contain bacterial collagenase within their
cells has potential long-term safety implications. This study emphasises the
importance of further research to determine optimal methods of collagenase
delivery that enable optimal pancreas digestion, in order to liberate intact islets
that do not contain collagenase.
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1716 PERI-INSULAR COLLAGEN V AND VI WITHIN
PANCREASES OF YOUNG HUMAN DONORS ARE NOT
RESISTANT TO COLLAGENASE DIGESTION
P. Johnson1, S. Cross1, D. Gray1, A. Clark2, S. Hughes1
1
Nuffield Dept Surgery, University of Oxford, 2Oxford Centre for Diabetes,
Endocrinology & Metabolism, University of Oxford
Background: Efficient islet isolation is dependent on specific digestion with
collagenase of the extra-cellular matrix (ECM) within the islet-exocrine
interface of the human pancreas. Islets yields from young donors (<30 years) are
usually insufficient for transplantation, although these islets would potentially
provide better physiological function than those from older donors. The reason
for the poor yields is unknown. In this study, we used a novel assay to compare
collagenase digestion of two principle components of the ECM of the isletexocrine interface in young and old donors.
Methods: With appropriate consent and ethical approval, human pancreata
were retrieved from 5 young donors (aged 19-28 years) and 6 old donors (aged
45-60 years). Cold ischaemia time was <10 hours. Tissue blocks (~0.5 cm3)
were snap-frozen in liquid N2. Specimens were cryo-sectioned onto slides
at 10-15-ƒÝM thickness and stored at -25oC. Specimens were thawed and
incubated ¡ÓLiberase at 1.4mg/mL in HBSS for 5 min. at 37oC. Digestion of
the ECM within the islet-exocrine interface was analysed by double immunolabelling for insulin and Collagen V or VI and semi-quantified by morphometry
using image analysis (Zeiss KS-400). A mean number of 13¡Ó1 and 15¡Ó1
islets were assessed in control or Liberase-treated sections respectively. Data
were expressed as area of collagen sub-type/ islet area. Statistical analysis was
by Mann-Whitney U-test.
Results: After 5 minutes incubation, Liberase had begun to digest the exocrine
tissue although islets within the specimen were unaffected. The mean islet area
was unchanged in specimens from young (14572¡Ó2400 vs 12698¡Ó1604 ƒÝm2
in untreated) and old (11881¡Ó1095 vs 12541¡Ó806 ƒÝm2 in untreated) donors.
In contrast ECM components were undergoing digestion. Peri-islet Collagen
V content in young and old donors was significantly reduced by 34% (from
0.210¡Ó0.022 to0.138¡Ó0.014 /islet area) and by 35% (from 0.235¡Ó0.024 to
0.153¡Ó0.007/islet area) respectively by Liberase treatment. Similarly peri-islet
Collagen VI content in young and old donors was significantly reduced by 29%
(from 0.298¡Ó0.017 to 0.213¡Ó0.022/islet area) and by 34% (from 0.322¡Ó0.015
to 0.212¡Ó0.011/islet area) respectively. Collagen VI remained significantly
higher (p<0.05) than Collagen V in specimens from both young and old donors.
Conclusions: Collagenase digestion of peri-insular Collagen V and VI
within the pancreas of young donors is not impaired. These data suggest that
inadequate digestion of these components of the peri-insular ECM is not the
reason for poor islet yields from young donors. We are currently investigating
the digestion of other components of the ECM in young donors.
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M. Tsukada1, M. Gotoh1, T. Saito1, K. Ise1, A. Kenjo1, T. Kimura1, Y. Satoh1,
T. Anazawa1, S. Suzuki2
1
Surgery, Fukushima Medical University, 2Research and development division,
Kikkoman Co. LTD
Objectives: Recovery of the entire quantity of islets contained in a pancreas
is a goal of islet isolation for transplantation. In rodent models collagenase
digestion can be optimized at the time point to obtain peak yield, while in human
cases, timing of dilution is determined empirically by expertise of experienced
persons. However, once the timing is delayed, poor result is inevitable. Various
factors could affect quantity and quality of islets during digestion phase. In this
study, we unclose the component which injures the isolated islets during over
digestion and propose a new model for a study of optimal islet isolation.
Materials and methods: Wistar rat islets were isolated by stationary
collagenase digestion in which digestion time was varied from 15, 30, 60,
and 120 min. Measurement of adenosine nucleotides (ANs) and histological
studies including HE and TUNEL staining of digested pancreas was performed
for digested pancreas and isolated islets. In the next series of experiments in
order to assess the toxic environment around the islets during digestion, freshly
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1718 COMPARISON OF GMP SERVA COLLAGENASE AND
LIBERASE IN CLINICAL HUMAN ISLET ISOLATONS –
A VANCOUVER EXPERIENCE
Z. Ao1, M. Meloche, P. Ao, L. Dai, Z. He, D. Ou, D. Thompson2, G. Warnock
1
Department of Surgery, University of British Columbia, Canada,
2
Department of Medicine, University of British Columbia, Canada
Collagenase is a determinant component in a successful human islet isolation
process for clinical transplant. Recently, due to safety issues, most of clinical
islet isolation centers have started to use Good Manufacturing Practice (GMP)
grade enzymes, such as the GMP Serva collagenase. Many centers have been
assessing the efficacy of GMP Serva collagenase for human islet isolation,
however the results are inconsistent. In this study we assess the efficacy of
GMP Serva collagenase for human islet isolations in comparison with our
historic results with Liberase HI.
Materials and methods: Among 83 human islet isolations, 11 were processed
with GMP Serva collagenase and Neutral Protease (Nordmark Arzneimlttel
GmbH $ Co. KG, Uetersen, Germany), and 72 with Liberase HI (Roche
Diagnostics GmbH, Mannheim, Germany). The donor age 40±16 vs 45±14
yrs), body weight (81±8 vs 81±18 kg), pancreas weight (78±12 vs 83±20 g)
and organ cold storage time (211±50 vs 213±90 min) in both groups are very
similar without statistical difference. The islet isolation protocol was used as
previously described: briefly, continuous intraductal collagenase perfusion
of the pancreas, gentle tissue dissociation using a Ricordi chamber, and islet
purification with continuous Ficoll density gradients using a 2991 COBE. After
primary purification, all left over impure tissue were collected for 22&#730;C
culture over night, and re-purified for more islet yields. The average islet size
is estimated by counting all islets in a representative sample and calculated
the size index as “total counted islet equivalents (IE) / total counted number
of islets”. Islet viability was assessed by Syto-green staining and islet function
assessed by glucose perifusion test.
Results: The islet yields in Serva group was 503459±271520 IE with a purity
of 81±5%, which compared favorably with the Liberase group with a yield of
490602±227753 IE and 83±20% of purity (P=ns). Islet size index (IE/islet)
in Serva and Liberase group was 2.2±0.8 and 2.4±0.8 respectively (P=ns).
Islets in both group revealed similar viability with Syto-green staining (93±4%
vs 96±4%) and insulin secretion function by glucose perifusion. 8 of the11
(72.7%) islet isolations using Serva collagenase met release criteria and were
used for clinical transplant, while 52 of 72 (72.2%) of isolations in Liberase
group were used for transplant.
Conclusions: Our initial assessment of GMP Serva collagenase has
demonstrated it has comparable efficiency to Liberase HI in human islet
isolations for clinical transplant.
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1717 HIGHLY TOXIC ENVIRONMENT TO ISOLATED ISLETS
DURING COLLAGENASE OVERDIGESTION

isolated islets (40 islets) were co-cultured for 30 min with the pancreatic
digested fluid (supernatants obtained from collagenase digestion at different
digestion periods). Morphology and ANs of the islets were also examined.
Results: Peak yields of islets were 1316¦ }245 IEQ (n=8), obtained at 30 min
of digestion. Yields at shorter and longer digestion periods were significantly
lower than this, and the one at 120 min of digestion was less than 10% of
the peak yield. Histological study of digested pancreas showed that islets
were broken into pieces at 120 min of digestion with TUNEL being positive
at 60 and 120 min of digestion. ATP levels of 150mg of pancreatic tissue
significantly decreased at 60 and 120 min of digestion compared with the ones
of fresh pancreas (fresh, 60 min, 120 min; 22.1+/- 4.1, 10.6 +/-1.0, 1.8 +/- 0.4,
p<0.01).) As for the co-culture experiment, ATP levels of the islets decreased
with co-culture with collagenase as compared with Hanks alone (Hanks,
collagenase; 0.32 +/- 0.05, 0.24 +/-0.04, p<0.05). Furthermore, ATP levels of
the islets after co-culture with pancreatic digested fluid decreased markedly
in proportion to digestion time (15, 30, 60, and 120 min; 0.17 +/-0.03, 0.13
+/-0.02, 0.07+/-0.02, 0.03 +/- 0.02, p<0.01). Islets co-cultured with collagenase
and pancreatic digested fluid cracked at 60 minutes and didn’t hold circular
shape at 120 minutes.
Conclusion: Morphological deterioration of islets as well as marked ATP
decrease of the tissues were evident not only in whole digested pancreas, but
also in separated islets co-cultured with pancreatic digested fluid. Various
factors toxic to the islets can be analyzed in the future experiments using this
co-culture experimental model for obtaining a large scale of viable islets.
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1719 THE PURIFICATION METHOD USING IODIXANOL
(OPTIPREP)-BASED DENSITY GRADIENT SIGNIFICANTLY
REDUCE CYTOKINE/CHEMOKINE PRODUCTION FROM
HUMAN ISLET PREPARATIONS, LEADING TO PROLONG ~ ÀCELL SURVIVAL DURING CULTURE
A. Mita1,4, C. Ricordi1,2,3, A. Miki1, S. Barker1, A. Khan1, A. Alvarez1,
Y. Hashikura5, S. Miyagawa4, H. Ichii1,2,3
1
Diabetes Research Institute, University of Miami Leonard M. Miller
School of Medicine, 2DeWitt Family Department of Surgery, University of
Miami Leonard M. Miller School of Medicine, 3Jackson Memorial Hospital
Transplant Institute, University of Miami Leonard M. Miller School of
Medicine, 4Division of Transplantation, Department of Surgery, Shinshu
University School of Medicine, 5Transplantation Center, Shinshu University
School of Medicine
Background: Although Ficoll-based density gradient has been widely used
for human islet purification in most islet processing centers, OptiPrep-based
density gradient was recently used in the limited centers. It has been reported
that Islet preparations purified using OptiPrep-based density gradient provided
better clinical outcomes. It is well known that cytokine/chemokine production
from islet preparations widely varies. Reducing cytokine/chemokine production
from islet preparations may be a key to improve islet transplantation outcomes.
The aim of current study is to investigate the variability of pro-inflammatory
cytokine/chemokine production from human islet preparations purified using
different density gradients.
Methods: Human islet isolations were performed using automated method.
After digestion phase, pre-purification digests were divided into two groups and
purified using semi-automated cell processor with Ficoll-based or OptiPrepbased density gradient. Human Islet preparations were cultured for 2 days, and
assessed regarding glucose stimulated insulin release, islet cell viability (FDA/
PI), fractional ƒÀ-cell viability and ƒÀ-cell content. Cytokine/chemokine
production from islet preparations was also examined.
Results: Between Ficoll-based and OptiPrep-based density gradient groups,
islet purity (90.0 ¦ } 4.1% and 91.3 ¦ } 3.2%, respectively, p=0.718), postpurification IEQ (128,504.0 ¦ } 28,893.4 IEQ and 140,881.0 ¦ } 16,644.0
IEQ, respectively, p=0.726) and islet recovery rate (46.4 ¦ } 4.2% and 69.7 ¦ }
22.8%, respectively, p=0.390) were comparable. Although stimulated insulin
release (stimulation index 0.5 ¦ } 0.2 and 0.8 ¦ } 0.3, respectively, p=0.123),
FDA/PI (92.4 ¦ } 2.5% and 90.6 ¦ } 3.6%, respectively, p=0.550) and fractional
ƒÀ-cell viability showed no significant differences (88.2 ¦ } 7.7% relative to
OptiPrep-based density gradient group, p=0.178), ƒÀ-cell survival during
culture significantly improved in OptiPrep-based density gradient group when
compared to Ficoll-based density gradient group (130.6 ¦ } 1.8% relative,
p<0.05). TNF-ƒ¿, IL-1ƒÀ, IFN-ƒÁ, IL-6 and MIP-1ƒÀ production from
OptiPrep-based density gradient group significantly decreased when compared
to Ficoll-based density gradient group (22.8 ¦ } 11.8% relative, p=0.003, 27.7
¦ } 14.0% relative, p=0.002, 37.3 ¦ } 11.2% relative, p=0.001, 45.3 ¦ } 16.2%
relative, p=0.015, and 38.5 ¦ } 18.6% relative, p=0.016, respectively).
Conclusions: The purification method using OptiPrep-based density gradient
can significantly reduce cytokine/chemokine production from islet preparations
when compared to Ficoll-based density gradient, leading to the improvement of
quantity of ƒÀ-cell mass. Our results suggest that the purification method using
OptiPrep-based density gradient may be of assistance in improving clinical
outcomes, and that Cytokine/chemokine profiling from islet preparations could
be helpful to develop better isolation methods.
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1720 STRONG INTER-INDIVIDUAL VARIATION OF
STRUCTURAL ELEMENTS IN THE HUMAN PANCREAS
MIGHT BE RELEVANT TO ISLET ISOLATION
H.A.M. Töns, D.E. Hilling, O.T. Terpstra, E. Bouwman
Department of Surgery, Leiden University Center, Leiden, The Netherlands
Objectives: The outcome of the isolation of the islets of Langerhans from the
pancreas is difficult to predict. Even in experienced centers, isolations often
do not lead to transplantation due to disappointing yields. The causes of these
differences in isolation outcome are not clear. The existence and the role of
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inter-individual differences in pancreatic anatomy are largely unknown. The
present study examined the heterogeneity of the structural elements of the donor
pancreata relevant to islet isolation. The amount of endocrine tissue, intraparenchymal fat and edema were determined. Total collagen was quantified
and the degree of encapsulation of the islets with collagen and the thickness
of the capsule were semi-quantitatively assessed. The relation between several
parameters was examined.
Material and methods: Tissue from 100 normal pancreata was used for
histochemical and immunochemical analyses. Aldehyde Fuchsine staining
was performed to evaluate the amount of endocrine tissue. One cm2 tissue was
investigated to assess the total endocrine content and the size distribution of
the islets. The percentage intra-parenchymal fat and pancreatic edema were
determined by the point counting method. Collagen was stained with Sirius
Red and quantified with image analysis (KS400). A double staining of Sirius
Red with anti-insulin was done to measure the degree of islet encapsulation
with collagen.
Results: All factors examined showed a strong inter-individual variation.
The total endocrine tissue varied fivefold from 0.25 to 1.25% (mean 0.77 ±
0.28 (SD)) with great differences in size distribution. When expressed as ratio
‘small’ versus ‘large’ islets (50-100 and > 100 μm respectively) a range from
0.96 to 4.9 (mean 2.25) was found. The intra-parenchymal fat varied from 0
to 8% (mean 1.34 ± 2.1) and for pancreatic edema a variation of 2.3 to 49.6%
(mean 18.45 ± 15.25) was found.
The total collagen content varied from 1.9 to 26.3% (mean 10.0 ± 5.2) and a
slight but not significant increase of total collagen with age was seen. There
was a wide variety in the degree of encapsulation and thickness of the collagen
capsule. Islets completely encapsulated varied from 0-98% (mean 57 ± 27.4)
per pancreas and the islets with a collagen capsule less than 25% of there
circumference varied from 0-95% (mean 19.5 ± 22.4) per pancreas. There
was no relation between age and the presence of totally encapsulated islets
(p=0.09) and between total collagen in the tissue and the presence of islets with
a collagen capsule (p=0.48).
Conclusions: The strong inter-individual variation observed for all factors
analyzed, strongly suggests their contribution to the unpredictable outcome of
the isolation process.
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1721 AMOUNT AND DISTRIBUTION OF COLLAGEN IN
THE PANCREAS HAVE NO EFFECT ON PORCINE ISLET
ISOLATION OUTCOME
D.E. Hilling, E. Bouwman, J.K.R.A. Rijkelijkhuizen, H.A.M. Töns,
O.T. Terpstra,
Department of Surgery, Leiden University Medical Center, Leiden,
The Netherlands
Background: Transplantation of islets of Langerhans can restore insulin
production in patients with type 1 diabetes. Because of the shortage of human
donor organs, transplantation of porcine islets is considered to be a suitable
alternative solution. However, porcine islet isolation procedures have been shown
to produce unpredictable, highly variable islet yields between pigs with similar
backgrounds. One of the variables that could account for this is the collagen
substrate within the pancreas. The aim of the present study was to determine
the total amount and distribution of collagen within porcine pancreases and
furthermore the effect of these determinants on islet isolation outcome.
Methods: 140 porcine pancreases were harvested in different slaughterhouses.
The population consisted of a juvenile group (6–12 months) of 64 animals and
an adult group (12–78 months) of 76 animals. Islet isolation was performed in
58 pancreases of the adult group.
To detect collagen, tissue samples were embedded in paraffin and stained with
Sirius red. Quantitative measurements were made using the KS-400 image
analysis system. The amount of the collagen stained area was quantified by
assessment of 30 random fields in each tissue sample. Collagen distribution
was determined by assessing the presence of collagen in the endocrine-exocrine
interface. Tissue samples were stained with Sirius Red in combination with
anti-insulin to allow identification of the islets. The presence of collagen in
the islet capsule was scored semi-quantitatively in an average of 100 islets per
tissue sample.
Both measurements were considered to be valid representations of the total
collagen content and islet encapsulation of the whole pancreas.

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Wednesday 13 August 2008

Poster Abstracts
Results: The mean (± SD) collagen content in the adult group was 5.9 ± 1.8%
(range 2.3–11.0), this was significant higher (p<0.001) than in the juvenile
group where the mean collagen content was 3.7 ± 1.3% (range 1.1–7.1).
Apparently, the pancreas undergoes a process of fibrosis as pigs grow older.
This was confirmed by a significant correlation between collagen content and
age in the overall group (r=0.33, p<0.001).
In a pancreas, an average of 80.7 ± 16.4% of the islets was encapsulated less than
50%. However, this average ranged from 23 – 100%, showing high variability
in islet encapsulation between pancreases. Between total collagen content
and islet encapsulation a significant positive correlation (r=0.33, p<0.05) was
found, indicating that in pancreases with high total collagen content, a larger
number of islets are encapsulated greater than 50%.
After isolation and purification, the average obtained islet yield was 545.4 ± 601.2
IE/g pancreas (range 18–3849). We found no significant correlation between
collagen content and obtained islet yield (r =-0.004, p=0.98). Furthermore, no
significant correlation was found between the percentage of islet encapsulation
in each pancreas and obtained islet yield (r=-0.053, p=0.69).
Conclusions: Neither the amount of collagen nor the islet encapsulation have
effect on porcine islet isolation outcome. Possibly the amount and distribution
of collagen subtypes (e.g. collagen type VI), rather than the total content, can
explain some of the variability in porcine islet isolation.
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1722 BENEFICIAL EFFECT OF HUMAN ISLET RESCUE
GRADIENT PURIFICATION ON EMBEDDED ISLET AND
FRACTIONAL BETA CELL VIABILITY

1723 THE SUCCESSFUL SWITCH TO SERVA COLLAGENASE
FROM ROCHE LIBERASE ON THE ISOLATION OF HUMAN
ISLETS
T. Loudovaris, L. Mariana, G. Jhala, B. Krishnamurthy, N. Sanders,
P. Campbell, S. Fynch, H. Junquan, H. Thomas, T. Kay
St. Vincent’s Institute, 41 Victoria Parade, Fitzroy Victoria 3065
The primary steps in isolating islets for transplantation into diabetic patients
involves the use of collagenase to break up the pancreas into small pieces
less than 500μm. March last year we were made aware that the collagenase
source that we were using, Liberase from Roche, was produced using bovine
brain products, whose source could not be guaranteed to be free of bovine
spongiform encephalitis (BSE) virus. This forced a change to Collagenase from
SERVA, Germany, which was certified to be BSE free.
Aim: To compare the islet yields, function and viability obtained with SERVA
collagenase to that obtained with Liberase.
Methods: Human islets are isolated from pancreata that are offered to the
Tom Mandel Islet Transplantation Program in Melbourne come from Victoria,
Tasmania and South Australia (SA). Because of limited availability, there was little
or no donor selection, with nearly all pancreata accepted, even ones that would
be considered to be from “poor” donors. Islets were isolated using the modified
Ricordi method. Isolated islets were evaluated functionally by static glucose
incubations (resulting in a stimulation index as a ratio of stimulated to basal islet
insulin release) and by transplantation into diabetic SCID mice. Viability was
determined by fluorescent mitochondrial dyes and flow cytometric analysis.
Results: Pancreata digested with Roche Liberase Lot#93401520
(n=15) achieved the best results with average pre-purification count of
416,445+/-201,393, post-purification count of 207,867+/-109,858, with
57.1% successful mouse transplants (>67% mice had corrected blood glucose
levels) 93.3% positive insulin stimulation index and 28.6% of preparations
had a beta cell viability index of >0.3. Pancreata digested with SERVA GMP
Collagenase Lot#20100005 (n=16) achieved an average pre-purification count
of 282,036+/-121,182, post-purification count of 182,780+/-167,725, with
50% successful mouse transplants, 93.8% positive insulin stimulation index
and 27.3% of preparations had a beta cell viability index of >0.3. Digestion
with other lots of Liberase (five test lots, total of 15 isolations) produced the
lowest average islet yields both pre and post-purification.
Conclusion: Although the Roche Liberase appeared to produce better yields of
islets and more successful mouse transplant results, the results achieved with
SERVA collagenase were not significantly different. The switch from Liberase
to SERVA collagenase has resulted in Victoria’s first successful islet transplant.
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1724 COMPARISON OF THE EFFICACY OF AVAILABLE
COLLAGENASES ON HUMAN ISLET ISOLATION FROM
RESEARCH GRADE PANCREATA
B. Barbaro, P. Salehi, J. Kuechle, M. Qi, S. Wang, L. Rodriguez, C. Groh,
Y. Wang, E. Benedetti, J. Oberholzer
Department of Surgery, Division of Transplantation, University of Illinois at
Chicago, USA
Backgorund: Islet transplantation is a promising therapeutic approach for the
treatment of type 1 diabetes. Although progressively improved, the success
of islet transplantation is still unpredictable. One of the major obstacles to
successful human islet isolation has been the variability of the enzymatic
digestion phase. The aim of this study was to compare enzyme efficiency
among three different collagenases: Liberase HI (Roche), Collagenase (Serva)
and Collagenase V (Sigma) during human islet isolation.
Methods: The data from 99 human islet isolations (44 with Roche, 11 with
Serva, and 44 with Sigma) of research grade pancreata were retrospectively
analyzed. Enzyme efficiency was evaluated in terms of islet yield, purity,
recovery rate, stimulation index and viability of the final product.
Results: Donor characteristics including age, sex, BMI and cause of death
were comparable among the three groups. Cold ischemia time was 10:39±2:19
h in Sigma, 9:05±2:45 in Serva and 8:48±2:06 h in Roche group. Isolations
with Sigma collagenase V yielded 269,020±21,214 IE whereas isolations with
Serva collagenase yielded 248,342±53,015 IE and Roche liberase yielded
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A. Miki, C. Ricordi, T. Yamamoto, A. Mita, S. Barker, A. Kahn, R. Alejandro,
H. Ichii
Diabetes Research Institute
Objective: It is difficult to consistently obtain sufficient post-purification islet
numbers from younger donors, due to the higher proportion of trapped islets
after pancreas digestion, even though several reports suggest islets isloated
from younger donor pancreata present better suitability for clinical islet
transplantation. Continuous Gradient Purification, which is currently used in
several islet processing centers, sometimes is not efficient in the purification
of trapped islets. Rescue gradient purification could improve post-purification
islet yields, resulting in an increased number of islet cell products that could
be transplanted.
Materials and methods: Islet isolation were performed by automated method
at Diabetes Research Institute of University of Miami. Seventy three human
islet isolations for clinical islet transplantation, in which Continuous gradient
purification was followed by Rescue gradient purification were analyzed. The
quality of islets from Continuous gradient purification and Rescue gradient
purification was assessed by beta cell fractional viability and ADP/ATP ratio
for islet potency test. Assessment of Cellular composition using Laser Scanning
Cyotometer /iCys was performed to assess the beta cell content.
Results: The overall percent rescue (Rescue islet IEQ/Continuous islet IEQ +
Rescue islet IEQ) is positively correlated with the% trapped islets (R=0.584,
P < 0.01) Donor age correlated negatively to the% islets recovered from RGP
(R=0.440, P < 0.01) and to the% of trapped islets (R=0.511, P < 0.01).
A significant age related difference (< 39 vs. > 40) was observed in pancreas
weight (91.6 ¦ } 22.9 vs. 115.0 ¦ } 33.4g; P < 0.01), digestion time (15.1 ¦ }
4.1 vs. 18.2 ¦ } 5.7min, P < 0.05) and islet yields from CGP (214,319 ¦ }
131,668 vs. 296,575 ¦ } 172,509 IEQ, P < 0.05), respectively. Importantly,
islets from Rescue gradient purification had an 11% higher beta cell fractional
viability compared to islets from Continuous gradient purification. ADP/ATP
ratio was also lower in Rescue gradient purification islets vs. Continuous
gradient purification islets (0.46 ¦ } 0.17 vs. 0.86 ¦ } 0.11, P<0.05). Beta cell
content in islet showed no significant difference (48.4 ¦ } 21.0 vs. 36.0 ¦ }
15.5, N.S)
Conclusion: RGP improved the efficiency in the purification of trapped islets,
which often come from younger donor pancreata and did not affect islet cell
viability, which was actually higher in Rescue gradient purification fractions,
indicating that rescued trapped islets from the pellet and lower purity layers are
not damaged by the extra purification step and may actually be more viable.
Rescue gradient purification could be used to rescue high quality islets from <
30% pure islet fractions, which are often discarded in the clinical setting.
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314,557±29,886 IE (p=0.43 for Sigma vs Roche and p=0.94 vs Serva). Islet
recovery rate was similar among all groups: 81.4±30.4% for Sigma, 62.7±28.9%
for Serva and 91.5±24.4% for Roche group. Similar enzyme efficiency was
observed among the three groups in terms of viability, functionality and purity.
Conclusion: Sigma V collagenase achieved similar islet isolation outcomes as
Liberase and Serva, and represents a cost-effective alternative product. This
result questions the validity of purified enzyme blends and indicates that more
research is needed to better understand the requirements for ideal enzymes for
human islet isolation.
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1725 THE EFFECTS OF PHYSICAL QUALITY OF LIFE, TIME,
AND GENDER ON CHANGE IN SYMPTOMS OF ANXIETY AND
DEPRESSION AFTER KIDNEY TRANSPLANTATION
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy3
Cairo University, Division of Nephrology, Department of Medicine, 2Cairo
University, Department of Urology, 3Cairo University, Department of
Clinical Pathology
Introduction: Previous research demonstrated that functional performance and
health-related quality of life (HRQOL) improve following kidney transplantation,
but the extent to which improvement in symptoms of anxiety and depression is
related to post-transplant physical HRQOL has not been characterized. The aim
of this study was to test the effects of physical HRQOL, time post transplant, and
gender on pre- to post-transplant change in symptoms of anxiety and depression.
Methods: Longitudinal HRQOL data were prospectively collected at specific
times before and after kidney transplantation using Health Survey, Center for
Epidemiologic Studies Depression Scale (CES-D), andBeck Anxiety Inventory
(BAI). Within-subject change scores were computed to represent the longest
follow-up for each patient. Multiple regression was used to test the effects of
time post transplant, gender, and post-transplant physical component summary
scores on change in BAI and CES-D scores. Baseline scores on outcome
measures were modeled to account for and quantify their expected effects.
Summary data are reported as mean±SD.
Results: 107 patients (74% male; 51% HCV; age#5498 years) reported 474
survey points over 43 months. Time post-transplant ranged 1 to 39 months
(mean#998). Patients with the poorest pre-transplant HRQOL showed the
greatest improvement on every model. Change in CES-D and PCS scores
continued with time post transplant. Reduced post-transplant physical quality
of life was associated with less improvement in symptoms of anxiety (model
1) and depression (model 2). This relationship is also reflected in model 3,
which quantifies the negative effect of post-transplant anxiety on change in
PCS. Gender did not affect these outcomes.
Conclusions: Despite improvement on all HRQOL measures, there was
less improvement in symptoms of anxiety and depression in those patients
with reduced physical HRQOL after kidey transplantation. Awareness of the
significant relationships between physical and mental quality of life indicators
in both men and women suggests the importance of early recognition and
intervention strategies to promote continued improvement in mental and
physical quality of life following kidney transplantation.

WEDNESDAY

1

POSTER BOARD NUMBER P3 – 152
1726 THE EFFECT OF SPONTANEOUS TWIN PREGNANCY ON
RENAL TRANSPLANT FUNCTION AND HAEMODYNAMICS
S. Bhandari
Hull And East Yorkshire Hospitals NHS Trust And Hull York Medical School
Pregnancies after transplantation are association with an increased risk for
both mother and fetus with higher rates of stillbirth and preterm deliveries.
Spontaneous twin pregnancy is uncommon in renal transplant recipients and
presents an even greater risk. The effects on transplant haemodynamics have
not been studied. We present a case of a successful outcome for both mother
and babies and detail the effects of the pregnancy on transplant function and
haemodynamics within the transplant kidney.
A 27-year old woman received a cadaveric transplant in December 1995 from
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a 10year old donor, HLA 111 mismatch. She had a past history of recurrent
urinary tract infections and hypertension and presented initially to the
nephrologists with bilateral dysplastic kidneys requiring peritoneal dialysis
prior to transplantation. Immunosuppression at induction was Neoral 200mg
BD, Azathioprine 75mg and Prednisone 20mg. At the time of spontaneous
conception (March 07) she was taking Neoral 100mg BD, Azathioprine 50 mg
daily and Prednisolone 5 mg daily.
The course of the pregnancy was uneventful apart from a modest increase in
proteinuria (0.3 to 1.0 g/24h) and blood pressure (121/81 baseline to 132/92
mmHg). At 32 weeks due to increasing blood pressure a semi-elective C-section
was performed with the delivery of two healthy babies which required minimal
medical input.
During the pregnancy serum creatinine fell by 36% (142 to 91μmol/L), urea
fell by 39% (9.0 to 5.5mmol/L) while eGFR (MDRD) rose by 29ml/min.
Albumin fell by 28% (39 to 28 g/L) while there was a modest increase in
uric acid to 0.51mmol/L. Transplant scans revealed a 21% increase in crosssectional area of the kidney with a 10% increase in main renal artery peak flow
and a 21% reduction in resistive index. Serum creatinine rose to 199μmol/L,
eGRF 48ml/min (baseline 40ml/min), urea 8.1mmol/L and albumin 38g/L
post pregnancy and remained stable. The RI remained unaltered and the peak
renal artery flow fell 50% while the cross-sectional area returned to baseline
post delivery.
Twin pregnancy can be successful with no increased risk in comparison to non
transplant females. Physiological changes in renal haemodynamics are similar
to non transplant pregnant patients (70% rise in renal blood flow, 25% fall in
urea and creatinine, 55% increase in GFR) with no detrimental effect to the
transplant function post pregnancy.

POSTER BOARD NUMBER P3 – 153
1727 KIDNEY TRANSPLANTATION FROM CADAVERIC
DONORS OLDER THAN 60 YEARS OF AGE
G. Miserlis, G. Vergoulas, V. Papanikolaou, A. Dinas, N. Antoniadis,
D. Vrochidis, I. Fouzas, G. Imvrios, D. Giakoustidis, D. Takoudas
Organ Transplant Unit, Hippokration General Hospital
Donor age was identified as a major factor that determines long term
outcome after kidney transplantation. However, the influence of other
parameters such as acute rejection (AR) and delayed graft function (DGF)
both on short and long-term kidney graft survival from elderly deceased
donors has not been well characterized. In this study we analyzed
retrospectively the impact of the above parameters on the outcomes of
40 kidney allograft recipients (mean age: 49.5±11.5 years) transplanted
between March 2001 and December 2006 from elderly (mean age:
64.9±4.6 years) deceased donors. Patient and graft survival rates at 1, 3
and 5 years post-transplantation were 97.4%, 97.4%, 80.4% and 87.3%,
81.5% and 69.8% respectively. Twenty (50%) of patients suffered DGF
and 11 (27.5%) AR episodes, while 8 (20%) lost the graft. Acute rejection
was a significant determinant for worse renal graft outcome and graft
loss (Risk Ratio [RR] for graft loss in pts with AR vs absence of AR =
7.0; p<0.001). DGF itself was not associated with graft loss (RR for graft
loss in pts with DGF vs absence of DGF =1.7; p=0.11). Mean GFR levels
(MDRD6 formula) at 6 months, 1 and 2 years were 26.6±9.1, 30.4±10.3
and 32.0±6.5 ml/min/1.73m2 in kidney graft recipients presented AR and
57.4±17.3, 54.6±15.8 and 54.7±18.2 ml/min/1.73m2 in patients without
rejection episodes (p<0.05). Mean 24h proteinuria was statistically
significant higher in patients with AR only 1 year post-transplantation
(766.6±391.9mg/24h in pts with AR vs 253.4±239.5mg/24h in pts without
AR, p<0.05). In conclusion, renal grafts from older deceased donors can be
successfully transplanted to younger recipients. Acute rejection episodes in
kidney allografts from elderly deceased donors had a significant negative
impact both on short and long term graft function and outcome.
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1728 KIDNEY TRANSPLANTATION, A UNIQUE CURE FOR
SEVERE LEFT VENTRICULAR DYSFUNCTION
S. Bhandari, S. Sajid, N. Nickolay
Department of Renal Medicine, Hull and East Yorkshire Hospitals NHS Trust
and Hull York Medical School, Kingston upon Hull, UK
Cardiovascular complications are the leading cause of mortality among patients
with end-stage renal disease, accounting for 50% of all deaths. Indeed, the
prevalence of heart failure amongst these patients is as high as 40% and is
responsible for 12% of the total deaths. The mechanisms underlying these cardiac
abnormalities remain unclear. Renal transplantation is normally contra-indicated.
We present a case of a dialysis patient with severe cardiac dysfunction who
demonstrated significant functional and clinical improvement as assessed by cardiac
MRI, symptoms and hospital admissions to highlight that patients with severe
cardiac dysfunction should be considered for possible renal transplantation.
A 37y Caucasian male with end stage renal disease secondary to IgA
nephropathy and significant left ventricular hypertrophy from hypertension had
been on dialysis for 4 years (6 months peritoneal and 42 months haemodialysis).
He was on maximal ACE and ARB inhibition. Cardiac transplant assessment
demonstrated poor LV systolic and diastolic function and evidence of mild
diffuse coronary artery disease with no focal lesion worthy of intervention. He
had symptomatic NYHA functional class 3 heart failure. Despite regular dialysis
and adequate fluid removal he had 48 admissions in the previous year. MRI
revealed significant cardiac dysfunction with an EF% of 27% (see Figure).
After successful cadaveric renal transplant, within the first year there was significant
function improvement with an EF% of 43%, a 19% reduction in LV mass and 24%
increase in stroke volume. In the 3 years since transplantation he has required no
hospital admissions and he has NYHA functional class 1 heart failure.
This case demonstrates the benefits of renal transplantation on cardiac function.
Possible mechanisms for this dramatic improvement could include
1. removal of uraemic toxins causing a uraemic cardiomyopathy
2. removal of the haemodynamic effects of dialysis
3. repletion of chronic carnitine deficiency
4. improved fluid balance
The main impact on a reduction on LV mass and hence hypertrophy suggests
that transplantation can abrogate the future need for cardiac transplantation.
Patients with cardiac failure on dialysis should be considered for renal
transplantation and not excluded. Cardiac MRI represents a useful method of
assessing and monitoring cardiac function in renal transplants.

Results: All candidates revealed normal chest X ray, echocardiography and
cardiac stress testing. CT scan showed severe aortic calcification in 8 candidates
(44%) in which the calcification occupied all around the aorta, and partial aortic
calcification in 7(39%). But all candidates had non calcified iliac artery site to
make vascular anastomosis possible. However, 13 candidates (72%) showed
significantly high PWV in average of 1601 sec, and one showed significantly
low ABPI which consequently required the interventional treatment for the
external iliac artery occlusion. One candidate showed ventricular tachycardia
which needs ablation treatment. One candidate revealed thrombocytopenia
which was due to liver cirrhosis by hepatitis C infection. Finally 3 candidates,
which all had more than 10 years of dialysis history, were not acceptable for
transplantation at the time of evaluations and 2 have been treated successfully.
Among 18 candidates, 7 had more than 10 years dialysis history and 43% of these
candidates had comorbidity which was not acceptable for transplantation.
Conclusions: Screening especially of cardiovascular and peripheral vascular
disease is mandatory on the renal transplant candidate who is on waiting list
for more than 10 years.
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1730 THE EFFECT OF SUCCESSFUL RENAL
TRANSPLANTATION ON ERECTILE DYSFUNCTION
G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Objective: To evaluate the prevalence of erectile dysfunction (ED) in
hemodialysis patients and the effect of successful renal transplantation on it.
Materials and methods: Two hundred and seventy hemodialyzed patients
underwent live unrelated renal transplantation from Sep. 2002 to Nov. 2005 in
Sina hospital, Tehran University of Medical Sciences, Iran.
Those who were younger than 20 years, positive history for diabetes mellitus,
ischemic heart disease, hypercholestrolemia, pelvis trauma or prostate surgery
cigarette smoking, previous renal transplantation and medication use with
adverse effect on erectile dysfunction were excluded. Eighty eligible patients
entered the study and were assessed by international index of erectile function,
version 5(IIEF-5) pre and six-month post renal transplantation.
Results: The prevalence of ED in hemodialyzed patients was 87.5%. Aging had
not statistically significant effect on it. There was no relationship between the
duration of dialysis and ED severity. Sixty four patients had good functioning
graft in 6-month follow-up and completed the study.
Successful transplantation improved IIEF-5 score significantly (P < 0.001).
Pretransplantation IIEF-5 score, age at the time of transplantation and
transplant artery anastomosis to common iliac artery had statistically significant
association with ED improvement, while duration of dialysis had not.
Conclusions: ED is highly prevalent in hemodialyzed patients. It improves
significantly after successful kidney transplantation.
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1729 HEALTH SCREENING OF THE RENAL TRANSPLANT
WAITING LIST
Y. Watarai, A. Kwaguchi, S. Maru, R. Ishikawa, N. Taniguchi
Kushiro City General Hospital
Purpose: Candidates on the renal transplant waiting list wait for significantly
long time, 18 years in average, in Japan and they are assumed to have increasing
numbers of comorbidity during dialysis period. Transplant centers need to ensure
that their candidates are acceptable for transplantation when the organ becomes
available. We have evaluated the renal transplant waiting list in our institute.
Methods: 18 out of 20 candidates on our waiting list, mean age of 49.8(28-60)
and duration on hemodialysis of 11.2 years(1-22 years), were evaluated 1)
complete blood tests, 2)chest X ray, 3) echocardiography and cardiac stress
testing, 4) measurement of Pulse wave velocity(PWV) and Ankle blood pressure
index(ABPI), 5) Plain CT scan with 3D reconstruction of the calcification of
aortic and iliac artery by maximum intensity projection.

1731 FACTORS INFLUENCING THE WAITING PERIOD
FOR KIDNEY TRANSPLANTATION
M. Heemskerk1, A. Hemke1, B. Haase-Kromwijk1, A. Hoitsma2
1
Dutch Transplant Foundation, 2Radbout University Medical Centre,
Nijmegen, The Netherlands
Background: Not all patients on the waiting list for a renal transplant have
equal chances on receiving one, nor is the waiting time for patients equally
spread. The question is what the reason is for this imbalance and which policies
can be changed to equalise the chances.
Methods: We performed an analysis on the kidney waiting list registrations,
for all recipients who awaited a non-pre-emptive deceased donor first kidney
transplant in the Netherlands between 2000 and 2007. We analyzed the
influence of several parameters on the average number of dialysis days prior
to kidney transplantation (waiting time). The analysis was performed on both
patients who received a kidney (n = 2096) as well as on patients who were still
on the kidney waiting list at the end of 2007 (n = 682).
Results: Transplanted patients: the average waiting time for a deceased donor
first kidney transplant was 3.4 years for all recipients. A significant difference in
waiting time was found for the different blood groups (AB: 2.5, A: 3.1, B: 3.5, O:
3.9 years, P<0.001). These differences in waiting time are probably the result of
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years of full house identical kidney exchange of blood group O donors to other
blood groups. This has resulted in an increase of the percentage of blood group O
patients on the list, which is illustrated by the fact that 53% of the patients on the
Dutch active kidney waiting list on 1-1-2006 had blood group O, in comparison to
46% of all Dutch organ donors in 2007. The type of transplant registration center
(<35% NHB transplants: 3.5 years, >35% NHB transplants: 3.3 years, P=0.050)
had no important influence. Surprisingly, patients with peritoneal dialysis had a
shorter waiting period than patients on haemodialysis: (3.0 years versus 3.7 years,
P<0.001). However, this might be due to the fact that patients who are a long time
on peritoneal dialysis have a high chance to be switched to haemodialysis due to
complications of the peritoneal treatment before being transplanted.
Patients still on the waiting list at the end of 2007: the mean waiting time for
these patients was 2.7 years. The waiting periods were significantly different per
blood group (AB: 2.0, A: 2.2, B: 2.8, O: 3.0 years, P<0.001) and center type,
although for center type the difference was only 0.2 years. For patients on the
waiting list there was no significant difference between the dialysis techniques.
Conclusion: For an individual on the waiting list the actual waiting time is
strongly influenced by his/her blood group; there is a disadvantage for blood
group O patients. We might have to abandon full house identical kidney
exchange of blood group O donors to other blood groups. The percentage of
NHBD transplants per center had no great effect on the waiting time.
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artificially terminated 5 times. Neonates were thus delivered in 21 of 29
pregnancies. One woman delivered twice and 2 women delivered twins. As a
result, a total of 23 neonates were delivered. Mean gestational period was 35.4
weeks (range, 27-41 weeks), and mean birth weight was 2229 g (range, 724-3544
g). Regarding fetal complications, intrauterine growth retardation was seen in
3 cases. One child with intrauterine growth retardation died at 3 months old
due to respiratory distress syndrome. One child displayed double-outlet right
ventricle and another child had congenital unilateral hydronephrosis. Regarding
maternal complications, prevalence of toxemia of pregnancy was 38.1%. In 4
of the 21 deliveries (19.0%), renal function exacerbated after delivery. Rates of
graft survival for the 20 women at 1, 5 and 10 years after delivery were 100%,
85.1% and 74.4%, respectively. Prognosis for renal transplant is significantly
poorer for recipients with hypertension before pregnancy than for recipients
without hypertension before pregnancy (log-rank test, p=0.043).
Conclusions: Rates of graft survival after delivery were mostly favorable.
However, prognosis for renal function was poor for recipients who displayed
hypertension prior to pregnancy.

POSTER BOARD NUMBER P3 – 158
1732 FLUCTUATIONS OF EXERCISE CAPACITY IN PATIENTS
AFTER KIDNEY TRANSPLANTATION
M. Zakliczynski1, U. Spiechowicz2, A. Wiecek2, M. Zembala1
Dept. of Cardiac Surgery & Transplantation, Silesian Center For Heart
Disease, 2Dept. of Nephrology, Endocrinology & Metabolic Dis., Medical
Univ. of Silesia, Katowice, Poland
Aim of the study was to assess changes in the exercise capacity in subjects
with end-stage renal failure undergoing kidney transplantation (RTx). Material
and methods: Study group consisted of 16pts. (9M/7F, 43.3±11y/o), control
group was composed of 7 healthy subjects (4M/3F, 43.9±10y/o). 1st visit took
place 4-8 weeks after RTx. Consecutive visits were scheduled for the 4th,
10th, 16th, 24th, 36th, and 48th month after RTx. Heart function was assessed
by echocardiography, and exercise test with the peak oxygen consumption
(VO2max) analysis. Results were correlated with VO2max (Pearson). MannWhitney U test was used to compare study and control group. Results: The
results of eligible VO2max tests were as follows (median & range): 1stm.
(n=15) 19.5 (8.8-27.5)ml/kg/min, 4thm. (n=9) 21.7 (16.0-29.3)ml/kg/min,
10thm. (n=8) 23.3 (13.1-30.0)ml/kg/min, 16thm. (n=9) 26.6 (18.3-36.0)ml/kg/
min, 24thm. (n=9) 22.3(14.1-35.0)ml/kg/min, 36thm. (n=9) 20.9(16.4-32.1)
ml/kg/min, 48thm (n=5) 19.7(17.0-30.9)ml/kg/min, and 26.8 (26.5-42.5)ml/
kg/min in the control group. VO2max result achieved by the study group
were significantly lower than in the control group, except for the 16th, 24th,
and 48th month after RTx. VO2max was found to be significantly negatively
correlated with the following ultrasound parameters: interventricular septum
diastolic and systolic diameter, and left ventricle systolic volume. Conclusion:
Exercise capacity of RTx recipients seems to be negatively affected by poor
blood pressure control, resulting in the heart muscle hypertrophy.
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1733 PREGNANCY AFTER RENAL TRANSPLANTATION
T. Abe1, M. Okumi1, R. Imamura1, N. Ichimaru1, A. Okuyama1, Y. Isaka2,
S. Takahara2, Y. Kokado3
1
Departments of Specific Organ Regulation (Urology), Osaka University
Graduate School of Medicine, 2Departments of Advanced Technology for
Transplantation, Osaka University Graduate School of Medicine, 3Takahashi
Clinic
Aim: We examined women with renal transplants who became pregnant and
delivered at our hospital.
Methods: Of 26 women who underwent renal transplantation between 1977
and 2002 and became pregnant and delivered at Osaka University Hospital, 20
women with complete data served as subjects.
Results: The 20 women became pregnant a total of 29 times after renal
transplantation. Spontaneous abortion occurred 3 times, and pregnancy was
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1734 IMPROVEMENT IN COGNITIVE FUNCTION AFTER
KIDNEY TRANSPLANTATION
L.E. Morales-Buenrostro4, J. Alberú-Gómez, S. Sánchez-Román1,2,
F. Ostrosky-Solís2, M.G. Nogués Vizcaíno3
1
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias
Medicas y Nutricion Salvador Zubiran (INCMNSZ), Mexico City,
2
Neuropsychology and Neurophysiology Laboratory, Universidad Nacional
Autonoma de Mexico, Mexico City, 3Department of Transplantation,
INCMNSZ, 4Nephrology Department, INCMNSZ
Purpose: Previously, we evaluated 41 ESRD patients (pts) and found that
35% showed impairment in attention and memory functions. This prospective,
longitudinal study was designed to evaluate a subset of ESRD pts before and
after KT to explore whether the impairment in cognitive areas is modified upon
restitution of renal function.
Methods: 15 KTR (11M/4F) and 13 donors -control group- (4M/9F) were
tested twice: 24-48 hrs before and 6-10 months after KT by comprehensive
neuropsychological battery for the evaluation of Attention and Executive
Functions and Memory Functions, Hospital Anxiety and Depression Scale
and Epworth Sleepiness Scale. The rate of cognitive change was defined by
the difference between each neuropsychological measure (post-operative vs.
baseline score). Renal function data was gathered for KTR and donors. Mean
group differences were assessed with paired samples T test or X 2. Bivariate
correlations and Linear regression analysis were used.
Results: Mean age (31±12.6) and years of education (13±3.8) of the KT group
were not significantly different from controls. A significant improvement
(p<0.01) in cognitive function, predominantly in the Attention and Executive
Functions scale was found after KT (before KT 27% showed mild-moderate or
severe impairment in this area; after KT all patients showed normal functioning).
Mild memory impairment persisted in 13.3% pts after KT. Although 7% of the
donors improved their performance, the improvement of the KT recipients was
significantly higher (p<0.05). The scores for both groups did not correlate with
the Hospital Anxiety and Depression Scale or Sleepiness Scale. Significant
correlation between SCr and Attention and Executive Functions was found
(r=-.433, p<0.05). SCr predicted Attention and Executive Functions (R=.433,
p<0.05).
Conclusions: Around 30% of ESRD pts had pre-KT cognitive alterations that
may interfere with their daily function. The results of the present study suggest
a better quality of life through the improvement attained in cognition after KT,
adding this to the multiple beneficial aspects of KT.
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1735 PSYCHIATRIC SYMPTOMS IN KIDNEY TRANSPLANT
RECIPIENTS
L.E. Morales-Buenrostro2, J. Alberú-Gómez3, S. Sánchez-Román1,
L.N. González de Jesús1,
1
Neurology and Psychiatry Department, Instituto Nacional de Ciencias
Medicas y Nutricion Salvador Zubiran (INCMNSZ), Mexico City, 2Nephrology
Department, INCMNSZ, Mexico City., 3Department of Transplantation,
INCMNSZ, Mexico City
Aim: Describe the presence of psychiatric symptoms in ESRD patients before
and after kidney transplant (KT).
Methods: We studied 75 ESRD patients (pts) (34 males, 41 females): 31 with
living related donors (LRD), 22 with deceased donors and 22 non transplant
candidates. The instruments used were: the Hospital Anxiety and Depression
Scale (HAD), which measures levels of anxiety and depression, but excludes
somatic symptoms of physical diseases avoiding false positives; and the
Symptom Checklist-90 (SCL-90), a self report inventory that assesses the level
of distress recently reported by the subject (in terms of psychiatric symptoms).
From these 31 pts with LRD, 15 were evaluated with the same scales 6 months
after KT. Descriptive statistics were done according to the measurement level
of the variables. We used paired T-Test, Chi-square test and paired proportions
comparison formula.
Results: Mean age of ESRD pts was 37.12±13.03. According to the HAD,
30.7% of the ESRD pts showed anxiety symptoms and 25.3% of them
manifested depression symptoms. No significant differences were found
between males and females in anxiety or depression symptoms. The results
in HAD scale of the 15 KTR (11 males, 4 females) that were followed are
presented below. The proportion of pts with depressive symptoms after KT was
significantly lower than in the pre-transplant evaluation (26.7% before KT and
13.3% after KT). Anxiety symptoms did not show differences in both evaluation
times. General Severity Index of SCL-90 scale was not significantly different
before and after KT in the subset of 15 kidney recipients. However, Positive
Symptom Distress Index (designed to measure the intensity of symptoms),
Phobic Anxiety and Paranoid Ideation (all subscales of the SCL-90) showed a
significant improvement (p<0.05) after KT.
Conclusions: Our results show the presence of psychiatric symptoms in a group
of ESRD patients and a decrease of some of these (depression, intensity of
symptoms, phobic anxiety) after KT. This is probably due to the improvement
in the quality of life and physical improvement after KT.
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1736 NEUROLOGICAL COMPLICATION IN KIDNEY
TRANSPLANT RECIPIENTS
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1737 PREPARATION OF DIALYSIS PATIENTS FOR KIDNEY
TRANSPLANTATION
P. Zámbó, A. Varga, M. Molnar
FMC Dialysis Center, Szigetvár
Introduction and aims: A successful kidney transplantation strongly depends
on the careful selection and thorough medical evaluation of the patients who are
suitable for transplantation. In this work we present the method of the medical
assessment of our patients, the results of diagnostic tests and the outcome of
medical interventions carried out prior to enlisting the patients on the waiting
list.
Patients and methods: In the FMC Dialysis Center, Szigetvár from 2003 to
2007, 29 dialysis patients (14 female, 15 male, mean age 48 years, 5 pts are
above 60 years) were added to the waiting list. All patients were screened for
viral infections: HCV, HIV, HBsAg, CMV, EBV, VZV. We scanned patients
for any potential source of infection, (dental, gynecological, urological, ENT
investigation, urinary culture) for malignancy, (abdominal ultrasound, chest
X-ray, mammography for every women above age 45 y, PSA for men age 45 y,
dermatology, haematest of stool) for cardiovascular risk factors (family history,
hypertension, diabetes, dyslipidemia, smoking, obesity) and for cardiovascular
complications (ECG, echocardiography, DPD SPECT; and if necessary, cardiac
catheterization, carotis Doppler, abdomen CT scan, pelvis X-ray)
Results: Urinary culture was positiv in 8 patients, who were treated with
antibiotics immediately. Dental infection were found in 5 patients, they were
treated by teeth extractions. We attenuated the effect of cardiovascular risk
factors in patients by strong control of the followings: abandoning of smoking,
keeping blood pressure below 130/80 Hgmm and serum LDL-cholesterol level
below 3 mmol/l).7 pts required coronarography (5 diabetic pts).
During the course of the survey we found malignancy in 2 pts, and severe
periferal atherosclerosis in 1 patient -they were excluded from the waiting list
15 out of 29 patient received cadaver kidney during the 5 years.
Conclusion: Potential transplant recipients require very detailed medical
assessment before enrolling into the waiting list and the treatable conditions
and diseases have to be managed, in order to ensure that the transplantation
procedure is done as safely as possible and to maximize the long-term survival
of the recipient.
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1738 RENAL TRANSPLANTATION IN PATIENTS ABOVE
60 YEARS OF AGE: A SINGLE CENTER EXPERIENCE
A. El Agroudy, S. Al Arrayed, A. Al Arrayed, S. Ghareeb, E. Fareed
Salmaniya Medical Complex
Aim: Renal transplantation is increasingly being carried out in older patients,
with generally acceptable results. Because we have an increasingly aging
population, we retrospectively reviewed the results of renal transplantation in
patients over 60 years of age at our center.
Patients and methods: A retrospective study was conducted of 212 Bahraini
patients receiving renal transplants from January 1979 to December 2007.
All medical records were reviewed for demographic data, graft function and
survival. Patient and graft survival was compared for patients above and below
the age of 60.
Results: Seventeen patients >60 years with a mean age of 64.1±3.6 years at the
time of transplantation. Sex: 76.5% Males. Diabetic nephropathy (52%) and
PCKD (12%) were the most common causes of ESRD. Mean donor age was
26±6 years and most of them were unrelated (82%). Follow-up was until death
or until 1/3/2008. Of the 17 study patients, 4 died: 3 with a functioning graft, 1
within one year of transplantation. Cardiovascular causes (3 patients, 75%) and
infection (1 patient, 25%) were most common. Common causes of graft loss
were death with a functioning graft (4) and chronic rejection (1). Univariate
analysis of risk factors showed pre transplant hypertension and diabetes mellitus
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P. Hon1, J. Dedochova2, V. Honova3, M. Bar1, F. Vlcek1, A. Martinek2
1
Department of Neurology, University Hospital Ostrava, 2Transplantation
Center, University Hospital Ostrava, 3Department of Nephrology, City
Hospital Novy Jicin
Background: Neurological complications after renal transplantation are
frequent. They are related to immunosuppressive therapy, comorbidity as
hypertension, diabetes and atherosclerosis, transplantation surgery. Analyse
these complications should lead to improve prevention and therapy renal
transplant recipients
Material and methods: 294 patients (from 17 to 66 year old) after renal
transplantation were analysed. Two parallel groups were installed. Group A (152
patients) with immunosuppressive combination cyclosporin A + mycofenolate
mofetil + methylprednisolon, and Group B (142 patients) - combination
tacrolimus + mycofenolate mofetil + methylprednisolon
Results: In group A: polyneuropathy was observed in 25,3%, stroke in 1,9%,
meningoencephalitis in 3,8%, transplant surgery complication in 0,7%. In
group B: polyneuropathy in 22,2% stroke in 2,1%, meningoencephalitis in
4,1% patients, transplant surgery complications in 0,7% patients. Peripheral
polyneuropathy was more frequent in patients with diabetes mellitus.
Polyneuropathy was less frequent in patients after transplantation compared to
them before transplantation. Stroke was observed more frequently in patients
with large vessel disease. Meningoencephalitis infection agent was detected
Herpes simplex virus and Listeria monocytogenes. As transplant surgery

complication was observed femoral nerve mononeuropathy. There were no
significant differences between group A and B.
Conclusion: Both combination of immunosuppressive therapy is similar safe.
Transplantation is important to decrease number of peripheral polyneuropathy
in patients without diabetes mellitus.
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significantly (p < 0.05) affected time of return to dialysis. Multi variate analysis
did not show these independent variables to be significant. After censoring
patients that died with functioning grafts, difference in graft survival between
>60 and <59 years was not significant (p > 0.2). In this study, 92% of older
patients had allografts functioning at 1 year.
Conclusions: The fact that older patients succumb over time from natural causes
should not keep patients from transplantation. Immunosuppressive agents need to
be limited to reduce the incidence of infection. Criteria need to be refined to define
those who are at prohibitive risk, who may not be candidates for transplantation.
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1739 AN ATTEMPT TO EXTEND THE DONOR CRITERIA
FOR SUCCESSFUL LIVING-RELATED KIDNEY
TRANSPLANTATION FROM A DONOR WITH MEMBRANOUS
NEPHROPATHY
K. Akioka1,4, M. Okamoto2, H. Ushigome1, S. Nobori1, A. Yoshizawa2,
S. Sakamoto1, K. Urasaki3, A. Yanagisawa3, N. Yoshimura1,2
1
Dept. Organ Transplant and Regenenative Surgery, Kyoto Prefectural
University of Medicine, 2Dept. of Organ Interaction Research Medicine,,
3
Department of Surgical Pathology, 4Omihachiman Community Medical
Center
Introduction: Because of the shortage of donors for renal transplantation,
marginally appropriate donors might be considered in order to extend the donor
criteria. Some reports have described successful outcomes after cadaveric
kidney transplantation from donors with pre-existing membranous nephropathy.
Here we report a successful outcome after kidney transplantation from a livingrelated donor diagnosed as having membranous nephropathy.
Case report: A 38-year-old male who had suffered proteinuria from the age of
22 years began to receive CAPD from the age of 37. His 63-year-old father had
mild proteinuria, and had been diagnosed as having membranous nephropathy
by needle biopsy. However, the father was found to have normal renal function
in a preoperative examination, except for mild proteinuria and minimal
pathology. As these two individuals expressed a willingness to participate in
living-related kidney transplantation, and gave adequate verbal and written
informed consent, we transplanted a kidney from the father with membranous
nephropathy into his son. Immunosuppression in the recipient was induced
and maintained with a CsA-based regimen, and the postoperative course was
good in both the recipient and the donor without rejection or infection. At 50
months after transplantation, the serum creatine level was 1.7 mg/dl in the
recipient and 1.4 mg/dl in the donor. Their renal functions were stable, and
no proteinuria was evident in the recipient, but minimal proteinuria was still
detected in the donor. The recipient underwent allograft needle biopsy at 38
months after transplantation, and the specimen showed mild spike formation
with partial thickening of the glomerular basement membrane (GBM) after
staining with periodic acid-silver methenamine (PAM). Mild membranous
glomerulonephritis was therefore diagnosed. There was no evidence of
acute rejection, and extracapillary proliferative glomerulonephritic change
and tubulointestinal injury, characteristic of chronic allograft change, were
observed. Electro microscopy showed decreases of electron-dense deposits
and electron-lucent washout lesions with thickening of the GBM. This was
diagnosed as Stage IV membranous nephropathy, resulting from clearance of
the immune complexes and histological repair of the GBM.
Conclusion: We have reported a favorable outcome of kidney transplantation
from a donor with membranous nephropathy. Careful observation of the natural
course of membranous nephropathy shows that some cases enter remission.
For the present donor, donation of the graft did not affect his residual renal
function. Pre-existing membranous nephropathy itself might show remission
after transplantation and immunosuppression in the recipient. It is difficult to
discriminate patients with membranous nephropathy who would be likely to
enter remission. The present attempt to extend the donor criteria for this family
represents an alternative choice for living-related kidney transplantation.
Although the outcome was sufficiently successful, careful long-term observation
of both the donor and recipient will be required. It is suggested that marginally
appropriate donors can be considered in order to extend the donor criteria for
kidney transplantation.
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1740 THE APPLICATIONS OF ETHICS FOR LIVING DONOR
KIDNEY TRANSPLANTQATION
X. Meng1, J. Liu2, L. He3, L. Cao4
1
Transplantation Center, The Second Affiliated Hospital, Chinese PLA
General Hosp, 2Transplantation Center, The Second Affiliated Hospital,
Chinese PLA General Hosp, 3Transplantation Center, The Second Affiliated
Hospital, Chinese PLA General Hosp, 4Transplantation Center, The Second
Affiliated Hospital, Chinese PLA General Hosp
Objective: To investigate <Provisional Administrative Regulation of Human
Organ Transplanting Technology in the Clinical Application> with its applied
procedure, method and significance of the ethics about the liver transplantation
in the relative living organism.
Method: Have a summary and analysis on the 6 examples of liver
transplantation in the relative living organism carried out in our hospital
according to <Provisional Administrative Regulation of Human Organ
Transplanting Technology in the Clinical Application> and have an analysis
and investigation on the receptor¡¯ reveovery and donor¡¯ physiological and
psychological recovery after transplantation.
Result: There were no complications happening during the surgery. 5 donors
were satisfied with their decisions according to the visiting a month later. Only
one donor had a psychological pressure because of the receptor¡¯ delayed renal
graft function. Other 5 receptor¡¯s renal function recovered as normal within
3-5 days, in which one receptor had acute rejection at 9th day after the surgery
and reversed by methylprednisolone pulse therapy.
Conclusion: The applications of ethics in the <Provisional Administrative
Regulation of Human Organ Transplanting Technology in the Clinical
Application> can as far as possible ensure the donor have safety and no
psychological pressure, which is necessary and important in the liver
transplantation.
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1741 EVALUATION OF RENAL FUNCTION IN KIDNEY
TRANSPLANT DONORS AFTER DONATION
T. Matuck, D. Carvalho, P. Gomes, E. Ribamar, A. Borela, F. Alvarenga
Hospital Geral De Bonsucesso
Introduction: Kidney transplant is the treatment of choice of chronic kidney
failure, as all the native kidney functions are recovered. The risk of surgical
complications is between 0.3 and 1%, with a per-operatory mortality around
0.03%. Proteinuria after kidney donation appears in about 3% of subjects and,
in some cases, severe chronic renal disease can supervene. Recent data show
the occurrence of clinical complications as hypertension, hematuria, proteinuria
and renal dysfunction in up to 54% of donors with long-term follow-up. The
presence of renal dysfunction can reach 7%.
Objective: To evaluate the presence of chronic renal dysfunction (CRD) after
kidney donation, according to DOQI/NKF criteria.
Methods: Retrospective analysis from 121 kidney transplant donors, between
1 and 132 months after donation, with a median of 12 months. We analyzed
weight, body mass index (BMI), blood pressure, BUN, creatinine, uric acid,
albumin, sodium, potassium, glomerular filtration rate (GFR) and proteinuria,
before and after donation. The methods used were media ± standard deviation
or median (maximum and minimum values) and the comparative statistics tests
were Mann-Whitney or Kruskal-Walis, according to the convenience. p values
< 0.05 were considered statistically significant.
Results: The results are listed on tables 1 and 2
Conclusions: Women were involved in 2/3 of kidney donations. After donation
statistically significant increase in SBP, BUN, creatinine, uric acid, as well as
decreased creatinine clearance were observed. Considering GFR<60ml/min or
proteinuria>300mg/24h, in this study, around 22% of donors presented CRD
according to DOQI/NKF criteria, showing that the prevalence of CRD in kidney
donors in long-term follow-up is more frequent than in general population. As
the median follow-up time was 12 months, we intend to continue the evaluation
in a longer period in order to have more consistent conclusions.
Table 1: Demographic, clinical and laboratorial data from 121 kidney donors
before and after donation:
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Age (years)
Sex: Male/Female
Race
Weight (kg)
BMI (kg/m²)
SBP (mmHg)
DBP (mmHg)
MBP (mmHg)
BUN (mg%)
Creatinine (mg%)
Uric acid (mg%)
Albumin (g%)
Potassium (mEq/l)
Sodium (mEq/l)
GFR (ml/min)
GFR (ml/min – CG)
Proteinuria(mg/24h)

Before donation
41±10.1
39.7% / 60.3%
W:70% / NW:30%
66 (114-43.7)
24.2 (38.5-17.2)
110 (160-90)
70 (90-50)
86.7 (113.3-63.3)
25 (45-11)
0.9 (1.2-0.4)
4.6 (9.7-2)
4.3 (5.2-2.9)
4.1 (4.8-2.8)
139 (146-131)
102.1 ± 30.4
113.7 (237.2-64.2)
102 (233-8)

After donation
67.1 (104-42.2)
24.8 (36.3-16.5)
120 (170-80)
70 (110-50)
86.7 (126-60)
30.4 (59-5)
1.1 (2.2-0.7)
5.1 (9.1-2.3)
4.4 (4.9-3.2)
4.2 (5.5-27)
139 (150-130)
80.2 ±31.1
88 (217.8-41.6)
102.5 (7334-10)

p value
p=0.489 (NS)
p=0.6057 (NS)
p=0.0338
p=0.842 (NS)
p=0.319 (NS)
p=0.00
p=0.00
p=0.00798
p=0.931 (NS)
p=0.0711 (NS)
p=0.536 (NS)
p<0.0001
p=0.00
p=0.600 (NS)

*W = white / NW = non-white; SBP = systolic blood pressure; DPP = diastolic blood pressure;
MBP = mean blood pressure; GFR = glomerular filtration rate; CG = Cockroft-Gault; NS = not
significant

Table 2: Evaluation of renal function before and after donation:
GFR < 60ml/min
Proteinuria: 150-300mg/24h
Proteinuria > 300m/24h

Before donation
0
3(2.4%)
0

After donation
19 (15.7%)
17 (14%)
8 (6.6%)
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1742 NEPHRECTOMY ELICITS IMPACT OF AGE AND BMI
ON RENAL HEMODYNAMICS: LOWER POST-DONATION
RESERVE CAPACITY IN OLDER OR OVERWEIGHT KIDNEY
DONORS
M. Rook1, R.J. Bosma1, H.S. Hofker2, J.J. Homan van der Heide1, R.J. Ploeg2,
P.M. ter Wee3, W.J. van Son1, G.J. Navis1
Departments of 1Nephrology and 2Surgery, University Medical Center
Groningen, the Netherlands and 3Department of Nephrology, VUMC
Amsterdam, the Netherlands
Renal functional reserve could be relevant for maintenance of renal function
after kidney donation. Older age and higher body mass index (BMI) may be
associated with reduced reserve capacity (RC). We therefore investigated RC
in 178 consecutive living kidney donors (period 1984-2005; 39% male, age
48±11 years, BMI 25.5±4.1). RC was determined as the rise in glomerular
filtration rate (GFR; 125I-iothalamate) after constant infusion of low-dose
dopamine, 4 months before and 2 months after donor nephrectomy.
Before donor nephrectomy, GFR was 114±20 mL/min, with a reduction to
72±12 mL/min after donor nephrectomy. The dopamine-induced rise in GFR
of 11±10% was reduced to 5±7% after donor nephrectomy (p<0.001). Before
donor nephrectomy, older age and higher BMI did not affect reserve capacity.
After donor nephrectomy, the response of GFR to dopamine independently and
negatively correlated with older age and higher BMI.

1743 LONG TERM SURVIVAL OF 932 LIVING DONORS
R. Espinoza, C. Gracida, J. Cancino, A. Ibarra, U. Cedillo
Transplant Unit, Hospital de Especialidades CMN Siglo XXI. México City,
D.F. México
The first successful renal transplant in the world was from a live donor. In
México, also the first renal transplant was from living donors. During the last
few years, in the entire world, increasing importance has been given to the live
donor, widening the criteria for donor selection.The reasons are well known by
all of you: Scarcity of viable organs for transplant, and long waiting lists, Better
graft survival rate at both short, and long term, Earlier renal function, Donor
nephrectomy by laparoscopy, donor emotional satisfaction.
The objective of the present study is to describe our experience in a single
transplant center in 14 years of follow up of living kidney donors with open
nephrectomy for renal transplant, including donors with risk factors for
donation.
Materials and methods: From january 1992 through december 2005 in our
transplant center, were carried 932 living donor transplant. All nephrectomies
were open.
We consider high risk patients for donation, donors older than 60, body mass
index more than 30 kg/m2, hypercholesterolemia, hyperuricemia, hypertension
of easy control with diet or just one drug. At the time of donation, were
registered, age, gender, glomerular filtration rate (GFR), serum creatinine,
uric acid, creatinine clearance, mean arterial pressure, number of arteries and
anatomical variations.
morbidity, and mortality rates at the short and long term follow-up study.
Average, mean, and standard deviation, were used.
Results: Mean follow up was of 50.9 ± 39.9 months. The groups of donors
that had changes in their studies of renal function, such as serum creatinine,
creatinine clearance, and glomerular filtration rate, were the hypertensive
donors and those over 60 years of age. (table 1).
Table 1. Follow-up of living donors 50.9±37.9 months (N=782)
Conclusions: In our transplant unit, renal donation from living donor is safe,
without death or morbidity increase.. Age over 60 years and arterial hypertension
significantly decrease glomerular filtration at the end of the follow-up. Increase
of weight, obesity, diabetes mellitus and metabolic syndrome are frecuent after
donation, but are comparable to the non-donor population.
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1744 A COMPREHENSIVE PROGRAME OF CARE FOR
LIVE KIDNEY DONORS – EXPERIENCE AND PLANS
IN ONE CENTRE
P. Domagala1, M. Bieniasz1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1,
M. Wszo³a1, A. Chmura1
1
Medical University of Warsaw, Department of General Surgery And
Transplantology, 2Medical University of Warsaw, Department of
Transplantology And Nephrology
Results of renal transplanatation from living donors, both related and unrelated,
are superior to renal cadaveric transplantation. Donorship carries a risk
associated with surgery and further life with one kidney, thus renal transplantion
from live donors may only be performed if the donor risk is low and probability
of a successful transplant high.
The aim of the paper is to present our own experience in introducing a
pioneering complex program of live donor care in Poland.
Patients and method: Beginning in 2006, the Polish Ministry of Health has
obligated transplantation centres performing live donor renal transplants to
carry out periodical medical assessments and to report the results to a newlycreated Live Donor Registry. Between 1996 and 2007 our transplantation
team performed ninety-one live donor nephrectomies. Beginning in 2005 we
introduced a system of control assessments of the donors (group A). Medical
examinations are carried out at 1, 3, 6 and 12 months following surgery and
every 12 months thereafter. Beginning at the end of 2007, medical assessments
of donors nephrectomized priot to 2005 were commenced (group B).
Results: Majority of group A donors responded to invitations for control
assessments. A one-day hospitalization included medical history, physical
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Figure 1 shows RC before and after donation according to normal weight,
overweight or obesity (left panel) and according to tertiles of donor age (right
panel). # ANOVA p<0.05. Post-donation reserve capacity was absent in obese
donors. Presence of overweight had more impact on loss of RC in younger
donors.
In conclusion, donor nephrectomy unmasked an age- and overweight-induced
loss of reserve capacity. Possibly, donors with advanced age and/or overweight
address their renal reserve to maintain renal function.
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examination, abdominal US, chest X-ray, peripheral blood count, C-reactive
protein, urine microscopy and culture and functional tests of the remaining
kidney. Most group B donors had not been followed up before the
commencement of the program. The first program visit, a 2-3 day hospital
stay consisted of various tests and consultations, including blood and
urine tests, abdominal US, chest X-ray, ABPM (ambulatory blood pressure
monitoring), renal isotope scan, ECG, ophtalmological and nephrology
consultation. Donors in both groups had significantly raised serum creatinine
and creatinine clearance decreased by 25-35mlkg/1,73m2. About 30% of
group B donors had previously undiagnosed hypertension and appropriate
treatment was implemented. 15% of donors presented abnormal body weight
or obesity, as well as disturbances in lipid profiles. Both groups of donors
were subjected to quality of life and pro-health behavioral assessment
of by standard questionnaires, in cooperation with a clinical psychology
specialist.
Conclusions: Live kidney donors should be subject to obligatory long-term
follow-up. A comprehensive system of care for live kidney donors with regular
multidisciplinary health check-ups and, if necessary, appropriate treatment
provides the donors with a feeling of safety and is aimed at decreasing the
number of long-term complications of donorship. The main goal of the followup team is to ensure satisfactory quality of life and health for live donors in
the long-term.
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1745 ASSESSMENT OF RESIDUAL KIDNEY FUNCTION
AFTER LIVING DONOR NEPHRECTOMY
M. Bieniasz1, P. Domagala1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1,
M. Wszola1, J. Trzebicki3, M. Durlik2, W. Rowinski1, A. Chmura1
1
Medical University of Warsaw, Department of General Surgery
And Transplantology, 2Medical University of Warsaw, Department
of Transplantology And Nephrology, 3Medical University of Warsaw,
Department of Anaesthesiology And Intensive Care
Background: The number of patients on the waiting list for kidney
transplantation is increasing as a result of cadaveric donor shortage. One of the
ways to expand the donor pool is living donor transplantation. However, only
2% of kidney transplants in Poland come from living related donors.
The aim of this study was to assess residual renal function, incidence of
hypertension and proteinuria in living kidney donors.
Patients and methods: Between 2004 and 2007, 46 living donor open
nephrectomies were performed. Physical examination, blood and urine tests
and ultrasonography were performed prior to nephrectomy and at every followup visit (1, 3, 12 and 24 months post-op). All donors underwent psychological
assessment before donation. Donor mean age was 39 years (range 25 – 57).
The donors were predominantly female (61%). Mean hospitalization time was
8 days (range 4 – 22 days). Nine donors did not report for follow-up visits.
Observation period ranged from 1 to 24 months.
Results: Mean creatinine concentration, mean creatinine clearance according
to Cockroft-Gault formula and mean creatinine clearance according to
abbreviated modification of diet in renal disease equation (aMDRD) changes
are presented. No cases of proteinuria were observed. Hypertension occurred
in one donor (2.7%).
Before

3 months

12 months

24 months

P

Creatinine concentration
(mg/dl)

0.83

1.16

1.13

1.15

< 0.05

Creatinine clearance according
to Cockroft-Gault formula

110

82

88

76

< 0.05

Creatinine clearance according
to aMDRD formula

95

64

67

65

< 0.05

Conclusion: Living kidney donation results in a reduced creatinine clearance
in the donor. Follow-up of living kidney donors is essential in determining risk
factors for deterioration of residual kidney function.
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1746 QUALITY OF LIFE OF OLDER LIVING KIDNEY DONORS
I.J.M. ten Berge1, R.C. Minnee2, W.A. Bemelman2, P.J. van Koperen2,
S.W. Polle2, S. Maartense2, K.A.M.I. van Donselaar1, F.J. Bemelman1,
M.M. Idu2
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of
Surgery, Academic Medical Centre, Amsterdam
Introduction: Increasing organ shortage forced transplant centers to be
inventive in discovering new sources. They increasingly pursue living
donor transplants and utilize marginal donors. Older living donors remains
controversial because of decline in glomerular filtration rate and increased
risks of surgical complications. In addition, little is known about quality of life
(QoL) of older living kidney donors. The purpose of this study is to examine
the QoL in older living donors.
Patients and methods: All consecutive donors between June 2002 and
February 2006 were prospectively included in the study. Older donors were
defined as fifty-five years or older. Results: Older donors had a significant
lower postoperative pain at rest at day 1 compared to the younger group
(p=0.019). At other time periods no statistical significant differences were
found in postoperative pain between the two groups. Although small
differences in Short Form 36 Health Survey (SF-36), Gastro-Intestinal
Quality of Life Index (GIQLI) and Multidimensional Fatigue Inventory-20
(MFI-20) between both groups were detected, in general quality of life of
older donors was not different than of younger donors. After six months all
items in different domains were on the same level as preoperative. In addition,
there were no significant differences in length of hospital stay, intraoperative
and postoperative complication rate and one year graft survival rate between
both groups.
Conclusion: Donor nephrectomy does not have an additional impact of
quality of life of older donors compared to younger donors. Therefore we have
to be less restraint to older donors and we can include more older donors in
screening programmes and ultimately perform more donor nephrectomies in
older donors.
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1747 CROSS-SECTIONAL STUDY OF LIVING KIDNEY
DONORS FROM 1964 TO 2005
I. Fehrman-Ekholm
Transplantation Institute
Background: The number of living donors is increasing worldwide. The
necessity of follow-up is still a debate. In this study we have gathered data from
living donors, half of them have never been followed up after donation.
Methods: 1112 kidney donors underwent nephrectomy at Sahlgrenska
University Hospital from 1965 to the end of 2005. All donors in Sweden were
localized and evaluated for kidney function, blood pressure, microalbuminuria
and parathormone (PTH) levels.
Results: Age at donation was 19-75 years, mean 47 (11). Age at investigation
time was 61.5 (13) years. 59% were females. Of 848 still alive and living in
Sweden we had follow-up data from 470 by the end of December 2007. Mean
plasma creatinine was 94 (25), median 90 with range 48-330 μmol/L. Two
donors had received a transplant, one because of nephrosclerosis and one
because of renal tumour in the remnant kidney. Mean estimated GFR was 65 ml/
min using Levey form and 72 ml/min according to cystatin C determinations.
20. 5% had microalbuminuira. Mean PTH levels was 5.2 (2.5) pmol/L which
was normal. 29% had hypertension.
Conclusions: Living donors have on the average very good renal function
with GFR 65 ml/min and only 20% microalbuminuria. Thus, all donors do not
develop hyper filtration damages. The preservation of renal function seems
very satisfactory even in “uncontrolled” cases. A few donors had developed
ESRD but not in increased rate compared to aged matched background
population. Living donor nephrectomy seems a safe procedure when studying
long-term data.
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1748 COMPLICATIONS OF 103 LIVING DONOR
NEPHRECTOMIES
R. Bernal-Maldonado, B. Aguilar-Álvarez, B. Aguilar-Álvarez,
M. Aragón-Castro, S.R. Mondragón
From the Division of Surgery and the Transplant Unit, Centro Medico
ISSEMYM, Metepec, State of Mexico
Introduction: Transplantation yields the best results of all renal replacement
therapies in therms of patient and graft survival. The livings donor transplantation
it’s the main method in many countries because of worsening patient outcomes
due to accumulation of aged patients with long periods dialysis or hemodialysis
and the impossibility of increased the cadaveric donors.
Aim: To analyze retrospectively the general health status and renal consequences
of living donation, as the long-term effects of unilateral nephrectomy.
Patients and methods: A retrospective study of the hospital charts of 103
living donors patients was performed in order to analyze complications and
their management. The information of blood group, serological tests, blood
tests for hematology and biochemistry, coagulation profile, urine reports,
nephrectomy site, duration of anesthesia, intra-operative, early and long-term
post-nephrectomy complications, comorbid conditions, and the function on the
kidney remain were analyze.
Results: It was noted that males donated more kidneys to their relatives (p
< 0.05) and females had a higher prevalence of anemia (p < 0.01). The site
of nephrectomy was similar between men and women with prevalence of
left nephrectomy. Complications were significantly greater in male donors
(p < 0.05). Hemorrhage occurred more commonly in association with right
nephrectomy (p < 0.05), while wound infection occurred more commonly in
men (p < 0.05). the mean stance of the patient in the hospital were 4 days. There
were no deaths related to this procedure.
Conclusions: Our results suggest that living donor nephrectomy is safe
procedure because had minimal adverse effects on overall health status, we
not found mortality related to the procedure, and a regular donor follow-up
identifies at-risk populations and potentially modifiable factors.
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1749 PROGRESSION OF RENAL ALLOGRAFT HISTOLOGY
AFTER RENAL TRANSPLANTATION IN RECURRENT AND
NON-RECURRENT IGA NEPHROPATHY
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1750 BCL-2 PROTECTS TUBULAR EPITHELIAL CELLS
FROM ISCHEMIA REPERFUSION INJURY VIA DUAL
MECHANISMS
T. Abe1, C. Suzuki1, Y. Isaka1, M. Okumi1, N. Ichimaru1, R. Imamura1,
E. Imai1, H. Rakugi1, S. Shimizu2, S. Takahara1
1
Osaka Universitu Graduate School of Medicine, 2Tokyo Medical and Dental
University
Ischemia/reperfusion (I/R) injury, which induces extensive loss of tubular
epithelial cells, is associated with delayed graft dysfunction in kidney
transplantation. Recent reports suggested that cell death by I/R injury occurs
by autophagy, a cellular degradation process responsible for the turnover of
unnecessary or dysfunctional organelles and cytoplasmic proteins, as well as
apoptosis. Accordingly we hypothesized that anti-apoptotic factor, Bcl-2 protein
augmentation may protect tubular epithelial cells by inhibiting apoptosis as
well as by promoting autophagy.
First, we used Bcl-2 transgenic mice (Bcl-2 TG), and their wild type litter mate
(WT). To investigate the effect of I/R injury, the left renal artery and vein were
clumped for 45 min, followed by reperfusion for 24hr, 48hr, 96hr. Bcl-2 TG
showed the decreased active caspase protein in tubular cells, and thereby resulted
in the reduction of TUNEL-positive apoptotic cells. Consequently, interstitial
fibrosis and phenotypic changes were ameliorated in Bcl-2 TG mice. Next, we
employed a transgenic mice model (LC3-GFP TG) in which autophagosomes
are labeled with LC3-GFP and Bcl-2/LC3-GFP double transgenic mice (Bcl-2/
LC3-GFP TG) to examine the effect of Bcl-2 on I/R-induced autophagy. Under
ischemic injury, Bcl-2 augmentation promoted the formation of LC3-GFP dots
which represented autophagosomes were extensively induced. Of interest is
that LC3-GFP dots included the texas-red-labeled mitochondria. Furthermore,
we observed autophagy-related tubular epithelial cell death in LC3-GFP TG,
but not in Bcl-2/LC3-GFP TG.
In conclusion, Bcl-2 augmentation protected renal tubular epithelial cells from
I/R injury by promoting autophagosomal degradation of injured mitochondria
as well as inhibiting tubular apoptosis.
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1751 INFLAMMATORY MICROENVIRONMENT RESCUES
B-CELLS OF TERTIARY LYMPHOID ORGANS FROM ANTICD20 THERAPY DURING CHRONIC ANTIBODY-MEDIATED
REJECTION
O. Thaunat1, N. Patey2, C. Gautreau3, A. Nicoletti4
1
Service De Transplantation Et D’Immunologie Clinique, Hopital Edouard
Herriot, 2Service d’Anatomopathologie, Hopital Necker, Paris, France,
3
Laboratoire d’Immunologie, Hopital Saint-Louis, Paris, France, 4Centre de
Recherche des Cordeliers, INSERM U872, Paris, France
Background: Rituximab is emerging as a potent therapeutic option in chronic
inflammatory diseases associated with a prominent humoral component.
Recent studies have demonstrated that chronic inflammatory infiltrate organize
progressively themselves into ectopic lymphoid tissues (tertiary lymphoid
organs; TLOs) supporting a local humoral immune response.
In the present study we evaluated the impact of rituximab therapy on TLOs
associated with chronic active antibody-mediated rejection (CAAMR), a
prototypic humoral chronic inflammatory condition.
Methods: Renal allografts removed for terminal chronic rejection were
prospectively collected in 4 transplantation centers over 4 years. Among 38
grafts collected, 2 were explanted after rituximab therapy for CAAMR. Clinical
characteristics and circulating B cell count were recorded for these two patients.
The composition and the microarchitecture of the inflammatory infiltrate were
analyzed by flow cytometry and immunohistochemistry. Organotypic cultures
were performed to evaluate the intragraft production of alloantibody. Levels of
expression of BAFF (Blys, CD257) were evaluated by quantitative RT-PCR.
Results: Despite the complete depletion of circulating B cells in peripheral
blood, TLOs were evidenced in the interstitium of both explanted grafts. Their
functionality was assessed by the demonstration of a persistent local production
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Yonsei University College of Medicine Department of Pathology, 2Ulsan
University College of Medicine Department of Pathology, 3Yonsei University
College of Medicine Department of Surgery, 4Yonsei University College of
Medicine Department of Surgery, 5Yonsei University College of Medicine
Department of Surgery, 6Choongnam University College of Medicine
Department of Pathology
Little information is available regarding renal histology in cases of chronic
allograft dysfunction and graft failure in patients with recurrent IgA nephropathy
(IgAN). We compared 55 renal allograft biopsies of 44 patients with recurrent
IgAN to 45 biopsies of 33 patients without IgAN recurrence. Clinical parameters
like patient demography and biopsy indications did not differ between the two
groups, with the exception of time to biopsy. Renal allograft injury, which was
assessed by semi-quantitative scoring of glomerular, tubulointerstitial, and
arteriolar changes, increased linearly over time after transplantation in both
recurrent and non-recurrent samples. Glomerular injuries were significantly
correlated with tubulointerstitial injuries in both groups, but the correlation
graph reflected an increasing gap in the degrees of tubulointerstitial injury
between the two groups over time. The levels of glomerulosclerosis, mesangial
proliferation, and crescent formation were significantly higher in recurrent
samples, while the prevalence of chronic rejection was significantly higher
in non-recurrent samples. The presence of segmental sclerosis was associated
with significant proteinuria in recurrent samples. Graft survival was better in
recurrent IgAN patients than in non-recurrent patients (74.4% versus 51%) at
10 years post-transplantation. In conclusion, slow and progressive glomerular
injury is the major cause of long-term graft failure in patients with recurrent

IgAN. In contrast, rapidly increasing tubulointerstitial injury is responsible for
graft failure in non-recurrent patients.
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of alloantibody.
BAFF, a potent survival factor for B cells, was found to be overexpressed (both
at the gene and the protein levels) in chronically rejected grafts as compared
with normal kidneys and lymph nodes.
Conclusions: In certain patients, inflammatory microenvironment provides
BAFF-dependent paracrine survival signal to B-cells in TLOs, allowing them to
escape rituximab-induced apoptosis, thereby thwarting therapeutic efficiency.
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1752 DOES LONG GRAFT COLD ISCHEMIA TIME
INFLUENCE ARTERIAL STIFFNESS IN RENAL TRANSPLANT
RECIPIENTS?
A. Adamowicz1, P. Stró¿ecki2, M. Koz³owski2, Z. W³odarczyk1, J. Manitius2
Dept of Transplantation and Surgery, Collegium Medicum UMK, 2Dept of
Nephrology, Hypertension and Internal Diseases, Collegium Medicum UMK
Introduction: Graft cold ischemia time (CIT) significantly influences the
outcome of renal transplant. It was also found in experimental model that
increased CIT promotes aortic graft arteriosclerosis. Increased pulse wave
velocity (PWV) – a marker of arterial stiffness – is associated with increased
cardiovascular risk in renal transplant recipients (RTR). PWV depends on
reciepints related factors (age, blood pressure, graft function) as well as donor
related factor (donor age). The aim of the study was to evaluate whether
relationship exist between CIT and PWV in RTR.
Patients and Methods: Carotid – femoral PWV was measured with Complior
device in 103 cadaveric RTR (F=37, M=66), aged 45 ± 12 years. Graft CIT was
taken from patients’ charts. Clinical data: recipient and donor age, sex, body
mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), delayed
graft function (DGF) and immunosupressive therapy were also analysed. GFR
was estimated using MDRD equation (eGFR). Patients were devided into 2
groups: with CIT < 24 hours and (n=24) and with CIT ≥ 24 hours (n=79).
Results are presented as mean ± SD.
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CIT (hours)
PWV
RTR age
Donor age
RTR sex (male)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
eGFR (ml/min/1,73m2)
DGF (%)

CIT < 24 h
19,9 ± 3,3
8,3 ± 1,6
42 ± 13
39 ± 15
58%
25,8 ± 3,8
135 ± 16
83 ± 10
56,8 ± 19,7
67%

CIT ≥ 24 h
29,3 ± 3,9
9,2 ± 2,0
46 ± 12
45 ± 14
66%
25,3 ± 4,1
138 ± 18
85 ± 11
51,5 ± 14,7
67%

P
< 0,001
< 0,05
NS
NS
NS
NS
NS
NS
NS
NS

In all patients significant positive correlation was found between PWV and:
recipient age (r=0,49;p<0,001), SBP (r=0,38;p<0,001) and fasting blood
glucose (r=0,32;p<0,01) and CIT (r=0,23; p<0,05) but not with eGFR, DBP,
BMI and donor age. No significant differences were found in prevalence of
cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine and
prednisone therapy between study groups.
Conclusions: Long cold ischemia time is associated with increased arterial
stiffness in renal transplant recipients. Further studies are necessary to confirm
it and to understand the cause-effect relationship of this finding.
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1753 DONOR KIDNEY HISTOLOGICAL CHANGES AS RISK
FACTORS FOR DELAYED AND SLOW KIDNEY ALLOGRAFT
(KAG) FUNCTION
A. Trailin, T. Nikonenko, A. Nikonenko, T.I. Ostapenko, N.N. Polyakov
Zaporizhzhya Medical Academy of Postgraduate Education, Interregional
transplantation center
Purpose: Delayed graft function (DGF) or need for dialysis within the first
week post-transplant has adverse consequences on KAG subsequent shortand long-term survival. Slow graft function (SGF) or low temp of creatinine
declining, also has negative after-effects. The aim of our current study was to
determine morphological predictors for DGF and SGF.
Methods: Morphological predictors of DGF and SGF were investigated in 75
recipients of cadaveric kidneys transplanted in our centre during 2005-2007.
Paraffin sections of pre- and post-implantation kidney biopsies were stained
with H&E, Masson’s trichrome, PAS, and silver stain. Cellularity (0/1), increase
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of mesangial matrix (0-4), basement membrane thickening (0-4), percentages
of glomeruli with global sclerosis or segmental sclerosis were scored in
glomeruli. Severity of tubular atrophy, ischemic damage up to necrosis was
quantified in cortical tubules (0-4). Interstitial fibrosis in cortex and medulla
was scored (0-4). The thickening of the wall in arteries and arterioles, reflecting
arteriosclerosis/arteriolohyalinosis, was estimated (0-4). DGF was defined as
the requirement for dialysis within the first week post-transplant. Criterion for
SGF was serum creatinine level on the 3d day &#8805; 600 μmol/l and/or
&#8805; 300 μmol/l on the 7th day post-transplant. Patients with acute KAG
rejection in SGF group were considered as having an immediate graft function
(IGF).
Results: IGF occurred in 55 patients, SGF – in 20 patients (26,7%). Only
patients from SGF group (N=13) were dialyzed, and 7 patients had SGF
without need for dialysis. Hence, the frequency of DGF was 17,3%. Degree
of interstitial fibrosis, arteriosclerosis and percentages of glomeruli with global
sclerosis in SGF group, and the basement membrane thickening, cellularity of
glomeruli, degree of arteriolohyalinosis in DGF group were significantly higher
than in IGF patients. The only significant difference between SGF and DGF
groups was the degree of arteriosclerosis: 2,8±1,3 vs. 1,0±0,9, respectively.
Univariate binary logistic regression followed by multivariate analysis did
not uncover independent predictors for DGF. Cellularity of glomeruli was
established as an independent predictor for SGF (OR=2,47, ð=0,01). Then we
examined histological predictors for SGF without requirement for dialysis.
Only arteriosclerosis was uncovered as an independent predictor (OR=2,80,
ð=0,025).
Conclusion: Morphological predictors of DGF were not found, in contrast
with SGF. Histological changes in SGF kidney match those in DGF kidney. It
is part of the reason why patients with SGF are almost at the same risk of posttransplant complications, as patients with DGF. Urgent examination of donor
biopsies is essential for assessment of impaired initial KAG function risk and
applying approaches for its minimizing.
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1754 THE PATHOLOGICAL SIGNIFICANCE OF MEDULLARY
RAY INJURY (MRI) IN RENAL ALLOGRAFTS
A. Kobayashi1, I. Yamamoto1, Y. Kanetsuna1, S. Ito2, Y. Akioka3, S. Teraoka4,
M. Hattori3, K. Tanabe5, Y. Yamaguchi1
1
Jikei University, Kashiwa Hospital, Department of Pathology, 2Gifu
University, Department of Urology, 3Tokyo Women’s Medical University,
Department of Pediatric Nephrology, 4Tokyo Women’s Medical University,
Department of Surgery, 5Tokyo Women’s Medical University, Department of
Urology
One of the focuses of the 8th Banff Conference was the definition of chronic
alloimmune injury/rejection, and the term ¦ echronic allograft nephropathy¦ f
replaced the term ¦ einterstitial fibrosis and tubular atrophy without any
specific etiology (IF/TA)¦ f. IF/TA has various etiologies (e.g., calcineurin
inhibitor (CNI) toxicity, obstructive uropathy, and pyelonephritis). However
ways to detect these etiologies are still under consideration. Medullary ray
injury (MRI) is one candidate for the early pathological determination of
CNI toxicity because MRI is reported to be related to arteriolar hyaline
changes and vasospasticity preceding the striped form of interstitial
fibrosis and tubular atrophy in an experimental model (Transplantation
1990;49:445-452). In this study, we investigated the significance of MRI
to determine the contribution of CNI toxicity to MRI or other etiologies in
renal allografts.
Methods: This study investigated 70 biopsies from renal allografts performed
at Tokyo Women¦ fs Medical University and Gifu University between March
2000 and February 2008 that showed evidence of MRI. The basic regimen
of immunosuppressants included a CNI (tacrolimus or cyclosporine),
mycophenolate mofetil, and prednisolone. We defined MRI as evidence of
fibrosis and inflammation that was localized exclusively to the medullary
ray. Pathological changes of MRI with evidence of ¦ earteriolar hyaline
nodules and/or isometric vacuolization of tubular cells¦ f, ¦ eInterstitial
Tamm-Horsfall protein deposits and/or thyroidization¦ f, and ¦ eintratubular
and peritubular infiltration of predominant neutrophils¦ f were considered to
indicate MRI related to CNI toxicity, obstructive uropathy, and pyelonephritis,
respectively.
Results: Overall (n=70), the etiology of MRI was CNI toxicity (23 cases,
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32.8%), obstructive uropathy (35 cases, 50%), pyelonephritis (6 cases, 8.6%),
and others (6 cases, 8.6%). We performed voiding cystography in five cases
of MRI related to obstructive uropathy and four of the five (80%) cases had
vesicoureteral reflux (VUR) clinically.
Conclusion: As we demonstrated here, MRI has various etiologies and is
not specific to CNI toxicity. Since half of the MRI was related to obstructive
uropathy and 80% (4/5) showed clinical VUR, MRI might predict the early
changes of obstructive uropathy.
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1755 UNTREATED SUBCLINICAL, BORDERLINE REJECTION
IN 12 AND 36-MONTH PROTOCOL BIOPSIES IS NOT
ASSOCIATED WITH PROGRESSIVE LOSS OF GFR AT
5-YEAR’S FOLLOW-UP

1756 “HUNGRY KIDNEY SYNDROME”: A CASE OF POST
RENAL TRANPLANT PARATHYROIDECTOMY RESULTING IN
GRAFT CALCIFICATIONA AND DYSFUNCTION
R. Baer1, E. Jarvis2, K. Oliver3, M. Mantha1, Dr Caroline Milton4
Cairns Base Hospital, 2Royal Brisbane and Women’s Hospital, 3Princess
Alexandra Hospital, 4Flinders Medical Centre, Adelaide, South Australia
“Hungry Kidney Syndrome” represents a significant but rare outcome
of parathyroidectomy which must be considered when contemplating
parathyroidectomy in the renal transplant population.
Background: Occasionally hyperparathyroidism persists beyond renal
transplant and may require surgical treatment. The literature is not clear about
the outcome of parathyroidectomy. Renal calcification and graft dysfunction
after parathyroidectomy have been described in a case series. In contrast, cases
of calcification in grafts related to high parathyroid hormone (PTH) levels
with benefit from parathyroidectomy have also been described. The following
case highlights that extraskeletal calcification may affect the graft and cause
dysfunction – a condition aptly named “Hungry Kidney Syndrome”. This
syndrome should be included in the differential diagnoses of nephrocalcinosis.
The Case: This case involved a 72 year old man who received a tumourectomised
renal allograft for autosomal dominant polycystic kidney disease. Persistent
severe hypercalcaemia (3.12 mmol/L corrected) and hyperparathyroidism (63
pmol/L) indicated a total parathyroidectomy eight months after transplantation.
Over a period of one month the patient’s serum creatinine rose from 129 to
217 ìmol/L. The graft dysfunction was associated with hypocalcaemia in the
postoperative period and he received oral calcium carbonate and calcitriol 1ug
bd. The patient was also being treated with cyclosporine 100mg bd (average
level 70 Lug/L), azathioprine, prednisolone, diltiazem, without diuretics.
Illustrative renal biopsy images demonstrate the extent of calcification within
tubules and the interstitium, without other features of calcineurin inhibitor
toxicity or rejection. Gradually, graft function improved (creatinine 164 ìmol/L)
after cyclosporin dose was dropped to 50mg bd.
Discussion: The positive outcome despite the calcification described here is
reassuring and new to the literature. It is yet to be determined why the renal
allograft is particularly sensitive to calcification. In this case, one could surmise
that this predisposition was due to calcineurin inhibitor related cellular toxicity.
Alternatively, graft dysfunction may be due to diminished perfusion as a result
of a rapid drop in PTH. This case illustrates the distribution and extent of
calcification within the parenchyma on biopsy, as well as suggesting potential
calcineurin inhibitor involvement in the process. It also promotes awareness
of the serious condition and the importance of managing hyperparathyroidism
prior to transplantation.
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1757 IDIOPATHIC CRESCENTIC GLOMERULONEPHRITIS
AFTER RENAL TRANSPLANTATION ASSOCIATED WITH
ANTIBODY MEDIATED REJECTION: A CASE REPORT
P. Gojaseni1, P. Chalermsanyakorn2, T. Pajareya1, K. Pakchotanon1
Department of medicine, Bhumibol Adulyadej Hospital, 2Department of
pathology, faculty of medicine, Ramathibodi hospital, Mahidol university
We experienced an unusual case of rapidly progressive glomerulonephritis
(RPGN) in a patient after renal transplantation. A 35 year old male who underwent
living donor renal transplantation from his younger brother in December 2003,
presented a rapid graft function deterioration with a creatinine level at 18 mg/
dL. Renal biopsy revealed cellular crescents in two-third of the glomeruli with
neutrophilic infiltration. Immunofluorescence study showed focal deposit
of IgM (1+), C3 (2+) and fibrin (1+). Antineutrophil cytoplasmic antibody
(ANCA) was not found in serum and workup for other causes of crescentic
glomerulonephritis was negative. Diffuse C4d deposition in peritubular
capillaries and circulating antibodies to donor HLA class I were detected
resulting in the possibility of antibody-mediated rejection. He was treated with
three consecutive methylprednisolone pulses followed by plasmapheresis and
hemodialysis. Immunosuppressive regimen was cyclophosphamide (2 mg/
kg/day) in a combination with cyclosporine and prednisolone. Treatment was
unsuccessful, the patient lost his graft and returned to regular hemodialysis
2 months after diagnosis. In conclusion, we diagnosed a rare case of pauci1
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Introduction: Calcineurin inhibitor nephrotoxicity and clinical acute rejection
are well-known predictors of chronic allograft dysfunction. Unclear is the
impact of late, subclinical, borderline rejection (SCR-B) in protocol biopsies
on graft function and survival.
Aim of the study: assessment on whether the untreatment of late SCR-B in 12
and 36-month protocol biopsies has a deleterious effect on renal function at 60
months after Tx.
Patients and methods: In a prospective study 42 low-risk patients were
randomized to either a reduced/withdrawn CsA dose and daclizumab (group
A, n=21) or to a normal CsA dose without daclizumab (group B, n=21). Both
groups received MMF and a standard dose of prednisone. In both groups we
performed histological assessment according to Banff¡¦97 classification in
protocol biopsies before transplantation (Tx) and then at 3, 12, 36 months after
Tx. GFR (Cockroft-Gault formula) were assessed at 3, 12, 36 and 60 months
after Tx. Statistical analysis was performed with the aid of Fisher¡¦s Exact test
and CATMOD Procedure (SAS System).
Results: Protocol biopsies showed 11 late cases of SCR-B episodes in
group A (nine at 12 month, two at 36 month) and seven cases of SCR-B
episodes in group B (two at 12 month and five at month 36). There were no
clinically suspected acute rejection episodes between month 36 and 60. In
50% of these late, SCR-B episodes we did not change immunosuppressive
treatment. In the remaining 50% of late SCR-B episodes we only increased
maintenance immunosuppression (MMF from 2.0 to 2.5/3.0g or daily dose
of prednisone by 5 mg). No treatment with pulses of methylprednisolone was
given. Among patients with late SCR-B episodes we observed two deaths,
unrelated to graft function (cancer, and cardiovascular complications): both
in group B; in one case a late SCR-B episode was untreated, in the other one
the dose of MMF was increased. In group A one patient with a late SCR-B
episode, in whom the dose of MMF was increased, returned to dialysis
because of chronic graft dysfunction. In other patients with late SCR-B
episodes, regardless of treatment or not late SCR, renal function was stable.
However GFR values were significantly higher in group A than in group
B during all the study; at 3 month mean GFR was: 65.8mL/min/1.73m2
+/-28.6 in group A vs. 52.9 mL/min/1.73m2 +/-14.4 in group B; at 12
month: 73.5 mL/min/1.73m2 +/-24 in group A vs. 57.5 mL/min/1.73m2
+/-14 in group B; at 36 month: 72.5 mL/min/1.73m2 +/-23 in group A vs.
56.4 mL/min/1.73m2 +/-18 in group B; at 60 month: 73.6 mL/min/1.73m2
+/-26 in group A vs. 56.4 mL/min/1.73m2 +/-18 in group B (p=0.005).
The risk of arteriolar hyalinization was lower in group A (odds ratio 0.37;
p<0.02). The degree of progression of chronic histopathological changes
did not differ between groups.
Conclusions: The importance of late subclinical acute rejection and the
necessity of its treatment are unclear. Late calcineurin inhibitors withdrawal or
their minimization in low-risk patients may improve long term graft survival.

POSTER BOARD NUMBER P3 – 182

Wednesday 13 August 2008
immune crescentic glomerulonephritis associated with antibody mediated
rejection. Further studies are required to explore the causative link between
alloantibody and glomerular process.

POSTER BOARD NUMBER P3 – 184
1758 INCIDENCE OF C4D DEPOSITION IN PROTOCOL
BIOPSIES IN LIVING RENAL ALLOGRAFT
TRANSPLANTATION
M.Minz1, T. Ahmed1, A. Sharma1, R. Minz2, K. Joshi3
Dept of Renal Transplant Surgery, PGIMER, 2Dept of Immunopathology,
PGIMER, 3Dept of Histopathology, PGIMER
Introduction: After the initial studies by Rush et al, subclinical cellular
rejection has become a well defined entity. Recently, increasing importance is
also being given to the humoral pathways of acute rejection and deposition of
the complement protein C4d in renal allograft biopsies has been accepted as a
sensitive marker of antibody-mediated acute rejection. It is not known whether
the humoral pathways can also produce a subclinical pathology in the graft.
The present study assessed the incidence of subclinical humoral rejection by
C4d staining on protocol renal biopsies in living donor renal allograft recipients
with stable renal function.
Material and methods: From April 2006 to December 2007, 50 renal allograft
recipients who underwent protocol biopsy with in six months after transplant
with stable renal function as defined by serum creatinine <1.5mg% were
included in the study. The biopsies were assessed for c4d stain[Cat B1-RC 4D,
Biomedica] by immunofluorescence in addition to the standard histopathology.
All patients were followed up for six months.
Results: Mean recipient age was 34.1+ 10.7 years, M:F 44:6, mean donor age
was 39.8 + 11.2 yrs. 41(82%) patients were on Tacrolimus & Mycophenolate,
8(16%) on cyclosporine & everolimus and 1 (2%) patient received cyclosporine
& azathioprine. All patients received Prednisolone. 2(4%) of the biopsies
however showed focal c4d positivity. None of the biopsies stained diffusely
for c4d. Histopathologic evidence of humoral rejection i.e. PTC dilation
and neutrophil deposition was noted in 3/50 (6%) of the biopsies .Patchy
dilation was noted in 1/50(2%) of the biopsies.5(10%) patients had evidence
of subclinical cellular rejection. The mean serum creatinine at the end of six
months was 1.16+ 0.3 mg%.
Conclusions: The incidence of C4d deposition in protocol biopsies in patients
with stable renal allograft function in the early postransplant period is very
low. This may be especially true in low risk situations like HLA and ABO
compatible living donor transplantation and with the use of current powerful
immunosuppressive therapy
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1759 KIDNEY TRANSPLANTATION FROM MARGINAL
DONORS. PREDICTIVE ROLE OF BIOPSY SCORE FOR LONG
TERM GRAFT SURVIVAL AND TRANSPLANT OUTCOME
S. Cristino1, M.P. Scolari1, G. La Manna1, A. Faenza2, G. Mosconi1,
L. Panicali1, O. Baraldi1, C. Fantinati1, A. Ferri1, S. Stefoni1
1
University of Bologna - Nephrology, Dialysis And Renal Transplant Unit,
2
University of Bologna - Renal Transplant Surgery Section
Introduction: In the last few years, the gap between organ supply and
demand represents a significant healthcare emergency, forcing the transplant
community to use suboptimal or “marginal” donors. In 2002 the United
Network Organ Sharing (UNOS) delineated the Expanded Criteria Donors,
defining “marginal” as a cadaveric donor either older than 60 or aged between
50 and 59 with at least one of the following risk factors: a) hypertension,
b) deaths caused by cerebrovascular diseases and c) serum creatinine higher
than 1.5 mg/dL (134 micromol/L). Organ quality is also evaluated by a renal
biopsy performed before transplant using the scoring system introduced by
Karpinski in 1999.
Aims: This study was designed to compare graft and patient survival between 3
groups of kidney transplant recipients divided according to the biopsy score of
the corresponding marginal donors. We also analysed the degree of predictivity
of total and partial biopsy score to estimate the risk of graft loss.
Patients and methods: One hundred and thirty-six cadaveric kidney
recipients who received a transplant from a marginal donor between

582

Poster Abstracts
September 2001 and September 2006 were retrospectively evaluated. The
patient population was divided into 3 groups according to the total biopsy
score as follows: Group A = 25 double renal transplants with average total
score between 4 and 5; Group B = 24 single renal transplants with score 4 and
Group C = 87 single renal transplants with score lower than 4. Patients who
received a second transplant or a combined transplant were not included. The
average follow-up was 41.8 ± 18.6 months. The therapy distribution scheme
was similar in all 3 groups.
Results: The 1- and 5-year patient and graft survival according to KaplanMeier curves were better in Group C (single transplants with score <4) than in
Group A (double transplants with score >4) and Group B (single transplants
with score 4), although the differences did not meet statistical significance
(p=0.3766 for patient survival and p=0.4249 for graft survival). In particular,
1-year patient survival was 99% in Groups A and B and 100% in Group C;
5-year patient survival was 92% in Group A, 87% in Group B and 97% in
Group C.
One-year kidney graft survival was 88% in Groups A and B and 95% in
Group C; 5-year graft survival was 88% in Group A, 83% in Group B and
91% in Group C. The total and partial biopsy score (vascular and interstitial
compartment) does not represent a risk factor for graft loss either using the
univariate analysis or using the multivariate analysis adjusted for donor age,
cardiovascular comorbidities, cold ischemia time, Delayed Graft Function and
rejection episodes.
Conclusions: The presents study suggests that total and partial biopsy score
to evaluate organs from marginal donors has a poor predictive value for short
and long-term kidney transplant outcomes. However this approach confirms its
validity as a tool it for the allocation of suboptimal organs, which demonstrate
a good survival.
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1760 CAUSES OF RENAL GRAFT DYSFUNCTION AS
DETECTED IN RENAL ALLOGRAFT BIOPSIES IN A LIVE
RELATED RENAL TRANSPLANT PROGRAM
M.M. Nuhari, J.I. Kazi, E. Ahmed, F. Akhtar, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Objective: To determine the spectrum of pathological changes in renal graft
biopsies performed for evaluation of graft dysfunction in a live related renal
transplant program.
Materials and methods: A retrospective review of 1210 biopsies from 700
renal transplant patients was carried out. Two cores of graft biopsies are
obtained under ultrasound guidance. Both are fixed in formalin and processed
for light microscopy. One additional core was obtained for IMF and EM study
in suspected cases of glomerulonephritides. The histological changes are
classified according to Banff 1997 working classification of renal allograft
pathology.
Results: A total of 1210 graft biopsies were performed in 700 patients. Acute
rejection was seen in 292 (24%) cases, followed by acute tubular injury and
CyA toxicity, found in 281 (23.2%) and 134 (11%) cases respectively. Chronic
allograft nephropathy with variable degree of tubular atrophy was seen in
361 (29.8%) cases. Acute pyelonephritis was seen in 79 (6.5%) cases. Thirty
(2.5%) cases of recurrent/denovo renal diseases were found. FSGS was the
most common lesion found in 15 cases. Eight cases of IgA nephropathy were
seen. Four cases of oxalosis were found. Two cases of MCGN and one case
of Fabry’s disease were also noted. A number of rare lesions were found in 33
(2.7%) cases.
Conclusion: The study defines the pattern of pathological lesions in a large
cohort of live related renal transplant patients. The incidence of acute rejection
is low in our patients and CyA toxicity is more common. Recurrent/ denovo
renal disease occurs in a significant minority of dysfunctional graft biopsies
and among these, recurrent/denovo FSGS is the most common lesion.
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1761 USING DNA TYPING OF HLA CLASS II GENES TO
IDENTIFY HISTIOCYTIC NECROTIZING LYMPHADENITIS
(KIKUCHI-FUJIMOTO DISEASE: KFD)
Y. Qazi, S. Schroff, M. Smogorzewski, Y. Iwaki, S. Qazi, M. Bulbul,
R. Mateo, L. Sher, R. Selby
University of Southern California
KFD is an uncommon, idiopathic, generally self-limited cause of
lymphadenitis. Clinically and histologically, the disease can be mistaken for
lymphoma but the disease runs a benign course.The disease is known to occur
in organ transplant recipients.However, the classic histological picture may
be altered by immunosuppressive drugs and misdiagnosed as a PTLD. We
present a case report of a KTx recipient in whom DNA typing was used to
identify KFD. 31 yr old HW received a 0mm, CMV D+/R+ DDKTx.. I/S
included Basiliximab induction and cyclo, MMF, pred maintanence.4 weeks
after the transplant, the patient developed a fever that was followed by not
tender, rubbery, lymphadenopathy around the cervical chain and a faint
transient body rash.Viral studies were unremarkable as was a LP and Gallium
scan. A diagnosis of a post transplant lymphoproliferative disorder was
considered. An excisional biopsy performed revealed no monoclonality of
the lymphocytes areas of necrosis were noted. EBV staining of the specimen
was negative. KD diagnosis was made. HLA associations to KFD haS been
described in a Japanese series where a positive relationship to DPA1*01 and
DPB1*0202 allele was noted.We sought to see if our patient shared the same
DP antigens association.DNA typing of HLA Class II genes (HLA-DP1 AND
HLA-DP1 was done by PCR-SSP. HLA-DP typing was performed using
Olerup SSP HLA-DP1 and HLA-DP1 kits (Genovision/QIAGEN). Analysis
of our patients sample showed the HLA typing to be HLA-DP1*0103
and HLA-DP1*0402. Our patient possessed the same HLA DP antigen as
described in the Japanese series. Though, initially described in Japan, KD
is being recognized more frequently world wide including North America.
Kikuchi-Fujimoto disease should be included in the differential diagnosis for
patients presenting with cervical lymphadenopathy and fever of unknown
origin. Early recognition of this entity can minimize unnecessary measures
such as discontinuing immunosuppression. infact some reports describe use
of immunosuppression as treatment. Increased awareness of KFD is needed
to minimize the risk of confusing this entity with PTLD or other serious
conditions. Our case demonstrates that detection of DPA1*01 or DPB1*0202
alleles may help making a diagnosis of KD when histology is confounded by
immunosuppression.

CONCURRENT ORAL SESSION 127: RENAL ABOI AND
SENSITISED
POSTER BOARD NUMBER P3 – 188
1762 IMMUNOGLOBULIN CLASS (IGG, IGM)
DETERMINATION BY DITHIOTHREITOL IN SENSITIZED
KIDNEY TRANSPLANT CANDIDATES

POSTER BOARD NUMBER P3 – 189
1763 CLINICAL IMPORTANCE OF ANTI-HLA SPECIFIC
ANTIBODY CONCENTRATION IN PERFORMING
CALCULATED PRA AND VIRTUAL CROSSMATCHES
S. Vaidya
University of Texas Medical Branch
Background: Highly sensitized patients develop multi-HLA specific
antibodies. In this study we measured concentrations of anti-HLA antibodies
in multi-specific sera by converting fluorescence intensity (FI) into molecules
of equivalent soluble fluorocrome (MESF) units. This was used to determine
MESF units required for a positive T and B flow crossmatches (FLXM).
Methods: MESF values of negative controls and sera from patients devoid of
HLA antibodies were measured by FLXM and FlowPRA screening beads. FI
values of anti-HLA specific antibodies determined by FlowPRA single antigen
beads of highly sensitized patients were converted in MESF units. In addition
endpoint titers, MESF units and% PRA of 26 sera were established.
Results: MESF analysis accurately predicted the outcomes of 100% of T
and B FLXM of sera with strong (MESF units>18,000) DSA. The predictive
values of T and B FLXM declined to 95% and 88% with weak DSA (6,000
MESF<10,000). End point titers of sera from highly sensitized patients
ranged from 1:512 to 1:8 with corresponding MESF values of 452,596 to
20,000 units. However there was no statistical difference in PRA values
among these sera (95%-100%). We successfully transplanted 5 patients
who had weak donor-specific HLA antibodies (MESF units >2,000). The
graft survival at one year was 100% and there was no evidence of DSA post
transplant.
Conclusion: MESF analysis is both a time and cost efficient way of measuring
antibody strength. The strength of the antibody present in the sera of transplant
candidates is critical for crossmatch prediction.
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1764 THE EVALUATION OF OPTIMAL DOSE OF RITUXIMAB
IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION
WITHOUT SPLENECTOMY
H. Shirakawa, H. Ishida, K. Omoto, T. Shimizu, K. Setoguchi, S. Iida,
D. Toki, K. Tanabe
Tokyo Women’s Medical University
Purpose: A new protocol for ABO-incompatible (ABOi) kidney transplantation
including rituximab instead of splenectomy was introduced since January 2005
in our institute. We started a dose of rituximab at 500mg/body at first and got
the excellent short-term results. And then, we reduced a dose of the rituximab
to 200mg/body since January 2007. We reviewed our results and evaluated the
optimal dose of rituximab in ABOi kidney transplantation.
Material and methods: Between January 2005 and November 2007, 33
de novo ABOi kidney transplantations were performed at Tokyo Women’s
Medical University. The immunosuppressive protocol, consisting of tacrolimus,
mycophenolate mofetil and methylprednisolone, was started 1 week prior
to the operation. All the patients received induction with basiliximab. The
preconditioning protocol included 3-4 sessions of plasmapheresis (PP) during
the preoperative period and a single dose of rituximab 5-7 days before the
operation. The dose of rituximab was 500mg/body between January 2005 and
December 2006 (Group I, n=22).
Since January 2007, the dose of rituximab was reduced to 200mg/body (Group
II, n=11). Splenectomy was not performed in any of the patients. Anti-blood
type antibody titers and CD 19 levels were monitored regularly. Protocol biopsy
was performed within 1 month of the transplantation and episode biopsy was
performed in the event of rejection.
Results:
Group I (n=22)
The mean follow-up duration of patients was 20.9 months (range 10 to 34).
All the patients underwent successful kidney transplantation. The mean serum
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K.M. Adib
Medical School.Isfahan University of Medical Sciences
Immunoglobulin class plays an important role in the histocompatibility
crossmatch test to predict hypercube rejection in kidney transplantation. The
existing data indicates that immunoglobulin (Ig) M antibodies, particularly
when they are autoantibodies, are not deleterious to the renal allograft. We
used the reducing agent dithiotreitol (DTT) to inactivate IgM but not IgG in
the crossmatch assay to help sensitized patients have the chance for successful
transplantation. In this descriptive study, 57 candidates for kidney transplantation
with final positive crossmatches who had a history of panel – reactive antibody
(PRA) greater than 30% were selected. Two of 57 patients had systemic
lupus erythematous (SLE). The sera of patients were treated by DTT and then
measured for cytotoxicity against donor lymphocytes and a panel of 12 cells
using the complement dependent cytotoxicity (CDC) method. Autocrossmatch
was also performed to differentiate autoantibodies and alloantibodies by the
CDC method. Of the 57 patients, six subjects (10.53%) had IgM and 51 patients
(89.47%) IgG in their serum against donor lymphocytes. Also against panel
cells, 39 of 57 patients (68.47%) had IgG, three patients (5.26%) had IgM, and
15 patients (26.31%) had both IgG and IgM antibodies. Autolymphocytotoxic

antibodies were detected in 1.7% patients (1 of 57) who had SLE. According to
our results, 5.26% of the patients who were IgM – positive and IgG – negative
for both crossmatch and PRA assays may experience successful kidney
transplantation.
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creatinine level of all the patients was 1.2 mg/dl. In most patients, the anti-blood
type antibody titer was maintained at ¡Ü1:32 during the postoperative period.
Only two patients showed increase of the IgG antibody titers up to 1:256 at 3
months post-transplantation. Nonetheless, the graft functions in these patients
were stable and there was no evidence of rejection on biopsy.
Group II (n=11)
The mean follow-up duration of patients was 5.6 months (range 1 to 10). All
the patients underwent successful kidney transplantation. The mean serum
creatinine level of all the patients was 1.5 mg/dl. In all patients, the anti-blood
type antibody titer was maintained at ¡Ü1:32 during the postoperative period.
In both group, the administration of single dose of rituximab effectively
removed all the peripheral blood CD19- positive cells and no side effect of
the rituximab infusion was noted, although in 6 patients of Group I, lateonset neutoropenia was observed (Grade 2: 1 case; Grade 3: 3 cases; Grade
4: 2 cases). Nevertheless, there was no serious infection. Except one patient
in Group II, there was no episode of antibody-mediated rejection during the
follow-up period.
Conclusion: We conclude that with the administration of rituximab and PP
prior to the operation, ABOi kidney transplantation can be performed with
excellent results without splenectomy. No serious adverse effect of rituximab
have been observed in our experience. We suggest that the a single dose of
200mg/body 3-5 days prior to the operation is sufficient and optimal dose.
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1765 PLASMAPHERESIS/IVIG STANDARD DOSE IN PATIENTS
WITH HIGH IMMUNOLOGICAL RISK
F.F. Gama, G.A.M. Ramirez, T.B. Riccardelli
Instituto Mexicano De Trasplantes
Background: In the search of the immunological tolerance desensitization
protocols directed to patients with high immunological risk have been
developed, nevertheless not yet has become general their use, thus relegating
the patients to the growing waiting list of an immunologically compatible
donor, being able to last the delay up to 3 years.
Objective: To report the experience of a center of transplants in the
desensitization of patients with high immunological risk.
Design: Descriptive, retrospective.
Material and methods: We included all the renal transplants from November
of 1999 to January of 2008 in which we used plasmapheresis and standard dose
of intravenous immunoglobulin (IVIG) as desensitization.
Results: The 1.5% of the renal transplants from November of 1999 to January
of 2008 had history of alloimmunity, 7 patients had positive crossmatch
with their donor and 1 exclusively had high Panel-Reactive of Antibodies
(PRA >30%); a patient with positive crossmatch and high PRA received 2
years before plasmapheresis and IVIG, whoever this was unsatisfactory. The
schedule of the plasmapheresis was in alternating days with exchange of 1.5
plasmatic volume, subsequent to each session we administered a standard dose
of Intravenous Immunoglubulin (IGIV 5gr/dose). In 6 patients were made 4
pretransplant sessions, 1 of them required a posttransplant session; in a patient
2 sessions were made pretransplant and in another case one pretransplant
and 2 posttransplant. The immunesuppression began equal than the first
plasmapheresis with calcineurin inhibitor (Tacrolimus) plus, 6 patients with
Mycophenolate Mofetil and 2 with Sirolimus. In 7 cases negative crossmatch
were obtained before the transplantation, except in the eighth case to whom
it wasn´t made. Two patients received humanized antibodies against CD25
(Basiliximab 20mg/dose) the day of transplantation and the fourth day. A
patient presented Delayed Graft Function (DGF) due to Acute Humoral
Rejection (AHR). A patient had pancreatitis the 3 months posttransplant.
Just one patient needed a graft biopsy the 20th month which showed mild
fibrosis. During their evolution all the patients have maintained a stable graft
function.
Conclusions: The renal graft outcome in patients with high immunological
risk after an adequate desensitization protocol is similar to that observed in
nonsensitized patients at least during the first year of transplantation, according
to our experience.
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1766 INCIDENCE OF REJECTION AND LONG-TERM
OUTCOME IN B-CELL CROSSMATCH-POSITIVE KIDNEY
TRANSPLANT RECIPIENTS TREATED WITH PREOPERATIVE
PLASMAPHERESIS AND ONE-WEEK IMMUNOSUPPRESSION
S. Iida, H. Ishida, K. Omoto, M. Furusawa, T. Ishizuka, T. Tokumoto,
T. Shimizu, H. Shirakawa, K. Setoguchi, D. Toki, H. Nishida, K. Tanabe
Department of Urology, Tokyo Womens Medical University, Tokyo, Japan
Introduction: B-cell crossmatch (BCXM) positivity is known to be the robust
immunological barrier to overcome and most kidney transplant recipients
with positive BCXM experience antibody-mediated rejection (AMR) or acute
vascular rejection (AVR) after kidney transplantation. We report incidence of
rejection and long-term results of BCXM-positive kidney transplant recipients
treated with preoperative plasmapheresis and one-week tacrolimus(FK)-based
immunosuppression.
Patients and methods: One hundred and sixty-seven patients underwent KT
following by theimmunosuppression with tacrolimus at our institute between
January 2001 and December 2004. BCXM positivity was determined by the
flow-BCXM test. Flow-PRA was also conducted on sera collected before
transplantation. The patients were classified into the following 4 groups:
BCXM(-)PRA(-); BCXM(+)PRA(-); BCXM(-)PRA(+); BCXM(+)PRA(+).
Rejection episodes were diagnosed by graft biopsy only.
Results: Of the 167 patients, 13 were positive and 154 were negative for
preoperative BCXM respectively. Graft survivals of BCXM(+) recipients were
92% and that of BCXM(-) recipients were 98% respectively. The incidence
of graft rejections was tabulated for following groups. Of 127 patients in
the BCXM(-)PRA(-) group, 22(17%) and 16(16%) had antibody-related and
cellular rejection, respectively. Of 28 patients in the BCXM(-)PRA(+) group,
8(29%) and 4(14%) had antibody-related and cellular rejection respectively.
Of 7 patients in the BCXM(+)PRA(-) group, 1(14%) had antibody-related
rejection. Of 6 patients in the BCXM(+)PRA(+) group, 4(67%) and 1(14%)
had antibody-related and cellular rejection.
Conclusions: These results suggest that there is a correlation between the
existence of anti-HLA antibody before renal transplantation and antibodyrelated graft rejection after surgery. However, long-term graft survival was not
significantly different between BCXM positive and negative groups.
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1767 CLINICAL EXPERIENCE IN LAPAROSCOPIC
SPLENECTOMY FOR ABO-INCOMPATIBLE KIDNEY
TRANSPLANTAION
N. Ichimaru1, T. Abe1, M. Okumi1, R. Imamura1, Y. Isaka1, S. Takahara1,
Y. Kokado2, T. Yoshioka3, M. Kyakuno4, A. Okuyama1
1
Osaka University, 2Takahashi Clinic, 3Sumitomo Hospital, 4Osaka
Seninhoken Hospital
Introduction: The serious shortage of cadaveric organs has prompted the
development of ABO-incompatible live donor kidney transplantation. Recently,
laparoscopic surgeries in kidney transplantation field have been spreading
dramatically. Laparoscopic splenectomy is one of the treatment options
for ABO-incompatible kidney transplantation or severe antibody mediated
rejection.
Aim: To evaluate the safety and efficacy of laparoscopic splenectomy for
ABO-incompatible kidney transplantation, 48 laparoscopic splenectomies for
ABO-incompatible kidney transplantation were reviewed retrospectively.
Patients and methods: From July 2000 to February 2008, 48 laparoscopic
splenectomies for ABO-incompatible kidney transplantation were performed
in our centers. Four-trocar technique was used in all patients. En-bloc stapling
of the splenic hilum using EndoGIA was performed for hilar vascular control.
Anti-ABO blood type antibody titer before and after splenectomy, operation
time, blood loss, conversion to open surgery, and complications were evaluated
retrospectively.
Results: The mean operative time was 113 minutes. Intraoperative blood loss
ranged from 10 mL to 600 mL (mean 120 mL). Transfusion was not required in
any case. One patient required open conversion because of bleeding from the
splenic hilum. One patient required conversion to hand-assisted laparoscopic
surgery because of severe obesity. The serum amylase value was slightly
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elevated postoperatively in five patients but normalized with no treatment.
One patient had bleeding from a trocar port wound, which was treated
conservatively. One pancreas tail injury occurred and the patient was treated
with drainage and Octreotide (smatostatin analogue). No fatal complications
were occurred.
Conclusion: Laparoscopic splenectomy is one of the safe and effective
treatment options for ABO-incompatible kidney transplantation.
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1768 ABO INCOMPATIBLE RENAL TRANSPLANTATION
IN AN HIV-SEROPOSITIVE PATIENT
J. Oberholzer, M. Campara, P. West-Thielke, J. Thielke, T. Ommert,
E. Benedetti, B. Kaplan
University of Illinois At Chicago
To date, there have been no reports of successful ABO blood group incompatible
(ABOI) renal transplantation in HIV patients. We describe a case of a 47 yearold African American male with ESRD secondary to HIV induced nephropathy
that underwent a live unrelated (spouse) donor ABOI transplant using an
IVIG/plasmapheresis preconditioning regimen with IL2 receptor antagonist
induction along with tacrolimus and mycophenolate mofetil maintenance. The
post-operative course was complicated by 2 acute cellular rejection (Banff
Ia) episodes that were successfully managed with corticosteroid boluses and
the addition of corticosteroids to maintenance immunosuppression. No acute
antibody mediated rejection occurred during the first 90 days. The patient
reached a SCr nadir of 2.0 mg/dL on POD20 which has now been maintained
for 90 days. His current CD4 count is 241 cells/μL.
Table1. ABO Anti-A titers
Date

IgM

Baseline

1:64

1:32

Pre-pheresis

N/A

N/A

Post-pheresis

1:8

1:8

Pre-pheresis

1:8

1:4

Post-pheresis

1:4

1:4

Pre-pheresis

1:8

1:4

Post-pheresis

1:1

1:1

POD*-3
POD-2
POD-1

IgG

1:1

1:1

Post-pheresis

1:1

1:1

POD1

Pre-pheresis

<1:1

<1:1

POD2

Pre-pheresis

<1:1

<1:1

POD3

Pre-pheresis

1:1

<1:1

POD4

Pre-pheresis

1:1

1:1

POD5

Pre-pheresis

1:1

<1:1

POD6

Pre-pheresis

1:1

<1:1

POD7

Pre-pheresis

1:1

<1:1

POD8

Pre-pheresis

1:2

1:1

POD9

Surveillance

1:2

1:1

POD10

Surveillance

1:4

1:2

POD11

Surveillance

1:4

1:2

POD12

Surveillance

1:4

1:2

% CD4

HIV Viral Load
(copies)

*POD - postoperative day

Table 2. CD4 Count and Viral Load
Date

Absolute CD4
(cells/μL)

Baseline

531

N/A

<50

POD* 34

595

30

<50

POD 62

564

30

<50

POD 90

241

24

<50

*POD - postoperative day

1769 TREATMENT OF ACUTE ANTIBODY-MEDIATED
REJECTION; SPECIFIC ANTI-T LYMPHOCYTE THERAPY
IS EFFECTIVE, WHILE SPECIFIC ANTI-B LYMPHOCYTE
THERAPY IS NOT
R. Higgins1, D. Zehnder2, K. Chen1, S. Fletcher1, H. Kashi1, L.C. Tan1,
C. Imray1, F.T. Lam1, R. Hamer1, N. Krishnan1
1
University Hospital, 2Warwick Medical School
Introduction: The optimal treatment regimen for acute renal transplant
rejection associated with donor-specific antibodies (DSA) has not been
established. There is a recent report of several graft failures when rejection was
treated with plasmapheresis (PP) and Rituximab, but successful reversal after
splenectomy. We report the outcomes of treatment with the monoclonal T cell
antibody muromonomab-CD3 (OKT3).
Methods: Fifty one patients were transplanted, 45 with HLA antibody
incompatibility (HLAi), 3 with blood group incompatiblity (ABOi), and 3 with
HLAi and ABOi. 24 patients had rejection or suspicious biopsy changes in the
first 3 months. 12 were treated with 5-7 day courses of OKT3; 11 of these cases
rejection was antibody-associated, 1 case had mixed cellular/vascular rejection
with low antibody levels.
Results: One patient with rejection was treated with Rituximab and PP, and
the graft failed from acute rejection (the only graft in our programme to have
failed from acute rejection). OKT3-treated rejection had onset at mean day
12 (range 0-16) post transplant. Mean creatinine was 230 (range 87-dialysis)
umol/l before rejection, peaked at 367 (range 126 – dialysis) umol/l, and fell
post-treatment to 157 (range 70-271) umol/l. 5 patients were treated with
dialysis for severe rejection. One graft failed from thrombotic microangiopathy
at 3 months, the others are currently functioning with mean creatinine 147
(range 78-245) umol/l. Examination of leucocyte subsets in renal biopsies
taken before rejection treatment showed that CD20+ cells made up <5% of
the infiltrate, with CD3+ and CD68+ cells predominating. Additionally, there
is little information on the effects of OKT3 on CD3- lymphocyte populations.
Preliminary results from peripheral leucocyte monitoring of patients during
OKT3 treatment showed changes in CD20+ and CD56+ populations in some
patients.
Discussion: The use of OKT3 for early rejection was associated with 92%
graft survival and 100% patient survival. The role of CD3+ cells in antibody
mediated rejection requires further investigation.
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1770 PROTOCOL CHANGES AND IMPROVED OUTCOMES OF
ANTIBODY INCOMPATIBLE RENAL TRANSPLANTATION
R. Higgins1, R. Hamer1, N. Krishnan1, F.T. Lam1, H. Kashi1, L.C. Tan1,
D. Lowe2, F.T. Lam1, D. Briggs2, D. Zehnder3
1
University Hospital, 2Dept Histocompatibility Laboratory, UK Blood and
Transplant, 3Warwick Medical School
Introduction: Although antibody incompatible transplantation (AIT) appears
reasonably successful in clinical practice, the outcomes for HLA antibody
incompatibility (HLAi), are not well defined outside the USA.
Methods: From 2003-2007, 54 patients entered our programme, 48 with HLAi,
3 with blood group incompatibility (ABOi), and 3 with HLAi and ABOi. The
early (06/2003 – 08/2006) and later (09/2006 – 12/2007) cohorts of 27 patients
each were compared. The initial protocol was similar to that used at the Johns
Hopkins University. From case 16, OKT3 was used for established rejection,
and IVIg and rituximab were not used. From case 29, ATG was used preemptively in selected patients, and post-transplant plasmapheresis (PP) was
phased out.
Results: The two cohorts were similar in respect of mean age (39.7 vs 42.6
years), proportions of regrafts (59% vs 56%), cytotoxic crossmatches +ve
(33% vs 22%), ABO incompatible or flow crossmatch +ve (41 vs 52%); >10yr
treatment of established renal failure (56% vs 56%) and serious comorbidity
(53% vs 41%), but differed in the proportions who had developed renal failure
as children (37% vs7%). One case in each cohort did not proceed to transplant,
and one case was excluded as +ve crossmatch was later found not to be due to
donor-specific antibodies.
At latest follow up in the early and late cohorts respectively, patient survival
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was 92% vs 92%, graft survival was 92% vs 100%. All losses so far have been
in the first 4 months. The mean number of pre-transplant PP sessions was
4.3 vs 3.1 and post transplant was 3.1 vs 0.28. In the early and late cohorts
respectively, the rates of delayed graft function were 8% and 32% (increase
due to immunological and non-immunological risks); acute rejection in
the first 3 months 42% vs 40%; mean eGFR at 3 months 49.7 vs 74.6 ml/
min/1.73m2.
Discussion: The results of AIT improved with experience and empirical
protocol changes, with graft function and graft survival in the later cohort
the same as in standard transplants performed in our unit, despite a high
rate of delayed graft function. Patient survival was less than that of standard
transplantation. This reflected increased comorbidity, and compared with a
survival of only 65% in another 23 patients not accepted for AIT because the
recipient was unfit.
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1771 DESENSITIZATION WITH PLASMAPHERESIS AND
LOW-DOSE IMMUNOGLOBULIN ALLOWS SUCCESSFUL
KIDNEY TRANSPLANTATION FROM LIVING DONORS IN
HIGHLY SENSITIZED RECIPIENTS
A. Yussim1, E. Mor1, B. Makogon1, T. Klein2, J. Orlin3, M. Davidovits4, R.
Michowicz1
1
Dept Transplantation, Rabin Medical Centre, 2Tissue Typing Laboratory,
3
Blood and Apheresis Service, 4Pediatric Nephrology Unit, Schneider
Children Medical Centre
Background: Highly sensitized patients have a markedly reduced chance
of receiving a compatible donor organ. Herein, we present the results of our
regimen used for the management of live kidney graft recipients with broad
alloantibody reactivity.
Methods: The study patients consisted of seventeen live donor kidney
transplant recipients (8 males and 9 females), aged 10-63 years, with mean
PRA of 60% (range 26-100%), awaiting for mean 20.9 ± 18.5 months for
their first (n 5), second (n 10) or third (n 2) transplant. Crossmatch (XM) by
CDC and AHG methods was negative in all patients, 8 patients (47%) had
positive T and/or B flow cytometry with channel shift of 36-375 and donor
specific antibodies (DSA) to class I (n 6) and class II (n 2) in dilutions of
1:64-1:128. The preemptive desensitization protocol consisted of 2-3
plasmapheresis sessions, each followed by low dose (0.5 gr/kg) IVIG infusion.
Postoperatively, all patients were maintained with conventionally dosed and
concentration controlled prednisone-tacrolimus-mycophenolate protocol after
induction with four daily 1mg/kg Thymoglobulin doses (n 9, 53%) or two
bi-weekly 1mg/kg doses of Daclizumab (n 8, 47%). In addition, two patients
with highest DSA received a single 375mg/m2 dose of Rituximab. Suspected
rejections were investigated by biopsy with C4d staining and repeated XM and
DSA determination. Treatment of cellular rejection consisted of Solumedrol
pulses followed by Thymoglobulin. Humoral rejection was treated with
Thymoglobulin, plasmapheresis and IVIG. The patients were followed for 13.8
± 2.1 months.
Results: 14 out of 17 patients were successfully transplanted (1 yr graft
survival 82.3%). In comparison, 1 yr graft survival in our own series of 38
non-sensitized, first live kidney transplants, done in the same period, was only
10% better (92%). In the desensitized patients, there were 4 cases (23.5%)
with delayed graft function caused by acute tubular necrosis, which were
followed with weekly biopsies and all recovered completely after 7-20 days.
Three grafts were lost, one to thrombosis, another to primary non function,
without rejection, and only one to refractory humoral rejection. There were
only two episodes of rejection, one of mixed cellular-humoral type which was
successfully reversed and another of predominantly humoral type with posttransplant positive XM and DSA, which was irresponsive to treatment. At the
end of follow up, all functioning grafts had excellent renal function, serum
creatinine of 1.05±0.42 mg%.
Conclusions: Our results suggest that selected crossmatch-positive patients
can be transplanted successfully with living-donor kidney allografts, using a
protocol of pretransplant plasmapheresis and intravenous immunoglobulin.
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1772 SUCCESSFUL TRANSPLANTATION WITHOUT
DESENSITISATION DESPITE THE PRESENCE OF DONOR
SPECIFIC ANTIBODIES
A. Asderakis1, M. Ilham1, T. Rees2, S. Lloyds2
1
Transplant Unit, University Hospital of Wales, UK, 2Welsh Transplantation
and Immunogenetics Laboratory
Introduction: Transplanting sensitised patients is a complicated issue involving
finding a reasonably matched organ, increasing level of immunosuppression
and also has long term implications to both patient and graft survival. In the last
few years desensitisation protocols have found widespread application in the
setting of live donation. Retransplanted (RTX) patients who have developed
donor specific antibodies (DSA) pose a significant risk for graft survival
although their outcome is not entirely clear.
Aim: To review the outcome of all retransplants that were performed with
negative cytotoxic crossmatch despite possessing DSA.
Method and results: From 1998 to 2003 there were 55 RTX from cadaver
donors. As all these patients were transplanted with the knowledge of a negative
cytotoxic crossmatch (CDCXM), no specific changes were made to their
immunosuppressive management. On retrospective analysis using solid phase
assay and then flow cytometry-based techniques we identified 10 patients with
DSA. On flow cytometry (FC) cross match out of those 10 patients, there were
three patients T-cell positive and B-cell positive, three were T-cell positive and
B-cell negative and four were T and B-cell negative.
Median follow up was 6 years. Two kidneys were lost early postoperatively,
due to renal vein thrombosis (on biopsy had no sign of rejection) and recurrent
FSGS respectively. No graft was lost due to acute rejection and no proven
humoral rejection occurred in the 1st year post transplant.
One patient died at 6 years with a functioning graft. Two grafts failed at 6 and
8 years, and 4 grafts are still functioning at 6 to 8 years post transplant giving a
5-year graft survival of 80%. Functioning grafts have a mean creatinine of 175
and median of 155 micromol/l.
Conclusion: DSA detection in the presence of negative CDCXM does not
always predict an adverse outcome or need for desensitisation even in the
presence of positive FC crossmatch. We present 10 patients with DSA and
surprisingly excellent long term outcome. In the current era the level of DSA
antibody as assessed by more sensitive/ sophisticated methods as Luminex
technique might be more predictive than the actual FC crossmatch results.
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1773 TOWARDS A THEORETICAL BASIS FOR THE
SELECTION OF PATIENT’S OPTIMAL FOR HLA SPECIFIC
ANTI-DONOR ANTIBODY TRANSPLANTATION
R. Vaughan1, O. Shaw2, K. Reddi2
1
King’s College, London, 2Guy’s Hospital
Recipient antibodies to donor HLA antigens are regarded as a contraindication
to solid organ transplantation, although liver transplantation is usually an
interesting exception. The sensitive flow-cytometry based single HLA antigen
bead methods that have recently become available are allowing fine definition
of complex antisera. It is now possible to be quite precise in defining the list
of HLA alleles to which a patient has raised antibodies. This can be seen as
preventing rather than facilitating solid organ transplantation. We propose that
antibodies to HLA are not necessarily a contraindication to transplantation if
reduced to low titre immediately prior to transplantation, but should be placed
in context.
It is well recognised that the T cell alloepitope, consisting of part of the HLA
groove and it’s embedded peptide is very different from the B cell epitope,
which may be represented by single or discrete clusters of amino acids scattered
more peripherally over the HLA molecule. There is also good experimental and
theoretical evidence to believe that antibodies are produced after indirect T
cell stimulation (1). However there is little or no evidence that the processed
alloantigen peptide presented within HLA Class II is the same as the B cell
epitope recognised by the antibody stimulated with T cell help. So although the
sensitising alloantigen may be the same the two epitopes will usually differ.
This gives a rational for antibody removal: a repeat HLA mismatch to which
a patient has raised antibodies is likely to involve T and B cell memory. If
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the antibody is crossreactive with other HLA antigens that are not direct
mismatches then this mismatch may only challenge B cell memory, with T cell
help being limited as the processed peptide(s) may be different. This scenario
would therefore present less of allostimulus. This has formed the theoretical
basis for our successful anti-donor HLA antibody removal programme and
examples will be given of the effectiveness of this approach. Ultimately it
is to be hoped that methods for the rapid assessment of T cell memory will
supercede our admittedly ad hoc approach. Our take home message is that T
cell memory is an important context in which to interpret a patient’s suitability
for antibody removal in renal transplantation.
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1
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Background: CD30 is a 120kd glycoprotein surface receptor that belongs to
the tumour necrosis factor superfamily. This is found on activated CD30+ T
cells that then release a soluble form of CD30 (sCD30) into the circulation.
CD30 is a costimulator molecule and a marker in the regulation of the balance
between Th1 and Th2 immune response.
Aims: The aim of this study was to investigate sCD30 level before and after
HLA antibody incompatible renal transplantation. A high level of pre-transplant
serum sCD30 in patients undergoing antibody compatible renal transplant has
been shown to be a risk factor for acute as well as chronic rejection. There are
no similar studies in HLA antibody incompatible renal transplantation.
Methods: The pre and post-transplant serum samples of the first five patients
who underwent desensitisation in a single unit were retrieved and analysed for
sCD30 using enzyme-linked immunosorbent assay (ELISA). All transplants
were performed between May 2005 and January 2007. Pre-transplant sCD30
levels were correlated with creatinine level at two months as well as biopsy
proven rejection up to one year. Pre-transplant sCD30 levels were also
compared with those of 22 antibody compatible renal transplant patients
performed during 2005. Fisher’s Exact Test and Mann-Whitney U test were
performed for categorical and numerical data respectively.
Results:
Desensitisation
group

HLA Antibody
compatible group

Number of cases

5

22

Mean Age (years)

45.8

43.9

Mean Pre-Plasmapheresis sCD30 (U/ml)

56.7

N/A

Mean Pre-Tx sCD30 (U/ml)

14.1

92.9

Mean 1 week Post-Tx sCD30 (U/ml)

17.0

N/A

Mean 6 month Post-Tx sCD30 (U/ml)

17.4

N/A

Number of patients with ≥1 rejection episodes at 1 year

2 (40%)

9 (41%)

1775 KIDNEY RECIPIENTS’ DEMOGRAPHICAL
AND SENSITIZATION ANALYSIS IN LITHUANIAN
TRANSPLANTATION CENTER IN VILNIUS: AN EIGHT-YEAR
ANALYSIS
R. Dobrovolskiene1, M. Miglinas, T. Rainiene, E. Asakiene
1
Vilnius University Hospital, Nephrology Center, 2Vilnius University Hospital,
Nephrology Center, director, 3Vilnius University Hospital, Immunology
laboratory, 4Vilnius University Hospital, Nephrology Center
Introduction: Kidney transplantation is the treatment of choice for most
patients with end-stage renal disease (ESRD). Optimal outcomes occur when
kidney transplantation is performed as early as possible after the onset of
ESRD, and risk of death and graft failure increase with the length of time on
dialysis.
Methods: We investigated 374 kidney recipients, who have been transplanted
between 01.01.2000 and 31.12.2007 and analyzed recipient/donor gender,
sensitization of recipients, length of time on dialysis before transplantation and
delayed graft function.
Results: There were 374 kidneys transplanted during the observation period: 68
(18.2%) from female donors and 306 (81,8%) from male donors. These kidneys
were received by 163 (43,6%) female and by 211 (56,4%) male recipients.
Duration of dialysis before transplantation was 37,45 months (0-172). 15 (4%)
from 374 transplanted recipients were sensitizied >50% panel reactive antibody
and 39 (10.4%) from 374 transplanted recipients were sensitizied with a panel
reactive antibody titer of 15-49%. In 28,3% recipients a delayed graft function
was detected.
Conclusion: We found a donor-recipient pair inadequacy in gender in our
transplant series in the studied period. There was also a significant proportion
of sensitizied recipients, high frequency of delayed graft function and a long
median duration of dialysis before transplantation.
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Y. Nakagawa, K. Saito, K. Takahashi
Division of Urology, Department of Regenerative And Transplant Medicine,
Graduate School of Medical And Dental Sciences, Niigata University
Background: Immunosuppression therapy for ABO-incompatible kidney
transplantations have previously been more rigorously practiced than ABOcompatible. However, we found that patients treated with this regimen developed
a high rate of complications. In our search for optimal immunosuppression,
we have evolved and made three major changes and one minor change in
the induction period immunosuppressive therapy in ABO-incompatible
kidney transplantation. We have been comparable with four induction period
immunosuppressive therapy.
Methods: 40 kidney recipients were enrolled in our study comparing the four
protocols. Group I (n=13) patients received a standard immunosupressants,
calcineurin-inhibitor (CNI), azathioprine or cyclophosphamide(CPA), and
standard-dose steroid with splenectomy during April, 1996-March, 2002.
Group II (n=6) patients were treated with low-dose CNI with MMF, and early
low-dose steroid and induction with Basiliximab and splenectomy during April,
2002 - August, 2004. Group III (n=13) patients were treated with low-dose CNI
with MMF, early low-dose steroid and Basiliximab induction with standarddose (375mg/m2 ¦ ~2) Rituximab without splenectomy during September,
2004-April, 2006. Group ‡W (n=8) patients were treated with low-dose
(100mg/m2) Rituximab in triple immunosuppressive therapy combined with
CNI/MMF/low-dose steroid desensitization started 1 month before surgery,
during May, 2006-february, 2008.
Results: Patient (93%versus 100%, 100% and 100%) and graft survival
(84.6% versus 66.6%, 92.3% and 100%) at 1year were not different between
the groups. Patients of Group III and Group ‡W experienced significantly
less acute rejections than those in Group I (36.3% and 12.5%, versus 77%
P=0.01). And Allograft function and incidence of adverse events and infections
were similar between the four groups. However, the early low-dose steroid
protocol Groups (GII, GIII and G‡W) patients experienced significantly less
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There was a reduction in sCD30 after plasmapheresis in the desensitisation
group. This was maintained over the first six months. Pre-transplantation sCD30
level was higher in the two patients that had rejection (mean 25.2U/ml) when
compared with the other three patients (mean 6.7U/ml) in the desensitisation
group but this difference was not significant (p=0.1). The creatinine level of the
two patients with rejection was also higher at two months (mean 241mmol/L)
when compared with the three patients who had no rejection (mean 123mmol/L)
but again this did not reach statistical significance (p=0.1) when compared with
pre-transplantation sCD30 level.
Moreover, pre-transplantation sCD30 level in the HLA antibody compatible
group did not correlate with creatinine (p=0.845), graft failure (p=0.464) or
rejection rate (p=0.393) at one year.
Interestingly, pre-transplant sCD30 levels were significantly lower in the
desensitisation group (p<0.001) compared with those of 22 antibody compatible
renal transplant patients.
Conclusions: Even though the group samples are small, there is a trend
between pre-transplant sCD30 and creatinine as well as pre-transplant sCD30
and rejection in the desensitisation group. Contrary to previous studies there
was no such relationship in the HLA antibody compatible group. Much bigger
studies are required to investigate the significance of a low pre-transplant
sCD30 level in HLA antibody incompatible renal transplantation.
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peptic ulcer and NODAT (new onsed diabetes after transplant). The Rituximab
Groups (GIII and G‡W) did not experience antibody-mediated rejection
(AMR). In the Rituximab Groups (GIII and G‡W) patients, B cells were
selectively suppressed. Furthermore, majority of patients of Group III evokes
elimination of B cell in peripheral blood after 2 year. In Group III, three Patients
developed leukocytopenia six months after rituximab treatment, but Group ‡W
experienced significantly less incidence of adverse events.
Conclusion: We have be able to improve graft survival and reduced complications,
through we have evolved in the induction period immunosuppressive therapy
in ABO-incompatible kidney transplantation.

POSTER BOARD NUMBER P3 – 203

WEDNESDAY

1777 COMPARISON OF ANTIBODY MONITORING SYSTEM
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TRANSPLANT RECIPIENT WTH HIGH PANEL REACTIVE
ANTIBODY
H.S. Hwang, B.J. Hyoung, S.Y. Lee, Y.J. Jeon, H.E. Yoon, J.Y. Kim,
B.S. Choi, Y.S. Kim, B.K. Bang, C.W. Yang
Departments of Internal Medicine, College of Medicine, The Catholic
University of Korea, Seoul, Korea
Purpose: We investigated the availability of antibody monitoring system(AMS)
which uses ELISA cross match assay to detect donor-specific anti HLA IgG
antibody(DS-HLA Ab). Until now, no comparative investigation between AMS
and flowcytometric crossmatch test (FCXM) has been reported. The objective
of this study was to compare the two methods in finding DS-HLA Abs in renal
transplant recipient with high panel reactive antibody(PRA) defined as more
than 50% reactivity.
Methods: A total of 32 sera from 17 pre-renal transplant recipients with high
ELISA PRA were screened for DS-HLA Abs. When anti-HLA Abs were
determined in ELISA PRA and the matched donor had the corresponding HLA
antigen, the detected anti-HLA Abs were considered to be DS-HLA Abs. And
all sera were screened for AMS and FCXM.
Results: DS-HLA Abs were detected in 23 serum samples (71%). Sensitivity,
specificity, positive predictive value and negative predictive value of AMS
assay in detecting DS-HLA Abs was 82.6%, 88.9%, 95%, 66.7%, respectively.
Significant concordance was observed (84.3%) between AMS and FCXM
(kappa=0.429, P<0.05). Discordance among the three tests was observed in
8 sera. Three sera (9.3%) had DS-HLA Abs, but none of AMS and FCXM
detected the DS-HLA Abs. In one serum sample(3.1%), DS-HLA Abs were
correctly detected in FCXM, but not in AMS. Also, one false positive result
was observed with AMS. However, in three sera, DS-HLA Abs which were
not detected in FCXM, was detected in AMS assays. From the concordant
point of view, AMS assay showed higher concordance rate (kappa = 0.649,
P<0.05) with DS-HLA Abs than FCXM (kappa = 0.302, P<0.05). Moreover,
higher concordance rate of AMS group was observed with DS-HLA Abs
class I (kappa = 0.813, P<0.05) compared to the T cell FCXM(kappa = 0.438,
P<0.05).
Conclusion: In renal transplant recipient with high ELISA PRA, AMS assay
detected DS-HLA Abs when FCXM did not. AMS assay may be a more useful
indicator to detect DS-HLA Abs, especially, DS-HLA Abs class I which has
more influence in graft kidney.
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1778 OPTIMAL DESENSITIZATION IN SUCCESSFUL
ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION
K. Saito, Y. Nakagawa, M. Suwa, M. Tasaki, T. Tanikawa, T. Nishiyama,
K. Takahashi
Division of Urology, Niigata University Graduate School of Medical And
Dental Sciences
Background and aim: More than 1,000 ABO-incompatible kidney
transplantation has been done in Japan since January 1989. Since September
2004, we have developed the ¦ g desensitization therapy for ABO-incompatible
kidney transplantation without splenectomy which utilizes preoperative 4
weeks MMF/low dose steroid combined with two doses of rituximab at 375
mg/m2. We perform two sessions of Double Filtration Plasmapheresis(DFPP)
before operation to achieve anti-donor blood type antibody titer lower than 8
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to 16 folds, but not routinely do any postoperative antibody removal or IVIG.
Original “Lymphoma treatment” dosage of rituximab was considered much
enough for this purpose, so we have tried to reduce the dosage for more safe
and effective desensitization.
Patients and methods: We have compared the high dose (375mg/m2 x 2)
rituximab administration group (Group 1; n=13) and low dose (100mg/m2 x 2)
group (Group 2; n=7). In Group 1, CNI was started just before surgery and two
doses of basiliximab were also administrated. In Group 2, CNI was initiated 4
weeks prior to surgery and basiliximab was not used. In both group, We have
evaluated the rituximab concentration profile, peripheral CD19, 20 positive
lymphocyte population, serum immunoglobulin level, anti-A/B antibody titer,
patient and graft survival, graft rejection and complication.
Results: Patient and graft survival was 100%, 92% in Group 1 and 100%,
100% in Group 2, respectively. Acute rejection was 4(Ia 3, Ib 1) in Group 1 and
1(IIa) in Group 2. Rituximab concentration was significantly lower in Group
2, however, there was no significant difference in serum immunoglobulin
level, anti-A/B antibody titre, peripheral CD19, 20 positive cell population and
serum creatinine level. There were 2 adenoviral infection, 10 CMV reactivation
and 3 late onset leucocytopenia in Group 1. In Group 2, there was 1 CMV
viremia which was successfully treated by ganciclovir. Except for 3 cases for
treatment of AMR, postoperative antibody removal or IVIG was not done in
both groups.
Conclusion: In ABO incompatible kidney transplantation without splenectomy,
low dose (100mg/m2 x 2) rituximab desensitization is safe and effective. No
additional antibody removal or IVIG is necessary.
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H.E. Yoon, B.J. Hyoung, S.Y. Lee, H.S. Hwang, Y.J. Jeon, B.S. Choi,
Y.S. Kim, B.K. Bang, C.W. Yang
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Background: Highly sensitized patients have a reduced chance of undergoing
renal transplantation, and the number of these patients is growing. Several
desensitization protocols have been developed, but there is no standard
treatment. This study reports our experience of living donor transplantation
with a desensitization protocol including pretransplant plasmapheresis, low
dose intravenous immunoglobulin (IVIG) and anti-CD20 antibody (rituximab)
in highly sensitized patients.
Methods: Ten patients with a current or historical positive crossmatch
test or high level (¡Ã 50%) of panel reactive antibody (PRA) underwent a
desensitization protocol, including six times of pretransplant plasmapheresis
and subsequent low dose IVIG (PP/IVIG). Rituximab was additionally used in
two patients. The clinical outcome and histological findings of protocol biopsy
were retrospectively analyzed.
Results: All ten patients underwent renal transplantation after achievement
of negative crossmatch tests or low level (<20%) of PRA. Donor-specific
anti-HLA antibodies were negative at the time of transplantation. Two acute
rejection episodes developed in early posttransplantation period, of which one
was reversible with posttransplant PP/IVIG and methylprednisolone therapy,
however the other resulted in allograft loss. A protocol biopsy was performed
in four patients, and all showed nonspecific findings with no C4d deposition
along the peritubular capillaries. Nine patients (90%) are currently dialysis-free
after a median follow-up of 22.6 months (range: 6.9-52.0), and there were no
more acute rejection episodes. The last mean serum creatinine concentration is
1.0¡¾0.2 mg/dl (range: 0.7-1.4).
Conclusions: The desensitization protocol using pretransplant PP/IVIG and
rituximab is effective and safe in reducing preformed alloantibodies. The
absence of donor-specific antibodies and stable allograft function promise a
successful long-term outcome in highly sensitized patients.
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ANTIBODIES AGAINST NON-HLA ANTIGENS
A. Vathsala1, H.X. Lou1, M.L. Lai2, T. Kee1
1
Singapore General Hospital, 2Health Sciences Authority
Renal transplantation across a positive HLA cross match (XM) is associated
with a high risk of acute rejection (AR) and worse graft survival. Enhanced
immunsuppression with Plasma exchange, anti-lymphocyte antibody preparations
(ALP), intravenous immunoglobulin (IVIG) in varying combinations is advocated
for renal transplant recipients (RTX) with donor-specific antibody (DSA) as
identified by HLA-coated beads. However, outcomes and immunosuppressive
strategy for those with no DSA, but a positive XM, presumably due to Non-HLA
antibodies, have not been well elucidated. The present study evaluated outcomes
for RTX with a positive XM due to antibodies against Non-HLA antigens as
detected by a Flow cytometric crossmatch (FCM).
From June 2005 to September 2007, 32 live donor renal transplant recipients
(LDRT, mean age 32 years, 50% female, 50% Chinese, mean PRA 32, 19% with
PRA>80%) with a positive (+) FCM undergoing RT at our centre were included
in the study population. FCM between donor and recipient demonstrated +TcellIgG in 4 (12.5%), +Tcell-IgM in 2 (6.2%), +Bcell-IgG and IgM in 14 (43.8%)
and +Bcell-IgM in 15 (46.9%). Mean channel shift (MCS) was 102, 78, 231 and
269 for those with positive Tcell-IgG, IgM and Bcell-IgG and IgM respectively.
CDC XM was positive in 28.1% (Normal Bcell in 25%, AHG-enhanced Bcell
in 28.1%). All FCM LDRT received IV thymoglobulin for 5 days starting 1
day prior to RT together with Cyclosporine (CsA) starting 3 days before RT,
MPA and steroids. Except for LDRT with a +Bcell-IgM, all received additional
intravenous immunoglobulin (IVIG) 1 day before RT, 6 hours after the dose of
Thymoglobulin was completed. CsA doses were adjusted to achieve C2 levels
of 1000 ng/mL at 1 month and MPA doses were adjusted to trough levels <4 ng/
mL. All LDRT received 3 months of CMV prophylaxis.
At a median (range) follow-up of 12 (4 – 32) months, graft and patient survivals
were 100% with the median 1- and 3-month creatinine of 105 (65 - 217) and
113 (78-178) ìmol/L respectively. The incidence of early AR at 6 months post
RT was 0%; however, 2 (6.2% of LDRT) with negative CDC Bcell XM RTX
experienced late AR at 225 and 516 days post RT respectively. One LDRT each
with +Bcell-IgG FCM and +Bcell-IgM developed Banff 2A and 1A rejection
respectively and were successfully treated with methylprednisolone. No AR
episodes were documented in CDC XM or FCM Tcell positive LDRT. Apart
from one LDRT with BK viruria, no other infections or malignancy were
documented. Our study documents a 6.2% incidence of AR, excellent survival
and low morbidity in LDRT with a positive FCM.
These results demonstrate the efficacy of pre-RT ALS together with CsAMPA in minimizing AR without an increased risk of morbidity. Depletion
of potentially alloreactive lymphocytes prior to antigen presentation may
contribute to this excellent outcome. The anti-idiotypic effects of IVIG may
further prevent potentially alloreactive antibodies to non-HLA antigens from
initiating AR. Evaluation with DSA, FCM and CDC XM should be used to
stratify LDRT so as to optimise immunosuppression.

1781 PRE- AND POST-TRANSPLANT BEHAVIOUR OF DSA
IN KIDNEY TRANSPLANT RECIPIENTS WITH NEGATIVE
CROSSMATCH TREATED BY PLAMAPHERESIS AND IVIG
L.E. Morales-Buenrostro1, C. De Leo2, M. Arvizu2, B. Gabilondo2,
M. Vilatoba2, J. Alberu2
1
Depto. Nephrology and Mineral Metabolism. Instituto Nacional de Ciencias
Medicas y Nutricion SZ, 2Department of Transplantation. Instituto Nacional
de Ciencias Medicas y Nutricion SZ
Background: The clinical significance of pre-transplant donor specific
antibodies (DSA), despite negative cytotoxicity and flow cytometry
crossmatches is unknown. Recently, it was reported a 20% incidence of acute
humoral rejection (AHR) in patients of these characteristics compared with a
2.5% incidence in patients without DSA (AJT 2007; 7: 2371).
Aim: In this pilot study we investigate the effect of 3 pre-transplant sessions of PP
followed by 100 mg/kg/session of IVIg on DSA detected by LABScreen® PRA

PATIENT
1
2
3
4
PATIENT
1
2
3
4
PATIENT
1
2
3
4

BASELINE
LABScreen
PRA
A24
A24, Cw7
B35
DR1, DQ5
PRE-KT
LABScreen
PRA
A24
A24
NAD
DR1,DQ5
POST-KT
LABScreen
PRA
NDSA
A24
NDSA
DR1,DQ5

% PRA
40%
64%
36%
49%

%PRA
20%
42%
0%
49%

%PRA
9%
33%
24%
54%

LABSCreen Single
Antigen
ND
A24, B73
ND
DQ5

8989

LABScreen Single
Antigen
A24
A24, B73
Cw4, DQ4
DQ5

701
333, 269
1304, 262
4879

LABScreen Single
Antigen
NDSA
A24, B73
Cw4, DQ4
DQ5

--333, 107
1667, 335
5943

LUMINESCENCE
7442, 8360

LUMINESCENCE

LUMINESCENCE

ND= Not done; NAD=No antibody detected

Conclusions: DSA were detected by both, LABScreen® PRA and LABScreen®
Single Antigen, and the specificities identified through these tests were
consistent at baseline, pre-, and post-transplant. These tests showed that
PP+IVIg decrease the PRA percentage and luminescence of the identified
DSA. Persistence of DSA in the post-transplant course was observed in 3 out
of 4 patients, although at lower levels compared to baseline. In this scenario, a
large scale study will be necessary to demonstrate if antibody reduction offers
a salutary effect in graft outcome of these patients.
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1782 DESENSITIZATION OF LIVING DONOR RENAL
TRANSPLANT RECIPIENTS USING RITUXIMAB AND
ALEMTUZUMAB INDUCTION THERAPY
J. Leventhal, L. Gallon, E. Power, A. Tambur, G. Ramsay, A. Zacharia,
J. Friedewald
Northwestern University
Sensitization to human leukocyte antigens,with resultant donor specific antibodies
(DSA), as well as ABO incompatibility (ABOi) is particularly frustrating for pts
who have a live donor (LD), as their waiting times could be extremely short
were it not for a positive crossmatch. We have used a strategy to desensitize LD
KTx recipients that integrates therapies to disrupt memory-dependent antibody
responses by purging both T helper and B cells (Alemtuzumab, Rituximab).
Methods/results: 30 pts with DSA and 8 pts with ABOi received a single
dose of Rituximab (375mg/m2) 2-4 wks pre-Tx. Plasmapheresis (PP) followed
by IVIG (0.2gm/kg) was initiated and continued daily or on alternate days
until DSA and/or anti-A or anti-B titers fell to < 1:8 or at least an 8 fold
reduction of titer was observed. Pts received alemtuzumab induction (30mg
i.v.) intraoperatively. Maintenance immunosuppression (IS) consisted of
Tacrolimus, MMF, and steroids. DSA titers were determined before, during,
and after desensitization using single-antigen (high definition) flow cytometry
based analysis. Anti-A/B titers were determined using hemagglutination
technique. The decision to transplant was based upon substantial reduction,
but not necessarily complete elimination, of DSA and/or anti- A/B antibodies.
Protocol biopsies were performed on Day 7 and 14 post-Tx. Elevation of

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

589

WEDNESDAY

POSTER BOARD NUMBER P3 – 207

class I and class II, and confirmed by LABScreen® Single Antigen HLA class I
and class II antibody detection test, and in the evolution of the renal grafts.
Patients and methods: Four adult patients (mean age 30.7 yr), 3 female (1st
transplant), and 1 male (2nd transplant), having DSA vs. 1-3 HLA specificities
despite repeatedly negative T- and B-cell CDCXMs with their prospective
living kidney donors, received the aforementioned pre-transplant treatment
(PP+IVIg). Immunosuppression, started the day of kidney transplantation was:
Daclizumab 2 mg/kg, tacrolimus, MMF and steroids.
Results: DSA specificities detected by LABScreen® PRA and LABScreen®
Single Antigen, at the first screening (baseline), post-PP+IVIg sessions preKT, and post-transplant (Post-KT) are displayed in the Table. Renal function
remains stable and no events of AHR have occurred at 2, 8, 10, and 19 mo
post-transplant follow-up, respectively. SCr and GFR (MDRD) at this followup were: 1.18 mg/dl and 72.2 ml/min, 1.0 mg/dl and 68 ml/min, 0.74 mg/dl and
125.9 ml/min, 0.83 mg/dl and 85.2 ml/min, respectively.
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DSA/anti-A/B post Tx, or findings of C4d+ staining on biopsy was treated
by additional PP/IVIG cycles, until titers were substantially reduced again.
Median follow up for DSA pts is 3 years and for ABOi pts is 6 months. 1 pt
experienced clinically evident antibody mediated rejection. 1 pt lost her graft
due to recurrent FSGS. 1 pt who developed recurrent, high titer DSA posttransplant has gone on to develop chronic allograft nephropathy. Significant
infectious complications include the development of BK virus nephropathy in
one patient. Pt survival is 100%.
Conclusions: A combination of rituximab, PP/IVIG, with alemtuzumab
induction and triple IS maintenance is a well tolerated, highly effective, and
durable means of antibody desensitization in renal transplantation. Consistent
monitoring of DSA and antii-A/B titre is crucial for early detection of increased
donor-specific humoral activity.
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1783 EXCELLENT GRAFT SURVIVAL USING
CYCLOPHOSPHAMIDE WITHOUT~ @RITUXIMAB
INDUCTION IN ABO-INCOMPATIBLE RENAL
TRANSPLANTATION
A. Katayama1, K. Uchida2, T. Kobayashi3, T. Ueki1, N. Goto2, T. Sato2,
T. Nagasaka2, Y. Watarai2, K. Morozumi2, A. Ito4
1
Transplant Surgery, Masuko Memorial Hospital, 2Kidney Center, Nagoya
Daini Red Cross Hospital, 3Applied Immunology, Nagoya University School
of Medicine, 4Internal Medicine, Masuko Memorial Hospital
Introduction: ABO-incompatible living donor kidney transplantation has been
performed to expand the donor pool and curtail the universal donor shortage.
For ABO-incompatible living kidney transplantation to be successful, the
suppression of T-cells as well as the positive removal and inhibition of the
production of blood type antibodies are essential. The aim of this study was to
evaluate clinical outcome between cyclosporine (CsA) and tacrolimus (Tac) in
ABO-incompatible kidney transplantation.
Methods: We performed ABO-incompatible living donor renal transplantation
in 99 patients (68 patients received CsA and 31 patients received Tac) since
1993. The mean age of patients was 38 years (11-63 years) in the CsA group
and 44 years (17-52 years) in the Tac group. To minimize the risk of antibody
mediated rejection, we performed a splenectomy 2 weeks before transplantation,
eliminated anti-A and/ or anti-B antibodies by double-filtration plasmapheresis
(DFPP), and administered a potent immunosuppressive regimen consisting
of cyclophosphamide, antilymphocyte globulin or anti-CD25 monoclonal
antibody and prednisolone in both groups. Especially, we avoided splenectomy
in 3 cases because of low titer of blood type antibodies before DFPP. Dosing of
calcineurin inhibitors was based on monitoring AUC0-4 target values.
Results: The incidence of acute rejection during the first 3 months post
transplantation was 19.1% (5 cellular, 7 antibody-mediated and 1 combined
type) in the CsA group compared with 12.9% (1 cellular, 3 antibody-mediated
type) in the Tac group (p=0.215). Graft survival rates were 98.5% in the CsA
group and 94.7% in the Tac group at 1 year (P=0.518). In both groups, antiA/B IgM and IgG antibody levels were maintained at less than 45% of the
pre-DFPP levels during 3 months after transplantation. No antibody binding to
the transplanted kidney was detected in either group at any time (1 hour to 1
year) posttransplantation.
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1784 ABO-INCOMPATIBLE RENAL TRANSPLANTATION
WITHOUT SPLENECTOMY OR RITUXIMAB – LOW
REJECTION RATES, LOW MORBIDITY AND EXCELLENT
CLINICAL OUTCOMES
S. Flint, R. Masterson, R. Walker, I. Fraser, A. Robertson, D. Francis,
R. Millar, S. Cohney
Department of Nephrology, Royal Melbourne Hospital
Although ABO incompatible renal transplantation no longer requires
splenectomy, overall immunosuppression has remained greater than
administered in blood group compatible transplantation. The added potential
morbidity, cost and inconvenience is of particular concern in older recipients
and patients with major comorbidities. More recently rituximab has been used
in a number of centres, though there is no trial evidence for its efficacy and
continued concerns about its additional expense and the long-term consequences
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of its use. Here we report a series of 28 patients (5 over the age of 65) who
received renal transplants from ABO blood group incompatible donors without
splenectomy at transplantation. 24 of the 28 did not receive rituximab.
With the exception of antibody removal (plasmapheresis and/or
immunoadsorption columns), and the commencement of mycophenolate
mofetil (MMF) 10 to 14 days pre-transplant, immunosuppression was identical
to that of “compatible” transplants at our institution, consisting of anti-CD25
antibody, mycophenolate mofetil (MMF) with tacrolimus and prednisolone
(both commenced at/after transplantation). MMF was maintained at 500mg bd
from around week 6, and prednisolone was weaned to 5mg/day by 8-12 weeks.
Average tacrolimus trough levels were: week 0 to 6, 10 ng/ml; week 8, 8.9ng/
ml; week 12, 7.2ng/ml; week 24, 5.6ng/ml; week 52, 4.8ng/ml.
Patients received a median of 4 exchanges pre-transplant and 3 exchanges posttransplant. Baseline titres ranged from 1:16 to 64,000 by tube method (1:2 to
2048 by Gelcard), though for 21 (75%) patients these were under 1:512. One
patient had a donor specific class II anti-HLA antibody (DSAb) with a positive
B cell CDC crossmatch.
At a median follow up of 13 months (range 3-29), patient & graft survival is
100%. In total, 3 patients have developed antibody-mediated rejection (AbMR).
In each case this occurred within the first 2 weeks, and was due in one patient
to DSAb rather than an ABO incompatibility. One patient experienced cellular
rejection and 1 patient subclinical cellular rejection (protocol biopsy and
concurrent with a UTI). All cases of rejection responded to treatment (biopsy
proven) though the patient with DSAb continues to receive IVIG for residual
AbMR. One case of AbMR was amongst the four patients who received
rituximab, while the other 4 cases (2 cellular and 2 AbMR) were amongst the
24 not receiving rituximab.
Recipient renal function is similar to donor renal function except in one
patient distinguished by mechanical/ureteric complications. One patient who
inadvertently did not receive appropriate prophylaxis developed CMV disease.
Five patients have had one or more episodes of BK viraemia, with complete
resolution in all cases. One patient developed post-transplant diabetes mellitus,
which has since resolved.
ABO Incompatible Kidney Transplantation (including moderate to high titre)
can be performed without excessive immunosupression and with low morbidity,
dramatically increasing transplant options for ESKD patients.

POSTER BOARD NUMBER P3 – 211
1785 ABO-INCOMPATIBLE RENAL TRANSPLANTATION
WITHOUT SPLENECTOMY OR RITUXIMAB – A LOW RATE
OF COMPLICATIONS
S. Flint, R. Masterson, R. Walker, D. Yip, S. Cohney
Department of Nephrology, Royal Melbourne Hospital
ABO incompatible (ABOI) renal transplantation is now routinely performed
without splenectomy but most regimens still use immunosuppression greater
than in blood group compatible transplantation. The added potential morbidity
is of particular concern in older recipients and those with major comorbidities.
Rituximab has been used in a number of centres though trial evidence is
lacking and reports are emerging of increased/late infection associated with
its use. Here we report a low rate of complications in a series of 28 patients
who received ABOI renal transplants without splenectomy, 24 of whom did
not receive rituximab. Fourteen of the patients had titres greater than or equal
to 1:256.
Patients received standard tacrolimus, mycophenolate mofetil and prednisolone
with anti-CD25. Antimicrobial prophylaxis was with trimethoprim/
sulfamethoxazole and valganciclovir.
At a median follow up of 13 months (range 3 to 29), patient & graft survival
is 100%. Renal function is stable with a median creatinine at present of
140umol/L. Three patients received treatment for antibody-mediated rejection
(one due to DSAb) and two were treated for cellular rejection.
Bacterial infections: 3 patients developed sepsis with a urinary focus and 2
transplant pyelonephritis, all but one during the first two weeks. There has been
one case of Staphylococcus aureus septicaemia related to a permacath and one
permacath exit site infection. There was one case of MRSE septicaemia related
to contaminated blood products. Two patients developed Campylobacter
gastroenteritis.
Opportunistic infections: A patient (D+/R-) who inadvertently did not receive
appropriate prophylaxis developed CMV disease. Five patients have had one or
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more episodes of BK viraemia, all without nephropathy and all with complete
resolution.
Post-transplant diabetes mellitus (PTDM): One patient had pre-existing
T2DM and one developed insulin requiring PTDM 1 month post-transplant.
At two years she has an HbA1c of 5.8% off all hypoglycaemic therapy. An
additional 7 patients have recorded at least one HbA1c > 6%; none of these
have required hypoglycaemic therapy, though 2 meet the diagnostic criteria for
PTDM. The current mean HbA1c of the cohort is 5.6%.
Urological: Two patients required re-operation for urinary leak and
haematoma. One needed a transurethral resection of prostate for post-operative
urinary retention and another with underlying reflux nephropathy has ongoing
problems with distal ureteric stenosis.
Haematological: Eight patients recorded brief episodes of neutropaenia
(neutrophil count < 1.0x10^9/L). Compared to living related ‘compatible’
transplants at our institution over the same period (n=100), ABOI transplant
patients were more likely to be anaemic at transplant (haemoglobin (Hb)
97.5g/L versus 117g/L, p < 0.05), a difference which became insignificant at
1 month.
Other: There was one case of pulmonary emboli 10 days post-operatively
A sepsis rate of 14% compares favorably with reported rates in ABOI centers.
The use of plasma exchange contributes to line sepsis and transient anaemia.
Despite this, our results show ABOI Kidney Transplantation (including
moderate to high titre) can be performed without excessive immunosupression
and with low morbidity.

POSTER BOARD NUMBER P3 – 212
1786 C4D STAINING IN ONE-HOUR POST-REPERFUSION
ZERO-BIOPSIES SEEMS NOT TO BE SENSITIVE ENOUGH
TO DETECT FURTHER ACUTE ANTIBODY-MEDIATED
REJECTION

1787 COMBINED ALEMTUZUMAB AND RITUXIMAB
INDUCTION ALLOWS FOR EXCELLENT RESULTS IN
HIGHLY SENSITIZED PATIENTS FOLLOWING RENAL
TRANSPLANTATION
G. Brandacher, C. Bösmüller, S. Schneeberger, E. Pirchner, M. Biebl,
R. Öllinger, H. Weiss, R. Margreiter, W. Mark
Department of General and Transplant Surgery, Innsbruck Medical
University, Austria
Background: The increasing pool of multiple kidney graft recipients requires
refined immunological strategies for HLA-sensitized patients. In this context,
high levels of pretransplant panel reactive antibodies (PRA) have been
associated with poor outcome due to an increased risk for acute as well as
chronic rejection. Therefore, we have investigated a novel treatment protocol
containing combined induction with alemtuzumab and rituximab in sensitized
renal allograft recipients.
Methods: Nineteen patients (13f / 6m; mean age: 44±13.2 years) with PRA of
>50% (50-98%) were transplanted from 1/2005 to 12/2007 and were included
in this study. Patients received induction therapy with alemtuzumab (30mg)
intraop and rituximab (375mg/m2) on day 1 post renal transplantation followed
by maintenance therapy with tacrolimus, steroids and MMF. Kidney function
and immunological follow up (PRA levels, renal biopsy) was assessed at
predefined timepoints.
Results: After a mean follow up of 334±263 days, patient and graft survival
was 95%, respectively with excellent renal function (mean creatinine 1.7±0.8,
mean urea 63.1±31.6). Mean cold ischemia time was 13.2±6.1 hours and
delayed graft function as defined by required posttransplant dialysis was
47.3%. Induction therapy was well tolerated and not associated with severe
infectious complications. Acute cellular rejection episodes could be controlled
by bolused steroids (n=3; 15.7%). In four (21.1%) cases humoral rejection was
suspected or diagnosed by positive C4d staining upon histology and treated by
plasmapheresis.
Conclusion: In highly immunized renal transplant candidates combined
alemtuzumab/rituximab induction is safe and may be considered a valuable
approach for successful transplantation in this difficult immunological setting.

POSTER BOARD NUMBER P3 – 214
1788 RISK FACTORS FOR ANTIBODY MEDIATED
REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX)
RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW
CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE
DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND
RATG THERAPY
A. Moss1, R. Heilman1, H. Chakkera1, M. Mazur1, S. Petrides2, E. Wosniak1,
K. Mekeel1, D. Mulligan1, K. Reddy1
1
Divisions of Transplant Surgery and Medicine, Mayo Clinic Arizona,
Phoenix, AZ, United States and 2AKDHC, Phoenix, AZ, United States
We reviewed our experience with ktx in patients (pts) with positive CDC B
and/or pos flow T/B-cell cxm treated (rx) with low dose IVIG and rATG in
order to determine the incidence, outcome of rx and risk factors for AMR.
From July 03 to Nov 07 we performed 69 ktx in pts that met the above criteria.
41 pts received live donor ktx; 33 were primary, 27 second, 6 third and 3 fourth
ktx. Panel reactive antibody (PRA) was ≥80 in 24 pts, 20-79 in 23 pts and < 20
in 22 pts. Donor specific antibodies (DSA) identified by ELISA were found in 26
pts (6 Class I; 14 Class II and 6 both). The cxm results are shown in Table 1.
Table 1
CDC B +

CDC B -

Flow B+ T+

9

23

Flow B+ T-

14

16

Flow B- T+

0

6

Flow not done

1

0

All pts received induction with rATG (6 mg/kg) and low dose IVIG (100 mg/kg
x 3). Maintenance immunosup consisted of tacrolimus, MMF and prednisone.
AMR was rx with plasmapheresis, IVIG, rituximab and steroids. Protocol
biopsies (bx) were performed at reperfusion, 1, 4, 12 months post ktx and then
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D.S.R. David, G.F. Ginani, P.S. Souza, M.C.R. Castro, N. Panajotopoulos,
H. Kanashiro, R. Falci Jr, I.M. Antonopoulos, A.C. Piovesan, W.C. Nahas,
E. David-Neto
From the Renal Transplantation Unit-Division of Urology, Laboratory of
Transplant Immunology and Division of Pathology – Hospital das Clínicas,
University of Sao Paulo School of Medicine
Renal transplantation in sensitized patients may be followed by acute antibodymediated rejection (AAMR) due to undetected levels of donor specific antibodies
(DSA) during pre-transplant CDC-AGH cross-matching (XM). There is some
evidence that C4d staining in zero-biopsies could detect the early phenomena
of antibody-mediated complement-activation in the graft. To analyze whether
C4d staining in zero-biopsies could predict the early (<100 days) occurrence
of AAMR, all transplants (n= 354) performed at our center between June 2005
and December 2007 entered into a prospective study of performing one-hour
post-reperfusion, zero-biopsies stained for C4d by immunohistochemistry
(IH). The biopsies were performed at least one-hour after removing the arterial
and venous clamps and before the closure of the surgical wound. All transplants
were performed against a negative T-lymphocytes CDC-AGH XM but three
cases that had a positive B-lymphocyte XM. Twenty patients (5,6%) developed
AAMR (defined as C4d+ staining plus circulating DSA) at a median time of 14
(5-97) days post-Tx. Pre-transplant PRA revealed that 14 (70%) were sensitized
against HLA-class I antigens and 14 (70%) against HLA-class II, with 13
(65%) sensitized for both. Mean pre-Tx PRA (ELISA) was 57% and 61% for
class I and II, respectively. Patients received kidneys with a median of 3 (2-5)
HLA-ABDR mismatches. Circulating DSA were detected after transplant by
CDC (n=6), FACS (n=13) or Luminex (n=1) at a median time of 14 (7-23) days
after Tx. Out of these 20 patients, 14 (70%) were submitted to zero-biopsies
and 6 (30%) were not due to many reasons. None of the zero-biopsies stained
positive for C4d. However, all biopsies documenting AAMR, performed at a
mean of 18 (4-95) days after transplant, revealed peritubular capillaries stained
by C4d either by imunofluorescence (IF) and/or IH. By IF, C4d was positive in
10-50% PTC in 4 patients (29%) and in >50%PTC in 10 patients (71%). These
data show that C4d staining in one-hour post-perfusion zero-biopsies seems not
to be sensitive enough for the early detection of AAMR when the CDC_AGH
XM is negative. In sensitized patients, early biopsies after Tx,, performed in
the first/second week, plus the frequent search for circulating DSA is possibly
a more sensitive procedure for the early diagnosis of AAMR.
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once a year.
22 pts developed acute rejection episodes, 14 AMR, 1 acute cellular rejection
(ACR) and 7 both ACR and AMR. There were 14 clinical and 8 subclinical (4
AMR, 3 ACR/AMR and 1 ACR) rejections. Graft survival was 93% (2 graft
thrombosis, 1 HUS, 1 CAN and 1 death with function) and pt survival was 99%
with a median follow-up of 20 months (1-46 months). There was no graft loss
from AMR. CrCl at 1-year was similar in pts with and without AMR (55±16
cc/min). Univariate and multivariate analysis showed that positive CDC B-cell
and presence of DSA Class II were risk factors for AHR. Retransplantation
was a risk factor in univariate analysis only. The incidence of rejection in the
different groups is shown in Table 2
Table 2
n

AMR

p value

Class II DSA +

20

13 (65%)

0.0004

Class II DSA -

48

8 (17%)

CDC B-cell +

24

16 (67%)

CDC B-cell -

46

5 (11%)

Retransplant

36

16 (43%)

Primary Tx

33

5 (15%)

0.0001
0.017

Positive CDC B-cell cxm and presence of Class II DSA were risk factors for AMR.
AMR can be successfully treated without compromising graft function or survival.
Further long-term follow-up is needed to confirm these encouraging results.
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1789 AN EASY AND COST-EFFECTIVE DESENSITIZATION
PROTOCOL FOR HIGH PRA/ POSITIVE CROSS MATCH
P. Varma, A. Hooda, A. Kumar
Armed Forces
Introduction: Patients with high PRA or positive cross match have preformed
humoral antibodies to class I HLA antigens and are vulnerable to acute/
hyperacute rejection following transplantation.To remove/suppress these
antibodies various approaches like plasmapheresis, immunoadsorption,
cytoxan, IVIG or rituximab have been tried with variable success. Cost of such
desensitization protocol is unaffordable by many, in developing countries.
Aim: Present study was done to test a simple and cost effective strategy of
desensitization with mycophenolate and plasmapheresis.
Methods: All prospective renal transplant recipients with high PRA or positive
cross match (at-least on two occasions during previous month) were subjects
of the present study. Patients were started on mycophenolate mofetil 1 gm
twice a day. Twenty days after start of MMF patients underwent 5 sittings of
plasmapheresis over 1 week period. During this period and afterwards MMF
was continued. On day 30 PRA and Cross match was repeated. If cross match
and PRA were negative, the patient was taken up for transplantation and MMF
was continued through the transplantation.
Results: 11 patients with mean age 39.55 years (range 23-58 years), with
male: female ratio 8:3 were the subjects. The mean waiting period to
transplantation due to high PRA/ Cross match in these patients was 5 months
(range 1-18 m). Mean PRA before therapy was 75.5 (range 40-100%) and
mean cross match was 32% (range 10-100%). After one month of treatment,
mean cross match dropped to <10% and PRA also to <10% in 10/11 patients
(90.9%)[p<0.05] except in one patient. All these 10 patients underwent renal
transplantation with triple drug immunosuppression (Tacrolimus, MMF and
presdnisolone), in addition to induction therapy with IL-2 blockers (6 pts)/
ATG (4 pts). One patient developed graft venous thrombosis and required
graft nephrectomy. The remaining 9 patients have been doing well and none
of them have developed any episode of rejection. Their mean creatinine is
1.38 mg/dl (range 0.8-2.3 mg/dl) after a mean follow up period of 4.6 m
(range 2-8 m).
Conclusion: Though on small number of patients, our study shows that
effective desensitization can be achieved by judicious use of plasmapheresis
and MMF.
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CONCURRENT ORAL SESSION 128: GLOBAL DONOR
PROBLEMS
POSTER BOARD NUMBER P3 – 216
1790 PATIENTS SEEKING LIVER TRANSPLANTATION
TURN TO CHINA: OUTCOME OF 15 EGYPTIAN PATIENTS
UNDERWENT CADAVERIC LIVER TRANSPLANTATION
IN CHINA
H. Abdeldayem, K. Abo Elella, I. Salamah, S. Soliman, K. Gameel, A.
AboGabal, M. Rady, A. Helmy
National Liver Institute
Introduction: In Egypt liver transplantation is restricted to living related cases.
Many of the liver transplant candidates do not have a suitable living donor.
Increasing numbers of Egyptian patients with end stage liver disease are seeking
cadaveric liver transplantation in China. They are attracted by the lower costs
and shorter waiting time compared to living related liver transplantation in
Egypt. The aim of this study was to evaluate the outcome of Egyptian patients
who underwent cadaveric liver transplantation in China and to address our
ethical concerns.
Material and methods: Fifteen Egyptian patients who underwent
cadaveric liver transplantation in China were included in this study.
Preoperative data before traveling to China, all available reports from
China and data concerning their follow up after coming back from China
were retrospectively reviewed.
Results: Of the 15 patients, 11 were men and 4 were women. Their mean
age was 52 years. Indications included hepatitis C-related liver cirrhosis
(n=9), hepatitis C-related liver cirrhosis with hepatocellular carcinoma (n=4),
and hepatitis B-related liver cirrhosis (n=2). Nine of the 15 patients were
evaluated for living related liver transplantation but none of their potential
donors was considered suitable. Three patients had advanced hepatocellular
carcinoma and were not accepted by any center in Egypt for living related liver
transplantation. Two patients did not have any potential living related donor.
One patient refused the option of having living related liver transplantation
in Egypt and elected from the start to get a whole liver graft from China.
Waiting time in China before getting liver transplantation: ranged from 5 to
days 22, median 13 days. All our patients were told exactly when they should
arrive at the hospital and the organs usually arrive on time. Duration of stay in
China: ranged from 28 to 89 days, median 49 days.The cause of death of the
donors for all cases was severe brain injury (as per reports from the Chinese
Hospitals). Putting in mind that the method of executions in China is known to
be by gun-shooting the back of the head of the prisoner (Guttmann, 1992),we
suggest that all donors were executed prisoners. The overall survival rate
was 80.0% at 6 months and 73.3% at 12 months. There were four deaths,
two of which occurred in China. Of the 11 surviving patients, nine (82%)
developed complications. Nineteen complications were seen in the 13 patients
who were managed following their return from China. Infective and biliary
complications accounted for 46% and 23% respectively. Major complications
necessitated prolonged hospitalization occurred in 4 patients. Two patients
required further laparotomy.
Conclusions: Increasing numbers of patients from all over the world including
Egypt travel to China for organ transplantation.Quite how hospitals meet patient
needs so quickly is a question with legal and medical ethics implications.
The organs are readily available but the source of “donors” is questionable.
Clinicians considering referral of patients to China for consideration of
cadaveric liver transplantation as well as patients who decide to seek treatment
in China should be aware of these ethical issues and the potential risks they
may encounter.
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1791 ETHICAL AND LEGAL ASPECTS OF DONATION AFTER
CARDIAC DEATH (DCD) IN ITALY
P. Bruzzone
University of Roma
In Italy death of a human being must be declared either after brain death or
after 20 minutes of cardiac arrest, certified by continuous electrocardiography
(EKC) recording.
In Italy active or passive euthanasia is a crime and no law concerning the so
called “living will” has been yet approved. Therefore it is impossible to perform
Maastricht category 3 or “controlled” donation after cardiac death (DCD).
In the sixties, at the very beginning of organ transplantation in Italy, kidneys
have been removed from DCD or Non Heart Beating Donors (NHBD) and
subsequently transplanted. However this kind of procedure was discontinued
after that the Italian Parliament approved the “brain death” law.
Recently, DCD has been proposed again from some Italian transplant centers
for Maastricht category 2 or 4 “uncontrolled” NHBD. There is partial agreement
between some experts in Legal Medicine and some judges that cannulation
of the femoral vessels could be performed without previous family consent
in patients having sustained cardiac arrest but under timely and effective
cardiopulmonary resuscitation. No drugs unuseful for the patient are allowed.
After having obtained the relatives’ consent, it is required to stop resuscitation
it is mandatory to wait for at least 20 minutes of cardiac arrest, certified by
continuous EKC recording. Only afterwards is possible to start cold perfusion
and maybe cardiopulmonary by-pass, move the patients to the operating room
and proceed to organ harvesting.
In Italy a “presumed consent” transplant law has been approved but not really
enforce, mostly due to lack of information of the public opinion. Therefore I
think that is risky to perform premortem cannulation of the femoral vessels of
the potential donor unless he brings with himself a “donor card” or there is a
certain proof of his willingness to donate organs and tissues.
It is my personal opinion that this procedure will allow at best only the retrieval
of few marginal kidneys and some tissues, and therefore will not be very helpful
for our waiting list patients. I suggest instead modifying first the Italian law in
order to be able to declare cardiac death after only 5 minutes of cardiac arrest,
certified by continuous EKC recording.

POSTER BOARD NUMBER P3 – 218
1792 MORAL AND ETHICAL ISSUES IN LIVER
TRANSPLANTATION IN EGYPT

POSTER BOARD NUMBER P3 – 219
1793 SUCCESSFUL DECEASED DONOR RENAL
TRANSPLANTATION USING A DONOR WITH DISSEMINATED
INTRAVASCULAR COAGULATION
(DIC) AND ACUTE KIDNEY INJURY (AKI)
R. Villicana, A. Peng, S. Jordan
Cedars Sinai Medical Center Kidney Transplant Program
Purpose: Due to the widening gap between available donors and the deceased
donor renal transplant list there has been an interest in methods that expand the
donor pool. Expanded criteria donation (ECD), donation after cardiac death
(DCD) and marginal dual kidneys (DK) are sources used to expand the donor
pool. Despite these methods, our current supply can not keep up with our
increasing transplant wait list. Possible donors with acute kidney Injury (AKI)
have traditionally been turned down.
We report 2 cases of successful renal transplantation from a deceased donor
with AKI due to disseminated intravascular coagulation (DIC) requiring pre
donation hemodialysis.
Methods: Our center accepted 2 kidneys from a 19 y/o male without
significant past medical history who died from a gunshot wound to the head.
Renal function, CBC and coagulation panel was normal on admission. Patient
developed progressive non-oliguric AKI requiring hemodialysis and had
laboratory evidence of DIC. Patient’s peak and terminal creatinine was 6.1. At
procurement the kidneys had diffuse capsular petechiae. Pathology revealed
severe ATN without evidence of glomerular thrombi or chronic changes.
Results: Recipient number one was a 58 y/o female with history of ESRD
due to polycystic kidney disease. Patient was initially anuric and remained in
delayed graft function (DGF) for 10 days before beginning to improve. She
received thymoglobulin for induction and was eventually on triple therapy
consisting of steroids, tacrolimus and MMF. Her creatinine at one month was
1.2 mg/dl, at 6 months was 1.0 mg/dl and was 0.8 mg/dl at one year.
Recipient number two was a 63 y/o male with history of ESRD due to
hypertension and diabetes mellitus. He also was anuric and received similar
induction and maintenance immunosuppression. He remained in DGF for 2.5
weeks before gradual improvement. His creatinine at 1 month was 1.6 mg/dl,
at 6 months was 1.1 mg/dl and was 1.3 mg/dl at one year.
Conclusion: Deceased donors with DIC and AKI may be suitable donors
assuming that there are no irreversible lesions seen on renal biopsy. Acceptance
of donors with DIC and AKI could possibly expand the donor pool.
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1794 CONCERNS OF ORGAN DONATION FROM PRISONS
WITH DAETH PENALTY: PERSPECTIVES OF TAIWAN S AND
MAINLAND CHINA S HEALTH PROFESSIONALS
F-J. Shih1, S-S. Wang2, R-B. Hsu3, S-S. Chu4
Professor & Dean, National Yang-Ming University School of Nursing, Taipei,
Taiwan, 2,3Division of Cardiovascular Surgery, Department of Surgeon,
National Taiwan University Hospital, Taipei, Taiwan, 4Superintendent, FarEastern Memorial Hospital, Taipei, Taiwan.
Purpose: This study aimed to compare the dilemmas of the use of prisons with
death penalty (PDP) from the perspectives of Taiwan s (TW¡¦s) and Mainland
China s (MC s) organ transplant health professionals (OTHP).
Method: A purposive sample including Tw s OTHP (including transplant
surgeons, nurses, researchers, social workers, medical religious and legal
experts), and MC s team (including surgeons and nurses) was obtained in
this qualitative research. TW s subjects received face-to-face interview, and
MC s subjects received telephone interview due to limited communication
opportunities. Data were analyzed by content analysis.
Results: A total of 105 subjects participated in this project (TW n = 95, MC n =
6). They were surgeons (n = 18, TW n = 14, MC n = 4), registered nurses (n =
42, TW n= 40, MC n = 2), OT coordinating nurses (n = 10 TW), OT researchers
(n = 5 TW), social workers (n = 10 TW), medical religious experts (n = 15
TW), and medical legal experts (n = 5 TW).
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H. Abdeldayem, N. Allam, N.M. Adawy, E. Salah, A. Helmy
National Liver Institute
The non-acceptance of brain death criteria in Egypt meant that, only organs
acquired from live donors could be used.
Objective: to highlight the ethical issues caused by living related liver
transplantation (LDLT) in Egypt.
Methods: research ethics consultation that involved collaboration between
physicians, religion scholars and clinical ethicists.
Results: The first successful LDLT in Egypt was in the National Liver Institute
in 1991, however, this program did not continue because of poor early results.
In August 2002, the program was revived at Dar-Al-Foaud Hospital; since
then almost 500 cases of LDLT were performed in 9 centers. In Egypt, liver
donors are restricted to relatives up to third degree or spouse. The donor must
be competent, meaningfully informed, able to reiterate the risk and benefits for
both donor and recipients, and the alternatives available, willing to donate, with
no evidence of coercion. Although the donor risk is estimated to be low, there
were 2 reported donor deaths (0.4%). To not violate the principal of physician
do no harm requires extraordinary proof that such a procedure is required,
The ethical principle that should best be applied to LDLT is that of equipoise
and informed consent or understanding, not primum non nocere, as the donor
derives emotional benefit from donation and the opportunity to save a life. It is
important to stress that the alternative to living-donor liver transplantation in
Egypt is not deceased-donor liver transplantation; there are no doubts that this
is a beneficial procedure for the recipient with acceptable risks to the donor.
Conclusion: In absence of law that permits cadaveric organ donation, it is

ethically appropriate to perform liver transplantation using living donors. It
is important to maintain the highest of medical and ethical standards to obtain
maximum benefit for both donor and recipient.

Wednesday 13 August 2008
The following 8 ethical dilemmas were reported: (a) questioned legitimacy
of the PDP s motivation (TW 100%, MC 100%); (b) recipients worry about
public’s discrimination (TW 89%, MC 50%); (c) difficulties in approaching
PDP (TW 100%); (d) health professionals and volunteers hesitation in
helping PDP (TW 37%); (e) questioning social contribution of PDPs as
donor sources (TW 32%); (f) complex legal details of PDP s OT issues (TW
26%); (g) potential threat from PDPs families (TW 23%); and (h) difficulties
in helping PDP s families cope with post-organ donation syndrome (TW
11%).
Conclusion: Finally, 5 strategies were further developed in managing these
challenges. They were: (a) OTHPs should empower their basic and social
science knowledge as well as empirical competence; (b) Taiwan s government
should form a task group to work on this issue, and OTHP leaders should foster
interdisciplinary collaboration with public within short-, middle- and long-term
time frame; (c) establishing evidence-based center(s) to provide systematically
literature review for clinical and policy decision making and educational
resources; (d) improving the quality of PDP s organ harvesting and donation
practice in jails/health institutes; and (e) developing reliable assessment tools
and evaluation criteria for this issue.
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1795 ETHICAL ISSUES OF ORGAN TRANSPLANTATION
IN CHINESE COMMUNITY: PERSPECTIVES OF HEALTH
PROFESSIONALS, LEGAL PROFESSIONALS AND RELIGIOUS
EXPERTS IN TAIWAN AND MAINLAND CHINA
F-J. Shih1, S-S. Wang2, R-B. Hsu3, S-S. Chu4
1
National Yang-Ming University School of Nursing, Taipei, Taiwan, 2Division
of Cardiovascular Surgery, Department of Surgeon, National Taiwan
University Hospital, Taipei, Taiwan, 3Division of Cardiovascular Surgery,
Department of Surgeon, National Taiwan University Hospital, Taipei, Taiwan,
4
Far-Eastern Memorial Hospital, Taipei, Taiwan
Purpose: This study aimed to compare the perspectives of leading ethical
issues perceived by the health professionals (HP), legal professionals (LP) and
religious experts (RE) from Taiwan (TW) and Mainland China (MC).
Method: A purposive sample including Tw s OTHP (including transplant
surgeons, nurses, researchers, social workers) LP and RE, and MC s HP
(including surgeons and nurses) was obtained in this qualitative research. TW s
subjects received face-to-face interview, and MC s subjects received telephone
interview due to limited communication opportunities. Data were analyzed by
content analysis.
Results: A total of 127 subjects participated in this project (TW n = 92, MC n =
8). They were HP (n = 92) [surgeons (n = 20, TW n = 14, MC n = 6), registered
nurses (n = 47, TW n= 45, MC n = 2), OT coordinating nurses (n = 10 TW), OT
researchers (n = 5 TW), social workers (n = 10 TW)], religious experts (n = 25
TW), and legal professionals (n = 10 TW).
The following 8 ethical dilemmas were reported: (a) difficulties in touching
public and conveying the values of OT to various age populations (HP
100%, LP 100%, RE 100%); (b) challenges in helping donors and their
families cope with multidimensional crisis across recovery stages (HP 96%,
RE 80%, LP 50%); (c) health professionals competence and availability in
providing holistic care for cadaveric donors, recipients, and their families
(HP 93%, RE 72%, LP 50%); (d) questioning social farewell to cadaveric
donors, recipients, and their families (HP 92%, RE 20%, LP 100%); (e)
questioning social farewell to cadaveric donors, recipients, and their
families (HP 92%, RE 20%, LP 100%); (f) questioned legitimacy of the
PDP s motivation (LP 90%, RE 64%, HP 60%); (g) recipients & families
worry about public s discrimination (LP 90%, HP 50%, RE 20%); and (h)
challenges to families in taking care of the recipients (HP 87%, LP 70%,
RE 52%).
Conclusion: In order to provide holistic care, the health professionals need to
invite religious experts to provide spiritual support systems for the cadaveric
donors, recipients, and their families The cadaveric donors¡¦ families often feel
helpless in dealing with sophisticated legal procedures, and became vulnerable
populations. With the help from this triangulation collaborative team, the quality
of OT will be more visible and appreciated by the public. Future researchers
are suggested to explore the context contributing to these challenges and to
develop strategies for the concerns of leading ethical issues reported by these
three agents.
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1796 THE ROLE OF THE COMMITTEE FOR ETHIC AND
APPLICATION OF ORGAN TRANSPLANTATION IN THE
MEDICAL AND ETHICAL EVALUATION OF LIVING DONOR
RENAL TRANSPLATATION
M. Cai1, L. Xu2, X. Xu3, Z. Li4, Y. Qian5, B. Shi6, G. Li7
1
Transplantation Center, The Second Affiliated Hospital, Chinese PLA
General Hospital, 2Transplantation Center, The Second Affiliated Hospital,
Chinese PLA General Hospital, 3Transplantation Center, The Second
Affiliated Hospital, Chinese PLA General Hospital, 4Transplantation
Center, The Second Affiliated Hospital, Chinese PLA General Hospital,
5
Transplantation Center, The Second Affiliated Hospital, Chinese PLA
General Hospital, 6Transplantation Center, The Second Affiliated Hospital,
Chinese PLA General Hospital, 7Transplantation Center, The Second
Affiliated Hospital, Chinese PLA General Hospital
Objective: To ensure the success for kidney transplantation and the feasibility
of ethical principles, the Committee for Ethic and Application of Organ
Transplantation (CEAOT) make the medical and ethical evaluation for livingdonor and recipient in pre-transplantion.
Methods: CEAOT was composed of the experts included physician, surgeon,
anesthetist, pharmacologist, primary nurse, medical ethic and barrister etc. 28
pairs of living kidney donors and recipients, that they were consisted of 16
pairs of a lineal consanguinity, 8 pairs of a second collateral consanguinity,
2 pairs of a tertiary collateral consanguinity, and 2 of spouses, had received
the evaluation by CEAOT. The donors ages ranged 26 to 61 years old (mean
54years), and the recipients years old is form24 to 51, mean 35.5 years old. The
inverse proportion of male donors and female donors is 7:21. However, 16 of
parents donated own kidney to their offspring, non offspring give a donation
for their parents.
Results: 24 pairs of 28 cases were pass by CEAOT one-off, 1 case had donated
kidney for his young brother when his overweight got banting (BMI<30kg/
m2). 3 of 28 cases were excluded by CEAOT because of suffering from
the II-diabetes, the spouse of donor refused the inquiry for evaluation by
CEAOT, and it is not affirmed whether pulmonary tuberculosis (TB) had
been cured, respectively. After transplantion both donors and recipients got
recovered well.
Conclusion: The Committee for Ethic and Application of Organ Transplantation
(CEAOT) is an essential agency for Living Donor Kidney Transplantation. It
is important significance that the intervention of CEAOT makes the maximal
benefit for living donors, and to ensure the medical safety for donors, recipients
and doctors. The fact of the more female and more eldership donors than males
and junior reflect the traditional moral and ethical outlook in our country. It
impulses us to explore farther in the medical and ethic in the future.
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1797 ORGAN DONATION IN GERMANY – PERSPECTIVES
TO INCREASE POST MORTEM ORGAN DONATION
F. Schaub, C. Wesslau, G. Kirste
Deutsche Stiftung Organtransplantation
Background: Organ donation in Germany is organised by the Deutsche
Stiftung Organtransplantation (DSO) - German Transplantation Foundation.
Covering a population of 82 million people DSO entertains seven regional
offices, each responsible for eight to eighteen million inhabitants.
Analysis of potential: In order to detect the donor potential in Germany
a retrospective study has been conducted. Data was collected on deceased
persons on ICU’s with primary or secondary brain damage. This was done
via data entry forms which were especially designed for this purpose.
Through this study it could be shown that the number of potential donors
per million population (pmp) is comparable with the international standard
of other OPO’s with 40 donors pmp. The analysis showed that refusal of
relatives to organ donation is the main obstacle in order to realise organ
donation. The study revealed an increase of refusal rate over the years
2006 to 2007 (2006 37,1%; 2007 37,8%). These findings enables us to
develop strategies in order to enhance organ donation. This strategy focuses
primarily on measurements in order to ensure the detection and referral of
potential donors to the OPO’s, to reduce obstacles to organ donation based
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on medical reasons and last but not least the reduction of the family refusal
rates.
Results: The total number of organ donors in 2007 amounted to 1.313. This
corresponds to an augmentation of five percent compared to the preceding
year. Therewith Germany ranks among the first worldwide when it comes to
the absolute number of organ donors. But looking at the number of effective
donors per million population being 16,0, Germany does rather poor in
the international comparison. However the study revealed considerable
differences regarding the organ donation rates among the German regions
(13,3 vs. 19,7 effective donors pmp). The conversion rate in the individual
regions covers a range from 41,5 to 57, 2%. However reasons for these
regional discrepancies can not be explained by the lack of epidemiological
studies.
Strategies to enhance organ donation in Germany: The analysis shows, that
the donor potential has by far not been bailed out. Essential for the increase of
the conversion rate in the DSO area is:
• Increase of the referral of potential donors by the donor hospital.
• Reduction of the refusal rates.
In order to realise these goals “increasing of referrals” and “decreasing of
refusals” a concept is being elaborated to optimize communication. That
apparently is the breakthrough in succeeding. This concept is based on two
pillars:
• Improvement of the communication between DSO and donor hospitals
• Improvement of the communication with the relatives of the deceased
We started our Trainee-Program for hospital communication in the year 2006.
Our coordinators are trained in specially designed workshops and coached
individually as well as in groups. Quality management circles have been
installed in most of the hospitals.
The training based on the newly developed concept for the family interviews
will start in 2008.
Organ donation is a multidisciplinary task and a lot of factors influence the
donation rate. Improvement of communication with hospital staff as well as
donor families is at least one key for success.
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1798 ETHICAL CONSIDERATIONS IN ORGAN ALLOCATION
FOR TRANSPLANTATION

1799 THE ENLIGHTENMENT OF THE NEUROSURGEONS
AND EMERGENCY ROOM DOCTORS WITH RESPECT TO
THE KIDNEY DONATION UNDER CARDIAC DEATH
S-I. Yoshikai1, K. Hokao1, K. Yamamoto2, C. Kaino2, H. Anai2
1
Department of Neurosurgery, Shinkomonji Hospital, 2Deparment of Intensive
Care Unit, Shinkomonji Hospital
Backgrounds: The rate of the donation card possession is 8%, and the rate of the
affirmative opinions for the organ donation is 42% in the general population in
Japan. The number of the potential donors after brain death is estimated as 7000
and the potential donors after cardiac death is also estimated as 70000 annually
statistically. Suppose 8% of these potential donors possess donation cards, there
should be 560 donations after brain death (DBD) and 5600 donations after cardiac
death (DCD) theoretically. However, only 866 donation cards were proposed and
the DBD were done only in 56 cases for the recent 10 years in Japan eventually.
Also the kidney DCD were done approximately 100 cases annually. This poverty
of the donation is mainly caused by the negativism of the neurosurgeons and ER
doctors. They are not interested in the organ transplantation medicine and they
usually do not confirm the donation card possession because they are afraid of the
negative campaign by the news media.
Methods: In our hospital, we are mainly focusing on the kidney DCD. From
March 2003 to December 2007, we confirmed the donation card possession and
proposed the option of the kidney donation after cardiac death to the families in
29 potential donation candidate cases.
Results: Families of 20 cases agreed with the donation. Among the total 29 cases,
donation cards were presented in 2 cases, donation cards were possessed but lost in
2 cases and strong will for the donation were confirmed in 2 cases. In the remaining
23 cases, patients and their families had never discussed about the organ donation.
However, 14 families agreed with the kidney donation eventually. Finally, total 20
families agreed with the kidney donation out of all 29 cases. Three cases dropped
out afterwards because of the HTLV-1 infection in 1 case and persistent vegetative
state course in 2 cases. Seventeen cases donated their kidneys finally.
Discussions: The donation card possession rate is 7% (2/29) in our study.
This resembles the 8% possession rate in the general population. The overall
rate of the agreement with the kidney donation was 69% (20/29). Even in the
patients and their families who had never discussed about the organ donation
beforehand, the rate of the agreement was 61% (14/23). This suggests that the
families tend to consider the donation more positively in the patients’ emergent
critical conditions than in their usual daily life.
Conclusions: The enlightenment of the organ donation seems sufficient in the
general population in Japan. The issues of the kidney shortage will be solved
only if the neurosurgeons and the ER doctors ask the donation card possession
and propose the option of the kidney donation. Also the issues of the DBD will be
also solved gradually if the kidney DCD is well accepted and prevails generally.
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1800 2007, THE YEAR OF REGULATORY CHANGE
J.M. Millis1, J. Huang2, A. Millis3, Y. Mao2, M. Simmerling4, Y. Liu2
1
University of Chicago, 2Peking Union Medical Center, 3Rhodes College,
4Weill Cornell Medical College
The two countries that performed the most organ transplants in 2006, US and
China, initiated significant regulatory change in 2007 that continues into 2008
and likely several more years. The purpose of this abstract is to highlight the
reasons behind the regulatory initiatives, document the new regulations and
assess the impact thus far.
Methods: Review of US and China governmental regulations emphasizing the
underlying principles and impact.
Results:
US
Principle
° Equity and transparency

° Understanding Tx Process

Regulatory Change
Objectively apply process and
criteria for each tx Candidate and
Recipient

Impact
Eliminates arbitrary and capricious
evaluation and transplant candidacy
decisions

Document Waitlist Management
and Communication

Ensures appropriate allocation of
organs
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A. Jafarian, S. Sadeghi, S.H. Emami Razavi
Tehran University of Medical Sciences
Organ transplantation is a standard treatment for end stage organ failure which
has several ethical and social considerations. Deceased donor organ allocation
in the era of organ shortage and rapidly increasing number of recipient is a
major ethical problem.
Resource allocation theories are mainly established on the ethical principle
of justice and the cost effectiveness issue. There are different definitions for
justice in resource allocation including Fairness, Equality and Equity which are
mainstay of any decision planning format.
Medical need is the major criterion for receiving an organ but non-medical
indications such as age or registration priority are intervening factors that is
discussed more. Other problematic cases are retransplantation and allocating
an organ to a person with behavioral diseases (e.g. Alcoholic cirrhosis).
Explanation of these viewpoints is coming in details.
Achieving justice in organ allocation not only reinforces the public trust to
medical community but also increases the overall organ donation which is
the rate limiting factor for transplantation. The lack of a universally accepted
protocol forces us to have a clear decision making process to clarify the
problems and resolve pitfalls of organ allocation. This decision is sometimes of
nonmedical type and help of others could be effective.
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° Field Strength

Document appropriate surgeon
Minimizes lack of access to
and physician coverage. Document
transplantation due to lack of
availability of other associated
institutional commitment
services

° Informed Consent

Independent Living Donor
Advocate team and specific
information regarding deceased
donor organs that may impact organ
function and donor transmitted
diseases

Separate process for living donor
organs and deceased donor
organs that increases the level of
knowledge for the living donor and
recipient

Regulatory Change

Impact

° Equity

Ban Transplant Tourism and
payment for organs

Allows improved access to Chinese
and minimizes exploitation

° Field Strength

Defined criteria of institutions that
are able to perform transplantation

Ensures patients undergoing
transplants receive their transplants
at institutions with a high level of
commitment

° Donor Informed Consent

Requires consent of donor and
donor’s family

Decreases exploitation of Prisoner
donors

CHINA
Principle

Conclusion: Both countries have made significant progress in attempting to
improve the process for both donors and recipients. The US is a more mature
system while China is attempting to move toward an International standard. In
the short-term there may be decreased overall access to transplantation while
transplant centers and policies adjust to the new regulations in both countries.
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1801 ACCESS OF NON RESIDENTS TO TRANSPLANTATION
MEDICINE
D. Norba, G. Kirste
Deutsche Stiftung Organtransplantation
When it comes to medical treatment of non nationals or non residents limitations
usually exist due to financial reasons. In terms of transplantation another factor
becomes important: The scarcity of organs available for transplantation purposes.
The question to be raised is: Does an increase of transplantations of nonresidents jeopardize the willingness of residents to donate? The answer is not
simple in particular the role of the mass media must not be underestimated.
An examination of the existing regulations in Europe and the US dealing with the
access of non-residents; respectively the restriction of access to transplantation
medicine two general approaches can be distinguished. The first one limits the access
of non residents to the (national) waiting list. That means those who are denied access
can not be transplanted, no matter how urgent the case might be. Usually a random
percentage between 0 -10% is chosen. Registration for transplantation serves as a
funnel. This approach was chosen by Eurotransplant and UNOS for example.
The alternative approach is to allow the registration on national waiting list
for everybody who is suitable for a transplant but to consider certain groups of
persons such as non residents subordinately in the actual allocation process. In
this second category various differentiations are possible in particular with view
to high urgency patients. This however leads to the consequence that due to the
lack of organs there are few chances to receive an organ of good quality or to
receive an organ at all. This approach was chosen by UK and Switzerland.
It is however highly doubtful whether the existing regulations would stand
the legal proof in the light of constitutional rights in particular human rights
assigned to every person irrespective of nationality or residency. Human rights
that are at stake are in particular the right to life and to physical integrity but also
the prohibition of discrimination. Hence exceptions need to be made at least for
high urgency patients. In Europe furthermore European community law needs to
be taken into consideration as well in particular the free movement of patients.
When stipulating a regulation for non residents in transplantation medicine the
following questions need to be answered. Is there really a need for restricting
regulations? Who has the competence to legislate on a national or European
level? Does the intended regulation violate constitutional or European law?
There is no easy answer to this but it can be summarized that access of non
residents to transplantation medicine should be given due consideration in a
European perspective, in order to be solved on a national level from a legal
point of view. Any regulation should however be in accordance with national
constitutions as well as European law (e.g. Art. 12, 18, 39, 43, 49 TEC and
Council Regulation (EC) no 1408/71).
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1802 THE IMPACT OF TRANSPLANT COORDINATOR ON
LIVE RELATED DONORS KIDNEY TRANSPLANT PROGRAM
AT A TERTIARY CARE HOSPITAL IN KINGDOM OF SAUDI
ARABIA
S.E-D. Al-Horani, T. Tassadaq, S. Abdel Raouf, S. Fahim Hassan
Saad Specialist Hospital
The shortage of organs available for transplantation is a universal problem.
There are multiple reasons for this. The role of a transplant coordinator is
well established in increasing the number of organs in cadaveric transplant
programme. However the impact of a transplant coordinator in an exclusive
live donor program has not been looked in detail. We present our data and
asses the impact of a transplant coordinator at our centre, which is exclusively
carrying out live donor kidney transplants. We also look at the factors related to
transplant coordinators that have contributed to an exponential increase in the
number of transplant at our centre.
Our transplant program started in June 2005. We managed to have four live
related kidney transplants till December 2005. Meanwhile, another four
cases were performed from January 2006 to November 2006. Two transplant
coordinators were appointed in November 2006. We carried out eight live
related kidney transplants in the last two months of year 2006. In year 2007, a
total of forty-two live related kidney transplants were performed which elevated
our center from the last place to the second among 13 transplant centers in
Kingdom of Saudi Arabia.
Our experience shows that trained transplant coordinators are essential to a live
related kidney transplant program.
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1803 EXCELLENT LONG-TERM GRAFT SURVIVAL WAS
ACHIEVED IN KIDNEY TRANSPLANTS FROM NON-HEART
BEATING DONORS. EXPERIENCE OF 107 CONSECUTIVE
RENAL TRANSPLANTS AT A SINGLE CENTER
K. Hoshinaga, H. Sasaki, M. Kusaka, T. Maruyama, K. Hayakawa, R. Shiroki,
A. Sugitani
Fujita Health University
Introduction: Although kidneys donated after cardiac death (DCD) have
marked severe ischemic damage, they have been recently accepted as the
optional resource in the deceased donor renal transplants because of a severe
shortage of renal grafts. In Japan, more than 90% of the deceased donor grafts
have been recovered from DCD donors using in situ regional cooling technique
for more than 3 decades. In this clinical communication, the outcome of the
107 consecutive DCD donor renal transplants at a single center is reported.
Study subjects: Since November 1990, using in situ cooling technique, 107 renal
grafts from DCD donors were engrafted at our center. Most of donors are classified
as Maastricht, category IV. The mean follow up period is 129 months. The ages of
donors and recipients ranged from 3 to 75 years (mean; 47.1) and 15 to 63 years
(mean; 42.7 years), respectively. The recipients’ pretransplant dialysis periods
ranged from 12 to 359 months (mean; 110.9 months). Warm ischemic time and total
ischemic time were from 1 to 57 minutes (mean; 9.6 minutes) and from 325 to 2603
minutes (mean; 967 minutes), respectively. A quadruple immunotherapy consisting
of cyclosporine (CsA), methylprednisolone (MP), anti-human lymphocyte globulin
(ALG) and azathioprine or mizoribine was administered in 79 recipients, and a
triple immunotherapy consisting of CsA, MP and mycophenolate mofetil (MMF)
was administered in 13 recipients. Other 15 patients received tacrolimus (Tac),
basiliximab, MP and MMF. Low dose CsA (4mg/kg) or Tac (0.15 mg/kg) was
given initially and increased after the recovery of the graft function.
Results: Following renal transplants, the immediate graft function was noted
in 22 recipients and other 83 patients had delayed graft function necessitating
posttransplant dialyses for one to 39 days (mean; 11.9 days). Two grafts never
recovered renal function. The 1,3,5, and 10 year patient survival rates are
98.1%, 95.1%, 92.8% and 85.2%, respectively, and the 1, 3,5 and 10 year graft
survival rates are 96.2%, 93.1%, 87.7% and 66.4%, respectively.
Conclusion: The current graft survival is excellent and seems to be comparable
to the graft survival of living donor kidney transplants. Our result indicates that
DCD donors should be considered as an excellent resource of renal allografts
when appropriate in situ regional cooling technique can be applied.
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1804 NON-HEART BEATING DONATION IN EUROPE;
AN OVERVIEW
B. Haase-Kromwijk1, H. van Leiden1, F. Mühlbacher2, A. Hoitsma1
1
Dutch Transplant Foundation, 2Univ. Hospital of Vienna
Background: Expanding deceased donor criteria includes the use of non-heart
beating (NHB) donors. We studied the existence of a NHB donor program in
27 European countries.
Methods: A questionnaire was send to all the member states of the Council of
Europe in 2007.
Results: Only 9 out of the 27 countries that replied had a NHB donation
program, using different NHB categories, organ types, organization, and notouch period after death.
The no-touch period after death ranged from 0-20 minutes. In all 9 countries
NHB donation category II and IV was performed, in only 6 countries NHB
category III and in 4 countries NHB category I. Besides NHB kidney donation,
NHB liver donation was performed in 5 countries. In 3 countries there was
also a NHB lung program, while 2 countries performed NHB pancreas
transplantations as well. In 2006 the United Kingdom had the largest number
of NHB donors (124), reflecting 19% of the total number of deceased donors,
followed by the Netherlands with 90 NHB donors, reflecting 45% of the total
number of deceased donors. In the 5-year period 2002-2006 these countries
also had the largest number of transplants from NHB donors (respectively 945
and 872). In 3 of the 9 countries with a NHB program organs were allocated
via the national allocation program. In the other countries the NHB organs are
kept locally or are allocated via a special program.
In the 18 countries without a NHB program NHB donation was legally not
allowed (5) or not possible due to organizational reasons and/or lack of
expertise (13).
Conclusion: Although NHB donation is increasingly accepted in Europe, the
majority of the European countries has not (yet) a NHB donation program
and if available the use of NHB donor programs differs in NHB categories of
donors, organs used and organization and procedures.
The UK has the largest NHB donation program in numbers, the Netherlands in
percentage of the total deceased donor pool. Evaluation of these differences in
programmes can be useful.
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1805 COGNITION, INTENTION AND BEHAVIOR SURVEY ON
LIVING ORGAN DONATION IN CHINESE LIVING KIDNEY
DONORS AND GENERAL POPULATION
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1806 PRISONERS AS ORGAN DONORS: IS IT WORTH THE
EFFORT? IS IT ETHICAL?
M.A. Millis1, J.M. Millis2, M. Simmerling3
Rhodes College, 2University of Chicago, 3Cornell University
With the waiting list for organs approaching 100,000 and the impact of the
National Collaborative leveling off, additional avenues need to be explored
to help alleviate this shortage. Prisoners have generally been excluded
from donation because of the ethical and infectious disease concerns.
We propose a plan, which would address both concerns and examine the
potential impact.
Plan: Interested inmates of State and Federal correctional facilities would
approach the medical team at the correctional facility expressing their interest
in living donation. The prisoner would be provided a packet of information
explaining the process. Principle steps in the process are a consent to
evaluation and a two-step surgical consent of the inmate (separated by at
least three weeks) and a consent signed by the next of kin (if available).
After the consent for evaluation, standard blood testing including antibody
testing for HIV, HCV, HBV would be performed in addition to the usual
organ specific blood testing. If the results of these tests are acceptable,
more invasive tests CT scans, renal scans, liver biopsy, if needed, would be
performed. If these tests are acceptable, the patient would sign the initial
surgical consent. At this point a Nucleic Acid Amplification Test (NAAT)
for HIV, HCV, HBV would be performed and the patient would be placed
in medical isolation for three weeks. During this period the patient would
be isolated from all other inmates, and would be subjected to random drug
screens. At the conclusion of the 3-week period, NAAT testing for the same
infectious agents would be obtained. If the inmate was negative for HIV, a
suitable recipient would be identified and the inmate would be scheduled
for living donor surgery. The inmate would be in medical isolation until the
time of donation.
Infectious concerns: Medical advances, specifically, NAAT testing has
enabled the window period to be small enough to allow close observation and
monitoring of the prisoner, which enables safe donation.
Ethical concerns: The paternalist protection of prisoners is to ensure that
procedures are not performed on the inmates that cannot/should not be perform
on non-inmate populations. This is a plan to allow prisoners the opportunity
to participate in opportunities provided non – incarcerated people. In terms
of informed consent, allowing prisoners the opportunity to consent for organ
transplantation has already tested this concept.
Impact: There are currently 2.2 million inmates; the incidence of HIV is 1.8
percent, decreasing the potential pool to 2.1 million. A consent rate of 1% could
provide 21,000 kidneys.
Conclusions: Advances in medical technology and the acknowledgement
that prisoners can consent to complex, but standard medical procedures have
opened up a potential pool of organ donors that could dramatically impact the
organ shortage.
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C. Wang, C. Xiao, S. Chen, L. Chen, J. Fei, S. Deng, J. Qiu, J. Li, G. Chen
Kidney Transplant Department, Organ Transplant Center, The First Affiliated
Hosp
Objective: To study the cognitive, intentional and behavioral status of living
kidney donors in comparison with general population, so as to investigate
the relevant factors affecting decision of living organ donation in general
population.
Method: Questionnaire on cognition, intention and behavior about living organ
donation was designed and the anonymous survey was done from July 2007
to February 2008 in 70 living kidney donors and 115 citizens from physical
check-up center. Mental status of living donors were assessed with SCL-90
Symptom Rating Scale simultaneously.
Results: Seventy living kidney donors (male:female=36:34) are overall
psychologically normal. Among this group 60% were less than 38 years
old, 62.86% received high school education, 88.57% were manual workers;
82.58% believed they’ve known enough about living organ donation and
transplantation; 97.14% gave a positive comment on the outcome of organ
donation; 62.86% considered their relationship to recipients were the most
important factors affecting their decision of donation while 94.28% of them
would prefer to donate to their parents or children; 64.29% were against
organ trading; 75.71% considered organ donation to be a noble action;
2.86% believed that living organ donation do more harm than good. In
the sample of general population, 36.5% refused to become living donors,
which composed of 47.72% (21/44) of female interviewers and 28.17%
(20/71) of the male interviewers. When compared to living donors, more

of those refused to donate agreed with organ trading (61.90% vs. 5.71%,
p<0.05) believed that organ donation would seriously compromise their
health (38.10% vs. 1.43%, p<0.05); and their biggest concern when
considering organ donation was the impact on their own health. In those
who were willing to become living donors, 54.05% believed it appropriate
to ask for compensation when only 14.29% of the donors agreed with
that (p<0.05). The most accepted form of compensation in all groups is
comprehensive health insurance or priority in receiving organs when they
need transplants.
Conclusion: In general population, the decision-making process on nonrewarded living organ donation is the process of balancing gains and losses.
Most living donors and those who would accept to donate their organs believed
they would get more benefit than harm, when many of those refused to consider
organ donation had an exaggerated idea about related risks. Therefore public
education and promotion activities on organ donation and transplantation shall
be able to enlarge the donor pool and thus prevent organ trading.
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1807 SUCCESSFUL SOLID ORGAN TRANSPLANTATIONS
FROM SEPTISEMIC CADAVERIC DONORS
H. Sozen1, D. Erer2, E. Singin3, N. Doðucan3, A. Dalgýc1
Gazi University General Surgery, 2Gazi University Cardiovascular Surgery,
3
Gazi University Transplantation
Systemic donor infection especially gram negative organism originated is
regarded as being an absolute contraindication to cadaver organ donation for
transplantation. This is largely due to fear of transmitting pathogenic organisms
to the immunosuppressed recipient. However, due to the current shortage of
organs available for transplantation, clinicians are faced with the option of
using organs from infected donors. Here we report successful solid organ
transplantation from blood cultures positive donors.
Material and method: Between 1996 to January 2006 totally 47 solid
organs (hearts, livers and kidneys) collected. Three out of 10 donors had
positive blood cultured microorganism. Case 1: 23 years old of female.
Cause of brain death was intracerebral bleeding due to traffic accident. The
donor had stayed 9 days prior to brain death onset. Two kidneys, 2 livers
(splited) and heart were used from this donor. Klebsiella was the organism
yield at blood culture. Case 2: 35 years old, male, cause of brain death was
cerebral hematoma due to traffic accident. The donor has been stayed 6
day prior to brain death onset. Liver and two kidneys transplantations were
performed. Acitenobacter baumanii was organism yield at the blood culture.
All donors were treated until the negative blood culture was guarantied
with appropriate antibiotics. Targocit, Neutromysine and Sulperazone were
used for at least 48 hr prior to organ procurement while recipients received
same culture-specific antibiotics 10 days following transplantation. Case
3: 5 years old boy, Intracerebral bleeding due to traffic accident was the
reason of brain death. Liver was not able to use because of%70 steatoz. Two
kidneys and hearts were used. Yeast enfection was detected by PCR of the
blood just before procurement. All recipients were received Flucanozol after
transplantation. One of donor’s (case 1) heart and all donors’ corneas were
not used due to infection.
Results: All recipients are alive with excellent graft function on median 192
days following transplantation.
In conclusion, our results suggest that bacteremic donors with severe sepsis and
septic shock under proper treatment can be considered for transplantation. In
light of the decreasing availability of organ donors and increasing waiting lists,
more studies such as ours which challenge conventional contraindications to
organ transplantation are required.
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1808 PREDICTORS OF LIVER DISEASE IN POTENTIAL
ORGAN DONORS
E. Torres1, A. Garcia-Soto2, E. Garcia-LaTorre2, L. Morales1, M. Saade1
LifeLink of Puerto Rico, 2University of Puerto Rico School of Medicine
The shortage of livers for transplantation demands the consideration of all
candidates as potential liver donors. Rejection of a liver-only donor at the
operating room because of unsuspected liver disease is costly and frustrating.
The identification of predictive factors for liver disease in a liver-only donor
may justify a pre-operative percutaneous biopsy to avoid futile recovery
efforts.
Aim: The aim of this study is to describe risk factors for liver disease in
potential donors and correlate these factors with the outcome of liver recovery:
recovered (transplanted or rejected), or not recovered.
Methods: Records of all donors considered for recovery of the liver from
2004-06 were reviewed. Risk factors were identified and correlated with
outcome of organ recovery and biopsy findings. Factors evaluated were age,
gender, weight, BMI, alcohol and illegal drug use, diabetes, history of liver
disease, AST and ALT levels.
Results: There were 255 donors, 153 male and 102 female, with a mean age
of 41.6 +/-18.5 yrs (range 10m – 81yr). Of these, 214 livers were recovered
from133 males and 81 females. Mean age of liver donors was 40 +/- 18.6
(range 10m-81y). 9/214 (4%) were rejected, 41/255 (16%) were not recovered.
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23/24 liver-only donors were transplanted. Reasons for non-transplantation
were fatty liver, anatomical damage, Chagas + test, abnormal biopsy, and
death of recipient. Reasons for non recovery were poor organ function, fatty
liver, donor quality, positive serology for hepatitis, and non placement. Age
and gender distribution were similar in liver donors and all donors. Among the
risk factors, obesity (OR 2.00, p=0.04), diabetes (OR 6.68, p<0.0001), ALT>50
(OR 2.65, p=0.002), but not alcohol (OR 0.93,p=0.8) or drug use (OR 0.76,
p=0.6), nor AST>50 (OR 0.93, p=0.83), correlated with non-transplant. Of the
36 donor livers biopsied, 22 were transplanted, 5 were rejected and 9 were not
recovered. 5/9 livers had significant fatty changes, all had BMI> 25 and one
third had diabetes.
Conclusions: Steatosis was the major cause for non-recovery. It was more
prevalent in donors with BMI> 25 and diabetics. These findings suggest that
liver-only donors with these factors should be considered for percutaneous
biopsy as part of donor evaluation.
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1809 ORGAN RECIPIENTS SUFFERING FROM
UNDIFFERENTIATED NEUROENDOCRINE SMALL-CELL
CARCINOMA OF DONOR ORIGIN
D. Foltys1, A. Hinkelmann2, A. Heumann1, I. Ruth1, M. Heise1, A. Schad1,
J. Schneider1, K. Bender1, D. Mauer3, G. Otto1
1
University Hospital Mainz, Germany, 2University Hospital Kiel, Germany,
3
DSO Region Mitte, Germany
Background: Transmission of donor-derived cancer due to organ transplantation
is rare, but the risk based on the aging donor pool has been increased.
Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor
with the tendency to spread. The origin of this tumor has clinical impact on
further decision-making therapy. In a case study, we demonstrate the case-bycase strategy regarding liver and kidney recipient.
Methods and results:
Case 1: Liver transplantation (LT) was performed in a 60-year old male
suffering from hepatocellular carcinoma. In the donor, there was no history
of malignancy. Medical examination, chest X-ray and situs at the time of
organ retrieval were inconspicuous. CT scan of the recipient 4 months after
LT demonstrated hypodense nodules in the liver. Biopsy confirmed the
diagnosis of a small-cell carcinoma of donor origin (DNA fingerprinting). ReLT was scheduled in the case of tumour restriction to the graft, but during
exploration extrahepatic tumour manifestation was discovered. We reduced
immunosuppression and started chemotherapy. Despite this treatment, the
patient died 7 months after LT.
Case 2: In a different transplantation centre a 54-year old male received a
renal graft from the same donor. When the tumour manifestation in our patient
became apparent, meticulous follow-up of the renal recipient was initiated. One
year after kidney transplantation, liver metastases were discovered. Biopsy
confirmed the diagnosis of a small-cell carcinoma which originated from the
same donor in DNA analysis. The kidney was removed, the immunosuppression
was stopped and additional chemotherapy was started. Hepatic metastases
disappeared completely.
Conclusion: In this report on two cases, we demonstrate that the strategy of
treatment after transmission of donor-derived malignancy is strongly influenced
by the transplanted organ. If the graft can be removed and if immunosuppression
may be stopped, the outcome of recipients may be favourable as the donorderived tumour is rejected. In contrast to this the outcome in a liver recipient
is dismal. Based on this, meticulous exploration during the retrieval procedure
is mandatory and even CT scan before donation may be advisable in donors
exceeding a certain age.
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1810 RADIOPAQUE CONTRAST ADMINISTRATION DURING
DECEASED DONOR EVALUATION: EFFECTS ON RENAL
TRANSPLANT OUTCOMES
A. Al-Waal, G. Li, R. Balshaw, C.Y.C. Nguan1
1
UBC Department of Urologic Sciences
Introduction and objective: Coronary angiography is an important
investigative tool in the evaluation of the deceased donor during multiorgan
procurement for transplantation. It is a definitive tool for the assessment of
atherosclerosis in the donor heart, and its use will likely only increase with
increasing limits of acceptability of cardiac donor demographics. Although
radiographic contrast agents used in angiography are relatively safe, adverse
effects such as contrast induced nephropathy (CIN) can occur following
administration. In fact, most institutions adhere to strict guidelines as to who
is an acceptable patient for contrast studies, and use renoprotective protocols
as additional prevention. Unlike in the typical patient undergoing contrast
study, the deceased donor usually generates concurrent significant additional
systemic insults kidneys (i.e. – catecholamine storm, hemodynamic instability,
etc). As such, these cumulative factors may contribute to allograft performance
following transplantation. We present our single program experience with
the use of radiocontrast agents in the evaluation of deceased donors for renal
transplantation.
Methods: A retrospective review of the British Columbia renal transplant
program was conducted comparing the clinical outcomes of 32 recipients who
were transplanted with kidneys procured from deceased donors who received
intravenous contrast administration during evaluation, and 64 matched control
recipients transplanted with contrast naïve kidneys. The study period was
between 2002 and 2006.
Results: No difference was found between the two groups in terms of frequency
of delayed graft function, slow graft function or primary nonfunction of the
transplanted allografts. Likewise, no significant difference was determined
between groups with regards to frequency of acute rejections. Allograft function
between groups determined through calculated GFR failed to demonstrate a
difference at 3, 6 and 24 months post transplantation (p = 0.38, 0.395, and 0.07
respectively), however did demonstrate a difference at 12 months (p = 0.03).
Multivariate analysis at 12 months showed a p value of (0.067).
Conclusions: Based on the results of this experience, there appears to be
minimal lasting effect of pre-implant contrast administration in the donor on
renal allograft function. It remains important to be vigilant with regards to
evaluation and treatment of the deceased donor, as numerous interacting factors
occur between the time of donor death and time of implantation of the donated
organ. The continued study of these factors and development of strategies to
minimize these detrimental effects may be crucial in extending the quality and
longevity of the transplanted organ.
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M. Fukushima1, M. Minami1, T. Nakatani2, M. Ono3,
S. Konaka4, J. Ashikari4
1
Osaka University Hospital, 2National Cardiovascular Center, 3Tokyo
University Hospital, 4Japan Organ Transplant Network
As donor shortage is extremely severe in Japan because of very strict Japanese
Organ Transplantation Law, special strategies for maximizing heart and lung
transplant (HTx and LTx) opportunities should be established. The purpose of
this study is to review our special strategies to identify and manage heart and
lung donors.
Method: Since brain dead organ transplantation was restarted in 1999,
transplant doctors themselves assessed their own donor heart and lung function
by echocardiography and bronchoscopy before starting procurement operation,
and skillful staff surgeons, not resident surgeons, harvested their organ. Since
November in 2002, a special transplant consultant doctor has been sent to donor
hospitals. He assessed donor organ function and identified which organs were
useful. He also intensively cared the donor, stabilized the donor hemodynamics
using anti-diuretic hormone (ADH) if required, and improved donor cardiac
and lung function by preventing and treating lung infection before harvest
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1812 GLOBAL EXPRESSION PROFILES IN ONE
HOUR BIOPSY SPECIMENS OF HUMAN KIDNEY
TRANSPLANTATION FROM DONORS AFTER CARDIAC
DEATH
M. Kusaka1,2, Y. Kuroyanagi1,2, T. Mori2, K. Nagaoka2, H. Sasaki1,
T. Maruyama1, K. Hayakawa1, R. Shiroki1, H. Kurahashi2,3, K. Hoshinaga1,2
1
Department of Urology, Fujita-Health University, 2Institute for
Comprehensive Medical Science and 21st Century COE program,
Development Center for Targeted and Minimally Invasive Diagnosis and
Treatment, Fujita-Health University, 3Division of Molecular Genetics, FujitaHealth University
Because of the world-wide shortage of renal grafts, kidney transplantation
(KTx) from donors after cardiac death (DCD) is an alternative way to
obtain KTx from brain-dead donors. Although the prognosis of DCD KTx
is gradually improving, the graft often undergoes delayed graft function
(DGF) rendering the control of DGF essential for post-KTx patient care. In
an attempt to characterize etiology of DGF, genome-wide gene expression
profiling was performed using renal biopsy samples performed at 1 hour after
KTx from DCD and the data was compared with those of KTx from living
donors (LD). A total of 526 genes were differentially expressed between
them. Genes involved in acute inflammation were activated, while metabolic
pathways were consistently down-regulated in DCD. These findings imply
the inferior performance of the DCD grafts relative to LD grafts. Several
genes were identified where the expression levels were correlated well with
parameters indicating short- and long-term prognosis of the DCD patients. To
identify novel biomarkers that might provide an indication of the prognosis
of the DCD recipients, the expression levels of each gene was correlated
with the parameters that reflect prognosis of the patients. The length of
dialysis post DCD KTx was used as a parameter indicating short-term
prognosis. When the expression levels of the 526 genes were examined for
any correlation with the length of dialysis post KTx, two genes, FTHL17
and GLA were found to be significant (p<0.05). On the other hand, for a
long-term prognosis, the lowest serum creatinine levels during 1 year post
KTx were used. The expression levels of two genes, GJA12 and PSMB10
were found to be correlated with the serum creatinine values (p<0.05). In
addition, several genes encoding secretory proteins were identified that might
reflect the performance of the graft and be potential non-invasive biomarkers.
The identified genes included REG1A, TIMP1, SLPI and LTF, which are
not known to be associated with renal transplantation graft failures. The
validation of the microarray experiments was performed by real-time PCR.
All four genes were up-regulated significantly in the DCD group relative to
the LD group (p<0.05). These data provide a good source for candidates of
biomarkers that are potentially useful for the control of DGF.
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1811 STRATEGIES FOR MAXIMIZING HEART AND LUNG
TRANSPLANT OPPORTUNITIES IN JAPAN

teams arrived at the donor hospital.
Results: Only 63 brain-dead donors have been available in Japan. However,
50 HTx (79.3%) and 40 LTx (21 bilateral and 19 single) from 37 donors
(58.7%) have been performed. Out of 50 HTx, 24 donors were marginal. 26
donors were treated with high-dose catecholamine. Left ventricular ejection
fraction of 5 donors was less than 50%. 15 had a history of cardiopulmonary
resuscitation. 5 were older than 55 years. Out of 40 lung donors, 19 donors
had infectious sputa or showed pneumonia by chest-X-ray. None of 50 HTx
died of primary graft function (PGF). Patient survival at 1 and 3 years after
HTx were 97.6 and 97.6%, respectively. Although 5 of 40 LTx died early after
Tx, two died of PGF. Patient survival at 1 and 3 years after LTx were 76.9 and
68.2%, respectively.
Conclusion: Although the number of Tx was still very small, the availability
of heart and lung has been very high and the outcomes of HTx/LTx were
acceptable. These strategies may be useful to maximizing HTx/LTx
opportunities.
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1813 MOTTEP: SAVING LIVES AND TAXPAYERS DOLLARS!!
C. Callender
Howard University
The MOTTEP program provides organs which saves lives and over time decreases
health care expenditures on dialysis by 236 million dollars for kidneys alone.
Since 1982 we have participated in the growth and development of a national
donor education program which relies on a grass roots strategy that emphasizes
community education and empowerment requiring the community to be an
efficient and economically appropriate change agent.
Methodology: The data presented provide compelling evidence of the
efficiency of a community-based grass roots approach.
Table 1: The Scientific Transplant Registry Data demonstrate MOTTEP sites
had statistically significantly improved donation rates when compared to
regions in which there were no MOTTEP sites!
Ethnicity
White, Non Hispanic
White, Hispanic
Black
Other

MOTTEP
Donation Rate
59.3
106.9
43.4
50.7

Donors
4,928
1,055
1,263
228

NON-MOTTEP
Donation Rate
59.2
47.4
32.9
42.4

Donors
11,279
886
1,286
272

%value
p-value
0.02
<.01
<.01
<.01

Table 2: (UNOS Data)
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Ethnicity
Black
Hispanic/Latino
Asian
Minority Donor Total

Number of Donors
1990
2000
659
1373
518
1319
73
278

Donors/Million
1990
2000
22.4
40.8
22.9
40.2
10.3
26.2

Donation%
2000
2005
11.2%
14%
11.2%
13.2%
2.7%
2.6%
25.1%
30% (29.8%)

Dialysis costs are in excess of $40,000.00/yr per patient much of which are
taxpayers dollars, and transplants which break even after 3 years would provide
an average savings of at least $30,000.00/yr for each year the organs survives
over 3 years. Since 50% of all kidney transplants survive from 5.3 African
Americans (A.A.) to 12.2 (Asian) years, and most more than 9 years, it is
clear that the financial benefit to the government supporting a national donor
education program such as this would save millions of dollars. Assuming an
organ survival rate of 6 years, each donor (living or deceased) organ would
save at least $135,000.00 per donor (1.5 x $30,000.00 x 3 years).
These data are based upon the current census that identifies 25% of the
American population as minorities. The MOTTEP goal is by 2010 to have 35%
of the donors being minorities and to have A.A. and Latino O.D.M. to increase
from 41 O.D. M. to 50 O.D.M. This would allow for the recovery of 1750
minority donor organs and save the Government 236 million dollars.
While MOTTEP has received a total of $16 million dollars from the Federal
Government between 1992 and 2008, none of these dollars have been allocated
for organ donation after 2007. This would mean this unique program which
has made a national contribution to the donor shortage would cease to exist
after midyear 2008. Currently MOTTEP exists in 11 sites; only 5 of which
are partially funded. To optimize this unique community grass roots education
program, funding for 15-25 sites would require 3-5 million dollars a year for an
additional 5 years. A small amount when compared to the 236 million (kidney)
dollars saved from kidney transplants alone and are more than 1 billion dollars
saved when kidney, liver, hearts, and other organs are combined.
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1814 WORKING THROUGH THE DONATION AFTER
CARDIAC DEATH (DCD) PROCESS OR HOW DID WE GET
HERE?
S. Potdar1, L. Fields1, B. Spear, L. Racher, J. Wilson, B. Martin, R. Klaric2
1
Summa Health System, 2Lifebanc OPO
The organ donation process can be complicated, controversial, and politically
charged, especially in situations involving Donation after Cardiac Death
(DCD). Brain death is relatively straightforward for donor hospitals as long as
there is a working definition that is clinically practical. The process of organ
donation is further complicated by the number of staff involved including
hospital physicians, nurses, respiratory, clergy, as well as Organ Procurement
Organizations (OPO), multiple organ receiving hospitals and their recipients
and operating room times. A 925 bed Level 1 Trauma Center in Ohio decided
to reorganize the process into workable sections that would improve the
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infrastructure between the hospital and the OPO. The goal of reorganization
was to develop internal standards of practice and communication that would
result in a smoother organ donation process, improved outcomes and increased
organs donated. The process involved enhancing communication with the
OPO; developing guidelines/roles and then educating all team members;
increasing involvement of Intensivists in the entire donation process;
developing a reference manual; revising policies and procedures in the critical
care areas as well as surgical services; and using a debriefing model for process
improvement. The tool developed to accomplish all of the above is an on-line
and printed manual that contains hospital and OPO emergency numbers, order
sets, policies and procedures, roles and articles. As a result, the hospital and
the OPO enhanced their partnership and allowed the hospital to maintain their
standing as a leading donor hospital and HRSA Medal of Honor recipient.

POSTER BOARD NUMBER P3 – 241
1815 10-YEAR RESULTS OF THE TRANSATLANTIC KIDNEY
TRANSPLANT AIRLIFT BETWEEN THE NETHERLANDS
ANTILLES AND THE NETHERLANDS
R. Minnee1, N. Ajubi2, R. Kock3, M. Idu1, D. Legemate1,
K. Donselaar van der Pant4, I. ten Berge4, F. Bemelman4
1
Dept. of Surgery, Academic Medical Center, 2Dept. of Haemodialysis,
St. Elisabeth Hospital, Curaçao, the Netherlands Antilles, 3Dept. of
Haemodialysis Horacio E. Oduber Hospital, Aruba, the Netherlands Antilles,
4
Dept. of Nephrology, Academic Medical Center
Aim: The prevalence of end-stage renal failure in Curaçao (Caribbean) is
one of the highest in the world. In 1998, the St. Elisabeth Hospital started
collaboration with the Academic Medical Center (AMC) in Amsterdam, the
Netherlands, and the Eurotransplant Foundation, aimed to achieve a structured
transplantation programme for patients in the Netherlands Antilles. It resulted
in an airlift between Curaçao and the AMC. The distance between both places is
8000 km, with a travelling time of approximately nine hours. Here, we present
the 10-year results of this transatlantic transplantation programme.
Methods: We retrospectively analysed 41 consecutive transplantations
performed between January 1998 and April 2007. All donor kidneys were
machine-preserved. Immunosuppressive therapy consisted of prednisone, a
calcineurin inhibitor and mycophenolate mofetil. From 2003, basiliximab was
added as induction therapy. One year graft survival and complication rates
were the primary endpoints. In addition cold ischemia time and acute rejection
episodes up to six months after transplantation were recorded.
Results: 24 Males and 17 females were transplanted with a median age of
54 years. 36 Patients were managed with haemodialysis and 5 patients were
on peritoneal dialysis. The median dialysis period prior to transplantation was
6.8 years (range 1 – 20). The median body mass index was 29 kg/m2 (range
19 - 47). 38 Patients underwent a first kidney transplantation. Panel-reactive
antibody (PRA) level was 0% in 29 (71%) patients, 1% to 10% in 7 (17%)
patients, 11% to 25% in 2 (5%) patients, and greater than 25% in 3 (7%)
patients. In 7% (n = 3) of the transplantations no mismatches was involved
between the donor and recipient. 1 or 2 HLA mismatches was presented in 9
(22%) patients, 3 or 4 HLA mismatches was presented in 20 (49%) patients and
5 or 6 HLA mismatches was presented in 9 (22%) patients. 29 Patients (71%)
received a graft mismatched for 1 HLA-DR allele.
Median cold ischemia time was 33 hours (range 16 – 52 hours), median
operating time 150 minutes (range 102 – 257). Initial graft function occurred
in 28 patients (68%); primary non function occurred in 4 patients (10%) and
delayed graft function developed in 9 patients (22%). Acute rejection was
diagnosed in 11 patients; in 5 of them superponed on delayed graft function.
Eight grafts were lost within 3 months, due to therapy resistant rejection (3),
sepsis (3) or thrombosis (2). The one-year graft survival rate was 69% (95%
confidence interval (CI): 52% to 80%). All patients returned to the Netherlands
Antilles within 3 months.
Conclusion: Our transatlantic kidney transplant programme is a good
alternative for the majority of patients with end-stage renal failure in the
Netherlands Antilles. As compared to our centre one year graft survival of
93%, this transatlantic graft survival rate was rather low. This may be due both
to the long cold ischemia time and to the characteristics of the transplanted
population: i.e. high lean body mass, negroid, high cardiovascular risk profile,
which are all factors known to negatively influence the outcome of renal
transplantation.
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1816 TELEHEALTH: ENGAGING NEW SOUTH WALES
REGIONAL HOSPITALS IN DONATION

1818 A TEN YEAR RETROSPECTIVE ANALYSIS OF
DONATION AFTER CARDIAC DEATH IN NSW

M. Sgorbini
Royal Prince Alfred Hospital
Telehealth is the transmission of images, voice and data between two
or more health units delivered by digital telecommunications to provide
clinical consultations, case management, in-service training, education
and administrative services. Connecting Critical Care is a research project
by New South Wales Health looking at the use of Telehealth in Intensive
Care and Emergency Departments. It is a multi-site project involving rural,
regional and metropolitan hospitals along with the Medical Retrieval Unit.
In April 2007, Telehealth was utilised by a regional hospital to consult with
an Intensivist from Royal Prince Alfred with regards to a potential organ
donor. Telehealth, in this particular case, was used to deliver advice regarding
brain death examination and the process for obtaining consent to a regional
hospital that has very limited experience in organ donation. A review and
evaluation of the consultation was conducted by the Intensivists involved and
the Donor Coordinator and the potentials for Telehealth in organ donation
were explored. The review found that Telehealth provide the opportunity
to enhance the communication between rural and metropolitan hospitals
by providing assistance and advice to rural clinicians. The effective use of
Telehealth in organ donation will enhance early referral to LifeGift nsw/act,
provide outreach support to rural/regional hospitals and offer educational
support for medical and nursing staff. The aim of the presentation is to
describe Telehealth through a short powerpoint presentation and demonstrate
the consultation between Orange and RPA hospitals in a re-enactment
recorded on DVD.

C. Alvaro, L. McKay, D. Bhonagiri, N. Seifert
LifeGift nsw/act - Australian Red Cross Blood Service
Introduction: Donation after Cardiac Death or Non- Heart Beating Organ
Donation was the only cadaveric solid organ donation pathway in the 1960s
before widespread acceptance of the criteria to declare death using loss of
all brain function. Resurgence in DCD in the late 1990’s and early 2000’s in
Europe and USA was closely monitored in Australia and low levels of DCD
donors were reported since 1997. The “Organ Donation After Cardiac Death
NSW Guidelines” in 2007 recognised the need for a state-wide policy on DCD
in an era of increasing disparity between the numbers of organs available for
transplantation and prolonged waiting times for transplant recipients.
Purpose: This review presents the profile of DCD donors in NSW from 1997
to 2007 and the outcomes of the recipients and transplanted organs from those
donors. The outcomes are compared to non- DCD (donors declared dead by
brain stem criteria and living related donors).
Method: Donor records at LifeGift nsw/act were reviewed and de-identified.
Demographic data, cause of death, time interval between extubation and
death, organs retrieved and organs transplanted were recorded into a Microsoft
Excel® database. Recipient outcome data held in databases by Transplant
Coordinators in transplanting hospitals were queried and the outcomes of
organs and recipients were obtained. No recipients were identified during the
process and all data was transferred using secure servers. Age and outcomes
data were analysed and presented as mean and median with relevant ranges
quoted.
Results: Analysis of the donor profile revealed that the donor demographics
from DCD donors closely resembled the demographics from Donation after
Brain Death (DBD) donors. All DCD donations occurred within metropolitan
Sydney however Westmead hospital {which was the only NSW hospital to
develop and implement a local DCD policy in the early 1990’s}, far exceeded
other hospitals. CVA and traumatic head injury continues to be the leading
cause of death in both groups of patients however DCD donors are on average
aged less than that of brain-dead donors. Early reports indicate that the long
term kidney function and patient survival rates are not significantly different
between DCD and DBD.
Conclusion: Long term graft function and recipient outcome is not significantly
different in our cohort of patients. DCD is associated with acceptable outcomes
for kidney transplantation in NSW. Outcomes for recipients of liver, lung and
pancreas transplantation in multi-organ DCD will need to be reviewed and
reported.
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1817 VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN
(VCP) IMPROVES KIDNEY STRUCTURE AND FUNCTION
FOLLOWING ISCHEMIA/REPERFUSION INJURY IN RATS

POSTER BOARD NUMBER P3 – 245
1819 THE AVAILABILITY OF 99MTC-MAG3 RENOGRAPHY
IN RENAL TRANSPLANTATION FROM NON HEART BEATING
DONORS
T. Majima, R. Hattori, S. Yamada, M. Katou, O. Kamihira, O. Matuura,
T. Kinukawa, M. Gotou
Department of Urology, Faculty of Medicine, Nagoya University
Purpose: Seventy percent of patients who undergo renal transplantation from
non heart beating donors (NHBD) develop acute tubular necrosis (ATN) and
require dialysis for about 2 weeks. For the evaluation of graft function during the
ATN period, we performed 99mTc-MAG3 renography regularly as soon after
transplantation as possible. We estimated whether 99mTc-MAG3 renography
can monitor the recovery of graft function during the anuria period.
Patients: Fifteen patients underwent renal transplantation from NHBD from
2 June 2005 to 24 May 2007. One patient was excluded from the study due to
acute rejection which developed during the dialysis period. The median ages
of the recipient and the donor were 49 (range 8¦ ]72) and 52 (range 15¦ |68)
years old, respectively. The medians of WIT and TIT were 6.5 (range 2¦ |57)
and 847 minutes (range 91¦ |1835), respectively. The median dialysis period
after transplantation was 8 days (range 0¦ |16).
Methods: The first 99mTc-MAG3 renography after operation was performed
as early as possible¦ @(within 4 days) and repeated weekly thereafter until the
recipient was weaned from dialysis. We adopted RUNQ method to quantify
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D. Kahn, Y.T. Ghebremariam, G. Engelbrecht, M. Tyler, Z. Lotz,
D. Govender, G. Kotwal
University of Cape Town/Groote Schuur Hospital
Renal transplantation is performed in most major centres throughout the world.
During the transplant procedure there is an ischemia reperfusion (I/R) injury
that accounts for a delayed physiological recovery of the graft. This surgically
and biologically induced injury often results in activation of the complement
system. The vaccinia virus complement control protein (VCP) regulates
both the classical and the alternative pathways of complement activation
by preventing the formation of C3b, a complement component where both
pathways converge.
The aim of the study was to investigate the effect of VCP on the I/R injury
in the kidney. Long Evans rats were subjected to laparotomy, mobilization of
both kidneys and clamping of the renal arteries for 60 min followed by 24 h
reperfusion time. The rats were randomly allocated to receive natural VCP,
humanized recombinant VCP (hrVCP) or phosphate buffered-saline (PBS)
or sham group. Blood samples were collected at various intervals for urea
and creatinine studies, and the kidneys removed for histopathological and
immunohistochemical studies.
The biochemical studies showed that the PBS group displayed 2.7-fold and
10-fold increases in the serum urea and creatinine concentrations respectively
compared to the VCP/hrVCP groups. The renal histopathological study
revealed focal necrosis of the tubular epithelial cells in the VCP/hrVCP treated
rats compared to the diffuse and markedly elevated field scores in the PBS
controls. The immunohistochemical study showed significant C3 deposition
in the renal tubules of the PBS controls compared to the VCP/hrVCP treated
groups suggesting that VCP/hrVCP has reduced ischemia/reperfusion-induced
renal injury by inhibiting the biosynthesis of C3.
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MAG3, and calculated the corrected Tubular Extraction Rate (cTER) (ml/
min/1.73m2), that is MAG3 clearance corrected by body surface area.
Results: Corrected TER (cTER) was low (mean 53 ml/min/1.73m2)
immediately after transplantation, but increased gradually until 2-3 weeks after
the operation, and then plateaued. Likewise, the change in the cTER based on
the day of weaning showed an upward tendency during the dialysis dependent
period, and plateaued 5-10 days after weaning.
By analyzing the relation between the early cTER and the dialysis dependent
period, a significant correlation between these two parameters was found
(R=-0,780, p=0.001). The following regression formula was obtained:
y=0.269x+22.024 R2¦ ¦ 0.609¦ @p=0.001.
There was no significant relationship between the early cTER and best cCCr,
donors¦ f age, WIT, and TIT.
Conclusion: Recovery of graft function can be monitored by routinely
performing 99mTc-MAG3 renography on transplanted grafts from NHBD
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1820 LEARNING TO BE AN ORGAN DONOR – AN ORAL
HISTORY APPROACH TO UNDERSTANDING HOW PEOPLE
FROM THREE ETHNIC BACKGROUNDS BECAME POSITIVE
ABOUT ORGAN DONATION
G. Smith1, A. Warrens1, S. Saxena1, J. Car1, H. Dulku2, P. Reece2, N. Jain3
1
Imperial College London, 2Hammersmith Hospital NHS Trust,
3
Kidney Research UK
Aim: To understand how people from a white British/Irish, African Caribbean
and South Asian/Indo-Asian ethnic background successfully integrated the
idea of organ donation into their lives and ethnic identity.
Objective: To increase donation rates overall and particularly from ethnic
minorities.
Design: A United Kingdom based qualitative study using in-depth oral history
style interviews with 56 participants (18+) from diverse social, religious and
economic backgrounds.
Analysis: The interviews were transcribed, the data coded and emerging
themes discussed to reach a consensus on interpretation.
Results: The ability to achieve a positive view of organ donation is hindered or
encouraged by an interplay of family background, cultural and religious values,
feelings about death, personal relationships, age, personality, and experiences
of donation and identity over time. These dynamic relationships are influenced
by their historical and social contexts.
The white British/Irish saw organ donation and death in practical or secular
terms, and some older participants recalled the media coverage of the
development of organ donation as a cultural and social advancement that
connected with their growing sense of ethnic identity.
Developing a positive view of organ donation was more complex for the
two ethnic minorities. The idea of organ donation generated stronger and
more emotional conflicts concerning individual and social identities that
were often already in a state of tension. Many participants overcame these
issues by: emphasising religious values over religious rituals; discussing
and thinking about organ donation over time; rationally separating out good
publicity from bad publicity about organ donation; believing in religious
fate; thinking of themselves or family as potential organ recipients in the
future; real life exposure to the benefits of organ donation; seeing organ
donation as another struggle against “oppression.” Some participants from
an African Caribbean ethnic background hinted that they would like to see
a positive shift in opinion about organ donation from people of the same
ethnic background before fully embracing the idea of organ donation. The
experience and perception of racism was cited by some participants from
an African Caribbean ethnic background as tempering and changing their
positive attitude towards organ donation.
Despite being positive about organ donation many people failed to register this
view or sign an organ donor card.
Conclusion: Future campaigns should be grounded in peoples’ realities and
identity politics to reflect more openly the tensions that people face when
deciding to be an organ donor. The public can then learn how others have
negotiated and overcome those tensions. Unfortunately, previous campaigns
that have highlighted the lack of donors from ethnic minorities may have
reinforced the idea that organ donation goes against cultural “norms.” Some
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peoples’ positive views towards organ donation can become negative over
time and so campaigns must strive to sustain an ongoing presence in our
social environment. Developing new strategies to motivate and support people
to embrace and maintain a positive view of organ donation alongside more
conventional educational programmes is crucial.

POSTER BOARD NUMBER P3 – 247
1821 VARIOUS RECONSTRUCTIONS OF PANCREAS
VASCULATURE PRIOR TO TRANSPLANTATION
Z. Galazka, T. Jakimowicz, T. Grochowiecki, S. Nazarewski, K. Grygiel,
J. Szmidt
Department of General, Vascular And Transplant Surgery, Medical University
of Warsaw, Poland
Approximately 40% of all organ procurements in Poland are from multiorgan
harvesting (MOH). Pancreas and liver have joint arterial supply from celiac
trunk which requires vessel division during simultaneous pancreas and liver
procurement for transplantation. For the same reason reconstruction of the
pancreas vasculature must be done to achieve usefulness of both organs.
The aim of the study was to assess various methods of vascular reconstructions
used to prepare the pancreas for transplantation.
Between January 1999 and February 2008, 75 whole pancreas transplantations
were performed in our Department. Of this number, 66 pancreases came from
MOH and necessitated arterial reconstruction. The splenic artery (SA) and
superior mesenteric artery (SMA) were sewn into a single trunk using the
common iliac arterial bifurcation in 62/66 (94%) cases. Occasionally, the iliac
Y-graft was unsuitable for vascular reconstruction due to atherosclerosis or
iatrogenic injury. In 2/66 (3%) cases the SA was anastomosed to the side of
the SMA. In another 2/66 (3%) cases the brachiocephalic trunk bifurcation was
utilized. Portal vein elongation was done using a donor procured external iliac
vein in all 55/66 (83%) cases.
In all 66 transplanted pancreases good blood perfusion was achieved
intraoperatively. In the early follow-up period, 6 venous and 5 arterial
thrombosis were noted in first postoperative month. All 11 (17%) organs were
removed. In one case unsuccessful trombectomy was performed followed by
graftectomy in the subsequent day. In remaining cases 2-86 months followup reviled no vascular complications. Vessels patency was proven by either
Doppler ultrasound or spiral angio-CT scan.
Reconstruction of the pancreas vasculature does not affect the long-term
function of the allograft while significantly increases the available donor organ
pool.
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1822 MULTI-ORGAN DONATION AFTER CARDIAC DEATH
– AUSTRALIAN PERSPECTIVE
C. Russell1, J. Chen2, G. O’Callaghan2, G. Snell3, C. Hannan4
The Queen Elizabeth Hospital, Adelaide, 2Flinders Medical Centre, Adelaide,
3
The Alfred Hospital, Melbourne, 4South Australian Organ Donation Agency,
Adelaide
Donation after cardiac death (DCD) donors have greatly increased the rate of
kidney transplantation in various parts of the world. Both Maastricht category
II and III donors have been utilised, depending on the country involved. An
initial reluctance to use organs other than kidney was due to the increased
risk because of a longer warm ischaemic time. More recently however, liver
and pancreas have been used and lungs from DCD donors can now also be
transplanted. Currently, this is only really a viable option in Australia with
Maastricht category III donors, due to the amount of organisation and critical
timing involved.
We describe here a method of multi-organ retrieval in donors after cardiac
death, which enabled rapid retrieval and viable organs. In all cases a meeting
was undertaken with all teams, including retrieval surgeons from each
team, ICU and theatre staff and donor co-ordinators, such that everyone
was aware of the process. Withdrawal of life-sustaining treatment was
undertaken in theatre, or in ICU followed by rapid removal to the operating
theatre, with a mandatory 5 minute stand off period. The movement to
theatre took place within this 5 minute period. Rapid laparotomy and
simultaneous thoracotomy were performed with cannulation of the distal
1
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aorta and pulmonary artery. The thoracic aorta was clamped in the chest to
prevent mixing of the two solutions. Venting was via the right atrium and
inferior vena cava. Ice was packed around the organs and some dissection
undertaken whilst perfusion was ongoing, which would normally have been
done pre perfusion.
Two retrievals have occurred in South Australia where lungs, liver and
kidneys were taken. Of these two cases where multi-organ retrieval occurred,
all organs were transplanted. The kidney recipients had some initial delayed
function, but good function was achieved with all organs. During this period,
two other donors were considered for DCD. Unfortunately, neither proceeded
to cardiac death in the allowable time frame of 90 minutes.
There are a number of scoring options available, to help predict the progression
to cardiac death within 90 minutes. A more accurate method of assessing the
likelihood of cardiac death before 90 minutes would be useful. A pre-prepared
protocol can also help with the organisation of this procedure.
The increased utilisation of donation after cardiac death donors could lead
to increased rates of transplantation of organs other than kidney. In order to
increase the use of DCD’s there needs to be more acceptance of the process,
both by the public and also by intensive care staff.

POSTER BOARD NUMBER P3 – 249
1823 CAVAL APPROACH FOR THE SEPARATION OF THE
ARTERIS IN MULTI-ORAGAN PROCUREMENT

1824 SERUM TISSUE INHIBITOR OF
METALLOPROTEINASES 1 (TIMP-1) AS A PREDICTOR OF
ORGAN RECOVERY FROM DELAYED GRAFT FUNCTION
AFTER KIDNEY TRANSPLANTATION FROM DONORS AFTER
CARDIAC DEATH
M. Kusaka1,2, Y. Kuroyanagi1, M. Ichino1,2, H. Sasaki, T. Maruyama1,
K. Hayakawa1, R. Shiroki1, A. Sugitani4, H. Kurahashi2,3, K. Hoshinaga1,2
1
Department of Urology, Fujita-Health University School of Medicine,
2
Institute for Comprehensive Medical Science and 21st Century COE
program, Development Center for Targeted and Minimally Invasive Diagnosis
and Treatment, Fujita Health University School of Medicine, 3Division
of Molecular Genetics, Fujita Health University School of Medicine,
4
Department of Organ Transplantation and Regenerative Medicine, FujitaHealth University School of Medicine
Because of a world-wide shortage of renal grafts, kidneys procured from donors
after cardiac death (DCD) have recently become an important source of renal
transplants. However, DCD kidneys often have complications with delayed
graft function (DGF) and recipients require hemodialysis (HD) in the early
period after kidney transplantation (KTx). From our previous gene expression
profiling using renal biopsy samples performed at 1 hour after KTx from DCD,
several genes encoding secretory proteins were identified that might reflect
the performance of the graft and be potential non-invasive biomarkers. The
identified genes included tissue inhibitor of metalloproteinases 1 (TIMP1),
which is not known to be associated with renal transplantation graft failures.
This study evaluated serum TIMP-1 as a potential specific parameter to predict
early functional recovery of transplanted DCD kidneys. The average serum
TIMP-1 level in normal samples was 190 ng/ml, while that in patients with
chronic renal failure requiring HD was almost the same level (241 ¦ } 8 ng/
ml (n=38)). In patients undergoing a living-related KTx from a living donor
(n=26), serum TIMP-1 level had no increase after KTx (POD1: 226 ¦ } 12,
POD2: 211 ¦ } 12 and POD3: 191 ¦ } 10 ng/ml), and only in one case, with
serum NGAL levels over 360 ng/ml on POD1, was HD required due to DGF. In
contrast, patients undergoing a KTx from a DCD (n=12), ten patients required
HD due to DGF. Even in these cases required HD due to DGF, serum TIMP-1
levels increase rapidly after a KTx (POD1: 435 ¦ } 32, POD2: 412 ¦ } 42 and
POD3: 293 ¦ } 26 ng/ml), and in two cases, with serum TIMP-1 levels under
370 ng/ml on both POD1 and POD2, was immediate function. These data
suggest that monitoring of serum TIMP-1 levels on POD 1 and 2 may allow us
to predict graft recovery and the need for HD after a KTx from a DCD.
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1825 SPLIT LIVER TRANSPLANTATION FROM A DONOR
SUPPORTED BY A BERLIN HEART
M. Misra1, L. Krawczuk1, R. Jenkins2, B. Linden1, C. Weldon1, H.B. Kim1
Children’s Hospital Boston, 2Lahey Clinic
Introduction: Patients on cardiac assist devices are often considered to
be high-risk solid organ donors. Factors that contribute to this perception
include the need for anticoagulation, the potential for embolic disease, and the
possibility of organ injury due to cardiogenic shock. We report a reduced size
liver transplant performed using the left lateral segment of a 4-year old donor
whose cardiac function was supported by a Berlin Heart.
Methods: This study was conducted by retrospective review of both donor and
recipient medical records.
Patient: The donor was a 4 year-old, 16 kg girl that initially presented for
elective repair of an atrioventricular septal defect. She developed postoperative low cardiac output syndrome and decreased left ventricular function.
She was transferred to a tertiary medical center where she first required a left
ventricular assist device to support cardiac function and then had a Berlin heart
placed as a bridge to her own transplant. Her condition continued to deteriorate,
and she eventually developed bilateral infarcts of her anterior and posterior
cerebral circulation, suggestive of an embolic pattern. She was declared brain
dead 17 days after her transfer. Her family made her an organ donor. Her
liver transaminases were marginally elevated at the time of brain death. The
recipient was a 22 day-old, 3.3 kg boy who presented in liver failure shortly
after birth secondary to neonatal hemochromatosis. He was listed Status 1A for
a liver transplant after medical treatment failed to slow the progression of his

1
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S. Nishida1, H. Haider1, J. Kadono2, J. Moon1, E. Island1, G. Selvaggi1,
D. Levi1, S. Ganz1, A. Tzakis1
1
University of Miami, Miami Transplant Institute, 2Kagoshima University,
Second Department of Surgery
Purpose: The crucial step during multi-organ procurement is excision of the
arteries including the superior mesenteric artery (SMA), renal arteries, celiac
trunk, and any aberrant hepatic arteries. We present a caval approach technique
in which arterial dissection is performed after dividing the inferior vena cava,
with the goal of secure exposure and separation of each artery.
Method: In the period between December 1994 and October 2006, multiorgan procurements were performed using the previously described technique
of multiple organ procurements with University of Wisconsin solution in our
program.
After dividing the inferior vena cava, the left renal vein is mobilized to the foot.
This transection of the cava permits wide exposure of the abdominal aorta at
the root of mesentery. The abdominal aorta, SMA, and the right renal artery
are exposed thereafter. This secure exposure permits comfortable separation of
SMA and renal arteries on the abdominal aorta.
Results: From July 2005 to October 2006, 23 donors including 5 pediatric and
18 adult donors underwent organ recovery using a caval approach technique.
Recovered graft types consisted of the following: 67 grafts including 35 kidney
grafts, 19 liver grafts, 8 pancreas grafts, 4 multivisceral grafts (liver, stomach,
pancreas and intestine) and 1 modified multivisceral grafts(stomach, pancreas
and intestine). Of these donors, the aberrant renal artery was visualized in 2
donors and the right replaced hepatic artery was visualized in 3 donors. All
the excision of the abdominal aorta was successfully performed with enough
margins of each artery using a caval approach technique and all the transplanted
organs functioned well.
Conclusions: A new approach to a safer and easier dissection and excision
of the abdominal aorta for an organ recovery is attempted. We believe this
caval approach presents several advantages: 1) it gives a wide exposure
of the abdominal aorta at the level of the root of the mesentery and renal
arteries, 2) this secure exposure facilitates the separation of SMA and renal
arteries on the abdominal aorta, 3) anatomical variations of the inferior
vena cava and renal veins are low in incidence and dissection of this
area is technically straight forward, and 4) it is especially useful in small
pediatric donors.
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liver failure.
Procurement and transplant: Procurement proceeded as usual with
cannulation of the abdominal aorta and portal vein. Due to the presence of
the Berlin Heart drive lines, full anticoagulation and a high CVP secondary to
right heart failure, minimal dissection was performed prior to cross clamp. The
donor liver was procured as a whole organ and reduced on the back table. There
was no suitable recipient for the right tri-segment graft but the segment2,3 graft
was of the appropriate size for our recipient. Interestingly, the kidneys were
found to have multiple infarcted areas, but the liver appeared normal.
The transplant was complicated by mild delayed graft function, which required
delayed biliary reconstruction and abdominal wall closure, as well as a bile
leak. However, the graft function improved quickly over the first week and
the patient was discharged home with normal liver function 8 weeks after
transplant.
Conclusions: The presence of a cardiac assist device should not be considered
an absolute contraindication for abdominal organ donation. Normal organ
procurement procedures may require alteration due to the unusual technical
obstacles that are encountered when the donor has a cardiac assist device.
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1826 CALORIE RESTRICTION AND FASTING PROTECT
AGAINST ACUTE OXIDATIVE DAMAGE INDUCED BY
ISCHEMIC INJURY IN MICE
M. Verweij1, J.R. Mitchell2, H.P. Roest1, S. van den Engel1,
J.H.J. Hoeijmakers2, J.N.M.I. Jzermans1, R.W.F. de Bruin1
1
Erasmus Medical Centre, Departments of Surgery and 2Cell Biology and
Genetics, Rotterdam, The Netherlands
Introduction: The primary mediators of renal ischemia reperfusion (I/R)
injury are reactive oxygen species (ROS), which cause oxidative damage to
lipid membranes, DNA and proteins.
The only known non-invasive intervention that extends lifespan is calorie
restriction (CR). CR is thought to prolong lifespan in part by reducing oxidative
damage in the body, which is thought of as the most important reason why we
age. CR reduces the production of ROS in the mitochondria, and upregulates
antioxidant defence systems.
Aim: To investigate if CR protects against renal I/R injury in mice.
Materials and methods: Male C57BL/6 mice were subjected to either 30%
CR for 2 or 4 weeks, 24-72 hours of fasting, or were fed ad libitum. Renal
ischemia was induced by clamping the left renal pedicle for 37 minutes
followed by contralateral nephrectomy. Survival, kidney function, histology
and inflammatory markers were assessed. Partial (70%) liver ischemia was
induced by clamping the portal triad for 75 minutes. Liver injury was assessed
by histology and serum ALAT levels.
Results: In the ad libitum fed group, 70% of the animals died within 2-4 days
due to acute renal failure, whereas all animals in the four and two weeks 30%
CR group survived. Renal function was significantly better in CR animals on
days 1, 2, and 7 than in the surviving ad libitum fed mice.
Following these striking results, we investigated whether fasting was also
able to protect against renal I/R injury. Already 24 hours of fasting was
significantly beneficial for survival (90% vs. 30%), with a maximal survival
benefit reached by 48 hours (100%). Kidney function was best in the 72 hours
fasted group. Three day fasted animals showed significantly less acute tubular
necrosis 24 hours after reperfusion. Renal mRNA levels for IL-6 and p-selectin
were significantly reduced at 6 hours post-reperfusion in 30% CR and fasted
animals.
We next investigated if these benefits were organ specific, by inducing
hepatic I/R injury. Mice fasted for 48-72 hours were significantly protected
from hepatic injury as shown by significantly lower ALAT levels and less
hemorrhagic necrosis.
Conclusions: Two or four weeks of CR protects C57BL/6 mice against a
potentially lethal ischemic insult to the kidney. Similar beneficial effects were
seen after 24-72 hours of water-only fasting. Benefits of fasting were protective
against liver ischemia as well. These results suggest that the mechanisms
involved in extended longevity by dietary restriction may also be tapped for
short-term benefits such as protection against ischemia reperfusion injury.
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1827 CHARACTERIZATION OF LIPID TRANSFER/
METABOLIC PROTEINS IN A RAT NON-ALCOHOLIC
STEATOHEPATITIS MODEL
Y.F. Cheng1, T. Nakano1, C.Y. Lai1, L.W. Hsu1, J.L. Wong1, Y.C. Chung1,
T.L. Huang1, H.L. Eng1, S. Goto1,2, C.L. Chen1
1
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center, 2Iwao Hospital
Aims: Non-alcoholic steatohepatitis (NASH) is becoming a big problem for
both donors and recipients in living related liver transplantation. However,
there is no unified standard for diagnosis and therapeutics of NASH. This study
aimed to establish a noninvasive approach for diagnosis of NASH in rats.
Methods: After 1-week acclimation period on a standard diet, LEW rats (male,
5 weeks of age) were switched to a choline deficient and iron supplemented
L-amino acid defined (CDAA) diet for 1-12 weeks to produce livers with
different degrees of steatosis (NASH). For histological examination, sections
of liver tissue were stained with hematoxylin and eosin (HE). Western and
real-time PCR analyses were performed to detect the apolipoprotein E (apo-E),
adiponectin and its receptors.
Results: The livers of CDAA diet group indicated a serious fatty liver (40-60%)
at 2 weeks, hepatitis (NASH) at 6 weeks and fibrosis at 12 weeks with early
elevation of aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) and latter elevation of alkali phosphatase (ALP). Serum apo-E level
was dramatically reduced after CDAA diet feeding. Similarly to the apo-E,
high molecular weight adiponectin (HMW-Ad) level was gradually reduced.
AdipoR1 mRNA level was significantly elevated in the livers with the
progression of NASH. On the other hand, low molecular weight adiponectin
(LMW-Ad) level was dramatically elevated with the progression of fibrosis in
CDAA diet group.
Conclusions: These results suggest that serum apo-E and adiponectin (HMWAd and LMW-Ad) may be effective biomarkers for noninvasive diagnosis of
fatty liver, NASH and fibrosis, and that proteomic approach combined with
pathological examination has potential to distinguish NASH from normal fatty
liver disease.
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1828 THE REASONS GIVEN TO NSW AND ACT ORGAN
DONOR COORDINATORS BY POTENTIAL DONOR FAMILIES
FOR THEIR DECISION REGARDING ORGAN AND TISSUE
DONATION
J. Treloggen1, G. Ross2, E. Phillips3, A. Barnwell4
1
LifeGift nsw/act, 2Charles Sturt University, 3Heartbeat Trends Pty Ltd,
4
LifeGift nsw/act
The number of multi-organ donors per year in New South Wales (NSW) and
the Australian Capital Territory (ACT) has been consistent for many years
but refusal and selective consent nominated by the donor themselves and/
or their family, limits the number of organs and tissues made available for
transplantation.
Most of the information known about decision making related to organ and
tissue donation has been gained from surveys undertaken with the general
public responding to hypothetical situations. By contrast, very little is known
about the reasoning for decisions made at the time of approach to a potential
donor family.
Given the sensitive nature and timing of such discussions, this research used a
non-experimental descriptive study design, to indirectly identify the decision
making reasons given by potential donor families. Using semi-structured
interviews, NSW and ACT donor coordinators were asked to recall and share
their experience working with the families of potential donors.
In NSW and ACT the initial approach to potential donor families is mostly
undertaken by the treating clinician and the majority of families make their
decision at this time. The donor coordinators are invited into the process and
rarely get to meet families who refuse consent. The overwhelming feedback
from the donor coordinators is that the primary focus of all families at the
time approach is on their family member with reasons for declining consent
associated with wanting to protect their loved one and to avoid conflict within
their family. Families who gave consent most often saw donation as a fulfilment
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of the donor’s wishes, a reflection of a generous nature and way of making sense
of a person’s death. Selective consent was related to emotional attachment or
religious beliefs linked to specific organs. Of interest, there appeared to be little
concern for recipients at this time but it was suggested that they might become
more relevant for the donor family at a later time.
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1829 NSW ORGAN DONATION INDICATOR: OUTCOMES OF
12 MONTH AUDIT 1 JANUARY – 31 DECEMBER 2007
J. Treloggen, T. Wills
LifeGift nsw/act
The Australian Organ Donor Register (AODR) was established in 2000 to
register the individual’s decision to donate all, some or no organs and tissue for
transplantation at the time of their death. The decisions of families to allow or
refuse the retrieval of organs and tissues for transplantation may be influenced
by the existence of a prior directive from the potential donor.
The Australian Health Ministers Advisory Committee (AHMAC) and the
National Health and Medical Research Council (NHMRC) advocated that the
AODR be routinely consulted at the end of life to ascertain an individual’s
decision. In addition to direct registration to these registries, notifications from
State based drivers licence databases have been transferred to the AODR.
However, in NSW residents still have the option to lodge a decision regarding
organ and tissue donation with both databases.
In response to the AHMAC and NHMRC directives and the Australians Donate
National Organ Donation Collaborative key performance indicators, the NSW
state organ donation agency, LifeGift nsw/act now routinely search both the
Roads and Traffic Authority (RTA) and the AODR databases for indications
of refusal and consent for all potential organ and tissue donors. Of note, in
accordance with the 1983 NSW Human Tissue Act an indication of ‘refusal’
on the databases cannot be over ridden by the Senior Available Next of Kin
(SANOK).
During the audit period from 1 January 2007 to 31 December 2007, 129
database searches were conducted in NSW, requested from 27 different sites.
The total number of NSW multi-organ donors for the same period was 53.
Brain death was confirmed 34% at the time of the search request; the remaining
cases were identified as either potential donor after cardiac death (DCD) 17%,
potential tissue only donors (1.5%) or brain death was not yet confirmed (45%).
Occasionally the request for a search was made prior to brain death testing to
assist decisions regarding the instigation of further treatment or diagnosis.
Consent for all or some organs was registered for 46% of the searches, 58%
became multi-organ donors, 3 were tissue only donors and one was an intended
DCD. Final consent was only revoked 5 times by the SANOK and once by the
Coroner.
Overall 30% did not have a decision registered and from this group 35% became
multi-organ donors and one was an intended DCD. Refusal was registered for
23% of the searches with none becoming donors. However on 9 occasions the
SANOK had already indicated provisional consent prior to the database checks
and were reported to be surprised and disappointed to know of the ‘refusal’
documentation and that their family member could not be a donor.

1830 HORMONAL RESUSCITATION HAS BENEFICIAL
EFFECTS ON DONOR PULMONARY FUNCTION IN A
PORCINE MODEL OF BRAIN-DEAD ORGAN DONATION
A.J. Watson1,2, M. Hicks1, L. Gao1, A. Jabbour1,2, S.C. Faddy1,
S.H. Kesteven1,3, A.F. Sharland4, R.D.M. Allen4, P.C. Jansz2, P.S. Macdonald1,2
1
Transplant Program, Victor Chang Cardiac Research Institute, Sydney
NSW Australia, 2Heart & Lung Transplant Unit, St Vincent’s Hospital,
Sydney NSW Australia, 3Cardiovascular Mechanics Program, Victor Chang
Cardiac Research Institute, Sydney NSW Australia, 4Collaborative Transplant
Research Group, University of Sydney, Sydney NSW Australia
Introduction: The beneficial effects of hormonal resuscitation (HR) on
cardiovascular function and systemic haemodynamics are well established. We
sought to evaluate what effects an HR protocol had on pulmonary vascular
function and gas exchange in a porcine model of brain death.
Methods: Brain death was induced in juvenile large white landrace pigs by

Conclusions: These data provide encouraging preliminary evidence that HR
attenuates brain death induced donor pulmonary haemodynamic dysfunction
and reduction in gas exchange. Further investigation into the effects of
hormonal resuscitation on donor lung function is warranted.
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1831 IT’S NOT EASY. CONSENT ISSUES SURROUNDING A
DCD DONOR: A CASE REPORT
E. Treasure, S. Brean
LifeGift - Victoria
Aim: This case report demonstrates a fundamental delay in obtaining designated
officer consent after cardiac death and highlights the impact on staff and the
effect of extended warm ischaemic time on graft function.
Body: A 19yr old male suffered extensive head and chest injuries in a high
speed motor vehicle accident. His injuries were considered non-survivable
and discussions were held with his family regarding withdrawal of treatment
and palliation. The family raised organ donation. Medical staff deemed
he was unlikely to progress to brain death and on Christmas day, the DCD
pathway was initiated. The family consented for renal only donation as they
did not want their son’s chest to be opened. The state coronial service and
the designated officer were informed of the case including planned withdrawal
of treatment time. The coroner provided verbal consent subject to death. The
donor family were not present at withdrawal of treatment as they felt it would
be too distressing. The patient was extubated in ICU and inotropic support
ceased. One minute later the patient became apnoeic then after a further ten
minutes - loss of cardiac output. Death was certified five minutes later. The
designated officer was unable to be contacted following certification of death.
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inflation of a subdural balloon catheter. After one hour of brain death, pigs were
randomised to receive either HR (comprising bolus methylprednisolone, and
infusions of tri-iodothyronine and vasopressin, n = 8) or noradrenaline infusion
(NAd, n = 9) titrated to maintain mean arterial blood pressure (MAP) 60-70
mmHg. Invasive systemic and pulmonary haemodynamic monitoring was
performed in conjunction with arterial blood gas sampling. Experiments were
terminated after 6 hours of brain death. Data are expressed as mean ± SEM.
Results: Despite the high peak noradrenaline requirements of NAd animals
(0.485 ± 0.085 μg/kg/min), systemic haemodynamic performance was
significantly better in HR animals after 6 hours of brain death than in NAd
animals (MAP 67 ± 5 mmHg vs 53 ± 2 mmHg, p = 0.009; heart rate 100
± 7 bpm vs 154 ± 7 bpm, p = 0.0001). There was no significant change in
transpulmonary gradient (TPG) in HR animals (12.0 ± 3.5 to 14.0 ± 4.0 mmHg,
p = 0.33) as opposed to a significant 42% rise in NAd animals (10.8 ± 1.5 to
15.2 ± 4.3 mmHg, p = 0.007).
Gas exchange deteriorated in both groups of animals, but to a lesser extent
in the HR group. PaO2 declined by 13% in HR animals (413 ± 26 to 354 ± 24
mmHg, p = 0.07) versus 28% in NAd animals (438 ± 17 to 315 ± 45, p = 0.02).
Similarly, there was an increase in alveolar-arterial (A-a) gradient, again to a
lesser extent in HR animals. A-a gradient increased by 32% in HR animals (250
± 26 to 313 ± 23 mmHg, p = 0.06) versus 55% in NAd animals (224 ± 17 to 343
± 44 mmHg, p = 0.02). Differences between the two groups at 6 hours however
did not reach statistical significance.
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This was distressing for the staff involved and discussions regarding the plan
included abandoning organ donation. Seventeen minutes later after numerous
attempts consent was obtained from the hospital’s CEO. The patient was rapidly
transferred to theatre where a further delay occurred as there was no clamp
on the setup tray for cross clamp. Prior to loss of cardiac output the patient
had sustained a SBP > 80 for all but two minutes. Thirty five minutes elapsed
between SBP < 60 and commencement of cold perfusion – forty four minutes
after extubation. Both kidneys were successfully procured and transplanted.
Both recipients experienced delayed graft function and required dialysis for
up to two weeks.
Conclusion: The processes involved for organ and tissue donation are a
complex mix of emotional, legal and logistical factors. Given this, hospitals
considering implementing DCD programs need to ensure extensive consultation
of all relevant stakeholders and extensive planning and education of all relevant
staff prior to embarking on this process. DCD may not be appropriate for all
institutions. It is important that whilst considering DCD we don’t compromise
patient, family or staff safety and expectations and also that we are not
negatively impacting the brain dead donor pool. Evaluating our processes
and improving practices is vital to meet expectations of the community, donor
families, transplant recipients and critical care staff. In this case both grafts
are reported to be functioning well, and the patients have returned home. The
extended consent process, although not ideal, has not affected the outcome for
these recipients.
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1832 SUCCESSFUL CADAVER TRANSPLANTATION
BY SHIFTING BRAIN DEAD VICTIMS BY ROAD
– UNIQUE EXPERIENCES FROM INDIA
R. Balasubramaniyam, J. Das, N. Soosai, S. Das
KG Hospital And Post Graduate Medical Institute
Background: Cadaver transplantation is a very common modality of organ
transplantation in the developed countries. Organ retrieval and transportation
are integral components of cadaver transplantation. However, the situation
is different in Indian transplant scenario. Here majority of the transplants
are living donor transplants and cadaver transplants happen in few selected
centers. Organs are generally retrieved and utilized in the same center and
organ transportations have started happening.
No where brain dead victims are transported towards organ retrieval and for
transplantation. Here we share our unique experiences where we shifted 2 brain
dead victims by road and performed cadaveric renal transplantation.
Aim: To share our experience where we shifted two brain dead victims by road
and performed cadaveric renal transplantation.
Materials and methods: In the year 2003, patient Ms.D, 48 years old non
diabetic, non hypertensive woman with no other significant past medical illness
from our town, was declared brain dead following cerebral aneurismal clipping
surgery at another hospital located 400 miles away. In 2007,Patient S, 7 years
old girl who met with a road traffic accident and was admitted in a hospital,
located 100 miles where she was declared brain dead.
In both the instances the family members wanted to shift the patient for cadaver
transplantation. Since the base hospitals were not equipped for organ retrieval
and the family preferred to shift the brain dead patients to their hometown
before organ retrieval we decided to shift them to our hospital by road. (We do
not have the facility to airlift the donors in India).
We sent our medical team in our fully equipped ambulance and transported
both the donors. Enroute the patients were maintained hemodynamically by
our medical team.
We identified 2 adult recipients for the adult donor and transplantations were
performed successfully. In the pediatric donor, it was decided to transplant
both the kidneys to a single recipient. The kidneys were removed enblock and
utilized for transplantation.
All three patients did well post transplantation.
Conclusions: In a country where cadaveric renal transplantation is a rarity, we
could shift two cadaveric donors and perform transplantation. We have no data
of similar events that happened across the world.
We thought of presenting these two incidences because of their uniqueness.
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1833 DOUBLE KIDNEY COMPARED TO SINGLE KIDNEY
TRANSPLANTATION: A MULTICENTRIC ITALIAN STUDY
A. Faenza1, R. Bertelli1, E. Capocasale2, G. Cappelli3, F. Neri1, M. Tsivian1, G.
Cavallari1, B. Nardo1, G. Fuga1, S. Stefoni1
1
Transplant Center of Bologna, University of Bologna, Italy, 2Transplant
Center of Parma, University of Parma, Italy, 3Transplant Center of Modena,
University of Modena, Italy
Introduction: Organs from marginal donors not suitable for single kidney
transplantation (SKT) are considered for double kidney transplantation (DKT).
The aim of the study is to determine the outcome of DKT compared to SKT.
Methods: Between March 2001 and July 2007, 80 DKTs were performed
in transplant centers of Bologna, Parma and Modena. 167 SKTs from
marginal donors (SKTMD) based on United Network for Organ Sharing
criteria and 229 SKT from ideal donors (SKTID) were performed in the
same period in the transplant center of Bologna. All grafts from marginal
donors underwent biopsy to decide the allocation for SKT or DKT
(according to Remuzzi et al).
Mean follow-up was 3.2±1.7 years. Recipients’ mean age was 61.4, 42.4 and
57.5 in DKT, SKTID and SKTMD respectively. The main indications for
transplant were similar in all groups with glomerular nephropathy being the
most common. Mean HLA A,B,DR mismatches were: 3.1, 2.5 and 2.8 in DKT,
SKTID and SKTMD respectively. Donors’ mean age was: 68.8, 40.1 and 65.3
in DKT, SKTID and SKTMD respectively. Donors’ mean creatinine clearance:
75.1 mL/min in DKT, 111.7 in SKTID and 85 in SKTMD. The kidneys were
perfused predominantly with Celsior solution. Mean biopsy score was 4.4
and 2.7 in DKT and SKTMD groups respectively. Immunosuppression was
tacrolimus or cyclosporine based.
The outcomes were assessed for early graft function, acute rejection episodes, serum
creatinine at discharge, hospital stay, re-operations and graft and patient survival.
Results: The incidence of delayed graft function was 37.5, 28.8 and 47.9%
in DKT, SKTID and SKTMD respectively(p=0.00). Acute rejection incidence
was 10, 28.8 and 8.8% in DKT, SKTID and SKTMD respectively (p=0.03).
Urological complications incidence was similar in all three groups (13.7, 11.8
and 14.8% in DKT, SKTID and SKTMD). We found no statistical difference
in early (within 30 days) or late re-operation rate and mean hospital stay (22.1,
21.9 and 23.9 days in DKT, SKTID and SKTMD respectively). Mean serum
creatinine at discharge was lower in DKT (1.5 mg/dl vs 1.6 in SKTID and 1.8
in SKTMD; p=0.00).
At last control mean serum creatinine was lower in the DKT group (1.6 mg/dl
vs 1.7 in SKTID and 1.9 in SKTMD).
Patient survival at 1 and 5 years was not statistically different among the groups:
97.5% in DKT, 98,6% and 96,9% in SKTID and 98,8% and 95,8% in SKTMD.
Graft survival at 1 and 5 years was 93,7% in DKT, 92,5% and 86,9% in SKTID
and 91% and 87,4% in SKTMD.
Discussion: DKT is a safe way to face organ shortage employing kidneys from
suboptimal donors. The outcomes of DKT are more than satisfying both in
short and long terms compared to SKT.

POSTER BOARD NUMBER P3 – 260
1834 INCREASED INTESTINAL PERMEABILITY IN
DECEASED BRAIN DEAD DONORS
H. Leuvenink, L. Koudstaal, M. Nijboer, V. Nieuwenhuijs, H. Burgerhof, H.
van Goor, R. Ploeg,
University Medical Center Groningen
Transplantation of organs derived from deceased brain dead (DBD)
donors results in worse organ function and more acute rejection episodes
compared with organs derived from living donors. Over the past years, we
and others have shown in humans and in experimental animal models that
brain death induces inflammation in various potential donor-organs. The
underlying mechanism of this inflammatory state and subsequent inferior
transplant outcome has not been unravelled yet. In several conditions, such
as severe burns, brain injury and acute respiratory distress syndrome, an
increased intestinal permeability is associated with distant organ injury.
We hypothesized that the observed inflammation in organs from DBD
donors may result from increased intestinal permeability. To test this
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assumption, we measured LPS Binding Protein (LBP) as a permeability
marker and intestinal fatty acid binding protein (I-FABP) as a marker of
enterocyte injury, in serum of 21 DBD donors and 20 living donors. Serum
was collected immediately after the determination of brain death (T0) and
just before organ retrieval (T1). LBP and I-FABP levels were measured by
ELISA. C-Reactive Protein (CRP) was measured as a general marker of
inflammation.
In the serum of DBD donors we found significantly higher LBP levels.
Results are expressed as median and 25-75 quartiles. Living vs. DBD donors
at T0 (10 ng/mL [7-12 ] vs. 31 ng/ mL [25-39], at T1: 8 ng/mL [5-10] vs.
26 ng/mL [17-37]. Serum I-FABP was non detectable in most donors. No
differences were observed between DBD and living donors with detectable
I-FABP levels. In addition, we found a significant correlation between
serum LBP with serum CRP levels (T0: R= 0.740 p=0.001 and T1: R=0.552
P=0.009).
Summarizing, LBP is significantly enhanced in the brain dead donors suggesting
that the systemic inflammatory response may be induced by an enhanced
bacterial pressure. The absence of I-FABP in the serum of DBD donors, despite
the higher LBP levels may be caused by the renal secretion of I-FABP. Our
present findings support the concept of early intervention and adjustment of
management in DBD donors prior to retrieval aiming to enhance donor organ
viability after preservation and transplantation.

POSTER BOARD NUMBER P3 – 261
1835 DOPKI - IMPROVEMENT OF KNOWLEDGE AND
PRACTICE OF ORGAN DONATION IN EUROPE

1836 INITIALIZING BRAIN DEATH PRACTICE AND
STANDARD ORGAN DONATION IN CHINA – REPORT OF “A
MISSION IMPASSIBLE”
Z.K. Chen, H.M. Zhou, F.J. Zeng, C.S. Ming
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of
Science and Technology
The unique situation of using inmate organ for transplantation in China has
its special history and un-transparent background. It was initially clean and
secret clinical trial started from our hospital and proved by local government
in the 1970’s. The idea was to develop transplant technology and save life.
As the results were poor and the program was on a small scale, no one even
care about the organ source. However the nature of the practices dependent
on this type of organs has dramatically changed and gradually extended
to the whole country when modern immunosuppresant producers entered
China and provided better clinic outcomes. Increased demand biased the
initial nature and it soon contaminated with organ trafficking and transplant
tourism. It became a severe human rights issue and was widely condemned
by international organizations and academic societies. However, conflicts
of interest, for instance, long waiting list with high mortality and absence
of the alternative organ source, acted as the strong resistance to discontinue
the malpractice. Furthermore, the existing national regulations on organ
transplantation gave no description on how the ¡°sensitive source¡± should be
legally controlled and ethically approached as a formal resource for medical
care. The malpractice also challenged public trust on organ donation and
allocation. Moreover, there was no brain-death practice at all in the entire
medical care system, so that it left no space for practicing this kind organ
donation.
Current study demonstrated that the concept of brain death can be gradually
accepted by the society through constant public education and brain death
organ donation is also possible even if brain death regulation is currently a
legal vacuum. Professional teams (the Chinese OPO) work together with a
properly drafted protocol under the surveillance of the Red Cross Association.
Our initial strategies were:
1. Including the proposed program into an existed national research program
named ¡°985 Plan¡±.
2. Establishing the Chinese Organ Donation Website: www.organdonation.org.
cn; the Chinese Transplant Games Website: www.transplantgames.org.cn;
and the Chinese Brain Death Website: www.braindeath.org.cn; to promote
the concepts.
3. Calling for a national-wide cooperation and encouraging medical professions
to adopt brain death criteria into their practice and provide organ donation as
one of the choices beside withdraw of ventilation.
4. Establishing OPO teams.
5. Inviting the Red Cross to join the social work and family care.
6. Releasing typical cases at regular press conferences for public education.
From 2004 to 2007, 71 deceased organ donors had been achieved and 323
quality organs have been recovered (kidney: 130; liver: 54; heart: 18; lung: 6;
pancreas: 2; and coniea: 113). In 2007, the organ recovery rate including eyes
was 0.15/mp. So far, more than 40 hospitals all over the country were included
into this pioneer action.
Conclusion: Brain-death organ donation is a potential organ source in the
future to replace the current one related to executed prisoners. The efforts are
crucial for healthy development of Chinese medical care system, and gain
wider international acceptance.
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B. Dominguez-Gil
Organizacion Nacional De Trasplantes
DOPKI is a European Union funded collaborative action on the Improvement
of Knowledge and Practice of Organ Donation. It consists of a consortium
of 13 transplant organizations from 16 European countries. Between them,
these organisations are responsible for 80% of all the organ donation activity
in the EU. The main objective of the project is to improve knowledge of
organ donation and develop an applicable methodology to determine both the
potential of donation and its outcome, as well as to define the limits of organ s
safety and quality. This work will lead to the development of actions that will
improve organ availability across Europe.
The first step in this project was to describe the current state of organ
donation in the participating countries. This analysis was based on data
returned by the individual countries on a wide range of factors concerned
with donation activity. This included the number of potential, consented,
actual and the utilized donors. From this data we obtained the classical
conversion rate from potential to actual donor but also calculated the rates
of conversion from potential to consented, consented to actual and actual to
utilized donors.
This showed that the percentage of potential donors who were consented
ranged from 51.5% in the UK to 92.9% in Hungary; the percentage of potential
donors who became actual donors ranged from 50.2% in the UK to 89.9%
in Spain. The higher rates occurred in countries with presumed consent but
there are many other factors that may contribute to theses differences. A more
homogeneous picture emerges from the percentage of consented donors who
became actual donors, which varied from 80.8% in Hungary to almost 100%
in Slovenia. Similarly the percentage of actual to utilized donors ranged from
89% in Spain to almost 100% in a number of countries.
The lack of harmonized and complete data across the participating countries was
apparent in this initial analysis. One of the aims of the DOPKI-Project is to develop
a common methodology to determine the true picture regarding organ donation in
Europe. This methodology is being piloted in 30 hospitals across Europe.
One of the highlights of projects is the development of a European Registry
focused on the use of specific types of expanded criteria donor including
neoplasia, acute intoxication and rare diseases as well as the corresponding
transplantation outcomes. These data will help to establish the limits of safe
transplantation in Europe.
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1837 VERAPAMIL-LIDOCAINE DONOR DECREASES
ACUTE TUBULAR NECROSIS, IN CADAVERIC KIDNEY
TRANSPLANTATION
A. López-Hernández, B. Castro, L. Solis, P. Cancino, P. Escarcega,
J.M. Rosales, J. De-los-Santos, F. Vasquez, J. Soto, B.O. Aquino, F. Benitez
From the transplant program Centro Especialidades Médicas “ Dr.Rafael
Lucio”, Xalapa, México
Introduction: The lidocaine is a sodium channel blocker. Other groups has
demonstrated in papers, lidocaine administration to the donor increased the
incidence of immediate function of the kidney after transplantation. Verapamil
is a calcium blocker, and administration before warm ischemic provides partial
and short-lasting functional protection renal function. The Acute tubular
necrosis is the 30 to 50% in cadaveric graft transplantation in several reports in
the literature. Several pathway involved in ischemia-reperfusion damage. We
purpose is report our clinical experience with deceased donors pretreated with
Verapamil-lidocaine to avoid Acute tubular necrosis.
Material and methods: The deceased donors received verapamil-lidocaine
as a bolus injection systemic of 30 to 60 minutes before renal ischemic. We
administered 5mg of verapamil clorhydrate slowly and 1-2mg/kg Lidocaine
clorhydrate body weight IV before harvesting. All donors were managed
similar including adequade hydratation. At the time of nephrectomy 30 000
U of heparin was given to all patients before kidney dissection. Kidney were
flushed ex vivo with University Wisconsin or in custodiol solution, and stored
in simple hypothermia at 4oC.All recipients received 250ml mannitol 20%,
furosemide 100mg, albumin 0.5gr/kg body weight, hydrated under the control
of central venous pressure at 8 to 12 of water, just before clamp removal.
Results: Forty seven consecutive cadaveric kidney transplants performed
between December 2001 and March 5, 2008. All recipients received kidneys
from verapamil-lidocaine pretreated donors. 19 women and 28 man. Aged
12-67 yr (37 +_ 14 average).The cold ischemia was 3 to 33hrs (9 hrs average).
In 17kidney flushed ex vivo with Wisconsin solution and 30 kidney with
custodial solution. Only two patient developed Acute tubular Necrosis, and
time cold storage 26 and 33hrs, and recovery normal function renal after 3
weeks of transplantation.
Conclusions: In our series Acute tubular necrosis was present only in 2 of 47
cases, which is 4.02%. Is better than that reported in the literature. verapamillidocaine clorhydrate administration to the cadaver donor before kidney
harvesting, increased the incidence of immediate function of the kidneys after
transplantation.The presents results suggest that the use of Verapamil-Lidocaine
clorhydrate protects the kidney against ischemia-reperfusion injury. These
observations may offer a novel approach for reducing the incidence of reducing
the incidence of Acute tubular necrosis in cadaveric kidney transplantation.
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1838 EVALUATION OF ORGAN DONATION IN SLOVENIA
D. Avsec Letonja1, A. Špec-Marn2
1
Institute for Transplantation of Organs and Tissues of the Republic of
Slovenia, Ljubljana, Slovenia, 2Clinical Department of Anaesthesiology and
Intensive Therapy, University Clinical Centre, Ljubljana, Slovenia
Objectives: To determine the number of cadaveric donors in Slovenia and the
prevailing reason for non-donation from potential donors.
Design: An audit of all brain death in intensive care units from the 1st of
January 2000 to 31th of December 2007.
Setting: 23 intensive care units in 10 hospitals in Slovenia.
Results:
Table 1.1 Number of cadaveric donors from 2000 to 2007
Year
No. RD
RD PMP

2000
22
11

2001
23
11,5

2002
35
17,5

2003
28
14

2004
36
18

2005
21
10,5

2006
30
15

2007
24
12

RD - realised donor, PMP – per million population

The number of realised cadaveric donors per million inhabitants in Republic
Slovenia from 2000 to 2007 is between 10,5 to 18. In Europe in average this
number is 14,5 PD PMP. Comparing 2000 and 2001 there was 4,5% increase
in 2001 in number of cadaveric donors. A sharp increase was noted in 2002
(+52,2%) in Europe (-1,1%), decrease in 2003 (-20,0%) in Europe (+ 8,7%), a
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second sharp increase in 2004 (+ 28,6%) in Europe (-4,8%), sharp decrease in
2005 (-41,7%) in Europe (+8,4%), sharp increase in 2006 (+42,9%) in Europe
(+4%) and again sharp decrease in 2007 (-20%).
Table1.2. Number of refusal rate for relatives of potential donors from 2000
to 2007
Year
PD PM
% RR

2000
15
37

2001
15,6
36

2002
21
20

2003
17
22

2004
22
23,4

2005
13,6
30

2006
17,8
19

2007
15,9
33

PD- potential donors, RR – refusal rate

High percentage of refusal rate for families of PD were noticed in 2000 (37%),
2001 (36%), 2005 (30%) and 2007 (33%).
Conclusion: The great obstacle to improve organ donation is high refusal rate
for families of PD. When discussing this issue, we have to realize that solutions
lies in increasing efficiency of informing the public of organ donation.
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1839 NON-HEART-BEATING DONORS: A RENEWED SOURCE
FOR KIDNEY GRAFTING
M. Rengel, Ú. Verdalles, A. Mossé, S. Abad, A. Vega, E. Verde
Hospital General Universitario
The use of Non-Heart-Beating Donors (NHBD)kidneys to expand transplant
programmes offers an answer to the problem of donor shortage.Despite renewed
interest in NHBD kidney transplantation, very few clinical programmes have
been developed this type of grafting. We analyzed the function and outcome of
kidney transplants performed from NHBD in our hospital.
From 1999, 30 patients were grafted with kidneys from NHBD(28 grafts
from Hospital Clínico San Carlos of Madrid). This group was compared
with recipients of heart beating donor (HBD) matched for age, sex, number
of transplants and HLA.Immunosupression was performed with Basiliximab,
Predinisone, Tacrolimus and Micophenolate Mofetil. Acute rejection episodes
were treated with Methylprednisolone boluses, and ATG-FRESENIUS® when
necessary.The delayed graft function rate was higher on NHBD transplants than
in HBD graft. Serum creatinine levels was significantly better in the NHBD.
Graft survival at 1 year was 81% in NHBD and 85% in HBD. Patient survival
in both groups was 100%. Patients grafted with NHBD were hospitalized
longer and needed more dialysis. Acute rejection episodes were more frequent
in NHBD.
Conclusion: This source of kidneys has evidence of equivalent graft function
and survival, compared with standard cadaveric donor organ and may expand
de donor pool.
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1840 INFLUENCE OF A MODIFIED PRESERVATION
SOLUTION IN PROLONGING THE COLD ISCHEMIC PERIOD
– A COMPARATIVE STUDY IN A PORCINE MODEL OF
ALLOGRAFT KIDNEY TRANSPLANTATION
H. Fonouni1, A. Mehrabi1, G. Kuttymuratov1, T. Longerich2, M. Golriz1,
M. Tahmasbi Rad1, M. Esmaeilzadeh1, P. Jarahian1, M.W. Büchler1,
J. Schmidt1, M.M. Gebhard3
1
Department of General, Visceral, and Transplantation Surgery, 2Department
of Pathology, 3Department of Experimental Surgery, University of Heidelberg;
Heidelberg, Germany
Introduction: One of the big challenges following kidney transplantation is the
inevitable ischemia reperfusion (IR) injury. The prolongation of the ischemic
period has a direct correlation with the magnitude of the IR injury. Furthermore,
in reperfusion phase free oxygen radicals play a pivotal rule in extension of cell
damage. One of the important factors in this regard is preservation solution. To
minimize these problems introducing new or modified solutions which contain
new antioxidants or energy substrates seems mandatory to reduce the adverse
metabolic changes during cold preservation.
Our aim was to evaluate a modified preservation solution in improving
the viability of kidney organs in a porcine model of allograft kidney
transplantation.
Materials and methods: Thirty landrace pigs (mean weight=30kg) underwent
allograft kidney transplantation (KTx). For implantation, the pigs divided into
three identical groups; group 1 (n=10) received kidneys perfused and preserved
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for 30hrs in standard histidine-triptophane-ketoglutarate (HTK) solution, group
2 underwent KTx using kidneys, perfused and stored in University of Wisconsin
solution for 30hrs, and in group 3 the pigs received kidneys which were perfused
and preserved in a new modified HTK solution for 30hrs. The technique of
implantation was standardized, laying the kidney in right lower quadrant of
the abdomen, performing standard vascular anastomosis and ureterocystomy
as well as both-side nephrectomy of native kidneys. The follow-up period was
7 days. During this period, we analyzed renal laboratory parameters including
serum creatinine, blood urea nitrogen (BUN), hemoglobin, hematocrit, urine
creatinine, and urine osmolality. Moreover, histopathologically, the tissues were
assessed for the degree of tubular injury or rejection. All samples were taken in
four steps; after explantation, before reperfusion, 20 min. after reperfusion, and
before sacrificing the animals 7 days post-transplant.
Results: All laboratory data are summarized in Table 1. The kidney parameters
of HTK-new group have a better trend specifically in serum creatinine as
compared to other preservation solutions, but without reaching any significance.
The histopathological assessment shows various degrees of acute tubular
damage in different phases in all groups, but overall the HTK-new group
showed minimal destructive changes comparing to UW and HTK and a better
trend toward regeneration and restoration of brush border of tubular epithelial
cells on day 7 post-transplant.
Table 1. The laboratory parameters of three groups of allograft kidney
transplantation 7 days after transplantation.
Group
Parameters

Group 1 (HTK old)

Group 2 (UW)

Group 3 (HTK new)

10.46±4.25

9.53±5.71

8.46±4.87

Serum BUN (mean±SEM)

251±104

240±125

240±99

Hemoglobin (mean±SEM)

10.1±1.9

11.2±1.6

11.5±2.8

Serum creatinine (mean±SEM)

Hematocrit (mean±SEM)

27±6

31±3

31±6

Urine creatinine (mean±SEM)

49.3±25.6

51.9±23.4

61.1±19.9

Urine osmolality (mean±SEM)

319±34

318±46

294±36

Conclusion: We could show an overall improvement of renal parameters with
the usage of new HTK, although this improvement did not reach significance. It
can be speculated that HTK could preserve the kidney organs more efficiently
but the real advantage of this solution should be confirmed in clinical setting,
where the accompanying factors including atherosclerosis, old-for-old, or long
cold ischemia time may interfere with the outcome.
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1841 THE ONCOSTATIN M PATHWAY PLAYS A KEY ROLE IN
THE RENAL ACUTE PHASE RESPONSE

1842 QUALITY ASSESSMENT OF THE ORGAN DONOR
RETRIEVAL PROCESS
R.D.M. Allen1, M. Azanza2, T. Wills2, P. Robertson1, G. Kyd1, M. Crawford1,
H.C.C. Pleass1, D.J. Verran1
1
NSW Deceased Donor Organ Procurement Service, Sydney, Australia,
2
ARCBS Organ Donation Network NSW/ACT, Sydney, Australia
High quality organ procurement surgery is the first step towards successful
organ transplantation. However, it is essentially a nocturnal pursuit with
inherent risk of surgical and other misadventures. Furthermore, trainee surgeons
are attracted to donor surgery because of the scope of the surgery involved and
the opportunity to gain surgical confidence. When a single statewide deceased
donor organ procurement service (DDOPS) was established in NSW in 2003
to simplify retrieval of intra-abdominal organs for subsequent transplantation
in 17 possible transplant centres, an Organ Retrieval Report Form (ORRF) was
created as a communication tool between the organ donor network/retrieving
team and the transplanting centres. The aim of the ORRF was to identify and
rectify systemic problems in the retrieval process, as assessed by the recipient
transplanting centre, from time of declaration of death to donor organ delivery
at the transplanting hospital.
Methods: The surgical technique for multi-organ retrieval was standardised. ORRF
were distributed with each kidney, whole liver, liver lobe and pancreas and returned
to a central data co-ordinator. Identified problems were collated and reviewed by
medical advisors. Findings were fed back to all DDOPS team members for review
and action as required. Statistical analysis was performed using Fisher’s exact test.
Results: 520 abdominal organs from 176 deceased donors (11% donation
after cardiac death) were transplanted in the 3 year period from July 2004. 12
organs were deemed unsuitable for transplantation arterial disease or liver fat
content, and none because of surgical injury. Compliance with ORRF return
from transplant centres was 98%. Donor surgeons reported an iatrogenic
injury to kidney and liver vasculature in 7.4% (n=13) and 4.4% (n=5) of
donors respectively (P=0.45). The annual rate of donor surgeon recognition
of injury increased in time from 5 to 14% (P= 0.067). Transplanting teams
reported problems in an additional 23% of donors. Combining donor and
retrieval reported data, structural injury occurred in 12.6% of retrieved
kidneys, no pancreases (P=0.008) and 5.3% of livers (p=0.014). 6% of organs
had preservation, packaging and documentation concerns. Injury contributed
to loss of one kidney graft and one fatty liver failed to function. Unsolicited
positive comments by transplant centres were welcomed.
Conclusions: The ORRF proved a valuable quality tool for productive
communication. Transplanting centres offered critical evaluation of the
organ retrieval process that served to strengthen retrieval protocols. To
reduce documentation errors, co-ordinator numbers were increased. To
reduce packaging errors, check-lists were created. To reduce the significant
disproportion of kidney versus liver donor related injuries, the senior donor
surgeon now remains with the donor til removal of all donor organs rather than
retreating to the back table after liver retrieval.

CONCURRENT ORAL SESSION 130: QUALITY OF LIFE AND
ECONOMICS
POSTER BOARD NUMBER P3 – 269
1843 EFFECT OF AN EDUCATIONAL INTERVENTION
ON NURSES’ KNOWLEDGE OF A PERITONEAL
DIALYSIS CIRCLER
B.A. Markazi, A. Ghafarimoghadam, E. Ahamadnezhad, R. Erfani, N.
Sepehrvand, S. Hatami
Introduction: After several years from the initial stage of CAPD usage, still
the percent of those using this method is very low (15% of all patients with
end-stage-renal disease).In this study we have tried to define the impact of
educational program of CAPD.
Methods: This is a quasi- experimental study (before-after) with educational
investigation, include: workshop, teaching by Booklet and show the film.
Sample method is base on our aim. Study was done in Urmia .we designed a
questionnaire for collection of data. Sample size was 35. We use descriptive
and Friedman test for analysis.
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T. Mueller, L. Cairo, C. Compson, V. Luyckx
University of Alberta
The acute phase response (APR) robustly differentiates deceased (DD)
and living (LD) donor kidneys. To further analyze the renal APR transcript
levels of target genes in human post-reperfusion implant biopsies, discarded
donor kidneys (DK), nephrectomy samples (Nx), liver tissue, and cell
lines (PTEC and HK2) were measured by real-time PCR, microarray, and
immunohistochemistry.
Fibrinogens (FGB) and serine proteinase inhibitors (SERPINA1) were
highly expressed in kidney tissue, reflecting cause of brain death and
extent of renal damage. The levels were highest in DK > DD > LD > Nx
controls. PTECs expressed high levels of FGB and SERPINA1, which
increased significantly after serum starvation or oncostatin M (OSM)
supplementation. On the other hand an antibody against gp130 inhibited
the induction of FGB and SERPINA1. The results further indicated that
OSM receptor (OSMR), rather than IL6R is the major gateway for the renal
APR. The ratio of OSMR to IL6R was significantly higher in all kidney
versus liver tissues. OSMR mRNA levels were higher than IL6R in the cell
lines. In HK2 cells, serum starvation or OSM administration increased the
OSMR levels by 40 and 200% respectively. Immunohistochemistry in DK
samples revealed OSMR expression in larger peritubular arterioles, parietal
podocytes, and occasional proximal tubules, whereas OSM was largely
restricted to the mesangium.
Thus the renal APR, induced by brain death and ischemia-reperfusion injury,
is characterized by high levels of fibrinogens and serpins and most likely
regulated through OSM OSMR rather than IL6 IL6R pathways.
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Results: Nurses total information about CAPD defined by total scoring was as
follow: little information: 75%, Moderate 19%, and good only in 6% of patients.
All of the information were increased after investigation and was 80%.
Conclusion: Unawareness about the existence, required facilities treatment
method and advantages and disadvantages of CAPD among patients can be
important factors in the very slow development of CAPD.
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1844 EXPERIENCE OF RACISM CONTRIBUTES TO RISK OF
DIABETES
S. Madhere, A. Campbell, C. Callender
Howard University
Diabetes is one of the primary precursors of renal dysfunction. Therefore,
factors that are significant to the metabolism of glucose are relevant to the
understanding of renal disease. Previous research has examined the relationship
of physiological variables such as obesity, lifestyle risks, to glucose metabolism
and socioeconomic factors. But, although the death rate from diabetes is higher
for African Americans than it is for European Americans, few researchers have
paid attention to racism as a relevant contributor to the prevalence of diabetes
in the black population.
This study attempts to understand variations in glucose level as a function of
predictor variable including obesity (body-mass), lifestyle (alcohol abuse), and
socioeconomic status (income and education), perceived racism and other daily
stress. The relationships were studied in a community sample of 92 African
Americans (average age of 47 years). A multiple regression was applied for
the analysis. It was found that 17.3% of the variance in glucose level could be
explained by this set of predictors. Among them, perceived job-related racism
was the most significant contributor, (B .236 to .282). This finding suggests that
the higher the level of perceived racism, the higher the level of glucose.
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1845 PATIENT HEALTH PERCEPTIONS: A MANDATE FOR
PHYSICIANS
J. Harrell, C. Callender, A. Campbell Jr.
Howard University
Though physicians commonly elicit from their patients a subjective report of
symptoms, these responses are not commonly viewed as highly correlated with
objective markers of disease. Instead, self-perceptions of health status are taken
as indices of the patient’s sense of the seriousness of their condition or as an index
of motivational or emotional states that may affect compliance with therapy.
The present study sought to identify the source of what patients tell doctors
about their health and selected objective indices of disease. Specifically we
tested models that proposed perceived stress and depressive symptoms mediate
the relationship between health perceptions and cholesterol. These models
argue that health perceptions may be related to objective indices of stress
because they are correlated with stress and the negative affect brought on by
poorer health.
As part of a large study of psychoneuroimmunological, factors and end-stage
renal disease, 150 African American volunteers completed the Beck Depression
Scale, Cohen’s Perceived Stress Inventory, and the General Health Perception
domains of the SF-36 Health Survey. Blood samples were obtained and nonfasting HDL and LDL levels were determined. A moderately strong relationship
between General health Perceptions and HDL levels (r=.41) indicated that
positive perceptions of health were associated with higher HDL levels. We tested
the mediation model first by determining that HDL levels were correlated with the
two candidate mediators, Perceived Stress (r=-.20) and Depression (r=.23). The
second step of the test of mediation involved demonstrating that General Health
Perceptions were negatively related to Perceived Stress (r=-.23) and Depression
(r=-.34). However, using multiple regression analyses, the final step in testing
mediation reviewed that the relationship between General health Perceptions and
HDL levels persisted when depression or perceived stress were controlled.
Hence, though perceptions of one’s health status tend to be related to stress
and depression, these emotional variables did not account for the relationship
between health perceptions and HDL> While the underlying mechanisms
linking these two variables are not clear, these findings mandate that physicians
attend more closely to the self-reports their patient provide.
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1846 COMPARISON OF QUALITY OF LIFE BETWEEN
KIDNEY TRANSPLANT PATIENTS AND DIALYSIS PATIENTS
M.H. Kim, O.J. Kwon, J.Y. Kwak, C.M. Kang
Organ Transplantation Center, Hanyang University Hospital
Purpose: Kidney transplant recipients have a higher quality of life and consume
fewer health care resources compared to patients on dialysis. The aims of this
study are to provide basic materials necessary for enhancing quality of life
among kidney transplant patients and dialysis patients through conducting a
survey and comparing their perceived quality of life.
Materials and methods: The subjects of this study were 108 kidney transplant
patients performed in our center, from 1990 to 2007, and 46 dialysis patients.
These data have been collected from August to September in 2007 by
questionnaire. We used a structured questionnaire consisting of 9, 5, 4, and
42 questions about general characteristics, disease related features of kidney
transplant patients and dialysis patients, and quality of life, respectively, as a
study tool. We analyzed and evaluated the collected data through conducted
T-test, frequency analysis, one way ANOVA by employing a statistics package,
SPSS 12.0 and we used Cronbach’s Alpha Coefficient in order to verify
accuracy and reliability of the measurement tools.
Results: 1) In examining the averages of quality of life with minimum 1 and
maximum 5, attitudes toward life indicated the highest point as 3.66, followed
by somatic symptoms, 3.50, affective state, 3.29, perceptions of health, 3.03,
and family relationships and financial situation 3.00, in both groups. 2) Kidney
transplant patients were shown statistically significant higher quality of life
than the dialysis patients, in affective state (p=0.000), social activities (p=.001),
somatic symptoms (p=.000), attitudes toward life (p=.000), and perceptions
of health (p=.000). On the contrary, In the family relationship and financial
situation, kidney transplant patients were shown higher scores than dialysis
patients, but it was not significant statistically (p=.202).
Conclusion: In this study, kidney transplant patients enjoy higher quality of
life than dialysis patients with statistically significant differences, and there
showed different levels of the quality of life according to general characteristics
and disease-related features between the two types of patients. Therefore, we
should help them to enjoy healthy life without complicating diseases through
providing them the follow-up care taking individuals’ general characteristics
and disease related features into consideration after transplantation, and also
make efforts to enhance kidney transplant patients’ quality of life by developing
effective self-management programs.
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1847 QUALITY OF LIFE ASSESSED BY SF-36 HEALTH
SURVEY IN OLDER VERSUS YOUNGER AND RELATED
VERSUS NON-RELATED LIVE KIDNEY DONORS
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, D. Tacu,
E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis and Renal Transplantation, Fundeni
Clinical Institute, Bucharest, Romania
Introduction: SF-36 Health Survey is a proper assessment method of health
status in general. This study was designed to compare and to assess the
quality of life (QOL) in four groups of renal donors - related versus nonrelated live kidney donors and younger versus older donors. We defined the
border age of 65 (retirement age in Romania) in order to compare the two
age donor groups.
Methods: From June 1997 until March 2008, 855 renal transplantations (710
living and 145 cadaver, 807 adults and 48 pediatric transplants) have been
performed in our center, with an average of 81 /year (116 in 2007). In all
cases, general preoperative evaluation, immunological and vascular anatomy
study was performed. Standard minimal lombotomy nephrectomy technique
was preferred. The evaluation was performed before surgery, one month and
six months after surgery. One group of 62 young donors (mean age 45) was
compared with a group of 38 older donors (mean age 68) using SF 36 protocol
and a group of 50 related donors were compared with a group of 50 unrelated
donors using the same questionnaire.
Results: Eight scales of SF-36 health survey were scored in all four groups:
physical functioning (PF), role physical functioning (RP), bodily pain (BP),
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general health (GH), vitality (VT), social functioning (SF), role emotional
functioning (RE), and mental health (MH). Baseline QOL was better in
younger versus older group. Summarizing the results, PF, RP, VT and GH were
deteriorated after one month in older group (p<0.001- 0.003) and recovered
close to baseline after six months. Bodily pain was worst in younger group
one month and six months after surgery, while all the other scales recovered
close to baseline. PF, RE and MH were deteriorated significantly in non related
versus related donors after one month while BP,VT and SF follow the same
returning in both groups. Six months after surgery non significant differences
were detected.
Conclusion: QOL in non-related versus related donors returned at a baseline
but following a slowly curve in the first group. Bodily pain scale in young
donors recovered less effective than older donors while QOL in general return
close to a baseline in older patients after six month following a slowly curve
than younger donors. Considering that surgical results and graft function are
comparable in all four groups, further expansion of borderline older donor pool
is accepted.
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1848 COMPARATIVE QUALITY OF LIFE ASSESSED BY
SF-36 HEALTH SURVEY IN RENAL TRANSPLANT PATIENTS,
HEMODIALYSIS PATIENTS, ANEPHRIC PATIENTS FOR
RENAL MALIGNANCIES AND PATIENTS WITH MALIGNANT
UROLITHIASIS

1849 PERCEPTIONS OF GRAFT REJECTION AMONG SOLID
ORGAN TRANSPLANT RECIPIENT – STRIVING TO CONTROL
THE UNCONTROLLABLE
M. Nilsson1, A. Forsberg2, L-O. Persson2
Ward 324, Queen Silvias Childrens Hospital, 2Institute of Health and Care
Sciences, Salgrenska Academy, University of Gothenburg, Gothenburg,
Sweden
Background: Rejection is the most common cause of graft loss and graft
dysfunction in clinical transplantation. Little is known about organ transplant
recipients’ own models of explanation related to graft rejection.
Aim: To investigate perceptions of experiences of graft rejection.
Method: A qualitative phenomenographic approach was chosen, since
phenomenography is the empirical study of the different ways in which
people experience, perceive, apprehend, understand and conceptualise various
phenomena in and aspects of the world around them. A strategic selection
included patients who had undergone a kidney, liver, heart or lung transplant.
Sixteen patients, 6 males and 10 females, aged between 21-63 years, with a
follow-up time of between 3 months to 10 years, were interviewed.
Results: The result comprised five domains of variations in perceptions of graft
rejection:
the abstract threat to life
the concrete threat to health
trust in the body
striving to control the threat
one’s identity
The inner perspective and personal explanation models involved threat, fear,
trust, control and identity adjustment. Different approaches had the same
purpose; ‘striving to control the uncontrollable’.
Clinical relevance: The inner perspective of graft rejection leads to several
clinical implications in terms of patient education and recipients’ differing ways
of obtaining knowledge about graft rejection. We suggest that patient education
should be tailored in a different way, offering support and advice in line with
their personal models of explanation of graft rejection as a complement to the
explanation from the biomedical model of disease.

1
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1850 EXAMINATIONS CONCERNING ORGAN-INTEGRATION
AFTER LIVING KIDNEY DONATION
U. Ott2, U. Wutzler1, K. Therolf-Henke1, T. Steiner3, M. Geyer1, M. Venner4
1
Clinik of Psychotherapy und Psychosomatic Medicin, University of Leipzig,
Germany, 2Department of Internal Medicine III, Friedrich-Schiller-University
Jena, Germany, 3Department of Urology, Friedrich-Schiller-University
Jena, Germany, 4Institute of Psychotherapy and Psychoanalysis e.V., Jena,
Germany
Background: In the course of an organ transplantation the recipient appropriates
a part of the donor. As yet little is known about the necessary process of psychic
organ integration. It is the goal of the present study to describe this process in
the context of living kidney transplantation.
Methodology: We carried out a survey among 49 recipients (30 men, 19
women; average age: 48 years, 19 - 70 years) concerning organ integration at
the transplantation centre of the Friedrich Schiller University Jena (Germany).
Among other things, participants were asked to describe their organ-related
conceptions and fantasies.
Results: 2/3 of the sample concern themselves with the transplanted kidney.
Half of these perceive the transplant as a foreign organ. The transplanted kidney
is associated with a great variety of fantasies and associations by the recipient.
The analysis of the open-end questions of the inventory makes clear a positive
perception of the transplanted kidney. At the same time the fear of organ loss is
perceptible. This manifests itself in exhortations to hold out and the hope of a
long functionality of the organ.
Conclusions: A positive perception of the foreign organ helps the recipient to
overcome existing anxieties and fears. In living organ donation the emotional
tie to the donor appears to have a positive effect on the integration process of
the foreign organ.
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M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, D. Tacu, E. Kerezsy,
L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni
Clinical Institute
Introduction: SF-36 Health Survey is an assessment method of health status.
This study was designed to examine the quality of life (QOL) in four groups of
patients: renal transplant patients, patients in hemodialysis program with native
kidneys, anephric patients in dialysis program for renal malignancies and nondialysis chronic renal failure urolithiasis patients.
Patients and methods: 104 renal transplant recipients, 70 patients in
hemodialysis program, 11 anephric patients for renal malign condition and
25 patients suffered of severe urolithiasis complicated with chronic renal
failure were included in this study. Eight scales of SF-36 health survey were
scored: physical functioning (PF), role physical functioning (RP), bodily
pain (BP), general health (GH), vitality (VT), social functioning (SF), role
emotional functioning (RE), and mental health (MH). The scores of scales
were compared among three groups and a correlation with clinical parameters
was made.
Results: The scale scores of PF, RP, BP, GH, VT, SF, RE, and MH were
as follows: 84.6, 77.4, 78.6, 56.3, 64.1, 80.2, 79.1, 68.8, for the recipients
of renal transplant, 81.8, 65.6, 69.2, 49.8, 59.4, 72.2, 70.6, 74.2, for the
patients receiving hemodialysis, 82.2, 68.6, 71.2, 49.9, 61.2, 73.3, 72.6,
69.9 for anephric patients secondary to a malignancy and 80.2, 70.2, 48.6,
50.2, 62.4, 70.1, 73.5, 71.9 for the patients suffered of renal failure due to
urolithiasis.
Conclusion: SF-36 health survey is a proper method for evaluating the quality
of life, PF, VT and GH scores were quite similar for the four categories
of patients in comparison with a general population sample. They were
significantly dependent on serum creatinine level. The BP score were the
lowest in the malignant urolithiasis.
In our study, excepting the mental health score, all the other seven scores were
better in the transplant group. Considering a general population sample score
as 100% (which represents in reality 76.6% of the ideal score), the quality of
life was 96% in the Tx group, 88.6% in the hemodyalisis group, 88.5% in the
anephric by renal malignancy group and 86% in the urolithiasis group. In our
study, transplantation improved the quality of life.
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1851 QUALITY OF LIFE AFTER LIVER TRANSPLANTATION
IN ESTABLISHED AND INDIVIDUAL SCALES
M. Schenk, K. Landgrebe, W. Steurer, A. Königsrainer
University Hospital Tuebingen - General, Visceral and Transplant Surgery
Liver transplantation is an event that changes life radically. A lot of hopes
for a better life are involved, some are justified some are not. However, the
individual picture of life quality is different. The current study tries to address
this issue by comparing data of life quality using the fixed scales of an SF-36
questionnaire and comparing them to the results of the SEIQoL questionnaire
an to the results of a normal population.
In an interview style 71 patients (77% male, median of age 54 years, 21 months
from transplantation) were asked to complete the SF-36 and the SEIQoL
questionnaire in a cross-section design after liver transplantation (Follow-up:
0.5-159 month, Median: 21 month). The scales were calculated and compared
to the published results of a normal population. 26 scales were set up, 5 scales
were mentioned more than any other (family, friends, sports, partner and job).
People with a high priority for the job reported a significantly lower quality of
life (65 SD 19) than the others (79 SD 12).
It became clear that in the SF-36 scores the total life quality of our transplant
patients (sum score) was excellent an directly comparable to a normal
population. The transplant recipients only were lower in two scales directly
linked to physical strength. In the SEIQoL questionnaire resulted in 72 (SD 17)
points compared to 77 (SD 10) in the normal population.
Comparing the age-dependency in three groups (A:≤; 40 y; B:40- 60 y; C:≥;
60 y) it became obvious that the results of the SF-36 resulted comparable in all
three groups (75 SD15, 72 SD17 and 76 SD17), but raised with age in the more
individual scores (A: 66 SD21, B: 71 SD17 and C: 80 SD13 points.)
Beside many more details the results of this study can be used for interviews
with transplants candidates. The complete analysis of the former data can make
this large change a little bit smaller and shows more or less helpful items in the
personal transplant preparation.
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1852 COMPARISON AND ESTIMATION OF QOL BY
SF-36 BETWEEN RENAL TRANSPLANT PATIENTS AND
HEMODIALYSIS PATIENTS
M. Ikeda1, K. Yoshida1, T. Hyodo1, Y. Takeuchi2, H. Wakai2, M. Sueki1,
F. Noguchi1, T. Endo1, S. Baba1
1
Kitasato University Urology, 2Kitasato University Nephrology
Marked improvement of quality of life (QOL) is expected in patients of
hemodialysis (HD) after renal transplantation (RTX). However there have been
very few studies to investigate about change of QOL from HD to RTX. We
estimated QOL in the patients of HD and RTX using Short Form questionair-36
(SF-36) and compared them.
Materials and methods: We sent SF-36 questionnaire to 42 RTX patients
(male/female: 25/17)(average age 44.4+/-12.0) who underwent renal graft in
our hospital, and 45 HD patients (male/female: 23/22)(average age 63.3+/-10.6)
who received HD in HD clinic nearby our institute. Average period of post
transplant was 113.1+/-112.6 months in RTX patients, and average period
of HD was 82.2*/-56.8 months in HD patients. SF-36 questionnaires were
retrieved at the out-patient clinic or in the HD clinic after HD.
Results: QOL in the patients of RTX was significantly better in social function
(SF) (p=0.231) and in role-emotional (RE) (p<0.001) but no difference was
recognized neither in vitality (VT) nor mental health (MH). Those QUL scores
were found better in RTX patients than in HD in all subscales. However, both
QOL scores were much worse when comparing to those of national standard.
Discussion: The improvement in QOL by RTX in end stage renal disease
patients was recognized by SR-36 questionnaire. However, improvement
was less then we expected. The study we conducted in this paper was crosssectional study. The patients in both groups were stable stage for the therapy
and may be satisfied and accept their situation. On the other hand the patients
who underwent RTX may desire much better condition than they are in now.
We should conduct longitudinal study about QOL in each patients along the
time course before and after RTX.
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1853 IMMUNOSUPRESSION-FREE PROTOCOL IN SOLID
ORGAN TRANSPLANTATION YEARS FOLLOWING
BONE-MARROW TRANSPLANTATION
E. Mor1, N. Bar-Nathan1, Y. Frishberg2, R. Becker-Cohen2, T. Klein3,
D. Krist3, R. Shapiro4, Y. Avitzur4
1
Department of Transplantation, Rabin Medical Center, Petah-Tiqwa,
2
Division of Pediatric Nephrology, Sharee Zedek Medical Center, Jerusalem,
3
The cross-match laboratory, Rabin Medical Center and 4Institute of
Gastroenterology and Nutrition, Schneider Children’s Medical Center of
Israel, Petach-Tiqwa, Israel
In reported cases of solid-organ transplantation immediately following bonemarrow transplant (BMTX), immunosuppression was initially administered
to prevent GVHD and gradually withdrawn. We report two children who
received solid-organ grafts years after BMTX from the same donor without
any immunosuppression.
Patients and methods: The first patient is a 17-y/o boy who underwent BMTX
for ALL from his fully HLA-matched sister at the age of 3-years. Chronic renal
failure developed following total body irradiation. The patient underwent
kidney transplantation from the same donor with a single i.v. steroid-bolus
before reperfusion and without any immunosupression thereafter. The second
patient is a 10-y/o boy who received a BMTX from his HLA-matched sister
at the age of 7-months for SCID. Chronic liver disease associated with
hepatopulmonary syndrome developed 9-years after BMTX. Following testing
for chimerism, the child received a segmental-liver graft from his sister using a
single steroid-bolus with no further immunosuppression. Chimerism was tested
in DNA extracted from peripheral blood lymphocytes by the STR method and
the presence of XX genotype by the FISH technique.
Results: Nine months post-transplant the first child has creatinine levels of
1.0mg/dL. The second child was weaned off oxygen 4 weeks post-transplant
and at 3-months has normal liver function tests. Both children have had no
episode of acute rejection or GVHD
Conclusion: Children who are full chimeras may benefit from immunosuppressivefree protocol when a solid organ transplant is performed from the same HLAmatched living donor years after the bone-marrow transplant.
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1854 BILIARY STRICTURES IN PAEDIATRIC DECEASED
DONOR SPLIT LIVER TRANSPLANTS (SPLITX)
E. O’Loughlin1, M. Stormon1, A. Shun1, D. Verran2, M. Crawford2,
L. Resurruccion1, V. Jermyn1, C. Wong1, D. Lord1
1
Children’s Hospital At Westmead, 2Royal Prince Alfred Hospital
Biliary strictures are a common complication of SpliTx. While hepatic artery
thrombosis (HAT) is a known risk factor, biliary strictures are more common
than HAT post SpliTx.
Aim: is to review biliary strictures in SpliTx (2000-2007) and to determine
possible risk factors for stricture.
Method: Deceased donor grafts (usually segment II and III) were split off
site (majority insitu) and transferred to CHW and inserted using standard
surgical procedures. Cold (CI) and warm (WI) ischemia times were measured
during surgery. Intraoperative “Transonic” probe measurement (IO) of hepatic
artery (HA) and portal vein (PV) flow was performed and post operative (PO)
HA and PV flow patterns were assessed 2nd or 3rd daily for 7-10 days and
regularly thereafter by Doppler ultrasound. Biliary strictures were identified by
abdominal ultrasound and percutaneous cholangiogram.
Results: 47 patients underwent SpliTx and 14 developed biliary strictures.
Weight PO-HA
(Kg)
abnormality*
Stricture 14
13.9±2.2 8 (3HAT)
No Stricture 33 13.2±1.3 3 (1HAT)
p
ns
<0.001

CI (Hr)

WI (Hr)

8.5±0.7
8.7±0.5
ns

1.1±0.3
1.3±0.2
ns

IO-HA
(ml/min)
87.5±9.0
127.8±10.1
<0.02

IO-PV
(ml/min)
494±104
534±84
ns

Death/ reTx
2
4
ns

Table: Data is X±SE; *HAT or loss of HA flow or abnormal Doppler wave
form.
Ten strictures were anastomotic, 5 with normal PO-HA and 4 intrahepatic, 1
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with normal PO-HA. PV thrombosis occurred in one patient without stricture.
Conclusions: In addition to HAT, abnormal HA flow patterns on Doppler
ultrasound are associated with the development of biliary strictures. Donor
graft factors other than ischemia may contribute to stricture formation.

POSTER BOARD NUMBER P3 – 281
1855 SHORT-TERM OUTCOMES OF PEDIATRIC RENAL
TRANSPLANT RECIPIENTS RECEIVING A NOVEL STEROID
MINIMIZATION IMMUNOSUPPRESSION PROTOCOL
L. Butani1, K. Lau1, G. Berg1, R. Perez2
1
Department of Pediatrics, University of California, Davis, 2Department of
Surgery, University of California, Davis
Background: Although steroid minimization regimens are commonly used in
adult renal transplant (tx) recipients, the pediatric community has been slow to
follow suit. At our center, we have been using a novel and convenient steroidminimization regimen in children after renal tx since 2004.
Objective: To determine the safety and efficacy of a novel steroid minimization
protocol after renal tx at our center.
Design/methods: Records of children receiving renal tx at UC Davis from
1/04 - 11/07 were retrospectively abstracted for data. Protocol included 3
tapering daily doses of steroids, along with 5 doses of Thymoglobulin followed
by maintenance therapy with tacrolimus (FK) and mycophenolate mofetil.
Surveillance renal biopsies (bx) were performed at 6 and 12 months. Student’s
t-test was performed to compare pre-tx and last FU data.
Results: 16 pts underwent tx during the study period; 31% received preemptive
tx. Median age at tx was 12.3 yrs with median follow up (FU) of 1.3 yrs.
Compared to pre-tx levels, at last FU, median serum creatinine improved from
7.8 to 1.0 mg/dL (p<0.05); hemoglobin changed from 12.3 to 11.8 g/dL (p=0.1);
WBC changed from 8.6 to 5.8 x 103/L (p<0.05); glucose changed from 92 to
87 mg/dL (p=0.78); cholesterol improved from 163 to 128 mg/dL (p<0.05).
Only 1 pt switched from FK to sirolimus due to calcineurin nephropathy on
surveillance bx. At last FU 6% and 25% of pts were on erythropoietin and
antihypertensives respectively. No pt became diabetic. There was no clinical
acute cellular rejection or post-tx lymphoproliferative disease. None of the bx
showed subclinical rejection. 2 pts had recurrent FSGS and were treated with
plasmapheresis (pp). One pt received a positive crossmatch kidney, developed
humoral rejection and was successfully treated with pp and IVIg. There was no
incidence of EBV infection/viremia. One CMV negative pt had asymptomatic
virema at 9 months post-tx and is maintained on valganciclovir. 1 pt developed
pneumonia (pna) and pleural effusion at 2 months post-tx. Another pt with
HUS related chronic lung disease had episodes of pna. 3 pts developed stentrelated UTI. All these infections were successfully treated with antibiotics.
Conclusions: Our novel steroid-minimization immuosuppression is safe in
children after renal tx and associated with a very low risk of rejection and
infection. A larger number of pts and longer FU are required to further confirm
the effectiveness and safety of this approach.
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L. Butani1, K. Lau1, G. Berg1, Y. Schjoneman1, R. Perez2
1
Department of Pediatrics, University of California, Davis, 2Department of
Surgery, University of California, Davis
Background: Due to the ongoing shortage in organ supply, en-bloc renal
transplantation from small donors has become more common for children with
ESRD. However, because of concern of higher complication rates, it is not
being performed in every center. Its safety in the setting of steroid minimization
immunosuppression has not been investigated.
Objectives: To determine the safety and short term outcomes of en-bloc renal
transplantation in children at a single transplant center.
Methods: Medical records of all children (< 18 years) receiving en-bloc renal
transplants at our institution from 1/07 - 12/07 were retrospectively abstracted for
data. Data collected included age, sex, ethnicity, and pre-transplant mode of renal
replacement. Donor age, cold and warm ischemic time and surgical technique were
also recorded. Laboratory values included the serum creatinine, hemoglobin, white
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1857 IMPROVED OUTCOME WITH IMMUNOSUPPRESSIVE
MONOTHERAPY AFTER RENAL TRANSPLANTATION IN
SCHIMKE-IMMUNO-OSSEOUS DYSPLASIA
L. Pape1, N. Kanzelmeyer1, A. Baradaran-Heravi2, C. Boerkoel2, M. Burg3,
J. Ehrich1, T. Lücke1
1
Department of Pediatric Nephrology, Medical School of Hannover, Germany,
2
Centre for Molecular Medicine and Therapeutics, University of British
Columbia, Canada, 3Nephrologic Center Lower Saxony, D- 34346 Hann. Münden
Schimke-immuno-osseous dysplasia (SIOD) is a multisystem disorder caused
by a mutant chromatin remodeling protein. The main clinical findings are
spondyloepiphyseal dysplasia with dysproportionate growth restriction,
defective cellular immunity, and nephrotic syndrome with focal and segmental
glomerulosclerosis (FSGS) leading to renal failure. Concerning renal
insufficiency, kidney transplantation is the therapy of choice since FSGS does
not show recurrence in the transplanted organ. However, with respect to the
underlying immune disorder and the increased susceptibility to life threatening
infections, the question of the optimal immunosuppressive therapy after renal
transplantation remains unsolved. Under conventional immunosuppressive
regimens some SIOD patients have developed severe disseminated cutaneous
papilloma virus infections or Epstein-Barr virus associated lymphoproliferative
disease. We have found that immunosuppressive monotherapy results in
a good outcome with a reduced number of severe infections. Therefore
mild immunosuppression in SIOD may be possible due to the underlying
immunodeficiency without an elevated risk of acute or chronic rejections.
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1858 LONG TERMS OUTCOMES AFTER LIVER TRANSPLANT
FOR PEDIATRIC ACUTE LIVER FAILURE (ALF)
J.S. Bagia, R. Mohanka, Z. Machaidze, R. Squires, B. Schneider,
A. Thompson, K. Soltys, G. Bond, R. Sindhi, G. Mazariegos
Childrens Hospital Pittsburgh
Aim: to report our experience in liver transplant for fulminant liver failure in
the pediatric population with particular focus on long term outcomes and the
impact of live donor transplantation.
Methods: Children with fulminant liver failure treated between 1997 and
2007 were reviewed for cause of liver failure, time to treatment, treatment,
complications and long-term immunologic and clinical outcomes.
Results: 32 children (17 boys and 15 girls) with a median age of 23 months
(range = 2 weeks to 17 years) with fulminant liver failure underwent transplant
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1856 PEDIATRIC EN-BLOC KIDNEY TRANSPLANTATION
INTO PEDIATRIC RECIPIENTS WITH STEROID
MINIMIZATION PROTOCOL: SINGLE CENTER EXPERIENCE

blood cell count, blood glucose and cholesterol. Post-operative immunosuppression
included 3 tapering daily doses of steroids with 5 doses of Thymoglobulin ®
followed by maintenance therapy with tacrolimus and mycophenolate mofetil.
Surveillance renal biopsies were performed at 6 and 12 months.
Results: Three patients (ESRD due to HUS in 1; unknown etiology in 2)
underwent en-bloc renal transplantation during the study period. Median age
at transplantation was 16.7 years with a median follow-up of 0.7 years. Donor
age ranged from 9-49 months with a body weight from 10 to 22 kg. The grafts’
aortas were anastomosed to either the common or external iliac artery, while
the inferior vena cava was anastomosed to the external iliac vein. No technical
complication was observed in the post-operative period. One patient had
delayed graft function due to acute tubular necrosis secondary to prolonged
hypoxia in the donor. Another patient suffered from acute deterioration of serum
creatinine due to tacrolimus toxicity. Both patients recovered without long term
consequences. Nuclear medicine renal scans documented good function of
both renal allografts before hospital discharge in all patients. All grafts showed
increased renal size at follow up ultrasound. There was no clinical rejection at
last follow-up. Two patients underwent surveillance biopsies; neither showed
sub-clinical rejection or chronic changes.
Conclusions: Based on our experience, albeit very limited, we feel that en-bloc
renal transplantation from young donors is an acceptable and safe procedure
with low complication rates in the pediatric recipient. The short term clinical
outcomes using our steroid minimization protocol on these patients were
satisfactory. A larger number of patients and longer term follow up are needed
to confirm the safety of this approach.
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during the study period. 8 children underwent living related liver transplant
(LRLT) with left lateral segments, and 24 received deceased donor livers
(DDLT) with 7 split/reduced livers and 17 whole livers. Indication for transplant
in the 8 patients who had LRLT were acute fatty liver in one, cryptogenic in
two, enteroviral sepsis in 2, autoimmune hepatitis in one, tyrosinemia in one
and neonatal herpes simplex hepatitis in one. Median time to transplant was 2
(range 0-23) days in LRLT and 5 days (0-21) for deceased donor transplant.
Overall patient survival is 94% and graft survival is 90% at 84 months median
follow up (range 1-245 months). Re transplantation was successful in 1 LRLT
for hepatic artery thrombosis (HAT). One DDLT was retransplanted for late
HAT (3 years). There were 2 deaths after DDLT due to PTLD in one and primary
non function and subsequent sepsis while awaiting retransplant in the other.
Liver function is normal in all 30 survivors. Current immunosuppresion in the
8 LRLT is once daily tacrolimus in 5, tacrolimus and prednisone in 2 and 1 is
off immunosuppression treatment for EBV infection. In the 22 DDLT 10 are
currently on tacrolimus and prednisone, 1 is on tacrolimus and sirolimus, 6
are on once daily CNI (5 on tacrolimus and 1 on sirolimus) and 5 are on twice
daily tacrolimus
Conclusions: Long term results after LT for acute liver failure are comparable
to transplant for non-ALF indications. LRLT improves timing of transplant and
minimization of immunosuppression may contribute to success of transplant in
this challenging patient population.
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1859 ACCELERATED VASCULAR ALLOGRAFT
CALCIFICATION IN YOUNG TRANSPLANTATION IS NOT
RELATED TO IMMUNE RESPONSE BUT TO ITS ACTIVE
BONE GROWTH
H. Yamauchi1, N. Motomura1, M. Sata1, D. Takai1, U. Chung1, A. Saito2,
S. Takamoto1
1
University of Tokyo, 2University of Western Ontario
Background: Vascular allografts transplanted in youth tend towards early
graft failure due to accelerated calcification, but the etiology is still unknown.
Immunoreactivity may promote graft calcification, whereas physiological
hyperphosphatemia resulting from active osteogenesis in youth could be
involved in the pathogenesis. We examined the development due to youth of
allograft calcification, associated with immunoreactions and hyperphosphatemia
in a rat model on a phosphorus control diet.
Methods: Three-week-old “young” and 10-week-old “adult” Lewis (Lew) and
Brown-Norway (BN) rats were used and a standard diet (0.9% of phosphorus)
was given. Fresh descending aortas of donors were transplanted under the
abdominal skin of recipients, and were explanted 14 days later. Syngeneic
transplantation between young Lew (“Y-syn”), between adult Lew (“A-syn”),
and allotransplantation from young BN to young Lew (“Y-allo”), from adult BN
to adult Lew (“A-allo”) were performed. Pre-transplant donors of young and
adult rats were defined as “Preop-Y” and “Preop-A”. Then, a low phosphorus
(LP) diet (0.2% of phosphorus) was given to recipients of Y-syn and Y-allo
(“Y-syn-LP” and “Y-allo-LP”). Calcification of all explants, serum and graft
inorganic phosphorus (Pi) levels, and gene expression of syngeneic transplants
were analyzed.
Results: Graft calcification was severe in Y-syn and Y-allo, mild in A-allo, but
absent in A-syn and the Preop animals in von Kossa staining. Atomic absorption
spectroscopy revealed that the graft calcium contents of Y-syn, Y-allo, A-syn,
A-allo, Preop-Y, and Preop-A were 4.35, 4.29, 0.16, 0.43, 0.07, and 0.04 mg/
dry&#903;g, respectively, showing significantly higher levels for Y-syn and
Y-allo than for A-syn, A-allo, and Preop (p<0.0001), but no difference between
Y-syn and Y-allo. The serum Pi levels of Y-syn and A-syn were significantly
different (10.98 and 8.29 mg/dl, p<0.05), unlike serum calcium (10.88 and
11.01 mg/dl). The graft Pi contents of Y-syn, A-syn, Preop-Y, and Preop-A were
1.95, 0.14, 0.80, and 0.21 mg/dry&#903;g: significantly higher in Y-syn than in
the others (p<0.001). Electron microscopy showed phenotypic changes of graft
media cells from the contractile to the synthetic type. Realtime RT-PCR revealed
90% down-regulated myogenic {ƒ¿-smooth muscle actin (SMA)}, 500% upregulated pro-inflammatory (tumor necrosis factor-ƒ¿), and up-regulated
osteogenic (Runx2, 650%; osteocalcin, 250%) gene expressions in both Y-syn
and A-syn, postoperatively. Immunohistochemistry showed reduced ƒ¿-SMA
protein and induced CD68 (macrophage), Runx2, and osteocalcin protein in
both Y-syn and A-syn, especially in Y-syn calcified regions. Following a low Pi
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diet, Y-syn-LP and Y-allo-LP showed no graft calcification. In Y-syn-LP, serum
Pi (8.94 mg/dl, p<0.01), graft Pi (0.43 mg/dry&#903;g, p<0.001), and graft
calcium (0.49 mg/dry&#903;g, p<0.005) were all lower than Y-syn, and similar
relationships were seen in the Y-allo-LP and Y-allo groups.
Conclusions: These data suggested that: (1) in youth, vascular allograft
calcification was accelerated; (2) immunoreactivity did not significantly
affect acceleration of graft calcification in youth, but did somewhat in adults;
(3) osteogenic transformation of graft media cells, which may cause graft
calcification, was triggered by the inflammatory stimulus in both young and
adults; and (4) a sufficient supply of tissue inorganic phosphorus was a critical
factor in graft calcification in youth.
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1860 REHABILITATION AND TRANSITION AFTER LUNG
TRANSPLANTATION IN CHILDREN
J.H. Burton, J-M. Marshall, P. Munro, W. Moule, G. Westall
Paediatric Lung Transplant Service, The Alfred, Melbourne, Australia
In 2005, a paediatric lung transplant service was established alongside the
existing adult lung transplant program at The Alfred Hospital, Melbourne,
Australia. This necessitated the development of an age appropriate version
of the adult recovery and rehabilitation program by the multidisciplinary
team to best meet the needs of children and their families following lung
transplantation.
The aim is to describe the key components, structure and content of the
outpatient recovery and rehabilitation programme provided by the Paediatric
Lung Transplant Service at The Alfred Hospital.
To date the service has transplanted 5 children (age 9-15 yo; 80% female; cystic
fibrosis n = 3, obliterative bronchiolitis n = 1, bronchiectasis n = 1) who pretransplant lived both locally and interstate (Queensland).
Following discharge post lung transplant, in addition to their regular transplant
clinic reviews, all patients and families participated in a 3 month outpatient
rehabilitation programme. This comprised of 3 physiotherapy sessions, 1
occupational therapy session and 1 education session per week for the child and
2 education sessions per week for parents. The overall aim of the programme
was to comprehensively address physical rehabilitation, psychosocial and
educational needs. Sessions were tailored to meet the individual needs of
the children and their families and reflected a flexible approach with active
participation. After each session feedback was provided to parents regarding
issues discussed and the management plan. Dietetic reviews were carried out
during this time as required.
Physiotherapy included a progressive aerobic and strength training program,
postural re-education and core stability. Age appropriate play activities
(running, dancing, jumping, ball skills, etc) were incorporated.
Occupational Therapy sessions included addressing the primary occupational
roles of patient, student and player, through therapeutic use of play. Themes
included returning to school, friends and the community. Issues discussed
include adjustment to new health status, participating fully again within the
family, strategies to manage side effects of medications and altered body image
issues.
Education sessions for both the children and parents focussed on medications,
infection and rejection, nutrition, physiotherapy/rehabilitation, occupational
roles and stress management, donor issues and psychosocial readjustment.
Information for children was presented at an appropriate age and cognitive
level. Tools used included drawing, open ended questions, internet health
websites and the Roche CC Care Program.
A weekly paediatric multidisciplinary team meeting was used to discuss and
plan the rehabilitation progress, ensuring consistence in the delivery of care
and information to the child and their family.
School liaison and visits occurred prior to school commencement and follow
up contact and visits are also offered to review the ongoing transition process.
Patients, their families and the multidisciplinary team report a high level of
satisfaction with this model of care. Our plan is to review this service formally
in the near future. It is hoped that this programme will continue to promote and
ensure appropriate recovery and rehabilitation of children and their families
post lung transplant. In preparing them for transition, ensuring a greater quality
and a life filled with increased opportunity for meaningful engagement.
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1861 SUCCESSFUL MANAGEMENT OF RECURRENCE OF
FAMILIAL HUS POST RENAL TRANSPLANTATION
E. Ball, W. Wong, T. Kara, M. Morris, J. Ronaldson
Starship Childrens’ Hospital
Familial haemolytic uraemic syndrome (HUS) frequently leads to end stage
kidney disease and often recurs after transplantation. Long term graft survival after
recurrence of is very poor, with almost all grafts being lost over a period of time.
We present the case of a 20 year old girl who developed recurrent HUS in
infancy and progressed to end stage kidney at the age of 11. An older sibling
had died of HUS in the first year of life. She has no known mutations in the
Factor H, Factor I or MCP genes and further mutation analysis for complement
defects is underway. She received a well matched deceased donor kidney at the
age of 18. Her initial immunosuppression regimen consisted of basiliximab,
methylprednisolone and mycophenolate mofetil. The introduction of
tacrolimus was delayed until day 5 when her renal function had stabilised. She
received fresh frozen plasma (FFP) pre operatively, then daily for one week
post transplant, twice weekly for a further fortnight and then weekly as part of
a recurrence prevention plan.
She had immediate graft function and the first post operative month was
uneventful. On day 49, she had a sharp rise in serum creatinine to 150μmol/L
(baseline 80-90μmol/L). This was associated with a rise in LDH, although
haemoglobin and platelet counts remained stable. She was commenced on high
dose FFP infusions (30ml/kg/day) for 4 days. Transplant biopsy confirmed early
HUS recurrence and she began plasmapheresis with FFP on day 54. She received
daily plasmapheresis sessions for one week, then 2-3 weekly sessions for a further
3 weeks, then weekly sessions for a further 5 weeks. Following discontinuation
of plasmapheresis she received daily high dose FFP for a week and the frequency
of these infusions was weaned and finally stopped 6 months post transplant.
At present she has excellent allograft function with a serum creatinine of
80μmol/L and has shown no further signs of disease recurrence.
A high level of suspicion should be maintained for recurrent HUS post
transplantation even in the absence of typical features of thrombotic
microangiopathy. Early diagnosis and prompt treatment with high dose FFP
infusions, a prolonged course of plasmapheresis and slow tapering of the FFP
infusions may have been beneficial in retaining allograft function in our patient.
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value=0.0148, p<0.005). Titre read by immunospot plate reader was higher
overall but failed to reach significance. Similar results were obtained for anti-B
titre (n=17, difference in mean OD value=0.0094824, p<0.005). Our method
required 200 uL of serum to complete the test as compared to the tube test that
required 900 uL.
Conclusions: Micro-plate hemagglutination assay is an efficient and sensitive
technique to measure anti-A and anti-B titre and easily reproducible. This
method can be standardized in all centres with minimal variation that will
facilitate the development of new management protocols. Sample volume is
also a major limiting factor especially in a growing number of infant recipients
of ABO-incompatible heart transplantation and our method is of particular
benefit in this patient population.
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1863 POSTOPERATIVE CARE AFTER PEDIATRIC COMBINED
HEPATORENAL TRANSPLANTATION (CHRTX)
M.J. Kemper1, K. Helmke2, R. Ganschow3, L. Fischer4, B. Nashan4,
D.E. Müller-Wiefel1, E. Harps5
1
Pediatric Nephrology, 2Pediatric Radiology, 3Pediatric Gastroenterology,
4
Transplantation Surgery, 5Pediatric Intensive Care
CHRTx may be indicated for structural disorders involving kidney and liver
(e.g. autosomal recessive polycystic kidney disease, ARPKD) or metabolic
disorders where the hepatic enzyme defect results in damage of the kidney
(e.g. primary hyperoxaluria, PH1). Since 1998 we have performed CHRTx
in 9 children, 3 with ARPKD and 6 with PH1. This included 3 girls and 6
boys with a median age of 8 years (range 1.5-16) and a median weight of 18
kg (range 9.6-55). Median stay of ICU was 9 days (range 5-50). Mechanical
ventilation varied significantly: 4 children could be extubated within 24 h after
CHRTx, while 3 required ventilation for longer than 25 Days (24, 34 and 42,
respectively). Renal replacement therapy was necessary in 6 patients, mostly
to decrease plasma oxalate load in PH1; median duration was 2 days (range
0-30). Erythrocyte transfusions were necessary in a median of 2 (0-31), FFP
in 2 (0-31) and platelet transfusion median 1 (0-12). Complications included
bleeding, infections, primary graft failure and rejection. One patient required a
second CHRTx and later a third liver graft. All patients were discharged from
ICU in stable condition, there was no mortality. Long-term graft function is
excellent in 8 patients with sufficient follow-up (>9 months). In summary and
conclusion CHRTx is a multidisciplinary challenge that has to face a variety of
complications. Long-term results are excellent.

1862 MICRO-PLATE HEMAGGLUTINATION ASSAY: A
SIMPLE AND SENSITIVE TECHNIQUE TO MEASURE ANTI-A
AND ANTI-B ANTIBODY TITRE IN PATIENTS UNDERGOING
ABO-INCOMPATIBLE ORGAN TRANSPLANTATION

1864 RADIATION EXPOSURE IN THE FIRST YEAR
FOLLOWING PAEDIATRIC LIVER TRANSPLANTATION

M. Jeyakanthan, L. Podlosky, S. Senthilselvan, S. Maier, I. Larsen,
S. Nahirniak, L. West
University of Alberta
Introduction: Accurate and reliable measurement of anti-A and anti-B antibody
titre is important in the management of patients undergoing or being considered
for ABO-incompatible organ transplantation. Development of new protocols
on the basis of clinical experience is important in improving outcomes.
However due to lack of a standardized method for measuring antibody titres,
results from different centres are not comparable. The purpose of this study
was to develop a simple, reliable and sensitive method for measuring anti-A
and anti-B antibody titre.
Methods: Serum samples from human volunteers of different ABO-blood types
(n=20) were tested for anti-A and anti-B titre by our newly developed microplate assay and the widely used tube test. Micro-plate assay was performed on
a 96 well round bottom plate with each well containing 50uL 2-fold serially
diluted serum (1 to 2048) incubated with 25uL of 2-4% A1 and B erythrocytes
for 1 hour; agglutination was read using either immunospot plate reader or
an inverted microscope. Tube tests were done according to our institutional
protocol. Antibody titres obtained by the two methods were compared to antiA/B IgM measured by ABO-ELISA. Paired t-test analysis was performed by
comparing the corresponding ELISA OD value for each titre measured by the
two different methods.
Results: The overall anti-A titre (n=17) read by inverted microscope was
significantly higher than that measured by the tube test (difference in mean OD

I. Diamond1, B. Ahmed2, K. Thomas2, E. Hoppe1, B. Connolly2, D. Grant1,
V. Ng1, P. Wales1, A. Fecteau1
1
Paediatric Academic Multiorgan Transplant Program, 2Department of
Diagnostic Imaging, The Hospital for Sick Children
Introduction: As survival of children undergoing transplantation continues to
improve greater emphasis is being placed on the potential long term sequelae
related to therapy. There is an increasing awareness that ionizing radiation
related to diagnostic imaging may be a risk factor for future malignancy.
However, little is known of the cumulative effective radiation dose received
by children undergoing transplantation. We sought to examine diagnostic and
therapeutic radiation exposure over the first year following liver transplantation
in a cohort of paediatric patients.
Methods: All children who received a liver transplant at our institution between
1 July 2001 and 30 June 2006 were included in this retrospective cohort study.
Records of all diagnostic and therapeutic procedures with exposure to ionizing
radiation, within 1 year of transplant, were obtained from our electronic
diagnostic imaging database. Age-specific effective radiation dose estimates
were assigned to each study using institutional dose data and estimates derived
from the pediatric radiological literature. Cumulative effective dose estimates
at 60 days and 1 year following transplant were calculated for each patient.
Results: Sixty-seven children were included in this study, with an overall
survival of 92.5% at 1-year. Median age at transplant was 4.7 (range 0.1 –
17.9) years. Estimated median effective dose of radiation in the first 60 days
following transplant was 8.0 (range: 0.1 – 86.6) milisieverts [mSv] and 14.2
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(range: 0.2 – 189.6) mSv in the year following transplant. At 1-year, the median
effective dose amongst our patients represents a 4.7 fold increase over annual
background radiation exposure (3mSv), or a dose equivalent to approximately
865 chest x-rays. Nineteen (28%) children had an estimated cumulative effective
dose in excess of 10 times background exposure. Computed Tomography (CT)
scans contributed 58.3%, Interventional procedures 23.5%, Nuclear Medicine
studies 12.6%, Fluoroscopy 4.1%, and Plain Film Radiography 1.5% to the
total dose. These contributions are in contrast to the relative frequency of the
procedures: Plain Film Radiography 72.3%, Interventional procedures 11.4%,
CT scans 8.7%, Nuclear Medicine studies 5.3%, and Fluoroscopy 2.3%.
Conclusions: Although there is wide variability in radiation exposure which is
likely related to differences in post-transplant morbidity, children undergoing
liver transplantation have the potential to be exposed to a substantial amount
of iatrogenic radiation following transplantation. Clinicians should be aware
of the potential long term risks associated with ionizing radiation and employ
strategies to reduce exposure wherever possible. Although radiographic
procedures are necessary for the detection and management of post-transplant
complications, the risk benefit ratio should always be considered when
requesting diagnostic studies. This is especially important in children who have
already had considerable radiation exposure. As well, alternative non-ionizing
modalities such as ultrasound and magnetic resonance imaging should be used
whenever feasible. When ionizing radiation is necessary, specific pediatric
dose-saving protocols should be employed.
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y.o.). The mean follow-up period was 12 years. The primary diseases of the
recipients were biliary atresia in 18, Byler disease in 1, patent ductus venosus
in 1. At the time of LDLT, 6 recipients had growth retardation and their body
weight was low for their age by 2 SD. But 4 out of 6 recipients who underwent
LDLT before the age of 2 caught up and reached the average height and body
weight for their age. The average frequency of re-admission after LDLT was
7.4 times, and one recipient was re-admitted 30 times because of biliary
stenosis. Two recipients suffered from PTLD, they cured after withdrawal of
immunosuppressants. Six recipients were diagnosed acute rejection by biopsy
more than 5 years after LDLT; 5 of them improved with steroid pulse therapy.
One recipient had steroid resistant acute rejection and was administered
deoxyspergualin after steroids. Chronic rejection was not observed in this
series. Three ABO-incompatible LDLT were included in this group, no one
showed antibody mediated rejection during the long-term follow-up period.
The present immunosuppressive therapy includes tacrolimus in 9 cases and
cyclosporine in 6 cases. One recipient has not required immunosuppresive
therapy for more than 4 years and her present condition is good. One recipient
had PTDM and another had HBV hepatitis. All these recipients, except for
one, attend a normal school or have an occupation.
Conclusion: The majority of LDLT recipients have achieved a good QOL
during their long-term survival and are pursuing normal studies. But biliary
complications may affect their QOL.

POSTER BOARD NUMBER P3 – 291
1865 THE PING PONG BALL AS A SURGICAL AID IN LIVER
TRANSPLANTATION
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V. Jones, G. Thomas, M. Stormon, A. Shun
The Children’s Hospital At Westmead
Background: Liver transplantation using split adult segmental grafts in infants
can be a technical challenge as the small abdominal cavity cannot comfortably
accommodate the graft, leading onto graft compression. This size mismatch can
be a particularly difficult problem when the anterior-posterior (AP) diameter of
the graft is greater than the infant’s available AP peritoneal space. We describe
a simple and novel technique to prevent this complication.
Methods and results: Two infants with biliary atresia weighing 5 kgs and
aged 6 and 5 months received split adult liver left lobe transplants from donors
weighing 55 and 65 kgs respectively. Congestion of the graft and inadequate
perfusion was prevented by placing a sterilized ping pong ball in the retrohepatic space to elevate the graft off the native hepatic fossa. Delayed closure
of the wound was performed after 5 days when it was possible to remove the
ping pong ball in one of the patients. Both patients have recovered well from
the transplant. A follow-up of 1 year in the patient with the in-situ ping pong
ball shows it to be well anchored and causing no symptoms.
Conclusions: In children undergoing large for size split liver grafts, delaying
the closure of the abdominal wound along with elevating the graft using a ping
pong ball can be a useful and simple adjunct to prevent the complications of
graft compression.
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1866 QOL AND PROBLEMS AFFECTING RECIPIENTS
MORE THAN 10 YEARS AFTER LIVING DONOR LIVER
TRANSPLANTATION
N. Kawagishi, A. Nakamura, T. Iwane, I. Takeda, S. Miyagi, K. Satoh,
Y. Akamatsu, S. Sekiguchi, S. Satomi
Division of Transplantation, Reconstruction and Endoscopy
Background and purpose: We started a living donor liver transplantation
(LDLT) program in 1991; 17 out of 21 recipients have survived for more than
10 years. The aim of this study was to review our experience with LDLT in
children and analyse the long-term outcome.
Methods: We have performed 116 LDLT from 1991 up to the present, and
17 recipients have survived for more than 10 years. The long-term outcome
of these 17 recipients was evaluated in relation to growth, immunosuppresive
therapy, complications, and quality of life.
Results: The average age at LDLT was 5.4 years old (from 6 months to
17 y.o.), and the present average age is 17.2 years old (from 11 y.o. to 28
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1867 IPC CATHETER IMPLANTATION FOR INTRACRANIAL
PRESSURE MONITORING IN CHILDREN WITH SEVERE
COAGULOPATHY DUE TO LIVER FAILURE
H. Ismail, M. Markiewicz-Kijewska, S. Barszcz, M. Migda³, J. Teisseyre,
M. Szymczak, P. Nachulewicz, T. Drewniak, P. Kaliciñski,
A. Ostoja-Chy¿yñska
The Childrens Memorial Health Institute
Neurological complications of brain edema and increased intracranial pressure
in patients with acute liver failure are main causes of mortality and morbidity in
these patients, both before and after successful liver transplantation. Therefore
we include ICP probe insertion and ICP monitoring in our standard of treatment
in all patients with acute liver failure or decompensation developing stage II
coma, despite the risk of intracranial bleeding due to severe coagulopathy
present in most of these children.
The aim of our study was retrospective analysis of safety and risks of ICP
implantation in this particular group of children.
Materials and methods: Between1997-2007 we implanted 19 ICP catheters
in 18 children with liver failure (in one two catheters were implanted). Patients
age was between 1,7 - 20,5 yrs (mean 10.43 yrs). Before all procedures of
catheter implantation except two, we used recombinant activated factor VII
(rFVIIa) to improve coagulation and diminish risk of intracranial bleeding. We
administered between 17-100 mcg/kg body mass. Six patients had done this
procedure a few days before LTx. One patient was not transplanted due to too
long waiting for new liver and multiorgan failure. Patients were in coma 3-11
fays (mean 5,8).
Results: Administration of rFVIIa improved INR before ICP catheter placement
from 2,88 - 8 (mean 3,43) to 1 - 1,6 (mean 1,3). ICP monitoring was done 2-12
days (mean 4,53 days). ICP catheter was removed routinely when patient was
awakning of coma. Complications related to ICP catheter insertion developed
in 2 patients (11,1%; subdural hematoma and bleeding in to brain cavity),
both underwent neurosurgical intervention (one during liver transplantation
procedure). Out of 18 children 13 are alive (all after LTx), 5 died of MOF
and brain damage due to brain oedema (4 after LTx) as the course of liver
failure. None of survivors (including 2 children with early complications of
ICP monitoring), developed any persistent neurological complications related
to ICP catheter.
Conclusions: With the possibility of immediate and effective correction of
coagulopathy before ICP catheter implantation we consider ICP monitoring
as safe and very useful in the treatment of children with acute liver failure and
coma.
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1870 MITOCHONDRIAL RESPIRATORY CHAIN
HEPATOPATHIES: ROLE OF LIVER TRANSPLANTATION. A
CASE SERIES OF 5 PATIENTS

J. Teisseyre, M. Markiewicz- Kijewska, H. Ismail, M. Szymczak, S. Prokurat,
I. Jankowska, A. Ostoja-Chy¿yñska, A. Apanasiewicz, P. Kaliciñski
The Childrens Memorial Health Institute
Fulminant Wilson’s disease (FWD) is rare and has been considered as fatal
in children without liver transplantation, however introduction of new
technologies as albumin dialysis could change this poor prognosis.
The aim of our study was retrospective analysis of clinical course, treatment
and outcome of children with FWD treated in our institution.
Material and methods: Between 1977-2007 we’ve treated in our hospital 13
patients aged 4-22 yrs (mean 15,5 yrs) with FWD. We performed retrospective
analysis of clinical course, biochemical parameters, MELD/PELD score,
Wilson score and Kings-College criteria for LTx in ALF in all patients.
Results: The initial symptoms of FWD usually were weakness and abdominal
pain which appeared 5-60 days (mean 20 days) before icterus. Eleven patients
developed neurological symptoms with coma lasting for 2-11 days. Maximal
serum bilirubin concentration at time of qualification for LTx was 4,5-71,6
mg% (mean 42,24 mg%) and INR 2,9-10,0 (mean 5,4). MELD/PELD score at
time of qualification for LTx was between 21-58 (mean 38), 9 patients fulfilled
King’s-College criteria for transplantation in acute liver failure ALF, Wilson’s
score ranged between 11 and 17 points (mean 13 points).
In all except two children urgent liver transplantation was performed in 11 patients
(in 5 with ABO incompatible grafts), One patient improved with intensive therapy
and albumin dialysis (MARS) without the need for LTx and one died on the
waiting list for LTx due to brain edema. Two children died in early post after
transplantation period (pTx d3 and pTx d7). In summary 10 of children with FWD
are alive (total survival of 76,9%): 1 without LTx (7,7% survival) and 9/11 after
LTx (survival 81,8%). Actual follow-up of living patients is 0,5-7,5 years (mean
2,5 yrs), all are doing well with good graft function and one with native liver.
Conclusions: FWD almost in all patients lead to death or LTx, however with
modern intensive care with early application of albumin dialysis and chelating
therapy occasional survival without transplantation or at least prolongation of
time necessary for LTx can be achieved improving overall survival of these
patients. Wilson’s score seemed to better predict need for LTx than classical
Kings-College criteria for ALF.

M.O. Stormon1, E. De Greef1, J. Christodoulou2, S. Dorney1, A. Shun3,
G. McCaughan3, E.V. O’Loughlin1, V. Jermyn3
1
Department of gastroenterology, Children’s Hospital at Westmead, 2Genetic
Metabolic Disorders Service, Children’s Hospital at Westmead, 3Australian
National Liver Transplant Unit, Royal Prince Alfred Hospital; Sydney,
Australia
Introduction: Liver transplantation in patients with mitochondrial respiratory
chain disorders (MRCD) remains controversial. The possibility of multi-organ
involvement requires thorough screening before considering orthotopic liver
transplantation (OLT).
Aim: To report 5 patients with proven MRCD to illustrate the diversity in
clinical presentation, the difficulty in obtaining adequate tissue to make a
timely and accurate diagnosis, and how this influences decision making for
OLT in these patients.
Methods: Retrospective chart review over a 12 year period (1995-2007) at a
tertiary referral paediatric liver transplant centre where 5 children with hepatic
MRCD were identified.
Results: Patient 1 was diagnosed as ‘cryptogenic’ cirrhosis and transplanted
at 13 years of age. The explant was noted to have macrovesicular steatosis
and the diagnosis of Complex I deficiency was subsequently made. Five
years after transplant there are no manifestations of extrahepatic disease
with good graft function. Patient 2 presented with fulminant liver failure at
3 months of age and was diagnosed with complex I deficiency after an open
liver biopsy with fresh frozen plasma (FFP) support. Although there were no
extrahepatic manifestations, OLT was not considered and the patient died
3 weeks later. Patient 3 presented with recurrent hypoglycaemia and was
transplanted for fulminant hepatic failure at the age of 12 months. Although
MRCD was suspected and open liver biopsy performed, results (Complex I,
II and IV deficiency) were not known till just after transplant. Despite good
graft function, death occurred 9 months later due to pulmonary hypertension,
a new manifestation of MRCD1. Patient 4 was diagnosed with Complex I, III
and IV deficiency at the age of 2 years because of sensorineural hearing loss,
hypoglycaemia and liver dysfunction2. She subsequently developed severe
renal impairment and was listed for combined liver-kidney transplantation at
14 years of age because no new organ system was affected. Death occurred,
while listed, after a stroke-like episode following severe sepsis. Patient 5, a 5
year old girl with mild developmental delay and epilepsy, developed valproic
acid induced liver failure. Mt DNA depletion syndrome was diagnosed after
open liver biopsy with FFP support; OLT was not offered and death occurred
4 weeks later.
Conclusion: Hepatic MRCD can present with fulminant liver failure or chronic
liver disease. The diagnosis requires a high index of suspicion. The diagnosis
is confirmed by measuring respiratory chain enzymes on liver tissue which
may necessitate open liver biopsy with FFP support. The decision to perform
OLT in a child with MRCD is difficult, with a good outcome in a minority
of cases, but MRCD should not be considered an absolute contraindication.
Careful assessment of extrahepatic manifestations is necessary. The correlation
between the type (enzymatic defect), the extent of multi-organ involvement,
the natural history of MRCD and the underlying genetic aetiology is unclear
and requires further investigation.
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1869 BENIGN TRANSIENT HYPERPHOSPHATASIA IN A
RENAL TRANSPLANT- NOT SO BENIGN
F. Mackie1,2, S. Kennedy2, G. Kainer2, A. Rosenberg1,2
University of N.S.W., 2Sydney Children’s Hospital
‘Benign’ transient hyperphosphatasia (BTH) with spontaneous elevation of
alkaline phosphatase (ALP) infrequently accompanies viral infections in children.
We report the first case of ALP rise heralding primary EBV infection in a paediatric
renal transplant recipient. A 2 year old with ESRD secondary to congenital
nephrotic syndrome received her first graft from her father. Donor was CMV and
EBV positive, recipient negative. Immunosuppression consisted of prednisone,
mycophenolate, tacrolimus and basiliximab. Valgancylovir prophylaxis was
given. 7 weeks post transplant, elevation in ALP to 2789 (N. 80-300U/L) was
noted. 4 days later isolated fever developed and resolved spontaneously. Bone
and liver isoenzymes of ALP were elevated, consistent with a diagnosis of BTH.
Within 1 week of valgancyclovir cessation (at 4mths) diarrhoea developed.
Plasma EBV and CMV PCR’s were negative. 1 week later the patient presented
with a prolonged partial seizure and encephalopathy following 3 days of fever and
coryza. MRI demonstrated bilateral signal abnormalities in the dorsal brainstem
and periventricular white matter. EEG was consistent with encephalopathy. ALP
continued to rise to 4447. CSF had raised total protein and EBV PCR was positive
(plasma negative) leading to a diagnosis of EBV encephalitis. IV gancyclovir was
started with marked clinical improvement and decline in ALP within 2 weeks to
944. Serology 4 weeks later was consistent with early primary EBV infection.
Immunosuppression was reduced. Full neurological recovery was made. ALP
levels normalised within 1 month. Elevated ALP levels after renal transplantation
may be associated with serious viral infection.

1
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1871 THE USE OF ORAL VALGANCICLOVIR IN THE
TREATMENT OF CYTOMEGALOVIRUS IN A PAEDIATRIC
LIVER TRANSPLANT RECIPIENT
M. Cree1, H. Miller1, C. Noble2, J. Fawcett2
1
Pharmacy Department Royal Children’s Hospital, 2Liver Transplant Unit
Royal Children’s Hospital
The use of oral valganciclovir in the treatment of cytomegalovirus in a
paediatric liver transplant recipient
Introduction: Cytomegalovirus (CMV) is an important pathogen and a major
cause of mortality in children following solid organ transplantation. Children
are particularly vulnerable to CMV as many of them have not developed
immunity to CMV at the time of transplantation.
Objective: To describe the use of valganciclovir for the treatment of CMV in a
paediatric liver transplant recipient.
Clinical Features: In January 2007 a 9 year old female received a liver
transplant following liver failure associated with Wilson disease. In February
2007 the patient became unwell and CMV infection was confirmed by
polymerase chain reaction (PCR) testing. It was decided to treat the CMV with
oral valganciclovir.
Intervention, progress and outcome: The standard treatment for CMV is
intravenous ganciclovir twice a day for approximately 3 weeks; this has an
increased risk of infection and requires hospital admission. A literature review
was undertaken and it was proposed that oral valganciclovir be used for one
month for treatment of the CMV infection at a dose of 520mg/m2 twice a
day. CMV PCR samples were taken frequently to monitor the effectiveness
of valganciclovir in treating the CMV infection. Results revealed the CMV
infection was successfully treated with oral valganciclovir in this patient.
Conclusion: Valganciclovir is indicated for CMV prophylaxis for renal transplant
recipients. Further studies are required to confirm the future role of valganciclovir
in the treatment of CMV infection in paediatric liver transplant recipients.
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1872 PEDIATRIC LIVING DONOR LIVER
TRANSPLANTATION FOR METABOLIC DISEASES OF THE
LIVER
A.D. Concejero, C.L. Chen, C.C. Wang, S.H. Wang, Y.W. Liu, C.H. Yang,
C.C. Yong
Liver Transplant Program, Department of Surgery, Chang Gung Memorial
Hospital-Kaohsiung Medical Center
Objective: We reviewed our experience in living donor liver transplantation
(LDLT) for metabolic disease of the liver in children including outcomes of
surgery and decisive factors for post-transplant patient survival.
Methods: From June 1994-December 2007, a total of 347 LDLT were
performed. One hundred fifty-six (156) were performed for pediatric patients.
Nineteen (19, 12.2%) were transplanted for metabolic disease of the liver. The
records of these patients were reviewed.
Results: There were 13 (68%) glycogen storage disease (type I, n=10; type
III, n=3), 2 (11%) Wilson’s disease, 2 (11%) familial intrahepatic cholestasis
(type I, n=1; type II, n=1), 1 (5%) urea cycle disorder (hyperammonemia),
and 1 (5%) congenital hepatic fibrosis patients. The mean age at time of
transplant was 7.8 years (range, 0.7-18) but the liver-oriented diseases
(urea cycle disorder, familial intrahepatic cholestasis, congenital hepatic
fibrosis) were younger. All patients presented with metabolic abnormalities.
In addition 8 patients presented with growth retardation. Twelve received
left lobe, 3 left lateral segment, 1 extended left lateral segment, and 3 right
lobe grafts. The postoperative complications included 3 bile duct strictures,
1 bile leak, 2 hepatic vein stenoses, 1 hepatic artery thrombosis (HAT),
and 1 refractory ascites. The single HAT case required re-exploration and
interposition grafting using a radial artery graft. The bile duct strictures
required revision to Roux-en-Y hepaticojejunostomy. All surviving
recipients are living with their original grafts. There was a single mortality
at 2 months posttransplant due to acute pancreatitis and sepsis. The
mean overall follow-up was 35.1 months (range, 10-108). The metabolic
abnormalities and catch-up growth were corrected; and renal function
remained within acceptable limits.
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Conclusion: Our pediatric LDLT experience in patients transplanted for
metabolic diseases of the liver shows that normal metabolic balance and
catch-up growth are restored posttransplant. Long-term follow-up after LT for
shows excellent graft and patient survivals.
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1873 EATING BEHAVIOUR IN CHILDREN AFTER RENAL
TRANSPLANTATION
D.E. Mueller-Wiefel1, G. Holst1, S. Feile2, I. Landthaler3, S. Schley4,
C. Sprengel5, U. Spiering6, S. Steinmann7
1
University Children’s Hospital, Hamburg, Germany, 2University Children’s
Hospital, Heidelberg, Germany, 3University Children’s Hospital, Munich,
Germany, 4University Children’s Hospital, Berlin, Germany, 5University
Children’s Hospital, Essen, Germany, 6University Children’s Hospital,
Cologne, Germany, 7University Children’s Hospital, Hannover, Germany
Nutrition as a major life-style parameter with predominant roots in childhood
essentially contributes to long-term survival especially in chronic renal failure
even after renal transplantation. We therefore analyzed eating behaviour in a
total of 238 (139 male, 99 female) children (age 2 - 18, mean 12.4 yrs) treated
over a mean period of 4.4 (at least 0.5) yrs after RTx in 7 German transplant
centres. 38% (60% male, 40% female) of them had been tube-fed over a mean
period of 29 months with a maximal range up to 9 yrs. Data were retrospectively
collected by means of a food frequency questionnaire on a vast spectrum of
nutrients, differentiating between optimal, adequate and inadequate eating
behaviour. Consumption of healthy nutrients like fruit was equally distributed
between optimal (31%), adequate (33%) and inadequate (36%), however with
a low optimal incidence in obese boys (10%), in contrast to obese girls (62%).
Vegetable consumption was far better and optimal in 42, adequate in 36 and
inadequate in only 23%, respectively. Dairy products served as negative example
and their consumption was optimal in only 28, adequate in 30, but inadequate
in 42%, with evidently better results in formerly tube-fed boys (optimal 42%)
and girls (optimal 43%). Best results were achieved with basic nutrients (rice,
potatoes, noodles): optimal 58, adequate 34, and inadequate only 8%, even
better than with meat: optimal 58, adequate 16, and inadequate 35%, or even
wholemeal bread: optimal 24, adequate 29, and inadequate 47%. The use of
chocolate was still worse (inadequate 52%), whereas fast food consumption
was at least adequate in 72%. Best results were achieved with the drinking
behaviour of water and tea (optimal 82%). Data demonstrate that the eating
behaviour of transplanted children and adolescents is scattered over a wide
range, and is usually more unfavourable than in normals, so that nutritional
education should play a major role in the medical care of transplanted children
and their parents.
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1874 NUTRITIONAL STATUS IN CHILDREN AFTER RENAL
TRANSPLANTATION
D.E. Mueller-Wiefel1, G. Holst1, E. Bürkel2, I. Landthaler3, S. Schley4,
C. Sprengel5, U. Spiering6, S. Steinmann7
1
University Children’s Hospital, Hamburg, Germany, 2University Children’s
Hospital, Heidelberg, Germany, 3University Children’s Hospital, Munich,
Germany, 4University Children’s Hospital, Berlin, Germany, 5University
Children’s Hospital, Essen, Germany, 6University Children’s Hospital,
Cologne, Germany, 7University Children’s Hospital, Hannover, Germany
To evaluate the nutritional status after renal transplantation (RTx) we
performed a multicentre cross-sectional study in a total of 238 (139 male, 99
female) children (age 2 - 18, mean 12.4 yrs) treated over a mean period of 4.4
(at least 0.5) yrs after RTx in 7 German transplant centres. 38% (60% male,
40% female) of them had been tube-fed over a mean period of 29 months with
a maximal range up to 9 yrs. Data were collected as body mass index (BMI,
kg body weight / m2 height) and classified as normal between the 10th and
90th, as underweight below the 10th, as overweight above the 90th percentile,
calculated by the “Working Group of Obesity in Childhood and Adolescence
of the German Society of Obesity” and compared with a representative
cohort of 17.641 healthy 0-17 yrs old children and adolescents in Germany
(collected by the “Robert-Koch-Institute”) as controls (C). In 68.8% of the
transplanted children the nutritional status was normal with 70% in males and
68% in females, respectively, however with a 10% lower incidence compared
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to C in males as well as in females. 12.6% of transplanted children suffered
from underweight and 18.5% from overweight compared to 7% and 15% in
C, respectively. In boys there was a higher incidence of underweight (15%),
whereas in girls the incidence of overweight (23%) was higher. In formerly
tube-fed children the normal nutritional status was comparable to the non tubefed children (70 vs. 68.8%), however with an overrepresentation of underweight
(16.7 vs. 10%) but an under representation of overweight (13.3 vs. 22%). A
change of the distribution of the nutritional status within the course of time
could not be observed in non-tube fed children, whereas after tube-feeding no
child had overweight within the 1st year after RTx and the highest amount of
a normal nutritional status could be achieved after 5 yrs (82%). Taken together
after RTx there is an increased risk for overweight in girls and underweight in
boys, whereas tube-feeding in the pre RTx period seems to be associated with
a positive nutritional long-term effect.
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1875 ANTIOXIDANTS, TOTAL HOMOCYSTEINE AND LIPIDS
AFTER PEDIATRIC KIDNEY TRANSPLANTATION (KTX)
M.J. Kemper, N. Rink, N. Melikyan, B. Finckh, D.E. Müller-Wiefel
Pediatric Nephrology
Experimental data indicate that oxygen free radicals, total homocysteine and
lipids are involved in acute postoperative but also long-term tissue damage
after KTx. Clinical data however are very scarce, especially in children. We
hypothesized, that antioxidant mechanisms are reduced after pediatric KTx
exposing the patient to a higher risk of ROS damage. We therefore studied
vitamin A and E, total homocysteine and lipid profile in 31 children after renal
transplantation and 20 age and sex matched controls. Patients did not receive
vitamin supplements. Median age was (range 3-18) years, and median time after
KTx was 44 (range 10-121) months. Mean vitamin A and E plasma levels were
significantly higher after KTX than in controls (1.04±0.41 and 4.1±2.0 mg/l
versus 0.66±21 and 9.0±2.1 mg/l, p< 0.001 and p<0.02, respectively. Vitamin
A and E levels corrected to total lips, were similar between KTx and controls,
however and also total homocysteine concentration did not differ between the
groups. However fasting triglyceride levels were significantly higher after
KTx (197±152 vs 109±46 mg/dl, p<0.01), resulting in significantly lower
total lipis (p<0.002), although cholesterol, HDL and LDL were comparable.
Vitamin A levels correlated with serum-creatinine (r=0.66, p<0.0001) and
age (r=0.43, p<0.02) and with vitamin E (r=0.50, p<0.005). Vitamin A and E
showed a strong association with total lipids (r=0.62 and 0.57, p<0.0001 and
p<0.001, respectively), both, triglyceride and cholesterol levels. In summary
and conclusion there is no deficiency of vitamin A and E in our cohort of
children after KTx, however this might be related to hypertrigliceridemia.
Whether this results in antioxidant mechanisms, that may have an important
impact on long-term graft function or is an epiphenomenon of hyperlipidemia,
deserves further study.
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A. LePage1, S. Kennedy1, G. Kainer1, F. Mackie1,2, M. Rossleigh1,2,
A. Rosenberg1,2
1
Sydney Children’s Hospital, 2University of New South Wales, Sydney
Introduction: We previously reported the results of DMSA scans of allograft
kidneys performed in 19 children within 2 years of transplantation:- 10 allograft
kidneys were normal (group 1), but 9 showed striking defects in isotope uptake
with large cortical defects (group 2) (J Nucl Med 32: 1542-4, 1991).
Aim: To determine whether early abnormal DMSA scan appearance is related
to longterm graft function.
Methods: Serum creatinine values were obtained at longterm follow up.
Creatinine clearance was estimated by the methods of Counahan-Barratt (for
children) or Cockroft-Gault (for adults), as appropriate.
Results: Follow up data was available for 7 / 10 patients in group 1 and 7 / 9
in group 2. There was no significant difference in graft loss (1 in group 1, 3 in
group 2). The median follow-up period was 8 years; there was no difference in
mean creatinine clearance between the groups (group1 40.7 ml/min/1.73sqm
vs 37 ml/min/1.73sqm).
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1877 SUCCESSFUL TRANSPLANTATION OF KIDNEY AND
LIVER GRAFTS FROM PEDIATRIC CARDIAC DEATH
DONORS
W. Van der Werf1, L. Belnap1, E. Roach2, S. Bratton3
Division of Abdominal Transplant, Department of Surgery, Intermountain
Medical Center, 2Intermountain Donor Services, 3Department of Pediatrics,
Primary Children’s Medical Center, Salt Lake City, Utah, United States
The shortage of cadaveric donors has led many transplant centers to expand
their criteria for accepting life-saving organs. Utilization of donation after
cardiac death (DCD) donors has been estimated to increase the number of
cadaveric donors. We report our experience with a recently established DCD
program at a pediatric hospital and the outcome with the transplanted grafts.
Methods: In 2005 to 2006 all patients undergoing withdrawal of care were
evaluated for DCD. Patients meeting criteria for DCD underwent withdrawal
by the critical care team and organ retrieval was initiated if asystole was reached
in less than 60 minutes. In addition, one DCD liver was imported and was
included in the liver results. Results: During the 2 year study period 7 patients
(25% of total donors) underwent DCD resulting in 14 organs (11 kidneys and
3 livers) transplanted. The 7 cases had a mean donor age of 9 yrs (range 3-16),
WIT of 22 min (9-55), time sBP < 60 of 11 min (7-15), and time from asystole
to aortic flush of 8 min (6-12). Four kidneys were transplanted locally with CIT
5-14 hrs, no DGF, and one month creat 1.2-1.7. The remaining 7 kidneys were
exported for transplant. Four livers were transplanted locally with donor age 7
mth-16 yrs, WIT 12-28 min, recipient age 14 mth-61 yrs, CIT 6-15 hrs, AST
peak 190-3630, AST day 7 33-44, INR peak 1.4-1.8, INR day 7 1.0-1.1, Total
Bili one month 0.3-1.0, and all grafts functioning at 1.5-2.9 yrs. There were
no vascular or biliary complications. Conclusions: A protocol for DCD at a
pediatric hospital increased the number of pediatric cadaveric donors by 25%.
Liver and kidney grafts from pediatric DCD donors demonstrated excellent
graft function and survival.
1
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1878 BASILIXIMAB DOSE IN PEDIATRIC RENAL
TRANSPLANT BASED ON PHARMACOKINETIC DATA
T. Nagai1, Y. Goth2, K. Uchida3
Aichi Children’s Health And Medical Center, 2Naogya Daini Red Cross
Hospital Kidney Center Pediatrics, 3Naogya Daini Red Cross Hospital
Kidney Center Surgery
Objective: Apart from adults, basiliximab is also being established for use
in pediatric renal transplant worldwide. However, its pharmacokinetics in
pediatric patients, particularly those weighing 35 kg or less, have hardly been
investigated. This study examined the setting of the dose and maintenance of
efficacy and the results are hereby reported.
Methods: The subjects were 11 de novo pediatric renal transplant recipients.
Of these, 2 underwent the transplant due to relapse of nephrosis and bleeding.
Three (weighing 35 kg or more) received two administrations of basiliximab
20 mg and 6 (weighing less than 35 kg) received two administrations of the
10 mg dose. All the subjects received two administrations of basiliximab. The
first administration was on the day of the transplant (Day 0 post transplant)
and the next one four days post transplant. Subjects weighing at least 35 kg
received the 20 mg dose and those weighing less than 35 kg, the 10 mg dose.
The drug was administered by intravenous drip infusion over about 20 min.
Serum concentration of basiliximab was measured over time by enzyme-linked
immunosorbent assay over 12 weeks. All the subjects received concomitant
immunosuppressant therapy that consisted of cyclosporine, prednisolone, and
mycophenolate mofetil. Serum concentration was measured by body weight
group and the PK profile determined.
Results: Maximum serum concentration for the three subjects that weighed at
least 35 kg was a mean of 8.7ƒÊg /mL¦ i2.9-12.4¦ j after the first administration
and 9.7ƒÊg /mL¦ i3.6-14.1¦ j after the second administration. Although there
was no subject where the reported effective plasma concentration of basiliximab
of 0.2ƒÊg/mL was maintained for up to 12 or more weeks, the effective
threshold maintenance period was 56-60 days in the subjects weighing at least
1
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1876 LACK OF RELATIONSHIP BETWEEN EARLY DMSA
SCAN APPEARANCE AND LONG TERM FUNCTION OF RENAL
ALLOGRAFTS

Conclusion: We found no correlation between the early DMSA scan appearance
of renal allografts and their longterm function.

Wednesday 13 August 2008
35 kg and 42-55 days in those weighing less than 35 kg. The dose/weight ratio
was 0.290-0.971, which is a broad range. When divided into the low-ratio
group (one subject), moderate-ratio group (six subjects) and high-ratio group
(two subjects), the efficacy maintenance period was 46-55 days with the low
and high-ratio groups and 70-84 days with the moderate-ratio group.
Conclusion: Analysis of the PK data of basiliximab revealed that there is no
fixed rule regarding dose per weight and efficacy maintenance period. The highratio group will consist of children with a low age and therefore, the metabolic
rate of IgG may have an effect. However, the low-ratio group will consist of
children weighing about 35 kg, but in this group, the efficacy maintenance period
will not be shortened and adequate immunosuppressant effect can be obtained.
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1879 PREVALENCE OF POLYOMAVIRUS VIRURIA (JCV/BKV)
IN CHILDREN AFTER LIVER TRANSPLANTATION
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F. Brinkert, P-M. Kaulfers, M.J. Kemper, R. Ganschow
Department of Pediatrics, University Medical Center Hamburg-Eppendorf,
Germany, Department of Medical Microbiology, Virology and Hygiene,
University Medical Center Hamburg-Eppendorf, Germany
BK virus infection is a known cause of morbidity and graft loss after kidney
transplantation. But as well in nonrenal organ transplant patients, polyomavirus
infection has potential implication in renal dysfunction. Furthermore,
polyomaviruses are tumor inducing viruses and molecular data suggest an
association with malignancies among solid organ transplant patients. JC virus
is the causative agent of progressive multifocal leukoencephalopathy (PML)
which is reported in solid organ transplant recipients.
We performed a prospective prevalence study at an average of 2187 (20-5671)
days after transplantation in 100 consecutive children admitted for the yearly
follow-up examination post liver transplantation. The urine was screened
for BKV and JCV DNA by using a quantitative PCR in each case. A plasma
analysis by PCR was added if more than 100.000 copies/ml urine were detected.
Additional data regarding date of transplantation, immunosuppressive agents
and kidney function (GFR) were collected.
BKV or JCV DNA was found in 19% (n=19) of our patients. 15 patients had
BK, 4had JC viruria. Only three (2 BKV, 1 JCV) had more than 50.000 copies/
ml urine, but no DNA was detected in the plasma. All patients were free of
clinical signs of viral infection, PML or nephropathy. GFR was normal in all
patients and we found no statistical difference between patients with and without
BK/JC viruria. 15 out of 19 patients had a cyclosporine or tacrolimus mono
immunosuppressive therapy, 4of them had additional mycophenolic mofetil.
None of the 3 patients with high viruria had an intensified immunosuppression.
We found a higher prevalence of polyomavirus viruria in our pediatric liver
transplanted children than reported in adult patients. But only more than
100.000 copies/ml urine, (3 patients) and high plasma levels (not detected), are
reported with renal dysfunction. The extent of immunosuppressive therapy had
no influence on the polyomavirus infection. Further studies are needed to assess
the risk of polyomavirus infection in children following liver transplantation.
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1880 DEFINITIVE ABDOMINAL WALL CLOSURE
USING A BIODEGRADABLE MEMBRANE FROM
PORCINE INTESTINAL SUBMUCOSA IN PEDIATRIC
TRANSPLANTATION
J. Karpelowsky, G. Thomas, A. Shun
Department of Pediatric Surgery Children’s Hospital At Westmead, Australia
Introduction: Abdominal closure in children less than 10kg post transplantation
can be challenging. Excessive pressure used to attain closure can result in
abdominal compartment syndrome, graft compromise and loss. Concerns over
using prosthetic patches are that of infection and dehiscence. We report a series
of definitive abdominal wall closure using a Biodegradable Membrane from
Porcine Intestinal Submucosa (Surgisis®-Cook Il USA)
Method: A prospective collection and follow up of liver and kidney transplant
patients weighing less than10 kg who required abdominal wall augmentation
with Surgisis® in order to achieve safe closure.
Results: There were 10 liver transplant patients and 2 renal transplant patients.
The average weight of the liver transplant patients was 6.59kg(5.4-8.5Kg) and
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the renal 9.8kg. The average area od Surgisis® used was 71.2cm2 (25-160 cm2)
and length of follow up was 15.3 months (1-27months).. Systemic complications
were one death fro multiple organ failure at 1 month post transplant secondary to
concomitant pathology (combined immune deficiency syndrome) and one patient
with hepatic artery thrombosis which was salvaged at re-look. Concomitant
measures to aid abdominal closure were recipient nephrectomy for the renal
patients and reduction by 33% of the lateral segments in 2 patients. Delayed
closure occurred in all patients except one and the average days to closure from
the first surgery was 3.75 days (0-6 days). There were two wound complications
One patient developed 2 small sinuses and some skin dehiscence which healed
over 4 months and the second developed a skin sinus following trans patch liver
biopsy which healed in 3 weeks. Both had positive microbial cultures but neither
necessitated removal of the graft. There were no incisional hernias.
Conclusion: Surgisis® is a safe method for abdominal closure in transplant
patients. It appears to have long term durability with no incisional hernias in
the series of patients, and fairly resistant to infection.
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1881 INTRA- AND INTERPERFORMER VARIABILITY OF
KAOLIN-ACTIVATED THROMBOELASTOGRAPHY IN
CHILDREN
J.F. Goorhuis, S.E. Timmerman, M.J.I.J. Albers
Department of Pediatrics, Division of Pediatric Intensive Care, Beatrix
Children’s Hospital, University Medical Center Groningen, University of
Groningen
Introduction: Thromboelastography (TEG®) is a whole blood coagulation
test measuring the viscoelastic properties of blood during the dynamic process
of blood clotting and blood lysis. During hepatic surgery in adults and children
TEG® analysis proved useful in assessment of coagulopathies allowing
optimization and reduction of blood product selection. Performance of TEG
® in a point of care setting has not been assessed. We therefore studied the
intra- and inter performer variability of TEG® performed by nurses in a tertiary
paediatric intensive care unit.
Methods: In a prospective observational study (approved by the medical ethical
board commission) 100 paired kaolin TEG® samples (50 paired samples in
each group) were compared for intra- and interperformer variability of reaction
time and maximum amplitude by Bland Altman analysis.
Results: Table 1. Mean differences and 95% confidence interval of differences of
TEG® values reaction time (R) and maximum amplitude (MA) in both groups.

R (sec)
MA (mm)

Mean (min-max)
measured values (n
= 100)
512 (70-1640)
62 (25-88)

Intraperformer
variability (n=50)

Interperformer
variability (n=50)

-7 (-45 – 32)
0,8 (-0,1 – 1,7)

28 (-20 – 75)
1,3 (0,2 – 2,3)

Conclusions: In the setting of a tertiary paediatric intensive care unit TEG®
performed by trained nurses has narrow limits of agreement for intra- and
interperformer variability, that allow its clinical use to guide hemostatic
management (after transplantation).
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1882 LONG-TERM OUTCOME OF INTENSIVE INITIAL
IMMUNOSUPPRESSION PROTOCOL IN DECEASED DONOR
RENAL TRANSPLANTATION IN CHILDREN
O.K. Olaitan, J.A. Zimmermann, W. Shields, G. Rodriguez, P. Mohan,
D.M. Little, D.P. Hickey
National Kidney and Pancreas Transplantation Centre, Beaumont Hospital,
Dublin, Ireland
Aim: To report long-term outcome of deceased donor kidney transplantation in
children using intensive initial immunosuppression protocol.
Method: All children less than 18 years that had deceased donor kidney
only transplant between January 1991 and December 1997 were included;
82 renal allografts were transplanted into 75 children. Mean recipient age at
transplantation was 12.9 years and the mean follow-up period was 12.6 years.
All patients received quadruple immunosuppression with steroid, cyclosporine,
azathioprine and rabbit anti-thymocyte globulin (R-ATG-Fresenius®).
Results: Actual 1, 5 & 10 year patient survival rates were 99%, 97%
& 94% respectively; only one patient (1.2%) developed post-transplant
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lymphoproliferative disorder (PTLD). Actual 1, 5, & 10 year overall graft
survival rates were 84%, 71% & 50% respectively; there were 5 cases (6%) of
graft thrombosis and the actual immunological graft loss was 14.6%. The longterm survival rates of the first grafts were superior to that of the retransplant
grafts but were not statistically significant (P=0.69). The long-term graft
survival rates of the pre-emptively transplanted patients were superior to that of
those maintained on dialysis prior to transplantation but were not statistically
significant (P=0.66).
Conclusion: The use of R-ATG resulted in excellent immunological graft
survival without an increase in PTLD or other neoplasms over a minimum
10-year follow up. We conclude that R-ATG is safe and results in excellent
long-term graft survival.

were anastomosed to aorta and inferior vena cava, while one transplant was
done extraperitoneally with anastomosis with external iliac vessels. All ureteric
reimplantations were done by standard lich gregoir technique.
Results: To date patient survival and graft survival is 100%. One patient
had delayed graft function that resolved without the need of dialysis. Mean
creatinine level was 1.6mg/dl.rate. Acute rejection rate was 33.3%(4), 3 were
salvaged by ATG and one by solumederol. Two patients had urinary tract
infections. One patient had acute pancreatitis and one patient had mitrofanoff
failure, which had to be redone using appendix.
Conclusion: Pre Renal Transplant surgery for correction of upper and lower
urinary tract abnormalities is a safe and effective option to improve graft
outcome and survival in pediatric patients.
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1883 DE NOVO AUTOIMMUNE HEPATITIS AFTER
25 DAY NEWBORN BABY LIVING DONOR LIVER
TRANSPLANTATION

1885 EPSTEIN-BARR PCR IN KIDNEY-TRANSPLANTED
CHILDREN IS ANOTHER PARAMETER TO INDIVIDUALICE
IMMUNOSUPPRESSION

H. Oya1, Y. Sato1, S. Yamamoto1, T. Kobayashi1, T. Watanabe1, H. Okajima2,
K. Asonuma2, Y. Inomata2, K. Hatakeyama1
1
Division of Digestive And General Surgery, Niigata University, 2Department
of Transplantation and Pediatric Surgery, Kumamoto University
De novo autoimmune hepatitis has been recently described as a new type of
graft dysfunction in pediatric patients receiving liver transplantation. We report
a case of a boy, diagnosed as neonatal hemochromatosis, received a reduced
left lateral graft 25 days after birth. Pretransplant autoantibodies and serological
tests were negative. Postoperative course was smooth and the episode of
vascular, biliary complication and acute cellular rejection was not observed.
The immuosuppressants was tacrolimus only. Liver dysfunction occurred 13
months after living donor liver transplantation. Liver biopsies showed no acute
cellular rejection but apoptosis of liver cells at the centrolobular area. At that
time, various autoantibodies including anti-nuclear antibodies, anti-double
stranded DNA antibodies, and anti-smooth muscle antibodies. In addition,
serum IgG was elevated. Based on these findings, he was diagnosed as de novo
autoimmune hepatitis. The treatment consisted of reducing the dose of tacrolimus
and reinduction of steroids. After 12 months treatment, liver dysfunction was
improved, serum autoantibodies became negative and serum IgG level had
normalized. Presently, 26 months after liver transplantation, the patient is doing
well with normal liver function tests and no positive antibodies. Currently his
immunosuppressive therapy consists of low dose tacrolimus and prednisolone.
In conclusion, the present case demonstrates that de novo autoimmune
hepatitis can appear in living donor liver transplant patients despite appropriate
immunosuppression. Reducing the dose of tacrolimus and reinduction of
prednisolone could sustain the graft and prevent retransplantation.

R. Vilalta1, E. Lara, A. Madrid, A. Vazquez, S. Chocron, A. Casquero, J. Nieto
1
Hospital Infantil Vall DHebron Barcelona, 2Id, 3id, 4id, 5id, 6id, 7id
Background: Despite “normal” blood levels of immunossuppressors, some
kidney-transplanted children exhibits oportunistic infections by different
pathogen agents. Between them, one of the most significants is Epstein-Barr
virus (EBV), because is related to posttransplant lymphoproliferative disorder
(PTLD) and also with other clinical situations in which there are polyclonal
expansion of B-lymphocytes, for exemple febrile-necrotic tonsillitis. Drastic
reduction or withdrawal of immunosuppression added to anti-viral therapy
with valganciclovir for EBV is the primary treatment of both entities, plus
rituximab in PTLD.
Case report: A youg boy,(IgG EBV positive) 6 years-old received a cadaveric
kidney transplant (EBV negative) at 5 years of age because an hemolitic-uremic
syndrome.He was treated with basiliximab, FK, mophetil mycophenolate
(MMF) and tappered steroids. The immediate post-trasplant period was
uneventful. FK levels were maintained between 8 and 10 ng/ml and MMF
between 1 and 1.5 mcgr/ml.
Evolution: At the month 8 post-transplant, he developped a febrile-necrotic
tonsillitis with a PCR title of 77.000 copies, and an histologic study showed
polyclonal expansion of B-lymphocites. Immnunossupresion was reduced to
obtain FK levels of 2-2.5 and MMF of 0.8-1.2. Valganciclovir oral was started
(400mg /m2/24h).
4 weeks later, PCR EBV title was 47.000, with no healing of tonsille lesions.
8 weeks later, PCR EBV under 5000 copies was achieved with resolution of
tonsille lesions. Valganciclovir was maintained for 3 months. In a 6-months
follow-up PCR EBV tittle was maintained under 5000 copies with an optimal
renal function (creatinine 0.4mg/100ml).
Conclusion: PCR EBV monitoring of kidney-transplanted children could
anticipate or at less help control of non-PTLD EBV disorders, and always
indicates valganciclovir treatment (if PCR EBV copies are over 5.000) and
also a drastic reduction of immunossuppressor levels.
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S. Akhter, M.W. Iqbal, M.T. Talib, M.A. Khawaja
Shifa International Hospital
Introduction: It is well recognized that optimization of urinary tract prior
to renal transplant has improved the graft outcome. Recurrent UTI and high
pressure in bladder are well known to be detrimental to graft survival/outcome.
Methods: At Shifa International Hospital Islamabad, Pakistan 12 Paediatric
Transplants were done between August 2002 and February 2008, with median
follow up of 56 months. Age ranged between 6 - 16 years and weight between
13-50kg. Six were male and 6 were female. The causes of ESRD included
1 case of stone disease, 5 cases of neurogenic bladder/vesicoureteric reflux
with recurrent urinary tract infections, 1 focal segmental glomerulosclerosis,
1 chronic Glomerulonephritis, 1 posterior urethral valve and 3 unknown. Five
cases underwent pre transplant Nephrectomy among them three underwent
nephroureterctomy and Augmentation cystoplasty with mitrofanoff. All patients
were induced with single dose Anti Thymocytic Globulim (ATG) (9mg /kg)
except one with simulect, who had reaction with ATG, Cellcept and Solumedrol.
Neoral was started when the serum creatinine became less then 50%. Eleven
patients underwent transplantation via intraperitoneal approach, renal vessels
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1886 FOLLOW-UP OF CYTOMEGALO- UND ADENOVIRUSSPECIFIC T CELLS DURING THE FIRST YEAR AFTER
PEDIATRIC KIDNEY TRANSPLANTATION
T. Ahlenstiel1, U. Sester2, M. Sester2, A. Heim3, L. Pape1
1
Medical School of Hannover, Department of Pediatric Nephrology,
2
University of the Saarland, Department of Nephrology, 3Medical School of
Hannover, Department of Virology
Introduction: Post-transplant immunosuppression leads to impaired
cellular immune defense resulting in increased risk for severe virus-induced
complications, e.g. by Cytomegalo Virus (CMV) and Adenovirus (ADV). Posttransplant follow-up of virus-specific T-cells might serve as marker to estimate
the individual risk to develop virus-induced diseases.
Method: Within a prospective longitudinal study we monitored CMV- and
ADV-specific T cells in 16 pediatric patients (aged 1-16 years) during the
first year after kidney transplantation. The immunosuppression consisted of
basiliximab, prednisolon, ciclosporin and everolimus. No antiviral prophylaxis
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1884 PRE TRANSPLANT SURGERY FOR CORRECTION OF
UPPER AND LOWER URINARY TRACT ABNORMALITIES IN
PEADIATRIC PATIENTS IMPROVE GRAFT
SURVIVAL/OUTCOME
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was performed independent of donor/recipient CMV-status. In case of
detectable CMV-DNA we started preemptive intravenous antiviral therapy
with ganciclovir.
T cells were stimulated with CMV and ADV antigen in vitro. Based on specific
cellular activation and induction of intracellular cytokines, the frequency of
CMV and ADV-specific CD4-T cells was determined using flow cytometry.
Viral load was quantified by PCR. Serologic studies were performed for CMV.
Results: Prevalence of CMV-specific T cells correlated with CMV-serology:
The CMV-seronegative children never showed detectable CMV-specific T
cells. In case of primary CMV-infection (2 out of 16) we found an increasing
level of CMV-specific T cells simultaneously with a decrease of CMV-DNAload. The level of CMV-IgG-titres did not correlate with the quantity of virusspecific T cells.
Asymptomatic ADV-infections were characterized by boost of ADV-specific T
cells without relevant detection of ADV-DNA.
As long as the virus–specific T cells remained at a constant detectable level, we
found no virus-reactivation.
Conclusion: Virus-specific T cells represent a parameter for control of virus
replication. After transplantation an insufficient level of virus-specific T cells
is probably associated with increased risk of virus-induced complications.
Accordingly, virus-specific T cells might serve as prognostic marker to estimate
the individual risk for post-transplant virus-diseases. Therefore virus-specific
T cells might improve posttransplant management and optimize individual
timing of antiviral therapy. Moreover, virus-specific T cells probably offer
the possibility for effect-related drug monitoring by quantifying individual
inhibitory effects of immunosuppressive drugs. Further studies will have to
determine the minimal level of virus-specific T cells needed for effective
protection against viral disease.
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1888 REFERENCE DEPENDENT VARIABILITY OF BONE
MINERAL DENSITY (BMD) CHANGES IN PEDIATRIC KIDNEY
TRANSPLANT RECIPIENTS
L.A. Hamiwka, M. Hanna, J.P. Midgley, A.W. Wade, S. Grisaru
Southern Alberta Renal and Transplant Program, Alberta Children’s Hospital,
Division of Pediatric Nephrology, Calgary, Alberta, Canada
In children, interpretation of BMD values requires estimation of z-scores related
to an age and gender matched healthy pediatric population. Calculation of
volumetric BMD (vBMD) is more appropriate in growing children. Currently
there are 3 major references for lumbar spine BMD z-scores in children: Hologic
Inc., Bachrach et al and Kalkwarf et al. We have recently reviewed a cohort of
pediatric kidney transplant recipients who have been longitudinally followed
before and after kidney transplant with yearly dual energy x-ray absorptiometry
(DXA) bone mineral density measurements. We herein report the estimated
z-score values in our cohort of 40 pediatric renal transplant recipients using the
3 references currently available for clinical practice.
Methods: Lumbar spine BMD measurements were obtained using DXA
(Hologic QDR 4500W) prior to transplant and yearly thereafter. vBMD values,
vBMD z-scores and areal BMD (aBMD) z-scores were estimated as described
in the above mentioned references.
Results: Transplantation was associated with a significant and sustained decline
in both vBMD and aBMD which was directly related to cumulative steroid
dose. Significant differences in estimated z-score values we found between the
3 references for both vBMD and aBMD.
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1887 STEROID-FREE IMMUNOSUPPRESSION IN
PEDIATRIC RENAL TRANSPLANTATION
– LONG TERM FOLLOW-UP ANALYSIS
R. Esmeraldo1, P. Pinheiro1, M. Oliveira1, C. Ponte1, M. Donadi1, S. Costa1, F.
Paes1, C. Soares1, R. Evangelista2
1
Hospital Geral de Fortaleza, 2Universidade Federal do Ceara
Background: Despite their well-recognized adverse effects, corticosteroids
are still the mainstay of immunosuppressive protocols for renal transplant
recipients, but successful attempts at steroid withdrawal or steroid avoidance in
adult and pediatric renal transplant patients were already reported. The goal of
this study was to test the safety and efficacy of a steroid-free immunosuppressive
protocol in pediatric renal transplant patients, in a long-term follow-up.
Methods: In a prospective, nonrandomized clinical study 36 nonsensitized
pediatric recipients of first renal allografts (age between 3-17 years; mean = 12.5
years) received induction therapy with daclizumab (n = 32), thymoglobulin (n =
3) or basiliximab (n = 1), in combination with Tacrolimus and Mycophenolate
Mofetil (MMF)or Sodic (MMS). Protocol biopsies were performed at 3, 6, and
12 months posttransplantation. Clinical outcomes were analyzed.
Results: At a mean follow-up time of 38,2 months (range 2-79 months), patient
and graft survival were 100% and 92%, respectively. Only 2 patients (5,5%)
experienced biopsy proven acute rejection during the first year posttransplant,
one graded Banff borderline and the other Banff IIA. Both cases were readily
reversed, one with methylprednisolone and the other with OKT3. Protocol
biopsies revealed 4 patients with borderline lesions and 1 patient with mild
chronic allograft nephropathy (Banff grade I). Mean serum creatinine was 1.0
+/- 0.9 mg/dl at discharge, 1.0 +/- 0.4 mg/dl at 6 months, 1.1 +/- 0.4 mg/dl at
12 months, 1.4 +/- 1.2 mg/dl at 24 months, 1.3 +/- 0.4 mg/dl at 36 months, 1.4
+/- 0.6 mg/dl at 48 months, and 1.4 +/- 0.5 mg/dl over 5 years posttransplant.
Lipid levels were not significantly different from pre-operative levels. Four
patients (11%) presented cytomegalovirus disease. One patient (2,8%)
presented posttransplant Diabetes Mellitus. Despite excellent renal function,
hemoglobin was only normalized between 6 and 12 months.
Conclusions: The use of induction therapy followed by tacrolimus and MMF
or MMS allowed complete avoidance of steroids in this selected group of
patients. This protocol has the advantage of avoiding the side effects of steroids
without increasing the prevalence of acute rejection episodes, while providing
long term graft function.
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Conclusion: BMD z-scores in pediatric kidney transplant recipients vary
significantly depending on the reference used, but all references showed
a decline in both vBMD and aBMD post- transplant. The negative effect of
transplant on BMD necessitates careful longitudinal BMD monitoring and
minimization of steroid immunosuppression.
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1889 DIAGNOSIS AND TREATMENT OF ACUTE REJECTION
CAUSED BY DONOR SPECIFIC ANTI-MICA ANTIBODY IN
A HIGHLY SENSITIZED, PEDIATRIC RENAL TRANSPLANT
RECIPIENT (MAJOR-HISTOCOMPATIBILITY-COMPLEX
(MHC) CLASS-I RELATED CHAIN A ANTIGEN)
S. Narayan1, E. Tsai1, J.Q. Zhang2, E. Reed2, R. Ettenger1
1
Mattel Children’s Hospital At UCLA, Department of Pediatrics, Division of
Nephrology, UCLA Medical Center, Los Angeles, 2Department of Pathology,
Immunogenetics Center, UCLA Medical Center, Los Angeles
Introduction: Recent studies have demonstrated that pre-transplant
sensitization against MICA (Major-histocompatibility-complex class-I related
chain A) antigens are associated with renal allograft rejection and failure.
Because MICA antigens are expressed on endothelial cells, current crossmatch measures, using donor lymphocytes, fail to detect MICA antibodies.
Furthermore, MICA antibodies are not routinely tested prior to transplantation.
This case report describes the clinical course and treatment of donor specific
MICA antibody mediated rejection in a pediatric renal re-transplant recipient.
Methods: The patient is a 14 year old female with end stage renal disease
secondary to Branchio-oto-renal syndrome who lost her first graft due to
recurrent rejection. Following allograft nephrectomy, she became highly
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sensitized with panel reactive antibody greater than ninety-five percent.
She remained on dialysis for four years. After pre-transplant desensitization
with high dose IVIG (2g/kg once a month for four months) and Rituximab
750mg/m2 for two doses, she received a cross-match negative, deceased
donor transplantation. She was induced with anti-thymocyte globulin and
continued on prednisone, mycophenolate mofetiel and tacrolimus. She
maintained good allograft function until post-operative day ten when she
presented with an acute rise in creatinine and anuria. A biopsy revealed acute
cellular type 2 and antibody-mediated rejection diagnosed by complement
4d (C4d) positive staining. She was treated with plasmapheresis and IVIG.
Serial donor specific HLA antibody measurements remained negative. An
extended search for a non-HLA antibody detected donor specific *012
MICA antibody. Donor specificity was confirmed by MICA genotyping
of the patient and donor. Serial anti-MICA antibody titers were measured
using luminex technology using median fluorescence intensity. (See
Figure one)
Results: Pre-transplant serum revealed the existence of pre-formed *012
MICA antibody, with an elevated level at pre-transplantation and at the time
of rejection. Resolution of rejection and return of patient’s graft function
correlated well with the decline in MICA antibody titer following treatment
with plasmapheresis and IVIG (see figure one). Interestingly, the MICA
antibody titer increased during an episode of acute gastroenteritis, but continued
to decline following the resolution of the illness and continuation of treatment
with plasmapheresis and IVIG.

Conclusions: Our case emphasizes the importance of screening for donor
specific MICA antibodies in re-transplant recipients, specifically when
donor-specific anti-HLA antibodies are not detected during rejection. Current
desensitization protocols using high dose IVIG and Rituximab may not
effectively decrease MICA antibodies. Therefore, preformed MICA antibodies
can lead to both acute antibody mediated and acute cellular rejection (type 2).
Plasmapheresis followed by high dose IVIG may be an effective treatment of
acute rejection caused by MICA antibodies.
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E. Baskin1, U.S. Bayrakci1, H. Ozdemir2, B. Demirhan2, H. Karakayali3,
S. Sevmis3, M. Haberal3
1
Baskent University Faculty of Medicine, Department of Pediatric
Nephrology, 2Baskent University Faculty of Medicine, Department of
Pathology, 3Baskent University Faculty of Medicine, Department of General
Surgery
Background: The recurrence of focal segmental glomerulosclerosis (FSGS)
after renal transplantation has a potentially detrimental impact leading to
the loss of renal function. Although, plasmapheresis (PF) and rituximab are
commonly recommended the treatment is still a matter of debate.
Aim: We report our single-center experience to assess the outcome of the renal
transplantation in children with FSGS.
Patients and methods: Medical records of 10 (F/M: 4/6) renal transplanted
patients with FSGS were evaluated. Among 10 grafts 7 were from living related
and 3 from deceased donor. The original diagnosis of FSGS as well as recurrences
was biopsy-proven in all patients. All patients treated with calcineurin-based
immunosuppressive therapy. PF was done at days -3,-2,-1 and 5 consequitive
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1891 RITIXUMAB FOR POSTTRANSPLANT RECURRENCES
OF FSGS
E. Baskin1, U.S. Bayrakci1, H. Sakalli1, H. Ozdemir2, H. Karakayali3,
M. Haberal3
1
Baskent University Faculty of Medicine, Department of Pediatric
Nephrology, 2Baskent University Faculty of Medicine, Department of
Pathology, 3Baskent University Faculty of Medicine, Department of General
Surgery
The recurrence of focal segmental glomerulosclerosis (FSGS) after
transplantation is a well-known problem. Disease recurs in 30% of patients
with FSGS receiving a first renal transplant and in over 80% of patients
receiving a second transplant after a recurrence. The pathogenesis remains
unknown and may involve a circulating permeability factor that initiates
injury to the glomerular capillary. Rituximab has been used to treat several
glomerular diseases. B cells may play a role in the pathogenesis of recurrent
FSGS. We report a 14-year-old boy whose primary kidney disease was FSGS
developed severe recurrence of proteinuria immediately after a second living
related kidney transplant. Despite pre and post operative plasmapheresis and
immunosuppressive treatment consisting of steroids, cyclosporin A (CycA),
daclizumab and mycophenolate mofetil (MMF), daily protein excretion and
serum creatinine increased. We therefore administered rituximab on the 4th day
of transplantation. He received 4 weekly doses of rituximab (375mg/m2/dose)
which resulted in a rapid clearing of circulating CD19 and CD20 positive B
cells and remission of proteinuria was achieved 6 weeks after the first rituximab
treatment. Graft function was excellent 6 months after transplantation with
proteinuria of 8 mg/m2/h. We conclude that rituximab may be an effective
treatment for post-transplant recurrence of FSGS.
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1892 SUCCESSFUL CADAVERIC RENAL TRANSPLANTATION
IN A 3.9 KG INFANT
O. Amon1, A. Bosk1, P. Szavay2, J. Fuchs2, O. Beringer1, W. Steurer3
1
Pediatrics, University Hospital of Tuebingen,Germany, 2Pediatric Surgery,
University Hospital of Tuebingen,Germany, 3General,Visceral and Transplant
Surgery, University Hospital of Tuebingen, Germany
A preterm infant with a birth weight of 2.700 gms and end-stage renal disease
from posterior urethral valves had to be started on peritoneal dialysis shortly
after birth. Because of multiple obstructions of the Tenckhoff catheter by
fibrinous plugs,he was switched to intermittent hemodialysis via a Permcath
catheter. Two life-threatening events, presumably related to his extreme arterial
hypertension, lead to the decision to attempt an early renal transplantation.
Augmentation cystoplasty was performed successfully, followed 6 weeks
later by a cadaveric kidney transplantation with a 4-year old child as donor.
The renal artery was anastomosed to the aortic bifurcation and the renal vein
to the inferior vena cava.The graft immediately resumed full function. Body
weight after transplantation was 3.9 kg and length 56 cm. Immunosuppression
consisted of methylprednisolone, tacrolimus, mycophenolate mofetil and 2
doses of daclizumab. Steroids were tapered and eventually stopped within 2
months.The clinical course was uneventful during the 9 months up till now and
the boy is thriving, with a current body weight of 7.8 kg. His serum creatinine is
stable at 0.3 mg/dl. His blood pressure is normal without any antihypertensive
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1890 THE OUTCOME OF RENAL TRANSPLANTATION
IN CHILDREN WITH FSGS

days following transplantation to all living related donor transplanted patients.
Patients with deceased donation had only post-transplant PF.
Results: The mean age was 12.6±4.7 years. The mean duration of follow-up
was 23.1±16.2 months. Two patients with hyperacute rejection were followedup for less than 1 month. One of them had biopsy-proven humeral hyperacute
rejection while the second was implicating recurrence of FSGS. Post-transplant
recurrence of FSGS was confirmed in 3 (33%) patients and all of them were
treated with pre and post-transplant PF while 2 have also received rituximab.
Remission was obtained in 1 of 2 patients that have received rituximab while
the other had responded partially. The one who did not receive rituximab had a
graft loss at the 2nd month of transplantation.
Conclusion: Recurrence of FSGS in the transplanted kidney is a severe condition
associated with graft loss. New therapeutic regimens and the efficacy of rituximab
and PF should be evaluated in prospective studies with large groups.
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medication.
This has been the smallest infant worldwide to undergo renal transplantation
up till now. From this experience we draw the conclusion, that augmentation
cystoplasty (in case of a dysfunctional lower urinary tract) and kidney
transplantation are viable options even in very small infants, if they experience
life-threatening complications on dialysis.

POSTER BOARD NUMBER P3 – 319
1893 SUCCESSFUL THERAPY OF A DISSEMINATED
CYTOMEGALOVIRUS (CMV) INFECTION WITH ORAL
VALGANCICLOVIR IN A 4 YEAR-OLD BOY AFTER KIDNEY
TRANSPLANTATION
O. Amon1, R. Beck2, O. Beringer1, P. Szavay3, J. Fuchs3, W. Steurer
1
Department of Pediatrics, University Hospital of Tuebingen, Germany,
2
Department of Medical Virology, University Hospital of Tuebingen, Germany,
3
Department of Pediatric Surgery, University Hospital of Tuebingen,Germany,
4
Department of General,Visceral and Transplant Surgery, University Hospital
of Tuebingen, Germany
A 3 year-old boy with a complex malformation syndrome developed endstage renal failure as a consequence of renal abscesses caused by multiple
urinary infections and a recto-urethral fistula. He was started on intermittend
hemodialysis. One year later he received a kidney transplant from a CMVpositive donor (the recipient being CMV-negative). During the transplantation
an ileum conduit was created with implantation of the graft ureter into the
conduit. He received standard immunosupperssion and induction therapy
with daclizumab x 5. For CMV prophylaxis Ganciclovir i.v., followed by oral
Valganciclovir (11 mg/kg/day) were administered. Additionally 4 infusions of
CMV Hyperimmune Globulin (100 mg/kg each) were given.
3 months after transplantation CMV DNA as determined by PCR could be detected
in the patients blood. The CMV DNA copy number was 14.000/ml plasma,
indicating disseminated CMV infection. The viral load subsequently increased
to 25.300 /ml plasma. The Valganciclovir dose was increased to 19 mg/kg daily.
Within 2 weeks the CMV copy number decreased to less than 600/ml plasma. Two
weeks later Valganciclovir could be stopped with a negative CMV PCR.
All the time the boy could be treated as an outpatient. The platelet count
decreased transiently to 95.000/μl. Otherwise he experienced no adverse
effects of the antiviral therapy.
From this experience we draw the conclusion that - depending on the clinical
status, which was excellent all the time in our patient - outpatient oral
Ganciclovir treatment may be an alternative therapeutic option to inpatient
intravenous ganciclovir treatment for disseminated CMV infection after solid
organ transplantation. Blood level determinations of the drug might be helpful
in further exploring this therapeutic approach, which makes hospital admission
of two weeks for intravenous therapy unnecessary.
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1894 LOW DOSE HEPARIN INFUSION REDUCES
VASCULAR THROMBOSIS AFTER PEDIATRIC RENAL
TRANSPLANTATION
P. Acott, J. Crocker
IWK Health Centre and Dalhousie University
The purpose of this study was to assess if low dose continuous heparin could
reduce the risk and outcome of thrombosis in pediatric renal transplants.
Thrombosis is an infrequent but significant complication, which often leads to
graft loss in the pediatric population with its smaller native vessel size, lower
mean arterial pressure, and higher rejection rates. Pediatric thrombosis rates
are 4-10% with increased rates in children ƒq6 y, cadaveric kidneys, with acute
tubular necrosis (ATN), and in centres <50 transplants/decade. Five allografts
(7.2%) in 69 consecutive pediatric renal transplants were lost secondary to
vascular thrombosis in our program from 1971 - 1992.
Low dose continuous heparin (10 units/kg/hour) was routinely implemented for
1 wk in high risk pediatric renal transplants: 1) age ƒq 6 yr; 2) laboratory profile
of hypercoagulability: Anti-Thrombin III < 80%, elevated fibrinogen, elevated
Von Willebrand¡¦s Factor, or reduction of Protein C or S availability; 3) oliguric
ATN > 24 h; 4) surgical complications with venous or arterial anastomosis; or
5) past patient history of access thrombosis or vasculitis. Over the past 15 years
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(1992-2007), 80 children (19 ƒq 6 yr) have been transplanted and 40 received
low dose heparin for one week. All received antibody induction therapy
(ATG/ALG [n=31], Daclizumab [n=1] or Basiliximab [n=48]), calcineurin
inhibitors (CyA [n=76] or FK506 [n=4]), anti-metabolites (azathioprine or
Mycophenolate), and steroids. Surveillance renal scans were obtained on days
1, 3, 5 and when clinical deterioration occurred. Graft survival at 1 year was
>97.5%.
Only two thrombotic events were noted (2.5%) and did not cause graft loss:
1) a 2 yr male LRD transplant with a venous thrombosis confirmed and
removed surgically 2hr post-op which occurred on heparin with stabilization
of renal function thereafter; 2) a 17 yr female with a double renal artery
cadaveric graft who developed arterial thrombosis of the smaller inferior
renal artery on day 10 with heparin discontinued 3 days prior. One patient
on heparin infusion for Anti-Thrombin III deficiency required laparotomy 3
hours after surgery for thrombosis external to the anastomosis, which was
considered our only complication of low dose heparin therapy. One other
patient not on heparin also required laparotomy in the first 24 hours post-op
for hematoma evacuation.
The risk and outcome of thrombosis was reduced by routine heparinization
of our high-risk patients. Identification, surveillance and treatment of
children who are at high risk of thrombosis appears warranted. We report a
low thrombosis rate and no organ loss despite a high proportion of high-risk
patients < 6 yr.
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1895 SIROLIMUS CONVERSION IN PEDIATRIC BIOPSY
PROVEN CHRONIC ALLOGRAFT NEPHROPATHY HAS
NO SUB-CLINICAL REJECTION ON 3 & 12 MONTH FOLLOWUP BIOPSY
P. Acott, J. Crocker
IWK Health Centre and Dalhousie University
Pediatric renal transplantation has made significant improvements in 1st year
allograft survival but chronic allograft nephropathy (CAN) is a major cause
of late allograft decline and loss. Sirolimus (SRL) has been promoted as a
calcineurin inhibitor (CNI) sparing or replacement strategy with variable
outcomes. This study evaluates pediatric patients with biopsy evidence of CAN
and loss of glomerular filtration measured by 24 hr urine creatinine clearance
(CrCl) that were converted from CNIs to SRL. Data is presented as mean ±
SE.
Twelve children (6 female; 6 male; 9 LD; 3 DD) all had biopsy proven CAN and
reduced CrCl = 34.8 +/- 3.6 ml/min/1.73 m2. The patients (age= 10.3 +/- 1.7 yr)
were 3.2 +/- 0.9 yr post renal transplant and their baseline immunosuppressant
therapy prior to conversion to SRL consisted of CNI (Cyclosporin A = 11;
FK506 = 1), Cellcept or Myfortic, and alternate day prednisone. SRL dosing
was altered to achieve SRL drug levels 5 to 15 mcg/ml. Follow-up included
laboratory data (monthly), CrCl (3 & 12 month), and renal biopsies (3 & 12
months) to exclude sub-clinical rejection.
No child had biopsy evidence of sub-clinical rejection (3 & 12 month post
conversion) and improvement of CrCl by 12 months (baseline CrCl = 34.8
+/- 3.6; 3 month CrCl = 42.0 +/- 4.2 [p = 0.188]; 12 month CrCl = 48.0 +/- 4.8
[p=0.038] ml/min/1.73 m2). Potential SRL related side effects included vulvar
ulceration (n=1); necrotizing pneumonitis (n=1); and progressive anemia
requiring blood transfusion and/or erythropoietin (n=2). Baseline hemoglobin
levels (g/l) (89.4 +/- 4.4) initially reduced at 3 months (78.3 +/- 3.1 [p=0.042])
but were above baseline at 12 months (100.6 +/- 4.8 [p=0.095]). No child had
to be taken off SRL and there was no allograft loss during the observation
period.
This is the first Sirolimus conversion study documenting no increase of subclinical rejection in the first year post cessation of CNI therapy. In pediatric
patients with renal biopsy established CAN with reduced CrCl, serious SRL
side effects were infrequent and amenable to SRL dose reduction and medical
management. Conversion from CNIs to SRL in pediatric renal transplant
recipients with biopsy proven CAN is well tolerated with improved renal
function and no increased risk of rejection.
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1896 KIDNEY TRANSPLANTATION IN CHILDREN AND
ADOLESENTS - AN ANALYSIS OF OPTN/UNOS DATABASE
B. Hardy1,3, T. Shah2, J. Cicciarelli2,3, K. Lemley1, I. Hutchinson2,3, Y. Cho2,3
1
Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC
School of Medicine
Background: It is very important to investigate whether specific pediatric
allocation schemes can not only lead to minimization of waiting time, but also
to better clinical outcomes for children with end-stage renal disease (ESRD).
Materials and methods: We analyzed the OPTN/UNOS data for all patients
aged 2-20 years who received kidney transplants from living or deceased
donors aged 5-35 years between January 1, 1994 and December 31, 2006.
Multiple organ transplants were excluded from this study. The outcome of 4,125
deceased donor kidney transplants (DDKT) was compared with those of 6,456
living donor kidney transplants (LDKT) using univariate and multivariate Cox
regression analyses.
Results: Unadjusted graft survival rates of DDKT were significantly lower
than those of LDKT (HR=1.53, P<0.001). Chronic rejection was reported
in 416 (10.1%) of 4,125 DDKT group compared with 537 (8.3%) of 6,456
LDKT group (P<0.001). Among black recipients, 65 (3.3%) grafts were lost
due to non-compliance as a contributory cause of failure compared with 126
(1.5%) among other races (P<0.001). A significantly lower incidence of noncompliance was observed in children (0.9%) compared with adolescent (2.2%
in age 10-14, P<0.001) and high teens (2.0% age 15-20, P<0.001). Multivariate
analysis showed that adjusted graft survival rates of LDKT were superior to
DDKT (HR=1.22, P<0.001) after adjusting for recipient race, recipient age,
regraft status, and HLA mismatch.
Conclusion: It is recommended that LDKT be offered first to children instead
of DDKT.
Table. Results of univariate and multivariate analyses.
Unadjusted
HR (95% CI)

P value

Adjusted
HR (95% CI)

P value

1.53 (1.42-1.65)

<0.001

1.22 (1.12-1.34)

<0.001

Recip race Black vs others 2.01 (1.85-2.20)

<0.001

1.81 (1.66-1.98)

<0.001

Recip Age 10-14 vs 2-9

1.47 (1.30-1.66)

<0.001

1.43 (1.27-1.62)

<0.001

1.91 (1.72-2.12)

<0.001

1.87 (1.68-2.08)

<0.001

Regraft vs primary

1.51 91.35-1.68)

<0.001

1.39 (1.24-1.56)

<0.001

HLA mismatch (0-6)

1.14 (1.11-1.16)

<0.001

1.07 (1.04-1.10)

<0.001

DDKT vs LDKT

15-20 vs 2-9
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1897 SINGLE CENTER EXPERIENCE WITH PARTIAL
LIVER GRAFTS FOR PEDIATRIC PRIMARY LIVER
TRANSPLANTATION
E. Island, T. Kato, G. Selvaggi, J. Moon, S. Nishida, D. Levi, A. Tzakis
University of Miami
Split, reduced, and live donor liver grafts have been shown to reduce
waiting time for pediatric liver transplantation, while at the same time
expanding both the pediatric and adult donor pools. Retrospective analysis
of prospectively collected data was undertaken to evaluate the long-term
outcome of these techniques in a single center’s experience. From 1993 to
2007 we performed 226 primary pediatric liver transplants. There were 147
whole organs and 79 partial organs. The partial organs consisted of 11 grafts
from living related donors, 34 grafts from split livers, 31 grafts were reduced
at the back table, and three grafts were reduced after implantation. The
long-term (>10 year) outcome with partial livers was excellent, however
both patient and graft survival were diminished when compared to whole
liver transplants (p<0.01). Partial livers were more likely to be used in
younger recipients with lower body weights (P<0.05). However there was
no significant difference found in ischemic time or blood product usage.
Within the partial liver group, patient and graft survival was equivalent in
the reduction, live donor, and split liver cohorts. Partial liver grafts provide
acceptable long-term outcomes for pediatric liver recipients, however both
patient and graph survival are diminished when compared to whole organ
transplant. Outcomes with split liver and size reduced grafts are equivalent;
therefore split livers should be used whenever possible to further expand
the donor pool.
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1898 PEDIATRIC ACUTE HEPATIC FAILURE AND
TRANSPLANTATION
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T. Heffron1, T. Pillen2, G. Smallwood1, R. Romero1
1
Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Purpose: It has been reported that acute hepatic failure in the pediatric liver
transplant arena has diminished survival when compared to chronic liver failure.
The aim of this study is to report our experience of emergent transplantation of
20 pediatric fulminate failure patients.
Method: All patients received similar immunosuppression with induction
therapy of daclizumab with tacrolimus, mycophenolate, and prednisone.
Results: Five of the 20 children received ABO incompatible liver allografts.
Three with blood group A received group B, one with blood group B received
group A, one with blood group O received group A. One year and three
year actuarial patient survival for the 15 ABO matched grafts versus 5 ABO
incompatible grafts was the same for both groups [(94.1% and 100%, (p =
NS)]. There was a trend in 1 and 3 year graft survival in favor of the ABO
incompatible group. Living donor and split liver transplant were used. A
reduced rate of rejection was noted in the ABO incompatible group [1 of 5
(20%) vs.12/15 (84.6%); p = 0.058]. ABO incompatible median time to first
rejection was 44 days versus 573 +/- 402 days in the ABO matched group (p
= 0.236). There was no hepatic artery, portal vein thrombosis, or vena caval
occlusion in the ABO incompatible group. One and three year actuarial patient
and graft survival for the entire group was 92.1% and 88.4%, and 84.9% and
77.1%, respectively.
Conclusion: Overall patient and graft survival was better than expected in the
fulminant failure patient. ABO mismatched grafts, split liver transplantation
and living donor can aggressively be utilized to enable increased patient/graft
survival in a patient group which is at risk of poor outcomes.
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1899 KIDNEY TRANSPLANTATION IN RECIPIENTS
YOUNGER THEN 5 YEARS
M.M. Kaabak, N.N. Babenko, A.K. Zokoyev, J.I. Kurakina, T.U. Cheprasova,
S.V. Kirillov, A.A. Abovjan, I.D. Rotova
Russian Scientific Center of Surgery RAMS
When ESRD is established, the results of kidney transplantation in young
children are as better as earlier the operation is performed. Here we analyze our
first experience with this tender cohort of patients.
At the Russian Scientific Center of Surgery since November 2003 till May
2007 15 kidney transplants were performed in children aged from 7 months to
5 years (3±1,7 years).
All transplants were first and from living related donors. Opposite to general
practice, all transplants were placed extraperitonealy.
Two patients died from the reasons not linked to graft function – one 4-years
old boy from gelmintose 1,5 years posttransplant, another 1,5-years old boy on
the 2-nd day after surgery from brain hemorrhage. Both patients maintained on
dialysis 24 and 13 months. Thirteen patients followed up in our center, their
demography presented in table 1.
Table 1. Demography of transplanted patients.
Age at transplant

0 – 1,5 years

1,5 – 3 years

Number patients

3

3

7

DMS1 1
dysplasia 2

reflux 1
DMS1 1
Finish type 1

HUS 1
DMS1 1
FSGS 4
Unknown 1

Duration of dialysis (months)
(M±m)

2,9±3

10,7±8,8

13,1±13,6

Age at start of dialysis, years
(M±m)

0,7±0,62

1,2±1,1

4,2±1,1

Follow-up posttransplant, M±m
(min - max)

327±476
(44- 867)

363±416
(90-842)

336±215
(36-643)

Height at Тх, cm (M±m)

84,7±8,9

86,0±10,7

91,2±12

Weight at Tx, kg (M±m)

11,1±3,4

11,5±3,7

13,7±4,4

Donor age, years (M±m)

30,5±8,1

33,1±8,4

32,8±10,2

Diagnosis

3 – 5 years

DMS – diffuse mesangial sclerosis
2
One patient was transplanted preemptively
1

Donors were parents (12), grandparents (2), uncle (1). In all cases native
bilateral nephrectomy were performed at the time of transplantation. Surgical
details summarized in table 2.
Table 2. Surgical details of transplants in children under age of 5 years.

WEDNESDAY

Age at transplant

0 – 1,5 years (n=3)

1,5 – 3 years (n=3)

Arterial inflow

aorta 100%

aorta 2
a iliaca com 2#

Venous outflow

v cava inf 1
v iliaca com 2

v cava inf 2
v iliaca com 1

pelvis 4*
bladder 1
right 2
left 1
0

pelvis 2
bladder 1
right 2
left 1
1 of 3

Urology reconstruction
Side of transplantation
Graft turn over**

3 – 5 years
(n=7)
aorta 1
a iliaca com 1
a iliaca int 6#
v cava inf 2
v iliaca com 2
v iliaca ext 3
pelvis 5
bladder 2
right 6
left 1
5 of 7

*in one recipient for urine drainage were used both native and donor ureters because of neck cystitis.
#
grafts with multiple arteries were used.
**Turn over of the graft facilitate arterial reconstruction, allow ipsilateral graft placement and feasible
when native ureter used.

All grafts have a good function at the moment. Since September 2006 Campath
1H is used for induction with early steroid withdrawal and late conversion from
CNIs to micophenolates or rapamycines.
Conclusion: Kidney transplantation in children under 5 years is can be
successfully performed with adult kidneys. Extraperitoneal placement of the
grafts is feasible in all cases, even in kids of 1-st year of life, and allows to
create adequate blood supply and urine outflow. Preemptive transplantation
will improve the results of treatment by decrease of prevalence of chronic
uremia complications.
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1900 INCREASE INCIDENCE OF ACUTE CELLULAR
REJECTION IN PEDIATRIC RENAL TRANSPLANT PATIENTS
RECEIVING STEROID FREE IMMUNE SUPPRESSION
J. Johnson, E. Tsai, R. Ettenger
UCLA - Dept of Pediatrics/Division of Nephrology
Introduction: Many renal transplant centers have moved towards steroidfree immunosuppressive regimens to avoid long-term toxicities. However,
there have been anecdotal reports of increased acute rejection with steroidfree regimens. Moreover the factors associated with this increase have not
been fully elucidated. The aim of this study was to compare the risk of acute
cellular rejection in pediatric renal transplant recipients receiving optimal
verse suboptimal dosing of mycophenolate mofetil (MMF) on a steroid free
regimen.
Methods: We performed a retrospective chart review of 26 steroid free
patients transplanted at Mattel Children’s Hospital at UCLA between 9/1/2004
and 2/25/2007. Our steroid-free regimen consisted of daclizumab induction
(7 doses of 1mg/kg), intraoperative solumedrol (10mg/kg x1)), prograf
(0.1 mg/kg dose bid, goal trough levels initially 8-10) and mycophenolate
mofetil (600 mg/m2/dose bid). We examined potential factors associated
with increased risk of acute rejection including withholding or minimizing
MMF. Suboptimal dosing of MMF was defined as less than 75% of 600
mg/m2/dose, with maximum adult dose being 1000 mg. We calculated the
incidence of acute rejection for patients receiving optimal verse suboptimal
dosing. Biopsy proven acute rejection was defined by the modified 1997 Banff
criteria. Inclusion criteria were first transplants with PRA< 30%. Exclusion
criteria were retransplants; patients induced with Thymoglobulin; patients
with PRA>30%; and patients with recurrent disease requiring plasmapheresis
and/or Rituximab.
Results: We found 9 patients in the defined control group with optimal MMF
dosing; 22% (2/9) of these patients were found to have biopsy proven acute
cellular rejection. We identified 17 patients on suboptimal MMF: 59% (10/17)
these had biopsy proven acute cellular rejection, one of these patients also had
an equivocal findings for antibody mediated rejection. Patients with suboptimal
MMF dosing had a 5 fold increase (95% confidence interval 0.79 – 31.62) risk
of acute rejection verse patients on optimal dosing.
Conclusions: We have found that while steroid free immunosuppression
can be effective, patients with suboptimal MMF dose may have an increased
risk of developing acute cellular rejection. This risk maybe as high as five
fold compared to patients on optimal MMF. This study is limited due to
the small sample size. In the future, larger studies may help further define
this risk.

POSTER BOARD NUMBER P3 – 327
1901 CHIMERISM IN PEDIATRIC PATIENTS WITH
ALLOGENEIC TRANSPLANT OF HEMATOPIETIC
PRECURSORS
J. Larriba, M. Makiya, M. Tambutti, L. Molina, E. Dibar, M. Redal
Hospital Italiano De Buenos Aires
Introduction: The importance of establishing the degree of chimerism on
haematopoietic precursor recipients has long been recognised. This allows for
the early detection of graft dysfunction, as well as the need for appropriate
additional immunosuppression.
Objective: To determine the degree of chimerism on peripheral blood samples
of patients undergoing a haematopoietic precursors transplant by the specific
amplification of DNA microsatelites.
Methods: Nine paediatric patients (mean age, 9.44 years; range 2-17 years;
female, 4; male, 5) were included. Cause of transplantation was acute
lymphoid leukaemia (ALL) in 2 patients; acute myeloid leukaemia (AML),
3; myelodisplastic syndrome (MDS), 2; acute aplasia (AA), 1; and chronic
lymphoid leukaemia (CLL), 1. Blood samples were obtained before transplant
and at 1, 3, and 12 months post-transplant. Peripheral blood samples were also
obtained from the donors. In two cases, bone marrow samples were used for the
study. Chimerism was studied on different chromosomes by polymerase chain
reaction (PCR) of polymorphic repetitive sequences (PRS) of genetic markers.
The microsatelites analysed were D16S539, D7S820, D13S317, CSF1PO,

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Wednesday 13 August 2008

Poster Abstracts
TPOX, TH01, F13A01, FESFPS, vWA, LPL, F13B, and HUMPRTB. Products
of PCR were subject to electrophoresis of polyacrilamide denaturing gels and
visualized by staining with silver nitrate.
Results: A complete chimerism (CC) was observed at one month post-transplant
on all patients. At 3 months post-transplant, 1 out of 9 patients (11%) showed
mixed chimerism (MC). At one year post-transplant 2 patients (22%) showed
MC and 7 CC (78%). All patients presented acute graft versus host disease
(GVHD) (grade 3, n=4; grade 2, n= 4; grade 1, n=1). Chronic GVHD affected
two patients (grades 4 and 3), who died at month 16 and 18 post-transplant,
respectively. Additionally, one patient presented GVHD grade 3 with partial
reversal, and 4 patients had grade 1 disease of which one had partial and three
complete reversals.
Conclusions: PCR-PRS and staining with silver nitrate is a relatively simple
and sensitive method that allows for the detection of chimerism on recipients
of haematopoietic precursors.

CONCURRENT ORAL SESSION 132: BIOARTIFICIAL ORGANS
AND TISSUE ENGINEERING
POSTER BOARD NUMBER P3 – 328
1902 ALBUMIN DIALYSIS IN SEVERE LIVER FAILURE:
AN ANTICOAGULANT-FREE APPROACH

1903 DEVELOPMENT OF A NEW TREATMENT FOR BILE
DUCT STENOSIS USING TISSUE ENGINEERING TECHNIQUES
– DEVELOPMENT OF A BILE DUCT PATCH MADE OF
BIOABSORPABLE POLYMER –
M. Miyazawa, M. Aikawa, Y. Toshimitsu, K. Okada, K. Okamoto, I. Koyama
Saitama Medical University International Medical Center
Purpose: Along with the recent widespread use of living-donor liver
transplantation, complications involving the biliary system are increasing. Stent
or T-tube insertion is a common treatment for bile duct stenosis. However, there
are some disadvantages with both stent and T-tube, and new means of treatment
have been called for. We investigated whether a bioabsorbable polymer patch
that dilated the narrowed bile duct could be available for the treatment of bile
duct stenosis.
Materials and methods: Hybrid pigs were laparotomized under general
anesthesia and the extrahepatic bile duct was identified. Then a portion of the
duodenal side of the bile duct was resected, 3¦ ~2 cm in size and spindle in
shape, and substituted by a patch made of bioabsorbable polymer of the same
size. The patch was designed to degrade in six to eight weeks in the body.
There was no prior cell seeding onto the patch. Animals were re-laparotomized
four months after implantation to recover graft sites for gross, histological and
blood chemical studies.
Results: All recipient pigs survived until they were sacrificed for collection
of graft sites four months after implantation. All of them gained weight. On
gross examination, the patch was found to have been absorbed and the graft
site was indistinguishable from the native extrahepatic bile duct. Stenosis did
not occur, adhesion to surrounding tissue was mild and the graft site could
be freed manually. Histology revealed a neo-bile duct growing in the graft
site with the epithelium of highly uneven thickness and increased accessory
glands compared with the native duct. Blood chemistry data at four months
post implantation did not show change from baseline values.
Conclusion: This study demonstrated that the patch could be used for the
treatment of bile duct stenosis. Thus, dilation of the bile duct with this patch
can be a substitute for T-tube insertion in transplantation surgery.
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1904 MOLECULAR ADSORBENT RECYCLING SYSTEM AS
PREDICTIVA CRITERIA OF SURVIVAL IN PATIENTS WITH
ACUTE LIVER FAILURE
G. Novelli, M. Rossi, V. Morabito, S. Novelli, F. Pugliese, G. Spoletini,
A. Bussotti, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: The aim of our study is directed towards the assessment of these
resources in our possession that could facilitate a decision to transplant or not.
For this reason, we examined whether the Molecular Adsorbent Reciclyng
System (MARS) can be seen as a predictor of survival in patients with IEA
Material and methods: We treated 40 patients suffering from fulminant
hepatitis (FH) with MARS. Treatment MARS was made in exchange for
continued kits every 8 hours, because the method can be applied in safety and
tolerability. All patients were treated at the Intensive Care (ICU). Moreover, in
14 patients cerebral edema was assessed by monitoring intracranial pressure
(ICP). Univariate analysis for quantitative variables was calculated using
the Student’s t-test and using the chi-square test for qualitative variables.
Significance was defined as p < 0.05. Graft and patient survival rates were
analysed using the Kaplan– Meier; the differences between curves were
assessed by log-rank test.
Results: Of the 40 patients, twenty six of which survived,14 went to the
transplant within 5 days of treatment while 12 have continued extracorporeal
method for a maximum period of 17 days indicating a positive resolution of the
clinical condition.Fourteen patients have died, including 5 before transplant for
multi organ failure, while nine after transplantation (5 for Primary No Fuction,
4 for sepsis). The MARS showed a specificity of 93% and a sensitivity of
90%.
Conclusion: From our clinical experience, we consider the seriousness of
the patient’s neurological status and hemodynamic instabilty an important
negative of the disease. Where we have achieved a significant improvement
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H.K. Tan, W.S. Yang, H.L. Choong, K.S. Wong
Department of Renal Medicine, Singapore General Hospital, Singapore
Introduction: Severe liver failure is associated with profound coagulopathy
and can be treated with artificial liver support. The molecular adsorbent
recirculating system (MARS) is one such device. Maintaining circuit patency
with anticoagulation increases already high bleeding risk. Our hypothesis
was: omission of heparin-saline prime and intradialytic heparin is safe and
efficacious.
Method: MARS was performed with neither heparin-saline prime nor
intradialytic heparin. Duration and ultrafiltration were as clinically indicated.
Intermittent saline flushing of blood circuit was performed. Contraindications to
MARS were poor pre-morbid status and severe hypotension SBP≤90 mmHg.
Results: A total of 12 patients (M:F=10:2; age 49±9 years) were studied.
Six patients had fulminant hepatic failure (FHF) and the other 6 had acute
decompensation of chronic liver disease (CLD). Two patients underwent
liver transplant but only one survived. Overall mortality was 92% (11/12). A
total of 44 MARS sessions were performed (average 8±7 session per patient).
Prescribed versus achieved MARS duration were 13±3 vs. 11±4 h, p<0.05.
Twenty-three percent (10/44) of MARS sessions developed filter clotting, 11%
(5/44) of treatments were electively terminated, and 2% (1/44) experienced
vascular catheter blockage. Spontaneous bleeding around vascular catheter sites
occurred in 9% (4/44) of sessions. Pre- vs. post-MARS systolic blood pressure
(SBP): 135±23 vs.131±26, p=0.105; and, diastolic blood pressure (DBP):
64±10 vs. 61±9, p=0.043. Pre- vs. post-MARS transmembrane pressures
(TMP) (mmHg) were comparable: 62±32 vs. 55±36, p=0.071. Circuit pressures
were stable: pre- vs. post-MARS Aa pressure (mmHg): 127±32 vs. 130±50,
p=0.659; and, Ae pressure (mmHg): 261±61 vs. 248±67, p=0.128. Saline
flushing was used to maintain circuit patency: 2664±2420 ml per treatment
(range: 500 – 12800 ml). Coagulation indices were (pre- vs. post-MARS):
prothrombin time (PT) in seconds 36±30 vs. 42±33, p=0.143; activated partial
thromboplastin time (aPTT) in seconds 78±43 vs. 88±45, p=0.117; and, platelet
count (x103/L) 87±40 vs. 76±48, p=0.004. Systemic blood concentrations of
water-soluble and protein-bound solutes were all reduced: pre- vs. post-MARS
serum urea (mmol/l) 8±7 vs. 5±3, p<0.05; serum creatinine (μmol/L) 213±176
vs.144±115, p<0.05; total bilirubin (μmol/L) 504±150 vs. 351±87, p<0.05;
and, plasma ammonia (μmol/L) 109±50 vs. 76±39, p<0.05.
Conclusions: Anticoagulant-free albumin liver dialysis with intermittent saline
circuit flush is associated with low bleeding risk but relatively higher clotting
episodes. Overall, neither circuit performance nor blood depurative efficacy
was adversely affected. Although coagulopathy did not worsen significantly,
pre-MARS thrombocytopenia significantly deteriorated following MARS.
This observation is of clinical importance but its basis and significance need
further elucidation.
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of these factors in the first 48 hours thanks to MARS and the support of ICU,
we decided to continue the extracorporeal treatment. The results lead us to
continue this research by adjusting the number of patients to be treated.
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1905 MONITORING HEMODYNAMIC PARAMETERS DURING
MOLECULAR ADSORBENT RECYCLING SYSTEM SESSIONS
IN PANTIENTS WITH PRIMARY NON FUNCTION
G. Novelli, M. Rossi, L. Poli, F. Ruberto, F. Pugliese, G. Mennini,
V. Morabito, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: Patients with Acute Liver Failure show an aggravated
hyperdynamic circulation. We evaluated potential changes in systemic
haemodynamics induced by the Molecular Adsorbent Recirculating System
(MARS) in a group of patients with Primary no Function (PNF).
Material and methods: In Intensive Care Unite we treated 18 patients with
PNF (8 female and 10 male) after liver transplantation with a mean age 47.8
(range 28-60). Continuous MARS treatment was carried on all patients with
kit change every 8 hours for mean days 10(range 2-20). Veno-venous access
(double-lumen catheter type) was used for blood supply. Blood flow rate was
150-250 mL/min, depending on the hemodynamic situation of the patient.
Blood passed through an albumin non-permeable, high flux dialysis membrane.
During MARS treatment the hemodynamic condition, using a series of
parameters such as Heart Rate (HR), Mean Arterial Pressure (MAP), Cardiac
Index (CI), Systemic Vascular Resistance Index (SVRI), Pulmonar Vascular
Resistance Index (PVRI), were monitored before (base value), after one hour
(T1), after three hours (T2) and at the end of treatment (T3). Neurological
status was value through Glasgow Coma Score (GCS).The Sequential Organ
Failure Assessment score (SOFA) was used as predictive criteria. Univariate
analysis for quantitative variables was calculated using the Student’s t-test and
using the chi-square test for qualitative variables. Significance was defined as p
< 0.05. Graft and patient survival rates were analysed using the Kaplan– Meier;
the differences between curves were assessed by log-rank test.
Results: There was a progressive decrease in the positive inotropic
(dobutamine,norephinefrine) and significant improvement of hemodynamic
parameters such as MAP (p<0.001), CI (p<0.001) and SVRI (p<0.002). Eleven
patients alive: 6 to liver transplantation (LT), 5 patients without LT. Seven
patients dead: 4 after LT while 3 before liver transplantation for Multi-Organ
Failure.
Conclusions: The MARS device significantly improves the hemodynamic
targets in acute liver failure that also determine patients survival (52%) with
PNF awaiting a re-transplantation presumably by a difference in removal rate
of certain vasoactive substances
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1906 MONITORING CITOKINES LEVELS IN ACUTE ON
CHRONIC LIVER FAILURE PATIENTS DURING MOLECULAR
ADSORBENT RECIRCULATING SYSTEM VERSUS STANDARD
MEDICAL THERAPY
G. Novelli, M. Rossi, S.G. Corradini, G. Di Folco, G. Ferretti, F. Pugliese,
F. Ruberto, V. Morabito, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: The various definitions of Acute on Chronic Liver Failure
(AoCHF) do not accurately reflect the differences in clinical signs and in
prognosis. In AoCHF physiopathology, inflammatory and metabolic factors
and oxidative stress seem to be considered ‘precipitating’. The aim of this
study was to compare the effect of Molecular Adsorbent Reciculating System
(MARS™) and Standard Medical Therapy (SMT) in the correction of these
precipitating factors. The results of MARS patients were compared with the
performance of cytokines in 15 patients who had performed the liver transplant
without AoCHF.
Material and methods: We monitored cytokines changes in 30 Acute on
Chronic Liver Failure(AoCHF) patients(Pt) with different aetiology and
similar Model End-stage Liver Disease (score 20-30): 15 Pt with MARS and
15 with SMT. Five patients were excluded from MARS treatment: 1 Pt to Liver
Transplantation (4 treatments), 2 Pt death for sepsis (2 treatments), 2 Pt death
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for Multi Organ Failure (3 treatments). Two patients were excluded from SMT
group because of death within 30 days.
All ten patients were treated for 8 hour every session and for number 9 of
MARS treatments. All twenty-three patients were valued during 30 days from
inclusion and follow up of patients survival at three-months. In patients of
two group we valued: IL-1â. IL-6. IL-10. TNF-á. TNF-R1. TNF-R2. Hepatic
Growth Factor (HGF). Nitrites and Nitrates.
Intensive Care Unite (ICU) treatment was applied to optimize regeneration and
to prevent cardiovascular complications.
Results: In the Mars group at the end of 9 treatments we valued a significant
change for IL-1â(pre MARS 32±16.9, post MARS 20.5±13.4 p<0.002),
IL-6(pre MARS 38.14±11.1, post MARS 23.48±9.68 p<0.01), IL-10(pre
MARS 17.04±6.81, post MARS 10.84±4.36 p<0.05) and TNF-á(pre MARS
19.41±7.85, post MARS 11.5±6.57 p<0.03). We observed a significant
improvement of HGF (<0.001). At the three months 5 patients on 10 were lived
(50%). In the SMT group IL-10(<0.01) and TNF-á (<0.2) were significant. At
three months 5 patients on 13 were lived (38%). Since IL-6 plays an important
role in both pro-inflammatory and in regenerative, we compared the values in
15 additional patients who had performed the liver transplant. After thirty days
by liver transplant the values of IL-6 (23.05 ± 4.1) were similar to those found
at the end of the cycle MARS treatments.
Conclusions: In this study, MARS therapy did show a clearly identifiable
efficacy at removing circulating cytokines.
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1907 DEVELOPMENT OF RENAL COMPONENTS FROM
RAT MESENCHYMAL STEM CELLS USING A MOUSE
XENOBIOTIC SCAFFOLD
K. Kai1,3, S. Teraoka1, T. Yokoo2, T. Murakami3, E. Kobayashi3
1
Tokyo Women’s Medical University, Surgery 3, 2The Jikei University School
of Medicine,Internal Medicine, 3Jichi Medical University, Organ Replacement
Research
Background: The terminal goal of transplantation is to establish functional
tissues derived from recipient autologous stem cells. Various organogenesis
studies have been carried out using artificial scaffolds. We previously focused
on fetal primordia as an ideal bioscaffold for organogenesis because fetal organs
lack antigenicity and they have the potential to produce several cytokines that
are essential for organogenesis. In this study, we successfully developed renal
components from rat mesenchymal stem cells (MSCs) using mouse xenobiotic
fetal primordia as a bioscaffold.
This technology is a new strategy for organogenesis.
Methods: Fetal renal primordia (metanephroi) of C57/B6 mice at embryonic age
(E) 13.5 were transplanted onto the omentum of a unilaterally nephrectomized
wild-type Lewis (LEW) rat and a LacZ transgenic (Tg) LEW rat, which enable
us to detect the host-derived cells in the transplanted metanephroi. Each recipient
was treated with tacrolimus (0.64 mg/kg/d) administered subcutaneously from
day 0 to day 13 after transplantation; tacrolimus administration was then
stopped. Bone marrow-derived MSCs (1 ¦ ~ 104/metanephroi) were cultured
on MatrigelTM and injected into the metanephroi at transplantation. The MSCs
were harvested from the luciferase (luc) and LacZ dual marker Tg LEW rat.
The luc marker enabled us to chase the MSC-derived cells using an in vivo
bioluminescent imaging system (IVISTM) without animal sacrifice, and the
Lac-Z marker enabled us to evaluate the MSC-derived cells by a pathological
assay. The transplanted metanephroi were harvested at day 14 and day 28.
Results: Harvested metanephroi grew in size from 2 mm to 8 mm, and neovascularization from the recipient omentum was observed. Host-derived
LacZ-positive tissue was not detected. Using bioluminescent imaging, MSCderived luminescent expression was observed at day 7, 14, and 21. Pathological
findings revealed MSC-derived LacZ-positive cells in the renal tubules. There
was no evidence of rejection.
Summary: In this study, we succeeded in transdifferentiating autologous MSCs
to renal cell components in a xenobiotic neokidney under the administration of
short-term tacrolimus monotherapy.
However, the reconstruction ratio of xenobiotic fetal organs as a bioscaffold
still remains to be evaluated; this technology has the potential to establish neoorgans derived from recipient autologous stem cells.
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1908 TREATMENT OF NON ALBUMIN RATS BY
TRANSPLANTATION OF IMMORTALIZED HEPATOCYTES
USING ARTIFICIAL HUMAN CHROMOSOME
M. Ito, M. Ikeno, H. Nagata, T. Yamamoto, A. Horiguchi, S. Miyakawa
Fujita-Health University
The shortage of organ donors has impeded the development of human hepatocyte
transplantation. Immortalized hepatocytes could provide an unlimited supply
of transplantable cells. To determine whether immortalized hepatocytes could
provide global metabolic support in end-stage liver disease, 42 immortalized
rat hepatocytes clones were developed by transduction with Artifical Human
Chromosome (HAC) encoding the Simian virus 40 T antigen (SV40Tag) .
The SV40Tag sequence and a suicide gene, herpes simplex virus thymidine
kinase (HSV-tk), were flanked by FRT sequences so that they could be excised
by FRT recombination.
When transplanted into the spleen of retrosin treated non albumin rats with
2/3 hepatectomy with FK506 (R-NARs), immortalized hepatocyte clones
prevented the development of albumin. The protection was reversed by
Ganciclovir treatment, which kills HSV-tk expressing cells.
Three experimental groups were used for alnumin analysis: (G1) non albumin
rats with 2/3 hepatectomy only (R-NARs) (n=4); (G2) R-NARs and intrasplenic
transplantation of 3x107 primary hepatocytes (pHTx) (n=4); (G3) R-NARs and
intrasplenic transplantation of 3x107 immortalized hepatocytes (iHTx) (n=4)
All HTx group(G2-3) were made albumin but immortalized hepatocytes were
not significantly elevated albumin level conpared with primary hepatocyte.
Immortalized hepatocytes group were not shown up tumor after one month
HTx.
The metabolic support provided by the immortalized cells not equalled that
observed after transplantation of primary rat hepatocytes, but in afuthur can be
engineered to contain safeguards that could make them clinically useful.

POSTER BOARD NUMBER P3 – 335
1909 SKIN PRESERVED FOR MONTHS IN ANHYDROUS
SODIUM CHLORIDE IS TAKEN BY RECIPIENT WITH ONLY
MINOR XENOGENEIC RESPONSE

POSTER BOARD NUMBER P3 – 336
1910 DOSAGE DEPENDED ACETAMINOPHEN-INDUCED
ACUTE LIVER FAILURE IN PIGS
M. Schenk1, C. Thiel1, K. Knubben1, M.H. Morgalla2, A. Etspüler3,
A. Königsrainer1
1
University Hospital Tuebingen - General, Visceral and Transplant Surgery,
2
University Hospital Tuebingen - Neurosurgery, 3University Hospital
Tuebingen - Anaesthesiology
Objective: A reproducible pig model of acute liver failure due to intoxication
for evaluation of therapeutic strategies and devices, omitting the variability
induced by multiple non-liver injury sites (e.g. anaemia, cardiac failure), is
urgently needed.
Methods: Twelve pigs underwent an intoxication with a single enteric
acetaminophen bolus of 1500 mg/kg b.w.(n=3), 1250 mg/kg b.w (n=3),1000
mg/kg b.w (n=6). Seven pigs received a bolus of 500 mg/kg b.w.(n=3) or 250
mg/kg b.w. (n=4) and afterwards blood levels of 300-400 mg/l acetaminophen
were maintained by continuous enteric administration until acute liver
failure occurred (decline of liver depended clotting factors and albumin).
Pigs remained under deep narcosis with pressure controlled ventilation until
death. Sodium chloride 0,9%, hydroxyethylstarch 6% were used for volume
substitution and noradrenalin for hemodynamic stability. Parameters like heart
rate, mean arterial pressure, pulse oximetry were continuously monitored, blood
gas analysis was performed hourly and corrected as required. Acetaminophen
blood levels, albumin, AST, ALT and liver depending clotting factors were
measured every 8 hours after intoxication.
Results: All animals receiving 1500 mg/kg b.w. or 1250 mg/kg b.w. died within
11&#61617;10 or 13&#61617;7 hours caused by cardiocirculatory failure.
Three of the pigs receiving 1000 mg/kg b.w. died due to acute liver failure
within 30&#61617;8 hours, but 3 animals recovered after severe liver damage
and were killed after 48 hours. Animals with 500 mg/kg b.w. bolus and blood
levels of 300-400 mg/l died after 21&#61617;9 hours due to cardiac arrest.
Pigs with 250 mg/kg b.w. bolus and blood levels of 300-400 mg/l survived
minimum 27 and maximum 45 hours (mean 37&#61617;7) and died due to
acute liver failure.
Conclusions: A low acetaminophen bolus and continuous enteral administration
adjusted to blood levels delivers a well reproducible pig model of acute hepatic
failure with defined survival times.

POSTER BOARD NUMBER P3 – 337
1911 ALLOSENSITIZATION ELICITED BY AORTIC
ALLOGRAFT TRANSPLANTATION IN RATS IS PREVENTED
BY GLUTARALDEHYDE TREATMENT
B. Laing1, I.M. Rebeyka1, C.C. Anderson1, D.R. Ross1, L.J. West1,2
Department of Surgery, University of Alberta, Edmonton, AB, 2Department of
Pediatrics, University of Alberta, Edmonton, AB
Introduction: Aortic and pulmonary artery allografts implanted during
congenital heart surgery are associated with a significant immune response.
This immune sensitization can complicate future transplantation should it
be required. Commercial xenografts used in cardiac surgery are treated with
glutaraldehyde to enhance tissue strength and durability. The aim of this study
was to assess the effect of glutaraldehyde on the immune response associated
with aortic allograft implantation.
Methods: Aortic grafts were harvested from the abdomen of Brown Norway
rats (RT1n) and treated with a 1% glutaraldehyde solution. The treated grafts
were orthotopically transplanted into ten Lewis rats (RT11). The humoral
immune response was assessed at 16-weeks. Donor splenocytes were exposed
to recipient serum. Bound antibody was detected with FITC-conjugated
F[ab]2 fragment goat anti-rat IgG. Results were compared to serum from six
1
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W.L. Olszewski1,2,3, M. Moscicka1, D. Zolich1
Dept. of Surg. Res. & Transpl., Medical Research Center, Polish Academy
of Sciences, Warsaw, Poland, 2Central Clinical Hospital, Ministry of Internal
Affairs, Warsaw, Poland, 3Norwegian Radium Hospital-Rikshospitalet, Oslo,
Norway
Introduction: We have been searching for methods of long-term preservation
of skin for subsequent tx. Since epidermis and dermis are, relatively to other
tissues, resistant to ischemia and dehydration, we tried to use dehydration
method for preservation of skin fragments for tx. Our study revealed that
skin fragments dehydrated in powdered sodium chloride can retain their vital
properties and can be successfully tx. Interestingly, we found only minor
cellular infiltrates around the grafts.
Aim: To study the xenogeneic reaction to sodium chloride preserved human
skin grafts.
Methods: Human skin fragments (30) from lower limbs were harvested during
elective vascular surgery (consent of ethical committee). They were placed in
heat-dried fine sodium chloride powder (1part skin 9 parts of NaCl), kept at
room temperature for 3 to 6 months. They were desalinated and fragments 1x1
cm were transplanted to the dorsum or recipient: in group 1 to scid mice (60)
and in group 2 to WIS rats. After 21 to 90 days, the grafts were harvested.
Results: Skin grafts were taken by the recipient. In group 1, on histology,
keratinocytes looked normal. They were all HLA class I. Staining with mAbs
against human p63(stem cells), CD29 (transient cells), PCNA (proliferating
cell nuclear antigen) revealed normal pictures of basal layer cells. In mice
receiving BdUr injection 24 h before harvesting a number of nuclei of basal
cells were stained. Staining against mouse MHC I and II antigens, macrophages
and granulocytes did not reveal presence of mouse antigens in the tx human
epidermis. In dermis, fibroblasts looked normal and there were some large
HLA DR+ cells in the intercapillary spaces. In group 2, histological pictures
were as in group 1. There was no infiltration of recipient cells into the grafts.
1

The peri-graft mononuclear accumulations were limited to 3-4 layers of cells
expressing classII antigens.
Conclusions: Human epidermal stem cells survive in a dehydrated state for
months and upon transplantation give rise to keratinocyte progenies. Also,
skin fibroblasts and some immune cells survive and can be shown in the tx
graft. Moreover, grafts transplanted to xenogeneic recipient evoke only minor
response. The mechanism of low responsiveness is studied.
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syngeneic transplant recipients and from recipients of nine untreated allogeneic
transplants. Immunohistochemistry of glutaraldehyde-treated tissue was
performed to detect changes in MHC staining.
Results: Allogeneic aortic transplantation is associated with a profound donorspecific antibody response. (1.4% vs. 25.0% cell antibody bound (p=0.002)).
There was no difference between antibody development in syngeneic allograft
recipients and glutaraldehyde-treated allograft recipients (1.4% vs. 1.7%
cells antibody bound (p=0.74). Graft treatment with glutaraldehyde prevents
development of this antibody (Figure).
Conclusion: Glutaraldehyde-treatment of aortic allograft prevents the
formation of donor-specific antibodies in the rat. This simple technique has
potential to prevent allosensitization in patients receiving vascular allograft
tissue in the repair of congenital heart lesions. This has profound implications
for patients with congenital heart lesions in which the need for future cardiac
transplantation may become a necessity. These findings correlate with
recent preliminary work showing lower panel reactive antibody in recipients
of glutaraldehyde-treated patches following the Norwood procedure for
hypoplastic left heart syndrome.
Figure:
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the transplanted mice were followed up for 13 weeks, only one of six mice
receiving 50 islets plus control silica-gel converted to normoglycemia, while
all of mice receiving 50 islet alone and all of mice receiving 50 islets plus
silica-gel containing 6.4 μg AMT became normoglycemia. The temporary
post-transplantation hyperglycemia for mice receiving 50 islets alone and
mice receiving 50 islets plus silica-gel containing AMT was 40±5 and 39±7
days, respectively. The insulin content of islet grafts retrieved at 13 weeks
after transplantation was 0.17±0.16 (n=6), 1.41±0.11 (n=4), and 1.28±0.30
μg (n=6) for mice receiving 50 islets plus control silica-gel, 50 islets alone,
and 50 islets plus silica-gel containing AMT, respectively. The insulin content
of pancreatic remnants did not differ significantly among three groups. In
conclusion, (1) AMT, an iNOS inhibitor protects islet isograft from a nonspecific inflammatory destruction. (2) although silica gel per se is non-toxic to
islet beta cells, it induces a nonspecific inflammation and offsets the protection
of AMT on islet grafts.

POSTER BOARD NUMBER P3 – 339
1913 OUTCOMES OF DONOR HEPATECTOMY IN
LIVING DONOR LIVER TRANSPLANTATION: A SINGLE
INSTITUTION’S EXPERIENCE WITH 136 CONSECUTIVE
CASES
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1912 ENTRAPMENT OF AN INOS INHIBITOR, AMT, IN
SOL-GEL GLASSES FOR USE IN PREVENTING EARLY
DYSFUNCTION OF ISLET TRANSPLANT
B.R.S. Hsu1, Y.T. Chen2, S.H. Fu1, J.P. Chen2
1
Divsion of Endocrinology and Metabolism, Chang-Gung Medical Center,
2
Department of Chemical and Materials Engineering, College of Engineering,
Chang-Gung University
Non-specific inflammation at the islet surrounding milieu causes by-stander
damage to the islet β-cells and results in early dysfunction of islet transplant.
To investigate whether a locally released inhibitor of an inducible form of nitric
oxide synthase (iNOS) protects islet β-cells from inflammatory destruction,
we co-transplanted islets with silica-gel powder entrapping 4H-1,3-Thiazin-2amine,5,6-dihydro-6-methyl (AMT) and evaluated the effect of AMT on islet
β-cells engraftment and function. The mean diameter of silica gel particles
is 595±275 nm. The cumulative release of AMT is about 70% at 72 hours.
The in-vitro culture of RIN-m5F cells revealed that 4 and 20 nM AMT could
preserve 30% more of proliferating cells from cytotoxic inhibition mediated
by 1 ng/ml of IL-1β. Silica-gel per se did not influence islets survival or
function in vitro in terms of cell proliferation assay and glucose-stimulated
insulin secretion. At 3 days following transplantation, the serum level of nitrite
of mice receiving 50 islets plus control silica-gel powder were significantly
higher than that of mice receiving 50 islets alone (nitrite: 84±72 μM, n=6 vs.
46±26 μM, n=4, p<0.05) and that of mice receiving 50 islets plus silica-gel
containing 6.4 μg AMT (84±72 μM, n=6 vs. 67±41 μM, n=6, p<0.05). When
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S. Kawachi1, M. Tanabe1, H. Obara1, M. Shinoda1, K. Hoshino2,
Y. Fuchimoto2, N. Shimojima2, Y. Morikawa2, Y. Kitagawa1
1
Department of Surgery, Keio University School of Medicine, 2Department of
Pediatric Surgery, Keio University School of Medicine
Aim: The aim of this study was to evaluate the morbidity and mortality of
living liver donation and to facilitate a better understanding of donor risk in
living donor liver transplantation (LDLT).
Methods: Living donor-morbidity was evaluated in 136 consecutive cases of
LDLT carried out from April 1995 to December 2007 at Keio University. A left
lateral segment (LS) graft (n=44), a left liver (LL) graft with middle hepatic
vein (n=30), a LL plus caudate lobe (LL+CL) graft (n=28), or a right liver
(RL) graft (n=34) was selected so that at least 0.8 of graft recipient weight ratio
(GRWR) was ensured. RL graft harvesting was strictly limited when RL volume
was no more than 70% of whole donor liver. Perioperative complications were
classified according to the Clavien system.
Results: Complications occurred in 36 patients (Clavien grade 1: 12 patients,
grade 2: 13 patients, grade 3a: 8 patients, grade 3b: 3 patients). The overall
complication rate was 26.5% and major complication rate defined by a Clavien
grade >or= 3 was 8.1% (n=11). There was no death or no life-threatening
complication in the perioperative course of our donors and no significant
difference was observed in the overall complication rate for the graft type.
Postoperative hospital stay was 13.2±0.3 (days) in patients without morbidity,
21.8±2.0 in those with Clavien grade =1 or 2 complications, and 33.9±5.3
in those with Cavien grade =3 complications. Eight to 11 (73%) of major
complications were biliary complications such as biliary leak or stricture.
Interestingly, we experienced no major biliary complication in RL graft
harvesting. Seven to 8 of major biliary complications occurred in LL (±CL)
graft harvesting. A significantly longer operation time and more intraoperative
blood loss was observed in LL (±CL) graft harvesting compared to LS or RL
graft harvesting.
Conclusion: Living liver donation is performed with a low risk of major
morbidity in our institution. Although the hepatic functional loss was less great,
LL (±CL) graft harvesting was technically more difficult and often suffered
biliary complications compared to RL graft harvesting. Consideration of both
merit and demerit of each graft type may be important in graft selection in
LDLT.
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1914 PROTECTION AND RECOVERY FROM AUTOIMMUNE
HEPATITIS BY ANTI-HISTONE H1 AUTOANTIBODY
C.Y. Lai1, T. Nakano1, S. Goto1,2, L.W. Hsu1, J.L. Wong1, S. Kawamoto3,
T. Goto4, K. Ono3, Y.F. Cheng1, C.L. Chen1
1
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology,
Graduate School of Advanced Sciences of Matter, Hiroshima University,
4
Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences,
Josai International University
Aims: We previously demonstrated the immunosuppressive activity of antihistone H1 autoreactive antibody (auto-Ab) induced in a rat spontaneous liver
transplantation (LTx) tolerance model (Transplantation 2004; 77: 1595) and
a clinical drug-free patient after living related LTx (Transplantation 2007;
83: 1122). This study aimed to explore the immunological aspects of antihistone H1 Ab in Concanavalin A (ConA)-induced liver injury, which is well
characterized as a model for T-cell mediated autoimmune hepatitis.
Methods: To establish ConA-hepatitis model in rats, 20 mg/kg of ConA
was intravenously injected and serum levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH)
were measured. To evaluate the anti-inflammatory activity of anti-histone H1
Ab, rabbit polyclonal Ab against histone H1 was intraperitoneally injected
immediately after ConA injection.
Results: We found the protection from ConA-induced liver injury (elevation
of serum AST, ALT and LDH) by anti-histone H1 Ab, and that ConA-induced
liver injury is spontaneously recovered at 3 to 7 days after ConA injection. In
the recovery stage from ConA-induced liver injury, anti-histone H1 auto-Ab
was transiently induced in the sera (peak at 3 days after ConA injection).
Conclusions: These results suggest that anti-histone H1 auto-Ab, which
possesses imunosuppressive activity in vitro and in vivo, may be natural immune
regulative factor to protect inflamed livers suffered from autoimmune hepatitis,
and that the induction of anti-histone H1 auto-Ab may be not associated with
any specific clinical manifestations.

POSTER BOARD NUMBER P3 – 341
1915 FUNCTIONAL IMPROVEMENT OF PRIMARY PIG ISLET
WITH EXOCRINE CAPSULATION

POSTER BOARD NUMBER P3 – 342
1916 POST-TRANSPLANT TGF- BETA AND S100A4
EXPRESSION IN RAT KIDNEY ALLOGRAFTS
PREDICTCHRONIC REJECTION CHANGES
S. Rintala1, J. Savikko1,2, J. Rinta1, N. Malmström1, P. Koskinen1,3
1
Transplantation Laboratory, 2Department of Surgery, Päijät-Häme Central
Hospital, Lahti, 3Department of Medicine, Division of Nephrology, Helsinki
University Hospital
Background: Chronic rejection remains the primary reason for late allograft
loss in kidney transplantation. Chronic changes are characterized by fibrosis
and vessel changes. Transforming growth factor beta (TGF-beta) contributes to
renal interstitial fibrosis by epithelial to mesenchymal transition (EMT). Here
we investigated the role of TGF-beta and S100A4 as a marker for EMT in posttransplant kidney allografts.
Methods: Kidney transplantations were performed from DA to WF rats
and syngenic control transplantations between DA rats. Allografts were
immunosupressed with CsA (1.5 mg/kg/d sc) and no immunosuppression
was given to syngenic grafts. Grafts were harvested 3,5,7 and 90 days after
transplantation for histology and immunohistochemistry (TGF-beta, TGFbetaR1 and S100A4) and in situ hybridisation (TGF-beta).
Results: In syngenic grafts, no signs of acute or chronic rejection were seen
whereas intense acute and chronic rejection were seen in CsA-treated allografts.
In syngenic grafts only mild TGF-beta expression was seen in all time points.
Also the number of S100A4-positive cells remained low in syngenic grafts. In
CsA-treated allografts, moderate to intense TGF-beta expression was seen 5,7
and 90 days after transplantation. The number of tubular S100A4-positive cells
was significantly increased at days 5 and 7 in CsA-treated allografts, but no
difference was seen in S100A4 staining between syngenic grafts and allografts
at 90 days after transplantation.
Conclusions: Based on our results, the TGF-beta and S100A4 expression are
increased already after 5 days in CsA-treated allografts, which later develop
chronic changes. The high number of S100A4 cells early after transplantation
is a sign of active EMT, and at 90 days this transition has already reached its
peak and slowed down. These results support that TGF-beta has an important
role in EMT leading to subsequent chronic changes. Therefore it seems that
early post-transplant TGF-beta inhibition could be a potential intervention in
preventing chronic rejection changes in clinical kidney transplantation.

POSTER BOARD NUMBER P3 – 343
1917 THE ROLE OF MACROPHAGE IN THE PATHOGENESIS
OF CHRONIC CYCLOSPORINE NEPHROPATHY
J.Y. Ghee1, H.K. Song1, D.H. Han1, W.Y. Kim2, Y.K. Kim1, S.H. Kim1,
Y-S. Kim1, J. Kim2, C.W. Yang1
1
Department of Internal Medicine, Kangnam St. Mary’s Hospital,
2
Department of Anatomy, The Catholic University
Infiltration of macrophage is observed in chronic cyclosporine (CsA)
nephropathy, but role of macrophage is still undetermined. This study was
performed to evaluate the direct role of macrophage in the pathogenesis
of CsA-induced renal injury. Chronic CsA nephropathy was induced by
administering CsA (15mg/kg per day) for 28 days, and macrophage was
depleted by administering liposome-encapsulated clodronate (CL, 20mg/kg
per seven day). For weeks treatment of CsA caused intersititial fibrosis and
inflammation, but CL treatment decreased both parameters. At molecular
level, upregulated proinflammatory (osteopontin) and profibrotic (©¬igh-3)
cytokines in CsA-treated rats were decreased with CL treatment. In addition
to anti-inflammatory and anti-fibrotic effect, CL treatment decreased immune
response, demonstrated by decreased toll-like receptor and MHC class II
in CsA-treated rat kidney which was upregulated on renal tubular cells and
infiltrating inflammatory cells. Macrophage depletion decreased oxidative
stress, and this may be responsible for decreased apoptotic cell death in CsAinduced renal injury. In conclusion, macrophages play a pivotal role in not only
non-immunologic but also immunologic injury in chronic CsA nephropathy.
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1
The Research Institute for Transplantation, 2Department of Surgery, 3BK21
Team of Nanobiomaterials for Cell-Based Implants, Yonsei University College
of Medicine, Seoul, Korea
Introduction: Improved success in human islet transplantation is often
limited by the shortage of donors. This favors utilization of pig donors for
islet xenotransplantation in near future. However, it is difficult to purify the
pig islets in the routine isolation procedure that are attributed to the intrinsic
fragility of islets during enzymatic digestion. Porcine-specific difficulties of
islet isolation often result in low purity or contamination of exocrine tissues. To
prevent these events, we invented new technique of capsulation with unneeded
exocrine itself as a beneficial material.
Method: Porcine islets were isolated from adult pig (PW Genetics) using
COBE2991. Highly purified islets (HI, > 95% purity), and low purity islets (LI,
around 50% purity) were selected and calculated by islet equivalents (IEQ). In
either purity islets, we performed ordinary static culture (ST) or shaking culture
(SK). After 24 hours of the incubation, functions of islets group were investigated
by glucose challenging test (100mg/dl, 400mg/dl, 100mg/dl, 1 hour each). Amounts
of insulin from islets were measured for 6 days culture period by ELISA.
Result: Islets function of SK culture was better than that of ST culture after
24 hr assessed by stimulation index. After 3 days culture, it was possible to
examine the ideal morphology of LI after SK culture, which showed smooth
surface of islets, and exocrine cells seemed to be reduced or eliminated from
LI, whereas morphology of HI after SK culture was not changed. Insulin
secretion from LI after SK culture was maintained higher than that of other
culture conditions (LI-ST, HI-SK, HI-ST) during 6 days.
Conclusion: SK culture of low purity pig islet with exocrine tissue may enhance
the function of islet by condensing into firmer islets, providing natural scaffold of
extracellular matrix that keep the shape of islet and the ability of insulin production

of islets. If the problems related to contamination of exocrine cells in pig islet
isolation, the capsulation with exocrine tissue it self using SK culture, could serve
as an essential prerequisite for successful human islet transplantation of lower
purity, and, moreover, pig islets transplantation for type 1 diabetic recipients.
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1918 IN VIVO SUPPRESSION OF THE CD8 T CELL RESPONSE
BY SELECTIVE DEPLETION OF CROSS-PRESENTING
DENDRITIC CELLS
R.M. Sutherland, Y. Zhan, M.L. Lin, E. Carrington, J.A. Villadangos,
A.M. Lew
Walter And Eliza Hall Institute of Medical Research
Cross-presentation, i.e. presentation of exogenous antigen by MHC class
I molecules, is an important process for generating CD8 T cell responses.
However, the inability to selectively manipulate cross-presentation in vivo
has limited our understanding of its contribution to allograft and xenograft
rejection. We have exploited the specific cytosolic export feature of crosspresenting dendritic cells together with the property of cytosolic cytochrome c
in initiating Apaf-1-dependent apoptosis to selectively deplete cross-presenting
dendritic cells. Intravenous injection of cytochrome c in mice produced
a selective 2 to 3-fold reduction in splenic CD8+ dendritic cells, the major
cross-presenting population. Using Annexin V staining and Apaf-1-deficient
mice we showed that this depletion occurred by Apaf-1 dependent apoptosis.
Cytochrome c-resistant dendritic cells retained the capacity to present
exogenous antigen to CD4 T cells, and endogenous antigen directly to CD8
T cells, but were inefficient at cross-presentation to CD8 T cells and had a
reduced capacity to produce IL12 upon TLR engagement. In vivo CD8 T cell
proliferative and cytotoxic responses to exogenous antigen were profoundly
inhibited in cytochrome c-treated mice. Thus, cytochrome c treatment provides
the opportunity to specifically target cross-presenting dendritic cells in vivo
and manipulate the CD8 T cell response to transplants.
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1919 INDUCTION OF NRP1+T CELLS IN VITRO
M. Cai , H-M. Zhou , C. Liu , X-K. Per , W. Huang , J-M. Huang , L-J. Xu ,
B-Y. Shi1, Z-K. Chen2
1
Organ Transplantation Center, 2nd Affiliatted Hospital of Great Wall
Hospital of P.L.A. Beijing, 100091, P.R.China., 2Institute of Organ
Transplantation, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology. Key Lab of Organ Transplantation of
Ministry of Education and Ministry of Health. Hubei, 430030, P.R.China
Background: Many kinds of ceslls expresse Neuropin-1(NRP1), It was
reported to play an important role during Neuron development, and recent
researches shows NRP1 takes part in the immune synaps formation, and NRP1
+T Cells functiones as immun-regulatory cells, but the quauntity is limited.
Some scientsts induced CD4+CD25+T cells with Estrogen, whether it can be
used to induce NRP1+T cells has not been testified. This study aimed to induce
NRP1+T cells in vitro with Estrogen, and find out the whether NRP1 and it’s
ligands, such as VEGF, get involved in the procedure.
Methods: Spleen cells from C57BL/6 mice were stained with CFSE and
2¡Á105 cells were seeded into 96 cell-plate at a reactor/target ration 1/1,
cultured with mitomycin pre-treated Balb/C mice spleen cells (Bm); with the
addition of CD3 and CD28 monoclonal antibody, 2¡Á10-7 M Estrogen was
applied as inducor. Effects of VEGF-antibody, NRP1-antibody on induction of
NRP1+T cells were checked. 5 days after the cells seeded, the percentage of
CD4+CD25+NRP+T cells and the proliferation of blast cells were detected by
FACS and analyzed by Diva and ModFit LT software.
Results: The percentage of CD4+CD25+NRP+T in blast cells increased
when Estrogen was applied (from 11.06311¡À1.006% increase to
42.7¡À0.5787%£¨P=0.012£©) but decreased when VEGF-antibody or Nrp1
antibody added. (7.1859¡À0.27356, 27.73147¡À0.64089, respectly. Compared
to Estrogen group, P<0.05). The Proliferation Index(PI) decreased when VEGF/
NRP1 antibody added (from 90.503¡À0.5 to 68.0¡À2.0 or 72.923¡À2.6053,
compared to EstrogensP<0.05). (table 1).
Conclusion: From our preliminary data, we found that Estrogen would induce
Nrp1+T cells from C57BL/6 mice, when added with VEGF/NRP1 antibody,
the proliferation would be inhibited. Which implied that NRP1 involved in the
induction and proliferation of NRP1+T cells, but not only a regulatory T cells’
surface marker. And the ligand VEGF got involved in these procesure.
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1920 IMMUNOMODULATORY EFFECT OF SECONDARY
METABOLITES OF A NEWLY ISOLATED TOLYPOCLADIUM
INFLATUM WILD STRAIN
M. Ramachandran
The American College, Madurai Kamaraj University, Madurai, India
Cyclosporine (Cys) is a potent immunosuppressive drug approved for use
in organ transplantations to prevent graft rejection in kidney,liver and lung
transplants. Cys is known to be produced by the soil fungi Tolypocladium
inflatum(Ti). The present study highlights the immunomodulatory effect of the
secondary metabolites of a newly isolated wild strain of Ti collected from the
soil samples of Western Ghats of India (Lat.10°12’N, Long.77°30’E). HPLC
analysis of the secondary metabolite from wild Ti isolates confirmed the
presence of high levels of cyclosporine when compared to Ti culture of MTCC989 (Microbial Culture Collection Centre ,Chandigarh, India). The T cell, B
cell & macrophage functional assays were performed to study the specific and
nonspecific immunity in New Zealand white rabbits. The secondary metabolite
(0.5mg/kg/day) was given orally for 21 days prior to the administration of SRBC
antigen (25% PCV, 0.5ml) intraperitoneally. Experimental studies on specific
and nonspecific immunity showed a significantly higher immunosuppressive
effects when compared to Ti culture of MTCC - 989 secondary metabolites.

POSTER BOARD NUMBER P3 – 347
1921 EPIDERMAL GROWTH FACTOR INHIBITION BY
ERLOTINIB PREVENTS NEOINTIMA FORMATION IN
EXPERIMENTAL ACCLERATED ATHERIOSCLEROSIS
J. Savikko1,2, J. Rintala1, S. Rintala1, N. Malmström1, P. Koskinen1,3
1
Transplantation Laboratory, University of Helsinki, and Helsinki University
Central Hospital, 2Department of Surgery, Päijät-Häme Central Hospital,
3
Department of Medicine, Division of Nephrology, Helsinki, University
Central Hospital
Background: In clinical transplantation chronic rejection is a major reason for
late allograft loss. Accelerated atherosclerosis is one pathological manifestation
of chronic allograft rejection. The typical feature in atherosclerosis is
uncontrolled proliferation and migration of vascular smooth muscle cells
and their deposition in the vascular intima. Neointimal formation leading to
occlusion of arteries is believed to be a pathological response to injury. Several
peptide growth factors, for example PDGF and IGF-1, have been identified
to be operational in the formation of atherosclerotic dysplasias in vessels of
transplanted organs by inducing migration and proliferation of smooth muscle
cells. Inhibition of these growth factors has been experimentally shown
to be potential intervention site after denudation injury and in transplant
atherosclerosis. Epidermal growth factor (EGF) is also a mitogenic growth
factor but its’ role in transplant atherosclerosis is unknown. Here we investigated
the effect of erlotinib, a selective EGF receptor tyrosine kinase inhibitor, on
neointima proliferation after arterial endothelial injury in vivo.
Materials and methods: The aorta of male Wistar rats weighing 350 to 370g
was denuded of endothelium by the intraluminal passage of a French Fogarty
arterial embolectomy catheter introduced through the left iliaca artery. Rats
were treated per orally either with erlotinib (1 or 5 mg/kg/d) or with vehicle
only (polyethylene glycol). Histological changes and analysis of neointimal
area were evaluated from midaortic sections 14 days after injury.
Results: In the vehicle-treated group, moderate neointima formation was
detected 14 days after denudation. Erlotinib prevented the neointima formation
after denudation in a dose-dependent way. The lower 1mg/kg/d dose slightly
reduced neointima formation compared to controls. With the higher 5mg/kg/d
dose a significant reduction in neointima formation between erlotinib-treated
animals and controls was seen. In these animals only mild neointima formation
was detected in the denuded aortas. Erlotinib was well tolerated and no adverse
effects were seen in animals treated with erlotinib.
Conclusions: Our results demonstrate that EGF plays a role in the neointima
formation and erlotinib is a potent inhibitor of accelerated arteriosclerosis after
arterial endothelial injury. Based on these findings erlotinib could be a potential
intervention in preventing vascular changes in chronic allograft dysfunction.
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1922 DONOR PRE-TREATMENT WITH TACROLIMUS
EDUCES TRANSPLANT VASCULOPATHY
R.W.F. de Bruin1, D. Susa1, S. van den Engel1, L.A. van Damme2, H.P. Roest1,
R. Krams2, J.N.M.I. Jzermans1
1
Department of Surgery, Laboratory for Experimental Surgery ,and
2
Biomedical Engineering, Thoraxcenter, Erasmus MC, Rotterdam, The
Netherlands
Donor pre-treatment with immunosuppressive agents has been shown to preserve
kidney function after experimental transplantation, but it is not known whether
pre-treatment of the donor is able to protect organ grafts against long-term
structural deterioration, such as transplant vasculopathy. We tested in an allogeneic
rat aorta transplantation model whether transplant vasculopathy can be reduced
by pre-treatment of the donor with commonly used immunosuppressive agents.
Male Brown-Norway donor rats received no pre-treatment, tacrolimus,
methylprednisolone, rapamycin, or mycofenolate mofetil (MMF) 16 and
2 hours before transplantation into WAG rats (n=5 / group). Eight weeks
after transplantation, aorta allografts were harvested. Percent intima area
/ intima + media area (I/I+M), inflammatory cells and in-situ MMP-2 and
–9 activity were determined. In pre-transplantation graft biopsies, MMP-2
and 9 ratio, and mRNA levels for genes of interest were determined.
Aorta allografts pre-treated with tacrolimus, showed significantly lower I/
I+M ratio compared to untreated controls (p<0.01). Pre-treatment with
methylprednisolone, rapamycin or MMF did not significantly reduce I/
I+M ratio. In-situ MMP-2/ MMP-9 activity was significantly reduced
in grafts treated with tacrolimus and rapamycin compared to controls
(p<0.05). Immunohistochemistry revealed a high number of CD4+
cells and high CD4/CD8 ratio in grafts pre-treated with tacrolimus.
To test if the protective effect of tacrolimus was mediated by induction of
cytoprotective genes and inhibition of apoptosis, we measured mRNA levels of
Bcl-2, Bax, HIF-1α, HO-1, TGF-β, and p21 in pre-transplantation biopsies. No
differences were found between controls and tacrolimus pre-treated grafts. In
addition, we found no differences in MMP-2/9 ratio in pre-transplantation biopsies.
In conclusion, donor pre-treatment with tacrolimus significantly reduces
transplant vasculopathy. Transcriptional changes in anti-apoptotic or
cytoprotective genes were not seen in pre-transplantation biopsies, but
the observed reduction in vasculopathy was associated with reduced insitu MMP-activity and increased numbers of CD4+ cells eight weeks after
transplantation.

POSTER BOARD NUMBER P3 – 349
1923 PRODUCTION OF A SOLUBLE AND ACTIVE
HUMANIZED SINGLE-CHAIN VARIABLE FRAGMENT
ANTIBODY RECOGNIZING CD25

POSTER BOARD NUMBER P3 – 350
1924 THE EFFECTS OF DIFFERENT IMMUNOSUPPRESANTS
ON C4D DEPOSITION IN RATS UNDERGOING CHRONIC
ALLOGRAFT NEPHROPATHY
Y.P. Lu, L. Yang, G.H. Luo, J. Song, Y.J. Shi, Y.P. Li
Transplantation Institute, West China Hospital
Aims: Deposition of C4d in peritubular capillaries (PTC) has been considered
to be a marker of humoral immunity in renal transplant. This study is to
investigate C4d deposition in rat renal allografts undergoing CAN and the
effects of immunosuppressants on it.
Methods: Fisher344 rat renal grafts were transplanted into Lewis rats
following the procedure of Kamada with our modification. All the recipients
were given CsA 10mg/kg-1.d-1¡Á10d and then divided into 5 groups (each
n=9):(1)Vehicle: vehicle orally,(2)CsA: 6mg/kg-1.d-1,(3)RAPA: 0.8mg/kg1.d-1,(4)FK506: 0.15mg/kg-1.d-1,(5)MMF: 20mg/ kg-1.d-1. At 4w, 8w, 12w,
the rats were sacrificed, renal allografts were harvested and sera were collected.
The deposition of C4d was detected by immunofluorescence and analyzed by
Integrated Optical Density (IOD). The pathological changes were accessed
according to the Banff 97 criteria.
Results: C4d deposition in PTC was found in all the allografts at 4w, while
there was no obvious CAN in all the groups; the differences of Banff Score
between all groups were not significant (p>.05). The values of IOD in group of
RAPA and MMF were lower than those in other 3 groups (p=.002, .006). The
differences between RAPA and MMF, and between other 3 groups were not
significant (p>.05). The intensity of C4d increased along with the progression
of CAN, the heaviest C4d deposits in PTC were found at 12w, and meanwhile
the severest CAN was found. Comparing with Vehicle group, CsA and FK506
had no effect on C4d deposition (p>.05), however, MMF and RAPA obviously
decreased the C4d deposition (p=.000). The intensity of C4d deposition had a
significant correlation with the severity of CAN (r=.894, p=.000).
Conclusions: Our study suggests that the deposition of C4d in allografts
appears earlier than pathological changes of CAN and has a correlation with
the progression of CAN. MMF and RAPA can attenuate CAN by inhibiting
humoral immunity. In contrast, CsA and FK506 have no effect on humoral
immunity.

POSTER BOARD NUMBER P3 – 351
1925 FK506 VERSUS RAPAMYCIN HAVE DIFFERENT
EFFECTS ON EXPRESSION OF ANGIOPOIETINS1, 2 AND TIE2
IN RAT RENAL ALLOGRAFT WITH CAN
Y.P. Lu, X. Ma, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University
Objective: Previous studies have shown that angiopoietins-1, angiopoietins-2
and Tie2 regulate the maintenance and integrity of blood vessels and have
potential of anti-inflammatory properties in cardiac allografts. This study is
to investigate whether there is difference between Rapamycin (RAPA) and
FK506 in the ability of affecting expressions of Ang1, Ang2 and Tie2 in the rat
renal allografts with chronic allograft nephropathy (CAN).
Methods: Male inbred F344 to Lewis rat renal CAN model was established
via modified Kamada’s procedure. The recipients were first treated with
CsA 10mg/kg • d*10d and then allocated randomly into three oral treatment
groups: (1)Control group: vehicle orally, (2) FK506 group: 0.15 mg/kg • d,
(3)RAPA group: 0.8mg/ kg • d. At 4w, 8w, 12w post transplant, the rats were
sacrificed and the renal allografts were harvested. The serum creatinine (SCr)
was measured and the pathologic changes were accessed according to Banff 97
criteria. The expression of mRNA(Äct) and protein of Ang1, Ang2 and Tie2
was determined and localized by real-time fluorescence quantitative PCR and
by immunohistochemistry.
Results: The elevation of SCr and the pathologic changes of CAN were
observed in Control and FK506 group at 8w and 12w, the differences
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L. Wan, H. Cai, Y. Lu, H. Yang, S. Li, J. Zhang, Y. Li, Y. Li, J. Cheng, X. Lu
Key Laboratory of Transplant Engineering And Immunology, Ministry of
Health, West China Hospital, Sichuan University
Background: CD25, an activation marker of lymphocytes, is a potential target
in selective depletion for alloreactive cells in transplantation. Daclizumab is a
generally used humanized anti-CD25 antibody. We attempted here to produce
a single-chain variable fragment antibody (scFv) derived from daclizumab to
develop scFv-based therapeutics.
Methods: The C-terminal 6His-tagged scFv gene was synthesized based on
the variable regions of the heavy and light chains of daclizumab and cloned
into a yeast vector for expression in P. pastoris. The recombinant scFv with
6His-tag was purified by one step Ni-agarose affinity chromatography and
then labeled with fluorescein isothiocyanate (FITC). The binding ability of the
scFv was tested using human CD25-positive cells SNT-8 and ConA-activated
hPBMCs. And CD25-negative cells Raji and resting hPBMCs were used as
negative control.
Results: The soluble scFv was obtained from supernatants of P. pastoris
culture. A strong membrane staining was observed in CD25-positive cells
treated with the FITC-labeled scFv under fluorescence microscope, whereas
no obvious staining was visualized on CD25-negative cells. Flow cytometry
(FCM) analysis showed that more than 95% of SNT-8 cells incubated with the
FITC-labeled scFv were positive, as compared to less than 5% of Raji cells.
Activation of hPBMCs increased the positive rate from 1.1% to 26.5%.

Conclusions: The recombinant scFv derived from daclizumab expressed
using P. pastoris was secreted in a soluble form, which was easily purified,
and found to retain good reactivity and specificity for target antigen CD25,
suggesting its potential use for the development of immunosuppressants for
allotransplantation.
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between the 2 groups were not significant (p>0.05). The levels of SCr and
Banff score in RAPA group were lower than those in other 2 groups (p<0.05).
The expressions of Ang1 and Ang2 were localized in epithelial cells and
endothelium of vascular bundles of glomeruli, and Tie2 was specifically
expressed in endothelium of vessels in all the 3 groups. At 4w, the differences
of mRNA expression of Ang1, Ang2 and Tie2 between 3 groups were not
significant (p>0.05). Comparing with the Control and FK506 groups, the
mRNA expression of Ang1 was increased (p<0.05), and the mRNA expression
of Ang2 and Tie2 were decreased (p<0.05) in RAPA group at 8w and 12w. The
differences between groups of Control and FK506 were not significant at 8w
and 12w (p>0.05).
Conclusions: The results indicate that compared with FK506, RAPA can
regulate beneficially the expressions of angiopoietins/Tie2 in rat renal allograft
with CAN. It suggests that Rapamycin may improve the long-term survival of
renal allografts through its vasculoprotective property.
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1926 TACROLIMUS(FK506) INDUCED APOPTOTIC
SIGNALLING WITH ENDOPLASMIC RETICULUM STRESS
PATHWAY PROTEINS
S.J.N. Choi, H.S. You, H.K. Lee, S.Y. Chung
Department of Surgery, Chonnam National University Medical School,
Gwangju, Korea
Tacrolimus(FK506) is an effective immunosuppressive drug used for the
prevention of graft rejection in organ transplantation. We investigated
the effects of FK506 on apoptosis, cell viability, measurement of H2O2
generation, intracellular accumulations of Ca2+ and NO, and western blottings
of endoplasmic reticulum(ER) stress pathway proteins, such as phosphoPERK, PERK, CHOP, Grp78, Grp94, Bcl-2, and Bak proteins. Cells were
cultured with the presence or absence of FK506. Flow cytometric analysis
was performed after PI stain. Viability of Jurkat cells were decreased by the
addition of FK506 in a dose-dependent manner. FK506 induced cytotoxicity
was characterized by sub G0/G1 phase arrest. FK506 induced cell death was
confirmed as apoptosis characterized by nuclear fragmentation and caspase-3
protease activation. Intracellular accumulations of Ca2+ and NO production
were identified in FK506 treated Jurkat cells after 24 hours. Expression of
iNOS protein was also noted. Generation of H2O2 was identified. Deceased
activation of procaspase-12 protease confirmed activation of caspase-12
after 48 hours. Activation of phospho-PERK protein peaked at 36 hours
after FK506 treatment. Expressions of CHOP/GADD153, Grp78 and Grp94/
BiP proteins were also identified after 36 hours. Expression of Bak protein
was also noted. In conclusion, activation of caspase-12 and changes of other
ER located proteins ascertained that ER stress mediated apoptosis. Also,
FK506 increased NO production by iNOS expression. FK506 induced H2O2
generation revealed that cytotoxicity was achieved by generation of H2O2
which might modulate the expression of Bak protein. These data indicate
that the effect of FK506 on ER stress mediated apoptosis of Jurkat cells via
generation of H2O2. Understanding of ER stress pathway would be a new
approach to develop immunosuppressive drugs useful in organ transplantation
cares.

POSTER BOARD NUMBER P3 – 353
1927 EFFECT OF MYCOPHENOLIC ACID MEDIATED
APOPTOSIS IN HUMAN JURKAT CELLS VIA REGULATION
OF HEME OXYGENASE-1 EXPRESSION
S.Y. Chung, H.K. Lee, H.S. You, S.J.N. Choi
Department of Surgery, Chonnam National University Medical School,
Gwangju, Korea
Mycophenolic acid (MPA) is the active agent of mycophenolate mofetil(MMF).
MPA is a selective inhibitor of inosine monophosphate dehydrogenase. Heme
oxygenase-1(HO-1), the rate-limiting enzyme of heme catabolism, is known
to modulate various cellular functions, including cytokine production, cell
proliferation, and apoptosis in stress-related conditions. However, the role
of HO-1 in the immunosuppressive response system remains elusive. This
study demonstrate that pharmacologic induction of HO-1 along with catalytic
activation significantly modulated apoptosis of Jurkat cells induced by MPA.
MPA induced apoptotic cell death showing nuclear fragmentation and sub
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G0/G1 phase arrest in Jurkat cells. Caspase-3 proteases expression on MPA
treated-Jurkat cells in a time-dependent manner. Treatment of MPA resulted
in reactive oxygen species (ROS) generation in Jurkat cells. Decreased HO-1
expression on MPA treated-Jurkat cells after 36 hours. Change of mitochondrial
membrane potential transition (MPT) was also noted. Expression of Bax
proteins was identified. CoPPIX, HO-1 inducer, induced expression of HO-1
proteins in MPA treated Jurkat cells. CoPPIX inhibited generation of H2O2.
CoPPIX, significantly inhibited the MPA induced apoptosis. In conclusion,
HO-1 inducer suppressed ROS generation, Bax protein expression and
mitochondrial permeability transition in MPA-treated cells. This result
suggests that the protective mechanism of HO-1 on MPA-induced cytotoxicity
is associated with direct inhibition of ROS generation and mitochondrial
permeability transition.

POSTER BOARD NUMBER P3 – 354
1928 MMF AND CSA HAVE DIFFERENT EFFECTS ON
EXPRESSION OF CTGF IN RATS KIDNEY WITH
CHRONIC ALLOGRAFT NEPHROPATHY
Y.P. Lu, G.H. Luo, L. Yang, J. Song, L. Luo, X. Ma, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University,
Chengdu, China
Aim: CTGF is an important mediator of fibrosis and is capable of inducing
epithelial-mesenchymal transformation (EMT). Cyclosporine A (CsA)
is associated with renal fibrosis in long term using. It has been proved that
Mycophenolate Mofetil (MMF) could inhibit or attenuate fibrosis process. This
study is designed to determine whether the difference exists between MMF and
CsA on the expression of CTGF and the fibrosis-associated genes in rat kidney
underwent chronic allograft nephropathy (CAN).
Methods: F344 rat renal grafts were orthotopically transplanted into
Lewis rats following the procedure of Kamada with our modification. All
the recipient rats were given CsA 10mg/kg-1.d-1x10d and then divided into
three oral treatment groups (each group n=9): (1) Vehicle: given vehicle
orally, (2) CsA: 6mg/kg-1.d-1, (3) MMF: 20mg/kg-1.d-1. At 4w, 8w, 12w,
SCr and pathological changes were measured; The expression of CTGF,
collagen I, IV, α-SMA and E-cadherin in grafts were assessed. The urine
CTGF concentration was detected by a competitive indirect enzyme- linked
immunosorbent assay.
Results: SCr and Banff score were increased in a time-dependent manner in
all the 3 groups. The differences of SCr and Banff score among 3 groups
were not significant at 4w (p>0.05). At 8w and 12w, Scr(umol/L) in Vehicle,
CsA and MMF group were 275±23.51, 516±32.00; 281±10.59, 516±31.6
and 138±28.48, 305±32.92, respectively. The differences between MMF
and other two groups were statistically significant (p<0.05). The histological
lesions of CAN in Vehicle and CsA groups were more serious than those in
MMF group. At 8w and 12w, the Banff score between MMF and other two
groups were statistically significant (p<0.01). Urine CTGF increased at 4w
and kept in high level till 12w. At 4w, 8w and 12w, The expression of CTGF
mRNA / protein(DQ ratio) in renal graft in Vehicle, CsA and MMF group were
23.00±0.50/0.54±0.02, 25.16±0.76/0.81±0.01, 26.50±0.50/0.86±0.05; 22.66±0.57/0.57±0.01,
26.50±0.86/0.90±0.02
and
21.33±0.57/0.38±0.02,
24.66±0.76/0.78±0.02,
23.50±0.50/0.62±0.01, 24.50±0.50/0.72±0.02, respectively. The difference between
MMF and other two groups were statistically significant (4w, p<0.05; 8w/12w,
p<0.01). The expression of collagen I, IV and α-SMA in MMF group at all
the time points were significantly down regulated, and E-cadherin’ lose was
abated in MMF group.
Conclusion: We demonstrate that the expression of CTGF in epithelial cells
could act as a molecular marker of interstitial fibrosis in CAN. MMF can
ameliorate fibrogenesis in transplant kidney by inhibiting the expression of
CTGF, down-regulating the expression of the fibrosis-associated genes and
inhibiting the EMT. Cyclosporine A has no these effects.
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1929 INHIBITION OF MINERALOCORTICOID RECEPTORS
WITH EPLERENONE ALLEVIATES SHORT-TERM
CYCLOSPORINE A NEPHROTOXICITY IN THE RAT
F.T. Nielsen1, B.L. Jensen1, N. Marcussen2, O. Skøtt1, P. Bie1
1
University of Southern Denmark, 2Odense University Hospital
Background: Recent data indicate that aldosterone aggravates cyclosporin A
(CsA)-induced nephrotoxicity. We examined whether the mineralocorticoid
receptor (MR) blocker eplerenone (EPL) antagonized early deterioration of
renal function and blood pressure increase in CsA-treated rats.
Methods: Male Sprague-Dawley rats received CsA (15 mg/kg/day i.p.) and/or
EPL (100 mg/kg/day p.o.) for 21 days. After two weeks, arterial, venous, and
urinary bladder catheters were implanted and the rats were trained to accept a
restraining device allowing arterial blood sampling and direct measurement
of blood pressure (BP) and renal function. BP was measured on-line in
conscious rats.
Results: CsA significantly increased systolic BP: 139 ± 4 vs. 134 ± 2
mmHg, reduced body weight gain: -5±6 vs. 36±7 g, GFR: 1.02±0.16 vs.
2.64±0.27 ml/min, RBF: 5.3±2.4 vs. 13.5±2.1 ml/min, and lithium clearance
(CLi+): 0.16±0.04 vs. 0.26±0.07 ml/min compared to controls. These
changes were prevented by simultaneous EPL treatment: Systolic BP: 130±4
mmHg, weight gain: 53±7 g, GFR: 1.67±0.26 ml/min, RBF: 12.3±2.1 ml/
min and CLi+: 0.27±0.03 ml/min. Analysis of kidney morphology after CsA
treatment showed hyaline vacuolization in tubules and vascular depositions
in arterioles; these changes were less pronounced after combination therapy.
No significant changes were seen regarding haemoglobin, haematocrit,
plasma renin, and vasopressin, plasma and urinary sodium, potassium, or
osmolality.
Conclusions: MR blockade by EPL prevented short-term alterations in GFR,
RBF and hypertension associated with CsA nephrotoxicity. We conclude that
the aldosterone-MR pathway contributes markedly to the renal toxicity induced
by this calcineurin inhibitor.

POSTER BOARD NUMBER P3 – 356
1930 A NOVEL NF-KB INHIBITOR,
DEHYDROXYMETHYLEPOXYQUINOMICIN, SUPPRESSES
THE IMMUNOSTIMULATORY FUNCTION OF HUMAN
DENDRITIC CELLS

POSTER BOARD NUMBER P3 – 357
1931 RAPAMYCIN DECREASES CHOLESTEROL EFFLUX
AND ABCA1 PROTEIN EXPRESSION WITHIN THP-1
MACROPHAGES
R. Tory1, K. Sachs-Barrable2, J.S. Hill1, K.M. Wasan2
1
Department of Pathology and Laboratory Medicine, Fac. of Medicine,
University of British Columbia, 2Faculty of Pharmaceutical Sciences,
University of British Columbia
Background: Rapamycin (RAPA) has been widely used in solid organ
transplantations. Unfortunately, RAPA has been known to contribute directly or
indirectly to cardiovascular disease, one of the major long-term complications
of solid organ transplantation. Side effects such as hypercholesterolemia
and hypertriglyceridemia are associated with RAPA, representing major risk
factors for cardiovascular disease. The mechanism, by which RAPA causes
dyslipidemia is not well understood. In this study, we investigated the effects
of RAPA on cholesterol efflux and the expression of ATP-binding cassette A1
(ABCA1) in THP-1 macrophages. Macrophages have been implicated in the
etiology of cardiovascular disease, especially atherosclerosis; they accumulate
lipids and change into foam cells that later become the atherosclerotic plaque.
In addition, ABCA1 is involved in ApoA-1 mediated cholesterol efflux from
these cells.
Hypothesis: RAPA treatment of THP-1 macrophages will be associated with a
decrease in cholesterol efflux and ABCA1 protein expression.
Methods: THP-1 cells were differentiated with 1x10-7M with phorbol12-myristate-13-acetate (PMA) for 3 days. Cells were then exposed to
appropriate drug treatments (1, 5, 10 and 20 ng/mL of RAPA) for 24 hours.
The effect of RAPA on the ABCA1 protein expression of THP-1 macrophages
was examined by Western blotting. The effect of RAPA on cholesterol efflux
was investigated by loading cells with [3H] cholesterol and appropriate drug
treatments for 24 hours. Cholesterol efflux was performed in the presence
and absence of ApoA1 or HDL. To calculate percent efflux, [3H] cholesterol
was counted in the medium and divided by the sum of the cellular and media
counts x 100.
Results and conclusions: We observed statistically significant reductions in
cholesterol efflux and protein expression of ABCA1 following treatment with
increasing concentrations of RAPA. Our data showed that RAPA induced
reduction in the percent cholesterol efflux to ApoA1 and HDL respectively
compared to untreated control cells: 1 ng/mL (17±1%) and (24±2%), 5 ng/mL
(20±2%) and (14±1%), 10 ng/mL (27±2%) and (19±2%), 20 ng/mL (42±2%)
and (34±7%), respectively. Finally, consistent with the inhibition of cholesterol
efflux to ApoA1, RAPA was associated with a marked decrease in ABCA1
protein expression compared to untreated cells: 1 ng/mL (13±9%), 5 ng/mL
(32±12%), 10 ng/mL (81±7%), 20 ng/mL (87±1%). These findings suggest that
a RAPA-mediated decrease in cholesterol efflux and ABCA1 protein expression
may contribute in part to an increased cardiovascular risk in transplant patients
administered RAPA.
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K. Shinoda1, K. Nakagawa1, H. Kono1, M. Oya1, K. Umezawa2
Department of Urology, Keio University, School of Medicine, 2Department of
Applied Chemistry, Faculty of Science and Technology, Keio University
Background: Dendritic cells (DC) are the most potent professional antigenpresenting cells, and mature DCs play a pivotal role in the initiation of immune
responses including the direct and indirect pathways. In the maturation of DCs,
nuclear factor (NF)-kB is one of the most critical regulators. We synthesized
a novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), and
examined its effect on DC maturation.
Method: DCs were obtained from human peripheral blood monocytes by
culturing with granulocyte macrophage-colony stimulating factor (GM-CSF)
and interleukin-4 (IL-4), and were then used as immature DCs (im-DCs),
lipopolysaccharide (LPS)-stimulated mature DCs (m-DCs), LPS-stimulated
after treatment with DHMEQ DCs (dl-DCs), and LPS-stimulated before
treatment with DHMEQ DCs (ld-DCs). First, we evaluated cytotoxity of
DHMEQ on DCs and determined the concentration of DHMEQ (5 ƒÊg/ml) that
was the maximum concentration that did not raise cytotoxity. We investigated
four forms of DCs to determine the surface molecule expressions (by flow
cytometry), cytokine production (by ELISA using culture supernatants),
endocytosis (by FITC-dextran uptake evaluated by flow cytometry), and
allogenic T cell stimulation (by mixed leukocyte reaction using 5-bromo2¦ f deoxy-uridine labeling and detection kit). To investigate effective time
of DHMEQ, we quantified NF-kB translocation into the nuclear of dl-DCs
from 0 to 24 hours after LPS stimulation and analyzed expression levels of an
IL-12 p40 gene by real-time PCR (by TaqMan cytokine gene expression plates,
Applied Biosystems).
Results: DHMEQ significantly inhibited both the upregulation of DC
surface activation markers (CD40, 80, 86, HLA-DR) and the production of

1

cytokines, which were IL-6 (30686 pg/ml and 12682 pg/ml for 0 and 5 ƒÊg/
ml), TNF-a (9845 pg/ml and 4967 pg/ml for 0 and 5 ƒÊg/ml), and IL-12 p40
(7695 pg/ml and 225 pg/ml for 0 and 5 ƒÊg/ml) in a dose-dependent manner
(at 1.0-10 ƒÊg/ml). More interestingly, not only dl-DCs but also ld-DCs
demonstrated an inhibition in cytokine production after the administration of
DHMEQ. Im-DCs exhibited a higher endocytotic capacity than did m-DCs
(56.2% and 21.6% respectively, p<0.05). DHMEQ inhibited the downregulation of endocytosis induced by LPS (48.6% and 21.6% for dl-DCs
and m-DCs, p<0.05). Furthermore, the proliferation response of allogenic
T cells was effectively suppressed by dl-DCs and ld-DCs in comparison to
that by m-DCs (at DC: T cell ratio being 1:10, 38.8%, 27% and 100% for
dl-DCs, ld-DCs, and m-DCs respectively, p<0.05). Finally, we confirmed
that DHMEQ completely inhibited the NF-kB translocation to the nuclear
of DCs and the expression of mRNA of IL-12 p40 of DHMEQ-treated DCs
for 24 hours.
Conclusion: DHMEQ markedly inhibits the phenotypic and functional
maturation of DCs by inhibiting the nuclear translocation of NF-kB in the
course of LPS-stimulation of DCs. DHMEQ-treated DCs demonstrated the
reduced production of cytokines and have less impacts on T cell stimulation
than m-DCs.
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1932 THE EFFECTS OF INOSINE MONOPHOSPHATE
DEHYDROGENASE INHIBITION ON OLEIC ACID-INDUCED
FIBRONECTIN SECRETION AND CELLULAR ROS IN
MESANGIAL CELLS
K.H. Huh1, H.J. Ahn2, M.S. Kim1, Y.S. Kim1
1
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea,
and 2Department of Surgery, Korea University College of Medicine, Seoul,
Korea
Background: Mycophenolic acid (MPA), an inosine monophosphate
dehydrogenase (IMPDH) inhibitor, suppresses mesangial proliferation.
However, the mechanism has not been clearly elucidated. We investigated
the effects of MPA and IMPDH2 reduction (by using siRNA) on oleic acid
(OA)-induced fibronectin secretion and cellular reactive oxygen species (ROS)
production in mouse mesangial cells (MMCs).
Methods: Cells were treated with 100 μM OA, with or without MPA (0.1-10
μM), IMPDH2 siRNA (10-50 nM), or 5 mM N-acetylcystein (NAC).
Fibronectin was measured by Western blot, transforming growth factor
(TGF)-β was measured by ELISA, and levels of DCF-sensitive cellular ROS
were measured using flow cytometry.
Results: OA increased fibronectin secretion and ROS. A TGF-β neutralizing
antibody (25 μg/ml) effectively suppressed OA-induced fibronectin secretion.
MPA (10 μM) and NAC totally suppressed OA-induced fibronectin secretion,
TGF-β synthesis, and ROS production. IMPDH2 siRNA partially inhibited
OA-induced mesangial activation.
Conclusions: TGF-β mediated OA-induced fibronectin synthesis, and MPA
might have inhibited OA-induced cell activation partly through inhibiting
IMPDH2, but other mechanisms also contributed to the MPA-mediated
mesangial inhibition in MMCs.
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1933 IS INHALED TACROLIMUS A SAFE TREATMENT
OPTION TO PREVENT ACUTE AND CHRONIC REJECTION IN
AN AIRWAY TRANSPLANT MODEL?
T. Deuse1, D. Weill1, J. Fink2, F. Blankenberg1, C. Peter1, R. Robbins1,
S. Schrepfer1
1
Stanford University School of Medicine, 2Nektar Therapeutics, Mountain
View, CA, USA
Background: Tacrolimus blocks T cell activation by interfering with the
Ca2+-dependent phosphatase, calcineurin. The airway offers a selective route
for drug delivery in tracheal/lung transplantation achieving high tissue levels
without systemic side-effects. Although local immunosuppression may be
advantageous to control acute and chronic rejection after airway transplantation,
higher graft concentrations by local tacrolimus delivery could damage the local,
graft protective airway epithelium. Therefore, we examined its direct effects on
airway cells in vivo and in vitro.
Methods: To investigate the efficacy of inhaled tacrolimus to prevent
airway graft rejection, in vivo studies using 160 orthotopic BN-Lew tracheal
transplantations were performed and tacrolimus (4mg/kg) was administered
via aerosol (TA) using different nebulizers. The control groups received either
oral tacrolimus (TO) or remained untreated (UA). Donor-specific cellular
and humoral responsiveness was measured after a short-term treatment (1
week), OAD development and side-effects were determined after a long-term
treatment (2 months). Pharmacokinetics were measured by analyzing tissue
and blood levels after QD or TID dosings. Drug distribution was measured
by 3D-SPECT. The drug effect on the airway epithelium was quantitated by
histology (PAS staining of goblet cells) and quantitative real time RT-PCR for
MUC4, MUC5AC, and MUC5B gene expression. Cell viability, proliferation,
MUC expression and phenotyp of airway epithelial cells grown at an air-liquid
interface were investigated in vitro.
Results: Tracheal drug deposition is higher using nebulizers creating large
particle sizes (10.2+/-0.3um), whereas lung deposition is increased with
smaller particles (2.8+/-0.5um). Both, TO and TA treatments markedly
suppressed the cellular (IFN-gamma spots:TA and TO vs UA p<0.001;
IL-4 spots:TA p=0.579 and TO p<0.001 vs UA) and humoral response
(IgM:TA p=0.004 and TO p<0.001 vs UA; IgG:TA p=0.241 and TO
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p=0.011 vs UA). Although TO was far more effective to suppress cellular
and humoral response, luminal obliteration was similarly inhibited with
TO (15+/-3%) and TA (13+/-4%) vs UA (44+/-7%,p<0.001) and the airway
epithelium was preserved (TO:96+/-7%,TA 97+/-6% vs.UA 67+/-26%).
Quantitative real time RT-PCR showed that higher local graft tissue levels
(peak levels for TA: 901+/-175ng/g vs. TO: 502+/-93ng/g; p<0.001) did
not alter physiologic gene expression of MUC4, MUC5AC, MUC5B. TO
animals showed significantly higher systemic side-effects, demonstrated by
elevated BUN, cholesterol and triglyceride levels compared to TA animals
(p<0.041).
Conclusions: These studies indicate that aerosolized tacrolimus shows
promising potency to protect the graft against acute and chronic rejection, and
such local immunosuppression may not impact the respiratory epithelium.
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1934 SAIREITO, A JAPANESE HERBAL MEDICINE, INDUCES
INDEFINITE SURVIVAL OF FULLY MISMATCHED CARDIAC
ALLOGRAFTS AND GENERATES REGULATORY CELLS IN
MICE
Q. Zhang1, D. Iwami1, O. Aramaki2, K. Watanabe3, A. Ishige3, N. Shirasugi1,
M. Niimi1
1
Teikyo University, 2Nihon University, 3Keio University, Tokyo, Japan
Aims: Saireito (TJ114) is a Japanese herbal medicine which consists of
Shosaikoto (TJ9) and Goreisan (TJ17). A couple of reports have previously
shown the immunomodulatory and anti-tumor activities of orally administered
TJ114. However, there were not any reports about the effect of TJ114 on
alloimmune responses in experimental or clinical transplantation. Here, the
authors examined whether TJ114 could induce unresponsiveness to fully
mismatched cardiac allografts in mice.
Methods: CBA mice (H2k) underwent transplantation of C57BL/6 (B6, H2b)
hearts and received oral administration of TJ114 (2g/kg/day) from day 0 to day
7 after grafting. An adoptive transfer study was performed to determine whether
regulatory cells were generated in the TJ114-treated recipients. Histological
examination and cell proliferation assay were performed.
Results: Untreated CBA mice rejected B6 cardiac grafts acutely (median
survival time [MST], 9 days). In mice given TJ114, all allografts survived
indefinitely (MST, >100 days). However, neither TJ9 nor TJ17 prolonged
the allografts survival (MST, 7 and 8 days, respectively). Moreover, TJ9 is
extracts from seven herbal materials such as Bupleuri radix, Scutellariae
radix, Pinelliae tuber, Ginseng radix, Ginseng radix, Zingiberis rhizoma and
Zizyphi fructus, one of which did not induce graft survival. TJ17 is extracts
from five herbal materials such as Polyporus, Poria, Rhizoma atractylodis,
Alismatis rhizoma and Cinnamomi cortex, one of which did not induce
graft survival. Taken together, TJ9 and TJ17 are both essential to induce
unresponsiveness. Next, adoptive transfer study was performed. Secondary
CBA recipients (naïve) given whole splenocytes from primary TJ114treated CBA recipients with B6 cardiac allografts 30 days after grafting had
prolonged survival of B6 hearts (MST, >60 days) compared to that in the
secondary recipients with adoptive transfer of naïve splenocytes (MST, 8
days), suggesting that regulatory cells were generated. BALB/c (third-party)
hearts were eventually rejected in the secondary CBA recipients with the
adoptive transfer of whole splenocytes from TJ114-treated recipients (MST,
11.5 days), suggesting that the regulatory function is donor specific. When
CD4+ cells were purified from the spleen of the TJ114-treated recipients
and were adoptively transferred into naïve secondary CBA recipients, the
secondary recipients enjoyed prolonged survival of cardiac allografts (MST,
>30 days), compared to that in the recipients with adoptive transfer of naïve
CD4+ cells (MST, 13 days).
Conclusion: Treatment with TJ114 induced unresponsiveness to fully
allogeneic cardiac allograft and generated donor-specific regulatory cells. The
regulatory cells contained CD4+ population. Neither TJ9 nor TJ17 can induce
prolongation of allograft survival, suggesting that cocktail of TJ9 and TJ17
works synergistically to induce regulatory cells. Traditional knowledge of
Japanese herbal medicine may contribute to immunomodulation after modern
transplantation surgery.
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1935 MYCOPHENOLIC ACID-MEDIATED SUPPRESSION OF
IMPDH IN CIRCULATING CD4+ CELLS IS NOT ASSOCIATED
WITH IMMEDIATE GTP REDUCTION: A SINGLE-DOSE
CROSSOVER EXPOSURE-RESPONSE STUDY IN HEALTHY
INDIVIDUALS
N.T. Vethe1,2, S. Bremer1,2, H. Rootwelt1, I. Sæves1,2, S. Bergan1,3
1
Dept of Medical Biochemistry, Rikshospitalet University Hospital, Oslo,
2
Institute of Clinical Biochemistry, University of Oslo, 3School of Pharmacy,
University of Oslo
Background: Mycophenolic acid (MPA) is an uncompetitive, tight-binding
inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme
in the guanine nucleotide synthesis. Due to highly variable pharmacokinetics
and pharmacodynamics it is hypothesized that personalized MPA treatment
may improve the clinical outcome. The aim of our study was to characterize
the exposure-response relationship for MPA at the molecular level, in order to
guide future strategies of individualized treatment based on pharmacodynamic
monitoring.
Methods: A single-dose (100, 250, 500 and 1000 mg mycophenolate mofetil)
crossover exposure-response study of MPA pharmacodynamics in CD4+ cells
was performed in five healthy individuals. IMPDH activity, IMPDH gene
expression and purine nucleotides were examined in relation to MPA plasma
concentration.
Results: IMPDH was strongly inhibited by MPA; median EC50 was 2.5 (range
1.3 to 4.3) mg/L. At the standard dose of 1000 mg, the median Cmax was 27
(range 17 to 43) mg/L. The overall IMPDH activity (area under the curve;
AUC) approached maximum suppression at MPA AUC0-12h 22 mg*h/L
(corresponding to the 500 mg dose), and MPA plasma concentrations exceeding
6 mg/L did not increase the IMPDH inhibition any further. The suppression of
IMPDH was associated with reduced IMPDH gene expression. In contrast to
the expected reduction of guanosine triphosphate (GTP), an increasing trend
was observed in response to MPA.
Conclusions: The standard dose of 1000 mg was in the upper range of the
response curve. Reduced IMPDH gene expression adds to the mechanismof-action of MPA. The absence of GTP reduction indicates that the cells
possess mechanisms counteracting the expected molecular effect of MPA, and
suggests that GTP may not serve as an immediate response biomarker of MPA
pharmacodynamics in circulating lymphocytes.
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1936 EFFECT OF SIROLIMUS ON CYCLOSPORINE-INDUCED
DIABETES MELLITUS
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1937 SYNERGISTIC EFFECT OF CYCLOSPORINE IN
RAPAMYCIN-INDUCE DIABETIC DISEASE
C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim,
H.E. Yoon, Y.S. Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Rapamycin (RAPA) is a new drug with both immunosuppressant and
antiproliferative properties that has a unique mechanism of action distinct from
that of the calcineurin inhibitor. Several studies have investigated the effect of
immunosuppressive agents on ƒÒ-cell function and effects of RAPA on insulin
secretion are still debated. We investigated the influence of RAPA on insulin
secretion in chronic cyclosporine (CsA)-induced nephropathy.
Methods: Sprague-Dawley rats maintained on a low salt diet (0.05% sodium)
were treated subcutaneously with vehicle (olive oil, VH, 1mL/kg per day) and
CsA (15mg/kg per day) for 21 days. RAPA (0.3mg/kg per day) was concurrently
administered via subcutaneously to CsA and VH groups. This study was
performed to evaluate the effect of RAPA with or without CsA treatment on
pancreatic and renal injury. The effect of RAPA on CsA induced pancreatic
injury was evaluated by intraperitoneal glucose tolerance test (IPGTT), plasma
insulin concentrations, blood glucose level and pancreatic ƒÒ-cell morphology.
The effect of RAPA on CsA-induced renal injury was evaluated by assessing
renal function and pathology mediators of inflammation and fibrosis such as
osteopontin (OPN) and apoptotic cell death.
Results: Three weeks of CsA treatment caused diabetes, renal dysfunction,
typical pathologic lesions and apoptotic cell death. VH+RAPA group
significantly increased blood glucose concentration, Calculated AUC (806 „b
34 vs. 599 „b 13 mg/dL min, p < 0.05) decreased plasma insulin concentration
(0.37 „b 0.01 vs. 0.42 „b 0.01 ng/mL, p < 0.05) compared with the VH group.
CsA+RAPA group improved renal function and histopathology compared with
the CsA group. Also pro-inflammatory and pro-fibrotic molecules such as OPN
and apoptotic cell death increased compared with the CsA group. In addition
CsA+RAPA group significantly increased blood glucose concentration,
Calculated AUC (1546 „b 38 vs. 1069 „b 49 mg/dL min, p < 0.05) and plasma
insulin concentration (0.29 „b 0.02 vs. 0.33 „b 0.01 ng/mL, p < 0.05) compared
with the CsA group. Immunohistochemical staining for insulin in the VH group
and VH + RAPA group strong and uniform pattern in a large proportion of the
islet cells. In contrast, a lower intensity of staining and vacuolization in islet
cells in the CsA group. CsA+RAPA group higher degree of vacuolization in the
pancreas islet cells and decreased pancreatic ƒÒ islet mass.
Conclusion: Combination of RAPA with CsA treatments reduction in insulin
production may be the result of beta cell death coupled with impaired beta cell
regeneration.
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1938 INFLUENCE OF RAPAMYCIN ON RENAL TUBULAR
FUNCTION IN RATS WITH OR WITHOUT CYCLOSPORINE
TREATMENT
C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim,
H.E. Yoon, Y.S.Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Rapamycin (RAPA) is a promising drug for sparing calcineurin
inhibitors in clinical practice. But recent studies RAPA given around the time
of renal injury can augment injury and combined treatment with RAPA and
CsA increase synergistic effect of nephrotoxicity. However, it is undetermined
whether the effect of rapamycin on renal tubule is related to the preexisting
cyclosporine-induced renal injury or rapamycin itself. We investigated the effect
of RAPA on renal function in rats with or without cyclosporine treatment.
Methods: Sprague-Dawley rats maintained on a low salt diet (0.05% sodium)
were treated subcutaneously with vehicle (olive oil, VH, 1mL/kg per day)
and CsA (15mg/kg per day) for 21 days. RAPA (0.3mg/kg per day) was
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C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim,
H.E. Yoon, Y.S. Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Sirolimus (SRL) is a promising drug for replacing calcineurin
inhibitors (CNI), but the effect of SRL on CNI-induced diabetes mellitus (DM)
remains unclear. This study was performed to investigate the influence of SRL
on established CNI-induced DM.
Method: Sprague-Dawley rats were divided into four groups: Vehicle (VH
group), conversion of VH to SRL (VH/SRL group), CsA withdrawal (CsAW
group) and conversion of CsA to SRL (CsA/SRL group). Rats on a low salt
diet (0.05% sodium) were treated with VH (olive oil, 1mL/kg per day) and
CsA (15mg/kg per day) for 28 days. And then, SRL (0.3 mg/kg per day) was
concurrently administered via subcutaneously to CsA and VH groups for 28
days. The effect conversion of CsA to SRL was evaluated by intraperitoneal
glucose tolerance test, plasma insulin concentrations, blood glucose level and
immohistochemistry of insulin in pancreatic ¥â-cell.
Results: The CsAW group showed complete recovery of DM, demonstrated by
similar blood glucose concentration, calculated AUC and plasma insulin level
compared with the VH group. The VH/SRL group showed increased blood
glucose concentration, calculated AUC (581¡¾37 vs. 484¡¾30 mg/dL min,
p<0.05) and decresed plasma insulin levels (3.90¡¾0.27 vs. 4.38¡¾0.35 mg/
dL min, p<0.05) compared with the VH group. The CsA/SRL group showed
further increased blood glucose concentration and calculated AUC (983¡¾46
vs. 581¡¾37 mg/dL min, p<0.05) and decreased plasma insulin concentration

(3.70¡¾0.21 vs. 3.90¡¾0.27 mg/dL min, p<0.05) compared with the VH/SRL
group. Immunoreactivity of insulin in pancreatic beta cells in the CsAW/SRL
group was lower than other three groups other groups.
Conclusion: CsA withdrawal improves established CsA-induced DM, but
conversion to SRL does not improve CsA-induced DM.
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concurrently administered via subcutaneously to CsA and VH groups. The
effect of RAPA with or without CsA treatment was renal function measured
by serum creatinine, creatinine clearance, histological parameters, electrolyte
level, detection of proteinuria in 24hr-urine collection and urine osmolality
were studies. And the influence of RAPA with or without CsA on the kidney¡¦s
ability to concentrate urine was evaluated using functional parameters and
expression of aquaporins.
Results: Three weeks of VH+RAPA group Scr and Ccr with VH group
not different, CsA+RAPA group significant increase in Scr compared with
the CsA group (1.21 „b 0.04 vs. 0.98 „b 0.03 mg/dl, p < 0.05). VH+RAPA
group significantly increased 24hr urine concentration (28 „b 4 vs. 14 „b 4
ml, p < 0.05) and decreased urine osmolality (1007 „b 59 vs. 1283 „b 134,
mOsm/kg, p < 0.05) is compared with VH group. Also CsA+RAPA group
significantly increased 24hr urine concentration (60 „b 7 vs. 15 „b 2 ml, p
< 0.05) and decreased urine osmolality (467 „b 59 vs. 717 „b 47 mOsm/
kg, p < 0.05). The level of electrolyte in VH+RAPA group significantly
decreased potassium (3.3 „b 0.05 vs. 4.0 „b 0.08 mmol/L, p < 0.05) and
magnesium (1.3 „b 0.1 vs. 1.9 „b 0.1 mmol/L, p < 0.05) compared with VH
group. CsA+RAPA group significantly decreased potassium (2.9 „b 0.10 vs.
3.9 „b 0.15 mmol/L, p < 0.05) and magnesium not different. In addition,
CsA+RAPA group significantly higher increased tubulointerstitial fibrosis,
inflammatory cell infiltration and apoptosis cell death compared with CsA
group. Immunoblot analysis of AQP2 protein expression, CsA+RAPA group
significantly decrease compared with CsA group (36 „b 6.2% vs. 83 „b 3.5%
p < 0.05).
Conclusion: RAPA treatments impair renal function and combination with
CsA augments nephrotoxicity.
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1940 INFLUENCE OF RENIN-ANGIOTENSIN SYSTEM ON
THE EXPRESSION OF KLOTHO, AN ANTI-AGING GENE, IN
EXPERIMENTAL MODEL OF CHRONIC CYCLOSPORINE
NEPHROPATHY
H.E. Yoon, H.K. Song, J.Y. Ghee, B.S. Choi, Y.S. Kim, B.K. Bang, C.W. Yang
Kangnam St Mary’s Hospital, The Catholic University of Korea
Background: Klotho gene plays an important role in suppressing aging
process. The present study evaluated the expression of Klotho gene in chronic
cyclosporine (CsA) nephropathy, and in CsA nephropathy with angiotensin II
receptor blockade.
Methods: Two separate experiments were performed. In the first experiment,
mice on the normal salt diet (NSD, 0.3%) or low salt diet (LSD, 0.05%) were
treated with vehicle (VH group, olive oil, 1 mg/kg per day) or CsA (CsA group,
30 mg/kg per day) for one or four weeks. In the second experiment, mice on
a NSD were given VH or CsA with losartan (LSRT, 100 mg/L per day) for 4
weeks.
Results: Klotho protein was selectively expressed in connecting tubules in the
VH group. The CsA group with NSD or LSD revealed decreased expression
of Klotho mRNA and protein compared with the VH group. The CsA group
with LSD revealed further decreased expression of Klotho mRNA and protein
compared with the CsA group with NSD. Concomitant administration of LSRT
in CsA group increased the expression of Klotho protein compared with the
CSA group.
Conclusions: CsA-induced renal injury decreases the expression of Klotho
gene, and angiotensin II blockade protects aging process by upregulating the
expression of Klotho gene.
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1941 SIROLIMUS TREATMENT IS BENEFICIAL IF GIVEN
PROPHYLACTICALLY OR LATE AFTER RENAL
MASS REDUCTION
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1939 SUNITINIB PREVENTS NEOINTIMA PROLIFERATION
AFTER AORTIC DENUDATION IN RATS
J. Rintala1, J. Savikko1,2, S. Rintala1, N. Malmström1, P. Koskinen1,3
Transplantation Laboratory, University of Helsinki, 2Department of Surgery,
Päijät-Häme Central Hospital, Lahti, Finland., 3Helsinki University Central
Hospital; Department of Medicine, Division of Nephrology
Background: Platelet-derived growth factor (PDGF) is one of the key
mediators of atherosclerosis. The role of vascular endothelial growth factor
(VEGF) in atherosclerosis is somewhat controversy. However, it also may
induce atheroma proliferation. Accelerated atherosclerosis is one pathological
manifestation of chronic allograft rejection. Sunitinib is a potent inhibitor of
both VEGF and PDGF receptors. Therefore sunitinib could be a potential
intervention for chronic rejection in the future. Here we investigated the
effect of sunitinib on neointima proliferation after arterial endothelial injury
in vivo.
Materials and methods: The aorta of male Wistar rats weighing 350 to
370 g was denuded of endothelium by the intraluminal passage of a French
Fogarty arterial embolectomy catheter introduced through the left iliaca artery.
Rats were treated eather with sunitinib (5 or 20mg/kg/d) or with vehicle only
(polyethylene glycol). Histologic changes and analysis of neointimal area were
evaluated from midaortic sections 14 days after injury.
Results: In the vehicle-treated group, moderate neointima formation was
detected. Sunitinib prevented the neointima formation almost completely
already with the lower dose. Higher dose of sunitinib decreased neointima
formation even further altough no statistical difference was seen between these
two sunitinib-groups. Sunitinib was well tolerated with both doses.
Conclusions: Our results demonstrate that sunitinib is a potent inhibitor of
neointima formation after arterial endothelial injury. Based on these findings
sunitinib could prevent accelerated atherosclerosis also in experimental solid
organ transplantation. However, to define the true potential of sunitinib in the
treatment of allograft rejection more experiments are needed.
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J. Rovira1, E.M. Arellano1,2, J. Carreras3, E. Banon-Maneus1,
M.J. Ramirez-Bajo1, D. Moya-Rull1, A. Sole-Gonzalez1, I. Revuelta1,
J.M. Campistol1, F. Diekmann1,4
1
LENIT. Nephrology and Renal Transplantation, Hospital Clinic i Provincial
de Barcelona, Spain, 2Nephrology. Hospital Universitario, 3Pathology,
Hospital Clinic i Provincial de Barcelona, Spain, 4Nephrology, Charite
Campus Mitte, Berlin, Germany
Sirolimus (SRL) has been associated with a beneficial effect in terms of
proteinuria and histological damage if initiated six weeks after renal mass
reduction (RMR) in a rat model. The aim was to evaluate the influence of SRL
treatment on proteinuria and renal histology if initiated before and very late
after RMR in a rat model.
Methods: Rats either underwent cryoablation of 2/3 of the left kidney and
subsequent right nephrectomy (group N; n=42) or sham operations (group S;
n=29). Two weeks before (B) or twelve weeks after (L) RMR, treatment with
SRL or vehicle (VEH) was initiated at 1.0 mg/kg three times a week (SRL levels
in blood 38 ng/mL). Creatinine clearance and proteinuria were evaluated in all
8 groups. 18 weeks after RMR, glomerular hypertrophy, glomerular sclerosis,
tubular atrophy, interstitial fibrosis and chronic inflammatory infiltrate in the
left kidney were evaluated.
Results: Immediately after RMR creatinine clearance was lower in rats
with reduced renal mass (4.48 mL/min·kg vs. 1.81 mL/min·kg; p<0.001).
At the end of treatment, the creatinine clearance was not different between
N+VEH and N+SRL (B and L) groups. Four weeks after RMR, a significant
increase of proteinuria was observed, the SRL administration before and
after RMR led to a stabilization of proteinuria until the end of the study,
whereas the group N+VEH experienced a further increase of proteinuria
(Table 1). RMR rats treated with SRL have less structural damage in all
evaluated parameters.
Conclusion: SRL treatment has the potential to halt progression of proteinuria
at any time during the course of progression in a model of reduced renal mass.
Proteinuria (mg/24h)

4 weeks

8 weeks

12 weeks

18 weeks

S+VEH

20.8±2.9

15.3±7.2

17.9±4.2

16.5±4.4
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Nx+VEH

84.5±72.0#

95.9±58.0##

142.5±19.2###

231.0±56.0###

S+SRL+B

5.5±1.3

9.7±0.6

14.2±7.3

---

Nx+SRL+B

40.5±30.2

79.3±49.1#

56.3±17.3#*

---

S+SRL+L

25.2±4.4

20.6±6.2

18.6±7.4

11.4±6.2

Nx+SRL+L

90.6±74.4

95.6±62.8#

124.0±64.2#

154.8±31.1#*

# p<0.05 versus Sham; * p<0.05 versus VEH
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1942 IMMUNOSUPPRESSIVE AGENTS AND THEIR
INFLUENCE ON HCV RNA REPLICATION AND INFECTIVITY
IN VITRO

1943 EFFECTS OF INHIBITING NUCLEAR FACTOR-KAPPA B
ON ACUTE VASCULAR REJECTION
Z. Shen, X. Zhu, M. He, Y. Chen, Z. Zhu, Y. Zhu, S. Guo
The First Affiniatied Hospital of Soochow University
Objective:To evaluate the effect of nuclear factor-kappa B (NF-¦ÊB)
inhibitor pyrrolidine dithiocarbamate (PDTC) on the cell-surface expression
of costimulatory molecules (CD80, CD86) on dendriteic cells (DC) and the
discordant cardiac xenograft rejection with the model of heterotopic cardiac
xenotransplantation from guinea pig.
Methods: SD rats were pretreatment with Chinese Cobra Venom Factor
(CVF) to preclude hyperacute rejection and PDTC was injected before Cardiac
xenograft from guinea pig into the abdomen of SD rat. mixed lymphocyte
reaction (MLR) was performed to test the tolerance effect in vitro, NF-¦ÊB
activation in recipients was reflected by positive nuclear staining of NF-¦ÊB
(p65 subunit), Expression of OX-62, CD80 and CD86 on DCs from spleen
were detected by flow cytometry. The mean survival time (MST) and the
pathology of grafted heart were also observed.
Results: The immune response was suppressed by PDTC proved by MLR
assay. The increase of CD80 and CD86 expression was suppressed and MST
was prolonged in experiment group.
Conclusion: Pretreatment with PDTC could inhibit the expression of
costimulatory molecules on DCs in the recipients after transplantation, which
also prolonged the MST and suppress AVR in some extent.
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1944 INFLUENCE OF TIMING AND DOSE OF CALCINEURIN
INHIBITORS EXPOSURE ON GRAFT ACCEPTANCE, TREGS
GENERATION AND FOXP3 REGULATION
K. Takahashi1,4, M. Kawai1,4, T. Soma1,4, E. Lerut, H. Kitade1,4, C. Mathieu,
M. Waer, J. Pirenne1,4
1
Abdominal Transplant Surgery Department, Catholic University of Leuven,
2
Morphology and Molecular Pathology, Catholic University of Leuven,
3
Laboratory for Experimental Medicine and Endocrinology (LEGENDO),
Catholic University of Leuven, 4Laboratory for Experimental Transplantation,
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Introduction: Regulatory T cells (Treg) play a crucial role for the induction and
maintenance of tolerance. Transcription factor FoxP3 is specifically expressed
on Treg and is important for the maintenance of their function. Several studies
report that Cyclosporine A (CsA) prevents Tregs generation by inhibiting the
expression of FoxP3 in organ transplantation. We previously showed Tregs
generation was not only determined by the dose but also by the timing of CsA
exposure in vivo. Therefore, we hypothesized FoxP3 expression may also be
influenced by the pattern of CsA exposure and studied that in a rat model.
Methods: PVG rat recipients of an MHC fully mismatched RA heart were
orally exposed to an identical overall dose of CsA for 12 days (starting the day
of transplantation). However, the pattern of CsA exposure varied according
to three groups (Gr). Gr1: constant exposure to a low dose of 10mg/kg/day;
Gr2: gradually increasing exposure from 0 to 40mg/kg/day; Gr3: gradually
decreasing exposure from 40 to 0mg/kg/day. Another group (Gr4) was exposed
to a high dose CsA at 50mg/kg/day.
Grafts were harvested on post-Tx day 3, 7, 14 and 30. mRNA was extracted and
intragraft FoxP3 expression was measured by real time RT-PCR. In addition,
to assess the presence of Treg in vivo, adoptive cell transfer experiments were
performed on post-Tx day 21.
Results: 8 of 10 rats in Gr1 and 7 of 9 in Gr2 accepted grafts indefinitely
(median graft survival time (MST) > 90 days), while 10 of 11 rats in Gr3
and all 10 in Gr4 underwent rejection (MST = 20 and 34 days, respectively).
Adoptive cell transfer experiments showed the presence of Treg in vivo in low
dose CsA group (Gr1) and ¦ gearly low/late high¦ h dose CsA group (Gr2) but
not in ¦ gearly high/late low¦ h dose CsA group (Gr3) or high dose CsA group
(Gr4). Intragraft FoxP3 mRNA on post-Tx day 30 was significantly increased
compared with those on post-Tx day 14 in each group (P < 0.05). However, the
levels of FoxP3 in the low dose CsA group (Gr1) and ¦ gearly low/late high¦ h
dose CsA group (Gr2) were significantly higher than those of ¦ gearly high/late
low¦ h dose CsA group (Gr3) and high dose CsA group (Gr4), (P < 0.05).
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End stage liver disease that is associated with chronic hepatitis C infection
is one of the leading causes for liver transplantation worldwide. Moreover,
patients with recurrent hepatitis develop cirrhosis within five years of their
transplant. Several recent data suggest that the outcome of hepatitis C
after liver transplantation has worsened in individuals transplanted in the
late nineties. Beside older donor age immunosuppressive regimens may
contribute to the outcome of graft hepatitis. Single substances have been
shown to display antiviral effects in the replicon model while others are
believed to have antifibrotic properties. Until now, there are only limited data
available characterizing the influence of immunosuppressive compounds
on HCV replication and infection in a fully permissive cell culture system
which reproduces the complete viral replication cycle in tissue culture. As a
consequence, no definite recommendation for an “optimal” immunosuppressive
regimen based on in vitro data can be given at this stage. Therefore, in this
study we assessed the influence of different immunosuppressive compounds
routinely used upon hepatitis c associated liver transplantation with regard to
their effect on HCV RNA replication and infectivity.
To this end, we transfected a highly permissive human hepatoma cell line
with HCV reporter virus genomes,and monitored HCV RNA replication
and infection in the presence of varying doses of the respective compounds.
Cellular toxicity of the immunosuppressive agents was analyzed utilizing a
commercially available cytotoxicity assay.
Tacrolimus, everolimus, prednisolone and the IL-2 receptor antagonist
basiliximab neither influenced HCV RNA replication nor affected the
infectivity of released virions. In contrast, the addition of mycophenolic acid
(MPA) at a concentration of 40 μg/ml or of 0.25 μg/ml Ciclosporin A (CsA)
to the cell culture medium caused a 90% (IC90) reduction of HCV RNA
replication of the genotype 2a reporter virus as compared to the untreated
control. Moreover, when target cells were inoculated with virus particles
prepared in the absence of the drugs, addition of MPA or CsA at concentrations
of 5 μg/ml and 0.1 μg/ml, respectively, reduced infectivity by more than
90% indicating that these compounds also inhibited HCV RNA replication
in infected cells. Finally, we tested various combinations of frequently used
immunosuppressive compounds. None of the tested combinations abrogated
the antiviral effect of CsA on HCV replication. Further studies characterizing
additive and/or synergistic effects between individual compounds are
ongoing.
While we did not observe any cytotoxicity of CsA in the applied concentration
range higher doses of MPA (≥; 50 μg/ml) inhibited proliferation of the cells.
In conclusion, CsA exerts a potent antiviral effect on HCV RNA replication
in the cell culture model fully permissive for HCV replication. In contrast, the
ability of MPA to inhibit HCV replication is likely at least in part attributable
to its interference with cell proliferation. Whether the direct antiviral effect of
CsA ameliorates fibrosis progression has to be investigated in future controlled
randomized studies.
1
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Conclusion: The study shows the expression of intragraft FoxP3 is influenced
by the overall dose and timing of exposure to CsA intimately corresponding
with Treg generation. Particularly, immediate exposure to high dose CsA
post-Tx prevents the propagation of FoxP3 in grafts and Tregs generation,
and provokes rejection. On the contrary, starting CsA at lower doses post-Tx
and progressively increasing it allows substantial expansion of FoxP3, Tregs
generation and better graft outcome.
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1945 THE INFLUENCE OF CURRENT IMMUNOSUPPRESSION
ON THE GENERATION AND MAINTENANCE OF
REGULATORY T CELLS
M. Schulze1, E. Muller2, D. Kahn2
1
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2
Department of Surgery, University of Cape Town, South Africa
The immunosuppressive drugs rapamycin, tacrolimus and cyclosporin A are
widely used to prevent allograft rejection, although the relative merits of each
agent in tolerance-inducing immunosuppressive protocols remain contentious.
In part, this reflects our limited understanding of the effect of these drugs on
the CD4+CD25+ regulatory T cell (T reg) population in humans, which play an
important role in the development of tolerance to allografts.
Recently, it was reported that alloantigen-driven expansion of human CD4+
CD25+ T regs gives rise to a distinct subset of CD27+ T regs, which are more
potently suppressive than the CD27- subset. In the current study, we investigated
the effect of rapamycin, tacrolimus and cyclosporin on the generation of
CD27+ T regs after alloantigen-driven expansion in vitro and showed that,
unlike cyclosporin, both rapamycin and tacrolimus promoted the development
of CD27+ T regs over the development of the CD27- T regs. Likewise, the
relative number of CD27+ T regs in the peripheral blood of patients on
rapamycin-based immunosuppressive regimens was greater than in patients
treated with either tacrolimus or cyclosporin. We propose that the differential
effect of rapamycin, tacrolimus and cyclosporin on the predominance of the
CD27+ T reg subset may favour the use of rapamycin-based regimens in
tolerance-inducing immunosuppressive protocols.
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1946 IMMUNOMODULATORY EFFECTS OF COBALT
PROTOPORPHYRIN WHEN ADMINISTERED IN
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1
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Introduction: Immunosuppressive strategies are designed to take advantage of
potential synergy between drugs, and ultimately decrease the risk of side-effects.
Porphyrins have been used to upregulate expression of heme oxygenase-1
(HO-1), a cytoprotective and anti-apoptotic protein capable of reducing ischemia/
reperfusion injury and increasing graft survival in allo- and xenotransplantation
models. In addition, HO-1 has been shown to modulate T-cell activation and
proliferation. Based on our preliminary in vitro results, indicating increased
immunosuppressive effects of cyclosporine A (CsA) when combined with cobalt
protoporphyrin (CoPP, kindly donated by Frontier Scientific Inc., Logan, USA),
we investigated the capacity of such drug combination to prolong survival of
heterotopically transplanted cardiac allografts in a rat model.
Material and methods: Heterotopic cardiac allotransplantation procedures
were performed using D’Agouti (n=24) and Lewis rats (n=24) as heart donors
and recipients, respectively. Postoperatively, recipients were divided into
6 experimental groups using different dose combination of CsA (Novartis)
(suboptimal immunosuppression: 1.5mg/kg CsA; optimal immunosuppression:
5mg/kg CsA, once daily administered by oral gavage) and different dosages
of CoPP (5mg/kg, 10mg/kg or 20mg/kg of subcutaneous CoPP on the day
of surgery and twice a week thereafter). Control animals received either
CsA or CoPP. Grafts and whole blood samples were retrieved at cessation
of heartbeat, as detected by abdominal palpation. Tissues were sectioned to
evaluate the presence and degree of rejection. Blood samples were collected
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for pharmacodynamic studies by quantification of concanavalin A (Con
A) stimulated lymphocyte proliferation, after carboxyfluorescein diacetate
succnimidyl ester (CFSE) labelling.
Results: Considerable differences in graft survival were observed between the
different groups. In particular, animals immunosuppressed with CsA 1.5mg/kg
only had a median survival of 7 days, whilst animals immunosuppressed with
CsA 1.5mg/kg and CoPP 20mg/kg had a median survival of 10 days. Proliferation
of Con A stimulated PBMC was not influenced by CsA treatment. In contrast,
Con A stimulated PBMC isolated from animal treated with CsA in combination
with CoPP (10 or 20mg/kg), showed blocked or delayed cell proliferation.
Conclusions: Our preliminary in vivo studies suggest that CoPP may potentiate
the immunomodulatory effects of CsA and extend allograft survival.
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1947 EFFECT OF B-CELL DEPLETIONAL THERAPIES
ON ALLOIMMUNE HUMORAL RESPONSES IN A
MURINE MODEL
B. Book, G. Martens, R. Sidner, M. Volz, M. Pescovitz
Indiana University School of Medicine
There is growing interest in B-cell-directed therapy in transplantation, yet
there are limited data on its immunologic impact. We report the effect of two
distinct B-cell depletion regimens on allo-antibody (Ab) responses using
a murine model. B-cell depletion was accomplished with a BR3-Fc fusion
protein (soluble BAFF antagonist), and anti-BR3 (dual function BAFF agonist
and cell depleter). C57BL/6 mice received BR3-Fc or anti-BR3. Initial flow
cytometric (FCM) analysis documented B-cell depletion and recovery. Cohorts
received one dose intraperitoneal (IP) anti-BR3 (200?g/mouse). BR3-Fc (200
?g) was given IP twice weekly for 6 weeks (wk). To examine the impact of
B-cell depletion, immunization was performed at 7 days (D) after the dose
of anti-BR3 and 14 D after the first dose of BR3-Fc. Cohorts of mice (n=3)
were immunized IP with BALB/c splenocytes (2x107 cells) and boosted 1
month later. Controls included no anti-B-cell therapy (positive control, PC) and
autologous sera for negative control. Serum samples were obtained weekly for
6 weeks. Two-fold dilutions of sera were incubated with cells and secondary
anti-IgG- or –IgM-FITC. Binding was detected by FCM. The sum of the
mean fluorescence channel was calculated after subtracting autologous serum
control. Statistical analyses used Kruskal-Wallis one-way analysis of variance
and Dunn’s Method of pairwise comparison. B220 expression in peripheral B
cells was determined at baseline, 1,2,4,6,8,10 and 12 wks post therapy by FCM.
Statistical analyses utilized Student s t-test (p<0.05 was significant). Anti-BR3
led to rapid B-cell depletion from 42% to 6% at one week with recovery to
35% at 12 weeks(wks). BR3-Fc required 4 wks for B-cell depletion from 43%
to 8% and continued to be low at wk 12 (7%). Both agents suppressed the allo
Ab response. IgG, but not IgM Allo-Ab was suppressed significantly with antiBR3 and despite recovery of peripheral B cells a booster response was delayed
and the level reduced. There was a slight effect on antibody with BR3-Fc. This
difference could be due to small sample size, the level of B-cell depletion at
time of immunization, or a qualitative difference in residual B cells. From a
clinical perspective, the more rapid and complete inhibition with anti-BR3
makes it a more favorable agent to move into clinical trials.
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1948 TARGETED DELIVERY OF RAPAMYCIN TO DENDRITIC
CELLS USING BIODEGRADABLE MICROPARTICLES IS
HIGHLY EFFECTIVE IN SUPPRESSING THEIR MATURATION
AND FUNCTION
G. Raimondi2,5, S. Jhunjhunwala1, A.W. Thomson2,3,5, S.R. Little1,3,4,6
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Introduction: Degradable microparticles (MPs) have potential to protect and
release drugs over extended periods and, if sized appropriately, can be targeted
passively to phagocytic cells. Previously, we have shown that dendritic cells
(DC) treated with the immunosuppressive pro-drug rapamycin (rapa) are
resistant to maturation and prolong vascularized transplant survival in a mouse
vascularized heart allograft model. Targeting of rapa to immature DC using
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MPs may potentiate the tolerogenic potential of these cells and minimize the
need for systemic immunosuppression.
Methods: Rapa was encapsulated into ~3.4 μm-sized poly-lactic-co-glycolic
acid (PLGA) MPs (rapaMPs) and release behavior was examined under intraphagosomal (pH = 5) and extracellular (pH = 7.4) conditions. Bone marrowderived CD11c+ DC were exposed to rapaMPs. RapaMPs internalization and
their effect on DC immuno-biology was investigated.
Results: RapaMPs are characterized by a similar biphasic release profile at
the two pH values tested. However, at pH=5 the amount of Rapa released
was significantly higher, suggesting a more favorable release of the drug once
MPs are internalized. Following overnight incubation with DC, rapaMPs were
internalized in numbers that correlated with the initial concentration of particles,
as determined by microscopic and flow cytometric analyses. Internalization of
rapaMPs did not reduce DC viability. Maturation marker expression (MHC
class II, CD80, CD86, and CD40) confirmed that the cells were preserved in
an immature state. Further, DCs that took up rapaMPs had markedly reduced
ability to activate allogeneic T cells to induce their differentiation toward
effector T cells compared to DCs exposed to an excess of soluble rapa.
Significantly, loading of DC with rapaMPs did not prevent up-regulation of
maturation markers following LPS exposure, but these “mature-like” cells
remained markedly compromised in promoting alloreactive T cell proliferation
in vitro. In vivo injection of rapaMPs-loaded DC confirmed a reduced T cell
stimulatory ability in vivo compared with control DC.
Conclusions: DC-targeted intracellular delivery of rapa using biodegradable
MPs results in improved efficacy of the drug (with respect to its ability to
modulate DC allostimulatory capacity) when compared to treating DCs with
extracellular rapa. These data suggest that rapaMP-loaded DCs are promising
novel vectors for prevention of transplant rejection.
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1949 R348, A JAK3 INHIBITOR, IS IMMUNE CELL SPECIFIC
AND PRESERVES THE RESPIRATORY EPITHELIUM WHILE
STABILIZING MUCIN GENE 4 (MUC4) EXPRESSION IN THE
PREVENTION OF OBLITERATIVE AIRWAY DISEASE (OAD)
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Background: Despite use of potent immunosuppressants, obliterative
bronchiolitis (OB) remains a major hurdle for achieving long-term graft
survival in lung transplant recipients. The transcription factor, NF-κB plays a
crucial role upon inflammation and acute allograft rejection. In this study, we
examined the effect of a novel NF-κB inhibitor, DHMEQ in combination with
tacrolimus on OB in mice.
Method: The trachea including main bronchi from BALB/c (H-2d) mice were
transplanted heterotopically into subcutaneous pocket in C57BL6 (H-2b) mice.
Recipient animals were given i.p. either control vehicle, DHMEQ (20 or 40 mg/
kg/day), tacrolims (1.5 mg/kg/day) or DHMEQ (20 mg/kg/day) plus tacrolimus
daily after transplantation, and euthanaized at 28 days post-transplantation.
Graft histology (lumen opening and epithelium remaining) and frequency of
alloreactive IFN-γ producing cells (ELISPOT) within splenocytes of transplant
mice were examined.
Results: In the control animals, all trachea allografts were completely obliterated
(Fig. A) along with epithelial destruction (Fig. B) and luminal fibrosis. Daily
administration of DHMEQ at 20 mg/kg did not prevent graft OB (n=8). In
contrast, twice daily DHMEQ at 20 mg/kg (n=9) significantly attenuated both
luminal obliteration and epithelial destruction (both p<0.005) in the allografts
as compared to control (Fig. A, B). Furthermore, graft protection against OB as
assessed by luminal opening and epithelium remaining rates (both p<0.001) was
further enhanced when tacrolimus was combined with daily DHMEQ at 20 mg/
kg (n=10). The frequency of allo-specific IFN-γ producing cells (Fig. C) was not
affected by either DHMEQ or tacrolimus alone, whereas that was significantly
reduced in the DHMEQ+tacrolimus given recipients (n=3, p<0.01).
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Objective: This is the first study to investigate the effect of R348, a Jak3
inhibitor, on different cell types involved in the development of obliterative
airway disease (OAD), specifically investigating the respiratory epithelium,
inflammatory cascade, and smooth muscle cells.
Methods: Trachea from Brown-Norway (BN) donors were transplanted
heterotopically into the greater omentum of Lewis (Lew) rats. Recipients were
treated with either R348 (40 mg/kg/d), rapamycin (3mg/kg/d), or left untreated
for 28 days. Trachea specimens were evaluated histologically to determine
quantitative levels of PAS-positive respiratory epithelial cells (=goblet cells).
Tracheal epithelial mucin gene 4 (Muc4) RNA levels were determined between
all groups using quantitative real time reverse transcription polymerase chain
reaction (qRT-PCR). Prevention of cellular rejection was investigated between
all groups using enzyme-linked immunosorbent spot (ELISPOT) assays on
day 5 and tracheal grafts were analyzed by immunohistochemistry for total
mononuclear cell infiltration. To assess the role of R348 on smooth muscle
cells, platelet derived growth factor (PDGF)-stimulated human coronary
artery smooth muscle cells (hSMCs) were incubated with each respective drug
(100nM) for 5 days and a MTT proliferation assay was performed.
Results: R348 40 mg/kg/d treated recipients and syngeneic (Lew-Lew)
recipients contained moderate and outstanding levels of PAS-positive goblet
cells, respectively. Both rapamycin 3 mg/kg/d and untreated recipients
expressed no PAS-positive goblet cells. These histological results were
confirmed by qRT-PCR that showed R348 40 mg/kg/d treated recipients had
176-fold greater Muc4 RNA levels compared to untreated recipients (1.04
± 0.9 vs. 0.0059 ± 0.003, p<0.02) and also significantly expressed 16-fold
greater Muc4 RNA levels versus rapamycin 3 mg/kg/d treated recipients (1.04
± 0.9 vs. 0.06 ± 0.1, p<0.02). R348 40 mg/kg/d treated recipients expressed
similar Muc4 RNA levels compared to syngeneic recipients. Both, R348 and
rapamycin, significantly reduced the Th1 (IFN- ã) and Th2 (IL-4) immune
response as evidenced by decreased spot frequencies of IFN-ã (1064 ± 117 vs.

366 ± 50 and 194 ± 115, p<0.0001) and IL-4 (111 ± 30 vs. 48 ± 26 and 23 ± 18,
p<0.0001) versus untreated recipients with rapamycin producing a significant
reduction in IFN-ã and IL-4 compared to R348 treated recipients (194 ± 115
vs. 366 ± 50 and 23 ± 18 vs. 48 ± 26, p<0.01). Both R348 and rapamycin
treated recipients expressed significantly decreased amounts of peritracheal
mononuclear cells versus untreated recipients (1087 ± 518 cells/mm2 and 1014
± 209 cells/mm2 vs. 8018 ± 1788 cells/mm2, p<0.0001). R348 had no effect
on hSMC proliferation similar to untreated control cells, whereas rapamycin
significantly inhibited hSMC proliferation.
Conclusion: R348 effectively attenuates OAD while preserving the respiratory
epithelium and possessing immune cell specificity, in contrast to rapamycin which
possesses inferior epithelial preservation capability and exerts its effects on multiple
cell types. R348 provides a favorable alternative to the current immunosuppressive
regimen in the prevention of chronic airway allograft rejection.

Conclusion: Inhibition of NF-κB activation by DHMEQ attenuates development
of OB in mice. Addition of tacrolimus to DHMEQ strengthens the protective
effect, and such strategy may become a new modality in preventing OB.
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1951 LOW DOSE THYMOGLOBULIN INDUCTION THERAPY
FOR KIDNEY TRANSPLANTATION IS EFFECTIVE AND WELL
TOLERATED IN ELDERLY PATIENTS
M.R. Laftavi1, S. Sharma1, R. Koholi2, P.D.M. Danek1, L. Feng1,
J. Toullock1, M.Dayton1, D. Dunn1, O. Pankewycz2
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Current immunosuppressive therapies and protocols have led to significant
improvements in early (<1 year) patient and graft survival rates following
kidney transplantation. Whether induction therapies such as Thymoglobulin
(TGL) contribute to these improved results remains controversial. Fulldose TGL induction therapy (7-10 mg/kg total dose) has been associated
with increased morbidity following renal transplantation which may be
especially true in a high risk population such as the elderly. Therefore, we
studied the efficacy and tolerability of a low-dose TGL induction strategy in
older recipients (>65 years) (Gr.1, n=45). We compared their post-transplant
outcomes to a group of patients less than 65 years old (Group 2, n=45)
transplanted during the same period. All patients were transplanted at a single
center between Jan. 2001 and Sept. 2007. Both groups received a similar lowdose of TGL induction therapy (Gr.1= 2.96+/-1.29 vs. Gr.2= 3.2+/-2.11 mg/
kg). The average age in years for Gr.1 was 73.8+/-5.4 and for Gr.2, 48+/-10.7
(p<0.001). The two groups were similar in number of men (66%), African
Americans (28%), diabetics (35%), patients with PRA > 30% (6%), CIT (16.1
hrs.), DGF (26%) and living donors (10%). All patients were maintained on
a calcineurin inhibitor, mycophenolic acid and low dose prednisone (5 mg/
day). To date, none of the older patients experienced AR whereas 1 younger
patient had AR. Initial hospital stays were equal (Gr.1= 7.8+/-3.2 vs. Gr.2=
7.5+/-4.4 days, p=0.35). Within the first 6 months, 9 older patients required rehospitalization compared to 15 younger patients (p=0.15). Bacterial infections
in both groups (Gr.1 vs. Gr 2) were equal including wound (4 vs. 0), urine (20
vs. 15), lung (1 vs. 1) and skin (0 vs. 2). There were 2 BK viral infections in
Gr.1. Gr.2 had 3 viral infections, 2 CMV and 1 H. zooster. eGFR was equal in
both groups (Gr.1=55.7+/-18.5 vs. Gr.2=52.7+/-18.5 ml/min). 3-year patient
and graft survival rates were equivalent in both groups (Gr1. 86.6% vs. Gr 2.
97.6%). In conclusion, low dose TGL induction therapy is safe and effective
in patients >65 years of age. When compared to younger patients, low-dose
TGL leads to equivalent graft survival and function without incurring excess
morbidity in the older population.
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Hospital General Alicante
Thymoglobulin is a polyclonal antilymphocyte agent specific for T-cell epitopes,
which is included in the therapy of high immunological risk recipients due to
its therapeutic potential.
The aim of this prospective and observational study is to evaluate the incidence
of acute rejection, oportunistic infections and malignancies, beside of the graft
and recipient survivals between a group of 50 high immunological risk renal
transplant recipients and a group of 50 pacients without immunological risk,
who received grafts from the same cadaveric donors, since 2001 to 2006.
The risk group included pacients with high rate of performed antibodies (50%),
recipients who had lost their first graft due to early acute rejection, crossmatch positive, black race or important histoincompatibility. They received
thymoglobulin to mantein T-cell count around 10 cells/μl, FK after five
days, Mycophenolate mofetyl and steroids, with ganciclovir prophilaxis for
CMV.The normal risk group received Cyclosporine, Mycophenolate mofetyl
and steroids. Recipients who lost their graft due to thecnical failure were
not included. The mean follow up was 41,7 months, always more than one
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year. Both groups were similar respect to donor and recipient gender and age,
HLA-incompatibility, but the percentage of pacients with high rate of perform
antibodies and second transplant recipients was higher in the high risk group.
The incidence of acute rejection, histologically proved, was significantly
higher in the normal risk group (28,6% against 6,1%, p=0,03). There
was no difference in opportunistic infections, CMV included, or
malignancies,although 2 recipients of the normal risk group developed
lymphoproliferative disorders. The recipient survival was 97,9% at 1 year
and 3 years in both groups, and the graft survival was 89,8% and 84,8% in
the high risk group against 93,8% and 90,4% at 1 year and 3 years in the
normal risk group (p=ns).
We conclude that the evolution of high immunological risk renal transplant
recipients is similar to normal risk pacients if we use a immnunossuppresion
potent enough.The incidence of acute rejection was significantly higher in the
normal risk group.
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POSTTRANSPLANT IN RENAL TRANSPLANT PATIENTS
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Objective: Antithymocyte globulins (ATGs) are used as induction therapy. They
contain antibodies against functional molecules on the surface of mononuclear
blood cells and affect target cell functions. The in vivo mechanisms of ATGs
remain largely unclear. Previous studies did not evaluate the impact of ATGs on
plasma cytokines during the posttransplant period. In this study, we analyzed
the association of Thymoglobulin (TG) induction therapy with posttransplant
cytokines plasma levels in renal transplant recipients.
Material and Methods: We analyzed immediately pre- and early (7±1 and
26±7 days) posttransplant T lymphocyte subpopulations, sIL-1RA, IL-2, sIL2R, IL-4, IL-6, sIL-6R, IL-10, TNF-α, TGF-ß2, IFN-γ, and neopterin plasma
levels in patients with TG therapy (n=17). Matched patients without TG
therapy served as controls.
Results: One week posttransplant, total lymphocyte counts (p=0.001), CD3+
(p=0.001), CD4+ (p=0.0002), CD4+DR+ (p=0.002), and CD16+ (p=0.001)
cells were significantly lower in TG+ than TG- patients. One month
posttransplant, TG+ patients still had slightly lower total lymphocyte counts
(p=0.008), CD3+ cells (p=0.017), CD4+ (p=0.006), CD3+DR+ (p=0.045),
and CD19+ (p=0.011) cells than TG- patients. Although TG+ and TGpatients had similar plasma levels of the different cytokines pretransplant
(p=n.s.), one week (p=n.s.) and one month posttransplant (p=n.s.), changes
of cytokine plasma levels during the posttransplant course in the two patient
groups were significantly different. TG+ patients had similar cytokine levels
pre- and one week posttransplant (p=n.s.), whereas in TG- patients sIL-1RA
(p=0.007) decreased and sIL-6R (p=0.002) increased during that time period.
These results suggest that posttransplant sIL-6R production is reduced in
TG+ patients. One month posttransplant, plasma IFN-γ (p=0.003) in TG+
patients, and sIL-2R (p=0.003) and TGF-ß (p=0.008) plasma levels in TGpatients, were significantly lower than pretransplant.
Conclusion: Our data indicate that TG as induction therapy reduces T cell
subsets and inhibits inflammatory cytokines, including the release of IFN-γ and
sIL-6R, during the first posttransplant month.
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1954 T10B9 MONOCLONAL ANTIBODY: SHORT ACTING
NON-STIMULATING MONOCLONAL ANTIBODY THT SPARES
GAMMA DELTA T-CELLS AND TREATS AND PREVENTS
CELLULAR REJECTION.
J. Thompson, T. Waid1, M. Siemionow2, S. Brown1
University of Kentucky, 2Cleveland Clinic
T10B9.1A-31/MEDI-500/TOLERA-101 is a non-mitogenic IgM kappa
murine monoclonal antibody (mAb) directed against the alpha-beta (¥á-©¬)
heterodimer of the T-lymphocyte receptor complex. The clones were first
produced by fusing spleen cells from BALB/C mice immunized with human
peripheral blood T-lymphocytes with SP2/O-Ag14 mutant myeloma cells.
The small mAb is produced and purified using multi-step ion exchange and
molecular sieve chromatography protocols.
T10B9 has been used successfully to treat acute cellular rejection in renal
transplantation and as an immunosuppression induction agent in heart and
simultaneous kidney-pancreas transplantation. Because T10B9 is nonmitogenic and causes minimal cytokine release, both treatment of rejection
and induction of immunosuppression were accomplished with significantly
fewer and milder untoward effects (cytokine release syndrome) than its
comparator OKT3.
Since T10B9 is directed against the ¥á-©¬ heterodimer of the CD3 epitope, it
spares the gamma delta (¥ã¥ä) region. These gamma delta (¥ã¥ä) T cells have
a unique role in the immune response controlling many serious human diseases
and perhaps facilitating the development of immunologic tolerance.
T10B9 has a relatively short duration of action, depleting T cells for only
10 to 14 days, unlike the protracted depletion seen with thymoglobulin
and CAMPATH 1-H. There is no B-lymphocyte depletion with T10B9 as
there is with both of the aforementioned reagents. The lack of prolonged
lymphocyte depletion may account for less infection observed with
T10B9 treatment.
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POSTER BOARD NUMBER P4 – 05
1955 EFFICACY AND SAFETY OF SINGLE BOLUS
ANTITHYMOCYTE GLOBULIN INDUCTION TREATMENT
AFTER RENAL TRANSPLANTATION
Z. Nikolic2, D. Radivojevic-Djokic1, R. Blagojevic-Lazic1, S. Ristic1,
V. Lezaic1
1
Clinical Centre of Serbia, Department of Nephrology, 2Fresenius Biotech
Background: Antithymocyte globulins have been used as induction agents
after organ transplantation for many years, but there are concerns with costs,
adverse events, and the inconvenience of repeated dosing via a central vein.
The aim of this 1-year, open-label, randomized trial was to compare the
safety and efficacy of antithymocyte globulin (ATG)-Fresenius for 1- year
graft function and prevention of acute rejection (AR) in living related renal
transplant recipients given in different dosage.
Method: During 2005-2006, 41 patients were randomized to single (9 mg/ kg
b.w.) dose ATG (group 1, consisted of 8 patients) or continued ATG treatment (3
mg/kg b.w.) for next four days (group 2, consisted of 33 patients). Maintenance
immunosuppression consisted of cyclosporine (Neoral, CsA) or tacrolimus
(Prograf-Tac), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids.
CsA (6.0 mg/kg b.w.) or Tac (0.15 mg/kg/b.w.) was introduced in the first
(group 1) or the forth day (group 2) after transplantation.
Results: Demographic characteristics of both donor and recipient were
similar between two groups (age, gender, underlying kidney disease, period
on dialysis). Pre-emptive transplantation was performed in ten patients: one
from group 1,and 9 from group 2. All the patients received blood transfusion
before transplantation however 13 group 2 patients were transfusion naïve.
Immunological risk was similar in both groups (ABO and HLA mismatches
between donor and recipient, panel reactive antibody- PRA, and response in
mixed lymphocyte culture). Graft function was established immediately in
all but two patients from group 2 who had slow graft function. Nevertheless,
graft function maintained similarly until the end of the first year after
transplantation (clearance of creatinine 57.4±17.1 ml/min for group 1 vs.
56.7±20.8 ml/min for group 2, serum creatinine 136.0±21.4 vs 138.4±33
micromol/L). Only one patient from group 1 had suspected AR in the first

month after transplantation (12.5%). The rate of biopsy-proven AR was
36.4% in group 2 (the mean time to rejection was 2.9 months). All AR were
steroid-sensitive and graft function recovered fully. Five-day ATG treatment
was associated with leucopenia in 5 patients, which required stimulating
agent treatment (Neupogen), while three patients had infections (CMV and
bacterial urinary tract infection). At the end of the first year, slight proteinuria
(less than 1 g/day) was noted in four patients from group 1 and 20 patients
from group 2. Among the latter group three patients had proteinuria above 1
g/day (maximum 3.6 g/day).
Conclusions: Single dose ATG is safe and equally efficient as repeated ATG
doses after renal transplantation. Also, it is efficient in prevention of acute
rejection episodes in renal transplant patients.

POSTER BOARD NUMBER P4 – 06
1956 CLINICAL OBSERVATIONS WITH INDUCTION
REGIMENS IN RENAL TRANSPLANTATION
D. Mital, R. Nubani, S. Jensik, S. Saltzberg, M. DyLiacco, E. Chan,
F. Dodson
Rush University Medical Center
Purpose: The use of induction therapy in our center has evolved over the past 5
years based on results from the literature. This retrospective review is designed
to examine and compare the short-term and long-term outcomes of various
induction therapies in a heterogeneous group of renal transplant recipients.
Methods: This is a single center retrospective review of 151 consecutive
unselected renal transplant recipients between 1/03/04 and 12/31/04. All
patients have completed at least 3 year follow-up. In this cohort, 50 patients
received alemtuzumab, 65 received Thymoglobulin, 17 received basiliximab,
and 19 received steroids alone as induction. Baseline characteristics and
transplant outcomes were analyzed and compared among the four groups.
Multivariate analyses using Cox regression were performed to identify risk
factors for acute rejection, graft loss, and death.
Results: All patients had at least one high donor or recipient risk factor.
There were no differences in recipient and donor demographics and transplant
characteristics among the groups except for older donors, longer cold ischemia
times, more extended criteria donors, and more pumped kidneys in the
Thymoglobulin group. The incidences of early (90 days) death and graft loss,
especially from thrombosis, were higher in the alemtuzumab group compared
to the other three groups. At 3 years, basiliximab treated patients had the highest
rate of acute rejection and graft failure. Thymoglobulin treated patients had
the highest graft survival rate. There were no differences in the incidence of
infection, hospital readmissions, and serum creatinine among the three groups
at 3 years.
Steroids

Alemtuzumab

Basiliximab

Thymoglobulin

n=19

n=50

n=17

n=65

p-value

3 Year Outcomes
Death

5.3%

6.0%

0.0%

3.1%

0.6912

Graft loss

10.5%

16.0%

35.3%

6.2%

0.0148

Acute rejection*

31.6%

16.0%

47.1%

38.5%

0.0296

Includes both clinical and biopsy-proven acute rejection
Multivariate analyses were performed to identify independent risk factors for
adverse outcomes after adjustment of various cofounders. The use of extended
criteria donor (HR 2.944, p=0.013) and DGF (HR 2.053, p=0.045) were the
only independent risk factors that were found to be associated with increase
risk of acute rejection. The use of ECD (HR 4.274, p=0.0399) and DGF (HR
6.405, p<0.001) were both associated with increase risk of graft failure, while
Thymoglobulin was associated with a decrease risk of graft failure (HR 0.318,
p=0.028). None of the risk factors evaluated was found to be an independent
risk factor for death.
Conclusions: In our clinical experience, alemtuzumab induction was associated
with an unexpectedly high incidence of early graft failure and basiliximab was
associated with high incidence of late acute rejection and graft failure in this
relatively high risk transplant recipients. The use of ECD was associated with
increase risk of both acute rejection and graft failure. However, compared to
the other induction agents, the use of Thymoglobulin appeared to reduce the
risk of graft failure.
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1957 ANTITHYMOCYTE GLOBULIN VERSUS IL-2R
ANTAGONIST INDUCTION THERAPY IN FIRST CADAVERIC
KIDNEY TRANSPLANTATION
G. Vergoulas, G. Miserlis, I. Ioannidis, S. Karaba, P. Chatzimichailidou, A.
Papagiannis, V. Papanikolaou, D. Takoudas
Hippokrateio General Hospital of Thessaloniki
Background and objectives: Induction therapy reduces the frequency of acute
rejection in kidney transplantation and is used in patients with high probability
of delayed graft function (DGF). We compared retrospectively the safety
and efficacy of antithymocyte globulin (ATG)and antiinterleukin 2 receptor
antagonists (IL-2R ab) in patients with high risk of DGF who received a renal
allograft from a deceased donor.
Material and methods: From March 1989 to Sept 2004, 173 patients, 117 men,
with mean age 48 years, received a first cadaveric transplant with induction
therapy ATG (group A: 110 pts) or IL-2R ab (daclizumab or basiliximab, Group
B: 63 pts) and maintenance therapy involving steroids, mycophenolate mofetil/
azathioprine and CsA. Serum creatinine (Sc) of the 1st, 2nd, 3rd, 4th and 5th
post – transplant year, delayed graft function, cold ischemia time, days of first
hospitalization, were retrospectively studied. Patients under the age of 16, as
well as patients lost to follow up were not included in the study. End of the
follow up was 29 February 2008. Descriptive statistics, Kaplan Meier analysis
(Log rank, Breslow, Tarone Ware), t test, x square test and repeated measures
analysis were used.
Results: Patient survival at one and five year was 91.82%/81.82% for group
A and 88.89%/79.21% for group B respectively (p:NS). Graft survival at one
and five years was 83.64%/67.27% for group A and 85.71%/69.52% for group
B respectively (p: NS). Sc of the 1st and 5th year was 1,10±0.37/1.28±0.64
and 1,15±0.26/1.40±0.35 for group A and group B respectively (p: NS). There
was no significant difference on age, DGF, cold ischemia time and first patient
hospitalization.
Conclusions: Induction therapy with ATG and IL-2R abs does not present
differences on five year patient and graft survival. There is a tendency, not
significant, for lower Sc levels in the ATG group during time.

POSTER BOARD NUMBER P4 – 08
1958 COMPARISON OF OUTCOME WITH LOW-DOSE ANTITHYMOCYTE GLOBULIN, BASILIXIMAB OR NO ANTIBODY
INDUCTION THERAPY IN ADULT LIVING DONOR KIDNEY
RECIPIENTS

THURSDAY

P.W. Baron, J. Weissman, R. Ben-Youssef, E. Franco, A. Kore, A. Rashid,
O. Ojogho,
Loma Linda University Medical Center, Transplantation Institute
Background: Low-dose anti-thymocyte globulin (cumulative dose of 3-4.5
mg/kg of LDATG) has proven its safety and efficacy as an induction therapy in
both kidney and pancreas transplantation. We analyzed the clinical outcome of
LDATG in living donor kidney recipients.
Method: We retrospectively reviewed the data of 176 adults who underwent
living donor kidney transplant between Jan 2000 and Dec 2006. They were
divided into 3 groups based on their induction therapy. Sixty-nine patients treated
with LDATG were compared to 79 patients who received basiliximab (BASI)
and 28 patients who did not receive induction therapy (NAI). Donor and recipient
ages, and recipient ethnicity were comparable between the groups. All received
mycophenolate mofetil, calcineurin inhibitor and prednisone. We analyzed
PRA%, delayed graft function (DGF), serum creatinine at discharge (D/C) and
6 mo, acute rejection rate (AR), cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) infection rates, and graft and patient survival at 1 and 6 months
Results: The number of living unrelated donor kidney recipients, cold ischemia
time and PRA% were significantly higher in the LDATG group in comparison
to BASI and NAI groups (37.7%, 21.5%, and 10.7%, p = 0.01; 130 min, 94 min
and 52 min, p = <0.0001; 1726%, 616%, and 1.44%, p<0.0001). The cumulative
dose per LDATG patient was 4.050.75 mg/kg. Mean serum creatinine levels
at D/C, 1 mo, and 6 mo, DGF, AR, CMV, and EBV infection rates were not
significantly different among the groups (Table 1). Patient and graft survival
rates at 6 mo were 100% in all groups. No one developed posttransplant
lymphoproliferative disease.
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Table 1. Clinical outcome
Ser cr @ D/C (mg/dL)
Ser cr @ 1 mo (mg/dL)
Ser cr @ 6 mo (mg/dL)
DGF, n (%)
Cumulative AR @ 6 mo, n (%)
EBV infection @ 6 mo, n (%)
CMV infection @ 6 mo, n (%)

LDATG (n=69)
1.611.72
1.310.47
1.360.4
2(2.9)
7(10.1)
0
4(5.8)

BASI (n=79)
1.561.35
1.420.76
1.390.35
3(3.8)
5(6.3)
2(2.5)
2(2.5)

NAI (n=28)
1.611.14
1.551
1.420.56
1(3.6)
3(10.7)
0
2(7.1)

P-value
NS
NS
NS
NS
NS
NS
NS

Conclusion: These data showed that high immunologic risk living donor
kidney recipients treated with low dose anti-thymocyte globulin therapy
achieved excellent short-term clinical outcome compared to basiliximab and no
antibody induction therapy. Larger prospective randomized trials are warranted
to confirm these results.

POSTER BOARD NUMBER P4 – 09
1959 IS INDUCTION A NECESSARY STRATEGY FOR RENAL
TRANSPLANTATION?
R.C. Madarasu, S. Hussaini, V. Reddy, H.K. Marri, L. Guri,
S.B. Padabukkala
CARE Hospitals, The Institute of Medical Sciences
Between May 2004 and March 2008 a total of 72 renal transplants were
performed inour unit. Of this 09 were cadaver renal transplants, 19 were
spousal transplants and 44 were live related transplants.
There was no HLA match as expected in cadaver and spousal transplants.
All the recipients were on triple immunosuppression consisting of Tacrolimus
(or Cyclosporine), MMF and steroid. Expect for one pt in the cadaver group
and one who had live related Tx all other recipients received no induction
therapy.
Seven of the 72 recipients were HCV positive before Tx. Two of the 72
recipients were HBsAg positive before TX. Almost four years into our Tx
programme we find no added benefit of using induction even in unmatched
recipients and donors like cadver or spousal TX. With this strategy out of 72
transplants during this period only three patients had acute cellular rejection
which responded to pulse methyl prednisolone.
we conclude that induction is not a necessary strategy to improve renal transplants
outcomes in the first few years with routine use of triple immunosuppression
including MMF, Tacrolimus and steroid.

POSTER BOARD NUMBER P4 – 10
1960 SINGLE-DOSE INDUCTION WITH RABBIT ANTITHYMOCYTE GLOBULIN(RATG) SAFELY IMPROVES
RENAL ALLOGRAFT FUNCTION AND REDUCES CHRONIC
ALLOGRAFT NEPHROPATHY
R.B. Stevens, T. Rigley, J. Skorupa, K. Nielsen, L. Wrenshall
University of Nebraska Medical Center
We conducted a prospective, randomized trial in renal transplant recipients
comparing two dosing protocols [single dose (6mg/kg) vs. divided doses (1.5mg/
kg for 4 doses)] of rabbit anti-thymocyte globulin (rATG; Thymoglobulin).
We present herein the results of the first 142 patients [single dose (n = 70),
divided dose (n = 72)]. After a mean follow-up of 16.2 ± 10.9 months, there
were no significant differences between groups in adverse events related to
rATG infusion, patient and graft survival, and biopsy-proven acute rejection.
Estimated glomerular filtration rate (eGFR) on day 4 was significantly higher
in the single-dose group than in the divided-dose group (50.0 ± 24.8 vs. 41.2
± 25.7ml/min/1.73, p = 0.05), and the rate of improvement in eGFR from day
1 to 4 was significantly greater (p = 0.02). Throughout the first 6 months posttransplantation, recipients of kidneys from non-marginal deceased donors
derived the greatest benefit in renal function (eGFR) from the single-dose
regimen (p = 0.006). The incidence of chronic allograft nephropathy (CAN)
was also lower in the single-dose group, in both clinically-indicated and
protocol biopsies combined (p = 0.045) and in 12-month protocol biopsies
alone (p = 0.05). This study demonstrates that administration of 6mg/kg rATG
as a single 24-hour infusion is safe and is associated with better renal function
than conventional administration in divided doses.
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1961 ATG INDUCTION IN RENAL TRANSPLANTATION –
A SINGLE CENTER EXPERIENCE
D. Khullar, J. Gaikwad, M. Malik, S. Ojha, A. Gupta, A.K. Bhalla, D.S. Rana,
S. Chadha, H. Jauhari
Sir Ganga Ram Hospital
Introduction: Polyclonal antithymocyte globulin used effectively as an
induction agent in kidney transplantation produces a profound and durable
lymphopenia that lasts beyond one year & has been found to be safe &
effective.
In this prospective, randomized study we share our experience of using rabbit
ATG (r-ATG) as induction therapy in living donor renal transplantation carried
out at our centre between 2005 & 2007.
Material & Methods: 37 kidney transplant recipients received r-ATG in the
dose ranging from 1-1.5 mg/kg body weight per dose in addition to maintenance
immunosuppression consisting of tacrolimus, MMF and prednisolone.
33 patients received 2 doses each of r-ATG while 4 received 3 doses of ATG.
Tacrolimus was started in the dose of 0.1mg/kg & the dose adjusted to
maintain target levels of 8-10 ng/ml & 6-8 ng/ml during the first month post
transplantation & 1-3 months respectively & 4-6ng/ml thereafter.
Mycophenolate mofetil was used in the dosage of 1- 1.5 gm daily in divided
dosages while prednisolone started as 0.5 mg/kg per day was tapered to 5 mg/
day at three months. Valganciclovir and cotrimoxazole prophylaxis was started
in all the patients as soon as the graft function normalized
Results: The mean age of recipients & donors was 42 ± 9 and 47 ± 12 years
respectively.
Six antigen HLA mismatch was present in 9, five antigen mismatch in 9, four
in 6, while 9 were haploidentical & two antigen mismatch was found in 4
patients.
The mean CD3 count on Day 0 was 513.5 ± 443.9 which decreased to 36.8 ±
54.73 on Day 3 & at one year was 186 cells ± 83.7cells/μl which suggested a
sustained response. The mean CD4 count on Day 0 was 244 ± 249.8 which
decreased to 17.2 ± 29.6 on Day 3 & 100 ± 97.9cells/μl at one year
The mean CD8 count on Day 0 was 227 ±180.9 which decreased to 16.1 ± 26.2
on Day 3 and 65.3 ± 40.4cells/μl at one year.
No significant leucopenia, thrombocytopenia or allergic reactions were
encountered.
One year patient as well as graft survival was 97.2%.
Two patients (5.4%) had biopsy proven acute rejections which were steroid
responsive.
Mean serum creatinine was 1.94 ± 1.32 on day 3, 1.50 ± 0.31 on day 30, &
1.60 ± 0.28 mg/dl at one year. Infectious complications seen during the study
period were CMV disease in 2 patients (5.4%), UTI in 3 patients (8.1%) &
Herpes zoster in 2 patients (5.4%).All recovered with treatment.Six patients
had new onset diabetes mellitus (16%). None of the patients developed cancer
during this period.
Conclusions: Induction therapy with r-ATG is safe & efficacious. The severity
and incidence of acute rejection was found to be low. The risk of infective
complications can be decreased by use of appropriate prophylaxis. It is possible
to maintain low dosages of calcineurin inhibitors & corticosteroids under the
effect of ATG induction without any rise in the incidence of acute rejection
thereby possibly decreasing the incidence of long term side effects associated
with them.

POSTER BOARD NUMBER P4 – 12
1962 OUR EXPERIENCE OF RABBIT ANTITHYMOCYTE
GLOBULIN INDUCTION IN RENAL TRANSPLANTATION AND
COMPARISON WITH IL-2 RECEPTOR BLOCKERS
A. Dutta1, K. Sengupta, S. Nandi
1
Wockhardt Hospital & Kidney Institute, Kolkata, India, 2Wockhardt Hospital
& Kidney Institute, Kolkata, India, 3Wockhardt Hospital & Kidney Institute,
Kolkata, India
Introduction: Antithymocyte Globulin (ATG) induction in renal transplantation,
have been used sparingly in India primarily due to concerns regarding infective
risks as Gancyclovir prophylaxis is unaffordable. A recent trial (Brennan D
C et al, NEJM 2006), which showed no major difference in the risk profile,
prompted us to do this study.
Aims & objectives: To study the efficacy & safety of rATG induction in renal
transplant recipients with particular reference to CMV & non CMV viral
infections and compare the results with that of IL-2 receptor blockers.
Materials & Methods: We studied 22 renal allograft recipients who received
induction therapy with rabbit ATG (Dose: 1.25 – 1.5 mg/kg, 2-3 days) between
September 2006 and February 2008 and compared with other 2 groups (15
patients each) who had received either Basiliximab or Daclizumab as induction
therapy at our center. All the recipients in the ATG group received Tacrolimus,
MMF, Prednisolone as maintenance immunosuppression.
Results: In the rATG group, the median age of the recipients was 35.7 yrs,
& that of the donors was 40.1 yrs. Of the donors there were 8 spouses, 12
first degree relatives and 2 were unrelated. 54.5% of patients (12/22) had
HLA mismatch of 5 or more & 31.8% (7/22) had mismatch of 3 – 4. CMV
seropositivity: 72.7% (16/22) were D+/R+; 18.1% (4/22) were D+/R-. The
HLA matching & CMV seropositivity were comparable in the three groups.
Prophylactic Acyclovir & Trimethoprim – Sulphamethoxazole were given in
all the patients. Renal function was stable at the end of 1 month, 6 months
& 12 months. No incidence of acute rejection or delayed graft function
was noted. There was no incidence of thrombocytopenia or leucopenia. No
incidence of CMV or non CMV viral infection were noted in follow up of
total 174 patient months. Fifteen patients have completed 6 months. Among
the adverse events, there were 5 episodes of UTI, 2 instances of PTDM.
The observations were similar in the other 2 groups who had received either
Basiliximab or Daclizumab as induction therapy. The overall cost of ATG is
20% less compared to IL2 receptor blockers.
Conclusion: In our study, use of rATG as induction therapy was found to be
effective and safe even without Gancyclovir prophylaxis despite seropositivity
and HLA mismatches. A lower net immunosuppression (lower Tacrolimus
dosing, steroid minimization) made possible by induction therapy may have
contributed.

CONCURRENT ORAL SESSION 136: MISCELLANEOUS
IMMUNOSUPPRESSION
POSTER BOARD NUMBER P4 – 13
1963 AUTOIMMUNITY IN RENAL TRANSPLANT PATIENTS
J. Klassen
Foothills Medical Centrel
The recurrence of certain putative autoimmune glomerular diseases in renal
transplants is well known. It is also common knowledge that systemic lupus
erythematosus does not recur to any significant degree in renal patients, who
had SLE glomerular disease as a cause of their end stage renal disease. The
occurrence of other autoimmune diseases is not well described. I would like to
present three such cases that had excellent renal function for 10-15 years out of
a group of 250 long-term renal transplant patients, with functioning transplants
who developed classical primary autoimmune disease: One with multifocal
acquired demyelinating sensory and motor neuropathy, one with classical
temporal arteritis, and one with mononeuritis multiplex. I also successfully
treated a stable heart transplant recipient for leucocytoclastic vasculitis 17
years after her heart transplant. The possible explanations for these diseases
occurring in an immunosuppressed host will be discussed.
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1964 SUCCESSFUL RENAL TRANSPLANTATION FOR
PATIENT WITH PYODERMA GANGRENOSUM
T. Fujita, S. Ishida, T. Shimoji, T. Kimura, M. Kato, Y. Tsuji, T. Kinukawa
Chukyo Hospital
Pyoderma Gangrenosum (PG) is a rare skin disease of unknown etiology which
forms intractable skin ulcers on surgical sites or traumatic sites. The case is a
39 years old woman with PG who became end-stage renal disease from type
1 diabetes mellitus. Creation of arteriovenous fistula (AVF) and insertion of
peritoneal dialysis catheter were considered to be difficult and risky, because
severe ulceration was observed on surgical site of AVF previously. Therefore
the patient received dialysis continuously by using central venous catheter,
changing access points of the catheter-insertion for central venous. But it
became difficult gradually due to venous stenosis because of frequent central
venous accesses. Therefore considering of renal transplant became necessary
as a lifesaving measure. We performed living renal transplant, after controlled
ulcers with steroid that were formed on previous surgical sites of trigger finger,
appendicitis and AVF. Induction immunotherapy was started with tacrolimus,
mycophenolate mofetil, steroids and basiliximab. Intravenous pulse of
methylprednisolone was performed to prevent ulceration of the surgical site on
day 0-2. Postoperative course was good and ulceration on surgical site of renal
transplant was not observed. To our knowledge, renal transplant for patients
with PG has not been reported previously, but only 2 cases of liver transplant
reported.

to BKV infection and one after 12 months due to CMV infection. Three
patients experienced acute rejections and eight of the ten patients experienced
one or several infectious complications. One patient discontinued all
immunosuppressive drugs except prednisone after 34 months due to intolerable
side effects but still maintains a good and stable graft function at 40 months
post transplant on Prednisone 5 mg daily only.
Control group: No graft losses occurred in the control group. One patient died
with a functioning graft 12 months post transplant. Four patients experienced
acute rejections and seven patients experienced one or several infectious
complications.
Conclusion: We conclude that photopheresis treatment did not prevent acute
rejection after kidney transplantation in this group of patients. Since patients
with ongoing acute cellular rejection that was refractory to conventional
treatment were successfully treated with photopheresis in the pilot study, we
also conclude that the immune system must be more activated than in the
present group of patients in order to achieve an immunomodulatory effect from
photopheresis treatment.
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1965 PHOTOPHERESIS AS PREVENTION FOR ACUTE
REJECTION AFTER KIDNEY TRANSPLANTATION – A CASE
CONTROL STUDY WITH A 2-YEAR FOLLOW-UP
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G. Kumlien1, H. Genberg2, G. Tydén2
1
Dept of Clin Immunol and Transfusion Medicine, Karolinska University
Hospital Huddinge, 2Dept of Transplantation Surgery, Karolinska University
Hospital Huddinge
Background: We have previously published a pilot study (Photopheresis
for the Treatment of Refractory Renal Graft Rejection, Transplantation
2005;79(1):123-5. Kumlien G et al) with seven consecutive patients with
ongoing biopsy-proven acute cellular kidney graft rejection that was refractory
to treatment with steroids and monoclonal antibodies (OKT3 or ATG) but was
successfully treated with photopheresis.
In the present study we wanted to investigate if photopheresis can be used to
prevent rejection after kidney transplantation.
Method: Between October 2004 and October 2005 ten patients receiving first
time kidney grafts from cadaveric donors were treated with photopheresis on
days +5, +6, +10, +11, +17, +18, +27, and +28. No patient showed clinical
signs of rejection at the time of the photopheresis treatment. Immunosuppression
was given with tacrolimus, azathioprine and prednisolone. Only patients
with existing suitable vascular access for apheresis were included in the
photopheresis group. For the photopheresis treatment, mononuclear cells were
collected using Cobe Spectra apheresis machine (Gambro BCT, Lakewood,
CO, USA). Apheresis products were treated with psoralen (8-methoxypsoralen
200 ng/ml) plus UVA-irradiation, UVA 365 nm, 2 J/cm2, (BioGenic, Vilber
Lourmat, Marne-la-Vallée, France) and subsequently retransfused to the
patients.
During this period ten other patients received first time kidney grafts from
cadaveric donors and the same immunosuppressive protocol (tacrolimus,
azahioprine and prednisolone) at our center. These ten patients either lacked
suitable vascular access for apheresis or declined to be included in the
treatment group, and they constitute the control group. Only patients receiving
other immunosuppressive protocols or kidneys from living donors were
excluded from the study. We have chosen to study patients receiving kidneys
from cadaveric donors since these patients more frequently experience acute
rejection episodes than patients receiving kidneys from living donors.
Results: Event free survival time (time to first rejection, graft loss or death)
was not significantly different in the two groups (Fishers´ two-sided exact test
n.s., p=0.65) (see Figure). Follow-up was 28-40 months in both groups.
Photopheresis group: Two patients lost their grafts, one after 10 months due
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POSTER BOARD NUMBER P4 – 16
1966 INDUCTION IMMUNOTHERAPY WITH RITUXIMAB IN
HIGHLY SENSITIZED KIDNEY TRANSPLANT PATIENT
S.C. Park, J.I. Kim, C-W. Yang, I.S. Moon
The Catholic University of Korea, Kangnam St. Mary’s Hospital
The transplantation in highly sensitized patient is one of the major concerns in
kidney transplantation. The development of new immunosuppressive agents is
designed to reduce the early acute post-transplant rejection. Recently, several
new protocols have been developed to allow the transplantation of highly
sensitized patients. One potential target for more specific immunosuppressive
therapy with monoclonal antibodies is appeared to be effective, less toxic than
the oral long-term maintenance agents and well-tolerated in kidney transplant
recipients. Rituximab is a high-affinity CD 20 specific antibody that depletes the
B-cell compartment by inducing cellular apoptosis. We successfully performed
kidney transplantation in high sensitized patients and we report our experience
with rituximab induction protocol involving pretransplant plasmapheresis,
intravenous immunoglobulin. One case was a 43 year-old man for third kidney
transplantation with high panel-reactive antibodies (PRA class I: 96.4%, class
II: 58.3%) and positive flow cytometric crossmatch (T: 15%, B: 10%). Another
case was 51 year-old woman with donor specific antibody positive (anti-A11,
anti-A33), high panel-reactive antibodies (PRA class I: 39.3%, class II: 33.3%)
and positive flowcytometric crossmatch. Preoperative Rituximab induction
therapy is effective in high risk kidney transplant patients but we must keep in
mind that rituximab is associated with a high rate of infectious complications.
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1967 ELIMINATION OF IMMUNOSUPPRESSION IN KIDNEY
TRANSPLANTATION FOLLOWING SUCCESSFUL BONE
MARROW TRANSPLANTATION IN FANCONI’S ANEMIA
R. Kadiyala, M. Eng, R. Nagubandi, M. Marvin, J. Buell
Transplant Center, Jewish Hospital, University of Louisville, KY, USA
Introduction: Fanconi’s anemia is an autosomal recessive condition causing
bone marrow failure and renal dysfunction with an increased incidence of
leukemias and solid tumors. Bone marrow transplant repairs the hematological
problem but the risks of neoplasia persist. Avoidance of immunosuppression in
this patient population may be crucial to prevent onset of neoplasia. We report
a case of successful elimination of immunosuppression in a patient with treated
Fanconi’s anemia who required a subsequent kidney transplant.
Patient & Results: A 21 year old woman with Fanconi’s anemia and renal
failure was evaluated for a live donor kidney transplant from her sibling. The
patient had received matched stem cell transplant with cord blood transfusion
from the same sibling at 4 years of age. She had received conditioning with
cyclophosphamide and thoraco-abdominal radiation prior to the successful
stem cell transplant. Her anemia was cured but the renal disease progressed
to end stage renal failure at the age of 20 years. She was evaluated for kidney
transplantation and the sibling who donated the stem cells was evaluated
and found suitable to be a live donor. Bone marrow engraftment analysis by
STR revealed the patient to have 100% donor cells. With the presence of
complete marrow identity the patient underwent live donor renal transplant
from her sibling in July 2006. No immunosuppression was used either in the
perioperative period or since. The transplant procedure was successful and the
patient has normal renal function at a follow-up of 18 months.
Conclusions: This report highlights a unique immunological situation where a
patient with Fanconi’s syndrome had a prior stem cell transplant with complete
engraftment of her marrow with the donor cells. This facilitated subsequent
kidney transplantation 17 years later from the same donor without any
immunosuppression. The elimination of immunosuppression has the potential
benefit of not escalating her predisposition to development of cancers due to
the underlying Fanconi’s syndrome.

POSTER BOARD NUMBER P4 – 18
1968 ASSOCIATION OF HIGH IFN-G PLASMA LEVELS WITH
LOW B CELL COUNTS IN RENAL TRANSPLANT RECIPIENTS
WITH STABLE GRAFT FUNCTION LATE POSTTRANSPLANT.
V. Daniel1, C. Naujokat1, M. Sadeghi1, R. Weimer2, F. Renner2, S. Yildiz2, G.
Opelz1
1
Department of Transplantation-Immunology, Institute of Immunology,
University of Heidelberg, Germany, 2Department of Internal Medicine,
University of Giessen, Germany
Objective: Recently, we reported that patients with long-term stable good graft
function have higher interferon-gamma (IFN-g) and lower interleukin-4 (IL-4)
plasma levels late than early posttransplant. These patients had more often
detectable CD3+CD4+CD25+IFN-g+Foxp3+ peripheral blood lymphocytes
(PBL) late posttransplant than patients with impaired graft function. We
therefore speculated that high plasma IFN-g late posttransplant might contribute
to the maintenance of graft acceptance.
Methods: Using ELISA and four-color flow cytometry, plasma cytokines
and PBL subpopulations were measured in 65 renal transplant recipients with
stable graft function late posttransplant (mean+/-SD: 1755+/-1476 days; serum
creatinine: 2.0+/-0.8 mg/dl).
Results: High IFN-g plasma levels were strongly associated with low CD19+ B
PBL (r=-0.329; p=0.009) and low activated CD3+CD8+DR+ T PBL (r=-0.266;
p=0.035). Thus our data demonstrate an association of high plasma IFN-g
with low B cells and low levels of activated cytotoxic T cells. Plasma IFN-g
increased with time posttransplant (r=0.288; p=0.022) and was not associated
with the dosis of immunosuppressive drugs (p=n.s.). High plasma IFN-g
was not associated with serum creatinine (r=0.038; p=0.765), indicating that
high plasma IFN-g does not originate from accumulation or from an immune
response against the graft. Serum creatinine was neither associated with
CD19+ B PBL counts (r=0.038; p=0.764) nor with the dosis or blood levels
of calcineurin inhibitors or MMF (p=n.s.). Five patients showed evidence

of biopsy-proven chronic allograft nephropathy and none of them exhibited
increased plasma IFN-g.
Conclusion: In patients with good long-term graft function, high IFN-g
plasma levels were associated with low numbers of B PBL and activated CD8+
T PBL. These low B and T cell counts might be involved in preventing the
development of an immunological alloresponse against the graft and support
the maintenance of graft acceptance.

POSTER BOARD NUMBER P4 – 19
1969 STEROID-FREE IMMUNOSUPPRESSION FOR KIDNEY
TRANSPLANTATION IN BIPOLAR DISEASE LITHIUM
TOXICITY
M.l. Shapiro1, J. Abra2
1
Touro University College of Medicine, 2Hackensack University Medical
Center
Lithium carbonate, often used for the treatment of bipolar disorder, can
frequently cause renal disease (nephrogenic diabetes insipidus, interstitial
nephritis) and may occasionally result in chronic renal failure. Management of
transplant recipients with bipolar disorder is complicated by their psychiatric
disease, and exacerbated by chronic steroid administration. The use of a rapid
steroid taper has permitted successful renal transplantation in these patients.
Between 1/2000 and 2/2008, 18 patients with CKD secondary to lithium
toxicity were listed for renal transplantation at a single center. Six patients,
multiply listed, were transplanted elsewhere, Two patients died waiting, and
three continue to wait. Seven patients were transplanted at our center; one has
been lost to follow-up. The remaining six patients are the subject of this report.
Mean age was 60 (range 56-65). Two were living donor recipients; four received
deceased donor grafts. All were treated with an anti-IL-2 receptor antibody,
calcineurin inhibitor (Csa, 4; tac, 2), MMF and a 5-day steroid taper (500, 250,
125, 60, 30 mg). There were no episodes of acute rejection, and no subsequent
use of corticosteroids. Patient and graft survival, at 2 mos to 8 years is 100%.
Mean creatinine at one and three years is 1.3 mg/dl (range 0.7-1.9) and 1.45
mg/dl (1.0 to 1.8). No patient has subsequently required psychiatric admission.
Only one patient, who was taking lithium to the day of transplantation, required
re-institution of lithium therapy post-transplantation for severe depression. All
others have been adequately maintained on other psychotropic medications.
Patients with renal failure secondary to lithium toxicity can be successfully
transplanted without long-term steroid use, and without major psychiatric
exacerbation.

POSTER BOARD NUMBER P4 – 20
1970 TWO DOSE DACLIZUMAB IN PREVENTION OF ACUTE
REJECTION IN LIVE DONOR KIDNEY TRANSPLANTATIONS
D.S. Ray
Armenian Church Trauma Centre
Aim: Daclizumab induction has shown to reduce incidence of acute rejection.
Since, conventional five doses of Daclizumab is expensive, we tried two doses
of Daclizumab as induction therapy to find out its effect in incidence of early
acute rejection.
Methods: Fourteen patients received Daclizumab in a dose of 1 mg/
kg body weight on Day 0 and Day 14 as induction therapy besides their
immunosuppressive medicines in the form of steroids, Techrolimus and
Mycophenolate. They were compared with seventeen patients who received
only steroids, Techrolimus and Mycophenolate. Incidence of acute rejection
and side-effects were observed for a period of six months.
Observation: Both the groups were more or less comparable as for the age, sex,
aetiology of kidney disease and HLA mismatch between donors and recipients.
In the Daclizumab induction group there was no acute rejection over a period
of six months. But, three patients had significant infections (Herpis simplex of
G.I. tract in one, recurrent urinary tract infection in one and CMV disease in
one).In the control group there were four acute rejections(three were steroidresponsive and one with acute vascular rejection did not respond to steroid or
OKT3). One patient in the control group had CMV disease.
Conclusion: Two doses of Daclizumab (I mg/kg body weight) as induction
therapy significantly reduces the incidence of early Acute Rejection.
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POSTER BOARD NUMBER P4 – 21
1971 TWO-DOSE DACLIZUMAB PROVIDES EFFECTIVE
INDUCTION IMMUNOSUPPRESSION IN KIDNEY
TRANSPLANTATION
J. Wynn1, D. Siler2, R. Cannon1, T. Merchen1, M. Jagadeesan1, . Mulloy1,
D. Willia3, D. Vasil3
1
Medical College of Georgia, 2College of Pharmacy, University of Georgia,
3
MCG Health
Anti-IL2r antibody provides effective induction immunosuppression in kidney
transplantation. Basiliximab (BAS) is generally given on transplant days 0 and
4, while daclizumab (DAC) typically requires a much longer course of therapy.
Two-dose DAC therapy is much less costly than BAS, but is unclear whether it
is as effective in preventing acute rejection as BAS. We began to preferentially
use two DAC therapy in mid-2006, and report our initial experience herein.
Methods: Patient charts and our transplant database were reviewed
retrospectively. Differences in proportions were assessed with Chi-square while
differences in means were assessed with one-way ANOVA. Survival analysis
was conducted using Kaplan-Meier, and logistic and Cox proportional hazards
regression were used to evaluate the impact of induction regimen on delayed
graft function (DGF) and acute rejection (AR), respectively.
Findings: 145 patients (92 white, 46 black, 5 other) received kidney transplants
between 4/2005 and 5/2007. Anti-IL2r therapy was given to 97 low-risk
recipients (65 BAS, 32 DAC) and thymoglobulin (THY) to 48 at higher risk of
rejection or delayed graft function. Steroids were aggressively withdrawn in all
patients beginning 1 month post-transplants.
92% of THY patients received deceased donor (DD) kidneys, compared to 72%
of BAS and 59% of DAC patients. There were no significant differences in
age, race, sex, BMI, renal failure etiology, PRA, cold ischemia time or warm
ischemia time between DAC and BAS groups. DGF was common in DD
recipients (47%) but did not vary among induction therapy groups.
The overall incidence of rejection was 17% in DD and 15% in LD recipients.
There was no association of induction therapy with rejection in either DD or
LD recipients when analyzed by Kaplan-Meier or Cox. Serum creatinine was
not different in the three induction groups up to 12 months, and prednisone
withdrawal was equally successful in all between groups (mean dose at 6
months = 3.4mg/day for BAS and 2.6mg/day for DAC).
Conclusion: A short course of daclizumab is effective in preventing acute
kidney allograft rejection.

POSTER BOARD NUMBER P4 – 22
1972 KIDNEY TRANSPLANTATION WITHOUT ANTIBODY
INDUCTION THERAPY: A SINGLE CENTER EXPERIENCE

THURSDAY

P. Patel, S. Katznelson, L. Bohannon, V.R. Peddi, W. Bry, A. Hassoun,
H. Mahanty, V. Warvariv, K. Ueda
California Pacific Medical Center
Background And Aim: Although most centers currently use some form of
antibody induction therapy for immunosuppression in kidney transplant
recipients, it remains unclear if all patients require such therapy. Often at our
center, low immunologic risk recipients or recipients of allografts expected
to have immediate function (e.g. short cold ischemia times, non-ECD or
DCD grafts) do not receive antibody induction therapy. This study aims to
evaluate patient outcomes in recipients who did not receive antibody induction
immunosuppression.
Methods: From April 2002 to June 2004, 171 patients underwent kidney
transplantation without using antibody induction for immunosuppression. All
patients received intravenous steroids perioperatively and maintenance therapy
using mycophenolic acid, tacrolimus or cyclosporine, and prednisone.
Results: 104 patients received deceased donor transplants and 67 received live
donor transplants. Mean patient age at the time of transplantation was 48.5
years. Mean kidney cold ischemia time was 9.9 hours. At a follow up period of
one, three, and five years, acute rejection rates were 13.5%, 18.1%, and 20.4%,
respectively. Patient survival was 97.8%, 93.6%, and 89.5% at one, three, and
five years and graft survival was 95.3%, 87.7%, and 82.5% at one, three, and
five years. Mean serum creatinine levels at one, three, and five years were 1.5, 1.4,
and 1.3, respectively. At a mean follow-up of 4.6 years, 18 patients died, 11 with
a functioning allograft. Causes of death were MI (3), stroke (1), sepsis (2), cancer
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(1), pulmonary embolus (1), pneumonia (1), ARDS (2), surgical complication (1)
(this occurred 5 years post-transplantation), and unknown (6).
Conclusions: The optimal induction regimen for immunosuppression remains
controversial and most centers currently use some form of antibody induction
for all patients. Our experience suggests that a regimen avoiding antibody
induction therapy in a low risk population can still be a viable option, resulting
in acceptable long-term patient and allograft survival.

CONCURRENT ORAL SESSION 137: ALEMTUZUNAB
POSTER BOARD NUMBER P4 – 23
1973 CAMPATH 1H PRETREATMENT OF THE LIVE DONOR
KIDNEY GRAFT RECIPIENTS. DOES IT PROMOTE DONORSPECIFIC TOLERANCE?
N. Babenko, M. Kaabak, A. Maschan, A. Zokoev
Russian Scientific Center of Surgery RAMS
Costimulatory pathway (CD28-B7) is considered to play a key role in the
decision of the host immune system what to do with foreign antigen-bearing
cells – reject or accept. An attempts to create monoclonal antibodies, blocking
this pathway, clinically failed. Having in mind, that costimulatory pathway
is realizing mostly through the mesenhimal cells, as well as Campath-1H
capability to deplete these cells, we tried next hypothesis: Campath-1H infusion
2-3 week prior to transplantation will promote donor-specific tolerance.Patient
population: thirty patients (18 male), age from 0,7 to 52 years (16,2±13,3),
transplanted from September 2006 to May 2007. Diagnoses: chronic
glomerulonephritis – 10, hypoplasia – 8, obstructive uropathy – 6, congenital
nephritic syndrome – 4, HUS – 1, Alport syndrome – 1. Twenty-six patients
were dialyzed before transplantation within 0,7-52 month (11,3±13,6). Patients
were followed 282-541 days (419±79). All transplants were first and from live
donors, two were ABO incompatible (anti-A/B-antibodies titer 1:8 and 1:32
before transplantation).
Immunosupression protocol: independently of body weight 30 mg of Campath
1H was infused to all patients at 13-42 days prior to transplantation. Next 30
mg was given just before graft reperfusion, after bolus of methylprednisolone
10 mg/kg. After surgery steroids were given orally at dose 60 mg/m2 with rapid
taper down and withdrawal at day 14. Cyclosporine was given orally within
12 hours after surgery, with target trough level 100-200 first week, thereafter
75-150 and 50-100 ng/ml after one month. After one year CNIs considered to
be withdrawn. Decision was made by the comparison of two protocol biopsies
(see below). Mycophenolates were added after WBC recovery (2-6 month).
Follow up: besides routine kidney transplant patient monitoring we checked
their blood and urine for DNAs of CMV, EBV and BKV. Rising viral load was
a signal to decrease total amount of immunosupression. The graft biopsies were
taken per protocol 14 days and 1 year post transplant, as well as at the time of
graft dysfunction.
Results: one patient had delayed graft function (due to urinary tract clotting)
– 5 dialyses 11 days after surgery with creatinine drop below 3mg% at day
36. Eight patients developed acute rejection at 21-214 days post transplant
(94±63), which was borderline in 1 patient, 1a in 6 and 2a in one patient. Two
patients died 162 and 452 days post transplant from brain edema (7 month and
7 years at transplantation), developed due to improper fluid management during
acute urine outflow disorder (parent’s noncompliance). Uncensored KaplanMayer one-year graft and patient survival is 94,7%. In one patient (graft from
haploidentical mother) immunosupression was stepwise decreased until total
withdrawal at day 76, and this patient lives with excellent graft function and
without immunosupression already 16 month.
The change of graft function by comparison of CFR (Schwartz formula) and
proteinuria at discharge (38±19 days) and at the last control (419±79) was not
significant: 82±23 and 82±32 ml per min; 221±241 and 161±139 mg per day.
Immunosupression at the last control among 28 survived patients is follows:
CsA+MMF – 14, CsA+MMF+Pred – 4, MMF monotherapy – 3, Tacro+MMF – 2,
Tacro+MMF+Pred – 1, CsA+Pred – 1, Tacro monotherapy – 1, CsA monotherapy
– 1, nothing – 1. As listed above, 79% of patients are free of steroids.
Conclusion: the pretreatment of kidney allograft recipients with Campath
1-H 13-42 days before transplantation allows to reach satisfactory short-term
results with little immunosuppressive treatment and some patients develop
donor-specific tolerance. The available tools of tolerance diagnosis in clinical
practice need to be improved.
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1974 ALEMTUZUMAB (CAMPATH 1H) INDUCTION IN
EXTENDED CRITERIA DECEASED DONOR KIDNEY
TRANSPLANTATION: A SINGLE INSTITUTION EXPERIENCE
J. Gleason Jr, M. Eng, R. Kadiyala, A. Afanasyev, D. Woo, R. Nagubandi,
J. Buell
Transplant Center, Jewish Hospital, University of Louisville, Louisville, KY,
United States
Introduction: Alemtuzumab (Campath 1H) reduces the incidence of Acute
Cellular Rejection (ACR), presumably by allowing allograft tolerance, thus
permitting steroid free maintenance of deceased donor recipients.We present
our single institution experience with Campath 1H in Extended Criteria Donor
(ECD) Kidney Transplantation.
Protocol: Standard UNOS criteria were used in ECD donor selection. ECD
recipients were first time recipients over the age of 55 with a BMI under 35.
Preoperatively, recipients were given Campath 1H 30 mg iv once, Mycophenolate
mofetil 1gm. po bid or 1.5 gm. po bid if African American (AA). Solumedrol
500 mg. was given iv preoperatively and daily post operatively on days 1-3.
Tacrolimus (FK506), given bid, was started when graft function was present.
FK506 was monitored for trough levels of 8-10 ng/ml for the first three months
and then 6-8 ng/ml thereafter. Recipients were monitored for acute rejection
and post transplant complications by frequent laboratory evaluation and clinic
follow-up. Renal ultrasound and biopsy were performed for any unexplained
elevation of serum creatinine (CR).
Results: From 11/1/2004 to 12/30/2006, 13 patients received ECD Kidneys.
Characteristics of recipients included 11 Caucasians and 2 AA, mean age of 59
yrs., mean wt. of 189 lbs. and mean BMI of 28.4. Characteristics of the deceased
donors included mean age of 60 yrs. and mean terminal CR of 1.08 mg/dl. 6 of
13 recipients had delayed graft function, with recovery of graft function. Mean
recipient serum creatinine at twelve months was 1.78 mg/dl, with no incidence
ACR or humeral rejection in the first year of follow-up. One patient lost graft
function at 11 months after an Aortic valve replacement and coronary artery
bypass grafting. The biopsy showed chronic rejection. No incidence of CMV or
BK virus infection was documented. Readmits were otherwise minor.
Discussion: In this pilot experience, Campath 1H tends to be associated with
a lower incidence of ACR under a steroid-free regimen. Recipients of kidneys
from extended criteria donors induced with Campath 1H had good graft
function at 1 year.

POSTER BOARD NUMBER P4 – 25
1975 ALEMTUZUMAB INDUCTION WITH STEROID
SPARING IMMUNOSUPPRESSION IN HIGH RISK KIDNEY
TRANSPLANTATION
R. Kadiyala, R. Ouseph, M. Eng, M. Marvin, J. Gleason Jr, R. Nagubandi,
C. Stepp, J. Buell
Divisions of Transplantation and Nephrology, Jewish Hospital, University of
Louisville, KY, USA
AIntroduction: Alemtuzumab is widely used in steroid sparing
immunosuppression protocols. At our center a single dose of Alemtuzumab
has been used for induction in all kidney transplant recipients since December
2004.
Aim: To analyze the results of the use of Alemtuzumab in kidney transplantation
with emphasis on acute rejection, infectious complications and to compare the
low and high risk groups.
Methods: High risk was defined as Afro-Americans aged less than 40 years,
PRA > 20% and re-transplantation. All kidney recipients received a single 30
mg dose of Alemtuzumab during surgery and were maintained on Tacrolimus
(8-10 ng/ml for 6 months and 6-8 ng/ml later on) and Mycophenolate mofetil.
Three doses of steroids were used in the peri-operative period. A prospective
database was maintained. Chi square test was used for analysis.
Results: Between December 2004 and June 2007, 226 patients undergoing
kidney transplant received Alemtuzumab induction.
Comparison of high & low risk groups
High risk

Number
56

DGF
11/56

Acute rejection Infections
2/56
6/56

Creatinine at 1 year
1.68

Low risk
p-value

170

30/170
0.84

8/170
1.0

6/170
0.07

1.42
0.20

There were 56 and 170 patients in the high and low risk groups. The median
age was 44 and 53 years respectively. The median follow-up was 446 and 562
days respectively. The median serum creatinine at 12 months was 1.68 and 1.42
mg/dl; patient and graft survivals were 96.3 & 98.3% and 93.8% & 96.6% in
the high and low risk groups respectively. Delayed graft function (hemodialysis
post-transplant) was seen in 19.6% of the high risk group and in 17.6% in the
normal risk group (p =0.84). Acute cellular rejection developed in 3.6% and
4.7% in the two groups (p=1.0). No humoral rejection was seen.The incidence
of viral infections (CMV/BK) was 6/56 (10.7%) and 6/170 (3.5%,p=0.07).
Conclusions: Alemtuzumab induction proved extremely effective in an
unselected kidney transplant population with a low rate of acute rejection and
infectious complications. There was no significant difference in the patient/
graft survival, delayed graft function, acute rejection or complications between
the normal and high risk recipients. Steroid elimination with Alemtuzumab
induction is safe even in the immunological high risk category of patients.

POSTER BOARD NUMBER P4 – 26
1976 TRANSPLANTATION OF ACUTE RENAL FAILURE
KIDNEYS UNDER CAMPATH-1H INDUCTION WITH MINIMAL
POST-TRANSPLANT IMMUNOSUPPRESSION
S. Potdar1, J. Pennington, N. Carter, D. Redovian, H. Bonilla, C. Boshkos,
B. Eltayeb, S. Schmidt, W. Fallon
1
Summa Health System- Transplant Surgery, 2Summa Health SystemTransplant Surgery, 3Summa Health System- Transplant Surgery, 4Summa
Health System- Transplant Surgery, 5Summa Health System- Infectious
Disease, 6Summa Health System- Nephrology, 7Summa Health SystemNephrology, 8 Summa Health System- Surgical Research, 9 Summa Health
System- General Surgery
Background: The availability of optimal kidneys for transplantation is limited.
Most transplant surgeons will not accept kidneys from deceased donors with
acute renal failure because traditional regimens of immunosupression can
be problematic for outcomes using these kidneys. Prior studies have shown
that pre-treatment of recipients transplanted with kidneys from optimal
donors using Campath-1H induction followed by minimal post-transplant
immunosuppression (Starzl principle), results in excellent outcomes and we
have adopted this regimen as the standard of care in our transplant program.
We hypothesized that using these same principles, kidneys from deceased
donors with acute renal failure could also be successfully transplanted in
selected recipients. This report provides early results of outcomes in patients
transplanted with kidneys derived from donors with acute renal failure using
the Starzl principles of immunosuppression.
Methods: Kidneys obtained from deceased donors with acute renal failure were
considered for transplant if the following donor criterion were met: Donor age
¡Ü 50 years; no previous history of renal disease; and, negative pre-transplant
biopsy for structural changes except acute tubular necrosis (ATN). The
recipients all had BMI¡¯s less than 30 and were on chronic dialysis regimens.
The immunosuppression regimen consisted of Campath-IH (30mg x dose) for
induction immunosuppression followed by maintenance immunosuppression
with mycophenolate mofetil (1g every12 hours) and prednisone (20mg
daily). The prednisone was tapered by 2.5mg/week over 8 weeks and then
off. Mycophenolate mofetil was replaced by Tacrolimus once the recipient¡¯s
creatinine was less than 2 mg/dl. Post-transplant biopsies were performed as
clinically indicated.
Results: Over a 1 year period from March 2007 – March 2008, a total of 44
kidneys were transplanted using the Starzl principles of immunosupression
Nine (9) of these kidneys (24.5%) were obtained from donors with acute renal
failure. Donor ages ranged from 24-46 years with mean age of 37.6 years.
Donor creatinine on admission ranged from 0.8-2.3 mg/dl with mean of 1.26
mg/dl. Donor creatinine clearance on admission ranged from 68-208 mg/
dl with a mean of 102 mg/dl. Donor terminal creatinine ranged from 2.7-5.7
mg/dl with a mean of 3.63 mg/dl, and donor terminal creatinine clearance
ranged from 21-58 mg/dl with a mean of 38.3 mg/dl. All donor biopsies were
negative for chronic tubulointersitital disease and ATN was the most prevalent
change noted. Patient survival and graft survival are each 100% after 9 months.
Recipient mean serum creatinine is 1.5 mg/dl with a mean creatinine clearance
of 62.7mg/dl. No patients have exhibited biopsy proven rejection thus far
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during follow-up.
Conclusion: We have had excellent results transplanting kidneys from donors
with acute renal failure using Campath-1H induction with minimal posttransplant immunosupression. This regimen increased the availability of donor
kidneys by 24.5%. Minimal post-transplant immunosupresion may provide
an opportunity for these sub-optimal kidneys to recover function. Long term
follow-up will be required to validate these conclusions.

POSTER BOARD NUMBER P4 – 27
1977 A PHASE III UNICENTRIC, NON-RANDOMIZED STUDY
FOR THE EVALUATION OF SECURITY AND EFFICACY OF
CAMPATH 1H ASSOCIATED WITH SIROLIMUS, MOFETIL OR
SODIUM MYCOPHENOLATE AND LOW DOSES OF STEROIDS
IN ECD KIDNEY RECIPIENTS OR KIDNEYS AT RISK OF
DELAYED GRAFT FUNCTION.
L. Santiago Re, M. Rial, S. Cuevas, L. Reniero, D. Casadei
Instituto De Nefrología De Buenos Aires
Introduction: In the actual context of shortage of organs for transplantation,
expanded criteria donors usage plus the nephrotoxicity associated with
calcineurin-inhibitors drugs (CNI), we designed an immunosuppressive
protocol using Alemtuzumab (Campath 1H) as induction agent, followed by
a CNI-free maintenance therapy for kidney recipients of expanded criteria
donors as defined by the UNOS or recipients of kidneys at high risk of DGF.
Materials and methods: 25 patients received Campath 1H 30 mg IV just
before the surgery. Maintenance therapy consisted in Sirolimus (adjusted to
levels between 8-12 ng/ml), Mofetil or Sodium Mycophenolate and low doses
of steroids.
Results: 1-year patient survival: 92% (2 patients died due to septic shock)
1-year graft survival 72%: (1 primary non-function, 1 graft loss at 6 months
due to CAN, 1 renal artery thrombosis, 1 recidive of primary glomerulopathy,
1 loss due to discontinuation of the immunosuppression in the context of TB
pericarditis).Death censored graft survival: 80%. 6 months-creatinine clearance:
46.25 ml/min. 1-year creatinine clearance: 63.5 ml/min. 1-year acute cellular
rejection incidence: 0%.
CMV: 0%. Tuberculosis 2/25 (8%). Urinary tract infection 6/25 (24%). Wound
surgery infection 4/25 (16%).
Conclusions: The utilization of this immunosuppressive scheme was associated
with a null incidence of 1-year acute cellular rejection and CMV infection. Graft
losses were not associated with Campath 1-H use. The incidence of septic shock
was not different of that observed in our previous study using Thymoglobulin
as induction agent, but due to these results in the forthcoming patients we will
start to minimize the immunosuppressive therapy. Campath 1-H constitutes an
efficacious agent as induction therapy for ECD kidney recipients.

All patients received a single 30mg dose of alemtuzumab intra-operatively, and
continued maintenance immunosuppression therapy with low dose tacrolimus
(Target concentration: 5-10 ng/ml for 3 months and 5-8 ng/ml thereafter).
The target MMF dose was 2 gm/day and no corticosteroids were used for
maintenance. Results were analyzed according to patients’ outcome.
Results: Six females and 2 males, ages 29 to 64, received 4 living and 4
deceased donor kidneys. Risk factor included PRA ≥ 25% (n=2), re-transplant
(n=2), history of antibody mediated rejection (n=1), African Americans (n=7),
DM (n=3) and Obesity, dylipidemia and hypertension in all cases.
All patients presented 100% CDC-PRA and a mean absolute lymphocyte count
of 0.2 after alemtuzumab treatment (fig 1 and 2)
Patients with stable renal function (n=5) mean CDC-PRA dropped to 50%
by 6 weeks and retuned to pre-transplant values 16 wks after alemtuzumab
administration. Reciprocally, Lymphocyte mean count improved to 0.5 and
reached the lower limit of normal after 16 weeks as well (Fig. 3)
CDC-PRAs may return to their pre-treatment values as early as 3 wks. Presensitized (n=2) and patients with ongoing AMR (n=2) may require more than
16 wks.
Conclusions:
Serial CDC-PRA and lymphocyte counts are informative of the remaining
biologic activity of the depleting antibody. Once CDC-PRA has returned to
baseline, we should assume that the depleting antibody has been removed from
the patient’s serum. These results apparently correlate with the lymphocyte
count recovery.
Serial CDC- PRA may be useful to guide the timing for serial doses of antibodylymphocyte-depleting agents.
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1978 BIOLOGIC EFFECTS OF ALEMTUZUMAB INDUCTION
ON HIGH RISK RENAL ALLOGRAFT RECIPIENTS: THE
VALUE OF SERIAL CDC-PRA AND LYMPHOCYTE COUNT.

THURSDAY

A. Hernandez, C.O. Callender, T. Newberry, D. Joyce, R. Scott, J. Coton,
N. Kramer
Howard University Hospital
Background: The CDC-PRA test, a classical cytotoxicity assays for detecting
antibodies relies on their ability to kill target cells by activating complement.
This test uses lymphocytes from individuals who were chosen to represent
a wide range of HLA antigens. However; this tests cannot determine if the
reactive antibodies are directed against HLA or some other molecules that
reside on the lymphocytes.
Alemtuzumab (Campath 1H), a humanized monoclonal antibody, binds
to the CD 52 molecule present in variable concentrations on all peripheral
mononuclear cells including lymphocytes. Alemtuzumab has a depleting effect
on such cells and therefore its blood concentration will be reflected on the
CDC-PRA assay.
Objective: To analyze the effects of alemtuzumab induction on serial CDC-PRA
and peripheral lymphocyte counts in high risk kidney allograft recipients.
Methods: We prospective collected data on serial CDC-PRA, lymphocyte
count and renal function on 8 consecutive high risk renal allograft recipients.
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1979 A CALCINEURIN INHIBITOR-FREE
IMMUNOSUPPRESSIVE STRATEGY IN OLD RECIPIENTS
OF RENAL ALLOGRAFTS: 1-YEAR RESULTS FROM A
PROSPECTIVE SINGLE CENTRE TRIAL
H.P. Arbogast1, J.N. Hoffmann1, W-D. Illner1, G.F. Hillebrand2,
M. Fischereder3, K-W. Jauch1, W. Land4
1
Department of Surgery, University of Munich – Grosshadern, 2Medical
Department I, Division of Nephrology, University of Munich – Grosshadern,
3
Department of Medicine, University of Munich – City, 4Baskent University,
Ankara, Turkey
Introduction: Recently published data from our centre demonstrated the
feasibility of an application of a nephrotoxicity- and atherogenicity-free,
MMF-based immunosuppressive induction/maintenance protocol in elderly
recipients of kidneys from elderly cadaver donors. With the aim to decrease
the potential infectious and tumorogenic potency of polyclonal antibody
induction treatment in old recipients of cadaveric renal allografts, we applied
and investigated a therapeutic regimen consisting of a combined polyclonalmonoclonal induction regime and CNI-free, mycophenolate mofetil (MMF)
– based immunosuppressive maintenance protocol. In the following, the 1 year
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results of this clinical trial are published.
Methods: Between 1997 and 2007, a total of 118 elderly patients were treated
with an MMF-based, CNI-free immunosuppressive protocol. In a final cohort,
30 old recipients (67.8 + 3.8 y) of renal transplants from deceased donors (69.4
+ 13.3 y) were recruited consecutively, for this 5-year, prospective, open, single
centre, pilot trial. Induction therapy consisted of a low-dose, single shot of
rabbit ATG (ATG-Fresenius®) and the IL-2R-antibody Basiliximab (d0 and d4)
in conjunction with MMF and steroids. Maintenance treatment was performed
with MMF/steroids or MMF alone under strict therapeutic drug monitoring by
aiming target MPA-trough levels between 2 – 6 μg/mL.
Results: Cumulative 1-year patient and renal allograft survival was 87% and
83%, respectively, death-censored graft survival at one year was 97%. However,
in 46% of all patients, rejection episodes were observed, mostly being steroid
sensitive with only 3 patients requiring serum therapy. Function of the old renal
allografts proved to be satisfactory as reflected by serum Creatinine-values of
1.78 + 0.45 mg/dl and Nankivell GFR-values of 48.8 + 13.9 mg/dl, at 6 months.
23% of all patients demonstrated CMV infections, however only in 3.3%, CMV
disease was observed.
Conclusions: Application of a combined polyclonal-monoclonal induction
regime using a nephrotoxicity- and atherogenicity-free, MMF-based
immunosuppressive maintenance protocol in elderly renal cadaver transplant
recipients leads to acceptable short-term outcomes in old recipients of old
organs, however at the expense of an increased rejection rate, being comparable
to previously published data for elderly (> 50 y) recipients having received
allografts from elderly (> 50 y) cadaver donors.
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1980 SUCCESSFUL ALEMTUZUMAB INDUCTION AND
STEROID WITHDRAWAL IN AFRICAN AMERICAN AND
CAUCASIAN RECIPIENTS OF RENAL TRANSPLANTS
R. Barth, C. Gurk-Turner, D. Klassen, M. Cooper, E. Schweitzer, L. Campos,
S. Bartlett, B. Philosophe
University of Maryland School of Medicine
Alemtuzumab induction therapy has been reported to decrease early rates of
rejection and be permissive of immunosuppressive minimization strategies.
We have implemented a protocol for alemtuzumab induction and steroid
withdrawal of renal transplant recipients and report on our early results with
this strategy. We have collected data from 19 living and 119 deceased donor
renal transplant recipients from our center with median follow-up of 11 months.
Immunosuppression consisted of 30 mg alemtuzumab at transplant, and
maintenance with tacrolimus, mycophenolate mofetil, and steroid withdrawal
over 21 days. Kaplan-Meier analysis was performed to determine patient and
graft outcomes. Of 138 renal transplant recipients, 58% were African American
(AA), 39% female, and median age was 52 yrs old. DGF rate was 48.6% and
median length of stay was 7 days. 1-yr graft survival was 87.8%, and patient
survival was 93.7%. Differences in 1-yr graft survivals of 84.7% for AA and
97.9% for non-AA and 1-yr patient survivals of 90.4% AA and 100% for
non-AA were not statistically significant. Rejection rates at 1,3, and 6 mos
were 3.6%, 8.0%, and 12.0% and were not different between AA and non-AA
(p=0.7). Rejection-rates were 19.0% at 1-yr for all recipients (AA 17.4% vs
non-AA 24.7%, p=0.7). ACR was observed in 15.7% patients at 1 year (AA
11.8%, non-AA 14.7%, p=0.7); and AMR was observed in 2.9% patients at 1
year (AA 5.0%, non-AA 0%, p=0.06). Steroid-withdrawal was attempted in 112
patients and accomplished and maintained in 82% of these patients. Patients
who reached 6 and 12 months time points had median creatinines of 1.8 mg/dL
(n=125) and 1.7 mg/dL (n=54). CMV rate was 4.6% in non-CMV mismatched
Pts and 16% in CMV mismatched Pts. Significant leukopenia (WBC<2000/
uL) was observed in 26.6% of Pts, for which 53% received therapy with
G-CSF. Rates of leukopenia between AA (21.5%) and non-AA (34.7%) were
not significantly different (p=0.15). We have demonstrated excellent early
results with a protocol of alemtuzumab induction and steroid withdrawal in
both African American and non-African American renal transplant recipients.
Alemtuzumab induction allowed for successful steroid withdrawal, low rates
of rejection, and short lengths of stay in a population with a majority of African
American recipients and high rates of DGF.

CONCURRENT ORAL SESSION 138: LIVER TRANSPLANT
OUTCOMES: RENAL FUNCTION
POSTER BOARD NUMBER P4 – 31
1981 ETIOLOGICAL AGENTS OF URINARY TRACT
INFECTIONS (UTI’S) IN THE EARLY PERIOD AFTER LIVER
TRANSPLANTATION.
D. Kawecki1, A. Sawicka-Grzelak1, K. Kot1, E. Swoboda-Kopec1,
M. Pacholczyk2, B. Lagiewska2, P. Malkowski3, A. Chmura2, W. Rowinski2,
M. Luczak1
1
Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of
General Surgery and Transplantation Medical University of Warsaw, 3Dept.
of Surgical Nursing and Transplantation Medical University of Warsaw
Urinary Tract Infection (UTI) is a one of the common infection in liver
transplantation (LT).
Material and methods: The study covered 83 adult patients undergoing
liver transplantation (piggy back technique) between September 2001 and
October 2004. All the patients were followed prospectively for urinary tract
infections from the LT date and during the first four weeks after surgery. Basic
immunosuppression consisted of steroids and tacrolimus (Prograf ®; Fujisawa,
Germany). Antimicrobial prophylaxis was administered intravenously from
the day of transpalntation: piperacillin/tazobactam (Tazocin ®, Wyeth, USA),
fluconazole (Diflucan ®; Phizer, USA) and selective bowel decontamination
(orally a liquid suspension of amikacin and nystatin) was carried out.
Samples of urine were investigated for bacteriological cultures. The
microorganisms were cultured and identified in accordance with standard
bacteriological procedures. Susceptibility testing was carried out using National
Committee for Clinical Laboratory Standards (NCCLS) procedures.
Results: Urine specimens were examined in 53 pre-operative recipients (63.9%)
and in 64 patients (77.1%) during the first month after transplantation. Of the
182 samples investigated, 73 were positive. Bacterial strains were cultured
from 17 recipients before LT and from 28 patients after surgery. Among the
bacterial strains isolated in early period after LT (n = 71), the most common
were Gram-negative rods n = 46 (63%) isolates, the Enterobacteriaceae family
n = 44 (95,6%) isolates among them n = 12 (27,3%) of the Gram-negative rods
were Extended-Spectrum Beta-Lactamases ESBL(+) strains.
Gram-positive bacteria were cultured 34% (n = 25) and fungal strains 3%
(n=2).
Conclusions: 1.The predominance of Gram-negative rods was caused by
ESBL(+) and use of broad spectrum antimicrobial prophylaxis. 2.The increased
proportion of isolation Multi-Drug-Resistant (MDR) bacteria to antimicrobial
agents may be due to the frequent use of these agents for prophylaxis of bacterial
infections in liver transplant patients. 3. These (MDR) bacterial strains caused
severe UTI’s in patients after LT.

POSTER BOARD NUMBER P4 – 32
1982 KIDNEY TRANSPLANTATION AFTER LIVER
TRANSPLANTATION
J. Moon, A. Manta, C. Lyssikatos, A. Tzakis, T. Kato, W. Kupin, D. Roth
Miami Transplant Institute, University of Miami School of Medicine
Introduction: Liver transplantation is often complicated by chronic renal
failure, which significantly increased the risk of death. A population-based
cohort analysis recently reported 18.1% cumulative incidence of chronic
renal failure at 5 years after liver transplantation. Treatment of end stage renal
disease with kidney transplantation has been proved significantly lower risk of
death than dialysis.
Objective: We reviewed our experience of kidney transplantation in the liver
transplant patients who developed end stage renal disease.
Material and Method: This is a retrospective study using prospectively
maintained data base from a single center. Patient and graft survival was
examined by Kaplan-Meier analysis.
Result: Since 1994 we have 22 kidney transplantations (3 living and 19
deceased donors) among 1802 adult liver transplantation patients. Mean age
of the patient is 56 ± 13 years old (range 18 to 72). There are 13 male and
9 female patients. The reason for liver transplantation was cryptogenic liver
cirrhosis (8, 36.4%), hepatitis C (6, 27.3%), alcoholic liver cirrhosis (2, 9.1%),
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and others (autoimmune hepatitis, primary sclerosing cholangitis, polycystic
liver disease, cystic fibrosis, amyloidosis, fulminant hepatic failure). Interval
between liver and kidney transplantation was 7.1 ± 4.0 years (range 3.1 to 16).
Causes of end stage renal disease was calcineurin inhibitor nephrotoxicity (12,
54.5%), diabetic nephropathy (7, 31.8%), irreversible hepatorenal syndrome
(1, 4.5%), hypertensive nephropathy (1, 4.5%), and polycystic kidney
disease (1, 4.5%). Mean waiting time on the kidney transplant list was 350 ±
198 days (range 24 to 820). Induction immunotherapy was daclizumab (10,
45.5%), daclizumab with antithymocyte globulin (6, 27.3%), corticosteroid
(5, 22.7%), and antithymocyte globulin (1, 4.5%). Tacrolimus, mycophenolate
mofetil, and corticosteroid were used as a maintenance immunosuppression
in all patients. Corticosteroid was slowly tapered out at 6 to 9 months after
kidney transplantation. Mycophenolate mofetil was stopped in 3 patients due to
significant gastrointestinal adverse effect. There were 5 mortalities at 1.8, 13.5,
23.7, 35.7, and 86.6 months after kidney transplantation. Cause of death was
pneumonia (2), recurrent hepatitis C (2), and cardiac failure due to underlying
amyloidosis (1). The rest of patients maintained good kidney graft function
without graft loss. Liver allograft function did not show significant change
after kidney transplantation. Patient and graft survival at 5 years after kidney
transplantation was 72.6%.
Conclusion: Kidney transplantation is an excellent renal replacement therapy
in liver transplant patients who developed end stage renal disease. Our study
does not find liver graft deterioration after kidney transplantation.
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1983 PREDISPOSING FACTOR OF ACUTE RENAL FAILURE
REQUIRING CONTINUOUS RENAL REPLACEMENT
THERAPY AFTER LIVER TRANSPLANTATION
M.S. Kim1,3, M.K. Ju1,3, G.H. Choi1, B.S. Kim2, J. Choi1, D.J. Joo1, S.J. Kim1,
S.I. Kim1,3, Y.S. Kim1,3
1
Yonsei University College of Medicine, Department of Surgery, 2Yonsei
University College of Medicine, Department of Internal Medicine, 3Yonsei
University College of Medicine, The Research Institute for Transplantation
Acute renal failure (ARF) is a severe complication in patients undergoing liver
transplantation, which predicts a poor outcome. ARF increases the incidence
of postoperative sepsis, the need for dialysis, the number of days spend in the
intensive care unit, and poor outcomes. Continuous renal replacement therapy
(CRRT) is widely used for treatment of ARF in liver transplantation patients. The
aims of this study are to analyze predisposing factors for development of ARF.
Eighty adult liver transplant recipients from September 2005 to November 2007
were enrolled in this study. Pre-transplant and transplantation-related clinical
manifestations were retrospectively collected. All recipients used tacrolimusbased immunosuppression with 10-15 ng/ml of trough level.
Of the 80 recipients, 10 recipients (12.5%) experienced ARF needing
CRRT therapy during early transplantation period. The deceased donor liver
transplantation, presence of ascites, hepatorenal syndrome and history of using
Molecular Adsorbents Recirculation System (MARS) were also common in
ARF needing CRRT group (p=0.037, 0.040, 0.04, and p<0.001, respectively).
The pre-transplant serum creatinine level, total bilirubin level, and Model for
End-stage Liver Disease (MELD) score is significantly high in ARF needing
CRRT group than no-ARF group (p<0.001, p<0.001, p=0.022, and 0.001,
respectively). The ARF patients needing CRRT showed higher peri-operative
mortality rate (40%) and inferior 1-year survival rate (45.0%) than no-ARF
group (2.9% and 97.1%)(p<0.05).
The necessity for CRRT in patients after liver transplantation correlates with
severity of liver disease such as Hepatorenal SD and MELD score. And it also
directly correlated with immediate post-operative mortality.
Clinical manifestations
N
Age (years)
Gender (Male:Female)
Donor type (Deceased:Living)
Encephalopathy +
Ascites +
Esophageal varix +
Hepatorenal syndrome +
MARS history +
2
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BMI (kg/m )
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No-ARF

ARF needing CRRT

Total

70
51.0±7.2
56: 14
(80.0%: 20.0%)
19: 51
(27.1%: 72.9%)
15 (21.4%)

10
49.5±9.7
6:4
(60.0%: 40.0%)
6:4
(60.0%: 40.0%)
5 (50.0%)

39 (55.7%)
22 (31.4%)
1 (1.4%)
3 (4.3%)
23.5±2.4

9 (90.0%)
3 (30.0%)
2 (20.0%)
4 (40.0%)
23.7±3.3

80
50.8±7.5
62: 18
(77.5%: 22.5%)
25: 55
(31.3%: 68.8%)
20: 60
(25.0%: 75.0%)
48 (60.0%)
25 (31.3%)
3 (3.8%)
7 (8.8%)
23.58±2.5

p-value

0.557
0.159
0.037
0.052
0.040
0.928
0.004
<0.0001
0.834

Serum creatinine level (mg/dl)
Total bilirubin level (mg/dl)
MELD score
Operation time (hours)

0.9±0.2
5.6±8.9
14.8±7.3
10.8±1.9

1.4±0.9
13.4±15.1
23.6±10.6
10.7±2.2

0.9±0.4
6.6±10.1
15.9±8.2
10.8±1.9

<0.001
0.022
0.001
0.925
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1984 LIVING KIDNEY DONATION FOLLOWING PREVIOUS
RIGHT LOBE LIVER DONATION – FIRST REPORT IN WORLD
LITERATURE
R. Kadiyala, M. Eng, R. Nagubandi, M. Marvin, J. Buell
Transplant Center, Jewish Hospital, University of Louisville, KY, USA
Introduction: The past few years have witnessed an increasing disparity
between patients awaiting organ transplants and the deceased donor organs
available resulting in an increase in wait list mortality. This has led to a rise in
living donation rates particularly kidneys. We report a patient who donated a
kidney following a previous liver donation
Case report: A 48 year old woman was evaluated as a potential kidney donor
for a friend who had end stage renal failure from polycystic kidney disease. She
had previously donated her right lobe of liver for transplantation to her mother
who had cirrhosis of liver. Her liver surgery 8 years prior was uneventful and
imaging showed regeneration of her liver remnant. She was found to be in good
health with no medical contraindications. CT angiography revealed normal
kidneys bilaterally with single artery and vein on either side. She underwent
extensive screening by the psycho-social team and cleared for kidney donation.
She underwent laparoscopic left donor nephrectomy without any peri-operative
complications and was discharged home 2 days later. The recipient, a 46 year
old man, had good graft function and has been off dialysis since. At a followup of 2 months, both the donor and recipient are in good health with normal
renal function
Conclusion: This is the first report of living kidney donation from a previous
liver donor. In the era of organ shortage, this patient exemplifies the safety of
live organ donation. Previous organ donation should not be a contraindication
to further donation in properly screened patients
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1985 PREDICTIVE VALUE OF PRE-TRANSPLANT
CREATININE ON RENAL IMPAIRMENT ONE YEAR AFTER
LIVER TRANSPLANTATION
C.K. Burghuber, G.P. Gyoeri, R. Steininger, F. Muehlbacher, T. Soliman,
G.A. Berlakovich
Dept. Transplant-Surgery, Medical University Vienna
Purpose: Chronic renal failure after orthotopic liver transplantation (OLT) is
common and is a cause for a reduced quality of life and survival. The course
of renal function peri- and postoperatively is difficult to foresee. Means to
predict the development of postoperative renal impairment (RI) would help to
concentrate on early minimization of nephrotoxic medication in these patients.
Methods: All adult patients who received a primary liver graft between 1999
and 2006 and were followed at our center for at least 1 year post-OLT were
considered for analysis (n=269). Data were collected from our prospective
electronic database.
Postoperative RI was defined as a serum creatinine ≥;1.5 at 1 year post-OLT.
We conducted an analysis of the predictive value of creatinine 3, 2, and 1
months preoperatively and on the day of OLT. Sensitivity and specificity as
well as positive and negative predictive values were calculated.
Results: Renal impairment was diagnosed in 69 patients (26%) at 1 year after
OLT.
Pre-OLT serum creatinine values at 3-, 2-, 1-month and at transplant were
compared with renal function 1 year post-OLT. The correlation coefficient was
0.43, 0.26, 0.44 and 0.33, respectively. Detection of RI post-OLT by pre-OLT
serum creatinine at the 4 time points had a sensitivity of 25%, 27%, 33% and
7% and a specificity of 95%, 92%, 94% and 83%, respectively. The proportion
of true positive test results among all the positive test results (positive predictive
value) amounted to 44% and the negative predictive value to 75%.
Conclusion: Pre-transplant serum creatinine had no predictive value for longterm renal function in patients listed for liver transplantation. Measuring
serum creatinine alone does not permit to sort out patients with high risk for
developing renal failure after OLT.
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1986 THE IMPACT OF RENAL DISEASE IN LIVER
TRANSPLANTATION
F. Nolasco, A.C. Ferreira, S. Sampaio, A. Baptista, P. Pessegueiro,
E. Monteiro, A. Martins, E. Barroso
Hospital Curry Cabral
Renal dysfunction often complicates the course of orthotopic liver transplant
(OLT) recipients and is associated with an increase morbidity and mortality.
The aim of this study was to determine the incidence of renal disease (acute and
chronic), possible risk factors and to determine the impact on the patient survival.
Clinical data included age, gender, aetiology for hepatic failure, presence of
diabetes mellitus, hypertension, hepatitis B and C infection, renal dysfunction pre
transplant (RD pre) and immunosuppression. Laboratorial data included serum
creatinine at day 1, 7, 21, month 6, and every year. The glomerular filtration rate
(GFR) was determined by Cockcroft-Gault equation. We studied, retrospectively,
from September 1992 to March 2007, 708 OLT recipients, 82 being retransplanted. Mean age 44 ±12.6 years, 64% males, 17% diabetic, 18.8% with
hypertension, 19.9% with C hepatitis and 3.8% B hepatitis. Renal dysfunction
was known in 21.6%. Mean follow-up was 3.6 years (0- 15). Mean transplant
survival was 75% at 12 months and 69% at 3 years. 152 patients died. Uni and
multivariate analysis were performed and a p<0.05 was considered significant.
Renal dysfunction in this population was observed in more than 50% and was divided
in 2 groups: acute renal failure (ARF) in the immediate post transplant period (33.8%)
and chronic kidney disease (CKD) according to KDIGO definition (50.2%).
ARF occurred in 33.8% of the patients. Only 14% recovered the renal function with
GFR > 60 ml/min (r = 0.686, p <0.001), 15.5% did not recovered renal function
and are on dialysis (r= 0.454, p <0.001), 30.5% died (r= 0.222, p<0.001).
In the time of this study, half of the population had CKD 3, 29% with a GFR<
45 ml/min, 9% had CKD 4 and 5.6% CKD5d.
Persisting renal failure (GFR < 45 ml/min) was positively correlated with age
(r=0.199, p<0.001), diabetes (r=0.88, p=0.032), alcohol (r=0.097, p=0.015), RD
pre (r=0.279, p<0.0001), ARF post transplant (r=0,319 p<0.0001) and with high
mortality (r=0.188, p<0.0001). On multivariate analysis, it was positively correlated
with age (p<0.001), RD pre (p<0.001), ARF post transplant (p=0.03) and with
mortality (p=0.015). It was not correlated with aetiology of hepatic failure.
Mortality was also correlated, on multivariate analysis, with RD pre (p=0.006),
ARF post transplant (p<0.001), CKD stage 3 post transplant (p=0.002), CKD
5d (p<0.001) and haemodialysis treatment (p<0.001). There was no correlation
between mortality and need of re transplant.
In conclusion, OLT recipients are disposed to renal complications that have a
negative impact in the survival of these patients. Renal dysfunction seems to be
more important than the need of re transplant in what concerns clinical prognostic.
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1987 CHRONIC KIDNEY DISEASE FOLLOWING
ORTHOTOPIC LIVER TRANSPLANTATION.
J. Frazier1, G. Lipka1, D.W. Johnson1, C. Hawley1, S. Campbell1,
D. Mudge1, C. Van Epps1, N. Isbel2, G. Macdonald2
1
Princess Alexandra Hosital, 2CCRE, University of Queensland
Background: Chronic Kidney Disease (CKD) is a frequent complication of
liver transplantation. It is associated with increased morbidity and mortality
including the development of End Stage Renal Disease (ESRD) requiring
either Chronic Renal Replacement Therapy (CRRT) or renal transplantation.
This study examines the prevalence of CKD and its predictors in a population
of liver transplant patients at the Princess Alexandra Hospital.
Methods: Retrospective analysis of 80 liver transplant recipients transplanted
at the Princess Alexandra Hospital, Brisbane between 1st July 1997 and 31st
December 2001. Median follow up time was 6.24 years. CKD was defined as
MDRD Estimated Glomerular Filtration Rate (eGFR) < 30mls/min/1.73m2 or
the development of ESRD
Results: Patients transplanted in-centre had a lower prevalence of chronic
renal failure (6.25% vs 18.1%) than previously reported (Ojo et al,NEJM
2003,349:931-940). One patient with CKD required CRRT and none underwent
renal transplantation. Renal function steadily deteriorated post transplant with
a mean eGFR loss of 1.47ml/min/year. Independent predictors of impaired

post-transplant renal function (eGFR<60 ml/min) were eGFR<60ml/min
at pretransplant assessment (â 0.982 95% CI 0.971-0.994 p=0.004), male
gender (â 0.48 CI 0.253-0.909 p=0.024), low BMI at assessment (â 0.957
CI 0.906-1.01 p= 0.11), and higher number of antihypertensive medications
(â 1.527 CI1.164-2.002 p=0.002). eGFR <60 ml/min post transplant was
significantly associated with increased mortality (p=0.004).
Conclusions: CKD is a prevalent complication following liver transplantation
and is associated with significant morbidity and mortality. Post transplant renal
function progressively declined with time, which with improved survival postliver transplantation will result in an increased burden of CKD in these patients
in the future.
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1988 LONG-TERM SURVIVAL AND OUTCOMES OF
COMBINED LIVER-KIDNEY (SIMULTAENOUS AND
SEQUENTIAL) TRANSPLANTS IN SPAIN
D.D. Castillo1, A. Otero2, O. Bestard3, N. Esforzado4, M.L. González5,
L. Capdevila6, L. Castells6, J.J. Amenábar7, S. Gatell8
1
Hosp. Univ. Reina Sofía, Córdoba, Spain, 2Hosp. Juan Canalejo, A Coruna,
Spain, 3Hosp. Bellvitge, Hospitalet de Llobregat, Spain, 4Hosp. Clínic i Univ,
Barcelona, Spain, 5Hosp. Univ. Central de Asturias, Oviedo, Spain, 6Hosp.
Vall d´Hebron, Barcelona, Spain, 7Hosp. de Cruces, Barakaldo, Spain, 8
Novartis Farmacéutica, S.A.
Objective: To describe long-term survival and grafts function of all patients
who have received simultaneous or sequential liver and kidney transplant in
Spain in the last 15 years.
Methods: An observational, retrospective and multicenter study was conducted,
including all adult patients receiving double liver-kidney transplant between
1991 and 2006 in Spain.
Results: 178 patients were analyzed: 139 with simultaneous transplant and 39
with sequential transplant (5 kidney-liver (KL) and 34 liver-kidney (LK)). Patients
were mainly men and mean age was 51±9, 47±5, 53±11 years, respectively. The
most frequent reasons for renal failure were glomerulonephritis and secondary
glomerulonephritis, whereas alcoholic cirrhosis was the main cause of liver
disease. The prevalence of positive HBV recipients before the first transplant was
14.9%, 50.0% and 7.1% respectively, positive HCV, 42.0%, 75.0% and 35.7%,
respectively, and positive HBC and HCV, 16.3%, 33.3% and 10.0%, respectively.
The most common immunosuppresive regimen at discharge was anticalcineurin
plus MMF/EC-MPS plus steroids. The mean creatinine clearance and bilirubin
values for combined transplants were 55.7 ml/min and 1.3mg/dl at five years and
59.2 ml/min and 1.2 mg/dl at ten years, respectively. At five years after double
transplantation, 75% of patients were alive, and, at ten years, 55%. The estimated
mean survival time was 9.2 years, 7.5 years and 6.9 years for combined, KL and
LK, respectively. Main cause of death was infection. Post-transplant hypertension
and hyperlipemia were the most commonly reported complications.
Conclusion: Data from clinical practice in Spain suggests that the combined
liver-kidney transplantation presents good survival, similar to that obtained
with liver transplantation alone. Simultaneous or sequential liver-kidney
transplantation can be considered a valid option for patients waiting for a liver
who also suffer kidney disease.

POSTER BOARD NUMBER P4 – 39
1989 THE RISK OF KIDNEY AFFECTION IN ADULT PATIENTS
WITH ORTHOTOPIC LIVER TRANSPLANTATION FROM
CADAVERIC DONORS
M. Mihaila1, L. Micu1, I. Popescu2, M. Voiculescu1
1
Fundeni Clinical Institute, Center of Internal Medicine-Nephrology, 2Fundeni
Clinical Institute, Center of General Surgery and Liver Transplantation
Introduction: Kidney affection develops frequently (40-60%) and influences
the prognosis of patients with non-kidney transplants.
Objective. The aim of this study is to evaluate the frequency and risk factors of
kidney affection in patients with orthotopic liver transplantation.
Material and methods: We evaluated 61 adult patients (M=34, F=27) with
orthotopic liver transplantation performed between 2000-2007, out of a
total of 131 patients with liver transplantation for end stage liver disease of
various etiologies. None of the 61 patients presented kidney affection before
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transplantation. Standard immunosuppression protocols were used, consisting
in tacrolimus and mycophenolat mophetil (MMF) or with ciclosporin and
MMF in case of adverse reactions to tacrolimus.
We evaluated the risk of developing kidney affection in the absence of o preexisting renal conditions. Kidney affection was considered in case of: proteinuria
> 0.3 gr/24 hours or hematuria > 2000/min (Addis-Hamburger probe), the
presence of cilinders in urine spot or a creatinine clearance of < 90 mL/min
calculated using the MDRD formula (Modification of Diet in Renal Disease).
Results: Proteinuria > 3 gr/24 hours and hematuria (>2000/min) were present in 2
cases (3.27%); II-nd degree chronic kidney failure in 27 cases (44,26%) and IIIrd degree chronic kidney failure in 18 cases (29.5%). Renal substitution was not
necessary in any of the patients alter a mean follow-up period of 47.5 months. Of
the patients with chronic kidney failure, 30 (66.66%) are treated with tacrolimus,
and 15 (33.33%) with ciclosporin in classic immunosuppressive doses.
Conclusions: Kidney affection occurs frequently in liver transplantation
(73.76%). Tacrolimus, as well as Ciclosporin, may be considered as risk factors
for kidney affection. Although kidney function was found to be significantly
restricted in these cases, renal substitution was not necessary in any patients.

POSTER BOARD NUMBER P4 – 40
1990 GFR ASSESSED BY MDRD FORMULE IN LIVER
TRANSPLANT PATIENTS WITH ACUTE KIDENY DISEASE
E. Varo, L. Vizcaino, C. Ponton, A. Lopez, S. Tome, M. Bustamante,
J. Martínez, E. Otero, C. Javier, F. Segade
Abdominal Transplant Unit
Accurate assessment of Chronic and acute renal failure (AKF) results a key
point for management of patients after liver transplantation (LT).
Aim: To estimate the degree of renal impairment by other formules than
Creatinin clearance like MDRD during the first year after LT.
Methods: From 290 Liver transplant patients during a period of time from 1999
to 2004 we assessed 52 patients who developed AKF.AKF has been defined
as either the increase of serum creatinin up to 1.5 mgrs /dl, BUN up to 70
mgrs/ dl or GFR assessed by creatinin clearance (Ccr (Cockroft& Gault) less
than 50 ml/min. We performed the correlation between Ccr and formules as
recomended the International kidney fundation(MDRD) during the different
stages of Renal failure as well as different period of time after first year after
liver transplantation
Results: From 52 patientes (67% Males and 33% Females). Median age 52 y.
The correlation between different estimations as well as the concordance as
assessed by Kappa statistics can be seen on figure 1.
Time

GFR
(C-G)

Day 1

57.14
±25.1*

r

Kappa

p

47.59±26.1 44.55±23.06 41.09±21.5

0.748

0.667

<0.01

Day 14 85.58±33.9 71.40±33.1 61.53±28.8 56.62±25.5

0.579

1.00

<0.01

Day 30 81.00±34.1 71.28±25.4 66.29±22.9 58.13±20.0

0.634

0.480

<0.01

Day 90 81.45±42.9 68.39±30.5 62.97±26.9 63.30±25.3

0.736

0.450

<0.01

0.725

0.420

<0.01

Day
365

GFR
MDRD4

GFR
MDRD5

GFR
MDRD6

70.09±26.6 60.26±22.8 59.41±22.4 58.04±22.6

*SD

THURSDAY

Conclusions: The estimation of AKF assessed by MDRD 4, 5 and 6 formules
results in a very good correlation and fairly well concordance. So that it can be
recommended as a safe method to the current clinical manage
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1991 COMBINED LIVER-KIDNEY TRANSPLANTATION:
MELD ERA TRENDS
R. Ruiz, H. Randall, R. Goldstein, G. Klintmalm, M. Levy, G. McKenna, N.
Onaca, L. Jennings, E. Sanchez, S. Chinnakotla
Baylor Regional Transplant Institute
An increase in the number of combined liver-kidney transplants (CLKTs)
performed nationwide has been well-documented since the implementation
of the Model for End-stage Liver Disease (MELD) allocation system. While
indications have not changed, an elevated serum creatinine (SCr) in patients
with end-stage renal disease or renal dysfunction has been the main contributor
to the MELD score. In this analysis, we sought to find any differences in
outcomes before and during this era.
In this study, we retrospectively examined 75 CLKTs performed at our center
over a 23-year period. Overall, patient survival rates were 82%, 73% and 64%
at 1, 3 and 5 years, respectively. There was no difference in survival whether
or not a recipient was on pretransplant dialysis. However, the requirement for
post transplant hemodialysis portended a poor overall prognosis (p=0.0006).
Patients undergoing a liver retransplantation at the time of CLKT had a survival
rate of 40% at 3 months. Only seven patients (9%) had biopsy-proven acute
kidney rejection episodes.
Twenty-nine CLKTs (39%) were performed during the MELD era. Patient
survival was poorer in the MELD era when compared to the preMELD era,
but not statistically significant (p=0.398). This was likely due to an older age
population (p=0.003) and a greater number of Hepatitis C patients transplanted
(p=0.04). With regard to pretransplant laboratory analysis, SCr was not
statistically different in both groups. However, the median total bilirubin
(Tb) was 1.6 mg/dL in the preMELD era and 0.8 mg/dL in the MELD era
(p=0.0001). Likewise, the median prothrombin time (PT) was 13.5 seconds in
the preMELD era compared to 12.2 seconds in the MELD era (p=0.04). The
percentage of patients undergoing retransplantation in either group was similar.
Hospital length of stay was significantly shorter in the MELD era (p=0.005).
There is no statistically significant difference in patient survival before and
after the implementation of the MELD system. Patients requiring a liver
retransplantation should be excluded from an additional kidney allograft.
Based on our data, there is a trend in allocating both a liver and kidney to
recipients with better liver function by laboratory analysis. Should end-stage
renal disease drive the MELD score of a patient with end-stage liver disease
and lead to CLKT? Whether this is a result of increased referrals of patients
with renal failure or patient selection should be further investigated. Finally,
the liver allograft confers immunologic protection to the kidney.

POSTER BOARD NUMBER P4 – 42
1992 EVALUATION OF PRE-TRANSPLANT CHANGES IN
CREATININE AND GLOMERULAR FILTRATION RATE AS
INDICATOR FOR LONG-TERM RENAL FUNCTION IN LIVER
TRANSPLANT PATIENTS
G. Gyoeri, C. Burghuber, R. Steininger, T. Soliman, F. Muehlbacher,
G. Berlakovich
Medical University Vienna, Dept. of Transplant Surgery
Hypothesis: Aim of this study was to analyze the predictive value of pretransplant changes in serum creatinine (Delta-SCr) and glomerular filtration rate
(GFR) on post-transplant renal function 1 year following liver transplantation.
Methods: Included were all adult patients from a single center receiving their
1st liver graft between 1999 and 2006 (n=269). All included patients received
our standard immunosuppressive regimen with Thymoglobulin induction for 3
days, low dose cyclosporine from day 4 and rapid steroid taper. Maintenance
immunosuppression consisted of low dose cyclosporine monotherapy. An
adaptation of the regimen by protocol was performed in case of developing
renal impairment (RI).
SCr values 3months (mo), 2mo, 1mo pre transplant and just before OLT and
1a after transplantation were considered for analysis. GFR was calculated
according to the MDRD formula. Renal impairment (RI) was defined as SCr
>1.5mg/dl or GFR <60ml/min.
Data were collected prospectively in our Transplant Surgery database and
reviewed retrospectively. Sensitivity and specificity as well as positive and
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negative predictive values were calculated.
Results: 69 patients were identified with RI defined by SCr 1a post-OLT. Then
correlation of Delta SCr pre-transplant to RI after 1 year was evaluated.
Patients with a Delta-SCr >0.5 and >0.25 had a correlation coefficient of 0.0933
and 0.1553, respectively. The sensitivity was 13% and 20%, the specificity was
97% and 91%, the positive predictive value (PPV) was 67% and 46% and the
negative predictive value (NPV) was 74% and 74%, respectively.
132 patients were identified with RI defined by GFR 1a post-OLT, 37 patients
with severe RI (GFR <40) and 95 patients with moderate RI (<60- >40). The
correlation coefficient comparing GFR at selected time points pre-transplant
and 1-year post OLT are shown in Tab. 1.
Tab. 1 Patients with GFR <60ml/min at 1 year post OLT
Correlation Sensitivity% Specificity% PPV%
coefficient
3mo pre
0.4964
29
88
75
2mo pre
0.4460
37
84
74
1mo pre
Pre TX

0.2925
0.1893

44
42

90
83

82
71

NPV%
51
50
62
60

Conclusion: In this study we could not validate our hypothesis that changes in
SCr before OLT (Delta SCr) had predictive value to identify patients at risk for
postoperative renal impairment at 1 year after OLT.
Further GFR at 3mo, 2mo, 1mo and right before OLT neither had correlation
with renal impairment after OLT. We conclude, that renal function after liver
transplantation is influenced by many factors and further studies will be needed
to identify patients at risk for renal impairment.

POSTER BOARD NUMBER P4 – 43
1993 CHRONIC RENAL INSUFFICIENCY IS ASSOCIATED
WITH INFERIOR OUTCOMES AFTER COMBINED
ORTHOTOPIC HEART/LIVER TRANSPLANTATION
S. Kreml, C. O’Mahony, N. Sussman, J. Vierling, R. Stribling, J. Goss
Baylor College of Medicine
Introduction: Combined orthotopic heart transplantation (OHT) and orthotopic
liver transplantation (OLT) continues to be indicated only for the rare instances
where patients are not expected to survive transplantation of either organ alone.
Because these cases are so infrequently performed, it is difficult to determine
risk factors that may affect outcome.
Purpose: The purpose of this study was to identify risk factors that would
affect outcomes in patients undergoing combined OHT-OLT.
Methods: This study consisted of a retrospective review of all patients who
underwent combined OHT-OLT at our institution from June 2004 through
January 2008.
Results: A total of six patients underwent OHT-OLT at our institution, including
four male and two female patients having a mean age of 55 years (42-67) with
a mean followup of 26.3 months (10-45.7). The indications for transplantation
were hemochromatosis in two patients, cirrhosis secondary to hepatitis C with
concomitant ischemic cardiomyopathy in two patients, restrictive non-ischemic
cardiomyopathy causing cardiac cirrhosis in one patient, and cryptogenic
cirrhosis with idiopathic cardiomyopathy in one patient. At transplant, mean
MELD score for all patients was 13.5 (7-18) and the mean serum creatinine was
1.4 mg/dL (1.1-1.9). None of the patients required pre-transplant mechanical
ventilation or hemodialysis.
Five of the six patients are alive with functioning grafts. Four patients had
uncomplicated postoperative courses with an average length of stay of 13
days (10-15). Two patients required postoperative renal replacement therapy.
Of these two patients, one died on postoperative day 25 from sepsis and
complications of dialysis access and the other had a prolonged hospital course
with a 36 day length of stay.
The mean preoperative serum creatinine for the patients with an uncomplicated
postoperative course was 1.2 mg/dL (1.1-1.4), while the mean preoperative
serum creatinine was 1.8mg/dL (1.7-1.9) for the patients with prolonged hospital
courses. Age, sex, etiology of disease, and MELD score did not appear to influence
length of stay or mortality (p>0.4). However, a preoperative creatinine > 1.5 mg/
dL was associated with a tendency for a prolonged length of stay (p=0.067).
Conclusion: Based on our experience with combined OHT-OLT, worse outcomes
are associated with preoperative renal insufficiency. These findings emphasize
the importance of careful patient selection for these uncommon cases.

POSTER BOARD NUMBER P4 – 44
1994 RENAL FUNCTION IN PIGGYBACK VERSUS CAVAL
INTERPOSITION IN ADULT LIVER TRANSPLANTATION
A. Cheaito, A. Yoshida, M. Abouljoud, D. Kim
Henry Ford Hospital
Background: Orthotopic liver transplantation has become an accepted mean to
treat end-stage liver disease. Although the technique of LTX has been refined to
a relatively standardized approach, the operation remains a formidable surgical
challenge. As such, LTX can have numerous technical complications, in which
the recipient’s pretransplant condition, donor and immunologic factors, may
all contribute. Renal insufficiency is a common finding with end-stage liver
disease. Renal insufficiency is generally not regarded as a contraindication
to liver transplantation. However, the impact of RI on outcome following
transplantation is not well understood. Acute renal failure (ARF) occurs
in 5–50% of patients undergoing orthotopic liver transplantation (OLT).
The aim of our study is to identify technical factors (Piggyback vs. Caval
Interposition) that may contribute to worsening renal function in orthotopic
liver transplantation.
Method and Results: We performed a retrospective analysis of consective
OLT performed from 2004-early 2007. Demographic data were collected. The
etiology of the liver disease was similar between the PT and CI cohorts, with
hepatitis C and alcoholic liver disease accounting for more than 60%. The age,
sex, and percentage of patients with previous abdominal surgeries were also
similar between the two groups. Serum creatinine was measured pretransplant,
three month post transplant, and one year post transplant. During the study
period 237 patients were identified. Eleven patients were excluded because of
LRLT(living related liver transplant), 22 patients were excluded for receiving
SLK(simulataneous liver-kidney), and 28 patients were lost to follow-up. One
hundred seventy-six patients were included, Anova Stastical Analysis was
perfomred. Of those 136 patient underwent the PT and 40 were CI. The average
pre-transplant creatinine was 1.26 (0.7-2.8) for the PT group and 1.31 (0.7-3.8)
for CI group. At three month the average creatine for the PT was 1.12 with an
absolute change of 11%. For the CI group the average creatine at 3 month was
1.29 with an absolute change of 1.5%. At one year the average creatine for the
PT was 1.22 with an absolute change of 3%. On the other hand the CI group the
average creatine was 1.27 with an absolute change of 3%.
Conclusion: We concluded that surgical approach to liver transplantation
has no direct effect on renal function at one year post transplant. However,
the difference in the absolute reduction in the creatinine at three months post
transplant needs to be further investigated. There may be bias in which we
perform PB technique on and that there seems to be no obvious detrimental
effect on renal function by PB.

CONCURRENT ORAL SESSION 139: LIVER
TRANSPLANTATION OUTCOMES (GENERAL)
POSTER BOARD NUMBER P4 – 45
1995 EXPECTED NUMBER OF DEATHS IN THE LIVER
TRANSPLANTATION WAITING LIST IN THE STATE OF SÃO
PAULO, BRAZIL
E. Chaib1, E. Massad2
1
University of Sao Paulo School of Medicine, 2University of Sao Paulo School
of Medicine
São Paulo is a pioneer Brazilian state on transplantation surgery. The biggest
challenge facing the field of transplantation is the critical shortage of donors
organs, which has led to a dramatic increase in the number of patients on the
waiting-list as well as in their waiting time.
We wish to report the expected number of deaths in the waiting-list of liver
transplantation in the State of São Paulo for a projected period of 10 years
starting in 2005. We collected official data about our liver transplantation
program between July 1997 to October 2004. Only cadaver liver transplantation
was recorded. Living-related liver transplantation was excluded.
The data related to the actual number of liver transplantation, Tr and the
incidence of new patients in the list, I, in the State of São Paulo since 1997 can
be seen in table 1.
We take the data of Tr and of I from table 1 and fitted a continuous curve
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by the method of maximum likelihood, in order to project the number of
transplantations, Tr, and the incidence of new patients in the list, I, in future
time. Next we calculated the number of deaths in the list assuming an average
survival time in the list of 18 months and assuming also that death is the
inexorable fate of those patients. Taking the difference between the incidence of
new cases and the incidence of transplantations did this.The results, projected
for 10 years from 2005 can be visualized in figure 1.
The gap between the number of available organs from deceased donors and
the number of patients in the waiting-list continues to rise each year. Liver
transplantation has increased, approximately, 1.84-fold (from 160 to 295) from
1988 to 2004. On the other hand, the number of patients on the liver waitinglist have jumped to 2.71 (from 553 to 1500). As a result of that the number of
deaths on the liver waiting-list have moved to a higher level from 321 to 671
increasing 2.09 fold.
The present study found that 4.7 liver transplantation were performed per
million inhabitants in 2003 when we should have performed at least 33
transplantation per million inhabitants.
In conclusion, provided the conditions of the present study remain unchanged
the number of deaths in the liver transplantation waiting-list will grow in an
exponential function in the years to come. Therefore there is an urgent need for
both increasing the number of liver transplantation in the State of São Paulo
as well as by changing the law introducing non-heart-beating donors in order
to avoid this overwhelming number of deaths in the liver transplantation
waiting- list.
Table 1
Year
1997
1998
1999
2000
2001
2002
2003
2004

Tr
63
160
188
238
244
242
289
295

I
553
923
1074
1248
1486
1564
1500

POSTER BOARD NUMBER P4 – 47
1997 LONG-TERM FOLLOW-UP OF PEDIATRIC ALLOGRAFT
RECIPIENTS SURVIVING FOR MORE THAN 5 YEARS. A
SINGLE CENTER EXPERIENCE
A. Sonzogni1, M. Dremmen2, D. Alberti3, M.G. Alessio, V. Corno3,
A. Lucianetti3, D. Pinelli3, P. Stroppa 3, G. Torre3, M. Colledan3
1
Pathology Unit, Ospedali Riuniti – I 24128 Bergamo, 2Faculty of Health,
Medicine and Life Science, University of Maastricht – NL Maastricht,3Liver
and Lung Transplantation Center, Ospedali Riuniti – I 24128 Bergamo
Pediatric orthotopic liver transplantation (OLTx) has undergone a revolution
over the past decades, resulting in a rising new population of long-term
survivors with a long life-expectancy. Identification of factors influencing
prognosis would bring more knowledge concerning the long term outcome
Consequently, the patients selection and management can be improved.
From October 1997 to July 2002, 166 children received a liver transplant at
Ospedali Riuniti di Bergamo. Mean follow-up was 5.9 years. There were 83
male (50.0%) and 83 (50.0%) female recipients. Median age at time of OLTx
was 3.8 years (range 0.1-17.5 years). Biliary atresia was the most frequent
indication for liver transplantation (99 patients; 59.6%). Patients received split
livers (118; 71.1%), whole-size livers (41; 24.7%), and reduced-size livers (7;
4.2%). Retransplantation was indicated in 22 patients (13.3%). Posttransplant
immunosuppression was cyclosporine (CsA)-based in 50 patients (30.1%) and
tacrolimus (TAC)-based in 116 patients (69.9%). Long-term follow-up after
hospital discharge was scheduled and standardized.
Overall patient survival rates at 1, 3, and 5 years were 87%, 84%, and 83%.
Re-transplantation rate was 13.3%. Respective graft survival rates were 82%,
78%, and 77%. Pre-transplantation variables with a significant adverse effect
on patient were United Network for Organ Sharing (UNOS) status (p<0.015)
and CsA-based immunosuppressive therapy (p<0.001). Graft survival was
negatively influenced by fulminant hepatic failure as indication for liver
transplantation (p = 0.004), UNOS status (p<0.02), ischemia time (p = 0.016),
CsA-based immunosuppression (p<0.001), and episodes of respectively
PTLD, vascular complications and functional cholestasis (p = 0.001, p < 0.001,
p < 0.001). Several risk factors were identified for long-term complications
after pediatric OLTx, as donor variables, CMV and EBV infection, developing
auto-antibodies after transplantation, short-term complications, and type of
immunosuppressive therapy.
Despite the good results of pediatric liver transplantation, improvement of the
outcome is still possible.
Total rehabilitation with a high quality of life after transplantation can be
attained in most children.

POSTER BOARD NUMBER P4 – 46
1996 A CORRELATION BETWEEN PRETRANSPLANTATION
MELD SCORE AND DEGREE OF HEPATIC FIBROSIS IN
EXPLANTED LIVERS

THURSDAY

L. Yan, H. Zuo, Y. Zeng, W.Y. Lau
Division of Liver Transplantation, West China Hospital, West China Medical
School
Objectives: To correlate the pretransplantation MELD score with the degree of
hepatic fibrosis using the computer imaging analysis and the Ishak pathological
grading in the explanted livers.
Methods: A MELD score was determined on 58 patients with chronic liver
disease before liver transplantation. The area ratios of hepatic fibrosis were
determined using the computer imaging analysis in the explanted livers.
Pathological grading of the degree of cirrhosis were also done on these
specimens using the Ishak grading by two independent pathologists.
Results: The MELD score ranged from 11 to 38 (mean ¡À SD, 22.85 ¡À 9.32).
The area ratio of hepatic fibrosis of the 58 livers ranged from 23.2% to 88.4%
(mean: 56.7%). There were 0, 2, 7, 12, 18, 12, and 7 patients in the Ishak
grading 0 to 6, respectively. The bigger the MELD score, the higher was the
Ishak grading and the larger was the area ratio of hepatic fibrosis (Spearman¡¯s
rank correlation test, p < 0.01). Linear regression analysis showed a linear
relationship between the MELD score and the degree of hepatic fibrosis.
Conclusions: The MELD score correlated with the area ratio of hepatic fibrosis
as determined by computer imaging techniques, and with the Ishak pathological
grading.
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1998 TWO SUCCSESFUL ORTHOTOPIC LIVER
TRANSPLANTATIONS USING LIVER GRAFTS FROM
DECEASED DONORS WITH OPISTHORCHIASIS
E. Bessonova, I. Serebryakov, O. Lyasnicova, O. Nikiforova, B. Fadin, M.
Prudkov, S. Alpherev, O. Orlov, N. Osadchaya
1
Ekaterinburg Regional Hospital, Regional Hepatological Centre
Introduction: Opisthorchiasis is a parasitogenic disease caused by
Opisthirchis felineus(cat liver fluke).Most infections are asymptomatic. In
rare cases,cholangitis,cholecystitis with involvment of the pancreatic ducts
may develop. Diagnosis is based on microscopic identification of eggs in stool
specimens.O.Felineus is found mainly in Asia,including the former Soviet
Union.
Aim: To report two cases of liver transplantations using liver grafts from
deceased donors with opisthorchiasis.
Method: Two 36 and 38-year-old women were submitted to a liver
transplantation,one for HCV related liver disease and one for cirrhosis from
autoimmune hepatitis.
As far as it is highly difficult to detect opisthorchiasis is deceased donor it is
impossible to assess it as donor risk factor in advance. In both cases Opisthirchis
felineus were revealed in donors during surgery. Post operative course in the
intensive care unit was marked by massive drainage of opisthichises through
external hepaticojejunostomy tube(hepaticojejunostomy was done in the aim to
avoid mechanical obstraction of the bile duct).

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Poster Abstracts
Results: The patients were discharged after 18 and 16 days on
cyclosporin,prednisolone and mycophenolic acid. 24 months(in one case)
and 21 months (in another) after transplantation both patiens are negative for
opisthorchiasis(by serology and microscopic identification of eggs in stool
specimens). One of the patients has recurrence of chronic hepatitis C and
receive antiviral therapy.
Conclusion: This report clearly illustrates the possibility the donor pool of
organs for transplantation purposes in the regions endemic for opisthorchiasis.
This the first case reported.

alcoholic liver disease compared to other parenchymal aetiologies (p=0.015).
No relationships were identified between measured dark adaptation and retinol,
retinol binding protein, zinc or Child Pugh score. Dark adaptation improved by
2.9±3.4 dB (p=0.05) one month later.
Conclusions: Impaired dark adaptation was commonly present in patients with
chronic liver disease and vitamin A deficiency, especially those with alcoholic
aetiology, and was frequently unrecognized. Dark adaptation improved after
vitamin A, allowing light of half the previous intensity to be seen.

POSTER BOARD NUMBER P4 – 51
POSTER BOARD NUMBER P4 – 49
1999 LIVER FAILURE AND NEED FOR LIVER
TRANSPLANTATION IN PATIENTS WITH ADVANCED
HEPATOPORTAL SCLEROSIS
B. Geramizadeh1, S.A. Malek-Hosseini, S. Nikeghbalian, H. Salahi,
A. Bahador
1
Transplant Research Center, Pathology Department, 2Transplant Research
Center, 3Transplant Research Center, 4Transplant Research Center,
5
Transplant Research Center
Introduction: Hepatoportal sclerosis (HPS) is one of the causes of noncirrhotic
portal hypertension.
In general, hepatic synthetic function is preserved and treatment is aimed at
relief of the portal hypertension.
Material and Methods: In this study, we present the clinical and pathologic
features of HPS cases who underwent liver transplantation (LT). LT cases with
confirmed gross and microscopic diagnosis of HPS are included. Weight of the
explanted liver, presence of thrombi in the main blood vessels, and gross and
microscopic characteristics were assessed. Clinical information was gathered
from chart review.
Results: From 2005-6 patients were diagnosed with HPS. Two of the cases
were labeled as cryptogenic cirrhosis and one of them as primary sclerosing
cholangitis. All the three patients had ascites, huge splenomegaly, jaundice,
and esophageal varices.
At the time of LT, mean values were: prothrombin time of 13 seconds, serum
albumin 3.2 g/dL, serum bilirubin 1.6 mg/dL, alkaline phosphatase 468 IU/L,
aspartate aminotransferase 43IU/L, and alanine aminotransferase 35 IU/L.
Explanted livers were shrunken, with weights ranging from 715 to 1199 g (mean
934). Nonocclusive portal vein thrombosis was present in 1 patients. On histologic
examination, there was dense portal fibrosis, and marked phlebosclerosis.
Conclusion: In conclusion, HPS can cause hepatic synthetic dysfunction
that may necessitate LT. Small liver volume, significant portal fibrosis, and
phlebosclerosis may contribute to hepatic parenchymal loss and subsequent
synthetic compromise.

POSTER BOARD NUMBER P4 – 50
2000 DARK ADAPTATION IMPAIRMENT IN VITAMIN A
DEFICIENT ADULTS AWAITING LIVER TRANSPLANTATIONIMPROVEMENT WITH INTRAMUSCULAR VITAMIN A.
W. Abbott-Johnson1, P. Kerlin1, G. Abiad2, A. Clague3, R. Cuneo4
1
Princess Alexandra Hospital, 2Prince of Wales Hospital, 3Queensland Health
Pathology Service, 4University of Queensland
Background and Aims: Vitamin A deficiency and night blindness occur in
chronic liver disease but measures of dark adaptation impairment and response to
vitamin A administration are limited. This prospective study aimed to 1) measure
dark adaptation in patients with chronic liver disease and vitamin A deficiency 2)
compare symptoms of night blindness with measured dark adaptation 3) explore
relationships between dark adaptation and vitamin A, zinc and Child Pugh score
4) quantify improvements in dark adaptation after intramuscular vitamin A.
Methods: Twenty patients (15M, 5F, mean age 51 years) (alcoholic liver disease
10, other parenchymal disease 6, cholestatic disease 4) were selected based on
plasma retinol ≤; 0.7 μmol/L (NR 1.6-2.3). There were 15 healthy age-matched
controls. Dark adaptation was measured using a SST-1 dark adaptometer and
perception was assessed by questionnaire. Eight patients received 50,000 IU of
aqueous retinyl palmitate by injection and were restudied one month later.
Results: Eight (40%) patients had impaired dark adaptation. Most (75%)
did not perceive a problem. Impaired dark adaptation was more prevalent in

2001 SURGICAL MORBIDITY & MORTALITY AFTER LIVER
TRANSPLANTATION IN 87 EGYPTIANS TRANSPLANTED IN
USA.
A. Salah1, H. Khalaf2, M. El-Mansy3
1
Cairo University, 2King Faiasal Hospital, 36th October University
Objective: To study the long term outcome after liver transplantation (LT) in
Egyptian patients who underwent LT in USA
Methods: Between May 1994 and February 2007, over 94 Egyptians underwent
cadaveric LT in the States. Data of 87 patients were collected in Egypt through
personal communications with the Overseas Liver Transplant Centers and
through the records of the Egyptian Liver Transplant Association (ELTA).
Results: Of the 87 patients, there were 68 men and 19 women. Median age was
47 (4-68 years). Hepatitis C virus (HCV) cirrhosis whether alone or mixed with
schistosomiasis was the main indication for LT. Primary nonfunctioning (PNF)
was encountered in eight (9.2%) patients, of whom three were retransplanted
and only one survived. Biliary complications were encountered in 22 patients
(25.3%); this included simple bile leak in 5 patients, biliary obstruction in
8, and biliary peritonitis in one. Seven patients were treated by endoscopic
stenting and dilatation, whereas surgical reconstruction was needed in the
remaining patients. Vascular complications were encountered in 7 patients
(8.1%): two had hepatic artery thrombosis and was successfully retransplanted
and five had venous outflow obstruction which were successfully treated by
transjugular balloon dilatation. Postoperative bleeding was encountered in
7 (9.2%) patients, only three of them required surgical exploration and one
died due to ruptured splenic artery aneurysm. Incisional hernia occurred in 4
patients (4.6%). Out of those 87 recepients, 68 (78.2%) survived after a median
follow up of 4.7 years (range 1-12.5 years). Death was due to PNF & early graft
failure in 6 patients, postoperative bleeding in one patient, recurrent HCV in 9
patients and chronic rejection in three patients.
Conclusion: The peculiar pattern of mixed pathology (hepatitis C and
schistosomal periportal fibrosis), and may be the frequent use of marginal
donor livers in Egyptian patients are factors that impair the results of LT.
Although living donor liver transplantation has been introduced recently in
Egypt, cadaveric liver donation is still not legalized by the government. We
strongly believe that immediate steps should be taken to establish a cadaveric
LT program in Egypt. This would be a convenience for patients and would save
the money spent on treatment in foreign countries.

POSTER BOARD NUMBER P4 – 52
2002 THE CLINICAL RELEVANCE OF THE ANHEPATIC
PHASE DURING LIVER TRANSPLANTATION
A.J.C. IJtsma, C.S. Van Der Hilst, E.M. TenVergert, .T. De Boer,
K.P. De Jong, P.M.J.G. Peeters, R.J. Porte, M.J.H. Slooff
University Medical Center Groningen
The aim of this study was to assess the relation between the duration of the
anhepatic phase and the outcome after liver transplantation in terms of patient
and graft survival and graft dysfunction.
A single center cohort of consecutive adult primary liver transplant recipients
transplanted with the piggyback technique using heart-beating donors without
veno-venous bypass between 1994 and 2004 was analysed. All patients had
at least one year follow-up. The study group consisted of 169 patients. Study
variables were donor age and body mass index, recipient age, – body mass index,
– diagnosis and – MELD score, peroperative RBC transfusions, blood loss and
the duration of the cold and warm ischemia time and of the anhepatic phase.
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up was 25.7 &#61617; 19.8 months (range, 2-69 months). Retransplant
was required in 1 patient 12 days after the first LT owing to primary graft
nonfunction. Five of the 27 patients died within 4 months of the surgery.
The remaining 21 survivors (81.5%) have remained well, with normal liver
function and no disease recurrence. In conclusion, LT is a curative procedure
for Wilson’s disease in patients presenting with fulminant hepatic failure and
others with end-stage hepatic insufficiency. After LT, the serum ceruloplasmin
level increases to the normal range, urinary copper excretion decreases, and
neurologic manifestations improve.

POSTER BOARD NUMBER P4 – 54
Fig 1. Definition of ischemia time and anhepatic phases
The functional anhepatic phase (FAHP) and anatomical anhepatic phase
(AAHP) were separately analysed and defined as in figure 1. ROC curves were
constructed to determine optimal cut-off values. Graft dysfunction was defined
as either primary non function or initial poor function. Primary non function
was defined as graft failure leading to either patient death or retransplantation
within a week after transplantation. Initial poor function was defined by the
Ploeg-Maring criteria as an ASAT > 2000 U/l and PT > 16 seconds at any time
point between days 2-7 post-transplantation.
Median AAHP was 76 minutes (37 – 321). Median FAHP was 98 minutes (45 –
321). Graft dysfunction occurred in 27 patients (16%), consisting of 6 patients
(4%) with primary non function and 21 patients (12%) with initial poor function.
Univariate analysis showed an AAHP over 100 mins, recipient BMI over 25
kg/m2 and peroperative RBC transfusion to be predictive factors for graft
dysfunction. In patients with an AAHP below 100 minutes, the incidence of
graft dysfunction was 16 out of 135 (12%) while in patients with an AAHP over
100 minutes this was 11 out of 33 (33%) (p < 0.003).
Multivariate analysis proved the same three variables to be independent
predictors for graft dysfunction. Corresponding odds ratios for AAHP over 100
minutes, recipient BMI over 25 kg/m2 and peroperative RBC transfusion were
4.02, 3.42 and 3.22 respectively.
Graft dysfunction was the only study variable independently associated with
patient survival. One year patient survival in patients with graft dysfunction
was 67% versus 90% in patients without graft dysfunction (p<0.001). A
direct relation between the AAHP duration and patient or graft survival could,
however, not be established.
In conclusion, this study shows that liver transplant patients with an anatomical
anhepatic phase over 100 minutes have a threefold higher incidence of graft
dysfunction. Patients with graft dysfunction had a significantly worse one year
patient survival.

POSTER BOARD NUMBER P4 – 53
2003 LIVER TRANSPLANT FOR WILSON’S DISEASE
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S. Sevmis1, H. Karakayali1, G. Moray1, N. Savas2, F. Ozcay3, U. Yilmaz2, A.
Torgay3, G. Arslan3, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Gastroenterology,
3
Baskent University Faculty of Medicine, Department of Anesthesiology
Wilson’s disease is an inherited disorder of copper metabolism characterized
by reduced biliary copper excretion, which results in copper accumulation in
the tissues with liver injury and failure. Liver transplant (LT) can be lifesaving
for patients with Wilson’s disease who present with fulminant liver failure
and for patients’ unresponsive to medical therapy. The aim of this study is to
review our experience with LT for patients with Wilson’s disease. Between
September 2001 and January 2008, 28 LTs were performed at our center in 27
patients with Wilson’s disease. Our Wilson’s disease series comprised 7 female
and 20 male patients (mean age, 15.6 &#61617; 9.9 years; range, 5-51 years).
Six patients were transplanted owing to coexistent fulminant hepatic failure.
Twenty patients presented with chronic advanced liver disease with (n = 10)
or without (n =10) associated neurologic manifestations. We performed fullsize, deceased-donor in 3 LTs and living-related donor in the remaining 25 LTs.
Eight patients had a family history of Wilson’s disease. We detected a KayserFleischer ring in 21 patients. All patients had a low serum ceruloplasmin level
(mean, 27.8 mg/dL) and a high urinary copper excretion level (mean, 4119
μg/d) before LT. Following successful LT, there was a significant reduction
in urinary copper excretion (median, 37.1 μg/d) in all patients. Mean follow-
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2004 LIVER TRANSPLANTATION FOR BILLIARY ATRESIA
H. Karakayali1, F. Ozcay2, S. Sevmis1, G. Moray1, N. Yavuzer1, A. Torgay3, G.
Arslan3, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Pediatry,
3
Baskent University Faculty of Medicine, Department of Anesthesiology
Biliary atresia is the most common indication for liver transplantation (LT) in
the pediatric population. The aim of this study is to present our institutional
experience with LT as a treatment for end-stage liver disease in children with
biliary atresia. A retrospective review of transplant records was performed.
Twenty –four billiary atresia recipients (11 males, 13 female; mean age, 10.3 ±
5.4 months; range, 6 to 26 months) underwent LT. Mean preoperative weight
and height were 11.2 kg and 72.5 cm respectively. Nineteen recipients were
younger than 1 year of age and 18 recipients weighed less than 10 kg at the time
of transplantation. Seventeen recipients had a previous Kasai operation prior to
transplant. Mean serum total bilürübin level was 18.3 ± 16 mg/dL (range; 5.5
to 59.8 mg/dL) before LT. Twenty-two left lateral segment grafts and 2 whole
grafts were transplanted. The mean recipient operative time was 8.9 ± 1.8 hours
(range; 6 to 10 hours). The mean recipient intraoperative blood loss was 1.5
units. Two hepatic arterial thromboses and 2 billiary leak occurred in the early
postoperative period. Portal vein stenosis developed in 1 recipient 16 months
after LT. Three recipients died during follow-up 17 ± 14.6 months (range, 1 to
45 months). The remaining 21 recipients (87.5%) are alive with a good graft
functioning. In conclusion, our results confirm the effectiveness of LT for the
treatment of children with billiary atresia and failed Kasai procedure. Livingrelated liver grafts represent an excellent organ supply for these patients.

POSTER BOARD NUMBER P4 – 55
2005 PARTIAL SPLENIC EMBOLIZATION FOR
HYPERSPLENISM AFTER LIVER TRANSPLANT
G. Moray1, F. Boyvat2, H. Karakayali1, I. Aliosmanoglu1, Y. Ekici1, N. Savas2,
C. Aydogan1, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Gastroenterology
Partial splenic embolization has been demonstrated to be an effective alternative
to splenectomy for patients with hypersplenism. Splenectomy in these patients can
be associated with an increased risk of perioperative complications, overwhelming
postsplenectomy sepsis, and mortality. Partial splenic embolization has the
advantages of nonoperative intervention and resolution of the complications of
hypersplenism. We report the use of this technique in patients with hypersplenism
who had undergone liver transplant with persistent hypersplenism after surgery.
Six patients with persistent hypersplenism after liver transplant were treated
at our center between September 2001 and January 2008. Four patients were
male and 2 were female. The mean age of the patients was 32.5&#61617;196
years (range, 5 to 54 years) All 6 patients had concomitant thrombocytopenia
and neutropenia with platelet counts below 50 000. Patients underwent selective
arterial catheterization and embolization via 500 to 700 micron polyvinyl alcohol
particles. The lower pole of the spleen was selectively embolized in all patients
to achieve a 30% to 50% reduction in flow as determined by angiography.
Patients were followed with routine computed tomography scans, and platelet
and white blood cell counts for a mean of 16.6 months. All patients had persistent
resolution of thrombocytopenia and neutropenia after embolization. One patient
required splenectomy 12 months after treatment owing to a splenic abscess. No
procedure-related complications occurred in any patient. In conclusion; partial
splenic embolization appears to be a safe and effective treatment of persistent
hypersplenism in patients with hypersplenism after liver transplant.
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2006 CYTOMEGALOVIRUS INFECTIONS AFTER LIVER
TRANSPLANTATION: INCIDENCE, RISK FACTORS AND
OUTCOMES
Y. Nakamura, J.C. Hong, R.M. Ghobrial, B. Nonthasoot, J.C. Kim,
T.E. Collins, D.G. Farmer, R.W. Busuttil
Division of Liver and Pancreas Transplantation, Department of Surgery,
David Geffen School of Medicine, UCLA
Introduction: Cytomegalovirus disease (CMV) is a common cause of
morbidity and mortality complication after liver transplantation (LT). Females
and over-immunosuppression, CMV D+/R- have been reported as risk factors.
We sought to determine the incidence, risk factors and outcomes of patients
who developed CMV after LT.
Methods: We conducted a single center retrospective analysis on 805 LT
performed from June 1, 2003 to Dec 31, 2006. We defined CMV disease
included both CMV syndrome and tissue-invasive CMV. The criteria of CMV
syndrome was defined as persistent fever (temperature>38 Ž for >2 days) and
wasting, with or without leucopenia(WBC<3.5 ~109/L) and thrombocytopenia
(Platelet count <100,000 ~109/L) Cwhich could not attributed to other causes
in a patient with CMV viremia. CMV disease of the liver or gastrointestinal
tract was diagnosed by finding histologic or culture evidence of CMV in a
biopsy of the liver and gastrointestinal tract in a patient with liver dysfunction
or gastrointestinal symptoms not explainable by other causes.
Results: Among 805 patients, 17 patients developed CMV infections (2.1%).
In these patients, 10 patients were CMV diseases, other 7 patients were CMV
syndrome. There were all 17 adults, 5 males (%) and 12 females%). Mean
recipient age was 51.4 (range 28-72) years while mean donor age was 32.3 (range
14-70) years. There were 6 patients with CMV serologic D+/R-. As preoperative
risk factors, four patients have been taken prior liver transplantation, two patients
have been performed liver and kidney transplantation, one patient has done liver
and small intestinal transplantation. Mean MELD score was 33.5. All of the
patients are alive after exprosuring CMV infection. Five patients have been
received artificical hemodialysis before LT. In term of initial immunosuppression,
14 patients have been administered consist of Tacrolimus and 2 patients were
Tacrolimus and Predonisone, the other was Predonisone and Mycofenolate
Mofetil. CMV on set mean time was 152 days (52-597). Prophylaxis of CMV
disease has been continued fo 100days. 13 patients developed CMV infection
after period of prophylaxis. Seven patients have happen acute rejection with
need for management, Five in all were injected by Steroid pulse, the other
two patients were only increased base line immunosuppression therapy.
Nevertheless two patients occurred secondary acute rejection with treatment of
increasing base line immunosuppression. 13 patients had complications with
other bacterial infection or fungal infection. Three patients were died, because
of multiple organ filure or Sepsis or disseminated fungal infection.
Conclusion: Female must be risk factors in our patients. The further study
is needed to identify definite risk factors and appropriate treatment of this
dreadful complication.

POSTER BOARD NUMBER P4 – 57
2007 EXPERIENCE OF THE FIRST 20 LIVER
TRANSPLANTATIONS FAILURES AND SUCCESSES
A. Jafarian1, M.N. Toosi1, J. Salimi2, A. Najafi2, M. Moeeni2,
Z. Ahmadinejad1, S. Seifi1, F.S. Ardalan1, M.A. Mohagheghi1,
A. Rabbani1
1
Imam Khomeini Hospital Complex- Tehran University of Medical Sciences,
2
Sina Hospital- Tehran University of Medical Sciences
Introduction: Liver transplantation has been accepted as the standard treatment
for end stage liver disease since 1983. Establishment of a new program has
specific problems and lessons.
Patients & Methods: From January 2002 to December 2007, 20 liver
transplantations were done in Imam Khomeini Hospital Complex, Tehran,
IR Iran. In the first series of 9 cases which was performed within 4 years, the
standard technique was done in all except one patient. We changed the procedure
to piggy back hepatectomy and cavocavoplasty in the second series of 11 patients
except for 1 case. This group was operated on in a 13 months period.
Results: Mean age of the patients in the two groups were 29 and 42.3

respectively. Mean Child-Pough score was 10.1 in group one and 9.45 in group
two. There were 5 female patients in the group one and 4 in the latter. The most
common indication for transplantation was hepatitis B followed by cryptogenic
cirrhosis. We had 5 early postop mortalities in the first group and 2 in the second.
Causes of death in the first group were intra operative hemorrhage, primary non
function, post op hemorrhage due to DIC (two patients) and Klebsiella sepsis.
Two mortalities in the second group were due to primary non function and
pulmonary sepsis. We had no early biliary complication.
Conclusion: Outcome of liver transplantation could be rapidly progressed with
judicious refinement of technique and increasing number of transplants. 82%
one month survival may be an indicator of passing learning curve.

POSTER BOARD NUMBER P4 – 58
2008 CYTOMEGALOVIRUS INFECTION AFTER LIVING
DONOR LIVER TRANSPLANTATION IN ONE INSTITUTION
Y. Tsukamoto, H. Okajima, S. Ogata, T. Murokawa, K. Lee, H. Yamamoto, T.
Takeichi, K. Asonuma, Y. Inomata
Pediatric and transplantation surgery,Kumamoto University
Introduction: Cytomegalovirus (CMV) infection after organ transplantation
can be well treated with antiviral drugs in the recent time, however, sometimes
still develops fatal disease. It is necessary to take care before developing CMV
disease after CMV infection. The aims of this study were to evaluate risk
factors for CMV infection after living donor liver transplantation and to assess
our strategy for CMV infection.
Patients & Methods: One hundred and ninety-one patients who received
living donor liver transplantation in our institution from September 2000 to
February 2008 were enrolled in this study. There were 66 pediatric and 125 adult
patients. Blood type combination between recipient and donor was identical or
compatible in 172 cases and incompatible in 19. CMV infection was identified
with more than one positive cells of CMV early antigen in the peripheral blood.
10 mg/kg/day of Ganciclovir for 2 weeks were used for patients with more than
two positive cells of CMV early antigen. Incidence of CMV infection according
to the combination of donor/recipient CMV-IgG serology (donor-/recipient-,
donor-/recipient+, donor+/recipient-, and donor+/recipient+) was evaluated.
Results: CMV infection was identified in 93cases (48.7%). 95% of these
patients were identified within two months after transplantation and 70 cases
(75%) marked more than 2 positive cells. There were no significant differences
of positive ratio between pediatric and adult patients. 84% of patients with
ABO blood type incompatible were identified CMV infection. Regarding to
the combination of donor’s and recipient’s CMV antibody, D+/R- patients had
higher rate of CMV infection (82.4%), and the recipients with donor negative
had very small possibility of CMV infection. Seven out of 70 recipients who
treated with Ganciclovir needed to increase dosage of the drug and to decrease
of immune-suppression due to initial poor response. However, none of the
patients developed CMV disease in our series.
Conclusion: CMV-IgG combination between the recipient negative and the
donor positive is the risk factor for CMV infection after living donor liver
transplantation. Our strategy for CMV infection was effective to prevent
developing CMV disease.
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2009 COMBINED LIVER-KIDNEY TRANSPLANTATION
ACROSS A POSITIVE FLOW CROSSMATCH: A CAUSE FOR
CONCERN?
L. Shen, A. Agarwal, N. Turgeon, T. Pearson, C. Larsen, R. Bray, H. Gebel,
A. Kirk, K. Kokko
Emory University
Background: The number of reported combined liver and kidney transplants
(CLKT) across a positive (+) flow crossmatch (FCXM) is small. Although it is
known that kidney transplants alone have a poor outcome with +FCXM, it is
not considered a major risk factor for liver transplant.
Methods: A retrospective review of CLKT between March 2003 and November
2007 was performed to determine whether or not there was an adverse effect on
patient or graft outcomes in transplants across a +FCXM.
Results: A total of 29 CLKT were performed at our institution that included
13 (45%) recipients with a +FCXM. Of the 24 patients who underwent a liver
or kidney biopies for organ dysfunction, there were 5 instances of recurrent
Hepatitis C, one liver biopsy with acute cellular rejection (ACR), and one
kidney biopsy with positive C4d staining antibody mediated rejection (AMR).
ACR was treated with high-dose steriods only. AMR was treated with two
series of thymoglobulin, IV immunoglobulin, and plasmapheresis therapy for
persistent humoral rejection. After therapy, both patients had good resolution
of rejection and return to good organ function.
The median follow-up was 15 months. The overall patient survival for
the CLKT was 96.4%, 75.9%, and 66.4% at 1 month, 1 year, and 3 years
respectively. The survival rate for the +FCXM (91.7%, 64.2%, 32.1%)
was lower than the negative (-) FCXM (100%, 88.9%, 66.7%) but was not
statistically different (p=0.31) in this small group. For comparison, the survival
for kidney transplants alone (97.9%, 91.9%, 76.3%) and liver transplans alone
(92.3%, 72.5%, 65.6%) during the same time periods was not different.
Five (38.5% – 5/13) deaths occurred in the +FCXM versus 2 (12.5% – 2/16)
deaths in the -FCXM. Two deaths were from liver graft failure. Three patients
died from sepsis resulting in acute renal failure at time of death. Two deaths
were from cardiovascular events. For those who have survived to this date,
each has good renal and hepatic allograft function.
Conclusions: In combination with liver transplant, kidney transplant can be
successfully performed despite a +FCXM. Although hyperacute rejection does
not occur, complications including graft failure and infection suggest that a
+FCXM may adversely influence the outcome in ways other than graft failure.
Although a +FCXM is not considered a contraindication to liver transplantation,
both cellular and humoral rejection can occur in CLKT but can be treated with
aggressive therapy. CLKT may lead to adverse long term survival outcomes
compared to single organ transplantation but this needs further study.
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2010 BACTERIAL INFECTIONS IN THE EARLY
POSTTRANSPLANT PERIOD AFTER LIVER
TRANSPLANTATION – ETIOLOGICAL AGENTS AND THEIR
SUSCEPTIBILITY.
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D. Kawecki1, A. Sawicka-Grzelak1, K. Kot1, E. Swoboda-Kopec1,
A. Chmura2, M. Pacholczyk2, B. Lagiewska2, P. Malkowski3, W. Rowinski2,
M. Luczak1
1
Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of
General Surgery and Transplantation Medical University of Warsaw, 3Dept.
of Surgical Nursing and Transplantation Medical University of Warsaw
An analysis of bacterial infections in the early posttransplant period after liver
transplantation in adults.
Material and methods: The study covered 83 adult patients undergoing liver
transplantation from 2001 to the end of 2004. All the patients were followed
prospectively for infections from the LT date and during the first four weeks
after surgery. Basic immunosuppression consisted of steroids and tacrolimus
(Prograf®; Fujisawa, Germany). Antimicrobial prophylaxis was administered
intravenously from the day of transpalntation: piperacillin/tazobactam
(Tazocin®, Wyeth, USA), fluconazole (Diflucan®; Phizer, USA) and selective
bowel decontamination (orally a liquid suspension of amikacin and nystatin)
was carried out.
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Samples of clinical materials (blood, urine, wound swabs, stool and other)
were investigated. The microorganisms were cultured and identified in
accordance with standard bacteriological procedures. Susceptibility testing
was carried out using (NCCLS) procedures. The statistical analysis was made
by chi-square test.
Results: 913 clinical samples taken from liver recipients were investigated
in microbiological laboratory. In total 469 strains were cultured. Among
the bacterial strains, the most common were Gram-positive bacteria n=331
strains (70,6%), Gram-negative bacteria n=133 strains (28,4%) and yeast
like fungi n=5 strains (1%). In the early posttransplant period the common
isolates were taken from Surgical Site Area n=284 (60%) with predomination
of Gram(+) strains n=222 (78%), Gram(-) strains n=61 (21,5%). From
blood n=99 strains (21,1%) were cultured: Gram(+) n=75 (75,8%) and
Gram(-) n=22 (22,2%). Urine samples n=73 (15,6%): among them Gram(-)
n=46 (63%), Gram(+) n=25 (34%), fungi n=2 (3%). Samples taken from
respiratory tract n=13 (2,8%) strains were cultured: Gram(+) n=9 (69%),
Gram(-) n=4 (31%). From 54 stool samples Clostridium difficile toxins were
positive in 63%, only in 16,7% of samples C. difficile strains were detected,
30% were negative.
We analyzed the susceptibility of cultured strains to antibacterial agents. In total
n=10 strains of (MRSA), n=138 of (MRCNS) staphylococci were detected,
86% of enterococci were (HLAR) strains and from Enterobacteriaceae family
12,5% (ESBL) rods were detected.
Conclusions: The presence of (MDR) bacterial strains after liver transplantation
such as: methicillin-resistant staphylococci (MRSA) – 52,6%, (MRCNS) –
81,7%, enterococci (HLAR) – 86%, enteric Gram(-) bacteria (ESBL) – 12,5%
required better professional infection controls.

POSTER BOARD NUMBER P4 – 61
2011 GENETIC SIMILARITY OF CANDIDA KRUSEI STRAINS,
ISOLATED FROM LIVER TRANSPLANT RECIPIENT, ON
THE BASE OF GENOTYPIC ANALYSIS AND PHENOTYPIC
FEATURES – THE CLINICAL CASE OF THE PATIENT WITH
INVASIVE FUNGAL INFECTION.
D. Kawecki1, M. Krawczyk2, M.S.M. Sikora1, E. Swoboda-Kopec1, M.S.M.
Dabkowska1, M. Luczak1
1
Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of
General Surgery Liver and Transplantation
Introduction: The significant increase of Candida krusei isolates number which
are resistant for antifungal agents could be a serious menace for transplant
recipiens. This fact concerns mainly immunodeficient patients.
Aim: of the Study: Analysis of C. krusei strains isolated from different
parts of the body of patient with multiorgan infection who underwent liver
transplantation procedure to compare their phenotypic features and genetic
similarity.
Material and Methods: The analysis was perform for the 7 strains isolated
from: oral cavity swab (1 isolate), nose swab (1 isolate), abdominal cavity swab
(1 isolate), drain I (1 isolate), drain II (1) and III (1 isolate) and bile (1 isolate)
from patient after liver transplantation hospitalized in Department of General
Surgery and Liver Diseases. Isolation and identification of the isolates was
done according to standard mycological methods of diagnostic. Determination
of genetic similarity was performed with RAPD method. Enzymatic activity
analysis was conducted using API-ZYM test.
Results: The RAPD analysis demonstrated the existence of 4 different genetic
types among 7 isolates. It was established that isolates from oral cavity and
from nose had the same band pattern – type 1. Isolates from drains: I and III
and bile were classified to type 2. But isolates from drain II and abdomen
were distinguished as the separate types (3 and 4). Enzymatic activity analysis
determined the occurrence of two biotypes with different hydrolytic enzymes
synthesis profile.
Conclusion: 1. The application of RAPD technique and phenotypic diagnostic
of API-ZYM of Candida krusei isolates allowed for detailed identification of
the strains. 2. Candida krusei is the yeastlike species with reduced susceptibility
for antifungal agents and it is one of the factors of heavy fungal infections in
solid organ recipients.
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2012 EVOLUTION OF HYPERSPLENISM AFTER LIVER
TRANSPLANT: @CT/MRI VOLUMETRY ANALYSIS
F. Chikamori1, S. Nishida2, T. Panaqiotis2, A. Maki2, A. Tekin2, J. Moon2, D.
Levi2, T. Kato2, G. Selvaggi2, A. Tzakis2
1
Kuniyoshi Hospital, 2University of Miami, Miami Transplant Institute
Objective: The aim of this study was to evaluate the effect of liver
transplantation on the spleen size, and spontaneous spleno-renal shunt (SRS)
by CT/MRI volumetry.
Methods: Between December 2001 and February 2007, 462 adult patients
underwent orthotopic liver transplantations (OLTX) at our institution. Of these
patients, CT or MRI information was reviewed retrospectively in fifty-five
patients. Volumetory of the spleen and liver, spleen/liver volume ratio (S/L ratio),
presence and size of SRS, platelet counts were evaluated before and after OLTX.
Results: Mean spleen volume decreased from 827±463 cm3 to 662±376 cm3
after OLTX (P<0.01). The distribution of normal/mild/severe splenomegaly
changed from 8/10/37 before OLTX to 10/22/23 after OLTX (p<0.05).
Five (11%) patients returned to normal range spleen size after OLTX. SRS
was observed in 19 patients (35%). The diameter of SRS also significantly
decreased from 1.0±0.5 cm before OLTX to 0.7±0.5 cm after OLTX (P<0.05).
SRS disappeared in 16% of patients (3/19). S/L ratio significantly decreased
from 0.65±0.33 to 0.38± 0.17 (P<0.01) after OLTX. Improvement of the
platelet count in the group with postoperative S/L ratio of >0.35 was not as
good as the group with S/L ratio <0.35 (P<0.05). Recurrent thrombocytopenia
in the former group was more frequently observed (P<0.05).
Conclusion: Spleen size and SRS size became significantly smaller after
OLTX. However, patients with S/L ratio >0.35 after OLTX tend to have low
platelet counts.

POSTER BOARD NUMBER P4 – 63
2013 BILIARY INDOCYANINE GREEN EXCRETION – AN
ADDITIONAL USEFUL TOOL FOR THE ASSESSMENT OF
ALLOGRAFT FUNCTION AFTER LIVER TRANSPLANTATION
F. Rauchfuss1, E. Bärthel1, M. Paxian2, M. Siering2, A.S. Kortgen2,
A. Kornberg1, M. Bauer2, U. Settmacher1
1
Department for General, Visceral and Vascular Surgery, Friedrich-SchillerUniversity Jena, Germany, 2Department of Anaesthesiology and Critical Care
Medicine, Friedrich-Schiller-University Jena, Germany
Background: The assessment of the indocyanine plasma disappearance rate
(ICG-PDR) is a common tool for evaluating the liver function after major liver
surgery. The uptake of the dye (ICG) takes place at the hepatocyte’s basolateral
membrane and ICG will be excreted into the bile.
The aim of this study was to correlate the ICG-bile excretion with the allograft
function after liver transplantation (LT).
Methods: Eleven liver recipients were included in this study, so far. The postLT ICG-PDR measurement was performed in standard practice twelve hours
after reperfusion. Moreover, we quantified the dye excretion in the bile fluid.
Spectrophotometric assessment of the ICG concentration (wave length 800 nm)
was read using a NanodropTM spectrophotometer (Nanodrop Technologies,
Wilmington, USA).
The allograft function was evaluated at day one post-LT using the following
criteria: Good liver viability: GOT max. < 1000 U/l; spontaneous PT > 50%
and no need for clotting factor substitution; bile production > 100 ml/day;
Fair graft function: GOT 1000-2500 U/l; clotting factor support < 2 days; bile
production < 100 ml/day; Poor graft function GOT > 2500 U/l, clotting factor
support > 2 days, bile production < 20 ml/day.
Statistical analysis was performed using a MWU-Test, a p-value < 0,05 was
considered to be significant.
Results: Two patients had a good graft function (18,8%), six had a fair one
(54,54%) and three had a poor graft function (27,27%), one of them needed a
retransplantation.
Biliary ICG-excretion was significantly different between patients with fair
and poor graft function (fair graft function: 229,28 ng/μl ± 282,33; poor graft
function: 8,37 ng/μl ± 14,5; p=0,024). There was no difference between patients
with good and fair graft function (p=0,143).

Conclusion: Our first results of an ongoing study are very encouraging. We assume
that the analysis of the biliary ICG-excretion can be a helpful additional tool for
early identification of liver transplant patients with poor initial allograft function.

POSTER BOARD NUMBER P4 – 64
2014 POST-TRANSPLANT EMBOLOTHERAPY FOR
INTRAPULMONARY SHUNTS IN A PATIENT WITH SEVERE
HEPATOPULMONARY SYNDROME
K-S. Suh , H.W. Lee , W.Y. Shin , J. Kim , N-J. Yi , J.Y. Cho , E.M. Kim ,
K.U. Lee
1
Seoul National University College of Medicine, Department of Surgery
Background: Hepatopulmonary syndrome (HPS), one of the most serious
complications of the liver disease may be improved after liver transplantation
(LT). However, post-transplant mortality has been reported to be much higher
in patients with severe HPS than in patients without HPS. The purpose of
this report was to introduce our experience of post-transplant embolotherapy
performed in a patient who had suffered from sustained dyspnea after LT.
Methods: A 10-year-old male patient who had undergone Kasai operation for
biliary atresia at 3 months after birth was referred for LT. He had recurrent
variceal bleeding and severe HPS. His arterial O2 pressure (PaO2) and saturation
(SaO2) was only 40mmHg and 70-75% in room air. A diffuse pulmonary
ateriovenous shunt was identified by saline contrast echocardiography and
pulmonary arteriography. The calculated amount of the shunt fraction was
44.5% on macroaggregated albumin scan. He received extended left liver graft
including middle hepatic vein from his father.
Results: Hypoxemia and dyspnea remained and he was still bed-ridden till postLT one month. We performed embolization for tortuous and dilated vascularity
in left upper lung field on post-LT 30th day. The abnormal vascularity
markedly decreased and oxygen saturation increased by about 10% right after
embolotherapy. The second embolotherapy was performed in right lower lung
field on 37th day. His activity got better and better and he showed some active
movements such as wheel-chair ambulation at the time of discharge, 40th day.
His PaO2 and SaO2 increased up to 65mmHg and 93% 3 months after LT and
he showed the same activity as children in his age group.
Conclusion: A patient with severe HPS may suffer from sustained hypoxemic
symptoms for a long time even after LT. We found that embolization improved
these symptoms by reducing the amount of the shunt. Therefore, we think
that post-transplant embolotherapy might be useful to reduce the risk of
postoperative mortality and morbidity and to accelerate the recovery in a
patient with severe HPS.

POSTER BOARD NUMBER P4 – 65
2015 POSITIVE LYMPHOCYTOTOXIC CROSS-MATCH
DOES NOT INFLUENCE LONG-TERM OUTCOME IN LIVING
DONOR LIVER TRANSPLANTATION
A.D. Concejero1, C.L. Chen1, C.C. Wang1, S.H. Wang1, Y.W. Liu1,
C.H. Yang1, C.C. Yong1, H.L. Eng2
1
Liver Transplant Program, Department of Surgery, Chang Gung Memorial
Hospital-Kaohsiung Medical Center, 2Liver Transplant Program, Department
of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Center
Background and objective: The influence of lymphocytotoxic cross-match
in living donor liver transplantation (LDLT) remains controversial. We
retrospectively investigated the influence of lymphocytotoxic cross-match
in our LDLT series using acute rejection episodes, and graft and patient
survivals.
Patients and methods: The transplant records of 300 consecutive LDLT
performed between June 1994 and March 2007 were reviewed. All live donors
and recipients were preoperatively screened for lymphocytotoxic crossmatching. All recipients received the protocol immunosuppression therapy
of cyclosporine-prednisone-azathioprine in pediatric cases or tacrolimusprednisone-mycophenolate in adult cases. The recipients¡¦ liver enzymes and
total bilirubin were determined during follow-up. All acute cellular rejections
were biopsy-proven and graded according to the Banff schema. The indications
for biopsy were based on significant increase in total bilirubin and/or liver
enzyme levels, or suspicion of sub-clinical acute rejection. Rejection episodes
were treated with intravenous boluses of steroid, and/or increase in the current
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calcineurin-inhibitor, and/or an increase or addition of mycophenolate. The
recipients were grouped into: negative cross-match (control), positive T&B
(T&B), and positive B (B) only lymphocytotoxic cross-matches. The mean
follow-up was 45 months (range, 12-168).
Results: There were 269 (90%) patients with negative, 16 (5.4%) with positive
T&B lymphocytotoxic, and 14 (4.6%) with positive for B cell only crossmatches. One case with a positive cross-match for T cell only was excluded.
The recipient characteristics were similar in all groups. Control, T&B, and B
group rejection episodes were 42/254 (17%), 2/16 (12.5%), and 2/13 (15.4%)
at 3 months, respectively. The actual, non-estimated one-year rejection rate
was 50/221 (22.6%), 4/10 (40%) and 2/9 (22%) for the control, T&B, and B
groups, respectively. Multiple rejections were 14/65 (21.5%) for the control,
1/5 (20%) for T&B, and 2/2 (100%) for B only. Although the T&B group had
lower incidence of rejection during the first 3 months which rapidly increased
within a year, the differences in the rejection rate in the groups were not
statistically significant (p=0.494). There were 18 steroid resistant episodes in
this series. Seventeen came from the control group and none from the T&B
group (p=0.458). The actuarial 5-year survival rate was 88.6%, 100%, and
82.5% for the control, T&B, and B groups, respectively (p=0.400). No graft
loss occurred in the positive T&B group while the graft losses in the B group
were non-immunologic in nature.
Conclusion: Positive lymphocytotoxic cross-matching in LDLT does not
significantly worsen the rejection rates, and graft and patient survivals
in the long-term; and should not be considered as a contraindication to
transplantation.

POSTER BOARD NUMBER P4 – 66
2016 ACUTE GRAFT- VERUS- HOST- DISEASE POST
ORTHOTOPIC LIVER TRANSPLANT: 2 CASES AND THE
NOVEL USE OF ETANERCEPT.
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L. Delriviere, L. Thin, G. Jeffrey, G. MacQuillan, L. Adams, G. Garas,
C. Seow
Sir Charles Gairdner Hospital
Acute graft-versus host disease (GVHD) following orthotopic liver transplant
(OLT) is a rare but feared complication arising in 1-2% of cases with a high
mortality rate of 85%. It most often presents as fever, rash, diarrhea with or
without pancytopenia. Patients die for the complications of marrow failure
such as sepsis or bleeding.
There is yet no clear treatment protocol for this complication of OLT. Both
increasing and decreasing immunosuppresion have been trialed with variable
success. However a closer look at the immunobiology of GVHD offers a
variety of targeted treatments which have been reported with variable success
in the literature. These include high dose steroids, anti T-cell therapies (OKT3,
ATG, Campath etc), anti IL-2 therapy (Basiliximab, dacluximab), and now anti
TNF-a therapy (Etanercept, infliximab).
Whilst anti- TNF therapy have been widely used for treatment of steroid
resistant acute GVHD in the haematopoietic stem cell transplant (HSCT)
setting, there has been no known reported cases of use in GVHD post OLT at
the time this case report was written.
We report of 2 cases of GVHD post OLT ever managed at our institution.
Case1: A 57 year old Chinese man presented with febrile neutropenia 3 weeks
post liver transplant for hepatitis C and hepatocellular carcinoma (HCC). This
was preceded by one week of pancytopenia refractory to G-CSF and removal
of marrow suppressing drugs. He subsequently developed a rash and severe
diarrhoea. His bone marrow was hypocellular and his viral serologies were
negative.The diagnosis of graft versus host disease (GVHD) was suspected and
confirmed on a skin biopsy and chimerism studies of his bone marrow aspirate
which demonstrated 34% XX cells (donor was a female).
Broad spectrum antibiotics were initiated for his febrile neutropenia. Upon
confirmation of GVHD, he was commenced on pulsed methylprednisolone
and increased doses of cyclosporine. However, the pancytopaenia, fever and
diarrhoea persisted despite supportive measures and he continued to deteriorate
culminating in death secondary to sepsis.
Case 2: A 65 year old Chinese man presented with rigors and neutropenia 3
weeks post liver transplant for hepatitis B and HCC. This was preceded by 1
week of pancytopenia refractory to drug withdrawal and G-CSF support. He
became febrile within 24hrs of admission and developed a generalised rash
and severe diarrhoea. Broad spectrum antibiotics were commenced and his
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immunosuppression was withdrawn on the suspicion of GVHD.
Viral serologies were negative. GVHD was confirmed on a skin biopsy (Grade
II) and chimerism studies of his bone marrow trephine and skin biopsy showing
donor lymphocytes present –XX cells (donor was female). Chimerism was also
demonstrated in his marrow via detection of variable number tandem repeats
(VNTR) on donor lymphocytes.
He was re-commenced on heavy immunosuppression with methylprednisolone,
cyclosporin, mycophenolate mofetil with the addition of etanercept. Two weeks
later, his symptoms and pancytopaenia resolved. The patient continues to do
well and is followed up as an outpatient

POSTER BOARD NUMBER P4 – 67
2017 LONG TERM FOLLOW UP OF LIVER TRANSPLANT
RECIPIENTS AFTER COMPLETE WITHDRAWAL OF
IMMUNOSUPPRESSION
P. Tryphonopoulos, A. Tzakis, D. Weppler, J. Moon, R.G. Morales,
G. Selvaggi, D. Levi, S. Nishida, R. Cirocco, A. Sornaraz, A. Berlanga,
H. Takahashi, E. Island, T. Kato, P. Ruiz
University of Miami
Objective: To evaluate the long term effect of complete withdrawal of
immunosuppression in liver transplant recipients.
Methods: We followed up liver transplant recipients that had participated in
an immunosuppression withdrawal study. Immunosuppression was gradually
withdrawn over a period of 3 years. At the end of the study, 20 patients
were completely withdrawn (Group 1) and 74 patients developed rejection
and were4 put back on maintenance immunosuppression(Group 2). There
were no significant differences in primary liver disease, donor/recipient age,
gender combinations, and HLA allelic frequency and mismatch between the
2 groups.
Results: Patient/graft survival: With an average follow up of 5.48 years, there
were 3 mortalities in Group 1 (15%) vs. 12 (16%) in Group 2. The remaining
patients in Group 1 are stable off ISP for 5.48 years (4.8-6.9 years). There were
no retransplants. Rejection episodes: There were no rejection episodes in Group
1 vs 23 rejection episodes in Group 2. Other complications: In Group 1, one
patient (5%) experienced diabetic nephropathy 6 years after drug withdrawal.
In Group 2, 7 patients (9.5%) had hemodialysis or kidney transplantation; 15
additional patients (20%) required renal-sparing drug conversion. There was 1
cancer associated death in Group 1 vs. 3 in Group 2. Quality of life scores show
a better score in Group 1 (95 vs. 88.5).
Conclusions: Patients that have achieved operational tolerance after liver
transplantation have a better quality of life and present less ISP-associated
complications (neoplasms, organ toxicity).

POSTER BOARD NUMBER P4 – 68
2018 ESTABLISHMENT OF A NEW LIVER TRANSPLANT
PROGRAM: CHALLENGES DURING THE FIRST 100 CASES.
G. Selvaggi1, E. Island1, D. Levi1, A. Taylor2, A. Lopez2, A. Tzakis2
University of Miami, 2Broward General Medical Center
The program at Broward General Medical Center in Fort Lauderdale, FL
officially started in February 2004. Over the past 4 years, up until February
2008, we have performed 106 adult liver transplants in 99 patients. The
initiation of an adult liver program in a public trust hospital initially faced
multiple obstacles. At an administrative level, we had to assess competency
and train the finance personnel in the specifics of transplant finances. This
included, but was not limited to, application to Medicare/Medicaid coverage,
financial contracting with private health insurers, and generating the first cost
of organ acquisition report. Within the hospital, specific transplant training
was required for the floor and operating room nursing staff, as well as general
laboratory, pharmacy, nutritional services and physical therapy staff. We
developed specific protocols within the radiology department, both in general
radiology and interventional procedures, to serve the needs of the pre- and posttransplant patient population. The department of pathology assigned dedicated
pathologists to the reading and interpretation of liver transplant biopsies, in
addition to the capability of providing same day service on a routine basis
for most of the specimens submitted. Interaction with the hospital medical
staff was on two levels: the primary care/internal medicine physicians and the
1
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consulting specialties. For the primary caregivers, focused attention was given
to the identification of pre-transplant candidates who could be evaluated for
work-up. While critical care is provided by the transplant team, specialists in
gastroenterology, nephrology, endocrinology, cardiology, infectious diseases,
pulmonary medicine, psychology/psychiatry, neurology were all selected
and involved in patients’ care to provide additional care when required.
Each of the abovementioned steps involved lectures and in-service updates,
development of close collaboration and open communication with specialists,
which allowed the program to grow from 12 liver transplants performed in
2004 to 40 cases in 2007.

POSTER BOARD NUMBER P4 – 69
2019 MODEL FOR END-STAGE LIVER DISEASE: IMPACT OF
THE NEW DECEASED DONOR LIVER ALLOCATION POLICY
IN SÃO PAULO, BRAZIL.
F. Monteiro12, R.N.S. Coria1, R. Boni1, L. Pereira1
1
1São Paulo Organ Allocation System, Health Secretariat of São Paulo,
2
Laboratory of Immunology, Heart Institute, Scholl of Medicine, University of
São Paulo
Since July 2006, São Paulo Organ Allocation System following the Brazilian
policy has been allocating deceased donor liver based on Meld/Peld score.
Before July 2006, those organs were allocated to recipients based on wait-list
timing. The aim of this study was to analyze the impact on graft survival now
transplanted under the allocation policy for Meld/Peld–based score. All data
were acquired from São Paulo Organ Allocation System database. The study
involved 895 consecutive liver recipients transplanted in São Paulo, Brazil
from Feb/05 to Dec/07. Kaplan-Meier method was used to construct graft
survival curves and the curves were compared with log-rank test. From July
2006 to December 2007, 501 liver grafts were transplanted in 473 recipients
(22 were split-liver – 4,4% and 426 – 89,8% were adults and 75 – 14,8%
were pediatric recipients, it means, under 12 years old). The graft allocations
were in 83 (16,7%) recipients under urgency transplantation requirement
(acute liver failure and early re-transplantation), 158 (31,5%) under “special
situation” (recipients with hepatocelular carcinoma, hepatopulmonary
syndrome, familial amiloidotic neuropathy, liver adenomatosis and metabolic
diseases) and 206 (41,1%) recipients without Meld/Peld score adjustment.
Among pediatric recipients (N=75), those transplanted with Peld score up
to 5; between 6-10 and 11-14; and above 15 were, respectively: 6 (8,0%),
3 (4,0%%), 10 (13,3%) and 56 recipients (74,7%). Among adult recipients
(N=426), those transplanted with Meld score up to 10, between 11-18
and 19-24; and above 25 were, respectively: 68 (16,0%), 106 (24,9%), 68
(16,0%) and 184 recipients (43,2%). For those, recipients transplanted with
Meld score up to 10 (N=67) had better 18 months recipient survival rates
than those with 11-18 (N=32), 19-24 (N=64) and up 25 (N=177) (85,6%
vs. 81,25% vs. 68,45% vs. 59,83% P<0.050) Regarding the Meld vs. Peld
score recipients, the 18 months recipient survival rates between adults and
children was not different (68,2% – n=406 vs. 66,77% – n=66, P>0.050). On
the other hand, recipients (n=149) transplanted under special situation, had
a better 18 months survive rates than those (n=257) not transplanted under
special situation (76,16% vs. 63,78%, P<0.025). Also, recipients (n=199)
without urgency transplantation requirement had a better 18 months survival
rates than those (n=58) with urgency transplantation requirement (66,56%
vs. 53,45%, P<0.005). Finally, the results have shown no differences in 1
year recipient survival curves between transplanted in the first 18 months
after Jul/06 (N=473) and recipients (N=422) transplanted 18 months before
Jul/06 (68.11% for Meld/Peld–based score vs. 72,62% based on wait-list
timing, P>0.050). In conclusion, current allocation balances the high survival
of recipients transplanted under special situation with the low survival of
recipients with high Meld score.

POSTER BOARD NUMBER P4 – 70
2020 HEREDITARY HEMORRHAGIC TELEANGIECTASIA OF
THE LIVER: TWO PATIENTS – ONE DIAGNOSIS – DIFFERENT
CONSEQUENCES
B. Ringe2, K. Ringe1, M. Galanski1, T. Maroney3, A. Trebelev3, B. Ringe4
Medizinische Hochschule Hannover, Institut fuer Radiologie,
2
Medizinische Hochschule Hannover, Klinik fuer Allgemein-, Viszeralund Transplantationschirurgie, 3Drexel University College of Medicine,
Department of Interventional Radiology, 4Drexel University College of
Medicine, Center for Liver, Biliary and Pancreas Disease
Liver involvement in hereditary hemorrhagic teleangiectasia (HHT) is
characterized by widespread diffuse vascular malformations. Symptoms may
occur in about 8% of these patients. Treatment depends on clinical presentation,
and is only needed in symptomatic patients. This is a report of two interesting
cases that we have seen within a period of over twenty-three years.
Case # 1: A female patient was 41 years old when she presented with epigastric
pain and peripheral edema. Clinical examination revealed an epigastric and
right upper quadrant thrill which eventually led to the diagnosis of HHT with
high-output cardiac failure, portal hypertension and an intrahepatic biliary
cyst. She underwent hepatic artery ligation which failed to permanently
control her intrahepatic shunt and cholangitis, and finally received an
orthotopic liver transplant in November 1985. Over 22 years later she is alive
and well with normal liver function tests, and no sign of recurrent disease.
According to the literature this patient is the longest survivor with a liver
transplant for HHT.
Case # 2: A 54-year old mother volunteered to be evaluated as a living liver
donor for her daughter suffering from end stage liver disease. She appeared
to be healthy with a completely negative medical and surgical history. As part
of the evaluation process she had an MRI which showed multiple enhancing
lesions throughout the liver representing intrahepatic shunts. As confirmed by
hepatic arteriography this picture was consistent with HHT, and the patient was
excluded from donation. Since she was free of any symptoms, no treatment was
required at this time.
The spectrum of liver involvement in HHT is ranging from discrete vascular
malformations eventually detected incidentally (case # 2), to extensive
intrahepatic shunts, with subsequent heart failure, hepatic disintegration and
portal hypertension (case # 1). The radiologist plays a key role in diagnosing
HHT, especially in asymptomatic patients. Whether hepatic artery embolization
can help to temporize or ameliorate symptoms in less advanced HHT remains
to be seen. As has been shown repeatedly, liver transplantation may be the only
curative treatment option in symptomatic patients.
1

POSTER BOARD NUMBER P4 – 71
2021 BODY MASS ALTERATION AFTER LIVER
TRANSPLANTATION FOR NON-ALCOHOLIC
STEATOHEPATITIS
M. Marvin, R. Nagubandi, R. Kadiyala, M. Eng, L. Marsano, C. McClain,
M. Cave, T. Martin, J. Buell
Division of Transplantation, Jewish Hospital, University of Louisville,
Louisville, KY, United States
Body: Objective: The true incidence of non-alcoholic steatohepatitis (NASH)
in chronic liver failure patients is unknown. It is not clear whether transplantation
impacts post-operative body mass index (BMI) or NASH recurrence.
Method: Retrospective review of all liver transplants from 11/ 2000 to 11/
2007 was performed. Patient demographics, incidence of recurrent NASH,
trends in the BMI and liver function were examined.
Results: 19 of 280 (6.8%) liver transplant patients had NASH confirmed on
explantation. Overall survival was 89.5% at one year. One patient died of
recurrent NASH at 9 months. 7 patients underwent post-transplant biopsy of
which 2 had evidence of recurrent NASH. The overall incidence of recurrent
NASH was 10.5%. On examination of post-transplant BMI, all patients lost
weight at 3 months post operatively but gradually regained to above their
pre-transplant levels with an associated increase in the mean cholesterol
and triglyceride levels. The mean triglyceride levels significantly increased
(p=0.005) at 2 years compared to 3 months post-operative levels.
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Patient A: underwent orthotopic liver transplantation at 7 months using a
deceased donor split adult graft. There were multiple surgical issues secondary
to marked portal hypertension from hepatic venous outlet obstruction including
an inability to perform a Roux loop because of bowel wall oedema plus inability
to achieve primary closure of the abdomen. Other complications included
recurrent episodes of sepsis and malnutrition. Severe haemophagocytosis led
to multi-organ failure and death, 32 days post-transplant.
Patient B: gradually progressed into liver failure and at 17 years of age
underwent orthotopic liver transplantation with a reduced adult graft from a
deceased donor. The hepatectomy was extremely difficult, owing to severe
portal hypertension, dense adhesions due to previous primary peritonitis and
a previously unrecognized Morgagni diaphragmatic hernia containing an
accessory lobe of the right liver. The initial graft function was good. However
the post-operative course was marked by multiple infections, graft-versushost disease of the gastrointestinal tract, poor nutrition, renal impairment and
expanding intracranial lesions of suspected fungal aetiology. Death occurred
due to these complications plus graft failure 5 months post-liver transplant.
Conclusion: The poor outcomes of liver transplantation in these two children
with VODI suggest that this therapy should not be offered to children with
this condition. Furthermore, other children with a primary immune deficiency
should be considered high risk liver transplant candidates.

POSTER BOARD NUMBER P4 – 73
2023 PLATELET-TRANSFUSION REFRACTORINESS
FOLLOWING LIVING RELATED LIVER TRANSPLANTATION
No significant alteration in liver or renal function was noted.
Conclusion: Transplantation for NASH is increasing. Unfortunately the true
incidence of recurrent NASH is still unknown. A statistically significant rise
in the mean triglyceride levels associated with a rise in the mean BMI and
cholesterol levels approaching significance would make one wonder if this
affects the risk for recurrent NASH in the transplant liver.

POSTER BOARD NUMBER P4 – 72
2022 PAEDIATRIC LIVER TRANSPLANTATION FOR HEPATIC
VENO-OCCLUSIVE DISEASE WITH IMMUNODEFICIENCY
SYNDROME
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S. Siew1, E. O’Loughlin1, A. Shun1,2, D. Verran2, M. Wong1, V. Jermyn1,2,
M. Stormon1,2
1
The Children’s Hospital At Westmead, 2Australian National Liver Transplant
Unit
Introduction: Hepatic Veno-Occlusive Disease with Immunodeficiency
(VODI) is a rare autosomal recessive condition characterised by primary
combined immunodeficiency with hepatic centrilobular and sinusoidal fibrosis,
leading to hepatic venous occlusion, portal hypertension and liver failure.
Roscioli et al recently described the genetic basis of VODI: mutations in the
SP110 immunoregulatory gene on chromosome 2q36.3-37.1. The majority
of reported cases are children of consanguineous Lebanese parents, living in
Sydney, Australia. The prognosis for children with VODI is extremely poor
with death often occurring due to either the primary immune deficiency and/
or liver failure.
Objective: We aim to report the poor outcomes of liver transplantation for
VODI in two children.
Results: Both children were of consanguineous Lebanese parents and each
presented in early infancy. Patient A was a young male infant diagnosed at
3 months when he presented in liver failure with intractable ascites, severe
portal hypertension and presumed Pneumocystis jiroveci infection. Patient B
presented at 4 months with hepatosplenomegaly, ascites and thrombocytopenia.
Her brother died at 4 months from overwhelming Pneumocystis pneumonia
and suspected VODI.
Immune function tests in each case showed severe hypogammaglobulinaemia
with normal B-lymphocyte numbers. There was clinical evidence of T-cell
immunodeficiency but normal circulating T-lymphocyte numbers, normal CD4+
and CD8+ percentages, and normal T-lymphocyte proliferation assays. Both patients
received cotrimoxazole prophylaxis and monthly immunoglobulin infusions.
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A. Kenjo1, T. Saito1, T. Tsuchiya1, Y. Sato1, T. Kimura1, T. Ogata2, H. Ohto2,
H. Yasuda2, K. Kawabata2, M. Gotoh1
1
Fukushima Medical University, Department of Surgery, 2Fukushima
Medical University, Department of Blood Transfusion and Transplantation
Immunolory
Thrombocytopenia is common findings in patients with end-stage liver disease
who need liver transplantation. Sometimes we encounter platelet-transfusion
refractoriness (PTR) in the posttrasplant patients in whom repeated platelet
transfusion fails to increase its count in peripheral blood enough to stop
bleeding tendency. It is crucial to understand the mechanism in each patient
causing PTR. In this study, we focused on PTR following living-related liver
transplantation and discuss appropriate diagnosis and treatment.
In 22 consecutive recipients of living-related liver transplantation, a poor
response to transfusions of random donor platelets was observed in 2 cases
who showed the count of platelets in blood fluctuated between 2 and 4 x 1010
/L in spite of repeated platelet transfusion. Most of antibodies against antigens
presented on platelets including anti-human leukocyte antigen (HLA) antibody
and anti-human platelet antibody (HPA) were examined in the cases.
The case 1, a 23-year-old Japanese woman with fulminant hepatitis, received a
liver transplant from her sister with one HLA locus mismatch. Platelets from 8
donors had been transfused by day 5 against severe thrombocytopenia. The titer
of anti-HLA antibody was negative on day 1, but went up to x512 on day 6, and
x4096 on day 9. These antibodies positively reacted with lymphocytes which
showed HLA A 24, 33 or B 7, 44, 48, 51, 60, 61, 67 by panel reactive assay, but
did not react with donor HLA. The recipient had been pregnant for 6 times prior
to liver transplantation. HLA sensitization was not detected in the sera before
transplantation, but came apparent as a cause of PTR after transplantation.
The platelet count of the patient started to recover within several days after
cessation of platelet transfusion, and recovered uneventfully.
The case 2, a 47-year-old Japanese man with hepatitis B virus-related liver
cirrhosis, received a liver transplant from his brother with one HLA locus
mismatch. Platelets from 21 donors had been transfused by day 8 against severe
thrombocytopenia, however, platelet count was not increased showing PTR.
No anti-HLA or anti-HPA antibodies, but anti-CD36 (GP IV, Naka) antibody
was detected. The recipient and donor were negative for CD36 antigen. The
patient was transfused effectively with platelets from CD36 negative, but HLA
non selected, donors. After 4 months when the titer went down to x16, and the
platelet count recovered.
In conclusion, frequent platelet transfusion or pregnancy might induce
antibodies causing PTR. Liver transplant recipients with PRT should be
examined for anything out of the ordinary antibodies to select an appropriate
treatment.
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2024 EFFECTS OF HEPATIC CYP3A4 ACTIVITY ON
DISPOSITION OF SIRORIMUSU IN LIVER TRANSPLANT
RECIPIENT

2026 IMPACT OF INTRAPORTAL DONOR SPECIFIC
LEUKOCYTES TRANSFUSION FOR ADULT ABOINCOMPATIBLE LIVER TRANSPLANTATION

S. Kishino1, N. Mochizuki1, K. Ohno1, T. Shimamura2, H. Furukawa2,
S. Todo2
1
Meiji Pharmaceutical University, 2First Department of Surgery, Hokkaido
University Hospital
Sirolimus is extensively metabolized by cytochrome P450 3A (CYP3A) in
the liver. The urinary ratio of 6b-hydroxycortisol to cortisol (6b-OHF/F) is
considered to be the estimation of hepatic CYP3A4 activity. The aims of this
study were to clarify the effects of hepatic CYP3A4 activity on disposition of
sirorimusu in liver transplant recipient. The results in this study show that the
urinary 6b-OHF/F ratio is an useful probe for estimating the inter- and intraindividual variability of CYP3A4 activity, but not for predicting the optimal
silorimus dose in recipients.

H. Oya, Y. Sato, S. Yamamoto, T. Kobayashi, Y. Hara, H. Kokai,
K. Hatakeyama
Division of Digestive And General Surgery, Niigata University
Adult ABO-incompatible liver transplantation is poor outcome associated
with an extremely complicated postoperative course. We have reported that
repeated donor specific transfusion via portal vein bring the rapid reduction of
immunosuppressants and the decrease of acute cellular rejection. In this study,
we investigated whether new strategy of immunosuppression by intraportal
transfusion of donor specific leukocytes (DSLT) separated from donor whole
blood would bring up the immunological benefits in adult ABO-incompatible
living related liver transplantation.
Materials and Methods: Ten patients (age: 51 }9y.o., range 31-60y.o.)
(MELD score: 19.4 }7.3, range 12-29) who underwent living-related donor
liver transplantation from ABO-incompatible donors (GRWR: 0.90 }0.28,
range 0.63-1.46) from August 2003 to November 2007, were investigated.
The antirejection therapy included multiple perioperative plasmapheresis,
splenectomy, quadruple immunosuppression. In addition to these conventional
approaches, we performed 4 times of intraportal administration of DSLT
after transplantation. The clinical effects for the immunosuppression and
the humoral and cellular rejection, and the immunological analysis were
studied.
Results: There was no humoral rejection in the all patients. There was only one
mild acute cellular rejection in the all patients. Donor specific both IgM and IgG
A/B antibodies of all patients have decreased following transplantation within 16
times. In the immunological analysis by flowcytometry, it was recognized that
the donor type of CD56+NKT cells existed in the liver graft as macrochimerism
one month after liver transplantation. Furthermore, IL-10 production of Th2
type of cytokine was up regulated on the day1 after transplantation. Three
patients died on 2months, 4months and 8months after operation respectively
because of the sepsis caused by preoperative MRSA pyothorax, MRSA and
MRSE catheter infection. Seven patients were discharged in condition. 4 years
survival is 67.5% by Kaplan-Meier method.
Conclusion: Adult ABO-incompatible liver transplantation can be performed
with acceptable patient and graft survival rates with very low risk of antibodymediated rejection with our new strategy of immunosuppression by intraportal
administration of DSLT. Donor type CD56+NKT cells may induce tolerance by
veto mechanism and anti-idiotype network mechanism.

POSTER BOARD NUMBER P4 – 75
2025 DE NOVO MALIGNANCIES AFTER LIVER
TRANSPLANTATION
R. Charco1, I. Bilbao1, G. Sapichosin1, C. Dopazo1, A. Escartin1,
J.L. Lazaro1, L. Castells2, M. Caralt1
1
Department of HBP Surgery And Transplants. Hospital Vall D’Hebron,
2
Department of Hepatology
Aim: To asses our experience with the use and management of m-TOR after
liver transplantation (LT).
Material: From 1988 to 2007, 783 LT has been performed in 725 patients. Fifty
one patients (7%) received immunosuppression with m-TOR: Rapamicine 36
and everolimus 15. Mean age was 54.8 years old (r:24-70). Indication of use,
time between LT and introduction of m-TOR, eficacy, side effects and survival
were analysed.
Results: Indications were: refractory rejection in the context of renal
insufficiency 20 (39%), renal insufficiency 5 (10%), other side effects of
CNI 6 (12%), extended HCC in the explanted live 7 (14%), HCC recurrence
in the follow-up 7 (14%) and the novo tumour 3 (6%). Mean time between
LT and m-TOR were 18 ± 29 months with a median of 3 months (r:10 days122months). Mean follow-up after conversion was 12 months (r: 1-65),
with a median of 7. Half of the patients converted for refractory rejection,
resolved the event. Four required re-LT, 3 progresed to chronic rejection and
3 died due to non resolved rejection, overimmunosuppression and sepsis.
Of 19 patients with renal insufficiency at time of conversion, 10 (52%)
resolved. Three out of 7 patients with extended HCC, died and 4 out of 7
patients with recurrent HCC, died. The 3 the novo tumour were operated and
are perfectly healthy. Half of the patients presented side effects related to
m-tor: diarrhea in 4 (8%), hematologic complications in 5 (10%), dyslipemia
in 22 (43%), and infection in 8 (16%). Ten patients (20%) developed acute
rejection after conversion. Nineteen patients (33%) discontinued drug: 9 due
to ineficacy, 4 due to resolution of the cause, 3 due to intercurrent surgery
and 3 due to advers event. Actuarial survival postconversion is 55% and
15% at 1y and 3y.
Conclusion: m-TOR are indicated in critical and irreversible situations where
other immunosuppressants have failed: in the early period for refractory
rejection or as prophylaxis for recurrence of extended tumors; in the late period
for patients with serious side effects of CNI.

POSTER BOARD NUMBER P4 – 77
2027 RISKS FACTORS AND OUTCOME OF PATIENTS WITH
ISCHEMIC-LIKE CHOLANGIOPATHY WITH SECONDARY
SCLEROSING CHOLANGITIS (IN CRITICALLY ILL PATIENTS,
SC-CIP) AFTER LIVER TRANSPLANTATION
G. Kirchner1, M. Scherer2, A. Obed2, P. Ruemmele3, R. Wiest1, M. Froh1, H.J.
Schlitt2, J. Schoelmerich1, C. Gelbmann1
1
University of Regensburg, University Hospital, Dept. of Internal Medicine,
2
University of Regensburg, University Hospital, Dept. of Surgery and
Transplantation, 3University of Regensburg, University Hospital, Institute of
Pathology
Background: Sclerosing cholangitis in critically ill patients (SC-CIP) with
sepsis and acute respiratory distress syndrome (ARDS) is a recently newly
described cholestatic liver disease with a rapid progression to liver cirrhosis.
It is defined by an ischemic injury of the biliary tree with formation of biliary
casts and subsequent ongoing biliary infection due to multiresistent bacteria
inflammation. The exact mechanisms leading to this form of cholangiopathy
with stricture formation and complete obliteration of bile ducts are unknown.
Clinical and endoscopic features of SC-CIP are comparable with those of
primary sclerosing cholangitis, but patients with SC-CIP have no prior history
of liver disease and no known pathologic process or injury responsible for bile
duct obstruction. Liver transplantation (LTx) is the only curative therapy option
for patients with SC-CIP-induced liver cirrhosis. Until now, little is known
about of liver transplantation (LTx) in patients with SC-CIP.
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Material, Methods, Results: From 2004 to 2007 eight patients (40+8 yrs;
7m, mean MELD score: 24+5) with SC-CIP underwent LTx at our institution.
Four patients had a severe polytrauma with multiple bone fractures, sepsis
and ARDS. SC-CIP was diagnosed within 2+3 months after polytrauma.
Four non-traumatic patients acquired SC-CIP in the context of long-term
intensive care unit stays with sepsis and ARDS based on internal diseases.
SC-CIP was diagnosed by ERCP and approved in the explanted liver.
Early endoscopic findings of severe bile duct damage were intraductal
filling defects of all intrahepatic bile ducts due to extensive biliary casts.
In patients with endoscopic examination several weeks after the beginning
of cholestasis, intrahepatic bile ducts showed multiple irregular strictures
of different degrees and remnants of biliary cast among the strictures. As
far as possible, biliary cast were removed by dormia basket of a balloon
catheter after endoscopic sphincterotomy. Primary immunosuppression
was: anti-IL2-antibody, ciclosporin and prednisolone and/or mycophenolate
mofetil. After LTx all patients received ursodesoxycholic acid (15-20 mg/
kg body weight per day). The three main isolated bacteria in the bile were:
enterococcus (n=4), candida albicans (n=3), multi-resistance E. coli (ESBL)
(n=2). The mean follow-up after LTx was 13+10.0 months. Five of 8 patients
are still alive and have a good quality of life. One female patient (HELPP
with sepsis) underwent LTx despite of infection. She died 26 days post-LTx
within a sepsis. Seven of 8 patients survived the post-operative course. Two
(non-traumatic) patients died from sepsis within 4 and 8 months after LTx.
Five (including all 4 patients with polytrauma) of the 8 patients are still alive
and have a good quality of life.
Summary,Conclusion: Our prospective study shows that LTx is a curative
therapy option in patients with SC-CIP. Patients transplanted by SC-CIP due
to polytrauma have a significant superior outcome within the first year after
LTx than patients who aquired SC-CIP in the context of non-traumatic disease.
Without exception, sepsis was the main cause of death after LTx. Further
reasons for sepsis after LTx need to be determined, especially in the nontraumatic group, to improve outcome and survival in these patients.
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2028 PREDICTORS OF SUBSTANCE ABUSE AFTER LIVER
TRANSPLANTATION IN PATIENTS WITH ALCOHOLIC LIVER
DISEASE

THURSDAY

D. Ranjan, P. McHugh, H. Jeon, T. Johnston, R. Gedaly
University of Kentucky Transplant Center
Background: Alcoholic liver disease (ALD) is a common, yet controversial,
indication for liver transplantation (LT) worldwide. Many patients with
ALD also have a history of substance abuse, with return to drugs or alcohol
consumption further complicating their post-transplant management. The aim
of this study was to identify predictors of relapse to drug use after LT in these
patients.
Methods: A retrospective analysis of LT recipients with ALD was performed
at our institution. Demographic, socioeconomic, and laboratory data were
reviewed. Univariate and multivariate analyses of prognostic factors for
recurrence to drug use were performed.
Results: Between July 1995 and November 2007, 387 patients underwent
LT at our center. Of these, 147 patients (37.9%) were found to have ALD.
Five patients (3.4%) were excluded due to perioperative mortality. Drug abuse
history was identified in nearly half of patients with ALD (n=65, 45.8%), most
frequently marijuana (n=39). Twenty-eight patients (19.7%) had documented
drug use after LT. Predictive factors of drug relapse found by univariate
analysis included recipient age >50 (p=0.019), unemployment (p=0.019), HCV
(p<0.001), and any history of substance abuse (p<0.001). Multivariate analysis
revealed history of substance abuse to be the only independent predictor of
drug abuse after LT (p=0.013) when controlling for age, working status, and
HCV status.
Conclusion: ALD patients with any history of drug abuse are those most likely
to return to this behavior after LT. Substance abuse counseling during evaluation
should be emphasized in this subgroup of patients to improve compliance.
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2029 IMPACT OF CCR5DELTA32 MUTATION ON ISCHEMIC
TYPE BILIARY LESIONS AFTER LIVER TRANSPLANTATION
I. Ruth1, M. Hoppe-Lotichius1, A. Lautem1, M. Sprinzl2, J. Thies1, G. Otto1
Department of Transplantation and Hepatobiliary Surgery, Johannes
Gutenberg Univ, 2Department of Internal Medicine, Johannes Gutenberg
University, Mainz, Germany
Background: Ischemic-type biliary lesions (ITBL) occur after orthotopic
liver transplantation (LT) with a reported incidence of up to 26% and lead
to considerable morbidity, graft loss, and even mortality. A multi-factorial
etiology is assumed. CC-chemokines and their receptors have been identified
to play a key role in cell survival and proliferation. The CC-chemokine receptor
5delta32 (CCR5delta32) mutant has been shown to be a major risk factor for
the development of ITBL after LT.
Method: 338 LT recipients (374 LT including 36 retransplantations)
transplanted between September 1997 and December 2007 (116 female and
222 male) were included in the study. The CC-chemokine receptor 5 (CCR5)
was analyzed by PCR to identify patients with CCR5delta32.
ITBL were identified by increased parameters of cholestasis followed by
imaging of the bile ducts.
Results: CCR5 wild-type and CCR5delta32 (3 homocygous, 45 heterocygous)
were identified in 290 and 48 patients, respectively. ITBL occurred in 35 of
the 322 transplantations performed in patients with wild-type and in 12 of 52
grafts in patients with CCR5delta32 mutation (p= 0.022). Patient survival was
reduced in patients with CCR5delta32 to 67%, 65%, 61% after 1, 3 and 5 years,
respectively. In patients with CCR5 wild type the respective figures are 89%,
80%, and 75% (p=0.011). Graft survival was equally reduced to 65%,60%, and
52% after 1,3 and 5 years in patients with CCR5delta32 versus 85%, 73%, and
66% in patients with wild-type (p= 0.040).
Rate of rejection was not affected (p= 0.282). CCR5Ä32 showed no influence
on reinfection, rate of retransplantation, and fibrosis (within a year) after
liver transplantation in patients with hepatitis C (p=0.721). In patients with
CCR5delta32 mutation the mode of perfusion was without influence on the
occurrence of ITBL (p=0.366) whereas in patients with wild type arterial backtable pressure perfusion was capable of preventing ITBL (p=0.009).
Conclusion: In a large collective CCR5delta32 was shown to be a significant
risk factor for the development of ITBL following LT. The mutation not only
leads to a reduction of patient and graft survival but also to an increased
retransplantation rate.
1
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2030 LIVER TRANSPLANTATION FOR SMALL CHILDREN IN
CHILE: EXPERIENCE AND LONG-TERM OUTCOME.
M. Uribe, A. Alba, G. Gonzàlez, R. Iñiguez, M. Ferrario, J. Godoy, B. Hunter,
S. Cavallieri, E. Buckel
Liver Transplantation Program Clínica Las Condes – Hospital Luis Calvo
Mackenna
Introduction: The outcome of orthotopic liver transplantation (OLT) in
pediatric patients has improved in last decades, but the subgroup of small
children, weighting 10 kilograms or less, still presents several clinical problems.
Despite optimal results reported elsewhere, complications are more frequent
than in older patients, specially from vascular anastomoses. The aim of this
study is to present the experience of liver transplantation in patients weighing
10 kilograms or less, in a multicenter liver transplantation program in Chile.
Patients and Methods: From November 1993 to February 2008, we performed
348 OLT, 188 of them in pediatric patients younger than 15 years. 37 patients,
weighing 10 kilograms or less were transplanted. The data of these cases was
reviewed. Kaplan Meier test was used for actuarial survival.
Results: 37 children received 45 grafts. 6 patients required retransplant, 2 of
them received a third graft. Twenty patients were males (54%). Median age
and weight were 1.1 years (range 8 months-6 years) and 8.1 kg. (range 4.8-10)
respectively. Primary liver disease was biliary atresia in 25 patients (68%),
Alagille syndrome in 4 (11%), fulminant hepatitis in 2 (5%), Byler disease in
2 (5%), neonatal hepatitis in 2 (5%), hepatoblastoma in 1 (3%) and metabolic
disease in 1 (3%). Grafts from living donor (segments II-III) were used in
23 cases (51%); deceased donor grafts in 22 patients (49%) (11 complete
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liver, 10 reduced grafts, and 1 split-liver). Graft-to-recipient weight ratio was
greater than 1% in all the cases. Two patients underwent delayed abdominal
wall closure. Immunossupresion was based on cyclosporin or tacrolimus plus
steroids. Daily hepatic ultrasound with doppler was performed in the first 10
days after OLT.
Regarding vascular complications, 8 cases of portal vein thrombosis (PVT)
were seen, 5 hepatic arthery thrombosis (HAT), and one patient with both
(PVT-HAT). Of them, 10 required reoperation (7 PVT, 2 HAT and 1 PVTHAT). Five patients had biliary leaks, requiring surgical repair. There were 3
biliary stenosis managed percutaneously.
Patient survival at 1 and 5 years is 75% and 64%. Main cause of death within
this group was infection (7 patients, 19%).
Only 2 patients have died due to vascular complications. Of the 8 retransplants, 1 was
due to HAT and 3 to PVT. There have been no deaths due to vascular complications
in the last 11 years, and no graft lost for this cause in the last 4 years.
Comments: Liver transplantation in small children is a major medical and
surgical challenge. Our results are comparable to countries with similar
conditions of pediatric liver transplantation, although still below large series
published. The improvement in the surgical technique in the last years has lead
to fewer vascular complications and trends to better outcome. This is the largest
series in our country.

first postoperative hours were collected. We chose SAPS II (simplified acute
physiology score) as a severity marker and compared length of stay in ICU
(intensive care unit) and death at day 7.
Results:

D. Wang, C-F. Chen1, R-T. Hu
1
Department of Medicine, Cheng Hsin General Hospital, 2Department of
Medicine, Fu Jen Catholic University, 3Liver Center, Cathay General Hospital
Objectives: Ischemia/reperfusion (I/R) of the rat¡¦s liver could induce liver
injury in which oxidative stress and nitrosative stress are involved. In this study
we used antioxidants of lyceum barbarum and ascorbic to study their protective
effects on this reperfusion liver injury model.
Methods: Ischemia was induced by clamping off the common hepatic artery
and portal vein for 40 minutes and reperfused for 90 minutes. Blood samples
collected before I and after R were analyzed for ALT, LDH, hydroxyl radical,
nitric oxide and tumor necrosis factor (TNF£\).
Results: This protocol resulted in elevation of the blood NO (p<0.01), hydroxyl
radical (p < 0.01), TNF£\, ALT and LDH (p < 0.01) in the I/R but not in the
sham-operated group. Ascorbic acid (100 mg/kg) significantly attenuated the
reperfusion liver injury. Lyceum barbarum (alcoholic extract from the crude
Gogi berries; 600 mg/100 ml of drinking water for 2 weeks) alleviated the liver
injury but the difference was not significant.
Discussion and Conclusions: This I/R protocol resulted in oxidative and
nitrosative stress and liver injury. Ascorbic acid showed significant protection
in this reperfusion liver injury. Although the crude extract of lyceum barbarum
had antioxidant effects but in this reperfusion liver injury model it did not show
any protective effect.
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2032 COMPARISON OF TWO TRANSFUSION STRATEGIES
FOR ORTHOTOPIC LIVER TRANSPLANTATION
S. Roullet, M. Biais, A. Vallet, P. Revel, F. Sztark
Service Anesthésie Réanimation, CHU Bordeaux, France
Introduction: Orthotopic liver transplantation is a hemorrhagic surgery. In 1999
a multicenter study showed great differences in transfusion strategy for OLT in
France (Ozier, Anesth Analg 2003). At this time, in our centre, all patients received
fresh frozen plasma (FFP), while other centre never transfused FFP for OLT. All
volemic compensation was done with FFP. After reflection and evaluation we
changed our strategy and volemic compensation was done with albumin 4%. 2005
was the year of transition. We assess the affect of this change on our transfusion
strategy with a two-period comparison: 1999-2001 versus 2006-2007.
Patients and methods: This is a retrospective study including all patients who
benefit from an OLT in our centre from 1999 to 2001 and from 2006 to 2007.
Preoperative data noted were: sex ratio, age, and blood analysis. Albumin
transfused during OLT and blood products transfused during OLT and the 24th

2006-2007

n=74

n=73

Sex ratio M/F
Age (years)

p

52/22

50/23

NS

53 (46-59)

52 (46-58)

NS

11.3 (9.8-12.6)

12.4 (10.4-14.2)

0.022
NS

Pre-transplant values
Hb (g/dl)
Platelets (/mm3)

Fibrinogen (g/l)

87500

111500

(61250-139250)

(58750-160250)

2.5 (1.8-3.2)

2.7 (2.0-3.4)

NS

TP (%)

61 (48-73)

62 (52-78)

NS

Factor V (%)

56 (41-78)

63 (46-85)

NS

Albumin 4% (OLT)

1 (0-2)

6 (5-9)

<0.0001

red blood cells (24h)

4 (2-7)

5 (2-9)

NS

15 (10-19)

5 (0-12)

<0.0001

Blood products transfused
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2031 THE PROTECTIVE EFFECTS OF ANTIOXIDANTS
OF LYCIUM BARBARUM AND ASCORBIC ACID ON THE
REPERFUSION LIVER INJURY IN RATS

1999-2001

fresh frozen plasma (24h)

0 (0-1)

0 (0-1)

NS

SAPS II

platelets (24h)

30 (22-35)

33 (26-39)

0.048

Length of stay ICU

16 (10-23)

14 (7-28)

NS

2

6

NS

Death at day 7

Data are in numbers or median (IQ 25-75).
Comparisons are done with a Mann-Whitney test, a χ2 test or a Fisher’s exact
test.
Discussion: Volemic compensation with albumin instead of FFP was not
associated with coagulation disorder and haemorrhage. Transfusion of red
blood cells or platelets was alike. Despite slightly higher SAPS II for the
second period, length of stay in ICU or mortality at day 7 were not significantly
different.
These results led us to optimize our transfusion strategy and limit the use of
FFP for haemorrhagic syndromes.
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2033 CAN MELD EXCEPTIONS PREDICT DEATH ON LARGE
WAITING LISTS?
S. Iacob1, L. Gheorghe1, R. Iacob1, C. Gheorghe1, I. Popescu2
Fundeni Clinical Institute, Gastroenterology and Hepatology Center,
2
Fundeni Clinical Institute, General Surgery and Liver Transplantation
Center
Background: Currently, the most recent MELD score available for each
waiting list patient is used to prioritize organs, because it accurately predicts
short-term mortality. Cirrhosis related complications, considered MELD
exceptions, proved to add prognostic value to the MELD score in predicting
waitlist mortality.
Aim: To identify the predictive value for death on a large waiting list (WL)
for the complications of liver disease, current MELD and variation of MELD
scores at certain time intervals.
Methods: During 2004-2007, 372 consecutive adult patients were listed for
liver transplantation (OLT) in our Center. To identify the potential predictors of
patient death, univariate and multivariate Cox’s proportional hazards regression
model was used.
Results: We included in the study 58.1% men and 41.9% females with a mean
age at OLT of 46.6 ± 10.9 years. The 12 months actuarial survival was 76.7%.
OLT was performed in 9.4% of patients. In the univariate survival analysis
the following variables were significant: spontaneous bacterial peritonitis,
refractory ascites, hepatic encephalopathy, renal failure, current MELD score,
MELD score at inclusion on WL, maximal variation of MELD score, maximal

1
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variation of INR, creatinine and bilirubin, MELD score variation in the last 3
months (p<0.0001 for each), as well as INR (p<0.0001), creatinine (p=0.01) and
bilirubin (p<0.0001) variation in the last 3 months. The independent predictors
of death on our WL were: current MELD score (p=0.0006), refractory ascites
(p=0.001), renal failure (p=0.01), hepatic encephalopathy (p=0.03). Based
on a logistic regression analysis a new score has been developed including
these independent predictors of death on the WL: Score= 1/(1+ exp(-(-4.59 +
1.51 x Refractory ascites + 0.18 x Current MELD), where refractory ascites is
registered as 1 if the event occurs. The c-statistic for the new score for prediction
of death on the WL was 0.84 compared to 0.80 for current MELD score.
Conclusion: Refractory ascites should add valuable points to the current
MELD in order to better prioritize for liver transplantation patients included
on large WL.
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2034 SIX-YEAR FOLLOW-UP OF A DOMINO LIVER
TRANSPLANTATION USING A GRAFT FROM A DONOR WITH
FAMILIAL HYPERCHOLESTEROLEMIA

THURSDAY

I. Popescu1, S. Dima1, N. Hancu2, L. Gheorghe3, S. Iacob3, M. Mihaila4, E.
Matei1, B. Dorobantu1, F. Botea5
1
Center of General Surgery and Liver Transplantation, Fundeni Clinical
Institute, Bucharest, Romania, 2Institute of Diabetes and Nutritional Diseases
Cluj-Napoca, Cluj-Napoca, Romania, 3Center of Gastroenterology and
Hepatology, Fundeni Clinical Institute, Bucharest, Romania, 4Department
of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania, 53rd
Department of Surgery, University School of Medicine – Humanitas Clinical
Institute IRCCS, Rozzano, Milan, Italy
Background: Domino liver transplantation (DLT) has been developed as a
method to increase the donor pool.
Material and Method: Material and Method: We present here the case of
a 46-year-old female with hepatocellular carcinoma (HCC) and hepatitis
B virus liver cirrhosis, non-responsive to chemoembolization. The patient
that was in a severe condition received a domino liver graft from a 25-yearold female with homozygous familial hypercholesterolemia (HFHC) in
September 2001. Before transplantation, the donor’s serum cholesterol level
was 500 mg/dl under treatment with Simvastatin and 800 mg/dl without it,
and after transplantation the level was maintained within the normal range.
During follow-up examination of the graft recipient, hypercholesterolemia
occurred within one year after the liver transplant and was partially controlled
by atorvastatin (the highest serum cholesterol value was 410 mg/dl). Three
years after the transplantation, an autologous CD34+ cell transplantation
was performed in order to better control the hypercholesterolemia. In 2003
we published only preliminary results of with this case, without a long-term
analysis of the effects of hypercholesterolemia.
Results: Subsequent to domino liver transplantation, the average plasma
cholesterol level in the domino donor rapidly normalized and after more than
six years of follow-up, plasma cholesterol was 182 mg/dl. The patient was
metabolically stable. She showed no sign of lipid imbalance and only minimal
modifications in her most recent Doppler echocardiography. The domino
recipient currently has no HCC recurrence; tumoral markers are within the
normal range and CT is negative. Moreover, no signs of cardiovascular or
atherosclerotic lesions were noted despite an elevated plasma cholesterol level
(320 mg/dl after 76 months of follow-up) resistant to drug therapy and stem
cell autotransplantation.
Conclusion: Domino liver transplantation using a liver graft from a patient
with homozygous familial hypercholesterolemia provides a viable option for
marginal recipients.
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2035 ANALYSIS OF RISK FACTOR FOR ATELECTASIS AND
THE EFFECT OF PRONE POSITION THERAPY AFTER LIVING
DONOR LIVER TRANSPLANTATION
S. Nakahashi1, T. Shimamura2, M. Taniguchi3, T. Suzuki4, K. Yamashita5, M.
Ota6, T. Kamiyama7, M. Matsushita8, H. Furukawa9, S. Todo10
1
Department of General Surgery Hokkaido University Graduate School of
Medicine, 2Department of General Surgery Hokkaido University Graduate
School of Medicine, 3Department of General Surgery Hokkaido University
Graduate School of Medicine, 4Department of General Surgery Hokkaido
University Graduate School of Medicine, 5Department of General Surgery
Hokkaido University Graduate School of Medicine, 6Department of General
Surgery Hokkaido University Graduate School of Medicine, 7Department
of General Surgery Hokkaido University Graduate School of Medicine, 8
Department of General Surgery Hokkaido University Graduate School of
Medicine, 9 Department of General Surgery Hokkaido University Graduate
School of Medicine, 10Department of General Surgery Hokkaido University
Graduate School of Medicine
Background: Pulmonary complications occur with a high rate after liver
transplantation, resulting in the extended hospital stay and sometimes
poor prognosis. Especially, pneumonia demonstrates high mortality. As an
underlying condition, persistent atelectasis is considered to be a risk factor.
However, little has been reported about the pulmonary atelectatsis after living
donor liver transplantation (LDLT), or the effective therapy to prevent this
unfavorable complication.
Purpose: We investigated the risk factors for atelectasis after LDLT and
assessed the effect of prone position therapy.
Patients and methods: Fifty two adult patients underwent LDLT at our center
from October 2003 to December 2007 were enrolled in this study. Eight and 17
patients were excluded from the reason of bilateral thracentesis and insufficient
clinical data respectively. Remaining 27 cases were retrospectively reviewed
retrospectively. Degree and type of atelectasis were assessed with computed
tomography at one and two weeks after LDLT. Degree of atelectasis was
expressed as the ratio between atelectatic area and whole lung area (A/WL
ratio). Preoperative patient’s condition, graft status, intraoperative factors were
analyzed as risk factors for atelectasis. Postoperative patient’s condition and
clinical course were compared between the patients who treated with prone
position therapy (treated group; n=9) and without (control group; n=18).
Result: All patients demonstrated various degree of dorsal atelectasis (27/27,
100%). A/WL ratio was correlated with MELD score (r= 0.5456, p= 0.0022),
Graft Volume/Standard Liver Volume ratio (r= -0.4003, p= 0.0314), length of
ICU stay (r= 0.5496, p= 0.0020), and intubation period (r =0.3792, p= 0.0425).
Although the A/WL ratio at 2 weeks after the operation was significantly lower
than that at 1 week after LDLT in both groups (treated group; p= 0.0001, control
group; p= 0.0055), atelectasis was remarkably ameliorated in the treated group
compared to the control group (p=0.0038). Further, the treated group showed
better postoperative condition and clinical course.
Conclusion: These results suggest that dorsal atelectasis after LDLT increases
duration of mechanical ventilation support and prolong ICU stay. Prone position
therapy is effective for dorsal atelectasis, and prevents deleterious pulmonary
complications after LDLT.
CT

Control (n=18)

1w Post

14.37

2w Post
1w Post – 2w Post

Treated (n=9)

± 9.306

19.98

± 8.457
± 0.95* #

6.969
7.4

± 9.418*
± 9.878
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Walking independence (POD)
Hospital stay¦ ¦ days¦
incidence
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2

0

Re-intubation after 14POD

3

0

Pneumonia after 14POD
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2036 PREGNANCY OUTCOME IN LIVER TRANSPLANT
RECIPIENTS AT THE UNIT OF LIVER TRANSPLANTATION –
UNICAMP, BRAZIL
I. Boin2 , M.L. Costa1, F. Surita1, E. Udo2, M. Leonardi2, C. Portugal2,
R. Stuchi2,
1
Centro de Atenção a Saude da Mulher – CAISM – Unicamp, 2Unit of Liver
Transplantation – Unicamp
Context: Transplantation has become an available and successful treatment
option for innumerous congenital and acquired hepatic disorders. Studies
have shown that when the pregnancy recipient graft function is stable and
adequate,the pregnancy is normally well tolerated with favorable newborn
outcomes. However, there are reports of increased incidences of hypertension
and preeclampsia as well as lower birth weights and prematurity. Patients
who were administered with tacrolimus-based therapies seem to have lower
incidence of these complications.
Case Reports: The five patients aged from 19 to 37 years, had, at the time
of conception, 2 to 9 years since transplantation. One preterm delivery, for
fetal distress, was the most important complication in these patients. Were
observed one episode of acute genital herpes infection, a liver hematoma in
an anticoagulated patient with history of deep vein thrombosis and in another
patient an urinary tract infection. Despite complications all five pregnancies
were succesfull. The mean gestational age at delivery was 37.7 weeks. No
structural malformations or early complications were observed in the newborns.
All cases showed stable liver parameters and the patients and babies have been
relating well-being.
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2037 THE RELEVANCE OF PCT AFTER LIVER
TRANSPLANTATION
V. Müller, T. Meyer, W. Hohenberger, M. Hoffmann
Chir.Uni Klinik Erlangen/Nürnberg
Introduction: Orthotopic liver transplantation (OLT) is a treatment for end
stage liver disease. Shortage of available organs leads to the acceptance of
marginal grafts and increases the risk of perioperative complications like acute
rejection, infection and graft dysfunction. PCT was shown to be a reliable
marker for complicated course after trauma and in the course of SIRS and
sepsis. The aim of the study was to evaluate Procalcitonin (PCT) as an early
prognostic marker for occurrence of complication in the postoperative course
after OLT.
Methods: We included 32 patients who underwent 33 OLTs and analysed
the levels of PCT and clinical and paraclinical data. The highest PCT was
defined as peak- PCT. Patients were stratified in a non-complication and a
complication group. Renal replacement therapy, respiratory insufficiency,
postoperative bleeding, refractory ascites and pleural effusion, rejection, sepsis
and fatal outcome were defined as complication. A secondary stratification was
performed using a peak- PCT of 5ng/ml in each group. Then, we analysed
the risk of occurrence of a complication according to a peak- PCT of 5ng/ml.
Further we analysed the course of PCT after OLT in each group.
Results: The peak- PCT occurred between the first and third postoperative day
in 30 patients, followed by halvening every second day. Nevertheless, 3 of
them died because of sepsis. A constantly rising PCT or a secondary rise was
seen in 2 patients and associated with fatal outcome.18 patients were stratified
in the non- complication group, 8 with peak- PCT lower than 5ng/ml and 10
higher. 14 patients with 15 transplantations were stratified in the complication
group, only 1 patient developed a peak- PCT below 5ng/ml. The odds ratio
of running a complication was 11.2 (10.81 – 11.59; p<0,025) when the peakPCT was higher than 5ng/ml. However, the course of mean PCT levels was
significant between the complication and non- complication group not before
the 7th postoperative day.
Discussion: PCT is a reliable marker for SIRS and sepsis and rises with the
severity of the disease and due to operative trauma. A decline was seen in 31
cases, in 2 cases we observed a constantly rising level, and both patients had
a fatal outcome. This observation was described before for non transplant
patients. In transplant patients, an elevation of PCT was only seen in bacterial
infections, but not in rejection or wound infection. We have seen a rise of PCT

in respiratory failure and sepsis, but not in renal replacement therapy, ascites,
pleural effusion, rejection or bleeding. An initial high PCT is described not to
indicate a poor prognosis, and patients of the non-complication group also had
levels exceeding 15ng/ml. The patients of the complication group had a higher
mean PCT, which turned significant not before the 7th day, most probably
because of the high variation of levels. Still, a peak- PCT above 5ng/ml has an
odds ratio of 11.2 for patients to experience a complication.
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2038 REVERSAL OF SEVERE HYPOXEMIA IN
HEPATOPULMONARY SYNDROME BY CPAP AND NON
INVASIVE POSITIVE PRESSURE VENTILATION
J.F. Goorhuis1, R. Scheenstra2, W. Dieperink3, M.J.I.J. Albers1
Department of Pediatrics, Division of Pediatric Intensive Care, Beatrix
Children’s Hospital, University Medical Center Groningen, University of
Groningen. The Netherlands., 2Department of Pediatrics, Division of Pediatric
Gastroenterology, Beatrix Children’s Hospital, University Medical Center
Groningen, University of Groningen. The Netherlands., 3Department of Surgery,
Division of Surgical Intensive Care, Surgical Intensive Care Unit, University
Medical Center Groningen, University of Groningen. The Netherlands.
Introduction: Hepatopulmonary syndrome (HPS) is characterized by advanced
liver disease and arterial hypoxemia in the presence of intrapulmonary shunting.
The only reported curative option is orthotopic liver transplantation. Reversal
of severe arterial hypoxemia offers a bridge to transplantation and ameliorates
the perioperative phase. We describe two patients with severe hypoxemia in
HPS who are treated with CPAP and non invasive positive pressure ventilation
(NIPPV) with an improvement in oxygenation and respiratory symptoms.
Case reports: The first patient is a 14 year old girl with HPS because of liver cirrhosis
due to primary sclerosing cholangitis. Despite continuous oxygen supplementation
with a ventimask FiO2 60% her oxygen saturation remained around 80% and her
exercise tolerance was minimal one month after liver transplantation. Introduction
of CPAP 4 cm H2O FiO2 100% using a CPAP machine and later a light weight
Boussignac CPAP device increased her arterial pO2/oxygen saturation from 5,8
kPa/79% to 11,5 kPa/97%. After 4 weeks continuous CPAP she was weaned. Three
months after liver transplantation she was discharged home with 1 L/min via a
nasal cannula with oxygen saturations > 90%.
The second patient is a 15 year old girl with HPS of liver cirrhosis due to
cystic fibrosis. After extubation the first day after liver transplantation she
developed progressive respiratory distress with oxygen saturations between
80- 85% with a ventimask of 60% (without CO2 retention). After introduction
of NIPPV with FiO2 60% her oxygen saturation increased to 96% with relieve
of respiratory symptoms. In two weeks NIPPV was weaned and one month
after liver transplantation she could be discharged with oxygen saturation 96%
without supplemental oxygen.
Conclusions: CPAP and NIPPV can reverse severe hypoxemia in
hepatopulmonary syndrome. When supplemental oxygen does not sufficiently
improve oxygenation in HPS CPAP and/or NIPPV therapy should be considered
to bridge patients to recovery of HPS after liver transplantation.
1

POSTER BOARD NUMBER P4 – 89
2039 EFFICACY OF CARDIAC OUTPUT DETERMINATIONS
BY ECHO-ESOPHAGEAL DOPPLER IN LIVER TRANSPLANT
PATIENTS WITH LOW MELD SCORE.
V. Perilli1, A.W. Avolio2, R. Caserta1, M.T. Cazzato1, N. Martella1, E. Nure2, S.
Agnes2, L. Sollazzi1
1
Dpt of Anaesthesiology, Catholic University of Rome, Rome, Italy, 2Dpt of
Surgery – Transplantation Service, Catholic University of Rome, Rome, Italy
Objective: The aim of this study was to evaluate the suitability of a
transesophageal echo-Doppler device (HemosonicTM – Arrow, Reading,
PA) (ED) as a minimally invasive device for measurement of cardiac output
in liver transplantation. This device was compared to standard pulmonary
artery catheter (Opticath, Abbott, Illinois, USA) (PAC), taking into account the
disease severity of liver candidate recipients as scored by the Model for End
stage Liver Disease score (MELD).
Materials and methods: Forty two cirrhotic patients were enrolled. At standard
times, three thermodilution cardiac output (COPAC) measurements were taken by
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a pulmonary artery catheter, and the most recent ED measurement (COED) was
also recorded. Paired measurements of CO were carried out at standard times,
unless clinical needs. Recipients were stratified in three groups according to
chemical MELD score, and a low risk group (MELD score ≤15; 14 patients),
an intermediate risk group (15< MELD score <29; 17 patients), and a high risk
group (MELD score ≥29; 11 patients) were identified. Statistical analysis was
performed by Bland-Altman, analysis of variance and linear regression.
Results: Four hundred ninety five paired measurements of CO were carried out.
Echo Doppler signal detection was not optimal in 55 determinations (11.1%).
These determinations have not been considered for the comparison. Mean bias
was 0.34± 0,9 l min-1 and limits of agreement were –1.46 l/min-1 and 2.14
l/min-1. Variations in COPAC correlated well with those measured using ED
(p<0,01, R=0,79). Moreover, we observed a significant correlation between
COPAC and relative error between COED and COPAC (p<0.01, R=0.15). As for the
three patient groups (table), the low risk group exhibited significantly lower
mean bias and relative error than the other two groups. In particular patients
with MELD score under 16 exhibited a bias of 0.12 ± 0.55 (p<0.01).
l min-1

addition to standard medical therapy and included in this retrospective study.
Results: Seven patients median age of 52 years, with primary non function
(2 cases) and graft dysfunction (5 cases) after LTx, were included in
the study. Five patients received a extended criteria donor organ. Six
months overall survival was 57%; 4 cases of GD (1 re-LTx) were alive
at the end of the follow up, 2 cases of PNF (1 re-LTx) and 1 case of GD
died. After MARS therapy we observed reductions in serum bilirubin
(40.0±11.3 vs 29.5±7.3 mg/dL), bile acids (131±73 vs 81±38 μmol/L),
creatinine (2.2±1.2 vs 2.0±1.5 mg/dL), and ammonia levels (152±177
vs 143±179 γ/dL). Differences were significant for bilirubin and bile
acids (p<.05). Liver, neurological, renal, and hemodynamic functions
did not improve in the 2 PNF patients. The liver synthetic function
(prothrombin time and serum albumin level) was improved in 4 out of
5 patients with GD, while all of them showed a significant improvement
of HE grade (defined as a reduction by > 1 grade). In 2 patients suffering
from intractable pruritus, the symptom was effectively treated by MARS
therapy. In one patient pruritus disappeared completely after 5 MARS
sessions (VAS decreased from 10 to 0), allowing the discontinuation of
symptomatic therapy; in the other patient pruritus decreased, but did not
disappear (VAS from decreased from 10 to 4-5). In all patients, MARS
therapy was well tolerated, and no MARS-related adverse event occurred.
Conclusions: MARS therapy is a promising and safe therapeutic option to
treat severe GD after LTx.
N (yrs)

MELD ≤15

MELD 16-28

MELD ≥29

COED l min

6.73 ± 2.04

8.5 ± 3.5

7.40 ± 1.77

COPAC l min-1

6.75 ±1.87

-1

8.85± 3.5

7.67 ±1.56

Relative error% 1.66± 8.1

4.67 ± 11.3 *

4.41± 11.05 *

Bias l min-1

0.38 ±1.10 *

0.33± 0.84 *

0.12 ±0.55

p<0.05 compared to MELD ≤15 group

Conclusions: Even if the trend of COED was comparable with COPAC and
variations of COED fitted well with changes of COPAC, ED is not interchangeable
in all cases with PAC because of the large limits of agreement. However in
cirrhotic patients with MELD score under 16 the precision of the new method
is quite similar to that of PAC (12,7 vs 10%), and the mean bias is close to zero
(0,12 l min-1); thus, in this subset of patients, it may represent a reliable less
invasive alternative to PAC.
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2040 MOLECULAR ADSORBENT RECIRCULATING SYSTEM
(MARS) IN PATIENTS WITH PRIMARY NON-FUNCTION AND
OTHER CAUSES OF GRAFT DYSFUNCTION AFTER LIVER
TRANSPLANTATION IN THE ERA OF EXTENDED CRITERIA
DONORS ORGANS

THURSDAY

R. Gaspari1, A.W. Avolio2, L. Zileri dal Verme3, S. Agnes2, V. Perilli1,
R. Proietti1, A. Gasbarrini3
1
Dpt of Anaesthesiology and Intensive Care, Catholic University of Rome,
Rome, Italy, 2Dpt of Surgery – Transplantation Unit, Catholic University of
Rome, Rome, Italy, 3Dpt of Medicine, Catholic University of Rome, Rome, Italy
Background and aims: Liver Dysfunction following liver transplantation
(LTx) is an important cause of morbidity and mortality. It can present as
Primary Non Function (PNF) or Graft Dysfunction (GD) and it’s prevalence
is increasing because of the more frequent use of extended criteria donor
organs. The Molecular Adsorbent Recirculating System (MARS) is an
albumin-based dialysis system designed to enhance the excretory function
of a failing liver. This study is to evaluate the potential role of MARS in
this particular setting of patients. Primary end-point: six months survival.
Methods: All cases of Liver Dysfunction following LTx during the last 6
years were referred to our Intensive Care Unit. Patients presenting with
progressively increasing jaundice (serum bilirubin level >15 mg/dl), and
hepatic encephalopathy and/or renal dysfunction were treated with MARS in
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2041 LEVEL OF ANXIETY DE LIVER PRETRANSPLANTATIONS RECIPIENTS
I. Boin, G. Santos, I. Pereira, C. Portugal, E. Udo, M. Leonardi, R. Stucchi
Unit of Liver Transplantation – Unicamp
Liver transplantation is a treatment for end-stage liver disease and represents an
important cause of fellings for the patients.
Objective: To evaluate anxiety level of pre-transplant recipients who are in
waiting list to liver transplant.
Methods: Thirty five adult patients were following at the Unit of Liver
Transplantation and Psychology team of Gastrocentro – HC-Unicamp, all of
them in waiting list to liver transplantation. All of them were submitted to
query to psychological evaluation by the Inventory of Beck.
Results: The group had 31(88.6%) men and 4(11.4%) women, average of 40.28
years-old, MELD score value was 17. Of them, 18(51.4%) had imcomplete
middle school, 7(20%)had superior level and the others had complete high
school. After querying we observed that 29(54.3%) patients had light level of
anxiety, 14(40%) had moderate level and 2(5.7%)had severe.
Conclusion: These results have demonstrated the importance of a psychological
team in the liver transplantation unit to command the patients and the families
to obtain good results after surgery and the well-being of the patients.
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2042 INFLUENCE OF MARGINAL ORGANS ON BILIARY
COMPLICATIONS AFTER LIVER TRANSPLANTATION
M. Loss1, K. Mantouvalou1, J. Rochon2, T.Y. Tsui1, A. Obed1, H.J. Schlitt1
Departments of Surgery, University of Regensburg Medical Center, Germany,
2
Center for Clinical Studies, University of Regensburg, Germany
Introduction: Biliary complications are a significant cause of morbidity,
graft loss and mortality after orthotopic liver transplantation (OLT). The
reported incidence of biliary complications varies substantially between
centers (6%-40%). Due to organ shortage, marginal donors are increasingly
used in OLT. In our center, we observed a rise in the number of major biliary
complications over the last years. We speculated this effect may be attributable
to the increasing use of extended donor criteria (EDC) organs. Thus, the
objective of this study was to evaluate the incidence of biliary complications in
a contemporary series and to study potential donor and recipient risk factors as
well as the influence of marginal donor organs.
Patients And Methods: We retrospectively analyzed 115 whole organ OLT
performed between 01/2004 and 06/2007. Patients were divided into three
groups: no biliary complications, minor complications (anastomotic strictures,
leakages and other complications which could be managed interventionally
by <5 procedures), and major complications (>5 interventions, reoperation
or retransplantation necessary) Different donor and recipient factors were
evaluated and correlated to biliary problems.
Results: The overall incidence of biliary complications was 41.7% (8.7% minor,
33.0% major complications). 77/115 (67%) donor organs were classified as
EDC organs. High donor age and high donor BMI were statistically significant
risk factors for major biliary complications. However, the frequency of major
biliary complications was not higher in EDC organs. When regarding followup, minor complications did not seem to have an impact on overall outcome,
whereas major complications increased morbidity and even mortality.
Conclusion: We here report a high incidence of biliary complications in a
contemporary series after OLT. There is currently no international consensus as
to what criteria define “marginal organs”. Our results suggest that some donor
characteristics are related to a higher rate of biliary complications and mortality,
whereas other aspects linked to the definition of marginal organs do not seem
to have an effect on biliary complications. Prospective studies are needed in
order to identify significant risk factors for major biliary complications, thus
allowing for a better assessment of organ quality and improving long term
outcome after OLT.

1
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2043 SEXUAL DYSFUNCTION (SD) AND QUALITY OF LIFE
(QOL) AFTER LIVER TRANSPLANTATION (LT) IN MALE
RECIPIENTS
P. Burra1, A. Masier1, A. Salonia2, G. Germani1, M. Gambato1, E. De Martin1,
M. Senzolo1, F.P. Russo1, G. Zanus3,
1
Gastroenterology, Department of Surgical And Gastroenterological
Sciences, University of Padua, Italy, 2Department of Urology, University
Vita-Salute San Raffaele, Milan, Italy, 3Surgery, Department of Surgical and
Gastroenterological Sciences, University of Padua, Italy
Background and aim: Sexual dysfunction is highly prevalent in men with
liver cirrhosis and it remain highly prevalent after LT. The aim of our study
was to determine the prevalence of sexual dysfunction in men after LT and its
relationship with QoL.
Methods: 44 male liver transplanted patients (mean age 56.3±3yrs) were
enrolled. Sexual hormones (17&#61538;-estradiol, PRL, thyroid hormones,
testosterone total and free, &#61508;4, DEAS, SHBG, 17-OH progesteron)
were assessed in all patients. Three validated questionnaires [International
Index Erectile Function (IIEF), Beck Depression Inventory (BDI), SF36 (for
determination of QoL) were used. Statistical analysis: Student’s t test, data
expressed by mean±SE.
Results: Etiology of liver disease was alcohol related in 17/44 and non-alcohol
related in the remaining 27 patients. The hormone status in transplanted
patients – compared to normal values – was: low DHEAS (1,6±0,5 umol/L),
high 17&#61538;-estradiol (141,9±18,8 pmol/L). Sexual dysfunction was not
associated with sexual hormones and etiology of liver disease. 7/44 (16%) patients

reported mild or moderate depression. 29/37 (78%) of transplanted patients
reported mild or moderate erectile dysfunctions (ED). No difference in age was
seen in transplanted patients with or without ED but ED was worse in depressed
vs non depressed transplanted patients (p<0.05). The SF36 total, Mental health
and, among variables of SF36, Role emotional, Social function and Role-physical
have a better score in patients without ED vs patients with ED (p<0.05). No
difference in IIEF, ED, BDI and sexual hormone levels was observed between 28
patients on tacrolimus confronted to 16 patients on cyclosporine.
Conclusion: Sexual dysfunction, highly prevalent in liver transplanted patients
is not associated with age and hormone status. However, it is associated with
depression and consequently with impaired Qol. Prognosis of psycological
support are badly needed.
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2044 THERAPEUTIC DRUG MONITORING OF LIVER
TRANSPLANT PATIENTS RECEIVING EVEROLIMUS
THERAPY BY FPIA
T. Jones1, B. Ulbricht2, M. Van der Linden3, P. de Simone4, P. Marbach2,
L. Arabshahi1
1
Thermo Fisher Scientific Inc., 2Novartis Pharma AG, 3Eurofins Medinet B.V.,
4
Cisanello Hospital
Everolimus is a macrolide immunosuppressant derived by chemical modification
of the natural product rapamycin; rapamycin is produced by certain strains of
Streptomyces hygroscopicus. The mechanism of action of everolimus consists
of binding to the mammalian target of rapamycin (mTOR).. As the result
everolimus is routinely used in combination with calcineurin inhibitors due to
synergistic mechanism of action. The clinical use of everolimus/cyclosporine
A (CsA) regimens requires blood concentration-guide dosing. The preferred
matrix is whole blood because at therapeutic concentrations both compounds
are predominately partitioned into membranes of erythrocytes. Liquid
chromatography alone as well as coupled to mass spectrometry (LC/MS and
LC/MS/MS), and fluorescent polarization immunoassay (FPIA) have been
used to measure concentration of everolimus in blood.
The Innofluor® Certican® Immunoassay System is a homogeneous fluorescence
polarization immunoassay used for the analysis of everolimus in whole blood
samples. This assay has previously been validated for kidney and heart samples.
The Innofluor Certican Immunoassay system has been developed for use on an
FPIA analyzer.
Using Innofluor Certican value assigned calibrators with the following
target values 0, 2.5, 5.0, 10.0, 20.0, 40.0 ng/mL, a 6-point calibration curve
is generated that is stable for at least 2 weeks. Control recovery over the
course of the 3 month study for control level 1 (3.92 ng/mL), 2 (10.76 ng/
mL) and 3 (22.04 ng/mL) was 12, 8 and 6% CV respectively. One hundred
and fifty liver transplant patient samples consisting of EDTA anticoagulated
whole blood ranging from 0 ng/mL to 16 ng/mL were tested. Results from
the immunoassay on the FPIA system were compared with LCMS/MS data
collected at a reference lab and resulted in a slope by Passing-Bablock
analysis of 1.18, y-intercept of -0.29, and correlation coefficient 0.94. The
immunoassay has an analytical sensitivity of 2.0 ng/mL and a functional
sensitivity of 0.8 ng/mL. This study suggests that the Innofluor Certican
assay is suitable for the therapeutic drug monitoring of everolimus in liver
transplant patients.
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2045 LONG-TERM SURVIVAL BENEFIT IN RELATION TO
MELD CLASS CATEGORIZATION. A SINGLE INSTITUTION
INTENTION TO TREAT ANALYSIS OF WAIT LISTING FOR
LIVER TRANSPLANTATION.
A.W. Avolio1, M. Siciliano2, G.L. Caracciolo2, R. Barbarino1, R. Gaspari3,
F. Frongillo1, A. Gasbarrini2, S. Agnes1
1
Catholic University of Rome, Dpt of Surgery – Transplantation Service,
2
Catholic University of Rome, Dpt of Internal Medicine, 3Catholic University
of Rome, Dpt of Anaesthesiology
Background: Survival benefit (SB) has been designed to compare, among
patients on the waiting list, survival of those who are transplanted to survival
of patient who are not transplanted. As yet, SB has been evaluated only at 12
and 36 months.
Patients and methods: From Jannuary 2002 to December 2007, 171
consecutive cirrhotic patients were candidates to liver transplantation at
Catholic University of Rome, Italy. In all patients biochemical MELD score
was calculated according to standard original formula. No correction for coexistence of hepatocarcinoma was utilized. Patients included on the waiting
list were retrospectively stratified and arbitrarily classified into 4 Intention-toTreat (ITT) classes according to the MELD score. Classes were MELD 6-14
(N=85), MELD 15-18 (N=41), MELD 19-25 (N=30), MELD 26-40 (N=15).
Patients were retrospectively stratified into 2 subgroups according to stay on
the Waiting List (LWL) or to be transplanted (LTx).
Results: Of the 171 patients listed, 110 patients were transplanted (64%).
The overall ITT patient survival at 12, 24, 36, 48, 60 months was 76%, 72%,
66%, 61% and 61% respectively. The patient survival for the LWL subset at
12, 24, 36, 48, 60 months was 66%, 58%, 47%, 34% and 34% respectively.
The patient survival for the LTx subset was 82%, 79%, 73%, 73% and 73%
respectively. Differences were significant (log rank, p<0.01). Medium term
(30 months) survivals range from 87% in the MELD class 6-11 to 36% in the
MELD class 26-40. Long term (60 months) survival are similar for patients
in the MELD classes 6-14, 15-18, and 19-25 ranging between 61% and 69%,
while for patients in the MELD class 26-40 remains 36%. Differences between
survival curves are significant (p<0.05 to p<0.001). For each MELD class the
outcomes of staying on the list or being transplanted is shown on figure. The
differences in terms of survival benefit is represented by the distance between
curves. Considering survival benefit a dynamic process, a change over time
was observed in the different MELD classes after listing. Patients in the MELD
class 6-14 show a SB of waiting list for the first 36 month of follow up. Patients
in the MELD class 15-18, show a SB of waiting list for the first 6 months of
follow up. There is any benefit of waiting list for the MELD class 19-25 and for
the MELD class 26-40 (log rank, p<0.001).
Conclusions: In summary, we demonstrated that in our series all listed patients
present SB. SB appears late for low MELD classes than for high MELD classes
but is always present.
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2046 ALBUMIN DIALYSIS SYSTEM PROMETHEUS (FPSA) AS
SUPPORT TREATMENT BEFORE LIVER TRANSPLANTATION
IN PATIENTS WITH WILSON’S DISEASE.
M. Kotulski, K. Zieniewicz, M. Grodzicki, A. Mackiewicz, M. Krawczyk
Department of General, Transplant and Liver Surgery, Medical University of
Warsa
Introduction: Wilson’s disease (Wd), also called hepatolenticular degeneration,
is an inherited disorder of copper metabolism, which, in consequence, leads
to its accumulation in the liver and/or brain (among other) causing damage to
those organs. There might be several forms of liver damage in the course of the
disease: acute or chronic liver failure and acute or chronic liver inflammation.
Aim: The purpose of this study was to compare and evaluate the efficiency
of the Wd treatment, when either liver transplantation (OLTx) and/or albumin
dialysis system Prometheus (FPSA) were employed.
Material & Method: The research is based on the data provided by the
Department of General, Transplantation and Liver Surgery, Medical University
of Warsaw, 1996-2007. Case histories of 33 patients (26 women and 7 men)
with Wd, aged 33±9, who were treated in the Department either by OLTx and/
or FPSA, were analysed in a retrospective study. All patients in the examined
group were qualified for OLTx. 11 patients had periodically decompensed
chronic liver failure (CLF) – UNOS 3, and 22 patients suffered from acute on
chronic liver failure (AoCLF) – UNOS 1 and 2A.
Results: 11 patients with Wd in the form of CLF didn’t need FPSA treatment
before transplantation; no deaths occurred in this group after the OLTx was
employed (observation period: 120-20m). There were 5 transplantations before
FPSA treatment was introduced in the group of patients with acute liver failure
in the course of Wd; 4 patients died during the early postoperative period. 6
patients with AoCLF UNOS 1/2A underwent FPSA treatment. However, due to
the lack of organs, there was no transplantation. All those patients died. In the
group of 8 patients who underwent OLTx after the preparation/the prolonging
of possible time of anticipation of organ donation by FPSA treatment, 5 patients
survived. Other 3 patients with AoCLF underwent OLTx without previous
FPSA because the organ for transplantation was available within 24 hours after
the urgent organ recipient was registered at Euro/Poltransplant.
Conclusion: The only efficient treatment for a advanced liver form of the
Wilson’s disease is the liver transplantation. The albumin dialysis system
Prometheus (FPSA) is an efficient and safe form of bridge treatment before the
organ transplantation.
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2047 MULTIPLE LIVER RETRANSPLANTATIONS FOR
RECURRING HEPATIC GRAFT FAILURE
E. Akpinar1, R. Zamora1, T. Kato1, S. Nishida1, D. Levi1, J.G. Moon1,
G. Selvaggi1, E. Prietto2, L. Arosemana3, A. Tzakis1
1
Miami Transplant Institute, Univ of Miami, Liver-GI Transplantation,
Miami-FL, USA, 2Dept of Anestesiology, Univ of Miami, Miami-FL, USA,
3
Dept of Hepatology, Univ of Miami, Miami-FL, USA
Background: Multiple liver retransplantation (RE-LT) for recurring
irreversible acute or chronic liver allograft failure has not been addressed in
the literature. Here we present our patients who received multiple RE-LTs.
Graft#

TX1

TX2

TX3

TX4

ADULT (n=2066)

1808

229 (13%)

25 (1.5%)

4 (0.2%)

TX5
-

PEDIATRIC (n=305)

257

37 (14%)

8 (3%)

2 (0.8%)

1 (0.05%)

THURSDAY

Material and Methods: A retrospective analysis was performed on patients
who received liver transplantation in our institution. Demographics, primary
diagnoses, indications for RE-LT, perioperative technical problems, hospital
stay (LOS), immunosuppressive regimens, and survival data were analyzed
and compared between patients who received first (TX1), second (TX2),
third (TX3), fourth (TX4) and fifth (TX5) liver transplants. Non-parametric
methods were used for statistical comparisons, Kaplan-Meier method was
used for survival analysis and p<0.05 was considered significant. Results: A
total of 1808 adult pts received 2065 and 257 pediatric pts received 306 liver
allografts respectively between March-1987 and July-2007 (see Table). RE-LT
indications in adults for TX2, TX3 and TX4 were primary non-function (PNF)

672

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Poster Abstracts
(25%, 36% and 25%), arterial thrombosis (HAT) (21%, 14% and 0%), chronic
rejection (CR) (21%, 14% and 25%), recurrent disease (RD) (12%, 20% and
0%), biliary complication (BC) (4%, 0%, and 0%) and portal vein thrombosis
(PVT) (3%, 0% and 0%) respectively.In pediatric patients, the indications for
RE-LT were PNF (29%, 29% and 0%), HAT (42%, 29% and 50%), CR (21%,
0% and 50%), RD (21%, 0% and 0%) and PVT (3%, 0% and 0%) for TX2, TX3
and TX4 respectively. Mass clamping was used for allograft hepatectomy in
the majority of patients. The mortality rate before discharge, LOS and survival
rates were not significantly different after TX2, TX3 and TX4 in pediatric
and in adult groups respectively. Cox proportional hazard model analysis of
survival predictors in adult RE-LT population showed that HCV+ and LOS>25
days were significant risk factors predicting graft survival. Only LOS>10 days
was found to be a predictor risk factor for pediatric RE-LT patients.
Conclusion: In carefully selected patients, multiple RE-LT can be life saving
procedure and it can confer survival comparable to survival after first RE-LT.
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versus 47(12-79) years for W [p< 0.000]. Of the RLS donors 1/43(2.3%) were
aged > 60 years versus 41/182(22.5%) of the W donors [p<0.00]. Only 3% of the
RLS had > mild steatosis versus 8.4% of the W [p<0.2]. The median recipient age
was similar at 51.9(17.2-69.3) years for W and 53.05(16.6-66.6) years for RLS
[p<0.56]. The median MELD score was higher at 18(6-50) for W recipients versus
13(7-23) for RLS [p<0.00]. More recipients were transplanted for hepatocellular
carcinoma (25.6%) and primary sclerosing cholangitis (23.6%) with RLS versus
12% and 7.7% respectively with W [p<0.05]. Overall actuarial 5 year graft survival
was 88.4% for RLS versus 78.5% for W [p<0.3]. The retransplantation rate was
1/43(2.3%) for RLS [hepatic artery thrombosis (HAT)] versus 9/182(4.9%) for
W [HAT 4, primary non function 3, intrahepatic biliary stricturing 2]. There was
no primary non function with RLS. Mortality rate was 3/43(6.9%) with RLS
[haemorrhage 1, disease recurrence 1, sepsis 1], versus 25/182(13.7%) with W
[disease recurrence 6, rejection 4, sepsis 4, cardiovascular disease 4, other 6].
Conclusions: Good short and long term outcomes are achievable with RLS
versus W allografts. Application of selection criteria to both donors and
recipients may contribute to these results with RLS allowing expansion of the
limited deceased donor pool.

2048 LIVER TRANSPLANTATION IN A PEDIATRIC PATIENT
WITH BILIARY ATRESIA AND POLYSPLENIA SYNDROME: A
CASE REPORT
G-S. Choi, H-J. Park, K. Jung, J. Chun, G-O. Jung, J-M. Kim, S-J. Kim,
J-W. Joh, S-K. Lee
Samsung Medical Center, Seoul, Korea
Background: Biliary atresia (BA) is the most common disease for which liver
transplantation (LT) is done among pediatric patients, and, in 9-37% of cases,
it is accompanied by another congenital anomaly. Polysplenia syndrome (PS)
is the most common congenital anomaly occurring among patients with BA,
and is a syndrome which consists of polysplenism, midgut malrotation, situs
inversus, preduodenal portal vein, interrupted or absent infrahepatic vena cava
with azygous or hemiazygous continuation, anomalous hepatic arterial supply,
symmetric or isomeric liver, and bilobed right lung or pulmonary levoisomerism.
The authors report a case of living donor liver transplantation (LDLT) in a
patient with BA and PS. Case: A 5 year 11 months old boy was referred to
the clinic for digital clubbing. He had received Kasai portoenterostomy at 2
months for BA at another hospital. Hepatopulmonary syndrome was diagnosed
and elective LDLT with left lateral lobe from his older sister was planned
and undertaken. Intraoperative findings showed splenomegaly along with
polysplenia, symmetric liver, intestinal malrotation and preduodenal portal
vein. An interrupted inferior vena cava was observed with collateral flow into
the azygous vein, so the donor hepatic vein was anastomosed with the recipient
azygous vein. The boy recovered well from the surgery and all the vessels
showed good patency on Doppler ultrasonography. Postoperative computed
tomography scan and Diisopropyl-iminodiacetic acid (DISIDA) scan showed
no abnormal findings and the boy was discharge in good condition on the 17th
postoperative day. In a patient with biliary atresia and polysplenia syndorme,
living donor liver transplantation is a safe and acceptable treatment.
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2049 COMPARABLE LIVER ALLOGRAFT SURVIVAL WITH
RIGHT LOBE SPLIT VESUS WHOLE LIVER ALLOGRAFTS IN
ADULT RECIPIENTS
D. Verran, C. Sandroussi, . Lockwood, J. Gallagher, P. Tang, N. Shackel,
H. Pleass, S. Strasser, M. Crawford, G. McCaughan
Australian National Liver Transplantation Unit
Comparable Liver Allograft Survival with Right Lobe Split versus Whole Liver
Allografts in Adult Recipients
Introduction: Split liver transplantation has not been widely adopted
internationally partly due to concerns of inferior allograft outcomes in adult
recipients. The aim was to review our units short and longer term recipient and
graft outcomes undertaking split liver transplantation as a means of expanding
our static deceased donor liver allograft pool.
Methods: Retrospective analysis of outcome data on all adults who underwent isolated
liver transplantation from 7/2002-3/2007 with a minimum recipient follow up of 6
months. Data was obtained from the unit database/ Statistics were by Stata version 8.
Results: 43/225(19%) of transplants were with right lobe splits (RLS) versus
182(81%) whole grafts (W). The median donor age was 39(13-61) years for RLS
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2050 SECOND LIVER RETRANSPLANTATION: INDICATIONS
AND OUTCOME
A. Pascher, F. Ulrich, S. Kohler, S. Weiss, G. Puhl, O. Guckelberger,
U. Neumann, P. Neuhaus, J. Pratschke
Dept. of Visceral and Transplant Surgery, Charité, Campus Virchow
Although the outcome of liver retransplantation (re-LT) is still limited, it is
the only available therapy option for irreversible liver graft dysfunction. The
purpose ofthis study was to evaluate the role of second re-LT and to analyze
indications, outcome and specific problems.
Methods: Between 1989 and 2007, we performed 1912 (88,8%) LTs, 217 (10%)
re-LTs and 25 second re-LTs (1,2%) in 1924 patients. Patients were analyzed
for demographic and clinical variables, indication for re-LT, postoperative
complications and treatment outcome. Statistical analysis was performed with
ANOVA or Mann-Whitney U test, Kaplan Meier curves and log-rank test.
Results: The main indications for a second re-LT were thrombosis of the
hepatic artery (24%), initial nonfunction (20%) and acute or chronic rejection
(20%). The second re-LT was performed after a median period of 70 (2-5320)
days and the mean age of the recipients was 41,5±10,1 years. There was no
significant difference concerning mean operation time or course of serum
aspartate aminotransferase (AST). Merely serum alkaline phosphatase (AP)
was significantly higher 6 months after second re-LT. The main causes of death
were cardiopulmonary complications (26,7%) as well as multiorgan failure and
bleeding complications (13,3% each). Overall, 15 out of 25 patients (60%) died
after second re-LT. Patient survival after second re-LT was 62% after 1 year,
53% after 5 years and 46% after 10 years. In comparison to the patient survival
of primary LT or first re-LT, these inferior results differ significantly.
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2051 ARTIFICIAL LIVER SUPPORT SYSTEM USING HUGE
BUFFER VOLUMES REMOVES SIGNIFICANT GLUTAMINE
FROM PATIENT PLASMA WHICH IS A IDEAL BRIDGE FOR
LIVER TRANSPLANTATION
K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Background and aims: Bleeding tendency and brain edema are two major
life-threatening symptoms of fulminant hepatic failure (FHF). Artificial liver
support (ALS) systems should effectively treat these symptoms. Plasma
exchange has been the prevailing method used in Japan. Although able to
supply depleted coagulation factors, plasma exchange shows limited efficacy
for removing toxic substances with a large body pool such as glutamine. In vitro
studies showed that mitochondrial function is compromised by accumulated
glutamine, considered to mediate brain edema. We have developed a new ALS
system that combines plasma exchange and hemodiafiltration (HDF), and
report here its effect on various patient symptoms and its capacity to remove
glutamine.
Methods: Fifty-two patients with FHF and 16 patients with severe
acute exacerbation of chronic hepatitis B underwent plasma exchange in
combination with HDF from 1998 to 2006. The plasma exchange used 40-60
units of fresh frozen plasma, and HDF was carried out by conventional or
online route using polysulphone membrane. The total buffer volume used in
one session was 370-510 l. FHF symptoms were evaluated and the levels of
glutamine in patient plasma and in discarded buffer were assayed using an
automatic analyzer.
Results: Of the 68 patients who underwent combined plasma exchange/HDF,
62 (91.2%) fully regained consciousness from their initial coma and 45 (66%)
patients survived. Brain edema was observed in 2 patients who fell into grade
IV coma before admission, and hepatorenal syndrome was observed in 2
patients. One session of ALS decreased the plasma glutamine level by 40-60%,
which represents a distribution volume of removed glutamine per HDF session
of 30-60 l of plasma equivalent.
Conclusions: Plasma exchange in combination with HDF showed good clinical
effects and effective removal of plasma glutamine. This ALS system appears
promising for purifying the blood of patients with FHF. It is an ideal bridging
therapy for liver transplantation
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2052 EFFECTIVE ARTIFICIAL LIVER SUPPORT SYSTEM
ENABLE US TO DO I LIVER TRANSPLANTATION IN
PATIENTS WITH AHEPATIC STATE

THURSDAY

K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Purpose: Fulminant hepatic failure is a fatal disease and its clinical course
is variable. It is classified into acute form and subacute form in Japan. Acute
form carries favorable prognosis, however, some patients rapidly fall into an
ahepatic state. To avoid unnecessary liver transplantation and to perform it
safely in ahepatic patients, the establishment of a safe and effective artificial
liver support system is indispensable.
Method: The present study included four patients with fulminant hepatic
failure. Cause of FHF was acute infection with HBV. They fell rapidly into
an ahepatic state. We developed the artificial liver support system consists of
plasma exchange in combination with hemodiafiltration using polysulfone high
performance membrane.
Results: All patients were diagnosed as suffering from the acute form of FHF
due to acute HBV infection. The patients were placed on the ALS system
immediately after their referral to ensure timely bridging to liver transplantation.
One patient underwent living donor liver transplantation four days after the
onset of hepatitis. No donor organ could be found for the remaining patients
who were therefore continued on ALS for more than 2 weeks. We could
maintain these patients by ALS treatment without any severe complications
for the period.
Conclusion: Safe and effective ALS treatment can have sufficient capacity
to sustain patients through an ahepatic state and is valuable for identifying
patients who really do need liver transplantation.

674

POSTER BOARD NUMBER P4 – 103
2053 DOES A POSITIVE CROSSMATCH AFFECT OUTCOMES
FOLLOWING LIVER TRANSPLANTATION?
S. Asthana, C. Toso, G. Meeberg, T. Kawahara, D. Bigam, J. Shapiro,
P. Campbell, N. Kneteman
Multiorgan Transplant Unit, University of Alberta Hospital
Background: The impact of a positive crossmatch in liver transplantation
remains controversial, with some studies reporting higher rejection rates
(Posner et al, 1996) and worse outcomes in such patients. However, LT has
a protective effect on other organs in multiorgan transplant recipients. The
purpose of this study was to determine what impact a pretransplant crossmatch
had upon the clinical outcome following liver transplantation.
Patients and methods: Preoperative crossmatch status was determined
prospectively in 396 consecutive adult liver transplants performed between
January 2000 and December 2006. Data was collected on demographic
variables, as well as on pretransplant crossmatch results. The outcome variables
studied included the number and intensity of rejection episodes, as well as the
graft and patient survival. Chi-square tests and Mann-Whitney ‘u’ tests were
used for categorical and continuous data, while Kaplan-Meier curves were used
for survival outcomes.
Results: Data on 396 adult LT recipients was collected, of whom 252 (65.3%)
were male. The median follow-up for the cohort was 36.3 months (range
1-96 months). Twenty-nine patients (7.2%) had a positive T-cell cross match,
while 23 patients had PRA >15%. There was no difference in rejection rates in
the two groups, but rejection occurred earlier in patients with high PRA (1.7
months vs 6.9 months, p<0.001). Crossmatch status did not impact patient or
graft survival (p=0.24).
Conclusion: The presence of cytotoxic antibodies pretransplantation is
associated with increased early rejection. However, the presence of cytotoxic
antibodies is not deleterious to patient or liver allograft survival
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2054 TREATMENT WITH THE ANTI-COMPLIMENT C5
ANTIBODY ECULIZUMAB ALLOWS FOR SUCCESSFUL
LIVER TRANSPLANT IN A PATIENT WITH BUDD CHIARI
SYNDROME SECONDARY TO PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA
J. Locke, A. Singer, J. Hamilton, Z. Stewart, P. Thuluvath, W. Maley,
R. Brodsky, A. Cameron
The Johns Hopkins Hospital
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare cause
of hepatic venous outflow thrombosis, Budd-Chiari syndrome (BCS),
and subsequent liver failure. PNH is a uncommon, acquired hemolytic
anemia resulting from clonal expansion of hematopoietic stem cells
having undergone somatic mutations in the phosphatidylinositol glycancomplementation class A (PIG-A) gene. PIG-A is necessary for the synthesis
of glycosylphosphatidylinositol (GPI) that anchors a variety of proteins
to the cell surface including CD59, a key complement regulatory protein.
Affected red blood cells undergo complement-mediated lysis with resultant
anemia, hemoglobinuria and commonly venous thromboses. The rare reports
of outcomes in patients undergoing liver transplant for BCS secondary to
PNH detail instances of recurrent BCS as well as early portal vein occlusion
and hepatic artery thrombosis requiring retransplantation. Therefore, most
regard PNH as a contraindication to liver transplantation. Here we present
the first case report of a patient with BCS resulting from PNH treated with
Eculizumab, a humanized monoclonal antibody that blocks the activation of
terminal complement at C5, and subsequently undergoing successful liver
transplantation.
Case Report: In 1992, a healthy 17 year old male patient was diagnosed with
PNH having developed severe hemoglobinuria associated with flank pain,
nausea with emesis, and significant anemia and thrombocytopenia. Over the
next twelve years his disease remained relatively stable with only occasional
bouts of PNH crisis. In 2004, he developed persistent right upper quadrant
pain and weight loss and imaging revealed splenic vein thrombosis, marked
splenomegaly and gastric varices, and portal vein occlusion with cavernous
transformation. Despite therapeutic anticoagulation with Warfarin (INR 2-3),
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in 2006 he developed BCS with hepatomegaly, caudate hypertrophy, and
worsening ascites. With progressive liver failure his renal function deteriorated
to the point that he required dialysis. When evaluated for liver transplant, his
candidacy was predicated on his ability to receive Eculizumab under FDA
compassionate use and a favorable response to treatment. In December 2006,
he began weekly infusions of Eculizumab. He showed reduction in hemolysis
as measured by lactate dehydrogenase (LDH) levels and had decreased
transfusion requirements. After the first month of treatment, doses were given
twice monthly. On February 7, 2007, a high quality organ became available
from a 55-year-old brain dead donor and our recipient underwent a classic
orthotopic liver transplant. Given his portal vein thrombosis, an SMV jump
graft with donor iliac vein was required. His post-operative hospital course
was unremarkable and he was discharged on POD#9. He has continued
maintenance Eculizumab therapy and, more than a year since transplant, has
stable graft function, no radiographic evidence of thrombotic recurrence, has
had no hospital readmissions, and has returned to work as an accountant.
Conclusion: Outcomes for liver transplant for BCS caused by PNH historically
have been dismal due to recurrent thrombotic complications. With use of
the anti-complement antibody Eculizumab, such thrombotic pitfalls have
been avoided and the first successful liver transplant without subsequent
complications in the setting of PNH has been possible.
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2055 LIVER TRANSPLANTATION IN PATIENTS WITH LIFE
SUPPORT: SIGNIFICANT PROGNOSTIC IMPROVEMENT
ACHIEVED IN THE PAST DECADE
E. Akpinar, E. Palaois, J. Montes de Oca, T. Kato, S. Nishida, D. Levi,
J. Moon, G. Selvaggi, E. Island, A. Tzakis
Miami Transplant Institute, Liver-GI Transplantation, Miami-FL, USA
Background: Liver transplantation (LT) in patients who need life support in
intensive care (ICU) was reported to have worse outcome compared to the rest
of patients. Here we review two decades of liver transplant experience in ICU
patients from one institution.
Material and Methods: A retrospective analysis was performed on patients
who received LT in our institution between 1994 and 2007. Pts were divided
into two groups: pts who were transplanted in the period of 1994-2000
(OLD) and pts who were transplanted in the period of 2001-2007 (NEW).
Demographics, primary diagnoses, laboratory tests, posttransplant hospital stay
(LOS), and survival data were analyzed and compared between two groups.
Non-parametric methods were used for statistical comparisons, Kaplan-Meier
method was used for survival analysis and p<0.05 was considered significant.
Results: A total of 2219 adult and pediatric LT were performed between 1994
and 2007 in our institution.
Adult/Pediatric
LOS median (min-max)
Req RELT (<1mo)
MORT (1 mo)

1994-2000
N= 127
101/26 (20%)
28 (0-221)
14 (11%)
17 (17%)

2001-2007
N=73
44/29 (40%)
19 (1-367)
7 (10%)
7 (10%)

P
<0.05
NS
NS
<0.05

Among them 336 patients were transplanted while they were under care in
ICU. After exclusion of retransplant (RELT) patients (n=113), a total of 200
primary LT patients were included into this evaluation. The NEW group
consisted of 40% pediatric population which was significantly higher than
the OLD group (see Table). Overall comparison of survival between groups
showed a significant difference favoring the NEW group for pediatric and adult
patients respectively. Univariate survival analysis of the NEW group showed
that patients with pretransplant level of prealbumin>10 mg or pO2>60 mmHg
or HCO3>15 had significantly better survival.

Conclusion: Prognosis after liver transplantation in patients who are on life
support has had significantly improved. Better nutritional and respiratory status
before transplantation correlates with better posttransplant survival.
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2056 CORRELATION BETWEEN SELECTED PROGNOSTIC
FACTORS AND A POSTOPERATIVE COURSE IN LIVER
TRANSPLANT RECIPIENTS
W. Patkowski1, M. Krawczyk2, K. Zieniewicz3
1
Medical University of Warsaw, 2Medical University of Warsaw, 3Medical
University of Warsaw
The objective was to identify the major prognostic factors influencing the liver
function after the transplantation and predicting postoperative course and longterm survival in liver transplant recipients. These factors were analyzed on the
basis of the clinical trials, results of biochemical, microbiological, serological,
pathological studies of the donor and recipient, as well as intraoperative data.
215 of 542 liver transplant recipients (39.7%) were analyzed in the period 1989
– 2006. Patients with irreversible liver failure caused by hepatotropic viruses B
and C infection were prevailing. They were divided into 3 groups:
Group I – cirrhosis caused by HCV infection (RNA virus), 80 patients (37.0%)
Group II – cirrhosis caused by HBV infection (DNA virus), 33 patients (15.0%)
Group III – cirrhosis caused by HBV and HCV infection, 13 patients (6.0%).
Another group consisted of the patients with chronic liver failure caused by
alcoholic liver disease:
Group IV – alcoholic cirrhosis, 66 patients (31.0%).
Group V – autoimmunological hepatitis and cirrhosis, 23 patients (11.0%).
Analyzed factors affecting the long-term results after liver transplantation was
comprised intraoperative details (type of implantation, cold and warm ischemia
time, total operation time, post-reperfusion syndrome, bile ducts drainage), as
well as with the data regarding the quality of transplanted liver (degree of liver
steatosis, anatomic variations).
It was proved that patient survival prediction based on clinical parameters had
a better prognostic value than prediction based only on the liver function tests.
It was also concluded application of the transplant urgency scores MELD, delta
MELD and UNOS enables to predict early and long-term patients survival
after liver transplantation. Update of these scores, adequately to the patient
condition, enables to evaluate effectively pretransplantation life-threatening
factors and urgency level.
In case of the organ donor the highest value of predictive factors are: age,
viral status and degree of liver steatosis. Liver transplant technique, piggy-back
or classical has a major prognostic value. Complications are more frequent
for classical technique. Additionally it was proved that the occurrence of
complications during liver transplantation has a disadvantageous prognostic
effect on patient’s fate.
It was confirmed that cold/warm ischemia time has been a major prognostic
factor, and occurrence of postoperative complications, surgical or medical –
had a negative effect on the prognosis. Routine biliary drainage resulted in
worse long-term survival when compare to non-drained patients.
Liver transplantation for alcoholic cirrhosis was affected with the highest
complications ratio. Chronic liver rejection occurred more frequently in the
patients transplanted for autoimmunological cirrhosis when compare to the
other groups of indications.
The most useful predictive factors of 1-year survival are liver function tests
(AST, ALT, GGTP, INR, Quick) and urea/creatinine.
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2057 CORRELATION BETWEEN INTRAOPERATIVE
RBC, FFP, PLATELET AND RECOMBINANT ACTIVATED
FACTOR VII TRANSFUSION AND SURVIVAL AFTER LIVER
TRANSPLANTATION
W. Patkowski, K. Zieniewicz, P. Nyckowski, M. Krawczyk
Medical University of Warsaw
Aim: We analyzed the influence of intraoperative transfusion blood agents and
factor VII (NovoSeven) on the postoperative survival and complication after
OLTx.
Method: In the period 1989 ¨C 2006, 542 patients underwent OLTx. Among
them 215 liver transplant recipients were retrospectively analyzed. 80 pts (37.0%)
were transplanted for HCV liver cirrhosis, 33 pts (15.0%) for HBV cirrhosis, 13
pts for HBV+HCV cirrhosis (6.0%), 66 pts (31.0%) for ALD and 23 pts (11.0%)
for AIH. Surgical blood loss and number of packed blood agents and dose of
NovoSeven given were collected. Multivariable regression analysis was used.
Results: 70 pts received at least 10 units of red blood cells (RBC) and it was
worse prognostic factor. An overall 1-,3- and 5-year survival in this group was
76.6%, 67.5% and 67.5% respectively. Patients who received <10 units of RBC
showed a trend to higher rate of posttransplant survival ¨C 1 year 92.2%, 3
year 87.6% and 5 year 83.2% (p=0.001). 48 pts needed more than 15 units
of fresh frozen plasma (FFP). We observed 1-, 3- and 5 year survival rates
72.2%, 64.4% and 64.4% in that group of patients compared to 90.9%, 86.0%
and 82.9% respectively when patients required < 15 units of FFP (p=0.0015).
NovoSeven transfusion during transplantation was associated with higher
mortality. 8 pts received intraoperatively activated factor VII and 6 pts of them
died 1 week after OLTx. 27 pts were given more than 8 units of platelets. No
significance occurred between patients who required more and less units of
platelets for long-term survival. They reached 1-,3-, and 5 year survival 88.1%
vs 77.8%, 82.5% vs 77.8% and 79.2% vs 77.8% (for > 8 units of platelets and
¡Ü 8 units, respectively).
Conclusion: Transfusion requirements during liver transplantation are
multifactorial with intraoperative circumstances contributing significantly. Poor
outcome were associated with RBC, FFP and activated factor VII transfusion.
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2059 DE NOVO HEPATOCELLULAR CARCINOMA IN A LIVER
ALLOGRAFT ASSOCIATED WITH ISCHEMIC TYPE BILIARY
LESIONS
M. Heise1, G. Otto1, C. Dueber2, M. Schuchmann3
1
Department of Transplantation and Hepatobiliopancreatic Surgery,
2
Department of Radiology, 3Department of Internal Medicine I
Recurrent hepatocellular carcinoma (HCC) is well described following
liver transplantation. However, de novo HCC in the allograft liver is rare.
Ischemic type biliary lesions (ITBL) are a severe complication following liver
transplantation and a source of morbidity and even mortality. De novo HCC
arising in a cirrhotic allograft due to ITBL has not been described previously.
This report is intended to summarize the clinical features of a case of de novo
HCC arising in an allograft liver 17 years after the first transplantation.
Clinical History: A 23-old female received an orthotopic liver transplantation
in 1989 for acute hepatic failure of unknown origin. The postoperative course
was complicated by an anastomotic leakage of the bile duct. A revision and
neo-anastomosis was performed two weeks after transplantation. The further
postoperative course was uneventful.
In 1993, approximately 4 years after transplantation, multiple dilatations and
nonanastomic strictures of bile ducts occurred due to ITBL (Fig.1).
Fig.1 Percutaneous transhepatic cholangiogram (PTD) shows multiple
strictures and dilatations of intrahepatic ducts.
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2058 PROGNOSIS AFTER LIVER TRANSPLANTATION
PREDICTED BY PREOPERATIVE MELD, Ä MELD AND UNOS
SCORE

THURSDAY

W. Patkowski, K. Zieniewicz, M. Urban, M. Krawczyk
Medical University of Warsaw
Aim: To determine patients survivals and outcomes according to prognostic
scores and alterations of the MELD, ¦¤ MELD and UNOS during waiting
time.
Method: 215 liver transplant recipients were retrospectively analyzed. Among
them 80 pts (37.0%) for HCV liver cirrhosis, 33 pts (15.0%) for HBV cirrhosis,
13 pts for HBV+HCV cirrhosis (6.0%), 66 pts (31.0%) for ALD and 23 pts
(11.0%) for AIH. The MELD score at time on listing and of transplantation and
UNOS as well were gathered. Additionally the delta-MELD was calculated.
Results: Mean MELD score was 23(range 6-40), mean delta-MELD was 2.5
(range 0 -7). 2.3% of patients were transplanted with UNOS status 1, 15.3% of
patients with UNOS 2a, 48.9% of patients with UNOS 2b and 33.0% of all group
with UNOS status 3. Patients with MELD < 20 had an overall 1-, 3-, 5-year
survival rates 100.0%, 98.1% and 98.1% compared to 79.1%, 72.9% and 69.8%
for MELD ¡Ý 20 (p<0.0001). We observed than patients with delta-MELD <
3 had an overall survival rates higher than patients with delta-MELD ¡Ý 3 and
it was 91.5% vs 69.6%, 85.6% vs 67.1% and 83.3% vs 67.1% (1-,3-,5-year
respectively) (p<0.0001). According to patient¡¯s UNOS criteria we found
1-,3-,5-year survival rates for UNS 1 20.0%, 20.0% and 20.0%, for UNOS 2a
61.5%, 54.4%, 54.4%, for UNOS 2b 85.6%, 79.3%, 76.1% and for UNOS 3
100.0%, 95.4% and 95.4% respectively (p=0.0013). Only one patient died for
acute pancreatitis 21 months after OLTx from all patients reached MELD< 20.
Conclusion: We suggest that preoperative MELD, delta-MELD and UNOS
score can be a good predictor of short-term prognosis after OLTx. Patients
with a substantial increase of these prognostic scores during waiting time had a
poorer 1 year posttransplant survival.
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In 1994, she delivered a healthy son after an uneventful pregnancy. One year
after the delivery portal vein thrombosis and splenomegaly were diagnosed.
In December 1996, a liver biopsy demonstrated the histological features
of a fibrotic liver parenchyma. At the same time, balloon dilatation of the
biliary strictures was performed. Since October 1999, the patient was treated
by percutaneous transhepatic drainage (PTD) for recurrent cholangitis
and obstruction of intrahepatic bile ducts. In February 2000, a liver biopsy
demonstrated histological appearance of liver cirrhosis due to ITBL. Between
October 1999 and November 2003, PTD was replaced routinely every 6 to
8 weeks or in the case of cholangitis. In April 2001, the patient experienced
hepatic decompensation after hernioplasty of an incisional hernia. After
recompensation, the course was characterized by the moderately impaired
liver function but largely stable until March 2006. At that time, CT-scan
revealed a nodule of 2.8 cm in diameter in the transitional zone of segments 4
and 8 suspicious for HCC (Fig.2).
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Fig.2 Contrast enhanced CT scan shows hyperdense lesion in transition zone
of segment 4 and 8 (arrow).
The AFP was 25 ng/ml (upper limit of normal 10 ng /ml). HCC was confirmed
by biopsy and histological examination. As the Milan criteria were fulfilled,
the patient was listed for retransplantation. During waiting time, transarterial
chemoembolization (TACE) was performed every 6 weeks. Between May and
November 2006, the patient received a total of 5 TACE cylces, and neither
local tumor progress nor tumor dissemination was observed (Fig.3).

Fig.3 CT scan immediately after fifth transarterial chemoembolization shows
uptake in the tumour (arrow).
In November 2006, the patient was retransplanted 17 years following the previous
transplantation. Examination of the explant disclosed a singular HCC of 2 cm
in diameter in the aforementioned location graded as G1. The AFP was 9ng/ml
at the time of retransplantation. The postoperative course was uncomplicated.
An episode of acute rejection (RAI 6) 8 days after retransplantation was
successfully treated with intravenous steroid bolus therapy. The patient was
discharged from the hospital 3 weeks after retransplantation.
Discussion: The increased risk of cancer in organ transplant recipients is
well recognized. De novo malignancies after liver transplantation have been
reported comprising particularly skin cancer, lymphoproliferative disease
(PTLD), colon cancer, cervical cancer and vulvar/perineal cancer (1, 2).
In the liver allograft de novo HCC is rare with most cases arising in liver
transplantation for chronic hepatitis C and B (3-5). Cirrhosis is a major risk of
de novo HCC and occurs in approximately 10% of allografts, usually because
of recurrent viral hepatitis.
ITBL are nonanastomic strictures in the absence of hepatic artery thrombosis.
So far, the exact pathogenesis remains unclear. The incidence of ITBL ranges
from 1.4% to 26% after liver transplantation (6-8). According to the bile duct
involvement, ITBL may be classified as type I (extrahepatic lesions), type
II (intrahepatic lesions) and type III (extra- and intrahepatic lesions) (9).
Several risk factors have been identified, including prolonged cold ischemia
time (7, 10-14), delayed rearterialization of the allograft (12), ischemiareperfusion injury (15) insufficient perfusion of biliary arterial vessels (16-18),
immunological factors (10-11, 19), chronic ductopenic rejection (11, 20-21),
ABO incompatibility (11), polymorphism in genes coding for chemokines (19)
and pre-existing immunologically mediated diseases such as primary sclerosing
cholangitis and autoimmunehepatitis (22-25) These risk factors may affect the
biliary epithelium or damage the microvascularisation of the biliary tree and
finally lead to secondary cirrhosis.
De novo HCC arising in liver cirrhosis due to ITBL has not been described
previously. The unusual case of a de novo HCC in a patient with no previous
history of specific malignancy or liver disease leading to liver cirrhosis
emphasizes the risk of malignant degeneration in liver allografts with long
standing ITBL.
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2060 DEPRESSIVE SYMPTOMS, IMMUNITY, AND SURVIVAL
IN HEPATOBILIARY CARCINOMA
J. Steel1, D. Geller, T.C. Gamblin, M. Olek, B. Carr
1
University of Pittsburgh School of Mediicne, 2University of Pittsburgh School
of Mediicne, 3University of Pittsburgh School of Mediicne, 4University of
Pittsburgh School of Mediicne, 5University of Pittsburgh School of Mediicne
Purpose: The aims of the present study were to: (1) at diagnosis assess the prevalence
of depressive symptoms; (2) test the association between depressive symptoms and
survival; and (3) test preliminarily a mediational model of depression, immunity,
and survival in people with hepatobiliary carcinoma (HBC).
Patients and Methods: One hundred and one patients diagnosed with HBC
were prospectively studied. Depressive symptoms were measured at diagnosis
using the Center for Epidemiological Studies-Depression (CES-D) scale.
Sociodemographic and disease-specific data was gathered from the patients’
chart. In a subsample of patients, stress; alcohol, tobacco, and drug use; sleep
quality; physical activity; social support; natural killer (NK) cell number and
cytotoxicity; and plasma levels of IL4, IL5, TNF-alpha, and IFN-gamma were
measured. Survival was measured from date of diagnosis to death.
Results: At diagnosis, 37% of patients reported a CES-D score >16 (clinical
range). Using Cox Regression analysis, sociodemographic and disease-specific
variables and CES-D score significantly predicted survival [Breslow ChiSquare=32.4, p=0.006]. Only vascular invasion (p=0.001) and CES-D>16
(p=0.03) were significant predictors. In a subsample of 23 patients, those who
reported a CES-D>16 were found to have significantly lower NK cell numbers
than those who reported a CES-D score<16 [F(1,21)=9.39, p=0.003]. A robust
trend was found in which NK cell number was associated with survival. A
mediational model linking depressive symptoms and survival, with NK cell
number as a mediator, was preliminarily supported.
Conclusion: Secondary to the high prevalence of depressive symptoms, and
impact on survival, psychological and pharmacological interventions should be
designed and implemented in patients diagnosed with hepatobiliary carcinoma.
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2061 COMPARASION OF LONG-TERM RATES OF
HEPATOCELLULAR CARCINOMA RECURRENCE AND
SURVIVAL BETWEEN PATIENTS UNDERWENT PARTIAL
HEPATECTOMY AND LIVER TRANSPLANTATION
C-M. Ho, M-C. Ho, Y-M. Wu, R-H. Hu, P-H. Lee
National Taiwan University Hospital
Background: Recurrence of hepatocellular carcinoma (HCC) is the major
problem after curative resection. Whether partial hepatectomy alone or total
hepatectomy and liver transplantation is/are the preferred management procedure
for HCC in the concern of long-term recurrence and survival is unknown.
Materials and Methods: Patients with HCC underwent liver resections
during 2000-2002 and those received liver transplantation in National Taiwan
University Hospital were enrolled. Patients were excluded with previous liver
surgeries for HCC. Demographic data (age and sex) and clinical parameters
(HBV and HCV status, cirrhosis confirmed pathologically, and pathological
tumor staging according to AJCC version 2006) were collected for adjustment
in Cox regression analysis of recurrence and survival. Kaplan-Meier curves for
long-term survival and recurrence were plotted, compared with log-rank test,
between those received partial hepatectomy and those liver transplantation.
P<0.05 was considered significant.
Results: A total of 217 patients (169 males and 48 females) received
liver resections and 40 patients (28 males and 12 females) received liver
transplantations were included. With adjusting the parameters of age, sex, virus
status, cirrhosis and tumor staging, patients underwent liver transplantations
had lower recurrence (odds ratio: 0.39, p=0.03) and longer tendency of survival
(odds ratio: 1.9, p=0.09) than those receive partial hepatectomy only. The 3and 5-year recurrent rates for patients received liver resection and those liver
transplantation were 54 vs. 38% and 65 vs. 38%, respectively (p=0.04). The
3-, 5-, and 7-year survival rates were 72 vs. 79%, 59 vs. 72%, and 55 vs. 72%,
respectively (p=0.44).
Conclusion: For patients with HCC, liver transplantation had lower rates of
recurrence than partial hepatectomy and a tendency of longer survival.
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2062 LIVER TRANSPLANTATION FOR CHILDHOOD
HEPATIC TUMOR
M. Haberal1, S. Sevmis1, H. Karakayali1, G. Moray1, F. Ozcay2,
F. Sarialioglu2, B. Demirhan3, A. Torgay4, G. Arslan4
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Pediatry, 3Baskent
University Faculty of Medicine, Department of Pathology, 4Baskent
University Faculty of Medicine, Department of Anesthesiology
Liver transplantation (LT) is the only treatment option for unresectable liver
tumors. In this study, we present our experience with LT in the treatment of
13 children with unresectable liver tumor. Between January 2001 and October
January 2008, we performed 104 LTs in 101 children at our center. Thirteen
of these 101 children (12.8%; mean age, 8.2 &#61617; 6.2 years; age range,
6 months to 16 years; male-to-female ratio, 8:5) underwent an living-donor
liver transplantation because of liver tumor. Ten children had hepatocellular
carcinoma, 2 had hepatoblastoma, and 1 had neuroblastoma causing consumption
coagulopathy. Liver tumor was diagnosed before transplantation in 10 children
(76%), and in 3 children (24%), we identified an incidental tumor. One child
had combined hepatic arterial chemoembolization and systemic chemotherapy,
and 4 had systemic chemotherapy before LT. Two children received a right lobe
graft, 6 received a left lateral segment graft, and the remaining 5 received a left
lobe graft. The pathological findings demonstrated a mean tumor size of 3.3 ±
2.5 cm (range, 0.5 to 8 cm). The number of tumors was < 5 in 8 children, and
> 10 in remaining 5 children. The largest tumor size was 8 cm. Three children
had microvascular invasion. One child who had neuroblastoma causing
consumption coagulopathy received systemic chemotherapy after LT. The
mean follow-up was 25.9 &#61617; 12.9 months (range, 3-42 months). There
has been only 1 tumor recurrence, which occurred in the omentum 26 months
after LT. One child with hepatoblastoma experienced lymphoproliferative
disease 22 months after his LT, and he died 2 months later due to chemotherapy
related sepsis. At the time of this writing, remaining 12 (93%) children are
alive with good graft functioning. In conclusion, LT remains a viable option
for pediatric patients with unresectable hepatic tumor and provides long patient
and disease-free survival.
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2063 POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE
IN PEDIATRIC LIVER TRANSPLANT

THURSDAY

H. Karakayali1, S. Sevmis1, F. Ozcay2, B. Demirhan3, F. Sarialioglu2,
F. Karakayali1, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Pediatry, 3Baskent
University Faculty of Medicine, Department of Pathology
Posttransplant lymphoproliferative disease (PTLD) is a well-recognized
complication of solid organ transplant and therapeutic immunosuppression,
first reported in 1968. PTLD encompasses a spectrum of abnormalities
ranging from a benign infectious mononucleosis like illness to non-Hodgkin’s
lymphoma with nodal and extranodal site involvement. Between September
2001 and January 2008, 104 liver transplants were performed in 101 children
at our center. Five recipients (4.9%) developed PTLD. This retrospective study
examines the incidence of PTLD, reasons for the original transplants, presenting
symptoms, radiologic findings, immunosuppression regimens, and outcomes in
these 5 recipients. The average age of these recipients at the time of transplant
was 3.9 years (range, 6 months to 10 years), with a female-to-male ratio of
3:2. The indications for transplant were hepatoblastoma in 1 recipient and
cholestatic liver disease in remaining 4. PTLD was diagnosed 5, 12, 17, 22, and
27 months after liver transplant imaging abnormalities identified generalized
lymphadenopathy in 1 recipient, multiple liver masses in 1, a large portal mass
in 1, multiple ulcer in stomach in 1, and a large mediastinal mass in 1. At
the time of diagnosis, 1 recipient with a large mediastinal mass had a cough;
the remaining 4 recipients were asymptomatic. Histologic findings showed
B-cell lymphoma in 3 recipients and T-cell lymphoma in 2. The result of in
situ hybridization for Epstein-Barr virus was negative in 1 recipient, and it was
positive in 4. Four recipients were treated with chemotherapy; the remaining
recipient was treated with anti-CD20 monoclonal antibodies (Rituximab). One
recipient who had a large mediastinal mass died 2 months after diagnosis due
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to chemotherapy-related sepsis; the remaining 4 children are alive 4, 5, 18,
and 19 months after treatment. In conclusion, our rate of PTLD is similar to
those published in the literature. From a few months to several years after liver
transplant, radiologists must be alert to the possibility of PTLD, and thorough
imaging is required to detect the wide variety of potential presentations.
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2064 LIVER TRANSPLANTATION FOR EXPANDED
HEPATOCELLULAR CARCINOMA
H. Karakayali1, G. Moray1, S. Sevmis1, N. Savas2, U. Yilmaz2, F. Ozcay3, A.
Torgay4, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Gastroenterology,
3
Baskent University Faculty of Medicine, Department of Pediatry,
4
Baskent University Faculty of Medicine, Department of Anesthesiology
Various criteria for liver transplantation have been reported for patients with
hepatocellular carcinoma (HCC). Although the Milan criteria are often used
to determine which patients will benefit from liver transplantation, many
centers have their own criteria for patient selection. In this study, we aimed
to evaluate the results of liver transplantation in patients with HCC beyond
the Milan criteria. Between January 2004 and January 2008, 35 patients with
preoperatively diagnosed or incidental HCC underwent liver transplantation
at our center. In 20 of these 35 patients, the tumors were beyond the Milan
criteria. We analyzed these 20 patients retrospectively. Sixteen were males and
4 were females (mean age, 41.6 ± 20.5 years [range, 12-64 years]. Seven of the
20 grafts were from cadaveric donors, and 13 were from living-related donors.
Five patients had neoadjuvant chemoembolization, 2 had percutaneous ethanol
injections, and 3 had combined chemoembolization and percutaneous ethanol
injections before transplantation. None of our patients received adjuvant
chemotherapy. According to the Tumor size-lymph Nodes-Metastases staging
system, 2 patients had stage III, and the remaining 18 patients had stage IVA1
carcinoma. The number of tumors was < 5 in 2 patient, 5 to 10 in 9 patients, and
> 10 in 9 patients. The largest tumor size was 11 cm. At the time of this writing
and with a mean follow-up period of 25.1 &#61617;15.9 months (range, 2-49
months), 17 patients are well and exhibit excellent graft function. Remaning 3
patients died 7, 15, and 23 months after transplantation because of recurrence
of HCC, HCC, and sepsis, respectively. The longest graft survival in the study
subjects is 49 months. There have been 5 tumor recurrences, which occurred
3, 4, 24, 26, and 29 months after liver transplantation, respectively. Three of
theses 5 patients are still alive with good functioning grafts. In conclusion, liver
transplantation provides long patient and disease-free survival, even in patients
with HCC that exceeds the Milan criteria.
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2065 INCIDENTAL HEPATOCELLULAR CARCINOMA AFTER
LIVER TRANSPLANT
G. Moray1, S. Sevmis1, N. Savas2, H. Karakayali1, F. Ozcay3, A. Torgay4,
G. Arslan4, M. Haberal1
1
Baskent University Faculty of Medicine, Department of General Surgery,
2
Baskent University Faculty of Medicine, Department of Gastroenterology,
3
Baskent University Faculty of Medicine, Department of Pediatry, 4Baskent
University Faculty of Medicine, Department of Anesthesiology
The incidence of detecting hepatocellular carcinoma (HCC) in a removed
recipient liver after a liver transplant is not rare. The aim of this study was to
evaluate incidental HCC at our center. We retrospectively analyzed 5 patients
with incidental HCC among 35 patients whom were operated with HCC on
between January 2004 and January 2008. The proportion of incidental HCC was
14.2%. There were 3 children and 2 adult patients (mean age, 22.6 ± 24.5 years;
range, 1-49 years). Two of these patients were 1 year old. The alpha-fetoprotein
level was normal in all patients. Preoperative imaging studies demonstrated
regenerative or dysplastic nodules or no specific lesion in all patients. One of
the grafts was from a deceased donor, and 4 were from living-related donors.
We encountered no complications after transplants. The pathological findings
showed a mean tumor size of 0.94 ± 0.2 cm (range, 0.5-1.2 cm) and multiplicity
in 1 patient (20%). One patient with multiple tumors had microvascular
invasion. According to the TNM staging system, 4 patients had stage-I, and
the remaining 1 patient had stage-II, carcinoma. There were no recurrences of
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HCC, and no mortality occurred during the follow-up (mean, 35 ± 8.5 months;
range 26-45 months). In conclusion, the incidence of HCC in cirrhotic patients
who underwent liver transplant is similar to that of other studies in literature.
The incidentally found HCC showed less invasive pathological features and a
better prognosis than preoperatively detected HCC.
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2066 THE UCSF CRITERIA ACCORDING TO THE
PRE-TRANSPLANT RADIOLOGIC STUDY CAN NOT
ASSURE SIMILAR POST-TRANSPLANT RESULTS OF
HEPATOCELLULAR CARCINOMA PATIENT WITHIN MILAN
CRITERIA
M.K. Ju1,3, M.S. Kim1,3, J. Choi1, G.H. Choi1, D.J. Joo1, S.J. Kim1,
D.Y. Kim2, S.I. Kim1,3, Y.S. Kim1,3
1
Yonsei University College of Medicine Department of Surgery, 2Yonsei
University College of Medicine Department of Internal medicine, 3Yonsei
University College of Medicine The Research Institute for Transplantation
The recurrence of hepatocellular carcinoma (HCC) after transplantation is
main limitation of liver transplantation. Therefore the several selection criteria
for liver transplantation in HCC patients are established. The objective of this
study was to verify the clinical validity of selection criteria by pretransplant
radiologic imaging study.
September 2005 to May 2007, 69 recipients (49 whole liver transplant and
20 partial liver transplant) were enrolled this study. We analyzed the posttransplant survival and recurrence rate by radiologic selection criteria and other
clinical factors. Grouping by pre-transplant criteria for liver transplantation, 16
recipients (23.2%) were above Milan criteria and 7 recipients (10.1%) were
above the UCSF (University of California, San Francisco) criteria. According
to combined categories, nine recipients (13.0%) were grouped as above Milan/
below UCSF group.
The recipients who met Milan criteria (below Milan) and UCSF criteria (below
UCSF) showed 85.8% and 82.7% of 1-year survival rate respectively, which
was comparable to that of non-HCC (91.6%) without significance (p=0.767
in below Milan, p=0.2604 in below UCSF). During post-transplant followup period (1-52 months, 14.8 ± 12.0 months), 16 recurrences (23.2%) were
diagnosed. There was a significant difference in the 1-year recurrence-free
survival rate according to the selection criteria, recipients who satisfied the
Milan criteria was 78.6% and of those that did not meet these criteria was
22.7% (p<0.0001), with regard to the UCSF criteria, 72.0% and 14.2%,
respectively (p<0.0001). According to combined grouping, 1-year recurrencefree survival rate was 25.4% in above Milan/below UCSF group. There was
significant difference among each groups (overall p<0.0001)(Figure) which
was confirmed in multivariate survival analysis.
The application of the UCSF criteria by pre-transplant radiologic findings as
patient selection criteria for liver transplantation is limited.
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2067 PRE-LIVER TRANSPLANT TRANSARTERIAL
CHEMOEMBOLIZATION FOR HEPATOCELLULAR
CARCINOMA BEYOND MILAN CRITERIA
P. De Simone1, C. Vignali2, P. Carrai1, I. Bargellini2, S. Petruccelli1,
G. Catalano1, L. Coletti1, D. Campani3, C. Bartolozzi2, F. Filipponi1
1
Liver Transplant Unit, 2Radiology, 3Pathology
Background: The role of transarterial chemoembolization (TACE) for
downsizing/downstaging of hepatocellular carcinoma (HCC) before liver
transplantation (LT) has expanded on the assumption that TACE may allow
for reduced dropout from waitlist and longer disease-free survival rates. We
report here our experience with pre-transplant TACE in patients undergoing
LT for HCC.
Materials and methods: single-center experience, prospective data collection,
retrospective analysis of patients with histology-proven HCC beyond Milan
criteria. Tumor necrosis on explants histology was reviewed by two blinded
pathologists and graded as nil, minimal (≤25%), partial (≤50%), subtotal
(≤75%), and total (75-100%).
Results: Forty-one consecutive patients transplanted between December
1997 and August 2006 with histology proven HCC beyond Milan criteria
were included (M:F= 39:2; mean age 55±6.4 years). All patients underwent
pre-transplant TACE (mean procedures 1.2±0.5). On explant histology, mean
number of tumor nodules was 3.3±1.5, and mean total tumor diameter was
7.3±2.7 cm. Complete tumor necrosis was present in 26.8% patients (11/41);
subtotal in 34.1% (14/41); partial in 31.7% (15/41); and nil in 2.4% (1/41). At
a mean follow-up of 48±33 months, 70.7% patients (29/41) patients are alive,
7% (2/29) of them with HCC recurrence. After censoring for deaths unrelated
to HCC, actuarial patient survival was 94.5% at 6 months; 94.5% at 1 year;
88.7% at 2 years; 85.1% at 3 years; 81.2% at 4 and 5 years.
Conclusions: Use of pre-transplant TACE allows to improve results of LT for
HCC beyond Milan criteria in the presence of necrosis of the tumor mass. No
negative impact on the risk of recurrence for partial vs. subtotal/total necrosis
was observed in the current experience.
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2068 THE SILVER STUDY: AN INVESTIGATOR-INITIATED
TRIAL TO DETERMINE IF SIROLIMUS USE CAN IMPROVE
HCC RECURRENCE-FREE SURVIVAL IN AFFECTED LIVER
TRANSPLANT RECIPIENTS
E. Geissler, A. Schnitzbauer, C. Zuelke, P. Lamby, I. Mutzbauer, H. Schlitt
University of Regensburg, Department of Surgery, Representing the
International SilVER Study Workgroup
Background: Hepatocellular carcinoma (HCC) recurrence after liver
transplantation (LT) limits LT success as a treatment for this malignancy.
Since the mTOR pathway is critical for angiogenesis and tumor development,
it is an attractive target for cancer therapy. Considering mTOR inhibitor
immunosuppressive activities, and potential to inhibit malignancy, we initiated
a global, multi-center, clinical trial to evaluate sirolimus-based therapy in
patients following LT for HCC, regarding HCC recurrence-free patient
survival. The University of Regensburg is the study sponsor. Protocol: This
is an open-labeled, randomized, trial comparing sirolimus-containing vs.
mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC.
A 2-3 year enrollment period with a 5-year follow-up is planned. Patients with
histologically confirmed HCC are randomized into one of two groups after
LT. The first group is kept on a center-specific mTOR-inhibitor-free protocol.
This control group will be compared to a second group that is maintained
on a center-specific mTOR-inhibitor-free regime for the first 4-6 weeks, at
which time sirolimus is incorporated as a monotherapy, or in combination
with non-mTOR-based immunosuppression. Patients are stratified into
statistically-independent high or low risk HCC recurrence groups, based on
factors including Milan status and presence of cirrhosis. Status: As of February
2008, 287 patients (482 planned) have been enrolled. Forty-two centers from
13 countries are presently recruiting (11 in Europe + Canada and Australia).
The first Data Safety Monitoring Board meeting was held in August 2007 and
resulted in a recommendation to continue the study. We have a current drop-out
rate of <5%. Efforts are presently being made to include sites from the United
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States into the study. Current recruitment is averaging 15 patients per month
since the beginning of 2007, which is expected to increase with additional
sites being initiated. Outlook: The positive development of this study was
only possible with a scientifically motivated and energetic study group. Vital
lessons can be learned from the setup of this trial. This initiative demonstrates
that complex, investigator-driven, studies can be successfully organized on a
multi-continental basis. Scientifically, the trial is critical because it is the first
prospectively randomized study to determine if mTOR inhibitors can improve
HCC recurrence-free survival in affected LT patients.

recurrence-free survival rate of PET- patients was significantly higher than that
of PET+patients(89.2% vs. 61.7%)(P=0.0005). Of 18 PET+ patients who did
not meet the Milan criteria, 12 patients(66.7%) had recurrence, but 14 PETpatients who did not meet the Milan criteria, 5 patients(35%) had recurrence.
Conclusions: PET imging is useful for predicting the post-LT risk of tumor
recurrence, because vascular invasion and histological grade cannot be
determined preoperatively. The tumor recurrence could be highly anticipated
for PET+ HCC patients who do not meet Milan criteria. PET+ HCC patients
could be considered seriously for LT.
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2069 LIVER TRANSPLANTATION OR LIVER RESECTION AS
TREATMENT OF HEPATOCELLULAR CARCINOMA
K.K. Lee, D.G. Kim, S.K. Lee, I.S.M. Lee
The Catholic University of Korea
Introduction: Surgical treatment including liver resection and liver
transplantation remains mainstay of treatment offering a hope of cure in
hepatocellular carcinoma with cirrhosis. The authors tried to evaluate the
indication of surgical procedure for the treatment of hepatocellular carcinoma
by comparing the outcome of treatment between transplantation and liver
resection. Method: Our department performed surgical treatment in 248
patients with hepatocellular carcinoma including 129 patients in liver resection
and 119 patients in living donor liver transplantation from Oct. 1997 to Jul.
2007. We analyzed patients, tumor characteristics and survival and disease
free survival according to resection group and transplantation group. Result:
Most patients were Child A in resection group in contrast to Child B or C in
transplantation. Other factors were not significantly different between two
groups. The patients who underwent transplantation had significantly higher
survival and disease free survival rate than the patient with surgical resection in
all patients. According to Milan criteria, the patients who are the tumor within
Milan criteria had better survival and disease free survival rate in transplantation
group than surgical resection group. In contrast, in the tumor beyond Milan
criteria, there is no significant difference in survival and disease free survival
rate in both group. The tumor size and vessel invasion influenced on the disease
free survival rate in multivariate analysis. Conclusion: Liver transplantation
and resection are appropriate treatment modalities of hepatocellular carcinoma
and in tumor within Milan criteria, liver transplantation shows better result
than liver resection and in cases beyond Milan criteria, the transplantation and
resection show no significant difference and liver transplantation should be
carefully considered.
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2071 COMBINED HEPATOCELLULAR CARCINOMA
AND CHOLANGIOCELLULAR CARCINOMA IS
CONTRAINDICATION OF LIVER TRANSPLANTATION:
REPORT OF A CASE
Y.S. Han, D.L. Choi, M.S. Kim, E.J. Jang, J.Y. Park, M.K. Kim
Department of Hepatobiliary Surgery and Transplantation, Daegu Catholic
Medical
Combined Hepatocellular carcinoma and cholangiocarcinoma(cHCCCCC) is a rare subtype of primary liver cancer, and clinicopathological
features have seldom been reported in detail. We report a case with liver
transplantation for cHCC-CCC. 50-year old man received deceased donor
liver transplantation at June 2007 because of HCC and hepatitis B & C
related liver cirrhosis. At April 2006, HCC was diagnosed on computed
tomography(CT) and TACE was performed. On CT performed right before
transplantation, newly developed multiple hypervascular lesions were
detected. His serum value of alpha-fetoprotein(aFP) and CA19-9 were
was 65 ng/§¢ and 54 U/§¢. Transplantation was performed successfully.
Postoperatively, acute rejection was developed and steroid pulse therapy
was performed once. The biopsy result of explanted liver was surprisingly
cHCC-CCC of collision type. Three months after transplantation, regardless
of adjuvant chemotherapy with doxorubicin, multiple metastases were
detected on both lower lung field. The duration of survival was 10 months.
Our patient with cHCC-CCC was not diagnosed before operation. And the
progression of cHCC-CCC was more rapid than that of HCC and the patient
had a significantly worse survival outcomes. Accordingly, even though
HCC is strongly suspected on imaging studies, if an increased CA19-9
level, intrahepatic bile duct dilatation, or lower aFP level are detected,
further evaluations should be performed to rule out the cHCC-CCC before
liver transplantation.

POSTER BOARD NUMBER P4 – 122

2070 POSITIVE EMISSION TOMOGRAPHY WITH FLUORINE18-FLUORODEOXYGLUCOSE IS USEFUL FOR PREDICTING
THE PROGNOSIS OF LT PATIENTS WITH HEPATOCELLULAR
CARCINOMA

2072 OUTCOME OF LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA IN PATIENTS IN AND
OUTSIDE THE MILAN CRITERIA – A SINGLE CENTER
EXPERIENCE

J-H. Ryu, S-G. Lee, S. Hwang, K-H. Kim, C-S. Ahn, D-B. Moon, T-Y. Ha,
K-W. Song, K-W. Kim, N-G. Choi
Department of Surgery, Asan Medical Center
Backgrounds and aims: Positive Emission Tomography with Fluorine-18fluorodeoxyglucose(FDG-PET) has established itself as a useful diagnostic
imaging for metastatic liver tumors. However, in case of hepatocellular
carcinoma(HCC), several investigators have reported controversial results
and have an inadequate sensitivity of PET(50-55%). Nevertheless, a high
positive rate of FDG accumulation has been reported in patients with highgrade HCC. We retrospectively reviewed 110 HCC cases that received liver
transplantation(LT) at our center between Jan 2003 and December 2005 and
underwent whole-body PET imaging.
Methods: FDG uptake was accessed in the liver, and its prognostic factors was
investigated. Of 110 patients enrolled, 34 patients had positive PET scans for
liver tumor.
Results: When we analyzed the association between tumor factors and
PET+(greater PET lesion uptake)in the liver, vascular invasion, number of
tumors(>3nodules), and tumor size(>5cm) were found to be significantly
associated with PET+(P<0.001, P=0.004,and P<0.001, retrospectively).
However, the preoperative AFP level and histological grade was not
significantly associated with PET+(P=0.418 and P=0.064). The 2-year

M. Olausson, M. Sternby-Eilard, F. Badri, L. Backman, C. Cahlin, S. Friman,
L. Hafstrom, M. Rizell, P. Lindner
Department of Transplantation
Introduction: Orthotopic liver transplantation (OLT) is increasingly being
used in the treatment of patients with cirrhosis and concomitant hepatocellular
carcinoma (HCC). In recipients with limited tumor burden, OLT achieves
reasonable long-term outcome. Selection criteria for hepatocellular carcinoma
is still under debate, where expansion of Milanocriteria has been suggested,
an approach hampered by the lack of liver grafts. Prognosis seem to differ
between Asian and Western countries, and might differ between Northern and
Southern countries in Europe.
Aim: The aim of the present study was to determine survival in patients
transplanted with HCC, to define prognostic factors and compare the results in
patients transplanted inside and outside the Milan criteria (MC).
Material and methods: From 1996 to 2007, 76 patients underwent OLT for
cirrhosis and/or HCC. Malignancy was diagnosed in 63 patients prior to OLT
and in 13 patients on pathologic examination of the explant. 6 patients with
HCC were non-cirrhotic. The following clinical and pathologic variables were
considered: TNM stage, nodularity, vascular invasion, Milan criteria, incidental
lesion, tumor size. Based on preoperative imaging studies, 32 patients met the
MC and 30 did not.
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Results: Overall patient survival rate at 1, 3 and 5 years was 83, 61 and 49%
respectively. Recurrence-free survival (RFS) was 76, 53 and 41% at 1, 3, and
5 years respectively. The overall survival rate of patients inside the MC after
1, 3 and 5 years was 83, 64 and 48% compared to 80, 45 and 36% (0,478)
in patients outside the MC. In patients with incidental tumors, the 1, 3 and
5-year-survival was 92, 92 and 79%. Recurrence-free survival (RFS) inside the
MC after 1, 3 and 5 years was 83, 55 and 44% compared to 68, 35 and 20%
(p=0,157) outside the MC.
The preoperative staging differed from the pathologic examination concerning
the MC in 37 out of 76 patients. Nodule size seemed more important than
nodule number. Information about vascular invasion was often missing, but
was an important predictive factor. After 3.5 years there was no RFS in patients
with vascular invasion on pathology.
Our results suggest that MC is a predictive factor for survival, although in
this study the difference was not significant. The results questions if staging
or biology differ from other reports. MC is one supporting factor for selecting
transplantation candidates but cannot in our experience be used as the sole
determinating factor.
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2073 PREDICTORS OF SURVIVAL FOR HEPATOCELLULAR
CARCINOMA
N. Savas1, H. Gokcan1, R. Sezer1, F. Boyvat2, H. Selcuk1, U. Yilmaz1, H.
Karakayali3, M. Haberal3
1
Baskent University Faculty of Medicine, Department of Gastroenterology,
2
Baskent University Faculty of Medicine, Department of Radiology, 3Baskent
University Faculty of Medicine, Department of General Surgery
Introduction: Hepatocellular carcinoma (HCC) is the fifth most common
tumor worldwide, with an incidence equal to the death rate.
Aim: & Methods: Our aim was to detect the prognostic factors for patients
with hepatocellular carcinoma. We retrospectively analysed the 12 years
(1993-2008)data of 108 patients who have biopsy proven HCC diagnosis in our
institution. Clinical and demographic characteristics of patients with treatment
modalities, survival rates and prognostic factors all were searched. Results
Ninety-one (84.3%) of them were male, 17 (15.7%)of them were female.
Mean age of patients was 63.9Â±12.0 (20-94)years. Out of 108 patients 8
(7.4%) of them had HCC without cirrhosis, 8 (7.4%) had alcoholic cirrhosis,
7 (6.5%) had cryptogenic cirrhosis and 85 (78.7%) patients had cirrhosis
due to viral hepatitis. Median follow-up time was 12 months (l month-7
years) after the diagnosis of HCC. At the time of diagnosis 64 (59%) patients
had alfa-feto protein (AFP)> normal level (range: 0-15ng/mL) with a mean
AFP level of 391.2Â± 997.0 ng/mL. Ten (9.2%) patients had a history of
alcohol consumption and 31 (28.7%) patients had cigarette smoking history.
Serum HBVDNA level was positive in 20 of 64 (31.2%) patients with HBV
infection, and serum HCVRNA level was positive in 13 of 21 (62%) patients
with HCV infection at the time of diagnosis of HCC. Mean tumor size was
48Â±35 mm at the time of diagnosis of HCC. Twenty-eight (26%) patients
had been liver transplanted, 15 (14%) had HCC resection, 30 (28%) had
only radiological treatment (chemoembolization, radiofrequence ablation,
alcohol injection or both of them) 35 (32%) had not been treated. Tumor
size of half of the patients in transplanted group were exceeding the Milan
criteria. On follow up mean survival rates for first and third years were 96%
and
89% for transplantation, 90%, 52% for resection and 49%, 17% for paliative
treatments, respectively. There were only statistically significant differences
between the age of the patients (p=0.003), hepatic resection (p=0.04) and liver
transplantation (p=0.001) with disease free survival time.
Conclusion: The only factors that affect the survival for patients with
hepatocellular carcinoma are young age at the time of diagnosis of hepatocellular
carcinoma and the treatment modalities of liver transplantation and hepatic
resection.
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2074 BENEFIT OF NEEDLE BIOPSY BEFORE LIVER
TRANSPLANTATION
G.M. Otto1, F. Bittinger2, M. Hoppe-Lotichius1, M. Pitton3
Department of Transplantation Surgery, University, 2Institute of Pathology,
University, 3Department of Radiology, University
According to our treatment protocol patients with hepatocellular carcinoma
(HCC) are repeatedly treated by transarterial chemoembolization (TACE)
before liver transplantation (LT). Needle core biopsies (NCB) were performed
before including the patients into protocol. As grading is a prognostic factor
of tumor recurrence after LT and response to TACE may depend on grading,
NCB is compared to histology of the surgical specimen (HSS) in order to assess
its benefit.
Patients and methods: Grading in NCB was available in 65 of 82 patients before
TACE (median 5 cycles) followed by LT and in 15 of 52 patients without TACE
before LT. Grading of NCB was compared to HSS and both were correlated to
angioinvasion as assessed in HSS and to tumor progress during TACE.
Results: Results of grading in NCB and HSS are shown in table 1 and 2.
Table 1: Grading in patients with TACE before LT
Grading surgical specimen
1

NCB

good

mod.

poor

total

Good

7

9

3

19

Moderate

1

34

5

40

Poor

0

1

5

6

Total

8

44

13

65

Table 2: Grading in patients w/o TACE before LT
Grading surgical specimen
NCB

good

mod.

poor

total

Good

1

3

0

4

Moderate

0

8

0

8

Poor

0

1

2

3

Total

1

12

2

15

In patients with TACE before LT, concordance of grading in NCB compared
to HSS was 71%, in patients w/o TACE this figure was 73%. Pooling good
and moderate grading to one group, sensitivity and specificity to detect poorly
diffentiated tumors are 39 and 98% in patients with TACE and 100 and 92% in
patients w/o TACE, respectively. NCB was capable of identifying angioinvasion
(P = 0.023) in patients with TACE, but not in patiens w/o TACE (P = 0.519).
Both grading in NCB and HSS were incapable of predicting patients with
tumor progress during TACE (P = 0.830, and 0.278, respectively).
Conclusions: In contrast to other studies, NCB proved useful in predicting
definitive grading. The rate of concordance reaches 70%. According to
comparable figures (tables), there is no significant shift in grading caused by
TACE pre-treatment. In patients with TACE, NCB may be used to predict
angioinvasion. Tumor response to TACE is not reflected by grading which hints
at different factors influential on response during TACE.
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2075 ADVANTAGE OF LIVER TRANSPLANT IN TERMS OF
SURVIVAL FOR PATIENTS WITH HCC AND CIRRHOSIS.
R. Verzaro, F. di Francesco, S. Li Petri, G. Vizzini, B. Gridelli
Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione
(ISMETT), Palermo Italy. University of Pittsburgh Medical Center Italy
Background: Liver transplantation (LTx) is considered a valid therapeutic
option to treat patients with HCC and cirrhosis due to the possibility of curing
both liver failure and malignancy. Loco-regional treatments, such as trans-arterial
chemoembolization (TACE) are considered adequate options for patients that are
not candidate to either surgical resection or liver transplantation. Loco-regional
treatments are also used to downstage HCC or as a bridge for liver transplant. The
advantages in terms of survival of liver transplant versus loco-regional therapies
are well defined in the literature as far as the long term survival is concerned
but little is known about the gain of survival in the first one or two years after
transplant. Moreover, HCV infection might impair patients’ survival after
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transplant when compared to not-transplant patients. We analyze our experience
in order to clearly define survival after liver transplant for HCC patients with and
without HCV infection in the first two years after transplantation.
Patients and Methods: We compared survival of patients with HCC and
cirrhosis that underwent liver transplant (HCC-LTx group) versus patients with
HCC and cirrhosis on the waiting list that did not received a liver transplant
(HCC-List group). In a 9-year period, 136 patients underwent liver transplant
whereas 270 received several treatments of chemoembolization while on the
waiting list. All transplanted patients were in the Milan criteria and had a
MELD score of 22. Drop out from the list (tumor growth outside the Milan
or criteria extremely critical clinical conditions) was considered also death of
the patient. Actuarial survival time was calculated for both groups at 6, 12,
24, 36, and 48 months. Patients’ survival was also calculated for HCC and
HCV infected patients (96 patients) as compared to the same group of nottransplanted patients receiving chemoembolization (196 patients).
Results: At 6, 12, and 24-month survival was as follows: for HCC-LTx
group 94.5%, 91.8% and 90.7%. For the HCC-list group 90.8%, 85,5% and
69.4%. Survival was significant different (p 0.0001) for the HCC-LTx patients
beginning at 24 months after LTx and remained significant at 36 and 48 months.
No difference was noted before 24 months for both groups. For the HCVHCC patients that underwent LTx a significant advantage in term of survival
(p 0.0008) was noted as early as 6 months after transplantation and remained
significant at 12, 24, 36 and 48 months thereafter.
Conclusions: Liver transplant offers a real advantage in terms of survival even
in the first 12-24 months post transplant for patients with HCC and cirrhosis that
are good candidate for transplantation. Mortality related to surgical procedure
itself does not increase mortality if compared to not-transplant patients. HCVHCC patients experienced a significant increase in survival as early as 6 months
after LTx when compared to HCC-HCV patients on the waiting list.
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2076 THE TREATMENT OF SMALL HEPATOCELLULAR
CARCINOMA FULFILLING THE MILAN CRITERIA:
HEPATIC RESECTION VERSUS LIVING DONOR LIVER
TRANSPLANTATION

THURSDAY

N. Kusunoki, M. Tominaga, T. Iwasaki, T. Fukumoto, M. Kido, S. Ogata,
M. Takahashi, H. Kinoshita, K. Kuramitsu, Y. Ku
KobeUniversity Graduate School of Medical Sciences
Background: Hepatic resection (HR) is the treatment of choice for small
hepatocellular carcinoma (HCC) in Child A patients, whereas living donor
liver transplantation (LDLT) is usually reserved for Child B and C patients in
Japan. However, it is still debated whether HR or LDLT in the best strategy
for Child A patients. This study was to compare HR and LDLT for HCC within
the Milan criteria.
Methods: Between June 2000 and June 2007, 38 patients underwent LDLT and
20 of 38 complicated by HCC at Kobe University. Fourteen of 20 recipients
were within Milan criteria. During the same period, 161 patients underwent
HR. Sixty-seven patients of 161 were within Milan criteria. In this study, we
compared demographic data, tumor characteristics and survival of 14 LDLT
patients and 67 HR patients with HCC within Milan criteria. All date were
expressed by mean }SD.
Results: Mean age of LDLT and HR group were 56 }8 and 64 }14 respectively.
Gender was similar in two groups (male/female: 12/6 vs 44/23). Rate of
Hepatitis C virus infection was significantly higher in the LDLT group (78%
vs 56%, P<0.05). ICG R15 of LDLT group was also higher than HR group (40
}15% vs 16 }6%, P<0.05). Tumor size, tumor number (solitary/oligonodular)
and AFP levels were not significant two groups (2.5 }1.5cm vs 2.6 }1.4cm,
8/10 vs 37/30, 59 }55 ng/ml vs 43 }39ng/ml). Three- and 5- year patient
survival rate were no significant difference, however, 3- and 5- year diseasefree survival rate was better for LDLT (100% and 100%) than for HR (60% and
35%) (P<0.05). Recurrences of 67 patients treated by HR were observed in 31
(47%). Initial recurrence of 25 patients (80%) in HR group was within Milan
criteria and that of remaining 6 patients (9%) was without Milan criteria.
Conclusions: Disease-free survival rate was significantly better in the LDLT
groups, whereas 5-year survival rate was similar in both groups. In HR groups,
80% of initial recurrence was within Milan criteria. When initial recurrence
was recognized, we usually consider rescue LDLT. We concluded that HR is the
best initial treatment in patients with resectable HCC within Milan criteria.
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2077 OUTCOMES OF PATIENTS WITH HEPATOCELLULAR
CARCINOMA THAT ARE TREATED VERSUS UNTREATED
WHILE WAITING FOR LIVER TRANSPLANT
T. Heffron1, T. Pillen2, G. Smallwood1, C. Fasola1, A. Stieber1
Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Background: Hepatocellular carcinoma (HCC) is the most common
malignant tumor originating in the liver. Current practice is to treat HCC with
chemoembolization and/or radiofrequency oblation while the patient is awaiting
transplant to avoid progression of the tumor. The United Network of Organ
Sharing (UNOS) policy bases allocation of liver allografts on a calculated
model for endstage liver disease (MELD) score. With the implementation of
the MELD policy, the patients with HCC have been giving an inflated MELD
score to shorten their wait time. Current wait times nationally for HCC patients
are 0.69 years (251 days) based on UNOS data.
Aim: The aim of this study is to report our experience and outcomes of liver
transplant recipients with HCC that had received treatment of their tumors to
patients that had not been treated while awaiting transplant.
Methods: Patients were retrospectively reviewed at our center for time on
waiting list, UNOS MELD score at time of transplant, actual MELD score at
time of transplant, type of treatment for HCC, if any, and outcomes.
Results: 50 patients were reviewed that received a liver transplant with HCC.
The control group (n = 23) did not receive any type of treatment for HCC while
the treatment group (n = 27) received chemoembolization ± radiofrequency
oblation. The control group had similar UNOS MELD scores [25.2 (± 6.9)
vs. 24.1 (± 2.7); p =0.774] and actual calculated MELD scores [17.6 (± 9.1)
vs. 14.1 (± 6.8); p = 0.238] at transplant compared to the treatment group.
The control group had longer time on the waiting list [421 (± 468) days vs.
133 (± 183) days; p = 0.010] in part due to the longer follow-up period [617
(± 393) days vs. 369 (± 400) days; p = 0.032]. Outcome comparisons were
similar, 2 (8.7%) deaths in the control group compared to 4 (14.8%) deaths in
the treatment group. In the treatment group, 4 (14.8%) patients had systemic
effects of chemoembolization (alopecia and neutropenia) with one requiring
total gastrectomy. There was a trend towards lower survival by Kaplan-Meier
[81.05% (±0.1) vs. 88.9% (± 0.07); p = 0.194] in the treated group. Recurrence
of hepatitis C (n=5) was the predominant cause of death, 2 patients in the
control group and 3 patients in the treatment group. One died of metastatic
breast cancer in the treatment group.
Conclusion: Due to the short wait time prior to liver transplant and the
possibilities of adverse events associated with chemoembolization, patients
that did not receive treatment for HCC faired as well, if not better, than those
receiving treatment. Further studies concerning this population are required.
1
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2078 PREVALENCE AND CORRELATES OF INFLUENZA
VACCINATION AMONG RENAL TRANSPLANT PATIENTS
L. Berben1, K. Denhaerynck1, S. Schaub2, S. De Geest1
Institute of Nursing Science, University of Basel, Switzerland, 2Division
of Transplant Immunology and Nephrology, University Hospital Basel,
Switzerland
Background: Immunosuppressive regimens increase kidney transplant
patients’ risk of contracting life-threatening influenza. However, little
information exists about the prevalence and correlates of influenza vaccinations
in this population.
Purpose: The purpose of this study was to determine the prevalence and
explore correlates of influenza vaccination in RTx recipients.
Methods: This cross-sectional study used data of the Supporting Medication
Adherence in Renal Transplantation (SMART) study. The convenience sample
consisted of 356 adult RTx recipients (58.1% male; mean age 52.9 years
(SD 13.53)) recruited from two Swiss transplant outpatient clinics. Influenza
vaccination status was assessed by self-report (yes/no). Known correlates of
vaccination in chronically ill patients (older age, cohabitation, higher education,
higher socio-economic status, financial stability, more co-morbidities, negative
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smoking status, and follow-up center attendance) were entered into a multiple
logistic regression.
Results: Of the 356 patients, only 83 (23.3%) reported having been vaccinated
against influenza in the previous year. Positive vaccination status was
significantly related to older age (OR: 1.04; 95% CI: 1.02-1.06).
Conclusion: Despite national and international guidelines recommending
influenza vaccination in RTx patients, influenza vaccination prevalence was
low in this sample. This study’s results suggest that transplant centers need to
implement policies to maximize influenza vaccination of their patients.
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2079 EFFECT OF ALEMTUZUMAB ON KIDNEY TRANSPLANT
RECIPIENTS WITH HEPATITIS C
R. Ouseph1,2, K. Ravindra2, M. Eng2, J. Gleason2, R. Nagubandi2, J. Buell2, H.
Kumar1
1
University of Louisville, 2Jewish Hospital
Kidney transplant recipients (KTR) with hepatitis C virus (HCV) have a
higher risk of mortality and morbidity. The effect of immunosuppression on
outcomes in HCV patients has not been well studied. Our protocol is to check
HCV antibodies (Ab) in potential recipients. If the HCV Ab and follow up
PCR are positive a liver biopsy is done. All HCV patients had evidence of
fibrosis but no cirrhosis. This is a retrospective case control study of KTR
with HCV liver disease treated with basiliximab induction, cyclosporine or
tacrolimus (TAC), steroids, and mycophenolate mofetil (MMF) (Era 1 Jan
1, 1994 – Oct 31, 2004) versus those treated with alemtuzumab, steroids (in
operating room and day 1), TAC, and MMF (Era 2 11/1/2004-7/31/207).
In addition, outcomes of KTR with and without liver disease receiving
alemtuzumab were compared.
There was no significant difference in 1 year creatinine (1.83 0.8 mg/dl and 2.00
1.2 mg/dl) or SGOT (25.2 11.0 IU/L and 29.2 16.4 IU/L) between the recipients
with hepatitis C liver disease in the Pre- and Post- Alemtuzumab era.
There was no significant difference in 1 year creatinine (1.80 0.4, 1.60 0.9 mg/
dl) or SGOT (29.2 16, 23.6 16) in the Alemtuzumab groups with or without
hepatitis C.
In summary, there was no significant differences in 1 year data in HCV liver
disease patients receiving alemtuzumab compared to historical control. There is
no significant differences in patients with and without HCV liver disease receiving
Alemtuzumab. In conclusion, this preliminary data suggests alemtuzumab is safe
in patients with liver disease from HCV. Future studies are needed to evaluate the
effect of Alemtuzumab on HCV viral load and liver pathology.
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2080 ADEFOVIR DIPIVOXIL IN COMBINATION WITH
LAMIVUDIN IN RENAL TRANSPLANTATION PATIENT WITH
YMDD MUTAION.
Y.K. Son, Y.H. Shin, J.K. Kim, S.S. Lee, K Hur
Bong Seng Memorial Hospital
Lamivudin resistant mutation in hepatitis B virus genome may occur during
therapy. Adefovur dipivoxil has been found to be effective in patients
with lamivudin resistant HBV, whether liver disease is compensated or
decompensated.
We report a 22-year-old man who was normal HBV carrier (HBsAg+, HBeAb+,
and HBcAb+) with no hepatitis activity on liver biopsy, who was transplanted for
end-stage renal disease in 2005. Directly after transplantation he took lamivudin
50mg qd for prophylaxis. Sixteen months posttransplant he had an HBV flare
with an AST of 328IU/ml. At that time his HBV DNA was > 108 copies/ml
and virologic study showed HBeAg positive and YMDD mutation. He became
jaundiced with peripheral edema, asictes, coagulopathy but No encephalopathy
and hepatorenal syndrome was found. He was placed on adefovir dipivoxil
10mg qod combined with lamivudin with initial rapid decreased in serum
aminotransferase to < 100 IU/ml. And then 14 weeks later his HBV DNA
became <2000 copies/ml and HBe Ag seroconversion was occurred.
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2081 CASE REPORT: A FEMALE PATIENT FROM A COUNTRY
AREA IN COLOMBIA, WHO RECEIVED 18 YEARS AGO A
RENAL TRASPLANT, PRESENTS WITH A DIAGNOSIS OF
DISSEMINATED HISTOPLASMOSIS CHARACTERIZED FOR
SEVERE CUATANEOUS INVOLVEMENT.
FINDINGS ARE DISCUSSED AND A COMPLETE REVISION OF
THE DISEASE IS DONE.
E.L. Marquez
Universidad Nacional De Colombia Departamento De Cirugía Y Morfología
Case report: A female patient from a country area in Colombia, who received
18 years ago a renal trasplant, presents with a diagnosis of disseminated
histoplasmosis characterized for severe cuataneous involvement. Findings are
discussed and a complete revision of the disease is done.

POSTER BOARD NUMBER P4 – 132
2082 FULMINANT LEPTOSPIROSIS IN RENAL TRANSPLANT:
FIRST NORTH -AMERICAN CASE
D. Samarapungavan, L. Gerasymchuk, A. Swami, C. Carpenter, J. Szela,
S. Cohn, M. Batke, B. Robinson-Dunn, R. Kanhere
William Beaumont Hospital
Leptospirosis, globally perhaps the most widespread zoonosis, results from
infection with pathogenic spirochetes of the genus Leptospira. More common
in the tropics, rodents, farm animals, and pets are reservoirs of this pathogen.
Humans acquire the infection from direct exposure to infected urine, or through
contaminated water or soil. About 100-200 cases are identified annually in the
United States with about 50% of cases occurring in Hawaii. There are only two
prior reported cases of leptospirosis in renal transplant recipients, from Iran
and Brazil.
A 48-year-old male with idiopathic MPGN type-I received a deceaseddonor renal transplant. At 3 months he developed transplant-glomerulopathy
associated with donor-specific antibodies to Cw6 HLA antigens, treated with
plasmapheresis & IVIg. At 6 months, Cellcept was switched to leflunomide for
BK-polyoma virus nephropathy. At 13 months, he developed unexplained fever,
sweats, intermittent diarrhea, and gradual weight loss. Therapy of low-grade
CMV viremia did not alleviate the symptoms. Over the next 5 months extensive
investigations for infections, inflammatory or occult malignant diseases
were fruitless. At 18 months, he developed jaundice. Physical examination
revealed icterus with moderate ascites, and hepato-splenomegaly. A blanching
erythematous macular rash was noted over the pre-tibial skin. Liver tests
showed a cholestatic pattern: total bilirubin 3.8 mg/dL, direct bilirubin 3.5 mg/
dL, alkaline phosphatase 414 IU/L, ALT 57 IU/L, AST 118 IU/L. His bilirubin
continued to rise, peaking at 17.2 g/dl, while transaminases remained less than
twice the upper limit of normal. Liver biopsy revealed a moderate cholestatic
process with well preserved hepatic architecture. Scattered spirochetes,
predominantly located in the hepatic sinuses, were identified on Steiner stain
and subsequently confirmed as leptospira by specific immunoperoxidase
staining performed at the U.S. Center for Disease Control and Prevention
(CDC) in Atlanta. Skin biopsy of the pretibial rash also identified a spirochete on
Steiner stain. Commercial serum leptospira antibodies remained negative two
weeks apart. He was treated with penicillin and immunosuppressant reduction.
Unfortunately, his course was complicated by recurrent lower gastrointestinal
bleeding, and overwhelming sepsis due to multidrug-resistant Acinetobacter
baumannii pneumonia eventually causing his demise. Post-mortem serum was
positive for Leptospira interrogans serovar icterohaemorrhagiae (LIsI) strain
RGA by microscopic agglutination test performed at the CDC.
The clinical presentation of leptospirosis varies from subclinical infection
to undifferentiated febrile illness to jaundice, renal failure and pulmonary
hemorrhage. Colitis and vasculitis have been described in human disease.
Molecular taxonomic studies at the CDC and elsewhere have identified 13
named and 4 unnamed species of pathogenic leptospires. Disease pathogenesis,
poorly understood, probably includes both direct effects by leptospira and host
immune response.
The protracted nature of our patient’s symptoms suggests a progressive
subacute illness likely influenced by his immunosuppressants. Zoonotic
exposures included two healthy outdoor dogs and a cat which died of renal
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failure a month prior to the onset of his symptoms. There was no antecedent
travel. Although we were unable to test his deceased cat, the dogs had negative
leptospira titers. Rats are the typical reservoir hosts for LIsI. We suspect that
the patient acquired the leptospira from his infected cat.
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2083 HCV+ RENAL TRANSPLANT PATIENTS DO NOT
PROGRESS TO LIVER CIRRHOSIS FOLLOWING
T-CELL DEPLETION
A. Sener, R. Barth, M. Cooper, L. Campos, E. Schweitzer, S. Bartlett,
B. Philosophe
University of Maryland Medical Center
Kidney transplantation prolongs survival in hepatitis C virus-positive (HCV+)
patients with end-stage renal disease (ESRD). However, the effects of induction
therapy and chronic immunosuppression are unknown on the course of HCV
infection and potential for cirrhosis in renal transplantation (RTx) recipients.
We have retrospectively assessed parameters of liver function, Child-Pugh
(CP) and MELD scores in HCV+ ESRD patients who received induction
therapy with T-cell depletion (Group 1: Thymoglobulin, n=30) or an IL-2
inhibitor (Group 2: Basiliximab, n=46). Pre-RTx liver biopsies were similar
in Group 1 and 2. Patients were followed for a mean of 826 days (range 47 to
2679 days) following RTx and received tacrolimus, mycophenolate mofetil,
and sometimes steroids post-transplant. Overall graft survival was 84% in
Group 1 and 85% in Group 2 (p > 0.05). Data were analyzed pre-RTx, at 30
and 365 days and at time of last follow-up. Serum AST, ALT, platelets, INR,
albumin and bilirubin did not change following RTx in either group. CP scores
in Group 1 were not significantly changed after RTx (5.5 ± 0.9 to 5.7 ± 0.9
at last follow-up, p=0.53). Group 1 patients on steroid-free protocols (n=8)
demonstrated declining CP scores from 6.0 ± 1.0 to 5.3 ± 0.5 at last follow-up
that were not statistically significant (p=0.31). Group 1 patients on steroids
showed opposite trends of CP: 5.3 ± 0.6 pre-RTx vs 5.8 ± 1.1 at last follow-up
that similarly did not reach statistical significance (p=0.18). Group 2 CP scores
declined from 5.8 ± 0.8 to 5.4 ± 0.9 at last follow-up (p=0.04). There was no
difference between CP or MELD scores at any point between the groups. As
expected, MELD scores improved significantly following RTx and remained
low up until the final visit (p=0.001); this was attributed to the drop in serum
creatinine post-RTx. Neither the use of Thymoglobulin or Basiliximab resulted
in acute hepatitis resurgence or the development of cirrhosis post-transplant.
We have not identified any association between choice of induction agent or
maintenance immunosuppression regimens, including steroid withdrawal,
with impaired hepatic function or progression to liver cirrhosis in HCV+
RTx patients. T cell depletion was well-tolerated by HCV+ RTx patients and
resulted in good graft outcomes. Interestingly, CP scores declined after renal
transplantation in the Basiliximab induction group.
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2084 COMPARISON OF REAL TIME PCR AND CMV
ANTIGENEMIA ASSAY IN TREATMENT OF CMV INFECTION

THURSDAY

S.H. Kim1,4, H.E. Yoon1, E-J. Oh2, S.C. Park3, B.S. Choi1, Y.S. Kim1,
I.S. Moon3, B.K. Bang1, S.Y. Kim1, C.W. Yang1
1
Department of Internal Medicine, The Catholic University of Korea,
2
Department of Laboratory Medicine, The Catholic University of Korea,
3
Department of Surgery, The Catholic University of Korea, 4Department of
Internal Medicine, Chung-Ang University
Background: Cytomegalovirus (CMV) infection is one of the most important
infectious complications in the kidney transplantation. We evaluated the
efficacy and accuracy of CMV RT-PCR compared to pp65 CMV antigenemia
assay which was commonly used diagnostic method for monitoring the CMV
infection.
Methods: We investigated all suspect CMV cases with the qualitative plasma
DNA PCR assay (PCR) and the pp65 antigenemia assay (AG) in kidney
transplant recipients. And if results were positive, we measured both tests
weekly.
Results: Ninety three patients (mean age 48 ± 13 years, 49 male) provided 139
samples for both test. Nine patients developed symptomatic CMV infection. The
statistically significant correlation between both tests was found (R2 = 0.754,
p <0.001). The PCR (more than 1,000 CMV DNA copies) had a sensitivity,

684

specificity and positivie value and negative predictive value of 100, 98, 81 and
100%, respectively, compared with 56, 100, 100 and 95%, respecitively, for
antigenemia test (more than 10 of 20,000 peripheral blood mononuclear cells).
And antigenemia assay was rapidly decreased after ganciclovir treatment
(median negative conversion time; 1week), but the PCR assay was more slowly
decreased (median negative conversion time: 2.5 week). Conclusion: The PCR
assay was more accurate reflected the course of CMV disease compared with
the antigenemia assay.
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2085 INFECTIOUS COMPLICATIONS IN 142 PERSIAN
KIDNEY TRANSPLANT RECIPIENTS DURING ONE YEAR
FOLLOW-UP
G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Introduction: Infectious complications after renal transplantation are
associated with significant morbidity and mortality. In developing countries,
the infections spectrum, their chronological occurrence and the risk factors are
different from developed regions. A considerable amount of time and money is
spent on the Medicare of these patients.
Material and Methods: In a 2-year period (2002-2004), 142 patients were
studied and followed for 1-year. Immunosuppressive regimen contained
Cyclosporine A, Cellcept and Prednisolone. Each patient was assessed on
regular visits according to the ward protocol then results of the investigations
were registered.
Results: The major causes of renal failure were hypertention(41%) and diabetic
nephropathy(15%). The overall incidence of infections was 54.2%. The most
common site of infections was lower urinary tract (41.5%). The most common
causes of infections were Klebsiella(22.5%) and Cytomegalovirus(17.6%).
Wound infection occurred in 4.9% patients. There were 24.6% episodes of acute
rejection. Of these, 14 cases were administered Anti Thymocyte Globulin and
4 received cadaveric allografts. Overall mortality was 7.7%. Infection-related
mortality was 3.5% with developing sepsis. Graft loss was seen in 11.2%cases,
of whom 2 had developed Cytomegalovirus infection, 2 experienced urinary
tract infection(UTI) and 5 developed sepsis. Female gender had no impact on
UTI incidence. Mycobacterial and Hepatitis C infections were noticeably low,
compared with other studies.
Conclusion: This study identifies infections as the cause of morbidity and
mortality in post-transplant period. Patients having higher creatinine level and
receiving high dosage of drugs at the discharge time are considered as risky
cases and should be evaluated more obsessively.

POSTER BOARD NUMBER P4 – 136
2086 EPIDEMIOLOGIC STUDY OF KDNEY TRANSPLANT
PATIENTS, SUFFERING FROM TUBERCLOSIS IN EMAM
EDUCATIONAL SURVEY TREATMENT HOSPITAL IN URMIA
IN 2007.
B.A. Markazi, E. Ahmadnezhad, A. Ravandi, S. Hatami, N. Sepehrvand
Introduction: Using immunosuppressive drugs in transplant patients leads to
immune system suppress and causes intracellular infection.Mycobacterium
Tuberculosis is one of the bacteria, hidden inside Tcells and if a person suffers
from an immunodeficiency problem, it will become active and the person will
be involved.
The risk of infection in these patients is 50 times and the mortality is 10 times
more than among the normal population and furthermore the probability of
kidney transplant rejection is 30% more in Tuberculosis patients.
According to mentioned subjects, it’s necessary to study characteristics of
transplant patients suffering from Tuberculosis.
Methods: The cross-section study in descriptive analytical way was done with
studying the documents of transplant patients suffering from Tuberculosis
in Emam hospital during 10 years from 2007-1997.Totally 33 patients were
under study the Pierson coefficient and chi- score test were used for statistic
analyses.
Conclusion: The total infection prevalence was 3.79%.The most prevalence
rate was between the ages classes of 40 to 50.There was no sex differences
in infection. The average duration of analysis before transplant was 8+1.5
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months.97% of the cases have been transplanted once before. The PPD was
negative in 100% cases.The average interval between infection of TB and
transplantation was 19.5+4.5 months. Pulmonary, milliary and meningeal TB
were the most found types in this group.
A disorder in kidney function occurred in 24.2% of people suffering from TB
in the form of Cr increase. Kidney transplant rejection of 12% of patients made
them a comeback to dialysis.
A meaningful statistic relation between infection to Tb and kidney transplant
rejection was found (P<0/000).
The rate of mortality among patients suffering from TB was 30.3%.There’s a
meaningful statistical relation between infection and death in these patients.
Discussion: According to high rate of death and transplant rejection in people
suffering from TB, It’s necessary to study all transplanted cases, treat them on
time and continue the follow-up treatments of the patients.

POSTER BOARD NUMBER P4 – 137
2087 POST KIDNEY TRANSPLANT HEPATITIS C VIRUS AND
ITS IMPACT ON GRAFT AND PATIENT SURVIVAL
M. Taherimahmoudi, P.G. Pourmand, A. Mehrsai, H. Wahhabaghai,
M. Nikoobakht
Urology Research Center, Tehran University of Medical Sciences,
Tehran, Iran
Objectives: 1-to determine the post transplant positive anti – HCV patients
who were negative before transplantation.
2-Does graft and patient survival alter in whom became positive anti HCV?
Materials and Methods: From 1989 –2005, 1000 kidney transplantation were
performed in our center. 162 anti HCV negative patients were included in this
study. The mean age was 32 years (7- 69) (33.9% female and 66.1% male),
and followed for 4 years. Liver function tests and viral markers measurements
carried out every three months. During follow up period any acute or chronic
rejection and mortality were recorded.The results were analyzed by statistical
package SPSS using Exact, chi square and ANOVA tests.
Results: Anti HCV positive was occurred in 24 patients (14.8%), all were
confirmed with third generation recombinant immunoblot assay (RIBA 3)
and HCV RNA polymerase reaction. All of them had history of pre-transplant
transfusion, and 83% of them were under hemodialysis for more than 30
months. We found no acute or chronic rejection in Anti HCV positive patients.
three patients (12.5%) had liver enzymes increase.Two anti HCVpositive
patient expired.due to acute hepatitis. No chronic hepatitis C were seen.
Conclusions: Although, in our study the impact of post – transplant anti
HCV positive on graft survival was not significant, but long term evaluation
for better prejudice is mandatory, so, we highly recommend evaluation of anti
HCV negative patients after kidney transplantation.

excluded from subgroup analysis. The data collected on patients and the
various patterns of tuberculosis was entered on Excel spreadsheet and analyzed
statistically. The overall incidence of tuberculosis in the 3 groups was compared
as well as the incidence at 6, 12 and 24 months post-transplant using the ML
chi-square test. Graft- and patient survival were estimated using Kaplan-Meier
analyses, and compared with recipients who did not develop post-transplant
tuberculosis using the log-rank test.
Results: Of 672 renal allograft recipients treated over 340 months, 43 (6.4%)
developed tuberculosis. There was no difference in the cumulative incidence
between patients on conventional and triple therapy respectively, but in patients
on a cyclosporine-based regimen, INH prophylaxis significantly reduced the
incidence of Tuberculosis (p = 0.021). Because unfair bias would exist towards
patients on Azathioprine, due to the longer duration of time elapsed since
transplantation compared to the two groups on cyclosporine and cyclosporine
with INH prophylaxis, we compared the incidence of tuberculosis in the three
groups at 6, 12 and 24 months after kidney transplantation. We were able to
show a trend of benefit towards the use of INH prophylaxis at 6 and 12 months
post-transplant, which culminated in a statistically significant difference in
the incidence of tuberculosis from 24 months post transplantation onwards
(p=0.024).

POSTER BOARD NUMBER P4 – 139
2089 RENAL TRANSPLANTATION IN HCV POSITIVE
PATIENTS
S. Soni
Sathya Kidney Centre
Introduction: Hepatitis C virus (HCV) infection is highly prevalent in end
stage renal disease patients. Effect of HCV on transplant outcome is not well
established. The aim of the present study was to determine the effect of HCV
infection on the outcome of kidney transplantation at a single transplant center.
Methods: The study analysed 100 patients who underwent kidney
transplantation between 1998 to 2003. Minimum post transplant period follow
up was of five years. Of this, twenty four patients were HCV+. Complete clinical
data including type and duration of dialysis, pre- and post- transplantation
transfusions, donor, immunosuppression, PTDM and rejection episodes was
collected. The patients were divided in two groups: HCV positive and negative.
Strata 6 software was used for statistical analysis.
Results: Of 100 patients 68 were males and 32 females. Most donors were live
related (65%) followed by live unrelated(30%) and cadaver donors(5%). All
patients in HCV positive group were on hemodialysis while 10.4% cases were
on CAPD in HCV negative group. Although, one year graft survival was similar
in both groups, five year graft survival as well as patient survival was higher in
HCV negative. HCV+ patients had higher rate of acute rejection and PTDM
Conclusion: Our results show that HCV+ patients have similar one year but
inferior five year outcome post transplant compared with HCV negative.

POSTER BOARD NUMBER P4 – 138
2088 ISONIAZID PROPHYLAXIS SIGNIFICANTLY REDUCES
THE INCIDENCE OF TUBERCULOSIS IN PATIENTS AFTER
RENAL TRANSPLANT
J. Nel , C.S.H. Bouwens , D.J. Nel , M.R. Moosa
Division of Nephrology, Tygerberg Hospital and University of Stellenbosch,
2
Centre for biostatistical sciences, University of Stellenbosch
Tuberculosis frequently complicates renal transplantation and often leads
to loss of graft function and even loss of life. This study undertook to
retrospectively establish the incidence and nature of tuberculosis in our kidney
transplant population under different immunosuppression regimens, and assess
the efficacy of prophylactic isoniazid against tuberculosis.
Patients and Methods: All laboratory-confirmed cases of tuberculosis were
identified from the records of patients transplanted between April 1976 and
31 July 2004. Recipients were categorized according to immunosuppressive
regimen and whether they received tuberculosis prophylaxis: patients in group
A received steroids and azathioprine (conventional therapy); those in group B
received cyclosporine as part of triple therapy; group C received triple therapy
and isoniazid 300 mg/day prophylaxis for the first year after transplantation.
Patients who underwent multiple transplants were counted once only and
categorized in the group under which the primary transplant was performed.
Three patients who contracted tuberculosis after a second transplant were
1
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POSTER BOARD NUMBER P4 – 140
2090 HISTOPLASMOSIS IN RENAL TRANSPLANT
R. Schiavelli, E. Maiolo, D. Di tullio, R. Sabbatiello, M. Raño, M. Pattin
Hospital General De Agudos “Dr Cosme Argerich”
The prevalence of mycotic infections in solid organ transplant patients varies
from 5to 50% and it is similar in renal and cardiac transplant patients and
much higher in liver transplant. The most important incidence of invasive
mycotic infections is observed in bone marrow transplant and it is the major
morbidmortality cause in this group of patients.
In all transplants, 80% of invasive mycotic infections are caused by Candida
and Aspergillus, and may be primary infections or reactivations.
The main disadvantages in immunosupressed patients are the absence of signs
and symptoms as well as the lack of detectable infections in the blood.
Histoplasmosis in renal transplant is frequently caused by reactivation in patients
who live in endemic areas. Enviromental exposure and immunosuppression
determine the severity of the infection.
In our patients the incidence of cutaneous manifestations is more frequent than
the one that is reported.
Aim: To analyze the incidence, clinical manifestations and prognosis of renal
transplant recipients with histoplasmosis diagnosis.
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Methods: We evaluated the clinical records of patients with histoplasmosis
diagnosed by means of the following methods:
Giemsa stain and cultures of cutaneous lesion materials or from material
obtained through biopsies of the skin, liver and intestine.
Blood cultures by lysis centrifugation and bone marrow, bronchoalveolar and
cerebrospinal fluid cultures and serological techniques of immunodifusion and
contraimmunoelectrophoresis.
We excluded patients with superficial mycosis.
Results: Out of 580 transplant patients, 31 showed mycotic infections (18
M/13 F) mean age 41.8 (19 – 69). There were 32 isolations and 1 coinfection
episode with two different agents. Seven patients developed histoplasmosis
(22%) Tabla 2.
The typical cutaneous manifestations were observed in 4 of the 7 patients and
they are slightly painful reddish purple nodules with a tendency to soften and to
develop cytosteatonecrosis and suppuration. Histopathological findings reveal
necrotic areas and neutrophilic and histiocytic infiltrate with the presence of
yeastlike elements, compatible with Histoplasma capsulatum. Two patients had
pulmonary involvement, one lobar infiltrate and the other one, miliary.
Three cases were manifested before 180 days; two were related to the
antirejection treatment. one of them with a reactivation of CMV and another
one with chronic C-virus hepatopathy. All the patients received anphotericin B
and itraconazole, and two of them died.
Conclusion: The incidence of histoplasmosis is slightly higher than the one
reported, probably due to epidemiological reasons. The cutaneous manifestation
was observed in more than 50% of the patients therefore enabling us to reach an
early diagnosis of the infection.

POSTER BOARD NUMBER P4 – 141
2091 STATISTICAL MODEL FOR PREDICTION OF CMV
INFECTION RECURRENCE AFTER INITIAL TREATMENT IN
KIDNEY ALLOGRAFT RECIPIENTS
B. Matlosz , D. Dêborska-Materkowska , M. Cieciura , A. Sadowska ,
A. Kwiatkowski3, T. Grochowiecki4, M. Durlik1
1
Dept of Transplantation Medicine And Nephrology, 2Higher School of
Electronic Technology, 3Dept of General and Transplantation Surgery, 4Dept
of General Transplantation and Vascular Surgery
Introduction: CMV infection is the most prevalent opportunistic infection
in solid organ transplantation. Although it is possible to control the infection
easily with gancyclovir it is not rare for patients to have recurrence. There are
several factors that can influence the recurrence rate.
Methods: We have analyzed retrospectively medical records of all consecutive
kidney allograft recipients transplanted at our center since 01.03.2004 till
01.10.2007. Out of 397 patients transplanted in this period 56 were treated
for CMV disease. 10 were excluded from analysis because they did not meet
criteria for CMV disease. Clinical data were collected regarding the course of
the disease and the treatment, rejection episodes, immunosuppressive therapy,
prophylactic antiviral treatment, recurrence of the disease. Finally 24 parameters
were chosen for statistical analysis. In order to predict the recurrence of the
disease after initial treatment MANOVA was used.
Results: Mean observation time was 737 days (69-1524). Out of 46 patients
with CMV disease the recurrence was observed in 9 (19,5%). In 90% of
cases CMV disease developed within first 40 weeks after transplantation. The
MANOVA analysis revealed that it is possible to predict CMV recurrence using
6 of the parameters (PRA value, initial dose of steroids, dose of cyclosporine
or tacrolimus per kg body weight, mycophenolate dose per kg body weight and
time after transplantation) using the following equation:
DF (discriminant function) = (PRA x -0,0784) + (initial steroids x -0,1374) +
(csa/kg x 0,6914) + (tac/kg x 45,8910) + (mmf/kg x -0,1047) + (time after tx
x 0,0315)
The mean discriminant variables were -3,2473 and -5,6757. The sensivity of
the test was 90,9%, specifity 46,1%, predictive value was 81% and accuracy
–; 78%.
Conclusions: The most important factors for CMV recurrence after initial
treatment included immunosuppressive treatment used (4 out of 6 features).
Using described statistical method it is possible to accurately define the group
of patients at high risk for recurrent disease.
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POSTER BOARD NUMBER P4 – 142
2092 INFECTION-RELATED MORTALITY IN RENAL
TRANSPLANTATION (RT)
M. Cherif1, S. Barbouch1, R. Goucha1, M. Ounissi1, E. Abderrahim1,
F.B. Hamida1, F. Elyounsi1, Y. Gorgi2, T.B. Abdallah1.2, A. Kheder1
1
Charles Nicolle Hospital Department of internal medicine A, Charles Nicolle
Hospital Tunis, 2Immunology Laboratory, Charles Nicolle Hospital Tunis
Infections represent a major cause of morbidity and mortality among renal
transplant recipients. Our aim was to analyze the incidence and aetiology of
infection-related mortality among a cohort of renal transplant recipients.
From 1986 to 2006 we collected all causes of mortality among patients receiving
a renal transplantation. The date of transplant, the last follow-up/death, type of
transplant, age and cause of death were tabulated into a database.
296 adults RT were performed at Charles Nicolle Hospital. 56 (18.9%) were
cadaveric, 240 (81.08%) were living transplants. Recipients were 194 males
(65.5%) and 102 females (34.5%), whose mean age (±SD) was 31.96 ± 9.4
years (range 16-61 years).
244 (82.43%) patients presented at least one episode of infection during the
follow-up. The causes of mortality were: infection 32 (58.18%), cardiovascular
7 (12.72%), cancer 6 (10.9%), other causes 9 (16.34%) and unknown 1 (1.81%).
Infection-related mortality were sepsis 18 (56.25%), pneumonia 7 (21.87%),
invasive viral infection 4 (12.5%) and invasive fungal infection 3 (9.37%).
The actuarial patients survival rates at 1, 5 and 10 years in the group of patients
who have presented at least one infection was respectively: 95.8%, 87% and
75.5%, whereas in the group of patient who have never presented an infection,
was respectively 98%, 94.9% and 94.9%. The differences between the two
groups were statistically significant (P = 0.01).
This study confirmed that infections remain a major complication in the post
transplant period and increase the risk for death of patients.

CONCURRENT ORAL SESSION 142: LONG TERM OUTCOMES
– BONES/ANAEMIA
POSTER BOARD NUMBER P4 – 143
2093 ANEMIA AMONG LONG-TERM RENAL TRANSPLANT
RECIPIENTS
A. Ghafari
Urmia University of Medical Sciences
Background: The effects of anemia on cardiovascular disease among the endstage renal disease population suggest that it may be one of the major factors
explaining this complication among kidney transplant recipients. Systematic
investigation into the prevalence of post transplantation anemia (PTA) is
therefore of critical importance.
Materials and Methods: This cross-sectional study of data from 650 patients
followed at a single outpatient transplant clinic utilized the guidelines of the
American Society of Transplantation to define anemia as a hemoglobin (Hb)
<130 g/L in men or <120 g/L in women.
Results: Mean age was 43 ± 12 years, and included 52% of men. Mean GFR
was 64 ± 33 mL/min, and mean time since transplantation was 63 ±51 months.
Mean Hb for the total sample was 139 ± 32 g/L (males: 141 ± 37 g/L; females:
129 ± 28 g/L; P <.005). Overall we defined 254 patients (39%) as anemic.
Among the total population, 137 patients (21%) had mild; 78 (12%) moderate;
and 39 (6%) severe anemia. Upon bivariate analysis, there was no correlation
between age and Hb level. Anemia was more prevalent among women than
men (45% vs 33%; P <.01). Among all patients, 98 (15%) were iron deficient
(TSAT <20%). Iron deficiency was more prevalent among women than
men (19% vs 12%; P <.05). Upon bivariate analysis, serum transferrin was
positively correlated with albumin (r =.254, P <.001) and negatively with
CRP (r =2.11, P <.001). Serum albumin levels positively correlated with Hb (r
=.214, P <.001) and negatively with CRP (r =154, P <.001). Upon multivariate
linear regression analysis (dependent variable: serum transferrin), CRP and
albumin remained significantly and independently associated with serum
transferrin after controlling for potential confounding variables (P<.001). For
the whole population, there was a significant correlation between GFR and
Hb (r =.376, P <.01). When analyzed individually, only MMF was associated
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with more frequent anemia (P <.01; Table 1); Therapy with ACEI, which was
prescribed in 163 patients (25%), was associated with lower mean serum Hb
levels: 130 ± 23 vs 133 ± 15 g/L (P <.05). Multivariate Analysis To analyze
the complex relationship between anemia (Hb as the dependent variable)
and the multiple, potentially relevant covariables, we used linear regression
analysis. In this model (r =.383, P <.01), serum transferrin, gender, GFR,
serum albumin, iron deficiency, ACEI, and MMF were significantly and
independently associated with blood Hb. Among all patients, 66 (10%) were
given iron supplementation. Only 22 (22.5%) of the 98 iron-deficient patients
received iron therapy and 18 (7%) of the 254 anemic patients were treated
with EPO.
Conclusions: PTA is a prevalent, under treated condition. Based on our results,
we suggest that protein/energy malnutrition and/or chronic inflammation were
independently associated with anemia.

POSTER BOARD NUMBER P4 – 144
2094 PROTRACTED FEBRILE MYALGIA SYNDROME IN
A RENAL TRANSPLANT RECIPIENT WITH FAMILIAL
MEDITERRANEAN FEVER
M.A. Halim, T. Al-Otaibi, M.R.N. Nampoory, P.A. Asif, F. Donia, T. Said,
P. Nair, M. Samhan
Hamed Alessa Organ Transplantation Center
Background: Drug induced toxic myopathy is repeatedly reported in familial
Mediterranean fever (FMF) patients receiving cyclosporine (CsA) and
colchicine combination. Protracted febrile myalgia syndrome (PFMS) is a
severe form of FMF which may need aggressive treatment including high dose
of steroids.
Case summary: A 34 years old male who is known to have FMF for more than
15 years. He developed renal failure due to secondary amyloidosis. He was on
hemodialysis for 6 months till he received live unrelated renal transplant which
is functioning normally.
There were no acute attacks of FMF for 3 years before transplantation. He was
on 0.5 mg colchicine once daily which was continued after transplantation.
His immunosuppressive regime was antithymocyte globulin as induction and
prednisolone, mycophenolate mofetil and CsA as maintenance therapy.
After 2 months he presented with severe myopathy and muscle biopsy
showed evidence of toxic myopathy most likely due to cyclosporine when
it was initiated in addition to colchicine. CsA was changed to sirolimus and
colchicine was stopped. He was gradually improving apart from residual
chronic myalgia requiring oral analgesics. Prednisolone dose was reduced
gradually to 5 mg daily.
Eight months posttransplant he was readmitted with severe arthralgia,
prolonged fever, pleuritic pain, diffuse abdominal pain, macroscopic
hematuria, protienuria and diarrhea. All investigations for infections, internal
malignancy, hyperparathyroidism and rheumatic diseases were negative other
than high C-reactive protein (192mg/l) and erythrocyte sedimentation rate
(120mm/hour).
The clinical diagnosis was acute attack of FMF presenting as PFMS as he was
not receiving colchicine for 6 months. In spite of the history of toxic myopathy
6 months earlier he was challenged with colchicine as 0.5mg twice daily which
was well tolerated. There was significant improvement of most of his symptoms
within days and graft function continued to be normal.
Conclusion: FMF may reactivate after renal transplantation if colchicine is
discontinued and present as PFMS which responded to restarting colchicine in
our case in spite of the history of toxic myopathy.

POSTER BOARD NUMBER P4 – 145
2095 IMPROVED BONE METABOLIC MARKERS AND
DECREASED BONE MINERAL DENSITY: ONE YEAR
FOLLOW-UP IN A DIABETIC RENAL ALLOGRAFT RECIPIENT
R. Murakami1, N. Nakamura1, T. Fujita1, M. Shimada1, K. Okumura1,
S. Narumi2, M. Sasaki2, T. Yoneyama3, T. Koie3, C. Ohyama3
1
Department of Nephrology, Hirosaki University Transplantation
Research Center, 2Department of Digestive Surgery, Hirosaki University
Transplantation Research Center, 3Department of Urology, Hirosaki
University Transplantation Research Center

Bone disease in type 2 diabetes mellitus is characterized by a low rate of bone
formation especially caused by the marked reduction in serum osteocalcin (OC)
levels, that is a characteristic finding in diabetic patients both with and without
renal dysfunction. On the other hand, metabolic bone disease leading to bone
mineral loss is a well-recognized problem in patients with end stage renal disease
(ESRD). Therefore, osteodystrophy which causes ostealgia or bone fracture is one
of the most severe complications in ESRD patients with diabetes mellitus because
ESRD and diabetes mellitus have unfavorable effects on bone metabolism. Even
renal transplantation, which is one of the excellent renal replacement therapies,
is not able to solve this problem completely because most patients need to be
treated with corticosteroids which affect bone metabolism and worsen diabetes.
In the present study, we investigated the changes of bone metabolism markers and
bone mineral density (BMD) up to 1-year after successful renal transplantation
with minimum administration of corticosteroids and good glycaemic control in a
male patient with type 2 diabetes. We report the influence of renal transplantation
upon the bone metabolism under both unfavorable circumstances of ESRD and
diabetes mellitus.
A 39-year-old man received a living related renal transplantation in June 2006
after 3 months on hemodialysis. He was treated with triple immunosuppressive
regimen for the maintenance which consisted of tacrolimus, mycophenolate
mofetil and predonisolone. Fortunately, he has not experienced any rejection or
infection until one year after the surgery with stable creatinine levels of 1.8~2.0
mg/dL. We measured plasma OC and bone specific alkaline phosphatase (BAP)
levels as bone formation markers, tartrate resistant acid phosphatase (TRAP)
and osteoprotegerin (OPG) levels as bone resorption markers and BMD from
day 0 to 12 months, respectively.
The bone formation markers started to increase from 2 and 4 months after
transplantation, respectively, and reached the normal range for patients
without renal insufficiency at 12 months after transplantation. On the other
hand, as for the bone resorption markers, both TRAP and OPG levels remained
unchanged or slightly increased throughout the period. In spite of the increased
bone formation markers and the unchanged bone resorption markers, BMD
levels had decreased gradually throughout the period. However, his lumbar
spine BMD remained decreased 6.9% at 12 months, which is the same rate of
decrease as non-diabetic patients.
It is reported that in renal transplant recipients, corticosteroid withdrawal
resulted in an increase in BMD with a corresponding increase in serum OC.
Moreover, it is also reported that in diabetic patients without renal insufficiency,
good glycaemic control improved osteoblast function with increased OC
levels and resulted in more favorable bone metabolism. Considering above,
even in renal allograft recipients whose primary cause of ESRD is diabetic
nephropathy, the reduction of corticosteroid, or the withdrawal of it if possible,
and strict glycaemic control may contribute to the prevention of metabolic bone
disease with bone mineral loss such as ostealgia or bone fracture, which greatly
affects their daily life.

POSTER BOARD NUMBER P4 – 146
2096 EARLY MEASUREMENT OF PARATHYROID HORMONE
LEVELS IN RENAL TRANSPLANT PATIENTS UNDERGOING
ELECTIVE PARATHYROIDECTOMY FOR TERTIARY
PARATHYROIDISM: A POTENTIAL TOOL FOR PREDICTING
SATISFACTORY EXCISION?
S. Bhandari1, J. England2
Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School,
2
Department of ENT, Hull and East Yorkshire Hospitals NHS Trust
Background: Adequacy of parathyroid surgery to normalise PTH values
remains problematic in terms of predicting satisfactory tissue remove without
leading to adynamic bone disease.
Aim: To examine the utility of intra-operative and early postoperative
parathyroid hormone (PTH) levels to predict effectiveness of parathyroid tissue
excision in a cohort of kidney transplant patients undergoing elective primary
parathyroidectomy for tertiary hyperparathyroidism.
Methods: Renal transplant recipients (RT) undergoing elective total
parathyoidectomy for tertiary hyperparathyroidism were eligible for inclusion.
Intact PTH levels were measured at induction of anaesthesia (PTH0), intraoperatively immediately following removal of parathyroid tissue (PTH1) and
15 minutes after tissue resection (PTH2).
PTH levels were subsequently measured 3, 6 and 12 months post-operatively.
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Raised PTH levels at these time points were used as a measure of potential
active remnant parathyroid tissue. Calcium, phosphate and the product were
compared pre-operatively with measurements made at intervals following
surgery. Data are given as means±SEM. Comparison of data at different time
points is made using the Wilcoxon signed ranks test.
Results: Twelve patients (7 male, 5 female; mean age 58±3years) underwent
surgery. PTH levels fell significantly from baseline (PTH0 247.6±50pg/ml)
at each of the two time points (PTH1 116.2±44pg/ml; PTH2 67.3±35pg/ml;
p<0.001) and when the postoperative levels (PTH2) were compared to baseline
levels (PTH0) with p<0.001. Calcium levels at baseline (2.82±0.04mmol/L)
significantly dropped at 3 and 6 months levels postoperatively (2.42±0.02
and 2.44±0.02mmol/L; p<0.001)), while there was also a significant increase
in phosphate over the time period (0.86±0.06mmol/L to 1.15±0.07 and
1.1±0.06mml/L respectively; p<0.05) and an increase in the calcium phosphate
product (2.43±0.15 mmol2/L2 versus 2.79±0.18mmol2/L2; p<0.01).
Three patients had raised PTH levels at 6 months post procedure. Analysis of
these cases showed a fall in peri-operative PTH at each of the time points. There
was no change in renal function from baseline to 1 year post parathyroidectomy
(161±11 at baseline versus 174+12μmol/L at 1 year, p=0.18). No rejection
episodes occurred in the follow-up period.
Conclusion: PTH levels fall rapidly following removal of parathyroid tissue in
transplant patients with tertiary hyperparathyroidism. Intra-operative and early
post operative measures of PTH, although suggestive of surgical success may
not indicate satisfactory parathyroid tissue excision. Raised PTH levels seen
later in patients with remnant parathyroid tissue may be due to reactivation
following removal of the suppressive effects of high circulating PTH levels
or due to parathyroid tissue re-growth. Surgery is not detrimental to long-term
transplant function.

POSTER BOARD NUMBER P4 – 147
2097 CHANGES IN BONE MINERAL DENSITY AND
SELECTED METABOLIC PARAMETERS OVER 36 MONTHES
FOLLOWING RENAL TRANSPLANTATION
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D.S. AL– Gabri1, J. Zadražil 2, K. Krejčí2, P. Horák2, P. Strebpl 2,
V. Horcicka2, K. Baker1
1
Nephrology and transplantation dep., General Military Hospital, Sanaa,
Yemen
2 rd
3 Department of Internal Medicine Teaching Hospital and school of
Medicine, Palacky University, Olomouc, Czech Republic
Aim: The aim was to evaluate the changes in serum levels of selected
bone metabolism indicators and bone density over 36 months following
renal transplant. A partial objective was assessment of the effectiveness of
prophylactic administration of D-vitamin and calcium preparations to prevent
the progression of osteopathy after kidney transplantation.
Patients and methods: The population consisted of 80 patients after kidney
transplantation 47 males and 33 females, average age of 53,9 ± 9,4 years.All
patients were treated after transplantation by acombination of cyclosporineA,mycophenolate mophetil or azathioperin and prednison.They were
prophylactically given AD-vitamin 800 IU and calcium 1000mg a day. During
the monitoring, the serum creatinine concentration in all recipients was < 200
μmol/l (subgroub A with creatinine concentration <120μmol/l, subgroup B
with creatinine 120-200μmol/l). The concentration of serum parathormon,
serum level of bone fraction of alkaline phosphatase, serum phosphorus and
calcium concentration and phosphorus and calcium 24 hours excretion were
examined 2 weeks and 3 years after transplantation. In the same time period,
radiographs of thoracic, lumbar spine and hip joints were taken and the bone
density (BMD) of lumbar (L) spine and hip was determined by Dual – EnergyX–Ray (Lunar Prodigy).
Results: Three years after the transplantation- in subgroup A, there was a
BMD decrease in 75% recipiens in L spine area and the hip. BMD increase
was in 20% recipiens. In subgroup B, BMD decrease was in 83% recipiens,
BMD increase was in 30% recipiens. In subgroup A three years after kidney
transplant, the average PTH serum concentration was 94,7+-57,2pg/ml, while
in subgroup B, the average PTH concentration was 163 ± 42,9pg/ml.
No clinical either radiographic fracture was detected in these subgroups.
Conclusions: We conclude that prophylactically adminestration of vit.D
and calcium is not enouph effective to prevent the progression of osteopathy
after renal transplantation.Changes in bone density evaluated after the kidney
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transplantation is affected by graft function.
PTH concentration seems to correspond with serum creatinin. Alarge number
of patients with low BMD in the post-transplantation period indicates the
seriousness of the problem and is a challenge for optimal prevention and
treatment of the metabolic complication of kidney transplantation to be found.

POSTER BOARD NUMBER P4 – 148
2098 LACK OF ASSOCIATION BETWEEN OSTEOPOROSIS
AND OSTEOPENIA WITH VERTEBRAL FRACTURES IN
LONG-TERM RENAL TRANSPLANT RECIPIENTS.
R. Marcén1, N. Rodriguez1, C. Caballero2, C. Vaamonde3, A. Fernandez1, B.
Ponte1, J.J. Villafruela1, J. Pascual1, F.J. Burgos4, J. Ortuño1
1
Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal
University Hospital – Nuclear Medicine, 3Ramón Y Cajal University Hospital
– Radiology, 4Ramón Y Cajal University Hospital – Urology
Background: In the general population, osteoporosis is associated with an
increased risk of vertebral fractures. Bone loss and the development of both
osteopenia or osteoporosis frequently occurs early after transplantation. Their
long-term prevalences and their association with the risk of fractures are not
well kown. The objective of the present work was to determine the incidence
of osteopenia and osteoporosis and vertebral fractures in renal transplant
recipients with stable graft function and with a follow-up of at least 10 years.
Patients and methods: 84 renal transplant recipients, 49 male and 35 female,
were included in the study. The mean age was 42.5±12.6 years and the followup was 131±20 months (range 120-150 months). Initial immunosuppression
consisted of cyclosporine in double or triple therapy. Measurements of
bone mass density (BMD) were done by dual-energy X-ray absorptiometry
(DEXA). The assessment of vertebral fractures was performed by conventional
radiography using a semiquantitative technique.
Results: Serum creatinine at the time of the study was 1.7±0.5 mg/dl (range
0.9-3.4), BMD at lumbar spine 0.863± 0.122 g/cm2, T-score -1.90±1.14 and
Z-score -1.11±1.13. According to the WHO classification: 23 patients (27.4%)
had osteoporosis (T score <-2.5), 43 patients (51.2%) had osteopenia (T
score >-2.5 and <-1) and 17 patients (20.2%) were normal. BMD was better
preserved at femoral neck: 37 patients (44.0%) had normal BMD; 37 (44.0%)
had osteopenia and 10 (11.9%) osteoporosis. When analyzed together, patients
with osteoporosis or osteopenia were older at the time of transplant (37.5±11.7
vs 43.6±12.7; p=0.061) and had lower body weight (78.6±16.9 vs 71.3±13.4 kg;
p=0.053). There were no differences in age, sex distribution, time on dialysis,
iPTH, calcidiol and calcitriol blood levels, or other biochemical parameters.
Vertebral fractures (mostly mild vertebral deformities) were observed in 69.6%
of patients with osteoporosis, in 55.2% of patients with osteopenia and in
52.9% of patients with normal lumbar spine BMD. Peripheral fractures were
more common in patients with osteoporosis (p=0.053)
Conclusions: Osteoporosis or osteopenia were present in about 80% of
long-term renal transplant recipients. Lumbar spine BMD osteoporosis was
associated with peripheral fractures. However, mild vertebral deformities were
not associated with the presence of osteopenia or osteoporosis. The significance
of mild vertebral deformities has to be elucidated.

POSTER BOARD NUMBER P4 – 149
2099 THE IMPACT OF LOW CYCLOSPORINE DOSE
ASSOCIATED WITH EVEROLIMUS IN BONE LOSS AFTER
KIDNEY TRANSPLANTATION
R. Marcén1, C. Caballero2, J. Pascual1, J.J. Villafruela1, A. Fernandez1,
J.L. Teruel1, F.J. Burgos3, J. Ortuño1
1
Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal
University Hospital – Nuclear Medicine, 3Ramón Y Cajal University Hospital
– Urology
Background: Bone loss is a common complication after renal transplantation. It
has been associated with immunosuppression with steroids and anticalcineurin
inhibitors. There are no data about the effects of sirolimus and everolimus on
bone mineral density (BMD) in renal transplant recipients. It has been postulated
that these agents could have a sparing effect on bone loss. The purpose of the
present study was to prospectively investigate the impact of treatment with
everolimus and low dose cyclosporine in BMD after renal transplantion.
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Patients and methods: 15 patients, 6 males and 9 females with a mean age of
50.5±13.5 years and on treatment with cyclosporine, everolimus (1.5 or 3 mg/
day) and prednisone (CsA-EVE) were included in the study. The group was
compared with another 15 renal transplant recipients transplanted immediately
before and treated with tacrolimus, mycophenolate mofetil and prednisone
(TAC-MMF). Measurements of BMD were done by dual-energy X-ray
absortiometry (DEXA) at the lumbar vertebral bodies L2-L4 and in the right
femoral neck at the time of transplant and at 1 year..
Results: In CsA-EVE patients, lumbar spine BMD decreased from
0.860±0.201 g/cm2 at baseline to 0.822±0.199 g/cm2 at 1 year (p<0.05).
Femoral neck BMD slightly increased, it was 0.800±0.239 g/cm2 at baseline
and 0.787±0.179 g/cm2 at 1 year (NS). There was a tendency to higher bone
loss with the higher everolimus dose. On the contrary, lumbar spine BMD
did not significantly change in recipients on TAC-MMF, lumbar spine BMD
at baseline was 0.980±0.150 g/cm2 and 0.959±0.119 at 1 year. Femoral
neck BMD increased from 0.825±0.199 at baseline to 0.866±0.166 g/cm2
at 1 year. There were no differences between the groups in age at transplant,
sex distribution, number of post-menopausal women, time on dialysis, body
mass index at transplant, graft function at 12 months (SCr 1.4±0.3 mg/dl in
TAC-MMF vs 1.6±0.7 mg/dl in CsA-Eve; NS), iPTH levels at the time of
transplant and at 12 months.
Conclusions: Our findings do not support the hypothesis that immunosuppression
with everolimus could have bone-sparing effects. But the number of patients is
too small to draw definitive conclusions.

POSTER BOARD NUMBER P4 – 150
2100 ANEMIA IN KIDNEY TRANSPLANTED PATIENTS.
PREVALENCE AND RISK FACTORS.
R. Marcén1, B. Ponte1, N. Rodriguez1, A. Fernandez1, J. Pascual1,
J.J. Villafruela1, J.L. Teruel1, F.J. Burgos2, J. Ortuño1
1
Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal
University Hospital – Urology
Background: Anemia after kidney transplantation is a common complication
in the first post-operative months and when graft function declines. It has been
associated with adverse effects on patient and graft outcomes. Furthermore, the
target hemoglobin levels recommended by the transplant clinical guidelines is
not generally achieved. The purpose of the present study was to investigate the
prevalence of anemia, the risk factors associated with its development and the
adequacy of its treatment in a cohort of patients with funcioning grafts.
Patients and methods: 555 patients, 328 men and 228 women with a mean
age at transplant of 45.9±14.6 years were included in a cross-sectional study.
Anemia was defined as a serum hemoglobin (Hb) £ 13 g/dl in men and £ 12 g/
dl in women.
Results: The mean Hb was 13.5±1.7 g/dl, serum ferritin 153±185 ng/dl
(41.4% <100 ng/ml) and the estimated glomerular filtration rate (eGFR) by
the abreviated MDRD equation 47.3±18.7 ml/min/1.72 m2. A total of 157
patients had anemia (28.3%): mild 17.6%, moderate 6.7% and severe 4.0%.
In the univariate analysis, Hb levels correlated with eGFR (r=0.44; p=0.000)
and seroalbumin (r=0.29; p=0.000). Anemia was more common in the 179
patients on treatment with angiotensin converting enzyme inhibitors (ACEI)
or with angiotensin II receptor antagonists (ARA): 38% vs 24% (p=0.001).
The multivariate analysis showed the same risk factors observed in the
univariate analysis. Anemia was negatively associated with eGFR (OR=0.96;
CI95% 0.94-0.97; p=0.000), serum albumin levels (OR=0.19; CI 95%
0.09-0.50; p=0.000) and with the treatment with ACEI or ARA (OR=1.65;
CI 95% 1.04-2.62; p=0.033). Anemia was not related to sex, serum ferritin
levels or immunosuppressant agents. About 27% of anemic patients and 41%
of those with Hb<11 g/dl were on treatment with erythropoiesis-stimulating
agents.
Conclusions: Anemia was common after transplantation and some patients
were not adequately treated. The factors associated with this complication
were graft function, protein/energy malnutrition or chronic inflammation and
antihypertensive agents.

POSTER BOARD NUMBER P4 – 151
2101 POST RENAL TRANSPLANT ERYTHROCYTOSIS –
SINGLE CENTER INDIAN EXPERIENCE.
R. Balasubramaniyam, J. Das, N. Soosairaj, S. Das
KG Hospital and Post Graduate Medical Institute
Aim: To evaluate the incidence, presentation and the outcome of ‘post renal
transplantation erythrocytosis’ among our transplant recipients.
Materials and Methods: Patients who underwent renal transplantation in our
center from July 1999 to Jan 2008 were retrospectively evaluated. The pre and
post transplantation Hemoglobin, Erythropoietin usage, graft function, timing
of the erythrocytosis, treatment and the outcome were analyzed. Persistent
elevation of Hematocrit more than 51% was defined as ‘post transplantation
erythrocytosis’.
Results: Total number of patients was 157 (M: F = 129: 28). 150 patients
underwent live related renal transplantation and 7 were cadaver transplant
recipients. 85 patients (54%) received Erythropoietin on dialysis, though 75%
inadequately. (Due to financial constrains).
Pre transplant hemoglobin was < 6 gms% in 20 patients (12.7%), between 6-8
gms% in 71 patients (45.2%), 8 – 10 gms% in 49 patients (31.2%) between 10 –
12 gms% in 14 patient’s (9%) and > 12 gms% in 3 patients (1.9%). 13 patients
smoked prior to their transplantation and none post transplantation. Native
kidneys were preserved in 154 patients and 3 patients with massive polycystic
kidneys underwent bilateral native nephrectomy. 110 patients had functioning
grafts and 37 had graft dysfunction/loss at the end of the study period.
Total number of patients with post transplant erythrocytosis were 13 patients
(8.2%). There were 12 men and 1 woman of which 7 had used Erythropoietin
pre transplant. 9 patients developed erythrocytosis within the first year, 3 in
the second year and 1 patient in the third year after transplantation. 1 patient
was symptomatic and in others erythrocytosis was detected on routine testing.
All patients had normal graft function when they had erythrocytosis. All of
them were treated with ARB’s and theophylline. One patient with symptomatic
erythrocytosis underwent venesection.
11 patients responded to therapy and 2 patients who developed erythrocytosis
recently have persistent elevation of hemoglobin at the end of the study
period.
Conclusions: Our incidence of post renal transplantation erythrocytosis is 8.2%.
Majority were asymptomatic and showed good response to treatment. Most of
them were men and had good graft function. Low pre transplant hemoglobin,
less of smoking and inadequate pre transplant erythropoietin usage are the
possible reasons for lower incidence of erythrocytosis in our experience.

POSTER BOARD NUMBER P4 – 152
2102 ANEMIA AFTER KIDNEY TRANSPLANTATION: ROLE
OF HEPCIDIN, ERYTHROPOIETIN, IRON STATUS AND RENAL
FUNCTION.
G.F. Hillebrand, U. Schoenermarck, M. Wessely, K. Kehl, T. Wendler,
B. Hartmann, W. Samtleben
Nephrology Division, Department I of Internal Medicine, University Hospital
Munich – Großhadern
Aim: Anemia remains prevalent after successful kidney transplantation. Aim
of the study was to determine the relation between the occurrance of posttransplant anemia and hepcidin, erythropoietin, iron status and renal graft
function.
Patients and methods: In a cross-sectional study 102 kidney transplant
recipients were investigated (70 men, 32 women, in average 17 months after
kidney transplantation). Serum pro-hepcidin and erythropoietin were measured
using commercially available kits. Creatinine and parameters of iron status
were analysed by routine clinical laboratory methods. 20 healthy controls with
normal renal function were analysed as control group.
Results: Anemia was found in >50% of kidney transplant recipients, although
mostly mild (hemoglobin in average 12,4 g/dl). There was a significant negative
correlation between haemoglobin and creatinine (r = -0,44, p<0,001), ferritin (r
= -0,34, p<0,001), ferritin index (r = -0,43, p<0,001) and erythropoietin (-0,24,
p<0,03). Serum pro-hepcidin was not increased in kidney transplant patients
as compared to healthy controls (96 vs. 115 ng/ml). Pro-hepcidin correlated
significantly with ferritin (r = 0,268, p=0,007), but not with hemoglobin or

689

THURSDAY

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Poster Abstracts

renal graft function. The type of immunosuppression had no significant effect
on levels of hemoglobin or pro-hepcidin. Patients with anemia as compared
to patients without anemia had a significantly higher degree of renal graft
dysfunction (creatinine 2,3 vs. 1,4 mg/dl), a higher ferritin value (798 vs. 257
ng/ml) and a lower ferritin index (8,9 vs. 12,3).
Conclusions: Anemia is a frequent finding in kidney transplant recipients. In
this study the presence of anemia was associated with impaired renal function
and higher levels of ferritin, possibly reflecting a low-grade inflammatory state.
There was no correlation between hepcidin and the degree of anemia or the
type of immunosuppression.

POSTER BOARD NUMBER P4 – 153
2103 ANEMIA AFTER RENAL TRANSPLANTATION – AN
UNDERESTIMATED PROBLEM?
U. Ott1, M. Busch1, T. Steiner2, G. Wolf1
Department of Internal Medicine III, 2Department of Urology
Anemia is an underestimated disease after renal transplantation. In end stage
renal disease anemia is known to be an independent risk factor for cardiovascular
disease and death. However, data about anemia after renal transplantation
are rare.
We investigated 208 stable patients who underwent first renal transplantation
during 2000 and 2006. Patients were 66 women and 142 men. Immunosuppression
was performed with Cyclosporin A and Mycophenolate Mofetil, Tacrolimus
and Mycophenolate Mofetil or Rapamycin with Mycophenolate Mofetil. About
one third of the patients were treated with corticosteroids.
37.5% (78 patients) had anemia at time of investigation. 8.6% of the patients
had severe anemia with hemoglobin level < 6.8 mmo/l in men and < 6.2 mmol/l
in women. In 8.2% of the cases we found moderate anemia (hemoglobin 6.8
– 7.4 mmol/l in men and 6.2 – 6.8 mmol/l in women). 20.6% (29 men and 14
women) had mild anemia with hemoglobin level <8 mmol/l in men and less
than 7.45 mmol/l in women. 55.5% of patients with severe anemia, 53% of
patients with moderate and 11.6% of patients with mild anemia were treated
with erythropoietin. We found a significant correlation with the glomerular
filtration rate calculated by MDRD formula (p < 0.05). Of the patients with a
serum creatinine level > 200 μmol/l, 63% were anemic, compared with 22%
of those with a serum creatinine level < 200 μmol/l (p < 0.05). No correlation
was found to immunosuppressive medication or to the treatment with ACE
inhibitors and angiotensin II receptor antagonists. Iron deficiency may be
another reason.
The prevalence of anemia after renal transplantation is high. Most patients
suffer from mild anemia. We found an unexpectedly high incidence of anemia
in patients with functioning graft, more than one third of all patients are anemic.
Anemia as a risk factor for cardiovascular events, mortality and graft failure
should be treated more carefully in patients after renal transplantation.

1
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2104 EFFECTIVE PROPHYLAXIS OR TREATMENT WITH
BISPHOSPHONATES IN SOLID ORGAN RECIPIENTS
NON-INVASIVELY MONITORED WITH BONE TURNOVER
MARKERS

THURSDAY

M. Durlik1, E. Nowacka-Cieciura1, A. Sadowska1, T. Cieciura1, T.
Bczkowska1,
S. Nazarewski2, A. Chmura3
1
Transplantation Medicine and Nephrology Dept., Medical University of
Warsaw, 2General, Vascular and Transplantation Surgery, Medical University
of Warsaw, 3General and Transplantation Surgery, Medical University of
Warsaw
Reduced bone density and fractures are common problem before and after
solid organ transplantation (Tx). Short courses of bisphosphonates (bisph)
are proposed as prophylaxis early after Tx or as the treatment of established
osteoporosis. The aim of the study was to define the risk factors for reduced
bone mineral density (BMD) in organ transplant recipients, and to evaluate the
effects of bisph therapy on BMD and bone turnover markers. Methods: This
is a pool analysis of 125 kidney, liver or simultaneous pancreas and kidney
(SPK) recipients, 61% of whom (group Bi, n=76) received bisph (alendronate
or risedronate) therapy as: 1) prophylaxis in case of baseline osteopenia or
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osteoporosis early after Tx, n=54 (40 kidney, 14 liver Tx) or 2) treatment of
established osteoporosis in the late period after Tx, n=22 (8 SPK, 14 kidney Tx).
Group C (n=49) with normal T-score in the early period after Tx (21 kidney, 1
SPK, 14 liver transplant recipients) and with osteopenia or normal T-score late
after Tx (13 SPK) served as control. The recipients received corticosteroids,
calcineurine inhibitors and in most cases mycophenolate mofetil as well as
alphacalcidiol. BMD (DXA) and bone turnover markers (serum bone alkaline
phosphatase – BAP, osteocalcine – OC, active isoform 5b of the tartrateresistant acid phosphatase 5b – TRACP5b, pyridinoline crosslinks – PYD, and
urine deoxypyridinoline crosslinks -DPD/creat, were evaluated. The therapy
lasted for 13,4 months. Results: The groups did not differ according to age,
gender, menopause frequency, and the time after Tx. The number of patients
with second or third transplant was significantly higher in group Bi than in
control group. The patients in group Bi had lower BMI at baseline and in the end
of the treatment compared to group C. The time on dialysis in renal recipients
was longer in group Bi than in control group. In group Bi mean lumbar T score
improved from (-)2,42±1,04 to (-)2,08±1,04 (p<0,05). The relative changes in
lumbar BMD under bisph therapy and in control group were: (+)5,0±10,4%
and (-)2,4±7,3%, respectively, p<0001. Baseline BAP, OC and TRACP5b were
significantly higher in Bi than in C group. In general, baseline BAP, OC and
DPD/creat negatively correlated with baseline BMD. Significant decrease in
OC, TRACP5b and PYD was observed under bisph therapy. The treatment was
well tolerated, GFR was >60 ml/min. Conclusion: Low BMI, retransplantation,
and – in renal Tx – long time on dialysis, are risk factors for posttransplant bone
disease. Bisph prevent early bone loss in organ transplant recipients as well as
effectively treat established osteoporosis in this population. The higher baseline
bone turnover markers in patients with lower BMD suggest the prevalence of
high turnover bone disease in these patients. The increase of BMD after bisph
is paralleled by the fall in bone markers. '

CONCURRENT ORAL SESSION 143: LONG-TERM OUTCOMES
– GENERAL/MIXED THEME
POSTER BOARD NUMBER P4 – 155
2105 KIDNEY GRAFT SURVIVAL RATE DON’T IMPROVE BY
ERA: THE IMPACT OF FACTOR “AGE”
M. Salvadori, E. Bertoni
Renal Unit Careggi University Hospital
Accordin registry data on kidney transplantation, graft survival rate improves
because of rejection rate reduction but is impaired by the increasing number
of older donors and recipients. As the age of both donors and recipients
dramatically increaed in our country,aim of this study was to verify in our
center how the graft survival rate (GSR) changed by era.
We compared both the 5 year actual GSR and the 5-year death censored
GSR of 89 recipients transplanted in 1991-1995 (period A) with 221
recipients transplanted in 1996-2000 (period B). Due to the introduction of
immunosuppressants such as MMF, Neoral and IL-2R inhibitors, we expected
an improvement in GSR in period B. The two period rejection rates and the
incidence of donors and recipients >50 years were considered. Kaplan-Meier
Estimates and Log-Rank test were performed by the Collaborative Transplant
Study (CTS) whom our data had been regularly sent to.
Period B 5-year GSR was lower with respect to period A (76.3% vs 82%).
The death censored GSR was similar (87.1% vs 87.5%). The period B acute
rejection incidence was 18% vs 40% of period A (p<0.001). Both overall donor
and recipient age had the highest impact on 5 year GSR: for donor age 21-50 yrs
86.2% vs 65.7% for donor age >50 yrs (p<0.0001). Similar effect was observed
for recipient age: 84.1% for age 21-50 vs 68% for age >50 yrs (p=0.0023). In
period A donors >50yrs were 23.6% vs 50.2% in period B (p<0.001). Similarly
period A recipients >50 were 35.9% vs 42.9% in period B (p<0.01). 5 year GSR
of recipients with donor <50 yrs improved in period B with respect to period
A (89.2% vs 87.2%). Similarly the 5-year GSR of recipients <50yrs improved
(85.2% vs 81.5%). Considering the death censored 5-year GSR for period B
with respect to period A we observed a significant improvement either for
donor >50 yrs (82.5% vs 65.8%) and for recipient >50 yrs (90.2% vs 81.2%).
Kidney GSR of patients transplanted in 1991-1995 was higher with respect
to 1996-2000. This data disagree with the GSR expected by the reduction of
1-year rejection rate due to immunosuppressants. Expanded donor criteria can
account for such discrepancy. Indeed in period B with had more donor and
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recipients >50 years. Most of graft failure were due to death with function, but
also a poorer quality of kidneys accounts for this phenomenon. Indeed looking
for GSR of patients <50 years we observed an improvement as expected.

POSTER BOARD NUMBER P4 – 156
2106 EVALUATION OF RENAL TRANSPLANT RECIPIENT IN
A SINGLE CENTRE OF BANGLADESH.
S. Islam1, R. Alam1, H. Rahman1, H.U. Rashid1, F. Khan2, N.U. Chowdhury3
Bangabandhu Sheikh Mujib Medical University, 2National Institute of kidney
diseases and urology, 3Dhaka Medical College Hospital
Renal transplantation (Tx) is the treatment of choice for most patients with end
stage renal disease. In our centre renal Tx started and continue from 1988, but
post Tx patient evaluation has been not well established. In this study we tried
to establish the evaluation of post transplant recipient
Total 214 ESRD patients were transplanted from July 1995 to December 2005.
Maximum number of Tx were done (33) on 2002 & minimum (7) on 1995. All
patients were live related donors, mothers were the major donors which was
about 33% followed by brothers (29%), sisters (16%) and fathers about 14%.
Among the transplanted patients 138 (64.48%) were survivors, 19 (8.87%)
under went graft failure and returned on dialysis and 57 (26.73%) died.
Among the survived patients, 115 Tx recipients were evaluated and revealed
that, 83(72.17%) developed HTN, 32 (27.83%) chest infection (specific and
non-specific), 29 (25.22%) graft dysfunction, 29 (25.22%) UTI, 22 (19.19%)
diabetes, 18 (15.65%) CMV infection, 9 (7.83%) CVD, & 9 (7.83%) having
post Tx proteinuria.
Over all graft survival in first year was 85%, third year 75%, fifth year 65% &
tenth year 50%
In conclusion, results of renal Tx in this center is not enough. So to increase
number of transplantation needed to overcome the existing live related donor
scarcity as well as increased number of transplant centers in our country.
1
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2107 A NATIONAL SCREENING STUDY FOR ANDERSONFABRY DISEASE AMONG MALE KIDNEY TRANSPLANT
RECIPIENTS
J. Kleinert1, P. Kotanko2, M. Spada3, S. Pagliardini4, E. Paschke5,
T. Voigtländer6, C. Schwarz7, H. Holzer8, M. Födinger9,
G. Sunder-Plassmann1
1
Division of Nephrology and Dialysis, Department of Medicine III, Medical
University Vienna, 2Renal Research Institute, New York, USA, 3Department
of Pediatrics, University of Torino, Italy, 4Newborn Screening Unit, Regina
Margherita Children’s Hospital, Torino, Italy, 5Laboratory of Metabolic
Diseases, Department of Pediatrics, Medical University Graz, Austria,
6
Institute of Neurology, Medical University Vienna, Austria, 7Krankenhaus
der Elisabethinen, Linz, Austria, 8 Division of Nephrology, Department of
Medicine, Medical University Graz, Austria, 9 Clinical Institute of Medical
and Chemical Laboratory Diagnostics, Medical University Vienna, Austria
Anderson-Fabry disease is a rare X-linked lysosomal storage disorder due to the
deficiency of alfa-galactosidase A (AGAL), resulting in cellular accumulation
of glycosphingolipids. Typical early symptoms include pain in the legs, cold
intolerance, hypohidrosis and gastrointestinal complaints during childhood.
The progression of the disease leads to cardiac, renal, and central nervous
system complications, as well as premature demise.
The incidence of Anderson-Fabry disease is reported between 1 in 117000 and 1
in 240000 life births. However, recent studies suggest a much higher incidence
among male newborns. Although the awareness for this rare disease has
increased recently, the diagnosis is often delayed for many years or even missed.
In this context, studies among patients with cardiomyopathy, juvenile stroke,
or chronic kidney disease on dialysis revealed a surprisingly high prevalence
of Anderson-Fabry disease among these high-risk groups. For example, casefinding studies of dialysis patients revealed a 10-times higher prevalence of
Anderson-Fabry disease as compared to European dialysis registry data.
We therefore hypothesized that Anderson-Fabry disease is under-recognized in
prevalent male kidney transplant recipients. To test this hypothesis, we initiated
a nationwide case-finding study for Anderson-Fabry disease in Austria. This
nation-wide study in Austria enrolled 1306 patients (~65% of all kidney

transplanted males) from 30 kidney centers. AGAL activity was determined
from filter paper dried blood spots by a fluorescence assay. A positive screening
test was defined by an AGAL activity below 1.5 nmol/h/mL. In patients with
a positive blood spot-screening test, AGAL activity was re-examined in
peripheral blood leukocytes. Genetic testing for mutations in the GLA gene was
done by sequencing to confirm the diagnosis of Anderson-Fabry disease. Two
previously not recognized cases with Anderson-Fabry disease were identified.
Together with three already known renal allograft recipients with AndersonFabry disease, 5 out of the 1306 patients enrolled in this study suffered from
Anderson-Fabry disease (prevalence of 0.383%; 1 per 261 patients). Our study
is the first showing that a diagnosis of Anderson-Fabry disease can be missed
even in patients who undergo kidney transplantation. Case-finding strategies
may be considered a useful tool for diagnosis of this rare disease that may be
somewhat more prevalent among kidney transplant recipients as compared to
dialysis populations.

POSTER BOARD NUMBER P4 – 158
2108 A CASE OF GUILLAIN BARRE SYNDROME IN A
KIDNEY TRANSPLANTED PATIENT TREATED WITH
IMMUNOSUPPRESSIVE AGENTS: IS THE CAUSE DUE TO
DRUG COMPLICATIONS OR AN OPPORTUNISTIC VIRAL
INFECTION?
S. Lee2, J.H. Shin1, H.K. Song1, W. Byon2, K.J. Yoon2, D.J. Kim2,
S.J. Hyun2
1
Dept. of Neurology, Hallym Univ. College of Mediciene, 2Dept. of Surgery,
Hallym Univ. College of Mediciene
Backgrounds: The Guillain-Barre syndrome(GBS) has not only been
commonly reported in viral infection with upper respiratory symptoms but also
rarely in organ transplanted patients treated with immunosuppressive agents,
especially cyclosporine.
Case: 47 year old male who had been taking immunosuppressive agents
after kidney transplantation 6 years ago was admitted for weakness of the
upper and lower extremities and painful discomfort on both calves starting
from 4 days before admission. He had no previous infection history but
immunosuppressive agents had been changed from cyclosporine to tacrolimus
1 month prior to admission. On neurologic examination, he showed ascending
quadriparesis and absence of deep tendon reflexes of all extremities. Despite
the lack of albuminocytologic disproportion in the cerebrospinal fluid(CSF),
conduction block and decreased compound muscle action potential(CMAP)
were revealed on nerve conduction study. After starting continuous infusion
of Immunoglobulin G (400mg/kg) intravenously for 7 days, he showed
improvement in motor weakness and pain.
Conclusion: Organ transplanted patients have more chance of opportunistic
viral infection owing to immunosuppressive agents. Preceding viral infection
may precipitate GBS or correlate with it. Furthermore, immunosuppressive
agents may induce the Guillain-Barre-like syndrome as an acute drug
complication in itself.

POSTER BOARD NUMBER P4 – 159
2109 EFFECT OF RENAL TRANSPLANTATION ON SPERM
QUALITY AND SEX HORMONES LEVEL
G. Pourmand, A.R. Mehrsai, M. Taherimahmoudi, M.R. Nikoobakht
Urology Research Center,Tehran University of Medical Sciences
Objectives: we examined the effect of successful renal transplantation on
semen parameters, sexual function and sex hormones profile in a clinical trial.
Material and Methods: A total of 30 patients on hemodyalysis underwent
renal transplantation. Preoperative and postoperative sperm density, motility,
and morphology were analyzed. Preoperative follicle-stimulating hormone
(FSH), luteinizing hormone (LH), prolactin and testostrone levels were
measured and compared to six months postoperative results. Sexual function
was measured before and after transplantation using an abbreviated version of
the International Index of Erectile Function (IIEF), with a successful outcome
defined as a level of satisfaction of 4 or 5 on a 5-point scale. The paired-samples
T-test was used to measure level of statically significance in all analysis.
Results: We found that sperm motility improved significantly (p<0.05)
without concomitant significant changes in morphology and density (p>0.05).
Testostrone level increased and FSH, LH and prolactin decreased significantly
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(p<0.05) after renal transplantation. Of 30 patients 16 were impotent before
operation and filled the questionnaire. There was a significant positive correlation
between baseline sexual function and postoperative sexual function.
Conclusion: Although sperm morphology and density did not improve after
renal transplantation, there was highly significant changes in motility of sperms.
Hormonal changes in hemodyalysis patients improve after transplantation and
return to near normal. Sexual function is also significantly improved. Future
studies need to confirm these data.

POSTER BOARD NUMBER P4 – 160
2110 OUTCOME OF 18 CASES OF SIMULTANEOUS KIDNEY
AND DONOR SPECIFIC BONE MARROW TRANSPLANTATION
A. Seraji, G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Objectives: To evaluate the effect of simultaneous donor specific bone marrow
transplantation on patient survival.
Materials & Methods: Since 1997, 81 patients received renal transplantation
in our center and were followed up for presence and magnitude of
michrochimerism using DRB1 region of HLA class by PCR. 18 of these
patients were selected to receive donor’s bone marrow. The bone marrow was
extracted from iliac crest of the donor just prior to nephrectomy. The cell count
was determined and enough volume containing 3-5 million celis per Kg weight
of recipient was ingected just after the transplantation. The rest of the patients
were regarded as control group. The blood sample of recipients were taken
pre operatively and one week, 1, 3, 6, 12, 18, 24 months after operation.The
blood sample donor were also taken before the operation. The samples were
tested for urea, creatinine, sodium, potasium, calcium, phospher, blood cell
count hemogiobin and cyclosporine A levels. Samples prior to operation were
also tested for DRB1 alleles in both donor and recipients by PCR.Afterward the
recipients samples taken at above mentioned intervals were tested for presence
and persistence of donors DRB1 alleles.
Results: Our results indicates that creatinine levels at all intervals does not
differ significantly in DMBT and control group. The rate of acute rejection is,
however, lower in patients who received DMBT as compared to the control
group (one case, 5.6% and 6 cases, 9.5% respectively). In control group 4 of
the patients with acute rejection episode responded to therapy. The chronic
rejection episodes were also lower in DBMT group (1 case, 5.5%). There were
7 cases of chronic rejection (11.1%) in control group. The graft survival rate
was 94.4% in DBMT group and 87.3% in control group.
Conclusion: Our results shows that simultaneous DBMT and renal
transplantation may have some positive effect on graft and patient’s survival.

failure with acute or hyper-acute rejection or bleeding, the nephrectomy was
associated with an increased risk of death. Except 12 cases for 2nd kidney
transplantation, the transplant nephrectomy was not common (5.6%), but the
number of transplant nephrectomy are gradually increasing in recent years
(prior 5 years: 13 cases, recent 5 years: 30 cases).

POSTER BOARD NUMBER P4 – 162
2112 A CASE OF SPINAL CORD COMPRESSION
COMPLICATING TERTIARY HYPERPARATHYROIDISM IN A
RENAL TRANSPLANT PATIENT
C. Milton, J Barbara
Department of Renal Medicine, Flinders Medical Centre
Introduction: Tertiary Hyperparathyroidism is commonly present in patients
with End Stage Kidney Failure (ESKF) who have a functioning renal allograft.
We describe renal osteodystrophy of the thoracic vertebrae leading to spinal
cord compression in a patient with a functioning
renal allograft. In addition, a reduction in glomerular filtration rate (GFR) was
observed in the renal allograft following parathryoidectomy.
Case Report: A thirty one year old male presented with severe thoracic
back pain and an unsteady gait four years after a renal allograft. He had
ESKF commencing peritoneal dialysis at age twenty three and three years
later had a deceased donor renal allograft. Renal allograft function has been
suboptimal with best post transplant creatinine of 226 micromoles/litre. Prior to
transplantation he had established secondary hyperparathyroidism with a PTH
of 174 picomoles/litre. Following transplantation the hyperparathyroidism
persisted with a PTH of 250 picomoles/litre.
At presentation, CT and MR imaging showed a lytic lesion in the twelfth
vertebral body with extradural extension and compression of the thecal sac.
Histopathology demonstrated a brown tumour. Subtotal parathyroidectomy
was performed 2 months post spinal decompression. Prior to this the creatinine
was stable at 274 micromoles/litre and post parathyroidectomy the baseline
creatinine increased to be 386 micromoles/litre 6 months later.
Conclusion: Tertiary Hyperparathyroidism is often present in patients with a
functioning renal allograft. Renal osteodystrophy of the vertebral bodies leading
to spinal cord compression is exceptionally rare in tertiary hyperparathyroidism.
Parathyroidectomy is often delayed in patients with ESKF who are likely to
receive a transplant in the near future as there is likely to be regression of
the hyperparathyroidism. In patients who require parathyroidectomy post renal
allograft there appears to be a risk of loss of GFR. This raises the question as
to whether parathyroidectomy, either surgical or medical, should be undertaken
routinely on patients with secondary hyperparathyroidism who are likely to
have a renal allograft.

POSTER BOARD NUMBER P4 – 161
2111 TRANSPLANT NEPHRECTOMY DURING LAST 10
YEARS IN CUMC

THURSDAY

I.S. Moon1, S.C. Park1, Y.S. Won1, J.I. Kim1, Y.B. Koh2
1
The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2JungAng
University Medical Center
The transplant nephrectomy was performed in cases of nonfunctioning grafts
due to various causes. There are increased number of kidney transplantations
in the worldwide, and there are also increasing numbers of allograft failures.
But the management of the failed allograft that is not immediately symptomatic
remains controversial. The transplant nephrectomy was more common nearly
twice in patients with early compared to late graft failure. Some reports have
advocated against the removal of the asymptomatic failed allograft due to the
morbidity and mortality associated with transplant nephrectomy. Other reports
have advocated that because of a source of sepsis or chronic inflammation of
failed allograft, it should be routinely removed. Our study was performed by
retrospective reviewing of medical data. Among 555 kidney transplant patients
for 10 years between Jan 1997 and Nov 2007, there were 43 cases (7.7%)
of transplant graft nephrectomy. The duration of interval between kidney
transplantation and transplant nephrectomy ranges from 1 day to 168 months
with mean 26.8 months. The main reasons of transplant nephrectomy were
acute or hyper-acute rejection with anemia within 1 month (14 cases (32.6%)),
for the space of 2nd kidney transplantation (12 cases (27.9%)), infection signs
like pain, fever and pyuria (9 cases (20.9%)). In patients with early graft
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2113 LONG TERM EXPERIENCE WITH SIROLIMUS IN
KIDNEY TRANSPLANTATION – WHAT TO DO WHEN IT
FAILS?
J. Mayer1, F. Keller2, S. Kolodziej1, S. Stracke2
Viseral- & Transplantation Surgery, 2Nephrology
Little data exists on the long-term adherence to a proliferation signal inhibitor
(PSI) based immunosuppression after kidney transplantation (KTx). We
therefore retrospectively examined 90 patients that were switched from a CNIto a PSI- based immunosuppression in average 36.7 months after KTx (75 to
sirolimus and 15 to everolimus). Reasons for the replacement of sirolimus by
everolimus were unwanted side effects (acne, pneumonitis, proteinuria) or
patient incompliance.
Eleven of the 75 sirolimus patients (15%) were switched within an average
of 17 months, six to everolimus and five to CNIs. After re-introducing CNIs,
creatinine did not further increase but hemoglobine and cholesterine levels
improved. Replacing sirolimus with everolimus reduced triglyceride and
cholesterol blood levels but increased GOT, GPT and gGT levels. Patients that
remained on sirolimus throughout the observation period had a lower creatinine
and a better hemoglobine than those where sirolimus was later replaced.
Sirolimus- based immunsosuppression is tolerated in 85% of patients over more
than three years. The need for an unscheduled replacement of sirolimus is higher
in patients with a worse graft function at the introduction of a CNI free regimen.

1
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Replacing sirolimus by everolimus improves the blood lipid profile. A reintroduction
of CNIs does not further increase creatinine but improves hemoglobine. In
conclusion, nonadherence to a sirolimus based immunosuppression is rare and
sirolimus can safely be replaced by CNIs or everolimus.

POSTER BOARD NUMBER P4 – 164
2114 IS IT POSSIBLE TO REDUCE THE CARDIOVASCULAR
RISK THROUGH CALCINEURIN INHIBITORS (CNI) TO
SIROLIMUS CONVERSION IN RENAL TRANSPLANT?
R. Schiavelli, F. Margulis, C. Cuevas, R. Sabbatiello, M. Raño, D.D. Tullio,
M. Pattin
Hospital General De Agudos
Prevalence of cardiovascular disease in transplant patients is 5 fold increased
regarding general population and it is the most important cause of death with
functional graft. Hypertension and left ventricular hypertrophy are independent
risk factors of cardiovascular morbidity
Ambulatory blood pressure monitoring (ABPM) has shown a better correlation
with target organ damage than office blood pressure (O-BP)
Aim: To evaluate the evolution of hypertension and left ventricular mass index
after CNI to sirolimus retrospectively.
Methods: We evaluated 10 renal transplant patients (7M/3F), mean age 38,6
± 9 that were converted to sirolimus for different reasons (neoplasias, chronic
allograft nephropathy)
Before conversion, a 24-hour ABPM and a Trans-thoracic m-mode
echocardiograms (ATL ULTRAMARK) were performed and were repeated
20± 5 months after conversion.
ABPM was recorded noninvasively with an Accutracker II (Suntech Medical
Inc.) over 24 hs on a regular working day. We evaluated the 24 hs blood pressure
(24-BP), the awake blood pressure (AwBP) and asleep blood pressure (AsBP)
according to the awake/asleep report of each participant.
LV mass was calculated according to the Penn convention and corrected for
body surface area to produce the LV mass index (LVMI),
There were not any changes in antihypertensive treatment before and after
conversion.
Mann-Whitney test was used and P values < 0.05 was considered to be
statistically significant. Results are expressed as mean ± SD.
Results: There was a significant decrease in diastolic 24-BP (88 ± 4 vs. 83 ±
4 mmHg p<.001), diastolic AwBP (91 ± 5 vs. 88 ± 5 mmHg, p<.01), diastolic
AsBP 83 ± 6 vs. 74 ± 6 mmHg p<.003) and in the diastolic O-DBP (94 ± 7 vs.
85 ± 6 mmHg p<.007)
We also observed a significant decrease of LVMI (156 ± 41 vs. 125 ± 33 g/
m2 p<.04)
Conclusion: Study findings could explain a decrease in cardiovascular risk in
these patients.

POSTER BOARD NUMBER P4 – 165
2115 ANALYSIS OF POST RENAL TRANSPLANT MORTALITY
– A RETROSPECTIVE, SINGLE CENTER INDIAN STUDY.
R. Balasubramaniyam, J. Das, N. Soosai, S. Das
KG Hospital and Post Graduate Medical Institute
Background: Advances in immunosuppression have improved the short-term
survival after transplantation. Chronic graft loss secondary to ‘chronic allograft
nephropathy’ and mortality with functioning grafts contribute to major causes
of graft loss in the long term. Currently cardio vascular disease is the leading
cause of death in the developed countries in the post transplant period. Not
much data is available from the developing countries.
Aim: To retrospectively analyze the incidence, causes and the timing of post
renal transplant mortality in our renal transplant patients.
Materials and methods: Patients who underwent renal transplantation in our
hospital from July 1999 to Jan 2008 were retrospectively analyzed. All patients
were followed post transplantation and the causes of their death and the time of
death in relation to their transplantation were analyzed.
Results: Total number of renal transplantations done in this period was 157. (M:
F = 129: 28). 150 patients underwent live related renal transplantation and 7 were
cadaver transplant recipients. Follow-up varied from 2 months to 8 ½ years.

Basic renal diseases were chronic glomerulonephritis in 62, chronic tubulo
interstitial nephritis in 40, Diabetic nephropathy in 23, Hypertensive
nephrosclerosis in 20 and other causes in 12 patients.
34 patients died (21.6%) during the follow up period after transplantation.
Of these 19 patients 3 returned to dialysis and 16 patients (47%) died due to
chronic allograft nephropathy and inability to afford subsequent treatment is
the commonest cause of mortality seen in our population. The other causes of
mortality were sepsis in 6 (17.7%), Ischemic heart disease in 4 (11.8%), hepatic
failure in 4 (11.8%), suicide in 2 (5.9%), pancreatitis in 1 (2.9%) and cerebro
vascular disease in 1 patient (2.9%).
11 patients (32.3%) died in the first year after transplantation, 7 each in the
second and third year (20.5%), 3 patients (8.8%) in the fourth year and 6
patients (17.6%) died beyond the fifth year.
Conclusions: In our experience 21.6% died during the follow up after renal
transplantation. In contrast to the western world, where the commonest cause
of mortality is cardio vascular deaths, chronic graft loss and inability to afford
further treatment is the commonest cause in our population.

POSTER BOARD NUMBER P4 – 166
2116 CAPD IS A MORE SUITABLE DIALYSIS MODALITY
THAN HD FOR PATIENTS WHO WERE UNDERGOING KT: A
MATCHED CASE STUDY
D. Sirivongs, U. Toimamueang, C. Pongskul
Khon Kaen University, Faculty of Medicine
Objective: KT is the ideal therapeutic modality for ESRD patients. However
it was unclear whether a difference in dialysis modality could affect the KT
outcome. To evaluate the influence of dialysis modality on the outcome, the
study was performed.
Methods: Medical records of CAPD pts who were undergoing KT were
reviewed. By matching for age, gender, and timing of KT operation, KT
cases who were on HD before the operation were recruited in the ratio 2:1.
Clinical data of both groups were analyzed. Analyses were performed with the
SPSS statistical data program. Results: Since 1990, 307 KT operations were
performed in our hospital. Twenty-nine KT adult pts (age 45.66+5.37 yr) who
had been treated with CAPD (CAPDgr.) for 4-107 mo. (39.79+23.30 mo.) were
compared with 58 KT pts (age 45.31+5.25 yr)who had been treated with HD
(HDgr.) for 2 110 mo. 32.59+26.01 mo.). Regarding the immunosuppressive
agents, 2-drug regimen was administered for living related KT and 3- drug
regimen for cadaveric KT in both groups. The mean hospitalized duration in
CAPDgr. Vs HDgr. was 37.04+31.77 days Vs 32.59+23.30 days. Delayed graft
function was found in 13.8% of CAPDgr. compared to 36.2% of HDgr. (p =
0.043). Acute allograft rejection during post-operation period was comparable
between both groups (2 episodes Vs 3 episodes). Graft loss was found in
3.4% of CAPDgr. compared to 15.5% of HDgr. (p=0.51). Even actuarial graft
survival compared between CAPDgr. with HDgr. was 89% Vs 91% at one
year and was 48% Vs 44.83% at five years, there was no significant difference
between the two groups (p = 0.703).
Conclusion: Even overall outcome of both groups is quite comparable, but
higher rate of DGF and graft loss is seen in HD group. Therefore CAPD
might be a more suitable modality than HD for patients awaiting kidney
transplantation.

POSTER BOARD NUMBER P4 – 167
2117 FACTORS INFLUENCING LONG TERM OUTCOME OF
KIDNEY TRANSPLANTATION IN A THAI MEDICAL CENTER.
D. Sirivongs, U. Toimamueang, C. Pongskul, S. Reungjui
Khon Kaen University, Faculty of Medicine
Introduction: To analyze outcome and to find the factors that influence survival
in kidney transplantation recipients, we conducted an analytic retrospective
study.
Methods: A retrospective analysis was undertaken on records of all patients
who underwent transplantation from 1990 to 2007. Survival studies were
calculated using the Kaplan-Meier method. The outcome endpoints were death,
redialysis, lost to follow-up, and study termination.
Results: Eighty-five living-related KT [LRKT] and 205 cadaveric KT
[CDKT]) were recruited. Age of patients was 40.26 + 10.21 years (range,
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15-60 years). Male to female ratio was 1.8:1. The mean waiting time was 24.45
+ 26.4 months. Underlying DM was in 17.7%. Mean survival of CDKT was
46.56 +2.13 mo. compared to 58.27 + 5.75 mo. of LRKT. The 50% survival
rate of CDKT (47.6 mo.) was slightly higher than that of LRKT(49.6 mo.) (p
= 0.0019). The following factors were found to significant negative influence
on graft survival: low economical status (p=0.0000), ATN (p=0.000), DGF
(p=0.0003), hemodialysis modality (p=0.0175), but PTDM showed positive
influence (p=0.014). Surprisingly, patients who received cyclosporine (CSA),
prednisone (Pred), and azathioprine (Aza) showed better graft survival than
ones on CSA, Pred, and mycophenolate mofetil (MMF) (p = 0.0000).
Conclusion: CDKT was showed better graft survival than LRKT. Factors that
had negative influence on survival were low economical status, ATN, DGF, and
HD modality, but PTDM showed the opposite influence. Immunosuppressive
regimen with Aza showed better survival than the one with MMF.

sepsis and aneurysmal dilatation. Of the 48 patients returned to alternative
RRT, 29 (60%) demonstrated a patent, useable fistula and were all able to
restart haemodialysis without disruption. Of the remaining 19 (40%) patients,
17 (35%) of them required creation of a new VA and 2 patients opted for
peritoneal dialysis. The distribution by anatomical site of fistulae in use prior
to transplantation was as follows: autogenous (wrist: 162; forearm: 79; and
cubital fossa: 94) and PTFE grafts (groin: 11; forearm: 14 and upper arm: 3).
Of these 56, 15, 37, 6, 4 and 1 accesses respectively were lost during the life
of the renal allograft. The median time to failure of the VA following RT was
651 days (range 0-4378 days).
Conclusions: Our data shows that majority of patients with failed RTs did
have functioning VAs despite no active surveillance programme and majority
of patients did not have significant morbidity related to the presence of VAs
after RT warranting surgical intervention. Therefore we do not recommend
prophylactic ligation of VAs following renal transplantation.

POSTER BOARD NUMBER P4 – 168
2118 LONG KIDNEY GRAFT SURVIVAL FROM
ANENCEPHALIC DONOR: CASE REPORT
C. Gracida1, R. Espinoza2, J. Cancino3, A. Ibarra4
Transplant Unit, Hospital De Especialidades CMN SXXI, 2Transplant Unit,
Hospital De Especialidades CMN SXXI, 3Transplant Unit, Hospital De
Especialidades CMN SXXI, 4Transplant Unit, Hospital De Especialidades
CMN SXXI
Introducction: Kidneys from newborn donors frecuently are discharged due to
primary dysfunction, two decades ago in many transplant centers kidneys from
anencephalic donors were transplanted in block.
We report a case of female 35 years old who was transplanted at 11 years old
from anencephalic donor at august 1984. Both kidneys were used in block to
the right comun iliac artery with aortic segment. Patient received Azathiprine
and prednisone as initial immunosuppression. 10 years after transplantation
was added Cyclosporine A (CsA)at 3mg/kg/day. after 20 years of follow of
CsA was changed to MMF 2 g/day du to albuminuria.Patient have had follow
up in our transplant unit since then, actual renal function stable. with serum
Creatinine 1.3mg/dL, Creatinine clearance 50ml/min, albuminuria 0.5 g/L.
MRI shows both kidney well perfused, and it shows stenosis of infra renal
comun iliac artey.
Conclusions: Follow up of this case shows that pediatric kidneys in block
could have long survival, they can be used in pediatric patients or in small
adult patients with good results.
1

POSTER BOARD NUMBER P4 – 169
2119 OUTCOMES OF HAEMODIALYSIS VASCULAR ACCESS
IN THE RENAL TRANSPLANT RECIPIENTS: A SINGLE
CENTRE EXPERIENCE

THURSDAY

I. Butt, W.S. McKane, P. Brown, A.T. Raftery, B.M. Shrestha
Sheffield Kidney Institute
Introduction: Maintaining the functionality of vascular access (VA) is central
to the well-being of the haemodialysis patients. After a successful renal
transplant (RT), the management of VA has remained a subject of dispute,
particularly with respect to intervention for thrombotic complications. The aim
of this study was to evaluate the fate of haemodialysis VA in our RT recipients
and to assess whether an alternative management strategy should be adopted.
Methods: A retrospective study of a cohort 570 RT performed over a period
of 14 years between January 1993 and October 2007 was conducted. Data
was collected from a prospectively maintained departmental database, case
notes and through telephone interviews. VAs presenting with thrombotic
complications were not subjected to salvage procedures and those with
symptomatic complications were considered for ligation.
Results: A total of 363 patients were on haemodialysis prior to undergoing
renal transplantation. Of these, 57 patients died during the period of study.
Out of the 306 living patients, 258 (85%) patients have a functioning RT
whereas 48 (15%) have returned to alternative mode of renal replacement
therapy (RRT). Of the 258 with a currently functioning transplant the fistula
in use prior to the transplant has stopped functioning in 78 (30%) patients
(57 spontaneous thromboses, 21 operative ligations). Ligations were
performed for steal syndrome, Raynaud’s syndrome, venous hypertension,
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2120 LONG TERM FOLLOW-UP OF RENAL TRANSPLANT
PATIENTS A SINGLE CENTER EXPERIENCE.
R. Mondragon1, R. Bernal, B. Aguilar
1
Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico
ISSEMyM
Introduction: Renal transplantation is considered the optimal form of renal
replacement therapy for patients with end stage renal disease, the determinators
of patient survival after renal transplantation are incompletely known, and
conflicting results have been reported. AIM: The purpose of this study is to
analyze retrospectively the general health status and survival rates of grafts
and patients.
Patients And Methods: A retrospective database analysis of the hospital
charts of 176 kidney recipients was perform in order to analyze the effects
of following parameters on mortality: age, sex, blood type, cause of renal
failure, comorbid conditions, previous renal treatment, date of transplantation,
immunosuppressive therapy, surgical and medical complications. We calculated
1-, 5-, and 10-year Kaplan-Meier survival rates.
Results: 176 transplants were performed in the Centro medico ISSEMyM
from August of 1982 to October of 2007; the follow up period was 0 to 120
months postoperatively. Age average was 30 years old (range of 12 to 62),
106 (60%) males and 70 (40%) females. Age average of the donor was 32
years. The related living donors was 89 (51%) cadaveric donations 73 (41%),
non related living donors 14(8%). the average duration of substitutive renal
therapy before transplantation was 1 to 3 years, 61% were treated with dialysis,
31% with hemodialysis and 17.3% with booth. The most common cause of
renal failure was glomerulonephritis, the predominant group of blood was 0+.
The immunosuppressive include triple therapy (Ciclosporine, Micophenolate
mofetil, Tracolimus) and all episodes of rejection were treated with pulse of
methyl prednisolon. We had no complications in 60% of our patients, 89%
had medical complications and 11% surgery related complications them
had a similar distribution between urological and vascular complications,
only one case of infectious complications required drainage of a perirrenal
abscess. Patient survival rates at 1, 5 and 10 years were 94%, 91%, and 89%
respectively while the graft survival rate at 1, 5 and 10 years were 96%, 97%
and 99% respectively. These results were found to be comparable to the average
values of others centers. The total mortality was 11%, Patient death was more
prominent during the first two years after transplantation. Most common causes
of death were infectious (45%), cardiovascular (25%) metabolic (20%), cancer
(10%), due to the surgical procedure non case were related.
Conclusions: Many individual factors contributed to the risk of mortality
incidence of renal transplant patients like infectious complications especially
pneumonia and CMV, retard graft function or repeated rejections.
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2121 DEATH WITH A FUNCTIONING GRAFT INCREASES
WITH RECIPIENT AGE AT KIDNEY TRANSPLANT
R. Wolfe1, K. McCullough1, A. Leichtman2
Arbor Research Collaborative for Health, 2Dept of Medicine, Div. of
Nephrology, U. of Michigan
Introduction: Death with a functioning graft (DWFG) is an important cause of
renal allograft failure in developed countries. We investigated the relationship
between age at transplant and the probability of DWFG.
Methods: 131,225 cadaveric kidney-alone transplants reported to the Scientific
Registry of Transplant Recipients database between 1987 and 2004 were
analyzed for cause of graft loss within 3 or 5 years. Death ascertainment and
graft failure were supplemented by data from the US Social Security Death
Master File and the Centers for Medicare and Medicaid Services.
Results: The percentage of kidney transplants with DWFG increases with
recipient age at transplant. Less than 10% of graft loss at 5 years up to a
recipient age of 40 years. By recipient age 69, fully 34% of graft loss by five
years results from DWFG.
Discussion: DWFG decreases the total number of years of graft survival that
can be achieved from the donor pool. Kidney allocation policy to match the
projected survival of the recipient to the estimated potential survival of the
donated organ offers the promise of reducing DWFG, and of improving overall
kidney graft survival.
1

POSTER BOARD NUMBER P4 – 173
2123 SUCCESSFUL CALCINEURIN-INHIBITOR (CI)
DISCONTINUATION FOLLOWING EARLY STEROID
WITHDRAWAL (ESW) IN RENAL ALLOGRAFT RECIPIENTS;
REDUCED CHRONIC ALLOGRAFT NEPHROPATHY (CAN)
AND IMPROVED RENAL FUNCTION WITHOUT INCREASED
REJECTION OR GRAFT LOSS
R.B. Stevens, T. Rigley, J. Skorupa, K. Nielsen, L. Wrenshall
University of Nebraska Medical Center
We hypothesized that rATG induction would enable safe discontinuation of CI
maintenance in renal transplant patients on steroid-free immunosuppression.
We compared two rATG induction protocols (6/mg/kg x 1 dose vs. 1.5 mg/kg
x 4 doses) in a prospective randomized trial of CI discontinuation (tacrolimus/
sirolimus vs. mycophenolate mofetil/sirolimus) combined with ESW in kidney
recipients.
We enrolled 152 patients with an average follow-up of 19.7 ± 11.7 months.
Subjects were 19 to 65 years old and included primary and re-transplants, with
primary endpoints of renal function and CAN. Follow-up averaged 16.6 ± 9.5
months in 47 patients withdrawn from CI (26 single-dose rATG induction,
21 divided-dose rATG induction). We found no increased rejection (p = 0.8)
after CI discontinuation and that both rATG induction dosing regimen and CI
discontinuation significantly impacted renal function and the development of
CAN (both p < 0.03).
Conclusions: We successfully discontinued both calcineurin inhibitors and
steroids with either single or divided-dose rATG induction, and single-dose
rATG induction independently associated with improved renal function and
reduced CAN.

POSTER BOARD NUMBER P4 – 174
2124 LATE CONVERSION TO EVEROLIMUS COMPLICATED
WITH NECROTIZING GLOMERULONEPHRITIS IN RENAL
ALLOGRAFT RECIPIENT – CASE REPORT
POSTER BOARD NUMBER P4 – 172
2122 BODY MASS INDEX,C-REACTIVE PROTEIN, AND
BLOOD PRESSURE IN A COMMUNITY-BASED STUDY OF
AFRICAN-AMERICAN WOMEN
D. Morehead, J. Hurrell, C. Callender, A. Campbell
Howard University
Introduction: Obesity has been declared to be the 21st century epidemic,
a problem that is out of control, with no signs of abatement. Obesity
disproportionately affects people of low income and socioeconomic status,
particularly African-American, as compared to white women. Obesity is defined
as an excess of body fat and is commonly measured by the body mass index
(BMI). BMI values above 30 kg/m² denote obesity and are known correlates
of C-reactive protein (CRP), an acute-phase inflammatory reactant, and blood
pressure (BP).
Objective: To investigate the relationship between BMI, CRP, and BP in a
community-based cohort of African-American women.
Hypotheses: 1) African-American women who have higher elevations of CRP
will have higher BMIs; and, 2) African-American women who have higher
blood pressures will have higher BMIs.
Methods: African-American women (N=60), 18 years of age and older, were
the participants in this study. Weight and height measurements were assessed
for BMI, ELISA assay procedures were performed for serum CRP, and, three
blood pressure measurements were taken.
Results: As predicted, both hypotheses were supported. Elevated CRP levels
were associated with higher BMIs (r=.594, p≤0.01); and, higher SBPs, but
not DBPs, were associated with higher BMIs (1st r=.277, p≤0.05; 2nd r=.278,
p≤0.05; 3rd r=.410, p≤0.01).
Conclusion: Obesity is an inflammatory related disease and adverse
physiological outcomes that can lead to kidney failure and death.
Implication: There is a need to identify the underlying biopsychosocial
mechanisms that contribute to the problem of obesity in the African-American
female population.

M. Durlik1, E. Nowacka-Cieciura1, A. Perkowska-Ptasiñska1, A. SulikowskaRowiñska2, T. Cieciura1, E. Wa¿na1
1
Transplantation Medicine and Nephrology Dept, Medical University of
Warsaw, 2Department of Pathology, Children Hospital, Medical University of
Warsaw
Conversion from calcineurin inhibitors (CNI) to proliferation signal
inhibitors (PSI), such as sirolimus or everolimus (EV) may improve renal
function in patients with chronic allograft nephropathy. We present a case
of 39-years old male kidney allograft recipient with chronic cyclosporine
(CsA) nephrotoxicity, recognized in a biopsy performed 5,5 years after Tx.
The patient’s proteinuria was 0,5g/day, serum creatinine (creat) was stable
at the level of 2,3 mg/dl. Concomitant medication consisted of MMF and
prednisone (P), as well as losartan (L). In the preconversion biopsy arteriolar
hyalinization, chronic ischemic glomerulopathy with focal, segmental
glomerulosclerosis, double-contouring of some glomerular capillaries, mild
interstitial fibrosis and tubular atrophy were found. Immunofluorescence
(IFL) was negative for Ig, C3, C1q, and C4d. Electron microscope (EM)
(performed on the material regained from the paraffin block) showed focal
glomerulosclerosis, GMB reduplication, no electron dense deposits. With the
introduction of EV (2 mg twice a day, target blood levels 8-12 ng/ml) CsA
was withdrawn 8 days later. The patient continued MMF in the reduced dose,
P and L. Two months after the conversion the patient presented with rush,
proteinuria (1,8 g/day), erythrocyturia, and mild leukocyturia with negative
urine culture. Creat increased from 2,1 to 2,3 mg/dl, serum C3 was below
normal range. In biopsy: focal, segmental necrosis of the glomerular tuft with
the formation of segmental cellular crescents, an increase in endocapillary
cellularity. IFL: granular deposits of IgG, IgM, and C3 mostly along the
capillary walls. Negative for C4d. EM: electron dense deposits within the
GBM and in a subendothelial region, significant reduction in the capillaries
lumen due to GBM reduplication and widening of lamina rara interna with the
formation of fibrillary structures within it. Focal segmental glomerulosclerosis.
EV was withdrawn, CNI (tacrolimus) concomitantly with steroid pulses were
administered. The rush disappeared, proteinuria decreased to 0,6 g/d, there
was no active urine sediment, creat was 2,5 mg/dl. Five months after the
withdrawal of EV creat level increased to 3,4 mg/dl with no proteinuria. The
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third graft biopsy showed double contouring of glomerular capillaries, some
scanty deposits of IgG and C3 in some of glomerular segments, negative
for C4d, more advanced glomerulosclerosis. EM (performed on the material
regained from the paraffin block): the reconstitution of glomerular capillary
lumens with the decrease in endocapillary cellularity, the presence of scanty
intramembranous and subendothelial granular electron dense deposits in some
of glomerular capillary loops. There was subsequent decline in renal graft
function during the next year and the patient demanded dialysis 17 months
after conversion to EV. Conclusion: Necrotizing glomerulonephritis with
immune complexes deposition in renal allograft was possibly induced by late
conversion from CNI to EV. The re-conversion to CNI could be recommended
in case of PSI-associated post-transplantation glomerulonephritis but the
long-term prognosis is uncertain.

POSTER BOARD NUMBER P4 – 175
2125 LONG-TERM KIDNEY GRAFT FUNCTION AFTER
COMBINED LIVER-KIDNEY TRANSPLANTATION

THURSDAY

R. Ruiz1, B. Fischbach2, N. Onaca1, G. McKenna1, H. Randall1,
G. Klintmalm1, R. Goldstein1, M. Levy1, S. Chinnakotla1, E. Sanchez1
1
Baylor Regional Transplant Institute, 2Dallas Transplant Institute
The number of combined liver-kidney transplants (CLKTs) has steadily
increased in large part to the implementation of the MELD (Model for Endstage Liver Disease) allocation system. When to include a kidney allograft has
been debated extensively. In this study, we analyzed preoperative factors which
may influence allocation. In addition, long-term graft survival and function are
also assessed.
In this study, we retrospectively examined 75 CLKTs performed at our center
over a 23-year period. Overall, patient survival rates were 82%, 73% and 64%
at 1, 3, and 5 years, respectively. Kidney graft survival rates were 76%, 68%
and 60% at 1, 3, and 5-years, respectively. There was no difference in patient
or graft survival whether or not a recipient was on pretransplant dialysis.
However, the requirement for post transplant hemodialysis portended a poor
overall prognosis (p=0.0006). We prospectively assessed kidney function using
glomerular filtration rates (GFR) as measured by the I125-iothalamate method
(Glofil) before transplant and at predetermined intervals post transplant. There
was no difference in patient survival when GFR was greater or less than 20 ml/
min pretransplant. We retrospectively calculated creatinine clearance using the
Modification of Diet in Renal Disease (MDRD) formula and found a strong
correlation between GFR and MDRD values after one-year post transplant
(p=NS). Only seven patients (9%) had biopsy-proven acute kidney rejection
episodes.
Kidney graft survival mirrors patient survival in CLKT. MDRD is a reliable
estimate of renal function greater than one-year post transplant. The liver
allograft is renoprotective.
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2126 THE PROBLEM WITH COMPLIANCE IN
TRANSPLANTATION.
M. Bos
Health Council of The Netherlands- Eurotransplant
Non-compliance with the medical regimen, e.g. non-adherence to
immunosuppressants,is described as a major factor affecting the health,
quality of life and the graft survival in transplant patients. Many episodes of
late acute rejection and graft loss can be retraced to non-compliant behavior of
the recipient, resulting in erratic timing or missed doses of medication. This is
particularly distressing in paediatric and young adult patients. Non-compliance
not only results in a personal loss for the patient, but also in considerable
societal and economic loss. This issue has often been observed, but has not
been extensively studied and analyzed in the context of transplantation. This
has resulted in rather poor definition of what precisely constitutes (non)
compliance and insufficient insight in its possible causes and predictors.
Because of this, efficient strategies to enhance compliance and prevent nonadherence have not been developed and implemented widely and effectively.
This presentation focuses on developing new concepts and finding practical
solutions. The key strategy is on improving communication between doctor
and patient.
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2127 IS RENAL TRANSPLANTATION THE CURE TO FATAL
NEPHROGENIC SYSTEMIC FIBROSIS: A CASE SERIES OF A
RARE DISEASE.
N. Shah, M. Ramkumar, C. Wu, M. Unruh, J. McCauley, A. Basu, H. Tan, C.
Morgan, R. Shapiro
UPMC
Nephrogenic Systemic Fibrosis (NSF) is a recently described systemic disease
diagnosed at increasing frequencies with a high rate of morbidity and mortality.
This systemic disorder involves a progressive, severe expansion and fibrosis of
the dermis and can involve vital organs with no cure. An unproven multi-hit
hypothesis includes: kidney disease, gadolinium use, prothrombotic state, high
erythropoietin dosing, and acidosis. Systemic NSF has been reported to be fatal
on autopsy studies.
We describe 3 patients with biopsy proven NSF, with common risk factors,
each with a different response with renal transplantation, suggesting a possible
explanation.
Case 1: 37 year old female with ESRD from IgA Nephropathy, thrombophillia
with lupus anticoagulant, on erythropoietin therapy while on HD for 1 year
prior to a deceased donor renal transplantation. She received multiple MRI’s
with gadolinium for workup of CVA’s, the last within 2 months of onset of skin
tightness. She had biopsy confirmed NSF with cutaneous involvement. She
received as a well functioning allograft with baseline creatinine of 1.1 and no
episodes of rejection. Within 9 months of transplant she had marked clinical
improvement in signs and symptoms of NSF with less skin tightness and full
mobility of extremities.
Case 2: 62 year old female with ESRD secondary to hypertension, thrombophillia
with lupus anticoagulant, was on HD 4 years prior to transplantation. She received
epogen on HD and had an MRI with gadolinium prior to transplant. Her NSF
(biopsy proven) was precipitated by renal allograft vein thrombosis and acute
allograft dysfunction after a laproscopic cholecystectomy with improvement in
Cr to 1.2 with thrombolysis. She subsequently suffered recent ACR with baseline
of 2.9. She describes minimal improvement cutaneous NSF and noted to have
persistent induration and swelling but no progression of disease.
Case 3: 37 year old with ESRD from bilateral nephrectomy from Von Hippel
Lindau with multiple MR angiograms for intracranial hemiangioma. He was on
HD for 7 years prior to transplantation. He had severe, cutaneous NSF (biopsy
proven) symptoms for 2 years, with resulting severe contractures in upper
extremities. He underwent living related renal transplantation with excellent
allograft function and creatinine of 1.2mg/dl one year from transplant with no
improvement in chronic contractures but no progression of symptoms of NSF.
Conclusions: We present 3 patients of biopsy confirmed NSF who are
transplanted at different stages in disease progression. We are to first to
demonstrate that renal transplantation, if done early, with a well functioning
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allograft, offers the best chance at halting and reversing the progression of this
chronic progressive, potentially fatal systemic disease.
Patients presenting for transplantation with NSF should not be delayed but
expedited and explored for living donors if possible. In addition, as documented
in the literature, a majority of cases of NSF have a prothrombotic condition that
should be investigated and consideration given to of the use of perioperative
anti-coagulation. Finally, gadolinium use in severe CKD should be avoided if
possible.

CONCURRENT ORAL SESSION 144: IMMUNOSUPPRESSION –
POST TRANSPLANT MALIGNANCY
POSTER BOARD NUMBER P4 – 178
2128 LYMPHOCYTES SUBSETS IN RENAL TRANSPLANT
RECIPIENTS WITH DE NOVO GENITOURINARY
MALIGNANCIES
G. Guichard1, J-M. Rebibou2, D. Simula-Faivre3, D. Ducloux4,
J.M. Chalopin5, P. Tiberghien6, H. Bittard7, P. Saas8, F. Kleinclauss9
1
Urology, 2Renal transplantation
Background: Renal transplant recipients are at high risk of developing de
novo malignancies. This increased risk has been associated with high level
of immunosuppression. CD4 cell lymphocytopenia has been involved in skin
cancer and non cutaneous neoplasia after renal transplantation.
The aim of this study was to investigate the role of CD4 lymphocytopenia on
the development of de novo urological malignancies (prostate cancer, renal cell
carcinoma, bladder cancer) in renal transplant recipients.
Methods: From January 1989 to December 2003, 434 patients were
transplanted in our institution. All patients were followed for the development
of urological malignancies. Lymphocytes subsets (CD3, CD4, CD8, CD19)
were measured annually by flow cytometry. We considered the mean of at least
three different values out the first year post-transplant. Patients who developed
urological cancers were compared to patients without cancer for gender, age,
haemodialysis duration, transplant duration, immunosuppressive regimen and
lymphocytes subsets.
Results: Fourteen patients (3,2%) developed a urological cancer after kidney
transplantation (6 prostate cancers, 7 renal cell carcinoma and 1 bladder
cancer). These patients were male (93% vs 63%, p=0,022) and significantly
older (55,5 +/- 6,5 vs 43,6 +/- 14, p=0,002) than patients without cancer.
They did not differ in haemodialysis mode, haemodialysis time and serum
creatinine concentration. No difference was observed in CD3, CD4 and CD19
lymphocytes counts but patients with urological cancer present significantly
more CD8 than patients without cancer (672+/- 743 vs 490+/- 313, p=0,04). No
difference was observed in immunosuppression duration, induction regimen,
immunosppressive maintenance and acute rejection.
Six patients presented a prostate cancer. Mean age at diagnosis was 61,4
years and the median interval between diagnosis and transplantation was 83,3
months [17-127]. Mean Gleason score was 7,5 [4-10]. Four patients are alive
without recurrence and with a functional graft with a mean follow up of 48
month [10,5-155].
Seven patients developed renal cell carcinoma on native kidneys. Mean age
was 60,8 years and the median interval from diagnosis and transplantation
was 56,9 months [11-113]. Four patients are alive after radical surgery with
functioning graft. The mean follow up is 26 months [2-57].
Conclusion: Although CD4 lymphocytopenia has been involved in cutaneous
and non cutaneous cancer development, we cannot confirm his role on the
development of urological cancer. Likewise no other immunologic factors
such as immunosuppression duration, induction regimen, or acute rejection
can be involved in the de novo urological malignancies development. Further
investigations, with lymphocytes counts in patient who develop urological
cancer after renal transplant, are needed to confirm this data.

POSTER BOARD NUMBER P4 – 179
2129 PRE-TRANSPLANT SERUM VITAMIN D LEVELS AND
RISK OF CANCER AFTER RENAL TRANSPLANTATION
A. Kazory1, C. Courivaud1,2, J. Bamoulid1,2, G. Dumoulin4, J-M. Chalopin1,2,3,
D. Ducloux1,2,3
1
University of Franche-Comte, Besancon, France, 2INSERM, U645,
Besançon, F-25020; University of Besançon, F-25020; IFR133, Besançon,
F-25000,, 3CIC Biotherapy, Saint Jacques University Hospital, Besançon,
4
Laboratory of Renal and Metabolic Exploration, Jean-Minjoz University
Hospital, Besançon
Background: Serum levels of 25-OH-D3 inversely correlate with the incidence
of various types of cancers in the general population. Since risk factors and
incidence of cancer in renal transplant recipients (RTRs) are different from
the general population, this study was designed to determine whether pretransplant 25-OH-D3 levels could be predictive of cancer risk in RTRs.
Methods: Pre-transplant 25-OH-D3 levels were reviewed in 363 consecutive
RTRs. The impact of 25-OH-D3 levels on development of cancer was then
analyzed with respect to other known risk factors.
Results: One hundred twenty four patients (34.2%) showed vitamin D
deficiency, 185 (51%) vitamin D insufficiency, and 54 (14.8%) with normal
vitamin D levels. Thirty two cancers (8.8%) occurred in 32 patients. A higher
incidence of cancer was observed in patients with vitamin D deficiency (13.7%
vs. 7% for patients with vitamin D insufficiency [p=0.068] and 3.7% for those
with normal vitamin D levels [p=0.007]). 25-OH-D3 levels were lower in
patients who developed cancer after transplantation (13.7 +/- 6 vs. 18.3 +/17.8 ng/ml; p=0.022). Age (HR, 1.06; 95% CI, 1.02 to 1.11, for each one year
increase; p=0.009) and low 25-OH-D3 levels (HR, 1.12; 95% CI, 1.04 to
1.23, for every 1 ng/ml decrease; p=0.021) were independent risk factors for
development of cancer.
Conclusion: Pre-transplant level of 25-OH-D3 is an important determinant for
subsequent development of cancer after renal transplantation. Future studies
should examine whether 25-OH-D3 supplementation can effectively decrease
the incidence of cancer in RTRs.

POSTER BOARD NUMBER P4 – 180
2130 SPECTRUM OF LYMPHOPROLIFERATIVE DISORDERS
FOLLOWING RENAL TRANSPLANTATION IN NORTH INDIA
V. Sakhuja1, H. Kohli1, V. Jha1, K. Gupta1, K. Joshi2
Department of Nephrology Post Graduate Institute of Medical Education
And Research, 2Department of Pathology Post Graduate Institute of Medical
Education And Research
Lymphoproliferative disorder is a common and serious complication of organ
transplantation. This study was a retrospective analysis of 1400 patients
who underwent renal transplantation over a period of 25 years (1980-2005).
Thirty malignancies were diagnosed in 26 patients. Nineteen patients (1.6%)
developed post transplant lymphoproliferative disorder (PTLD) accounting
for 63.3% of all malignancies. Diagnosis was made by biopsy of the involved
organ in 13 patients (68.4%) and aspiration cytology in 3 patients (15.8%).
In 3 patients the diagnosis was made only at autopsy Mean age at the time of
diagnosis of PTLD was 40.2 years (range 21 to 62 years). The interval between
transplantation and PTLD was less than a year in 21% and more than a year
in 79%. Involvement was primarily extranodal in 14 patients (73.7%). Twelve
(63.2%) patients had disseminated disease at diagnosis and 7 (36.8%) had
localized involvement of a single organ (brain -2, allograft -1, perigraft node-1
and retroperitoneal lymph nodes- 3). Direct infiltration of graft was noted in
2 patients while one patient presented with a perigraft mass. One patient was
positive for anti-HCV antibodies, 3 had CMV antigenemia and 1 had IgG
antibodies to EBV. PTLD was of B cell origin in 16 cases (84.2%), 2 t cells
and 1 myeloma.. CD 20 staining was done only in 6 cases, of which 4 stained
positive. Of the 16 patients diagnosed during life, 13 (81.3%) died within 1
year of diagnosis. In India, PTLD is the commonest post transplant malignancy
but occurs predominantly in the late post transplant period.

1
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2131 SIROLIMUS DECREASES SERUM PSA POSTTRANSPLANT
Z. Kaposztas1, D. Hosey1, W. Etheridge2, S. Laneri1, B. Childs1,
C. Van Buren1
1
University of Texas, HSC At Houston, Division of Immunology And Organ
Transplantation, 2St Luke`s Episcopal Hospital
Objective: Immunosuppressive medications following solid organ
transplantation increase the risk of cancer. With improved management and
better outcomes immediately after transplantation, complications related to
post-transplant malignancy may become an increasingly important cause of
death. Prostate cancer has been documented to be responsive to testosterone
via surface receptors. Sirolimus (Sir) is a novel immunosuppressant that acts by
blocking signal transduction, lowering the incidence of malignancies.
Method: To test the hypothesis that Sir decreases Prostate-Specific Antigen
(PSA) expression, which is correlated with prostate cancer, a cohort of 83
male, kidney transplanted patients has been studied. We have been sought
the relationship of Sir to PSA serum level between the ages of 50 – 65. Two
groups have been established based on the maintenance immunosuppression
of subjects: Group A patients who have never been treated with Sir (n=19)
and Group B patients who have been treated with Sir based maintenance
immunosuppression (n=64).
Results: Data analysis revealed that the mean PSA level in Group A was
2.18+/-2.1 and in Group B: 1.39+/-1.15 (independent samples t test; p=0.039).
We divided the patients according to their PSA levels into 3 groups: PSA 0-2 (low
risk for prostate cancer); PSA 2.1-3.5 (moderate risk, prostate biopsy should be
considered) and PSA>3.5 (high risk). The distribution of PSA levels between
the 2 groups showed significant difference (Cross tabulation, Chi Square test;
p value = 0.032). The vast majority of patients being on Sir belonged to the
PSA level 0-2 group (n=53). There was no significant difference in distribution
of African-Americans and Whites in these PSA groups (Crosstabulation, Chi
Square test; P=0.58). Duration for post-transplant was comparable in both
groups (Group A: 2730±1901 days; Group B: 1761.8±1478 days; Independent
Samples t-test; P=0.055).
Conclusion: This is the first study to examine correlation of immunosuppression
with PSA. Significantly lower PSA serum levels were found among subjects in
Group B, treated with Sir as baseline immunosuppression. If these data are
validated in a larger study, the hypothesis that Sir reduces prostate cancer posttransplant should be tested.
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cancer patients (56%), but there was no significant difference.
Conclusion: In 1990 fs, the Japanese multicenter study in regard to cancer
incidences of renal transplant patients showed that most frequent malignancies
were renal, liver, gastric and colorectal cancers. The results showed that the
incidence of cutaneous cancer and lymphoma are increasing in Japanese renal
transplant recipients in the last decade probably due to strong suppressive
drugs of T-cell function.

POSTER BOARD NUMBER P4 – 183
2133 CHRONOLOGICALLY DIFFERENT INCIDENCE OF
POST-TRANSPLANT MALIGNANCY IN RENAL TRANSPLANT
RECIPIENTS; 25 YEARS EXPERIENCE IN KOREAN SINGLE
CENTER
M.S. Kim1,2, H.K. Chang1,2, M.K. Ju1,2, D.J. Joo1,, S.J. Kim1, S.I. Kim1,2,
Y.S. Kim1,2, K. Park3
1
Yonsei University College of Medicine, Department of Surgery, 2Yonsei
University College of Medicine, The Research Institute for Transplantation,
3
Kwandong University Myongji Hospital, Department of Surgery
The incidence of malignancy in transplant recipients is known to be higher than
that of normal population. But the types of malignancies vary geographically
and relative risks compared with general population are also different country
by country. In this study, we investigated the incidence and characteristics of
malignancy after renal transplantation in single center.
A total 2,650 renal recipients who were operated from April 1979 to June
2007 were enrolled in this study. The accumulative and interval (per 3 years)
incidence of malignancy was calculated by post-transplant period. Synchronous
or metachronous malignancies were counted as different events.
A total 190 cases of post-renal malignancy among 177 recipients (6.73%) were
reported until June 2007. The post-transplant malignancy was detected from
6 months to 290 months after transplantation with mean duration of 112.6
± 66.0 months. As the post-transplant duration was prolonged, the interval
incidence of malignancy was extremely increased [figure1]. Skin cancer
(n=35,18.4%) was the most common, followed by thyroid cancer(n=25,13.2%),
stomach cancer(n=22,11.6%), colorectal cancer(n=22,11.6%), urologic
cancer(n=19,10.0%), lymphoproliferative disorders (PTLD)(n=12,6.3%),
and Kaposi’s sarcoma(n=12,6.3%). Virus-related malignancy such Kaposi’s
sarcoma and cervix cancer developed in earlier post-transplant period, but on
the other hand urologic cancer, colorectal cancer and PTLD developed in late
post-transplant period [figure2].
Therefore, we should establish the strategies for post-transplant malignancy
based on characteristics of post-transplant malignancy in each country.
Figure 1

2132 MALIGNANCY AFTER KIDNEY TRANSPLANTATION IN
JAPAN

THURSDAY

M. Nojima1, Y. Higuchi1, Y. Ueda1, S. Yamamoto1, H. Shima1, H. Ihara2,
T. Yoshimoto3
1
Department of Urology, Hyogo College of Medicine, 2Ihara Clinic,
3
Department of Urology, Kawanishi City Hospital
Objectives: Cancer development is a major cause of patient morbidity and
mortality in patients after kidney transplantation, due to longer survival under
immunosuppressive status. To determine the incidence of cancer after kidney
transplantation, we analyzed a Japanese multicenter database.
Materials and methods: The data of 3184 kidney transplant recipients from
13 transplant centers were collected, and the incidence of malignancies were
analyzed.
Results: 206 out of 3184 (6.5%) recipients developed malignant tumors. The
mean age of patients who developed cancer was 36 years old at transplantation
and 46 years old at cancer development, showing that cancers occurred around
10 years after transplantation. Most frequent malignancies were cutaneous (25),
renal (22), lymphoma (22) and liver (21) cancers followed by colorectal (17),
uterine (16), breast (15), gastric (15), tongue/ oral cavity (11) and urotherial (9)
cancers. Twelve of 22 lymphoma occurred within 5 years after transplantation
and the average onset time of lymphoma was 6.8 years after transplantation. On
the other hand, the average onset time of non-lymphoma was 11.0 years after
transplantation (p= 0.0004). Eighty-one out of 206 (39%) patients developing
cancers died after diagnosis of cancer. The survival rates of patients associated
lymphoma was 50%, which was slightly lower than that of non-lymphoma
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2134 TYPE OF MALIGNANCY AMONG RENAL
TRANSPLANTATION PATIENTS IN URMIA RENAL
TRANSPLANT CENTER

2136 USEFULNESS OF EVEROLIMUS AS ALTERNATIVE
IMMUNOSUPPRESSION IN PATIENT WHO DEVELOP A
NEOPLASIA AFTER RENAL TRANSPLANTATION.

B.A. Markazi, E. Ahmadnezhad, A. Ravandi, S. Hatami, N. Sepehrvand
Background: The overall incidence of cancer in renal transplant recipients is
greater than in dialysis patients and general population. The several reasons
include immunosuppression and primary renal disease.
Method: In Urmia there are 1997 patients who carried out renal transplantation
from the beginning until now (Aug 2007). Among them, 159 cases developed
cancer. Questioner has been used for data collection.
Results: Among 1997 kidney recipient patients, 7/96% affected by cancer.
Mean age was 46.7 year, duration of pretransplant dialysis include 1-5 year in
53.8%, < 1 year in 42/3% and >5 year in 3.8% of cases. The immunosuppressive
drugs include Cyclosporine plus azathioprine and Prednisolone in 84/6%.
The detected tumors included: Kaposi sarcoma 42/3%, Lymphoma 11/5%,
Hepatoma, Leukemia and RCC each one 3/8%.In 34/6% of patients we couldn’t
detect malignancy.
Conclusion: Incidence of malignancy in kidney recipients in our center is
lower than other centers. It can be due to age of patients, state of residency, type
of immunosuppressive drugs, duration of dialysis and renal allograft survival.
Monitoring of patients in certain interval recommended.

E. González, E. Gutiérrez, E. Morales, N. Polanco, A. Hernández,
E. Gutiérrez-Solis, D. Parés, A. Andrés, J.M. Morales
Cancer is a growing complication in renal transplant patients. Everolimus a
new m-TOR inhibitor is an useful immunosuppressive drug with antineoplasic
properties.
The aim of the study was to evaluate the safety of Everolimus immunosuppresion
in patients who developed a neoplasia after renal transplantation.
In this retrospective observational single-center study we include 24 renal
transplant patients with cancer who were transplantated during 2005-2008.
Seventeen developed non-melanoma skin cancer, one melanoma without
visceral involvement, two prostatic cancer, one bladder cancer, one lymphoma,
one tongue cancer and the last one Kaposi’s sarcoma. Everolimus was
added to immunosuppressive regimen (1mg/day), decreasing the dose
calcineurin inhibitors (CNI) or stopping the dose of CNI drug (especially in
non-skin cancer).
Immunosuppressive combinations at the end of follow-up (18±11 months)
were:steroids, tacrolimus and everolimus (37,5%), steroids, Cyclosporine and
everolimus (20,8%), Tacrolimus, everolimus (12,5%), Cyclosporine everolimus
(12,5%) and Everolimus monotherapy in (16,6%). Blood levels of CNI were
significant decreased (Cyclosporine 143 vs 43 ng/dl and Tacrolimus 8.9 vs 5.6
ng/dl) during follow-up,
Notably nobody presented acute rejection, acute worsening of renal function
or increase of proteinuria (initial 0.3 vs 0.4 gm/d final). Renal function was
stable (serum creatinine initial 1.4 vs final 1.3 mg/dl) and nobody develop
cardiovascular complications.
Remarkably, evolution of cancer was excellent: there was no recurrence of
neoplasia in 21 cases, the skin Kaposi’s sarcoma improved, skin melanoma
was stable and only bladder cancer recurred
In conclusion, these encouraging results suggest that Everolimus
immunosuppression,with or without CNI, could be safe in patients who
developed cancer after renal transplantation. Prospective and controlled studies
to test this therapeutical option are mandatory.
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2135 INHIBITION OF MTOR KINASE ACTIVITY BY
SIROLIMUS IN THE MANAGEMENT OF MALIGNANCIES IN
RENAL TRANSPLANT RECIPIENTS
M. Boratynska1, E. Watorek1, D. Smolska1, D. Patrzalek2, M. Klinger1
Department of Nephrology and Transplantation Medicine Wroclaw Medical
University, 2Department of General, Vascular and Transplantation Surgery
Wroclaw Medical University
The mTOR kinase abundantly expressed in neoplastic cells may be a target for
proliferation signal inhibitors in post-transplant malignancies. The influence
of conversion to sirolimus after malignancy diagnosis on patient and renal
allograft survival was investigated.
From 957 patients transplanted in Wroclaw between 1983-2006 malignancy
was diagnosed in 50 patients (5%). In this group 28 renal allograft recipients
(9 women, 19 men) of ages 26 to 73 years (mean 56 years), who developed
malignancies within 6 to 168 months (mean 58 months) after transplantation
were converted to sirolimus in dose 2 mg per day (target level 4.0-8.0 ng/
ml). Prednisone was maintained. The observation time of sirolimus therapy
was 2-62 months (mean 21 months). Four patients developed post-transplant
lymphoproliferative disease (PTLD), 4 Kaposi’s sarcoma, 3 lung cancer,
4 malignant melanoma, 3 breast cancer, 4 renal cell carcinoma, 1 Merkel
cell carcinoma, 1 larynx cancer and 1 patient gingival cancer, 2 carcinoma
urotheliale of the bladder, in the remaining one patient metastatic planoepithelial
carcinoma was found in the lymph node.
Two patients with PTLD (large B-cell lymphoma) and 4 with Kaposi’s
sarcoma had full regression. Mean remission time on sirolimus is 40
months until now. Twenty patients (larynx cancer, melanoma, breast cancer,
T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma and skin
lymphoma) apart from sirolimus therapy, underwent oncologic treatment:
surgery and/or chemotherapy. Seven patients died from disseminated
malignancy 3-15 months after conversion. In the remaining patients, who
achieved remission, serum creatinine levels since conversion to sirolimus
have been stable.
In conclusion, conversion to sirolimus resulted in regression of large B-cell
lymphoma and Kaposi’s sarcoma. In patients with advanced or disseminated
malignancy tumor progressed. Graft function after conversion to sirolimus was
preserved

1
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2137 MALIGNANCY IN KIDNEY TRANSPLANT RECIPIENTS
IN HYOGO PREFECTURE, JAPAN
Y. Ichikawa1, H. Kishikawa1, K. Nishimura1, M. Takeda2, M. Fujisawa2, M.
Nojima3
1
Hyogo Prefectural Nishinomiya Hospital, 2Kobe University, 3Hyogo Medical
College
Background: Organ transplantation increases the incidence of cancer because
of immunocompromised sate and/or use of carcinogenic agents and kidney
recipients are known to have a higher cancer risk than the general population.
We studied the incidence of and risk factors for malignancy in a long-term
follow-up study of patients living in Hyogo Prefecture, Japan who underwent
kidney transplantations.
Materials and Methods: A total of 770 transplants was performed for 743
patients between 1973 and 2007 at three medical centres in Hyogo Prefecture.
We investigated the patient records to determine the incidence and sites of
malignancy and computed the cumulative incidence and survival rates. The
effects of immunosuppressant administration were also examined with the
results divided into three groups based on the medication received azathioprine,
cyclosporine and tacrolimus. A Kaplan-Meier method and the log-rank test
were employed to compare survival rates between the patients with and without
malignancy.
Results: A total of 77 malignant diseases were developed in 71 (9.5%) of the
patients. The mean follow-up time after the initial transplantation was 14.1 } 0.4
years. The cumulative incidence of malignancy increased yearly and the overall
rates were 1.7% at 5, 4.6% at 10, 7.9% at 15, 10.9% at 20 and 15.4% at 25 years.
Patients without malignancy had significantly superior survival rate in the second
and third post-transplant decades as compared to those with cancer (p<0.0001). The
survival rates with and without malignancy were 83.8% and 89.5%, respectively,
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at 10 years, and 60.6% and. 83.7%, respectively, at 20 years. There were no
significant differences in cancer incidence among the three inumosuppressive
administration groups though the graft survival rate for tacrolimus group was
significantly higher. At 15 years, the rates of incidence were 8.3%, 7.9% and 5.1%
in the azathioprine, cyclosporine and tacrolimus.groups, respectively while the
graft survival were 47.4%, 51.0% and 70.6% in azathioprine, cyclosporine and
tacrolimus.groups, respectively (p<0.0001). The common types of malignancy
were skin cancer, renal cell carcinoma (RCC) in the native kidney, hepatocellular
carcinoma (HCC) and post-transplant disease. On the other hand, lung cancer,
breast cancer and ovarian cancer were rare in our series.
Conclusion: The incidence of malignancy following renal transplantation was
relatively lower in our long-term follow-up cohort as were the sites of malignancy
as compared to the reports from other nations. RCC and HCC were characteristic
findings in our patients which were considered to result from the very long waiting
time in regard to the former and the endemic spread of hepatitis B virus in far-east
Asia including Japan in regard to the latter. Our results also showed that tacrolimus
was the most powerful agent of immunosuppression for the best graft survival rate
and had the same carcinogenic effect as azathioprine and cyclosporine.

POSTER BOARD NUMBER P4 – 188
2138 INCIDENCE AND BIOPSY FINDINGS OF COLORECTAL
POLYP IN KIDNEY TRANSPLANTATION RECIPIENTS
Y.J. Jeon, H. Yoon, S. Kim, J. Kim, S. Lee, B. Choi, Y. Kim, S. Kim, B. Bang,
C. Yang
Catholic University of Korea
Purpose: The risk of colorectal malignancy after kidney transplantation is
increasing, but incidence of colorectal polyp in these patients is rarely reported.
We reviewed the incidence and biopsy findings of colorectal polyp in renal
transplant recipients.
Methods: The database was queried for all cases of transplant recipients who
underwent colonoscopy were included. Pretransplant history of colorectal
cancer or polyp was excluded. Two hundred and forty kidney transplantation
recipients were surveyed. The mean follow-up after kidney transplantation was
144 months (0 to 362), and mean age was 51.2 years (21 to 77).
Results: We identified 82 cases (34.2% of surveyed recipients) of colorectal
polyps using colonoscopy or sigmoidoscopy. Biopsy findings revealed tubular
adenoma (n=52, 63.4%), inflammatory polyps (n=22, 26.8%), hyperplastic
polyps (n=7, 8.5%), villous adenoma (n=4, 4.9%), adenocarcinoma (n=4, 4.9%)
and lymphoid polyps (n=3, 4.9%), in that order. Mean number of polyp was 2.1
(1 to 13), and 52.4% of polyp was observed in patients under 50 years. In patients
with adenocarcinoma, the mean age at diagnosis was 63.5 years (52 to 79).
Conclusion: Incidence of colorectal polyps is high in renal transplant recipients.
Regular colonoscopy should be performed for early detection of polyps which
have malignant potential.

POSTER BOARD NUMBER P4 – 189
2139 B-CELL PTLD EPSTEIN-BARR VIRUS NEGATIVE IN
PAEDIATRIC KIDNEY TRANSPLANTATION.

THURSDAY

R. Vilalta, E. Lara, A. Madrid, S. Chocron, A. Casquero, J. Nieto
Hospital Infantil Vall DHebron Barcelona
We report our experience with paediatric B-PTLD, PCR EBV negative after
kidney transplantation.Ultrasonographyc study was diagnostic.
Background: Post-transplant lymphoproliferative disorder (PTLD) is the most
common immusupression related malignancy that occurs after solid organ
transplantation (SOT) in children. PTLD has extended its range from its initial
description as an Epstein-Barr virus (EBV)-driven-B-cell proliferation (PCR
positive high titer) to include EBV-negative cases in whom only protocol
ultrasonographyc study is helpful.
Patients and evolution: Case 1, male 18 years old, transplanted 10 years before,
abdominal PTLD B-lymphoma CD19CD20 negative, had a bimodal response to
therapy with initial erradication of bulky nodal disease with COP regimen, but
because persisted mesenteric disease, more intensive treatment with CHOPP
was necessary with remision. Was converted from tacrolimus to sirolimus.
Case 2, male 19 years old, transplanted 16 years before, PTLD abdominal, B
lymphoma CD19 CD20 negative had a satisfactory response Rituximab and
immunosupression was switched from tacrolimus to sirolimus.
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Case 3, female 20 years old, transplanted 18 years before, PTLD abdominal,
B-lymphoma CD19 CD 20 negative had a satisfactory response to therapy with
COP regime and switched to sirolimus-base regime.
Conclusions: Depite initial association between EBV infection and B-cell PTLD,
development of this disease in EBV-negative kidney transplanted children is also
observed. After reduction of immunosuppression and (and/or switch to PSI-based
immunosuppression), CD 19-20 positivity offers a good chance to rituximab. COP
or CHOPP theraphy could be necessary and overall survival is in the literature
around 60%. This fact should promote an increase of ultrasonic monitoring added
to a systematic PCR-EBV determination to early detection of PTLD cases.

POSTER BOARD NUMBER P4 – 190
2140 SIROLIMUS CONVERSION FOR PATIENTS WITH
POSTTRANSPLANT KAPOSI’S SARCOMA
K. Charfeddine, S. Yaich, S. Zagdane, A. Bahloul, M. Masmoudi, M. Kharrat,
J. Hachicha
University-Hospital Sfax
Introduction: Recipients ofrenal transplantation are susceptible to Kaposi’s
Sarcoma as result of treatment with immunosuppressive drugs. Sirolimus
(Rapamun), an immunosuprressive drug, may also have antitumor effects.This
retrospective study aimed to evaluate the benefit of switching from calcineurin
inhibitors (CnI) to sirolimus in posttransplant Kaposi’s Sarcoma (KS)
Methods: Five patients who developed posttransplant KS were switched
from CnI to sirolimus from February 2004 to May 2006.They were 1 woman
and 4 men, their mean age at switch was 32 years (21-44).All of them were
renal recipients. The mean time from graft to KS diagnosis was 12.3 months
(2-24).Four patients had only cutaneous lesions ; the fifth had a digestive
lesion (stomach).When KS was diagnosid, switching from CnI to Sirolimus
was abrupt for all patients(SRL: 18 mg day1;15mg day2; then 4mg daily);
mycophenolate mofetil or azathioprin was stopped 2 week later and one dose
of anti CD20 monoclonal antibody was administreted at d0 and d20.
Results: Three out of 5 (60%) patients had complete KS remission within 3
months of follow-up. Two patients lost the skin lesions eight months after the
switch and the fifth patient had a partial remission of her cutaneous lesions at
6 months and complete remission of both skin and digestif lesions 18 months
after switch. The tolerance of sirolimus was excellent except for one patient
who developed a n asymptomatic lung’s fibrosis 4 months after switch.
Conclusion: In conclusion, our observations suggests that sirolimus based
immunosuppression brings the possibility of KS regression with concomitant
renal function preservation in renal graft recipients. It is difficult to ascertain
whether the KS regression may be attributed to sirolimus treatment or to
reduction in immunosuppression. And what is the real role of Rituximab?

POSTER BOARD NUMBER P4 – 191
2141 POSTTRANSPLANT MALIGNANCY IN KIDNEY
TRANSPLANT RECIPIENTS: SINLGE CENTER EXPERIENCE
H.T. Kim1, W.H. Cho1, Y.M. Seo1, H.C. Kim2, S.B. Park2, S.Y. Han2,
E.A. Hwang2, H.S. Jang3
1
Dept. of Transplant & Vascular Surgery, Keimyung University Dongsan
Medical Center, 2Dept. of Nephrology, Keimyung University Dongsan Medical
Center, 3Dept. of Urology, Keimyung University Dongsan Medical Center
Introduction: Posttransplant malignancy is second leading cause of death
among longterm survivors of organ transplant recipients. Skin cancers
and lymphomas are reported as two most frequent malignancies in western
countries. But little is known about the pattern of posttransplant malignancies
in Korea. To see the patterns of posttransplant malignancies in Korean kidney
transplant recipients, we analyzed our experience of posttransplant malignancy
at our transplant center.
Patients and Method: From Feb. 1984 to Feb. 2008, 792 kidney transplantations
were performed at the Department of Surgery, Keimyung University Dongsan
Medical Center. Among them, 761 patients followed at least 12 months were
included. Their clinical records were analyzed retrospectively. Incidence and
types of malignancies, intervals developing malignancy after transplantation,
demographic characteristics, and prognosis were analyzed.
Results: There were 25 posttransplant malignancies (3.3%). Six cases of
lymphomas, three cases of stomach, lung, liver (HCC) and thyroid cancers,
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two cases of renal cancers, and one case of bile duct, breast, laryngeal, prostate,
and skin cancer. There was no case of Kaposi¡¯s sarcoma. Fifteen of recipients
and 15 of donors were male. Mean age of the recipients and donors were 40.8
¡¾ 11 (21-58) and 38.5 ¡¾ 13.1 (17-60), respectively. Fourteen transplants
were from living related donors, 7 from living unrelated donors and 3 from
deceased donors. All transplantations were first transplantation except one.
Mean interval of development of malignancy after transplantation was 73.3 ¡¾
38.1 months. No one received lymphocyte depleting induction therapy. Main
immunosuppressant was cyclosporine in 19 patients and was tacrolimus in 6.
Seven patients showed far advanced state at the time of diagnosis and died
within 1 month after diagnosis of cancer.
Summary: Incidence of malignancy in kidney recipients is 10 times higher
than general population. Types of posttransplant malignancy are different in
Korea compare to western countries. Since far advanced malignancies are
common and their prognosis is poor, regular screening of malignancy is needed
in kidney transplant recipients.

POSTER BOARD NUMBER P4 – 192
2142 SURVIVAL WITHOUT IMMUNOSUPPRESSION IN POST
RENAL TRANSPLANT KAPOSI’S SARCOMA
T. Aziz, E. Ahmed, J.I. Kazi, F. Akhtar, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Introduction: Kaposi’s sarcoma is one of the common malignancy after renal
transplantation in some geographical regions. Withdrawl of immunosuppression
leads to regression but predisposes to rejection and graft loss.
Patients and Methods: We have studied the outcome of patients with Kaposi’s
sarcoma at our center in whom immunosuppression was withdrawn.
Results: A total of 1800 renal transplant performed between November
1985 and December 2007. Kaposi’s sarcoma (KS) developed in 11 of 1800
recipients (0.6%) which account for 36% of total malignancies developing in
transplant recipients during this period. All patients were male with a mean
age at presentation was 31.9± 8.9 years. Mucocutaneous involvement was
present in 9 of 11 patients (82%) with visceral evidence of KS was present in
6 of 11 patients (55%). All of sarcomas developed after one year of transplant.
Azathioprine and cyclosporine were withdrawn after the diagnosis of tumor
and patients were kept on low dose prednisolone only. Serum creatinine at the
time of diagnosis of tumor was 1.87±0.77 mg/dl. Four patients had one episode
of rejection prior to diagnosis of KS. They received pulse steroid therapy.
But none of the patient had acute rejection episode after the withdrawal of
immunosuppression. Three patients died due to aggressive pulmonary disease
and two later on became dialysis dependent. Six patients had functioning graft
with a mean creatinine 2.5 ± 1.7 mg/dl after a follow up period of 49 months
(10-108 months) with no evidence of KS.
Conclusion: Kaposi’s sarcoma is the 2nd most common malignancy
after Non Hodgkin’s lymphoma in our transplant recipients. Reduction in
immunosuppression leads to regression of KS in majority of our patients with
relative preservation of graft function in medium term.

CONCURRENT ORAL SESSION 145: CAN – FIBROSIS AND DSA
POSTER BOARD NUMBER P4 – 193
2143 IMPACT OF HLA ANTIBODIES IN SHORT AND LONGTERM COURSE AFTER RENAL TRANSPLANTATION
G.F. Hillebrand1, T. Kauke2, M.C. Heydenreich1, W-D. Illner3, K-W. Jauch3,
W. Samtleben1, H. Arbogast3
1
Nephrology Division, Medical Clinic I, University of Munich, Campus
Grosshadern, 2Tissue Typing Lab, Institute of Transfusion Medicine,
University of Munich, Campus Grosshadern, 3Surgical Clinic, Transplant
Centre,University of Munich, Campus Grosshadern
Aim: Despite an excellent improvement in the early period after renal
transplantation due to new powerful immunosuppressive drugs, the late outcome
is still hampered by chronic transplant loss. The reasons for this are not fully
understood. Chronic allograft dysfunction is considered to be a multifactor
damage caused only partially by immunological attacks on the donated kidney.
However, the impact of anti HLA especially donorspecific antibodies (ab) are
considered to play an important role in late allograft dysfunction. They seem to

be important to discriminate such immunological attacks from other reasons.
Patients And Methods: We examined 205 pts after renal transplantation (RT)
in the outpatient clinic: Group I (n=66) in the early period after RT followed up
by the transplantation unit and Group II (n= 139) in long-term follow up under
care of the Div of Nephrology. Time from RT was 3.9±4.3 years in group I and
12.0±7.2 years in group II. The impact of HLA- ab after RT especially in respect to
donor-specific ab (DSA) was investigated. Sera were screened by Luminex® for
the presence of HLA class I and class II IgG antibodies, and positively screened
sera were confirmed by an identification assay (Tepnel Lifecodes,USA).
Results: 35.6% (73/205) pts showed HLA ab. In 16.6% (22/205) DSA could be
detected. In group I 42.4% (28/66) pts were positive for HLA-ab with 12.1%
DSA versus 37.4% (45/139) HLA ab positive pts and 10.8% detectable DSA
in group II. There was no statistical difference between group I and group II.
However, in group I ab against HLA class I were significantly higher (31.8%
[21/66]) than in group II (15.8% [22/139]) (p<0.001). Also, DSA against HLA
class I was more pronounced in group I: 13.6% (9/66) as in group II: 5% (13/139)
p>0.05. In group I with the short follow up the combination of ab against HLA
class I and II was seen more often (12.1%) in contrast to the long-term followed
group II (9.3%) p<0.05. The frequency of DSA against HLA class I and II was
higher in group I (19.1%) than in group II (2.1%) p<0.05. Ab against HLA class
II revealed no significant difference between the two groups.
Conclusion: The lower frequency of HLA- class I- ab, either DSA or non donor
specific (NDSA), in long-term graft survivors indicate an adverse influence of
HLA-ab on graft outcome. Regular monitoring in the follow up should be an
important tool in adjusting the immunosuppressive therapy.

POSTER BOARD NUMBER P4 – 194
2144 RAPAMYCIN IS LESS FIBROGENIC THAN FK506 IN RAT
MODEL OF CHRONIC ALLOGRAFT NEPHROPATHY
G.H. Luo, Y.P. Lu, L. Yang, J. Song, L.Y. Zhang, X. Ma, Y.P. Li
Transplantation Institute
Aim: FK506 is associated with significant chronic nephrotoxicity, which mainly
manifests as renal fibrosis. There have been proved that Rapamycin (RAPA)
could inhibit or attenuate fibrosis process. This study is to determine whether
the differences on expression of fibrosis-associated genes exist between FK506
and RAPA in rat kidney underwent chronic allograft nephropathy (CAN).
Methods: F344 rat renal grafts were orthotopically transplanted into Lewis rats
following the procedure of Kamada with our modification. All the recipient rats
were given CsA 10mg/kg-1.d-1×10d and then divided into three oral treatment
groups (each group n=9): (1) Vehicle: given vehicle orally, (2) FK506: 0.15mg/
kg-1. d-1, (3) RAPA: 0.8mg/kg-1.d-1. At 4w, 8w, 12w, SCr and pathological
changes were measured. The expression of CTGF, collagen I, IV, α-SMA and
E-cadherin were assessed by real time PCR and Western blot.
Results: The CAN model of the rat kidney allograft, which was reinforced
with cold ischemia injury was successfully built. The SCr and Banff score
increased in a time dependent manner in all the three groups. The differences
of SCr and Banff score between the three groups were not significant at 4w
(p>0.05). At 8w and 12w, SCr(μmol/L) in Vehicle, FK506 and RAPA group
were 275±23.5,516±32.0; 230±18.01, 476±61.63 and 110±11.3, 321±59.15.
The differences between RAPA and other two groups were statistically
significant (p<0.05). The histological lesions of CAN in Vehicle and FK506
groups were more serious than those in RAPA group. At 8w and 12w, the
Banff score in Vehicle, FK506 and RAPA group were 5.33±0.58, 13.33±1.52;
5.00±1.00, 12.33±3.79 and 1.33±1.52, 7.33±3.78, respectively. The difference
between RAPA and other two groups were statistically significant (p<0.01).
CTGF positively expressed in tubular epithelial cell (TEC) in allografts at 4w.
Although at 8w, many tubules in allografts were damaged and vanished, the
remained TEC still positively expressed CTGF. α-SMA was also expressed in
TEC. Collagens I and IV were expressed in interstitium since 8w. E-cadherin
was lost dramatically in atrophied tubules since 4w and only a few of the
remained tubules were E-cadherin positive at 12w. Comparing with the Vehicle
and FK506 group, the expressions of the fibrosis-associated genes in RAPA
group were obviously weaker except E-cadherin.
Conclusion: We demonstrate that RAPA can ameliorate fibrogenesis in
transplant kidney by inhibiting the expression of CTGF mRNA and protein,
down-regulating the expression of collagen I, IV and α-SMA, abating for
E-cadherin’s lose and inhibiting the epithelial-mesenchymal transformation
(EMT). FK506 has no these effects.
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POSTER BOARD NUMBER P4 – 195
2145 COMPARISON OF RAPAMYCIN VS. FK506 ON
EXPRESSION OF CYTOPROTECTIVE GENES IN THE RATKIDNEY ALLOGRAFTS UNDERGOING CHRONIC REJECTION
D.H. Teng, Y. Lu, R. Gao, Y. Xin, G. Cao, X. Li, L. Wang, J. Wang
Transplantation Institute
Aims: Cytoprotective genes are named after their known anti-inflammatory
and anti-apoptotic function. It is increasing recognized that expression of
cytoprotective genes in grafts can affect the progress of chronic rejection. Little
is known about the influence of different immunosuppressive regimens on
expression of cytoprotective genes in allografts undergoing chronic rejection.
We investigate whether there is difference between rapamycin and FK506 in
the ability of affecting expression of cytoprotective genes in the rat kidney
allografts undergoing chronic rejection.
Methods: SD rat renal grafts were orthotopically transplanted into Wistar
rats following the procedure of Kamada with our modification. The recipients
were divided into three oral treatment groups: (1) vehicle group (CsA 10mg/
kg.dX10d followed by vehicle), (2) rapamycin group (CsA 10mg/kg.dX10d
followed by rapamycin 0.8mg/kg.d), (3) FK506 group (CsA 10mg/kg.dX10d
followed by FK506 0.15mg/kg.d). At the same time points after transplantation,
the rats were sacrificed and the renal allografts were harvested. The expression
of four cytoprotective genes, A20, heme oxygenase (HO)-1, Bcl-2 and BclX/L in these grafted kidneys were analyzed by quantitative RT-PCR and
immunohistochemistry.
Results: Four cytoprotective genes are all detected in the rat-kidney allografts
undergoing chronic rejection. The expression of A20 in grafted kidneys is
significantly higher in rapamycin group than that in FK506 group and in vehicle
group (P<0.05)(Table1 and 2). There is no significant difference between
rapamycin group and FK506 group in the expression of HO-1, Bcl-2 and
Bcl-X/L (Table2). A20 is expressed in vascular structures, cellular infiltrates
and at very low levels in glomerular structures. Expression of HO-1 is mainly
localized in cellular infiltrates, but it is also detected in tubular structures.
Expression of Bcl-2 and Bcl-X/L are mainly in tubular structures.
Table 1. Rate of positive area of A20, HO-1, Bcl-2 and Bcl-X/L in kidney allografts (%)
Group
Vehicle
Rapamycin
FK506

A20
1.47±0.25
12.43±1.04
7.92±0.87

HO-1
1.72±0.18
3.37±0.49
3.34±0.51

Bcl-2
3.98±0.53
15.04±4.26
15.18±3.97

Bcl-X/L
3.04±0.47
17.29±1.58
16.94±2.26

Table 2. Expression of A20, HO-1, Bcl-2 and Bcl-X/L mRNA in kidney allografts (X±SD)
Group

A20(copy×104)

HO-1(copy×104)

Bcl-2(copy×104)

Vehicle
Rapamycin
FK506

0.72±0.30
92.17±11.26
46.37±9.92

1.18±0.26
8.92±1.04
8.89±0.73

1.27±0.41
4.87±0.69
4.91±0.53

Bcl-X/
L(copy×104)
1.19±0.34
9.87±1.12
9.84±1.04

POSTER BOARD NUMBER P4 – 196
2146 DETECTION OF CITRATE SYNTHASE
AUTOANTIBODIES IN RATS WITH CHRONIC ALLOGRAFT
NEPHROPATHY

THURSDAY

L.Y. Zhang, Y.P. Lu, Y. Li, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital
Background: There are only some sparse records of test on autoantibodies
against mitochondria1 innermembrane enzymes in some autoimmune
diseases and vasculopathy after heart transplantation,and the roles of those
autoantibodies are more and more emphasized. Citrate synthase(CS) is an
important mitochondrial autoantigen and one of the key enzymes in citric
acid cycle,which is central to the regulation of energy homeostasis and cell
metabolism.However,the autoimmune responses against CS have never been
studied in chronic allograft nephropathy(CAN).In this study we aimed to
investigate CS specific autoantibodies in renal allograft rats with CAN.
Methods: Fisher344 rat renal grafts were orthotopically transplanted into
Lewis rats following the procedure of Kamada with our modification.All the
recipients were given CsA 10mg/kg-1.d-110d and then divided into 4 groups
(each n=9):(1)Vehicle:vehicle orally;(2)CsA:6mg/kg-1.d-1;(3)FK506:0.15mg/
kg-1.d-1; (4)MMF:20mg/ kg-1.d-1. At 4w, 8w and 12w,the rats were sacrificed,
renal allografts were harvested and sera were collected. The SCr was measured
and the pathological changes were assessed according to the Banff 97 criteria.
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IgM and IgG isotype CS antibodies of all the recipients were detected
differently by binding indirect enzyme-linked immunosorbent assay(ELISA).
Results: Both IgM and IgG isotype CS autoantibodies were found in the sera of
all recipients before and after transplant,but the level of IgM CS autoantibodies
are more obviously stable and higher than IgG isotype in all different blood
samples. At 4w, the Banff scores in Vehicle, CsA,FK and MMF groups were
1.670.58,1.330.58, 1.001.00 and 0.670.58 respectively,the differences of Banff
score between different groups were not significant (p>.05). The OD values
of IgG isotype CS autoantibodies in Vehicle, CsA,FK and MMF groups were
0.068±0.007, 0.081±0.009,0.0830.003 and 0.0560.006, respectively(P>.05).
With progression of CAN(Banff score:5.330.58 and 12.671.16 in vehicle group
at 8w and 12w, respectively,P=0.001),the OD values of IgG in Vehicle group
were increased gradually(0.1710.015,0.3350.009,at 8w,12w,P=0..005);in CsA
group,with the progression of CAN(Banff score:4.671.53,13.331.53),CsA
did not prevent the formation of IgG isotype autoantibodies,but the OD
(0.1370.001,0.2790.019 respectivly at 8w,12w,p>0.5) values had no
significant difference;in FK group,with the progression of CAN(5.670.58,
12.333.79 at 8w,12w), the OD values were 0.1510.011,0.2910.009 at
8w,12w,respectively,p=0.005;MMF could decrease significantly the formation
of IgG(OD values:0.1330.000 and 0.0990.007 respectively at 8w,12w,
p=0.078) and the progression of CAN(1.671.16,6.671.53) at 8w and 12w.
Conclusions: This study suggests IgG isotype CS autoantibodies may
contribute to CAN after kidney transplantation,but IgM isotype autoantibodies
may be physiological.

POSTER BOARD NUMBER P4 – 197
2147 RAPAMYCIN CAN AMELIORATE CAN IN RAT
ALLOGRAFTS BY AFFECTING RHO/ROCK SIGNAL PATHWAY
J. Song, Y.P. Lu, G. Luo, L. Yang, X. Ma, Q.J. Xia, Y.J. Shi, Y.P. Li
West of China Transplantation Institute
Aim: The small GTPase Rho and ROCK play an important role in graft
fibrosis. This study is to investigate whether the difference exist between
rapamycin(RAPA) and FK506 by affecting small GTPase Rho and ROCK
signal pathway in rat renal allografts with chronic allograft nephropathy
(CAN)
Methods: Male inbred F344 rat renal grafts were orthotopically transplanted
into Lewis rats following the procedure of Kamada with our modification. F344
rats were also autografted. The allograft rats were first treated with CsA10mg/
kg-1.d-1×10d and then divided into 3 groups (each n=9):(1)CAN:Vehicle
orally,(2)FK506:0.15mg /kg-1.d-1,(3)RAPA:0.8mg/kg-1.d-1. At 4w, 8w, 12w, SCr
was measured and the pathological changes were accessed according to Banff
97 criteria. The expression of RhoA and ROCK-1 was determined by real-time
RT-PCR and immunohistochemistry. The expression of α-SMA, CTGF were
observed simultaneously.
Results: As showing in Table, SCR and Banff score increased since 4w
in CAN group, and obviously increased both in CAN and FK506 group at
8w, 12w. The differences between CAN/FK506 and autograft group were
significant(P=.000). SCR and Banff score in RAPA group increased mildly
and moderate at 8w and 12w, respectively; but were significantly lower than
those in CAN/FK506 group(p<.05). α-SMA and CTGF were observed in
renal epithelium and tubular cells and the expression increased along with
progression of CAN. RhoA and ROCK-1 were observed in mesangial cells
and tubule cells and increased gradually along with CAN. There was negative
correlation between RhoA/ROCK-1mRNA and Banff score(r=-.637, p=.000;
r=-.676, p=.000) and SCR(r=-.705, p=.000; r=-.756, p=.000). RAPA downregulated the expression of gene and protein of RhoA and ROCK-1. FK506
had little effect on them.
4W

8W

12W

Groups
SCr

Banff
Score

RhoA

ROCK-1

SCr

Banff
Score

RhoA

ROCK-1

SCr

Autograft

63.44
±0.94

0

11.84
±0.24

22.68
±0.48

62.27
±0.51

0

12.00
±0.00

22.50
±0.00

71.21
±2.01

CAN

110.97
±55.84

1.67
±0.58

4.18
±0.25

7.54
±0.75

275.23
±23.51

5.33
±0.58

3.55
±0.43

8.08
±0.83

516.78
±31.60
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RhoA ROCK-1
11.84 22.68
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FK506

86.07
±18.13

1.00
±1.00

8.05
±1.25

15.20
±2.38

263.64
±50.97

5.33
±0.57

5.68
±0.24

9.71
±0.64

476.93 12.33
±61.63 ±3.79

5.17 9.00
±0.25 ±0.00

RAPA

66.08
±4.88

0.67
±1.15

9.21
±0.64

17.20
±0.65

110.35
±11.30

1.33
±1.53

8.02
±0.42

12.72
±0.85

321.81 7.33
±59.15 ±3.79

6.53 1 0 . 5 3
±0.42 ±0.42

Conclusion: We demonstrate that abnormal expression of RhoA and ROCK-1
signal pathway may play a role in CAN. RAPA can attenuate CAN by downregulating the expression of RhoA and ROCK-1.

POSTER BOARD NUMBER P4 – 198
2148 ROLE OF DIFFERENT IMMUNOSUPPRESANTS IN
VSMC BY AFFECTING THE TGF-BETA AND SMADS SIGNAL
PATHWAY
Y.P. Lu, R. Gao, Y.P. Xin, X.H. Zhang, J. Wang, Y.P. Li
West of China Transplantation Institute
Objective: TGF-β is a key mediator in the development of CAN. It can promote
vascular smooth muscle cell (VSMC) proliferation and has a great influence
on the ECM turnover in SMC. The discovery of Smad proteins has revealed
the intracellular signal transduction of TGF-β. We investigated the effect of
different immunosuppresants on TGF-β1/ Smads Signal Pathway in VSMC in
order to clarify the role of immunosuppresants in CAN.
Methods: Vascular smooth muscle cell (VMSC) from rat aorta were incubated
with different immunosuppresants (CsA 3μg /ml, FK506 1μg/ml, MMF 0.3μg/
ml, Rapa 10μg/ml, CsA 1μg/ml+ MMF 0.3μg/ml), respectively for 6 or 12
hours, as control without anything. The immunohistochemistry and real-time
fluorescence quantitative PCR, were used to comprehend the expression of
TGF-β1 and Smad2, 7 in VMSC.
Results: Comparing with control groups, CsA and FK506 increased expression
of TGF-β1 and Smad2 and inhibited expression of Smad7, whereas MMF and
Rapa could down-regulate the expression of TGF-β1 and Smad2 and up-regulate
expression of Smad7. We demonstrated that increased TGF-β1 was associated
with over expression of Smad2 and down-regulated Smad7 in VSMC. There
is no significant difference between CsA group and FK506 group, as well as
MMF group and Rapa group. We also showed that CsA and FK506 affected
TGF-β1, Smad2 and Smad7 in VSMC in a time-dependent manner.
Conclusion: Our data indicated that Smads proteins were expressed in
VSMC and that they mediated TGF-β signaling in those cells. Different
immunosuppresants can affect TGF-β1/Smads signal pathway in VSMC, CsA
and FK506 can up-regulate the expression of Smad2 and down-regulate Smad7
expression in VSMC, and caused the over expression of TGF-β1. This will
contribute to arteriosclerosis. However, MMF and Rapa have an opposite role
in VSMC compared with CsA and Fk506.

POSTER BOARD NUMBER P4 – 199
2149 MMF CAN PREVENT THE PROGRESSION OF CAN IN
ALLOGRAFT BY AFFECTING RHOA/ROCK-1
J. Song, Y.P. Lu, G.H. Luo, L. Yang, Q. Xia, Y.J. Shi, Y.P. Li
West of China Transplantation Institute
Aim: The small GTPase RhoA/ROCK-1 play a role in the processing of organ
fibrosis. We studied whether MMF can prevent the progression of chronic
allograft nephropathy (CAN) in allograft by affecting RhoA/ROCK-1 signal
pathway.
Methods: Specific pathogen free animal male inbred F344 rat renal grafts were
orthotopically transplanted into Lewis rats following the procedure of Kamada
with our modification in CAN models. F344 were autografted as control. F344
rats were also autografted as control. The allograft rats were first treated with
CsA10mg/kg-1.d-1×10d and then divided into 3 groups (each n=3): (1) CAN:
Vehicle orally, (2) CsA (Cyclosporin A): 6 mg/kg-1.d-1, (3) MMF: 20mg/kg1.d-1. After 60days, SCR was measured and the pathological changes were
accessed. RhoA/ROCK-1 was examined by real-time PCR and fibrosis factors
a-SMA, CTGF were observed by immunohistochemistry.
Results: Showing in Table, SCR and Banff score increased obviously
increased both in CAN and CsA group. The differences between CAN/CsA and
autografts were significant (n=3/group, p=.000). SCR and Banff score changed
with fibrosis factors α-SMA and CTGF in MMF group increased moderate
at 60days, but were significantly lower than those in CAN/CsA group(n=3/

group,p<.05). Seeing in Figure, the fibrosis factors a-SMA and CTGF were
observed in renal epithelium and tubular cells. Protein of RhoA and ROCK-1
were observed in mesangial and tubule cells and increased gradually in the
processing of CAN. There was negative correlation between RhoA/ROCK1mRNA (¦ Ct values, ¦ Ct values were in inverse proportion to gene copies
in the cells and tissues) and Banff score(r=-.637, p=.000; r=-.676, p=.000) and
SCR(r=-.705, p=.000; r=-.756, p=.000). CsA can accelerate the expression of
fibrosis factors gene and protein. MMF attenuated the fibrosis factors α-SMA,
CTGF and down-regulated the expression of gene and protein of RhoA/
ROCK-1 in kidney allograft.
Conclusion: The findings of our study highlight the importance of abnormal
expression of RhoA/ROCK-1 signal pathway in the pathogenesis of CAN.
MMF can prevent the progression of CAN by down-regulating the expression
of the fibrosis factors α-SMA, CTGF and GTPase RhoA/ROCK-1.
Groups(each
n=9)

SCr(μmol/L)

Banff Score

RhoA(¦ Ct)

ROCK-1(¦ Ct)

Autograft

62.27±0.51

0

12.00±0.00

22.50±0.00

CAN

275.23±23.50

5.33±0.58

3.55±0.43

8.08±0.83

CsA

295.26±32.07

4.67±1.52

5.68±0.24

9.71±0.64

MMF

138.26±28.45*

1.67±1.16*

8.02±0.42*

12.72±0.85*

* p<.05
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2150 THE AUTOANTIBODY LEVEL OF CITRATE SYNTHASE
ARE CORRELATED WITH C4D DEPOSITION IN RATS WITH
CHRONIC ALLOGRAFT NEPHROPATHY
L.Y. Zhang, Y.P. Lu, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital
Background: C4d deposition after kidney transplantation is thought to
be associated with alloantibodies. Citrate synthase (CS) is an important
mitochondrial autoantigen and one of the key enzymes in citric acid cycle, which
plays a central role in regulation of energy homeostasis and cell metabolism.
This study is to investigate the relationship between C4d deposition and antiCS autoantibodies in rats with CAN post renal allotransplant.
Methods: Fisher344 rat renal grafts were orthotopically transplanted into
Lewis rats following the procedure of Kamada with our modification. All
the recipients were given CsA 10mg/kg-1.d-1×10d and then divided into three
groups: (1)Vehicle: vehicle orally, (2)CsA: 6mg/kg-1.d-1, (3)MMF: 20mg/
kg-1.d-1. At 4w, 8w, 12w after transplant, the rats were sacrificed, the renal
allografts were harvested and the sera was collected. The SCr was measured
and the pathological changes were assessed according to the Banff 97 criteria.
The isotype of CS antibodies, including IgM and IgG in all the recipients
were detected by binding indirect enzyme-linked immunosorbent assay
(ELISA) before and after transplant. The deposition of C4d was detected
by immunofluorescence and analyzed by Integrated Optical Density (IOD).
Results: With progression of the CAN from 4w post-transplant, the C4d
deposition in peritubular capillaries (PTC) increased. The level of IgM of
CS autoantibodies was more obviously stable and higher than IgG isotype in
all blood samples. With the progression of CAN from 4w,there was a strong
positive correlation between the level of IgG isotype of CS and C4d deposition
(r=0.973, p=.000) in vehicle group. CsA didn’t prevent the formation of IgG
isotype of CS (OD: 0.1370.001 and 0.2790.019 at 8w,12w, respectively,
p>0.5) and the deposition of C4d(IOD: 8.81040.3104 and 19.31042.1104 at
8w,12w, respectively, p=0.016). The values of IgG isotype of CS(OD) and
C4d (IOD) in groups of Vehicle, CsA and MMF at 12w post-transplant were
0.3350.009, 0.2790.019, 0.1130.000, and 21.11041.3104, 19.31042.1104,
8.21040.7104, respectively.The differences of IgG and deposition of C4d
between MMF and other two groups were all statistically significant (p=.000).
Conclusions: This study shows that there was a strong positive correlation
between the level of IgG isotype of CS and C4d deposition. The CS
autoantibodies may contribute to progression of CAN. MMF may inhibit the
progression of CAN by decreasing the formation of IgG autoantibodies of CS
and the deposition of C4d. CsA has no these effects.
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2151 IMPACT OF POST TRANSPLANT PANEL REACTIVE
ANTIBODIES ON LONG TERM GRAFT OUTCOMES IN
DECEASED DONOR RENAL TRANSPLANTATION
J.C.J. Choo1, M.L. Lai2, A. Vathsala1
1
Department of Renal Medicine, Singapore General Hospital, 2Health
Sciences Authority-Centre for Transfusion Medicine
The presence of panel-reactive antibodies(PRA) prior to transplantation has
been associated with a higher risk of graft failure in deceased donor renal
transplantation(DDRT). However, the role of PRA occurring post-transplant
has not been hitherto examined. Furthermore, the role of pre and post-transplant
PRA on long term survival is unestablished. The present study examined
the role of pre and post-transplant PRA in renal transplant recipients(RTX)
undergoing DDRT between 1988 and 2006 at our centre. All RTX had a
negative B and T-cell CDC crossmatch against donor lymphocytes. PRA was
tested against a panel of lymphocytes using the CDC method. From 1988
to 2000, RTX received Cyclosporine(CsA) and Prednisolone(Pred) with or
without Azathioprine(AZA) as primary immunosuppression(IS). From 2000,
AZA was substituted with Mycophenolate analogs(MPA) for RTX with PRA
>25%. From September 2002, RTX with a functioning graft at 1 year had
repeat PRA tested post-transplant annually. The present study examined the
change in PRA levels, pre and post-transplant, and evaluated their impact on
graft and patient outcomes.
The study population included 426 RTX (52.6% Female, 89.7% Chinese,
Mean Age 49.9 years) with at least one PRA measurement beyond 1 year posttransplant; those with graft loss and patient death prior to 1 year were excluded
from the study. IS consisted of CsA-Pred with or without AZA in 72.1%, CsAPred-MPA in 19.7%, and other combinations in the remainder. All deaths,
including death with a functioning graft were considered as graft failures.
Overall actuarial graft survival at 5, 10 and 15 years was 96.3%, 90.4% and
76.2% respectively. 42% of RTX were not sensitized pre-transplant; proportions
with PRA of 1-10% and >10% were 12.2% and 45.8% respectively. RTX with
pre-transplant PRA<10% had significantly better graft survival to 15 years
(82.4% vs. 67.1%, p=0.003). There were no differences in incidence of either
early or late rejection in sensitised vs. non-sensitised RTX.
In comparison to pre-transplant PRA, mean post-transplant PRA was
significantly higher (18% vs. 42%, pre vs. Average of all post-transplant
PRA, p=0.000). Indeed, in relation to the pre-transplant PRA, 72.3% had an
increase in post-transplant PRA, while 23.5% had a decrease, while 4.2%
remaining unchanged. Furthermore, RTX with a decrease in post-transplant
PRA or unchanged PRA, in comparison to pre-transplant PRA, had no survival
advantage. Separate analyses evaluated the impact on graft survival of PRA at
each of the 1st four years post-transplant as well as of averaged values during
various post-transplant periods from the 1st to 4th years and at 5-yearly intervals
thereafter till 19 years. Each analysis included stratification for different levels
of PRA values; none demonstrated any correlations with graft survival.
These results demonstrate that broad sensitisation as measured by pre-transplant
PRA has a significant impact on long-term outcomes to 15 years post DDRT.
Post-transplant, the majority of RTX experience an increase in PRA; however,
this change neither confers benefit nor risk to graft survival in DDRT. Identifying
post-transplant Anti-HLA antibodies, donor specific antibodies or cellular
alloreactivity may better identify RTX at risk for chronic allograft failure.

POSTER BOARD NUMBER P4 – 202
2152 PROSPECTIVE TESTS ON THE PREDICTIVE VALUE OF
ANTI HLA AND MICA ANTIBODIES
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P. Terasaki, M. Ozawa
Terasaki Foundation Laboratory
In two prior studies involving 1329 patients and 1219 patients a strong
predictive value on subsequent graft function was noted for HLA and MICA
antibodies. This data was based on kidney transplants, and confirmatory results
on 235 heart and 150 lung transplant patients was recently published.
We have now completed the prospective testing of the sera of 4,977 functioning
patients of 4,081 kidney, 164 liver, 456 heart, 194 lung transplants. A total of
76 centers from 20 countries are participating in this study. This new study
involving an entirely new set of patients should provide definitive evidence
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of the predictive value of these antibody tests. The new tests also incorporate
the testing with single antigen beads, allowing for separation of donor specific
antibodies from other non specific antibodies.
We will report on the outcomes from the earliest study (now 6 years post
testing), up through the recently tested patients with one year follow-up.
Thus far we have confirmed that transplanted patients with well functioning
grafts, nevertheless often do have anti HLA and anti MICA antibodies. The
frequencies in patients with more than 1 year of good function are given in
Table 1.
In summary, 4,977 patients who have functioning transplants were tested for
anti HLA and MICA antibodies, and then followed up for subsequent graft
failure. We will present the predictive value of antibodies on graft survival data
for kidneys, heart, lung, and liver transplants.
Organ

HLA #

HLA%

MICA

Heart

349

47%

114

MICA%
15.8%

Kidney

2120

26.1%

907

20.5%

Lung

117

31.6%

56

12.5%

Liver

82

43.9%

56

12.5%

Total

2695

29.4%

1104

19.3%
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2153 THE IMPACT OF PRE-TRANSPLANT ANTI-HLA AND
MICA ANTIBODIES ON LONG-TERM GRAFT OUTCOMES
M.D. Wavamunno1, P.J. O’Connell1, C.L-S. Fung1, R.D.M. Allen2,
N. Watson3, F. Aboud-Daher3, J.R. Chapman1, B.J. Nankivell1
1
Dept Renal Medicine and Transplantation Westmead Hospital,
2
Transplantation Surgery, Westmead Hospital, 3Tissue Typing,Australian
Redcross and Blood service
Introduction: HLA antibodies are associated with late graft loss of kidney
transplants. Solid phase assays can detect low levels of circulating antibody
however the clinical consequences of antibodies detected by these techniques
are not fully understood. The aim of this project was to determine the clinical
significance of pre-transplant antibodies detected by luminex microsphere
assays on long-term renal function, survival and graft histology.
Methods: We retrospectively screened simultaneous kidney pancreas
recipients (n=117) transplanted at our centre for pre-transplant HLA and
MICA antibodies where there was availability of pre-transplant sera. Sera were
screened to determine the presence or absence of anti-HLA Class I or Class II
and MICA antibodies using luminex. Sequential prospective protocol kidney
biopsies (n=318) from implantation to 5 years post transplant were evaluated
for histological parameters using the Banff schema and for deposition of C4d in
peritubular and glomerular capillaries by immunoperoxidase staining. Findings
were evaluated against clinical outcomes including isotopic DTPA GFR from 1
yr to 10 yrs and graft survival.
Results: Class I and/or Class II anti-HLA antibodies were found in 60 of 117
(52%) patients (17 Class I and II,38 Class I and 5 Class II). Of 60 patients
with anti HLA antibodies 19(31%) had a peak PRA >25% compared with 7
(12.2%) in the group without HLA antibodies, (÷2=6.8, P<0.02). Presence of
anti-HLA antibodies was associated with Banff Cg score >1 beyond 2 year
after transplantation (÷2 =6.3, P<0.02). The 1,3 and 5 year isotopic GFR
levels were higher in the cohort without HLA antibodies compared to those
with HLA antibodies (54.5 ±4.2 vs. 64.2±2.9, 49.5±3.4 vs. 63.6±3.6 and
43.2±3.8 vs58.9±4.0 ml/min/1.73 respectively (P <0.05). Beyond 5 years
after transplantation there was no difference in GFR between groups. Total
uncensored graft loss was higher in the group with HLA antibodies 16/60
(26%) compared to 5/57 (9%) in the group without HLA antibodies (P<0.01).
There was a trend to higher death-censored graft loss 8/60 (13%) compared
to 2/57(3.5%) (p=0.06). MICA antibodies were present in 28 of 105 (26%)
patients. There was no association between peak panel reactive antibodies and
presence of MICA antibodies. Isotopic GFR and graft loss were comparable
in both groups.
Conclusions: Presence of pre-transplant MICA antibodies is not associated
with reduced GFR or graft survival. Pre- transplant Anti HLA antibodies
detected by sensitive solid phase assays are associated with poor long-term
histological and clinical outcomes in renal allograft recipients.
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2154 HLA MISMATCHES AND PRA IN KIDNEY RETRANSPLANTS
K. Mizutani1, G. Monokazu2, P. Terasaki1
1
Terasaki Foundation Laboratory, 2Nagoya University
Kidney re-transplants are increasingly performed worldwide even though they
are considered high-risk. One reason for the extra risk is that re-transplants
have higher PRA than first transplants, giving rise to serious issues—including
the fact that highly sensitized patients often lose their opportunity for transplant
specifically because the risk of their higher PRA renders them less desirable
candidates. Currently, there are many patients on the waiting list and those
numbers have been increasing. Defining the effect of HLA mismatches and PRA
on re-transplants will give more opportunities to patients awaiting transplants.
Here, we examine the trends of change, over the years, in the relationships
between PRA, HLA mismatch, and 1st, 2nd, 3rd and multiple transplants from
deceased donors.
Data from 1987 up to November 2007 was obtained for 163,967 deceased
kidney transplants reported to the Organ Procurement and Transplantation
Network/United Network for Organ Sharing (OPTN/UNOS).
HLA mismatches have increased nearly every year with both 1st and 2nd
transplants while the percent of low PRA with 1st transplants and high PRA
with 2nd transplants both increased. Although high PRA levels can reduce the
rate of graft survival, that rate with 2nd transplants improved to almost the same
levels expected with 1st transplants. However, some difference between the two
groups did persist for 5-year graft survival.
In conclusion, the graft survival of all HLA mismatches and PRA levels
improved. And effect of HLA mismatches and PRA on re-transplants has been
decreased. However, although advances in immunosuppression during the last
decade have resulted in better short term graft survival, our analysis suggests
that new drug treatments may not be enough to affect long term transplant
outcomes.

POSTER BOARD NUMBER P4 – 205
2155 CYLEX IMMUKNOW® IN THE MANAGEMENT OF POST
KIDNEY TRANSPLANT RECIPIENTS.
M.R. Carreño, G. Ciancio, G.W. Burke, L. Chen, J. Sageshima, P. Ruiz
Departments of Surgery and Pathology, University of Miami-L. Miller School
of Medicine
The ImmuKnow® assay has proven to have utility in the assessment of
immunosuppression in organ transplantation. In the present study, we
evaluated Immuknow responses pre- and post-renal transplantation of serially
drawn specimens obtained randomly, during quiescence, rejection, or infection
episodes and correlated these findings with other tests and clinical outcomes.
Renal transplant patients received induction therapy with depleting antibodies
and were maintained on Prograf and low dose steroids. A total of 2096
specimens from 339 transplants were evaluated using Immuknow. Levels of
ATP were categorized as Low or Strong when outside the Moderate range of
225-525 ng/ml.
Several patterns were observed with healthy adult volunteers or patients. In
general the mean responses of healthy adults (Controls) was 432+150 ng/mL
(n= 20). Pre-transplant specimens from kidney transplant recipients showed

lower levels than controls with a mean of 342.1+155 (n=91, not all tested), but
significantly higher (p<0.005) than post-transplant values at 1-30 (203.7+171
ng/mL), 30-365 (249.1+162 ng/mL), 366-730 (278.3+147 ng/mL), or 730-1090
(263.5+136 ng/mL) days post-transplant. Patients that tested Strong pre-Tx
(n=10) remained Strong in subsequent testing without notable evidence of
rejection (1st. year n=11, 2nd. year n=10, 3rd. year n=4). Of those with cellular
(C) (n=8) or humoral (H)(n=2) rejections while monitoring, all in the C group
had increases >200 ng/mL with rapid return 1-2 days after function was restored,
and the H group did not have any ATP changes. Of those with infections (n=23)
except for two, there was a tendency to go below >150 ng/ml. Stable patients
remained within a 200 ng/ml range (quiescent zones) within Low/Moderate
levels. Patients with persistent low levels (<100ng/ml) (n=29) did not have
major consequences as reported by others. In addition, low absolute CD4+ T
cells (100 cells/mm3) did not impede Strong Immuknow responses.
Serial monitoring with ImmuKnow is crucial to establish individual patient
baseline levels, which vary significantly in clinically stable patients.
Significant changes in ImmuKnow throughout the post-transplant period helps
individualize and tailor immunosuppression levels. Our results suggest that the
Immuknow assay can aid significantly in the clinical management of kidney
post-transplant recipients.

POSTER BOARD NUMBER P4 – 206
2156 OUTCOMES OF ALLOGRAFT DYSFUNCTION IN RENAL
TRANSPLANT RECIPIENTS WITH MHC CLASS I CHAIN
RELATED PROTEIN A ANTIBODIES (MICA): SINGLE CENTER
ANALYSIS.
Y. Qazi, V. Pradeep, E. Solbes, M. Hermes, M. Smogorzewski, M. Koss,
R. Mateo, L. Sher, R. Selby, Y. Iwaki
University of Southern California
Antibody mediated rejection is a significant contributor of allograft dysfunction
(GD) and detection of post transplant HLA antibodies has been shown to
correlate with poorer graft survivals. Newer techniques can now detect
antibodies to MICA with better accuracy but the frequency and significance of
these antibodies is unclear. Aim: To evaluate sera of Kidney Tx recipients (KTx)
with GD for the presence of MICA and to asses its impact on outcomes.
Methods: The study was a retrospective, observational study of KTx recipients
with GD from 03/2002 – 07/2007. GD was defined as a clinical event requiring
a kidney biopsy (KBx). MICA and Class I &/or Class II HLA Ab (HLA Ab)
were detected by using Single Antigen Beads (Luminex) and analyzed with
Labscreen software (One Lambda). A positive result was characterized by
an increase in fluorescent intensity of >100 raw data units. The histology of
allografts was defined using the Banff classification.
Results: 200 KBx were performed during this period and concurrent serum
samples were available for 66 biopsies on which MICA and HLA Ab antibody
testing was performed. MICA was detected in 44/66 patients. MICA with a
positive or equivocal C4d but no HLA Ab was detected in 5 patients (1C4d +,
4 C4d equivocal).MICA with a negative C4d and HLA Ab was detected in 14
patients. MICA and HLA Ab was detected in 25 patients. Of the 5 MICA(+)
patients found to be C4d + /equivocal but HLA Ab negative, 2 had graft loss.
Graft loss occurred in the patient who was C4d + and in another patient with a
equivocal C4d but a recipient of a combined Liver Kidney Tx. The mean [Cr]
at time of biopsy was 2.74 mg/dl (1.4 – 6.0 mg/dl). Of the two patients with
graft loss, the mean duration before graft loss was lost was 41.5 months (range
35-48 months) and the mean Cr at last follow up for the remaining grafts was
1.57mg/dl (0.8 – 2.3 mg/dl). Of the 14 patients that were negative for C4d and
HLA Ab, 10 were found to have mild ACR but no patient had lost a graft. At
the time of biopsy, mean [Cr] was 2.75 mg/dl (1.4-6.9 mg/dl). Mean follow-up
from transplant was 23.4 months (5.6 –48.9 months) with last follow-up mean
[Cr] of 1.59 mg/dl (1-3.2 mg/dl). Since the presence of HLA Ab would make
it difficult to evaluate the significance of MICA, this group was not studied
further.
Conclusion: Our study demonstrates that in KTx with allograft dysfunction,
detection of MICA in the presence of a positive or equivocal C4d independent
of HLA Ab is a risk factor for graft loss and that all C4d + or C4d equivocal
biopsies without HLA Ab should be evaluated for MICA. Detection of MICA
in the absence of C4d or HLA Ab is a risk factor for ACR and may account for
late allograft dysfunction which may require alteration in immunosuppression.
Data is being collected prospectively to confirm these observations.

705

THURSDAY

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Poster Abstracts

CONCURRENT ORAL SESSION 146: DONOR ATTITUDES
AND EDUCATION
POSTER BOARD NUMBER P4 – 207
2157 COMPARING THE DYNAMICS OF KIDNEY AND LIVER
TRANSPLANTATION WAITING LIST IN THE STATE OF SAO
PAULO, BRAZIL.
E. Chaib1, E. Massad2
1
University of Sao Paulo School of Medicine, 2University of Sao Paulo School
of Medicine
São Paulo is a pioneer brazilian state on transplantation surgery. Kidney and
liver transplantation was first performed at Sao Paulo Medical School. Since
then the patient waiting list for both kidney and liver transplantation has
increased now approximately 600 and 150 new cases, respectively, per month.
The aim of this study was to compare the performance of our state kidney and
liver transplantation program and analyze when the number of transplantations
for both will meet our waiting list demand.
We collected official data about our kidney and liver transplantation program
between July 1997 to October 2004. The data related to actual number of liver
and kidney transplantation, (Tr), the incidence of new patients on the list (I),
and the number of patients who died in the waiting list, (D) in the State of Sao
Paulo since 1997 are shown in Table 1. We projected the size of the waiting list,
L, by taking into account the incidence of new patients per year, I, the number
of transplantations carried out in that year, Tr, and the number of patients that
died in the waiting list, D. The dynamics of the waiting list is given by the
difference equation:, that is, the list size at time t+1 is equal to the size of
the list at the time t, plus the new patients getting into the list at time t, minus
those patients who died in the waiting list at time t, and minus those patients
who received a graft at time t. The variables I, and D, from 2004 onward were
projected by fitting an equation by maximum likelihood, in the same way that
we did for Tr. The waiting list, compared to the number of transplantations, can
be seen in figure 1.
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2158 BE BLESSED: A BIOPSYCHOSOCIAL MODEL FOR
RUDUCING HEALTH DISPARITIES
A. Campbell Jr., C. Callender, M. Lofton, L. Keen, A. Turner, J. Wiley,
L. Adams, E. Clark, D. Morehead, T. Willis
Howard University
Background: Most biopsychosocial models contend that health and wellness
are determined by biological, psychological, and social factors. The present
study introduces a health model that broadens the biopsychosocial view to
include a spiritual factor that also influences health-related physiological
processes. The BE BLESSED Health Model™, as it is called, is a
biopsychosocial-spiritual model of health that has been primarily derived
from findings in an empirical study of psychosocial stress and health that
our research group has been conducting with a community-based sample
of adult African Americans. This conceptual model recognizes that health
outcomes are determined by the dynamic interplay of activities across
nine biopsychosocial-spiritual sub-domains expressed by the acrostic BE
BLESSED.
Objective: The current study examines the socioeconomic gradient in health
and discusses its implications in relation to objective biomarkers of health,
renal disease, health perception, and elements of racism.
Methods: Participants in our study include 125 African American (males=
60 and females=65) between the ages of 18 to 85. Each participant in the
study provided a blood and urine sample to determine the levels of immune,
endocrine, cardiovascular, and metabolic functions. Participants were also
given a battery of neuropsychological tests, psychosocial measures, and a
health related quality of life survey.
Results: The present study focuses on those findings that involve measures
of metabolic activity (HDL, triglycerides, waist to hip ratio), cardiovascular
functions (blood pressure), health related quality of life, and perceived racism.
As expected, socio-economic status (SES) was inversely related to HDL levels
and directly related to triglyceride levels, waist- to- hip- ratio, and systolic blood
pressure. Regression analyses show that in addition to SES, perceived racism
accounted for a significant proportion of the variance in general (physical)
health perception and mental health.
Conclusions: These findings suggest that in addition to social class, elements
of racism are independently related to subjective impressions of physical and
mental health. They are also consistent with other studies which show a greater
proportion of sub-clinical markers of disease risk and chronic health conditions
among lower SES persons. These findings are examined in the context of
the BE BLESSED model and its potential for identifying the underlying
mechanisms that link biological, psychological, social, and spiritual factors 1)
to the onset and progression of renal disease and other disease processes, 2) to
physical healing and recovery, and 3) to health disparities among ethnic and
racial minorities.
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In conclusion, provided the conditions of the present day, the two projected
curves will never meet each other. In other words, the list size grows at a rate
much higher than the number of transplantations actually done.
Table 1. Actual number of liver and renal transplantation, Tr, the incidence of
new patients in the list, I, and the number of patients who died in the waiting
list, D, in the State of São Paulo since 1997
Liver
I

Kidney
I

D

541

1598

492

787

2980

834

548

907

3430

1014

1248

604

921

3440

1248

242

1486

725

874

1910

976

2003

289

1564

723

891

2544

1080

2004

295

1500

671

1001

2146

695

Year

Tr

1997

63

1998

160

553

321

1999

188

923

414

2000

238

1074

2001

244

2002

706

D

Tr
450

S.E-D. Al-Horani
Saad Specialist Hospital
Introduction: The availability of organs and tissue for transplantation is driven
by public attitudes towards transplantation. To increase organ donation, public
awareness campaigns simply urge individuals to discuss organ donation with
their families. A representative sample of 50 people (age range 20–57 years)
who were registered as potential for renal transplant donors (n=26) or members
of the general public (n=24) participated in this study. It was designed to
explore the feelings, ideas and public attitudes towards donating a kidney for
transplantation.
Methods: Unstructural interviews were conducted for 30-40 minutes. Analysis
of transcripts was based on hermeneutics and focused on identification of
typical attitude patterns related to donating organs.
Findings: Thirty six respondents had positive attitudes about organ donation,
six had negative attitudes, and eight were undecided. Respondents seemed to fit
into one of four typical attitude patterns regarding willingness to donate organs.
The attitude pattern of willingness to give was characterized by a perspective
of the body as an object or machine, where parts could easily be exchanged.
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The focus was on functioning of organs. Respondents with a willingness not to
give (unwilling to give) seems that their strong anxiety regarding death made
them unwilling to donate their own or a relative’s organs. An attitude pattern
of mixed feelings initially willing to give, preferably to family members was
characterized by initial intention to donate and give a family member either for
life saving or enhancing a quality of live. Respondents who had mixed feelings
about willingness to give (undecided) focused on there was no clear idea abut
willing to give, it is still unclear for them about for whom they can give, or
when to donate?
Conclusion: Four attitude patterns about organ donation seemed to reflect
two conceptions of the body: the body as machine, where bodies were seen as
machine like objects that did not express personal identity or self. In this way,
donating organs does not present an internal conflict to the person. On the other
hand the influenced body, where body parts comprised the whole, which could
be affected by transplanted organs.
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2160 VALUATION OF PRIORITY CRITERIA FOR
THE ALLOCATION OF DECEASED DONOR KIDNEY
TRANSPLANTS; VIEWS OF PATIENTS, PROFESSIONALS AND
DONOR FAMILIES
R. Higgins1 , M. Clark2, A. Gumber2, A. Szczepura2, D. Leech2, D. Moro3,
N. West1,
1
University Hospital, 2Warwick Medical School, 3Universita’ Cattolica del
Sacro Cuore
Aims: Those designing systems for the allocation of deceased donor kidney
transplants need to be informed by the views of professionals and patients in
order to produce equitable allocation algorithms. We studied a large sample
of patients and professionals, including carers and for the first time donor
families.
Methods: Extensive piloting was used to establish criteria (attributes) that
may be valued when prioritising patients. Discrete choice experiments
(DCE) (using questionnaires) were used to explore the different weightings
respondents placed on these criteria. Final analysis was undertaken using
appropriate regression techniques, and according to respondents’ ethnicity,
gender, transplant status, quality of life, age, dependents (adults or children),
and stated altruism.
Results: Final priority criteria included waiting time; level of HLA matching;
differences in the patients’ number of dependents; age of recipients; and
illnesses affecting both length of life and quality of life. Responses came
from 908 patients; 113 healthcare workers; 41 carers and 48 donors. All the
attributes were statistically significant. Significant differences in preferences
were observed in some categories of patients. Patients of non-white ethnicity
had less strong preference for HLA matching. There were also differences
by transplant status, age, respondent quality of life, altruism of responders,
and whether patients had dependent children. Respondents’ gender and
having adult dependents did not influence preferences. Compared to
patients, healthcare workers placed more value on prioritizing young
patients and on prioritizing those with diseases having a moderate effect on
life expectancy.
Summary: This large study indicated that respondents valued multiple
factors affecting the allocation of deceased donor kidneys. DCE
methodology had not previously been used in this area, but proved very
powerful. The results are broadly supportive of the changes made in the
UK 2006 transplant allocation policy, in which more priority was given to
long waiters and young adults. Despite HLA matching now only producing
a small numerical benefit in transplant survival, it remained an attribute
valued by all groups of patients and professionals, though was valued less
by patients of non-white ethnicity, who may be disadvantaged by allocation
systems using HLA matching.
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2161 “ORGANS TO BE TAKEN WITHOUT CONSENT”- THE
INFLUENCE OF MEDIA ON DISCUSSIONS OF THE “OPT OUT”
SCHEME
N. Stitt, A. Bakran
Royal Liverpool University Hospital
On 13th January 2008 the Prime Minister Gordon Brown released a statement
in a newspaper article supporting the “opt-out” scheme for organ donation and
suggesting debate on the issue. The article made headline news and, with the
release of the Organ Donation Task Force Recommendations two days later, it
kept Organ donation in the news for most of that week. There was considerable
media and public response. Five newspaper broadsheets, four tabloids and the
BBCs news website were reviewed to assess how they managed the Prime
Minister’s statement and subsequent discussion of the “opt-out” proposal.
60% of the media group gave a positive interpretation of the Task Force
recommendations and discussed the “opt-in/opt-out” consent issue. Only two
newspapers gave information about how to join the Organ Donor Register or
details of UK Transplant website.
30% of the media group were negative on the “opt-in/opt-out” consent issue
and gave little or no information regarding Task Force Recommendations. The
newspapers were politically motivated in their comments. The subject of Organ
Donation did not seem to be the focus of their discussions and organ donation
was used as a platform with which they could vent their objections to Prime
Minister Gordon Brown!
The remaining 10% of newspapers were neutral in their opinion; however they
did tend to focus again on the consent issue.
The newspapers that were positive in their reporting also had the most positive
reader comments and those negative had the most negative reader comments.
The Daily Mail was particularly negative and its columnist wrote the most
disturbing article and also spoke on national Radio. Her description of brain
stem death was not only completely inaccurate but more worryingly her
interpretation was believed by readers. Comments posted on the Mail’s forum
included.” I think donating one’s organs is wonderful… However I’ve heard
too many scare stories to want to be a donor now”. This comment supports
the theory that adverse publicity can cause enormous damage to altruistic
organ donation. Surprisingly, no comments were sought or published from the
Transplant Community.
The saying “There is no such thing as bad publicity” is unlikely to hold true in
the case of organ donation. The Transplant Community has to use the media to
its advantage and gain some control over what is written although we cannot
control the debate. The involvement of politicians in the “opt-in/opt-out” debate,
unfortunately, may not always be helpful and, indeed, may be harmful!
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2162 REGULATED UNRELATED LIVING DONATION
PROGRAM AND TRANSPLANT TOURISM: WHO IS THE
WINNER?
E. Mor, R.N.R. Michowiz, R. Rahamimov
Dept. of Transplantation, Rabin Medical Center
Objective: In 1998, with an attempt to offer an alternative to the growing
number of patients traveling abroad a national regulated unrelated-donation
kidney transplant program was implemented. We sought to determine whether
that program had any effect on transplant tourism of Israelis abroad.
Material and Methods: A chart review of 216 potential living donors
interviewed at our pre-transplant clinic between 1/00-12/07 was performed.
The number of transplants performed yearly at our center categorized into
living-unrelated and living-related were recorded. Patients who discontinued
the evaluation process before the interview at the Ministry of Health (MOH)
committee or whose donation was disapproved were categorized into those who
remained on the waiting list, transplanted in Israel, transplanted abroad or died.
Results: The proportion of unrelated transplants increased over time (table).
The approval rate of donation at the committee was 55.5% (120/216); 95/120
underwent transplantation including 2 with a second unrelated-donor. A medical
problem prohibited donation in 16 donors, another 3 patients underwent
deceased-donor transplantation and 6 others underwent transplantation abroad.
Of the remaining 96 patients whose donor discontinued the process or declined
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at the MOH committee, 23 are still waiting, 16 were transplanted in Israel, 43
underwent transplant abroad and 13 patients died.
Conclusions: The Israeli regulated-unrelated living donation program failed to
reduce transplant tourism and actually provided an alternative option to livingrelated donation.
Living Related
Living Unrelated

2000

2001

2002

2003

2004

2005

2006

2007

34
7

38
6

32
8

35
7

20
22

19
20

22
16

30
22
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2163 FACTORS WHICH IMPACT ON ORGAN DONOR
REFERRALS IN SOUTH AFRICA
E. Muller, Z. Barday, R. Cauley, F. McCurdie, D. Kahn
University of Cape Town
The significant decline in the number of cadaveric organ donors in recent years
is a universal problem and of major concern. We undertook a retrospective
review of all organ donor referrals to the Transplant Unit at Groote Schuur
Hospital between 1996 and 2005, in an attempt to identify potentially remedial
causes for the decline in the number of donors.
Hospital records of all organ donors referred to our institution were retrospectively
reviewed, and the demographics, causes of death, outcomes, reasons for refusal
of consent, and factors which influenced consent rates analyzed.
There were 824 donor referrals during the 10 year study period. The number of
referrals has declined from n = 115/year in 1996 to n = 63 in 2005. The male
to female ratio was 3:1, and the mean age was 26.15 years. There were 321
black patients, 318 of mixed racial origin and 154 white patients. The decline
in referrals was apparent in all racial groups. The cause of death was related
to trauma in 640 donors (gunshot wounds n = 151, motor vehicle accidents n
= 280, and assault n = 143), and medical reasons in 171 donors. A total of 315
donors (37%) were used successfully. Consent was refused in 222 donors (27%)
and 176 were found to be unsuitable. Nineteen (2.3%) donors were found to be
HIV positive. The consent rate was higher in white donors (66%) compared to
black donors (33%) and those of mixed racial origin (50%). Consent rates were
not influenced by age or gender. Consent rates were higher in suicide victims
(62%) and lower in gunshot (34%) and MVA Pedestrian victims (39%).
In conclusion, the decline in the number of referrals is a concern. Furthermore
the overall success rate of 37% is disappointing, and the lower consent rates in
black and mixed race donors should be addressed with public awareness and
education programmes. The HIV crisis has not affected organ donation yet.
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2164 ORGAN DONATION WITHOUT ALTRUISM? COULD
EDUCATION HELP TO SOLVE THIS DILEMMA?
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F. Cantarovich
Catholic University Argentina
Organ shortage (OS) is a “modern disease”. The solution should be to use
every acceptable deceased donor (DD). However, stagnant DD donation
has intensified living donors; and recently paid donation has been proposed.
Rationale for payment is to rescue dialysis patients for suffering and death.
Public surveys were discordant. We observed that from 2321 respondents 25%
considered payment convenient and 19% ethical. These results encourage the
evaluation for non-economic incentives.
Non-economic approaches proposed are: 1) “ethical incentives” such as donor
social/medical protection, 2) improving dialysis patient’s survival and transplant
outcome, 3) access to better healthcare systems, 4) education programs.
Education may improve OS sustaining altruism, fairness, and respect for
autonomy. It has been argue that much money has been spent in education
without success. Why this result? 1) The message “organ donation a gift of life”
did not impact society. By education people should acknowledged that sharing
DD organs more than a gift is a right and a duty for everybody. 2) Media did
not address valid notions, e.g.: the intrinsic value of the DD, the concept that
during life we might be more organ recipients than donors, the number of
patients dying on the waiting lists, the standpoint of monotheist religions.
A worldwide effort is being attempted to correct these issues by school’s
education programs. All these programs targeted high schools. The studies
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arrived to similar conclusions about the positive changes observed in students
and the need to include information about organ donation and transplantation
in school curriculum.
Surveys performed among well educated people n: 2320 (A) and transplant
specialists n: 139 (B) showed: 1) 66% of A and 89% of B agreed that “sharing”
organs might be consider as a conceptual agreement between individuals and
society. 2) 85% of A and 82% of B were in agreement with education at schools.
A pilot assay on school education on transplantation was performed in Canada
and Argentina. Teaching subjects were: brain death, the DD, waiting lists,
religious opinions, etc. Between 75% and 100% of the students (10 to 19 years)
enjoy and agreed with the presentation
As Childress said “rationalistic policies to increase the supply of a transplantable
organ may appear to be quite defensible but then turn out to be ineffective and
perhaps even counterproductive”
Ethical and legal issues regarding live paid donation have been largely
discussed, and the controversial is sluggish. Undoubtedly a factual issue is that
DD is the source of extra renal transplants. Potential slowing down of altruistic
DD=death of thousand of patients or to developing a savage organ market: A
risk of opening Pandora’s Box.
Altruism is the cornerstone of organ donation; economic incentives would turn
into organ trade, would authenticate the exploitation of poor people and will
dissuade the real altruist.
Organ donation should be recognized trough education as a social compromise,
between individuals and society and the logical award for this kind of
engagements are exclusively ethical and moral.
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2165 RELATIVES’ REFUSAL RATE FOR ORGAN DONATION
IN RELATION TO DONOR REGISTER AND DONOR AGE
H. Van Leiden, N. Jansen, A. Hoitsma, B. Haase-Kromwijk
Dutch Transplant Foundation
Purpose: In the Netherlands consent for donation is based on an opting in
system. Before consent for donation is requested from relatives, the national
Donor Register (DR) must be consulted in which Dutch citizens can state their
will to donate. Since the introduction of the DR in 1998 the number of donors
did not increase until 2007 (~200 donors/year). In order to stimulate consent
for donation more efficiently, the relation between the registered donor will, the
decision to donate given by relatives and the donor age has to be clarified.
Methods: We used data from a centrally registered medical record review of
all deceased patients from intensive care units of 73 hospitals in the years 2005
and 2006. Out of 947 recognized medical potential organ donors, the outcome
of DR consultation and corresponding relatives’ refusal for donation were
analyzed. DR outcome and relatives’ refusal for organ donation were studied
for different groups of donor age.
Results: 947 recognized medical potential organ donors finally resulted in 312
referrals to the Dutch Transplant Foundation for organ donation. The DR was
consulted in 88% of all potential organ donors. If the DR was consulted, no
registration was present in 56% and in 18% consent was found in the DR. In
7% donors left the decision for donation in the DR to the relatives and in 18%
a refusal was registered. The consent/refusal ratio in the DR (51% vs. 49%)
after consulting for these donors differed from the ratio among all registered
people in the DR nationally (65% vs. 35%, December 2006). This is because
the age of potential donors is on average higher than the age of all registered
people in the DR. Among all DR consults in this study the refusal rate in the
DR increased by donor age from 15% in donors aged 18-35 years to 36% in
donors of 66 years or older.
When consent was present in the DR, relatives still refused donation in 6%.
When no consent/refusal was found in the DR, relatives were not requested
for donation in 11%, but if requested, relatives refused donation in 68% of the
cases. The refusal rate among relatives was significantly higher for potential
donors who were not registered in the DR (68%) than for potential donors who
were registered and left the decision in the DR to relatives (42%). Relatives’
refusal increased from 49% in donors aged 0-17 years to 83% in donors of 66
years or older when the DR was not decisive.
Conclusion/ discussion: The refusal rate for organ donation in the Netherlands
is high and increases in donors of older generations, both in the DR and among
relatives requested for donation.
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Donation rate could increase when people are better informed about organ
donation and about each others will to donate. This could be improved by
continuous stimulation of public and family discussions about donation,
especially among the elderly.

POSTER BOARD NUMBER P4 – 216
2166 WHAT DONOR FAMILIES CAN TEACH US ABOUT
OBTAINING CONSENT: DONOR FAMILY VIDEO INTERVIEWS
L. Dinhofer
Hood College, KoDen, LLC
Purpose: This presentation will highlight video clips and coordinating
educational components of a video interview project investigating: the
experience, decision-making factors, coping mechanisms and out-comes in
electing organ and tissue donation subsequent to homicide, suicide, pediatric
death and multiple simultaneous loss within one family; understanding the
impact of positive and negative death notifications on consent; short/longterm perceptions of brain death and decision-making; the transformative
power of donation on traumatic/stigmatized death during and after consent;
the psychological/spiritual perceptions of a living host for an anatomical gift;
presumed consent vs. an opt-in election.
Methods/Materials: Individually videotaped interviews of Caucasian and
African American organ and tissue donor families who had experienced
traumatic loss through a mid-west U.S. organ procurement organization.
Participating families were voluntarily consented verbally and in writing
regarding the purpose, scope and educational intent of the project with release
for application in various settings. Interviews averaged 90 minutes in length
and were edited to accompany didactic educational training curriculums for
state conferences, Requestors, Hospital Development and Aftercare staff,
community healthcare professionals and college students. Individual family
anonymity was maintained until after the project was completed when a
reception was held for a screening and group discussion.
Results: Participating families highlighted much needed information regarding
how to work with them from the initial notification of crisis, to consent through
to bereavement, and confirmed the option of donation as a powerful coping
mechanism and transformative tool for dealing with traumatic and unexpected
loss.
Conclusion: The project has been successful in highlighting donor family needs
and converting negative bias, misinformation and stereotyping about donation;
caring for families experiencing traumatic loss and the impact that care has on
the decision-making process and outcomes. Feedback from professional and
lay viewers in various educational settings has been overwhelmingly positive
and educational.
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the understanding of different donation and transplantation models used
internationally is an important consideration for training. Course programs
are designed to facilitate the exchange of experiences among participants and
faculty members.
Results: TPM acquired an international dimension soon after its inception,
thanks to a vast network of qualified professionals throughout the world that have
collaborated as faculty members. Each year health professionals from all over the
world participate in the TPM training programs, as shown in the Table 1.

Up to now, 5676 participants from 90 countries have been trained by the TPM
considering all the training modalities.

Figure 1. Number of TPM courses participants displayed by continent and year
of attendance.
Conclusion: The learning process has reinforced the communication amongst
professionals, enhancing international information sharing and collaboration.
This established network has also allowed TPM to engage health professionals
in International Projects to analyze and improve the donation and transplantation
activity among European countries.
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2167 INTERNATIONAL DIVERSITY AS THE KEY TO AN
EFFECTIVE TRAINING PROGRAM

2168 NATIONAL SURVEY OF POTENTIAL ORGAN DONORS
IN SWEDEN

T. Coco1, G. Paez2, R. Valero2, M. Manyalich2
Queenslanders Donate – Princess Alexandra Hospital, Australia, 2
Transplant Procurement Management, IL3– Universitat de Barcelona, Spain
Purpose: Transplant Coordinators require a multidisciplinary profile to
effectively manage the organ and tissue donation process. They have to
develop solid and comprehensive skills in technical, scientific, psychological
and human capabilities by integrating the theoretical and practical knowledge
in their daily clinical practice. Furthermore, they should be able to work with
the everyday challenges in the field and consequently, integrate their skills and
knowledge within the work environment to reflect international best practice.
Method: Based on the learning-through-experience model, Transplant
Procurement Management – TPM has been developing since 1991 a training
methodology aimed at answering the needs of health professionals involved
in organ and tissue donation and transplantation: face-to-face courses, online modules and blended-learning programs, such as the International
Master’s Course. Special attention is given to adapt the courses to the
specific needs of the different country’s issues. In order to do so, TPM
works closely with the partner organization in order to include local experts
in the curriculum.
Whether organizing national or international courses, TPM considers that

C. Möller, Å. Welin
Swedish National Council For Organ And Tissue Donation
Background: Sweden has about 135 organ donors a year/9,2 millions.
Estimated numbers implicates 250-300 annual donors. This is the first
nationwide survey to establish the number of potential donors, based on all
reported patient deaths in Swedish Intensive Care Units (ICUs).
Methods: A potential donor is defined as “a patient in ICU on mechanical
ventilation with the diagnosis of brain death”. 84 units out of 84 possible
ICUs in Sweden, were included to report patient deaths over a period of 3
months (October-December 2007). The protocol consisted of 10 questions. The
majority of the protocols were reported electronically by the ICU staff to the
“Swedish Intensive Care Registry”.
Results: 841 patient deaths were reported by all 84 participating ICUs. 6,5%
were defined as potential donors. 4% became actual donors while 2,5% did not
become donors due to refusals and medical contraindications.
Conclusions: The result of the survey shows that the number may be less than
the estimated number of potential donors. Another interesting observation is
the group of patients on mechanical ventilation with brain injury and were
death was diagnosed by cardiac arrest. This group will most likely end up in
forth coming projects.
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2169 EDUCATION ON ORGAN DONATION AND
TRANSPLANTATION IN SCHOOLS
F. Cantarovich1, M. Cantarovich2, L. Falco3, R. Revello4, C. Legendre1, A.
Herrera-Gayol5
1
Hôpital Necker, Paris, France, 2McGill Univesity Health Center, Montreal,
Canada, 3The Study School, Montréal, Canada, 4Catholic University, Buenos
Aires, Argentina, 5ScienceMedAdvice, Montréal, Canada.
Purpose: To assess the impact of education on organ donation and
transplantation (Tx) in elementary and high school students.
Methods: Lectures about organ donation and Tx were given by the same
speaker in one school in Argentina and one in Canada. Concepts regarding
medical, legal, historical, and religious aspects of Tx, including brain death and
organ shortage were presented. New concepts were discussed: “During life, we
are at higher risk of becoming organ recipients rather than organ donors”; “The
dead body is a source of health”; “Organ donation means that we are sharing
a chance of life for everyone”; “Organ donation and Tx might be considered
as a right and a duty for everybody”. Thereafter, the students were invited to
complete the following questionnaire: 1) Before this presentation did you have
any knowledge about organ Tx?; 2) Did you enjoy the presentation?; 3) Did
you understand all the topics?; 4) Which ones did you not?; 5) What was the
information you found the most interesting?; 6) What are your conclusions of
this presentation?; 7) With whom would you discuss this topic?
Results: 316 questionnaires were analyzed, including 108 from elementary
school and 108 from high school students from a co-ed school in Argentina;
and 55 and 45 from elementary and high school students, respectively, from
a girls’ school in Canada. Students were divided into pre-adolescents (<12
yrs) and adolescents (>13 yrs). 71% of Argentinean pre-adolescents had some
knowledge about organ Tx vs. 45% of Canadians (P=0.02). Pre-adolescents
enjoyed the presentation (Argentina 90% vs. Canada 89%) and understood
the topics (80% in both countries). Adolescents were more informed vs.
pre-adolescents (Argentina 90% vs. 71% (P=0.01) and Canada 80% vs.
45% (P=0.008)). Argentinean adolescents enjoyed less the presentation vs.
Canadians (74% vs. 89%, P=0.007), and vs. Argentinean pre-adolescents (74%
vs. 90%, P=0.007). Pre-adolescents and adolescents would discuss the topics
with their parents, friends or both (in Argentina 90% and 81% and in Canada
75% and 80%, respectively).
Conclusion: This study suggests that students are open to learn about organ
donation and Tx, to accept new concepts and to discuss this with their entourage.
Education programs on organ donation and Tx should be adapted to age and
idiosyncrasy of students of different countries, and should be incorporated to
school curriculum.
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2170 FOUNDATION OF LOCAL NETWORK FOR INCREASING
ORGAN DONATION IN SOUTHERN IRAN
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P. Janghorban, S. Gholami, A. Bahador, H. Salahi, S. Nikeghbalian,
S.A. Malekhosseini
Nemazee Hospital
After decades of organ transplantation, main problem is still shortage of
donors. In many European countries, “presumed consent” rule has facilitated
than process. In our country that informed consent should be obtained from the
first relatives of deceased donors, the problem is complicated. To overcome
this problem, based on Shiite cleric’s Fatwa, we established a local Network
in southern Iran. Kidney transplantation program was started in 1988 in Shiraz
when the national organization for organ procurement has not been founded yet.
For 3 years, kidney transplantation was performed only with living donors. In
1992, the first consent was gained form a deceased donor family. Between 1988
and 1993, we were able to obtain only six consents. Liver transplant program
started in 1993. To increase the donation, we began educating ICU, ER, and
neurosurgery wards nurses, neurosurgeons, anesthesiologists, and neurologists
of our province and 7 other neighbor provinces in southern Iran. The necessity,
diagnosis and reporting of deceased donor were discussed. These sessions were
repeated every 6 months or yearly. First consent from a deceased donor family
was obtained in 1992. During 7 years (1992-8), only 21 out of 128 deceased
cases (16.4%) were harvested. In 1998, we educated 7 transplant coordinator

710

nursed and one-hundred staff nurses for 7 other provinces. Sixty neurosurgeons,
anesthesiologists, and neurologists, working in 20 cities, had several seminars
about transplantation and brain-death. The consents rate increased from seven
in 1998, to 12 in 1999, and to 264 between 2000 and 2008 (each year around
40 consents). Repeated education of ICU, neurosurgical and ER nurses,
neurosurgeons, anesthesiologists, and neurologists is helpful in increasing the
issued consent rates form deceased donor families and cooperation between
the transplant wards.
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2171 FACTORS INFLUENCING OBTAINED CONSENT RATE
FROM THE DECEASED DONOR FAMILIES: AN ONGOING
EXPERIENCE IN SOUTHERN IRAN
S. Gholami, P. Janghorban, A. Bahador, H. Salahi, S. Nikeghbalian, S.M.
Dehghani, S.A Malekhosseini
Nemazee Hospital
Donor shortage is still major problem of transplantation programs. Even in
a country with a system or an organization for transplantation, the rates of
gained consents in different areas are not the same. At our center, we obtained
informed consent for kidney and liver transplantation programs since 1988 and
1993, respectively. At beginning, we encountered with difficulty of gaining
consents from deceased donor families. We undertook this study to evaluate
factors influencing consent rate from the deceased donor families between
1988 and 2007, 1800 kidney and 430 liver transplantation were performed
in our center. During this period, 243 consents were obtained from the
deceased donor families. Data of age, sex, residential place, number of family
members, marital status, education, cause of brain death, and religious beliefs
was collected. Statistical analysis performed by student T and Chi squire
test. Informed consent was obtained from 293 deceased donors (194males,
99females), with a mean age of 29.8 years. 211(72%) of cases had less than
30 years. 198(67.5%) were single. 61(20.8%) were younger than 15 years. 21
cases (7.1%) were older than 50. cause of brain death in 249 cases (84.9%) was
vehicle accident. Families of 16(84.2%) brain death cases of 19, issued consent
in private hospitals. All families of donors wit suicide attempts issued consent.
230 brain death cases were from rural of suburb areas. 65% of cases had not
academic education. Less consent was obtained from crowded families than
smaller ones (38% versus 62% P<0.05). issued consents from singles, young
cases, suicidal victims, patients admitting private hospitals, those with small
families, or live in rural areas were higher than consents obtained from donors
of large cities, married or those admitted in charity hospitals.
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2172 THE EFFECTIVENESS OF ROUTINE REFERRAL
SYSTEM IN JAPAN
N. Shinozaki, K. Asamizu, Y. Matsumoto
Cornea Center & Eye Bank, Tokyo Dental College Ichikawa General Hospital
Background: In Japan, there has been a constant problem in the insufficiency
of donors for all organs and tissue. Contrastingly, in the US, there have been
many donors, particularly in the corneal donation, after the eye banks installed
the will checking system for donation in hospitals. The system is called Routine
Referral System, RRS. Now we have installed this system in our hospital, and
bringing results, therefore we report the effectiveness of RRS.
Methods: The medical staff in our hospital informs our eye bank, when a patient
died. Our eye bank fs transplant coordinator checks the patient fs both medical
and social histories to see the donor potential. Then the coordinator meets the
family member of the deceased and asks the will of donation.
Results: There were 1,235 death cases within 3 years from October 04 to
September 07 in our hospital. We received 991 (80.2%) calls from the medical
staff. Our coordinator met 456 (46.0%) families after the contraindication case
was eliminated, and asked the will. Eventually, 82 (18.0%) families expressed
the will to do donation.
Conclusion: Over 200,000 blind patients exist in Japan, where nearly 5,000
patients are on the waiting lists on eye banks. With the RRS, it is possible to
reach 18.0% of donation consent from all the potential donors. There has been
a discussion of cultural and religious issues leading the luck of donation in
Japan. But education of medical staff, there is high potential donors among the
general population.
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2173 ORGAN DONATION AS THE’GIFT OF LIFE’:WHO ARE
WE KIDDING?
M. Sque1, T. Long1, S. Payne2
University of Southampton, 2University of Lancaster
Background: In the United Kingdom family members’ consent is usually sought
before organ donation from their deceased relative can proceed. The ‘gift of life’
is recognised as a popular discourse associated with pro-donation activists, its
use seemingly directed at heightening public awareness about the perceived
benefits of organ donation. However such rhetoric remains over simplistic as
it does not reflect the depth and complexity of families’ decision-making about
organ donation. Families’ wishes to protect the dead body may stimulate tension
between the notions of ‘gift of life’, as supported by transplant policy, and the
decision to facilitate the removal of organs from the deceased, through post
mortem surgical intervention upon the body. It has therefore been suggested
that the donation event is better represented as a ‘sacrifice’; a discourse that
acknowledges the suffering of the bereaved family and the possible difficulties
encountered in their decision-making about organ donation.
Method: The aim of this paper was to provide insights into the relevance of
‘gift of life’ or ‘sacrifice’ as discourses that inform families’ decision-making
about organ donation. Data were interrogated, from a self selected sample
of 26 relatives of 23 organ donors who chose not to donate organs of their
deceased relatives, for evidence of families’ literal, symbolic or metaphorical
representations of ‘gift of life’ or ‘sacrifice’ in describing their experiences of
donation. Participants were recruited via three, geographically diverse, staged
media campaigns in large conurbations of England and Wales, and four hospital
intensive care units. Data were collected in 2005 via single, face to face or
telephone interviews.
Findings: An unexpected finding was how many of the participants and
their deceased relatives, in life, held pro-donation views. The decision to
decline donation was most influenced by factors related to protecting the
body of the deceased. Participants whose pro-donation views may well have
embraced the ‘gift of life’ notion appeared to make their decision to decline
donation in the context of deeply distressing concerns related to the cultic
sacrificial element of this gift giving. A decision to facilitate the removal of
organs from the deceased through post mortem surgical intervention upon
the body should therefore never be underestimated. Data revealed many
examples of descriptions by participants, which could be linked to the ‘gift
of life’ discourse. Similarly several explicit or metaphorical examples were
also found, which were related to cutting and mutilation, relevant to the
cultic notion of sacrifice; examples which evidenced the nature of the hardwrought decision-making by families and the existence of their emotional
and physical sacrifice.
Conclusions: We propose that the compelling nature of sacrifice and the
manner in which it appears to impinge on families’ decision-making may help
to explain the high refusal rates in populations that appear generally aware of
the benefits of organ transplantation. Understanding that ‘sacrifice’ may assume
greater significance for the family at the bedside faced with a donation decision
and could become a barrier to actualising donation may be key to the support
offered to them, potentially increasing the incidence of donation.
1

POSTER BOARD NUMBER P4 – 224
2174 ORGAN DONATION ETHICS – EAST EUROPEAN POINT
OF VUE
S.M. Copotoiu, L. Azamfirei, K. Branzaniuc, R. Copotoiu, C. Copotoiu
University of Medicine and Pharmacy
Organ donation is a medical action observing philosophical principles and
practically impossible without theological agreement. The ultimate aim is
preserving human life of an acceptable quality, satisfying the interests of the
survivor and of his family, direct beneficiaries of the process.
Living in an era on blame and litigation and being able to use medical
technology to guarantee successful donation creates the premises to suspect
inappropriate use of organs, abuse, unfairness, preferential prioritization of
the recipients, shortly to incriminate donor exploitation and trauma of their
families. No matter the type of donor, living and healthy, voluntarily donating
and with no constraint and no remuneration, in a state of brain death or non-

heart beating donor (NHBD), the donors share some problems. The living
donors, theoretically the most altruistic category are raising suspicions of
interest, or constraint to donation to the extent of being abused. The donors in a
state of brain death or NHBD have the right to being respected as to their own
scale of values expressed during their lifetime and this respect is extended to
the moral of the society who manipulates the organs.
The ethical principles that apply to both the donors and the recipients are:
autonomy, nonmaleficience, beneficence, confidentiality, the right to a better
life, justice and fairness.
Autonomy implies that the adult discerning patient fully informed on the
benefits and the risks of organ donation and transplantation agrees to donate
or to receive an organ. It is a relatively new principle derived of the principle
of the respect own to a person. This is opposed to paternalism where any
action a living person is to accept in his/her interest is subject to approval or
denial by a dominant member of the family, the society, the confessor or by the
physician himself who takes action in the name of the patient regardless of his/
her opinion.
Beneficence is the meaning of all medical actions, the very purpose of medicine
that is to do good to the patient. This is an undeniable principle and as long as for
a living donor completing an act of altruism and generosity leads to satisfaction,
the very act of donation can be therefore beneficial even for the donor.
The right to a better life is a consequence of the progress medicine has
achieved and of the societal rights modern living observes. Societies not being
equal in terms of assistance and quality of life granted to the members, cannot
therefore be comparable as to the level of organ transplantation, but should
thrive to do so
The countries of East European regions involved with organ donation are acting
according to these medical and societal principles, but this does not necessarily
mean that justice is being done.
Another aspect of justice is the rightness of resource distribution, and this is
beyond the medical reach, rarely a problem of medical management. Fairness is
rather the term for justice applied to individuals while equity would better reflect
a right distribution of medical benefits to individuals in similar condition.

POSTER BOARD NUMBER P4 – 225
2175 IMPLEMENTATION OF TRANSPLANT COORDINATOR
(TC) EDUCATIONAL INITIATIVES FOCUSED ON THE
BENEFITS OF RESEARCH DRAMATICALLY INCREASES
RESEARCH CONSENT RATES AND THE NUMBER OF
ORGANS PLACED FOR RESEARCH
R.D. Hasz, H.M. Nathan, S.M. West
Gift of Life Donor Program
Purpose: To demonstrate how one organ procurement organization’s (OPO’s)
implementation of routine educational initiatives regarding utilization of organs
for research combined with offering the opportunity for research to all donor
families could increase the number of organs successfully placed for research.
Methods: To enable TCs to be effective in explaining the need and benefits
of research the following key educational initiatives were implemented:
1) Information on research was incorporated into TC orientation didactics,
immediately establishing the organization’s commitment to research
science; 2) Local researchers and national research organizations were
invited to be part of the continuing education curriculum. Each researcher
was asked to discuss the goals and impact of their research, and to provide
TCs with information that could be utilized to help families understand
the benefits of research; 3) TCs practiced integrating research request into
the donation conversation during scenario-based role-plays, conducted in
mandatory tri-annual consent workshops; 4) TCs were provided with a
pocket card, clipped to each consent form, describing the research projects
that the OPO was supporting including specifics on how the gift could be
used. Additionally request for research was embedded into all donation
conversations, as a standard component of the informed consent process.
The OPO’s consent form contained language that specifically requested
research consent.
Results: Sustained increases in consent rates for research resulted in the
placement of 1,816 organs for research in a six-year period. Comparing 2002
to 2007, consent rates for research increased by 23% (60% vs. 83%), and the
total number of organs placed for research increased by 55% (210 vs. 325).
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Placed Year

# Organ Donors

Research Consent Rate
from Organ Donors

# Organs for Research

2002

354

60%

210

2003

344

76%

236

2004

387

81%

317

2005

382

85%

367

2006

401

84%

361

2007

389

83%

325

% Change from
2002 vs. 2007

10%

23%

55%

POSTER BOARD NUMBER P4 – 226
2176 EVALUATING THE IMPACT OF PRINT MEDIA
PUBLICITY ON ORGAN DONATION

THURSDAY

K. McKay1, S. Bhonagiri, P. Wills
1
LifeGift Australian Redcross and Bloodbank Service, 2LifeGift Australian
Redcross And Bloodbank Service, 3LifeGift Australian Redcross and
Bloodbank Service
Introduction: Organ donation has a high profile in all forms of media- print,
radio and television in most countries. Most media reports in Australia on
organ donation are positive. LifeGift nsw & act monitors media related to
organ donation in Australia.
In probono ads negotiated with Fairfax Media, four eal life experiences of
one organ donor family and three organ transplant recipients were reported
in advertisements in the Sydney Morning Herald (smh) on behalf on LifeGift.
These were published in the lead up to and during Organ Donor Awareness
Week 2008 on Wednesday Friday and Saturday for a four week rotation which
is still continuing. In the days following this publication a spike in internet
activity via the LifeGift website to the Medicare Australia Australian Organ
Donor Registry and an increase in the number of telephone call to the AODR
were reported.
Methods: before and after report on internet and telephone activity to assess
efficacy of media publicity related to organ donation. The number of internet
hits to the AODR were recorded at the AODR from the LifeGift website and
supplied by Medicare Australia. In addition calls to the 1800 number were
recorded but do not differentiate the source of enquiry..
Results: The articles appeared in the smh on 1st, 2nd, 6th, 9th, 11th, 13th, 15th,
16th, 20th, 22nd, 23/24th, 27, 29th and 1st March to date,
The no of hits and traffic prior to the dates was less than 30 hits per week
The hits and traffic following was 57 in the first week and 43 in the second
week
This activity continues to be greater than the 30 hits in the second week of
March.
Discussion: Media related to organ donation is generally positive and has a
high impact. Measuring the impact of media on the number of donors in a
low donation environment as seen currently in Australia is difficult. Organ
donation occurs in the setting of immense grief to the donor family and surveys
of donor families to assess the impact of media on their decision to donate
or not donate are ethically challenging. The advertisements in the smh were
associated temporally with an increase in internet traffic and telephone calls to
the AODR. Organ Donation intent registration were increased too. However
this increased activity may be due to other factors such as the Australian Organ
Donor Awareness Week.
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CONCURRENT ORAL SESSION 147: INFECTIOUS DISEASE –
CMV AND OTHER VIRAL INFECTION
POSTER BOARD NUMBER P4 – 227
2177 CYTOMEGALOVIRUS PNEUMONIA AFTER SIROLIMUS
BASED KIDNEY TRANSPLANTATION: HIGH RESOLUTION
CT FINDINGS
A. Soliman, A. Lotfy, S. Zamil, E. Ismail
Cairo University
Cytomegalovirus (CMV) pneumonia is one of the most common pulmonary
complications after sirolimus based kidney transplantation (SBRT). We
describe the high resolution CT (HRCT) findings of 13 patients with CMV
pneumonia diagnosed after SBRT. The study included 13 patients who
developed CMV pneumonia after SBRT and who had HRCT of the chest
performed within 24 h of the onset of symptoms. HRCT scans were reviewed
by two radiologists who assessed pattern and distribution of findings. There
were eight male and five female patients, ranging from 19 years to 56 years
of age. The time elapsed until diagnosis ranged from +98 days to +425 days.
The predominant patterns of abnormality on HRCT scans were ground-glass
opacities (79%), small centrilobular nodules (79%) and air-space opacities
(64%). The abnormalities were distributed in the central and peripheral
zones of the lungs in seven cases, only in the periphery in three cases, and
only in the central zone in three cases. In all cases the lung lesions were
bilateral, and asymmetry was observed in six cases. We can conclude that the
most common HRCT findings in patients with CMV pneumonia after SBRT
consist of bilateral asymmetric ground-glass, air-space opacities and small
centrilobular nodules.

POSTER BOARD NUMBER P4 – 228
2178 CAMPATH 1-H INDUCTION AND STEROID-FREE
MAINTENANCE IMMUNOSUPPRESSION IN HEPATITIS C
POSITIVE KIDNEY RECIPIENTS
J. Ortiz1, J. Horton2, A. Bingaman1, J. Palma1, P. Foster1, F. Wright1, F.
Membreno1
1
Texas Transplant Institute, 2Beaumont Medical Center
Introduction: Safety and efficacy of immunosuppression in hepatitis C positive
(HCV+) kidney transplant recipients is of concern due to possible acceleration
of disease or allograft loss. Campath 1-H has been used effectively for induction
therapy in kidney recipients without liver disease. This paper reports results of
Campath induction in HCV+ patients receiving tacrolimus and mycophenolate
maintenance immunosuppression without steroids.
Methods and Materials: An IRB approved retrospective review of HCV+
recipients was done. Hepatitis C positivity was determined by antibody
and PCR testing. From 2002 to 2007, 24 recipients were identified with the
following characteristics: 21 males (87%), age range 40 – 71 years (mean 59
years), 18 first transplants (75%), 4 second and 2 third transplants, 19 deceased
donors (79%) with 14 HCV+ donors, and 5 living donors (21%) all HCV
negative. Five patients (21%) had PRA > 30% and the mean HLA mismatch
was 3.9 for all patients. Liver biopsies were done in 23 patients with 2 patients
showing cirrhosis and 3 showing bridging fibrosis.
Results: Follow-up ranges from 3 to 45 months (mean 15 months). Patient
survival is 83% with 3 deaths, 2 with allograft function: one due to accidental
head trauma, one due to tuberculosis after a third transplant and one due to
myocardial infarct 6 months after allograft loss due to chronic nephropathy.
Two other graft losses occurred, both in sensitized patients, one due to acute
rejection and one due to chronic allograft nephropathy for an overall allograft
survival of 79%. Mean creatinine is 1.5 mg/dl (range 0.9 – 3.0 mg/dl) with a
creatinine >2 mg/dl in 3 patients. Increased liver function tests were noted in 3
patients (12.5%); one had fatty liver, one was treated with steroids for rejection
and one had BK virus treated with lelunamide. No exacerbation of hepatitis C
has been noted to date.
Conclusions: Campath 1-H induction and steroid free maintenance with
tacrolimus and mycophenolate appears to be safe and effective in HCV+
kidney recipients. Wait time was significantly shorter for HCV+ deceased
donor organs. Risk factors for graft failure include previous transplant and
sensitization. Progression of hepatitis C has not occurred in short-term followup. Longer follow-up data needs to be obtained.
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2179 SURVEY THE SEROPREVALENCE OF CMV AMONG
HEMODIALYSIS PATIENTS IN URMIA, IRAN
Z.R.Z. Khameneh1, N. Sepehrvand, F. Eslamlu, S. Masoodi, R.Y. Gharebagh
1
Urmia University of Medical Sciences, 2Student Research Committee
Cytomegalovirus (CMV) causes infection in immunocompromised, transplant
recipients and those who receive blood transfusion frequently. Risk factors for
primary CMV infection are blood transfusion (Including clotting factors, etc),
recipients of infected transplants, hemodialysis and the frequency of dialysis
in a week. This study aimed to determine the prevalence of cytomegalovirus
(CMV) antibodies in end-stage renal disease (ESRD) patients which undergo
hemodialysis.
Material & Methods: This study has a cross-sectional design, which
is executed in 2007 among hemodialysis patients in Urmia, Iran. Sera
of 84 Hemodialysis patients have been investigated by CMV-specific
immunoglobulin G (IgG) using a CMV IgG enzyme-labeled antigen test.
Collected data were analyzed by descriptive statistics and chi-square test via
SPSS software ver11.5.
Results: In our study, 84 patients who regularly underwent hemodialysis
were studied. Forty-four patients were male and 40 female with the range
23-82 years age. In the time of evaluation, 65 patients (77.4%) were antiCMV IgG positive and 6 (7.1%) were anti-CMV IgM positive. There was no
relationship between the antibody titer and dialysis duration, or frequency of
HD in a week.
Conclusion: We recommend that every patient who has undergone
hemodialysis received blood products free of CMV. Development of a vaccine
against cytomegalovirus is essential and could be very life & cost-saving.

POSTER BOARD NUMBER P4 – 230
2180 POPULATION PHARMACOKINETICS OF
VALGANCICLOVIR IN SOLID ORGAN TRANSPLANT
RECIPIENTS INFECTED BY CYTOMEGALOVIRUS
A. Caldés2, H. Colom1, S. Gil-Vernet2, L. Lladó3, N. Manito4, Y. Armendariz2,
N. Lloberas2, L. Pou5, M.J. Garrido6, J.M. Grinyó2
1
Pharmacokinetics and Biopharmacy Dept. Pharmacy Faculty. Universidad
De Barcelona, 2Nephrology Dept. Hospital of Bellvitge, 3Hepatology Dept.
Hospital of Bellvitge, 4Cardiology Dept. Hospital of Bellvitge, 5Biochemestry
Dept. Hospital Vall D’hebron, 6Pharmacy And Pharmaceutical Technology
Dept. School of Pharmacy, University of Navarra
Background: Cytomegalovirus (CMV) is a leading cause of disease in
immunocompromised subjects, such as solid organ transplant recipients.
Valganciclovir (VGC), a L-valyl ester prodrug of ganciclovir, was developed to
offer an alternative to long-term IV and low oral bioavailability of ganciclovir
(GCV).
Objective: The aim of this study was to establish the population pharmacokinetics
of GCV after iv GCV/oral VGC as treatment of CMV infection in heart, liver
and kidney transplant recipients, and explore the influence of patient covariates
on drug disposition
Patients and Methods: An open-label clinical trial was performed in twenty
patients with solid organ transplantation (SOT) and CMV infection (11 renal,
5 heart and 4 liver) at the Hospital Universitari de Bellvitge. The following
demographic and clinical covariates were recorded: body weight, gender, age,
serum creatinine, creatinine clearance, transplant type, CMV serostatus and
concomitant immuosuppresive medication. Patients received 5 mg/kg/12 h of
GCV for five days as an 1-hour intravenous infusion, followed by oral VGC
doses (900 mg/12 h), given for 15 days. In both cases doses were adjusted
by creatinine clearance (CRCL). At the end of each treatment, blood samples
were collected at 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 h post-dose. A population
pharmacokinetic (PK) analysis was performed using NONMEM VI.
Results: As previously reported (1), the PK of GCV was best described by a
two compartment open model with elimination from the central compartment.
Interindividual variability (IIV), was included in total plasma clearance
(41.0%), central distribution volume (46.8%), absorption rate (47.2%)
and bioavailability (24.9%). Total plasma clearance was linearly related
to creatinine clearance (CLCR) and body weight (WGT) according to the
following relationship: CL=7.58x(CLCR/56.3)x(WGT/66.8) (56.3 mL/min

and 66.8 kg: mean values of CLCR and WGT, respectively, in the studied
population). Creatinine clearance and body weight explained part of the
interindividual variability in CL and it decreased in a 27.3% (from 68.3%
to 41.0%). According to this relationship, total plasma clearance would
increase with increasing body weight and renal function. The final population
estimates of the rest of the PK parameters were: VC, volume of distribution
of the central compartment =31.8 L;VP, volume of distribution of peripheral
compartment =32.7 L; CLD, intercompartmental clearance =10.3 L/h; KA,
1st order rate constant of absorption=0.895 h-1; F1, bioavailability =82.6%
and Lag time=0.38 h.
Conclusions: A population PK model for GCV, after GCV iv and/or VGC
po, has been developed. The effects of body weight and renal function are
substantial and clinically relevant, making dose adjustment by both covariates
important to achieve the required GCV exposure to assure efficacy and avoid
adverse events.

POSTER BOARD NUMBER P4 – 231
2181 PRIMARY CMV INFECTIONS AFTER 6 MONTHS
VALGANCYCLOVIR PROPHYLAXIS IN RENAL TRANSPLANT
RECIPIENTS
I. Helanterä1, I. Lautenschlager2, P. Koskinen1
Helsinki University Hospital, Dept of Medicine, Division of Nephrology,
2
Helsinki University Hospital, Department of Virology
Background: Cytomegalovirus (CMV) seronegative kidney transplant
recipients receiving an organ from seropositive donors (D+/R-)
nowadays in most centres receive prophylaxis with valgancyclovir after
transplantation. However, many patients develop primary CMV infection
after the cessation of prophylaxis. The occurrence and clinical course
of these late primary CMV infections developing after valgancyclovir
prophylaxis are poorly described.
Material and Methods: All our university hospital district adult patients, who
received a kidney allograft between 2004-2007 (N=175) were investigated.
Baseline immunosuppression was usually a triple-drug regimen with
Cyclosporine A, mycophenolate mofetil and steroids. In immunologically
high-risk patients cyclosporine was replaced by tacrolimus. Patients with
D+/R- CMV serostatus and at least one year follow-up were included (N=24).
These patients received oral valgancyclovir prophylaxis for 6 months after
transplantation (900mg once daily if normal renal function). After the cessation
of prophylaxis, patients were monitored for CMV-DNAemia with real-time
quantitative plasma PCR with 2-6 weeks interval, and also if CMV infection
was suspected. Infections were treated with i.v. gancyclovir or high-dose
valgancyclovir (900mg twice daily if normal renal function), followed by 1-3
months secondary oral valgancyclovir prophylaxis.
Results: CMV infection developed in 12/24 patients mean 107 days (range
30-330) after the cessation of prophylaxis. Two were asymptomatic, and in ten
patients symptoms included: fever (N=7), gastrointestinal (nausea, vomiting,
diarrhea, abdominal pain) (N=4), upper respiratory tract (N=3), and elevated
liver enzymes (N=2). One patient with infection had prophylaxis terminated
after 5 months due to leukopenia. One patient with a non-functioning graft
(delayed graft function) developed CMV infection 24 days after transplantation,
before prophylaxis was started. Mean viral load at diagnosis was 49517 (range
490-325300) copies/ml, and peak viral load 84654 (range1250-527400)
copies/ml. Five infections were treated with oral valgancyclovir and 6 with i.v.
gancyclovir, all resulting with negative PCR results. One mild infection with low
viral load was treated successfully with minimization of immunosuppression.
Infection relapse developed in 4 patients mean 31 (range 15-61) days after the
end of the therapy. Relapses were treated with oral valgancyclovir in 3, and
with i.v. gancyclovir in one patient.
Conclusions: CMV primary infections were common after 6 months
valgancyclovir prophylaxis, and mostly symptomatic. Relapses commonly
occurred. Primary infections seem to be delayed, but not efficiently prevented
by 6 months prophylaxis.
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2182 LATE CYTOMEGALOVIRUS INFECTION WITH
MULTIPLE COLONIC PERFORATIONS IN RENAL
TRANSPLANT RECIPIENT – CASE REPORT.

2183 SEVERE APLASTIC ANEMIA IN RENAL TRANSPLANT
RECIPIENTS CAUSED BY CHRONIC PARVOVIRUS B 19
INFECTION

A. Olejnik, L. Koziol, I. Idasiak-Piechocka, A. Oko, S. Czekalski
Department of Nephrology, Transplantology and Internal Diseases, Poznan
University of Medical Sciences, Poland
Cytomegalovirus (CMV) infection after renal transplantation is major cause
of morbidity and mortality. Cytomegalovirus disease typically occurs in first 6
months after transplantation and causes fever, leukopenia, thrombocytopenia
and slightly elevated transaminases. More invasive forms of CMV infections
are rare because of prophylactic regimen in high-risk patients and early
treatment with gancyclovir.
We report the case of 36-year-old patient who developed CMV related colonic
multiple perforations 3 years after renal transplantation.
Initially after transplantation the immunosupressive regimen consisted
of steroids(Metypred),calcineurin inhibitor(Prograf)and mycophenolate
mofetil(CellCept).
CMV infection was not present.
Three weeks and 3 months after transplantation the patient presented two
incidents of acute rejection treated successfully with antithymotic globulin(first
episode) and steroids(second episode).
Furthermore in the first year after transplantation patient demonstrated recurrent
urinal tract infections and severe Pneumocystis carinii infection treated with
Pentamidine.
At the same time Prograf was withdrawal.
Three years after transplantation patient presented symptoms of
enterocolitis(abdomen pain, diarrhea, nausea, weight loss) with biochemical
disorders hypoproteinemia, hypoalbuminemia and temporary graft
dysfunction.
At the beginning of enterocolitis manifestation, investigation of CMV pp65
antigenemia test and CMV-DNA polymerase chain reaction (CMV-DNA PCR)
were negative.
However CMV IgG antibodies were positive.
At that time conversion from CellCept to Myfortic was performed with
temporary improvement of symptoms.
Six months after first symptoms, colonic biopsy was performed – the histological
investigation gave evidence of typical CMV infection. CMV infection was also
confirmed by positive CMV pp65 antigenemia test and CMV-DNA PCR.
Ganciclovir therapy was initiated immediately and resulted in improvement of
symtoms. However periodically abdomen pain and diarrhea was observed.
Control examination of CMV pp65 antigenemia test and CMV-DNA PCR were
negative.
Three months after ganciclovir therapy symptoms of colonic perforation
occured and total colectomy was necessary.
The relationship between CMV infection and colonic perforation has been
confirmed by histological examination of the resected colon.
Colonic perforationas are often fatal and life-threatening complications in
transplant recipients with CMV infection. In such cases only rapid diagnosis
and agressive surgical treatment can save the patient from death.
The history of our patient illustrated the need to consider CMV infection in
patients with enterocolitis symptoms even more than 3 years after solid organ
transplantation.

C.A. Bucsa1, B.D. Tacu1, C. Dobrea2, E. Kerezsy1, C. Tacu1, I. Ursuleac3,
I. Alexiu4, V. Uscatescu3, I. Sinescu1
1
Department of Renal Transplantation, Fundeni Clinical Institute,
2
Department of Hematopathology, Fundeni Clinical Institute, 3Department of
Hematology Fundeni Clinical Institute, 4Institute of Virology Stefan Nicolau
Bucharest
Background: Parvovirus B19 is a single – stranded DNA erythroid virus. It is a
highly contagious community – acquired infection in children, 30-60% of people
being sero-positive by adulthood. Most infections are asymptomatic or presenting
as an erythema infectiosum- a mild illness also known as “fifth disease”. In
immunocompromised patients like renal transplant recipients, the infection may
be prolonged and can lead to recurrent and severe aplastic anemia.
Purpose: To identify the risk factors for persistent infection, the most efficient
treatment and to develop a preventive strategy.
Material: 6 recipients with new onset, severe, relapsing anemia after renal
transplantation in our center between December 2006- Oct 2007. The mean
follow-up period was three months. Serologic status for Parvovirus before
transplantation was not available.
Results: The diagnostic, suggested by clinical characteristics (severe and
areticulocytotic anemia, resistant to therapy) was made by giant pronormoblasts
in the bone marrow biopsy and the detection of viral DNA using a qualitative
polymerase chain reaction assay.
4/6 patients have received cadaveric renal grafts, 2 have received living related
grafts. The medium HLA mismatches was 50%. All recipients had induction
therapy with IL 2 receptors blockers and the maintenance immunosuppressive
regimen included tacrolimus (through levels 8-15 ng/ml), mycophenolate
mofetil (2 g/day) and corticosteroids for 5 patients and cyclosporine (C 2 level
1500 ng/ml) for the last one. None of them had delayed graft function. 5/6
experienced at least one early acute rejection episode efficiently treated with
metil prednisolon. The medium hemoglobin level was 7.1 g/dl. The mean
serum clearance creatinine 57 ml/min. The evolution was complicated by CMV
infection (pp 65 antigenemia positive) in 5/6 patients even with prophylaxis
therapy with valganciclovir 3 months post transplant for all patients. Another
significant complication was acute venous thrombosis in 4/6, two of them being
lupus anticoagulant positive on pro-coagulants factors screening.
Evolution: 3/6 patients experienced clinical persistent remission with presence
of Ig G antibodies but with persistent viraemia on qualitative DNA- PCR
at 3 months. The clinical remission was associated with decreasing the
immunosuppression: switching the tacrolimus to sirolimus for CAN in 2 two
cases, and the third remission has occurred to the patient on cyclosporine.
Conclusions: Reducing the immunosupression could be the optimal treatment
for persistent viral infection – in our experience, the switching or avoidance of
tacrolimus was effective.
It is necessary in our center a routine screening serology for Parvovirus B19 in
order to identify the subjects in high risk for infection. The vaccination may be
indicated in selected patients pre-transplantation.
Persistent infection with CMV could have an immunomodulatory role –
predisposition to other persistent viral infection.

POSTER BOARD NUMBER P4 – 234
2184 QUANTITATIVE HHV-6B ANTIGENEMIA TEST FOR THE
MONITORING OF TRANSPLANT PATIENTS

THURSDAY

K. Höckerstedt1, I. Lautenschlager1, R. Loginov1, D. Ablashi2
1
Helsinki University Hospital, 2HHV-6Foundation
Background: Human herpesvirus-6 (HHV-6) activation, mostly of the variant
B, is common after organ transplantation. The viral activation can be detected
from peripheral blood by PCR or by the HHV-6 antigenemia test. Here we
report a new modification of the HHV-6 antigenemia test using a HHV-6B
glycoprotein IgG-antibody, OHV-3, and attempt to quantify the HHV-6
antigenemia and the viral load after liver transplantation.
Patients and methods: Twenty-four adult liver transplant recipients were

714

Supplement to Transplantation July 27, 2008, Volume 86 Number 2S

Thursday 14 August 2008

Poster Abstracts
frequently monitored by the qualitative HHV-6 antigenemia test, which
detects the HHV-6B virion protein in peripheral blood mononuclear cells
(PBMC). For the HHV-6 antigenemia test, PBMC were isolated by density
gradient centrifugation and cytocentrifuged onto microscope slides. HHV6B antigens were now demonstrated using a glycoprotein OHV-3 IgGantibody in the immunoperoxidase staining from the same specimens and
quantified as positive cells/10,000 PBMC. Altogether 206 blood specimens
were analyzed.
Results: During the first six months, HHV-6 antigenemia was detected in
17/24 (71%) recipients by using HHV-6B virion antibody. Altogether, 37%
(77/206) of specimens were positive with the virion antibody and 39%
(78/201) by the OHV-3 antibody. The peak number of OHV-3 positive cells
in the PBMC`s varied from 5 to 750/10,000 (mean 140/ 10,000).
Conclusions: The glycoprotein antibody OHV-3 was useful to quantify the
HHV-6B antigenemia. The findings of the HHV-6B quantitative antigenemia
correlated well with the previous qualitative HHV-6 antigenemia assay, and
can be used as a quantitative method in the monitoring of HHV-6 in transplant
patients.

POSTER BOARD NUMBER P4 – 235
2185 REDUCED RESPIRATORY SYNCYTIAL VIRUS
LOWER RESPIRATORY TRACT INFECTIONS AND
HOSPITALIZATIONS IN PEDIATRIC LIVER TRANSPLANT
RECIPIENTS WITH PALIVIZUMAB
A. Campbell1,2, N. Kerkar1
Mount Sinai School of Medicine, 2Abbott
Background: Respiratory syncytial virus (RSV) lower respiratory tract
infection (LRTI) in the post-transplant period is associated with significant
morbidity and mortality. Palivizumab, a RSV-specific monoclonal antibody,
has been shown to reduce the incidence of RSV hospitalization and the severity
of breakthrough disease in preterm infants with and without chronic lung
disease and infants with hemodynamically significant congenital heart disease.
As part of a comprehensive immunization program in pediatric liver transplant
(PLT) candidates and recipients at Mount Sinai, palivizumab (15 mg/kg IM
monthly during RSV season) was recommended for PLT recipients <4 years
of age beginning 2003.
Objective: To describe the impact of palivizumab prophylaxis on RSV
infections in PLT recipients at Mount Sinai School of Medicine.
Methods: Retrospective chart review of PLT recipients <4 years of age
transplanted between 01/01/2000 and 12/31/2005 was performed.
Results: 76 PLT recipients were identified; 36 received palivizumab
prophylaxis and 40 did not. Demographics did not differ between PLT
recipients who received palivizumab and those that did not with respect to
gender (55.6% and 60.0% female, p=0.814), race (63.9% and 57.5% nonwhite, p=0.150) mean age at transplant (0.94 years and 1.2 years, p=0.600)
and indication for transplantation (61.1% and 60.0% extrahepatic biliary
atresia, p=0.641). The rate of RSV infections did not differ between the
PLT recipients who received palivizumab and those who did not (8.3%
and 10%, p=0.802); however, the rate of RSV hospitalization did differ
(0% palivizumab and 10% no palivizumab, p=0.05). RSV infections
manifested more frequently as a LRTI in children who did not receive
palivizumab prophylaxis compared to those who did (75% and 0%,
p=0.047). The mean hospital length of stay was 7.5 days (range, 3-13
days). Two children required admission to the intensive care unit and
mechanical ventilation; all required supplemental oxygen. There were no
deaths attributed to RSV.
Conclusion: This retrospective review suggests that palivizumab may prevent
progression of a RSV URTI to a LRTI and prevent hospitalization when
administered prophylactically in PLT recipients. To understand the full extent
of the benefit of palivizumab prophylaxis in this population prospective studies
are necessary.
1
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2186 TRANSFER OF ADOPTIVE IMMUNITY TO HEPATITIS B
VIRUS BY LIVING LIVER TRANSPLANTATION*
M. Lindemann1, A. Schumann1,2, M. Fiedler2, C. Valentin-Gamazo3,
D. Knop4, C.E. Broelsch3, H. Grosse-Wilde1, M. Roggendorf2
1
Institut für Immunologie, 2Institut für Virologie, 3Klinik für Allgemein-,
Viszeral- und Transplantationschirurgie, 4Institut für Transfusionsmedizin,
Universitätsklinikum
Background: In chronically hepatitis B virus (HBV) infected patients liver
transplantation is often the ultimate option of therapy. Despite antiviral therapy
reinfection is still a problem. Adoptive transfer of HBV immunity with the liver
after vaccination of living liver donors could be a new approach to prevent
reinfection in the recipients. However, the period in which to achieve HBV
immunity in donors is usually short (1-2 months).
Aim: To investigate if HBV immunity from an immunized living liver donor
can be transferred to the recipient.
Methods: In this study we vaccinated living liver donors in a short time
immunization protocol (4 injections in two weeks intervals) using Sci-B-Vac,
a recombinant vaccine that contains the PreS1, PreS2, and S proteins of HBV
(SciGen Ltd., Singapore, n=39), or boosted donors with prior HBV vaccination
using a standard vaccine (HBVAXPRO, Sanofi Pasteur MSD, Frankfurt,
Germany, n=7). Humoral (anti-HBs titer) and cellular (proliferation assay
and interferon-gamma ELISpot) immune responses were examined prior to
each immunization, pre and post transplantation. Out of 46 potential donors
receiving HBV immunizations 14 were selected for liver donation.
Results: In 3 out of 14 recipients adoptive immune transfer was clearly
detectable. One HBV naive recipient developed humoral and cellular immune
responses post transplantation (anti-HBs of 1800 IU/l and stimulation index of
4.9), another naive recipient showed cellular immune responses (stimulation
indices of up to 40, 22 spots increment). Furthermore, in one chronically HBV
infected recipient specific immune responses were measurable at day 5 (antiHBs of 120 IU/l) and vigorously increased thereafter (anti-HBs of 58000 IU/l
and stimulation index of 3.1). This finding most likely reflects the boosting of
HBV specific immunity by HBs antigen persisting in the host. Taken together,
we were able to show that in principle HBV specific humoral and cellular
immunity can be transferred to recipients with the liver graft.
Conclusion: By immunization of living liver donors, the reinfection in
chronically HBV infected recipients could be prevented.

POSTER BOARD NUMBER P4 – 237
2187 ACUTE NECROTIC PANCREATITIS AFTER LIVER
TRANSPLANTATION DUE TO HUMAN HERPESVIRUS 2
I. Gonzalez-Pinto, M. Rodriguez, A. Miyar, L. Gonzalez-Dieguez,
C. García-Bernardo, V. Cadahia, L. Vazquez, P. Diaz, L. Barneo
Hospital Universitario Central de Asturias
Aim: to report a case that reminds us of the risk of severe pancreatitis in the
course of a viral infection.
Case presentation: A 67-year-old woman affected of advanced primary biliary
cirrhosis, with frequent decompensations, underwent liver transplantation.
The donor was young, and the surgical procedure uneventful. However,
postreperfussion biopsy showed a 40% alcoholic steatohepatitis, which led to
severe graft dysfunction with non-oliguric renal insufficiency, but with good
progressive recovery. Immunosuppression consisted of basiliximab and low
level tacrolimus, with delayed introduction of mophetil mycophenolate. Since
post-op day 3 she presented blisters in right arm which extended progressively.
After misdiagnosis and treatment with topical steroids, culture on day 19
revealed human herpesvirus 2. On day 33 she developed septic shock with
renal failure due to acute necrotic pancreatitis, which required 2 reoperations
for drainage and debridement, and 1 TC-guided percutaneous drainage. She
was treated with acyclovir in addition to antibiotics and ICU management,
and immunosuppression was temporarily withdrawn. Liver biopsy culture also
showed human herpesvirus 2.
After several additional complications, the patient recovered completely, was
discharged, and maintains a normal life.
Conclusions: – Viral cutaneous infection can produce visceral involvement in
immunosuppressed patients. – Viral necrotic pancreatitis with renal failure in
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transplanted patient carries a high mortality. – Viral infection as a cause of
pancreatitis is probably underestimated. – Withdrawal of immunosupression
should be readily considered.
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2188 ROLE OF REGULATORY T CELLS IN ADOPTIVE
CMV-SPECIFIC T-CELL THERAPY
A. Fischer1, S. Zwinger1, G. Brestrich2, A. Roemhild2, J.P. Maciejewski3,
M. Wlodarski1, M. Hammer2, A. Kurtz2, P. Reinke2, H-D. Volk1
1
Institute of Medical Immunology, Charite-University Medicine, Berlin,
2
Department of Nephrology and Intensive Care Medicine, Charite-Unviersity
Medicine, Berlin, 3Experimental Hematology and Hematopoiesis Section,
Cleveland Clinic, Cleveland
Cytomegalovirus (CMV) is a major cause of morbidity and mortality after
transplantation. In haematopoietic stem cell transplantation (HSCT) adoptive
immunotherapy with healthy donor-derived T cells directed against CMV has
been proven to prevent clinical manifestation of the virus.
The aim of our study is to introduce this promising treatment option also in the
setting of solid organ transplantation (SOT) by generating autologous T-cell
lines from peripheral blood of the immunosuppresed organ recipients suffering
from CMV disease.
For this approach we established an HLA-type independent generation
protocol to isolate and expand T cells specific for the immunodominant
CMV proteins pp65 and IE-1. Analysis on surface-expression, antigenspecific cytokine release and cytotoxic-activity revealed that these CMVspecific T cells do not only contain Th-1 and cytotoxic T cells, but also
cells possessing the phenotype of regulatory T cells (Treg). Regarding the
well described involvement of Tregs in modulation of immune response to
pathogens we studied the functional role of these CMV-specific Tregs on
the control of effector T-cell response. Our data showed that after specific
triggering CD4+ Tregs inhibit CMV-peptide specific IL-2 secretion of
Teff cells. Detailed analysis of classical Treg-markers, cytokines, Foxp3
expression and epigenetic signature suggest the presence of an induced
Tr1 (T-regulatory type-1) phenotype. Our data on the clonotypic repertoire
revealed that CMV-epitope specific T effector and Treg are clonally identical
T cells. Using a TCR Vb-specific cell sorting we are now able to directly
compare pure effector and reglulatory T cell clones. Furthermore, our results
facilitated us to design a TCR Vb-CDR3 sequence-specific PCR to monitor
fate and clonal distribution of ex-vivo isolated and in vitro expanded CMVspecific CD4+ Tregs.
In summary, CMV can induce both Teff and Tr1 that can be expanded in
parallel. Using adoptive T-cell therapy we presume targeting regulatory T cells
to improve the in vitro and in vivo efficacy of CMV-specific T-cell lines.

POSTER BOARD NUMBER P4 – 239
2189 WHY DO WE NEED CYTOMEGALOVIRUS-SPECIFIC
MEMORY T CELLS?

THURSDAY

I.J.M. ten Berge1, E. Remmerswaal1,2, N.A. Lages2, E.M.M. van Leeuwen1,2,
R.A.W. van Lier2
1
Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of
Experimental Immunology, Academic Medical Centre, Amsterdam
Memory T cells are believed to protect the host against re-infection with the
same virus or, in case of persistent viruses, to enforce viral latency. Next to
resting IL7RƒÑ- effector cells, cytomegalovirus (CMV) carriers also possess a
variable number of CD8+IL7RƒÑ+ T cells, which resemble long term antigenindependent memory cells that are generated against cleared viruses. We aimed
to clarify the putative role of IL7RƒÑ+ and IL7RƒÑ- CD8+ T cells during
CMV latency and CMV reactivation.
IL7RƒÑ+ CMV-specific CD8+ cells indeed had phenotypic traits of memory
T cells and expressed granzyme K and CXCR3 which may allow them to
migrate to draining lymph nodes. In contrast, IL7RƒÑ- cells were resting,
granzyme B-containing effector cells and expressed CX3CR1+ which could
drive homing to inflamed tissue. To clarify the possible clonal relation
between these subsets TCR repertoire analyses were performed. A highly
diverse TCR usage in the acute response was found that narrowed down in
both IL7RƒÑ+ and IL7RƒÑ- subsets. However, hardly any overlap in VƒÒ
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usage and CDR3 sequences was found between the populations. Upon viral
reactivation IL7RƒÑ- cells expanded significantly and acquired a broad usage
of TCRs, that resembled the primary response, but interestingly we found no
evidence that T cell clones from the IL7RƒÑ+ fraction were recruited to this
expanded pool.
Thus, IL7RƒÑ+ and IL7RƒÑ- CD8+ T cells represent separate subsets of virusspecific T cells that differ in migration potential, effector functions and TCR
usage. In addition, IL7RƒÑ+ T cells are not being recruited to the expanded
pool during virus reactivation suggesting that they do not provide a source
for effector cells during latency or virus reactivation. Rather, different sets
of CMV specific T cells may be involved in maintaining latency in different
compartments.

POSTER BOARD NUMBER P4 – 240
2190 TREATMENT OF HIGH VIRAL LOAD
CYTOMEGALOVIRUS WITH VALGANCYCLOVIR A CASE
STUDY
M. Castle, T. Evans-Walker
Cleveland Clinic
Purpose: The severity of Cytomegalovirus ranges from asymptomatic to tissue
invasive, organ specific disease, allograft failure, and death. The highest risk
of developing subsequent CMV infection and disease is donor+/recipient-.
Clinical practice has shifted toward oral valganciclovir for preemptive therapy
and not surprisingly, outpatient treatment as opposed to IV gancyclovir. The
validity of treating active CMV infection with an oral therapy was shown in
recent studies, including the VICTOR study (2007), but in the trials reviewed,
the median initial viral loads were modest, 19 750 copies per mL. This case
study is to observe the course of treatment for an individual (D+/R-), eight
months post Living-Unrelated kidney transplant, detected with 616 960 copies/
mL CMV.
Method: High Viral loads of CMV and tissue-invasive disease are more
likely to be treated with IV gancyclovir. However, this case represents, per
one patient’s preference (AMA), the efficacy of outpatient oral treatment with
an endpoint yet to be determined. All D+/R- and other high risk individuals
have preemptive screening for CMV every 2 weeks for the first year post
kidney transplant. For symptomatic viremia or CMV disease; standard therapy
would include (reducing or discontinuing the antimetabolite, as applicable) and
intravenous gancyclovir 5mg/kg twice daily for 21 days and preferable until
CMV DNA assay becomes negative, followed by valganciclovir 900 po daily
for an additional 28 days. This individual had No CMV DNA Detected on
16 consecutive screening tests until January of 2008 when he presented with
616 960 copies/mL. Before his leaving from the hospital, he did receive one
dose of gancyclovir 5mg/kg IV. The multidisciplinary team discussed the risks
associated with CMV. The patient determined that the plan of care would need
to be coordinated from home since his informed choice was not to be treated
in the hospital.
Results: Oral Valganciclovir per renal dose was ordered for therapy as the
transplant and ID team discussed PICC/home care, with local physician
collaboration. The next CMV DNA had fallen within one week to 61 971.
Continued oral therapy was prescribed as patient preference. The following
CMV results were as follows; weekly, 178 960, 14,898 then No CMV DNA
detected. The next 2 weeks; No CMV DNA detected. After three consecutive
negative results, the Valganciclovir was discontinued. The following week 1558
copies/mL detected and the following week 60 505. The individual remains
free from complaints. The valcyte was reintroduced at 900mg PO BID. There
is a test presently pending.
Conclusion: Although there was much encouragement during the course
of treatment, follow up of recurrences and better understanding of duration
of therapy versus resistance warrants ongoing investigation. This case
study reflects the importance of diligent screening to diagnose as quickly
as possible. Ongoing trials will yield additional data in providing a true
measure whether oral Valganciclovir is comparable in efficacy to the IV
gancyclovir.
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2191 FATAL OSELTAMIVIR-RESISTANT INFLUENZA A/
SOLOMAN ISLANDS/3/2006 (H1N1) INFECTION IN A CORDBLOOD HAEMATOPOIETIC STEM CELL TRANSPLANT
(HSCT) RECIPIENT
P. Ferguson1,2, I. Kerridge2,3, B. Wang4, K. McPhie5, N.K. Saksena4, A. Hurt6,
T. Sloots7, M. Nissen7, T. Sorrell1,2, D. Dwyer1,2
1
Centre for Infectious Diseases and Microbiology, Westmead Hospital,
2
Centre of Clinical Research Excellence, Infection and Bioethics in
Haematological Malignancies, 3Bone Marrow Transplant Unit, Westmead
Hospital, Sydney, Australia, 4Westmead Millennium Institute, 5Institute of
Clinical Pathology and Medical Research, 6WHO Collaborating Centre,
7
Queensland Paediatric Infectious Diseases Laboratory
A 21 year old woman underwent a double cord-blood HSCT for Acute
Lymphoblastic Leukaemia in third remission during the 2007 influenza
season in Sydney, Australia. She received oseltamivir on admission (75mg
daily bd on Days -5 to +1) because of prolonged close contact with nonvaccinated household members with influenza-like illness. Pneumonia with
upper respiratory symptoms developed on Day +12 (total white cell count 0.1
x109/L). Influenza A was detected by immunofluorescence (IF) and culture of
nose/throat swabs (NTS). Treatment with oseltamivir 75mg bd, meropenem and
amphotericin was initiated. Influenza A and coronavirus OC43 were detected
subsequently by PCR of DNA extracted from NTS. Moderate-severe acute
GVHD developed Day +20 on cyclosporin and mycophenolate prophylaxis and
was treated with IV methylprednisolone (2mg/kg), thence a tapering steroid
regimen. Although a further NTS was influenza IF and culture negative on Day
+25, PCR for influenza and OC43 remained positive and there was no clinical
improvement. Bronchoscopy on Day +29 was IF and PCR positive for influenza
A only. Aspergillus flavus and adenovirus were cultured from the same specimen.
Despite neutrophil recovery (>0.5 x109/L) on Day +30 and ongoing treatment
(oseltamivir 75mg bd then 100mg bd from Day +34, liposomal amphotericin,
voriconazole, meropenem), the patient developed respiratory failure and required
invasive ventilation from Day +44. A bronchoscopic respiratory sample on Day
+47 was IF and culture-negative for influenza, adenovirus and Aspergillus, and
oseltamivir was ceased after a total of 34 days. The patient deteriorated rapidly.
A bronchoscopic sample on Day +51 was positive for influenza A (IF, culture
and PCR), and OC43 (PCR) but negative for other respiratory viruses and
Aspergillus. The patient died of respiratory failure on Day +53.
DNA from cultured Influenza A isolates on days +12 and +51 demonstrated
oseltamivir resistance with the H274Y mutation being detected.. Both wild-type
and resistant virus were present on day +12, but only resistant virus, on day +51.
The H274Y mutation was confirmed by rolling circle amplification (RCA) applied
directly to clinical specimens collected on days +12, +29, +42, +47 and +51.
Treatment-associated development of influenza A and B resistance to oseltamivir
has been described, although the clinical significance is uncertain. This is the
first report of fatal, oseltamivir-resistant, influenza A infection associated with
prolonged oseltamivir treatment in an HSCT recipient. Novel molecular methods,
such as RCA, may facilitate detection of gene mutations that confer oseltamivir
resistance and predict therapeutic failure in patients on prolonged therapy.
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2192 VIRAL AND HOST FACTORS ASSOCIATED WITH CMV
INFECTION IN LIVER TRANSPLANT RECIPIENTS
W. Rawlinson1,2,3,4, G. Scott1,3,4, Z. Naing1,3, J. Pavlovic5, P. Angus5,
N. Rismanto2, R. Jones5,
1
Virology Research, POWH & UNSW Research Laboratories, Prince of Wales
Hospital, Sydney, AUS, 2Virology Division, Department of Microbiology,
SEALS, Prince of Wales Hospital, Sydney, AUS, 3School of Medical Sciences,
Faculty of Medicine, University of New South Wales, Sydney, AUS, 4School of
Biotechnology and Biomolecular Sciences, University of New South Wales,
Sydney, AUS, 5Liver Transplant Unit, Austin Health, Melbourne, AUS
Aims: We are investigating the efficacy of valganciclovir (valGCV) prophylaxis
in liver transplant recipients and the effect on cytomegalovirus (CMV) infection,
CMV-related disease, development of antiviral resistance and other secondary
complications of liver transplantation. We aim to determine optimum strategies
for the prevention of these complications following liver transplantation.

Methods: Transplant recipients who are seronegative for CMV and receiving
a liver from seropositive donor (D+/R-) are at high-risk for CMV infection
and disease and are therefore automatically placed in the valGCV prophylaxis
arm of the study. All other recipients (D+/R+; D-R+; D-R-) are randomised
to receive valGCV prophylaxis at the time of transplantation or valGCV
pre-emptive therapy if laboratory evidence of active CMV infection exists
(increasing CMV load, CMV PCR positivity on consecutive specimens). We
have enrolled 45 patients to date at the Austin Hospital, Melbourne.
Results: ValGCV prophylaxis reduces the incidence of active CMV infection
in D-/R+ liver transplant recipients (0% in recipients receiving prophylaxis
versus 50% in recipients who did not receive prophylaxis) and D+/R+ recipients
(67% versus 25%). However, CMV infection (71%) and disease (43%) was
still evident in seronegative recipients of a liver from a seropositive donor,
indicating D+/R- patients are still at highest risk for CMV-related disease even
when valGCV prophylaxis is used.
We find an association between CMV disease and severe acute or chronic
rejection of the transplanted organ, although our data do not address whether
CMV is causative. Antiviral resistance to valGCV was evident in two of
the CMV strains infecting D+/R- recipients, equating to 10% of recipients
receiving valGCV prophylaxis. These resistant strains were evident after the
initial 100 days of valGCV prophylaxis. One of these patients (with HCV
related liver disease) developed CMV gastritis, duodenitis and hepatitis as a
result of this resistant CMV infection and later died from multi-organ failure
despite subsequent change in antiviral therapy to foscarnet. The other D+/Rrecipient with an antiviral resistant CMV infection did not develop CMV-related
disease and remains well. The CMV infection of this patient has resolved
without antiviral treatment, and presumably in accordance with reversal of the
post-transplant immunosuppression and development of anti-CMV immune
response. Mixed infections with two different CMV genotypes were evident in
D+/R+ recipients, reflecting concomitant reactivation of latent CMV infection
in the recipient, and transmission of CMV from the donated organ. However,
mixed CMV infections did not reflect worse outcomes for these liver transplant
recipients, as has been shown for lung transplant recipients. No association
between CMV infection and Toll-like receptor (TLR2, TLR4) polymorphisms
was evident in this liver transplant population.
Conclusions: Investigations to date suggest the major host factor for CMV
infection and life threatening disease is D+/R- serostatus. The major viral
factions associated with adverse clinical outcomes include increasing and
sustained viral load in blood, sometimes as the result of resistant infection.
ValGCV prophylaxis appears to provide protection to D-/R+ and D+/R+
recipients but improvements to prophylactic regimens (including prolonged
prophylaxis) may be necessary to reduce the incidence of CMV disease in
D+/R- liver transplant recipients.

POSTER BOARD NUMBER P4 – 243
2193 PRE-EMPTIVE TREATMENT OF CMV INFECTION
FOLLOWING RENAL TRANSPLANTATION – A SINGLE
CENTRE CLINICAL EXPERIENCE
S. Rajakumar, F. Ierino, D. Tomlinson
Austin Health
Cytomegalovirus (CMV) infection after renal transplantation is an important
cause of morbidity due to both direct and indirect complications and has
been associated with higher mortality rates. Two approaches have generally
been used to prevent CMV disease: universal prophylaxis and a pre-emptive
treatment strategy involving serial monitoring for viraemia to allow early
treatment. Universal prophylaxis is easier logistically but may unnecessarily
expose a proportion of patients to the adverse effects and costs of antiviral
therapy. A pre-emptive approach requires an effective monitoring strategy and
is more resource-intensive. We report our experience using a PCR-based preemptive treatment strategy for renal transplant recipients.
Forty-six consecutive renal transplant patients (average age 46.5 years, 73%
male, 72% cadaveric) were managed with a pre-emptive CMV treatment
protocol and had a minimum of 6 months follow-up (range: 6 – 39 months).
CMV seronegative recipients receiving a graft from a seropositive donor (D+R-)
received 3 months prophylaxis with either oral valaciclovir or valganciclovir.
The remaining patients (D+R+, D-R+, D-D-) had plasma CMV PCR tested
fortnightly for 6 months. Patients with a viral load > 10,000 copies/ml were
treated with ganciclovir followed by 3 months valganciclovir. Those with <
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10,000 copies/ml were treated with valganciclovir for 3 months. Patients with
CMV disease were treated with 2 weeks ganciclovir followed by 3 months of
oral therapy. Very low-level asymptomatic viraemia was treated only if rising
rapidly. Patients receiving OKT3 were given prophylaxis. Immunosupression
was reduced as tolereated.
Seven of 46 patients were D-R-. During the 6 month period of fortnightly PCR
surveillance none developed CMV infection. After follow-up of 6 – 39 months
none had developed CMV disease. This low rate, in keeping with published
data, suggests that prophylaxis may not be warranted in this group.
Seven of 46 patients were D+R- and received 3 months prophylaxis during
which none developed CMV disease or viraemia. One patient developed
CMV disease (pneumonitis) and another had subclinical viraemia 12 and 4
months after ceasing prophylaxis respectively. The trend of later presentation
with prophylaxis is consistent with published data and a longer period of
prophylaxis or a period of surveillance after prophylaxis may be beneficial.
Thirty-two transplants were with seropositive recipients. Five patients remained
free of CMV viraemia or disease and 4 had CMV disease (1 severe). Twentythree (69%) developed subclinical viraemia. This occurred at an average of
6.9 weeks after transplantation and 17 of these patients received anti-viral
treatment. None of the patients with subclinical viraemia (treated or observed)
developed CMV disease.
The rate of exposure to anti-viral agents with this protocol was relatively high
(53% of R+ and 87% of all non D-R- transplants). This suggests that a universal
prophylaxis regime may not entail a significantly larger complication rate. The
high incidence of subclinical viraemia is notable as the prognosis for this subset
of patients has not been well-defined and lends itself to further research. This
may guide the development of strategies to prevent CMV disease after renal
transplantation.

POSTER BOARD NUMBER P4 – 245
2195 DETECTION OF CYTOMEGALOVIRUS (CMV) AND
HUMAN HERPESVIRUS-6 (HHV-6) DNA IN BIOPSY OF LIVER
DONOR.
A. Guardia1, A. Sampaio1, I. Pereira2, R. Stucchi2, M. Leonardi2, I. Boin2,
S. Costa1
1
Molecular Biology Laboratory – FCM – Unicamp, 2Unit of Liver
Transplantation – Unicamp
Introduction: Cytomegalovirus (CMV), Human Herpesvirus-6 (HHV-6)
and Human Herpesvirus-7 (HHV-7) belong to the herpesvirus subfamily.
These viruses remain latent or at a low level of viral replication after primary
infection and can reactive during immunosuppressed states as following organ
transplantation.
Objective: Detection of Cytomegalovirus (CMV) and Human Herpesvirus-6
(HHV-6) DNA in biopsy of liver donors’ by nested polymerase chain reaction
(Nested-PCR).
Methods: Seventy-two liver biopsies were tested for the presence of CMV and
HHV-6 genome using a Nested-PCR.
Results: Thirty of seventy (41,1%) liver biopsies were HHV-6 PCR positive
and eight (11%) of seventy liver biopsies were positive CMV. Only six (8,3%)
of seventy biopsies were both CMV and HHV-6 positive.
Conclusions: The presence of the viruses observed in the samples of the donor,
indicate that pretransplant HHV-6 and CMV infection may be a risk factor
post-transplantation. They stayed aware to the neurological manifestation
of unknown origin because they can be related to the active infection by
HHV-6 isolated.

POSTER BOARD NUMBER P4 – 244
2194 ADOPTIVE IMMUNOTHERAPY: FUNCTIONAL
CHARACTERISATION OF EPSTEIN-BARR-VIRUS (EBV)
SPECIFIC T CELLS GENERATED BY SHORT TIME
STIMULATION WITH EBV PEPTIDES

POSTER BOARD NUMBER P4 – 246

A. Roemhild , S. Zwinger , G. Brestrich , I. Noack , H-D. Volk , P. Reinke
1
Department of Nephorology, Charite Berlin, 2Institute of Medical
immunology
Patients undergoing an immunosuppressive treatment, e.g. after transplantation,
have an increased susceptibility to infection and neoplasia, in general and to
B-cell lymphomas, in particular. EBV plays an essential role in development
of the majority of these posttransplant lymphoproliferative disorders (PTLD).
PTLD affects 2-25% of solid organ transplant (SOT) recipients for instance and
still carries a high morbidity and mortality.
In healthy individuals EBV infection is controlled by EBV-specific cytotoxic
T lymphocytes (CTLs). Under immunsupression some patients are unable to
control EBV efficiently and are therefore in risk of developing B cell tumours
or active chronic infections with transplant damage.
Immunotherapy with cytotoxic T cells (CTLs) as a new approach is increasingly
used to treat such malignancies and viral infections. For re-establishing a
functional immune response in-vitro expanded autologous virusspecific T cells
are retransferred into the patient.
Currently the generation of these T cells is mostly carried out by repetitive
stimulations with EBV-infected autologous lymphoblastoid cells (LCLs),
which takes approximately 2-3 months. Due to this generation time many
severe cases of patients suffering from missing viral immunity and subsequent
viral disease are excluded from therapeutic benefit.
Recently our group developed a shortened generation protocol for the
production of EBV specific T cells. T cells are detected via peptide stimulated
cytokine secretion combined with immunomagnetic cell isolation. Using
multicolour flow cytometry, we characterized these cells functionally after
expansion. Besides determining diverse surface markers and intracellular
cytokine production we also analysed the cytotoxic capacity and specificity by
calcein release assay.
In summary we were able to shorten the generation time for EBV specific T
cells dramatically without affecting the phenotyp or the specificity of neither
CD8+ nor CD4+ cells in the culture. The detailed characterization of these cells
should help to further improve the adoptive immunotherapy and its outcome.
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2196 CORRELATION OF TNFD MICROSATELLITE AND
HEMATOPOIETIC STEM CELL TRANSPLANTATION
K. Stingl1, Z. Grubic1, R. Zunec1, R. Serventi-Seiwerth2, E. Cecuk-Jelicic1, B.
Labar2, V. Brkljacic-Kerhin1
1
Tissue Typing Centre, University Hospital Centre Zagreb, 2Department of
Hematology, Internal Clinic, University Hospital Centre Zagreb
Correlation between serum levels of TNFá and occurrence of posttransplantion
complications such as acute GvHD was demonstrated in previous studies. The
release of this proinflammatory cytokine is a consequence of conditioning
regimens performed before hematopoietic stem cell transplantation (HSCT).
Furthermore, an association between TNFá production and TNFd microsatellite
polymorphism was also reported previously. The aim of the present study was
to investigate the possible correlation between this polymorphism and the
survival of patients.
Eighty patients who underwent HSCT were included in the analysis. All
of them received a transplant from a sibling identical for HLA-A, -B, and
-DRB1 loci. The analysis of the TNFd microsatellite was performed using
PCR amplification with specific primers followed by electrophoresis on a
polyacrylamide gel in ALFexpress sequencer with the B cell lines from 10th
Workshop as controls.
The distribution of alleles at TNFd locus among the patients did not differ
from the results obtained for healthy individuals tested in previous studies. The
predominance of TNFd4 allele (53.8% and 56.6% respectively) was observed
in both groups and the frequencies of all other alleles were in agreement. The
patients were divided according to the survival at day 100 post HSCT. No
statistically significant difference was observed between patients who survived
longer than 100 days post HSCT (N=68) and those who have not (N=12)
with respect to the distribution of allele and genotype frequencies at TNFd
locus as well as to the percentage of homozygous individuals. No correlation
with worse survival rates was observed for the presence of alleles with higher
number of repeats as previously suggested. The only marginally significant
difference was found for TNFd3 allele, which was increased among patients
with worse survival. Finally, this finding is in agreement with previous reports,
but further studies with a larger group of patients are necessary in order to reach
a final conclusion.
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Statin use at Transplant

Statin use at 3 months

No
(n=139)

Yes (n=61) P value

No
(n=116)

Yes (n=84) P value

Viruria (%)

37

31

0.521

38

31

0.298

Viremia (%)

12

10

0.810

14

8

0.266

Time to Viruria (days)

37± 7

47± 11

0.467

32± 9

57± 10

0.726

60± 33

0.221

55± 9

88± 37

0.753
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2197 PROPHYLAXIS NOT PROTECTION!!
A. Asderakis, M. Ilham, R. Egan, R. Bradley
Transplant Unit, University Hospital of Wales, UK
Introduction: 8% to 20%of renal transplant recipients experience
symptomatic Cytomegalovirus (CMV) infection. CMV disease leads to
reduction of patients and graft survival. This results not only from the CMV
virus direct pathogenic effect but also from its immunomodulating effects.
This is associated with other infections and a higher incidence of graft
rejection and chronic fibrosis.
Therefore prophylactic and pre-emptive treatment regimes against CMV have
been developed and are used in most transplant centers.
Aim: Identify the incidence of CMV disease in renal transplant recipients who
had a three month course of Valganciclovir prophylaxis following completion
of the course.
Method: All renal transplant recipients in the period between January 2004
to December 2007, who received valganciclovir prophylaxis were eligible for
the study. During this period Valganciclovir was given orally for 100 days post
transplant to seronegative patients that received an organ from a seropositive
donor and all recipients irrespective of CMV status who received T-Cell
depleting agents. CMV disease was diagnosed on the basis of a positive CMV
PCR in the context of clinical symptoms of viral disease, kidney dysfunction or
tissue invasive disease (colitis, gastritis).
Results: 361 kidney and kidney pancreas transplants were performed during
this period. 306 of the patients received prophylaxis according to the described
criteria.
Three patients developed CMV disease during the time they were receiving
prophylaxis. Thirty two patients (10.5%) developed CMV disease following
the completion of the prophylactic course. CMV developed from one week to
7 months (median 2 months) after completing the prophylaxis. These patients
proceeded to receive IV Ganciclovir and/or Oral Valganciclovir treatment and
went subsequently on additional prophylaxis adding a significant cost to the
overall transplant management. All patients responded to the treatment and no
resistance developed against Valganciclovir
Conclusion: Valganciclovir is effective in preventing CMV disease in a cohort
of medium and high risk patients during the 100 days that is given.
However it does not confer satisfactory longer term protection, as 10.5% of the
patients still developed CMV disease following completion of this prophylactic
course. This poses along term risk that is difficult to quantify.
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2198 THE INFLUENCE OF STATINS ON POLYOMA VIRUS
D. Brennan1, K. Hardinger2, A. Godolbo-Brooks1, R. Schuessler1, B. Lluhka1,
M. Schnitzler3
1
Washington University, 2University of Kansas City Missouri, 3Saint Louis
University
Statins have recently been shown, in vitro, to inhibit polyomavirus uptake. The
purpose of the study was to determine whether statins have a clinical effect
on the incidence, timing or severity of polyoma virus infection post kidney
transplant transplant.
Methods: A retrospective review of data collected in a randomized, singlecenter trial (n=200) that compared the influence of calcineurin inhibitors on
development of polyoma and the influence of reduced immunosuppressive
therapy for treatment of BK viremia.
Results: During the twelve month trial, 70 patients (35%) developed
viruria and 23 patients (11.5%) developed viremia. The median time to
onset of viruria and viremia were 40 and 60 days, respectively. At the
time of transplant 61 patients (31%) and at three months after transplant
84 patients (42%) received a statin. Patients on statins at the time of
transplant continued on their pre-transplant medication as soon as they are
able to tolerate medications. There was no difference in the use of statins
at baseline (P=0.85) or at 3 months after transplant (P=0.6) by type of
calcineurin inhibitor used. There were no differences in the incidence of
viruria, viremia, or the time to development of viruria or viremia based on
statin use.

Time to Viremia (days) 57± 29

There were no differences in other measures of viral severity based on presence
of a statin at the time of transplant or 3 months after transplant including the
following: peak urine viral load (baseline use P=0.904 and 3 months P=0.962) or
peak blood viral load (baseline use P=0.515 and 3 months P=0.789), time from
onset of viruria to peak viruria (baseline use P=0.977 and 3 months P=0.966), or
time from viruria to viremia (baseline use P=0.891 and 3 months P=0.538).
Conclusion: Based on the results of this study, statins do not influence the
incidence, timing or severity of BK infection after renal transplantation.
However, our lack of finding an effect may reflect a type II error.
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2199 SUCCESSFUL TREATMENT OF SEVERE ADENOVIRUS
INFECTION WITH INTRAVENOUS CIDOFOVIR IN A KIDNEY
TRANSPLANTATION PATIENT
S. Watcharananan1, S. Jirasirithum1, V. Mavichak2, C. Leenanupunth1,
S. Dithbanchong1, V. Chantarathitaya1, K. Malathum1, R. Avery3
1
Ramathibodi Hospital, Mahidol University, 2Institute of Kidney
Transplantation, Praram 9 Hospital, 3Cleveland Clinic Foundation
Adenovirus infection following kidney transplantation is not common. Most of
the infections are self-resolved. We present a patient who developed adenovirus
viremia with severe urethritis and hemorrhagic cystitis 3 weeks after cadaveric
kidney transplantation. Adenovirus was detected in the blood, urine and bladder
tissue. Reduced dosages of immunosuppressive drugs in conjunction with oral
ribavirin and intravenous immunoglobulin were administered without effect.
Intravenous cidofovir was efficacious. Patient became defervesced within
72 hours of treatment. There was no serious side effect and no detrimental
outcome on graft function. Reversible anterior uveitis after cidofovir use was
observed. Blood and urine for adenovirus became undetectable 2 weeks and 5
weeks after the initiation of cidofovir, respectively. Although the efficacy of
reduced dose cidofovir has not been proven in clinical trial, this is the first case
report to support the treatment of severe adenovirus infection with reduced
dose of cidofovir in kidney transplant patient.
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2200 CURRENT STATUS OF CMV-REACTIVATIONS IN ADULT
LIVER TRANSPLANT PATIENTS MONITORED BY FREQUENT
QUANTITATIVE PCR TESTING
K. Höckerstedt, I. Lautenschlager, R. Loginov, H. Mäkisalo
Helsinki University Hospital
Background: Cytomegalovirus (CMV) is a significant infectious agent
causing morbidity in transplant patients. CMV-infection mostly appears within
2-3 first months after transplantation. To prevent CMV, most liver centers use
prophylaxis for high risk patients of CMV-seronegative recipients receiving
an organ from a seropositive donor (R-/D+) and many centers even for all
seroposive recipients (R+). Preemptive treatment is mainly used for those at a
moderate or low risk of CMV, with a major advantage of reduced drug expose.
Preemptive therapy is based on the screening for early evidence of CMV by
frequent monitoring of viral load. The current status of CMV-reactivations
demonstrated by quantitative PCR-monitoring of adult CMV-seropositive (R+)
liver transplant patients was studied.
Patients and methods: Altogether 211 adult patients were transplanted
2003-2007. The basic immunosuppression consisted of CNI inhibitors,
azathioprine/MMF plus steroids in tapered or ceased doses. High risk patients
received valganciclovir (or ganciclovir) prophylaxis, i.v. ganciclovir was used
for preemptive therapy for (R+) patients, and in the case of symptomatic CMV.
Most recipients, 176 (84%), were CMV-seropositive (R+). Of those, 161 (R+)
patients with a follow-up over six months were studied. The patients were
frequently monitored for CMV by a real-time quantitative plasma PCR.
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Results: In most cases, 98/161 (61%) no evidence of CMV was seen, and just
63/161 (39%) developed CMV-DNAemia during the post transplant monitoring
of six months. Only 25/63 reactivations exceeded 5000 copies/ml considered
as cutoff level for preemptive treatment, and most had self-limiting, low-level
CMV-DNAemia. Thus, low-level CMV-reactivation occurred in 38/161 (R+)
patients (23.5%), and only 25/161 (15.5%) demonstrated significant viral loads.
No correlation to immunosuppression regimen could be found. No patient or
graft was lost due to CMV.
Conclusions: These results demonstrate that most CMV-seropositive liver
recipients do not develop CMV-reactivation, and even if reactivations occur,
most of them are temporal, low-level DNAemias. Thus, universal prophylaxis
for all R+ patients would not seem to be reasonable in this patient population.
Indirect effects and long term results are analyzed later.
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2201 POLYMERASE CHAIN REACTION (PCR) NEGATIVE
CYTOMEGALOVIRUS (CMV) ENTERO-COLITIS: A
CLINICALLY SIGNIFICANT ENTITY

THURSDAY

P. Masson1, K. Wyburn1, J. Eris1, P. Collett2, S. Chadban1
1
Royal Prince Alfred Hospital, Sydney, 2Concord Repatriation General
Hospital, Sydney
Background: CMV infection is a common complication of solid organ
transplantation which can be diagnosed serologically based either on
sero-conversion, or by detection of viral DNA using a nested PCR. PCR
is increasingly used as the ‘gold standard’ test in clinical practice as a
sensitive and specific qualitative and quantitative test in the surveillance
and detection of CMV, and in the measurement of anti-viral treatment
efficacy.
Methods: Retrospective analysis of four patients with symptoms of diarrhoea,
fever and weight loss who were found to be CMV PCR negative but confirmed
to have CMV colitis or enteritis following histopathological examination of
surgical or biopsy specimens. Quantitative PCR using an in-house assay of
human whole blood was performed, with dynamic range: <1000 copies/ml –
unlikely; 1000-5000 copies/ml – possibly; >5000 copies/ml – highly likely to
be associated with clinical disease.
Results: All patients were recipients of primary renal allografts (3 cadaveric,
1 living-unrelated) and three were CMV IgG antibody positive prior to
transplant. Donor CMV serology was positive in two cases and unknown
in two. Mean age of patient at time of transplant was 49.5 years (36 – 70)
with PCR negative CMV disease occurring an average of 147 months
post transplantation (10 – 212) at the mean age of 61.5 years (53 – 71).
One patient had experienced a prior episode of serologically proven CMV
disease. Baseline immunosuppression regimens all included Cyclosporin and
Prednisone in combination with an anti-proliferative agent (Azathioprine
or Mycophenolate Mofetil). Basiliximab induction was used in one case.
One patient discontinued calcineurin inhibition and one other switched to
Tacrolimus prior to the episode of CMV infection. One patient had ceased
anti-proliferative therapy. Three patients experienced acute cellular rejection
episodes, all receiving intravenous Methylprednisolone, and two receiving
T-cell depletion therapy (OKT-3). CMV prophylaxis had been given in only
one case. Serum CMV IgM was positive in one case, but not measured in
three others, nor were changes in IgG titres or CMV antigenaemia studies
performed. All responded to treatment with intravenous Gancyclovir and
subsequent oral Valgancylclovir.
Conclusions: PCR negative CMV infection is a clinically significant entity.
Undetectable CMV DNA by PCR does not exclude organ-invasive disease,
specifically intestinal disease. In cases where clinical suspicion of CMV disease
is high, alternative investigations should be employed and tissue diagnosis may
be required.
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2202 EPSTEIN BARR VIRUS ENCODED LATENT MEMBRANE
PROTEIN 1 ACTIVATES THE JAK/STAT PATHWAY
INDIRECTLY THROUGH PRODUCTION OF IFN-G
O. Martinez1,2, M. Vaysberg1,2, S. Lambert1,2, S. Kra1,2, C. Esquivel1
1
Stanford University School of Medicine, Dept of Surgery, 2Program in
Immunology
Background and Aims: Epstein Barr virus (EBV) is associated with multiple
human malignancies including post-transplant lymphoproliferative disease
(PTLD)-related B cell lymphomas. Latent membrane protein 1 (LMP1) is an
EBV-encoded protein expressed in PTLD tumors that can drive tumor growth
through constitutive activation of NFκ;B, Erk, p38, Akt, and JNK. We have
shown that EBV+ B cell lines from PTLD patients express LMP1 and have a
constitutively active Jak/STAT pathway. Dysregulated Jak/STAT activation has
been observed in several B cell malignancies. Here we determine the role of the
viral protein LMP1 in STAT activation in B cells.
Methods: Direct interaction of LMP1 with JAK3 was analyzed by
immunoprecipitation of PTLD cell line lysates with anti-LMP1 antibody and
Western blotting for JAK3. NGFR-LMP1 chimeric proteins were expressed
in the EBV negative Burkitt’s lymphoma cell line BL41 to permit inducible
LMP1 signaling. Gel shift assays were performed with whole cell extracts
from BL41. NGFR-LMP1 cells after 0-24 h of LMP1 activation. Additionally,
lysates were resolved on SDS-PAGE and Western Blotting (WB) was performed
with phospho (p) STAT1, STAT1, pSTAT3 and STAT3 antibodies. Cytokine
secretion was assayed by pan-cytokine luminex assay and ELISA. IFNγ;R1
and IFNγ; specific antibodies were used to block IFNγ; signaling in cells prior
to pSTAT1/STAT1 WB.
Results: Although JAK3 could associate with the common γ; chain in EBV+
B cell lines derived from PTLD tumors and in the BL41 B cell lymphoma line
infected with the B95.8 strain of EBV, no interaction of LMP1 with JAK3 was
observed. STAT/DNA complexes were detected in NGFR-LMP1 BL41 clones
after 24 hours of LMP1 signaling but not after 20-30 minutes of LMP1 signaling,
suggesting that STAT activation is indirect. STAT1 was the predominant STAT
activated by LMP1. Inhibition of cytokine secretion with brefeldin A prior to
LMP1 activation abolished STAT binding to DNA indicating that a secreted
protein is responsible for STAT activation. IFNs are known inducers of the STAT
pathway and cytokine luminex assays revealed that LMP1 can induce IFNγ;
but not IFNα;. Moreover, IFNγ; receptor blockade prior to LMP1 activation
dramatically decreased STAT1 activation. Finally, silencing of STAT1 by RNAi
markedly inhibited proliferation of BL41 cells and diminished expression of the
IFN-γ; inducible genes Mig1 and p21
Conclusion: Together, these data demonstrate that LMP1 does not activate the
Jak/STAT pathway through direct interaction with JAK3 but rather through an
indirect pathway involving IFNγ; induction. Moreover, activation of STAT1
via this pathway contributes to tumor cell growth. Thus the oncogenic protein
LMP1 of EBV usurps cellular cytokine pathways to augment tumor growth.
Understanding the viral-host cell interactions that promote tumorigenesis will
lead to novel strategies for treatment of PTLD.
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2203 EARLY POSTOPERATIVE URETERAL NECROSIS
ASSOCIATED WITH CYTOMEGALOVIRUS INFECTION
K. Malathum1, S. Jirasiritham2, W. Mawijak3, W. Kittikowit4
1
Department of Internal Medicine, Faculty of Medicine, Ramathibodi
Hospital, Mahidol University., 2Department of Surgery, Faculty of Medicine,
Ramathibodi Hospital, Mahidol University, 3Praram 9 Hospital, 4High Tech
Laboratories
Ureteritis associated with cytomegalovirus infection has rarely been reported in
medical literature although other syndromes caused by this virus are quite common
and pose a real challenge in transplantation medicine. We report here a case of
ureteritis accidentally identified in a renal transplanted recipient in Thailand.
A 57-year-old Thai man came to Praram 9 Hospital, Bangkok, Thailand in
late December, 2007 because of fever and shaking chill. He had undergone
cadaveric kidney transplantation one month earlier. Post-operatively, he
developed a large hematoma at the surgical site and urinary tract infection
caused by Klebsiella pneumoniae, which finally subsided. Pre-transplant
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serologic screening revealed CMV IgG positivity both in the patient and
the donor. Current medications included mycophenolate, prednisolone, and
cyclosporin. A diagnosis of urinary tract infection for which broad-spectrum
antibiotic was given was made and microbiologically confirmed later. A large
urinoma was found and he subsequently underwent a surgical operation. Partial
ureteral wall necrosis was found. Histopathology revealed subacute, organizing
ureteritis with rupture and atypical large endothelial lining possessing large
nuclei containing basophilic intranuclear inclusion and pink cytoplasmic
inclusions. The urothelial lining was markedly eroded. Immunohistochemical
staining confirmed these abnormalities as cytomegalovirus infection. CMV
viral load in the blood and urine were determined immediately after this finding
and it was 4890 copies/ml and <600 copies/ml, respectively. The patient was
treated with a 2-week course of ganciclovir and completely recovered.
This report emphasizes the importance of CMV infection in transplantation
recipient. Our case was in keeping with previous cases in that CMV infection
might be under recognized.
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2204 DIFFERENTIAL BINDING OF UL-16
CYTOMEGALOVIRUS PROTEINS TO POLYMORPHIC MHC
CLASS I CHAIN RELATED B (MICB) RELEVANT TO IMMUNE
EVASION.
C. Leelayuwat1, K. Klumkrathok1,2, A. Jumnainsong1, W. Wongsena1,3
1
The Centre for Research and Development of Medical Diagnostic
Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University,
2
PhD Program in Medical Technology, Faculty of Medical Technology,
Mahidol University, Bangkok, Thailand, 3Faculty of Allied Health Sciences,
Naraesuan University, Pisanuloke, Thailand
Human cytomegalovirus causes an opportunistic infectious disease in an
immunocompromized host. It is one of the clinical problems in transplantation
patients. The UL16 glycoprotein is present in human cytomegalovirus infected
cells but not in the virion envelop and down modulates NKG2D ligands by
forming stable intracellular complex leading to immune evasion. The purpose
of this study was to examine the functional variants of UL16 affecting the
binding activities to a polymorphic cellular NKG2D ligand, MHC Class I chain
related B (MICB). The soluble Fc fusion variants of the UL16 proteins from
four human cytomegalovirus strains (AD169, Toledo, PH and TR) and allelic
MICB expressing stable cell lines were produced. The binding activities of
UL16 variants to allelic MICB proteins were analyzed by flowcytometry. The
results showed that the variants of UL16 did not affect the binding activities
to the MICB proteins. However, the polymorphisms of MICB did affect the
UL16 binding activities. MICB*008 containing Methionine (M) at the amino
acid position 98 in the alpha 2 domain showed decreased binding activities to
UL16 when compared to MICB*003 and MICB*00502 containing Isoleucine
(I). This result suggests that the alpha 2 domain is critical to UL16 binding,
especially the residue M98I. Differential binding of diverse MICB alleles
could contribute to CMV immune evasion affecting immune responses to
human cytomegalovirus.
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2205 PROLONGATION THE MAJOR HISTOCOMPATIBILITY
COMPLEX-COMPATIBLE CARDIAC ALLOGRAFT SURVIVAL
DURING PREGNANCY
X -K. Li1, N. Funeshima-Fuji1, L. Xie1, H. Kimura1, T. Ezaki2, S. Takahara3,
B-T. Zhu4,
1
Lab of Transplantation Immunology, National Research Institute For Child
Health And Development, 2Department of Anatomy & Development Biology,
Tokyo Women fs Medical University School of Medicine, 3Department of
Advanced Technology for Transplantation, Osaka University Graduate
School of Medicine, 4Department of Pharmacology, The University of Kansas
Medical Center
Background: It has been suggested that the pregnancy hormones may play a critical
role in mediating selective immune tolerance during pregnancy. An understanding
of how the woman’s body normally never rejects the fetus, escapes the maternal
immune system may be relevant for the prevention of transplant rejection.

Materials & Methods: Female inbred DA (RT1a) or F344 rat (RT1lvl) hearts
were transplanted into normal Lewis (RT1l, nLewis) or pregnancy (pLewis)
rats, respectively. The mean survival time (MST) of the cardiac allografts
between the pLewis and nLewis groups was statistically compared using
unpaired student’s t test analysis. The proliferation of the PanT cells isolated
from nLewis and pLewis rats to ConA, antibody and alloantigen stimulation
was performed. The cytokines mRNA expression of these cells was analyzed
with quantitative RT-PCR.
Results: The pLewis recipients on day 12 had significantly prolonged
F344 cardiac graft survival (MST 13.3 days) compared with a group of
the nLewis recipients (MST 8 days), while no significantly difference
on day 6 and 18 of the pLewis (MST 10 and 10.2 days). Otherwise,
the MST was 5.7 days for DA to nLewis, and 6 days for DA to pLewis,
respectively. The pLewis PanT cell proliferation stimulated by alloantigen
and antibody was reduced, while not by ConA. The Th1/Th2 cytokine
profile of the PanT cells mRNA had no difference between the nLewis
and pLewis rats.
Conclusions: These results demonstrated that pregnancy hormones appeared
to play a critical role not only in the maternal acceptance of the fetus, but
also have therapeutic potential for prolongation the major histocompatibility
complex (MHC)-compatible allograft survival during pregnancy.
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2206 SUPERAGONIST CD28 ANTIBODY PREFERENTIALLY
EXPAND FOXP3-EXPRESSING NTREG CELLS TO PREVENT
GRAFT-VERSUS-HOST DISEASE
X-K. Li1, Y. Kitazawa1, L. Xie2, H. Kimura1, T. H?nig3, S. Takahara2
Lab of Transplantation Immunology, National Research Institute for
Child Health, 2Department of Advanced Technology for Transplantation,
Osaka University Graduate School of Medicine, 3Institute for Virology and
Immunobiology, University of W?rzburg,
It is well known that the naturally occurring CD4+CD25+ regulatory T
(nTreg) cells comprise a separate lineage of T cells that are essential for
maintaining immunological tolerance to self and represent a potential
therapy for the treatment of autoimmune disease, inflammation and allograft
rejection. Therefore, reagents that are capable of expanding the pool of nTreg
and enhancing their suppressive activity should prove to be very efficient
therapeutic tools. We previously presented a novel class of superagonistic
CD28-specific monoclonal antibodies (supCD28 mAb, JJ316) that can
induce the in vitro and in vivo expansion of T cells without a need for TCR
engagement. The dramatic polyclonal T cell response after in vivo application
of supCD28 mAb significantly prolonged the full MHC mismatch (DA to
Lewis) cardiac allografts survival. In the present study, we demonstrated that
the nTreg cells were preferentially proliferated to a 4-fold increase within 3
days in response to a single antibody administration. The appearance of the
Foxp3 and CTLA-4 molecules were significantly increased in the expanded
CD4+CD25+ Treg subset and the polarization toward a Th2 cytokine profile
with decreased production of IFN-ƒÁ and increased production of IL-4
and IL-10 was also observed in these expanded T cells. It was clarified that
isolated expanded Foxp3-expressing Treg cells by supCD28 mAb in vivo
exhibited immunomodulatory properties capable of inhibiting both naive or
activated CD4+CD25- T cell proliferation stimulated by alloantigens, antiCD3/CD28 mAbs, and ConA in a dose-dependent manner in vitro as well as
nai Nve fs, and, upon adoptive transfer, suppressed local and systemic Lewis
to F1 hybrid (Lewis x DA) GvH reaction. Furthermore, we found the Foxp3
positive Treg cells were maintained at the high level in the peripheral blood
of the GvHD host and immunostaining showed that the intragraft Foxp3
positive cell were significantly higher in supCD28 mAb-treated recipients. In
summary, our data identified a subpopulation of nTreg that are preferentially
expanding in vivo by the supCD28 mAb-treatment and maintaining not only
their phenotype but also their potent regulatory functions for suppressing
the immune response by the conventional T cells. We also demonstrated that
these preferentially expanded Treg are maintained in the peripheral blood
and recruited to the grafts for suppress the local immune and inflammatory
response resulting the graft survival prolongation, represent a major advance
towards the therapeutic use of these cells as cellular therapy for treatment
allograft rejection and GvHD.
1
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2207 INDUCTION OF LONG-TERM SURVIVAL OF CARDIAC
ALLOGRAFTS IN WILD-TYPE MICE BY ALLOANTIGEN
(ALLOAG)-SPECIFIC FOXP3+CD4+CD25+ NATURAL
REGULATORY T (NTREG) CELLS
G. Xia, J. He, J. Leventhal
Northwestern University, Dept. of Surgery – Organ Transplantation
Aims: Current study was aimed at preventing heart allograft rejection in wildtype mice by alloAg-specific Foxp3+CD4+CD25+ nTreg.
Methods: Fresh naive CD4+CD25+ nTreg were isolated from congeneic B6.PL
mice via autoMACS and enriched for alloAg specificity by in vitro culture with
either anti-CD3/CD28-coated Dynabeads (d0-11), then donor bone marrowderived dendritic cells ([DC] d11-20 (Beads/DC-expansion) or first with
donor DC (d0-8) then anti-CD3/CD28-coated Dynabeads (d8-16] (DC/Beadsexpansion) in the presence of interleukin(IL)-2, IL-2/transforming growth
factor(TGF)- or IL-2/TGF-/retinoic acid(RA).
Results: The% of intracellular Foxp3+ nTreg quickly decreased from 96.2%
(fresh) to 7.1% (d+18) during Beads/DC-expansion or to 6.2% (d+16)
during DC/Beads-expansion with IL-2 alone. Addition of TGF- (2.5 ng/mL)
significantly rescued the loss with Foxp3 expressed at 21.3% (d+18) for Beads/
DC-expanded nTreg and at 66.8% (d+16) for DC/Beads-expanded nTreg, while
total fold of expansion of nTreg remained similar (24.830.2 for Beads/DC- or
5.27.1 for DC/Beads-expansion) regardless of the presence or absence of TGF-.
Introducing RA (100 nM) into Bead/DC-based, TGF-/IL-2-conditioned culture
resulted in marginal improvement with 25.3% (d+18) nTreg being Foxp3+. In
MLR assays, nTreg expanded with TGF-/IL-2 exerted more potent suppression
than cells conditioned with IL-2 alone. In vivo, Beads/DC-expanded, TGF-/IL2-conditioned nTreg synergized with transient host T cell-depletion (anti-Thy1.2
mAb i.p. 50 g at d-3 25 g on d+1) in C57BL/6 mice to suppress BALB/c heart
allograft rejection with 57.1% (n=7) and 100% (n=7) allografts surviving over
100 days when 4x107 or 8x107 cells/mouse were injected immediately posttransplant, respectively. Anti-Thy1.2 treatment alone led to only 10% long-term
survival. Infused nTreg survived long-term (5.8% circulating T cells (8x107 cell
dose) or 1.2% (4x107 cell dose) at d+7 post-transplant) and expressed high level
Foxp3 (38.556.7%) in vivo. Interestingly, Beads/DC-expanded, TGF-/IL-2/RAconditioned nTreg expressed even higher Foxp3 (57.6~69.8%) during in vivo
suppression of allograft rejection. However, post-transplant RA treatment did
not enhance expansion of and/or conversion into host-derived Foxp3+ Treg (16.4%
vs. 21.7% in controls at d+7 post-transplant). Long-term surviving allografts
showed characteristics of acquired immune privilege with cellular infiltrates that
were Foxp3+, TGF-+, IL-10+ and indoleamine 2,3-dioxygenase (IDO)+, although
signs of mild to moderate chronic rejection were still evident.
Conclusions: AlloAg-specific Foxp3+CD4+CD25+ nTreg synergize with
peritransplant host T cell-depletion to induce long-term survival of allografts in
wild-type mice. Our ongoing study has shown >50% (d+18) of ex vivo-expanded
nTreg were Foxp3+ when cells were cultured in the presence of trichostatin A,
an histone deacetylase inhibitor, in the aforementioned Beads/DC-based, TGF-/
IL-2/RA-conditioned protocol. The efficacy of these cells to suppress allograft
rejection or to induce allograft tolerance will be tested in vivo.
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2208 ALLOREACTIVE REGULATORY T CELLS CAN
CONTROL THE EARLY STAGE OF REJECTION BY THE
DIRECT PATHWAY.

THURSDAY

C. Daniel, M. Belghith
Inrs Institut Armand Frappier
The reactivity of the 2.102 T cell clone with two independent ligands, the
alloantigen I-Ep and the self-restricted ligand Hb(64-76)/I-Ek, provides a unique
opportunity to study both direct and indirect pathways of allorecognition.
Although the two pathways have similar kinetics of rejection, the initiation
of immune responses leading to graft rejection is different. Using ab T celldeficient mice reconstituted with purified CD4+ T cells from 2.102 TCR Tg
mice, we first evaluated the infiltration of cells in grafts and lymphoid organs
by flow cytometry at various times post transplantation. 2.102 CD4+ T cells
were detected inside the graft as early as 7 days in the direct pathway and their
frequency decreased by day 11. This infiltration correlated with high expression
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of IFN-γ and IL-17 mRNA, as determined by qRT-PCR analyses. In contrast,
no significant infiltration could be observed before day 11 after priming through
the indirect pathway, infiltration that peaked at day 15, and which correlated
with a progressive transition from Th1 (IFN-γ) to mixed Th1/Th2 (IL-4)
mRNA expression. These observations suggested that a regulatory mechanism
was responsible for this delay in graft rejection by the direct pathway, in spite
of early effector T cells infiltration. qRT-PCR analyses showed that direct
pathway alloreactivity was specifically associated with the expression of Foxp3
in the allografts. Furthermore, depletion of the CD25+ cells in the population
of purified CD4+ T cells adoptively transferred significantly accelerated
allograft rejection by the direct pathway only, suggesting that regulatory T
cells are able to control the early stage of allograft rejection, but these are
eventually overwhelmed by the burst of T cell activation that occurs later in the
draining lymph nodes. Studies are currently in progress in order to confirm this
hypothesis. (Supported by CIHR and Fondation Armand-Frappier).

POSTER BOARD NUMBER P4 – 259
2209 ISOLATION AND CHARACTERIZATION OF A
CD45+ SUBSET OF FIBROBLASTIC CELLS IN CARDIAC
ALLOGRAFTS UNDERGOING CHRONIC REJECTION
A. Klein, G. Wu, Y. He, H. Wang
Cedars-Sinai Medical Center
Objective: Fibrocytes which express the phenotype CD34/CD45/αSMA/
Collagen-1 are believed to be one of the progenitors of myofibroblasts in
healing wounds and organ fibrosis. However, their role in allograft fibrosis
remains unclear.
Materials and Methods: Studies have been conducted using a rat model of
heart transplant (LEW-to-F344). Intragraft fibroblastic cells (IFC) were isolated
and characterized to qualify 1) the presence of fibrocytes in allografts; and 2)
phenotypic characteristics of the CD45+ and CD45- IFC.
Results: Dish-adherent fibroblastic cells were isolated from cardiac allografts,
native hearts and bone marrow of the recipients. These cells were then analyzed
for CD45 expression using flow cytometry. Dynamic changes in the proportion
of CD45+ and CD45- cells were observed in primary cultures. Approximately
60% of intragraft fibroblastic cells (IFC) were CD45+ at 24 hours in culture. The
cells dramatically decreased to 30% at day 4, 15% at day 7 and <1% at day 14 of
cultures; while CD45-negative fibroblasts increased proportionally. CD45+ IFC
co-expressed low levels of αSMA, displaying a CD45+/αSMAdim cytometric
phenotype whereas CD45- cells expressed high levels of αSMA, displaying
a CD45-/αSMAhigh phenotype. In contrast, cardiac fibroblasts isolated from
native hearts only had 2% cells expressing CD45 at day 7 and this percentage
diminished quickly over time. qPCR studies showed that CD45+ IFC expressed
stem cell marker CD34, hematopoietic markers CD14, CD11b, CD45, low
levels of αSMA and pre-collagen-α1, a phenotype characteristic of fibrocytes.
These cells also expressed high levels of PDGFα, TGF-β, MMP-9, IL-1 and
TNF-α, which are important inflammatory/fibrogenic factors. In contrast,
CD45-/αSMAhigh cells expressed high levels of pre-collagen α1, αSMA, and
TIMP-1, a myofibroblast phenotype. Microscopic examination demonstrated
that CD45+ IFC are small oval or spindle shaped, and co-express cytoplasmic
non-stress α-actin. To study whether intragraft fibrocytes can give rise to
myofibroblasts, CD45+ and CD45- fibroblastic cells isolated from primary IFC
cultures were evaluated for myofibroblast differentiation in cultures stimulated
with TGF-β. At 24-48 hours cultures CD45+ cells exhibited a small oval or
spindle-shaped morphology. Few myofibroblasts were sporadically seen. A few
polygonal cells emerged at 72-96 hours in cultures. The cells expressed αSMA,
as demonstrated by immunofluorescent microscopy and grew into αSMA
expressing colonies in 7-9 days. In comparison CD45- IFC at day 2 cultures
exhibited typical fibroblast morphology and expressed redundant stress αSMA.
Similar patterns of CD45+ cell-to-myofibroblast transition were also observed
in cultures of the blood fibrocytes and bone marrow stromal cells.
Conclusion: The data demonstrate that two distinct subpopulations of
fibroblastic cells exist in chronically rejecting allografts. The CD45- subset
represents the end-differentiated fibroblasts (myofibroblasts). The CD45+
subset, on the other hand, exhibits a phenotype consistent with description
of fibrocytes. Since the CD45+ subset has the potential to differentiate into
myofibroblast and the ability to produce pro-inflammatory cytokines these cells
may play important roles in allograft fibrogenesis, either as the precursors or/
and the regulators of myofibroblasts.
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2210 IMMUNE RESPONSE IN OLDER TRANSPLANT
RECIPIENTS IS CHARACTERIZED BY AN IMPAIRED
EFFECTOR AND INTACT REGULATORY T-CELL RESPONSE
C. Denecke1, X. Ge1, I. Kim1, D. Bedi1, A. Jurisch1, J. Pratschke2,
P. Neuhaus2, S. Tullius1
1
Div of Transplant Surgery, BWH, 2Dept of Surgery, Charite Berlin
Elderly recipients represent the most rapid growing segment of patients on the
waiting list. However, little is known about age-dependent alterations of the
immune response in organ transplantation. We examined age dependent T-cell
functions in a transgenic mouse transplant model.
Effector T-cell phenotype, -function, cytokine production and regulatory T-cell
function were analyzed in 3 and 18mths old B6 mice. In an in vivo transplant
model, BL/6 nude mice were reconstituted with 2x106young or old transgenic
alloantigen-specific CD4+T-cells and engrafted with bm12 skin grafts. T-cell
phenotype and cytokine secretion were analyzed in all lymphatic compartments.
Splenocytes of naïve old B6 mice contained significantly higher frequencies of
T-cells with an effector/memory phenotype (CD4+CD44highCD62Llow and
CD8+CD44highCD62Llow; p<0.005). However, in vitro proliferation (MLR:
p<0.005) and IFNγ;-production (ELISPOT (p<0.001) were significantly
reduced in aged mice
Older wild-type (WT) skin transplant recipients showed a modified immune
response. While graft survival in elderly native recipients was prolonged (11
vs. 13 d, p= n.s.), increasing recipient age was associated with an impaired
proliferation and IFNγ;-production. Significantly diminished numbers of
early activated (CD69+) T-cells, IFN&#61543;+ – and IL-2+ T-cells and
CD4+ T-cells expressing CXCR3+ and CCR5+ were observed. In parallel,
regulatory functions remained age-independent as alloantigen-specific
CD4+CD25+FoxP3+ T-cells isolated from sensitized old mice demonstrated a
dose-dependent well preserved suppressor function.
We then examined the impact of age in a transgenic skin transplant model
analyzing the alloantigen –specific CD4+ T-cell response: Rejection kinetics were
also moderately prolonged with increasing recipient age in this model (young vs.
old: 10.1 vs. 14.3 d, n.s.) However, the T-cell response was significantly different:
Fewer numbers of activated CD4+CD25+ (spleen and draining lymph node,
dln) and effector/memory phenotype T-cells (CD4+CD44highCD62Llow) (dln)
were found after transfer of old T-cells (p<0.05). In parallel, T-cell migration was
impaired since less CXCR3+ and CCR7+ T-cells were detected in dln following
the transfer of old T-cells (total cell numbers x104: CXCR3+: 10.9±4.2 vs.0.95
±0.2, CCR7+: 4.7±1.0 vs. 0.35±0.2, p<0.05). As a consequence, intragraft CD4+
T-cell infiltration was reduced compared to recipients of young T-cells.
In summary, elderly mice showed an overall impaired effector T-cell response.
In vivo allospecific CD4+ T-cell activation and migration was delayed in elderly
transplant recipients while regulatory -T-cell function remained preserved.
These experimental findings may have important clinical implications for an
age-adapted immunosuppression.

POSTER BOARD NUMBER P4 – 261
2211 THE IMMUNOLOGICAL ASPECTS OF ANTI-HISTONE
H1 AUTOANTIBODY ON LYMPHOCYTE BIOLOGY IN LIVER
TRANSPLANTATION TOLERANCE
T. Nakano1, S. Goto1,2, L.W. Hsu1, C.Y. Lai1, J.L. Wong1, S. Kawamoto3,
T. Goto4, K. Ono3, Y.F. Cheng1, C.L. Chen1
1
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology,
Graduate School of Advanced Sciences of Matter, Hiroshima University,
4
Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences,
Josai International University
Aims: We previously demonstrated the immunosuppressive activity of antihistone H1 autoreactive antibody (Ab) induced in a rat spontaneous liver
transplantation (LTx) tolerance model (Transplantation 2004; 77: 1595) and
a clinical drug-free patient after living related LTx (Transplantation 2007; 83:
1122). This study aimed to explore the immunological aspects of anti-histone
H1 Abs on intracellular signaling pathway via T cell receptor (TCR).
Methods: Purified T-cells were cultured on anti-CD3 Ab-immobilized dishes
with anti-histone H1 Abs or standard immunosuppressant cyclosporine (CsA)

for 0-6 hr. Western analyses were performed to evaluate the effects of antihistone H1 Abs and CsA on mitogen activated protein kinase (MAPK), nuclear
factor-kappaB (NF-kB) and calcineurin signaling pathways.
Results: Anti-histone H1 Ab possesses immunosuppressive activity with
a comparable ability to block T-cell activation as the CsA. Western analyses
revealed that anti-histone H1 Ab altered the phosphorylation levels of
extracellular signal-regulated kinase (ERK), p38, and inhibitory NFkB (IkBa) via
TCR signaling. We also found lower expression of calcineurin due to treatment
with anti-histone H1 Ab. Intriguingly, we observed a higher phosphorylation of
c-Jun N-terminal kinase (JNK) during TCR signaling with anti-histone H1 Ab,
while CsA downregulated the JNK activity, suggesting the existence of different
immune regulative mechanism(s) between anti-histone H1 Ab and CsA.
Conclusions: These results suggest a therapeutic advantage of anti-histone
H1 Ab compared with current immunosuppressants and that the selective
regulation of MAPK, NF-kB and calcineurin signaling may be important in the
T-cell growth arrest led by anti-histone H1 Ab.

POSTER BOARD NUMBER P4 – 262
2212 THE INVOLVEMENT OF GAMMA-DELTA T
LYMPHOCYTES IN LIVER TRANSPLANT TOLERANCE
W. Li2, F. Malone1, K. Carper2, J. Reyes2
1
Children’s Hospital & Regional Medical Center, Seattle, WA, 2University of
Washington, Seattle, WA
The gamma delta T lymphocytes are considered a non-conventional T cell subset
and are found throughout the body, but mainly located in the cutaneous, gastric
and intestinal epithelia as reported. The role of gamma delta T cells in innate
and adaptive immunity is just emerging; remaining poorly understood in many
aspects. It has recently been shown that gamma delta T cells have an important
anti-tumor and anti-infectious effect. The involvement of gamma delta T cells
in the immunologic response to hematopoietic cell transplantation and the
development of graft versus host disease remains controversial, with divergent
results depending on the murine strains and model systems employed. Whether
gamma delta T cells are involved in solid organ transplantation is understudied.
In this study, we have characterized the gamma delta T cell population in mouse
livers and spleens, and further evaluated their contributions in liver transplant
tolerance throughout the time course of posttransplantation by using our unique
model of mouse spontaneous transplant tolerance. Our studies revealed that
gamma delta T cells mainly reside in the liver and comprise about 20% of the
population of liver nonparenchymal cells in either naïve B6 or C3H mice. Most
of those cells are CD4, CD8, and NK1.1 negative. The percentage of gamma
delta T cells was decreased in the liver grafts in the spontaneous tolerance model
from day 1 to day 100 posttransplantation; they were all below 10% in the liver
grafts vs 20% in naïve mice. In contrast, the percentage was increased in the
rejected liver grafts, which was induced by anti-CTLA4 and anti-CD25 mAb
administration. The percentages of gamma delta T cells were 33% and 35% in the
anti-CTLA4 and anti-CD25 mAb treated recipients at day 5 posttransplantation,
respectively. There was a slightly increased frequency of CD8 expression on
gamma delta T cells in the tolerated livers post transplantation (10-20%), but
not in the rejected livers. Thus, the data from our preliminary study suggests that
gamma delta T cells are involved in the liver transplant tolerance and rejection
processes, but may favor the induction of liver graft rejection.

POSTER BOARD NUMBER P4 – 263
2213 IL-6R BLOCKADE ENHANCES TREGS AND LIMITS
TH17 CELLS IN PROTEINURIC RENAL DISEASE
Y.M. Wang1, G.Y. Zhang1, Y. Wang2, T.P. Polhill1, M. Hu1, D.C.H. Harris2, S.I.
Alexander1
1
Centre For Kidney Disease, Children’s Hospital At Westmead, Sydney, NSW.
Australia., 2Centre for Transplant and Renal Research, University of Sydney
at Westmead, Sydney, NSW, Australia.
IL-17-producing T lymphocytes comprise a distinct lineage of pro-inflammatory
T helper cells, termed Th17 cells. IL-6 is crucial with TGF-b in the development
of Th17 cells. Blockade of the IL-6R may shift T cells from Th17 to regulatory
T cells (Tregs).
Aim: The aim of this study was to evaluate whether IL-6R blockade inhibits
Th17 and enhances Tregs in a model of chronic proteinuric renal injury.
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Methods: Adriamycin nephropathy was induced in BALB/c mice by
a single injection of Adriamycin. Anti-IL-6R or isotype controls were
administered to mice one day prior to Adriamycin administration, and on
days 6, 13 and 20.
Results: Urinary protein excretion was reduced in ADR mice receiving antiIL-6R (ADR+anti-IL-6R), compared to those not receiving antibody (ADR)
and those receiving isotype control (ADR+isotype). Serum creatinine,
glomerular sclerosis and tubulointerstitial damage were significantly lower in
the ADR+anti-IL-6R group than in the ADR group and ADR+isotype group
(p<0.01). Body weight was maintained in the anti-IL6R group. Enhanced
Foxp3 expression occurred in the IL-6R blockade group. In vitro blockade
with IL-6R inhibited TH17 cells induction and enhanced generation of Foxp3
Tregs by TGF-β.
Conclusions: We conclude that antibody blockade of IL-6R can be used
to protect against renal damage in a murine model of chronic immune
injury. Protection may be due to enhanced Treg numbers and limiting Th17
development.

POSTER BOARD NUMBER P4 – 264
2214 LIVER STELLATE CELLS, AS NON-PROFESSIONAL
ANTIGEN-PRESENTING CELLS, PREFERENTIALLY EXPAND
TREG CELLS IN AN IL-2 DEPENDENT MANNER
G. Jiang1, L. Wang2, J. Fung2, S. Qian1,2, L. Lu1,2
Department of Immunology, Lerner Research Institute, Cleveland Clinic,
2
Department of General Surgery, Cleveland Clinic
Liver tolerance is demonstrated by spontaneous acceptance of liver allografts
in many species, but hepatocytes are acutely rejected in the same donorrecipient combinations, suggesting an immunosuppressive effect of liver
nonparenchymal components. Some tissue cells, upon activation, acquire
ability to present antigens, and act as non-professional APC leading to
immune suppression. Thus, hepatic stellate cells (HpSC) constitutively
express MHC class I, CD80 and ICAM-1. The expression of MHC class
II, CD80, B7-H1 and IL-10 is upregulated following IFN-ƒ× activation,
which conferred ability to stimulate allogeneic CD4+ T cell proliferation.
However, activated (a) HpSC demonstrate profound immune suppressive
activity, and effectively protect co-transplanted islet allografts from rejection.
The underlying mechanisms remain unclear. In this study, we examined
responses of allogeneic CD4+ T cells to aHpSC, compared to professional
APC, dendritic cells (DC). CD4+ T cells of BALB/c (H2d) were cultured
with irradiated B6 (H2b) aHpSC, at 10:1 for 5 days promoted CD25+ cells
from 5% to 13%, among which 85% were FoxP3+. Addition of expanded
CD4+CD25+ cells inhibited proliferative responses in reporter T cells (CD4+
or CD4+CD25- cells) in a dose dependent manner. Whereas, DC stimulated
pronounced allogeneic CD4+ T cell proliferation with CD25+ cells
increasing to 63.7%, but majority (81%) were Foxp3- effector cells, and did
not show immune suppressive activity. Neutralization of IL-2 by anti-IL-2
mAb almost totally eliminated the ability of aHpSC to expand Treg cells. To
determine the origin of Foxp3+ T cells, aHpSC were cultured with purified
CD4+CD25+ or CD4+CD25- cells, showing that FoxP3+ cells were only
differentiated from CD4+CD25+, which required exogenous IL-2 (100 U/
ml). This was confirmed by using Thy1.1+ congenic mice. CD25- cells from
normal BALB/c (Thy1.1-) were mixed with CD25+ cells from Thy1.1+ mice
at 10:1 ratio. The CD25+FoxP3+ cells was increased to 13.8% following
5 days culture, in which 95.2% were Thy1.1+, similar to the composition
of the original CD4+CD25+ cells that contained 93.4% Thy1.1+ cells. In
vivo, systemic administration of aHpSC (106) into allogeneic recipients
resulted in significant increases in CD25+FoxP3+ cells in lymph nodes and
spleen. These results strongly suggest that professional APC generate mostly
effector cells, whereas, non-professional APC selectively drive Tregs, which
may explain their capacity of inducing T cell hyporesponsiveness. This may
represent a portion of complex mechanisms by which immune responses are
regulated in the liver.
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2215 REGULATION OF ALLOSPECIFIC T CELL RESPONSES
BY DONOR ANTIGEN PRESENTING CELLS DEPENDS ON
LOCAL GENERATION OF COMPLEMENT C5A
K. Li, Q. Peng, S. Sacks, W. Zhou
King’s College London
The innate system of immunity an important role in ischemia-reperfusion
injury and allograft rejection. The early stages of inflammatory processes
are accompanied by complement activation. One biological consequence of
this activation is the release of potent inflammatory anaphylatoxins, C3a and
C5a, which have been reported to regulate a range of inflammatory responses.
We previously reported that DCs express C3aR and C5aR, and C3a-C3aR
interaction has a positive impact on murine BM DCs, in terms of activation
phenotype and capacity for Ag uptake and allostimulation. However, the role
of C5a in modulating DC function remains unclear. The aim of this study is
to investigate the role of local C5aR signalling in modulating murine BM DC
function and subsequent regulation of the allospecific T cell response. We first
evaluated if C5a-C5aR interaction could result from local expression of factors.
Our results showed that C5aR mRNA was detected in WT DCs at different
stage of DC culture by RT-PCR, and C5a was detected by ELISA in the culture
supernatants from different stages of DC culture. We next determined if C5aC5aR interaction modulates DC function in allospecific T cell stimulation
in vitro and in vivo. We found that BM DCs cultured from C5aR-/- mice or
treated with C5aR antagonist (C5aRa, W54011) exhibited a less activated
phenotype (producing significantly less IL-12 and more IL-10, in response to
LPS stimulation); both C5aR-/- and antagonist-treated DCs (LPS stimulated)
showed reduced capacity to stimulate naïve alloreactive T cells, as measured
by IFN-γ; production and thymidine uptake. As regards interaction in vivo,
following i.p. administration of the C5aRa-treated DCs into allogeneic mice for
10 days, ex vivo mixed lymphocyte reaction showed that CD4+ T cells from
those recipients have reduced thymidine uptake, but increased IL-4 production
compared to that with untreated DCs. Conversely, DCs treated with C5aR
agonist (C5a) exhibited a more activated phenotype (producing more IL-12
and less IL-10) and were more potent in allospecific T cell stimulation.
Our findings demonstrate that murine BM DCs can express C5aR and C5a
can be generated locally; C5a-C5aR interaction up-regulates murine BMDC
activation and their allostimulatory capacity. Thus, targeting C5a-mediated
signal may be able to prevent allograft injury.

POSTER BOARD NUMBER P4 – 266
2216 REGULATORY T CELLS INHIBIT THE PROLIFERATION
OF LYMPHOCYTES THROUGH TIM-3-TIM-3L PATHWAY
J. Yuan1, K. Wu2, Y. Xu2, Z.K. Chen2
1
Department of Nephrology, Tongji Hospital, 2Institute of Transplantation,
Tongji Hospital
Objective: To explore the role of TIM-3-TIM-3L pathway to modify the
immunosuppressive effect of natural Treg (nTreg) and induced Treg (iTreg).
Methods: Firstly, we separate nTreg from C57BL/6 by MACS and induce
na&iuml;ve T cells to differentiate into iTreg by TGF-¦Â1. And then Foxp3 and
TIM-3L expression in these Treg, and the ability of inhibiting the proliferation
of lymphocytes were measured. The TIM-3-TIM-3L pathway was blocked
with TIM-3.Ig and anti-TIM-3, which could combine with TIM-3L and
TIM-3 expressed on the surface of nTreg and iTreg respectively. And then, the
immunosuppressive ability of these Treg was measured by MLC.
Results: Both of nTreg and iTreg expressed Foxp3, and could inhibit
proliferation of lymphocytes. TIM-3L(galectin-9) mRNA was measured in
nTreg and iTreg with RT-PCR. The expression of galectin-9 in nTreg and
iTreg was lower than that in splenocytes(p<0.05). Immunosuppressive effects
of nTreg and iTreg were partially reduced with TIM-3.Ig interference. It was
weaker than control group(p<0.05). But anti-TIM-3 did not affect nTreg and
iTreg obviously(p>0.05).
Conclusion: TGF-¦Â1 could induce iTreg population. nTreg and iTreg could
express TIM-3L, and inhibited the proliferation of lymphocytes through TIM3-TIM-3L pathway. Even while TIM-3-TIM-3L pathway was blocked, Treg
could still inhibit the lymphocytes to proliferate partly. These results imply that
TIM-3-TIM-3L pathway was not the only mechanism of Treg function.
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2217 RAPAMYCIN PREFERENTIALLY BLOCKS
THE EXPANSION OF POTENTIALLY TOLEROGENIC
PLASMACYTOID DENDRITIC CELLS IN VIVO
A.W. Thomson1,2, H.R. Turnquist1
1
T. E. Starzl Transplantation Institute And Department of Surgery, University
of Pittsburgh, Pittsburgh, PA, 2Department of Immunology, University of
Pittsburgh
Introduction: Previously, it has been shown that rapamycin (RAPA), a novel,
‘tolerance-sparing’ immunosuppressive pro-drug with anti-proliferative
properties, inhibits myeloid (m) dendritic cell (DC) differentiation and
maturation in vitro. In addition, RAPA decreases the number of CD11c+ DC
in the mouse spleen and suppresses the massive expansion of total CD11c+
DC typically observed following administration of the endogenous DC growth
factor, fms-like tyrosine kinase 3 ligand (Flt3L). However, the influence of
RAPA on plasmacytoid (p) DC,- the principal type-1 IFN producers in the body,
that regulate innate and adaptive immune responses, and promote experimental
transplant tolerance, has not been evaluated.
Methods: DC were propagated from bone marrow cells for 10 days (d) in
Flt3L, in the absence or presence of a clinically-relevant concentration of
RAPA (10 ng/ml). In addition, DC were mobilized in C57BL/10 mice by
i.p. administration of Flt3L (10 μg/d for 10 d; d1-10). Groups of untreated
and Flt3L-treated animals also received RAPA (0.5 mg/kg/d i.p.; d3-10).
On d11, DC were isolated from spleen preparations by density gradient
centrifugation and CD11c+ DC positively selected (purity >97%) using antiCD11c immunomagnetic beads. Identification of mDC (CD11c+CD11b+) and
pDC (CD11cloCD11b-B220+) was completed by assessment of surface Ag
expression by flow cytometry.
Results: RAPA suppressed pDC and mDC generation in vitro. RAPA-DC-treated
BM cultures had only 22% of the pDC and 40% of the mDC found under control
conditions. RAPA also reduced the steady-state absolute numbers of splenic DC
in normal mice. Both mDC (54% of vehicle-treated control) and pDC (24%)
numbers were reduced significantly by RAPA administration. Furthermore,
administration of RAPA, when given concurrently with Flt3L, blunted the
typical profound expansion of mDC. Specifically, Flt3L and RAPA-treated mice
displayed a 47-fold increase over control steady state numbers compared to the
145-fold increase in mice treated with Flt3L alone. Flt3L-induced expansion of
pDC was impacted to a much greater extent by RAPA, as the absolute numbers
of pDC increased only 6-fold over control steady state numbers compared to a
51-fold increase in absolute splenic pDC in Flt3L-treated mice.
Conclusion: These data identify RAPA as a selective suppressor of pDC
generation. This has significant clinical implications, given the use of RAPA
following organ transplantation and the importance of pDC in IFNα production.
Likewise, pDC have been implicated as critical antigen presenting cells in the
secondary lymphoid tissue and instrumental in the promotion of experimental
transplant tolerance. As such due attention to these possible disparate effects of
RAPA on potentially immunoregulating cell populations will be necessary to
optimize therapeutic tolerogenic regimens for safe promotion of tolerance.

POSTER BOARD NUMBER P4 – 268
2218 DIFFERENTIAL EXPRESSION OF FOXP3 IN
PLASMACYTOID AND MYELOID DENDRITIC CELLS (DC)
GENERATED FROM RAT BONE MARROW CELLS (BMC)
H. Kimura1, A. Tsuji2, H. Mizuguchi3, X-K. Li1, N. Fuji-Funeshima1, R.
Haba1, K. Matsumoto1, H. Saito1, Y. Kitazawa1, I. Nozawa4
1
National Research Center For Child Health & Development, 2National
Institute of Radiological Sciences, 3National Institute of Biomedical
Innovation, 4RNAi Co., Ltd.
Backgrounds: Currently Foxp3 is considered to encode a transcription
suppressor with a forkhead/winged helix motif at the carboxy terminus, a
C2H2 zinc finger domain, and a 3-heptad Zip motif.
Heretofore, numerous studies have shown that Scurfin, a protein of FoxP3
gene, is a master gene for regulatory T cells (Treg) that down regulate T cell
function in general.
Thus it has been reported that Foxp3 is exclusively expressed by a sunset of
T cells, i.e., CD4+CD25+ T cells, and currently is it representing the most

definitive marker for this population.
To the best of our knowledge, there has been no single study that specialized
antigen presenting cells (APC), dendritic cells (DCs) express Foxp3.
Materials & Methods: Employing DCs generated from long term culture
driven by Flt3 ligand and IL-6, i.e., currently classified as plasmacytoid DCs,
PCR cloning of cDNA obtained from rat DC was completed and real time PCR
was applied to measure the mRNA of cytokines related to immune regulation.
Results: Sequencing of 29 cDNA clones revealed 3 isoforms of rat Foxp3, i.e.,
major isoform 1, and two additional minor forms of 2 and 3.
Real time RT-PCR analysis revealed that the level of Foxp3 expression
was time dependent and ultimately reached the same as or higher than
CD4+CD25+ T cells.
Although western blotting analysis revealed that isoform 1 was indeed
expressed by a subset of DCs and the Foxp3+ DCs were found to express a high
level of various immunoregulatory cytokines and molecules, such as IL-10,
TGF-b, and iNOS, Foxp3+ DCs were found to be fully functional in terms of
antigen presentation to nai Nve T cells.
In contrast to this, DC generated from a short-term culture driven by GM-CSF
and IL-4, i.e., myeloid DCs, did not express Foxp3.
It appears that Foxp3 is expressed differentially on a subset of DCs such as
plasmasytoid DCs and myeloid DCs.
Conclusion: Inasmuch as Foxp3 appears to be a key element of cause and result
of the fatal lymphoproliferative disorder of scurfy mice and a human X-linked
autoimmune and inflammation syndrome, our finding would give a new insight
in the function of Foxp3 that plays a role of immune regulation by DCs.
Taken together, our findings indicated that Foxp3 is not only a master gene for
the developmental program of CD4+CD25+ Treg cells rather it may represent
a more broader function of the gene regulation responsible for a subset of
specialized antigen presenting cells such as DCs and macrophages.
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2219 RENAL FUNCTION IS STRONGLY PREDICTIVE OF A
RENAL TRANSPLANT PATIENT’S REGULATORY T CELL (T
REG) PHENOTYPE, USING FLOW CYTOMETRIC ANALYSIS
OF CD127 TO IDENTIFY T REGS WITHIN THE PERIPHERAL
BLOOD.
D. Gracey1, B. Pussell1, J. Charlesworth1, C. Zhu2, B. Fazekas de St Groth2
Prince of Wales Hospital, 2Centenary Institute
Assessment of the role of regulatory T cells within the transplant clinic has been
hampered by the complexity of the techniques involved in their identification,
as well as the inability to reliably distinguish between activated CD4+ cells,
and true regulatory T cells. We have utilised a novel flow cytometric approach
using the expression of interleukin (IL)-2 and IL-7 (CD 127) to discriminate
between regulatory and activated T cells. This technique may be undertaken
using a sample of peripheral blood, with subsequent flow cytometric analysis
using a standard protocol. We wished to investigate its clinical utility amongst
renal transplant patients.
The immune phenotype of the renal transplant population was compared to
those with CKD, those on dialysis and to the normal population. Clinical
correlates were sought, with particular attention paid to the effects of renal
function. Samples of peripheral blood (n=20 in each group) were assayed
using six-colour flow cytometry to identify a highly purified population of
T regs (CD25+, CD127lo). Phenotypic analysis further classified these cells
as naïve, or effector/memory. An individual’s serum creatinine and eGFR
were highly predictive of T reg phenotype. The relationship between renal
function and effector/memory cell number was strongest (for serum creatinine
R=0.587, p<0.001, for eGFR R=-0.532, p<0.001), with increasing numbers
of effector/memory T regs demonstrated with increased creatinine. There
was also a trend for increased numbers of naïve memory cells with declining
renal function (for serum creatinine R=0.177, p=0.18). The renal transplant
population demonstrated more normal T reg subset proportions, however, the
overall number of T regs remained abnormally low compared to the normal
population.
This study indicates that the cell surface expression of IL-2 and IL-7 can
be used to reliably identify a pure population of T regs in renal transplant
patients, using a standard flow cytometric approach on a sample of peripheral
blood. Additionally, we have demonstrated a strong relationship between
1
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renal function and T reg phenotype, with higher numbers of both naive and
effector/memory T regs with worsening renal function. The renal transplant
group demonstrated proportions of regulatory subsets more reminiscent of the
control group, possibly related to their superior renal function. The effect of
immunosuppressive regimen upon T reg phenotype, if any, will be investigated
using this technique.

POSTER BOARD NUMBER P4 – 270
2220 CTLA4-IG INHIBITS THE INDUCTION OF ADAPTIVE
FOXP3+ T REGULATORY CELLS IN COCULTURES OF NAÏVE
CD4+ T CELLS IN AN ALLOGENEIC DENDRITIC-T CELL MLR
R. Krishnan1,2, J. McIntyre1
1
The Queen Elizabeth Hospital, 2University of Adelaide
Human CD4+CD25+ T regulatory cells express the transcription factor FoxP3
and have potent immunosuppressive properties that may facilitate allograft
tolerance. While naturally occurring CD4+CD25+ T regulatory (Treg) cells
occur in the thymus, adaptive Treg expand in the periphery from naïve CD4+ T
cells. In this study we investigated the ability of dendritic cells (DC) to induce
the adaptive Treg population during an allogeneic DC-T cell MLR. The role of
costimulation in the induction of adaptive Treg was verified by firstly comparing
the propensity of immature versus mature DC to generate FoxP3+ T cells and
secondly by the blockade of costimulation with CTLA4-Ig fusion protein.
Immature DC (iDC) were obtained by differentiating human monocytes with
the cytokines IL-4 and GM-CSF and mature DC (mDC) were generated by the
subsequent addition of TNF-α and prostaglandin-E2. Both iDC and mDC were
co-cultured with immunomagnetically isolated naïve T cells (CD4+CD25-) for
3 and 6 days in a stimulator: responder ratio of 1:100. Adaptive Treg were
detected by flow cytometry by the expression of intracellular Foxp3 and the
cell surface markers, CD4 and CD25. The FoxP3+ cells also showed low or
no expression of the IL-7 receptor, CD127. At 3 days of co-culture, mDC
produced higher numbers of Treg compared to iDC (14.7% vs 9.4%; p<0.001)
however, by day 6 both populations of DC produced similar levels of Treg.
Furthermore, immunomagnetically isolated CD25+ adaptive Treg obtained
from both iDC and mDC co-cultures showed potent immunosuppression (74%
inhibition compared to control; p<0.001) in the mixed lymphocyte reaction.
CTLA4-Ig (100 ng/ml) added directly to the MLR inhibited T cell proliferation
by 33.4±13.6% (p=0.02) and 12.1±5% (p=0.004) with iDC and mDC as
stimulators, respectively. However, while CTLA4-Ig showed inhibition of the
MLR it surprisingly demonstrated a reduction in the numbers of FoxP3+ Treg
compared to untreated cocultures.
In conclusion, this study shows that mature DC due to their increased
costimulatory profile are better inducers of adaptive Treg in an MLR compared
to immature DC. Moreover, the blockade of the B7 costimulation pathway
signalling mediated by CTLA4-Ig affects the propensity of dendritic cells to
induce the generation of adaptive T regulatory cells.

POSTER BOARD NUMBER P4 – 271
2221 CHRONIC ALLOGRAFT NEPHROPATHY IS
ASSOCIATED WITH REDUCED EXPRESSION OF FOXP3
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T. Muthukumar, D. Dadhania, C. Snopkowski, R. Ding, C. Chang, B. Li,
S. Seshan, V. Sharma, M. Suthanthiran
Nephrology and Transplantation Medicine, Cornell University Medical
College, New York, NY, USA
A specialized subset of CD4+CD25+ T lymphocytes, termed regulatory
T lymphocytes (Treg cells), is critical for suppressing autoimmunity and
maintaining self-tolerance. Emerging data suggest that Treg cells may exert a
cytoprotective role including protection of allograft. Treg cells express FoxP3,
the X-linked forkhead/ winged helix transcription factor, and the non-redundant
contribution of this specification factor to immune homeostasis is vividly
demonstrated by the occurrence of a fatal multi-focal inflammatory disease in
mice and humans with a loss-of-function mutation in the FoxP3 gene.
In an experimental model of allograft tolerance, the relative levels of cytopathic
cells and FoxP3+ Treg cells have been reported to impact allograft outcome,
with higher levels of cytopathic cells compared to FoxP3+ Treg cells being
associated with graft destruction whereas higher levels of Treg cells compared
to cytopathic cells being associated with allograft tolerance (Zheng et al,
Immunity. 2003).
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Chronic allograft nephropathy (CAN) is a relentlessly progressive process.
Both immune and non-immune mechanisms have been implicated in the
pathogenesis of CAN. A deficiency in Treg cells may contribute to the
pathogenesis of CAN. Herein, we examined the novel hypothesis that Foxp3+
Treg cells are deficient in renal allograft recipients with CAN and that the
balance between cytopathic cells and Treg cells is “tipped” towards cytopathic
T cells in subjects with CAN.
We measured urinary cell mRNA levels for FoxP3, CD3ε, perforin and 18s
rRNA from 76 renal allograft recipients. All urine samples were obtained
at the time of allograft biopsy. Twenty-five urine samples were obtained
from 25 subjects with CAN and 51 urine specimens were obtained from 51
subjects with normal protocol biopsies (Normal Biopsy). Transcript levels
were measure by the use of pre-amplification assisted real time quantitative
PCR assay developed in our laboratory. mRNA levels were expressed as copy
numbers per microgram of total RNA and were normalized using 18S rRNA
copy numbers. The ratios FoxP3/ CD3ε and FoxP3/perforin were calculated
and log transformed to reduce the skew.
The log mean (±SE) ratio of FoxP3/ CD3ε was -3.49±0.42 in the 25 subjects
with CAN and -1.28±0.45 in the 51 subjects with Normal Biopsy (Panel A,
P=0.002, Mann –Whitney test); the FoxP3/ perforin ratio was -3.74±0.52 in the
25 subjects with CAN and -0.87±0.38 in the 51 subjects with Normal Biopsy
(Panel B, P= 0.0003, Mann –Whitney test).

Our findings demonstrate that CAN is characterized by a deficiency in Foxp3+
Treg cells, and that the balance between cytopathic T cells and Treg cells is
“tipped” towards cytopathic T cells. In the BDC2.5/NOD.FoxP3 scurfy mice,
Treg cells prevent destructive insulitis by restraining destructive T cells within
the islets. Whether the lack of intragraft damage control by Treg cells contribute
to CAN and whether the use of calcineurin inhibitor associated IL-2 inhibition
contributes to Treg cell deficiency remains unresolved.

CONCURRENT ORAL SESSION 149: CHIMERISM
POSTER BOARD NUMBER P4 – 272
2222 INTRACELLULAR RETENTION OF CD80/86 BY
DENDRITIC CELLS, UNLIKE TRYPTOPHAN CATABOLISM,
AS A MECHANISM TO INDUCE REGULATORY T CELLMEDIATED DONOR-SPECIFIC TOLERANCE
A. Khan1, J. Harper1, S. Beutelspacher2, G. Lombardi3, M. McClure4, A.
George1
1
Department of Immunology, Imperial College London, 2University
Eye Hospital, University of Heidelberg, 3Department of Nephrology
and Transplantation, King’s College London, 4Jefferiss Research Trust
Laboratories, Imperial College London
Background: Allogeneic T cell stimulation requires not only antigen-specific
signals but also costimulatory signals, most importantly between CD80/86 on the
antigen presenting cell (APC) and CD28 and CTLA4 on the T cell. Engagement
of the T cell receptor in the absence of costimulation can lead to anergy and
the subsequent induction of regulatory T cells (Tregs). T cell activation is also
controlled by expression of the tryptophan-catabolising enzyme indoleamine
2,3-dioxygenase (IDO). Depletion of this essential amino acid, and/or the
production of tryptophan metabolites inhibits T cell proliferation.
Methods: In this study, a genetic approach to confer tolerogenic properties
on murine dendritic cells (DCs) has been explored using lentiviral vectors,
based on the Equine Infectious Anaemia Virus. Firstly, an intracellular method
that prevents costimulation has been developed: A fusion protein consisting
of CTLA4 and KDEL [an endoplasmic reticulum (ER) retention signal]
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is expressed in DCs. The CTLA4-KDEL binds to CD80/86 in the ER and
prevents expression of these proteins on the DC surface. A second approach
uses an elevated expression of the IDO enzyme by transduced DCs.
Results: CTLA4-KDEL- or IDO-transduced DCs were unable to induce and/or
sustain allogeneic T cell proliferation. However, using two-stage DC:T cell coculture assays, it was shown that CTLA4-KDEL-, but not IDO-transduced DCs,
can induce donor-specific T cell anergy both in vitro and in vivo. Tolerance to
both the direct and indirect pathways of alloantigen presentation was shown
using CTLA4-KDEL-transduced DCs, and linked suppression was mediated
by the generation of donor-specific Tregs. We have also shown reversibility of
anergy in these T cells by the addition of exogenous IL-2 to rechallenge cultures.
EIAV IDO-transduced DCs were unable to generate Tregs. Furthermore, it was
demonstrated that DCs expressing IDO whilst lacking CD80/86 expression for
potential ligation by CTLA4 (although CTLA4-CD80/86 ligation upregulates
IDO, it downregulates T cell activation) failed to generate or sustain FoxP3+
Treg populations. The ability of the transduced DCs to induce tolerance to
allografts was assessed in a corneal allograft model, in which rejection results
predominantly from the indirect pathway. We have used strain combinations
in which we have compared separately the effect of tolerance induction to the
direct and indirect pathways on corneal allograft survival, and demonstrated an
initial role of the direct pathway in corneal allograft rejection.
Conclusions: These results strongly support a clinical strategy to induce
Treg-mediated, donor-specific transplantation tolerance using CTLA4-KDELexpressing, rather than IDO-expressing DCs.

POSTER BOARD NUMBER P4 – 273
2223 THE SUPPRESSOR CD8 T CELL GENERATED IN THE
MIXED CHIMERA MEDIATES SUPPRESSIVE FUNCTION VIA
IL-10 PRODUCTION IN CD4 T CELLS
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu
University
Background: The acute and chronic rejection remain the major obstacle to the
clinical organ transplantation. Utilization of regulatory cell populations can be
provided for the improvement of the graft survival. Cyclophosphamide (CP)
induced tolerance (CPIT) conditioning is a mixed chimerism based tolerance
induction protocol, which consisted with donor splenocyte (SC) and CP. Long
lasting donor mixed chimerism and donor skin graft tolerance were induced in the
recipients with MHC matched and minor antigen mismatched donors. In the present
study, we found that the CD8 T cell of the tolerance mice possess the suppressive
function, which is mediated by the enhanced IL-10 production in CD4 T cells.
Method: DBA/2 (H-2d, Ly-5.1, Mls-a) and BALB/c (H-2d, Ly-5.2, Mls-b) mice
were used as the donor and the recipient. IL-10 knockout (KO) recipient on BALB/c
background was also used as the recipient. Recipient mice were treated with 100
millions of donor splenocyte (SC) and 200mg/kg CP. Donor mixed chimerism and
the clonal deletion on donor reactive Vb6 positive T cell population were followed
by the flow cytometry. Donor skin grafting was performed on day 14. Recipients
thymus, lymph nodes (LN) and splenocyte (SC) were harvested over 12 weeks
after treatments, and CD8 positive cells were collected by magnetic cell sorting
(MACS). The CD8 suppressive function was examined in vivo and in vitro. In
vivo, secondary BALB/c recipient mice recieved donor DBA/2 or allogenic B10.
D2 (H-2d) heart grafts with 40 millions CD8 suppressor T cells from primary
mixed chimeras. In vitro, the suppressor function on the CD4 responder T cells
(Tresp) in mixed lymphocyte reaction was assessed by readout assay.
Results: Long lasting donor mixed chimerism and permanent acceptance of
donor skin graft were observed in recipient mice. Permanent acceptance of
donor DBA/2 heart grafts was observed in the secondary recipient mice with
CD8 T cells, but not CD4 T cells, from primary chimera. If IL-10 KO mice
were used as primary recipients, the donor mixed chimerism and the donor
skin graft acceptance were similarly observed. CD8 T cells from IL-10 KO
mixed chimera showed the comparable suppressive function to the CD8 T cells
from WT chimera in vitro, suggestive that the IL-10 production from Tsupp
cells is dispensable for the suppressive function. However, if na&#239;ve CD4
T cells from IL-10 KO mice were used for Tresp and WT chimera for Tsupp,
suppressive function was abrogated in vitro.
Conclusion: We found that the suppressor CD8 T cells were generated in
the mixed chimera. Our results indicated that the suppressor T cell mediates
suppressive function via promoting IL-10 secretion from CD4 T cells.

POSTER BOARD NUMBER P4 – 274
2224 INDUCTION OF THE DONOR MIXED CHIMERISM AND
TOLERANCE MEDIATED BY THE IMMATURE PHENOTYPE
OF DONOR BONE MARROW DERIVED DENDRITIC CELLS
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu
University
Background: The acute and chronic rejection remain the major obstacle to the
clinical organ transplantation. Induction of donor mixed chimerism is one of
the ideal methods to induce donor specific tolerance. Previously, we reported
that the induction of donor mixed chimerism and the skin/heart graft tolerance
in recipients with MHC matched and minor antigen mismatched donors in
Cyclophosphamide induced tolerance (CPIT) conditioning, which consists
with donor splenocyte (SC) on day 0 and Cyclophoshamide (CP) on day 2. To
apply this protocol to the large animal model, the more refining protocol with
less toxic conditioning may required. It was reported that the pretreatment with
Flt3L to the donor mice expanded the feasibility of the induction of tolerance
in MHC mismatched recipients with CPIT conditioning. In the present study,
we evaluated the role of the immature or mature phenotype of the bone marrow
derived dendritic cells (imBMDC) in CPIT conditioning.
Method: C57BL/6xBALB/c F1 (CBF1, H-2b/d) and C57BL/6 (B6, H-2b) were
used as donors and recipients. imBMDC was generated by 7 days culture of donor
BM in the presence of GM-CSF (20ng/ml) and IL-4 (1000u/ml). To generate
maBMDC, LPS (1ƒÊg/mL) was added in the last 8 hours of incubation. Recipient
mice were injected of 1-3x107 imBMDC or maBMDC on day 0, 200mg/kg CP
on day 2, followed with the whole body irradiation (3-5Gy) and 2x107 donor
bone marrow cells (BMC) on day3. Donor skin grafting was performed on day
14. Donor mixed chimerism was examined by flow cytometry.
Results: As previously reported, higher level of CD80/86 and CD40, as well
as MHC Class I/II expression was observed in maBMDC comparing to the
imBMDC. The maBMDC was used in the first series of experiments. Donor
mixed chimerism was not observed in the recipient mice after the treatments
with donor maBMDC and CP, with 20 millions of BMC. Donor chimerism was
still not observed by the additional treatment with T cell depletion on day -4,
or 3Gy WBI on day 3. Minimal level of donor mixed chimerism was observed
in 2 out of 6 recipient mice treated with maBMDC, CP, BMC and 5Gy WBI.
In clear contrast, donor mixed chimerism with permanent acceptance of donor
skin graft was observed in the all recipient mice treated with imBMDC, CP,
3Gy WBI and BMC. The level of donor mixed chimerism was correlated with
the amount of imBMDC, since higher level of chimerism was observed in the
group of mice injected with 3 times more imBMDC.
Conclusion: These results indicated that the immature phenotype of DC, but not
the mature phenotype, is able to induce tolerance in clinically corresponding F1
into B6 model. Since large number of imBMDC can be generated from the low
number of BMC, the newly modified protocol can be appreciable to the large
animal model.

POSTER BOARD NUMBER P4 – 275
2225 MYCOPHENOLIC ACID IMPEDES ANTIGEN
PRESENTING AND LYMPH NODE HOMING CAPACITIES OF
HUMAN BLOOD MYELOID DENDRITIC CELLS
V.R. Cicinnati1,2, J. Hou2, M. Lindemann3, A. Radtke2, C.G. Klein1,2,
G. Gerken1, S. Beckebaum1,2
1
Department of Gastroenterology and Hepatology, University Hospital Essen,
Germany, 2Department of General, Visceral and Transplantation Surgery,
University Hospital Essen, Germany, 3Institute of Immunology, University
Hospital Essen, Germany
Background: Mycophenolic acid (MPA) is the pharmacologically active
compound of mycophenolate mofetil, a recently introduced immunosuppressive
drug which inhibits the inosine monophosphate dehydrogenase and thereby
constrains lymphocyte proliferation. Alloantigen-presenting dendritic cells (DC)
are the key for initiating and priming the adaptive immune response leading to
graft rejection. We investigated the effects of MPA on DC homeostasis with a
particular emphasis on DC trafficking properties.
Methods: Isolated peripheral blood mononuclear cells (PBMC) from healthy
donors were cultured in with MPA for 48 hours without the addition of exogenous
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growth factors. Flow cytometric techniques were used for phenotypic and functional
analysis of MDC within the cultured PBMC population. Freshly isolated MDC
were employed for assessment of endocytotic and allostimulatory properties.
Results: MPA exposure lowered the expression of CC chemokine receptor
(CCR) 7 and increased the expression of CCR1 in MDC. In line with their
CCR expression profile, MPA treated MDC lessened their response to lymph
node chemokines and at the same time showed an increasing migration towards
inflammatory chemokines. MDC cultured in the presence of MPA exhibited
an immature phenotype with higher endocytotic capacity. MPA impaired also
MDC activation in response to toll-like receptor 3 ligation and abrogated their
capacity to stimulate allogenic T cells in mixed lymphocyte reaction.
Conclusions: MPA interferes with the initiation of acquired immunity by abating
lymph node homing and allostimulatory capacity of MDC. MPA treatment of
patients after solid organ transplantation may promote allograft tolerance.

POSTER BOARD NUMBER P4 – 276
2226 IMMUNE TOLERANCE INDUCED BY EXOSOMES
DERIVED FROM REGULATORY DENDRITIC CELLS
H. Fan, Y. Liu, L. Zhao
Shanghai Blood Center
Background: Exosomes are membrane nanovesicles generated by reverse
budding of the limiting membrane of multivesicular late endosomes. Exosomes
originating from dendritic cells are thought to play a role in either an immunostimulating or suppressive manner.
Aim: To explore the role of Exosomes derived from regulatory dendritic cells
in induction of immune tolerance.
Methods: Immature DCs (iDC) were induced from mouse bone marrow cells
with GM-CSF and regulatory DCs (rDC) were induced by treating iDC with
TGF-¦Â1 and IL-10. The phenotypes of regulatory DC and normal DC were
assayed by flow cytometry. Exosomes from immature DC (iDex) and regulatory
DC (rDex) were isolated by ultracentrifugation and ultrafiltration. The function
associated molecules of rDex were detected by Western blotting. The inhibitory
effect of iDex and rDex to the proliferation of T lymphocytes was analyzed
by mixed lymphocyte reaction (MLR) in vitro. A skin transplantation model
was established with the recipient BALB/c mice and the donor C57BL/6
mice. Recipients were divided into PBS control group, iDex group (injection
10¦Ìg iDex of donor C57BL/6 mice via tail vein 7 and 3 days before skin
transplantation) and rDex group (injection 10¦Ìg rDex of donor C57BL/ 6 mice
via tail vein 7 and 3 days before skin transplantation).
Results: TGF-¦Â1 and IL-10 might down-regulate the expression of costimulatory
molecules on dendritic cell, such as CD80, CD86 and CD40. The inhibitory effect
of rDex to the proliferation of T lymphocytes was significantly stronger than
iDex, and rDex might express more FasL molecules to induce potent suppression
of MLR. The graft mean survival time (MST) in control group, iDex group and
rDex group was 7.8, 10.7 and 18.8 days, respectively. There was significant
difference in MST between iDex group and control group (p©‚0.05), and between
rDex group and iDex group(p©‚0.01). The results of MLR assays showed donorspecific hyporeactivity especially in rDex group, while the recipient BALB/c
mice were still immunocompetent to unrelated allogeneic DBA mice.
Conclusion: Exosomes secreted from regulatory dendritic cells can induce
immune tolerance in skin transplantation. It has the potential application to
prevent allogeneic transplantation rejection in the future.

POSTER BOARD NUMBER P4 – 277
2227 REQUIREMENT OF INKT CELLS FOR THE
MAINTENANCE OF MIXED CHIMERISM IN
CYCLOPHOSPHAMIDE-INDUCED TOLERANCE
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T. Onzuka, Y. Tomita, I. Shimizu, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu
University
Purpose: Cyclophosphamide (CP)-induced tolerance is a mixed chimerismbased tolerance conditioning, which donor skin graft tolerance is achieved in
recipients with MHC-matched minor antigen-mismatched donors. Previously,
we have elucidated the essential role of invariant Natural Killer T (iNKT) cells
in CP-induced tolerance. In the present study, we investigate the need of iNKT
cells for adequate mixed chimerism in CP-induced tolerance.
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Methods: DBA/2 (DBA; H-2d, Ly1.1) mice and BALB/c (BALB; H-2d, Ly1.2)
wild type (WT), or iNKT knockout (KO) (Jα18-/-, BALB background) mice
were used as donors and recipients.¦ To deplete recipient Thy1.2+ cells, WT or
iNKT KO recipients were injected with 100μg of anti-Thy1.2 mAb (MAb) on
day -4 prior to our conventional conditioning, which consist of 108 donor DBA
spleen cells (DBA SC) on day 0 and 200 mg/kg CP on day 2. To effectively
raise donor mixed chimerim, WT or iNKT KO recipients were treated with
DBA SC and CP, followed by 2~10×107¦ SC from tolerant DBA mice on day
3. Tolerant DBA SC was harvested from DBA mice that had been treated with
1×108 BALB SC and CP two weeks earlier. Donor DBA skin grafting was
performed at 4 weeks. The level of mixed chimerism (Ly1.1+ cells in Ly1+
cells) and the kinetics of donor-reactive T cells (Mls-1a-reactive CD4+Vβ6+ T
cells) were assessed by flow cytometry.
Results: The skin graft tolerance with stable mixed chimerism was observed
in WT recipients treated with DBA SC and CP. However, donor skin grafts
were chronically rejected in iNKT KO recipients treated with DBA SC and CP
(median 71.5 days, n=10). Donor mixed chimerism was clearly observed in
WBC of iNKT recipients at 2 weeks but diminished (<1.0%) at 8 weeks. When
WT or iNKT KO recipients received additional treatment with either MAb or
tolerant donor cells, all recipients developed elevated mixed chimerism at 8
weeks and showed permanent skin graft survival. Twenty millions of tolerant
DBA SC was enough for the tolerance induction in iNKT KO recipients.
The clonal deletion of CD4+Vβ6+ T cells was insufficient in the thymus of iNKT
KO recipient treated with DBA SC and CP. In contrast, the intrathymic clonal
deletion was profoundly induced in iNKT KO recipients, if the skin graft tolerance
was induced by the additional treatment with MAb or tolerant donor cells.
Conclusions: The skin graft survival was always correlated with the induction
of mixed chimerism in CP-induced tolerance. Invariant NKT cells are essential
for the maintenance of stable mixed chimerism. The additional treatment
with either MAb or tolerant donor cells was effective alternative methods for
the maintenance of mixed chimerism, even in the absence of the regulatory
function of iNKT cells.

POSTER BOARD NUMBER P4 – 278
2228 DETERMINATION OF CYTOTOXIC T LYMPHOCYTE
ACTIVITY AGAINST HUMAN SPLEEN CELLS AND
ESTIMATION OF MICROCHIMERISM FOR TOLERANCE
MEASUREMENT
M. Schenk, P. Kaur-Gill, A. Königsrainer
University Hospital Tuebingen – General, Visceral and Transplant Surgery
Clinical organ transplantation between genetically disparate individuals
presently requires non-specific immunosuppressive agents to prevent rejection.
However, the use of immunosuppressive drugs caused side effects and does not
always guarantee success of the graft. Therefore, there is a need to establish
methods of “donor specific transplantation tolerance” and that could not be
achieved directly in patients. So, aim was to establish mixed lymphocytes
culture (MLC) and fluorescence activated cell sorting (FACS) cytotoxicity
assay and a very sensitive assay for microchimerism based on cytospin
preparation of peripheral blood lymphocytes.
In this study, the spleen cells and PBMC from different patients were stimulated
with different concentration of Con-A (2-6 μg) up to 6 days. Than, spleen cells
were labelled (5x105 cells/ml in PBS buffer) with 3 μM of Dio18(3) for 45
min at 37°C, 5% CO2. Dio18 dye remains stably incorporated in the membrane
for long periods of time (20 days). The MLC were established by culturing
different ratios (1:1, 2:1, 4:1) of unstained PBMC (effectors lymphocytes)
with an 105-106 cells/ml irradiated (30 Gy) spleens cells in RPMI medium
supplemented with 50 μg/ml Gentamycin, 10% FCS, 200 mM Glutamin, 10
mM Hespes pH 7.2 and 2 μg Con-A into 96 well flat bottom plates. After
different time intervals, the cells suspension were harvested and by adding
PI to samples, FACS analysis was carried out on a FACScan cytometer. By
excitation at 488 nm with an argon laser, the emission of two fluorochromes
was recorded through specific band pass filter 520 nm for Dio18(3) (FL1) and >
425 for PI (FL3). Cytospin preparations of Bw4/Bw6-different donor-recipient
combinations were stained with the corresponding antibody.
Maximum stimulation of spleen cells was observed with 2 μg Con-A after 24
h. Whereas, the stimulation of peripheral blood lymphocytes (PBMC) was
also with 2 μg Con-A, but after 8 days of activation of PBMC from different
patients, generated markedly higher levels of cytotoxicity against targets cells.
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Maximum reduction of spleen cells (2-3%) in the MLC was observed after
6 days of incubation at 37°C, 5% CO2. The degree of decrease of spleen
cells was 95% using PBMCs from healthy persons and from third-party
immunosuppressed patient 20%. With PBMC from the recipient no decrease
was observed.
In conclusion, the Dio18(3) assay is a quantitative methods for the detection of
cell- mediated cytotoxicity and providing a greater insight into the mechanisms of
cell-mediated cytolysis by different effector populations. Cytospin preparations
provide reproducible results in mircochimerism rates even below 1%. A clinical
study using both methods on liver transplant recipients is on the way.

POSTER BOARD NUMBER P4 – 279
2229 PROLONGED TRANSPLANT SURVIVAL AFTER DONOR
MACROPHAGE TRANSFUSION IN PORCINE PULMONARY
TRANSPLANTATION
G. Warnecke1, S. Thissen1, B. Kruse1, M. Avsar1, R. Reinhard1, F. Fändrich2, F.
Länger3, R. Baumann4, A. Haverich1, M. Strüber1
1
Division of Heart, Thoracic, Transplantation and Vascular Surgery,
Hannover Medical School, 2Department of General and Thoracic Surgery,
University Kiel Germany, 3Institute of Pathology, Hannover Medical School,
4
Department of Radiotherapy and Special Oncology, Hannover Medical
School.
Objective: Cotransplantation of donor suppressor macrophages has been shown
to prolong allograft survival in small animals models. The aim of our study was to
analyze the effect of donor macrophage cotransplantation on transplant survival in
a preclinical large animal model of porcine allogenic pulmonary transplantation.
We compared the survival of porcine lung allografts after induction therapy with
immunosuppression and immunosuppression plus irradiation with the same
protocols extended by donor macrophage cotransplantation.
Methods: Left sided lung transplantation from MHC and sex mismatched
donors was performed in female 26 minipigs. Immunosuppression included
1.5 mg/kg per day methylprednisolone and tacrolimus, adjusted to 16–26 ng/
ml. All immunosuppressive drugs were discontinued on postoperative day 28.
Six animals received intravenous immunosuppression only. The same protocol
extended by postoperative macrophage cotransplantations from the lung donor
was performed in seven animals. Six pigs received preoperative irradiation
and immunosuppression. Seven animals were treated with irradiation and
immunosuppression combined with macrophage transplantation. Peripheral
blood cells were screened for donor leukocyte chimerism after macrophage
cotransplantation and CD4/CD25 expression.
Results: In comparison between the groups, transplant survival was prolonged
in animals that received donor macrophages in combination with irradiation
and immunosuppression. The degree of donor cell chimerism did not increase
after macrophage transplantation. The frequency of CD4+CD25+ T cells
was slightly higher in the group which received irradiation and macrophage
cotransplantation, however, the difference was not statistically significant.
Conclusion: The results of our study show that donor macrophage
transplantation in a clinically feasible manner prolongs pulmonary allograft
survival in a large animal model, especially combined with irradiation and
immunosuppression.

POSTER BOARD NUMBER P4 – 280
2230 CD26/DPPIV ENZYMATIC INHIBITION IN A MURINE
MODEL OF MIXED CHIMERISM.
E. Schwaiger1, K. Christoph1, U. Baranyi1, N. Pilat1, S. Korom2,
V. Matheeussen3, I. De Meester3, F. Mühlbacher1, T. Wekerle1
1
Medical University of Vienna, Austria, 2University Hospital Zurich,
Switzerland, 3University of Antwerp, Belgium
Background: Methods to enhance stem cell engraftment would be important
for the development of minimally toxic bone marrow transplantation (BMT)
protocols. CXCL12/SDF-1α has an important role in the homing of hematopoietic
stem cells to bone marrow (BM). The ectopeptidase CD26/dipeptidylpeptidase
IV (DPPIV) cleaves CXCL12/SDF-1α and thus inhibits homing. Inhibition
of CD26/DPPIV enzymatic activity would thus be an appealing strategy for
promoting BM engraftment. The CD26/DPPIV enzymatic activity inhibitor
diprotin A has been reported to promote engraftment of purified stem cells in

lethally irradiated recipients, but little is known about the effects of CD26/
DPPIV enzymatic inhibition in non-myeloablative allogeneic BMT protocols
for the induction of mixed chimerism and transplantation tolerance. We therefore
explored inhibition of CD26/DPPIV enzymatic activity with diprotin A or the
clinically available inhibitor sitagliptin for the purpose of enhancing engraftment
of unseparated bone marrow after non-myeloablative recipient conditioning.
Materials and methods: B6 CD45.1 mice received a non-myeloablative dose
of total body irradiation (1Gy, day –1) and 15x106 CD45-congenic bone marrow
cells from CD45.2 donors. Donor bone marrow of one group was incubated
in vitro with diprotin A (Ile-Pro-Ile, for blocking CD26/DPPIV activity; for
15 minutes). Multi-lineage macrochimerism was followed by flow cytometry.
Naïve C57BL/6 mice received 200mg/kg of sitagliptin by oral gavage (0h and
+12h). Blood samples were collected after 2 and 24 hours and serum enzymatic
activity of CD26/DPPIV was measured by a kinetic fluorimetric enzyme assay
with glycyl-L-proline-4-methoxy-2-naphthylamide as substrate.
Results: Similar rates and levels of multi-lineage chimerism were observed
with or without CD26/DPPIV enzymatic inhibition by diprotin A (10/10 with
diprotin A vs. 9/9 mice without). After 76 days mean chimerism of the group
treated with diprotin A reached about 26% in the CD4 T-cell, 17% in the CD8
T-cell, 37% in the B-cell and 28% in the myeloid-cell lineage. The group
receiving untreated bone marrow showed comparable levels of chimerism
(30% in the CD4 T-cell, 21% in the CD8 T-cell, 44% in the B-cell and 36%
in the myeloid cell lineage). Treatment of naïve C57BL/6 mice showed about
72% after 2x15mg/kg sitagliptin 24 hours post treatment. Mice treated with
the high dose sitagliptin (2x200mg/kg) showed almost complete inhibition of
CD26 serum enzymatic activity after 2 hours and more than 90% inhibition
after 12 hours.
Conclusion: We have found no evidence that treatment of unseparated bone
marrow with diprotin A leads to an enhanced engraftment of unseparated bone
marrow in a CD45-congeneic model using non-myeloablative conditioning. We
identified a dosing regimen with the clinically approved CD26/DPPIV inhibitor
sitagliptin which virtually completely blocks CD26/DPPIV enzymatic activity
in the murine system and which is now under investigation in congeneic and
allogeneic BMT protocols.
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2231 HYPERACUTE REJECTION FOLLOWING
PREOPERATIVE DONOR SPECIFIC CELL TRANSFUSION
IS ASSOCIATED WITH A LOSS OF HEMATOPOETIC
CHIMERISM
B. Kruse1, S. Thissen 2, G. Warnecke1, M. Avsar1, F. Länger3, V. Kaever4,
R. Baumann5, J.H. Karstens5, A. Haverich1, M. Strüber1
1
Division of Cardiac, Thoracic, Transplantation and Vascular Surgery,
Hannover Medical School, 2Division of Cardiac, Thoracic, Transplantation
and Vascular Surgery, Hannover Medical School, 3Institute of Pathology,
Hannover Medical School, 4Institute of Pharmacology, Hannover Medical
School, 5Department of Nuclear Medicine and Radiation Oncology, Hannover
Medical School
Purpose: Donor alloantigen infusion has been shown to induce transplantation
tolerance in small animal models. Here, we wished to study the effect of a
donor splenocyte infusion (SpTx) on hematopoetic chimerism and transplant
survival in a large animal model of porcine allogenic lung transplantation.
Procedures: Left-sided lung transplantation from MHC and sex mismatched
donors was performed in 20 adult female minipigs. All received intravenous
pharmacologic immunosuppression with methylprednisolone and tacrolimus
for 28 postoperative days (POD). Animals in the IRR+SpTx POD 0 group
additionally received 1.5 Gy whole body and 7 Gy thymic irradiation (IRR) on
pre-operative day one and a donor splenocyte cotransplantation on the day of
lung transplantation (n=6), the same protocol without irradiation was performed
in the SpTx POD 0 group (n=5). IRR+SpTx POD–28 animals (n=3) received
IRR and donor splenocyte infusion 28 days before transplantation under and a
7 day course of tacrolimus. Pigs in the SpTx POD –28 group (n=6) received the
same protocol without irradiation. Allograft survival was monitored by chest
radiographs and transbronchial biopsies (TBB). Peripheral blood chimerism was
analyzed by Y-chromosomal quantitative real time polymerase chain reaction
(RTQ-PCR). Results: Transplant survival in the IRR+SpTx POD 0 group was
significantly prolonged compared to all other groups. Median allograft survival
was: IRR+SpTx POD0 371d, SpTx POD0 73d, SpTx POD-28 110d, IRR+SpTx
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POD-28 64d. Chimerism following lung transplantation and SpTx was
significantly increased in irradiated groups. In all animals donor cells peaked
one hour after reperfusion of the graft, but compared to reperfusion levels, SpTx
only caused a small additional increase in chimerism in the IRR+SpTx POD
0 group. Splenocytes infused 28 days before lung transplantation remained
detectable during the first seven days, but rapidly decreased after withdrawal
of immunosuppressive drugs. Only in the IRR+SpTx POD –28 group a residual
amount of chimerism was detectable before lung transplantation. In the SpTx
POD –28 group hyperacute rejection occurred in two animals which was
associated with extremely low chimerism after reperfusion of the lung.
Conclusion: Miniature swine conditioned with irradiation and perioperative
donor splenocyte infusion have a higher ratio of donor cells to recipient cells
and develop long term pulmonary allograft survival. Pre-operative donor cell
transfusion is not benefitial for transplant survival, furthermore it bears a high
risk of hyperacute rejection due to sensitization which is associated with a rapid
elimination of donor cells after lung transplantation.
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2232 LONG TERM DONOR CELL CHIMERISM INSIDE
THE LUNG IS ASSOCIATED WITH A PROLONGED GRAFT
SURVIVAL AFTER PULMONARY TRANSPLANTATION
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B. Kruse1, G. Warnecke 1, S. Thissen 1, M. Avsar 1, B. Pabst2, J. Hohlfeld 1,
V. Kaever 3, A. Haverich 1, M. Strüber 1
1
Division of Cardiac, Thoracic, Transplantation and Vascular Surgery,
Hannover Medical School, 2Institute of Human Genetics, Hannover Medical
School, 3Department of Respiratory Medicine, Hannover Medical School,
7
Institute of Pharmacology, Hannover Medical School
Purpose: We have reported earlier on marked prolongation of pulmonary
allograft survival in minipigs treated with various immunosuppressive protocols.
Although mean survival differed somewhat among groups, long term allograft
survival occurred under a variety of protocols and several groups revealed similar
distributions of long term surviving and rejecting animals. Taking into consideration
the failure of a given “tolerance induction protocol” to predict outcome, we studied
alternative factors possibly explaining prolonged survival. Here we wished to
examine postoperative chimerism in the peripheral blood and inside the graft
of tolerant and rejecting animals. Groups for eventual analysis were defined by
outcome, i.e. animals with acute rejection of the lung were randomized into one
group (n=16) and animals with long term allograft survival (LTS, n=11) into the
other group regardless of the immunosuppressive protocol. Procedures: Left-sided
lung transplantation from gender mismatched male donors was performed in 27
minipigs. Intravenous pharmacologic immunosuppression was maintained for
28 postoperative days (POD). Peripheral blood chimerism was analyzed by flow
cytometry and Y-chromosomal quantitative real time polymerase chain reaction
(RTQ-PCR). For flow cytometry donors had prospectively been selected positive
for the SLA I specific antibody 74-11-10, and recipients had been selected negative.
To analyze intra-graft chimerism cells harvested from bronchoalveolar lavage fluid
were screened for their sex genotype by fluorescence in situ hybridization (FISH).
Results: Peripheral blood chimerism was not stable. Chimerism detected by
the SLA I mAb 74-11-10 and RTQ-PCR peaked within 24 h of pulmonary
transplantation. In samples drawn 1 h after reperfusion significantly higher
donor cell levels (11.7-18.2%) were detected in LTS (p<0.05). In the followup period the percentage of donor cells constantly decreased, with a trend
towards higher microchimerism in long term surviving animals. In case of
acute rejection microchimerism was lost in all except two animals. In all long
term surviving animals microchimerism was detectable for more than 90
postoperative days. Later analyses demonstrated a lack of male DNA in six
LTS. Anyhow graft function remained stable, and rejection episodes did not
occur over an observation period of up to 36 months. FISH-analysis showed
consistent results. The percentage of male nuclei in BALF was equally high
in all animals under immunosuppression (median value of 86% on POD 7;
78% on POD 28). In rejecting animals the percentage of Y-chromosomal cells
rapidly decreased after withdrawal of immunosuppressive drugs, and was lost
almost completely when acute rejection occurred. In tolerant pigs chimerism
in BALF in the range of 70% was detectable for more than 100 postoperative
days, decreased slowly in the follow up and reached a stable state of 7-12%.
Conclusion: These data seem to support an important role of peripheral blood
cell chimerism for the induction, but not for the maintenance of tolerance in
lung transplanted pigs. In rejecting animals the rapid decrease of donor cells
in BALF after discontinuation of immunosuppression was predictive of acute
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rejection, but in long term surviving animals a gradual replacement occurred
which was not associated with acute rejection.
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2233 THE DISTINCT ROLES OF THE CD40 COSTIMULATION
PATHWAY IN DONOR AND RECIPIENT IN A MIXED
CHIMERISM MODEL
C. Klaus, N. Pilat, E. Schwaiger, M. Gattringer, F. Muehlbacher, T. Wekerle
Vienna Medical University
Background: Bone marrow transplantation (BMT) together with costimulation
blockade induces mixed chimerism and tolerance in various protocols with antiCD40L (CD154) mAb being an essential component in all of them. Unfortunately,
it has not been possible to create a safe anti-CD154 mAb for clinical use. In the
literature there are contradictory reports on the mechanism of anti-CD154 therapy.
Some studies show that a signal is essential for the effect of anti-CD154, while
others demonstrate that only its blocking properties are required. Besides, little
is know about the separate effects of anti-CD154 therapy on donor and recipient
APC. As the donor BM is amenable to in vitro manipulation (e.g. transfection,
siRNA technology), it is important to delineate the role of donor CD40.
Materials & Methods: B6 recipient mice (WT or knock-out) received
approximately 20x106 fully mismatched Balb/C (WT our knock-out) bone
marrow (BM) cells (d0), total body irradiation (2Gy, d-1) and costimulation
blockade consisting of CTLA4Ig (d+2) with or without anti-CD154 (d0, MR1, as
indicated). The following donor-recipient strain combinations were used (7-8 mice/
group): Group 1: WT Balb/C and WT B6; Group 2: WT Balb/C and CD154 KO
B6; Group 3: as group 2 but without anti-CD40L; Group 4: CD40KO Balb/C and
CD40KO B6; Group 5: as group 3 but without anti-CD40L; Group 6: CD40KO
Balb/C and WT C57BL/6; Group 7: as group 6 but without anti-CD40L. Multilineage chimerism and deletion of donor-reactive T cells were followed by flow
cytometry. Tolerance was assessed by grafting donor and 3rd party skin.
Results: Mixed chimerism developed in mice of all groups except when CD40
KO BM was transplanted into WT recipient without using MR1 (group 7).
Chimerism levels among myeloid and lymphoid lineages were significantly
different between group 6 vs. group 7 was p<0.05 in whereas differences between
all other groups were not significant. Chimeras in control group 6 (CD40KO
into WT plus MR1) showed skin graft tolerance during the entire observation
period, whereas neither chimerism nor tolerance developed in group 7. Third
party skin was rejected in all mice. Chimerism in all groups (except group 7)
was comparable to WT to WT combination (group 1), which is our established
protocol for chimerism induction. When used WT donor to CD154 KO recipient
w/o MR1 (group 3), 7/8 mice developed stable multi-lineage chimerism and
donor skin was accepted in chimeric mice for more than 50 days with 5 continuing
for more than 80 days (ongoing). Similar results were true for control group (2,
with MR1). All chimeric mice in CD40 KO to CD40 KO combination were also
tolerant for more than 80 days (ongoing), whether MR1 is added or not.
Conclusion: We show that in a fully mismatched costimulation-blockade BMT
model involving CTLA4Ig, anti-CD40L treatment is effective independent of
triggering a signal or cytotoxic target cell elimination. Eliminating the CD40
pathway in the (APC of the) donor alone is not sufficient to replace antiCD40L treatment, pointing to the importance of blocking the indirect antigen
presentation pathway through eliminating CD40 signals in recipient APC.
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2234 PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL
BY ADMINISTRATION OF ANTIGEN-PULSED RECIPIENT
DENDRITIC CELLS TRANSDUCED BY LENTIVIRUS-SIRNA
TARGETING CD80 AND CD86
X. Gu1, Z. Chen1, J. Xiang1, L. Lu2, S. Qian2
Department of General Surgery, Hua Shan Hospital, University of Fudan,
2
Department of Immunology and General Surgery, Cleveland Clinic
Dendritic cells (DC)-based therapies in transplantation using genetic engineering
approach will reduce dependency on nonspecific immunosuppression. Its
development has been limited by the inability to appropriately transfect DC
using conventional vectors. Thus, infection of retroviruses requires cells to
be actively dividing, as a result, many cells, including DC, are very resistant
to retrovirus infection. Although adenovirus infects non-dividing cell, it
does not integrate into the genome and is not replicated during cell division.
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Lentivirus belongs to a subclass of retroviruses with ability to integrate into
the genome of non-dividing cell, and can pass on to the progeny of the cell
when it divides. In this study, the DC were cultured from C3H (H2k) bone
marrow cells in the presence of GM-CSF plus IL-4, and, at day 2, exposed
for 48 hours to lentivirus- GFP-siRNA-anti-CD80- or RFP-siRNA-anti-CD86
at Mal of 2-20. Cells were then washed, cultured for six additional days,
and exposed to 1ƒÝg/ml LPS for final 48 hours. The infection efficiency at
Mal of20 was 79.78:!:4.95% without affecting cellular viability (by annexin
V and propidium iodine staining). DC transduced with lentiviruses-antiCD80 or anti-CD86 siRNA expressed markedly lower CD80 and CD86
(18.03%„b2.97% and18.61%„b3.00%,respectively, vs. 64.24%„bl.21% and
70.02%„b0.42%in scrambled RNA controls, both p<0.05). To test effect
oftransduction of targeting siRNA on DC function, DC transduced with antiCD80 and CD86 were pulsed with debris of B6 (H2b) spleen cells, and showed
low stimulatory activity in an MLR culture in which C3H spleen T cells were
responders, compared to DC transduced with scrambled control RNA. 2x106
DC that were infected with lentivirus-antiCD80 and anti-CD86 siRNA were
intravenously injected into C3H recipients 7 days before receiving a B6 heart
allograft in the absence of immunosuppressive therapy. Survival of cardiac
allografts was significantly prolonged in treated group [median survival
time (MST) 22days] compared with non-treat group (MST 6 days) or PBStreat group (MST 10 days, both p<0.05 vs. DC treat group). In conclusion,
lentivirus vector effectively infects DC with low cytotoxicity. Use of recipient
DC for vaccination provides a more feasible approach for deceased donor
organ transplantation.

POSTER BOARD NUMBER P4 – 285
2235 TARGETED BONE MARROW RADIOABLATION
ENHANCES HEMATOPOIETIC CHIMERISM AND
PREVENTION DIABETES ONSET IN NOD MICE.
A. Pileggi1, R.D. Molano1, S.S. Jose1, E. Zahr1, J. Molina1, W. An1,
J. Gonzalez-Quintana1, M.A. Atkinson2, C. Ricordi1, L. Inverardi1
1
University of Miami Miller School of Medicine – Diabetes Research Institute,
2
Department of Pathology, University of Florida, Gainesville, FL, USA
Transplantation of allogeneic bone marrow cells (BMC) may result in stable
chimerism and tolerance to donor-specific tissues. NOD mice develop
autoimmune diabetes spontaneously and are resistant to tolerance-inducing
protocols proven successful in non-autoimmune strains. Stable chimerism has
been reported in NOD mice using anti-CD3 antibody treatment and infusion of
CD8+ splenocytes plus high doses BMC (two inocula of 200x106 each). The
use of bone-seeking isotopes [153Samarium(153Sm)-EDTMP] has allowed
for targeted bone marrow (BM) radioablation and enhanced hematopoietic
chimerism in non-autoimmune mice.
In the present study, we tested whether inclusion of 153Sm-EDTMP at
induction would allow for BMC dose reduction in an allogeneic (FVB) BMC
transplantation in prediabetic female NOD mice (7-8wk old). Animals received
153Sm-EDTMP (0.5mCi i.v. on day -10), anti-CD3 antibody (0.5mg i.v. on
day -7). Two doses of FVB BMC (50x106) and CD8+ splenocytes (20x106)
were given on days 0 and 7. Recipients were monitored for chimerism levels
and diabetes onset.
Control untreated female NOD mice (n=7) invariably developed diabetes
during the follow-up period. Animals receiving the induction protocol without
153Sm-EDTMP did not achieve stable chimerism (n=8) developed diabetes in
62.5% of the cases. 153Sm-EDTMP inclusion in the induction protocol resulted
in stable chimerism in 71.5% of the animals (n=7), with only nonchimeric
animals developing diabetes during follow-up in this group. Chimeric animals
accepted donor-specific skin allografts and rejected third-party (C57BL/6) skin
grafts.
Targeted BM radioablation prior allows reducing substantially the mass of BMC
inoculum needed to achieve stable chimerism and tolerance in the challenging
NOD mouse model. The use of bone-seeking isotopes to selectively target the
BM compartment may represent a valuable strategy to complement chimerismbased tolerance inducing protocols for clinical use.
Supported in part by the Juvenile Diabetes Research Foundation.
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2236 SIMULTANEOUS INJECTION OF DONOR-DERIVED
OX62+-SPLENIC DENDRITIC CELLS AND NON-DEPLETING
ANTI-CD4 MONOCLONAL ANTIBODIES INTO A FISCHER TO
LEWIS RAT COMBINATION GENERATES CD4+CD25+FOXP3+
T CELLS WHICH ABROGATE THE PRODUCTION OF DONORSPECIFIC ALLO-ANTIBODIES AND INDUCE INDEFINITE
SKIN GRAFT SURVIVAL
M. Alawieh, G. Rifle, O. Bouchot, C. Mousson, L. Martin
University of Burgundy, IFR 100 Santé STIC
Aim: Donor-specific antibodies (DSA) are probably one of the main
immunological factors involved in the genesis of chronic allograft rejection
and one of the hurdles to overcome to achieve tolerance. This preliminary
study tests (1) the ability of a tolerance induction protocol using donor-derived
dendritic cells (DC) and anti-CD4 monoclonal antibodies (MoAb) to generate
donor-specific CD4+CD25+ regulatory T cells (Treg) and (2) the capacity of
these cells to abrogate the production of DSA after skin graft in rats.
Material and methods: OX62+-splenic DC (non plasmocytoid DC) were
isolated from Fischer rats with magnetic beads (Miltenyi-Biotec) and injected
(2.106) into Lewis recipients with or without non depleting anti-CD4 (W3/25)
MoAb. CD4+CD25+ T cells were harvested with magnetic beads from
“tolerized” animals and injected (1.106) into Lewis recipients at day 1 before
they receive a skin graft from Fischer (n=4) or third party (Brown Norway, n=4)
donors. DSA were detected in the recipient blood using flow cytometric cross
matches with donor lymphocytes at several time points after transplantation
(d0, d7, d15, d30).
Results: After injection of CD4+CD25+FOXP3+ T lymphocytes isolated from
the “tolerized-rats”, Lewis recipients accepted skin grafts from Fischer rats
indefinitely (>100days), whereas skin grafts from a third party were rejected.
DSA were detected at low levels at days 7, 15 and 30 in only one recipient
receiving Treg prior to grafting. Treg coming from Fischer receiving DC alone
are unable to inhibit DSA production and to prolong skin graft survival in
Lewis rats. In addition, it was shown that DSA induced by a single injection
of allogenic OX62+ DC are abrogated when anti-CD4 MoAb was associated
with DC.
Conclusion: These preliminary data suggest that splenic non plasmocytoid
DC and anti-CD4-MoAb-induced donor-specific Treg that can, in most cases,
inhibit the production of DSA and indefinitely prolong allogenic skin grafts
survival. Experiments are now in progress in order to check if this protocol can
inhibit chronic rejection lesions after heart transplantation in this model.
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2237 PERSISTENT MOLECULAR CHIMERISM IS NOT
REQUIRED TO MAINTAIN NEONATALLY-INDUCED CARDIAC
ALLOGRAFT TOLERANCE IN MICE
L. West, H. Mewhort, K. Tao, S. Maier, J. Brown
University of Alberta
Long-term acceptance of both donor-specific BALB/c (BALB, H-2d) and thirdparty C57BL/6 (B6, H-2b) cardiac allografts is induced by treating neonatal
C3H/He (C3H, H-2k) mice with either semi-allogeneic BALBxC3H spleen (F1/
SP, H-2d/k) cells or fully allogeneic BALB fetal liver cells (FLC). The cellular
mechanisms responsible for tolerance differ: the former involves alloreactive
T-cell deletion and the latter involves induction of non-specific regulatory
T-cells. Previous studies suggested that persistent chimerism is important to
preserve neonatally-induced tolerance into adulthood. Cellular chimerism
can be detected in the F1/SP cell model 3-100 days post-treatment, but only
up to 10 days in the FLC model suggesting either that molecular chimerism
is responsible for FLC-induced tolerance or that persistent chimerism is not
required. This study assessed whether molecular chimerism persists in FLCtreated mice.
Female C3H neonatal mice were treated with either male F1/SP cells or FLC.
Genomic DNA was isolated from various tissues of treated mice at 3 days and
6-8 weeks post-treatment. PCR for the SRY gene was used to detect molecular
chimerism.
Molecular chimerism was detected in mice treated with F1/SP cells 3 days and
6-8 weeks post-treatment. While molecular chimerism was detected in FLC-
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treated mice 3 days post-treatment, molecular chimerism could not be detected
in the tissues tested 6-8 weeks post-treatment.
These results demonstrate that molecular chimerism is lost prior to adulthood
after neonatal FLC treatment. Chimerism at a molecular and cellular level is
thus not required for neonatal tolerance to either donor-specific or third-party
cardiac allografts, suggesting that induction of non-specific regulatory T-cells
occurs early post-injection.

fragments is studied.
Conclusion: Detection of donor male DNA in nuclei isolated from female
cells suggests its spontaneous transport into recipients cells and their nuclei.
The question remains open whether this finding may have any relevance to the
rejection or tolerance process.

CONCURRENT ORAL SESSION 150: GENE REGULATION IN
TRANSPLANTATION

2240 IMPACT OF CYTOKINE GENE POLYMORPHISM ON
RENAL ALLOGRAFT OUTCOME COULD BE MODULATED BY
IMMUNOSUPPRESSANT?
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2238 CYP3A5 GENOTYPE INFLUENCES THE BLOOD
CONCENTRATION OF TACROLIMUS IN RESPONSE TO
INHIBITION BY KETOCONAZOLE
V. Jha, N. Chandel, P. Aggarwal, M. Minz, V. Sakhuja
Postgraduate Institute of Medical Education and Research
There is marked heterogeneity in blood concentrations of tacrolimus following
standard body-weight-based dosing. Differences in hepatic and intestinal
cytochrome P4503A activity have been postulated as contributing to this
problem, probably through linkage with an SNP in the CYP3A5 gene. It has been
shown that patients with at least one CYP3A5*1 allele achieved twofold lower
dose-normalized tacrolimus blood concentrations compared with CYP3A5*3/*3
homozygote. We investigated the role of this polymorphism on response to
inhibition of the enzyme activity by ketoconazole (used to bring down the cost
of therapy). A total of in 64 stable renal transplant recipients were started on
100 mg/day of ketoconazole and tacrolimus dose was reduced by 40% 2 days
later. Dose-normalized blood concentrations of tacrolimus before and 1 week
after starting ketoconazole were related to CYP35 genotypes determined by
polymerase chain reaction followed by restriction fragment length polymorphism
analysis. A total of 35 and 2 patients were homozygous for the *3 and *1 alleles
respectively whereas 27 were *1/*3 heterozygotes. Before starting ketoconazole,
the dose-normalized concentrations were similar in *3 homozygotes and *1/*3
heterozygotes. However, the post-ketoconazole tacrolimus trough concentration
were higher in *3 homozygotes. Also, the magnitude of increase in the dosenormalized concentrations was bigger in the *3 homozygotes. We conclude that
CYP35 genotype is important in determining the dose requirement for tacrolimus
in response to metabolic inhibitors, and determination of the CYP3A5*1/*3
genotype could be used to predict the tacrolimus dose requirement. This finding is
of value in optimizing immunosuppressive therapy in cost-constrained settings.

POSTER BOARD NUMBER P4 – 289
2239 IS DONOR DNA INCORPORATED INTO RECIPIENT
LYMPHOID CELLS GENOME?
J. Tyszka1, W.L. Olszewski1,2,3, J. Rutkowska1
Department of Surgical Research & Transplantation, Medical Research
Center, Poli, 2Central Clinical Hospital, Ministry of Internal Affairs, Warsaw,
Poland, 3The Norwegian Radium Hospital-Rikshospitalet, Oslo, Norway
Introduction: Processing and incorporation of fragments of DNA and
oligonucleotides by mammalian and bacterial cells is a continuing physiological
process. It is strongly intensified in inflammation, cancer and after tissue and
organ transplantation. The outcome of DNA transfer between mammalian cells
remains not well understood. It has been suggested that donor DNA may play
a role in rejection or creating partial tolerance.
Aim: to study whether donor DNA may be identified in recipient immune cells
and if so, whether it locates in cytoplasm or penetrates into nucleus.
Methods: In sex- mismatched combination male rat DNA was injected i.v. into 10
female rats. Recipient blood (PBM), lymph node (LN) and spleen (SPL) mononuclear
cells were examined 24 hr later for the presence of SRY gene characteristic for
Y-chromosome. SRY was detected using polymerase chain reaction (PCR) method
and real-time PCR. The PCR products was analyzed by electrophoresis in12,5%
polyacrylamide gel (PAGE; Phast System, Amersham Pharmacia Biotech) and
silver stained (Silver Staining Kit; Amersham Pharmacia Biotech).
Results: SRY gene was detected in female PBM, LN and SPL cell cytoplasm
in 2 out of 10 rats. Moreover, it was detected in PBM nuclei in 4 out of 10
rats and in LN cell nuclei also in 4 out of 10 rats. Location of the incorporated
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Y.J. Park1, S-K. Min1, S-H. Kim1, Y.J. Jung1, Y.S. Kim2, M.H. Park3,
S.J. Kim1, J. Ha1
1
Department of Surgery, Seoul National University College of Medicine,
2
Department of Internal Medicine, Seoul National University College of
Medicine, 3Department of Laboratory Medicine, Seoul National University
College of Medicine
It has been suggested that genetic polymorphisms of cytokines could affect graft
outcome due to the different levels of cytokine produced in individual patients.
However, there is little agreement between different research groups as to the
functional significance of each polymorphism and its role in transplantation.
To evaluate the association of tumor necrosis factor α (TNF-α) and
transforming growth factorβ1 (TGF-β1) gene polymorphisms with renal
allograft outcomes, TNF-α (-308 G/A) and TGF-β1 (codon 10 T/C) single
nucleotide polymorphism (SNP) sites were evaluated using polymerase chain
reaction (PCR) in 234 recipients and 193 donors. One hundred normal controls
were also studied. Recipients were mismatched by at least 1 human leukocyte
antigen (HLA), and all organs were from living donors. Of recipients, 11.3%
were TNF-α high producers (-308 G/A), whereas 22.3% were TGF-β1 low
producers (codon 10 C/C). Allele frequency did not differ between controls and
patients. The acute rejection rate, recurrent rejection rate, and chronic allograft
nephropathy in TNF-α high producers and TGF-β1 low producers were not
different from the other group; however, if groups were subdivided according
to immunosuppressant, the recurrent rejection rate was significantly increased
in the cyclosporine-based dual therapy group. The triple regimen group did
not show a significant difference, and the tacrolimus (TAC)-treated group
did not show any recurrent rejection. Graft survival was better in the TNF-α
low-producer and TGF-β1 high-producer groups than the others, respectively;
however, only the latter group showed a significant difference in CsA-based
regimen group, of which the result was more prominent in the triple regimen
group (Fig. 1 & 2). There was no significant difference in graft survival in
patients with TAC-based regimen with dual nor triple agents.
Although TNF-α and TGF-β1 gene polymorphism may have an influence on
graft outcomes, its significance could be modulated at least in part by a more
potent immunosuppression regimen.
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Fig 1. P=0.043 Graft survival in patients with CsA-based agents according to
TGF-β1 codon10 polymorphism. (In TAC-based group, P=NS)
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Fig 2. P=0.018 Graft survival in patients with CsA-based triple agents according
to TGF-β1 codon10 polymorphism. (In CsA-based dual group, P=NS)

POSTER BOARD NUMBER P4 – 291
2241 EFFECT OF GENETIC POLYMORPHISMS OF MRP2
AND UGT2B7 ON GASTROINTESTINAL SYMPTOM RATING
SCALE IN KIDNEY TRANSPLANT RECIPIENTS TAKING
MYCOPHENOLIC ACID
P.H. Lee1, J.W. Yang3,5, I. Hutchinson3,4, V. Pravica3,4, T. Shah2,3, D. Min3,5
1
Singapore General Hospital, 2St. Vincent Medical Center, 3National Institute
of Transplantation, 4University of Southern California, 5Western University of
Health Sciences
Background: Gastrointestinal (GI) symptoms are the most common
complications with mycophenolic acid (MPA) therapy. MRP2 and UGT2B7
which are involved in the excretion and production of the metabolites of MPA
respectively may play a role in the presentation of GI symptoms.
Objectives: To determine the relationship between single nucleotide
polymorphisms in MRP2 and UGT2B7 and the incidence and severity of
the GI symptoms in patients receiving MPA. Methods: Genotypes of MRP2
C-24T and UGT2B7 C802T were determined and the incidence and severity
of GI symptoms were assessed using the validated Gastrointestinal Symptom
Rating Scale (GSRS) at baseline, 2 weeks, 1 month, 3 months and 6 months
post transplant. The mean overall GSRS score and subscale score for diarrhea
were compared using Student’s t-test and linear regression was performed to
determine the predictors of GI symptoms.
Results: Fifty-six kidney transplant recipients were included in the study. The
overall GSRS score was not significantly different between the MRP2 C-24T
heterozygous variant and the homozygous wild type (1.6 vs 1.8, p=0.084).
However the GSRS subscale score for diarrhea was significantly lower in the
MRP2 C-24T heterozygous variant compared to the homozygous wild type
(1.2 vs 1.7, p=0.004). For the UGT2B7 C802T, the overall GSRS score (1.6
vs 1.8, p=0.158) and diarrhea subscale score (1.4 vs 1.8, p=0.127) were not
significantly different between the heterozygous and homozygous variant
and the homozygous wild type. When the genotypes for MRP2 and UGT2B7
are considered together, the variant MRP2 C-24T and UGT2B7 C802T had
significantly lower overall GSRS (1.5 vs 1.9, p=0.032) and diarrhea subscale
score (1.1 vs 1.8, p=0.014) compared to the wild type. There were however
no differences in the scores between patients receiving either mycophenolate
mofetil or enteric-coated mycophenolate sodium; and patients receiving the
different calcineurin inhibitors.
Conclusion: This study demonstrates that among patients receiving MPA,
those with MRP2 C-24T and UGT2B7 C802T variant genotypes are potentially
protected from the GI side effects, in particular diarrhea, regardless of the
formulation administered.

POSTER BOARD NUMBER P4 – 292
2242 SYSTEMS BIOLOGY IN DONOR KIDNEYS OF
RECIPIENTS WITH POST-TRANSPLANT ANEMIA
J. Wilflingseder1,2, A. Kainz1, P. Perco2, B. Mayer2, R. Oberbauer1,3
KH Elisabethinen, Linz, Austria, 2Emergentec Biodevelopment, Vienna,
Austria, 3Medical University of Vienna, Austria
Post-Transplantation anemia is a common phenomenon after renal
transplantation, and the cause is usually multi-factorial. Molecular mechanisms
leading to anemia after renal transplantation are not fully understood. Focus of
this present study was to further elucidate the biological processes of anemia in
the post-transplantation setting.
The analysis of 52 renal transplant recipients (25 treated with ESAs within the
first year after transplantation and 27 without ESA treatment) will be presented.
The analysis include genome-wide gene expression profiles of donor kidney
biopsies with subsequent systems biology approaches such as transcription
factors analysis, regulatory networks, and protein-protein interaction data.
Multivariable logistic regression analysis was used to quantify the association
of genes identified in the systems biology studies with the outcome ESA use
adjusted for clinical predictors such as donor age, biopsy confirmed acute
rejection (BCAR) and glomerular filtration rate.
Unsupervised hierarchical clustering of experimental data suggests a distinct

1

molecular signature associated with activated inflammation in the donor kidney
biopsies with subsequent ESA requirement. Selection of 1.5fold differentially
upregulated genes in the ESA group yielded 28 significant sequences that can
be categorized according to PANTHER ontologies into three main biological
processes: Cell adhesion-mediated signalling (p<0.004), immunity and defense
(p<0.004), oncogenesis (p<0.007). In the multivariable analysis, several genes
were found to be independent predictors of post-transplant anemia.
Our data suggest that genes involved in the inflammation cascade predict posttransplant anemia.

POSTER BOARD NUMBER P4 – 293
2243 INFLUENCE OF MRP2 AND UGT1A9 POLIMORPHISMS
IN THE MPA PHARMACOKINETICS IN RENAL TRANSPLANT
RECIPIENTS. RESULTS OF THE PHARMACOGENETIC
SUBSTUDY WITHIN THE SYMPHONY STUDY.
N. Lloberas1, M. Brunet2, J. Torras1, F. Oppenheimer3, J. Sanchez-Plumed4,
M.A. Gentil5, H. Ekberg6, J.M. Grinyó1
1
Nephrology Service and Laboratory of Experimental Nephrology,
Department of Medicine, Hospital Universitari De Bellvitge, L´Hospitalet
de Llobregat, Spain, 2Centre de Diagnostic Biomedic, Barcelona, Spain,
3
Hospital Clinic i Provincial, Barcelona, Spain, 4Hospital La Fe, Valencia,
Spain, 5Hospital Virgen del Rocío, Sevilla, Spain, 6Malmoe, Sweeden
Introduction: Mycophenolic acid (MPA) is an effective immunosuppressant
used in renal transplantation and is mainly metabolized by uridine diphosphateglucuronosytransferases (UGTs). The latter metabolites are excreted trough the
kidney at least in part by multidrug resistance protein 2 (MRP2), which play
an important role in the enterohepatic recirculation of the MPA. Furthermore,
the inhibition of MRP2 by cyclosporine (CsA) is the main mechanism
responsible for the interaction between CsA and MPA. The Symphony study
compares 4 immunosuppressant regimens in renal transplant patients in terms
of clinical outcomes. Patients included in the Pharmacogenetic sub-study had
complete cyclosporine (CsA) and mycophenolic acid (MPA) pharmacokinetic
assessments (in the Symphony PK sub-study) and they were genotyped for
MRP2 and UGT1A9.
Objective: To determine the relationship between single nucleotide
polymorphisms (SNPs) in the MRP2 (C-24T and C3972T) and UGT1A9
(UGT1A9*3 and UGT1A9-2152) genes and the MPA pharmacokinetics in
renal transplant recipients of the Symphony Pharmacogenetic sub-study.
Subjects And Methods: 70 renal transplant recipients (58.6% males; mean
age: 47.9±11.8 years) at 8 Spanish centres were randomized to 4 branches
of immunosuppressive regimen: low and standard dose of CsA (N=30),
tacrolimus (Tac) (N=13) and sirolimus (SRL) (N=23) all in addition to
mycophenolate mofetil and steroids. Low and standard dose of CsA were
summed into one group for the present analysis. Patients were genotyped for
SNPs in MRP2, C24T and C3972T, and for SNPs in UGT1A9, *3 and 2152.
Pharmacokinetic sampling was done before administration and at 20, 40, 75
min, 2, 3, 6, 8, 10 and 12 hours post-dose at scheduled intervals during the
study (7, 30 and 90 days). Association of different Area Under Curve (AUC)
plasma samplings with the presence of MRP2 and UGT1A9 polymorphisms
and with the immunosuppressive regimens were studied using ANOVA
analysis (Kruskal-Wallis).
Results: At 90 days, MPA AUC was associated with the presence of C24T
(CC: 82.3 ± 48.3; *T: 50.6 ± 21.0; p= 0.009; N= 48) and with treatment with
CsA (Tac and SRL: 82.9 ± 46.9; CsA: 52.9 ± 518.5; p= 0.003; N= 54). MPAG
AUC was associated with the presence of UGT1A9*3 at 30 days (C*: 857.3
± 558.6; TT: 1496.9 ± 888.2; p= 0.036; N= 53) and at 90 days (C*: 321.2 ±
22.2; TT: 972.2 ± 518.5; p= 0.024; M= 57). MPA AUC was associated with the
presence of UGT1A9*3 at 30 days (C*: 68.3 ± 19.1; TT: 50.5 ± 26.6; p= 0.056;
N= 53) but not at 90 days.
Conclusions: Renal transplant recipients with C-24T MRP2 SNPs were
associated with a reduced MPA exposure in the steady-state conditions and CsA
treated patients showed a reduction in MPA AUC in the steady-state conditions.
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2244 POLYMORPHISMS OF THE MDR1 GENE IN RENAL
TRANSPLANT RECIPIENTS AFFECT THE PGP ACTIVITY.
RESULTS OF THE PHARMACOGENETIC SUBSTUDY WITHIN
THE SYMPHONY STUDY.

THURSDAY

N. Lloberas1, I. Llaudó1, J. Torras1, A. Caldes1, J.M. Cruzado1,
F. Oppenheimer2, J. Sanchez-Plumed3, M.A. Gentil4, H. Ekberg5, J.M. Grinyó1
1
Nephrology Service and Laboratory of Experimental Nephrology,
Department of Medi, 2Hospital Clinic i Provincial, Barcelona, Spain,
3
Hospital La Fe, Valencia, Spain, 4Hospital Virgen del Rocío, Sevilla, Spain,
5
Malmoe, Sweeden
Introduction: The human multidrug resistance gene (MDR1) encodes for
the membrane efflux transporter, P-glycoprotein (Pgp). The search for key
genetic determinants that predispose individuals to drugs that are substrates or
inhibitors of Pgp has just begun. Reports in the literature, particularly focusing
on the C3435T polymorphism may be of interest to individualization therapy
and has been related to nephrotoxicity drug disposition. Pgp functional studies
may provide new insights on the relevance of Pgp polymorphisms on therapy
individualization. The Symphony study compares 4 immunosuppressant
regimens in renal transplant patients in terms of clinical outcomes.
Objective: To investigate the association of 4 SNPs in MDR1 gene with Pgp
activity as measured by means of rhodamine fluorescence. Correlation of
different immunosuppressive drugs with Pgp activity in vivo.
Subjects And Methods: Patients included in the Pharmacogenetic substudy were genotyped for MDR1 gene. In total, 70 renal transplant
recipients (58.6% males; mean age: 47.9±11.8 years) at 8 Spanish centres
of the Symphony Pharmacogenetic sub-study were included. Patients were
randomized to 4 branches of immunosuppressive regimen: low and standard
dose of cyclosporine (CsA) (N=30), tacrolimus (TRL) (N=13) and sirolimus
(SRL) (N=23) all in addition to mycophenolate mofetil and steroids. Low
and standard dose of CsA were summed into one group for present analysis.
Patients were genotyped for SNPs in MDR1 C3435T, C1236T, G2677T and
T129C. Pgp was measured in peripheral lymphocytes by means of rhodamine
fluorescence and expressed as fluorescence units (FU).
Results: Pgp activity was influenced by different MDR1 polymorphisms:
C3435T (CC: 48.8 ± 14.7 FU; CT: 40.6 ± 10.8 FU; TT: 33.1 ± 9.3 FU;
p= 0.013), C1236T (CC: 46.4 ± 15.4; CT: 40.0 ± 9.7; TT: 32.6 ± 8.5; p=
0.030) and G2677T: (GG: 46.0 ± 15.2; *T: 38.7 ± 9.9; p= 0.042). Pgp
activity was lower for CsA and SRL groups than for TRL groups (p= 0.081).
No association was found between Pgp activity and age (p=0.431) and sex
(p=0.478).
Regression analysis: in C3435T MDR1 gene SNP (R-squared= 0.24),
presence of CC was associated with higher Pgp activity than CT (coef:
-10.34; p= 0.024) and TT (coef:-20.14; p= 0.001); in C1236T MDR1
gene SNP (R-squared= 0.20), presence of CC was associated with higher
Pgp activity than CT (coef: -7.79; p= 0.066) and TT (coef:-17.26; p=
0.005); and in the MDR1 gene SNP G2677T (R-squared= 0.13), presence
of GG was associated with higher Pgp activity than *T (coef: -9.35; p=
0.022).
Conclusions: The polymorphisms of the human multidrug resistance gene
MDR1 (C3435T, C1236T and G2677T) were influenced by Pgp function in
vivo in lymphocytes isolated from renal transplant recipients. Pgp activity in
vivo also was modified depending on the immunosuppressant drug treatment.
Patients treated with TRL showed an increase of Pgp activity compared with
CsA and SRL treatment.

734

POSTER BOARD NUMBER P4 – 295
2245 IDENTIFICATION OF BIOMARKERS FOR MEDIUM
GRAFT FUNCTION IN PREIMPLANTATION KIDNEY
BIOPSIES.
P. Perco1,2,3,4, A. Kainz1,2, M.. Wilflingseder2, C. Mitterbauer1, B. Mayer3,4,
R. Oberbauer1,2
1
Medical University of Vienna, 2KH Elisabethinen, Linz, 3University of
Vienna, 4emergentec biodevelopment GmbH
Several studies investigated the association of histological scores of donor
kidney biopsies obtained before engraftment with post transplant outcomes.
Discrimination and goodness of fit of these scores however is low. Thus we
sought to identify and elucidate the performance of molecular rather than
histological markers for this purpose.
We identified 80 unique differentially regulated genes in 82 samples showing
no histological damage versus those with histological damage in at least one
of the six BANFF07 categories. Main biological categories enriched with
upregulated genes in damaged tissue were “immunity and defense”, “cell
communication”, or “apoptosis”. Interestingly genes involved in cell structure,
cell adhesion and protein trafficking were specific for tubular atrophy.
Histology (CADI score) correctly predicted creatinine at one year in only
14% (adjusted r2 for PRA, BCAR, MMsum) whereas a combination of four
biomarkers without clinical covariables explained 33% of the creatinine
variability at one year. The top two biomarkers alone still explained 29% of
the variability.
In summary, we identified biomarkers in transplant kidney biopsies, which are
predictive for medium term allograft function. The individual markers will be
presented at the conference.

POSTER BOARD NUMBER P4 – 296
2246 ASSOCIATION OF MDR-1 AND CYP3A5
POLYMORPHISM WITH TACROLIMUS DISPOSITION IN
KOREAN RENAL TRANSPLANTATION RECIPIENTS
Y.J. Park2, Y.J. Moon1, S-H. Kim2, H.J. Hong2, E.H. Ji1, Y.J. Joeng2,
S-K. Min2, J. Ha2, J.M. Oh1, S.J. Kim2
1
Collegy of Pharmacy, Seoul National University, 2Department of Surgery,
Seoul National University College of Medicine
Background: Tacrolimus is a major immunosuppressant which has a narrow
therapeutic range and wide interindividual variation. Because tacrolimus
is a substrate of cytochrome P450 3A5 and P-glycoprotein, which play a
key role in drug pharmacokinetics, it was expected that these gene would be
associated with different drug response. Furthermore, studies have shown
that there are clear ethnic differences in the prevalence of the CYP3A5
genotypes. Therefore, the purpose of this study was to characterize the
genetic variations of MDR1 and CYP3A5 on the tacrolimus disposition in
Korean renal transplantation recipients.
Methods: Genotyping for MDR1 C1236T, G2677T/A, and C3435T and
CYP3A5 were performed on 104 kidney recipients receiving tacrolimus-based
immunosuppressant. Clinical data was collected retrospectively on 0.5, 1, 3, 6,
and 12 months after transplantation. Dose-adjusted trough levels (ng/ml per mg/
kg) as well as doses (mg.kg) required to achieve target blood concentration was
compared among patients according to the genotypes of CYP3A5 and MDR1.
Results: The mean dose required to achieve target concentration at 0.5, 1, 3,
6, and 12 months was significantly higher in patients with CYP3A5*1/*1 and
*1/*3 compared to CYP3A5 *3/*3 (p<0.001). Dose-adjusted trough level at
week 2 was significantly higher in TT variant of MDR1 C3435T (p=0.01) and
dose requirement at week 2 was significantly lower in homozygous mutant of
MDR1 G2677T/A (p=0.022), but there was no significant difference in other
SNPs of MDR1. A total of 14 patients out of 104 presented with the biopsyproven acute rejection within one month of transplantation, but the genetic
variation had no effect on the incidence of acute graft rejection.
Conclusion: Our data has identified that polymorphism of CYP3A5 is
significantly associated with dose-adjusted trough levels of tacrolimus.
Genotyping for CYP3A5*1/*1 and *1/*3 to identify CYP3A5 expressers has
the potential to identify individuals with a high dose requirement for tacrolimus
and may be a useful tool for individualizing immunosuppressive drug treatment
in Korean renal transplantation recipients.
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2247 EARLY POST TRANSPLANT ANAEMIA IS NOT
ASSOCIATED WITH THE ANGIOTENSIN II TYPE 1
A1166C SINGLE NUCLEOTIDE POLYMORPHISM OR
ANGIOTENSIN CONVERTING ENZYME INSERTIN/DELETION
POLYMORPHISM IN RENAL TRANSPLANTATION
J. Irvine1, A. Pilbrow1, C. Frampton1, Z. Endre2, M. Richards1, V. Cameron1
Cardioendocrine Reseach Group, Christchurch, 2Renal Research Group,
Christchurch
Introduction: Post-transplant anaemia (PTA) is a common phenomenon. The
cause of PTA is multi-factorial. ACE inhibitors can contribute to PTA and their use
to alleviate post transplant erythrocytosis is a well-recognised management option.
However the response can be variable and the mechanism is poorly understood
The angiotensin II type 1 receptor (AT1R) has an important role in determining
serum erythropoietin levels. The AT1R has a single base substitution of the
adenine to cytosine at position 1166 of the 3’ untranslated region (A1166C).
The C-allele of this single nucleotide polymorphism (SNP) has been associated
with increased activity of the renin-angiotensin system (RAS) with augmented
angiotensin II activity. The angiotensin converting enzyme insertion/deletion
(ACE I/D) polymorphism is a 287 base pair insertion of the ACE gene. The
D-allele is associated with higher serum ACE concentration.
The aim of this study was to investigate associations between kidney transplant
recipient AT1R A1166C and ACE I/D genotype and PTA 6 months post
transplantation. We hypothesised that the presence of an AT1R C-allele and/or
ACE D-allele would be associated with a reduced prevalence of PTA.
Methods: This is a retrospective study. Recipients (n=163) were genotyped for
the AT1R A1166C and ACE I/D polymorphisms. All recipients were older than
18 years and had a functioning graft for more than 90 days. Anaemia was defined
using the World Health Organisation criteria as a serum haemoglobin concentration
<130 g/L in men and <120g/L in women. For statistical analyses AT1R AC and CC
genotypes were combined, and ACE ID and DD genotypes were combined.
Results: The gene frequency of the AT1R A1166C polymorphism was 53% AA,
40% AC and 7% CC. and the frequency of the ACE I/D polymorphism was 20%
II, 45% ID and 35% DD. As expected, haemoglobin concentration 6-months
post-transplant was significantly associated with gender, with males having a
higher concentration (133g/L versus 122g/L, p<0.001). In a univariate model
adjusted for gender and use of ACE inhibitors or angiotensin receptor blockers,
there was no significant association between haemoglobin concentration
and AT1R or ACE genotype (AT1R C-allele p=0.72, ACE D-allele p=0.82).
Furthermore, there was no synergistic interaction between AT1R and ACE
genotypes on haemoglobin concentration after adjustment for gender, ACE
inhibitor and angiotensin receptor blocker treatment and genotype main effects.
In anaemic recipients, the frequency of the AT1R C-allele or ACE D-allele did
not differ from non-anaemic recipients (p=0.90 and p=0.70 respectively).
Conclusions: In this cohort of graft recipients, the AT1R A1166C and ACE I/D
genotypes were not associated with early post transplant haemoglobin or the
presence of anaemia.
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POSTER BOARD NUMBER P4 – 298
2248 LONGITUDINAL PATTERN OF DIFFERENTIAL GENE
EXPRESSION WITHIN THE FIRST 3 MONTHS FOLLOWING
RENAL TRANSPLANTATION
P. Keown, Z. Hollander, O. Gunther, G. Cohen-Freue, D. Lin,
J. Wilson-McManus, R. Balshaw, R. Ng, R. McMaster, B. McManus
University of British Columbia
Introduction: Whole-genome expression analysis was used to identify patterns
of differential expression prior to and during the first 3 months following renal
transplantation in patients with a quiescent clinical course. A longitudinal
cohort design was employed for discovery and validation of genomic markers.
Blood, tissue and urine samples were obtained throughout the first 12 weeks
in 106 sequential subjects receiving a renal transplant with rigorous control
of treatment variables in a single university centre. Samples were analyzed
using Affymetrix Human Genome U133 plus 2.0 microarrays, analysed using
Linear Models for Microarray Data (Limma) after conventional normalization
and pre-filtering.
Results: Baseline expression was compared in 72 subjects, comprising

52 uremic pre-transplant patients and 20 normal controls. After RMA
normalization and prefiltering, hierarchical clustering and multivariate
analysis of normal subjects and uremic pre-transplant patients showed distinct
segregation between these populations with statistically significant differential
expression in 11,156 probe sets encompassing bioamine synthesis, cellular
metabolic processes, hormonal function, erythropoiesis, macromolecular
processes, cell communications, neutrophil functions and other key biological
processes. Differential expression within the pre-transplant cohort was noted
according to primary renal disease, with discrete patterns for subjects with
diabetic nephropathy, glomerulonephritis, polycystic disease and other
renal disorders. Principal components analysis showed clear definition by
treatment, accurately categorizing subjects who were pre-dialysis from those
receiving hemodialysis or peritoneal dialysis therapies according to GO terms
of cell growth and maintenance, cell communication, transcription and protein
metabolism. Transplantation caused a profound alteration in gene expression
even in quiescent patients, with a rapid and transient increase or decrease
in expression of almost 200 probesets during the first post-operative week
which returned to baseline by weeks 2-4. Subjects with sustained clinical
and immunological quiescence throughout the first 3 months post-transplant
exhibited profound suppression of probesets encompassing immunoglobulin
genes, inflammatory cytokines, chemokines and other mediators of
inflammatory injury. Subsets of these genes returned gradually to normal
levels by 3 months post-transplant, commensurate with the gradual reduction
in dose of immunosuppressive agents.
Summary: Monitoring gene expression in the peripheral blood identifies
longitudinal biological processes, and may provide the first insight into the
mechanisms of immunological accommodation permitting controlled reduction
of immunosuppression.

POSTER BOARD NUMBER P4 – 299
2249 DIFFERENTIAL GENE EXPRESSION IN ACUTE
AND CHRONIC REJECTION FOLLOWING RENAL
TRANSPLANTATION.
Z. Hollander, G. Cohen-Freue, D. Lin, J. Wilson-McManus, R. Balshaw,
R. Ng, R. McMaster, B. McManus, P. Keown
University of British Columbia
Introduction: Whole-genome expression analysis was used to identify
molecular mechanisms and to identify predictive biomarkers of acute and
chronic immune injury following renal transplantation. A total of 165 sequential
renal allograft recipients were divided into early and late-phase discovery and
validation cohorts. RNA was collected longitudinally at weeks 1, 2, 3, 4, 8,
12, 24, 36 and 52 and every 3 months thereafter, along with renal allograft
tissue at the time of graft dysfunction or potential rejection. Gene expression
was measured using Affymetrix Human Genome U133 plus 2.0 microarrays,
analysed using Linear Models for Microarray Data (Limma) after conventional
normalization and pre-filtering.
Results: All subjects received standard quadruple immunosuppression. Graft
function was determined using clinical, laboratory and histological (Banff
97) criteria, and patients were selected to eliminate confounding events
including DGF, CMV, sepsis and disease recurrence. Analysis compared gene
expression in patient cohorts with clinical quiescence, borderline rejection,
acute rejection (Banff grade „d1) and chronic graft injury. There was a marked
perturbation in gene expression/inhibition during the first 4 weeks reflecting
surgery, healing and intervention. Principal component analysis showed that
few genes were differentially expressed in borderline rejection, but 135 genes
were highly significantly differentially expressed in acute rejection compared
to quiescence, comprising cellular, macromolecular, regulatory and immune
system processes. In the late phase, no genes were differentially expressed
in classical chronic rejection and 3 key candidates were identified in nonspecific chronic allograft nephropathy (CAN).
Summary: Gene expression is markedly perturbed post-transplant reflecting
concomitant processes of injury, healing and immunity. Acute rejection
is accompanied by a characteristic signal of molecular events which may
provide a valuable biomarker, but chronic injury appears relatively silent in
the peripheral blood.
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2250 THE EXPRESSION OF RENAL KLOTHO IS DECREASED
IN DECEASED DONOR KIDNEYS

2252 DECREASED NEUTROPHIL-MEDIATED RENAL
DYSFUNCTION AND TUBULAR APOPTOSIS FOLLOWING
RENAL ISCHEMIA-REPERFUSION IN CCR1-DEFICIENT MICE

T. Mueller, P. Halloran, V. Luyckx
University of Alberta
Klotho is a gene almost exclusively expressed in renal distal tubules and
loss of expression is associated with accelerated aging. In various models
of acute and chronic renal injury, and with normal aging, renal klotho
expression has been found to decrease. Increased donor age is associated
with poorer long term allograft function. We hypothesized that klotho
mRNA expression in renal implant biopsies would correlate with donor
kidney quality, as determined by donor chronologic age and peri-transplant
renal injury.
Our recent unsupervised microarray analysis of 87 renal implant biopsies
revealed a continuum of organ quality across all samples ranging from the
best living donor (LD) kidneys at one end to the worst performing deceased
donor (DD) kidneys at the other (Am J Transpl 2007, Nov 16,epub). Three
predominant groups were identified of LD, DD1 kidneys with low risk
(9.5%) of delayed graft function (DGF) and DD2 kidneys with high risk
(35%) of DGF (p < 0.05). Analysis of klotho gene expression among these
groups also revealed a spectrum of expression from highest levels in LD to
lowest in DD2 kidneys, especially those who developed DGF. Differences
were highly significant among LD vs DD kidneys (p < 0.001), although
donor age was not different between these groups.
Klotho transcript levels were significantly different among kidneys that
developed DGF compared to those with immediate graft function (IGF) (p <
0.05). An additional analysis of different post-transplant complications in 114
samples from kidney biopsies for cause showed an age-independent association
of Klotho expression with extent of tubular damage.
In conclusion, reduced klotho gene expression is associated with grafts at risk
of poorer function and appears to be independent of donor age. Decreases in
klotho expression likely reflect other factors impacting the renal tissue, which
may impact potential for repair and ultimately allograft function.

M. Araki1,2, H. Kumon2, R. Fairchild1
1
Cleveland Clinic, 2Okayama University School of Medicine
Objective: Ischemia/reperfusion (I/R) injury is an unavoidable component
of solid organ transplantation that negatively impacts graft function and
survival. Neutrophil infiltration is a key mediator of I/R injury. Neutrophils
express CCR1 which may play a role in directing this infiltration. The goal of
the current study was to investigate the induction and role of the chemokine
receptor, CCR1, in a model of renal I/R injury.
Methods: C57BL/6 wild-type and CCR1-/- mice were anesthetized and the
renal hilum was clamped for 45 min while the temperature was maintained at
32°C. At various times post-reperfusion, ischemic and control kidneys were
removed, whole cell RNA was prepared and tested for expression of chemokine
receptor genes by ribonuclease protection assay. Frozen or paraffine sections were
prepared from kidneys and stained for neutrophils, macrophages, MIP-1a by
immunohistochemistry. Serum creatinine was measured each day post-reperfusion.
In some experiments mice were depleted of neutrophils by treatment with antimouse Ly-6G rat IgG. TUNEL assay was performed to detect apoptosis.
Results: CXCR2 and CCR1 were the most highly expressed receptors in
ischemic kidneys with expression peaking 18 h after reperfusion and increasing
again after 24 hr. The ligands for CCR1, MIP-1a and RANTES, were clearly
present in the tubular epithelial cells at these time points. Renal dysfunction was
abrogated in CCR1-/- mice and histopathology analyses indicated markedly less
renal tissue damage and apoptosis of tubular epithelial cells when compared to
wild-type mice. Immunohistochmistry indicated less neutrophil infiltration in
the renal tissue. Survival of CCR1-/- mice was significantly better following
renal I/R injury than wild-type mice.
Conclusions: CCR1 plays an important role in kidney ischemia/reperfusion injury
by decreasing neutrophil infiltraion in renal tissue after reperfusion. CCR1 can be
the target to reduce renal ischemia reperfusion injury in the clinical situation.

POSTER BOARD NUMBER P4 – 303
2253 THE ROLE OF CALCIUM (CA2+) IN MODULATION OF
SMOOTH MUSCLE CELLS REACTIVITY TO ANGIOTENSIN II
(ANG II) DURING ISCHEMIA/REPERFUSION (I/R).

CONCURRENT ORAL SESSION 151: ISCHEMIA AND
REPERFUSION
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2251 RECOVERY OF TACROLIMUS ASSOCIATED BRACHIAL
NEURITIS AFTER CONVERSION TO EVEROLIMUS IN
A PEDIATRIC RENAL TRANSPLANT RECIPIENT; CASE
REPORT AND REVIEW OF THE LITERATURE
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S. Quader, O.A. Masri, W. Fathalla
Sheikh Khalifa Medical City
Abstract: Tacrolimus (TAC) has been shown to be a potent immunosuppressive
agent for solid organ transplantation in pediatrics. Neurotoxicity is a
potentially serious toxic effect. It is characterized by encephalopathy,
headaches, seizures or neurological deficits. Here we describe an 8 ½ -yearold renal transplant boy with right Brachial Neuritis (BN). MRI demonstrated
hyperintense T2 signals in the cervical cord and right brachial plexus roots
indicative of both myelitis and right brachial plexitis. Symptoms persisted for
3 months despite TAC dose reduction, administration of IVIG and 4 doses of
methylprednisolone pulse therapy. Improvement and eventually full recovery
only occurred after TAC was completely discontinued and successfully
replaced by Everolimus.
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M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, M. Jasinski1,
G. Grzesk2
1
Department of Transplantation And General Surgery, Collegium Medicum
Nicolaus Copernicus University, Bydgoszcz, Poland, 2Department of
Pharmacology and Therapeutics, Collegium Medicum Nicolaus Copernicus
University, Bydgoszcz, Poland
Background: The aim of this study was to examine the role of Ca2+ in reactivity
of arteries to ANG after I/R and to determine the function of antioxidative
system in this phenomenon.
Material and methods: Experiments were performed on male Wistar rats tail
artery retrieved and preserved in the UW solution for 12 hours. The effects of
ANG II were examined after I/R in the presence of catalase or aminotriazole. To
determine the role of intra and extracellular Ca2+ experiments were performed
in Ca2+ free PSS (FPSS) and PSS.
Results: ANG II increased perfusion pressure in both FPSS (66mmHg) and
PSS (91mmHg). After ischemia reactions induced by ANG II were lower
(17mmHg in FPSS; 24mmHg in PSS), while after 120 min. of reperfusion
were higher (117 mmHg in FPSS; 209mmHg in PSS). In the presence of
catalase perfusion pressure was 39 mmHg in FPSS and 48 mmHg in PSS,
after ischemia: 28 mmHg in FPSS and 30 mmHg in PSS, after 120 min of
reperfusion: 73 mmHg in Ca2+-free PSS and 139 mmHg in PSS. In the
presence of aminotriazole perfusion pressure was 89 mmHg in FPSS and 127
mmHg in PSS, after ischemia: 43 mmHg in FPSS and 77 mmHg in PSS, after
120 min of reperfusion: 124 mmHg in FPSS and 263 mmHg in PSS.
Conclusion: Contractile effects of ANG II are mediated by both intra- and
extracellular Ca2+. Results suggest that antioxidative system plays a role in
modulating reactions induced by ANG II after I/R injury.
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2254 N-ACETYL CYSTEINE HÁS A BENEFICIAL EFFECT
ON PANCREAS AND KIDNEY FOLLOWING PANCREATIC
ISCHEMIA-REPERFUSION

2255 THE ROLE OF G PROTEIN AND CALCIUM (CA2+)
IN THE REACTIVITY OF ARTERIES DURING ISCHEMIA/
REPERFUSION (I/R) INJURY

R. Meirelles, T. Bacchella, M. Kubrusly, M. Machado
Disciplina de Transplante do Hospital Das Clínicas Da FMUSP – LIM37
Introduction: Simultaneous pancreas-kidney transplantation became the
first treatment option for type I diabetes patients with end stage renal failure.
However, graft acute pancreatitis remains a frequent complication (35%) on
immediate pos-operative time. It may contribute to pancreas graft loss and
kidney delay graft function (KDGF). Ischemia-reperfusion injury may be
involved in the pathogenesis of graft pancreatitis and KDGF. GlutathioneS-transferases (GST) enzymes provide protection against reactive oxygen
species, by catalyzing the formation of glutathione conjugates and by
eliminating peroxides during ischemia-reperfusion injury. N-acetyl cysteine
(NAC) has been shown to improve pancreatic microcirculation alterations and
renal function.
AIM: Evaluate pancreatic and renal injury and expression level of isoform
GST-á after pancreatic ischemia-reperfusion induction on rat model.
Methods: Twenty-four Wistar rats weighting 300-350g were divided into
four groups: Group 1 – sham; Group 2 – ischemia-reperfusion; Group 3 –
ischemia-reperfusion plus NAC iv; Group 4 – ischemia-reperfusion plus NAC
po. Splenic pancreatic portion underwent to 1 hour ischemia followed by 4
hours of reperfusion. Group 3 received intravenously150mg/kg body weight
15 minutes before reperfusion followed by 50mg/kg body weight during the
remaining time. Group 4 received NAC (4800 mg/L) ad libitum 48 hours
before the experiment. Blood, splenic pancreatic and renal tissue samples
were collected after 4hour of reperfusion. Serum amylase and creatinine were
determined. Expression level of isoform GST-á was evaluated by quantitative
real-time polymerase chain reaction (qRT-PCR) for both tissue samples. Total
pancreatic and renal RNA (20ng) from all animals were subjected to qRT-PCR.
Normalized qRT-PCR data were determined from the ratio of GST-á/â-actin
values for each sample.
Results: Serum amylase level were 6.11 (sd=0.55) mg/mL/min, 10.30
(sd=0.50) mg/mL/min, 9.77 (sd=1.24) mg/mL/min and 7.82 (sd=0.38) mg/mL/
min in Groups 1, 2, 3 and 4, respectively. There was an increase in serum
amylase when compared group 1 with group 2 (p=0.0002) and a decrease when
compared group 2 with group 4 (p=0.003). An increase in GST-á expression
was observed in groups 3 and 4 when compared to group 2 (p=0.016). Serum
creatinine level were 0.52 (0.07) mg/dL, 0.77 (0.18) mg/dL, 0.48 (0.13) mg/
dL and 0.25 (0.83) mg/dL in Groups 1, 2, 3 and 4, respectively. There was
an increase in serum creatinine level when compared group 1 with group 2
(p=0.012) and a decrease when compared Groups 2 and 3 (p=0.03). An increase
in renal GST-á gene expression was observed in group 2 when compared to
group 1 (p=0.013).
Conclusion: NAC given 48 hours before experimental ischemia-reperfusion
injury induction normalizes hyperamilasemia. This protective effect in
pancreatic tissue under ischemia-reperfusion injury may be due to an increase
in expression level of GST-á gene. NAC given iv improves renal function.
Finally, renal GST-á gene expression is already increased during pancreatic
ischemia-reperfusion injury. NAC may have a potential benefit in pancreaskidney transplantation. (FAPESP)

M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2,
M. Jasinski1, G. Grzesk2
1
Department of Transplantation and General Surgery, Collegium Medicum
Nicolaus Copernicus University, Bydgoszcz, Poland, 2Department of
Pharmacology and Therapeutics, Collegium Medicum Nicolaus Copernicus
University, Bydgoszcz, Poland
Background: The aim of this study was to examine the role of G protein and
Ca2+ in the reactivity of the vascular smooth muscle cells during I/R injury to
angiotensin II (ANG II), phenylephrine (PHE) in comparison to Bay K8644.
Material and methods: Experiments were performed on isolated and perfused
male Wistar rats tail artery retrieved and preserved in the UW solution for 12
hours. We investigated the effects of ANG II, PHE and BAY K8644 on vascular
tone in Ca2+- free PSS (FPSS) and PSS. The results were compared with
reactions after I/R, without or in presence of G protein blocker – Bordetella
pertussis toxin (P 7208).
The constriction of the rat tail artery in response to ANG II, PHE and BAY
K8644 was measured as an increase of perfusion pressure at a constant flow of
the perfusion fluid (about 1ml/min.).
Results: ANG II and PHE increased perfusion pressure in FPSS (ANG II: 66
mmHg, PHE: 61 mmHg) and PSS (ANG II: 91 mmHg; PHE: 86 mmHg). After
ischemia, reactions were lower (ANG II: 33 mmHg in FPSS; 37 mmHg in
PSS; PHE: 28 mmHg in FPSS; 35 mmHg in PSS), while after 120 min. of
reperfusion were higher (ANG II: 93 mmHg in FPSS; 193 mmHg in PSS; PHE:
84 mmHg in FPSS; 181 mmHg in PSS). In the presence of P 7208 reaction
induced by ANG II was decreased only in FPSS to 36 mmHg, while reactions
on PHE were inhibited in both – FPSS (36 mmHg) and in PSS (54 mmHg).
Bay K8644 increased perfusion pressure only in PPS (74 mmHg), and it wasn’t
influenced by P 7208 and I/R.
Conclusion: Results suggest that G protein modulates effects of ANG II
mediated by intracellular Ca2+ and plays a role in reactions of PHE mediated
by both intra- and extracellular Ca2+.
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2256 THE ROLE OF ENDOTHELIUM IN CONTRACTION
OF THE VASCULAR SMOOTH MUSCLE CELLS DURING
ISCHEMIA/REPERFUSION.
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2,
L. Szadujkis-Szadurski2, M. Jasinski1
1
Department of Transplantation and General Surgery, Collegium Medicum
Nicolaus Copernicus University, 2Department of Pharmacology and
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: The aim of this study was to examine the role of endothelium
in contraction of the vascular smooth muscle cells induced by angiotensin II
(ANG II) during I/R.
Material and methods: Experiments were performed on perfused male
Wistar rats’ tail artery with or without endothelium. The influence of ANG II
on vascular contraction estimated for vessels with or without endothelium was
compared with reactions in the presence of SNP (sodium nitroprusside) and
8Br-cGMP. Then effect of ANG II on vessels with or without endothelium was
compared with reactions after ischemia and reperfusion.
Results: Vascular contraction induced by ANG II (in vessels with or
without endothelium) was decreased by SNP and 8Br-cGMP (10-100μM/l)
respectively to 37(±14)% and 44(±14)% for SNP and 33(±12)% and
29(±9)% for 8Br-cGMP. EC50 for ANG II were 1.22(±0.23)x10-8 and
1.44(±0.24)x10-8, in the presence of SNP 3.33(±0.34)x10-8 and 5.92(±0.24)
x10-7, in the presence of 8BrcGMP 5.26(±0.22)x10-7 and 5.02(±0.27)x10-7.
After ischemia CRC for ANG II was shifted to the right with reduction
in maximal response, but this effect was not observed in vessels without
endothelium, where after 30, 60 and 90 min. of reperfusion CRCs were
shifted to the left with increase in maximal responses. EC50 for ANG II
were 1.22(±0.23)x10-8, after ischemia 2.89(±0.33)x10-8, after 90 min. of
reperfusion 2.17(±0.22)x10-9.
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Conclusion: Reduction of the vascular contraction on ANG II caused by
ischemia is connected with the presence of endothelium, synthesis of NO and
activation of cGMP.
The increase of reaction on ANG II induced by reperfusion is not dependent
on endothelium.

POSTER BOARD NUMBER P4 – 307
2257 CHANGES IN THE CONTRACTILITY OF THE
VASCULAR SMOOTH MUSCLE CELLS IN REACTION TO ANG
II INDUCED BY CATALASE AND AMINOTRIAZOLE DURING
ISCHEMIA/REPERFUSION.
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, G. Grzesk2,
M. Jasinski1
1
Department of Transplantation and General Surgery, Collegium Medicum
Nicolaus Copernicus University, 2Department of Pharmacology and
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: The aim of this study was to examine the effect of I/R injury
on reactivity of arteries to ANG II and to determine the role of antioxidative
system in this phenomenon.
Material and methods: Experiments were performed on male Wistar rats tail
artery retrieved and preserved in the UW solution for 12 hours.
The effects of ANG II on vascular tone were examined after 30 min. of
ischemia and 30, 60 and 90 min. of reperfusion. Then influence of catalase and
aminotriazole on contraction was investigated. Cumultative response curves
(CRCs) to agonists KA and EC50, pD2 values were calculated using commonly
approved methods.
Results: After ischemia, CRC for ANG II was shifted to the right with reduction
in maximal response, while after 30, 60 and 90 min. of reperfusion CRCs were
shifted to the left with increase in maximal responses. EC50 for ANG II were 1.22
(±0.23) x 10-8, after ischemia 2.89 (±0.33) x 10-8, after 90 min. of reperfusion 2.17
(±0.22) x 10-9. In the presence of catalase calculated EC50 values were higher,
while in the presence of aminotriazole EC50 values were lower. EC50 for ANG II
in the presence of catalase were 8.26 (±0.29) x 10-8, after ischemia 1.29 (±0.31) x
10-7, after 90 min. of reperfusion 5.57 (±0.24) x 10-9.
Conclusion: Ischemia reduces, but reperfusion augments vascular tone
induced by ANG II. Catalase inhibits, while aminotriazole increases contractile
response of vascular smooth muscle cells to ANG II after I/R. This results
suggest that antioxidative system modulates reactions induced by ANG II, and
reperfusion impairs the balance between antioxidants and the production of
reactive oxygen species.
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2258 THE INFLUENCE OF ISCHEMIA/REPERFUSION (I/R)
INJURY ON THE REACTIVITY OF ARTERIES INDUCED BY
ANGIOTENSIN II (ANG II) AND PHENYLEPHRINE (PHE).

THURSDAY

M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2,
L. Szadujkis-Szadurski2, M. Jasinski1
1
Department of Transplantation and General Surgery, Collegium Medicum
Nicolaus Copernicus University, 2of Pharmacology and Therapeutics,
Collegium Medicum Nicolaus Copernicus University
Introduction: The aim of this study was to examine reactivity of arteries
during I/R on ANG II and PHE in the presence of G protein blocker (Bordetella
pertussis toxine, P 7208), phospholipase C inhibitor (D609) and antagonist of
the IP3 receptor – xestospongin C (XeC).
Material and methods: Experiments were performed on male Wistar rats tail
artery retrieved and preserved in the UW solution for 12 hours. The effects of
ANG II and PHE were examined after I/R in the presence of P 7208, D609,
XeC. Experiments were performed in Ca2+ free PSS (FPSS) and PSS.
Results: ANG II and PHE increased perfusion pressure in FPSS (ANG II: 66
mmHg, PHE; 61 mmHg) and PSS (ANG II: 91 mmHg; PHE: 86 mmHg). After
ischemia reactions were weaker (ANG II: 33 mmHg in FPSS; 37 mmHg in
PSS; PHE: 28 mmHg in FPSS; 35 mmHg in PSS), while after 120 min. of
reperfusion were stronger (ANG II: 93 mmHg in FPSS; 193 mmHg in PSS;
PHE: 84 mmHg in FPSS; 181 mmHg in PSS). In the presence of P 7208 and
D609 perfusion pressure induced by ANG II was decreased only in FPSS (36
mmHg; 10 mmHg), while reactions on PHE were inhibited in both – FPSS (36
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mmHg; 39 mmHg) and in PSS (54 mmHg; 51 mmHg). XeC inhibited reactions
only in FPSS (ANG II: 12 mmHg, PHE: 33 mmHg).
Conclusion: Contractile effects of ANG II and PHE are mediated by intraand extracellular Ca2+. P 7208 and D609 inhibit reaction to ANG II only in
Ca2+ free PSS. In distinction from ANG II, reaction of the smooth muscle cells
induced by PHE is inhibited by P 7208 and D609 in both – Ca2+ free PSS and
PSS. These results suggest that G protein and phospholipase C play a role in
vascular contraction induced by ANG II mediated by intracellular Ca2+ and
modulate reactions to PHE mediated by both intra- and extracellular Ca2+.

POSTER BOARD NUMBER P4 – 309
2259 THE INFLUENCE OF ISCHEMIA-REPERFUSION INJURY
ON THE EFFECT OF RHO-KINASE INHIBITORY-27632 ON
CONTRACTILE ACTIVITY INDUCED BY ANG II IN HUMAN
MESENTERIC ARTERIES RETRIEVED AND CONSERVED
UNDER THE SAME CONDITIONS AS TRANSPLANTED
ORGANS.
M. Slupski1, R. Szadujkis-Szadurski2, K. Szadujkis-Szadurska2,
L. Szadujkis-Szadurski2, M. Jasinski1, Z. Wlodarczyk1
1
Department of Transplantation and General Surgery, Collegium Medicum
Nicolaus Copernicus University, 2Department of Pharmacology and
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: In this study the influence of Rho-kinase inhibitor and
calcium on reactions of the smooth muscle cells induced by ANG II after I/R
were investigated.
Material and methods: Experiments were performed on perfused human
mesenteric superior arteries. The influence of ANG II on vascular contraction,
mediated by intra- or extracellular calcium, in the presence of Y-27632,
after ischemia and reperfusion was analyzed using classical pharmacometric
methods.
Results: Vascular contraction induced by ANG II was decreased by Y-72632.
Maximal response was reduced after ischemia, but after reperfusion an increase
was observed. Y-72632 reduces vascular contraction after reperfusion, mediated
by both intra- and extracellular calcium.
Conclusion: Reperfusion augments vascular contraction in reaction to ANG
II. Rho-kinase inhibitor – Y-27632 reduces the effect induced by ANG II after
reperfusion.
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2260 ERYTHROPOIETIN TREATMENT PROTECTS AGAINST
RENAL ISCHEMIA/REPERFUSION INJURY THROUGH THE
UP-REGULATION OF SERUM AND GLUCOCORTICOIDREGULATED KINASE-1
K. Rusai1, V. Muller2, A. Prokai1, A. Fekete1, B. Szebeni1, A. Vannay3, A.
Treszl3, U. Heemann4, J. Lutz4, A.J. Szabo1
1
Semmelweis University, I. Dept. of Pediatrics, 2Semmelweis University, Dept.
of Pulmonology, 3Szentagothai Research Center, 4Klinikum rechts der Isar,
Dept. of Nephrology
The serum- and glucocorticoid-inducible protein kinase 1 (SGK1) is an antiapoptotic serine-threonine protein kinase mainly induced through the p38
MAPK pathway. It has been shown that the phosphorylated form mediates
protection against various forms of cellular stress. We determined the effect of
the erythropoietin (EPO), of which apoptosis inhibiting properties have been
proved in several forms of ischemic injury on SGK1 expression both in an in
vitro and in vivo models of renal ischemia/reperfusion (I/R) injury.
In vitro, EPO exerted a protective effect on hypoxic human embryonic kidney
(HEK) cells detected by Annexin V FACS analysis which was paralleled by
a significant overexpression of SGK1 shown by RT-PCR and Western blot
analysis. Treatment of HEK cells with the p38 MAPK inhibitor resulted in
a decreased induction of SGK1 after EPO administration. Downregulation of
SGK1 expression by small interfering RNA abolished the anti-apoptotic effect
of the EPO treatment. In renal I/R injury, pre-treatment of rats with EPO had
a significant protective effect on tissue injury and renal function. Furthermore,
expression and phosphorylation of SGK1 were higher in EPO treated animals
compared to vehicle treated rats assessed by real-time PCR, Western blot and
immunofluorescence techniques.
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In conclusion, SGK1 could mediate the protective effects of the anti-apoptotic
EPO under ischemic conditions demonstrated in the I/R injury of the kidney.
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2261 THE EXPRESSION OF CYSTEINYL-LT1 RECEPTOR
(CYSLT1R) IN RENAL ISCHEMIA-REPERFUSION INJURY OF
LEWIS RAT MODEL
M. Matsuyama1,2, K. Funao1, J. Chargui2, J-L. Touraine2, T. Nakatani1,
R. Yoshimura1
1
Department of Urology, Osaka City University Graduate School of Medicine,
2
Department of Transplantation and Clinical Immunology, Claude Bernard
University of Lyon and Lyon Hospitals, Lyon, France
Background: Renal transplantation has made substantial strides in the past few
decades, with the introduction of improved immunosuppressive regimens, organ
preservation, and pre- and postoperative care. Nevertheless, there is considerable
room for improvement, particularly in terms of improving long-term outcome.
The pathogenesis of ischemia-reperfusion (I/R) injury is known to involve
cytokines and particularly surface adhesion molecules, the expression of which
initiates the attachment of inflammatory cells. Renal I/R injury is also clinically
important problem and invariable consequence of renal transplantation. The
problem begins at the onset of acute tubular necrosis, when the transplantation
takes a long ischemic interval by using the cardiac arrest donor’s kidney. In
addition, the longer the ischemic interval, the higher in the incidence rate of
acute tubular necrosis. Generally, cysteinyl leukotriene1 receptor (CysLT1R)
is am important mediator of human bronchial asthma and CysLT1R antagonist
is clinically used in treating human bronchial asthma. However, no report has
addressed the relationship between renal I/R injury and CysLT1R. In this study,
we researched the expressions CysLT1R in renal I/R injury.
Materials and Methods: Male Lewis rats (270-320g) were used in this study.
Under laparotomy using pentobarbital sodium anesthesia, the right kidney was
harvested and then the left renal artery and vein were clamped with a hemostasis
clip for 90 minutes. The clip was subsequently removed to permit reperfusion.
The abdomen was closed during I/R. The left kidneys were reperfused, the rats
were sacrificed at 0, 3, 5, 12 and 24 hours after reperfusion. The kidneys were
harvested for HE staining and immunohistochemistry. Samples of ischemic
and nonischemic kidney tissue were fixed in 10% buffered formalin for 24
hour for immunohistochemical staining.
Results: CysLT1R expression was observed only in endothelial cells of normal
kidney. From 0 to 3 hours after reperfusion, CysLT1R expression gradually
became stronger on endothelial cells. CysLT1R expression was most intense on
endothelial cells at 3 hour after reperfusion. Five hours after reperfusion, internal
spaces of the tubular epithelial cells were expanded, and slight destruction of
the tubular epithelial cells appeared. Twelve hours after reperfusion, necrosis
extended throughout the ischemic kidney and nearly all the tubular epithelial
cells were destroyed, but from 3 to 12 hours after reperfusion, CysLT1R
expression gradually became weaker on endothelial cells. Twenty-four hour after
reperfusion, CysLT1R expression was almost normal level of normal kidney.
Naturally, renal I/R injury gradually progressed at time flow after reperfusion.
Several hours after the maximum of CysLT1R expression, the maximum of
renal I/R injury was observed.
Conclusions: These results suggest CysLT1R play very important roles on
renal I/R injury in rat, and CysLT1R plays very important roles on renal I/R
injury in rat.
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2262 SYNTHETIC OLIGOPEPTIDES RELATED TO HUMAN
CHORIONIC GONADOTROPIN AMELIORATE RENAL
ISCHEMIA-REPERFUSION INJURY
R.W.F. de Bruin1, D. Susa1, N.A. Khan2,3, M. Huisman1, M.H. Ameling2, S.
van den Engel1, H.P. Roest1, J.N.M. IJzermans1, R. Benner2
1
Erasmus Medical Centre, Department of Surgery, Rotterdam, The
Netherlands, 2Erasmus Medical Centre, Department of Immunology,
Rotterdam, The Netherlands, 3Biotempt b.v., Koekange, The Netherlands
We have previously reported that small synthetic oligopeptides related to the
primary structure of the pregnancy hormone human β-chorionic gonadotropin
(β-hCG) can reduce inflammation. Here we investigated whether such

oligopeptides are able to reduce ischemia reperfusion injury (I/R) of the
kidney.
I/R injury was induced by clamping the left kidney of male C57BL6J mice
for 25 minutes. After releasing the clamp, the contralateral kidney was
removed.
Ten different oligopeptides were administered intravenously at a dosage
of 5 mg/kg BW one minute before induction of ischemia and 1 minute
before reperfusion. Mice were sacrificed at 6, 24 and 72 hours postreperfusion. Survival, kidney function, inflammatory cells, proliferation,
apoptosis, serum cytokine levels and mRNA levels for genes of interest
were determined.
Ischemia reperfusion injury resulted in a 50% mortality in placebo treated
mice three days after reperfusion. In contrast, mortality was significantly
reduced in mice treated with the peptide LQG (90%), and completely
prevented in animals treated with MTRV, VLPALPQ or AQGV. AQGV was
the most effective peptide since it not only completely prevented mortality
but also best preserved kidney function as assessed by serum urea and
creatinine levels.
Upon treatment with AQGV, E-selectin mRNA levels in kidneys were
significantly decreased at 6 hours post-reperfusion. At 24 hours postreperfusion, a significantly lower influx of neutrophils was found, renal tubular
epithelial cell proliferation as assessed by KI-67 immunohistochemistry was
significantly increased, and the number of TUNEL-positive apoptotic cells was
significantly decreased. Serum levels of TNF-α, INF-γ, IL-6 and IL-10 were
significantly decreased at 24 hours post reperfusion.
This study shows that small synthetic oligopeptides related to the primary
structure of β-hCG, especially AQGV, are promising potential drugs for the
treatment of ischemic renal injury.
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2263 CONNECTIVE TISSUE GROWTH FACTOR STIMULATES
ENDOTHELIAL-MESENCHYMAL TRANSITION OF RAT
AORTIC ENDOTHELIAL CELLS
Z. Ding, Z. Chen, X. Chen, M. Cai, H. Guo
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College
Objective: Although epithelial-mesenchymal transition has already
been investigated in transplant area, another kind of transition, termed as
endothelial-mesenchymal transition (EMT), finds few works on it. The
present study is to explore the effect of connective tissue growth factor
(CTGF) on EMT in rat aortic endothelial cells for the further research of
allograft arteriosclerosis.
Methods: The rat arotic endothelial cells were primary cultured. The cells
were randomly divided into two groups: (1) control group, the cells were
cultured in DMEM medium supplemented with 10% fetal bovine serum
only; (2) experimental group, the cells were cultured in DMEM medium
supplemented with 10% fetal bovine serum, and recombinan CTGF was added
a final concentration of 5 ng/ml. The cells were collected at time points of 24h,
48h and 72h. Immunohistochemistry and Western-blot were used to detect
the E-Cadherin¡¢Vimentin¡¢and ¦Á-SMA for samples. In another series, the
Boyden Chamber was used to detect the migration capability of the aortic
endothelial cells at 1d, 3d, and 5d.
Results: In experimental group, a process of less E-Cadherin and more
Vimentin expression was found in the cells, indicating EMT happening. The
¦Á-SMA was detected until 48h and was markedly expressed at 72h. On the
other hand, no ¦Á-SMA expression was found from 0h to 72h in control group.
In the duration of the first two days the migration of the aortic endothelial cells
in the two groups was no difference, no cells migrated through the pores to
the opposite side of the transwell filters. But 2 days later, the transited cells
emerged and began to migrate to the opposite side of filters in the experimental
group. At day 5, more and more transited cells was found on the opposite side
of filters in the experimental group compared with the control group (79¡À1.1
VS 15¡À1.2 P<0.05).
Conclusion: The aortic endothelial cells also has the transition capability to
mesenchymal cells and the process also can be stimulated by CTGF, similar
as epithelial cells. Our results remind that the endothelial cells EMT should be
paid more attention in the study of allograft arteriosclerosis.
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2264 REPERFUSION TOLERANCE OF ISOLATED ISCHEMIC
PORCINE KIDNEYS IMPROVED BY WARM PRESERVATION
AND ERYTHROPOIETIN
B. Yang1, S. Hosgood, A. Bagul, G. Bicknell, M. Nicholson
1
University Hospitals of Leicester, 2University of Leicester
Ischemia/reperfusion tolerance is important in kidney transplantation.
Erythropoietin inhibits apoptosis and inflammation, and provides renoprotection.
This study investigated the effects of different preservation methods on
reperfusion tolerance of kidneys. Porcine kidneys subjected to 10-minutes
ischemia were preserved by four approaches: 16-hours cold storage (CS)
followed by 2-hours warm preservation (WP) ± 5000 units/L erythropoietin; or
18-hours CS ± 5000 units/L erythropoietin, and assessed by haemoreperfusion
for 3 hours on an isolated organ perfusion system. All parameters were measured
on termination of CS, WP and reperfusion. Both WP and reperfusion increased
caspase-3 activity, the expression of heat shock protein 70, apoptosis in tubular
areas (excluding kidneys preserved by 18-hours CS), tubular lumens and the
interstitium compared with CS kidneys. The presence of erythropoietin in WP
further raised caspase-3 activity and apoptosis in tubular lumens, sustained
interstitial apoptosis and reduced tubular apoptosis; also subsequently improved
tubular vacuolation and interstitial expansion, oxygen consumption and renal
blood flow after reperfusion. Erythropoietin increased urine production more
than renal blood flow. WP and erythropoietin improved reperfusion tolerance
and early renal structure and function over that seen in CS alone. This was
probably through caspase-3 activation, HSP70 induction and subsequently
improved clearance of inflammation and damaged cells.
Caspase-3 activity (pmol
AMC liberated/min/ug
protein)

Apoptosis in tubules
(400× field)

Apoptosis in tubular
lumen (400× field)

Apoptosis in interstitium
(400× field)

pre3hR

pre3hR

pre3hR

pre3hR

post3hR

post3hR

post3hR

16hCS+ WP 0.048 ± 0.017 0.045 ± 0.018 0.15 ± 0.04 1.34 ± 0.21 1.65 ± 0.33 0.58 ± 0.11 0.58 ± 0.08

post3hR
1.75 ± 0.31

16hCS+
(WP+EPO)

0.114 ± 0.021 0.070 ± 0.018 0.03 ± 0.02 0.94 ± 0.25 2.35 ± 0.72 0.31 ± 0.06 0.52 ± 0.23

2.83 ± 0.53

18hCS

0.009 ± 0.001 0.069 ± 0.024 0.07 ± 0.03 0.27 ± 0.17 0.03 ± 0.02 0.64 ± 0.03 0.20 ± 0.09

1.58 ± 0.93

(18hCS+
EPO)

0.010 ± 0.003 0.09 ± 0.015

1.26 ± 0.64

0.08 ± 0.06 1.73 ± 0.66 0.05 ± 0.04 1.73 ± 0.66 0.10 ± 0.03

% of SCr
fall

HSP70 (OD*mm2)

Renal blood flow
(ml/min/100g)

Oxygen consumption
(ml/min/g)

Urine output (ml/h)

post3hR

pre3hR

post3hR

pre3hR

post3hR

pre3hR

post3hR

pre3hR

64.3 ± 7.0

31.1 ± 2.6

18.5 ± 3.1

75.9 ± 9.6

70.5 ± 6.7

40.6 ± 5.6

39.4 ± 4.0

76.3 ± 19.6

53.7 ± 18.9

59.5 ± 4.6

31.3 ± 2.3

34.6 ± 10.7

73.6 ± 6.0

74.3 ± 6.6

41.1 ± 4.1

45.4 ± 4.0

155.0 ±
18.2

92.5 ± 20.9

43.8 ± 5.3

11.2 ± 1.3

34.7 ± 9.5

38.2 ± 6.3

23.7 ± 4.8

36.5 ± 13.2

51.8 ± 3.3

13.3 ± 3.3

34.8 ± 8.0

60.0 ± 12.2

24.1 ± 3.7

88.8 ± 14.4

post3hR
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2265 RENAL ISCHEMIA AND REPERFUSION INJURY LEADS
TO SYSTEMIC INFLAMMATION RESPONSE INVOLVING
PULMONAR DYSFUNCTION

THURSDAY

G. Campanholle1, R. Landgraf1,2, V.N. Paiva1, J.O. Martins1, P.H.M. Wang1,
R.M.M. Monteiro1, R.C. Silva2, A. Pacheco-Silva2, S. Jancar1,
N.O.S. Camara1,2
1
Universidade De São Paulo, 2Universidade Federal de São Paulo
Introduction: Renal ischemia and reperfusion injury (IRI) is the mainly
cause of acute renal failure (ARF) in native and transplanted kidneys. The
inflammation plays a major role in its pathophysiology. ARF is frequently
combined with adult respiratory distress syndrome (ARDS) and associated
with high mortality.
Aim: To study the pulmonary inflammatory systemic response after renal IRI.
Methods: Male C57Bl/6 mice were subjected to 45 min of bilateral renal
ischemia, followed by 4, 6, 12, 24 and 48h of reperfusion. Blood was collected
to measure serum creatinine. Bronchoalveolar lavage fluid (BAL) was
collected to determine the number of cells. Expressions of iNOS and COX-2 in
lung were determined by Western blot. Gene analyses were quantified by real
time PCR. Results: Serum creatinine increased in IRI group compared to sham
mainly at 24h after IRI, (2.57±0.16 vs 0.43±0.07, p<0.01).The total number
of cells in BAL fluid was higher in IRI group in comparison with sham, with
12h (100x104 ±15.63 vs 29.5x104 ±10.5, p<0.05), 24h (117.3x104 ±8.94 vs
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30.5x104 ±3.5, p<0.05) and 48 hours (87x104 ±15.72 vs 34x104 ±4.2, p<0.05),
mainly by mononuclear cells and neutrophils. Pulmonary COX-2 and iNOS
were up regulated in IRI group in comparison with sham (COX-2 1084±97.09
vs 129±10 AU; iNOS 1172±126.2 vs 529±59 AU). IRI group had an increase
in IL-1â expression (2.97±0.57, p<0.05) and MCP-1(2.27±0.46) and a decrease
in IL-4 (0.52±0.07, p<0.05), in comparison to sham group.
Conclusion: Renal IRI induces an inflammatory systemic response that
reaches lung increasing cell infiltration, up regulating COX-2 and iNOS and
a Th1 cytokine profile.
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2266 ISCHEMIA/REPERFUSION OF THE PANCREAS
INDUCED HYPERRESPONSIVENESS OF THE AIRWAYS IN
RATS
D. Wang, C-F. Chen1, F-J. Leu
1
Department of Medicine, Cheng Hsin General Hospital, 2Department of
Medicine, Fu Jen Catholic University, 3Department of Pathology, Catholic
Cardinal Tien Hospital
Objectives: Ischemia-reperfusion (I/R) of the rat¡¦s pancreas induced acute
pancreatitis with systemic inflammatory response syndrome. Activated
inflammatory cells sequestered in the lung and the proteases released from the
inflammatory pancreas both could induce lung inflammation and lung injury.
Methods: Ischemia was induced by clamping off the gastroduodenal artery
and the splenic artery for 2 hrs to induce ischemia of pancreas, followed by
reperfusion for 6 hrs and then observed the airways reactivity to methacholine.
Pulmonary function tests including Penh and airway resistance were used as
parameters to reflect the airway responses. mRNA expression of iNOS and
TNF£\ in lung tissue were measured after the experiments.
Results: This protocol resulted in elevation of the blood NO (p<0.01), amylase
(p < 0.001) and white cells (p<0.01) in the I/R group. The mRNA expression
of iNOS and TNF£\ in the lung tissues were significantly increased after I/R.
Pulmonary function data showed that I/R of the pancreas induced significant
increases in the responses to methacholine challenge: Penh and airway resistance
were significant increases in I/R group when compared with sham group.
Discussion and Conclusions: I/R of the pancreas induced systemic
inflammatory responses and increased white cells sequestered in the lung.
Hyperresponsive response in the airways of the reperfusion group could be
related the inflammatory response, increased white cells sequestered and the
expressions of the inflammatory mediators of iNOS and TNF£\.
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2267 PROTECTIVE ROLE OF MACROPHAGE STIMULATING
PROTEIN ON RENAL TUBULAR EPITHELIAL CELLS:
RELEVANCE FOR REGENERATION AFTER DELAYED
KIDNEY GRAFT FUNCTION
V. Cantaluppi1, F. Figliolini2, S. Beltramo2, G.M. Romanazzi2, D. Medica2, M.
Migliori3, C. Mannari3, L. Biancone1, G.P. Segoloni1, G. Camussi2
1
Renal Transplantation Unit, University of Torino, 2Centre for Experimental
Medical Research (CeRMS), University of Torino, 3Department of
Neuroscience, Section of Pharmacology, University of Pisa
Delayed graft function (DGF) is a form of acute renal failure in the early posttransplantation period after ischemia-reperfusion injury that is characterized by
histological signs of tubular injury and by an increased risk of acute rejection
due to the enhanced cell immunogenicity. DGF, together with other immune
and non-immune causes, represents a risk factor for the development of chronic
allograft nephropathy. For these reasons, the identification of new growth
factor-based therapeutic strategies aimed to improve tubular regeneration may
avoid or decrease DGF, therefore promoting long term kidney graft function.
Macrophage stimulating protein (MSP) belongs to the plasminogen-related
growth factors family and exerts proliferative and anti-apoptotic effects on
different cell types after binding to its specific receptor, the tyrosine kinase
RON. However, little is known about the biological activity of MSP in the adult
human naïve and transplanted kidneys.
In this study, we evaluated the plasmatic levels of MSP in uremic patients before
and at different time points after kidney transplantation and the activation of
the MSP/RON pathway in tubular regeneration in an experimental rat model
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of kidney ischemia/reperfusion injury. In vitro, we studied the biological
effects of MSP in human proximal tubular epithelial cells cultured in different
experimental conditions.
MSP plasmatic levels were elevated in renal allograft recipients in the first week
after transplantation in association with tubular regeneration after ischemia/
reperfusion injury. MSP subsequently declined at basal levels after eight weeks,
when renal function became stable. MSP and RON were markedly up-regulated
in the regenerative phase following ischemia-reperfusion injury in rats. In vitro,
MSP elicited proliferation and resistance to hypoxia-induced apoptosis in human
tubular epithelial cells through the inhibition of caspases. MSP stimulated
migration, scattering, branching morphogenesis and tubulogenesis in vitro and
in vivo. In addition, MSP induced de-differentiation of surviving tubular cells
leading to an enhanced expression of the mesenchymal marker vimentin and to
the re-expression of Pax-2, an embryonic gene crucial for kidney development.
In conclusion, the MSP/RON pathway was up-regulated during the regeneration
of injured tubular cells. Furthermore, MSP exerted multiple in vitro biological
effects beneficial for the recovery from acute tubular injury. These results
suggest a potential therapeutic application of MSP to avoid or to limit the
duration of DGF in transplanted kidneys.
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2268 BENEFICIAL EFFECTS OF CARBON MONOXIDE ON
ISCHEMIA-REPERFUSION INJURY OF LUNG IN MINIATURE
SWINE
H. Sahara, M. Oku, M. Okumi, K. Setoyama, A. Shimizu, K. Yamada
Frontier Science Research Center, Kagoshima University
Background: Carbon monoxide (CO) is produced endogenously as a byproduct
of heme catalysis, and has been shown to provide protection against ischemiareperfusion injury (IRI) in a variety of organs in murine models. Since CO
is also known to be a toxic gas, translational research using large animals is
essential prior to its use in the clinic. We developed an in situ lung model of
warm IRI in miniature swine, and evaluated the cytoprotective effects of lowdose inhaled CO in this model.
Methods: Eight miniature swine were evenly divided into two groups (CO-treated
and control group). In both groups, warm ischemia was induced for 90 minutes
by clamping the left pulmonary artery and veins. Simultaneously, the left main
bronchus was dissected; it was reanastomosed just prior to reperfusion. One group
(CO-treated group) of animals was additionally treated with inhaled CO at a
concentration of 250 ppm throughout the procedure. Lung function and structure
were serially assessed via blood gas analysis, chest X-ray (CXR) and lung biopsy.
Results: In the control group, 90 minutes of warm ischemia resulted in
a significant decrease PaO2, and one animal died 4 hours after reperfusion
due to severe pulmonary edema. In the CO-treated group, COHb levels were
maintained at 12.1 +/-0.3% without apparent adverse effects. CO inhalation
dramatically decreased lung injury associated with ischemia and reperfusion.
Two hours after reperfusion, the PaO2 of the CO-treated group was 454 +/-34
mmHg, almost double the PaO2 of the control group (227 +/-57 mmHg).
In the control group, biopsies taken at two hours after reperfusion showed
inflammatory cell infiltrates, consisting mainly of neutrophils, with intraalveolar edema. Biopsies 2 days after transplant showed persistence of the
neutrophil infiltrates in alveolar capillaries and pulmonary arterioles with
accompanying alveolar hemorrhage and fibrin deposition. In contrast, the COtreated group had a marked reduction in the degree of neutrophil cell infiltrates
and intra-alveolar edema at these time points. Electron microscopy also
revealed decreased endothelial cell injury in the CO-treated group. Sequential
measurements of systemic early phase cytokines IL-1ƒÀ and IL-6 showed that
the concentrations of these proteins were markedly lower in the CO-treated
group 2 days after reperfusion (IL-1ƒÀ: 9 +/-4 vs. 43 +/-9 pg/ml; IL-6: 2.1
+/-1.5 vs. 30 +/-9 pg/ml). High-mobility group box 1 (HMGB1), recently
reported to be an important early mediator of inflammation and cell injury, was
also significantly lower in the CO-treated group 2 days after reperfusion (0.04
+/-0.1 vs. 14 +/-6 ng/ml).
Conclusions: To our knowledge, this is the first demonstration of the beneficial
effects of CO on Ischemia-Reperfusion Injury of the lung in a large animal
model. The perioperative administration of low-dose inhaled CO decreases warm
ischemic-reperfusion injury in lungs in miniature swine. This protective effect is
mediated in part by the downregulation of pro-inflammatory mediators that are
associated with inflammatory cell infiltration and endothelial cell damage.
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2269 BILIRUBIN AND BILIVERDIN DI-TAURATE FOR THE
TREATMENT OF RENAL ISCHEMIA REPERFUSION INJURY
R. Öllinger1, M. Thomas2,3, F. Bösch1, C. Koidl1, P. Kogler1, R. Sucher1,
J. Troppmair1, F. Bach2, R. Margreiter1
1
D. Swarovski Research Laboratory, Surgery, Medical University of
Innsbruck, 2Immunobiology Research Center, Surgery, Harvard Medical
School, 3Surgery, Ludwig-Maximilians-University Munich
Introduction: Heme Oxygenase-1 (HO-1) is playing a crucial role in ischemia
reperfusion injury (IRI). HO-1 degrades heme into carbon monoxide, free iron
and biliverdin, which subsequently is converted to bilirubin by the enzyme
biliverdin reductase. Experimentally both, biliverdin and bilirubin, at least in
part, account for the protective effects mediated by HO-1. In order to develop
strategies how to potentially clinically use the bile pigments for the treatment/
prevention of IRI, we tested conjugated, thus water soluble, forms of bilirubin
and biliverdin at various doses and time points in a model of warm renal IRI
and a model of kidney transplantation in rats.
Methods: Renal arteries of contralaterally nephrectomized Wistar rats were
clamped for 45 minutes prior to reperfusion. Further, Wistar rat kidneys were
transplanted after 18 hours of cold ischemia into isogenic recipients. Animals
were treated with saline (as a control) or various doses of bilirubin or biliverdin ditaurate, applied as three i.v. injections covering the perioperative period or a single
injection given either before or after reperfusion. Serum total bilirubin was assessed
five minutes and serum urea and creatinine was assessed 24 hours after reperfusion
(n=4 in each group). Activation of mitogen activated protein kinases (MAPK) has
been assessed by western blot and measurement of optical densities.
Results: Perioperative and preoperative treatment with bilirubin di-taurate at
3, 10 and 30 but not 1mg/kg resulted in a significant increase in serum total
bilirubin levels after reperfusion (p<0,0001 vs. control). Similarly, treatment
with biliverdin di-taurate prior to reperfusion increased serum total bilirubin
(p<0,0001 vs. control). The increase in serum total bilirubin was associated
with significantly lower serum creatinine and urea levels at 24 hours after
reperfusion as well as substantial changes in MAPK activation in the clamp
model when compared to the control (p<0,05) with no significant difference
within the various doses. However, when the bile pigments were applied post
reperfusion, no effect on kidney function was being observed. In the transplant
model, application of biliverdin di-taurate at 30mg/kg but not at 3 or 10mg/kg
significantly improved kidney function when compared to the control (p<0,05).
Summary. Intravenous application of water soluble bilirubin and biliverdin
di-taurate is feasible and effective in improving kidney function after renal
IRI. Bilirubin serum levels should be increased prior to reperfusion in order
to achieve sufficient renoprotection. Bilirubin and biliverdin di-taurate may
become a valuable tool to improve outcome after kidney transplantation.
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2270 PROLONGED WARM RENAL ISCHEMIA IN RATS
UNDER CONTROLLED INHALATION ANESTHESIA
RESULTS IN HIGHER SURVIVAL RATES THAN EXPECTED:
IMPLICATIONS FOR RENAL ISCHEMIA-REPERFUSION
STUDY DESIGN
R. Raman1,2, C. PIvetti3, R. Ramsamooj4, D. Matthews1,2, S. Demos1,5, C.
Troppmann3
1
University of California, Davis, Center For Biophotonics, Sacramento, CA
95817, 2University of California, Davis, Dept of Applied Science, Davis, CA
95616, 3University of California, Davis, Dept of Surgery, Sacramento, CA
95817, 4University of California, Davis, Dept. of Pathology, Sacramento, CA
95817, 5Lawrence-Livermore National Laboratory, Livermore, CA 94550
Introduction: Until now, most rat renal warm ischemia-reperfusion models have
been designed based on expected animal survival rates of ~50% if warm ischemia
time (WIT) exceeds 60 min (e.g., Jablonski et al., Transplantation 1983; 35:198;
and Togashi, Acta Pathol Jpn 1982; 32:749). Most prior studies, however, relied on
intraperitoneal anesthetic agent (e.g., pentobarbital) delivery, which is associated
with unpredictable absorption and highly variable systemic effects. Currently,
technological advances coupled with more stringent animal care regulatory
requirements are leading to increased use of inhalation anesthesia—even in
rodents. The impact of these more advanced anesthetic methods with significantly
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improved delivery control is unknown and may be associated with less significant
systemic (e.g., hemodynamic) side effects. These changes in practice may be
particularly relevant during post-ischemic renal recovery, and may decrease animal
mortality from renal dysfunction. We studied rat survival after prolonged WIT
under controlled-delivery isoflurane anesthesia in several strains.
Methods: Following laparotomy, we subjected Sprague-Dawley (SD), WistarFurth (WF), Dahl salt-sensitive (DS), and Spontaneously Hypertensive Rat (SHR)
rats to 150 min unilateral renal WIT (by complete renal vascular occlusion),
subsequent reperfusion, and immediate contralateral nephrectomy. General
anesthesia was induced by inhaled isoflurane delivered by a calibrated vaporizer
(inspired maintenance isoflurane concentration: 1.25% to 2%; 90% O2). Rat survival
was monitored for up to one month, when all surviving animals were euthanized.
Autopsies were done to determine cause of death. Rat survival (censored for deaths
from surgical complications) was calculated according to Kaplan-Meier.
Results: (see Table 1)
Conclusions: Advanced controlled-delivery anesthesia methods and rat strain
both had a profound effect on long-term rat survival after extreme renal WIT. Our
findings suggest that (i) rat strain selection for experimental protocols that involve
warm ischemic renal injury is paramount, and (ii) with increasing implementation
of clinical anesthesia techniques, experimental protocols for inducing renal warm
ischemia injury in rats must be re-designed. These recommendations will allow
to continue to devise experimental protocols with intermediate survival rates
which are necessary to conduct meaningful studies.
Strain
SD
WF
DS
SHR

n
12
6
9
10

Table 1.
Rat Survival [# days]
4**,4, 5, 6, 8, 10, 30, 30, 30, 30, 30, 30
5, 5, 30, 30, 30, 30
8, 9, 30, 30, 30,30, 30, 30, 30
4, 4, 5, 5, 5, 5, 5, 5, 6, 8

30-day Survival Rate*
55%
67%
78%
0%

*: p<0.01 for SHR vs. SD, WF, DS
**: death due to surgical complication
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2271 GLYCINE PRE-TREATMENT REDUCES THE PORTAL
VEIN PRESSURE AND IMPROVES INITIAL LIVER FUNCTION
AFTER SUBTOTAL HEPATECTOMY IN THE RAT
Y. Gu1, U. Rauen2, F. Saner3, J. Sowa4, S.Y. Shue5, J.F. Schlaak6
Department of General, Visceral And Transplantation Surgery, 2Institute
of Physiological Chemistry, University Hospital of Essen,, 3Department
of General, Visceral And Transplantation Surgery, 4Department of
Gastroenterology and Hepatology, University Hospital of Essen,, 5Institute of
Pathology und Neuropathology, University Hospital of Essen,, 6Department of
Gastroenterology and Hepatology, University Hospital of Essen,
Aims: It is known that Kupffer cells (KC) can be activated during liver
resection and liver graft harvest. Activated KC releases numerous mediators of
inflammation and potent vasoconstrictors, leading to hepatic microcirculatory
failure and increasing portal vein pressure. The amino acid glycine has been
shown to inhibit the activation of KC and thus, possibly reduce KC mediated
hepatocyte damage. We therefore investigated the influence of glycine pretreatment on the outcome after subtotal partial hepatectomy (PH) in the rat.
Methods: Male Wistar rats (250-300g) were used. Animals were pre-treated with
glycine (5% glycine in rat chow) 5 days prior to operation. Resection of 90% of liver
mass was then performed. Rats receiving 90% PH without glycine pre-treatment
and sham operation were used as control groups. Animals were sacrificed at 2 or 6
hours after hepatectomy. Portal vein pressure was monitored and blood was taken
for analysis of initial liver function prior to sacrifice. Liver tissue was snap-frozen
in liquid nitrogen and fixed in formalin for subsequent histological analysis.
Results: A significant decrease in portal pressure 2 hours after PH in the glycine
pre-treated animals was found (12.7±0.77 cmH2O in 90% PH with glycine pretreated group; 14.6±1.66 cmH2O in 90% PH group (p<0.05); 9.7±0.26 cmH2O
in sham-operated group). Significantly lower levels of alkaline phosphatase
(AP) and prothrombin time (PTT) were shown in the glycine pre-treated group
at both 2 hours and 6 hours postoperatively (p<0.05). Nuclear factor kappa B
(NF-KB) was also less activated 6 hours after hepatectomy in the treatment
group (p<0.05).
Conclusions: Subtotal hepatectomy induced severe liver damage and increased
portal vein pressure. This damage can be reduced through glycine pretreatment. The
inhibition of the activation of NF-KB in KC might contribute to the effects observed.
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2272 ENDOTHELIAL PROGENITOR CELLS (EPC) HOME TO
ISCHEMIC KIDNEYS FOLLOWING ISCHEMIA REPERFUSION
INJURY (IRI)
T. Matthews1, W. Sun2, N. Rogers1,3, S. Sen1,3, C. Bonder2, P. Coates1,3,4
Department of Nephrology And Transplantation Services, The Queen
Elizabeth Hospital, 2Hanson Institute, Institute of Medical and Veterinary
Sciences, Adelaide, 3Department of Medicine, University of Adelade, 4Center
for Stem Cell Research, University of Adelaide.
Introduction: EPC are a subset of peripheral blood cell stem cells that contribute
to vascular repair and angiogenesis following vascular injury or ischemia. IRI
is an inevitable consequence of organ transplantation contributing significant
allograft damage. Following renal transplantation IRI commonly leads to the
development of acute tubular necrosis (ATN) which is closely associated with
the development of delayed graft function (DGF). DGF, ATN and the onset of
acute allograft rejection are all major predictors of poor graft outcome. Whilst
most of the injury in the kidney has focussed on the tubular compartment,
intra renal vascular injury is also plays a significant role in the renal injury. We
hypothesised that EPC would be recruited to murine vascular compartment of
kidneys subjected to IRI.
Methods: EPC were derived from the tibia and femur bone marrow of C57B6
mice and cultured in 20% fetal calf serum for 4 days on fibronectin coated
plates at 1.5 x 105 cells/cm2. Non-adherent cells were removed after 24 hours.
In a typical experiment 1 mouse yielded 6 x 107 EPC. Purity was assessed by
the presence of the lin-, sca1+ and ckit+ lineage and development into endothelial
cells 10 days post seeding. IRI was induced in syngeneic C57B6 mice by
occluding the left renal pedicle for 30 minutes using a microvascular clamp. 1
x 107 EPC were labelled with CarboxyFluoroscein Succinimidyl Ester (CFSE),
washed and injected intravenously following reperfusion. SHAM operated
animals were injected with EPC but were not subjected to renal ischemia. After
24 hours left and right kidneys were removed and analysed by flow cytometry
following enrichment by Ficoll gradient and immunohistochemistry.
Results: Mice subjected to 30 minutes IRI developed typical changes of ATN,
characterised by histological damage, upregulation of mRNA for heat shock
protein 70 (HSP70) and toll like receptor 4 (TLR4). In kidneys subjected to 30
minutes ischemia a small but distinct population of CFSE labelled cells were
identified in kidney lysate (n= 5) from ischemic but not contralateral kidneys
(n=7). In contrast no CFSE labelled cells were identified in SHAM operated
kidneys (n=3). Using Zeiss Apotome fluorescence microscopy, CFSE labelled
cells were easily identified within the glomeruli and peritubular regions in
ischaemic kidneys but only occasional cells were identified in contralateral
controls. CFSE labelled cells colocalised with the vascular adhesion molecule
PECAM, suggesting the incorporation of EPC into ischaemic damaged vessels
both in renal cortex and medulla.
Conclusions: We show for the first time EPC home to ischemic kidney
following IRI, incorporating in both vascular and tubular compartments of
the kidney. Manipulation of EPC recruitment may provide a novel pathway to
modulate repair of ischemic organs following reperfusion.
1
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2273 THE FIBRIN DERIVED PEPTIDE BÂ15-42 AMELIORATES
ORGAN FUNCTION IN AN EXPERIMENTAL RAT MODEL OF
KIDNEY ISCHEMIA REPERFUSION INJURY
S. Scheidl1, D. Wiedemann2, S. Schneeberger1, F. Peter3, N. Wick4,
K. Zacharowski5, R. Margreiter1, G. Laufer2, P. Petzelbauer3, S. Semsroth2
1
Dept. of General And Transplant Surgery, Innsbruck Medical University,
Austria, 2Dept. of Cardiac Surgery, Innsbruck Medical University, Austria,
3
Dept. of General Dermatology, Vienna Medical University, Austria,
4
Dept. of Clinical Pathology, Vienna Medical University, Austria, 5Dept. of
Anaesthesia, Duesseldorf University Medical Center, Germany
Backgorund: The shortage of available organs has led to widespread use of
extended criteria and nonheart-beating donor (NHBD) grafts. Graft infiltration
by recipient leukocytes is one of the key mechanisms of ischemia-reperfusion
injury (IRI). The fibrin derived peptide Bbeta15-42 has been shown to attenuate
leukocyte infiltration in various models by inhibiting the transmigration process.
Previous work in experimental heart transplantation and myocardial infarction
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models suggest that Bbeta15-42 is capable of reducing cardiac IRI. The aim of
the current study was to assess the effects of Bbeta15-42 in rat kidney IRI.
Material and Methods: Male Lewis rats (250-300g) underwent median
laparotomy with removal of the right kidney, followed by clamping of the
left renal artery for 60 min. Animals were divided into two control and two
treatment groups, with 24 hours and 7 days observation periods, respectively.
Treatment group animals received 1,2mg Bbeta15-42 intravenously at two
separate timepoints (, one minute prior to and one minute after removal of
the arterial clamp). Serum samples for the evaluation of creatinine and BUN
levels were collected at several time points. Kidneys were harvested at the end
of the observation period for follow-up histologic, immunohistochemical and
molecular biological analyses.
Results: Over the course of the reperfusion period we could observe, that 60
min of ischemia leads to a pronounced increase in creatinine and BUN levels
with values peaking at day 2. After day 2 renal function starts to recover,
reaching normal levels on day 7 again. Administration of Bbeta15-42 led to
a marked reduction of creatinine and BUN levels, with normal levels detected
of which was significant by day 2 and day 5. In fact, animals receiving
Bbeta15-42 displayed normal creatinine and BUN levels over the course of the
entire observation period.
Conclusion: Our experiments provide evidence that Bbeta15-42 is a promising
agent for minimizing renal ischemia-reperfusion injury and for the preservation
of early graft function.
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2274 THE FIBRIN DERIVED PEPTIDE B-BETA15-42
AMELIORATES ISCHEMIA-REPERFUSION INJURY AFTER
HEART TRANSPLANTATION IN RATS
D. Wiedemann1, S. Schneeberger2, P. Friedl3, N. Wick4, F. Bösch2, K.
Zacharovski5, P. Petzelbauer3, R. Margreiter2, G. Laufer1, S. Semsroth1
1
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3
Department of General Dermatology, Vienna Medical University,
4
Department of Clinical Pathology, Vienna Medical University, 5Department
of Anesthesia; University Hospital Duesseldorf
Purpose: Ischemia-reperfusion injury still represents one of the major problems
in solid organ transplantation. On one hand it is associated with primary nonfunction, on the other with delayed function of transplanted organs which
goes along with increased rates of acute and chronic rejection episodes. The
inflammatory response after ischemia and reperfusion is caused by leukocytes
migrating from the bloodstream into graft tissue. The fibrin derived peptide
B-beta15-42 has been shown to reduce leukocytemigration by inhibiting
the transmigration process. The purpose of our study was to investigate the
protective effect of B-beta 15-42 on ischemia reperfusion injury in a rat heart
transplant model.
Methods and Materials: Hearts of male Lewis rats (250-300g) were flushed
with chilled (0-1 C) Custodiol preservation solution and either transplanted
immediately or stored in the same solution for 4 or 8 h and then transplanted
into syngenic recipients. 1,2mg of B-beta15-42 were given i.v. immediately
after implantation of the heart or added to the preservation solution prior to
harvest. At 24h and 10d hearts were retrieved for histological evaluation and
MPO (myeloperoxidase) immunohistochemistry. At time of harvest, serum
samples were collected for troponin T level analysis. Pumpfunction of hearts
subjected to 8h of cold ischemia followed by 24h of reperfusion was evaluated
in an isolated working heart model (pressure-volume).
Results: Hearts transplanted immediately or after 4h of cold ischemia did
not show any morphological damage. In contrast 8h of cold ischemia showed
severe myocardial damage associated with an inflammatory response at 24h.
Lesions further progressed after 10d. Administration of B-beta15-42 resulted
in a significant amelioration of myocardial necrosis together with a reduced
leukocyte infiltration. The protective effect of the peptide was further underlined
by reduced troponin T levels in the treatment groups. The working heart
preparation showed poor cardial function in the control group. Administration
of B-beta15-42 resulted in a significant amelioration of graft function.
Conclusions: The fibrin derived peptide B-beta15-42 ameliorates I/R injury in
a rat heart transplant model and represent a promising drug for a clinical use.
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2275 LUNG ADENOMA DEVELOPMENT UNDER FTY720
TREATMENT
V. Bueno1, C.T. Lopes1, N.R. Salinas1, P.M. Cury2, C.T.F. Oshima1,
P.V.B. Palma3
1
UNIFESP – Federal University of Sao Paulo, 2FAMERP Sao Jose do Rio
Preto Medical School, 3FMRPUSP – Medical School
Background: FTY720 is a new compound whose main mechanism of action
has been associated with lymphocyte trapping in secondary limphoid organs
[1]. Experimental models of tumors are inhibited by FTY720 administration [2].
However, there is no report of FTY720 action in lung adenoma development.
Objective: To evaluate whether FTY720 plays any role in urethane-induced
lung cancer model.
Methods: BALB/c mice (male, 8-10 weeks old) were submitted to two doses
(1,5 mg/Kg/day) of Urethane (Ur) intraperitoneal administration. Mice received
a five-day course of FTY720 (1mg/Kg/day) orally starting immediately after
the last dose of Ur (G2), 30 days after Ur (G3) or were not treated (G1). Four
months after Ur administration mice were anesthetized and blood, spleen and
lungs were harvested. Blood leucocytes were counted and flow cytometry
for CD4+ splenocytes was performed. Lungs were stained (H&E) and their
histology evaluated for presence of lesions/nodules. Using a software for image
analysis, nodules and hyperplasia areas were measured. Lung sections were
evaluated for VEGF staining using immunohistochemistry.
Results: Ur-induced non-treated mice (G1) presented two deaths (34, 73 days)
whereas no mice died in FTY720-treated Groups during 120 days. FTY720
caused a decrease in blood lymphocytes (G2= 47.8±4.8, G3=45.9±6.5) when
compared to Ur (G1=67.5±2.6) and Control (69.3±4.4) p<0.005. On the
other hand, neutrophils increased in FTY720-treated mice (G2=50.4±5.1,
G3=50.1±5.1) in comparison with G1 (31.6±3.0) p<0.005. Monocytes were
higher in G3 (4.2±2.0) versus G1 (2.5±1.4), G2 (2.6±1.0) and Control (3.1±0.6).
Total lung lesions were similar in all groups (G1=2.5±1.3, G2=2.9±0.9,
G3=2.4±0.9) but nodules area was smaller in G3 (1661 ìm2) than in G1 (2184
ìm2) and G2 (2254 ìm2). Intense VEGF staining was observed in 67% of
nodules in G1, 16.5% in G2 and 47% in G3.
Conclusions: FTY720 prevented death caused by Ur-induced lung tumors. The
drug inhibited tumor area growth when administered 30 days after Ur injection
and decreased VEGF expression by tumor cells although it did not impair
lung nodules development. This finding was associated with lymphopenia and
decrease of CD4+ T cells in spleen, whereas in blood there was increase of
neutrophils and monocytes.
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2276 IMPACTS OF NKT CELLS ON CD4+CD25+T AND
CD4+CD25-T CELL PROLIFERATION IN VITRO
H-M. Zhou1,2, W. Huang2, X-K. Pei1, C. Liu1, J-M. Huang2, L-J. Xu2,
B-Y. Shi1, M. Cai1, Z-K. Chen2
1
Organ Transplantation Center, 2nd Affiliatted Hospital of Great Wall
Hospital of P.L.A., 2Institute of Organ Transplantation, Tongji Hospital,
Tongji Medical College, Huazhong University of Science and Technology. Key
Lab of Organ Transplantation of Ministry of Education and Health. Hubei,
430030, P.R.China.
Background: NKT Cells is a special member of immune system which
connects the innate and adaptive immune responses. Their complicated role
differs from case to case, according to the local and neighbor circumstances.
Resent research reported that NKT cells may be involved in CD4+CD25+ T cell
induction in vivo. This research focused on their impact on CD4+CD25+T cell
induction in single-way mixed lymphocyte culture (MLC) system in vitro.
Methods: Innate CD4+CD25+T cells, CD4+CD25-T cells from C57BL/6 mice
spleen were sorted by Flow cytometry (FacsAria, BD. LTD), as reactor, these
cells were stained with CFSE and 2×105 cells were seeded into 96 cell-plate at
a reactor/target ration 1/1, cultured with mitomycin pre-treated Balb/C mice
spleen cells (Bm), with or without the addition of CD3 and CD28 monoclonal
antibody. NKT cells from C57BL/6 mice spleen were sorted and added into
the single-way MLC system. namely, these cells were divided in 8 groups:
group 1, C57BL/6 CD4+CD25+T cells with Bm; group 2, NKT cell added
to cells as group 1; group 3, and 4, CD3 and CD28 monoclonal antibody
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added into system as group1, 2; group 5, C57BL/6 CD4+CD25-T cells with
Bm; group 6, NKT cell added to cells as group 5; g group 7, and 8, CD3 and
CD28 monoclonal antibody added into system as group5, 6. After 5 days, the
percentage of CD4+CD25+T cells, CD4+CD25-T cells among reactor cells and
the proliferation of the reactor cells were detected by FACS and analyzed by
Diva and ModFit LT software.
Results: The percentage of CD4+CD25+T, CD4+CD25-T cells increased
when added with NKT cells, and got even more higher with the addition of
CD3 and CD28 monoclonal antibody (see table 1, P<0.05); except that of
CD4+CD25+T from group 6 (decreased to 25.1% from 40% after NKT added)
and CD4+CD25-T cells from group 8 (decreased to 12.6% from 17.9% after
NKT added). The proliferation index of reactor cells decreased after NKT
addition (table 1).
Conclusion: From our preliminary data, we found that innate NKT cells from
C57BL/6 mice inhibited the reactor cells’ proliferation and involved in the
transdifferantiation of CD4+CD25-T and CD4+CD25+T cells of MLC system in
vitro, the functional impacts of NKT on these cells and the potent application
of this character of NKT needs further observation.
Table 1:
Percentage of CD4+CD25+T, CD4+CD25-T cells and the Proliferation Indedx of
the reactor cells in different groups.
Group
1
2
3
4
5
6
7
8

+

+

+

+

+

Compared to
group 1
Compared to
group 3
Compared to
group 5
Compared to
group 7

Note: 25+C57:CFSE stained C57BL/6 mice spleen CD4+CD25+ cells 25-C57:CFSE
stained C57BL/6 mice spleen CD4+CD25- cells Bm:mitomycin pre-treated Balb/C mice
spleen cells MA: CD3 and CD28 monoclonal antibody PI:Proliferation Index
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2277 THE MITOGEN-ACTIVATED PROTEIN KINASE
KINASE 1/2 (MEK1/2) INHIBITION AMELIORATES LIVER
TRANSPLANT ISCHEMIA-REPERFUSION (I/R) INJURY.

THURSDAY

S. Ueki1, N. Murase1, J. Yoshida1, Y. Koike1, N.G. Puttaraju1, L. Shao1,
R. Sugimoto1, A. Nakao1, D.B. Stolz2, D.A. Geller1
1
University of Pittsburgh Medical Center, Surgery, 2University of Pittsburgh,
Center for Biologic Imaging
Background: Hepatic I/R injury is a major risk factor significantly affecting
outcome of liver transplantation (LTx). Cold liver I/R injury is a robust
proinflammatory response involving a prompt activation of multiple signaling
pathways, including p38, ERK, and JNK MAPK pathways. To elucidate the
molecular mechanisms of hepatic I/R injury, current study investigated the
role of ERK1/2 MAPK pathways using selective upstream MEK1/2 inhibitor,
U0126.
Methods: Syngenic LTx was performed in LEW rats after 18-hr cold
preservation in UW solution. U0126 (50 μg/kg) was iv injected into recipients
at 30 min before and 5 min after reperfusion. Hepatic injury was assessed by
serum ALT levels and graft histopathology. Proinflammatory cytokine mRNA
(real time RT-PCR) and phosphorylated ERK1/2 MAPK (Western blot) were
analyzed. To determine the effects of U0126 on Kupffer cells, rat Kupffer cells
were isolated from the liver and stimulated with LPS (0.1 μg/ml) with and
without U0126.
Results: Cold preservation of liver grafts for 18 hrs resulted in severe
hepatic I/R injury with a marked increase of serum ALT levels at 24 hrs
and significant hepatic necrosis by 48 hrs. U0126 effectively reduced ALT
levels and hepatic necrosis (table). In untreated control liver grafts, rapid
phosphorylation (p) of p38, ERK1/2, and JNK MAPK pathways were
seen at 1 hr and subsided by 3 hrs. At the same time, proinflammatory
cytokine mRNA (TNF-α, IL-6) levels were upregulated at 1 hr in untreated
grafts. U0126 treatment significantly suppressed p-ERK1/2 expression.
Interestingly, however, beneficial effects of U0126 did not associate with
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Group

ALT 24h
(IU/l)

Necrotic area
(%)

TNF-α mRNA
(fold increase)

IL-6 mRNA
(fold increase)

control (DMSO)

5611±1697

30.1

10.4

28.5

U0126

1274±699

6.7

38.2

88.4

-

CFSE CD4 CD25 T/ CFSE CD4 CD25 T/ PI of Reactor cells
+
+
(CFSE cells)%
(CFSE cells)%
25+C57,Bm
49.76±0.69
28.2±0.75
54.10±1.10
51.73±0.64
32.4±0.66
69.26±1.10
25+C57,Bm,NKT
(P=0.022002)
(P=0.001897)
(P=0.007)
25+C57,Bm,MA
65.56±2.45
19.46±3.41
67.21±3.59
25+C57,
57.63±2.22
18±1.93
59.26±3.26
Bm,MA,NKT
(P=0.014)
(P=0.5526)
(P=0.04669)
25-C57,Bm
39.1±1.64
31.2±0.56
33.44±0.51
25.3±0.62
46.27±0.80
25.61±0.54
25-C57,Bm,NKT
(P=0.0017)
(P=0.001)
(P=0.005)
25-C57,Bm,MA
66.6±3.40
12.2±2.33
8.8±1.73
56.63±2.97
20.3±2.75
15.26±3.07
25-C57,Bm,MA,NKT
(P=0.01877)
(P=0.01761)
(P=0.03366)
MLC system

proinflammatory cytokine downregulation, and notably high mRNA levels
for TNF-α and IL-6 were seen in liver grafts. In in vitro study, U0126 did not
inhibit LPS-stimulated Kupffer cell production of NO and showed marginal
(20%) inhibition of TNF-α production.
Conclusions: These data suggest that ERK1/2 MAPK pathway plays a
significant role in hepatic I/R injury. As U0126 inhibits hepatic I/R injury
without effective proinflammatory cytokine downregulation, further
investigation is needed to elucidate the roles of ERK1/2 MAPK pathways in
hepatic I/R injury. This study provides valuable insightful information on the
molecular mechanisms of hepatic I/R injury.
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2278 EVALUATION OF FACTORS ASSOCIATED WITH COLD
ISCHAEMIC/WARM REPERFUSION INJURY IN HEPATIC
TRANSPLANT
H. Noujaim1, E. Montero2, C. Ribeiro1, V. Capelozzi3, R. Gomes1,
L. Curvello1, F. Crescentini1, M. Casagrande1, M. de Miranda1, T. Genzini1
1
HEPATO – Hospital Beneficencia Portuguesa De São Paulo, 2UNIFESP,
3
FMUSP
Introduction: Apoptosis has been considered the key mechanism of ischemia
/reperfusion in non-steatotic liver grafts. In liver transplant (LTx), cold
ischemia- warm reperfusion (CI/WR) injury is responsible for the release of
inflammatory mediators, such as ICAM-1, apoptosis and cellular necrosis.
Purpose: To analyse the mechanism of inflammatory response after CI/WR
injury in LTx, with special attention to apoptosis and ICAM-1 release.
Methods: Between Jan/06 and Feb/08 41 liver biopsies were performed
on back table time (pre reperfusion) and 2 hours after reperfusion (pos
reperfusion). The biopsies were assessed for the following histological features
(hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3),portal inflammation
(degree 0 – absent, I- mild, II- moderate, III– severe), parenchymal neutrophilic
infiltration (degree 0- absent, I –rare around zone 3, II-moderate in zone 3,
III- since zone 3 to1) and presence of apoptosis cells; steatosis was classified in
macro and/or microvesicular, and its degree classified as absent, mild (<30%),
moderate (30to59%), severe(≥60%). ICAM-1 and apoptosis were assessed by
the apoptosis index (TUNEL and Caspase-3 cleaved assays). Results significant
when p<0.05.
Results:
No biopsies

Pre reperfusion
(n=41)

Pos reperfusion
(n=41)

p

neutrophilic infiltration
degree 1
2+3

60%
12%

24%
72%

<0.001

Suzuki score
Degree 0

100%

80%

0.02

portal inflammation (I)

40%

52%

0.8

apoptosis
index(TUNEL)

0.14±0.11

0.21±0.1

0.01

apoptosis index
(Caspase-3 cleaved)

0.12±0.1

0.18±0.14

0.13

ICAM-1 Index

0.20±0.12

0.22±0.17

0.7

Conclusion: In LTx, after warm reperfusion, significant increases in the
parenchymal neutrophilic infiltration, Suzuki score and apoptosis index
(TUNEL assay) were observed. However, the migration of neutrophils,
presence of ICAM-1 and apoptosis process started at cold ischemia. Further
research must be carried out to develop agents to bloc the inflammatory
response initiated at cold ischemia in LTx.
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2279 ROLE OF ICAM-1 IN ISCHAEMIC/REPERFUSION
INJURY WHEN USING STEATOTIC GRAFTS IN LIVER
TRANPLANTS
H. Noujaim1, E. Montero2, C. Ribeiro1, R. Gomes1, V. Capelozzi3,
L. Curvello1, M. de Miranda1, T. Genzini1
1
HEPATO – Hospital Beneficencia Portuguesa De São Paulo, 2UNIFESP,
3
FMUSP
Introduction: In liver transplantation, during the cold ischemia/warm
reperfusion (CI/WR), liberation of ROS and cytokynes occurs and adhesion
molecules such as ICAM-1, resulting in increase of neutrophils adhesion,
apoptosis e necrosis cellular and consequently graft dysfunction. In steatotic
liver grafts this process is little known.
Purpose: to analyse the role of ICAM-1 in cold ischemia and warm reperfusion
(CI/WR) using steatotic and non steatotic grafts after LTx.
Patients and methods: this is a prospective study performed between
May/02 and Feb/08. In 115 LTx liver biopsies were collected 2 hours after
graft reperfusion. The biopsies were assessed for the following histological
features (hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3), portal
inflammation (degree 0 – absent, I- mild, II- moderate, III– severe),
parenchymal neutrophilic infiltration (degree 0- absent, I –rare around zone
3, II-moderate in zone 3, III- since zone 3 to1) ; steatosis was classified
in macro and/or microvesicular, and its degree classified as absent, mild
(<30%), moderate (30to59%), severe(≥60%). ICAM-1 was assessed by
the ICAM-1 index. The 115 LTx were divided according to their steatosis
degree in 4 groups: absent –ASG (n=36), mild –MSG (n=36), moderateMoSG(n=26), severe – SSG(n=17). Macrosteatosis were predominantly
present in mild – G1(n=10) and moderate+severe- G2+3 (n=12), and
microsteatosis in mild-G1 (n=29) and moderate+severe- G2+3 (n=24),
and 4 cases presented macro and microsteatosis simultaneously. Results
significant when p<0.05.
Results: The macrosteatosis groups presented ICAM-1 index in G1= 0.20±0.14
and G2+3 = 0.21±0.11 (p-0.8) and the microsteatosis in G1 = 0.17±0.15 and
G2+3= 0.26±0.18 (p-0.13).
No LTx

MoSG(n=26) SSG(n=17)

ASG(n=36)

p

neutrophilic infiltration 42%
(II + III)

MSG(n=36)

55%

68%

56%

0.4

ICAM-1 index

0.21±0.18

0.27±0.15

0.18±0.13

0.3

0.19±0.14

Conclusion: There was no significant difference among the groups (steatosis vs
non-steatotic) regarding neutrophils infiltration and ICAM-1 index, but severe
steatosis group and microsteatosis (>30%) had high ICAM-1 index than others.
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2280 LYMPHOCYTIC INVOLVEMENT IN WARM ISCHAEMIC
REPERFUSION INJURY
M. Martyn1,2, B. Loveland1,3, P. Crawly2, R. Jones1,2
1
University of Melbourne, 2Austin Hospital, 3Burnett Institute
Warm ischaemic reperfusion injury, in a non-transplant setting, usually
involves an inflammatory response. Monocytes and neutrophils are considered
the usual effectors. TNF and interleukin cytokines are believed to mediate
this response. However, very little attention has focused on lymphocytes and
their role in warm ischaemic injury in a non-transplant setting. Our study
investigated the presence of lymphocytes within a 24 hour period following
warm ischaemic-reperfusion injury of rat livers in a non-transplant setting, and
compared that with syngeneic and allogeneic transplants monitored at 24 hours
post operative.
Method: Hepatic surgery was conducted on Sprague Dawley rats. A vertical
abdominal incision was made to expose the liver, and the infra-hepatic vena
cava, supra-hepatic vena cava and the hepatic artery were clamped for either
15 or 30 minutes. Rats were sacrificed at 0, 2, 6, 12 or 24 hours post ischaemia;
total N = 15. For transplants, Lewis rat livers were harvested, stored in UW
solution for 1 hour or 24 hours flushed with saline and transplanted to DA
rat recipients and sacrificed at 24 hours post transplant. Livers were fixed,
embedded and H&E staining was conducted. Liver sections were coded and
assessed double blinded for injury and lymphocytic infilitration using the Banff

scoring system.
Results: Non-transplanted livers that had a 30 minute ischaemic event had an
average Banff score of 6, whereas 15 min ischaemia lead to a score of zero.
The livers that had a positive Banff score, had venulitis, bile duct infiltrate and
portal infiltrate, but the profiles differed at the progressive observation points.
Transplanted livers assessed after 24 hours showed mild rejection in livers
stored for 1 hour and severe rejection in livers stored for 24 hours.
Discussion: These findings suggest that lymphocytes may be involved
in warm ischaemic injury in a non-transplant setting. It also suggests that
their involvement is dependent on the severity of the ischaemic injury. The
appearance of lymphocytes at 2 hours post ischaemia and their disappearance
at 6 hours post ischaemia suggests that their involvement is transient in the
absence of alloantigens.
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2281 COMPARISON BETWEEN ELISA-CROSSMATCH
AND THE CLASSICAL MICROLYMPHOCYTOTOXICITY
CROSSMATCH ASSAY
J. Mytilineos, K. Pabst, H. Schrezenmeier
University Hospital of Ulm, Transplantation Immunology Laboratory
Pre-transplant crossmatches are routinely performed by the complement
depended cytotoxicity assay (CDC). This method, however, has several
drawbacks among which is also the fact that no differentiation between
antibodies against HLA-class I and class II antigens is possible. In contrast,
antibody screening can be performed by solid phase assays (SP), like ELISA
or Luminex, and allows precise and sensitive definition of antibodies,
both against class I and class II HLA molecules. SP-screening and CDC
crossmatch may therefore lead to conflicting pre-transplant crossmatch
result interpretation. Recently, ELISA based crossmatch techniques became
commercially available. We compared CDC and ELISA crossmatch results
of 20 sera from kidney transplant waiting list patients which were tested
against T- and B-cells of 4 different donors. A total of 160 crossmatch assays
with each method were performed. In discrepant cases additional tests with
DTT as well as ELISA based antibody specificity identification assays were
performed. 69 of the 80 (86.3%) crossmatch tests against HLA-class I targets
were concordant between CDC and ELISA. 7 cases were CDC positive/
ELISA negative. Of those 3 had DTT reactive antibodies (IgM) whereas
another 3 showed non-donor specific ELISA-screening detectable antibodies.
In one case (1,25%) the discrepancy remained unresolved. In 4 cases a
CDC negative/ELISA positive result was obtained. All four cases showed
ELISA detectable donor specific antibodies. 54 of the 80 (67.5%) crossmatch
assays against B-cells/HLA-class II targets were concordant between CDC
and ELISA. 23 cases were CDC positive/ELISA negative. Of those 12 had
HLA-class I antibodies which, as expected, reacted positively with B-cells
in the CDC test. Another 9 cases (11.25%) showed donor specific, ELISA
screening detectable HLA-DQ antibodies that cannot be detected in this
particular ELISA crossmatch assay. Two cases (2.5%) remained unresolved
(DP-antibodies?). In 3 cases a CDC negative/ELISA positive result was
obtained. All three cases showed ELISA detectable antibodies against donor
HLA-DRB1 antigens.
Although HLA-DQ and possibly HLA-DP antibodies – the role of which is
currently not clarified in the outcome of solid organ transplantation- could not
be detected by the ELISA crossmatch, this test may be a helpful tool in the
final donor selection process prior to allogeneic kidney transplantation, since
it proved to be more sensitive and more specific than conventional CDC. In
addition, it allows differentiation between antibodies against HLA-class I and
II antigens.
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2282 REAPPRAISAL OF HLA ANTIBODY ANALYSIS AND
CROSSMATCHING IN KIDNEY TRANSPLANTATION
P-C. Lee1, C-J. Hung1, Y-J. Lin1, S-S. Chang1, T-C. Chou1, J-P. Chuang2
1
Department of Surgery, National Cheng-Kung Medical College and Hospital,
2
Department of surgery, Tainan Hospital, Tainan, Taiwan
In general, a negative crossmatch is a prerequisite for renal transplantation.
Complement-dependent lymphocytoxicity crossmatch (CDCXM) test remains
the most commonly used crossmatch technique in pretransplant immunologic
evaluation. The presence of preformed donor-specific HLA antibodies (DSA)
is a major risk factor for early antibody-mediated rejection and graft loss. The
antibody specificity and crossmatch should be assessed prior to transplantation.
Screening for such alloreactive antibodies was traditional performed using
complement-dependent lymphocytotoxicity (CDC) assay. More recently,
ELISA and flow cytometry-based techniques were introduced to overcome the
limited sensitivity and specificity of the CDC assay. This retrospective study
using the LAT-M screen and identification HLA class I and II specificity and
evaluated the accuracy of pretransplant CDC crossmatch.
In this study, a total of 481 serum samples from patients awaiting kidney
transplantation were tested by ELISA method: LAT-M (One Lambda). The
results the overall prevalence of HLA antibodies positive were 24% to 17%
according to optical density (OD) reaction strength increase. The positive
predictive value (PPV) from PRA positive sera responsible to positive CDC
crossmatch at the time of putative transplant was found to be 43% to 54%.
The negative predictive value (NPV) from PRA negative sera responsible to
negative CDC crossmatch was found to be 88%. Furthermore, PPV was 52% to
64% from the HLA class I DSA positive sera and 46% to 58% from HLA class
II DSA positive sera. On the other hand, NPV were 88% from the HLA class
I DSA negative sera and 87% from HLA class II DSA negative sera.Based on
our results, we believe HLA antibody identification using ELISA still had the
role in the negative predictive value in CDC crossmatch before transplantation.
Further analysis of HLA antibody using flow cytometry technology based
Luminex will be done to compare with present data.
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2283 EIGHTEEN-YEAR FOLLOW-UP OF A RETROSPECTIVE
STUDY OF HLA ANTIBODY ON KIDNEY GRAFT SURVIVAL
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P-C. Lee1, C-J. Hung1, Y-J. Lin1, S-S. Chang1, T-C. Chou1, J-P. Chuang2
1
Department of Surgery, National Cheng-Kung Medical College and Hospital,
2
Department of surgery, Tainan Hospital
In general, a negative crossmatch is a prerequisite for renal transplantation.
Complement-dependent lymphocytoxicity crossmatch (CDCXM) test remains
the most commonly used crossmatch technique in pretransplant immunologic
evaluation. The presence of preformed donor-specific HLA antibodies (DSA)
is a major risk factor for early antibody-mediated rejection and graft loss. The
antibody specificity and crossmatch should be assessed prior to transplantation.
Screening for such alloreactive antibodies was traditional performed using
complement-dependent lymphocytotoxicity (CDC) assay. More recently,
ELISA and flow cytometry-based techniques were introduced to overcome the
limited sensitivity and specificity of the CDC assay. This retrospective study
using the LAT-M screen and identification HLA class I and II specificity and
evaluated the impact of long-term graft survival.
In this study, a total of 288 pre-transplant serum samples were tested by ELISA
method: LAT-M (One Lambda). The results the overall prevalence of HLA antibodies
positive before transplantation were 19%. Five years, ten years an fifteen years after
transplantation, functional graft survival among 234 patients not having antibodies
was 85%, 76% and 56% compared to 65%, 53% and 28% for 54 patients with HLA
antibodies (P=0.0021). Among patients with PRA positive before transplantation,
twelve of them had donor-specific antibody (DSA) positive, six patients was HLA
class I DSA positive and eight patients was HLA class II DSA positive. Comparison
of the functional survival between DSA positive patients and PRA negative patients
showed the trend of different, however, not statistically significant.
Based on our results, we believe HLA antibody identification using ELISA
still had the role to predict long term graft survival. Further analysis of HLA
antibody using flow cytometry technology based Luminex will be done to
compare with present data.
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2284 PRETRANSPLANT CROSSMATCH USING PERIPHERAL
BLOOD DERIVED LYMPHOCYTES (PBL) IS RELIABLE AND
REDUCES CIT
A. Asderakis1, M. Ilham1, S. Lloyd2, R. Walters2, T. Rees2
1
Transplant Unit, University Hospital of Wales, UK, 2Welsh Transplantation
and Immunogenetics Laboratory
Introduction: Pre-transplant crossmatch (CXM), along with identification of
HLA specific antibodies is prerequisite for a successful kidney and pancreas
transplant. Organs from donors after cardiac death (NHB) represent one of the
attractive solutions to organ shortage, whilst pancreas transplantation (PTX),
simultaneously or following a kidney transplant, is a successful treatment for
selected diabetic patients. Cold Ischemic Time (CIT) is an important predictor
of long-term kidney survival and is known to be detrimental in early and late
pancreas survival, thus it might be even more important in those situations.
Therefore every effort that can effectively minimise CIT should be used.
Aim: Evaluate crossmatch using donor peripheral blood derived lymphocytes
(PBL) rather than spleen or lymph nodes once a donor has been identified (in
some cases even before the donor procedure takes place) in NHB and PTX.
Methods: In a 2-year period all NHB and PTX donors were CMX against recipient’s
most rent serum sample available. All recipients had HLA specific antibodies
previously identified and actively avoided. There were 28 CMX for NHB and 10
for PTX performed using donor PBL. Both complement dependent (CDCXM) and
flow cytometry cross match (FCXM) were performed. In 12 patients the CMX was
performed using spleen cells (as PBL were not available prior to spleen becoming
available from the donor), and were excluded from further analysis. All 26 remaining
CMX were repeated the following day using spleen cells and the results compared.
Results: All CDCXM using donor PBL were negative, and concurred with
CDCXM results against spleen-derived lymphocytes (SDL). Two FCXM were
not performed with PBL due to lack of enough cell yield while six were not
performed with SDL for the same reason.
One case was FCXM positive with both materials. Only one case had negative
B-cell FCXM on PBL and was positive on SDL (linear channel shift 21 vs 51,
cut off 41), whereas it was CDC and flow T-cell negative on both. There were
no immunologic Pancreas or kidney losses among those patients. The median
CIT for the kidney for those cases was 13 hours and compared to our unit
overall CIT of 18 hours. There were 3 cases of NHB donors where the CIT of
the first kidney transplanted was less than 6 h.
Conclusion: Pre-transplant final crossmatch using donor PBL is as reliable and
precise as crossmatch using cells derived form donor spleen or lymph nodes.
This method might significantly reduce CIT in NHB and Pancreas transplantation
and may also have wider implications for classic brain stem kidney donors.
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2285 ALLOCATION OF DECEASED DONOR KIDNEYS IN SÃO
PAULO, BRAZIL: EFFECT OF HUMAN LEUCOCYTE ANTIGEN
COMPATIBILITY ON GRAFT SURVIVAL.
F. Monteiro12, S. Coria1, R. Boni1, L. Pereira1
1
São Paulo Organ Allocation System, Health Secretariat of São Paulo,
2
Laboratory of Immunology, Heart Institute, Scholl of Medicine, University of
São Paulo
Since Jan/2002, São Paulo Organ Allocation System following the Brazilian
policy has been allocating deceased donor kidneys based on HLA-mismatches
(MM). In this System are attributed to the HLA compatibility as follow: 6,
3, 0pt to 0, 1, or 2 HLA-DR MM, respectively; 4, 2, 0pt to 0, 1 or 2 HLA-B
MM, respectively; 1, 0,5 or 0pt to 0, 1, or 2 HLA-A MM, respectively (total:
0 to 11pt). Before 2002, deceased donor kidneys were allocated to receptors
based on wait-list timing. The aim of this study was to measure the 5-year
kidney graft survival now transplanted under the allocation policy for HLAMM. Also, we investigated whether a well-matched graft is difficult to achieve
in patients that are homozygous for the HLA antigens. The study involved
3312 consecutive kidney patients transplanted in São Paulo, Brazil from
Jan/00 to Dec/06. All transplants were ABO compatible and were performed
with a negative XM against donor T and B cells. Endpoints for graft loss
were recipient death or return to dialysis. The review time point was Dec/07.
Kaplan-Meier method was used to construct graft survival curves and the
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curves were compared with log-rank test. The results has shown better graft
survival curves of patients (N=913) transplanted in the first 2 years after jan/02
than patients (N=715) transplanted 2 years before jan/02 (78.1% vs. 64.9% P
< 0.001). After Jan/02 until Dec/06, a total of 2597 consecutive transplants
were performed. From those, transplants with zero (N=121) HLA-A, -B, -DR
MM had a significantly better survival rate than those with 1-2 (N=862) or
3-4 (N=1271) or 5-6 (N=343) HLA-A, -B, -DR MM (72.42% vs. 63.44% vs.
58.25% vs. 56.71% P<0.050). Transplants (N=1467) with no HLA-DR MM
had a significantly better survival rate than those (N=1130) with one and two
HLA-DR MM (62.4% vs. 59.13.0%, P<0,005). Finally, HLA homozygous
patients (N=17) wait longer for suitable crossmatch negative organ compared
to HLA heterozygous patients (N=2008, – 51mth vs. 35mth) and they have
a significantly reduced survival rate compared to the same group (31% vs.
60% P<0.050). In conclusion, HLA compatibility is still a feasible criterion
to allocate deceased donor kidneys. However, regarding to HLA homozygous
patients, some adjustment must be done to guarantee equal distribution.

ancestral HLA-DR supertypes, namely: DR51 [DR15(2), DR16(2)], DR52
[DR11(5), DR12(5), DR13(6), DR14(6), DR17(3), DR18(3)], DR53 [DR4,
DR7, DR9], DR1 [DR1, DR10] and DR8. Gametic phase and linkage between
paired genotypes were determined using ARLEQUIN 3.01 software, and
significance was determined by Chi-square and Markov chain/Fisher’s exact
test analysis.
Results: Significant allelic associations were evident across the 6p region
examined.
VEGF

2286 IMPACT OF THE NON-CLASSICAL HLA-E EXPRESSION
ON KIDNEY ALLOGRAFT OUTCOME.
J.C.O. Crispim , L.T. Saber , R.A. Duarte , C.P. Soares , R.S. Costa ,
J.S. Silva2, C.T. Mendes-Júnior5, E.A. Donadi5
1
Renal Transplant Unit, Hospital Das Clinicas, University of São PauloRibeirão P, 2Department of Biochemistry and Immunology, FMRP-USP,
Brazil, 3Department of Clinical Analysis; School of Pharmaceutical Sciences,
UNESP, University of São Paulo State., 4Department of Pathology, FMRPUSP, Brazil., 5Division of Clinical Immunology, FMRP-USP, Brazil
Human leukocyte antigen (HLA)-E belongs, with HLA-G and HLA-F, to the
non-classic major histocompatibility complex (MHC) class I (Ib) molecules,
broadly defined by a limited polymorphism and a restricted pattern of
cellular expression, and may display tolerogeneic functions. In solid organ
transplantation, the expression and function of HLA-E in physiological and
pathologic processes remain poorly established. Since the expression of the of
HLA-E in renal biopsies has not been performed, in this study we performed
a cross-sectional study, systematically comparing the expression of HLA-E in
post-transplanted renal grafts, stratifying patients according to the presence or
not of rejection.
Patients and Methods: Ninety-four renal specimens (12 with acute rejection
(AR) and 19 chronic allograft nephropathy (CAN), and 63 with no signs of
rejection were immunohistochemically evaluated for HLA-E expression.
Results: In the group as a whole, HLA-E molecules were detected in 23 cases
(24.5%). On the hand, among specimes that presented HLA-E expression,
12 out of 23 (52.2%) exhibited AR and CAN, and the remaining 11 (47.8%)
exhibited no signs of rejection. The comparison between patients with rejection
with those without rejection, the expression of HLA-E was significantly
increased in specimens exhibiting signs of rejection (p<0.0396).
Conclusions: Our results suggest that HLA-E expression in the kidney allograft
is associated with susceptibility to CAN.
2

1

3

3

4
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2287 LONG-RANGE LINKAGE ON CHROMOSOME 6P OF
VEGF, FKBP5, HLA AND TNF ALLELES ASSOCIATED WITH
TRANSPLANT REJECTION
I. Hutchinson1,2, Y. Chen1,2, J. Cicciarelli1,2, V. Pravica1,2
University of Southern California, 2National Institute of Transplantation, Los Angeles
Introduction: Polymorphisms in several genes on the short arm of chromosome
6 (6p), among them VEGF (6p12), FKBP5 (6p21.2), HLA-DR (6p21.3) and
TNF-α (6p21.3), have been associated with inflammation and transplant
outcome. Each of these genes is associated with acute rejection. Independent
segregation of these genes is unproven, so we investigated linkage between
distant genes on 6p and the putative existence of evolutionarily-conserved
long-range 6p haplotypes.
Methods: SNPs studied were VEGF-2578*C/A (rs699947), TNF-α -308*G/A
(rs1800629) and FKBP5*C/T (rs1360780) in 206 random and 80 selected
HLA-DR52 positive individuals. HLA-DR was typed by serology or SSP. To
simplify the analysis, the HLA-DR genotypes were collapsed to the 5 human
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TNFα

P<0.05

P<0.05
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P<0.05

P<0.05
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P<0.05
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*
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FKBP5

P<0.05

HLADR

P<0.05

TNFα

P<0.05
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Two putative extended haplotypes were identified, associated with DR52 and
DR1.
DR52
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FKBP5

VEGF

VEGF*C

FKBP*T

TNF*A

VEGF*A

FKBP*C

Chi sq

6.79

4.19

32.54

DR1

17.14

8.76

P value

<0.05

<0.05

<0.001

<0.001

<0.05

Within the HLA-DR52 supertype, TNF*A was associated with DR3, while
FKBP5*T was associated with DR6.
Discussion: The interval between VEGF and TNF-α is 12.31Mb. Therefore,
allelic associations are surprising considering expected recombination and
the evolutionary time (c10MY) since divergence of DR supertypes. This
suggests that DR1 and DR52 haplotypes have a survival advantage. Within the
DR52 supertype, VEGF*C-DR3-TNF*A is a ‘high inflammatory’ haplotype
associated with acute and chronic rejection, while the FKBP5*T-DR6 haplotype
is associated with resistance to endogenous and exogenous glucocorticoids.
Conversely, the DR1 haplotype is a ‘low inflammatory’ haplotype.
Conclusion: Distant genes on chromosome 6p co-segregate. This has implications
for transplantation and the definition of HLA-disease associations.

POSTER BOARD NUMBER P4 – 338
2288 DIFFERENT IMPACTS OF PRE-TRANSPLANT AND
POST-TRANSPLANT FLOW-PRA AND DSA ON LIVING DONOR
RENAL GRAFTS
W. Huang, F. Zeng, P. Zhou, Z. Zhen, W. Zhang, D. Cheng
Institute of Organ Transplantation, Tongji Hospital,Tongji Medical College,
Huaz
Background: The presence of preformed alloantibodies may pose tremendous
risk for humoral rejection to kidney allografts. The objective of this study
was to measure the serum creatinine levels of living donor kidney transplant
recipients, and find out what were the impacts of pre-transplant and posttransplant panel reactive antibodies (PRA) and donor-specific antibodies
(DSA) on the renal grafts.
Methods: We reviewed the data of 135 recipients of living donor kidney
transplants from our hospital from 2001 to August 15, 2007, including 19
positive pre-transplant HLA flow PRA (6 anti-HLA-IFlow PRA ;2 anti-HLAIIFlow PRA and 11 anti-HLA-¦ &¦ Flow PRA). All 135 patients (with 2.3±1.2
HLA-Ι mismatches and 1.0±0.6 HLA-I mismatches¦ post-transplant 2.7±1.3ys)
had negative pre-transplant flow cytometry crossmatch (FCXM). There was
no graft lost during observation. All serum samples from the recipients were
screened for preformed or post-transplant Flow-PRA and DSA, DSA were
detected by the flow T- and B-cell crossmatch FCXM (FTXM and FBXM),
while the creatinine levels were monitored. And, relation of humoral rejection
with preformed or post-transplant PRA and DSA was evaluated.
Results: Approximately 30%(41/135) of tested sera were found to contain
anti-HLA-antibody (12 anti-HLA-IFlow PRA ;5 anti-HLA-IFlow PRA
and 20 anti-HLA-¦ &¦ Flow PRA), and 45 tested sera¦ 45/135 33.3%¦
had positive FCXM results (26 FTXM-positive and 18 FBXM-positive).
We found that all recipients with positive pre-transplant HLA-IPRA got
higher creatinine levels (1.80 ± 0.51mg/dl; n=17¦ than the patients with
negative pre-transplant HLA-IPRA¦ 1.12±0.37 mg/dl; n=118¦ (p<0.05); 6
of 8(75%) recipients with positive pre-transplant HLA-IPRA got pathology
proved humoral rejection, but none in later group. There were no statistically
differences between creatinine levels after transplantation of recipients
with positive and negative pre-transplant HLA-¦ PRA. Creatinine levels
of recipients with positive post-transplant anti-HLA-Ior¦ Flow PRA (1.17
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± 0.33mg/dl; n =22) were not significantly different from that of PRAnegative (1.09 ± 0.30 mg/dl; n= 94) (p>0.05). Similarly, creatinine levels
of recipients with positive FCXMs (FBXM or FTXM) (1.15 ± 0.34 mg/dl;
n=45) were not significantly different from the ones with negative FCXMs
(1.10 ± 0.31 mg/dl; n=90) (p>0.05).
Conclusion: The data showed serum creatinine levels of recipients with positive
pre-transplant anti-HLA-¦ PRA were higher than that of negative ones. AntiHLA antibodies would be induced by transplantation, blood-transfusion or
gestation¦ so recipients who waits for renal regraft, who got blood transfusion
and childbearing women would be at higher risk of graft failure. This preliminary
result would be helpful for distinguishing the recipients with higher risk of
graft failure, and reminding the doctor to implement new therapeutic strategies,
so as to keep the recipients from the disastrous hurts.

POSTER BOARD NUMBER P4 – 339
2289 GRAFT SURVIVAL IN RENAL TRANSPLANT
RECIPIENTS ENHANCED BY HUMAN LEUKOCYTE
MATCHING-SINGLE CENTER STUDY (UNIVERSITY
HOSPITAL ZAGREB, CROATIA)

THURSDAY

I. Humar, L. Bubic, N. Martinez, B. Palfi, V. Kerhin-Brkljacic
University Hospital Zagreb
One of the most hotly debated HLA typing topics throughout the years has
been the significance of HLA matching, including the importance of different
match grades (if any) to transplant survival. HLA typing and the time a
patient has spent on the waiting list are the primary criteria used to allocate
deceased kidneys for transplantation in Croatia. Candidates with no HLA-A,
B, and DR mismatches are given top priority, followed by candidates with the
fewest mismatches at the HLA-B and DR loci. There has been an ongoing
contention that new immunosuppressive drugs improve graft survival rates,
which proscribes the need for HLA matching.
Aim: The purpose an analysis of 572 renal transplants based on 6, 7 3, 7
years (form 1-19 years) is to examine recent findings in HLA matching
as they are associated with organ transplant survival and to look at trends
immunosuppressive treatments.
Methods: We investigated the effect of HLA matching, using a Cox
regression model for the survival rate. The results of the analyses were
used to estimate the possible change in balance of graft survival rates that
would result from the elimination of HLA-B matching or HLA-B and DR
matching as a means of assigning priority. All P values are two-sided and
considered statistically significant if less than 0.05. All calculations were
performed by STATA 7.0.
Results: The effect of increasing the number of mismatches at each locus
is compared with the effect of one mismatch at each locus. Having one
mismatch at the HLA-A or B locus, as compared with 5 mismatches, had
statistically significant effect after adjustment for mismatches at the other
two loci (P values ranged from 0.012 to 0.01) relative risk from 1.63-2.1. One
or two mismatches at the HLA-DR locus, as compared with 5 mismatches,
did increase the risk of graft failure (relative risk with one mismatch, 1.93;
P<0.071; two mismatches, 2.22; P<0.028). These results suggest that
eliminating HLA-DR matching as a priority would have a greater negative
effect on graft survival than would eliminate HLA-A or B matching. In every
instance, notwithstanding the difference in immunosuppressive drugs used,
the 10-year graft survival difference between 0-2 mismatch and 3-6 antigens
mismatch is 14, 3%.
Conclusion: From the difference between zero and five mismatch, it is clear
that even one antigen mismatch was enough for the immune system to respond
and react with an additive increase in graft survival for each mismatched
antigen. Until we don’t have specific immunosuppression to eliminate the
responding cells to the donor mismatched antigens, we will not achieve a
tolerance state. It is important to acknowledge that immunosuppression is
always going to put us in the predicament of too little -resulting in graft
rejection, or too much- subjecting the recipient to infection and toxicity.
Until we make strides in the direction of specific immunosuppression so that
cells responding to mismatched donor antigens eliminated or specifically
modulated them, we will need HLA matching to generate this specific no
response to the donor antigens.
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2290 THE BANFF 2007 WORKING CLASSIFICATION OF
SKIN-CONTAINING COMPOSITE TISSUE ALLOGRAFT
PATHOLOGY
L.C. Cendales1, J. Kanitakis2, S. Schneeberger3, C. Burns4, P. Ruiz5,
L. Landin6, M. Remmelink7, C.W. Hewitt8, T. Landgren9, B. Lyons10,
C.B. Drachenberg11, K. Solez12, A.D. Kirk13, D.E. Kleiner14, L. Racusen15.
1
Emory Transplant Center, Emory University and Atlanta Veterans Affairs
Medical Center, Atlanta, Georgia, USA, 2Department of Dermatology and
Dermatopathology, Ed. Herriot Hospital, Lyon, France, 3Department of
General and Transplant Surgery, Medical University Innsbrück, Innsbrück,
Austria and Division of Plastic and Reconstructive Surgery, UPMC, Pittsburg,
Pennsylvania, USA, 4Jewish Hospital Pathology Department, Jewish Hospital
and St Mary’s Healthcare, Louisville, Kentucky, USA, 5Department of
Pathology and Surgery, University of Miami, Miami, Florida, USA, 6and and
Reconstructive Surgery Unit, Pedro Cavadas Foundation, “La Fe” University
Hospital, Valencia, Spain, 7Department of Surgical Pathology. CUB-ULB
Hôpital Erasme, Brussels, Belgium, 8Robert Wood Johnson Medical School,
Camden, UMDNJ Cooper Health System, Camden, New Jersey, USA,
9
Department of Anatomical Pathology, Melbourne Health Pathology, Royal
Melbourne Hospital, Victoria, Australia, 10Department of Histopathology,
Derriford Hospital, Plymouth, United Kingdom, 11Department of Pathology,
University of Maryland School of Medicine, Baltimore, Maryland, USA,
12
Department of Laboratory Medicine and Pathology, University of Alberta,
Edmonton, Alberta, Canada, 13Emory Transplant Center, Emory University,
Atlanta, Georgia, USA, 14Laboratory of Pathology, National Cancer Institute,
Bethesda, Maryland, USA, and 15Department of Pathology, The Johns
Hopkins University School of Medicine, Department of Pathology, Baltimore,
Maryland, USA
Composite Tissue Allotransplantation (CTA) is a recently introduced option for
limb replacement and reconstruction of tissue defects. As with other allografts.
CTA can undergo immune-mediated rejection; therefore standardized criteria
are required for characterizing and reporting severity and types of rejection.
This manuscript documents the conclusions of a symposium on CTA rejection
held at the Ninth Banff Conference on Allograft Pathology in La-Coruňa, Spain
on June 26,2007, and proposes a working classification, the Banff CTA-07,
for the categorization of CTA rejection. This classification was derived from
a consensus discussion session attended by the first authors of three published
classification systems, pathologists and researchers from international centers
where clinical CTA has been performed. It was open to all attendees to the
Banff conference. To the extent possible, the format followed the established
National Institutes of Health (NIH) guidelines on Consensus Development
Programs. By consensus, the defining features to diagnose acute skin rejection
include inflammatory cell infiltration with involvement of epidermis and/
or adnexal structures, epithelial apoptosis, dyskeratosis, and necrosis. Five
grades of severity of rejection are defined. This classification refines proposed
schemas, represents international consensus on this topic, and establishes a
working collective classification system for CTA reporting of rejection in skincontaining CTAs.
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2291 STEROID ELIMINATION DURING LONG TERM
FOLLOW-UP IN HAND TRANSPLANTATION
M. Marvin1,2, K. Ravindra1,2, C. Kaufman3, J. Buell1,2, R. Nagubandi1,2,
S. Ildstad2, B. Blair3, W. Breidenbach4
1
Jewish Hospital, Transplant Center, 2Department of Surgery, University of
Louisville, 3Christine M Kleinert Institute, 4Kleinert Kutz & Associates
Background: Steroids have formed the backbone of post transplant
immunosuppression since clinical success was attained in the 1950s. However,
long term use is associated with untoward sequelae such as hypertension, diabetes,
osteoporosis, weight gain etc. There has been a move towards elimination of long
term use of steroids in solid organ transplantation. We applied the same principle
to the first 2 hand transplant recipients at our center.
Method: Two hand transplants were performed at our center in 1999 and
2000 in men aged 37 and 38 respectively. The first patient was induced with
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Basiliximab and then maintained on Tacrolimus, Mycophenolate mofetil
(MMF) and Prednisone. He had two episodes of rejection in the first 6 months
and none after. The Carroll test score improved from 54 to 72 over 6 years.
The second patient was induced with Basiliximab and started on Tacrolimus,
MMF and Prednisone. He became a diabetic in the weeks following
transplant. In order to improve glycemic control, MMF was replaced with
Sirolimus (to permit lower levels of Tacrolimus). This patient had multiple
episodes of rejection during the initial 6 months (treated with intravenous
steroids) and another episode at 6 years (treated with Thymoglobulin). He
developed bilateral osteonecrosis of femoral head needing hip replacement.
In early 2007 a plan was instituted to taper the Prednisone dose and stop
the drug.
Results: The taper of Prednisone was performed in steps of 2.5mg every 6
weeks. Over a 5 month period this was achieved. Both the patients have been
off steroids for the past 4 months. There has been no change in the appearance or
function of the hand in either patient. They are both on 2 drugs only: tacrolimus
(5-6 ng/ml) and MMF/Rapamycin.
Conclusions: This is the first report of early success with steroid elimination
in hand transplantation. Despite the patients having been on Prednisone for 8 7
years prior to cessation, no change in the appearance or function of the grafts
has been observed. As acute rejection is uncommon after the first year of hand
transplantation, elimination of steroids after this period should be considered
in these patients.
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2292 ALEMTUZUMAB INDUCTION IN HAND
TRANSPLANTATION: PROGRESS TOWARDS MINIMIZING
IMMUNOSUPPRESSION IN COMPOSITE TISSUE
ALLOTRANSPLANTATION (CTA)
M. Marvin1,2, K. Ravindra1,2, J. Buell1,2, C. Kaufman4, R. Nagubandi1,2,
S. Ildstad1, B. Blair4, W. Breidenbach3
1
Department of Surgery, University of Louisville, 2Jewish Hospital, Transplant
Center, 3Kleinert Kutz & Associates, 4Christine M. Kleinert Institute
Background: Progress in CTA has been hampered by concerns related to
complications caused by long term immunosuppression. We attempted steroid
avoidance to lower the immunosuppression in hand transplantation.
Methods: The third hand transplant at our center was done in November 2006.
The 54 year old man received a right proximal forearm transplant. He was
induced with a single dose of Alemtuzumab and maintained with Tacrolimus
and MMF. Tacrolimus levels were maintained at 10-12 ng/ml in the first 6
months and lowered to 6-9 ng/ml later. MMF was initiated at 1gm bid and
lowered to 500 mg bid due to neutropenia. Steroids were given only perioperatively (3 doses) to prevent adverse reaction to Alemtuzumab. The patient
was also started on CMV prophylaxis.
Results: The patient tolerated the Alemtuzumab induction well and has had
only one significant episode of rejection in the first year post transplant.
As a result of low WBC (0.7), at day 54, Valcyte, CellCept and Bactrim
were temporarily discontinued, and the patient received three doses of
Filgrastim. He subsequently developed a CMV infection and concomitant
rejection (Grade 2-3 skin biopsy) The concurrent CMV infection and acute
rejection were treated with Ganciclovir and topical Tacrolimus Clobetasol
respectively. Since the resolution of these events, the patient has remained
incident free, and does not take oral steroids. He has returned to a productive
life. His renal function has been stable but has needed statin therapy to
control hyperlipidemia.
Conclusions: This is the first report of success with steroid avoidance in
hand transplantation. It has the potential to prevent long term sequel such as
hypertension, diabetes, osteoporosis etc. Dose reduction of Tacrolimus to a
trough of 6-9 ng/ml and MMF to 500 mg bid is a step towards the goal of
minimizing immunosuppression in CTA. This strategy, we hope, will reduce
the long term complications associated with systemic immunosuppression and
lead to wider application of CTA.
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2293 RENAL FUNCTION IN LONG TERM HAND
TRANSPLANT RECIPIENTS: IMPACT OF TACROLIMUS AND
IMMUNOSUPPRESSION
W.C. Breidenbach1, K. Ravindra3,4, M. Marvin3,4, J. Buell3,4, B. Blair2,
C. Kaufman2
1
Kleinert Kutz & Associates, 2Christine M. Kleinert Institute, 3Department of
Surgery, University of Louisville, 4Jewish Hospital, Transplant Center
Calcineurin based immunosuppression is nephrotoxic and is associated with
Creatinine Creep with long term use. This has serious implications for the field
of CTA as the transplant is not a life saving venture. This data will 1) Contrast
the management differences of monitoring kidney function in hand CTA versus
solid organ transplantation and 2) determine if there is any deterioration in
renal function in our three hand CTA patients.
The first patient was a diabetic prior to transplantation and has received
Tacrolimus, MMF and prednisone since the transplant. The average Creatinine
values were 1.34 +/- 0.21 and the current GFR is 57. The patient with 7 years
follow-up received Tacrolimus, Sirolimus and prednisone. The GFR in this
patient has been higher and was over 100 at 5 years. The most recent patient
showed the predictable drop in GFR attributed to use of calcineurins but has
returned to a calculate GFR of 74 at the one year follow-up. This patient was
induced with Alemtuzumab and has been on Tacrolimus and MMF without
any steroids.
An initial decrease in GFR is to be expected with use of calcineurin inhibitors
(CNI). Pre-existing disease such as diabetes and hypertension may compound
the effect of calcineurin nephrotoxicity (patient 1). Avoidance of steroids
(patient 3), maintaining lower levels of CNI and the use of Sirolimus (patient
2) have the potential of minimizing nephrotoxicity. Recent experience
would also suggest a more aggressive approach to immunosuppression
minimization is feasible in hand CTA. The renal toxicity incurred with the
use of CNI for lifesaving allografts is more tenable than that incurred for a
quality of life allograft such as a hand.. Kidney function must be carefully
monitored so that the patient and the CTA team have the information to make
long term decisions on the prospect of either losing the limb or needing a
renal transplant.
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2294 THE ROLE OF SKIN BIOPSIES IN DIAGNOSING
CLINICAL REJECTION IN HAND COMPOSITE TISSUE
ALLOTRANSPLANTATION (CTA)
C. Kaufman1, R. Gonzales1, K. Ravindra2,3, B. Blair1, J. Buell2,3,
W. Breidenbach4
1
Christine M. Kleinert Institute, 2Department of Surgery, University of
Louisville, 3Jewish Hospital, Transplant Center, 4Kleinert Kutz & Associates
Aim: Traditionally allograft biopsy has dictated treatment of allograft rejection.
We hypothesize that histological grade of the biopsy may over diagnose
rejection in CTA Hand CTA is unique in that the organ is external and early
signs of rejection can be viewed directly. Skin is the first tissue in the CTA graft
to show rejection.
Methods: For this study, rejection by defined by requirement of treatment.
These episodes were compared with histological grade, and hand appearance.
We reviewed 127 skin biopsies taken during 9, 7 and 1 years of follow up.
Results: Three observations surfaced. First, a rejection grading scale for
CTA is still evolving. A review of the literature showed at least four different
criteria are in use. The criteria used to grade biopsies at our center changed
over the 9 year follow up. Bias towards calling higher grades of rejection,
and more aggressive treatment occurred in the first two patients. A re-read
of random biopsies taken from the first two patients showed a down-grade
of rejection to grade II or I in five cases. Secondly, concomitant CMV
infection in the last patient prevented the aggressive treatment of rejection.
Despite high grade histology, the swelling, rash and redness responded to
topical immunosuppression. Systemic treatment was not necessary. Analysis
indicated that swelling and/or rash, and the percentage of skin involvement
seemed to be more informative markers of existing (or resolving) alloreactivity
than was histology. The biopsies taken from the graft shown below showed
a grade III histology.
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2295 EVALUATION AND SCREENING OF POTENTIAL HAND
TRANSPLANT RECIPIENTS
C. Kaufman1, B. Blair1, K. Ravindra3,4, J. Buell3,4, W. Breidenbach2
Christine M. Kleinert Institute, 2Kleinert Kutz & Associates, 3Department of
Surgery, University of Louisville, 4Jewish Hospital, Transplant Center
Introduction: In the last 10 years, great interest has been generated in the
scientific community and the public regarding hand transplantation. As the
only center in the US performing the procedure many amputees contact our
unit exploring their candidacy for the procedure. Each candidate is extensively
assessed from the surgical, medical and psycho-social standpoint..
Aim: The goal of this study was to assess the entire evaluation process and
determine the reasons for denial and acceptance of potential recipients.
Methods: A retrospective analysis of all enquiries from potential recipients
was performed. The data was divided into 2 time periods based on the first
successful hand transplant pre 2000 and post 2000 era.
Results: The data in table 1 shows that nearly 25% show no further interest
after the initial explanation of risks and benefit. Inappropriate amputation
and technical difficulty account for nearly 40% of those denied. Congenital
problems account for 14 -20% of those turned down. Medical reasons
(advanced age, cardiac disease, cancer, infections etc.) are responsible for most
of the remaining denials. Overall only 15 of 421 (3.5%) of enquiries led to
complete evaluation. Of these 15, 5 (33%) were eventually listed and 3 have
undergone transplantation. No major differences were noted between the two
time periods. Most surprisingly, when we examined the data, there were no
patients who could not be transplanted because of a lack of sufficient insurance
coverage.
Conclusions: Hand transplantation is still in infancy and there exists a need
for public education. As understanding increases we expect the number of
unsuitable interested candidates to decrease. Also, as clinical experience
increases, we will be able to broaden our inclusion criteria, (particularly the
surgical reasons). At the present time, centers considering CTA should be
prepared to screen a large number potential candidates.
Interested subject screening outcomes

the third was transplanted under a steroid avoidance protocol. Both patients
(Tx 1 and 3) who were maintained on tacrolimus and mycophenolate mofetil
had stable CDRPS. However, a notable increase in the CDRPS was observed
in patient #2 (Tx 2) who required the addition of sirolimus for an episode of
late rejection.
Tx 1

Tx 1

Tx 2

Tx 2

Tx 3

Tx – 3

Date

Pre-Tx

9 yrs post-Tx

Pre-Tx

6.8 yrs post-Tx

Pre-Tx

1yr post-Tx

Age

37

46

36

43

54

55

LDL

85

42

84

121

142

81

HDL

50

44

60

63

50

34
130/88

1

1999 Data (N=213)

Post CTA Tx Data (N=208)

Not Interested

28%

26%

Inappropriate Amputation

27%

39%

Congenital problem

14%

20%

Technical Difficulty

6%

2.4%

Cancer

3%

0.5%

Infectious Disease

2%

0.5%

Other

16%

7%

Eligible and Interested

4%

5%
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2296 FRAMINGHAM RISK ASSESSMENT IN COMPOSITE
TISSUE ALLOGRAFT (CTA) RECIPIENTS
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M. Marvin1, R. Nagubandi1, R. Kadiyala1, C. Kaufman2, W. Briedenbach2,
J. Buell1
1
Divisions of Transplantation, Jewish Hospital, University of Louisville,
Louisvi, 2Kleinert, Kutz and Associates, Hand Care Center, Jewish Hospital,
Louisville, KY, United States
Background: Technical issues in hand transplantation have been overcome
in the last decade. Despite increased interest and performance of this
procedure, significant concerns have been raised over the impact of chronic
immunosuppression and its associated complications for a non-life saving graft.
As cardiovascular death is a serious long-term risk to transplant recipients,
we examined the Framingham risk of our composite tissue allograft (CTA)
patients.
Methods: Three unilateral hand-forearm transplants have been performed at
our institution. All three have been prospectively followed on a yearly basis.
The length of follow-up for these patients are 9, 6 and 1 year. To address the
issue of cardiovascular risk we calculated the pre and post transplant Coronary
Disease Risk Prediction Score (CDRPS).
Results: The first two transplants recently underwent steroid withdrawal, while
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No cardiac events have occurred.

Discussion: TOR inhibitors have been known to increase cholesterol and
triglycerides. In the Coronary Risk Prediction Score, HDL and LDL contribute
significantly to the risk profile.
Conclusion: In our experience with CTA hand allografts, we believe steroid
elimination and immunosuppression minimization does not increase the
cardiovascular risk for most recipients. However, we noted in our one patient
maintained on sirolimus that there was an increase in cardiovascular risk mostly
attributed to an altered cholesterol profile.
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In this study we reported our experience about bilateral hand
allotransplantation.
The first bilateral hand transplantation was performed in January 2000, the
second case on April 30, 2003 and the third case on February 19, 2007. The
first recipient was a 33-year old man with bilateral amputation from four
years, the second recipient was a 22-year old man with amputation from two
years and the third recipient a 27-year old woman with amputation from 2
years. The immunosuppressive protocol included tacrolimus, mycophenolate
mofetil, prednisone and, for induction, antithymocyte globulins.
All our patients presented two episodes of acute skin rejection (asymptomatic
maculopapular lesions). In the first two recipients they occurred in the first
three months after transplantation and were resolved by increasing oral steroid
dose. The third patient experienced two episodes of acute rejection on day 16
and 271 after transplantation and they were resolved by 3 bolus of steroid.
The patients did not show other macroscopic or histological signs of acute or
chronic rejection during the follow-up.
The first recipient presented hyperglycemia and serum sickness while the second
recipient suffered a thrombosis of the right ulnar artery and an osteomyelitis of
left ulna. All the complications were successfully treated.
Eight and five years post-transplantation the first two recipients show a relevant
sensorimotor recovery particularly of sensibility and activity of intrinsic
muscles and a degree of motor coordination. Although both patients present a
limited range of motion of their joints because of fibrosis and adherences with
a degree of impaired function and a diminished muscular power, they perform
the majority of daily activities and live a normal social life, in fact the first
patient started to work in March 2003. One year after transplantation the third
patient shows protective sensation and a certain degree of tactile sensation.
Intrinsic muscle recovery is starting.
It is interesting to remark that the recovery of sensitivity and the aesthetic
aspect of the grafted hands are very important issues for hand transplanted
recipients, who are very satisfied with their grafted hands.
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Introduction: A major obstacle to the wider application of hand
transplantation is the long term complications associated with
immunosuppression. Minimization of immunosuppression is an important
goal in all transplant recipients. Currently there are no accurate tools to
evaluate the immunological responsiveness which might help tailor the level
of immunosuppression for an individual patient. The response of recipient
lymphocytes to PHA, Candida, and alloantigen may represent laboratory tool
towards this end. It has been reported that these 3 responses are hierarchical
with response to alloantigen being the first to be lost, followed by Candida
and finally PHA.
Patient & Method: A 54 year old male received a proximal forearm
transplant in November 2006. Immunosuppression included induction with
a single 30 mg dose of alemtuzumab and maintenance with tacrolimus and
mycophenolate mofetil (MMF). Six weeks post-transplant Valganciclovir,
Bactrim and MMF were stopped due to neutropenia. The patient developed
an episode of cytomegalovirus infection followed by acute rejection after
reduction of his immunosuppression during the third post-operative month.
These were successfully treated with intravenous Ganciclovir and topical
tacrolimus & steroids respectively. Blood samples were drawn at selected
time points and subjected to phenotyping of lymphocyte subsets and
immune monitoring for circulating peripheral blood regulatory T cells (Treg)
and proliferative responses to phytohemagglutinin (PHA), Candida, and
alloantigen.
Results: Alemtuzumab induction resulted in profound lymphopenia. At week
2 and 1 month, the response to PHA was intact (stimulation index 110 and 24
respectively), but response to alloantigen and Candida suppressed (SI <3). A
similar immunologic profile persisted up through 6 months. At 1 year, the PHA
and Candida responses are robust (SI 69 and 38 respectively), but alloresponses
have not returned. Current immunosuppression consists of tacrolimus (6-9 ng/ml)
and mycophenolate mofetil (500 mg b.i.d.). There is no gross evidence of acute
or chronic rejection.
Conclusions: Induction with alemtuzumab alters the recovery of immune
response: recovery to Candida was delayed beyond 6 months and to alloantigens
beyond a year. It is interesting to note that despite severe neutropenia and a lack
of response to alloantigen and Candida, acute rejection still occurred in the
third month. However, the rejection was easily reversed with topical agents.
Immune response monitoring combined with clinical findings could help tailor
immunosuppression to individual patients.
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Introduction: Most regulatory T cells are known to express FoxP3, but also
skin homing receptors such as CCR4 and CLA.
Methods: PBMCs were collected at different time-points post-transplantation.

Biopsies were performed in the right and left oral mucosa, or in the piece of
vascualized skin that has been grafted together with the face, as sentinel. The
levels of FoxP3, Perforin, CCR4, CLA mRNA and CD62E, were measured by
Q-RT-PCR.
Results: During the first year post-transplantation, two rejection episodes
were observed in our patient. The second episode occurred one month
after a sub-clinical CMV reactivation and local herpes infection. Inside
the graft, two weeks post-transplantation, there was no detectable levels
of CD3epsilon mRNAs, indicating no T cell infiltration. During rejection
episodes, CD3, FoxP3 and Perforin mRNA levels increased inside graft and
sentinel skin, but not in blood. While FoxP3 mRNA levels were sustained,
those of Perforin were transient. During the viral infection episode, Perforin
mRNA levels strongly increased in peripheral blood, right mucosa and
sentinel skin. However, at the same period, FoxP3 mRNA levels, which
also increased in blood, dramatically decreased in the sentinel skin and the
right mucosa. The kinetics of CCR4 and CLA mRNA levels followed that
of FoxP3 but not that of Perforin. CD62E, which binds to CLA, followed
the same kinetics, as opposed with CX3CR1, which was used as a negative
control.
Conclusion: We show here that upon rejection episodes both FoxP3 and
Perforin mRNA levels were increased inside graft. But, during systemic viral
infection, a dissociation was observed since FoxP3 profoundly decreased from
graft, while Perforin mRNA levels increased. Kinetics of expression of CCR4
and CLA mRNAs followed that of Foxp3, but not of Perforin. Our results
suggest that the dysregulation of the effectors/Tregs balance, observed inside
graft during the infection episode, could account for the occurrence of the
second rejection episode.
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Purpose: Technetium99m sestamibi (MIBI) has poor sensitivity and specificity
when applied to patients with secondary hyperparathyroidism. We investigate
whether the combination of MIBI with preoperative parameters increases its
accuracy.
Patients and Methods: This is a prospective study of 453 consecutive patients
with secondary hyperparathyroidism who underwent parathyroidectomy
(bilateral neck exploration). All of them underwent preoperative MIBI
scintigraphy. MIBI readings were compared with intraoperative and
histopathology findings and four patient groups were comprised according to
the results: TP group for true positivity, TN group for true negativity, FP group
for false positivity and FN group for false negativity.
Results: MIBI scintigraphy sensitivity, specificity, positive predictive
value and negative predictive value were 66.4%, 50%, 76.3% and 37.9%
respectively. For the TP group, mean age and mean parathormone (PTH)
value were 56 and 754 respectively. The binary logistic regression for the
prediction (1) or no (2) of the true positivity was: 0.138 + (-.011) * age +
0.001 * PTH (p =.012). For the TN group, mean age and mean phosphate
value were 49 and 5.24 respectively. The binary logistic regression for the
prediction (1) or no (2) of the true negativity was: -1.463 + age * (-.029) +
phosphate * 0.233 (p =.012).
Conclusion: MIBI accuracy in patients with secondary hyperparathyroidism is
increased when combined with other preoperative parameters. The sensitivity
is increased as patients get older and the PTH levels get lower. The specificity
is increased as patients get younger and the phosphate levels get lower.
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Introduction: While graft survival and good functional outcome encourage to
continue hand transplantation in humans, skin rejection remains to be one of the
remaining obstacles. To understand in greater depth the molecular mechanisms
involved, molecular markers of lymphocyte trafficking and cellular rejection
have been investigated in human hand transplantation and targeted in an
experimental limb transplant model.
Methods: Skin biopsies taken from three bilateral hand transplants were assessed
by H&E histology and graded as per previously a published classification 0-IVb.
Based on the analysis of a multitude of molecular markers lymphocyte infiltration
and trafficking, VE-cadherin was selected and targeted with the fibrin derivative
Bβ;15-42. Bβ;15-42 was investigated for its capacity to inhibit lymphocyte
migration in a Brown Norway to Lewis rat hind-limb allotransplant model.
Animals treated with subtherapeutic doses of Tacrolimus (0.1mg/kg) together
with Bβ;15-42 (5mg/kg) were compared to untreated controls.
Results: The majority of infiltrating lymphocytes in skin rejection are positive for
CD11a. Upon rejection, VE-cadherin was expressed exclusively on endothelial
cells with a tendency towards higher expression prior to and during early stages
of rejection. When tested in the animal model, treatment with Bβ;15-42 together
with subtherapeutic doses of Tacrolimus significantly prolonged limb allograft
survival from 7 +/- 0 days to 17.25 +/-2.872 days (p=0.0056).
Conclusion: Molecular markers involved in lymphocyte trafficking are upregulated upon skin rejection after hand transplantation and represent promising
target for prophylaxis and treatment of rejection in limb transplantation. When
targeted in an animal model, blockade of VE-cadherin on endothelial cells
resulted in significant prolongation of limb allograft survival.
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RECIPIENT OUTCOME FOLLOWING LIVE DONOR KIDNEY
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S. Tiwari, A. Panda, D. Bhowmik
All India Institute of Medical Sciences
Aim: To study the association between transferred donor kidney volume
(TDKV), transferred donor glomerular filtration rate (TDGFR) and donor age
(DA) to the recipient glomerular filtration rate (eGFRr) at different time points
(m) after transplantation (3, 6, 9 and 12 m).
Material and methods: A prospective study was conducted in 53 living,
related, voluntary kidney donors and their recipients. The TDKV was assessed
using the formula V = 0.49 x L x W1 x W2 (L= length, W= width). DTPA GFR
of the donor was used and transferred kidney GFR (TDGFR) was derived. The
donor parameters were used to stratify recipients into two groups and they were
compared. Factors influencing the eGFRr at different time points were also
studied using linear regression analysis.
Results: The mean donor age was 41.4 ¡À 11.9 years (y) while that of recipient
was 34 ¡À 10.6 y. The mean TDKV and TDGFR were 93 ¡À 22.2 mm3 and
47.3 ¡À 8.6 ml/min/1.73 m2 respectively. Recipient eGFRr for those with better
donor parameters [TDKV (¡Ý90 mm3), TDGFR (¡Ý40ml/min/1.73 m2) and
DA (<45y)] and worse donor parameters [TDKV (<90 mm3), TDGFR (<40ml/
min/1.73 m2) and DA (¡Ý45y)] were segregated and compared. There was no
statistical difference between the two groups. The recipient eGFRr(time) was
84.63¡À23.4 (3m), 80.2¡À20.45 (6m), 78.82¡À21.33 (9m) and 77.80¡À17.6

752

(12m) ml/min/1.73 m2. By linear regression (univariate and multivariate) DA
had an influence on eGFRr at 3m and 12m. TDKV influenced eGFRr at 3 and
6m. TDGFR influenced eGFRr at 6m.
Conclusion: TDKV, TDGFR and DA influence the recipient eGFRr. The
associations vary at different points. Serial assessment can predict graft
function during follow-up.
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2303 BENEFICIAL EFFECTS ON THE RENAL FUNCTION OF
BOTH THE RECIPIENTS AND DONORS IN LIVING DONOR
KIDNEY TRANSPLANTATION
S-U. Choi, C-K. Oh, S.N. Yoon, B.M. Lee, J.H. Kim, S.J. Kim, H. Kim,
G.T. Shin
Ajou University School of Medicine
Objectives: In living donor kidney transplantation, initial function of donor¡¯s
bilateral kidneys before donation would be split into the function of donor¡¯s
remnant kidney and recipient¡¯s implanted kidney after transplantation. The
questions whether the function of donor¡¯s remnant kidney would increase or
decrease after donation and whether that of donor¡¯s donated kidney would be
more or less than that of recipient¡¯s implanted kidney after transplantation were
addressed.
Methods: The functional ratio of each kidney using 99mTcDTPA as well
as serum creatinine (Scr) and creatinine clearance (Ccr) with 24-hour urine
from 100 donors were measured and calculated. The heights and weights of
donors were measured and recorded. The body surface area (BSA) and the
lean body weight (LBW) were calculated. The Ccr was also calculated using
Cockcroft and Gault formula (Ccr-CG). After kidney donation, Scr and Ccr
of the remnant kidney with 24-hour urine from the donors were measured and
calculated within 7 days post-nephrectomy. The Ccr of the remnant kidney
of the donors was also calculated using Cockcroft and Gault formula (CcrCG).
For the recipients, Scr and Ccr of the implanted kidney with 24-hour urine from
the recipient were measured and calculated within 7 days post-transplantation.
The BSA and LBW of recipients were also calculated. The Ccr-CG of the
implanted kidney of the recipients was also calculated. The cases of the patients
with an episode of rejection within 7 days post-transplantation were excluded.
Results: The average functional ratio of donated kidney vs. remnant kidney
before donation was 50.7:49.3. The average Scr, Ccr, and Ccr-CG of the
donors were 0.85 ¡¾ 0.17, 110.4 ¡¾ 20.8, and 82.8 ¡¾ 17.3, respectively.
Before donation, the average fractions of Ccr and Ccr-CG of donated kidneys
were 55.9 ¡¾ 11.8 and 42.0 ¡¾ 9.9, respectively, compared to those of remnant
kidneys 54.5 ¡¾ 11.4 and 40.8 ¡¾ 9.3, respectively. After donation, the Ccr
and Ccr-CG of donor¡¯s remnant kidney increased to 68.0 ¡¾ 14.3 and 53.6
¡¾ 11.6, respectively. On the recipient side, after implantation, the Ccr and
Ccr-CG of donor¡¯s donated kidney also increased to 78.4 ¡¾ 18.0 and 53.3
¡¾ 16.4, respectively.
Conclusion: Kidney transplantation from a living donor should be encouraged
based on the total functional benefit of both donors and recipients after kidney
donation and implantation.
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2304 TOWARD PATIENT SAFETY: SCREENING FOR
POTENTIAL LIVE KIDNEY DONORS
S.E-D. Al-Horani
Saad Specialist Hospital
Background: It seems that there has been an increase in patients waiting for renal
transplantation each year. However, the major source of organs, heart beating
cadaveric donors is declining. For that living donation is the other method of
addressing the gulf between supply and demand for kidney transplants. However,
few donors manage to complete the extensive work up. This study looked at
the reasons for failure to complete the live donor renal assessment and suggests
options, which may improve the situation as per needed.
Methods: Retrospective analysis of data collected from June 2006 till August
2007 of all potential live donors entering the assessment program at Saad
Specialist Hospital.
Results: Between June 2006 and August 2007, Sixty-two potential live
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donors were seen for assessment of renal donation (37 males and 25
females). Forty-one (66.1%) of the potential live donors seen actually went
on to donated. Nineteen (46.3%) were brothers or sisters, nine (21.9%)
siblings, six (14.6%) parents, four (9.7%) cousins and three (7.3%) were
spouses. In our series there was a male preponderance. The reasons for
non-donation classified as either fixed (absolute) or modifiable. Of the 21
(33.9%) who did not donate, immunological problems (positive crossmatching or blood grouping incompatibility) combined accounted for six
(28.0%). Three potential donors were found to have inadequate glomerular
filtration rate (GFR). Two potential donors (10%) were deemed unsuitable
for a live donation after review by transplant surgeons, these individuals had
ejection fraction (EF) less than 30% while there are eleven (52.0%) potential
donors who did not donate because of medical reasons. There were eleven
(52.0%) potential donors who were unable to donate for medical reasons.
Cardiovascular disease mainly cardiac failure (36.3%) is the commonest
reason for non-donating. Renal stone disease accounted for (18.2%),
diabetes mellitus (18.2%), and proteinuria (18.2%). Hematuria was found
in (9.1%) potential donors. This individual was found to have an inadequate
glomerular filtration rate.
Conclusion: Promotion of donor safety is the golden rule of living donor
program. Potential donors who did not donate because of either positive crossmatching or blood grouping incompatibility accounted for 28.0%. These were
taken out of the transplantation pool. If we considered them and inserted them
in the pooled exchange it will accelerate the wheel of transplantation and
minimize the long transplant waiting list. Donor exchange program could be
the potential solution.
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2305 DO THE DONOR-SPECIFIC TRANSFUSION INFLUENCE
THE OUTCOME OF LIVING KIDNEY TRANSPLANTATION?
T Rainiene1, N. Izvolskaja2, B. Dainys1,3, G. Kucinskis1
1
Vilnius University Hospital Santariskiu Klinikos, 2Vilnius University
Antakalnio HospitalVilnius University
A pretransplant donor blood transfusion to the patients (pts) – the donorspecific transfusion (DST) – is still being explored today. However, the
DST benefits are controversial and its long-term effects have not been well
discussed. We aimed at evaluating the efficacy of the DST in living kidney
transplantation (Tx) performed between 1992 -2000. This is a report of our
experience with 19 pts (the study group), who received the DST 1-3 times
with a 2-week interval under CsA or AZA during the course of the DST.
One pt (5.3%) produced a donor specific antibody after the first transfusion,
one pt was not transplanted because of the donor’s disease, 17 – were
grafted: 13 – from relatives and 4 – from spouses. The 17 transplanted pts
were compared with a group of 47 living kidney transplant pts without the
DST. The groups were comparable for the recipients’ age (29.7±15.0 vs
30.6±9.6), the donors’ age (44.1±6.2 vs 45.6±6.1), the male/female ratio
(0.8 vs 0.8), HLA mismatches (3.1±0.9 vs 3.1±0.5), cold ischemia time,
time on dialysis (14.6±12.9 months vs 10.7±7.1 months), the first Tx or
re-transplantation, the panel reactive antibody (PRA). The maintenance
immunosuppressive therapy was the same in both groups (prednisone,
mycophenolate mofetil or azathioprine, cyclosporine). We did not reveal
significant differences in actuarial graft survival, calculated by KaplanMeier, at 1, 5 and 10 years. In the DST group it was 100%, 93.8%, 87.1%
and in the control group – 91.5%, 87.3%, 70.5%, respectively. Graft
function, evaluated by the serum creatinine level, was excellent (<130
ìmol/l) one year after Tx in 52.9% of the DST group pts and in 33.3%
of the control group pts. The differences were not significant. The DST
group had significantly lower acute rejection episodes during the first year
(11.8% of pts vs 46.8%, ÷2=4.2899, p<0.05).
Our results demonstrate that in spite of an unavoidable low risk of sensitization,
a beneficial effect of the DST – a significantly lower incidence of acute rejection
and tendency for better graft survival and function – was observed.
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2306 THE IMPACT OF GRAFT VOLUME AND WEIGHT
ON EARLY LIVING DONOR KIDNEY TRANSPLANTATION
OUTCOME
R.J. Soewardi1, R.M.R. Liquete2, M.L.S. Chua-Garcia1
Center for Renal Diseases, St. Luke’s Medical Center, Philippines, 2The
Transplant Service, St. Luke’s Medical Center, Philippines
Background: The impact of graft mass on living donor kidney transplantation
outcome has not been studied extensively. Graft weight to recipient mass
ratio represents a potentially important parameter on kidney transplantation
outcome. Weight disproportion between donor and recipient is a risk factor for
the development of chronic graft nephropathy. The objective of this study is to
determine the effect of graft volume and weight, and recipient body mass on
early living kidney transplantation outcome.
Methods: 57 living non-related kidney transplantation, older than 18 years old,
were included in the study. Subjects were excluded if they had simultaneous
pancreas-kidney transplant, cadaveric donors, highly sensitized recipients
(previous kidney transplant, positive panel reactive antibodies (PRA), multiple
pregnancies, multiple blood transfusion prior to transplant), had systemic
or local infection, and any complications such as urologic adverse events
post-operatively. Immunosuppressive protocol consisted of induction with
monoclonal antibody and maintenance with tacrolimus, mycophenolate mofetil
and corticosteroid. Parameters of the metabolic demands of donor and recipient
consisted of body weight, height and body mass index (BMI) were collected.
The size of the graft was measured in-situ before retrieval, and the weight of
the graft was measured directly before cold perfusion. Serum creatinine was
measured on daily basis until it reached the level of less than or equal to 1.5 mg/
dL. 125I-iothalamate glomerular filtration rate (GFR) of the graft was obtained
on day 7 post transplant. Independent samples t-test, chi-square test and logistic
regression analysis were carried out to determine the significant predictors of
acute rejection or delayed graft function.
Results: Higher donor kidney weight/recipient BMI (DKW/RBMI) ratio
was associated with better graft function (p < 0.001). Donor BMI is an
independent predictor of kidney graft volume and weight (p < 0.001 and p <
0.001 respectively). Graft function was significantly associated with donor and
recipient BMI, and graft volume and weight.
Conclusions: In living donor kidney transplantation, donor and recipient BMI,
and graft volume and weight should be considered in order to achieve better
early graft function. Donor BMI can be used to predict kidney graft volume and
weight for donor allocation prior to transplantation.
Keywords: kidney transplantation, living donor, graft function, graft weight,
graft volume, glomerular filtration rate
1
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2307 ANALYSIS OF THE REASONS FOR APPLYING FOR
LIVING DONOR KIDNEY TRANSPLANTATION
R. Kushiyama, K. Sakai, T. Suzuki, S. Nobori, A. Yoshizawa, H. Ushigome,
S. Sakamoto, M. Okamoto, N. Yoshimura
Kyoto Prefectural University of Medicine, Graduate School of Medicine,
Department of Transplantation Surgery
Background: In Japan, kidney transplantation (KTx) is mainly performed from
living donors (almost 80% of all KTx). The background of decision for living
donor kidney transplantation (LDKTx) is more complicated than cadarveric
donor kidney transplantation, because the will of donors as well as recipients
should be taken into consideration. In this study, we analyze the motivation
for LDKTx.
Method: From April 2006 till May 2007, eighty-eight patients were referred
for LDKTx. We analyzed the background and motivation of both donors and
recipients referred for LDKTx through several times of interviews.
Result: Sex of the recipients were 48 males, and 40 female, and the median
age was 45 (3 – 71). Three quarters of them were under hemolytic dialysis
(HD). The relations between recipients and donors were spouse (30%), parents
(38.7%), child (1.1%), siblings (19.3%), cousins (1.1%), and others (5.7%). A
quarter of them gave up LDKTx. The reasons were followed; medical reasons
(66.7%), patients f will (14.3%), and donors f will (14.3%). The reasons for
applying for LDKTx were followed; escape from HD (28.4%), improvement
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of patient’s QOL (20.5%), wish for pregnancy (5.7%), improvement of family
fs QOL (10.2%), donor fs will (12.5%), and others(22.8%). While 48.9% of
recipients hope LDKTx for themselves, 30% of patients were referred for
LDKTx because of the donor’s will rather than the resipent’s hope.
Conclusion: The background of reference for LDKTx is various, and nearly
half of patients were referred for LDKTx because their family member including
donor hopes LDKTx rather than HD or CAPD as a treatment for chronic
renal failure. This study shows that the donors do not reluctantly propose for
donation, but they propose for donation in expectation of improvement of their
own and families f QOL.
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2308 EARLY EXPERIENCE OF LIVE RELATED KIDNEY
TRANSPLANTATION IN A NEW CENTER, BANGLADESH
N. Hassan, S. Iqbal, W.M.M. Haque, M.A. Mansur, Z. Ahmed
BIRDEM Hospital
Number of patients developing ESRD from diabetes is increasing world wide
including Bangladesh. Between November,2004 to December 2007 total 30
cases had undergone Living Related Kidney Transplantation. Average age
was 35 years (Range 19 – 53 years) male 23 and female 7. Cause of ESRD
was Glomerulonephritis in 20 (66.6%), Diabetic Nephropathy in 7 (23.3%)
and Hypertension in 3 (10%). Three cases were preemptive. All donors were
live related. Relationship between donor and recipient were siblings 22(73%),
mother 6(20%), spouse 1(3%), and uncle 1(3%).
Immediate post-operative graft nephrectomy was required in 1 patient due
to renal artery thrombosis, HD required in 1 patient due to ATN. Among
the rest 28 recipients, renal function came to normal (1.1+0.2mg/dl) on
discharge at 10th postoperative day in 21(70%) cases and Serum creatinine
was elevated (2.1+0.4) in 7(23%). Blood pressure was controlled (<130/80)
by 3 or more antihypertensive in 5 cases, 2 antihypertensive in 7 cases, only 1
antihypertensive in 6 and without any antihypertensive in 9 patients 3 months
after transplantation. We used Cyclosporin, Mycophenolate and Prednisolone
as immunosupressive regimen in all recipients. Average Cyclosporin dose
requirement was 6 mg/kg/day at 2 weeks. In last 3 years follow up 7 (23%)
patients expired 1 due to surgical complication, 2 due to septicaemia, 1 due to
hemorrhagic stroke, and another 3 due to chronic rejection. At one year patient
survival was 86.6%.
Initial out come of live related renal transplantation in a new center including
diabetic patients and with these immunosuppressive regimens is encouraging.
Long term follow up with increased number of patients is required for further
assessment.
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2309 WHEN FAMILY SECRETS ARE UNCOVERED:
DISCOVERY OF MISATTRIBUTED PATERNITY
INFORMATION AT US TRANSPLANT CENTERS
N. Schroder1, A. Haririan2, C. Welsh3, M. Cooper4
University of Maryland Medical Center, Dept. of Social Work, 2Dept. of
Medicine, 3Dept.of Psychiatry, 4Dept. of Surgery
Background: We sought to determine the prevalence of the discovery
misattributed paternity (MP) in parent-child living kidney donor (LKD)
transplants among other US transplant (Tx) centers. Established policies/
practices in treatment of such powerful and potentially explosive information
were investigated.
Methods: Questions regarding MP were a component of a 68-question online
survey examining various psychosocial policies and practices among US Tx
centers. The survey was mailed via listserv to 2 professional Tx societies.
Characteristics of the 69 participating Tx centers are summarized in Table 1.
1

Number/yr

Overall Tx
(% of centers)

LKD Evaluations
(% of centers)

LKD Tx
(% of centers)

≤ 50

21.9

43.9

63.4

51-100

37.5

22.8

22.2

101-200

23.4

19.3

11

200+

17.7

14

3.2
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Results: 70% of the centers claimed to have discovered MP upon review of
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HLA testing of parent and offspring pairs evaluated for LKD transplantation.
Significant variability was demonstrated in the manner in which Tx centers
proceeded upon discovery. 17.6% of centers continued with evaluation and
donation without disclosing the paternity information to either party. 2 centers
addressed the information only if the donor and recipient were found to be a
viable match. 3 centers disclosed the information only to the donor and 1 center
disclosed the information only to the recipient. 44.1% discussed the results
with a multidisciplinary team on a case-by-case basis but did not indicate a
final outcome.
24.6% of centers include the potential for the discovery of MP information as
part of informed consent prior to HLA testing. Although the majority of centers
queried have encountered the discovery of MP, only 28% of centers currently
have a policy upon discovery of this information. Transplant center volume
showed no correlation with policy development.
Discussion: The results of this survey clearly demonstrate that discovery of MP
is an ethical dilemma commonly experienced by many US Tx centers. There
is, however, no consensus among transplant professionals as to the need for a
more inclusive informed consent accounting for such discovery or the process
in which such information should be shared and/or utilized in the decision for
donor suitability.
Conclusion: These results call for intense discussion and debate by the Tx
and bioethics communities with the aim of exploring policies and standards of
practice for this area of transplantation.

POSTER BOARD NUMBER P4 – 360
2310 OUTCOME OF ASSESSMENT OF POTENTIAL LIVING
KIDNEY DONORS
S. Stacey1, J. Akoh
1
Plymouth Hospitals NHS Trust, 2Plymouth Hospitals NHS Trust
Introduction: The living donor transplant programme was re-established in
January 2003, with the appointment of a living donor transplant coordinator
(LDTC) and meticulous assessment of all potential living donors in conjunction
with local and national guidelines. The UK law was altered to allow altruistic
non-directed donation and paired exchange in September 2006 and thereafter,
these schemes were introduced. The aim of this study is to highlight the
outcome of assessment of potential donors within a single centre.
Method: Between January 2003 and February 2008, 364 potential donors (237
related, 120 unrelated and 7 altruistic) where referred to the stages assessment
process for living kidney donation. By the end of February 2008, 351 of these
had completed first stage and 143 in various levels of second stage assessment.
Records of assessment and outcomes were entered prospectively into a
spreadsheet maintained by the LDTC.
Results: The reasons for exclusion from stage 1 are shown in Table 1. Of the
143 proceeding to stage 2 assessments, 25 were excluded for medical and other
reasons and 46 currently being assessed. Sixty five donor nephrectomies were
performed with 7 awaiting surgery giving a donation rate of 21.3% (65/305)
and a potential donation rate of 24% (72/305) if the 7 successfully donate.
Unusual discoveries during assessment of potential donors include 1 donor
with breast cancer, 1 with non-Hodgkin’s lymphoma identified on abdominal
CT scan and another discovered to have non-Hodgkin’s lymphoma in the
transplanted kidney. This was possible only following the fortuitous transplant
nephrectomy due to renal vein thrombosis on day zero.
Conclusion: The yield rate was 21.3%. There are psychological and
economic implications of exclusion on medical grounds. The recent
introduction of paired exchange and non-directed donation will improve
donation rates. ABO incompatible transplantation or desensitization of
potential recipients may also improve living donation rates.. Seventy four
patients would have been referred for paired donation were this option
available during the entire period.
Death while on the waiting list for transplantation still constitutes a significant
problem. Perhaps relatives and significant others should be invited to consider
the option of living donation at the time of patient entry on the transplant
waiting list.
Table 1 Stage One (n = 351)
Reason for exclusion

Number

ABO incompatible

49

Donor/recipient withdrawal

41
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Positive crossmatch

25

Unacceptable antigens

9

More suitable live donor (multiple donors)

43

Cadaveric transplant

34

Death of prospective recipient

7

Progressed to stage two

143

Total

351

donors were worked up within that period. We have transplanted 107(50%)
living kidney recipients with 18(7%) waiting to be transplanted and 20 are
still in the middle of the work-up. In total 125(48.6%) potential living kidney
donors were refused and excluded. Thirteen potential kidney donors did not
proceed with the work up due to incompatible blood group. There were 30
potential donors refusal and 5 recipients refusal. Seventy-seven donors were
excluded based on their medical reason as below:

POSTER BOARD NUMBER P4 – 361
2311 COMPARISON OF IMMEDIATE AND SLOW GRAFT
FUNCTION IN LIVING DONOR KIDNEY TRANSPLANTATION
S.Y. Lee, H. Yoon, B. Hyoung, D.Y. Jeon, H. Hwang, B. Choi, Y. Kim,
B. Bang, C. Yang
Division of Nephrology, Department of Medicine, The Catholic University of
Korea Kangnam St. Mary’s Hospital, Seoul
Purpose: Slow recovery of graft function (SGF) is frequently observed in
decreased donor transplantation. But, the definition and clinical outcome of
SGF in living donor kidney transplantation are unclear. The purpose of this
study is to evaluate the clinical characteristics and pathologic findings in
patients with SGF in living donor transplantion.
Methods: Among, 204 adult living kidney transplants, one hundred and seventy
four recipients were included. According to serum creatinine (SCR) level at
day 14 after transplantation, recipients were categorized into immediate graft
function (IGF,SCR <1.5 mg/dL) and SGF (SCR ¡Ã1.5 mg/dL) based on serum
creatininine level at day 14 after transplantation. Of the 174 recipients, 144
(82.8%) had IGF, 30 (17.2%) had SGF. Immunesuppressants were cyclosporine
(n=107), FK506 (n=66) and rapamune (n=1). Clinical characteristics and
pathologic findings, and clinical course were compared between groups.
Results: Female recipients were dominant (95.7%) in the IGF group, but male
recipients (90%) was dominant in the SGF group (p = 0.05). In part of the
donor characteristics, mean donor age in the IGF group was younger than the
SGF group (37.4 years vs. 43.2 years, p = 0.009), and donor height was higher
in the IGF than the SGF group (165.29 cm vs. 161.65 cm, p = 0.038). Donor
creatinine clearance in the IGF group was higher than the SGF group (98.42
mL/min/m2 vs. 85.84 mL/min/m2, p = 0.009), and donor serum albumin level
in the IGF group was higher than the SGF group (4.37 g/dL vs. 4.25 g/dL. p
= 0.04). Of the 141 protocol biopsy performed at day 14 after transplantation,
114 (80.9%) was in the IGF group and 27 (19.1%) was included in the SGF.
Of the 114 IGF, 77 (67.5%) showed normal, 12 (10.5%) borderline, 10 (8.8%)
acute rejection, 7 (6.1%) CsA toxicity, 5 (4.4%) acute tubular necrosis, and 3
(2.6%) obsolescence. On the other hand, near half of patients with SGF showed
borderline change (n=13, 48.1%). And in the rest of SGF group, 7 (25.9%)
showed normal, 5 (18.5%) CsA nephrotoxicity, and 2 (7.4%) obsolescence. (p
< 0.05) Immunesuppressive agents also influenced the graft function. In the
CsA group, 96 (89.7%) was in IGF and 11 (10.3%) was in SGF. In the FK506
group, 47 (71.2%) was in IGF and 19 (28.8%) was in SGF. (p = 0.007).
Conclusion: SGF in living donor transplantation is influenced by donor and
receipient factors.
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2312 LIVING KIDNEY DONORS: EVALUATION, EXCLUSION
AND ELIGIBILITY.
Y.L. Thye1, D. Lincoln2, R. Paul2, C. Jeremy
1
University Malaya Medical Centre, 2Westmead Hospital, Sydney
The use of living kidney donors increased dramatically in number nowadays
following the successful outcome of both genetically or emotionally related
live donor kidney transplantations. The Amsterdam Forum has set forth a
list of medical criteria including psychosocial evaluation that is now used
internationally in the evaluation of potential kidney donors. We conduct a
review on our living kidney donors and to examine on the centres’ practice of
donors evaluation and exclusion criteria.
Objective: To evaluate the potential living kidney donors based on the centres’
practice and to compare with the Amsterdam Forum’s criteria.
Methods: A retrospective analysis of all potential kidney donors evaluated
from January, 2003 till December, 2006 in a single transplant centre.
Results: There were 214 potential kidney recipients with 257 potential kidney

Medical reason:
Glomerulonephritis
Renal vessels abnormalities (Bilateral double or triple renal arteries, FMD)
Medical unfit (ischemic heart disease, obese (BMI>35), chronic obstructive lung
disease, glucose intolerance, hypertension, continue to drink and smoke
Positive crossmatch
Low GFR(< 85 ml/min/1.73m2)
Previous h/o melanoma
Hepatitis C
Psychiatry unfit
Abnormal kidney anatomy: duplex kidney, size mismatch

No. of donors
3
11
27
21
3
1
2
1
8

Out of the 107 living kidney donors, 99 had laproscopic donor nephrectomy
and 8 were open nephrectomy with 4 unplanned. The living kidney donor
transplants were mainly siblings (30%) followed by parents and spouses
(25.5% and 24.5% respectively) with one undirected living donor. The mean
age of the donors were 45, the youngest was 22 year old and the eldest was
71 year old. We have 12 donors who are hypertensive and 1 well controlled
newly diagnosed diabetic. There were 8 with previous history of malignancy in
remission and 3 donors with history of renal calculi. Three has borderline GFR
of 85 ml/min/1.73m2.
Conclusions: We found that our selection for donation are more restricted on
certain medical criteria but we are now accepting older donors and even those
with treated history of renal stones, hypertension and diabetes. Variability in
the selection criterias among centres should be accepted provided they meet
additional criterias as discussed elaborately at the Amsterdam Forum. The
exclusion criteria and the eligibility criteria in our centre were comparable
to the Amsterdam guidelines. Longer follow-up on the donors and recipients
outcome are required.
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2313 EXPANDING THE POOL OF NON-TRADITIONAL LIVING
KIDNEY DONORS
W. Zuidema1, J. van de Wetering1, J. IJzermans2, W. Weimar1
1
Internal Medicine; Erasmus MC, 2General Surgery; Erasmus MC
Background: In most countries the wait time for deceased donor kidney
transplantation has increased over the last decennia. Therefore several
approaches were undertaken to overcome the discrepancy between demand and
supply, e.g. by the (re)introduction of living kidney donation programs.
Traditionally, living genetically related donors provided these kidneys.
However, after it appeared that excellent results could also be obtained with
kidneys from genetically unrelated donors, a number of non-traditional
donation programs emerged. We here describe the shift from traditional to nontraditional programs including donation by partners, friends, Good Samaritans,
crossover and domino-paired donors.
Methods: We analysed all 694 living kidney donations performed in our centre
between 1981 and 2007, and stratified them in three tertiles, which took place
from 1981-2000 (N=231), 2000-2004 (N=232), and 2005-2007 (N=231).
Results: The number of years needed to complete tertiles dramatically decreased
from 19 years for the first to 3 years for the last, reflecting the increasing living
donation activities. At the same time we observed in the living donor group a
steadily growing proportion of non-traditional donors: from 12% in the first, to
35% in the second and to 57% in the last tertile. Within this unrelated donor
group the proportion of partners decreased from 100% in the first tertile to 64%
in the second and 43% in the most recent one, reflecting the emergence of other
donor categories in the two last tertiles. Indeed, while the absolute number
of partner donations remained stable in these last two tertiles, the number of
other non-traditional donors increased 2.6-fold. In the last tertile (2005-2007),
100 related and 131 unrelated kidney donations took place, of which 56 were
derived from partners and 75 from others. These other non-traditional donors
were friends (N=27), crossover donors (N=20), Good Samaritans (N=18) and
domino-paired donors (N=10).
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Conclusion: The number of living kidney donation is spectacular rising with
a shift to non-traditional donors. The number of donating partners seems to
stabilise, but the rise in other non-traditional donors still continues and further
expands the living donor pool.
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2314 MEDICAL EXCLUSIONS TO SUCCESSFUL LIVING
KIDNEY DONATION
S. Norman, P. Song, A. Ojo, Y. Hu
University of Michigan
Background: Given the disproportionate prevalence of hypertension (HTN)
and diabetes mellitus (DM), African American (AA) potential live kidney
donors may be at increased risk of being medically unsuitable as donor
candidates. We examined the barriers due to medical diagnosis and other factors
in a large cohort of living donor candidates presenting at a large Midwestern
kidney transplant program.
Materials and Methods: All adult (age > 18 years) potential living kidney
donor candidates initially evaluated between January 1, 1996 and June 30, 2006
were studied and classified according to the following primary outcomes of
the donation process: Successful donation; medical exclusion; or non-medical
exclusion from donation. Logistic regression was used to evaluate the effect
of age, race, gender and other medical factors on the likelihood of successful
donation.
Results: Of 2,520 donor candidates in the study, 60% and 74% were female and
Caucasian (CA), respectively. The mean age of donor candidates was 41 and
the median body mass index (BMI) was 26.4 kg/m2. Donor BMI was higher
in AA vs. CA candidates (1.07, p< 0.0001) and increased by 0.25% per year of
age (p < 0.0001). Overall, 46% of donor candidates were successful. Male and
female candidates were equally successful as donors. AA were less likely than
CA to successfully donate (OR 0.54 p< 0.0001). Age was a significant factor,
with each advanced year of age increasing odds of donor exclusion by 2% (OR
0.98 p < 0.0001)(fig 1). Among donor candidates excluded for medical reasons,
the common diagnoses leading to exclusion were HTN (23.64%), a positive
final crossmatch (11.14%) and reduced renal function or low glomerular
filtration rate (GFR, 10.77%). HTN was the most frequent exclusion diagnosis
in female candidates, but less prevalent than in males (18% vs. 33%, p <
0.0001). HTN was equally prevalent in excluded AA and CA donors (23% and
25% respectively, p=ns). In excluded AA donors, obesity accounted for 12.75%
of medical exclusions. Among excluded CA donors, low GFR accounted for
10.59% of all cases.
Conclusion: Hypertension, increasing age and African American race are the
leading contributors to disqualification of living donor candidates. Relative to
Caucasians, obesity accounted for a significant fraction of excluded African
American donor candidates.
Figure 1: Plot of success rate vs. age in difference races. Red =African
American, black = Caucasian, blue = overall effect
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2315 LIVING-UNRELATED RENAL TRANSPLANTATION
PROVIDES COMPARABLE RESULTS TO LIVING-RELATED
RENAL TRANSPLANTATION: A 10-YEAR SINGLE-CENTER
EXPERIENCE.
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B. Aguilar1, R. Bernal, R. Mondragon
1
Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico
ISSEMyM
Introduction: The increasing success of renal transplantation is paralleled by
the increased size of the waiting list. Efforts to increase the donor pool have
included the use of living-unrelated kidney donors. AIM: The purpose of this
study is to compare the long-term results of kidney transplantation from living
unrelated donors with that from living related donors.
Patient And Methods: During a 10-year period our center performed 176
transplants, 103 transplants came from living donors; 89 patients received
living-related donations (LRD), and 11 patients received living non-related
donations (LURD). During the same period 73 patients received cadaveric
renal donor transplants. We reviewed and compared the long-term data from
these cases.
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Results: The LURD group included 8 mens and 4 females with an overall
mean age of 41(range 24 to 62) years with mean follow-up of 120 months. The
LRD group included 65 males and 24 females recipients with overall mean age
of 28 (range 14 to 50). A total of 8 (72%) of living non-raleted transplants were
spousal transplants and three (28%) were from family friends, four cases were 0
human leukocytes antigen–identical, 7 were identical and 0 were haploidentical
of the patients who received LURD group, versus 0 human leukocytes antigenidentical in four cases, identical in 78 cases and haploidentical in seven cases
on the LRD group, the crossmatch proteins were negative in all cases.
Results: Eigth (72%) Of 11 LURD recipients are alive, as are 81 (91%) of 89
LRD recipients. Mean current creatinine is 1.04 mg/dl for the LURD group
and 1.4 mg/dl for the LRD group Kaplan-Meier 1- and 5-year graft survival
was 97% and 94% for the LRD group, 91% and 82% for the LURD group (p
= not significant),
Conclusions: LURD patient and graft survival is comparable to LRD transplants
despite inferior human leukocyte antigen matching. LURD transplant survival
is superior to that of cadaveric renal donor transplants. LURDs are an excellent
but underused source of organs for renal transplant recipients.
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2316 COMPARISON OF THE DECISION TO DONATE AND
ATTITUDES FOLLOWING DONATION IN BLACK AND WHITE
LIVING RENAL DONORS
M.T. Nolan1,2, L.E. Boulware3, L.E. Taylor1, J.K. Melancon3, A.E. Belcher1,
L. Rose1, K. Dane4, S. Klunk4, M. Hoffman1, R.E. Thompson5
1
Johns Hopkins University School of Nursing, 2Johns Hopkins Berman
Institute of Bioethics, 3Johns Hopkins University School of Medicine, 4The
Johns Hopkins Hospital Department of Surgery, 5Johns Hopkins Bloomberg
School of Public Health
Background: Blacks awaiting renal transplantation are less likely to receive
living donor organs than Whites but few studies have prospectively explored
racial differences in living renal donors from evaluation to the recovery period.
Therefore, this study compared Black and White living renal donors/candidates
in level of family stress in the year prior to donor evaluation, family income,
family involvement in the decision to donate, and postoperative perceptions of
the donation experience and attitude toward donation.
Methods: In interviews during donor evaluation, we measured family stress
during the past year, family income and the donor’s relation to the recipient. Three
months after donation, we asked about family involvement in the decision to
donate, satisfaction with the care received while hospitalized and after discharge,
and attitudes towards donation. Descriptive statistics, chi square analysis and
a t-test were used. Satisfaction with care during and after hospitalization and
attitude toward living donation were each measured on a scale ranging from 3 to
18 with higher scores indicating a more favorable response.
Results: Among 390 donor candidates, the mean (range) age was 44 (18-79)
years, 61% were female, 79% were White, 80% had at least some college
education, and 61% were married. In the 174 who went on to donate, Blacks
had higher levels of family stress in the year before donation (323.63 vs.
236.25, p =.01) and were more likely to report a total household annual
income of 40,000 or less (43% vs. 16%, p =.001). Blacks were less likely
than Whites to donate to a non-family member (12% vs. 25%, p =.02)
and were less likely to involve a family member in the decision to donate
(52% vs. 76%, p =.01). At three months however, there were no significant
differences in satisfaction with care during and after hospitalization (16.13
vs 15.89, p =.71) and attitude toward living kidney donation (17.29 and
17.15 respectively, p =.70) between Blacks and Whites respectively.
Conclusions: Transplant professionals should include family members of donor
candidates in education about donation to the extent desired by the candidate.
The lack of racial differences in the experience of donation and attitude toward
donation after surgery may provide some reassurance to Black donor candidates
who worry that they might have a more negative experience compared to White
donors. Financial risks should be carefully explained or support considered for
donors with limited income who might more readily suffer negative financial
consequences if recovery takes longer than anticipated.
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2317 REASONS FOR NON PROGRESSION OF POTENTIAL
LIVE DONOR AND RECIPIENT PAIRS TO RENAL
TRANSPLANTATION
J. Mawson, D. Verran, S. Chadban, C. Baker, R. Allen, K. Morris, K. Wyburn,
J. Eris
Renal Transplant Programme
Introduction: Static deceased donor rates are helping increase the demand
for live donor renal transplantation. With new initiatives in live donor renal
transplantation such as ABO incompatible and paired exchange it is important
to understand the reasons for potential live donor pairs not proceeding to
transplantation.
Methods: Retrospective review of records held from 2003-2007 of results
of assessment of blood group compatible prospective live kidney donor and
recipient pairings. The number declined for ABO incompatibility cannot be
reliable determined.
Results: 151/306(49%) of potential pairs did not proceed to transplantation.
Reasons for non progression to transplantation were donor issues in
65/151(43%), a positive X-match in 47/151(31%), recipient issues in
39/151(26%). In potential donors issues precluding donation were medical
in 24/65(40%)[abnormal GFR 10; diabetes 8; cardiac 6], followed by
psychosocial in 21/65(32%) and problems with renal anatomy on imaging
9/65(14%). In recipients medical issues in 34/39(87%) most frequently
precluded transplantation followed by psychosocial issues in 5/39(13%).
Recipient medical issues predominantly included cardiac in 8/34(23%),
malignancy in 5/34(15%), ongoing treatment of hepatitis C in 4/34(12%),
complications of diverticular disease in 3/34(9%). Renal function stabilised in
4/34(12%) of these recipients precluding transplantation in the short term. Two
recipients (6%) were deemed to not be suitable for ABOI renal transplantation
(programme commenced mid 2007), due to high Antibody titres and 2/34(6%)
recipients deceased during the workup period.
Conclusions: In the last 5 years close to 50% of potential live donor renal
transplant pairs did not proceed to transplantation. This has implications
both for resourcing of the programme and future strategies that may allow
transplantation between pairs previously turned down during workup.
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2318 EVALUATION OF DISCARDED LIVING DONOR IN
RENAL TRANSPLANTATION. EFFECTIVENESS OF OUR
LIVING DONOR KIDNEY TRANSPLANT PROGRAM
J. Campistol, I.R. Vicente1, R.G. del Pozo2, C. Camacho1, M.C. Sebastiá3, C.
Nicolau3, J. Martorell4, J. Vilardell5, A.A. Asensio2, J.M.C. Plana1, F.O. Salina1
1
Renal Transplant Unit. Department of Nephrology and Renal Transplant.
University Clinic Hospital, 2Department of Urology. University Clinic
Hospital, 3Department of Radiology and Radiodiagnosis. University
Clinic Hospital, 4Department of Immunology. University Clinic Hospital,
5
Transplant Services Foundation. University Clinic Hospital
Introduction: Living kidney transplantation is a good option for patients with
kidney chronic disease. An exhaustive study in potential living donors has an
important role in order to minimize the donor risks and guarantee the success
of the kidney transplant. Our aim is to review the main reasons of donation
discard of different donor – recipient couples who were studied in our living
kidney transplant program.
Materials and methods: Retrospective, unicentre, frequency- descriptive
study was made from January/2005 to December/2007. 155 donor- recipient
couples were evaluated. For initial evaluation we used a basic protocol based
on laboratory tests (general, renal function, immunological and blood group
type), radiological techniques, and medical history. Medical guidelines from
Amsterdam Forum were followed in order to evaluate the potential donors
and receptors. All living kidney donor nephrectomies were made by hand –
assistant laparoscopic technique.
Results: 72 donor- receptor couples (46.45%) were ruled out for the donation
versus 83 transplanted (53.55%). Donor mean age was similar in both
groups (52.75 ± SD13.88/49.95 ± SD12.25 years). Renal patient discarded
for transplantation were older than transplanted (46.9 ± SD13.74 vs 42.52 ±
SD14.25). Female sex was more prevalent in discarded and transplanted donors

meanwhile male sex in renal patients (68.1%- discarded/64.2%- transplanted)
In discarded couples, donor- receptor relationship most prevalent were married
couple (40.3%), mother-son/daughter (25%) and brothers/sisters (18.1%).
The most frequent reason of discard was donor pathology (45.8%) as Mellitus
Diabetes, low glomerular filtration rate, previous cardiovascular pathology,
tumoural pathology during the study, and proteinuria, followed by positive crossmatch (16.7%), cadaveric renal transplant during the evaluation (15.3%) and
incompatibility of blood group type (6.9%, not to fulfil transplant criteria used in
our center). 67.2% of discarded couples could be ruled out for transplantation with
our basic protocol, minimizing sanitary costs. In renal transplant couples, donor
survival was 100%, with recipient survival of 98.8%, graft survival 98.7% and
90.1% free- acute rejection rate. Graft function has been excellent in donors (mean
plasmatic creatinine: 1.2016 ± 0,171 mg/dl; mean creatinine cleareance: 83,69 ±
22,23 ml/min/1,73m2; proteinuria 113,61 ± 55,513 mg/ day) and recipients (mean
plasmatic creatinine: 1,3616 ± 0,403; mean creatinine cleareance: 80,34 ± 29.181
ml/min/1,73m2; proteinuria 290,28 ± 405,029 mg/day).
Conclusions: The evaluation of living donor for renal transplantation is
necessary to guarantee its health and the successful of the transplant. Two
thirds of discarded living donors can be ruled out by a basic protocol of study,
minimizing sanitary costs
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2319 FIRST CADAVER- THEN LIVING-RELATED Ï¿½
WHAT IS THE APPROPRIATE SEQUENCE OF RENAL FIRST
AND RE-TRANSPLANTATION WHEN LIVING RELATEDTRANSPLANTATION IS AVAILABLE?
W-D. Illner, M. Rentsch, C.D. Wimmer, H. Arbogast, K-W. Jauch,
Department of Surgery
Living related (LR) kidney transplantation is associated with better graft and
patient survival as compared to cadaver grafts. Since renal allograft survival
is not infinite, the necessity for renal re-transplantation becomes a clinical
condition with increasing frequency. In children renal transplantation, therefore
the recommended policy ‘first cadaver, then live donor’ has been questioned
in the past. However, rare information is available on the outcome of retransplantation in the context of living related graft donation. In this study, we
analyzed the outcome after LR kidney transplantation and LR-re-transplantation
in special respect to the sequence of second graft origin.
Patients and methods: All LR kidney transplantations (n= 262 transplantations,
233 patients), performed between 12-1982 and 03-2006, were retrospectively
analyzed, based on a prospectively updated database. Three subgroups of graft
recipients were distinguished: (1) recipients of first living related kidney grafts
(n=208), and (2) those receiving a second living related graft after a cadaver first
graft (n=25) or (3) any second graft after first living related transplantation (n=7).
The median follow-up was 87 months [7-329]. Analyses included measurements
of patient and graft survival, frequency of rejections and re-operations. Survival
rates were calculated with log-rank comparisons of Kaplan-Meier plots. Statistic
calculations were performed with SPSS, version 15.0.
Results: Mean age of the patients was 40.5 years (women 37.8, men 41.7), with
a median of 40 [17-68], 38 [16-66] and 35.5 [14-62] years in group 1, 2 and 3
respectively. The median HLA-mismatch was 3 in all groups, the rejection rates
were 15 (group 1) and 28% in both groups 2 and 3. The percentage of patients
with a pre-emptive transplantation, indicated as remaining diuresis at the time of
transplantation was markedly lower in group 2 (16%) compared to group 1 and
3 (56.3 and 42%). In addition, the rate of primary graft dysfunction was 20%
in group 2 vs. 5.7 and 0% in group 1 and 3. Twenty-four re-operations were
indicated after transplantation for minor complications, all in group 1. One graft
was lost due to arterial stenosis. Post transplant patient survival did not differ
between the groups 1, 2 and 3, with rates of 91.5, 95 and 100% at 5 years, and
90.4, 89.1 and 100% at 10 years. Evaluation of death-censored graft survival
showed rates of 95.9, 81.3 and 100% after 5 years and 94.0, 100 and 73.9 percent
after 10 years in group 1, 2 and 3 respectively (p=0.014, group 2 vs. 3).
Conclusion: Our data suggests that renal allograft survival following LR retransplantation, following previous cadaver transplantation (group 2) is not
necessarily reduced compared to first LR transplantation. However, a lower
percentage of preemptive transplantations and to a higher rate of primary
dysfunction was noted in this patient- as compared the other subgroups. LRre-transplantation may serve as reserve after loss of a cadaveric first graft in
adult recipients.
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2320 PREEMPTIVE EXPANDED CRITERIA LIVING
DONOR RENAL TRANSPLANTATION- FIRST CHOICE OF
TREATMENT OF ESRD ON THE BALKANS?
N. Ivanovski1, J. Masin1, S. Dohcev2, I. Rambabova-Busljetic1, V. Pusevski1,
Z. Popov2
1
Department of Nephrology, Skopje Medical Faculty, Republic of Macedonia,
2
Department of Urology, Skopje Medical Faculty, Republic of Macedonia
Background: Despite the efforts for transplants, dialysis remains the usual
way of treatment of ESRD in the Balkans. The living renal transplantation
(LRT) is still predominant but there is an enormous gap between the demand
and supply of kidneys.Due to the very well known reasons, there is still no
any cooperation in the field of transplantation among the Balkan countries.
Trying to solve the problem, we started to accept expanded criteria living
donors (ECD) as well as preemptive transplants from ECD as a first choice
of treatment of ESRD.
Methods: 185 LRT are performed in our Department in the last 18 years. ECD
group has 54 donors older than 65 years, 2 ABO incompatible, 21 unrelated, 10
with mild arterial hypertension, 4 with large simple cyst, and 2 with multiple
renal arteries, one with double ureter. 30 of ECD transplantations were
preemptive without performing any dialysis and blood access. The quadruple
sequential immunosuppressive protocol was used in all cases including
induction with ATG or Il-2R antagonists, Cyclosporine A, MMF/AZA and
Steroids. In ABO incompatible transplants a special preconditioning regimen
for recipients was used including laparoscopic splenectomy, Rituximab,
plasmapheresis and IvIg. The Kaplan-Meier one, three and five years graft
survival rate, rejection episodes, DGF and actual renal function were analysed.
The results were compared with the group of 80 LRT with younger donors
(YGD) performed in the same time.
Results: One, three and five years Kaplan-Meier graft survival rate for the
ECD was 94%, 83% and 65% respectively compared with 95%, 87% et 75%
of YGD. The group of preemptive ECD living transplantation showed superior
graft (95, 87 and 78%) survival compared with the younger group of donors.
The percentage of DGF was 15% in ECD group compared with 8% in YGD.
Both differences are statistically significant. The rejection episodes rate in ECD
and YGD was 24% and 21%, respectively. The actual serum creatinin in ECD
was 178 micromol/lit, compared with 154 in the YGD. The last two differences
are not statistically significant.
Conclusion: The results in our study fully justify the use of ECD especially in
the regions where the LRT is predominant transplant activity. Expanded criteria
living donors are available and their use is much more easily. The treatment
is cheaper and more effective compared with the cadaver transplantation. As
elsewhere, it may ameliorate the actual organ shortage in the Balkans. Bearing
in mind the very good results, the dialysis cost and underdevelopped cadaver
program, the preemptive living ECD transplantation is recommended as a first
choice in the treatment of ESRD on the Balkans.

POSTER BOARD NUMBER P4 – 371
2321 THE UTILITY OF CREATININE-BASED PREDICTION
EQUATIONS AND RENAL CLEARANCE STUDIES IN
EVALUATING THE GLOMERULAR FILTRATION RATE OF
POTENTIAL KIDNEY DONORS
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T. Jie, K. Billingham, A. Humar, H. Ibrahim, R. Kandaswamy, B. Kasiske, D.
Sutherland, A. Matua
University of Minnesota
Introduction: The assessment of glomerular filtration rate (GFR) is one of
the important steps in living kidney donor evaluation. Renal clearance studies
are expensive and cumbersome. For healthy kidney donors, the accuracy of
estimated GFR (eGFR) calculated from creatinine-based prediction equations
is controversial.
Method: Retrospective review of single center kidney donor evaluation.
Result: Among 733 potential kidney donors evaluated between January 2005
and December 2007, 43 patients had low eGFR based on the Cockcroft-Gault
(CG) or the modification of renal disease (MDRD) formula and underwent
either Iohexol or Tc-diethylenetriamine-pentaacetic acid renal clearance
studies. Among them, 13 were declined for donation because of low GFR
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(10) or other medical issues (3). The 30 approved kidney donors had the
following characteristics: 87.0% women, age 48.4±1.4 years (mean±SEM),
body mass index (BMI) 23.1±0.6 kg/m². The GFR was 73.9, 71.0 and 98.3
± 3.0 ml/min by CG, MDRD, and renal clearance studies respectively. The
creatinine-based prediction equations underestimated the GFR in this group
of patients (Pearson correlation coefficient r= -0.110 and 0.226 for CG and
MDRD respectively). In comparison, patients declined for donation because
of low GFR were older (60.2 ± 3.0, p = 0.034) and had lower GFR (68.6 ±
2.7, p < 0.001) by renal clearance studies, but with similar BMI 23.9, and
eGFR 63.3 and 65.5 by CG and MDRD. Of the 30 patients approved for
kidney donation, 26 proceeded to living donor kidney transplant (average
creatinine changed from 0.95 pre-donation to 1.29 mg/dL one month postdonation) with no renal insufficiency during follow-up (1.83 ± 0.90 years),
and 4 patients are waiting scheduling pending completion of the recipient
workups. During the same period, 384 living donor kidney transplants
were performed in our center. Excluding patients in this study, the average
kidney donors were younger (41.3 ± 0.6 years) and heavier (BMI 26.6 ±
0.2 kg/m²).
Conclusion: Cockcroft-Gault equation underestimates the GFR of potential
kidney donors and can be safely used as a screening tool to identify patients with
low GFR. Renal clearance studies can be selectively used in living kidney donor
evaluation, especially in healthy middle age women with low eGFR and BMI.

POSTER BOARD NUMBER P4 – 372
2322 SUB-OPTIMAL GRAFT FUNCTION EARLY AFTER LIVE
DONOR KIDNEY TRANSPLANTATION
A. Natfaji1, J. Eris1,2, K. Wyburn1, D. Verran2, A. Vasilaras2, J. Boulas2,
R.D.M. Allen2, S. Chadban1,2
1
Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney,
2
Transplantation Services, Royal Prince Alfred Hospital, Sydney
Background: Delayed graft function is common following deceased donor
kidney transplantation and is usually due to acute tubular necrosis (ATN) caused
by ischaemia-reperfusion injury (IRI). In contrast, immediate graft function is
expected following live-donor kidney transplantation, presumably due to the
lesser degrees of IRI. We sought to determine the incidence and causes of suboptimal graft function following live donor kidney transplantation.
Methods: Retrospective study of all live donor kidney transplant recipients
at our centre from 2004 to 2007. Data were extracted from medical records,
including daily serum creatinine and eGFR (MDRD formula). Donor
nephrectomy and implantation were performed sequentially and 11 of 14
donor nephrectomies were laparoscopic. Recipients received quadruple
immunosuppression with either basiliximab or Thymoglobulin, steroids, a
mycophenolate and a calcineurin inhibitor CNI. Sub-optimal graft function
was defined by failure to achieve a >10% decline in serum creatinine each
day for the first 5 days after transplantation, or oliguria unresponsive to fluid
challenge and diuretics.
Results: Fourteen (10.6%) of 132 consecutive live-donor recipients (30
open and 102 laparoscopic nephrectomy) experienced sub-optimal graft
function. This was not associated with laparoscopic donor nephrectomy
(t test P= NS). Four (28%) recipients had renovascular causes detected by
duplex ultrasonography, 2 patients developed thrombosis, 1 kink and 1
anastomotic stenosis, of which 3 required urgent surgical correction. Three
(21%) had urological causes with 2 ureteric obstructions and 1 urine leak,
all of which required surgical correction. Three (21%) recipients developed
acute rejection confirmed on renal biopsy. Three (21%) had ATN due to
prolonged or complicated donor surgery, third space fluid loss and CNI
toxicity. One (7%) recipient experienced acute recurrence of primary disease
and remained dialysis dependent until experiencing sudden death thirty days
after transplant. The overall outcome in this group of patients was 1 death,
1 graft loss from thrombosis and 12 functioning grafts, 2 of which required
short term HD.
Conclusion: 10% of our total live donor kidney transplantation experience was
associated with sub-optimal graft function immediately after transplantation. In
all cases, a cause was identified and frequently (12/14) corrected thus restoring
graft function. Implantation surgery related problems were the cause for half of
the patients who developed sub-optimal graft function.
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2323 POST TRANSPLANTATION LYMPHOPROLIFERATIVE
DISORDER AFTER LIVER TRANSPLANTATION: A SINGLE
CENTER EXPERIENCE AMONG 400 PATIENT SERIES
S. Marzban, B. Geramizadeh, S-A. Malek-Hosseini, A. Bahador, H. Salahi, K.
Bagheri-Lankarani, M-H. Imanieh
Transplant Research Center, Shiraz University of Medical Sciences
Introduction: Post transplant lymphoproliferative disorders (PTLD) are a
heterogenous group of lymphoid proliferation occurring in the setting of solid
organ or BM transplantation.
In this review we will consider the incidence and clinical features of this group
of patients in our center.
Material and Methods: In this study, we present the clinical and pathologic
features of PTLD cases after liver transplantation (LT). In the period of liver
transplantation we had 3 pathology confirmed cases of PTLD out of 430 liver
transplant cases.
Results: Among 430 liver transplantation 3 cases were diagnosed as PTLD. Two
of the patients were child (both 6 year-old) and the other was adult (45 year-old).
One of the children was presented with diarrhea after 6 months of transplant and
PTLD (polymorphic type) was diagnosed on duodenal biopsy, she expired despite
of reducing the immunosuppressive therapy and starting of chemotherapy. The
other child was present with cervical lymphadenopathy one year after transplant.
He was also expired. The reason of liver transplantation was biliary atresia in
both of them. The last one was an HCV positive male patient who presented
with a very small cervical lymphnode( 1 cm) 1 year after liver transplant. He was
diagnosed as Hodgkin’s-like type of PTLD, now after 3 years he is doing well. In
all the three case EBV was positive in the involved tissue.
Conclusion: In conclusion, PTLD is a life treating disorder in liver transplant
patients. According to the present data (3/430) it seems that the incidence of
this disorder is lower than other parts of the world.

POSTER BOARD NUMBER P4 – 374
2324 ASSESSMENT OF CAUSATIVE FACTORS FOR
LYMPHOCELE FORMATION FOLLOWING RENAL
TRANSPLANTATION
J. Kothari, H. Talreja, A. Supariwala, R. Sirsat, A. Almeida
Pd Hinduja Hospital
Introduction: Lymphocele is a fluid collection between the renal graft and the
urinary bladder. It is an uncommon complication (0.6% to 18%) following renal
transplantation. It is associated with incomplete ligation of lymphatic vessels
of graft, extensive perivascular dissection in the recipient, acute rejection and
use of high dose steroids.
Objective: To determine the incidence of lymphocele in post renal transplant
patients at our center and identify potential factors responsible or associated to
its development.
Materials and Methods: All patients who underwent renal transplantation at
our centre from Jan 2004 to Oct 2007 with complete medical records were
reviewed.
Results: Out of 138 patients who had undergone renal transplantation, 48
developed lymphocele(34.7%).28 patients (58%) required surgical drainage
or pigtail catherization. Significant variation was noted in yearly incidence of
lymphocele which coincided with the yearly change in the surgical registrar
preparing the ‘bed’ for the recipient. Significantly, 25 out of 52 patients with
urinary tract infection developed lymphocele as compared to 23 out of 86
without evidence of urinary infection (p=0.016) . A total of 25 Acute rejection
episodes was seen in total with similar incidence in the two groups, with &
without lymphocele. Gram negative bacteria causing UTI, especially those
resistant to beta lactam antibiotics (ESBL) were the commonest organisms
isolated in patients with lymphocele formation.Use of IL-2R antagonists for
induction was not associated with increased incidence of lymphocele. There is
no association of lymphocele formation with the different immunosuppressive
regimens used at our center. Diabetic patients had a higher incidence of
lymphocele, but the difference was statistically insignificant (p=0.056).
Conclusion: More attention to careful ligation of lymphatic vessels both during

graft bed preparation and during graft implantation can significantly contribute
to reducing the incidence of lymphocele following renal transplantation. Cases
requiring surgical treatment cause significant morbidity. Preventive methods,
such as laparoscopic fenestration need to be done routinely to minimise
lymphocele formation. Urinary infections post-transplant is associated with
increased incidence of lymphocele formation. Diabetics may be more prone
for higher lymph collection, probably due to delayed healing of the dissected
lymphatics, but that remains to be proven conclusively.

POSTER BOARD NUMBER P4 – 375
2325 LAPAROTOMIC LIVE DONOR NEPHRECTOMY: IS IT
STILL JUSTIFIED?
M.A. Zargar, H. Shahrokh, M.J. Soleimani, K. Kamali, S.K. Hosseini, S.M.R.
Rabani, A. Barzegarnejad, E. Azimi
Shaheed Hasheminejad Hospital, Iran University of Medical Sciences
Purpose: We report our experience with laparatomic Live Donor Nephretomy
during the last 23 years.
Patents and methods: Between August 1985 and November 2007, 2260
consecutive live donors who underwent laparatomic nephrectomy at the
university hospital of Hasheminejad in Tehran, were included in this audit.
All donors underwent routine preoperative assessments including renal
angiography, to evaluate the anatomy of the renal arteries. Patients underwent
a high midline laparatomy under general anesthesia. Principally the left kidney
was the preferred side unless multiple left sided renal arteries were present.
For the left kidney, in most cases, the inferior mesenteric vein was ligated and
the retroperitoneum entered with a good access to left kidney and its pedicle.
On the right side after duodenal kocherization, the right kidney and its pedicel
were easily accessible. After removal of the kidney the posterior peritoneum
defect is closed and a short term drain is placed.
Result: 2260 live donors underwent laparatomy during a period of near 23
years. They were 1440 male and 820 female. Left kidney was used in 95% of
the cases. The mean donor age was 26 years (20-48 years). The mean hospital
stay was 3 days (2-5 days). The mean incisional length was 12 cm (± 2.5 cm).
The mean warm ischemia time was always less than 1 minute. The mean
operation time was 55 minutes (40-70 minutes). The mean intraoperative blood
loss was 200mls and there were no post operative transfusions. There were no
significant gastrointestinal complications. Postoperative morality occurred in
one case with sudden death of a 31 years old male who developed abdominal
pain 16 hours after operation. He was suspected of massive bleeding from renal
artery stump. Incision hernia in four cases, which required operative repair.
Significant lymphocele occurred in one case, which responded well to surgical
intervention.
Conclusion: In our experience midline laparatomy, is a very safe and efficacious
approach for live donor nephrectomy. It is associated with short operative
time and low morbidity rates and despite the rapid development of minimally
invasive techniques, this approach will continue to have a definite place in high
volume units such as ours. In our experience the only long-term disadvantage
of laparatomic donor nephrectomy has been in the cosmetic results.

POSTER BOARD NUMBER P4 – 376
2326 PROTEIN TRANSDUCTION TECHNOLOGY FOR STEM
CELL REPROGRAMMING: A NOVEL STRATEGY TO OBTAIN
INSULIN-PRODUCING CELLS
M. Ramírez-Domínguez1,2, N. Vicente-Salar2, A. Santana3, J. DomínguezBendala1, L. Inverardi1, C. Ricordi1, K. Hmadcha4, B. Soria4, E. Roche2
1
Diabetes Research Institute. University of Miami, 2 Instituto de
Bioingenieria.Universidad Miguel Hernandez de Elche, Spain, 3 Hospital
Universitario de Las Palmas, Spain, 4 Centro Andaluz de Biologia Molecular
y Medicina Regenerativa (CABIMER), Sevilla, Spain
Several reports have demonstrated the potential of mouse and human embryonic
stem (ES) cells to differentiate into insulin-producing cells and revert diabetes
in transplanted animal models. However, in vitro protocols are still inefficient,
as they give rise to heterogeneous cell populations that include undifferentiated
cells and derivatives of the three embryonic layers. Thus, there is a need for
alternative approaches to improve the efficiency of beta cell differentiation.
The feasibility of reprogramming strategies has already been demonstrated.
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Collas and colleagues, for instance, showed that rat insulinoma cell extracts
were able to reprogram fetal rat fibroblast towards a β-cell phenotype (1).
However, the permeabilization method results in an uncontrolled loss of cell
components that might be essential for cell function.
We hypothesized that the uptake of key beta cell transcription factors by ES
cells might reprogram them towards a pancreatic β-cell phenotype. In a first
series of experiments, we introduced a cocktail of transcription factors from
protein extracts of mouse embryonic pancreatic buds (donor cells) into mouse
embryonic stem cells (target cells). We used a synthetic protein transduction
domain (PTDs) as a vehicle for the protein cocktail inside the target cells. PTDs
are short peptides that have been used to favor the uptake of a variety of proteins,
including critical transcription factors involved in pancreatic development (2).
Here we report a 5% reprogramming efficiency from the initial cell population,
measured as the percentage of cells that express insulin. However, this
expression was transient and the signal became diluted 11 days after the
introduction of the proteins.
We conclude that reprogramming ES cells by PTD-aided transduction of
embryonic pancreatic explants is feasible, but transient. Combination of this
strategy with other differentiation/selection methods may improve the overall
efficiency of the method and the stability of the reprogrammed phenotype.
This research work was supported by the Spanish Ministry of Science and
Technology.

POSTER BOARD NUMBER P4 – 377
2327 INCIDENCE OF FEMORAL NEUROPATHY AFTER
KIDNEY TRANSPLANTATION
I. Chang, T. Kim
Anesthesiology and Pain Dept, Sungkyunkwan University Hospital, Seoul,
Korea
Purpose: Femoral neuropathy after kidney transplantation is not common and
often reversible, but it can cause a discomfort to the patients. The incidence
of this complication has not yet been reported in Korea. The objective of this
study is to estimate the incidence of femoral neuropathy in our institution and
to clarify individual risk factors including anastomosis sites, donor type, and
etiology in kidney transplantation recipients.
Methods: From February 1995 to March 2007, a total of 869 patients who underwent
kidney transplantation in our center were enrolled in this study. Femoral neuropathy
was defined as the numbness of medial side of upper thigh or immobilization. We
reviewed the medical records including electromyographies finding, replies of
consultations, nursing records, and anesthetic records, retrospectively.
Results: For the 869 patients who were analyzed, 12 patients (1.38%)
developed femoral neuralgia which was ipsilateral to the kidney transplantation
site. Among these 12 patients, 11 patients (91.7%) had an anastomosis to the
internal iliac artery and other to the common iliac artery. 12 patients (100%)
had an anastomosis to the external iliac vein. Femoral neuropathy occurred
in 4 living donors (33.3%) and 8 cadaver donor (66.7%), respectively.
Electrodiagnostic studies were postoperatively performed in 11 patients.
3 patients had lateral femoral cutaneous nerve damages, and 1 patient had
an obturator nerve damage. All patients were fully recovered without any
complications.
Conclusions: Femoral neuropathy is uncommon (1.38%) and a reversible
complication of kidney transplantation often yielding good prognosis.

POSTER BOARD NUMBER P4 – 378
2328 VASCULAR COMPLICATIONS IN RENAL
TRANSPLANTATION: A SINGLE CENTER EXPERIENCE OF
1.367 RENAL TRANSPLANTATIONS

THURSDAY

P. Katsaronis, D. Dimitroulis, J. Bokos, G. Zavos, D. Oikonomopoulou, E.
Avgerinos, E. Antoniou, N. Nikiteas, A. Kostakis
2nd Department of Propedeutic Surgery, Athens University
Introduction: Vascular complications are common after renal transplantation;
however few reports on large scale series with a long follow up exist. We
present a single center experience of 1367 renal transplantations with an
average 65-month follow up.
Methods: We analyze retrospectively, the data from 1367 consecutive renal
transplants performed during the period of September 1980 to April 2005.
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Vascular complications were recorded.
Results: Actuarial graft survival was 89%, 70%, and 52% at one, five, and
10 years, respectively. Overall there were 57 (4.2%) vascular complications,
including 38 early ones (1-16months): 27 renal artery thromboses, 4 renal vein
thromboses, 4 renal artery aneurysms and 3 cases of anastomotic bleeding and
19 late ones (6-28months), all transplant renal artery stenoses (TRAS). All early
complications led to graft loss, while PTA-managed TRAS was successful in
16 (84%) cases. Univariate analysis showed that vascular complications
associated with cadaveric allografts were statistically significant compared to
the living renal grafts (P<0.05).
Conclusions: Vascular complications still represent a challenge that
increments poor graft outcome among kidney transplant recipients. Optimal
surgical technique and close patient screening, particularly during the early
postoperative period and in cadaveric transplants can potentially reduce early
vascular complications and subsequent graft losses.

POSTER BOARD NUMBER P4 – 379
2329 THE PROTECTIVE EFFECTS OF ULINASTATIN AND
ADENOSINE TRIPHOSPHATE ON ISLET FUNCTION DURING
ISLET ISOLATION AND AFTER ISLET TRANSPLANTATION
F-R. Li, L. Qiu, X-F. Yang, H. Qi, L-L. Ren, H-X. Zhou
Clinical Medical Research Center, The Second Clinical Medical College
(Shenzhen Peoples Hospital) Jinan University
Background: To observe the protective effects of trypsin inhibitor-ulinastatin
or ATP on islet function during islet isolation and islet transplantation.
Methods: Ulinastatin or ATP were used in the entire process of collagenase
digestion and islet isolation, while the equal amount of physiological saline
was used in the control group. Islet yield, apoptosis and islet function
were measured for purified islets. Two hundred islets treated with ATP,
ulinastatin and physiological saline was respectively transplanted beneath
renal subcapsule of diabetic SCID mouse models. The blood glucose levels
were consecutively monitored after transplantation and intraperitoneal
glucose tolerance test (IPGTT) was performed in recipient mice 21 days after
transplantation.
Results: The islet cell apoptosis rates in ulinastatin and ATP group were
significantly lower than that in control group (P £¼0.01) but the insulin release
levels in glucose stimulation test were significantly higher than that in control
group (P £¼0.01). The islet yield in ulinastatin group was significantly higher
than that in control group (P £¼0.01). Compared ATP and ulinastatin group
with control group, there were no significant differences in blood glucose
reduction and IPGTT after islet transplantation.
Conclusion: During islet isolation, ulinastatin can inhibit islet cell apoptosis,
raise islet yield and protect islet viability, and ATP can inhibit islet cell apoptosis.
Compared ATP and ulinastatin group with control group, islet function and
ability response to glucose after transplantation were nearly equal.

POSTER BOARD NUMBER P4 – 380
2330 EVALUATION OF LEISHMANIASIS DEVELOPMENT
DURING A SHORT COURSE OF FTY720
V. Bueno 1, C.T. Lopes 1, D. Paula 1, P.M. Cury 2, V. Valero 1
1
Unifesp - Federal University of Sao Paulo, 2 FAMERP - Sao Jose do Rio
Preto Medical School
Aims: L.amazonensis (La) infects macrophage and impairs the activation
of antigen-specific T cells. FTY720 (FTY) is a compound which alters T cell
homing by trapping these cells into secondary lymphoid organs. Our aim was
to investigate leukocytes changes due to FTY administration in leishmaniasis
development.
Methods and Results: BALB and C57BL female adult mice were inoculated
with 5x105 forms of La. Lesion sizes were measured and 7½ weeks later
mice received FTY (1mg/kg/day) orally for 10 days. Controls BALB(A)
and C57BL(B), BALB+La(C), C57BL+La(D), BALB+La+FTY(E),
C57BL+La+FTY(F).Nine weeks after La inoculation blood (leukocytes
counting), spleen (counting, flow cytometry) and hind feet were harvested.
Hind feet thickness (mm) increased (A=B=4.0±0.0, C=10.3±0.4, D=7.7±0.4,
p=0.002) and was not modified by FTY (E=10.1±0.2, F=6.8±1.0). Spleen
cell numbers (x106) decreased in BALB but not in C57BL (A=42.1±3.7,
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B=46.2±5.4, C=28.6±6.1, D=46.6±13.7, p=0.007). FTY caused a higher
decrease in spleen cell numbers (E=11.1±0.6, F=22.4±4.9). Total lymphocytes
(%) increased in C57BL and BALB after La inoculation (A=53.6±8.0,
B=43.2±16.9, C=74.8±1.0, D=70.8±3.2, p=0.02) whereas FTY decreased
this parameter (E=65.8±3.6, F=51.9±9.4). CD4 and CD8 T cells (%)
increased (A=25.1±7.3, B=17.3±5.1, C=34.4±2.1, D= 25.8±3.4 for CD4)
in both mice strains but while C57BL presented no change in CD4 T cells
after FTY (F=25.7±2.8) BALB decreased significantly (E=26.1±5.9). CD8
T cells decreased both in C57BL and BALB after FTY. CD11b decreased
(A=56.7±3.9, B=48.2±7.1, C=14.0±0.8, D=10.4±1.5, p=0.001) whereas FTY
promoted an increase in this cell population (E=22.5±4.1, F=13.2±0.3). There
was no increase in blood lymphocytes after La infection but FTY caused an
important lymphopenia in parasited mice.
Conclusions: FTY did not interfere with leishmaniasis development in late
phase probably due its preferential effects on naive cells instead of effector/
memory subpopulations.

POSTER BOARD NUMBER P4 – 381
2331 UPDATE ON ORGAN SOURCING IN CHINA
D. Matas
Former Canadian Minister of State David Kilgour and I wrote a report on
organ sourcing in China, released first June 2006 and, in a second version,
January 2007 under the title "Bloody Harvest: Organ Harvesting of Falun
Gong practitioners in China". In that report we concluded that between 2001
and 2006 China killed Falun Gong practitioners in the tens of thousands so
that their organs could be sold to foreign transplant tourists. Falun Gong is an
exercise regime with a spiritual foundation based on ancient Chinese traditions
banned in 1999.
China has no national organized organ donation system, nor a law allowing
organ sourcing from the brain dead, cardiac alive. There is a strong cultural
aversion against both organ donations and organ sourcing from the cardiac
alive. Nor does China have a national organ matching and distribution system.
Organs for transplants almost exclusively come from prisoners, whether
prisoners sentenced to death or Falun Gong practitioners.
Since the report was released, David Kilgour and I travelled to over forty
countries and over seventy cities to seek to end the abuse we identified.
Subsequent to our report, China changed both its death penalty and organ
transplant laws. The combined impact was to cut down on transplant tourism
to China. One question this presentation would address is the extent to which
abusive sourcing of organs from Falun Gong practitioners remains in light of
these changed laws and their application.
The initial response of the Government of China to the report David Kilgour
and I wrote was propagandistic, without addressing the substance of the
research. More recently, particularly in the last few months, the Government
of China has come out with specific responses - by way of letter to the
United Nations Rapporteur on Torture Manfred Nowak and also by way
of video, interviewing some of the sources of our report. The presentation
would evaluate these responses and re-assess our own conclusions in light
of these responses.
Because of our travels and the publicity surrounding our report, we received
much additional evidence relevant to the subject of our report. Some it was just
more of the same. For instance, we continued to find new examples of Falun
Gong practitioners who in Chinese detention were systematically blood tested
while their co-prisoners who were not practitioners were not blood tested.
As well, categories of evidence relevant to the conclusion of our report but
not previously considered need to be examined. One example is the presence
or absence of holding cells for those awaiting execution after having been
sentenced to death.
Some of the new evidence is quite recent. For instance, a new witness, a former
prisoner, testifying to organ sourcing from Falun Gong practitioners, has
surfaced just a few weeks ago. A third purpose of the presentation would be to
bring the evidentiary analysis of our report up to date by referring to the most
recent evidence available.

POSTER BOARD NUMBER P4 – 382
2332 PRE- AND POST-TRANSPLANT MONITORING OF
GRANZYME B ENZYME-LINKED IMMUNOSPOT ASSAY IN
PEDIATRIC LIVER RECIPIENTS
D.Q. Truong1, A. Cornet2, G. Wieërs3, A. Robert4, R. Reding5, D. Latinne6
1
Pediatric Surgery Department, Children’s Hospital 2, Medical University
Centre, Ho Chi Minh City, Viet Nam., 2Laboratory of Transplant Immunology,
Saint-Luc University Clinics, Université catholique de Louvain, Brussels,
Belgium, 3Pediatric Liver Transplant Program, Saint-Luc University Clinics,
Université catholique de Louvain, Brussels, Belgium, 4Epidemiology and
Biostatistics, Université catholique de Louvain, Brussels, Belgium, 5Pediatric
Liver Transplant Program, Saint-Luc University Clinics, Université
catholique de Louvain, Brussels, Belgium, 6Laboratory of Transplant
Immunology, Saint-Luc University Clinics, Université catholique de Louvain,
Brussels, Belgium
This study aims to investigate potential role of granzyme B enzyme-linked
immunosorbent spot (GrB ELISPOT) for immunological monitoring in
pediatric liver transplantation. Patients and methods: Peripheral blood
mononuclear cells from 28 pediatric recipients were serially tested for GrBproducing donor-reactive cells at day 0 pre-transplantation (baseline) and days
7, 14, 28 post-transplantation. Results: At baseline, no difference of GrB value
was found in acute rejection (14/28) compared to normal graft function patients
(day 0: 4(3.9) spots versus 5(2.9) spots, respectively: p=0.65). At day 7 posttransplantation, acute rejection patients showed frequencies of GrB ELISPOT
higher than those with normal graft function, but the differences observed
were not statistically significant (day 7: 15(4.9) spots versus 10(4.0) spots,
respectively: p=0.55). GrB increased significantly at day 7 from baseline in
the rejection group (15(4.9) spots versus 4(3.9), respectively p=0.04), whereas
corresponding changes were not significant in the group without rejection
(10(4.0) versus 5(2.9), respectively: p=0.15). Conclusion: GrB ELISPOT pretransplantation could not predict the occurrence of early post-transplant acute
rejection; similarly frequencies at days 7, 14 and 28 could not be correlated
with acute rejection in pediatric liver recipients. However, a kinetic study of
GrB ELISPOT could be helpful to predict or confirm early rejection in the
small group of liver allograft recipients analyzed in this study.

POSTER BOARD NUMBER P4 – 383
2333 ACTIVE CYTOMEGALOVIRUS INFECTION IN THE
CARDIAC ALLOGRAFT PRECEDES AND CORRELATES WITH
CARDIAC ALLOGRAFT REJECTION EPISODES
M. Dzabic, A. Rahbar, M. Grudzinska, P. Religa, C. Söderberg-Nauclér
Department of Medicine, Center for Molecular Medicine, Karolinska
Institutet, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
Background: Cytomegalovirus (CMV) infection has been suggested to be a
contributing factor in acute and chronic rejection via direct and indirect effects.
Although CMV infection has been associated with acute rejection episodes and
chronic rejection in organ transplant recipients it has been difficult to detect the
virus in the affected organs.
Methods: In this retrospective observational cohort study 35 patients receiving
a cardiac allograft between 1998 and 2000 at the Silesian Centre for Heart
Disease in Zabrze, Poland, were included. All patients received Ganciclovir
during the first 28 days after transplantation. Endomyocardial biopsies were
examined for the presence of CMV proteins using a new high sensitivity
immunohistochemistry staining (HSIS) method.
Results: In 91 examined endomyocardial biopsies, we detected CMV
immediate early and late antigens in 98,9%, and the CMV matrix protein pp65
in 92,3% of the biopsy samples. Linear regression analysis demonstrated a
correlation between the level of CMV pp65 and ISHLT rejection grade (p<0.05).
Furthermore, the presence of CMV proteins preceded rejection episodes.
Conclusions
A vast majority of cardiac transplant patients have an active CMV infection
in the cardiac allograft, which can be detected using the HSIS method but not
with regular staining techniques. CMV infection in the graft precedes and is
associated with rejection episodes. The HSIS method for CMV pp65 may be of
clinical value in predicting cardiac allograft rejection episodes.
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2334 EFFICACY COMPARISON BETWEEN INTRAPORTAL
AND SUBCAPSULAR ISLETS IN MURINE DIABETIC MODELS
E. Hathout, N. Sakata, J. Chrisler, A. Tan, N. Chan, P. Hayes, J. Mace,
R. Chinnock, L. Sowers, A. Obenaus,
Loma Linda University
Background: Islet transplantation is a useful therapeutic option for type 1
diabetes mellitus. Intraportal transplantation is the most effective method
at present. However, transplanted islets are very unstable partly due to
nonspecific inflammation, hypoxia, and the metabolic condition of the
recipient. Approximately 60% of transplanted islets are lost in the first couple
of days. In clinical practice, multiple transplantations are often required for one
recipient to maintain normoglycemia. Therefore, it is important to determine
the efficacy of intraportal transplantation in comparison with other transplant
sites. In this study, we tried to determine the optimal number of islets to achieve
normoglycemia following transplantation into the liver versus kidney using a
mouse model.
Methods: Balb/C female mice were used as donors and recipients.
Streptozotocin induced diabetic mice were transplanted with syngeneic islets
via the intraportal (IP) and renal subcapsule (SC) routes. The transplanted
islet numbers were: zero (n=4, as a control), 100 (n=5 for IP and n=4 for SC),
200 (n=5 for IP and SC), 300 (n=4 for IP and SC), 500 (n=6 for IP and n=4
for SC) and 800 (n=5 for IP only). Blood glucose levels of the transplanted
mice were measured through postoperative day (POD) 28. We calculated the
parameters indicated below, assessed the correlation between these parameters
and islet numbers and compared the parameters in the IP versus SC groups. The
parameters were, (1) Percentage achieving normoglycemia in each group; (2)
Postoperative days to normoglycemia; (3) Mean blood glucose level at various
points from pre-transplantation to end of the study (POD28). We also tested the
correlation between mean blood glucose levels and islet number.
Results: Two hundred islets could achieve normoglycemia in renal
subcapsular grafts, while 800 islets were the minimum required in intraportal
transplantation. Data from both groups were approximated using the quadratic
function, and showed that intraportal transplants required 5 times the number
of islets as renal subcapsular transplants for an equivalent percentage of
normoglycemia. The days to normoglycemia did not significantly differ by
the number of transplanted islets, however, they were significantly different
between intraportal and renal subcapsular islets (13.25 ± 4.38 days vs. 3.33
± 0.70 days, p = 0.007). There was a significant negative correlation between
islet number and mean blood glucose level in both intraportal and subcapsular
transplantation. The transplantation efficacy of the liver was one fourth that of
the kidney in this assessment.
Conclusion: Efficay of islet transplantation in murine diabetic models is
significantly higher under the kidney capsule. This may reflect an advantage
of maintained juxtaposition versus dispersion of islet cells. Clinical islet
transplantation could benefit from trials of alternative transplantation sites.
This work was supported by NIH/NIDDK Grant # 1R01-DK077541 [EH].

cultured at 37oC in HAM-F12 medium in a humidified atmosphere of 5% CO2
and 95% air. Cells were subcultured and grown for 1 day to the stage of 50%
confluence. The medium was then changed to one containing CRH (10, 25, 50,
100 or 200nM) or vehicle (saline, pH2.79) and incubated for 24hours. RNA
and Protein was extracted from these cells for subsequent analysis using RealTime PCR (RT-PCR) and SDS-PAGE respectively. The supernatants from cell
cultures were extracted for exosomes using differential centrifugation and
sucrose cushion methods prior to protein analysis using silver staining and
western blotting.
Results: Real-time PCR analysis showed an upregulation in Syncytin 1, Syncytin
2 and FasL mRNA following 24 hour CRH treatment in a dose dependent
fashion. There were no significant differences in protein levels of Syncytin
and FasL with increasing doses of CRH. However, there was an increase in the
production of exosomal protein following stimulation with CRH.

POSTER BOARD NUMBER P4 – 385
2335 LESSONS FROM PREGNANCY THAT MAY HELP IN
TRANSPLANTATION

THURSDAY

J.E. Schjenken1, J.M. Tolosa1, 2, V. Clifton3, B. Tuch4, R. Smith1
1
Mothers and Babies Research Centre, University of Newcastle, Newcastle,
Australia, 2 Faculty of Medical Sciences, University of Santiago of Chile,
Santiago, Chile, 3 Department of Pediatrics and Reproductive Health,
University of Adelaide, Adelaide, SA, Australia, 4 Diabetes Transplant Unit,
University of NSW, Randwick, NSW, Australia
Background: During pregnancy the placenta expresses Syncytin, an
immunosuppressive retroviral envelope protein, and secretes placental
exosomes with immunomodulatory functions. The human placenta also secretes
Corticotropin Releasing Hormone (CRH), an inducer of cAMP which stimulates
the production of Fas Ligand (FasL). Syncytin also responds to cAMP stimulation.
We hypothesised that CRH induces the expression of Syncytin and FasL which
stimulate the production of exosomes carrying endogenous retroviruses (ERV)
and FasL which modulate the maternal response to the fetal allograft.
Methods: BeWo cells (a human placental choriocarcinoma cell line) were

762

Figure 1) Real-time PCR analysis of Syncytin 1, Syncytin 2 and FasL in BeWo
cells treated with different concentrations of CRH. Expression levels are
normalised against the respective vehicle
Conclusions: We show that CRH stimulation of BeWo cells results in the
increase of the mRNA of Syncytin-1, Syncytin-2 and FasL. Both Syncytin-2
and FasL have known immunosuppressive functions. Surprisingly, Western
Blot analysis of the total cell proteins revealed no increase in Syncytin or FasL
at any time points. In contrast, proteins from exosomal fractions increased
following CRH treatment. These data suggest that CRH stimulates BeWo cell
protein production of these immunosuppressive factors resulting in a transfer
of the immunomodulatory proteins into an exosomal secretory pathway. This
knowledge could be applied to transplantation strategies.
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2336 EFFECT OF KIDNEY TRANSPLANTATION ON
CONTROLLING ARTERY-VENOUS FISTULA SIDE EFFECTS
IN END STAGE RENAL DISEASE
S.M.M. Ghoreishi1, S.A. Tabatabaie2, T. Ghoraishi3, A.A. Beigi4, A.
Mirmohammadsadeghy 5, A. Khosravi6, M. Karamy7, R. Amighian 8
1
Esfahan University School of Medicine, 2Esfahan University School of
Medicine, 3Najafabad University School of Medicine,, 4Esfahan University
School of Medicine, 5Esfahan University School of Medicine, 6 Esfahan
University School of Medicine, 7Esfahan University School of Medicine, 8
Najafabad University School of Medicine,
Introduction: One of the main complications of End Stage Renal Disease
(ESRD) is pulmonary hypertension. In fact creation of temporary Artery-Venous
Fistula (AVF) for dialysis considerably, accelerates the rise in cardiac output
and pulmonary artery pressure in these patients. We have evaluated the effect of
kidney transplantation on improving cardiac indices such as Pulmonary Artery
Pressure (PAP) and Cardiac Output (CO) post transplantation.
Material and Method: 50 patients with ESRD were included in the retrospective
clinical trial study. Echocardiography was performed to evaluate systolic PAP,
CO and Ejection Fraction (EF) prior to creating AVF. 12 patients underwent
kidney transplantation. None of the AV fistulas of graft recipients were subjected
to surgical closure post-transplantation. After a follow up interval of at least 6
months, second echocardiography assessments and Doppler sonogram of their
fistula flow were done. Transplanted and non transplanted cases were compared.
The two groups were matched on age, medical co-morbidities and AVF creation
surgical technique and flow. P-values were obtained using the Student’s t-test.
Results: The mean systolic PAP was 20.7 mmHg prior to AVF creation in
graft recipients (n=12); which has significantly decreased to 14.8 mmHg posttransplantation (P=0.016). Post-transplant systolic PAP increased in none of the
recipients compared to pre-transplant values.
In non-transplanted group (n=38) a significant rise in the mean systolic PAP from
21.3 mmHg to 25.16 mmHg pre and post AVF creation was observed. There
was no significant change observed in CO post-transplant compared to pre-AVF
creation value (6120 ml/min). Mean CO was 510 ml/min less in those who
were not transplanted (5610 ml/min). No considerable decrease in CO may be
explained by levels of still-existing AVF flow in transplanted group (P=0.32).
The non-transplanted group has shown a 7% decrease in mean EF during the
study period, whereas the recipients had 7.5% increase in mean EF, which was
significantly different (P=0.03).
Conclusion: The outcomes of this study are in accordance with other studies’,
confirming that kidney transplantation should be regarded as the best available
method to control the end organ damage of renal failure including complications
caused by AVF creation . Improvements in Cardiac indices after kidney
transplantation even with open AVF can reverse clinical manifestations of
ESRD. Moreover, surgical closure of the temporary AVF in suitable candidates
after reassurance of graft acceptance can improve the complications; however
more investigations are required to affirm the accuracy.

POSTER BOARD NUMBER P4 – 387
2337 RENOPORTAL ANASTOMOSIS AS A RESCUE
TECHNIQUE IN POSTOPERATIVE PORTAL THROMBOSIS
AFTER LIVER TRANSPLANTATION
I. Gonzalez-Pinto, A. Miyar, C. Garcia-Bernardo, L. Vazquez, L. Barneo, E.
Cortes, P.Y. Diaz, N. Gutierrez, L. Fernandez
Hospital Universitario Central de Asturias
Renoportal anastomosis has been used as the primary portal revascularization
technique in grade 4 portal thrombosis, but never after posttransplant portal
thrombosis.
Case presentation: A 55 year-old patient with hepatocellular carcinoma on
alcoholic and virus C cirrhosis received a liver transplant in late march/08. He
had partial portal thrombosis.
Portal thrombosis of 2/3 of the lumen was found at surgery. The thrombus
was removed and a good portal flow was obtained after reperfusion (2.8 L/
min). Severe transaminases rise took place at 9th PO day, and doppler US
revealed complete portal thrombosis from the spleno-mesenteric confluence.
At emergency reoperation, newly formed and fragments of old thrombus were

removed. Portal vein branches were flushed with heparin and urokinase. After
reconstruction of the anastomosis, a final flow of 1 L/min was achieved.
Two days later there is a new rise in transaminases and rethrombosis is
demonstrated again on the 13th PO day by doppler US. At reoperation,
thrombus is removed again. However, this time portal flow is not recovered,
due to hepatofugal flow associated with both the presence of collaterals and
pancreatic edema. Collaterals were localized in the distal retropancreatic area
and were not accessible for ligation or shunting. The left renal vein was of larger
diameter than the right, so we decided to perform an end-to-end renoportal
anastomosis, by means of an interposed iliac vein graft. A catheter was placed
in the portal vein through a recanalization of the umbilical vein of the graft.
Postoperative course was good, with progressive normalization of liver tests and
no further thrombosis. However, some areas of bad perfusion remained in the right
lobe, and ascites persisted, but improved with treatment. Angiography on the 41st
PO day showed a good portal flow from the renal vein, with a good and uniform
distribution within the liver. The patient was discharged on the 48th PO day.
Conclusion: Renoportal anastomosis can be useful for recovery of liver failure
after posttransplant portal thrombosis, in the absence of portal flow.

POSTER BOARD NUMBER P4 – 388
2338 SEQUENTIALLY INCREASING 4-FOLDS GRAFT BLOOD
FLOW ACCORDING TO PHI(¥Õ) RATIO IN RIGHT LOBE
LIVING DONOR LIVER TRANPLANTATION
Y-H. Kim1, Y.H. Roh1, G.J. Jung1, K.J. Cho2, J.H. Cho3
1
Department of Surgery, College of Medicine, Dong-A University, Busan,
Korea, 2Department of Cardiac Surgery, College of medicine, Dong-A
University, Busan, Korea, 3Department of Diagnostic Radiology, College of
medicine, Dong-A University, Busan, Korea
In end to side hepatic vein anatomosis, to promote smooth blood flow through
inflow and outflow, the construction should be slightly angulated. Insufficient
stoma causes end vessel congestion, excessive opening narrows the lumen1.
To optimize outflow2,3, we applied the golden ratio(¥Õ, approtimately 1.618)
to outflow/inflow ratio. At the back table, septoplasty and venoplasty, great
saphenous vein interposition graft, and then hepatic vein and inferior vena
cava (IVC) anastomosis in the operation field, sequentially the graft blood flow
increased to 4 folds.(1.6 x 1.6 x 1.6)
Better
saphenous
vein
harvest:
Recently
cryopreserved4,
polyetrafluoroethylene(PTFE)5 graft were introduced, but autologus great
saphenous vein is more physiologic, less time consuming, familiarity for the
small capacity transplantation program (less than 5 cases in a year) like us. to
improve wound healing and cosmetic efforts, 2 or 3, 4cm long separate skin
incision on the groin area were made(Fig.1).
Back table procedure: In the right hepatic vein(RHV), septum with
intervening tissue exist, making an incision on the septum6 and peformed
interrupted absorbable 7-0 sutures. The orifice were completely separates
but not far apart, removing the undelying liver parenchym using the Cavitron
ultrasonic surgical aspirator(CUSA, Excel, Valleylab, Inc, Boulder, Co),
vessel edges were approximmted using contineous 7-0 sutures to make a wide
opening7(Fig.2). With these kinds of septoplasty and venoplasty, the diameter
could be increased to approximately x 1.6 and then the long diameter of great
saphenous vein(GSV) was fenced along the edge of RHV using continous 7-0
Prolene suture.(the diameter enlarged approximately x 1.6)(Fig.3).
If the diameter of drainage vein of the graft were larger than 5mm and isolated,
remanied saphenous vein was used as venous conduit and implanted directly
into the IVC.
Liver transplant precedure: An elliptical defect, approximately 1.6 times the
diameter of donor RHV was created in the IVC and anchoring sutures are placed
at the apex and base of the ellipse and then contineous 5-0 Prolene suture were
made(Fig. 4), so far the graft blood flow increased sequentially about 4 folds.
But we assumed that postoperative actual venous blood flow depends on the
recepient portal inflow, resistance of the graft, vena caval outflow rate.
Since 2005, 8 consecutive right lobe graft living donor liver transplantation using
same kind of procedure were performed. All outflow of the graft was satisfactory.
There have been many reports reparding outflow tract reconsruction, some are
too small, others are too large. We believe to achieve the appropriate smooth
blood flow in end to side anastomosis, keep the outflow/infolw ratio to natural
golden ratio Phi(¥Õ) 1.6 is ideal.
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2339 INCISIONAL AND INGUINAL HERNIA AFTER RENAL
TRANSPLANTATION

THURSDAY

R.E. Samani, S.M.M. Ghoreishi
Medical University of Isfahan
Purpose: End Stage Renal Disease (ESRD) is one of the serious problems for
human population in the world. Renal transplantation is one of the methods
of treatment for these patients. After operation for renal transplantation, many
complications threaten the patient including rejection, infection, hernia and etc.
This study is about the frequency of complications including hernia after renal
transplantation and the results of surgical repair of hernia.
Methods: This is descriptive-analytic study that conducted in Al-Zahra hospital
in ISFAHAN. From 2004 to 2006, 170 patients with renal transplantation
were studied in order to determine the frequency of complications including
incisional and inguinal hernia .Surgical correction was established using
propylene mesh and patient outcome was studied.
Results: Of 170 patients with renal transplantation 13 (7.6%) patients developed
surgical site complications. 5 patients had infection, 3 patients had seroma , 2
patients had hematoma , 1 patient had bleeding, 8 patients with urinary leakage
and 1 patient had chronic pain. 3 patients developed hernia (2 incisional hernias
and 1 inguinal hernia) that two of them had seroma collection. The prevalence
of hernia was 1.8% .Incidence of hernia had no significant relation with gender
(P= 0.99), age (P= 0.86), Diabetes Mellitus (P=0.7), and Smoking (P=0.8).
Surgical repair was performed using propylene mesh. No complications and no
relapses were noted at a mean follow up of 2 years.
Conclusion: Lower incidence of hernia after kidney transplantation can be
achieved by primary health care such as prevention of constipation, respiratory
care and physical activity although surgical complications are important
predisposing factors for hernia after renal transplantation. Surgical repair by
propylene mesh is safe and effective in these patients.
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NOTES

Your Partner in
Transplantation
At Astellas, we are committed to uncovering
new possibilities in immunology through
broad scale research aimed at new product
development.
Through the transference and sharing of
scientiﬁc knowledge, we work in partnership
with healthcare professionals like you to
positively impact patient care.
Our goal remains clear:
Enhance the practice of transplantation.
It is our passion and our priority.
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